<SEC-DOCUMENT>0001213900-24-042529.txt : 20240514
<SEC-HEADER>0001213900-24-042529.hdr.sgml : 20240514
<ACCEPTANCE-DATETIME>20240513211137
ACCESSION NUMBER:		0001213900-24-042529
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		101
FILED AS OF DATE:		20240514
DATE AS OF CHANGE:		20240513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279387
		FILM NUMBER:		24941169

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>ea0205122-01.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 13 23:21:15 UTC 2024 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:abio="http://www.arcabiopharma.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head><title> </title>
<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="margin:0;padding:0;border-width:0;text-justify-trim: punctuation; margin: 0; padding: 10pt;"><div style="margin:0;padding:0;border-width:0;width:600px;margin: 0 auto;">
	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">As filed with the Securities and Exchange Commission on May 13, 2024</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:right;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">No. 333-<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;"> UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/>Washington, D.C. 20549</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:2pt;text-align:center;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-35018">S-4</ix:nonNumeric><br/>REGISTRATION STATEMENT<br/></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-size:9pt;">UNDER<br/>THE SECURITIES ACT OF 1933</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-30"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:16pt;">ARCA BIOPHARMA, INC.</span></ix:nonNumeric><span class="Bold" style="font-style:normal;font-weight:bold;"><br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">(Exact name of registrant as specified in its charter)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-41"><span class="Bold" style="font-style:normal;font-weight:bold;">Delaware</span></ix:nonNumeric></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2835</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">36-3855489</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">(State or other jurisdiction of <br/>incorporation or organization)</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">(Primary Standard Industrial <br/>Classification Code Number)</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">(I.R.S.&#160;Employer <br/>Identification No.)</span></p>	</td>	</tr>	</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:4pt;text-align:center;margin-top:4pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>(720)&#160;940-2100<br/>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;text-align:center;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Thomas A.&#160;Keuer<br/>President and Chief Operating Officer<br/>ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>(720)&#160;940</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">-2100</span></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;"><br/>(Name, address, including zip code, and telephone number, including area code, of agent for service)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:1pt;text-align:center;margin-top:1pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-size:9pt;">Copies of all communications, including communications sent to agent for service, should be sent to:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Brent Fassett <br/>Ethan Lutske <br/>Ross Tanaka <br/>Savir S.&#160;Punia <br/>Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. <br/>1881 9</span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;vertical-align:super;">th</span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;"> Street, Suite 110 <br/>Boulder, CO&#160;80302 <br/>(303)&#160;256</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">-5900</span></span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Ryan A.&#160;Murr, Esq.</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Branden C.&#160;Berns, Esq.</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Chris W.&#160;Trester, Esq.</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Gibson, Dunn&#160;&amp; Crutcher LLP</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">One Embarcadero Center, Suite 2600</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">San Francisco, CA&#160;94111</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">(415)&#160;393</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">-8373</span></span></p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Approximate date of commencement of proposed sale of the securities to the public: </span>As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">If this Form is a post<span class="nobreak">-effective</span> amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non<span class="nobreak">-accelerated</span> filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b<span class="nobreak">-2</span> of the Exchange&#160;Act.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#160;biopharma,&#160;Inc. <br/></span>Large&#160;accelerated&#160;filer</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 2', sans-serif;"><br/>&#163;</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Accelerated filer</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-167">Non<span class="nobreak">-accelerated</span>&#160;filer</ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9746;</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Smaller reporting company</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-179"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9746;</span></ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Emerging growth company</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-193"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></ix:nonNumeric></p>	</td>	</tr>	</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act. <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">If applicable, place an&#160;X in the box to designate the appropriate rule provision relied upon in conducting this transaction:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Exchange&#160;Act Rule&#160;13e<span class="nobreak">-4</span>(i)&#160;(Cross<span class="nobreak">-Border</span> Issuer Tender Offer) <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Exchange&#160;Act Rule&#160;14d<span class="nobreak">-1</span>(d)&#160;(Cross<span class="nobreak">-Border</span> Third<span class="nobreak">-Party</span> Tender Offer) <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the Securities Act&#160;of&#160;1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</span></p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:justify;margin-top:8pt;"><span class="CharOverride-6" style="color:#d2232a;">The information in this preliminary proxy statement/prospectus is not complete and may be changed. ARCA biopharma, Inc. may not sell the securities described in this preliminary proxy statement/prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</span></p>
		</div>
	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">PRELIMINARY PROXY STATEMENT/PROSPECTUS <br/>SUBJECT TO COMPLETION, DATED MAY</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">13, 2024</span></p>
		<table class="Basic-Table _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="Basic-Table _idGenTableRowColumn-19" style="height:12pt;">
					<td class="Basic-Table CellOverride-9" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;vertical-align:bottom;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="Basic-Table CellOverride-10" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-10" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 35.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Basic-Paragraph" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><img alt="" src="tarca_001.jpg" style="width:206.08px;max-width:100%;"/></p>
					</td>
					<td class="Basic-Table CellOverride-10" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-10" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 35.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Basic-Paragraph" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><img alt="" src="toruka_logo.jpg" style="width:107.52px;max-width:100%;"/></p>
					</td>
					<td class="Basic-Table CellOverride-10" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-10" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSED MERGER<br/>YOUR VOTE IS VERY IMPORTANT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">_______________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">To the Stockholders of ARCA biopharma, Inc. and Oruka Therapeutics, Inc.,</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). After the completion of the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; The term &#8220;combined company&#8221; when used in the following proxy statement/prospectus refers to the post<span class="nobreak">-Merger</span> corporate structure including Oruka Therapeutics, Inc. (f/k/a ARCA biopharma, Inc.) as the parent entity and Oruka Therapeutics Operating Company, LLC as its wholly<span class="nobreak">-owned</span> subsidiary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">At the closing of the First Merger (the &#8220;First Effective Time&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (as defined below) and excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page&#160;134 of the accompanying proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B non<span class="nobreak">-voting</span> convertible preferred stock, par value $0.001 per share (&#8220;ARCA Series&#160;B Preferred Stock&#8221;), which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Oruka Options</span>&#8221; beginning on page 137 of the accompanying proxy statement/prospectus, (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Oruka Warrants</span>&#8221; beginning on page 137 of the accompanying proxy statement/prospectus, (v)&#160;each in<span class="nobreak">-the-money</span> option to acquire shares of ARCA&#8217;s common stock that is issued and outstanding (whether vested or unvested) will be cancelled and converted into the right to receive an amount in cash equal to the excess (if any) of the volume weighted average closing price of ARCA&#8217;s common stock for the five consecutive&#160;trading days ending three (3)&#160;trading days prior to the closing of the First Merger (the &#8220;Parent Closing Price&#8221;) over the option&#8217;s exercise price and (vi)&#160;each share of ARCA common stock that is issued and outstanding at the First Effective Time will remain issued and outstanding in accordance with its terms and such shares, subject to the proposed reverse stock split, and will be unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Based on ARCA&#8217;s and Oruka&#8217;s capitalization as of April&#160;3, 2024 (the date the Merger Agreement was executed) and taking into account ARCA&#8217;s current cash position, each share of Oruka capital stock is currently estimated to be entitled to receive approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock. This estimated exchange ratio does not give effect to the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">proposed ARCA reverse stock split and is subject to adjustment based on ARCA&#8217;s estimated net cash at the closing of the First Merger as described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 134 of the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA&#8217;s board of directors expects to declare a special cash dividend (the &#8220;special cash dividend&#8221;) to stockholders of record of outstanding shares of ARCA common stock as of a record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the First Effective Time. The ex<span class="nobreak">-dividend</span> date in respect of such special cash dividend will be determined by The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;). ARCA stockholders of record who continue to hold their eligible shares of ARCA common stock until market open on the ex<span class="nobreak">-dividend</span> date will be entitled to payment of the special cash dividend. The special cash dividend will be equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) is expected to exceed $5.0&#160;million. ARCA currently estimates that the aggregate amount of cash to be distributed to stockholders of record as of the record date of the special cash dividend will be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, concurrently with the execution and delivery of the Merger Agreement, Oruka entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with certain investors to purchase shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), referred to herein as the &#8220;Oruka pre<span class="nobreak">-closing</span>&#160;financing,&#8221; immediately prior to the closing of the Merger. The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants that are issued in the Oruka pre<span class="nobreak">-closing</span>&#160;financing will be converted into the right to receive a number of shares of ARCA common stock and warrants to purchase shares of ARCA common stock, respectively, equal to the exchange ratio described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page&#160;134 of the accompanying proxy statement/prospectus. ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing have also agreed to enter into a registration rights agreement (the &#8220;registration rights agreement&#8221;) at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415 under the Securities Act (&#8220;Rule&#160;415&#8221;). The Oruka pre<span class="nobreak">-closing</span> financing is more fully described in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Registration Rights Agreement</span>&#8221; beginning on page 151 and 153, respectively, of the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, based solely on the estimated exchange ratio as described in the accompanying proxy statement/prospectus, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), and former holders of Oruka securities (including those issued in the Oruka pre<span class="nobreak">-closing</span> financing) are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 134 of the accompanying proxy statement/prospectus, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is less than $5.0&#160;million. ARCA currently estimates that its net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;margin-top:8pt;">Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application for the combined company with Nasdaq. After completion of the Merger, ARCA will be renamed &#8220;Oruka Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;ORKA.&#8221; On May &#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the last&#160;trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of ARCA common stock was $<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> per share.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA stockholders are cordially invited to attend the special meeting in lieu of the annual meeting of ARCA stockholders. ARCA is holding its special meeting in lieu of the annual meeting of stockholders (the &#8220;ARCA special meeting&#8221;) on<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, at&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Mountain Time, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the Merger and related matters. At the ARCA special meeting, ARCA will ask its stockholders to:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal&#160;No. 1&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000<span class="nobreak"> </span>shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to the accompanying proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal&#160;No. 2&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal&#160;No. 3&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span> (the &#8220;Officer Exculpation Proposal&#8221; or &#8220;Proposal&#160;No. 4&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal&#160;No. 5&#8221;), provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal&#160;No. 6&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal&#160;No. 7&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal&#160;No. 8&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger (the &#8220;the Merger Compensation Proposal&#8221; or &#8220;Proposal&#160;No. 9&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal&#160;No. 10&#8221;); and</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in the accompanying proxy statement/prospectus, certain ARCA stockholders who in the aggregate owned approximately 28.5% of the outstanding shares of ARCA capital stock as of May<span class="nobreak"> </span>3, 2024, and certain Oruka stockholders who in the aggregate owned approximately 90% of the outstanding shares of Oruka capital stock as of May&#160;3, 2024, are parties to stockholder support agreements with ARCA and Oruka, respectively, whereby such stockholders have agreed to vote in favor of the adoption of the Merger Agreement and the approval of the Merger and related transactions contemplated by the Merger Agreement, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form&#160;S<span class="nobreak">-4</span> of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement, Oruka stockholders holding a sufficient number of shares of Oruka capital stock to adopt the Merger Agreement and approve the Merger and related transactions will be asked to execute written consents providing for such adoption and approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After careful consideration, each of ARCA&#8217;s and Oruka&#8217;s boards of directors have approved the Merger Agreement and have determined that it is advisable to consummate the Merger. ARCA&#8217;s board of directors has approved the proposals described in the accompanying proxy statement/prospectus and recommends that its stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the proposals described in the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">More information about ARCA, Oruka, the Merger Agreement and transactions contemplated thereby and the foregoing proposals is contained in the accompanying proxy statement/prospectus. ARCA urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE 15 OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are excited about the opportunities the Merger brings to ARCA&#8217;s and Oruka&#8217;s stockholders and thank you for your consideration and continued support.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">President and Chief Operating Officer</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Chief Executive Officer</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ARCA biopharma, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oruka Therapeutics, Inc.</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy&#160;statement/prospectus. Any representation to the contrary is a criminal offense.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The accompanying proxy statement/prospectus is dated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, and is first being mailed to ARCA&#8217;s stockholders on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS IN LIEU OF ANNUAL MEETING OF STOCKHOLDERS</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the stockholders of ARCA biopharma, Inc.:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTICE IS HEREBY GIVEN</span> that a special meeting in lieu of annual meeting of stockholders (the &#8220;ARCA special meeting&#8221;) will be held on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.m. Mountain Time, unless postponed or adjourned to a later date. The ARCA special meeting will be held in person at the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The ARCA special meeting will be held for the following purposes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized from 100,000,000 to issue to&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to the accompanying proxy statement/prospectus;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I </span>to the accompanying proxy statement/prospectus;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These proposals are collectively referred to as the &#8220;Proposals.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has fixed<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 as the record date (the &#8220;Record Date&#8221;) for the determination of stockholders entitled to notice of, and to vote at, the ARCA special meeting and any adjournment or postponement thereof. Only holders of record of shares of ARCA common stock at the close of business on the Record Date are entitled to notice of, and to vote at, the ARCA special meeting. At the close of business on the Record Date, ARCA had&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of common stock outstanding and entitled to vote.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Your vote is important. The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">1, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">6, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">7, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">8, Proposal&#160;No. 9 and Proposal&#160;No. 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;No. 2 and Proposal&#160;No. 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">5, the director is elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">All stockholders are cordially invited to attend the special meeting in person. Even if you plan to attend the ARCA special meeting, ARCA requests that you sign and return the enclosed proxy or vote by mail or online to ensure that your shares will be represented at the ARCA special meeting if you are unable to attend. You may change or revoke your proxy at any time before it is voted at the ARCA special meeting.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;S BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS OF, AND ADVISABLE TO ARCA AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL.&#160;ARCA&#8217;S BOARD OF DIRECTORS RECOMMENDS THAT ARCA STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#8217; Meeting to Be Held on<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 at&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Mountain Time</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The proxy statement/prospectus and annual report to stockholders are available at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">By Order of ARCA&#8217;s Board of Directors,</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Thomas A.&#160;Keuer</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">President and Chief Operating Officer</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">EXPLANATORY NOTE</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The issuances of (i)&#160;all shares of ARCA common stock in exchange for each share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing), (ii)&#160;all shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, and (iii)&#160;all shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for each share of Oruka preferred stock, are intended to be covered by this registration statement on Form&#160;S<span class="nobreak">-4</span> of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of ARCA common stock that will be issued in exchange for each share of Oruka common stock issued in the pre<span class="nobreak">-closing</span> financing, the shares of ARCA common stock that will be issued in exchange for each other share of Oruka common stock, the shares of ARCA common stock that will be issuable upon the exercise of pre<span class="nobreak">-funded</span> warrants that will be issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the pre<span class="nobreak">-closing</span> financing and the shares of ARCA common stock that will be issuable upon conversion of ARCA Series&#160;B Preferred Stock that will be issued in exchange for each share of Oruka preferred stock.</p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">REFERENCES TO ADDITIONAL INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying proxy statement/prospectus incorporates important business and financial information about ARCA biopharma, Inc. that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission (&#8220;SEC&#8221;) website (<span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>) or upon your written or oral request by contacting 10170 Church Ranch Way, Suite 100, Westminster, Colorado, Attention: Corporate Secretary, or by calling (720)&#160;940<span class="nobreak">-2100</span>. ARCA also maintains a website at <span class="Italic" style="font-style:italic;font-weight:normal;">https://arcabio.com/</span>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.&#160;However, the information contained in or accessible through ARCA&#8217;s website is not part of the accompanying proxy statement/prospectus or the registration statement of which the accompanying proxy statement/prospectus forms a part.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">To ensure timely delivery of these documents, any request should be made no later than<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 to receive them before the ARCA special meeting.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For additional details about where you can find information about ARCA, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 317 of the accompanying proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="TOC001"></a><p class="H1_TOC" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">TABLE OF CONTENTS</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;font-variant:normal;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T27"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">QUESTIONS AND ANSWERS ABOUT THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">iii</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T26"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROSPECTUS SUMMARY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T25"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MARKET PRICE AND DIVIDEND INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">14</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T24"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">RISK FACTORS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">15</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T23"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">88</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T22"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE SPECIAL MEETING IN LIEU OF ANNUAL MEETING OF ARCA STOCKHOLDERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">91</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T991188"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">96</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T21"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE MERGER AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">133</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T20"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">AGREEMENTS RELATED TO THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">151</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T19"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">154</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T18"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ADDITIONAL INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">157</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T17"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA EXECUTIVE COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">164</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T16"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA EQUITY COMPENSATION PLAN INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">170</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T15"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA EXECUTIVE COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">171</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T14"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA DIRECTOR COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">173</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9980"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MATTERS BEING SUBMITTED TO A VOTE OF ARCA STOCKHOLDERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">174</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9981"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 1 &#8212; THE NASDAQ STOCK ISSUANCE PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">174</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9982"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 2 &#8212; THE AUTHORIZED SHARE INCREASE PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">176</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9983"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 3 &#8212; THE REVERSE STOCK SPLIT PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">178</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9984"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 4 &#8212; THE OFFICER EXCULPATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">185</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9985"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 5 &#8212; THE DIRECTOR ELECTION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">187</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9986"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 6 &#8212; THE AUDITOR RATIFICATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">188</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9992"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 7 &#8212; THE STOCK PLAN PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">189</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9993"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 8 &#8212; THE ESPP PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">192</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9994"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 9 &#8212; THE MERGER COMPENSATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">194</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9987"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 10 &#8212; THE ADJOURNMENT PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">195</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T13"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA&#8217;S BUSINESS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">196</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T12"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA&#8217;S BUSINESS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">212</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9988"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">248</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T11"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">259</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T10"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MANAGEMENT FOLLOWING THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">271</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9989"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">278</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">282</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9990"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">287</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T8"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">DESCRIPTION OF ARCA CAPITAL STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">294</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T7"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">COMPARISON OF RIGHTS OF HOLDERS OF ARCA CAPITAL STOCK AND ORUKA CAPITAL STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">299</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T6"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ARCA</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">309</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T5"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ORUKA</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">312</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T4"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">314</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T3"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">LEGAL MATTERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">316</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T2"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">EXPERTS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">316</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T1"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">WHERE YOU CAN FIND MORE INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">317</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9991"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR 2025 ANNUAL MEETING</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">318</span></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">i</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;font-variant:normal;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T111">INDEX TO FINANCIAL STATEMENTS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">F-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T100"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;A AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">A-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T101"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;B OPINION OF LUCID CAPITAL MARKETS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">B-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T102"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;C FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">C-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T103"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;D FORM OF ARCA STOCKHOLDER SUPPORT AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">D-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T104"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;E FORM OF LOCK-UP AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">E-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T105"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;F CERTIFICATE OF DESIGNATION OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">F-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T106"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;G CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT INCREASE&#160;IN AUTHORIZED SHARES*</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">G-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T107"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;H CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT REVERSE&#160;STOCK SPLIT*</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">H-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T108"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;I CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT DELAWARE&#160;LAW PROVISIONS REGARDING OFFICER EXCULPATION*</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">I-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T109"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;J Appraisal Rights (Section&#160;262 of the Delaware General Corporation&#160;Law)</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">J-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T110"><span class="CharOverride-2" style="font-variant:normal;text-transform:uppercase;">Annex&#160;K 2024 Oruka Therapeutics, Inc. Stock Incentive Plan*</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">K-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T112"><span class="CharOverride-2" style="font-variant:normal;text-transform:uppercase;">Annex&#160;L 2024 Oruka Therapeutics, Inc. Employee Stock Purchase Plan*</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">L-1</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To be filed by amendment.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">ii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T27"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">QUESTIONS AND ANSWERS ABOUT THE MERGER</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No.&#160;3 of this proxy statement/prospectus</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">All references to Oruka&#8217;s &#8220;product candidates,&#8221; &#8220;programs,&#8221; &#8220;portfolio&#8221; and &#8220;pipeline&#8221; in this proxy statement/prospectus refer to the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to those certain antibody discovery and option agreements, each dated March&#160;6, 2024 and subsequently amended and restated on March&#160;28, 2024, by and among Oruka, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Paruka Holding LLC (&#8220;Paruka&#8221;) (the &#8220;Paragon Option Agreements&#8221;).</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following section provides answers to frequently asked questions about the Merger. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross<span class="nobreak">-referenced</span> sections.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What is the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>On April&#160;3, 2024, ARCA, Oruka, First Merger Sub and Second Merger Sub entered into the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span>.&#160;The Merger Agreement contains the terms and conditions of the proposed Merger. Pursuant to the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger. Oruka will then merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. This entire transaction is referred to in this proxy statement/prospectus as the Merger. In connection with the Merger, ARCA will change its corporate name to &#8220;Oruka Therapeutics, Inc.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 134 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Each share of ARCA common stock that is issued and outstanding at the First Effective Time will remain issued and outstanding in accordance with its terms and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Immediately after the Merger, based solely on the estimated exchange ratio as described in this proxy statement/prospectus, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities (including those issued in the Oruka pre<span class="nobreak">-closing</span> financing) are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 134 of this proxy statement/prospectus, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is less than $5.0&#160;million. ARCA currently estimates that its net cash as of closing will be approximately $5.0<span class="nobreak"> </span>million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA&#8217;s board of directors expects to declare the special cash dividend to stockholders of record of outstanding shares of ARCA common stock as of the record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the First Effective Time. The ex<span class="nobreak">-dividend</span> date in respect of such special cash dividend </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">iii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">will be determined by Nasdaq. ARCA stockholders of record who continue to hold their eligible shares of ARCA common stock until market open on the ex<span class="nobreak">-dividend</span> date will be entitled to payment of the special cash dividend. The special cash dividend will be equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) is expected to exceed $5.0&#160;million. ARCA currently estimates that the aggregate amount of cash to be distributed to stockholders of record as of the record date for the special cash dividend will be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Why are the two companies proposing to merge?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA and Oruka believe that combining the two companies will result in a company with a promising pipeline, a strong leadership team and substantial capital resources, focused on developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. For a more complete description of the reasons for the Merger, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;ARCA&#8217;s Reasons for the Merger</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Oruka&#8217;s Reasons for the Merger</span>&#8221; beginning on pages 104 and 110, respectively, of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What will happen to ARCA if, for any reason, the merger with Oruka does not close?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA has invested significant time and incurred, and expects to continue to incur, significant expenses related to the proposed merger with Oruka. In the event the Merger does not close, ARCA will have a limited ability to continue its current operations without obtaining additional financing. Although ARCA&#8217;s board of directors may elect, among other things, to attempt to complete another strategic transaction if the merger with Oruka does not close, ARCA&#8217;s board of directors may instead divest all or a portion of ARCA&#8217;s business or take steps necessary to liquidate or dissolve ARCA&#8217;s business and assets if a viable alternative strategic transaction is not available. If ARCA decides to dissolve and liquidate its assets, ARCA would be required to pay all of its contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurance as to the amount of and the timing of such liquidation and distribution of available cash left to distribute to stockholders after paying the obligations of ARCA and setting aside funds for reserves.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Why am&#160;I receiving this proxy statement/prospectus?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>You are receiving this proxy statement/prospectus because you have been identified as a stockholder of ARCA as of the applicable Record Date, and you are entitled to vote to approve the matters set forth herein. This document serves as:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a proxy statement of ARCA used to solicit proxies for the ARCA special meeting to vote on the matters set forth herein; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a prospectus of ARCA used to offer (i)&#160;shares of ARCA common stock issued in exchange for shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing), (ii)&#160;shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, and (iii)&#160;shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What is the Oruka pre</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-closing</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> financing?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>On April&#160;3, 2024, concurrently with the execution and delivery of the Merger Agreement, Oruka entered into the Subscription Agreement with certain investors named therein, including, among others, Fairmount, Venrock Healthcare Capital Partners, RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi<span class="nobreak">-Asset</span> Investing, Avidity Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP and Redmile Group, pursuant to which such investors agreed to purchase shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). Shares of Oruka common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants issued pursuant to this financing transaction will be converted into shares of ARCA common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants to acquire shares ARCA common stock, in accordance with the exchange ratio and the Merger Agreement.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">iv</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Immediately after the First Merger, the shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants issued in the Oruka pre<span class="nobreak">-closing</span> financing are expected to represent approximately 58.2% of the outstanding shares of common stock of the combined company, on a fully<span class="nobreak">-diluted</span> basis. ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing have also agreed to enter into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415. The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">For a more complete description of the Oruka pre<span class="nobreak">-closing</span> financing, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Registration Rights Agreement</span>&#8221; beginning on pages&#160;151 and 153 of this proxy statement/prospectus, respectively.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What proposals will be voted on at the ARCA special meeting in connection with the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Pursuant to the terms of the Merger Agreement, the following proposals must be approved by the requisite stockholder vote at the ARCA special meeting in order for the Merger to close:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 1 &#8212;&#160;The Nasdaq Stock Issuance Proposal</span> to approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 2 &#8212;&#160;Authorized Share Increase Proposal</span> to approve an amendment to the ARCA Charter to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Additionally, Proposal&#160;No. 2 must be approved to have an adequate number of authorized but unissued shares of ARCA common stock to complete the Merger; and</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 3 &#8212;&#160;Reverse Stock Split Proposal</span> to approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to 1:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, inclusive, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors, the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">In addition to the requirement of obtaining ARCA stockholder approval of Proposal&#160;No. 1 and Proposal&#160;No.<span class="nobreak"> </span>2, the closing of the Merger is subject to the satisfaction or waiver of each of the other closing conditions set forth in the Merger Agreement. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger</span>&#8221; beginning on page 146 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The presence, by attending in person or being represented by proxy, at the ARCA special meeting of the holders of at least one<span class="nobreak">-third</span> of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting for the Proposals.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">v</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What proposals are to be voted on at the ARCA special meeting, other than the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal and the Authorized Share Increase Proposal?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>At the ARCA special meeting, the holders of ARCA common stock will also be asked to consider the following proposal:</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;4 &#8212;&#160;The Officer Exculpation Proposal</span> to approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span>;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;5 &#8212;&#160;The Director Election Proposal</span> to elect one (1)&#160;Class&#160;III director nominee named in the accompany proxy statement/prospectus to ARCA&#8217;s board of directors, to serve until ARCA&#8217;s 2027 annual meeting of stockholders or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;6 &#8212;&#160;The Auditor Ratification Proposal</span> to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;7 &#8212;&#160;The Stock Plan Proposal</span> to approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;8 &#8212;&#160;The ESPP Proposal</span> to approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;9 &#8212;&#160;The Merger Compensation Proposal</span> to approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger; and</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;10 &#8212;&#160;The Adjournment Proposal</span> to approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The approval of Proposal&#160;Nos.<span class="nobreak"> </span>3,<span class="nobreak"> </span>4,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10 are not a condition to the Merger. ARCA does not expect that any matter other than the Proposals will be brought before the ARCA special meeting.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The presence, by attending in person or being represented by proxy, at the ARCA special meeting of the holders of at least one<span class="nobreak">-third</span> of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting for the purpose of approving the Proposals.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What stockholder votes are required to approve the Proposals at the ARCA special meeting?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos. 2 and 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.&#160;5, directors are elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.<span class="nobreak"> </span>1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What will Oruka stockholders, participants in Oruka&#8217;s 2024 Equity Incentive Plan, option holders and warrant holders receive in the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Oruka stockholders will receive shares of ARCA common stock. ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan, as amended, along with issued and outstanding awards under such plan. Outstanding and unexercised options to purchase shares of Oruka common stock immediately prior to the First Effective Time will be converted into options to purchase shares of ARCA&#8217;s common stock, with necessary adjustments being made to the number of shares and exercise price underlying such options in order to reflect the economic equivalent of the prior equity award in light of the exchange ratio. Oruka warrant holders&#8217; outstanding and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">vi</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">unexercised warrants to purchase shares of Oruka common stock immediately prior to the First Effective Time will be assumed by ARCA and each outstanding and unexercised warrant will be converted into a warrant to purchase shares of ARCA&#8217;s common stock, with necessary adjustments to the number of shares and exercise price to reflect the exchange ratio. Applying the exchange ratio, the former Oruka securityholders immediately before the Merger are expected to own approximately 97.61% of the aggregate number of shares of the combined company&#8217;s capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), and ARCA securityholders immediately before the Merger are expected to own approximately 2.39% of the aggregate number of shares of the combined company capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash less than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">For a more complete description of the treatment of Oruka common stock, Oruka&#8217;s 2024 Equity Incentive Plan, Oruka options and Oruka warrants in the Merger, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Merger Consideration</span>&#8221;<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>and<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>&#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on pages 133 and 134, respectively, of this proxy statement/prospectus. For a description of the effect of the Oruka pre<span class="nobreak">-closing</span> financing on ARCA&#8217;s and Oruka&#8217;s current securityholders, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; beginning on page 151 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Will the common stock of the combined company trade on an exchange?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application for the common stock of the combined company with Nasdaq. After completion of the Merger, ARCA will be renamed &#8220;Oruka Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;ORKA.&#8221; On May&#160;&#160;&#160;&#160;, 2024, the last&#160;trading day before the date of this proxy statement/prospectus, the closing sale price of ARCA common stock was $&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> per share.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who will be the directors of the combined company immediately following the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Immediately following the Merger, the combined company&#8217;s board of directors will be composed of six members, all of whom will have been designated by Oruka.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">Effective as of the First Effective Time, ARCA&#8217;s board of directors will appoint the following Oruka designees: Lawrence Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle, to the board of directors of the combined company and concurrently therewith all of ARCA&#8217;s current directors will resign from their positions as directors of ARCA&#8217;s board of directors effective as of the First Effective Time. Dr.&#160;Kulkarni is expected to be appointed as Chair of the board of directors of the combined company.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The staggered structure of three classes of directors of ARCA&#8217;s board of directors will remain in place for the combined company following the completion of the Merger. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>&#8221; for additional information.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who will be the executive officers of the combined company immediately following the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Immediately following the Merger, the executive management team of the combined company is expected to consist of the following members of the Oruka executive management team:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Title</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">vii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>As an ARCA stockholder, how does ARCA&#8217;s board of directors recommend that&#160;I vote?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA&#8217;s board of directors, in consultation with financial and legal advisors and management, evaluated the terms of the Merger Agreement and the related transactions contemplated thereby and: (i)&#160;determined that the Merger and the related transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of ARCA and its stockholders; (ii)&#160;approved and declared advisable the Merger Agreement and the related transactions contemplated by the Merger Agreement and the Subscription Agreement, including the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in connection with the Merger and the Oruka pre<span class="nobreak">-closing</span> financing, respectively; and (iii)&#160;recommends that ARCA&#8217;s stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; each of the Proposals.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What risks should&#160;I consider in deciding whether to vote in favor of the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>You should carefully review the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus and the documents incorporated by reference herein, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the combined company&#8217;s business will be subject, and risks and uncertainties to which each of ARCA and Oruka, as independent companies, are subject.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>When do you expect the Merger to be consummated?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The Merger is anticipated to close in the third quarter of 2024, but the exact timing cannot be predicted. For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger</span>&#8221; beginning on page 146 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What do&#160;I need to do now?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA urges you to read this proxy statement/prospectus carefully, including the annexes and the documents incorporated by reference, and to consider how the Merger affects you.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder of Record: Shares Registered in Your Name</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If you are a stockholder of record, you may vote in person at the ARCA special meeting, vote by proxy over the telephone, vote by proxy through the Internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person even if you have already voted by proxy.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote in person, come to the special meeting and we will give you a ballot when you arrive.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote over the telephone, dial toll<span class="nobreak">-free</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;using a touch<span class="nobreak">-tone</span> phone and follow the recorded instructions. You will be asked to provide the company number and control number found on the Notice. Your vote must be received by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mountain Time on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 to be counted.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote through the Internet, go to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to complete an electronic proxy card. You will be asked to provide the company number and control number from the Notice. Your vote must be received by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mountain Time on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 to be counted.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Beneficial Owner: Shares Registered in the Name of Broker or Bank</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a Notice containing voting instructions from that organization rather than from ARCA.&#160;Simply follow the voting instructions in the Notice to ensure that your vote is counted. You may vote by telephone or over the Internet as instructed by your broker or bank. To vote in person at the ARCA special meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">viii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What if&#160;I return a proxy card or otherwise vote but do not make specific choices?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#8220;For&#8221; the Nasdaq Stock Issuance Proposal, &#8220;For&#8221; the Authorized Share Proposal, &#8220;For&#8221; the Reverse Stock Split Proposal, &#8220;For&#8221; the Officer Exculpation<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>Proposal, &#8220;For&#8221; the Director Election Proposal, &#8220;For&#8221; the Auditor Ratification Proposal, &#8220;For&#8221; the Stock Plan Proposal, &#8220;For&#8221; the ESPP Proposal, &#8220;For&#8221; the Merger Compensation Proposal, and &#8220;For&#8221; the Adjournment Proposal. If any other matter is properly presented at the meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What happens if&#160;I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are an ARCA stockholder, the failure to return your proxy card or otherwise vote or provide proxy instructions will reduce the aggregate number of votes required to approve Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8,<span class="nobreak"> </span>9, and 10.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If my ARCA shares are held in &#8220;street name&#8221; by my broker and&#160;I do not provide my broker or bank with voting instructions, what happens?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion or your shares may constitute &#8220;broker non<span class="nobreak">-votes</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If an ARCA stockholder does not return voting instructions to their broker on how to vote their shares of ARCA common stock, such broker may be prevented from voting, or may otherwise choose not to vote, such shares held by such broker, resulting in broker non<span class="nobreak">-votes</span> with respect to such shares. To make sure that your vote is counted, you should instruct your broker to vote your shares of ARCA common stock, following the procedures provided by your broker.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are broker non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-votes</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> and do they count for determining a quorum?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Generally, a &#8220;broker non<span class="nobreak">-vote</span>&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s)&#160;with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote on the matter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Broker non<span class="nobreak">-votes</span>, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect as votes &#8220;AGAINST&#8221; Proposal&#160;No. 4.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>May&#160;I revoke and/or change my vote after&#160;I have submitted a proxy or provided proxy instructions?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA stockholders of record, unless such stockholder&#8217;s vote is subject to a support agreement, may revoke and/or change their vote at any time before their proxy is voted at the ARCA special meeting in one of four ways:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may submit another properly completed proxy with a later date by mail or via the internet.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can provide your proxy instructions via telephone at a later date.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may send a notice that you are revoking your proxy over the internet, following the instructions provided on your proxy card.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may attend the ARCA special meeting in person and vote during the meeting. Simply attending the ARCA special meeting will not, by itself, revoke your proxy and/or change your vote.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the Merger to U.S.&#160;holders of Oruka common stock and Oruka preferred stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) for U.S.&#160;federal income tax purposes. It is not a condition to Oruka&#8217;s obligation or ARCA&#8217;s obligation to complete the Merger that the Merger so qualifies, however. </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">ix</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">Assuming that the Merger so qualifies, a U.S.&#160;holder of Oruka stock (as defined in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 125) will generally not recognize any gain or loss for U.S.&#160;federal income tax purposes on the receipt of ARCA stock (as defined in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 125) in the Merger. For a more complete discussion of the material U.S.&#160;federal income tax consequences of the Merger, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 125.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the reverse stock split to holders of ARCA common stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The reverse stock split is intended to be treated as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code for U.S.&#160;federal income tax purposes. Assuming it so qualifies, a U.S.&#160;holder of ARCA common stock should not recognize gain or loss for U.S.&#160;federal income tax purposes upon the reverse stock split, except with respect to cash received in lieu of a fractional share of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Please review the information in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Proposal&#160;No. 3 &#8212;&#160;The Reverse Stock Split Proposal&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Reverse Stock Split</span>&#8221; beginning on page&#160;182 of this proxy statement/prospectus for a more complete description of the material U.S.&#160;federal income tax consequences of the reverse stock split to a U.S.&#160;holder of ARCA common stock.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the special cash dividend that ARCA will declare and pay to holders of ARCA common stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The U.S.&#160;federal income tax consequences of a holder&#8217;s receipt of the special cash dividend generally should be treated first as a dividend to the extent of ARCA&#8217;s current and accumulated earnings and profits, then as a non<span class="nobreak">-taxable</span> return of capital to the extent of the holder&#8217;s basis in ARCA common stock, and then as capital gain from the sale or exchange of ARCA common stock with respect to any remaining amount. ARCA currently has an accumulated deficit and expects additional losses in the current period. Thus, ARCA expects most or all of the distribution of the special cash dividend to be treated as other than a dividend for U.S.&#160;federal income tax purposes. However, there can be no assurance that it will be so treated. Please review the information in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Considerations &#8212; Material U.S.&#160;Federal Income Tax Consequences of the Special Cash Dividend to Holders of ARCA Common Stock</span>&#8221; beginning on page 127 of this proxy statement/prospectus for a discussion of the material U.S.&#160;federal income tax consequences of the special cash dividend to holders of ARCA common stock.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who can help answer my questions?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are an ARCA stockholder and would like additional copies of this proxy statement/prospectus without charge or if you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact:</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">x</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<a id="T26"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROSPECTUS SUMMARY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the ARCA special meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/prospectus, and the documents incorporated by reference therein. For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 317 of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No.<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>3 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Companies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is a biotechnology company dedicated to applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka&#8217;s mission is to offer patients suffering from chronic skin diseases like psoriasis (&#8220;PsO&#8221;) the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a proprietary portfolio of antibodies that were engineered by Paragon and target the core mechanisms underlying PsO and other dermatologic and inflammatory diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (IL<span class="nobreak">-23p19</span>) for the treatment of PsO.&#160;Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> for the treatment of PsO, psoriatic arthritis (&#8220;PsA&#8221;), and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large inflammatory and immunology (&#8220;I&amp;I&#8221;) markets with continued unmet need.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s principal executive offices are located at 221 Crescent Street, Building<span class="nobreak"> </span>23, Suite 105, Waltham, MA&#160;02453, and its telephone number is (650)&#160;606<span class="nobreak">-7910</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">First Merger Sub</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">First Merger Sub is a direct, wholly owned subsidiary of ARCA and was formed solely for the purpose of carrying out the Merger. First Merger Sub&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Second Merger Sub</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Second Merger Sub is a direct, wholly owned subsidiary of ARCA and was formed solely for the purpose of carrying out the Merger. Second Merger Sub&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Merger</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 96)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the satisfaction or waiver of the conditions to closing set forth in the Merger Agreement, at the closing of the Merger, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Reasons for the Merger</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (see page 104)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The financial condition and prospects of ARCA and the risks associated with continuing to operate ARCA on a stand<span class="nobreak">-alone</span> basis as well as the risks of accomplishing those objectives;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that, after a thorough review of strategic alternatives, including further advancing the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with ARCA&#8217;s senior management, financial advisors and legal counsel, the Merger is more favorable to ARCA stockholders than the potential value that might have resulted from other strategic alternatives available to ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that the $6.0&#160;million enterprise value ascribed to ARCA would provide the existing ARCA stockholders significant value for ARCA&#8217;s public listing and afford the ARCA stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view, following a review with ARCA&#8217;s management and advisors of Oruka&#8217;s current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the Merger to fund development of Oruka&#8217;s product candidates through upcoming value inflection points, including Oruka&#8217;s ongoing IND<span class="nobreak">-enabling</span> preclinical development work and its anticipated initiation of its Phase&#160;1 trials of ORKA<span class="nobreak">-001</span> in the first half of 2025 and Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Reasons for the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 110)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of reaching its decision to approve the Merger and the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, Oruka&#8217;s board of directors held numerous meetings, consulted with Oruka&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, Oruka&#8217;s board of directors concluded that a merger with ARCA, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, was the best option to generate capital resources to support the advancement of Oruka&#8217;s pipeline and fund the combined organization.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional factors Oruka&#8217;s board of directors considered included the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Oruka&#8217;s pipeline, compared to the capital and investors Oruka could otherwise gain access to if it continued to operate as a privately<span class="nobreak">-held</span> company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential benefits from increased public market awareness of Oruka and its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical and current information concerning Oruka&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, were reasonably likely to create greater value for Oruka stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Oruka board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, would be a higher probability and more cost<span class="nobreak">-effective</span> means to access capital than other options considered, including an initial public offering (&#8220;IPO&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected financial position, operations, management structure and operating plans of the combined company (including the ability to support the combined company&#8217;s current and planned preclinical and clinical trials);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the business, history, operations, financial resources, assets, technology and credibility of ARCA; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger, the Oruka pre<span class="nobreak">-closing</span> financing, and the other transactions contemplated by the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that the Merger or Oruka pre<span class="nobreak">-closing</span> financing might not be completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>there is no adjustment to the exchange ratio if ARCA&#8217;s net cash as of closing is above $5.0&#160;million, and thus Oruka stockholders are expected to own at least approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis) following the completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential effect of the $440,000 termination fee payable by Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential reduction of ARCA&#8217;s net cash to an amount below $5.0&#160;million prior to the closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that ARCA could consider certain unsolicited acquisition proposals;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs, time and effort involved in connection with completing the Merger, related disruptions or potential disruptions to Oruka&#8217;s business and related administrative challenges associated with combining the companies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the additional expenses and obligations to which Oruka&#8217;s business will be subject following the Merger as a public company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recommendation of ARCA&#8217;s Board of Directors </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 92)</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement, and the change of control of ARCA resulting from the Merger, is fair to, in the best interests of, and advisable to, ARCA and its stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the increase in authorized shares. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the reverse stock split, if necessary. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Reverse Stock Split Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the amendment to the ARCA Charter to provide for the exculpation of officers, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Officer Exculpation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to elect Jacob Ma<span class="nobreak">-Weaver</span> to serve on the ARCAs board of directors in the class of directors with terms expiring at ARCA&#8217;s 2027 annual meeting of stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the director nominee named in the Director Election Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December<span class="nobreak">&#160;</span>31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Auditor Ratification Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes it that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Stock Incentive Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that adjourning the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, ARCA and its stockholders and has approved and adopted the proposal. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of ARCA&#8217;s Directors and Executive Officers in the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 119)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of ARCA&#8217;s board of directors with respect to issuing shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in the Merger and the other matters to be acted upon by the ARCA stockholders at the ARCA special meeting, the ARCA stockholders should be aware that ARCA&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of ARCA stockholders generally. These interests may present ARCA&#8217;s directors and executive officers with actual or potential conflicts of interest. These interests include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>in connection with the Merger, each option to purchase shares of ARCA common stock held by ARCA&#8217;s executive officers and directors will accelerate and fully vest, and (i)&#160;each such option with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain of ARCA&#8217;s executive officers will be eligible to receive retention bonuses and severance payments in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain of ARCA&#8217;s directors will be eligible to receive special committee fees in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million, and any of ARCA&#8217;s directors and executive officers that are also ARCA stockholders will share in any such cash dividend proportionally to their pre<span class="nobreak">-First</span> Merger ownership of ARCA common stock (see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>&#8221; beginning on page 309 of this proxy statement/prospectus for additional information regarding ARCA&#8217;s directors&#8217; and officers&#8217; holdings of ARCA common stock; notably, Jacob Ma<span class="nobreak">-Weaver</span> and affiliated entities together hold 4,000,452<span class="nobreak"> </span>shares of ARCA common stock, representing over 27% of outstanding shares of ARCA common stock); and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>under the Merger Agreement, ARCA&#8217;s directors and executive officers are entitled to continued indemnification, expense advancement and insurance coverage.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the ARCA stockholders approve the proposals to be presented to the ARCA stockholders for consideration at the ARCA special meeting as contemplated by this proxy statement/prospectus. As of<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the directors and executive officers of ARCA owned or controlled&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>% of the outstanding shares of ARCA common stock entitled to vote at the ARCA special meeting.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of Oruka&#8217;s Directors and Executive Officers in the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 122)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of Oruka&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that Oruka&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Oruka stockholders generally. These interests may present them with actual or potential conflicts of interest. These interests include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>as of May<span class="nobreak">&#160;</span>13, 2024, Oruka&#8217;s current non<span class="nobreak">-employee</span> directors and executive officers beneficially owned, in the aggregate, approximately 73.5% of the shares of Oruka capital stock, which for purposes of this subsection excludes any Oruka shares issuable upon exercise or settlement of Oruka options held by such individual;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Fairmount Healthcare Fund&#160;II L.P. (&#8220;Fairmount Fund&#160;II&#8221;), an affiliate of Peter Harwin, an Oruka director, currently holds shares of Oruka capital stock and an unsecured convertible promissory note with an initial principal amount of $25.0&#160;million at an interest rate of 12% per annum (the &#8220;Convertible Note&#8221;) of Oruka and has agreed to purchase shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>in connection with the Merger, each option to purchase shares of Oruka common stock held by Oruka&#8217;s executive officers and directors, whether or not vested, will be converted into an option to purchase shares of the combined company&#8217;s common stock, on the same terms and conditions (including any vesting and acceleration provisions);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s directors and executive officers are expected to become directors and executive officers of the combined company upon completion of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Oruka stockholders approve the Merger as contemplated by this proxy statement/prospectus. As of May&#160;13, 2024, the directors and executive officers of Oruka owned or controlled 73.5% of the outstanding shares of Oruka capital stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion of Lucid Capital Markets to the ARCA Board</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 112)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;2, 2024, Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) orally rendered its opinion to ARCA&#8217;s board of directors (which was subsequently confirmed in writing by delivery of Lucid&#8217;s written opinion addressed to ARCA&#8217;s board of directors dated April&#160;2, 2024), that, as of such date and based upon and subject to the various assumptions and limitations made, and such other factors Lucid deemed relevant upon the review undertaken by Lucid in preparing its opinion, the exchange ratio proposed to be paid by ARCA pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to the holders of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The full text of the written opinion of Lucid, dated April&#160;2, 2024, which describes the assumptions made and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;B</span> to this proxy statement/prospectus and is incorporated herein by reference. <span class="Bold" style="font-style:normal;font-weight:bold;">Lucid&#8217;s financial advisory services and opinion were provided for the information and assistance of ARCA&#8217;s board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of ARCA&#8217;s board of directors&#8217; consideration of the Merger and the opinion of Lucid addressed only the fairness, from a financial point of view, as of the date thereof, to the holders of ARCA common stock of the exchange ratio proposed to be paid by ARCA pursuant to the terms of the Merger Agreement. The opinion of Lucid did not address any other term or aspect of the Merger Agreement or the Merger and does not constitute a recommendation to any stockholder of ARCA or Oruka as to whether or how such holder should vote with respect to the Merger or otherwise act with respect to the Merger or any other matter.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The full text of the written opinion of Lucid should be read carefully in its entirety for a description of the assumptions made and qualifications and limitations upon the review undertaken by Lucid in preparing its opinion.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Merger Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 133)</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Consideration </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 133)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 134 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis). Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million. ARCA management currently anticipates that ARCA&#8217;s net cash as of closing to be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Options and Oruka&#8217;s 2024 Equity Incentive Plan</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 172)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan and each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka stock option assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka stock option assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka stock option assumed by ARCA, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka stock option assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of such Oruka stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka stock option assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka stock option will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each Oruka stock option shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, the combined company&#8217;s compensation committee will succeed to the authority and responsibility of Oruka&#8217;s board of directors as administrator of the Oruka 2024 Equity Incentive Plan.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Warrants</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 137)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each warrant to purchase shares of Oruka capital stock that is outstanding and unexercised immediately prior to the First Effective Time (including any pre<span class="nobreak">-funded</span> warrant issued pursuant to the Oruka pre<span class="nobreak">-closing</span>&#160;financing), whether or not vested, will be converted into a warrant to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka warrant assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka warrant assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka warrant assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka warrant assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka warrant will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each Oruka warrant shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA Common Stock and ARCA Options</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 138)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except as contemplated by the proposed increase in the number of authorized shares of ARCA common stock described in Proposal No. 2 of this proxy statement/prospectus and the proposed reverse stock split of issued and outstanding ARCA common stock described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA common stock will remain unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA common stock will be cancelled for no consideration.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Conditions to the Completion of the Merger</span> (see page 146)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To complete the Merger, ARCA stockholders must approve Proposal&#160;No. 1 and Proposal&#160;No. 2 and Oruka stockholders must adopt the Merger Agreement and approve the Merger and the related transactions contemplated by the Merger Agreement. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non</span><span class="nobreak"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">-Solicitation</span></span> (see page 142)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains&#160;non<span class="nobreak">-solicitation</span>&#160;provisions prohibiting ARCA and Oruka from soliciting a competing transaction. Each of ARCA and Oruka have agreed that, subject to certain exceptions, ARCA and Oruka and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize or permit any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>furnish any non<span class="nobreak">-public</span> information with respect to it to any person in connection with or in response to an acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>execute or enter into any letter of intent or any contract contemplating or otherwise relating to any acquisition transaction; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>publicly propose to do any of the foregoing.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Board Recommendation Change</span> (see page 144)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Neither Oruka&#8217;s board of directors nor ARCA&#8217;s board of directors may change its recommendation in favor of the Merger, except that prior to receipt by such party of its stockholder approval, such party&#8217;s board of directors may effect a change in recommendation as a result of a material development or change in circumstances (&#8220;Intervening Event&#8221;) or with respect to a superior offer that did not result from a material breach of the Merger Agreement if:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party&#8217;s board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to effect such change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party has provided at least four&#160;business days&#8217; prior written notice to the other party that it intends to effect a change in recommendation, and during such period has, and has caused its lead financial advisor and outside legal counsel to, negotiate with the other party in good faith to make such adjustments to the terms and conditions so that the acquisition proposal ceases to constitute a superior offer; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if after the other party shall have delivered to such party a written offer to alter the terms or conditions of the Merger Agreement during the four<span class="nobreak">-business</span>&#160;day period referred to above, such party&#8217;s board of directors shall have determined in good faith (based on the advice of its outside legal counsel), that the failure to effect a change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of any material amendment to any superior offer, the party considering the superior offer would be required to provide the other party with notice of such material amendment and there would be a new three<span class="nobreak">-business</span>&#160;day period following such notification during which the parties would be obligated to comply again with the requirements described above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of an Intervening Event, the party suffering such event shall promptly notify the other party before effecting a change in recommendation. The written notice is required to state the material facts and circumstances related to the applicable Intervening Event and that such party&#8217;s board of directors intends to make a change in recommendation.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 147)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Either ARCA or Oruka may terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fee </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 147)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $440,000 or Oruka could be required to pay ARCA a termination fee of $440,000.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Support Agreements </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 151)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain Oruka stockholders holding approximately 90% of the outstanding shares of Oruka capital stock have entered into support agreements with ARCA and Oruka to vote all of their shares of Oruka capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals (the &#8220;Oruka Support Agreements&#8221;). Certain ARCA stockholders holding approximately 28.5% of the outstanding shares of ARCA common stock have entered into support agreements with ARCA and Oruka to vote all of their shares of ARCA common stock in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal and against any alternative acquisition proposals (the &#8220;ARCA Support Agreements,&#8221; and, together with the Oruka Support Agreements, the &#8220;Support Agreements&#8221;).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lock-Up Agreements </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 151)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of Oruka&#8217;s executive officers, directors and stockholders have entered into&#160;lock<span class="nobreak">-up</span>&#160;agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of ARCA&#8217;s common stock or any securities convertible into or exercisable or exchangeable for ARCA common stock, currently or thereafter owned, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger, but excluding, as applicable, shares purchased in the Oruka pre<span class="nobreak">-closing</span>&#160;financing (including any shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing), until 180&#160;days following the closing of the Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Subscription Agreement and Registration Rights Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see pages 151 and 153)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately prior to the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka entered into the Subscription Agreement with Oruka, pursuant to which such investors have agreed to purchase Oruka common stock or, in lieu thereof, Oruka pre<span class="nobreak">-funded</span> warrants, representing an aggregate commitment of $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants that are issued in the Oruka pre<span class="nobreak">-closing</span> financing will be or will have the right to be, respectively, converted into shares of ARCA common stock in the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contains customary representations and warranties of Oruka and also contains customary representations and warranties of the purchaser parties thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement also contemplates ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing entering into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Management Following the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 271)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth the name, age as of May&#160;3, 2024 and position of each of the individuals who are expected to serve as executives and directors of the combined company following completion of the Merger:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Age</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">41</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">50</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">61</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">45</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chair and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">52</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">39</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">38</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 125)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code for U.S.&#160;federal income tax purposes. It is not a condition to Oruka&#8217;s obligation or ARCA&#8217;s obligation to complete the Merger that the Merger so qualifies, however. Assuming that the Merger so qualifies, a U.S.&#160;holder of Oruka stock (as defined in the section entitled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 125) will generally not recognize any gain or loss for U.S.&#160;federal income tax purposes on the receipt of ARCA stock in the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risk Factors </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 15)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Both ARCA and Oruka are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to the Merger</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Failure to complete, or delays in completing, the potential merger with Oruka could materially and adversely affect ARCA&#8217;s results of operations, business, financial results and/or common stock price.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The exchange ratio will not change or otherwise be adjusted based on the market price of ARCA common stock.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by ARCA stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Oruka stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If ARCA completes the Merger, the combined company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s expected disposal of its historical assets and operations in connection with its proposed Merger with Oruka will make it a shell company. As a result, ARCA will be subject to more stringent reporting requirements, offering limitations and resale restrictions.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Some of ARCA and Oruka directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA stockholders and Oruka stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to ARCA</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Failure to complete, or delays in completing, the proposed merger with Oruka could expose ARCA to other operational and financial risks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA has a limited operating history, no history of commercializing products, has not generated any product revenue, has incurred significant operating losses since inception and anticipates continuing to incur net losses for the foreseeable future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If ARCA does not successfully consummate the Merger or another strategic transaction, ARCA&#8217;s board of directors may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If the Merger is not consummated and should ARCA pursue additional clinical trials for its product candidates, it may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of its common stock, which could have a material adverse effect on its ability to consummate the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to Oruka</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Even if the Merger and Oruka pre<span class="nobreak">-closing</span> financing are successful, Oruka will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern. If Oruka is unable to raise such capital when needed, or on acceptable terms, Oruka may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts and/or file for bankruptcy or cease operations altogether;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka has never generated any revenue from product sales and may never be profitable;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is a preclinical stage biopharmaceutical company with a limited operating history on which to assess its business; it has not initiated, conducted or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Oruka or its current or future collaborators are unable to complete development of or commercialize Oruka&#8217;s product candidates, or experience significant delays in doing so, Oruka&#8217;s business will be materially harmed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is substantially dependent on the success of its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, and its anticipated clinical trials of such programs may not be successful;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka currently relies on licensing arrangements with Paragon through the Paragon Option Agreements. If Oruka is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Oruka&#8217;s business could be negatively impacted;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>In order to successfully implement Oruka&#8217;s plans and strategies, Oruka will need to grow the size of its organization and it may experience difficulties in managing this growth;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s ability to obtain and protect its patents and other proprietary rights is uncertain, exposing Oruka to the possible loss of competitive advantage; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The regulatory approval processes of the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) and other comparable foreign regulatory authorities are lengthy, time<span class="nobreak">-consuming</span> and inherently unpredictable. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to the Combined Company</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company may incur losses for the foreseeable future and might never achieve profitability;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by its stockholders to replace or remove its management;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>After completion of the Merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka pre<span class="nobreak">-closing</span> financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These risks and other risks are discussed in greater detail under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus. ARCA and Oruka both encourage you to read and consider all of these risks carefully.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 125)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nasdaq Stock Market Listing </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 129)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka intends to file an initial listing application for the combined company common stock with Nasdaq. If such application is accepted, it is anticipated that the common stock of the combined company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;ORKA.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anticipated Accounting Treatment </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 129)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is expected to be treated by ARCA as a reverse merger and will be accounted for as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as, at close, the transaction is, in essence, the issuance of equity for ARCA&#8217;s net asset, which primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. For accounting purposes, Oruka is considered to be acquiring the assets and liabilities of ARCA in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Oruka&#8217;s equity holders will own a substantial majority of the voting rights in the combined company; (ii)&#160;Oruka&#8217;s largest stockholder will retain the largest interest in the combined company; (iii)&#160;Oruka will designate all of the initial members of the board of directors of the combined company; and (iv)&#160;Oruka&#8217;s executive management team will become the management of the combined company. The combined company will be named Oruka Therapeutics, Inc. and be headquartered in&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Accordingly, the Merger is expected to be treated as the equivalent of Oruka issuing stock to acquire the net assets of ARCA.&#160;As a result of the Merger, the net assets of ARCA will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Oruka. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in-capital</span>. See the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 130)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Holders of ARCA common stock are not entitled to appraisal rights in connection with the Merger under Delaware law. Holders of Oruka capital stock are entitled to appraisal rights in connection with the Merger under Delaware law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Comparison of Stockholder Rights </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 299)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Both ARCA and Oruka are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the Delaware General Corporation Law (&#8220;DGCL&#8221;). If the Merger is completed, Oruka stockholders will become ARCA stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of ARCA (the &#8220;ARCA Bylaws&#8221;) and the ARCA Charter, as may be further amended by Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 if approved by the ARCA stockholders at the ARCA special meeting. The rights of ARCA stockholders contained in the ARCA Charter and ARCA Bylaws differ from the rights of Oruka stockholders under the amended and restated certificate of incorporation of Oruka (the &#8220;Oruka Charter&#8221;) and bylaws of Oruka (the &#8220;Oruka Bylaws&#8221;), as more fully described under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Comparison of Rights of Holders of ARCA Capital Stock and Oruka Capital Stock</span>&#8221; beginning on page 299 of this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T25"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MARKET PRICE AND DIVIDEND INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The closing price of the ARCA common stock on April&#160;2, 2024, the last&#160;day of trading prior to the announcement of the Merger, as reported on The Nasdaq Capital Market, was $1.71 per share. The closing price of the ARCA common stock on<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, as reported on The Nasdaq Capital Market, was $&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the market price of the ARCA common stock is subject to fluctuation, the market value of the shares of the ARCA common stock that the Oruka stockholders will be entitled to receive in the Merger may increase or decrease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a private company, and its shares of common stock and preferred stock are not publicly traded.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming approval of Proposal&#160;Nos. 1 and 2 and successful application for initial listing with Nasdaq, following the consummation of the Merger, shares of ARCA common stock will trade on Nasdaq under ARCA&#8217;s new name, &#8220;Oruka Therapeutics, Inc.,&#8221; and new trading symbol &#8220;ORKA.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the Record Date for the ARCA special meeting, there were approximately&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>registered holders of record of the ARCA common stock. As of&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, Oruka had&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>holders of record of Oruka common stock and one holder of record of Oruka preferred stock. For detailed information regarding the beneficial ownership of certain ARCA and Oruka stockholders, see the sections of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of Oruka</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of the Combined Company</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Dividends</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never declared or paid any cash dividends on the ARCA common stock and does not anticipate paying cash dividends on the ARCA common stock for the foreseeable future, except the&#160;special&#160;cash&#160;dividend&#160;that ARCA will declare and pay to the holders of record of outstanding shares of ARCA common stock as of a record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the anticipated closing date of the First Merger. The aggregate amount of the special cash dividend shall be up to an amount equal to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as calculated pursuant to the terms and conditions of the Merger Agreement) will exceed $5,000,000. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Merger will be at the discretion of the combined organization&#8217;s then<span class="nobreak">-current</span> board of directors and will depend upon a number of factors, including the combined organization&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then<span class="nobreak">-current</span> board of directors deems relevant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has never paid or declared any cash dividends on Oruka capital stock. If the Merger does not occur, Oruka does not anticipate paying any cash dividends on the Oruka capital stock in the foreseeable future, and Oruka intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future determination to pay dividends will be at the discretion of the Oruka board of directors and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed by applicable laws and other factors the Oruka board of directors deems relevant.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T24"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">RISK FACTORS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained or incorporated by reference in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of ARCA common stock. You should also read and consider the other information in this proxy statement/prospectus. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 317 of this proxy statement/prospectus for further information.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Merger</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Failure to complete, or delays in completing, the potential merger with Oruka, announced on April&#160;3, 2024, could materially and adversely affect ARCA&#8217;s results of operations, business, financial results and/or common stock price.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA entered into the Merger Agreement with Oruka, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub, with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger.&#160;Consummation of the Merger is subject to certain closing conditions, a number of which are not within ARCA&#8217;s control. Any failure to satisfy these required conditions to closing may prevent, delay or otherwise materially adversely affect the completion of the transaction. ARCA cannot predict with certainty whether or when any of the required closing conditions will be satisfied or if another uncertainty may arise and cannot assure you that it will be able to successfully consummate the Merger as currently contemplated under the Merger Agreement or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, its business, which may materially adversely affect its results of operation and its business. Uncertainty as to whether the Merger will be completed in a timely manner or at all may affect ARCA&#8217;s ability to retain and motivate existing employees. Uncertainty as to whether the Merger will be completed in a timely manner or at all could adversely affect ARCA&#8217;s business and its relationship with collaborators, suppliers, vendors, regulators and other business partners. For example, vendors, collaborators and other counterparties may defer their decisions to work with ARCA or seek to change their existing business relationships with ARCA.&#160;Changes to, or termination of, existing business relationships could adversely affect ARCA&#8217;s results of operations and financial condition, as well as the market price of ARCA common stock. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transaction or termination of the Merger Agreement.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the conditions to the Merger are not satisfied or waived, the Merger may not occur.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if the Merger is approved by the stockholders of Oruka and ARCA, specified conditions must be satisfied or, to the extent permitted by applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and described further in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; of this proxy statement/prospectus. ARCA cannot assure you that all of the conditions to the consummation of the Merger will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or the closing may be delayed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The exchange ratio will not change or otherwise be adjusted based on the market price of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Applying the exchange ratio, the former Oruka securityholders immediately before the Merger are expected to own approximately 97.61% of the aggregate number of shares of the combined company&#8217;s capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), and ARCA securityholders immediately before the Merger are expected to own approximately 2.39% of the aggregate number of shares of the combined company capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">closing being equal to $5.0&#160;million. In the event ARCA&#8217;s net cash is below $5.0&#160;million, the exchange ratio will be adjusted such that the number of shares issued to Oruka&#8217;s pre<span class="nobreak">-closing</span> securityholders will be increased, and ARCA stockholders will own a smaller percentage of the combined company following the consummation of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any changes in the market price of ARCA&#8217;s stock before the completion of the First Merger will not affect the number of shares Oruka stockholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the First Merger, the market price of ARCA common stock increases from the market price on the date of the Merger Agreement, then Oruka stockholders could receive merger consideration with substantially more value for their shares of Oruka capital stock than the parties had negotiated when they established the exchange ratio. Similarly, if before the completion of the First Merger, the market price of ARCA common stock declines from the market price on the date of the Merger Agreement, then Oruka stockholders could receive merger consideration with substantially lower value. The Merger Agreement does not include a price<span class="nobreak">-based</span> termination right.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The issuance of ARCA common stock, including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by ARCA stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Oruka stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before the Merger can be completed, ARCA stockholders must approve, among other things, the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger, and Oruka stockholders must adopt the Merger Agreement and approve the Merger and the related transactions. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the Merger. Any delay in completing the Merger may materially adversely affect the timing and benefits that are expected to be achieved from the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, neither ARCA nor Oruka is obligated to complete the Merger if there is a material adverse effect affecting the other party between April&#160;3, 2024, the date of the Merger Agreement, and the closing of the Merger. However, certain types of causes are excluded from the concept of a &#8220;material adverse effect.&#8221; Such exclusions include, but are not limited to, changes in general economic or political conditions, industry<span class="nobreak">-wide</span> changes, changes resulting from the announcement of the Merger, natural disasters, pandemics, other public health events or force majeure events and changes in U.S.&#160;generally accepted accounting principles. Therefore, if any of these events were to occur and adversely affect ARCA or Oruka, the other party would still be obliged to consummate the closing of the Merger notwithstanding such material adverse effect. If any such adverse effects occur and ARCA consummates the closing of the Merger, the stock price of the combined company may suffer. This in turn may reduce the value of the Merger to the stockholders of ARCA, Oruka or both.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the Merger is not completed, ARCA&#8217;s stock price may decline significantly.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of ARCA common stock is subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of ARCA common stock will likely be volatile based on whether stockholders and other investors believe that ARCA can complete the Merger or otherwise raise additional capital to support ARCA&#8217;s operations if the Merger is not consummated and another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. The volatility of the market price of ARCA common stock has been and may be exacerbated by low trading volume. Additional factors that may cause the market price of ARCA common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the entry into, or termination of, key agreements, including commercial partner agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the loss of key employees;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>future sales of ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general and industry<span class="nobreak">-specific</span> economic conditions that may affect ARCA&#8217;s research and development expenditures; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span> fluctuations in financial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of ARCA common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA completes the Merger, the combined company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, Oruka entered into the Subscription Agreement with certain investors, including existing investors of Oruka, pursuant to which the investors agreed to purchase, in the aggregate, $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note) in shares of common stock and pre<span class="nobreak">-funded</span> warrants of Oruka immediately prior to the closing of the Merger, referred to as the Oruka pre<span class="nobreak">-closing</span> financing. The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions. The shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants issued in the Oruka pre<span class="nobreak">-closing</span> financing will result in dilution to all securityholders of the combined company (i.e., both ARCA&#8217;s pre<span class="nobreak">-Merger</span> securityholders and former Oruka securityholders). Furthermore, pursuant to the amended and restated offer letter agreement between Oruka and Lawrence Klein, Oruka is obligated to issue additional options to purchase shares of Oruka common stock in order to maintain Mr.&#160;Klein&#8217;s ownership in Oruka at approximately 5.0% on a fully<span class="nobreak">-diluted</span> basis (the &#8220;Target Ownership Percentage&#8221;) until Oruka has raised an aggregate of $200.0&#160;million (the &#8220;Covered Limit&#8221;). As a result, Oruka expects to issue Mr.&#160;Klein additional options of Oruka to maintain his ownership in Oruka at the Target Ownership Percentage concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing up to the Covered Limit. Such additional options granted will result in further dilution to all securityholders of the combined company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional financing may not be available to the combined company when it is needed or may not be available on favorable terms. To the extent that the combined company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the combined company, including ARCA&#8217;s pre<span class="nobreak">-Merger</span> securityholders and Oruka&#8217;s former securityholders. It is also possible that the terms of any new equity securities may have preferences over the combined company&#8217;s common stock. Any debt financing the combined company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the combined company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the combined company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the combined company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, as a result of ARCA&#8217;s assumption of the Paragon Option Agreements in connection with the Merger, the combined company will be subject to the obligation to grant to Paruka, on each of December&#160;31, 2024 and December&#160;31, 2025, warrants to purchase a number of shares equal to 1.00% of the outstanding shares of ARCA common stock as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. Such warrants granted will result in further dilution to all securityholders of the combined company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transfers of the combined company&#8217;s securities utilizing Rule&#160;144 of the Securities Act may be limited.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A significant portion of the combined company&#8217;s securities will be restricted from immediate resale. Holders should be aware that transfers of the combined company&#8217;s securities pursuant to Rule&#160;144 may be limited as Rule&#160;144 is not available, subject to certain exceptions, for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. ARCA&#8217;s expected disposal of its historical assets and operations in connection with the Merger with Oruka </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">will make it a shell company. ARCA anticipates that following the consummation of the Merger, the combined company will no longer be a shell company. As a result, ARCA anticipates that holders will not be able to sell their restricted combined company securities pursuant to Rule&#160;144 without registration until one year after ARCA files the Current Report on Form&#160;8<span class="nobreak">-K</span> following the closing that includes the required Form&#160;10 information that reflects that the combined company is no longer a shell company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s expected disposal of its historical assets and operations in connection with its proposed Merger with Oruka will make it a shell company. As a result, ARCA will be subject to more stringent reporting requirements, offering limitations and resale restrictions.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has two remaining ongoing development programs, and it will dispose of (or is in the process of disposing of) its legacy technology and intellectual property. As such, ARCA may become a shell company, and its Merger with Oruka would be subject to the requirements applicable to shell company business combinations, which are as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will need to file a Form&#160;8<span class="nobreak">-K</span> to report the Form&#160;10 type information after closing with the SEC reflecting its status as an entity that is not a shell company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA is not, and the combined company will not be, eligible to use a Form&#160;S<span class="nobreak">-3</span> until 12 full calendar&#160;months after closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will need to wait at least 60 calendar&#160;days after closing to file a Form&#160;S<span class="nobreak">-8</span> for any equity plans or awards;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will be an &#8220;ineligible issuer&#8221; for three&#160;years following the closing, which will prevent the combined company from (i)&#160;incorporating by reference in its Form&#160;S<span class="nobreak">-1</span> filings, (ii)&#160;using a free writing prospectus, or (iii)&#160;taking advantage of well<span class="nobreak">-known</span> seasoned issuer status despite its public float;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>investors who (i)&#160;are affiliates of Oruka at the time the Merger is submitted for the vote or consent of Oruka stockholders, (ii)&#160;receive securities of the combined company in the Merger (i.e., Rule&#160;145(c)&#160;securities) and (iii)&#160;publicly offer or sell such securities, will be deemed to be engaged in a distribution of such securities, and therefore to be underwriters with respect to resales of those securities, and accordingly such securities may not be included in the Form&#160;S<span class="nobreak">-1</span> resale shelf registration statement anticipated to be filed after the closing of the Merger unless such securities are sold only in a fixed price offering in which such investors are named as underwriters in the prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Rule&#160;144(i)(2)&#160;will limit the ability to publicly resell Rule&#160;145(c)&#160;securities per Rule&#160;145(d), as well as any other &#8220;restricted&#8221; or &#8220;control&#8221; securities of the combined company per Rule&#160;144 (i.e., holders of restricted securities and any affiliates of the public company are also affected) until one year after the Form&#160;10 information is filed with the SEC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing SEC requirements would increase the combined company&#8217;s time and cost of raising capital, offering stock under equity plans, and complying with securities laws. Further, such requirements will add burdensome restrictions on the resale of combined company shares by affiliates of Oruka and any holders of &#8220;restricted&#8221; or &#8220;control&#8221; securities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Some of ARCA&#8217;s and Oruka&#8217;s directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Directors and executive officers of ARCA and Oruka may have interests in the Merger that are different from, or in addition to, the interests of other ARCA stockholders generally. These interests with respect to ARCA&#8217;s directors and executive officers may include, among others, retention bonus payments, extension of exercisability periods of previously issued stock option grants, severance payments if employment is terminated in a qualifying termination in connection with the Merger and rights to continued indemnification, expense advancement and insurance coverage.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, certain current members of Oruka&#8217;s board of directors will continue as directors of the combined company after the effective time, and, following the closing of the Merger, will be eligible to be compensated as non<span class="nobreak">-employee</span> directors of the combined company pursuant to ARCA&#8217;s non<span class="nobreak">-employee</span> director compensation policy that is expected to remain in place following the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors was aware of and considered those interests, among other matters, in reaching their decisions to approve and adopt the Merger Agreement, approve the Merger, and recommend the approval of the Merger Agreement to ARCA and Oruka stockholders. These interests, among other factors, may have influenced the directors and executive officers of each company to support or approve the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA stockholders and Oruka stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Oruka common stock issued in the Oruka pre-closing financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, ARCA stockholders and Oruka stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA securityholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the completion of the Merger, ARCA&#8217;s current stockholders will generally own a smaller percentage of the combined company than their ownership of ARCA prior to the Merger. Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. The Chief Executive Officer of Oruka will serve as the Chief Executive Officer of the combined company following the completion of the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the Merger Agreement is in effect, each party is generally prohibited from, among other things, soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry. In addition, ARCA&#8217;s current directors and executive officers and certain significant stockholders have entered into support agreements pursuant to the terms of the Merger Agreement, and as an inducement to Oruka&#8217;s willingness to enter into the Merger Agreement, by which they have agreed to vote all of their shares of ARCA capital stock in favor of the Merger Agreement and the transactions contemplated thereby and against any competing proposals, subject to certain limited exceptions. These provisions could discourage a potential competing acquirer from considering or proposing an acquisition or merger, even if it were prepared to pay consideration with a higher value than that implied by the merger consideration in the combination.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Because the lack of a public market for Oruka common stock makes it difficult to evaluate the fair market value of its capital stock, the value of ARCA common stock to be issued to Oruka stockholders may be more or less than the fair market value of Oruka common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The outstanding capital stock of Oruka is privately held and is not traded on any public market. The lack of a public market makes it difficult to determine the fair market value of Oruka capital stock. Because the percentage of ARCA&#8217;s equity to be issued to Oruka stockholders was determined based on negotiations between the parties, it is possible that the value of ARCA common stock and ARCA Series&#160;B Preferred Stock to be issued to Oruka stockholders will be more or less than the fair market value of Oruka capital stock.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the Merger does not qualify as a reorganization under the Code, U.S.&#160;holders of Oruka capital stock may be taxed on the full amount of the consideration received in the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is intended to qualify for U.S.&#160;federal income tax purposes as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code such that no gain will be recognized by U.S.&#160;holders of Oruka capital stock who receive only ARCA common stock in the Merger. None of the parties to the Merger Agreement have sought or intend to seek any ruling from the IRS regarding the qualification of the Merger as a reorganization within the meaning of Section&#160;368(a)&#160;of the Code. If the Merger does not qualify for the U.S.&#160;federal income tax treatment described herein, U.S.&#160;holders of Oruka capital stock may be taxed on any gain realized up to the full fair market value of any of ARCA common stock they receive in the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lawsuits may be filed against ARCA, Oruka, or any of the members of their respective boards of directors arising out of the Merger, which may delay or prevent the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against ARCA, ARCA&#8217;s board of directors, Oruka, Oruka&#8217;s board of directors and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and ARCA or Oruka may not be successful in defending against any such future claims. Lawsuits that may be filed against ARCA, ARCA&#8217;s board of directors, Oruka, or Oruka&#8217;s board of directors could delay or prevent the Merger, divert the attention of ARCA&#8217;s and Oruka&#8217;s management and employees from their&#160;day<span class="nobreak">-to-day</span> business and otherwise adversely affect ARCA and Oruka financially.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has never paid and, other than in connection with the Merger with Oruka, does not intend to pay any cash dividends in the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never paid cash dividends on any of its capital stock. Pursuant to the terms of the Merger Agreement, ARCA may declare and pay a special cash dividend to ARCA stockholders of record prior to the Merger consisting of cash up to an amount equal in the aggregate of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million. The amount of such special cash dividend is currently uncertain, pending the determination of ARCA&#8217;s outstanding obligations and net cash position as of the closing of the Merger. Other than such potential special cash dividend in connection with the closing of the Merger, ARCA does not currently anticipate declaring or paying cash dividends on its capital stock in the foreseeable future.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA does not successfully consummate the Merger or another strategic transaction, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation of ARCA.&#160;In such an event, the amount of cash available for distribution to ARCA stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities, as to which ARCA can give you no assurance.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There can be no assurance that the Merger will be completed. If the Merger is not completed, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation of ARCA.&#160;In such an event, the amount of cash available for distribution to ARCA stockholders will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as ARCA funds its operations while pursuing the Merger. In addition, if ARCA&#8217;s board of directors were to approve and recommend, and ARCA stockholders were to approve, a dissolution and liquidation of ARCA, ARCA would be required under Delaware law to pay ARCA&#8217;s outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to stockholders. ARCA&#8217;s commitments and contingent liabilities may include obligations under ARCA&#8217;s employment and related agreements with certain employees that provide for severance and other payments following a termination of employment occurring for various reasons, including a change in control of ARCA, litigation against ARCA, and other various claims and legal actions arising in the ordinary course of business, and other unexpected and/or contingent liabilities. As a result of this requirement, a portion of ARCA&#8217;s assets would need to be reserved pending the resolution of such obligations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, ARCA may be subject to litigation or other claims related to a dissolution and liquidation of ARCA.&#160;If a dissolution and liquidation were to be pursued, ARCA&#8217;s board of directors, in consultation with ARCA&#8217;s advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Accordingly, holders of ARCA common stock could lose all or a significant portion of their investment in the event of liquidation, dissolution or winding up of ARCA.&#160;A liquidation would be a lengthy and uncertain process with no assurance of any value ever being returned to ARCA stockholders.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA is substantially dependent on its remaining employees to facilitate the consummation of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of April&#160;4, 2024, ARCA had only three full<span class="nobreak">-time</span> employees and one part<span class="nobreak">-time</span> employee. ARCA&#8217;s ability to successfully complete the Merger depends in large part on its ability to retain certain remaining personnel. Despite ARCA&#8217;s efforts to retain these employees, one or more employees may terminate their employment with ARCA on short notice. The loss of the services of certain employees could potentially harm ARCA&#8217;s ability to consummate the Merger and run its&#160;day<span class="nobreak">-to-day</span> business operations, as well as fulfill its reporting obligations as a public company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Proposed Reverse Stock Split</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may not increase the combined company&#8217;s stock price over the long-term.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The principal purposes of the reverse stock split are to (i)&#160;increase the&#160;per<span class="nobreak">-share</span>&#160;market price of ARCA common stock above the minimum bid price requirement under the Nasdaq rules so that the listing of ARCA and the shares of ARCA common stock being issued in the Merger on Nasdaq will be approved and (ii)&#160;increase the number of authorized and unissued shares available for future issuance in connection with the Merger, though such increase will not alone be sufficient to complete the Merger. It cannot be assured, however, that the reverse stock split will accomplish any increase in the per<span class="nobreak">-share</span> market price of ARCA common stock for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of ARCA common stock will proportionally increase the market price of ARCA common stock, it cannot be assured that the reverse stock split will increase the market price of ARCA common stock by a multiple of the reverse stock split ratio mutually agreed by ARCA and Oruka, or result in any permanent or sustained increase in the market price of ARCA common stock, which is dependent upon many factors, including ARCA&#8217;s business and financial performance, general market conditions and prospects for future success. Thus, while the stock price of ARCA common stock might meet the listing requirements for Nasdaq initially after the reverse stock split, it cannot be assured that it will continue to do so.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may decrease the liquidity of the combined company&#8217;s common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although ARCA&#8217;s board of directors believes that the anticipated increase in the market price of the combined company&#8217;s common stock resulting from the proposed reverse stock split could encourage interest in its common stock and possibly promote greater liquidity for its stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the combined company&#8217;s common stock. In addition, the reverse stock split may not result in an increase in the combined company&#8217;s stock price necessary to satisfy Nasdaq&#8217;s initial listing requirements for the combined company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may lead to a decrease in the combined company&#8217;s overall market capitalization.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should the market price of the combined company&#8217;s common stock decline after the reverse stock split, the percentage decline will be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in the combined company&#8217;s overall market capitalization. If the per share market price does not increase in proportion to the reverse stock split ratio, then the value of the combined company, as measured by its stock capitalization, will be reduced. In some cases, the&#160;per<span class="nobreak">-share</span>&#160;stock price of companies that have effected reverse stock splits subsequently declined back to&#160;pre<span class="nobreak">-reverse</span>&#160;split levels, and accordingly, it cannot be assured that the total market value of the combined company&#8217;s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the combined company&#8217;s stock price due to the reduced number of shares outstanding after the reverse stock split.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to ARCA</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to ARCA&#8217;s Business and Financial Condition</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA is not able to successfully develop, obtain FDA approval for and provide for the commercialization of Gencaro or rNAPc2 in a timely manner, it may not be able to continue its business operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA currently has no products that have received regulatory approval for commercial sale. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure to demonstrate that a product candidate, including Gencaro or rNAPc2, is safe and effective, or significant delays in demonstrating such safety and efficacy, would adversely affect ARCA&#8217;s business. Failure to obtain marketing approval of Gencaro or rNAPc2 from appropriate regulatory authorities, or significant delays in obtaining such approval, would also adversely affect ARCA&#8217;s business and could, among other things, preclude ARCA from completing a strategic transaction or obtaining additional financing necessary to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if approved for sale, a product candidate must be successfully commercialized to generate value. ARCA does not currently have the capital resources or management expertise to commercialize Gencaro, rNAPc2 or any of its other product candidates and, as a result, will need to complete a strategic transaction or, alternatively, raise substantial additional funds to enable commercialization of Gencaro, rNAPc2 or any of its other product candidates, if approved. Failure to successfully provide for the commercialization of Gencaro, rNAPc2 or any other product candidate, if approved, would damage ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA encounters difficulties enrolling patients in its future clinical trial of Gencaro, any potential enrollment milestones or potential regulatory approvals could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may encounter difficulty enrolling a sufficient number of patients in its clinical trials, due to circumstances which are outside its control, including other clinical trials that may limit the availability of study participants. As a result, ARCA may need to delay or terminate its trials, which would have a negative impact on its business. Delays in enrolling patients in the clinical trial would also adversely affect ARCA&#8217;s ability to meet projected enrollment milestones or timelines for completing the study and obtaining regulatory approval.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s clinical trials from its product candidates may not yield results that will enable ARCA to further develop its products as a therapy and obtain regulatory approvals necessary to be used as a drug.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will receive regulatory approval for its product candidates only if it can demonstrate, in carefully designed and conducted clinical trials, that the product candidate is safe and effective. ARCA does not know whether any future clinical trials for Gencaro, rNAPc2 or any other product candidate will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The results from preclinical testing and early clinical trials may not be predictive of results from later studies. ARCA may suffer significant setbacks in advanced clinical trials, even after seeing promising results in earlier studies. Based on results at any stage of clinical trials, ARCA may decide to repeat or redesign a trial or discontinue development of one or more of ARCA&#8217;s product candidates. If ARCA fails to adequately demonstrate the safety and efficacy of its product candidates, ARCA will not be able to obtain the required regulatory approvals to commercialize those product candidates and ARCA&#8217;s business, results of operations and financial condition would be materially adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, administering ARCA&#8217;s product candidates to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of ARCA&#8217;s product candidates, and could result in the FDA or other regulatory authorities denying approval of ARCA&#8217;s product candidates, for any or all targeted indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA may not achieve its projected development goals in the time frames it announces and expects.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA sets goals for, and makes public statements regarding, the timing of certain accomplishments, such as the initiation of its clinical trials, the steps for commencing and continuing its clinical trials, the disclosure of trial results, the obtainment of regulatory approval and the sale of drug products, which ARCA sometimes refers to as milestones. These milestones may not be achieved, and the actual timing of these events can vary </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">dramatically due to a number of factors such as delays or failures in ARCA&#8217;s clinical trials, disagreements with any collaborative partners, the uncertainties inherent in the regulatory approval process and manufacturing scale<span class="nobreak">-up</span>, delays in achieving manufacturing or marketing arrangements sufficient to commercialize ARCA&#8217;s products or ARCA&#8217;s inability to obtain sufficient financing in a timely manner. There can be no assurance that ARCA will make regulatory submissions or receive regulatory approvals as planned. If ARCA fails to achieve one or more of these milestones as planned, its business will be materially adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA expects a Phase&#160;3 PRECISION-AF clinical trial will require substantially more capital, and ARCA cannot guarantee when or if it will be able to secure such additional financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will need to secure additional financing in order to initiate enrollment of its Phase&#160;3 PRECISION<span class="nobreak">-AF</span> clinical trial. Even if ARCA can<span class="BoldItalic" style="font-style:italic;font-weight:bold;"> </span>begin enrolling patients, it expects to have to raise significant additional capital to continue enrollment. If ARCA is not able to obtain financing in the future or on acceptable terms, it may have to terminate the clinical trial early, which could adversely affect its business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic transactions or partnerships, to continue development of Gencaro, rNAPc2 or any of its other product candidates. If ARCA is unable to raise such financing or complete such a transaction, it may not be able to continue operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result of the expected development timeline to potentially obtain FDA approval for Gencaro or rNAPc2, if at all, the substantial additional costs associated with the development of ARCA&#8217;s product candidates, including the costs associated with clinical trials related thereto, and the substantial cost of commercializing Gencaro or rNAPc2, if approved, ARCA will need to raise substantial additional funding through public or private equity or debt transactions or a strategic combination or partnership. If ARCA is delayed in obtaining funding or are unable to complete a strategic transaction, it may discontinue its development activities on Gencaro, rNAPc2 and its other product candidates or discontinue its operations. Even if ARCA is able to fund continued development of Gencaro, rNAPc2 or any of ARCA&#8217;s other product candidates, ARCA expects that it will need to complete a strategic transaction or raise substantial additional funding through public or private equity or debt securities or partnership to successfully commercialize Gencaro, rNAPc2 or any other product candidate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial clinical trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, ARCA common stock in an &#8220;at the market offering.&#8221; As of December&#160;31, 2022, ARCA sold an aggregate of 9,928,272<span class="nobreak"> </span>shares of ARCA common stock pursuant to the terms of such sales agreement for aggregate gross proceeds of approximately $54.0&#160;million. Net proceeds received in this offering were approximately $52.2&#160;million, after deducting expenses for executing the &#8220;at the market offering&#8221; and commissions paid to the placement agent. In 2021, ARCA amended the new sales agreement and the amount available for the offering under its prospectus to its registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. Sales of ARCA common stock dilute the ownership interest of ARCA stockholders and may cause the price per share of ARCA common stock to decrease. Changing circumstances may cause ARCA to consume capital significantly faster or slower than it currently anticipates. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2 and ARCA&#8217;s other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of ARCA common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial dilution to ARCA stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of its capital stock and could contain covenants that would restrict its operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has received a Special Protocol Assessment agreement from the FDA relating to its planned Phase&#160;3 program for Gencaro. This Special Protocol Assessment agreement does not guarantee approval of Gencaro or any other particular outcome from regulatory review.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2019, ARCA received a Special Protocol Assessment (&#8220;SPA&#8221;) agreement from the FDA for its planned Phase&#160;3 clinical trial of Gencaro. The FDA&#8217;s SPA process is designed to facilitate the FDA&#8217;s review and approval of drugs by allowing the FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product&#8217;s efficacy. Upon specific request by a clinical trial sponsor, the FDA will evaluate the protocol and respond to a sponsor&#8217;s questions regarding, among other things, primary efficacy endpoints, trial conduct and data analysis, within 45&#160;days of receipt of the request. The FDA ultimately assesses whether the protocol design and planned analysis of the trial are acceptable to support regulatory approval of the product candidate with respect to the effectiveness of the indication studied. All agreements and disagreements between the FDA and the sponsor regarding a SPA must be clearly documented in a SPA letter or the minutes of a meeting between the sponsor and the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, an SPA agreement does not guarantee approval of a product candidate, even if the trial is conducted in accordance with the protocol. Moreover, the FDA may revoke or alter ARCA&#8217;s SPA agreement in certain circumstances. In particular, a SPA agreement is not binding on the FDA if public health concerns emerge that were unrecognized at the time of the SPA agreement, other new scientific concerns regarding product safety or efficacy arise, ARCA fails to comply with the agreed upon trial protocols, or the relevant data, assumptions or information provided by ARCA in its request for the SPA change or are found to be false or omit relevant facts. In addition, even after an SPA agreement is finalized, the SPA agreement may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study. The FDA retains significant latitude and discretion in interpreting the terms of the SPA agreement and the data and results from any study that is the subject of the SPA agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even though ARCA obtained an agreement on its SPA, ARCA cannot assure you that its planned Phase&#160;3 clinical trial will succeed, will be deemed binding by the FDA under its SPA agreement or will result in any FDA approval for Gencaro. ARCA may also alter the design of the trial to focus on endpoints that are not covered by the SPA.&#160;Moreover, if the FDA revokes or alters its agreement under ARCA&#8217;s SPA, or interprets the data collected from </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the clinical trial differently than ARCA does, the FDA may not deem the data sufficient to support an application for regulatory approval, which could materially adversely affect ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA is not able to maintain the requirements for listing on the Nasdaq Capital Market, it could be delisted, which could have a material adverse effect on its ability to consummate the Merger, raise additional funds as well as the price and liquidity of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is currently listed on the Nasdaq Capital Market. To maintain the listing of ARCA common stock on the Nasdaq Capital Market, ARCA is required to meet certain listing requirements, including, among others, (i)&#160;a minimum closing bid price of $1.00 per share, (ii)&#160;a market value of publicly held shares (excluding shares held by ARCA&#8217;s executive officers, directors and 10% or more stockholders) of at least $1&#160;million and (iii)&#160;either: (x)&#160;stockholders&#8217; equity of at least $2.5&#160;million; or (y)&#160;a total market value of listed securities of at least $35&#160;million. In addition, pursuant to the terms of the Merger Agreement ARCA is required to use commercially reasonable efforts to maintain its listing on Nasdaq until the First Merger Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has received three potential delisting notices from Nasdaq since 2012. In each of 2012, 2015 and 2018, ARCA received notification from Nasdaq of potential delisting of its shares from the Nasdaq Capital Market because the closing bid price of ARCA common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30&#160;business days. ARCA subsequently regained compliance with Nasdaq&#8217;s minimum closing bid price requirements related to the 2012, 2015 and 2018 notices, by effecting a 1<span class="nobreak">-for-6</span> reverse split of ARCA common stock in March&#160;2013, a 1<span class="nobreak">-for-7</span> reverse split of ARCA common stock in September&#160;2015 and a 1<span class="nobreak">-for-18</span> reverse split of ARCA common stock in April&#160;2019. Despite effecting a 1<span class="nobreak">-for-18</span> reverse split of ARCA common stock in April&#160;2019, there can be no assurance that the market price per share of ARCA common stock will remain in excess of the $1.00 minimum bid price for a sustained period of time. The continuing effect of ARCA&#8217;s reverse stock split on the market price of ARCA common stock cannot be predicted with any certainty, and the history of similar stock split combinations for companies in like circumstances is varied. It is possible that the per share price of ARCA common stock after the reverse stock split will not rise in proportion to the reduction in the number of shares of common stock outstanding resulting from the reverse stock split, effectively reducing ARCA&#8217;s market capitalization, and there can be no assurance that the market price per post<span class="nobreak">-reverse</span> split share will either exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time. The market price of ARCA common stock may vary based on other factors that are unrelated to the number of shares outstanding, including ARCA&#8217;s future performance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The delisting of ARCA common stock from a national exchange may impair ARCA&#8217;s ability to consummate the Merger and could impair the liquidity and market price of the common stock. It could also materially adversely affect ARCA&#8217;s access to the capital markets, and any limitation on market liquidity or reduction in the price of the common stock as a result of that delisting could adversely affect ARCA&#8217;s ability to consummate the Merger or raise capital on terms acceptable to ARCA, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In future periods, if ARCA does not meet the minimum stockholders&#8217; equity, minimum closing bid price requirements, or any other listing requirements, it would be subject to delisting from the Nasdaq Capital Market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;9, 2024, the closing price of ARCA common stock was $3.37 per share, and the total market value of ARCA&#8217;s listed securities was approximately $48.9&#160;million. As of March&#160;31, 2024, ARCA had stockholders&#8217; equity of $35.1&#160;million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s financial statements for the quarter ended March&#160;31, 2024 were prepared assuming that ARCA will continue as a going concern. ARCA&#8217;s management has concluded that due to ARCA&#8217;s need for additional capital, and the uncertainties surrounding ARCA&#8217;s ability to raise such funding, there may be uncertainty about ARCA&#8217;s ability to continue as a going concern in future&#160;years.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s financial statements for the quarter ended March&#160;31, 2024 were prepared assuming that ARCA will continue as a going concern. The going concern basis of presentation assumes that ARCA will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from ARCA&#8217;s inability to continue as a going concern. As of December&#160;31, 2019, ARCA&#8217;s management and independent </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">registered public accounting firm concluded that, due to ARCA&#8217;s need for additional capital and the uncertainties surrounding ARCA&#8217;s ability to raise such funding, substantial doubt existed as to ARCA&#8217;s ability to continue as a going concern for a period from one year after ARCA&#8217;s annual financial statements had been issued. ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and ARCA&#8217;s ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see discussion above regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. ARCA&#8217;s Merger Agreement discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuits of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. ARCA cannot be certain that it will be able to make any other sale of ARCA common stock in any future offering to cover its future capital needs, or at all. Changing circumstances may cause ARCA to consume capital significantly faster or slower than it currently anticipates. If ARCA is delayed in completing or is unable to complete additional funding and/or a strategic transaction, it may discontinue its development activities or operations, but there are no assurances that these reductions would be sufficient to allow ARCA to continue to operate as a going concern. Therefore, even if ARCA resolves this uncertainty, its independent registered public accountants and/or management could conclude that uncertainty as to its ability to continue as a going concern could exist at a future date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. ARCA may be forced to reduce its operating expenses and raise additional funds to meet its working capital needs, principally through the additional sales of its securities or debt financings. However, ARCA cannot guarantee that it will be able to obtain sufficient additional funds when needed or that such funds, if available, will be obtainable on satisfactory terms. If ARCA is unable to raise sufficient additional capital or complete a strategic transaction, it may be unable to continue to fund its operations, develop Gencaro, rNAPc2 or its other product candidates, or realize value from its assets and discharge its liabilities in the normal course of business. If ARCA cannot raise sufficient funds, it may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its financial statements, and stockholders may lose all or part of their investment in ARCA&#8217;s securities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Market conditions and changing circumstances, some of which may be beyond ARCA&#8217;s control, could impair ARCA&#8217;s ability to access its existing cash, cash equivalents and investments and to timely pay key vendors and others.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Market conditions and changing circumstances, some of which may be beyond ARCA&#8217;s control, could impair ARCA&#8217;s ability to access its existing cash, cash equivalents and investments and to timely pay key vendors and others. For example, on March&#160;10, 2023, Silicon Valley Bank (SVB), where ARCA maintains certain accounts, was placed into receivership with the Federal Deposit Insurance Corporation (FDIC), which resulted in all funds held at SVB being temporarily inaccessible by SVB&#8217;s customers. If other banks and financial institutions with whom ARCA has banking relationships enter receivership or become insolvent in the future, ARCA may be unable to access, and may lose, some or all of its existing cash, cash equivalents and investments to the extent those funds are not insured or otherwise protected by the FDIC.&#160;In addition, in such circumstances, ARCA might not be able to timely pay key vendors and others. ARCA regularly maintains cash balances that are not insured or are in excess of the FDIC&#8217;s insurance limit. Any delay in ARCA&#8217;s ability to access its cash, cash equivalents and investments (or the loss of some or all of such funds) or to timely pay key vendors and others could have a material adverse effect on ARCA&#8217;s operations and cause it to need to seek additional capital sooner than planned.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s business could be adversely affected by the effects of health epidemics in regions where ARCA or third parties on which ARCA relies may have clinical trial sites or other business operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s business could be adversely affected by health epidemics in regions where ARCA may have concentrations of future clinical trial sites or other business operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, third<span class="nobreak">-party</span> manufacturing of ARCA&#8217;s drug product candidates and suppliers of the materials used in the production of ARCA&#8217;s drug product candidates may be impacted by significant delays or restrictions resulting from any future health epidemic which may disrupt ARCA&#8217;s supply chain or limit ARCA&#8217;s ability to manufacture drug product candidates for its clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ultimate impact of any future health epidemic is highly uncertain and subject to change. These effects could have a material impact on ARCA&#8217;s operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA encounters difficulties enrolling patients in any future clinical trials, its future trials could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA has difficulty enrolling a sufficient number of patients in any future clinical trial, ARCA may need to delay or terminate its trial, which would have a negative impact on its business. Delays in enrolling patients in any future clinical trials would also adversely affect ARCA&#8217;s ability to generate any product, milestone and royalty revenues under collaboration agreements, if any, and could impose significant additional costs on ARCA or on any future collaborators.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For example, the development of vaccines for the SARS<span class="nobreak">-CoV-2</span> virus and the development of other therapies for COVID<span class="nobreak">-19</span> disease impacted ARCA&#8217;s ability to enroll patients in its rNAPc2 (AB201) Phase&#160;2b clinical trial and such enrollment was slower than expected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The GENETIC<span class="nobreak">-AF</span> clinical trial required that ARCA identify and enroll a large number of patients with the condition under investigation and the trial enrolled only those patients having a specific genotype, and certain patients who have or are willing to have a Medtronic device implanted for monitoring and recording AFB data. As a result, enrollment for GENETIC<span class="nobreak">-AF</span> was slower than expected, with ARCA&#8217;s first patient enrolled in June&#160;2014 and enrollment completed in August&#160;2017. Because of the rigorous enrollment criteria, ARCA&#8217;s clinical trial timelines were delayed from ARCA&#8217;s original projections. ARCA anticipates that any future Phase&#160;3 clinical trial of Gencaro, including PRECISION<span class="nobreak">-AF</span>, may have similar enrollment criteria, and ARCA cannot guarantee that it will not have similar enrollment issues in any future clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may also encounter difficulty enrolling a sufficient number of patients in any future clinical trial, due to circumstances which are outside ARCA&#8217;s control, including as a result of continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will rely on contract research organizations to conduct substantial portions of its clinical trials, including any future clinical trial of Gencaro, rNAPc2, and as a result, ARCA will be unable to directly control the timing, conduct and expense of all aspects of its clinical trials.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not currently have sufficient staff with the requisite experience to conduct its clinical trials and therefore will rely on third parties to conduct certain aspects of any future clinical trials. ARCA previously contracted with a CRO to conduct components of its GENETIC<span class="nobreak">-AF</span> clinical trial and anticipate contracting with a CRO to conduct components of any future clinical trial for Gencaro and components of the clinical study of rNAPc2 or any future clinical trials for ARCA&#8217;s other product candidates. As a result, ARCA will have less control over many details and steps of any clinical trial, the timing and completion of any clinical trial, the required reporting of adverse events and the management of data developed through any clinical trial than would be the case if ARCA were relying entirely upon its own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties, such as CROs, may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct ARCA&#8217;s clinical trial. ARCA may experience unexpected cost increases that are beyond its control. Problems with the timeliness or quality of the work of a CRO may lead ARCA to seek to terminate the relationship and use an alternative service provider. However, making any change may be costly </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and may delay ongoing trials, if any, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct clinical trials in an acceptable manner and at an acceptable cost.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even though ARCA anticipates relying on CROs in the future, it will likely have to devote substantial resources and rely on the expertise of ARCA&#8217;s employees to manage the work being done by the CROs. Due to ARCA&#8217;s limited experience in managing clinical trials, ARCA cannot guarantee its employees will do so effectively.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA expects to depend on existing and future collaborations with third parties for the development of some of ARCA&#8217;s product candidates. If those collaborations are not successful, ARCA may not be able to complete the development of these product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA collaborated with one or more clinical trial networks in its development program for rNAPc2. As a result, ARCA lacked direct control over certain aspects of the development program and the amount and timing of resources that these collaborators devote to the project.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA had a collaboration agreement with Medtronic that supported ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. If ARCA&#8217;s arrangement with Medtronic, as amended, is continued as part of ARCA&#8217;s future development of Gencaro, ARCA will have limited control over the amount and timing of resources that they dedicate to the development of Gencaro. This is also likely to be true in any future collaboration with third parties and ARCA may seek additional third<span class="nobreak">-party</span> collaborators for the development of Gencaro, rNAPc2 or any other product candidates. ARCA&#8217;s ability to benefit from these arrangements will depend on its collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaborations involving ARCA&#8217;s product candidates pose the following risks to us:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not pursue development and commercialization of ARCA&#8217;s product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with ARCA&#8217;s product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ARCA&#8217;s;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not properly maintain or defend ARCA&#8217;s intellectual property rights or may use ARCA&#8217;s proprietary information in such a way as to invite litigation that could jeopardize or invalidate its proprietary information or expose it to potential litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>disputes may arise between the collaborators and ARCA that result in the delay or termination of the research, development or commercialization of ARCA&#8217;s product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may elect to take over manufacturing rather than retain ARCA as manufacturer and may encounter problems in starting up or gaining approval for their manufacturing facility and so be unable to continue development of product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to undertake the expenditure of substantial operational, financial and management resources in connection with any collaboration;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to issue equity securities to collaborators that would dilute ARCA&#8217;s existing stockholders&#8217; percentage ownership;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to assume substantial actual or contingent liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not commit adequate resources to the marketing and distribution of ARCA&#8217;s product candidates, limiting ARCA&#8217;s potential revenues from these products; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may experience financial difficulties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA faces a number of challenges in seeking additional collaborations. Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether ARCA reaches a definitive agreement for a collaboration will depend, among other things, upon its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors, such as the design or results of ARCA&#8217;s clinical trials, the potential market for ARCA&#8217;s product candidates, the costs and complexities of manufacturing and delivering ARCA&#8217;s product candidates to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of ARCA&#8217;s intellectual property, and industry and market conditions generally. If ARCA were to determine that additional collaborations for its Gencaro development are necessary and were unable to enter into such collaborations on acceptable terms, ARCA might elect to delay or scale back the development or commercialization of Gencaro in order to preserve its financial resources or to allow it adequate time to develop the required physical resources and systems and expertise itself.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaboration agreements may not lead to development or commercialization of ARCA&#8217;s product candidates in the most efficient manner, or at all. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If a present or future collaborator of ARCA were to be involved in a business combination, the continued pursuit and emphasis on ARCA&#8217;s product development or commercialization program could be delayed, diminished or terminated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any future clinical trial for Gencaro will require the use of a third-party diagnostic services provider to administer a genetic test needed to identify the patient receptor genotypes of clinical trial participants, and as a result, ARCA will be unable to directly control the timing, conduct and expense of the genetic test.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA anticipates that any future clinical trial of Gencaro, if any, will require a companion diagnostic test that identifies the patient&#8217;s receptor genotype. The trial would only enroll those patients with the receptor that has the potential for enhanced efficacy, the beta<span class="nobreak">-1</span> 389 Arg receptor as detected by a beta<span class="nobreak">-1</span> 389 Arg/Arg genotype. Accordingly, ARCA anticipates that any future clinical trial for Gencaro will require the use of a third<span class="nobreak">-party</span> diagnostic service to perform the genetic testing. There has been limited experience in ARCA&#8217;s industry in prospective development of companion diagnostics required to perform the required molecular profiling. ARCA entered into an agreement with LabCorp to provide the diagnostic services of the genetic test needed to support ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. To provide those services, LabCorp obtained from the FDA an investigational device exemption (&#8220;IDE&#8221;) for the companion diagnostic test being used in ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA would expect a similar agreement and approval would be necessary for any companion diagnostic used in any future clinical trials for Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA and similar regulatory authorities outside the United&#160;States regulate companion diagnostics. Companion diagnostics require separate or coordinated regulatory approval prior to commercialization. Changes to regulatory advice could delay ARCA&#8217;s development programs or delay or prevent eventual marketing approval for ARCA&#8217;s product candidates that may otherwise be approvable. In July&#160;2011, the FDA issued draft guidance that stated that if safe and effective use of a therapeutic depends on an <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> diagnostic, the FDA generally will not approve the therapeutic unless the FDA approves or clears this &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> companion diagnostic device&#8221; at the same time that the FDA approves the therapeutic. The approval or clearance of the companion diagnostic would occur through the FDA&#8217;s Center for Devices and Radiological Health. In 2014, the FDA issued guidance on in vitro companion diagnostic devices. The guidance allows for flexibility by the FDA in the case of therapeutic products to treat serious conditions for which no alternative treatment exists and the benefits of using the companion diagnostic outweigh the risk, but it is unclear how this discretion may be applied by the agency with respect to the companion diagnostic test related to any Gencaro clinical trials. The FDA&#8217;s evolving position on the topic of companion </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">diagnostics could affect ARCA&#8217;s clinical development programs that utilize companion diagnostics. In particular, the FDA may limit ARCA&#8217;s ability to use retrospective data, otherwise disagree with ARCA&#8217;s approaches to trial design, biomarker qualification, clinical and analytical validity, and clinical utility, or make ARCA repeat aspects of a trial or initiate new trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Given ARCA&#8217;s limited experience in developing diagnostics, ARCA expects to rely primarily on third parties for the design and manufacture of the companion diagnostics for its product candidates. If ARCA, or any third parties that ARCA engages to assist it, are unable to successfully develop companion diagnostics for its product candidates that require such diagnostics, or experiences delays in doing so, the development of its product candidates may be adversely affected, its product candidates may not receive marketing approval and it may not realize the full commercial potential of any products that receive marketing approval. As a result, ARCA&#8217;s business could be materially harmed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will need to establish a collaborative arrangement with a third-party diagnostics services provider to obtain marketing clearance or approval of the companion genetic test for Gencaro. There is no guarantee that the FDA will grant timely clearance or approval of the genetic test, if at all, and failure to obtain such timely clearance or approval would adversely affect ARCA&#8217;s ability to market Gencaro.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The drug label ARCA intends to seek for Gencaro would identify the patient receptor genotype for which the drug is approved. Accordingly, ARCA believes developing a genetic test that is simple to administer and widely available will be critical to the successful commercialization of Gencaro. The genetic test will be subject to regulation by the FDA and by comparable agencies in various foreign countries. The process of complying with the requirements of the FDA and comparable agencies is costly, time consuming and burdensome.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Despite the time and expense expended, regulatory clearance or approval is never guaranteed. If regulatory clearance or approval is delayed, or if one or more third<span class="nobreak">-party</span> diagnostic services providers are unable to obtain FDA approval of the genetic test at all or in parallel with the approval of Gencaro, or are unable to commercialize the test successfully and in a manner that effectively supports the commercial efforts for Gencaro, or if the information concerning the differential response to Gencaro resulting from certain genetic variation is not included in the approval label for Gencaro, the commercial launch of Gencaro may be significantly and adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Regulatory approval is required for the genetic test to be used in ARCA&#8217;s Gencaro clinical trials and to support the commercialization of the test, if approved. Delays or failures in obtaining such regulatory approval, including any required validation analyses may prevent a third-party diagnostics provider from commercializing such genetic test and will adversely affect ARCA&#8217;s business, operating results and prospects.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before a genetic test can be used commercially, including in conjunction with Gencaro, if it is approved for marketing, the third<span class="nobreak">-party</span> diagnostics provider must obtain FDA Premarket Approval (&#8220;PMA&#8221;), for such test. The FDA may require additional validation of the genetic test ARCA used in GENETIC<span class="nobreak">-AF</span> prior to any approval of Gencaro or the genetic test or prior to the use of such test in any future clinical trials for Gencaro. ARCA anticipates the genetic test will be required as a condition to prescribing Gencaro. There is no guarantee the FDA will approve the anticipated PMA submission for the genetic test. Even if the genetic test is eventually approved, performing additional validation work necessary to support the PMA, if required, for current or future genetic test products, including one associated with Gencaro, would require additional time and expense and the outcome would be uncertain. Moreover, such delays or increased costs or failures could adversely affect ARCA&#8217;s business, operating results and prospects for commercializing the genetic test.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If a third-party diagnostics provider responsible for the genetic test associated with Gencaro or certain of its third-party suppliers fails to comply with ongoing FDA or other foreign regulatory authority requirements, or if there are unanticipated problems with the genetic test, these products could be subject to restrictions or withdrawal from use in a trial or from the market.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any diagnostic for which a third<span class="nobreak">-party</span> diagnostics provider obtains clearance or approval, and the manufacturing processes, reporting requirements, post<span class="nobreak">-approval</span> clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. With respect to the genetic test, to the extent applicable, any third<span class="nobreak">-party</span> diagnostics provider and certain of its suppliers will be required to comply with the FDA&#8217;s Quality System </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Regulation (&#8220;QSR&#8221;) and International Standards Organization (&#8220;ISO&#8221;) requirements which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which clearance or approval is obtained. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by a third<span class="nobreak">-party</span> diagnostics provider, or certain of its third<span class="nobreak">-party</span> manufacturers or suppliers, as the case may be, to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, enforcement actions. If any of these actions were to occur, it could harm ARCA&#8217;s reputation and cause product sales and profitability of Gencaro, if approved, to suffer and may prevent ARCA from generating revenue or utilizing the genetic test further in any clinical trial. Even if regulatory clearance or approval is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce ARCA&#8217;s potential to successfully commercialize the product and generate revenue from the product.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of Gencaro may suffer if its marketplace acceptance is negatively affected by the genetic test.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The genetic test is an important component of the commercial strategy for Gencaro in addition to being required for ARCA&#8217;s clinical trials. ARCA believes that the genetic test helps predict patient response to Gencaro, and that this aspect of the drug is important to its ability to compete effectively with current therapies. The genetic test adds an additional step in the prescribing process, an additional cost for the patient and payors, the risk that the test results may not be rapidly available and the possibility that it may not be available at all to hospitals and medical centers. Although ARCA anticipates that Gencaro, if approved in a timely manner, would be the first genetically<span class="nobreak">-targeted</span> cardiovascular drug, Gencaro will be one of a number of successful drugs in the beta<span class="nobreak">-blocker</span> class currently on the market. Prescribers may be more familiar with these other beta<span class="nobreak">-blockers</span>, and may be resistant to prescribing Gencaro as an AF therapy in patients with HF.&#160;For instance, the top<span class="nobreak">-line</span> results of ARCA&#8217;s Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial indicated that Gencaro demonstrated a similar treatment benefit compared to the active comparator, metoprolol succinate (TOPROL<span class="nobreak">-XL</span>). If ARCA&#8217;s future clinical trials in Gencaro do not show that Gencaro has a clear therapeutic benefit as compared to other drugs in the beta<span class="nobreak">-blocker</span> class currently on the market, then prescribers may be unlikely to prescribe Gencaro to patients, even if approved. Any one of these factors could affect prescriber behavior, which in turn may substantially impede market acceptance of the genetic test, which could cause significant harm to Gencaro&#8217;s ability to compete, and in turn harm ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Unless ARCA is able to generate sufficient product revenue, it will continue to incur losses from operations and will not achieve or maintain profitability. ARCA is&#160;years away from commercializing a product and generating product revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s historical losses have had, and will continue to have, an adverse effect on ARCA stockholders&#8217; equity and working capital, among other things. ARCA is&#160;years away from commercializing a product and generating any product revenue. As a result, ARCA expects to continue to incur significant operating losses for the foreseeable future. Even if ARCA ultimately receives regulatory approval for Gencaro, rNAPc2 or ARCA&#8217;s other product candidates, sales of such products may not generate sufficient revenue for it to achieve or maintain profitability. Because of the numerous risks and uncertainties associated with developing therapeutic drugs, ARCA may experience larger than expected future losses and may never reach profitability.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase ARCA&#8217;s future development costs or impair ARCA&#8217;s future revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, and subsequent advertising, promotion, sale, marketing, and distribution, if approved, of ARCA&#8217;s product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United&#160;States and elsewhere. These regulations also vary in important, meaningful ways from country to country. ARCA is not permitted to market a potential drug in the United&#160;States until it receives approval of a New Drug Application (&#8220;NDA&#8221;) from the FDA for such drug. ARCA has not received an NDA approval from the FDA for Gencaro, rNAPc2 or any of its other product candidates. There can be no guarantees with respect to ARCA&#8217;s product candidates that clinical studies will adequately support an NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To receive regulatory approval for the commercial sale of any product candidates, ARCA must demonstrate safety and efficacy in humans to the satisfaction of regulatory authorities through preclinical studies and adequate and well<span class="nobreak">-controlled</span> clinical trials of the product candidates. This process is expensive and can take many&#160;years, and failure can occur at any stage of the testing. ARCA&#8217;s failure to adequately demonstrate the safety and efficacy of ARCA&#8217;s product candidates will prevent regulatory approval and commercialization of such products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2008, ARCA submitted and the FDA accepted ARCA&#8217;s NDA filing for Gencaro for the treatment of chronic HF.&#160;In 2009, the FDA issued a Complete Response Letter in which the FDA stated that it could not approve the Gencaro NDA in its current form and specified actions required for approval of the NDA, including conducting an additional Phase&#160;3 clinical trial of Gencaro in patients with HF.&#160;ARCA completed a Phase&#160;2B clinical study of Gencaro in HF patients to assess its efficacy in reducing or preventing AF.&#160;ARCA enrolled 267 HF patients with AF in the Phase&#160;2B clinical trial. ARCA reported top<span class="nobreak">-line</span> Phase&#160;2B data in February&#160;2018. In the third quarter of 2018, ARCA submitted a SPA to the FDA for a Phase&#160;3 clinical trial. In 2019, the FDA approved ARCA&#8217;s SPA request for a Phase&#160;3 clinical trial of Gencaro. Even though the FDA approved ARCA&#8217;s SPA, this product candidate will require&#160;years of additional clinical development. Even if ARCA conducts additional studies in accordance with ARCA&#8217;s SPA agreement or further FDA guidance and submit or file a new or amended NDA, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event that ARCA or its collaborators conduct preclinical studies that do not comply with Good Laboratory Practices (&#8220;GLP&#8221;) or incorrectly design or carry out human clinical trials in accordance with Good Clinical Practices (&#8220;GCP&#8221;) or those clinical trials fail to demonstrate clinical significance, it is unlikely that ARCA will be able to obtain FDA approval for product development candidates. ARCA&#8217;s inability to successfully initiate and effectively complete clinical trials for any product candidate on schedule, or at all, will severely harm ARCA&#8217;s business. Significant delays in clinical development could materially increase product development costs or allow ARCA&#8217;s competitors to bring products to market before ARCA does, impairing ARCA&#8217;s ability to effectively commercialize any future product candidate. ARCA does not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to ARCA&#8217;s product candidates or similar product candidates of ARCA&#8217;s competitors or failure to follow regulatory guidelines;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidates for use in trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of clinical materials to meet pre<span class="nobreak">-established</span> specifications at product release or during ongoing stability studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in reaching agreement on acceptable terms with prospective study sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining approval of ARCA&#8217;s clinical trial protocol from an institutional review board to conduct a clinical trial at a prospective study site;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays in recruiting patients to participate in a clinical trial, which may be due to the size of the patient population, eligibility criteria, protocol design, perceived risks and benefits of the drug, availability of other approved and standard of care therapies or, availability of clinical trial sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other clinical trials seeking to enroll subjects with similar profile;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of ARCA&#8217;s clinical trials and clinical investigators to be in compliance with GCP;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>unforeseen safety issues, including negative results from ongoing preclinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>inability to monitor patients adequately during or after treatment;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>difficulty recruiting and monitoring multiple study sites;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of ARCA&#8217;s third<span class="nobreak">-party</span> contract research organizations, clinical site organizations and other clinical trial managers, to satisfy their contractual duties, comply with regulations or meet expected deadlines; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an insufficient number of patients who have, or are willing to have, a Medtronic device implanted for monitoring and recording AF burden data.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, any approvals ARCA may obtain may not cover all of the clinical indications for which it seeks approval or permit it to make claims of superiority over currently marketed competitive products. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use. If the FDA determines that a risk evaluation and mitigation strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks, ARCA may be required to include as part of the NDA a proposed REMS that may include a package insert directed to patients, a plan for communication with healthcare providers, restrictions on a drug&#8217;s distribution, or a Medication Guide, to provide better information to consumers about the drug&#8217;s risks and benefits. Finally, an approval could be conditioned on ARCA&#8217;s commitment to conduct further clinical trials, which ARCA may not have the resources to conduct or which may negatively impact ARCA&#8217;s financial situation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The manufacture and analytical testing of Gencaro and rNAPc2 is performed by third<span class="nobreak">-party</span> suppliers, who must also meet cGMP requirements and pass a pre<span class="nobreak">-approval</span> inspection of their facilities before ARCA can obtain marketing approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All of ARCA&#8217;s product candidates are prone to the risks of failure inherent in drug development. The results from preclinical animal testing and early human clinical trials may not be predictive of results obtained in later human clinical trials. Further, although a new product may show promising results in preclinical or early human clinical trials, it may subsequently prove unfeasible or impossible to generate sufficient safety and efficacy data to obtain necessary regulatory approvals. The data obtained from preclinical and clinical studies are susceptible to varying interpretations that may delay, limit or prevent regulatory approval, and the FDA and other regulatory authorities in the United&#160;States and elsewhere exercise substantial discretion in the drug approval process. The numbers, size and design of preclinical studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the product candidate, the disease or condition for which the product candidate is intended to be used and the regulations and guidance documents applicable to any particular product candidate. The FDA or other regulators can delay, limit or deny approval of any product candidate for many reasons, including, but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>side effects;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>safety and efficacy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>defects in the design of clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that the FDA or other regulatory officials may not approve ARCA&#8217;s or ARCA&#8217;s third<span class="nobreak">-party</span> manufacturer&#8217;s processes or facilities; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that new regulations may be enacted by the FDA or other regulators may change their approval policies or adopt new regulations requiring new or different evidence of safety and efficacy for the intended use of a product candidate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In light of widely publicized events concerning the safety of certain drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of certain drug products, revisions to certain drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and approval. Data from clinical trials may receive greater scrutiny with respect to safety and the product&#8217;s risk/benefit profile, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense, and a delay or failure in obtaining </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approval or approval for a more limited indication than originally sought. Aside from issues concerning the quality and sufficiency of submitted preclinical and clinical data, the FDA may be constrained by limited resources from reviewing and determining the approvability of the Gencaro NDA in a timely manner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In pursuing clinical development of Gencaro for an AF indication, ARCA will be required to amend the Gencaro HF NDA or prepare a new NDA.&#160;The FDA could approve Gencaro, but without including some or all of the prescribing information that ARCA has requested. For instance, the FDA could approve Gencaro for AF in a more limited patient population or include additional warnings in the drug&#8217;s label. This, in turn, could substantially and detrimentally impact ARCA&#8217;s ability to successfully commercialize Gencaro and effectively protect ARCA&#8217;s intellectual property rights in Gencaro.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA&#8217;s product candidates receive regulatory approval, ARCA would be subject to ongoing regulatory obligations and restrictions, which may result in significant expenses and limit its ability to develop and commercialize other potential products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a product candidate of ARCA&#8217;s is approved by the FDA or by another regulatory authority, ARCA would be held to extensive regulatory requirements over product manufacturing, testing, distribution, labeling, packaging, adverse event reporting and other reporting to regulatory authorities, storage, advertising, marketing, promotion, distribution, and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the product candidates. Potentially costly follow<span class="nobreak">-up</span> or post<span class="nobreak">-marketing</span> clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in additional regulatory controls or restrictions on the marketing or use of the product or the need for post marketing studies, and could include suspension or withdrawal of the products from the market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, ARCA&#8217;s third<span class="nobreak">-party</span> manufacturers and the manufacturing facilities that they use to make ARCA&#8217;s product candidates are regulated by the FDA.&#160;Quality control and manufacturing procedures must continue to conform to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and products manufactured annually with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, state and/or other foreign authorities. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by ARCA or its collaborators, may result in restrictions on the product, or on the manufacturing or laboratory facility, including a withdrawal of the drug from the market or suspension of manufacturing. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. ARCA and its third<span class="nobreak">-party</span> manufacturers will also be subject to ongoing FDA requirements for submission of safety and other post<span class="nobreak">-market</span> information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The marketing and advertising of ARCA&#8217;s drug products by its collaborators or itself will be regulated by the FDA, certain state agencies or foreign regulatory authorities. Violations of these laws and regulations, including promotion of ARCA&#8217;s products for unapproved uses or failing to disclose risk information, are punishable by criminal and civil sanctions and may result in the issuance of enforcement letters or other enforcement action by the FDA, U.S.&#160;Department of Justice, state agencies, or foreign regulatory authorities that could jeopardize ARCA&#8217;s ability to market the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the FDA, state or foreign regulations, the marketing of ARCA&#8217;s drug products by itself or its collaborators will be regulated by federal, state or foreign laws pertaining to health care &#8220;fraud and abuse,&#8221; such as the federal anti<span class="nobreak">-kickback</span> law prohibiting bribes, kickbacks or other remuneration for the order or recommendation of items or services reimbursed by federal health care programs. Many states have similar laws applicable to items or services reimbursed by commercial insurers. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state health care programs, including the Medicare, Medicaid and Veterans Affairs healthcare programs. Because of the far<span class="nobreak">-reaching</span> nature of these laws, ARCA may be required to discontinue one or more of its practices to be in compliance with these laws. Healthcare fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. Any violations of these laws, or any action against ARCA for violations of these laws, even if ARCA successfully defends against it, could have a material adverse effect on ARCA&#8217;s business, financial condition and results of operations.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA could also become subject to false claims litigation under federal statutes, which can lead to civil money penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state health care programs. These false claims statutes include the False Claims Act, which allows any person to bring a suit on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, under federal programs or contracts claims or other violations of the statute and to share in any amounts paid by the entity to the government in fines or settlement. These suits against pharmaceutical companies have increased significantly in volume and breadth in recent&#160;years. Some of these suits have been brought on the basis of certain sales practices promoting drug products for unapproved uses. This new growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay fines or restitution, or be excluded from the Medicare, Medicaid, Veterans Affairs and other federal and state healthcare programs as a result of an investigation arising out of such action. ARCA may become subject to such litigation and, if ARCA is not successful in defending against such actions, those actions may have a material adverse effect on its business, financial condition and results of operations. ARCA could also become subject to false claims litigation and consumer protection claims under state statutes, which also could lead to civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in state health care programs. Of note, over the past few&#160;years there has been an increased focus on the sales and marketing practices of the pharmaceutical industry at both the federal and state level. Additionally, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be adopted that could prevent or delay regulatory approval of ARCA&#8217;s product candidates or limit ARCA&#8217;s ability to commercialize its products. ARCA cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United&#160;States or elsewhere.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA, its collaborators or its third<span class="nobreak">-party</span> manufacturers fail to comply with applicable continuing regulatory requirements, ARCA&#8217;s business could be seriously harmed because a regulatory agency may:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>issue untitled or warning letters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspend or withdraw ARCA&#8217;s regulatory approval for approved products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seize or detain products or recommend a product recall of a drug or medical device, or issue a mandatory recall of a medical device;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refuse to approve pending applications or supplements to approved applications filed by ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspend ARCA&#8217;s ongoing clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrict ARCA&#8217;s operations, including costly new manufacturing requirements, or restrict the sale, marketing and/or distribution of ARCA&#8217;s products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seek an injunction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue criminal prosecutions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>close the facilities of ARCA&#8217;s contract manufacturers; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>impose civil or criminal penalties.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Reliance on third parties to commercialize Gencaro, rNAPc2 or ARCA&#8217;s other product candidates could negatively impact ARCA&#8217;s business. If ARCA is required to establish a direct sales force in the United&#160;States and are unable to do so, its business may be harmed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Commercialization of Gencaro, rNAPc2 or any other product candidate, if approved, particularly the establishment of a sales organization, will require substantial additional capital resources. ARCA currently intends to pursue a strategic partnership alternative for the commercialization of Gencaro or rNAPc2, if it is approved, and ARCA has suspended its efforts to build internal sales, marketing and distribution capabilities. If ARCA elects to rely on third parties to sell Gencaro, rNAPc2 and any other products, then it may receive less revenue than if it sold such products directly. In addition, ARCA may have little or no control over the sales efforts of those third parties. If ARCA is unable to complete a strategic transaction, ARCA would be unable to commercialize Gencaro, rNAPc2 </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">or any other product candidate without substantial additional capital. Even if such capital were secured, ARCA would be required to build internal sales, marketing and distribution capabilities to market Gencaro or rNAPc2 in the United&#160;States. None of ARCA&#8217;s current employees have experience in establishing and managing a sales force.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event ARCA is unable to sell Gencaro, rNAPc2 and other selected product candidates, either directly or through third parties via a strategic transaction, the commercialization of Gencaro or rNAPc2, if approved, may be delayed indefinitely.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA is dependent on ARCA&#8217;s key personnel.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The success of ARCA&#8217;s business is highly dependent on the principal members of ARCA&#8217;s board of directors and executive management. The loss of the services of any such individual might seriously harm ARCA&#8217;s product development, partnering and financing efforts. Recruiting and training personnel with the requisite skills is challenging and ARCA competes for talent with companies that are larger and have more financial resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has no manufacturing capacity which puts it at risk of lengthy and costly delays of bringing its products to market.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not currently operate manufacturing facilities for clinical or commercial production of its product candidates, including their drug substance or active pharmaceutical ingredients, or API.&#160;ARCA has no experience in drug formulation or manufacturing, and it lacks the resources and the capabilities to manufacture any of its product candidates on a clinical or commercial scale. ARCA does not intend to develop facilities for the manufacture of product candidates for clinical trials or commercial purposes in the foreseeable future. ARCA has contracted with several third<span class="nobreak">-party</span> manufacturing organizations for production and analytical testing of its product candidates. These contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute ARCA&#8217;s products. In addition, these manufacturers may have staffing difficulties, may experience delays due to key material or component availability, may not be able to manufacture ARCA&#8217;s products on a timely basis or may become financially distressed. In the event of errors in forecasting production quantities required to meet demand, natural disaster, equipment malfunctions or failures, technology malfunctions, strikes, lock<span class="nobreak">-outs</span> or work stoppages, regional power outages, product tampering, war or terrorist activities, actions of regulatory authorities, business failure, strike or other difficulty, ARCA may be unable to find an alternative third<span class="nobreak">-party</span> manufacturer in a timely manner and the production of its product candidates would be interrupted, resulting in delays and additional costs, which could impact ARCA&#8217;s ability to commercialize and sell its product candidates. ARCA or its contract manufacturers may also fail to achieve and maintain required manufacturing standards, which could result in patient injury or death, product recalls or withdrawals, an order by governmental authorities to halt production, delays or failures in product testing or delivery, stability testing failures, cost overruns or other problems that could seriously hurt ARCA&#8217;s business. Contract manufacturers also often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. In addition, ARCA&#8217;s contract manufacturers are subject to ongoing inspections and regulation by the FDA, the U.S.&#160;Drug Enforcement Agency and corresponding foreign and state agencies and they may fail to meet these agencies&#8217; acceptable standards of compliance. If ARCA&#8217;s contract manufacturers fail to comply with applicable governmental regulations, such as quality control, quality assurance and the maintenance of records and documentation, ARCA may not be able to continue production of the API or finished product. If the safety of any API or product supplied is compromised due to failure to adhere to applicable laws or for other reasons, this may jeopardize ARCA&#8217;s regulatory approval for Gencaro, rNAPc2 and other product candidates, and ARCA may be held liable for any injuries sustained as a result. Upon the occurrence of one of the aforementioned events, the ability to switch manufacturers may be difficult for a number of reasons, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number of potential manufacturers is limited and ARCA may not be able to negotiate agreements with alternative manufacturers on commercially reasonable terms, if at all;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>long lead times are often needed to manufacture drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the manufacturing process is complex and may require a significant learning curve; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the FDA must approve any replacement prior to manufacturing, which requires new testing and compliance inspections.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transitioning from a clinical development stage company will require successful completion of a number of steps, many of which are outside of ARCA&#8217;s control and, consequently, ARCA can provide no assurance of its successful and timely transition from a clinical development stage company.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is a clinical development stage biopharmaceutical company with a limited operating history. To date ARCA has not generated any product revenue and has historically funded ARCA&#8217;s operations through investment capital. ARCA&#8217;s future growth depends on its ability to emerge from the clinical development stage and successfully commercialize or provide for the commercialization of Gencaro, rNAPc2 and ARCA&#8217;s other product candidates, which in turn will depend, among other things, on ARCA&#8217;s ability to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>conduct additional clinical trials and develop and obtain regulatory approval for Gencaro, rNAPc2 or other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully partner a companion genetic test with the commercial launch of Gencaro or rNAPc2;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into a strategic transaction enabling the continued development and commercialization of Gencaro or rNAPc2, or alternatively, raise significant additional capital to enable these activities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue additional indications for Gencaro or rNAPc2 and develop other product candidates, including other cardiovascular therapies; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtain commercial quantities of Gencaro, rNAPc2 or other product candidates at acceptable cost levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any one of these factors or other factors discussed in this report could affect ARCA&#8217;s ability to successfully commercialize Gencaro and other product candidates, which could impact ARCA&#8217;s ability to earn sufficient revenues to transition from a clinical development stage company and continue ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If approved by the FDA, Gencaro or rNAPc2 will be entering a competitive marketplace and may not succeed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro is a new type of beta<span class="nobreak">-blocker</span> and vasodilator being developed for AF.&#160;While ARCA anticipates that this drug, if approved, would be the first genetically<span class="nobreak">-targeted</span> cardiovascular drug, and potentially the only beta<span class="nobreak">-blocker</span> approved for AF, Gencaro will be one of a number of accepted treatments for AF.&#160;In addition, ARCA&#8217;s proposed prescribing information for Gencaro is expected to include a requirement for genetic testing of the patient to ascertain if they have the genotype that ARCA believes responds best to Gencaro. This additional step will add incremental cost and procedures to prescribing Gencaro, which could make it more difficult to compete against existing therapies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not yet know what the commercial opportunity will be, if any, for rNAPc2 if it is approved for treating COVID<span class="nobreak">-19</span> disease. ARCA does not know how and to whom rNAPc2 would be marketed and what the commercial arrangements would be for its sales and reimbursement. While ARCA anticipates that rNAPc2, if approved, could potentially be used in combination with antiviral drugs and other therapies, there are other vaccines and therapies under development.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s commercial opportunity may be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than Gencaro. If products with any of these properties are developed, or any of the existing products are better marketed, then prescriptions of Gencaro by physicians and patient use of Gencaro could be significantly reduced or rendered obsolete and noncompetitive. Further, public announcements regarding the development of any such competing drugs could adversely affect the market price of ARCA common stock and the value of ARCA&#8217;s assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of ARCA&#8217;s products may suffer if they are not accepted in the marketplace by physicians, patients and the medical community.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro, rNAPc2 or ARCA&#8217;s other product candidates may not gain market acceptance among physicians, patients and the medical community. The degree of market acceptance of Gencaro, rNAPc2 or ARCA&#8217;s other product candidates will depend on a number of factors, such as its effectiveness and tolerability, as compared with competitive drugs. For instance, if rNAPc2 is approved, by that time there may be superior alternatives in terms of vaccines and/or therapeutics that may significantly impact the relative medical benefits offered by rNAPc2. If </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ARCA&#8217;s future clinical trials for rNAPc2 do not show that rNAPc2 has a clear therapeutic benefit as compared to other therapies or vaccines that are approved in the interim, then there may be a limited or no commercial market for rNAPc2. Also, prevalence and severity of side<span class="nobreak">-effects</span> could negatively affect market acceptance of rNAPc2. Failure to achieve market acceptance of Gencaro or rNAPc2 would significantly harm ARCA&#8217;s business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA is unable to obtain acceptable prices or adequate reimbursement from third<span class="nobreak">-party</span> payors for Gencaro, rNAPc2, or any other product candidates that it may seek to commercialize, then ARCA&#8217;s revenues and prospects for profitability will suffer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2, or any other product candidates that ARCA may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>governmental payors, such as Medicare and Medicaid;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>private health insurers, including managed<span class="nobreak">-care</span> organizations; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other third<span class="nobreak">-party</span> payors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Many patients will not be capable of paying for ARCA&#8217;s potential products themselves and will rely on third<span class="nobreak">-party</span> payors to pay for their medical needs. A primary current trend in the U.S.&#160;health care industry is toward cost containment. Large private payors, managed<span class="nobreak">-care</span> organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third<span class="nobreak">-party</span> payors, including Medicare, are challenging the prices charged for medical products and services, and many third<span class="nobreak">-party</span> payors limit reimbursement for newly approved health care products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cost<span class="nobreak">-control</span> initiatives could decrease the price ARCA might establish for products, which could result in product revenues lower than anticipated. If the prices for ARCA&#8217;s product candidates decrease, or if governmental and other third<span class="nobreak">-party</span> payors do not provide adequate coverage and reimbursement levels, then ARCA&#8217;s revenue and prospects for profitability will suffer.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Health care reform measures could materially and adversely affect ARCA&#8217;s business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third<span class="nobreak">-party</span> payors to contain or reduce the costs of health care. The U.S.&#160;Congress has enacted legislation to reform the health care system. While ARCA anticipates that this legislation may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid managed care organizations as well as expansion of the 340(B)&#160;Public Health Services drug discount program. In addition, such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion, including new fees or taxes on certain health<span class="nobreak">-related</span> industries, including medical device manufacturers. Each medical device manufacturer has to pay an excise tax (or sales tax) in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices. Such excise taxes may impact any potential sales of the genetic test if it is approved for marketing. On January&#160;22, 2018, legislation was enacted suspending the medical device tax in 2018 and 2019. In December&#160;2019, a permanent repeal of the medical device tax was enacted. The Gencaro Test (as defined elsewhere in this proxy statement/prospectus) is likely to be subject to this tax if this tax is reinstated in the future. In foreign jurisdictions there have been, and ARCA expects that there will continue to be, a number of legislative and regulatory proposals aimed at changing the health care system. For example, in some countries other than the United&#160;States, pricing of prescription drugs is subject to government control and ARCA expects to see continued efforts to reduce healthcare costs in international markets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform in the future although ARCA is unable to predict what additional legislation or regulation, if any, relating to the health care industry or third<span class="nobreak">-party</span> coverage and reimbursement may be enacted in the future or what effect such legislation or regulation would have on ARCA&#8217;s business. ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2, or any other product candidates that ARCA may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from government payors, such as Medicare and Medicaid, private health insurers, including managed care organizations, and other third<span class="nobreak">-party</span> payors, and any change in reimbursement levels could materially and adversely affect ARCA&#8217;s business. Further, the pendency or approval of future proposals or reforms could result in a decrease in ARCA&#8217;s stock price or limit ARCA&#8217;s ability to raise capital or to obtain strategic partnerships or licenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s competitors may be better positioned in the marketplace and thereby may be more successful than ARCA at developing, manufacturing and marketing approved products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Many of ARCA&#8217;s competitors currently have significantly greater financial resources and expertise in conducting clinical trials, obtaining regulatory approvals, managing manufacturing and marketing approved products than ARCA.&#160;Other early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, these third parties compete with ARCA in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring therapies and therapy licenses complementary to ARCA&#8217;s programs or advantageous to ARCA&#8217;s business. ARCA expects that its ability to compete effectively will depend upon its ability to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully and rapidly complete clinical trials for any product candidates and obtain all requisite regulatory approvals in a cost<span class="nobreak">-effective</span> manner;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>build an adequate sales and marketing infrastructure, raise additional funding, or enter into strategic transactions enabling the commercialization of ARCA&#8217;s products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>develop competitive formulations of ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>attract and retain key personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>identify and obtain other product candidates on commercially reasonable terms.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA fails to identify and license or acquire other products or product candidates, then it may be unable to expand its business, and the acquisition or licensing of other products or product candidates may put a strain on its operations and will likely require it to seek additional financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of ARCA&#8217;s strategies is to license or acquire clinical<span class="nobreak">-stage</span> products or product candidates and further develop them for commercialization. The market for licensing and acquiring products and product candidates is intensely competitive and many of ARCA&#8217;s competitors may have greater resources than ARCA does. If ARCA undertakes any additional acquisitions, whether of product candidates or other biopharmaceutical companies, the process of integrating an acquired product candidate or complementary company into ARCA&#8217;s business may put a strain on ARCA&#8217;s operations, divert personnel, financial resources and management&#8217;s attention. In 2020, ARCA&#8217;s research and development activities were dedicated to initiating the clinical trial of rNAPc2. If ARCA is not able to substantially expand ARCA&#8217;s research and development efforts, or identify, or license or acquire other products or product candidates or complete future acquisitions, then it will likely be unable expand its pipeline of product candidates. In addition, any future acquisition would give rise to additional operating costs and will likely require ARCA to seek additional financing. Future acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, contingent liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect ARCA&#8217;s operating results.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA would be subject to applicable regulatory approval requirements of the foreign countries in which it markets its products, which are costly and may prevent or delay ARCA from marketing its products in those countries.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to regulatory requirements in the United&#160;States, ARCA would be subject to the regulatory approval requirements in each foreign country where it markets its products. In addition, ARCA might be required to identify one or more collaborators in these foreign countries to develop, seek approval for and manufacture ARCA&#8217;s products and any companion genetic test for Gencaro. If ARCA decides to pursue regulatory approvals and commercialization of its product candidates internationally, it may not be able to obtain the required foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause ARCA to incur additional costs or prevent it from marketing it products in foreign countries, which may have a material adverse effect on its business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA&#8217;s internal control over financial reporting is not considered effective, ARCA&#8217;s business and stock price could be adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act&#160;of&#160;2002 requires ARCA to evaluate the effectiveness of its internal control over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of its internal control over financial reporting in its annual report on Form&#160;10<span class="nobreak">-K</span> for that fiscal year. ARCA&#8217;s management, including ARCA&#8217;s principal executive officer and principal financial officer, does not expect that ARCA&#8217;s internal control over financial reporting will prevent all error and all fraud. ARCA continues to operate with a small staff for financial reporting. Though the process and design of ARCA&#8217;s internal controls over financial reporting have not been altered, the small number of staff involved in financial reporting may limit ARCA&#8217;s ability to properly segregate internal control procedures which could result in deficiencies or material weaknesses in ARCA&#8217;s internal controls in the future. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and ARCA cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become ineffective because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost<span class="nobreak">-effective</span> control system, misstatements due to error or fraud may occur and not be detected. ARCA cannot assure you that it or its independent registered public accounting firm will not identify a material weakness in ARCA&#8217;s internal control over financial reporting in the future. A material weakness in ARCA&#8217;s internal control over financial reporting would require management to consider ARCA&#8217;s internal control over financial reporting as ineffective. If ARCA&#8217;s internal control over financial reporting is not considered effective, ARCA may experience a loss of public confidence, which could have an adverse effect on its business and on the market price of ARCA common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Changes in tax laws or regulations that are applied adversely to ARCA or its customers may have a material adverse effect on ARCA&#8217;s business, cash flow, financial condition or results of operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of ARCA&#8217;s domestic and foreign earnings. Any new taxes could adversely affect ARCA&#8217;s domestic and international business operations, and ARCA&#8217;s business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to ARCA.&#160;For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, significantly revised the Internal Revenue Code of 1986, as amended, or the Code. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Cuts and Jobs Act may affect ARCA, and certain aspects of the Tax Cuts and Jobs Act could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to ARCA&#8217;s operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act or future reform legislation could have a material impact on the value of ARCA&#8217;s deferred tax assets, could result in significant one<span class="nobreak">-time</span> charges, and could increase ARCA&#8217;s future U.S.&#160;tax expense.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s ability to use ARCA&#8217;s net operating losses to offset future taxable income may be subject to certain limitations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, ARCA had net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA had net operating loss carryforwards of $156.4&#160;million generated prior to 2018, which will expire beginning in 2025 if not utilized. Under the Tax Cuts and Jobs Act, ARCA&#8217;s U.S.&#160;federal NOLs of $51.7&#160;million incurred in tax&#160;years beginning after December&#160;31, 2017, may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax&#160;years beginning after December&#160;31, 2017, is limited to 80% of taxable income. In addition, under Section&#160;382 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; (as defined under Section&#160;382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its pre<span class="nobreak">-change</span> NOLs to offset future taxable income. ARCA has not determined whether it has experienced an ownership change in the past, and ARCA may experience ownership changes in the future as a result of subsequent shifts in ARCA&#8217;s stock ownership, some of which may be outside of ARCA&#8217;s control. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, ARCA&#8217;s existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state tax purposes. For these reasons, ARCA may not be able to utilize a material portion of the NOLs reflected on its balance sheet, offset by a full valuation, even if it attains profitability, which could potentially result in increased future tax liability to ARCA and could adversely affect its operating results and financial condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Security breaches, cyber-attacks, or other disruptions or incidents could expose ARCA to liability and affect its business and reputation.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is increasingly dependent on its information technology systems and infrastructure for its business. ARCA, its collaborators and its service providers collect, store, and transmit sensitive information including intellectual property, proprietary business information, clinical trial data and personal information in connection with ARCA&#8217;s business operations. The secure maintenance of this information is critical to ARCA&#8217;s operations and business strategy. Some of this information could be an attractive target of criminal attack by third parties with a wide range of motives and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; patient groups, disgruntled current or former employees, nation<span class="nobreak">-state</span> and nation<span class="nobreak">-state</span> supported actors, and others. Cyber<span class="nobreak">-attacks</span> are of ever<span class="nobreak">-increasing</span> levels of sophistication, and despite ARCA&#8217;s security measures, ARCA&#8217;s information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has implemented information security measures to protect ARCA&#8217;s systems, proprietary information and sensitive data against the risk of inappropriate and unauthorized external use and disclosure and other types of compromise. However, despite these measures, and due to the ever<span class="nobreak">-changing</span> information cyber<span class="nobreak">-threat</span> landscape, ARCA cannot guarantee that these measures will be adequate to detect, prevent or mitigate security breaches and other incidents and ARCA may be subject to data breaches through cyber<span class="nobreak">-attacks</span>, malicious code (such as viruses and worms), phishing attacks, social engineering schemes, and insider theft or misuse. Any such breach could compromise ARCA&#8217;s networks and the information stored there could be accessed, modified, destroyed, publicly disclosed, lost or stolen. If ARCA&#8217;s systems become compromised, ARCA may not promptly discover the intrusion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any security breach of other incident, whether real or perceived, could cause ARCA to suffer reputational damage. Such incidents could result in costs to respond to, investigate and remedy such incidents, notification obligations to affected individuals, government agencies, credit reporting agencies and other third parties, legal claims or proceedings, and liability under ARCA&#8217;s contracts with other parties and federal and state laws that protect the privacy and security of personal information. Any one of these events could cause ARCA&#8217;s business to be materially harmed and its results of operations would be adversely impacted.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect ARCA&#8217;s operating results and business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and its partners may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United&#160;States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and federal and state consumer protection laws and regulations (e.g., Section&#160;5 of the FTC Act), that govern the collection, use, disclosure, and protection of health<span class="nobreak">-related</span> and other personal information could apply to ARCA&#8217;s operations or the operations of ARCA&#8217;s partners. In addition, ARCA may obtain health information from third parties (including research institutions from which ARCA obtains clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act&#160;of&#160;1996, as amended, or HIPAA.&#160;Depending on the facts and circumstances, ARCA could be subject to criminal penalties if it knowingly obtains, uses or discloses individually identifiable health information maintained by a HIPAA<span class="nobreak">-covered</span> entity in a manner that is not authorized or permitted by HIPAA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the California Consumer Privacy Act, or the CCPA, became effective on January&#160;1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt<span class="nobreak">-out</span> of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for clinical trial data and the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, the CCPA may increase ARCA&#8217;s compliance costs and potential liability. Many similar privacy laws have been proposed at the federal level and in other states.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Foreign data protection laws, including, without limitation, the European Union Directive 95/46/EC (the &#8220;Directive&#8221;) and the European Union&#8217;s General Data Protection Regulation (the &#8220;GDPR&#8221;) that became effective in May&#160;2018, and member state data protection legislation, may also apply to health<span class="nobreak">-related</span> and other personal information obtained outside of the United&#160;States. These laws impose strict obligations on the ability to process health<span class="nobreak">-related</span> and other personal information of data subjects in the European Union and the United Kingdom, including in relation to use, collection, analysis, and transfer (including cross<span class="nobreak">-border</span> transfer) of such personal information. These laws include several requirements relating to the consent of the individuals to whom the personal data relates, limitations on data processing, establishing a legal basis for processing, notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects, the security and confidentiality of the personal data and various rights that data subjects may exercise.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Directive and the GDPR prohibit, without an appropriate legal basis, the transfer of personal data to countries outside of the European Economic Area, or EEA, such as the United&#160;States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United&#160;States, uncertainty about compliance with European Union data protection laws remains. For example, ongoing legal challenges in Europe to the mechanisms allowing companies to transfer personal data from the EEA to the United&#160;States could result in further limitations on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain existing agreements that support cross<span class="nobreak">-border</span> data transfers, such as the European Union<span class="nobreak">-U</span>.S.&#160;and Swiss<span class="nobreak">-U</span>.S.&#160;Privacy Shield framework. Additionally, other countries have passed or are considering passing laws requiring local data residency.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the GDPR, regulators may impose substantial fines and penalties for non<span class="nobreak">-compliance</span>. Companies that violate the GDPR can face fines of up to the greater of 20&#160;million Euros or 4% of their worldwide annual turnover (revenue). The GDPR increases ARCA&#8217;s responsibility and potential liability in relation to personal data that ARCA processes, and ARCA may be required to put in place additional mechanisms to ensure compliance with the GDPR and other EU and international data protection rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Compliance with U.S.&#160;and foreign privacy and security laws, rules and regulations could require ARCA to take on more onerous obligations in its contracts, require it to engage in costly compliance exercises, restrict its ability to collect, use and disclose data, or in some cases, impact its or its partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. Failure to comply with U.S.&#160;and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties), fines, private litigation, and/or adverse publicity and could negatively affect ARCA&#8217;s operating results and business. Moreover, patients about whom ARCA or its partners obtain information, as well as the providers who share this information with ARCA, may contractually limit ARCA&#8217;s </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ability to use and disclose the information. Claims that ARCA has violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached its contractual obligations, even if ARCA is not found liable, could be expensive and time<span class="nobreak">-consuming</span> to defend and could result in adverse publicity that could harm ARCA&#8217;s business.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Intellectual Property and Other Legal Matters</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If product liability lawsuits are successfully brought against ARCA, then ARCA will incur substantial liabilities and may be required to limit commercialization of Gencaro, rNAPc2 or other product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA faces product liability exposure related to the testing of its product candidates in human clinical trials, and may face exposure to claims by an even greater number of persons once it begins marketing and distributing ARCA&#8217;s products commercially. If ARCA cannot successfully defend against product liability claims, then it will incur substantial liabilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit or eventual outcome, liability claims may result in:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>decreased demand for ARCA&#8217;s products and product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injury to ARCA&#8217;s reputation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>withdrawal of clinical trial participants;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>costs of related litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>substantial monetary awards to patients and others;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>loss of revenues; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the inability to commercialize ARCA&#8217;s products and product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has obtained limited product liability insurance coverage. Such coverage, however, may not be adequate or may not continue to be available to ARCA in sufficient amounts or at an acceptable cost, or at all. ARCA may not be able to obtain commercially reasonable product liability insurance for any product candidate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defending against claims relating to improper handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be time consuming and expensive.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s research and development of product candidates may involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials. ARCA cannot eliminate the risk of accidental contamination or discharge and any resultant injury from the materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. ARCA may be sued or be required to pay fines for any injury or contamination that results from its use or the use by third parties of these materials. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair ARCA&#8217;s research, development and production efforts.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The loss of any rights to market key products would significantly impair ARCA&#8217;s operating results.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s patent portfolios relating to Gencaro, including a patent that issued in 2021, are either owned by ARCA or are subject to licenses that impose no royalty obligations or milestone payments relating to the further development, approval and commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Termination of ARCA&#8217;s license agreements could result in the loss of its further rights to develop and commercialize Gencaro for any indication. The termination of any such license, or of any other agreement which enables ARCA to market a key product or product candidate, could significantly and adversely affect its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain intellectual property licensed by ARCA is the subject of additional licensing arrangements to which the party that has licensed rights to ARCA is subject. If such parties were to breach the terms of such licenses or such licenses were otherwise to terminate, ARCA&#8217;s and ARCA&#8217;s partners&#8217; rights to use such technology and develop and commercialize their products such as the genetic test may terminate and ARCA&#8217;s business would be materially harmed.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Third parties may own or control patents or patent applications that ARCA may be required to license to commercialize ARCA&#8217;s product candidates or that could result in litigation that would be costly and time consuming.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2 and other product candidates depends upon ARCA&#8217;s ability to develop, manufacture, market and sell these drugs without infringing the proprietary rights of third parties. A number of pharmaceutical and biotechnology companies, universities and research institutions have or may be granted patents that cover technologies similar to the technologies owned by or licensed to ARCA.&#160;ARCA may choose to seek, or be required to seek, licenses under third<span class="nobreak">-party</span> patents, which would likely require the payment of license fees or royalties or both. ARCA may also be unaware of existing patents that may be infringed by Gencaro or rNAPc2, the genetic testing ARCA intends to use in connection with Gencaro or its other product candidates. Because patent applications can take many&#160;years to issue, there may be other currently pending applications that may later result in issued patents that are infringed by Gencaro, rNAPc2 or ARCA&#8217;s other product candidates. Moreover, a license may not be available to ARCA on commercially reasonable terms, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that ARCA is infringing on its technology, then ARCA&#8217;s business and results of operations could be harmed by a number of factors, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>infringement and other intellectual property claims, even if without merit, are expensive and time<span class="nobreak">-consuming</span> to litigate and can divert management&#8217;s attention from ARCA&#8217;s core business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>monetary damage awards for past infringement can be substantial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a court may prohibit ARCA from selling or licensing product candidates unless the patent holder chooses to license the patent to ARCA; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if a license is available from a patent holder, ARCA may have to pay substantial royalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may also be forced to bring an infringement action if its believes that a competitor is infringing ARCA&#8217;s protected intellectual property. Any such litigation will be costly, time<span class="nobreak">-consuming</span> and divert management&#8217;s attention, and the outcome of any such litigation may not be favorable to ARCA.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s intellectual property rights may not preclude competitors from developing competing products and ARCA&#8217;s business may suffer.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s competitive success will depend, in part, on ARCA&#8217;s ability to obtain and maintain patent protection for its inventions, technologies and discoveries, including intellectual property that ARCA licenses. The patent positions of biotechnology companies involve complex legal and factual questions, and ARCA cannot be certain that its patents and licenses will successfully preclude others from using its technology. Consequently, ARCA cannot be certain that any of its patents will provide significant market protection or will not be circumvented or challenged and found to be unenforceable or invalid. In some cases, patent applications in the United&#160;States and certain other jurisdictions are maintained in secrecy until patents issue, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, ARCA cannot be certain of the priority of inventions covered by pending patent applications. Moreover, ARCA may have to participate in interference proceedings declared by the U.S.&#160;Patent and Trademark Office to determine priority of invention, in opposition proceedings in a foreign patent office, or in a post<span class="nobreak">-grant</span> challenge proceeding such as an <span class="Italic" style="font-style:italic;font-weight:normal;">ex parte</span> reexamination or <span class="Italic" style="font-style:italic;font-weight:normal;">inter partes</span> review at the U.S.&#160;Patent and Trademark Office, any of which could result in substantial cost to ARCA, even if the eventual outcome is favorable. There can be no assurance that a court of competent jurisdiction would hold any claims in any issued patent to be valid and enforceable. An adverse outcome could subject ARCA to significant liabilities to third parties, require disputed rights to be licensed from third parties or require ARCA to cease using such technology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA owns the clinical development program of rNAPc2, including Phase&#160;2b clinical trials. If rNAPc2 is successfully developed, ARCA believes it will have intellectual property protection for a specific use, including 12&#160;years of market exclusivity as an innovative biologic product under FDA law in the United&#160;States, 10&#160;years data protection exclusivity in the EU, and potentially patent protection in addition to this. However, another competitor could develop a compound with similar biological properties to rNAPc2 that may not be barred by ARCA&#8217;s exclusivity. ARCA has also filed a patent application for rNAPc2 and its use for COVID<span class="nobreak">-19</span> disease, but there is no assurance that this application will ultimately result in an issued patent.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit, the listing of patents in the FDA Orange Book for Gencaro may be challenged as being improperly listed. ARCA may have to defend against such claims and possible associated antitrust issues. ARCA could also incur substantial costs in seeking to enforce its proprietary rights against infringement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the composition of matter patents on the compound that comprises Gencaro have expired, ARCA holds intellectual property concerning the interaction of Gencaro with the polymorphisms of the beta<span class="nobreak">-1</span> and alpha<span class="nobreak">-2C</span> receptors. ARCA has obtained patents that claim methods involving Gencaro after a patient&#8217;s receptor genotype has been determined. ARCA anticipates that any NDA for Gencaro will request a label including a claim that efficacy varies based on receptor genotype and a recommendation in the prescribing information that prospective patients be tested for their receptor genotype. ARCA believes that under applicable law, a generic bucindolol label would likely be required to include this recommendation as it pertains directly to the safe or efficacious use of the drug. Such a label may be considered as inducing infringement, carrying the same liability as direct infringement. If the label with the genotype information for Gencaro is not approved or it is approved after the relevant patents expire, or if generic labels are not required to copy the approved label, competitors could have an easier path to introduce competing products and ARCA&#8217;s business may suffer. The approved label may not contain language covered by the patents, or ARCA may be unsuccessful in enforcing them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has obtained intellectual property related to the use of Gencaro for various cardiovascular indications in the genetic population it plans to study in Phase&#160;3. The approved label may not contain language covered by ARCA&#8217;s patents and it is possible the intellectual property may not preclude others from commercializing a generic version of Gencaro, which could cause ARCA&#8217;s business to suffer. Additionally, the patents may be invalidated and/or ARCA may be unsuccessful in enforcing them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may not be able to effectively protect its intellectual property rights in some foreign countries, as its patents are limited by jurisdiction and many countries do not offer the same level of legal protection for intellectual property as the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA requires its employees, consultants, business partners and members of its scientific advisory board to execute confidentiality agreements upon the commencement of employment, consulting or business relationships with ARCA.&#160;These agreements provide that all confidential information developed or made known during the course of the relationship with ARCA be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions resulting from work performed for ARCA, utilizing the property or relating to ARCA&#8217;s business and conceived or completed by the individual during employment shall be ARCA&#8217;s exclusive property to the extent permitted by applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Third parties may breach these and other agreements with ARCA regarding its intellectual property and ARCA may not have adequate remedies for the breach. Third parties could also fail to take necessary steps to protect ARCA&#8217;s licensed intellectual property, which could seriously harm ARCA&#8217;s intellectual property position.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA is not able to protect its proprietary technology, trade secrets and know<span class="nobreak">-how</span>, then its competitors may develop competing products. Any issued patent may not be sufficient to prevent others from competing with ARCA.&#160;Further, ARCA has trade secrets relating to rNAPc2 and Gencaro, and such trade secrets may become known or independently discovered. ARCA&#8217;s issued patents and those that may issue in the future, or those licensed to ARCA, may be challenged, opposed, invalidated or circumvented, which could allow competitors to market similar products or limit the patent protection term of ARCA&#8217;s product candidates. All of these factors may affect ARCA&#8217;s competitive position.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the manufacture, use or sale of ARCA&#8217;s products infringe on the intellectual property rights of others, ARCA could face costly litigation, which could cause it to pay substantial damages or licensing fees and limit its ability to sell some or all of its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Extensive litigation regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims, enforce patent rights, protect trade secrets or know<span class="nobreak">-how</span> and determine the enforceability, scope and validity of certain proprietary rights. Litigation may even be necessary to defend disputes of inventorship or ownership of proprietary rights. The defense and prosecution of intellectual property lawsuits, U.S.&#160;Patent and Trademark Office interference proceedings, and related legal and administrative proceedings (e.g., a reexamination, <span class="Italic" style="font-style:italic;font-weight:normal;">inter partes</span> review, or post<span class="nobreak">-grant</span> review) in the United&#160;States and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time<span class="nobreak">-consuming</span> to pursue, and their outcome is uncertain.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit or outcome, ARCA&#8217;s involvement in any litigation, interference or other administrative proceedings could cause it to incur substantial expense and could significantly divert the efforts of its technical and management personnel. Any public announcements related to litigation or interference proceedings initiated or threatened against ARCA could cause ARCA&#8217;s stock price to decline. Adverse outcomes in patent litigation may potentially subject ARCA to antitrust litigation which, regardless of the outcome, would adversely affect ARCA&#8217;s business. An adverse determination may subject ARCA to the loss of its proprietary position or to significant liabilities, or require it to seek licenses that may include substantial cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse determination or a failure to obtain necessary licenses may restrict or prevent ARCA from manufacturing and selling its products, if any. These outcomes could materially harm ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Ownership of ARCA Common Stock and Stock Price Volatility</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s stock price has been and is expected to be volatile.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock has in the past been, and in the future could be, subject to significant fluctuations. Market prices for securities of early<span class="nobreak">-stage</span> pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of ARCA common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to complete, or delays in completing, the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the regulatory status of Gencaro, rNAPc2 and the genetic test, and whether and when they are approved for sale, if at all, and the labeling or other conditions of use imposed by the FDA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to secure additional funding or complete a strategic transaction or to complete development of and commercialize Gencaro or rNAPc2;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>progress of any future clinical trials for Gencaro, rNAPc2 or ARCA&#8217;s other product candidate, including enrollment and any data that may become available;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results of ARCA&#8217;s future clinical trials and any future NDAs of ARCA&#8217;s current and future product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the entry into, or termination of, key agreements, including key strategic alliance agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results and timing of regulatory reviews relating to ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of any of ARCA&#8217;s product candidates, if approved, to achieve commercial success;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general and industry<span class="nobreak">-specific</span> economic conditions that may affect ARCA&#8217;s research and development expenditures;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results of clinical trials conducted by others on drugs that would compete with ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>issues in manufacturing or testing ARCA&#8217;s product candidates or any approved products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initiation of or material developments in or the conclusion of litigation to enforce or defend any of ARCA&#8217;s intellectual property rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the loss of key employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the introduction of technological innovations or new commercial products by ARCA&#8217;s competitors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in estimates or recommendations by securities analysts, if any, who cover ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>future sales of ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in the structure of health care payment systems;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span> fluctuations in ARCA&#8217;s financial results; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of ARCA common stock on the Nasdaq Capital Market.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict. These broad market fluctuations may also adversely affect the trading price of ARCA common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm ARCA&#8217;s profitability and reputation.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales or the possibility of future sales of ARCA common stock may depress the market price of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sales in the public market of substantial amounts of ARCA common stock could depress prevailing market prices of ARCA common stock. As of March&#160;31, 2024, approximately 14.5<span class="nobreak"> </span>million shares of common stock were outstanding, and all of these shares are freely transferable without restriction or further registration under the Securities Act&#160;of&#160;1933, as amended, or the Securities Act, except for shares held by ARCA&#8217;s directors, officers and other affiliates and unregistered shares held by non<span class="nobreak">-affiliates</span>. The sale of these additional shares, or the perception that such sales may occur, could depress the market price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, there were approximately 646,000<span class="nobreak"> </span>shares of ARCA common stock which may be issued upon the exercise of outstanding stock options, and ARCA anticipates that it will continue to issue stock option and restricted stock unit awards to its employees and consultants in the fiscal year ended December&#160;31, 2024 and thereafter. If and when these options are exercised, such shares will be available for sale in the open market without further registration under the Securities Act. The existence of these outstanding options may negatively affect ARCA&#8217;s ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options, and the prompt resale of shares of ARCA common stock received, may also result in downward pressure on the price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the absence of a significant strategic transaction, ARCA will need to raise significant additional capital to finance the research, development and commercialization of Gencaro, rNAPc2 and its other product candidate. If future securities offerings occur, they would dilute ARCA&#8217;s current stockholders&#8217; equity interests and could reduce the market price of ARCA common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA does not expect to pay cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never paid cash dividends on any of its capital stock. As a result, other than the potential special cash dividend described below, only appreciation of the price of ARCA common stock will provide a return to stockholders. Investors seeking cash dividends should not invest in ARCA common stock. In addition, pursuant to the terms of the Merger Agreement, ARCA may declare and pay a special cash dividend to ARCA stockholders of record prior to the closing of the Merger consisting of cash up to an amount equal in the aggregate of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million. See, &#8220;ARCA has never paid and, other than in connection with the Merger with Oruka, do not intend to pay any cash dividends in the foreseeable future&#8221; for further discussion on the special cash dividend.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s business could be negatively affected as a result of actions of activist shareholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Responding to actions by activist shareholders could be costly and time<span class="nobreak">-consuming</span>, disrupt ARCA&#8217;s operations and divert the attention of management and ARCA&#8217;s employees. For example, in connection with the negotiation and entry into a cooperation agreement in June&#160;2022 with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span>, collectively, Cable Car, one of ARCA&#8217;s stockholders, ARCA appointed two new directors in 2022. Activist shareholders may advocate for certain governance and strategic changes at ARCA.&#160;In the event of stockholder activism, particularly with respect to matters which ARCA&#8217;s board of directors, in exercising their fiduciary duties, disagree with or have determined not to pursue, ARCA&#8217;s business could be adversely affected because responding to actions by activist stockholders can be costly and time<span class="nobreak">-consuming</span>, disrupting ARCA&#8217;s </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">operations and diverting the attention of management, and perceived uncertainties as to ARCA&#8217;s future direction may result in the loss of potential business opportunities and may make it more difficult to attract and retain qualified personnel, business partners, and customers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, if faced with a consent solicitation or proxy contest, ARCA may not be able to respond successfully to the contest or dispute, which would be disruptive to its business. If individuals are elected to ARCA&#8217;s board of directors with a differing agenda, ARCA&#8217;s ability to effectively and timely implement its strategic plan and create additional value for ARCA stockholders may be adversely affected. In addition, ARCA&#8217;s share price could experience periods of increased volatility as a result of shareholder activism.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has implemented anti-takeover provisions that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to ARCA stockholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provisions of the ARCA Charter and ARCA Bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire ARCA, even if doing so would benefit ARCA stockholders. These provisions:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establish a classified board of directors so that not all members of ARCA&#8217;s board may be elected at one time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authorize the issuance of up to approximately 5&#160;million additional shares of preferred stock that could be issued by ARCA&#8217;s board of directors to increase the number of outstanding shares and hinder a takeover attempt;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit who may call a special meeting of stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of ARCA stockholders; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establish advance notice requirements for nominations for election to ARCA&#8217;s board of directors or for proposing matters that can be acted upon at a stockholder meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Specifically, the ARCA Charter provides that all stockholder action must be effected at a duly called meeting and not by a written consent. The ARCA Bylaws provide, however, that ARCA stockholders may call a special meeting of stockholders only upon a request of stockholders owning at least 50% of ARCA&#8217;s outstanding common stock. These provisions of the ARCA Charter and ARCA Bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. ARCA designed these provisions to reduce its vulnerability to unsolicited acquisition proposals and to discourage certain tactics that may be used in proxy fights. These provisions, however, could also have the effect of discouraging others from making tender offers for ARCA&#8217;s shares. As a consequence, they also may inhibit fluctuations in the market price of ARCA&#8217;s shares that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in ARCA&#8217;s management.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is permitted to issue shares of ARCA preferred stock without stockholder approval upon such terms as ARCA&#8217;s board of directors determines. Therefore, the rights of the holders of ARCA common stock are subject to, and may be adversely affected by, the rights of the holders of ARCA preferred stock that may be issued in the future. In addition, the issuance of preferred stock could have a dilutive effect on the holdings of ARCA&#8217;s current stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to the Delaware anti<span class="nobreak">-takeover</span> laws regulating corporate takeovers. These anti<span class="nobreak">-takeover</span> laws prevent a Delaware corporation from engaging in a merger or sale of more than 10% of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15% or more of the corporation&#8217;s outstanding voting stock, for three&#160;years following the date that the stockholder acquired 15% or more of the corporation&#8217;s stock unless:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the board of directors approved the transaction where the stockholder acquired 15% or more of the corporation&#8217;s stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>after the transaction in which the stockholder acquired 15% or more of the corporation&#8217;s stock, the stockholder owned at least 85% of the corporation&#8217;s outstanding voting stock, excluding shares owned </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>on or after this date, the merger or sale is approved by the board of directors and the holders of at least two<span class="nobreak">-thirds</span> of the outstanding voting stock that is not owned by the stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The provisions of ARCA&#8217;s governing documents and current Delaware law may, collectively:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lengthen the time required for a person or entity to acquire control of ARCA through a proxy contest for the election of a majority of ARCA&#8217;s board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>discourage bids for ARCA common stock at a premium over market price; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>generally deter efforts to obtain control of ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Financial Condition and Capital Requirements</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if the Merger and Oruka pre-closing financing are successful, Oruka will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, Oruka had $27.7&#160;million of cash. Should this financing be successful, Oruka will need to raise additional capital to continue to fund its operations and service its debt obligations in the future. If Oruka is unable to raise additional capital when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern. As a result, Oruka has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve months from the date its financial statement as of February<span class="nobreak"> </span>6, 2024 is available to be issued. In light of these concerns, Oruka&#8217;s independent registered public accounting firm included in its opinion on the financial statement an explanatory paragraph expressing substantial doubt about Oruka&#8217;s ability to continue as a going concern beyond twelve months from the date Oruka&#8217;s financial statement is available to be issued.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Developing Oruka&#8217;s product candidates requires a substantial amount of capital. Following the Merger and Oruka pre<span class="nobreak">-closing</span> financing, the combined company will also incur additional costs associated with operating as a public company. Oruka expects its research and development expenses to increase in connection with its ongoing activities, particularly as it advances its product candidates through clinical trials. Oruka will need to raise additional capital to fund its operations and such funding may not be available to Oruka on acceptable terms, or at all, and such funding may become even more difficult to obtain due to rising interest rates and the current downturn in the U.S.&#160;capital markets and the biotechnology sector in general. Competition for additional capital among biotechnology companies may be particularly intense during this present economic downturn. Oruka may be unable to raise capital through public offerings of its common stock and may need to turn to alternative financing arrangements. Such arrangements, if Oruka pursues them, could involve issuances of one or more types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities. These securities could be issued at or below the then prevailing market price for Oruka common stock. In addition, if Oruka issues debt securities, the holders of the debt would have a claim to Oruka&#8217;s assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make<span class="nobreak">-whole</span> has been paid. Interest on any newly<span class="nobreak">-issued</span> debt securities and/or newly<span class="nobreak">-incurred</span> borrowings would increase Oruka&#8217;s operating costs and reduce its net income (or increase its net loss), and these impacts may be material. If the issuance of new securities results in diminished rights to holders of Oruka common stock, the market price of Oruka common stock could be materially and adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently have any products approved for sale and does not generate any revenue from product sales. Accordingly, Oruka expects to rely primarily on equity and/or debt financings to fund its continued operations. Oruka&#8217;s ability to raise additional funds will depend, in part, on the success of its preclinical studies and clinical trials and other product development activities, regulatory events, its ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect its value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond Oruka&#8217;s control. There can be no assurances that sufficient funds will be available to Oruka when required or on acceptable terms, if at all.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka is unable to raise additional capital when required or on acceptable terms, it may be required to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>significantly delay, scale back, or discontinue the development or commercialization of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seek strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise would be desirable or that Oruka otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>dispose of technology assets, or relinquish or license on unfavorable terms, Oruka&#8217;s rights to technologies or any of its product candidates that it otherwise would seek to develop or commercialize itself;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue the sale of the company to a third party at a price that may result in a loss on investment for Oruka&#8217;s stockholders; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>file for bankruptcy or cease operations altogether (and face any related legal proceedings).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any of these events could have a material adverse effect on Oruka&#8217;s business, operating results, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if successful in raising new capital, Oruka could be limited in the amount of capital it raises due to investor demand restrictions placed on the amount of capital it raises or other reasons.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, any capital raising efforts are subject to significant risks and contingencies, as described in more detail under the risk factor titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Raising additional capital may cause dilution to Oruka&#8217;s stockholders, restrict its operations, or require it to relinquish rights.</span>&#8221;</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka has never generated any revenue from product sales and may never be profitable.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no products approved for commercialization and has never generated any revenue from product sales. Oruka&#8217;s ability to generate revenue and achieve profitability depends on its ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of its product candidates. Oruka does not anticipate generating revenue from product sales for the foreseeable future. Oruka&#8217;s ability to generate future revenue from product sales depends heavily on its success in many areas, including but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>completing research and development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtaining regulatory and marketing approvals for its product candidates for which it completes clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and Oruka&#8217;s supply needs in sufficient quantities to meet market demand for its product candidates, if approved;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>qualifying for adequate coverage and reimbursement by government and third<span class="nobreak">-party</span> payors for any product candidates for which Oruka obtains regulatory and marketing approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>marketing, launching, and commercializing product candidates for which Oruka obtains regulatory and marketing approval, either directly or with a collaborator or distributor;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>gaining market acceptance of Oruka&#8217;s product candidates as treatment options;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>addressing any competing products and technological and market developments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>implementing internal systems and infrastructure, as needed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>protecting and enforcing Oruka&#8217;s intellectual property rights, including patents, trade secrets, and&#160;know<span class="nobreak">-how</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>negotiating favorable terms in any collaboration, licensing, or other arrangements into which Oruka may enter;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtaining coverage and adequate reimbursement from third<span class="nobreak">-party</span> payors and maintaining pricing for Oruka&#8217;s product candidates that supports profitability; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>attracting, hiring, and retaining qualified personnel.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if one or more of the product candidates that Oruka develops is approved for commercial sale, Oruka anticipates incurring significant costs associated with commercializing any approved product candidate. Oruka&#8217;s expenses could increase beyond expectations if it is required by regulatory authorities to perform clinical and other studies in addition to those that Oruka anticipates. Even if Oruka is able to generate revenues from the sale of any approved products, it may not become profitable and may need to obtain additional funding to continue operations. Oruka will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of its product candidates. For instance, if the costs of manufacturing Oruka&#8217;s drug product are not commercially feasible, Oruka will need to develop or procure its drug product in a commercially feasible manner in order to successfully commercialize a future approved product, if any. Additionally, if Oruka is not able to generate revenue from the sale of any approved products, it may never become profitable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is a preclinical stage biopharmaceutical company with a limited operating history on which to assess its business; it has not initiated, conducted or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a preclinical stage biopharmaceutical company with a limited operating history. Since February&#160;6, 2024 (inception), Oruka has incurred significant operating losses. For the period between February&#160;6, 2024 (inception) to March&#160;31, 2024, Oruka reported a net loss of $7.1&#160;million and had an accumulated deficit of $7.1&#160;million. Oruka will need to raise substantial additional capital to continue to fund its operations in the future. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on Oruka&#8217;s financial condition and its ability to develop its product candidates. Changing circumstances may cause Oruka to consume capital significantly faster or slower than it currently anticipates. If Oruka is unable to acquire additional capital or resources, it will be required to modify its operational plans to complete future milestones and it may be required to delay, limit, reduce or eliminate development or future commercialization efforts of product candidates and/or programs. Oruka has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Oruka may be forced to reduce its operating expenses and raise additional funds to meet its working capital needs, principally through the additional sales of its securities or debt financings or entering into strategic collaborations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has devoted substantially all of its financial resources to identify, acquire, and develop its product candidates, organizing and staffing its company, and providing general and administrative support for its operations. To date, Oruka has funded its operations primarily from the sale and issuance of convertible preferred and common equity securities and unsecured convertible notes. The amount of Oruka&#8217;s future net losses will depend, in part, on the rate of its future expenditures and its ability to obtain funding through equity or debt financings, strategic collaborations, or grants.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Oruka expects its losses to increase as its product candidates enter more advanced clinical trials. It may be several&#160;years, if ever, before Oruka completes pivotal clinical trials or has a product candidate approved for commercialization. Oruka expects to invest significant funds into the research and development of its current programs to determine the potential to advance product candidates to regulatory approval. If Oruka obtains regulatory approval to market a product candidate, its future revenue will depend upon the size of any markets in which its product candidates may receive approval, and its ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third<span class="nobreak">-party</span> payors, and adequate market share for its product candidates in those markets. Even if Oruka obtains adequate market share for its product candidates, because the potential markets in which its product candidates may ultimately receive regulatory approval could be very small, Oruka may never become profitable despite obtaining such market share and acceptance of its products.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to continue to incur significant expenses and increasing operating losses for the foreseeable future and its expenses will increase substantially if and as it:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues the preclinical development and initiates the clinical development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues efforts to discover and develop new product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues the manufacturing of its product candidates or increases volumes manufactured by third parties;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>advances its product candidates into larger, more expensive clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>initiates additional preclinical studies or clinical trials for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks regulatory and marketing approvals and reimbursement for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establishes a sales, marketing, and distribution infrastructure to commercialize any products for which it may obtain marketing approval and market for itself;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to identify, assess, acquire, and/or develop other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>makes milestone, royalty, or other payments under third<span class="nobreak">-party</span> license agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to maintain, protect, and expand its intellectual property portfolio;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>is required to pay penalties under its registration rights agreement for failing to timely register the applicable securities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to attract and retain skilled personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>experiences any delays or encounters issues with the development and potential regulatory approval of its clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer&#160;follow<span class="nobreak">-up</span>&#160;for planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no significant experience as a company in initiating, conducting or completing clinical trials. In part because of this lack of experience, Oruka cannot be certain that its planned clinical trials will begin or be completed on time, if at all. In addition, Oruka has not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial<span class="nobreak">-scale</span> product or arrange for a third party to do so on its behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about Oruka&#8217;s future success or viability may not be as accurate as they could be if Oruka had a longer operating history. Further, the net losses Oruka incurs may fluctuate significantly from quarter to quarter and year to year, such that a&#160;period<span class="nobreak">-to-period</span>&#160;comparison of its results of operations may not be a good indication of its future performance.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to Oruka&#8217;s stockholders, restrict its operations, or require it to relinquish rights.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Until such time, if ever, as Oruka can generate substantial revenue from the sale of its product candidates, Oruka expects to finance its cash needs through a combination of equity offerings, debt financings and license and development agreements. To the extent that Oruka raises additional capital through the sale of equity securities or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of Oruka common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Oruka&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka raises additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, it may be required to relinquish valuable rights to its research programs or product candidates or grant licenses on terms that may not be favorable to it. If Oruka is unable to raise additional </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">funds through equity or debt financings or other arrangements with third parties when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that Oruka would otherwise prefer to develop and market itself.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that Oruka raises additional capital through the sale of equity, including pursuant to any sales under convertible debt or other securities convertible into equity, the ownership interest of its stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of its stockholders. For instance, in March&#160;2024, Oruka sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A preferred stock and the Convertible Note to Fairmount Fund&#160;II for gross proceeds of $28.0&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Debt financing, if available, would likely involve agreements that include covenants limiting or restricting Oruka&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If Oruka raises additional funds through strategic collaborations or licensing arrangements with third parties, Oruka may have to relinquish valuable rights to its product candidates or future revenue streams or grant licenses on terms that are not favorable to Oruka. Oruka cannot assure that it will be able to obtain additional funding if and when necessary to fund its entire portfolio of product candidates to meet its projected plans. If Oruka is unable to obtain funding on a timely basis, it may be required to delay or discontinue one or more of its development programs or the commercialization of any product candidates or be unable to expand its operations or otherwise capitalize on potential business opportunities, which could materially harm Oruka&#8217;s business, financial condition, and results of operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Discovery, Development and Commercialization</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka faces competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed by Oruka.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The development and commercialization of drugs is highly competitive. Product candidates developed by Oruka, if approved, will face significant competition and Oruka&#8217;s failure to effectively compete may prevent it from achieving significant market penetration. Oruka competes with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which Oruka is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trial conduct, regulatory approvals, and marketing than Oruka does. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Oruka&#8217;s competitors. Smaller or early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Oruka in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting participants for clinical trials, as well as in acquiring technologies complementary to, or necessary for, Oruka&#8217;s product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s competitors have developed, are developing or will develop programs and processes competitive with its programs and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Oruka&#8217;s success will depend partially on its ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Oruka&#8217;s commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products Oruka develops, or if Oruka&#8217;s competitors develop competing products or if biosimilars enter the market more quickly than Oruka does and are able to gain market acceptance. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Competition</span>&#8221; for more discussion about Oruka&#8217;s competitors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, because of the competitive landscape for&#160;I&amp;I indications, Oruka may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential clinical trial participants choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials for programs that are under development for the same indications as Oruka&#8217;s programs. An increase in the number of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approved products for the indications Oruka is targeting with its programs may further exacerbate this competition. Oruka&#8217;s inability to enroll a sufficient number of participants could, among other things, delay its development timeline, which may further harm its competitive position.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Oruka or its current or future collaborators are unable to complete development of or commercialize Oruka&#8217;s product candidates, or experience significant delays in doing so, Oruka&#8217;s business will be materially harmed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no products on the market, and all of its programs are in preclinical stages of development and have not been tested in humans. As a result, Oruka expects it will be many&#160;years before it commercializes any product candidate, if ever. Oruka&#8217;s ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, its product candidates, either alone or with third parties, and Oruka cannot guarantee you that it will ever obtain regulatory approval for any of its product candidates. Oruka has not yet demonstrated its ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture a clinical or commercial scale product or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of Oruka&#8217;s product candidates, Oruka or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of Oruka&#8217;s programs and product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka or its collaborators may experience delays in initiating or completing clinical trials. Oruka or its collaborators also may experience numerous unforeseen events during, or as a result of, any clinical trials that they could conduct that could delay or prevent Oruka&#8217;s ability to receive marketing approval or commercialize its product candidates, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulators or institutional review boards (&#8220;IRBs&#8221;), the FDA or ethics committees may not authorize Oruka or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>clinical trial sites deviating from trial protocol or dropping out of a trial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results, and Oruka may decide, or regulators may require it, to conduct additional preclinical studies or clinical trials or Oruka may decide to abandon product development programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number of subjects required for clinical trials of any product candidates may be larger than Oruka anticipates, especially if regulatory bodies require completion of&#160;non<span class="nobreak">-inferiority</span>&#160;or superiority trials, enrollment in these clinical trials may be slower than Oruka anticipates or subjects may drop out of these clinical trials or fail to return for post<span class="nobreak">-treatment</span>&#160;follow<span class="nobreak">-up</span>&#160;at a higher rate than Oruka anticipates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s third<span class="nobreak">-party</span> contractors may fail to comply with regulatory requirements or meet their contractual obligations to Oruka in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that Oruka add new clinical trial sites or investigators;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka may elect to, or regulators, IRBs or ethics committees may require that Oruka or its investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in Oruka&#8217;s trials are being exposed to unacceptable health risks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the cost of clinical trials of any of Oruka&#8217;s programs may be greater than Oruka anticipates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the quality of Oruka&#8217;s product candidates or other materials necessary to conduct clinical trials of Oruka&#8217;s product candidates may be inadequate to initiate or complete a given clinical trial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s inability to manufacture sufficient quantities of its product candidates for use in clinical trials;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reports from clinical testing of other therapies may raise safety or efficacy concerns about Oruka&#8217;s programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidates as well as data emerging from other therapies in the same class as Oruka&#8217;s product candidates; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the FDA or other regulatory authorities may require Oruka to submit additional data such as long<span class="nobreak">-term</span> toxicology studies, or impose other requirements before permitting Oruka to initiate a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Commencing clinical trials in the United&#160;States is subject to acceptance by the FDA of an investigational new drug application (&#8220;IND&#8221;), biologics license application (&#8220;BLA&#8221;) or similar application and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires Oruka to complete additional preclinical studies or it is required to satisfy other FDA requests prior to commencing clinical trials, the start of Oruka&#8217;s first clinical trials may be delayed. Even after Oruka receives and incorporates guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that Oruka has satisfied their requirements to commence any clinical trial or change their position on the acceptability of Oruka&#8217;s trial design or the clinical endpoints selected, which may require Oruka to complete additional preclinical studies or clinical trials, delay the enrollment of Oruka&#8217;s clinical trials or impose stricter approval conditions than Oruka currently expects. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union (&#8220;EU&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if it experiences any issues that delay or prevent regulatory approval of, or its ability to commercialize, its product candidates. Oruka or its current or future collaborators&#8217; inability to complete development of, or commercialize Oruka&#8217;s product candidates, or significant delays in doing so, could have a material and adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is substantially dependent on the success of its two most advanced programs, ORKA-001 and ORKA-002, and its anticipated clinical trials of such programs may not be successful.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future success is substantially dependent on its ability to timely obtain marketing approval for, and then successfully commercialize, its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. Oruka is investing a majority of its efforts and financial resources into the research and development of these programs. Oruka anticipates initiating a Phase&#160;1 clinical trial in healthy volunteers of ORKA<span class="nobreak">-001</span> in the first half of 2025 and of ORKA<span class="nobreak">-002</span> in the second half of 2025, each subject to the filing of an IND or foreign equivalent and regulatory approval. The success of Oruka&#8217;s programs is dependent on observing a longer half<span class="nobreak">-life</span> of Oruka&#8217;s product candidates in humans than other extended half<span class="nobreak">-life</span> monoclonal antibodies (&#8220;mAbs&#8221;) currently marketed and in development as Oruka believes this longer half<span class="nobreak">-life</span> has the potential to result in a more favorable dosing schedule for Oruka&#8217;s product candidates, assuming they successfully complete clinical development and obtain marketing approval. This is based in part on the assumption that the longer half<span class="nobreak">-life</span> Oruka has observed in&#160;non<span class="nobreak">-human</span>&#160;primates (&#8220;NHPs&#8221;) will translate into an extended half<span class="nobreak">-life</span> of Oruka&#8217;s product candidates in humans. To the extent Oruka does not observe this extended half<span class="nobreak">-life</span> when it doses humans with its product candidates, it would significantly and adversely affect the clinical and commercial potential of its product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, product development, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before Oruka generates any revenues from product sales. Oruka is not permitted to market or promote these programs, or any other programs, before it receives marketing approval from the FDA and comparable foreign regulatory authorities, and Oruka may never receive such marketing approvals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The success of Oruka&#8217;s product candidates will depend on a variety of factors. Oruka does not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to Oruka&#8217;s intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, Oruka cannot assure you that it will ever be able to generate revenue through the sale of these product candidates, even if approved. If Oruka is not successful in commercializing its ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span> programs, or is significantly delayed in doing so, Oruka&#8217;s business will be materially harmed.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka does not achieve its projected development goals in the time frames it announces and expects, the commercialization of Oruka&#8217;s product candidates may be delayed and its expenses may increase and, as a result, its stock price may decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka estimates the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which it sometimes refers to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the anticipated commencement of Oruka&#8217;s Phase&#160;1 studies, clinical trials in PsO and other target indications, as well as the submission of regulatory filings. From time to time, Oruka may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to Oruka&#8217;s estimates, in some cases for reasons beyond Oruka&#8217;s control. If Oruka does not meet these milestones as publicly announced, or at all, the commercialization of its product candidates may be delayed or never achieved and, as a result, its stock price may decline. Additionally, delays relative to Oruka&#8217;s projected timelines are likely to cause overall expenses to increase, which may require Oruka to raise additional capital sooner than expected and prior to achieving targeted development milestones.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any drug delivery device that Oruka potentially uses to deliver its product candidates may have its own regulatory, development, supply and other risks.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to deliver its product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. Oruka&#8217;s product candidates may not be approved or may be substantially delayed in receiving approval if the devices that Oruka chooses to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single<span class="nobreak">-source</span> unaffiliated third<span class="nobreak">-party</span> companies. Oruka may be dependent on the sustained cooperation and effort of those third<span class="nobreak">-party</span> companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, Oruka may also be dependent on those third<span class="nobreak">-party</span> companies continuing to maintain such approvals or clearances once they have been received. Failure of third<span class="nobreak">-party</span> companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for expanded labels for new indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s approach to the discovery and development of its programs is unproven, and Oruka may not be successful in its efforts to build a pipeline of programs with commercial value.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s approach to the discovery and development of the research programs with respect to which it has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements leverages clinically validated mechanisms of action and incorporates advanced antibody engineering to optimize half<span class="nobreak">-life</span> and other properties designed to overcome limitations of existing therapies. Oruka&#8217;s programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well<span class="nobreak">-established</span> mechanisms of action. However, the scientific research that forms the basis of Oruka&#8217;s efforts to develop programs using half<span class="nobreak">-life</span> extension technologies is ongoing and may not result in viable programs. There is limited clinical data available on product candidates utilizing half<span class="nobreak">-life</span> extension technologies, especially in&#160;I&amp;I indications, demonstrating whether they are safe or effective for long<span class="nobreak">-term</span> treatment in humans. The long<span class="nobreak">-term</span> safety and efficacy of these technologies and the extended half<span class="nobreak">-life</span> and exposure profile of Oruka&#8217;s programs compared to currently approved products is unknown.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may ultimately discover that utilizing half<span class="nobreak">-life</span> extension technologies for its specific targets and indications and any programs resulting therefrom does not possess certain properties required for therapeutic effectiveness. Oruka currently has only preclinical data regarding the increased half<span class="nobreak">-life</span> properties of its programs and the same results may not be seen in humans. In addition, programs using half<span class="nobreak">-life</span> extension technologies may </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">demonstrate different chemical and pharmacological properties in participants than they do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven. If Oruka&#8217;s discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable for treating human disease, Oruka may not be able to develop viable additional programs. Oruka and its existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if Oruka or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as Oruka intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have a material and adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If Oruka&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Oruka may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, Oruka must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Oruka&#8217;s clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, Oruka depends on the availability of NHPs to conduct certain preclinical studies that it is required to complete prior to submitting an IND and initiating clinical development. There is currently a global shortage of NHPs available for drug development. This could cause the cost of obtaining NHPs for Oruka&#8217;s future preclinical studies to increase significantly and, if the shortage continues, could also result in delays to Oruka&#8217;s development timelines.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early<span class="nobreak">-stage</span> clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, Oruka expects to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of Oruka&#8217;s control, and can vary widely from&#160;day<span class="nobreak">-to-day</span> for a particular participant, and from participant to participant and from site to site within a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka cannot be sure that the FDA will agree with its clinical development plan. Oruka plans to use the data from its planned Phase&#160;1 trials of its ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> programs in healthy volunteers to support Phase&#160;2 trials in PsO and other&#160;I&amp;I indications. If the FDA requires Oruka to conduct additional trials or enroll additional participants, Oruka&#8217;s development timelines may be delayed. Oruka cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vivo&#160;</span>or&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro&#160;</span>data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays in manufacturing, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">testing, releasing, validating or importing/exporting sufficient stable quantities of Oruka&#8217;s product candidates for use in clinical trials or the inability to do any of the foregoing; failure by Oruka&#8217;s CROs, other third parties or Oruka to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current Good Clinical Practice requirements (&#8220;GCPs&#8221;) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to facilities operated by a contract manufacturing organization (&#8220;CMO&#8221;) and delays or failure by Oruka&#8217;s CMOs or Oruka to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka could also encounter delays if a clinical trial is suspended or terminated by it, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or Oruka&#8217;s clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If Oruka is required to conduct additional clinical trials or other testing of its product candidates beyond those that Oruka currently contemplates, if Oruka is unable to successfully complete clinical trials of its product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, Oruka&#8217;s business and results of operations may be adversely affected and it may incur significant additional costs.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka encounters difficulties enrolling participants in its future clinical trials, its clinical development activities could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may experience difficulties in patient participant enrollment in its future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on Oruka&#8217;s ability to enroll a sufficient number of participants who remain in the trial until its conclusion. The enrollment of participants in future trials for any of Oruka&#8217;s programs will depend on many factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if Oruka&#8217;s competitors have ongoing clinical trials for programs that are under development for the same indications as its programs, and participants instead enroll in such clinical trials. Additionally, the number of participants required for clinical trials of Oruka&#8217;s programs may be larger than Oruka anticipates, especially if regulatory bodies require the completion of&#160;non<span class="nobreak">-inferiority</span>&#160;or superiority trials. Even if Oruka is able to enroll a sufficient number of participants for its future clinical trials, it may have difficulty maintaining participants in its clinical trials. Oruka&#8217;s inability to enroll or maintain a sufficient number of participants would result in significant delays in completing clinical trials or receipt of marketing approvals and increased development costs or may require Oruka to abandon one or more clinical trials altogether.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preliminary, &#8220;topline&#8221; or interim data from Oruka&#8217;s clinical trials that it announces or publishes from time to time may change as more participant data become available and are subject to audit and verification procedures.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka may publicly disclose preliminary or topline data from its preclinical studies and clinical trials, which are based on a preliminary analysis of then<span class="nobreak">-available</span> data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. Oruka also makes assumptions, estimations, calculations and conclusions as part of its analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that Oruka reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, Oruka may also disclose interim data from its preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available or as participants from Oruka&#8217;s clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with Oruka&#8217;s assumptions, estimates, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and Oruka&#8217;s company in general. In addition, the information Oruka chooses to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Oruka determines is material or otherwise appropriate information to include in its disclosure. If the preliminary, topline or interim data that Oruka reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, Oruka&#8217;s ability to obtain approval for, and commercialize, its product candidates may be harmed, which could harm its business, operating results, prospects or financial condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s future clinical trials or those of its future collaborators may reveal significant adverse events or undesirable side effects not seen in Oruka&#8217;s preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of Oruka&#8217;s product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Results of Oruka&#8217;s clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. While preclinical studies in NHPs conducted with respect to Oruka&#8217;s programs have not shown any such characteristics to date, Oruka has not yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of Oruka&#8217;s future clinical trials, Oruka may have difficulty recruiting participants to such trials, participants may drop out of the trials, or Oruka may be required to abandon the trials or its development efforts of one or more programs altogether. Oruka, the FDA or other applicable regulatory authorities, or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early<span class="nobreak">-stage</span> studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. In addition, an extended half<span class="nobreak">-life</span> could prolong the duration of undesirable side effects, which could also inhibit market acceptance. Treatment<span class="nobreak">-emergent</span> adverse events could also affect participant recruitment or the ability of enrolled subjects to complete Oruka&#8217;s clinical trials or could result in potential product liability claims. Potential side effects associated with Oruka&#8217;s product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from Oruka&#8217;s product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm Oruka&#8217;s business, financial condition, results of operations and prospects significantly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, even if Oruka successfully advances its product candidates or any future product candidates through clinical trials, such trials will only include a limited number of participants and limited duration of exposure to Oruka&#8217;s product candidates. As a result, Oruka cannot be assured that adverse effects of its product candidates will not be uncovered when a significantly larger number of participants are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using Oruka&#8217;s product candidates over a multi<span class="nobreak">-year</span> period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any of the foregoing events occur or if one or more of the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements prove to be unsafe, Oruka&#8217;s entire pipeline could be affected, which would have a material adverse effect on its business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may expend its limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka has limited financial and managerial resources, it focuses its research and development efforts on certain selected programs. For example, Oruka is initially focused on its most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. As a result, Oruka may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Oruka&#8217;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. Oruka&#8217;s spending on current and future research and development programs for specific indications may not yield any commercially viable product candidates. If Oruka </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">does not accurately evaluate the commercial potential or target market for a particular product candidate, it may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for it to retain sole development and commercialization rights to such product candidate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any approved products resulting from Oruka&#8217;s current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and Oruka may not generate any future revenue from the sale or licensing of such products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if regulatory approval is obtained for a product candidate resulting from one of Oruka&#8217;s current or future programs, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. Oruka may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There are several approved products and product candidates in later stages of development for the treatment of PsO.&#160;However, Oruka&#8217;s programs incorporate advanced antibody engineering to optimize the half<span class="nobreak">-life</span> and formulation of antibodies; to date, no such antibody has been approved by the FDA for the treatment of PsO.&#160;Market participants with significant influence over acceptance of new treatments, such as clinicians and third<span class="nobreak">-party</span> payors, may not adopt a biologic that incorporates half<span class="nobreak">-life</span> extension for Oruka&#8217;s targeted indications, and Oruka may not be able to convince the medical community and third<span class="nobreak">-party</span> payors to accept and use, or to provide favorable reimbursement for, any programs developed by it or its existing or future collaborators. An extended half<span class="nobreak">-life</span> may make it more difficult for patients to change treatments and there is a perception that half<span class="nobreak">-life</span> extension could exacerbate side effects, each of which may adversely affect Oruka&#8217;s ability to gain market acceptance. Market acceptance of Oruka&#8217;s product candidates will depend on many factors, including factors that are not within Oruka&#8217;s control.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. Oruka cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that its product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any of Oruka&#8217;s product candidates is approved but does not achieve an adequate level of acceptance by such parties, Oruka may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certain of Oruka&#8217;s programs may compete with its other programs, which could negatively impact Oruka&#8217;s business and reduce its future revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is developing product candidates for the same indication, PsO, and may in the future develop its programs for other&#160;I&amp;I indications. Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively impact Oruka&#8217;s business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit Oruka&#8217;s future revenue.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may conduct clinical trials for programs at sites outside the United&#160;States, and the FDA may not accept data from trials conducted in such locations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may choose to conduct one or more of its future clinical trials outside the United&#160;States. Although the FDA may accept data from clinical trials conducted outside the United&#160;States, acceptance of this data is subject to conditions imposed by the FDA.&#160;For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S.&#160;population, and the data must be applicable to the U.S.&#160;population and U.S.&#160;medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S.&#160;laws and regulations. If the FDA does not accept the data from any trial that Oruka conducts outside the United&#160;States, it would likely result in the need for additional trials, which would be costly and time<span class="nobreak">-consuming</span> and would delay or permanently halt Oruka&#8217;s development of the applicable product candidates. Even if the FDA accepted such data, it could require Oruka to modify its planned clinical trials to receive clearance to initiate such trials in the United&#160;States or to continue such trials once initiated.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, conducting international clinical trials presents additional risks that may delay completion of Oruka&#8217;s clinical trials. These risks include the failure of enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit Oruka&#8217;s ability to conduct its clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Government Regulation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The process of obtaining regulatory approvals, both in the United&#160;States and abroad, is unpredictable, expensive and typically takes many&#160;years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Oruka cannot commercialize product candidates in the United&#160;States without first obtaining regulatory approval from the FDA.&#160;Similarly, Oruka cannot commercialize product candidates outside of the United&#160;States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Oruka&#8217;s product candidates, including its most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, Oruka must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that its product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, Oruka&#8217;s product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude Oruka&#8217;s obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that Oruka&#8217;s data are insufficient for approval and require additional preclinical, clinical or other data. Oruka&#8217;s product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Oruka&#8217;s clinical trials; Oruka may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug<span class="nobreak">-related</span> side effects may be experienced by participants in Oruka&#8217;s clinical trials or by individuals using drugs similar to Oruka&#8217;s product candidates; Oruka may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with Oruka&#8217;s interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of Oruka&#8217;s product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United&#160;States or elsewhere, and Oruka may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of Oruka&#8217;s product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third<span class="nobreak">-party</span> manufacturers with which Oruka contracts for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Oruka&#8217;s clinical data insufficient for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in Oruka&#8217;s failing to obtain regulatory approval to market its product candidates, which would significantly harm Oruka&#8217;s business, results of operations and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka were to obtain approval, regulatory authorities may approve any of Oruka&#8217;s product candidates for fewer or more limited indications than Oruka requests, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post<span class="nobreak">-marketing</span> clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the successful commercialization of that product candidate. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates and its ability to generate revenue will be materially impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not be able to meet requirements for the chemistry, manufacturing and control of its programs.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to receive approval of its products by the FDA and comparable foreign regulatory authorities, Oruka must show that it and its contract manufacturing partners are able to characterize, control and manufacture its drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that Oruka&#8217;s drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If Oruka is not able to meet the chemistry, manufacturing and control requirements, it may not be successful in getting its products approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s product candidates for which it intends to seek approval as biologics may face competition sooner than anticipated.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes a subtitle called the Biologics Price Competition and Innovation Act&#160;of&#160;2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an&#160;FDA<span class="nobreak">-licensed</span>&#160;reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four&#160;years following the date that the reference product was first approved by the FDA.&#160;In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first approved. During this&#160;12<span class="nobreak">-year</span>&#160;period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well<span class="nobreak">-controlled</span> clinical trials to demonstrate the safety, purity and potency of their product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that any of its product candidates approved as biologics under a BLA should qualify for the&#160;12<span class="nobreak">-year</span>&#160;period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider Oruka&#8217;s product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for&#160;non<span class="nobreak">-biological</span>&#160;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if Oruka receives regulatory approval of its product candidates, Oruka will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and Oruka may be subject to penalties if it fails to comply with regulatory requirements or experiences unanticipated problems with its product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any regulatory approvals that Oruka may receive for its product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post<span class="nobreak">-approval</span> study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) in order to approve Oruka&#8217;s product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve Oruka&#8217;s product candidates, its product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United&#160;States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post<span class="nobreak">-marketing</span> information and reports, registration, as </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">62</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">well as&#160;on<span class="nobreak">-going</span>&#160;compliance with current cGMPs and GCPs for any clinical trials that Oruka conducts following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or Oruka, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, restrictions on Oruka&#8217;s ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit Oruka&#8217;s ability to commercialize its product candidates and generate revenue and could require Oruka to expend significant time and resources in response and could generate negative publicity.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may face difficulties from healthcare legislative reform measures.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of Oruka&#8217;s product candidates. Oruka cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United&#160;States or abroad. If Oruka is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if it is not able to maintain regulatory compliance, Oruka may lose any marketing approval that it may have obtained and it may not achieve or sustain profitability. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Healthcare Reform</span>&#8221; for a more detailed description of healthcare reform measures that may prevent or limit Oruka&#8217;s ability to generate revenue, attain profitability, or commercialize its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose Oruka to penalties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third<span class="nobreak">-party</span> payors, patient organizations and customers may expose Oruka to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which Oruka conducts its operations, including how Oruka researches, markets, sells and distributes its product candidates, if approved. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Other Healthcare Laws and Compliance Requirements</span>&#8221; for a more detailed description of the laws that may affect Oruka&#8217;s ability to operate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Ensuring that Oruka&#8217;s internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If Oruka&#8217;s operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to it, Oruka may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government<span class="nobreak">-funded</span> healthcare programs, integrity oversight and reporting obligations to resolve allegations of&#160;non<span class="nobreak">-compliance</span>,&#160;disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Oruka&#8217;s operations. Further, defending against any such actions can be costly and time<span class="nobreak">-consuming</span> and may require significant personnel resources. Therefore, even if Oruka is successful in defending against any such actions that may be brought against it, its business may be impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if Oruka is able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, it may not be able to offer such product candidates at competitive prices which would seriously harm its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka intends to seek approval to market its product candidates in both the United&#160;States and in selected foreign jurisdictions. If Oruka obtains approval in one or more foreign jurisdictions for its product candidates, Oruka will be subject to rules and regulations in those jurisdictions. Oruka&#8217;s ability to successfully commercialize any product candidates that it may develop will depend in part on the extent to which reimbursement for these product </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">63</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">candidates and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third<span class="nobreak">-party</span> payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third<span class="nobreak">-party</span> payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over Oruka&#8217;s products in an attempt to reduce their costs, which may reduce Oruka&#8217;s commercial opportunity. Additionally, if any of Oruka&#8217;s product candidates are approved and Oruka is found to have improperly promoted off<span class="nobreak">-label</span> uses of those product candidates, Oruka may become subject to significant liability, which would materially adversely affect its business and financial condition. See the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Coverage and Reimbursement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Other Government Regulation&#160;Outside of the United&#160;States&#160;&#8212;&#160;Regulation in the European Union</span>&#8221; for a more detailed description of the government regulations and third<span class="nobreak">-party</span> payor practices that may affect Oruka&#8217;s ability to commercialize its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is subject to U.S.&#160;and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Oruka can face criminal liability and other serious consequences for violations, which can harm its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs regulations, various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S.&#160;Foreign Corrupt Practices Act&#160;of&#160;1977, as amended, the U.S.&#160;domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S.&#160;Travel Act, the USA PATRIOT Act, and other state and national anti<span class="nobreak">-bribery</span> and anti<span class="nobreak">-money</span> laundering laws in the countries in which Oruka conducts activities. Anti<span class="nobreak">-corruption</span> laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. Oruka may engage third parties to sell its products outside the United&#160;States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. Oruka has direct or indirect interactions with officials and employees of government agencies or government<span class="nobreak">-affiliated</span> hospitals, universities, and other organizations. Oruka can be held liable for the corrupt or other illegal activities of its employees, agents, contractors, and other collaborators, even if Oruka does not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Governments outside the United&#160;States tend to impose strict price controls, which may adversely affect Oruka&#8217;s revenue, if any.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In some countries, particularly member states of the EU (&#8220;EU Member States&#8221;), the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between&#160;low<span class="nobreak">-priced</span>&#160;and high<span class="nobreak">-priced</span> EU Member States, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, Oruka or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost<span class="nobreak">-effectiveness</span> of Oruka&#8217;s product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third<span class="nobreak">-party</span> payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, Oruka&#8217;s business, financial condition, results of operations or prospects could be materially and adversely affected. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing of prescription pharmaceuticals, as the United Kingdom (&#8220;UK&#8221;) determines which EU laws to replicate or replace. If the UK were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, Oruka could face significant new costs.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">64</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">A breakthrough therapy, fast track, or other expedited designation for Oruka&#8217;s product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are within the discretion of the FDA, or other comparable regulatory authorities. The receipt of a designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA.&#160;In addition, even if one or more of Oruka&#8217;s product candidates qualifies under one of FDA&#8217;s designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Expedited Development and Review Programs</span>&#8221; for a more detailed description of the process for seeking expedited designations such as fast track or breakthrough therapy designations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Intellectual Property</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s ability to obtain and protect its patents and other proprietary rights is uncertain, exposing Oruka to the possible loss of competitive advantage.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka relies upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Paragon Option Agreements to protect the intellectual property related to its programs and technologies and to prevent third parties from competing unfairly with it. Oruka&#8217;s success depends in large part on its ability to obtain and maintain patent protection for its platform technologies, programs and their uses, as well as its ability to operate without infringing on or violating the proprietary rights of others. Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-23</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-001</span>. In addition, Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-17</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-002</span>. However, Oruka may not be able to protect its intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on programs worldwide would be expensive and Oruka&#8217;s intellectual property rights in some foreign jurisdictions can be less extensive than those in the United&#160;States; the reverse may also occur. As such, Oruka may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if it applies for them. Oruka&#8217;s competitors may operate in countries where Oruka does not have patent protection and can freely use Oruka&#8217;s technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where Oruka does have patent protection or pending patent applications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of Oruka&#8217;s programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that Oruka may license or own covering Oruka&#8217;s programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United&#160;States or abroad, including the United&#160;States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if Oruka encounters delays in its clinical trials or delays in obtaining regulatory approval, the period of time during which Oruka could market its product candidates under patent protection would be reduced. Thus, the patents that Oruka may own and license may not afford Oruka any meaningful competitive advantage.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to seeking patents for some of its technology and programs, Oruka may also rely on trade secrets, including unpatented&#160;know<span class="nobreak">-how</span>,&#160;technology and other proprietary information, to maintain its competitive position. Any disclosure, either intentional or unintentional, by Oruka&#8217;s employees, the employees of third parties with whom Oruka shares its facilities or third<span class="nobreak">-party</span> consultants and vendors that Oruka engages to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of Oruka&#8217;s trade secrets or proprietary information could enable competitors to duplicate or surpass Oruka&#8217;s technological achievements, thus eroding Oruka&#8217;s competitive position in its market. In order to protect </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">65</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Oruka&#8217;s proprietary technology and processes, it relies in part on confidentiality agreements with its collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Oruka may need to share its proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while Oruka undertakes efforts to protect its trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, Oruka may not be able to assert any trade secret rights against such party. Costly and time<span class="nobreak">-consuming</span> litigation could be necessary to enforce and determine the scope of Oruka&#8217;s proprietary rights and failure to obtain or maintain trade secret protection could adversely affect Oruka&#8217;s competitive business position.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lastly, if Oruka&#8217;s trademarks and trade names are not registered or adequately protected, then Oruka may not be able to build name recognition in its markets of interest and its business may be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not be successful in obtaining or maintaining necessary rights to its programs through acquisitions and&#160;in-licenses.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka&#8217;s development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of Oruka&#8217;s business may depend in part on its ability to acquire,&#160;in<span class="nobreak">-license</span>,&#160;or use these third<span class="nobreak">-party</span> proprietary rights. Oruka may be unable to acquire or&#160;in<span class="nobreak">-license</span>&#160;any compositions, methods of use, processes or other third<span class="nobreak">-party</span> intellectual property rights from third parties that it identifies as necessary for its programs. The licensing and acquisition of third<span class="nobreak">-party</span> intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third<span class="nobreak">-party</span> intellectual property rights that Oruka may consider attractive or necessary. These established companies may have a competitive advantage over Oruka due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Oruka to be a competitor may be unwilling to assign or license rights to Oruka. Oruka also may be unable to license or acquire third<span class="nobreak">-party</span> intellectual property rights on terms that would allow it to make an appropriate return on Oruka&#8217;s investment or at all. If Oruka is unable to successfully obtain rights to required third<span class="nobreak">-party</span> intellectual property rights or maintain the existing intellectual property rights it does obtain, Oruka may have to abandon development of the relevant program, which could have a material adverse effect on its business, financial condition, results of operations, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka plans to obtain the right to control prosecution, maintenance and enforcement of the patents relating to its programs, there may be times when the filing and prosecution activities for patents and patent applications relating to Oruka&#8217;s programs are controlled by its current and future licensors or collaboration partners. If any of Oruka&#8217;s current and future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of Oruka&#8217;s business, including by payment of all applicable fees for patents covering its product candidates, Oruka could lose its rights to the intellectual property or its exclusivity with respect to those rights, its ability to develop and commercialize those product candidates may be adversely affected and it may not be able to prevent competitors from making, using and selling competing products. In addition, even where Oruka has the right to control patent prosecution of patents and patent applications it has licensed to and from third parties, Oruka may still be adversely affected or prejudiced by actions or inactions of its licensees, its future licensors and their counsel that took place prior to the date upon which Oruka assumed control over patent prosecution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may rely on third<span class="nobreak">-party</span> consultants or collaborators or on funds from third parties such that Oruka&#8217;s future licensors are not the sole and exclusive owners of the patents Oruka&#160;in<span class="nobreak">-licenses</span>.&#160;If other third parties have ownership rights to Oruka&#8217;s future&#160;in<span class="nobreak">-licensed</span>&#160;patents, they may be able to license such patents to Oruka&#8217;s competitors, and Oruka&#8217;s competitors could market competing products and technology. This could have a material adverse effect on Oruka&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is possible that Oruka may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if Oruka is able to obtain a license, it may be&#160;non<span class="nobreak">-exclusive</span>,&#160;thereby giving Oruka&#8217;s competitors access to the same technologies licensed to Oruka. In that event, Oruka may be required to expend significant time and resources </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">66</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to redesign its technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Oruka is unable to do so, it may be unable to develop or commercialize the affected product candidates, which could harm its business, financial condition, results of operations, and prospects significantly. Oruka cannot provide any assurances that third<span class="nobreak">-party</span> patents do not exist which might be enforced against Oruka&#8217;s current technology, manufacturing methods, programs, or future methods or products resulting in either an injunction prohibiting Oruka&#8217;s manufacture or future sales, or, with respect to its future sales, an obligation on Oruka&#8217;s part to pay royalties and/or other forms of compensation to third parties, which could be significant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Disputes may arise between Oruka and its future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation<span class="nobreak">-related</span> issues; whether and the extent to which Oruka&#8217;s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; Oruka&#8217;s right to sublicense patents and other rights to third parties; Oruka&#8217;s right to transfer or assign the license; the inventorship and ownership of inventions and&#160;know<span class="nobreak">-how</span>&#160;resulting from the joint creation or use of intellectual property by Oruka&#8217;s future licensors and it and its partners; and the priority of invention of patented technology.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to patent infringement claims or may need to file claims to protect its intellectual property, which could result in substantial costs and liability and prevent Oruka from commercializing its potential products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess Oruka&#8217;s freedom to operate and guarantee that Oruka can operate without infringing on or violating third<span class="nobreak">-party</span> rights. If certain of Oruka&#8217;s product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable, could be alleged to render one or more of Oruka&#8217;s product candidates infringing. If a third party successfully brings a claim against Oruka, Oruka may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret theft) brought against Oruka, whether or not successful, may cause Oruka to incur significant legal expenses and divert the attention of its management and key personnel from other business concerns. Oruka cannot be certain that patents owned or licensed by it will not be challenged by others in the course of litigation. Some of Oruka&#8217;s competitors may be able to sustain the costs of complex intellectual property litigation more effectively than Oruka can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Oruka&#8217;s ability to raise funds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Competitors may infringe or otherwise violate Oruka&#8217;s patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, Oruka may be required to file claims, which can be expensive and time<span class="nobreak">-consuming</span>. Any such claims could provoke these parties to assert counterclaims against Oruka, including claims alleging that Oruka infringes their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents Oruka asserts is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that Oruka&#8217;s patents do not cover the technology. Similarly, if Oruka asserts trademark infringement claims, a court or administrative body may determine that the marks Oruka has asserted are invalid or unenforceable or that the party against whom Oruka has asserted trademark infringement has superior rights to the marks in question. In such a case, Oruka could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if Oruka is successful, any award of monetary damages or other remedy Oruka receives may not be commercially valuable.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, Oruka may be required to protect its patents through procedures created to attack the validity of a patent at the USPTO.&#160;An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, Oruka&#8217;s patent rights, which could adversely affect Oruka&#8217;s competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S.&#160;federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">67</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, if Oruka&#8217;s programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against Oruka&#8217;s future licensees and other parties with whom Oruka has business relationships and Oruka may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require Oruka to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, Oruka may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to Oruka&#8217;s intellectual property rights, there is a risk that some of Oruka&#8217;s confidential information could be compromised by disclosure during this type of litigation or other proceedings.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to claims that it has wrongfully hired an employee from a competitor or that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As is common in the biotechnology industry, in addition to Oruka&#8217;s employees, Oruka engages the services of consultants to assist it in the development of its programs. Many of these consultants, and many of Oruka&#8217;s employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including Oruka&#8217;s competitors or potential competitors. Oruka could in the future be subject to claims that it or its employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although Oruka tries to ensure that its employees and consultants do not use the intellectual property, proprietary information,&#160;know<span class="nobreak">-how</span>&#160;or trade secrets of others in their work for Oruka, Oruka may become subject to claims that it caused an employee to breach the terms of his or her&#160;non<span class="nobreak">-competition</span>&#160;or&#160;non<span class="nobreak">-solicitation</span>&#160;agreement, or that Oruka or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka may litigate to defend itself against these claims, even if it is successful, litigation could result in substantial costs and could be a distraction to management. If Oruka&#8217;s defenses to these claims fail, in addition to requiring it to pay monetary damages, a court could prohibit Oruka from using technologies or features that are essential to its programs, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect Oruka&#8217;s reputation, its ability to form strategic alliances or sublicense its rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on Oruka&#8217;s business, results of operations and financial condition. Even if Oruka is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Changes to patent laws in the United&#160;States and other jurisdictions could diminish the value of patents in general, thereby impairing Oruka&#8217;s ability to protect its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Changes in either the patent laws or interpretation of patent laws in the United&#160;States, including patent reform legislation such as the Leahy<span class="nobreak">-Smith</span> America Invents Act (the &#8220;Leahy<span class="nobreak">-Smith</span> Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of Oruka&#8217;s owned and&#160;in<span class="nobreak">-licensed</span>&#160;patent applications and the maintenance, enforcement or defense of its owned and&#160;in<span class="nobreak">-licensed</span>&#160;issued patents. The Leahy<span class="nobreak">-Smith</span> Act includes a number of significant changes to United&#160;States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost<span class="nobreak">-effective</span> avenues for competitors to challenge the validity of patents, and enable third<span class="nobreak">-party</span> submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO<span class="nobreak">-administered</span> post<span class="nobreak">-grant</span> proceedings, including post<span class="nobreak">-grant</span> review, inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the United&#160;States, the first to invent the claimed invention was entitled to the patent, while outside the United&#160;States, the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy<span class="nobreak">-Smith</span> Act, the United&#160;States transitioned to a&#160;first<span class="nobreak">-to-file</span>&#160;system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">68</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">claimed invention. As such, the Leahy<span class="nobreak">-Smith</span> Act and its implementation could increase the uncertainties and costs surrounding the prosecution of Oruka&#8217;s patent applications and the enforcement or defense of its issued patents, all of which could have a material adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S.&#160;Supreme Court and U.S.&#160;Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United&#160;States Supreme Court in&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen, Inc. v. Sanofi</span>&#160;(<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen</span>) recently held that Amgen&#8217;s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided twenty<span class="nobreak">-six</span> exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that Oruka will be granted U.S.&#160;patents with composition of matter claims directed to antibodies functionally defined by their ability to bind a particular antigen. Even if Oruka is granted claims directed to functionally defined antibodies, it is possible that a third party may challenge Oruka&#8217;s patents, when issued, relying on the reasoning in&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen</span>&#160;or other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the United&#160;States and other countries that, if adopted, could impact Oruka&#8217;s ability to enforce its proprietary technology. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S.&#160;Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on Oruka&#8217;s patent rights and its ability to protect, defend and enforce its patent rights in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Geopolitical instability in the United&#160;States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United&#160;States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on Oruka&#8217;s business. In addition, a decree was adopted by the Russian government in March&#160;2022 allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit<span class="nobreak">-making</span> activities in the United&#160;States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, Oruka would not be able to prevent third parties from practicing its inventions in Russia or from selling or importing products made using its inventions in and into Russia. Accordingly, Oruka&#8217;s competitive position may be impaired, and its business, financial condition, results of operations and prospects may be adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although Oruka does not currently own any European patents or applications, if it obtains such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on Oruka&#8217;s business and its ability to commercialize or license its technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect Oruka&#8217;s ability to enforce or defend the validity of any European patents it may obtain. Oruka may decide to opt out from the UPC any future European patent applications that it may file and any patents it may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for&#160;non<span class="nobreak">-compliance</span>&#160;and brought under the jurisdiction of the UPC.&#160;Oruka cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if Oruka decides to opt out of the UPC.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">69</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and Oruka&#8217;s patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.&#160;Non<span class="nobreak">-compliance</span>&#160;events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits,&#160;non<span class="nobreak">-payment</span>&#160;of fees and failure to properly legalize and submit formal documents. If Oruka fails to maintain the patents and patent applications covering its programs, Oruka&#8217;s competitive position would be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect Oruka&#8217;s ability to develop and market its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka cannot guarantee that any of its patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can Oruka be certain that it has identified each and every third<span class="nobreak">-party</span> patent and pending application in the United&#160;States and abroad that is relevant to or necessary for the commercialization of its product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Oruka&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, Oruka may incorrectly determine that its products are not covered by a third<span class="nobreak">-party</span> patent or may incorrectly predict whether a third<span class="nobreak">-party</span>&#8217;s pending application will issue with claims of relevant scope. Oruka&#8217;s determination of the expiration date of any patent in the United&#160;States or abroad that it considers relevant may be incorrect. Oruka&#8217;s failure to identify and correctly interpret relevant patents may negatively impact its ability to develop and market its products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, because some patent applications in the United&#160;States may be maintained in secrecy until the patents are issued, patent applications in the United&#160;States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, Oruka cannot be certain that others have not filed patent applications for technology covered by its issued patents or its pending applications, or that Oruka was the first to invent the technology. Oruka&#8217;s competitors may have filed, and may in the future file, patent applications covering products or technology similar to Oruka&#8217;s. Any such patent application may have priority over Oruka&#8217;s patent applications or patents, which could require Oruka to obtain rights to issued patents covering such technologies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may become subject to claims challenging the inventorship or ownership of its patents and other intellectual property.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may be subject to claims that former employees, collaborators or other third parties have an interest in Oruka&#8217;s patents or other intellectual property as an inventor or&#160;co<span class="nobreak">-inventor</span>.&#160;The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing Oruka&#8217;s programs or as a result of questions regarding&#160;co<span class="nobreak">-ownership</span>&#160;of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, Oruka may enter into agreements to clarify the scope of its rights in such intellectual property. If Oruka fails in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on Oruka&#8217;s business. Even if Oruka is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">70</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may rely on third<span class="nobreak">-party</span> consultants or collaborators or on funds from third parties, such as the U.S.&#160;government, such that Oruka&#8217;s licensors would not be the sole and exclusive owners of any patents Oruka&#160;in<span class="nobreak">-licenses</span>.&#160;If other third parties have ownership rights or other rights to Oruka&#8217;s&#160;in<span class="nobreak">-licensed</span>&#160;patents, they may be able to license such patents to Oruka&#8217;s competitors, and Oruka&#8217;s competitors could market competing products and technology. This could have a material adverse effect on Oruka&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect the competitive position of Oruka&#8217;s product candidates for an adequate amount of time.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Patents have a limited lifespan. In the United&#160;States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest United&#160;States&#160;non<span class="nobreak">-provisional</span>&#160;filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering Oruka&#8217;s product candidates are obtained, once the patent life has expired, Oruka may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, Oruka&#8217;s owned and licensed patent portfolio may not provide it with sufficient rights to exclude others from commercializing products similar or identical to Oruka&#8217;s.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s technology licensed from various third parties may be subject to retained rights.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may retain certain rights under the relevant agreements with Oruka, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether Oruka&#8217;s licensors limit their use of the technology to these uses, and Oruka could incur substantial expenses to enforce its rights to its licensed technology in the event of misuse.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Reliance on Third Parties</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies on licensing arrangements with Paragon through the Paragon Option Agreements. If Oruka is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Oruka&#8217;s business could be negatively impacted.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka currently relies on its licensing arrangements with Paragon through the Paragon Option Agreements for a substantial portion of its discovery capabilities and&#160;in<span class="nobreak">-licenses</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaborations or licensing arrangements that Oruka enters into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of Oruka&#8217;s current or future collaborators or licensors experiences delays in performance of, or fails to perform its obligations under their agreement with Oruka, disagrees with Oruka&#8217;s interpretation of the terms of such agreement or terminates their agreement with Oruka, the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements and development timeline could be adversely affected. If Oruka fails to comply with any of the obligations under its collaborations or license agreements, including payment terms and diligence terms, Oruka&#8217;s collaborators or licensors may have the right to terminate such agreements, in which event Oruka may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by its agreements or may face other penalties under its agreements. Oruka&#8217;s collaborators and licensors may also fail to properly maintain or defend the intellectual property Oruka has licensed from them, if required by Oruka&#8217;s agreement with them, or even infringe upon, Oruka&#8217;s intellectual property rights, leading to the potential invalidation of Oruka&#8217;s intellectual property or subjecting it to litigation or arbitration, any of which would be time<span class="nobreak">-consuming</span> and expensive and could harm Oruka&#8217;s ability to commercialize its product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with Oruka&#8217;s programs and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than Oruka&#8217;s.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">71</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of Oruka&#8217;s strategy, Oruka plans to evaluate additional opportunities to enhance its capabilities and expand its development pipeline or provide development or commercialization capabilities that complement Oruka&#8217;s. Oruka may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require Oruka to incur&#160;non<span class="nobreak">-recurring</span>&#160;and other charges, increase its near and long<span class="nobreak">-term</span> expenditures, issue securities that dilute its existing stockholders or disrupt its management and business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third<span class="nobreak">-party</span> intellectual property rights that Oruka considers attractive. These companies may have a competitive advantage over Oruka due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Oruka to be a competitor may be unwilling to assign or license rights to Oruka. Whether Oruka reaches a definitive agreement for a collaboration will depend upon, among other things, its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time<span class="nobreak">-consuming</span> to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. Oruka may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If Oruka fails to enter into collaborations and does not have sufficient funds or expertise to undertake the necessary development and commercialization activities, it may not be able to further develop its product candidates or bring them to market.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies, and plans to rely in the future, on third parties to conduct and support its preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, Oruka may not be able to obtain regulatory approval of or commercialize its product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has utilized and plans to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support its preclinical studies and clinical trials under agreements with Oruka. Oruka will rely heavily on these third parties over the course of its preclinical studies and clinical trials, and Oruka controls only certain aspects of their activities. As a result, Oruka will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if it were relying entirely upon its own staff. Nevertheless, Oruka is responsible for ensuring that each of its studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and its reliance on these third parties does not relieve Oruka of its regulatory responsibilities. Oruka and its third<span class="nobreak">-party</span> contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of Oruka&#8217;s programs in clinical development. If Oruka or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in Oruka&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Oruka to perform additional clinical trials before approving Oruka&#8217;s marketing applications. Oruka cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Oruka&#8217;s clinical trials comply with GCP regulations. In addition, Oruka&#8217;s clinical trials must be conducted with products produced under cGMP regulations. Oruka&#8217;s failure to comply with these regulations may require it to repeat clinical trials, which would delay the regulatory approval process. Moreover, Oruka&#8217;s business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any third parties conducting Oruka&#8217;s clinical trials will not be Oruka&#8217;s employees and, except for remedies available to Oruka under its agreements with such third parties, Oruka cannot control whether they devote sufficient time and resources to Oruka&#8217;s programs. These third parties may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including Oruka&#8217;s competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on Oruka&#8217;s behalf and the timing thereof and could lead to products that compete directly or indirectly with Oruka&#8217;s product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to Oruka&#8217;s clinical protocols or regulatory requirements or for other reasons, Oruka&#8217;s clinical trials may be extended, delayed or terminated and Oruka may not be able to complete development of, obtain regulatory approval of or successfully commercialize its product candidates.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">72</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka currently relies on foreign CROs and CMOs, including WuXi Biologics (Hong&#160;Kong) Limited (&#8220;WuXi Biologics&#8221;) and will likely continue to rely on foreign CROs and CMOs in the future. The BIOSECURE bill, if passed, would prohibit federal agencies from entering into procurement contracts with an entity that uses biotechnology equipment or services from a biotechnology company of concern. Foreign CMOs may be subject to U.S.&#160;legislation, including the proposed BIOSECURE bill, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to Oruka, delay the procurement or supply of such material or have an adverse effect on Oruka&#8217;s ability to secure significant commitments from governments to purchase its potential therapies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on Oruka&#8217;s collaborators in China which could have an adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the United&#160;States and the UK, could also negatively impact Oruka&#8217;s ability to manufacture its product candidates for its planned clinical trials or have an adverse effect on its ability to secure government funding, which could adversely affect Oruka&#8217;s financial condition and cause it to delay its clinical development programs. Furthermore, if the BIOSECURE bill is passed and one or more of Oruka&#8217;s collaborators in China, including WuXi Biologics, is deemed to be a biotechnology company of concern, Oruka&#8217;s operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while Oruka has established relationships with CROs and CMOs outside of China, moving to those suppliers in the event of a geopolitical instability affecting Oruka&#8217;s collaborators in China could introduce delays into the development program.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies and expects to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture its product candidates, and Oruka may rely on third parties to produce and process its products, if approved. Oruka&#8217;s business could be adversely affected if it is unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently own any facility that may be used as its clinical or commercial manufacturing and processing facility and must currently rely on CMOs to manufacture its product candidates. Oruka has not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of its product candidates, if approved. Oruka currently has a sole source relationship for its supply of the ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> program. If there should be any disruption in such supply arrangement, including any adverse events affecting Oruka&#8217;s sole supplier, it could have a negative effect on the clinical development of Oruka&#8217;s programs and other operations while Oruka works to identify and qualify an alternate supply source. Oruka may not control the manufacturing process of, and may be completely dependent on, its contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of its product candidates. Beyond periodic audits, Oruka has limited control over the ability of its CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of Oruka&#8217;s product candidates or if it withdraws any approval in the future, Oruka may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs, delays, and materially adversely affect Oruka&#8217;s ability to develop, obtain regulatory approval for or market its product candidates, if approved. Similarly, Oruka&#8217;s failure, or the failure of its CMOs, to comply with applicable regulations could result in sanctions being imposed on Oruka, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Oruka&#8217;s product candidates or drugs and harm Oruka&#8217;s business and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, Oruka&#8217;s CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes or unstable political environments. If any CMOs on which Oruka will rely fail to manufacture quantities of Oruka&#8217;s product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows Oruka to achieve profitability, Oruka&#8217;s business, financial condition and prospects could be materially and adversely affected. In addition, Oruka&#8217;s CMOs are responsible for transporting temperature<span class="nobreak">-controlled</span> materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, Oruka&#8217;s </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">73</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">integrity and purity specifications. Oruka and any of its CMOs may also face product seizure or detention or refusal to permit the import or export of products. Oruka&#8217;s business could be materially adversely affected by business disruptions to its third<span class="nobreak">-party</span> providers that could materially adversely affect its anticipated timelines, potential future revenue and financial condition and increase its costs and expenses. Each of these risks could delay or prevent the completion of Oruka&#8217;s preclinical studies and clinical trials or the approval of any of its product candidates by the FDA, result in higher costs or adversely impact commercialization of its product candidates. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Manufacturing</span>&#8221; for a more detailed description of Oruka&#8217;s manufacturing plans and assumptions and the factors that may affect the success of Oruka&#8217;s programs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Oruka&#8217;s Business</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">In order to successfully implement Oruka&#8217;s plans and strategies, Oruka will need to grow the size of its organization and it may experience difficulties in managing this growth.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to experience significant growth in the number of its employees and the scope of its operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage Oruka&#8217;s anticipated future growth, Oruka must continue to implement and improve its managerial, operational and financial personnel and systems, expand its facilities and continue to recruit and train additional qualified personnel. Due to Oruka&#8217;s limited financial resources and the limited experience of its management team working together in managing a company with such anticipated growth, Oruka may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is highly dependent on its key personnel and anticipates hiring new key personnel. If Oruka is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a preclinical stage biotechnology company with a limited operating history, and, as of May&#160;3, 2024, it had ten full<span class="nobreak">-time</span> employees. Oruka has been and will continue to be highly dependent on the research and development, clinical and business development expertise of its executive officers, as well as the other principal members of its management, scientific and clinical team. Any of Oruka&#8217;s management team members may terminate their employment with Oruka at any time. Oruka does not maintain &#8220;key person&#8221; insurance for any of its executives or other employees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Attracting and retaining qualified personnel will also be critical to Oruka&#8217;s success, including with respect to any strategic transaction that it may pursue. The loss of the services of Oruka&#8217;s executive officers or other key employees could impede the achievement of its research, development and commercialization objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in Oruka&#8217;s industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize product candidates. Competition to hire from this limited pool is intense, and Oruka may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. Oruka also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka relies on consultants and advisors, including scientific and clinical advisors, to assist it in formulating its discovery and nonclinical and clinical development and commercialization strategy. Oruka&#8217;s consultants and advisors may be employed by employers other than Oruka and may have commitments under consulting or advisory contracts with other entities that may limit their availability to Oruka. If Oruka is unable to continue to attract and retain high quality personnel, its ability to pursue its growth strategy will be limited.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s future growth may depend, in part, on its ability to operate in foreign markets, where it would be subject to additional regulatory burdens and other risks and uncertainties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future growth may depend, in part, on its ability to develop and commercialize its product candidates in foreign markets for which it may rely on collaboration with third parties. Oruka is not permitted to market or promote any of its product candidates before it receives regulatory approval from the applicable foreign </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">74</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">regulatory authority, and may never receive such regulatory approval for any of its product candidates. To obtain separate regulatory approval in many other countries, Oruka must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of its product candidates, and Oruka cannot predict success in these jurisdictions. If Oruka fails to comply with the regulatory requirements in international markets and receive applicable marketing approvals, its target market will be reduced and its ability to realize the full market potential of its product candidates will be harmed and its business will be adversely affected. Moreover, even if Oruka obtains approval of its product candidates and ultimately commercializes its product candidates in foreign markets, Oruka would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which Oruka competes achieve the forecasted growth, its business may not grow at similar rates, or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Oruka&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Oruka competes meet Oruka&#8217;s size estimates and growth forecasts, Oruka&#8217;s business may not grow at similar rates, or at all. Oruka&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Oruka owns the commercial rights for that territory. If the number of Oruka&#8217;s addressable patients is not as significant as it estimates, the indication approved by regulatory authorities is narrower than it expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Oruka may not generate significant revenue from sales of such products, even if approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is exposed to the risk that its employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on its behalf may engage in misconduct or other improper activities. Oruka has adopted a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions Oruka takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Oruka from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s internal information technology systems, or those of any of its CROs, manufacturers, other contractors or consultants, third-party service providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of Oruka&#8217;s proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to Oruka&#8217;s brand and material disruption of its operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of its business, Oruka and the third parties upon which it relies collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Despite the implementation of security measures in an effort to protect systems that store Oruka&#8217;s information, given their size and complexity and the increasing amounts of information maintained on Oruka&#8217;s internal information technology systems and those of its third<span class="nobreak">-party</span> CROs, other contractors (including sites performing Oruka&#8217;s clinical trials), third<span class="nobreak">-party</span> service providers and supply chain companies, and consultants, these systems are </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">75</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by Oruka&#8217;s employees, contractors, consultants, business partners and/or other third parties, or from cyber<span class="nobreak">-attacks</span> by malicious third parties, which may compromise Oruka&#8217;s system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, Oruka&#8217;s data.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some actors now engage and are expected to continue to engage in cyber<span class="nobreak">-attacks</span>, including without limitation nation<span class="nobreak">-state</span> actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, Oruka, and the third parties upon which it relies, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber<span class="nobreak">-attacks</span>, that could materially disrupt Oruka&#8217;s systems and operations, supply chain, and ability to produce, sell and distribute its goods and services. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in Oruka&#8217;s operations, ability to provide its products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but Oruka may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, Oruka&#8217;s data or applications, or for it to be believed or reported that any of these occurred, Oruka could incur liability and reputational damage and the development and commercialization of its product candidates could be delayed. Further, Oruka&#8217;s insurance policies may not be adequate to compensate it for the potential losses arising from any such disruption in, or failure or security breach of, its systems or third<span class="nobreak">-party</span> systems where information important to Oruka&#8217;s business operations or commercial development is stored.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s fully<span class="nobreak">-remote</span> workforce may create additional risks for its information technology systems and data because its employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose Oruka to additional cybersecurity risks and vulnerabilities, as its systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka has implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Oruka may be unable in the future to detect vulnerabilities in its information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, Oruka may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require Oruka to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka relies on third<span class="nobreak">-party</span> service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts. Oruka&#8217;s ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If Oruka&#8217;s third<span class="nobreak">-party</span> service providers experience a security incident or other interruption, Oruka could experience adverse consequences. While Oruka may be entitled to damages if its third<span class="nobreak">-party</span> service providers fail to satisfy their privacy or security<span class="nobreak">-related</span> obligations to it, any award may be insufficient to cover Oruka&#8217;s damages, or Oruka may be unable to recover such award. In addition, supply<span class="nobreak">-chain</span> attacks have increased in frequency and severity, and Oruka cannot guarantee that third parties&#8217; infrastructure in its supply chain or its third<span class="nobreak">-party</span> partners&#8217; supply chains have not been compromised.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka (or a third party upon whom it relies) experiences a security incident or are perceived to have experienced a security incident, Oruka may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in Oruka&#8217;s operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting Oruka&#8217;s platform, deter new customers from products, and negatively impact Oruka&#8217;s ability to grow and operate its business.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">76</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in Oruka&#8217;s contracts are sufficient to protect Oruka from liabilities, damages, or claims related to its data privacy and security obligations. Oruka cannot be sure that its insurance coverage will be adequate or sufficient to protect it from or to mitigate liabilities arising out of its privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect Oruka&#8217;s operating results and business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and third parties who it works with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. Oruka is or may become subject to the terms of contractual obligations related to privacy, data protection and data security. Oruka&#8217;s obligations may also change or expand as its business grows. The actual or perceived failure by Oruka or third parties related to Oruka to comply with such laws, regulations and obligations could increase Oruka&#8217;s compliance and operational costs, expose it to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on its business, financial condition, and results of operations. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Data Privacy and Security</span>&#8221; for a more detailed description of the laws that may affect Oruka&#8217;s ability to operate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka fails to comply with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Oruka&#8217;s operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, Oruka may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair Oruka&#8217;s research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which may have retroactive application) could adversely affect Oruka&#8217;s stockholders or Oruka. Oruka assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it has operations to determine the potential effect on its business and any assumptions it has made about its future taxable income. Oruka cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. For example, the United&#160;States recently enacted the Inflation Reduction Act&#160;of&#160;2022 (&#8220;IRA&#8221;), which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and&#160;Jobs Act&#160;eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years for research activities conducted in the United&#160;States and over 15&#160;years for research activities conducted outside the United&#160;States. The U.S.&#160;Congress is considering legislation that would restore the current deductibility of research and development expenditures; however, Oruka has no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect Oruka&#8217;s effective tax rate, results of operation and general business condition.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">77</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that it believes will complement or augment its existing business. If Oruka acquires businesses with promising markets or technologies, it may not be able to realize the benefit of acquiring such businesses if it is unable to successfully integrate them with its existing operations and company culture. Oruka may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent it from realizing their expected benefits or enhancing Oruka&#8217;s business. There is no assurance that, following any such acquisition, Oruka will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on Oruka&#8217;s business and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka maintains its cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect Oruka&#8217;s ability to pay its operational expenses or make other payments.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s cash held in&#160;non<span class="nobreak">-interest-bearing</span>&#160;and interest<span class="nobreak">-bearing</span> accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, Oruka could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that Oruka may experience in the future or inability for a material time period to access its cash and cash equivalents could have an adverse effect on its ability to pay its operational expenses or make other payments, which could adversely affect its business.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General Risk Factors</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s estimates&#160;of market&#160;opportunity&#160;and forecasts&#160;of market&#160;growth may&#160;prove&#160;to be inaccurate,&#160;and even if the markets&#160;in which Oruka competes&#160;achieve&#160;the forecasted&#160;growth, its business&#160;may&#160;not grow at similar&#160;rates, or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Oruka&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Oruka competes meet its size estimates and growth forecasts, Oruka&#8217;s business may not grow at similar rates, or at all. Oruka&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which Oruka gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Oruka owns the commercial rights for that territory. If the number of its addressable patients is not as significant as Oruka estimates, the indication approved by regulatory authorities is narrower than Oruka expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Oruka may not generate significant revenue from sales of such products, even if approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and its product liability insurance may not cover all damages from such claims.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While Oruka currently has no products that have been approved for commercial sale, the future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose Oruka to liability claims. These claims may be made </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">78</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against Oruka, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for Oruka&#8217;s products or any prospects for commercialization of its products. Although Oruka intends to obtain product liability insurance for its future clinical trials, it is possible that any liabilities could exceed Oruka&#8217;s insurance coverage or that in the future Oruka may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against Oruka for uninsured liabilities or in excess of insured liabilities, Oruka&#8217;s assets may not be sufficient to cover such claims and its business operations could be impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Litigation costs and the outcome of litigation could have a material adverse effect on Oruka&#8217;s business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time&#160;Oruka&#160;may&#160;be&#160;subject&#160;to&#160;litigation&#160;claims through the ordinary course of its business operations regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with collaborators and intellectual property rights. Litigation to defend itself against claims by third parties, or to enforce any rights that Oruka may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of its resources, causing a material adverse effect on its business, financial condition, results of operations or cash flows.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on its results of operations and financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. For example, the&#160;COVID<span class="nobreak">-19</span>&#160;pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect Oruka&#8217;s business or the third parties on whom Oruka relies. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect Oruka by increasing its costs, including labor and employee benefit costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on Oruka&#8217;s results of operations and financial condition.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Combined Company</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If any of the events described in &#8220;Risks Related to ARCA&#8221; or &#8220;Risks Related to Oruka&#8221; occur, those events could cause potential benefits of the Merger not to be realized.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following completion of the Merger, the combined company will be susceptible to many of the risks described in the sections herein entitled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risks Related to ARCA</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risks Related to Oruka</span>.&#8221; To the extent any of the events in the risks described in those sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the combined company could be adversely affected in a material way. This could cause the market price of the combined company&#8217;s common stock to decline.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">79</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of the combined company&#8217;s common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the combined company&#8217;s common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>results of clinical trials and preclinical studies of the combined company&#8217;s product candidates, or those of the combined company&#8217;s competitors or the combined company&#8217;s existing or future collaborators;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to meet or exceed financial and development projections the combined company may provide to the public;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to meet or exceed the financial and development projections of the investment community;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>actions taken by regulatory agencies with respect to the combined company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company&#8217;s ability to obtain patent protection for its technologies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>additions or departures of key personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>significant lawsuits, including patent or stockholder litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if securities or industry analysts do not publish research or reports about the combined company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in the market valuations of similar companies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sales of securities by the combined company or its securityholders in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if the combined company fails to raise an adequate amount of capital to fund its operations or continued development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>trading volume of the combined company&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the introduction of technological innovations or new therapies that compete with the products and services of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span>&#160;fluctuations in the combined company&#8217;s financial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#8217;s common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect the combined company&#8217;s business and the value of its </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">80</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the combined company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the combined company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results, financial condition and cash flows.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company may incur losses for the foreseeable future and may never achieve profitability.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company may never become profitable, even if it is able to complete clinical development for one or more product candidates and eventually commercialize such product candidates. The combined company will need to successfully complete significant research, development, testing and regulatory compliance activities that, together with projected general and administrative expenses, is expected to result in substantial increased operating losses for at least the next several&#160;years. Even if the combined company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the combined company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s ability to compete in the highly competitive pharmaceuticals industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The combined company will be highly dependent on its management and scientific personnel. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of the combined company&#8217;s product pipeline, completion of its planned clinical trials, commercialization of its product candidates or&#160;in<span class="nobreak">-licensing</span>&#160;or acquisition of new assets and could impact negatively its ability to implement successfully its business plan. If the combined company loses the services of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The combined company might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will require substantial additional funds to conduct the costly and time<span class="nobreak">-consuming</span> clinical efficacy trials necessary to pursue regulatory approval of each potential product candidate and to continue the development of ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span> and Oruka&#8217;s other programs and future product candidates. The combined company&#8217;s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could, for example, through the sale of common stock or securities convertible or exchangeable into common stock, significantly dilute the combined company&#8217;s stockholders&#8217; ownership interests or inhibit the combined company&#8217;s ability to achieve its business objectives. If the combined company raises additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely the rights of its common stockholders. In addition, any debt financing may subject the combined company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the combined company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the combined company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. Even if the combined company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the combined company or its stockholders.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">81</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will incur significant legal, accounting and other expenses as a public company that Oruka did not incur as a private company, including costs associated with public company reporting obligations under the Securities Exchange&#160;Act&#160;of&#160;1934, as amended (the &#8220;Exchange&#160;Act&#8221;). The combined company&#8217;s management team will consist of the executive officers of Oruka prior to the Merger. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the combined company complies with all of these requirements. Any changes the combined company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the combined company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Upon completion of the Merger, failure by the combined company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon completion of the Merger, ARCA, under the new name &#8220;Oruka Therapeutics, Inc.,&#8221; will be required to meet the initial listing requirements to maintain the listing and continued trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements. Pursuant to the Merger Agreement, ARCA agreed to use its commercially reasonable efforts to cause the shares of ARCA common stock being issued in the Merger (including any common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) to be approved for listing on Nasdaq at or prior to the effective time of the Merger. Based on information currently available to ARCA, ARCA anticipates that its stock will be unable to meet the $4.00 minimum bid price initial listing requirement at the closing of the Merger unless it effects a reverse stock split. ARCA&#8217;s board of directors intends to effect a reverse stock split of the shares of ARCA common stock at a ratio of between 1:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split. Following the Merger, if the combined company is unable to satisfy Nasdaq listing requirements, Nasdaq may notify the combined company that its shares of common stock will not be listed on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon a potential delisting from Nasdaq, if the common stock of the combined company is not then eligible for quotation on another market or exchange, trading of the shares could be conducted in the&#160;over<span class="nobreak">-the-counter</span>&#160;market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the common stock of the combined company; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the common stock of the combined company. Also, it may be difficult for the combined company to raise additional capital if the combined company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the common stock of the combined company and could have a material adverse effect on the combined company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Once the combined company is no longer a smaller reporting company or otherwise no longer qualifies for applicable exemptions, the combined company will be subject to additional laws and regulations affecting public companies that will increase the combined company&#8217;s costs and the demands on management and could harm the combined company&#8217;s operating results and cash flows.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will be subject to the reporting requirements of the Exchange&#160;Act, which requires, among other things, that the combined company file with the SEC, annual, quarterly and current reports with respect to the combined company&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b<span class="nobreak">-2</span> under the Exchange&#160;Act, in at least the near term, the combined company may take advantage of exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act and reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus and in the combined company&#8217;s periodic reports and proxy statements. Once the combined </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">82</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company is no longer a smaller reporting company or otherwise no longer qualifies for these exemptions, the combined company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If the combined company is not able to comply with the requirements in a timely manner or at all, the combined company&#8217;s financial condition or the market price of the combined company&#8217;s common stock may be harmed. For example, if the combined company or its independent auditor identifies deficiencies in the combined company&#8217;s internal control over financial reporting that are deemed to be material weaknesses the combined company could face additional costs to remedy those deficiencies, the market price of the combined company&#8217;s stock could decline or the combined company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the combined company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provided the combined company continues to be listed on Nasdaq, the combined company will be subject to the reporting requirements of the Exchange&#160;Act, the Sarbanes<span class="nobreak">-Oxley</span> Act and the rules and regulations of Nasdaq. The Sarbanes<span class="nobreak">-Oxley</span> Act requires, among other things, that the combined company maintain effective disclosure controls and procedures and internal control over financial reporting. The combined company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form&#160;10<span class="nobreak">-K</span>&#160;filing for that year, as required by Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act. As a private company, Oruka has not been required to document and test its internal controls over financial reporting nor has its management been required to certify the effectiveness of its internal controls and its auditors have not been required to opine on the effectiveness of its internal control over financial reporting. Following the Merger, the combined company will be required to incur substantial professional fees and internal costs to expand its accounting and finance functions and expend significant management efforts. The combined company may experience difficulty in meeting these reporting requirements in a timely manner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company may discover weaknesses in its system of internal financial and accounting controls and procedures that could result in a material misstatement of its financial statements. The combined company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the combined company is not able to comply with the requirements of Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act, or if it is unable to maintain proper and effective internal controls, the combined company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The unaudited pro forma condensed combined financial information for ARCA and Oruka included in this proxy statement/prospectus are preliminary, and the combined company&#8217;s actual financial position and operations after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma financial information for ARCA and Oruka included in this proxy statement/prospectus are presented for illustrative purposes only and is not necessarily indicative of the combined company&#8217;s actual financial condition or results of operations of future periods, or the financial condition or results of operations that would have been realized had the entities been combined during the period presented. The combined company&#8217;s actual results and financial position after the Merger may differ materially and adversely from the unaudited pro forma financial information included in this proxy statement/prospectus. The exchange ratio reflected in this proxy statement/prospectus is preliminary. The final exchange ratio could differ materially from the preliminary exchange ratio used to prepare the pro forma adjustments. For more information see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; beginning on page&#160;282.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">83</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by its stockholders to replace or remove its management.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provisions that will be included in the combined company&#8217;s certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the combined company that stockholders may consider favorable, including transactions in which its common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of the combined company&#8217;s common stock, thereby depressing the market price of its common stock. In addition, because the combined company&#8217;s board of directors will be responsible for appointing the members of the combined company&#8217;s management team, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of the combined company&#8217;s board of directors. Among other things, these provisions will:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continue the use of a classified board of directors such that not all members of the combined company board of directors are elected at one time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>allow the authorized number of the combined company&#8217;s directors to be changed only by resolution of its board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit the manner in which stockholders can remove directors from the combined company&#8217;s board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>provide for advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by its stockholders by written consent;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit who may call a special meeting of stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authorize the combined company&#8217;s board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the combined company&#8217;s board of directors; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>require the approval of the holders of at least 66 2/3% of the votes that all combined company stockholders would be entitled to cast to amend or repeal certain provisions of the combined company&#8217;s certificate of incorporation or bylaws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, because the combined company will be incorporated in Delaware, it is governed by the provisions of Section&#160;203 of the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined company voting stock from merging or combining with the combined company. Although ARCA and Oruka believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with the combined company&#8217;s board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The bylaws of the combined company will provide that, unless the combined company consents in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between the combined company and its stockholders, which could limit its stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the combined company or its directors, officers, employees or stockholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The bylaws of the combined company will provide that, unless the combined company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">84</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of Delaware) is the sole and exclusive forum for the following types of proceedings (i)&#160;any derivative action or proceeding brought on the combined company&#8217;s behalf, (ii)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any of the combined company&#8217;s current or former directors, officers, employees or stockholders to the combined company or its stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv)&#160;any action asserting a claim arising pursuant to any provision of the combined company&#8217;s certificate of incorporation or its bylaws (in each case, as they may be amended from time to time) or that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers to herein as the &#8220;Delaware Forum Provision.&#8221; The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act and the Exchange&#160;Act. The bylaws of the combined company will further provide that, unless it consents in writing to an alternative forum, federal district courts of the United&#160;States will be the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act, which for purposes of this risk factor refers to herein as the &#8220;Federal Forum Provision.&#8221; In addition, the bylaws of the combined company will provide that any person or entity purchasing or otherwise acquiring any interest in shares of its capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived the combined company&#8217;s compliance with the U.S.&#160;federal securities laws and the rules and regulations thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Delaware Forum Provision and the Federal Forum Provision may impose additional costs on stockholders of the combined company in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, the forum selection clauses in the bylaws of the combined company may limit its stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with the combined company or its directors, officers, employees or stockholders, which may discourage such lawsuits against the combined company and its directors, officers, employees and stockholders even though an action, if successful, might benefit its stockholders. Alternatively, if a court were to find the Delaware Forum Provision or the Federal Forum Provision contained in the combined company&#8217;s bylaws to be inapplicable or unenforceable in an action, the combined company may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect its business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA and Oruka do not anticipate that the combined company will pay any cash dividends in the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current expectation is that the combined company will retain its future earnings, if any, to fund the growth of the combined company&#8217;s business as opposed to paying dividends. As a result, capital appreciation, if any, of the common stock of the combined company will be your sole source of gain, if any, for the foreseeable future.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the Merger, there had been no public market for shares of Oruka capital stock. An active trading market for the combined company&#8217;s shares of common stock may never develop or be sustained. If an active market for the combined company&#8217;s common stock does not develop or is not sustained, it may be difficult for the combined company&#8217;s stockholders to sell their shares at an attractive price or at all.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If existing securityholders of ARCA and Oruka sell, or indicate an intention to sell, substantial amounts of the combined company&#8217;s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the combined company could decline. Based on shares outstanding as of March&#160;31, 2024, after giving effect to the estimated exchange ratio and the shares of Oruka common stock and the Oruka&#160;pre<span class="nobreak">-funded</span>&#160;warrants to be issued in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing and shares expected to be issued upon completion of the Merger and prior to giving effect to the anticipated ARCA reverse stock split, the combined company is expected to have outstanding a total of approximately 357.5<span class="nobreak"> </span>million shares of common stock immediately following the completion of the Merger. Of the shares of common stock, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">85</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approximately <span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares are freely tradeable upon completion of the Merger and approximately&#160;&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares will be available for sale in the public market beginning 180&#160;days after the closing of the Merger as a result of the expiration of&#160;lock<span class="nobreak">-up</span>&#160;agreements between ARCA on the one hand and certain securityholders of Oruka on the other hand (and without giving effect to any restrictions on resale under securities laws). In addition, shares of common stock that are subject to outstanding options or warrants of Oruka (excluding the&#160;pre<span class="nobreak">-funded</span>&#160;warrants issued in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing) will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of the combined company&#8217;s common stock could decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">After completion of the Merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the completion of the Merger, and giving effect to the issuance of the shares of Oruka common stock and the Oruka&#160;pre<span class="nobreak">-funded</span>&#160;warrants prior to the closing of the Merger pursuant to the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the combined company&#8217;s outstanding shares of common stock (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the combined company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the combined company on terms that other stockholders may desire.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined company, its business or its market, its stock price and trading volume could decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The trading market for the combined company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect to not provide research coverage of the combined company&#8217;s common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts or the content and opinions included in their reports. The price of the combined company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka&#160;pre-closing&#160;financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will have broad discretion over the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing. You may not agree with the combined company&#8217;s decisions, and its use of the proceeds may not yield any return on your investment. The combined company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the combined company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence its decisions on how to use the combined company&#8217;s cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect the combined company or its </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">86</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">stockholders. The combined company will assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where the combined company has operations to determine the potential effect on its business and any assumptions the combined company will make about its future taxable income. It cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. For example, the United&#160;States recently enacted the IRA, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Act eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years. The U.S.&#160;Congress is considering legislation that would restore the current deductibility of research and development expenditures, however, there is no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect its effective tax rate, results of operation and general business condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company&#8217;s ability to use NOL carryforwards and other tax attributes may be limited, including as a result of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed above, ARCA has incurred losses during its history, and the combined company does not expect to become profitable in the near future and may never achieve profitability. As of December&#160;31, 2023, ARCA had NOL carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA had operating loss carryforwards of $156.4&#160;million generated prior to 2018, which will expire beginning in 2025 if not utilized. Under current law, ARCA&#8217;s U.S.&#160;federal NOLs of $51.7&#160;million incurred in tax&#160;years beginning after December&#160;31, 2017 may be carried forward indefinitely, but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections&#160;382 and 383 of the Code, U.S.&#160;federal net operating loss carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&#160;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three<span class="nobreak">-year</span> period. The combined company&#8217;s ability to utilize its net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Merger or other transactions. Similar rules may apply under state tax laws. If the combined company earns taxable income, such limitations could result in increased future income tax liability to the combined company, and the combined company&#8217;s future cash flows could be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect the combined company&#8217;s business, financial condition, results of operations or cash flows.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to the combined company&#8217;s business, including, weakened demand for the combined company&#8217;s product candidates and the combined company&#8217;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain the combined company&#8217;s suppliers, possibly resulting in supply disruption, or cause the combined company&#8217;s customers to delay making payments for its services. Any of the foregoing could harm the combined company&#8217;s business and the combined company cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">87</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T23"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This proxy statement/prospectus contains or incorporates statements that constitute forward<span class="nobreak">-looking</span> statements within the meaning of the federal securities laws in relation to ARCA, Oruka, the Merger and the other proposed transactions contemplated thereby. Any express or implied statements that do not relate to historical or current facts or matters are forward<span class="nobreak">-looking</span> statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward<span class="nobreak">-looking</span> statements. These forward<span class="nobreak">-looking</span> statements include, but are not limited to, express or implied statements regarding ARCA&#8217;s or Oruka&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In some cases, you can identify forward<span class="nobreak">-looking</span> statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;target,&#8221; &#8220;endeavor,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;contemplate&#8221; or the negative of these terms or other comparable terminology, but the absence of these words does not mean that a statement is not forward<span class="nobreak">-looking</span>. These forward<span class="nobreak">-looking</span> statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting ARCA, Oruka or the proposed transaction will be those that have been anticipated. These forward<span class="nobreak">-looking</span> statements involve a number of risks, uncertainties (some of which are beyond ARCA&#8217;s or Oruka&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward<span class="nobreak">-looking</span> statements. In addition to other factors and matters contained in or incorporated by reference in this document, ARCA and Oruka believe the following factors could cause actual results to differ materially from those discussed in the forward<span class="nobreak">-looking</span> statements:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the conditions to the closing of the Merger are not satisfied, including the failure to obtain stockholder approval required to complete the Merger and transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to meet expectations regarding the timing and completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Oruka pre<span class="nobreak">-closing</span> financing is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>uncertainties as to the timing and costs of the consummation of the Merger and the ability of each of ARCA and Oruka to consummate the Merger and the transactions contemplated thereby, including the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>statements regarding the special cash dividend that ARCA may pay to ARCA stockholders in connection with the completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>risks related to ARCA&#8217;s continued listing on the Nasdaq until closing of the proposed Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expectations regarding the strategies, prospects, plans expectations and objectives of management of ARCA or Oruka for future operations of the combined company following the closing of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of the combined company to recognize the benefits that may be derived from the Merger, including the commercial or market opportunity of the product candidates of ARCA, Oruka and the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>risks related to ARCA&#8217;s and Oruka&#8217;s ability to correctly estimate their respective operating expenses and expenses associated with the transaction, uncertainties regarding the impact any delay in the closing of the Merger would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company&#8217;s cash resources;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the accuracy of the parties&#8217; estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that under the terms of the Merger Agreement, ARCA and Oruka are restrained from soliciting other acquisition proposals during the pendency of the Merger, except in certain circumstances;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">88</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the effect of the announcement or pendency of the Merger on ARCA&#8217;s or Oruka&#8217;s business relationships, operating results and business generally, including disruption of ARCA&#8217;s and Oruka&#8217;s management&#8217;s attention from ongoing business operations due to the Merger and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Merger Agreement may be terminated in circumstances that require ARCA or Oruka to pay a termination fee;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the outcome of any legal proceedings that may be instituted against ARCA, Oruka or any of their respective directors or officers related to the Merger Agreement or the transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of ARCA and Oruka to protect their respective intellectual property rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>competitive responses to the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>legislative, regulatory, political and economic developments beyond the parties&#8217; control;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initiation, timing and success of clinical trials for ARCA&#8217;s and Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>success in retaining, or changes required in, ARCA&#8217;s and Oruka&#8217;s officers, key employees or directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s public securities&#8217; potential liquidity and trading;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory actions with respect to ARCA&#8217;s and Oruka&#8217;s product candidates or their respective competitors&#8217; products and product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to manufacture their product candidates in conformity with the FDA&#8217;s requirements and to scale up manufacturing of their product candidates to commercial scale, if approved;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s reliance on third<span class="nobreak">-party</span> contract development and manufacturer organizations to manufacture and supply product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of ARCA&#8217;s and Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected potential benefits of strategic collaboration with third parties and ARCA&#8217;s and Oruka&#8217;s ability to attract collaborators with development, regulatory and commercialization expertise;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to successfully commercialize product candidates, if approved, and the rate and degree of market acceptance of such product candidates; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>developments and projections relating to ARCA&#8217;s and Oruka&#8217;s competitors or industry.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should one or more of these risks or uncertainties materialize, or should any of ARCA&#8217;s or Oruka&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward<span class="nobreak">-looking</span> statements. There may be additional risks that ARCA or Oruka considers immaterial or which are unknown. You are urged to carefully review the disclosures ARCA and Oruka make concerning these risks and other factors that may affect ARCA&#8217;s and Oruka&#8217;s business and operating results under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus. Additional factors that could cause actual results to differ materially from those expressed in the forward<span class="nobreak">-looking</span> statements are discussed in reports filed with the SEC by ARCA and incorporated by reference herein. Please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 317 of this proxy statement/prospectus. There can be no assurance that the Merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected benefits of the Merger will be realized.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">89</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of ARCA, Oruka or the combined company could differ materially from the forward<span class="nobreak">-looking</span> statements. Any public statements or disclosures by ARCA and Oruka following this proxy statement/prospectus that modify or impact any of the forward<span class="nobreak">-looking</span> statements contained in this proxy statement/prospectus will be deemed to modify or supersede such statements in this proxy statement/prospectus. You are cautioned not to place undue reliance on these forward<span class="nobreak">-looking</span> statements, which speak only as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. ARCA and Oruka do not intend, and undertake no obligation, to update any forward<span class="nobreak">-looking</span> information to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, unless required by law to do so.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">90</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T22"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">THE SPECIAL MEETING IN LIEU OF ANNUAL MEETING OF ARCA STOCKHOLDERS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Date, Time and Place</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA special meeting will be held on&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, commencing at&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Mountain Time, unless postponed or adjourned to a later date. The ARCA special meeting will be held at&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. ARCA is sending this proxy statement/prospectus to its stockholders in connection with the solicitation of proxies by ARCA&#8217;s board of directors for use at the ARCA special meeting and any adjournments or postponements of the ARCA special meeting. This proxy statement/prospectus is first being furnished to ARCA stockholders on or about&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Purpose of the ARCA Special Meeting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purposes of the ARCA special meeting are:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal&#160;No. 1&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000<span class="nobreak"> </span>shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal&#160;No. 2&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to this proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal&#160;No. 3&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span> (the &#8220;Officer Exculpation Proposal&#8221; or &#8220;Proposal&#160;No. 4&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal&#160;No. 5&#8221;), provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal&#160;No. 6&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal&#160;No. 7&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal&#160;No. 8&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger (the &#8220;the Merger Compensation Proposal&#8221; or &#8220;Proposal&#160;No. 9&#8221;);</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">91</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal&#160;No. 10&#8221;); and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. The amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock will not take place unless Proposal&#160;No. 2 is approved by the requisite ARCA stockholders. The amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock will not take place unless Proposal&#160;No. 3 is approved by the requisite ARCA stockholders. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recommendation of ARCA&#8217;s Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ARCA&#8217;s board of directors recommends that you vote:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement is fair to, in the best interests of, and advisable to, ARCA and its stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the increase in authorized shares. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the reverse stock split, if necessary. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Reverse Stock Split Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the amendment to the ARCA Charter to provide for the exculpation of officers, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Officer Exculpation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to elect Jacob Ma<span class="nobreak">-Weaver</span> to serve on ARCA&#8217;s board of directors in the class of directors with terms expiring at ARCA&#8217;s 2027 annual meeting of stockholders, provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. ARCA&#8217;s board of directors that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the director nominee named in the Director Election Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December<span class="nobreak">&#160;</span>31, 2024, provided that </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">92</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Auditor Ratification Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Stock Incentive Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that adjourning the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, ARCA and its stockholders and has approved and adopted the proposal. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Record Date and Voting Power</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Only holders of record of ARCA common stock at the close of business on the Record Date of<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, are entitled to notice of, and to vote at, the ARCA special meeting. At the close of business on the Record Date, there were&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>registered holders of record of ARCA common stock and there were&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA common stock issued and outstanding. Each share of ARCA common stock entitles the holder thereof to one vote on each matter submitted for stockholder approval.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Voting and Revocation of Proxies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The proxy accompanying this proxy statement/prospectus is solicited on behalf of ARCA&#8217;s board of directors for use at the ARCA special meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If, as of the Record Date referred to above, your shares were registered directly in your name with the transfer agent for ARCA common stock, Computershare Trust Company, N.A., then you are a stockholder of record. As a stockholder of record, you may vote in person at the ARCA special meeting or vote by proxy. Whether or not you plan to attend the ARCA special meeting, we urge you to vote by proxy over the telephone or on the Internet as instructed below or return the proxy card we may mail to you to ensure your vote is counted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The procedures for voting are as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a stockholder of record, you may vote at the ARCA special meeting. Alternatively, you may vote by proxy by using the accompanying proxy card, over the internet or by telephone. Whether or not you plan to attend the ARCA special meeting, ARCA encourages you to vote by proxy to ensure your vote is counted. Even if you have submitted a proxy before the ARCA special meeting, you may still attend the ARCA special meeting and vote. In such case, your previously submitted proxy will be disregarded.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote in person, come to the ARCA special meeting and we will give you a ballot when you arrive. If you attend the ARCA special meeting and vote in person, your vote will revoke any proxy that you have previously submitted. Simply attending the ARCA special meeting will not, by itself, revoke your proxy.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">93</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can vote by proxy over the telephone by calling the toll<span class="nobreak">-free</span> number found on the proxy card.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can vote by proxy over the internet by following the instructions provided on the proxy card.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a voting instruction card and voting instructions with these proxy materials from that organization rather than from ARCA.&#160;Simply complete and mail the voting instruction card to ensure that your vote is counted. To vote at the ARCA special meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA provides internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you hold shares beneficially in street name and do not provide your broker or other agent with voting instructions, your shares may constitute &#8220;broker non<span class="nobreak">-votes</span>.&#8221; A &#8220;broker non<span class="nobreak">-vote</span>&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s)&#160;with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote on the matter. Abstentions will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Abstentions will be counted towards the vote totals for each proposal, and will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>4,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;No. 4. If an ARCA stockholder does not return voting instructions to their broker on how to vote their shares of ARCA common stock, such broker may be prevented from voting, or may otherwise choose not to vote, such shares held by such broker, resulting in broker non<span class="nobreak">-votes</span> with respect to such shares. To make sure that your vote is counted, you should instruct your broker to vote your shares of ARCA common stock, following the procedures provided by your broker.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All properly executed proxies that are not revoked will be voted at the ARCA special meeting and at any adjournments or postponements of the ARCA special meeting in accordance with the instructions contained in the proxy. <span class="Bold" style="font-style:normal;font-weight:bold;">If a holder of ARCA common stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; all of the proposals in accordance with the recommendation of ARCA&#8217;s board of directors.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The presence at the ARCA special meeting of the holders of a majority of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will be counted towards the presence of a quorum. The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos. 2 and 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.&#160;5, directors are elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.<span class="nobreak"> </span>1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">94</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. The amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock will not take place unless Proposal&#160;No. 2 is approved by the requisite ARCA stockholders. The amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock, if deemed necessary, will not take place unless Proposal&#160;No. 3 is approved by the requisite ARCA stockholders. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR,&#8221; &#8220;AGAINST&#8221; and &#8220;WITHHOLD&#8221; votes, abstentions and broker non<span class="nobreak">-votes</span>, if any, as applicable to each proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Abstentions will be counted towards the vote totals for each proposal, and will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>4,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;No. 4.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-indent:24pt;margin-top:8pt;">As of&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the directors and executive officers of ARCA owned or controlled&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>% of the outstanding shares of ARCA common stock entitled to vote at the ARCA special meeting. As of&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the ARCA stockholders that are party to a support agreement, including the directors, executive officers and certain stockholders of ARCA, owned an aggregate number of shares of ARCA common stock representing approximately&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>% of the outstanding shares of ARCA common stock. Each stockholder that entered into a support agreement, including the directors and executive officers of ARCA, has agreed to vote all shares of ARCA common stock owned by him or her as of the Record Date in favor of the adoption of the Merger Agreement and the transactions contemplated thereby, including the Merger, the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to the stockholders of Oruka pursuant to the Merger Agreement and the change of control resulting from the First Merger, and against any alternative acquisition proposals.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Solicitation of Proxies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to solicitation by mail, the directors, officers, employees and agent of ARCA may solicit proxies from ARCA stockholders by personal interview, telephone, email, fax or otherwise. ARCA and Oruka will share equally the costs of printing and filing this proxy statement/prospectus and proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of ARCA common stock for the forwarding of solicitation materials to the beneficial owners of ARCA common stock. ARCA will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out of pocket expenses they incur in connection with the forwarding of solicitation materials. ARCA has retained<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Other Matters</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this proxy statement/prospectus, ARCA&#8217;s board of directors does not know of any business to be presented at the ARCA special meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the ARCA special meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">95</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T991188"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE MERGER</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">This section and the section titled &#8220;The Merger Agreement&#8221; beginning on page 133 of this proxy statement/prospectus describe the material aspects of the Merger and the Merger Agreement. While ARCA and Oruka believe that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus for a more complete understanding of the Merger and the Merger Agreement and the other documents to which you are referred in this proxy statement/prospectus. See the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 317 of this proxy statement/prospectus.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Background of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">ARCA&#8217;s board of directors and management regularly review ARCA&#8217;s operating and strategic plans in an effort to enhance stockholder value. This review involves, among other things, discussions of opportunities and risks associated with ARCA&#8217;s product candidates, development programs, financial condition and market, as well as a consideration of strategic alternatives available to ARCA.&#160;On March&#160;28, 2022, members of ARCA&#8217;s board of directors and management reviewed the results of ARCA&#8217;s Phase&#160;2 clinical trial of Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) (the &#8220;Clinical Trial&#8221;). The results of the Clinical Trial indicated that neither studied dose of rNAPc2 achieved statistical significance for the primary efficacy endpoint.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In light of these results, ARCA&#8217;s board of directors initiated a process to identify and evaluate strategic alternatives available to ARCA that ultimately resulted in the execution of the Merger Agreement. The following is a summary of the background of the process undertaken by ARCA, the identification and evaluation of strategic alternatives and the negotiation of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On March&#160;28, 2022, ARCA&#8217;s board of directors held video conference meetings with members of ARCA&#8217;s management and a representative of its legal advisor, Cooley LLP (&#8220;Cooley&#8221;) in attendance, to review the Clinical Trial results. ARCA&#8217;s board of directors discussed strategic alternatives available to ARCA in light of the negative Clinical Trial results, including continuation of the development of ARCA&#8217;s current products, possible licensing opportunities or a sale of ARCA.&#160;Following this meeting, Mr.&#160;Conway, Chairman of ARCA&#8217;s board of directors, instructed management to provide ARCA&#8217;s board of directors with management&#8217;s assessment of the viability of continuing to develop ARCA&#8217;s current products in light of the negative Clinical Trial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On March&#160;29, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance to discuss a proposed product development plan prepared by ARCA&#8217;s management which included a plan to conduct a Phase&#160;3 trial for ARCA&#8217;s Gencaro product in patients with higher ejection fraction heart failure. ARCA&#8217;s board of directors instructed management to further refine ARCA&#8217;s product development plan and to explore other potential strategic alternatives to the product development plan available to ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Following the close of markets on March&#160;31, 2022, ARCA publicly announced the Clinical Trial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;10, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance to discuss a refined product development plan prepared by ARCA&#8217;s management and the strategic alternatives to that development plan including a sale of ARCA or other strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Later that same&#160;day, ARCA&#8217;s board of directors held a video conference meeting without members of ARCA&#8217;s management or representatives of Cooley in attendance. ARCA&#8217;s board of directors discussed ARCA&#8217;s prospects as a stand<span class="nobreak">-alone</span> company pursuant to the refined product development plan presented by ARCA&#8217;s management earlier that same&#160;day, and the potential strategic alternatives thereto that were available to ARCA including a broad outreach to potential reverse merger counterparties or a liquidation of ARCA.&#160;It was the consensus of ARCA&#8217;s board of directors that in light of the negative Clinical Trial results, ARCA should explore and evaluate its strategic alternatives while continuing to evaluate its ability to continue on as a stand<span class="nobreak">-alone</span> enterprise. ARCA&#8217;s board of directors discussed the evaluation and retention of a financial advisor to assist ARCA&#8217;s board of directors in its exploration and evaluation of strategic alternatives.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;17, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance. ARCA&#8217;s board of directors discussed the formation of a special committee of ARCA&#8217;s  board of directors (the &#8220;Special Committee&#8221;) for the purpose of identifying, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">96</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">considering, evaluating and making recommendations to ARCA&#8217;s board of directors regarding potential strategic alternatives. ARCA&#8217;s board of directors approved the formation the Special Committee and appointed Mr.&#160;Conway, Dr.&#160;Hove and Dr.&#160;Grais to serve on the Special Committee, with Mr.&#160;Conway serving as chair. The Special Committee was not formed for the purposes of addressing potential or actual conflicts of interest of any director or officer of ARCA.&#160;ARCA&#8217;s board of directors delegated to the Special Committee the full power and authority of ARCA&#8217;s board of directors to, among other things, identify, consider, evaluate and make recommendations to ARCA&#8217;s board of directors regarding potential strategic alternatives and proposals which may be available to ARCA and further resolved to not approve any transaction unless the Special Committee had recommended that ARCA&#8217;s board of directors approve such a transaction. It was also discussed and concluded that: (1)&#160;ARCA&#8217;s board of directors would continue to have an active role in (i)&#160;the evaluation of any acquisition proposal, (ii)&#160;any discussions with potential acquirers with respect to a potential strategic transaction and (iii)&#160;any broader review of strategic alternatives; (2)&#160;the Special Committee would update and seek input from ARCA&#8217;s board of directors as appropriate; and (3)&#160;members of ARCA&#8217;s board of directors who were not also members of the Special Committee would be invited to attend the meetings of the Special Committee. ARCA&#8217;s board of directors also discussed potential candidates to act as financial advisor to ARCA in connection with a potential strategic transaction and directed the Special Committee to interview potential candidates and engage a financial advisor in connection with a strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;18, 2022, ARCA publicly announced its initiation of a process to evaluate strategic options for maximizing stockholder value and the establishment of the Special Committee to assist in the pursuit of such a transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Between April&#160;25, 2022, and April&#160;29, 2022, the Special Committee, and members of ARCA&#8217;s management team met with representatives from five investment banking firms telephonically to assess their ability to act as ARCA&#8217;s financial advisor in connection with a review of potential strategic alternatives.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;2, 2022, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team in attendance. The Special Committee discussed the qualifications of the financial advisors it had interviewed. After consideration of the relative qualifications and expertise of the candidates, including industry expertise, knowledge, access to potential transaction candidates, and recent transaction experience, the Special Committee approved the selection of Ladenburg Thalmann&#160;&amp; Co., Inc. (&#8220;Ladenburg&#8221;) as ARCA&#8217;s financial advisor to assist ARCA in its review of potential strategic alternatives and authorized and directed ARCA&#8217;s management to negotiate an engagement letter with Ladenburg. The Special Committee also determined that Ladenburg&#8217;s outreach should be focused on identifying potential reverse merger transaction candidates because the Special Committee believed such a transaction had the highest likelihood of presenting the highest value for stockholders in light of (i)&#160;the value that would be ascribed to ARCA&#8217;s public listing in such a transaction which would not be taken into account in a traditional merger or other similar strategic transaction and (ii)&#160;ARCA&#8217;s limited non<span class="nobreak">-cash</span> assets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;4, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance. ARCA&#8217;s board of directors reviewed the qualifications of the potential candidates to serve as ARCA&#8217;s financial advisor, the terms of the proposed engagement letter with Ladenburg and the Special Committee&#8217;s recommendation to appoint Ladenburg as ARCA&#8217;s financial advisor. ARCA&#8217;s board of directors approved the engagement of Ladenburg and authorized ARCA&#8217;s management to enter into an engagement letter in substantially the form presented to ARCA&#8217;s board of directors, which ARCA&#8217;s management executed later that same day.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;5, 2022, ARCA publicly announced it had retained Ladenburg to act as its financial advisor to explore and review a range of strategic alternatives focused on maximizing stockholder value including an acquisition, merger, business combination or other strategic transaction involving ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;6, 2022, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Cooley and Ladenburg in attendance. At this meeting, Ladenburg reviewed the process it proposed to undertake in order to identify and evaluate potential strategic alternatives and over 250 potential counterparties that it believed may be interested in pursuing a reverse merger transaction with ARCA.&#160;The Special Committee discussed the anticipated timeline for contacting and receiving and evaluating proposals from interested parties in connection with a strategic transaction. Ladenburg also reviewed its proposed selection criteria to be used by the Special Committee in identifying and evaluating potential counterparties. This criteria included an evaluation of (i)&#160;the quality of the assets owned by the potential counterparty, (ii)&#160;whether the potential counterparty had clear, proof of concept clinic data, (iii)&#160;the development stage of the potential counterparty, (iv)&#160;the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">97</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">counterparty&#8217;s product pipeline, (v)&#160;whether the counterparty was pursuing a concurrent private placement financing in order to ensure the counterparty had sufficient cash resources to reach the upcoming milestones with respect to the counterparty&#8217;s product candidates, (vi)&#160;the quality of the potential investors that would participate in such a concurrent financing, (vii)&#160;the amount of cash from ARCA required by the potential counterparty and the amount of cash ARCA would be able to distribute to its stockholders in a special dividend immediately prior to the closing of a transaction, (viii)&#160;the industry within which the counterparty was engaged, (ix)&#160;whether the counterparty was willing to ascribe any value to ARCA&#8217;s products in the proposed transaction, (x)&#160;whether the counterparty was expected to have value inflection points within 18&#160;months, (xi)&#160;the capital structure of the counterparty, (xii)&#160;whether the counterparty had sufficient infrastructure to maintain ARCA&#8217;s public listing or the ability to maintain such infrastructure, including whether the counterparty had financial statements sufficient to satisfy public company reporting standards, and (xiii)&#160;whether the relative valuations ascribed to ARCA and the potential counterparty in light of the foregoing factors was fair. Ladenburg also proposed limiting outreach efforts to companies in the pharmaceutical and biotechnology industry in light of ARCA&#8217;s enhanced ability to evaluate and assess the products, and related operational, industry, regulatory, financial, market and other risks and opportunities, of companies within those particular industries. Following a discussion, the Special Committee authorized Ladenburg to begin outreach to all of the potential counterparties presented by Ladenburg and adopted the proposed criteria for purposes of evaluating potential offers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beginning on May&#160;6, 2022, Ladenburg conducted a process of identifying and evaluating potential counterparties for a strategic transaction with assistance from the Special Committee and members of ARCA&#8217;s management. In its outreach efforts, members of ARCA&#8217;s board of directors, ARCA&#8217;s management, and representatives of Ladenburg, contacted over 250 companies that met the criteria adopted by the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From May&#160;6, 2022 until June&#160;15, 2022, ARCA delivered bid process letters to 74 companies, received a total of 50 formal non<span class="nobreak">-binding</span> proposals (all of which were for reverse merger styled transactions) and entered into 37&#160;non<span class="nobreak">-disclosure</span> agreements to facilitate further diligence with potential counterparties which also contained a customary &#8220;standstill&#8221; restriction that would terminate upon entry into a definitive agreement for an acquisition of more than 50% of the shares of capital stock of ARCA. During that same period, the Special Committee, members of ARCA&#8217;s management and outside advisors met numerous times to consider the various non<span class="nobreak">-binding</span> proposals, and to receive updates regarding the solicitation and evaluation of the proposals. The Special Committee determined not to pursue 48 of the 50 non<span class="nobreak">-binding</span> proposals that were submitted due to, among other reasons, the failure of those potential counterparties to adequately satisfy many of the criteria adopted by the Special Committee. Of the two non<span class="nobreak">-binding</span> proposals that the Special Committee determined to pursue, the Special Committee determined to abandon one in June&#160;2022 in light of that counterparty&#8217;s early stage of development and substantial cash needs. The other counterparty informed the Special Committee in December&#160;2022 that it was no longer interested in pursuing a transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;15, 2022, ARCA entered into a Cooperation Agreement with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span>. Pursuant to the Cooperation Agreement, ARCA&#8217;s board of directors appointed Jacob Ma<span class="nobreak">-Weaver</span> as a Class&#160;III director with a term expiring at ARCA&#8217;s 2024 annual meeting of stockholders, effective June&#160;15, 2022, and appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> to the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From June&#160;15, 2022 until December&#160;15, 2022, at the direction of the Special Committee, ARCA&#8217;s management engaged third<span class="nobreak">-party</span> experts to examine and evaluate its ability to further develop Gencaro as a stand<span class="nobreak">-alone</span> enterprise and prepared an analysis of the potential value of ARCA&#8217;s assets in a liquidation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and representatives of Wilson Sonsini Goodrich &amp; Rosati, P.C. (&#8220;Wilson Sonsini&#8221;) (who at such point had been engaged as ARCA&#8217;s counsel) and Ladenburg in attendance to discuss the strategic alternatives available to ARCA including having Ladenburg undertake a renewed search for new strategic transaction counterparties, pursuing a liquidation or continuing to pursue ARCA&#8217;s development plans as a stand<span class="nobreak">-alone</span> enterprise. The Special Committee determined that continuing to pursue potential strategic transactions was reasonably likely to result in a superior alternative to a liquidation and ARCA&#8217;s development plan as a stand<span class="nobreak">-alone</span> enterprise and as a result authorized and directed Ladenburg to re<span class="nobreak">-engage</span> with potential counterparties. As part of that authorization, it directed Ladenburg to broaden the scope of potential counterparties to include companies outside the pharmaceutical and biotechnology industry in order to evaluate all possible alternatives available to ARCA and determined to further refine its selection criteria to favor companies with later stage assets and/or near<span class="nobreak">-term</span> revenue as well as companies that did not require all of ARCA&#8217;s cash in order to achieve its key milestones to ensure a significant dividend of its </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">98</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">cash assets could be made as part of any such transaction. In addition, the Special Committee also determined that ARCA&#8217;s management should continue to further refine and pursue its development plan as a potential alternative if a compelling counterparty for a strategic transaction was not able to be found.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From December&#160;15, 2022, until January&#160;5, 2023, the Special Committee and representatives of Ladenburg met on multiple occasions to review eleven potential counterparties for a strategic transaction in light of ARCA&#8217;s board of directors&#8217; revised selection criteria and ultimately refined the number of potential counterparties down to three potential counterparties that presented a reasonable likelihood of resulting in a superior alternative to the strategic alternatives the Special Committee was considering including a liquidation of ARCA or the continuation of its business as a standalone enterprise. ARCA and these three potential counterparties entered into non<span class="nobreak">-disclosure</span> agreements to facilitate their discussions which contained a customary &#8220;standstill&#8221; restriction that would terminate upon entry into a definitive agreement for an acquisition of more than 50% of the shares of capital stock of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From January&#160;5, 2023, until January&#160;20, 2023, the Special Committee, members of ARCA&#8217;s management and representatives of Ladenburg met with and reviewed presentations prepared by the three potential counterparties selected by the Special Committee. Following the presentations, the Special Committee determined that a potential transaction with Party A was the most attractive because (i)&#160;it had a promising late stage asset that was expected to reach near term value inflection points along with a promising early stage product candidate and (ii)&#160;it did not require all of ARCA&#8217;s cash to fund its operations. While it did not abandon the other two potential counterparties, the Special Committee focused its efforts on engaging with Party A in light of the attractiveness of that counterparty when compared to the other two potential counterparties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On January&#160;26, 2023, members of ARCA&#8217;s management and representatives of Ladenburg were given access to a virtual data room hosted by Party A.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From January&#160;26, 2023, until March&#160;10, 2023, ARCA&#8217;s management and representatives of Ladenburg undertook an extensive preliminary due diligence review of Party A and engaged numerous advisors to assist ARCA in its due diligence review.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On March&#160;10, 2023, at the direction of the Special Committee, representatives of Ladenburg delivered a draft term sheet to Party A providing for a reverse merger transaction and which ascribed an enterprise value to ARCA in the merger of $10,000,000 and an enterprise value to Party A of $75,000,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From March&#160;10, 2023, until May&#160;30, 2023, the Special Committee and representatives of Party A met multiple times to negotiate the substantive economic terms of a potential reverse merger transaction including the size and type of investor for a private placement transaction contemplated to close substantially concurrently with the closing of a reverse merger transaction and the relative valuations to be ascribed to each party.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On May&#160;30, 2023, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the final terms of the term sheet negotiated with Party A, which provided for a reverse merger transaction ascribing a $11,000,000 enterprise valuation to ARCA and a $60,000,000 enterprise valuation to Party A.&#160;The term sheet also, among other things, allowed ARCA to distribute to its pre<span class="nobreak">-closing</span> stockholders all of ARCA&#8217;s net cash in excess of $21,000,000 and gave ARCA&#8217;s stockholders a contingent value right representing the right to receive net proceeds of any sale of ARCA&#8217;s legacy product candidates. The term sheet also obligated each party to exclusively negotiate a transaction with one another. The Special Committee determined that it should continue to pursue a transaction with Party A on an exclusive basis in light of (i)&#160;the Special Committee&#8217;s view that each of (A)&#160;pursuing ARCA&#8217;s corporate objectives on a stand<span class="nobreak">-alone</span> basis, including the proposed development plan and (B)&#160;the liquidation of ARCA, was not reasonably likely to result in superior value to ARCA&#8217;s stockholders when compared to the proposed transaction; (ii)&#160;the Special Committee&#8217;s view that the $11&#160;million enterprise value ascribed to ARCA would give ARCA&#8217;s stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend; (iii)&#160;the Special Committee&#8217;s view that the combined company was likely to possess sufficient cash resources at the closing of the Merger to fund development of Party A&#8217;s product candidates through upcoming value inflection points; (iv)&#160;ARCA&#8217;s positive preliminary due diligence performed to date and the recommendations of its advisors with respect to the viability of Party A&#8217;s assets and (v)&#160;the Special Committee&#8217;s view that the proposal from Party A was more favorable to ARCA than the potential value that might have resulted from further pursuing other strategic transactions available to ARCA in light of the extensive outreach process undertaken to date. As a result of that determination, the Special Committee authorized and directed ARCA&#8217;s management to execute and deliver the term sheet to Party A and began exclusively negotiating a potential reverse merger transaction with Party A.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">99</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same day, ARCA and Party A executed the non<span class="nobreak">-binding</span> term sheet and representatives of ARCA, Party A, and each of their respective legal and financial advisors participated in a video conference meeting during which the timeline and process for the signing of definitive agreements providing for a potential business combination were discussed, including the signing of definitive agreements for a private placement in ARCA that was contemplated to close concurrently with the business combination. The participants tentatively agreed on a work plan that contemplated the execution of definitive agreements in late June or early July&#160;2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between May&#160;30, 2023, and July&#160;20, 2023, representatives of ARCA and Party A engaged in exclusive negotiations regarding a potential reverse merger and conducted detailed due diligence reviews of one another.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;20, 2023, Party A informed ARCA that its product approval had been delayed due to a request for additional information by the Office of New Drugs at the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between July&#160;20, 2023, and August&#160;25, 2023, the Special Committee, Party A, and each of their respective legal and financial advisors participated in a numerous video conference meetings to discuss the current status of Party A&#8217;s drug approval with the Office of New Drugs at the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, the Special Committee met with members of ARCA&#8217;s management, and representatives of Wilson Sonsini and Ladenburg to review the status of Party A&#8217;s application with the Office of New Drugs at the FDA and discussed the other strategic alternatives available to ARCA if Party A&#8217;s approval continued to be delayed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;25, 2023, the Special Committee determined that it was no longer viable to continue to exclusively pursue a transaction with Party A in light of Party A&#8217;s ongoing financing challenges, regulatory difficulties, increased expenditures and the Special Committees determination that Party A would not be able to successfully market or obtain commitments for the private placement investment contemplated by the term sheet in light of the foregoing. On that same&#160;day, ARCA allowed its obligation to exclusively negotiate with Party A lapse without extension.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From August&#160;25, 2023, until December&#160;7, 2023, the Special Committee continued to participate in a numerous video conference meetings to discuss the current status of Party A&#8217;s drug approval with the Office of New Drugs at the FDA.&#160;At each of these meetings, Party A stated that regulatory approval was imminent.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During this same period, the Special Committee conducted video conference meetings with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the strategic alternatives available to ARCA if Party A&#8217;s regulatory approval continued to be delayed including a renewed search by Ladenburg for potential reverse merger partners or a liquidation of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December<span class="nobreak"> </span>7, 2023, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> called Mr.<span class="nobreak"> </span>Conway and verbally proposed a potential partial tender offer for 50.1% of the shares of ARCA&#8217;s capital stock at a price per share range of $1.95 to $2.05 to be led by a stockholder affiliated with Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same day, the Special Committee conducted a video conference meeting (without Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> attending) with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance. The Special Committee further discussed the strategic alternatives available to ARCA including the proposal made by Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> earlier that day. The Special Committee discussed the proposal and noted that the proposal was unlikely to be attractive in light of (i)&#160;the fact that ARCA stockholders were expected to receive approximately $2.25 per share in cash if ARCA liquidated at that time based on the previous liquidation analysis prepared by ARCA&#8217;s management in June&#160;2022 and (ii)&#160;the outcomes that the Special Committee expected it could achieve in a potential strategic transaction. The Special Committee authorized Mr.&#160;Conway to continue conversations with Mr.&#160;Ma<span class="nobreak">-Weaver</span> regarding a potential tender offer in order to see if negotiations with Mr.&#160;Ma<span class="nobreak">-Weaver</span> could eventually result in a price per share that presented a superior alternative to the various strategic alternatives the Special Committee was considering and instructed ARCA&#8217;s management to prepare an updated liquidation analysis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From December&#160;7, 2023, until January&#160;12, 2024, the Special Committee (without Mr.&#160;Ma<span class="nobreak">-Weaver</span> attending), conducted numerous video conference meetings to discuss the strategic alternatives available to ARCA which included, a liquidation of ARCA, a renewed search by Ladenburg for potential reverse merger partners, and a tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, Mr.&#160;Conway and Mr.&#160;Ma<span class="nobreak">-Weaver</span> met multiple times to discuss and negotiate a potential tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">100</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, on December&#160;12, 2023, the Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors met to discuss, among other matters, the compensation that should be paid to each of the directors serving as members of the Special Committee in light of the prolonged strategic process that the committee had undertaken and the extensive work that the Committee had performed and was expected to continue to perform. The Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors determined that each member of the Special Committee would be entitled to $7,500 for each month of substantive service on the Special Committee that each such member had previously performed and would perform going forward.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;12, 2024, the Special Committee conducted a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the strategic alternatives ARCA had been considering. At this meeting representatives of Ladenburg delivered a presentation comparing the potential value to ARCA&#8217;s stockholders that would result from a traditional merger, a reverse merger, a partial tender offer, or a liquidation. The Special Committee also reviewed a presentation prepared by ARCA&#8217;s management comparing the tender offer proposal made by Mr.&#160;Ma<span class="nobreak">-Weaver</span> on December<span class="nobreak"> </span>7, 2023 to the liquidation analysis that it had prepared which showed a potential value of $2.04 per share to stockholders in a liquidation. For more information regarding the liquidation analysis including the key assumptions therein, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; ARCA Liquidation Analysis</span>,&#8221; beginning on page 108 of this proxy statement/prospectus. Following those presentations, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> left the meeting. The Special Committee then discussed the presentations and determined that pursuing a tender offer at the price per share offered by Mr.&#160;Ma<span class="nobreak">-Weaver</span> did not have a reasonable likelihood of resulting in a superior alternative when compared to the other strategic alternatives available to ARCA.&#160;In light of that determination, and the continuing delay of regulatory approvals for Party A, the Special Committee directed Ladenburg to renew its search for potential reverse merger partners and to focus its outreach on companies that did not require a material amount of cash to remain on ARCA&#8217;s balance sheet after the closing of a transaction. The Special Committee further instructed Mr.&#160;Conway to continue negotiating the terms and conditions of a potential tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span> in parallel with Ladenburg&#8217;s renewed search and ARCA&#8217;s continued discussions with Party A.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From January&#160;12, 2024, until February&#160;26, 2024, Ladenburg renewed its search for a potential counterparty in line with the Special Committee&#8217;s revised criteria and received non<span class="nobreak">-binding</span> proposals from eight potential counterparties interested in a reverse merger transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, Mr.&#160;Conway continued his discussions with Mr.&#160;Ma<span class="nobreak">-Weaver</span> regarding a potential tender offer and the Special Committee met multiple times to discuss the status of those discussions, and the other strategic alternatives the Special Committee was considering.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February<span class="nobreak"> </span>15, 2024, the Special Committee (without Mr.&#160;Ma<span class="nobreak">-Weaver</span> attending) conducted a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini attending. As a result of the negotiations that Mr.<span class="nobreak"> </span>Conway and Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> had been engaging in, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> increased his verbal offer to a price per share of $2.25 for 50.1% of the shares of ARCA&#8217;s capital stock. Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> then left the meeting. The Special Committee discussed Mr.&#160;Ma<span class="nobreak">-Weaver</span>&#8217;s offer of $2.25 per share and determined that while the price per share was higher than the most recent liquidation analysis presented at the January&#160;12, 2024, meeting, the offer was still not reasonably likely to result in a superior alternative when compared to the other strategic alternatives available to ARCA, including a reverse merger transaction which was expected to provide ARCA&#8217;s stockholders additional value for ARCA&#8217;s public listing. Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> then rejoined the meeting and the Special Committee informed him that his offer was not compelling in light of the other strategic alternatives available to ARCA, and that the stockholder affiliated with Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> needed to increase its proposal to a price per share of at least $2.50 per share for 100% of the shares of ARCA&#8217;s capital stock. The Special Committee directed Mr.&#160;Conway to continue negotiations with the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February<span class="nobreak"> </span>15, 2024, until February&#160;23, 2024, Mr.&#160;Conway and Mr.&#160;Ma<span class="nobreak">-Weaver</span> met multiple times to continue to discuss the potential tender offer. On February&#160;23, 2024, Mr.&#160;Ma<span class="nobreak">-Weaver</span> informed the Special Committee that the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span> was no longer interested in pursuing a tender offer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;26, 2024, the Special Committee conducted a video conference meeting with representatives of Ladenburg to review, discuss and evaluate the eight non<span class="nobreak">-binding</span> proposals it had received to date as a result of Ladenburg&#8217;s renewed outreach. The Special Committee determined that Oruka was a counterparty that merited serious consideration because (i)&#160;it required the least amount of ARCA&#8217;s cash and would therefore permit ARCA to distribute the largest amount of cash to its stockholders, (ii)&#160;the company was backed by a reputable investor </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">101</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">with a history of successful reverse merger transactions and (iii)&#160;the company already had informal commitments for a substantial private placement investment that was contemplated to close concurrently with the closing of the Merger. As a result, the Special Committee focused its efforts on pursing a transaction with Oruka while continuing to discuss a potential transaction with two of the other potential counterparties that had submitted non<span class="nobreak">-binding</span> proposals in case a transaction with Oruka did not come to fruition. The Special Committee determined that the remaining five non<span class="nobreak">-binding</span> proposals that had been submitted were not compelling in light of the quality of the counterparties&#8217; assets, the substantial cash needs of the potential counterparties, and the valuations sought by the potential counterparties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;28, 2024, the Special Committee conducted a video conference meeting with representatives of Ladenburg and Oruka in attendance to discuss Oruka&#8217;s fitness as a strategic transaction partner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, at the direction of the Special Committee, representatives of Ladenburg delivered a draft term sheet to representatives of Wedbush Securities Inc. (&#8220;Wedbush&#8221;), Oruka&#8217;s financial advisor, which proposed a reverse merger transaction ascribing a $10,000,000 enterprise valuation to ARCA and a $175,000,000 enterprise valuation of Oruka (which would be reduced to the extent the price per share in the proposed private placement financing ascribed a value to Oruka of less than $175,000,000) and setting forth certain other material terms including (1)&#160;the minimum investment amount to be received by Oruka as a result of a private placement transaction investment to close substantially concurrent with the business combination; (2)&#160;conditions to execution of any definitive agreement, (3)&#160;conditions to the closing of the business combination transaction; (4)&#160;the ability of ARCA to distribute any net cash in excess of $5,000,000 to the pre<span class="nobreak">-Merger</span> stockholders of ARCA; and (5)&#160;the exclusivity period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;28, 2024 and February&#160;29, 2024, the Special Committee conducted video conference meetings with representatives of Ladenburg and the other two counterparties that it was considering in attendance to discuss each counterparty&#8217;s value as a strategic transaction partner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;29, 2024, representatives of Wedbush delivered a revised term sheet to Ladenburg which ascribed a $6,000,000 enterprise valuation to ARCA and included proposed changes to a number of the other legal terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, Mr.&#160;Conway spoke with representatives of Oruka and proposed an ascribed enterprise value of $7,500,000. Representatives of Oruka informed Mr.&#160;Conway that it was not willing to pursue a transaction at an ascribed enterprise value over $6,000,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, the Special Committee held a video conference meeting with members of ARCA&#8217;s management and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the revised proposal received by Oruka. The Special Committee determined that the revised proposal represented a promising strategic alternative that was worth pursuing on an exclusive basis in light of: (i)&#160;the Special Committee&#8217;s view that ARCA was not likely to accomplish its corporate objectives on a stand<span class="nobreak">-alone</span> basis in light of its financial condition and product candidates; (ii)&#160;the Special Committee&#8217;s view that the $6,000,000 enterprise value ascribed to ARCA was within the range of values ascribed in other recent reverse merger transactions and would give ARCA&#8217;s stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving an immediate cash payment on account of the special cash dividend ARCA would be permitted to make; (iii)&#160;the fact that the $175,000,000 enterprise value ascribed to Oruka would be validated by independent third parties in the private placement investment and that any reduction in the valuation ascribed to Oruka by such investors would also reduce Oruka&#8217;s valuation for purposes of calculating the exchange ratio; (iv)&#160;the Special Committee&#8217;s view that as a result of the substantial private placement financing that Oruka was committing to obtain at the closing of the Merger the combined company was likely to possess sufficient cash resources to fund development of Oruka&#8217;s product candidates through upcoming value inflection points; (vi)&#160;the increased likelihood that the transaction could be consummated in a timely manner in light of the informal private placement commitments that Oruka had already obtained, and (vii)&#160;the Special Committee&#8217;s view that the proposal from Oruka was more favorable to ARCA than the potential value that might have resulted from further pursuing other strategic alternatives available to ARCA in light of the extensive outreach process undertaken to date. The Special Committee concluded the meeting by directing Ladenburg to continue negotiating the final legal terms of the term sheet and authorized ARCA&#8217;s management to execute and deliver the term sheet once the remaining legal terms had been finalized.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">102</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the morning of March&#160;1, 2024, representatives of Ladenburg delivered an updated draft term sheet to representatives of Wedbush finalizing the remaining legal terms in the term sheet and finalizing the $6,000,000 enterprise value that Mr.&#160;Conway and representatives of Oruka had agreed to. Later that afternoon, representatives of Wedbush returned a proposed final draft term sheet which finalized the remaining legal terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, at the direction of the Special Committee, ARCA&#8217;s management executed and delivered the term sheet to Oruka and began exclusively negotiating a transaction with Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;4, 2024, the Special Committee met with representatives of ARCA&#8217;s management team, representatives of Wilson Sonsini and Ladenburg, Oruka&#8217;s management team, and representatives of Wedbush and Gibson, Dunn&#160;&amp; Crutcher LLP (&#8220;Gibson&#8221;), Oruka&#8217;s legal advisor, via video conference to discuss the timeline and process for signing definitive agreements providing for a potential business combination and a concurrent private placement financing and discussed and tentatively agreed on a work plan for such definitive agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, ARCA provided Oruka and its advisors with access to an online data room for purposes of conducting further business, financial, legal, tax, intellectual property, insurance and other due diligence with respect to ARCA and its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;7, 2024, Oruka provided ARCA and its advisors with access to an online data room for purposes of conducting further business, financial, legal, tax, intellectual property, insurance and other due diligence with respect to Oruka and its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also on March&#160;7, 2024, Oruka met with representatives of Jefferies LLC and Cowen and Company, LLC (together, the &#8220;Placement Agents&#8221;), representatives of Cooley, counsel to the Placement Agents, and Gibson, via video conference, to discuss the timeline and process for completing the concurrent private placement financing. Later that&#160;day, representatives of Gibson and Cooley met, via video conference, and tentatively agreed on a work plan for the definitive agreements related to such concurrent private placement financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;11, 2024, Mr.&#160;Conway met with ARCA&#8217;s management team and representatives of Wilson Sonsini to discuss the proposed terms of a draft of the Merger Agreement prepared by representatives of Wilson Sonsini. Mr.&#160;Conway then authorized Wilson Sonsini to distribute the draft Merger Agreement to Gibson which was sent out later that same&#160;day.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also on March&#160;11, 2024, Oruka authorized representatives of Gibson to distribute the draft form of subscription agreement for the concurrent financing and other related documents to Cooley and Wilson Sonsini, on behalf of the Placement Agents and ARCA, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;15, 2024, the Special Committee met with representatives of Oruka and ARCA&#8217;s management team in attendance to discuss Oruka&#8217;s business and answer the Special Committee&#8217;s questions regarding the materials provided in the virtual data room.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between March&#160;15, 2024 and April&#160;2, 2024, representatives of ARCA&#8217;s management team conducted further business and financial due diligence with respect to Oruka, its business and the market for treatment of chronic skin diseases and, over the same period of time, ARCA&#8217;s legal and financial advisors conducted due diligence with respect to Oruka and its business based on information available in the data room and written responses from Oruka&#8217;s management team, and such advisors negotiated the terms and conditions of the Merger Agreement at the direction of and in coordination with the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, representatives of Wilson Sonsini and Gibson met on numerous occasions to discuss and negotiate the legal terms of the Merger Agreement, including the form of subscription agreement for the Oruka pre<span class="nobreak">-closing</span> financing attached as an exhibit thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, representatives of Oruka and its financial advisors held conversations with the representatives of the Placement Agents and prospective investors to discuss the contemplated private placement financing, addressed questions from potential investors and negotiated the terms and conditions of the definitive agreements for such a transaction, including the form of subscription agreement for the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">103</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;19, 2024, at the direction of the Special Committee, ARCA entered into a new engagement letter with Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) engaging Lucid as ARCA&#8217;s financial advisor in light of restructuring events that had occurred at Ladenburg which resulted in the financial advisors primarily responsible for this transaction moving from Ladenburg to Lucid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;20, 2024, at the direction of the Special Committee, ARCA terminated its engagement letter with Ladenburg.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;2, 2024, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Lucid in attendance. At the meeting, ARCA&#8217;s board of directors was provided with an overview of the proposed Merger (including the potential benefits and the risks related thereto), the key terms of the related ancillary documents, and its fiduciary duties. ARCA&#8217;s board of directors also reviewed the proposed resolutions which would be adopted by ARCA&#8217;s board of directors in order to approve the entry into the proposed Merger and related transactions, including among other things, the form of Certificate of Designation of Preferences, Rights and Limitations of Series B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock. Lucid then presented its oral opinion that, as of the date thereof, and subject to the assumptions more fully described below under the caption &#8220;The Merger&#160;&#8212;&#160;Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s board of directors,&#8221; beginning on page 112 in this proxy statement/prospectus, the Exchange Ratio is fair, from a financial point of view to the holders of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors&#8217; meeting was then adjourned and a meeting of the Special Committee was held via video conference with members of ARCA&#8217;s management team and representatives of Wilson Sonsini in attendance. The Special Committee then unanimously (i)&#160;determined that the transactions contemplated by the Merger Agreement including the Merger Agreement and related ancillary agreements contemplated thereunder, are fair to, advisable and in the best interests of ARCA and its stockholders and (ii)&#160;recommended that ARCA&#8217;s board of directors approve and adopt the Merger Agreement, the related ancillary agreements and the transactions contemplated by the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Special Committee meeting was then adjourned and a meeting of ARCA&#8217;s board of directors was held via video conference with members of ARCA&#8217;s management team and representatives of Wilson Sonsini in attendance. Based on the factors described below under the caption &#8220;The Merger&#160;&#8212;&#160;ARCA&#8217;s Reasons for the Merger,&#8221; ARCA&#8217;s board of directors then adopted and approved, among other resolutions, resolutions (a)&#160;determining that it is in the best interests of ARCA and its stockholders to adopt and approve the execution and delivery of the Merger Agreement and the ancillary documents thereto, (b)&#160;adopting and approving the Merger Agreement and ancillary documents thereto and approving ARCA&#8217;s execution, delivery and performance of the same and the consummation of the transactions contemplated by the Merger Agreement and the ancillary documents thereto, (c)&#160;recommending that the ARCA stockholders vote in favor of the Proposals with Dr.&#160;Bristow abstaining from voting on the passage of such resolutions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, the parties entered into the Merger Agreement and the related ancillary documents and the private placement investors executed and delivered the Subscription Agreement for the $275.0<span class="nobreak"> </span>million Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, ARCA and Oruka issued a joint press release announcing the execution and delivery of the Merger Agreement, and ARCA filed a Current Report on Form&#160;8<span class="nobreak">-K</span>, which filed as an exhibit (a)&#160;the Merger Agreement, (b)&#160;the form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, (c)&#160;the form of Oruka Support Agreement, (d)&#160;the form of Oruka Subscription Agreement, (e)&#160;form of ARCA Support Agreement, (f)&#160;the form of Lock<span class="nobreak">-up</span> Agreement, (g)&#160;a joint press release, dated April&#160;3, 2024 (h)&#160;an investor presentation providing information on Oruka, and (i)&#160;a transcript of a conference call held to announce the proposed transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Reasons for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the course of its evaluation of the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors and the members of its Special Committee held numerous meetings, consulted with ARCA&#8217;s senior management, ARCA&#8217;s legal counsel and financial advisors, and reviewed and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">104</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">assessed a significant amount of information. In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors took into account the input and recommendations of the Special Committee, as well as other information presented to it during the process, and considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The financial condition and prospects of ARCA and the risks associated with continuing to operate ARCA on a stand<span class="nobreak">-alone</span> basis in light of:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s decision, announced on May<span class="nobreak">&#160;</span>5, 2022, to initiate a process to explore strategic alternatives in light of and its subsequent decision announced in July of 2022 to reduce its workforce by 67%, which were each driven in large part by the results of ARCA&#8217;s Phase&#160;2 clinical trial of its primary product candidate Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201), which found that neither studied dose of rNAPc2 achieved statistical significance for the primary efficacy endpoint;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>investor interest and value perception for possible further development of its programs, the product candidates&#8217; efficacy and safety profiles, stage of development, regulatory agencies&#8217; feedback regarding development pathways, and probability of success in relation to the requisite time and costs; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>difficulties encountered in ARCA&#8217;s related business development efforts to license, sell or otherwise partner its assets that could result in meaningful new capital or shared future development costs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s product pipeline and development candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the recommendation of the Special Committee that ARCA&#8217;s board of directors approve the contemplated transactions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that, after a thorough review of strategic alternatives, including further advancing the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with ARCA&#8217;s senior management, financial advisors and legal counsel, the Merger is more favorable to ARCA stockholders than the potential value that might have resulted from other strategic alternatives available to ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that the $6.0&#160;million enterprise value ascribed to ARCA would provide the existing ARCA stockholders significant value for ARCA&#8217;s public listing and afford the ARCA stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief, after thorough discussions with ARCA&#8217;s management, financial advisors and legal counsel, that a potential liquidation and dissolution was not reasonably likely to create greater value for ARCA stockholders than the Merger based on, among other things, the need to hold back a potential meaningful amount of ARCA&#8217;s current cash balance to cover current and potential unknown future liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that, as a result of arm&#8217;s length negotiations with Oruka, terms of the Merger Agreement include the most favorable terms to ARCA in the aggregate that were achievable and consistent with other similar transactions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that Oruka&#8217;s product candidates have the potential to create meaningful value for the stockholders of the combined company and an opportunity for ARCA&#8217;s stockholders to participate in the growth of the combined company, based on the business, scientific, regulatory, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">105</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">intellectual property, financial, accounting and legal due diligence conducted by ARCA management and advisors (which included diligence calls and a comprehensive review of Oruka&#8217;s due diligence materials) regarding:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the regulatory pathway for, and market opportunity of, Oruka&#8217;s product candidates, including in light of the stage of development of Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the quality and scope of the preclinical and clinical results available for Oruka as opposed to other parties with which ARCA engaged in discussions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s plans to explore the potential of its product candidates to treat other diseases, including through collaborations; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood of value inflection milestones prior to the time in which the combined company would need to raise additional financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; consideration of the expected cash balances of the combined company as of the closing of the Merger resulting from the approximately $5.0&#160;million of net cash, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, expected to be held by ARCA upon completion of the Merger, together with the cash Oruka currently holds and the $275&#160;million of expected gross proceeds from the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view, following a review with ARCA&#8217;s management and advisors of Oruka&#8217;s current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the Merger to fund development of Oruka&#8217;s product candidates through upcoming value inflection points, including Oruka&#8217;s ongoing IND<span class="nobreak">-enabling</span> preclinical development work and its anticipated initiation of its Phase&#160;1 trials of ORKA<span class="nobreak">-001</span> in the first half of 2025 and Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected operations, management structure, operating plans and cash burn rate of the combined company and the expected cash resources of the combined company (including the ability to support the combined company&#8217;s current and planned clinical trials and operations);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of Oruka to take advantage of the potential benefits resulting from becoming a public reporting company listed on Nasdaq, should it be required to raise additional capital in the future through the sale of equity or debt securities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the prospects of and risks associated with the other strategic candidates that had made proposals for a strategic transaction with ARCA based on the business, scientific, regulatory, intellectual property, financial, accounting and legal due diligence conducted by the Special Committee, ARCA&#8217;s management and its advisors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that the combined company will be led by an experienced senior management team from Oruka, many members of which have extensive experience in drug development, research and development, business and regulatory expertise; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the financial analysis reviewed by Lucid with ARCA&#8217;s board of directors as well as the oral opinion of Lucid rendered to ARCA&#8217;s board of directors on April<span class="nobreak">&#160;</span>2, 2024 (which was subsequently confirmed in writing by delivery of Lucid&#8217;s written opinion dated April<span class="nobreak">&#160;</span>2, 2024 addressed to ARCA&#8217;s board of directors), as to, as of April<span class="nobreak">&#160;</span>2, 2024, the fairness, of the exchange ratio from a financial point of view, to ARCA&#8217;s stockholders, as more fully described below under the caption &#8220;Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s Board of Directors,&#8221; beginning on page 112 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors also reviewed the terms of the Merger Agreement and related transaction documents, including those described below, and concluded that the terms of the Merger Agreement and related transaction documents, in the aggregate, were reasonable under the circumstances:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the calculation of the exchange ratio, closing net cash and the estimated number of shares of ARCA common stock to be issued in the Merger;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">106</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to dividend all of its net cash (as determined in accordance with the terms of the Merger Agreement) in excess of $5.0&#160;million to the current ARCA stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number and nature of the conditions to Oruka&#8217;s and ARCA&#8217;s respective obligations to complete the Merger and the likelihood that the Merger will be completed on a timely basis, including the fact that Oruka&#8217;s obligation to complete the Merger would not be conditioned on ARCA having a specified level of closing net cash, as more fully described below under the caption &#8220;The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger,&#8221; beginning on page 146 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the respective rights of, and limitations on, ARCA and Oruka under the Merger Agreement to consider and engage in discussions regarding unsolicited acquisition proposals under certain circumstances, and the limitations on the board of directors of each party to change its recommendation in favor of the Merger, as more fully described below under the caption &#8220;The Merger Agreement&#160;&#8212;&#160;Non<span class="nobreak">-Solicitation</span>,&#8221; beginning on page 142 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential termination fee of $440,000, in the case of the fee payable by ARCA, or $440,000, in the case of the fee payable by Oruka, if the Merger Agreement is terminated in certain circumstances, as more fully described below under the caption &#8220;The Merger Agreement&#160;&#8212;&#160;Termination and Termination Fees,&#8221; beginning on page 147 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lock<span class="nobreak">-up</span> agreements, pursuant to which certain stockholders of Oruka and ARCA, respectively, have, subject to certain exceptions, agreed not to transfer their shares of ARCA common stock during the period of 180&#160;days following the completion of the Merger, as more fully described below under the caption &#8220;Agreements Related to the Merger&#160;&#8212;&#160;Lock<span class="nobreak">-Up</span> Agreements,&#8221; beginning on page 151 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the support agreements, pursuant to which certain stockholders of ARCA and Oruka, respectively, have agreed, solely in their capacities as stockholders, to vote all of their shares of ARCA common stock or Oruka common stock in favor of the proposals submitted to them in connection with the Merger and against any alternative acquisition proposals, as more fully described below under the caption &#8220;Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements,&#8221; beginning on page 151 in this proxy statement/prospectus; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expectation that the Merger will qualify as a reorganization within the meaning of Section&#160;368(a)&#160;of the Code, and will constitute a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Section&#160;1.368<span class="nobreak">-2</span>(g)&#160;and 1.368<span class="nobreak">-3</span>(a), with the result that Oruka stockholders will generally not recognize taxable gain or loss for U.S.&#160;federal income tax purposes upon the exchange of Oruka common stock for ARCA common stock pursuant to the Merger Agreement, as more fully described below under the caption &#8220;The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger,&#8221; beginning on page 125 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of its deliberations, and in addition to the consideration, input and recommendations of the Special Committee, ARCA&#8217;s board of directors also considered a variety of risks, uncertainties and other countervailing factors related to entering into the Merger, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the potential benefits of the Merger may not be fully achieved, or may not be achieved within the expected timeframe;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the future financial performance of Oruka may not meet ARCA&#8217;s board of directors&#8217; expectations due to factors both in and outside of Oruka&#8217;s control;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that, while ARCA&#8217;s management team performed an extensive due diligence review of Oruka, there may have been relevant Oruka information not considered by ARCA&#8217;s management team and accordingly, ARCA may not have properly valued Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential effect of the $440,000 termination fee payable by ARCA upon the occurrence of certain events in deterring other potential companies from proposing an alternative acquisition proposal that may be more advantageous to ARCA&#8217;s stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s obligation to not solicit alternative acquisition proposals during the pendency of the Merger;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">107</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the substantial expenses to be incurred by ARCA in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possible volatility of the trading price of the ARCA common stock resulting from the announcement, pendency or completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the scientific, technical, regulatory and other risks and uncertainties associated with development and commercialization of Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various risks impacting the financial condition, results of operations and prospects for ARCA, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and challenges associated with pursuing any strategic alternative to the Merger available to ARCA, including the discussions that ARCA&#8217;s management and ARCA&#8217;s board of directors of directors previously conducted with other potential transaction partners, and the time to negotiate and complete an alternative strategic transaction and anticipated cash burn;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and delays associated with, and uncertain value and costs to ARCA stockholders of, liquidating ARCA, including the uncertainties of continuing cash burn while contingent liabilities are resolved, uncertainty of timing of release of cash until contingent liabilities are resolved, and the risks and costs associated with being a shell company prior to cash distribution;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and challenges of attempting to continue to operate ARCA on a stand<span class="nobreak">-alone</span> basis, including, without limitation, (i)&#160;the considerable time and resources that would have been required to successfully address the uncertainties associated with its Gencaro product, (ii)&#160;the inability to finance ARCA&#8217;s continuing operations through the sale of securities in the capital markets due to, among other things, the lack of near term data catalysts and the general downturn in the U.S.&#160;capital markets for biotechnology companies and (iii)&#160;ARCA&#8217;s other product candidate profiles, stage of development, feedback from regulatory agencies regarding development pathway, and probability of success in relation to the requisite time and costs required as well as management&#8217;s related business development efforts to license, sell or otherwise partner the assets;.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the challenges of retaining or rebuilding staff with limited cash runway in light of the reductions in force that ARCA previously undertook; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the challenges of maintaining ARCA&#8217;s Nasdaq listing without completing the merger and the transactions contemplated in the Merger Agreement, including the reverse stock split; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the various other risks associated with the combined company and the Merger, including those described in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Cautionary Note Regarding Forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Statements</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing information and factors considered by the Special Committee and ARCA&#8217;s board of directors are not intended to be exhaustive but are believed to include all of the material factors considered by the Special Committee and ARCA&#8217;s board of directors. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, the Special Committee and ARCA&#8217;s board of directors did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of the Special Committee and ARCA&#8217;s board of directors may have given different weight to different factors. The Special Committee and ARCA&#8217;s board of directors conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, ARCA&#8217;s management team and the legal and financial advisors of ARCA, and considered the factors overall to be favorable to, and to support, its determination.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Liquidation Analysis</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the evaluation of the Merger by ARCA&#8217;s board of directors and the Special Committee, ARCA&#8217;s management prepared an analysis with respect to the estimated value of the liquidation or dissolution of ARCA as a potential alternative to the Merger, including for such purposes ARCA&#8217;s estimated cash position at the time of the potential dissolution or liquidation, ARCA&#8217;s estimated expenses in connection with any such liquidation or dissolution, and the amount of cash available to be distributed to ARCA&#8217;s stockholders in connection with any such proposed future dissolution or liquidation (the &#8220;Liquidation Analysis&#8221;). Although the Liquidation Analysis </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">108</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">assumes that the entirety of ARCA&#8217;s cash balance at the time of the dissolution or liquidation would be available for distribution to ARCA&#8217;s stockholders, it is unlikely that the entirety of such cash balance would be available at the time of an actual dissolution or liquidation due to the requirements of applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The inclusion of the Liquidation Analysis should not be deemed an admission or representation by ARCA or any of its officers, directors, affiliates, advisors, or other representatives with respect to the Liquidation Analysis. The Liquidation Analysis is not included to influence your views on the Merger, the Merger Agreement and the transactions contemplated thereby and is summarized in this proxy statement/prospectus solely to provide stockholders access to certain information considered by ARCA&#8217;s board of directors and the Special Committee in connection with its evaluation of the Merger, the Merger Agreement and the transactions contemplated thereby. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of ARCA do not purport to be appraisals or reflect the prices at which shares of ARCA common stock may actually be valued or trade, either before or after the consummation of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Liquidation Analysis was not prepared with a view toward public disclosure, nor was it prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information, or GAAP.&#160;Neither the independent registered public accounting firm of ARCA nor any other independent accountant has audited, reviewed, compiled, examined or performed any procedures with respect to the accompanying unaudited prospective financial information for the purpose of its inclusion herein, and accordingly, neither the independent registered public accounting firm of ARCA nor any other independent accountant expresses an opinion or provides any form of assurance with respect thereto for the purpose of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The prospective financial information included in this proxy statement/prospectus has been prepared by, and is the responsibility of, ARCA management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled nor applied agreed<span class="nobreak">-upon</span> procedures with respect to the accompanying prospective financial information and, accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The PricewaterhouseCoopers LLP report included in this proxy statement/prospectus relates to Oruka&#8217;s financial statement. It does not extend to the prospective financial information and should not be read to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Liquidation Analysis includes estimates of cash and of certain expenditures, which for the purpose of the Liquidation Analysis were not calculated in accordance with GAAP.&#160;Non<span class="nobreak">-GAAP</span>&#160;financial measures should not be viewed as a substitute for GAAP financial measures and may be different from&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures used by other companies. Furthermore, there are limitations inherent in&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Accordingly,&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures should be considered together with, and not as an alternative to, financial measures prepared in accordance with GAAP.&#160;The SEC rules, which otherwise would require a reconciliation of a&#160;non<span class="nobreak">-GAAP</span>&#160;financial measure to a GAAP financial measure, do not apply to&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures provided to a board of directors or financial advisors in connection with a proposed business combination transaction such as the Merger if the disclosure is included in a document such as this proxy statement/prospectus to comply with requirements under state laws, including case law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">In light of the foregoing factors and the uncertainties inherent in estimated cash balances, stockholders are cautioned not to place undue reliance, if any, on the Liquidation Analysis.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The below summary of the Liquidation Analysis is subject to the statements above, and it represents estimates prepared by ARCA&#8217;s management of the cash which could be distributed to stockholders as permitted under applicable law pursuant to a plan of dissolution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Key assumptions underlying the Liquidation Analysis included: (i)&#160;that the entire distribution of ARCA&#8217;s net cash would be made in June&#160;2024; (ii)&#160;that ARCA would have approximately $29.65&#160;million of net cash as June&#160;2024, after deducting costs and expenses, including legal fees, the fees payable to ARCA&#8217;s strategic financial advisor, accounting fees, employee retention bonuses, severance and benefits, insurance expenses, other transaction<span class="nobreak">-related</span> costs and other liabilities; (iii)&#160;that these costs and expenses were forecasted to total approximately $7.28&#160;million assuming the closing of a liquidation in June&#160;2024; and (iv)&#160;approximately 14.5&#160;million total shares of ARCA common stock outstanding as of December&#160;31, 2023. The analysis resulted in an estimated cash distribution per share in June&#160;2024 of $2.04 per share.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">109</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Reasons for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of reaching its decision to approve the Merger and the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, Oruka&#8217;s board of directors held numerous meetings, consulted with Oruka&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, Oruka&#8217;s board of directors concluded that a merger with ARCA, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, was the best option to generate capital resources to support the advancement of Oruka&#8217;s pipeline and fund the combined organization.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional factors Oruka&#8217;s&#160;board of directors considered included the following (which factors are not necessarily presented in any order of relative importance):</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Oruka&#8217;s pipeline, compared to the capital and investors Oruka could otherwise gain access to if it continued to operate as a privately<span class="nobreak">-held</span> company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Oruka pre<span class="nobreak">-closing</span> financing will generate capital resources to fund the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential benefits from increased public market awareness of Oruka and its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical and current information concerning Oruka&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the competitive nature of the industry in which Oruka operates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; fiduciary duties to Oruka stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, were reasonably likely to create greater value for Oruka stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Oruka board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, would be a higher probability and more cost<span class="nobreak">-effective</span> means to access capital than other options considered, including an IPO;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected operations, management structure and operating plans of the combined company (including the ability to support the combined company&#8217;s current and planned preclinical and clinical trials);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the business, history, operations, financial resources, assets, technology and credibility of ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the availability of appraisal rights under the DGCL to holders of Oruka capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Oruka capital stock as determined by the Delaware Court of Chancery;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the determination that the expected relative percentage ownership of ARCA stockholders and Oruka stockholders in the combined organization was appropriate, based on Oruka&#8217;s board of directors&#8217; judgment and assessment of the approximate valuations of ARCA (including the value of the net cash ARCA is expected to provide to the combined organization) and Oruka (including the value of the amount of proceeds from the Oruka pre<span class="nobreak">-closing</span> financing);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expectation that the Merger will be treated as a reorganization for U.S.&#160;federal income tax purposes, with the result that the Oruka stockholders will generally not recognize taxable gain or loss for U.S.&#160;federal income tax purposes with respect to the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the limited number and nature of the conditions of the obligation of ARCA to consummate the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the rights of Oruka under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should Oruka receive a superior offer;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">110</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the rights of Oruka under the Merger Agreement to effect a change in recommendation in favor of the Merger as a result of a material development or change in circumstances (i.e., applicable Intervening Events);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the conclusion of Oruka&#8217;s board of directors that the potential termination fees payable by ARCA or Oruka to the other party, and the circumstances when such fee may be payable, were reasonable; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the shares of ARCA&#8217;s common stock issued to Oruka stockholders, including shares of ARCA common stock issued in exchange for shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, will be registered on a Form&#160;S<span class="nobreak">-4</span> registration statement and will become freely tradable for Oruka stockholders who are not affiliates of Oruka and who are not parties to lock<span class="nobreak">-up</span> agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the support agreements, pursuant to which certain directors, officers and stockholders of Oruka and ARCA, respectively, have agreed, solely in their capacity as stockholders of Oruka and ARCA, respectively, to vote all of their shares of Oruka capital stock or ARCA common stock in favor of the adoption or approval, respectively, of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability to obtain a Nasdaq listing and the change of the combined organization&#8217;s name to Oruka Therapeutics, Inc. prior to or upon the closing of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood that the Merger will be consummated on a timely basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that the Merger might not be completed and the potential adverse effect of the public announcement of the Merger on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Merger is not completed; the possibility that the Oruka&#160;pre<span class="nobreak">-closing</span> financing might not be completed or completed in accordance with the terms of the Merger Agreement and the potential adverse effect of the public announcement of the Oruka&#160;pre<span class="nobreak">-closing</span> financing on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Oruka&#160;pre<span class="nobreak">-closing</span> financing is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the exchange ratio used to establish the number of shares of ARCA&#8217;s common stock to be issued to Oruka&#160;stockholders in the Merger is fixed, except for adjustments due to ARCA&#8217;s net cash balances, the amount of proceeds from the Oruka&#160;pre<span class="nobreak">-closing</span> financing and outstanding capital stock at closing, and thus the relative percentage ownership of ARCA stockholders and Oruka&#160;stockholders in the combined organization immediately following the completion of the Merger is similarly fixed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential reduction of ARCA&#8217;s net cash prior to the closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that ARCA could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Merger might not be consummated in a timely manner or at all, for a variety of reasons, such as the failure of ARCA to obtain the required stockholder vote or the failure of Oruka&#160;to close the Oruka&#160;pre<span class="nobreak">-closing</span> financing, and the potential adverse effect on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Merger is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs involved in connection with completing the Merger, the time and effort of Oruka&#160;senior management required to complete the Merger, the related disruptions or potential disruptions to Oruka&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Oruka, and related administrative challenges associated with combining the companies;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">111</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the additional expenses and obligations to which Oruka&#8217;s business will be subject to following the Merger that Oruka&#160;has not previously been subject to, and the operational changes to Oruka&#8217;s business, in each case that may result from being a public company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that the representations and warranties in the Merger Agreement do not survive the closing of the Merger and the potential risk of liabilities that may arise post<span class="nobreak">-closing</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that future sales of common stock by existing ARCA stockholders may cause the price of ARCA common stock to fall, thus reducing the potential value of ARCA common stock received by Oruka stockholders following the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing information is not intended to be exhaustive, but is believed to include a summary of all of the material factors considered by Oruka&#8217;s&#160;board of directors in its consideration of the Merger Agreement, the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, and the transactions contemplated thereby. After conducting an overall analysis of these and other factors, including thorough discussions with, and questioning of, Oruka&#8217;s senior management and legal counsel, Oruka&#8217;s&#160;board of directors concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. Based on this overall analysis of the factors described above, Oruka&#8217;s&#160;board of directors unanimously approved the Merger Agreement, the Merger, the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing and the other transactions contemplated by the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As stated above, pursuant to an engagement letter dated March&#160;19, 2024 (the &#8220;Engagement Letter&#8221;), ARCA retained Lucid to act as a financial advisor in connection with the Merger and to render Lucid&#8217;s opinion (the &#8220;Lucid Opinion&#8221;) to ARCA&#8217;s board of directors as to the fairness of the exchange ratio, from a financial point of view, to the stockholders of ARCA.&#160;On April&#160;2, 2024, at the request of ARCA&#8217;s board of directors, Lucid rendered the oral opinion, subsequently confirmed by delivery of the written opinion dated April&#160;2, 2024, to ARCA&#8217;s board of directors, that the exchange ratio was fair, from a financial point of view, to the stockholders of ARCA as of the date of the Lucid Opinion and based upon the various assumptions, qualifications and limitations set forth therein.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The full text of the Lucid Opinion is attached as Annex&#160;B to this proxy statement and is incorporated by reference. ARCA encourages its stockholders to read the Lucid Opinion in its entirety for the assumptions made, procedures followed, other matters considered and limits of the review by Lucid. The summary of the Lucid Opinion set forth herein is qualified by reference to the full text of the Lucid Opinion. Lucid provided the Lucid Opinion for the sole benefit and use by ARCA&#8217;s board of directors in its consideration of the Merger. The Lucid Opinion is not a recommendation to ARCA&#8217;s board of directors or to any stockholder as to how to vote with respect to the proposed Merger or to take any other action in connection with the Merger or otherwise.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Lucid Opinion, Lucid took into account an assessment of general economic, market and financial conditions as well as its experience in connection with similar transactions and securities valuations generally and, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed a draft of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain publicly available financial and other information for each of ARCA and Oruka, respectively, including equity research on comparable companies and on ARCA, and certain other relevant financial and operating data furnished to Lucid by the management of each of ARCA and Oruka, respectively;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain relevant historical financial and operating data concerning Oruka furnished to Lucid by the management of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Discussed with certain members of the management of ARCA the historical and current business operations, financial condition and prospects of ARCA and Oruka;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">112</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain operating results of Oruka as compared to operating results and the reported price and trading histories of certain publicly traded companies that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of completed IPOs for certain companies that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed certain pro forma financial effects of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next year, projections as to cost and expenses and whether concurrent capital raised would sufficiently cover select programs, reports, and other information  concerning Oruka prepared by Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as Lucid deemed relevant for the purposes of the Lucid Opinion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conducting Lucid&#8217;s review and arriving at the Lucid Opinion, Lucid has, with ARCA&#8217;s consent, assumed and relied, without independent verification or investigation, upon the accuracy and completeness of all financial and other information provided to or discussed with Lucid by ARCA and Oruka, respectively (for their respective employees, representatives or affiliates), or which is publicly available or was otherwise reviewed by Lucid. Lucid has not undertaken any responsibility for the accuracy, completeness or reasonableness of, or independent verification of, such information. Lucid has relied upon, without independent verifications, the assessment of ARCA management and Oruka management as to the viability of, and risks associated with, the current and future products and services of Oruka (including without limitation, the development, testing and marketing of such products and services, the receipt of all necessary governmental and other regulatory approvals for the development, testing and marketing thereof, and the life and enforceability of all relevant patents and other intellectual and other property rights associated with such products and services). In addition, Lucid has not conducted, nor has it assumed any obligation to conduct any physical inspection of the properties or facilities of ARCA or Oruka. Furthermore, Lucid has assumed, with ARCA&#8217;s consent, that there will be no further adjustments to the exchange ratio between the date hereof and the date the final exchange ratio is determined. Lucid has, with ARCA&#8217;s consent, relied upon the assumption that all information provided to Lucid by ARCA and Oruka is accurate and complete in all material respects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid expressly disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting the Lucid Opinion of which Lucid has become aware after the date of the Lucid Opinion. Lucid assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of ARCA or Oruka since the date of the last financial statements made available to Lucid. Lucid has not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of ARCA or Oruka, nor has Lucid been furnished with such materials. Further, as ARCA&#8217;s board of directors was aware, Oruka&#8217;s management did not provide Lucid with, and Lucid did not otherwise have access to, financial forecasts regarding Oruka&#8217;s businesses, other than certain cash burn projections, and, accordingly, Lucid did not perform either a discounted cash flow analysis or any multiples<span class="nobreak">-based</span> analyses with respect to Oruka. In addition, Lucid has not evaluated the solvency or fair value of ARCA or Oruka under any state or federal laws relating to bankruptcy, insolvency or similar matters. The Lucid Opinion does not address any legal, tax or accounting matters related to the merger, as to which Lucid has assumed that ARCA and ARCA&#8217;s board of directors have received such advice from legal, regulatory, tax and accounting advisors as each has determined appropriate. The Lucid Opinion addresses only the fairness of the exchange ratio, from a financial point of view, to the ARCA stockholders. Lucid expresses no view as to any other aspect or implication of the merger or any other agreement or arrangement entered into in connection with the merger. The Lucid Opinion is necessarily based upon economic and market conditions and other circumstances as they existed and could be evaluated by Lucid on the date of the Lucid Opinion. It should be understood that although subsequent developments may affect the Lucid Opinion, Lucid does not have any obligation to update, revise or reaffirm the Lucid Opinion and Lucid expressly disclaims any responsibility to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid did not consider any potential legislative or regulatory changes currently being considered or recently enacted by the United&#160;States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission, the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">113</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of rendering the Lucid Opinion, Lucid assumed in all respects material to Lucid&#8217;s analysis, that the representations and warranties of each party contained in the merger agreement were true and correct, that each party will perform all of the standards of the covenants and agreements required to be performed by it under the merger agreement and that all conditions to the consummation of the merger will be satisfied without waiver or amendment of any term or condition thereof. Lucid has assumed that the final form of the merger agreement will be substantially similar to the last draft reviewed by Lucid. Lucid has also assumed that all governmental, regulatory and other consents and approvals contemplated by the merger agreement or otherwise required for the transactions contemplated thereby will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed or waivers made that would have an adverse effect on ARCA, Oruka or the contemplated benefits of the Merger. Lucid has assumed that the merger will be consummated in a manner that complies with the applicable provisions of the Securities Act&#160;of&#160;1933, as amended, the Securities Exchange&#160;Act&#160;of&#160;1934, as amended, and all other applicable federal and state statutes, rules and regulations. ARCA has informed Lucid, and Lucid has assumed, that the merger is intended to constitute a reorganization within the meaning of Section&#160;368(a)&#160;of the Code and the Treasury Regulations promulgated thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is understood that the Lucid Opinion is intended for the benefit and use of ARCA&#8217;s board of directors in its consideration of the financial terms of the Merger and, except as set forth in Lucid&#8217;s Engagement Letter, may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without Lucid&#8217;s prior written consent, unless pursuant to applicable law or regulations or required by other regulatory authority by the order or ruling of a court or administrative body, except that the Lucid Opinion may be included in its entirety in any filing related to the merger to be filed with the Securities and Exchange Commission and the proxy statement to be mailed to the ARCA stockholders. The Lucid Opinion does not constitute a recommendation to ARCA&#8217;s board of directors of whether or not to approve the merger or to any ARCA stockholder or any other person as to how to vote with respect to the merger or to take any other action in connection with the merger or otherwise. The Lucid Opinion does not address ARCA&#8217;s underlying business decision to proceed with the merger or the relative merits of the merger compared to other alternatives available to ARCA.&#160;Lucid expressed no opinion as to the prices or ranges of prices at which shares or the securities of any person, including ARCA, will trade at any time, including following the announcement or consummation of the merger. Lucid has not been requested to opine as to, and the Lucid Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the merger, or any class of such persons, relative to the compensation to be paid to the ARCA stockholders in connection with the merger or with respect to the fairness of any such compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Lucid Opinion may not be published or otherwise used or referred to, nor shall any public reference to Lucid be made, without Lucid&#8217;s prior written consent.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Principal Financial Analyses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of the principal financial analyses performed by Lucid to arrive at the Lucid Opinion. Some of the summaries of financial analyses include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data set forth in the tables without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses. Lucid performed certain procedures, including each of the financial analyses described below and reviewed with ARCA&#8217;s board of directors the assumptions on which such analyses were based and other factors, including the historical and projected financial results of ARCA and Oruka.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transaction Overview as of the Date of the Lucid Opinion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based upon the exchange ratio of 7.4631 at the time of the signing of the merger agreement, it was estimated that at the closing: (a)&#160;Oruka equity holders as of immediately prior to the merger (including the shares issued in the approximately $275&#160;million Oruka pre<span class="nobreak">-closing</span> financing) will own approximately 97.61% of the fully<span class="nobreak">-diluted</span> shares of ARCA common stock at the closing of the merger, and (b)&#160;the ARCA equity holders as of immediately prior to the merger (excluding for this purpose the ARCA Out of the Money Options) will own approximately 2.39% of the fully<span class="nobreak">-diluted</span> shares of ARCA common stock at the closing of the merger, in each case, subject to adjustment of the exchange ratio as set forth in the merger agreement and described herein.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">114</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pre-Financing Oruka Equity Value</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the purpose of the Lucid Opinion, Lucid utilized a Oruka equity value of $175.0&#160;million, which was the pre<span class="nobreak">-money</span> valuation utilized in the Oruka pre<span class="nobreak">-closing</span> financing. The post<span class="nobreak">-money</span> Oruka valuation is calculated by adding the negotiated value of $175.0&#160;million plus $275.0&#160;million raised in the pre<span class="nobreak">-closing</span> financing totaling $450.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Selected Initial Public Offering Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed certain publicly available information for the IPOs of 19 dermatology/inflammation/autoimmune<span class="nobreak">-focused</span> biopharmaceutical companies that have completed an IPO since September&#160;2017 and whose lead product at the time of IPO was in a preclinical or Phase&#160;1 stage of clinical development. Although the companies referred to below were used for comparison purposes, none of these companies are directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. These companies, which are referred to as the &#8220;Selected Precedent IPO Companies,&#8221; were:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Apogee Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Applied Molecular Transport</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Avidity Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Azitra</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Biora Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Cabaletta Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>DICE Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Dyne Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Evelo Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Hoth Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kezar Life Sciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Krystal Biotech</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kymera Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kyverna Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Morphic Holding</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Prometheus Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Third Harmonic Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Ventyx Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Virpax Pharmaceuticals</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The total enterprise value at IPO is defined as the&#160;pre<span class="nobreak">-money</span>&#160;equity value plus indebtedness, liquidation value of preferred stock and&#160;non<span class="nobreak">-controlling</span>&#160;interest, minus cash and cash equivalents at the time of its IPO.&#160;The Selected Precedent IPO Companies had total enterprise values between $33.0&#160;million and $638.5&#160;million. Lucid derived a median total enterprise value of $315.2&#160;million for the Selected Precedent IPO Companies. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span>&#160;percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">115</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">total equity values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $177.4&#160;million to $504.2&#160;million. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent IPO Companies</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Filing Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Issuer</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Enterprise<br/>Value&#160;($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/7/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kyverna Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">511.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/13/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Apogee Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">384.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/15/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Azitra</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58.6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Third Harmonic Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">359.8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/20/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ventyx Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466.6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">DICE Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">343.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/11/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prometheus Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">442.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/16/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Virpax Pharmaceuticals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/17/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dyne Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">460.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/20/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kymera Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/19/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Biora Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">638.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/12/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Avidity Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">292.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/4/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Applied Molecular Transport</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">260.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/24/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cabaletta Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/26/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Morphic Holding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">154.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/15/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hoth Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/20/18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kezar Life Sciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">141.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/8/18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Evelo Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">315.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/19/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Krystal Biotech</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.3</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Selected Publicly Traded Companies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on its experience and professional judgment and using financial screening sources and databases to find companies that share similar business characteristics to Oruka within the biopharmaceutical industry, Lucid selected financial data of 13 publicly traded companies (referred to as the &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">Selected Publicly</span>&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Traded</span>&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Companies</span>&#8221;). Each of the Selected Publicly Traded Companies had a lead candidate in preclinical or Phase&#160;I stage of clinical development and focused on the dermatology/inflammation/autoimmune space. Although the companies referred to below were used for comparison purposes, none of those companies is directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. The total enterprise values are based on closing stock prices on April&#160;1, 2024. The Selected Publicly Traded Companies were:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Aditxt</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Apogee Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Astria Therapeutics, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Azitra</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Cabaletta Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Forte Biosciences, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kyverna Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Rani Therapeutics</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">116</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Spyre Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Surrozen, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Tharimmune</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Third Harmonic Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ZyVersa Therapeutics</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Selected Publicly Traded Companies had implied total enterprise values between negative $18.8&#160;million and $2.9&#160;billion. Lucid derived a median implied total enterprise value of $63.1&#160;million for the Selected Publicly Traded Companies. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $5.3&#160;million to $539.2&#160;million. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Publicly Traded Companies</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Company Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Enterprise <br/>Value&#160;($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Apogee Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,863.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Spyre Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">818.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cabaletta Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">575.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kyverna Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">536.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Astria Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">370.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Third Harmonic Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rani Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Azitra</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aditxt</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ZyVersa Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tharimmune</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forte Biosciences, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(11.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Surrozen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(18.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Analysis of Selected Precedent M&amp;A Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of the 9 most recent qualifying merger transactions of companies in the biopharmaceutical industry, which had a lead candidate in the preclinical or phase&#160;I stage of clinical development and focused on the dermatology/inflammation/autoimmune space (referred to as the &#8220;Selected Precedent&#160;M&amp;A Transactions&#8221;). Although the precedent transactions referred to below were used for comparison purposes, none of the target companies is directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical, but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the companies involved and other factors that could affect the merger value of such companies and Oruka to which they are being compared. Lucid reviewed the total enterprise values of the target companies (including future milestone payments). These transactions, including the date each was closed, were as follows below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Selected Precedent M&amp;A Transactions had total implied enterprise values between $20.0&#160;million and $2.0&#160;billion. Lucid derived a median total enterprise value of $250.0&#160;million for the Selected Precedent M&amp;A Transactions. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied total enterprise values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $65.0&#160;million to $1.0&#160;billion. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">117</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent M&amp;A Transactions</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Announced Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Target</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Acquirer</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Implied&#160;Enterprise</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value ($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/13/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">IMF Tre</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Novartis AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">90.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/15/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aiolos Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">GSK</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,000.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/18/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Calypso Biotech</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Novartis AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/9/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">DICE Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Eli Lilly</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,028.7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/1/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ORIGIMM Biotechnology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Sanofi</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">62.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/1/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pandion Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Merck</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,850.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/20/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rodeo Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amgen</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/8/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Confluence Life Sciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aclaris Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/26/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Delinia, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Celegene Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">300.0</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The summary set forth above does not purport to be a complete description of all the analyses performed by Lucid. The preparation of a fairness opinion involves various determinations as to the most appropriate and relevant methods of financial analysis and the application of these methods to the particular circumstances. Therefore, such an opinion is not readily susceptible to partial analysis or summary description. Lucid did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Accordingly, notwithstanding the separate factors summarized above, Lucid believes, and advised ARCA&#8217;s board of directors, that its analyses must be considered as a whole. Selecting portions of its analyses and the factors considered by it without considering all analyses and factors could create an incomplete view of the process underlying the Lucid Opinion. In performing its analyses, Lucid made numerous assumptions with respect to industry performance, business and economic conditions and other matters, many of which are beyond the control of ARCA and Oruka. These analyses performed by Lucid are not necessarily indicative of actual values or future results, which may be significantly more or less favorable than suggested by such analyses. In addition, analyses relating to the value of businesses do not purport to be appraisals or to reflect the prices at which businesses or securities may actually be sold. Accordingly, such analyses and estimates are inherently subject to uncertainty, being based upon numerous factors or events beyond the control of the parties or their respective advisors. None of ARCA, Oruka, Lucid or any other person assumes responsibility if future results are materially different from those projected. The analyses supplied by Lucid and the Lucid Opinion were among several factors taken into consideration by ARCA&#8217;s board of directors in making its decision to enter into the merger agreement and should not be considered as determinative of such a decision.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid was selected by ARCA&#8217;s board of directors to render an opinion to ARCA&#8217;s board of directors because Lucid is a nationally recognized investment banking firm and because, as part of its investment banking business, Lucid is continually engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. In addition, in the ordinary course of its business, Lucid and its affiliates may trade the equity securities of ARCA for its own account and for the accounts of their customers, and, accordingly, may at any time hold a long or short position in such securities. In the two&#160;years preceding the date hereof, Lucid has not received any fees from ARCA.&#160;In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Oruka and has not received any fees from Oruka. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to ARCA and Oruka and/or certain of their respective affiliates and expect to receive fees for the rendering of these services.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Engagement Letter between Lucid and ARCA as of the time the merger agreement was approved, if the merger is consummated, Lucid will be entitled to receive a transaction fee of $800,000 payable in cash at the closing of the transaction. ARCA has also paid Lucid a fee for the Lucid Opinion of $250,000 (in addition to the $800,000 transaction fee payable upon closing of the transaction) upon delivery of the Lucid Opinion. Additionally, ARCA has agreed to reimburse Lucid for its&#160;out<span class="nobreak">-of-pocket</span>&#160;expenses and has agreed to indemnify Lucid against certain liabilities, including liabilities under the federal securities laws. The terms of the fee arrangement with Lucid, which are customary in transactions of this nature, were negotiated at arm&#8217;s length between ARCA and Lucid, and ARCA&#8217;s board of directors was aware of the arrangement, including the fact that a portion of the fee payable to Lucid is contingent upon the completion of the merger.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">118</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of ARCA&#8217;s Directors and Executive Officers in the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In considering the recommendation of ARCA&#8217;s board of directors with respect to issuing shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in the Merger and the other matters to be acted upon by the ARCA stockholders at the ARCA special meeting, the ARCA stockholders should be aware that ARCA&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of ARCA stockholders generally. These interests may present ARCA&#8217;s directors and executive officers with actual or potential conflicts of interest.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the ARCA stockholders approve the proposals to be presented to the ARCA stockholders for consideration at the ARCA special meeting as contemplated by this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treatment of ARCA Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration. The following table sets forth, for each ARCA executive officer and each member of ARCA&#8217;s board of directors the aggregate number of ARCA stock options that were unvested and vested as of May&#160;3, 2024 and the weighted<span class="nobreak">-average</span> exercise price.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Unvested<br/>ARCA<br/>Options<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted-Average<br/>Exercise&#160;Price&#160;of<br/>Unvested&#160;ARCA<br/>Options<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Vested&#160;ARCA<br/>Options<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted-Average<br/>Exercise&#160;Price&#160;of<br/>Vested&#160;ARCA<br/>Options<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,443</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">87,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.95</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,828</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53,872</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.86</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Directors</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.06</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.06</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,499</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.82</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,166</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.96</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,834</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,166</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.05</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,834</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.17</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Retention Bonus Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Each of ARCA&#8217;s current executive officers is party to a retention bonus letter, as amended from time to time, pursuant to which the ARCA executive officer will receive a retention bonus of $165,000, subject to his continued employment with ARCA in good standing through the earlier of a corporate transaction of ARCA or certain clinical development decisions. The Merger will constitute a corporate transaction of ARCA for purposes of the retention bonus letters.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Each of ARCA&#8217;s current executive officers is party to an employment agreement that provides certain payments and benefits upon a termination of employment without cause by ARCA or a resignation by the officer for good reason (each as defined below) on the same&#160;day as a corporation transaction of ARCA or within 13&#160;months after a corporation transaction of ARCA.&#160;The Merger will constitute a corporate transaction of ARCA for purposes of the employment agreements. These payments and benefits include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Severance pay equal to (i)&#160;12&#160;months of the ARCA executive officer&#8217;s base salary, payable in installments over 12&#160;months, plus (ii)&#160;a pro rata portion of any bonus compensation approved for the fiscal year in which the termination occurs, payable when bonuses for such year are otherwise paid;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reimbursement of out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for up to 12&#160;months.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">119</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the employment agreements provides that ARCA may, in its sole discretion, pay additional severance pay of up to 12&#160;months of base salary to extend the term of the restrictive covenants applicable to the ARCA executive officer. The severance payments and benefits are subject to the ARCA executive officer&#8217;s release of claims in a form acceptable to ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The employment agreements do not contain tax gross<span class="nobreak">-up</span> provisions with respect to excise taxes under Section&#160;4999 of the Code. Instead, the severance payments and benefits are subject to a &#8220;best<span class="nobreak">-of-net</span>&#8221; provision in the event of excess parachute payments under Section&#160;280G of the Code. In the event excise taxes under Section&#160;4999 of the Code would be imposed on payments made under the employment agreements, the ARCA executive officer will either pay the excise tax or have his payments and benefits reduced to an amount at which an excise tax no longer applies, based on which result is more favorable to the ARCA executive officer on an after<span class="nobreak">-tax</span> basis</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">For purposes of the employment agreements:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Cause&#8221; generally means that the ARCA executive officer has committed or engaged in: (i)&#160;willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; (ii)&#160;refusal, unwillingness, failure, or inability to perform material job duties or habitual absenteeism; or (iii)&#160;violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of the employment agreement, intellectual property agreement or any other contract with ARCA</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Good Reason&#8221; generally means, with the ARCA executive officer&#8217;s consent: (i)&#160;geographic relocation by more than 30 miles; (ii)&#160;a decrease in base salary by more than 15%, other than a decrease resulting from a general reduction in the base salary of all ARCA executive officers; or (iii)&#160;significant detrimental reductions in the ARCA executive officer&#8217;s job responsibilities, in each case, subject to standard notice and cure provisions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As discussed under &#8220;ARCA Director Compensation&#8221; below, Chairman of ARCA&#8217;s board of directors, Robert&#160;E. Conway, and other members of ARCA&#8217;s board of directors, including Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span> (served from June 2022 to April 2024), served on the Special Committee beginning in 2022, pursuant to which they each received enhanced retainers totaling: $105,000 for each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and $90,000 for Jacob Ma<span class="nobreak">-Weaver</span>. In April 2024, James Flynn replaced Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> on the Special Committee. Each member of the Special Committee will continue to be paid $7,500 per month for each month of substantive service on the Special Committee.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Dividend</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash will exceed $5.0<span class="nobreak"> </span>million, and any of ARCA&#8217;s directors and executive officers that are also ARCA stockholders will share in any such cash dividend proportionally to their pre<span class="nobreak">-First</span> Merger ownership of ARCA common stock (see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>&#8221; beginning on page 309 of this proxy statement/prospectus for additional information regarding ARCA&#8217;s directors&#8217; and officers&#8217; holdings of ARCA common stock; notably, Jacob Ma<span class="nobreak">-Weaver</span> and affiliated entities together hold 4,000,452<span class="nobreak"> </span>shares of ARCA common stock, representing over 27% of outstanding shares of ARCA common stock).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Under the Merger Agreement, ARCA&#8217;s directors and executive officers are entitled to continued indemnification, expense advancement and insurance coverage. For a discussion of the indemnification and insurance provisions related to the ARCA directors and officers under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement &#8212; Indemnification and Insurance for Directors and Officers</span>&#8221; beginning on page 145 of this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In accordance with Item&#160;402(t)&#160;of Regulation&#160;S<span class="nobreak">-K</span>, the table below sets forth the compensation that is based on or otherwise relates to the Offer and the Merger that may be paid or become payable to each of ARCA named executive officer in connection with the Merger. Please see the previous portions of this section for further information regarding this compensation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">120</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The amounts indicated in the table below are estimates of the amounts that would be payable assuming, solely for purposes of this table, that (i)&#160;the Merger was consummated on May&#160;1, 2024, (ii)&#160;each ARCA named executive officer&#8217;s employment was terminated by ARCA without cause immediately following consummation of the Merger, (ii)&#160;the value per share of ARCA common stock on consummation of the Merger is $3.09 (which, in accordance with SEC requirements, is equal to the average closing price of a share of ARCA common stock over the first five&#160;business days following the first public announcement of the Merger on April&#160;3, 2024), and (iii)&#160;the Parent Closing Price is $3.09. The ARCA named executive officer will not receive pension, tax reimbursement or other benefits in connection with the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some of the amounts set forth in the table would be payable solely by virtue of the consummation of the Merger. In addition to the assumptions regarding the consummation date of the Merger and the termination of employment, these estimates are based on certain other assumptions that are described in the footnotes accompanying the table below. Accordingly, the ultimate values to be received by an ARCA named executive officer in connection with the Merger may differ from the amounts set forth below.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Equity&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Perquisites/<br/>Benefits&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total&#160;($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">370,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">380,555</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">505,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,889</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,746</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">549,635</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">435,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,310</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,579</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473,889</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The cash amounts represent: (i)&#160;with respect to Mr.&#160;Bristow, the cash severance payments that are payable to him in connection with his prior termination of employment pursuant to his Separation Agreement and Release with ARCA dated April&#160;3, 2024, as described under &#8220;ARCA Executive Compensation&#160;&#8212;&#160;Narrative Disclosure to Summary Compensation Table&#160;&#8212;&#160;Employment Agreements or Arrangements&#8221; below, which are being included herein out of an abundance of caution but which will be payable notwithstanding the consummation of the Merger, and (ii)&#160;with respect to Mr.&#160;Keuer and Mr.&#160;Dekker, (A)&#160;a $165,000 retention bonus payable in connection with the closing of the Merger, which constitutes a single<span class="nobreak">-trigger</span> benefit, and (B)&#160;aggregate cash severance payments of $340,000 with respect to Mr.&#160;Keuer and $270,000 with respect to Mr.&#160;Dekker that may be payable in connection with the Merger pursuant to their respective employment agreements upon a termination by ARCA without Cause or by the ARCA named executive officer for Good Reason on or within 13&#160;months following a Corporate Transaction (as such terms are defined in the applicable employment agreement) subject to their timely execution and non<span class="nobreak">-revocation</span> of a release in favor of ARCA, which constitutes a double<span class="nobreak">-trigger</span> benefit. For more information, please see the section above captioned &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Employment Agreements</span>.&#8221;</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents ARCA stock options (which ARCA refers to as the &#8220;Executive Equity Awards&#8221;) that will accelerate and vest in the Merger, assuming, solely for purposes of this table, continued employment or service of each ARCA named executive officer through the Closing Date. Pursuant to the Merger Agreement, each Executive Equity Award will fully accelerate on the Closing Date and thus constitute a single<span class="nobreak">-trigger</span> benefit. No value is reflected herein for any Executive Equity Award with an exercise price in excess of $3.09, as Executive Equity Awards with values in excess of the Parent Closing Price will be cancelled for no consideration. The values for each Executive Equity Award with an exercise price in excess of $3.09 in the table below represent the product of (i)&#160;the difference between $3.09 and the applicable exercise price of the Executive Equity Award, multiplied by (ii)&#160;the number of shares of ARCA common stock subject to the Executive Equity Award, as applicable, that accelerate and vest in connection with the Merger:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number&#160;of ARCA<br/>Shares&#160;Subject&#160;to<br/>Executive&#160;Equity<br/>Award (#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Per&#160;Share&#160;Value<br/>of&#160;Executive<br/>Equity&#160;Award ($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total ($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,194</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,555</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,861</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,889</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,458</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,966</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C. Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,458</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.03</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344</p>
					</td>
				</tr>

		</table>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the estimated value of the premiums ARCA would be required to reimburse to Messrs. Keuer and Dekker for continued health coverage under COBRA for a period of 12&#160;months that may be payable in connection with the Merger pursuant to their respective employment agreements upon a termination by ARCA without Cause or by the ARCA named executive officer for Good Reason on or within 13&#160;months following a Corporate Transaction (as such terms are defined in the applicable employment agreement) subject to their timely execution and non<span class="nobreak">-revocation</span> of a release in favor of ARCA, which constitutes a double<span class="nobreak">-trigger</span> benefit. For more information, please see the section above captioned &#8220;&#8212;&#160;Employment Agreements.&#8221;</p>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer, terminated employment with ARCA on April&#160;3, 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">121</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of Oruka&#8217;s Directors and Executive Officers in the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of Oruka&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that Oruka&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Oruka stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Oruka stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Ownership Interests</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;13, 2024, Oruka&#8217;s current non<span class="nobreak">-employee</span> directors and executive officers beneficially owned, in the aggregate approximately 73.5% of the shares of Oruka capital stock, which for purposes of this subsection excludes any Oruka shares issuable upon exercise or settlement of Oruka options held by such individual. Each of Oruka&#8217;s officers, directors and affiliated stockholders have also entered into a support agreement in connection with the Merger. For a more detailed discussion of the support agreements, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 151 of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As noted above, Fairmount Fund&#160;II, an affiliate of Peter Harwin, an Oruka director, Lawrence Klein, Oruka&#8217;s President and Chief Executive Officer, and Turtle Family Trust, of which Cameron Turtle, an Oruka director, is a trustee, also currently hold shares of Oruka capital stock. The table below sets forth the ownership of Oruka capital stock by Fairmount Fund&#160;II, Lawrence Klein and Turtle Family Trust as of May&#160;13, 2024. Fairmount Fund II also holds the Convertible Note and has agreed to purchase shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing. For a more detailed discussion of these relationships, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions of the Combined Company&#160;&#8212;&#160;Oruka Transactions&#160;&#8212;&#160;Private Placement of Securities</span>&#8221; beginning on page 279 of this proxy statement/prospectus.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Stockholder</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares of <br/>Capital Stock <br/>hel</span>d</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fairmount Healthcare Fund&#160;II L.P.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Turtle Family Trust</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149,164</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000<span class="nobreak"> </span>shares of Oruka Series&#160;A Preferred Stock held by Fairmount Fund&#160;II.&#160;Fairmount Healthcare Fund&#160;II GP LLC (&#8220;Fairmount GP&#160;II&#8221;) is the general partner of Fairmount Fund&#160;II.&#160;Fairmount Funds Management LLC (&#8220;Fairmount Funds Management&#8221;), as the investment manager, along with Fairmount GP&#160;II, as the general partner, exercise voting and investment power over Fairmount Fund&#160;II.&#160;Fairmount Funds Management has voting and dispositive power over the common stock held by Fairmount Fund&#160;II, which is deemed shared with Fairmount GP&#160;II.&#160;As managing members of Fairmount Funds Management and Fairmount GP&#160;II, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any securities beneficially owned by Fairmount Funds Management. Fairmount Funds Management, Fairmount GP&#160;II, Mr.&#160;Harwin and Mr.&#160;Kiselak disclaim beneficial ownership of such shares of Oruka Series&#160;A Preferred Stock and the underlying shares of Oruka common stock except to the extent of their pecuniary interest therein. The principal business address for these persons and entities is 200&#160;Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania 19428.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by Lawrence Klein. Such shares were purchased by Mr.<span class="nobreak"> </span>Klein, in anticipation of his service as Oruka&#8217;s Chief Executive Officer, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on February 26, 2025 and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 149,164<span class="nobreak"> </span>shares of Oruka common stock held by Turtle Family Trust, of which Cameron Turtle is a trustee. Such shares were purchased by Dr. Turtle, in anticipation of his service on the Oruka board of directors, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on March 1, 2025 and in equal monthly installments for the 36 months thereafter.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">122</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Klein Anti-Dilution Provision</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the amended and restated offer letter agreement between Oruka and Lawrence Klein, Oruka is obligated to issue additional options to purchase shares of Oruka common stock in order to maintain Mr.&#160;Klein&#8217;s ownership in Oruka at the Target Ownership Percentage until Oruka has raised an aggregate of the Covered Limit. As a result, Oruka expects to issue Mr.&#160;Klein additional options of Oruka to maintain his ownership in Oruka at the Target Ownership Percentage concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing up to the Covered Limit.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the effective time of the First Merger under Oruka&#8217;s 2024 Equity Incentive Plan and that, following assumption by ARCA at the effective time of the First Merger, will be eligible to be registered on Form&#160;S<span class="nobreak">-8</span>, whether or not vested, will be converted into an option to purchase shares of ARCA common stock. ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan and each such outstanding option to purchase shares of Oruka common stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of Oruka&#8217;s 2024 Equity Incentive Plan and the terms of the stock option agreement by which such option to purchase shares of Oruka common stock is evidenced. The table below sets forth information regarding the Oruka stock options held as of May&#160;13, 2024 by each of Oruka&#8217;s current executive officers and non<span class="nobreak">-employee</span> directors. The number of shares of common stock underlying such options and the exercise price will be adjusted appropriately to reflect the exchange ratio.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Vested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options&#160;Held<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Weighted</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Average</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Exercise&#160;Price</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">of Vested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Unvested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options&#160;Held<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Weighted</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Average</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Exercise&#160;Price</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">of Unvested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">225,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Non-Employee Directors</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">350,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Management Following the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in the section captioned &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>&#8221; beginning on page 271 of this proxy statement/prospectus certain of Oruka&#8217;s directors and executive officers are expected to become the directors and executive officers of the combined company upon the closing of the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For a discussion of the indemnification and insurance provisions related to the Oruka directors and officers under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Indemnification and Insurance for Directors and Officers</span>&#8221; beginning on page 145 of this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">123</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Form of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with the DGCL, (i)&#160;at the First Effective Time, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and (ii)&#160;as part of the same overall transaction at the completion of the Second Merger (the &#8220;Second Effective Time&#8221;), Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Consideration and Adjustment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing and excluding shares to be canceled pursuant to the Merger Agreement and dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 134 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment based on the exchange ratio as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment based on the exchange ratio as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No fractional shares of ARCA common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of ARCA common stock resulting from the conversion of shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) shall be issued as follows: (i)&#160;one share of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is equal to or exceeds 0.50 or (ii)&#160;no shares of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of ARCA Series&#160;B Preferred Stock that a holder of Oruka preferred stock would otherwise be entitled to receive will be aggregated with all fractional shares of ARCA preferred stock issuable to such holder and rounded up to the nearest whole share of ARCA&#8217;s convertible preferred stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedures for Exchanging Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On or prior to the closing date, ARCA and Oruka will select an exchange agent and, at the First Effective Time (as defined herein), ARCA will deposit with the exchange agent evidence of book<span class="nobreak">-entry</span> shares representing the shares of ARCA common stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) and the shares of ARCA Series&#160;B Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka preferred stock calculated in accordance with the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after the First Effective Time, the exchange agent will mail to each record holder of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) and each record holder of Oruka preferred stock who will receive ARCA Series&#160;B Preferred Stock issuable in exchange for such Oruka preferred stock pursuant to the terms, and calculated in accordance with, the Merger Agreement (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the exchange agent of such other documents as may be reasonably </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">124</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">required by the exchange agent or ARCA, the record holder of such stock certificates or book<span class="nobreak">-entry</span> shares, as applicable, will be entitled to receive in exchange therefor book<span class="nobreak">-entry</span> shares representing the number of whole shares of ARCA common stock or ARCA Series&#160;B Preferred Stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Oruka common stock or Oruka preferred stock will be canceled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the First Effective Time, each certificate representing Oruka common stock or Oruka preferred stock that has not been surrendered will represent only the right to receive shares of ARCA common stock or ARCA Series&#160;B Preferred Stock, as applicable, issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">HOLDERS OF ORUKA COMMON STOCK OR ORUKA PREFERRED STOCK SHOULD NOT SEND IN THEIR ORUKA STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF ORUKA STOCK CERTIFICATES.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">First Effective Time and Second Effective Time</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two&#160;business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Oruka stockholders and the approval by the ARCA stockholders of the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The First Merger will become effective upon the filing of a certificate of merger (the &#8220;First Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the First Certificate of Merger. The Second Merger will become effective upon the filing of a certificate of merger (the &#8220;Second Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the Second Certificate of Merger. Neither ARCA nor Oruka can predict the exact timing of the consummation of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, ARCA must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka&#8217;s stockholders in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC.&#160;ARCA and Oruka do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following discussion is a summary of U.S.&#160;federal income tax consequences of the Merger generally applicable to a U.S.&#160;holder (as defined below) of Oruka common stock or Oruka preferred stock (&#8220;Oruka stock&#8221;). This discussion applies only to a U.S.&#160;holder that holds its Oruka stock as a capital asset for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or U.S.&#160;holders with special status, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">125</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pass<span class="nobreak">-through</span> entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold their Oruka stock that constitutes &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their Oruka stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who exercise dissenters&#8217; rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of Oruka stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their Oruka stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof and all of which are subject to change, which change could apply retroactively and could affect the tax consequences described herein. This discussion does not address (i)&#160;the tax consequences of the Merger under U.S.&#160;federal non<span class="nobreak">-income</span> tax law (including estate, gift, or other non<span class="nobreak">-income</span> taxes), (ii)&#160;the tax consequences of the Merger under state, local or non<span class="nobreak">-U</span>.S.&#160;tax laws, (iii)&#160;the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations) or the Medicare contribution tax on net investment income, (iv)&#160;the tax consequences of transactions effectuated before, subsequent to or concurrently with the Merger (whether or not any such transactions are consummated in connection with the Merger), including any transaction in which shares of Oruka stock are acquired, or (v)&#160;the tax consequences to holders of Oruka stock options, Oruka warrants or similar rights to acquire Oruka stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has not and does not intend to seek any rulings from the Internal Revenue Service (the &#8220;IRS&#8221;) regarding the Merger. There can be no assurance that the IRS will not take positions inconsistent with the consequences discussed below or that any such positions would not be sustained by a court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds Oruka stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Each partnership holding any Oruka stock and each person that is treated as a partner of such partnership should consult its tax advisor as to the particular U.S.&#160;federal income tax consequences of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of Oruka stock that is, for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual citizen or resident of the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is classified as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof, or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">126</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effects of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka intend that the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Assuming the Merger so qualifies, a U.S.&#160;holder of Oruka stock generally will not recognize any gain or loss for U.S.&#160;federal income tax purposes upon receipt of ARCA common stock or ARCA Series&#160;B Preferred Stock (&#8220;ARCA stock&#8221;) in the Merger, as applicable. Each U.S.&#160;holder&#8217;s aggregate tax basis in the ARCA stock received in the Merger will equal such U.S.&#160;holder&#8217;s aggregate adjusted tax basis in the Oruka stock surrendered in the Merger. The holding period of the ARCA stock received by a U.S.&#160;holder in the Merger will include such U.S.&#160;holder&#8217;s holding period for the Oruka stock surrendered in the Merger. If a U.S.&#160;holder holds different blocks of Oruka stock (generally, Oruka stock acquired on different dates or at different prices), such U.S.&#160;holder is urged to consult his, her or its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of ARCA stock received in the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each U.S.&#160;holder who receives ARCA stock in the Merger is required to retain permanent records pertaining to the Merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S.&#160;holder who owned immediately before the Merger at least one percent (by vote or value) of the total outstanding stock of Oruka is required to attach a statement to its tax return for the year in which the Merger is consummated that contains the information listed in Treasury Regulation&#160;Section&#160;1.368<span class="nobreak">-3</span>(b). Such statement must include the U.S.&#160;holder&#8217;s tax basis in such U.S.&#160;holder&#8217;s Oruka stock surrendered in the Merger, the fair market value of such Oruka stock, the date of the Merger and the name and employer identification number of each of Oruka and ARCA.&#160;Each U.S.&#160;holder is urged to consult with its tax advisor to comply with these rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">This discussion of U.S.&#160;federal income tax considerations of the Merger is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the Merger to you may be complex and will depend on your specific situation and on factors that are not within ARCA&#8217;s knowledge or control. You should consult your tax advisor with respect to the application of U.S.&#160;federal income tax laws to your specific situation as well as any tax consequences arising under the U.S.&#160;federal estate or gift tax rules or under the laws of any state, local, non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-U</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">.S.&#160;or other taxing jurisdiction.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Special Cash Dividend to Holders of ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following discussion is a summary of the material U.S.&#160;federal income tax considerations generally applicable to U.S.&#160;holder (as defined below) of ARCA common stock who receive the special cash dividend. This section applies only to U.S.&#160;holders that hold their ARCA common stock as capital assets for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or status including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations; qualified foreign pension funds (or entities wholly owned by one or more qualified foreign pension funds);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold shares of ARCA common stock that constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">127</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their ARCA common stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock in a transaction subject to the gain rollover provisions under Section&#160;1045 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion right under convertible instruments; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein. This discussion does not address U.S.&#160;federal taxes other than those pertaining to U.S.&#160;federal income taxation (such as estate or gift taxes, the alternative minimum tax or the Medicare tax on investment income), nor does it address any aspects of U.S.&#160;state or local or non<span class="nobreak">-U</span>.S.&#160;taxation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has not and does not intend to seek any rulings from the IRS regarding the special cash dividend. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds ARCA common stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Partnerships holding any ARCA common stock and persons that are treated as partners of such partnerships should consult their tax advisors as to the particular U.S.&#160;federal income tax consequences of the special cash dividend to them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of ARCA common stock that is, for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual who is a citizen or resident of the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is treated as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons (within the meaning of Section&#160;7701(a)(30)&#160;of the Code) have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person (within the meaning of Section&#160;7701(a)(30)&#160;of the Code).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion assumes that the distribution of the special cash dividend to holders of ARCA common stock will be treated for U.S.&#160;federal income tax purposes as a transaction that is separate and distinct from the Merger and the proposed reverse stock split. If, contrary to that assumption, the distribution of the special cash dividend to a holder of ARCA common stock were integrated for tax purposes with the proposed reverse stock split, this could affect the calculation of the extent to which the distribution constitutes a taxable dividend or capital gain.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Receipt of the Special Cash Dividend by U.S.&#160;Holders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of the special cash dividend should be treated first as a dividend to the extent of ARCA&#8217;s current and accumulated earnings and profits, then as a non<span class="nobreak">-taxable</span> return of capital to the extent of the U.S.&#160;holder&#8217;s basis in its ARCA common stock, and then as capital gain from the sale or exchange of ARCA common stock with respect to any remaining value. Such capital gain will be long<span class="nobreak">-term</span> capital gain if the U.S.&#160;holder&#8217;s holding </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">128</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">period in the ARCA common stock exceeds one year at the time of the special cash dividend. Preferential tax rates may apply to long<span class="nobreak">-term</span> capital gains of non<span class="nobreak">-corporate</span> U.S.&#160;holders (including individuals). ARCA currently has an accumulated deficit and expects additional losses in the current period. Thus, ARCA expects most or all of the distribution of the special cash dividend to be treated as other than a dividend for U.S.&#160;federal income tax purposes. However, there can be no assurance that it will be so treated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder of ARCA common stock may be subject to information reporting and backup withholding for U.S.&#160;federal income tax purposes with respect to the special cash dividends. Backup withholding will not apply, however, to a U.S.&#160;holder who (i)&#160;furnishes a correct taxpayer identification number and certifies the holder is not subject to backup withholding on IRS Form&#160;W<span class="nobreak">-9</span> or a substantially similar form, or (ii)&#160;certifies the holder is otherwise exempt from backup withholding. If a U.S.&#160;holder does not provide a correct taxpayer identification number on IRS Form&#160;W<span class="nobreak">-9</span> or other proper certification, the stockholder may be subject to penalties imposed by the IRS.&#160;Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the federal income tax liability of a U.S.&#160;holder of ARCA common stock, if any, provided the required information is timely furnished to the IRS.&#160;U.S.&#160;holders should consult their tax advisors regarding their qualification for an exemption from backup withholding, the procedures for obtaining such an exemption, and in the event backup withholding is applied, to determine if any tax credit, tax refund or other tax benefit may be obtained.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nasdaq Stock Market Listing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA has agreed to use commercially reasonable efforts to (a)&#160;maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq; (b)&#160;to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of ARCA common stock to be issued in connection with the Merger and transactions contemplated thereunder, and to cause such shares to be approved for listing (subject to official notice of issuance); (c)&#160;prepare and timely submit to Nasdaq a notification form for the proposed reverse stock split (if required) and to submit a copy of the amendment to the ARCA Charter effecting the proposed reverse stock split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the closing date of the Merger; and (d)&#160;to the extent required by Nasdaq Marketplace Rule&#160;5110, assist Oruka in preparing and filing an initial listing application for the ARCA common stock issued to Oruka stockholders (including any common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) (the &#8220;Nasdaq Listing Application&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, under the Merger Agreement, each of ARCA&#8217;s and Oruka&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the closing of the Merger, of various conditions, including that the Nasdaq Listing Application shall have been approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Nasdaq Listing Application is approved, ARCA anticipates that the common stock of the combined company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;ORKA.&#8221; In order for the Nasdaq Listing Application to be accepted, among other requirements, the combined company must maintain a bid price of $4.00 or higher for a certain period of time following the proposed reverse stock split.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anticipated Accounting Treatment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is expected to be treated by ARCA as a reverse merger and will be accounted for as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka in accordance with U.S.&#160;GAAP as, at close, the transaction is, in essence, the issuance of equity for ARCA&#8217;s net asset, which primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. For accounting purposes, Oruka is considered to be acquiring the assets and liabilities of ARCA in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Oruka&#8217;s equity holders will own a substantial majority of the voting rights in the combined company; (ii)&#160;Oruka&#8217;s largest stockholder will retain the largest interest in the combined company; (iii)&#160;Oruka will designate all of the initial members of the board of directors of the combined company; and (iv)&#160;Oruka&#8217;s executive management team will become the management of the combined company. The combined company will be named Oruka Therapeutics, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">129</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Inc. and be headquartered in<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. Accordingly, the Merger is expected to be treated as the equivalent of Oruka issuing stock to acquire the net assets of ARCA.&#160;As a result of the Merger, the net assets of ARCA will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Oruka. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in-capital</span>. See the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the DGCL, ARCA stockholders are not entitled to appraisal rights in connection with the Merger. Oruka stockholders are entitled to appraisal rights in connection with the Merger under Section&#160;262 of the DGCL.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The discussion below is not a complete summary regarding Oruka&#8217;s stockholders&#8217; appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span> in this proxy statement/prospectus. Stockholders intending to exercise appraisal rights should carefully review <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span>.&#160;Failure to follow precisely any of the statutory procedures set forth in <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span> may result in a termination or waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that Oruka stockholders exercise their appraisal rights under Delaware law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Section&#160;262, where a merger is adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section&#160;228 of the DGCL, either the constituent corporation before the effective date of such merger or the surviving corporation, within ten&#160;days after the effective date of such merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of such merger, the effective date of such merger and that appraisal rights are available.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger is completed, within ten&#160;days after the effective date of the Merger, Oruka will notify its stockholders that the Merger has been approved, the effective date of the Merger and that appraisal rights are available to any stockholder who has not approved the Merger. Holders of shares of Oruka capital stock who desire to exercise their appraisal rights must deliver a written demand for appraisal to Oruka within 20&#160;days after the date of mailing of that notice, and that stockholder must not have delivered a written consent approving the Merger. A demand for appraisal must reasonably inform Oruka of the identity of the stockholder and that such stockholder intends thereby to demand appraisal of the shares of Oruka capital stock held by such stockholder. Failure to deliver a written consent approving the Merger will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section&#160;262. All demands for appraisal should be addressed to c/o Oruka Therapeutics, Inc., 221&#160;Crescent Street, Building<span class="nobreak"> </span>23, Suite 105, Waltham, MA&#160;02453 and should be executed by, or on behalf of, the record holder of shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ALL DEMANDS MUST BE RECEIVED BY ORUKA WITHIN&#160;20 DAYS AFTER THE DATE ORUKA MAILS A NOTICE TO ITS STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you fail to deliver a written demand for appraisal within the time period specified above, you will be entitled to receive the merger consideration for your shares of Oruka capital stock as provided for in the Merger Agreement, but you will have no appraisal rights with respect to your shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To be effective, a demand for appraisal by a holder of shares of Oruka capital stock must be made by, or in the name of, the registered stockholder, fully and correctly, as the stockholder&#8217;s name appears on the stockholder&#8217;s stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to Oruka. The beneficial owner must, in these cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">130</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">executing the demand, he or she is acting as agent for the record owner. A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner. In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you hold your shares of Oruka capital stock in a brokerage account or in other custodian form and you wish to exercise appraisal rights, you should consult with your bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At any time within 60&#160;days after the effective time, any stockholder who has demanded an appraisal, but has neither commenced an appraisal proceeding or joined an appraisal proceeding as a named party, has the right to withdraw such stockholder&#8217;s demand and accept the terms of the Merger by delivering a written withdrawal to Oruka. If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section&#160;262, you will have the right to receive the merger consideration for your shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Within 120&#160;days after the effective date of the Merger, any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares. This written statement will be mailed to the requesting stockholder within 10&#160;days after the stockholder&#8217;s written request is received by the surviving corporation or within 10&#160;days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120&#160;days after the effective date of the Merger, either the surviving corporation or any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders. Upon the filing of the petition by a stockholder, service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and ARCA, which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder&#8217;s previously written demand for appraisal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20&#160;days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation. After notice to dissenting stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section&#160;262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the Merger, but may include a fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i)&#160;the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of Chancery and (ii)&#160;interest theretofore accrued, unless paid at that time.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">131</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In determining fair value and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In Weinberger v. UOP, Inc., the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors involving the value of a company.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;262 provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; In Cede&#160;&amp; Co. v. Technicolor, Inc., the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In Weinberger, the Delaware Supreme Court construed Section&#160;262 to mean that &#8220;elements of future value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You should be aware that the fair value of your shares as determined under Section&#160;262 could be more than, the same as, or less than the value that you are entitled to receive under the terms of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs of the appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after the effective time, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the effective time; however, if no petition for appraisal is filed within 120&#160;days after the effective time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the Merger within 60&#160;days after the effective time, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his or her Oruka capital stock pursuant to the Merger Agreement. Any withdrawal of a demand for appraisal made more than 60&#160;days after the effective time may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure to follow the steps required by Section&#160;262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section&#160;262, stockholders who may wish to dissent from the Merger and pursue appraisal rights should consult their legal advisors.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">132</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T21"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">THE MERGER AGREEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached to this proxy statement/prospectus as Annex&#160;A and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about ARCA, Oruka, First Merger Sub or Second Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement contains representations and warranties that ARCA, First Merger Sub and Second Merger Sub, on the one hand, and Oruka, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure letters exchanged by the parties in connection with signing the Merger Agreement. While ARCA and Oruka do not believe that these disclosure letters contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure letters do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about ARCA or Oruka, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between ARCA, First Merger Sub, Second Merger Sub and Oruka and are modified by the disclosure letters.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with Delaware law, at the closing of the Merger, First Merger Sub, a wholly owned subsidiary of ARCA formed by ARCA in connection with the Merger, will merge with and into Oruka, with Oruka surviving as a wholly owned subsidiary of ARCA, and immediately following such Merger, and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub and with Second Merger Sub being the surviving entity of such Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Completion and Effectiveness of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two&#160;business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Oruka stockholders and the approval by the ARCA stockholders of the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The Merger will become effective upon the filing of certificates of Merger with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the certificates of Merger. Neither ARCA nor Oruka can predict the exact timing of the consummation of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Consideration</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each share of Oruka common stock (including any shares of Oruka common stock issued pursuant to Oruka&#8217;s pre<span class="nobreak">-closing</span> financing) outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio described in more detail below, and each share of Oruka&#8217;s preferred stock outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA&#8217;s convertible preferred stock equal to (x)&#160;the exchange ratio described in more details below <span class="Italic" style="font-style:italic;font-weight:normal;">divided by</span> (y)&#160;1,000. No fractional shares of ARCA common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of ARCA common stock resulting from the conversion of shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) shall </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">133</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">be issued as follows: (i)&#160;one share of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is equal to or exceeds 0.50 or (ii)&#160;no shares of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of ARCA Series&#160;B Preferred Stock would otherwise be entitled to receive will be aggregated with all fractional shares of ARCA preferred stock issuable to such holder and rounded up to the nearest whole share of ARCA&#8217;s convertible preferred stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exchange Ratio</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The exchange ratio is calculated using a formula intended to allocate existing ARCA and Oruka securityholders a percentage of the combined company. Based on ARCA&#8217;s and Oruka&#8217;s capitalization as of April&#160;3, 2024, the date the Merger Agreement was executed, the exchange ratio was estimated to be equal to approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock. This estimate is subject to adjustment prior to closing of the First Merger for net cash as of 11:59&#160;p.m. Eastern Time on the business&#160;day prior to the anticipated closing date (and as a result, ARCA securityholders could own less, and Oruka securityholders (including, for this purpose, investors in the Oruka pre<span class="nobreak">-closing</span> financing) could own more, or vice versa, of the combined company). ARCA management currently anticipates that ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on the estimates set forth above, after giving effect to the Oruka pre<span class="nobreak">-closing</span> financing, and certain other assumptions, immediately following the completion of the Merger, ARCA securityholders would own approximately 2.39% of the capital stock of the combined company post<span class="nobreak">-Merger</span>, and Oruka securityholders, including shares of Oruka common stock and Oruka warrants purchased in the Oruka pre<span class="nobreak">-closing</span> financing, would own approximately 97.61% of the capital stock of the combined company post<span class="nobreak">-Merger</span>. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at closing when the final exchange ratio is determined. For more information on the Oruka pre<span class="nobreak">-closing</span> financing, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger &#8212; Subscription Agreement</span>&#8221; beginning on page 151 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The exchange ratio formula is the quotient obtained (rounded to four decimal places) by dividing the number of Oruka merger shares (defined below) by the Oruka outstanding shares (defined below), in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Aggregate valuation&#8221; means the sum of (i)&#160;the Oruka valuation plus (ii)&#160;the ARCA valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka allocation percentage&#8221; means the percentage (rounded to four decimal places) determined by subtracting the ARCA allocation percentage from 100%.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka merger shares&#8221; means the product determined by multiplying (i)&#160;the post<span class="nobreak">-closing</span> ARCA shares by (ii)&#160;the Oruka allocation percentage.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka outstanding shares&#8221; means, without duplication, the total number of shares of Oruka capital stock outstanding immediately prior to the First Effective Time, (including any shares of Oruka common stock or Oruka preferred stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Oruka pre<span class="nobreak">-closing</span> financing), expressed on a fully diluted and as<span class="nobreak">-converted-to-Oruka</span> common stock basis, assuming, without limitation or duplication, the exercise of all options and warrants to acquire Oruka&#8217;s capital stock and other rights or commitments to receive shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock, including the convertible promissory note convertible into Oruka common stock), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. The calculation of Oruka outstanding shares:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>excludes, to avoid the double<span class="nobreak">-counting</span> of, any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock, including any convertible promissory note convertible into Oruka common stock) to the extent such shares or securities are contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing; and</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">134</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>includes to the extent not already issued prior to the First Effective Time, (i)&#160;any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock) issuable to the &#8220;Paragon Entities&#8221; (as such term is defined in Oruka&#8217;s organizational documents) as a result of the contemplated transactions pursuant to Oruka&#8217;s organizational documents and (ii)&#160;any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock) issuable pursuant to an offer letter set forth in the Oruka disclosure letter.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka valuation&#8221; means (i)&#160;$175&#160;million <span class="Italic" style="font-style:italic;font-weight:normal;">plus</span> (ii)&#160;the amount of proceeds actually received by Oruka from the Oruka pre<span class="nobreak">-closing</span> financing (including in the proceeds actually received from any convertible promissory notes convertible into Oruka common stock, and any interest thereon, contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA allocation percentage&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by dividing (i)&#160;the ARCA valuation by (ii)&#160;the aggregate valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA outstanding shares&#8221; means, without duplication, (including, without limitation, the effects of any reverse split, if completed) the total number of shares of ARCA common stock outstanding immediately prior to the First Effective Time expressed on a fully<span class="nobreak">-diluted</span> basis, and assuming, without limitation or duplication, the issuance of shares of ARCA common stock in respect of all options, warrants or other rights or commitments to receive shares of ARCA common stock or ARCA preferred stock (or securities convertible or exercisable into shares of ARCA common stock or ARCA preferred stock, but excluding any ARCA convertible preferred stock issuable as a result of the Merger), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time other than options to acquire shares of ARCA common stock to the extent cancelled at or prior to closing under Section&#160;6.6(c)&#160;of the Merger Agreement.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA valuation&#8221; means (i)&#160;$11,000,000, minus (ii)&#160;the amount by which ARCA net cash is less than $5,000,000 (if any).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Post<span class="nobreak">-closing</span> ARCA shares&#8221; means the quotient determined by dividing (i)&#160;the ARCA outstanding shares by (ii)&#160;the ARCA allocation percentage. The estimated exchange ratio for purposes of the unaudited pro forma condensed combined financial information was derived on a fully<span class="nobreak">-diluted</span> basis as of March<span class="nobreak">&#160;</span>31, 2024 using a stipulated value of Oruka of approximately $450&#160;million (including the Oruka pre<span class="nobreak">-closing</span> financing) and of ARCA of approximately $11&#160;million. For more information, see &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information.</span>&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Calculation of ARCA&#8217;s Net Cash</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Merger Agreement, ARCA&#8217;s &#8220;net cash&#8221; means, as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date, the sum (without duplication) of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in ARCA&#8217;s SEC filings or ARCA&#8217;s balance sheet;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Certain ARCA prepaid expenses set forth in ARCA&#8217;s disclosure letter; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All receivables which ARCA and Oruka may mutually agree are recoverable by or provide benefit to ARCA after the First Effective Time (if any).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">minus</span> the sum (without duplication) of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s consolidated short<span class="nobreak">-term</span> and long<span class="nobreak">-term</span> contractual obligations and liabilities accrued at the closing date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the ARCA&#8217;s SEC reports and its balance sheet;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">135</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The aggregate amount (without duplication) of all fees and expenses incurred by ARCA prior to the First Effective Time in connection with the contemplated transactions or the sale of ARCA&#8217;s legacy business, in each case, to the extent unpaid as of the First Effective Time, including;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of ARCA in connection with the transactions contemplated by the Merger Agreement or the sale of ARCA&#8217;s legacy business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees paid to the SEC in connection with filing this registration statement and any amendments and supplements thereto, with the SEC;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees and expenses in connection with the printing, mailing and distribution of this proxy statement and any amendments and supplements thereto;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees associated with the filing of Oruka&#8217;s initial listing application with Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any bonus, retention payments, severance, change<span class="nobreak">-in-control</span> payments or similar payment obligations (including payments with &#8220;single<span class="nobreak">-trigger</span>&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the contemplated transactions or the sale of ARCA&#8217;s legacy business, together with any payroll taxes associated therewith;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the dividend by ARCA of any excess net cash (but only to the extent declared and unpaid) and all costs and expenses associated therewith; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to Section&#160;6.7 of the Merger Agreement.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All remaining rent payments and any other liabilities under ARCA&#8217;s lease obligations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Any unpaid taxes of ARCA and its subsidiaries for tax periods (or portions thereof) ending on or before the closing date;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All costs and expenses to be mutually agreed by ARCA and Oruka relating to the winding down of ARCA&#8217;s legacy business, including the sale, license or other disposition of any or all of ARCA&#8217;s legacy business to the extent unpaid as of the closing; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The amounts due and payable to holders of options to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price that are cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such options, in accordance with the Merger Agreement, to the extent unpaid as of the First Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No later than five&#160;business days prior to the anticipated closing date, (i)&#160;ARCA will deliver to Oruka a net cash schedule setting forth, in reasonable detail, ARCA&#8217;s good faith estimated calculation of its net cash and (ii)&#160;Oruka will deliver to ARCA a Oruka valuation schedule setting forth, in reasonable detail, Oruka&#8217;s good faith estimated calculations of the components of Oruka&#8217;s valuation, in each case, as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date, prepared and certified by ARCA&#8217;s and Oruka&#8217;s chief financial officer (or if there is no chief financial officer, the principal financial and accounting officer), as the case may be, and, if requested, the relevant work papers and back<span class="nobreak">-up</span> materials used or useful in preparing the net cash schedule and Oruka valuation schedule, respectively. No later than three&#160;business days after delivery of such net cash schedule (the last&#160;day of such period referred to as the response date), Oruka will have the right to dispute any part of the net cash schedule by delivering a written notice to that effect to ARCA (referred to herein as a dispute notice). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to ARCA&#8217;s net cash calculation. No later than three&#160;business days after delivery of such Oruka valuation schedule (the last&#160;day of such period referred to as the response date), ARCA will have the right to dispute any part of such schedule by delivering a written notice to that effect to Oruka (referred to herein as an Oruka valuation dispute notice). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to Oruka&#8217;s valuation calculation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">136</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka disputes the net cash schedule or ARCA disputes the Oruka valuation schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed<span class="nobreak">-upon</span> determination of net cash and/or Oruka&#8217;s valuation, as the case may be. If the parties are unable to negotiate an agreed<span class="nobreak">-upon</span> determination of the disputed items or component thereof within three&#160;days after the delivery of the relevant dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by ARCA and Oruka. The determination of the amount of net cash or Oruka valuation made by such auditor shall be final and binding on ARCA and Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s net cash balance is subject to numerous factors, some of which are outside of ARCA&#8217;s control. The actual amount of net cash will depend significantly on the timing of the closing of the Merger. In addition, the closing of the Merger could be delayed if ARCA and Oruka are not able to agree upon the amount of ARCA&#8217;s net cash as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka stock option assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka stock option assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka stock option assumed by ARCA, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka stock option assumed by will be determined by dividing (A)&#160;the per share exercise price of such Oruka stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka stock option assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka stock option will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent provided under the terms of a Oruka stock option assumed by ARCA in accordance with the terms of the Merger Agreement, such Oruka stock option shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, ARCA&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of Oruka&#8217;s board of directors or any committee thereof with respect to each Oruka option assumed by ARCA in accordance with the terms of the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Warrants</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each warrant to purchase shares of Oruka capital stock (including any pre<span class="nobreak">-funded</span> Oruka warrants issued pursuant to the Oruka pre<span class="nobreak">-closing</span> financing) that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be converted into a warrant to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka warrant assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka warrant assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock issuable upon exercise of the Oruka warrant that were subject to such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price for the ARCA common stock issuable upon exercise of each Oruka warrant assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of ARCA common stock subject to such Oruka warrant as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka warrant assumed by ARCA will otherwise continue in full force and effect and the term, any restriction on the exercise and other provisions of such Oruka warrant will otherwise remain unchanged.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">137</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent provided under the terms of a Oruka warrant assumed by ARCA in accordance with the terms of the Merger Agreement, such Oruka warrant shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, ARCA&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of Oruka&#8217;s board of directors or any committee thereof with respect to each Oruka warrant assumed by ARCA in accordance with the terms of the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Common Stock and ARCA Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except as contemplated by the proposed increase in the number of authorized shares of ARCA common stock described in Proposal No. 2 of this proxy statement/prospectus and<span class="Superscript" style="vertical-align:super;"> </span>the proposed reverse stock split of issued and outstanding ARCA common stock described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA common stock will remain unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the volume weighted average closing trading price of a share of ARCA common stock on Nasdaq for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;) will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedures for Exchanging Oruka Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the closing date of the First Merger, ARCA will select an exchange agent and, at the First Effective Time, ARCA will deposit with the exchange agent evidence of book<span class="nobreak">-entry</span> shares representing the shares of ARCA common stock and ARCA Series&#160;B Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka common stock and Oruka preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after the First Effective Time, the exchange agent will mail to each record holder of Oruka common stock or Oruka preferred stock (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the Merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent or ARCA, the record holder of such stock certificates or book<span class="nobreak">-entry</span> shares, as applicable, will be entitled to receive in exchange therefor book<span class="nobreak">-entry</span> shares representing the number of whole shares of ARCA common stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Oruka common stock or Oruka preferred stock will be canceled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the First Effective Time, each certificate representing Oruka common stock or Oruka preferred stock that has not been surrendered will represent only the right to receive shares of ARCA common stock or preferred stock (as applicable) issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">HOLDERS OF ORUKA COMMON STOCK OR ORUKA PREFERRED STOCK SHOULD NOT SEND IN THEIR ORUKA STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF ORUKA STOCK CERTIFICATES.</span></p>
		</div>


		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">138</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Directors and Officers of ARCA Following the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Merger Agreement, each of the directors and officers of ARCA will resign effective as of the First Effective Time and ARCA&#8217;s board of directors will thereafter consist of a total of six new directors designated by Oruka. Oruka has designated Lawrence Klein, Kristine Ball, Carl Dambkowski, Cameron Turtle, Peter Harwin, and Samarth Kulkarni to serve as members of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, upon the closing of the Merger, Lawrence Klein will serve as Chief Executive Officer and President, Arjun Agarwal will serve as Senior Vice President, Finance and Treasurer, Joana Goncalves will serve as Chief Medical Officer, and Paul Quinlan will serve as General Counsel and Secretary.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendment of the Amended and Restated Certificate of Incorporation of ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA agreed to amend its amended and restated certificate of incorporation to (i)&#160;change ARCA&#8217;s name to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii)&#160;effect the proposed reverse stock split, if needed, (iii)&#160;authorize a sufficient number of shares of common stock to issue the Merger consideration and (iv)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to the amount proposed in this Proxy Statement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Representations and Warranties</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains customary representations and warranties of ARCA, First Merger Sub and Second Merger Sub, on one hand, and Oruka, on the other hand, for a transaction of this type relating to, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>corporate organization and power, and similar corporate matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>due organization;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>organizational documents;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authority to enter into the Merger Agreement and the related agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>votes required for completion of the Merger and approval of the proposals that will come before the ARCA special meeting of stockholders and that will be the subject of the Oruka stockholder approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as otherwise specifically disclosed in the Merger Agreement, the fact that the consummation of the Merger would not contravene the organizational documents, certain laws, governmental authorizations or certain contracts of the parties; result in any encumbrances on the parties&#8217; assets or require the consent of any third party;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the parties&#8217; efforts with respect to ensuring the inapplicability of Section&#160;203 of the DGCL and other similar takeover laws;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>capitalization;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>financial statements and, with respect to ARCA, documents filed with the SEC and the accuracy of information contained in those documents;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>material changes or events;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>title to assets;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real property and leaseholds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>intellectual property;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>material contracts;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">139</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the validity of material contracts to which the parties or their subsidiaries are a party and any violation, default or breach of such contracts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory compliance, permits and restrictions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>legal proceedings and orders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>tax matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>employee and labor matters and benefit plans;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>environmental matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>insurance;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>financial advisors fees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain transactions or relationships with affiliates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>privacy and data security;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>with respect to ARCA, the valid issuance in the Merger of ARCA common stock; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>with respect to Oruka, the lack of ownership of ARCA&#8217;s common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the Merger. The accuracy of the representations and warranties of the Company form the basis of certain of the conditions to the obligations of ARCA and Oruka to complete the Merger, subject to materiality thresholds.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Covenants; Conduct of Business Pending the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has agreed that, except as permitted by the Merger Agreement, as required by law, or unless Oruka has provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, ARCA and its subsidiaries will use commercially reasonable efforts to conduct their business and operations in the ordinary course consistent with past practices and in compliance with all applicable laws, regulations and certain material contracts. ARCA has also agreed that, subject to certain limited exceptions, without the consent of Oruka, it will not, and will not cause or permit any of its subsidiaries to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of ARCA common stock from terminated employees, directors or consultants of ARCA);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any capital stock or other security (except for ARCA common stock issued upon the valid exercise of outstanding ARCA options or ARCA RSUs), any option, warrant or right to acquire any capital stock or any other security or any instrument convertible into or exchangeable for any capital stock or other security;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as required to give effect to anything in contemplation of the closing, amend the certificate of incorporation, bylaws or other similar organizational documents of ARCA or its subsidiaries, or effect or be a party to any Merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>form any subsidiary or acquire any equity interest or other interest in any other entity or enter into any joint venture with any other entity;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">140</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others; or make any capital expenditure or commitment in excess of $25,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adopt, establish or enter into certain agreements, plans or arrangements relating to employment or benefits matters; cause or permit any such agreement, plan or arrangement to be amended other than as required by law or in order to make amendments for purposes of Section&#160;409A of the Code; pay any bonus or make any profit<span class="nobreak">-sharing</span> or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or independent contractors; increase the severance or change of control benefits offered to any current or new employees, directors or consultants; or hire any officer, employee or consultant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property rights of ARCA (other than pursuant to non<span class="nobreak">-exclusive</span> licenses in the ordinary course of business);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of business: make, change or revoke any material tax election; file any amended income or other material tax return; adopt or change any material accounting method in respect of taxes; enter into any material tax closing agreement or settle any material tax claim or assessment; consent to any extension or waiver of the limitation period applicable to or relating to any material tax claim or assessment; or surrender any material claim for refund;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>waive, settle or compromise any pending or threatened legal proceeding against ARCA or any of its subsidiaries, other than waivers, settlements or agreements for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and that do not impose any material restrictions on the operations or businesses of ARCA or its subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by ARCA or any of its subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>forgive any loans to any person, including its employees, officers, directors or affiliate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>terminate or modify in any material respect, or fail to exercise renewal rights to, any material insurance policy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>materially change pricing or royalties or other payments set or charged by ARCA or any of subsidiaries to its customers or licensees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree to materially change pricing or royalties or other payments set or charged by persons who have licensed intellectual property to ARCA or any of subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into, amend in a manner adverse to ARCA or terminate any of ARCA&#8217;s material contracts outside the ordinary course of business; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree, resolve or commit to do any of the foregoing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the foregoing restrictions, ARCA is expressly permitted to engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or winding down of its legacy business (including terminating its real estate leases and other contracts) and is expressly permitted to declare and pay a dividend on the shares of ARCA common stock outstanding prior to the First Effective Time (excluding for the avoidance of doubt any shares of ARCA&#8217;s common stock issuable pursuant to the Merger), up to an amount equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash at the First Effective Time will exceed $5.0&#160;million.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">141</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has agreed that, except as permitted by the Merger Agreement, as required by law, or unless ARCA shall have provided its written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, Oruka will use commercially reasonable efforts to conduct its business and operations in the ordinary course consistent with past practices and in compliance with all applicable laws, regulations and certain contracts. Oruka has also agreed that, subject to certain limited exceptions, without the consent of ARCA, it will not, and will not cause or permit its subsidiary to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of common stock from terminated employees, directors or consultants of Oruka);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as required to give effect to anything in contemplation of the closing, amend the certificate of incorporation, bylaws or other organizational documents of Oruka or its subsidiaries, or effect or be a party to any Merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of its business, sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing actions with respect to more than 25% of the shares of Oruka capital stock outstanding as of the date the Merger Agreement was signed: any capital stock or other security of Oruka or its subsidiaries (except for shares of outstanding Oruka common stock issued upon the valid exercise or settlement of Oruka options or warrants in accordance with their terms as in effect as of the date of the Merger Agreement); any option, warrant or right to acquire any capital stock or any other security; or any instrument convertible into or exchangeable for any capital stock or other security of Oruka or its subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of its business, acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties, except in the ordinary course of business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property rights owned by Oruka, other than pursuant to non<span class="nobreak">-exclusive</span> licenses in the ordinary course of business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>waive, settle or compromise any pending or threatened legal proceeding against Oruka, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Oruka or any equitable relief on, or the admission of wrongdoing by Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into, amend in a manner adverse to Oruka or terminate any material contract outside of the ordinary course of its business; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree, resolve or commit to do any of the foregoing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">142</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Non-Solicitation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka have agreed that, except as described below, ARCA and Oruka and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>furnish any non<span class="nobreak">-public</span> information with respect to it to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>execute or enter into any letter of intent or any contract contemplating or otherwise relating to an Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>publicly propose to do any of the foregoing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Inquiry&#8221; means, with respect to a party, an inquiry, indication of interest or request for non<span class="nobreak">-public</span> information (other than an inquiry, indication of interest or request for information made or submitted by Oruka, on the one hand, or ARCA on the other hand, to the other party) that would reasonably be expected to lead to an Acquisition Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Proposal&#8221; means, with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Oruka or any of its affiliates, on the one hand, or by or on behalf of ARCA or any of its affiliates, on the other hand, to the other party) contemplating or otherwise relating to any Acquisition Transaction with such party.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Transaction&#8221; means any transaction or series of related transactions (other than a sale by ARCA of its legacy assets, the issuance of convertible notes by Oruka or the Oruka pre<span class="nobreak">-closing</span> financing) involving:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any merger, consolidation, amalgamation, share exchange, business combination, issuance or acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or similar transaction: (i)&#160;in which any individual, entity, governmental entity, or &#8220;group,&#8221; as defined under applicable securities laws, directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of ARCA or Oruka or any of their respective subsidiaries or (ii)&#160;in which ARCA, Oruka or Merger Subs or any of their respective subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of ARCA or Oruka and their respective subsidiaries, as applicable, taken as a whole.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the foregoing, before obtaining the applicable approvals of the ARCA stockholders or Oruka stockholders required to consummate the Merger, each party may furnish non<span class="nobreak">-public</span> information regarding such party and its subsidiaries to, and may enter into discussions or negotiations with, any third party in response to a bona fide written Acquisition Proposal, which such party&#8217;s board of directors determines in good faith, after consultation with such party&#8217;s financial advisors and outside legal counsel, constitutes or is reasonably likely to result in a Superior Offer (and is not withdrawn), if:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of the Merger Agreement;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">143</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party&#8217;s board of directors concludes in good faith, based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the fiduciary duties of such board of directors under applicable law;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at least two&#160;business days prior to furnishing any non<span class="nobreak">-public</span> information or entering into discussions with a third party, such party gives the other party written notice of the identity of the third party and of that party&#8217;s intention to furnish non<span class="nobreak">-public</span> information to, or enter into discussions with, such third party;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party receives from the third party an executed confidentiality agreement containing provisions at least as favorable to such party as those contained in the confidentiality agreement between ARCA and Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at least two&#160;business days prior to furnishing any non<span class="nobreak">-public</span> information to a third party, such party furnishes the same non<span class="nobreak">-public</span> information to the other party to the extent not previously furnished.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A &#8220;Superior Offer&#8221; means an unsolicited <span class="Italic" style="font-style:italic;font-weight:normal;">bona fide</span> written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that (a)&#160;was not obtained or made as a direct or indirect result of a breach of the Merger Agreement, (b)&#160;is on terms and conditions that the board of directors of the party receiving the offer determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to that party&#8217;s stockholders than the terms of the transactions contemplated by the Merger Agreement, (c)&#160;is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d)&#160;is reasonably capable of being completed on the terms proposed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement also provides that each party will promptly (and in no event later than one business&#160;day after such party receives any such Acquisition Proposal or Acquisition Inquiry) advise the other party of the status and terms of, and keep the other party reasonably informed with respect to, any Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Recommendation Change</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Merger Agreement, subject to certain exceptions described below, both Oruka and ARCA agreed that their respective board of directors may not withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of such party&#8217;s board of directors in a manner adverse to the other party except for in limited circumstances described below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At any time prior to the approval of the Merger by each party&#8217;s respective stockholders, if (i)&#160;such party has received a bona fide written Acquisition Proposal that the such party&#8217;s board of directors determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii)&#160;a material development or change in circumstances (other than any such event, development or change to the extent related to any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, the fact, in and of itself, that ARCA meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations or, in the case of ARCA, any sale of ARCA&#8217;s legacy business) that affects the business, assets or operations of such party and occurs or arises after the date the Merger Agreement was executed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of a change recommendation due to a material development or change in circumstance, such party&#8217;s board of directors must first promptly notify the other party, in writing, at least four&#160;business days before making a change in its recommendation, stating the material facts and circumstances related to the applicable material development or change in circumstance and that such party&#8217;s board of directors intends to make a change in its recommendation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of a change its recommendation due to a Superior Offer, such party&#8217;s board of directors must first:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>determine in good faith, based on the advice of its outside legal counsel, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; and</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">144</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>negotiate with the other party in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, during the required four business&#160;day notice period and provide the other party with certain information regarding such Superior Offer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the other party delivers a written offer to alter the terms or conditions of the Merger Agreement during the required four business&#160;day notice period, the party considering a change in the recommendation of its board of directors must redetermine in good faith, based on the advice of its outside legal counsel and financial advisors, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement);</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Stockholder Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is obligated under the Merger Agreement to take all action necessary under applicable law to call, give notice of and hold a meeting of the holders of ARCA common stock for the purpose of considering and voting to approve the Merger Agreement and the transactions contemplated thereby (including the Merger) and an amendment to the ARCA Charter as further described herein (collectively, the &#8220;Merger proposals&#8221;). The ARCA special meeting will be held as promptly as practicable after this registration statement on Form&#160;S<span class="nobreak">-4</span> is declared effective under the Securities Act, and in any event no later than 45&#160;days after the effective date of this registration statement on Form&#160;S<span class="nobreak">-4</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after this registration statement on Form&#160;S<span class="nobreak">-4</span> has been declared effective, and no later than two business days thereafter, Oruka is required to obtain the approval by written consent from the holders of a majority of the outstanding shares of Oruka&#8217;s capital stock, voting as a single class on an as<span class="nobreak">-converted</span> basis and the holders of a majority of the outstanding shares of Oruka Series&#160;A preferred stock, voting as a separate class, in each case, to (x)&#160;adopt and approve the Merger Agreement and the Merger or the transactions contemplated thereby (including the Merger), (y)&#160;acknowledge that the approval given thereby is irrevocable and that such stockholders are aware of their rights to demand appraisal for their shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (z)&#160;acknowledge that by their approval of the Merger, they are not entitled to appraisal rights with respect to their shares in connection with the Merger and thereby waive any rights to receive payment of the fair value of their capital stock under the DGCL.&#160;Reasonably promptly following receipt of such consents, Oruka will prepare, and cause to be mailed to its stockholders who did not execute such consents, a notice in accordance with the DGCL.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each party agreed to use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, and to submit promptly any additional information requested by any such governmental authority. ARCA and Oruka do not intend to seek any regulatory approval from antitrust or other regulatory authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Indemnification and Insurance for Directors and Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Merger Agreement, from the First Merger Effective Time through the sixth anniversary of the date on which the First Merger Effective Time occurs, ARCA and the surviving entity in the Second Merger agreed to indemnify and hold harmless each person who is now, or has been at any time prior to the date of the Merger Agreement, or who becomes prior to the First Merger Effective Time, a director or officer of ARCA or Oruka, respectively, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified officer or director is or was a director or officer of ARCA or of Oruka, whether asserted or claimed prior to, at or after the First Merger Effective Time. From and after the First Merger Effective Time, ARCA and the surviving corporation in the Merger will also fulfill ARCA&#8217;s and Oruka&#8217; indemnity obligations, respectively, to each person who is, has been, or who becomes prior to the First Merger Effective Time, a director or officer of ARCA or Oruka.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">145</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The certificate of formation and limited liability company agreement of the surviving entity will contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the ARCA Charter and ARCA Bylaws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From and after the First Merger Effective Time, ARCA will maintain director and officers&#8217; liability insurance policies, with an effective date as of the closing date of the First Merger, on commercially available terms and conditions and with coverage limits customary for U.S.&#160;public companies similarly situated to ARCA.&#160;In addition, ARCA will secure and purchase a six year &#8220;tail policy&#8221; on ARCA&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy with an effective date as of the date of the closing of the First Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to use its reasonable best efforts to cause to be taken all actions necessary to consummate the Merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in connection with the transactions contemplated by the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any applicable law or contract, or otherwise) in connection with the Merger and the other transactions contemplated by the Merger Agreement or for such contract to remain in full force and effect;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the transactions contemplated by the Merger Agreement; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Merger Agreement, ARCA and Oruka have further agreed that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA will use its commercially reasonable efforts to maintain its listing on Nasdaq and cause the shares of ARCA common stock (including any shares of ARCA&#8217;s common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) being issued in the Merger to be approved for listing on Nasdaq at or prior to the First Merger Effective Time.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA will keep Oruka reasonably informed regarding any stockholder litigation against ARCA or any of its directors relating to the Merger Agreement or the transactions contemplated thereby.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">ARCA will (i)&#160;give Oruka the opportunity to participate in, but not control, the defense, settlement or prosecution of any such litigation (to the extent that the attorney<span class="nobreak">-client</span> privilege is not undermined or otherwise adversely affected), (ii)&#160;consult with Oruka with respect to the defense, settlement and prosecution of any such litigation and (iii)&#160;consider in good faith Oruka&#8217;s advice with respect to such litigation.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Conditions to the Completion of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following contains a description of all material conditions to the completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each party&#8217;s obligation to complete the Merger is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the closing, of various conditions, which include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, must have been declared effective by the SEC in accordance with the Securities Act and must not be subject to any stop order or any proceeding seeking a stop order that has not been withdrawn; and any material state securities laws applicable to the issuance of the shares of ARCA&#8217;s capital stock in connection with the Merger or any of the other transactions contemplated by the Merger Agreement shall have been </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">146</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">complied with and no stop order (or similar order) shall have been issued or threatened in writing in respect of such shares of ARCA&#8217;s capital stock by any applicable state securities commissioner or court of competent jurisdiction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>there must not have been issued, and remain in effect, any order preventing the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement by any governmental authority of competent jurisdiction, and no law, statute, rule, regulation, ruling or decree will be in effect which has the effect of making the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement illegal;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the holders of a majority of the outstanding shares of Oruka common stock, voting as a single class on an as<span class="nobreak">-converted</span> basis and the holders of a majority of the outstanding shares of Oruka Series&#160;A preferred stock, voting as a separate class, must have adopted and approved the Merger Agreement and the transactions contemplated thereby by written consent (the &#8220;Oruka stockholder approval&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the holders of the shares of ARCA common stock constituting a majority of the votes properly cast at the ARCA special meeting must have approved the Merger Agreement and the transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initial listing application for ARCA&#8217;s common stock on Nasdaq (including any shares of ARCA&#8217;s common stock issuable upon conversion of the shares of ARCA Series&#160;B Preferred Stock) shall have been approved by Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lock<span class="nobreak">-up</span> agreements executed by certain stockholders of Oruka will continue to be in full force and effect;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ARCA Charter amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by the Merger Agreement; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA shall have filed a Certificate of Designation with the Secretary of State of the State of Delaware designating the ARCA Series&#160;B Preferred Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, each party&#8217;s obligation to complete the Merger is further subject to the satisfaction or waiver by that party of the following additional conditions:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party&#8217;s representations and warranties being true and correct as of the closing date, subject to applicable materiality qualifiers;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party to the Merger Agreement must have performed or complied with in all material respects all of such party&#8217;s agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the First Merger Effective Time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lack of a material adverse effect that is continuing with respect to the other party; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party having delivered certain certificates and other documents required under the Merger Agreement for the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the obligation of ARCA and Merger Subs to complete the Merger is further subject to the Subscription Agreement being in full force and effect and cash proceeds of not less than $175&#160;million having been received by Oruka, substantially simultaneously with the closing of the First Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">147</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Termination and Termination Fees</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement may be terminated at any time before the First Merger Effective Time, whether before or after the required stockholder approvals to complete the Merger have been obtained, as set forth below:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by mutual written consent of ARCA and Oruka;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if the Merger has not been consummated by October&#160;3, 2024 (subject to possible extension as provided in the Merger Agreement); <span class="Italic" style="font-style:italic;font-weight:normal;">provided, however</span>, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure of the Merger to occur on or before October&#160;3, 2024 and such action or failure to act constitutes a breach of the Merger Agreement; and <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, that such date will be extended by 60&#160;days by either party in the event that the SEC has not declared effective the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, by the date which is 60&#160;days following October&#160;3, 2024;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if a court of competent jurisdiction or governmental entity has issued a final and non<span class="nobreak">-appealable</span> order, decree or ruling or having the effect of permanently restrains, enjoins or otherwise prohibits the Merger or any of the transactions contemplated by the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by ARCA, if the Oruka stockholder approval has not been obtained within two&#160;business days of the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, becoming effective; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that this right to terminate the Merger Agreement will not be available to ARCA once Oruka obtains such stockholder approval;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if the ARCA special meeting has been held and completed and ARCA stockholders have taken a final vote on the Merger proposals set forth herein to be considered at the ARCA special meeting, and such proposals have not been approved by the ARCA stockholders; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that ARCA may not terminate the Merger Agreement pursuant to this provision if the failure to obtain the approval of ARCA stockholders was caused by the action or failure to act of ARCA and such action or failure to act constitutes a material breach by ARCA of the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(f)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by Oruka, at any time prior to obtaining the approval by ARCA stockholders of the Merger proposals set forth herein to be considered at the ARCA special meeting, if any of the following circumstances shall occur:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA fails to include in this proxy statement/prospectus ARCA&#8217;s board of directors&#8217; recommendation that ARCA stockholders vote to approve the Merger proposals set forth herein to be considered at the ARCA special meeting;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors, or any committee thereof, makes an ARCA board recommendation change or publicly approves, endorses or recommends any Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a confidentiality agreement permitted pursuant to the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(g)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by ARCA, at any time prior to obtaining the Oruka stockholder approval, if any of the following circumstances shall occur:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors makes a Oruka board recommendation change or publicly proposes, endorses or recommends any Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">148</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(h)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by Oruka, if ARCA or Merger Subs have breached any of their representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of ARCA has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that Oruka is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, if such breach or inaccuracy is curable, then ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30<span class="nobreak">-day</span> period after delivery of written notice of such breach or inaccuracy from Oruka to ARCA or Merger Subs and Oruka&#8217;s intention to terminate pursuant to this paragraph (it being understood that ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by ARCA or Merger Subs is cured prior to such termination becoming effective);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by ARCA, if Oruka has breached any of its representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Oruka has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; <span class="Italic" style="font-style:italic;font-weight:normal;">provided </span>that ARCA is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, if such breach or inaccuracy is curable, then ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30<span class="nobreak">-day</span> period after delivery of written notice of such breach or inaccuracy from ARCA to Oruka and ARCA&#8217;s intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Oruka is cured prior to such termination becoming effective); or</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(j)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by ARCA (at any time prior to obtaining the ARCA stockholder approval), upon ARCA&#8217;s board of directors authorizing ARCA to enter into a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a superior offer, subject to certain conditions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fees Payable by ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA must pay Oruka a termination fee of $440,000 if (i)&#160;the Merger Agreement is terminated by ARCA or Oruka pursuant to clause (e)&#160;above or by Oruka pursuant to clause (f)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and prior to the ARCA special meeting, an Acquisition Proposal with respect to ARCA will have been publicly announced, disclosed or otherwise communicated to ARCA&#8217;s board of directors (and will not have been withdrawn), and (iii)&#160;in the event the Merger Agreement is terminated pursuant to clause (e)&#160;above, within 12&#160;months after the date of such termination, ARCA enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fees Payable by Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka must pay ARCA a termination fee of $440,000 if (i)&#160;the Merger Agreement is terminated by ARCA pursuant to clause (d)&#160;or (g)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and before obtaining the Oruka stockholder approval, an Acquisition Proposal with respect to Oruka will have been publicly announced, disclosed or otherwise communicated to Oruka&#8217;s board of directors (and will not have been withdrawn), and (iii)&#160;in the event the Merger Agreement is terminated pursuant to clause (d)&#160;above, within 12&#160;months after the date of such termination, Oruka enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendment and Waiver</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties to the Merger Agreement and authorized by such party&#8217;s boards of directors at any time, unless the Merger Agreement has been adopted and approved by any party&#8217;s stockholders, in which case no amendment which by law requires further approval by the such party&#8217;s stockholders, may be made without such further approval.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">149</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any provision of the Merger Agreement may be waived by any party solely on that party&#8217;s behalf, without the consent of any other party. The waiver must be expressly set forth in a written instrument duly executed and delivered on behalf of such party, which will only be valid in the specific instance in which it is given. No failure or delay on the part of any party with respect to the exercise of any power, right, privilege or remedy under the Merger Agreement will operate as a waiver of such power, right, privilege or remedy. Furthermore, no single or partial exercise of any such power, right, privilege or remedy will preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">150</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T20"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">AGREEMENTS RELATED TO THE MERGER</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Support Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain Oruka stockholders holding approximately 90% of the outstanding shares of Oruka capital stock have entered into Oruka Support Agreements with ARCA and Oruka to vote all of their shares of Oruka capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals. Certain ARCA stockholders holding approximately 28.5% of the outstanding shares of ARCA common stock have entered into ARCA Support Agreements with ARCA and Oruka to vote all of their shares of ARCA common stock in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal and against any alternative acquisition proposals.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Lock-Up Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of Oruka&#8217;s executive officers, directors and stockholders have entered into&#160;lock<span class="nobreak">-up</span>&#160;agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of ARCA&#8217;s common stock or any securities convertible into or exercisable or exchangeable for ARCA common stock, currently or thereafter owned, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger, but excluding, as applicable, shares purchased by existing Oruka stockholders in the Oruka pre<span class="nobreak">-closing</span>&#160;financing (including any shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing), until 180&#160;days after the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Oruka stockholders who have executed&#160;lock<span class="nobreak">-up</span>&#160;agreements as of March&#160;31, 2024 owned, in the aggregate, approximately 90% of the shares of Oruka&#8217;s outstanding capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing description of the&#160;lock<span class="nobreak">-up</span>&#160;agreements does not purport to be complete and is qualified in its entirety by the full text of the form of&#160;lock<span class="nobreak">-up</span>&#160;agreement, which is attached hereto as&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;E</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka entered into the Subscription Agreement with Oruka, pursuant to which such investors have agreed to purchase immediately prior to the First Merger, shares of Oruka common stock or, in lieu thereof, Oruka pre<span class="nobreak">-funded</span>&#160;warrants, representing an aggregate commitment of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), in the Oruka pre<span class="nobreak">-closing</span>&#160;financing. Under the Subscription Agreement, the number of shares of Oruka common stock or pre<span class="nobreak">-funded</span> warrants, as applicable, shall be determined at a purchase price per share or warrant equal to (i)&#160;a valuation for Oruka equal to approximately $175.0&#160;million, (ii)&#160;divided by the number of shares of Oruka common stock outstanding immediately prior to the First Effective Time of the Merger (but excluding the securities being issued under the Subscription Agreement). Each share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, calculated in accordance with the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants that are issued in the Oruka pre<span class="nobreak">-closing</span>&#160;financing will be or will have the right to be, respectively, converted into shares of ARCA common stock in the Merger. Accordingly, by approving Proposal&#160;No.&#160;1 relating to the Merger, ARCA stockholders will also be approving the issuance of shares of ARCA common stock to be issued in exchange for all shares of Oruka common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants that are sold in the Oruka pre<span class="nobreak">-closing</span>&#160;financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contains customary representations and warranties of Oruka and also contains customary representations and warranties of the purchaser parties thereto.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">151</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each purchaser&#8217;s obligation to purchase shares of Oruka common stock and/or Oruka pre<span class="nobreak">-funded</span> warrants from Oruka pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s representations and warranties in the Subscription Agreement being true and correct in all respects as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date for the Oruka pre<span class="nobreak">-closing</span> financing, subject to certain exceptions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka having performed and complied in all material respects with all covenants, agreements, obligations and conditions required to be performed or complied with by it;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of a compliance certificate by the chief executive officer of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all registrations, qualifications, permits and approvals, if any, required under applicable state securities laws having been obtained;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of a secretary&#8217;s certificate by the secretary of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the satisfaction or waiver of all conditions to the closing of the Merger set forth in the Merger Agreement (other than the condition regarding the Oruka pre<span class="nobreak">-closing</span> financing) and the closing of Merger being set to occur substantially concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no injunction having been issued prohibiting the consummation of the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka having delivered the registration rights agreement required by the Subscription Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>this registration statement on Form&#160;S<span class="nobreak">-4</span> shall have been become effective under the Securities Act, no stop order shall be suspending the effectiveness of this registration statement and no proceeding for that purpose shall have been initiated or threatened in writing by the SEC;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Nasdaq Listing Application shall have been approved by Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no material adverse effect shall have occurred that is continuing, since the date of the Subscription Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka shall receive at closing aggregate proceeds from the purchase of securities pursuant to the Subscription Agreement of not less than $175,000,000 (including in the proceeds any convertible securities contributed as consideration in accordance with the Subscription Agreement); and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an opinion from Company counsel, dated as of the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s obligation to sell shares of Oruka common stock to each purchaser pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the representations and warranties made by the purchasers being true and correct as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date of the Oruka pre<span class="nobreak">-closing</span> financing, subject to certain exceptions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each purchaser having performed and complied with all covenants, agreements, obligations and conditions required to be performed or complied with by each purchaser;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all registrations, qualifications, permits and approvals, if any, required under applicable state securities laws having been obtained; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the satisfaction or waiver of all conditions to the closing of the Merger set forth in the Merger Agreement (other than those conditions which are to be satisfied at the closing of the transactions contemplated by the Merger Agreement)) and the closing of Merger being set to occur substantially concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">152</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Registration Rights Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contemplates ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing entering into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of Oruka common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time, including the shares of ARCA common stock issued in exchange for shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing and ARCA pre<span class="nobreak">-funded</span> warrants assumed upon conversion of the Oruka pre<span class="nobreak">-funded</span> warrants sold in the Oruka pre<span class="nobreak">-closing</span> financing (including shares issuable upon exercise of such warrants).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the registration rights agreement, the combined company will agree to prepare and file a shelf registration statement covering the resale of the ARCA common stock within 45&#160;days of the closing of the merger pursuant to&#160;Rule&#160;415&#160;and to use its reasonable best efforts to keep such registration statement continuously effective under the&#160;Securities Act&#160;until the earlier of (a)&#160;the date that all registrable securities covered by such registration statement (i)&#160;have been sold, thereunder or pursuant to&#160;Rule&#160;144&#160;of the&#160;Securities Act&#160;(&#8220;Rule&#160;144&#8221;), or (ii)&#160;may be sold without volume or manner<span class="nobreak">-of-sale</span> restrictions pursuant to&#160;Rule&#160;144&#160;and without the requirement for the combined company to be in compliance with the current public information requirement under&#160;Rule&#160;144, and (b)&#160;five&#160;years after the date of the registration rights agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the registration rights agreement, the combined company will agree that neither the combined company nor securityholders of the combined company (other than the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing and party to the registration rights agreement) may have &#8220;piggyback&#8221; registration rights and that the combined company will be prohibited from filing any other registration statements until all of the registerable securities subject to the registration rights agreement are registered pursuant to an effective registration statement, subject to certain exceptions. The registration rights agreement also provides that the combined company will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities. The form of registration rights agreement is attached as Exhibit A to the Subscription Agreement filed as Exhibit 10.2 to this registration statement on Form&#160;S<span class="nobreak">-4</span> of which this proxy statement/prospectus is a part, and the foregoing description of the registration rights agreement is qualified in its entirety by reference thereto.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">153</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T19"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following sets forth certain information, as of May&#160;3, 2024, concerning ARCA&#8217;s directors and executive officers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s directors, executive officers and key employees as of May&#160;3, 2024 are as follows:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;">Name</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Age</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Position</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">65</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Operating Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">59</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Financial Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#160;Linda Grais<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(2)*(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">67</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)*(2)(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;II Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#160;Anders Hove<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(3)*(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">58</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;Jacob Ma-Weaver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">36</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;III Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">43</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Committee Chairperson</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Audit Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Compensation Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Special Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>See &#8220;Election of Board of Directors&#8221; below for discussion of Class&#160;I&#160;&#8212;&#160;III Director service terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Thomas A.&#160;Keuer</span>. Mr.&#160;Keuer has served as ARCA&#8217;s Chief Operating Officer since December&#160;2014, and ARCA&#8217;s President since April&#160;2024. Mr.&#160;Keuer served as ARCA&#8217;s Executive Vice President, Pharmaceutical Operations from 2006 to 2014. Prior to joining ARCA, Mr.&#160;Keuer served as the SVP of Operations for Insmed, Inc. from 2004 to 2006. Prior to Insmed, Mr.&#160;Keuer served as the VP of Engineering for Baxter Healthcare from 1998 to 2004. Prior to Baxter, Mr.&#160;Keuer served as the VP of Operations for Somatogen, Inc. Mr.&#160;Keuer received his M.S. in Biochemical Engineering from Rice University and received his B.S. in Chemical Engineering from the University of Texas, Austin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">C. Jeffrey Dekker</span>. Mr.&#160;Dekker has served as ARCA&#8217;s Chief Financial Officer and Treasurer since May&#160;2021 and ARCA&#8217;s Secretary since April&#160;2023. Prior to joining ARCA, Mr.&#160;Dekker served in multiple roles of increasing responsibility at GlobeImmune, Inc. from 2006 to 2021, including President, Vice President of Finance, and Senior Director, Finance and Controller. Before joining GlobeImmune, Mr.&#160;Dekker held leadership positions in finance and accounting at private software companies since 1993, including posts ranging from Corporate Controller to Vice President at Webroot Software Inc., Requisite Technology Inc. and NxTrend Technology Inc. Earlier in his career, Mr.&#160;Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He earned a B.S. in accounting from Utah State University and is a certified public accountant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Linda Grais, M.D.</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span>Dr.&#160;Grais has served as a member of ARCA&#8217;s board of directors since May&#160;2007. Dr.&#160;Grais was a director of Ocera Therapeutics, Inc., a public biopharmaceutical company, since January&#160;2008 and became President and Chief Executive Officer of Ocera in June&#160;2012, and served in that role until Ocera&#8217;s acquisition by Mallinckrodt Pharmaceuticals in December&#160;2017. Dr.&#160;Grais served as a Managing Member at InterWest Partners, a venture capital firm from May&#160;2005 until February&#160;2011. From July&#160;1998 to July&#160;2003, Dr.&#160;Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich&#160;&amp; Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr.&#160;Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr.&#160;Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. Since September&#160;2015, Dr.&#160;Grais served on the board of PRA Health Sciences, which was acquired by ICON plc in 2021, a public contract research organization, and currently serves on the board of ICON plc. Dr.&#160;Grais also joined the board of Corvus Pharmaceuticals., a publicly traded pharmaceutical company, in January&#160;2019, and joined the board of Collective Health, a private healthcare services company, in March&#160;2023. ARCA believes Dr.&#160;Grais is an appropriate member of the Board of Directors because of her diverse training and experience as both a medical doctor and a lawyer, her experience as a founder and senior executive of a pharmaceutical company, and her experience as an investor in new life sciences companies. She also has extensive experience with and knowledge of ARCA&#8217;s business from her service on ARCA&#8217;s board of directors since 2007.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">154</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Robert E.&#160;Conway</span><span class="Bold" style="font-style:normal;font-weight:bold;"> </span>Mr.&#160;Conway was appointed to ARCA&#8217;s board of directors in September&#160;2013, and has served as the Chairman of ARCA&#8217;s board of directors since 2014. Mr.&#160;Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded biopharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr.&#160;Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr.&#160;Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of directors of eResearch Technology, Inc., a private company, and from 2015 to July&#160;2017, Advarra, Inc. from 2019 to August&#160;2022, and he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company. In July&#160;2017, Nivalis Therapeutics, Inc. combined with Alpine Immune Sciences, Inc., a public, clinical stage pharmaceutical company, and Mr.&#160;Conway continues to serve on the board of directors following such combination. In addition, Mr.&#160;Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is a member of the board of directors of Signant Health. In April&#160;2023, Mr.&#160;Conway became Executive Chairman and member of the board of directors of ClinOne, Inc. Mr.&#160;Conway received a B.S. in accounting from Marquette University in 1976. ARCA believes Mr.&#160;Conway is an appropriate member of ARCA&#8217;s board of directors given his experience and expertise in the pharmaceutical industry, in pharmaceutical development and clinical trials, and in corporate finance, governance, accounting and public company compliance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Anders Hove, M.D.</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span>Dr.&#160;Hove has served as a member of ARCA&#8217;s board of directors since February&#160;2017. Dr.&#160;Hove is the manager of Acorn Bioventures, a partnership focusing on long<span class="nobreak">-term</span> investments in biotech, specialty pharma and medical device companies. Before Dr.&#160;Hove was a general partner of Venrock Associates, a venture capital firm, which he joined in 2004 and remained at through 2016. In 2008, Dr.&#160;Hove was a founder of Venrock Healthcare Capital Partners, Venrock&#8217;s public funds focused on small capitalization biotech companies and late<span class="nobreak">-stage</span> private companies. From 1996 to 2004, Dr.&#160;Hove was a fund manager at BB Biotech, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, an investment company. Dr.&#160;Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba<span class="nobreak">-Geigy</span> and Novartis. Mr.&#160;Hove was a member of the boards of directors of Anacor Pharmaceuticals, a publicly traded pharmaceutical company, from 2005 until its acquisition by Pfizer in June&#160;2016, and Edge Therapeutics, a publicly traded biotechnology company, from 2015 to 2016. In addition, Dr.&#160;Hove is a member of the board of directors of MC2 Therapeutics. He received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from INSEAD (the Institut Europ&#233;en d&#8217;Administration des Affaires). ARCA believes Dr.&#160;Hove is an appropriate member of ARCA&#8217;s board of directors, given his extensive training and experience as a medical doctor and masters of business administration, an executive in the pharmaceutical industry, and as an investor in biotechnology companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Jacob Ma</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Weaver</span></span> Mr.&#160;Ma<span class="nobreak">-Weaver</span> was appointed to ARCA&#8217;s board of directors in June&#160;2022. He is the Managing Member of Cable Car Capital LLC, an investment adviser he founded in 2013. Cable Car Capital LLC is the General Partner of Funicular Funds, LP, a hedge fund. From 2012 to 2013, Mr.&#160;Ma<span class="nobreak">-Weaver</span> was employed as an investment analyst at Amici Capital LLC, where he focused on healthcare. He was previously employed as an equity research associate at Dodge&#160;&amp; Cox and a corporate finance business analyst at McKinsey&#160;&amp; Company. Mr.&#160;Ma<span class="nobreak">-Weaver</span> received a Bachelor of Arts in Comparative Literature&#160;&amp; Society and Economics and a Master of Arts in Statistics from Columbia University. He is a Chartered Financial Analyst (CFA) charterholder. ARCA believes Mr.&#160;Ma<span class="nobreak">-Weaver</span> is an appropriate member of ARCA&#8217;s board of directors because of his experience as an investor in life sciences companies, an analyst for investment firms and his academic background.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">James Flynn</span> Mr.&#160;Flynn has served as a member of ARCA&#8217;s board of directors since December&#160;2022. Mr.&#160;Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Mr.&#160;Flynn has served as a board member for Axiom Health (a provider of software and big<span class="nobreak">-data</span> solutions to the healthcare industry) since 2022, a board member for MEI Pharma, Inc (a pharmaceutical company committed to the development of novel and differentiated cancer therapies) since 2023, and joined the board of RiceBran Technologies (an innovative specialty ingredients company) in January&#160;2024. From 2017 to 2018, Mr.&#160;Flynn worked as a therapeutics analyst at Aptigon Capital (a Citadel Company), an investment firm. Prior to that, from 2003 to 2017, Mr.&#160;Flynn served in various roles at Amici Capital, LLC, an investment firm, including healthcare portfolio manager (2008 to 2017). From 2002 to 2003, Mr.&#160;Flynn worked in the credit research/high yield group at Putnam Investments, an investment firm. Mr.&#160;Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachusetts Institute of Technology (MIT). Mr.&#160;Flynn is a </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">155</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Chartered Financial Analyst (CFA) charterholder. ARCA believes Mr.&#160;Flynn is an appropriate member of ARCA&#8217;s board of directors because of his experience as an investor in life sciences companies, an analyst for investment firms and his academic background.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Diversity Matrix (as of May&#160;3, 2024)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The table below provides certain highlights of the composition of ARCA&#8217;s board members as of May&#160;3, 2024. Each of the categories listed in the table below has the meaning as it is used in Nasdaq Rule&#160;5605(f).</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12">
					<td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Diversity Matrix as of May&#160;3, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Total&#160;Number&#160;of&#160;Directors&#160;and&#160;nominees:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" colspan="7" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">5</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Part&#160;I:&#160;Gender Identity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Male</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Female</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Non-Binary</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Did Not <br/>Disclose&#160;Gender</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Part&#160;II:&#160;Demographic Background</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">African American or Black</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Alaskan Native or American Indian</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Asian</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hispanic or Latinx</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Native Hawaiian or Pacific Islander</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">White</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Two or More Races or Ethnicities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">LGBTQ+</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Did Not Disclose Demographic Background</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">156</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T18"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ADDITIONAL INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Independence of The Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As required under the Nasdaq listing standards, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the board of directors. ARCA&#8217;s board of directors consults with ARCA&#8217;s counsel to ensure that the board of directors&#8217; determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of the Nasdaq, as in effect from time to time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and ARCA, its senior management and its independent registered public accounting firm, the Board of Directors has affirmatively determined that the following five directors are independent directors within the meaning of the applicable Nasdaq&#160;listing standards: Mr.&#160;Conway, Dr.&#160;Grais, Dr.&#160;Hove and Mr.&#160;Flynn. In making this determination, the Board of Directors found that none of the directors had a material or other disqualifying relationship with ARCA.&#160;Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer was not an&#160;independent director in 2023 by virtue of his employment relationship with ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Leadership Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has structured its board of directors in a way that ARCA believes effectively serves its objectives of corporate governance and management oversight. ARCA separates the roles of President and Chairman of the board of directors in recognition of the differences between the two roles. ARCA believes that the President should be responsible for the&#160;day<span class="nobreak">-to-day</span> leadership and performance of ARCA, while the Chairman of the board of directors should work with the President and the rest of the board of directors to set the strategic direction for ARCA and provide guidance to, and oversight of the President. The Chairman also sets the agenda for meetings of the board of directors and presides over them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Mr.&#160;Conway, who is an independent director, was elected Chairman of the board of directors in 2014. In this capacity, Mr.&#160;Conway, among other things, calls and presides over board meetings, including meetings of the independent directors, and sets meeting agendas. In this role, Mr.&#160;Conway can effectively coordinate between the board of directors and management regarding risk management issues and the implementation of appropriate responses, and can help ensure the effective independent functioning of the board of directors in its oversight responsibilities. Accordingly, the Chairman has substantial ability to shape the work of the board of directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Role of the Board of Directors in Risk Oversight and Risk Management</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of the board of directors&#8217; key functions is informed oversight of ARCA&#8217;s risk management process. The board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of the board of directors that address risks inherent in their respective areas of oversight. In particular, while the board of directors is responsible for monitoring and assessing strategic risk exposure, the Audit Committee has the responsibility to consider and discuss the major financial risk exposures and the steps management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of ARCA&#8217;s accounting and financial reporting processes. The Nominating and Corporate Governance Committee monitors the effectiveness of the corporate governance guidelines, including whether they are successful in preventing illegal or improper liability<span class="nobreak">-creating</span> conduct. The Compensation Committee of the board of directors of ARCA (the &#8220;Compensation Committee&#8221;) assesses and monitors whether any compensation policies and programs have the potential to encourage excessive risk<span class="nobreak">-taking</span>. The entire board of directors and its committees address risk management issues from time<span class="nobreak">-to-time</span> and at least annually meet with the employees responsible for risk management in the committees&#8217; respective areas of oversight. Both the board of directors as a whole and the various standing committees receive periodic reports </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">157</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">from the employees responsible for risk management, as well as&#160;incidental reports as matters may arise. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the board of directors as quickly as possible.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Meetings of The Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors met three times during the 2023 fiscal year. The independent members of the board of directors met separately as a group at each of the board meetings in 2023. All members of the board of directors attended at least 75% of the aggregate of (i)&#160;the total number of meetings of the board of directors held during the period for which each director served and (ii)&#160;the total number of meetings held by all committees of the board of directors of which each director was a member during the periods that they served. All of ARCA&#8217;s directors then on the board of directors attended ARCA&#8217;s 2023 annual meeting of stockholders (the &#8220;2023 Annual Meeting&#8221;) whether in person or via telephone.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Election of Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors at ARCA&#8217;s annual stockholders&#8217; meetings. The ARCA Charter, as amended, provides that the board of directors is divided into three classes to provide for staggered terms and that each director will serve for a term of three&#160;years or less, depending on the class to which the board of directors has assigned a director not previously elected by the stockholders. There is currently one Class&#160;III director whose term expires at the annual stockholders&#8217; meeting in 2024, three Class&#160;I directors whose terms expire at the annual stockholders&#8217; meeting in 2025 and one Class&#160;II directors whose term expires at the annual meeting in 2026. The one Class&#160;III director, Mr.&#160;Jacob Ma<span class="nobreak">-Weaver</span>, is currently scheduled for re<span class="nobreak">-election</span> to the board of directors at this 2024 special meeting in lieu of an annual stockholders&#8217; meeting, for a three<span class="nobreak">-year</span> term ending on the date of the annual meeting in 2027 or until his successor is duly elected and qualified or appointed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s executive officers are appointed by and serve at the discretion of ARCA&#8217;s board of directors. There are no family relationships between ARCA&#8217;s directors and executive officers.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Code of Ethics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has adopted the ARCA biopharma, Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabiopharma.com</span>. If ARCA makes any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, ARCA will promptly disclose the nature of the amendment or waiver on its website and file any current report on Form&#160;8<span class="nobreak">-K</span> required by applicable law or Nasdaq listing standards.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Insider Trading Policy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has adopted an Insider Trading Policy that governs the purchase, sale and/or other dispositions of its securities by its directors, officers and employees, as well as their immediate family members and entities owned or controlled by them, and that is designed to promote compliance with insider trading laws, rules and regulations.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">158</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Information Regarding Committees of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">ARCA&#8217;s board of directors has three standing committees: The Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. The following table provides membership and meeting information for the fiscal year ended December&#160;31, 2023, for each of the committees of the board of directors:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Audit</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Compensation</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Nominating <br/>and <br/>Corporate <br/>Governance</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Linda Grais</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Raymond L.&#160;Woosley</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">X*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Mr.&#160;Robert E.&#160;Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Mr.&#160;Dan J.&#160;Mitchell</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">X</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">X</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total meetings in fiscal 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Committee Chairperson.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, the board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value. The Special Committee includes ARCA board Chairman Robert E.&#160;Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D and James Flynn (joined the Special Committee in April&#160;2024). Jacob Ma<span class="nobreak">-Weaver</span> served as a member of the Special Committee from June&#160;2022 to April&#160;2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:12pt;">Below is a description of each committee of the board of directors. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities.<span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">&#160;</span>The board of directors has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding &#8220;independence&#8221; and that each member is free of any relationship that would impair his or her individual exercise of independent judgment regarding the Company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Audit Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;">The Audit Committee of ARCA&#8217;s board of directors of ARCA (the &#8220;Audit Committee&#8221;) was established by the board of directors in accordance with Section&#160;3(a)(58)(A)&#160;of the Exchange&#160;Act, to oversee ARCA&#8217;s corporate accounting and financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent registered public accounting firm; determines and approves the engagement of the independent registered public accounting firm; determines whether to retain or terminate the existing independent registered public accounting firm or to appoint and engage a new independent registered public accounting firm; reviews and approves the retention of the independent registered public accounting firm to perform any proposed permissible non<span class="nobreak">-audit</span> services; monitors the rotation of partners of the independent registered public accounting firm on ARCA&#8217;s audit engagement team as required by law; reviews and approves or rejects transactions between the company and any related persons; confers with management and the independent registered public accounting firm regarding the effectiveness of internal controls over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by ARCA regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and meets to review ARCA&#8217;s annual audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including a review of ARCA&#8217;s disclosures under the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; discussion in its Annual Reports on Form&#160;10<span class="nobreak">-K</span> and Quarterly Reports on Form&#160;10<span class="nobreak">-Q</span>.&#160;The Audit Committee is currently composed of three<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>directors: Mr.&#160;Conway (chair), Mr.&#160;Flynn and Dr.&#160;Grais. The Audit Committee met six times during the 2023 fiscal year. The board of directors has adopted a written charter of the Audit Committee that is available to stockholders<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>on ARCA&#8217;s website at&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">159</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors reviews the Nasdaq<span class="SmallCaps" style="font-variant:small-caps;"> </span>listing standards definition of independence for audit committee members on an annual basis and has determined that all members of the Audit Committee are independent (as independence is currently defined in Rule&#160;5605(c)(2)(A)(i)&#160;and (ii)&#160;of the Nasdaq<span class="SmallCaps" style="font-variant:small-caps;"> </span>listing standards). The board of directors has also determined that Mr.&#160;Conway qualifies as an &#8220;audit committee financial expert,&#8221; as defined in applicable SEC rules. The board of directors made a qualitative assessment of Mr.&#160;Conway&#8217;s level of knowledge and experience based on several factors, including his prior experience, business acumen and independence.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Compensation Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee is currently composed of three directors: Mr.&#160;Conway, Dr.&#160;Grais (chair) and Dr.&#160;Hove. All members of the Compensation Committee are independent, as independence is currently defined in Rule&#160;5605(a)(2)&#160;of the Nasdaq listing standards. The Compensation Committee met two times during the 2023 fiscal year. The Compensation Committee has adopted a written charter that is available to stockholders on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee of ARCA&#8217;s board of directors acts on behalf of the board of directors to review, adopt and oversee ARCA&#8217;s compensation strategy, policies, plans and programs, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>overseeing succession planning for senior management of ARCA, including a review of the performance and advancement potential of current and future senior management and succession plans for each and recommending, as appropriate, the retention of potential succession candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>assessing the overall compensation structure of ARCA and evaluating and recommending changes to ARCA&#8217;s compensation philosophies and strategies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing and approving performance<span class="nobreak">-based</span> compensation plans or programs, including establishing goals and targets, applicable to the Chief Executive Officer and other members of the management team;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>administering, reviewing, and approving all executive compensation programs or plans, and all of ARCA&#8217;s incentive compensation and stock plans and awards thereunder of ARCA, including amendments to the programs, plans or awards made thereunder; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>preparing and approving the report of the Compensation Committee to be included as part of ARCA&#8217;s annual meeting proxy statement, to the extent required.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Compensation Committee Processes and Procedures</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Typically, the Compensation Committee meets, as it deems appropriate. The agenda for each meeting is usually developed by the Chair of the Compensation Committee. However, from time to time, various members of management and other employees as well as outside advisors or consultants<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>may be invited by the Compensation Committee to make<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>presentations, to provide financial or other<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The Compensation Committee has the sole authority to retain compensation consultants to assist in its evaluation of<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>executive<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. In general, the Compensation Committee has set executive compensation to be in line with peer companies identified by the Compensation Committee and to incentivize ARCA&#8217;s executive officers in achieving ARCA&#8217;s short- and long<span class="nobreak">-term</span> corporate goals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, the Compensation and Nominating and Corporate Governance Committees of ARCA reviewed ARCA&#8217;s current employee and director compensation, including ARCA&#8217;s 2013 Equity Incentive Plan. As part of this review, the Committees considered certain changes to the ARCA&#160;2013 Equity Incentive Plan that were included in the 2020 ARCA Equity Incentive Plan. Both Committees recommended approval of the 2020 ARCA Equity Incentive Plan, and the Plan was subsequently approved by the board of directors and ARCA&#8217;s stockholders on December&#160;10, 2020.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">160</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current compensation for the ARCA named executive officers was set by the Compensation Committee and the board of directors in 2020. On December&#160;21, 2020, the Compensation Committee approved the following base salary compensation and target bonus percentages for the ARCA named executive officers and principal financial officer for the 2021 fiscal year:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Michael R.&#160;Bristow, former President and Chief Executive Officer, $345,000 base salary and target bonus of 50% of base salary; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Thomas A.&#160;Keuer, Chief Operating Officer, $340,000 base salary and target bonus of 40% of base salary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May&#160;3, 2021, the Compensation Committee approved a $270,000 base salary and target bonus of 35% of base salary for C.&#160;Jeffrey Dekker, Chief Financial Officer, ARCA&#8217;s principal financial officer hired in May&#160;2021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Historically, the Compensation Committee has made most of the significant adjustments to annual compensation, determined bonus and equity awards and established new performance objectives at one or more meetings held during the first quarter of the year. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high<span class="nobreak">-level</span> strategic issues, such as the efficacy of ARCA&#8217;s compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee&#8217;s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee reviews and approves the compensation of the President and the other executive officers of ARCA, including annual base salaries, annual and long<span class="nobreak">-term</span> incentive or bonus awards, employment agreements, and severance and change in control agreements/provisions, in each case as, when and if appropriate, and any special or supplemental benefits. For executives other than the President, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>by the President. The Compensation Committee evaluates the performance of the President in light of Company and individual goals and objectives, and makes appropriate recommendations for improving performance. In performing the evaluation, the Chair of the Compensation Committee may solicit comments from the other non<span class="nobreak">-employee</span> members of the board of directors and lead the board of directors in an overall review of the President&#8217;s performance in an executive session of non<span class="nobreak">-employee</span> members of the board of directors. If the compensation for the President or any other executive officer is governed by an employment agreement, the Compensation Committee approves such employment agreement and any amendments thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For all executives as part of its deliberations, the Compensation Committee may review and consider, as appropriate,<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company<span class="nobreak">-wide</span> compensation levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee also considers the results of any &#8220;say<span class="nobreak">-on-pay</span>&#8221; vote of ARCA&#8217;s stockholders with regard to the compensation of ARCA&#8217;s executive officers when making compensation decisions. At the 2023 Annual Meeting, ARCA&#8217;s stockholders approved, on an advisory basis, the compensation of ARCA named executive officers as described in the proxy statement for such annual meeting, with over 81% of stockholder votes cast in favor of ARCA&#8217;s &#8220;say<span class="nobreak">-on-pay</span>&#8221; resolution. The Compensation Committee believes that this advisory vote supports that ARCA&#8217;s current compensation practices are aligned with the best interests of stockholders and anticipates taking into account the results of the advisory vote, and any future advisory votes, when making compensation decisions in the future.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nominating and Corporate Governance Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nominating and Corporate Governance Committee of the board of directors of ARCA (the &#8220;Nominating and Corporate Governance Committee&#8221;) is responsible for identifying, reviewing and evaluating candidates to serve as directors of ARCA (consistent with criteria approved by the board of directors), reviewing and evaluating incumbent directors, recommending to the board of directors candidates for election to the board of directors , making recommendations to the board of directors regarding compensation for service on the board of directors and the committees thereof, making recommendations to the board of directors regarding the membership of the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">161</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">committees of the board of directors, assessing the performance of the board of directors and developing a set of corporate governance principles for ARCA.&#160;The Nominating and Corporate Governance Committee is currently composed of three<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>directors: Dr.&#160;Hove (chair), Mr.&#160;Conway and Dr.&#160;Grais. All members of the Nominating and Corporate Governance Committee in 2023 were independent (as independence is currently defined in Rule&#160;5605(a)(2) of the Nasdaq listing standards). The Nominating and Corporate Governance Committee met once during the 2023 fiscal year. The Nominating and Corporate Governance Committee has adopted a written charter that is available to stockholders on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nominating and Corporate Governance Committee periodically reviews the compensation of non<span class="nobreak">-employee</span> Directors for service on the board of directors and committees thereof. In 2015, the Nominating and Corporate Governance Committee began a review of its Director compensation levels considering general market conditions in the life science industry, and in comparison to other clinical stage biopharmaceutical companies, and in early 2016, the Committee recommended, and the board of directors approved, revised compensation for non<span class="nobreak">-employee</span> Directors, discussed in &#8220;ARCA Director Compensation&#8221; below. Since adoption of this policy, the Nominating and Corporate Governance Committee has reviewed Director compensation on an annual basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, the Nominating and Corporate Governance Committee (together with the Compensation Committee) engaged a consultant to evaluate the current compensation of ARCA&#8217;s non<span class="nobreak">-employee</span> directors and make recommendations to the Nominating and Corporate Governance Committee. The changes made as a result of this evaluation are discussed in &#8220;ARCA Director Compensation&#8221; below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The board of directors has adopted a process for identifying and evaluating director nominees, including stockholder nominees. Before recommending an individual to the board of directors for membership on the board of directors, the Nominating and Corporate Governance Committee canvasses its members and ARCA&#8217;s management team for potential candidates for the board of directors. The Nominating and Corporate Governance Committee also uses its network of contacts to identify potential candidates and, if it deems appropriate, may also engage a professional search firm. The Nominating and Corporate Governance Committee will consider stockholders&#8217; recommendations for nominees to serve as director if notice is timely received by the Secretary of ARCA.&#160;Candidates nominated by stockholders will be evaluated in the same manner as other candidates. The Nominating and Corporate Governance Committee keeps the board of directors apprised of its discussions with potential nominees, and the names of potential nominees received from its current directors, management, and stockholders, if the stockholder notice of nomination is timely made.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although the board of directors has not adopted a fixed set of minimum qualifications for candidates for membership on the board of directors, the Nominating and Corporate Governance Committee generally considers several factors in its evaluation of a potential member, such as the candidate&#8217;s education, professional background and field of expertise including industry or academic experience in the pharmaceutical and biotechnology fields, experience in corporate governance and management, the reasonable availability of the potential member to devote time to the affairs of ARCA, as well as any other criteria deemed relevant by the board of directors or the Nominating and Corporate Governance Committee. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the board of directors, the operating requirements of ARCA and the long<span class="nobreak">-term</span> interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, age, skills and such other factors as it deems appropriate given the current needs of the board of directors and ARCA, to maintain a balance of knowledge, experience and capability. The Nominating and Corporate Governance Committee believes it is essential that board of directors members come from a variety of backgrounds and experiences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors&#8217; overall contributions to ARCA and the board of directors during their terms, including level of attendance, level of participation, quality of performance and contribution to the board of directors&#8217; responsibilities and actions, and any relationships and transactions that might impair the directors&#8217; independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq and SEC purposes, which determination is based upon applicable Nasdaq<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">162</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">backgrounds and qualifications of possible candidates after considering the function and needs of the board of directors. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates&#8217; qualifications and then determines whether to recommend a nominee to the board of directors by majority vote.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the board of directors may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee addressed to the Corporate Secretary, between 60 and 90&#160;days before the one<span class="nobreak">-year</span> anniversary date of ARCA&#8217;s last annual meeting of stockholders. Recommendations must include the full name of the proposed nominee, a description of the proposed nominee&#8217;s business experience for at least the previous five&#160;years, complete biographical information, a description of the proposed nominee&#8217;s qualifications as a director, and a representation that the recommending stockholder is a beneficial or record owner of ARCA&#8217;s stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected. To date, the Nominating and Corporate Governance Committee has not rejected a timely director nominee from a stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2023, the Nominating and Corporate Governance Committee did not pay any fees to assist in the process of identifying or evaluating director candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anti-Hedging Prohibition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s employees, directors and consultants are prohibited from engaging in any hedging transactions of ARCA&#8217;s securities, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds, as required by ARCA&#8217;s insider trading policy.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholder Communications with the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders who wish to communicate with ARCA&#8217;s board of directors may do so by e<span class="nobreak">-mail</span> by using the following email address: <span class="Italic" style="font-style:italic;font-weight:normal;">directors@arcabio.com</span>; or by mail by following the directions as set forth on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>, under the section titled &#8220;Corporate Governance&#8221; and the subsection titled &#8220;Governance Documents&#8221;. Communications sent in accordance with this process will be transmitted by ARCA to the appropriate board members.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">163</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T17"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA EXECUTIVE COMPENSATION</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal&#160;years ended December&#160;31, 2023 and December&#160;31, 2022, compensation awarded to, paid to, or earned by ARCA&#8217;s principal executive officer and its two most highly compensated executive officers as of December&#160;31, 2023, collectively, the ARCA named executive officers:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Summary Compensation Table</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name and Principal Position</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Year</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Salary <br/>($)(1)</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Bonus <br/>($)(2)</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Stock <br/>Awards <br/>($)</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">All&#160;Other <br/>Compensation <br/>($)(3)</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Total <br/>($)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">345,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,800</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">358,800</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">Former President and Chief Executive Officer<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">345,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,800</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">358,800</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">340,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,802</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,802</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">President and Chief Operating Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">340,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88,400</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,593</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">448,993</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">270,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,072</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">323,072</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Salary&#8221; in the above table represent the actual amounts paid during the calendar year. Because ARCA&#8217;s actual pay dates do not always coincide with the first and last&#160;days of the year, these amounts may differ from the base salary amounts authorized by ARCA&#8217;s board of directors.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Bonus&#8221; in the above table represent retention bonuses paid to each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker in December&#160;2023. These amounts were previously reported as &#8220;All Other Compensation&#8221; in ARCA&#8217;s Annual Report on Form&#160;10<span class="nobreak">-K</span> for the fiscal year ended December&#160;31, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents 401(k)&#160;Company match in the amount of $13,800 for Michael R.&#160;Bristow in each of 2023 and 2022, $15,000 and $13,600 for Thomas A.&#160;Keuer in 2023 and 2022, and $11,579 for C.&#160;Jeffrey Dekker in 2023, Health Savings Account contributions by ARCA in the amount of $850 for Thomas A.&#160;Keuer in 2022, and $3,960 for C.&#160;Jeffrey Dekker in 2023, group term life premiums in the amount of $9,602 and $4,989 for Thomas A.&#160;Keuer in 2023 and 2022, and $2,533 for C.&#160;Jeffrey Dekker in 2023, and cell phone reimbursements in the amount of $1,200 and $1,154 for Thomas A.&#160;Keuer in 2023 and 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow and ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment effective April&#160;3, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Narrative Disclosure to Summary Compensation Table</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Employment Agreements or Arrangements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Michael R.&#160;Bristow, M.D., Ph.D.</span>&#160;&#160;&#160;&#160;Dr.&#160;Bristow served as ARCA&#8217;s President and Chief Executive Officer under an Employment and Retention Agreement dated as of June&#160;4, 2008, as amended. Pursuant to such employment agreement, Dr.&#160;Bristow was permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute, so long as it did not interfere with his duties as President and Chief Executive Officer of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation on April&#160;3, 2024, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) pursuant to which ARCA paid Dr.&#160;Bristow a lump sum amount equal to $370,000, less applicable tax withholding, which consisted of (i)&#160;12&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a $25,000 cash payment. The separation payments were conditioned on Dr.&#160;Bristow not revoking the Separation Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow also entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow provides certain consulting services to ARCA through the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;a change of control of ARCA (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;)). During the consulting term, Dr.&#160;Bristow will continue to vest in his outstanding equity awards.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">164</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Thomas A.&#160;Keuer.</span>&#160;&#160;&#160;&#160;Mr.&#160;Keuer serves as ARCA&#8217;s President and Chief Operating Officer under an Amended and Restated Employment Agreement that was effective as of January&#160;1, 2015.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Keuer, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Keuer to (i)&#160;increase the aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the vesting of certain ARCA restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Keuer&#8217;s retention bonus was paid on December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter between ARCA and Mr.&#160;Keuer to increase the aggregate amount of the retention bonus by 33.33% to $200,000. The remaining portion of the retention bonus with respect to Mr.&#160;Keuer, consisting of $165,000, will become payable consistent with the original terms of the retention bonus letter and the first amendment to the retention bonus letter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA terminates Mr.&#160;Keuer&#8217;s employment without &#8220;cause,&#8221; or if Mr.&#160;Keuer terminates his employment with &#8220;good reason&#8221; (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr.&#160;Keuer a severance payment equivalent to (i)&#160;(a)&#160;12&#160;months of his base salary, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (b)&#160;six&#160;months of his base salary if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, (ii)&#160;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by ARCA&#8217;s board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&#160;reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for (x)&#160;12&#160;months, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (y)&#160;six&#160;months if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, whether he elects or is eligible to receive COBRA (provided, in either event, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12&#160;months of base salary, which additional payment would extend the covenants and obligations under Mr.&#160;Keuer&#8217;s Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&#160;Keuer of a legal release in a form acceptable to ARCA.&#160;A termination for &#8220;cause&#8221; includes Mr.&#160;Keuer&#8217;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement, or any other agreement, with ARCA. &#8220;Good reason&#8221; includes a relocation by us of Mr.&#160;Keuer&#8217;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA&#8217;s unilateral decision to significantly and detrimentally reduce Mr.&#160;Keuer&#8217;s job responsibilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, ARCA&#8217;s board of directors appointed Mr.&#160;Keuer to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s employment is expected to conclude upon closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">C.&#160;Jeffrey Dekker.</span>&#160;&#160;&#160;&#160;Mr.&#160;Dekker serves as ARCA&#8217;s Chief Financial Officer under an Employment Agreement that was effective as of May&#160;10, 2021. Mr.&#160;Dekker has served as ARCA&#8217;s Secretary since April&#160;2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under his employment agreement, Mr.&#160;Dekker is entitled to receive an annual base salary of $270,000, subject to annual increases if approved by ARCA&#8217;s board of directors or Compensation Committee and is eligible to receive an annual target bonus of 35% of his base salary as determined by ARCA&#8217;s board of directors or Compensation Committee in its sole discretion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Dekker, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Dekker to (i)&#160;increase the aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the vesting of certain ARCA </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">165</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Dekker&#8217;s retention bonus was paid on December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter between ARCA and Mr.&#160;Dekker to increase the aggregate amount of the retention bonus by 33.33% to $200,000. The remaining portion of the retention bonus with respect to Mr.&#160;Dekker, consisting of $165,000, will become payable consistent with the original terms of the retention bonus letter and the first amendment to the retention bonus letter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA terminates Mr.&#160;Dekker&#8217;s employment without &#8220;cause,&#8221; or if Mr.&#160;Dekker terminates his employment with &#8220;good reason&#8221; (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr.&#160;Dekker a severance payment equivalent to (i)&#160;(a)&#160;12&#160;months of his base salary, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (b)&#160;six&#160;months of his base salary if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, (ii)&#160;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by ARCA&#8217;s board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&#160;reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for (x)&#160;12&#160;months, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (y)&#160;six&#160;months if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, whether he elects or is eligible to receive COBRA (provided, in either event, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12&#160;months of base salary, which additional payment would extend the covenants and obligations under Mr.&#160;Dekker&#8217;s Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&#160;Dekker of a legal release in a form acceptable to ARCA.&#160;A termination for &#8220;cause&#8221; includes Mr.&#160;Dekker&#8217;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement, or any other agreement, with ARCA. &#8220;Good reason&#8221; includes a relocation by us of Mr.&#160;Dekker&#8217;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA&#8217;s unilateral decision to significantly and detrimentally reduce Mr.&#160;Dekker&#8217;s job responsibilities.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">166</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Outstanding Equity Awards at Fiscal Year End</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal year ended December&#160;31, 2023, certain information regarding outstanding equity awards at fiscal year<span class="nobreak">-end</span> for ARCA named executive officers.</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="8" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option Awards</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>Underlying <br/>Unexercised<br/>Options<br/>(#) <br/>Exercisable</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>Underlying <br/>Unexercised<br/>Options<br/>(#) <br/>Unexercisable</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option <br/>Exercise<br/>Price<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option<br/>Expiration<br/>Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow, Former President and Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">408</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">245.70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/26/2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">84.42</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/11/2025</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,511</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59.40</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6/8/2026</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,333</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.00</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/15/2027</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">142,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.27</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/21/2030</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63,334</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,666</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer, President and Chief Operating Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">83</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">245.70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/26/2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">84.42</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/11/2025</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">866</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59.40</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6/8/2026</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,400</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.00</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/15/2027</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.27</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/21/2030</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23,334</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,666</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker, Secretary, Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,521</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,479</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.06</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5/10/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,800</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,900</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vest in 48<span class="nobreak"> </span>monthly installments measured from December&#160;21, 2020.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vest in 36<span class="nobreak"> </span>monthly installments measured from December&#160;14, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vested 25% after one year, then in 36<span class="nobreak"> </span>monthly installments measured from May&#160;10, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a change in control of ARCA, 50% of the unvested shares subject to this award shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i)&#160;the one<span class="nobreak">-year</span> anniversary of the closing date or (ii)&#160;involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">167</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">ARCA Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal year ended December&#160;31, 2023, certain information with respect to the compensation of all non<span class="nobreak">-employee</span> directors of ARCA:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Director Compensation </span><span class="Bold" style="font-style:normal;font-weight:bold;">(1)</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Fees&#160;Earned <br/>or&#160;Paid&#160;in <br/>Cash&#160;($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option <br/>Awards <br/>($)(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Nonqualified <br/>Deferred <br/>Compensation <br/>Earnings&#160;($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">All&#160;Other <br/>Compensation <br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Total&#160;($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">162,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">162,500</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Raymond L.&#160;Woosley, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">195,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">195,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dan J.&#160;Mitchell<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver<span class="Superscript" style="vertical-align:super;font-size:58%;">(8)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(9)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,000</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer, was also a director during the year ended December&#160;31, 2023, but did not receive any additional compensation for his service as a director. Dr.&#160;Bristow&#8217;s compensation as an executive officer is set forth above under &#8220;Executive Compensation&#160;&#8212;&#160;Summary Compensation Table.&#8221;</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Option Awards&#8221; in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic&#160;718, Compensation&#160;&#8212;&#160;Stock Compensation, excluding the effects of estimated forfeitures. The value of stock option awards was estimated using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The valuation assumptions used in the valuation of option grants may be found in Note&#160;8 to ARCA&#8217;s financial statements included in this annual report on Form&#160;10<span class="nobreak">-K</span> for the year ended December&#160;31, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Grais was 19,458, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Woosley was 19,458, all of which were fully vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Conway, Chairman of ARCA&#8217;s board of directors, was 19,458, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Mitchell was 19,577, all of which were fully vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Hove was 18,999, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Ma<span class="nobreak">-Weaver</span> was 18,000, of which 12,000 shares were fully vested. Includes $37,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(9)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Flynn was 12,000, of which 4,000 shares were vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(10)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>These directors resigned from ARCA&#8217;s board of directors effective February&#160;2, 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA revised its compensation plan for non<span class="nobreak">-employee</span> directors to provide that non<span class="nobreak">-employee</span> directors will be compensated for their service on ARCA&#8217;s board of directors, as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-employee</span> director will receive an annual retainer fee of $40,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>As additional compensation for their services, each non<span class="nobreak">-employee</span> director will receive (i), upon joining ARCA&#8217;s board of directors, an initial option grant to purchase 12,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan, (ii), in 2021 the members of the board of directors received a one<span class="nobreak">-time</span> retention option grant to purchase 12,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan and (iii), on an annual basis as of the date of ARCA&#8217;s annual stockholder meeting, an annual option grant to purchase 6,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan; provided that such non<span class="nobreak">-employee</span> director </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">168</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">has served on ARCA&#8217;s board of directors for at least six&#160;months prior to the date of grant (unless such six<span class="nobreak">-month</span> period is modified by recommendation of the Nominating and Corporate Governance Committee and approved by the Compensation Committee);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The Chairman of ARCA&#8217;s board of directors will receive an additional annual retainer fee of $30,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s Audit Committee chair will receive an additional annual retainer fee of $15,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The chairs of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance Committee will each receive an additional annual retainer fee of $10,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-chair</span> member of ARCA&#8217;s Audit Committee will receive an additional annual retainer fee of $7,500; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-chair</span> member of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance Committees will receive an additional annual retainer fee of $5,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;30, 2024, ARCA approved paying compensation to its existing non<span class="nobreak">-employee</span> directors, pursuant to ARCA&#8217;s Director Compensation Policy, by granting to Dr.&#160;Linda Grais, Dr.&#160;Anders Hove, Mr.&#160;Robert Conway, Mr.&#160;Daniel Mitchell, Dr.&#160;Raymond Woosley, Mr.&#160;James Flynn and Mr.&#160;Jacob Ma<span class="nobreak">-Weaver</span> options to purchase 6,000<span class="nobreak"> </span>shares of common stock at an exercise price of $1.64 per share, the closing price of ARCA&#8217;s common stock on January&#160;30, 2024. The options are subject to the terms and conditions of the Plan and ARCA&#8217;s standard forms of Stock Option Agreement and Option Grant Notice for the Plan. The options vest in 12 equal monthly installments beginning on January&#160;30, 2024, assuming Dr.&#160;Grais&#8217;, Dr.&#160;Hove&#8217;s, Mr.&#160;Conway&#8217;s, Mr.&#160;Mitchell&#8217;s, Dr.&#160;Woosley&#8217;s, Mr.&#160;Flynn&#8217;s and Mr.&#160;Ma<span class="nobreak">-Weaver</span>&#8217;s continued service on the Board for such periods.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA&#8217;s board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value. The Special Committee includes ARCA board Chairman Robert E.&#160;Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>. In December&#160;2023, based on the recommendation of the Nominating and Corporate Governance Committee, the board determined that each member of the Special Committee will be paid $7,500 per month for each month of substantive service on the Special Committee. In December&#160;2023, payments for 2022 service were made to the members of the Special Committee of $52,500 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and $37,500 to Jacob Ma<span class="nobreak">-Weaver</span> (joined the Committee in June&#160;2022). Payments for 2023 service were paid in 2024 to the members of the Special Committee consisting of $52,500 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>. Payments for 2024 service through April&#160;2024 were paid in 2024 to the members of the Special Committee consisting of $30,000 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">169</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T16"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA EQUITY COMPENSATION PLAN INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth information as of December&#160;31, 2023, for all of ARCA&#8217;s equity compensation plans:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-33" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Plan Category</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>to&#160;be&#160;Issued&#160;Upon <br/>Exercise&#160;of <br/>Outstanding <br/>Options&#160;or&#160;Upon Vesting&#160;of <br/>Restricted&#160;Stock <br/>Unit</span>s<br/><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">(a)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Weighted <br/>Average <br/>Exercise <br/>Price&#160;of <br/>Outstanding <br/>Options<br/>($)<br/>(b)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of&#160;Securities <br/>Remaining <br/>Available&#160;for <br/>Future&#160;Issuance <br/>Under&#160;Equity <br/>Compensation <br/>Plans&#160;(Excluding <br/>Securities <br/>Reflected&#160;in<br/>Column(a)) <br/>(c)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Equity compensation plans approved by security holders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">459,718</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Equity compensation plans not approved by security holders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">459,718</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;10, 2020, ARCA stockholders approved the ARCA biopharma, Inc. 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) at ARCA&#8217;s 2020 annual meeting of stockholders. The 2020 Plan is the successor to the Amended and Restated ARCA biopharma, Inc. 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;). A description of the 2020 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in this proxy statement/prospectus. The 2020 Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan; therefore, all values in the above table relate solely to the outstanding options.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;17, 2013, ARCA stockholders approved the 2013 Plan at ARCA&#8217;s 2013 annual meeting of stockholders. On June&#160;9, 2016, ARCA stockholders approved an amendment to the 2013 Plan (as amended, the &#8220;Amended 2013 Plan&#8221;). A description of the 2013 Plan and the Amended 2013 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in this proxy statement/prospectus. The Amended 2013 Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan; therefore, all values in the above table relate solely to the outstanding options.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Compensation Risks</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance results assist in mitigating excessive risk<span class="nobreak">-taking</span> that could harm the value or reward poor judgment by its executives. ARCA believes several features of its programs reflect sound risk management practices. ARCA believes it has allocated compensation among base salary and short and long<span class="nobreak">-term</span> compensation target opportunities in such a way as to not encourage excessive risk<span class="nobreak">-taking</span>. The multi<span class="nobreak">-year</span> vesting of equity awards properly accounts for the time horizon of risk. Furthermore, ARCA&#8217;s Compensation Committee assesses and monitors whether any of ARCA&#8217;s compensation policies and programs has the potential to encourage excessive risk<span class="nobreak">-taking</span> on an annual basis.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">170</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T15"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA EXECUTIVE COMPENSATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following completion of the Merger, certain executive officers of Oruka will become executive officers of the combined company. Because Oruka was not formed until 2024, there were no executive officers during 2023. This section sets forth the current compensatory arrangements for the following executive officers of Oruka as of March&#160;31, 2024, each of whom is expected to become an executive officer of the combined company.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">February&#160;26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">April&#160;30, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">April&#160;18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">March&#160;22, 2024</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Employment Agreements</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreement with Mr.&#160;Klein</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Klein are party to an employment letter agreement, pursuant to which Mr.&#160;Klein receives an annual base salary of $600,000 and a target annual bonus of 50% of his base salary, pro<span class="nobreak">-rated</span> for 2024. In connection with his entry into his employment agreement, Mr.&#160;Klein purchased 1,491,646<span class="nobreak"> </span>shares of Oruka common stock at the fair market value on the purchase date, which will vest as to 25% on February&#160;26, 2025 and in equal monthly installments for the 36&#160;months thereafter. The employment agreement also provides that Mr.&#160;Klein will receive periodic grants of stock options, subject to approval by Oruka&#8217;s board of directors, sufficient to maintain Mr.&#160;Klein&#8217;s ownership at approximately 5% on a fully<span class="nobreak">-diluted</span> basis until Oruka has raised an aggregate of $200&#160;million in financing. Any such stock options will vest in equal monthly installments over 48&#160;months.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of Mr.&#160;Klein&#8217;s termination by Oruka without cause prior to (or more than 12&#160;months following) a change in control of Oruka, Mr.&#160;Klein is eligible for the following severance benefits, subject to his execution and non<span class="nobreak">-revocation</span> of a release of claims: (i)&#160;severance payments equal to 12&#160;months of his base salary, (ii)&#160;any earned but unpaid bonus for the year preceding the date of termination, (iii)&#160;accelerated vesting of 30% of the unvested portion of any outstanding time<span class="nobreak">-based</span> equity awards, and (iv)&#160;Oruka<span class="nobreak">-subsidized</span> continuation coverage under Oruka&#8217;s group health plans for up to 12&#160;months. If Mr.&#160;Klein is terminated by Oruka without cause or by Mr.&#160;Klein for good reason on or within 12&#160;months following a change in control of Oruka, Mr.&#160;Klein will receive the foregoing benefits, as well as full acceleration of all outstanding time<span class="nobreak">-based</span> equity awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements with Other Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Quinlan are party to an employment letter agreement, pursuant to which Mr.&#160;Quinlan receives an annual base salary of $460,000 and a target annual bonus of 40% of his base salary, pro<span class="nobreak">-rated</span> for 2024. Mr.&#160;Quinlan&#8217;s employment agreement also provided for an initial grant of stock options to purchase 400,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of his start date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Dr. Goncalves are party to an employment letter agreement, pursuant to which Dr. Goncalves receives an annual base salary of $460,000 and a target annual bonus of 40% of her base salary, pro<span class="nobreak">-rated</span> for 2024. In connection with her appointment, Dr. Goncalves was granted stock options to purchase 400,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of her start date and in equal monthly installments for the 36&#160;months thereafter. The employment agreement also provided for a $100,000 signing bonus, which is subject to pro<span class="nobreak">-rata</span> repayment if Dr. Goncalves is terminated for cause or resigns within one year following her start date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Agarwal are party to an employment letter agreement, pursuant to which Mr.&#160;Agarwal receives an annual base salary of $360,000 and a target annual bonus of 35% of his base salary. Mr.&#160;Agarwal&#8217;s employment agreement also provided for an initial grant of stock options to purchase 225,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of his start date and in equal monthly installments for the 36&#160;months thereafter.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">171</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The employment agreements with Messrs. Quinlan and Agarwal and Dr. Goncalves provide for the following severance benefits upon their termination by Oruka without cause prior to (or more than 12&#160;months following) a change in control of Oruka, subject to the executive&#8217;s execution and non<span class="nobreak">-revocation</span> of a release of claims: (i)&#160;severance payments equal to six&#160;months of the executive&#8217;s base salary, (ii)&#160;any earned but unpaid bonus for the year preceding the date of termination and (iii)&#160;Oruka<span class="nobreak">-subsidized</span> continuation coverage under Oruka&#8217;s group health plans for up to six&#160;months. If the executive is terminated by Oruka without cause or by the executive for good reason on or within 12&#160;months following a change in control of Oruka, the executive will receive the foregoing benefits, as well as full acceleration of all outstanding time<span class="nobreak">-based</span> equity awards.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary Description of Oruka&#8217;s 2024 Equity Incentive Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka maintains the 2024 Equity Incentive Plan, the purpose of which is to advance the interests of Oruka&#8217;s stockholders by enhancing Oruka&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to Oruka and by providing such persons with equity ownership opportunities and performance<span class="nobreak">-based</span> incentives that are intended to better align the interests of such persons with those of Oruka&#8217;s stockholders. The 2024 Equity Incentive Plan provides for the issuance of up to 872,912<span class="nobreak"> </span>shares of Oruka common stock, which may be granted as stock options, restricted stock, restricted stock units and other stock<span class="nobreak">-based</span> awards to eligible employees, officers, directors, consultants and advisors of Oruka on such terms and conditions as approved by Oruka&#8217;s board of directors or any committee appointed by Oruka&#8217;s board of directors to administer the 2024 Equity Incentive Plan. No grants will be made under the 2024 Equity Incentive Plan following consummation of the Merger.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">172</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T14"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA DIRECTOR COMPENSATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka was not formed until 2024, there were no directors during 2023. In connection with his appointment as a member of Oruka&#8217;s board of directors, Dr.&#160;Kulkarni entered into a letter agreement, pursuant to which he received: (i)&#160;stock options to purchase 250,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter; and (ii)&#160;stock options to purchase 100,000<span class="nobreak"> </span>shares of Oruka common stock, which vest upon the first anniversary of the date Dr.&#160;Kulkarni is appointed Chairman of Oruka&#8217;s board of directors and will be forfeited if Dr.&#160;Kulkarni is not appointed Chairman of Oruka&#8217;s board of directors prior to March&#160;22, 2025. In connection with her appointment as a member of Oruka&#8217;s board of directors, Ms. Ball entered into a letter agreement, pursuant to which she received stock options to purchase 125,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of her appointment date and in equal monthly installments for the 36&#160;months thereafter. In connection with his appointment as a member of Oruka&#8217;s board of directors, Mr.&#160;Dambkowski received stock options to purchase 125,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In anticipation of his service on the Oruka board of directors, Dr.&#160;Turtle purchased 149,164<span class="nobreak"> </span>shares of Oruka common stock at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is expected that Oruka will implement cash retainers for all non<span class="nobreak">-employee</span> directors, including an annual cash retainer.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">173</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9980"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MATTERS BEING SUBMITTED TO A VOTE OF ARCA STOCKHOLDERS </span></p>
		<a id="T9981"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 1&#160;&#8212;&#160;THE NASDAQ STOCK ISSUANCE PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve (i)&#160;the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to the stockholders of Oruka pursuant to the Merger Agreement, which shares of ARCA common stock will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the First Merger and (ii)&#160;the change of control of ARCA resulting from the First Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the First Merger, ARCA securityholders as of immediately prior to the First Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down, including if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will assume outstanding and unexercised options and warrants to purchase shares of Oruka common stock, and such securities will be converted into options and warrants, as applicable, to purchase shares of ARCA common stock, subject to certain adjustments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The terms of, reasons for and other aspects of the Merger Agreement and the Merger are described in detail in the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>.&#8221; A copy of the Merger Agreement is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reason for the Proposal</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Nasdaq Listing Rule&#160;5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock, among other things, in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess of 20% of the number of shares of common stock then outstanding. The potential issuance of the shares of ARCA common stock in the Merger exceeds the 20% under the Nasdaq Listing Rules and is expected to represent approximately 97.61% of ARCA common stock on a fully<span class="nobreak">-diluted</span> basis immediately following the Merger. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(a)(1), ARCA must obtain the approval of ARCA stockholders for the issuance of these shares of common stock in the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Nasdaq Listing Rule&#160;5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of stock that will result in a &#8220;change of control&#8221; of the listed company. It is expected that Nasdaq will determine that the Merger constitutes a &#8220;change of control&#8221; of the listed company. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(b), ARCA must obtain the approval of ARCA stockholders of the change of control resulting from the Merger.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">174</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting is required to approve the Nasdaq Stock Issuance Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Nasdaq Stock Issuance Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Nasdaq Stock Issuance Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is conditioned upon the approval of the Nasdaq Stock Issuance Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nasdaq Stock Issuance Proposal is conditioned on the approval of the Authorized Share Increase Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Authorized Share Increase Proposal is not approved, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected and the Merger will not be consummated.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Nasdaq Stock Issuance Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 151 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Nasdaq Stock Issuance Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE NASDAQ STOCK ISSUANCE PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">175</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9982"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 2&#160;&#8212;&#160;THE AUTHORIZED SHARE INCREASE PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve an amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock (the &#8220;ARCA Share Increase Amendment&#8221;). On<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, ARCA&#8217;s board of directors approved a proposal to amend the ARCA Charter to increase the number of authorized shares of ARCA common stock from 100,000,000<span class="nobreak"> </span>shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, which would also have the effect of increasing the total number of authorized shares from 105,000,000, including ARCA preferred stock, to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(the &#8220;ARCA Share Increase&#8221;), in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus. On the Record Date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock issued and outstanding, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock reserved for issuance. Accordingly, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the total number of ARCA common stock currently authorized remain available for issuance or may be reserved for issuance.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Form of the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Share Increase Amendment would amend and restate the first paragraph of Article&#160;IV of the ARCA Charter in its entirety as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">&#8220;The total number of shares of all classes of stock this Corporation shall have authority to issue is<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, consisting of&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of Common Stock, par value $0.001 per share, and 5,000,000<span class="nobreak"> </span>shares of Preferred Stock, par value $0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Background and Reasons for the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter currently authorizes the issuance of up to 100,000,000<span class="nobreak"> </span>shares of ARCA common stock and 5,000,000<span class="nobreak"> </span>shares of preferred stock. As of the close of business on the Record Date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock issued and outstanding, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock reserved for issuance. Accordingly, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the total number of ARCA common stock currently authorized remain available for issuance or may be reserved for issuance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in greater detail in the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>,&#8221; pursuant to the Merger Agreement, ARCA will be required to issue shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders and to assume Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The number of shares of ARCA common stock currently authorized and unissued and not reserved for issuance is not sufficient for (i)&#160;the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement and (ii)&#160;the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock. In addition, there will not be sufficient shares of ARCA common stock available for issuance in connection with possible future acquisitions, equity and equity<span class="nobreak">-based</span> financings, possible future awards under employee benefit plans and other corporate purposes that ARCA&#8217;s board of directors may determine to be desirable. Therefore, ARCA&#8217;s board of directors has determined that the ARCA Share Increase Amendment is in the best interests of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved by stockholders, upon its effectiveness, and without giving effect to the proposed reverse stock split described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA will have a total of&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>authorized shares of ARCA common stock, with&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA common stock issued and outstanding (as of the Record Date), and&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares reserved for issuance (as of the Record Date), leaving a balance of&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA common stock authorized and unissued and not reserved for any specific purpose. The ARCA Share Increase Amendment will have no effect on the authorized shares of ARCA Preferred Stock.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">176</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except for (i)&#160;the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and (ii)&#160;the issuance of shares of ARCA common stock that may result from the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock, each pursuant to the terms of the Merger Agreement, ARCA does not currently have any plans, proposals or arrangement to issue any of its authorized but unissued shares of common stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Possible Effects of the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved and becomes effective, the additional authorized shares would be available for issuance at the discretion of ARCA&#8217;s board of directors and without further stockholder approval, except as may be required by law or Nasdaq rules. The additional shares of authorized ARCA common stock would have the same rights and privileges as the shares of ARCA common stock currently issued and outstanding. Holders of ARCA common stock have no preemptive rights. The ARCA Share Increase would not change the number of shares of common stock outstanding, nor will it have any immediate dilutive effect; however, the issuance of additional shares of ARCA common stock authorized by the ARCA Share Increase may, among other things, have a dilutive effect on earnings per share and on stockholders&#8217; equity and voting rights. Furthermore, future sales of substantial amounts of ARCA common stock, or the perception that these sales might occur, could adversely affect the prevailing market price of ARCA common stock or limit ARCA&#8217;s ability to raise additional capital. ARCA stockholders should recognize that, as a result of this proposal, they will own a smaller percentage of shares relative to the total authorized shares of the company than they presently own.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal or Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the ARCA Share Increase Amendment or the ARCA Share Increase.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Effectiveness of Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved by the stockholders at the ARCA special meeting, it will become effective upon the filing of a certificate of amendment, a copy of which is attached as&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G&#160;</span>to this proxy statement/prospectus, with the Delaware Secretary of State or such later effective date and time as specified in the certificate of amendment in accordance with Delaware law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Copies of the ARCA Charter and the certificates of amendment to the ARCA Charter are available as exhibits to this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the votes properly cast for or against the Authorized Share Increase Proposal by the holders of ARCA common stock is required to approve the Authorized Share Increase Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Authorized Share Increase Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nasdaq Stock Issuance Proposal and the Merger are conditioned upon the approval of the Authorized Share Increase Proposal. In order to have an adequate number of available shares to effect the Merger, the stockholders of ARCA will need to approve the Authorized Share Increase Proposal. Additionally, ARCA&#8217;s board of directors may determine to effect the Authorized Share Increase Proposal, if approved, even if the Nasdaq Stock Issuance Proposal is not approved by the ARCA stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Authorized Share Increase Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 151 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Authorized Share Increase Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUTHORIZED SHARE INCREASE PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">177</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9983"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 3&#160;&#8212;&#160;THE REVERSE STOCK SPLIT PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range of<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span class="nobreak">-for</span>-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span class="nobreak">-for</span>-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, to be determined mutually by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors (the &#8220;Split Ratio&#8221;). The final Split Ratio and effectiveness of such amendment and the abandonment of such amendment will be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time, assuming this proposal is approved by ARCA&#8217;s stockholders. On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, ARCA&#8217;s board of directors adopted resolutions approving the proposed certificate of amendment to the ARCA Charter in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to this proxy statement/prospectus. If this certificate of amendment is filed with the Secretary of State of the State of Delaware, upon its effectiveness (the &#8220;reverse stock split effective time&#8221;), it will effect the reverse stock split by the Split Ratio but will not increase the par value of ARCA common stock. At the reverse stock split effective time, the issued and outstanding shares of ARCA common stock immediately prior to the reverse stock split effective time will automatically without further action on the part of ARCA be combined into a smaller number of shares in accordance with the final Split Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">By approving the Reverse Stock Split Proposal, ARCA stockholders will approve the amendment to the ARCA Charter pursuant to which any whole number of issued and outstanding shares of ARCA common stock, between and including<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, would be combined into one share of ARCA common stock, and will authorize ARCA&#8217;s board of directors to file the certificate of amendment. As of the Record Date, 100,000,000<span class="nobreak"> </span>shares of ARCA common stock were authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock were outstanding and no shares of ARCA common stock were held in treasury.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA common stock or preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All holders of ARCA common stock will be affected proportionately by the reverse stock split. No fractional shares of ARCA common stock will be issued as a result of the reverse stock split. Instead, ARCA stockholders who otherwise would be entitled to receive fractional shares will be entitled to receive cash as set forth below under the caption &#8220;No Fractional Shares.&#8221; Each ARCA stockholder will hold the same percentage of the outstanding ARCA common stock immediately following the reverse stock split as that ARCA stockholder did immediately prior to the reverse stock split, except to the extent that the reverse stock split results in ARCA stockholders receiving cash in lieu of fractional shares.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reasons for the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors approved the proposal approving the amendment to the ARCA Charter effecting the reverse stock split for the following reasons:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes effecting the reverse stock split will result in an increase in the minimum bid price of ARCA common stock and reduce the risk of a delisting of ARCA common stock from Nasdaq in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes a higher stock price may help generate investor interest in ARCA, and ultimately the combined company, and help ARCA attract and retain employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes a higher stock price may increase trading volume in ARCA common stock and facilitate future financings by the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes that the resulting increase in the number of authorized and unissued shares available for future issuance will be necessary for the issuance of shares to the stockholders of Oruka pursuant to the Merger Agreement, as described in the Nasdaq Stock Issuance Proposal, the issuance of shares of ARCA common stock that may result from the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock, pursuant to the Merger Agreement, and ultimately the consummation of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes that a range of reverse stock split ratios provides it with the most flexibility to achieve the desired results of the reverse stock split.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">178</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Requirements for Listing on Nasdaq</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application pursuant to the terms of the Merger Agreement for the combined company to list the securities of the combined company on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the Nasdaq rules, an issuer must, in a case such as this, apply for initial inclusion following a transaction whereby the issuer combines with a non<span class="nobreak">-Nasdaq</span> entity, resulting in a change of control of the issuer and potentially allowing the non<span class="nobreak">-Nasdaq</span> entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require ARCA to have, among other things, a $4.00 per share minimum bid price for a certain number of&#160;trading days preceding the closing of the Merger. Therefore, the reverse stock split may be necessary in order to satisfy Nasdaq requirements and consummate the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, it is a condition to the closing of the Merger that the shares of ARCA common stock to be issued in the Merger pursuant to the Merger Agreement have been approved for listing on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of the effects of the reverse stock split will be to effectively increase the proportion of authorized shares which are unissued relative to those which are issued. This could result in ARCA&#8217;s management being able to issue more shares without further stockholder approval. The reverse stock split will not affect the number of authorized shares of ARCA capital stock, which will continue to be authorized pursuant to the ARCA Charter.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Increased Investor Interest</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:0pt;text-indent:24pt;margin-top:8pt;">On<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, ARCA common stock closed at $&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>per share. An investment in ARCA common stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower priced stocks. Also, ARCA&#8217;s board of directors believes that most investment funds are reluctant to invest in lower priced stocks.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There are risks associated with the reverse stock split, including that the reverse stock split may not result in an increase in the per share price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA cannot predict whether the reverse stock split will increase the market price for ARCA common stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share of ARCA common stock after the reverse stock split will rise in proportion to the reduction in the number of shares of ARCA common stock outstanding before the reverse stock split;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the reverse stock split will result in a per share price that will increase the ability of ARCA to attract and retain employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq for continued listing; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share will achieve and maintain the $4.00 minimum bid price requirement for a sufficient period of time for the combined company&#8217;s common stock to be approved for listing by Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of ARCA common stock will also be based on the performance of ARCA, and after the Merger, on the performance of the combined company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price of ARCA common stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of ARCA may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity of ARCA common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">179</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effects of the Reverse Stock Split</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the reverse stock split is implemented, after the reverse stock split effective time, the issued and outstanding shares of ARCA common stock immediately prior to the reverse stock split effective time will automatically, without further action on the part of ARCA, be combined into a smaller number of shares proportionately based on the Split Ratio and each ARCA stockholder will own a reduced number of shares of ARCA common stock. The reverse stock split will affect all ARCA stockholders uniformly and will not affect any stockholder&#8217;s percentage ownership interests in ARCA, except that ARCA stockholders who would have otherwise received fractional shares will receive cash in lieu of such fractional shares. After the reverse stock split, each share of ARCA common stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to the ARCA common stock now authorized, and ARCA common stock issued pursuant to the reverse stock split will remain fully paid and non<span class="nobreak">-assessable</span>. The reverse stock split is not intended as, and will not have the effect of, a &#8220;going private transaction&#8221; covered by&#160;Rule&#160;13e<span class="nobreak">-3</span>&#160;under the&#160;Exchange&#160;Act. ARCA will continue to be subject to the periodic reporting requirements of the&#160;Exchange&#160;Act.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on Shares of ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the reverse stock split effective time, ARCA common stock would have a new committee on uniform securities identification procedures number, which is used to identify ARCA common stock. ARCA common stock is currently registered under Section&#160;12(b)&#160;of the&#160;Exchange&#160;Act&#160;and ARCA is subject to the periodic reporting and other requirements of the&#160;Exchange&#160;Act.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on ARCA Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA preferred stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Reduction in Stated Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not affect the par value of ARCA common stock. As a result, after the reverse stock split effective time, the stated capital on ARCA&#8217;s balance sheet attributable to ARCA common stock will be reduced proportionately based on the Split Ratio, subject to a minor adjustment in respect of the treatment of fractional shares, and the additional paid<span class="nobreak">-in</span> capital account will be credited with the amount by which the stated capital is reduced. ARCA stockholders&#8217; equity, in the aggregate, will remain unchanged.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on Equity Plans and Outstanding Derivative and Convertible Securities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Proportionate adjustments will be made to the per share exercise price, the number of shares issuable upon the exercise, vesting or settlement of all outstanding options and warrants to purchase or acquire, as applicable, shares of ARCA common stock, and the number of shares reserved for issuance pursuant to ARCA&#8217;s existing equity incentive, stock option and employee stock purchase plans will be reduced proportionately based on the Split Ratio.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If (i)&#160;the ARCA stockholders approve the Nasdaq Stock Issuance Proposal and the Reverse Stock Split Proposal, (ii)&#160;ARCA&#8217;s board of directors and Oruka&#8217;s board of directors mutually agree that a reverse stock split is necessary, and (iii)&#160;ARCA&#8217;s board of directors still believes that a reverse stock split is in the best interests of ARCA and its stockholders, ARCA will file the certificate of amendment to the ARCA Charter with the Secretary of State of the State of Delaware at such time as ARCA&#8217;s board of directors has determined to be the appropriate reverse stock split effective time at the Split Ratio. If the Reverse Stock Split Proposal is approved and the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, ARCA&#8217;s board of directors and Oruka&#8217;s board of directors may mutually agree to delay effecting the reverse stock split without resoliciting stockholder approval or abandon effecting the reverse stock split; otherwise, ARCA&#8217;s board of directors may, in its sole discretion, delay without </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">180</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">resolicitation of stockholder approval or abandon effecting the reverse stock split. Beginning at the reverse stock split effective time, each stock certificate representing pre<span class="nobreak">-split</span> shares will be deemed for all corporate purposes to evidence ownership of post<span class="nobreak">-split</span> shares.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Beneficial Owners of Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the implementation of the reverse stock split, ARCA intends to treat shares held by stockholders in &#8220;street name&#8221; (i.e., through a bank, broker, custodian or other nominee), in the same manner as registered stockholders whose shares are registered in their names. Banks, brokers, custodians or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding ARCA common stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the reverse stock split and making payment for fractional shares. If a stockholder holds shares of ARCA common stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Registered Holders of Common Stock in Book-Entry Form</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of ARCA&#8217;s registered holders of common stock hold some or all of their shares electronically in book<span class="nobreak">-entry</span> form with ARCA&#8217;s transfer agent,<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>Computershare Trust Company, N.A.&#160;These stockholders do not hold physical stock certificates evidencing their ownership of ARCA common stock. However, they are provided with a statement reflecting the number of<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>shares of ARCA common stock registered in their accounts. If a stockholder holds registered shares in book<span class="nobreak">-entry</span> form with ARCA&#8217;s transfer agent, no action needs to be taken to receive post<span class="nobreak">-reverse</span> stock split shares or payment in lieu of fractional shares, if applicable. If a stockholder is entitled to post<span class="nobreak">-reverse</span> stock split shares, a transaction statement will automatically be sent to the stockholder&#8217;s address of record indicating the number of shares of ARCA common stock held following the reverse stock split.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Registered Holders of Common Stock in Certificate Form</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As soon as practicable after the reverse stock split effective time, the ARCA stockholders will be notified that the reverse stock split has been effected. ARCA expects that the ARCA transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders of pre<span class="nobreak">-split</span> shares will be asked to surrender to the exchange agent certificates representing pre<span class="nobreak">-split</span> shares held in certificated form in exchange for certificates representing post<span class="nobreak">-split</span> shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by ARCA.&#160;No new certificates will be issued to a stockholder until such stockholder has surrendered such stockholder&#8217;s outstanding certificate(s)&#160;together with the properly completed and executed letter of transmittal to the exchange agent. Any pre<span class="nobreak">-split</span> shares submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged for post<span class="nobreak">-split</span> shares.&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders should not destroy any stock certificate(s)&#160;and should not submit any certificate(s)&#160;unless and until requested to do so</span><span class="Italic" style="font-style:italic;font-weight:normal;">.</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">No Fractional Shares</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No fractional shares will be issued in connection with the reverse stock split. Stockholders of record who otherwise would be entitled to receive fractional shares because they hold a number of pre<span class="nobreak">-split</span> shares not evenly divisible by the number of pre<span class="nobreak">-split</span> shares for which each post<span class="nobreak">-split</span> share is to be reclassified, will be entitled, upon surrender to the exchange agent of certificates representing such shares, to a cash payment in lieu thereof at a price equal to the fraction of a share to which the stockholder would otherwise be entitled multiplied by the closing price of the common stock on Nasdaq on the date of the filing of the certificate of amendment to the ARCA Charter effecting the reverse stock split. For the foregoing purposes, all shares of common stock held by a holder will be aggregated (thus resulting in no more than one fractional share per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefor as described herein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where ARCA is domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by ARCA or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">181</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Anti-Takeover Effect</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti<span class="nobreak">-takeover</span> effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of ARCA&#8217;s board of directors or contemplating a tender offer or other transaction for the combination of ARCA with another company, the reverse stock split is not being proposed in response to any effort of which ARCA is aware to accumulate shares of ARCA common stock or obtain control of ARCA, other than in connection with the Merger, nor is it part of a plan by management to recommend a series of similar amendments to ARCA&#8217;s board of directors and stockholders. Other than the proposals being submitted to the ARCA stockholders for their consideration at the ARCA special meeting, ARCA&#8217;s board of directors does not currently contemplate recommending the<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>adoption of any other actions that could be construed to affect the ability of third parties to take over or change<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>control of ARCA.&#160;For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to the Combined Company</span>&#8221; beginning on page 79 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a discussion of material U.S.&#160;federal income tax consequences of the reverse stock split that are applicable to a U.S.&#160;holder (as defined below) of ARCA common stock. This discussion applies only to a U.S.&#160;holder that holds its ARCA common stock as a capital asset for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or U.S.&#160;holders with special status including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pass<span class="nobreak">-through</span> entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold their shares of ARCA common stock that constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their ARCA common stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their ARCA common stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof and all of which are subject to change, which change could apply retroactively and could affect the tax consequences described herein. This discussion does not address (i)&#160;the tax consequences of the reverse stock split under U.S.&#160;federal non<span class="nobreak">-income</span> tax law (including estate, gift, or other non<span class="nobreak">-income</span> taxes), (ii)&#160;the tax consequences of the reverse stock split under state, local or non<span class="nobreak">-U</span>.S.&#160;tax laws, (iii)&#160;the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations) or the Medicare contribution tax on net investment income, or (iv)&#160;the tax consequences of transactions effectuated before, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">182</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">subsequent to or concurrently with the reverse stock split (whether or not any such transactions are consummated in connection with the reverse stock split), including, any transaction in which shares of ARCA common stock are acquired.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have not and do not intend to seek any rulings from the IRS regarding the reverse stock split. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds ARCA common stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Each partnership holding any ARCA common stock and each person that is treated as a partner of such partnerships is urged to consult its tax advisor as to the particular U.S.&#160;federal income tax consequences of the reverse stock split.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of ARCA common stock that is for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual citizen or resident of the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is classified as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof, or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treatment of U.S.&#160;Holders in the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA intends to treat the reverse stock split as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Assuming the reverse stock split so qualifies, a U.S.&#160;holder generally will not recognize gain or loss upon the reverse stock split. A U.S.&#160;holder&#8217;s aggregate tax basis in the shares of ARCA common stock received pursuant to the reverse stock split will equal the aggregate tax basis of the shares of the ARCA common stock surrendered, and such U.S.&#160;holder&#8217;s holding period in the shares of ARCA common stock received will include the holding period in the shares of ARCA common stock surrendered. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of ARCA common stock surrendered for the shares of ARCA common stock received in a recapitalization pursuant to the reverse stock split. If a U.S.&#160;holder holds different blocks of ARCA common stock (generally, ARCA common stock acquired on different dates or at different prices), such U.S.&#160;holder is urged to consult its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of ARCA common stock received in the reverse stock split.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder that receives cash in lieu of a fractional share of ARCA common stock pursuant to the reverse stock split will generally recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S.&#160;holder&#8217;s tax basis in the shares of ARCA common stock surrendered that is allocated to such fractional share of ARCA common stock. Any such gain or loss will be long<span class="nobreak">-term</span> capital gain or loss if, as of the effective time of the reverse stock split, the U.S.&#160;holder&#8217;s holding period for such fractional share exceeds one year. Long<span class="nobreak">-term</span> capital gains of certain non<span class="nobreak">-corporate</span> taxpayers, including individuals, are generally taxed at preferential rates. The deductibility of capital losses is subject to limitations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming the reverse stock split qualifies as a recapitalization within the meaning of Section&#160;368(a)&#160;of the Code, each U.S.&#160;holder who receives shares of ARCA common stock in the reverse stock split is required to retain permanent records pertaining to the reverse stock split and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">183</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">as part of such reorganization. Each U.S.&#160;holder who owned immediately before the reverse stock split at least five percent (by vote or value) of the total outstanding stock of ARCA is required to attach a statement to its tax return for the year in which the reverse stock split is consummated that contains the information listed in Treasury Regulation&#160;Section&#160;1.368<span class="nobreak">-3</span>(b). Such statement must include the U.S.&#160;holder&#8217;s tax basis in such holder&#8217;s ARCA common stock surrendered in the reverse stock split, the fair market value of such stock, the date of the reverse stock split and the name and employer identification number of ARCA.&#160;Each U.S.&#160;holder is urged to consult with its tax advisor to comply with these rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder may be subject to information reporting and backup withholding for U.S.&#160;federal income tax purposes on cash paid in lieu of fractional shares in connection with the reverse stock split. Backup withholding will not apply, however, to a U.S.&#160;holder who (i)&#160;furnishes a correct taxpayer identification number and certifies the holder is not subject to backup withholding on IRS Form&#160;W<span class="nobreak">-9</span> or a substantially similar form, or (ii)&#160;certifies the holder is otherwise exempt from backup withholding. If a U.S.&#160;holder does not provide a correct taxpayer identification number on IRS Form&#160;W<span class="nobreak">-9</span> or other proper certification, the stockholder may be subject to penalties imposed by the IRS.&#160;Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the federal income tax liability of a U.S.&#160;holder of ARCA common stock, if any, provided the required information is timely furnished to the IRS.&#160;U.S.&#160;holders should consult their tax advisors regarding their qualification for an exemption from backup withholding, the procedures for obtaining such an exemption, and in the event backup withholding is applied, to determine if any tax credit, tax refund or other tax benefit may be obtained.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">This discussion of U.S.&#160;federal income tax considerations of the reverse stock split is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the reverse stock split to you may be complex and will depend on your specific situation and on factors that are not within ARCA&#8217;s knowledge or control. You should consult your tax advisor with respect to the application of U.S.&#160;federal income tax laws to your specific situation as well as any tax consequences arising under the U.S.&#160;federal estate or gift tax rules or under the laws of any state, local, non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-U</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">.S.&#160;or other taxing jurisdiction.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal or Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the proposed amendment to the ARCA Charter to effect the reverse stock split.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the votes properly cast for or against the Reverse Stock Split Proposal by the holders of ARCA common stock is required to approve the Reverse Stock Split Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Reverse Stock Split Proposal. Additionally, ARCA&#8217;s board of directors may determine to effect the Reverse Stock Split Proposal, if approved, even if Proposal&#160;No. 1 is not approved by the ARCA stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Reverse Stock Split Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on&#160;page 151 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE REVERSE STOCK&#160;SPLIT&#160;PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">184</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9984"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 4&#160;&#8212;&#160;THE OFFICER EXCULPATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;102(b)(7)&#160;of the DGCL was amended effective August&#160;1, 2022 to authorize exculpation of certain officers of Delaware corporations (the &#8220;Section&#160;102(b)(7)&#160;Amendment&#8221;). Specifically, the amendments extend the opportunity for Delaware corporations to exculpate their officers, in addition to their directors, for personal liability for breach of the duty of care in certain actions (the &#8220;officer exculpation&#8221;). This provision would not exculpate officers from liability for breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or any transaction in which the officer derived an improper personal benefit. Nor would this provision exculpate such officers from liability for claims brought by or in the right of the corporation, such as derivative claims.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors believes it is necessary to provide protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Similar protection has long been afforded to directors. Accordingly, ARCA&#8217;s board of directors believes that the proposal to extend exculpation to officers is fair and in the best interests of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A copy of the proposed form of certificate of amendment to the ARCA Charter to effect the officer exculpation is attached as<span class="Italic" style="font-style:italic;font-weight:normal;"> Annex&#160;I</span> to this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors may determine to effect the officer exculpation, if it is approved by the stockholders, even if the other proposals to be acted upon at the meeting are not approved, including the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal. In addition, notwithstanding approval of this proposal by ARCA stockholders, ARCA&#8217;s board of directors may, in its sole discretion, abandon the proposed amendment and determine prior to the effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the officer exculpation, as permitted under Section&#160;242(c)&#160;of the DGCL.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reasons for the Proposal</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors desires to amend the ARCA Charter to maintain provisions consistent with the governing statutes contained in the DGCL, as it may be amended from time to time. Prior to the Section&#160;102(b)(7) Amendment, Delaware law has permitted Delaware corporations to exculpate directors from personal liability for monetary damages associated with breaches of the duty of care, but that protection did not extend to a Delaware corporation&#8217;s officers. Consequently, stockholder plaintiffs have employed a tactic of bringing certain claims that would otherwise be exculpated if brought against directors, against individual officers to avoid dismissal of such claims. The Section&#160;102(b)(7)&#160;Amendment was adopted to address inconsistent treatment between officers and directors and address rising litigation and insurance costs for stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As is currently the case with directors under the ARCA Charter, this provision would not exculpate officers from liability for breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or any transaction in which the officer derived an improper personal benefit. Nor would this provision exculpate such officers from liability for claims brought by or in the right of the corporation, such as derivative claims. ARCA&#8217;s board of directors believes it is necessary to provide protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Similar protection has long been afforded to directors, and accordingly, ARCA&#8217;s board of directors believes that this proposal which would extend exculpation to officers, as specifically permitted by the Section&#160;102(b)(7)&#160;Amendment, is fair and in the best interests of ARCA and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the outstanding shares of ARCA common stock is required to approve the Officer Exculpation Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Officer Exculpation Proposal.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">185</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Officer Exculpation Proposal. If the Merger is not consummated for any reason, the actions contemplated by the Officer Exculpation Proposal may still be effected if the Officer Exculpation Proposal is approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Officer Exculpation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE OFFICER EXCULPATION&#160;PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">186</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9985"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 5&#160;&#8212;&#160;THE DIRECTOR ELECTION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors currently consists of five members. In accordance with the terms of the ARCA Charter and ARCA Bylaws, ARCA&#8217;s board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with members of each class serving staggered three<span class="nobreak">-year</span> terms. The members of the classes are divided as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;I directors are James Flynn, Linda Grais, M.D. and Anders Hove, M.D., whose terms will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2025;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;II director is Robert E.&#160;Conway, whose term will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2026; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;III director is Jacob Ma<span class="nobreak">-Weaver</span>, whose term will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the expiration of the term of a class of ARCA&#8217;s board of directors, any director in that class will be eligible to be elected for a new three<span class="nobreak">-year</span> term at the annual meeting of stockholders in the year in which their term expires.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter and ARCA Bylaws provide that the authorized number of directors shall not be less than two nor more than ten and may be changed only by resolution of ARCA&#8217;s board of directors. ARCA Bylaws also provide that ARCA&#8217;s directors may be removed only for cause by the affirmative vote of the holders of at least two<span class="nobreak">-thirds</span> of the voting rights of the shares of capital stock then entitled to vote in an annual election of directors, and that any vacancy on ARCA&#8217;s board of directors, including a vacancy resulting from an increase in the size of ARCA&#8217;s board of directors, may be filled only by vote of a majority of its directors then in office.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has nominated Jacob Ma<span class="nobreak">-Waver</span> for election as a Class&#160;III director at the ARCA special meeting. Mr.&#160;Ma<span class="nobreak">-Weaver</span> is currently a director and has consented to continue to serve as a director if elected. If Mr.&#160;Ma<span class="nobreak">-Weaver</span> becomes unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA stockholders should understand, however, that if the Merger is consummated, the approval of the director nominee named in the Director Election Proposal will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. Following the Merger, the combined company&#8217;s board of directors will consist of six members designated by Oruka, including Carl Dambkowski, Peter Harwin, Lawrence Klein, Samarth&#160;Kulkarni, Cameron Turtle and Kristine Ball. All of ARCA&#8217;s current directors are expected to resign from their positions as directors of ARCA, effective as of the closing of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The nominee for Class&#160;III director who receives the most votes properly cast (also known as a plurality) will be elected. You may either vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the nominee or &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">WITHHOLD</span>&#8221; your vote from the nominee. Withheld votes and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Director Election Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the election of the director nominee named in the Director Election Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the election of the director nominee named in the Director Election Proposal. However, if the nominee is unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominee as ARCA&#8217;s board of directors may designate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE DIRECTOR NOMINEE NAMED IN THE DIRECTOR ELECTION PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">187</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9986"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 6&#160;&#8212;&#160;THE AUDITOR RATIFICATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to ratify the appointment by the audit committee of ARCA&#8217;s board of directors (the &#8220;ARCA audit committee&#8221;) of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for the fiscal year ending December&#160;31, 2024 if the Merger is completed. KPMG LLP has served as ARCA&#8217;s independent registered public accounting firm since 2006.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA audit committee is solely responsible for selecting ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024. Stockholder approval is not required to appoint KPMG LLP as ARCA&#8217;s independent registered public accounting firm. However, ARCA&#8217;s board of directors believes that submitting the selection of KPMG LLP to ARCA stockholders for ratification is good corporate governance. If ARCA stockholders do not ratify this appointment, the ARCA audit committee will reconsider whether to retain KPMG LLP.&#160;If the selection of KPMG LLP is ratified, the ARCA audit committee, at its discretion, may direct the selection of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A representative of KPMG LLP is expected to be present at the ARCA special meeting and will have an opportunity to make a statement if he or she desires to do so and to respond to appropriate questions from ARCA stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the Auditor Ratification Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Auditor Ratification Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUDITOR RATIFICATION PROPOSAL, PROVIDED THAT PRICEWATERHOUSECOOPERS LLP IS EXPECTED TO BE APPOINTED FOR THE FISCAL YEAR ENDING DECEMBER</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2024 IF THE MERGER IS COMPLETED.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">188</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9992"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 7</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE STOCK PLAN PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;2024 Stock Plan&#8221;) to be effective on the closing date of the Merger. The 2024 Stock Plan was approved by ARCA&#8217;s board of directors on<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, subject to stockholder approval. If the 2024 Stock Plan is approved by stockholders, no further awards will be granted under the 2020 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purpose of the 2024 Stock Plan is to promote and closely align the interests of employees, officers, non<span class="nobreak">-employee</span> directors and individual consultants of the combined company and its stockholders by providing stock<span class="nobreak">-based</span> compensation and other performance<span class="nobreak">-based</span> compensation. The objectives of the 2024 Stock Plan are to attract and retain the best available employees, officers, non<span class="nobreak">-employee</span> directors and individual consultants for positions of substantial responsibility and to motivate participants to optimize the profitability and growth of the combined company through incentives that are consistent with the combined company&#8217;s goals and that link the personal interests of participants to those of the combined company&#8217;s stockholders. The 2024 Stock Plan allows for the grant of stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted stock, restricted stock units (&#8220;RSUs&#8221;), other stock<span class="nobreak">-based</span> awards and incentive bonuses (collectively, &#8220;Awards&#8221;).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary of the 2024 Stock Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following description of the 2024 Stock Plan is not intended to be complete and is qualified in its entirety by the complete text of the 2024 Stock Plan, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;K</span> to this proxy statement. Stockholders are urged to read the 2024 Stock Plan in its entirety.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Federal Income Tax Consequences</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of the U.S.&#160;federal income tax treatment applicable to the combined company and the participants who receive Awards under the 2024 Stock Plan based on the federal income tax laws in effect on the date of this proxy statement/prospectus. This summary is not intended to be exhaustive and does not address all matters relevant to a particular participant based on their specific circumstances. The summary expressly does not discuss the income tax laws of any state, municipality, or non<span class="nobreak">-U</span>.S.&#160;taxing jurisdiction, or the gift, estate, excise (including the rules applicable to deferred compensation under Section&#160;409A of the Code), or tax laws other than U.S.&#160;federal income tax law. Because individual circumstances may vary, all participants should consult their own tax advisor concerning the tax implications of Awards granted under the 2024 Stock Plan.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Incentive Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Options granted under the 2024 Stock Plan may be either incentive stock options, which satisfy the requirements of Section&#160;422 of the Code, or non<span class="nobreak">-qualified</span> stock options, which are not intended to meet such requirements. No taxable income is recognized by the optionee at the time of the option grant, and no taxable income is recognized for ordinary income tax purposes at the time the option is exercised, although taxable income may arise at that time for alternative minimum tax purposes. Unless there is a &#8220;disqualifying disposition&#8221;, as described below, the optionee will recognize long<span class="nobreak">-term</span> capital gain in an amount equal to the excess of (i)&#160;the amount realized upon the sale or other disposition of the purchased shares over (ii)&#160;the exercise price paid for the shares. A disqualifying disposition occurs if the disposition is less than two&#160;years after the date of grant or less than one year after the exercise date. If there is a disqualifying disposition of the shares, then the excess of (i)&#160;the fair market value of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii)&#160;the exercise price paid for the shares will be taxable as ordinary income to the optionee. Any additional gain or loss recognized upon the disposition will be a capital gain or loss. If the optionee makes a disqualifying disposition of the purchased shares, then the combined company will be entitled to an income tax deduction for the taxable year in which such disposition occurs equal to the amount of ordinary income recognized by the optionee as a result of the disposition. The combined company will not be entitled to any income tax deduction if the optionee makes a qualifying disposition of the shares.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">189</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Nonqualified Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No taxable income is recognized by an optionee upon the grant of a non<span class="nobreak">-qualified</span> stock option. The optionee in general will recognize ordinary income, in the year in which the option is exercised, equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares, and the optionee will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the optionee with respect to the exercised non<span class="nobreak">-qualified</span> stock option.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Appreciation Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No taxable income is recognized upon receipt of a SAR.&#160;The participant will recognize ordinary income in the year in which the SAR is exercised, in an amount equal to the excess of the fair market value of the underlying shares of common stock on the exercise date over the base price in effect for the exercised right, and the participant will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant in connection with the exercise of the SAR.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A participant who receives unvested shares of combined company common stock will not recognize any taxable income at the time those shares are granted but will have to report as ordinary income, as and when those shares subsequently vest, an amount equal to the excess of (i)&#160;the fair market value of the shares on the vesting date over (ii)&#160;the cash consideration (if any) paid for the shares. The participant may, however, elect under Section&#160;83(b)&#160;of the Code to include as ordinary income in the year the unvested shares are issued an amount equal to the excess of (a)&#160;the fair market value of those shares on the issue date over (b)&#160;the cash consideration (if any) paid for such shares. If the Section&#160;83(b)&#160;election is made, the participant will not recognize any additional income as and when the shares subsequently vest. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time such ordinary income is recognized by the participant.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units, Other Stock-Based Awards, Incentive Bonuses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Generally, no taxable income is recognized upon the grant of RSUs, other stock<span class="nobreak">-based</span> awards or incentive bonuses. The participant will recognize ordinary income in the year in which the award is settled in shares or cash. The amount of that income will be equal to the fair market value of the shares on the date of issuance or the amount of the cash paid in settlement of the award, and the participant will be required to satisfy the tax withholding requirements applicable to the income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued or the cash amount is paid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deductibility of Executive Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;162(m)&#160;of the Code limits the deductibility for federal income tax purposes of certain compensation paid to any &#8220;covered employee&#8221; in excess of $1&#160;million. It is expected that compensation deductions for any covered employee with respect to awards granted under the 2024 Stock Plan will be subject to the $1&#160;million annual deduction limitation. The Administrator may grant Awards under the 2024 Stock Plan or otherwise that are or may become non<span class="nobreak">-deductible</span> when it believes doing so is in the best interests of the combined company and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">New Plan Benefits</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA cannot currently determine the benefits or number of shares subject to Awards that may be granted in the future to eligible participants under the 2024 Stock Plan because the grant of Awards and terms of such Awards are to be determined in the sole discretion of the Administrator.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">190</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the Stock Plan Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Stock Plan Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE STOCK PLAN PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">191</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9993"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 8</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE ESPP PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) to be effective on the closing date of the Merger. The ESPP was approved by ARCA&#8217;s board of directors on <span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, subject to stockholder approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purpose of the ESPP is to provide employees of the combined company and its designated subsidiaries with an opportunity to purchase Common Stock through accumulated contributions. The ESPP, and the rights of participants to make purchases thereunder, is intended to qualify under Section&#160;423 of the Code; however, sub<span class="nobreak">-plans</span> that do not meet the requirements of Section&#160;423 of the Code may be established for the benefit of eligible employees of non<span class="nobreak">-U</span>.S.&#160;subsidiaries of the combined company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary of the ESPP</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following description of the ESPP is not intended to be complete and is qualified in its entirety by the complete text of the ESPP, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;L</span> to this proxy statement. Stockholders are urged to read the 2024 Stock Plan in its entirety.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Federal Income Tax Consequences</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a brief description of the federal income tax treatment that will generally apply to the grant and exercise of rights under the ESPP, based on federal income tax laws in effect on the date of this proxy statement/prospectus. The exact federal income tax treatment of options will depend on the specific nature of any such option and the individual tax attributes of the participant. The following summary is not intended to be exhaustive and, among other considerations, does not describe gift, estate, social security, state, local or international tax consequences. In addition, if one or more sub<span class="nobreak">-plans</span> are established for employees of non<span class="nobreak">-U</span>.S.&#160;subsidiaries, the tax rules may be different than discussed below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code and, as a result, employees who participate in the ESPP will be afforded favorable tax treatment subject to meeting certain requirements specified by the Code. In general, there are no federal income tax consequences to a participant upon the grant of the option to purchase shares under the ESPP at the beginning of an option period or upon its exercise on the exercise date at the end of an option period. Upon the disposition of shares of common stock acquired upon exercise of an option, the participant will generally be subject to tax and the nature and amount of the tax will depend on whether the employee has satisfied the statutory holding period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the employee holds shares acquired under the ESPP for at least two&#160;years from the grant date of his or her option and at least one year from the date he or she acquired the shares (referred to as the &#8220;statutory holding period&#8221;), any gain on the sale of the shares will be taxed as ordinary income to the extent of the lesser of (i)&#160;the amount by which the fair market value of the shares on the grant date (i.e., the first&#160;day of the option period) exceeded the exercise price for the option, or (ii)&#160;the amount by which the fair market value of the shares on the date of sale exceeds the exercise price of the option. Any additional gain or loss will be taxed as long<span class="nobreak">-term</span> capital gain or loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the participant sells or otherwise disposes of the shares before the expiration of the statutory holding period, then in the year of such &#8220;disqualifying&#8221; disposition, the participant will be required to recognize ordinary income equal to the difference between the fair market value of the shares on the date of the exercise of the option and the exercise price of the option. Any additional gain or loss will be short<span class="nobreak">-term</span> or long<span class="nobreak">-term</span> capital gain or loss depending on the length of time the employee has held the shares.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company is not entitled to any deduction with respect to the difference between the fair market value of the common stock and the option exercise price if the participant satisfies the statutory holding period described above. If shares are sold before the statutory holding period is satisfied, the combined company receives a tax deduction for any ordinary income recognized by the participant.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">192</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">New Plan Benefits</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The benefits that will be received by or allocated to eligible employees under the ESPP cannot be determined at this time because the amount of payroll deductions contributed to purchase shares of combined company common stock under the ESPP is entirely within the discretion of each participant (subject to the limitations discussed above).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the ESPP Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the ESPP Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ESPP PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">193</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9994"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 9</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE MERGER COMPENSATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to Section&#160;14A of the Exchange&#160;Act and Rule&#160;14a<span class="nobreak">-21</span>(c)&#160;thereunder, ARCA is seeking non<span class="nobreak">-binding</span>, advisory stockholder approval of certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation&#160;S<span class="nobreak">-K</span> in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; Interests of ARCA&#8217;s Directors and Executive Officers in the Merger&#160;&#8212;&#160;Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span>&#8221; beginning on page 120 of this proxy statement/prospectus. At the ARCA special meeting, ARCA will therefore ask its stockholders to adopt the following resolution:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#8220;RESOLVED:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>That certain compensation arrangements for ARCA named executive officers in connection with the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation&#160;S</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-K</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> in the section titled &#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Merger &#8212; Interests of ARCA&#8217;s Directors and Executive Officers in the Merger&#160;&#8212;&#160;Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#8221; in the proxy statement/prospectus, are hereby APPROVED on a non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-binding</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">, advisory basis.&#8221;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the vote is advisory in nature only, it will not be binding on ARCA.&#160;Accordingly, to the extent ARCA is contractually obligated to pay the compensation, the compensation will be payable to the named executive officers, subject only to the conditions applicable thereto, if the Merger is completed, regardless of the outcome of the advisory vote.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA common stock is required to approve the Merger Compensation Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Merger Compensation Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE MERGER COMPENSATION PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">194</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9987"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 10&#160;&#8212;&#160;THE ADJOURNMENT PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA fails to receive a sufficient number of votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal, ARCA may propose to adjourn the ARCA special meeting, for a period of not more than 60&#160;days, for the purpose of soliciting additional proxies to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal. ARCA currently does not intend to propose adjournment at the ARCA special meeting if there are sufficient votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a quorum is not present at the ARCA special meeting, under ARCA Bylaws, stockholders holding a majority of the shares present in person or by proxy and entitled to vote, or if no stockholders are present any officer entitled to preside at or act as secretary of the special meeting, will have the power to adjourn the special meeting until a quorum is present or represented.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a quorum is present, the affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting is required to approve the Adjournment Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Adjournment Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Adjournment Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Adjournment Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Adjournment Proposal.</p>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ADJOURNMENT PROPOSAL, IF NECESSARY.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">195</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T13"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA&#8217;S BUSINESS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is a biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA&#8217;s board of directors established a Special Committee and subsequently retained Lucid to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value (the &#8220;Strategic Review&#8221;). ARCA and Lucid have reviewed several potential strategic transactions and continue to evaluate further potential development of ARCA&#8217;s existing assets, in order to maximize stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, First Merger Sub, Second&#160;Merger Sub and Oruka entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the Second Merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, ARCA may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation, (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that ARCA is developing for the treatment of atrial fibrillation in patients with heart failure. ARCA believes the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is developing Gencaro to treat AF in patients with HF.&#160;AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction (&#8220;EF&#8221;) of 40% and higher who also have the genotype ARCA believes is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United&#160;States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro is based on ARCA&#8217;s published analysis of the Phase&#160;2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC<span class="nobreak">-AF</span>.&#160;This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. ARCA currently has an agreement with the FDA, known as a Special Protocol Assessment (&#8220;SPA&#8221;) for the requirements of a Gencaro Phase&#160;3 clinical trial, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">196</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">PRECISION<span class="nobreak">-AF</span>, that would support approval of Gencaro if successful. The Phase&#160;3 pivotal clinical trial of Gencaro conducted under an SPA will include secondary endpoints that are intended to capture some of this information, such as a reduction in the need to deploy rhythm control interventions including electrical cardioversion, catheter ablation and use of anti<span class="nobreak">-arrhythmic</span> drugs and avoidance of drug<span class="nobreak">-related</span> complications such as bradycardia. ARCA was issued a United&#160;States patent in February&#160;2021 for the use of Gencaro in a patient population identified as part of the clinical trial. ARCA believes this patent will substantially extend the patent protection for ARCA&#8217;s planned development of Gencaro into 2039. ARCA has sought or is seeking similar patent protection in other countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United&#160;States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline<span class="nobreak">-recommended</span> therapies for these patients to treat either their AF or HF.&#160;AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta<span class="nobreak">-blockers</span> approved for HF are commonly used off<span class="nobreak">-label</span> to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti<span class="nobreak">-arrhythmic</span> drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti<span class="nobreak">-arrhythmic</span> drugs post<span class="nobreak">-intervention</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF.&#160;ARCA believes there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>More effective rhythm control compared to the current standard of care;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti<span class="nobreak">-arrhythmic</span> drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Maintenance of rhythm control after a successful AF catheter ablation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Effective rate control with lower risk of treatment<span class="nobreak">-limiting</span>, adverse event producing bradycardia;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in symptoms and improvement in quality of life;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduced health care burden;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Foundational beta<span class="nobreak">-blocker</span> benefits for HF and unique evidence of efficacy in HF patients with AF;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an international patent portfolio for Gencaro in the United&#160;States, the EU, and other major markets, as well as new chemical entity status, including a new patent that ARCA believes will give it a strong intellectual property position to at least approximately 2039 in the United&#160;States; ARCA has filed applications similar to this new patent in international territories. ARCA has developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase&#160;2B clinical trial. ARCA retains all rights to this test platform; ARCA expects to use it in future clinical trials, and ARCA believes it could be one of multiple diagnostic platforms used for commercialization.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">rNAPc2 (AB201) for treatment of COVID-19</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Recombinant Nematode Anticoagulant Protein c2 (&#8220;rNAPc2&#8221;) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID<span class="nobreak">-19</span>. Based on its unique mechanism of action, development history and the clinical evidence from the SARS<span class="nobreak">-CoV-2</span> pandemic, ARCA believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. ARCA initiated a Phase&#160;2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID<span class="nobreak">-19</span> in the fourth quarter of 2020 and completed patient enrollment in the fourth quarter 2021. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients based on the coagulation biomarker D<span class="nobreak">-dimer</span>, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D<span class="nobreak">-dimer</span> level from Baseline to Day 8 compared to standard of care heparin.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">197</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the secondary endpoints measuring thrombotic events and time<span class="nobreak">-to-recovery</span>, there was a numerical imbalance in favor of rNAPc2 that was non<span class="nobreak">-significant</span>. rNAPc2 was well<span class="nobreak">-tolerated</span> at both doses. There were no serious treatment<span class="nobreak">-related</span> adverse events and no dose dependent increase in adverse events was observed. There was no difference between rNAPc2 and standard<span class="nobreak">-of-care</span> heparin in major or non<span class="nobreak">-major</span> clinically relevant bleeding. ARCA currently does not plan additional clinical development of rNAPc2 unless ARCA is able to find a commercial or government partner to pay for development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and ARCA&#8217;s general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or are unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipate; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s mission is to become a leading biopharmaceutical company developing precision targeted cardiovascular therapies to enhance therapeutic response, improve patient outcomes, and reduce healthcare costs. To achieve this goal, ARCA is pursuing the following strategies:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Evaluate strategic options.&#160;&#160;&#160;&#160;</span>In April&#160;2022, ARCA&#8217;s board of directors established the Special Committee and, subsequently retained Ladenburg Thalmann to evaluate the Strategic Review. In March&#160;2024, ARCA terminated its engagement with Ladenburg Thalmann and retained Lucid Capital Markets to evaluate the Strategic Review. ARCA and Lucid have reviewed several potential strategic transactions and continue to evaluate further potential development of ARCA&#8217;s existing assets, in order to maximize stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction. Following a comprehensive review, on April<span class="nobreak">&#160;</span>3, 2024, ARCA, First Merger Sub, Second Merger Sub and Oruka, entered into Merger Agreement pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Advance the development of Gencaro for the treatment of AF in HF patients.&#160;&#160;&#160;&#160;</span>ARCA is planning a Phase&#160;3 clinical trial for Gencaro as a therapy for AF in HF patients, focusing on patients with EF &#8805; 40%, a patient population for whom few approved or effective drug therapies currently exist.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Partner the development of rNAPc2.&#160;&#160;&#160;&#160;</span>ARCA plans to pursue strategic development and partnering opportunities with commercial or government partners for rNAPc2 development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:normal;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Build a cardiovascular pipeline.&#160;&#160;&#160;&#160;</span>ARCA&#8217;s management, employees and consultants are experienced in cardiovascular research, molecular genetics and clinical development of cardiovascular therapies. ARCA is seeking to leverage this expertise to identify, acquire and develop other cardiovascular products or candidates, particularly those with potential for targeted development based on genetic or other biomarkers.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">198</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The above strategies are dependent upon ARCA&#8217;s ability to obtain additional funding through the sale of public or private equity or debt securities, the completion of a strategic transaction, or a combination thereof. If ARCA is unable to secure additional funding or complete a strategic transaction, ARCA may not be able to continue development of Gencaro or rNAPc2, or to continue operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Atrial Fibrillation in Heart Failure</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Market Background and Opportunity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Heart failure is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. HF has numerous serious consequences, including severe impacts on quality of life, increased hospitalizations, loss of economic productivity, and premature death. HF is a leading cause of death in the developed world, and despite the availability of multiple effective drug classes, mortality due to HF is increasing. According to the 2020 American Heart Association (&#8220;AHA&#8221;) Heart Disease and Stroke Statistics, there were an estimated 6.2&#160;million Americans aged 20&#160;years or more with HF in 2016, projected to increase to between 8.3&#160;million and 10.7&#160;million by 2030. One of the fundamental classifications of heart failure is based on the percentage of blood in the left ventricle of the heart that is ejected with each heartbeat, known as EF.&#160;The spectrum of HF includes HF in which EF is 50% or more and is considered preserved ejection fraction, known as HFpEF; HF in which the EF is less than 40%, considered reduced ejection fraction (&#8220;HFrEF&#8221;); and HF in which the EF is at least 40%, but less than 50%, sometimes referred to as mid<span class="nobreak">-range</span> ejection fraction, known as HFmrEF.&#160;Together, HFmrEF and HFpEF, that is HF with EF &#8805; 40%, comprise more than half of all chronic HF in the United&#160;States and Europe. In 2012, the economic cost of HF in the United&#160;States was estimated to be nearly $31&#160;billion, of which two<span class="nobreak">-thirds</span>, or over $20&#160;billion, was attributable to direct medical costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Atrial fibrillation, the most common sustained cardiac arrhythmia, is a serious disorder in which the normally regular and coordinated contraction pattern of the heart&#8217;s two small upper chambers, or the atria, becomes irregular, rapid and uncoordinated. AF can have significant quality of life impacts and potentially serious medical consequences, including increasing the risk of stroke and other cardiovascular problems. In individuals with HF, AF contributes to the disease processes that lead to the progression of HF and worsening of clinical outcomes. AF is considered an epidemic cardiovascular disease and a major public health burden, similar to HF.&#160;The estimated number of individuals with AF globally in 2015 was 33.3&#160;million. According to AHA Heart Disease and Stroke Statistics Reports from&#160;2017<span class="nobreak">-2020</span>, the prevalence of AF in the United&#160;States was estimated to be 5.2&#160;million people in 2015. In the European Union, the prevalence of AF was estimated to be 8.8&#160;million (age 55 and over) in 2010. It is estimated that AF costs the U.S.&#160;economy about $6.0&#160;billion annually.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">AF and HF share many of the same risk factors and commonly occur together. It has been estimated that&#160;30<span class="nobreak">-60</span>% of HF patients will also develop AF, with this incidence increasing in HF patients with higher EF; ARCA estimates that&#160;40<span class="nobreak">-60</span>% of HF patients with EF &#8805; 40% will also be diagnosed with AF.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Medical Need and Current Therapy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The goals of current medical therapy for AF are to provide anticoagulation to reduce the risk of stroke, and also either maintain sinus rhythm (known as rhythm control), or reduce the high heart rate caused by AF (known as rate control), in both cases to minimize patient symptoms and reduce the risk of further complications and disease progression. Unfortunately, the current treatment options for treating AF in patients with HF have significant limitations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beta<span class="nobreak">-blockers</span> are considered standard of care for the treatment of HF patients, including in patients with co<span class="nobreak">-morbid</span> AF.&#160;They are also viewed as foundational therapy to treat AF in HF patients for their ability to provide rate control. Their safety in this patient population is well established.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, current beta blockers approved for HF patients are only modestly effective at providing rhythm control, and none are FDA approved for this indication. Importantly, none of these drugs have been shown to be effective for treating HF in patients with EF &#8805; 40%, so they are currently used off<span class="nobreak">-label</span> in this setting. When used for rate control, these drugs can cause bradycardia, a condition in which the heart rate drops below a safe threshold, which often leads to dose reductions and potential loss of the drug&#8217;s treatment effect. Furthermore, recent evidence indicates that the mortality and other clinical benefits of these beta blockers in heart failure patients are uncertain when sustained or permanent AF is present.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">199</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Anti<span class="nobreak">-arrhythmic</span> drugs are a drug class that is often prescribed to provide rhythm control. These drugs are frequently used in patients with both HF and AF when a rate control strategy using a beta blocker fails to control the patient&#8217;s symptoms. However, these agents have significant safety issues. For example, in the United&#160;States, anti<span class="nobreak">-arrhythmic</span> drug therapy for AF used in addition to beta<span class="nobreak">-blockers</span> is generally confined to the drugs amiodarone and dofetilide, which have multiple safety and toxicity concerns. Because of these concerns, physicians treating HF patients seek to limit the use of these anti<span class="nobreak">-arrhythmic</span> drugs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Non<span class="nobreak">-pharmacologic</span> interventions such as catheter ablation and electrical cardioversion (ECV), are also used to treat AF in patients with HF.&#160;Catheter ablation is now guideline<span class="nobreak">-recommended</span> in this patient population and its use is increasing. However, it is not a replacement for drug therapy; it is invasive, expensive and generally impermanent. Drug therapy, including beta blockers, is generally continued in patients post<span class="nobreak">-ablation</span>, both for rhythm control and for HF benefit. ECV is expensive and less permanent than ablation, but like ablation, post<span class="nobreak">-ECV</span> patients will generally remain on drug therapy to treat their AF and HF, including beta<span class="nobreak">-blockers</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In light of the serious medical consequences presented by AF in the presence of HF as well as, the limitations of current therapies, ARCA believes there is an unmet need for a drug therapy that can provide greater rhythm control compared to the current standard of care; can reduce the need for toxic anti<span class="nobreak">-arrhythmic</span> drugs, catheter ablation, and electrical cardioversion; can provide effective rate control with a lower risk of treatment<span class="nobreak">-limiting</span> bradycardia; and can provide foundational beta<span class="nobreak">-blocker</span> benefits for HF.&#160;This need is particularly significant for HF patients with EF &#8805; 40%, for whom there are few approved or Class&#160;I guideline<span class="nobreak">-recommended</span> drug therapies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro Clinical Development</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The GENETIC-AF Phase&#160;2B Clinical Trial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">GENETIC<span class="nobreak">-AF</span> enrolled 267 patients from the United&#160;States, Canada and Europe. The primary analysis compared the evidence of safety and efficacy of Gencaro versus an active comparator, TOPROL<span class="nobreak">-XL</span>.&#160;The primary endpoint of the trial was time to first event of AF/atrial flutter (AFL) or All Cause Mortality (ACM) during a 24<span class="nobreak">-week</span> follow<span class="nobreak">-up</span> period after the establishment of sinus rhythm. Randomized patients had an EF &#8804; 55%, a history of AF in the past 6&#160;months, and the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype that ARCA believes responds best to Gencaro. Laboratory Corporation of America (&#8220;LabCorp&#8221;) developed the genetic test, obtained an IDE from the FDA and provided the companion diagnostic test and services to support ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the primary endpoint of time to AF recurrence, Gencaro demonstrated a similar treatment benefit in the overall population (p = 0.961) compared to the active comparator, TOPROL<span class="nobreak">-XL</span>.&#160;However, based on further analysis of the trial, ARCA believes it has identified a population that shows greater response to Gencaro compared to TOPROL<span class="nobreak">-XL</span> across multiple important clinical assessments, including the primary endpoint of time to AF recurrence, maintenance of normal sinus rhythm, cumulative AF burden, and AF<span class="nobreak">-related</span> clinical interventions and complications. ARCA plans to study this population in ARCA&#8217;s Phase&#160;3 clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These further analyses of the GENETIC<span class="nobreak">-AF</span> population (shown in the table below) demonstrated that Gencaro, as compared to metoprolol, reduced AF burden, improved maintenance of sinus rhythm and lowered the need for additional rhythm control interventions.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">200</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Endpoint</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Entire GENETIC-AF Cohort</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Time to 1</span><span class="CharOverride-3" style="font-size:58%;font-style:normal;font-weight:bold;vertical-align:super;">st</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;"> AF/AFL/ACM <br/>(Primary Endpoint)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.01<br/>(neutral)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.71, 1.42)<br/>p = 0.961<br/>N = 267</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Cumulative 24-week AF Burden <br/>(substudy</span>)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.64<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">36%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.46, 0.86)<br/>p = 0.002<br/>N = 67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">AF Burden at Week 24</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.45<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">55%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.39, 0.50)<br/>p &lt; 0.001<br/>N = 67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">ECGs in Normal Sinus Rhythm</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.39<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">39%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(1.22, 1.58)<br/>p &lt; 0.001<br/>N = 257</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">AF Interventions <br/>(ECVs, Ablations,&#160;&amp; Class&#160;3 AA Drugs)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.68<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">32%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.50, 0.91)<br/>p = 0.011<br/>N = 257</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 26.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:4pt;text-indent:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Bradycardia prevalence <br/></span>(Buc. vs. met., VR &lt; 60 bpm) </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 12.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">0.39<br/>(</span><span class="CharOverride-4" style="font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">61%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.57%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:6pt;text-indent:0pt;">(0.31, 0.49)<br/>P &lt; 0.001<br/>N = 256</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Dose reductions</span> <br/>(pts. w/bradycardia vs. non-b.)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 10.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.25<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8593;</span><span class="Bold" style="font-style:normal;font-weight:bold;">4X)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:4pt;text-indent:0pt;">(2.06, 9.60)<br/>P &lt; 0.001<br/>N = 257</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Time to first AF/AFL/ACM treatment effect = hazard ratio (95% CI). AF burden = % time in AF per&#160;day. Cumulative AF burden treatment effect = AUC ratio (i.e., AUC<span class="Subscript" style="vertical-align:sub;font-size:58%;">BUC</span>/AUC<span class="Subscript" style="vertical-align:sub;font-size:58%;">MET</span>) over 24<span class="nobreak">-week</span> follow<span class="nobreak">-up</span> period with significance assessed via null permutation. AFB at Week 24 = Instantaneous estimates of average daily AF burden at week 24 with comparison between groups expressed as the ratio of the estimates and tested for significance using a Wald test. Normal Sinus Rhythm = total number ECGs in sinus rhythm with ventricular rate&#160;&#8805;&#160;60&#160;and&#160;&#8804;&#160;100 bpm during efficacy follow<span class="nobreak">-up</span> period. AF Interventions = ECV, ablation, or guideline<span class="nobreak">-recommended</span> antiarrhythmic use during efficacy follow<span class="nobreak">-up</span> period. Treatment effect for normal sinus rhythm, AF interventions and bradycardia&#160;=&#160;prevalence rate ratio (i.e., PRR<span class="Subscript" style="vertical-align:sub;font-size:58%;">BUC</span>/PRR<span class="Subscript" style="vertical-align:sub;font-size:58%;">MET</span>) modeled to test significance using Poisson regression.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Treatment with Gencaro was associated with a 36% reduction in cumulative AF burden over 24&#160;weeks of follow<span class="nobreak">-up</span> compared to metoprolol, leading to a 55% reduction in AF burden at the end of 24&#160;weeks. Consistent with the results in the device substudy, there was a 39% increase in the prevalence of ECGs demonstrating normal sinus rhythm in the overall study population. Treatment with Gencaro also led to a 32% lower utilization of adjunctive rhythm control therapies, including electrical cardioversion, catheter ablation and antiarrhythmic drug therapy. There was also a 61% reduction in bradycardia with Gencaro versus metoprolol. The consequence of bradycardia is a reduction in beta<span class="nobreak">-blocker</span> dose, which 4.2<span class="nobreak">-fold</span> higher in patients exhibiting bradycardia than without bradycardia.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The BEST Phase&#160;3 Heart Failure Trial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The effect of Gencaro on heart failure endpoints in an advanced HFrEF population was evaluated in the 2,708&#160;patient, placebo<span class="nobreak">-controlled</span> Phase&#160;3 BEST clinical trial co<span class="nobreak">-sponsored</span> by the NHLBI and Department of Veterans Affairs. In addition to the parent population, BEST included a 1,040 patient DNA substudy that evaluated the effects of adrenergic receptor (&#8220;AR&#8221;) polymorphisms on Gencaro effectiveness. The BEST trial was terminated early because, after positive mortality results from two HF trials involving other beta<span class="nobreak">-blockers</span> had been reported, a substantial number of BEST trial investigators concluded that it was unethical to continue to give placebo to BEST trial participants. ARCA&#8217;s reanalysis of the BEST results in accordance with the FDA approved, pre<span class="nobreak">-specified</span> statistical analysis plans (which had not been performed by the sponsors of BEST) demonstrated a 13% risk reduction on the primary endpoint of ACM in the BEST trial with a p<span class="nobreak">-value</span> of 0.053. The risk reduction on HF clinical efficacy endpoints such as mortality and hospitalization ranged from 34% to 48% in this beta<span class="nobreak">-1</span> 389 arginine homozygous genotype. The DNA substudy revealed that Gencaro exhibited greater efficacy in patients homozygous for the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (<span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg), encoding for receptors that exhibit higher function and greater affinity for norepinephrine compared to the patients who did not have the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (i.e., beta<span class="nobreak">-1</span> 389 Gly carriers). In the 47% of BEST trial patients with a <span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg genotype Gencaro reduced (p &lt;0.05) the primary endpoint of mortality or heart transplantation by 43%, all<span class="nobreak">-cause</span> mortality, cardiovascular mortality, heart failure hospitalizations, heart failure progression, development of atrial </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">201</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">fibrillation, and incidence of ventricular tachycardia or ventricular fibrillation with degrees of reduction (effect sizes) ranging from 34% (heart failure progression) to 74% (atrial fibrillation). Beta<span class="nobreak">-1</span> 389 Gly carriers had no statistically significant reduction in any endpoint.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pharmacology and Pharmacogenetics of Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro (bucindolol hydrochloride) is a nonselective (blocks both beta<span class="nobreak">-1</span> and beta<span class="nobreak">-2</span> adrenergic receptors) beta- receptor blocking agent with mild vasodilator properties. This combination of properties initially placed Gencaro in the &#8220;3<span class="CharOverride-6" style="font-size:58%;vertical-align:super;">rd</span> Generation&#8221; category of beta<span class="nobreak">-blockers</span> that is based on the strategy of their development. When its pharmacogenetic properties were elucidated and its development became pharmacogenetically based, ARCA subsequently considered Gencaro a fourth<span class="nobreak">-generation</span> beta<span class="nobreak">-blocker</span>. The dominant beta<span class="nobreak">-receptor</span> on human heart cells is the beta<span class="nobreak">-1</span>, with smaller number of beta<span class="nobreak">-2</span> receptors present. Importantly, beta<span class="nobreak">-2</span> receptors are also present on adrenergic nerve terminals in the heart, where they regulate the release of the neurotransmitter norepinephrine (&#8220;NE&#8221;). The blocking of these receptors prevents them from binding with other molecules, primarily NE, which activates these receptors to release more NE.&#160;ARCA believes Gencaro has two unique anti<span class="nobreak">-adrenergic</span> properties not possessed by other beta<span class="nobreak">-blockers</span> currently approved for the treatment of HF: (1)&#160;it is moderately sympatholytic, i.e., by blocking beta<span class="nobreak">-2</span> receptors on adrenergic nerves it lowers adrenergic drive to a level that can be detected on measurements of central or systemic venous NE levels, and, (2)&#160;through &#8220;inverse agonism,&#8221; as it binds to a polymorphic &#8220;389 arginine&#8221; form of heart cell beta<span class="nobreak">-1</span> receptor in isolated human heart preparations it promotes the inactivation of the active<span class="nobreak">-state</span> of this receptor. These properties, as described below, were observed to interact with receptor polymorphisms in such a way that ARCA believes targeting a specific genotype of the beta<span class="nobreak">-1</span> receptor gene (known as ADRB1) could improve the therapeutic response of patients. ARCA believes Gencaro&#8217;s efficacy is enhanced in patients with the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (<span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg), which has been shown to be present in approximately 50% of the North American and European general populations. To date no other beta<span class="nobreak">-blocker</span> has been shown to possess pharmacological sympatholysis, or beta<span class="nobreak">-1</span> AR inverse agonism in human heart preparations. ARCA believes that Gencaro&#8217;s sympatholytic and beta<span class="nobreak">-1</span> AR inverse agonist properties contribute to its enhanced lowering of HF and arrhythmia event rates in patients who have an <span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg genotype.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro Clinical and Regulatory Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA intends to advance Phase&#160;3 clinical development of Gencaro as a therapy for HF patients with AF, focusing on HF with EF &#8805; 40%. The regulatory strategy for Gencaro is to obtain an initial approval to treat AF in a HF population with EF &#8805; 40% and &#8804; 55% and the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype; the population demonstrating the greatest efficacy in the Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial. Indication expansion for Gencaro will focus on genotype<span class="nobreak">-positive</span> HF patients with EF &gt;55%, which ARCA believes would substantially expand the addressable patient population, if successful. ARCA has obtained an SPA agreement with the FDA to conduct a single, 400<span class="nobreak">-patient</span> Phase&#160;3 clinical trial that, if successful at a statistical threshold of p &#8804; 0.01, may be sufficient to support an NDA for the marketing approval of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The clinical trial design is similar to GENETIC<span class="nobreak">-AF</span>, including the active comparator, TOPROL<span class="nobreak">-XL</span>, and the primary endpoint of time to AF or atrial flutter (&#8220;AF/AFL&#8221;) recurrence or mortality during a 6<span class="nobreak">-month</span> follow<span class="nobreak">-up</span> period. The planned clinical trial will use a standard significance criterion of p &#8804; 0.05 for the primary endpoint; however, if the primary endpoint is significant with a p<span class="nobreak">-value</span> &#8804; 0.01, then this single Phase&#160;3 clinical trial may be sufficient for regulatory approval per the SPA agreement. The NDA submission for Gencaro is eligible for expedited review in the United&#160;States under the Fast Track development program designation that was granted to Gencaro in 2015. Based on the use of this same endpoint in GENETIC<span class="nobreak">-AF</span> it is anticipated that &#8805;90% of the primary events will be due to recurrent AF/AFL.&#160;Secondary objectives will examine other important endpoints, such as AF burden and AF treatment<span class="nobreak">-related</span> interventions. The planned clinical trial will use a standard significance criterion of p&#160;&#8804;&#160;0.05 for the primary endpoint; however, if the primary endpoint is significant with a p<span class="nobreak">-value</span> &#8804; 0.01, then this single&#160;Phase&#160;3 clinical trial may be sufficient for regulatory approval per the SPA agreement.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Gencaro Test</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If approved, ARCA believes that Gencaro will be the first cardiovascular drug to be integrated with a companion diagnostic. This would be a test for the patient genotype approved for the drug, and could be performed by a variety of laboratory processes or platforms.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">202</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In collaboration with LabCorp, ARCA developed one such genetic test, obtained an IDE from the FDA and used this test in ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA retains all rights to this particular test platform, and ARCA believes it could be used for commercialization. Future clinical trials of Gencaro, including PRECISION<span class="nobreak">-AF</span>, are expected to use a similar diagnostic test to identify the patient&#8217;s receptor genotype (the &#8220;Gencaro Test&#8221;). ARCA believes the Gencaro Test could be developed and commercialized through one or more diagnostic providers, by the company potentially marketing Gencaro, or a combination of approaches. ARCA also believes that point of care genetic tests, which could be performed during the patient&#8217;s visit to the physician, will be part of the commercialization strategy for Gencaro.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Development Pipeline</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro, is a potential treatment for HF patients with AF.&#160;Gencaro (bucindolol hydrochloride) is a pharmacogenetic<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that is considered a fourth<span class="nobreak">-generation</span> beta<span class="nobreak">-blocker</span> based on its novel pharmacogenetic profile. ARCA believes the treatment of AF in HF patients with EF &#8805; 40% is an unmet medical need with a near term and straightforward regulatory pathway.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s plan is to obtain an initial approval for Gencaro to treat AF in a genotype specific HF population; HF patients with EF between 40% and 55% in patients with the genotype ARCA studied in the Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA believes that, if approved, there are additional indication expansion opportunities for Gencaro in other AF populations, including expanding the patient population to selected HF patients with EF &gt;55%. ARCA continues to evaluate the feasibility and potential timing for initiating PRECISION<span class="nobreak">-AF</span> relative to the COVID<span class="nobreak">-19</span> pandemic. ARCA may seek additional capital or a strategic partnership for the Phase&#160;3 clinical trial and potential commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA plans to pursue strategic development and partnering opportunities with commercial or government partners for rNAPc2 development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has exclusive pharmacogenetic and other patent rights to drug targets and candidates that have potential indications in cardiovascular disease, oncology and other therapeutic areas. ARCA may seek partners to assist it in the development of these candidates or who may license them. ARCA may also seek funds to advance the development of the compounds on ARCA&#8217;s own.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Financial Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and its general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or is unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes ARCA&#8217;s cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund ARCA&#8217;s operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipate; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">203</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Licensing and Royalty Obligations</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s patent portfolios relating to Gencaro, including a patent issued in 2021, are either owned by ARCA or are subject to licenses that impose no royalty obligations or milestone payments relating to the further development, approval and commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is also a party to licenses for patents relating to Gencaro that are now expired. ARCA believes that there are no future milestone or royalty obligations that will be payable under these licenses.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Competition</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Current HF treatments include three beta<span class="nobreak">-blockers</span> approved for HF in the United&#160;States. However, their efficacy in providing control of the arrhythmia caused by AF, or rhythm control, is only mild. It is also now acknowledged that evidence is lacking that the approved beta<span class="nobreak">-blockers</span> provide outcome benefits for patients who develop permanent AF.&#160;Furthermore, these drugs have not demonstrated efficacy for HF patients with EF &#8805; 40%, which is the focus of the Gencaro development program. Current AF treatments include pharmaceutical, procedural or device intervention. There are several antiarrhythmic drugs approved by the FDA for the treatment and/or prevention of recurrent AF.&#160;However, these drugs have safety and/or administration concerns and all but one have contraindications or label warnings regarding their prescription in patients with HF.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Drugs that are currently approved or used for the treatment or prevention of AF in HF either have not demonstrated efficacy in these patients, or have notable risks due to adverse side effects or lack sufficient efficacy. Therefore, in HF, and specifically in HF patients with EF &#8805; 40%, ARCA believes there is a substantial unmet medical need for AF therapies that are more effective and have fewer side effects than those currently available. ARCA believes that Gencaro&#8217;s treatment of AF in HF patients could provide a more effective and safer pharmacotherapy than treatments currently used in these patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The pharmaceutical industry is highly competitive. ARCA faces significant competition from pharmaceutical companies and biotechnology companies that are researching and selling products designed to treat cardiovascular conditions. Most of these companies have significantly greater financial, product development, manufacturing, and commercial resources than ARCA has.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If approved, some of the drugs which Gencaro would potentially compete with are generic in the United&#160;States and are used, though not approved or shown to be effective, for the treatment of AF or in HF patients with EF &#8805; 40%. Gencaro could be priced at a premium compared to some of these therapies. In addition, Gencaro, if approved, would be prescribed in conjunction with a diagnostic test, adding additional procedures to the process of prescribing Gencaro, which could make it more difficult for ARCA to compete against existing or future therapies.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Manufacturing and Product Supply</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro is a small molecule drug with an established manufacturing history. Multiple manufacturers of both the active pharmaceutical ingredients (&#8220;API&#8221;) and drug product have successfully produced Gencaro for use in clinical trials over the course of its clinical development. ARCA outsources all manufacturing and analytical testing of the Gencaro API and drug product. ARCA has selected third<span class="nobreak">-party</span> contract manufacturing organizations on the basis of their technical and regulatory expertise. ARCA&#8217;s approach with its contract manufacturing partners has been to replicate the manufacturing processes that were used to support the prior pivotal clinical trial with Gencaro, and to minimize any changes from these baseline processes, thereby reducing technical and regulatory risk. For API production, ARCA contracted with Groupe Novasep which completed the drug substance registration batches successfully. The resulting drug substance was used to manufacture the drug product used in the clinical trial material for the Phase&#160;2B clinical trial and is expected to be used in the proposed Phase&#160;3 clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For drug product production, ARCA has contracted with Patheon, Inc. to manufacture the Gencaro tablets. Gencaro is produced in a tablet form, utilizing standard solid oral dosage processing techniques. Six separate dosage strengths have been manufactured, with the maximum recommended dose of 100mg twice daily. Registration </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">204</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">batches were successfully completed by Patheon, Inc. and tablets from these runs were placed in cGMP storage to supply clinical trials. In addition, ARCA contracted with a separate service provider for packaging and distribution of its clinical trial materials.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Government Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Governmental authorities in the United&#160;States at the federal, state, and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, marketing, distribution, sampling, and import and export of pharmaceutical and medical device products. In the United&#160;States, the FDA regulates these activities at the federal level pursuant to the Federal Food Drug and Cosmetic Act (&#8220;FDCA&#8221;) and the regulations promulgated thereunder. In Canada, Health Canada regulates these activities. In Europe, the Competent Authorities and Ethics Committees of the respective countries regulate these activities. In South America, the Health Authorities and Ethics Committees of their respective countries regulate these activities. ARCA anticipates that all of its product candidates will require regulatory approval by governmental agencies prior to commercialization. The process of obtaining approval and the subsequent process of maintaining compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. In addition, these statutes, rules, regulations and policies may change and ARCA&#8217;s products may be subject to new legislation or regulations. Both before and after approval or clearance, failure to comply with the requirements of the FDA and other state and federal statutes can lead to significant penalties or could disrupt ARCA&#8217;s ability to manufacture and sell these products. In addition, the FDA could refuse to provide certificates needed to export ARCA&#8217;s products if the agency determines that ARCA is not in compliance.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Premarket Approval of Drugs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">FDA approval is required for marketing of any new drug, dosage form, indication, or strength. The steps required before new human therapeutic drug products are marketed in the United&#160;States and foreign countries include rigorous preclinical and clinical testing and other approval requirements by regulatory agencies, such as the FDA and comparable agencies in foreign countries. There is no guarantee that products will be approved in a specific timeframe or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preclinical Phase.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Preclinical studies are generally conducted in the laboratory to identify potential drug candidates and to evaluate their potential efficacy and safety. These studies include laboratory evaluation of product chemistry, formulation and stability, as well as studies to evaluate short and long<span class="nobreak">-term</span> toxicity in animals. Preclinical studies are governed by numerous regulations, including but not limited to FDA&#8217;s Good Laboratory Practices.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical Phase.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Before human clinical trials can commence, an Investigational New Drug (&#8220;IND&#8221;) application, submitted to FDA must become effective. For an IND to become effective, the applicant must submit, among other things, information on design of the proposed investigation, reports necessary to assess the safety of the drug for use in clinical investigation, and information on the chemistry and manufacturing of the drug, controls available for the drug, and primary data tabulations from animal or human studies. The clinical phase of development involves the performance of human studies, including adequate and well<span class="nobreak">-controlled</span> human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication. Typically, clinical evaluation involves three sequential phases, which may overlap. During Phase&#160;1, clinical trials are conducted with a relatively small number of subjects or patients to determine the early safety profile of a product candidate, as well as dose tolerance, absorption, and the pattern of drug distribution and drug metabolism. Phase&#160;2 trials are conducted with groups of patients afflicted by a specific target disease to determine preliminary efficacy, optimal dosages and dosage tolerance and to identify possible adverse effects and safety risks. In Phase&#160;3, larger<span class="nobreak">-scale</span>, multi- center trials are conducted with patients afflicted with a specific target disease over a longer term to confirm Phase&#160;2 results and provide reliable and conclusive data supporting efficacy and safety of a drug as required by regulatory agencies for drug approval. The conduct of clinical trials is subject to extensive regulation. FDA may delay or suspend clinical trials through clinical holds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">NDA Submission.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>In the United&#160;States, the results of preclinical and clinical testing along with chemistry, manufacturing and controls information, are submitted to the FDA in the form of a NDA.&#160;Under the current Prescription Drug User Fee Act after submission of an NDA and payment, or waiver, of the required fee, the FDA&#8217;s goal is to review most standard NDAs within 10&#160;months from the time that a sponsor&#8217;s application is accepted as </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">205</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">filed by the FDA, which can occur within a 60<span class="nobreak">-day</span> window following the initial submission of the application. At the end of the 10&#160;months, the FDA&#8217;s goal is to issue a &#8220;complete response,&#8221; or approve the NDA.&#160;While FDA&#8217;s goal is to issue a complete response within 10&#160;months, the process may take longer than 10&#160;months, particularly if multiple review cycles are required. Gencaro has been granted Fast Track Designation which allows for a rolling review of a marketing application. A rolling review allows FDA to consider reviewing portions of an NDA before the sponsor submits the complete application.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In responding to an NDA, the FDA may grant marketing approval or deny the application if the FDA determines that the application does not satisfy the statutory and regulatory approval criteria. A denial may include a request for additional information, including additional clinical data and/or an additional Phase&#160;3 clinical trial. Data from clinical trials are not always conclusive and FDA may interpret data differently than ARCA interprets data. Under the Food and Drug Modernization Act&#160;of&#160;1997, the FDA is authorized to approve a drug based on a single adequate and well<span class="nobreak">-controlled</span> study if such study and other confirmatory data are sufficient to establish the drug&#8217;s effectiveness. However, it has long been the FDA&#8217;s general position that the standard of proof of a drug&#8217;s effectiveness generally requires at least two well<span class="nobreak">-controlled</span> and adequate Phase&#160;3 clinical studies demonstrating statistically significant results as compared to a placebo or active control (with p<span class="nobreak">-values</span> of less than 0.05) with respect to the primary endpoint or endpoints of the trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, in accordance with current FDA law and regulations, the FDA may refer a drug to an advisory committee for review prior to approval. Most new compounds are referred to an FDA advisory committee, which could add additional time to the review process. There is no guarantee that the advisory committee will recommend approval of a drug candidate. In some cases, FDA may require completion, within a specified time period, of additional clinical studies after approval, referred to as Phase&#160;4 clinical studies, to monitor the effect of a new product and may prevent or limit future marketing of the product based on the results of these post<span class="nobreak">-marketing</span> programs. Furthermore, prior to granting approval, the FDA generally conducts an inspection of the facilities, including outsourced facilities that will be involved in the manufacture, production, packaging, testing and control of the drug substance and finished drug product for compliance with current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the FDA approves the NDA, the sponsor is authorized to begin commercialization of the drug in accordance with the approval. Even if the FDA approves the NDA, the FDA may decide later to suspend or withdraw product approval if compliance with regulatory standards is not maintained or if safety problems are recognized after the product reaches the market. In addition, the FDA requires surveillance programs to monitor approved products that have been commercialized, and the agency has the power to require additional clinical studies, to require changes in labeling or to prevent further marketing of a product based on the results of these post<span class="nobreak">-marketing</span> programs. The FDA also has authority to request implementation of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) that could restrict distribution of Gencaro or require ARCA to provide additional risk information to prescribers. Whether or not FDA approval has been obtained, approval of a product candidate by comparable foreign regulatory authorities is necessary prior to the commencement of marketing of a product candidate in those countries. The approval procedures vary among countries and can involve additional testing. The time required to obtain approval may differ from that required for FDA approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-approval</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Compliance.&#160;&#160;&#160;&#160;</span>If regulatory approval for a drug or medical device is obtained, the product and the facilities manufacturing the product are subject to periodic inspection and continued regulation by regulatory authorities, including compliance with cGMP, as well as labeling, advertising, promotion, recordkeeping, and reporting requirements, including the reporting of adverse events. In addition, the FDA closely regulates the post<span class="nobreak">-approval</span> marketing and promotion of drugs, including standards and regulations for labeling, promotion to health care professionals, direct<span class="nobreak">-to-consumer</span> advertising, off<span class="nobreak">-label</span> promotion, industry<span class="nobreak">-sponsored</span> scientific and educational activities and promotional activities involving the Internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Companies are responsible for compliance with such requirements and would be responsible to ensure that all contract manufacturing organizations who perform work for them also comply with such requirements. Similarly, if a drug manufacturer hires contract sales representatives or consultants to promote its products, such organizations or individuals must comply with all of the same requirements applicable to the drug manufacturer. The FDA regularly inspects companies to determine compliance with cGMPs and other post<span class="nobreak">-market</span> requirements. Failure to comply with statutory requirements and the FDA&#8217;s regulations can result in a variety of administrative or enforcement actions, including but not limited to an FDA Form&#160;483 (which is issued by the FDA at the conclusions of an inspection when an investigator has observed </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">206</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">any conditions that may constitute violations), a public warning letter, suspension or withdrawal of regulatory approvals, product recalls, product detentions, refusal to provide export certificates, seizure of products and criminal prosecution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug Price Competition and Patent Term Restoration Act&#160;of&#160;1984.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Under the Drug Price Competition and Patent Term Restoration Act&#160;of&#160;1984, also known as the Hatch<span class="nobreak">-Waxman</span> Act, Congress created an abbreviated FDA review process for generic versions of pioneer (brand name) drug products. The Hatch<span class="nobreak">-Waxman</span> Act also provides for patent term restoration and the award, in certain circumstances, of non<span class="nobreak">-patent</span> marketing exclusivities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Generic Drug Approval.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The Hatch<span class="nobreak">-Waxman</span> Act established an abbreviated FDA review process for drugs that are shown to be equivalent to approved pioneer drugs. Approval for a generic drug is obtained by filing an abbreviated NDA, or ANDA.&#160;Generic drug applications are &#8220;abbreviated&#8221; because they generally do not include clinical data to demonstrate safety and effectiveness. Instead, an ANDA applicant must establish that its product is bioequivalent to an approved drug and that it is the same as the approved drug with respect to active ingredient(s), route of administration, dosage form, strength and recommended conditions of use (labeling). The FDA will approve the generic as suitable for an ANDA if it finds that the generic does not raise questions of safety and effectiveness as compared to the pioneer drug. A drug is not eligible for ANDA approval if the FDA determines that it is not equivalent to the pioneer drug or if it is intended for a different use. Any applicant who files an ANDA seeking approval of a generic version of an approved drug listed in FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;) must certify to the FDA that (i)&#160;no patent information on the drug has been listed in the Orange Book; (ii)&#160;that each patent listed in the Orange Book for that approved drug has expired; (iii)&#160;FDA should approve the product on the date on which a listed patent expires; or (iv)&#160;that such patent is invalid, unenforceable or will not be infringed by the manufacture, use or sale of the generic drug. If the ANDA applicant makes a certification pursuant to (iv)&#160;above, or a Paragraph&#160;IV certification, and the NDA holder files an infringement suit against the ANDA applicant within 45&#160;days of receiving the Paragraph&#160;IV notification, the NDA owner is entitled to an automatic 30<span class="nobreak">-month</span> stay of FDA&#8217;s ability to approve the ANDA.&#160;This 30<span class="nobreak">-month</span> stay will end early upon any decision by a court that the patent is invalid, unenforceable or not infringed by the generic drug.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Patent Term Extension.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>While the term of a U.S.&#160;patent is generally 20&#160;years from the earliest priority date of a patent application (excluding a provisional patent application), a U.S.&#160;patent that covers subject matter requiring regulatory approval to market is eligible for an extension of that patent term. The Hatch<span class="nobreak">-Waxman</span> Act provides for the restoration of a portion of the patent term lost during product development and FDA review of an application. Patent Term Extension (&#8220;PTE&#8221;), extends the term of an issued patent for generally (i)&#160;the length of the FDA approval process, i.e., the complete period of NDA review, and (ii)&#160;half of the time spent in clinical trials, i.e., the IND period. However, the maximum period of restoration cannot exceed five&#160;years, or restore the total remaining term of the patent to greater than 14&#160;years from the date of FDA approval of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under 35 U.S.C. &#167; 156(a), a patent covering a method of using a product is eligible for PTE if the following conditions are met:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent has not yet expired;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent was not previously extended;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent owner submits an application for PTE that includes all necessary supporting information within 60&#160;days of FDA approval;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the product was subject to regulatory review before its commercial marketing or use; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the drug application is for the first permitted commercial marketing of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that, if Gencaro is approved by the FDA, one of its U.S.&#160;patents may be eligible for PTE, which could provide up to 5&#160;years of additional patent life for that patent based on ARCA&#8217;s current clinical trial plans.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A Supplementary Protection Certificate (&#8220;SPC&#8221;) is a form of patent term extension that is available for pharmaceutical products approved for marketing in the European Union (&#8220;EU&#8221;). ARCA obtained a patent in Europe on methods for using Gencaro that is similar to one of its U.S.&#160;patents and this EU patent is in force in certain countries in Europe, including the United Kingdom, France, Germany, Italy and Spain. ARCA believes that this </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">207</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">patent may be eligible for an SPC, if Gencaro is approved for marketing in any European country in which the patent is in force, which could provide up to five&#160;years of additional patent life. ARCA believes that its patents in other jurisdictions may also be eligible for similar term extensions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Non</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Patent</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Marketing Exclusivities.&#160;&#160;&#160;&#160;</span>Separate and apart from patent protection, the Hatch<span class="nobreak">-Waxman</span> Act entitles approved drugs to various periods of non<span class="nobreak">-patent</span> statutory protection, known as marketing exclusivity. The Hatch<span class="nobreak">-Waxman</span> Act provides five&#160;years of &#8220;new chemical entity&#8221; marketing exclusivity to the first applicant to gain approval of an NDA for a product that contains an active moiety not found in any other approved product. This exclusivity means that another manufacturer cannot submit an ANDA or 505(b)(2)&#160;NDA until the marketing exclusivity period ends. This exclusivity protects the entire new chemical entity franchise, including all products containing the active ingredient for any use and in any strength or dosage form, but will not prevent the submission or approval of stand<span class="nobreak">-alone</span> NDAs where the applicants have conducted their own clinical studies to demonstrate safety and effectiveness. There is an exception, however, for a competitor that seeks to challenge a patent with a Paragraph&#160;IV certification. Four&#160;years into the five<span class="nobreak">-year</span> exclusivity period, a manufacturer who alleges that one or more of the patents listed with the NDA is invalid, unenforceable or not infringed may submit an ANDA or 505(b)(2) NDA for a generic or modified version of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Hatch<span class="nobreak">-Waxman</span> Act also provides three&#160;years of &#8220;new use&#8221; marketing exclusivity for the approval of NDAs, and supplements, where those applications contain the results of new clinical investigations (other than bioavailability studies) essential to the FDA&#8217;s approval of the applications. Such applications may be submitted for new indications, dosage forms, strengths, or new conditions of use of approved products. So long as the studies are essential to the FDA&#8217;s approval or were conducted by or for the applicant, this three<span class="nobreak">-year</span> exclusivity prohibits the final approval of ANDAs or 505(b)(2)&#160;NDAs for products with the specific changes associated with those studies. It does not prohibit the FDA from approving ANDAs or 505(b)(2)&#160;NDAs for other products containing the same active ingredient, without those changes.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar non<span class="nobreak">-patent</span> market exclusivity is provided for in the EU and other international jurisdictions. ARCA believes that, if approved in the EU, Gencaro may be eligible for ten&#160;years of market exclusivity in the EU, measured from the date of approval there.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">FDA Premarket Review of Medical Devices</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless an exemption applies, each medical device that a company wishes to market in the United&#160;States requires either approval of a premarket approval application (&#8220;PMA&#8221;), or clearance of a premarket notification, commonly known as a &#8220;510(k)&#8221; from the FDA.&#160;The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risks are placed in either class&#160;I or&#160;II, which may require the manufacturer to submit to the FDA a 510(k)&#160;requesting permission to commercially distribute the device. Clearance of a 510(k)&#160;usually requires between three&#160;months and one year from the time of submission of the 510(k), although the process may take longer. The FDA&#8217;s 510(k)&#160;clearance procedure is less rigorous than the PMA approval procedure, but is available only to companies who can establish that their device is substantially equivalent to a legally<span class="nobreak">-marketed</span> &#8220;predicate&#8221; device that was (i)&#160;on the market prior to the enactment of the Medical Device Amendments of 1976, (ii)&#160;reclassified from Class&#160;III to Class&#160;II, or (iii)&#160;has been cleared through the 510(k)&#160;procedure. 510(k)s must typically be supported by performance data, including preclinical data, bench testing, and in some cases, clinical data. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risks, or for which there is no predicate, are placed in class&#160;III, and require a PMA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">PMA Pathway.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Generally, a PMA must be supported by extensive data and valid scientific evidence, including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use. After a PMA is sufficiently complete, the FDA will accept the application and begin an in<span class="nobreak">-depth</span> review of the submitted information and will generally conduct a pre<span class="nobreak">-approval</span> inspection of the manufacturing facility or facilities to ensure compliance with FDA&#8217;s QSR. By statute, the FDA has 180&#160;days to review the &#8220;accepted application&#8221;, although, generally, review of the application can take between one and three&#160;years, and it may take significantly longer. The PMA application process can be expensive, and there is a substantial &#8220;user fee&#8221; that must be paid to FDA in connection with the submission of a PMA application. If the FDA&#8217;s evaluation of the PMA application or the manufacturing facility is not favorable, the FDA may deny approval of the PMA application or issue a &#8220;not approvable&#8221; letter. The FDA may also require additional clinical trials, which can delay the PMA approval process by several&#160;years. In addition, if FDA discovers that an applicant has </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">208</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">submitted false or misleading information, FDA may refuse to review submissions until certain requirements are met pursuant to its Application Integrity Policy. If the FDA approves the PMA, it may place restrictions on the device. After the PMA is approved, if significant changes are made to a device, its manufacturing or labeling, a PMA supplement containing additional information must be filed for prior FDA approval. PMA supplements often must be approved by the FDA before the modification to the device, the labeling, or the manufacturing process may be implemented. Delays in receipt of or failure to receive such clearances or approvals, the loss of previously received clearances or approvals, or the failure to comply with existing or future regulatory requirements could have a material adverse effect on ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical Trials.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Clinical trials are generally required to support a PMA application and are sometimes required for 510(k)&#160;clearance. These trials generally require an IDE application approved in advance by the FDA for a specified number of patients, unless the proposed study is deemed a non<span class="nobreak">-significant</span> risk study, which is eligible for an exemption from the IDE requirements. The IDE application must be supported by appropriate data, such as animal and laboratory testing results. Clinical trials may begin if the IDE application is approved by the FDA and the appropriate IRBs at the clinical trial sites. Submission of an IDE application does not give assurance that the FDA will issue the IDE.&#160;If the IDE application is approved, there can be no assurance the FDA will determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to and approved by the FDA before a sponsor or investigator may make a change to the investigational plan in such a way that may affect its scientific soundness, study indication or the rights, safety or welfare of human subjects. The trial must also comply with the FDA&#8217;s regulations, including the requirement that informed consent be obtained from each subject. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA clearance to market the product in the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">In Vitro Diagnostic Companion Diagnostic Devices.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The FDA has described <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> diagnostics (&#8220;IVD&#8221;) companion diagnostic devices as in vitro diagnostic devices that provide information that is essential for the safe and effective use of a corresponding therapeutic product. The use of an IVD companion diagnostic device with a particular therapeutic product is stipulated in the instructions for use in the labeling of both the diagnostic device and the corresponding therapeutic product, as well as in the labeling of any generic equivalents of the therapeutic product. An IVD companion diagnostic device could be used to (i)&#160;identify patients who are most likely to benefit from a particular therapeutic product; (ii)&#160;identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic product; or (iii)&#160;monitor response to treatment for the purpose of adjusting treatment (e.g., schedule, dose, discontinuation) to achieve improved safety or effectiveness. Although FDA&#8217;s regulation of IVD companion diagnostic devices is evolving and implemented on a case<span class="nobreak">-by-case</span> basis, FDA&#8217;s stated policy for a novel therapeutic product is that an IVD companion diagnostic device should be developed and approved or cleared contemporaneously to support the therapeutic product&#8217;s safe and effective use. The clinical performance and clinical significance of the IVD companion diagnostic device is to be established using data from the clinical development program of the corresponding therapeutic product. FDA recognizes, however, that there may be cases where contemporaneous development may not be possible. With respect to the Gencaro Test, there is no assurance that ARCA will be able to develop and obtain approval or clearance contemporaneously with Gencaro. Failure to develop the Gencaro Test or obtain clearance or approval could delay approval of Gencaro, if FDA regards the Gencaro Test as an IVD companion diagnostic test that is essential to the safe and effective use of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Continuing Regulation.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>After a device is placed on the market, numerous regulatory requirements apply to the manufacturer, or holder of a PMA approval. Unless subject to an exemption, medical devices distributed in the United&#160;States must be manufactured in compliance with the FDA&#8217;s QSRs and current good manufacturing practices. These regulations govern the manufacturing process, including design, manufacture, testing, release, packaging, distribution, documentation and purchasing, as well as complaint handling, corrective and preventative actions and internal auditing. In complying with the QSRs, manufacturers must expend significant time, money and effort. Companies are also subject to other post<span class="nobreak">-market</span> and general requirements, including but not limited to product listing and establishment registration, post<span class="nobreak">-market</span> surveillance requirements, limitations on promotion, and requirements for recordkeeping and reporting of certain adverse events, malfunctions, corrections and removals. As discussed above, FDA regularly inspects companies to assess compliance with the QSRs and other post<span class="nobreak">-market</span> requirements. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, and potential civil and criminal penalties. As part of such arrangement, ARCA will seek to have the diagnostic company take responsibility for compliance with the FDA&#8217;s device approval and on<span class="nobreak">-going</span> regulatory requirements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">209</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">International Marketing Approvals.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country and are subject to change. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Regulatory Requirements.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>ARCA is also subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its work. The extent and character of governmental regulation that might result from future legislation or administrative action cannot be accurately predicted.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Medical Device Tax</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2010, the U.S.&#160;Congress adopted and President Obama signed into law comprehensive health care reform legislation. Among other initiatives, these laws impose significant new taxes on medical device makers in the form of a 2.3% excise tax on U.S.&#160;medical device sales, with certain exemptions, beginning on January&#160;1, 2013. On January&#160;22, 2018, legislation was enacted suspending the medical device tax in 2018 and 2019. In December&#160;2019, a permanent repeal of the medical device tax was enacted. The Gencaro Test is likely to be subject to this tax if this tax is reinstated in the future.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intellectual Property</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The future success of ARCA&#8217;s business will partly depend on its ability to maintain market exclusivity for its product candidates, if approved, in the United&#160;States and important international markets, and for other products or product candidates that ARCA may acquire or develop. ARCA will rely on statutory protection, patent protection, trade secrets, know<span class="nobreak">-how</span>, and in<span class="nobreak">-licensing</span> of technology rights to maintain protection for ARCA&#8217;s products.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, will have market exclusivity in the United&#160;States and in major international markets. ARCA recently obtained a patent in the United&#160;States for the use of Gencaro for the patient population ARCA plans to study in the Phase&#160;3 pivotal trial. ARCA has filed similar patent applications in international jurisdictions. If Gencaro is approved by the FDA or international regulatory agencies based on this planned clinical development, ARCA believes that the commercialization of Gencaro will have patent protection extending into 2039.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an existing patent portfolio of United&#160;States and international patents covering the use of Gencaro for various cardiovascular indications in the genetic population it plans to study in Phase&#160;3, that ARCA believes will provide additional patent protection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to patent protection, Gencaro will qualify as a new chemical entity and if approved will have data protection in the United&#160;States and other jurisdictions in which it is approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has other patent rights in additional drug candidates having possible indications in cardiovascular disease, oncology, and other therapeutic areas; these are in both early and later stages of development. ARCA may seek collaborators to assist it in the development of these candidates or it may seek to raise funds to advance the development of the compounds on its own.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Information about ARCA&#8217;s Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Information relating to ARCA&#8217;s executive officers is included under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Directors, Executive Officers and Corporate Governance</span>&#8221; in the proxy statement/prospectus and such information is incorporated herein by reference.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Human Capital Management</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, ARCA had 5 employees, 4 of which are full<span class="nobreak">-time</span>. None of ARCA&#8217;s employees are represented by any collective bargaining unit. ARCA believes that it maintains good relations with its employees.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">210</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Information relating to compensation of ARCA executive officers is included in &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Executive Compensation</span>&#8221; of this proxy statement/prospectus and such information is incorporated herein by reference. The structure of ARCA&#8217;s compensation programs balances incentive earnings for both short<span class="nobreak">-term</span> and long<span class="nobreak">-term</span> performance. ARCA is committed to providing comprehensive benefit options and offering benefits that will allow ARCA&#8217;s employees and their families to live healthier and more secure lives. Some examples are employees are eligible for health insurance, prescription drug benefits, dental insurance, vision insurance, life insurance, disability insurance, health savings accounts, flexible spending accounts, paid and unpaid leaves, a retirement plan and life and disability/accident coverage. ARCA also offers a variety of voluntary benefits that allow employees to select the options that meet their needs, including hospital indemnity insurance, accident insurance and critical illness insurance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA continually monitors employee turnover rates as its success depends upon retaining its highly trained personnel. ARCA believes the combination of competitive compensation and career growth and development opportunities have helped increase employee tenure and reduce voluntary turnover. The average tenure of ARCA&#8217;s employees, as of March&#160;31, 2024, was approximately eleven&#160;years and approximately 40% of ARCA&#8217;s employees, as of March&#160;31, 2024, have been employed by ARCA for more than ten&#160;years.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Corporate Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;27, 2009, ARCA completed a business combination between Nuvelo, Inc., a corporation originally incorporated in 1992, and its subsidiary, ARCA biopharma, Inc. Immediately following the business combinations, ARCA changed its name from Nuvelo, Inc. to ARCA biopharma, Inc. ARCA&#8217;s principal offices are located in Westminster, Colorado.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA files its annual reports on Form&#160;10<span class="nobreak">-K</span>, quarterly reports on Form&#160;10<span class="nobreak">-Q</span> and current reports on Form&#160;8<span class="nobreak">-K</span> pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange&#160;Act electronically with the SEC.&#160;The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.&#160;The address of that site is <span class="Italic" style="font-style:italic;font-weight:normal;">http://www.sec.gov</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You may obtain a free copy of ARCA&#8217;s annual reports on Form&#160;10<span class="nobreak">-K</span>, quarterly reports on Form&#160;10<span class="nobreak">-Q</span>, current reports on Form&#160;8<span class="nobreak">-K</span> and amendments to those reports on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">http://www.arcabiopharma.com</span> on the earliest practicable date following the filing with the SEC or by contacting the Investor Relations Department at ARCA&#8217;s corporate office by calling (720)&#160;940<span class="nobreak">-2100</span>. Information found on ARCA&#8217;s website is not incorporated by reference into this report.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Properties and Facilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s headquarters facility consists of approximately 5,200 square feet of office space in Westminster, Colorado, of which approximately 5,200 square feet is leased until September&#160;2024, after which ARCA can continue to lease on a month<span class="nobreak">-to-month</span> basis. ARCA believes that this facility is adequate to meet its current needs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, ARCA may become involved in legal proceedings. ARCA is not currently a party to or aware of any proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on ARCA because of defense and settlement costs, diversion of management resources and other factors.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">211</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T12"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA&#8217;S BUSINESS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">All references to Oruka&#8217;s &#8220;product candidates,&#8221; &#8220;programs,&#8221; &#8220;portfolio&#8221; and &#8220;pipeline&#8221; in this proxy statement/prospectus refer to the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company focused on developing novel monoclonal antibody therapeutics for PsO and other&#160;I&amp;I indications. Oruka&#8217;s name is derived from <span class="Italic" style="font-style:italic;font-weight:normal;">or</span>, for &#8220;skin,&#8221; and <span class="Italic" style="font-style:italic;font-weight:normal;">arukah</span>, for &#8220;restoration&#8221; and reflects the company&#8217;s mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Oruka&#8217;s strategy is to apply antibody engineering and format innovations to validated modes of action, which Oruka believes will enable it to improve meaningfully upon the efficacy and dosing regimens of standard<span class="nobreak">-of-care</span> medicines while significantly reducing technical and biological risk. Oruka&#8217;s programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue<span class="nobreak">-resident</span> memory T cells (&#8220;TRMs&#8221;). Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (IL<span class="nobreak">-23p19</span>) for the treatment of PsO.&#160;Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> (&#8220;IL<span class="nobreak">-17A</span>/F&#8221;) for the treatment of PsO, PsA, and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large&#160;I&amp;I markets with continued unmet need.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Pipeline</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_001.jpg" style="width:601.6px;max-width:100%;"/></span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ORKA-001</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> monoclonal antibody (&#8220;mAb&#8221;) designed to target IL<span class="nobreak">-23p19</span>. IL<span class="nobreak">-23</span> is a pro<span class="nobreak">-inflammatory</span> cytokine that plays a critical role in the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL<span class="nobreak">-23</span> is composed of two subunits: a p40 subunit that is shared with IL<span class="nobreak">-12</span> and a p19 subunit that is specific to IL<span class="nobreak">-23</span>. First<span class="nobreak">-generation</span> IL<span class="nobreak">-23</span> antibodies bound p40 and inhibited both IL<span class="nobreak">-12</span> and IL<span class="nobreak">-23</span> signaling, while more recent IL<span class="nobreak">-23</span> antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical evidence, Oruka believes that ORKA<span class="nobreak">-001</span> could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL<span class="nobreak">-23p19</span>. ORKA<span class="nobreak">-001</span> is engineered with YTE half<span class="nobreak">-life</span> extension technology, a specific three amino acid change in the fragment crystallizable (&#8220;Fc&#8221;) domain to modify the pH<span class="nobreak">-dependent</span> binding to the neonatal Fc receptor (&#8220;FcRn&#8221;). As a result, it has a pharmacokinetic profile designed to support a subcutaneous (&#8220;SQ&#8221;) injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Oruka believes that the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">212</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">expected characteristics of ORKA<span class="nobreak">-001</span> increase its potential to deliver these disease<span class="nobreak">-modifying</span> benefits. Oruka plans to initiate a Phase&#160;1 trial of ORKA<span class="nobreak">-001</span> in the first half of 2025 that will have the potential not only to generate important pharmacokinetic and safety data but also to demonstrate its efficacy in PsO patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence. It is the largest pharmaceutical market within dermatology, with annual sales of approximately $25&#160;billion in 2022, which is estimated to grow to $32&#160;billion by 2028. Around half of PsO patients have moderate or severe disease that cannot be adequately addressed by topical corticosteroids or oral therapies. The American Academy of Dermatology<span class="nobreak">-National</span> Psoriasis Foundation recommends biologics as first<span class="nobreak">-line</span> therapy for moderate<span class="nobreak">-to-severe</span> PsO.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Several classes of biologic therapies have been approved for PsO over the past 20&#160;years, resulting in progressively more complete symptom relief. Efficacy in PsO is typically measured via the psoriasis area and severity index (&#8220;PASI&#8221;) scoring system. The first biologics approved for PsO were tumor necrosis alpha (&#8220;TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>&#8221;) inhibitors such as Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab), which achieved a 90%&#160;improvement in PASI score (&#8220;PASI 90&#8221;) at 16&#160;weeks in around&#160;25&#160;&#8211;&#160;50% of patients and a 100% improvement in PASI score (&#8220;PASI 100&#8221;) in&#160;around 5&#160;&#8211;&#160;20% of patients. Stelara (ustekinumab), which targets the p40 subunit of IL<span class="nobreak">-23</span> that is shared with IL<span class="nobreak">-12</span>, was approved next and achieved efficacy on par with Humira. IL<span class="nobreak">-17A</span> inhibitors Cosentyx (secukinumab), Taltz (ixekizumab), and Siliq (brodalumab) followed and achieved responses of PASI 90 in around&#160;70% of patients and PASI 100 in&#160;around 40% of patients with some risk of certain side effects such as oral candidiasis. Most recently, IL<span class="nobreak">-23p19</span> inhibitors such as Ilumya (tildrakizumab), Tremfya (guselkumab), and Skyrizi (risankizumab) have achieved responses of PASI 90 in&#160;around 70&#160;&#8211;&#160;80% of patients and PASI 100 in around 30&#160;&#8211;&#160;50% of patients with highly tolerable profiles. Finally, IL<span class="nobreak">-17A</span>/F inhibitors such as Bimzelx (bimekizumab) have recently shown even higher response rates than IL<span class="nobreak">-23</span> inhibitors, but with slightly less tolerable profiles.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Treatment expectations in PsO have evolved progressively with this continued innovation. A 75% improvement in PASI score was previously thought to be an adequate depth of response, and weekly SQ dosing was viewed as acceptable. With each subsequent generation of innovation, patient and caregiver expectations have advanced. Today, Skyrizi, is widely viewed as the leader in PsO biologic therapy and achieves PASI 100 in&#160;40&#160;&#8211;&#160;50% of patients at the 16<span class="nobreak">-week</span> primary endpoint with maintenance dosing every three&#160;months. While this is a remarkable advancement, there is still significant unmet need. Approximately half of moderate<span class="nobreak">-to-severe</span> PsO patients do not achieve full skin clarity, and a continued desire for more convenient dosing options has driven significant interest in orally delivered medicines targeting these same pathways. However, oral therapies have yet to match the efficacy and safety profile of biologics. Oruka believes that a long<span class="nobreak">-acting</span> biologic with higher efficacy and potential for disease modification represents the next step in advancing the standard of care in PsO.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is expected to enter Phase&#160;1 clinical trials in the first half of 2025. Oruka plans to carry out a Phase&#160;1 program that could provide validation of half<span class="nobreak">-life</span> extension in 2025. In addition, Oruka plans to include PsO patients in its Phase&#160;1 program, which would give Oruka the opportunity to demonstrate 16<span class="nobreak">-week</span> PASI response rates by the end of 2026. Oruka then plans to proceed into Phase&#160;2/3 development. Based on recent precedent for PsO, Oruka anticipates that the entire development program from first<span class="nobreak">-in-human</span> to biologics license application (&#8220;BLA&#8221;) filing could take as little as six to seven&#160;years based on the averages for recently approved medicines.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-002</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span> and IL<span class="nobreak">-17F</span> (IL<span class="nobreak">-17A</span>/F). IL<span class="nobreak">-17</span> inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications, such as hidradenitis suppurativa (&#8220;HS&#8221;) and axial spondyloarthritis (&#8220;axSpA&#8221;). More recently, the importance of inhibiting the IL<span class="nobreak">-17F</span> isoform along with IL<span class="nobreak">-17A</span> has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has led to higher response rates in patients than blockade of IL<span class="nobreak">-17A</span> alone. ORKA<span class="nobreak">-002</span> is designed to bind IL<span class="nobreak">-17A</span>/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half<span class="nobreak">-life</span> extension technology that could enable more convenient dosing intervals. Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka views ORKA<span class="nobreak">-002</span> and ORKA<span class="nobreak">-001</span> as highly complementary. Patients with moderate<span class="nobreak">-to-severe</span> PsO that have purely skin manifestations are most often treated with IL<span class="nobreak">-23</span> inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">213</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">PsA, an IL<span class="nobreak">-17</span> inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL<span class="nobreak">-17</span> inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL<span class="nobreak">-23</span> inhibitor. Together, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additional&#160;I&amp;I indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Additional Pipeline Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, designed to target an undisclosed pathway. Oruka&#8217;s strategy as a company is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Oruka&#8217;s third program provides the potential for indication expansion beyond PsO and creates combination opportunities with Oruka&#8217;s more advanced programs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Team, Investors, and Paragon Collaboration</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka was founded in February&#160;2024 by leading healthcare investor Fairmount Funds Management and hold options to acquire intellectual property rights with respect to certain research programs, including ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, from Paragon. Fairmount Funds Management has launched other successful biotechnology companies leveraging antibody technologies generated by Paragon, including Apogee Therapeutics and Spyre Therapeutics. Oruka is led by a management team with significant experience in developing novel treatments for patients at biopharmaceutical companies such as CRISPR Therapeutics, Celgene, Novartis, and Protagonist Therapeutics. Together, Oruka&#8217;s team has a proven track record of building successful biotech organizations in high<span class="nobreak">-growth</span> environments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since its inception, Oruka has raised $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note. On April&#160;3, 2024, Oruka entered into a definitive merger agreement with ARCA to create a new public company focused on advancing Oruka&#8217;s pipeline of antibody therapies. In support of the Merger, Oruka has secured commitments for a $275.0&#160;million private investment (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note) in Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase Oruka common stock from a syndicate of premier healthcare investors led by Fairmount Funds Management and Venrock Healthcare Capital Partners, with participation from RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi<span class="nobreak">-Asset</span> Investing, Avidity Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP, and Redmile Group, as well as other investors, including multiple large investment management firms, that is expected to close immediately prior to completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the exercise of its Options (defined below) under the Paragon Option Agreements and execution of the respective license agreements, Oruka will have exclusive worldwide development and commercialization rights to Oruka&#8217;s programs, with IL<span class="nobreak">-23</span> rights for all indications outside of inflammatory bowel disease (&#8220;IBD&#8221;), pursuant to such agreements, as applicable. Fairmount Funds Management founded Paragon in 2021 as the firm&#8217;s discovery engine for biologics that potentially overcome limitations of existing therapies. Paragon leverages a dedicated in<span class="nobreak">-house</span> team of scientific experts in antibody development, as well as its partnership with FairJourney Biologics, to generate unique therapeutic concepts and enable its rapid proof<span class="nobreak">-of-concept</span> validation. Oruka considers Paragon to be a related party. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions&#160;&#8212;&#160;Oruka Transactions&#160;&#8212;&#160;Oruka&#8217;s Relationship with Paragon and Paruka</span>&#8221; for additional information.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">214</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To achieve its goal of developing leading therapeutic antibodies for patients with inflammatory skin diseases, Oruka is applying antibody engineering to validated modes of action. Oruka believes this approach will enable it to improve meaningfully upon the efficacy and convenience of standard<span class="nobreak">-of-care</span> medicines while significantly reducing technical and biological risk. The key elements of Oruka&#8217;s strategy include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employ advanced antibody engineering to build biologics that could significantly improve upon existing therapies:&#160;&#160;&#160;&#160;</span>Oruka and its collaborators at Paragon have optimized a variety of parameters using a suite of antibody technologies to develop candidates with the potential to improve upon existing therapies. These parameters include extending half<span class="nobreak">-life</span> to increase exposure and reduce dosing frequency, enhancing affinity and specificity to maximize potency and safety, and optimizing developability to ensure consistency and enable convenient, high<span class="nobreak">-dose</span> formulations. Together, Oruka believes these features have the potential to translate into more efficacious and convenient medicines for patients.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Target validated mechanisms of action:&#160;&#160;&#160;&#160;</span>Oruka&#8217;s initial targets, IL<span class="nobreak">-23p19</span> and IL<span class="nobreak">-17A</span>/F, have established efficacy and safety for the treatment of PsO, PsA, and other indications. The FDA has approved four biologics in the IL<span class="nobreak">-23</span> class, including three targeting IL<span class="nobreak">-23p19</span>, and four biologics in the IL<span class="nobreak">-17</span> class, including one targeting IL<span class="nobreak">-17A</span>/F.&#160;While these therapies have advanced the standard of care in PsO and PsA, they have not addressed these diseases completely, and a significant fraction of patients do not achieve complete skin clearance. By applying Oruka&#8217;s advanced antibody engineering to these validated targets, Oruka believes it can maximize its chances of developing superior medicines for patients. In addition, the reduced technical and biological risk of these validated mechanisms may allow Oruka to progress its programs more efficiently and rapidly.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leverage insights from earlier entrants to optimize Oruka&#8217;s approach:&#160;&#160;&#160;&#160;</span>Oruka benefits from a large body of clinical evidence generated by prior therapies targeting IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. Oruka continues to extract and apply learnings from this precedent to its programs, including in development candidate selection, clinical trial design, dosing regimens, formulations and presentations, regulatory pathway, and indication prioritization. For instance, based on correlations between affinity and efficacy, Oruka has designed ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> to bind to similar epitopes and at similar or greater affinities as the leading antibodies in each class: risankizumab and bimekizumab, respectively, with the aim of maximizing efficacy. Also, by understanding the exposure<span class="nobreak">-response</span> relationships for efficacy and safety for other therapies, Oruka plans to select dose levels and regimens that could maximize efficacy and maintenance of response while maintaining safety.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pursue opportunities with strong prospects of yielding meaningful new medicines as a &#8220;base case&#8221; and the potential to shift the treatment paradigm entirely as an &#8220;upside case&#8221;:&#160;&#160;&#160;&#160;</span>Oruka&#8217;s strategy seeks to maximize the potential for Oruka&#8217;s programs to reach a base case product profile that could meaningfully advance the standard of care&#160;&#8212;&#160;for instance, for ORKA<span class="nobreak">-001</span>, SQ dosing one or twice a year with equal or greater efficacy compared to today&#8217;s standard of care. At the same time, Oruka aims to deliver an upside case that dramatically improves outcomes for patients&#160;&#8212;&#160;for instance, significantly increasing rates of complete skin clearance via higher antibody exposures or offering patients durable remissions free from therapy by introducing patient<span class="nobreak">-specific</span> dosing intervals.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Build a preeminent biotechnology company focused on chronic skin disease and other&#160;I&amp;I indications:&#160;&#160;&#160;&#160;</span>Oruka is assembling a team of exceptional people and helping them reach their full potential and flourish so that together it can bring forward meaningful new medicines for patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that pursuing the focused strategy outlined above will help it to succeed in its mission of offering patients living with PsO, PsA, and other dermatologic and inflammatory diseases the greatest possible freedom from their condition.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Targeting IL-23 and IL-17 to Treat Multiple&#160;I&amp;I Indications</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s programs benefit from significant advances in the understanding of the biology of&#160;I&amp;I diseases over the past four decades. ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> are designed to target two key cytokines that play a related role in multiple indications. IL<span class="nobreak">-23</span> is an upstream regulator of Th17 cells, a pro<span class="nobreak">-inflammatory</span> subset of T helper cells </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">215</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">characterized by their production of IL<span class="nobreak">-17</span>. IL<span class="nobreak">-23</span> has a critical role in maintaining Th17 cells in the tissue as well as activating these cells to secrete IL<span class="nobreak">-17</span>, which acts downstream to trigger inflammation and other disease symptoms. Th17 cells are involved in PsO, PsA, HS, axSpA, and many other diseases. They play a particularly central role in PsO and PsA.&#160;The diagram below depicting the immunopathogenesis of PsO provides an example of how Th17 cells can mediate disease and how blocking IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> can break the inflammatory cycle that drives disease.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Immunopathogenesis of PsO and the role of IL-23 and IL-17</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><img alt="" src="timage_002.jpg" style="width:599.04px;max-width:100%;"/></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO develops when environmental triggers and a genetic predisposition combine to cause activation of an inflammatory cycle in the skin that leads to the formation of plaques and other disease manifestations. This process begins with the aberrant activation of the dendritic cells (&#8220;DCs&#8221;), specifically those producing IL<span class="nobreak">-23</span> and other cytokines like IL<span class="nobreak">-1</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#946;</span>, IL<span class="nobreak">-21</span>, TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, and IL<span class="nobreak">-12</span>. These cytokines induce the differentiation of Th17 cells, as well as other cell types, such as T helper type 1 (&#8220;Th1&#8221;) cells that produce IFN<span class="CharOverride-1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#947;</span> and TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> and T helper type 22 (&#8220;Th22&#8221;) cells that produce IL<span class="nobreak">-22</span>. IL<span class="nobreak">-23</span> plays a key role in the differentiation and activation of Th17 cells to secrete IL<span class="nobreak">-17</span>, as well as Th22 cells to produce IL<span class="nobreak">-22</span>. IL<span class="nobreak">-17</span> and these other cytokines induce keratinocyte hyperproliferation leading to plaque formation and a feedforward inflammatory response, with changes in gene expression in keratinocytes, the production of antimicrobial peptides, and neutrophil recruitment driving further inflammation. While many cytokines and cell types contribute to the pathogenesis of PsO, the IL<span class="nobreak">-23</span>/IL<span class="nobreak">-17</span> axis plays an important role, as supported by the success of therapies targeting this axis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the successful treatment of PsO&#160;&#8212;&#160;for instance, with mAbs targeting IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> &#8212;&#160;can result in lesional skin returning to an apparently normal state, disease tends to recur at previously affected sites following cessation of therapy, suggesting a mechanism of &#8220;immunological memory&#8221; that predisposes individuals to recurrence in the same locations. Evidence suggests that pathogenic TRMs play a critical role in this memory. TRMs may arise from the Th17 cells and other cells that drove disease in the first place and remain in their resident tissue, in this case the epidermis and dermis, for long periods of time. Upon a disease trigger, these TRMs can actively produce proinflammatory cytokines, causing disease recurrence. IL<span class="nobreak">-23</span> appears to play an important role in maintaining and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">216</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">potentiating TRMs, as indicated by the depletion of TRMs following treatment with an IL<span class="nobreak">-23</span> inhibitor but not an IL<span class="nobreak">-17</span> inhibitor, which may explain the longer remissions observed with IL<span class="nobreak">-23</span> inhibitors following withdrawal of therapy. This type of data has raised the prospect that efficient IL<span class="nobreak">-23</span> blockade could modify the disease biology of PsO, possibly leading to durable remissions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The scientific discoveries that refined our understanding of the immunopathogenesis of PsO have led to waves of therapeutic advances, ultimately leading to today&#8217;s standard of care. Before the 1980s, PsO was not even thought of as an immunologic disease, but rather a disease of keratinocyte dysfunction, leading to treatments such as phototherapy, methotrexate, and retinoids. The discovery in the 1980s that PsO results from immune dysfunction led to the use of broad immunosuppressants like cyclosporine. From 1990 to 2008, it was believed that Th1 cells, a subpopulation of T helper cells that produce pro<span class="nobreak">-inflammatory</span> cytokines such as IFN<span class="CharOverride-1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#947;</span> and TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, were the predominant mediators of the disease, which led to the use of biologics targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> such as Enbrel (etanercept) and Humira (adalimumab). Finally, the revelation that PsO is driven principally by Th17 cells resulted in the development of the primary therapies used today, which target IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. This increasingly refined understanding of the disease has narrowed the standard of care from broad immunosuppressive agents (such as cyclosporine) to more specific immunomodulators (TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitors) to precise biologic therapies targeting the key cytokines involved in disease pathology (IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span> inhibitors), with each new therapeutic class raising the bar on both safety and efficacy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biologic therapies, especially mAbs, are now mainstays in the treatment of a wide variety of&#160;I&amp;I diseases, including PsO and PsA.&#160;Each biologic approved in PsO has raised the bar on standard of care, with therapies that have improved upon efficacy and/or reduced dosing frequency achieving the most commercial success, even when launching many&#160;years after other biologics. Enbrel was first approved for PsO in 2004 with a weekly maintenance dosing schedule. Four&#160;years later, Humira was approved for PsO with an every<span class="nobreak">-other-week</span> (Q2W) dosing schedule. Stelara (ustekinumab) was approved a year later with similar Phase&#160;3 data to Humira, but with a significantly improved dosing schedule of every twelve&#160;weeks (Q12W). Several drugs for PsO have been approved since 2009 that demonstrated higher efficacy in their pivotal studies compared to Stelara, but with more burdensome dosing schedules, including Tremfya (guselkumab), which has a dosing schedule of every eight&#160;weeks (Q8W), and Cosentyx (secukinumab) and Taltz (ixekizumab), which have dosing schedules of every four&#160;weeks (Q4W). While these therapies have all become generally successful products, the most commercially successful drug in the PsO market today is Skyrizi (risankizumab), which combines Stelara&#8217;s Q12W dosing schedule with improvements in efficacy, as evidenced by higher PASI 90 and PASI 100 rates in clinical trials. In addition, Bimzelx (bimekizumab), approved by the FDA in 2023, has shown evidence of efficacy that exceeds even Skyrizi, though with a less convenient Q8W dosing schedule. Although many biologics have entered the PsO market over the past two decades, new entrants have had significant commercial success when they have improved upon efficacy and/or dosing frequency, and room remains to improve in both areas to set a new standard for the treatment of PsO.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Biologics have raised the bar on the standard of care in PsO, but leave room for improvement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_003.jpg" style="width:500.48px;max-width:100%;"/></span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">217</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The biology driving PsO and PsA is well understood today, and the standard of care has progressed dramatically. Oruka believes that it is unlikely that a novel mechanism will emerge that is as safe and efficacious as targeting the IL<span class="nobreak">-23</span>/IL<span class="nobreak">-17</span> axis. Therefore, Oruka believes that innovation now should be focused on optimizing the product profile that can be offered to patients. While much effort is being directed toward daily oral formats to inhibit this axis, oral medicines have yet to match the efficacy of biologics. Oruka believes that a better biologic with a longer dosing interval and the potential for improved efficacy will present a more attractive product profile for most patients.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of Psoriasis (PsO)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence, estimated to be around&#160;2&#160;&#8211;&#160;3% of the population currently, according to the World Psoriasis Day consortium. The most common form of PsO is plaque psoriasis. Patients with chronic plaque psoriasis have well<span class="nobreak">-demarcated</span>, erythematous plaques with overlying, coarse, silvery<span class="nobreak">-scaled</span> patches. These plaques can occur anywhere on the body, though are typically found on the scalp, extensor areas of the knees and elbows, and gluteal cleft. Involvement of the palms, soles, or nails, and intertriginous areas, including the genitals, can also occur and can be particularly difficult to treat. Around half of PsO patients have moderate disease, defined as having 3% to 10% of the body surface area (&#8220;BSA&#8221;) involved, or severe disease, defined as having more than 10% BSA involvement. The chronic inflammation in PsO is associated with multiple comorbidities, including PsA, obesity, metabolic syndrome, hypertension, diabetes, and atherosclerotic cardiovascular disease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed earlier, PsO is a complex immune<span class="nobreak">-mediated</span> disease driven primarily by Th17 cells and the cytokines IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. The interplay of environmental and behavioral risk factors and genetics is believed to trigger PsO.&#160;Multiple lines of evidence support a genetic component to the disease, including the observation that approximately 40% of patients with PsO and PsA have a family history of the disease and the identification of multiple susceptibility loci, many containing genes related to the regulation of the immune system, in genome<span class="nobreak">-wide</span> association studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Current PsO Treatments and Limitations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While patients with mild PsO typically rely on topical corticosteroids or oral therapies like Otezla (apremilast), these agents often do not provide an adequate response for patients with moderate<span class="nobreak">-to-severe</span> PsO.&#160;As a result, the American Academy of Dermatology<span class="nobreak">-National</span> Psoriasis Foundation recommends biologics as first<span class="nobreak">-line</span> therapy for moderate<span class="nobreak">-to-severe</span> PsO.&#160;Today, Skyrizi (risankizumab) is widely viewed as the leader in PsO biologic therapy. In Phase&#160;3 clinical trials, 43% and 58% of patients achieved PASI 100 at 16 and 52&#160;weeks, respectively, with SQ maintenance dosing every three&#160;months. Most recently, Bimzelx (bimekizumab) has shown evidence of efficacy that exceeds even Skyrizi, achieving a 64% PASI 100 rate at 16&#160;weeks in Phase&#160;3 trials. However, the increased efficacy comes with a less convenient Q8W dosing schedule and an increased risk of certain side effects, most notably oral candidiasis. While agents like Skyrizi and Bimzelx reflect the remarkable advancement in PsO treatment, there remains significant unmet need. Approximately half of moderate<span class="nobreak">-to-severe</span> PsO patients do not achieve full skin clarity, and while early signs are present, the promise of disease modifying therapy remains unrealized. Oruka believes that ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> could represent the next step in biologic innovation in PsO, with the potential for higher rates of complete skin clearance, more durable remissions, and markedly more convenient dosing regimens.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of Psoriatic Arthritis (PsA)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsA is a chronic inflammatory condition that affects both the skin and joints, and often coexists with PsO.&#160;Around a quarter to a third of patients with moderate<span class="nobreak">-to-severe</span> PsO also have PsA.&#160;Most individuals develop PsO before being diagnosed with PsA, with a median gap of seven to eight&#160;years between the diagnosis of skin and joint disease, though in up to 30% of patients with PsA, joint symptoms appear before or simultaneously with skin manifestations. Patients with PsA present with joint pain, stiffness, and swelling affecting the peripheral joints, axial skeleton, or both. Entheses, dactylitis, nail lesions, fatigue, and ocular inflammation all occur commonly. PsA can lead to irreversible joint damage, including bony fusion across a joint (ankylosis). The pathogenesis of PsA is likely to be closely related to the mechanisms that underlie PsO.&#160;Like PsO, the exact cause of PsA remains unknown, but environmental triggers, including infection and trauma, and genetic factors play a role.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">218</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Current PsA Treatments and Limitations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective treatment of PsA requires a coordinated approach to address the unique combination of disease manifestations each patient has, which can include peripheral and axial arthritis, enthesitis, dactylitis, and skin and nail involvement. Many patients with milder disease symptoms will start with nonsteroidal anti<span class="nobreak">-inflammatory</span> drugs (&#8220;NSAIDs&#8221;) and/or local treatments to address specific disease manifestations. However, those with more moderate or severe disease and/or multidomain involvement will typically receive a biologic therapy targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> or IL<span class="nobreak">-17</span>, or less commonly an oral Janus kinase (&#8220;JAK&#8221;) inhibitor. Comorbid conditions can also influence treatment selection. For example, an IL<span class="nobreak">-17</span> inhibitor would be preferred for a patient with significant skin involvement, but not for patients with IBD or ocular symptoms, where a TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitor would be preferred. The most common endpoint used to measure the efficacy of TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> or IL<span class="nobreak">-17</span> inhibitors in PsA is ACR response, or the proportion of patients achieving a specified percent improvement in American College of Rheumatology (&#8220;ACR&#8221;) score, which measures peripheral joint disease. Approved TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitors, including Humira (adalimumab) and Cimzia (certolizumab), achieved a placebo<span class="nobreak">-adjusted</span> ACR50 response of around&#160;30&#160;&#8211;&#160;35% at 24&#160;weeks with Q2W dosing. Approved IL<span class="nobreak">-17</span> inhibitors, including Cosentyx (secukinumab) and Taltz (ixekizumab), achieved a slightly lower placebo<span class="nobreak">-adjusted</span> ACR50 response of around&#160;25&#160;&#8211;&#160;30% at 24&#160;weeks, but with more convenient Q4W dosing. Bimzelx (bimekizumab) has not yet received approval in the United&#160;States for PsA; however, in two Phase&#160;3 clinical trials, bimekizumab achieved a placebo<span class="nobreak">-adjusted</span> ACR50 response of 34% and 37% at 16&#160;weeks with Q4W dosing. A significant fraction of patients with PsA still do not achieve a satisfactory response with available therapies, and even the most convenient regimens require monthly SQ dosing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of additional opportunities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to PsO and PsA, inhibition of IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> has demonstrated efficacy in a number of additional&#160;I&amp;I indications, including HS and axSpA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HS is a chronic inflammatory skin disease characterized by lesions that include deep<span class="nobreak">-seated</span> nodules and abscesses, draining tracts, and fibrotic scars that occur most commonly in intertriginous areas, such as the armpits and groin. Due to the associated pain, sensitive locations, drainage, odor, and scarring, this condition can have a particularly negative psychosocial impact on affected individuals. HS is believed to be underdiagnosed and could have a prevalence well above 1% worldwide. Treatment varies depending on severity and can include topical and systemic antibiotics, hormone therapy, immune modulators, and surgery. Humira (adalimumab) was the only FDA<span class="nobreak">-approved</span> medication for the treatment of moderate<span class="nobreak">-to-severe</span> HS from its approval in 2015 until the approval of Cosentyx (secukinumab) in October&#160;2023. However, now multiple other biologics, including Bimzelx (bimekizumab), are advancing through development and have demonstrated encouraging data in clinical trials, though a significant fraction of patients still do not achieve adequate responses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">axSpA is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints that comprise the axial skeleton. The disease causes severe pain, stiffness, and fatigue, and can have additional clinical manifestations like uveitis, enthesitis, peripheral arthritis, and PsO.&#160;Patients with axSpA may develop further structural damage in their spine, which can lead to the fusion of vertebra (spinal ankylosis), which has a massive negative impact on mobility, physical function, and quality of life. The overall prevalence of axSpA is estimated to be around 1% in the United&#160;States. Treatment of axSpA starts with physical therapy and NSAIDs. If patients do not have an adequate response to NSAIDs, a TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitor is typically used, followed by an IL<span class="nobreak">-17</span> inhibitor, such as Cosentyx (secukinumab), Taltz (ixekizumab), or Bimzelx (bimekizumab), or less frequently a JAK inhibitor. Patients often need to cycle through therapies over time due to inadequate responses or loss of response.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Solution: Half-Life Extension and Antibody Engineering Technologies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s antibody engineering campaigns are designed to optimize multiple attributes in parallel: binding affinity, potency in a variety of assays, developability, and consistently extended serum half<span class="nobreak">-life</span> in non<span class="nobreak">-human</span> primates (&#8220;NHPs&#8221;). Half<span class="nobreak">-life</span> extension is possible by modifying the pH<span class="nobreak">-dependent</span> binding affinity of the antibody Fc domain for FcRn. A primary mechanism of elimination of antibodies from the serum is through pinocytosis and degradation in the lysosomes of cells. Throughout this process, antibodies can be recycled back into the serum by binding to FcRn while they are in endosomes. The interior of the endosome is acidic, and therefore the efficiency of this recycling process depends on the ability of the antibody Fc domain to bind to FcRn at low pH.&#160;If this low pH binding is efficient enough, antibody recycling can be favored over degradation, potentially resulting in a much longer serum half<span class="nobreak">-life</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">219</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Antibody engineers have discovered methods of modifying the Fc domain to optimize the efficiency of recycling via FcRn binding. Several engineering strategies have been identified over the past two decades, with the so<span class="nobreak">-called</span> &#8220;YTE&#8221; mutations (M252Y/S254T/T256E) and &#8220;LS&#8221; mutations (M428L/N434S) being the most frequently used. Importantly, while these strategies have been known for some time, it was only relatively recently that enough clinical precedent was established to provide confidence in how these mutations perform in humans. Two products incorporating YTE modification were approved in 2023 by the FDA, Beyfortus (nirsevimab) and Evusheld (tixagevimab and cilgavimab), and several more candidates are in clinical trials. Two products using LS mutations were approved in 2021 and 2022, Xevudy (sotrovima) and Ultomiris (ravulizumab), respectively, and several more candidates are in clinical trials. Based on clinical data in humans, antibodies with YTE mutations typically have a half<span class="nobreak">-life</span> that is two to four times longer than wildtype antibodies. In addition, preclinical data in NHPs can be used to predict the approximate half<span class="nobreak">-life</span> in humans, with the human half<span class="nobreak">-life</span> equaling around 3.1&#160;times the NHP half<span class="nobreak">-life</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Clinical experience with YTE-modified mAbs predicts significant half-life extension over wildtype mAbs</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_004.jpg" style="width:380.16px;max-width:100%;"/></span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While this increasing body of clinical precedent serves to validate half<span class="nobreak">-life</span> extension, Oruka does not yet have clinical data showing that the introduction of these amino acid substitutions in its programs leads to a longer serum half<span class="nobreak">-life</span>. However, Oruka aims to establish this favorable pharmacokinetic profile early in the clinical development of its product candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-001</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Summary</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target the p19 subunit of IL<span class="nobreak">-23</span>. Based on preclinical data generated to date, Oruka believes ORKA<span class="nobreak">-001</span> has the potential to become the leading IL<span class="nobreak">-23</span> inhibitor and achieve an optimal product profile in PsO consisting of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:bold;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">One to two maintenance doses per year.&#160;&#160;&#160;&#160;</span>Standard<span class="nobreak">-of-care</span> therapies targeting IL<span class="nobreak">-23</span> require maintenance dosing every eight to twelve&#160;weeks. Oruka engineered the Fc portion of ORKA<span class="nobreak">-001</span> to include YTE mutations to increase the half<span class="nobreak">-life</span> of ORKA<span class="nobreak">-001</span> in circulation, which may enable dosing every six to twelve&#160;months&#160;&#8212;&#160;a dosing interval made feasible by half<span class="nobreak">-life</span> extension technology. In </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">220</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">preclinical studies, serum levels from&#160;NHPs indicated an elimination half<span class="nobreak">-life</span> of 24&#160;days following SQ administration of a precursor antibody to ORKA<span class="nobreak">-001</span>. Based on published scientific literature on other antibodies incorporating YTE mutations and pharmacokinetic modeling, Oruka anticipates this half<span class="nobreak">-life</span> in NHPs to translate to a half<span class="nobreak">-life</span> in humans that could allow subcutaneous dosing every six to twelve&#160;months while maintaining high antibody exposures.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Higher PASI 100.&#160;&#160;&#160;&#160;</span>ORKA<span class="nobreak">-001</span> benefits from the robust validation of IL<span class="nobreak">-23</span> inhibition in PsO by multiple approved therapies, such as Skyrizi (risankizumab) and Tremfya (guselkumab), while leveraging insights from these therapies to improve upon their clinical profile. ORKA<span class="nobreak">-001</span> is designed to bind a similar epitope to the market<span class="nobreak">-leading</span> anti<span class="nobreak">-IL-23</span> antibody, Skyrizi, with similar or greater affinity and could achieve much higher exposures in patients due to half<span class="nobreak">-life</span> extension. Skyrizi and Tremfya both have a robust exposure<span class="nobreak">-response</span> relationship, with higher drug exposures leading to higher response rates. Published data indicates that these therapies have not saturated this exposure<span class="nobreak">-response</span> relationship, and ORKA<span class="nobreak">-001</span> could lead to higher response rates, including higher rates of complete skin clearance, or PASI 100, through increased exposure, even while having more convenient dosing with as few as one or two maintenance doses per year.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Validated IL</span><span class="nobreak"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">-23p19</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;"> safety profile.&#160;&#160;&#160;&#160;</span>Existing commercially approved antibodies targeting IL<span class="nobreak">-23</span> provide a robust precedent for the safety of IL<span class="nobreak">-23</span> inhibition. Across thousands of patients dosed in dermatology and IBD indications, no correlations have been observed at the patient level between exposure and safety. While Oruka is not pursuing IBD, the approved Skyrizi regimen for Crohn&#8217;s disease supports the safety of high peak exposures. Peak Skyrizi exposures during the&#160;IV induction phase in Crohn&#8217;s disease are over 2.5 times higher than the peak ORKA<span class="nobreak">-001</span> exposures at dose levels Oruka currently plans to evaluate in PsO.&#160;In addition, an exposure<span class="nobreak">-response</span> analysis for Skyrizi in ulcerative colitis showed no relationship between exposures and evaluated safety endpoints in the 12<span class="nobreak">-week</span> induction or 52<span class="nobreak">-week</span> maintenance periods. In this assessment, the top quartile of average exposures spanned 176 to 342 &#181;g/mL in the induction period and 25 to 62 &#181;g/mL in the maintenance period, which are approximately 7 and 5 times higher, respectively, than the highest anticipated exposures with ORKA<span class="nobreak">-001</span> in the same periods.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Potential to offer longer term remission to some patients.&#160;&#160;&#160;&#160;</span>Emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Dr.&#160;Andrew Blauvelt, chair of Oruka&#8217;s Scientific Advisory Board, pioneered some of this work by using two- and four<span class="nobreak">-times</span> the approved dose levels of risankizumab to achieve best<span class="nobreak">-in-indication</span> response rates. This study, called KNOCKOUT, showed a robust depletion of TRMs following high dose IL<span class="nobreak">-23</span> inhibition, which could lead to longer<span class="nobreak">-lasting</span> remissions in some patients. Additional evidence from a study of guselkumab, called GUIDE, showed that intervention early in the disease course can lead to longer treatment<span class="nobreak">-free</span> remissions. In addition, retrospective claims data suggests that treatment with an IL<span class="nobreak">-23</span> inhibitor could help prevent progression to PsA, though this finding has yet to be confirmed by a prospective clinical trial. Given the high antibody exposures expected with ORKA<span class="nobreak">-001</span>, Oruka believes that ORKA<span class="nobreak">-001</span> could lead to durable remissions for some patients, especially those with short disease duration. Oruka plans to pursue patient<span class="nobreak">-specific</span> dosing intervals to provide each patient the greatest possible freedom from their disease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that this target profile for ORKA<span class="nobreak">-001</span> could offer improved freedom from disease to many patients affected by PsO and represent a step forward in the standard of care.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical Data</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka evaluated ORKA<span class="nobreak">-001</span> in numerous preclinical studies for several key features:</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Potency that matches or exceeds Skyrizi (risankizumab) in vitro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has tested the potency of ORKA<span class="nobreak">-001</span> <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span>&#160;in multiple assays, including assays evaluating the inhibition of IL<span class="nobreak">-17</span> release from human peripheral mononuclear blood cells, in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. Based on the results of these </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">221</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">experiments, Oruka believes ORKA<span class="nobreak">-001</span> has the potential for greater potency than risankizumab. Data from the existing commercially approved therapies targeting IL<span class="nobreak">-23</span> indicate that the potency of IL<span class="nobreak">-23</span> inhibition, in this case, measured by affinity, correlates tightly with efficacy.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The affinity of approved mAbs targeting IL-23 correlates tightly with efficacy</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_005.jpg" style="width:272.64px;max-width:100%;"/></span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Significant half-life extension in NHPs that could enable a maintenance dosing interval of once or twice a year in humans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka assessed the impact of incorporating YTE modifications into a precursor antibody to ORKA<span class="nobreak">-001</span> in NHPs in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. The mAb with YTE modifications had a significantly longer half<span class="nobreak">-life</span>, reaching approximately 24&#160;days with SQ administration. Based on clinical experience with YTE<span class="nobreak">-modified</span> mAbs and pharmacokinetic modeling, Oruka believes that this half<span class="nobreak">-life</span> extension could enable dosing once or twice per year, as shown in the figure below.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The incorporation of YTE mutations significantly extends half-life in NHPs, which could enable once or twice yearly dosing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_006.jpg" style="width:590.08px;max-width:100%;"/></span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to enabling less frequent dosing, an extended half<span class="nobreak">-life</span> would increase the exposure of ORKA<span class="nobreak">-001</span>, which has the potential to increase efficacy. Based on published literature, Skyrizi (risankizumab) demonstrates a clear relationship between antibody exposure and efficacy, with higher average serum antibody concentration correlating with higher PASI 90 and PASI 100 rates short<span class="nobreak">-term</span> (at 16&#160;weeks) and long<span class="nobreak">-term</span> (at 52&#160;weeks), as shown for PASI 100 in the figure below. In addition, the KNOCKOUT study, which evaluated two- and four<span class="nobreak">-times</span> higher doses of Skyrizi than the approved regimen, yielded some of the highest PASI 100 rates observed to date, reaching 67% at 16&#160;weeks. Based on Oruka&#8217;s pharmacokinetic modeling, ORKA<span class="nobreak">-001</span> could achieve four<span class="nobreak">-fold</span> higher average exposures than the approved Skyrizi regimen over the first 16&#160;weeks and over two<span class="nobreak">-fold</span> higher average exposures at steady<span class="nobreak">-state</span>, exceeding even the exposures in KNOCKOUT.&#160;Based on the exposure<span class="nobreak">-response</span> relationship observed with other IL<span class="nobreak">-23</span> inhibiting antibodies, Oruka believes that these increased exposures could result in higher efficacy.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">222</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-001 is projected to extend the exposure-response relationship established by studies of Skyrizi</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_007.jpg" style="width:536.32px;max-width:100%;"/></span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Safety in vitro and in vivo</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has evaluated ORKA<span class="nobreak">-001</span> in several&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span>&#160;and&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vivo</span>&#160;preclinical studies to assess safety. In addition, Oruka has initiated a robust nonclinical program to characterize the toxicology, toxicokinetics, and anti<span class="nobreak">-drug</span> antibody profile of ORKA<span class="nobreak">-001</span> in NHPs, including a single<span class="nobreak">-dose</span> non<span class="nobreak">-GLP</span> dose<span class="nobreak">-range</span> finding study and one<span class="nobreak">-month</span> and six<span class="nobreak">-month</span> GLP toxicology studies. Collectively, this nonclinical program is designed to support the initiation of clinical trials. In addition, ORKA<span class="nobreak">-001</span> benefits from the favorable safety precedent for IL<span class="nobreak">-23</span> inhibition provided by the existing commercially approved IL<span class="nobreak">-23-targeted</span> antibodies across several indications.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Characteristics that support ease of manufacturing and potentially enable high-concentration formulations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Finally, Oruka has assessed a variety of attributes essential for manufacturability and high<span class="nobreak">-concentration</span> formulation, including viscosity, solubility, and stability, among others. ORKA<span class="nobreak">-001</span> shows evidence of desirable properties across these characteristics, which Oruka believes will enhance its ability to manufacture ORKA<span class="nobreak">-001</span> successfully and consistently and to deliver high doses of ORKA<span class="nobreak">-001</span> subcutaneously using convenient, low<span class="nobreak">-volume</span> presentations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Clinical Development Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on these potential advantages and preclinical data, Oruka is advancing ORKA<span class="nobreak">-001</span> towards a Phase&#160;1 clinical trial in the first half of 2025. This trial will encompass a Phase&#160;1a single<span class="nobreak">-ascending</span> dose portion in healthy volunteers, followed by a Phase&#160;1b, multiple<span class="nobreak">-dose</span> portion in patients with moderate<span class="nobreak">-to-severe</span> PsO.&#160;Following completion of Phase&#160;1b, patients will become eligible for an open<span class="nobreak">-label</span> extension study. Initial data from the Phase&#160;1a cohort has the potential to provide key validation of both early safety and pharmacokinetics, including half<span class="nobreak">-life</span>, to support extended dosing intervals. Initial data from the Phase&#160;1b cohort has the potential to provide preliminary efficacy data in patients with PsO.&#160;Pending the results from the Phase&#160;1 clinical trial, Oruka plans to initiate a Phase&#160;2 clinical trial in PsO in 2026. Several aspects of PsO facilitate clinical development, including well<span class="nobreak">-established</span>, reproducible endpoints based on PASI scores, low placebo rates, particularly with PASI 90 and PASI 100, a rapid efficacy readout at 16&#160;weeks, and potentially rapid enrollment due to the large patient population.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-002</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Summary</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span>/F.&#160;Dual inhibition of both IL<span class="nobreak">-17A</span> and IL<span class="nobreak">-17F</span> has shown superior efficacy compared to IL<span class="nobreak">-17A</span> inhibition alone in PsO and other indications, as shown by the performance of Bimzelx (bimekizumab) compared to Cosentyx (secukinumab) and Taltz (ixekizumab) in Phase&#160;3 trials. These therapies all utilize Q8W dosing in PsO and Q4W dosing in PsA.&#160;By binding IL<span class="nobreak">-17A</span>/F at similar epitopes and affinity ranges as Bimzelx while incorporating half<span class="nobreak">-life</span> extension technology to potentially enable dosing two to three times a year in PsO and PsA, Oruka believes that ORKA<span class="nobreak">-002</span> could become the leading therapy in the IL<span class="nobreak">-17</span> class.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">223</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical Data</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preclinical program Oruka is conducting to inform development candidate selection and support clinical trial initiation for ORKA<span class="nobreak">-002</span> mirrors that for ORKA<span class="nobreak">-001</span> and spans potency, pharmacokinetics, safety, and manufacturing characteristics. Based on the results of these experiments, Oruka believes ORKA<span class="nobreak">-002</span> has the potential for comparable potency to bimekizumab, but with a significantly longer half<span class="nobreak">-life</span>, which Oruka believes could support dosing two or three times per year based on extrapolation from clinical precedent and pharmacokinetic modeling.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Clinical Development Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025 following ORKA<span class="nobreak">-001</span>. As with ORKA<span class="nobreak">-001</span>, initial data on ORKA<span class="nobreak">-002</span> in healthy volunteers has the potential to provide key validation of both early safety and pharmacokinetics to support extended dosing intervals. Though clinical development of ORKA<span class="nobreak">-002</span> will initially focus on one lead indication, Oruka plans to evaluate ORKA<span class="nobreak">-002</span> in a range of indications over time. Oruka sees ORKA<span class="nobreak">-002</span> as highly complementary to ORKA<span class="nobreak">-001</span>, with the potential to provide an optimal therapy for the approximately one<span class="nobreak">-quarter</span> to one<span class="nobreak">-third</span> of moderate<span class="nobreak">-to-severe</span> PsO patients who have PsA, as well as for PsO patients with highly resistant skin symptoms that do not respond adequately to an IL<span class="nobreak">-23</span> inhibitor. Furthermore, ORKA<span class="nobreak">-002</span> could address indications beyond PsO, including PsA with limited skin involvement, HS, axSpA, and additional&#160;I&amp;I diseases.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional Pipeline Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, that targets an undisclosed pathway. A core tenet of Oruka&#8217;s strategy is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. ORKA<span class="nobreak">-003</span> provides the potential for indication expansion beyond PsO as well as combination opportunities with Oruka&#8217;s more advanced programs. In the future, Oruka may add additional programs to its portfolio beyond ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span>, and ORKA<span class="nobreak">-003</span> that fit its strategic focus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intellectual Property</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka strives to protect the proprietary programs and technologies that it believes are important to its business, including seeking and maintaining patent protection intended to cover the composition of matter of its programs, their methods of use and manufacture, related technologies, diagnostics, and other inventions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Paragon has filed provisional patent applications, and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-23</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-001</span>. In addition, Paragon has filed provisional patent applications, and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-17</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-002</span>. Oruka has not yet exercised its option to acquire exclusive rights to any IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> patent applications, but retains the right to do so. If the provisional patent applications are pursued non<span class="nobreak">-provisionally</span> and mature into one or more issued patents covering ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>, Oruka would expect those patents to expire in 2045, absent any applicable patent term adjustments or extensions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Commercial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should any of its product candidates be approved for commercialization, Oruka intends to develop a plan to commercialize them in the United&#160;States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable Oruka to realize the full commercial value of its programs. Given its stage of development, Oruka has not yet established a commercial organization or distribution capabilities. Oruka currently holds exclusive Options (as defined below) to acquire worldwide development and commercialization rights to all of its programs.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">224</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Manufacturing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently own or operate facilities for product manufacturing, testing, storage, and distribution. Oruka has contracted and expect to continue to contract with third parties for the manufacture and distribution of its product candidates. Because Oruka relies on contract manufacturers, it employs personnel with extensive technical, manufacturing, analytical and quality experience. Oruka&#8217;s team has deep knowledge and understanding of the regulations that govern manufacturing, documentation, quality assurance, and quality control of drug supply that are required to support Oruka&#8217;s regulatory filings.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Competition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition. While Oruka believes that its programs, technology, development experience and scientific knowledge provide it with competitive advantages, Oruka faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. Any product candidates that Oruka successfully develops and commercialize will compete with existing therapies and new therapies that may become available in the future. Many of the companies with which Oruka is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than Oruka does. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Oruka&#8217;s competitors. Smaller or early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Oruka in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies complementary to, or necessary for, Oruka&#8217;s programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Key competitive factors affecting the success of all of Oruka&#8217;s product candidates that it develops, if approved, are likely to be efficacy, safety, convenience, presentation, price, the level of generic competition, and the availability of reimbursement from government and other third<span class="nobreak">-party</span> payors. Oruka&#8217;s competitors may also obtain FDA or other regulatory approval for their products more rapidly than Oruka may obtain approval for its products, which could result in Oruka&#8217;s competitors establishing a strong market position before Oruka is able to enter the market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Specifically, there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as Oruka&#8217;s two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, including major pharmaceutical companies. Oruka does not yet have clinical data for any of its programs and there can be no assurance that its programs will have similar or comparable results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There are several approved biologic therapies for the treatment of moderate<span class="nobreak">-to-severe</span> PsO.&#160;These include mAbs targeting IL<span class="nobreak">-23</span>, such as Skyrizi (risankizumab) from AbbVie, Tremfya (guselkumab) from Janssen, and Ilumya (tildrakizumab) from Sun Pharma, also marketed as Ilumetri by Almirall in Europe, which all target the p19 subunit, and Stelara (ustekinumab) from Janssen, which targets the p40 subunit; mAbs targeting IL<span class="nobreak">-17</span>, such as Bimzelx (bimekizumab) from UCB, which targets IL<span class="nobreak">-17A</span>/F, Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab) from Eli Lilly, which both target IL<span class="nobreak">-17A</span>, and Siliq (brodalumab) from Ortho Dermatologics, also marketed as Kyntheum by LEO Pharma in Europe, which targets IL<span class="nobreak">-17</span> receptor A; and biologics targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, such as Humira (adalimumab) from AbbVie, Enbrel (etanercept) from Amgen, and Remicade (infliximab) from Janssen, and various biosimilar versions of each. In addition, there are several approved oral medicines in these indications, including the phosphodiesterase<span class="nobreak">-4</span> (PDE4) inhibitor Otezla (apremilast) from Amgen and the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) from Bristol<span class="nobreak">-Myers</span> Squibb. Many of these therapies also are approved or in development for PsA, HS, axSpA, and other&#160;I&amp;I indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka is aware of several product candidates in clinical development for moderate<span class="nobreak">-to-severe</span> PsO, along with PsA, HS, axSpA, and other indications. These include the biologics picankibart from Innovent Biologics targeting IL<span class="nobreak">-23p19</span>, sonelokimab from MoonLake Immunotherapeutics targeting IL<span class="nobreak">-17A</span>/F, and izokibep from ACELYRIN targeting IL<span class="nobreak">-17A</span>.&#160;Also, there are several oral agents in development, including JNJ<span class="nobreak">-2113</span> from Janssen targeting the IL<span class="nobreak">-23</span> receptor, DC<span class="nobreak">-806</span> and DC<span class="nobreak">-853</span> from Eli Lilly targeting IL<span class="nobreak">-17A</span>, and TAK<span class="nobreak">-279</span> from Takeda and ESK<span class="nobreak">-001</span> from Alumis, both targeting TYK2.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">225</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">License Agreements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Paragon Therapeutics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, Oruka entered into the Paragon Option Agreements. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. Each Paragon Option Agreement initially included one of two selected targets: IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17A</span>/F.&#160;Under the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s)&#160;(each, an &#8220;Option&#8221;). In the case of IL<span class="nobreak">-23</span>, Oruka&#8217;s Option excludes the therapeutic area of IBD.&#160;From time to time, Oruka can choose to add additional targets to the collaboration by mutual agreement with Paragon and Paruka. As of the date hereof, Oruka has not exercised any Options.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Paragon Option Agreements, Oruka initiated certain research programs with Paragon that generally focus on a particular target (each, a &#8220;Research Program&#8221;). Each Research Program is aimed at discovering, generating, identifying, and/or characterizing antibodies directed to the respective target. For each Research Program, Oruka established or may establish in the future a research plan with Paragon that sets forth the activities that will be conducted, and the associated research budget (each, a &#8220;Research Plan&#8221;). Oruka&#8217;s exclusive option with respect to each Research Program is exercisable at Oruka&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following (i)&#160;with respect to any Research Program other than ORKA<span class="nobreak">-001</span>, the delivery of the data package from Paragon related to the results of the Research Plan activities or (ii)&#160;with respect to ORKA<span class="nobreak">-001</span>, the completion of the IL<span class="nobreak">-23</span> antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless terminated earlier, each Paragon Option Agreement shall continue in force on a Research Program<span class="nobreak">-by-Research</span> Program basis until the earlier of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)&#160;the expiration of the 30<span class="nobreak">-day</span> period after Oruka exercises its Option with respect to a Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii)&#160;the expiration of the applicable Research Term (as defined under each Paragon Option Agreement) (the &#8220;Term&#8221;). Oruka may terminate any Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that Oruka must pay certain unpaid fees due to Paragon upon such termination, as well as any non<span class="nobreak">-cancellable</span> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreement or a Research Program immediately upon written notice to Oruka if, as a result of any action or failure to act by Oruka or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Paragon Option Agreements or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30<span class="nobreak">-day</span> period and (ii)&#160;the other party&#8217;s bankruptcy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon signing of the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million became payable by Oruka to Paragon. This amount was recognized by Oruka as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred by Paragon prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred by Paragon prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of filing of this proxy statement/prospectus, Oruka has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred by Paragon prior to March&#160;31, 2024. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred by Paragon from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>, Oruka was required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 (the &#8220;pre<span class="nobreak">-effective</span> date development costs&#8221;). This amount was recognized as a research and development expense during the period from </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">226</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">February 6 (inception) to March<span class="nobreak"> </span>31, 2024, and accounts payable as of March<span class="nobreak"> </span>31, 2024. Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period ended March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. Oruka will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March<span class="nobreak"> </span>31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the filing date of this proxy statement/prospectus, Oruka has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of these agreements, if Oruka exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Paragon Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, Oruka will grant Paruka warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Government Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post<span class="nobreak">-approval</span> monitoring and post<span class="nobreak">-approval</span> reporting of biologics such as those Oruka is developing. Oruka, along with its third<span class="nobreak">-party</span> contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which Oruka wishes to conduct studies or seek approval or licensure of its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">United&#160;States Biologics Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, biological products are subject to regulation under the FDCA, the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S.&#160;requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United&#160;States generally involves the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) regulation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>approval by an independent IRB, or ethics committee at each clinical site before the trial is commenced;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>performance of adequate and well<span class="nobreak">-controlled</span> human clinical trials in accordance with GCP requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>satisfactory completion of an FDA Advisory Committee review, if applicable;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a determination by the FDA within 60&#160;days of its receipt of a BLA to file the application for review;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">227</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>satisfactory completion of an FDA pre<span class="nobreak">-approval</span> inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United&#160;States.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preclinical and Clinical Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to beginning any clinical trial with a product candidate, in the United&#160;States, Oruka must submit an IND to the FDA.&#160;An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30<span class="nobreak">-day</span> period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;1.&#160;&#160;&#160;&#160;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">228</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;2.&#160;&#160;&#160;&#160;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&#160;2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase&#160;3 clinical trials.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;3.&#160;&#160;&#160;&#160;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so<span class="nobreak">-called</span> Phase&#160;4 studies may be made a condition to approval of the BLA.&#160;Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND.&#160;When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">BLA Submission and Review</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company<span class="nobreak">-sponsored</span> clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan within sixty&#160;days after an end<span class="nobreak">-of-Phase</span>&#160;2 meeting or as may be agreed between the sponsor and FDA.&#160;Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Within 60&#160;days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten&#160;months after the filing date, or, if the application qualifies </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">229</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">for priority review, six&#160;months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post<span class="nobreak">-marketing</span> testing and surveillance to monitor safety or efficacy of a product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post<span class="nobreak">-marketing</span> requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase&#160;4 post<span class="nobreak">-market</span> studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post<span class="nobreak">-marketing</span> studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expedited Development and Review Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life<span class="nobreak">-threatening</span> disease or condition and data demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">230</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A product intended to treat a serious or life<span class="nobreak">-threatening</span> disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase&#160;1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if there is evidence it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six&#160;months of the 60<span class="nobreak">-day</span> filing date (as compared to ten&#160;months under standard review).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, products studied for their safety and effectiveness in treating serious or life<span class="nobreak">-threatening</span> diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well<span class="nobreak">-controlled</span> post<span class="nobreak">-marketing</span> clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act&#160;of&#160;2022 the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post<span class="nobreak">-marketing</span> studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre<span class="nobreak">-approval</span> of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post-Approval Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any products manufactured or distributed by Oruka pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record<span class="nobreak">-keeping</span>, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA.&#160;Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon Oruka and its third<span class="nobreak">-party</span> manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon Oruka and any third<span class="nobreak">-party</span> manufacturers that Oruka may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">231</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post<span class="nobreak">-market</span> studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>fines, warning letters or holds on post<span class="nobreak">-approval</span> clinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>product seizure or detention, or refusal of the FDA to permit the import or export of products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>mandated modification of promotional materials and labeling and the issuance of corrective information;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injunctions or the imposition of civil or criminal penalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off<span class="nobreak">-label</span> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by Oruka and approved by the FDA.&#160;Such off<span class="nobreak">-label</span> uses are common across medical specialties. Physicians may believe that such off<span class="nobreak">-label</span> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off<span class="nobreak">-label</span> use of their products.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Biosimilars and Reference Product Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA<span class="nobreak">-approved</span> reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA<span class="nobreak">-approved</span> reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.&#160;In September&#160;2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">232</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA.&#160;In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12<span class="nobreak">-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well<span class="nobreak">-controlled</span> clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A reference biologic is granted twelve&#160;years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i)&#160;one year after the first commercial marketing, (ii)&#160;18&#160;months after approval if there is no legal challenge, (iii)&#160;18&#160;months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv)&#160;42&#160;months after the application has been approved if a lawsuit is ongoing within the 42<span class="nobreak">-month</span> period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A biological product can also obtain pediatric market exclusivity in the United&#160;States. Pediatric exclusivity, if granted, adds six&#160;months to existing exclusivity periods and patent terms. This six<span class="nobreak">-month</span> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA<span class="nobreak">-issued</span> &#8220;Written Request&#8221; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA.&#160;In July&#160;2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December&#160;20, 2020, Congress amended the PHSA as part of the COVID<span class="nobreak">-19</span> relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12<span class="nobreak">-year</span> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed below, the Inflation Reduction Act&#160;of&#160;2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Healthcare Laws and Compliance Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti<span class="nobreak">-Kickback</span> Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act&#160;of&#160;1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Oruka&#8217;s practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">233</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">se illegal under the AKS.&#160;Instead, the legality of the arrangement will be evaluated on a case<span class="nobreak">-by-case</span> basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that &#8220;caused&#8221; the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third<span class="nobreak">-party</span> payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S.&#160;federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid&#160;&amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse<span class="nobreak">-midwives</span>, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January&#160;1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are also subject to additional similar U.S.&#160;state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If Oruka&#8217;s operations are found to be in violation of any of such laws or any other governmental regulations that apply, Oruka may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government<span class="nobreak">-funded</span> healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non<span class="nobreak">-compliance</span>, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Oruka&#8217;s operations.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Data Privacy and Security</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health<span class="nobreak">-related</span> information. In the United&#160;States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health<span class="nobreak">-related</span> and other personal information could apply to Oruka&#8217;s operations or the operations of Oruka&#8217;s partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;), and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable protected health information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health or condition or information about a </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">234</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to individuals and regulators. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S.&#160;Department of Health and Human Services (&#8220;HHS&#8221;) to settle allegations of HIPAA non<span class="nobreak">-compliance</span>. A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that Oruka submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to Oruka may be delayed or denied.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a)&#160;of the Federal Trade Commission Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, certain state laws, such as the California Consumer Privacy Act&#160;of&#160;2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act&#160;of&#160;2020 (&#8220;CPRA&#8221;), govern the privacy and security of personal information, including health<span class="nobreak">-related</span> information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA/CPRA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked with a particular consumer or household&#160;&#8212;&#160;unless it is subject to HIPAA&#160;&#8212;&#160;and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. Additionally, Oruka&#8217;s use of artificial intelligence and machine learning may be subject to laws and evolving regulations regarding the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the CPRA expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia, Colorado, Connecticut and Utah, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While the laws in these states, like the CCPA, also exempt some data processed in the context of clinical trials, such developments further complicate compliance efforts, and increase legal risk and compliance costs for Oruka and the third parties upon whom Oruka relies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Coverage and Reimbursement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which Oruka obtains regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third<span class="nobreak">-party</span> payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third<span class="nobreak">-party</span> payors. Decisions regarding whether to cover any of Oruka&#8217;s product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan<span class="nobreak">-by-plan</span> basis. Further, no uniform policy for coverage and reimbursement exists in the United&#160;States, and coverage and reimbursement can differ significantly from payor to payor. Third<span class="nobreak">-party</span> payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">235</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time<span class="nobreak">-consuming</span> and costly process that will require Oruka to provide scientific and clinical support for the use of Oruka&#8217;s product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Third<span class="nobreak">-party</span> payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost<span class="nobreak">-containment</span> measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third<span class="nobreak">-party</span> reimbursement for any product or a decision by a third<span class="nobreak">-party</span> not to cover a product could reduce physician usage and patient demand for the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the U.S.&#160;government, state legislatures and foreign governments have continued implementing cost<span class="nobreak">-containment</span> programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out<span class="nobreak">-of-pocket</span> costs. Each year, CMS will select and negotiate a preset number of high<span class="nobreak">-spend</span> drugs and biologics that are covered under Medicare Part&#160;B and Part&#160;D that do not have generic or biosimilar competition. On August&#160;29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. These price negotiations will begin in 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part&#160;B and Part&#160;D increases faster than the rate of inflation. To support biosimilar competition, beginning in October&#160;2022, qualifying biosimilars may receive a Medicare Part&#160;B payment increase for a period of five&#160;years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two&#160;years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Healthcare Reform</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The United&#160;States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United&#160;States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government<span class="nobreak">-funded</span> health care programs, and increased governmental control of drug pricing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ACA, which was enacted in March&#160;2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United&#160;States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and Oruka expects there will be additional challenges and amendments to the ACA in </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">236</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out<span class="nobreak">-of-pocket</span> cost and creating a new manufacturer discount program.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act&#160;of&#160;2011. These reductions went into effect in April&#160;2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the Bipartisan Budget Act&#160;of&#160;2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point<span class="nobreak">-of-sale</span> discounts that manufacturers must agree to offer under the Medicare Part&#160;D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part&#160;D.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May&#160;2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part&#160;B drugs, permitting Medicare Part&#160;D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part&#160;D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January&#160;1, 2021. In response to the Biden administration&#8217;s October&#160;2022 executive order, on February&#160;14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December&#160;7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march<span class="nobreak">-in</span> rights under the Bayh<span class="nobreak">-Dole</span> Act. On December&#160;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March<span class="nobreak">-In</span> Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march<span class="nobreak">-in</span> rights. While march<span class="nobreak">-in</span> rights have not previously been exercised, it is uncertain if that will continue under the new framework.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the IRA, continued legislative and enforcement interest exists in the United&#160;States with respect to specialty drug pricing practices. Specifically, Oruka expects regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Government Regulation&#160;Outside of the United&#160;States</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to regulations in the United&#160;States, Oruka is subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post<span class="nobreak">-approval</span> monitoring and reporting of Oruka&#8217;s products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Whether or not Oruka obtains FDA approval for a product, Oruka must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United&#160;States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post<span class="nobreak">-authorization</span> requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">237</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Regulation in the European Union</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">European Data Laws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May&#160;2018, and related data protection laws in individual EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area (&#8220;EEA&#8221;) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). With regard to the transfer of data from the EEA to the United&#160;States, on July&#160;10, 2023, the EC adopted its adequacy decision for the EU<span class="nobreak">-US</span> Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S.&#160;companies participating in the framework.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#8364;20&#160;million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU.&#160;Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation&#160;No. 536/2014 (&#8220;CTR&#8221;), European Medical Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against Oruka, harm to Oruka&#8217;s reputation, and adversely impact Oruka&#8217;s business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that Oruka faces with regard to data protection regulation. With regard to the transfer of personal data from the EEA to the UK, personal data may now freely flow from the EEA to the UK since the UK is deemed to have an adequate data protection level.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four&#160;years after their entry into force. Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the UK GDPR (as defined </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">238</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in section&#160;3(10)&#160;(as supplemented by section 205(4)) of the Data Protection Act&#160;2018 (the &#8220;DPA&#160;2018&#8221;)), the DPA&#160;2018, and related data protection laws in the UK). Separate from the fines that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of &#163;17.5&#160;million or 4% of global turnover.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the UK&#8217;s withdrawal from the EU and the EEA, companies are subject to specific transfer rules under the UK regime; personal data may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules broadly mirror the GDPR rules. On February&#160;2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March&#160;21, 2022 and replaced the old SCCs for the purposes of the UK regime. However, the transitional provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September&#160;21, 2022 on the basis of any old SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March&#160;21, 2024, provided that the processing operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal data is subject to appropriate safeguards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">With regard to the transfer of personal data from the UK to the United&#160;States, the UK government has adopted an adequacy decision for the United&#160;States, the UK<span class="nobreak">-US</span> Data Bridge, which came into force on October&#160;12, 2023. The UK<span class="nobreak">-US</span> Data Bridge recognizes the United&#160;States as offering an adequate level of data protection where the transfer is to a U.S.&#160;company participating in the EU<span class="nobreak">-US</span> Data Privacy Framework and the UK Extension.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug and Biologic Development Process</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January&#160;31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the former regime, which will expire after a transition period of three&#160;years as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees. NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A more unified procedure will apply under the new CTR.&#160;A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal (the &#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an &#8220;opt<span class="nobreak">-out</span>&#8221; from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three<span class="nobreak">-year</span> transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January&#160;31, 2023, submission of initial clinical trial applications via CTIS is mandatory, and by January&#160;31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS.&#160;On July&#160;19, 2023, the EC </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">239</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">published guidance concerning the steps to be taken in this transition. This guidance provides, among other things, that (i)&#160;documentation which was previously assessed will not be reassessed, (ii)&#160;templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance with the CTR do not need to be updated and (iii)&#160;there is no need to retrospectively create a site suitability form, which are only necessary for new trial sites.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk<span class="nobreak">-management</span> programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug Marketing Authorization</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a MA.&#160;To obtain a MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application. National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations generally takes up to 210&#160;days, excluding time taken to provide any additional information or data required by the MHRA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;) for MAAs. The IRP applies since January&#160;1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g., Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast<span class="nobreak">-tracked</span> MHRA review to obtain and/or update a MA in the UK or Great Britain.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post<span class="nobreak">-authorization</span> procedures including line extensions, variations and renewals.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Centralized Authorization Procedure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional member states of the EEA.&#160;The centralized procedure is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto<span class="nobreak">-immune</span> and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May&#160;20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a MA through the centralized procedure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post<span class="nobreak">-authorization</span> and maintenance activities, such as the assessment of modifications or extensions to an existing MA.&#160;Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210&#160;days from receipt of a valid MAA.&#160;However, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">240</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150&#160;days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67&#160;days after receipt of the CHMP opinion.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Decentralized Authorization Procedure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i)&#160;they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii)&#160;they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii)&#160;they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national MA (mutual recognition procedure).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Risk Management Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i)&#160;at the request of EMA or a national competent authority, or (ii)&#160;whenever the risk<span class="nobreak">-management</span> system is modified, especially as the result of new information being received that may lead to a significant change to the benefit<span class="nobreak">-risk</span> profile or as a result of an important pharmacovigilance or risk<span class="nobreak">-minimization</span> milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA.&#160;Since October&#160;20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">MA Validity Period</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">MAs have an initial duration of five&#160;years. After these five&#160;years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk<span class="nobreak">-benefit</span> balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five<span class="nobreak">-year</span> renewal. Applications for renewal must be made to the EMA at least nine&#160;months before the five<span class="nobreak">-year</span> period expires.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">241</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three&#160;years after authorization ceases to be valid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the UK, the period of three&#160;years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA.&#160;Conversion refers to the procedure by which, as of January&#160;1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically converted into UK MAs effective in Great Britain only.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January&#160;31, 2020 and ending on December&#160;31, 2020 (the &#8220;Brexit Transition Period&#8221;) will be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining EU Member States, the three<span class="nobreak">-year</span> period will start running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advanced Therapy Medicinal Products</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, medicinal products, including ATMPs are subject to extensive pre- and post<span class="nobreak">-market</span> regulation by regulatory authorities at both the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the mandatory RMP, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Exceptional Circumstances/Conditional Approval</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar to accelerated approval regulations in the United&#160;States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i)&#160;the benefit/risk balance of the product is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii)&#160;unmet medical needs will be fulfilled by the grant of the MA and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Data and Market Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As in the United&#160;States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight&#160;years of data exclusivity and 10&#160;years of marketing exclusivity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An additional non<span class="nobreak">-cumulative</span> one<span class="nobreak">-year</span> period of marketing exclusivity is possible if during the data exclusivity period (the first eight&#160;years of the 10<span class="nobreak">-year</span> marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">242</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU.&#160;After eight&#160;years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two&#160;years later (or a total of 10&#160;years after the first MA in the EU of the innovator product), or three&#160;years later (or a total of 11&#160;years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight<span class="nobreak">-year</span> data exclusivity period. Additionally, another non<span class="nobreak">-cumulative</span> one<span class="nobreak">-year</span> period of data exclusivity can be added to the eight&#160;years of data exclusivity where an application is made for a new indication for a well<span class="nobreak">-established</span> substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Another year of data exclusivity may be added to the eight&#160;years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre<span class="nobreak">-trial</span> tests or clinical trials (when examining an application by another applicant for or holder of MA for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include an NCE.&#160;Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g., a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its entry into force.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Orphan Designation and Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the U.S.&#160;The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life<span class="nobreak">-threatening</span> or chronically debilitating condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, orphan drug designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a MA, as not all orphan<span class="nobreak">-designated</span> medicines reach the authorization application stage) must be submitted first before an application for MA of the medicinal product is submitted. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MA is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional MA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a MA; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of MA review by the EMA and approval by the EC.&#160;Additionally, any MA granted for an orphan medicinal product must only cover the therapeutic indication(s)&#160;that are covered by the orphan drug designation. Upon the grant of a MA, orphan drug designation provides up to ten&#160;years of market exclusivity in the orphan indication.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the 10<span class="nobreak">-year</span> period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for MA, accept an application to extend an existing MA or grant a MA for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two&#160;years of market exclusivity for an orphan<span class="nobreak">-designated</span> condition when the results of specific studies are reflected in the Summary of Product </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">243</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Characteristics (&#8220;SmPC&#8221;) addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The 10<span class="nobreak">-year</span> market exclusivity may be reduced to six&#160;years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e., the condition prevalence or financial returns criteria under Article&#160;3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a MA may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, following the post<span class="nobreak">-Brexit</span> transition period, a system for incentivizing the development of orphan medicines was introduced. Overall, the requirements for orphan designation largely replicate the requirements in the EU and the benefit of market exclusivity has been retained. Products with an orphan designation in the EU can be considered for an orphan MA in Great Britain, but a UK<span class="nobreak">-wide</span> orphan MA can only be considered in the absence of an active EU orphan designation. The MHRA will review applications for orphan designation at the time of a MA, and will offer incentives, such as market exclusivity and full or partial refunds for MA fees to encourage the development of medicines in rare diseases.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Pediatric Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA.&#160;The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g., until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g., because the relevant disease or condition occurs only in adults) has been granted by the EMA.&#160;The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six<span class="nobreak">-month</span> extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval), or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January&#160;1, 2021 have been adopted as UK PIPs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">PRIME Designation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small<span class="nobreak">-and</span> medium<span class="nobreak">-sized</span> enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non<span class="nobreak">-clinical</span> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick<span class="nobreak">-off</span> meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">244</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post-Approval Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar to the United&#160;States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure by Oruka or by any of its third<span class="nobreak">-party</span> partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti<span class="nobreak">-corruption</span> or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post<span class="nobreak">-authorization</span> safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk<span class="nobreak">-management</span> measures, which may be time consuming and expensive and could impact Oruka&#8217;s profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post<span class="nobreak">-authorization</span> Phase&#160;4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA.&#160;Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">More generally, non<span class="nobreak">-compliance</span> with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU.&#160;Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">245</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Sales and Marketing Regulations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The advertising and promotion of Oruka&#8217;s products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off<span class="nobreak">-label</span> promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off<span class="nobreak">-label</span> promotion is prohibited. Direct<span class="nobreak">-to-consumer</span> advertising of prescription<span class="nobreak">-only</span> medicines is also prohibited in the EU.&#160;Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of Oruka&#8217;s products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA.&#160;Following Brexit, the requirements to display the common logo no longer apply to UK<span class="nobreak">-based</span> online sellers, except for those established in Northern Ireland.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Anti-Corruption Legislation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self<span class="nobreak">-regulation</span> codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU.&#160;The provision of benefits or advantages to physicians is also governed by the national anti<span class="nobreak">-bribery</span> laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act&#160;2010. Due to the Bribery Act&#160;2010&#8217;s far<span class="nobreak">-reaching</span> territorial application, the potential penalized act does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Bribery Act&#160;2010 is comprised of four offenses that cover (i)&#160;individuals, companies and partnerships that give, promise or offer bribes, (ii)&#160;individuals, companies and partnerships that request, agree to receive or accept bribes, (iii)&#160;individuals, companies and partnerships that bribe foreign public officials, and (iv)&#160;companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act&#160;2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a maximum term of ten&#160;years and in some cases both.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Regulations in the UK and Other Markets</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The UK formally left the EU on January&#160;31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long<span class="nobreak">-term</span> set of arrangements for the supply of medicines into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting the life </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">246</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The UK government has adopted the Medicines and Medical Devices Act&#160;2021 (the &#8220;MMDA&#8221;) to enable the UK&#8217;s regulatory frameworks to be updated following the UK&#8217;s departure from the EU.&#160;The MMDA introduces regulation<span class="nobreak">-making</span>, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting on future regulations for medicines and medical devices in the UK.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka fails to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Employees and Human Capital Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;3, 2024, Oruka had ten full<span class="nobreak">-time</span> employees. Oruka also engages temporary employees and consultants to augment its existing workforce. None of Oruka&#8217;s employees are represented by a labor union or covered under a collective bargaining agreement. Oruka considers its relationship with its employees to be good.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka recognizes that attracting, motivating, and retaining talent at all levels is vital to continuing its success. Oruka invests in its employees through high<span class="nobreak">-quality</span> benefits, professional development opportunities, and various health and wellness initiatives and offers competitive compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes of Oruka&#8217;s incentive plans (bonus and equity) are to align with the long<span class="nobreak">-term</span> interests of its stakeholders and stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Properties and Facilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka currently operates as a virtual company and does not maintain physical corporate offices. Oruka&#8217;s employees currently work remotely. Oruka believe these arrangements support its current needs. Oruka maintains a mailing address at 221 Crescent St., Building<span class="nobreak"> </span>23, Suite 105, Waltham, MA.&#160;In April&#160;2024, Oruka entered into a lease agreement with Oak Grove LP for office space located in Menlo Park, California. The lease begins on June&#160;15, 2024 with an initial term of 39.5&#160;months.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka may become involved in legal proceedings. Oruka is not currently a party to or aware of any proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on Oruka because of defense and settlement costs, diversion of management resources and other factors.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">247</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9988"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following discussion and analysis of ARCA&#8217;s financial condition and results of operations should be read in conjunction with ARCA&#8217;s consolidated financial statements and notes thereto appearing elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to ARCA&#8217;s plans and strategy for ARCA&#8217;s business, includes forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements that involve risks and uncertainties. As a result of many factors, ARCA&#8217;s actual results could differ materially from the results described in or implied by the forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements contained in the following discussion and analysis</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is dedicated to applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, First Merger Sub, Second Merger Sub and Oruka entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA&#8217;s and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA&#8217;s and the surviving entity of the Second Merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA&#8217;s common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock calculated in accordance with the Merger Agreement, (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA&#8217;s common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA&#8217;s then outstanding but not then vested or exercisable, and cancel each Out of the Money Options to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA&#8217;s common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing) will own approximately 97.61% of the combined </p>
		</div>


		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">248</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately 2.39% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA&#8217;s common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA&#8217;s common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be adjusted to the extent that ARCA&#8217;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million. ARCA management currently anticipates that ARCA&#8217;s net cash as of closing to be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA&#8217;s common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the ARCA Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA&#8217;s common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA&#8217;s common stock that it is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of ARCA&#8217;s common stock on Nasdaq and cause the shares of ARCA&#8217;s common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the SEC and causing to become effective a registration statement to register shares of ARCA&#8217;s common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA&#8217;s stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the Subscription Agreement (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to its&#8217; transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">249</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Preferred Stock, par value $0.001 per share (the &#8220;ARCA Series&#160;B Preferred Stock&#8221;). Holders of the ARCA Series&#160;B Preferred Stock will be entitled to receive dividends on shares of ARCA Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock basis, and in the same form as dividends actually paid on shares of ARCA&#8217;s common stock. Except as otherwise required by the Certificate of Designation or law, the ARCA Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of ARCA Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the ARCA Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the ARCA Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend ARCA&#8217;s certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the ARCA Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the ARCA Series&#160;B Preferred Stock, (e)&#160;issue further shares of the ARCA Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the ARCA Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which ARCA&#8217;s stockholders immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The ARCA Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of ARCA Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the ARCA Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA&#8217;s common stock, subject to certain limitations, including that a holder of ARCA Series&#160;B Preferred Stock is prohibited from converting shares of ARCA Series&#160;B Preferred Stock into shares of ARCA&#8217;s common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA&#8217;s common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Merger Effective Time (the &#8220;Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of six (6)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into the Subscription Agreement with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreement, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the Subscription Agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the exchange ratio and the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. There can be no assurance that the strategic review process or any transaction relating to a specific asset, including the Merger or any asset sale, will result in ARCA pursuing such a transaction(s), or that any transaction(s), if pursued, will be completed on terms favorable to ARCA and its stockholders in the existing entity or any possible entity that results from a combination of entities. If the strategic review process is unsuccessful, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">250</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that ARCA is developing for the treatment of atrial fibrillation in patients with heart failure. ARCA believes the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is developing Gencaro to treat AF in patients with chronic HF.&#160;AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction, or EF, of 40% and higher who also have the genotype ARCA believes is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United&#160;States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro is based on ARCA&#8217;s published analysis of the Phase&#160;2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC<span class="nobreak">-AF</span>.&#160;This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. ARCA currently has an agreement with the FDA, known as a Special Protocol Assessment (&#8220;SPA&#8221;), for the requirements of a Gencaro Phase&#160;3 clinical trial, PRECISION<span class="nobreak">-AF</span>, that would support approval of Gencaro if successful. The Phase&#160;3 pivotal clinical trial of Gencaro conducted under a SPA will include secondary endpoints that are intended to capture some of this information, such as a reduction in the need to deploy rhythm control interventions including electrical cardioversion, catheter ablation and use of anti<span class="nobreak">-arrhythmic</span> drugs and avoidance of drug<span class="nobreak">-related</span> complications such as bradycardia. ARCA was issued a United&#160;States patent in February&#160;2021 for the use of Gencaro in a patient population identified as part of the clinical trial. ARCA believes this patent will substantially extend the patent protection for its planned development of Gencaro into 2039. ARCA has sought or is seeking similar patent protection in other countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United&#160;States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline<span class="nobreak">-recommended</span> therapies for these patients to treat either their AF or HF.&#160;AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta<span class="nobreak">-blockers</span> approved for HF are commonly used off<span class="nobreak">-label</span> to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti<span class="nobreak">-arrhythmic</span> drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti<span class="nobreak">-arrhythmic</span> drugs post<span class="nobreak">-intervention</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF.&#160;ARCA believes there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>More effective rhythm control compared to the current standard of care;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti<span class="nobreak">-arrhythmic</span> drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Maintenance of rhythm control after a successful AF catheter ablation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Effective rate control with lower risk of treatment<span class="nobreak">-limiting</span>, adverse event producing bradycardia;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in symptoms and improvement in quality of life;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduced health care burden;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">251</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Foundational beta<span class="nobreak">-blocker</span> benefits for HF and unique evidence of efficacy in HF patients with AF;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an international patent portfolio for Gencaro in the United&#160;States, the EU, and other major markets, as well as new chemical entity status, including a new patent that ARCA believes will give it a strong intellectual property position to at least approximately 2039 in the United&#160;States; ARCA has filed applications similar to this new patent in international territories. ARCA has developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase&#160;2B clinical trial. ARCA retains all rights to this test platform; ARCA expects to use it in future clinical trials, and ARCA believes it could be one of multiple diagnostic platforms used for commercialization.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">rNAPc2 (AB201) for treatment of COVID-19</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Recombinant Nematode Anticoagulant Protein c2 (&#8220;rNAPc2&#8221;) (AB201) is a protein therapeutic in clinical development as a potential treatment for patients with COVID<span class="nobreak">-19</span>. Based on its unique mechanism of action, development history and the clinical evidence from the SARS<span class="nobreak">-CoV-2</span> pandemic, ARCA believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. ARCA initiated a Phase&#160;2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID<span class="nobreak">-19</span> in the fourth quarter of 2020 and completed patient enrollment in the fourth quarter 2021. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients based on the coagulation biomarker D<span class="nobreak">-dimer</span>, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D<span class="nobreak">-dimer</span> level from Baseline to Day 8 compared to standard of care heparin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the secondary endpoints measuring thrombotic events and time<span class="nobreak">-to-recovery</span>, there was a numerical imbalance in favor of rNAPc2 that was non<span class="nobreak">-significant</span>. rNAPc2 was well<span class="nobreak">-tolerated</span> at both doses. There were no serious treatment<span class="nobreak">-related</span> adverse events and no dose dependent increase in adverse events was observed. There was no difference between rNAPc2 and standard<span class="nobreak">-of-care</span> heparin in major or non<span class="nobreak">-major</span> clinically relevant bleeding. ARCA currently does not plan additional clinical development of rNAPc2 unless ARCA is able to find a commercial or government partner to pay for development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and ARCA&#8217;s general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or is unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund ARCA&#8217;s operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and ARCA&#8217;s ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; in this proxy statement/prospectus. Should ARCA pursue additional clinical trials for its product candidates, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. The Merger discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuit of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">252</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, in an &#8220;at the market offering.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the new sales agreement and the amount available for the offering under ARCA&#8217;s prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. No sales were made under this sales agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Results of Operations</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses primarily consist of personnel costs, consulting and professional fees, insurance, facilities and depreciation expenses, and various other administrative costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses were $2.3&#160;million for the three&#160;months ended March&#160;31, 2024 compared to $1.4&#160;million for the corresponding period of 2023, an increase of $0.9&#160;million. During the three&#160;months ended March&#160;31, 2023, ARCA recorded $159,000 for one<span class="nobreak">-time</span> termination benefits related to the mutually agreed to conclusion of Christopher D.&#160;Ozeroff&#8217;s employment, the former Secretary, Senior Vice President and General Counsel of ARCA, effective March&#160;31, 2023. The increase for the three<span class="nobreak">-month</span> period was primarily a result of a $1.1&#160;million increase in professional fees primarily related to the Merger Agreement discussed above, offset by $0.2&#160;million lower one<span class="nobreak">-time</span> termination benefits and lower personnel costs from the reduction discussed above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses were $6.3&#160;million for the year ended December&#160;31, 2023, compared to $5.8&#160;million for 2022, an increase of approximately $0.4&#160;million. During the year ended December&#160;31, 2023, ARCA recorded $159,000 for one<span class="nobreak">-time</span> termination benefits related to the mutually<span class="nobreak">-agreed</span> to conclusion of Christopher D.&#160;Ozeroff&#8217;s employment, the former Secretary, Senior Vice President and General Counsel of ARCA, effective March&#160;31, 2023. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits. The increase in expenses during 2023 was primarily a result of increases in professional fees and fees to the Special Committee in connection with the Strategic Review, offset by lower one<span class="nobreak">-time</span> termination benefits and lower personnel costs from the reductions discussed above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses in 2024 are expected to be higher than those in 2023 as ARCA incurs professional fees related to the Merger Agreement discussed above and maintains administrative activities to support its ongoing operations. ARCA does expect to incur significant costs related to ARCA&#8217;s exploration of strategic alternatives and the Merger, including legal, accounting and advisory expenses and other related charges.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While ARCA does not believe that inflation had a material effect on its financial condition and results of operations during the periods presented, it may result in increased costs in the foreseeable future.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development (&#8220;R&amp;D&#8221;) expense is comprised primarily of personnel costs, clinical development, manufacturing process development, and regulatory activities and costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense for the three&#160;months ended March&#160;31, 2024 was $0.2&#160;million compared to $0.4&#160;million for the corresponding period of 2023, a decrease of $0.2&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D personnel costs decreased approximately $0.2&#160;million for the three&#160;months ended March&#160;31, 2024, as compared to the corresponding period of 2023, due to decreased headcount.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Manufacturing process development costs for the three&#160;months ended March&#160;31, 2024 and 2023 were consistent.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense decreased $0.1&#160;million related to the unrestricted research grants with ARCA&#8217;s former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">253</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, the Company made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the former President and Chief Executive Officer resigned.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s research and development expenses were $1.0&#160;million for the year ended December&#160;31, 2023 as compared to $4.7&#160;million for 2022, a decrease of $3.7&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D personnel costs decreased approximately $1.2&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding periods of 2022, due to one<span class="nobreak">-time</span> termination benefits incurred in 2022 and decreased headcount from the July&#160;2022 personnel reduction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Clinical expense decreased approximately $1.0&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding period of 2022. Manufacturing process development costs decreased approximately $1.1&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding period of 2022.&#160;The majority of clinical and manufacturing close out costs related to ARCA&#8217;s rNAPc2 (AB201) international Phase&#160;2b clinical trial were incurred in the first half of 2022, with no comparable costs for the corresponding periods of 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense in 2024 is expected to be lower than 2023, as ARCA completed its rNAPc2 (AB201) international Phase&#160;2b clinical trial. Should ARCA resume clinical trials of product candidates, it expects research and development costs to increase significantly for the foreseeable future as ARCA&#8217;s product candidate development programs progress.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Interest and Other Income</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest and other income was $473,000 and $450,000 in the three&#160;months ended March&#160;31, 2024 and 2023, respectively. Interest income was higher due to higher interest rates in 2024 compared to the corresponding periods of 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest and other income was $2.0&#160;million of interest income for the year ended December&#160;31, 2023 as compared to $0.7&#160;million for 2022, resulting in an increase of $1.3&#160;million. Interest income was higher due to higher interest rates in 2023 compared to the corresponding periods of 2022. ARCA expects interest income in 2024 to be lower than 2023, as ARCA continues to use its cash and cash equivalents to fund operations, assuming interest rates remain consistent with 2023.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There was no other expense for the year ended December&#160;31, 2023. Other expense was $5,000 for the year ended December&#160;31, 2022. The amounts were nominal to ARCA&#8217;s overall operations. Based on ARCA&#8217;s current capital structure, other expense is expected to be negligible in 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash and Cash Equivalents as of March&#160;31, 2024 and 2023</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,903</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37,431</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, ARCA had total cash and cash equivalents of $35.9&#160;million, as compared to $37.4&#160;million as of December&#160;31, 2023. The net decrease of $1.5&#160;million primarily reflects the cash used in operating activities during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash and Cash Equivalents as of December&#160;31, 2023 and 2022</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37,431</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,445</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">254</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, ARCA had total cash and cash equivalents of approximately $37.4&#160;million, as compared to $42.4&#160;million as of December&#160;31, 2022. The net decrease of $5.0&#160;million during the year primarily reflects cash used in operating activities during the year ended December&#160;31, 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows from Operating, Investing and Financing Activities</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,528</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net decrease in cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,528</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in operating activities for the three&#160;months ended March&#160;31, 2024 was consistent with the same period in 2023. This was primarily due to lower outflows related to changes in operating assets and liabilities and a higher net loss in 2024, as discussed in Results of Operations above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no investing activities in the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">There were no financing activities in the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by (used in):</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,014</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,912</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase in cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,014</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,914</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">Net cash used in operating activities for the year ended December&#160;31, 2023 decreased approximately $5.9&#160;million compared with 2022. This was primarily due to lower outflows related to changes in operating assets and liabilities and a lower net loss in 2022, as discussed in Results of Operations above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no investing activities in the year ended December&#160;31, 2023. Net cash used in investing activities for the year ended December&#160;31, 2022 was $2,000 for the purchase of property and equipment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no financing activities in the&#160;years ended December&#160;31, 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Sources and Uses of Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s primary sources of liquidity to date have been capital raised from issuances of shares of its preferred and common stock. The primary uses of ARCA&#8217;s capital resources to date have been to fund operating activities, including research, clinical development and drug manufacturing expenses, license payments, and spending on capital items.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, in an &#8220;at the market offering.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the new sales agreement and the amount available for the offering under its prospectus to its registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. No sales were made under this sales agreement in 2024 or 2023.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">255</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s ability to execute its development programs in accordance with ARCA&#8217;s projected timeline depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2 or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; in this proxy statement/prospectus. Should ARCA pursue additional clinical trials for its product candidates, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. The Merger Agreement discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuit of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than ARCA currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. If ARCA resumes the development of product candidates, ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development and potential commercialization Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of ARCA&#8217;s board of directors to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Contractual Obligations and Commitments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s board of directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">256</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain ARCA restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. On April&#160;20, 2024, ARCA&#8217;s board of directors approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker will be paid by ARCA via payroll within 30&#160;business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.&#160;As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020, ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (the &#8220;October&#160;2020 Lease&#8221;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in ARCA&#8217;s primary business office. The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation. Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively. As of March&#160;31, 2024, the lease liability was $48,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Critical Accounting Policies and Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A critical accounting policy is one that is both important to the portrayal of ARCA&#8217;s financial condition and results of operation and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. While ARCA&#8217;s significant accounting policies are described in Note&#160;1 of ARCA&#8217;s consolidated financial statements and notes thereto appearing elsewhere in this proxy statement/prospectus, ARCA believes the following critical accounting policy affected its most significant judgments, assumptions, and estimates used in the preparation of ARCA&#8217;s financial statements and, therefore, is important in understanding ARCA&#8217;s financial condition and results of operations. ARCA had no significant outsourcing expense activity in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing ARCA&#8217;s financial statements, ARCA may be required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">257</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnifications</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, ARCA enters into contractual arrangements under which it may agree to indemnify certain parties from any losses incurred relating to the services they perform on ARCA&#8217;s behalf or for losses arising from certain events as defined within the particular contract. Such indemnification obligations may not be subject to maximum loss clauses. ARCA has entered into indemnity agreements with each of ARCA&#8217;s directors, officers and certain employees. Such indemnity agreements contain provisions, which are in some respects broader than the specific indemnification provisions contained in Delaware law. ARCA also maintains an insurance policy for its directors and executive officers insuring against certain liabilities arising in their capacities as such.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">258</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T11"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">You should read the following discussion and analysis of Oruka&#8217;s financial condition and results of operations together with the sectioned titled &#8220;Oruka&#8217;s Business&#8221; and Oruka&#8217;s financial statements and the related notes appearing elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to Oruka&#8217;s plans and strategy for its business and related financing, includes forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements that involve risks, uncertainties, and assumptions. As a result of many factors, including those factors set forth in the section titled &#8220;Risk Factors&#160;&#8212;&#160;Risks Related to Oruka,&#8221; Oruka&#8217;s actual results could differ materially from the results described in or implied by these forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements. You should carefully read the section titled &#8220;Risk Factors&#160;&#8212;&#160;Risks Related to Oruka&#8221; to gain an understanding of the factors that could cause actual results to differ materially from Oruka&#8217;s forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements. Please also see the section titled &#8220;Cautionary Note&#160;Regarding Forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Statements.&#8221;</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company focused on developing novel monoclonal antibody therapeutics for psoriasis and other&#160;I&amp;I indications. Oruka&#8217;s name is derived from <span class="Italic" style="font-style:italic;font-weight:normal;">or</span>, for &#8220;skin,&#8221; and <span class="Italic" style="font-style:italic;font-weight:normal;">arukah</span>, for &#8220;restoration&#8221;&#8212;&#160;reflects Oruka&#8217;s mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Oruka&#8217;s strategy is to apply antibody engineering and format innovations to validated modes of action, which Oruka believes will enable it to improve meaningfully upon the efficacy and dosing regimens of standard<span class="nobreak">-of-care</span> medicines while significantly intending to reduce technical and biological risk. Oruka&#8217;s programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue<span class="nobreak">-resident</span> memory T cells. Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (&#8220;IL<span class="nobreak">-23p19</span>&#8221;) for the treatment of psoriasis. Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> (&#8220;IL<span class="nobreak">-17A</span>/F&#8221;) for the treatment of PsO, PsA, and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large&#160;I&amp;I markets with continued unmet need.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka Therapeutics, Inc. was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka Therapeutics, Inc. was founded by Paragon and has since assembled a management team with significant experience in clinical development.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-23p19</span>. IL<span class="nobreak">-23</span> is a pro<span class="nobreak">-inflammatory</span> cytokine that plays a critical role in the proliferation and development of Th17 cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO.&#160;IL<span class="nobreak">-23</span> is composed of two subunits: a p40 subunit that is shared with IL<span class="nobreak">-12</span> and a p19 subunit that is specific to IL<span class="nobreak">-23</span>. First<span class="nobreak">-generation</span> IL<span class="nobreak">-23</span> antibodies bound p40 and inhibited both IL<span class="nobreak">-12</span> and IL<span class="nobreak">-23</span> signaling, while more recent IL<span class="nobreak">-23</span> antibodies targeting the p19 subunit have shown improved efficacy and safety when applied by other companies. Based on preclinical evidence, Oruka believes that ORKA<span class="nobreak">-001</span> could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL<span class="nobreak">-23p19</span>. ORKA<span class="nobreak">-001</span> is engineered with YTE half<span class="nobreak">-life</span> extension technology, a specific three amino acid change in the Fc domain to modify the pH<span class="nobreak">-dependent</span> binding to the neonatal FcRn. As a result, it has a pharmacokinetic profile designed to support an SQ injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Oruka believes that the expected characteristics of ORKA<span class="nobreak">-001</span> increase its potential to deliver these disease<span class="nobreak">-modifying</span> benefits. Oruka plans to initiate a Phase&#160;1 trial of ORKA<span class="nobreak">-001</span> in the first half of 2025 that will have the potential to not only generate important pharmacokinetic and safety data but also to demonstrate its efficacy in PsO patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span>/F.&#160;IL<span class="nobreak">-17</span> inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications, such as HS and axSpA.&#160;More recently, the importance of inhibiting the IL<span class="nobreak">-17F</span> isoform along with IL<span class="nobreak">-17A</span> has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">259</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">led to higher response rates in patients than blockade of IL<span class="nobreak">-17A</span> alone. ORKA<span class="nobreak">-002</span> is designed to bind IL<span class="nobreak">-17A</span>/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half<span class="nobreak">-life</span> extension technology that could enable more convenient dosing intervals. Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka views ORKA<span class="nobreak">-002</span> and ORKA<span class="nobreak">-001</span> as highly complementary. Patients with moderate<span class="nobreak">-to-severe</span> PsO that have purely skin manifestations are most often treated with IL<span class="nobreak">-23</span> inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of PsA, an IL<span class="nobreak">-17</span> inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL<span class="nobreak">-17</span> inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL<span class="nobreak">-23</span> inhibitor. Together, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additional&#160;I&amp;I indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, designed to target an undisclosed pathway. Oruka&#8217;s strategy as a company is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Oruka&#8217;s third program provides the potential for indication expansion beyond PsO and creates combination opportunities with Oruka&#8217;s more advanced programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since Oruka&#8217;s inception in February&#160;2024, it has devoted substantially all of its resources to raising capital, organizing and staffing the company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties for the manufacture of Oruka&#8217;s programs and component materials, and providing general and administrative support for these operations. Oruka does not have any programs approved for sale and have not generated any revenue from product sales. To date, Oruka has funded its operations primarily with proceeds from the issuance of its Series&#160;A convertible preferred stock and the issuance of the Convertible Note, both of which were related party transactions. Through March&#160;31, 2024, Oruka received gross proceeds of $3.0&#160;million from the issuance of its Series&#160;A convertible preferred stock and gross proceeds of $25.0&#160;million from the issuance of the Convertible Note. Under the Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which the Convertible Note was sold, Oruka can sell up to an additional $30.0&#160;million in convertible notes. Oruka intends to sell an additional $30.0&#160;million in convertible notes but there is currently no expectation as to when that will occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has incurred operating losses since inception. Oruka&#8217;s ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs Oruka may develop. Oruka generated net losses of $7.1&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024. As of March&#160;31, 2024, Oruka had an accumulated deficit of $7.1&#160;million. Oruka expects to continue to incur significantly increased expenses for the foreseeable future if and as it:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues its research and development and discovery<span class="nobreak">-related</span> development of its programs, ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span>, and ORKA<span class="nobreak">-003</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>submits for and receives allowance to proceed with its investigational new drug applications, or INDs, for certain of its programs in order to commence future clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully completes future preclinical studies for its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks and identifies additional research programs and product candidates and initiates discovery<span class="nobreak">-related</span> activities and preclinical studies for those programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>hires additional research and development and clinical personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>experiences any delays, challenges, or other issues associated with the pre<span class="nobreak">-clinical</span> and clinical development of its programs, including with respect to its regulatory strategies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks marketing approvals for any programs for which it successfully completes clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>develops, maintains and enhances a sustainable, scalable, reproducible and transferable manufacturing process for the programs it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ultimately establishes a sales, marketing and distribution infrastructure to commercialize any programs for which it may obtain marketing approval;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">260</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adds operational, financial and management information systems and personnel, including personnel to support its product development;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks timely and successful completion of preclinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursues effective investigational new drug applications or comparable foreign applications that allow commencement of its planned clinical trials or future clinical trials for any programs it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>initiates enrollment and successful completion of clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursues positive results from its future clinical trials that support a finding of safety and effectiveness, and an acceptable risk<span class="nobreak">-benefit</span> profile in the intended populations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks marketing approvals from applicable regulatory authorities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>maintains, expands, enforces, defends and protects its intellectual property portfolio and other intellectual property protection or regulatory exclusivity for any products it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks maintenance of a continued acceptable safety, tolerability and efficacy profile of any programs it may develop following approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>further acquires or in<span class="nobreak">-licenses</span> product candidates or programs, intellectual property and technologies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establishes and maintains any future collaborations, including making royalty, milestone or other payments thereunder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>maintains a continued acceptable safety profile of its products following approval; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>incurs additional costs of operating as a public company, including audit, legal, regulatory and tax related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premium and investor relation cost.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any changes in the outcome of any of these variables with respect to the development of programs that Oruka may identify could mean a significant change in the costs and timing associated with the development of such programs. For example, if the FDA or another regulatory authority were to require Oruka to conduct clinical trials beyond those that Oruka currently anticipates will be required for the completion of clinical development of a program, or if Oruka&#8217;s experiences significant delays in its clinical trials due to patient enrollment or other reasons, Oruka would be required to expend significant additional financial resources and time on the completion of clinical development. Oruka may never obtain regulatory approval for any of its programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka will not generate revenue from product sales unless and until it successfully initiate and complete clinical development and obtain regulatory approval for any product candidates. If Oruka obtains regulatory approval for any of its programs and do not enter into a commercialization partnership, Oruka expects to incur significant expenses related to developing Oruka&#8217;s commercialization capability to support product sales, manufacturing, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result, Oruka will need substantial additional funding to support its continued operations and growth strategy. Until such a time as Oruka can generate significant revenue from product sales, if ever, it expects to finance its operations through the sale of equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. Oruka may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If Oruka fails to raise capital or enter into such agreements as, and when, needed, Oruka may have to significantly delay, scale back or discontinue the development and commercialization of one or more of Oruka&#8217;s programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because of the numerous risks associated with product development, Oruka is unable to accurately predict the timing or amount of increased expenses or when or if Oruka will be able to achieve or maintain profitability. Even if Oruka is able to generate product sales, it may not become profitable. If Oruka fails to become profitable or are unable to sustain profitability on a continuing basis, then Oruka may be unable to continue Oruka&#8217;s operations at planned levels and be forced to reduce or terminate its operations.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">261</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that the expected net proceeds from the Merger and the Oruka pre<span class="nobreak">-closing</span> financing, together with Oruka&#8217;s existing cash and sales of additional convertible notes under the Purchase Agreement, will enable Oruka to fund its operating expenses through 2027. Oruka has based this estimate on assumptions that may prove to be wrong, and Oruka could exhaust its available capital resources sooner than Oruka expects. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Liquidity and Capital Resources</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to Oruka&#8217;s Financial Condition and Capital Requirements</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Without giving effect to any proceeds from this Merger and the Oruka pre<span class="nobreak">-closing</span> financing, as well as any proceeds from additional borrowings under the Convertible Note, as of March&#160;31, 2024, Oruka expects that its existing cash will be sufficient to fund its operating expenses through the end of second quarter of 2024. Beyond that point, Oruka will need to raise additional capital to finance its operations, which cannot be assured. As disclosed in Oruka&#8217;s financial statements for the period February&#160;6, 2024 (inception) to March&#160;31, 2024, Oruka concluded that there is substantial doubt about its ability to continue as a going concern within one year of the date those financial statements are available to be issued. See Note&#160;1 to Oruka&#8217;s financial statements appearing at the end of this proxy statement/prospectus for additional information on its assessment.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Impact of Risk Factors on Oruka&#8217;s Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Uncertainty in the global economy presents significant risks to Oruka&#8217;s business. Oruka is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, rising interest rates, recent bank failures, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and Israel and Gaza and the responses thereto, and supply chain disruptions. While Oruka is closely monitoring the impact of the current macroeconomic conditions on all aspects of Oruka&#8217;s business, including the impacts on its participants in future clinical trials, employees, suppliers, vendors and business partners, the ultimate extent of the impact on its business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside Oruka&#8217;s control and could exist for an extended period of time. Oruka will continue to evaluate the nature and extent of the potential impacts to Oruka&#8217;s business, results of operations, liquidity and capital resources. For additional information, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to Oruka</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Components of Results of Operations</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Revenue</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To date, Oruka has not generated revenue from any sources, including product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If Oruka&#8217;s development efforts for its product candidates are successful and result in regulatory approval, Oruka may generate revenue in the future from product sales or payments from future collaboration or license agreements that Oruka may enter into with third parties, or any combination thereof. Oruka cannot predict if, when, or to what extent it will generate revenue from the commercialization and sale of its product candidates. Oruka may never succeed in obtaining regulatory approval for any of its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Expenses</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses consist primarily of costs incurred in connection with the development and research of Oruka&#8217;s programs. These expenses include costs of funding research performed by third parties, including Paragon, that conduct research and development activities on Oruka&#8217;s behalf, expenses incurred in connection with continuing Oruka&#8217;s current research programs and discovery<span class="nobreak">-phase</span> development of any programs Oruka may identify, including under future agreements with third parties, such as consultants and contractors, and personnel related expenses, including salaries, bonuses, benefits, and equity<span class="nobreak">-based</span> compensation expense.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expenses research and development costs as incurred. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 Oruka recognized $5.0&#160;million of expenses, in connection with services provided by Paragon and Paruka under the Option Agreements, including nonrefundable research and development expense fees associated with each Research Plan on its condensed statement of operations and comprehensive loss. See &#8220;&#8212;<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;Contractual Obligations and Commitments</span>&#8221; below for further details on Oruka&#8217;s research plans.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">262</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s primary focus since inception has been the identification and development of its pipeline programs. Oruka&#8217;s research and development expenses primarily consist of external costs, such as fees paid to Paragon under the Paragon Option Agreements. Oruka separately tracks the amount of costs incurred under the Paragon Option Agreements with Paragon between ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. See &#8220;&#8212;&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Contractual Obligations and Commitments</span>&#8221; below for further details on the Paragon Option Agreements.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and Administrative</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses consist primarily of personnel related expenses, including salaries, bonuses, benefits, and equity<span class="nobreak">-based</span> compensation, for individuals in Oruka&#8217;s executive, finance, operations, human resources, business development and other administrative functions. Other significant general and administrative expenses include legal fees relating to corporate matters, professional fees for accounting, auditing, tax, information technology, insurance, and recruiting costs. Oruka currently operates as a virtual company. Therefore, Oruka does not incur material operating expenses for the rent, maintenance and insurance of facilities or for depreciation of fixed assets. In April&#160;2024, Oruka entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The Oak Grove Lease begins on June&#160;15, 2024 with an initial term of 39.5&#160;months. Oruka&#8217;s lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects that its general and administrative expenses will increase substantially for the foreseeable future as Oruka increases its headcount to support the expected growth. Oruka also expects to incur increased expenses associated with a reverse merger public transaction and becoming a public company, including increased costs of accounting, audit, legal, regulatory and tax related services associated with maintaining compliance with SEC requirements, additional director and officer insurance costs, and investor and public relations costs. Oruka also expects to incur additional intellectual property<span class="nobreak">-related</span> expenses as Oruka files patent applications to protect innovations arising from its research and development activities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Other Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest expense of $0.2&#160;million incurred for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 relates to the Convertible Note issued to Fairmount Fund&#160;II in March&#160;2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No provision for income taxes was recorded for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024. Deferred tax assets generated from Oruka&#8217;s net operating losses have been fully reserved as Oruka believes it is not more likely than not that the benefit will be realized due to its cumulative losses generated to date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Results of Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s statement of operations and comprehensive loss for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Net loss and comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $5,051 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">263</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $848 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $214 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s research and development expenses incurred for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">External research and development costs by selected target:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">ORKA-002<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,155</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">ORKA-001<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">750</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Other research and development costs:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Personnel-related (including stock-based compensation)<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">264</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:30pt;">Total research and development expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $4,155 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $750 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $146 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses were $5.2&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 and consisted primarily of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$4.2&#160;million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.8&#160;million of research initiation fee expense due to Paragon related to the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.2&#160;million of personnel<span class="nobreak">-related</span> costs related to recruiting costs, salaries, benefits and other compensation<span class="nobreak">-related</span> costs, including stock<span class="nobreak">-based</span> compensation of less than $0.1&#160;million and $0.1&#160;million of personnel<span class="nobreak">-related</span> costs are amounts due to Paragon related to recruiting costs for hiring Oruka&#8217;s research and development team.</p>
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s total general and administrative expenses for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Personnel-related (including stock-based compensation)<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">781</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Professional and consulting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">444</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Legal fees related to patent<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">256</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">189</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">Total general and administrative expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $505 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $256 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $87 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">264</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses were $1.7&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 and consisted primarily of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.8&#160;million of personnel<span class="nobreak">-related</span> costs related to recruiting costs, salaries, benefits and other compensation<span class="nobreak">-related</span> costs, including stock<span class="nobreak">-based</span> compensation of less than $0.1&#160;million and $0.5&#160;million of personnel<span class="nobreak">-related</span> costs are amounts due to Paragon related to recruiting costs for hiring Oruka&#8217;s executive team, legal, and finance and accounting functions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.4&#160;million of professional and consulting fees associated with increases in accounting, audit, and legal fees due to an increase in Oruka&#8217;s business activity and as Oruka began preparation to become a public company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.3&#160;million of legal fees due to Paragon associated with patent related activities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.1&#160;million of investor and public relations costs and fees associated with company formation; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.1&#160;million of costs due to Paragon related to company formation fees.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since Oruka&#8217;s inception, Oruka has incurred significant operating losses. Oruka expects to incur significant expenses and operating losses for the foreseeable future as Oruka commences the pre<span class="nobreak">-clinical</span> and clinical development of its programs and continue its early<span class="nobreak">-stage</span> research activities. Oruka has not yet commercialized any products and Oruka does not expect to generate revenue from sales of products for several&#160;years, if at all. To date, Oruka has funded its operations primarily with proceeds from the sale of its Series&#160;A convertible preferred stock and the issuance of the Convertible Note. In March&#160;2024, Oruka received $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note, both of which were related party transactions. As of March&#160;31, 2024, Oruka had cash of $27.7&#160;million.</p>
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s cash flows for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,911</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase in cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Operating Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February&#160;6, 2024 (inception) to March&#160;31, 2024, net cash used in operating activities was $0.2&#160;million and was primarily attributable to a net loss of $7.1&#160;million, offset by a $6.1&#160;million increase in related parties accounts payable and other current liabilities and a $0.8&#160;million increase in accrued expenses and other current liabilities. The increase in amounts due to related parties and accrued expenses and other current liabilities was primarily due to an increase in Oruka&#8217;s business activity, as well as vendor invoicing and payments.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Financing Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February&#160;6, 2024 (inception) to March&#160;31, 2024, net cash provided by financing activities was $27.9&#160;million, consisting of $2.9&#160;million of net proceeds from the issuance of Oruka&#8217;s Series&#160;A convertible preferred&#160;stock and $25.0&#160;million of net proceeds from the issuance of the Convertible Note.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">265</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Funding Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To date, Oruka has not generated any revenue from product sales. Oruka has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if Oruka&#8217;s development efforts are successful, it is uncertain when, if ever, Oruka will realize significant revenue from product sales. If Oruka obtains regulatory approval for any of its product candidates and start to generate revenue, Oruka expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes its existing cash, together with the anticipated net proceeds from this Merger and the Oruka pre<span class="nobreak">-closing</span> financing, as well as issuances of additional convertible notes under the Purchase Agreement, will be sufficient to fund its operating expenses requirements through 2027. Oruka has based this estimate on assumptions that may prove to be wrong, and Oruka could exhaust its available capital resources sooner than Oruka expects. Oruka expects that it will require additional funding to advance its potential product candidates through development, regulatory approval and commercialization if any of its product candidates are approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Until such time, if ever, as Oruka can generate substantial product revenue, Oruka expects to finance its cash needs through a combination of equity offerings and debt financings. To the extent that Oruka raises additional capital through the sale of equity or convertible debt securities, ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include restrictive covenants that limit Oruka&#8217;s ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Oruka is unable to raise additional funds, it may be required to delay, reduce or eliminate some or all of its planned operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Contractual Obligations and Commitments</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Paragon Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Paragon Option Agreements. Under the terms of the Paragon Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to Oruka. The Option Agreement includes two selected targets, IL<span class="nobreak">-23</span> (ORKA<span class="nobreak">-001</span>) and IL<span class="nobreak">-17A</span>/F (ORKA<span class="nobreak">-002</span>). Under each of the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and potential products directed to the selected targets. If Oruka exercises its options, Oruka will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale. From time to time, Oruka can choose to add additional targets to the collaboration by mutual agreement with Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Paragon Option Agreements, the parties initiated certain Research Programs. Each Research Program is aimed at discovering, generating, identifying and/or characterizing antibodies directed to the respective target. For each Research Program, the parties established a Research Plan that sets forth the activities that will be conducted, and the associated research budget. Oruka and Paragon will agree on initial Research Plans that outline the services that will be performed commencing at inception of the arrangement related to IL<span class="nobreak">-17</span> and IL<span class="nobreak">-23</span>. Oruka&#8217;s exclusive option with respect to each Research Program is exercisable at Oruka&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following the delivery of the data package from Paragon related to the results of the Research Plan activities. There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">266</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Paragon Option Agreements, on a research program<span class="nobreak">-by-research</span> program basis following the finalization of the Research Plan for each respective research program, Oruka was required to pay Paragon a nonrefundable fee in cash of $0.8&#160;million related to the research initiation fee for ORKA<span class="nobreak">-001</span>. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of issuance of Oruka&#8217;s condensed financial statements, Oruka has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expense during the period from February 6 (inception) to March<span class="nobreak"> </span>31, 2024, and accounts payable as of March<span class="nobreak"> </span>31, 2024. Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> Research Plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. Oruka will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March<span class="nobreak"> </span>31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, the Paragon Option Agreements provide for an annual equity grant of warrants to purchase 1.00% of the then outstanding shares of Oruka common stock, on a fully diluted basis, on each of December&#160;31, 2024 and December&#160;31, 2025, during the term of the Paragon Option Agreements, at the fair market value determined by Oruka&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying statement of operations and comprehensive loss.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Note&#160;Payable with Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Purchase Agreement with Fairmount Fund&#160;II, whereby Oruka issued a convertible note, with an initial principal amount of $25.0<span class="nobreak"> </span>million that can be converted into Series&#160;A Preferred Stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for aggregate proceeds of $25.0&#160;million. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without prior written consent of Fairmount Fund II. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible Note.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the proposed reverse recapitalization transaction, the Convertible Note will convert into a number of shares of common stock based on the aggregate principal amount, plus any unpaid accrued interest, divided by the conversion price, which is an amount to be determined based upon Oruka&#8217;s fully<span class="nobreak">-diluted</span> capitalization immediately prior to the reverse recapitalization transaction. In the event the proposed reverse recapitalization transaction or any other proposed corporate transactions do not close prior to Oruka&#8217;s next equity financing, the Convertible Note will convert into the series of issued convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the aggregate principal amount of outstanding borrowings under the Convertible Note was $25.0&#160;million and Oruka has the right to issue and sell up to an additional $30.0&#160;million in convertible notes under the Purchase Agreement.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">267</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s management&#8217;s discussion and analysis of its financial condition and results of operations is based on its financial statements, which have been prepared in accordance with U.S. GAAP.&#160;The preparation of these condensed financial statements requires Oruka to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Oruka&#8217;s estimates are based on its historical experience and on various other factors that Oruka believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka&#8217;s significant accounting policies are described in more detail in Note&#160;2 to its financial statement and condensed financial statements included elsewhere in this proxy statement/prospectus, Oruka believes the following accounting policies used in the preparation of its financial statements require the most significant judgments and estimates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing Oruka&#8217;s financial statements, Oruka is required to estimate its accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the services when Oruka has not yet been invoiced or otherwise notified of actual costs. The majority of Oruka&#8217;s service providers invoice the company in arrears for services performed, on a pre<span class="nobreak">-determined</span> schedule or when contractual milestones are met; however, some require advance payments. Oruka makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to Oruka at that time. At each period end, Oruka corroborates the accuracy of these estimates with the service providers and make adjustments, if necessary. Estimated accrued research and development expenses include those related to fees paid to vendors in connection with discovery development activities and any research organizations in connection with studies and testing. Although Oruka does not expect its estimates to be materially different from amounts actually incurred, Oruka&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka measures stock<span class="nobreak">-based</span> awards granted to employees, directors, and non<span class="nobreak">-employees</span> in the form of stock options to purchase shares of Oruka common stock, based on their fair value on the date of the grant using the Black<span class="nobreak">-Scholes</span> model. Oruka measures restricted common stock awards using the difference, if any, between the purchase price per share of the award and the fair value of Oruka common stock at the date of grant. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award for employees. Compensation expense for awards to non<span class="nobreak">-employee</span> with service<span class="nobreak">-based</span> vesting conditions is recognized in the same manner as if Oruka had paid cash in exchange for the goods or services, which is generally the over the vesting period of the award. Oruka uses the straight<span class="nobreak">-line</span> method to recognize the expense of awards with service<span class="nobreak">-based</span> vesting conditions. Oruka accounts for forfeitures as they occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Black<span class="nobreak">-Scholes</span> model uses inputs that are determined by the Board on the date of grant and assumptions Oruka makes for the volatility of stock<span class="nobreak">-based</span> awards, the expected term of stock<span class="nobreak">-based</span> awards, the risk<span class="nobreak">-free</span> interest rate for a period that approximates the expected term of Oruka&#8217;s stock<span class="nobreak">-based</span> awards and its expected dividend yield. Oruka has historically been a private company and lack company<span class="nobreak">-specific</span> historical and implied volatility information of Oruka&#8217;s stock. Therefore, Oruka estimates its expected stock volatility based on the historical volatility of a representative group of public companies in the biotechnology industry for a term equal to the remaining time of the expected term. The expected term of Oruka&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain<span class="nobreak">-vanilla</span>&#8221; stock options. The risk<span class="nobreak">-free</span> interest rate is determined by reference to the U.S.&#160;Treasury yield curve for time periods approximately equal to the remaining contractual term of the options on the date of measurement. Oruka has estimated a 0% dividend yield based on the expected dividend yield and the fact that Oruka has never paid, and do not expect to pay, any cash dividends in the foreseeable future.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">268</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Determination of Fair Value of Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As there has been no public market for Oruka&#8217;s stock<span class="nobreak">-based</span> awards to date, the estimated fair value of stock<span class="nobreak">-based</span> awards has been determined by Oruka&#8217;s board of directors as of the date of grant, with input from management, and with consideration of additional objective and subjective factors that it believed were relevant. In addition, Oruka&#8217;s board of directors considered various objective and subjective factors to determine the fair value of its share<span class="nobreak">-based</span> awards as of each grant date, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the prices at which Oruka sold shares of Series&#160;A convertible preferred stock and preferences of the Series&#160;A convertible preferred stock relative to Oruka&#8217;s stock<span class="nobreak">-based</span> awards at the time of each grant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the progress of Oruka&#8217;s research and development programs, including the status of discovery<span class="nobreak">-phase</span> studies for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s stage of development and business strategy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>external market conditions affecting the biotechnology industry and trends within the biotechnology industry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s financial position, including cash on hand, and Oruka&#8217;s historical and forecasted performance and operating results;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lack of an active public market for Oruka common stock and its Series&#160;A convertible preferred stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood of achieving a liquidity event, such as the proposed reverse recapitalization transaction, or sale of Oruka in light of prevailing market conditions; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the analysis of reverse recapitalization transactions and market performance of similar companies in the biotechnology industry.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method (&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value&#160;of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability<span class="nobreak">-weighted</span> expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM.&#160;The PWERM is a scenario<span class="nobreak">-based</span> methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based on the probability<span class="nobreak">-weighted</span> present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk<span class="nobreak">-adjusted</span> discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if Oruka had used significantly different assumptions or estimates, the fair value of Oruka&#8217;s incentive shares and its stock<span class="nobreak">-based</span> compensation expense could have been materially different.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Once a public trading market for Oruka common stock has been established in connection with the completion of this Merger, it will no longer be necessary for Oruka&#8217;s board of directors to estimate the fair value of its stock<span class="nobreak">-based</span> awards in connection with its accounting for granted stock<span class="nobreak">-based</span> awards or other such awards Oruka may grant, as the fair value of Oruka&#8217;s common stock and share<span class="nobreak">-based</span> awards will be determined based on the quoted market price of Oruka&#8217;s common stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recently Issued Accounting Pronouncements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A description of recently issued accounting pronouncements that may potentially impact Oruka&#8217;s financial position, results of operations or cash flows is disclosed in Note&#160;2 to Oruka&#8217;s condensed financial statements as of March&#160;31, 2024 appearing at the end of this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">269</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Off-Balance Sheet Arrangements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, Oruka did not have any off<span class="nobreak">-balance</span> sheet arrangements, as defined in the rules and regulations of the SEC.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Quantitative and Qualitative Disclosures about Market Risk</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Interest Rate Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Convertible Note bears interest until December&#160;2025 at a fixed rate per annum equal 12%. An immediate 10% change in the prime rate would not have a material impact on Oruka&#8217;s debt<span class="nobreak">-related</span> obligations, financial position or results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Inflation Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s results of operations and financial condition are presented based on historical cost. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, Oruka believes the effects of inflation, if any, on Oruka&#8217;s results of operations and financial condition have been immaterial. Oruka cannot assure you its business will not be affected in the future by inflation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">270</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T10"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MANAGEMENT FOLLOWING THE MERGER</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Officers and Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the completion of the Merger, the business and affairs of the combined company will be managed under the direction of the combined company&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s board of directors will initially be fixed at six members, consisting of six current Oruka board members, namely Lawrence Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle. The staggered structure of the current ARCA board of directors will remain in place for the combined company following the completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each executive officer of the combined company will serve at the discretion of the combined company&#8217;s board of directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of the proposed combined company&#8217;s directors or executive officers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All of ARCA&#8217;s current directors are expected to resign from their positions as directors of ARCA, effective as of the closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth the name, age as of May&#160;3, 2024 and position of each of the individuals who are expected to serve as executives and directors of the combined company following completion of the Merger:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Age</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">41</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">50</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">61</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">45</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chair and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">52</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">39</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">38</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lawrence Klein, Ph.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Klein has served as Chief Executive Officer of Oruka and as a member of its board of directors since February&#160;2024. Prior to joining Oruka, Dr.&#160;Klein was a Partner at Versant Venture Management, LLC, a healthcare and biotechnology venture capital firm, from January&#160;2023 to February&#160;2024, where he invested in and helped to grow early<span class="nobreak">-stage</span> biotechnology companies. Prior to Versant, Dr.&#160;Klein served in various positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January&#160;2020 to October&#160;2022, Chief Business Officer from January&#160;2019 to January&#160;2020, Senior Vice President, Business Development and Strategy from November&#160;2017 to December&#160;2018 and as Vice President, Strategy from February&#160;2016 to November&#160;2017, where he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee important pipeline programs and led several functions, including program and portfolio management. Before joining CRISPR, Dr.&#160;Klein was an Associate Partner at McKinsey&#160;&amp; Company, a global management consulting firm, from October&#160;2014 to February&#160;2016. Dr.&#160;Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September&#160;2019 to May&#160;2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September&#160;2021 to June&#160;2023. Dr.&#160;Klein received his B.S. in biochemistry and physics from the University of Wisconsin<span class="nobreak">-Madison</span> and his Ph.D. in biophysics from Stanford University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Klein is qualified to serve as a member of the board of directors of the combined company because of his business development, operational and senior management experience in the biotechnology industry and his academic expertise and accomplishments.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">271</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Arjun Agarwal.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Agarwal has served as the Senior Vice President of Finance of Oruka since March&#160;2024, where he is responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Oruka, Mr.&#160;Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company, from June&#160;2021 to March&#160;2024, including through multiple financings and the company&#8217;s successful transition to become a publicly traded entity. Before joining Jasper, Mr.&#160;Agarwal served as Vice President, Corporate Controller at Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology company, from August&#160;2019 to June&#160;2021, where he was responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Protagonist, Mr.&#160;Agarwal served in various roles of increasing responsibility at McKesson Corporation (NYSE:&#160;MCK),&#160;an international healthcare services company, from 2009 to 2019. Prior to McKesson, Mr.&#160;Agarwal worked at PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant accredited by the Institute of Chartered Accountants of India.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Joana Goncalves, MBChB.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Goncalves has served as the Chief Medical Officer of Oruka since April&#160;2024. Prior to joining Oruka, Dr.&#160;Goncalves served as Chief Medical Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company, from October&#160;2018 to April&#160;2024, where she was responsible for representing Cara Therapeutics in interactions with regulatory agencies, the investor and scientific communities and the board of directors, building multifunctional terms and developing the clinical development strategy in dermatological conditions. Prior to Cara, Dr.&#160;Goncalves held various positions at Celgene Corporation, a pharmaceutical company, which was later acquired by Bristol<span class="nobreak">-Myers</span> Squibb Company, from April&#160;2014 to October&#160;2018, where she most recently served as Vice President, Medical Affairs for Dermatology and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA&#174; for psoriasis. Prior to Celgene, Dr.&#160;Goncalves served as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S.&#160;subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, from February&#160;2012 to April&#160;2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas from 2001 to 2012. Dr.&#160;Goncalves received her MBChB from the University of Cape Town, South Africa.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Paul Quinlan.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Quinlan has served as General Counsel of Oruka since April&#160;2024. Prior to joining Oruka, Mr.&#160;Quinlan served as General Counsel, Chief Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from October&#160;2020 to March&#160;2024, where he was responsible for the general supervision of the company&#8217;s legal affairs. From December&#160;2017 to February&#160;2020, he served as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision of the company&#8217;s legal affairs. Prior to CymaBay, Mr.&#160;Quinlan served as General Counsel and Secretary, from 2010 to January&#160;2018, and Chief Legal Officer from 2016 to January&#160;2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible for the general supervision of the company&#8217;s legal affairs. Prior to joining TerraVia, Mr.&#160;Quinlan served as General Counsel of Metabolex, Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining Metabolex, Mr.&#160;Quinlan held various positions at Maxygen, Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen, Mr.&#160;Quinlan practiced law at Cooley LLP and Cravath, Swaine,&#160;&amp; Moore LLP.&#160;Mr.&#160;Quinlan received a law degree from Columbia Law School and an M.Sc. in Medical Biophysics from the University of Toronto.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Kristine Ball.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Ms. Ball has served as a member of the board of directors of Oruka since May&#160;2024. Ms.&#160;Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private biopharmaceutical company, since April&#160;2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics, Inc., a private biotechnology company, from September&#160;2020 to August&#160;2022. Prior to joining Soteria, Ms. Ball served as Senior Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq<span class="nobreak">-listed</span> biopharmaceutical company, which later became VYNE Therapeutics Inc. (Nasdaq: VYNE), from September&#160;2017 to March&#160;2020, where she was responsible for leading all non<span class="nobreak">-R</span>&amp;D functions, including strategic planning, corporate development, commercial, human resources, legal, finance and information technology. Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a Nasdaq<span class="nobreak">-listed</span> pharmaceutical company, which was later acquired by Galenica Group, from November&#160;2012 to October&#160;2016. Prior to Relypsa, Ms. Ball held various other finance roles in the life sciences industry, including Senior Vice President of Finance&#160;&amp; Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc., a biopharmaceutical company, and Vice President of Finance at Exelixis, Inc. (Nasdaq: EXEL), a biotechnology </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">272</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company. Prior to that, Ms. Ball served as a senior manager in life sciences audit practice of Ernst&#160;&amp; Young LLP. Ms.&#160;Ball has served as a member of the board of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company, since May&#160;2020. She previously served on the board of directors of Soteria from September&#160;2020 to August&#160;2022 and Forty Seven, Inc., a Nasdaq<span class="nobreak">-listed</span> biotechnology company, which was later acquired by Gilead Sciences, Inc., from 2018 to 2020. Ms. Ball received a B.S. from Babson College.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Carl Dambkowski, M.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Dambkowski has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since September&#160;2022. Prior to joining Apogee, Dr.&#160;Dambkowski served as a strategic and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology company, from July&#160;2021 to September&#160;2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private bioecology company, from March&#160;2018 to June&#160;2021; and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology company, from January&#160;2020 to September&#160;2022, where he served as the clinical lead starting prior to IND for BBP<span class="nobreak">-398</span> through the out licensing of the compound to Bristol<span class="nobreak">-Myers</span> Squibb based on initial clinical data and for low<span class="nobreak">-dose</span> infigratinib in achondroplasia through initial proof<span class="nobreak">-of-concept</span> data. He was part of the core team that brought TRUSELTIQ<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> (infigratinib) and NULIBRY<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> (fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively. From July&#160;2016 to March&#160;2018, Dr.&#160;Dambkowski was an associate at McKinsey&#160;&amp; Company, a global management consulting firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr.&#160;Dambkowski co<span class="nobreak">-founded</span> Novonate, Inc., a private medical device company focused on building life<span class="nobreak">-saving</span> devices for neonates, in January&#160;2015. Dr.&#160;Dambkowski has coauthored numerous peer<span class="nobreak">-reviewed</span> publications and scientific abstracts and is a named inventor on multiple published and granted patents. Dr.&#160;Dambkowski was trained as a physician at Stanford University, where he also received his M.D. with a concentration in bioengineering. He also received a B.A. (with honors) from Stanford University and an M.A. from Columbia University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Dambkowski is qualified to serve as a member of the board of directors of the combined company because of his significant experience and innovations in the biotechnology industry and his academic expertise and accomplishments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Peter Harwin.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Harwin has served as a member of the board of directors of Oruka since February&#160;2024. Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment firm he co<span class="nobreak">-founded</span> in April&#160;2016. Prior to Fairmount Funds Management, Mr.&#160;Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (Nasdaq: SYRE). Mr.&#160;Harwin received a B.B.A. from Emory University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Mr.&#160;Harwin is qualified to serve as a member of the board of directors of the combined company because his experience serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Samarth Kulkarni, Ph.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Kulkarni has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, since December&#160;2017, where he has also served as a member and chair of the board of directors since June&#160;2018 and September&#160;2023, respectively. Previously, Dr.&#160;Kulkarni served as CRISPR&#8217;s President and Chief Business Officer from May&#160;2017 to November&#160;2017 and as Chief Business Officer from August&#160;2015. Prior to joining CRISPR, Dr.&#160;Kulkarni was at McKinsey&#160;&amp; Company, a global management consulting firm, from 2006 to 2015, with various titles, his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr.&#160;Kulkarni has also served as a member of the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology company, since 2019, including as lead independent director since September&#160;2023, Repare Therapeutics Inc. (Nasdaq: RPTX), a precision oncology company, since November&#160;2019 and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a biotechnology company, since February&#160;2021. Dr.&#160;Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.&#160;Tech. from the Indian Institute of Technology. Dr.&#160;Kulkarni has authored several publications in leading scientific and business journals.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">273</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that Dr.&#160;Kulkarni is qualified to serve as a member of the board of directors of the combined company because of his experience as a consultant and an executive in the biopharmaceutical industry and his academic expertise and accomplishments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cameron Turtle, D.Phil.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Turtle has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Turtle has served as Chief Executive Officer and a member of the board of directors of Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since November&#160;2023 and, before that, as Chief Operating Officer from June&#160;2023 to November&#160;2023. Prior to joining Spyre, Dr.&#160;Turtle was an advisor to Spyre Therapeutics, Inc., a private biotechnology company, from May&#160;2023 to June&#160;2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July&#160;2022 to May&#160;2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biotechnology company, from January&#160;2021 to April&#160;2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November&#160;2018 to January&#160;2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey&#160;&amp; Company, a global management consulting firm, where he worked with pharmaceutical and medical device companies on topics including M&amp;A, growth strategy, clinical trial strategy, and sales force optimization. Dr.&#160;Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John&#8217;s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under<span class="nobreak"> </span>30, San Francisco Business Times 40 Under<span class="nobreak"> </span>40, and the Biocom Life Sciences Catalyst Award.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Turtle is qualified to serve as a member of the board of directors of the combined company because of his experience as a leader in building, financing, and shaping biopharmaceutical organizations from preclinical development to late<span class="nobreak">-stage</span> clinical trials and commercialization.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Composition of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors currently consists of five members, divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three<span class="nobreak">-year</span> term. The staggered structure of the board of directors will remain in place for the combined company following the completion of the Merger, with Class&#160;I directors holding terms expiring at the 2025 annual meeting of stockholders, Class&#160;II directors holding terms expiring at the 2026 annual meeting of stockholders and Class&#160;III directors holding terms expiring at the 2027 annual meeting of stockholders. It is anticipated that the incoming directors will be appointed to classes of the combined company board of directors following the completion of the Merger as follows: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;I directors;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;II directors; and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;III directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Independence</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nasdaq listing rules require a majority of a listed company&#8217;s board of directors to be comprised of independent directors who, in the opinion of the board of directors, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating committees must be independent, and audit and compensation committee members must satisfy additional independence criteria under the Exchange&#160;Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on information provided by each proposed director concerning her or his background, employment and affiliations, ARCA and Oruka expect that the combined company&#8217;s board of directors will determine that each of the directors other than Lawrence Klein, Oruka&#8217;s current President and Chief Executive Officer, who is expected to serve as President and Chief Executive Officer of the combined company, and<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, will qualify as an &#8220;independent director&#8221; as defined under applicable Nasdaq listing rules. In making these determinations, the combined company&#8217;s board of directors will consider the current and prior relationships that each director has with ARCA and Oruka and all other facts and circumstances that the company&#8217;s board of directors deems relevant in determining the independence of each proposed director, including the interests of each combined company director in the Merger, any relevant related party transactions and the beneficial ownership of securities of ARCA, Oruka or the combined company by each combined company director. See also the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; Interests of </span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">274</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Directors and Executive Officers in the Merger</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions of the Combined Company</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of Oruka</span>&#8221; beginning on pages 122, 278 and 312, respectively, of this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Leadership Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, Dr.&#160;Kulkarni is expected to serve as Chair of the board of directors of the combined company. The combined company&#8217;s Principles of Corporate Governance will provide its board of directors with the flexibility to combine or separate the positions of Chair of the board of directors and Chief Executive Officer. Oruka believes that having these positions be separate is the appropriate leadership structure for the combined company at this time as it will help facilitate independent oversight of management by the board of directors of the combined company and allow the Chief Executive Officer to focus on strategy execution and managing the business while the Chair focuses on corporate governance and managing the combined company&#8217;s board of directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Committees of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, ARCA and Oruka anticipate that the board of directors of the combined company will establish an audit committee, a compensation committee, a nominating and corporate governance committee and science and technology committee, each of which will operate pursuant to a charter adopted by the board of directors of the combined company. ARCA and Oruka believe that following the completion of the Merger the functioning and composition of these committees of the combined company will comply with the requirements of Nasdaq listing rules and SEC rules and regulations. The board of directors of the combined company may also establish other committees from time to time to assist the combined company and its board of directors. Each of the audit committee, compensation committee, nominating and corporate governance committee and science and technology committee is expected to have the responsibilities described below.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Audit Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s audit committee are expected to be&#160;&#160;&#160;&#160;&#160;<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>,&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, each of whom qualifies as an independent director for audit committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial and auditing matters to serve on the combined company&#8217;s audit committee.&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>is expected to chair the audit committee.&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>is an &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)(ii)&#160;of Regulation&#160;S<span class="nobreak">-K</span> promulgated under the Securities Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary responsibilities of the combined company&#8217;s audit committee will be to oversee the combined company&#8217;s accounting and financial reporting processes, including the audits of the financial statements, and the internal and external audit processes. The audit committee will also oversee the system of internal controls established by management and the combined company&#8217;s compliance with legal and regulatory requirements. The audit committee will also be responsible for the review, consideration and approval or ratification of related party transactions. The audit committee will oversee the independent auditors, including their independence and objectivity. The audit committee will be empowered to retain outside legal counsel and other advisors as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms of the advisors.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Compensation Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s compensation committee are expected to be&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>,&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, each of whom qualifies as an independent director, as defined under applicable Nasdaq listing rules and also meets the additional, heightened independence criteria applicable to members of the compensation committee.&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>is expected to chair the compensation committee.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">275</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary responsibilities of the combined company&#8217;s compensation committee will be to periodically review and approve the compensation and other benefits for the combined company&#8217;s senior officers and directors. This will include reviewing and approving corporate goals and objectives relevant to the compensation of the combined company&#8217;s Chief Executive Officer and other executive officers, evaluating the performance of these officers in light of the goals and objectives and setting or recommending to the combined company&#8217;s board of directors the officers&#8217; compensation. The compensation committee will also administer and make recommendations to the combined company&#8217;s board of directors regarding equity incentive plans that are subject to the board of directors&#8217; approval and approve the grant of equity awards under the plans.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s nominating and corporate governance committee are expected to be&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>,&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, each of whom qualifies as an independent director, as defined under applicable Nasdaq listing rules.&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>is expected to be chair the nominating and corporate governance committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s nominating and corporate governance committee will be responsible for engaging in succession planning for the combined company&#8217;s board of directors, developing and recommending to the combined company&#8217;s board of directors criteria for identifying and evaluating qualified director candidates and making recommendations to the combined company&#8217;s board of directors regarding candidates for election or reelection to the board of directors at each annual stockholders&#8217; meeting. In addition, the nominating and corporate governance committee will be responsible for overseeing the combined company&#8217;s corporate governance matters. The nominating and corporate governance committee will also be responsible for overseeing the structure, composition and functioning of the combined company&#8217;s board of directors and its committees.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Science and Technology Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s science and technology committee are expected to be&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>,&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>.&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>is expected to chair the science and technology committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary responsibilities of the combined company&#8217;s science and technology committee will be to assist the combined company&#8217;s board of directors in overseeing the combined company&#8217;s innovation, new product development and research and development activities.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Compensation Committee Interlocks and Insider Participation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">None of the expected members of the combined company&#8217;s compensation committee has at any time been one of the officers or employees of the combined company. None of the combined company&#8217;s expected executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers that is or are expected to serve on the combined company&#8217;s board of directors or compensation committee following the completion of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Code of Conduct and Ethics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the combined company will adopt a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all of the combined company&#8217;s directors, officers and employees. The full text of the combined company&#8217;s Code of Conduct and Ethics will be posted on the combined company&#8217;s website at<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. The Code of Conduct and Ethics is expected to address, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. The combined company intends to disclose any amendments to the Code of Conduct and Ethics, or any waivers of its requirements, on its website to the extent required by applicable rules. The combined company&#8217;s audit committee will be responsible for applying and interpreting the Code of Conduct and Ethics in situations where questions are presented to it. Information contained on, or that can be accessed through, the combined company&#8217;s website is not incorporated by reference into this proxy statement/prospectus, and you should not consider information on the combined company&#8217;s website to be part of this proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">276</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the Merger, Oruka did not have a formal policy to provide any cash or equity compensation to its non<span class="nobreak">-employee</span> directors for their service on its board of directors or committees of its board of directors. Oruka&#8217;s non<span class="nobreak">-employee</span> director compensation is described under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Director Compensation</span>&#8221; in this proxy statement/prospectus. Except as described below, determinations with respect to director compensation after the closing of the Merger have not yet been made. In connection with closing of the Merger, it is expected that the board of directors of the combined company will adopt a non<span class="nobreak">-employee</span> director compensation policy designed to enable the combined company to attract and retain, on a long<span class="nobreak">-term</span> basis, highly qualified non<span class="nobreak">-employee</span> directors and align its directors&#8217; interests with those of its stockholders. Employee directors will not receive additional compensation for their services as directors. It is expected that each director who is not an employee will be paid cash and equity compensation for serving on the board of directors of the combined company, the amount and terms of which have not yet been determined. The combined company will also reimburse its non<span class="nobreak">-employee</span> directors for reasonable travel and out<span class="nobreak">-of-pocket</span> expenses incurred in connection with attending the board of director and committee meetings.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">277</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9989"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS<br/>OF THE COMBINED COMPANY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Oruka&#8217;s and ARCA&#8217;s directors and executive officers, including those discussed in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Executive Compensation</span>,&#8221; the following is a description of each transaction involving ARCA since January&#160;1, 2022, each transaction involving Oruka since February&#160;6, 2024 (inception) and each currently proposed transaction in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>either Oruka or ARCA has been or is to be a participant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Oruka&#8217;s or ARCA&#8217;s total assets at year<span class="nobreak">-end</span> for the last two completed fiscal&#160;years, as applicable; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any of Oruka&#8217;s or ARCA&#8217;s directors, executive officers or holders of more than 5% of Oruka&#8217;s or ARCA&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a smaller reporting company, SEC rules require ARCA to disclose any transaction for the last two completed fiscal&#160;years or any currently proposed transaction in which ARCA is a participant and in which any related person has or will have a direct or indirect material interest involving an amount in excess of $120,000 or 1% of the average of ARCA&#8217;s total assets at year<span class="nobreak">-end</span> for the last two fiscal&#160;years. A related person is any executive officer, director, nominee for director or holder of 5% or more of ARCA&#8217;s common stock or an affiliate or immediate family member of any of those persons.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other than the compensation arrangements and other arrangements disclosed above under the headings &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Director Compensation</span>&#8221; and the transactions described below, since January&#160;1, 2022, there has not been and there is not currently proposed, any transaction or series of similar transactions to which ARCA was, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of ARCA&#8217;s total assets amounts at December&#160;31, 2022 and 2023) and in which any director, executive officer, holder of 5% or more of any class of ARCA&#8217;s capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Transactions With ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cooperation Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is party to a Cooperation Agreement (the &#8220;Cooperation Agreement&#8221;) with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span> (collectively, &#8220;Cable Car&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Cooperation Agreement, ARCA&#8217;s board of directors appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> as a Class&#160;III director with a term expiring at ARCA&#8217;s 2024 annual meeting of stockholders, effective June&#160;15, 2022 and appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> to the Special Committee of ARCA&#8217;s board of directors (the &#8220;First Director Appointment&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, under the terms of the Cooperation Agreement, ARCA and Cable Car initiated a process and subsequently identified a mutually acceptable second independent director, Mr.&#160;James Flynn, to join ARCA&#8217;s board of directors. Mr.&#160;Flynn was elected as director at the 2022 annual meeting of stockholders.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">278</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Cooperation Agreement, Cable Car agreed to abide by customary standstill restrictions from the date of the Cooperation Agreement until the earlier to occur of (i)&#160;the 180<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span>&#160;day after the First Director Appointment is no longer serving as a director of ARCA and (ii)&#160;the 90<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the 2023 Annual Meeting (such period, the &#8220;Cooperation Period&#8221;), including that Cable Car will not, among other things, (i)&#160;seek additional representation, or the removal of an existing director, on ARCA&#8217;s board of directors, (ii)&#160;engage in any solicitation of proxies, or (iii)&#160;initiate, propose or otherwise solicit, including any solicitations of the type contemplated by Rule&#160;14a<span class="nobreak">-2</span>(b)&#160;promulgated under the Securities Exchange&#160;Act&#160;of&#160;1934 of ARCA&#8217;s stockholders for the approval of, any stockholder proposal. The Cooperation Period expired on November&#160;1, 2023, the 90<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span><span class="Superscript" style="vertical-align:super;">&#160;</span>day prior to the 2023 Annual Meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Cable Car also agreed to customary mutual non<span class="nobreak">-disparagement</span> obligations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Policies and Procedures for Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s Audit Committee reviews and approves all related party transactions. This review covers any material transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which ARCA was or will be a participant, and a related party had or will have a direct or indirect material interest, including, purchases of goods or services by or from the related party or entities in which the related party has a material interest, indebtedness, guarantees of indebtedness and employment by ARCA of a related party. In evaluating any related party transaction, ARCA&#8217;s Audit Committee considers, among&#160;other things, the relative benefits of the transaction to ARCA, what, if any, alternatives may be available from persons not affiliated to ARCA, if the terms of the transaction have been negotiated on an arm&#8217;s length basis and any other matters that ARCA&#8217;s Audit Committee may deem relevant in determining whether such related party transaction is in the best interests of ARCA and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of each transaction or series of similar transactions since February&#160;6, 2024 (inception) or any currently proposed transaction, to which Oruka was or is a party in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of Oruka&#8217;s total assets; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any of Oruka&#8217;s directors or executive officers, any holder of 5% of any class of Oruka capital stock or an affiliate or immediate family member of the foregoing persons had or will have a direct or indirect material interest.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Compensation arrangements for Oruka named executive officers and directors are described elsewhere in this proxy statement/prospectus under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Director Compensation</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Private Placements of Securities</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Series&#160;A Preferred Stock and Convertible Note&#160;Financing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, Oruka completed a preferred stock and convertible note financing (the &#8220;Oruka Series&#160;A Financing&#8221;) and issued and sold to Fairmount Fund&#160;II (i)&#160;an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A preferred stock at a purchase price of $0.15 per share and (ii)&#160;the Convertible Note with an initial principal amount of $25,000,000 at an interest rate of 12% per annum, for aggregate gross proceeds of $28&#160;million. Fairmount Fund&#160;II is expected to contribute the aggregate principal amount and all accrued interest under the Convertible Note in exchange for Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants in connection with Oruka&#8217;s pre<span class="nobreak">-closing</span> financing. Fairmount Funds Management is the investment manager of Fairmount. Peter Harwin, a director of Oruka, is a managing member of Fairmount Funds Management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Pre-Closing Financing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, in connection with the execution of the Merger Agreement, Oruka entered into the Subscription Agreement with certain investors to consummate the Oruka pre<span class="nobreak">-closing</span> financing. Pursuant to the Subscription Agreement, the investors agreed to purchase an estimated aggregate of 38,382,693<span class="nobreak"> </span>shares of Oruka common stock and 9,009,825 Oruka pre<span class="nobreak">-funded</span> warrants, at an estimated price of $5.80 per share of common stock </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">279</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and $5.79 per warrant, respectively, for aggregate gross proceeds of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). The aggregate purchase price of $275.0&#160;million is fixed, while the purchase price per share or warrant and the aggregate number of shares and warrants to be purchased is subject to change pursuant to the terms of the Subscription Agreement. Please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>.&#8221; The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the Merger as well as certain other conditions. Three of the investors or their affiliates are, or are expected to be as of immediately following the Oruka pre<span class="nobreak">-closing</span> financing, beneficial holders of more than 5% of Oruka&#8217;s capital stock, and the table below sets forth the number of shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants expected to be purchased by such holders at the closing of the Oruka pre<span class="nobreak">-closing</span> financing (based on the currently estimated purchase price per share or warrant, as applicable).</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Participant</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Shares of <br/>Oruka <br/>Common Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Pre-funded <br/>Warrants of Oruka</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Total <br/>Purchase <br/>Price</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Fairmount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,973,597</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,813,325</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">80,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Venrock Healthcare Capital Partners</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,973,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">196,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with FMR LLC</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,308,409</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes $25.0<span class="nobreak"> </span>million of proceeds previously received by Oruka from the issuance of the Convertible Note and accrued interest on such note, with the remainder of the purchase price to be paid in cash.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Relationship with Paragon and Paruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is party to a number of agreements with Paragon and Paruka. Paragon and Paruka each beneficially own more than 5% of Oruka&#8217;s capital stock through their respective holdings of Oruka common stock. Fairmount beneficially owns more than 5% of Oruka&#8217;s capital stock, has one seat on Oruka&#8217;s board of directors and beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon, but is not the beneficial owner of Paragon&#8217;s securities. Paruka is an entity formed by Paragon as a vehicle to hold equity in Oruka in order to share profits with certain employees of Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Paragon Option Agreements. Under the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon signing of the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million was due from Oruka to Paragon. This amount was recognized by Oruka as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of filing of this proxy statement/prospectus, Oruka has not received such rights and has not paid such development costs. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>, Oruka was required to reimburse Paragon for the pre<span class="nobreak">-effective</span> date development costs. During the period ended March&#160;31, 2024, this was recognized as a research and development expense, and Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period ended March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">280</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of filing of this proxy statement/prospectus, Oruka has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of the Paragon Option Agreements, if Oruka exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Paragon Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, Oruka will grant Paruka warrants to purchase a number of shares equal to 1.00% of Oruka&#8217;s outstanding shares on a fully<span class="nobreak">-diluted</span> basis as of the date of the grant, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For additional detail regarding Oruka&#8217;s arrangements with Paragon, including the Paragon Option Agreements, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;License Agreements</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Other Agreements with Oruka Stockholders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Oruka Series&#160;A Financing, Oruka entered into investors&#8217; rights, voting and right of first refusal and co<span class="nobreak">-sale</span> agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of Oruka preferred stock and certain holders of Oruka common stock. These stockholder agreements will terminate upon the closing of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Indemnification Agreements and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has entered into an indemnification agreement with each of its directors and officers and purchased directors&#8217; and officers&#8217; liability insurance. The indemnification agreements require Oruka to indemnify its directors and officers to the fullest extent permitted under Delaware law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Policies for Approval of Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not have a formal policy regarding approval of transactions with related parties. To date, all disclosable transactions with related parties have been approved by the directors not interested in such transaction pursuant to Section&#160;144(a)(1)&#160;of the DGCL.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">281</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Defined terms included below shall have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, Oruka entered into a Merger Agreement with ARCA and the Merger Subs, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the Merger. Immediately following the First Merger and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. The transaction is expected to be completed in the third quarter of 2024 (the &#8220;Closing Date&#8221; or the &#8220;Effective Time&#8221;) following the filed Form&#160;S<span class="nobreak">-4</span> being deemed effective by the SEC and receipt of approval by the stockholders of each of Oruka and ARCA, in the latter case pursuant to a special meeting. In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with an exchange ratio determined in accordance with the terms of the Merger Agreement (the &#8220;Exchange Ratio&#8221;) (together with the Oruka pre<span class="nobreak">-closing</span> financing, the &#8220;Transactions&#8221;), immediately prior to the Effective Time, (i) each share of Oruka common stock outstanding, including outstanding and unvested Oruka restricted stock and shares of Oruka common stock issued in connection with the Subscription Agreement (both defined in Note&#160;1 of the accompanying notes), will be converted into the right to receive shares of ARCA common stock, which will be subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Oruka Series A convertible preferred stock will be converted into the right to receive ARCA Series B convertible preferred stock, (iii) each option to purchase Oruka common stock will be converted into the right to receive an option to purchase ARCA common stock, which will be subject to the same vesting provisions as those immediately prior to the Merger, and (iv) each pre<span class="nobreak">-funded</span> warrant to purchase shares of Oruka common stock issued in connection with the Subscription Agreement will be converted into the right to receive a pre<span class="nobreak">-funded</span> warrant to purchase shares of ARCA common stock. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Exchange Ratio is currently estimated to be approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock for each fully<span class="nobreak">-diluted</span> share of Oruka common stock. Under the Exchange Ratio formula, the former Oruka stockholders immediately before the effective time, including those purchasing shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing, are currently estimated to own approximately 97.6% of the outstanding common stock of the combined company on a fully<span class="nobreak">-diluted</span> basis, and the stockholders of ARCA immediately before the effective time are currently estimated to own approximately 2.4% of the outstanding common stock of the combined company on a fully<span class="nobreak">-diluted</span> basis and are subject to certain assumptions, including, but not limited to, (a)&#160;ARCA&#8217;s net cash balance (as defined in the Merger Agreement) as of the Closing being approximately $5.0&#160;million, (b)&#160;Oruka closing on approximately $275.0&#160;million in the Oruka pre<span class="nobreak">-closing</span> financing described in this proxy statement/prospectus, (c)&#160;a valuation for ARCA equal to its net cash as of the business&#160;day immediately prior to the closing date of the Merger, plus $6.0&#160;million, and (d)&#160;a valuation for Oruka equal to $175.0&#160;million, in each case as further described in the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following unaudited pro forma condensed combined financial information gives effect to the Merger, which is expected to be accounted for as a reverse recapitalization under United&#160;States Generally Accepted Accounting Principles, or U.S.&#160;GAAP.&#160;For further detail related to the accounting for the Merger, please see Notes 1 and&#160;3 below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined balance sheet combines the historical balance sheets of ARCA and Oruka as of March&#160;31, 2024 and depicts the accounting of the transactions prepared pursuant to the rules and regulations of Article&#160;11 of SEC Regulation&#160;S<span class="nobreak">-X</span>, as amended (&#8220;pro forma balance sheet transaction accounting adjustments&#8221;). The unaudited pro forma condensed combined statements of operations for the three&#160;months ended March&#160;31, 2024 for ARCA, the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 for Oruka, and the year ended December&#160;31, 2023 for ARCA combine the historical results of ARCA and Oruka for those periods and depict the pro forma transaction accounting adjustments assuming that those adjustments were made as of January&#160;1, 2023 </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">282</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">(&#8220;pro forma statements of operations transaction accounting adjustments&#8221;). Collectively, pro forma balance sheet transaction accounting adjustments and pro forma statements of operations transaction accounting adjustments are referred to as &#8220;transaction accounting adjustments&#8221; or &#8220;pro forma adjustments&#8221;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction with:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical unaudited condensed financial statements of Oruka as of March<span class="nobreak">&#160;</span>31, 2024 and for the period from February<span class="nobreak">&#160;</span>6, 2024 (inception) to March<span class="nobreak">&#160;</span>31, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical unaudited condensed consolidated financial statements of ARCA as of and for the three&#160;months ended March<span class="nobreak">&#160;</span>31, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical audited consolidated financial statements of ARCA for the year ended December<span class="nobreak">&#160;</span>31, 2023, and the related notes included elsewhere in this proxy statement/prospectus; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</span>,&#8221; and other financial information relating to ARCA and Oruka included elsewhere in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and pro forma adjustments that are described in the accompanying notes. The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed including but not limited to additional financing, additional direct and incremental offering costs and a reverse stock split. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the Closing, may occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of operations in the future periods or the result that actually would have been realized had ARCA and Oruka been a combined organization during the specified periods. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited condensed combined pro forma financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">283</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET<br/>AS OF MARCH 31, 2024<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share amounts)</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Historical</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">5(A)<br/>ARCA<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">biopharma, <br/>Inc.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">5(B)<br/>Oruka<br/>Therapeutics,<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Inc.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">Transaction<br/>Accounting<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Adjustments</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Notes</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">Pro&#160;Forma<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Combined</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Current assets:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">35,903</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">27,743</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(1,687</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(a)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,004</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">249,786</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(19,512</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(4,973</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(256</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(i)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">767</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(716</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(f)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">51</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total current assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,670</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">27,743</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,642</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,055</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Operating lease right-of-use assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Property and equipment, net</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Other assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">12</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">488</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(488</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">12</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,706</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">28,231</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,130</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,067</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Current liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accounts payable</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">529</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">4</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">533</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accrued expenses and other current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,052</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,262</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(21</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,326</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(919</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(48</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Related party accounts payable and other current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">5,899</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">5,899</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,581</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,165</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(988</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,758</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Long term liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accrued interest payable, related party</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Notes payable to related parties, noncurrent</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">24,980</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(24,980</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,581</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">32,359</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(26,182</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,758</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Oruka convertible preferred stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(b)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">ARCA convertible preferred stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(b)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Stockholders&#8217; equity (deficit) </span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">ARCA common stock, $0.001 par value</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">14</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(14</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Oruka common stock, $0.0001 par value</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">0</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">6</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">4</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Additional paid-in capital</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">225,861</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">25,214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">263,449</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">249,782</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">22</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(i)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(197,446</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accumulated deficit</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(190,750</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,077</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(1,687</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(a)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,077</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(4,053</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(716</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(f)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">24</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(278</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">197,460</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total stockholders&#8217; equity (deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">35,125</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,059</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">228,312</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">256,378</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,706</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">28,231</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,130</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,067</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">284</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/>FOR THE THREE MONTHS ENDED MARCH 31, 2024<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 23.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Historical</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(A) <br/>ARCA <br/>biopharma, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(B) <br/>Oruka <br/>Therapeutics, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Transaction <br/>Accounting <br/>Adjustments</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Pro&#160;Forma <br/>Combined</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,358</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,317</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">263</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,250</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,482</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">263</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,608</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income (loss) from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,482</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(263</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,608</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,009</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(49</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,135</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,009</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,135</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average common shares outstanding, basic&#160;and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,964,662</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(g)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.02</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">285</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/>FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2023<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="6" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 21.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Historical</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(A) <br/>ARCA <br/>biopharma, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(B) <br/>Oruka <br/>Therapeutics, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.14%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Transaction <br/>Accounting <br/>Adjustments</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Pro&#160;Forma <br/>Combined</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,013</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,013</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,283</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,687</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,990</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">716</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(b)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(d)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,050</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,296</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income (loss) from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,296</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(11,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,046</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,046</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average common shares outstanding, basic&#160;and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,415,877</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,879,396</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(h)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.37</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.02</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">286</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9990"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1. Description of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Oruka, First Merger Sub, and Second Merger Sub entered into the Merger Agreement to which the First Merger Sub merges with and into Oruka, with Oruka becoming a wholly owned subsidiary of ARCA.&#160;Oruka will merge with and into the Second Merger Sub, with the Second Merger Sub being the surviving entity. Subsequent to the Second Merger, Second Merger Sub would remain a wholly owned subsidiary of ARCA and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; Subject to the terms and conditions of the Merger Agreement, at closing of the Merger (the &#8220;Closing&#8221;):</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">a)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding share of, and pre<span class="nobreak">-funded</span> warrant related to, Oruka common stock, including (i)&#160;outstanding and unvested Oruka Restricted Stock (defined below) will be converted into the right to receive a number of shares of, and pre<span class="nobreak">-funded</span> warrants related to, ARCA common stock, based on the Exchange Ratio;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">b)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding share of Oruka Series A convertible preferred stock at closing will be exchanged into ARCA Series B convertible preferred stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the Exchange Ratio divided by 1,000; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">c)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding and unexercised option to purchase shares of Oruka common stock (&#8220;Oruka options&#8221;) immediately prior to Closing will be assumed by ARCA and will be converted into an option to purchase shares of ARCA common stock which continues to vest pursuant to the original terms, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All Oruka restricted stock outstanding and unvested immediately prior to Closing (&#8220;Oruka Restricted Stock&#8221;) that is assumed by ARCA in the Merger will remain unvested to the same extent and will be subject to the same repurchase option, risk of forfeiture or other condition under any applicable restricted stock purchase agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, the board of directors of ARCA will take actions to accelerate the vesting of certain outstanding options to purchase ARCA common stock held by a current employee, director or consultant of ARCA as of the closing of the Merger. The acceleration of vesting of ARCA&#8217;s options occurs either upon a change of control as defined, pursuant to the terms of the original awards, or a modification of the awards as a result of the Merger. The incremental fair value of ARCA&#8217;s options associated with the modification to accelerate vesting has been included as an adjustment to the unaudited pro forma condensed combined financial information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately following the Merger, ARCA stockholders are expected to own approximately 2.4% of the outstanding capital stock of the combined company on a fully diluted basis, former Oruka stockholders are expected to own approximately 39.3% of the outstanding capital stock of the combined company on a fully diluted basis, and investors participating in the Subscription Agreement (defined below) are expected to own approximately 58.3% of the outstanding capital stock of the combined company on a fully diluted basis. Oruka stockholders are expected to receive approximately 238,540,759<span class="nobreak"> </span>shares on a fully diluted basis in connection with the Merger, including (i) 47,510,340<span class="nobreak"> </span>shares of ARCA common stock and stock options subject to vesting terms, based on the number of shares of Oruka common stock outstanding immediately prior to the Merger, including Oruka Restricted Stock, (ii) the number of shares of, and pre<span class="nobreak">-funded</span> warrants related to, Oruka common stock issued to investors participating in the Subscription Agreement (defined below), and (iii) Oruka convertible preferred stock outstanding as of March&#160;31, 2024, which will be exchanged into shares of ARCA Series B convertible preferred stock. These estimates are subject to certain inputs, which include, but are not limited to, (a)&#160;ARCA&#8217;s net cash balance (as defined in the Merger Agreement) as of the Closing being approximately $5.0&#160;million, (b)&#160;Oruka raising approximately $275.0&#160;million in the Oruka pre<span class="nobreak">-closing</span> financing described in this proxy statement/prospectus, (c)&#160;a valuation for ARCA equal to its net cash as of the business&#160;day immediately prior </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">287</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to the closing date of the Merger, plus $6.0&#160;million and (d)&#160;a valuation for Oruka equal to $175.0&#160;million, in each case as further described in the Merger Agreement. The following table summarizes the pro forma number of shares of common stock of the combined company outstanding following the consummation of the Transactions:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-31" style="height:12pt;">
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Equity Capitalization Summary (fully diluted basis) <br/>Upon Consummation of the Merger</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Pro&#160;Forma <br/>(Assuming&#160;ARCA&#160;Net&#160;Cash <br/>at&#160;Closing&#160;of&#160;$5.0&#160;Million)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares&#160;Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="font-style:normal;font-weight:bold;">% <br/>Ownership</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Oruka stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">238,540,759</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ARCA stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investors participating in the Subscription Agreement<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">353,695,101</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total common stock of the combined company</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">606,737,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes 67,241,225 pre<span class="nobreak">-funded</span> warrants related to the Subscription Agreement after reflecting the estimated Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the listing of the shares of ARCA common stock to be issued in connection with the Merger and (4)&#160;the effectiveness of a registration statement filed with the SEC in connection with the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The employment agreements for ARCA employees include entitlement to change in control payments for certain executives, and severance and retention bonus payments for certain non<span class="nobreak">-executives</span>, the aggregate of which will be treated as pre<span class="nobreak">-Merger</span> compensation expense of ARCA and will be reflected as an increase to accrued expenses of ARCA, which will be assumed by the combined company at Closing. Prior to the Closing, ARCA also (i)&#160;discontinued its research and development activities, (ii)&#160;sold its assets held for sale, and (iii)&#160;terminated and/or expired its operating leases. Additionally, ARCA&#8217;s current Directors&#160;&amp; Officers (&#8220;D&amp;O&#8221;) policy will be fully utilized at Closing.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Private Financing Transaction&#160;&#8212;&#160;Subscription Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution of the Merger Agreement, certain parties have entered into the Subscription Agreement with Oruka to purchase, prior to the consummation of the Merger, approximately 38,382,693<span class="nobreak"> </span>shares of Oruka common stock and 9,009,825 pre<span class="nobreak">-funded</span> warrants, at an estimated purchase price of $5.80 and $5.79 per share, respectively, for an aggregate purchase price of approximately $275.0&#160;million, which includes $25.0&#160;million proceeds received as of March&#160;31, 2024 from the issuance of a convertible note and accrued interest. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to the Subscription Agreement will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of ARCA common ctock at Closing per the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2. Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article&#160;11 of SEC Regulation&#160;S<span class="nobreak">-X</span>, as amended. The adjustments presented in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an understanding of the combined company upon consummation of the Merger. The unaudited pro forma condensed combined statement of operations data for the three&#160;months ended March&#160;31, 2024 and the unaudited pro forma condensed combined statement of operations data for the year ended December&#160;31, 2023, give effect to the Merger as if it had been consummated on January&#160;1, 2023. The unaudited pro forma condensed combined balance sheet as of March&#160;31, 2024 gives effect to the Merger and combines the historical balance sheets of ARCA and Oruka as of such date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary accounting conclusions and estimates and the final accounting conclusions and amounts may occur as a result of, among other reasons: (i)&#160;changes in initial assumptions in the determination of the accounting acquirer and related accounting, (ii)&#160;changes in the amount of ARCA&#8217;s net cash to be assumed at the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">288</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">Closing Date, and (iii)&#160;other changes in ARCA&#8217;s assets and liabilities, which are expected to be completed after the Closing, and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the combined company&#8217;s future results of operations and financial position.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3. Accounting for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The unaudited pro forma condensed combined financial information gives effect to the Merger, which will be accounted for under U.S.&#160;GAAP as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka, as the transaction is, in essence, the issuance of equity for ARCA&#8217;s net assets, which will primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. Under this method of accounting, Oruka will be considered the accounting acquirer for financial reporting purposes. This determination is based on the expectations that, immediately following the Merger:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is not a variable interest entity as it has sufficient equity at risk in order to fund its next development milestones;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka stockholders will own a substantial majority of the voting rights in the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s largest stockholder will retain the largest interest in the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will designate the initial members of the board of directors of the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s executive management team will become the management of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will be renamed &#8220;Oruka Therapeutics, Inc.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As a result of Oruka being the accounting acquirer, Oruka&#8217;s assets and liabilities will be recorded at their pre<span class="nobreak">-combination</span> carrying amounts. ARCA&#8217;s assets and liabilities will be measured and recognized at their fair values as of the effective time, which are expected to approximate the carrying value of the acquired cash and other non<span class="nobreak">-operating</span> assets, with no goodwill or other intangible assets recorded. Any difference between the consideration transferred and the fair value of the net assets of ARCA following the determination of the actual consideration transferred for ARCA will be reflected as an adjustment to additional paid<span class="nobreak">-in</span> capital. For periods prior to Closing, the historical financial statements of Oruka shall become the historical financial statements of the combined company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4. Shares of ARCA Common Stock, Convertible Preferred Stock, Options, and Warrants Issued to Oruka Stockholders upon Closing of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">At Closing, all outstanding shares of Oruka common stock, on a fully<span class="nobreak">-diluted</span> basis, will be exchanged for shares of ARCA common stock based on the preliminary estimated Exchange Ratio of 7.4631, determined in accordance with the terms of the Merger Agreement. The estimated number of shares of ARCA common stock that ARCA expects to issue to Oruka&#8217;s stockholders assumes ARCA&#8217;s net cash at Closing is $5.0&#160;million and is determined as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock outstanding as of March&#160;31, 2024<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,460,019</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock to be issued upon conversion of Oruka convertible preferred&#160;stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock issued upon exercise of Oruka stock options<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares to purchase Oruka common stock upon exercise of Oruka&#8217;s CEO&#8217;s stock options&#160;granted immediately prior to the closing of the Merger<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,804,003</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of Oruka common stock to be issued in connection with the Subscription Agreement, see Note&#160;5(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">38,382,693</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of Oruka common stock to be issued upon exercise of Oruka pre-funded warrants to be issued in connection with the Subscription Agreement,&#160;see Note&#160;5(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,009,825</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total Oruka fully diluted shares prior to the closing of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">79,355,209</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated Exchange&#160;Ratio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.4631</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated fully diluted shares to be issued to Oruka stockholders and Investors participating in Subscription Agreement upon closing of the Merger<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">592,235,860</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents shares of Oruka common stock outstanding as of March&#160;31, 2024, including 3,863,361 shares of unvested Oruka Restricted Stock.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the outstanding options to acquire Oruka common stock as of March&#160;31, 2024. Such stock options will become exercisable for shares of ARCA common stock following the Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">289</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents stock options expected to be issued to Oruka&#8217;s Chief Executive Officer to maintain 5.0% ownership of the combined company pursuant to his employment agreement immediately prior to the Merger.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the total estimated fully diluted shares to be issued to Oruka stockholders at Closing based on the preliminary estimated Exchange Ratio of 7.4631.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5. Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of March&#160;31, 2024</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(A)&#160;&#160;Derived from the unaudited condensed consolidated balance sheet of ARCA as of March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(B)&#160;&#160;Derived from the unaudited condensed balance sheet of Oruka as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma Balance Sheet Transaction Accounting Adjustments:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(a)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated incremental compensation expense of $1.7&#160;million related to severance, retention bonuses and change in control payments resulting from pre<span class="nobreak">-existing</span> employment agreements or from approval from ARCA&#8217;s board of directors that is expected to be incurred upon closing of the Merger. The pro forma adjustment is reflected as a decrease in cash of $1.7&#160;million for the severance and retention bonuses payments made subsequent to March&#160;31, 2024 and an increase to accumulated deficit of $1.7&#160;million.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(b)&#160;&#160;To reflect the exchange of all outstanding shares of Oruka Series&#160;A convertible preferred stock, with a carrying amount of $2.9&#160;million, into ARCA Series&#160;B convertible preferred stock at closing of the Merger, with the terms of ARCA Series B convertible preferred stock resulting in classification within stockholders&#8217; equity.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(c)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the issuance of 38,382,693<span class="nobreak"> </span>shares of Oruka common stock and 9,009,825 pre<span class="nobreak">-funded</span> warrants, pursuant to the Subscription Agreement entered into concurrently with the execution of the Merger Agreement, for an aggregate purchase price of $275.0&#160;million, which includes $25.0&#160;million proceeds received as of March&#160;31, 2024 from the issuance of the convertible note. The aggregate proceeds are net less than $0.1&#160;million of debt issuance costs and include accrued interest of $0.2&#160;million as of March&#160;31, 2024 adjusted through accumulated deficit (see Note&#160;6(e)), for net proceeds before issuance costs of $249.8<span class="nobreak"> </span>million. The proceeds received in connection with the Subscription Agreement are recorded net of transaction costs deemed to be direct and incremental costs of the equity financing in the amount of approximately $20.0&#160;million (see Note 5(d)). The issuance of shares in connection with the Subscription Agreement are recorded as the issuance of Oruka common stock at par value, with the remaining amount recorded to additional paid<span class="nobreak">-in-capital</span>. Additionally, 1,804,003 options to purchase shares of Oruka common stock will be issued to Oruka&#8217;s Chief Executive Officer to maintain 5.0% ownership of the combined company, pursuant to his employment agreement, subject to vesting conditions (see Note 6(f)).</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(d)&#160;&#160;To reflect preliminary estimated transaction costs of $19.5&#160;million, not yet reflected in the historical financial statements, that are expected to be incurred by Oruka in connection with the Merger, and $0.5&#160;million reflected in the historical financial statements as deferred offering costs, such as advisory, legal and auditor fees, as a reduction in cash and a reduction in other assets in the unaudited pro forma condensed combined balance sheet. As the Merger will be accounted for as a reverse recapitalization equivalent to the issuance of equity for the net assets, primarily cash, of ARCA, these direct and incremental costs are treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in</span> capital.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(e)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated transaction costs of $4.1&#160;million, not yet reflected in the historical financial statements and $0.9&#160;million reflected in the historical financial statements, which are expected to be incurred by ARCA in connection with the Merger, such as advisory, legal and auditor fees and including the estimated $1.7<span class="nobreak"> </span>million cost of a D&amp;O tail policy, as a reduction in cash of $5.0<span class="nobreak"> </span>million, a reduction in accrued expenses of $0.9<span class="nobreak"> </span>million, and a reduction in accumulated deficit of $4.1<span class="nobreak"> </span>million in the unaudited pro forma condensed combined balance sheet.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">290</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(f)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To derecognize $0.7&#160;million of ARCA&#8217;s prepaid expenses consisting of $0.1&#160;million of prepaid expenses related to software that will not be utilized and $0.6&#160;million of prepaid insurance primarily related to the current ARCA&#8217;s D&amp;O policy that will be fully utilized at Closing.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(g)&#160;&#160;To reflect the derecognition of ARCA&#8217;s operating leases that will expire prior to the closing of the Merger and the derecognition of property and equipment that will be fully depreciated prior to the closing of the Merger. The operating lease right<span class="nobreak">-of-use</span> assets and property and equipment of less than $0.1&#160;million will be derecognized.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(h)&#160;&#160;To reflect the one<span class="nobreak">-time</span> stock compensation expense of $0.3&#160;million in general and administrative expense related to the acceleration of stock options pursuant to pre<span class="nobreak">-existing</span> grant agreements, which provide for such acceleration upon a change in control provision, which will be triggered by the Merger, as well as a modification to accelerate vesting of in<span class="nobreak">-the-money</span> stock options, and to reflect the one<span class="nobreak">-time</span> cash payment of $0.3&#160;million to settle in<span class="nobreak">-the-money</span> stock options per terms of the Merger Agreement.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(i)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect an estimate of the one<span class="nobreak">-time</span> dividend of $20.0&#160;million declared and paid on the shares of ARCA common stock outstanding prior to the Merger. The dividend will be treated as a decrease in additional paid<span class="nobreak">-in</span> capital in the unaudited pro forma condensed combined balance sheet.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(j)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the recapitalization of Oruka, pursuant to the Merger Agreement, through the contribution of 238,540,759<span class="nobreak"> </span>shares of Oruka common stock, including 47,510,340<span class="nobreak"> </span>shares of Oruka Restricted Stock and Oruka stock options (see Note&#160;4), and the issuance of 286,453,876<span class="nobreak"> </span>shares of Oruka common stock and 67,241,224 pre<span class="nobreak">-funded</span> warrants and 149,262,000 preferred stock, reflecting the estimated Exchange Ratio of 7.4631 and to reflect the derecognition of the accumulated deficit of ARCA which is reversed to additional paid<span class="nobreak">-in</span> capital.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;margin-top:8pt;">The derecognition of accumulated deficit of ARCA of $197.5&#160;million is determined as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit of ARCA as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">190,750</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compensation expense related to ARCA severance, retention bonuses and change in control payments, see Note&#160;5(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,687</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Preliminary estimated transaction costs of ARCA, see Note&#160;5(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,053</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Derecognition of ARCA prepaid software expenses and prepaid insurance, see Note&#160;5(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">716</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Derecognition of ARCA operating leases, see Note&#160;5(g)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pre-Merger stock-based compensation expense for ARCA&#8217;s accelerated awards, see Note&#160;5(h)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total adjustment to derecognize the accumulated deficit of ARCA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">197,460</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6. Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(A)&#160;&#160;Derived from the unaudited condensed consolidated statement of operations and comprehensive loss of ARCA for the three&#160;months ended March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(B)&#160;&#160;Derived from the unaudited condensed statement of operations and comprehensive loss of Oruka for the period February&#160;6, 2024 (inception) to March&#160;31, 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">291</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(C)&#160;&#160;Derived from the audited consolidated statement of operations and comprehensive loss of ARCA for the year ended December&#160;31, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(D)&#160;&#160;Derived from the unaudited condensed statement of operations and comprehensive loss of Oruka for the year ended December&#160;31, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and ARCA did not record any provision or benefit for income taxes during the three&#160;months ended March&#160;31, 2024 because each company expects to incur a pre<span class="nobreak">-tax</span> loss in 2024 and each company maintains a full valuation allowance on its deferred tax assets. Accordingly, no pro forma adjustments have an impact on associated income tax.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma Statements of Operations Transaction Accounting Adjustments:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(a)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated incremental compensation expense related to severance, retention bonuses and change in control payments recorded in general and administrative expenses of $1.7&#160;million, resulting from pre<span class="nobreak">-existing</span> employment agreements or from approval from ARCA&#8217;s board of directors that will be incurred upon Closing assuming that the adjustment described in Note&#160;5(a)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(b)&#160;&#160;To reflect the derecognition of ARCA&#8217;s prepaid expenses of $0.1&#160;million related to software that will not be utilized, and prepaid insurance of $0.6&#160;million primarily related to the current ARCA D&amp;O policy that will be fully utilized at Closing, assuming the adjustment made in Note&#160;5(f)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(c)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the derecognition of ARCA&#8217;s operating leases that will expire prior to the closing of the Merger and the derecognition of property and equipment that will be fully depreciated prior to the closing of the Merger. The operating lease right<span class="nobreak">-of-use</span> assets and property and equipment of less than $0.1&#160;million will be derecognized, assuming the adjustment made in Note&#160;5(g)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(d)&#160;&#160;To reflect the one<span class="nobreak">-time</span> stock compensation expense of $0.3&#160;million in general and administrative expense related to the acceleration of stock options pursuant to pre<span class="nobreak">-existing</span> grant agreements which provide for such acceleration upon a change in control provision, which will be triggered by the Merger, as well as a modification to accelerate vesting of in<span class="nobreak">-the-money</span> stock options, assuming the adjustment made in Note&#160;5(h)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(e)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect Oruka&#8217;s interest expense related to its convertible note that is recorded in its historical financial statements, to be derecognized in the unaudited pro forma condensed combined statement of operations for the three&#160;months ended March&#160;31, 2024 assuming that the adjustment described in Note&#160;5(c)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(f)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect stock compensation expenses of $1.1&#160;million and $0.3<span class="nobreak"> </span>million for the year ended December<span class="nobreak"> </span>31, 2023 and the three months ended March<span class="nobreak"> </span>31, 2024, respectively, in general and administrative expense related to stock options expected to be issued to Oruka&#8217;s Chief Executive Officer to maintain 5.0% ownership pursuant to his employment agreement, assuming the adjustment was made on January&#160;1, 2023. These options vest over 4 years from the date of issuance.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">292</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(g)&#160;&#160;The pro forma combined basic and diluted net loss per share has been adjusted to reflect the pro forma net loss for the three&#160;months ended March&#160;31, 2024. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the combined company for the respective periods. Pro forma weighted average shares outstanding includes the pre<span class="nobreak">-funded</span> warrants related to the Subscription Agreement as the exercise price is negligible and they are fully vested and exercisable. For the three&#160;months ended March&#160;31, 2024, the pro forma weighted average shares have been calculated as follows:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31, 2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December 31, 2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basic and Diluted</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basic and Diluted</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Historical weighted average number of ARCA common shares outstanding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,415,877</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-37" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of ARCA common stock expected to be issued to Oruka stockholders upon Closing, assuming consummation of the Merger as of January&#160;1, 2023, see Note&#160;4<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">395,463,519</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">395,463,519</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pro forma combined weighted average number of common shares <br/>outstanding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,964,662</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,879,396</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the estimated shares of ARCA common stock expected to be issued to Oruka stockholders at Closing, excluding (i)&#160;the outstanding and unvested Oruka Restricted Stock and Oruka stock options at Closing that will be converted to the right to receive 28,832,649<span class="nobreak"> </span>shares of ARCA common stock and 18,677,691 stock options, respectively, after reflecting the estimated Exchange Ratio and (ii)&#160;the outstanding Oruka convertible preferred stock that will be exchanged for 149,262,000<span class="nobreak"> </span>shares of ARCA convertible preferred stock. The 28,832,649<span class="nobreak"> </span>shares of ARCA common stock and 18,677,691 stock options are subject to the same vesting conditions (see Note&#160;4).</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">293</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T8"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DESCRIPTION OF ARCA CAPITAL STOCK</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following description of ARCA capital stock and provisions of the ARCA Charter and ARCA Bylaws are summaries and are qualified by reference to such charter and bylaws and applicable provisions of Delaware corporate law. Copies of these documents are filed as exhibits to the registration statement of which this proxy/prospectus forms part.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Authorized Capital Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter authorizes ARCA to issue 100,000,000<span class="nobreak"> </span>shares of ARCA common stock and 5,000,000<span class="nobreak"> </span>shares of preferred stock, $0.001 par value per share (&#8220;ARCA preferred stock&#8221;).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Voting Rights.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Each holder of ARCA common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors; provided, however, holders of ARCA common stock may not, unless otherwise required by law, vote on any amendment to the ARCA Charter that relates solely to the terms of one or more series of ARCA preferred stock that ARCA may issue if the holders of such ARCA preferred stock are entitled to vote on such amendment. In all such matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, or represented by proxy at a meeting of the stockholders and entitled to vote generally on the subject matter shall be the act of the stockholders. Directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, or represented by proxy at a meeting of the stockholders and entitled to vote generally on the election of directors. ARCA&#8217;s stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors to be elected at any particular time. See the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Description of ARCA Capital Stock &#8212; Anti</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Takeover</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Effects of Delaware Law and Provisions of the ARCA Charter and ARCA Bylaws</span>&#8221; for a description of elections of members of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Dividends.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Subject to preferences that may be applicable to any then outstanding ARCA preferred stock, holders of ARCA common stock are entitled to receive dividends, if any, as may be declared from time to time by ARCA&#8217;s board of directors out of legally available funds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidation.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>In the event of ARCA&#8217;s liquidation, dissolution or winding up, holders of ARCA common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of ARCA&#8217;s debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of ARCA preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Rights and Preferences.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Holders of ARCA common stock have no preemptive, conversion, subscription or other rights, and there are no redemption provisions applicable to ARCA common stock. The rights, preferences and privileges of the holders of ARCA common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of ARCA preferred stock that ARCA may designate in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Fully Paid and Nonassessable.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>All outstanding shares of ARCA common stock are fully paid and nonassessable.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the ARCA Charter, ARCA&#8217;s board of directors has the authority, without further action by ARCA&#8217;s stockholders, to issue up to 5,000,000<span class="nobreak"> </span>shares of ARCA preferred stock, in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, voting rights, terms of redemption and repurchase, liquidation preferences and sinking fund terms, any or all of which may be greater than the rights of ARCA common stock. ARCA preferred stock may be convertible into ARCA common stock or other securities of ARCA, or may be exchangeable for debt securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. Because ARCA&#8217;s board of directors, without stockholder approval, can issue ARCA preferred stock with voting, conversion or other rights, ARCA preferred stock could be issued quickly </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">294</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">with terms calculated to delay or prevent a change in control of ARCA or make removal of management more difficult. Additionally, the issuance of ARCA preferred stock may have the effect of decreasing the market price of ARCA common stock and may adversely affect the voting power of holders of ARCA common stock and reduce the likelihood that ARCA&#8217;s common stockholders will receive dividend payments and payments upon liquidation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Delaware General Corporation Law provides that the holders of any class or series of ARCA preferred stock will have the right to vote separately as a class on any proposed amendment to the ARCA Charter that would alter or change the powers, preferences or special rights of the holders of such class or series of ARCA preferred stock so as to affect them adversely. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Series&#160;A Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has designated 135,000 of the 5,000,000 authorized shares of preferred stock as &#8220;Series&#160;A Convertible Preferred Stock.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Series&#160;A Convertible Preferred Stock ranks:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>senior to all of ARCA&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>on parity with any class or series of ARCA capital stock specifically ranking by its terms on parity with the Preferred Stock; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>junior to any class or series of ARCA capital stock specifically ranking by its terms senior to the Preferred Stock;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">in each case, as to distributions of assets upon ARCA&#8217;s liquidation, dissolution or winding up whether voluntarily or involuntarily.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A Convertible Preferred Stock is convertible into 100<span class="nobreak"> </span>shares of ARCA&#8217;s common stock (subject to adjustment as provided in the related certificate of designation of preferences) at any time at the option of the holder, provided that the holder is prohibited from converting Preferred Stock into shares of ARCA&#8217;s common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of ARCA&#8217;s common stock then issued and outstanding.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of ARCA&#8217;s liquidation, dissolution, or winding up, holders of Series&#160;A Convertible Preferred Stock will receive a payment equal to $0.001 per share of Series&#160;A Convertible Preferred Stock before any proceeds are distributed to the holders of ARCA&#8217;s common stock. In addition, each share of Series&#160;A Convertible Preferred Stock will be entitled to receive, on an as<span class="nobreak">-if-converted</span> basis, <span class="Italic" style="font-style:italic;font-weight:normal;">pari passu</span> with each share of ARCA&#8217;s common stock, any distributions of ARCA&#8217;s assets or surplus funds which ARCA makes upon shares of ARCA&#8217;s common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of Series&#160;A Convertible Preferred Stock have no voting rights, except as required by law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except for stock dividends or certain other distributions set forth in the certificate of designation, shares of Series&#160;A Convertible Preferred Stock will be entitled to receive dividends (on an as<span class="nobreak">-converted</span> basis) in the same form as dividends actually paid on shares of ARCA&#8217;s common stock when and if declared by ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to redeem or repurchase any shares of Series&#160;A Convertible Preferred Stock. Shares of Series&#160;A Convertible Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No shares of Series&#160;A Convertible Preferred Stock are currently issued and outstanding.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Series&#160;B Non-Voting Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors will designate<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA preferred stock as ARCA Series&#160;B Preferred Stock through its certificate of designation in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex</span>&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">F </span>(the &#8220;Certificate of Designation&#8221;). Holders of the ARCA Series&#160;B Preferred Stock will be entitled to receive dividends on shares of ARCA Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock basis, and in the same form as dividends </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">295</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">actually paid on shares of ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the ARCA Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of ARCA Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the ARCA Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the ARCA Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend ARCA&#8217;s charter, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the ARCA Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the ARCA Series&#160;B Preferred Stock, (e)&#160;issue further shares of the ARCA Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the ARCA Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The ARCA Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger (as defined elsewhere in this proxy statement/prospectus), each share of ARCA Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the ARCA Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of ARCA Series&#160;B Preferred Stock is prohibited from converting shares of ARCA Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anti-Takeover Effects of Delaware Law and Provisions of the ARCA Charter and ARCA Bylaws</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter and ARCA Bylaws include a number of provisions that may deter or impede hostile takeovers or changes of control. These provisions include:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Issuance of Undesignated ARCA preferred stock.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Under the ARCA Charter, ARCA&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to 5,000,000<span class="nobreak"> </span>shares of undesignated ARCA preferred stock with rights and preferences, including voting rights, designated from time to time by ARCA&#8217;s board of directors. The existence of authorized but unissued shares of ARCA preferred stock enables ARCA&#8217;s board of directors to make it more difficult or to discourage an attempt to obtain control of ARCA by means of a merger, tender offer, proxy contest or otherwise.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Classified Board.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter provides for a classified board of directors consisting of three classes of directors, with staggered three<span class="nobreak">-year</span> terms. Only one class of directors will be elected at each annual meeting of ARCA&#8217;s stockholders, with the other classes continuing for the remainder of their respective three<span class="nobreak">-year</span> terms. This provision may have the effect of delaying a change in control of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Board of Directors Vacancies.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter and ARCA Bylaws authorize only ARCA&#8217;s board of directors to fill vacant directorships, unless ARCA&#8217;s board of directors determines by resolution that the stockholders shall fill such vacant directorships. In addition, the number of directors constituting ARCA&#8217;s board of directors may be set only by resolution adopted by a majority vote of ARCA&#8217;s entire board of directors. These provisions prevent a stockholder from increasing the size of ARCA&#8217;s board of directors and gaining control of ARCA&#8217;s board of directors by filling the resulting vacancies with its own nominees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Action; Special Meetings of Stockholders.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter provides that ARCA&#8217;s stockholders may not take action by written consent, but may only take action at annual or special meetings of ARCA&#8217;s stockholders. Under the ARCA Bylaws, stockholders are not permitted to cumulate their votes for the election of directors. The ARCA Bylaws further provide that special meetings of the stockholders may be called by the chief executive officer, president, ARCA&#8217;s board of directors, or by holders of ARCA common stock who hold, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">296</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in the aggregate, not less than fifty percent (50%) of the outstanding shares of ARCA common stock for the purpose or purposes stated in the call of the meeting. These provisions may prevent stockholders from corporate actions as stockholders at times when they otherwise would like to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advance Notice Requirements for Stockholder Proposals and Director Nominations.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Bylaws provide advance notice procedures for stockholders seeking to bring business before ARCA&#8217;s annual meeting of stockholders, or to nominate candidates for election as directors at ARCA&#8217;s annual meeting of stockholders. The ARCA Bylaws also specify certain requirements as to the form and content of a stockholder&#8217;s notice. These provisions may make it more difficult for ARCA&#8217;s stockholders to bring matters before ARCA&#8217;s annual meeting of stockholders or to nominate directors at ARCA&#8217;s annual meeting of stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of ARCA&#8217;s board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of ARCA.&#160;These provisions are designed to reduce ARCA&#8217;s vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for ARCA&#8217;s shares and, as a consequence, they may also reduce fluctuations in the market price of ARCA&#8217;s shares that could result from actual or rumored takeover attempts.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Section&#160;203 of the Delaware General Corporation Law</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to Section&#160;203 of the Delaware General Corporation Law. Section&#160;203 generally prohibits certain Delaware corporations from engaging, under certain circumstances, in a &#8220;business combination&#8221; with any &#8220;interested stockholder for a period of three&#160;years following the time that such stockholder became an interested stockholder, unless:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prior to such time the board of directors approved either the business combination or transaction which resulted in the stockholder becoming an interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a)&#160;shares owned by persons who are directors and also officers and (b)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least&#160;66<span class="nobreak">-2</span>/3% of the outstanding voting stock which is not owned by the interested stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;203 defines a business combination to include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any merger or consolidation involving the corporation and the interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% or more of the assets of the corporation (or its majority<span class="nobreak">-owned</span> subsidiary);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section&#160;203, provided by or through the corporation.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">297</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of such entity or person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#8217; amendment approved by a majority of the outstanding voting shares. ARCA has not &#8220;opted out&#8221; of these provisions and do not plan to do so. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Effects of Authorized but Unissued Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock and ARCA preferred stock are available for future issuance without stockholder approval. ARCA may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions, payment as a dividend on the capital stock or as equity compensation to ARCA&#8217;s service providers under ARCA&#8217;s equity compensation plans.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The existence of unissued and unreserved ARCA common stock and ARCA preferred stock may enable ARCA&#8217;s board of directors to issue shares to persons friendly to current management or to issue ARCA preferred stock with terms that could render more difficult or discourage a third<span class="nobreak">-party</span> attempt to obtain control by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of ARCA&#8217;s management. In addition, ARCA&#8217;s board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of ARCA preferred stock, all to the fullest extent permissible under the Delaware General Corporation Law and subject to any limitations set forth in the ARCA Charter. The purpose of authorizing the board of directors to issue ARCA preferred stock and to determine the rights and preferences applicable to such ARCA preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of ARCA preferred stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from acquiring, a majority of ARCA&#8217;s outstanding voting stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also, if ARCA issues additional shares of authorized, but unissued, ARCA common stock, these issuances will dilute the voting power and distribution rights of ARCA&#8217;s existing common stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendments to Governing Documents</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Generally, the amendment of the ARCA Charter requires approval by ARCA&#8217;s board of directors and a majority vote of stockholders, provided that the provisions of the ARCA Charter relating to (i)&#160;the requirement that all stockholder action be taken only at a duly called annual meeting or special meeting; (ii)&#160;the authority and power of ARCA&#8217;s board of directors and the procedure required to amend ARCA Bylaws; (iii)&#160;the percentage of the shares necessary to amend the ARCA Charter; (iv)&#160;the elimination of directors&#8217; personal liability for monetary damages arising from their negligence and gross negligence; and (v)&#160;indemnification of directors, officers and other persons requires approval of ARCA&#8217;s stockholders holding at least&#160;66<span class="nobreak">-2</span>/3% of ARCA&#8217;s capital stock then outstanding and entitled to vote. Any amendment to ARCA Bylaws requires the approval of either a majority of ARCA&#8217;s board of directors or approval of ARCA&#8217;s stockholders holding at least&#160;66<span class="nobreak">-2</span>/3% of ARCA&#8217;s capital stock then outstanding and entitled to vote.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Listing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Transfer Agent and Registrar</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The transfer agent and registrar for ARCA common stock is Computershare Trust Company N.A.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">298</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T7"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">COMPARISON OF RIGHTS OF HOLDERS OF ARCA CAPITAL STOCK AND <br/>ORUKA CAPITAL STOCK</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger is completed, Oruka stockholders will receive shares of ARCA common stock and ARCA Series&#160;B Preferred Stock, pursuant to the terms of the Merger Agreement. Prior to or upon the closing of the Merger, assuming that Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 are approved by ARCA&#8217;s stockholders, the ARCA Charter will be amended to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, to effect the proposed reverse stock split and to reflect Delaware law provisions regarding officer exculpation, respectively, as set forth in the forms of certificates of amendment attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G, Annex&#160;H </span>and <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span>,<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>to this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are both incorporated under the laws of the State of Delaware. The rights of ARCA stockholders and Oruka stockholders are generally governed by the DGCL.&#160;Upon completion of the Merger, Oruka stockholders will become ARCA stockholders, and their rights will be governed by the DGCL, the ARCA Bylaws and the ARCA Charter, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The material differences between the current rights of Oruka stockholders under the Oruka Charter and Oruka Bylaws and their rights as ARCA stockholders, after the Merger, under the ARCA Charter and ARCA Bylaws, both as will be in effect immediately following the completion of the Merger and assuming that that Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 are approved by ARCA&#8217;s stockholders, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the governing corporate instruments, for a more complete understanding of the differences between being a stockholder of ARCA or Oruka before the Merger and being a stockholder of the combined company following the completion of the Merger. For more information on how to obtain these documents, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 317 of this proxy statement/prospectus.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Organizational Documents</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">The rights of ARCA stockholders are governed by the ARCA Charter, ARCA Bylaws and the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The rights of Oruka stockholders are governed by the Oruka Charter, Oruka Bylaws and the DGCL.&#160;Rights of certain holders of Oruka preferred stock are governed by the Investors&#8217; Rights Agreement (the &#8220;Oruka IRA&#8221;), the Right of First Refusal and Co<span class="nobreak">-Sale</span> Agreement (the &#8220;Oruka ROFR Agreement&#8221;), and the Voting Agreement, each dated as of March&#160;6, 2024.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Authorized Capital Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that ARCA is authorized to issue is 105,000,000, of which 100,000,000<span class="nobreak"> </span>shares are common stock, par value $0.001 per share, and 5,000,000<span class="nobreak"> </span>shares are preferred stock, par value $0.001 per share.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Oruka is authorized to issue is 85,000,000, of which 65,000,000<span class="nobreak"> </span>shares are common stock, par value $0.0001 per share, and 20,000,000<span class="nobreak"> </span>shares are preferred stock, par value $0.0001 per share. The number of authorized shares of Oruka common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Oruka preferred stock that may be required under the Oruka Charter) the affirmative vote of the holders of shares of Oruka capital stock representing a majority of the votes represented by all outstanding shares of Oruka capital stock entitled to vote, irrespective of the provisions of Section&#160;242(b)(2) of the DGCL.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">299</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Common Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA&#8217;s authorized common stock consists of 100,000,000<span class="nobreak"> </span>shares of common stock, par value $0.001 per share. </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">Each holder of a share of ARCA common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka&#8217;s authorized common stock consists of 65,000,000<span class="nobreak"> </span>shares of common stock, par value $0.0001 per share. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Each holder of a share of Oruka common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders (and written actions in lieu of meetings).</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preferred Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA&#8217;s authorized preferred stock consists of 5,000,000<span class="nobreak"> </span>shares of preferred stock of which ARCA&#8217;s board of directors has designated 135,000<span class="nobreak"> </span>shares of preferred stock as &#8220;Series&#160;A Convertible Preferred Stock.&#8221; </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">No shares of ARCA Series&#160;A Convertible Preferred Stock or undesignated preferred stock are currently outstanding. ARCA&#8217;s board of directors is authorized to issue shares of undesignated preferred stock in one or more series and to fix the designations, powers, preferences and relative, participating, optional and other rights, and any qualifications, limitations and restrictions, on such shares. </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">In connection with the Merger, ARCA&#8217;s board of directors intends to designate shares of undesignated preferred stock as Series&#160;B Non-Voting Convertible Preferred Stock through a certificate of designation in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;F </span>(the &#8220;Certificate of Designation&#8221;). No shares of Series&#160;B Non-Voting Convertible Preferred Stock are currently authorized or outstanding. As long as any shares of Series&#160;B Non-Voting Preferred Stock are outstanding, ARCA will not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Series&#160;B Non-Voting Preferred Stock: (i)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Non-Voting Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the ARCA Charter or ARCA Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of ARCA preferred stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Non-Voting Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the ARCA Charter or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii)&#160;issue further shares of Series&#160;B Non-Voting Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series&#160;B Non-Voting Preferred Stock, (iii)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A)&#160;any Fundamental Transaction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">All of Oruka&#8217;s 20,000,000<span class="nobreak"> </span>shares of preferred stock are designated as shares of &#8220;Series&#160;A Preferred Stock,&#8221; of which 20,000,000 are issued and outstanding. Each holder of a share of Oruka preferred stock is entitled to cast the number of votes equal to the number of whole shares of Oruka common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">300</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">(as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA with or into another entity or any stock sale to, or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority on an as<span class="nobreak">-converted-to-ARCA</span> common stock basis of the capital stock of ARCA, immediately after such transaction or (iv)&#160;enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Number and Qualification of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The number of ARCA directors is not less than two (2)&#160;nor more than ten (10), the exact number determined from time to time by resolution of ARCA&#8217;s board of directors, acting by the affirmative vote of a majority of the directors. The ARCA&#8217;s board of directors currently consists of five (5)&#160;members. No decrease in the authorized number of directors constituting ARCA&#8217;s board of directors will shorten the term of any incumbent director. Directors of ARCA need not be stockholders of ARCA.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The number of directors of Oruka is established from time to time by the board of directors. Oruka&#8217;s board of directors currently consists of six members.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Structure of Board of Directors; Term of Directors; Election of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA&#8217;s board of directors is divided into three classes, designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. Election of directors need not be by written ballot. The term of office of the first class expired at the first annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004, the term of office of the second class expired at the second annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004 and the term of office of the third class expired at the third annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004.&#160;At each succeeding annual meeting of stockholders, or special meeting in lieu thereof, directors are elected for a full term of three&#160;years to succeed the directors of the class whose terms expire at such annual meeting or special meeting lieu of thereof. Notwithstanding the foregoing, directors elected to each class hold office until their successors are duly elected and qualified.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka directors shall be elected at the annual meeting of stockholders by such stockholders as have the right to vote on such election. Election of directors need not be by written ballot. Each director shall hold office for a term of one year and until his or her successor is elected and qualified, or until such director&#8217;s earlier resignation or removal. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The holders of record of the shares of Oruka&#8217;s Series&#160;A Preferred Stock, voting together exclusively and as a separate class, are entitled to elect one director of Oruka. The holders of record of the shares of common stock and of any other class or series of voting stock (including the Series&#160;A Preferred Stock), exclusively and voting together as a single class on an as<span class="nobreak">-converted</span> to Common Stock basis, shall be entitled to elect the balance of the total number of directors.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Removal of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may be removed from office at any time, but only with cause and only by the affirmative vote of the holders of sixty<span class="nobreak">-six</span> and two<span class="nobreak">-third</span> percent or more of the voting power of the outstanding shares of capital stock of ARCA entitled to vote at an election of directors, unless otherwise provided under the DGCL or the ARCA Charter.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any one or more or all of the Oruka directors may be removed, with or without cause, by the holders of a majority of shares entitled to vote at an election of directors, except that any director elected by the holders of Series&#160;A Preferred Stock may be removed without cause only by the affirmative vote of the holders of a majority of the outstanding shares of Series&#160;A Preferred Stock, together as a single class on an as<span class="nobreak">-converted</span> to common stock basis, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">301</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Vacancies on the Board of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may resign at any time by giving notice in writing to ARCA Chairperson of the board of directors, if one is elected, the ARCA Vice Chairperson of the board of directors, if one is elected, the Chief Executive Officer or the President. Such resignation shall be effective upon receipt, unless the resignation otherwise provides. Any vacancies and any newly created directorships resulting from any increase in the number of directors, will be filled solely and exclusively by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum, or by a sole remaining director, and not by the ARCA stockholders. Any director elected in accordance with the preceding sentence will hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor is elected and qualified or until his or her earlier resignation, death or removal.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may resign at any time upon notice given in writing or by electronic transmission to Oruka. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. A vacancy in any director seat not reserved for holders of Series&#160;A Preferred Stock can be filled by either (A)&#160;the vote or written consent in lieu of a meeting of the stockholders entitled elect those directors, or (B)&#160;the vote or written consent in lieu of a meeting of a majority of the remaining director(s), although less than a quorum. Vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">If the holders of shares of Series&#160;A Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, then any directorship not so filled shall remain vacant until such time as the holders of the Series&#160;A Preferred Stock elect a person to fill such directorship.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Action by Written Consent</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">No action may be taken by the ARCA stockholders except at an annual or special meeting of the ARCA stockholders called in accordance with the ARCA Bylaws, and no action may be taken by the ARCA stockholders by written consent in lieu of a meeting.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60&#160;days of the earliest dated consent delivered to Oruka, a written consent signed by a sufficient number of stockholders to take action are delivered to Oruka.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">302</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Quorum</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Subject to the provisions of the ARCA Bylaws, ARCA Charter and the DGCL as to the vote that is required for a specified action, the presence in person or by proxy of the holders of at least one<span class="nobreak">-third</span> of the outstanding shares of ARCA entitled to vote at any meeting of stockholders shall constitute a quorum for the transaction of business.&#160;In the absence of a quorum, stockholders holding a majority of the shares present in person or by proxy and entitled to vote, regardless of whether or not they constitute a quorum, or if no stockholders are present, any officer entitled to preside at or act as secretary of the meeting, may adjourn the meeting to another time and place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by the DGCL or the Oruka Charter, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes. Where a separate vote by a class or series is required, a majority of the voting power of the shares of such class or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum. If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Special Meetings of Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Special meetings of the stockholders may be called by ARCA&#8217;s board of directors, Chief Executive Officer, President, or by holders of ARCA common stock who hold, in the aggregate, not less than fifty percent (50%) of the outstanding shares of ARCA common stock for the purpose or purposes stated in the call of the meeting.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by Oruka&#8217;s board of directors or the Chief Executive Officer if one is elected, or the President, and shall be held at such place, date, and time as they or he or she shall fix.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Notice of Stockholder Meetings</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Notice of all meetings of ARCA stockholders shall state the place, if any, date and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called, shall be given to each stockholder entitled to vote at the meeting, and unless otherwise provided in the DGCL, the ARCA Charter or the ARCA Bylaws, the notice shall be given not less than ten nor more than sixty&#160;days before the meeting to each stockholder entitled to vote at the meeting as of the record date for determining the stockholders entitled to notice of the meeting, and, if mailed, shall be deposited in the United&#160;States mail, postage prepaid, directed to the stockholder at the stockholder&#8217;s address as it appears on the records of ARCA.&#160;The notice to stockholders for any meeting will be given in accordance with Section&#160;232 of the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by the DGCL or the Oruka Charter, notice of the place, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, shall be given not less than 10&#160;days nor more than 60&#160;days before date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">303</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advance Notice Requirements for Stockholder Proposals</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Nominations of persons for election to ARCA&#8217;s board of directors and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders (i)&#160;pursuant to the corporation&#8217;s notice of meeting, (ii)&#160;by or at the direction of ARCA&#8217;s board of directors, or (iii)&#160;by any stockholder of ARCA who is a stockholder of record at the time of giving notice provided for in the ARCA Bylaws, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in the ARCA Bylaws as to such nomination or business. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">For the avoidance of doubt, the foregoing clause (ii)&#160;shall be the exclusive means for a stockholder to bring nominations or business properly before an annual meeting of stockholders (other than matters properly brought under Rule&#160;14a<span class="nobreak">-8</span> (or any successor rule) under the Exchange&#160;Act).</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Neither the Oruka Charter nor the Oruka Bylaws contain advance notice requirements for stockholder proposals.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Amendment of Certificate of Incorporation</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The ARCA Charter provides that it may be amended by the affirmative vote of the majority of the voting rights of all classes of capital stock entitled to vote, provided, however, that no amendment, alteration, change or repeal of any provision requiring the affirmative vote of the holders of more than a majority of the voting rights may be made unless approved by the affirmative vote of such greater number of holders. The affirmative vote of the holders of 66 2/3% of the voting rights is required to amend, repeal or adopt any provision inconsistent with the provisions of the ARCA Charter relating to: (i)&#160;the requirement that all stockholder action be taken only at a duly called annual meeting or special meeting; (ii)&#160;the authority and power of ARCA&#8217;s board of directors and the procedure required to amend the ARCA Bylaws; (iii)&#160;the percentage of the shares necessary to amend the ARCA Charter; (iv)&#160;the elimination of ARCA&#8217;s directors&#8217; personal liability for monetary damages arising from their negligence and gross negligence; and (v)&#160;indemnification of ARCA&#8217;s directors, officers and other persons.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter may be amended pursuant to Section&#160;242 of the DGCL; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the holders of at least a majority of the outstanding shares of preferred stock, voting together as a single class on an as<span class="nobreak">-converted</span> to common stock basis (the &#8220;Requisite Holders&#8221;), is required to (i)&#160;amend, alter or repeal of any provision of the Oruka Charter in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof, (ii)&#160;create or issue any capital stock unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences or (iii)&#160;increase the authorized number of shares of preferred stock or any additional class or series of capital stock of Oruka unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Amendment of Bylaws</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by law, the ARCA Bylaws may be amended or repealed by ARCA&#8217;s board of directors. The ARCA Bylaws may also be amended or repealed by the stockholders by the affirmative vote of not less than&#160;66<span class="nobreak">-2</span>/3% of the outstanding shares of capital stock entitled to vote, voting together as a single class.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Bylaws may be amended or repealed by Oruka&#8217;s board of directors or by the stockholders; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the Requisite Holders is required to amend, alter or repeal of any provision of the Oruka Bylaws in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">304</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Limitation on Director and Officer Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a director of ARCA shall not be personally liable to ARCA or its stockholders for monetary damages for breach of fiduciary duty as a director. Any amendment, repeal or modification of Article&#160;IX of the ARCA Charter shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as a director at the time of such amendment, repeal or modification.</p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by the DGCL, as the same exists or may hereafter be amended, an officer of ARCA shall not be personally liable to ARCA or its stockholders for monetary damages for breach of fiduciary duty as an officer. Any amendment, repeal or modification of Article XIII of the ARCA Charter shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as an officer at the time of such amendment, repeal or modification.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by law, a director or officer of Oruka shall not be personally liable to Oruka or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL or any other law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of Oruka shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended. Any amendment, repeal or elimination of the foregoing provisions by the Oruka stockholders shall not adversely affect any right or protection of a director of Oruka existing at the time of, or increase the liability of any Oruka director with respect to any acts or omissions of such director occurring prior to, such amendment, repeal or elimination.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Indemnification</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA will indemnify any person who was or is a party or is threatened to be made a party to, or otherwise becomes involved in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative and whether internal or external to ARCA (a &#8220;Proceeding&#8221;), by reason of the fact that the person is or was a director, officer, employee, or other agent of ARCA, or is or was serving at the request of ARCA as a director, officer, employee or agent of another foreign or domestic corporation, partnership, joint venture, trust or other enterprise (any such person, an &#8220;Agent of ARCA&#8221;). Expenses incurred by an Agent in connection with a Proceeding shall be paid by ARCA as they are incurred and in advance of the final disposition of such Proceeding, subject to certain conditions. These rights to indemnification and advancement of expenses shall not be deemed exclusive of any other rights to which a person seeking indemnification or advancement of expenses may be entitled. ARCA has the power to purchase and maintain insurance on behalf of any person who is or was an Agent of ARCA against any liability asserted against the person and incurred by the person in any such capacity, or arising out of the person&#8217;s status as such, whether or not ARCA would have the power to indemnify the person against such liability.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by applicable law, Oruka is authorized to provide indemnification of (and advancement of expenses to) its directors, officers and agents (and any other persons to which the DGCL permits Oruka to provide indemnification) through Oruka Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&#160;145 of the DGCL.&#160;Any amendment, repeal, modification or elimination of the foregoing provisions shall not (a)&#160;adversely affect any right or protection of any director, officer or other agent of Oruka existing at the time of such amendment, repeal, modification or elimination; or (b)&#160;increase the liability of any Oruka director, officer or agent with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal, modification or elimination. The Oruka Bylaws require Oruka to indemnify, to the fullest extent permitted by Delaware law, as the same exists or may hereafter be amended, and except in certain circumstances, each person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;proceeding&#8221;), by reason of the fact that he or she is or was a director or an officer of Oruka or is or was serving at the request of Oruka as a director, officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">305</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">plan, whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee (an &#8220;indemnitee&#8221;). The Oruka Bylaws also provide that an indemnitee will have the right to be paid by Oruka expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition, provided, however, that, if the DGCL requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer shall be made only upon delivery to Oruka of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses. The Oruka Bylaws also provide that the rights to indemnification and advance of expenses shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Oruka Charter, the Oruka Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Conversion Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have any outstanding shares of Series&#160;A Convertible Preferred Stock or undesignated preferred stock. When the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock is issued in connection with the Merger, the holders of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock will have the right to convert such shares into ARCA common stock at any time a ratio of 1<span class="nobreak"> </span>share of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to 1000<span class="nobreak"> </span>shares of ARCA common stock.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter provides that holders of preferred stock have the right to convert such shares into shares of common stock, at the option of the holder, at any time, at a conversion rate in accordance with the terms set forth in the Oruka Charter. In addition, upon the earliest to occur of (i)&#160;immediately prior to the closing of the sale of shares of common stock to the public at a price of at least $1.00 per share (subject to appropriate adjustment for any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock) in a firm<span class="nobreak">-commitment</span> underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in at least $50,000,000 of gross proceeds to Oruka and in connection with such offering the shares of Oruka common stock are listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New&#160;York Stock Exchange or another exchange or marketplace approved by Oruka&#8217;s board of directors; and (ii)&#160;the date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders, all outstanding shares of preferred stock will automatically be converted into shares of common stock, at the then effective conversion rate as calculated in accordance with the Oruka Charter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">306</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Right of First Refusal</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a right of first refusal in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Certain stockholders party to the Oruka ROFR Agreement wishing to transfer any shares of Oruka capital stock (other than any shares of preferred stock or common stock that are issued or issuable upon conversion of preferred stock) must first provide Oruka with the right to purchase such shares. In such an event, if Oruka does not elect to exercise its right of first refusal in full, certain stockholders party to the Oruka ROFR Agreement have a secondary refusal right to purchase all or any portion of such shares of Oruka capital stock which are proposed for sale or transfer and not purchased by Oruka pursuant to its right of first refusal.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Right of Co</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Sale</span></span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a right of co<span class="nobreak">-sale</span> in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Certain stockholders party to the Oruka ROFR Agreement have a right of co<span class="nobreak">-sale</span> with respect to any Oruka capital stock proposed to be transferred or sold that is not either purchased by Oruka by exercise of its right of first refusal (as further described above) or by any Oruka stockholder by exercise of their secondary refusal right (as further described above), each pursuant to the Oruka ROFR Agreement.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preemptive Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA stockholders do not have preemptive rights. Thus, if additional shares of ARCA common stock are issued, the current holders of ARCA common stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Pursuant to the Oruka IRA, if Oruka proposes to offer or sell certain new equity securities, Oruka must first offer such securities to each Major Investor (as defined in the Oruka IRA, who will then have a right to purchase securities in such new offering equal to the proportion of the ownership interest of such Major Investor prior to such offering.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Distributions to Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-27" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Dividends upon ARCA capital stock, subject to the provisions of the ARCA Charter and applicable law, if any, may be declared by ARCA&#8217;s board of directors. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the ARCA Charter and applicable law. ARCA&#8217;s board of directors may fix a record date for the determination of holders of ARCA capital stock entitled to receive payment of a dividend or distribution declared thereon, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date may not be more than 60&#160;days prior to the date fixed for the payment thereof.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka shall not declare, pay or set aside any dividends (other than dividends on shares of common stock payable in shares of common stock) unless holders of preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of preferred stock in an amount calculated in accordance with the Oruka Charter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">307</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Exclusive Forum</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have an exclusive forum in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter provides that, unless Oruka consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#160;any derivative action or proceeding brought on behalf of Oruka, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Oruka to Oruka or Oruka&#8217;s stockholders, (iii)&#160;any action asserting a claim against Oruka, its directors, officers or employees arising pursuant to any provision of the DGCL, the Oruka Charter or the Oruka Bylaws or (iv)&#160;any action asserting a claim against Oruka, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of Oruka, except for, as to each of (i)&#160;through (iv)&#160;above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten&#160;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Registration Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have any registration rights in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Under the Oruka IRA, certain holders of Oruka capital stock that are party to the Oruka IRA, have certain registration rights, including the right to demand that Oruka file a registration statement, so called &#8220;demand&#8221; registration rights, or request that their shares be covered by a registration statement that Oruka is otherwise filing, so<span class="nobreak">-called</span> &#8220;piggyback&#8221; registration rights. The registration rights granted under the Oruka IRA will terminate upon the earlier of: (i)&#160;the closing of a Deemed Liquidation Event (as such term is defined in the Oruka Charter), (ii)&#160;such time after Oruka&#8217;s initial public offering when all registrable securities could be sold under Rule&#160;144 of the Securities Act or a similar exemption without limitation during a three<span class="nobreak">-month</span> period without registration or (iii)&#160;the third anniversary of Oruka&#8217;s initial public offering.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock Transfer Restrictions Applicable to Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Shares of ARCA are transferable in the manner prescribed by the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Shares of Oruka are transferable in the manner prescribed by the DGCL, subject to additional limits on certain holders of Oruka capital stock party to the Oruka ROFR Agreement and Oruka IRA.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Rights Plan</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a stockholder rights plan in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka does not have a stockholder rights plan in place.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">308</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T6"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ARCA</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Security Ownership of Certain Beneficial Owners</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information regarding the ownership of ARCA common stock as of May&#160;3, 2024, by: (i)&#160;each director of ARCA, (ii)&#160;each ARCA named executive officer, (iii)&#160;all executive officers and directors of ARCA as a group and (iv)&#160;all those known by ARCA to be beneficial owners of more than five percent of its common stock. Unless otherwise noted below, the address of each beneficial owner listed on the table is c/o ARCA biopharma, Inc., 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has determined beneficial ownership in accordance with the rules of the SEC and includes voting or investment power with respect to ARCA common stock. Except as indicated by the footnotes below, ARCA believes, based on the information furnished to it, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of ARCA common stock that they beneficially own, subject to applicable community property laws. The table is based upon information supplied by officers, directors and principal stockholders of ARCA and Schedules 13G or 13D, Form&#160;4s or other ownership reports filed with the SEC.&#160;Except as contemplated by the Merger and the Merger Agreement, ARCA does not know of any arrangements, including any pledge by any person of its securities, the operation of which may at a subsequent date result in a change of control of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In computing the number of shares of ARCA common stock beneficially owned by a person and the percentage ownership of that person, ARCA deemed outstanding shares of ARCA common stock subject to options or warrants held by that person that are currently exercisable or exercisable within 60&#160;days of May&#160;3, 2024. ARCA did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">The percentages below are based on 14,507,143<span class="nobreak"> </span>shares of ARCA common stock outstanding as of May&#160;3, 2024.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Shares Beneficially<br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage<br/>Shares <br/>Beneficially<br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Directors and Named Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow, M.D., Ph.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">254,274</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133,521</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">97,146</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">71,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,499</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,016,952</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(8)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">All current directors and executive officers as a group (7 persons)</span><span class="Superscript" style="vertical-align:super;font-size:58%;font-style:normal;font-weight:bold;">(9)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,371,408</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">5% Stockholders</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Funicular Funds, LP<span class="Superscript" style="vertical-align:super;font-size:58%;">(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,016,952</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Adage Capital<span class="Superscript" style="vertical-align:super;font-size:58%;">(11)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,200,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Janus Henderson<span class="Superscript" style="vertical-align:super;font-size:58%;">(12)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,080,107</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Allostery Investments<span class="Superscript" style="vertical-align:super;font-size:58%;">(13)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,065,016</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Avidity Partners<span class="Superscript" style="vertical-align:super;font-size:58%;">(14)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Venrock<span class="Superscript" style="vertical-align:super;font-size:58%;">(15)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">754,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes the following: (i)&#160;1,109<span class="nobreak"> </span>shares owned by Investocor Trust, of which Dr.&#160;Bristow is the sole trustee; (ii)&#160;1,414<span class="nobreak"> </span>shares owned by NFS as Custodian for Michael Bristow&#8217;s IRA; and (iii)&#160;options to purchase 249,466<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 92,791<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 57,146<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">309</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 21,895<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 21,895<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 21,499<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 16,500<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024. Also see Footnote (10)&#160;below.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 8,500<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(9)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>See Notes (2)&#160;through (8)&#160;above.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(10)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Includes options to purchase 16,500<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024 by Jacob Ma<span class="nobreak">-Weaver</span> and shares reported on the Form&#160;4 filed on December&#160;19, 2022 by The Funicular Funds, LP (the &#8220;Fund&#8221;) and Mr.&#160;Ma<span class="nobreak">-Weaver</span>, reporting stock ownership as of December&#160;16, 2022. The Fund, the Funicular Fund (&#8220;Funicular&#8221;), Cable Car Capital LLC (&#8220;Cable Car&#8221;) and Mr.&#160;Ma<span class="nobreak">-Weaver</span> may be deemed to be a member of a Section&#160;13(d)&#160;group that may be deemed to collectively beneficially own more than 10% of ARCA&#8217;s outstanding shares of common stock. Despite such shared beneficial ownership, the reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. Funicular, as a feeder fund to the Fund, may be deemed to beneficially own the securities directly owned by the Fund. Cable Car, as the general partner of the Fund, may be deemed to beneficially own the securities directly owned by the Fund. Mr.&#160;Ma<span class="nobreak">-Weaver</span>, as the Managing Member of Cable Car, may be deemed to beneficially own the securities directly owned by the Fund.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(11)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13D filed on April&#160;5, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Adage Capital Management, L.P. (&#8220;ACM&#8221;), Robert Atchinson, and Phillip Gross. ACM and Messrs. Atchinson and Gross each reported that they hold shared voting power and shared dispositive power with respect to 1,200,000 shares of ARCA common stock. Adage Capital Partners L.L.C. (&#8220;ACPLLC&#8221;) serves as the general partner of ACM, Adage Capital Advisors, L.L.C. (&#8220;ACA&#8221;), serves as the managing member of ACPLLC, and Messrs. Atchinson and Gross serve as the managing members of ACA.&#160;The address of each of the entities and persons listed above is 200&#160;Clarendon Street, 52<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">nd</span> Floor, Boston, Massachusetts 02116.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(12)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;11, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Janus Henderson Group plc (&#8220;JHG&#8221;) and Janus Henderson Biotech Innovation Master Fund Ltd (&#8220;JHB&#8221;). JHG and JHB each reported that they hold shared voting power and shared dispositive power with respect to 1,080,107 shares of ARCA common stock. Janus Henderson has a 100% ownership stake in Janus Henderson Investors U.S.&#160;LLC (&#8220;JHIUS&#8221;), Janus Henderson Investors UK Limited and Janus Henderson Investors Australia Institutional Funds Management Limited, (each an &#8220;Asset Manager&#8221; and collectively as the &#8220;Asset Managers&#8221;). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of this filing. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as &#8220;Managed Portfolios&#8221;). As a result of its role as investment adviser or sub<span class="nobreak">-adviser</span> to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 1,080,107 shares of ARCA common stock held by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. The address of JHG is 201 Bishopsgate, EC2M 3AE, United Kingdom, and the address of JHB is C/O Janus Henderson Investors US LLC, 151 Detroit Street, Denver, Colorado 80206.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(13)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;15, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Allostery Master Fund LP (&#8220;Allostery Master Fund&#8221;), Allostery Investments LP (&#8220;Allostery Investments&#8221;), Allostery Investments GP LLC (&#8220;Allostery Investments GP&#8221;), Christopher Staral, and David Modest. Allostery Master Fund, Allostery Investments LP, Allostery Investments GP, and Messrs. Staral and Modest each reported that they hold shared voting power and shared dispositive power with respect to 1,065,016 shares of ARCA common stock. Allostery Investments, as the investment manager of Allostery Master Fund, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Master Fund. Allostery Investments GP, as the general partner of Allostery Investments, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Investments. Messrs. Modest and Staral, as the managing members of Allostery Investments GP, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Investment GP.&#160;The address of each of the entities and persons listed above is One Stamford Plaza, 9<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span> Floor, 263 Tresser Boulevard, Stamford, Connecticut 06901.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(14)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;9, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Private Master Fund&#160;I LP, David Witzke, Michael Gregory, which each reported that they hold shared voting power and shared dispositive power with respect to 1,000,000 shares of ARCA common stock. The address of each of the entities and persons listed above is 2828 N Harwood Street, Suite 1220, Dallas, Texas 75201.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">310</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(15)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;29, 2024 reporting stock ownership as of April&#160;17, 2024 with respect to the following reporting persons: Venrock Healthcare Capital Partners&#160;III, L.P., VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management&#160;III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, which each reported that they hold shared voting power and shared dispositive power with respect to 754,669 shares of ARCA common stock, consisting of (i)&#160;164,442 shares held by Venrock Healthcare Capital Partners&#160;III, L.P., (ii)&#160;16,450 shares held by VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC, and (iii)&#160;573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.&#160;VHCP Management&#160;III, LLC is the general partner of Venrock Healthcare Capital Partners&#160;III, L.P. and the manager of VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC.&#160;VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P.&#160;Messrs. Shah and Koh are the voting members of VHCP Management&#160;III, LLC and VHCP Management EG, LLC.&#160;The address of each of the entities and persons listed above is 7&#160;Bryant Park, 23<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">rd</span> Floor, New&#160;York, New&#160;York 10018.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">311</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T5"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ORUKA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information known to Oruka regarding beneficial ownership of Oruka capital stock on an as<span class="nobreak">-converted</span> to Oruka common stock basis as of May&#160;3, 2024 for:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person or group of affiliated persons, who is known by Oruka to be the beneficial owner of more than 5% of Oruka capital stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each of Oruka&#8217;s directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each Oruka named executive officer; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all of Oruka&#8217;s directors and executive officers and directors as a group.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beneficial ownership is determined in accordance with the rules of the SEC and thus represents voting or investment power with respect to Oruka&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of May&#160;3, 2024. Shares of Oruka&#160;common stock that an individual has the right to acquire within 60&#160;days of May&#160;3, 2024 are deemed to be outstanding and beneficially owned by the individual for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. To Oruka&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned. The percentage of beneficial ownership shown prior to the Merger and Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing in the table below is based on 29,460,019<span class="nobreak"> </span>shares of Oruka&#160;common stock deemed to be outstanding as of May&#160;3, 2024, assuming the conversion of all outstanding shares of Oruka&#160;preferred stock into shares of Oruka&#160;common stock. The following table does not reflect any shares of Oruka&#160;common stock or Oruka&#160;pre<span class="nobreak">-funded</span> warrants that such holders have agreed to purchase in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Oruka Therapeutics, Inc., 221 Crescent Street, Building<span class="nobreak"> </span>23, Suite 105, Waltham, MA&#160;02453.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name of Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares <br/>Beneficially <br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage <br/>of&#160;Shares <br/>Outstanding <br/>Beneficially <br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fairmount Healthcare Fund&#160;II, L.P.<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon Therapeutics, Inc.<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka Holding LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">McKenna Capital Partners LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Named Executive Officers and Directors:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cameron Turtle<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149,164</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Peter Harwin<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All executive officers and directors as a group (9 persons)<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,640,810</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">73.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000 Oruka Series&#160;A Preferred Stock held by Fairmount Fund&#160;II.&#160;Fairmount GP&#160;II is the general partner of Fairmount Fund&#160;II.&#160;Fairmount Funds Management, as the investment manager, along with Fairmount GP&#160;II, as the general partner, exercise voting and investment power over Fairmount Fund&#160;II.&#160;Fairmount Funds Management has voting and dispositive power over the common stock held by Fairmount Fund&#160;II, which is deemed shared with Fairmount GP&#160;II.&#160;As managing members of </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">312</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:0pt;">Fairmount Funds Management and Fairmount GP&#160;II, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any securities beneficially owned by Fairmount Funds Management. Fairmount Funds Management, Fairmount GP&#160;II, Mr.&#160;Harwin and Mr.&#160;Kiselak disclaim beneficial ownership of such shares of Oruka Series&#160;A Preferred Stock and the underlying shares of Oruka common stock except to the extent of their pecuniary interest therein. The principal business address for these persons and entities is 200 Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania 19428.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 2,500,000<span class="nobreak"> </span>shares of Oruka common stock held by Paragon. Paragon is managed by a board of directors.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 2,500,000<span class="nobreak"> </span>shares of Oruka common stock held by Paruka. Paruka is managed by a sole manager.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by McKenna Capital Partners LLC (&#8220;McKenna Capital Partners&#8221;). Mark McKenna is the Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office. Mr.&#160;McKenna disclaims beneficial ownership of such shares of Oruka common stock except to the extent of his pecuniary interest therein. The principal business address for these persons and entities is PO Box 9542, Rancho, Santa Fe, CA 92067.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by Lawrence Klein.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 149,164<span class="nobreak"> </span>shares of Oruka common stock held by Turtle Family Trust, of which Cameron Turtle is a trustee.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of (i)&#160;20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000<span class="nobreak"> </span>shares of Oruka Series&#160;A Preferred Stock and (ii)&#160;1,640,810<span class="nobreak"> </span>shares of Oruka common stock.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">313</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T4"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No.&#160;&#160;&#160;&#160;3 of this proxy statement/prospectus</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information regarding beneficial ownership of the combined company&#8217;s common stock immediately after consummation of the Merger, assuming the consummation of the Merger occurred on<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 for:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person or group of affiliated persons, who is expected by ARCA and Oruka to be the beneficial owner of more than 5% of the combined company&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person expected to be a director of the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person expected to be a named executive officer of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all of the combined company&#8217;s excepted directors and executive officers and directors as a group.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beneficial ownership is determined in accordance with the rules of the SEC and thus represents voting or investment power with respect to the combined company&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual or entity has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024. Shares of the combined company&#8217;s common stock that an individual or entity has the right to acquire within 60&#160;days of&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 are deemed to be outstanding and beneficially owned by the individual or entity for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. To ARCA&#8217;s and Oruka&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The table lists applicable percentage ownership based on<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of common stock expected to be outstanding upon consummation of the merger, after giving effect to the anticipated ARCA reverse stock split and the Oruka pre<span class="nobreak">-closing</span> financing. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60&#160;days, including upon the exercise of stock options and warrants. These stock options and warrants shall be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined company&#8217;s common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined organization&#8217;s common stock expected to be owned by any other person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at closing when the final exchange ratio is determined. The table below assumes that, based on ARCA&#8217;s and Oruka&#8217;s capitalization as of May&#160;3, 2024, the date the Merger Agreement was executed, the exchange ratio is estimated to be equal to approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock, prior to giving effect to the anticipated ARCA reverse stock split. The estimated exchange ratio was derived on a fully<span class="nobreak">-diluted</span> basis as of May&#160;3, 2024, using a stipulated value of Oruka of approximately $175.0&#160;million and of ARCA of approximately $11.0<span class="nobreak"> </span>million, assuming net cash of $5.0&#160;million as of closing. The final exchange ratio is subject to adjustment prior to closing of the Merger based upon ARCA&#8217;s net cash at closing and the aggregate proceeds from the sale of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">314</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Oruka Therapeutics, Inc., 221 Crescent Street, Building<span class="nobreak"> </span>23, Suite 105, Waltham, MA&#160;02453.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name of Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares <br/>Beneficially <br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage <br/>of&#160;Shares <br/>Outstanding <br/>Beneficially <br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Named Executive Officers and Directors:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All executive officers and directors as a group (<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> persons)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%. </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">315</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T3"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">LEGAL MATTERS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. will pass upon the validity of ARCA&#8217;s common stock offered by this proxy statement/prospectus.</p>
		<a id="T2"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">EXPERTS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements of ARCA biopharma, Inc. as of December&#160;31, 2023 and 2022 and for each of the&#160;years in the two<span class="nobreak">-year</span> period ended December&#160;31, 2023, have been included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statement of Oruka Therapeutics, Inc. as of February&#160;6, 2024 included in this proxy statement/prospectus has been so included in reliance on the report (which contains an explanatory paragraph relating to Oruka&#8217;s ability to continue as a going concern as described in Note&#160;1 to the financial statement) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">316</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T1"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">WHERE YOU CAN FIND MORE INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to the informational requirements of the Exchange&#160;Act and in accordance therewith, files annual, quarterly and current reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains ARCA&#8217;s filings as well as reports, proxy and information statements, and other information issuers file electronically with the SEC at <span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also makes available free of charge on or through its website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>, its Annual Reports on Form&#160;10<span class="nobreak">-K</span>, Quarterly Reports on Form&#160;10<span class="nobreak">-Q</span>, Current Reports on Form&#160;8<span class="nobreak">-K</span> and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange&#160;Act as soon as reasonably practicable after ARCA electronically files such material with or otherwise furnishes it to the SEC.&#160;The website addresses for the SEC and ARCA are inactive textual references and except as specifically incorporated by reference into this proxy statement/prospectus, information on those websites is not part of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has filed with the SEC a registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, under the Securities Act to register the shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock) to be issued to Oruka stockholders in the Merger. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about ARCA and ARCA common stock. This proxy statement/prospectus does not contain all of the information set forth in the registration statement because certain parts of the registration statement are omitted in accordance with the rules and regulations of the SEC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has supplied all information contained in this proxy statement/prospectus relating to ARCA and Oruka has supplied all information contained in this proxy statement/prospectus relating to Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you would like to request documents from ARCA or Oruka, please send a request in writing or by telephone to either ARCA or Oruka at the following addresses:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>Attn: Corporate Secretary<br/>Tel: (720)&#160;940-2100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Oruka Therapeutics, Inc.<br/>221 Crescent Street, Building<span class="nobreak"> </span>23, Suite 105<br/>Waltham, MA&#160;02453</p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Attn: Secretary<br/>Tel: (650)&#160;606<span class="nobreak">-7910</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a ARCA stockholder and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the Merger, including the procedures for voting your shares, you should contact ARCA&#8217;s proxy solicitor, <span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, at the following address and telephone number:</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">Banks and Brokers Call:<br/>Stockholders Call Toll Free: </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">317</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9991"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR&#160;2025 ANNUAL MEETING</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If an ARCA stockholder would like ARCA to consider including a proposal in ARCA&#8217;s proxy statement for its 2025 annual meeting pursuant to Rule&#160;14a<span class="nobreak">-8</span> of the Exchange&#160;Act, then the proposal must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices on or before&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. In addition, stockholder proposals must comply with the requirements of Rule&#160;14a<span class="nobreak">-8</span> regarding the inclusion of stockholder proposals in company<span class="nobreak">-sponsored</span> proxy materials. Proposals should be addressed to:</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">ARCA biopharma, Inc.<br/>Attention: Corporate Secretary<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, Colorado, 80021</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Bylaws also establish an advance notice procedure for stockholders who wish to present a proposal or nominate a director at an annual meeting, but do not seek to include the proposal or director nominee in ARCA&#8217;s proxy statement. In order to be properly brought before ARCA&#8217;s 2025 annual meeting, the stockholder must provide timely written notice to ARCA&#8217;s corporate secretary, at ARCA&#8217;s principal executive offices, and any such proposal or nomination must constitute a proper matter for stockholder action. The written notice must contain the information specified in the ARCA Bylaws. To be timely, a stockholder&#8217;s written notice must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no earlier than<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2025, and</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no later than<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event that ARCA holds its 2025 annual meeting more than 30&#160;days before, or more than 60&#160;days after, the one<span class="nobreak">-year</span> anniversary of this year&#8217;s annual meeting, then such written notice must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no earlier than the 90<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the&#160;day of ARCA&#8217;s 2025 annual meeting, and</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no later than close of business on the later of: (i)&#160;the 60<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the&#160;day of ARCA&#8217;s 2025 annual meeting or (ii)&#160;the 10<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day following the earlier of the&#160;day on which public announcement of the date of ARCA&#8217;s 2025 annual meeting is first made or notice is first given.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Availability of Bylaws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A copy of the ARCA Bylaws may be obtained by accessing ARCA&#8217;s filings on the SEC&#8217;s website at&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>. You may also contact ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Householding of Proxy Materials</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy materials with respect to two or more stockholders sharing the same address by delivering a single set of the proxy materials addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the ARCA special meeting, a number of brokers with account holders who are ARCA stockholders will be &#8220;householding&#8221; the proxy materials. A single set of the proxy materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate set of the proxy materials, please notify your broker or ARCA.&#160;Direct your written request to Secretary, ARCA biopharma, Inc., 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021 or contact Investor Relations at (720)&#160;940<span class="nobreak">-2100</span>. ARCA undertakes to promptly deliver a separate set of the proxy materials upon receiving your written request. Stockholders who currently receive multiple copies of the proxy materials at their addresses and would like to request &#8220;householding&#8221; of their communications should contact their brokers.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">318</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T111"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS </span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended December</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2023 and 2022</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Page</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T201">Report of Independent Registered Public Accounting Firm, KPMG LLP</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T202">Balance Sheets as of December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T203">Statements of Operations for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T204">Statements of Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T205">Statements of Cash Flows for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T206">Notes to Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-7</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three months ended March</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2024 and 2023 Interim Financial Statements (Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T207">Balance Sheets as of March 31, 2024 and December 31, 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T208">Statements of Operations for the three months ended March 31, 2024 and 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T209">Statements of Stockholders&#8217; Equity for the three months ended March 31, 2024 and 2023 and interim&#160;periods </a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T210">Statements of Cash Flows for the three months ended March 31, 2024 and 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T211">Notes to Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-23</p>
					</td>
				</tr>

		</table>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of February 6, 2024</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T212">Report of Independent Registered Public Accounting Firm</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T213">Balance Sheet as of February&#160;6, 2024</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T214">Notes to Financial Statement</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-36</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from February&#160;6, 2024 (Inception) to March&#160;31, 2024</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T215">Unaudited Condensed Balance Sheets</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-41</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T216">Unaudited Condensed Statement of Operations and Comprehensive Loss</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-42</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T217">Unaudited Condensed Statement of Convertible Preferred Stock and Stockholders&#8217; Deficit</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-43</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T218">Unaudited Condensed Statement of Cash Flows</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T219">Notes to Unaudited Condensed Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-45</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T201"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the Stockholders and Board of Directors <br/>ARCA biopharma, Inc.:</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Opinion on the Financial Statements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have audited the accompanying balance sheets of ARCA biopharma, Inc. (the Company) as of December&#160;31, 2023 and December&#160;31, 2022, the related statements of operations, stockholders&#8217; equity, and cash flows for the&#160;years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and December&#160;31, 2022, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with U.S.&#160;generally accepted accounting principles.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Basis for Opinion</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We conducted our audits in accordance with the standards of the PCAOB.&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Critical Audit Matters</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1)&#160;relate to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">/s/ KPMG LLP </p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have served as the Company&#8217;s auditor since 2006.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Boulder, Colorado <br/>February&#160;1, 2024</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T202"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>BALANCE SHEETS</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-35019">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-35020">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-35021">161</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-35022">254</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-35023">37,592</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-35024">42,699</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-35025">247</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-35026">343</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-35027">10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-35028">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-35029">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-35030">18</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-35031">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-35032">43,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-35033">362</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-35034">334</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35035">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35036">173</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities (related party&#160;&#8211;&#160;$<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35037">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35038">216</ix:nonFraction>&#160;at December&#160;31, 2023 and 2022, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35039">175</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35040">625</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35041">637</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35042">1,132</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-35043">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-35044">280</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-35045">841</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-35046">1,412</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; equity:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Preferred stock, $<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-35047"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-35048">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-35049"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-35050">5</ix:nonFraction></ix:nonFraction>&#160;million shares authorized; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-35051"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-35052"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35053"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35054">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares&#160;issued or outstanding at December&#160;31, 2023 and 2022</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-2; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-3; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-35055"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-35056">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-35057"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-35058">100</ix:nonFraction></ix:nonFraction>&#160;million shares authorized at December&#160;31, 2023 and 2022; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-35059"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35060">14,501,143</ix:nonFraction></ix:nonFraction>&#160;and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-35061"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35062">14,410,143</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-35063">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-35064">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-35065">225,747</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-35066">225,061</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-35067">188,741</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-35068">183,402</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35069">37,020</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35070">41,673</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities and stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-35071">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-35072">43,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T203"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF OPERATIONS</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Costs and expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-35073">6,283</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-35074">5,847</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development (related party&#160;&#8211;&#160;$(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" sign="-" unitRef="usd" id="ixv-35075">91</ix:nonFraction>)&#160;and $<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-35076">432</ix:nonFraction> as of the&#160;years&#160;ended December&#160;31, 2023 and 2022, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-35077">1,013</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-35078">4,749</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total costs and expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-35079">7,296</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-35080">10,596</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35081">7,296</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35082">10,596</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest and other income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-35083">1,957</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-35084">675</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-5; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" unitRef="usd" id="ixv-35085">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35086">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35087">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-7; -sec-ix-hidden: hidden-fact-6; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-35088">0.37</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-35089">0.69</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average shares outstanding:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-9; -sec-ix-hidden: hidden-fact-8; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-35090">14,415,877</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-35091">14,410,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T204"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; Equity</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Common stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional<br/>Paid-In<br/>Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2021</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35092">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35093">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35094">224,505</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-35095">173,476</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35096">51,043</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-14; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35097">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-15; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35098">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-16; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-17; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35099">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35100">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2022</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35101">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35102">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35103">225,061</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-35104">183,402</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35105">41,673</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of common stock upon vesting&#160;of Restricted Stock Units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" unitRef="shares" id="ixv-35106">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-18; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-19; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-20; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-21; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-22; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35107">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-23; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35108">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-24; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-25; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35109">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35110">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35111">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35112">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35113">225,747</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-35114">188,741</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35115">37,020</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T205"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF CASH FLOWS</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35116">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35117">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-35118">15</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-35119">20</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-35120">96</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-35121">94</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-35122">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-35123">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from disposal of property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-50; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" sign="-" unitRef="usd" id="ixv-35124">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-35125">93</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-35126">808</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-35127">6</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-51; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-35128">28</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-35129">783</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-35130">73</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-35131">752</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-35132">526</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-35133">934</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in operating activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-35134">5,014</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-35135">10,912</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from investing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Purchase of property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-52; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-35136">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in investing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-53; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-35137">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash provided by financing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-54; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-55; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net decrease in cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-35138">5,014</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-35139">10,914</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents, beginning of year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-35140">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-35141">53,359</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash and cash equivalents, end of year</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-35142">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-35143">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental cash flow information:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-56; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-57; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax refund received</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-58; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-59; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T206"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="ixv-19958"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_1" escape="true" name="abio:DescriptionOfBusinessPolicyTextBlock" id="ixv-19961"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_2" id="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p></ix:continuation>
		<ix:continuation id="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_1" escape="true" name="abio:LiquidityAndGoingConcernPolicyTextBlock" id="ixv-19969"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_2" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has <ix:nonFraction contextRef="c6" decimals="INF" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35144">no</ix:nonFraction>t generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_3" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_4" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_5" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_4"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_6" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_5"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_7" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_6"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_8" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_7"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_9" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_8"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_10" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_9"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_11" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_10"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;The Company and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_1"><ix:continuation id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_11"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-20019"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></ix:nonNumeric>
		<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-20025"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p></ix:nonNumeric>
		<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_UseOfEstimates-c6_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-20030"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p></ix:nonNumeric>
		<ix:continuation id="_UseOfEstimates-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-20035"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p></ix:nonNumeric>
		<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ConcentrationRiskCreditRisk-c6_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-20040"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p></ix:nonNumeric>
		<ix:continuation id="_ConcentrationRiskCreditRisk-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:fixed-zero" name="us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset" scale="0" unitRef="usd" id="ixv-35145">no</ix:nonFraction> off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-20046"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;The Company and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_2"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_ComprehensiveLossPolicyPolicyTextBlock-c6_cont_1" escape="true" name="abio:ComprehensiveLossPolicyPolicyTextBlock" id="ixv-20065"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p></ix:nonNumeric>
		<ix:continuation id="abio_ComprehensiveLossPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_LesseeLeasesPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-20071"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c6_cont_2" id="_LesseeLeasesPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p></ix:continuation>
		<ix:continuation id="_LesseeLeasesPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_AccruedOutsourcingExpensesPolicyTextBlock-c6_cont_1" escape="true" name="abio:AccruedOutsourcingExpensesPolicyTextBlock" id="ixv-20080"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p></ix:nonNumeric>
		<ix:continuation id="abio_AccruedOutsourcingExpensesPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-20085"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p></ix:nonNumeric>
		<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in <ix:nonFraction contextRef="c6" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-35146">one</ix:nonFraction> segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-20090"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p></ix:continuation>
		<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_3" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;The Company and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_3"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_4" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p></ix:continuation>
		<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c6_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-20113"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p></ix:nonNumeric>
		<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_IncomeTaxPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-20121"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p></ix:nonNumeric>
		<ix:continuation id="_IncomeTaxPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p></ix:continuation></ix:continuation>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-20126"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-35147">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-35148">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-35149">704,960</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-69; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-35150">91,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-35151">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-35152">795,960</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-20191"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#8217;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, ARCA had $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-35153">37.4</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c67" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-35154">42.4</ix:nonFraction>&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-72"><span style="-sec-ix-hidden: hidden-fact-73">no</span></span> transfers between any fair value hierarchy levels in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did <span style="-sec-ix-hidden: hidden-fact-70"><span style="-sec-ix-hidden: hidden-fact-71">not</span></span> have any debt outstanding.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-20212"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_PropertyPlantAndEquipmentTextBlock-c6_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-35155">Property and equipment consist of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35156">3</ix:nonNumeric>&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35157">39</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35158">39</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35159">5</ix:nonNumeric>&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35160">130</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35161">130</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35162">5</ix:nonNumeric>&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35163">37</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35164">44</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c75" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35165">3</ix:nonNumeric>&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35166">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35167">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35168">222</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35169">229</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-35170">212</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-35171">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-35172">10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-35173">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-35174">15</ix:nonFraction>,000 and $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-35175">20</ix:nonFraction>,000, respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-20372"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" sign="-" unitRef="usd" id="ixv-35176">91,000</ix:nonFraction>) and $<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-35177">432,000</ix:nonFraction>, respectively. In December&#160;2023, ARCA made a payment of $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfUnrestrictedResearchGrants" scale="0" unitRef="usd" id="ixv-35178">125,000</ix:nonFraction> for the grant period July&#160;2022 through December&#160;2023 under these arrangements.</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-20385"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-35179">265,000</ix:nonFraction>. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfRetentionBonuses" scale="-2" unitRef="pure" id="ixv-35180">50</ix:nonFraction>% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonusPaid" scale="0" unitRef="usd" id="ixv-35181">86,000</ix:nonFraction> was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-35182">311,000</ix:nonFraction>, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="0" unitRef="usd" id="ixv-35183">159,000</ix:nonFraction> for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-76">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA implemented a strategic reduction of the workforce by approximately <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" unitRef="pure" id="ixv-35184">67</ix:nonFraction>%, or <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" unitRef="pure" id="ixv-35185">12</ix:nonFraction> employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#8217;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-35186">755,000</ix:nonFraction>, of which $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-35187">470,000</ix:nonFraction> and $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-35188">285,000</ix:nonFraction> were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits, none of which remains unpaid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Lease</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqft" id="ixv-35189">5,200</ix:nonFraction> square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term is <ix:nonNumeric contextRef="c85" continuedAt="_LesseeOperatingLeaseTermOfContract-c85_cont_1" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-35190">42</ix:nonNumeric>&#160;months beginning October&#160;1, 2020 and includes an <ix:nonNumeric contextRef="c86" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="ixv-20402">option to renew for an additional <ix:nonNumeric contextRef="c85" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-35191">36</ix:nonNumeric><ix:continuation id="_LesseeOperatingLeaseTermOfContract-c85_cont_1"><span class="nobreak"> </span>month</ix:continuation> term at the then prevailing rental rate.</ix:nonNumeric> The exercise of the lease renewal option is at ARCA&#8217;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" scale="0" unitRef="sqft" id="ixv-35192">3,000</ix:nonFraction> square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was <span style="-sec-ix-hidden: hidden-fact-74">29</span>&#160;months and terminated in October&#160;2023. <ix:nonNumeric contextRef="c6" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" id="ixv-20406">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</ix:nonNumeric></p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-35193">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-35194">93</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-35195">96</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-35196">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd" id="ixv-35197">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-35198">314</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-35199">34</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-35200">76</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-35201">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-35202">119,000</ix:nonFraction> and $<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-35203">125,000</ix:nonFraction>, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the lease liability was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-35204">280,000</ix:nonFraction> and the current portion is included in accrued expenses and other liabilities and the non<span class="nobreak">-current</span> portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-35205">127,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-35206">131,000</ix:nonFraction>, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of December&#160;31, 2023 is <span style="-sec-ix-hidden: hidden-fact-75">3.2</span>&#160;years. The weighted<span class="nobreak">-average</span> discount rate for the operating lease is <ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-35207">7</ix:nonFraction>%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" scale="6" unitRef="eur" id="ixv-35208">1.6</ix:nonFraction>&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro License</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-20518"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;22, 2020, ARCA entered into a Capital on Demand<span class="Superscript" style="vertical-align:super;font-size:58%;">TM</span> Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $<ix:nonFraction contextRef="c92" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-35209">0.001</ix:nonFraction> per share (&#8220;ARCA&#160;common stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction contextRef="c92" decimals="-5" format="ixt:num-dot-decimal" name="abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell" scale="6" unitRef="usd" id="ixv-35210">54.0</ix:nonFraction>&#160;million (the &#8220;Shares&#8221;).</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA paid JonesTrading a commission rate equal to <ix:nonFraction contextRef="c93" decimals="3" format="ixt:num-dot-decimal" name="abio:SellingCommissionPerAdditionalSharesSoldPercentage" scale="-2" unitRef="pure" id="ixv-35211">3.0</ix:nonFraction>% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-35212"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-35213">No</ix:nonFraction></ix:nonFraction> sales were made in 2023 or 2022.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one<span class="nobreak">-third</span> of ARCA&#8217;s public float in any 12<span class="nobreak">-month</span> period.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-20545"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s equity incentive plan, <span class="Italic" style="font-style:italic;font-weight:normal;">the 2020 Equity Incentive Plan </span>(the &#8220;Equity Plan&#8221;),<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is <ix:nonFraction contextRef="c96" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares" id="ixv-35214">1,167,425</ix:nonFraction><span class="nobreak"> </span>shares.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase <ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-35215">601,900</ix:nonFraction><span class="nobreak"> </span>shares with a weighted average exercise price of $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35216">3.45</ix:nonFraction> per share were outstanding under the Equity Plan, and <ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-35217">459,718</ix:nonFraction><span class="nobreak"> </span>shares were reserved for future awards.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of <span style="-sec-ix-hidden: hidden-fact-98">three</span> to <span style="-sec-ix-hidden: hidden-fact-99">four</span>&#160;years from the date of grant and have a maximum term of <span style="-sec-ix-hidden: hidden-fact-100">ten</span>&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least <ix:nonFraction contextRef="c100" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-35218">100</ix:nonFraction>% of the fair market value on the grant date and exercise price of options granted to <ix:nonFraction contextRef="c98" decimals="INF" format="ixt:num-dot-decimal" name="abio:PercentageHoldingForStockOptionsExercisePrice" scale="-2" unitRef="pure" id="ixv-35219">10</ix:nonFraction>% (or greater) stockholders must be at least <ix:nonFraction contextRef="c101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-35220">110</ix:nonFraction>% of the fair market value on the grant date.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase <ix:nonFraction contextRef="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-35221">14,807</ix:nonFraction><span class="nobreak"> </span>shares with a weighted average exercise price of $<ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35222">57.73</ix:nonFraction> per share were outstanding under the 2013 plan.</p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did <ix:nonFraction contextRef="c103" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares" id="ixv-35223">no</ix:nonFraction>t grant options in 2023. ARCA granted options to purchase an aggregate of <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="abio:PurchaseAggregateShares" scale="0" unitRef="shares" id="ixv-35224">60,000</ix:nonFraction><span class="nobreak"> </span>shares of ARCA common stock in the year ended December&#160;31, 2022. <ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-20576">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-35225">5.5</ix:nonNumeric>&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-35226">107</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-35227">3.56</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-35228">0</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-35229">1.87</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-35230">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c6_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-35231">904,123</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35232">5.59</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-35233">60,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35234">2.31</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-35235">259,163</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35236">4.74</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-35237">704,960</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35238">5.62</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-35239">8.29</ix:nonNumeric></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-35240">18</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-35241">88,253</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35242">11.68</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-35243">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35244">4.76</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-35245">7.35</ix:nonNumeric></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-35246">463,068</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35247">5.28</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-35248">7.29</ix:nonNumeric></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-35249">616,661</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35250">4.76</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-35251">7.35</ix:nonNumeric></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#8217;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in<span class="nobreak">-the-money</span> options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $<ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" unitRef="usd" id="ixv-35252">367,000</ix:nonFraction> which is expected to be recognized over a weighted average period of <span style="-sec-ix-hidden: hidden-fact-101">1.1</span>&#160;years. ARCA recognizes compensation costs for its share<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA granted restricted stock units (&#8220;RSUs&#8221;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight<span class="nobreak">-line</span> basis over the respective vesting period. The stock awards granted had a requisite service period of <span style="-sec-ix-hidden: hidden-fact-102">one</span> year.</p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="ixv-35253">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-35254">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-35255">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-35256">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-35257">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-35258">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-35259">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-97; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, there was <ix:nonFraction contextRef="c108" decimals="INF" format="ixt:fixed-zero" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" unitRef="usd" id="ixv-35260">no</ix:nonFraction> unrecognized compensation cost related to unvested stock awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-cash Stock-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-21058">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35261">526</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35262">423</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35263">160</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35264">133</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35265">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35266">556</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not recognize any tax benefit related to employee stock<span class="nobreak">-based</span> compensation cost as a result of the full valuation allowance on its net deferred tax assets.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="ixv-21121"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Employee Benefit Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has a 401(k)&#160;plan and makes a <ix:nonNumeric contextRef="c6" name="us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" id="ixv-35267">matching contribution equal to <ix:nonFraction contextRef="c111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" unitRef="pure" id="ixv-35268">100</ix:nonFraction>% of the employee&#8217;s first <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" unitRef="pure" id="ixv-35269">3</ix:nonFraction>% of the employee&#8217;s contributions and <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" unitRef="pure" id="ixv-35270">50</ix:nonFraction>% of the employee&#8217;s next <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" unitRef="pure" id="ixv-35271">2</ix:nonFraction>% of contributions.</ix:nonNumeric> ARCA adopted the plan in 2006 and contributed $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-35272">56,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-35273">96,000</ix:nonFraction> for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-21125"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective June&#160;1, 2005, ARCA changed from an S<span class="nobreak">-Corporation</span> to a C<span class="nobreak">-Corporation</span>. As an S<span class="nobreak">-Corporation</span>, the net operating loss carryforwards were distributed to ARCA&#8217;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-35274">208.1</ix:nonFraction>&#160;million, and approximately $<ix:nonFraction contextRef="c113" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" unitRef="usd" id="ixv-35275">2.4</ix:nonFraction>&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#8217;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning <span style="-sec-ix-hidden: hidden-fact-109">2025</span> through <span style="-sec-ix-hidden: hidden-fact-110">2037</span>. <ix:nonNumeric contextRef="c6" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-35276">The net operating loss carryforwards beginning in 2018, have no expiration.</ix:nonNumeric> <ix:nonNumeric contextRef="c116" continuedAt="_TaxCreditCarryforwardLimitationsOnUse-c116_cont_1" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="ixv-35277">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit </ix:nonNumeric></p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_2" id="_IncomeTaxDisclosureTextBlock-c6_cont_1"><ix:continuation id="_TaxCreditCarryforwardLimitationsOnUse-c116_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.</p></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#8217;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance" scale="6" unitRef="usd" id="ixv-35278">55.5</ix:nonFraction>&#160;million at December&#160;31, 2023, reflecting an increase of approximately $<ix:nonFraction contextRef="c6" decimals="-5" format="ixt:num-dot-decimal" name="abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" scale="6" unitRef="usd" id="ixv-35279">1.2</ix:nonFraction>&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-35280">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-35281"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-35282">21</ix:nonFraction></ix:nonFraction>% for 2023 and 2022, as a result of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c6_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-35283">1,121</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-35284">2,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-35285">192</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-35286">357</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" scale="3" unitRef="usd" id="ixv-35287">47</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" scale="3" unitRef="usd" id="ixv-35288">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-35289">107</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-35290">186</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-35291">1,159</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-35292">2,254</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_IncomeTaxDisclosureTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-35293">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-35294">51,190</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-35295">50,008</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" unitRef="usd" id="ixv-35296">371</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" unitRef="usd" id="ixv-35297">393</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-35298">2,420</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-35299">2,420</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-35300">951</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-35301">979</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd" id="ixv-35302">354</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd" id="ixv-35303">356</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-35304">232</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-35305">205</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-35306">7</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-35307">6</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsLeaseLiabilities" scale="3" unitRef="usd" id="ixv-35308">69</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsLeaseLiabilities" scale="3" unitRef="usd" id="ixv-35309">94</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-35310">55,594</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-35311">54,461</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-35312">55,531</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-35313">54,372</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-35314">63</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-35315">89</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" unitRef="usd" id="ixv-35316">61</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" unitRef="usd" id="ixv-35317">84</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-35318">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-35319">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-107; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-108; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#8217;s open tax&#160;years extend back to <span style="-sec-ix-hidden: hidden-fact-111">2009</span>. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#8217;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:fixed-zero" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" unitRef="usd" id="ixv-35320"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:fixed-zero" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" unitRef="usd" id="ixv-35321">no</ix:nonFraction></ix:nonFraction> reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. <ix:nonFraction contextRef="c6" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" unitRef="usd" id="ixv-35322"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" unitRef="usd" id="ixv-35323">No</ix:nonFraction></ix:nonFraction> interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T207"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>BALANCE SHEETS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">March&#160;31, <br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">December&#160;31, <br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-35324">35,903</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-35325">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-35326">767</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-35327">161</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-35328">36,670</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-35329">37,592</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-35330">17</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-35331">247</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-35332">7</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-35333">10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-35334">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-35335">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-35336">36,706</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-35337">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-35338">529</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-35339">362</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35340">84</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35341">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35342">968</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35343">175</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35344">1,581</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-35345">637</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-4; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-35346">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-35347">1,581</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-35348">841</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; equity:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-35349"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-35350">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-35351"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-35352">100</ix:nonFraction></ix:nonFraction>&#160;million shares authorized at March&#160;31,&#160;2024 and December&#160;31, 2023; <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-35353"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-35354"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35355"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35356">14,501,143</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-35357">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-35358">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-35359">225,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-35360">225,747</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-35361">190,750</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-35362">188,741</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35363">35,125</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35364">37,020</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities and stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-35365">36,706</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-35366">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T208"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF OPERATIONS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Costs and expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-35367">2,317</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-35368">1,406</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development (related party&#160;&#8211;&#160;$<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-35369">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-35370">108</ix:nonFraction> as of March&#160;31,&#160;2024&#160;and 2023, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-35371">165</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-35372">390</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total costs and expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-35373">2,482</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-35374">1,796</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35375">2,482</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35376">1,796</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest and other income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-35377">473</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-35378">450</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35379">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35380">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-11; -sec-ix-hidden: hidden-fact-10; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-35381">0.14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-35382">0.09</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average shares outstanding:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-13; -sec-ix-hidden: hidden-fact-12; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-35383">14,501,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-35384">14,410,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T209"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; Equity</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Common stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional <br/>Paid-In <br/>Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2022</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35385">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35386">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35387">225,061</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-35388">183,402</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35389">41,673</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-26; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35390">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-27; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35391">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-28; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-29; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35392">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35393">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, March&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35394">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35395">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35396">225,265</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-35397">184,748</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35398">40,531</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-30; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35399">187</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-31; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35400">187</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-32; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-33; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35401">1,480</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35402">1,480</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, June&#160;30, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35403">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35404">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35405">225,452</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-35406">186,228</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35407">39,238</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-34; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35408">154</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-35; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35409">154</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-36; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-37; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35410">1,424</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35411">1,424</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, September&#160;30, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35412">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35413">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35414">225,606</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-35415">187,652</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35416">37,968</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of common stock upon vesting&#160;of Restricted Stock Units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" unitRef="shares" id="ixv-35417">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-38; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-39; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-40; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-41; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-42; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35418">141</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-43; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35419">141</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-44; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-45; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35420">1,089</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35421">1,089</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35422">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35423">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35424">225,747</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-35425">188,741</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35426">37,020</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-46; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35427">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-47; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-35428">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-48; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-49; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35429">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35430">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, March&#160;31, 2024</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-35431">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35432">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35433">225,861</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-35434">190,750</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-35435">35,125</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T210"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF CASH FLOWS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Quarter Ended March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35436">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-35437">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-35438">3</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-35439">4</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-35440">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-35441">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-35442">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-35443">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-35444">606</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-35445">598</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-35446">167</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-35447">32</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-35448">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" unitRef="usd" id="ixv-35449">62</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-35450">803</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-35451">22</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in operating activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-35452">1,528</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-35453">1,595</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from investing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in investing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-60; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-61; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash provided by financing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-62; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-63; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net decrease in cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-35454">1,528</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-35455">1,595</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents, beginning of year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-35456">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-35457">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash and cash equivalents, end of year</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-35458">35,903</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-35459">40,850</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental cash flow information:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-64; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-65; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax refund received</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-66; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-67; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental disclosure of noncash investing and financing transactions:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Leased assets and operating lease liabilities&#160;&#8211;&#160;amended lease term</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-35460">214</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-68; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T211"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="ixv-23356"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_1" escape="true" name="abio:DescriptionOfBusinessPolicyTextBlock" id="ixv-23359"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_2" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p></ix:continuation>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_3" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p></ix:continuation>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_4" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p></ix:continuation>
		<ix:continuation id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="abio:LiquidityAndGoingConcernPolicyTextBlock" id="ixv-23374"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has <ix:nonFraction contextRef="c0" decimals="INF" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35461">no</ix:nonFraction>t generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_5" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_6" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_5"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_7" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_6"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_8" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_7"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_9" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_8"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_10" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_9"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_11" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_10"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_12" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_11"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_13" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_12"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_14" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_13"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p></ix:continuation>
		<ix:continuation id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_14"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-23436"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-23456"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p></ix:nonNumeric>
		<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:fixed-zero" name="us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset" scale="0" unitRef="usd" id="ixv-35462">no</ix:nonFraction> off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1" escape="true" name="abio:ComprehensiveLossPolicyPolicyTextBlock" id="ixv-23462"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p></ix:nonNumeric>
		<ix:continuation id="abio_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-23468"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p></ix:continuation>
		<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_AccruedOutsourcingExpensesPolicyTextBlock-c0_cont_1" escape="true" name="abio:AccruedOutsourcingExpensesPolicyTextBlock" id="ixv-23477"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p></ix:nonNumeric>
		<ix:continuation id="abio_AccruedOutsourcingExpensesPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-23482"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p></ix:nonNumeric>
		<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-23495"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-35463">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-35464">645,845</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-35465">664,857</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-112; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-35466">91,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-35467">645,845</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-35468">755,857</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-23552"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were <span style="-sec-ix-hidden: hidden-fact-113"><span style="-sec-ix-hidden: hidden-fact-114">no</span></span> marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $<ix:nonFraction contextRef="c121" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-35469">35.9</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-35470">37.4</ix:nonFraction>&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-115">no</span> transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.</p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-23581"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-35471">Property and equipment consist of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c122" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35472">3</ix:nonNumeric>&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35473">39</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35474">39</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c123" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35475">5</ix:nonNumeric>&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35476">130</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35477">130</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c124" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35478">5</ix:nonNumeric>&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35479">37</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35480">37</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c125" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35481">3</ix:nonNumeric>&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35482">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35483">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35484">222</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-35485">222</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-35486">215</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-35487">212</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-35488">7</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-35489">10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-35490">3</ix:nonFraction>,000 and $<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-35491">4</ix:nonFraction>,000 respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-23741"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was <ix:nonFraction contextRef="c127" decimals="0" format="ixt:fixed-zero" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-35492">no</ix:nonFraction> expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-35493">108,000</ix:nonFraction>. In December&#160;2023, ARCA made a payment of $<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfUnrestrictedResearchGrants" scale="0" unitRef="usd" id="ixv-35494">125,000</ix:nonFraction> for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-23747"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-35495">265,000</ix:nonFraction>. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfRetentionBonuses" scale="-2" unitRef="pure" id="ixv-35496">50</ix:nonFraction>% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonusPaid" scale="0" unitRef="usd" id="ixv-35497">86,000</ix:nonFraction> was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-35498">311,000</ix:nonFraction>, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-35499">444,000</ix:nonFraction>. See Note&#160;10.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms </p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="0" unitRef="usd" id="ixv-35500">159,000</ix:nonFraction> for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-119">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqft" id="ixv-35501">5,200</ix:nonFraction> square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term was <ix:nonNumeric contextRef="c85" continuedAt="_LesseeOperatingLeaseTermOfContract-c85_alt_0_cont_1" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-35502">42</ix:nonNumeric>&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="ixv-35503">to extend the <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="ixv-35504">lease</ix:nonNumeric> term six (<ix:nonNumeric contextRef="c5" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-35505">6</ix:nonNumeric>)&#160;months through <ix:nonNumeric contextRef="c0" name="abio:OperatingLeasesExtendedExpiryYearsAndMonth" id="ixv-35506">September&#160;2024</ix:nonNumeric></ix:nonNumeric>. If ARCA elects to stay in the property after September&#160;2024, it will pay rent<ix:continuation id="_LesseeOperatingLeaseTermOfContract-c85_alt_0_cont_1"> month</ix:continuation> to month equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfBaseRentToBePaidMonthly" scale="-2" unitRef="pure" id="ixv-35508">125</ix:nonFraction>% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" scale="0" unitRef="sqft" id="ixv-35509">3,000</ix:nonFraction> square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was <span style="-sec-ix-hidden: hidden-fact-117">29</span>&#160;months and terminated in October&#160;2023. <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" id="ixv-23776">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</ix:nonNumeric></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-35510">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-35511">49</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-35512">49</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-35513">1</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-35514">48</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-35515">22,000</ix:nonFraction> and $<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-35516">31,000</ix:nonFraction>, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the lease liability was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-35517">48,000</ix:nonFraction>, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-35518">23,000</ix:nonFraction> and $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-35519">33,000</ix:nonFraction>, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of March&#160;31, 2024 is <span style="-sec-ix-hidden: hidden-fact-118">0.5</span>&#160;years. The discount rate for the operating lease is <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-35520">7</ix:nonFraction>%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately </p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">&#8364;<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" scale="6" unitRef="eur" id="ixv-35521">1.6</ix:nonFraction>&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-23855"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;">Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $<ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-35522">0.001</ix:nonFraction> per share (&#8220;ARCA common stock&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonFraction contextRef="c133" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-35523"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-35524">No</ix:nonFraction></ix:nonFraction> sales were made under the Sales Agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See &#8220;Financing Transaction&#8221; discussion in Note&#160;10 below.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-23869"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-23873">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35525">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35526">163</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-120; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35527">41</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35528">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-35529">204</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-35530">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-35531">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35532">4.76</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c137" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-35533">7.35</ix:nonNumeric></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-35534">42,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35535">1.64</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-121; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-122; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-35536">12,862</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35537">17.45</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-35538">645,845</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35539">4.30</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-35540">6.82</ix:nonNumeric></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-35541">502,517</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35542">4.71</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-35543">6.55</ix:nonNumeric></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-35544">645,816</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-35545">4.30</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-35546">6.82</ix:nonNumeric></p>	</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-24083"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#8217;s deferred tax assets will not be realized. ARCA&#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has <span style="-sec-ix-hidden: hidden-fact-123">no</span> reserve for uncertain tax positions.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-24088"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#8220;Out of the Money Options&#8221;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five (<ix:nonNumeric contextRef="c138" format="ixt-sec:durday" name="abio:NumberOfConsecutiveTradingDays" id="ixv-35547">5</ix:nonNumeric>)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the financing transaction described below) will own approximately <ix:nonFraction contextRef="c139" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-35548">97.62</ix:nonFraction>% of the combined company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately <ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-35549">2.38</ix:nonFraction>% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be </p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">adjusted to the extent that ARCA&#8217;s net cash at closing is less than $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="abio:ThresholdAmountOfAdjustedExchangeRatio" scale="6" unitRef="usd" id="ixv-35550">5.0</ix:nonFraction>&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="abio:ThresholdAmountOfDeclaredCashDividend" scale="0" unitRef="usd" id="ixv-35551">5,000,000</ix:nonFraction>.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $<ix:nonFraction contextRef="c142" decimals="INF" format="ixt:num-dot-decimal" name="abio:SubscriptionAgreementReceiptAmount" scale="0" unitRef="usd" id="ixv-35552">175,000,000</ix:nonFraction> (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to ARCA&#8217;s transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfOtherPartyTerminationFee" scale="0" unitRef="usd" id="ixv-35553">440,000</ix:nonFraction>.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, par value $<ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-35554">0.001</ix:nonFraction> per share (the &#8220;Series&#160;B Preferred Stock&#8221;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock </p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least <ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="abio:MinimumPercentageOfOriginallyIssuedShares" scale="-2" unitRef="pure" id="ixv-35555"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="abio:MinimumPercentageOfOriginallyIssuedOutstanding" scale="-2" unitRef="pure" id="ixv-35556">30</ix:nonFraction></ix:nonFraction>% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-35557">1,000</ix:nonFraction><span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at <ix:nonFraction contextRef="c147" decimals="4" format="ixt:num-dot-decimal" name="abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares" scale="-2" unitRef="pure" id="ixv-35558">9.99</ix:nonFraction>%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of <ix:nonFraction contextRef="c148" decimals="0" format="ixt-sec:numwordsen" name="abio:ExceptedNumberOfBoardMembers" scale="0" unitRef="pure" id="ixv-35559">five</ix:nonFraction> (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock (together, the &#8220;PIPE Securities&#8221;) for an aggregate purchase price of approximately $<ix:nonFraction contextRef="c149" decimals="-5" format="ixt:num-dot-decimal" name="abio:AggregatePurchasePrice" scale="6" unitRef="usd" id="ixv-35560">275.0</ix:nonFraction>&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (<ix:nonNumeric contextRef="c150" format="ixt-sec:durmonth" name="abio:NumberOfMonthsBaseSalary" id="ixv-35561">12</ix:nonNumeric>)&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="abio:CashPayment" scale="0" unitRef="usd" id="ixv-35562">25,000</ix:nonFraction>, less applicable withholdings. The severance benefits were conditioned on the non<span class="nobreak">-revocation</span> by Dr.&#160;Bristow of a legal release of claims.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_SubsequentEventsTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;Plan&#8221;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment of Thomas Keuer as President</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#8217;s Chief Operating Officer, to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on April&#160;3, 2024.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="abio:IncreaseOfRetentionBonusToEachExecutive" scale="0" unitRef="usd" id="ixv-35563"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="abio:IncreaseOfRetentionBonusToEachExecutive" scale="0" unitRef="usd" id="ixv-35564">200,000</ix:nonFraction></ix:nonFraction>. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-35565">165,000</ix:nonFraction>, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.</p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T212"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the Board of Directors and Stockholders of Oruka Therapeutics, Inc.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Opinion on the Financial Statement&#160;&#8212;&#160;Balance Sheet</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have audited the accompanying<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>balance sheet of Oruka Therapeutics, Inc. (the &#8220;Company&#8221;) as of February&#160;6, 2024, including the related notes (collectively referred to as the &#8220;financial statement&#8221;). In our opinion, the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement presents fairly, in all material respects, the financial position of the Company as of February&#160;6, 2024<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>in conformity with accounting principles generally accepted in the United&#160;States of America.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The accompanying financial statement has been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;1 to the financial statement, the Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception, which raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;1. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement is the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We conducted our audit of this financial statement in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United&#160;States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement is free of material misstatement, whether due to error or fraud.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our audit included performing procedures to assess the risks of material misstatement of the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement. We believe that our audit provides a reasonable basis for our opinion.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Critical Audit Matters</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Critical audit matters are matters arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that (i)&#160;relate to accounts or disclosures that are material to the financial statement and (ii)&#160;involved our especially challenging, subjective, or complex judgments. We determined there are no critical audit matters.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">/s/ PricewaterhouseCoopers LLP</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Boston, Massachusetts<br/><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">May&#160;13, 2024</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have served as the Company&#8217;s auditor since 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T213"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>BALANCE SHEET<br/>(In thousands, except share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">February&#160;6, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (Note&#160;5)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A convertible preferred stock, $0.0001 par value, 20,000,000 shares authorized, no shares issued and outstanding as of February&#160;6, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $0.0001 par value, 65,000,000 shares authorized, 5,596,658 issued and outstanding as of February&#160;6, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">1</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of this financial statement.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T214"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Nature of the Business and Basis of Presentation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Background and Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka was founded by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company is subject to risks and uncertainties common to early<span class="nobreak">-stage</span> companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third<span class="nobreak">-party</span> organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company&#8217;s potential products will require approval from the U.S.&#160;Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The financial statement and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The accompanying financial statement has been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of February&#160;6, 2024, the Company had no cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company will devote substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In March&#160;2024, the Company received $3.0&#160;million in proceeds from the sale of Series&#160;A convertible preferred stock and $25.0&#160;million in proceeds from the sale of an unsecured convertible promissory note, both of which were related party transactions (see Note&#160;7<span class="Italic" style="font-style:italic;font-weight:normal;"> Subsequent Events</span>).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Concurrent with the execution of the Merger Agreement, the Company entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in a private placement financing (the &#8220;Private Placement&#8221;) shares and pre<span class="nobreak">-funded</span> warrants of the Company&#8217;s common stock at an estimated purchase price of $5.80 per share of common stock and $5.79 per warrant for gross proceeds of approximately $275.0&#160;million, which will precede the closing of the Merger Agreement transaction. Shares of the Company&#8217;s common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private Placement will be converted into the right to receive shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to purchase ARCA common stock, respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private Placement are expected to advance the Company&#8217;s pipeline, business development activities, working capital, and other general corporate purposes.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">However, the agreements are subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $0.4<span class="nobreak"> </span>million or Oruka could be required to pay ARCA a termination fee of $0.4<span class="nobreak"> </span>million. Based on its expectation of continuing operating losses for the foreseeable future, as of May<span class="nobreak"> </span>13, 2024, the date the Company&#8217;s financial statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve&#160;months from the date the financial statement is available to be issued.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Summary of Significant Accounting Policies</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription receivable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As of February&#160;6, 2024, the Company has the authority to issue a total of 65,000,000<span class="nobreak"> </span>shares of common stock at a par value of $0.0001. As of February&#160;6, 2024, 5,596,658<span class="nobreak"> </span>shares of common stock were issued and outstanding for a nominal consideration, which was received in March&#160;2024, prior to the date the financial statement is available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock held of record by such holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s Board of Directors. Upon dissolution, liquidation or winding up of the Company, the holders of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall be entitled to receive the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company issued 5,596,658<span class="nobreak"> </span>shares of common stock, through a series of contribution agreements, to Paragon, Paruka Holding, LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and Oruka Advisors LLC (&#8220;Oruka Advisors&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February&#160;6, 2024, Paragon, Paruka and Oruka Advisors each beneficially own approximately 44.7%, 44.7% and 10.6%, respectively, of the Company through their common stock holdings.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Commitments and Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company may be subject to legal proceedings that arise in the ordinary course of business. As of February&#160;6, 2024, there were no material proceedings to which the Company was a party, nor did the Company have knowledge of any proceedings threatened against it.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;6, 2024, the Company&#8217;s Board of Directors approved the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), under which the Company may grant stock options, restricted stock awards, restricted stock units, or other stock<span class="nobreak">-based</span> awards to its employees, officers, directors, consultants, and advisors. The Company reserved 372,912<span class="nobreak"> </span>shares of its common stock for issuance under the 2024 Plan. As of February&#160;6, 2024, no awards had been issued under the plan.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated all events subsequent to February&#160;6, 2024, through May<span class="nobreak"> </span>13, 2024, the date on which the financial statement was available to be issued.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In February&#160;2024, the Company&#8217;s Board of Directors authorized and granted 2,073,387 restricted stock awards at a price of $0.0001 per share to employees of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March 2024, the Company&#8217;s Board of Directors authorized and granted 1,789,974 restricted stock awards at a price of $0.0001 per share to consultants and a director of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;5, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 372,912 to 872,912.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;22, 2024, the Company granted options for the purchase of an aggregate 698,669<span class="nobreak"> </span>shares of common stock, at an exercise price of $2.90 per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 872,912 to 2,063,669.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company granted options for the purchase of an aggregate 1,365,000<span class="nobreak"> </span>shares of common stock, at an exercise price of $3.89 per share.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Antibody Discovery and Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company entered into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March&#160;28, 2024, whereby the Company was granted an exclusive, worldwide option, on a research program<span class="nobreak">-by-research</span> program basis, to all of Paragon&#8217;s right, title and interest in and to the intellectual property (&#8220;ORKA<span class="nobreak">-001</span>&#8221;) resulting from the applicable research program to develop, manufacture and commercialize products directed at the selected target (&#8220;IL<span class="nobreak">-23</span>&#8221;), with the exception of pursuing ORKA<span class="nobreak">-001</span> for the treatment of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million was due to Paragon. This amount was recognized as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. The Company is also responsible for 50% of the development costs incurred prior to </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">March&#160;31, 2024, provided that the Company receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. As of the date this financial statement is available to be issued, the Company has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. The Company will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company also entered into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March&#160;28, 2024, whereby the Company was granted an exclusive, worldwide option, on a research program<span class="nobreak">-by-research</span> program basis, to all of Paragon&#8217;s right, title and interest in and to the intellectual property (&#8220;ORKA<span class="nobreak">-002</span>&#8221;) resulting from the applicable research program to develop, manufacture and commercialize products directed at the selected target (&#8220;IL<span class="nobreak">-17</span>&#8221;). The Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expenses during the period from February&#160;6 (inception) to March&#160;31, 2024 and accounts payable as of March&#160;31, 2024. The Company paid $3.3&#160;million to Paragon in April&#160;2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. The Company will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of issuance of the Company&#8217;s financial statement, the Company has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of these agreements, if the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Antibody Discovery and Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, the Company will grant Paruka warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of the Company&#8217;s common stock as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;A Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company issued 20,000,000<span class="nobreak"> </span>shares of Series&#160;A convertible preferred stock to Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), a related party of the Company, at a purchase price of $0.15 per share for gross proceeds of $3.0&#160;million. The Company incurred less than $0.1&#160;million of issuance costs in connection with this transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of Series&#160;A convertible preferred stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Series&#160;A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A convertible preferred stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Series&#160;A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i)&#160;the closing of a firm<span class="nobreak">-commitment</span> underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0&#160;million of gross proceeds to the Company, or (ii)&#160;the vote or written consent of the holders of a majority of the Preferred Stock, voting as a single class.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The conversion ratio of Series&#160;A convertible preferred stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original Issue Price is $0.15 per share for Series&#160;A convertible preferred stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The Conversion Price is $0.15 per share for Series&#160;A convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless the holders of the Series&#160;A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series&#160;A convertible preferred stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as<span class="nobreak">-converted</span> basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series&#160;A convertible preferred stock calculated based on the respective Original Issue Price of Series&#160;A convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Series&#160;A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series&#160;A convertible preferred stock are entitled to an amount equal to the greater of (i)&#160;the applicable Original Issue Price per share of Series&#160;A convertible preferred stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Series&#160;A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Series&#160;A convertible preferred stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Unless the holders of a majority in voting power of the then outstanding shares of Series&#160;A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Series&#160;A convertible preferred stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Convertible Notes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On March&#160;6, 2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount, whereby the Company issued a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0<span class="nobreak"> </span>million, that can be converted into Series&#160;A preferred stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for proceeds of $25.0&#160;million. The Convertible Note will automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the reverse recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025. Prepayment is not permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible Note.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oak Grove Lease</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;12, 2024, the Company entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement date is June&#160;15, 2024 with an initial term of 39.5&#160;months. The total lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T215"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED BALANCE SHEETS <br/>(UNAUDITED)<br/>(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">February&#160;6,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">488</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,231</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,262</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party accounts payable and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,899</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long term liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable, related party</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable to related party, noncurrent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,359</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (Note&#160;10)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized as of March&#160;31, 2024 and February&#160;6, 2024; 20,000,000 and no&#160;shares issued and outstanding as of March&#160;31, 2024 and February&#160;6, 2024, respectively; liquidation preference of $3,000 and $0 as of March&#160;31, 2024 and February&#160;6, 2024, respectively</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stockholders&#8217; deficit:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $0.0001 par value; 65,000,000 shares authorized, 9,460,019 and 5,596,658 shares issued and outstanding as of March&#160;31, 2024 and February 6, 2024, respectively</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,059</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,231</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T216"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS <br/>(UNAUDITED)<br/>(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Period&#160;from February&#160;6,<br/>2024 <br/>(Inception)&#160;to<br/>March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss and comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1.26</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average common shares outstanding, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,596,658</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $5,051 (see Note&#160;12)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $848 (see Note&#160;12)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $214 (see Note&#160;12)</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T217"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED&#160;STATEMENT&#160;OF&#160;CONVERTIBLE&#160;PREFERRED&#160;STOCK&#160;AND&#160;STOCKHOLDERS&#8217;&#160;DEFICIT<br/>(UNAUDITED)<br/>(In thousands)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Convertible<br/>Preferred Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-right-width:1pt;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-left-width:1pt;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Common Stock</span></p>
					</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Additional<br/>Paid-in<br/>Capital</span></p>
					</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 9.58%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" colspan="4" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Total<br/>Stockholders&#8217;<br/>Deficit</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-right-width:1pt;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-left-width:1pt;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Shares</span></p>
					</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Amount</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Balances as of February&#160;6, 2024 (inception)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;border-top-color:#000000;border-top-width:0pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB _idGenCellOverride-1" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">5,596,658</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-1" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Issuance of common stock</span><span class="Superscript" style="vertical-align:super;font-size:6pt;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">3,863,361</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Issuance of Series&#160;A convertible preferred stock, net of issuance costs of $69</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">20,000,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Stock-based compensation expense</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Net loss</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Balances as of March&#160;31, 2024</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">9,460,019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,059</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Textfootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Textfootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes issuance of 3,863,361 restricted stock awards (see Note 7)</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T218"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC. <br/>CONDENSED STATEMENT OF CASH FLOWS<br/>(UNAUDITED)<br/>(In thousands)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Period&#160;from<br/>February&#160;6,<br/>2024<br/>(Inception) to<br/>March&#160;31, <br/>2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-cash interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">773</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party accounts payable and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,831</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable, related party</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of Series&#160;A convertible preferred stock, net of issuance costs paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of notes payable to related parties, net of issuance costs paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,911</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net increase in cash</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash at beginning of period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash at end of period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Supplemental disclosure of non-cash financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred offering costs in accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">488</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T219"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Nature of the Business and Basis of Presentation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Background and Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka was founded by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is subject to risks and uncertainties common to early stage companies in biopharmaceutical industry, including, but not limited to, completing preclinical and clinical trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third<span class="nobreak">-party</span> organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s potential products require approval from the U.S.&#160;Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the U.S.&#160;Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial information. Accordingly, they do not include all of the information and notes required by U.S.&#160;GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments the Company believes are necessary to fairly state the Company&#8217;s financial position and the results of its operations and cash flows. The results for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 are not necessarily indicative of results expected for the full fiscal year or any subsequent interim period.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Going Concern</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying condensed financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of March&#160;31, 2024, the Company had $27.7&#160;million in cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred a net loss of $7.1&#160;million during the period from February&#160;6, 2024 (inception) to March&#160;31, 2024. As of March&#160;31, 2024, the Company had an accumulated deficit of $7.1&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company received $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) and $25.0&#160;million in gross proceeds from the issuance of a convertible note, both of which were related party transactions (see Note&#160;12).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrent with the execution of the Merger Agreement, the Company entered into a subscription agreement with certain investors pursuant to which the Company agreed to issue and sell to investors in a private placement financing (the &#8220;Private Placement&#8221;) shares of the Company&#8217;s common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of the Company&#8217;s common stock at an estimated purchase price of $5.80 per share of common stock and $5.79 per warrant for gross proceeds of approximately $275.0&#160;million, inclusive of $25.0&#160;million proceeds received as of March&#160;31, 2024 from the issuance of the Company&#8217;s convertible note, which will precede the closing of the Merger. Shares of the Company&#8217;s common stock and warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private Placement will be converted into the right to receive shares of ARCA common stock and warrants to purchase shares of ARCA common stock, respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private Placement are expected to advance the Company&#8217;s pipeline, as well as for general corporate purposes, which may include capital expenditure, working capital and general and administrative expenses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, the agreements are subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $0.4<span class="nobreak"> </span>million or Oruka could be required to pay ARCA a termination fee of $0.4<span class="nobreak"> </span>million. Based on its expectation of continuing operating losses for the foreseeable future, and the need to raise future capital, as of May<span class="nobreak"> </span>13, 2024, the date the Company&#8217;s condensed financial statements are available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern for one year from the date that these condensed financial statements are available to be issued.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the condensed financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Use of Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of the Company&#8217;s condensed financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock<span class="nobreak">-based</span> compensation awards and related expenses. The Company bases its estimates on known trends and other market<span class="nobreak">-specific</span> or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results may differ materially from those estimates or assumptions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash. The Company maintains its cash balances at an accredited financial institution in amounts that, at times, may exceed federally insured limits. However, the Company has not experienced any losses on its deposits of cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is dependent on third<span class="nobreak">-party</span> organizations to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s research and development activities are performed under its agreements with Paragon (see Note&#160;9).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company capitalizes certain legal, professional, accounting, and other third<span class="nobreak">-party</span> fees that are directly associated with in<span class="nobreak">-process</span> equity financings as deferred offering costs until such financings are consummated. After the consummation of equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders&#8217; deficit as a reduction of additional paid<span class="nobreak">-in</span> capital generated as a result of the offering. Should the in<span class="nobreak">-process</span> equity financing (see Note&#160;1) be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. As of March&#160;31, 2024, deferred offering costs of $0.5&#160;million were recorded as Other assets in the condensed balance sheet.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Debt Issuance Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Debt issuance costs incurred in connection with the Company&#8217;s convertible note (see Note&#160;4) are recorded as a reduction of the carrying value of the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription receivable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;1 &#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;2&#160;&#8212;&#160;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period. The Company accounts for its convertible note at amortized cost.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Classification of Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has classified the convertible preferred stock outside of stockholders&#8217; deficit on the Company&#8217;s condensed balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then<span class="nobreak">-outstanding</span> convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s Series&#160;A Preferred Stock is not redeemable, except in the event of deemed liquidation (see Note&#160;5). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the convertible preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Note&#160;Payable to Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for its convertible note at amortized cost. The Company considers if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the convertible note are recorded as a debt discount, amortized over the term of the convertible note (see&#160;Note&#160;4) and are accounted as interest expense in other expenses within the condensed statements of operations and comprehensive loss using the effective interest method.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Contract Costs Accruals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third<span class="nobreak">-party</span> service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related<span class="nobreak">-party</span> Paragon (see Note&#160;9).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;) between Paragon, Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of March&#160;31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segment Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock<span class="nobreak">-based</span> compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying condensed balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one<span class="nobreak">-time</span> cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses consist primarily of salaries and bonuses, stock<span class="nobreak">-based</span> compensation, employee benefits, finance and administration costs, human resources costs, information technology costs, professional service fees, and other general overhead costs to support the Company&#8217;s operations.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Commitments and Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of March&#160;31, 2024, no liabilities were recorded for loss contingencies (see Note&#160;10).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company measures all stock<span class="nobreak">-based</span> awards granted to employees, directors, and non<span class="nobreak">-employees</span> in the form of stock options to purchase shares of its common stock, based on the fair value of the awards on the date of grant using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The Company measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share of the award and the fair value of the Company&#8217;s common stock at the date of grant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company grants stock options and restricted stock awards that are subject to either service or performance<span class="nobreak">-based</span> vesting conditions. Compensation expense for awards to employees and directors with service<span class="nobreak">-based</span> vesting conditions is recognized using the straight<span class="nobreak">-line</span> method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non<span class="nobreak">-employees</span> with service<span class="nobreak">-based</span> vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance<span class="nobreak">-based</span> vesting condition will be achieved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has issued stock options and RSAs with service<span class="nobreak">-based</span> vesting conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company classifies stock<span class="nobreak">-based</span> compensation expense in its condensed statement of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Net Loss per Share Attributable to Common Stockholders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company applies the two<span class="nobreak">-class</span> method when computing net loss per share attributable to the Company&#8217;s common stockholders as the Company has issued shares that meet the definition of participating securities. The&#160;two<span class="nobreak">-class</span>&#160;method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The&#160;two<span class="nobreak">-class</span>&#160;method requires loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the undistributed earnings as if all loss for the period had been distributed. The Company considers its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock would be entitled to receive dividends on a basis consistent with the Company&#8217;s common stockholders. There is no allocation required under the two<span class="nobreak">-class</span> method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to the Company&#8217;s common stockholders by the weighted average number of common shares outstanding for the period, excluding potentially dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, the Company&#8217;s outstanding convertible preferred stock, stock options to purchase common stock and unvested RSAs are considered potential dilutive common shares.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company generated a net loss for the period presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti<span class="nobreak">-dilutive</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for uncertainty in income taxes recognized in the condensed financial statements by applying a two<span class="nobreak">-step</span> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In November&#160;2023, the FASB issued ASU No.&#160;2023<span class="nobreak">-07</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Segment Reporting</span> (<span class="Italic" style="font-style:italic;font-weight:normal;">Topic&#160;280</span>) (&#8220;ASU&#160;2023<span class="nobreak">-07</span>&#8221;), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU&#160;2023<span class="nobreak">-07</span> requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU&#160;2023<span class="nobreak">-07</span> are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its condensed financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2023, the FASB issued ASU&#160;2023<span class="nobreak">-09</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures</span>. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of this standard on its condensed financial statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Accrued Expenses and Other Current Liabilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">March&#160;31,</span><span class="CharOverride-2" style="text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued professional and consulting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,040</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued recruiting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued employee compensation and benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">78</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">56</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,262</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Note&#160;Payable with Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby the Company issued a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0<span class="nobreak"> </span>million, that can be converted into Series&#160;A Preferred Stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for aggregate proceeds of $25.0&#160;million. The Convertible Note will automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the Private Placement, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible Note. The principal payment along with the accrued interest on the Convertible Note is due in full on the Maturity Date. As of March&#160;31, 2024, the Company had outstanding borrowings of $25.0&#160;million from Fairmount under its Convertible Note.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the proposed reverse recapitalization transaction, the Convertible Note will convert into a number of shares of common stock based on the aggregate principal amount, plus any unpaid accrued interest, divided by the conversion price, which is an amount to be determined based upon the Company&#8217;s fully<span class="nobreak">-diluted</span> capitalization immediately prior to the reverse recapitalization transaction. In the event the proposed reverse recapitalization transaction or any other proposed corporate transactions do not close prior to the Company&#8217;s next equity financing, the Convertible Note will convert into the next series of issued convertible preferred stock. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting. The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host. However, these features did not meet the definition of a derivative under ASC&#160;815, <span class="Italic" style="font-style:italic;font-weight:normal;">Derivatives and Hedging</span>, and as a result did not require separate accounting as a derivative liability.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company paid debt issuance costs of less than $0.1&#160;million in relation to the Convertible Note. The debt issuance costs are reflected as a reduction of the carrying value of Convertible Note on the condensed balance sheet and are being amortized as interest expense over the term of the Convertible Note using the effective interest method. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the Company recognized interest expense related to the Convertible Note of $0.2&#160;million, which includes non<span class="nobreak">-cash</span> interest expense related to the amortization of debt issuance costs of less than $0.1&#160;million. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the weighted average effective interest rate of the Convertible Note was approximately 12.0%.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company issued and sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to Fairmount, at a purchase price of $0.15 per share, for gross proceeds of $3.0&#160;million. The Company incurred less than $0.1&#160;million of issuance costs in connection with this transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the issuance of the Series&#160;A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these features.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, convertible preferred stock consisted of the following (in thousands, except share amounts):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 73.93%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Preferred&#160;Stock<br/>Authorized</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Preferred Stock<br/>Issued and<br/>Outstanding</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Carrying<br/>Value</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Liquidation<br/>Preference</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Common Stock<br/>Issuable Upon<br/>Conversion</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A Preferred Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of the Series A Preferred Stock have the following rights and preferences:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Voting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of Series&#160;A Preferred Stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Series&#160;A Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. A majority vote of the holders of Series&#160;A Preferred Stock is required to liquidate or dissolve the Company, amend the certificate of incorporation or bylaws, reclassify common stock or establish another class of capital stock, create shares that would rank senior to or authorize additional shares of Preferred Stock, declare a dividend or make a distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the holders of shares of Series&#160;A Preferred Stock are entitled to elect one director of the Company. The holders of shares of common stock and any other class or series of voting stock (including Series&#160;A convertible preferred stock), exclusively and voting together as a single class, are entitled to elect the balance of the total number of directors of the Company. The Company controls the Board of Directors.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Conversion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Series&#160;A Preferred Stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i)&#160;the closing of a firm<span class="nobreak">-commitment</span> underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0&#160;million of gross proceeds to the Company, net of the underwriting discount and commissions, or (ii)&#160;the vote or written consent of the holders of a majority of the outstanding shares of preferred stock, voting as a single class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The conversion ratio of Series&#160;A Preferred Stock is determined by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $0.15 per share for Series&#160;A Preferred Stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The Conversion Price is $0.15 per share for Series&#160;A convertible preferred stock. As of March&#160;31, 2024, each outstanding share of Series&#160;A Preferred Stock was convertible into common stock on a one<span class="nobreak">-for-one</span> basis.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Dividends</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless the holders of the Series&#160;A Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series&#160;A Preferred Stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as<span class="nobreak">-converted</span> basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series&#160;A Preferred Stock calculated based on the respective original issue price of Series&#160;A Preferred Stock. For the period from February&#160;6, 2024 (inception) through March&#160;31, 2024, no cash dividends had been declared or paid by the Company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Series&#160;A Preferred Stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series&#160;A Preferred Stock are entitled to an amount equal to the greater of (i)&#160;the applicable original issue price per share of Series&#160;A Preferred Stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Series&#160;A Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Series&#160;A Preferred Stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless the holders of a majority in voting power of the then outstanding shares of Series&#160;A Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Redemption</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Series&#160;A Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the Board of Directors authorized up to 65,000,000<span class="nobreak"> </span>shares of common stock at a $0.0001 par value. As of March&#160;31, 2024, 5,596,658<span class="nobreak"> </span>shares of common stock were issued and outstanding and 3,863,361<span class="nobreak"> </span>shares of RSAs were issued and outstanding. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock and RSAs are subject to and qualified by the rights, powers and preferences of the holders of Series&#160;A Preferred Stock set forth above. Each share of common stock entitles the holder to one vote, together with the holders of Series&#160;A Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s Board of Directors, subject to the preferential dividend rights of Series&#160;A Preferred Stock.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, there are 20,698,669<span class="nobreak"> </span>shares of common stock reserved for issuance for the potential conversion of shares of Series&#160;A preferred stock into common stock, the exercise of outstanding stock options for common stock under the Company&#8217;s 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;).</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Stock-Based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">2024 Equity Incentive Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The 2024 Plan was adopted by the Company&#8217;s Board of Directors on February&#160;6, 2024. The 2024 Plan provides for the Company to grant stock options, restricted stock awards, restricted stock units, and other stock<span class="nobreak">-based</span> awards to employees, officers, directors, consultants, and advisors. The 2024 Plan is administered by the Board of Directors, or at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Stock options granted under the 2024 Plan generally vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although stock options have been granted with vesting terms less than four&#160;years. Upon adoption, the 2024 Plan authorized 372,912<span class="nobreak"> </span>shares of common stock reserved for issuance under the plan. On March&#160;5, 2024, the 2024 Plan was amended to increase the number of shares of common stock reserved for issuance by 500,000<span class="nobreak"> </span>shares. As of March&#160;31, 2024, the total number of shares of common stock reserved for issuance under the 2024 Plan was 872,912, with 174,243<span class="nobreak"> </span>shares available for future grants.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Option Valuation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of each stock option grant is estimated on the grant date using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The Company is a private company and lacks company<span class="nobreak">-specific</span> historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For stock options with service<span class="nobreak">-based</span> vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain<span class="nobreak">-vanilla</span>&#8221; stock options. The risk<span class="nobreak">-free</span> interest rate is determined by reference to the U.S.&#160;Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the weighted<span class="nobreak">-average</span> assumptions used in calculating the fair value of the awards from February&#160;6, 2024 (inception) to March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">103.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term (in&#160;years) </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the stock option activity for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of February&#160;6, 2024 (inception)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and expected to vest, March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercisable, March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The weighted average grant<span class="nobreak">-date</span> fair value of stock options granted from February&#160;6, 2024 (inception) to March&#160;31, 2024 was $2.37. As of March&#160;31, 2024, there was no aggregate intrinsic value for the outstanding options. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In February 2024 and March&#160;2024, the Company issued 3,863,361<span class="nobreak"> </span>shares of RSAs to certain employees, directors, and consultants at a price of $0.0001 per share, the par value of the common stock. Such RSAs have service<span class="nobreak">-based</span> vesting conditions only and vest over a four<span class="nobreak">-year</span> period, during which time all unvested shares are subject to forfeiture by the Company in the event the holder&#8217;s service with the Company voluntarily or involuntarily terminates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the RSAs activity for the period from February&#160;6, 2024 (inception) through March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>RSAs</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested balance as of February&#160;6, 2024 (inception)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested balance as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Paruka Warrant Obligation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paruka will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of then outstanding shares of the Company&#8217;s stock, on a fully diluted basis, on December&#160;31, 2024 and December&#160;31, 2025, at the fair market value determined by the Board of Directors of the Company (the &#8220;Paruka Warrant Obligation&#8221;). The grant dates for the issuance of warrants are expected to be December&#160;31, 2024 and December&#160;31, 2025 as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post<span class="nobreak">-grant</span> date service requirement. As of March&#160;31, 2024, the pro<span class="nobreak">-rated</span> estimated fair value </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of warrants to be granted on December&#160;31, 2024 was $0.7&#160;million. For the period February&#160;6, 2024 (inception) to March&#160;31, 2024, $0.1&#160;million was recognized as stock<span class="nobreak">-based</span> compensation expense related to the Paruka Warrant Obligation. The warrants expected to be granted to Paruka are liability<span class="nobreak">-classified</span> and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the classification of the Company&#8217;s stock<span class="nobreak">-based</span> compensation expense in the condensed statement of operations and comprehensive loss (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6,&#160;2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, total unrecognized compensation cost related to the unvested stock options was $1.6&#160;million, which is expected to be recognized over a weighted average period of approximately 3.40&#160;years. As of March&#160;31, 2024, total unrecognized compensation cost related to the unvested RSAs was less than $0.1&#160;million, which is expected to be recognized over a weighted average period of 3.92&#160;years. As of March&#160;31, 2024, the unrecognized compensation cost related to the Paruka Warrant Obligation was $0.6&#160;million, which is expected to be recognized over a weighted average period of 0.8&#160;years.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the award types of the Company&#8217;s stock<span class="nobreak">-based</span> compensation expense in the condensed statement of operations and comprehensive loss (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka warrant obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No provision for income taxes was recorded for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024. Deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized due to the Company&#8217;s cumulative losses generated to date.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Paragon Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company. The Option Agreements includes two selected targets, IL<span class="nobreak">-23</span> (ORKA<span class="nobreak">-001</span>) and IL<span class="nobreak">-17</span> A/F (ORKA<span class="nobreak">-002</span>). Under the Option Agreements, the Company has the exclusive options to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an &#8220;Option&#8221;), with </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the exception of pursuing ORKA<span class="nobreak">-001</span> for the treatment of inflammatory bowel disease. If the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale. From time to time, the Company can choose to add additional targets to the collaboration by mutual agreement with Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Option Agreements, the parties initiated certain research programs that generally focus on a particular target (each, a &#8220;Research Program&#8221;). Each Research Program is aimed at discovering, generating, identifying and/or characterizing antibodies directed to the respective target. For each Research Program, the parties will establish a research plan that sets forth the activities that will be conducted, and the associated research budget (each, a &#8220;Research Plan&#8221;). The Company and Paragon will agree on initial Research Plans that outline the services that will be performed commencing at the inception of the arrangement related to ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. The Company&#8217;s exclusive Option with respect to each Research Program is exercisable at its sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following (i) with respect to any Research Program other than ORKA<span class="nobreak">-001</span>, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with resepct to ORKA<span class="nobreak">-001</span>, the completion of the IL<span class="nobreak">-23</span> antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless terminated earlier, the Option Agreements shall continue in force on a Research Program<span class="nobreak">-by-Research</span> Program basis until the earlier of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&#160;the expiration of the 30<span class="nobreak">-day</span> period after Oruka exercises its Option with respect to such Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable research term (the &#8220;Term&#8221;). Upon the expiration of the Term for all then<span class="nobreak">-existing</span> Research Programs, under the Option Agreements, the Option Agreements will automatically expire in its entirety. The Company may terminate the Option Agreements or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non<span class="nobreak">-cancellable</span> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Each party has the right to terminate the Option Agreements or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30<span class="nobreak">-day</span> period and (ii)&#160;the other party&#8217;s bankruptcy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Option Agreements, on a research program<span class="nobreak">-by-research</span> program basis following the finalization of the research plan for each respective research program, the Company was required to pay Paragon a one<span class="nobreak">-time</span>, nonrefundable research initiation fee of $0.8&#160;million. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024 and accounts payable as of March&#160;31, 2024, and paid to Paragon in April&#160;2024. The Company is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that the Company receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date these condensed financial statements are available to be issued, the Company has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. The Company will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024, and accounts payable as of March&#160;31, 2024. The Company paid $3.3&#160;million to Paragon in April&#160;2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. The Company will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. The Company will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, the Paragon Agreement provides for an annual equity grant of warrants to Paruka to purchase 1.00% of the then outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, on December&#160;31, 2024 and December&#160;31, 2025, during the term of the Paragon Agreement, at the fair market value determined by the Board of Directors of the Company. The warrants are liability<span class="nobreak">-classified</span> and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss (see Note&#160;7).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying statement of operations and comprehensive loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in<span class="nobreak">-process</span> research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fee represents a one<span class="nobreak">-time</span> cost on a research program<span class="nobreak">-by</span> research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on<span class="nobreak">-going</span> development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreement that associated with services being rendered under the related Research Programs is recognized as research and development expense when incurred.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 the Company recognized $5.0&#160;million of expenses in connection with services provided by Paragon under the Option Agreements, including nonrefundable research and development expense fees following the finalization of a Research Plan.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Commitments and Contingencies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">401(k)&#160;Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company maintains a defined<span class="nobreak">-contribution</span> plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986 (the &#8220;401(k)&#160;Plan&#8221;). The 401(k)&#160;Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre<span class="nobreak">-tax</span> basis. Matching contributions to the 401(k)&#160;Plan may be made at the discretion of management. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the Company has not recorded any expense related to 401(k)&#160;match contributions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with each of its directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed financial statements as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of March&#160;31, 2024, the Company was not a party to any material legal proceedings or claims.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Net Loss per Share</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Numerator:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Denominator:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average common shares outstanding, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,596,658</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1.26</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the computation of basic net loss per share attributable to common stockholders, the amount of weighted<span class="nobreak">-average</span> common shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted<span class="nobreak">-average</span> number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have had an anti<span class="nobreak">-dilutive</span> effect:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible preferred stock (as converted to common stock)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock awards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options to purchase common stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,562,030</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">12.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Paragon and Paruka each currently beneficially own more than 5% of the Company&#8217;s capital stock through its common stock holdings. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 the Company recognized $5.0&#160;million of expenses, in connection with services provided by Paragon and Paruka under the Option Agreements, including nonrefundable research and development expense fees following the finalization of a Research </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Plan on its condensed statement of operations and comprehensive loss. As of March&#160;31, 2024, the Company had $5.8&#160;million in amounts due to related parties pertaining to services provided by Paragon and Paruka under the Option Agreements and reimbursements of recruiting and start<span class="nobreak">-up</span> fees on its condensed balance sheet. In addition, under the terms of the Option Agreements, Paruka will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, as of the date of the grants (see Note&#160;7). If the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fairmount Funds Management LLC (&#8220;Fairmount Funds Management&#8221;) beneficially owns more than 5% of the Company&#8217;s capital, currently has one representative appointed to the Company&#8217;s Board of Directors, and beneficially owns more than 5% of Paragon. In March&#160;2024, the Company issued and sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to Fairmount, an affiliated fund of Fairmount Funds Management, at a purchase price of $0.15 per share, for gross proceeds of $3.0&#160;million (see Note&#160;4). In March&#160;2024, Fairmount entered into the Purchase Agreement with the Company and holds a convertible note with an initial principal amount of $25.0&#160;million (see Note&#160;4). As of March&#160;31, 2024, the Company had $0.2&#160;million in amounts due to related parties pertaining to accrued interest related to the Company&#8217;s outstanding borrowings of $25.0&#160;million under the Purchase Agreement with Fairmount.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of related party accounts payable and other current liabilities (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon reimbursable Option Agreement fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,983</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon reimbursable recruiting and start-up fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">848</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka Warrant Obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,899</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">The following is a summary of noncurrent liability, related party (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,194</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">13.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Subsequent Events</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oak Grove Lease</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;12, 2024, the Company entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement date is June&#160;15, 2024 with an initial term of 39.5&#160;months. The total lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Amended 2024 Stock Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 872,912 to 2,063,669. On May&#160;7, 2024, the Company granted options for the purchase of an aggregate 1,365,000 stock options, at an exercise price of $3.89 per share.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T100"></a><p class="ParaOverride-1" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:right;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Annex A</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:210pt;orphans:3;text-align:center;widows:3;margin-top:210pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">among:</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA BIOPHARMA, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ATLAS MERGER SUB CORP.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Atlas Merger Sub II, LLC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; and</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA THERAPEUTICS, Inc.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Dated as of April 3, 2024</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;">Table of Contents</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;1. Definitions and Interpretative Provisions</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-2</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Definitions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other Definitional and Interpretative Provisions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-14</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;2. Description of Transaction</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-15</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">The Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effects of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Closing; First Effective Time; Second Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents; Directors and Officers</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Closing of the Company&#8217;s Transfer Books</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Surrender of Company Capital Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-18</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Calculation of Net Cash and Company Valuation.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Further Action</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intended Tax Treatment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Withholding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Appraisal Rights</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;3. Representations and Warranties of the Company</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-21</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Due Organization; Subsidiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Authority; Binding Nature of Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vote Required</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Contravention; Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalization.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Undisclosed Liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Title to Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Real Property; Leasehold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intellectual Property</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Agreements, Contracts and Commitments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-27</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compliance; Permits; Restrictions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal Proceedings; Orders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-30</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-31</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee and Labor Matters; Benefit Plans.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-32</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Environmental Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Financial Advisors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transactions with Affiliates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Privacy and Data Security</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ownership of Parent Capital Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Other Representations or Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;4. Representations and Warranties of Parent, First Merger and Second Merger Sub</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-35</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Due Organization; Subsidiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Authority; Binding Nature of Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vote Required</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-i</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Contravention; Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-37</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-37</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">SEC Filings; Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-38</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Undisclosed Liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Title to Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Real Property; Leasehold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intellectual Property</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Agreements, Contracts and Commitments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-42</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compliance; Permits; Restrictions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal Proceedings; Orders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-46</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-46</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee and Labor Matters; Benefit Plans</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-47</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Environmental Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transactions with Affiliates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Financial Advisors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valid Issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Privacy and Data Security</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Other Representations or Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-50</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;5. Certain Covenants of the Parties</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-50</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operation of Parent&#8217;s Business</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-50</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operation of the Company&#8217;s Business.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-52</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Access and Investigation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-53</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Solicitation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-54</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notification of Certain Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-55</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;6. Additional Agreements of the Parties</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-55</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Registration Statement, Proxy Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-55</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Stockholder Written Consent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-57</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Stockholder Meeting</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-58</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Efforts; Regulatory Approvals.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-60</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Options; Company Warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-60</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee Benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-61</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Indemnification of Officers and Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-62</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Disclosure</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-63</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Listing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-63</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legends</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Officers and Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Termination of Certain Agreements and Rights</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Section&#160;16 Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Allocation Information</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Wind-Down Activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Obligations of Merger Subs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pre-Closing Financing Restructuring</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Re-Domestication</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-ii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;7. Conditions Precedent to Obligations of Each Party</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-66</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effectiveness of Registration Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Regulatory Approvals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Restraints</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stockholder Approval</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Listing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lock-Up Agreements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Charter Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Certificate of Designation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;8. Additional Conditions Precedent to Obligations of Parent and Merger Subs</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-66</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accuracy of Representations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Performance of Covenants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Company Material Adverse Effect</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Stockholder Written Consent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Pre-Closing Financing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;9. Additional Conditions Precedent to Obligation of the Company</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-67</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accuracy of Representations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Performance of Covenants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Parent Material Adverse Effect</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;10. Termination</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-68</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Termination</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of Termination</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expenses; Termination Fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;11. Miscellaneous Provisions</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-71</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Survival of Representations and Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Waiver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Applicable Law; Jurisdiction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Assignability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notices</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cooperation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Severability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other Remedies; Specific Performance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Third-Party Beneficiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exhibits:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;A-1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Parent Stockholder Support Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;A-2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Company Stockholder Support Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;B</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Lock-Up Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;C</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Subscription Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;D-1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">First Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit&#160;A thereto, incorporated by reference into this Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;D-2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Second Certificate of Merger, incorporated by reference into this Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;E</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Certificate of Designation</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-iii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">This Agreement and Plan of Merger and Reorganization </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(this &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">ARCA biopharma, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Atlas Merger Sub Corp.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation and wholly owned subsidiary of Parent (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Atlas Merger Sub II, LLC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware limited liability company and wholly owned subsidiary of Parent (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and, together with First Merger Sub, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Oruka Therapeutics, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Certain capitalized terms used in this Agreement are defined </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Recitals</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">A.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and the Company intend to effect a merger of First Merger Sub with and into the Company (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) in accordance with this Agreement and the DGCL.  Upon consummation of the First Merger, First Merger Sub will cease to exist and the Company will become a wholly owned subsidiary of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">B.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and into Second Merger Sub (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and, together with the First Merger, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), with Second Merger Sub being the surviving entity of the Second Merger.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">C.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties intend that, (i) the First Merger and the Second Merger, taken together, will constitute an integrated transaction described in Rev. Rul. 2001-46, 2001-2 C.B. 321 that qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, and (ii) this Agreement will constitute, and is hereby adopted as, a plan of reorganization within the meaning of Treasury Regulations Sections&#160;1.368-2(g) and 1.368-3(a).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">D.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Transaction Committee of the Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders and (ii) recommended that the Parent Board approve and adopt this Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">E.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and the constructive issuance by the Company of shares of Company Common Stock to stockholders of Parent (as reflected in Rule&#160;145(a) of the Securities Act) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Constructive Issuance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve this Agreement and thereby approve the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement, the Constructive Issuance, and, if deemed necessary by the Parties, an amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">F.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The First Merger Sub Board has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of First Merger Sub and its sole stockholder, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">G.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The sole member of the Second Merger Sub has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole member of Second Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">H.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">I.<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, each of the officers, directors and stockholders set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter (solely in their capacity as stockholders of Parent) are executing support agreements in favor of the Company in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A-1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Stockholder Support Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of capital stock of Parent in favor of the approval of this Agreement and thereby approve the Contemplated Transactions, and, if deemed necessary by Parent, an amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split, and against any competing proposals.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">J.<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, each of the officers, directors and stockholders of the Company listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter (solely in their capacity as stockholders of the Company) are executing support agreements in favor of Parent in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A-2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stockholder Support Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Capital Stock in favor of the adoption of this Agreement and thereby approve the Contemplated Transactions and against any competing proposals.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">K.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s and the Company&#8217;s willingness to enter into this Agreement, all of the stockholders of the Company or Parent listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;B</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter are executing lock-up agreements in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;B</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Lock-Up Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Lock-Up Agreements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">L.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>It is expected that within two (2) Business Days after the Registration Statement is declared effective under the Securities Act, the holders of shares of Company Capital Stock sufficient to adopt and approve this Agreement and the Merger as required under the DGCL and the Company&#8217;s certificate of incorporation and bylaws will execute and deliver an action by written consent adopting this Agreement, in form and substance reasonably acceptable to Parent, in order to obtain the Required Company Stockholder Vote.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">M.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement, certain investors have executed a Subscription Agreement in the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;C</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> among the Company and the Persons named therein (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subscription Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons will have agreed to purchase in the amounts set forth therein (including by contribution of Company Notes) (i) shares of Company Common Stock and (ii) pre-funded Company Warrants, in each case, immediately prior to the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Pre-Closing Financing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Agreement</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Parties, intending to be legally bound, agree as follows:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions and Interpretative Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>For purposes of this Agreement (including this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">):</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acceptable Confidentiality Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any standstill, non-solicitation or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality agreement with Parent relating to a potential Acquisition Proposal on terms that are not materially less restrictive than the Confidentiality Agreement with respect to the scope of coverage and restrictions on disclosure and use shall not be required to enter into a new or revised confidentiality agreement, and such existing confidentiality agreement shall be deemed to be an Acceptable Confidentiality Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition Inquiry</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Party, an inquiry, indication of interest or request for non-public information (other than an inquiry, indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other Party) that would reasonably be expected to lead to an Acquisition Proposal.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Proposal</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any transaction or series of related transactions (other than any Parent Legacy Transaction, the issuance of Company Notes, or the Company Pre-Closing Financing) involving:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i) in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries or (ii) in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries, or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Affiliate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning given to such term in Rule&#160;145 under the Securities Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Affordable Care Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Patient Protection and Affordable Care Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Anticipated Closing Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the anticipated Closing Date, as agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Day</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any day other than a day on which banks in the State of New York are authorized or obligated to be closed.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Certificate of Designation of Preferences, Rights and Limitations of Parent Convertible Preferred Stock in the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;E</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">COBRA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as set forth in Section&#160;4980B of the Code and Section&#160;6 of Title I of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Code</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Internal Revenue Code of 1986, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Associate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any current employee, independent contractor, officer or director of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company Common Stock and the Company Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Capitalization Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Common Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock, $0.0001 par value per share, of the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract: (a) to which the Company or any of its Subsidiaries is a Party, (b) by which the Company or any of its Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation or (c) under which the Company or any of its Subsidiaries has or may acquire any right or interest.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Employee Plan that the Company or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes to, or (ii) provides benefits under or through, or (iii) has any obligation to contribute to or provide benefits under or through, or (iv) may reasonably be expected to have any Liability, or (v) utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of the Company or any of its Subsidiaries (or their spouses, dependents, or beneficiaries).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Fundamental Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company IP Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Intellectual Property rights that are owned or purported to be owned by, assigned to, exclusively licensed to, or controlled by the Company or its Subsidiaries that are necessary for, or used or held for use in, the operation of the business of the Company and its Subsidiaries as presently conducted.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company IP Rights Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract governing, related to or pertaining to any Company IP Rights other than any confidential information provided under confidentiality agreements.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Key Employee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any executive officer of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of the Company or its Subsidiaries, taken as a whole; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Company Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions, (b) the taking of any action, or the failure to take any action, by the Company that is required to comply with the terms of this Agreement, (c) any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (d) any change in GAAP or applicable Law or the interpretation thereof, (e) general economic or political conditions or conditions generally affecting the industries in which the Company and its Subsidiaries operate or (f) any change in the cash position of the Company and its Subsidiaries which results from operations in the Ordinary Course of Business; except in each case with respect to clauses&#160;(c), (d) and (e), to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Merger Shares</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the product determined by </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">multiplying</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (i) the Post-Closing Parent Shares </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">by</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) the Company Allocation Percentage, in which:</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Aggregate Valuation</span>&#8221; means the sum of (i) the Company Valuation, <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">plus</span> (ii) the Parent Valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Allocation Percentage</span>&#8221; means the percentage (rounded to four decimal places) determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">subtracting</span> (i)&#160;the Parent Allocation Percentage <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">from</span> (ii)&#160;100 percent.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Equity Value</span>&#8221; means $175,000,000.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Outstanding Shares</span>&#8221; means, without duplication, the total number of shares of Company Capital Stock outstanding immediately prior to the First Effective Time (including any shares of Company Common Stock or Company Preferred Stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Company Pre-Closing Financing), expressed on a fully diluted and as-converted-to-Company Common Stock basis assuming, without limitation or duplication the exercise of all Company Options, Company Warrants or other rights or commitments to receive shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including the Company Notes), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. For the avoidance of doubt, Company Outstanding Shares shall (a) exclude, to avoid the double-counting of, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including any Company Notes) to the extent such shares or securities are contributed as consideration in the Company Pre-Closing Financing and (b) include (i) to the extent not already issued prior to the First Effective Time, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock) issuable to the Paragon Entities (as such term is defined in the Company&#8217;s Organizational Documents) as a result of the Contemplated Transactions pursuant to the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;margin-left:72pt;text-indent:0pt;margin-top:8pt;">Company&#8217;s Organizational Documents and (ii) to the extent not already issued prior to the First Effective Time, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock) issuable pursuant to the offer letter set forth in Section&#160;3.6(d) of the Company Disclosure Letter.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Valuation</span>&#8221; means the (i) Company Equity Value plus (ii) the amount of proceeds actually received by the Company from the Company Pre-Closing Financing (including in the proceeds actually received from any Company Notes, and any interest thereon, contributed as consideration in the Company Pre-Closing Financing).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Exchange Ratio</span>&#8221; means the ratio (rounded to four decimal places) equal to the quotient obtained by dividing (i) the Company Merger Shares by (ii) the Company Outstanding Shares.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Allocation Percentage</span>&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">dividing</span> (i) the Parent Valuation <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">by</span> (ii)&#160;the Aggregate Valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Outstanding Shares</span>&#8221; means, without duplication, (including, without limitation, the effects of the Nasdaq Reverse Split, if completed) the total number of shares of Parent Common Stock outstanding immediately prior to the First Effective Time expressed on a fully-diluted basis, and assuming, without limitation or duplication, the issuance of shares of Parent Common Stock in respect of all Parent Options, warrants or other rights or commitments to receive shares of Parent Common Stock or Parent Preferred Stock (or securities convertible or exercisable into shares of Parent Common Stock or Parent Preferred Stock, but excluding any Parent Convertible Preferred Stock issuable in accordance herewith), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. Notwithstanding any of the foregoing, no Parent Options, if any, shall be included in the total number of shares of Parent Common Stock outstanding for purposes of determining the Parent Outstanding Shares to the extent cancelled at or prior to Closing under <span class="CharOverride-9" style="text-decoration:underline;">Section&#160;6.6(c)</span>.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Valuation</span>&#8221; means (i) $11,000,000, <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">minus</span> (ii) the amount by which Parent Net Cash is less than $5,000,000 (if any).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Post-Closing Parent Shares</span>&#8221; mean the quotient determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">dividing</span> (i) the Parent Outstanding Shares <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">by</span> (ii) the Parent Allocation Percentage.</p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Notes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the convertible notes issued pursuant to that certain Series A Preferred Stock and Convertible Note Purchase Agreement among the Company and the purchasers party thereto, dated as of March 6, 2024, or any additional convertible promissory notes that may be issued from time to time prior to the Closing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means options or other rights to purchase shares of Company Capital Stock issued by the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the shares of the Company&#8217;s capital stock designated as preferred stock, including the Company Series A Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Registered IP</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Company IP Rights that are owned or exclusively licensed by the Company that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications and registrations for any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Series A Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a series of the Company&#8217;s preferred stock designated as Series A Preferred Stock, $0.0001 par value per share.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stock Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company&#8217;s Amended and Restated 2024 Equity Incentive Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Triggering Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall be deemed to have occurred if, at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote: (a) the Company Board shall have made a Company Board Adverse Recommendation Change; (b) the Company Board or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">any committee thereof shall have publicly proposed, endorsed or recommended any Acquisition Proposal; or (c) the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Warrants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means warrants to purchase shares of Company Capital Stock issued by the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Confidentiality</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the letter agreement dated as of February 9, 2024, between the Company and Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Contemplated</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transactions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Merger, the Constructive Issuance and the other transactions contemplated by this Agreement (other than the Parent Legacy Transaction and Parent Charter Amendment), the Company Pre-Closing Financing and the Nasdaq Reverse Split (to the extent applicable and deemed necessary by Parent and the Company).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">DGCL</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the General Corporation Law of the State of Delaware.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">DLLCA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Delaware Limited Liability Company Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any effect, change, event, circumstance, or development.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (A) an &#8220;employee benefit plan&#8221; within the meaning of Section&#160;3(3) of ERISA whether or not subject to ERISA; (B) other plan, program, policy or arrangement providing for stock options, stock purchases, equity-based compensation, bonuses (including any annual bonuses and retention bonuses) or other incentives, severance pay, deferred compensation, employment, compensation, change in control or transaction bonuses, supplemental, vacation, retirement benefits (including post-retirement health and welfare benefits), pension benefits, profit-sharing benefits, fringe benefits, life insurance benefits, perquisites, health benefits, medical benefits, dental benefits, vision benefits, and all other employee benefit plans, agreements, and arrangements, not described in (A) above; and (C) all other plans, programs, policies or arrangements providing compensation to employees, consultants and non-employee directors.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Encumbrance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, exclusive license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Enforceability Exceptions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (b) rules of law governing specific performance, injunctive relief and other equitable remedies.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Entity</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any corporation (including any nonprofit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Environmental</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Law</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ERISA Affiliate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Entity, any other Person that would be treated as a single employer with such Entity or part of the same &#8220;controlled group&#8221; as such Entity under Sections&#160;414(b),(c),(m) or (o) of the Code.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ERISA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Employee Retirement Income Security Act of 1974, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exchange</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Sub Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of First Merger Sub.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Governmental Authority</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (b) federal, state, local, municipal, foreign, supra-national or other government, (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority) or (d) self-regulatory organization (including Nasdaq).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Governmental Authorization</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any: (a)&#160;permit, license, certificate, franchise, permission, variance, exception, order, approval, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law or (b)&#160;right under any Contract with any Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Hazardous Materials</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or by-products.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">HSR Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the U.S. Hart Scott-Rodino Antitrust Improvements Act of 1976, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">In the Money Parent Option</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall mean Parent Options with an exercise price equal to or less than the Parent Closing Price.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means: (a) United States, foreign and international patents, patent applications, including all provisionals, nonprovisionals, substitutions, divisionals, continuations, continuations-in-part, reissues, extensions, supplementary protection certificates, reexaminations, term extensions, certificates of invention and the equivalents of any of the foregoing, statutory invention registrations, invention disclosures and inventions (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Patents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), (b) trademarks, service marks, trade names, domain names, corporate names, brand names, URLs, trade dress, logos and other source identifiers, including registrations and applications for registration thereof and goodwill associated therewith, (c) copyrights, including registrations and applications for registration thereof, (d) software, including all source code, object code and related documentation, (e) formulae, customer lists, trade secrets, know-how, confidential information and other proprietary rights and intellectual property, whether patentable or not, and (f) all United States and foreign rights arising under or associated with any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IRS</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Internal Revenue Service.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Knowledge</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, (i) with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably be expected to know such fact in the ordinary course of the performance of such individual&#8217;s employment responsibilities, (ii) with respect Parent, the Knowledge of the individuals listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Schedule&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter as of the date of such knowledge is imputed and (iii) with respect to any Person that is an Entity (other than Parent) the Knowledge of any executive officer of such Person as of the date such knowledge is imputed. With respect to any matters relating to Intellectual Property, such awareness or reasonable expectation to have knowledge does not require any such individual to conduct or have conducted or obtain or have obtained any freedom to operate opinions of counsel or any Intellectual Property rights clearance searches.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Law</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any federal, state, national, supra-national, foreign, local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Legal Proceeding</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before any court or other Governmental Authority or any arbitrator or arbitration panel.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiemployer</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiemployer plan,&#8221; as defined in Section&#160;3(37) or 4001(a)(3) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiple Employer Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiple employer plan&#8221; within the meaning of Section&#160;413(c) of the Code or Section&#160;3(40) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiple Employer Welfare Arrangement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiple employer welfare arrangement&#8221; within the meaning of Section&#160;3(40) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Reverse Split</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a reverse stock split of all outstanding shares of Parent Common Stock effected by Parent for the purpose of maintaining compliance with Nasdaq listing standards.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means The Nasdaq Stock Market.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Order</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any judgment, order, writ, injunction, ruling, decision or decree of (that is binding on a Party), or any plea agreement, corporate integrity agreement, resolution agreement or deferred prosecution agreement with, or any settlement under the jurisdiction of, any court or Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Ordinary</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Course of Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its business and consistent with its past practice or, with respect to the Company, the customary practices of a recently formed company at a similar stage of development; provided, however, that during the Pre-Closing Period, the Ordinary Course of Business of Parent shall also include actions required to effect and effecting any Parent Legacy Transaction.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Person (other than an individual), (a) the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Out of the Money Parent Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall mean Parent Options with an exercise price greater than the Parent Closing Price.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Associate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any current employee, independent contractor, officer or director of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Balance Sheet</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the audited balance sheet of Parent as of December 31, 2023, included in Parent&#8217;s Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Parent Common Stock and the Parent Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Capitalization Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of Parent and Merger Subs set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;4.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Closing Price</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the volume weighted average closing trading price of a share of Parent Common Stock on Nasdaq for the five (5) consecutive trading days ending three (3) trading days immediately prior to the Closing Date as reported by Bloomberg L.P.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Common Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock, $0.001 par value per share, of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract: (a) to which Parent is a party, (b) by which Parent or any Parent IP Rights or any other asset of Parent is or may become bound or under which Parent has, or may become subject to, any obligation or (c) under which Parent has or may acquire any right or interest.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Convertible Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Parent&#8217;s non-voting convertible preferred stock, par value $0.001 per share, with the rights, preferences, powers and privileges specified in the Certificate of Designation.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Employee Plan that Parent or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes to, or (ii) provides benefits under or through, or (iii) has any obligation to contribute to or provide benefits under or through, or (iv) may reasonably be expected to have any Liability, or (v)&#160;utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of Parent or any of its Subsidiaries (or their spouses, dependents, or beneficiaries).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Fundamental Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of Parent and Merger Subs set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;4.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent IP Rights Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract governing, related or pertaining to any Parent IP Rights.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent IP Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Intellectual Property owned, licensed or controlled by Parent that is necessary for, or used or held for use in, the operation of the business of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Key Employee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) an executive officer of Parent; and (ii) any employee of Parent that reports directly to the Parent Board or to an executive officer of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Legacy Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the business of Parent as conducted at any time prior to the date of this Agreement, including but not limited to business related to the assets listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of the Parent Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of Parent and its Subsidiaries, taken as a whole; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Parent Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions, (b) any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (c) the taking of any action, or the failure to take any action, by Parent that is required to comply with the terms of this Agreement, (d) any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world, or any governmental or other response or reaction to any of the foregoing, (e) any change in GAAP or applicable Law or the interpretation thereof or (f) general economic or political conditions or conditions generally affecting the industries in which Parent or any of its Subsidiaries operates; except, in each case with respect to clauses&#160;(d), (e) and (f), to the extent materially and disproportionately affecting Parent or any of its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Parent or any of its Subsidiaries operates. Notwithstanding the above, a delisting of Parent Common Stock on Nasdaq shall constitute a Parent Material Adverse Effect, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that the Company has not refused or unreasonably delayed its consent to reasonable actions by Parent to maintain the listing of Parent Common Stock on Nasdaq.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Net Cash</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means without duplication, (i) Parent&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">plus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) all prepaid expenses set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">plus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (iii) all receivables which the parties may mutually agree (each in their sole discretion) are recoverable by or provide benefit to Parent after the First Effective Time (if any), </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (iv) the sum of Parent&#8217;s consolidated short-term and long-term contractual obligations and liabilities accrued at the Closing Date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (v) the aggregate amount (without duplication) </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of all fees and expenses incurred by Parent prior to the First Effective Time in connection with the Contemplated Transactions or the Parent Legacy Transaction, including: (a) any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of Parent in connection with the Contemplated Transactions or the Parent Legacy Transaction; (b) 50% of the fees paid to the SEC in connection with filing the Registration Statement and any amendments and supplements thereto, with the SEC; (c)&#160;50% of the fees and expenses in connection with the printing, mailing and distribution of the Proxy Statement and any amendments and supplements thereto; (d) 50% of the Nasdaq Fees; (e)&#160;any bonus, retention payments, severance, change-in-control payments or similar payment obligations (including payments with &#8220;single-trigger&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the Contemplated Transactions or any Parent Legacy Transaction, together with any payroll Taxes associated therewith; (f) the dividend of any excess Parent Net Cash (but only to the extent declared and unpaid) and all costs and expenses associated therewith; and (g)&#160;the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in each case, to the extent unpaid as of the First Effective Time, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi) all remaining rent payments and any other Liabilities under Parent&#8217;s lease obligations, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (vii) any unpaid Taxes of Parent and its Subsidiaries for Tax periods (or portions thereof) ending on or before the Closing Date, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (viii) all costs and expenses to be mutually agreed by Parent and the Company relating to the winding down of Parent Legacy Business, including the sale, license or other disposition of any or all of the Parent Legacy Business to the extent unpaid as of the Closing, including any costs incurred costs incurred by Parent following the Closing pursuant to Section&#160;6.17 and </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ix) the amounts due and payable to holders of Parent Options pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the extent unpaid as of the First Effective Time; </span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">that if any portion of the fees and expenses described in subclauses&#160;(b), (c), and (d) of clause&#160;(v) have been paid by Parent prior to the First Effective Time in an amount greater than Parent&#8217;s share of such fee and expense described in subclauses&#160;(b), (c), and (d), then (x) such portion in excess of Parent&#8217;s shares of such fee and expense described in subclauses&#160;(b), (c), and (d) shall not be deducted by reason of subclauses&#160;(b), (c), and (d) of clause&#160;(v) and (y) such portion shall be added to the calculation of Parent Net Cash.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means options or other rights to purchase shares of Parent Common Stock granted by Parent, including pursuant to any Parent Stock Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the shares of Parent&#8217;s capital stock designated as preferred stock, par value $0.001 per share of Parent, including the Parent Convertible Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Registered IP</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Parent IP Rights that are owned or exclusively licensed by Parent that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications for any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Restricted Stock Units</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any equity award with respect to Parent Common Stock that represents the right to receive in the future shares of Parent Common Stock pursuant to any Parent Stock Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Triggering Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall be deemed to have occurred if, prior to the approval of this Agreement and the Contemplated Transactions by Parent&#8217;s stockholders and subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">: (a) Parent shall have failed to include in the Proxy Statement the Parent Board Recommendation, (b) the Parent Board or any committee thereof shall have made a Parent Board Adverse Recommendation Change or subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, publicly proposed, endorsed or recommended any Acquisition Proposal or (c) Parent shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement permitted pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Party</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company, Merger Subs and Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Permitted Alternative Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a Superior Offer.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Permitted Encumbrance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (a) any statutory liens for current Taxes not yet due and payable or for Taxes that are being contested in good faith by the appropriate proceedings and for which adequate reserves have been made on the Company Budget or the Parent Balance Sheet, as applicable, in accordance with GAAP, (b)&#160;minor non-monetary liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair the operations of the Company or Parent, as applicable, (c)&#160;statutory liens to secure obligations to landlords, lessors or renters under </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">leases or rental agreements, (d) deposits or pledges made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by Law, (e) statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies for amounts that are not yet due and payable and (f) liens arising under applicable securities Law.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Person</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any individual, Entity or Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Personal Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any data or information that constitutes &#8220;personal information,&#8221; &#8220;personal data,&#8221; &#8220;personally identifiable information,&#8221; &#8220;protected health information,&#8221; or any analogous term under applicable Law, including any such information that identifies, relates to, describes, is linked to, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with any identified or identifiable individual or household.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Privacy Laws</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; mean, collectively, (i) all Laws governing privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information, including any such legally binding requirements set forth in regulations and agreements containing consent orders published by regulatory authorities of competent jurisdiction such as the U.S. Federal Trade Commission, U.S. Federal Communications Commission, and state data protection authorities, including HIPAA, Section&#160;5 of the Federal Trade Commission Act, the Telephone Consumer Protection Act and U.S. state consumer protection and data breach notification Laws, and (ii) any legally binding requirements of any self-regulatory organizations governing data privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Representatives</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means with respect to a Person, such Person&#8217;s directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and other representatives.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Sarbanes-Oxley Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Sarbanes-Oxley Act of 2002.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SEC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Securities and Exchange Commission.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Securities Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Act of 1933, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subsequent Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subsidiary</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to an Entity, a Person if such Person directly or indirectly owns or purports to own, beneficially or of record, (a) an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body or (b) at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Superior</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Offer</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (a) was not obtained or made as a direct or indirect result of a breach of this Agreement, (b) is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other Party to this Agreement to amend the terms of this Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Parent&#8217;s stockholders or the Company&#8217;s stockholders, as applicable, than the terms of the Contemplated Transactions, (c) is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d) is reasonably capable of being completed on the terms proposed.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax Return</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any return (including any information return), report, statement, declaration, claim or refund, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed or required to be filed with any Governmental Authority (or provided to a payee) in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any U.S. federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, employment tax, unemployment tax, national health insurance tax, environmental tax, excise tax, ad valorem tax, transfer tax, conveyance tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll tax, social security tax, customs duty, licenses tax, alternative or add-on minimum or other tax or similar charge, duty, levy, fee, tariff, impost, obligation or assessment in the nature of a tax (whether imposed directly or through withholding and whether or not disputed), and including any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto (or attributable to the nonpayment thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Treasury Regulations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Treasury regulations promulgated under the Code.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b) Each of the following terms is defined in the Section&#160;set forth opposite such term:</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">AAA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(i)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Accounting Firm</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(i)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Allocation Certificate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Assumed Option</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.5(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Assumed Warrant</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.5(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Capitalization Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.6(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cash Determination Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Certifications</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Closing Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Closing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company 409A Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(j)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Audited Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(e)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Board Adverse Recommendation Change</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Board Recommendation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Budget</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Disclosure Letter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Section&#160;3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Interim Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(e)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Intervening Event</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Material Contract</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Material Contracts</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Product Candidates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Real Estate Leases</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.11</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Regulatory Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Required S-4 Information</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Stockholder Support Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Stockholder Written Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Termination Fee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.3(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Calculation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Delivery Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Determination Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Dispute Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Response Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Schedule</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Concurrent Investment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.7(a)</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">D&amp;O Indemnified Parties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dispute Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dissenting Shares</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.12(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Drug/Device Regulatory Agency</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Employment-Related Laws</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(k)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">End Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.1(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Exchange Agent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">FDA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">FDCA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Step Surviving Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Form S-4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GAAP</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Intended Tax Treatment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lock-Up Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lock-Up Agreements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger Consideration</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.5(a)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger Subs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Nasdaq Fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Nasdaq Listing Application</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Notice Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ordinary Course Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.16(g)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent 409A Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.17(j)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Board Adverse Recommendation Change</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Board Recommendation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Charter Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.4(b)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Disclosure Letter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Section&#160;4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Intervening Event</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Legacy Transaction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Material Contract</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Material Contracts</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Net Cash Calculation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Net Cash Schedule</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Notice Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Pre-Closing Dividend Amount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Product Candidates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Real Estate Leases</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.11</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Regulatory Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stock Plans</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.6(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Meeting</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Support Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">PHSA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Post-Closing Welfare Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.6(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Pre-Closing Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Privacy Policies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Proxy Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Registration Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Required Company Stockholder Vote</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Required Parent Stockholder Vote</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Response Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Stockholder Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Subscription Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Surviving Entity</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tax Certificates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.10(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Transaction Litigation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.4(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">WARN Act</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(k)</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Other Definitional and Interpretative Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections, Exhibits and Schedules&#160;are to Sections, Exhibits and Schedules&#160;of this Agreement unless otherwise specified. Any capitalized terms used in any Exhibit&#160;or Schedule&#160;but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract (except for references to any agreements or Contracts listed on the Parent Disclosure Letter or Company Disclosure Letter) are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. The Exhibits to this Agreement, the Parent Disclosure Letter and the Company Disclosure Letter are integral parts of the interpretation of this Agreement, but only Exhibit&#160;D-1 (including Exhibit&#160;A to such Exhibit) and Exhibit&#160;D-2 is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United&#160;States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. The Parties agree that the Company Disclosure Letter or Parent Disclosure Letter shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, respectively. The disclosures in any section or subsection of the Company Disclosure Letter or the Parent Disclosure Letter shall qualify other sections and subsections in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, respectively, to the extent it is readily apparent from a reading of the disclosure that such disclosure is </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">applicable to such other sections and subsections. The words &#8220;delivered&#8221; or &#8220;made available&#8221; mean, with respect to any documentation, that prior to 5:00 p.m. (New York City time) on the date that is the day prior to the date of this Agreement, a copy of such material has been (a)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">&#160;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">posted to and continuously made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing Party for the purposes of the Contemplated Transactions or (b) delivered by or on behalf of a Party or its Representatives to the other Party or its Representatives via electronic mail or in hard copy form prior to the execution of this Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Description of Transaction</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">The Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon the terms and subject to the conditions set forth in this Agreement, at the First Effective Time, First Merger Sub shall be merged with and into the Company, and the separate existence of First Merger Sub shall cease. The Company will continue as the surviving corporation in the First Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Step Surviving Corporation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).  Upon the terms and subject to the conditions set forth in this Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Second Merger Sub, and the separate existence of the First Step Surviving Corporation shall cease.  As a result of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Surviving Entity</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effects of the Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The First Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL. As a result of the First Merger, the Company will become a wholly owned subsidiary of Parent. The Second Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL and the DLLCA.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Closing; First Effective Time; Second Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Unless this Agreement is earlier terminated pursuant to the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to the satisfaction or waiver of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the consummation of the Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Closing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall take place remotely, as promptly as practicable (but in no event later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Closing Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.&#8221; Immediately prior to the Closing on the Closing Date, Parent shall file the Certificate of Designation with the office of the Secretary of State of the State of Delaware. At the Closing, (i) the Parties shall cause the First Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger, satisfying the applicable requirements of the DGCL and in form and substance attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;D-1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and incorporated herein by reference (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) the Parties shall cause the Second Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Second Merger, satisfying the applicable requirements of the DGCL and the DLLCA and in form and substance attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;D-2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and incorporated herein by reference (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and together with the First Certificate of Merger, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The First Merger shall become effective at the time of the filing of such Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Certificate of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Second Merger shall become effective at the time of the filing of such Second Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Second Certificate of Merger with the consent of Parent and the Company (the time as of which the Second Merger becomes effective being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents; Directors and Officers</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation of the First Step Surviving Corporation shall be amended and restated in the Merger to read as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The bylaws of the First Step Surviving Corporation shall be identical to the bylaws of the Company as in effect immediately prior to the First Effective Time, until thereafter amended as provided by the DGCL and such bylaws; and</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the directors and officers of the First Step Surviving Corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the First Step Surviving Corporation, shall be such persons as shall be mutually agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the Second Effective Time:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of formation of the Surviving Entity shall be the certificate of formation of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such certificate of formation; provided, however, that at the Second Effective Time (as part of the Second Certificate of Merger), the certificate of formation shall be amended to (A) change the name of the Surviving Entity to &#8220;Oruka Therapeutics Operating Company, LLC,&#8221; and (B) make such other changes as are mutually agreed to by Parent and the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The limited liability company agreement of the Surviving Entity shall be amended and restated in its entirety to read identically to the limited liability company agreement of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such limited liability company agreement; provided, however, that following the Second Effective Time (but as soon thereafter as practicable), the limited liability company agreement shall be amended to change the name of the Surviving Entity to &#8220;Oruka Therapeutics Operating Company, LLC&#8221;;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the Second Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that at the Second Effective Time, Parent shall file an amendment to its certificate of incorporation to (i) change the name of Parent to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split (to the extent applicable and necessary), (iii) increase the number of shares of Parent Common Stock that Parent is authorized to issue to a number mutually agreed between Parent and the Company, and (iv) make such other changes as are mutually agreeable to Parent and the Company (such amendment, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Charter Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The directors and officers of Parent, each to hold office in accordance with the certificate of incorporation and bylaws of Parent, shall be as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The directors and officers of Surviving Entity, each to hold office in accordance with the certificate of formation and limited liability company agreement of Second Merger Sub, shall be as set forth in&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#160;after giving effect to the provisions of&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, or such other persons as shall be mutually agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Subs, the Company or any stockholder of the Company or Parent:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (A) each share of Company Common Stock (including any shares of Company Common Stock issued pursuant to the Company Pre-Closing Financing) outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio, and (B) each share of Company Preferred Stock outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock equal to (x) the Exchange Ratio </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">divided by</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (y) 1,000 (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Consideration</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If any shares of Company Capital Stock outstanding immediately prior to the First Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then the shares of Parent Capital Stock issued in exchange for such shares of Company Capital Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Capital Stock shall accordingly be marked with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the First Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No fractional shares of Parent Capital Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. Any holder of Company Common Stock who would otherwise be entitled to receive a fraction of a share of Parent Common Stock (after aggregating all fractional shares of Parent Common Stock issuable to such holder) shall receive from Parent, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and any accompanying documents as required therein: (i) one share of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii) no shares of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Parent Preferred Stock that a holder of Company Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Parent Preferred Stock issuable to such and any remaining fractional shares shall be, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and any accompanying documents as required therein, rounded up to the nearest whole share of Parent Preferred Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All Company Options outstanding immediately prior to the First Effective Time shall be treated in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All Company Warrants outstanding immediately prior to the First Effective Time shall be treated in accordance with&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.5(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each share of common stock, $0.001 par value per share, of First Merger Sub issued and outstanding immediately prior to the First Effective Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.001 par value per share, of the First Step Surviving Corporation. Each book entry share of First Merger Sub evidencing ownership of any such shares shall, as of the First Effective Time, evidence ownership of such shares of common stock of the First Step Surviving Corporation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, between the date of this Agreement and the First Effective Time, the outstanding Company Capital Stock or Parent Capital Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split to the extent such split has not previously been taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Capital Stock, Company Options, Company Warrants and Parent Capital Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or other like change; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital Stock or Parent Capital Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the Second Effective Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving Corporation, Second Merger Sub or their respective stockholders, each share of the First Step Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be canceled and extinguished without any conversion thereof and no payment or distribution shall be made with respect thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Closing of the Company&#8217;s Transfer Books</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. At the First Effective Time: (a)&#160;all Company Capital Stock outstanding immediately prior to the First Effective Time shall be treated in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and all holders of certificates representing Company Capital Stock that were outstanding immediately prior to the First Effective Time shall cease to have any rights as stockholders of the Company and (b) the stock </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">transfer books of the Company shall be closed with respect to all Company Capital Stock outstanding immediately prior to the First Effective Time. No further transfer of any such Company Capital Stock shall be made on such stock transfer books after the First Effective Time.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Surrender of Company Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>On or prior to the Closing Date, Parent and the Company shall jointly select a reputable bank, transfer agent or trust company to act as exchange agent in the Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exchange Agent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). At the First Effective Time, Parent shall deposit with the Exchange Agent evidence of book-entry shares representing the shares of Parent Capital Stock issuable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in exchange for Company Capital Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Promptly after the First Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of shares of Company Capital Stock that were converted into the right to receive the Merger Consideration: (i) a letter of transmittal in customary form and containing such provisions as Parent may reasonably specify (including a provision confirming that delivery of physical stock certificates representing shares of Company Capital Stock, (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stock Certificates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be effected, and risk of loss and title shall pass, only upon delivery of such Company Stock Certificates to the Exchange Agent) and (ii) instructions for effecting the surrender of Company Stock Certificates, or uncertificated shares of Company Capital Stock, in exchange for book-entry shares of Parent Capital Stock. Upon surrender of a Company Stock Certificate or other reasonable evidence of the ownership of uncertificated Company Capital Stock to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Parent: (A) the holder of such Company Stock Certificate or uncertificated shares of Company Capital Stock shall be entitled to receive in exchange therefor book-entry shares representing the Merger Consideration (in a number of whole shares of Parent Capital Stock) that such holder has the right to receive pursuant to the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (B) the Company Stock Certificate or uncertificated shares of Company Capital Stock so surrendered shall be canceled. Until surrendered as contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, each Company Stock Certificate or uncertificated shares of Company Capital Stock shall be deemed, from and after the First Effective Time, to represent only the right to receive book-entry shares of Parent Capital Stock representing the Merger Consideration. If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition precedent to the delivery of any shares of Parent Capital Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to such Company Stock Certificate and post a bond indemnifying Parent against any claim suffered by Parent related to the lost, stolen or destroyed Company Stock Certificate or any Parent Capital Stock issued in exchange therefor as Parent may reasonably request.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No dividends or other distributions declared or made with respect to Parent Capital Stock with a record date after the First Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Capital Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate or uncertificated shares of Company Capital Stock or provides an affidavit of loss or destruction in lieu thereof in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any shares of Parent Capital Stock deposited with the Exchange Agent that remain undistributed to holders of Company Stock Certificates as of the date that is 180 days after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates who have not theretofore surrendered their Company Stock Certificates or uncertificated shares of Company Capital Stock in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall thereafter look only to Parent for satisfaction of their claims for Parent Capital Stock and any dividends or distributions with respect to shares of Parent Capital Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Person shall be liable to any holder of any Company Stock Certificate or uncertificated shares of Company Capital Stock or to any other Person with respect to any shares of Parent Capital Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Calculation of Net Cash and Company Valuation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than five (5) Business Days before the Closing, Parent will deliver to the Company a schedule (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Net Cash Schedule</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) setting forth, in reasonable detail, Parent&#8217;s good faith, estimated calculation of Parent Net Cash (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Net Cash Calculation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) as of 11:59 p.m. on the Business Day prior to the Anticipated Closing Date (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Cash</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Determination Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) prepared and certified by Parent&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for Parent). Parent shall make available to the Company (electronically to the greatest extent possible) as reasonably requested by the Company, the work papers and back-up materials used or useful in preparing the Parent Net Cash Schedule&#160;and, if reasonably requested by the Company, Parent&#8217;s internal finance personnel and its accountants and counsel at reasonable times and upon reasonable notice. The Parent Net Cash Calculation shall include Parent&#8217;s determination, as of the Cash Determination Time, of the defined terms in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> necessary to calculate the Exchange Ratio.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than five (5) Business Days before the Closing, the Company will deliver to Parent a schedule (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Schedule</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) setting forth, in reasonable detail, the Company&#8217;s good faith, estimated calculations of the components of the Company Valuation (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Calculation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and the date of delivery of such schedule being (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Delivery Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) as of 11:59 p.m. on the last Business Day prior to the Anticipated Closing Date (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Determination Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) prepared and certified by the Company&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for the Company). The Company shall make available to Parent, as reasonably requested by Parent, the work papers and back-up materials used or useful in preparing the Company Valuation Schedule&#160;and, if reasonably requested by Parent, the Company&#8217;s accountants and counsel at reasonable times and upon reasonable notice.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than three (3) Business Days after the Cash Determination Time (the last day of such period, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Response Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company shall have the right to dispute any part of the Parent Net Cash Calculation by delivering a written notice to that effect to Parent (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Dispute Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Any Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Parent Net Cash Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than three (3) Business Days after the Company Valuation Delivery Date (the last day of such period, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Response Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), Parent shall have the right to dispute any part of the Company Valuation Calculation by delivering a written notice to that effect to the Company (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Dispute Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Any Company Valuation Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Company Valuation Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the Parent Net Cash Calculation or, if on the Response Date, the Company fails to deliver a Dispute Notice as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then the Parent Net Cash Calculation as set forth in the Parent Net Cash Schedule&#160;shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, on or prior to the Company Valuation Response Date, Parent notifies the Company in writing that it has no objections to the Company Valuation Calculation or, if on the Company Valuation Response Date, Parent fails to deliver a Company Valuation Dispute Notice as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then the Company Valuation Calculation as set forth in the Company Valuation Schedule&#160;shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Company delivers a Dispute Notice on or prior to the Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of Parent Net Cash, which agreed upon the Parent Net Cash amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If Parent delivers a Company Valuation Dispute Notice on or prior to the Company Valuation Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of the components of the Company Valuation, which agreed upon Company Valuation amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If Representatives of Parent and the Company are unable to negotiate an agreed-upon determination of Parent Net Cash as of the Cash Determination Time pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(g)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or the components of Company Valuation as of the Company Valuation Determination Time pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> within three days after delivery of the Dispute Notice or the Company Valuation Dispute Notice, as applicable, (or such other period as Parent and the Company may mutually agree upon), then any remaining disagreements as to the calculation of Parent Net Cash or Company Valuation shall be referred to an independent auditor of recognized national standing jointly selected by Parent and the Company. If the parties are unable to select an independent auditor within five (5) days, then either Parent or the Company may thereafter request that the Boston, Massachusetts Office of the American Arbitration Association (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AAA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) make such selection (either the independent auditor jointly selected by both parties or such independent auditor selected by the AAA, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Accounting Firm</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Parent and the Company shall promptly deliver to the Accounting Firm the work papers and back-up materials used in preparing the Parent Net Cash Schedule&#160;and the Dispute Notice and the Company Valuation Schedule&#160;and the Company Valuation Dispute Notice, and Parent and the Company shall use commercially reasonable efforts to cause the Accounting Firm to make its determination within five&#160;(5) Business Days of accepting its selection. Parent and the Company shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that no such presentation or discussion shall occur without the presence of a Representative of each of Parent and the Company. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Parent Net Cash or the components of the Company Valuation made by the Accounting Firm shall be made in writing delivered to each of Parent and the Company, shall be final and binding on Parent and the Company and shall (absent manifest error) be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time or the components of the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement. The Parties shall delay the Closing until the resolution of the matters described in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Parent Net Cash or the Company Valuation that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Parent Net Cash amount or the components of the Company Valuation. If this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> applies as to the determination of the Parent Net Cash at the Cash Determination Time or to the determination of the components of the Company Valuation at the Company Valuation Determination Time, as applicable, upon resolution of the matter in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Parties shall not be required to determine Parent Net Cash or the Company Valuation again even though the Closing may occur later than the Anticipated Closing Date, except that either Parent and the Company may request a redetermination of Parent Net Cash or the Company Valuation if the Closing Date is more than thirty (30) days after the Anticipated Closing Date.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Further Action</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If, at any time after the First Effective Time, any further action is determined by the Surviving Entity to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Entity with full right, title and possession of and to all rights and property of the Company, then the officers and directors of the Surviving Entity shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of the Company, in the name of First Merger Sub, in the name of Second Merger Sub, in the name of the Surviving Entity and otherwise) to take such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intended Tax Treatment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parties acknowledge and agree that, for U.S. federal (and applicable state and local) income Tax purposes, the Merger is intended to qualify as a reorganization within the meaning of Section&#160;368(a) of the Code (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Intended Tax Treatment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Parties adopt this Agreement as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections&#160;1.368-2(g) and 1.368-3.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Withholding</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of the Exchange Agent, Parent and the Surviving Entity shall be entitled to deduct and withhold from any consideration deliverable pursuant to this Agreement to any Person such amounts as are required to be deducted or withheld from such consideration under applicable Law; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">the Exchange Agent, Parent and the Surviving Entity shall use commercially reasonable efforts to promptly notify such Persons of any intention to withhold any portion of such consideration and cooperate with such Persons to reduce or eliminate any such withholding to the extent permitted by applicable Law. To the extent such amounts are so deducted or withheld and remitted to the appropriate Governmental Authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. All payments made under this agreement that constitute compensation to employees for services for Tax purposes shall be made through the payroll of the Surviving Entity or Parent, as applicable.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appraisal Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding any provision of this Agreement to the contrary, shares of Company Capital Stock that are outstanding immediately prior to the First Effective Time and which are held by stockholders or owned by beneficial owners who have exercised and perfected appraisal rights for such shares of Company Capital Stock in accordance with the DGCL (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Dissenting Shares</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall not be converted into or represent the right to receive the Merger Consideration described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> attributable to such Dissenting Shares. Such stockholders or beneficial owners shall be entitled to receive payment of the fair value of such shares of Company Capital Stock held by them in accordance with the DGCL, unless and until such stockholders or beneficial owners fail to perfect or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by stockholders or owned by beneficial owners who shall have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares of Company Capital Stock under the DGCL (whether occurring before, at or after the First Effective Time) shall thereupon be deemed to be converted into and to have become exchangeable for, as of the First Effective Time, the right to receive the Merger Consideration, without interest, attributable to such Dissenting Shares upon their surrender in the manner provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;2.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company shall give Parent prompt written notice of any demands by dissenting stockholders or beneficial owners received by the Company, withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company in connection with such demands, and Parent shall have the right to participate in all negotiations and proceedings with respect to such demands. The Company shall not, except with Parent&#8217;s prior written consent, not to be unreasonably withheld, delayed or conditioned, make any payment with respect to, or settle or offer to settle, any such demands, or approve any withdrawal of any such demands or agree to do any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as set forth in the written disclosure document delivered by the Company to Parent (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Disclosure Letter</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) concurrently with the execution of this Agreement, the Company represents and warrants to Parent and Merger Subs as follows:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Due Organization; Subsidiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is a corporation or other legal entity duly incorporated or otherwise organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary power and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under all Contracts by which it is bound.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has no Subsidiaries and the Company does not own any capital stock or membership interests of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity. The Company is not and has never otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company has not agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">future investment in or capital contribution to any other Entity. The Company has not, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has delivered to Parent accurate and complete copies of the Organizational Documents of the Company. The Company is not in breach or violation of its Organizational Documents in any material respect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Authority; Binding Nature of Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by Parent, First Merger Sub and Second Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Vote Required</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The affirmative vote (or written consent) of (i)&#160;the holders of a majority of the shares of Company Capital Stock outstanding on the record date, voting as a single class on an as-converted&#160;basis, and (ii) the holders of a majority of the shares of Company Series A Preferred Stock outstanding on the record date and entitled to vote thereon, voting as a separate class, is the only vote of the holders of any class or series of Company Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Required Company Stockholder Vote</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Contravention; Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to obtaining the Required Company Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, neither (x) the execution, delivery or performance of this Agreement by the Company, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation of any of the provisions of the Company&#8217;s Organizational Documents;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order by which the Company, or any of the assets owned or used by the Company, is subject;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or that otherwise relates to the business of the Company, or any of the assets owned, leased or used by the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Company Material Contract, (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract, (C) accelerate the maturity or performance of any Company Material Contract or (D) cancel, terminate or modify any term of any Company Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted Encumbrances).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for (i) the Required Company Stockholder Vote, (ii) the filing of the Certificate of Merger and Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iii) compliance with any applicable requirements of the HSR Act (if applicable) and (iv)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, the Company was not, is not, nor will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Stockholder Support Agreements or any of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Capitalization.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The authorized capital stock of the Company consists of (i) 65,000,000 shares of Company Common Stock of which 9,460,019 shares have been issued and are outstanding as of the date hereof and (ii) 20,000,000 shares of Company Preferred Stock, of which 20,000,000 shares have been designated Series A Preferred Stock and 20,000,000 have been issued and are outstanding as of the date hereof. The Company does not hold any shares of its capital stock in its treasury. As of the date of this Agreement, the Company&#8217;s capital stock is held by the Persons and in the amounts set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, which further sets forth for each such Person (i) the&#160;name of such Person and the number of shares held, (ii)&#160;the class and series of such shares, (iii)&#160;the number of the applicable book-entry positions representing such shares or the number of the certificate representing such shares, (iv)&#160;whether such Person is or has ever been an employee, and (v) the state of residence of such Person. Each share of Company Preferred Stock is convertible into one share of Company Common Stock. There are no declared or accrued but unpaid dividends with respect to any shares of the Company&#8217;s capital stock and the Company has never declared or paid any dividend or other distribution.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All of the outstanding Company Capital Stock as set out in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding Company Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding Company Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any Company Capital Stock. The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding Company Capital Stock or other securities. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately and completely describes all repurchase rights held by the Company with respect to Company Capital Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the Company Stock Plans and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter sets forth the following information with respect to each Company Option outstanding as of the date hereof: (i) the name of the holder, (ii) the number of shares of Company Common Stock subject to such Company Option as of the date hereof, (iii) the exercise price of such Company Option, (iv) the date on which such Company Option was granted, (v) the applicable vesting schedule, including any acceleration provisions, (vi)&#160;the date on which such Company Option expires, (vii) whether such Company Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii) in the case of a Company Option, the plan pursuant to which such Company Option was granted. The Company has made available to Parent accurate and complete copies of equity incentive plans pursuant to which the Company has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Company Stock Plans and any amendments thereto.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the outstanding Company Options or as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any Company Capital Stock or other securities of the Company, (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">capital stock or other securities of the Company, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which the Company is or may become obligated to sell or otherwise issue any Company Capital Stock or any other securities or (iv) condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All outstanding Company Capital Stock, Company Options and other securities of the Company have been issued and granted in compliance in all material respects with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth in applicable Contracts.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company Capital Stock are uncertificated.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.7(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter includes true and complete copies of the Company&#8217;s budget overview for March 2024 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Budget</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company maintains a system of internal accounting controls designed to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of the financial statements of the Company in conformity with GAAP and to maintain accountability of the Company&#8217;s assets, (iii) access to the Company&#8217;s assets is permitted only in accordance with management&#8217;s general or specific authorization and (iv)&#160;the recorded accountability for the Company&#8217;s assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences. The Company maintains internal controls consistent with the practices of similarly situated private companies over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.7(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists, and the Company has delivered to Parent accurate and complete copies of the documentation creating or governing, all securitization transactions and &#8220;off-balance sheet arrangements&#8221; (as defined in Item 303(c) of Regulation S-K under the Exchange Act) effected by the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof. Neither the Company nor its independent auditors have identified (i) any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii) any fraud, whether or not material, that involves the Company, the Company&#8217;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company or (iii) any claim or allegation regarding any of the foregoing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Changes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, between the date of its incorporation and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Company Material Adverse Effect or (b) action, event or occurrence that would have required consent of Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Undisclosed Liabilities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of its incorporation, the Company does not have any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise (each a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Liability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), except for: (a) Liabilities disclosed, reflected or reserved against in the Company Budget, (b) normal and recurring current Liabilities that have been incurred by the Company since the date of the Company Budget in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of the Company under Company Contracts, (d) Liabilities incurred in connection with the Contemplated Transactions and the Subscription Agreement, (e)&#160;Liabilities described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter and (f) those Liabilities that are not material to the Company.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Title to Assets</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company owns and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets reflected on the Company Budget and (b) all other tangible assets reflected in the books and records of the Company as being owned by the Company. All of such assets are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances, other than Permitted Encumbrances.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Real Property; Leasehold</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company does not own and has never owned any real property, nor is the Company party to any agreement to purchase or sell any real property. The Company has made available to Parent (a) an accurate and complete list of&#160;all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Real Estate Leases</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each of which is in full force and effect, with no existing material default thereunder by the Company or to the Company&#8217;s Knowledge, the other party thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter is an accurate, true and complete listing of all Company Registered IP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately identifies (i) all Company Contracts pursuant to which any Company IP Rights are licensed to the Company (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Company and its employees in Company&#8217;s standard form thereof) and (ii)&#160;whether the license or licenses granted to the Company are exclusive or nonexclusive.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately identifies each Company Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Company IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Company IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for the Company&#8217;s benefit).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not bound by, and no Company IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of the Company to use, exploit, assert or enforce any Company IP Rights anywhere in the world.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company exclusively owns all right, title and interest to and in Company IP Rights (other than (i) Company IP Rights licensed to the Company, or co-owned rights each as identified in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (ii) any non-customized software that (A) is licensed to the Company solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services and (iii) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All documents and instruments necessary to register or apply for or renew registration of Company Registered IP have been validly executed, delivered and filed in a timely manner with the appropriate Governmental Authority.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Person who is or was an employee or contractor of the Company and who is or was involved in the creation or development of any Intellectual Property for the Company has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to the Company and confidentiality provisions protecting trade secrets and confidential information of the Company.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of the Company, no current or former stockholder, officer, director or employee of the Company has any claim, right (whether currently exercisable, or exercisable in the future) or interest to or in any Company IP Rights purported to be owned by the Company. To the Knowledge of the Company, no employee of the Company is (a) bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for the Company or (b) in breach of any Contract with any former employer or other Person concerning Company IP Rights purported to be owned by the Company or confidentiality provisions protecting trade secrets and confidential information comprising Company IP Rights purported to be owned by the Company.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No funding, facilities or personnel of any Governmental Authority or any university, college, research institute or other educational institution were used, directly or indirectly, to develop or create, in whole or in part, any Company IP Rights in which the Company has an ownership interest, except for any such funding or use of facilities or personnel that does not result in such Governmental Authority or institution owning such Company IP Rights or the right to receive royalties or other remuneration for the practice of such Company IP Rights as of the date of this Agreement.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that the Company holds, or purports to hold, as confidential or a trade secret.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Company IP Rights to any other Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has delivered or made available to Parent, a complete and accurate copy of all Company IP Rights Agreements. With respect to each of the Company IP Rights Agreements: (i) each such agreement is valid and binding on the Company and in full force and effect, (ii) the Company has not received any written notice of termination or cancellation under such agreement, or received any written notice of breach or default under such agreement, which breach has not been cured or waived and (iii) the Company, and to the Knowledge of the Company, no other party to any such agreement, is not in breach or default thereof in any material respect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by the Company does not violate any license or agreement between the Company and any other third party, and, to the Knowledge of the Company, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company, no third party is infringing upon any Patents owned by Company within the Company IP Rights, or otherwise violating any Company IP Rights Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of the date of this Agreement, Company is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, enforceability, claim construction, ownership or right to use, sell, offer for sale, license or dispose of any Company IP Rights. The Company has not received any written notice asserting that any Company IP Rights or the proposed use, sale, offer for sale, license or disposition of products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that the Company has otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. None of the Company IP Rights is subject to any outstanding order of, judgment of, decree of or agreement with any Governmental Authority that limits the ability of the Company to exploit any Company IP Rights.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each item of Company Registered IP is and at all times has been filed and maintained in compliance in all material respects with all applicable Law and all filings, payments and other actions required to be made or taken to maintain such item of Company Registered IP in full force and effect have been made by the applicable deadline. To the Knowledge of the Company, all Company Registered IP that is issued or granted is valid and enforceable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of the Company, no trademark (whether registered or unregistered) or trade name owned, used or applied for by the Company conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which the Company has or purports to have an ownership interest has been impaired as determined by the Company in accordance with GAAP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.12(b),</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.12(k)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter or as contained in &#8220;off-the-shelf&#8221; license agreements entered into in the Ordinary Course of Business by the Company, (i) the Company is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to the Company, taken as a whole and (ii) the Company has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Company IP Rights, result in breach of, default under or termination of such Contract with respect to any Company IP Rights, or impair the right of the Company or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Company IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreements, Contracts and Commitments</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.13(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists the following Company Contracts in effect as of the date of this Agreement other than the Subscription Agreement (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Contracts</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract containing (A) any covenant limiting the freedom of the Company or the Surviving Entity to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Company&#8217;s products or services (B)&#160;any most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract (A) pursuant to which any Person granted the Company an exclusive license under any Intellectual Property, or (B) pursuant to which the Company granted any Person an exclusive license under any Company IP Rights;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company, any of its Subsidiaries, or of a product;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A)&#160;any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case, except for Company Contracts entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions and requiring payments by Company after the date in this Agreement in excess of $100,000 pursuant to its express terms;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract to which the Company is a party or by which any of its assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, the Company in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which the Company or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any other Company Contract that is not terminable at will (with no penalty or payment) by the Company, and (A) which involves payment or receipt by the Company after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to the business or operations of the Company taken as a whole; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Company Real Estate Leases.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto. There are no Company Material Contracts that are not in written form. The Company has not, nor to the Company&#8217;s Knowledge, as of the date of this Agreement has any other party to a Company Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract in such a manner, and, if such Company Material Contract provides for a cure period, the Company or such other party fails to have cured such breach, violation or default, so that any other party or the Company, as the case may be, is permitted to modify, cancel or terminate any such Company Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Company Material Adverse Effect. As to the Company, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material Contract or any other material term or provision of any Company Material Contract.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Compliance; Permits; Restrictions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is, and has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other Legal Proceeding or action by any Governmental Authority is pending or, to the Knowledge of the Company, threatened against the Company. There is no agreement or Order binding upon the Company which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company, any acquisition of material property by the Company or the conduct of business by the Company as currently conducted, (ii) is reasonably likely to have an adverse effect on the Company&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for matters regarding the U.S. Food and Drug Administration (or any successor agency thereto) (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">FDA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) or other comparable Governmental Authority responsible for regulation of the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or medical device products (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Drug/Device Regulatory Agency</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company holds all required Governmental Authorizations for the operation of the business of the Company as currently conducted (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.14(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter identifies each Company Permit. The Company is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Knowledge of the Company, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Company Permit. The rights and benefits of each Company Permit will be available to the Surviving Entity or its Subsidiaries, as applicable, immediately after the Second Effective Time on terms substantially identical to those enjoyed by the Company as of the date of this Agreement and immediately prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Legal Proceedings pending or, to the Knowledge of the Company, threatened with respect to an alleged violation by the Company of the Federal Food, Drug, and Cosmetic Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">FDCA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Public Health Service Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">PHSA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of the Company as currently conducted, and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its products or product candidates (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Product Candidates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Regulatory Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and no such Company Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any adverse manner, other than immaterial adverse modifications. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.14(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter identifies each Company Regulatory Permit. The Company has timely maintained and is in compliance in all material respects with the Company Regulatory Permits and has not received any written notice or correspondence or, to the Knowledge of the Company, other communication from any Drug/Device Regulatory Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Company Regulatory Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Company Regulatory Permit. The Company has made available to Parent all information requested by Parent in the Company&#8217;s possession or control relating to material Company Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Company Product Candidates, including but not limited to complete copies of the following (to the extent there are any): (x) adverse event reports; preclinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information is accurate and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All clinical, preclinical and other studies and tests conducted by or on behalf of, or sponsored by, the Company, or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated, were, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, in accordance in all material respects </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with the applicable protocols and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. The Company has not received any written notices, correspondence or other communications from any Drug/Device Regulatory Agency, Governmental Authority, institutional review board, ethics committee or safety monitoring committee requiring, or to the Knowledge of the Company threatening to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, the Company or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of the Company, on behalf of the Company has been disqualified from participating in studies involving the Company Product Candidates, and to the Knowledge of the Company, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not, and to the Knowledge of the Company, no contract manufacturer with respect to any Company Product Candidate, is the subject of any pending or, to the Knowledge of the Company, threatened investigation in respect of its business or products, including Company Product Candidates, by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. The Company has not, and to the Knowledge of the Company, no contract manufacturer, nor their respective officers, employees or agents, with respect to any Company Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto or a comparable policy of any other Drug/Device Regulatory Agency. None of the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a debarment or exclusion under (i) 21 U.S.C. Section&#160;335a or (ii) any similar applicable Law. To the Knowledge of the Company, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All manufacturing operations conducted by, or to the Knowledge of the Company, for the benefit of the Company in connection with any Company Product Candidate have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210, 211 and 600-610 and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor, to the Knowledge of the Company, any manufacturing site of a contract manufacturer or laboratory, with respect to any Company Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii) has received any Form FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of the Company, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legal Proceedings; Orders</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves the Company or any of its Subsidiaries or any Company Associate (in his or her capacity as such) or any of the material assets owned or used by the Company or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no Order to which the Company or any of its Subsidiaries, or any of the material assets owned or used by the Company or any of its Subsidiaries, is subject. To the Knowledge of the Company, no officer or Company Key Employee is subject to any Order that prohibits such officer or Company Key Employee from engaging in or continuing in any conduct, activity or practice relating to the Company or any of its Subsidiaries or any material assets owned or used by the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by the Company under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where the Company does not file Tax Returns that the Company is subject to taxation by that jurisdiction.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All material amounts of Taxes due and owing by the Company (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause&#160;(a) of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No deficiencies for a material amount of Taxes with respect to the Company have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of the Company. The Company has not granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not been a United States real property holding corporation within the meaning of Section&#160;897(c)(2) of the Code in the last five (5) years.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than customary commercial Contracts entered into in the Ordinary Course of Business the primary purpose of which does not relate to Tax (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Ordinary Course Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is the Company). The Company has no Liability for the Taxes of any Person under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations Sections&#160;1.6011-4(b)(2) or 301.6111-2(b)(2).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not aware of any facts or circumstances and has not taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee and Labor Matters; Benefit Plans.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an employee of the Company or any of its Subsidiaries, whether full- or part-time, such employee&#8217;s annual salary (or if hourly, hourly rate), most recent annual bonus received, and current annual bonus opportunity. No Company Key Employee has indicated to the Company, or any of its Subsidiaries, that he or she intends to resign or retire as a result of the transactions contemplated by this Agreement or otherwise. The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an individual independent contractor engaged by the Company, such contractor&#8217;s rate of compensation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The employment of the Company&#8217;s and each of its Subsidiaries&#8217; employees is terminable by the Company and/or its applicable Subsidiary at will. The Company has made available to Parent accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing its employees, and there are no labor organizations representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists all Company Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of the Company or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to Parent).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of the Company, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Company Employee Plan or the exempt status of any related trust.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of the Company, threatened with respect to any Company Employee Plan. All payments and/or contributions required to have been made with respect to all Company Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Company Employee Plan and applicable Law.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years, maintained, contributed to or been required to contribute to (i) any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer Welfare Arrangement. Neither the Company nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Company Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (1) pursuant to COBRA or an analogous state law requirement or (2) continuation coverage through the end of the month in which such termination or retirement occurs. The Company does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> No Company Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1) of the Code and the guidance thereunder) (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">409A Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) has been operated and maintained in all material respects in </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Company 409A Plan is or, when made in accordance with the terms of the Company 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1) of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company and each of its Subsidiaries is, and has been, in material compliance with all applicable federal, state and local laws, rules and regulations respecting employment, employment practices, terms and conditions of employment, worker classification, tax withholding, prohibited discrimination, retaliation and harassment, equal employment, fair employment practices, meal and rest periods, immigration status, employee and workplace safety and health, wages (including overtime wages), compensation, hours of work, &#8220;plant closings&#8221; and &#8220;mass layoffs&#8221; within the meaning of the Worker Adjustment and Retraining Act of 1988 or similar state or local law (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">WARN Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), labor practices or disputes, restrictive covenants, employment agreements, workers&#8217; compensation and long-term disability policies, leaves of absence and worker privacy (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Employment-Related Laws</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and in each case, with respect to employees of the Company and any of its Subsidiaries: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of the Company, threatened or reasonably anticipated against or involving the Company or any of its Subsidiaries or any trustee of the Company or any of its Subsidiaries relating to any employee, contingent worker, director, employment agreement or Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of the Company, there are no material pending or threatened or reasonably anticipated claims or actions against the Company, any trustee or any trustee of any Subsidiary of the Company under any workers&#8217; compensation policy or long-term disability policy. The Company is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries has any material liability with respect to any misclassification within the last four (4) years of: (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. Neither the Company nor any of its Subsidiaries has taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has the Company or any of its Subsidiaries been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Company&#8217;s Knowledge, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, by or with respect to any Company Associates. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Company&#8217;s Knowledge, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is, nor has the Company nor any of its Subsidiaries been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of the Company, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of the Company or any of its Subsidiaries including charges of unfair labor practices or discrimination complaints.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no contract, agreement, plan or arrangement to which the Company or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Environmental Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has complied with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Company Material Adverse Effect. The Company has not received any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that the Company is not in compliance with any Environmental Law and, to the Knowledge of the Company, there are no circumstances that may prevent or interfere with the Company&#8217;s compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company: (i) no current or prior owner of any property leased or controlled by the Company has received any written notice or other communication relating to property owned or leased at any time by the Company, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or the Company is not in compliance with or violated any Environmental Law relating to such property and (ii) the Company has no material liability under any Environmental Law. The Company has made available all environmental site assessments, environmental audits and other material environmental documents in the Company&#8217;s possession or control relating to the Company, including the Company&#8217;s business and current or former facilities.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Insurance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has delivered to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company. Each of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, the Company has not received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. The Company has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against the Company, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company of its intent to do so.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Financial Advisors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transactions with Affiliates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter describes any material transactions or relationships between, on one hand, the Company and, on the other hand, any (a)&#160;executive officer or director of the Company or any of such executive officer&#8217;s or director&#8217;s immediate family members, (b)&#160;owner of more than 5% of the voting power of the outstanding Company Capital Stock or (c)&#160;to the Knowledge of the Company, any &#8220;related person&#8221; (within the meaning of Item&#160;404 of Regulation S-K under the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of (a), (b)&#160;or (c)&#160;that is of the type that would be required to be disclosed under Item&#160;404 of Regulation&#160;S-K under the Securities Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.22<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Privacy and Data Security</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company is and has at all times been in compliance with all applicable Privacy Laws and the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with the Company in connection with the operation of the Company&#8217;s business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, the Company (i) has implemented and maintains reasonable written policies and procedures that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Privacy Policies</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, no Legal Proceeding has been asserted or threatened against the Company by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of the Company, there have been no data security incidents or data breaches or other adverse events or incidents that have resulted in any unauthorized access to, or collection, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of the Company or any service provider acting on behalf of the Company, in each case, where such incident, breach or event resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Company Contract.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.23<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Ownership of Parent Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. None of the Company or any of their directors, officers, or Affiliates or, to the knowledge of the Company or any of its controlled Affiliates, any employees of the Company or any of its controlled Affiliates (a) has owned any shares of Parent&#8217;s capital stock; or (b) has been an &#8220;interested stockholder&#8221; (as defined in Section&#160;203 of the DGCL) of Parent, in each case during the three years prior to the date hereof.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.24<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Other Representations or Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither Parent nor any other person on behalf of Parent makes any express or implied representation or warranty with respect to Parent or with respect to any other information provided to the Company, any of its stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Parent set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (in each case as qualified and limited by the Parent Disclosure Letter)) none of the Company, or any of its Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of Parent, First Merger and Second Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except (i) as set forth in the written disclosure document delivered by Parent to the Company (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Disclosure Letter</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) concurrently with the execution of this Agreement or (ii) as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system (but (A) without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (B) excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it being understood that any matter disclosed in the Parent SEC Documents shall be deemed to be disclosed in a section of the Parent Disclosure Letter only to the extent that is readily apparent from a reading of such Parent SEC Documents that is applicable to such section or subsection of the Parent Disclosure Letter, Parent, First Merger Sub and Second Merger Sub represent and warrant to the Company as follows:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Due Organization; Subsidiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent, First Merger Sub and Second Merger Sub is a corporation duly incorporated or formed, as applicable, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or formation, as applicable, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to own or lease and use its property </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under all Contracts by which it is bound. Since the date of its incorporation, Merger Subs have not engaged in any activities other than in connection with or as contemplated by this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Parent Material Adverse Effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has no Subsidiaries other than Merger Subs and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.1(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent does not own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control directly or indirectly, any other Entity other than Merger Subs. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.1(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Parent has not agreed and is not obligated to make, nor is Parent bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Parent has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent has delivered to the Company accurate and complete copies of Parent&#8217;s Organizational Documents. Parent is not in breach or violation of its Organizational Documents in any material respect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Authority; Binding Nature of Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and each Merger Sub has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Parent Board has: (a) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (b) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and (c) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Contemplated Transactions, and, if deemed necessary by Parent and the Company, the amendment to the certificate of incorporation of the Parent to (i) change the name of Parent to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split and (iii) make such other changes as are mutually agreeable to Parent and the Company pursuant to the terms of this Agreement. The First Merger Sub Board (by unanimous written consent) has: (x)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of First Merger Sub and its sole stockholder, (y) deemed advisable and approved this Agreement and the Contemplated Transactions and (z)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions.  The sole member of Second Merger Sub (by unanimous written consent) has:  (A) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and the sole member; and (B)&#160;deemed advisable and approved this Agreement and the Contemplated Transactions.  This Agreement has been duly executed and delivered by Parent and Merger Subs and, assuming the due authorization, execution and delivery by the Company and the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, constitutes the legal, valid and binding obligation of Parent and Merger Subs, enforceable against each of Parent and Merger Subs in accordance with its terms, subject to the Enforceability Exceptions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Vote Required</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the affirmative vote of a majority of the shares of Parent Common Stock properly cast at the Parent Stockholder Meeting is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve this Agreement and thereby approve the Contemplated Transactions and clauses&#160;(i), (ii) and (iii) of the definition of &#8220;Parent Charter Amendment&#8221; (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Required Parent Stockholder Vote</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Contravention; Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to obtaining the Required Parent Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, and assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, neither (x) the execution, delivery or performance of this Agreement by Parent or Merger Subs, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Parent or its Subsidiaries or any of the assets owned or used by Parent or its Subsidiaries, is subject;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or its Subsidiaries or that otherwise relates to the business of Parent, or any of the assets owned, leased or used by Parent;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Parent Material Contract, (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any such Parent Material Contract, (C)&#160;accelerate the maturity or performance of any Parent Material Contract or (D) cancel, terminate or modify any term of any Parent Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or its Subsidiaries (except for Permitted Encumbrances).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for (i) any Consent set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter under any Parent Contract, (ii) the Required Parent Stockholder Vote, (iii) the filing of the Certificate of Merger and Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iv) compliance with any applicable requirements of the HSR Act (if applicable) and (v) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, and assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, neither Parent nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Parent Board and the First Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Capitalization</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The authorized capital stock of Parent consists of (i)&#160;100,000,000 shares of Parent Common Stock of which 14,501,143 shares have been issued and are outstanding as of March 28, 2024 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Capitalization Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) 5,000,000 shares of Parent Preferred Stock, par value $0.001 per share, of which 135,000 have been designated Series A Convertible Preferred Stock. No shares of Parent Preferred Stock have been issued and are outstanding as of the Capitalization Date. Parent does not hold any shares of its capital stock in its treasury.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent. Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock. Parent is not under any obligation, nor is Parent bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately and completely describes all repurchase rights held by Parent with respect to shares of Parent Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the Parent 2004 Equity Incentive Plan, Parent 2013 Equity Incentive Plan and Parent 2020 Equity Incentive Plan, (each as may be amended from time to time, collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stock Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. Parent does not have any employee stock purchase plan or similar program. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter sets forth the following information with respect to each Parent Option outstanding as of the Capitalization Date, as applicable: (i) the name of the holder, (ii) the number of shares of Parent Common Stock subject to such Parent Option as of the Capitalization Date, (iii) the exercise price of such Parent Option, (iv) the date on which such Parent Option was granted, (v) the applicable vesting schedule, including any acceleration provisions, (vi) the date on which such Parent Option expires, (vii) whether such Parent Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii) in the case of a Parent Option, the plan pursuant to which such Parent Option was granted. Parent has made available to the Company accurate and complete copies of equity incentive plans pursuant to which Parent has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Parent Stock Plans and any amendments thereto.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the outstanding Parent Options or as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Parent, (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent, (iii) stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Parent is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities or (iv) condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Parent. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All outstanding shares of Parent Common Stock and Parent Options, and other securities of Parent have been issued and granted in compliance in all material respects with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth in applicable Contracts.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">SEC Filings; Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents required to be filed or furnished by it with the SEC under the Exchange Act or the Securities Act (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i) Rule&#160;13a-14 under the Exchange Act and (ii) 18 U.S.C. &#167;1350 (Section&#160;906 of the Sarbanes-Oxley Act) relating to the Parent SEC </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Documents (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certifications</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) are accurate and complete and comply as to form and content with all applicable Laws. As used in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules and regulations of the SEC applicable thereto, (ii)&#160;were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii) fairly present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof, there has been no material change in Parent&#8217;s accounting methods or principles that would be required to be disclosed in Parent&#8217;s financial statements in accordance with GAAP. The books of account and other financial records of Parent and each of its Subsidiaries are true and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined in Section&#160;2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of Parent, &#8220;independent&#8221; with respect to Parent within the meaning of Regulation S-X under the Exchange Act and (iii) to the Knowledge of Parent, in compliance with subsections (g) through (l) of Section&#160;10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.7(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on Nasdaq. Parent has not disclosed any unresolved comments in the Parent SEC Documents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act, the Exchange Act and the applicable listing and governance rules and regulations of Nasdaq.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent maintains a system of internal control over financial reporting (as defined in Rules&#160;13a-15(f) and 15d-15(f) of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i) that Parent maintains records that in reasonable detail accurately and fairly reflect Parent&#8217;s transactions and dispositions of assets, (ii)&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with the authorization policy and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#8217;s assets that could have a material effect on Parent&#8217;s financial statements. Parent has evaluated the effectiveness of Parent&#8217;s internal control over financial reporting and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed to Parent&#8217;s auditors and the Audit Committee of the Parent Board (and made available to the Company a summary of the significant aspects of such disclosure) (A) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (B) any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s or its </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Subsidiaries&#8217; internal control over financial reporting. Except as disclosed in the Parent SEC Documents filed prior to the date hereof, Parent&#8217;s internal control over financial reporting is effective at the reasonable assurance level and Parent has not identified any material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules&#160;13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that all information (both financial and nonfinancial) required to be disclosed by Parent in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to Parent&#8217;s principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosure and to make the Certifications and such disclosure controls and procedures are effective. Parent has carried out evaluation of the effectiveness of its disclosure controls and procedures as required by Rule&#160;13a-15 of the Exchange Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Changes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, between December 31, 2023 and the date of this Agreement, Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Parent Material Adverse Effect or (b) action, event or occurrence that would have required consent of the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Undisclosed Liabilities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since December 31, 2023, neither Parent nor any of its Subsidiaries has any Liability except for: (a) Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet, (b) normal and recurring current Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Contracts, (d) Liabilities incurred in connection with the Parent Legacy Business or the Contemplated Transactions, (e) Liabilities described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter and (f) those Liabilities that are not material to Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Title to Assets</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a)&#160;all tangible assets reflected on the Parent Balance Sheet and (b) all other tangible assets reflected in the books and records of Parent as being owned by Parent. All of such assets are owned or, in the case of leased assets, leased by Parent or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Real Property; Leasehold</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Neither Parent nor any of its Subsidiaries owns or has ever owned any real property, nor is Parent party to any agreement to purchase or sell any real property. Parent has made available to the Company (a) an accurate and complete list of&#160;all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Real Estate Leases</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each of which is in full force and effect, with no existing material default thereunder by Parent or its Subsidiaries or, to Parent&#8217;s Knowledge, the other party thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter is an accurate, true and complete listing of all Parent Registered IP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately identifies (i) all Parent Contracts pursuant to which any Parent IP Rights are licensed to Parent (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development, manufacturing, or distribution of, any of Parent products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Parent and its employees in Parent&#8217;s standard form thereof) and (ii) whether the license or licenses granted to Parent are exclusive or nonexclusive.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately identifies each Parent Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Parent IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Parent IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Parent&#8217;s benefit).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is bound by, and no Parent IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of Parent or any of its Subsidiaries to use, exploit, assert, or enforce any Parent IP Rights anywhere in the world.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Parent IP Rights (other than (i) Parent IP Rights licensed to Parent, or co-owned rights each as identified in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, (ii) any non-customized software that (A) is licensed to Parent solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated into, or material to the development, manufacturing or distribution of, any of Parent or its Subsidiaries&#8217; products or services and (iii) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All documents and instruments necessary to register or apply for or renew registration of Parent Registered IP have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Person who is or was an employee or contractor of Parent or any of its Subsidiaries and who is or was involved in the creation or development of any Intellectual Property for Parent or any of its Subsidiaries has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to Parent or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Parent and its Subsidiaries.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, no current or former stockholder, officer, director or employee of Parent or any of its Subsidiaries has any claim, right (whether currently exercisable, or exercisable in the future), or interest to or in any Parent IP Rights purported to be owned by Parent. To the Knowledge of Parent, no employee of Parent or any of its Subsidiaries is (a) bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for Parent or such Subsidiary or (b) in breach of any Contract with any former employer or other Person concerning Parent IP Rights purported to be owned by Parent or such Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Parent IP Rights purported to be owned by Parent or such Subsidiary.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No funding, facilities or personnel of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, any Parent IP Rights in which Parent or any of its Subsidiaries has an ownership interest.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that Parent or such Subsidiary holds, or purports to hold, as confidential or a trade secret.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent or any of its Subsidiaries has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Parent IP Rights to any other Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has delivered, or made available to the Company, a complete and accurate copy of all material Parent IP Rights Agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Parent does not violate any license or agreement between Parent or its Subsidiaries and any third party in any material respect, and, to the Knowledge </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Parent, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent, no third party is infringing upon any Patents owned by Parent within the Parent IP Rights, or violating any Parent IP Rights Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of the date of this Agreement, Parent is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of any Parent IP Rights. Parent has not received any written notice asserting that any Parent Registered IP or the proposed use, sale, offer for sale, license or disposition of any products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that Parent or any of its Subsidiaries have otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, no trademark (whether registered or unregistered) or trade name owned, used or applied for by Parent conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person except as would not have a Parent Material Adverse Effect. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which Parent has or purports to have an ownership interest has been impaired as determined by Parent in accordance with GAAP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as may be set forth in the Contracts listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.12(k)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter or as contained in &#8220;off-the-shelf&#8221; license agreements entered into in the Ordinary Course of Business by Parent, (i) Parent is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation or similar claim which is material to Parent taken as a whole and (ii) Parent has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Parent IP Rights, result in breach of, default under or termination of such Contract with respect to any Parent IP Rights, or impair the right of Parent or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Parent IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Parent Material Adverse Effect.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreements, Contracts and Commitments</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.13</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Parent Contract that is in effect as of the date of this Agreement (each, an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Contracts</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any material bonus, deferred compensation, severance, incentive compensation, pension, profit-sharing or retirement plans, or any other employee benefit plans or arrangements;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract requiring payments by Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to the employment of, or the performance of employment-related services by, any Parent Associate providing employment related, consulting or independent contractor services, not terminable by Parent on thirty (30) calendar days&#8217; or less notice without liability;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any agreement or plan, including any option plan, stock appreciation right plan or stock purchase plan, any of the benefits of which will be increased or the vesting of benefits of which will be accelerated, by the occurrence of any of the Contemplated Transactions (either alone or in conjunction with any other event, such as termination of employment), or the value of any of the benefits of which will be calculated on the basis of any of the Contemplated Transactions;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract containing (A) any covenant limiting the freedom of Parent or any of its Subsidiaries to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Parent&#8217;s products or services (B) any most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract (A) pursuant to which any Person granted Parent an exclusive license under any Intellectual Property, or (B) pursuant to which Parent granted any Person an exclusive license under any Parent IP Rights;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent, any of its Subsidiaries, or of a product;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which Parent or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of Parent or any loans or debt obligations with officers or directors of Parent;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract requiring payment by or to Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of Parent, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Parent or any of its Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Parent or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by Parent or such Subsidiary or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of Parent or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Parent or any of its Subsidiaries, in each case, except for Parent Contracts entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Parent in connection with the Contemplated Transactions and requiring payments by Parent after the date in this Agreement in excess of $100,000 pursuant to its express terms;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiv)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract to which Parent or any of its Subsidiaries is a party or by which any of their assets and properties is currently bound (other than Parent Real Estate Leases), which involves annual obligations of payment by, or annual payments to, Parent or such Subsidiary in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xv)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any Parent Real Estate Lease;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvi)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>a Contract disclosed in or required to be disclosed in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter; or</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvii)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>any other Parent Contract (other than Parent Real Estate Leases) that is not terminable at will (with no penalty or payment) by Parent or any of its Subsidiaries, and (A) which involves payment or receipt by Parent or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to the business or operations of Parent and its Subsidiaries taken as a whole.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto. There are no Parent Material Contracts that are not in written form. Parent has not nor, to Parent&#8217;s Knowledge as of the date of this Agreement, has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such a manner, and, if such Parent Material Contract provides for a cure period, Parent or such other party fails to have cured such breach, violation or default, so that any other party or Parent, as the case may be, is permitted to modify, cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Parent Material Adverse Effect. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Compliance; Permits; Restrictions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and each of its Subsidiaries is, and since January 1, 2023, has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other action by any Governmental Authority is pending or, to the Knowledge of Parent, threatened against Parent or any of its Subsidiaries. There is no agreement or Order binding upon Parent or any of its Subsidiaries which (i)&#160;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent or any of its Subsidiaries, any acquisition of material property by Parent or any of its Subsidiaries or the conduct of business by Parent or any of its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on Parent&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for matters regarding the FDA or other Drug/Device Regulatory Agency, each of Parent and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the business of Parent and Merger Subs as currently conducted (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.14(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Parent Permit. Each of Parent and its Subsidiaries is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Parent Permit. The rights and benefits of each Parent Permit, if any, will be available to Parent and Surviving Entity immediately after the Second Effective Time on terms substantially identical to those enjoyed by Parent and its Subsidiaries as of the date of this Agreement and immediately prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Legal Proceedings pending or, to the Knowledge of Parent, threatened with respect to an alleged violation by Parent or any of its Subsidiaries of the FDCA, PHSA, FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and its Subsidiaries holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of Parent and Merger Subs as currently conducted, and, as applicable, the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its product candidates (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Product Candidates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Regulatory Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and no such Parent Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any adverse manner other than immaterial adverse modifications. Section&#160;4.14(d) of the Parent Disclosure Letter identifies each Parent Regulatory Permit. Parent has timely maintained and is in compliance in all material respects with the Parent Regulatory Permits and neither Parent nor or any of its Subsidiaries has, since January 1, 2023, </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">received any written notice or correspondence or, to the Knowledge of Parent, other communication from any Drug/Device Regulatory Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Parent Regulatory Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Parent Regulatory Permit. Parent has made available to the Company all information requested by the Company in Parent&#8217;s or its Subsidiaries&#8217; possession or control relating to material Parent Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Parent Product Candidates, including, but not limited to, complete copies of the following (to the extent there are any): (x) adverse event reports; pre-clinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information are accurate and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, Parent or its Subsidiaries, in which Parent or its Subsidiaries or their respective product candidates, including the Parent Product Candidates, have participated were, since January 1, 2023, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. Since January 1, 2023, neither Parent nor any of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug/Device Regulatory Agency requiring or, to the Knowledge of Parent, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, Parent or any of its Subsidiaries or in which Parent or any of its Subsidiaries or its current product candidates, including the Parent Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of Parent, on behalf of Parent or any of its Subsidiaries has been disqualified from participating in studies involving the Parent Product Candidates, and to the Knowledge of Parent, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate is the subject of any pending or, to the Knowledge of Parent, threatened investigation in respect of its business or products by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg.&#160;46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer, nor their respective officers, employees or agents, with respect to any Parent Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto. None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a material debarment or exclusion under (i) 21 U.S.C. Section&#160;335a or (ii) any similar applicable Law. To the Knowledge of Parent, no material debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against Parent, any of its Subsidiaries, and to the Knowledge of the Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of its officers, employees or agents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All manufacturing operations conducted by, or to the Knowledge of Parent, for the benefit of, Parent or its Subsidiaries in connection with any Parent Product Candidate, since January 1, 2023, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210 and 211, and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any manufacturing site of a contract manufacturer or laboratory, with respect to any Parent Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii) has received any Form&#160;FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of Parent, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legal Proceedings; Orders</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves Parent or any of its Subsidiaries or any Parent Associate (in his or her capacity as such) or any of the material assets owned or used by Parent or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no Order to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries is subject. To the Knowledge of Parent, no officer or other Parent Key Employee or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing in any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or any material assets owned or used by Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and each of its Subsidiaries has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by it under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where Parent or any of its Subsidiaries does not file Tax Returns that Parent or any of its Subsidiaries is subject to taxation by that jurisdiction.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All material amounts of Taxes due and owing by Parent or any of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause&#160;(a) of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No deficiencies for a material amount of Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries has granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than Ordinary Course Agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is Parent). Neither Parent nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Parent or its Subsidiaries) under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations Sections&#160;1.6011-4(b)(2) or 301.6111-2(b)(2).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is aware of any facts or circumstances or has taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee and Labor Matters; Benefit Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parent has made available to Company a list setting forth, for each Parent Associate who is an employee of Parent or any of its Subsidiaries, such employee&#8217;s name, employer, title, hire date, location, whether full- or part-time, whether active or on leave (and, if on leave, the expected return), whether exempt from the Fair Labor Standards Act and applicable state law, annual salary (or if hourly, hourly rate), most recent annual bonus received and current annual bonus opportunity. The Parent has made available to Company a list setting forth, for each Parent Associate who is an individual independent contractor engaged by Parent or any of its Subsidiaries, such contractor&#8217;s name, duties and rate of compensation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The employment of Parent&#8217;s employees is terminable by Parent at will. Parent has made available to the Company accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is not a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing any of its employees, and there are no labor organizations representing or, to the Knowledge of Parent, purporting to represent or seeking to represent any employees of Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter lists all Parent Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of Parent or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to the Company).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of Parent, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Parent Employee Plan or the exempt status of any related trust.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Parent, threatened with respect to any Parent Employee Plan. All payments and/or contributions required to have been made with respect to all Parent Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Parent Employee Plan and applicable Law.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years, maintained, contributed to or been required to contribute to (i) any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer Welfare Arrangement. Neither Parent nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Parent Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (1) pursuant to COBRA or an analogous state law requirement or (2) continuation coverage through the end of the month in which such termination or retirement occurs. Parent does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> No Parent Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1) of the Code and the guidance thereunder) (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent 409A Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) has been operated and maintained in all material respects in operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Parent 409A Plan is or, when made in accordance with the terms of the Parent 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1) of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is in material compliance with all Employment-Related Laws and in each case, with respect to the employees of Parent: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of Parent, threatened or reasonably anticipated against or involving Parent or any trustee of Parent relating to any employee, contingent worker, director, employment agreement or Parent Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of Parent, there are no material pending or threatened or reasonably anticipated claims or actions against Parent, any Parent trustee or any trustee of any Subsidiary of Parent under any workers&#8217; compensation policy or long-term disability policy. Parent is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has no material liability with respect to any misclassification within the past three (3) years of: (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. Parent has not taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has Parent been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, with respect to any Parent Associate. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Knowledge of Parent, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is not, nor has Parent been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of Parent, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of Parent, including charges of unfair labor practices or discrimination complaints.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no contract, agreement, plan or arrangement to which Parent or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i) result in the payment of any &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code or (ii) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Environmental Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since January 1, 2023, Parent and each of its Subsidiaries has complied with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries has received since January 1, 2023, any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Parent or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the Knowledge of Parent, there are no circumstances that may prevent or interfere with Parent&#8217;s or any of its Subsidiaries&#8217; compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent: (i) no current or prior owner of any property leased or controlled by Parent or any of its Subsidiaries has received since January 1, 2023, any written notice or other communication relating to property owned or leased at any time by Parent or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Parent or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (ii) neither Parent nor any of its Subsidiaries has any material liability under any Environmental Law. Parent has made available all environmental site assessments, environmental audits and other material environmental documents in the Parent&#8217;s possession or control relating to the Parent and its Subsidiaries, including the Parent&#8217;s and its Subsidiaries&#8217; business and current or former facilities.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Insurance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Parent has delivered to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and its Subsidiaries (including Merger Subs). Each of such insurance policies is in full force and effect and Parent and its Subsidiaries (including Merger Subs) are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January 1, 2023, neither Parent nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Each of Parent and its Subsidiaries (including Merger Subs) has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against Parent or such Subsidiary for which Parent or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transactions with Affiliates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent&#8217;s last proxy statement filed with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation S-K promulgated by the SEC. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Person who is (or who may be deemed to be) an Affiliate of Parent as of the date of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Financial Advisors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.22<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Valid Issuance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Capital Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. The Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock has been duly reserved for issuance, and upon issuance in accordance with the terms of the Certificate of Designation, will be validly issued, fully paid and nonassessable.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.23<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Privacy and Data Security</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and its Subsidiaries are and since January 1, 2023, have been in compliance with all applicable Privacy Laws and the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with Parent or any of its Subsidiaries in connection with the operation of Parent&#8217;s and its Subsidiaries&#8217; business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, Parent (i) has implemented and maintains reasonable Privacy Policies that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information and (ii) has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, no Legal Proceeding has been asserted or threatened against Parent by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of Parent, there have been no data security incidents or data breaches, or other adverse events or incidents that have resulted in any unauthorized access to, or collection, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of Parent or any service provider acting on behalf of Parent, in each case, where such incident, breach, or event has resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Parent Contract.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.24<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Other Representations or Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither the Company nor any of its Subsidiaries nor any other person on behalf of the Company or its Subsidiaries makes any express or implied representation or warranty with respect to the Company or its Subsidiaries or with respect to any other information provided to Parent, Merger Subs or stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (in each case as qualified and limited by the Company Disclosure Letter)) none of Parent, Merger Subs nor any of their respective Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Covenants of the Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Operation of Parent&#8217;s Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv) unless the Company shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Pre-Closing Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (x) conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Parent Material Contracts and (y) continue to pay material outstanding accounts payable and other material current Liabilities (including payroll) when due and payable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#160;of the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv)&#160;with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit any of Subsidiaries to, do any of the following:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities, (except for shares of Parent Common Stock from terminated employees, directors or consultants of Parent);</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A) any capital stock or other security (except for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options or Parent Restricted Stock Units, as applicable), (B)&#160;any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>form any Subsidiary or acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) lend money to any Person, (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others or (D) make any capital expenditure or commitment in excess of $25,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) adopt, establish or enter into any Parent Employee Plan, including, for the avoidance of doubt, any equity awards plans, (B) cause or permit any Parent Employee Plan to be amended other than as required by law or in order to make amendments for the purposes of compliance with Section&#160;409A of the Code, (C) pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of this Agreement pursuant to any Parent Employee Plan disclosed to the Company), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or consultants, (D)&#160;increase the severance or change of control benefits offered to any current or new employees, directors or consultants, or (E)&#160;hire any officer, employee or consultant;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, assign, transfer, license, sublicense or otherwise dispose of any material Parent IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business: (A) make, change or revoke any material Tax election; (B) file any amended income or other material Tax Return; (C) adopt or change any material accounting method in respect of Taxes; (D) enter into any material Tax closing agreement, settle any material Tax claim or assessment; (E) consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment; or (F) surrender any material claim for refund;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>waive, settle or compromise any pending or threatened Legal Proceeding against Parent or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of Parent or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>forgive any loans to any Person, including its employees, officers, directors or Affiliate;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiv)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) materially change pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B) agree to materially change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent or any of Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xv)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into, amend in a manner adverse to Parent or terminate any Parent Material Contract outside of the Ordinary Course of Business; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvi)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>agree, resolve or commit to do any of the foregoing.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the First Effective Time. Prior to the First Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding any provision herein to the contrary (including the foregoing provisions of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), Parent may:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or winding down of the Parent Legacy Business (including terminating its Parent Real Estate Leases and other Parent Contracts) or the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or other disposition of any Parent Legacy Business (each, an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Legacy Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that to the extent any Parent Legacy Transaction results in material obligations of Parent that will extend beyond Closing, such terms shall be reasonably acceptable to the Company and any such post-Closing obligations shall be a reduction to Parent Net Cash; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare and pay a dividend on the shares of Parent Common Stock outstanding prior to the First Effective Time (excluding for the avoidance of doubt any shares of Parent Common Stock issuable pursuant to the Contemplated Transactions), up to an amount equal in the aggregate to Parent&#8217;s reasonable, good faith approximation of the amount by which Parent Net Cash will exceed $5,000,000 (such dividend, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and such amount, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Pre-Closing Dividend Amount</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Operation of the Company&#8217;s Business.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (iii) as required by applicable Law, (iv) with respect to the issuance of any Company Notes, which is expressly permitted, or (v)&#160;unless Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period the Company shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Company Material Contracts.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement, including the Subscription Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (iii) as required by applicable Law, (iv) with respect to the issuance of any Company Notes, which is expressly permitted, or (v) with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of Company Capital Stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company);</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>except as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries&#8217; Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business, sell, issue grant, or authorize any of the foregoing actions with respect to more than 25% of the shares of Company Capital Stock outstanding as of the date of this Agreement: (A) any capital stock or other security of the Company or any of its Subsidiaries (except for shares of outstanding Company Common Stock issued upon the valid exercise of Company Options or Company Warrants), (B) any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business, acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) lend money to any Person, (B) incur or guarantee any indebtedness for borrowed money, or (C) guarantee any debt securities of others;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, assign, transfer, license, sublicense or otherwise dispose of any material Company IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>waive, settle or compromise any pending or threatened Legal Proceeding against the Company, other than waivers, settlements or agreements (A) for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of the Company or any equitable relief on, or the admission of wrongdoing by the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into, amend in a manner adverse to the Company or terminate any Company Material Contract outside of the Ordinary Course of Business; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>agree, resolve or commit to do any of the foregoing.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the First Effective Time. Prior to the First Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Access and Investigation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (a) provide the other Party and such other Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries, (b) provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request, (c) permit the other Party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party&#8217;s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary, and (d) make </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">available to the other Party copies of any material notice, report or other document filed with or sent to or received from any Governmental Authority in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything herein to the contrary in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, no access or examination contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be permitted to the extent that it would require any Party or its Subsidiaries to waive the attorney-client privilege or attorney work product privilege, or violate any applicable Law; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that such Party or its Subsidiary (i) shall be entitled to withhold only such information that may not be provided without causing such violation or waiver, (ii) shall provide to the other Party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information) and (iii) shall enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other Party in order that all such information may be provided to the other Party without causing such violation or waiver.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and the Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize or permit any of its Representatives to, directly or indirectly: (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry, (ii)&#160;furnish any non-public information regarding such Party to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry, (iv)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction or (v) publicly propose to do any of the foregoing; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that, notwithstanding anything contained in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to compliance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, prior to the approval of this Agreement by a Party&#8217;s stockholders (i.e., the Required Company Stockholder Vote, in the case of the Company and its Subsidiaries, or the Required Parent Stockholder Vote in the case of Parent), such Party may furnish non-public information regarding such Party and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal by such Person which such Party&#8217;s board of directors determines in good faith, after consultation with such Party&#8217;s financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of this Agreement, (B) the board of directors of such Party concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the board of directors&#8217; fiduciary duties under applicable Law, (C) at least two&#160;(2) Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such Person, such Party gives the other Party written notice of the identity of such Person and of such Party&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such Person, (D) such Party receives from such Person an executed Acceptable Confidentiality Agreement and (E) at least two&#160;(2) Business Days prior to furnishing any such nonpublic information to such Person, such Party furnishes such nonpublic information to the other Party (to the extent such information has not been previously furnished by such Party to the other Party). Without limiting the generality of the foregoing, each Party acknowledges and agrees that, in the event any Representative of such Party takes any action that, if taken by such Party, would constitute a breach of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by such Party, the taking of such action by such Representative shall be deemed to constitute a breach of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by such Party for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If any Party or any Representative of such Party receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then such Party shall promptly (and in no event later than one&#160;(1) Business Day after such Party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other Party in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such Party shall keep the other Party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information provided to such Person.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notification of Certain Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. During the Pre-Closing Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a) any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions, (b)&#160;any Legal Proceeding against or involving or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge of such Party, threatened against such Party or, to the Knowledge of such Party, any director or officer of such Party, (c) such Party becomes aware of any inaccuracy in any representation or warranty made by such Party in this Agreement or (d) the failure of such Party to comply with any covenant or obligation of such Party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, as applicable, impossible or materially less likely. No such notice shall be deemed to supplement or amend the Company Disclosure Letter or the Parent Disclosure Letter for the purpose of (x)&#160;determining the accuracy of any of the representations and warranties made by the Company in this Agreement or (y) determining whether any condition set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> has been satisfied. Any failure by either Party to provide notice pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be deemed to be a breach for purposes of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, as applicable, unless such failure to provide such notice was knowing and intentional.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Agreements of the Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Registration Statement, Proxy Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As promptly as practicable after the date of this Agreement, Parent, in cooperation with the Company, shall prepare and file with the SEC a registration statement on Form S-4 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Form S-4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in which a proxy statement relating to the Parent Stockholder Meeting to be held in connection with the Merger (together with any amendments thereof or supplements thereto, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Proxy Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be included as a part (the Proxy Statement and the Form S-4, collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Registration Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in connection with the registration under the Securities Act of the shares of Parent Common Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) to be issued by virtue of the Contemplated Transactions, other than any shares of Parent Capital Stock which are not permitted to be registered on Form S-4 pursuant to applicable Law. Parent shall use commercially reasonable efforts to (i) cause the Registration Statement to comply with applicable rules and regulations promulgated by the SEC, (ii) cause the Registration Statement to become effective as promptly as practicable, and (iii) respond promptly to any comments or requests of the SEC or its staff related to the Registration Statement. Parent shall use commercially reasonable efforts to take all actions required under any applicable federal, state, securities and other Laws in connection with the issuance of shares of Parent Capital Stock pursuant to the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock). Each of the Parties shall reasonably cooperate with the other Party and furnish all information concerning itself and its Affiliates, as applicable, to the other Parties that is required by law to be included in the Registration Statement as the other Parties may reasonably request in connection with such actions and the preparation of the Registration Statement and Proxy Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL and DLLCA, and (ii)&#160;will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company covenants and agrees that the information supplied by or on behalf of the Company to Parent for inclusion in the Registration Statement (including the Company Budget) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, neither Party makes any covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided by the other Party or any of its Representatives regarding such other Party or its Affiliates for inclusion therein.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. If at any time before the First Effective Time, (i)&#160;Parent, Merger Subs or the Company (A) become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, (B) receives notice of any SEC request for an amendment or supplement to the Registration Statement or for additional information related thereto, or (C) receives SEC comments on the Registration Statement, or (ii) the information provided in the Registration Statement has become &#8220;stale&#8221; and new information should be disclosed in an amendment or supplement to the Registration Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in Parent filing such amendment or supplement with the SEC (and, if appropriate, in mailing such amendment or supplement to the Parent stockholders) or otherwise addressing such SEC request or comments and each Party and shall use their commercially reasonable efforts to cause any such amendment to become effective, if required. Parent shall promptly notify the Company if it becomes aware (1) that the Registration Statement has become effective, (2) of the issuance of any stop order or suspension of the qualification or registration of the Parent Capital Stock issuable in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) for offering or sale in any jurisdiction, or (3) any order of the SEC related to the Registration Statement, and shall promptly provide to the Company copies of all written correspondence between it or any of its Representatives, on the one hand, and the SEC or staff of the SEC, on the other hand, with respect to the Registration Statement and all orders of the SEC relating to the Registration Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company shall reasonably cooperate with Parent and provide, and cause its Representatives to provide, Parent and its Representatives, with all true, correct and complete information regarding the Company that is required by Law to be included in the Registration Statement or reasonably requested by Parent to be included in the Registration Statement (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Required S-4 Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Without limiting the foregoing, the Company will use commercially reasonable efforts to cause to be delivered to Parent a consent letter of the Company&#8217;s independent accounting firm, dated no more than two (2) Business Days before the date on which the Registration Statement is filed with the SEC (and reasonably satisfactory in form and substance to Parent), that is customary in scope and substance for consent letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement. The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC. Parent may file the Registration Statement, or any amendment or supplement thereto, without the prior consent of the Company, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent has included the Company Required S-4 Information in the Registration Statement in substantially the same form as it was provided to Parent by the Company pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if the prior consent of the Company is not obtained then, notwithstanding anything else herein, the Company makes no covenant or representation regarding the portion of such information supplied by or on behalf of the Company to Parent for inclusion in such Registration Statement that the Company reasonably identifies prior to such filing of the Registration Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As promptly as reasonably practicable following the date of this Agreement, the Company will use commercially reasonable efforts to furnish to Parent (i) audited financial statements for each of its fiscal years required to be included in the Registration Statement, or an audited period balance sheet, as applicable (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Audited Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) unaudited interim financial statements for each interim period completed prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Interim Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Each of the Company Audited Financial Statements and the Company Interim Financial Statements will be suitable for inclusion in the Registration Statement and prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto) and on that basis will present fairly, in all material respects, the financial position and the results of operations, changes in stockholders&#8217; equity and cash flows of the Company as of the dates of and for the periods referred to in the Company Audited Financial Statements or the Company Interim Financial Statements, as the case may be.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Stockholder Written Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than two (2) Business Days thereafter, the Company shall obtain the approval by written consent from Company stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to Section&#160;228 of the DGCL, for purposes of (i)&#160;adopting and approving this Agreement and the Contemplated Transactions, (ii) acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (iii) acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stockholder Written Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Under no circumstances shall the Company assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Reasonably promptly following receipt of the Required Company Stockholder Vote, and in any event no later than ten (10) days thereafter, the Company shall prepare and mail a notice (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Stockholder Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) to every stockholder of the Company that did not execute the Company Stockholder Written Consent. The Stockholder Notice shall (i) be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with Section&#160;251(b) of the DGCL and in the best interests of the stockholders of the Company and approved and adopted this Agreement, the Merger and the other Contemplated Transactions, (ii) provide the stockholders of the Company to whom it is sent with notice of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with Section&#160;228(e) of the DGCL and the certificate of incorporation and bylaws of the Company and (iii) include a description of the appraisal rights of the Company&#8217;s stockholders available under the DGCL, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be subject to Parent&#8217;s advance review and reasonable approval.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company agrees that, subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">: (i) the Company Board shall recommend that the Company&#8217;s stockholders vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the recommendation of the Company Board that the Company&#8217;s stockholders vote to adopt and approve this Agreement being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board Recommendation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to compliance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, if at any time prior to approval and adoption of this Agreement by the Required Company Stockholder Vote, (i) the Company receives a bona fide written Acquisition Proposal that the Company Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii) as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B) the fact, in and of itself, that the Company meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of the Company that occurs or arises after the date of this Agreement (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Intervening Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company Board may withhold, amend, withdraw or modify the Company Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Company Board Recommendation) in a manner adverse to Parent (collectively, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board Adverse Recommendation Change</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the Company Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) the Company has, during the Notice Period (as defined below), negotiated with Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii) if, Parent has delivered </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">to the Company a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (1) Parent receives written notice from the Company confirming that the Company Board has determined to change its recommendation at least four&#160;(4) Business Days in advance of the Company Board Adverse Recommendation Change (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Notice Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), which notice shall include a description in reasonable detail of the reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2) during any Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Company&#8217;s stockholders would receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and the Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in the case of a Company Intervening Event, the Company promptly notifies Parent, in writing, within the Notice Period before making a Company Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Company Intervening Event and that the Company Board intends to make a Company Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company&#8217;s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or Acquisition Inquiry, or by any Company Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Stockholder Meeting</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock to consider and vote to approve this Agreement and thereby approve the Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent the approval of the Parent Legacy Transaction (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stockholder Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and such meeting, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stockholder Meeting</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Parent Stockholder Meeting shall be held as promptly as practicable after the date that the Registration Statement is declared effective under the Securities Act, and in any event, no later than 45 days after the effective date of the Registration Statement. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably believes that (i) it will not receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not a quorum would be present, (ii) it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholder Meeting or (iii) that the failure to postpone or adjourn the Parent Stockholder Meeting would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent Stockholder Meeting is not postponed or adjourned more than an aggregate of 30 days in connection with any postponements or adjournments.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent agrees that (i) the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> above and (ii) the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s stockholders vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board Recommendation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to compliance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, if at any time prior to approval and adoption of this Agreement by the Required Parent Stockholder Vote, (i) Parent receives a bona fide written Acquisition Proposal that the Parent Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, the Parent Board may withhold, amend, withdraw or modify the Parent Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company or (ii) as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, (B) the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations or (C) any Parent Legacy Transaction) that affects the business, assets or operations of Parent that occurs or arises after the date of this Agreement (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Intervening Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), (collectively, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board Adverse Recommendation Change</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the Parent Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) Parent has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period (as defined below), negotiated with the Company in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, and (iii) if, after the Company has delivered to Parent a written offer to alter the terms or conditions of this Agreement during the Parent Notice Period, the Parent Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (1) the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation at least four (4) Business Days in advance of the Parent Board Adverse Recommendation Change (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Notice Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2) during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Parent&#8217;s stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the Parent Board shall not make a Parent Board Adverse Recommendation Change prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period before making a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s obligation to call, give notice of and hold the Parent Stockholder Meeting in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer, Acquisition Proposal or Acquisition Inquiry, or by any Parent Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Nothing contained in this Agreement shall prohibit Parent or the Parent Board from (i) complying with Rules&#160;14d-9 and 14e-2(a) promulgated under the Exchange Act; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that any disclosure made by Parent or the Parent Board pursuant to Rules&#160;14d-9 and 14e-2(a) shall be limited to a statement that Parent is unable to take a position with respect to the bidder&#8217;s tender offer unless the Parent Board determines in good faith, after consultation with its outside legal counsel, that such statement would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; (ii) complying with Item 1012(a) of Regulation </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">M-A promulgated under the Exchange Act; (iii) informing any Person of the existence of the provisions contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; or (iv) making any disclosure to the stockholders of Parent that the Parent Board (or a committee thereof), after consultation with its outside legal counsel, has determined in good faith is required by applicable Law.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Efforts; Regulatory Approvals.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties shall use reasonable best efforts to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each Party: (i) shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii) shall use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iii) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv)&#160;shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding the generality of the foregoing, each Party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental Authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Authority. Without limiting the generality of the foregoing, the Parties shall prepare and file, if required, (a) the notification and report forms required to be filed under the Hart&#8211;Scott&#8211;Rodino Antitrust Improvements Act of 1976 and (b) any notification or other document required to be filed in connection with the Merger under any applicable foreign Law relating to antitrust or competition matters, no later than ten (10) Business Days after the date the Company and Parent receive notification (in writing or otherwise) from the Federal Trade Commission, the Department of Justice, any state attorney general, foreign antitrust or competition authority or other Governmental Authority that a filing is required in connection with antitrust or competition matters.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Without limiting the generality of the foregoing, Parent shall give the Company prompt written notice (email being sufficient) of any litigation against Parent and/or its directors relating to this Agreement or the Contemplated Transactions (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transaction Litigation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (including by providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status thereof. Parent will (i) give the Company the opportunity to participate in, but not control, the defense, settlement or prosecution of any Transaction Litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent and the Company will use commercially reasonable efforts to find alternative solutions to not undermine or adversely effect the privilege such as entering into common interest agreements, joint defense agreements or similar agreements), (ii) consult with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation and (iii) consider in good faith the Company&#8217;s advice with respect to such Transaction Litigation. Parent will obtain the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed) prior to settling or satisfying any such claim.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Options; Company Warrants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, Parent shall assume each Company Stock Plan and each Company Option, whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Common Stock and shall be converted, at the First Effective Time, into an option to purchase shares of Parent Common Stock (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Assumed Option</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Company Option as of immediately prior to the First Effective Time, except for administrative or ministerial changes as determined by the Company Board (or, following the First Effective Time, the Parent Board or compensation committee). The number of shares of Parent Common Stock subject to each such Assumed Option shall be equal to (i) the number of shares of Company Common Stock subject to the respective Company Option immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Option shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to the respective Company Option immediately prior to the First Effective Time divided by (B) the Exchange Ratio; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the case of any Company Option </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">to which Section&#160;421 of the Code applies as of immediately prior to the First Effective Time (taking into account the effect of any accelerated vesting thereof, if applicable) by reason of its qualification under Section&#160;422 of the Code, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;424(a) of the Code; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the case of any Assumed Option to which Section&#160;409A of the Code applies as of the First Effective Time, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;409A of the Code in order to avoid the imposition of any additional taxes thereunder. The Company Board shall, prior to the First Effective Time, take all actions necessary to effect the foregoing.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, each Company Warrant (including any pre-funded Company Warrant issued pursuant to the Company Pre-Closing Financing), whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Capital Stock and shall be converted, at the First Effective Time, into a warrant to purchase shares of Parent Common Stock (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Assumed Warrant</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Assumed Warrant as of immediately prior to the First Effective Time. The number of shares of Parent Common Stock subject to each such Assumed Warrant shall be equal to (i) the number of shares of the Company Common Stock subject to each Assumed Warrant immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Warrant shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to such Assumed Warrant immediately prior to the First Effective Time divided by (B) the Exchange Ratio.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee Benefits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall comply with the terms of any employment, severance, retention, change of control, or similar agreement specified on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or contemplated by </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, subject to the provisions of such agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, with respect to each benefit plan maintained by Parent or the Surviving Entity that is an &#8220;employee welfare benefit plan&#8221; as defined in Section&#160;3(1) of ERISA (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Post-Closing Welfare Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) in which any current or former employee of Parent is or becomes eligible to participate (including under COBRA), Parent and the Surviving Entity shall use commercially reasonable efforts to cause each such Post-Closing Welfare Plan to (i) waive all limitations as to pre-existing conditions, waiting periods, required physical examinations and exclusions with respect to participation and coverage requirements applicable under such Post-Closing Welfare Plan for such current or former Parent employee and his or her eligible dependents to the same extent that such pre-existing conditions, waiting periods, required physical examinations and exclusions would not have applied or would have been waived under the corresponding Parent Employee Plan in which such current or former Parent employee was a participant immediately prior to his or her commencement of participation in such Post-Closing Welfare Plan, and (ii) provide each such current or former Parent employee and his or her eligible dependents with credit for any co-payments and deductibles paid in the plan year that includes the First Effective Time, and prior to the date that, such current or former Parent employee commences participation in such Post-Closing Welfare Plan in satisfying any applicable co-payment or deductible requirements under such Post-Closing Welfare Plan for the applicable plan year, to the extent that such expenses were recognized for such purposes under the comparable Parent Employee Plan.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of immediately prior to the First Effective Time, each Parent Option that is then outstanding but not then vested or exercisable shall become immediately vested and exercisable in full. At the First Effective Time, each In the Money Parent Option that is then outstanding shall be canceled and the holder thereof shall be entitled to receive (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A) the excess of the Parent Closing Price over the exercise price per share of the Parent Common Stock underlying such Parent Option by (B) the number of shares of the Parent Common Stock underlying such Parent Option (such amount, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stock Option Cash Consideration</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Parent shall cause the Surviving Entity to pay the Parent Stock Option Cash Consideration, less applicable withholdings, at or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">within ten (10) business days after the First Effective Time. At the First Effective Time, each Out of the Money Parent Option shall be cancelled for no consideration. Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Indemnification of Officers and Directors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, each of Parent and the Surviving Entity shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the First Effective Time, a director or officer of Parent or the Company, respectively (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">D&amp;O Indemnified Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Costs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Parent or of the Company, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL. Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Entity, jointly and severally, upon receipt by Parent or the Surviving Entity from the D&amp;O Indemnified Party of a request therefor; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. Without otherwise limiting the D&amp;O Indemnified Parties&#8217; rights with regards to counsel, following the First Effective Time, the D&amp;O Indemnified Parties shall be entitled to continue to retain Wilson Sonsini Goodrich &amp; Rosati or such other counsel selected by the D&amp;O Indemnified Parties.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation and bylaws of the Surviving Entity shall contain, and Parent shall cause the certificate of incorporation and bylaws of the Surviving Entity to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, (i) the Surviving Entity shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#8217;s Organizational Documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time and (ii) Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#8217;s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, Parent shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase at its sole expense, prior to the First Effective Time, a six (6) year prepaid &#8220;D&amp;O tail policy&#8221; for the non-cancelable extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six (6) years from and after the First Effective Time with respect to any claim related to any period of time at or prior to the First Effective Time with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under Parent&#8217;s existing policies as of the date of this Agreement, or otherwise acceptable to Parent, except that Parent will not commit or spend on such &#8220;D&amp;O Tail policy&#8221; annual premiums in excess of 250% of the annual premiums paid by Parent in its last full fiscal year prior to the date hereof for Parent&#8217;s current policies of directors&#8217; and officers&#8217; liability insurance and fiduciary liability insurance (nor, for the avoidance of doubt, shall Parent be obligated to spend any specific amount), and if such premiums for such &#8220;D&amp;O tail policy&#8221; would exceed 250% of such annual premium, then Parent shall purchase policies that provide the maximum coverage available at an annual premium equal to 250% of such annual premium. The Company shall in good faith cooperate with Parent prior to the First Effective Time with respect to the procurement of such &#8220;D&amp;O tail policy.&#8221;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-62</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, Parent shall pay all expenses, including reasonable attorneys&#8217; fees, that are incurred by the persons referred to in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in connection with their enforcement of the rights provided to such persons in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The provisions of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event Parent or the Surviving Entity or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall cause the Surviving Entity to perform all of the obligations of the Surviving Entity under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Unless directed otherwise by the Company in writing no less than three&#160;(3)&#160;Business Days before the Closing Date, Parent shall use reasonable best efforts to take all actions as are necessary to terminate any 401(k) or other plan(s) with a cash or deferred arrangement (as defined in Section&#160;401(k) of the Code), effective as of no later than the day immediately preceding the Closing Date.  Parent shall provide the Company copies of all such corporate actions or documentation related to the same at least three (3) Business Days before their adoption or approval for the Company&#8217;s reasonable review and comment.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Disclosure</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent&#8217;s Form 8-K announcing the execution and delivery of this Agreement. Without limiting any Party&#8217;s obligations under the Confidentiality Agreement, no Party shall, and no Party shall permit any of its Subsidiaries or any of its Representative to, issue any press release or make any public disclosure regarding the Contemplated Transactions unless: (a) the other Party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b) such Party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure is required by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such Party advises the other Party of, and consults with the other Party regarding, the text of such press release or disclosure; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that each of the Company and Parent may make any public statement in response to specific questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements are consistent with previous press releases, public disclosures or public statements made by the Company or Parent in compliance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding the foregoing, a Party need not consult with any other Parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Listing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. At or prior to the First Effective Time, Parent shall use its commercially reasonable efforts to (a) maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq, (b) to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance); (c) prepare and timely submit to Nasdaq a notification form for the Nasdaq Reverse Split (if required) and to submit a copy of the amendment to Parent&#8217;s certificate of incorporation effecting the Nasdaq Reverse Split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the Closing Date; and (d) to the extent required by Nasdaq Marketplace Rule&#160;5110, assist the Company in preparing and filing an initial listing application for the Parent Common Stock on Nasdaq (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Listing Application</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time. Each Party will reasonably promptly inform the other Party of all verbal or written communications between Nasdaq and such Party or its representatives. The Parties will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations. The Party not filing the Nasdaq Listing Application will cooperate with the other Party as reasonably requested by such filing Party with respect to the Nasdaq Listing Application and promptly furnish to such filing Party all information concerning itself and its members that may be required or reasonably requested in connection </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-63</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with any action contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All Nasdaq fees associated with any action contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, including any fees related to the engagement of a consultant (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Fees</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), shall be shared equally by the Company and Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties shall use reasonable best efforts (and each shall cause its Affiliates) to cause the Merger to qualify for the Intended Tax Treatment. No Party shall take any actions, or fail to take any action, which action or failure to act would reasonably be expected to prevent or impede the Intended Tax Treatment. The Parties shall report the Contemplated Transactions for all applicable Tax purposes in a manner that is consistent with the Intended Tax Treatment. No Party shall take any position that is inconsistent with the Intended Tax Treatment during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a determination within the meaning of Section&#160;1313(a) of the Code. The Parties shall comply with the recordkeeping and information reporting requirements imposed on them, including, but not limited to, those set forth in Treasury Regulation Section&#160;1.368-3.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall promptly notify the Company if, at any time before the First Effective Time, Parent becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment. The Company shall promptly notify Parent if, at any time before the First Effective Time, the Company becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the SEC requires that an opinion with respect to the Intended Tax Treatment be prepared and submitted in connection with the Registration Statement and Proxy Statement, (i) the Company shall use its reasonable best efforts to cause Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) to furnish an opinion (as so required and subject to customary assumptions and limitations), (ii) Parent shall use its reasonable best efforts to cause Wilson Sonsini Goodrich &amp; Rosati (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) to furnish an opinion (as so required and subject to customary assumptions and limitations), and (iii) Parent and the Company shall each deliver to each of Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) and Wilson Sonsini Goodrich &amp; Rosati (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) a Tax certificate, dated as of the date the Registration Statement and Proxy Statement shall have been declared effective by the SEC and signed by an officer of Parent or the Company, as applicable, containing customary representations and covenants reasonably acceptable to the Company and Parent, as applicable, in each case, as reasonably necessary and appropriate to enable such advisors to render such opinions (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax Certificates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Each of Parent and the Company shall use its commercially reasonable efforts not to take or cause to be taken any action that would cause to be untrue (or fail to take or cause not to be taken any action which would cause to be untrue) any of the Tax certifications, covenants or representations included in the Tax Certificates.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and the Company shall reasonably cooperate in the preparation, execution and filing of all Tax Returns, questionnaires, applications or other documents regarding any real property transfer, sales, use, transfer, value added, stock transfer and stamp taxes, and transfer, recording, registration and other fees and similar Taxes which become payable in connection with the Merger that are required or permitted to be filed on or before the First Effective Time. Each of Parent and the Company shall pay, without deduction from any consideration or other amounts payable or otherwise deliverable pursuant to this Agreement and without reimbursement from the other party, any such Taxes or fees imposed on it by any Governmental Authority, which becomes payable in connection with the Merger.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legends</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Parent Capital Stock to be received in the Merger by equityholders of the Company who may be considered &#8220;affiliates&#8221; of Parent for purposes of Rules&#160;144 and 145 under the Securities Act reflecting the restrictions set forth in Rules&#160;144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for any such shares of Parent Capital Stock.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Officers and Directors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the Parties shall use commercially reasonable efforts and take all necessary action so that the Persons listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter are elected or appointed, as applicable, to </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-64</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">the positions of officers or directors of Parent and the Surviving Entity, as set forth therein, to serve in such positions effective as of the Second Effective Time. If any Person listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving Entity, as set forth therein, the Party appointing such Person (as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter) shall designate a successor. The Parties shall use reasonable best efforts to have each of the Persons that will serve as directors and officers of the Parent following the Closing to execute and deliver a Lock-Up Agreement prior to Closing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination of Certain Agreements and Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of Parent and the Company shall cause any stockholder agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar Contracts between either Parent or the Company and any holders of Parent Common Stock or Company Capital Stock, respectively, including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director registration rights, to be terminated immediately prior to the First Effective Time, without any liability being imposed on the part of Parent or the Surviving Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;16 Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Prior to the First Effective Time, Parent shall take all such steps as may be required to cause any acquisitions of Parent Common Stock and any options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to Parent, to be exempt under Rule&#160;16b-3 promulgated under the Exchange Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Allocation Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company will prepare and deliver to Parent prior to the Closing a spreadsheet setting forth (as of immediately prior to the First Effective Time) (a) each holder of Company Capital Stock, (b)&#160;such holder&#8217;s name and address, (c) the number or percentage and type of Company Capital Stock held as of the Closing Date for each such holder and (d) the number of shares of Parent Capital Stock to be issued to such holder pursuant to this Agreement in respect of the Company Capital Stock held by such holder as of immediately prior to the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Allocation Certificate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. From the date of this Agreement to the First Effective Time, Parent shall use commercially reasonable efforts to timely file with the SEC all registration statements, proxy statements, Certifications, reports, schedules, exhibits, forms and other documents required to be filed by Parent with the SEC under the Exchange Act or the Securities Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each SEC Document filed by Parent with the SEC (a) shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act, and (b) shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Wind-Down Activities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Following the Closing, Parent shall use its commercially reasonable efforts to continue the wind-down activities of Parent associated with the Parent Legacy Business, including termination of its research and development activities set forth on Section&#160;6.17 of the Parent Disclosure Letter.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Obligations of Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent will take all action necessary to cause each Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Pre-Closing Financing Restructuring</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event the structure of the Company Pre-Closing Financing either violates applicable Law or materially and adversely effects Parent&#8217;s ability to cause the Registration Statement to become effective in a timely manner, and in any event 60 days prior to the End Date, then Parent and the Company shall, and shall use their reasonable best efforts to cause the investors in the Company Pre-Closing Financing, to cause the Company Pre-Closing Financing to be amended, modified and/or restructured such that such investment occurs as a direct acquisition of shares of Parent Common Stock substantially contemporaneously with the Closing in a manner which preserves to the extent possible, the amount of funds ultimately received by Parent and its Subsidiaries, and the number of Parent shares ultimately held by the investor in respect of such amounts as though the Company Pre-Closing Financing has been consummated by its terms.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-65</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If Parent declares the Parent Pre-Closing Dividend, then, prior to the First Effective Time, Parent shall deposit the Parent Pre-Closing Dividend Amount with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Common Stock outstanding as of the record date of the Parent Pre-Closing Dividend.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Re-Domestication</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The parties shall discuss in good faith whether to change the domicile of Parent prior to the First Effective Time.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conditions Precedent to Obligations of Each Party</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effectiveness of Registration Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or Legal Proceeding seeking a stop order with respect to the Registration Statement that has not been withdrawn. Any material state securities laws applicable to the issuance of the shares of Parent Capital Stock in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) shall have been complied with and no stop order (or similar order) shall have been issued in respect of such shares of Parent Capital Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) by any applicable state securities commissioner or court of competent jurisdiction.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Regulatory Approvals</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any applicable waiting periods (or any extensions thereof) under the HSR Act (if applicable) shall have expired or otherwise been terminated.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Restraints</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No Order preventing the consummation of the Contemplated Transactions shall have been issued by any Governmental Authority of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder Approval</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. (a) Parent shall have obtained the Required Parent Stockholder Vote (but solely with respect to such items as are necessary to consummate the transactions contemplated by this Agreement) and (b) the Company shall have obtained the Required Company Stockholder Vote.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Listing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Nasdaq Listing Application shall have been approved by Nasdaq.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lock-Up Agreements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Lock-Up Agreements shall be in full force and effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Charter Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certificate of Designation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall have filed the Certificate of Designation with the Secretary of State of the State of Delaware.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Conditions Precedent to Obligations of Parent and Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Accuracy of Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Company Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(x), as of such particular date). The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-66</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and the Company Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Performance of Covenants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall have received the following documents, each of which shall be in full force and effect:</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i) that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;8.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.6</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> have been duly satisfied and (ii) that the information (other than emails and addresses) set forth in the Allocation Certificate delivered by the company in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.15</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> is true and accurate in all respects as of the Closing Date;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate pursuant to Treasury Regulations Sections&#160;1.1445-2(c) and 1.897-2(h), together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section&#160;1.897-2(h), in each case, in form and substance reasonably acceptable to Parent;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Company Valuation Schedule; and</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Allocation Certificate.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Company Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of this Agreement, there shall not have occurred any Company Material Adverse Effect that is continuing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Stockholder Written Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company Stockholder Written Consent executed by the stockholders of the Company shall be in full force and effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Pre-Closing Financing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Subscription Agreement (as may be amended, restated or supplemented pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) shall be in full force and effect and proceeds of not less than $175,000,000 (including in the proceeds any Company Notes contributed as consideration in the Company Pre-Closing Financing) shall have been received by the Company (or, if applicable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, Parent or one or more of its affiliates) or will be received by the Company (or, if applicable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, Parent or one or more of its affiliates) substantially simultaneously with the Closing in connection with the consummation of the transactions contemplated by the Subscription Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If Parent declares the Parent Pre-Closing Dividend, then the Parent Pre-Closing Dividend Amount shall have been deposited by Parent with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Common Stock outstanding as of the record date of the Parent Pre-Closing Dividend.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Conditions Precedent to Obligation of the Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Accuracy of Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Parent Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-67</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(x), as of such particular date). The representations and warranties of Parent and Merger Subs contained in this Agreement (other than the Parent Fundamental Representations and the Parent Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Performance of Covenants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and Merger Subs shall have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company shall have received the following documents, each of which shall be in full force and effect:</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate executed by an executive officer of Parent certifying that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;9.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">9.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> have been duly satisfied;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>written resignations in forms satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by the officers and directors of Parent who are not to continue as officers or directors of Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> hereof; and</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Parent Net Cash Schedule.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Parent Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect that is continuing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.1<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement may be terminated prior to the First Effective Time (whether before or after adoption of this Agreement by the Company&#8217;s stockholders and whether before or after approval of the Parent Stockholder Matters by Parent&#8217;s stockholders, unless otherwise specified below):</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by mutual written consent of Parent and the Company;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if the Merger shall not have been consummated by October 3, 2024 (subject to possible extension as provided in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">End Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the right to terminate this Agreement under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be available to the Company or Parent if such Party&#8217;s (or in the case of Parent, Merger Subs&#8217;) action or failure to act has been a principal cause of the failure of the Merger to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that, in the event that the SEC has not declared effective under the Securities Act the Registration Statement by the date which is sixty (60) days prior to the End Date, then either the Company or Parent shall be entitled to extend the End Date for an additional sixty (60)&#160;days;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if a court of competent jurisdiction or other Governmental Authority shall have issued a final and nonappealable Order having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent if the Required Company Stockholder Vote shall not have been obtained within two (2) Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that once the Required Company Stockholder Vote has been obtained, Parent may not terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-68</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if (i) the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent&#8217;s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii)&#160;the Parent Stockholder Matters shall not have been approved at the Parent Stockholder Meeting (or at any adjournment or postponement thereof) by the Required Parent Stockholder Vote; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the right to terminate this Agreement under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be available to Parent where the failure to obtain the Required Parent Stockholder Vote shall have been caused by the action or failure to act of Parent and such action or failure to act constitutes a material breach by Parent of this Agreement;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by the Company (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) if a Parent Triggering Event shall have occurred;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent (at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote) if a Company Triggering Event shall have occurred;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Subs or if any representation or warranty of Parent or Merger Subs shall have become inaccurate, in either case, such that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if such inaccuracy in Parent&#8217;s or Merger Subs&#8217; representations and warranties or breach by Parent or Merger Subs is curable by Parent or Merger Subs, then the Company shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty (30) day period commencing upon delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii) Parent or Merger Subs (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (it being understood that the Company shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy if such breach by Parent or Merger Subs is cured prior to such termination becoming effective);</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if such inaccuracy in the Company&#8217;s representations and warranties or breach by the Company is curable by the Company then Parent shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty&#160;(30)&#160;day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii) the Company ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (it being understood that Parent shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) and following compliance with all of the requirements set forth in the proviso to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(j)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, upon the Parent Board authorizing Parent to enter into a Permitted Alternative Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Parent shall not enter into any Permitted Alternative Agreement unless: (i) Parent shall have complied in all material respects with its obligations under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law and (iii) Parent shall concurrently pay to the Company the Company Termination Fee in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-69</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Party desiring to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) shall give a notice of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.2<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effect of Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event of the termination of this Agreement as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Agreement shall be of no further force or effect; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that (a)&#160;this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.8)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the related definitions of the defined terms in such sections shall survive the termination of this Agreement and shall remain in full force and effect and (b) the termination of this Agreement and the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not relieve any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.3<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Expenses; Termination Fees</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If (i) this Agreement is terminated by Parent or the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or by the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) at any time after the date of this Agreement and prior to the Parent Stockholder Meeting, an Acquisition Proposal with respect to Parent shall have been publicly announced, disclosed or otherwise communicated to the Parent Board (and shall not have been withdrawn) and (iii)&#160;in the event this Agreement is terminated pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, within twelve (12) months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then Parent shall pay to the Company, within ten (10) Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $440,000 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Termination Fee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If this Agreement is terminated (i) by the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (when at the time this Agreement is terminated, the Company had the right to terminate this Agreement pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) then Parent shall pay to the Company within five (5) Business Days of such termination, the Company Termination Fee or (ii) by Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(j)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then Parent shall pay to the Company, concurrent with such termination, the Company Termination Fee.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If (i) this Agreement is terminated by Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(g)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) at any time after the date of this Agreement and before obtaining the Required Company Stockholder Vote, an Acquisition Proposal with respect to the Company shall have been announced, disclosed or otherwise communicated to the Company Board (and shall not have been withdrawn) and (iii) in the event this Agreement is terminated pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, within twelve&#160;(12) months after the date of such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then the Company shall pay to Parent, within ten (10) Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $440,000.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If either Party fails to pay when due any amount payable by it under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then (i) such Party shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii)&#160;such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties agree that, subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the payment of the fees and expenses set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be the sole and exclusive remedy of each Party following a termination of this Agreement under the circumstances described in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, it being understood that in no event shall either Parent or the Company be required to pay the individual fees or damages payable pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> on more than one occasion. Subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, following the payment of the fees and expenses set forth in </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-70</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by a Party, (i) such Party shall have no further liability to the other Party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii) no other Party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Party) in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (iii) all other Parties and their respective Affiliates shall be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the Parties acknowledges that (x) the agreements contained in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> are an integral part of the Contemplated Transactions, (y) without these agreements, the Parties would not enter into this Agreement and (z)&#160;any amount payable pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Parties in the circumstances in which such amount is payable; provided, however, that nothing in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall limit the rights of the Parties under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.10</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;11. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.1<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Survival of Representations and Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The representations and warranties of the Company, Parent and Merger Subs contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the First Effective Time, and only the covenants that by their terms survive the First Effective Time and this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.2<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Subs and Parent at any time (whether before or after the adoption and approval of this Agreement by the Company&#8217;s stockholders or before or after obtaining the Required Parent Stockholder Vote); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that after any such approval of this Agreement by a Party&#8217;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Subs and Parent.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.3<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Waiver</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any provision hereof may be waived by the waiving Party solely on such Party&#8217;s own behalf, without the consent of any other Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.4<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement and the other schedules, exhibits, certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that only Exhibit&#160;D (including Exhibit&#160;A to such Exhibit) is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-71</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.5<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause&#160;(a) of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (c)&#160;waives any objection to laying venue in any such action or proceeding in such courts, (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (f) irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.6<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.7<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one&#160;(1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand or (c) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">if to Parent or Merger Subs:</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO 80021 <br/>Attention: C. Jeffrey Dekker<br/>Email: ***</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with a copy to (which shall not constitute notice):</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Wilson Sonsini Goodrich &amp; Rosati<br/>1881 9</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> Street, Suite 110<br/>Boulder, CO 80302<br/>Attn: Brent Fassett<br/>Email: bfassett@wsgr.com</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Wilson Sonsini Goodrich &amp; Rosati<br/>One Market Plaza, Spear Tower, Suite 3300<br/>San Francisco, CA 94105<br/>Attn: Ethan Lutske, Ross Tanaka<br/>Email: elutske@wsgr.com, rtanaka@wsgr.com</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">if to the Company:</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Oruka Therapeutics, Inc.<br/>221 Crescent Street, Building 23, Suite 105<br/>Waltham, Massachusetts 02453<br/>Attention: Lawrence Klein<br/>Email: ***</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-72</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with a copy to (which shall not constitute notice):</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Gibson, Dunn &amp; Crutcher LLP<br/>One Embarcadero Center, Suite 2600<br/>San Francisco, CA 94111<br/>Attention: Ryan Murr, Branden Berns, Chris Trester<br/>Email: rmurr@gibsondunn.com, bberns@gibsondunn.com, ctrester@gibsondunn.com</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.8<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Cooperation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.9<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.10<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Other Remedies; Specific Performance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.11<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third-Party Beneficiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of page intentionally left blank</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-73</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">In Witness Whereof</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> the Parties have caused this Agreement to be executed as of the date first above written.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ARCA </span><span class="CharOverride-12" style="font-style:normal;font-variant:small-caps;font-weight:bold;">biopharma, Inc</span><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Financial Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ATLAS MERGER SUB CORP.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ATLAS MERGER SUB II, LLC</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Agreement and Plan of Merger and Reorganization</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-74</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">In Witness Whereof</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> the Parties have caused this Agreement to be executed as of the date first above written.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-12" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Oruka Therapeutics, Inc.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Executive Officer</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Agreement and Plan of Merger and Reorganization</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-75</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T101"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;B</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">OPINION OF LUCID CAPITAL MARKETS</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:14pt;">LUCID CAPITAL MARKETS, LLC</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">April&#160;2, 2024</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">ARCA biopharma, Inc.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">10170 Church Ranch Way, Suite 100</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Westminster, CO&#160;80021</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Attention: Robert E.&#160;Conway</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Chairman of the Board of Directors</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Members of the Board of Directors:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have been advised that ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221; or &#8220;Parent&#8221;), proposes to enter into an Agreement and Plan of Merger (the &#8220;Agreement&#8221;), by and among ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of ARCA (&#8220;Merger Sub&#8221;), and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka&#8221; or the &#8220;Company&#8221;). At the Effective Time, Merger Sub will be merged with and into the Company (the &#8220;Merger&#8221;), and the separate existence of the Merger Sub will cease. The Company will continue as the surviving corporation in the Merger (the &#8220;Surviving Corporation&#8221;). Pursuant to the terms of the Agreement, upon consummation of the Merger, each share of Company Capital Stock (other than shares of Company Capital Stock held as treasury stock immediately prior to the Effective Time which shall be canceled and retired and shall cease to exist and excluding Dissenting Shares) will be converted into and become exchangeable for a number of shares of Parent Common Stock equal to the Exchange Ratio. The terms and conditions of the Merger are more fully set forth in the Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Agreement contemplates that Parent may declare and pay a dividend on the shares of Parent Common Stock outstanding prior to the Effective Time (excluding for the avoidance of doubt any shares of Parent Common Stock issuable pursuant to the Contemplated Transactions) up to an amount equal in the aggregate to Parent&#8217;s reasonable, good faith approximation of the amount by which Parent Net Cash will exceed $5,000,000 (the &#8220;Parent Pre<span class="nobreak">-Closing</span> Dividend&#8221;). The Agreement also contemplates that concurrently with the execution and delivery of the Agreement, certain investors will execute a Subscription Agreement pursuant to which such Persons will have agreed to purchase (including by contribution of Company Notes) (i)&#160;shares of Company Common Stock and (ii)&#160;pre<span class="nobreak">-funded</span> Company Warrants, in each case immediately prior to the Effective Time (the &#8220;Company Pre<span class="nobreak">-Closing</span> Financing&#8221;). It is a condition precedent to the obligations of Parent and Merger Sub to effect the Merger that proceeds of not less than $175&#160;million be received from the Company Pre<span class="nobreak">-Closing</span> Financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have assumed, with your consent, that the Parent Net Cash amount is expected to be, and we have assumed, with your consent, that it will be approximately $5.0&#160;million at Closing after taking effecting the Parent Pre<span class="nobreak">-Closing</span> Dividend.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming that the Parent Pre<span class="nobreak">-Closing</span> Dividend has occurred, the holders of Company Common Stock, Company Options and Company Warrants will in the aggregate hold approximately 97.6% of the fully<span class="nobreak">-diluted</span> shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger and the holders of Parent Common Stock will in the aggregate hold approximately 2.4% of the fully<span class="nobreak">-diluted</span> shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger, in each case, after accounting for the Parent Pre<span class="nobreak">-Closing</span> Dividend and the Company Pre<span class="nobreak">-Closing</span> Financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have, with your consent, relied upon the assumption that all information provided to us by ARCA and Oruka is accurate and complete in all material respects. We expressly disclaim any undertaking or obligation to advise any person of any change in any fact or matter affecting our Opinion of which we become aware after the date hereof. We have assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of ARCA or Oruka since the date of the last financial statements made available to </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">us. We have not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of ARCA or Oruka, nor have we been furnished with such materials. In addition, we have not evaluated the solvency or fair value of ARCA or Oruka under any state or federal laws relating to bankruptcy, insolvency or similar matters.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our Opinion does not address any legal, regulatory, tax or accounting matters related to the Merger, as to which we have assumed that ARCA and the Board of Directors have received such advice from legal, tax and accounting advisors as each has determined appropriate. Our Opinion addresses only the fairness from a financial point of view of the Exchange Ratio as set forth in the Merger Agreement to the holders of Parent Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We express no view as to any other aspect or implication of the Merger or any other agreement or arrangement entered into in connection with the Merger. Our Opinion is necessarily based upon economic and market conditions and other circumstances as they exist and can be evaluated by us on the date hereof. It should be understood that although subsequent developments may affect our Opinion, we do not have any obligation to update, revise or reaffirm our Opinion and we expressly disclaim any responsibility to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have not considered any potential legislative or regulatory changes currently being considered or recently enacted by the United&#160;States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission (the &#8220;SEC&#8221;), the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In your capacity as members of the Board of Directors of ARCA (the &#8220;Board of Directors&#8221;), you have requested our opinion (our &#8220;Opinion&#8221;) as to the fairness, from a financial point of view and as of the date hereof, of the Exchange Ratio as set forth in the Agreement to the holders of Parent Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with our Opinion, we took into account an assessment of general economic, market and financial conditions as well as our experience in connection with similar transactions and securities valuations generally and, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed a draft of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain publicly available financial and other information for each of ARCA and Oruka, respectively, including equity research on comparable companies and on ARCA, and certain other relevant financial and operating data furnished to us by the management of each of ARCA and Oruka, respectively;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain relevant historical financial and operating data concerning Oruka furnished to us by the management of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Discussed with certain members of the management of ARCA the historical and current business operations, financial condition and prospects of ARCA and Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain operating results of Oruka as compared to operating results and the reported price and trading histories of certain publicly traded companies that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of completed initial public offerings for certain companies that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed certain pro forma financial effects of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next year, projections as to cost and expenses and whether concurrent capital raised would sufficiently cover select programs, reports, and other information concerning Oruka prepared by Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as we deemed relevant for the purposes of our Opinion.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of rendering our Opinion we have assumed, with your consent, that except as would not be in any way meaningful to our analysis: (i)&#160;the final form of the Agreement will not differ from the Draft Agreement that we have reviewed; (ii)&#160;the representations and warranties of each party contained in the Agreement are true and correct in all respects; (iii)&#160;each party will perform all of the covenants and agreements required to be performed by such party under the Agreement; and (iv)&#160;the transactions contemplated by the Agreement will be consummated in accordance with the terms of the Agreement, without any waiver or amendment of any term or condition thereof. We have also assumed that all governmental, regulatory and other consents and approvals contemplated by the Agreement or otherwise required for the transactions contemplated by the Agreement will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed, or waivers made that would have an adverse effect on ARCA, Oruka, or the contemplated benefits of the Merger. We have assumed that the Merger will be consummated in a manner that complies with the applicable provisions of the Securities Act&#160;of&#160;1933, as amended, the Securities Exchange&#160;Act&#160;of&#160;1934, as amended, and all other applicable federal and state statutes and the rules and regulations promulgated thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is understood that this letter is intended for the benefit and use of the Board of Directors (in its capacity as such) in its consideration of the financial terms of the Merger and, except as set forth in our engagement letter with ARCA, dated as of March&#160;19, 2024 (the &#8220;Engagement Letter&#8221;), may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without our prior written consent, except that this Opinion may be included in its entirety in any filing related to the Merger required to be filed with the SEC and any proxy statement to be mailed to holders of Parent Common Stock. This letter does not constitute a recommendation to the Board of Directors of whether to approve the Merger or to any stockholder of ARCA or any other person as to how to vote or act with respect to the transactions contemplated by the Agreement (including the Merger) or any other matter. Our Opinion does not address ARCA&#8217;s underlying business decision to proceed with the Merger or the relative merits of the Merger compared to other alternatives available to ARCA.&#160;We express no opinion as to the prices or ranges of prices at which shares or the securities of any person, including ARCA, will trade at any time, including following the announcement or consummation of the Merger, or as to the potential effects of volatility in the credit, financial, and stock markets on ARCA, Oruka or the transactions contemplated by the Agreement. We have not been requested to opine as to, and our Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the Merger, or any class of such persons, relative to the compensation to be paid to the holders of Parent Common Stock in connection with the Merger or with respect to the fairness of any such compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid is an investment bank providing investment banking, brokerage, equity research, institutional sales and trading services. As part of our investment banking services, we are regularly engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. We have acted as ARCA&#8217;s financial advisor in connection with the Merger and will receive a fee for our services pursuant to the terms of our Engagement Letter, a significant portion of which is contingent upon consummation of the Merger. In addition, ARCA has agreed to reimburse our expenses and indemnify us for certain liabilities that may arise out of our engagement. We will also receive an additional fee for rendering our Opinion set forth below pursuant to the Engagement Letter, which is not contingent upon consummation of the Merger. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with ARCA or its affiliates and has not received any fees from ARCA or any of its affiliates. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Oruka or any of its affiliates and has not received any fees from Oruka or any of its affiliates. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to ARCA and Oruka and/or their respective affiliates and expect to receive fees for the rendering of these services.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, Lucid or certain of our affiliates, as well as investment funds in which we or our affiliates may have financial interests, may acquire, hold or sell long or short positions, or trade or otherwise effect transactions in debt, equity, and other securities and financial instruments (including bank loans and other obligations) of, or investments in, ARCA, Oruka or any other party that may be involved in the Merger and/or their respective affiliates.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consistent with applicable legal and regulatory requirements, Lucid has adopted policies and procedures to establish and maintain the independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to ARCA and the proposed Merger that may differ from the views of Lucid&#8217;s investment banking personnel.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Opinion set forth below was reviewed and approved by a fairness opinion committee of Lucid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein and such other factors that we deem relevant, it is our opinion that, as of the date hereof, the Exchange Ratio is fair, from a financial point of view, to the holders of Parent Common Stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Very truly yours,</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;"><img alt="" src="tlucid_sig.jpg" style="width:179.2px;max-width:100%;"/></span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lucid Capital Markets, LLC</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T102"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;C</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Support Agreement (this &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and the undersigned stockholder (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Company. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RECITALS</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">First Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and Atlas Merger Sub II LLC, a Delaware limited liability company (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Second Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which (i) the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number of shares of Company Capital Stock as indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as an inducement to the willingness of Parent to enter into the Merger Agreement, Parent has required that Stockholder enter into this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOW, THEREFORE, intending to be legally bound, the parties hereby agree as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Definitions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Constructive Sale</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) all shares of Company Capital Stock beneficially owned by the Stockholder as of the date hereof, and (ii) all additional shares of Company Capital Stock acquired and beneficially owned by the Stockholder during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transferred</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer and Voting Restrictions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, the Voting Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Voting Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity limiting or affecting the Stockholder&#8217;s legal power, authority or right to execute and deliver the Company Stockholder Written Consent.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to such Stockholder&#8217;s Affiliates (in&#160;each case, directly or indirectly) (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) purchased from the Company pursuant to the Company Pre-Closing Financing on or about the Closing Date but prior to the Closing (including any shares of the Company issued upon conversion of any pre-funded Company Warrants), and (vii) to the extent required by applicable Law; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Company Capital Stock.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement to Vote Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Until the Expiration Date (as defined below), at any meeting of the stockholders of the Company, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of the Company, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the adoption and approval of the Merger Agreement, (B) in favor of approval of the Contemplated Transactions, and (C) against any Acquisition Proposal.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Stockholder is not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a stock split, stock dividend or distribution, or any change in the capital stock of the Company by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Action in Stockholder Capacity Only</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as the beneficial owner of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of the Company. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of the Company.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Irrevocable Proxy</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> at any applicable meeting of the stockholders of the Company or pursuant to any applicable written consent of the stockholders of the Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, the Company, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Company stockholders or at any meeting of the Company stockholders called with respect to any of the matters specified in, and in accordance and consistent with, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement. The Company agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein (including the next sentence), the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that the Company is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger Agreement is hereby incorporated by reference </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">mutatis mutandis</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documentation and Information</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement; provided, that, Parent and the Company provide such documents, schedules, press release or other disclosure document to the Stockholder in advance for its review and comment. Each of Parent and the Company is an intended third-party beneficiary of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Exercise of Appraisal Rights; Waivers</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby irrevocably and unconditionally (a)&#160;waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&#8217; rights and any similar rights (including any notice requirements related thereto) relating to the Merger that Stockholder may have by virtue of, or with respect to, any Shares (including all rights under Section 262 of the DGCL) and (b) agrees that the Stockholder will not bring, commence, institute, maintain, prosecute or voluntarily aid or participate in any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Authority, which (i) challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii) alleges that the execution and delivery of this Agreement by the Stockholder breaches any duty that such Stockholder has (or may be alleged to have) to the Company or to the other Company stockholders; provided, that (x) the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Company and (y) the foregoing shall not limit or restrict in any manner the Stockholder from enforcing the Stockholder&#8217;s rights under this Agreement and the other agreements entered into by the Stockholder in connection herewith, or otherwise in connection with the Merger, including the Stockholder&#8217;s right to receive the Merger Consideration pursuant to the terms of the Merger Agreement.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby represents and warrants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(i) The Stockholder is the beneficial owner of the shares of Company Capital Stock indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> unless otherwise expressly stated with respect to any shares in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement, the Voting Agreement, the Investors&#8217; </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Rights Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Investors&#8217; Rights Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Right of First Refusal and Co-Sale Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">ROFR</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), any lock-up agreement entered into by and between the Stockholder, the Company and Parent, and Encumbrances arising under applicable securities or community property laws; and (ii) the Stockholder does not beneficially own any securities of the Company other than the shares of Company Capital Stock and rights to purchase shares of Company Capital Stock set forth in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, except for the Voting Agreement, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Agreements</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each Stockholder, by this Agreement, and with respect to such Stockholder&#8217;s Shares, severally and not jointly, hereby agrees to terminate, subject to the occurrence of, and effective immediately prior to, the Effective Time each of (a) the Voting Agreement, the Investors&#8217; Rights Agreement and the ROFR and (b)&#160;any rights under any letter agreement providing for redemption rights, put rights, purchase rights, information rights, rights to consult with and advise management, inspection rights, preemptive rights, board of directors </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">observer rights or rights to receive information delivered to the board of directors or other similar rights not generally available to stockholders of the Company between the Stockholder and the Company, but excluding, for the avoidance of doubt, any rights the Stockholder may have that relate to any indemnification, commercial, development or employment agreements or arrangements between such Stockholder and the Company or any subsidiary of the Company, which shall survive in accordance with their terms. Each Stockholder hereby terminates and waives all rights of first refusal, redemption rights and rights of notice of the Merger and the other transactions contemplated by the Merger Agreement, effective as of immediately prior to, and contingent upon, the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without giving effect to any amendments thereto unless consented to by the Stockholder), (b) the Effective Time and (c) the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Expiration Date</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (i) </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this Agreement prior to the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">12.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendments</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of the parties hereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement constitutes the entire agreement between the parties to this Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12(c)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, (v) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12(h)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (vi)&#160;irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignment</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties and their respective successors and permitted assigns; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated (except by Merger) by such party without the prior written consent of the other party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third Party Rights</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Specific Performance</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Confidentiality</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.  Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein).  Neither the Stockholder nor any of its Affiliates (other than the Company, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to the Company, this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Interpretation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221;&#160;and&#160;&#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Left Intentionally Blank</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">COMPANY:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Oruka Therapeutics, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-9" style="font-variant:normal;text-transform:uppercase;">Parent</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA BIOPHARMA, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">[STOCKHOLDER],</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">in his/her capacity as the Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Signature:&#160;_______________________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T103"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;D</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF ARCA STOCKHOLDER SUPPORT AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Support Agreement (this &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and the undersigned stockholder (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Parent. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RECITALS</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">First</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and Atlas Merger Sub II, LLC, a Delaware limited liability company (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Second Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which (i) the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (together, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number of shares of Parent Common Stock as indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as an inducement to the willingness of the Company to enter into the Merger Agreement, the Company has required that Stockholder enter into this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOW, THEREFORE, intending to be legally bound, the parties hereby agree as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Definitions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Constructive Sale</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Stockholder Matters</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the approval of the Merger Agreement and the Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent the approval of the Parent Legacy Transaction.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) all shares of Parent Common Stock owned, beneficially or of record, by the Stockholder as of the date hereof, and (ii) all additional shares of Parent Common Stock acquired by the Stockholder, beneficially owned or of record, during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transferred</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer and Voting Restrictions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity in each case, which has the effect of limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares in favor of the Parent Stockholder Matters and against any competing proposals.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to such Stockholder&#8217;s Affiliates (in each case, directly or indirectly) (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) purchased from the Company on or about the Closing Date but prior to the Closing (including any shares of the Company issued upon conversion of any pre-funded Company Warrants), (vii) to the extent required by applicable Law and (viii) pursuant to the exercise of any option to purchase any Parent Common Stock, including in order to pay the exercise price of such option or satisfy taxes applicable thereto; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Parent Common Stock.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement to Vote Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Until the Expiration Date (as defined below), at any meeting of the stockholders of Parent called to vote upon the Parent Stockholder Matters, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of Parent, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the Parent Stockholder Matters, and (B) against any Acquisition Proposal.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a stock split, stock dividend or distribution, or any change in the capital stock of Parent by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Action in Stockholder Capacity Only</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as a record holder and beneficial owner, as applicable, of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of Parent. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of Parent.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Irrevocable Proxy</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> at any applicable meeting of the stockholders of Parent or pursuant to any applicable written consent of the stockholders of Parent, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Parent stockholders or at any meeting of Parent stockholders called with respect to any of the matters specified in, and in accordance and consistent with, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement. Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein, the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that Parent is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger Agreement is hereby incorporated by reference </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">mutatis mutandis</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documentation and Information</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement. Each of Parent and the Company is an intended third-party beneficiary of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby represents and warrants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(i) The Stockholder is the beneficial or record owner of the shares of Parent Common Stock indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> unless otherwise expressly stated with respect to any shares in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement), and Encumbrances arising under applicable securities or community property laws; and (ii) the Stockholder does not beneficially own any securities of Parent other than the shares of Parent Common Stock and rights to purchase shares of Parent Common Stock set forth in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without giving effect to any amendments thereto unless consented to by the Stockholder), (b) the Effective Time and (c) the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Expiration Date</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (i) </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this Agreement prior to the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendments</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of the parties hereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement constitutes the entire agreement between the parties to this Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in&#160;counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10(c)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (iii) waives any objection to laying </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, (v) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10(h)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (vi)&#160;irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignment</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties and their respective successors and permitted assigns; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated (except by the Merger) by such party without the prior written consent of the other party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third Party Rights</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Specific Performance</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Confidentiality</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.  Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided that such Persons are subject to confidentiality obligations at least as restrictive as those contained </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">herein).  Neither the Stockholder nor any of its Affiliates (other than Parent, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to Parent, this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Interpretation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221;&#160;and&#160;&#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Left Intentionally Blank</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">COMPANY:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-9" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Oruka Therapeutics, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-10" style="font-variant:normal;text-transform:uppercase;">Parent</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-9" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">arca biopharma, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">[STOCKHOLDER],</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">in his/her capacity as the Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Signature: _______________________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T104"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;E</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF LOCK-UP AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:right;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">April 3, 2024</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc.</span><span class="CharOverride-2" style="font-family:Calibri, sans-serif;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10170 Church Ranch Way, Suite 100</span><span class="CharOverride-2" style="font-family:Calibri, sans-serif;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Westminster, CO</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Ladies and Gentlemen:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned signatory of this lock-up agreement (this &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lock-Up Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) understands that ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), has entered into an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (as the same may be amended from time to time, the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) with Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent, Atlas Merger Sub II LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent, and Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As a condition and inducement to each of the parties to enter into the Merger Agreement and to consummate the transactions contemplated thereby, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Restricted Period</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that if a registration statement covering the shares of Company Common Stock and pre-funded Company Warrants issued and sold in connection with the Company Pre-Closing Financing (other than any shares or pre-funded Company Warrants held by affiliates of the Company) has not been declared effective by the SEC prior to the end of such 180-day period, then the Restricted Period shall end on such later date upon which such registration statement is first declared effective:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(1)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for shares of Parent Common Stock (including without limitation, shares of Parent Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities of Parent which may be issued upon exercise of an option to purchase shares of Parent Common Stock or a warrant to purchase shares of Parent Common Stock) that are currently or hereafter owned by the undersigned, except as set forth below (collectively, the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Undersigned&#8217;s Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(2)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (1) above or this clause (2) is to be settled by delivery of shares of Parent Common Stock or other securities, in cash or otherwise;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(3)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>make any demand for, or exercise any right with respect to, the registration of any shares of Parent Common Stock or any security convertible into or exercisable or exchangeable for shares of Parent Common Stock (other than such rights set forth in the Merger Agreement); or</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(4)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>publicly disclose the intention to do any of the foregoing.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The restrictions and obligations contemplated by this Lock<span class="nobreak">-Up</span> Agreement shall not apply to:</p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers of the Undersigned&#8217;s Shares:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(1)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) to any person related to the undersigned (or to an ultimate beneficial owner of the undersigned) by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (each, a &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Family Member</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), or to a trust formed for the benefit of the undersigned or any of the undersigned&#8217;s Family Members, (B) to the undersigned&#8217;s estate, following the death of the undersigned, by </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">will, intestacy or other operation of Law, (C) as a bona fide gift or a charitable contribution, (D) by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement or (E) to any partnership, corporation or limited liability company which is controlled by or under common control with  the undersigned and/or by any such Family Member(s);</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(2)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>if the undersigned is a corporation, partnership, limited liability company or other entity, (A)&#160;to another corporation, partnership, limited liability company or other entity that is a direct or indirect affiliate (as defined under Rule 12b-2 of the Exchange Act) of the undersigned, including investment funds or other entities that controls or manages, is under common control or management with, or is controlled or managed by, the undersigned, (B) as a distribution or dividend to equity holders, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders), (C) as a bona fide gift or a charitable contribution or otherwise to a trust or other entity for the direct or indirect benefit of an immediate family member of a beneficial owner (as defined in Rule 13d-3 of the Exchange Act) of the Undersigned&#8217;s Shares or (D) transfers or dispositions not involving a change in beneficial ownership; or</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(3)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>if the undersigned is a trust, to any grantors or beneficiaries of the trust;</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="text-decoration:underline;">provided</span> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value (other than transfers pursuant to 1(A), 1(E) or 2(A)) and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Parent a lock<span class="nobreak">-up</span> agreement in the form of this Lock<span class="nobreak">-Up</span> Agreement with respect to the shares of Parent Common Stock or such other securities that have been so transferred or distributed;</p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the exercise of an option to purchase shares of Parent Common Stock (including a net or cashless exercise of an option to purchase shares of Parent Common Stock ), and any related transfer of shares of Parent Common Stock to Parent for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers to Parent in connection with the net settlement of any other equity award that represents the right to receive in the future shares of Parent Common Stock, settled in shares of Parent Common Stock, to pay any tax withholding obligations; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Parent Common Stock; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that such plan does not provide for any transfers of shares of Parent Common Stock during the Restricted Period;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers by the undersigned of shares of Parent Common Stock purchased by the undersigned on the open market or in a public offering by Parent, in each case following the Effective Time;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent&#8217;s capital stock involving a change of control of Parent, </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>pursuant to an order of a court or regulatory agency; or</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers by the undersigned of shares of Parent Common Stock issued pursuant to the Merger Agreement in respect of shares of the Company (including any shares of the Company issued upon exercise of any pre-funded Company Warrants), if any, purchased from the Company on or about the Closing Date but prior to the Closing.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, further, that, with respect to each of (b), (c), and (d) above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section 16 of the Exchange Act or other public announcement shall be made voluntarily reporting a reduction in beneficial ownership of shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock in connection with such transfer or disposition during the Restricted Period (other than any exit filings) and if any filings under </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Parent Common Stock in connection with such transfer or distribution, shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes therein, in reasonable detail, a description of the circumstances of the transfer and that the shares remain subject to the lock-up agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">For purposes of this Lock-Up Agreement, &#8220;change of control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of the Company&#8217;s voting securities if, after such transfer, the Company&#8217;s stockholders as of immediately prior to such transfer do not hold a majority of the outstanding voting securities of the Company (or the surviving entity).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Parent. In furtherance of the foregoing, the undersigned agrees that Parent and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Lock-Up Agreement. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Parent Common Stock:</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE <br/>SUBJECT TO AND MAY ONLY BE TRANSFERRED IN <br/>COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY <br/>OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF <br/>THE COMPANY.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned understands that if the Merger Agreement is terminated for any reason, the undersigned shall be released from all obligations under this Lock-Up Agreement. The undersigned understands that Parent is proceeding with the transactions contemplated by the Merger Agreement in reliance upon this Lock-Up Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy.  The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Lock-Up Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached.  It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto.  Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">In the event that any holder of Parent&#8217;s securities that are subject to a substantially similar agreement entered into by such holder, other than the undersigned, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder (whether in one or multiple releases or waivers), the same percentage of shares of Parent Common Stock held by the undersigned on the date of such release or waiver as the percentage of the total number of outstanding shares of Parent Common Stock held by such holder on the date of such release or waiver that are the subject of such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Pro-Rata Release</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that such Pro-Rata Release shall not be applied unless </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders shares of Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock subject to a substantially similar agreement.  In the event of any Pro-Rata Release, the Company shall promptly (and in any event within two (2) business days of such release) inform each relevant holder of Parent Common Stock or warrants of the terms of such Pro-Rata Release.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Upon the release of any of the Undersigned&#8217;s Shares from this Lock-Up Agreement, Parent will reasonably cooperate with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned Shares without the restrictive legend above or the withdrawal of any stop transfer instructions by virtue of this Lock-Up Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws.  In any action or proceeding between any of the parties arising out of or relating to this Lock-Up Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with foregoing clause (i) of this paragraph, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party and (v) irrevocably and unconditionally waives the right to trial by jury. This Lock-Up Agreement constitutes the entire agreement between the parties to this Lock-Up Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.  The exchange of a fully executed Lock-Up Agreement (in&#160;counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-left:1pt;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[SIGNATURE PAGE FOLLOWS]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Very truly yours,</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:right;">Print Name of Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature (for individuals):</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature (for entities):</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[Signature Page to Lock-Up Agreement]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Accepted and Agreed<br/>by ARCA biopharma, Inc.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 2.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 34.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[Signature Page to Lock-Up Agreement]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T105"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;F</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Arca biopharma, Inc.</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF DESIGNATION OF PREFERENCES,</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RIGHTS AND LIMITATIONS</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">OF</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to Section 151 of the</span><span class="CharOverride-5" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:normal;"><br/></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">General Corporation Law of the State of Delaware</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of ARCA biopharma, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), that the following resolution was duly adopted by the Board of Directors of the Corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Board of Directors</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DGCL</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), at a meeting duly called and held on [&#8226;], 2024, which resolution provides for the creation of a series of the Corporation&#8217;s Preferred Stock, par value $0.001 per share, which is designated as &#8220;Series B Non-Voting Convertible Preferred Stock,&#8221; with the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets of the Corporation.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">WHEREAS</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>the Amended and Restated Certificate of Incorporation of the Corporation (as amended from time to time, the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Incorporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), provides for a class of its authorized stock known as Preferred Stock, consisting of 5,000,000 shares, $0.001 par value per share (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), issuable from time to time in one or more series.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RESOLVED</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i) a series of Preferred Stock of the Corporation be, and hereby is, authorized by the Board of Directors, (ii)&#160;the Board of Directors hereby authorizes the issuance of [&#8226;] shares of &#8220;Series B Non-Voting Convertible Preferred Stock&#8221; pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated April 3, 2024, by and among the Corporation, Atlas Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Corporation, Atlas Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent, and Oruka Therapeutics, Inc. (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Merger Agreement</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and (iii) the Board of Directors hereby fixes the designations, powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares of such series of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series, as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;text-indent:20pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">TERMS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For the purposes hereof, the following terms shall have the following meanings:</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Business Day</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to&#160;close.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Buy-In</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning set forth in </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Closing Sale Price</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, for any security as of any date, the last closing trade price for such security immediately prior to 4:00 p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Commission</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Securities and Exchange Commission.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Corporation&#8217;s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Shares</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series B Non-Voting Preferred Stock in accordance with the terms hereof.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Holder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a holder of shares of Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Person</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Trading Day</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a day on which the principal Trading Market is open for business.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Trading Market</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Designation, Amount and Par Value</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The series of Preferred Stock shall be designated as the Corporation&#8217;s Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and the number of shares so designated shall be [&#8226;]. Each share of Series B Non-Voting Preferred Stock shall have a par value of $0.001 per share.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Dividends</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series B Non-Voting Preferred Stock (on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series B Non-Voting Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Voting Rights</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided herein or as otherwise required by the DGCL, the Series B Non-Voting Preferred Stock shall have no voting rights. However, as long as any shares of Series B Non-Voting Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Series B Non-Voting Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series B Non-Voting Preferred Stock or alter or amend this Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws of the Corporation, as amended, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Non-Voting Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii) issue further shares of Series B Non-Voting Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series B Non-Voting Preferred Stock, (iii) at any time while at least [&#8226;] shares of Series B Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined below) or (B) any merger or consolidation of the Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before such transaction do not hold at least a majority on an as-converted-to-Common Stock basis of the capital stock of the Corporation, immediately after such transaction or (iv) enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction. Holders of shares of Common Stock acquired upon the conversion of shares of Series B Non-Voting Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any vote required or permitted under </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> may be taken at a meeting of the Holders or through the execution of an action by written consent in lieu of such meeting or other written waiver by such stockholders, provided that the consent or waiver is executed by Holders representing a majority of the outstanding shares of Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Rank; Liquidation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Series B Non-Voting Preferred Stock shall rank on parity with the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Liquidation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Upon any Liquidation,  each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series B Non-Voting Preferred Stock were fully converted (disregarding for such purpose any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">pari passu</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> with all holders of Common Stock, plus an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series B Non-Voting Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly declares that such Fundamental Transaction shall be treated as if it were a Liquidation.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion at Option of Holder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, each share of Series B Non-Voting Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation (as defined below) (each, an &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Optional Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:underline;">Annex A</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Notice of Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), duly completed and executed. Provided the Corporation&#8217;s transfer agent is participating in the Depository Trust Company (&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DTC</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#8217;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&#8217;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DWAC Delivery</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The date on which an Optional Conversion shall be deemed effective (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Date</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business hours by, the Corporation; provided, that the original certificate(s) (if any) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2) Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion Ratio</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Ratio</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for each share of Series B Non-Voting Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of each share of Series B Non-Voting Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Beneficial Ownership Limitation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of any share of Series B Non-Voting Preferred Stock with respect to a Holder, and a Holder shall not have the right to convert any portion of the Series B Non-Voting Preferred Stock pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion with respect to the Series B Non-Voting Preferred Stock, such Holder (or any of such Holder&#8217;s affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable rules and regulations of the United States Securities and Exchange Commission (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Commission</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Attribution Parties</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;)) would beneficially own a number of shares </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Common Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series B Non-Voting Preferred Stock subject to the Notice of Conversion with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series B Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission, and the terms &#8220;beneficial ownership&#8221; and &#8220;beneficially own&#8221; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission. For purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A) the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be, (B) a more recent public announcement by the Corporation that is filed with the Commission, or (C) a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within two (2) Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series B Non-Voting Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Beneficial Ownership Limitation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall initially be [19.99]% of the number of shares of Common Stock outstanding as of the applicable measurement date. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the foregoing, by written notice to the Corporation (which may be via email), (i) each Holder may reset the Beneficial Ownership Limitation percentage to a higher percentage applicable to such Holder, not to exceed 19.99%, which increase will not be effective until the sixty-first (61</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">st</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) day after such written notice is delivered to the Corporation, and (ii) each Holder may reset the Beneficial Ownership Limitation percentage to a lower percentage effective immediately after the delivery of such notice to the Corporation. Upon such an increase by a Holder of the Beneficial Ownership Limitation pursuant to clause (i) applicable to such Holder, not to exceed 19.99%, the Beneficial Ownership Limitation may not be further amended by such Holder without first providing the minimum notice required by this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding the foregoing, (x) at any time following notice of a Fundamental Transaction, each Holder may waive and/or change the Beneficial Ownership Limitation applicable to such Holder effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Corporation (y) at any time that the beneficial ownership of shares of Common Stock of a Holder (together with any of such Holder&#8217;s Attribution Parties) is equal to or less than 9.00% of the number of shares of Common Stock outstanding as of any given date, then such Holder&#8217;s Beneficial Ownership Limitation shall automatically be set to 9.99%. The provisions of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying the Series B Non-Voting Preferred Stock in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Mechanics of Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.1<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Delivery of Certificate or Electronic Issuance</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon Conversion not later than two (2)&#160;Trading Days after the applicable Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&#160;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Delivery Date</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Corporation shall either: (a)&#160;deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series B Non-Voting Preferred Stock, or (b)&#160;in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder&#8217;s </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series B Non-Voting Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series B Non-Voting Preferred Stock unsuccessfully tendered for conversion to the Corporation.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.2<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Obligation Absolute</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series B Non-Voting Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, in the event a Holder shall elect to convert any or all of its Series B Non-Voting Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series B Non-Voting Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted the Series B Non-Voting Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, issue Conversion Shares upon a properly noticed conversion.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.3<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Buy-In on Failure to Timely Deliver Certificates</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than a failure caused by materially incorrect or incomplete information provided by Holder to the Corporation or the application of the Beneficial Ownership Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Buy-In</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x) such Holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Series B Non-Voting Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3) Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series B Non-Voting Preferred Stock as required pursuant to the terms hereof.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.4<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Reservation of Shares Issuable Upon Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Corporation covenants that at all times it will reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series B Non-Voting Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series B Non-Voting Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) upon the conversion of all outstanding shares of Series B Non-Voting Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.5<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Fractional Shares</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No fractional shares of Common Stock shall be issued upon conversion of the Series B Non-Voting Preferred Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any fractional shares of Common Stock that a Holder of Series B Non-Voting Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded up to the nearest whole share.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.6<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer Taxes</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The issuance of certificates for shares of the Common Stock upon conversion of the Series B Non-Voting Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of Series B Non-Voting Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Status as Stockholder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon each Conversion Date, (i) the shares of Series&#160;B Non-Voting Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&#160;the Holder&#8217;s rights as a holder of such converted shares of Series B Non-Voting Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#8217;s failure to convert Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Adjustments</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stock Dividends and Stock Splits</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If the Corporation, at any time while this Series B Non-Voting Preferred Stock is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series B Non-Voting Preferred Stock) with respect to the then outstanding shares of Common Stock; (B) subdivides outstanding shares of Common Stock into a larger number of shares; or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Fundamental Transaction</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If, at any time while this Series B Non-Voting Preferred Stock is outstanding, (A) the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another Person </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C) any tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property, or (D) the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Fundamental Transaction</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), then, upon any subsequent conversion of this Series B Non-Voting Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had, immediately prior to such Fundamental Transaction, converted the Series B Non-Voting Preferred Stock immediately prior to such Fundamental Transaction (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Alternate Consideration</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series B Non-Voting Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.2</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and insuring that this Series B Non-Voting Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close. Notwithstanding anything to the contrary herein, any Parent Legacy Transaction (as defined in the Merger Agreement) shall not constitute a Fundamental Transaction.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Calculations</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All calculations under this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be made to the nearest cent or the nearest 1/100</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of a share, as the case may be. For purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Redemption</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The shares of Series B Non-Voting Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by law.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. A Holder may transfer any shares of Series B Non-Voting Preferred Stock together with the accompanying rights set forth herein, held by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i)&#160;do and perform, or cause to be done and performed, all such further acts and things, and (ii) execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series B Non-Voting Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 9</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The transferee of any shares of Series B Non-Voting Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor as of the time of such transfer.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Series B Non-Voting Preferred Stock Register</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Corporation shall maintain at its principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 11</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), a register for the Series B Non-Voting Preferred Stock, in which the Corporation shall record (i) the name, address, and electronic mail address of each holder in whose name the shares </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Series B Non-Voting Preferred Stock have been issued and (ii) the name, address, and electronic mail address of each transferee of any shares of Series B Non-Voting Preferred Stock. The Corporation may deem and treat the registered Holder of shares of Series B Non-Voting Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series B Non-Voting Preferred Stock or his, her or its legal representatives.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any notice required or permitted by the provisions of this Certificate of Designation to be given to a Holder of shares of Series B Non-Voting Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic transmission in compliance with the provisions of the DGCL, and shall be deemed sent upon such mailing or electronic transmission.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">12.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Book-Entry; Certificates</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Series B Non-Voting Preferred Stock will be issued in book-entry form; provided that, if a Holder requests that such Holder&#8217;s shares of Series B Non-Voting Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate to such Holder representing such Holder&#8217;s shares of Series B Non-Voting Preferred Stock. To the extent that any shares of Series B Non-Voting Preferred Stock are issued in book-entry form, references herein to &#8220;certificates&#8221; shall instead refer to the book-entry notation relating to such shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">13.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lost or Mutilated Series B Non-Voting Preferred Stock Certificate</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If a Holder&#8217;s Series B Non-Voting Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series B Non-Voting Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">14.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Waiver</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series B Non-Voting Preferred Stock granted hereunder may be waived as to all shares of Series B Non-Voting Preferred Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series B Non-Voting Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any provisions contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and materially adverse effect on any Holder shall require the consent of such Holder(s).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">15.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">16.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Status of Converted Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If any shares of Series B Non-Voting Preferred Stock shall be converted or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition, and shall not be reissued as a share of Series B Non-Voting Preferred Stock. Any share of Series B Non-Voting Preferred Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Intentionally Left Blank</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-indent:24pt;margin-top:8pt;"><span class="CharOverride-11" style="font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span>, ARCA biopharma, Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations of Series B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be duly executed by its [&#8226;] on [&#8226;], 2024.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 45.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-12" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA biopharma, Inc.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ANNEX A</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOTICE OF CONVERSION</span><span class="CharOverride-5" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:normal;"><br/><br/></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK)</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series B Non-Voting Convertible Preferred Stock (&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) indicated below, represented in book-entry form, into shares of common stock, par value $0.001 per share (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), of ARCA biopharma, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), as of the date written below. If securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) filed by the Corporation with the Secretary of State of the State of Delaware on [&#8226;], 2024.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#8217;s Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series B Non-Voting Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series&#160;B Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">CONVERSION CALCULATIONS:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Date to Effect Conversion:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number&#160;of&#160;shares&#160;of&#160;Series&#160;B&#160;Non-Voting&#160;Preferred&#160;Stock&#160;owned&#160;prior&#160;to&#160;Conversion:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number of shares of Series B Non-Voting Preferred Stock to be Converted:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number of shares of Common Stock to be Issued:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Address for delivery of physical certificates:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 43.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:justify;text-indent:0pt;">For DWAC Delivery, please provide the following:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">Broker No.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">_____________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">Account No.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">_____________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-13" style="font-variant:normal;text-transform:uppercase;">[HOLDER]</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T106"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;G</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT <br/>TO THE <br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION <br/>OF <br/>ARCA BIOPHARMA, INC. <br/>TO REFLECT INCREASE IN AUTHORIZED SHARES</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex G-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T107"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;H</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT <br/>TO THE <br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION <br/>OF ARCA BIOPHARMA, INC. <br/>TO REFLECT REVERSE STOCK SPLIT</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex H-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T108"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;I</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT <br/>TO THE <br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION <br/>OF ARCA BIOPHARMA, INC. <br/>TO REFLECT DELAWARE LAW PROVISIONS <br/>REGARDING OFFICER EXCULPATION</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex I-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T109"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;J</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights (Section&#160;262 of the Delaware General Corporation Law)</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">&#167; 262. Appraisal rights</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(a)&#160;Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&#160;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, or conversion, who has otherwise complied with subsection&#160;(d)&#160;of this section and who has neither voted in favor of the merger, consolidation or conversion nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&#160;and (c)&#160;of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(b)&#160;Appraisal rights shall be available for the shares of any class or series of stock of a constituent or converting corporation in a merger, consolidation or conversion to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g)&#160;of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264 or &#167; 266 of this title (other than, in each case and solely with respect to a domesticated corporation, a merger, consolidation or conversion authorized pursuant to and in accordance with the provisions of &#167; 388 of this title):</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(1)&#160;Provided, however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for conversion (or, in the case of a merger pursuant to &#167; 251(h)&#160;of this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f)&#160;of this title.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(2)&#160;Notwithstanding paragraph (b)(1)&#160;of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent or converting corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264 or &#167; 266 of this title to accept for such stock anything except:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">a. Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity if such entity is a corporation as a result of the conversion, or depository receipts in respect thereof;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">b. Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation or conversion will be either listed on a national securities exchange or held of record by more than 2,000 holders;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(3)&#160;In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(4)&#160;[Repealed.]</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(c)&#160;Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&#160;of this section, shall apply as nearly as is practicable.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(d)&#160;Appraisal rights shall be perfected as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(1)&#160;If a proposed merger, consolidation or conversion for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20&#160;days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c)&#160;of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&#160;or (c)&#160;of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation or conversion, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation or conversion shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10&#160;days after the effective date of such merger, consolidation or conversion, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation or conversion, and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section, of the date that the merger, consolidation or conversion has become effective; or</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(2)&#160;If the merger, consolidation or conversion was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent or converting corporation before the effective date of the merger, consolidation or conversion, or the surviving, resulting or converted entity within 10&#160;days after such effective date, shall notify each stockholder of any class or series of stock of such constituent or converting corporation who is entitled to appraisal rights of the approval of the merger, consolidation or conversion and that appraisal rights are available for any or all shares of such class or series of stock of such constituent or converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation or conversion, shall, also notify such stockholders of the effective date of the merger, consolidation or conversion. Any stockholder entitled to appraisal rights may, within 20&#160;days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, within the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20&#160;days after the date of giving such notice, demand in writing from the surviving or resulting entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation or conversion, either (i)&#160;each such constituent corporation or the converting corporation shall send a second notice before the effective date of the merger, consolidation or conversion notifying each of the holders of any class or series of stock of such constituent or converting corporation that are entitled to appraisal rights of the effective date of the merger, consolidation or conversion or (ii)&#160;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10&#160;days after such effective date; provided, however, that if such second notice is sent more than 20&#160;days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20&#160;days following the sending of the first notice, such second notice need </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting corporation may fix, in advance, a record date that shall be not more than 10&#160;days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation or conversion, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the&#160;day next preceding the&#160;day on which the notice is given.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(3)&#160;Notwithstanding subsection (a)&#160;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1)&#160;or (2)&#160;of this section, as applicable; provided that (i)&#160;such beneficial owner continuously owns such shares through the effective date of the merger, consolidation or conversion and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&#160;of this section and (ii)&#160;the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(e)&#160;Within 120&#160;days after the effective date of the merger, consolidation or conversion, the surviving, resulting or converted entity, or any person who has complied with subsections (a)&#160;and (d)&#160;of this section hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60&#160;days after the effective date of the merger, consolidation or conversion, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion. Within 120&#160;days after the effective date of the merger, consolidation or conversion, any person who has complied with the requirements of subsections (a)&#160;and (d)&#160;of this section hereof, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation or conversion (or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2)&#160;of this title), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3)&#160;of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10&#160;days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10&#160;days after expiration of the period for delivery of demands for appraisal under subsection (d)&#160;of this section hereof, whichever is later.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(f)&#160;Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20&#160;days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(g)&#160;At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation or conversion the shares of the class or series of stock of the constituent or converting corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger, consolidation or conversion for such total number of shares exceeds $1&#160;million, or (3)&#160;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(h)&#160;After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation or conversion, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation or conversion through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(i)&#160;The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(j)&#160;The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k)&#160;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(k)&#160;From and after the effective date of the merger, consolidation or conversion, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d)&#160;of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation or conversion); provided, however, that if no petition for an appraisal is filed within the time provided in subsection (e)&#160;of this section, or if a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e)&#160;of this section, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery shall be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&#160;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion within 60&#160;days after the effective date of the merger, consolidation or conversion, as set forth in subsection (e)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(l)&#160;The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T110"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;K</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024 Oruka Therapeutics, Inc. Stock Incentive Plan</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T112"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;L </span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024 Oruka Therapeutics, Inc. Employee Stock Purchase Plan</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PART&#160;II <br/>INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;20.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Indemnification of Directors and Officers</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Delaware</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are corporations under the DGCL.&#160;Section&#160;145(a)&#160;of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;145(b)&#160;of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of the State of Delaware or such other court shall deem proper.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a)&#160;and (b)&#160;of Section&#160;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&#160;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section&#160;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators. Section&#160;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&#160;145.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;102(b)(7)&#160;of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL, or (iv)&#160;for any transaction from which the director derived an improper personal benefit.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H5" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter contains provisions that eliminate, to the maximum extent permitted by the DGCL, the personal liability of directors for monetary damages for breach of fiduciary duty as a director. Please see Proposal&#160;No. 4 for details regarding the proposed amendment to the ARCA Charter to eliminate, to the maximum extent permitted by the DGCL, the personal liability of officers for monetary damages for breach of fiduciary duty as an officer. The ARCA Charter and ARCA Bylaws provide that ARCA shall indemnify its directors and executive officers and may indemnify its employees and other agents to the fullest extent permitted by the DGCL.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in the ARCA Charter and ARCA Bylaws, and it intends to enter into indemnification agreements with any new directors and executive officers in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her incurred by him or her in any such capacity, subject to certain exclusions.</p>
		<p class="H5" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Oruka Charter contains provisions that limit or eliminate the personal liability of Oruka&#8217;s directors or officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. These limitations of liability do not alter director or officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission. In addition, the Oruka Bylaws provide that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will indemnify its directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will advance expenses, including attorneys&#8217; fees, to its directors and officers in connection with legal proceedings relating to their service for or on behalf of Oruka, subject to limited exceptions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has entered into indemnification agreements with its directors and executive officers. These agreements provide that Oruka will indemnify each of its directors and executive officers to the fullest extent permitted by Delaware law. Oruka will advance expenses, including attorneys&#8217; fees (but excluding judgments, fines and settlement amounts), to each indemnified director or executive officer in connection with any proceeding in which indemnification is available and Oruka will indemnify its directors and officers for any action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of Oruka or in furtherance of Oruka&#8217;s rights. Additionally, certain of Oruka&#8217;s directors may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s services as a director referenced herein. Nonetheless, Oruka has agreed in the indemnification agreements that Oruka&#8217;s obligations to those same directors are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka also intends to maintain general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the&#160;Securities Act.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;21.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Exhibits and Financial Statement Schedules</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Exhibit Index</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A list of exhibits filed with this registration statement on Form&#160;S<span class="nobreak">-4</span> is set forth on the Exhibit Index and is incorporated herein by reference.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Financial Statements</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements filed with this registration statement on Form&#160;S<span class="nobreak">-4</span> are set forth on the Financial Statement Index and are incorporated herein by reference.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;22.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Undertakings</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(1)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To file, during any period in which offers or sales are being made, a post<span class="nobreak">-effective</span> amendment to this registration statement:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>To include any prospectus required by Section&#160;10(a)(3)&#160;of the Securities Act;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post<span class="nobreak">-effective</span> amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; table in the effective registration statement; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:72pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Provided, however</span>, that paragraphs (a)(1)(i)&#160;and (a)(1)(ii)&#160;herein do not apply if the information required to be included in a post<span class="nobreak">-effective</span> amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange&#160;Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(2)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>That, for the purpose of determining any liability under the Securities Act, each such post<span class="nobreak">-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(3)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To remove from registration by means of a post<span class="nobreak">-effective</span> amendment any of the securities being registered which remain unsold at the termination of the offering.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(4)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a)&#160;or Section&#160;15(d)&#160;of the Exchange&#160;Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d)&#160;of the Exchange&#160;Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(5)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(6)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The registrant undertakes that every prospectus: (i)&#160;that is filed pursuant to paragraph (a)(5)&#160;immediately preceding, or (ii)&#160;that purports to meet the requirements of Section&#160;10(a)(3)&#160;of the Act and is used in connection with an offering of securities subject to Rule&#160;415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act&#160;of&#160;1933, each such post<span class="nobreak">-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(7)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Item&#160;4, 10(b),<span class="nobreak"> </span>11, or 13 of this form, within one business&#160;day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(8)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes to supply by means of a post<span class="nobreak">-effective</span> amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex21.htm">Agreement and Plan of Merger and Reorganization, dated as of April&#160;3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub&#160;II, LLC, and Oruka Therapeutics, Inc. (included as Annex&#160;A to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex31.htm">Amended and Restated Certificate of Incorporation of ARCA biopharma, Inc., as amended (incorporated by reference to Exhibit 3.1 to ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513090814/d498361dex51.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 5.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on March&#160;5, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(b)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459015007723/abio-ex31_74.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;3, 2015).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459019010715/abio-ex31_7.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;3, 2019).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/0000907654/000156459021034792/abio-ex31_47.htm">Bylaws of ARCA biopharma, Inc., as currently in effect (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on June&#160;28, 2021).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513233692/d507513dex31b.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Convertible Preferred Stock of the Registrant (previously filed with the SEC as an Exhibit and incorporated herein by reference from ARCA biopharma, Inc.&#8217;s Form&#160;S-1, filed on March&#160;25, 2013, File No.&#160;333-187508).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex31.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.5*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex3-5_arcabio.htm">Amended and Restated Certificate of Incorporation of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.6*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex3-6_arcabio.htm">Bylaws of Oruka Therapeutics, Inc, as currently in effect.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509013220/dex41.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on January&#160;29, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459019017210/abio-ex42_106.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;8, 2019).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.3*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex4-3_arcabio.htm">Investor Rights Agreement, dated March&#160;6, 2024, by and among Oruka Therapeutics, Inc. and certain parties thereto.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex101.htm">Form of Oruka Support Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.2&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex102.htm">Form of Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex103.htm">Form of ACRA Support Agreement (incorporated by reference to Exhibit 10.3 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex104.htm">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_1.htm">Separation Agreement and Release, by and between ARCA and Michael Bristow, dated as of April&#160;3, 2024 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;4, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.6&#8224;&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_2.htm">Consulting Agreement, by and between ARCA and Michael Bristow, dated as of April&#160;3, 2024 (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;4, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.7#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017022026298/abio-ex10_1.htm">Memorandum Regarding Cash Retention Bonus between ARCA biopharma, Inc. and Thomas A, Keuer dated December&#160;8, 2022 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;9, 2022).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.8#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017023067790/abio-ex10_1.htm">Amendment to Retention Bonus Letter, dated December&#160;4, 2023, by and among ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;4, 2023).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.9#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_1.htm">Second Amendment to Retention Bonus Letter, dated April&#160;22, 2024, by and between ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;23, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.10#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017022026298/abio-ex10_2.htm">Memorandum Regarding Cash Retention Bonus between ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker dated December&#160;8, 2022 (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;9, 2022).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.11#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017023067790/abio-ex10_2.htm">Amendment to Retention Bonus Letter, dated December&#160;4, 2023, by and among ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;4, 2023).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.12#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_2.htm">Second Amendment to Retention Bonus Letter, dated April&#160;22, 2024, by and between ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;23, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020042033/abio-ex101_7.htm">Office Lease Agreement, effective August&#160;7, 2020, between ARCA biopharma, Inc. and Potens Partners&#160;LLC (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on August&#160;31, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024035373/abio-ex10_1.htm">First Amendment to Office Lease Agreement, dated March&#160;19, 2024, by and between ARCA biopharma, Inc. and Lotus Church Ranch, LLC (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on March&#160;22, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.15#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex101.htm">ARCA biopharma, Inc. 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.16#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex102.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.17#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex103.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.18#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex104.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Director) (incorporated by reference to Exhibit 10.4 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.19#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex105.htm">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.20#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex106.htm">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.6 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.21#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020056751/abio-ex101_7.htm">ARCA biopharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;10, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.22#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex101_6.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.23#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex102_11.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.24#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex103_7.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Director) (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.25#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex104_8.htm">Form of Restricted Stock Unit Award Agreement Notice of Grant Award under 2020 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.4 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.26#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex105_9.htm">Form of Restricted Stock Unit Award Agreement Notice of Grant Award under 2020 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.27&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509113082/dex101.htm">License and Sublicense Agreement, dated October&#160;28, 2003, by and between ARCA Discovery, Inc. and CPEC, L.L.C. (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;15, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.28&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509113082/dex102.htm">Amendment to License and Sublicense Agreement, dated February&#160;22, 2006, by and between ARCA Discovery, Inc. and CPEC, L.L.C. (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;15, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.29</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1046.htm">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc. (incorporated by reference to Exhibit 10.46 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.30</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1048.htm">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc. (incorporated by reference to Exhibit 10.48 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.31</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1052.htm">Form of Indemnification Agreement between ARCA biopharma, Inc. and its directors and officers (incorporated by reference to Exhibit 10.52 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.32&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312511223373/dex105.htm">Amended and Restated Exclusive License Agreement, dated August&#160;12, 2011, by and between the Regents of the University of Colorado and ARCA biopharma, Inc (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on August&#160;15, 2011).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.33#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1043.htm">Amended and Restated Employment and Retention Agreement, dated June&#160;4, 2008, by and between ARCA biopharma, Inc. and Michael R.&#160;Bristow (incorporated by reference to Exhibit 10.43 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.34#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459013000333/abio-ex10_20130629569.htm">Amendment Agreement by and between ARCA biopharma, Inc. and Michael R.&#160;Bristow, effective as of June&#160;13, 2013 (incorporated by reference to Exhibit 10.6 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed August&#160;13, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.35#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312514457143/d842508dex102.htm">Amended and Restated Employment Agreement, dated December&#160;29, 2014, by and between ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K/A filed on December&#160;30, 2014).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.36#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021026534/abio-ex102_75.htm">Employment Agreement, dated April&#160;21, 2021, by and between ARCA biopharma, Inc. and C.&#160;Jeff Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;11, 2021).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.37&#167;&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021040795/abio-ex103_140.htm">Assignment Agreement for Patent Rights, dated July&#160;1, 2021, by and between ARCA biopharma, Inc. and University Medical Center of the Johannes Gutenberg University Mainz (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on August&#160;4, 2021).</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.38**#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T110">Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;K </span>to the proxy statement/prospectus and incorporated herein by reference)</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.39**#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T112">Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;L </span>to the proxy statement/prospectus and incorporated herein by reference)</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.40*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex10-40_arcabio.htm">Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.41*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex10-41_arcabio.htm">Form of Restricted Stock Notice and Restricted Stock Purchase Agreement of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.42*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex10-42_arcabio.htm">Form of Stock Option Agreement under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.43*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex10-43_arcabio.htm">Amended and Restated Director Offer Letter, dated March&#160;22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.44*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex10-44_arcabio.htm">Director Offer Letter, dated April&#160;24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.45*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex10-45_arcabio.htm">Form of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.46*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex10-46_arcabio.htm">Amended and Restated Employment Offer Letter, dated February&#160;14, 2024, by and between Oruka Therapeutics, Inc. and Lawrence Klein</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.47*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex10-47_arcabio.htm">Employment Offer Letter, dated March&#160;11, 2024, by and between Oruka Therapeutics, Inc. and Arjun Agarwal</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.48*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex10-48_arcabio.htm">Employment Offer Letter, dated March&#160;15, 2024, by and between Oruka Therapeutics, Inc. and Joana Goncalves</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.49*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex10-49_arcabio.htm">Employment Offer Letter, dated April&#160;12, 2024, by and between Oruka Therapeutics, Inc. and Paul Quinlan</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.50**&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Amended and Restated Antibody Discovery and Option Agreement (IL-17), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.51**&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Amended and Restated Antibody Discovery and Option Agreement (IL-23), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">21.1*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex21-1_arcabio.htm">List of Subsidiaries of ARCA biopharma, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.1*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex23-1_arcabio.htm">Consent of KPMG LLP, independent registered public accounting firm of ARCA biopharma, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.2*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex23-2_arcabio.htm">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.3**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Consent of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. (included in Exhibit 5.1).</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">24.1*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T555">Power of Attorney (included in the signature page hereto).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.1**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Form of ARCA biopharma, Inc. proxy card.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.2**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T105">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Increase in Authorized Shares (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;F</span> to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.3**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T106">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Reverse Stock Split (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.4**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T107">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Officer Exculpation (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.5*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex99-5_arcabio.htm">Consent of Lucid Capital Markets, LLC.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.6*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex99-6_arcabio.htm">Consent of Lawrence Klein to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.7*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex99-7_arcabio.htm">Consent of Kristine Ball to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.8*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex99-8_arcabio.htm">Consent of Carl Dambkowski to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.9*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex99-9_arcabio.htm">Consent of Peter Harwin to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.10*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex99-10_arcabio.htm">Consent of Samarth Kulkarni to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">

						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.11*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex99-11_arcabio.htm">Consent of Cameron Turtle to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.INS*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Instance Document.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.SCH*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Schema.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.CAL*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Calculation Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.DEF*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Definition Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.LAB*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Label Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.PRE*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Presentation Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">107*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#bfbfbf;border-bottom-style:solid;border-left-color:#bfbfbf;border-left-style:solid;border-right-color:#bfbfbf;border-right-style:solid;border-top-color:#bfbfbf;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512201ex-fee_arcabio.htm">Filing Fee Table.</a></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Filed herewith.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">**<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To be filed by amendment.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">#<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Indicates management contract or compensatory plan or arrangement.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#8224;<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Exhibits and/or schedules have been omitted pursuant to Item&#160;601(a)(5)&#160;of Regulation&#160;S<span class="nobreak">-K</span>.&#160;The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule&#160;24b<span class="nobreak">-2</span> under the Exchange&#160;Act for any exhibits or schedules so furnished. Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#8224;&#8224;<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#167;<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Confidential treatment has been granted as to portions of the exhibit. Confidential materials omitted and filed separately with the SEC.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#167;&#167;<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Schedules have been omitted from this filing pursuant to Item&#160;601(b)(2)&#160;of Regulation&#160;S<span class="nobreak">-K</span>.&#160;ARCA agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that the Company may request confidential treatment pursuant to Rule&#160;24b<span class="nobreak">-2</span> of the Exchange&#160;Act for any schedule so furnished. Certain portions of the exhibit, identified by the mark, &#8220;*,&#8221; have been omitted because such portions contained information that is both (i)&#160;not material and (ii)&#160;would likely cause competitive harm if publicly disclosed.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">SIGNATURES</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Westminster, State of Colorado, on May<span class="nobreak"> </span>13, 2024.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ARCA BIOPHARMA, INC.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Thomas A.&#160;Keuer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Operating Officer</p>
					</td>
				</tr>

		</table>
		<a id="T555"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">POWER OF ATTORNEY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">KNOW ALL PERSONS BY THESE PRESENTS</span>, that each person whose signature appears below hereby constitutes and appoints Mr.&#160;Thomas A.&#160;Keuer and Mr.&#160;C.&#160;Jeffrey Dekker, as his or her true and lawful attorneys<span class="nobreak">-in</span> fact, proxies and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post<span class="nobreak">-effective</span> amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule&#160;462(b)&#160;increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys<span class="nobreak">-in-fact</span>, proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys<span class="nobreak">-in-fact</span>, proxies and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">

						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Signature</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Title</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">/s/ Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">President and Chief Operating Officer </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">May<span class="nobreak"> </span>13, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">(Principal Executive Officer)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">/s/ C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Chief Financial Officer </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">May<span class="nobreak"> </span>13, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">(<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Financial Officer and <br/>Principal Accounting Officer</span>)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:15pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;">/s/ Linda Grais</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;">May<span class="nobreak"> </span>13, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:15pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;">/s/ Robert Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;">May<span class="nobreak"> </span>13, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:15pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;">/s/ Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;">May<span class="nobreak"> </span>13, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:15pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;">/s/ Jacob Ma-Weaver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;">May<span class="nobreak"> </span>13, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:15pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;">/s/ James Flynn</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:15pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;">May<span class="nobreak"> </span>13, 2024</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-9</p>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c1" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-2" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-4" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-5" name="us-gaap:OtherNonoperatingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" decimals="2" id="hidden-fact-6" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.37</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-7" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.69</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="0" id="hidden-fact-8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14410143</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="0" id="hidden-fact-9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14415877</ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="2" id="hidden-fact-10" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.09</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-11" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.14</ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="0" id="hidden-fact-12" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14410143</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-13" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14501143</ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-14" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-15" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-16" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-17" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-22" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-23" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-24" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-26" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-28" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-29" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-32" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-33" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-34" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c46" id="hidden-fact-35" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-36" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-37" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-38" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-39" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-40" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-42" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-43" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-44" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-45" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-46" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-47" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-48" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-49" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-50" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-51" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-52" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-53" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-54" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-55" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-56" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-57" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-58" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-59" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-60" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-61" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-62" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-63" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-64" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-65" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-66" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-67" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-68" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c64" id="hidden-fact-69" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-70" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-71" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-72" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c68" id="hidden-fact-73" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c88" id="hidden-fact-74" name="abio:LesseeOperatingSubleaseTermOfContract">P29M</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" id="hidden-fact-75" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">P3Y73D</ix:nonNumeric>
<ix:nonFraction contextRef="c1" id="hidden-fact-76" name="us-gaap:RestructuringReserveCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-77" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-78" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-80" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-81" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-82" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-83" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-84" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-92" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c98" id="hidden-fact-98" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">P3Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c99" id="hidden-fact-99" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">P4Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c6" id="hidden-fact-100" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">P10Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c106" id="hidden-fact-101" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P1Y36D</ix:nonNumeric>
<ix:nonNumeric contextRef="c107" id="hidden-fact-102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">P1Y</ix:nonNumeric>
<ix:nonFraction contextRef="c6" id="hidden-fact-103" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-104" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-105" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-106" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-107" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-108" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c114" id="hidden-fact-109" name="abio:OperatingLossCarryforwardsExpirationYear">2025</ix:nonNumeric>
<ix:nonNumeric contextRef="c115" id="hidden-fact-110" name="abio:OperatingLossCarryforwardsExpirationYear">2037</ix:nonNumeric>
<ix:nonNumeric contextRef="c6" id="hidden-fact-111" name="us-gaap:OpenTaxYear">2009</ix:nonNumeric>
<ix:nonFraction contextRef="c119" id="hidden-fact-112" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-113" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-114" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-115" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-116" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c129" id="hidden-fact-117" name="abio:LesseeOperatingSubleaseTermOfContract">P29M</ix:nonNumeric>
<ix:nonNumeric contextRef="c5" id="hidden-fact-118" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">P6M</ix:nonNumeric>
<ix:nonFraction contextRef="c1" id="hidden-fact-119" name="us-gaap:RestructuringReserveCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c135" id="hidden-fact-120" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-121" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-122" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-123" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-35692">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-35693">0000907654</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="abio-20240331.xsd" xlink:type="simple"/></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-31</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a4bY39FGh5gLIYnmd1AwOGy2evgYTBuMezrcHZ8hWGuIKmV96PSoFEqIafU9sj92aZRi6oN90zR+hQ0m6IzU+mpUZ5p5Jpyw5MoU2z9VITI83t6K3dnZhN1cA66jv+uIcENw0EWmY3YnA==] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abio:ClinicalDevelopmentDecisionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-30</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-28</xbrli:startDate>
    <xbrli:endDate>2020-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abio:UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:PatentAssignmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndThirteenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:FirstThreePercentPayContributionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:NextTwoPercentPayContributionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SeperationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:PresidentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-20</xbrli:startDate>
    <xbrli:endDate>2024-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-20</xbrli:startDate>
    <xbrli:endDate>2024-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abio:ThomasAKeuerAndCJeffreyDekkerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="sqft">
  <xbrli:measure>utr:sqft</xbrli:measure>
</xbrli:unit><xbrli:unit id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>2
<FILENAME>ea020512201ex3-5_arcabio.htm
<DESCRIPTION>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.5</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AMENDED AND RESTATED<BR>
CERTIFICATE OF INCORPORATION<BR>
OF<BR>
ORUKA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Oruka Therapeutics, Inc.,
a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the
&ldquo;<B>DGCL</B>&rdquo;),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>DOES HEREBY CERTIFY:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.   </B></FONT>That
the name of this corporation is Oruka Therapeutics, Inc. (the &ldquo;<B>Corporation</B>&rdquo;). The original Certificate of Incorporation
of the Corporation was filed with the Secretary of State of the State Delaware on February 6, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.   </B></FONT>That
the Amended and Restated Certificate of Incorporation of the Corporation in the form attached hereto as <U>Exhibit A</U> has been duly
adopted in accordance with the provisions of Sections 242 and 245 of the DGCL by the directors and stockholders of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.   </B></FONT>The
text of the Certificate of Incorporation is amended and restated to read in full as set forth in <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF, this Amended
and Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this 6<SUP>th</SUP> day
of March, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>ORUKA THERAPEUTICS, INC.</B></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 35%">/s/ Lawrence Klein</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Lawrence Klein</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: left"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>First</B></FONT><B>:</B>
The name of this corporation is Oruka Therapeutics, Inc. (the &ldquo;<B>Corporation</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Second</B></FONT><B>:</B>
The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Company, 1209 Orange Street, in
the city of Wilmington, New Castle County, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Third</B></FONT><B>:</B>
The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation
Law of the State of Delaware (the &ldquo;<B>DGCL</B>&rdquo;), as the same exists or as may hereafter be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Fourth</B></FONT><B>:</B>
The total number of shares of all classes of stock which the Corporation shall have the authority to issue is 85,000,000. The Corporation
has two classes of stock, referred to as Common Stock and Preferred Stock. There are 65,000,000 shares of authorized Common Stock, $0.0001
par value per share (&ldquo;<B>Common Stock</B>&rdquo;) and 20,000,000 shares of authorized Preferred Stock, $0.0001 par value per share
(&ldquo;<B>Preferred Stock</B>&rdquo;), all of which are hereby designated as &ldquo;<B>Series A Preferred Stock</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following is a statement
of the designations and the powers, preferences and special rights, and the qualifications, limitations or restrictions thereof in respect
of each class of capital stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">A.   COMMON
STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Unless otherwise indicated,
references to &ldquo;Sections&rdquo; in this Part A of this Article &lrm;Fourth refer to sections of Part A of this Article &lrm;Fourth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.   <U>General</U>.
The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers, preferences
and special rights of the holders of the Preferred Stock set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.   <U>Voting</U>.
Except as otherwise provided herein or by applicable law, the holders of the Common Stock are entitled to one (1) vote for each share
of Common Stock held as of the applicable record date for each meeting of stockholders (and written actions in lieu of meetings). The
number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding)
by (in addition to any vote of the holders of one (1) or more series of Preferred Stock that may be required by the terms of this Amended
and Restated Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing
a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the
provisions of Section 242(b)(2) of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.   <U>Dilution
Events</U>. Upon each Dilution Event, the Corporation shall, for no additional consideration, grant Common Stock to each of Paragon Therapeutics,
Inc. and Paruka Holding LLC (collectively, the &ldquo;<B>Paragon Entities</B>&rdquo;) pursuant to a Subscription Agreement with the same
terms and conditions as set forth in such Paragon Entity&rsquo;s initial Subscription Agreement or Contribution Agreement, as applicable,
such that the aggregate Common Stock owned by each such Paragon Entity after such Dilution Event is equal to 8.38% of the sum of (A) the
Preferred Stock issued and outstanding (on an as-converted to Common Stock basis), (B) the Common Stock issued and outstanding, including
any Common Stock issued pursuant to this <U>Section &lrm;3</U>, (C) shares of Common Stock underlying any options issued pursuant to the
Corporation&rsquo;s 2024 Equity Incentive Plan, as amended from time to time (the &ldquo;<B>EIP</B>&rdquo;), and (D) any Common Stock
reserved by the Corporation for issuance under the EIP. For purposes of this <U>Section &lrm;3</U>, &ldquo;<B>Dilution Event</B>&rdquo;
means any sale of the Corporation&rsquo;s equity securities made after the date hereof other than sales pursuant to an effective registration
statement under the Securities Act of 1933, as amended, up to an aggregate amount of $20,000,000. For the avoidance of doubt, the issuance
of equity securities pursuant to the Corporation&rsquo;s EIP, shall not be considered a Dilution Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">B.   PREFERRED
STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The shares of the Preferred
Stock shall have the powers, preferences and special rights set forth in this Part B of this Article &lrm;Fourth. Unless otherwise indicated,
references to &ldquo;Sections&rdquo; in this Part B of this Article &lrm;Fourth refer to sections of Part B of this Article &lrm;Fourth.
References to &ldquo;Preferred Stock&rdquo; mean the Series A Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.   <U>Dividends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Corporation shall not
declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends
on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in
this Amended and Restated Certificate of Incorporation) the holders of the Preferred Stock then outstanding shall first receive, or simultaneously
receive, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (i) in the case of a dividend on Common
Stock or any class or series that is convertible into Common Stock, that dividend per share of Preferred Stock as would equal the product
of (A) the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series
had been converted into Common Stock and (B) the number of shares of Common Stock issuable upon conversion of a share of such Preferred
Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (ii) in the case of
a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Preferred Stock determined by (A)
dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such
class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization with respect to such class or series) and (B) multiplying such fraction by an amount equal to the applicable
Original Issue Price (as defined below); <U>provided</U> that, if the Corporation declares, pays or sets aside, on the same date, a dividend
on shares of more than one (1) class or series of capital stock of the Corporation, the dividend payable to the holders of a series of
Preferred Stock pursuant to this <U>Section &lrm;1</U> shall be calculated based upon the dividend on the class or series of capital stock
that would result in the highest dividend for such series of Preferred Stock. The &ldquo;<B>Original Issue Price</B>&rdquo; shall mean,
with respect to the Series A Preferred Stock, $0.15 per share, subject to appropriate adjustment in the event of any stock dividend, stock
split, combination or other similar recapitalization with respect to the applicable Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.   <U>Liquidation,
Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.1   <U>Preferential
Payments to Holders of Preferred Stock</U>. In the event of (a) any voluntary or involuntary liquidation, dissolution or winding up of
the Corporation, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation
available for distribution to its stockholders or (b) a Deemed Liquidation Event (as defined below), out of the consideration payable
to stockholders in such Deemed Liquidation Event or the Available Proceeds (as defined below), before any payment shall be made to the
holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i) one (1) times the Original
Issue Price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of
Preferred Stock been converted into Common Stock pursuant to Section &lrm;4 immediately prior to such liquidation, dissolution, winding
up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the &ldquo;<B>Liquidation Amount</B>&rdquo;).
If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation
available for distribution to its stockholders shall be insufficient to pay the holders of shares of Preferred Stock the full amount to
which they shall be entitled under this <U>Section &lrm;2.1</U>, the holders of shares of Preferred Stock shall share ratably in any distribution
of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares
held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.2   <U>Payments
to Holders of Common Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation,
after the payment in full of all Liquidation Amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets
of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not
payable to the holders of shares of Preferred Stock pursuant to <U>Section &lrm;2.1</U> or the remaining Available Proceeds, as the case
may be, shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2.3   <U>Deemed
Liquidation Events</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">2.3.1   <U>Definition</U>.
Each of the following events shall be considered a &ldquo;<B>Deemed Liquidation Event</B>&rdquo; unless the holders of at least a majority
of the outstanding shares of Preferred Stock, voting together as a single class on an as-converted to Common Stock basis (the &ldquo;<B>Requisite
Holders</B>&rdquo;), elect otherwise by affirmative vote or written notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(a)   a
merger, consolidation, statutory conversion, transfer, domestication or continuance, in each case with a person or persons other than
those that, directly or indirectly, control, are controlled by or under common control with the Corporation (each an &ldquo;<B>Affiliate</B>&rdquo;),
and in which</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">the Corporation is a constituent party or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital
stock pursuant to such merger, consolidation, statutory conversion, transfer, domestication or continuance, </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">except any such merger, consolidation, statutory
conversion, transfer, domestication or continuance involving the Corporation or a subsidiary in which the shares of capital stock of the
Corporation outstanding immediately prior to such merger, consolidation, statutory conversion, transfer, domestication, or continuance
continue to represent, or are converted into or exchanged for shares of capital stock or other equity interests that represent, immediately
following such merger, consolidation, statutory conversion, transfer, domestication or continuance, at least a majority, by voting power,
of the capital stock of (1) the surviving or resulting corporation or entity; or (2) if the surviving or resulting corporation or entity
is a wholly owned subsidiary of another corporation immediately following such merger, consolidation, statutory conversion, transfer,
domestication or continuance, the parent corporation or entity of such surviving or resulting corporation or entity; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(b)   (1)
the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation
or any subsidiary of the Corporation of all or substantially all the assets or intellectual property (other than a license in a field
of use not central to the Corporation&rsquo;s business) of the Corporation and its subsidiaries taken as a whole to persons that are not
directly or indirectly Affiliates of the Corporation or (2) the sale, lease, transfer, exclusive license or other disposition (whether
by merger, consolidation, statutory conversion, transfer, domestication or continuance or otherwise, and whether in a single transaction
or a series of related transactions) of one (1) or more subsidiaries of the Corporation if substantially all of the assets of the Corporation
and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries to persons that are not directly or indirectly Affiliates
of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">2.3.2   <U>Effecting
a Deemed Liquidation Event</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(a)   The
Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <U>Section &lrm;2.3.1(a)(i)</U> unless the agreement
or plan with respect to such transaction, or terms of such transaction (any such agreement, plan or terms, the &ldquo;<B>Transaction Document</B>&rdquo;)
provides that the consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event shall be allocated to
the holders of capital stock of the Corporation in accordance with <U>Sections &lrm;2.1</U> and <U>&lrm;2.2.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(b)   In
the event of a Deemed Liquidation Event referred to in <U>Section &lrm;2.3.1(a)(ii)</U> or <U>&lrm;2.3.1(b)</U>, if the Corporation does
not effect a dissolution of the Corporation under the General Corporation Law within ninety (90) days after such Deemed Liquidation Event,
then (i) the Corporation shall send a written notice to each holder of Preferred Stock no later than the ninetieth (90<SUP>th</SUP>) day
after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant
to the terms of the following clause (ii) to require the redemption of such shares of Preferred Stock, and (ii) if the Requisite Holders
so request in a written instrument delivered to the Corporation not later than one hundred twenty (120) days after such Deemed Liquidation
Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained
liabilities associated with the assets sold or technology licensed, any other expenses reasonably related to such Deemed Liquidation Event
or any other expenses incident to the dissolution of the Corporation as provided herein, in each case as determined in good faith by the
Board of Directors of the Corporation (the &ldquo;<B>Board of Directors</B>&rdquo;))<B>, </B>together with any other assets of the Corporation
available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the
&ldquo;<B>Available Proceeds</B>&rdquo;), on the one hundred fiftieth (150<SUP>th</SUP>) day after such Deemed Liquidation Event (the
&ldquo;<B>DLE Redemption Date</B>&rdquo;), to redeem all outstanding shares of Preferred Stock at a price per share equal to the applicable
Liquidation Amount; <U>provided</U>, that if the definitive agreements governing such Deemed Liquidation Event contain contingent indemnification
obligations on the part of the Corporation and prohibit the Corporation from distributing all or a portion of the Available Proceeds while
such indemnification obligations remain outstanding, then the DLE Redemption Date shall automatically be extended to the date that is
ten (10) business days following the date on which such prohibition expires. Notwithstanding the foregoing, in the event of a redemption
pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock,
the Corporation shall redeem a pro rata portion of each holder&rsquo;s shares of Preferred Stock to the fullest extent of such Available
Proceeds, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds
were sufficient to redeem all such shares, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing
distributions to stockholders. Prior to the distribution or redemption provided for in this <U>Section&nbsp;&lrm;2.3.2&lrm;(b)</U>, the
Corporation shall not expend or dissipate the Available Proceeds for any purpose, except to discharge expenses incurred in connection
with such Deemed Liquidation Event. In connection with a distribution or redemption provided for in <U>Section &lrm;2.3.2</U>, the Corporation
shall send written notice of the redemption (the &ldquo;<B>Redemption Notice</B>&rdquo;) to each holder of record of Preferred Stock.
Each Redemption Notice shall state:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">the number of shares of Preferred Stock held by the holder that the Corporation shall redeem on the date
specified in the Redemption Notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">the redemption date and the price per share at which the shares of Preferred Stock are being redeemed;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the
manner and at the place designated, his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">If the Redemption Notice shall
have been duly given, and if payment is tendered or deposited with an independent payment agent so as to be available therefor in a timely
manner, then notwithstanding that any certificates evidencing any of the shares of Preferred Stock so called for redemption shall not
have been surrendered, all rights with respect to such shares shall forthwith after the date terminate, except only the right of the holders
to receive the payment without interest upon surrender of any such certificate or certificates therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">2.3.3   <U>Amount
Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any such
merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property,
rights or securities to be paid or distributed to such holders pursuant to such Deemed Liquidation Event. The value of such property,
rights or securities shall be determined in good faith by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">2.3.4   <U>Allocation
of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to <U>Section &lrm;2.3.1&lrm;(a)&lrm;(i)</U>,
if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies
(the &ldquo;<B>Additional Consideration</B>&rdquo;), the Transaction Document shall provide that (a) the portion of such consideration
that is not Additional Consideration (such portion, the &ldquo;<B>Initial Consideration</B>&rdquo;) shall be allocated among the holders
of capital stock of the Corporation in accordance with <U>Sections &lrm;2.1</U> and <U>&lrm;2.2</U> as if the Initial Consideration were
the only consideration payable in connection with such Deemed Liquidation Event; and (b) any Additional Consideration which becomes payable
to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of
the Corporation in accordance with <U>Sections &lrm;2.1</U> and <U>&lrm;2.2</U> after taking into account the previous payment of the
Initial Consideration as part of the same transaction. For the purposes of this <U>Section &lrm;2.3.4</U>, consideration placed into escrow
or retained as a holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation
Event shall be deemed to be Additional Consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.   <U>Voting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">3.1   <U>General</U>.
On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the
Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be
entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held
by such holder are convertible (as provided in <U>Section &lrm;4</U> below) as of the record date for determining stockholders entitled
to vote on such matter. Except as provided by law or by the other provisions of this Amended and Restated Certificate of Incorporation,
holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and on an as-converted to Common Stock
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">3.2   <U>Election
of Directors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.2.1   The
holders of record of the shares of Preferred Stock, voting together exclusively and as a separate class on an as-converted to Common Stock
basis, shall be entitled to elect one (1) director of the Corporation (the &ldquo;<B>Preferred Director</B>&rdquo;) and the holders of
record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and
voting together as a single class on an as-converted to Common Stock basis, shall be entitled to elect the balance of the total number
of directors of the Corporation (the &ldquo;<B>At-Large Directors</B>&rdquo;); <U>provided</U>, <U>however</U>, for administrative convenience,
the initial Preferred Director may also be appointed by the Board of Directors in connection with the approval of the initial issuance
of Preferred Stock without a separate action by the holders of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.2.2   Any
director elected as provided in the <U>Section &lrm;3.2.1</U> may be removed without cause by, and only by, the affirmative vote of the
holders of a majority of the shares of the class or series of capital stock entitled to elect such director or directors, voting together
as a single class on an as-converted to Common Stock basis, given either at a special meeting of such stockholders duly called for that
purpose or pursuant to a written consent of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.2.3   </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(a)   If
the holders of shares of Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled
to elect directors, pursuant to <U>Section &lrm;3.2.1</U> (and to the extent any of such directorships is not otherwise filled by a director
appointed in accordance with the proviso in <U>Section &lrm;3.2.1)</U>, then any directorship not so filled shall remain vacant until
such time as the holders of the Preferred Stock fill such directorship in accordance with <U>Section &lrm;3.2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(b)   A
vacancy in any At-Large Director seat can be filled by either (A) the vote or written consent in lieu of a meeting of the stockholders
entitled elect the At-Large Directors, or (B) the vote or written consent in lieu of a meeting of a majority of the remaining director(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.2.4   At
any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding
shares of the Common Stock and of any other class or series of capital stock entitled to elect such director shall constitute a quorum
for the purpose of electing such director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">3.3
<U>Preferred Stock Protective Provisions</U>. At any time when shares of Preferred Stock (subject to appropriate adjustment in the event
of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Stock) are outstanding,
the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer, continuance, recapitalization,
reclassification, waiver, statutory conversion, or otherwise, effect any of the following acts or transactions without (in addition to
any other vote required by law or this Amended and Restated Certificate of Incorporation) the written consent or affirmative vote of the
Requisite Holders and any such&nbsp;act or transaction that has not been approved by such consent or vote prior to such act or transaction
being effected shall be null and void <I>ab initio</I>, and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.3.1   liquidate,
dissolve or wind-up the business and affairs of the Corporation or effect any Deemed Liquidation Event or any other merger, consolidation,
statutory conversion, transfer, domestication or continuance or consent to any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.3.2   amend,
alter or repeal any provision of this Amended and Restated Certificate of Incorporation or Bylaws of the Corporation (the &ldquo;<B>Bylaws</B>&rdquo;)
in a manner that adversely affects the special rights, powers and preferences of the Preferred Stock (or any series thereof);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.3.3   create,
or authorize the creation of, or issue or obligate itself to issue shares of, or reclassify, any capital stock unless the same ranks junior
to the Preferred Stock with respect to its special rights, powers and preferences;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.3.4   increase
the authorized number of shares of Preferred Stock or any additional class or series of capital stock of the Corporation unless the same
ranks junior to the Preferred Stock with respect to its rights, preferences and privileges;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.3.5   purchase
or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital
stock of the Corporation other than (i) redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein,
(ii) dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock and (iii)&nbsp;repurchases
of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary
in connection with the cessation of such employment or service at no greater than the original purchase price thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.3.6   create,
or hold capital stock in, any subsidiary that is not wholly owned (either directly or through one (1) or more other subsidiaries) by the
Corporation, or permit any subsidiary to create, or authorize the creation of, or issue or obligate itself to issue, any shares of any
class or series of capital stock, or sell, transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of
the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a
single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary, in each case without
the approval of the Board of Directors; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">3.3.7   enter
into any agreement or otherwise obligate the Corporation or any subsidiary to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.   <U>Optional
Conversion</U>. The holders of the Preferred Stock shall have conversion rights as follows (the &ldquo;<B>Conversion Rights</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4.1   <U>Right
to Convert</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.1.1   <U>Conversion
Ratio</U>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time, and without the payment
of additional consideration by the holder thereof, into such whole number of fully paid and non-assessable shares of Common Stock (calculated
as provided in <U>Section 4.2</U> below) as is determined by dividing the applicable Original Issue Price by the applicable Conversion
Price (as defined below) in effect at the time of conversion. The &ldquo;<B>Conversion Price</B>&rdquo; applicable to the Series A Preferred
Stock as of the Original Issue Date shall be equal to $0.15 per share. Such initial Conversion Price for a series of Preferred Stock,
and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided
in this <U>Section &lrm;4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.1.2   <U>Termination
of Conversion Rights</U>. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the
Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts
distributable on such event to the holders of Preferred Stock; <U>provided</U> that the foregoing termination of Conversion Rights shall
not affect the amount(s) otherwise paid or payable in accordance with <U>Section &lrm;2.1</U> to the holders of Preferred Stock pursuant
to such liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4.2   <U>Number
of Shares Issuable Upon Conversion</U>. The number of shares of Common Stock issuable to a holder of Preferred Stock upon conversion of
such Preferred Stock shall be rounded to the nearest whole share. For the avoidance of doubt, no fractional interests in shares of Common
Stock shall be created or issuable as a result of the conversion of the Preferred Stock pursuant to <U>Section 4.1.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4.3   <U>Mechanics
of Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.3.1   <U>Notice
of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock,
such holder shall (a) provide written notice to the Corporation&rsquo;s transfer agent at the office of the transfer agent for the Preferred
Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent) that such holder elects to convert
all or any number of such holder&rsquo;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent
and (b), if such holder&rsquo;s shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock
(or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement
reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account
of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the
principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder&rsquo;s
name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required by the Corporation,
any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form
satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close
of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of
such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the &ldquo;<B>Conversion
Time</B>&rdquo;), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of
record as of such date. The Corporation shall, as soon as practicable after the Conversion Time (i) issue and deliver to such holder of
Series A Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock
issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Series
A Preferred Stock represented by any surrendered certificate that were not converted into Common Stock, and (ii) pay all declared but
unpaid dividends on the shares of Preferred Stock converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.3.2   <U>Reservation
of Shares</U>. The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep available out of its
authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized
shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at
any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding
shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued
shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best
efforts to obtain the requisite stockholder approval of any necessary amendment to this Amended and Restated Certificate of Incorporation.
Before taking any action that would cause an adjustment reducing the Conversion Price for any series of Preferred Stock below the then
par value of the shares of Common Stock issuable upon conversion of such series of Preferred Stock, the Corporation will take any corporate
action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and
non-assessable shares of Common Stock at such adjusted Conversion Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.3.3   <U>Effect
of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be
deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except
only the right of the holders thereof to receive shares of Common Stock in exchange therefor and to receive payment of any dividends declared
but unpaid thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.3.4   <U>No
Further Adjustment</U>. Upon any such conversion, no adjustment to the Conversion Price shall be made for any declared but unpaid dividends
on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.3.5   <U>Taxes</U>.
The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares
of Common Stock upon conversion of shares of Preferred Stock pursuant to this <U>Section&nbsp;&lrm;4</U>. The Corporation shall not, however,
be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock
in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall
be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established,
to the satisfaction of the Corporation, that such tax has been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4.4   <U>Adjustments
to Preferred Stock Conversion Price for Diluting Issues</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.4.1   <U>Special
Definitions</U>. For purposes of this Article &lrm;Fourth, the following definitions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(a)   &ldquo;<B>Additional
Shares of Common Stock</B>&rdquo; means all shares of Common Stock issued (or, pursuant to <U>Section&nbsp;&lrm;4.4.3</U> below, deemed
to be issued) by the Corporation after the Original Issue Date (as defined below), other than (1) the following shares of Common Stock
and (2) shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1) and (2), collectively,
&ldquo;<B>Exempted Securities</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">as to any series of Preferred Stock shares of Common Stock, Options or Convertible Securities issued as
a dividend or distribution on such series of Preferred Stock (including dividends payable in connection with dividends on other classes
or series of stock);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split,
split-up or other distribution on shares of Common Stock that is covered by <U>Section &lrm;4.5</U>, <U>&lrm;4.6</U>, <U>&lrm;4.7</U>
or <U>&lrm;4.8</U><B>;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to,
the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved (i) prior to the Original Issue Date
or (ii) by the Board of Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: left">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares
of Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant
to the terms of such Option or Convertible Security;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: left">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other
financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction
approved by the Board of Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: left">shares of Common Stock, Options or Convertible Securities issued to suppliers or third party service providers
in connection with the provision of goods or services pursuant to transactions approved by the Board of Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: left">shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant
to the acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization
or to a joint venture agreement, <U>provided</U> that such issuances are approved by the Board of Directors; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: left">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board
of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(b)   &ldquo;<B>Convertible
Securities</B>&rdquo; means any evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable
for Common Stock, but excluding Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(c)   &ldquo;<B>Option</B>&rdquo;
means rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(d)   &ldquo;<B>Original
Issue Date</B>&rdquo; means the date the first share of Series A Preferred Stock is issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.4.2   <U>No
Adjustment of Preferred Stock Conversion Price</U>. No adjustment in the Conversion Price of any series of Preferred Stock shall be made
as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from
the Requisite Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional
Shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.4.3   <U>Deemed
Issue of Additional Shares of Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(a)   If
the Corporation at any time or from time to time after the Original Issue Date shall issue any Options or Convertible Securities (excluding
Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders
of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares of Common
Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility
or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the
exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible
Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date
shall have been fixed, as of the close of business on such record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(b)   If
the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Conversion Price of any series
of Preferred Stock pursuant to the terms of <U>Section &lrm;4.4.4</U>, are revised as a result of an amendment to such terms or any other
adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant
to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase or decrease in the
number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or
(2) any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective
upon such increase or decrease becoming effective, the Conversion Price of such series of Preferred Stock computed upon the original issue
of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Conversion
Price of such series of Preferred Stock as would have obtained had such revised terms been in effect upon the original date of issuance
of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this <U>Section 4.4.3(b)</U> shall
have the effect of increasing the Conversion Price applicable to a series of Preferred Stock to an amount which exceeds the lower of (i)
the Conversion Price for such series of Preferred Stock in effect immediately prior to the original adjustment made as a result of the
issuance of such Option or Convertible Security, or (ii) the Conversion Price for such series of Preferred Stock that would have resulted
from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result
of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(c)   If
the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities),
the issuance of which did not result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of
<U>Section &lrm;4.4.4</U> (either because the consideration per share (determined pursuant to <U>Section &lrm;4.4.5</U>) of the Additional
Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then in effect, or because such Option
or Convertible Security was issued before the Original Issue Date), are revised after the Original Issue Date as a result of an amendment
to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments
to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase
in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security
or (2) any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible
Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in <U>Section
&lrm;4.4.3&lrm;(a))</U> shall be deemed to have been issued effective upon such increase or decrease becoming effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(d)   Upon
the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which
resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Conversion Price of any series of
Preferred Stock pursuant to the terms of <U>Section&nbsp;&lrm;4.4.4</U>, the Conversion Price of such series of Preferred Stock shall
be readjusted to such Conversion Price for such series of Preferred Stock as would have obtained had such Option or Convertible Security
(or portion thereof) never been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(e)   If
the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or
the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or
Convertible Security is issued or amended but is potentially subject to adjustment based upon subsequent events, any adjustment to the
Conversion Price of a series of Preferred Stock provided for in this <U>Section&nbsp;&lrm;4.4.3</U> shall be effected at the time of such
issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments
(and any subsequent adjustments shall be treated as provided in <U>clauses &lrm;(b)</U> and <U>&lrm;(c)</U> of this <U>Section&nbsp;&lrm;4.4.3</U>).
If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security,
or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time
such Option or Convertible Security is issued or amended, any adjustment to the Conversion Price of a series of Preferred Stock that would
result under the terms of this <U>Section&nbsp;&lrm;4.4.3</U> at the time of such issuance or amendment shall instead be effected at the
time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for
purposes of calculating such adjustment to the Conversion Price for such series of Preferred Stock that such issuance or amendment took
place at the time such calculation can first be made. In the event an Option or Convertible Security contains alternative conversion terms,
such as a cap on the valuation of the Corporation at which such conversion will be effected, or circumstances where the Option or Convertible
Security may be repaid in lieu of conversion, then the number of shares of Common Stock issuable upon the exercise, conversion and/or
exchange of such Option or Convertible Security shall be deemed not calculable until such time as the applicable conversion terms are
determined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">4.4.4   <U>Adjustment
of Conversion Price Upon Issuance of Additional Shares of Common Stock</U>. In the event the Corporation shall at any time after the Original
Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Section&nbsp;&lrm;4.4.3</U>),
without consideration or for a consideration per share less than the Conversion Price of a series of Preferred Stock in effect immediately
prior to such issuance or deemed issuance, then the Conversion Price for such series of Preferred Stock shall be reduced, concurrently
with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CP<SUB>2</SUB> = CP<SUB>1</SUB>* (A + B) &divide;
(A + C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For purposes of the foregoing formula, the following
definitions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(a)   &ldquo;CP<SUB>2</SUB>&rdquo;
shall mean the Conversion Price of such series of Preferred Stock in effect immediately after such issuance or deemed issuance of Additional
Shares of Common Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(b)   &ldquo;CP<SUB>1</SUB>&rdquo;
shall mean the Conversion Price of such series of Preferred Stock in effect immediately prior to such issuance or deemed issuance of Additional
Shares of Common Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(c)   &ldquo;A&rdquo;
shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of Additional Shares
of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately
prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding
(assuming exercise of any outstanding Options therefor) immediately prior to such issue);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(d)   &ldquo;B&rdquo;
shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued
or deemed issued at a price per share equal to CP<SUB>1</SUB> (determined by dividing the aggregate consideration received by the Corporation
in respect of such issue by CP<SUB>1</SUB>); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(e)   &ldquo;C&rdquo;
shall mean the number of such Additional Shares of Common Stock issued in such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">4.4.5   <U>Determination
of Consideration</U>. For purposes of this <U>Section &lrm;4.4</U>, the consideration received by the Corporation for the issuance or
deemed issuance of any Additional Shares of Common Stock shall be computed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(a)   <U>Cash
and Property</U>. Such consideration shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">insofar as it consists of property other than cash, be computed at the fair market value thereof at the
time of such issue, as determined in good faith by the Board of Directors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: left">in the event Additional Shares of Common Stock are issued together with other shares or securities or
other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as
provided in <U>clauses &lrm;(i)</U> and <U>&lrm;(ii</U>) above, as determined in good faith by the Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(b)   <U>Options
and Convertible Securities</U>. The consideration per share received by the Corporation for Additional Shares of Common Stock deemed to
have been issued pursuant to <U>Section&nbsp;&lrm;4.4.3</U>, relating to Options and Convertible Securities, shall be determined by dividing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: left">The total amount, if any, received or receivable by the Corporation as consideration for the issue of
such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments
relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the
Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options
for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible
Securities, by</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: left">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without
regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the
conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options
for Convertible Securities and the conversion or exchange of such Convertible Securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">4.4.6   <U>Multiple
Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are a part of
one transaction or a series of related transactions and that would result in an adjustment to the Conversion Price of a series of Preferred
Stock pursuant to the terms of <U>Section &lrm;4.4.4</U>, then, upon the final such issuance, the Conversion Price for such series of
Preferred Stock shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and
without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4.5   <U>Adjustment
for Stock Splits and Combinations</U>. If the Corporation shall at any time or from time to time after the Original Issue Date effect
a subdivision of the outstanding Common Stock, the Conversion Price of each series of Preferred Stock in effect immediately before that
subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such
series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation
shall at any time or from time to time after the Original Issue Date combine the outstanding shares of Common Stock, the Conversion Price
of each series of Preferred Stock in effect immediately before the combination shall be proportionately increased so that the number of
shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate
number of shares of Common Stock outstanding. Any adjustment under this <U>Section &lrm;4.5</U> shall become effective at the close of
business on the date the subdivision or combination becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4.6   <U>Adjustment
for Certain Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the Original Issue Date
shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution
payable on the Common Stock in additional shares of Common Stock, then and in each such event the Conversion Price of each series of Preferred
Stock in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall
have been fixed, as of the close of business on such record date, by multiplying the Conversion Price of each such series of Preferred
Stock then in effect by a fraction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(1)   the
numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance
or the close of business on such record date, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(2)   the
denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or
distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Notwithstanding the foregoing, (a) if such record
date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the
Conversion Price of each series of Preferred Stock shall be recomputed accordingly as of the close of business on such record date and
thereafter the Conversion Price of each series of Preferred Stock shall be adjusted pursuant to this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.6</U>
as of the time of actual payment of such dividends or distributions; and (b) that no such adjustment shall be made if the holders of such
series of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number
of shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into
Common Stock on the date of such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4.7   <U>Adjustments
for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the Original Issue Date
shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution
payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common
Stock) or in other property and the provisions of <U>Section&nbsp;&lrm;1</U> do not apply to such dividend or distribution, then and in
each such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend
or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they
would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4.8   <U>Adjustment
for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Section &lrm;2.3</U>, if there shall occur any reorganization,
recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred
Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by <U>Sections &lrm;4.4</U>,
<U>&lrm;4.6</U> or <U>&lrm;4.7</U>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger,
each share of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such
event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation
issuable upon conversion of one (1) share of such Preferred Stock immediately prior to such reorganization, recapitalization, reclassification,
consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as
determined in good faith by the Board of Directors) shall be made in the application of the provisions in this <U>Section &lrm;4</U> with
respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this
<U>Section &lrm;4</U> (including provisions with respect to changes in and other adjustments of the Conversion Price of each series of
Preferred Stock) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter
deliverable upon the conversion of the Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4.9   <U>Certificate
as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Conversion Price of a series of Preferred Stock pursuant
to this <U>Section &lrm;4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later
than ten (10) days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder
of each series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities,
cash or other property into which such series of Preferred Stock is convertible) and showing in detail the facts upon which such adjustment
or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder
of Preferred Stock (but in any event not later than ten (10) days thereafter), furnish or cause to be furnished to such holder a certificate
setting forth (i) the Conversion Price then in effect for each series of Preferred Stock held by such holder, and (ii) the number of shares
of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of each
such series of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4.10   <U>Notice
of Record Date</U>. In the event:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(a)   the
Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon conversion
of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any
right to subscribe for or purchase any shares of capital stock of any class or series or any other securities, or to receive any other
security; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(b)   of
any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation
Event; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">(c) of the voluntary or
involuntary dissolution, liquidation or winding-up of the Corporation,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0in">then, and in each such case, the Corporation will send or
cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i) the record date for such
dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on
which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is proposed to
take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or
securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common
Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization,
reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up, and the amount per share and character of
such exchange applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least ten (10) days prior to the
record date or effective date for the event specified in such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.   <U>Mandatory
Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">5.1   <U>Trigger
Events</U>. All outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective
conversion rate as calculated pursuant to <U>Sections&nbsp;4.1.1</U> and <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>4.2</U>,
upon the earliest to occur of (the time of such conversion is referred to herein as the &ldquo;<B>Mandatory Conversion Time</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">5.1.1   Immediately
prior to the closing of the sale of shares of Common Stock to the public at a price of at least $1.00 per share (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock),
in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as
amended, resulting in at least $50,000,000 of gross proceeds, net of the underwriting discount and commissions, to the Corporation and
in connection with such offering the shares of Common Stock are listed for trading on the Nasdaq Stock Market&rsquo;s National Market,
the New York Stock Exchange or another exchange or marketplace approved by the Board of Directors; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1.5in">5.1.2
The date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">5.2   <U>Procedural
Requirements</U>. All holders of record of shares of Preferred Stock (or the applicable series thereof) shall be sent written notice of
the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this
<U>Section &lrm;5</U>. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such
notice, each holder of shares of Preferred Stock being converted that holds such shares of Preferred Stock in certificated form shall
surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost,
stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation
against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to
the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion
shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed
by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted
pursuant to <U>Section &lrm;5.1</U>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock),
will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates
at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders
(or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <U>Section &lrm;5.2</U>.
As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost
certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a) issue and deliver to such holder, or to his, her or
its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance
with the provisions hereof, and (b) pay any declared but unpaid dividends on the shares of Preferred Stock converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.   <U>Redeemed
or Otherwise Acquired Shares</U>. Unless approved by the Board of Directors and the Requisite Holders, any shares of Preferred Stock that
are redeemed, converted or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled
and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting
or other rights granted to the holders of Preferred Stock following redemption, conversion or acquisition. The Corporation may thereafter
take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of
Preferred Stock accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.   <U>Waiver</U>.
Except as otherwise set forth herein, (a) any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein
may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the holders that would otherwise
be required to amend such right, powers, preferences and other terms and (b) at any time more than one (1) series of Preferred Stock is
issued and outstanding, any of the rights, powers, preferences and other terms of any series of Preferred Stock set forth herein may be
waived on behalf of all holders of such series of Preferred Stock by the affirmative written consent or vote of the holders of such series
of Preferred Stock that would otherwise be required to amend such right, power, preference, or other term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.   <U>Notices</U>.
Any notice required or permitted by the provisions of this Article &lrm;Fourth to be given to a holder of shares of Preferred Stock shall
be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic transmission
in compliance with the provisions of the DGCL, and shall be deemed sent upon such mailing or electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Fifth</B></FONT><B>:</B>
Subject to any additional vote required by this Amended and Restated Certificate of Incorporation or the Bylaws, in furtherance and not
in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind
any or all of the Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Sixth</B></FONT><B>:</B>
Subject to any additional vote required by this Amended and Restated Certificate of Incorporation, the number of directors of the Corporation
shall be determined in the manner set forth in the Bylaws of the Corporation. Each director shall be entitled to one (1) vote on each
matter presented to the Board of Directors; <U>provided</U>, <U>however</U>, that, so long as the holders of Preferred Stock are entitled
to elect one or more Preferred Directors, the affirmative vote of such Preferred Directors shall be required for the authorization by
the Board of Directors of any of the matters set forth in the Investors&rsquo; Rights Agreement, dated on or about the Original Issue
Date, by and among the Corporation and the other parties thereto, as such agreement may be amended from time to time, to the extent required
by such provision and if such Preferred Directors are then serving.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Seventh</B></FONT><B>:</B>
Elections of directors need not be by written ballot unless the Bylaws shall so provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Eighth</B></FONT><B>:</B>
Meetings of stockholders may be held within or outside of the State of Delaware, as the Bylaws of the Corporation may provide. The books
of the Corporation may be kept (subject to any provision of applicable law) outside of the State of Delaware at such place or places or
in such manner or manners as may be designated from time to time by the Board of Directors or in the Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Ninth</B></FONT><B>:</B>
To the fullest extent permitted by law, a director or officer of the Corporation shall not be personally liable to the Corporation or
its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL or any other law of the State
of Delaware is amended after approval by the stockholders of this Article Ninth to authorize corporate action further eliminating or limiting
the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or
limited to the fullest extent permitted by the DGCL as so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any amendment, repeal or elimination
of the foregoing provisions of this <U>Article Ninth</U> by the stockholders of the Corporation shall not adversely affect any right or
protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with
respect to any acts or omissions of such director occurring prior to, such amendment, repeal or elimination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Tenth</B></FONT><B>:</B>
To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses
to) directors, officers and agents of the Corporation (and any other persons to which the DGCL permits the Corporation to provide indemnification)
through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise,
in excess of the indemnification and advancement otherwise permitted by Section 145 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">Any amendment, repeal, modification
or elimination of the foregoing provisions of this Article &lrm;Tenth shall not (a) adversely affect any right or protection of any director,
officer or other agent of the Corporation existing at the time of such amendment, repeal, modification or elimination; or (b) increase
the liability of any director, officer or agent of the Corporation with respect to any acts or omissions of such director, officer or
agent occurring prior to, such amendment, repeal, modification or elimination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Eleventh</B></FONT><B>:</B>
The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered
an opportunity to participate in, any Excluded Opportunity. An &ldquo;<B>Excluded Opportunity</B>&rdquo; is any matter, transaction or
interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i) any director
of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Preferred Stock or any
partner, member, director, stockholder, employee, affiliate or agent of any such holder, other than someone who is an employee of the
Corporation or any of its subsidiaries (collectively, the persons referred to in <U>clauses (</U>i) and <U>(ii)</U> are &ldquo;<B>Covered
Persons</B>&rdquo;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes
into the possession of, a Covered Person expressly and solely in such Covered Person&rsquo;s capacity as a director of the Corporation
while such Covered Person is performing services in such capacity. Any repeal or modification of this Article Eleventh will only be prospective
and will not affect the rights under this Article Eleventh in effect at the time of the occurrence of any actions or omissions to act
giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Amended and Restated Certificate of Incorporation,
in addition to any other vote required by law or this Amended and Restated Certificate of Incorporation, the affirmative vote of the Requisite
Holders, will be required to amend or repeal, or to adopt any provisions inconsistent with this Article &lrm;Eleventh.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Twelfth</B></FONT><B>:</B>
Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall
be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding
brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer
or other employee of the Corporation to the Corporation or the Corporation&rsquo;s stockholders, (iii)&nbsp;any action asserting a claim
against the Corporation, its directors, officers or employees arising pursuant to any provision of the DGCL or the Corporation&rsquo;s
Amended and Restated Certificate of Incorporation or Bylaws or (iv)&nbsp;any action asserting a claim against the Corporation, its directors,
officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of the Corporation,
except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable
party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction
of the Court of Chancery within ten (10) days following such determination), which is vested in the exclusive jurisdiction of a court
or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Thirteenth</B></FONT><B>:</B>
If any provision or provisions of this Amended and Restated Certificate of Incorporation shall be held to be invalid, illegal or unenforceable
as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity,
legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Amended and Restated
Certificate of Incorporation (including, without limitation, each portion of any sentence of this Amended and Restated Certificate of
Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal
or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected
or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">23</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>3
<FILENAME>ea020512201ex3-6_arcabio.htm
<DESCRIPTION>BYLAWS OF ORUKA THERAPEUTICS, INC, AS CURRENTLY IN EFFECT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORUKA
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BYLAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adopted
February 6, 2024</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;I</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
STOCKHOLDERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.&nbsp;<U>Annual
Meeting</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such
other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors
shall each year fix, which date shall be within 13 months of the last annual meeting of stockholders or, if no such meeting has been
held, the date of incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.&nbsp;<U>Special
Meetings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by the Board of Directors
or the Chief Executive Officer, if one is elected, or the President, and shall be held at such place, on such date, and at such time
as they or he or she shall fix.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.&nbsp;<U>Notice
of Meetings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
of the place, if any, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders
and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders
entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the
meeting, shall be given, not less than 10 nor more than 60 days before the date on which the meeting is to be held, to each stockholder
entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting, except as
otherwise provided herein or required by law (meaning, here and hereinafter, as required from time to time by the Delaware General Corporation
Law or the Certificate of Incorporation of the Corporation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place, if any, thereof,
and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote
at such adjourned meeting are announced at the meeting at which the adjournment is taken; <I>provided</I>, <I>however</I>, that if the
date of any adjourned meeting is more than 30 days after the date for which the meeting was originally noticed, notice of the place,
if any, date, and time of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders
may be deemed to be present in person and vote at such adjourned meeting, shall be given to each stockholder in conformity herewith.
If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors
shall fix a new record date for notice of such adjourned meeting, which record date shall not precede the date upon which the resolution
fixing the record date is adopted by the Board of Directors and, except as otherwise required by law, shall not be more than 60 nor less
than 10 days before the date of such adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record
entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting. At any adjourned meeting,
any business may be transacted which might have been transacted at the original meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.&nbsp;<U>Quorum</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any meeting of the stockholders, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the
meeting, present in person or by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence
of a larger number may be required by law. Where a separate vote by a class or classes or series is required, a majority of the voting
power of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to
take action with respect to that vote on that matter. The stockholders present at a duly constituted meeting may continue to transact
business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to
vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.&nbsp;<U>Organization</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
person as the Board of Directors may have designated or, in the absence of such a person, the President of the Corporation or, in his
or her absence, such person as may be chosen by the holders of a majority of the voting power of the shares entitled to vote who are
present, in person or by proxy, shall call to order any meeting of the stockholders and act as chairman of the meeting. In the absence
of the Secretary of the Corporation, the secretary of the meeting shall be such person as the chairman of the meeting appoints.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.&nbsp;<U>Conduct
of Business</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chairman of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation
of the manner of voting and the conduct of discussion as seem to him or her in order. The date and time of the opening and closing of
the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.&nbsp;<U>Proxies
and Voting</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any meeting of the stockholders, every stockholder entitled to vote may vote in person or by proxy authorized by an instrument in writing
or by a transmission permitted by law filed in accordance with the procedure established for the meeting. Any copy, facsimile telecommunication
or other reliable reproduction of the writing or transmission created pursuant to this paragraph may be substituted or used in lieu of
the original writing or transmission for any and all purposes for which the original writing or transmission could be used, <I>provided
</I>that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing
or transmission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation may, and to the extent required by law, shall, in advance of any meeting of stockholders, appoint one or more inspectors
to act at the meeting and make a written report thereof. The Corporation may designate one or more alternate inspectors to replace any
inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting
may, and to the extent required by law, shall, appoint one or more inspectors to act at the meeting. Each inspector, before entering
upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality
and according to the best of his or her ability. Every vote taken by ballots shall be counted by an inspector or inspectors appointed
by the chairman of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
elections shall be determined by a plurality of the votes cast, and except as otherwise required by law, all other matters shall be determined
by a majority of the votes cast affirmatively or negatively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.&nbsp;<U>Stock
List</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
officer who has charge of the stock ledger of the Corporation shall, at least 10 days before every meeting of stockholders, prepare and
make a complete list of stockholders entitled to vote at any meeting of stockholders, <I>provided</I>, <I>however</I>, if the record
date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders
entitled to vote as of the 10th day before the meeting date, arranged in alphabetical order and showing the address of each such stockholder
and the number of shares registered in his or her name. Such list shall be open to the examination of any stockholder for a period of
at least 10 days prior to the meeting in the manner provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
stock list shall also be open to the examination of any stockholder during the whole time of the meeting as provided by law. This list
shall presumptively determine (a)&nbsp;the identity of the stockholders entitled to examine such stock list and to vote at the meeting
and (b)&nbsp;the number of shares held by each of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.&nbsp;<U>Consent
of Stockholders in Lieu of Meeting</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
action required to be taken at any annual or special meeting of stockholders of the Corporation, or any action which may be taken at
any annual or special meeting of the stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent
or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the
minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon
were present and voted and shall be delivered to the Corporation by delivery to its registered office in Delaware, its principal place
of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are
recorded. Delivery made to the Corporation&rsquo;s registered office shall be made by hand or by certified or registered mail, return
receipt requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective
to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered to the Corporation, a
written consent or consents signed by a sufficient number of holders to take action are delivered to the Corporation in the manner prescribed
in the first paragraph of this Section. A telegram, cablegram or other electronic transmission consenting to an action to be taken and
transmitted by a stockholder or proxyholder, or by a person or persons authorized to act for a stockholder or proxyholder, shall be deemed
to be written, signed and dated for the purposes of this Section to the extent permitted by law. Any such consent shall be delivered
in accordance with Section&nbsp;228(d)(1) of the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for
any and all purposes for which the original writing could be used, <I>provided that</I> such copy, facsimile or other reproduction shall
be a complete reproduction of the entire original writing.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;II</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
BOARD OF DIRECTORS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.&nbsp;<U>Number
and Term of Office</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of directors who shall constitute the whole Board of Directors shall be such number as the Board of Directors shall from time
to time have designated. Each director shall be elected for a term of one year and until his or her successor is elected and qualified,
except as otherwise provided herein or required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
the authorized number of directors is increased between annual meetings of the stockholders, a majority of the directors then in office
shall have the power to elect such new directors for the balance of a term and until their successors are elected and qualified. Any
decrease in the authorized number of directors shall not become effective until the expiration of the term of the directors then in office
unless, at the time of such decrease, there shall be vacancies on the board which are being eliminated by the decrease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.&nbsp;<U>Removal
of Directors; Resignation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided by the Certificate of Incorporation or these bylaws, any director or the entire Board of Directors may be removed,
with or without cause, by the holders of a majority of shares entitled to vote at an election of directors. Any director may resign at
any time upon notice given in writing or by electronic transmission to the Corporation. Such resignation shall be effective upon receipt
unless it is specified to be effective at some other time or upon the happening of some other event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.&nbsp;<U>Vacancies</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided in the Corporation&rsquo;s Certificate of Incorporation, as it may be amended, if the office of any director becomes
vacant by reason of death, resignation, disqualification, removal or other cause, a majority of the directors remaining in office, although
less than a quorum, may elect a successor for the unexpired term and until his or her successor is elected and qualified. Unless otherwise
provided in the Corporation&rsquo;s Certificate of Incorporation, as it may be amended, vacancies and newly created directorships resulting
from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than
a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their
successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors
may be held in the manner provided by statute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.&nbsp;<U>Regular
Meetings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regular
meetings of the Board of Directors shall be held at such place or places, on such date or dates, and at such time or times as shall have
been established by the Board of Directors and publicized among all directors. A notice of each regular meeting shall not be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.&nbsp;<U>Special
Meetings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
meetings of the Board of Directors may be called by one-third of the directors then in office (rounded up to the nearest whole number)
or by the Chief Executive Officer, if one is elected, or, if there is no Chief Executive Officer, the President, and shall be held at
such place, on such date, and at such time as they or he or she shall fix. Notice of the place, date, and time of each such special meeting
shall be given to each director by whom it is not waived by mailing written notice not less than five days before the meeting or by telegraphing
or telexing or by facsimile or electronic transmission of the same not less than 24 hours before the meeting. Unless otherwise indicated
in the notice thereof, any and all business may be transacted at a special meeting. A meeting may be held at any time without notice
if all the directors are present (except as otherwise provided by law) or if those not present waive notice of the meeting in writing,
either before or after such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.&nbsp;<U>Quorum</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any meeting of the Board of Directors, the greater of (a) a majority of the directors then in office at the time quorum is to be determined
and (b) one-third of the total number of directors fixed pursuant to <U>&lrm;Section&nbsp;1</U> of <U>&lrm;Article&nbsp;II</U> of these
Bylaws shall constitute a quorum for the transaction of business. Less than a quorum may adjourn any meeting from time to time, and the
meeting may be held as adjourned without further notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.&nbsp;<U>Participation
in Meetings By Conference Telephone</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of the Board of Directors, or of any committee thereof, may participate in a meeting of such Board of Directors or committee by means
of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other,
and such participation shall constitute presence in person at such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.&nbsp;<U>Conduct
of Business</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any meeting of the Board of Directors, business shall be transacted in such order and manner as the Board of Directors may from time
to time determine, and all matters shall be determined by the vote of a majority of the directors present, except as otherwise provided
herein or required by law. Action may be taken by the Board of Directors without a meeting if all members thereof consent thereto in
writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes
of proceedings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be
in electronic form if the minutes are maintained in electronic form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.&nbsp;<U>Compensation
of Directors</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
as such, may receive, pursuant to resolution of the Board of Directors, fixed fees and other compensation for their services as directors,
including, without limitation, their services as members of committees of the Board of Directors.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;III</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
COMMITTEES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.&nbsp;<U>Committees
of the Board of Directors</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors may from time to time designate committees of the Board of Directors, with such lawfully delegable powers and duties
as it thereby confers, to serve at the pleasure of the Board of Directors and shall, for those committees and any others provided for
herein, elect a director or directors to serve as the member or members, designating, if it desires, other directors as alternate members
who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of any member of
any committee and any alternate member in his or her place, the member or members of the committee present at the meeting and not disqualified
from voting, whether or not he or she or they constitute a quorum, may by unanimous vote appoint another member of the Board of Directors
to act at the meeting in the place of the absent or disqualified member.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.&nbsp;<U>Conduct
of Business</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
committee may determine the procedural rules for meeting and conducting its business and shall act in accordance therewith, except as
otherwise provided herein or required by law. Adequate provision shall be made for notice to members of all meetings; one-third of the
members shall constitute a quorum unless the committee shall consist of one or two members, in which event one member shall constitute
a quorum; and all matters shall be determined by a majority vote of the members present. Action may be taken by any committee without
a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic
transmission or transmissions are filed with the minutes of the proceedings of such committee. Such filing shall be in paper form if
the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;IV</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
OFFICERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.&nbsp;<U>Generally</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
officers of the Corporation will be chosen by the Board of Directors and will consist of a President, a Secretary, a Treasurer and such
other officers, including, without limitation, a Chief Executive Officer and one or more Vice Presidents, as may from time to time be
appointed by the Board of Directors. Officers shall be elected by the Board of Directors, which shall consider that subject at its first
meeting after every annual meeting of stockholders. Each officer shall hold office until his or her successor is elected and qualified
or until his or her earlier resignation or removal. Any number of offices may be held by the same person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to any limitations which may be set forth in a resolution of the Board of Directors, all deeds, leases, transfers, contracts, bonds,
notes and other obligations to be entered into by the Corporation in the ordinary course of its business without director action may
be executed on behalf of the Corporation by a President or by any other officer, employee or agent of the Corporation as the Board of
Directors may authorize.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.&nbsp;<U>Chief
Executive Officer.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chief Executive Officer, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time
to time designate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.&nbsp;<U>President</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of these Bylaws and to the direction of the Board of Directors, the President shall have the responsibility for the
general management and control of the business and affairs of the Corporation and shall perform all duties and have all powers which
are commonly incident to the office of President or which are delegated to him or her by the Board of Directors. He or she shall have
power to sign all stock certificates, contracts and other instruments of the Corporation which are authorized and shall have general
supervision and direction of all of the other officers, employees and agents of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.&nbsp;<U>Vice
President</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Vice President shall have such powers and duties as may be delegated to him or her by the Board of Directors. One Vice President shall
be designated by the Board of Directors to perform the duties and exercise the powers of the President in the event of the President&rsquo;s
absence or disability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.&nbsp;<U>Treasurer</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Treasurer shall have the responsibility for maintaining the financial records of the Corporation. He or she shall make such disbursements
of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions and of the financial
condition of the Corporation. The Treasurer shall also perform such other duties as the Board of Directors may from time to time prescribe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.&nbsp;<U>Secretary</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Secretary shall issue all authorized notices for, and shall keep minutes of, all meetings of the stockholders and the Board of Directors.
He or she shall have charge of the corporate books and shall perform such other duties as the Board of Directors may from time to time
prescribe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.&nbsp;<U>Chairman
of the Board</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided by the Board of Directors, the Chairman of the Board of Directors, if one is elected, shall preside, when present,
at all meetings of the stockholders and the Board of Directors. The Chairman of the Board shall have such other powers and shall perform
such duties as the Board of Directors may from time to time designate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.&nbsp;<U>Delegation
of Authority</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding
any provision hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.&nbsp;<U>Removal</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
officer of the Corporation may be removed at any time, with or without cause, by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.&nbsp;<U>Action
with Respect to Securities of Other Corporations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise directed by the Board of Directors, the President or any officer of the Corporation authorized by the President shall have
power to vote and otherwise act on behalf of the Corporation, in person or by proxy, at any meeting of stockholders of or with respect
to any action of stockholders of any other corporation in which this Corporation may hold securities and otherwise to exercise any and
all rights and powers which this Corporation may possess by reason of its ownership of securities in such other corporation.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;V</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.&nbsp;<U>Certificates
of Stock</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of the Corporation shall be represented by certificates, <I>provided that</I> the Board may provide by resolution or resolutions
that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to
shares represented by a certificate until such certificate is surrendered to the Corporation. Each holder of stock represented by certificates
shall be entitled to a certificate signed by, or in the name of the Corporation, by any two of the President, a Vice President, the Secretary,
an Assistant Secretary, the Treasurer, an Assistant Treasurer or any other authorized officers of the Corporation, certifying the number
of shares owned by him or her. Any or all of the signatures on the certificate may be by facsimile or electronic means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.&nbsp;<U>Transfers
of Stock</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfers
of stock shall be made only upon the transfer books of the Corporation kept at an office of the Corporation or by transfer agents designated
to transfer shares of the stock of the Corporation. Except where a certificate is issued in accordance with <U>&lrm;Section&nbsp;4</U>
of <U>&lrm;Article&nbsp;V</U> of these Bylaws, an outstanding certificate, if one has been issued, for the number of shares involved
shall be surrendered for cancellation before a new certificate, if any, is issued therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.&nbsp;<U>Record
Date</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof,
the Board of Directors may, except as otherwise required by law, fix a record date, which record date shall not precede the date upon
which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor
less than 10 days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date
for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such
record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date
is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders
shall be at the close of business on the day next preceding the day on which notice is given or, if notice is waived, at the close of
business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice
of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided</I>, <I>however</I>, that the Board
of Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case
shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed
for determination of stockholders entitled to vote in accordance with the foregoing provisions of this <U>&lrm;Section&nbsp;3</U> at
the adjourned meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment
of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the
purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which
the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record
date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which
the Board of Directors adopts the resolution relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order that the Corporation may determine the stockholders entitled to consent to corporate action without a meeting, (including by telegram,
cablegram or other electronic transmission as permitted by law), the Board of Directors may fix a record date, which shall not precede
the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall be not more
than ten days after the date upon which the resolution fixing the record date is adopted. If no record date has been fixed by the Board
of Directors and no prior action by the Board of Directors is required by the Delaware General Corporation Law, the record date shall
be the first date on which a consent setting forth the action taken or proposed to be taken is delivered to the Corporation in the manner
prescribed by <U>&lrm;Section&nbsp;9</U> of <U>Article I</U> hereof. If no record date has been fixed by the Board of Directors and prior
action by the Board of Directors is required by the Delaware General Corporation Law with respect to the proposed action by consent of
the stockholders without a meeting, the record date for determining stockholders entitled to consent to corporate action without a meeting
shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.&nbsp;<U>Lost,
Stolen or Destroyed Certificates</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations
as the Board of Directors may establish concerning proof of such loss, theft or destruction and concerning the giving of a satisfactory
bond or bonds of indemnity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.&nbsp;<U>Regulations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issue, transfer, conversion and registration of certificates of stock shall be governed by such other regulations as the Board of Directors
may establish.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VI</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
NOTICES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.&nbsp;<U>Notices</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder at such
stockholder&rsquo;s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may
be given effectively to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&nbsp;232
of the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.&nbsp;<U>Waivers</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
written waiver of any notice, signed by a stockholder or director, or waiver by electronic transmission by such person, whether given
before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given
to such person. Neither the business nor the purpose of any meeting need be specified in such a waiver. Attendance of a person at a meeting
shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at
the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VII</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.&nbsp;<U>Facsimile
or Electronic Signatures</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the provisions for use of facsimile or electronic signatures elsewhere specifically authorized in these Bylaws, facsimile
or electronic signatures of any officer or officers of the Corporation may be used whenever and as authorized by the Board of Directors
or a committee thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.&nbsp;<U>Corporate
Seal</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall be in the charge of the Secretary.
If and when so directed by the Board of Directors or a committee thereof, duplicates of the seal may be kept and used by the Treasurer
or by an Assistant Secretary or Assistant Treasurer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.&nbsp;<U>Reliance
upon Books, Reports and Records</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
director, each member of any committee designated by the Board of Directors, and each officer of the Corporation shall, in the performance
of his or her duties, be fully protected in relying in good faith upon the books of account or other records of the Corporation and upon
such information, opinions, reports or statements presented to the Corporation by any of its officers or employees, or committees of
the Board of Directors so designated, or by any other person as to matters which such director or committee member reasonably believes
are within such other person&rsquo;s professional or expert competence and who has been selected with reasonable care by or on behalf
of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.&nbsp;<U>Fiscal
Year</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fiscal year of the Corporation shall be as fixed by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.&nbsp;<U>Offices</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from
time to time determine or the business of the Corporation may require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.&nbsp;<U>Records
and Reports</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
application and requirements of Section&nbsp;1501 of the California General Corporation Law are hereby expressly waived to the fullest
extent permitted thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.&nbsp;<U>Time
Periods</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying any provision of these Bylaws which requires that an act be done or not be done a specified number of days prior to an event
or that an act be done during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing
of the act shall be excluded, and the day of the event shall be included.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VIII</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
INDEMNIFICATION OF DIRECTORS AND OFFICERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.&nbsp;<U>Right
to Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding,
whether civil, criminal, administrative or investigative (hereinafter a &ldquo;<B>proceeding</B>&rdquo;), by reason of the fact that
he or she is or was a director or an officer of the Corporation or is or was serving at the request of the Corporation as a director,
officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect
to an employee benefit plan (hereinafter an &ldquo;<B>indemnitee</B>&rdquo;), whether the basis of such proceeding is alleged action
in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee,
shall be indemnified and held harmless by the Corporation to the fullest extent permitted by Delaware law, as the same exists or may
hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide
broader indemnification rights than such law permitted the Corporation to provide prior to such amendment) against all expense, liability
and loss (including attorneys&rsquo; fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably
incurred or suffered by such indemnitee in connection therewith; <I>provided</I>, <I>however</I>, that, except as provided in <U>&lrm;Section&nbsp;3
</U>of this <U>&lrm;Article&nbsp;VIII</U> with respect to proceedings to enforce rights to indemnification, the Corporation shall indemnify
any such indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only if such proceeding (or part thereof)
was authorized by the Board of Directors of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.&nbsp;<U>Right
to Advancement of Expenses</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the right to indemnification conferred in <U>&lrm;Section&nbsp;1</U> of this <U>&lrm;Article&nbsp;VIII</U>, an indemnitee
shall also have the right to be paid by the Corporation the expenses (including attorney&rsquo;s fees) incurred in defending any such
proceeding in advance of its final disposition (hereinafter an &ldquo;<B>advancement of expenses</B>&rdquo;); <I>provided</I>, <I>however</I>,
that, if the Delaware General Corporation Law requires, an advancement of expenses incurred by an indemnitee in his or her capacity as
a director or officer (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation,
service to an employee benefit plan) shall be made only upon delivery to the Corporation of an undertaking (hereinafter an &ldquo;<B>undertaking</B>&rdquo;),
by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision
from which there is no further right to appeal (hereinafter a &ldquo;<B>final adjudication</B>&rdquo;) that such indemnitee is not entitled
to be indemnified for such expenses under this <U>&lrm;Section&nbsp;2</U> or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.&nbsp;<U>Right
of Indemnitee to Bring Suit</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a claim under <U>&lrm;Section&nbsp;1</U> or <U>&lrm;2</U> of this <U>&lrm;Article&nbsp;VIII</U> is not paid in full by the Corporation
within 60 days after a written claim has been received by the Corporation, except in the case of a claim for an advancement of expenses,
in which case the applicable period shall be 20 days, the indemnitee may at any time thereafter bring suit against the Corporation to
recover the unpaid amount of the claim. To the fullest extent permitted by law, if successful in whole or in part in any such suit, or
in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the indemnitee shall
be entitled to be paid also the expense of prosecuting or defending such suit. In (i) any suit brought by the indemnitee to enforce a
right to indemnification hereunder (but not in a suit brought by the indemnitee to enforce a right to an advancement of expenses) it
shall be a defense that, and (ii)&nbsp;in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms
of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that, the indemnitee has not
met any applicable standard for indemnification set forth in the Delaware General Corporation Law. Neither the failure of the Corporation
(including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders)
to have made a determination prior to the commencement of such suit that indemnification of the indemnitee is proper in the circumstances
because the indemnitee has met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination
by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel,
or its stockholders) that the indemnitee has not met such applicable standard of conduct, shall create a presumption that the indemnitee
has not met the applicable standard of conduct or, in the case of such a suit brought by the indemnitee, be a defense to such suit. In
any suit brought by the indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the
Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the indemnitee
is not entitled to be indemnified, or to such advancement of expenses, under this <U>&lrm;Article&nbsp;VIII</U> or otherwise, shall be
on the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.&nbsp;<U>Non-Exclusivity
of Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights to indemnification and to the advancement of expenses conferred in this <U>&lrm;Article&nbsp;VIII</U> shall not be exclusive of
any other right which any person may have or hereafter acquire under any statute, the Corporation&rsquo;s Certificate of Incorporation,
Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.&nbsp;<U>Insurance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation
or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not
the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation
Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.&nbsp;<U>Indemnification
of Employees and Agents of the Corporation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification and to the advancement
of expenses to any employee or agent of the Corporation to the fullest extent of the provisions of this <U>&lrm;Article&nbsp;VIII</U>
with respect to the indemnification and advancement of expenses of directors and officers of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.&nbsp;<U>Nature
of Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights conferred upon indemnitees in this <U>&lrm;Article&nbsp;VIII</U> shall be contract rights and such rights shall continue as to
an indemnitee who has ceased to be a director, officer or trustee and shall inure to the benefit of the indemnitee&rsquo;s heirs, executors
and administrators. Any amendment, alteration or repeal of this <U>&lrm;Article&nbsp;VIII</U> that adversely affects any right of an
indemnitee or its successors shall be prospective only and shall not limit, eliminate, or impair any such right with respect to any proceeding
involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, alteration or
repeal.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;IX</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
AMENDMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
Bylaws may be amended or repealed by the Board of Directors at any meeting or by the stockholders at any meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF SECRETARY OF<BR>
<FONT STYLE="text-transform: uppercase">ORUKA Therapeutics, Inc.</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Evan Thompson, hereby certifies that he is the duly elected and acting Secretary of Oruka Therapeutics, Inc., a Delaware
corporation (the &ldquo;<B>Corporation</B>&rdquo;), and that the Bylaws attached hereto constitute the Bylaws of said Corporation as
duly adopted by Action by Written Consent of the Sole Director in Lieu of the Organizational Meeting of the Board of Directors on February
6, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the undersigned has hereunto subscribed his or her name on February 6, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ K. Evan Thompson</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K. Evan Thompson, Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>SIGNATURE
PAGE TO ORUKA THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BYLAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ea020512201ex4-3_arcabio.htm
<DESCRIPTION>INVESTOR RIGHTS AGREEMENT, DATED MARCH 6, 2024, BY AND AMONG ORUKA THERAPEUTICS, INC. AND CERTAIN PARTIES THERETO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 4.3</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INVESTORS&rsquo; RIGHTS AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">THIS INVESTORS&rsquo; RIGHTS
AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;), is made as of March 6, 2024, by and among Oruka Therapeutics, Inc. a Delaware corporation
(the &ldquo;<B>Company</B>&rdquo;), each of the investors listed on <U>Schedule A</U> hereto, each of which is referred to in this Agreement
as an &ldquo;<B>Investor</B>&rdquo;, and each of the securityholders listed on <U>Schedule B</U> hereto, each of whom is referred to herein
as a &ldquo;<B>Key Holder</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, the Company
and the Investors are parties to that certain Series A Preferred Stock and Convertible Note Purchase Agreement of even date herewith (the
&ldquo;<B>Purchase Agreement</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, in order to
induce the Company to enter into the Purchase Agreement and to induce the Investors to invest funds in the Company pursuant to the Purchase
Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company
to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future
equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>NOW, THEREFORE</B>, the
parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="text-transform: uppercase">1.</FONT></TD><TD STYLE="text-align: left"><U>Definitions</U>. For purposes of this Agreement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.1&nbsp;&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common
control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person,
or any venture capital fund or other investment fund now or hereafter existing that is controlled by one (1) or more general partners,
managing members or investment adviser of, or shares the same management company or investment adviser with, such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.2&nbsp;&ldquo;<B>Board
of Directors</B>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.3&nbsp;&ldquo;<B>Certificate
of Incorporation</B>&rdquo; means the Company&rsquo;s Amended and Restated Certificate of Incorporation, as amended and/or restated from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.4&nbsp;&ldquo;<B>Common
Stock</B>&rdquo; means shares of the Company&rsquo;s common stock, par value $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.5&nbsp;&ldquo;<B>Damages</B>&rdquo;
means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the
Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises
out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement
of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii)
an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein
not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities
Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or
any state securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.6&nbsp;&ldquo;<B>Derivative
Securities</B>&rdquo; means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly),
Common Stock, including options and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.7&nbsp;&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.8&nbsp;&ldquo;<B>Excluded
Registration</B>&rdquo; means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary
pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145 transaction;
(iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration
statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common
Stock issuable upon conversion of debt securities that are also being registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.9&nbsp;&ldquo;<B>Form
S-1</B>&rdquo; means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities
Act subsequently adopted by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.10&nbsp;&ldquo;<B>Form
S-3</B>&rdquo; means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities
Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed
by the Company with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.11&nbsp;&ldquo;<B>Holder</B>&rdquo;
means any holder of Registrable Securities who is a party to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.12&nbsp;&ldquo;<B>Immediate
Family Member</B>&rdquo; means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, life partner or similar statutorily-recognized
domestic partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive
relationships of a natural person referred to herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.13&nbsp;&ldquo;<B>Initiating
Holders</B>&rdquo; means, collectively, Holders who properly initiate a registration request under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.14&nbsp;&ldquo;<B>IPO</B>&rdquo;
means the Company&rsquo;s first underwritten public offering of its Common Stock under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.15&nbsp;&ldquo;<B>Key
Holder Registrable Securities</B>&rdquo; means (i) the 5,679,347 shares of Common Stock held by the Key Holders, and (ii) any Common Stock
issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.16&nbsp;&ldquo;<B>Major
Investor</B>&rdquo; means any Investor that, individually or together with such Investor&rsquo;s Affiliates, holds at least 2,500,000
shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification
effected after the date hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.17&nbsp;&ldquo;<B>New
Securities</B>&rdquo; means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options,
or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable
into or exercisable for such equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.18&nbsp;&ldquo;<B>Person</B>&rdquo;
means any individual, corporation, partnership, trust, limited liability company, association or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.19&nbsp;&ldquo;<B>Preferred
Director</B>&rdquo; means any director of the Company that the holders of record of Series A Preferred Stock are entitled to elect, exclusively
and as a separate class, pursuant to the Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.20&nbsp;&ldquo;<B>Registrable
Securities</B>&rdquo; means (i) the Common Stock issuable or issued upon conversion of the Series A Preferred Stock; (ii) any Common Stock,
or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company,
held by the Investors from time to time; (iii) the Key Holder Registrable Securities; <U>provided</U>, <U>however</U>, that such Key Holder
Registrable Securities shall not be deemed Registrable Securities and the Key Holders shall not be deemed Holders for the purposes of
Sections 2.1 (and any other applicable Section or Section with respect to registrations under Section 2.1), 2.10, 3.1 and 5.6; and (iv)
any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a
dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in <U>clauses (i</U>) and
(<U>ii</U>) above; excluding in all cases (other than the restrictions on transfer and legend requirements in <U>Section &lrm;2.12</U>),
however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned
pursuant to <U>Section &lrm;5.1</U>, and excluding for purposes of <U>Section &lrm;2</U> any shares for which registration rights have
terminated pursuant to <U>Section &lrm;2.13</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.21&nbsp;&ldquo;<B>Registrable
Securities then outstanding</B>&rdquo; means the number of shares determined by adding the number of shares of outstanding Common Stock
that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable
and/or convertible securities that are Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.22&nbsp;&ldquo;<B>Restricted
Securities</B>&rdquo; means the securities of the Company required to be notated with the legend set forth in <U>Section &lrm;2.12(b)</U>
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.23&nbsp;&ldquo;<B>SEC</B>&rdquo;
means the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.24&nbsp;&ldquo;<B>SEC
Rule 144</B>&rdquo; means Rule 144 promulgated by the SEC under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.25&nbsp;&ldquo;<B>SEC
Rule 145</B>&rdquo; means Rule 145 promulgated by the SEC under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.26&nbsp;&ldquo;<B>Securities
Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.27&nbsp;&ldquo;<B>Selling
Expenses</B>&rdquo; means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable
Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel
(as defined below) borne and paid by the Company as provided in <U>Section &lrm;2.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.28&nbsp;&ldquo;<B>Series
A Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series A Preferred Stock, par value $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="text-transform: uppercase">2.</FONT></TD><TD STYLE="text-align: left"><U>Registration Rights</U>. The Company covenants and agrees as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.1&nbsp;<U>Demand
Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;<U>Form
S-1 Demand</U>. If at any time after the earlier of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180)
days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of
the Registrable Securities then outstanding that the Company file a Form S-1 registration statement for which the anticipated aggregate
offering price would exceed $30,000,000, then the Company shall: (x) within ten (10) days after the date such request is given, give notice
thereof (the &ldquo;<B>Demand Notice</B>&rdquo;) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and
in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement
under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional
Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder
to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Sections
&lrm;2.1(c)</U> and <U>&lrm;2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;<U>Form
S-3 Demand</U>. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders
of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement
with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price of at least $5,000,000,
then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the
Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given
by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested
to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty
(20) days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Sections &lrm;2.1(c)</U> and <U>&lrm;2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)&nbsp;Notwithstanding
the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this <U>Section &lrm;2.1</U> a certificate
signed by the Company&rsquo;s chief executive officer or other most senior executive officer stating that in the good faith judgment of
the Board of Directors it would be materially detrimental to the Company for such registration statement to either become effective or
remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would
(i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company;
(ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential;
or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the
right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be
tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; <U>provided</U>,
<U>however</U>, that the Company may not invoke this right more than once in any twelve (12) month period; and <U>provided further</U>
that the Company shall not register any securities for its own account or that of any other stockholder during such ninety (90) day period
other than an Excluded Registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)&nbsp;The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Section &lrm;2.1(a)</U>, (i)
during the period that is sixty (60) days before the Company&rsquo;s good faith estimate of the date of filing of, and ending on a date
that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, <U>provided</U> that the Company
is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after
the Company has effected two (2) registrations pursuant to <U>Section &lrm;2.1(a)</U>; or (iii) if the Initiating Holders propose to dispose
of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to <U>Section &lrm;2.1(b)</U>.
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Section &lrm;2.1(b)</U>,
(i) during the period that is thirty (30) days before the Company&rsquo;s good faith estimate of the date of filing of, and ending on
a date that is ninety (90) days after the effective date of, a Company-initiated registration, <U>provided</U> that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company
has effected two (2) registrations pursuant to <U>Section &lrm;2.1(b)</U> within the twelve (12) month period immediately preceding the
date of such request. A registration shall not be counted as &ldquo;effected&rdquo; for purposes of this <U>Section &lrm;2.1(d)</U> until
such time as the applicable registration statement has been declared effective by the SEC and the offering of the Registrable Securities
registered under such registration statement has been closed, unless the Initiating Holders (i) withdraw their request for such registration
other than due to the Initiating Holders having learned of a material adverse change in the condition, business or prospects of the Company
from that known to the Initiating Holders at the time of their request for registration; (ii) elect not to pay the registration expenses
therefor; and (iii) forfeit their right to one demand registration statement pursuant to <U>Section &lrm;2.6</U>, in which case such withdrawn
registration statement shall be counted as &ldquo;effected&rdquo; for purposes of this <U>Section &lrm;2.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.2&nbsp;<U>Company
Registration</U>. If the Company proposes to register (including for this purpose a registration effected by the Company for stockholders
other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely
for cash (other than in an Excluded Registration or the IPO), the Company shall, at such time, promptly give each Holder notice of such
registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall,
subject to the provisions of <U>Section &lrm;2.3</U>, cause to be registered all of the Registrable Securities that each such Holder has
requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by
it under this <U>Section &lrm;2.2</U> before the effective date of such registration, whether or not any Holder has elected to include
Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne
by the Company in accordance with <U>Section &lrm;2.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.3&nbsp;<U>Underwriting
Requirements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;If,
pursuant to <U>Section &lrm;2.1</U>, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to <U>Section &lrm;2.1</U>, and the
Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Board of Directors and shall be
reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder&rsquo;s
Registrable Securities in such registration shall be conditioned upon such Holder&rsquo;s participation in such underwriting and the inclusion
of such Holder&rsquo;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their
securities through such underwriting shall (together with the Company as provided in <U>Section &lrm;2.4(e)</U>) enter into an underwriting
agreement in customary form with the underwriter(s) selected for such underwriting; <U>provided</U>, <U>however</U>, that no Holder (or
any of their assignees) shall be required to make any representations, warranties or indemnities except as they relate to such Holder&rsquo;s
ownership of shares and authority to enter into the underwriting agreement and to such Holder&rsquo;s intended method of distribution,
and the liability of such Holder shall be several and not joint, and limited to an amount equal to the net proceeds from the offering
received by such Holder. Notwithstanding any other provision of this <U>Section &lrm;2.3</U>, if the managing underwriter(s) advise(s)
the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating
Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of
Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including
the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such
other proportion as shall mutually be agreed to by all such selling Holders; <U>provided</U>, <U>however</U>, that the number of Registrable
Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities of the Company are
first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company
or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;In
connection with any offering involving an underwriting of shares of the Company&rsquo;s capital stock pursuant to <U>Section &lrm;2.2</U>,
the Company shall not be required to include any of the Holders&rsquo; Registrable Securities in such underwriting unless the Holders
accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters
in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities,
including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold
(other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering,
then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which
the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters
determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable
Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to)
the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such
selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round
the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall
(i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be
sold by the Company) are first entirely excluded from the offering, (ii) the number of Registrable Securities included in the offering
be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in
which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder&rsquo;s
securities are included in such offering or (iii) notwithstanding (ii) above, any Registrable Securities which are not Key Holder Registrable
Securities be excluded from such underwriting unless all Key Holder Registrable Securities are first excluded from such offering. For
purposes of the provisions in <U>Section &lrm;2.3(a) and </U>this <U>Section &lrm;2.3(b)</U> concerning apportionment, for any selling
Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders,
and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired
members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single &ldquo;selling Holder,&rdquo; and
any pro rata reduction with respect to such &ldquo;selling Holder&rdquo; shall be based upon the aggregate number of Registrable Securities
owned by all Persons included in such &ldquo;selling Holder,&rdquo; as defined in this sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)&nbsp;For
purposes of <U>Section &lrm;2.1</U>, a registration shall not be counted as &ldquo;effected&rdquo; if, as a result of an exercise of the
underwriter&rsquo;s cutback provisions in <U>Section &lrm;2.3(a)</U>, fewer than fifty percent (50%) of the total number of Registrable
Securities that Holders have requested to be included in such registration statement are actually included.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.4&nbsp;<U>Obligations
of the Company</U>. Whenever required under this <U>Section &lrm;2</U> to effect the registration of any Registrable Securities, the Company
shall, as expeditiously as reasonably possible:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts
to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier,
until the distribution contemplated in the registration statement has been completed; <U>provided</U>, <U>however</U>, that (i) such one
hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter
of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case
of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to
compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended, if necessary, to keep the registration
statement effective until all such Registrable Securities are sold;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;prepare
and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such
registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered
by such registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)&nbsp;furnish
to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act,
and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)&nbsp;use
its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities
or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; <U>provided</U> that the Company shall
not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless
the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e)&nbsp;in
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary
form, with the underwriter(s) of such offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f)&nbsp;use
its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a
national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued
by the Company are then listed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(g)&nbsp;provide
a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all
such Registrable Securities, in each case not later than the effective date of such registration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(h)&nbsp;promptly
make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration
statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial
and other records, pertinent corporate documents, and properties of the Company, and cause the Company&rsquo;s officers, directors, employees,
and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent,
in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate
due diligence in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)&nbsp;notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared
effective or a supplement to any prospectus forming a part of such registration statement has been filed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(j)&nbsp;after
such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement
such registration statement or prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, the Company shall
ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities
Act shall have become effective, its insider trading policy shall provide that the Company&rsquo;s executive officers and directors may
implement a trading program under Rule 10b5-1 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.5&nbsp;<U>Furnish
Information</U>. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this <U>Section &lrm;2</U>
with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to
effect the registration of such Holder&rsquo;s Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.6&nbsp;<U>Expenses of Registration</U>.
All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to <U>Section
&lrm;2</U>, including all registration, filing, and qualification fees; printers&rsquo; and accounting fees; fees and disbursements of
counsel for the Company; and the reasonable fees and disbursements, not to exceed $50,000 of one counsel for the selling Holders selected
by the Holders of a majority of the Registrable Securities to be registered (the &ldquo;<B>Selling Holder Counsel</B>&rdquo;), shall
be borne and paid by the Company; <U>provided</U>, <U>however</U>, that the Company shall not be required to pay for any expenses of
any registration proceeding begun pursuant to <U>Section &lrm;2.1</U> if the registration request is subsequently withdrawn at the request
of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses
pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders
of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to <U>Sections &lrm;2.1(a)</U>
or <U>&lrm;2.1(b)</U>, as the case may be; <U>provided</U>&nbsp;<U>further</U> that if, at the time of such withdrawal, the Holders shall
have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the
time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall
not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to <U>Sections &lrm;2.1(a)
</U>or <U>&lrm;2.1(b)</U>. All Selling Expenses relating to Registrable Securities registered pursuant to this <U>Section &lrm;2</U>
shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.7&nbsp;<U>Delay
of Registration</U>. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
<U>Section &lrm;2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.8&nbsp;<U>Indemnification</U>.
If any Registrable Securities are included in a registration statement under this <U>Section &lrm;2</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;To
the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors,
and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities
Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or
the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned
Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from
which Damages may result, as such expenses are incurred; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this
<U>Section &lrm;2.8(a)</U> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages
to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information
furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection
with such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of
its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the
meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any
other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against
any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon
and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably
incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses
are incurred; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this <U>Section &lrm;2.8(b)</U> shall not apply
to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which
consent shall not be unreasonably withheld; and <U>provided further</U> that in no event shall the aggregate amounts payable by any Holder
by way of indemnity or contribution under <U>Sections &lrm;2.8(b)</U> and <U>&lrm;2.8(d)</U> exceed the proceeds from the offering received
by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)&nbsp;Promptly
after receipt by an indemnified party under this <U>Section &lrm;2.8</U> of notice of the commencement of any action (including any governmental
action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is
to be made against any indemnifying party under this <U>Section &lrm;2.8</U>, give the indemnifying party notice of the commencement thereof.
The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory
to the parties; <U>provided</U>, <U>however</U>, that an indemnified party (together with all other indemnified parties that may be represented
without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying
party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure
to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying
party of any liability to the indemnified party under this <U>Section &lrm;2.8</U>, to the extent that such failure materially prejudices
the indemnifying party&rsquo;s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it
of any liability that it may have to any indemnified party otherwise than under this <U>Section &lrm;2.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)&nbsp;To
provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise
entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Section &lrm;2.8</U> but it is judicially
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the
denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this <U>Section
&lrm;2.8</U> provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any
party hereto for which indemnification is provided under this <U>Section &lrm;2.8</U>, then, and in each such case, such parties will
contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others)
in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection
with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect
any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission
of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties&rsquo; relative
intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; <U>provided</U>, <U>however</U>,
that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable
Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such
fraudulent misrepresentation; and <U>provided further</U> that in no event shall a Holder&rsquo;s liability pursuant to this <U>Section
&lrm;2.8(d)</U>, when combined with the amounts paid or payable by such Holder pursuant to <U>Section &lrm;2.8(b)</U>, exceed the proceeds
from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct
or fraud by such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e)&nbsp;Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into
in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f)&nbsp;Unless
otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of
the Company and Holders under this <U>Section &lrm;2.8</U> shall survive the completion of any offering of Registrable Securities in a
registration under this <U>Section &lrm;2</U>, and otherwise shall survive the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.9&nbsp;<U>Reports
Under Exchange Act</U>. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of
the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration
on Form S-3, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;make
and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Company for the IPO;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;use
commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)&nbsp;furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement
by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective
date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the
Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant
to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and
such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing
any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after
the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company
so qualifies to use such form).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.10&nbsp;<U>Limitations
on Subsequent Registration Rights</U>. From and after the date of this Agreement, the Company shall not, without the prior written consent
of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder
of any securities of the Company that would (i) provide to such holder the right to include securities in any registration on other than
a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities
that they wish to so include or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held
by such holder or prospective holder; <U>provided</U> that this limitation shall not apply to any additional Investor who becomes a party
to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.11&nbsp;<U>&ldquo;Market
Stand-off&rdquo; Agreement</U>. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter,
during the period commencing on the date of the final prospectus relating to the IPO, and ending on the date specified by the Company
and the managing underwriter (such period not to exceed one hundred eighty (180) days or such other period as may be requested by the
Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and
(2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2241 or any successor
provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase
any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly,
any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock
held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap, hedging or other
transaction or arrangement that transfers, or is designed to transfer, to another, in whole or in part, any of the economic consequences
of ownership, directly or indirectly, of such securities, whether or not any such transaction or arrangement described in <U>clause (i</U>)
or (<U>ii</U>) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions
of this <U>Section &lrm;2.11</U> shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to
an underwriting agreement for such IPO, shall not apply to shares purchased by the Holders in the IPO and shall be applicable to the Holders
only if all officers and directors of the Company and holders of at least one percent (1%) of the Company&rsquo;s outstanding Common Stock
(after giving effect to the conversion into Common Stock of all outstanding shares of Series A Preferred Stock) are subject to the same
restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this <U>Section &lrm;2.11</U>
and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further
agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent
with this <U>Section &lrm;2.11</U> or that are necessary to give further effect thereto. Any discretionary waiver or termination of the
restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that
are subject to such agreements, based on the number of shares subject to such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.12&nbsp;<U>Restrictions
on Transfer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;The
Series A Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except
upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities
Act and all other applicable U.S. laws and regulations. A transferring Holder will cause any proposed purchaser, pledgee, or transferee
of the Series A Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to
the provisions and upon the conditions specified in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;Each
certificate, instrument or book entry representing (i) the Series A Preferred Stock, (ii) the Registrable Securities, and (iii) any other
securities issued in respect of the securities referenced in <U>clauses (i</U>) and (<U>ii</U>), upon any stock split, stock dividend,
recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of <U>Section &lrm;2.12(c)</U>)
be notated with a legend substantially in the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">THE SECURITIES REPRESENTED
HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT
BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY
REQUIREMENTS OF SAID ACT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">THE SECURITIES REPRESENTED
HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS
ON FILE WITH THE SECRETARY OF THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Holders consent to the
Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement
the restrictions on transfer set forth in this <U>Section &lrm;2.12</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)&nbsp;The
holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
<U>Section &lrm;2</U>. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration
statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder&rsquo;s
intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale,
pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder&rsquo;s expense
by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company,
addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii)
a &ldquo;no action&rdquo; letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities
without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any
other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted
Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be
entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the
Company. The Company will not require such a legal opinion or &ldquo;no action&rdquo; letter (x) in any transaction in compliance with
SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration;
<U>provided</U> that each transferee agrees in writing to be subject to the terms of this <U>Section &lrm;2.12</U>. Each certificate,
instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer
is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in <U>Section &lrm;2.12(b)</U>, except that such certificate
instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company,
such legend is not required in order to establish compliance with any provisions of the Securities Act. Once the Restricted Securities
are eligible for transfer pursuant to SEC Rule 144, the Holder shall have the right to request that the Company remove the applicable
restrictive legend set forth in <U>Section &lrm;2.12(b)</U>, and the Company agrees to promptly comply with such request to remove such
legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.13&nbsp;<U>Termination
of Registration Rights</U>. The right of any Holder to request registration or inclusion of Registrable Securities in any registration
pursuant to <U>Sections &lrm;2.1</U> or <U>&lrm;2.2</U> shall terminate, as to such Holder, upon the earliest to occur of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;the
closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;such
time after consummation of the IPO as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of
all of such Holder&rsquo;s shares without limitation, during a three (3)-month period without registration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)&nbsp;the
third (3<SUP>rd</SUP>) anniversary of the consummation of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="text-transform: uppercase">3.</FONT></TD><TD STYLE="text-align: left"><U>Rights to Future Stock Issuances</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.1&nbsp;<U>Right
of First Offer</U>. Subject to the terms and conditions of this <U>Section &lrm;3.1</U> and applicable securities laws, if the Company
proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor
shall be entitled to apportion the right of first offer hereby granted to it among itself and its Affiliates in such proportions as it
deems appropriate; <U>provided</U> that each such Affiliate agrees to enter into this Agreement and the Voting Agreement of even date
herewith among the Company, the Investors and the other parties named therein (the &ldquo;<B>Voting Agreement</B>&rdquo;), as an &ldquo;Investor&rdquo;
under each such agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;The
Company shall give notice (the &ldquo;<B>Offer Notice</B>&rdquo;) to each Major Investor, stating (i) its bona fide intention to offer
such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes
to offer such New Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;By
notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or otherwise
acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion
that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon
conversion and/or exercise, as applicable, of the Series A Preferred Stock and any other Derivative Securities then held by such Major
Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of
all Series A Preferred Stock and any other Derivative Securities then outstanding and excluding all authorized but unissued shares of
Common Stock reserved pursuant to the Company&rsquo;s 2024 Equity Incentive Plan). If the right to purchase the New Securities has been
exercised by the Major Investors with respect to some but not all of the New Securities by the end of the twenty (20) day period specified
above, the Company shall send written notice to those Major Investors who fully exercised their preemptive rights within the initial notice
period (each, a &ldquo;<B>Fully Exercising Investor</B>&rdquo;). During the ten (10) day period commencing after the Company has given
such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number
of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were
not subscribed for which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion
and/or exercise, as applicable, of Series A Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor
bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the
Series A Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed
shares. The closing of any sale pursuant to this <U>Section &lrm;3.1(b)</U> shall occur within the later of ninety (90) days of the date
that the Offer Notice is given and the date of initial sale of New Securities pursuant to <U>Section &lrm;3.1(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)&nbsp;If
all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in <U>Section &lrm;3.1(b)</U>,
the Company may, during the ninety (90) day period following the expiration of the periods provided in <U>Section &lrm;3.1(b)</U>, offer
and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no
more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale
of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the
right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major
Investors in accordance with this <U>Section &lrm;3.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)&nbsp;Notwithstanding
any provision hereof to the contrary, in lieu of complying with the provisions of this <U>Section &lrm;3.1</U>, the Company may elect
to give notice to the Major Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type,
price, and terms of the New Securities. Each Major Investor shall have twenty (20) days from the date notice is given to elect to purchase
up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor&rsquo;s percentage-ownership
position, calculated as set forth in <U>Section &lrm;3.1(b)</U> before giving effect to the issuance of such New Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.2&nbsp;<U>Termination</U>.
The covenants set forth in <U>Section &lrm;3.1</U> shall terminate and be of no further force or effect (i) immediately before the consummation
of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange
Act, or (iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event
occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="text-transform: uppercase">4.</FONT></TD><TD STYLE="text-align: left"><U>Additional Covenants</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.1&nbsp;<U>Board
Matters</U>. The Company shall reimburse the directors for all reasonable out-of-pocket travel expenses incurred (consistent with the
Company&rsquo;s travel policy) in connection with attending meetings of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.2&nbsp;<U>Successor
Indemnification</U>. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not
the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall
be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members
of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company&rsquo;s
Bylaws, the Certificate of Incorporation, or elsewhere, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.3&nbsp;[Reserved]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.4&nbsp;<U>Matters
Requiring Preferred Director Approval</U>. During such time or times as the holders of Series A Preferred Stock are entitled to elect
a Preferred Director and such seat is filled, the Company hereby covenants and agrees with each of the Investors that it shall not, nor
shall it permit any subsidiary to, without approval of the Board of Directors, which approval must include at least one Preferred Director:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;make
any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless
it is wholly owned (directly or indirectly) by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;make
any loan or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances
and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board
of Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)&nbsp;guarantee,
directly or indirectly, any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of
business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)&nbsp;make
any investment inconsistent with any investment policy approved by the Board of Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e)&nbsp;incur
any indebtedness in excess of $1,000,000 that is not already included in a budget approved by the Board of Directors, other than trade
credit and equipment financing incurred in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f)&nbsp;otherwise
enter into or be a party to any transaction with any director, officer, or employee of the Company or any &ldquo;associate&rdquo; (as
defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except for transactions contemplated by this Agreement and
the Purchase Agreement, transactions resulting in payments to or by the Company in an aggregate amount less than $50,000 per year, or
transactions made in the ordinary course of business and pursuant to reasonable requirements of the Company&rsquo;s business and upon
fair and reasonable terms that are approved by a majority of the Board of Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(g)&nbsp;hire,
terminate, or change the compensation of the executive officers, including approving any option grants or stock awards to executive officers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(h)&nbsp;change
the principal business of the Company, enter new lines of business, or exit the current line of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)&nbsp;sell,
assign, license, pledge, or encumber material technology or intellectual property, other than licenses granted in the ordinary course
of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(j)&nbsp;increase
the number of shares of shares of Common Stock reserved pursuant to the Company&rsquo;s 2024 Equity Incentive Plan; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(k)&nbsp;enter
into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of money
or assets greater than $50,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.5&nbsp;<U>Expenses
of Counsel</U>. In the event of a transaction which is a Sale of the Company (as defined in the Voting Agreement), the reasonable fees
and disbursements of one counsel for the Major Investors (&ldquo;<B>Investor Counsel</B>&rdquo;), solely in their capacities as stockholders,
shall be borne and paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;<U>Sale
of the Company</U>. At the outset of considering a transaction which, if consummated would constitute a Sale of the Company, the Company
shall obtain the ability to share with the Investor Counsel (and such counsel&rsquo;s clients) and shall share the confidential information
(including, without limitation, the initial and all subsequent drafts of memoranda of understanding, letters of intent and other transaction
documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing
any of the transactions, which, individually or when aggregated with others, would constitute the Sale of the Company. The Company shall
be obligated to share (and cause the Company&rsquo;s counsel and investment bankers to share) such materials when distributed to the Company&rsquo;s
executives and/or any one (1) or more of the other parties to such transaction(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;<U>Joint
Defense/Common Interest Agreement</U>. In the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter
into a joint defense/common interest agreement or other arrangement to enhance the ability of the parties to protect their communications
and other reviewed materials under the attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver
to Investor Counsel and its clients such an agreement in form and substance reasonably acceptable to Investor Counsel and the Company&rsquo;s
counsel. In the event that one (1) or more of the other party or parties to such transactions require the clients of Investor Counsel
to enter into a confidentiality agreement and/or joint defense and/or common interest agreement in order to receive such information,
then the Company shall share whatever information can be shared without entry into such agreement and shall, at the same time, in good
faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate agreement(s) without undue
burden to the clients of Investor Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.6&nbsp;<U>Right
to Conduct Activities</U>. The Company hereby agrees and acknowledges that certain of the Investors are in the business of venture capital
investing and that such Investors (together with their Affiliates) invest in numerous portfolio companies, some of which may be deemed
competitive with the Company&rsquo;s business (as currently conducted or as currently propose to be conducted). Nothing in this Agreement
shall preclude or in any way restrict the Investors from evaluating or purchasing securities, including publicly traded securities, of
a particular enterprise, or investing or participating in any particular enterprise whether or not such enterprise has products or services
which compete with those of the Company; and the Company hereby agrees that, to the extent permitted under applicable law, such Investors
shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by such Investors in any entity competitive
with the Company, or (ii) actions taken by any partner, officer, employee or other representative of such Investor to assist any such
competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise,
and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any
of the Investors from liability associated with the unauthorized disclosure of the Company&rsquo;s confidential information and trade
secrets obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with such Person&rsquo;s
fiduciary duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.7&nbsp;<U>FCPA</U>.
The Company covenants that it shall not (and shall not permit any of its subsidiaries or Affiliates or any of its or their respective
directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment
to, or otherwise contribute any item of value to, directly or indirectly, to any third party, including any Non-U.S. Official (as such
term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;<B>FCPA</B>&rdquo;)), in each case, in violation
of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants that it
shall (and shall cause each of its subsidiaries and Affiliates to) cease all of its or their respective known activities, as well as remediate
any known actions taken by the Company, its subsidiaries or Affiliates, or any of their respective directors, officers, managers, employees,
independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery
or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and Affiliates to) maintain
commercially reasonable systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing
systems) to provide reasonable assurances regarding compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery
or anti-corruption law. Upon request, the Company agrees to provide responsive information and/or certifications concerning its compliance
with applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any allegation,
voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law. The
Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the
future, to make commercially reasonable efforts to comply with the FCPA. The Company shall use its commercially reasonable efforts to
cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all material respects with all
applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.8&nbsp;<U>Termination
of Covenants</U>. The covenants set forth in this <U>Section &lrm;4</U>, except for <U>Section &lrm;4.2</U> and <U>&lrm;4.3</U>, shall
terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) upon a Deemed Liquidation Event,
as such term is defined in the Certificate of Incorporation, whichever event occurs first; <U>provided</U>, that, with respect to <U>clause
(ii)</U>, the covenants set forth in <U>Section &lrm;4</U> shall only terminate if the consideration received by the Investors in such
Deemed Liquidation Event is in the form of cash and/or publicly traded securities or if the acquiring company or other successor to the
Company agrees to covenants comparable to those set forth in <U>Section &lrm;4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="text-transform: uppercase">5.</FONT></TD><TD STYLE="text-align: left"><U>Miscellaneous</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.1&nbsp;<U>Successors
and Assigns</U>. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of
Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder&rsquo;s Immediate Family Member or trust for the benefit
of an individual Holder or one (1) or more of such Holder&rsquo;s Immediate Family Members; or (iii) after such transfer, together with
its Affiliates, would be a Major Investor; <U>provided</U>, <U>however</U>, that (x) the Company is, within a reasonable time after such
transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which
such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and
subject to the terms and conditions of this Agreement, including the provisions of <U>Section &lrm;2.11</U>. For the purposes of determining
the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder
of a Holder; (2) who is a Holder&rsquo;s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such
Holder&rsquo;s Immediate Family Member shall be aggregated together and with those of the transferring Holder; <U>provided further</U>
that all transferees who would not qualify individually for assignment of rights shall, as a condition to the applicable transfer, establish
a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The
terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees
of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except
as expressly provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.2&nbsp;<U>Governing
Law</U>. This Agreement shall be governed by the internal law of the State of Delaware, without regard to conflict of law principles that
would result in the application of any law other than the law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.3&nbsp;<U>Counterparts</U>.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying
with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com) or other transmission method and any counterpart so delivered
shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.4&nbsp;<U>Titles
and Subtitles</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.5&nbsp;<U>Notices</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;All
notices and other communications given or made pursuant to this Agreement shall be in writing (including electronic mail as permitted
in this Agreement) and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be
notified; (ii) when sent, if sent by electronic mail during the recipient&rsquo;s normal business hours, and if not sent during normal
business hours, then on the recipient&rsquo;s next business day; (iii) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized
overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent
to the respective parties at their addresses as set forth on <U>Schedule A</U> or <U>Schedule B</U> (as applicable) hereto, or (as to
the Company) to the principal office of the Company and to the attention of the Chief Executive Officer, or in any case to such email
address or address as subsequently modified by written notice given in accordance with this <U>Section &lrm;5.5</U>. If notice is given
to the Company, a copy (which copy shall not constitute notice) shall also be sent to Gibson, Dunn &amp; Crutcher LLP, One Embarcadero
Center Suite 2600, San Francisco, CA 94111, Attn: Ryan A. Murr and Branden C. Berns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;<U>Consent
to Electronic Notice</U>. Each party to this Agreement consents to the delivery of any stockholder notice pursuant to the Delaware General
Corporation Law (the &ldquo;<B>DGCL</B>&rdquo;), as amended or superseded from time to time, by electronic mail pursuant to Section 232
of the DGCL (or any successor thereto) at the electronic mail address set forth below such party&rsquo;s name on the Schedules hereto,
as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means
of electronic mail is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new
or corrected electronic mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have
been given. Each party to this Agreement agrees to promptly notify the Company of any change in such stockholder&rsquo;s electronic mail
address, and that failure to do so shall not affect the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.6&nbsp;<U>Amendments
and Waivers</U>. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may
be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the
Company and the holders of at least a majority of the Registrable Securities then outstanding; <U>provided</U>; that the Company may in
its sole discretion waive compliance with <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>2.12(c)</U> (and the Company&rsquo;s failure
to object promptly in writing after notification of a proposed assignment allegedly in violation of <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>2.12(c)</U>
shall be deemed to be a waiver); and <U>provided further</U> that any provision hereof may be waived by any waiving party on such party&rsquo;s
own behalf, without the consent of any other party. Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or
terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor,
unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver
of the provisions of <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3</U> with respect to a particular transaction shall be deemed
to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may
nonetheless, by agreement with the Company, purchase securities in such transaction) and (b) <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3</U>
and any other section of this Agreement applicable to the Major Investors (including this <U>clause (b</U>) of this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>5.6</U>)
may be amended, modified, terminated or waived with only (and only with) the written consent of the Company and the holders of at least
a majority of the Registrable Securities then outstanding and held by the Major Investors. Further, this Agreement may not be amended,
modified or terminated, and no provision hereof may be waived, in each case, in any way which would adversely affect the rights of the
Key Holders hereunder in a manner disproportionate to any adverse effect such amendment, modification, termination or waiver would have
on the rights of the Investors hereunder, without also the written consent of the holders of at least a majority of the Registrable Securities
held by the Key Holders. Notwithstanding the foregoing, <U>Schedule A</U> hereto may be amended by the Company from time to time to add
transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and
<U>Schedule A</U> hereto may also be amended by the Company after the date of this Agreement without the consent of the other parties
to add information regarding any additional Investor who becomes a party to this Agreement in accordance with <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>5.9</U>.
The Company shall give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that
did not consent in writing to such amendment, modification, termination, or waiver. Any amendment, modification, termination, or waiver
effected in accordance with this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>5.6</U> shall be binding on all parties hereto,
regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement,
in any one (1) or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or
provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.7&nbsp;<U>Severability</U>.
In case any provision contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable
provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.8&nbsp;<U>Aggregation
of Stock; Apportionment</U>. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement and such Affiliate may apportion such rights as among themselves
in any manner they deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.9&nbsp;<U>Additional
Investors</U>. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of Series A Preferred
Stock after the date hereof, pursuant to the Purchase Agreement, any purchaser of such shares of Series A Preferred Stock may become a
party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be
deemed an &ldquo;Investor&rdquo; for all purposes hereunder. No action or consent by the Investors shall be required for such joinder
to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations
as an &ldquo;Investor&rdquo; hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.10&nbsp;<U>Entire
Agreement</U>. This Agreement (including the Exhibits and Schedules hereto), together with the other Transaction Agreements (as defined
in the Purchase Agreement) constitute the full and entire understanding and agreement among the parties with respect to the subject matter
hereof, and any other written or oral agreement relating to the subject matter hereof existing between or among any of the parties are
expressly canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.11&nbsp;<U>Dispute
Resolution</U>. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and
to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding
arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon
this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby
waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it
is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution,
that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper
or that this Agreement or the subject matter hereof may not be enforced in or by such court.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each of the parties to this Agreement consents to personal jurisdiction
for any equitable action sought in the U.S. District Court for the District of Delaware or any court of the State of Delaware having subject
matter jurisdiction.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WAIVER OF JURY TRIAL: EACH
PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER
TRANSACTION AGREEMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING
OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION,
CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION
HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY
FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have executed this Investors&rsquo; Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">COMPANY:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>ORUKA THERAPEUTICS, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ K. Evan Thompson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>K. Evan Thompson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page to Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this Investors&rsquo;
Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">KEY HOLDERS:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>PARAGON THERAPEUTICS, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ K. Evan Thompson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>K. Evan Thompson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>PARUKA HOLDING LLC</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ K. Evan Thompson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>K. Evan Thompson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>ORUKA ADVISORS LLC</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Damon Banks</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Damon Banks</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>MICHELLE PERNICE</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Michelle Pernice</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>LAWRENCE KLEIN</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Lawrence Klein</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>CHRISTOPHER FINCH</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Christopher Finch</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page to Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>MARK MCKENNA</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Mark McKenna</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>TURTLE FAMILY TRUST</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Cameron Turtle</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Cameron Turtle</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Trustee</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Sarah Turtle</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Cameron Turtle</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Trustee</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>LAURA SANDLER</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Laura Sandler</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page to Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">IN WITNESS WHEREOF, the parties have executed this Investors&rsquo;
Rights Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">INVESTORS:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>FAIRMOUNT HEALTHCARE FUND II, L.P.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Peter Harwin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Peter Harwin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Managing Member</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page to Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Investors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fairmount Healthcare Fund II, L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Schedule
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Key
Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Paragon Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Paruka Holding LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oruka Advisors LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michelle Pernice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lawrence Klein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Christopher Finch</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">McKenna Capital Partners LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Turtle Family Trust</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Laura Sandler</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>5
<FILENAME>ea020512201ex10-40_arcabio.htm
<DESCRIPTION>ORUKA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.40</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">ORUKA THERAPEUTICS,
INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>AMENDED and
RESTATED<BR>
2024 Equity INCENTIVE PLAN</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><U>Purpose</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The purpose of this Amended
and Restated 2024 Equity Incentive Plan (as amended and restated, the &ldquo;<B>Plan</B>&rdquo;) of Oruka Therapeutics, Inc., a Delaware
corporation (the &ldquo;<B>Company</B>&rdquo;), is to advance the interests of the Company&rsquo;s stockholders by enhancing the Company&rsquo;s
ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such
persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons
with those of the Company&rsquo;s stockholders. Except where the context otherwise requires, the term &ldquo;Company&rdquo; shall include
any of the Company&rsquo;s present or future parent or subsidiary corporations as defined in Sections&nbsp;424(e) or (f) of the Internal
Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &ldquo;<B>Code</B>&rdquo;) and any other business venture
(including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined
by the Board of Directors of the Company (the &ldquo;<B>Board</B>&rdquo;).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>Eligibility</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">All of the Company&rsquo;s
employees, officers, directors, consultants and advisors are eligible to be granted options, restricted stock, restricted stock units
(&ldquo;<B>RSUs</B>&rdquo;) and other stock-based awards (each, an &ldquo;<B>Award</B>&rdquo;) under the Plan. Each&nbsp;person who receives
an Award under the Plan is deemed a &ldquo;<B>Participant</B>&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><U>Administration and Delegation</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)&nbsp;<U>Administration
by Board of Directors</U>. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend
and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe
and interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any
omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry the
Plan into effect and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&rsquo;s
sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. No director
or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under
the Plan made in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)&nbsp;<U>Appointment
of Committees</U>. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or
more committees or subcommittees of the Board (a &ldquo;<B>Committee</B>&rdquo;). All references in the Plan to the &ldquo;<B>Board</B>&rdquo;
shall mean the Board or a Committee of the Board or the officers referred to in Section <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&lrm;</B></FONT>3(c)
to the extent that the Board&rsquo;s powers or authority under the Plan have been delegated to such Committee or officers. The Board may
abolish any Committee at any time, and notwithstanding any delegation of authority, the Board will always retain full authority to take
any action permitted under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c)&nbsp;<U>Delegation
to Officers</U>. To the extent permitted by applicable law, the Board may delegate to one or more officers of the Company the power to
grant Awards (subject to any limitations under the Plan) to employees or officers of the Company and to exercise such other powers under
the Plan as the Board may determine, <I>provided that</I> the Board shall fix the terms of the Awards to be granted by such officers (including
the exercise price of such Awards, which may include a formula by which the exercise price will be determined) and the maximum number
of shares subject to Awards that the officers may grant; <I>provided further, however</I>, that no officer shall be authorized to grant
Awards to any &ldquo;executive officer&rdquo; of the Company (as defined by Rule 3b-7 under the Securities Exchange Act of 1934, as amended
(the &ldquo;<B>Exchange Act</B>&rdquo;)) or to any &ldquo;officer&rdquo; of the Company (as defined by Rule 16a-1 under the Exchange Act).
The Board may rescind any such delegation at any time.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><U>Stock Available for Awards</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)&nbsp;<U>Number
of Shares</U>. Subject to adjustment under Section <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&lrm;</B></FONT>8
hereof, Awards may be made under the Plan covering up to 872,912 shares of common stock of the Company (the &ldquo;<B>Common Stock</B>&rdquo;),
all of which may be granted as Incentive Stock Options (as hereinafter defined). If any Award expires, lapses, or is terminated, surrendered
or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock
subject to such Award being repurchased by the Company at or below the original issuance price), in any case in a manner that results
in any shares of Common Stock covered by such Award not being issued or being so reacquired by the Company, the unused Common Stock covered
by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock delivered (whether by actual
delivery or attestation) or tendered to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award
and/or to satisfy any applicable tax withholding obligation (including shares retained by the Company from the Award being exercised or
purchased and/or creating the tax obligation) shall again be available for the grant of Awards under the Plan. However, in the case of
Incentive Stock Options) the foregoing provisions shall be subject to any limitations under the Code. Shares of Common Stock issued under
the Plan may consist in whole or in part of authorized but unissued shares, shares purchased on the open market, or treasury shares. At
no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California
on the date of grant of such Option, shall the total number of shares of Common Stock issuable upon exercise of all outstanding options
and the total number of shares provided for under any stock bonus or similar plan or agreement of the Company exceed the applicable percentage
as calculated in accordance with the conditions and exclusions of Section 260.140.45 of the California Code of Regulations (the &ldquo;<B>California
Regulations</B>&rdquo;), based on the shares of the Company which are outstanding at the time the calculation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)&nbsp;<U>Substitute
Awards</U>. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or
stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted prior to such
merger or consolidation by such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate
in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall
share limit set forth in Section <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&lrm;</B></FONT>4(a) hereof,
except as may be required by reason of Section 422 and related provisions of the Code.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><U>Stock Options</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)&nbsp;<U>General</U>.
The Board may grant options to purchase Common Stock (each, an &ldquo;<B>Option</B>&rdquo;) and determine the number of shares of Common
Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of
each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. An
Option that is not intended to be an Incentive Stock Option shall be designated a &ldquo;<B>Nonstatutory Stock Option</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)&nbsp;<U>Incentive
Stock Options</U>. An Option that the Board intends to be an &ldquo;incentive stock option&rdquo; as defined in Section 422 of the Code
(an &ldquo;<B>Incentive Stock Option</B>&rdquo;) shall only be granted to employees of the Company (including any of the Company&rsquo;s
present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Code but excluding any other business
venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest).
All Options intended to qualify as Incentive Stock Options shall be subject to and shall be construed consistently with the requirements
of Section 422 of the Code, and without limiting generality of the foregoing, such Options shall be deemed to include terms that comply
with the eligibility standards described section 422(b) of the Code. Subject to the remaining provisions of this Section <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&lrm;</B></FONT>5(b),
if an Option intended to qualify as an Incentive Stock Option does not so qualify, the Board may, at its discretion, amend the Plan and
Award with respect to such Option so that such Option qualifies as an Incentive Stock Option. To the extent that the aggregate Fair Market
Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time
by any Participant during any calendar year (under all plans of the Company and any affiliates) exceeds $100,000 (or such other limit
established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof
that exceed such limit (according to the order in which they were granted) or otherwise do not comply with the rules will be treated as
Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Award. Neither the Company nor the Board shall have
any liability to a Participant, or any other party, (i) if an Option (or any part thereof) which is intended to qualify as an Incentive
Stock Option fails to qualify as such or (ii) for any action or omission by the Company or Board that causes an Option not to qualify
as an Incentive Stock Option, including without limitation the conversion of an Incentive Stock Option to a Nonstatutory Stock Option
or the grant of an Option intended as an Incentive Stock Option that fails to satisfy the requirements under the Code applicable to an
Incentive Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c)&nbsp;<U>Exercise
Price</U>. The Board shall establish the exercise price of each Option and specify the exercise price in the applicable option agreement.
<FONT STYLE="background-color: white">The exercise price shall be not less than 100% of the Fair Market Value on the date the Option is
granted. In the case of an Incentive Stock Option granted to an employee who, at the time of grant of the Option, owns (or is treated
as owning under Section 424 of the Code) stock representing more than 10% of the voting power of all classes of stock of the Company (or
a &ldquo;parent corporation&rdquo; or &ldquo;subsidiary corporation&rdquo; thereof within the meaning of Sections 424(e) or 424(f) of
the Code, respectively) (such employee, a &ldquo;<B>10% Holder</B>&rdquo;), the per share exercise price shall be no less than 110% of
the Fair Market Value on the date the Option is granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d)&nbsp;<U>Duration
of Options</U>. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the
applicable option agreement, <I>provided that</I> the term of any Option shall not exceed 10 years. In the case of an Incentive Stock
Option granted to a 10% Holder, the term of the Option shall not exceed five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(e)&nbsp;<U>Exercise
of Option; Notification of Disposition</U>. Options may be exercised by delivery to the Company of a written notice of exercise signed
by the proper person or by any other form of notice (including electronic notice) approved by the Board together with payment in full
as specified in Section&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&lrm;</B></FONT>5(f) for the
number of shares for which the Option is exercised. Unless otherwise determined by the Board, an Option may not be exercised for a fraction
of a share of Common Stock. Shares of Common Stock subject to the Option will be delivered by the Company as soon as practicable following
exercise. If an Option is designated as an Incentive Stock Option, the Participant shall give prompt notice to the Company of any disposition
or other transfer of any shares of Common Stock acquired from the Option if such disposition or transfer is made (i) within two years
from the grant date with respect to such Option or (ii) within one year after the transfer of such shares to the Participant (other than
any such disposition made in connection with a Reorganization Event). Such notice shall specify the date of such disposition or other
transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such
disposition or other transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(f)&nbsp;<U>Payment
Upon Exercise.</U> Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)&nbsp;in
cash or by check, payable to the order of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ii)&nbsp;when
the Common Stock is registered under the Exchange Act, except as may otherwise be provided in the applicable option agreement, by (A)
delivery of an irrevocable and unconditional undertaking by a creditworthy broker acceptable to the Company to deliver promptly to the
Company sufficient funds to pay the exercise price and any required tax withholding or (B) delivery by the Participant to the Company
of a copy of irrevocable and unconditional instructions to a creditworthy broker acceptable to the Company to deliver promptly to the
Company cash or a check sufficient to pay the exercise price and any required tax withholding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iii)&nbsp;when
the Common Stock is registered under the Exchange Act and to the extent provided for in the applicable option agreement or approved by
the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant
valued at their fair market value as determined by (or in a manner approved by) the Board (&ldquo;<B>Fair Market Value</B>&rdquo;), <I>provided</I>
(A) such method of payment is then permitted under applicable law, (B) such Common Stock, if acquired directly from the Company, was owned
by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (C) such Common Stock
is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iv)&nbsp;to
the extent permitted by applicable law and provided for in the applicable option agreement or approved by the Board, in its sole discretion,
by (A) delivery of a promissory note of the Participant to the Company on terms determined by the Board, or (B)&nbsp;payment of such other
lawful consideration as the Board may determine;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(v)&nbsp;to
the extent provided for in the applicable option agreement or approved by the Board, in its sole discretion, by having the Company retain
from the shares of Common Stock otherwise issuable upon the exercise of such Option a number of shares valued at their Fair Market Value;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(vi)&nbsp;by
any combination of the above permitted forms of payment or any other lawful consideration as approved by the Board in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(g)&nbsp;<U>Early
Exercise of Options</U>. The Board may provide in the terms of an option agreement that the Participant may exercise an Option in whole
or in part prior to the full vesting of the Option in exchange for unvested shares of Restricted Stock (as defined below) with respect
to any unvested portion of the Option so exercised. Shares of Restricted Stock acquired upon the exercise of any unvested portion of an
Option shall be subject to such terms and conditions as the Board shall determine.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><U>Restricted Stock; Restricted Stock Units</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)&nbsp;<U>General</U>.
The Board may grant Awards entitling recipients to acquire shares of Common Stock (&ldquo;<B>Restricted Stock</B>&rdquo;), subject to
the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require
forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the applicable
Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. Instead
of granting Awards for Restricted Stock, the Board may grant Awards entitling the recipient to receive shares of Common Stock or cash
to be delivered at or following the time such Award vests (&ldquo;<B>Restricted Stock Units</B>&rdquo; or &ldquo;<B>RSUs</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)&nbsp;<U>Terms
and Conditions</U>. The Board shall determine and set forth in the applicable award agreement the terms and conditions of Restricted Stock
or RSUs, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<U>Additional
Provisions Relating to Restricted Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)&nbsp;<U>Dividends</U>.
Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such shares to the
extent such dividends have a record date that is on or after the date on which the Participant to whom such Restricted Stock is granted
becomes the record holder of such Restricted Stock, unless otherwise provided by the Board. Unless otherwise provided by the Board, if
any dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common Stock other than an ordinary
cash dividend, the shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares
of Restricted Stock with respect to which they were paid. Each dividend payment will be made as provided in the applicable award agreement,
but no later than the end of the calendar year in which the dividends are paid to shareholders of that class of stock or, if later, the
15th day of the third month following the later of (A) the date the dividends are paid to shareholders of that class of stock and (B)
the date the dividends are no longer subject to forfeiture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ii)&nbsp;<U>Stock
Certificates</U>. The Company may require that any stock certificates issued in respect of shares of Restricted Stock shall be deposited
in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the expiration of
the applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions
to the Participant or if the Participant has died, to the beneficiary designated, in a manner determined by the Board, by a Participant
to receive amounts due or exercise rights of the Participant in the event of the Participant&rsquo;s death (the &ldquo;<B>Designated Beneficiary</B>&rdquo;).
In the absence of an effective designation by a Participant, &ldquo;Designated Beneficiary&rdquo; shall mean the Participant&rsquo;s estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;<U>Additional
Provisions Relating to Restricted Stock Units</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)&nbsp;<U>Settlement</U>.
Upon or following the vesting of a Restricted Stock Unit, the Participant shall be entitled to receive from the Company one share of Common
Stock or an amount of cash or other property equal to the Fair Market Value of one share of Common Stock on the settlement date, as the
Board shall determine and as provided in the applicable award agreement. The Board may provide that settlement of Restricted Stock Units
shall occur upon or as soon as reasonably practicable after the vesting of the Restricted Stock Units or shall instead be deferred, on
a mandatory basis or at the election of the Participant, in a manner that complies with Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ii)&nbsp;<U>Voting
Rights</U>. A Participant shall have no voting rights with respect to any Restricted Stock Units unless and until shares are delivered
in settlement thereof.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iii)&nbsp;<U>Dividend
Equivalents</U>. To the extent provided by the Board, a grant of Restricted Stock Units may provide a Participant with the right to receive
Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, may be settled in cash
and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units
with respect to which the Dividend Equivalents are paid, as determined by the Board, subject, in each case, to such terms and conditions
as the Board shall establish and set forth in the applicable award agreement. &ldquo;<B>Dividend Equivalents</B>&rdquo; means a right
granted to a Participant to receive the equivalent value (in cash or shares of Common Stock) of dividends paid on shares of Common Stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><U>Other Stock-Based Awards</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Other Awards of shares of
Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock
or other property, may be granted hereunder to Participants (&ldquo;<B>Other Stock-Based Awards</B>&rdquo;), including without limitation
stock appreciation rights (&ldquo;<B>SARs</B>&rdquo;) (which shall be subject to the same limitations applicable to awards of Nonstatutory
Stock Options) and Awards entitling recipients to receive shares of Common Stock to be delivered in the future. Such Other Stock-Based
Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of
compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as
the Board shall determine. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other Stock-Based
Award, including any purchase price, transfer restrictions, vesting conditions and other terms and conditions applicable thereto.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><U>Adjustments for Changes in Common Stock and Certain Other Events</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)&nbsp;In
the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares,
spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an
ordinary cash dividend, (i) the number and class of securities available under this Plan, (ii) the number and class of securities and
exercise price per share of each outstanding Option, (iii) the number of shares subject to and the repurchase price per share subject
to each other outstanding Award, and (iv) the terms of each other outstanding Award shall be equitably adjusted by the Company (or substituted
Awards may be made, if applicable) in the manner determined by the Board; <I>provided that</I>, unless otherwise determined by the Board,
such changes to the Options shall comply with section 1.424-1 of the Treasury Regulations. Without limiting the generality of the foregoing,
in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of
shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record
date for such dividend), then a Participant who exercises an Option between the record date and the distribution date for such stock dividend
shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such
Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such
stock dividend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<U>Reorganization
Events</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)&nbsp;<U>Definition</U>.
A &ldquo;<B>Reorganization Event</B>&rdquo; means the consummation of: (A) the dissolution or liquidation of the Company, (B) the sale
of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (C) a merger, reorganization
or consolidation pursuant to which the holders of the Company&rsquo;s outstanding voting power immediately prior to such transaction do
not own a majority of the outstanding voting power of the surviving or resulting entity (or its ultimate parent, if applicable), (D) the
acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of a related transactions
by a person or group of persons, or (E)&nbsp;any other acquisition of the business of the Company, as determined by the Board; <I>provided,
however</I>, that the first firm commitment underwritten public offering pursuant to an effective registration statement under the Securities
Act of 1933, as amended, covering the offer and sale by the Company of its equity securities, as a result of or following which the Common
Stock shall be public, any subsequent public offering or another capital raising event, or a merger effected solely to change the Company&rsquo;s
domicile shall not constitute a &ldquo;Reorganization Event.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ii)&nbsp;<U>Consequences
of a Reorganization Event on Awards</U>. In connection with a Reorganization Event, the Board may take any one or more of the following
actions as to all or any (or any portion of) outstanding Awards on such terms as the Board determines: (A)&nbsp;provide that Awards shall
be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof);
<I>provided that</I>, unless otherwise determined by the Board, such assumption or substitution of the Options shall comply with section
1.424-1 of the Treasury Regulations, (B)&nbsp;upon written notice to a Participant, provide that the Participant&rsquo;s unexercised Awards
will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant within a specified
period following the date of such notice, (C)&nbsp;provide that outstanding Awards shall become vested, exercisable, realizable, or deliverable,
or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (D)&nbsp;in the event
of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each
share surrendered in the Reorganization Event (the &ldquo;<B>Acquisition Price</B>&rdquo;), make or provide for a cash payment to a Participant
equal to the excess, if any, of (I)&nbsp;the Acquisition Price times the number of shares of Common Stock subject to the Participant&rsquo;s
Awards (to the extent the exercise price does not exceed the Acquisition Price) over (II) the aggregate exercise price of all such outstanding
Awards and any applicable tax withholdings, in exchange for the termination of such Awards, (E)&nbsp;provide that, in connection with
a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of
the exercise price thereof and any applicable tax withholdings) and (F) any combination of the foregoing. In taking any of the actions
permitted under this Section <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&lrm;</B></FONT>8(b), the Board
shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">For purposes of clause (A) above,
an Option shall be considered assumed if, following consummation of the Reorganization Event, the Option confers the right to purchase,
for each share of Common Stock subject to the Option immediately prior to the consummation of the Reorganization Event, the consideration
(whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share
of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration,
the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); <I>provided, however</I>, that
if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation
(or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration
to be received upon the exercise of Options to consist solely of common stock of the acquiring or succeeding corporation (or an affiliate
thereof) equivalent in value (as determined by the Board) to the per share consideration received by holders of outstanding shares of
Common Stock as a result of the Reorganization Event.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><U>General Provisions Applicable to Awards</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)&nbsp;<U>Transferability
of Awards</U>. Except as the Board may otherwise determine or provide in an Award, Awards shall not be sold, assigned, transferred, pledged
or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws
of descent and distribution or, other than in the case of an Incentive Stock Option, pursuant to a qualified domestic relations order,
and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the extent relevant
in the context, shall include references to authorized transferees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)&nbsp;<U>Documentation</U>.
Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms
and conditions in addition to those set forth in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c)&nbsp;<U>Board
Discretion</U>. Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award.
The terms of each Award need not be identical, and the Board need not treat Participants uniformly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d)&nbsp;<U>Termination
of Status</U>. The Board shall determine the effect on an Award of the disability, death, retirement, termination or other cessation of
employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and
the period during which, the Participant, or the Participant&rsquo;s legal representative, conservator, guardian or Designated Beneficiary,
may exercise rights under the Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(e)&nbsp;<U>Withholding</U>.
The Company shall not be obligated to deliver certificates, release from forfeiture, otherwise recognize a Participant&rsquo;s unrestricted
ownership in an Award or the cash or property proceeds therefrom, until the Company satisfies all applicable federal, state, and local
or other income and employment tax withholding obligations. In its sole discretion, the Company may satisfy such withholding obligations
by any of the following means or by a combination of such means: (i) causing the Participant to tender to the Company cash payment; (ii)
withholding cash from an Award settled in cash; (iii)&nbsp;withholding from amounts otherwise payable by the Company to the Participant,
including but not limited to additional withholding on the Participant&rsquo;s salary or wages, or from proceeds from the sale of Common
Stock issued pursuant to an Award; (iv) delivery of shares of Common Stock, including shares retained from the Award creating the tax
obligation, valued at their Fair Market Value; <I>provided, however</I>, except as otherwise provided by the Board, that the total tax
withholding where stock is being used to satisfy such tax obligations cannot exceed the Company&rsquo;s minimum statutory withholding
obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable
to such supplemental taxable income), and <I>provided, further</I>, shares surrendered to satisfy tax withholding requirements cannot
be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements; or (v) by such other method as determined
by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;<U>Amendment
of Award</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)&nbsp;The
Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same
or a different type, changing the date of exercise or settlement, and converting an Incentive Stock Option to a Nonstatutory Stock Option.
The Participant&rsquo;s consent to such action shall be required unless (A) the Board determines that the action, taking into account
any related action, would not materially and adversely affect the Participant&rsquo;s rights under the Plan, (B) the change is permitted
under Section <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&lrm;</B></FONT>8 hereof, or (C) the change
is to ensure that an Option intended to qualify as an Incentive Stock Option qualifies as such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ii)&nbsp;The
Board may, without stockholder approval, amend any outstanding Award granted under the Plan to provide an exercise price per share that
is lower than the then-current exercise price per share of such outstanding Award. The Board may also, without stockholder approval, cancel
any outstanding award (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan covering the
same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price
per share of the cancelled award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(g)&nbsp;<U>Conditions
on Delivery of Stock</U>. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions
from shares previously delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of
the Company, (ii)&nbsp;in the opinion of the Company&rsquo;s counsel, all other legal matters in connection with the issuance and delivery
of such shares have been satisfied, including any applicable securities laws and any applicable stock exchange or stock market rules and
regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Company may
consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. The inability of the Company to obtain
authority from any regulatory body having jurisdiction, which authority is determined by the Board to be necessary to the lawful issuance
and sale of any securities hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such shares
at to which such requisite authority shall not have been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(h)&nbsp;<U>Acceleration</U>.
The Board may at any time provide that any Award shall become immediately exercisable in full or in part, free of some or all restrictions
or conditions, or otherwise realizable in full or in part, as the case may be.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify"><U>Miscellaneous</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)&nbsp;<U>No
Right To Employment or Other Status</U>. No person shall have any claim or right to be granted an Award, and the grant of an Award shall
not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly
reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim
under the Plan, except as expressly provided in the applicable Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)&nbsp;<U>No
Rights As Stockholder</U>. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any
rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record
holder of such shares. Notwithstanding any other provision of the Plan, unless otherwise determined by the Board or required by any applicable
laws, the Company shall not be required to deliver to any Participant certificates evidencing shares of Common Stock issued in connection
with any Award and instead such shares of Common Stock may be recorded in the books of the Company (or, as applicable, its transfer agent
or stock plan administrator). The Company may place legends on any stock certificates issued under the Plan deemed necessary or appropriate
by the Board in order to comply with applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c)&nbsp;<U>Effective
Date and Term of Plan</U>. The Plan shall become effective on the date on which it is adopted by the Board. No Awards shall be granted
under the Plan after the expiration of 10 years from the earlier of (i) the date on which the Plan was adopted by the Board or (ii) the
date the Plan was approved by the Company&rsquo;s stockholders, but Awards previously granted may extend beyond that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d)&nbsp;<U>Amendment
of Plan</U>. The Board may amend, suspend or terminate the Plan or any portion thereof at any time; <I>provided that</I> if at any time
the approval of a Company stockholder is required as to any modification or amendment under Section 422 of the Code or any successor provision
with respect to Incentive Stock Options or pursuant to any other applicable law or regulation, the Board may not effect such modification
or amendment without stockholder approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance
with this Section <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&lrm;</B></FONT>10(d) shall apply to, and
be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, <I>provided</I> the Board determines
that such amendment does not materially and adversely affect the rights of Participants under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(e)&nbsp;<U>Authorization
of Sub-Plans</U>. The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable
blue sky, securities or tax laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to this Plan
containing (i)&nbsp;such limitations on the Board&rsquo;s discretion under the Plan as the Board deems necessary or desirable or (ii)&nbsp;such
additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements
adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected
jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not
the subject of such supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(f)&nbsp;<U>Compliance
with Code Section 409A</U>. Unless otherwise expressly provided for in an Award, the Plan and Award will be interpreted to the greatest
extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A of the Code, and, to the
extent not so exempt, in compliance with Section&nbsp;409A of the Code. If the Board determines that any Award granted hereunder is not
exempt from and is therefore subject to Section&nbsp;409A of the Code, the Award will incorporate the terms and conditions necessary to
avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award is silent on terms necessary for compliance,
such terms as deemed necessary by the Board in its sole discretion are hereby incorporated by reference into the Award. Without limiting
the generality of the foregoing, if shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes
&ldquo;deferred compensation&rdquo; under Section 409A of the Code is a &ldquo;specified employee&rdquo; for purposes of Section 409A
of the Code, no distribution or payment of any amount that is due because of a &ldquo;separation from service&rdquo; (as defined in Section
409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following
the date of such Participant&rsquo;s &ldquo;separation from service&rdquo; or, if earlier, the date of the Participant&rsquo;s death,
unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will
be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. The Company
shall have no liability to a Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Section
409A of the Code is not so exempt or compliant or for any other action taken by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(g)&nbsp;<U>Governing
Law</U>. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of
the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a
jurisdiction other than such state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(h)&nbsp;<U>Data
Privacy</U>. As a condition of receipt of any Award, each Participant explicitly and unambiguously consents to the collection, use and
transfer, in electronic or other form, of personal data as described in this paragraph by and among, as applicable, the Company and its
subsidiaries and affiliates for the exclusive purpose of implementing, administering and managing the Participant&rsquo;s participation
in the Plan. The Company and its subsidiaries and affiliates may hold certain personal information about a Participant, including but
not limited to, the Participant&rsquo;s name, home address and telephone number, date of birth, social security or insurance number or
other identification number, salary, nationality, job title(s), any shares of stock held in the Company or any of its subsidiaries and
affiliates, details of all Awards, in each case, for the purpose of implementing, managing and administering the Plan and Awards (the
&ldquo;<B>Data</B>&rdquo;). The Company and its subsidiaries and affiliates may transfer the Data amongst themselves as necessary for
the purpose of implementation, administration and management of a Participant&rsquo;s participation in the Plan, and the Company and its
subsidiaries and affiliates may each further transfer the Data to any third parties assisting the Company in the implementation, administration
and management of the Plan. These recipients may be located in the Participant&rsquo;s country, or elsewhere, and the Participant&rsquo;s
country may have different data privacy laws and protections than the recipients&rsquo; country. Through acceptance of an Award, each
Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes
of implementing, administering and managing the Participant&rsquo;s participation in the Plan, including any requisite transfer of such
Data as may be required to a broker or other third party with whom the Company or the Participant may elect to deposit any shares of Common
Stock. The Data related to a Participant will be held only as long as is necessary to implement, administer, and manage the Participant&rsquo;s
participation in the Plan. A Participant may, at any time, view the Data held by the Company with respect to such Participant, request
additional information about the storage and processing of the Data with respect to such Participant, recommend any necessary corrections
to the Data with respect to the Participant or refuse or withdraw the consents herein in writing, in any case without cost, by contacting
his or her local human resources representative. The Company may cancel Participant&rsquo;s ability to participate in the Plan and, in
the Board&rsquo;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws his or her consents
as described herein. For more information on the consequences of refusal to consent or withdrawal of consent, Participants may contact
their local human resources representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(i)&nbsp;<U>Restrictions
on Shares; Clawback Provisions</U>. Shares of Common Stock acquired in respect of Awards shall be subject to such terms and conditions
as the Board shall determine, including, without limitation, restrictions on the transferability of shares of Common Stock, the right
of the Company to repurchase shares of Common Stock, the right of the Company to require that shares of Common Stock be transferred in
the event of certain transactions, tag-along rights, bring-along rights, redemption and co-sale rights and voting requirements. Such terms
and conditions may be additional to those contained in the Plan and may, as determined by the Board, be contained in the applicable Award
Agreement or in an exercise notice, stockholders&rsquo; agreement or in such other agreement as the Board shall determine, in each case
in a form determined by the Board. The issuance of such shares of Common Stock shall be conditioned on the Participant&rsquo;s consent
to such terms and conditions and the Participant&rsquo;s entering into such agreement or agreements. All Awards (including any proceeds,
gains or other economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the
receipt or resale of any shares of Common Stock underlying the Award) shall be subject to the provisions of any clawback policy implemented
by the Company, including, without limitation, any clawback policy adopted to comply with the requirements of the Dodd-Frank Wall Street
Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, to the extent set forth in such clawback policy
and/or in the applicable Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">ORUKA THERAPEUTICS,
INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>2024 Equity
INCENTIVE PLAN</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">CALIFORNIA SUPPLEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>10(e)
of the Plan, the Board has adopted this supplement for purposes of satisfying the requirements of Section 25102(o) of the California Law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any Awards granted under the
Plan to a Participant who is a resident of the State of California on the date of grant (a &ldquo;<B>California Participant</B>&rdquo;)
shall be subject to the following additional limitations, terms and conditions:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><U>Additional Limitations on Options</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)&nbsp;<U>Minimum
Vesting Rate</U>. Except in the case of Options granted to California Participants who are officers, directors, managers, consultants
or advisors of the Company or its affiliates (which Options may become exercisable at whatever rate is determined by the Board), Options
granted to California Participants shall become exercisable at a rate of not less than 20% per year over five years from the date of grant;
<I>provided, that</I>, such Options may be subject to such reasonable forfeiture conditions as the Board may choose to impose and which
are not inconsistent with Section 260.140.41 of the California Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)&nbsp;<U>Minimum
Exercise Price</U>. The exercise price of Options granted to California Participants may not be less than 85% of the Fair Market Value
of the Common Stock on the date of grant in the case of a Nonstatutory Stock Option or less than 100% of the Fair Market Value of the
Common Stock on the date of grant in the case of an Incentive Stock Option; <I>provided, however</I>, that if the California Participant
is a person who owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or its parent
or subsidiary corporations, the exercise price shall be not less than 110% of the Fair Market Value of the Common Stock on the date of
grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c)&nbsp;<U>Maximum
Duration of Options</U>. No Options granted to California Participants shall have a term in excess of 10 years measured from the Option
grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d)&nbsp;<U>Minimum
Exercise Period Following Termination</U>. Unless a California Participant&rsquo;s employment is terminated for cause (as defined by applicable
law, the terms of any contract of employment between the Company and such Participant, or in the instrument evidencing the grant of such
Participant&rsquo;s Option), in the event of termination of employment of such Participant, such Participant shall have the right to exercise
an Option, to the extent that he or she was otherwise entitled to exercise such Option on the date employment terminated, as follows:
(i) at least six months from the date of termination, if termination was caused by such Participant&rsquo;s death or &ldquo;permanent
and total disability&rdquo; (within the meaning of Section&nbsp;22(e)(3) of the Code) and (ii) at least 30 days from the date of termination,
if termination was caused other than by such Participant&rsquo;s death or &ldquo;permanent and total disability&rdquo; (within the meaning
of Section 22(e)(3) of the Code).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(e)&nbsp;<U>Limitation
on Repurchase Rights</U>. If an Option granted to a California Participant gives the Company the right to repurchase shares of Common
Stock issued pursuant to the Plan upon termination of employment of such Participant, the terms of such repurchase right must comply with
Section&nbsp;260.140.41(k) of the California Regulations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>Additional Limitations for Restricted Stock</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)&nbsp;<U>Minimum
Purchase Price</U>. The purchase price for Restricted Stock granted to a California Participant shall be not less than 85% of the Fair
Market Value of the Common Stock at the time such Participant is granted the right to purchase shares under the Plan or at the time the
purchase is consummated; <I>provided, however</I>, that if such Participant is a person who owns stock possessing more than 10% of the
total combined voting power or value of all classes of stock of the Company or its parent or subsidiary corporations, the purchase price
shall be not less than 100% of the Fair Market Value of the Common Stock at the time such Participant is granted the right to purchase
shares under the Plan or at the time the purchase is consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)&nbsp;<U>Limitation
of Repurchase Rights</U>. If Restricted Stock granted to a California Participant gives the Company the right to repurchase shares of
Common Stock issued pursuant to the Plan upon termination of employment of such Participant, the terms of such repurchase right must comply
with Section 260.140.42(h) of the California Regulations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><U>Additional Limitations for Other Stock-Based Awards</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The terms of all Awards granted
to a California Participant under Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>7 of the Plan shall comply, to the extent applicable,
with Section 260.140.41 or Section 260.140.42 of the California Regulations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><U>Additional Requirement to Provide Information to California Participants</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company shall provide
to each California Participant and to each California Participant who acquires Common Stock pursuant to the Plan, not less frequently
than annually, copies of annual financial statements (which need not be audited). The Company shall not be required to provide such statements
to key employees whose duties in connection with the Company assure their access to equivalent information.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><U>Additional Limitations on Timing of Awards</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">No Award granted to a California
Participant shall become exercisable, vested or realizable, as applicable to such Award, unless the Plan has been approved by the holders
of a majority of the Company&rsquo;s outstanding voting securities within 12 months before or after the date the Plan was adopted by the
Board.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><U>Additional Limitations Relating to Definition of Fair Market Value</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For purposes of Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>1(b)
and <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>2(a) of this supplement, &ldquo;Fair Market Value&rdquo; shall be determined in a
manner not inconsistent with Section 260.140.50 of the California Regulations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><U>Additional Restriction Regarding Recapitalizations, Stock Splits, Etc</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For purposes of Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>8
of the Plan, in the event of a stock split, reverse stock split, stock dividend, recapitalization, combination, reclassification or other
distribution of the Company&rsquo;s securities, the number of securities allocated to each California Participant must be adjusted proportionately
and without the receipt by the Company of any consideration from any California Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FIRST AMENDMENT TO THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ORUKA
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AMENDED
AND RESTATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>2024
EQUITY INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, Oruka Therapeutics,
Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), maintains the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity
Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, pursuant to
Section 10(d) of the Plan, the Board may amend the Plan at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B>NOW, THEREFORE</B>, pursuant
to its authority under Section 10(d) of the Plan, the Board hereby amends the Plan as follows, effective as of March 7, 2024 (the &ldquo;<B>Amendment
Effective Date</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: left">Section 8(b)(i) of the Plan is hereby amended and restated in its entirety to read as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: left; text-indent: 1in">&ldquo;(i)&nbsp;<U>Definition</U>.
A &ldquo;<B>Reorganization Event</B>&rdquo; means the consummation of: (A) the dissolution or liquidation of the Company, (B) the sale
of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (C) a merger, reorganization
or consolidation pursuant to which the holders of the Company&rsquo;s outstanding voting power immediately prior to such transaction do
not own a majority of the outstanding voting power of the surviving or resulting entity (or its ultimate parent, if applicable), (D) the
acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of a related transactions
by a person or group of persons, or (E) any other acquisition of the business of the Company, as determined by the Board; provided, however,
that (I) the first firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act
of 1933, as amended, covering the offer and sale by the Company of its equity securities, as a result of or following which the Common
Stock shall be public, (II) any subsequent public offering or another capital raising event, (III) a reverse merger or similar transaction
or (IV) a merger effected solely to change the Company&rsquo;s domicile, in each case, shall not constitute a &ldquo;Reorganization Event.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: left">This First Amendment shall be governed by and interpreted in accordance with the laws of the State of
Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction
other than such state.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: left">All capitalized terms used but not otherwise defined herein shall have the meaning assigned to them in
the Plan. Except as expressly amended hereby, the Plan shall remain in full force and effect in accordance with its terms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the undersigned has executed this First Amendment to the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity Incentive Plan, effective
as of the Amendment Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>ORUKA THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"> /s/ Lawrence Klein</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>Lawrence Klein</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">SIGNATURE PAGE TO</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">FIRST AMENDMENT TO THE</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">ORUKA THERAPEUTICS, INC.</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">AMENDED AND RESTATED</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">2024 EQUITY INCENTIVE PLAN</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>6
<FILENAME>ea020512201ex10-41_arcabio.htm
<DESCRIPTION>FORM OF RESTRICTED STOCK NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT OF ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.41</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORUKA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>RESTRICTED
STOCK NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Oruka Therapeutics, Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), hereby grants to Purchaser (as defined below) the number of Shares (as defined
below) of the Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;<U>Common Stock</U>&rdquo;) set forth below, upon
the terms and subject to the conditions set forth in the Restricted Stock Purchase Agreement attached hereto as <U>Exhibit A</U> (the
&ldquo;<U>Restricted Stock Purchase Agreement</U>&rdquo;), which is incorporated by reference in this Notice (as defined in the Restricted
Stock Purchase Agreement). The issuance and sale of the Shares shall be effective as of the Date of Grant, set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%">
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Purchaser:</P></TD>
    <TD STYLE="text-align: left; width: 72%">[&nbsp;&nbsp;] (&ldquo;<U>Purchaser</U>&rdquo;)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Date of Grant:</B></TD>
    <TD STYLE="text-align: left">February [&nbsp;&nbsp;], 2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><B>Vesting Commencement Date: </B></TD>
    <TD STYLE="text-align: left">[&nbsp;&nbsp;] (the &ldquo;<U>Vesting Commencement Date</U>&rdquo;)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Number of Shares:</B></TD>
    <TD STYLE="text-align: left">[&nbsp;&nbsp;] (the &ldquo;<U>Shares</U>&rdquo;)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Vesting Schedule:</B></TD>
    <TD STYLE="text-align: left">The Shares shall vest according to the following schedule (the &ldquo;<U>Vesting Schedule</U>&rdquo;): [&nbsp;&nbsp;]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Acceleration:</B></TD>
    <TD STYLE="font-weight: normal; text-align: left">[&nbsp;&nbsp;]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Forfeiture</B>:</TD>
    <TD STYLE="font-weight: normal; text-align: left">The Shares shall be subject to forfeiture in accordance with Section &lrm;7.2 of the Restricted Stock Purchase Agreement.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">By Purchaser&rsquo;s signature
below Purchaser agrees to be bound by the terms and conditions of the Restricted Stock Purchase Agreement and this Notice. Purchaser has
reviewed the Restricted Stock Purchase Agreement and this Notice in their entirety and has had an opportunity to obtain the advice of
counsel prior to executing this Notice and the Restricted Stock Purchase Agreement. To the extent the Shares are issued in uncertificated
form, Purchaser also acknowledges and agrees that the Restricted Stock Purchase Agreement constitutes the notice required by Section 151(f)
of the DGCL (as defined in the Restricted Stock Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Signature Page Follows</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ORUKA THERAPEUTICS, Inc.</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PURCHASER: </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[&#9679;]</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 8%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 37%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 39%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name:</FONT></TD>
    <TD STYLE="border-top: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K. Evan Thompson</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">221 Crescent Street, Building 23, <BR>
Suite 105, Waltham, MA 02453</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE PAGE TO ORUKA THERAPEUTICS, INC.<BR>
RESTRICTED STOCK NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT A</U></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TO RESTRICTED STOCK NOTICE<BR>
RESTRICTED STOCK PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the Restricted
Stock Notice (the &ldquo;<U>Notice</U>&rdquo;) to which this Restricted Stock Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;)
is attached, Oruka Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), has granted to Purchaser (as defined
in the Notice) the Shares (as defined in the Notice), upon the terms and subject to the conditions of this Agreement and the Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.   <U>Defined
Terms</U>. Capitalized terms not specifically defined herein shall have the meanings specified in the Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.   <U>Grant
of Restricted Stock</U>. In consideration of Purchaser&rsquo;s agreement to provide Services, and for other good and valuable consideration,
effective as of the Date of Grant set forth in the Notice, the Company grants to Purchaser the Shares upon the terms and conditions set
forth in the Notice and this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.   <U>Issuance
and Sale of Stock</U>. The issuance of the Shares shall be effective upon the Date of Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.   <U>Payment
for Shares</U>. The Purchaser shall pay the Company a purchase price of $0.0001 per Share, in cash, as consideration for the Company&rsquo;s
agreement to issue and sell the Shares to Purchaser. [Purchaser and the Company further acknowledge and agree that the forfeiture provisions
set forth below and the assignment of certain assets pursuant to the Assignment of IP and Other Assets Agreement, in the form attached
to this Agreement as <U>Exhibit A-1</U>, constitute a material inducement for the Company to enter into this Agreement and issue and sell
the Shares to Purchaser and thereby constitute additional consideration for the Company&rsquo;s agreement to issue and sell the Shares
to Purchaser.]<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP></SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.   <U>Delivery
of Certificates; Book Entry Form</U>. The Company shall issue to Purchaser one or more certificates (which may be issued by electronic
or other means) in the name of Purchaser for that number of Shares granted to Purchaser. Purchaser agrees that the Shares shall be subject
to the forfeiture provisions in Section <B>&lrm;</B>7 and the other restrictions set forth in this Agreement (collectively, the &ldquo;<U>Restrictions</U>&rdquo;).
To the extent the Shares will be issued in uncertificated form, the Shares shall be recorded in the name of Purchaser in the books and
records of the Company&rsquo;s transfer agent with appropriate notations regarding the Restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.   <U>Stockholder
Rights</U>. Subject to Sections <B>&lrm;</B>8 and <B>&lrm;</B>11, following issuance of the Shares to Purchaser and until the occurrence
of a Forfeiture (as defined below), Purchaser (or any successor in interest) shall have all the rights of a holder of Common Stock (including
voting and dividend rights, as applicable) with respect to the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.   <U>Forfeiture</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">7.1   <U>Vesting
Schedule</U>. The Shares shall vest according to the Vesting Schedule set forth in the Notice. Any Shares that, as of any given time,
have not vested pursuant to the Vesting Schedule are referred to herein as &ldquo;<U>Unvested Shares</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">7.2   <U>Forfeiture</U>.
[Except as otherwise set forth in Purchaser&rsquo;s offer letter agreement with the Company,]<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP></SUP></FONT>
Purchaser agrees that in the event of the voluntary or involuntary termination of Purchaser&rsquo;s continuous performance of services
to the Company or any of its subsidiaries, affiliates, successors or assigns (whether as an employee, consultant, advisor, director and/or
officer) (any of the foregoing, &ldquo;<U>Services</U>&rdquo;) for any reason or no reason (including death or disability), with or without
cause, such that Purchaser ceases to be providing Services to the Company (&ldquo;<U>Termination of Service</U>&rdquo;), any then-Unvested
Shares shall automatically be forfeited by Purchaser on the date that is 61 days following such Termination of Service without any consideration
therefor and without any further action by the Company, and such Unvested Shares shall thereafter be cancelled by the Company and shall
no longer be outstanding (&ldquo;<U>Forfeiture</U>&rdquo;); <U>provided</U>, <U>however</U>, that the Company shall, in its sole discretion,
have the ability to make such Forfeiture effective as of an earlier date following such Termination of Service, so long as such early
Forfeiture does not conflict with another provision in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.   <U>Limitations
on Transfer</U>. In addition to any other limitation on transfer pursuant to applicable securities laws, Purchaser shall not sell, assign,
transfer, pledge, hypothecate or otherwise dispose of, directly or indirectly, by operation of law or otherwise (any of the foregoing,
a &ldquo;<U>Transfer</U>&rdquo;) any Unvested Shares. After any Unvested Shares have vested subject to the Vesting Schedule, Purchaser
shall not Transfer any interest in such Shares except in compliance with the provisions herein, in the Company&rsquo;s Bylaws and applicable
securities laws. Furthermore, the Shares shall be subject to a right of first refusal in favor of the Company or its assignees as set
forth in Section <B>&lrm;</B>14. Notwithstanding the foregoing, Purchaser may, subject to compliance with the transfer restrictions set
forth in the Company&rsquo;s Bylaws, transfer Unvested Shares (i) to or for the benefit of any spouse, children, parents, uncles, aunts,
siblings, grandchildren and any other relatives approved by the Board of Directors (collectively, &ldquo;<U>Approved Relatives</U>&rdquo;)
or to a trust established solely for the benefit of Purchaser and/or Approved Relatives, <U>provided</U> that such Shares shall remain
subject to this Agreement and such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument
confirming that such transferee shall be bound by all of the terms and conditions of this Agreement or (ii) subject to Section <B>&lrm;</B>12.3
below, as part of the sale of all or substantially all of the shares of capital stock of the Company (including pursuant to a merger or
consolidation). The Company shall not be required (a) to transfer on its books any of the Shares that have been sold or otherwise transferred
in violation of any of the provisions of this Agreement or the provisions of the Company&rsquo;s Bylaws or (b) to treat as owner of such
Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom any such Shares shall have been so
sold or transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.   <U>Investment
Representations</U>. Purchaser represents, warrants and covenants to the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.1   <U>Purchase
for Own Account</U>. Purchaser is purchasing the Shares for Purchaser&rsquo;s own account for investment only, and not with a view to,
or for sale in connection with, any distribution of the Shares in violation of the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;), or any rule or regulation under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.2   <U>Disclosure
of Information</U>. Purchaser is aware of the Company&rsquo;s business affairs and financial condition and has acquired sufficient information
about the Company to permit Purchaser to evaluate the merits and risks of Purchaser&rsquo;s investment in the Company and to reach an
informed and knowledgeable decision to acquire the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.3   <U>No
Public Market</U>. Purchaser understands that the Shares have not been registered under the Securities Act by reason of a specific exemption
therefrom, which exemption depends upon, among other things, the bona fide nature of Purchaser&rsquo;s investment intent as expressed
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.4   <U>Restricted
Securities</U>. Purchaser understands that the Shares are &ldquo;restricted securities&rdquo; under applicable U.S. federal and state
securities laws and that, pursuant to these laws, the Shares must be held indefinitely unless they are subsequently registered under the
Securities Act or an exemption from such registration is available. Purchaser further acknowledges and understands that the Company is
under no obligation to register or qualify the Shares for resale. Purchaser further acknowledges that if an exemption from registration
or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale,
the holding period for the Shares, and requirements relating to the Company which are outside of Purchaser&rsquo;s control, and which
the Company is under no obligation and may not be able to satisfy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.5   <U>Economic
Risk</U>. Purchaser can afford a complete loss of the value of the Shares and is able to bear the economic risk of holding such Shares
for an indefinite period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.6   <U>Accredited
Investor</U>. To the extent Purchaser is not a director or executive officer of the Company, by Purchaser&rsquo;s execution of this Agreement,
such Purchaser hereby represents that (1)&nbsp;Purchaser is an &ldquo;accredited investor&rdquo; as that term is defined in Rule 501 of
Regulation D promulgated by the Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;) under the Securities Act and (2) Purchaser
has either (i)&nbsp;preexisting personal or business relationships with the Company or any of its officers, directors or controlling persons,
or (ii) the capacity to protect his or her own interests in connection with the purchase of the Shares by virtue of the business or financial
expertise of himself or herself or of professional advisors to Purchaser who are unaffiliated with and who are not compensated by the
Company or any of its affiliates, directly or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.7   <U>Tax
Consequences</U>. Purchaser understands that Purchaser may suffer adverse tax consequences as a result of the grant and issuance of the
Shares to Purchaser and Purchaser&rsquo;s holding or disposition of the Shares. Purchaser represents that Purchaser has consulted any
tax consultants Purchaser deems advisable in connection with the grant, issuance, holding and disposition of the Shares (or has knowingly
chosen not to consult a tax advisor) and that Purchaser is not relying on the Company or its employees, officers, directors, attorneys
or accountants for any tax advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.8   <U>Certain
Encumbrances</U>. Purchaser acknowledges that the Shares will be subject to certain encumbrances, including, but not limited to, limitations
on transfer and vesting pursuant to the Vesting Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.9   <U>Purchaser
Address</U>. If Purchaser is an individual, then Purchaser resides in the state or province identified in the address of Purchaser set
forth on the signature page hereto; if Purchaser is a partnership, corporation, limited liability company or other entity, then the office
or offices of Purchaser in which its investment decision was made is located at the address or addresses of Purchaser set forth on the
signature page hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.10   <U>Withholding</U>.
Purchaser acknowledges and agrees that the Company has the right to deduct from amounts otherwise due to Purchaser (including, for the
avoidance of doubt, the Shares) any federal, state or local taxes of any kind required by law to be withheld with respect to the issuance
of the Shares to Purchaser and/or the vesting of the Unvested Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9.11   <U>Bad
Actor Disqualifying Event</U>. No &ldquo;bad actor&rdquo; disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities
Act (a &ldquo;<U>Disqualification Event</U>&rdquo;) is applicable to Purchaser or any of its Rule 506(d) Related Parties, except, if applicable,
for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable. For purposes of this Agreement, &ldquo;<U>Rule
506(d) Related Party</U>&rdquo; shall mean any individual, corporation, partnership, trust, limited liability company, association or
other entity that is a beneficial owner of Purchaser&rsquo;s securities for purposes of Rule 506(d) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.   <U>Stock
Certificate Legends</U>. The stock certificate (whether in electronic or other form) evidencing the Shares issued hereunder shall be endorsed
with the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">10.1   THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION
THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">10.2   THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S) AND TRANSFER
RESTRICTIONS AS PROVIDED IN THE RESTRICTED STOCK PURCHASE AGREEMENT BETWEEN THE PURCHASER AND THE COMPANY. SUCH RIGHT OF FIRST REFUSAL
AND TRANSFER RESTRICTIONS ARE BINDING UPON TRANSFEREES OF THESE SECURITIES. A COPY OF THE RESTRICTED STOCK PURCHASE AGREEMENT OF THE COMPANY
MAY BE OBTAINED UPON WRITTEN REQUEST TO THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">10.3   <U>Other
Legends</U>. Any other notations required by any applicable federal or state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company may be authorized
from time to time pursuant to its certificate of incorporation to issue more than one class or series of stock. In such case and at any
time or from time to time thereafter the Company will furnish without charge to Purchaser upon request the powers, designations, preferences
and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations
or restrictions of such preferences and/or rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">To the extent the Shares are
issued in uncertificated form, (i) this Section &lrm;10 provides Purchaser with notice that the Shares are subject to the aforementioned
restrictions in satisfaction of the notice requirement set forth in Section 151(f) of the General Corporation Law of the State of Delaware
(the &ldquo;<U>DGCL</U>&rdquo;) and (ii) the recording of the Shares in the books and records of the Company shall be accompanied by the
legends included in this Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11.   <U>Lock-Up
Period</U>. Purchaser shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any
Shares (or other securities of the Company) or enter into any swap, hedging or other arrangement that transfers to another, in whole or
in part, any of the economic consequences of ownership of any Shares (or other securities of the Company) held by Purchaser (other than
those included in the applicable Registration Statement (as defined below)) for a period specified by the representative of the underwriters
of Common Stock (or other securities) of the Company not to exceed 180 days following the effective date of any registration statement
of the Company filed under the Securities Act (each a &ldquo;<U>Registration Statement</U>&rdquo;) (or such other period as may be requested
by the Company or the underwriters to accommodate regulatory restrictions on (i)&nbsp;the publication or other distribution of research
reports and (ii)&nbsp;analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2241,
or any successor provisions or amendments thereto) (the &ldquo;<U>Lock-Up Period</U>&rdquo;); <U>provided</U>, <U>however</U>, that nothing
contained in this Section <B>&lrm;</B>11 shall prevent a Forfeiture during the Lock-Up Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Purchaser agrees to execute
and deliver such other agreements as may be reasonably requested by the Company or the underwriter that are consistent with the foregoing
or that are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters
of Common Stock (or other securities) of the Company, Purchaser shall provide, within ten days of such request, such information as may
be required by the Company or such representative in connection with the completion of any public offering of the Company&rsquo;s securities
pursuant to a registration statement filed under the Securities Act. The obligations described in this Section <B>&lrm;</B>11 shall not
apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in
the future, or a registration relating solely to a SEC Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the
future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to
the foregoing restriction until the end of the Lock-Up Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.   <U>Adjustment
for Stock Split, Stock Dividend, etc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">12.1   <U>Stock
Split; Stock Dividends</U>. All references to the number of Shares in this Agreement shall be appropriately adjusted to reflect any stock
split, reverse stock split or stock dividend or other similar change in the Shares that may be made by the Company after the date of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">12.2   <U>Subject
to Vesting Schedule</U>. In the event of the declaration of a stock dividend, stock split or stock combination, a recapitalization or
a similar transaction affecting the Common Stock without receipt of consideration, any new, substituted or additional securities that
by reason of such transaction are distributed with respect to any Unvested Shares or into which such Unvested Shares thereby become convertible
shall immediately be subject to the Vesting Schedule, Right of First Refusal (as defined below) and forfeiture provisions (and shall be
released at the same rate as such Unvested Shares are, or would have been, released under this Agreement as set forth in Section &lrm;7).
Appropriate adjustments to reflect the distribution of such securities shall be made to the number and/or class of the Unvested Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">12.3   <U>Merger
or Consolidation</U>. Upon the occurrence of any merger or consolidation of the Company with or into another entity as a result of which
all of the Common Stock is converted into or exchanged for the right to receive cash, securities or other property or any exchange of
all of the Common Stock for cash, securities or other property pursuant to a share exchange transaction, the rights of the Company hereunder
shall inure to the benefit of the Company&rsquo;s successor and shall apply to the cash, securities or other property which the Shares
were converted into or exchanged for pursuant to such transaction in the same manner and to the same extent as they applied to the Shares
under this Agreement. If, in connection with such a transaction, a portion of the cash, securities and/or other property received upon
the conversion or exchange of the Shares is to be placed into escrow to secure indemnification or similar obligations, the mix between
the vested and unvested portion of such cash, securities and/or other property that is placed into escrow shall be the same as the mix
between the vested and unvested portion of such cash, securities and/or other property that is not subject to escrow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13.   <U>Section
83(b) Election</U>. Purchaser hereby acknowledges that he has been informed that, with respect to the purchase of Unvested Shares, that
unless an election is filed by Purchaser with the Internal Revenue Service and, if necessary, the proper state taxing authorities, <B>within
30 days</B> after the Date of Grant, electing pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;)
(and similar state tax provisions if applicable) to be taxed currently on any difference between the purchase price of the Shares and
the fair market value of the Shares on the date of purchase (the &ldquo;<U>Election</U>&rdquo;), there will be a recognition of taxable
income to Purchaser, measured by the excess, if any, of the fair market value of the Shares, at the time the Unvested Shares vest over
the purchase price for the Shares. Purchaser represents that Purchaser has consulted any tax consultant(s) or advisor(s) Purchaser deems
advisable in connection with the purchase of the Shares or the filing of the Election under Section 83(b) and similar tax provisions.
Purchaser is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. Purchaser
understands that Purchaser (and not the Company) shall be responsible for Purchaser&rsquo;s own income tax liability that may arise as
a result of the grant of the Shares contemplated by Section <B>&lrm;</B>2 this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>PURCHASER ACKNOWLEDGES
THAT IT IS PURCHASER&rsquo;S SOLE RESPONSIBILITY AND NOT THE COMPANY&rsquo;S TO FILE TIMELY THE ELECTION UNDER SECTION&nbsp;83(b), EVEN
IF PURCHASER REQUESTS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON PURCHASER&rsquo;S BEHALF.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">14.   <U>Right
of First Refusal</U>. Before any Shares held by Purchaser or any transferee of Purchaser (either being sometimes referred to herein as
the &ldquo;<U>Holder</U>&rdquo;) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company shall
first, to the extent the Company&rsquo;s approval is required by any applicable provisions of the Company&rsquo;s Bylaws, have the right
to approve such sale or transfer, in full or in part, and shall then have the right to purchase all or any part of the Shares proposed
to be sold or transferred, in each case, in its sole and absolute discretion (the &ldquo;<U>Right of First Refusal</U>&rdquo;). If the
Holder would like to sell or transfer any Shares, the Holder must provide the Company or its assignee(s) with a Transfer Notice (as defined
below) requesting approval to sell or transfer the Shares and offering the Company or its assignee(s) a Right of First Refusal on the
same terms and conditions set forth in this Section <B>&lrm;</B>14. The Company may either (1) exercise its Right of First Refusal in
full or in part and purchase such Shares pursuant to this Section <B>&lrm;</B>14, (2) decline to exercise its Right of First Refusal in
full or in part and permit the transfer of such Shares to the Proposed Transferee (as defined below) in full or in part or (3) decline
to exercise its Right of First Refusal in full or in part and, to the extent the Company&rsquo;s approval is required by any applicable
provisions in the Company&rsquo;s Bylaws, decline the request to sell or transfer the Shares in full or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">14.1   <U>Notice
of Proposed Transfer</U>. The Holder of the Shares shall deliver to the Company a written notice (the &ldquo;<U>Transfer Notice</U>&rdquo;)
stating: (A) the Holder&rsquo;s intention to sell or otherwise transfer such Shares; (B) the name of each proposed purchaser or other
transferee (&ldquo;<U>Proposed Transferee</U>&rdquo;); (C) the number of Shares to be sold or transferred to each Proposed Transferee;
(D) the terms and conditions of each proposed sale or transfer, including (without limitation) the purchase price for such Shares (the
&ldquo;<U>Transfer Purchase Price</U>&rdquo;); and (E) the Holder&rsquo;s offer to the Company or its assignee(s) to purchase the Shares
at the Transfer Purchase Price and upon the same terms (or terms that are no less favorable to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">14.2   <U>Exercise
of Right of First Refusal</U>. At any time within 30 days after receipt of the Transfer Notice, the Company and/or its assignee(s) shall
deliver a written notice to the Holder indicating whether the Company and/or its assignee(s) elect to permit or reject the proposed sale
or transfer, in full or in part, and/or elect to accept or decline the offer to purchase any or all of the Shares proposed to be sold
or transferred to any one or more of the Proposed Transferees, at the Transfer Purchase Price, provided that if the Transfer Purchase
Price consists of no legal consideration (as, for example, in the case of a transfer by gift), the purchase price will be the fair market
value of the Shares as determined in good faith by the Company. If the Transfer Purchase Price includes consideration other than cash,
the cash equivalent value of the non-cash consideration shall be determined by the Company in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">14.3   <U>Payment</U>.
Payment of the Transfer Purchase Price shall be made, at the election of the Company or its assignee(s), in cash (by check), by cancellation
of all or a portion of any outstanding indebtedness, or by any combination thereof within 60 days after receipt of the Transfer Notice
or in the manner and at the times set forth in the Transfer Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">14.4   <U>Holder&rsquo;s
Right to Transfer</U>. If any of the Shares proposed in the Transfer Notice to be sold or transferred to a given Proposed Transferee are
both (A) not purchased by the Company and/or its assignee(s) as provided in this Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>14
and (B) approved by the Company to be sold or transferred, then the Holder may sell or otherwise transfer any such Shares to the applicable
Proposed Transferee at the Transfer Purchase Price or at a higher price, provided that such sale or other transfer is consummated within
120 days after the date of the Transfer Notice; provided that any such sale or other transfer is also effected in accordance with the
Company&rsquo;s Bylaws and any applicable laws and the Proposed Transferee agrees in writing that the Company&rsquo;s Bylaws and the provisions
of this Agreement, including Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8, shall continue to apply to the Shares in the hands of
such Proposed Transferee. The Company, in consultation with its legal counsel, may require the Holder to provide an opinion of counsel
evidencing compliance with applicable laws. If the Shares described in the Transfer Notice are not transferred to the Proposed Transferee
within such period, or if the Holder proposes to change the price or other terms to make them more favorable to the Proposed Transferee,
a new Transfer Notice shall be given to the Company, and the Company and/or its assignees shall again have the right to approve such transfer
and be offered the Right of First Refusal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">14.5   <U>Exception
for Certain Family Transfers</U>. Anything to the contrary contained in this Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>14 notwithstanding,
the transfer of any or all of the Shares during Holder&rsquo;s lifetime or on Holder&rsquo;s death by will or intestacy to Holder&rsquo;s
Approved Relatives a trust for the benefit of Holder or Holder&rsquo;s Approved Relatives shall be exempt from the provisions of this
Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>14. In such case, the transferee or other recipient shall receive and hold the Shares
so transferred subject to the Company&rsquo;s Bylaws and the provisions of this Agreement, including Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8,
and there shall be no further transfer of such Shares except in accordance with the terms of Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8
and the Company&rsquo;s Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">14.6   <U>Assignment</U>.
The right of the Company to purchase any part of the Shares may be assigned in whole or in part to any holder or holders of capital stock
of the Company or other persons or organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">15.   <U>General
Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.1   <U>Governing
Law</U>. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed in accordance
with internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any
law other than the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.2   <U>Entire
Agreement</U>. This Agreement and the Notice set forth the entire agreement between the parties with respect to the purchase of the Shares
by Purchaser and supersede all prior agreements and understandings relating to the subject matter of this Agreement and the Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.3   <U>Notice</U>.
Any notice, demand or request required or permitted to be given by either the Company or Purchaser pursuant to the terms of this Agreement
shall be in writing and shall be deemed given when delivered personally or deposited in the U.S. mail, as certified or registered mail,
with postage prepaid, and addressed to the parties at the addresses of the parties set forth in the Notice or such other address as a
party may request by notifying the other in writing or when delivered by facsimile telecommunication or electronic mail to the electronic
mail address set forth in the Notice or such other electronic mail address as a party may request by notifying the other in writing. Subject
to the limitations set forth in Section 232 of the DGCL, Purchaser acknowledges that the Company may deliver any notice to Purchaser under
the DGCL or the Company&rsquo;s certificate of incorporation or bylaws by electronic transmission (as defined in the DGCL) pursuant to
Section 232 of the DGCL (or any successor thereto) at the electronic mail address for Purchaser set forth in the Notice, as updated from
time to time by notice to the Company, or as on the books of the Company, unless Purchaser notifies the Company in writing or by electronic
transmission of an objection to receiving notice by electronic mail. Purchaser agrees to promptly notify the Company of any change in
its electronic mail address, and the failure to do so shall not affect the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.4   <U>Successors
and Assigns</U>. The rights and benefits of the Company under this Agreement shall be transferable to any one or more persons or entities,
and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company&rsquo;s successors and assigns.
The rights and obligations of Purchaser under this Agreement may only be assigned with the prior written consent of the Company and any
purported transfer otherwise shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.5   <U>Amendment;
Enforcement of Rights</U>. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall
be effective unless in writing signed by the parties to this Agreement. Either party&rsquo;s failure to enforce any provision or provisions
of this Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent that party thereafter
from enforcing each and every other provision of this Agreement. The rights granted both parties herein are cumulative and shall not constitute
a waiver of either party&rsquo;s right to assert all other legal remedies available to it under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.6   <U>Cooperation</U>.
Purchaser agrees upon request to execute any further documents or instruments necessary or desirable to carry out the purposes or intent
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.7   <U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall
constitute one instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.8   <U>Electronic
and Facsimile Signatures</U>. Any signature page delivered electronically or by facsimile (including without limitation transmission by
..pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) shall be binding to the same
extent as an original signature page, with regard to any agreement subject to the terms hereof or any amendment thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.9   <U>Severability</U>.
If one or more provisions of this Agreement are held to be unenforceable under applicable law by a tribunal of competent jurisdiction,
the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable
replacement for such provision, then (i)&nbsp;such provision shall be excluded from this Agreement, (ii)&nbsp;the balance of the Agreement
shall be interpreted as if such provision were so excluded and (iii)&nbsp;the balance of the Agreement shall be enforceable in accordance
with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.10   <U>Attorney&rsquo;s
Fees</U>. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall
be entitled to reasonable attorneys&rsquo; fees, costs, and disbursements in addition to any other relief to which such party may be entitled.
The Company and Purchaser shall bear their own expenses and legal fees incurred on their behalf with respect to this Agreement and the
transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.11   <U>NO
EMPLOYMENT GUARANTEE</U>. PURCHASER ACKNOWLEDGES AND AGREES THAT THE RELEASE OF SHARES PURSUANT TO THIS AGREEMENT IS EARNED ONLY BY CONTINUING
SERVICE AS A [&nbsp;&nbsp;&nbsp;]<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP></SUP></FONT> OF THE COMPANY. PURCHASER
FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN
DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED EMPLOYMENT OF SERVICE OR SERVICE (WHETHER OR NOT AS AN EMPLOYEE) FOR THE
VESTING PERIOD OR ANY PERIOD AT ALL, AND SHALL NOT INTERFERE WITH PURCHASER&rsquo;S RIGHT OR THE COMPANY&rsquo;S RIGHT TO TERMINATE PURCHASER&rsquo;S
RELATIONSHIP WITH THE COMPANY AT ANY TIME, WITH OR WITHOUT CAUSE OR NOTICE IN ACCORDANCE WITH LAW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.12   <U>Cancellation
of Shares</U>. From and after the occurrence of a Forfeiture, no person shall have any rights as a holder of the forfeited Shares, and
such Shares shall be deemed forfeited in accordance with the applicable provisions hereof and the Company (or its assignees) shall be
deemed the owner and holder of such Shares. Purchaser hereby surrenders and agrees to surrender any and all interest in or claims to any
forfeited Shares following any Forfeiture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.13   <U>Purchaser&rsquo;s
Acknowledgments</U>. Purchaser acknowledges that he or she: (i) has read this Agreement; (ii) has been represented in the preparation,
negotiation, and execution of this Agreement by legal counsel of Purchaser&rsquo;s own choice or has voluntarily declined to seek such
counsel; (iii) understands the terms and consequences of this Agreement; (iv) is fully aware of the legal and binding effect of this Agreement;
and (v) understands that the law firm of Gibson, Dunn &amp; Crutcher LLP is acting as counsel to the Company in connection with the transactions
contemplated by the Agreement, and is not acting as counsel for Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15.14   <U>Titles
and Subtitles</U>. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing
or interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><I>&nbsp;&nbsp;</I></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>EXHIBIT A-1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP></SUP></FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO RESTRICTED STOCK PURCHASE AGREEMENT<BR>
FORM OF ASSIGNMENT OF IP AND OTHER ASSETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Assignment of IP and Other Assets (this &ldquo;<U>Agreement</U>&rdquo;)
is made and entered into effective as of [&#9679;], 2024 (this &ldquo;<U>Effective Date</U>&rdquo;) by and between Oruka Therapeutics,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and [&nbsp;&nbsp;&nbsp;] (the &ldquo;<U>Assignor</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, prior to the Effective Date, the Assignor
has developed certain technology and intellectual property on behalf of the Company and has developed or acquired other tangible personal
property, as further described below, which relate to the Company&rsquo;s actual and proposed business associated with [developing biotherapeutics
for the [&nbsp;&nbsp;&nbsp;]] (the &ldquo;<U>Business</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the Assignor desires such technology and
intellectual property and other tangible personal property to be assigned to and owned by the Company, in connection with the sale of
the shares of the Company&rsquo;s capital stock issued by the Company to the Assignor on or about the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW THEREFORE, in consideration of the foregoing
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement
hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.   <B><U>Certain
Definitions</U>.</B> As used herein, the following capitalized terms will have the meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)   &ldquo;<U>Technology</U>&rdquo;
means all inventions, technology, ideas, concepts, processes, business plans, documentation, financial projections, models and any other
items, authored, conceived, invented, developed or designed by the Assignor relating to the technology or Business of the Company that
is not otherwise owned by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)   &ldquo;<U>Derivative</U>&rdquo;
means: (i) any derivative work of the Technology (as defined in Section&nbsp;101 of the U.S. Copyright Act); (ii) all improvements, modifications,
alterations, adaptations, enhancements and new versions of the Technology (the &ldquo;<U>Technology Derivatives</U>&rdquo;); and (iii)
all technology, inventions, products or other items that, directly or indirectly, incorporate, or are derived from, any part of the Technology
or any Technology Derivative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)   &ldquo;<U>Intellectual
Property Rights</U>&rdquo; means, collectively, all worldwide patents, patent applications, patent rights, copyrights, copyright registrations,
moral rights, trade names, trademarks, service marks, domain names and registrations and/or applications for all of the foregoing, trade
secrets, know-how, mask work rights, rights in trade dress and packaging, goodwill and all other intellectual property rights and proprietary
rights relating in any way to the Technology, any Derivative or any Embodiment, whether arising under the laws of the United States of
America or the laws of any other state, country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)   &ldquo;<U>Embodiment</U>&rdquo;
means all documentation, drafts, papers, designs, schematics, diagrams, models, prototypes, source and object code (in any form or format
and for all hardware platforms), computer-stored data, diskettes, manuscripts and other items describing all or any part of the Technology,
any Derivative, any Intellectual Property Rights or any information related thereto or in which all of any part of the Technology, any
Derivative, any Intellectual Property Right or such information is set forth, embodied, recorded or stored.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)   &ldquo;<U>Business
Assets</U>&rdquo; means all business and marketing plans, worldwide marketing rights, software, customer and supplier lists, price lists,
mailing lists, customer and supplier records and other confidential or proprietary information relating to the Technology, as well as
all computers, office equipment and other tangible personal property owned (i.e., not leased) by Assignor immediately prior to the execution
and delivery of this Agreement and used in or related to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)   &ldquo;<U>Assigned
Assets</U>&rdquo; refers to the Technology, all Derivatives, all Intellectual Property Rights, all Embodiments and Business Assets, collectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.   <B><U>Assignment</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)   The
Assignor hereby sells, transfers, assigns and conveys, to the Company, and its successors and assigns, the Assignor&rsquo;s entire right,
title and interest in and to the Assigned Assets and all rights of action, power and benefit belonging to or accruing from the Assigned
Assets including the right to undertake proceedings to recover past and future damages and claim all other relief in respect of any acts
of infringement thereof whether such acts shall have been committed before or after the date of this assignment, the same to be held and
enjoyed by the Company, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, as fully
and entirely as the same would have been held and enjoyed by the Assignor, had this assignment not been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)   The
Assignor hereby appoints the Company the attorney-in-fact of the Assignor, with full power of substitution on behalf of the Assignor to
demand and receive any of the Assigned Assets and to give receipts and releases for the same, to institute and prosecute in the name of
the Assignor, but for the benefit of the Company, any legal or equitable proceedings the Company deems proper in order to enforce any
rights in the Assigned Assets and to defend or compromise any legal or equitable proceedings relating to the Assigned Assets as the Company
shall deem advisable. The Assignor hereby declares that the appointment made and powers granted hereby are coupled with an interest and
shall be irrevocable by the Assignor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)   The
Assignor hereby agrees that the Assignor and the Assignor&rsquo;s successors and assigns will do, execute, acknowledge and deliver, or
will cause to be done, executed, acknowledged and delivered such further acts, documents, or instruments confirming the conveyance of
any of the Assigned Assets to the Company as the Company shall reasonably deem necessary, provided that the Company shall provide all
necessary documentation to the Assignor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.   <B><U>Assignor
Representations and Warranties</U>.</B> The Assignor represents and warrants to the Company that to the best of Assignor&rsquo;s knowledge
the Assignor is the owner, inventor and/or author of, and can grant exclusive right, title and interest in and to, each of the Assigned
Assets transferred by the Assignor hereunder and that none of the Assigned Assets are subject to any dispute, claim, prior license or
other agreement, assignment, lien or rights of any third party, or any other rights that might interfere with the Company&rsquo;s use,
or exercise of ownership of, any of the Assigned Assets. The Assignor further represents and warrants to the Company that to the best
of Assignor&rsquo;s knowledge the Assigned Assets are free of any claim of any prior employer or third party client of the Assignor or
any school, university or other institution the Assignor attended, and that the Assignor is not aware of any claims by any third party
to any rights of any kind in or to any of the Assigned Assets. The Assignor agrees to immediately notify the Company upon becoming aware
of any such claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.   <B><U>Reimbursement
of Expenses</U>.</B> The Company shall as promptly as practicable, reimburse the Assignor for the Assignor&rsquo;s actual out-of-pocket
costs reasonably incurred with respect to Assignor&rsquo;s acquisition and maintenance of the Assigned Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.   <B><U>Miscellaneous</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)   <B><U>Governing
Law</U>.</B> The validity, interpretation, construction and performance of this Agreement, and all acts and transactions pursuant hereto
and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the state
of Delaware, without giving effect to principles of conflicts of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)   <B><U>Entire
Agreement</U>.</B> This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter herein
and supersedes all prior or contemporaneous discussions, understandings and agreements, whether oral or written, between them relating
to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)   <B><U>Amendments
and Waivers</U>.</B> No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective
unless in writing signed by the parties to this Agreement. No delay or failure to require performance of any provision of this Agreement
shall constitute a waiver of that provision as to that or any other instance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)   <B><U>Successors
and Assigns</U>.</B> Except as otherwise provided in this Agreement, this Agreement, and the rights and obligations of the parties hereunder,
will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors, administrators and legal representatives.
The Company may assign any of its rights and obligations under this Agreement. No other party to this Agreement may assign, whether voluntarily
or by operation of law, any of its rights and obligations under this Agreement, except with the prior written consent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)   <B><U>Notices</U>.</B>
Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be deemed sufficient
when delivered personally or by overnight courier or sent by email, or 48 hours after being deposited in the U.S. mail as certified or
registered mail with postage prepaid, addressed to the party to be notified at such party&rsquo;s address as set forth on the signature
page, as subsequently modified by written notice, or if no address is specified on the signature page, at the most recent address set
forth in the Company&rsquo;s books and records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)   <B><U>Severability</U>.</B>
If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision
in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i)&nbsp;such
provision shall be excluded from this Agreement, (ii)&nbsp;the balance of the Agreement shall be interpreted as if such provision were
so excluded and (iii)&nbsp;the balance of the Agreement shall be enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)   <B><U>Construction</U>.</B>
This Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and their respective counsel,
if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed
in favor of or against any one of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)   <B><U>Counterparts</U>.</B>
This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original,
and all of which together shall constitute one and the same agreement. Execution of a facsimile or scanned copy will have the same force
and effect as execution of an original, and a facsimile or scanned signature will be deemed an original and valid signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned have executed
this Assignment of IP and Other Assets Agreement effective as of the date and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ASSIGNOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[&nbsp;&nbsp;]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>the company:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ORUKA THERAPEUTICS, INc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: K. Evan Thompson</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE PAGE TO ORUKA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT OF IP AND OTHER ASSETS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>7
<FILENAME>ea020512201ex10-42_arcabio.htm
<DESCRIPTION>FORM OF STOCK OPTION AGREEMENT UNDER ORUKA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 10.42</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORUKA
Therapeutics, Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMENDED
AND RESTATED</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024
EQUITY INCENTIVE PLAN</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
Option Agreement</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Incentive
stock option // non-statutory stock option]</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
                                            of Option</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;This
Stock Option Agreement (this &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement</B>&rdquo;) evidences the grant by Oruka Therapeutics, Inc., a Delaware corporation
(the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company</B>&rdquo;), on __________________ (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant Date</B>&rdquo;) to __________________ (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant</B>&rdquo;)
of an option (this &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option</B>&rdquo;) to purchase, in whole or in part, on the terms provided herein and in the Oruka Therapeutics,
Inc. Amended and Restated 2024 Equity Incentive Plan (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan</B>&rdquo;), a total of __________ shares (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</B>&rdquo;)
of Common Stock at $_______ per Share (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price</B>&rdquo;). Unless earlier terminated, this Option shall expire
at 5:00 p.m., Eastern time, on __________________<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></SUP> (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration Date</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;This
Option is subject to the terms of the Plan, which are incorporated into this Agreement by reference. A copy of the Plan has been furnished
to the Participant with the Option. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the
Plan. Except as otherwise indicated by the context, Participant shall be deemed to include any person who acquires the right to exercise
this Option validly under its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;[<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Include
if granted to employee: </I></B>This Option is intended to qualify as an &ldquo;incentive stock option&rdquo; under Section 422 of the
Code. However, the Company does not represent or warrant that this Option qualifies as such. The Participant should consult with his
or her own tax advisors regarding the tax effects of this Option and the requirements necessary to obtain favorable income tax treatment
under Section 422 of the Code, including the holding period requirements. If the Participant disposes (whether by sale, gift, transfer
or otherwise) any Shares acquired upon exercise of this Option within the one-year period beginning on the exercise date or within the
two-year period beginning on the Grant Date, the Participant shall notify the Company within 30 days after such disposition. To the extent
that the aggregate Fair Market Value (determined as of the Grant Date) of the Shares with respect to which the Option (plus all other
incentive stock options held by the Participant) are exercisable for the first time by the Participant during any calendar year (under
all plans of the Company and its affiliates) exceeds $100,000, the Option or portions thereof that exceed such limit (according to the
order in which they were granted) will be treated as Nonstatutory Stock Options. In addition, to the extent any portion of this Option
does not qualify as an &ldquo;incentive stock option,&rdquo; such portion shall be deemed to be a Nonstatutory Stock Option.][<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Include
if granted to non-employee:</I></B> This Option is not intended to be an incentive stock option under Section 422 of the Code and will
be interpreted accordingly.]</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting
                                            Schedule</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;This
Option will become exercisable (&ldquo;<B>vest</B>&rdquo;) in accordance with the following schedule, subject to the Participant&rsquo;s
continued employment with or service to the Company through each vesting date:</FONT> [&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;In
the event of a Company Sale (as defined below), all of the Participant&rsquo;s then unvested Shares shall automatically accelerate and
become fully vested, subject to the Participant&rsquo;s continued employment with or service to the Company through such Company Sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;The
right of exercise shall be cumulative so that to the extent this Option is not exercised in any period to the maximum extent permissible
it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the
Expiration Date or the termination of this Option under Section&nbsp;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>3 hereof or the Plan.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
                                            of Option</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Exercise</U>. Each election to exercise this Option shall be accompanied by a completed Notice of Stock Option Exercise in the form
attached hereto as <U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;A</U> and signed by the Participant, and where applicable, a signed and completed Consent of Spouse
or Domestic Partner in the form attached hereto as <U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;B</U>, and received by the Company at its principal office, accompanied
by this Agreement, and payment of the Exercise Price in full in the manner provided in the Plan. The Participant may purchase less than
the number of Shares covered hereby; <I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided that</I> no partial exercise of this Option may be for any fractional Share or for fewer
than 10 whole Shares. Subject to applicable law and as a condition to the exercise of this Option and the issuance of any Common Stock
hereunder, the Participant agrees to become party to any stockholders&rsquo; agreement, voting agreement, drag along agreement, right
of first refusal and co-sale agreement, or any other agreement approved by the Board and creating obligations of or among any stockholder
of the Company, as the Company may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous
Relationship with the Company Required</U>. Except as otherwise provided in this Section&nbsp;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>3, this Option may not be exercised
unless the Participant, at the time this Option is exercised, is, and has been at all times since the Grant Date, an employee or office
of, or consultant or advisor to, the Company or any of its subsidiaries (an &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligible Participant</B>&rdquo;). The date on which
the Participant ceases to be an Eligible Participant shall be referred to as the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination Date</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
of Relationship with the Company</U>. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided
in Sections 3(d) and 3(e) below, the right to exercise this Option shall terminate three months after the Termination Date (but in no
event after the Expiration Date); provided that this Option shall be exercisable only to the extent that the Participant was entitled
to exercise this Option on the Termination Date. Notwithstanding the foregoing, if the Participant, prior to the Expiration Date, violates
any non-competition, non-solicitation, non-disparagement or confidentiality provisions of any employment or consulting contract, confidentiality
and nondisclosure agreement or other agreement between the Participant and the Company or its subsidiary, the right to exercise this
Option shall terminate immediately upon such violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
Period Upon Death or Disability</U>. If the Participant dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3) of the
Code) prior to the Expiration Date while he or she is an Eligible Participant and the Company has not terminated such relationship for
Cause (as defined below), this Option shall be exercisable by the Participant (or, in the case of death, by the Participant&rsquo;s Designated
Beneficiary) within the period of one year following the Termination Date (but in no event after the Expiration Date); provided that
this Option shall be exercisable only to the extent that this Option was exercisable by the Participant on the Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
for Cause</U>. If, prior to the Expiration Date, the Participant&rsquo;s employment or service is terminated by the Company for Cause,
the right to exercise this Option shall terminate immediately upon the Termination Date. If prior to the Expiration Date, the Participant
is given notice by the Company of the termination of the Participant&rsquo;s employment or service by the Company for Cause, and the
Termination Date is subsequent to the date of delivery of such notice, the right to exercise this Option shall be suspended from the
time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&rsquo;s
employment or service shall not be terminated for Cause as provided in such notice or (ii) the Termination Date (in which case the right
to exercise this Option shall, pursuant to the preceding sentence, terminate upon the Termination Date). If the Participant is party
to an employment or severance contract or agreement (excluding any non-competition agreement) with the Company that contains a definition
of &ldquo;cause&rdquo; for termination, &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cause</B>&rdquo; shall have the meaning ascribed to such term in such agreement. Otherwise,
&ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cause</B>&rdquo; shall mean (A) the Participant&rsquo;s dishonest statements or acts with respect to the Company or any affiliate
of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business
that results in or is reasonably anticipated to result in material harm to the Company; (B) the Participant&rsquo;s conviction or plea
of no contest to (1) a felony or (2) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (C) the Participant&rsquo;s
failure to perform in all material respects the Participant&rsquo;s assigned duties and responsibilities, which failure continues, in
the reasonable judgment of the Company, for 10 days after written notice given to the Participant describing such failure; (D) the Participant&rsquo;s
gross negligence, willful misconduct that results in or is reasonably anticipated to result in harm to the Company; or (E) the Participant&rsquo;s
violation of any material provision of any agreement(s) between the Participant and the Company or its subsidiary or any Company policies
including, without limitation, agreements relating to non-competition, non-solicitation, non-disparagement, non-disclosure and/or assignment
of inventions or policies related to ethics or workplace conduct.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
                                            Right of First Refusal</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
of Proposed Transfer</U>. If the Participant proposes to sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation
of law or otherwise (collectively, &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer</B>&rdquo;) any Shares acquired upon exercise of this Option, then the Participant
shall first give written notice of the proposed transfer (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer Notice</B>&rdquo;) to the Company. The Transfer Notice
shall name the proposed transferee and state the number of such Shares the Participant proposes to transfer (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offered Shares</B>&rdquo;),
the price per Offered Share and all other material terms and conditions of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Right to Purchase</U>. For 30 days following its receipt of such Transfer Notice, the Company shall have the option to purchase all or
part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase
all or part of the Offered Shares, it shall give written notice of such election to the Participant within such 30-day period. Within
10&nbsp;days after the Participant&rsquo;s receipt of such notice, the Participant shall tender to the Company at its principal offices
the certificate or certificates, if any, representing the Offered Shares to be purchased by the Company, duly endorsed in blank by the
Participant or with duly endorsed stock powers attached thereto, all in a form suitable for transfer of the Offered Shares to the Company.
Promptly following receipt of such certificate or certificates, the Company shall deliver or mail to the Participant a check in payment
of the purchase price for such Offered Shares; <I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided that</I> if the terms of payment set forth in the Transfer Notice were other
than cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer
Notice; and <I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided further</I> that any delay in making such payment shall not invalidate the Company&rsquo;s exercise of its option
to purchase the Offered Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
Not Purchased By Company</U>. If the Company does not elect to acquire all of the Offered Shares, the Participant may, within the 30-day
period following the expiration of the option granted to the Company under Section 4(b) above, transfer the Offered Shares which the
Company has not elected to acquire to the proposed transferee; <I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided that</I> such transfer shall not be on terms and conditions
more favorable to the transferee than those contained in the Transfer Notice. Notwithstanding any of the above, all Offered Shares transferred
pursuant to this Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4 shall remain subject to the right of first refusal set forth in this Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4 and
such transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall
be bound by all of the terms and conditions of this Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consequences
of Non-Delivery</U>. After the time at which the Offered Shares are required to be delivered to the Company for transfer to the Company
pursuant to Section 4(b) above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or permit
the Participant to exercise any of the privileges or rights of a stockholder with respect to such Offered Shares, but shall, insofar
as permitted by law, treat the Company as the owner of such Offered Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exempt
Transactions</U>. The following transactions shall be exempt from the provisions of this Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;any
transfer of Shares to or for the benefit of any spouse, child or grandchild of the Participant, or to a trust for their benefit;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;any
transfer pursuant to an effective registration statement filed by the Company under the Securities Act of 1933, as amended (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
Act</B>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;the
sale of all or substantially all of the outstanding shares of capital stock of the Company (including pursuant to a merger or consolidation);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided,
however</I>, that in the case of a transfer pursuant to clause (i) above, such Shares shall remain subject to the right of first refusal
set forth in this Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4 and such transferee shall, as a condition to such transfer, deliver to the Company a written
instrument confirming that such transferee shall be bound by all of the terms and conditions of this Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment
of Company Right</U>. The Company may assign its rights to purchase Offered Shares in any particular transaction under this Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4
to one or more persons or entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination</U>.
The provisions of this Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4 shall terminate upon the earlier of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;the
closing of the sale of shares of Common Stock in an underwritten public offering pursuant to an effective registration statement filed
by the Company under the Securities Act; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;the
sale of all or substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger, consolidation,
sale of assets or otherwise, excluding (A) a merger or consolidation in which all or substantially all of the individuals and entities
who were beneficial owners of the Company&rsquo;s voting securities immediately prior to such transaction beneficially own, directly
or indirectly, a majority (determined on an as-converted basis) of the outstanding securities entitled to vote generally in the election
of directors of the resulting, surviving or acquiring corporation in such transaction, (B) a reverse merger or similar transaction, and
(C) any other bona fide equity or debt financing of the Company, including a financing in which greater than 50% of the Company&rsquo;s
outstanding equity securities are acquired by a third-party, or reorganization required to effect an initial public offering (a &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Sale</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Obligation to Recognize Invalid Transfer</U>. The Company shall not be required (i) to transfer on its books any of the Shares which
shall have been sold or transferred in violation of any of the provisions set forth in this Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4, or (ii) to treat as
owner of such Shares or to pay dividends to any transferee to whom any such Shares shall have been so sold or transferred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legends</U>.
Any certificate representing Shares or notice of issuance of uncertificated stock evidencing the issuance of Shares shall bear a legend
substantially in the following form (in addition to, or in combination with, any legend required by applicable federal and state securities
laws and agreements relating to the transfer of the Company securities):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
shares [represented by this certificate][referenced herein] are subject to a right of first refusal in favor of the Company, as provided
in a certain stock option agreement with the Company.&rdquo;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
                                            in Connection with Initial Public Offering</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Participant agrees, in connection with the initial underwritten public offering of the Common Stock pursuant to a registration statement
under the Securities Act, (a) not to (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose
of, directly or indirectly, any shares of Common Stock or any other securities of the Company or (ii) enter into any swap or other agreement
that transfers, in whole or in part, any of the economic consequences of ownership of shares of Common Stock or other securities of the
Company, whether any transaction described in clause (i) or (ii) is to be settled by delivery of securities, in cash or otherwise, for
a period specified by the representative of the underwriters of Common Stock or other securities of the Company not to exceed 180 days
following the effective date of any registration statement of the Company filed under the Securities Act (or such other period as may
be requested by the Company or the underwriters to accommodate regulatory restrictions on (A) the publication or other distribution of
research reports and (B) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule
2241 or any successor provisions or amendments thereto), and (b) to execute any agreement reflecting clause (a) above as may be requested
by the Company or the managing underwriters at the time of such offering. The Company may impose stop-transfer instructions with respect
to the shares of Common Stock or other securities subject to the foregoing restriction until the end of the &ldquo;lock-up&rdquo; period.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
                                            Matters</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding</U>.
No Shares will be issued pursuant to the exercise of this Option unless and until the Company satisfies all applicable federal, state,
and local or other income and employment tax withholding obligations as described in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disqualifying
Disposition</U>. If this Option is intended to qualify as an &ldquo;incentive stock option&rdquo; under Section 422 of the Code and if
the Participant disposes of Shares acquired upon exercise of this Option within two years from the Grant Date or one year after such
Shares were acquired pursuant to exercise of this Option, the Participant shall notify the Company in writing of such disposition.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nontransferability
                                            of Option</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;This
Option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation
of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this Option shall be exercisable
only by the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;The
Participant agrees that the Participant will not transfer any Shares issued pursuant to the exercise of this Option unless the transferee,
as a condition to such transfer, delivers to the Company a written instrument confirming that such transferee shall be bound by all of
the terms and conditions of Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4 and Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>5; <I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided</I>, <I STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that</I> such a written confirmation
shall not be required with respect to (i)&nbsp;Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4 after such provision has terminated in accordance with Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>4(g)
or (ii) Section <B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lrm;</B>5 after the completion of the lock-up period in connection with the Company&rsquo;s initial underwritten
public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF</B>, the Company has caused this Option to be executed by its duly authorized officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka Therapeutics, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="width: 4%"></TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page &ndash; Stock Option Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PARTICIPANT&rsquo;S ACCEPTANCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby accepts the foregoing Option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges receipt
of a copy of the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PARTICIPANT:</B></FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"></TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page &ndash; Stock Option Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
A</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
OF STOCK OPTION EXERCISE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:_______________<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka
Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Treasurer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Sir or Madam:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
am the holder of an Option granted to me under the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity Incentive Plan (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan</B>&rdquo;)
on [_______________]<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </SUP>for the purchase of [__________]<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></SUP> shares of Common Stock of the Company at an exercise price
of $[__________]<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </SUP>per share. Capitalized terms used but not defined herein shall have the meanings set forth under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby exercise my option to purchase [__________]<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></SUP> shares of Common Stock (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</B>&rdquo;), for which I
have enclosed [__________]<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </SUP>in the amount of [__________]<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></SUP>. Please register the Shares as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name(s):_________________________
  <SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></SUP></FONT></TD>
  <TD STYLE="width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:_________________________</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________________________</FONT></TD>
  <TD STYLE="padding-left: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:_________________________</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax I.D.&nbsp;#:________________________<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></SUP></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page &ndash; Notice of Stock Option Exercise]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
represent, warrant and covenant as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">1.
&nbsp;I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any
distribution of the Shares in violation of the Securities Act of 1933, as amended (the &ldquo;</FONT><B>Securities Act</B><FONT STYLE="font-weight: normal">&rdquo;),
or any rule or regulation under the Securities Act.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">2.&nbsp;I
have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to
permit me to evaluate the merits and risks of my investment in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">3.&nbsp;I
have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of
the Shares and to make an informed investment decision with respect to such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">4.&nbsp;I
can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">5.&nbsp;I
understand that (a) the Shares have not been registered under the Securities Act and are &ldquo;restricted securities&rdquo; within the
meaning of Rule 144 under the Securities Act, (b) the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently
registered under the Securities Act or an exemption from registration is then available; (c) in any event, the exemption from registration
under Rule&nbsp;144 will not be available for at least one year and even then will not be available unless a public market then exists
for the Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of
Rule 144 are complied with; and (d) there is now no registration statement on file with the Securities and Exchange Commission with respect
to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 40%">Very
truly yours,</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>(Signature)</TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page &ndash; Notice of Stock Option Exercise]&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
B</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT
OF SPOUSE OR DOMESTIC PARTNER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
___________________________________________________, spouse or registered domestic partner of ___________________________________________________,
have read and approve the Stock Option Agreement dated _______________, _____ (the &ldquo;<B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Option Agreement</B>&rdquo;), between
my spouse or registered domestic partner and Oruka Therapeutics, Inc. In consideration of granting of the right to my spouse or registered
domestic partner to purchase shares of common stock of Oruka Therapeutics, Inc. set forth in the Stock Option Agreement, I hereby appoint
my spouse or registered domestic partner as my attorney-in-fact in respect to the exercise of any rights under the Stock Option Agreement
and agree to be bound by the provisions of the Stock Option Agreement insofar as I may have any rights in said Stock Option Agreement
or any options or shares issued pursuant thereto under the community property laws or similar laws relating to marital property in effect
in the state of our residence as of the date of the signing of the foregoing Stock Option Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:_______________,
______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD></TD>
  <TD></TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Signature of Spouse or Registered Domestic Partner</TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.43
<SEQUENCE>8
<FILENAME>ea020512201ex10-43_arcabio.htm
<DESCRIPTION>AMENDED AND RESTATED DIRECTOR OFFER LETTER, DATED MARCH 22, 2024, BETWEEN ORUKA THERAPEUTICS, INC. AND SAMARTH KULKARNI
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.43</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 34%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORUKA
    THERAPEUTICS, INC.</B>&nbsp;<BR>
    221 Crescent Street, Building 23, Suite 105 <BR>
    Waltham, MA 02453</FONT></TD>
    <TD STYLE="width: 33%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-43_001.jpg" ALT=""></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
22, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Via
Email </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samarth
Kulkarni, Ph.D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
to Oruka Therapeutics, Inc. Board of Directors</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Dr. Kulkarni,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
am pleased to present this formal offer to join the Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of Oruka Therapeutics, Inc. (the
&ldquo;<B>Company</B>&rdquo;). This offer is contingent upon (i) your completion of a Director &amp; Officer Questionnaire with responses
satisfactory to the Company, (ii) receipt of a background check satisfactory to the Company, and (iii) formal approval of your appointment
by the Board. This Offer Letter amends and restates that certain Offer Letter dated March 6, 2024. We very much look forward to your
joining the Board and your many contributions to the growth and governance of the Company. Details of the Company&rsquo;s offer are set
forth below. The date upon which you commence service on the Board is referred to herein as the &ldquo;<B>Effective Date</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation</I></B><I>.
</I>As soon as practicable following the Effective Date, you will be granted non-qualified stock options to purchase up to 250,000 shares
of the Company's common stock, par value $0.0001 (the &ldquo;<B>Common Stock</B>&rdquo;), with an exercise price equal to the fair market
value of a share of Common Stock on the date of the grant (the &ldquo;<B>First Option Award</B>&rdquo;). The First Option Award will
vest on the following schedule: (i) 25% of the First Option Award will vest on the first anniversary of the Effective Date and (ii) 1/48
of the First Option Award will vest on each monthly anniversary of the Effective Date thereafter, such that 100% of the First Option
Award will be vested by the fourth anniversary of the Effective Date, subject to your continued service on the Board through each vesting
date. As soon as practicable following the Effective Date, you will also be granted non-qualified stock options to purchase up to 100,000
shares of Common Stock, with an exercise price equal to the fair market value of a share of Common Stock on the date of the grant (the
&ldquo;<B>Second Option Award</B>&rdquo;). The Second Option Award will vest on the first anniversary of the date on which you become
Chairman of the Board, subject to your continued service on the Board through such vesting date. If you have not become Chairman of the
Board by the first anniversary of the date of this Offer Letter, the Second Option Award will no longer vest and immediately be deemed
to have been forfeited. The First Option Award and the Second Option Award will be governed by the terms of the related award agreements,
the Company&rsquo;s 2024 Equity Incentive Plan, and the terms and conditions approved by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
you will be entitled to cash compensation for service on the Board and standing Board committees. This is payable in equal quarterly
installments, in advance during the last month of each quarter in which service occurred, prorated for any months of partial service.
Cash and equity-based compensation for non-employee directors is generally reassessed annually and may be changed at any time by the
Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Meetings</I></B>.
As we have discussed, the Board generally will meet on a quarterly basis in-person (or virtually as needed). The Board may also hold
ad-hoc telephonic meetings from time to time as the need arises. Standing committees of the Board (<I>i.e.</I>, Audit, Compensation and
Nominating and Corporate Governance) will meet quarterly and on an ad-hoc basis as well. Generally, these committee meetings will be
scheduled to take place the day before or the day of the Board meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Documentation.
</I></B>We have enclosed with this Offer Letter a customary Director &amp; Officer Questionnaire, which seeks information required for
the Board to make independence determinations for Nasdaq and other purposes, as well as information that may be required to be disclosed
in SEC filings. Upon joining the Board, the Company will provide you with a customary indemnification agreement, which provides for indemnification
by the Company for certain expenses that may arise relating to your Board service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Approval
and Disclosure Process</I></B>. Following receipt of the above-referenced questionnaire, and subject to a formal vote of the Board, you
will officially join the Company&rsquo;s Board on a date to be mutually agreed between you and the Company. At a later time, we would
announce your appointment to the Board or include such appointment in an appropriate future SEC filing. We will work with you to ensure
that we have the necessary SEC filing codes to be able to file a Form 3 on your behalf in connection with your appointment to the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
very much look forward to your addition to the Board and your many contributions to the growth of the Company. If this offer is acceptable,
please countersign below and return a copy of this letter to my attention so that we may start the process of formalizing your new role
on the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Lawrence Klein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence Klein, Ph.D.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreed and Accepted:</FONT></TD>
    <TD STYLE="width: 60%; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Samarth Kulkarni</FONT></TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samarth Kulkarni, Ph.D.</FONT></TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.44
<SEQUENCE>9
<FILENAME>ea020512201ex10-44_arcabio.htm
<DESCRIPTION>DIRECTOR OFFER LETTER, DATED APRIL 24, 2024, BETWEEN ORUKA THERAPEUTICS, INC. AND KRISTINE BALL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Exhibit 10.44</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 33%">&nbsp;</TD>
  <TD STYLE="vertical-align: bottom; text-align: center; width: 34%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ORUKA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">221 Crescent Street, Building 23, Suite 105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Waltham, MA 02453</P>
</TD>
  <TD STYLE="text-align: right; width: 33%"><IMG SRC="ex10-44_001.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">April 24<SUP>th</SUP>, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Kristine Ball</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Re:&nbsp;&nbsp;&nbsp;&nbsp;Appointment to Oruka Therapeutics, Inc.
Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Dear Ms. Ball,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">I am pleased to present this formal offer to join
the Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of Oruka Therapeutics, Inc. (the &ldquo;<B>Company</B>&rdquo;) as a member and
chair of our Audit Committee. This offer is contingent upon (i) your completion of a Director &amp; Officer Questionnaire with responses
satisfactory to the Company, (ii) receipt of a background check satisfactory to the Company, and (iii) formal approval of your appointment
by the Board. We very much look forward to your joining the Board and your many contributions to the growth and governance of the Company.
Details of the Company&rsquo;s offer are set forth below. The date upon which you commence service on the Board is referred to herein
as the &ldquo;<B>Effective Date</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Compensation</I></B><I>.</I> As soon as practicable
following the Effective Date, subject to Board or committee approval, you will be granted non-qualified stock options to purchase up to
125,000 shares of the Company&rsquo;s common stock, par value $0.0001 (the &ldquo;<B>Common Stock</B>&rdquo;), with an exercise price equal
to the fair market value of a share of Common Stock on the date of the grant (the &ldquo;<B>Option Award</B>&rdquo;). The Option Award
will vest on the following schedule: (i) 25% of the Option Award will vest on the first anniversary of the Effective Date and (ii) 1/48
of the Option Award will vest on each monthly anniversary of the Effective Date thereafter, such that 100% of the Option Award will be
vested by the fourth anniversary of the Effective Date, subject to your continued service on the Board through each vesting date. The
Option Award will be governed by the terms of the related award agreements, the Company&rsquo;s 2024 Equity Incentive Plan, and the terms
and conditions approved by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, you will be entitled to cash compensation
for service on the Board and standing Board committees, which will be initially determined by the Board in consideration of market information
provided by an independent compensation consultant. This is payable in equal quarterly installments, in advance during the last month
of each quarter in which service occurred, prorated for any months of partial service. Cash and equity-based compensation for non-employee
directors is generally reassessed annually and may be changed at any time by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will reimburse you for ordinary and
reasonable out-of-pocket travel expenses to cover in-person attendance at and participation in Board and committee meetings; provided,
that you submit to the Company appropriate documentation substantiating such expenses in accordance with the Company&rsquo;s travel and
expense policy, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Meetings</I></B>. As we have discussed, the
Board generally will meet on a quarterly basis in-person (or virtually as needed). The Board may also hold ad-hoc telephonic meetings
from time to time as the need arises. Standing committees of the Board (<I>i.e.</I>, Audit, Compensation and Nominating and Corporate
Governance) will meet quarterly and on an ad-hoc basis as well. Generally, these committee meetings will be scheduled to take place the
day before or the day of the Board meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Documentation. </I></B>The Company will send
you a Director &amp; Officer Questionnaire that you will be required to complete, which seeks information required for the Board to make
independence determinations for Nasdaq and other purposes, as well as information that may be required to be disclosed in SEC filings.
Upon joining the Board, the Company will provide you with a customary indemnification agreement, which provides for indemnification by
the Company for certain expenses that may arise relating to your Board service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Approval and Disclosure Process</I></B>.
Following receipt of the above-referenced questionnaire, and subject to a formal vote of the Board, you will officially join the Company&rsquo;s
Board on a date to be mutually agreed between you and the Company. At a later time, we would announce your appointment to the Board or
include such appointment in an appropriate future SEC filing. We will work with you to ensure that we have the necessary SEC filing codes
to be able to file a Form 3 on your behalf in connection with your appointment to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We very much look forward to your addition to the
Board and your many contributions to the growth of the Company. If this offer is acceptable, please countersign below and return a copy
of this letter to my attention so that we may start the process of formalizing your new role on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 65%">&nbsp;</TD>
    <TD STYLE="width: 35%">Sincerely,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Lawrence Klein</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Lawrence Klein, Ph.D.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 35%">Agreed and Accepted:</TD>
    <TD STYLE="width: 65%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Kristine Ball</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Kristine Ball</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><BR>
<BR>
</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>10
<FILENAME>ea020512201ex10-45_arcabio.htm
<DESCRIPTION>FORM OF INDEMNIFICATION AGREEMENT BETWEEN ORUKA THERAPEUTICS, INC. AND ITS DIRECTORS AND OFFICERS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.45</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">INDEMNIFICATION
AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">THIS INDEMNIFICATION AGREEMENT
(the &ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of [&#9679;], 2024 between Oruka Therapeutics, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), and [&#9679;] (&ldquo;<U>Indemnitee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WITNESSETH THAT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, highly competent
persons have become more reluctant to serve companies as directors or officers, or in other capacities unless they are provided with adequate
protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their
service to and activities on behalf of the company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, the Board
of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;) has determined that, in order to attract and retain qualified individuals,
the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company
and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice
among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and
trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors,
officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming
litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise
itself. Indemnitee may also be entitled to indemnification pursuant to the Delaware General Corporation Law (as amended from time to time,
the &ldquo;<U>Act</U>&rdquo;). The Act, the Company&rsquo;s Certificate of Incorporation (as amended, restated and/or otherwise modified
from time to time, the &ldquo;<U>Certificate of Incorporation</U>&rdquo;) and the Company&rsquo;s Bylaws (as amended, restated and/or
otherwise modified from time to time, the &ldquo;<U>Bylaws</U>&rdquo;) expressly provide that the indemnification provisions set forth
therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the Board, officers
and other persons with respect to indemnification;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, the uncertainties
relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, the Board
has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company&rsquo;s
stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, it is reasonable,
prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons
to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that
they will not be so indemnified;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, this Agreement
is a supplement to and in furtherance of the Bylaws and Certificate of Incorporation of the Company and any resolutions adopted pursuant
thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>, Indemnitee
does not regard the protection available under the Company&rsquo;s Bylaws and insurance as adequate in the present circumstances, and
may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such
capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition
that he or she be so indemnified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of Indemnitee&rsquo;s agreement to serve or continue to serve, as applicable, as an officer or director of the Company from
and after the date hereof, the parties hereto agree as follows:</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">1.   <U>Indemnity
of Indemnitee</U>. The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by law, as such
may be amended from time to time. In furtherance of the foregoing indemnification, and without limiting the generality thereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)   <U>Proceedings
Other Than Proceedings by or in the Right of the Company</U>. Indemnitee shall be entitled to the rights of indemnification provided in
this <U>Section l(a)</U> if, by reason of such person&rsquo;s Official Status (as hereinafter defined), the Indemnitee is, or is threatened
to be made, a party to or participant in any Proceeding (as hereinafter defined) other than a Proceeding by or in the right of the Company.
Pursuant to this <U>Section 1(a)</U>, Indemnitee shall be indemnified against all Expenses (as hereinafter defined), judgments, penalties,
fines and amounts paid in settlement actually and reasonably incurred by such person, or on such person&rsquo;s behalf, in connection
with such Proceeding or any claim, issue or matter therein, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably
believed to be in or not opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable
cause to believe the Indemnitee&rsquo;s conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)   <U>Proceedings
by or in the Right of the Company</U>. Indemnitee shall be entitled to the rights of indemnification provided in this <U>Section 1(b)</U>
if, by reason of such person&rsquo;s Official Status, the Indemnitee is, or is threatened to be made, a party to or participant in any
Proceeding brought by or in the right of the Company. Pursuant to this <U>Section 1(b)</U>, Indemnitee shall be indemnified against all
Expenses actually and reasonably incurred by the Indemnitee, or on the Indemnitee&rsquo;s behalf, in connection with such Proceeding if
the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of
the Company; <I>provided</I>, <I>however</I>, if applicable law so provides, no indemnification against such Expenses shall be made in
respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company unless
and to the extent that the Court of Chancery of the State of Delaware shall determine that such indemnification may be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)   <U>Indemnification
for Expenses of a Party Who is Wholly or Partly Successful</U>. Notwithstanding any other provision of this Agreement, to the extent that
Indemnitee is, by reason of his or her Official Status, a party to (or participant in) and is successful, on the merits or otherwise,
in any Proceeding, he or she shall be indemnified to the maximum extent permitted by law, as such may be amended from time to time, against
all Expenses actually and reasonably incurred by him or her, or on his or her behalf, in connection therewith. If Indemnitee is not wholly
successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters
in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her, or on
his or her behalf, in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation,
the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful
result as to such claim, issue or matter.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">2.   <U>Additional
Indemnity</U>. In addition to, and without regard to any limitations on, the indemnification provided for in <U>Section 1</U> of this
Agreement, the Company shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties, fines
and amounts paid in settlement actually and reasonably incurred by him or her, or on his or her behalf if, by reason of his or her Official
Status, he or she is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the right
of the Company), including, without limitation, all liability arising out of the negligence or active or passive wrongdoing of Indemnitee.
The only limitation that shall exist upon the Company&rsquo;s obligations pursuant to this Agreement shall be that the Company shall not
be obligated to make any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set
forth in <U>Sections 6</U> and <U>7</U> hereof) to be unlawful.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">3.   <U>Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)   Whether
or not the indemnification provided in <U>Sections 1</U> and <U>2</U> hereof is available, in respect of any threatened, pending or completed
action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding),
the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such action, suit or proceeding without
requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have
against Indemnitee. The Company shall not enter into any settlement of any action, suit or proceeding in which the Company is jointly
liable with Indemnitee (or would be if joined in such action, suit or proceeding) unless such settlement provides for a full and final
release of all claims asserted against Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)   Without
diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any reason, Indemnitee shall
elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed action, suit or proceeding
in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall contribute
to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee
in proportion to the relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee,
who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on
the other hand, from the transaction or events from which such action, suit or proceeding arose; <U>provided</U>, <U>however</U>, that
the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference
to the relative fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable
with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, in connection
with the transactions or events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable
considerations which the applicable law may require to be considered. The relative fault of the Company and all officers, directors or
employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or
proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to
which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary
and the degree to which their conduct is active or passive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)   The
Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought by officers,
directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)   To
the fullest extent permissible under applicable law and without diminishing or impairing the obligations of the Company set forth in the
preceding subparagraphs of this <U>Section 3</U>, if the indemnification provided for in this Agreement is unavailable to Indemnitee for
any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether
for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim
relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances
of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or
transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees
and agents) and Indemnitee in connection with such event(s) and/or transaction(s).</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">4.   <U>Indemnification
for Expenses of a Witness</U>. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his
or her Official Status, a witness, or is made (or asked) to respond to discovery requests, in any Proceeding to which Indemnitee is not
a party, he or she shall be indemnified against all Expenses actually and reasonably incurred by him or her, or on his or her behalf,
in connection therewith.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">5.   <U>Advancement
of Expenses</U>. Notwithstanding any other provision of this Agreement, the Company shall advance all Expenses incurred by or on behalf
of Indemnitee in connection with any Proceeding by reason of Indemnitee&rsquo;s Official Status within thirty (30) days after the receipt
by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or
after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee
and shall include or be preceded or accompanied by a written undertaking by or on behalf of Indemnitee to repay any Expenses advanced
if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses. Any advances and undertakings
to repay pursuant to this <U>Section 5</U> shall be unsecured and interest free and not conditioned on Indemnitee&rsquo;s ability to repay
such advances.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">6.   <U>Procedures
and Presumptions for Determination of Entitlement to Indemnification</U>. It is the intent of this Agreement to secure for Indemnitee
rights of indemnity that are as favorable as may be permitted under the Act and public policy of the State of Delaware. Accordingly, the
parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled
to indemnification under this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)   To
obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith
such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what
extent Indemnitee is entitled to indemnification. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification,
advise the Board in writing that Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of Indemnitee to
provide such a request to the Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability
that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)   Upon
written request by Indemnitee for indemnification pursuant to the first sentence of <U>Section 6(a)</U> hereof, a determination with respect
to Indemnitee&rsquo;s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the
election of the Board: (i) by a majority vote of the Disinterested Directors, even though less than a quorum, (ii) by a committee of Disinterested
Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum, (iii) if there are no Disinterested
Directors or if the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall
be delivered to the Indemnitee, or (iv) if so directed by the Board, by the stockholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)   If
the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to <U>Section 6(b)</U> hereof, notwithstanding
<U>Section 6(b)</U> above, the Independent Counsel shall be selected as provided in this <U>Section 6(c)</U>. The Independent Counsel
shall be selected by a majority of the votes held by the Board. Indemnitee may, within 10 days after such written notice of selection
shall have been given, deliver to the Company a written objection to such selection; <U>provided</U>, <U>however</U>, that such objection
may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &ldquo;<U>Independent Counsel</U>&rdquo;
as defined in <U>Section 13</U> of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.
Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a written objection is made and substantiated,
the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined
that such objection is without merit. If, within 20 days after submission by Indemnitee of a written request for indemnification pursuant
to <U>Section 6(a)</U> hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may
petition the Court of Chancery of the State of Delaware or other court of competent jurisdiction for resolution of any objection which
shall have been made by the Indemnitee to the Company&rsquo;s selection of Independent Counsel and/or for the appointment as Independent
Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all
objections are so resolved or the person so appointed shall act as Independent Counsel under <U>Section 6(b)</U> hereof. The Company shall
pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant
to <U>Section 6(b)</U> hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this <U>Section
6(c)</U>, regardless of the manner in which such Independent Counsel was selected or appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)   In
making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination
shall presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption shall have
the burden of proof and the burden of persuasion by clear and convincing evidence. Neither the failure of the Company (including by its
directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that
indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination
by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall
be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e)   Indemnitee
shall be deemed to have acted in good faith if Indemnitee&rsquo;s action is based on the records or books of account of the Enterprise
(as hereinafter defined), including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in
the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to
the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise.
In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not
be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions
of this <U>Section 6(e)</U> are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and
in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this
presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f)   If
the person, persons or entity empowered or selected under <U>Section 6</U> to determine whether Indemnitee is entitled to indemnification
shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination
of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification absent (i)
a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s statement not
materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable
law; <U>provided</U>, <U>however</U>, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty
(30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires
such additional time to obtain or evaluate documentation and/or information relating thereto; and provided further, that the foregoing
provisions of this <U>Section 6(f)</U> shall not apply if the determination of entitlement to indemnification is to be made by the stockholders
pursuant to <U>Section 6(b)</U> of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for
such determination, the Board or the Disinterested Directors, if appropriate, resolve to submit such determination to the stockholders
for their consideration at an annual meeting thereof to be held within seventy five (75) days after such receipt and such determination
is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making
such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is
made thereat.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(g)   Indemnitee
shall cooperate with the person, persons or entity making such determination with respect to Indemnitee&rsquo;s entitlement to indemnification,
including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged
or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination.
Any Independent Counsel, member of the Board or stockholder of the Company shall act reasonably and in good faith in making a determination
regarding the Indemnitee&rsquo;s entitlement to indemnification under this Agreement. Any costs or expenses (including attorneys&rsquo;
fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be
borne by the Company (irrespective of the determination as to Indemnitee&rsquo;s entitlement to indemnification) and the Company hereby
indemnifies and agrees to hold Indemnitee harmless therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(h)   The
Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense,
delay, distraction, disruption and uncertainty. In the event that any action, claim or proceeding to which Indemnitee is a party is resolved
in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding
with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise
in such action, suit or proceeding. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion
by clear and convincing evidence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)   The
termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of
nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the
right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she
reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee
had reasonable cause to believe that his or her conduct was unlawful.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">7.   <U>Remedies
of Indemnitee</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)   In
the event that (i) a determination is made pursuant to <U>Section 6</U> of this Agreement that Indemnitee is not entitled to indemnification
under this Agreement, (ii) advancement of Expenses is not timely made pursuant to <U>Section 5</U> of this Agreement, (iii) no determination
of entitlement to indemnification is made pursuant to <U>Section 6(b)</U> of this Agreement within 90 days after receipt by the Company
of the request for indemnification, (iv) payment of indemnification is not made pursuant to this Agreement within ten (10) days after
receipt by the Company of a written request therefor or (v) payment of indemnification is not made within ten (10) days after a determination
has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to <U>Section
6</U> of this Agreement, Indemnitee shall be entitled to an adjudication in an appropriate court of the State of Delaware, or in any other
court of competent jurisdiction, of Indemnitee&rsquo;s entitlement to such indemnification. Indemnitee shall commence such proceeding
seeking an adjudication within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant
to this <U>Section 7(a)</U>. The Company shall not oppose Indemnitee&rsquo;s right to seek any such adjudication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)   In
the event that a determination shall have been made pursuant to <U>Section 6(b)</U> of this Agreement that Indemnitee is not entitled
to indemnification, any judicial proceeding commenced pursuant to this <U>Section 7</U> shall be conducted in all respects as a de novo
trial on the merits, and Indemnitee shall not be prejudiced by reason of the adverse determination under <U>Section 6(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)   If
a determination shall have been made pursuant to <U>Section 6(b)</U> of this Agreement that Indemnitee is entitled to indemnification,
the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this <U>Section 7</U>, absent (i) a
misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s misstatement not
materially misleading in connection with the application for indemnification, or (ii) a prohibition of such indemnification under applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)   In
the event that Indemnitee, pursuant to this <U>Section 7</U>, seeks a judicial adjudication of his or her rights under, or to recover
damages for breach of, this Agreement, or to recover under any directors&rsquo; and officers&rsquo; liability insurance policies maintained
by the Company, the Company shall pay on Indemnitee&rsquo;s behalf, in advance, any and all expenses (of the types described in the definition
of Expenses in <U>Section 13</U> of this Agreement) actually and reasonably incurred by him or her in such judicial adjudication, regardless
of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or insurance recovery.
The Company irrevocably authorizes the Indemnitee from time to time to retain counsel of Indemnitee&rsquo;s choice, at the expense of
the Company to the extent provided hereunder or under applicable law, to advise and represent Indemnitee in connection with any such judicial
adjudication or recovery, including, without limitation, the initiation or defense of any litigation or other legal action, whether by
or against the Company or any director, officer, stockholder or other person affiliated with the Company. Notwithstanding any existing
or prior attorney-client relationship between the Company and such counsel, the Company irrevocably consents to Indemnitee&rsquo;s entering
into an attorney-client relationship with such counsel, and in that connection the Company and Indemnitee agree that a confidential relationship
shall exist between Indemnitee and such counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e)   The
Company shall be precluded from asserting in any judicial proceeding commenced pursuant to this <U>Section 7</U> that the procedures and
presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound
by all the provisions of this Agreement. The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee,
shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law,
such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification
or advance of Expenses from the Company under this Agreement or under any directors&rsquo; and officers&rsquo; liability insurance policies
maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement
of Expenses or insurance recovery, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f)   Notwithstanding
anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required
to be made prior to the final disposition of the Proceeding.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">8.   <U>Non-Exclusivity;
Survival of Rights; Insurance; Primacy of Indemnification; Subrogation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)   The
rights of indemnification as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any
time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders, a resolution
of directors, of the Company or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit
or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Official
Status prior to such amendment, alteration or repeal. To the extent that a change in the Act, whether by statute or judicial decision,
permits greater indemnification than would be afforded currently under the Certificate of Incorporation, Bylaws and this Agreement, it
is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No
right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative
and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion
or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right
or remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)   To
the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees,
or agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other
enterprise that such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance
with its or their terms to the maximum extent of the coverage available for any director, officer, employee, agent or fiduciary under
such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director
and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers
in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action
to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the
terms of such policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)   In
the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery
of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such
documents as are necessary to enable the Company to bring suit to enforce such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)   The
Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent
that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e)   The
Company&rsquo;s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company
as a director, officer, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other
enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other
corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">9.   <U>Exception
to Right of Indemnification</U>. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement
to make any indemnity in connection with any claim made against Indemnitee:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)   for
which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with
respect to any excess beyond the amount paid under any insurance policy or other indemnity provision;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)   for
an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the
meaning of <U>Section 16(b)</U> of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common
law; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)   in
connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding)
initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized
the Proceeding (or any part of any Proceeding) prior to its initiation, (ii) the Proceeding is initiated by Indemnitee pursuant to Indemnitee&rsquo;s
rights under <U>Section 7</U> of this Agreement, or (iii) the Company provides the indemnification, in its sole discretion, pursuant to
the powers vested in the Company under applicable law.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">10.   <U>Duration
of Agreement</U>. All agreements and obligations of the Company contained herein shall continue during the period ending three years after
Indemnitee ceases to serve in an Official Status (or is or was serving at the request of the Company as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise) and shall continue thereafter so long as Indemnitee
shall be subject to any Proceeding (or any proceeding commenced under <U>Section 7</U> hereof) by reason of his or her Official Status,
whether or not he or she is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification
can be provided under this Agreement. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties
hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to
all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">11.   <U>Security</U>.
To the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to
Indemnitee for the Company&rsquo;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral.
Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">12.   <U>Enforcement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)   The
Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in order
to induce Indemnitee to serve as an officer or director of the Company, and the Company acknowledges that Indemnitee is relying upon this
Agreement in serving as an officer or director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)   This
Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior
agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)   The
Company shall not seek from a court, or agree to, a &ldquo;bar order&rdquo; which would have the effect of prohibiting or limiting the
Indemnitee&rsquo;s rights to receive advancement of expenses under this Agreement.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">13.   <U>Definitions</U>.
For purposes of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)   &ldquo;<U>Disinterested
Director</U>&rdquo; means a director of the Company who is not and was not a party to the action, claim or proceeding in respect of which
indemnification is sought by Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)   &ldquo;<U>Enterprise</U>&rdquo;
shall mean the Company and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee
is or was serving at the express written request of the Company as a director, officer, employee, agent or fiduciary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)   &ldquo;<U>Expenses</U>&rdquo;
shall include all reasonable attorneys&rsquo; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses,
duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses
of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating,
or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding.
Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding and any federal, state, local
or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, including,
without limitation, the premium, security for, and other costs relating to any cost bond, supersede as bond, or other appeal bond or its
equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against
Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)   &ldquo;<U>Independent
Counsel</U>&rdquo; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently
is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party
(other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification
agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing,
the term &ldquo;Independent Counsel&rdquo; shall not include any person who, under the applicable standards of professional conduct then
prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&rsquo;s
rights under this Agreement. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify
such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement
pursuant hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e)   &ldquo;<U>Official
Status</U>&rdquo; describes the status of a person who is or was a director, officer, employee, agent or fiduciary of the Company or of
any other limited liability company, corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such
person is or was serving at the express written request of the Company. For purposes of this Agreement, a director, officer, employee,
agent or fiduciary of the Company who is serving or has served as a director, officer, employee, agent or fiduciary of a subsidiary of
the Company shall be deemed to be serving in such capacity at the request of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f)   &ldquo;<U>Proceeding</U>&rdquo;
includes any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry,
administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise
and whether civil, criminal, administrative or investigative, in which Indemnitee was, is or will be involved as a party or otherwise,
by reason of his or her Official Status, by reason of any action taken by him or her, or of any inaction on his or her part, while acting
in his or her Official Status, or by reason of the fact that he or she is or was serving at the request of the Company as a director,
officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other Enterprise; in each case whether
or not he or she is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification
can be provided under this Agreement; including one pending on or before the date of this Agreement, but excluding one initiated by an
Indemnitee pursuant to <U>Section 7</U> of this Agreement to enforce his or her rights under this Agreement.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">14.   <U>Severability</U>.
The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.
Further, the invalidity or unenforceability of any provision hereof as to Indemnitee shall in no way affect the validity or enforceability
of any provision hereof as to the other. Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee
indemnification rights to the fullest extent permitted by applicable laws. In the event any provision hereof conflicts with any applicable
law, such provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">15.   <U>Modification
and Waiver</U>. No supplement, modification, termination or amendment of this Agreement shall be binding unless executed in writing by
both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">16.   <U>Notice
By Indemnitee</U>. Indemnitee agrees promptly to notify the Company in writing upon being served with or otherwise receiving any summons,
citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to
indemnification covered hereunder. The failure to so notify the Company shall not relieve the Company of any obligation which it may have
to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the Company.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">17.   <U>Notices</U>.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given:
(a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal
business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by registered
or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt. All communications shall be sent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">To Indemnitee at the address set forth below Indemnitee signature
hereto.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">To the Company at:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">221 Crescent Street, Building 23, Suite
105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">Waltham, MA 02453</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">Attention: President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">With a copy to (which shall not constitute
notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">Gibson, Dunn &amp; Crutcher LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">One Embarcadero Center, Suite #2600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">San Francisco, CA 94111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">Attention: Ryan Murr and Branden Berns</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">Email: rmurr@gibsondunn.com; bberns@gibsondunn.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">or to such other address as may have been furnished
to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">18.   <U>Counterparts</U>.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">19.   <U>Headings</U>.
The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this
Agreement or to affect the construction thereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal">20.   <U>Governing
Law and Consent to Jurisdiction</U>. This Agreement and the legal relations among the parties shall be governed by, and construed and
enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee
hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall
be brought only in the Chancery Court of the State of Delaware (the &ldquo;<U>Delaware Court</U>&rdquo;), and not in any other state or
federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction
of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection
to the laying of venue of any such action or proceeding in the Delaware Court, and (iv) waive, and agree not to plead or to make, any
claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement on and as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>ORUKA THERAPEUTICS, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>K. Evan Thompson</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>INDEMNITEE</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">Address:&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"><B></B>&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><FONT STYLE="font-variant: small-caps">Signature Page to Indemnification
Agreement (Oruka Therapeutics, Inc.)</FONT>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>11
<FILENAME>ea020512201ex10-46_arcabio.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT OFFER LETTER, DATED FEBRUARY 14, 2024, BY AND BETWEEN ORUKA THERAPEUTICS, INC. AND LAWRENCE KLEIN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right; text-indent: 0in">Exhibit 10.46</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in">ORUKA THERAPEUTICS,
INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">221 Crescent Street, Building 23, Suite
105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Waltham, MA 02453</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">February 14, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Lawrence Klein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Email &ndash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Re: Amended and Restated Oruka
Therapeutics CEO Offer Letter Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Dear Lawrence:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">On behalf of
the Board of Directors of Oruka Therapeutics, Inc. (the &ldquo;<U>Company</U>&rdquo;), I am very pleased to offer you a position as Chief
Executive Officer of the Company (&ldquo;<U>CEO</U>&rdquo;) and a member of the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;)
pursuant to this letter agreement (the &ldquo;<U>Agreement</U>&rdquo;), provided you accept such offer as indicated by your signature
below. This Agreement amends and restates that certain letter agreement dated February 6, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">Your position
as a member of the Board and as CEO of the Company will commence as of February 26, 2024 (the &ldquo;<U>Effective Date</U>&rdquo;) or
such other date as mutually agreed upon by you and the Board, which start date will occur no later than March 4, 2024 (the &ldquo;<U>Outside
Date</U>&rdquo;). Should you not commence services by the Outside Date or if this Agreement is otherwise terminated on or prior to the
Outside Date, you hereby agree that this Agreement shall be void <I>ab initio </I>and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>1.   Positions</B>.
As CEO, you will report to the Board, and you shall have all duties, authorities, and responsibilities customarily associated with a CEO
role. This is a full-time employment position. You will be a member of the Board until, pursuant to the terms of the Company&rsquo;s by-laws
(the &ldquo;<U>By-Laws</U>&rdquo;), your successor is elected and duly qualified or until your earlier death, disability, resignation
or removal. Notwithstanding the foregoing, for so long as you serve as CEO of the Company while the ownership interests of the Company
are privately held, you will also be a member of the Board. If at any time the Company, or any successor entity, is publicly traded while
you serve as CEO of the Company, you will be nominated for shareholder approval to serve as a member of the Board. Following the Effective
Date, you will be deemed to have resigned from the Board upon ceasing to serve as CEO for any reason unless the Board agrees otherwise.
It is understood and agreed that, commencing as of the Effective Date you will not engage in any other employment, consulting or other
business activities (whether full-time or part-time), except as a director for both Maro Bio and Nava Therapeutics, or as expressly authorized
in writing by the Board. Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long
as such activities do not unreasonably interfere or conflict with your obligations to the Company.</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0.5in; text-indent: 0in; text-align: left">2.
Equity<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(a)
Subject to approval by the Board , as soon as practicable following the Effective Date, you will be provided with the ability to
purchase 1,491,646 shares of the Company&rsquo;s common stock, par value $0.0001 (the &ldquo;<U>Restricted Shares</U>&rdquo;), at a
purchase price of $149.17. The Restricted Shares will vest as follows: (a) 25% of the Restricted Shares will vest on the one-year
anniversary of the Effective Date and (b) the balance of the Restricted Shares will vest thereafter in approximately equal monthly
installments for the next 36 months so that you would be fully vested on the four-year anniversary of the Effective Date, provided
that you continue to serve as CEO as of each such vesting date. The Restricted Shares will be governed by the terms of the related
Restricted Stock Notice and Restricted Stock Purchase Agreement and the terms and conditions approved by the Board. The Company shall
permit you to make, and you shall make, a timely Code Section 83(b) election in accordance with Treasury Regulation 1.83-2 with respect
to the Restricted Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(b) Subject
to approval by the Board, the Company will periodically grant you stock options to purchase shares of the Company&rsquo;s common stock,
at an exercise price as determined by the Board (the &ldquo;<U>Replenishment Options</U>&rdquo;), in order to maintain your ownership
at approximately 5.0% on a fully diluted basis until the Company has raised an aggregate of $200,000,000; provided, however, that the
Board shall have no obligation to grant you additional stock options thereafter. The Replenishment Options will vest in 48 approximately
equal monthly installments commencing on the applicable date(s) of grant; provided, that you continue providing services to the Company
through each vesting date. Any Replenishment Options will be governed by the terms of the related award agreement, the Company&rsquo;s
2024 Equity Incentive Plan or other equity incentive plan and the terms and conditions approved by the Board..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>3.   Cash
Compensation</B>. Upon and following the Effective Date, as cash compensation for your services, the Company will pay you an initial base
salary of $600,000 per year, payable in accordance with the Company&rsquo;s standard payroll schedule and subject to applicable deductions
and withholdings. Your base salary will be subject to periodic review and upward (but not downward) adjustments at the Board&rsquo;s discretion.
Your base salary in effect at any given time is referred to herein as the &ldquo;<U>Base Salary</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>4.   Annual
Bonus</B>. Commencing as of the Effective Date, you will initially be eligible to receive an annual performance bonus targeted at 50%
of your Base Salary. The target annual bonus in effect at any given time is referred to herein as &ldquo;<U>Target Bonus</U>.&rdquo; Your
2024 annual bonus will be prorated based on your period of employment following the Effective Date. The actual bonus amount is discretionary.
To earn an annual bonus, you must be (except as otherwise provided herein) employed by the Company as of the payment date of such bonus,
as it also serves as an incentive to remain employed by the Company. Any annual bonus will be paid no later than March 15th of the calendar
year following the calendar year to which such bonus relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>5.   Benefits/Paid
Time Off.</B> Commencing on the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to participate
in the employee benefits and insurance programs generally made available to the Company&rsquo;s full-time employees. Details of such benefits
programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you when such benefit(s)
become available. You will be entitled to paid time off consistent with the terms of the Company&rsquo;s paid time off policy, as in effect
from time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>6.   Board
Meetings; Expenses; Indemnification.</B> You will be expected to attend scheduled Board meetings in person whenever you are able and permitted
by applicable health regulations and to participate by telephone if you are not able to attend in person. The Company will reimburse you
for reasonable travel expenses in connection with attending Board meetings and for performing services as CEO in accordance with the policies
and procedures then in effect and established by the Company for its executives. The Company will indemnify you for your service as a
director and CEO in accordance with the Company&rsquo;s By-laws and as provided by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>7.   Location</B>.
Your primary work location as CEO will be remotely in California, as determined by the Board, provided that you may be required to engage
in reasonable travel for business, consistent with the Company&rsquo;s business needs. You may change your remote work location with prior
written notice to and approval from the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>8.   At-Will
Employment; Date of Termination</B>. At all times, your employment as CEO or any other employment position you may receive is &ldquo;at
will,&rdquo; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although
your job duties, title, reporting structure, compensation and benefits, as well as the Company&rsquo;s benefit plans and personnel policies
and procedures, may change from time to time (subject to the terms of this Agreement), the &ldquo;at will&rdquo; nature of your employment
may only be changed in an express written agreement signed by you and the Chairperson of the Board or a majority of the Board. Your last
day of employment for any reason is referred to herein as the &ldquo;<U>Date of Termination</U>.&rdquo; In the event that you elect to
end your employment with the Company, the Company requires you to provide at least 30 days&rsquo; advance written notice to the Company;
and in the event that the Company terminates you without Cause, you shall be given at least 30 days advance written notice by the Company.
Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result
in a termination by the Company without Cause for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">To the extent applicable, you shall
be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries
and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested
to confirm or effectuate any such resignations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>9.   Accrued
Obligations</B>. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if
applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly
incurred by you on behalf of the Company prior to any such termination and not yet reimbursed (the &ldquo;<U>Accrued Obligations</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>10.   Severance
Pay and Benefits Outside of the Change in Control Period</B>. In the event that the Company terminates your employment without Cause (and
not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in <U>Appendix
A</U>), then, in addition to the Accrued Obligations, and subject to (i) you signing and not revoking a separation agreement and release
in a form and manner reasonably satisfactory to the Company, which shall include, without limitation, a general release of claims against
the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide
that if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &ldquo;<U>Separation
Agreement and Release</U>&rdquo;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date
of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation
period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(a)   The
Company shall pay you an amount equal to 12 months of your Base Salary (the &ldquo;<U>Severance Amount</U>&rdquo;), payable in substantially
equal installments over the 12-month period following the Date of Termination in accordance with the Company&rsquo;s regular payroll practices
beginning on the Company&rsquo;s first regularly scheduled payroll date following the date that is 60 days after the Date of Termination;
provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination had
such installments commenced on the first regularly scheduled payroll date following the Date of Termination..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(b)   The
Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs,
payable at the time such bonuses are paid to other Company employees (the &ldquo;Prior Year Bonus&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(c)   Notwithstanding
anything to the contrary in any applicable equity-based award agreement, or plan, an additional 30% of the unvested portion of your then
outstanding equity-based awards (including the Restricted Shares) subject to time-based vesting (the &ldquo;<U>Time-Based Equity Awards</U>&rdquo;)
shall immediately accelerate and become
vested or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release
(such later date being the &ldquo;<U>Accelerated Vesting Date</U>&rdquo;); provided that no such acceleration of vesting shall occur if
the Date of Termination precedes the one-year anniversary of the Effective Date; and provided further that any termination or forfeiture
of the unvested portion of such Time-Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this
Agreement will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant
to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time
period set forth therein. Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the
period between the Date of Termination and the Accelerated Vesting Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt"> (d) Subject to your copayment of premium amounts at the applicable active employees&rsquo; rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&ldquo;<U>COBRA</U>&rdquo;), the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the 12 month anniversary of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer&rsquo;s group health plan; or (C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&rsquo;s regular payroll dates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>11.   Severance
Pay and Benefits Within the Change in Control Period</B>. In the event that the Company terminates your employment as CEO without Cause
(and not as a result of your death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then,
in addition to you being entitled to the Accrued Obligations, and subject to you signing and not revoking the Separation Agreement and
Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the
Separation Agreement and Release), which shall include a seven-day revocation period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(a)   You
will receive the severance pay and benefits set forth in Sections 10(a), 10(b) and 10(d) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(b)   Notwithstanding
anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your Time-Based Equity Awards
shall immediately accelerate and become vested or nonforfeitable as of the Accelerated Vesting Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">For the avoidance
of doubt, <U>Section 10</U> and <U>Section 11</U> of this Agreement are mutually exclusive and in no event shall you be entitled to payments
or benefits pursuant to both <U>Section 10</U> and <U>Section 11</U> of this Agreement.</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> 12. Continuing Obligations<FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(a)   <B>Restrictive
Covenants Agreement</B>. As a condition of your employment as CEO, you are required to enter into the Employee Confidentiality, Assignment
and Non-solicitation Agreement, which is enclosed with this Agreement (the &ldquo;<U>Restrictive Covenants Agreement</U>&rdquo;), which
must be signed prior to the Effective Date. For purposes
of this Agreement, the obligations in this <U>Section 12</U> and those that arise in the Restrictive Covenants Agreement and any other
agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the
&ldquo;<U>Continuing Obligations</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(b)   <B>Third
Party Agreements and Rights</B>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or
other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this
Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations
you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information
in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of
the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment
or other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(c)   <B>Litigation
and Regulatory Cooperation</B>. You shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions
now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that
transpired while you were engaged or employed by the Company, and (ii) the investigation, whether internal or external, of any matters
about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions
or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare
for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your engagement
and employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or
local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed
by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with your performance
of obligations pursuant to this <U>Section 12(c).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(d)   <B>Relief</B>.
You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing
Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you
breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies
that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual
damage to the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0.5in; text-indent: 0in; text-align: justify">13.
Golden Parachute Taxes<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt"><FONT STYLE="font-size: 10pt">(a) </FONT><B>Best
After-Tax Result</B>. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or
otherwise (&ldquo;<U>Payments</U>&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within the meaning of Section 280G
of the Code and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor
provisions, or any comparable federal, state, local or foreign excise tax (&ldquo;<U>Excise Tax</U>&rdquo;), then, subject to the
provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other
applicable agreement, or (B) provided as to such lesser extent which would result in the Payments being $1.00 less than the amount
at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the
applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation,
any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of payments and
benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise
Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by
independent tax counsel designated by the Company and reasonably acceptable to you (&ldquo;<U>Independent Tax Counsel</U>&rdquo;),
whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the
calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning
applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the
Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you
shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order
to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in
connection with any calculations contemplated by this Section. In the event that Section 13(a)(ii)(B) above applies, then based on
the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to
compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the Code and will otherwise
apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the &ldquo;<U>IRS</U>&rdquo;)
determines that any Payment is subject to the Excise Tax, then <U>Section 13(b)</U> hereof shall apply, and the enforcement of <U>Section
13(b)</U> shall be the exclusive remedy to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(b)   <B>Adjustments</B>.
If, notwithstanding any reduction described in <U>Section 13(a)</U> hereof (or in the absence of any such reduction), the IRS determines
that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or
pay back to the Company within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the
&ldquo;<U>Repayment Amount</U>.&rdquo; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as
shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into
account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount
with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such
Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is
not eliminated pursuant to this <U>Section 13(b)</U>, you shall pay the Excise Tax.</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0.5in; text-indent: 0in; text-align: justify">14.
Section 409A<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(a)   Anything
in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of
the Code, the Company determines that you are a &ldquo;specified employee&rdquo; within the meaning of Section 409A(a)(2)(B)(i) of the
Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation
from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section 409A(a) of
the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall
not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death.
If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch- up payment covering
amounts that would otherwise have been paid during the six-month period but for the application of this provision (without interest),
and the balance of the installments shall be payable in accordance with their original schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(b)   All
in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by
you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but
in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was
incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind
benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate
limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange
for another benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 71.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(c)   To
the extent that any payment or benefit described in this Agreement constitutes &ldquo;non-qualified deferred compensation&rdquo; under
Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such
payments or benefits shall be payable only upon your &ldquo;separation from service.&rdquo; The determination of whether and when a separation
from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(d)   The
parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision
of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that
all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate
payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably
requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations
in order to preserve the payments and benefits provided hereunder without additional cost to either party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 71.95pt">(e)   The
Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement
are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions
of, such Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>15.   Withholding;
Tax Effect</B>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and
payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation
policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to
tax liabilities arising from your compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>16.   Recoupment</B>.
Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures
adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable
under this Agreement. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason
under this Agreement or any other agreement between you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>17.   Interpretation
and Enforcement</B>. This Agreement, together with <U>Appendix A</U>, the Restrictive Covenants Agreement and the other agreements referenced
herein, constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and
supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The
terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising
out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you
and the Company (the &ldquo;<U>Disputes</U>&rdquo;) will be governed by California law, excluding laws relating to conflicts or choice
of law and Disputes arising under the 2024 Equity Incentive Plan or in connection with your Board service, both of which shall be governed
by the terms of the 2024 Equity Incentive Plan. You and the Company submit to the exclusive personal jurisdiction of the federal and state
courts located in the State of California in connection with any Dispute
or any claim related to any Dispute except for Disputes arising under the 2024 Equity Incentive Plan or in connection with your Board
service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>18.   Assignment</B>.
Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without
the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement
without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate
with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain
employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you
shall not be entitled to any payments, benefits or vesting pursuant to <U>Section 10</U> or pursuant to <U>Section 11</U> of this Agreement
solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each
of your and its respective successors, executors, administrators, heirs and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>19.   Waiver;
Amendment</B>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure
of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This
Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>20.   Enforceability</B>.
If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement)
shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or
the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable,
shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>21.   Conditions</B>.
As with any employee, you must submit satisfactory proof of your identity and your legal authorization to work in the United States on
or prior to the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>22.   Employee
Representations</B>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies
or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer
or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not
limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans
or strategies. In making this employment offer, the Company has relied on your representation that: (a) you are not currently a party
to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject
to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company
as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all
of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities
at the Company any materials, documents or work product of a former employer or other third party that are not generally available to
the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have
provided the Company with a copy of same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt"><B>23.   Other
Terms</B>. The Company will pay reasonable legal fees of your counsel incurred in connection with the review of this Agreement and related
documentation. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment
to the extent necessary to effectuate the terms contained
herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting,
construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts
are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective
as originals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">I look forward to working with you to make
the Company a great success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>Sincerely,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; width: 65%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ Peter Harwin</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Peter Harwin</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>On behalf of the Board of Directors</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Oruka Therapeutics, Inc.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Accepted and acknowledged:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%">Signature:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 27%">/s/ Lawrence Klein</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 65%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0in">Lawrence Klein, Ph.D.</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Date: February 14, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>Appendix A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1)</TD><TD STYLE="text-align: left">&ldquo;<U>Cause</U>&rdquo; shall mean (i) your dishonest statements or acts with respect to the Company
or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity
does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) your conviction or plead of
no contest to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform
in all material respects your assigned duties and responsibilities to the reasonable satisfaction of the Board, which failure continues,
in the reasonable judgment of the Board, for 30 days after written notice given to you describing such failure; (iv) your gross negligence,
willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v) your violation of any
material provision of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements
relating to non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0%"></TD><TD STYLE="text-align: left; width: 0.25in">2)</TD><TD STYLE="text-align: left">&ldquo;<U>Change in Control</U>&rdquo; shall have the meaning provided for the term &ldquo;Reorganization
Event&rdquo; under the Company&rsquo;s 2024 Equity Incentive Plan (or the meaning provided to any word of similar import under any successor
plan).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0%"></TD><TD STYLE="text-align: left; width: 0.25in">3)</TD><TD STYLE="text-align: left">&ldquo;<U>Change in Control Period</U>&rdquo; shall mean the twelve (12) month
period that immediately follows the first event constituting a Change in Control.</TD></TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0%"></TD><TD STYLE="text-align: left; width: 0.25in">4)</TD><TD STYLE="text-align: left">&ldquo;<U>Code</U>&rdquo; means the Internal Revenue Code of 1986, as amended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0%"></TD><TD STYLE="text-align: left; width: 0.25in">5)</TD><TD STYLE="text-align: left">&ldquo;<U>Disability</U>&rdquo; shall mean a permanent and total disability as defined in Section 22(e)(3) of the Code.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0%"></TD><TD STYLE="text-align: left; width: 0.25in">6)</TD><TD STYLE="text-align: left">&ldquo;<U>Good Reason</U>&rdquo; shall mean that you have complied with the Good
Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following events: (i) a material
diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions or no more than 10% based
on the Company&rsquo;s financial performance similarly affecting all or substantially all senior management employees of the Company;
(ii) a material change in the geographic location at which you are required to provide services to the Company or a requirement that you
change your remote location to a location outside the state of California; or (iii) a material reduction in your duties, authority or
responsibilities; or (iv) the failure of the Company to obtain the assumption of this Agreement by a successor; or (v) the material breach
of this Agreement (or any other agreements with you) by the Company.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0%"></TD><TD STYLE="text-align: left; width: 0.25in">7)</TD><TD STYLE="text-align: left">&ldquo;<U>Good Reason Process</U>&rdquo; shall mean that (i) you reasonably determine
in good faith that a &ldquo;Good Reason&rdquo; condition has occurred; (ii) you notify the Company in writing of the first occurrence
of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) you cooperate in good faith with the Company&rsquo;s
efforts, for a period not less than 30 days following such notice (the &ldquo;<U>Cure Period</U>&rdquo;), to remedy the condition; (iv)
notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your employment within 60 days after
the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to
have occurred.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47
<SEQUENCE>12
<FILENAME>ea020512201ex10-47_arcabio.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT OFFER LETTER, DATED MARCH 11, 2024, BY AND BETWEEN ORUKA THERAPEUTICS, INC. AND ARJUN AGARWAL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 10.47<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
11, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arjun
Agarwal</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
&ndash;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
Offer of Employment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Arjun:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of Oruka Therapeutics, Inc. (the &ldquo;<U>Company</U>&rdquo;), I am very pleased to offer you a position as Senior Vice President,
Finance (the &ldquo;<U>Role</U>&rdquo;) pursuant to this letter agreement (the &ldquo;<U>Agreement</U>&rdquo;), provided you accept such
offer as indicated by your signature below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment with the Company in the Role will commence as of March 22, 2024 (the &ldquo;<U>Effective Date</U>&rdquo;). Should you not
commence services by the Effective Date or if this Agreement is otherwise terminated on or prior to the Effective Date, you hereby agree
that this Agreement shall be void <I>ab initio </I>and of no force or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&nbsp;Position</B>.
While serving in the Role, you will initially report to the Company&rsquo;s Chief Executive Officer and have such duties, authorities,
and responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed
that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether
full- time or part-time), except as expressly authorized in writing by the Company. Notwithstanding the foregoing, you may engage in
religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;<FONT STYLE="color: Red"></FONT>Base Salary</B>. Upon and following the Effective Date, as cash compensation for your services, the Company will pay you
an initial base salary of $360,000 per year, payable in accordance with the Company&rsquo;s standard payroll schedule and subject to
applicable deductions and withholdings. Your base salary will be subject to periodic review and potential adjustment in the Company&rsquo;s
discretion. Your base salary in effect at any given time is referred to herein as the &ldquo;Base Salary.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&nbsp;Annual
Bonus. </B>Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 35% of
your Base Salary. In lieu of a sign-on bonus, the Company agrees that the target bonus for the first year will be calculated using the
Effective Date of January 1, 2024. The target annual bonus in effect at any given time is referred to herein as &ldquo;Target Bonus.&rdquo;
The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such
year. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid
no later than March 15th of the calendar year following the calendar year to which such bonus relates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>4.&nbsp;Equity</B>.
Subject to approval by the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;), the Company will grant you non-qualified
stock options to purchase 225,000 shares of the Company&rsquo;s common stock, par value $0.0001, with an exercise price equal to the
fair market value of the underlying shares on the date of grant as determined by the Board (the &ldquo;<U>Options</U>&rdquo;). The Options
will vest as follows: (a) 25% of the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
will vest on the one-year anniversary of the Effective Date and (b) the balance of the Options will vest thereafter in approximately
equal monthly installments for the next 36 months so that you would be fully vested on the four-year anniversary of the Effective Date,
provided that you remain continuously employed by the Company through each such vesting date. The Options will be governed by the terms
of the related award agreement, the Company&rsquo;s 2024 Equity Incentive Plan and the terms and conditions approved by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.&nbsp;Benefits/Paid
Time Off.</B> Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to
participate in the employee benefits and insurance programs generally made available to the Company&rsquo;s full-time employees. Details
of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to
you when such benefit(s) become available. You will be entitled to paid time off consistent with the terms of the Company&rsquo;s paid
time off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits
plans or programs at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.&nbsp;Expense
Reimbursement.</B> The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing
your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy
or practice on submitting, accounting for and documenting such expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.&nbsp;Location</B>.
Your primary work location will be in the San Francisco Bay Area, provided that you may be required to engage in reasonable travel for
business, consistent with the Company&rsquo;s business needs. You may change your remote work location with prior written notice to and
approval from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.&nbsp;At-Will
Employment; Date of Termination</B>. At all times, your employment with the Company is &ldquo;at will,&rdquo; meaning you or the Company
may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting
structure, compensation and benefits, as well as the Company&rsquo;s benefit plans and personnel policies and procedures, may change
from time to time (subject to the terms of this Agreement), the &ldquo;at will&rdquo; nature of your employment may only be changed in
an express written agreement signed by you and an authorized officer of the Company. Your last day of employment for any reason is referred
to herein as the &ldquo;<U>Date of Termination</U>.&rdquo; In the event that you elect to end your employment with the Company, the Company
requires you to provide at least 30 days&rsquo; advance written notice to the Company; and in the event that the Company terminates you
without Cause, you shall be given at least 30 days advance written notice by the Company. Notwithstanding the foregoing, the Company
may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause
for purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company
or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents
in reasonable form as may be requested to confirm or effectuate any such resignations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.&nbsp;Accrued
Obligations</B>. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if
applicable, any accrued but unused vacation, through the Date of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination,
and (ii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not
yet reimbursed. (the &ldquo;<U>Accrued Obligations</U>&rdquo;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.&nbsp;Severance
Pay and Benefits Outside of the Change in Control Period</B>. In the event that the Company terminates your employment without Cause
(and not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in <U>Appendix
A</U>), then, in addition to the Accrued Obligations, and subject to (i) your execution and non-revocation of a separation agreement
and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related
persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing
Obligations, all payments of the following severance pay and benefits shall immediately cease (the &ldquo;<U>Separation Agreement and
Release</U>&rdquo;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination
(or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;The
Company shall pay you an amount equal to six months of your Base Salary (the &ldquo;<U>Severance Amount</U>&rdquo;), payable in substantially
equal installments over the six-month period following the Date of Termination in accordance with the Company&rsquo;s regular payroll
practices beginning on the Company&rsquo;s first regularly scheduled payroll date following the date that is 60 days after the Date of
Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of
Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;The
Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs,
payable at the time such bonuses are paid to other Company employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;Subject
to your copayment of premium amounts at the applicable active employees&rsquo; rate and your proper election to receive benefits under
the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&ldquo;<U>COBRA</U>&rdquo;), the Company shall pay to the group
health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would
have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the six-month anniversary
of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer&rsquo;s group health plan; or
(C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot
pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable
law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll
payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and
withholdings and paid on the Company&rsquo;s regular payroll dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>11.&nbsp;Severance
Pay and Benefits Within the Change in Control Period</B>. In the event that the Company terminates your employment without Cause (and
not as a result of your death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then, in
addition to you being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement
and Release and it becoming fully effective, all within 60 days after the Date of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
(or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You will receive the severance pay and benefits set forth in <U>Section 10</U> above.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;Notwithstanding
anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your then outstanding equity-based
awards (including the Options) subject to time-based vesting shall immediately accelerate and become vested or nonforfeitable as of the
later of </FONT>(i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the avoidance of doubt, <U>Section 10</U> and <U>Section 11</U> of this Agreement are mutually exclusive and in no event shall you be
entitled to payments or benefits pursuant to both <U>Section 10</U> and <U>Section 11</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuing Obligations<FONT STYLE="font-weight: normal">.</FONT></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<B>PIIA
Agreement</B>. As a condition of your employment, you are required to enter into a Proprietary Information and Inventions Assignment
Agreement, (the &ldquo;<U>PIIA Agreement</U>&rdquo;), which must be signed prior to the Effective Date. For purposes of this Agreement,
the obligations in this <U>Section 12</U> and those that arise in the PIIA Agreement and any other agreement relating to confidentiality,
assignment of inventions, or other restrictive covenants shall collectively be referred to as the &ldquo;<U>Continuing Obligations</U>.&rdquo;
You are advised to discuss the PIIA Agreement with an attorney of your choice, and you have had an adequate opportunity to do so prior
to executing this Agreement or the PIIA Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<B>Third
Party Agreements and Rights</B>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or
other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this
Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations
you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information
in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of
the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment
or other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <B>Litigation
and Regulatory Cooperation</B>. You shall cooperate fully with the Company in</FONT> (i) the defense or prosecution of any claims or
actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or
occurrences that transpired while you were engaged or employed by the Company, and (ii) the investigation, whether internal or
external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection
with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to
answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.
During and after your engagement and employment, you also shall cooperate fully with the Company in connection with any
investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or
occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket
expenses incurred in connection with your performance of obligations pursuant to this <U>Section 12(c).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<B>Relief</B>.
You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing
Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you
breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies
that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving
any actual damage to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Golden Parachute Taxes<FONT STYLE="font-weight: normal">.</FONT></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<B>Best
After-Tax Result</B>. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or
otherwise (&ldquo;<U>Payments</U>&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within the meaning of Section 280G
of the Code and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor
provisions, or any comparable federal, state, local or foreign excise tax (&ldquo;<U>Excise Tax</U>&rdquo;), then, subject to the
provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other
applicable agreement, or </FONT>(B) provided as to such lesser extent which would result in the Payments being $1.00 less than the
amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into
account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without
limitation, any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of
payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject
to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be
made by independent tax counsel designated by the Company and reasonably acceptable to you (&ldquo;<U>Independent Tax
Counsel</U>&rdquo;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of
making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations
concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and
4999 of the Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The
Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably
request in order to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may
reasonably incur in connection with any calculations contemplated by this Section. In the event that <U>Section 13(a)(ii)(B)</U>
above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described
hereunder will apply as to compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the
Code and will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the
&ldquo;<U>IRS</U>&rdquo;) determines that any Payment is subject to the Excise Tax, then <U>Section 13(b)</U> hereof shall apply,
and the enforcement of <U>Section 13(b)</U> shall be the exclusive remedy to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<B>Adjustments</B>.
If, notwithstanding any reduction described in <U>Section 13(a)</U> hereof (or in the absence of any such reduction), the IRS determines
that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or
pay back to the Company within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to
the &ldquo;<U>Repayment Amount</U>.&rdquo; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any,
as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into
account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount
with respect to <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment
Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to
this <U>Section 13(b)</U>, you shall pay the Excise Tax.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 409A<FONT STYLE="font-weight: normal">.</FONT></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;Anything
in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A
of the Code, the Company determines that you are a &ldquo;specified employee&rdquo; within the meaning of Section 409A(a)(2)(B)(i) of
the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your
separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section
409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such
benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or
(B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-
up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision
(without interest), and the balance of the installments shall be payable in accordance with their original schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;All
in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by
you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but
in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was
incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind
benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate
limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange
for another benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;To
the extent that any payment or benefit described in this Agreement constitutes &ldquo;non- qualified deferred compensation&rdquo; under
Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such
payments or benefits shall be payable only upon your &ldquo;separation from service.&rdquo; The determination of whether and when a separation
from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;The
parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision
of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that
all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate
payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably
requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations
in order to preserve the payments and benefits provided hereunder without additional cost to either party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;The
Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement
are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions
of, such Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.&nbsp;Withholding;
Tax Effect</B>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and
payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation
policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to
tax liabilities arising from your compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.&nbsp;Recoupment</B>.
Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or
procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid
or payable under this Agreement. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for
Good Reason under this Agreement or any other agreement between you and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.&nbsp;Interpretation
and Enforcement</B>. This Agreement, together with <U>Appendix A</U>, the PIIA Agreement and any award agreement between you and the
Company constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company
and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.
The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or
arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between
you and the Company (the &ldquo;<U>Disputes</U>&rdquo;) will be governed by federal law to the extent applicable and otherwise by Massachusetts
law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan,
which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction
of the federal and state courts located in the State of Massachusetts in connection with any Dispute or any claim related to any Dispute,
except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive
plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.&nbsp;Assignment</B>.
Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without
the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement
without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate
with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain
employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you
shall not be entitled to any payments, benefits or vesting pursuant to <U>Section 10</U> or pursuant to <U>Section 11</U> of this Agreement
solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each
of your and its respective successors, executors, administrators, heirs and permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.&nbsp;Waiver;
Amendment</B>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure
of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.&nbsp;Enforceability</B>.
If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement)
shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement,
or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable,
shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent
permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.&nbsp;Conditions</B>.
You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize
by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to
the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.&nbsp;Employee
Representations</B>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies
or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer
or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is
not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business
plans or strategies. In making this employment offer, the Company has relied on your representation that: (a) you are not currently a
party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not
subject to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the
Company as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform
all of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities
at the Company any materials, documents or work product of a former employer or other third party that are not generally available to
the public, unless you have obtained written authorization from such former employer or third party for their possession and use and
have provided the Company with a copy of same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.&nbsp;Other
Terms</B>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment
to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience
and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement
may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document.
PDF copies of signed counterparts shall be equally effective as originals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
look forward to working with you to make the Company a great success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Lawrence Klein</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence Klein</FONT></TD>
    <TD STYLE="text-align: left; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted and acknowledged:</FONT></TD>
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Arjun Agarwal</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arjun Agarwal</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: 3/11/2024</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.05pt 0pt 0; text-align: right"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Appendix
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&ldquo;<U>Cause</U>&rdquo;
shall mean (i) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective
customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated
to result in material harm to the Company; (ii) your conviction or plea of no contest to: (A) a felony or (B) any misdemeanor involving
moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform in all material respects your assigned duties and responsibilities,
which failure continues for 30 days after written notice given to you describing such failure; (iv) your gross negligence, willful misconduct
that results in or is reasonably anticipated to result in material harm to the Company; or (v) your violation of any material provision
of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements relating to
non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&ldquo;<U>Change
in Control</U>&rdquo; shall have the meaning provided for the term &ldquo;Reorganization Event&rdquo; under the Company&rsquo;s 2024
Equity Incentive Plan (or the meaning provided to any word of similar import under any successor plan).</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&ldquo;<U>Change
in Control Period</U>&rdquo; shall mean the 12-month period that immediately follows the first event constituting a Change in Control.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Code</U>&rdquo; means the Internal Revenue Code of 1986, as amended.</FONT></P>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disability</U>&rdquo; shall mean a permanent and total disability as defined in Section 22(e)(3) of the Code.</FONT></P>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&ldquo;<U>Good
Reason</U>&rdquo; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without
your written consent, of any of the following events: (i) a material diminution in your base salary or Target Bonus except for across-the-board
salary and target bonus reductions of no more than 10% based on the Company&rsquo;s financial performance similarly affecting all or
substantially all senior management employees of the Company; (ii) a material change in the geographic location at which you are required
to provide services to the Company or a requirement that you change your remote location to a location from your then-current residence;
(iii) the failure of the Company to obtain the assumption of this Agreement by a successor; or (iv) the material breach of this Agreement
(or any other agreements with you) by the Company.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&ldquo;<U>Good
Reason Process</U>&rdquo; shall mean that (i) you reasonably determine in good faith that a &ldquo;Good Reason&rdquo; condition has occurred;
(ii) you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of
such condition; (iii) you cooperate in good faith with the Company&rsquo;s efforts, for a period not less than 30 days following such
notice (the &ldquo;<U>Cure Period</U>&rdquo;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition
continues to exist; and (v) you terminate your employment within 60 days after the end of the Cure Period. If the Company cures the Good
Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.48
<SEQUENCE>13
<FILENAME>ea020512201ex10-48_arcabio.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT OFFER LETTER, DATED MARCH 15, 2024, BY AND BETWEEN ORUKA THERAPEUTICS, INC. AND JOANA GONCALVES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.48</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 33%">&nbsp;</TD>
  <TD STYLE="vertical-align: bottom; text-align: center; width: 34%"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">ORUKA THERAPEUTICS,
INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">221 Crescent Street, Building
23, Suite 105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Waltham, MA 02453</P>

</TD>
  <TD STYLE="text-align: right; width: 33%"><IMG SRC="ex10-48_001.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">March 15, 2024</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Joana Goncalves</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Email &ndash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Re: Offer of Employment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dear Joanna:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">On behalf of Oruka Therapeutics,
Inc. (the &ldquo;<U>Company</U>&rdquo;), I am very pleased to offer you a position as Chief Medical Officer of the Company (the &ldquo;<U>Role</U>&rdquo;)
pursuant to this letter agreement (the &ldquo;<U>Agreement</U>&rdquo;), provided you accept such offer as indicated by your signature
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Your employment with the Company
in the Role will commence as of April 18<SUP>th</SUP>, 2024 (the &ldquo;<U>Effective Date</U>&rdquo;), or such other date as mutually
agreed upon by you and the Company, which start date will occur no later than April 30<SUP>th</SUP>, 2024 (the &ldquo;<U>Outside Date</U>&rdquo;).
Should you not commence services by the Outside Date or if this Agreement is otherwise terminated on or prior to the Outside Date, you
hereby agree that this Agreement shall be void <I>ab initio </I>and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>1.   Position</B>.
While serving in the Role, you will initially report to the Company&rsquo;s Chief Executive Officer, and have such duties, authorities,
and responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed
that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether
full- time or part-time), except as expressly authorized in writing by the Company. Notwithstanding the foregoing, you may engage in religious,
charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>2.   Base
Salary</B>. Upon and following the Effective Date, as cash compensation for your services, the Company will pay you an initial base salary
of $460,000 per year, payable in accordance with the Company&rsquo;s standard payroll schedule and subject to applicable deductions and
withholdings. Your base salary will be subject to periodic review and potential adjustment in the Company&rsquo;s discretion. Your base
salary in effect at any given time is referred to herein as the &ldquo;<U>Base Salary</U>.&rdquo;</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 3. Bonus Compensation</P>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(a)   <B>Signing
Bonus</B>. In connection with your commencement of employment with the Company, the Company will advance you a signing bonus of $100,000,
less applicable deductions and withholdings, which will be payable in the first payroll following the Effective Date. If you resign your
employment with the Company for any reason or the Company terminates your employment for Cause (as defined below), in either case within
one year following the Effective Date, you agree to repay the Company, within 30 days following your separation date, a prorated portion
of the signing bonus (based on the number of full months you worked for the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(b)   <B>Annual
Bonus</B>. Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 40% of your Base
Salary. The target annual bonus in effect at any given time is referred to herein as &ldquo;<U>Target Bonus</U>.&rdquo; Your 2024 annual
bonus will be prorated based on your period of employment following the Effective Date. The actual bonus amount is discretionary and may
be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be employed
by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar year following
the calendar year to which such bonus relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>4. Equity</B>.
Subject to approval by the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;), the Company will grant you stock
options to purchase 400,000 shares of the Company&rsquo;s common stock, par value $0.0001, with an exercise price equal to the fair
market value of the underlying shares on the date of grant as determined by the Board (the &ldquo;<U>Options</U>&rdquo;). The
Options will vest as follows: (a) 25% of the Options will vest on the one-year anniversary of the Effective Date and (b) the balance
of the Options will vest thereafter in approximately equal monthly installments for the next 36 months so that you would be fully
vested on the four-year anniversary of the Effective Date, provided that you remain continuously employed by the Company through
each such vesting date. The Options will be governed by the terms of the related award agreement, the Company&rsquo;s 2024 Equity
Incentive Plan and the terms and conditions approved by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>5.   Benefits/Paid
Time Off.</B> Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to
participate in the employee benefits and insurance programs generally made available to the Company&rsquo;s full-time employees. Details
of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you
when such benefit(s) become available. You will be entitled to paid time off consistent with the terms of the Company&rsquo;s paid time
off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans
or programs at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>6.   Expense
Reimbursement.</B> The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing
your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or
practice on submitting, accounting for and documenting such expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>7.   Location</B>.
Your primary work location will be remote in Connecticut, provided that you may be required to engage in reasonable travel for business,
consistent with the Company&rsquo;s business needs. You may change your remote work location with prior written notice to and approval
from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>8.   At-Will
Employment; Date of Termination</B>. At all times, your employment with the Company is &ldquo;at will,&rdquo; meaning you or the Company
may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting
structure, compensation and benefits, as well as the Company&rsquo;s benefit plans and personnel policies and procedures, may change from
time to time (subject to the terms of this Agreement), the &ldquo;at will&rdquo; nature of your employment may only be changed in an express
written agreement signed by you and an authorized officer of the Company. Your last day of employment for any reason is referred to herein
as the &ldquo;<U>Date of Termination</U>.&rdquo; In the event that you elect to end your employment with the Company, the Company requires
you to provide at least 30 days&rsquo; advance written notice to the Company; and in the event that the Company terminates you without
Cause, you shall be given at least 30 days advance written notice by the Company. Notwithstanding the foregoing, the Company may unilaterally accelerate
the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">To the extent applicable, you shall
be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries
and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested
to confirm or effectuate any such resignations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.   Accrued
Obligations</B>. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if
applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly
incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. (the &ldquo;<U>Accrued Obligations</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>10.   Severance
Pay and Benefits Outside of the Change in Control Period</B>. In the event that the Company terminates your employment without Cause (and
not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in <U>Appendix
A</U>), then, in addition to the Accrued Obligations, and subject to (i) your execution and non-revocation of a separation agreement and
release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons
and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing
Obligations, all payments of the following severance pay and benefits shall immediately cease (the &ldquo;<U>Separation Agreement and
Release</U>&rdquo;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination
(or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(a)   The
Company shall pay you an amount equal to six months of your Base Salary (the &ldquo;<U>Severance Amount</U>&rdquo;), payable in substantially
equal installments over the six-month period following the Date of Termination in accordance with the Company&rsquo;s regular payroll
practices beginning on the Company&rsquo;s first regularly scheduled payroll date following the date that is 60 days after the Date of
Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination
had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(b)   The
Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs,
payable at the time such bonuses are paid to other Company employees (the &ldquo;<U>Prior Year Bonus</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(c)   Subject
to your copayment of premium amounts at the applicable active employees&rsquo; rate and your proper election to receive benefits under
the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&ldquo;<U>COBRA</U>&rdquo;), the Company shall pay to the group
health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would
have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the six-month anniversary
of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer&rsquo;s group health plan; or
(C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot
pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law
(including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments
to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions
and withholdings and paid on the Company&rsquo;s regular payroll dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>11. Severance Pay and Benefits Within
the Change in Control Period</B>. In the event that the Company terminates your employment without Cause (and not as a result of your
death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then, in addition to you being
entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release and it
becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement
and Release), which shall include a seven-day revocation period:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(a)
You will receive the severance pay and benefits set forth in <U>Section 10</U> above.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(b)   Notwithstanding
anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your then-outstanding equity-based
awards subject to time-based vesting shall immediately accelerate and become vested or nonforfeitable as of the later of (i) the Date
of Termination or (ii) the effective date of the Separation Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">For the avoidance of doubt, <U>Section
10</U> and <U>Section 11</U> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant
to both <U>Section 10</U> and <U>Section 11</U> of this Agreement.</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: left">12.
Continuing Obligations<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(a)   <B>Restrictive
Covenant Agreement</B>. As a condition of your employment, you are required to enter into a Invention Assignment, Non-Disclosure, and
Business Protection Agreement, (the &ldquo;<U>Covenant Agreement</U>&rdquo;), which must be signed prior to the Effective Date. For purposes
of this Agreement, the obligations in this <U>Section 12</U> and those that arise in the Covenant Agreement and any other agreement relating
to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &ldquo;<U>Continuing
Obligations</U>.&rdquo; You are advised to discuss the Covenant Agreement with an attorney of your choice, and you have had an adequate
opportunity to do so prior to executing this Agreement or the Covenant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(b)   <B>Third
Party Agreements and Rights</B>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or
other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this
Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations
you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information
in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of
the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment
or other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(c) <B>Litigation
and Regulatory Cooperation</B>. You shall cooperate fully with the Company in (i) the defense or prosecution of any claims or
actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or
occurrences that transpired while you were engaged or employed by the Company, and (ii) the investigation, whether internal or
external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection
with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to
answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.
During and after your engagement and employment, you also shall cooperate fully with the Company in connection with any
investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or
occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket
expenses incurred in connection with your performance of obligations pursuant to this <U>Section 12(c).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(d)   <B>Relief</B>.
You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing
Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you
breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies
that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any
actual damage to the Company.</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -35.95pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: left">13.
Golden Parachute Taxes<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(a) <B>Best
After-Tax Result</B>. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or
otherwise (&ldquo;<U>Payments</U>&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within the meaning of Section 280G
of the Code and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor
provisions, or any comparable federal, state, local or foreign excise tax (&ldquo;<U>Excise Tax</U>&rdquo;), then, subject to the
provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other
applicable agreement, or (B) provided as to such lesser extent which would result in the Payments being $1.00 less than the amount
at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the
applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation,
any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of payments and
benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise
Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by
independent tax counsel designated by the Company and reasonably acceptable to you (&ldquo;<U>Independent Tax Counsel</U>&rdquo;),
whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the
calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning
applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the
Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you
shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order
to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in
connection with any calculations contemplated by this Section. In the event that <U>Section 13(a)(ii)(B)</U> above applies, then
based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as
to compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the Code and will otherwise
apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the &ldquo;<U>IRS</U>&rdquo;)
determines that any Payment is subject to the Excise Tax, then <U>Section 13(b)</U> hereof shall
apply, and the enforcement of <U>Section 13(b)</U> shall be the exclusive remedy to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(b) <B>Adjustments</B>. If, notwithstanding
any reduction described in <U>Section 13(a)</U> hereof (or in the absence of any such reduction), the IRS determines that you are liable
for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company
within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the &ldquo;<U>Repayment
Amount</U>.&rdquo; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as shall be required
to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment
of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such
Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment
Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to
this <U>Section 13(b)</U>, you shall pay the Excise Tax.</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: left">14.
Section 409A<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(a)   Anything
in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of
the Code, the Company determines that you are a &ldquo;specified employee&rdquo; within the meaning of Section 409A(a)(2)(B)(i) of the
Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation
from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section 409A(a) of
the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall
not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death.
If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch- up payment covering
amounts that would otherwise have been paid during the six-month period but for the application of this provision (without interest),
and the balance of the installments shall be payable in accordance with their original schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(b)   All
in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by
you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but
in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was
incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits
to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation
applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another
benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(c)   To
the extent that any payment or benefit described in this Agreement constitutes &ldquo;non- qualified deferred compensation&rdquo; under
Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such
payments or benefits shall be payable only upon your &ldquo;separation from service.&rdquo; The determination of whether and when a separation
from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(d)   The
parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision
of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that
all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate
payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably
requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations
in order to preserve the payments and benefits provided hereunder without additional cost to either party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 35.95pt">(e)   The
Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement
are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions
of, such Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>15.   Withholding;
Tax Effect</B>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and
payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation
policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to
tax liabilities arising from your compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>16.   Recoupment</B>.
Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures
adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable
under this Agreement. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason
under this Agreement or any other agreement between you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>17.   Interpretation
and Enforcement</B>. This Agreement, together with <U>Appendix A</U>, the Covenant Agreement and any award agreement between you and the
Company constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and
supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The
terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising
out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you
and the Company (the &ldquo;<U>Disputes</U>&rdquo;) will be governed by federal law to the extent applicable and otherwise by Connecticut
law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan,
which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction
of the federal and state courts located in the State of Connecticut in connection with any Dispute or any claim related to any Dispute,
except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>18.   Assignment</B>.
Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without
the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement
without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate
with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain
employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you
shall not be entitled to any payments, benefits or vesting
pursuant to <U>Section 10</U> or pursuant to <U>Section 11</U> of this Agreement solely as a result of such transaction. This Agreement
shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators,
heirs and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>19. Waiver; Amendment</B>. No waiver
of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require
the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent
any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or
modified only by a written instrument signed by you and by a duly authorized representative of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>20.   Enforceability</B>.
If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement)
shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or
the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable,
shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>21.   Conditions</B>.
You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize
by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to
the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>22.   Employee
Representations</B>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies
or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer
or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not
limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans
or strategies. In making this employment offer, the Company has relied on your representation that: (a) you are not currently a party
to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject
to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company
as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all
of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities
at the Company any materials, documents or work product of a former employer or other third party that are not generally available to
the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have
provided the Company with a copy of same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>23.   Other
Terms</B>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment
to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience
and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement
may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document.
PDF copies of signed counterparts shall be equally effective as originals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">I look forward to working with you to make the Company a great
success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lawrence Klein</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Lawrence Klein</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
    and acknowledged:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joana Goncalves</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Joana Goncalves</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    3/17/2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Appendix A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">1.   &ldquo;<U>Cause</U>&rdquo;
shall mean (i) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective
customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated
to result in material harm to the Company; (ii) your conviction or plea of no contest to: (A) a felony or (B) any misdemeanor involving
moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform in all material respects your assigned duties and responsibilities,
which failure continues for 30 days after written notice given to you describing such failure; (iv) your gross negligence, willful misconduct
that results in or is reasonably anticipated to result in material harm to the Company; or (v) your violation of any material provision
of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements relating to
non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">2.   &ldquo;<U>Change
in Control</U>&rdquo; shall have the meaning provided for the term &ldquo;Reorganization Event&rdquo; under the Company&rsquo;s 2024 Equity
Incentive Plan (or the meaning provided to any word of similar import under any successor plan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">3.   &ldquo;<U>Change
in Control Period</U>&rdquo; shall mean the 12-month period that immediately follows the first event constituting a Change in Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: -35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: left">4.
&ldquo;<U>Code</U>&rdquo; means the Internal Revenue Code of 1986, as amended.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: left">5.
&ldquo;<U>Disability</U>&rdquo; shall mean a permanent and total disability as defined in Section 22(e)(3) of the Code.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">6.   &ldquo;<U>Good
Reason</U>&rdquo; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without
your written consent, of any of the following events: (i) a material diminution in your base salary or Target Bonus except for across-the-board
salary and target bonus reductions of no more than 10% based on the Company&rsquo;s financial performance similarly affecting all or substantially
all senior management employees of the Company; (ii) a material change in the geographic location at which you are required to provide
services to the Company or a requirement that you change your remote location to a location from your then-current residence; (iii) the
failure of the Company to obtain the assumption of this Agreement by a successor; or (iv) the material breach of this Agreement (or any
other agreements with you) by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">7.   &ldquo;<U>Good
Reason Process</U>&rdquo; shall mean that (i) you reasonably determine in good faith that a &ldquo;Good Reason&rdquo; condition has occurred;
(ii) you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of
such condition; (iii) you cooperate in good faith with the Company&rsquo;s efforts, for a period not less than 30 days following such
notice (the &ldquo;<U>Cure Period</U>&rdquo;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues
to exist; and (v) you terminate your employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason
condition during the Cure Period, Good Reason shall be deemed not to have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.49
<SEQUENCE>14
<FILENAME>ea020512201ex10-49_arcabio.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT OFFER LETTER, DATED APRIL 12, 2024, BY AND BETWEEN ORUKA THERAPEUTICS, INC. AND PAUL QUINLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.49</B></P>

<P STYLE="margin: 0pt; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: center">&nbsp;</TD>
    <TD ROWSPAN="8" STYLE="vertical-align: bottom; width: 15%; text-align: right"><IMG SRC="ex10-49_001.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>ORUKA THERAPEUTICS, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">221 Crescent Street, Building 23, Suite 105</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waltham, MA 02453</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">April 12, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Paul Quinlan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Email &ndash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Re: Offer of Employment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Dear Paul:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On behalf of Oruka Therapeutics,
Inc. (the &ldquo;<U>Company</U>&rdquo;), I am very pleased to offer you a position as General Counsel of the Company (the &ldquo;<U>Role</U>&rdquo;)
pursuant to this letter agreement (the &ldquo;<U>Agreement</U>&rdquo;), provided you accept such offer as indicated by your signature
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Your employment with the Company
in the Role will commence as of April 30<SUP>th</SUP>, 2024 (the &ldquo;<U>Effective Date</U>&rdquo;). Should you not commence services
by the Outside Date or if this Agreement is otherwise terminated on or prior to the Outside Date, you hereby agree that this Agreement
shall be void <I>ab initio</I> and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>1.   Position</B>.
While serving in the Role, you will initially report to the Company&rsquo;s Chief Executive Officer, and have such duties, authorities,
and responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed
that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether
full- time or part-time), except as expressly authorized in writing by the Company. Notwithstanding the foregoing, you may engage in religious,
charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>2.   Base Salary</B>.
Upon and following the Effective Date, as cash compensation for your services, the Company will pay you an initial base salary of $460,000
per year, payable in accordance with the Company&rsquo;s standard payroll schedule and subject to applicable deductions and withholdings.
Your base salary will be subject to periodic review and potential adjustment in the Company&rsquo;s discretion. Your base salary in effect
at any given time is referred to herein as the &ldquo;<U>Base Salary</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>3.   Annual
Bonus</B>. Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 40% of your Base
Salary. The target annual bonus in effect at any given time is referred to herein as &ldquo;<U>Target Bonus</U>.&rdquo; Your 2024 annual
bonus will be prorated based on your period of employment following the Effective Date. The actual bonus amount is discretionary and may
be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be employed
by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar year following
the calendar year to which such bonus relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>4. Equity</B>. Subject to approval by the Company&rsquo;s Board
of Directors (the &ldquo;<U>Board</U>&rdquo;), the Company will grant you stock options to purchase 400,000 shares of the
Company&rsquo;s common stock, par value $0.0001, with an exercise price equal to the fair market value of the underlying shares on
the date of grant as determined by the Board (the &ldquo;<U>Options</U>&rdquo;). The Options will vest as follows: (a) 25% of the
Options will vest on the one-year anniversary of the Effective Date and (b) the balance of the Options will vest thereafter in
approximately equal monthly installments for the next 36 months so that you would be fully vested on the four-year anniversary of
the Effective Date, provided that you remain continuously employed by the Company through each such vesting date. The Options will
be governed by the terms of the related award agreement, the Company&rsquo;s 2024 Equity Incentive Plan and the terms and conditions
approved by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>5.   Benefits/Paid
Time Off.</B> Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to
participate in the employee benefits and insurance programs generally made available to the Company&rsquo;s full-time employees. Details
of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you
when such benefit(s) become available. You will be entitled to paid time off consistent with the terms of the Company&rsquo;s paid time
off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans
or programs at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>6.   Expense
Reimbursement.</B> The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing
your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or
practice on submitting, accounting for and documenting such expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>7.   Location</B>.
Your primary work location will be in California, provided that you may be required to engage in reasonable travel for business, consistent
with the Company&rsquo;s business needs. You may change your remote work location with prior written notice to and approval from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>8.   At-Will
Employment; Date of Termination</B>. At all times, your employment with the Company is &ldquo;at will,&rdquo; meaning you or the Company
may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting
structure, compensation and benefits, as well as the Company&rsquo;s benefit plans and personnel policies and procedures, may change from
time to time (subject to the terms of this Agreement), the &ldquo;at will&rdquo; nature of your employment may only be changed in an express
written agreement signed by you and an authorized officer of the Company. Your last day of employment for any reason is referred to herein
as the &ldquo;<U>Date of Termination</U>.&rdquo; In the event that you elect to end your employment with the Company, the Company requires
you to provide at least 30 days&rsquo; advance written notice to the Company; and in the event that the Company terminates you without
Cause, you shall be given at least 30 days advance written notice by the Company. Notwithstanding the foregoing, the Company may unilaterally
accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause for purposes
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">To the extent applicable, you shall
be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries
and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested
to confirm or effectuate any such resignations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>9.   Accrued
Obligations</B>. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if
applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly
incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. (the &ldquo;<U>Accrued Obligations</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>10.   Severance
Pay and Benefits Outside of the Change in Control Period</B>. In the event that the Company terminates your employment without Cause (and
not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in <U>Appendix
A</U>), then, in addition to the Accrued Obligations, and subject to (i) your execution and non-revocation of a separation agreement and
release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons
and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing
Obligations, all payments of the following severance pay and benefits shall immediately cease (the &ldquo;<U>Separation Agreement and
Release</U>&rdquo;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination
(or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(a)   The
Company shall pay you an amount equal to six months of your Base Salary (the &ldquo;<U>Severance Amount</U>&rdquo;), payable in substantially
equal installments over the six-month period following the Date of Termination in accordance with the Company&rsquo;s regular payroll
practices beginning on the Company&rsquo;s first regularly scheduled payroll date following the date that is 60 days after the Date of
Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination
had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(b)   The
Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs,
payable at the time such bonuses are paid to other Company employees (the &ldquo;<U>Prior Year Bonus</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(c)   Subject
to your copayment of premium amounts at the applicable active employees&rsquo; rate and your proper election to receive benefits under
the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&ldquo;<U>COBRA</U>&rdquo;), the Company shall pay to the group
health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would
have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the six-month anniversary
of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer&rsquo;s group health plan; or
(C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot
pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law
(including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll
payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and
withholdings and paid on the Company&rsquo;s regular payroll dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>11.   Severance Pay
and Benefits Within the Change in Control Period</B>. In the event that the Company terminates your employment without Cause (and not
as a result of your death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then, in addition
to you being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release
and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation
Agreement and Release), which shall include a seven-day revocation period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"> (a) You will receive the severance pay and benefits set forth in <U>Section 10</U> above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>




<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(b)   Notwithstanding
anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your then-outstanding equity-based
awards subject to time-based vesting shall immediately accelerate and become vested or nonforfeitable as of the later of (i) the Date
of Termination or (ii) the effective date of the Separation Agreement and Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">For the avoidance of doubt, <U>Section
10</U> and <U>Section 11</U> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant
to both <U>Section 10</U> and <U>Section 11</U> of this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="padding-top: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; padding-bottom: 0pt"> 12. Continuing Obligations<FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(a)   <B>Restrictive
Covenant Agreement</B>. As a condition of your employment, you are required to enter into a Invention Assignment, Non-Disclosure, and
Business Protection Agreement (the &ldquo;<U>Covenant Agreement</U>&rdquo;), which must be signed prior to the Effective Date. For purposes
of this Agreement, the obligations in this <U>Section 12</U> and those that arise in the Covenant Agreement and any other agreement relating
to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &ldquo;<U>Continuing
Obligations</U>.&rdquo; You are advised to discuss the Covenant Agreement with an attorney of your choice, and you have had an adequate
opportunity to do so prior to executing this Agreement or the Covenant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(b)   <B>Third
Party Agreements and Rights</B>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or
other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this
Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations
you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information
in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of
the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment
or other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(c) <B>Litigation and Regulatory
Cooperation</B>. You shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in
existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that
transpired while you were engaged or employed by the Company, and (ii) the investigation, whether internal or external, of any
matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such
claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer
questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During
and after your engagement and employment, you also shall cooperate fully with the Company in connection with any investigation or
review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that
transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses
incurred in connection with your performance of obligations pursuant to this <U>Section 12(c).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(d) <B>Relief</B>. You agree that it would be
difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and
that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or
propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that
it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any
actual damage to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 13. Golden Parachute Taxes<FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(a) <B>Best After-Tax Result</B>. In the event
that any payment or benefit received or to be received by you pursuant to this Agreement or otherwise
(&ldquo;<U>Payments</U>&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within the meaning of Section 280G of the
Code and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor
provisions, or any comparable federal, state, local or foreign excise tax (&ldquo;<U>Excise Tax</U>&rdquo;), then, subject to the
provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other
applicable agreement, or (B) provided as to such lesser extent which would result in the Payments being $1.00 less than the amount
at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the
applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation,
any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of payments and
benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise
Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by
independent tax counsel designated by the Company and reasonably acceptable to you (&ldquo;<U>Independent Tax Counsel</U>&rdquo;),
whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the
calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning
applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the
Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you
shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order
to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in
connection with any calculations contemplated by this Section. In the event that <U>Section 13(a)(ii)(B)</U> above applies, then
based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as
to compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the Code and will otherwise
apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the &ldquo;<U>IRS</U>&rdquo;)
determines that any Payment is subject to the Excise Tax, then <U>Section 13(b)</U> hereof shall apply, and the enforcement of <U>Section
13(b)</U> shall be the exclusive remedy to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(b) <B>Adjustments</B>. If, notwithstanding any
reduction described in <U>Section 13(a)</U> hereof (or in the absence of any such reduction), the IRS determines that you are liable
for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the
Company within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the
&ldquo;<U>Repayment Amount</U>.&rdquo; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any,
as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking
into account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the
Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise
Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the
Payments. If the Excise Tax is not eliminated pursuant to this <U>Section 13(b)</U>, you shall pay the Excise Tax.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 14. Section 409A<FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(a)   Anything
in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of
the Code, the Company determines that you are a &ldquo;specified employee&rdquo; within the meaning of Section 409A(a)(2)(B)(i) of the
Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation
from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section 409A(a) of
the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall
not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death.
If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch- up payment covering
amounts that would otherwise have been paid during the six-month period but for the application of this provision (without interest),
and the balance of the installments shall be payable in accordance with their original schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(b)   All
in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by
you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but
in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was
incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits
to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation
applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another
benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(c)   To
the extent that any payment or benefit described in this Agreement constitutes &ldquo;non- qualified deferred compensation&rdquo; under
Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such
payments or benefits shall be payable only upon your &ldquo;separation from service.&rdquo; The determination of whether and when a separation
from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(d)   The
parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision
of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that
all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate
payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably
requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations
in order to preserve the payments and benefits provided hereunder without additional cost to either party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">(e)   The
Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement
are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions
of, such Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>15. Withholding; Tax Effect</B>. All forms of compensation referred
to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.
You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax
liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>16.   Recoupment</B>.
Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures
adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable
under this Agreement. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason
under this Agreement or any other agreement between you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>17.   Interpretation
and Enforcement</B>. This Agreement, together with <U>Appendix A</U>, the Covenant Agreement and any award agreement between you and the
Company constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and
supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The
terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising
out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you
and the Company (the &ldquo;<U>Disputes</U>&rdquo;) will be governed by federal law to the extent applicable and otherwise by California
law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan,
which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction
of the federal and state courts located in the State of California in connection with any Dispute or any claim related to any Dispute,
except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>18.   Assignment</B>.
Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without
the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement
without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate
with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain
employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you
shall not be entitled to any payments, benefits or vesting pursuant to <U>Section 10</U> or pursuant to <U>Section 11</U> of this Agreement
solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each
of your and its respective successors, executors, administrators, heirs and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>19.   Waiver;
Amendment</B>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure
of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This
Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>20.   Enforceability</B>.
If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement)
shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or
the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable,
shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>21.   Conditions</B>.
You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize
by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to
the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>22.   Employee Representations</B>.
It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies or third parties.
If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third
party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not limited to, confidential
or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or strategies. In making
this employment offer, the Company has relied on your representation that: (a) you are not currently a party to any agreement that would
restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject to any noncompetition or non-solicitation
agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; (c) you have
the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d) you
will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work
product of a former employer or other third party that are not generally available to the public, unless you have obtained written authorization
from such former employer or third party for their possession and use and have provided the Company with a copy of same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>23.   Other
Terms</B>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment
to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience
and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement
may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document.
PDF copies of signed counterparts shall be equally effective as originals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">I look forward to working with you to make the Company a great
success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Sincerely,</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Lawrence Klein</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">Name:&nbsp;</TD>
    <TD STYLE="width: 34%">Lawrence Klein</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Accepted and acknowledged:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Paul Quinlan</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Paul Quinlan</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Date: 4/13/2024</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B><U>Appendix A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">1.   &ldquo;<U>Cause</U>&rdquo;
shall mean (i) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective
customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated
to result in material harm to the Company; (ii) your conviction or plea of no contest to: (A) a felony or (B) any misdemeanor involving
moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform in all material respects your assigned duties and responsibilities,
which failure continues for 30 days after written notice given to you describing such failure; (iv) your gross negligence, willful misconduct
that results in or is reasonably anticipated to result in material harm to the Company; or (v) your violation of any material provision
of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements relating to
non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">2.   &ldquo;<U>Change
in Control</U>&rdquo; shall have the meaning provided for the term &ldquo;Reorganization Event&rdquo; under the Company&rsquo;s 2024 Equity
Incentive Plan (or the meaning provided to any word of similar import under any successor plan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt">3.   &ldquo;<U>Change
in Control Period</U>&rdquo; shall mean the 12-month period that immediately follows the first event constituting a Change in Control.<SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 4. &ldquo;<U>Code</U>&rdquo; means the Internal Revenue Code of 1986, as amended.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 5. &ldquo;<U>Disability</U>&rdquo; shall mean a permanent and total disability as defined in Section 22(e)(3) of the Code.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">6.   &ldquo;<U>Good
Reason</U>&rdquo; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without
your written consent, of any of the following events: (i) a material diminution in your base salary or Target Bonus except for across-the-board
salary and target bonus reductions of no more than 10% based on the Company&rsquo;s financial performance similarly affecting all or substantially
all senior management employees of the Company; (ii) a material change in the geographic location at which you are required to provide
services to the Company or a requirement that you change your remote location to a location from your then-current residence; (iii) the
failure of the Company to obtain the assumption of this Agreement by a successor; or (iv) the material breach of this Agreement (or any
other agreements with you) by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">7.   &ldquo;<U>Good
Reason Process</U>&rdquo; shall mean that (i) you reasonably determine in good faith that a &ldquo;Good Reason&rdquo; condition has occurred;
(ii) you notify the Company in writing of the first occurrence of the Good</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Reason condition within 60 days
of the first occurrence of such condition; (iii) you cooperate in good faith with the Company&rsquo;s efforts, for a period not less than
30 days following such notice (the &ldquo;<U>Cure Period</U>&rdquo;), to remedy the condition; (iv) notwithstanding such efforts, the
Good Reason condition continues to exist; and (v) you terminate your employment within 60 days after the end of the Cure Period. If the
Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"><SUP>1</SUP></TD><TD STYLE="text-align: left"><B>Note to Draft</B>: Such definition of Reorganization Event
shall exclude (i) a merger or consolidation in which all or substantially all of the individuals and entities who were beneficial owners
of the Company&rsquo;s voting securities immediately prior to such transaction beneficially own, directly or indirectly, a majority (determined
on an as- converted basis) of the outstanding securities entitled to vote generally in the election of directors of the resulting, surviving
or acquiring corporation in such transaction, (ii) a reverse merger or similar transaction, and (iii) the Company&rsquo;s Series A Preferred
Stock financing, if any, or any other bona fide equity or debt financing of the Company, including a financing in which greater than
50% of the Company&rsquo;s outstanding equity securities are acquired by a third-party, or reorganization required to effect an initial
public offering.</TD>
</TR>
</TABLE>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>15
<FILENAME>ea020512201ex21-1_arcabio.htm
<DESCRIPTION>LIST OF SUBSIDIARIES OF ARCA BIOPHARMA, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSIDIARIES
OF ARCA BIOPHARMA, INC.</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
    Name</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State
    of Organization</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atlas Merger Sub Corp.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atlas Merger Sub II, LLC</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>16
<FILENAME>ea020512201ex23-1_arcabio.htm
<DESCRIPTION>CONSENT OF KPMG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCA BIOPHARMA, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Independent Registered Public Accounting
Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the use of our report dated February 1, 2024, with respect
to the financial statements of ARCA biopharma, Inc. included herein and to the reference to our firm under the heading &ldquo;Experts&rdquo;
in the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex23-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boulder, Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>17
<FILENAME>ea020512201ex23-2_arcabio.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the use in this Registration Statement on Form
S-4 of ARCA biopharma, Inc. of our report dated May 13, 2024 relating to the financial statement of Oruka Therapeutics, Inc., which appears
in this Registration Statement. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP<BR>
Boston, Massachusetts <B><BR>
</B>May 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>18
<FILENAME>ea020512201ex99-5_arcabio.htm
<DESCRIPTION>CONSENT OF LUCID CAPITAL MARKETS, LLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;99.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Lucid Capital Markets, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARCA biopharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10170 Church Ranch Way, Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Westminster, CO 80021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: Registration Statement on&nbsp;Form&nbsp;S-4&nbsp;of&nbsp;ARCA
biopharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Members of the Board:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the inclusion of our opinion letter, dated April
2, 2024, to the Board of Directors of ARCA biopharma, Inc. (&ldquo;ARCA&rdquo;) as Annex B to, and to the reference thereto under the
headings &ldquo;Prospectus Summary &mdash; Opinion of Lucid Capital Markets to the ARCA Board,&rdquo; &ldquo;The Merger &mdash; Background
of the Merger,&rdquo; &ldquo;The Merger &mdash; ARCA&rsquo;s Reasons for the Merger,&rdquo; and &ldquo;The Merger &mdash; Opinion of Lucid,
ARCA&rsquo;s Financial Advisor, to ARCA&rsquo;s Board of Directors&rdquo; in the proxy statement/prospectus relating to the proposed merger
involving ARCA and Oruka Therapeutics, Inc. (&ldquo;Oruka&rdquo;), which such proxy statement/prospectus forms a part of ARCA&rsquo;s
and Oruka&rsquo;s Registration Statement on Form S-4 (the &ldquo;Registration Statement&rdquo;) to be filed on the date hereof, which
this consent is filed as an exhibit thereto. In giving the foregoing consent, we do not admit (1) that we come within the category of
persons whose consent is required under Section 7 of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or the
rules and regulations of the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) promulgated thereunder, or (2) that we
are experts with respect to any part of the Registration Statement within the meaning of the term &ldquo;experts&rdquo; as used in the
Securities Act and the rules and regulations of the Commission promulgated thereunder.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Lucid Capital Markets, LLC</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LUCID CAPITAL MARKETS, LLC</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LUCID CAPITAL MARKETS, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">570 Lexington Ave, 40th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">New York NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>19
<FILENAME>ea020512201ex99-6_arcabio.htm
<DESCRIPTION>CONSENT OF LAWRENCE KLEIN TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE RENAMED ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent to be Named as a Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARCA biopharma, Inc. is filing a Registration Statement on Form S-4
(the &ldquo;Registration Statement&rdquo;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in
the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined
company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement
and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Lawrence Klein</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 35%"> <FONT STYLE="font-size: 10pt">Lawrence Klein</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>20
<FILENAME>ea020512201ex99-7_arcabio.htm
<DESCRIPTION>CONSENT OF KRISTINE BALL TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE RENAMED ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent to be Named as a Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARCA biopharma, Inc. is filing a Registration Statement on Form S-4
(the &ldquo;Registration Statement&rdquo;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in
the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined
company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement
and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Kristine Ball</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 35%"><FONT STYLE="font-size: 10pt">Kristine Ball</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.8
<SEQUENCE>21
<FILENAME>ea020512201ex99-8_arcabio.htm
<DESCRIPTION>CONSENT OF CARL DAMBKOWSKI TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE RENAMED ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent to be Named as a Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARCA biopharma, Inc. is filing a Registration Statement on Form S-4
(the &ldquo;Registration Statement&rdquo;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in
the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined
company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement
and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Carl Dambkowski</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 35%"><FONT STYLE="font-size: 10pt">Carl Dambkowski</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.9
<SEQUENCE>22
<FILENAME>ea020512201ex99-9_arcabio.htm
<DESCRIPTION>CONSENT OF PETER HARWIN TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE RENAMED ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent to be Named as a Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARCA biopharma, Inc. is filing a Registration Statement on Form S-4
(the &ldquo;Registration Statement&rdquo;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in
the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined
company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement
and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Peter Harwin</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 35%"> <FONT STYLE="font-size: 10pt">Peter Harwin</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.10
<SEQUENCE>23
<FILENAME>ea020512201ex99-10_arcabio.htm
<DESCRIPTION>CONSENT OF SAMARTH KULKARNI TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE RENAMED ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent to be Named as a Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARCA biopharma, Inc. is filing a Registration Statement on Form S-4
(the &ldquo;Registration Statement&rdquo;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in
the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined
company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement
and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Samarth Kulkarni</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 35%"> <FONT STYLE="font-size: 10pt">Samarth Kulkarni</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.11
<SEQUENCE>24
<FILENAME>ea020512201ex99-11_arcabio.htm
<DESCRIPTION>CONSENT OF CAMERON TURTLE TO SERVE AS A DIRECTOR OF ARCA BIOPHARMA, INC., TO BE RENAMED ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent to be Named as a Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARCA biopharma, Inc. is filing a Registration Statement on Form S-4
(the &ldquo;Registration Statement&rdquo;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in
the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined
company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement
and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Cameron Turtle</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 35%"> <FONT STYLE="font-size: 10pt">Cameron Turtle</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>25
<FILENAME>ea020512201ex-fee_arcabio.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Calculation of Filing
Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Form S-4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>ARCA BIOPHARMA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><U>Table&nbsp;1 - Newly
Registered and Carry Forward Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Security Type</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Security Class Title</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fee Calculation or Carry Forward Rule</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount Registered</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Proposed Maximum Offering Price Per Unit</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Maximum Aggregate Offering Price</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fee Rate</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount of Registration Fee</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Carry Forward Form Type</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Carry Forward File Number</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Carry Forward initial Effective Date</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Filing Fee Paid In connection with Unsold Securities to be Carried Forward</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="40" STYLE="text-align: center"><B>Newly Registered Securities</B></TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; width: 7%">Fees to be Paid</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 8%">Equity</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%">Common Stock, $0.001 par value per share</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 8%">Other</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">592,235,860 </FONT></TD><TD STYLE="width: 0.5%; text-align: left">(1)</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">(2</TD><TD STYLE="width: 0.5%; text-align: left">)</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,741.20</FONT></TD><TD STYLE="width: 0.5%; text-align: left">(2)</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">0.0001476</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">2.92</TD><TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Fees Previously Paid</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Carry Forward Securities</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&nbsp;</TD><TD COLSPAN="41" STYLE="text-align: center; font-weight: bold">Carry Forward Securities</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="8" STYLE="text-align: center"><B>Total Offering Amounts</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">19,741.20 </TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="8" STYLE="text-align: center"><B>Total Fees Previously Paid</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="8" STYLE="text-align: center"><B>Total Fee Offsets</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="8" STYLE="text-align: center"><B>Net Fee Due</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Relates
to common stock, $0.001 par value per share, of ARCA biopharma, Inc., a Delaware corporation (&ldquo;ARCA&rdquo;), issuable to holders
of common stock, $0.0001 par value per share of Oruka Therapeutics, Inc., a Delaware corporation (&ldquo;Oruka&rdquo;), in the proposed
mergers of (i) Atlas Merger Sub Corp, a Delaware corporation and a direct, wholly owned subsidiary of ARCA, with and into Oruka, with
Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation, and (ii) Oruka with and into Atlas Merger Sub II,
LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of ARCA, with Atlas Merger Sub II, LLC continuing as
the surviving entity. The amount of common stock of ARCA to be registered includes the estimated maximum number of shares of common stock
of ARCA that are expected to be issued (or become issuable) pursuant to the mergers, without taking into account the effect of a reverse
stock split of common stock of ARCA, assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing
of the mergers) of approximately 7.4631 shares of common stock of ARCA for each outstanding share of common stock of Oruka.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the U.S. Securities Act of 1933, as amended.
Oruka is a private company, no market exists for its securities, and it has an accumulated capital deficit. Therefore, the proposed maximum
aggregate offering price for the shares expected to be issued pursuant to the mergers&nbsp;&nbsp;is one-third of the aggregate par value
of the Oruka securities expected to be exchanged in the proposed mergers.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tarca_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tarca_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M3FSU5-C-S_,#M6HQLLGBJ9NJNGY*.6I@ DCF2DW!V/F*.LHRSHIBJJ;&XUP
M28,A>S>_=>ZNLZR_E5?R^>J:"&BP?Q;ZRW')&O[V0[-Q4O:U?5RE0'FF?L2H
MW)31,Y%]$$4,*']"+[]U[HRJ_&'XUHJHGQYZ-1$4*JKU-L%555%E55&  55
ML /I[]U[H'.QOY<?P3[5IJZGWA\5.EO+DDD2LRNUMF8W8&X)FD1XS.=R;"3;
M6>6J"OQ**@2*0MCZ5M[KW5,_RC_X3H; S%%D]Q_$CL_,;.SJ)4U4'6W:D_\
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M9))U&'$T,"$\ E;@ <#Y[/?+FB?G+W?YBYAG(/BWT\<9%:>#;M]/;\2<B*)
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MR'R594A(E9D! 9XQKL'M?:ILK<^\_%K79H:&.,=MQ?R'X(( <A6IW2TPH)7
M9T)[[F.1KP;)LE);QOB8YC@7\3R>I'DOK2OD"".]<Q5;FR;5TU/34-)3PK0X
MC$4,8BQV%Q4+R/2XVAB %HHO*S.[7EGE=Y9"TCLQA+GC=;KF?<FO)XT@AC7P
M[>",!8K:!22D,:@# J26/<[%G8EF)Z%FTVL>W0"%&+LQU.[&K.YI5F/SI@<
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M2P ]XA<[K/S'SC?75NAD>:=DC"@DLJ'PXP !4DJHZEC92FW;1#'(=(1 6)P
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M?NO=>]^Z]U[W[KW6LGCTN;_U:W^M]/?S4;>FJ3K/J8T7I=XR/D$_X $?F_\
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M%CS!O5I&+$/H,54^$%L&E"37APZ8=T;WZYZHBEIL3A\7)G0C 8O"4U)!4AB
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MHWMVSU;%_+V&GIG=(_IVEF__ 'E-E>^J']W_ (]G-S_Z75Q_V@[=UCE[U_\
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M98)71@58@^Z]U]-3K/L#;W;'76Q.S]I5(J]L=A[/VYO7 5 96:3$;FQ%)F*
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:17\_KY._Z8?EMCND\%6K4;.^-V!?
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MM9D<ID:D*\=!CQD,C+55<[#13P*\C>E3[]U[JU7_ *!_/Y@?_*ETU_Z,IO\
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M:_\ 1E-_]C_OW7NO?] _G\P/_E2Z:_\ 1E-_]C_OW7NO?] _G\P/_E2Z:_\
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MJ%)9UYM 7-'MQ=M%)?\ )%[#O]HHU'Z8TNXT\C/8M29?.I574 $DCH<;=O\
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MQ??NO=6*?RJ/D6?C/\Y.EMXUU8:/:>[\S_HHWVS&T!VOV'+3X9*NK;R1Z:3
M[D_AV4D-S84/T;Z'W7NOH>>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ^5?[]U[KWOW7NOH;?RC_P#MW)\5O_#%RW_O;;I]^Z]U8U[]U[I(=@;#VGVE
ML?=O7&^\-2[AV;OC;V5VON;"UBDP9'#9FCEH:ZG+*5DAE,,Q,<J%9(9 KHRN
MJD>Z]U\YCYQ_$O=GPL^1N^>D=QFLK\1CJA<WU]NBJA$2[QZ^S$DTNW,ZC1Q0
MT[UL<<;T=>L2B.')4E1&MU0$^Z]T47W[KW6PY_(A_F /TUV<OQ'[0S9CZO[A
MS:R]9Y')UJ)1[)[6KA'3Q86-ZIE%-ANQRD=,L:/I3,K3E(]5942>_=>ZW-/?
MNO=>]^Z]U[W[KW7O?NO=:P7_  I+Z7J,ALOXZ?(+'P,T6V=P;GZGW1)' TI,
M&ZZ*#=6T)I9D8?:TU#4[8RT9+*5>6MC 96 $GNO=:EGOW7NAR^,O;U3T%\AN
ME.Z*=YPG6G9NSMVY&*GC666MP6*S='-N+%K&UM:Y? _<TK %6TS'2RM9A[KW
M7TTL?7T65H*'*8VIAK<=DJ.FKZ"LIW$D%715D*5%+4P..'AG@D5U/Y4CW[KW
M4SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=$(_F9_)Z/XF?#3MSLRBKQ1;TR^)/7766ET6I?L#?
M$%5C,36T:R21K+/MG'K5YIDO=H<;)8,?2?=>ZT._AUT%7_*#Y.]+=%44<STV
M_M\8RCW%+ TL<U#LO%B7/;YR44L,4K1SX[:&+K9HR0%,J*"R@ZA[KW7TKL;C
MJ##XZ@Q&+I(*#&8NBI<=CJ&EC$5-14%#!'34E)3Q+98X*>GB5$4<!0![]U[J
M;[]U[KWOW7NO>_=>Z+1\Q^A*#Y/?%_NSHRLBIY*K?NQ,M1[<FJ5UPX_>N+5,
M[L7+.HDA+)BMX8NAJ&4.FM(RI(!/OW7NOFGUE'5XZKJL?D*6IH:^AJ9Z.MHJ
MR"6FJZ.KII6AJ:6JIIE2:GJ:>9&1T=0R,"" 1[]U[J;@,[F-K9W"[FV]D*C$
MY_;N6QV=P>4I&"U6-S&(K(<AC<A3,RLJU%'6TZ2(2" RCCW[KW7TP_C!W=B/
MDA\>^G^\L*(XZ7LK8F#W%5TD3K(N+STE,*3<^#9T)5I<#N2EJZ)R.-<!]^Z]
MT._OW7NO>_=>Z][]U[K6#B?1(K?XV/\ K'W\S*-I:O6?Y%13H1L3E:&@,<E+
M0Q5=2H1A4955J8(Y0H.N'&#_ "231(2"M2:J*0 $H.1[E'8M[VS;@KV-L)Y@
M!^I<T=5:G%+<?IX8G$IF5@ 2@J1T175M--42N54UPF"?M?C_ +SI(]3QZ7$F
MY<QFC3'*9&JK$I4,5'3R26HZ"$DG[;'T,82CQU,I^D4$:1K^ /8_;FG>M\:,
M[M=23K$*1H32.)?X(8EHD:>BHJJ/(=%:V%K:AOIHPA;+$#N8^K,<L?F23TI,
M?4_I(/\ 3\G_ (BW]/8LVZZ! %>D,T=>EK0U7Z2#_2W^W_V'L;V%U4#/11+'
M3H\O06P8,=CO])6[/%0TT4,DV"2O98(8*;21+G9S,55$D4E:;58:;R &\;>\
MS?9'DB*PV_\ UP.9:0H%+6XD(552F;EM7"HQ'7RJXXJ>HDYSWI[B?]P[;5V)
MI)IR2?*,4_XU^SU'4O???;5TDV(V8[TU'=HI\ZZE*NI'T(QT;#520GG]QAYF
M^JA+7*KG/WK-X[[7RDQ2+(:X(H[^OA _"O\ 2/<?(+Q+6S\F^"!<[J*MQ$?D
M/],?,_(8^WH6NOJ-=Y];T<&]::DW/0Y1JQ#29VCILE#44$-1)2PI5Q5<4BU1
MU0LP>0,Q##GZ>Y/Y)M5YMY BM^;XTW&&Z$BM'<QI*KQ!B@6174AZZ2:M4D'C
MT&MZE_=>^L^U,;=X].8V*D,0"2I!%.(P.B_9CXO_ !JW5N:LP.(.>VOG8I)#
M/1[8RU2M*TD*++4I ,W0YW&Q&  J\<>@(=0501Q >\_=D^[IS1O\VS;4MQM=
M\&)9;*=U2JT9PBW"7$*T&"JJ*9  (P-+;G_GS;K!+RY\.XA(%&E0:J' KH:-
MC7R)K7&>N-5\.NC-G4SYK/;@W]4XV QQ/#7Y?&M TDTBK& F$VS1US.Y&GTN
M  23:UPV_P!T/V4Y2B.[[W?;G/;I12LUQ%I)8BG^XUI%(3Y8:E"2>%1N/W/Y
MOW1Q:64-NLC5-51JT S_ &DK+_+HQW6.QNL=KX>"OZZP.,H*6O@TMDXTEJ<M
M4HCD/!6Y*O>HR;F*92&B>32C V ]Y#^W7)?MSRQM*7?(%C#;Q3J 95!:9P">
MV6:0M*U#7M9B :T Z V_[MO^X730[Y,[LA^$T"#YJJT7(\P,] )E.T]W[.WO
MGEJ:Z3*4]/E:JFFQE:Q%)+20SNE,:540"@=J<JRM$HU$@NK\CW#&Y>Y'-'*O
M.%ZMQ,;B-)G1H9#1"BL0FB@[#IH05&:U8-T,K?E[;-TVF$QH(V* AU^+41G5
MZY\C^5.ABEKMG]Z;1K,;1U2T^3A05"4]2$_B6$R"J5AJ3$"?/12,^AGC)5XV
M(NK\+*<MYRK[R<KS;?:2:)U&H*U/%MY1A7(!RAX$J:,I(J&P PL.Y\H;FEQ*
MNJ,FE173(OF*^1\Z'@1YCC7ENS'Y+;N7R&#R].]+D,=4/!4Q-R"P&I)8FL!+
M!-&P>-Q<.C!AP?>"7,]AN&P;I/L^ZH8IX&*LI_:&!\U((*D8((/4V[?<6]];
M)=VK:HW%0?\ )]HX$>1QT&V0JOJ >?SR?]A[CG<+JM3T>01^?2)K:QXY%EBD
M>*6)UDBDC<I(DB$,CHZZ65U8 @@@@\^P)?W\D,@FA8HZ$,K*:%2#4$$&H(\B
M/MZ-HHE<%6%0<$>1KQZ8LWNJNRA;^.%,U(0 U=6W.7X5D#',)IKJF2.-K(*E
MJB);*-!  ]AO?.<+_= 1OX6_/#Q9?]R0!45^I6DC$ ]OBF5!0=A ITJMMNAM
MO]PZQ ?A7X/LT?"/GITD^O0692:(MIA,FEE6XD"AE;2/(+J2&4-P&L+C\#W#
MF[S0/-_BQ;305U4J&ID @Y%>!QCR'0CMD95[Z5^7^S_J^?5NO\O/_F2VY_\
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M)(TBWC!&A1#6^I6_O<E@HD (R:^EK52@U2S?^8X_<"-6NQ3?E"H'4 +N*J*
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M[!5'VDTZLY^//P=./J*+>'=4%//402156-V%%-%5TL<L;:XIMSU5.\E-6:7
M(HH6>%A83.X+1>^F?W??N3KM-Q!S?[QHDL\95X=L5EDB1@:AKQU)60@T_24F
M/'>S@E! 7.WNUXZ/MG*I*J:AK@@@D'B(@:$?Z<T/\(&&ZLQ55151%5$10JJH
M"JJJ+*JJ+!54"P ^GOH\ % 510#@.H&))-3DGKE[WUKKWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NH]724E?33T5=2T];1U,;0U-)5PQU--40N+/%/!,KQ2QN/JK @^V;BWM[N
M![:ZC66.0%61U#*P/$,I!!!]#U>.22%Q+$Q5E-002"#Z@CHM>Z_A[\?]URR5
M+[(CV_5RZKS[4KZS!1+?Z&/%T\K82,J?III1_C<>\=N:/NE^PG-,IN)]BCLI
M2*:K*22T4?9#$PAK\_#_ )=#K;O<SG/;E$:W9F4>4RK(?S<C7_QKH+G_ )>O
M2KN[KN/LZ)6=F6),WM<I&&)(1#+LV20H@-AJ9FM]23S[BJ7[@'LS)*TB;AO*
M!B2%6YL]*@GX1JV]C0<!4D^I)ST(E]ZN:@ #!:FGF8Y<_/$XZX?\-Y]+?\]/
MVA_Y^MJ?_85[I_R;]]FO^CGO7_918_\ >NZW_KU\U?\ */:?[Q-_UOZ]_P -
MY]+?\]/VA_Y^MJ?_ &%>_?\ )OWV;_Z.>]?]E%C_ -Z[KW^O7S5_RCVG^\3?
M];^N0_E[=,K]-T]I#_R-[4_^PKWO_DW_ .S@_P"6GO7_ &46/_>NZ]_KU\T_
M\H]I_P XYO\ K?UD'\OKIL?\Q3V@?]?,[3_^PGW;_@ ?9W_HY[U_V46/_>NZ
MU_KT\T?\H]I_SCF_ZW]=_P##??3?_/4=G_\ GYVG_P#85[]_P /L]_T=-Z_[
M*+'_ +UW7O\ 7IYH_P"4>T_YQS?];^N!_E\]-G@[J[1_\_6TQ_O6R??C]P#V
M</\ RT]Z_P"RBQ_[UW7O]>KFG_E'M/\ G'-_UOZX'^7ITN?KNCM$_P"OF]J?
M_85[J?[O[V;/'<]Z_P"RBQ_[UW6_]>OFK_E'M/\ >)O^M_77_#>?2W_/3]H?
M^?K:G_V%>]?\F_?9K_HY[U_V46/_ 'KNO?Z]?-7_ "CVG^\3?];^O?\ #>?2
MW_/3]H?^?K:G_P!A7OW_ ";]]FO^CGO7_918_P#>NZ]_KU\U?\H]I_O$W_6_
MI2X+X(="8AT>NI-U[GT-J*9W<;0H]G+6<;=H]ODK8Z; BX'];DBG8ON/>PVS
MZ3>VUYN94UK=7;K7).1:+:CY<. S4U)07GN_SE<@B%X;>O\ ON('_JZ9.C.;
M0Z_V3L"B;'[+VM@]M4TEC.,3CX*::K90JB2MJU4U==*%4#7,[M8#GCWDIRKR
M/R=R-9G;^3]LMMMB8U86\*1ES0#5(R@,[4 &IB30#..@!N6\[KO$OC;I<23L
M.&MBP'R4' 'R '2O]BKHMZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J%D
M<EC\10U63RU?18O&T433UN0R-5!14-) GZYJJKJ7B@IXEORSL /?NO=)W96_
MMG=BXNIS>R,]1;CQ-'DZK#SY"@$QIER-''!+44Z2311"8)%51L'35&ZN"K$>
M_=>Z5_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[J%D<EC\10U63RU?18O&T433UN0R-5!14-) GZYJJKJ7B@IXEORSL /?NO
M=)[9>_=G]B8J?.;)S]#N/$4V2J\1-7X\RM3KD:'Q&IIPTL<1?2DZ.KJ"DB.K
M(65@3[KW2N]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T6#Y)[L^0VTL/'D>EMK[=S.
M)I,3DJ_<^4K62LS^*-'ID5L5A:FOH*>K1:4-)Z4K9'92OB6RF3W7NJ1M_=O=
ME]H5/W&^]YYO<""3S14%14BFPU++ZOW*/!T*4N'HY+-;5' K$<$FWOW7NKY/
MC;UP>K>F-D[7J(FBRSXU<WN!7 $B9S.G^)5U-)I)4MC?.M*"."L /OW7NAT]
M^Z]U[W[KW7O?NO=>]^Z]U5O\T?D[V3L;?L76W7^5DVK2X[$8W)YC+TU)3R93
M)5F266HBIJ:JK*>=:;'4U+XKM"%D>8NK/I72?=>Z%?X1_(+>G;^,W9MO?DZY
M;,;13%5='N):2*FGR&.RCUL)I<FM)!#1?>44M$/'(%1YXW.H%HV=O=>Z/C[]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NB[?(+,?(?$8G'R]#[<VUG6,&1?<$N3EADSM&8A3-0M@L
M?7Y#&XRI8QF8N'-3)(P54BO;7[KW5&&_^WNR^T:D5._-Y9G<"HYD@H9YUIL/
M2N2Q+TF$H$I<122'58M'"K$  D@"WNO=7F_$_8K; Z%V#C*B,QY'+XT[LR@9
M#'(*K<SG*P0S(0&2>BQL]/3N#R&B/OW7NC%^_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z+A\L.Q8^M>C=YY*.=8LMN"C;9V!4N$D?);BBFI)I8"3?S8_$BJJEX/,'O
MW7NJ>_BEUM_I/[OVAB:F SX7!U/][=P@J'B.+V_)%4Q4TZFP:#)Y5J:D<#G1
M.2/I[]U[K83]^Z]U[W[KW7O?NO=>]^Z]U[W[KW18^^/BML#OFMQ^<S%9EMO;
MFQU*F.7-X4TK&MQL<TDT='DJ.KAEBJ1323R&*1#'(FL@LR@*/=>Z67270VR.
MA\#6X?:2UU75Y>>"ISF=RTL,V4RLU,DB4L<AIX:>GIZ*C$TGAAC0!?(Q8LS%
MC[KW0U>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I$[^['V1U?
M@_[Q[]W#1[<P[5*4<535)55$M35R1RS)2T5#005=?75)A@=]$,3L$0FU@3[]
MU[I*=8=]]5=Q5&1H^O\ <XS%?B8$JLA038K,8JJ@I9)O!'4A,K04:U$#2D F
M(OI+ -I) ]^Z]T,/OW7NO>_=>Z][]U[KWOW7N@U[CWRG6W5V^=[L5$V V]6S
MX\.=*29BI5:#"0.UCI6HR]7 A-B0&^A^GOW7NM?/IW8\O9/:.QMD(ADBSVX:
M&#( %@4PU,QK\Y,-%FU08:DG<6(N5^H^H]U[K93CCCACCBBC2**)%CBBC54C
MCC10J1QHH"HB*   + >_=>ZY^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIS_F']E?
MQS?NW>M*"H#T.RL=_%<RD<ATMN+<$<4L,%1&"5+X[!QPO&W##[V0>_=>Z'K^
M7AUM_ ]@;A[*KH"M=O;)?PO$2.INNWMO2S02RPDHI45V<DG20 L#]I&?J"/?
MNO='#W-W7U'LW(G$;G[(V=ALLLRP38RKSU *^ED?]/WU''-)44"?[5,L:C\G
MW[KW0BT-=19.CILAC:RER%!6P1U-'74-1%5T=73S*'BJ*:I@>2&>"5""KJQ5
M@;@^_=>ZE>_=>Z][]U[K'++%!%)//)'###&\LTTKK'%%%&I>2221R$2-$!))
M(  N??NO=!I@^ZNI-R[@_NMM_L?9V8W 7:.'&8_.T%3/5RHC2214#1S&'(R1
MHI++ TA4*;@6-O=>Z$_W[KW7O?NO=>]^Z]U@J:FFHZ>:KK*B"DI::-YJBIJ9
M8X*>"&-2TDLTTK+'%&BBY9B ![]U[H)U^0/1[Y-<.G;/7[5[MH5!NG$&G:36
M(Q"*[[K[ SM(;"/RZR?H/?NO="ZCI*B21NLD<BJ\<B,'1T<!E=&4E65E-P1P
M1[]U[KE[]U[KWOW7NO>_=>ZIV_F*]@?Q??\ M7KNDGU4NSL,^7RD:,0!F]R&
M)XH)T^A>DPU'!)&?P*MOZ^_=>Z6WP=W%U/U1L'<>[M\;^VC@-Q;TRR4]-C*_
M,T0RT&W=O-)2TLS8U9I*^!:[+UM43^T!)'"C78+Z?=>ZLDVEV!L;?D$U3LO=
MVW=TQ4Q457\#R]%D9*0M8JM7!33//2,P/ D521[]U[I7^_=>Z][]U[KWOW7N
MJX_YC&_/X7L79_7M+-IJ=UYN;.9-$/)Q&W(E2""=?Q'5Y;(Q2(?RU(?Z&_NO
M= K_ "Z-A?Q7?F[NPJJG#TNT\)%A<9+(O"YG<<C&::G8KS+2XB@FC>Q%EJQ?
M]7OW7NK7]T;UV?LFDCK]X;IV_M>CF8I!49_+T&*CJ)% +1TQK9X342@$>E-3
M?X>_=>Z9]E]J];]B/4Q;(WKMW<U11H):NDQ>2@FKJ:$MH6>:A++61T[/Z1(4
MT$\ W]^Z]TO_ '[KW7O?NO=>]^Z]U[W[KW7O?NO=)C>&\]K[ P%;NG>.:I,!
M@<?XA59"L,A17GD6*"&&"".:JJJB:1@$BB1Y&_ -C[]U[H-.N?DATWVOG9]M
M;%W=_%\Y#35%<*";";AQ3ST-*T*35=/+EL50P2HK3KZ-8F N2@ O[]U[H<O?
MNO=>]^Z]TQ;CW/MS:&*FSFZL[B=NX>G94FR69KZ;'4:R27\</GJI(T:>720B
M EW(L ??NO=,6R^S>ONQ8ZN38V\,!N?[#1]]%B<A#455&LI98GJJ34M53Q3,
MC!'= KD&Q-C[]U[IWW1O#:NR,6^:W?N'#[:Q2.(OO\UD*;'T\D[*SI30-4R(
M:BJD5"5BC#2-8V!]^Z]TS[*[/Z\[&6L;8V\<#N=L>4^^AQ5?%/54BR?YN2HI
M"5JHH)3<+(4",P(!)! ]U[I=^_=>Z][]U[IIS>>PFVL959K<67QN"Q%$GDJ\
MGEJVGQ]!3*2%4S555)%"A=B H)NQ( N??NO=(K9/<?5O8U;4XW9&^=O[CR-)
M"]3/CZ&L KUIHYA!)5+1SK#4RTL<I4&5%9!K6YLZW]U[I?Y#(8_$T53DLK74
M>-QU'$9JNOR%3#1T5+"MM4M355+QP01+?EF8 >_=>Z""@^1W164SD&W,?VEM
M"JRU5,E/2Q1Y-12551+,:>&GILHZKBJBHGFLL:),SR$C2#J%_=>Z&OW[KW05
M[U[PZDZZJSC]Y]@;<PF25$DDQ4M:*O+11RE1')-BL>E7D88Y-5U9H@& )' )
M'NO=+3;&Z]M;TP]/G]I9W%[BPM476')8BLAK:5I(["6!WA9O%4PL;21/IDC/
M# 'W[KW2@]^Z]U[W[KW7O?NO=>]^Z]U[W[KW02=F=Z]5=0/1P=@;LIL)6Y&G
M:JH,9'1Y/*Y.JIU=XON!0XFCKIX:9YHF1991'$SJP#7!M[KW3YUQVCL;MK R
M;EV#FUSF)@K9,;53?99#'S4F1A@IZF:BJ*7)TE'4I-'#51M<*496!5F!O[]U
M[I?^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NFC<&<QVV,#FMR9>84^+P&*R&9
MR,YM^U0XRDEK*I^2+E8838?D^_=>ZUN,QD-Q=Q]GUE<$-1N3L3=Y%+3O(S1Q
MUF?R:P4%$)-+-'1T2SQPKQ:.&,<6'OW7NC^[Y[;WON5,-\9/B;296OQ6S\-2
M[<S^],(R4L^1;'Q)15DM)G&DIZ3!X>2JC<SY%I8FK:B0B%A'I:?W7NB.=N])
M]B=+93&T&_\ &P4KYVGJ*S%Y"BKX<E0Y(4KPK7K'4Q'6*FCDJ8_*DBJX\BM8
MJRD^Z]U:1_+PW17YCJ'/[?KIIIXMJ;OJ8,69#J6FQF7H*/("BB)8D)'DC4RV
ML /-Q_A[KW1_/?NO=-6=SN(VSA\EN#/Y"FQ.%P]'-7Y+(UDGCIZ2DIT+RRR-
M8L38655!9V(506(!]U[JJON[>O:OR+Z_W_OW!UIZ]^/NRX'.*ARAJJ+(]GUT
M%=#17F6G5FFIVJY D43$4D=0R1GRS+(\/NO=$G^/^%R6?[NZJQN)\JUAWWMR
MO,L.KR4]'A\E!F,E5KH9&_R/&T$LIL1PGU'U]^Z]UL@^_=>Z][]U[H.NU.S]
MK]0;+RF]=UU)BHJ%?%144)3[_-965)&HL/C8G($M95M&>39(XU:1RJ(S#W7N
MJ;\AO/N?YL]GT>SJ>M?$[<>HER$6 I9)_P"[6T\#2RHDV;S"1F%LWDJ:.946
M::SRU$HBA$*2!%]U[H\N\?A=T?M?IG>45#@JNJW/AMG9[+4F\J_*9&3+MF,7
MBI\A3U4E+!508E*5IZ15:G2!4\1(_62Y]U[H"/@)WQF%S[=)[FR-17XK(4-9
M7;%>KE>>7%5V,IWK,A@:=Y"S)C*K&02U$4=PD$L#!1^\;>Z]U;/[]U[KWOW7
MNBE]S?+O8G6%;7;6V[15O8^_Z)*S[K;FW"TE)AGH89)JPY_+0P5:TC4,<3M/
M##'/-#H82K$!J]^Z]U2INS<FY>X^R<EN"K@2?<V_-Q0K3T%)Y#"E5D9X,?BL
M51^9Y9OMZ6+PT\6IF;0@N2??NO=6=3_RW-CMAGCINQ-UQ;@-&!'63T6(J,,N
M0T#5(^-CIJ6M>C+WL@JU<#^T?H?=>ZK)@K=[=(]DU9QF0FP>\MB;AK\9+4TC
MN8FJ\762T=7"RNJ)78JN$1#)(ICG@?D%6]^Z]UL.]6;YINR^N]G[[I8EIUW+
MA*2OJ*9"62DR&DT^4HD9BS/'1Y*&6)6)NP2Y^OOW7NE][]U[KWOW7NJ#_FIO
MW^_/?FZ(:>H6?%[+BI-E8XHUT63$"2;-A@"4\J;AK*N,D<E8U!^EA[KW1CNO
M^U8_C5\>-D[8VGBQN/NOM]ZC>..P,--)7G'4F>DCH-OY6OHZ9C650JL+0TS4
M5*H7SS-(WZ%;7[KW27W!\+^_=][<SO9O8N]J.KWZV.J,M#M;)33Y3(3Q01-5
MG%2Y2GECQ&%J=.M8*6FCFI(VTIKC!.CW7NB*[&WGG>O-VX'>>VZN6CR^ R,%
M?3O'(\:5"1L!4T%5H(,M#D*8O!/&;K)%(RD$'W[KW6S925"U=+35:*RI54\-
M0BM;4JS1K(JM8D:@&YM[]U[J1[]U[KWOW7N@E[?[KV'TGMW^/;SR)2:I\D>&
MP-"$J,YG:J-=30X^C:2-1%%<>6>5HZ>+4 SAF16]U[HI^'7Y6?)B%<^-R'X[
M=8URF7"4^)IZJ;>F8H7*/35_W*S8S*B*9+Z)UJ,=%(C*T<$J$2'W7NB&?)N@
M[%ZXW;7=0;B[4W5V'MJC.'W10?Q_)9&I5:FKH:I8Y'HZ^OR0HZFG-74*1%*8
MY%<.0&-E]U[HZW\N[JO^$[8W%VUDJ;36[HF?;FVWD0:TV_BZE7RU5"]K^+)Y
MJ%8B/P<??Z'W[KW5D_OW7N@Y[5[0VOT_LO)[VW74,E%0A8:.A@:/[_,Y2=7^
MSQ.-CE=%EJZDH2;G3'$CR,0B,1[KW5.WR4Q_<N]-G[=[W[1R5+A\1NW/C%['
MZU6:M%1@,%58ZOR%+DQ22Q14R"JI\<IEE>]3/YHW8(I6-/=>Z:?AQNW'=<[Z
MWGV1GZN:DVWL_KK,U&22%U$N7K,ADL/1X7;]+&[HD^0RE>P,"MZ0T)=BJJ6'
MNO=.>^MF?)/Y-X_-]YUFW*RJVI0I6S;:P2UJ(:; 4\C-4P[2PTIBJ<K'2QP7
MGG2-9:^:,^,2.!&ONO=0/@[C=U5/R$VQ5X"#(?PW&4F<;=U3 CBBIL)48>OA
MC@RCZ3'XZK+"G6)&]1J%1EL4U+[KW5\/OW7ND#V9V3M?J?9V4WKNVL^VQF.3
M1#3Q&(UV6R,JN:/$8N"62(5.0K&C.E=0"JK.Y5$=A[KW51GR+INYNS^MZ;OO
MLG)TFT]HUF>H,?UWU@7JQ)_#<I'7/!ES&WCB?)3T=,TOGF3S55.'D00PB*-O
M=>Z"7XH;BQFQ^VZ?L7/UST&V]@[9W5G<X8[&>OBK,+5;<QN(I(FEA6IK\CF\
MY3+!&38N-3:55G3W7NC62;#[\^;GEW?G<U#UGU.DT_\ <S!5,=95PY%8Y76*
MO&+@EHCF9D"Z9,C4O&FLE:6/1K"^Z]U6]NS;M5M#=6YMIUL]-55NU]P9G;M7
M54;.])4U6$R-3C:B>E:1(Y&III:8LA958J1< \>_=>ZL\RGR![*W5LSJSH+I
MPU^4[9R^Q-JC?>[S*!)M:.3"T$E;#)D+.*/*P02J<C62?N4;-XE#5KD0^Z]T
M43Y&?&S</0L6U,GG]WX[=55O.3+M5-2T];!44V3QXH*BN9YJV667)0S/D@?N
M&$3LP]2 L/?NO=&J_EJ5F0:;MS'^:H;%11;.K!3DLU+#D*A]Q0&9005AJ*FF
MI@K6L9%B%[Z!;W7NK5??NO=>]^Z]U[W[KW13>\/E1A>M\O#U]L7#S=C]MY*6
M.DHMJXKRU%+BZJH ,"YN6C$E0U8R-Y%HH1YFC%Y'@1D=O=>Z"Y.@OE)VE1RY
MSL_O[)]?5]7%++0;,V)'5)C<4TH$E-3927"9C!TE0U'(-) >O<J+_<EK^_=>
MZJ1W7N/>6],]')NK.Y?=^>I8X-OTU=D*VJS.0J(:.HEBI:2&JF,M76!IYF*$
MEGD9[\D^_=>ZV#N@NLXNI.IMH;+*(,G2X]:_<,B$-YMQ94_?9?\ <%O+%2U,
MIIXFL"884X'OW7NAC]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$0^?_97]T^I
MJ/9-%/X\KV-DQ23*IM(FV\&U/D,O(& )4SUST=.0;:XI9!?@CW[KW53O3NR]
MX]@;_P -M78I:'.91*ZF;)$.(<-BJFCFH\QEJJ5 6@@I<=4R#4/7K95C_=*>
M_=>ZO[Z>Z>VCTKM"DVIM6E4OICFS>;FBC7*;AR80B3(9"5+G2"S"&$,8Z>,Z
M%_);W7NJ]?YD^Y:.;*=7[0B:)Z_'T.X=Q5PU S0TV5FQV.QHT@W1)Y,34DW'
MJT"WT/OW7NA]^ &S:K;?2$N=K86BFWONC)9JD$D?BD.'H8:7!T18-ZV26KQU
M3*C&P:.52HL0S>Z]T>/W[KW00]R=/8CNK!8;;.X,SFL;@:#<>/SF7QV(G6GC
MW'24*3C^#9&2WD2EDFE60.AUQL@9;/I9?=>ZK]^?O9-!A:#:'0>SS!C<3BZ.
MBS.Y,9C5$%+34E-&L&TL"8X2JK!3Q1R5;P,"/^ L@Y /OW7NGW^7AU!X*/.=
MSYFE_=KON-K[-\J?2CAE7^\68AO=3YZN):*-Q9D\%2I]+^_=>ZM#]^Z]U[W[
MKW5#/S([JJ>UNT\CA\?5LVS=A55;M_!P13:Z6NR%/,8,WG[(3'*U=5P^.%P6
M!I88R+%VO[KW5C7PCZ?@ZXZEHMS9"E";J['CIMP5\LB$34N!9&;;>+74%*1_
M93&K<6#>6J*L6$:6]U[H7ODGGXMM="]L9.:80"3969P\,I9E*U>Y(/[NT/C9
M&1EF:LRL80@\.1]?I[]U[JE+XH&8?(CJKP&0/_>-@WBU!O"<9D!4 Z.?&8"V
MO\:+WXO[]U[K8;]^Z]U[W[KW1&/F'4;/ZBZ:WS4[6P&%P6Z^XLTF!RF3QN/I
M:?)9=LL\V3W+5Y"H1%GJ(JK&TE1'(2=/GJ]9&IR3[KW1#O@SUXN]N\\9EZNG
M,N)V!05&[*@LA,+92-DH=OPEQ;1/'DJH5<8_/V;?B_OW7NKV/?NO=:Z?R:K8
M*_O_ +:GI]/C3>F6HFTLCCSXV1<=4W*$@-]S2O<?53<'D'W[KW5Q?PPIIZ3X
MT=8Q5,;12/!NBI56(),%;O?<M92R>DD:9J:=''YLW//OW7NC0^_=>Z2._P#=
MM)L/9&[-YUOC-/MG;^5S)CE8JM1-0T<LU-2 @@F2MJ52) ""6< <GW[KW6LU
MDLA69;(5^5R$[5-?DZVJR%=4O;745E;.]34SO:PU2S2,Q_Q/OW7NKN?BET+6
M[=IV[D[,I_NNS]W4L4N/I*N%0NR=MO2Q4V.Q=%3R*S4&0DQD:1NH(-+2!*50
MFF;7[KW1P-RU,-%MS/UE0VB"DPF5J9W_ -3#!0SRR-R0/2B$^_=>ZUDMN82J
MW-N' [;H/^!VX,SB\)1^DO\ Y5E:Z"@I_0"I;]ZH'%Q?W[KW6T#3P1TM/!31
M B*GAB@C#'41'$BQH"?R=*CGW[KW6;W[KW0,=Z=V;:Z,V34[IS=JW)5)DHMM
M;?BE6.KSN6T!EA5CJ,%!2!A)53V(BB^@:1HT?W7NB3?&CJ/<W?6ZY?D?WL[Y
MRE:K==C;?R$+?PRI^TJ9'BKH,>[M#3[8PU2SQT=,0PJ*@/+)J"ZI_=>ZLJSN
M<Q>V<+EMQ9RKCH,/@\=697)ULNHQTU#00/4U,Q50SN4BC)"J"S'@ D@>_=>Z
MUWMV9K<?R+[PK:^AIG_C'8FZZ7'X6BDUR#'8^22#&8>"I:+RVAQ.(@C-1(HT
M@1O)8#W[KW6PELW:F*V-M3;NS\'%XL5MO$4.(HQI57DCHX$B:IGT\/55<@:6
M5OJ\CLQN2??NO=*7W[KW03=E=+;([8RFR,GO.FK:]=BYBHS&/QBU97#Y-ZF*
M)9*3-XV1):>OI//30R6LCGQF,L8I)4?W7NJOOYAO82Y[LS =?T4^JAV%A149
M")&8(N?W*M/6R1/& $<TV$IZ)D:Y*F=U%N;^Z]T#WQ9ZBR?=N\4VE4^6#KW#
M5^/W9OZ:$SQ_Q".A6JI,'AGF1PBU=:U35Q0%?&\<$U5*"Q15'NO=7XT-#1XR
MBI,=CJ6GH:"@IH:.BHJ2)(*6DI*:-8:>FIX(E6.&"&) JJH 518>_=>ZR0T]
M/3^3P00P>60RR^&)(_)*WZI)-"KKD;\DW)]^Z]UF]^Z]T"G9_1>U.V]S;!SV
M[ZK)5F-V)5U]<FTS)$^W<]4U8I3 ^8HY8W\HI):520"!-&6C>Z,0?=>ZK(^?
MW:XW5V+C^M\54Z\)UY 3D5ADO!4;JRL,,M4&"?MR'$8[Q0+]6BFDJ$X-Q[]U
M[H-OB;T+6=W;ND3,1U,76VVJNCRNZY$\D,>9KX4F7%;>@G4J?N*A)I6E9#J@
MI6D-U>2(GW7NK?>\>Q\7T9T_G=R4=/1T<N*QD& V=B8(8X*0YFIA^QP5%3TL
M0CB6BQR)YWB32!2TSA;6'OW7NM=R-<EFLHBQK5Y7,9:O5414DK:[)9*OJ %4
M):26KJZRJEM:S-([?DGW[KW5^7Q<Z I>DME"?,1Q5?8NZ4BR&\,JS)434TDG
M[\.WJ6J!D+4F-+_O.KL*FJ+R7*^-4]U[JJGYA=OGM?M_*)CZDS;5V29]K;="
M->"H>EG(S67C )1CD\DC!''ZZ:&'^GOW7NK4_B'U&W4W3N'@R5+]ONC=S+NO
M<8=--132U\$0Q>)E+?N(<7BUC5XSPE2\Q'ZC?W7NC1>_=>Z][]U[HA?RY^4-
M5U[IZJZSF-7V7G8X:>OK:%34U&U:;)!$HJ>CBC5]>Y\JLRFG3EJ>-EETZGA/
MOW7NEY\6OC90].8$;GW/$F3[5W+3F?/Y6ID6LDPD58PJ),%CJDM)=]9#5M0K
M%JF<'U&-4]^Z]TI?E7V]!U#U'G,A3U/BW/N6&HVSM2*.15J$R60II4J,JBD,
MPBPE&7G+:2OF$2$@R#W[KW56OPCZL_TB=SX_+U]+Y]O=>0Q[JR)=%:"7+1R^
M+;5"^H,/))DE-4 19HZ.07!(]^Z]U>[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[J@[YG=DCL3O+<,5'4^?";)1-F8HH^J%Y<7)*^;J% )C9I<[/4('6
M^N**,WL!;W7NK'/A)TC#UIUK3[QR](B[R[#I*3*U$DB_OXS;4B"IP>)36H>!
MZB*05=2HL3)(B."85M[KW1P\SF,9M[$9/.YFLAQ^(PU!5Y/)UU0VB"DH:&!Z
MBJJ)6_"10QDFW)MQS[]U[JAV2FW1\QOD=724$=524.=R7E>9XPZ[4V!AVBI(
M:BI"EX%J8: (+7"3Y&HL"/)?W[KW5[N P6+VQ@\1MS"4J46(P6-HL3C*1/TP
M45!3QTU-'?ZLRQ1B['EC<GD^_=>Z=_?NO=);>^[\1L':.XMYYZ7PXG;>*JLI
M5D%1),*>,F&DI]1 :KKJ@I#"O]J611^??NO=:\D$6[_D/W*L9;S;H[)W4S2/
M9Y:?&P5,ADEDTW$G\*V[AX"=(-UIJ:PY'OW7NMB'9^U<1L?:V VA@8/M\/MS
M%4>)H(S8R-#1PK%YYW 'EJJIP9)7/,DKLQY)]^Z]TH_?NO=!SV_NF;9/5G86
M[*5RE9@MH9ZOQ[ABA7)1XZ=<:=8Y7_+WCY'(_'/OW7NM>7JO:#=@]E;(V:P=
MHMR;GQ..KF#,'3'35D;96<,K*^J#'++)P0?3P;^_=>ZV6X((::&&FIXHX*>G
MBC@@AB4)%##$@CBBC10%2.-%  '  ]^Z]U75_,4[$BQ6Q=L=:TDZ_P 1W9EA
MG<K"K*7CP. N*9)X[ZD2OS4\;Q-]":*0?CW[KW1;/Y??7\VX^WZW>TT&K%]?
M82IF2<BZ_P >W'#48C'0:2-+?[BS7RW^J-&O'((]U[JZWW[KW7O?NO=4M_S"
M>P3N+M;$[%I9]>/V!A(S51*1I&X=R)3Y*M)*\.(\/'0*+W*/K'%S[]U[HU_\
MOKKT[9ZER>]:RG,61[!S;ST[NC)(VWMO&?&XT%7 ($F3DKI%(X>-T(N+'W[K
MW1X\QEJ' XC*YW*3K38S"XVNRV1J7("T]#CJ66LJYV+%5"Q4\+,;D"P]^Z]U
MK2S+G>T>PJ@X^E>LW'O_ '?4S4](IU-+E=S9>28(T@4!4^YK/4Y 55!8V ]^
MZ]ULA['VM1['V;M;9V/8R4>V,!B<%#,5"O4#&44-(U5(!QYJIXC(_P#5F/OW
M7NE3[]U[HA7\P??G]W>H<9LRFE1:WL#/P0U$>H"1L%MMH,O7.@!U\9;[!#QI
MT.P/U%_=>Z(]\*.E8^T^STW!FZ7S[0Z]-)F\C'+'KI\GG'E<[?Q$@;T/":BG
M>JG4AU:*G\;"TH/OW7NKUO?NO=%]^4^[XME]!=E9)I_#4Y+;]1MC'Z7T325N
MZ"N"7[<@AO-3P5TD]QRJQ%A]/?NO=5D_ OJJ?>?:YWU6P$[?ZWA%>)'0^.KW
M+D8JBFPM(A( 8T48FK&*DF-X8@1:0'W[KW5W'OW7NHM=6TF,HJS(Y"HBHZ#'
MTM16UM7.XC@I:2DB>>IJ)I#PD4$,;,Q/  ]^Z]U1UE\[F?F=\F<-BS)64FSY
M,A+18JD#%#A=AX8RUV2KC&2T4&9S-+ TDC'5:JFCBU,D<8'NO=7@8O&8_"8S
M'X;$TD-!B\314N-QU#3KHIZ.AHH$IJ2EA3G3%!!&JJ/Z#W[KW55'SQ^0\.5F
MDZ1V?7++14%3!4;_ ,A2NKQ5.0IG$U'MB.525>/'3JL]9;Z5"QQ7!CE4^Z]T
MS?R[^K/XSNW</:^2I@U!M*!MO[>DD165]QY>F#9*H@<@Z9<5@Y1&WT)&04CZ
M'W[KW5O_ +]U[KWOW7NH.3R-'A\;D,OD9TI<?BZ&KR-?4R&T=/1T,$E353N3
MP$B@B9C_ (#W[KW6L_OS=>0[$WWNC=]4DSUVZ]PY#*)2W:>6%:^K=J+'0A06
M=:.G:."-1?TH /?NO=7Q?%SIV+IGJ?"X>KIA%NK.I'N+>$C >9<O70QF/%LW
M)$>#HPE-I!*&9))%_P X??NO=&,]^Z]U[W[KW7O?NO=!MV_V+C^J.M]V;[KS
M$QP>+F?&TLK$#(YNIM287'>D^0K69.:)'*@E(BSVLI]^Z]UKMX;$;K[5WW38
MN@27-;OWQN"9R[<-5Y3*U4M97U]4\:$0T\;225$\FG3%$K.>%/OW7NMA_I[J
M[!].]?X+8V"573'P^?*Y#1IFS.=JE1\IEJC^UJJ9UTQJ2?% D<0.E![]U[JK
M#^8!VV=U=@T'6>*JQ)@]@1"?++$Q,53N[)0J\ZR$7CE.&QCQPJ1S'--4(>;@
M>Z]TL_@1\?\ ^*5W^F[=5$&QV+GJ*/8-)4QDI696(O3Y#<FAP$>#%-JIZ4^H
M&J\CC2\"$^Z]T<_Y:=O_ .B#J',5N.JO!NO=.O:^U?&^FHIZRO@D^_S$=KLG
M\%QHDE1[%14F%6_6/?NO=52?#[I__2SV]C&R5+Y]J;+\.Z-Q^1-5/4M33C^#
M8>2X*/\ Q3)("\9_72PS?T]^Z]U?M[]U[KWOW7N@6^0';M#TGUEF]YS+#494
MZ,1M?'S$A,CN/(1S?8PN%L6IZ2*&6JG *EH*=PI#$>_=>ZKH^"_6];V7V5N?
MN_>SR9H[<R$LM'69 "9\GOO,EJVHR;W'C:7#4<IE TC1/50NEC&+>Z]U;CE<
MICL'C:_,Y>MI\=B\71U%?D:^KD$5-1T=)$TU143R-PD<42$D_P!![]U[K7U^
M2_>5;WIV)59N+S4^T\(LV(V;C9;JT.+$NJ;)U49L%R.:F032\7CC$<)+"(,?
M=>ZM?^%?5@ZXZ7Q.1KJ8P[A[ :+=N5+BTL5!50A=N4)^A5(<25G*, R354BG
MZ6'NO=&Z]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)7?6?;:FR-X[H4H&VWM7
M<.?4N-2!L/B*S(@NMFU(#3\BQN/?NO=:Y'6V&AWKVCL/ 9F62>GW7OS;.*RT
MTLEYIH,WGZ*ER$C22.I>>6*I<_74S'CD^_=>ZV6)IJ/'4DD]1+34%!0T[233
M3/%2TE'2T\99Y))'*0T]/!$ER20JJ/P/?NO=51_(_O//?(S<]#T%T/#4YW"U
M%<AS^:HM<=+N.>EDC8 5!"K2;/PLG[L]5+9*F559?VT1IO=>Z/)\=^@-O=";
M0.*HWBRFZ<QX*K=>Y/"(WKZN-"(J"BU*)H<+CB[B"-CJ9G>1K,Y ]U[HP/OW
M7NO>_=>ZJV_F)=M2PQ[<Z;Q4S(M7%!N[=C1M82P)//3[>Q3Z3ROW%/+5RHWT
M*4[#W[KW2%^%F.V9UCLS?WR2W_6P4M'B7J-G;9@8Q&NFJ5I:3(Y9,53321K5
MY7+&HIZ6F"%654J-1$;,P]U[HZ/QLS_<79%=NGMS?M5+@=C[LBIJ;KKKQJ9
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M&&2E#65D@IF )6=A[]U[H\'<79%!U+UMNK?E<J2MA<<W\-I') R&:K'6CPU
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*OW7NO>_=>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>timage_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M31>BU^QO^@>D/4=;= 35#Q4GQ]Z=E:)9/2O6V%?68[$W"T88+;\Z>/:Q;)V
M[G_:O_073+7BQX54/Y'_ "KTH-J];?&^NKIL?7_'SI>BFEB,]+)4]6X:6"XB
M!,+.^-LJZPX!OP /=C8./-_VK_T%U5=P5B 52G^E/_0/4:3J/I+RSP_[+ITI
M'%'5R0^9NG\.HL['F-GHA&U_P03<"]O=/HV]7_:O_072CZF+^%/V-_T#T\R=
M,]*4>#RM;3_&[I/)OAZ<5+4L?4V%C<QV0L5TX\%].IOHI(M>UK^V!"Y;3J?]
MH_Z"ZJ]XJ#"I3RP?^@>@CJH.A3*\--\9>C*93%H5GZPP,KAR3<,30CA0%X(!
MO<6]F*;.\O%F'YC_ *"Z*Y-\130HG^\G_H'IFCV#U;EIFDI.A>DHZ5M3BW3^
M"A-RQ&M?\D!DLND DV XM8>U4>U*GQ.W[1_T%U0;GXIJJ)^P_P#0/2UP?QAV
M#FYONZSJ;J#&0,"DJ?Z-,!2-'&(P2R+%CP=3-<$L+WL+_7WJ2%8EXM_QG_H+
MI9;"1^.G_C7_ $#T+F$^)W0K5$-'3]+=89=D\!JY:GK[#!5+A1ZG2E"V(:][
M@W^BFQ]E+RIZO^U?^@NCB.VIQ5?^-?\ 0/0MTOQ/^+N/I!4Y?HWI2 O&)9%G
MZXP99!>PYEHE"#\6T'GVC8LQHK/7[1_GZ6&*"-:LJ?L;_H'H%MV['^(--DI,
M3A/CQU#75RA T@ZKPT4(-R"!,N/96/TY!M];>U]O8RS =S?M7_/T1R[K;(^G
M2G^\M_T#T@8-I=!U#LJ?&?HVE2GGFC5ZOJK"52NE[!V<8U"#J_)U<"_/M8-L
MD'FW[5_Z"Z2-O"5-$2GEVGA_O/24SFV.C&>H>+H#I+'""+ZTO4V$75=G7A6H
M"26TDJP^H'T%O;\&U,U:EOVK_P!!=)IMW# 45?V'_H'I#IMWI*F,/EZ"ZJFD
M ,B@]:8>"-]5K6<4(8KJY8JEUYL#]/:Y=H(\V_:O_072%]^,9^%:?8?+\NA-
MVU4_&7'13TV5^(70U7+$L^BNEZ^P]9*7C9U5%UXQ@PUJS:F=;*2>>/:.;E^5
MFJI;_>E_Z"Z56_-$>FK(GYJ3_P ^])'.[<ZBS,ZR4/0O0>!4/(?M\5U!@7NC
M%="EWQ[^H1JP)0+=C?\ -_;\6SE0-9:OVCU_TW3+\PK<DZ%6GV'_ #=-3;-Z
M>H2D0Z)Z?F5?UU-3UCAXE>X_L@45V2_ / _VWM7^YP1@M^T?Y^J?OED^(*!]
MAI_QWI^I]H=&UD,@AZ Z9C^U;RSNW76'DX.G1R:/4FHNH/IL&XO?@IWV@^K?
MM'_076OWXA_A_8W_ $#TG*O:O1HEC$72'3]!-9QHEV!A&"FUE"Z*.TM^3_9X
M_!/M3#MN<AOVK_T%TB??R/3]C?YND7+UKTK 9?-UMUM+4A"0&VCC8U_=.H:4
M^V%_K:P!_P!;VO7:1)G2?^,_]!=)I-]9JDD_DS*/\(Z::S9G35-I>7K+J^GC
M"1C1_<S&VU.^D7#4]_0 Y('J  NHY'M4FQZ\:3_QG_H+I#/S&8U)+, /5V/\
MM1KT@ZR/H^G#3-UUUL=+Z)C'LS%L(R6TQW44X.ECRQT646//(]K8^6-?X3_Q
MG_H+HCN.=5@_']OQ_P";I+MD>F*JM6->O-BPJ2?(QV5C88?VC^E&%-&?2/H0
M"'_U7-_:D<KA>*G_ (S_ -!=%YYZ!X2?\?IZ_P /39D<;UI6$/B>N-BR('J%
M8OL^C(921I*6IFOS8$:K6_K^+C8X(?B4"OJJM_GIUJ3G65O[.23YZ"P_PZ>D
MW)M/:<\T<=+UQM.-9*D&::HVQ1Q*P4L?VB*4(+%OIY ;"UO?OW7;#R7_ )QK
M_P! ]%<O-U\YHLDV?5V_S_/K##UQCZNH5*;8VT9$D0L9&P5"D0,S:$#,8@00
MI!X)-KVO:Q4?06I75X:_\XE_Z!ZU'N^XR-AWK_S6;_H+Y]#QL'XX[%W)BJJ?
M,;=VO054;E@J;>QM4-'"KQX@Z@O',+DL +$M<LJ$=U]/'4A%'_-I?^@>A?87
M-S*OZLLH.<"1R/VUZC;E^/O66 KOMFVU@V0QFS';=#%?4?U:6B<ZOZ#^GND*
M03#X%_YQ+_T#U>ZO)DJ!/,/]N_\ T%T'K=<]84\E5$VU<0A17:"VTZ&6[+95
M+GQC0I(:Q%_I^GV9PV-N<:%_YQ+_ - ]$C;K<*?[>?\ YR/_ -!=<J387554
MYIQM;"I. CDMM:A\96,K=K^$M=BW *C^OT]W?;81^!1_S;7_ *!ZU%O<S&AN
M)S_S<?\ Z"Z5]#U+U56*\Z[8P3I&&2W]V,<[!E*.Y*& $'0C!?ZW]H)K*-#\
M"_\ .-?^@>C>WW*1US--_O;_ /073H>HNG4+_P"_+PLDT03RJFV* J&6,*6+
M> !>0I(O];VXY]M"TC/X%_YQK_T#T^=Q<_Z-,?D7<#_CW4REZOZ6M&S]8XVM
MD-2(XG.WJ (WC(U'_-6L2/P2H')87M[;DM8T_"O_ #C7_H'IU+^4?C?_ )RM
M_P!!=+.FZEZ6J]55#U)LB)P498IMNP5+60MP"\;&Y=7^I-K +92P9 \2DD!%
M_P"<:_\ 0/1DEXX74S-P_P!^,?\ G[K#5=:]0HKRGJKK6A$;,*AI-I448N+$
M/S J>H6) X%[!0;^]1V!<_#7[%1?Y]O^'IB3=_#R'>OJ)&&/]ZZ2V1VUTSCX
M0U7L[JVC#-Z?]^QBW!'T(LM(QN#]3>P_/LV@VC7QC/\ QC_H+I*_,PB^*1_^
M<C_]!=,L%-\=ZN.19-I]=11C]J2:#8U%';]=R'6CU$$QV!_)9?Z^]_U=]%/_
M !G_ *"Z8CYQC==7BO3YR/@_[UTD:RD^/2S12_W&P4PC10TL6SJ.!65K%B\1
MC!$2H)"#I4DH/5ZP ['RZ/X3_P 9_P"@NBZ7GI%;$\P^2M(1]OQ<?\E.LU*_
M3,LL]/CNE=I,JQ"2'^(;2HV:46U%G)C<+ZS(H -RP6SG])I_5P5H5/[5_P C
M=*8.=)9>T/*P_IEJ'\B2?Y=.55C=D5F.B%+TOU70/%Y!-4KM"B:5])0+Z6@)
MNCJ> .5L3[JNP0QMW \?Z/\ T%TM/,DCKVG_ (\/^?>D=5[!VKEG62JVWLVD
M&IE6+%;/QE(#X^&_S=*I:PYO<7_K?V\^UPQ_A)_WG_H+IE=^G? GD!] 'H/D
M.WIRH>EMBS$SUNV\33JI,44$N"I#>UQJ*R(K@.X4@@E=/T/U]H)8X4X+^U5;
M_H*G\NED5U<S'NGF-.%&D'^'3_EZ=FZAZRC1'BVGM<1^0*)Y<%3!O7RLB@1V
M>_\ J0;+_7VC98B::1^4:@_MH/V]',-PR"IFE)_T[?\ 077.IZTZKAEO3;-V
MU6HT4:EI<#21>I ;\"$GD_[5[]]+'_"W[5_Z"Z=_>,G^_9?][;_H+IGDZ^V2
MQ%MD[.A34%C4;=I&^@! N:?FW/Y_U_;;6T5>#?\ &?\ H+K1OV\V)^;%R3]N
M#_AX=08MD]?TDU//D-G[0EID1BT/]VZ6/4P34-3"+Z7-C[T;1&PJG_C(Q_O7
M5X]R*FI((_V_^;J-7X[JHB5DV+M!!#;0L6V:,ZK<@DO WT)(-N.![U^[_P"B
M?VK_ -!=._OA5]/V-_FZ2\^(V-65+.VT-K4D+:I1%2;3I)#86%B!#=1SP;\_
MTY]Z^A7T;_C/_0722/='.,?+XO\ -U@;:6P*B194V7B)U!)TC"04PL/]4%C4
MV]^_=VK@&_XS_P!!=*#NE?B('R[_ /H'IIR6*V-0*S1;&VNJCTLTV-IFN;?0
M(\186X_//'OW[L)\C_QG_H+IM]X5!4$?\;/_ #[T@JQ]J:M4>TMK A?]U82D
MY'/%@EP?]M?_ !]O+MBCR/\ QG_H+IH;U*YP//SU#_(.DU6)MUK"#;^&0F,E
MF7"TZ68_@<#@<?CW8V47H?Y?]!=.K>W#Y(_F>F)H,658C%8\%EXTT$"_X?A1
M[J+9!Y?X/\_2CQ)I#2I%/2HZ;YH: "W\,HSZ3>U)"/\ B1]?];W4PI_#_@_S
M]*$1^)9OV],;TU(;'^'4Z_\ !8(1_P!%>TQC''3_ (.GQ,_#N_:/\_44T-*W
M/@T?[2L<2CZ_Z_MMH%/E_@Z\ZF4US^T?Y^L+8^C4DB#5]?UQI_Q!]U,*CR/\
MO\_3BQFF:_MZCM3TXX6F4&U[*J#_ *+]MM$OH?Y?Y^E"1?,_M_V.HK+#RHAT
MM>UP%N+?\A'WK2H\O\'2M7"XX_LZASP1<$B8'U'@JO\ T5[HRCY_RZ<$H/X?
MY#_/U'$<'Y6>_P#P=?\ H_WZ@^?^K\^M^(/X?Y#KWC@_U,__ "6O_1_OV/G^
MW_9Z]X@_A_D.O>.#_4S_ /):_P#1_OV/G^W_ &>O>(/X?Y#KWC@_U,__ "6O
M_1_OV/G^W_9Z]X@_A_D.O>.#_4S_ /):_P#1_OV/G^W_ &>O>(/X?Y#KWC@_
MU,__ "6O_1_OV/G^W_9Z]X@_A_D.NQ'3?E:B_P#@Z?\ 1_O5!\_]7Y]>UC^'
M^0_S]=^.E_U-3_R6G_1_OU!\_P#5^?7M8_A_D/\ /U[QTO\ J:G_ )+3_H_W
MZ@^?^K\^O:Q_#_(?Y^O>.E_U-3_R6G_1_OU!\_\ 5^?7M8_A_D/\_7O'2_ZF
MI_Y+3_H_WZ@^?^K\^O:Q_#_(?Y^O>.E_U-3_ ,EI_P!'^_4'S_U?GU[6/X?Y
M#_/U[QTO^IJ?^2T_Z/\ ?J#Y_P"K\^O:Q_#_ "'^?KWCI?\ 4U/_ "6G_1_O
MU!\_]7Y]>UC^'^0_S]>\=+_J:G_DM/\ H_WZ@^?^K\^O:Q_#_(?Y^O>.E_U-
M3_R6G_1_OU!\_P#5^?7M8_A_D/\ /U[QTO\ J:G_ )+3_H_WZ@^?^K\^O:Q_
M#_(?Y^O>.E_U-3_R6G_1_OU!\_\ 5^?7M8_A_D/\_7O'2_ZFI_Y+3_H_WZ@^
M?^K\^O:Q_#_(?Y^O>.E_U-3_ ,EI_P!'^_4'S_U?GU[6/X?Y#_/U[QTO^IJ?
M^2T_Z/\ ?J#Y_P"K\^O:Q_#_ "'^?KWCI?\ 4U/_ "6G_1_OU!\_]7Y]>UC^
M'^0_S]>\=+_J:G_DM/\ H_WZ@^?^K\^O:Q_#_(?Y^O>.E_U-3_R6G_1_OU!\
M_P#5^?7M8_A_D/\ /U[QTO\ J:G_ )+3_H_WZ@^?^K\^O:Q_#_(?Y^O>.E_U
M-3_R6G_1_OU!\_\ 5^?7M8_A_D/\_71CI_PM1_L67_H_WO'S_;_L]>UC^'^0
MZZ\<'^IG_P"2U_Z/]^Q\_P!O^SU[Q!_#_(=>\<'^IG_Y+7_H_P!^Q\_V_P"S
MU[Q!_#_(=>\<'^IG_P"2U_Z/]^Q\_P!O^SU[6/X?Y#KWC@_U,_\ R6O_ $?[
M]CY_M_V>MZQ_#_+KWC@_U,__ "6O_1_OV/G^W_9Z]K'\/\NO>.#_ %,__):_
M]'^_8^?[?]GKVL?P_P AU[QP?ZF?_DM?^C_?L?/]O^SU[6/X?Y=>\<'^IG_Y
M+7_H_P!^Q\_V_P"SU[6/X?Y=>\<'^IG_ .2U_P"C_?L?/]O^SU[6/X?Y==:*
M<?V*C_DI3_T7[UCY_P"K\^M:Q_#_ "Z[M!_J)_\ DW_H[WNOV_R_S]>UC^'^
M775H?^.<W^W7_H[WZOV_R_S];U#T_E_L]>M#_P <YO\ ;K_Q7W[!]?Y?Y^O:
MP/+^7^SUZT/X2;_;K_T=[U@?ZA_GZWK!\OY?[/7>B/\ U+_[$K_T=[]U4Y\O
MY#KK2@^BN/\ 68'_ (GW4@#B>JBOI_J_;UWQ_4_[;_C?NF/GU?KKW7KW7O?N
MO=>]^Z]U[W[KW7)/U#W[IV$5<?:.OHV_&_\ E9]=9+X\="Y&E^5_\PO;E-7]
M+]75M/M[:?S)W/MW%4$=5@Z&1*+&8^F=*>AQ]*K"*GIXE$<,*I&@"J![@BZW
MR0RO6.W)U-DP1$G)XDK4GY]39!M4:HH#2@!10"5P *>0!QT,_P#PU-L'_O,C
M^95_Z7#NW_K[[8_?C_[ZMO\ LGB_Z!Z=_=:?QR_\Y9/^@NO?\-3;!_[S(_F5
M?^EP[M_Z^^_?OQ_]]6W_ &3Q?] ]>_=:?QR_\Y9/^@NO?\-3;!_[S(_F5?\
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MM_V3Q?\ 0/7OW6G\<O\ SED_Z"Z]_P -3;!_[S(_F5?^EP[M_P"OOOW[\?\
MWU;?]D\7_0/7OW6G\<O_ #ED_P"@NO?\-3;!_P"\R/YE7_I<.[?^OOOW[\?_
M 'U;?]D\7_0/7OW6G\<O_.63_H+KW_#4VP?^\R/YE7_I<.[?^OOOW[\?_?5M
M_P!D\7_0/7OW6G\<O_.63_H+KW_#4VP?^\R/YE7_ *7#NW_K[[]^_'_WU;?]
MD\7_ $#U[]UI_'+_ ,Y9/^@NO?\ #4VP?^\R/YE7_I<.[?\ K[[]^_'_ -]6
MW_9/%_T#U[]UI_'+_P Y9/\ H+KW_#4VP?\ O,C^95_Z7#NW_K[[]^_'_P!]
M6W_9/%_T#U[]UI_'+_SED_Z"Z]_PU-L'_O,C^95_Z7#NW_K[[]^_'_WU;?\
M9/%_T#U[]UI_'+_SED_Z"Z]_PU-L'_O,C^95_P"EP[M_Z^^_?OQ_]]6W_9/%
M_P! ]>_=:?QR_P#.63_H+KW_  U-L'_O,C^95_Z7#NW_ *^^_?OQ_P#?5M_V
M3Q?] ]>_=:?QR_\ .63_ *"Z]_PU-L'_ +S(_F5?^EP[M_Z^^_?OQ_\ ?5M_
MV3Q?] ]>_=:?QR_\Y9/^@NO?\-3;!_[S(_F5?^EP[M_Z^^_?OQ_]]6W_ &3Q
M?] ]>_=:?QR_\Y9/^@NO?\-3;!_[S(_F5?\ I<.[?^OOOW[\?_?5M_V3Q?\
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M63_H+KW_  U-L'_O,C^95_Z7#NW_ *^^_?OQ_P#?5M_V3Q?] ]>_=:?QR_\
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MO?\ #4VP?^\R/YE7_I<.[?\ K[[]^_'_ -]6W_9/%_T#U[]UI_'+_P Y9/\
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M[[]^_'_WU;?]D\7_ $#U[]UI_'+_ ,Y9/^@NO?\ #4VP?^\R/YE7_I<.[?\
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M5M_V3Q?] ]>_=:?QR_\ .63_ *"Z]_PU-L'_ +S(_F5?^EP[M_Z^^_?OQ_\
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M?4.JWS4Q1O!24]/!^R=)T Z7/U-Q]2>1?Z_X^_- JXH/V=&(OII1A: _M/\
M@Z2=;NS,UD?AEK-*,2Q$*F'AO]:X(_WGVUIT>GKPZ;:61CD'TR0?\&>DW/6S
M2+IDD9PK:O6Y?G_ '_8>VV;I4EO(.[R^1_S=0#5!?PFNW)90>/\ ;G_>?;)E
MIT816Y<"I-/M/4*6;R BPU$J1P/Q_P 3[:9M71BL9C/$T ]3UA\+N--N/Q<
M_7W0J3CI9XZQY)S]O6*2B((.EC_R2EK_ )L3_P 1[;9-/6EO!PKG\SU%^TLM
MV\CDFX$:J!Q_K_\ $<>V M>G1<$X%.'G_L=8&I78KIC$:DD%F(-_^(]T*USU
M9I]/GTWU B0L@L;']0L+V]MM0=*$9Y/GTT2$ DJ1]6X'^/\ Q3VG(Z7(A\P?
MV#J"["_Z5!N>3;VT>G*=1V8GD_C\#WKI7!I&?V]1C[9)->O,<]>]ZJ>M5/7O
M?JGKU3U[WZIZ]4]>]^J>O5/7O?JGKU3U[WZIZ]4]>]^J>O5/7O?JGKU3U[WZ
MIZ]4]>]^J>O5/7O?JGKU3U[WZIZ]4]>]^J>O5/7O?JGKU3U[WZIZ]4]>]^J>
MO5/7O?JGKU3U[WZIZ]4]>]^J>O5/7O?JGKU3U[WZIZ]4]>]^J>O5/7O?JGKU
M3U[WZIZ]4]>]^J>O5/7O?JGKU3U[WZIZ]4]>]^J>O5/7O?JGKU3U[WZIZ]4]
M>]^J>O5/7O?JGKU3U[WZIZ]4]>]^J>O5/7O?JGKU3U[WZIZ]4]>]^J>O5/7O
M?JGKU3U[WZIZ]4]>]^K7KU:]>]ZZUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]UR3]0_P!C[]T[!\8^T=?6G^+7_9,GQS_\01U%_P"\_C_>-UU_:O\ Z9O\
M)ZG^'X%^P?X.AW]L=.=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW58ORZ_[>"_RD_P#Q)GS"_P#?0;@]G6W?[BW?
M_-./_J_'T77?]M!_IW_ZM/U21_,+QN"RO\QWYUTU9EI\1EZ'MOJ:LIJVENQC
M23I7JY$>1%5G=#(K"R^HVL+_ $]RY[=C5MRD^;'_ (]U!O/9$5\Y\Z"GVZ>B
M4UV!RU1(@^[J,C)'(D1<1W)0FW /(!X-K7!^H'L>L4CR/\G^;J/9 TIJ/\O2
M>RW6^XJZ*008"IJ)'A=EE0M$S"?TE;A0S.?S9./K[O!<Z3\O3I!<[>\@KFOR
M'0*9.I?$9"=:NBK*=HRBM$D9CTLHD4G468( 3'?\<^DCV;J([C!H?EC_ "UZ
M#,@FMFH02*_/ISJMX4TE(5H8LKCZV/341U'W;31 KJ)7PJ#K\8(L6'KM>P)4
MCW[NC/!:_L_Z!Z4-O[1*%X4_I'_8Z56V.X]VTLD?^YAZE:2I_B<:5TD]1& C
M+(JB,RHQ0GQDQF10+D*P(L4T^U1JI.DC]G_0/2NTYDE4_P 7EQ;_ #GHZVS=
MY;XWOC(,E78&A;'%$ >528Y6 #@@N4/YDTV&FYT_V2S!B6+Z=B U*_ZO4=#J
MSO#>("R\?G6G[1U@S-#LZL9YY*6 9.:-DJ%CIU\;!=01@")!Z5(' ))'-_K[
M\&89U8_/_/TK-NE1P/Y#IPP,<%!#IBCD2)6@B\DT0C" \A-(4*T?^-A8V-O;
M+ZV-=7\C_GZ6(43!6O[/\W3/GL5M'(Y">MRN'JZZIIQ3+*],70&UM(NH74;
M&X/MU9F3B?\ #_GZ8E5)3A:?L_S=*S:V\(]@2*VV]JQJZZGGJ:@F42)(9)#Y
MI+/ZE<\ ,""_&D>GVFG'C8K^7$#I1]3].F!3Y@\?Y= [O;Y%YHY+)&LQ$BEJ
MB9ZJ.=&73(A"M&05#*IL?4O!^EOR32QV5)!4L/\ >1_GZ#.X;[I-*5-?XO\
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MOY='1WH.0U3C'#A^P_/SZD-W;NPI'3T46,H8J?0XBCB4ZVC%RK,0"8FY_/\
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MD\;&FAH[B=Z0*J:A*H104\A8,P!!7D_@[39)YP,8^W_8Z(9>;((#DU;/D?\
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M3R%2[<@>A0H_-_2JA;DDV']?>M-!3A_FZ7K A(+:B3C.FFH'@?E3B*\<5IU
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M_*F.@]RV H=U+304^W/[OTN39BE\A/-3O^E_3(Y;7R%(LJ,+*2 3;V;6R"
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M\6_R'J\6_P EJ1I.?D%(S_IATI\3W#V ^E8-J8QH@K"7[O(2MK1R2MV:R(R
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MC22&E,>II_@QT7SV=E;+4M4U^$:C_//2HI]F92J1GJ*F.&\:2(E/,E06N2'
ML]@4L?\ 7L?KP?;PC8\3T7-<P6XJ$%1ZT/RI_D)]>G3%8_:6-J9HJJ*3/5=-
M%-XZ?PRS!W2RR*H@)&G2Q-V#6(X]L,,T''_57J\.X>/4 4!(J-(I\O*OE_EZ
MXUV^:G[D?P;;-!B)55DD$,1D\OC"@J\,:0H#8"Y\=^+WO[3O%(YXGY?ZJ=*"
MJKDE:DTIY\*>0^7^K/21R6X=VY)VI:BIJS3JTZQ42*8PJ5#F0QBXU%+V(#,0
M/Q[;^GD4U],_ZJ]+[::V0CQ2",U6IJ0!7@""0?+I/3TE0%:6I]! *E9'#M^U
M8"X))%N+7^G^M[V4K\7^K^?2M;V(L/ CIC' _;^WA\QTU-,J?4*=5S;ZV/\
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M#B<_+/\ AZ*]PYDB5AX2,1CB0*'CY5'RSU*./H0Z)$T]7I75*Z*4!Y'(! (
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MCBWY/N3Q-/6IP,#CBOIP''I./DII#,4U()==B6N0&)'U!Y)O_3_8>VGW,N"
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M;\<BIT@#\O\ *#TQ)#-7M;6?Z1;T\J4R>LKY"E"#_(?+*D=B9JAY;-S=E5=
M ^E@3[JU[Z@FGSKTB?9;F^*B1T0!>TTTC/$8 -?GG''IM:JE$AECB*.1<651
MR!Q8<@>TKW<C&J@_L_XOI7%LEK;J$FD4DTP#P\N-14'[.L[5V4J8DA>::2(
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M"O#OW;&,V\,'A=I28Z.>&&/+5\V9CJ9JAP06?6T-XPS \*. ;7-A[0M$RFN
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M[]U[KWOW7NO>_=>Z][]U[KWOW7NN2?J'^Q]^Z=@^,?:.OK3_ !:_[)D^.?\
MX@CJ+_WG\?[QNNO[5_\ 3-_A/4_P_ OV#_!T._MCISKWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK%^77_;P7^4G
M_P"),^87_OH-P>SK;O\ <6[_ .:<?_5^/HNN_P"V@_T[_P#5I^M37^>)DJ>D
M_FU?-:"?'TM6ISO1+NTS$$B3JG80L+<K;2.;?6]OZ^\D_9JY6/9J'_?I_P"/
M=8@^\^S37V]%HSPC04H>!'KCJIRHGHIY&=*,4RL2VE&\HN3>P)5"!_MS[EOQ
M8I>('\NHG^BO+ X9O2E&'[*X_,=8U%$P!,;J2=1$1L0!_B?J3[NL,+# _8<]
M.)N5Y%\_+N4G_5^?7%J6FE \9G#:B?4]_P#;\?3_ &'MDV*2"JD\?7_/THDY
MBNX<.B'&!2E!]HZQ28MXU!;4G_!S>X/^P-O]X]LMM=.!_;TIMN="*B2(5KBA
M./Y=1FH9TL2Y16O8D,;@\BUQ;\>TYL''XL?GT]_6^V:H\*I^T=>$$BFX=>3_
M %/-O\.?>Q:2#@1^WI=:\Q6LZ&JE:'T%*_E3KQ@F96(92 M[*_\ C[VUI(1Y
M?MZ5'?;5>-?/BN.'6+PU*VM^G_@P_P"*WN/;!AE4_P"ST^MU97 U8Q]N//TZ
MZT3 &WB)/X+@'C_8>Z:) >'^#_-U<W%JU!4@?F?\HZZ*5']%_P!?4+#_ 'OW
MHK(?^+Z\D]H/(_[R:G\J==O%.O\ 8:]M0^G/^PX/T][,3CR/\NMI>6K^8 X'
MB*#CY=<=,X-EB(/-^0/=2K^0_GUL26_Q%OV@G'78CF;ZH=7_  8#G_C=_>_#
M<GY_:.MFZMD7C@^@/#\AUR,,Y#"R74<@R#\_Z_NQB<UK3]HZ:%];1T9=7R[6
MIG[/\O77BD' DB!^G^<)^G]??O#8>8_;U<;DIJ=+G_:=<EADY(E0VY))!M?\
M_P"]^[I"WD1T6W&Z0U[T<?D17_#_ *O/J7#"K#U5+1DM;TQEOI_C8>U4=L9!
M\1_9T5W&Z")NR($?,T^SA7_#^SKG]O&OJ-1.P YT0"W'U^K _P"\>W?H].=1
M/Y?[/2;]]NU?TE X_$QX9_AI_L=<+QD&QFD _)-N!_M_^)]THJ<2QZ5>-->J
M55(QQII!.?MI3]I&.I"O1*"#3SL238O+8V'T^G'/^M_L?;GB1J.!_P!7Y]%Y
ML+Z8UJN*T &*5]*?X>LL<^."R":C9KJRJ0Y^A^A))^OU'T]^#P^8Q_J^?5OI
M]QA(97R:4Q@&O#A0<//'62-\*BVF@GD;Z@*X3_87(/ _UO;G^+C%!_A_R])I
M)MU:M"?G04\_4#J9'7[>42>3'H"T8\>E9#8_XEI&'_)O^V]V#P#R'1-+=[F[
M4)8YH./'_5_J'4,/A68,7K6%V!5%5?HPN +"W!/Y/-AS^?++"_G\J?ZOMZ4"
M'<O#^#"U)_F:UK0X!_;^V3#4858BKP2HURX<0>9C:VE27;Z$GFP''];^W%,*
MD4'\NJ$[EH+2,545&"0,GC2HQ7SI^WRZ>KIS=H8C$%%S<  ?X$ :0/\ 87_J
M?:CQE/#'187D!KJ)_:<_;QZDT^4BB>(A87$<A*K)$MCSR>!<#_'C_8<^WTNH
MR*"GIQZ;N=OG;OR1\5"*C(KGYGT_9T_--55TT;-6. IUZZ=BX0.+\<@DD?7F
M_P!+^W54/PZ(M)C-)30^7^7_ "=8;82FD)J'R%3HB9GB6"RW(%M3+?T79+\_
M0VO?GWMITB&>/YGT]!TKAL9[O^P%1^0K0$_Q>="?\'ETXTFZ\+030R4.)J8#
M#412CQ1:P3'8<:_R03]03_B/:)[Y#P!_('I_^K-W?G]5@GG4N/F*&I_8.L];
MOQ9*J6KQ^'D E>0VJW$JD&Y 9%4$ '^CC^GO?CDC -/+_54],0\IJD@#R*>%
M2:>O^E K]AR/V],]3O[>,SW3)2T3+Y-'VL"1$"6]U4V)4>JW!O;VAEED? %/
M]7V]#>TY9L@M3)4_(J/\*DX_+[2>F2>/>N<B.0K9,GD("H'W4^N8:5]-B]K*
MHM]";"WM-%;W+\#3Y<#T91WFS[>P5JL *:@*@?[T?+Y?\5@QFSMPY^>6''43
MS-#%YZB1OV4"JQ&HNY M?^ER?Q]?=7VN64T)H?L/2N\YPM;=.U25%-.5QC\Z
M?+IX;KG*4A6&NR&(H9F;_-U-:!Z?U:BR(P"_ZY!_!]K(]A8#)_E3'15'[B1B
MH6($Y'QFH-!3'Y?+[.L$VUJ*B4F;/T19=/I@C:I'JY/*_P!/^"\^W3LPC%:G
M_!TPW.T\I[8UX^K&GV_9^7Y=0'QV*B,:_P 2EG+$L_@IVL ;:0 5N6(^OX!_
MK[T+)%&2?]7V ])I>8[V[.E448(/$?9EB/\ 5Y]="AQ\D#/'3Y>8V.MPOI4!
MB!9@MK&W-T!OP/ZFS6RO_%_,=(H[J2(C64##CE6R>'D?+YXZ[I\>K,OAP]1.
M2K*JR/*=7'U 6W(^OO:V0_A/YUZLNZLM:R+D<0%KQR*A:\/G_L*=-A[JJ0ZT
MNVW7P*)9@$!95:P!;4Y-@2O-AR;>W394X ?.H'^K_53I)%S+%(Q$CN:<*/0@
MX]?G\OGU*BZPWS)3"HCQC&%GDU>*6.;08 -0<)?1^KC4+M^![W]#)3C3\J]4
M_K'9:JZ*T_I 5SY\?E6E.H$/6NZZEG5*!V=#H8D&(*S\JIUJH!-QQQ];?4$>
MVI-O>E23Z=+K7FJQC;""H(--0X ?F?\ 4?R8\ELG<5!))#5XZ6*9"UXUD2H;
M]KEKB,M;2/J?H/H;'CVC.V/+6A_U?RZ.'YGM9E%!1B?AKCAZ#CPR*?8?1DGP
M]30S)#6QO#(Z*UV8 6;\W4-<?7CVW^[3$>ZO6I=]+*?"(H *"F>/I_Q8^74B
M>''0*P@G:H<R%0A5A95YU!BHY/X%OI_C;V_X$:_\7_L=(AO-U+0$G'R K04_
MU8_9U,H9\29XER>.O1^D2O2L3(.";^M@&Y'(XN/R#P=G2,4'2>Z:632VMB03
M7CBM,C/R_P WG1JJ9,8DL\M/?P2,3%#,NHJH_KI_)_I_C[1RO'%4G]G3EI!=
M;A15!J#35]N14_ZN/4..ND16,7IAY 0I:U_J1QJ!'XY^OM,+P<0,?9T<'E]V
M[6/>?/5Z^M:_\7U&^XA9O(R"3]S4WD-@2>.;6/X]M&YC8ZJ?\7TICVBXMR(M
M7E04/ 5U8KPX^O6):YHY8YJ8K',CZXREP5(^A6P%C[3-<ZC@ ?9T?6VT!0=1
M+8H:T)_;DTJ ?M ZCO53,2\[I*;VLYYX MR3>_']?;#R,<L0?MZ-8["->V,%
M?F!7S_P=1GJ2JD_Y.#8_YQM5K?T]IVF(]/S/7EL5<T&NOG0 >5,\?^+Z:I*E
MR0?-%I'((2_ZOK;CZ'VB>8GS'[.C&';T0X4G[2>/^?K":E&?]Z<M8<$ GZ\?
M0\#VV9*G)Z.H;4QIA13]G^#J#/4TIU:2[<\ZG'^] ?\ $^V7D7[>GUA(\@/2
M@XUZ@/4TYU>EK"Y"@C\?[S[89UZ>BM')K6GI7J'+5Q-;2A6PX_/T/MLN/+I:
MMBWK7J#)."";?XW/'Y_XCVPQ/ET\MHPX_P"#Y=-4M1J_' OP#_O/MHFO2M8>
MH$LE^/\ 7O\ ['VPQJ>O,M.HI-QJM<WX_P!C[H33JRKY]8R2>3[9)KTYU>1U
M+_PG=_F9=V=5=9=S;"V%UA6;&[<Z]V9V=LRKK^W,5C9Y<3OW&TV5QTD]-(PD
MIYGHZN%GC;U(Q*MR#[!UUSQ8V<KPOXFI&9&HF*J2IIW<*CH3VW*-W=1K*OAT
M=5858UHP!'X?GT'WR1_D-?S./B[UOG>W-^]#4FX^O=IXRMS6\<YUGOK#[[EQ
M-'CP'EJZS&TM6,LU)%%Y)99X*&>&GBCDEJ9(8P&+UCSG87[B-7*L2 H=2H8G
MYY'[2/ETW=\J7EFNLJ& !)T-4@#Y&A/Y ]%\^"?\L?Y7_P QO_2G_LL&W-I;
M@_T.?W(_OQ_>G>M'L_P_Z0OXQ_#/!]V1]QY/X'D->C_-Z4U?K'M?O/,%OL6C
MQ]7?JTZ5K\.FM<C^(=(]JV6;>-7@Z>S374:?%6GD?X3U8&__  F0_FOJC,O6
M_4\A5681IW5A@6('T&IU6Y^@NP']2/9'_K@;?_PS_>/]GHW_ *E7G_"_]Z/_
M $#U4=\H_AS\FOA7OREZU^4'4&Y>I-W9'''+X>ES,M'EJ/(4J.8GJ,;EL74U
MV)R444HT2-2UTPC>ROI8@$3[=NMONR%[=PX!H:5!!^88 CY8ST'[[;9]M8+.
MA4D5&00?L()'\^A7^$W\M?YB?S!<YE,;\9^J*O<V!V[6P8_=O8N>R$&U=MXF
M:IB,R0UF5JV2.2J:,*WVM+'4U>ATD,'C8/[3;OO]KL@'CM0D55%%6(K3AY#Y
MD@8-,]/[9LMQNQ_17 -"[&B@TKQ\S\@"<BN.K%^V?^$S7\TOJ[9M;O#&[*ZJ
M[=;'4<-=5[4ZF[(_BN9T-?RK!1Y:@PRUDT %VBIIII)/I LS>GV1V_/VWSL%
M)D2OXG4:?^,LQ_E]O1O-R9>1*6&AZ?A5C4_[TJC^?5!F9PV8VYF,KM[<.*R6
M"S^"R5=ALY@\S0RXNLHZS%RM!4TE733JDU/4T\R/'+%(BO&ZLCJ&!'L9HXD
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M?O5N\^P=ZT6\.M=Z;IV!NNCI.L<QD(HLELZNGQU=%'/%3M%/''54TJK(C%7
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M?4O3^+P)Z?\ 5NO\NK>]@[_V3VEL[;_8/7.Z<)O79&ZJ!,GMW=&W*^/)T=9
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M;0K-J03URPK/-!1_>I&]2::*2 S,B:$,J+J+:@J_=]EN-CD$5R%5R-6D,K$
M\*Z2:5]#GSZ*.7.9[/FN W-BS/$&*:VC>,%A2M/$520*Y(%*XK4$ U'LJZ$'
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1.>Q_G?\
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M#OUKS+:K>6;%XG+!6*LE=#%#AP"*$$9'\NJV_P#A_;^6S_S\O?O_ **7.?\
MU-[%/^MQN_\ OI?^<L?_ $%U'_\ KW<M_P#*4W_9/<?]:NCF_&+^89\/OF'D
M\CM_H'N;#[LW7B:6HKZW9N3Q.1V=E_MJ4QK)5P8_,4E#45E)&9H0\U.DL49=
M5D9'.GV1[ORU?;$ UU$44X# JRU-<:D+ '!P37SZ%G+G/.T\VEEL+A)&6I*$
M-')04JVB148KW :@"M32M<='2]D70LZ!?Y"]^]:_%[I_=_>G;V3K\/UWL?\
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M\-UA7CJ::HS>1R$/AA\I=*:.KU0-IHH(_9?L=H.:]SDDN:E0&D*YR P55XU
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MQ>2&9;O6Q;3N+AXKFW@(J&"M'I;_ &HD4 CU''SSTCVK>-RL5*RP3S#\)99
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MUM?^$ZO_ &^/^'O_ )<%_P"^LWO['W.W_),F_P";?_5V/H%\I_\ )0B_V_\
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M^*Q&2^^H98H8J!LM-)@(ZJ6C@J9LH08:J43QRS2(Z'/-6X[GN-M$+^V,8B(
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MD)'%V'9C-"Q!J*D'Q!7A7K#.3EFYYOVK<.:7UK/]2)H K4TPQ-20AJK4(K
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M*^O3T4PA_P!@=<8*%IY D,3S&Q8V/TMSSQ]/]C[\J:C0"O5I-S2)=3D#[?\
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MX;-J9IS!!19.*6HDGH7G^WAJ1!2MJBI:Y)U!NSW7]4=S=+@$(=2%J$]I(97
M\Q@5XFA.*BG0IW2W_K+8*T![L.HJ!W $%3\\D>E0,@=:_/\ +>_D+_/K?7S
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M&/PB"\<:AR/)@[$ T\P/V5IY=*/87;;F#8Y/J594FF=H0WG$T:*6 /!68-3
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MVYM^(&(6_;(B=T]-O2Q7Z$CW-'.9_P"0[8_]0O\ VC/UBW[7C_D;;M_U'_\
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MEM_IOXE8;L2MGG^[DDS6,W7L:')&6:Y\\PJTE$DO^[7#26&JP!O*$D4O,*M
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MY.6CK7Q&9H</MJACJ*B:4S4,U5+.M-&&?PK*2VW(\6T64UUO%4(IX2)(NHL
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M;]LN9CICBCLY)&H3I2.]F9C102: $T )/D.K<?\ A^#^65_S_+</_HGMW?\
MUE]@?_6ZW?\ WR/^<L7_ $'U+7^O7RU_REG_ +)[G_K3U;-M;<F(WEMG;N[\
M!4/5X'=6"Q&Y,)520/2M)29RGCJJ:1HI%62-GAE0E64,I-F ((]@N2,Q,5;B
M"0?M!IU*44@F4.O!@"/L(J.GWW3J_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW2>W=_P >IN?_ ,-[-?\ N-+[O'\0^T?X>J2?"?L/
M^#K6D_X3(_\ ,H?E3_XDCKW_ -UE=[E;W:_W*@_YI'_CYZQ[^[E_R3+K_GJ_
MZQ1],W_"?KJK9/>/P:^8'4/8^(CSNQ^Q.SY=K;EQCR- ST^3VYCT+Q2H5D@J
M('TRPRHRR13(DB,KHI%_<R[DL-SMYHCI=(E93Z$2.?/!^PX/3'L-M\6[;!>6
MLZZHY;F2-UJ157MX0<@@C!P001Q!KU2QO_J/NCXK_.+H#X==H9>KR^U>D/DY
MMC</4M7/$1#4XCM/<. G&1HF8#33Y%,9322P*2E/7"M2YD\I(ZM[VWWG;+F_
MA%'FMF68>CQ1N*>?#5@^:Z>HFO=LO>6-^L-FN6U0VU]'):L>)AN+B(UK0<3'
MD4P^NA(IU;Q_PJ"_[D>_\N7_ /F?^PC[0_\ $O\ YL?]9NI#^\K_ ,L[_J,_
M[5>C]=M?\* ?@/M;K[=&8ZOWCNWLW?\ 3X>O&TMHTO7.;VY'4U[1,*455;EJ
M*BIJ>C$^@S.'DD$88QQ2-92%[3VUW2:15E18U)&IC(C4'GA6))ZD/</?+E^V
MA=X9WE<*2D:PS*6:F!62-5&?,GH._P#A/?\ %+?O2O0G:7>O:&%RV!W1\D-Q
M[<JL!C=PPR05QP&QTK_M,C/'41K40-EJ_+9&0!R?/3Q4M1RLB$J?<K>HMQN8
M[> @I I%5IIUM2H%,$ *H^1J.D/L;RK<;'837EXK+->2*]'+:_#0-I+!LAF9
MW8\205)S@%P_DQ?]O1?YG'_AS]K?^_#J_9GSW_R2=N_YII_U93HD]HO^5AWW
M_GI?_M)N.@GZO[$F_DN_S-?D31]^[:W+#\9?DQ/F,SL[LK";9?(1+35N5DR^
M)J(5II&$ZX45V1QV2I8HC5B3Q545.L#0K.LNK4<][3;_ $K*;BV 5HBP!(TA
M#Q ^+2K*:Z>*U)&"K;]P/M)S'>G<%<65^QDCN%B9E#%VE4=A;X=<B,H!<D*X
M54.3-?,?^=]+O[<G3737\K2NK^X.W=W[]H?XKDZ_K"OBH:RF,$T4>!@H,_2X
MRN9ZFHF2>JJ_#3QTD%*SBJ5'DDC*]E]OC;++/O'Z,2)BDBE@:C-4UC' #B20
M #PZ/N9_>9;Y[>TY9_QJYEE (:&0)H"GMI)X1J202WPJJL6(&>EG_/>^1>_.
MN/A=U%\9Z_(T.7[Z^359MO#;ZBZ_QM=CH*NEV.E!4Y[^%4@FK:J&FRFX9L73
M4]++62R34LM1 34:92&/;K:X[N_DNZ:8;<,PUE30MJ":C1155#,6  !4'&.E
MGO7O\VW;/%MP.NZO62(B%774$T&30H+FCL501EB2KD5:AZ"[KO\ DQ_S ]J=
M&4G2.'_F'1[)ZMS6U\QBMP=/4.RZROQ,<6^EGES>-F3[\15D-1-6U:3,4TS!
MF-@I"A1=<];=<7/U+6.J0,I$GC$-5*!3A<$4%.DNW>U&][?8BPCW<);E'4P_
M1HZ4E+%U.J0D@EVK7C7TQTF/Y'6\MT?$WY9?*_\ EI]JUT?\4H=Q9;>FQIT5
M(*:LR>S4AI,C/3+YGDON#;AQ&1@C*LR4U#)Y620:&4^X,2;U9VV[P\&41N,D
M@&I X#X6UJ3YDBG1=[,SR\J[G?\ +5S\2.9XFH &H$4G#M37&8G5<D -J((I
MTI/^%-W_ #*'XK?^)(["_P#=90^VO:7_ '*G_P":0_X^.E/WC?\ DF6O_/5_
MUBDZV6]H_P#'J;8_\-["_P#N-%[BF3XC]I_P]9"1_"/L'^#K6#_DQ?\ ;T7^
M9Q_X<_:W_OPZOW+//?\ R2=N_P"::?\ 5E.L>/:+_E8=]_YZ7_[2;CH%NK^R
M<G_)/_F3?('&]Z[1W9+\8?DG69+*;5[!P6&DRO\ D<V4GR>&KH+5)2K;""OR
M%!DZ4$UH+"JBA*-"E4ONK0<^[3!],R_46P"M&6 /PA6X@?%I5E/P\5)J#0GL
M-Q;VBYBO?KT?Z*^8R)<+&S ,7>11VL?@\21'6A<T5PH4Y,__ #'?YTWQE[6^
M-F]_CW\1<MN;NWL_Y 82?JP-0;!SNW:?'4>\[4-=&(<MCJ"NR63K:::2EI*>
MDII5,TPD:3]M8IBKECD*\L[M+F]"PQPD2DET:I3N'PLP !%232@'1YSW[P;7
MN>W2V.UL]U/=(;=56*9:"8%">]%+-0T55!)8CRZ,#T!\4MT?$#^1[\D>OM_X
MR#"=D[O^,ORH[4["PT2 24=?N_9^2CIZ*J=21)74.(H\93U)Y"31/$C.D:NQ
M=N&\KOG,,,T9)C6XMXXR?-5D7(KP!8EA]OKT>;3RN_*7)=U:S*%F:RO99@ *
MB22"0T)!-650J$U/PXQ3H*?Y9_Q=V1\QOY*5/T)OE$AIMU[J[:GVYG=+-+B,
MWBLY538G*PZ&5RU'5A#(@8">!IJ>35%,ZE3S9NTFQ\P-<Q<4$51Y,IB4,I^T
M?LXC('2+VYY=@YKY,CL+BNB7QP"#0HZW,C*P^:L :<#P(()!I8^"=!W3L[^;
M3\3>D^]WJQO/XY[GS/2%'15C&8TN-VW2;FKJ2GAG95:IH0<G,]%*0 :)Z<1@
M1*@ \YC-M/L=S<VOP7&F8_Z=GB5L>1[>X?Q5ZB'DE;ZTYNL;'<*>)9+):K3_
M 'TD-PZ9Q44D[30'1IJ*];&/\UOYP_*_X([\^/O9.P=I[=W3\5\_E:#$]SNV
MTI<KDZ:JQV3BFJJ2/)??04V/?-865XL>TM/H6JIYB[MJ1!&')W+UGS&DT,CL
MEP%)A&H!6[3Q&DDZ6 +4-:' Q7J?/<SG+<N27M;J"))+-G"W;:"TD8UK\)$B
M %U+!2PTAP 3D U^?S&OG=_)O^2/QG[)J=L8# [\^1^?VI/%UW7X?H[+;(W)
MB\W6E7I:FOW'4XK%T[T5#4MY:R%<O51U$:R1I#4&0!A-RMRUONTW<==4<(<&
M0&9&C9!Q&@,V2,*=(()!J.( ?N#S[RES'MLX73/<F)A 1;2I*DAII/B/''15
M:C.-=&4$4:NDVF_R1NO^S>N?Y=O4.)[1H<MB,AF,KO7=FUL%G(GIZFCP6Y,C
M+48Y7BD)>*.K#2UD2D*1#4QG2+^P?S[<PW>Z3/ 05[067@650&_GBOF17J3/
M:.PN=NV"UBNPRO21@K_$J-(S(#G':00#0J" 0"*=6T>P=U)/7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW58ORZ_[>"_RD__ !)GS"_]]!N#V=;=_N+=_P#-
M./\ ZOQ]%UW_ &T'^G?_ *M/UJH_SM((W_FS?,YGIJ2J)W3TC"\-4@(*OU/U
M^+%[@I?40IO92=7O*+V.A5]E8$ TE/$5_$.L*/?R^>SWT%20#"*T-#2A/'_!
M\^JMOX?@]"ZZ6F\A2,-]O6,ERE[G2I++>XU K:Z\?7F8#9IY ?D*5_GU!3<R
MW:G#.17&0:9/RK_J^722K\%3"24T]2T=SJ$119 0?TKJ5C^>3<#CZ_T]EEQL
M_B,=& ?*E>ACMO/>@ SQ^(0!0F@(X#RK4T^0IT\46P*^LI4K($CE1I&33,12
M,RVN"@>R$_CAKW^H'MZ'8E''/J2*?Y\],7?N.5D-5*"E% HU&_,#!K]O62?9
MOBD*231TUK%_N>-)(4_6-9-0L1R" ?;TNTQK_D\NDEKSO/*>T$T%. (/F<4\
MJ\>FX[:D69@XIIX2RI%,K?MO?G@DHPM_K?7@CVG7:U).JA'V'A_+HPON=W*
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M&?D>H,D59BBPK::IB "K()Z?PNMC86NP(Y^OM.T;VV74TQDBG^7I6EC'NM!
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M)'^O8^VC-\AT^-N-*:SC/SZ:YY3-R"I=@;D*?]L+"P_V_MEFKTM5#!Y']O\
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M?S>R-)6_)WOW>G9E#C9VJ,3M25Z;;. HY&+$2TV P]/08:*H"MI\_P!D:AD
M5I6 'L[VW8[3:?[",*?-LLQ_-B3^0Q\NBF_WFYW+$SDC^$4"_L%*T\JU/0\_
M'7^<_P#S*_B=TWL[X_\ Q_\ DE_<'J/8/]X/[I;2_P!#VP=U?:?WJRM=FJ__
M "_-;6R63G\^3R5;-^]6R:/)XX]$21QJFO>5[#<96FFBU.U*G7(*T 485P.
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M6Q4F4IJJGCJXZ>JJHEF6,2+'-*@8+(X/K2^FL&+P2/&Q&DM&[(2*@TJI!I4
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M@"JH  ]L2RM.Q=R69B2S,222<DDG))\R>E<$$=JBQ1*J(BA410%5544  %
M * # '2 VIT)T7L/?6Y>T-C=+]3;,[,WG_&?[X=B;4ZYP^W<[EO[Q5D>1R'\
M2R]'1PY"N^^R$,-34>>H?S5")-)JD56"F;<KBYC6&261HUII1G9D72-(HI)
MH#04&!CHOM=CLK&=[F"W@CFDU>)*D4:2/K8.VIU4,VI@&-2:D5.>A8]HNC7K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@KSW
M1?26Z>P<%VUN?IWJO<?:NUXJ*#;79F>Z]Q&7W!CDQKRRTR4.:J*.3)4BT\E1
M.\8BJ4"-)(RV+L2LCW"XBB,"2R+&QJT8=@C$TXJ#0\!Q'D.BZ79[2XN%NY((
M6G0:4F:)#*@SA7*E@.XX!\SZGJ5FNF.GMR]A;>[;W%U1UKG^UMI4$>+VIV;F
MMBXO*[AQE-"]4Z4V/S4]+)DJ*!'KJUA'#4H@:HG(%Y9-54OIXHF@61Q&QJT8
M=@C'&2H-">T9(\AZ=;EVFTGN%NWAB:=!I29HT,J+W85R-0'>V 0.X^IZ4N\-
MF;/[#VUEMF;_ -J;:WQL_/0)2YW:F\,%2[FQM;%'(DJQU=#6Q3TM3&LL<;A9
M(F 958"X!#4,[VSB2-F5E-0RDJP/J"*$=*;FUBO8VBF19$<:61U#(P/D58$$
M?(CJ!L#K?KOJC;5-LSJW86R^M=GT515U='M38&UJ'9V-BER#F6>2*AQT%-2Q
MR3RLSR,L0+L2S$DW]VN;J6\<R3.SL:59V+,:"@J6).!TW8V$&V1"&VCCBC6N
MF.)%C05))HJ@ 5)).,DUZ +_ &0GX,?]X7_$[_TG39__ -9_9G_63<?^4JY_
MYSR_]!=$/]1MD_Z-]C_V20?]:^AYV%UEUMU7AAMWK#K[8_6^WU,97!;"VG0;
M/HP8AI4BEQ]/3P>E>!Z.!P/99<7,EVVN5V=CQ9V+$_F23T(+2RAL$$4$:1HH
M "1JJ* ,  *  !TN/;'2GI)[YV%L7L_:V4V-V5LO:?8>RLY]E_&MG[YVY1[M
MQ=9_#:B&LIONL?7PU%)4?;U=/!/'Y(6T31QR+9T5@_;W,EFXDB=D<5HR,585
M!!H5((J"1]G26]L8-RB:"YC26-J:HY$5T:A#"JL"#0@$5&" >(Z+U_LA/P8_
M[PO^)W_I.FS_ /ZS^S/^LFX_\I5S_P YY?\ H+H@_J-LG_1OL?\ LD@_ZU]"
M7UE\<OCUTKD<EF.F^B.F>I<MF:),;E\IUEU?@]AU-5312"5:>IGQ5#22SP+*
MH<([,H8!@+B_M'=[I<[@ )YI9 ,@22.X!/IJ)IT9[;L%CLQ8V=M! 6H&,,,<
M18"M*Z%6M*FE>'3YM#ICI[KW<^\-[;!ZHZUV/O/L.OJ,IO\ W=M#8N+VUD\Y
M4U51-5RU.8KZ*E@J\G/)5U%1,\E3+([2RR2$EW8EN>^GND6.61W5!1%9V94%
M **"2 * "@I@#IZTVFTV^226"&*-YCJE>.-$>5JDU=E +&K$U8DU)/F>L'9W
M1W2O=E+B:+N;J#J[MRBP$]558*D[.Z_Q._8J*6N5$GDI(\K25:4TDR1QJ[1A
M2X50Q(46W:;A/MY+0221DBA,;LA(]#I(KUK<MGM-Y4)>00SJIU*LT22A32E0
M'5@#3%1U"W5\?>A-]9_:6Z][](=0[RW3L"'&T^Q-R[JZUPVX<AA(\-,*FC3$
M5E7135&-2EJ%$L(IY(Q%( Z!6%_>X-QN+962.61%>NM5=E5ZBAU $ X-,]5N
M]EL[^2.6>"&1XB#$\D2.\9!!!0LI*D$ C21D ^70O>T?1GT$T_0?155V=#W9
M5=+=35/<U.8C!VW/USAYMSH8*/\ AR%,^U&<JNC'_P"3+:K%J?\ 9'[?I]K!
MN-PL/TXED\(\8];>&<U^&NGCGAQST6-LMF]R+PP0FX H)S$AF H5H'TZA@D<
M>!(X=![G_A1\-=UYW-;HW1\2?C)N3<VY,MD<_N+<6?Z%VKF*ZOKLQ,]15UM;
M5U&*DJ*JKJJB226::61I)9&9W9F8DJXN8+^%0B7-PJJ JJLT@  %   U  ,
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MV"@K8CZ<_7CV])I"Y_E3TZ1"&<S]E=/$Z@P'K@CC^1Z:@(A(2J.;DWN0?]Z
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M@<GNJ#_+U_R]!SK.H,FC4;V+J#^/]M_O'L,DYJ*5^?4H" "I:M !4 GA^?\
MGZR".25=+D6+7]*C\?7GW<(S\?Y#I]K](3J7@!YG _V>I24JHPM$=9X])M]/
MZ_6_X]J!;T/#/V](9]R\9<L*5_PUIY=<PQ#&XTL+CZ@#_'BQY]V!H>DC64DP
MJKFG''$_['3?,\;.3>VNY4FX^G^W]HY&5C]O1Q$DB47TP1@CKT"0,^J82.NF
MWH81<_3\@_Z_^/OT04FK5(IY8ZMN;R0I2$)JQ\0+>OIT_0)MV8K'4&LCDL0)
M;1RZ;#ZV)4GZ6X/T]F*+;28S]I\O\'0.DN=VX"B*?)1@\#YAN/3=/CJ5&?Q
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M /.KW[^JW_+Y??\ 91_T)U[^L/\ R[6G_.'_ *&Z]_P]1_X*8_DG_P#I!_\
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M_LH_Z$Z]_6'_ )=K3_G#_P!#=>_X>H_\%,?R3_\ T@__ /.KW[^JW_+Y??\
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M_H;KW_#U'_@IC^2?_P"D'_\ YU>_?U7_ .7R^_[*/^A.M_UA_P"76S_YP_\
M0W7O^'J/_!3'\D__ -(/_P#SJ]^_JO\ \OE]_P!E'_0G7OZP?\NMG_SA_P"A
MNO?\/4?^"F/Y)_\ Z0?_ /G5[U_5;_E\OO\ LH_Z$ZW_ %A_Y=;3_G#_ -#=
M>_X>H_\ !3'\D_\ ](/_ /SJ]^_JM_R^7W_91_T)U[^L/_+M:?\ .'_H;KW_
M  ]1_P""F/Y)_P#Z0?\ _G5[]_5;_E\OO^RC_H3KW]8?^7:T_P"</_0W7O\
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M .D'_P#YU>_?U6_Y?+[_ +*/^A.O?UA_Y=K3_G#_ -#=>_X>H_\ !3'\D_\
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M^_>'\S^WKW7O^&,O_!P_\];_ -."_P#YH^_>'\S^WKW7O^&,O_!P_P#/6_\
M3@O_ .:/OWA_,_MZ]U[_ (8R_P#!P_\ /6_]."__ )H^_>'\S^WKW7O^&,O_
M  </_/6_]."__FC[]X?S/[>O=>_X8R_\'#_SUO\ TX+_ /FC[]X?S/[>O=>_
MX8R_\'#_ ,];_P!."_\ YH^_>'\S^WKW7O\ AC+_ ,'#_P ];_TX+_\ FC[]
MX?S/[>O=>_X8R_\ !P_\];_TX+_^:/OWA_,_MZ]U[_AC+_P</_/6_P#3@O\
M^:/OWA_,_MZ]U[_AC+_P</\ SUO_ $X+_P#FC[]X?S/[>O=>_P"&,O\ P</_
M #UO_3@O_P":/OWA_,_MZ]U[_AC+_P '#_SUO_3@O_YH^_>'\S^WKW7O^&,O
M_!P_\];_ -."_P#YH^_>'\S^WKW7O^&,O_!P_P#/6_\ 3@O_ .:/OWA_,_MZ
M]U[_ (8R_P#!P_\ /6_]."__ )H^_>'\S^WKW7O^&,O_  </_/6_]."__FC[
M]X?S/[>O=>_X8R_\'#_SUO\ TX+_ /FC[]X?S/[>O=>_X8R_\'#_ ,];_P!.
M"_\ YH^_>'\S^WKW7O\ AC+_ ,'#_P ];_TX+_\ FC[]X?S/[>O=>_X8R_\
M!P_\];_TX+_^:/OWA_,_MZ]U[_AC+_P</_/6_P#3@O\ ^:/OWA_,_MZ]U[_A
MC+_P</\ SUO_ $X+_P#FC[]X?S/[>O=>_P"&,O\ P</_ #UO_3@O_P":/OWA
M_,_MZ]U[_AC+_P '#_SUO_3@O_YH^_>'\S^WKW7O^&,O_!P_\];_ -."_P#Y
MH^_>'\S^WKW7O^&,O_!P_P#/6_\ 3@O_ .:/OWA_,_MZ]U[_ (8R_P#!P_\
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M/[>O=>_X8R_\'#_SUO\ TX+_ /FC[]X?S/[>O=>_X8R_\'#_ ,];_P!."_\
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MUO\ TX+_ /FC[]X?S/[>O=>_X8R_\'#_ ,];_P!."_\ YH^_>'\S^WKW7O\
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M !74"JSU,67[2HDCU &5?'XC8_BZ#_>Q[33;S&U-)/[/\W2JUY*O&8F1$<<
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M>^\JO.Y#'Y1Z:6C>@@IJ,PUN9DJ'9H&#(=*^,@)$50%52PN0+W]NW][K;L-
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M/J<_['05CW#<>:1JDD*(*]H(2GRH!4@C@3_@Z;)<E$9&0F1U' 6*/5_L!86
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M:^1Z<H=XU,,BE)YT=>49O58 _P")/^VM[6#>)5\V_//^&O15+R-:2#$<?^U
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M"I=ZFX 8?FP^GT'^]>WXIE)^,C\\?X.DMQ8/;(5\%6%/PJ:FGVGI]_B%"::
MOE36>"3QQ43H9"%4?4%O2J_@<G^MA[,EN8D%-6KY4!Z!TFT7ER[/X7A\3JU,
M!P^1.3Z #]O3YC>V]UX/'Y?!8?.G&8?,MY,C1T<=)'Y=2Z+,RP^124)!TL+_
M %//M@;K0D5H/M'^;I:O)UJT2RF(ZL5[6&>&.X8X>70=_<XNDJ(*I)!)+Y1-
M8J:D:@;@L)-*F_)_I[0F6%2&R36I\_\ #3H6EIKY#&8]("A1A4P .&FI P.N
MY:_&M,]21*:AF+ETAC@4&W L&_WWX]Z>:$'4*ZOL '^'JMM!<!?#0*H&,LS&
MGGY?ZCUEH]V24+QM#)3PLLB@2W!<7O\ 2[&W)/('N\&ZF(XIG!ZJ_*(W DNS
MGCC('^#KE7;^J5.J.N,ATE2RQ ,";_1V4>WKCF%SA6Q\ATFM/;FRG8O-%D&@
M))S^0;_+TEZC<U36<L:J;]6LJP8<D?2VD<D_6W^Q]E,FYO<'))_U?+H36O+=
MK:C2JH@%*8SYGSJ>FB?(3L?&QBBL"06<AB3_ +=C[1O.2*$]&\5O$JT6IKC
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M$FJF<.S4'KY\2?\ 9Z1%5EZ9E>-VIYI@[AZA99I2==S90',6D'G])-_9/-N
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M7PITIGW2(+E6%#Z#K+/@JNHB]3P:%7C2.;"QYY_P]N/9.P\NO'F6VM:8;/\
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MTPK_ )NIHGD<DK%)&&X%K_[<_13;_6_U[^U E+>5.B^.U0'2S _D*_9Z^?\
MFZFP5,P)87!('I<:O]:Q/_%?:J.1ATGO-O@([N'J"!_@'4HSSMZIH% +6#&,
MC\#B]Q>_MTRLV2!T6+;V\>(W; X:AC)]0>N K:F+5XZ*C<!CZW])Y_UV/^]>
MZI<M'P1#]H_V>E0LX)*:I)EKY#AZ\0H_U?+KO^*US*4^PI ""0R<$?U((DM_
MMT]W;<784T)^6/\ G[_)TXNU6I;6)I:C%&H0?M&BO_&NHZ93(PR"2GB=&1[J
MT99>5'%B#<,#_C?VG%Y*N0/V5_S]/R[7;S+1V6A' TIQ]*4(ZGUNY]R5D/BF
ME<*?J)U>07-B>"0@:X_U_P"OM^7<;AUI11_M>D-IRM86K^(M&/H6Q7[,'I)R
M5E8% \CO<^M(X7'U_IP1_P G>RLW#G_+@]">W6WD-"JJWS*T'Y5_R=0Y(Z^9
M@WVE2;B]WC9N/\/;+)(QJ5.?D>E,DUO:Y9XJ'';I!'VY/^3J?1"6)&BDHIV8
MW&CQ&W)O_0-_MO;L%4P5)_+HMN&4L'CD0#UU _+R-.H.4QKB97^U>(,JJ$M8
M<?GZ<GVU=6Y4UH1\NEEI=JL9_4#$$DD?/\^FIZ- A;PREE'-KJ./SR/:,IZ#
MJRWGC&BN@/D.)_X]UU0H):F-4CU>JS%1]/\ >#^+^]PKK:E.GKB(I&3(:8XC
M_4?\/0B(E'3TKR$PP.BH%\B!KW/-^ 38?X^Q"JI"E< XX] .*XGDN!'W,M34
MJ2*>E,G/KCTZC4516U#1/343O$6!>>2)J>,6/U4MI#V']"1]/=+=Y)R-"X]2
M*#\N%>C/<;.)=2W$RH*'2JD&0BE>[+4/J:=&1V%T_FL[3XW+9/$UE909NI\.
M,H(*Z/%$K"R>2LJJB>*18L>/+;R  ,01K33J(ML[)4HUP10YH"!P]2:^OIU!
M6_\ / VUGM[52S@T5R'U>E H%2:T%:CS((Z!KN#%[2VSV#D\'L#+P[IQT%;-
M2PO3!I5!$FCQ)(MQ4%1_NQ+JQ^E[^PAO,D,,]+?(]"0<_D!_L=2YR3?76\[8
M&W &/%=65)4 FO>2?(9\^/2$R8FQ\T5'F,<<;5%%)2VE@KBX+6%P?]<7M[0R
MR!:!EI7TSC\NC>QI*&DL)&FT'N5ZC/IP\QTX0[:GKH348VFR58$9(Y6I*&29
M06&H>I8B =(/')/UO[?:S5LJ3]E/]CII=^TR,LRA /5QCRH:GU\\8Q3KD=O5
M,5DE/CT\$2Q%3SS9E9 ;W]JDVMCZ4_U?+IK^NEMJ*A6J,8S7/D1BF>N,VWF5
M8&D6E=9]7BNL?(3@WL+BQ*\'FWTO[;?;M/&F?6G7OZVQM4IKQY@L?Y?D?^*Z
M;YL901>1IJ&,V(_S+:0+<?07_P!O;VG>"-*U7]A_XOHPCWB9J /3!^(<:_;3
M]G3/5T>&<CP^6$W)*FH5>;GCD ^T<JP_AQZY'2M-ZNE;.@BGDK'_  $CJ <;
M0,^DU$R WM^\C?4<?46M_L?:?PXV/$_M'1A%N<S#N4&N?A8?/U/^#K.N(5X[
MPU$CQJI]0L?I_73?VYX (P2?V=;;=XD/Z@H?V?X>H0QS!N:QX_Z!K'\_X\_[
M;_;>VA&!Y]/'=8/(5_/_ ##_  ]=MB9 NO\ B04W8A?(5O?_ %A]/Z>_&$#\
M7\^JG>+>3&AL>>#_ ).I"XIVTG[TEN!8DG\6'&KZ?ZPY]W6('.K^?V=)_P!^
MP1U C/EQIZ_Z7KL[?KG)<M.SWL T&CZ#^I87_P!M_L?=OIF/^K_9Z5#?X" -
M*@#S&3^RAZCOAA&H%77&%2;'5)&M[7OR[V'^W]T>%5^(T_,?Y^O2;Y&3J2.I
M_P!*P_EH/6(XS&HUY<[3Z-#.3#.)GO?].E%;_>_;&E ?BQG@<],G>7;X(37R
MJ"!3UJ:=1VGVU#"Y1Z^KJROC597CID5OKJX\DK_ZWC7_ %_Z-F2)!^(G[0/\
MYZHDUR6!8J@R334QIZ>0_F>HA2:6*&55@BIJEF:(DA6(0Z6(0DN0#Q]!<\>Z
MARX\J=*DN*5U5J!Z'\OEGCTZ11TV.FJWJJBCJH*6LE@@A:2:-:H0$68+$=8A
ME%CZB+J;7OS[NFD5U'@<#U_97I&L@NZ* PJ!5ET]M?FU,CAC/^#K%DY::B2B
MDCEI*T5RO5S14CQND6MB%BMXQ(A"Z";L;7 OP?=966.E,USQ%/\ !7I-!;F:
M1J:UT4 )U5.,DYIQ]*>ORZD'<T--C:>CH=O8IY=9J*^OJX?OI966X506533Q
MHC %4)U'U:OH!KZC3P5?G7/5AMCRL2TL@X  &E/V$UK_ *ODT^6:OABD<T=-
M&\EI8J>GUL@U:;\LE_\  %OZ"X^ONK5D'D*_+Y_ET[<6Y@?2 QH =1/:<5]#
M^?1KNN/BAO??N#&XHXJW"8?RXP4E1DJ<I)5+D0VF:EADCC5Z9%4EYVE6%=0
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M_MX+_*3_ /$F?,+_ -]!N#V=;=_N+=_\TX_^K\?1==_VT'^G?_JT_6FM_/\
MED/\X7YH.(Y'B%;T&I*$\$]7;)X_'N8?;RO[M3[6_P"/'J(N:I4^ND6HU=M
M?L'502SP*H"!O)^79W3_ 'CV.]0'V_:>@H\<C'N IZ"A_P O6>.LG0@_;!U-
M@?WBWT_H#ZO]X]W$A'E_/J@M@:]U#]@Q_.G2ZQ&3IQ3>2KVG/4PEB/NHJF>
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M+AZT\L^O3O525,>OSU-1>50%J 6 ?QFU[L!K'] .5'U_I[44,?'S\^O6ZF(
MZ10>6"16I]<?L^SK%!*LCB.E^Y$K*P<B8KJ'YOR" ?\ 8_ZW]+JVKA7I4TH*
MEG"T&?AX9 _R]2J.-_XG!154,,8DE@CEU3Z4_<-B2XM8"ZF]OP?=XDJX#4R0
M#G'38,<MN9UJ: D8SCT!\^E_N/#18W)>.2AIMMSTR04<N.K/NJLF2D1(Y:CU
MP%@9I$9K@!1<Z>"/9A/;B!LT7RH:GAY\.BBPO$>+\4E<ZET+QR >\Y .14\>
M&.N%7)32TM/-2F1*XS%:A8558BOI4/'Z%9/[5U*,#];CW=Z, 5P?.G#\L#IB
MWA;6P;*4[=1.H')H>YJ_:"*>AZ4FTZ*DK*J)=Q19V:@)=Y#BRJN(XE:Y'EU
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MY7-C+;W3/!-)&S((M)*L<BLH-/M ZSEY?]DMPWRQ@O(Y[=5FB2158RZ@&4$
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MNO?\#]NG_*1:_ME_ZU=>_P!GHZZ_YY+>O_4NA_\ JSW[_@EMG_Y1KS_>8?\
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MZ_\ 4NA_^K/?O^"6V?\ Y1KS_>8?^MW7O^!^W3_E(M?VR_\ 6KKW^ST==?\
M/);U_P"I=#_]6>_?\$ML_P#RC7G^\P_];NO?\#]NG_*1:_ME_P"M77O]GHZZ
M_P">2WK_ -2Z'_ZL]^_X);9_^4:\_P!YA_ZW=>_X'[=/^4BU_;+_ -:NO?[/
M1UU_SR6]?^I=#_\ 5GOW_!+;/_RC7G^\P_\ 6[KW_ _;I_RD6O[9?^M77O\
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M\_WF'_K=U[_@?MT_Y2+7]LO_ %JZ]_L]'77_ #R6]?\ J70__5GOW_!+;/\
M\HUY_O,/_6[KW_ _;I_RD6O[9?\ K5U[_9Z.NO\ GDMZ_P#4NA_^K/?O^"6V
M?_E&O/\ >8?^MW7O^!^W3_E(M?VR_P#6KKW^ST==?\\EO7_J70__ %9[]_P2
MVS_\HUY_O,/_ %NZ]_P/VZ?\I%K^V7_K5U[_ &>CKK_GDMZ_]2Z'_P"K/?O^
M"6V?_E&O/]YA_P"MW7O^!^W3_E(M?VR_]:NO?[/1UU_SR6]?^I=#_P#5GOW_
M  2VS_\ *->?[S#_ -;NO?\  _;I_P I%K^V7_K5U[_9Z.NO^>2WK_U+H?\
MZL]^_P""6V?_ )1KS_>8?^MW7O\ @?MT_P"4BU_;+_UJZ]_L]'77_/);U_ZE
MT/\ ]6>_?\$ML_\ RC7G^\P_];NO?\#]NG_*1:_ME_ZU=>_V>CKK_GDMZ_\
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MB!=!BJ)(YB@/(4.0OX/U"@?X#VJ2[E2J*#C!K0TZ12VL!*S2Z*L:U4,NH^I
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MRW//NZW!'F3]N>O+8H>"4!XC K^SK*,^2/5KO8@6IXC:_P#K\6_V'NPN?7_
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MUYCY$,FWL/2QP4LK"5<')G5EJ=0T!XY/MQ%&%O\ 5)>2"1^?9F9K"W_ M/\
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M%HOJ IT4K3PXJT]=--9'Y<,_/H5G;]D63P"1KX?')2OH6KI!QP)XX^75+?\
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MG2;7VOA=K;FJ]O8>AS%8:/RT&,CQV(KIOML3-74=)5YC+SICY)YHV\5()8T
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MF7S%4LQCU1R%/W$5@54QDOO??[2\$F\[5+:VUP1HF#.2H/F5:,5H,E:JVGN
M. 9#;V>LMS29-IW*.XN( =4150&(\M2N=-3@-1EK@D9(,SV;V#2]>=>9S?JP
M1Y6'&4=%44=,LYA6H;)3PP0*)%60JKO.AU!#9;FUA[F'G'FE.5-JFW32)!&B
M,JUH',CJBBH#4!+C-#09ZBKE3EM^9=SBVZIC,C,&:E2@16=C0D9 4XJ,XZ*E
M2?+3LZOI8*V@Z SU;1U423TM722Y"IBD2075XY$Q;(Z,.002#^/<'P>^F\W2
M+)%L<[HP#*RF=E93D$$6Q!!\B.IAF]F]IMG,<F\0JRDAE80JRD<00;@$$>AZ
M/-CJF6LQ]#630-2S55'2U,M,U[QM.BLR&X!NA)'(!X^@]Y*6LIGB1V&DLJL5
M_A) )&:<.'6/]S$()'13J"LRAO4 D5_/J9[?Z8Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJQ?EU_P!O!?Y2?_B3/F%_[Z#<'LZV
M[_<6[_YIQ_\ 5^/HNN_[:#_3O_U:?K2T_P"%#4\4/\XOYE:G5;S]!$@ 7_YE
M?LH7Y^OU/N5.0Z#;4^UO^/'J+.8HO%O9?EI_XZ.J9J?)TT+:E9B?\88V_(_)
M1O\ >_8R20)T'A$5.?\ ":_R(Z>8]T"(%_)3DD:566F@/']"#$2/]L/:E;S3
M_P 4/\W34MK#-A@P-<E6<?LHPZER;[L$62IB:-;*55(X?]OHC7Z>W#N1]?\
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M/M]N>Y;=M0*QVT22H409E*6TS N3Q[A4 4%:$U(!Z'CXT_\ ,C>O/^U56?\
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M2_\ PHI663^<C\R#'PNOH F__B,=E_[S[D[D8?[KT^UO^/'J,]\_W.F^Q/\
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M3J=E-V9*O_1N(-$A @ITF-,J@@*RA5TKR+7XY_I[M-N#N</^S'^#I'8[9#;
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M5K?91QA(,CC,+!@<;%#5I*R325%='3Z80)J@4\E\NO:VTQN5*F<:-)%'6.C
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M:@'C3@?3K('V8WFSVNSW%;J>&$N(] EE2,O1)@=(=A7B.'J.L7S8VANS=?\
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MJ&GDGFCK*=&F@B%;"[I/23'_ #?H9UUJ=3A$,[\^_P!8+W:(;G96:&Y 22:
M)&7=60%D'C(2&1OP]I(J,M0=0QR4-CM-TEM]V59;<L\<,Q=PBE7(5CX3 %77
M\60#0X%3T6W?^\>X?D'@<'UG1=1;AVG4U&3H*O<V<S5-54E&IH05-VGI(1!
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M>]^Z]U[W[KW7)/U#_8^_=.P?&/M'6^_M#_CQ^OO_ !''7?\ [I*#WQ*]VO\
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ME?R2,97\F6/7NMCAE# JP#*P*LK"X(/U!'Y!]N]>ZUW_ .0]BL=UOVI_.+Z
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M$BH%16/.<O;G<.20LESH>)SI66(DH'I72VI5(- 2*BA -":&F'_3MA?]-?\
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MZ;=2O'KBHOJ.F]N?H?\ BOOQZH>O  D#21_KD^V]1ZK^?6<(O T7^G/^O[N
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M[W[KW7O?NO=!WV]_S*;M#_Q'>]?_ '6U/L)\^_\ )"W'_G@O/^T>3H3<E?\
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MIE=R0HT$=1_"ONF20L0-1JYYE@C4^IX(R]M"M:!K6Y7W'YYBOMN4FVL442W
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M_'T77?\ ;0?Z=_\ JT_6C_\ \*02/^'EOF&OYT=!+_[#/9ON0.413;D^T_\
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MD:QYG8,6,%PU :Y1C@#C2N,#*GY&G0E_RP_C_P#+O ?SM>E/CE\W-\2Y6?\
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M\T-B]3;;J\=-,E1-@NI(Z7,S+.\8C$<1J\!N*G=&=XWBG*,+S%1ZX_Q_?HU
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MM(9,A5[+WKT[E-P96A21_!3Y'9^2QOV60D2^@'PUU92ZM 9FJ4!8A4"K=O\
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MR7WOZ;D^I''[!_J^WH4^W4HDVI/B)65TJ,@#X\XX]WKP/5+K20J;WN?\.?\
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M(:O'#&6S(#4%VHU!@<-6/*M>E+;E9[=%)!:>(QEHKRN!A"*'2*K4BIXA<^=
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M>MIL,M8VVJ;O_;K[O-)',ZHLN#SR4+U9C)5:3[IM%Y4*?</3 ,LAC#/[J^A
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M&:]S;BY4$8(X'_(>G.5.:)N3KI]2ZD;LECQ6JDBHKC4,_(BH]"-4O>W\E?\
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M(1B#W'@0.NNOMU>PIL5@&D0$6L-064$=@^?2B_@>:_YT^4_\]\O_ $9[C_\
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M?\_7OX'FO^=/E/\ SWR_]&>_?NFZ_P!\R_\ .-_\W7OKX/\ ?D?^]K_GZ]_
M\U_SI\I_Y[Y?^C/?OW3=?[YE_P"<;_YNO?7P?[\C_P![7_/U[^!YK_G3Y3_S
MWR_]&>_?NFZ_WS+_ ,XW_P W7OKX/]^1_P"]K_GZ]_ \U_SI\I_Y[Y?^C/?O
MW3=?[YE_YQO_ )NO?7P?[\C_ -[7_/U[^!YK_G3Y3_SWR_\ 1GOW[INO]\R_
M\XW_ ,W7OKX/]^1_[VO^?KW\#S7_ #I\I_Y[Y?\ HSW[]TW7^^9?^<;_ .;K
MWU\'^_(_][7_ #]>_@>:_P"=/E/_ #WR_P#1GOW[INO]\R_\XW_S=>^O@_WY
M'_O:_P"?KW\#S7_.GRG_ )[Y?^C/?OW3=?[YE_YQO_FZ]]?!_OR/_>U_S]>_
M@>:_YT^4_P#/?+_T9[]^Z;K_ 'S+_P XW_S=>^O@_P!^1_[VO^?KW\#S7_.G
MRG_GOE_Z,]^_=-U_OF7_ )QO_FZ]]?!_OR/_ 'M?\_7OX'FO^=/E/_/?+_T9
M[]^Z;K_?,O\ SC?_ #=>^O@_WY'_ +VO^?KW\#S7_.GRG_GOE_Z,]^_=-U_O
MF7_G&_\ FZ]]?!_OR/\ WM?\_7OX'FO^=/E/_/?+_P!&>_?NFZ_WS+_SC?\
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M \U_SI\I_P">^7_HSW[]TW7^^9?^<;_YNO?7P?[\C_WM?\_7OX'FO^=/E/\
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MH&%7;T)&@<>X8ZLJI:6FH::GHJ*G@I*.D@BIJ6EIHE@CCC@4*D<:* J(B@
M   6'O,"&%+9%CC4*J@*JJ %50*  #  & !UBS+*T[%W)9F)9F8DLS$U)).2
M2<DGK/[<Z;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JL7Y=?]O!?Y2?_ (DSYA?^
M^@W![.MN_P!Q;O\ YIQ_]7X^BZ[_ +:#_3O_ -6GZT>?^%(+$?SF/F%_C'T
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M! (.?D>D@U0+\)<#\EO:>>Z ;MX=+O I\5*^=.L;5( _1;G\&_M,]R6'5T@
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MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZY)^H?['W[IV#XQ]HZ^M/\6O\
MLF3XY_\ B".HO_>?Q_O&ZZ_M7_TS?X3U/\/P+]@_P=#O[8Z<Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJQ?EU_
MV\%_E)_^),^87_OH-P>SK;O]Q;O_ )IQ_P#5^/HNN_[:#_3O_P!6GZT=_P#A
M2+_V^:^8(_YM_'[_ -]GLWV-N5<;?']I_P"/=1_O(_QQ_P O\ ZHY]B#I!UX
M&W(X/^''T]^ZT0#UW<GZD^_=>  ZZ]^ZWU[W[KW7O?NM5IU[W[KU:]>][H>K
M4/7O:A*4R/Y=4\-CU[WYJ'@.G(T(X]<22#Z=5_\ >/:23!ZH16M?4]<OK]?K
M[>05ZM$H_P!0IUX^_.OIUZ52,CKB2VKECI/]3Q[0MPZH .N0!)L![;6V,GF1
MU8$>@_9UE^ECZB0+6M[?CM?"S_J/33*>/7$LM[G2.#Q;\^WKB:BT&/6F/+KQ
M!I@9J/\ +U8A_*<VAMW?'\PWXOX/<W@?&TV^:O<T,4\2SJ]9L[&9',8]=+A@
M2V1H:4#CC@BQ /NNW.)7 .<_Y*= SW!GDBVB70"I+QJS+4$HSH",>1!H?(@D
M'!ZV:/\ A0'F]W8GX#Q46VHYGQ&X^\.N<+OTQWTKB8*;+Y"$RG4 L?\ ':#"
MBY# .5XO9E.=^8K!BN6 -,8H>HK]J+=;G=3J-"L$K(?/55 :?/2S?E7K2(\K
M,;E@2/Z\?3_#\?CV$T'@XK4?Y>LA?"$?P"H/ D5_U9ZLM_D][8CW?_,<^,]!
M/!)44V'W#NC=TA6(R+')LW 97)TLKW%@$K:6GLWU5K,I# 'V:;=%XTBGYU/V
M ]!/W N6VS:Y'+$,Y$8'F=5:CUX G\NK_P#_ (46YW<N.^)/5&'QM34T^V]Q
M=ZXZFW.L),:3MCL)F*J@IYF'U3S1R3*A_5) C#U(OLSY@#-&JC@6S^P]1A[2
M(OUTKGXTBJORK(@)'\A7Y^G6F:68$F-G0E2"P8CZ_P!/I[#+"F>LA]-1W9^W
M/5^G_"=WLG(;=^8F^NNVJ3_".S.E\^9:-Z@HC5VRZVAKZ698[V>:*D_B* E2
M5260J0/(":[(Y\<U8_#@5Q4L!_EZBKW;M=5E%**$B4J:Y(4QN^/3*CY?X>CR
M?\*3<[NVFZR^+&VJ.&1MAY;?G9&>W),(R57+[<Q^,I\(A8.+,]'E,^P'C-]!
M.I=-F--ZDTA%\CJ_:*=!WV=B4RW;_C$<2CUT,S%OYJE?MZU*?)&#<"Q-KFY_
ML_3_ &WLB#4X=3>4)X^E/R].MAW_ (3K=D;QQ?R<[3ZJI*RODV%NWI[);OR^
M'^XD>GBR6T<GBH**O\.OQ)(8,G5P&3QZV#JFJRD>S399];%<_$?/T_U?RZB'
MW7M5>WBG+'4LC+0_BU 5\OPZ1YUH3Z]#C_PI0S^Z4R?Q0VM]S5P[*J:#M?<*
MT<;LD-1E*"3!TQED .F26BI*I5C)6\8JI0I_=8>][\Y4H/*AI]N*_P"3IGV=
MA4BY< %ZQ@^H6CG'VD&OK0>G6KC8$@AR #>P_P /Z\6/L/PG437Y]32@*R4*
M@XIGRK^76T!_PFVWYN./=7R?ZL99ZC:4VW-A]@+.S22Q4V2HZB?'!8KWBC-?
M255VYU2+1Q'G0P00[!+J#K3@13TIG_,.H3]WK4'Z>8Z0WZB4  +!6 !)P<9^
M6?L/0,_\*-.Q<WD_E'TSUA]_Y-K[,Z-I=W4^/59%$65WYG,Q35LCW/C<O18/
M$Z;*"HU78ZK*FY@D.L*"<+P^9)_S#HX]GX!#932C!DE*,:_$B(A /RJ[8/6O
M&K!F/U!_K?\ U-O\/I[* P>+2?3J62P3 'J /($^8^8ZVFO^$V_8.[JFI^3?
M65169*LV/0477^],923U,L]-C\C62Y&DJ? C$Q0R9.!8FDTA3)]FA.K1P?<O
M3%ET4P!7^=.H*]X+&.&6*7&LBC<*MQXXKCYG@1Z=$-_GZ[0I=M_S LKEZ:@-
M!)OSJ/KG=M7.(DB%7+3K584U **I<B/#10ZG+->)EU:0JJ@WLF&>O\5/\%/\
MG0Q]K[AGV=">Y4GDCIDZ:]__ #_7\QU2KJ9KIS9E_)M] ./];V2D--7)P>''
MJ0O!6(!@:N#P_BK7\_EUM^?\)O\ L/=&9Z+^0?6>1,T^T]B=D;8W-MBHF+OX
MZCL"AJH\E31LW A7^"T4JHM@KS2MSY+D7<O5$9!_B_U?X>L?/=V#P[Z-B "T
M0) P!EA_/'[.J./YR-#B\;_,G^3\&(T"DFS/7M?((T"C[K)[/V[45U[*MV-=
M)47-N3>Y8W))=V53<.* TH?S(J?Y]2C[>Z[G:+8-^%)/G@2R ?R ZK'-QZ;(
M0/P5O_Q/LM":\BOY=#620LU>N# D<!%Y^JKI]V":,DG\^J@U\NN@"#ZF_P!Y
M][J.K==>3_#_ 'GVYI'KT[X+==JURW' 7CG\^TTYT\#TXD>GC3KF.=%KGCZ7
M_P!?W2(D^9ZTX K_ *O3KGH)^L;'_87_ .(]K%0^O2>M>O:%%B;B_P!>?Z_[
M#VZA-:=-Z\]=,%%M)O\ U_WUA[5Q5S7JK-JZD$6DM] --A[W_F_R#K39ZSJ
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M*RQ2SP3LW]@NXJ&!&H?"?+/D:5Z,.4.;)>3IWCE0M$QI)'P8,M0&6OF*D4-
M1BHP1K/T7\AC^8?7;T;:M1L[K;$X)?(5[)R'9V.EP;6**+04IJ=Q@L&+#_<
M.%8,0=(8.1[-<&3*A1ZZ@0?V$'^74P)[G[1 GBZW9A7L$;!R34^8T"G#X_\
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M%'NO(38ZGVSOW"O#1R5IJMT[+KMN4["-XT\:3U421O,3("$!U%5=@+*??NO
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MBJ8X3%)"?J'#:2.;V]^ZUJ^WI9[ASD6W,5/EIL=F\K' \"&BV]B)LY5-YW"
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M?4J)B _/T4D>[Q^722/XV^SJ6/J/]<>]]*?+\NI4?)XYX]J!GJB8ZE("2+W
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MWM?FH%C&/*C$?;C_ %?GTE]E(8F2[<T\0&(?,*1)3]IK7[!UJT!E+>DEA?\
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MS3M^M7&,_P";_8ZE#9-JL=IMUDL5C130^)&:EJ5&6J2W$\2:5-,8Z+-)J9F
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MKI52*\1C_":_R_;U.*>[6TO#XC"99*9CT YIP#!M)SP)I\Z=;#OP ^"?4_\
M*^Z,WGO+LK>VTJO?V4QISG<G<=:#@L908[%_NQ8F@EK'\D6*HY&9C(ZQ35U0
MRRO#':GIH!!8V2;6A9R*\6/ #_5_/TZA[FKF.;G>\1;>-P/@BB!+,Q)R2% &
MHT'D: 4U$"O0K?*OXT="_P TCXKX2BQ&]J*MP&X(H=^])]R[8I_XHM#7(DM.
ME2*>4TTE31R_O4N0H9'IY?2\9:FJX$DAO=6T>[Q"A^:MZ'_-Z])=BWJZY&OB
MQ7([)8B:!EKD5S1@1@T-#4$4J.M8[*_\)^/G90[LEP6+FZ<S6!->\$&^1ON6
M@I&IR[".HDHY:(Y*!A'I,D:4DQ#&R.X&KV&#R[<!J K3U\O\-?Y=32/=S;0H
MD_6K0'P_#&JHXC5JTFIX&HQY>76QG\*_B7TW_*E^,N]LWO\ ["QKY3(1T^]>
M[NSLFW\.H6DPL4L=#C<53LHG:DHUGEBI8RKU==5SRR+&C5$-' (K"S3:(BTC
M"O%VS3[ /]1)\O+J(.9-\N.?K]1!$PJ=,40.MA4U))H!QR30!1Q-!7IY^:WP
MYZ/_ )I'QUV?D-N;XQ*9""EGWCT9W3MZ!,]3Q#.1HE33S1AX99\9D1!%'5P"
M6*>&>"-R%FIC$=[A8IO,(TFAXHWI7U^1_P!G[6^4N:9N2;QF*B1-1CFBJ,E&
M*FAR R,".!S4'Y:UG_0/O\\CN]=O^3I@;?-<:<[[_P!(,OV(A//G-*,;_%CP
M/T#&EM1 MIN_L+KR[=J-&I:5!U>6/YY^SJ9O]=K:D0R?K,2*B,QT8&O"NHK3
MUS\_EUL#?&OX3_#7^4WTQE>Z>S<[MRIWQA,&DG8/?V]*3]\R6D88W;./9JJ6
M@CG=FCAI:,2U]>VA9I*@K#'"*(+:':(];D"@RQ_R?S^9ZB+>.8]PY[N1;P*X
M1CV6Z'M\LM0*#]I  \J=%<K?^%''Q9@W:,;1=,=X5^S5JYZ:;=>C"4U45C=4
M2>'%MDRKPR>M@'R,4JKIU1!F*H7_ -:82U K4^=*_L%?\/0C3V9OW0_K0^*!
M7P^_A2OQ:1G_ &M/GU8#V5U%\+_YM'QTI<_05F!WKA\G15E-LOM3;M,M)N+:
M^42-6:!_*D=72U%,\D35.-JU\,Z&.0QLCT\_LSEA@WB,^?$!J=RG_-_AZ!VT
M[U?\B7I"FA1AXL+=T;XX,,BM#AAD>1IUK6[\_P"$^?S=V_NVHPNR<EU/V%M(
MU9CQN\UW:=JLU/(UEDK<;6P-44TRJ;O%#+6(MB$FE-B0DW+5U$65"K \"3P_
M;G]G4U6_NUM4X,THF1R*F'1J ;T5@U/L-%^P=7M_RU?Y;&S/Y;.R-^=M]Q;_
M -J9WMC/[=5-Z[Z65L-@-LX'%K'556/HJRO,$DL$E5"L]773PTHE$--&E- (
M7>H$VU;8-JCK(06IW-P4 ?;U$O./-TO.L\<4$;!%.F)*5D<M3B%)%:C %?M/
M6K/_ #4?F11?-7Y8;DW[M26K'5^R<32];=8+4AZ9JC&82:IFFRLD!<^(Y6OJ
M:J=-4:2BF-+#,JR1, "]XOAN4Q8?",+Y8'G^VO607M_R_P#U:V]89 /$=C+*
M13#L -(/GI50/2M2./5;I+ ?6XN+'V6$ZC0]"THJF@ZXZV_K_O'OV@=;ZZN3
M]2?=NMUKUU[]UKKF2?$!_M3C_DT^W4'GUNO7<7^;7_8_[V?=^F'X]9S^@?Z_
M_%?;J<.DO6<?I;_8>WY.K#@>N2_YR3_D#_>O;@QTV_#K)[>4UZ9ZR)]#_P %
MD_WKW=>/5%-?VGKFOZ%_UV]N,:?ZOMZVQIUDUG_#V\JUZ2:SUE]OIQZ:?AUR
M'_!2?\?;^DGI.=/GUD7\^FWMR-#7/52%;'7+VJ IUM4"<.LD?Y_V'NDG34_E
M^?4F/Z2?\$/N\?ETDC^-OLZF+]1_K^[J,5Z4$T'Y=.$(L /]I'M3'GIE?+J8
MGZ?]B;>W>GR:=2H5!X_ )/MQ14=-**GJ4HN?^)]^/<>K'N/69?I_K$C_ &WO
M3'RZK7R^WKOW3K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7)?U#W[IV#XU^
MT=?4I^/?R<Z<VO\ '_HC;N9W%6TV6PW2O5./R$"8"NJ DM-@,>KJ'2!D< _D
M,0?P?>#V_P#O'R_LE]/:7-PRRQ2NCJ()FHP8U%5C(/Y'K,79_:C?-VM8KF"!
M6CEC5T)FB!*L 0:%P1^?0O?[-UT3_P ]17_^@UD/_J;V4?Z^_+/_ "E/_P!D
M]Q_UKZ,O]9?F'_E'3_G/#_T'U[_9NNB?^>HK_P#T&LA_]3>_?Z^_+/\ RE/_
M -D]Q_UKZ]_K+\P_\HZ?\YX?^@^O?[-UT3_SU%?_ .@UD/\ ZF]^_P!??EG_
M )2G_P"R>X_ZU]>_UE^8?^4=/^<\/_0?7O\ 9NNB?^>HK_\ T&LA_P#4WOW^
MOORS_P I3_\ 9/<?]:^O?ZR_,/\ RCI_SGA_Z#Z]_LW71/\ SU%?_P"@UD/_
M *F]^_U]^6?^4I_^R>X_ZU]>_P!9?F'_ )1T_P"<\/\ T'U[_9NNB?\ GJ*_
M_P!!K(?_ %-[]_K[\L_\I3_]D]Q_UKZ]_K+\P_\ *.G_ #GA_P"@^O?[-UT3
M_P ]17_^@UD/_J;W[_7WY9_Y2G_[)[C_ *U]>_UE^8?^4=/^<\/_ $'U[_9N
MNB?^>HK_ /T&LA_]3>_?Z^_+/_*4_P#V3W'_ %KZ]_K+\P_\HZ?\YX?^@^O?
M[-UT3_SU%?\ ^@UD/_J;W[_7WY9_Y2G_ .R>X_ZU]>_UE^8?^4=/^<\/_0?7
MO]FZZ)_YZBO_ /0:R'_U-[]_K[\L_P#*4_\ V3W'_6OKW^LOS#_RCI_SGA_Z
M#Z]_LW71/_/45_\ Z#60_P#J;W[_ %]^6?\ E*?_ +)[C_K7U[_67YA_Y1T_
MYSP_]!]>_P!FZZ)_YZBO_P#0:R'_ -3>_?Z^_+/_ "E/_P!D]Q_UKZ]_K+\P
M_P#*.G_.>'_H/KW^S==$_P#/45__ *#60_\ J;W[_7WY9_Y2G_[)[C_K7U[_
M %E^8?\ E'3_ )SP_P#0?7O]FZZ)_P">HK__ $&LA_\ 4WOW^OORS_RE/_V3
MW'_6OKW^LOS#_P HZ?\ .>'_ *#Z]_LW71/_ #U%?_Z#60_^IO?O]??EG_E*
M?_LGN/\ K7U[_67YA_Y1T_YSP_\ 0?7O]FZZ)_YZBO\ _0:R'_U-[]_K[\L_
M\I3_ /9/<?\ 6OKW^LOS#_RCI_SGA_Z#Z]_LW71/_/45_P#Z#60_^IO?O]??
MEG_E*?\ [)[C_K7U[_67YA_Y1T_YSP_]!]>_V;KHG_GJ*_\ ]!K(?_4WOW^O
MORS_ ,I3_P#9/<?]:^O?ZR_,/_*.G_.>'_H/KW^S==$_\]17_P#H-9#_ .IO
M?O\ 7WY9_P"4I_\ LGN/^M?7O]9?F'_E'3_G/#_T'U[_ &;KHG_GJ*__ -!K
M(?\ U-[]_K[\L_\ *4__ &3W'_6OKW^LOS#_ ,HZ?\YX?^@^O?[-UT3_ ,]1
M7_\ H-9#_P"IO?O]??EG_E*?_LGN/^M?7O\ 67YA_P"4=/\ G/#_ -!]>_V;
MKHG_ )ZBO_\ 0:R'_P!3>_?Z^_+/_*4__9/<?]:^O?ZR_,/_ "CI_P YX?\
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M*G<-2U;N;/&+R0X;"XR2(Y/+5!X 2D@<^-2?WJAH:= 7D52HM+=KF0*OS/\
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MX=>ZY1?YM?\ 8_[V?=NF7X]9S^@?Z_\ Q7VZG#I+UG'Z6_V'M^3JPX'KDO\
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M+O3_ /+M^+'S5^:&[N[NN<3VUT9\=-T[UW1B=TYO<-+_ 'C[?VO09:6&FQ>
MV[F,A#3S5<M5XP(&CB0!7D'!(3EYEW6YOI;6UTL5DE55TH.U&(XL0. ]>A+%
ML6W06<=Q< @&.,LVISW,H\EKYGTZG=8?R9OY!7SI.?ZX^%OR_P"R:CMO#[;D
MWC%%M[L"'<%5#1*T=*:NLP.X=O4=178ZGJ:JE%2M-/2S12/ DE1#Y0LE)>:=
MYVFCW,0T$Z>^/2*\<%2,T!I6OG@TZO'R]M>X]D#]PSV2:C3AP:N,BOY9ZH+^
M*W\M[#3?SCMK_P MWY029#*X#&=H]C[#WKD=DY0[?FR%+MS;&9SF)R-!.R5#
MTL61CIL=5*CHSK%*8GL^JPSW'?F;:C?6_:2JD5%:$R*C#/&F1_/H*V.SJNXB
MSG[@"P-"14:"P..'D?Y=*_\ F7?RQ<;U5_-*I?@3\(-G;WW;+NO =6R;/V_G
M<NVY:P5>[Z!:FOJJRN6GB6GQE&!)45$\D8BI::.265Q&A(9V#F$S;>UY>,!I
M9@2 !4"E !YDUH/7I[>=C$=ZMM:J>Y5-"2:5)J236@%,]69?-O\ E4?RK/Y4
M_P /-E9;Y5;D[,[U^:6[=M5D6V=@;![)_N519W-NSM-5I1"@GJ<7M'"O+%#+
M6S$S57C"Q(*JH\,1!M?,.Y<Q73+;:8X0:DE VA?M/%C3 ]?0"H.=PV7;]CMP
M9P7D(H &*EV^P'"CS/D/4G.N1\#OB]FOF=\O^@?C5AXZKP=G]A8?';IK:-S%
M)1;?Q9:OW%7H_CD5)*+"4M?-'J0AI51#^H>QYO6XC:K62<\54Z?FYPO\R*_*
MO0.VBQ.XW*1>18:O]*,GA\N'SIULL?SL_P"09\</AQ\.*CY+_$6G[';(=9[[
MVW#VYB]Z[Q;=R-MS=C'&I6TL<=!&T530YFIQ.O4ZQ_:SSRNP,**X#Y4YPN-Q
MNA!=,I#J=!"A>\9SPX@$>>:=#'F/EF&SMC+;J05(+59F[3CY\"0?+%>M._W*
M'4>=2:*BK,E64F.QU)4U^0KZF"BH:&B@>JFFFJG"1111(&>261V5555+,Q
M)/O3,$!)- ,DG  '6U4N0 "230 9))ZW3=G?R,OY5GPTZS^/&V/YHGR!WA1_
M)SY19.DVOM?"[6W-5[>P]#F*PT?EH,9'CL173?;8F:NHZ2KS&7G3'R3S1MXJ
M02QH(GFYNW'='D>P0"*(:C50QTYRU3Q-"0JYH#QH3U),/+5CMZ1I>-620T'<
MP&KT6E,#A4\2?*H'5%?\X/\ E4Y[^6;\D=J=<;4W!G>S>INY<349[I+<.2HH
MWS4YQ]1#1UV$R,-%#%!4Y:@J*FD_<IJ:..IBJJ=TABD9X8QARQS&-]@9Y $>
M/^TIA:$$@BI-!@\3BG'H+\P;"=HE54)99/@KEJB@(P!4Y%*#SIU>IL[^1E_*
ML^&G6?QXVQ_-$^0.\*/Y.?*+)TFU]KX7:VYJO;V'H<Q6&C\M!C(\=B*Z;[;$
MS5U'25>8R\Z8^2>:-O%2"6- #YN;MQW1Y'L$ BB&HU4,=.<M4\30D*N: \:$
M]"B'EJQV](TO&K)(:#N8#5Z+2F!PJ>)/E4#JDC^:U_*&WC_+]^7'67177.>R
MG:'7_P CIZ"+X^9[/"GHLI45=9D*7%3X/+-!'3T;9&AKJZA#5$,,4$T-5!*(
MX6,D48MY=YG7=[:2:4!6A!,@6M*4+5%23P!Q4\.@WO?+QVV=(XSJ64T35QK4
M"AH /,9IY_+J[7<'\F?^2U_+RV;TYL[^9I\F=^57?7=E-X:.JPF4RNW\+2U"
M-2PU<]#38/"U\N/PV/JIUA.2S58()=3S,D*H\< 27FC=MZ=VL8P$CR0 K&F:
M5+'+&G!17T'0D;E[;=I5%NW)9S0$E@*XK0+P ]6P*Y/5/'\[/^45C/Y8^_NL
M=R]4;YS?8_QU[UIMPR;$R^YVI:K*XJOVV*2:HQ>0JZ&&GHJ^*:DKZ:>BJXZ:
M#SH)T:$&G\LPIY3YF._*Z2@+(E"=-:,IQ6AK0@C/VBG0>YEV ;.5>,DQO49I
M52,TKBH(X?9GJC+V,.@MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1R/Y=.)Q6>_F#?!3!9W&8_-83-
M?,CXQ8G,8?+4<>1I:NER.]L'#44U33S*\,]//"[I)&Z,CHQ5@5)'LKWPE;*X
M(P1!+0_\VVZ,-H%;N$'_ '['_P ?7K8U_G=]6=8;/_GN?RW=E[1ZXV'M;9VX
M-M_#V3/;3VYM#'X3&5K97N/=E)5-5T%-3Q4M2:FEBBAE,D3&2)%C>Z*  +RK
M*[[-=,6)(,]"221^@G0QYA15W6V   _1Q3_AS=!=_P *M>M.N.L_DS\7,?UQ
MU_LGK^@R716X*S(T6R-J4&U(:B:+<%2BRSQT$%.DLBIZ0S*6"\ V]O>W,K2Q
M3:B3WIQ)/D?7IOGI%1X: #M?@*>:]:J?N2.@%U[W[KW6SY_)4_DM;0[\P757
MSZ^7O9W7^U_BQ'V#2X_8?6]1F!!D-VY_";@DP=)B\Q)51PT=%CJO/004\5)#
M-55F6+FF6.F$B/+'O-O-36A>RMU8RZ>]Z852H;MI4DZ3DFFGY\0..6>71<!+
MN9AHKV+7)8,5[JT%*C %:^?H1"_X5D;-VALWY._%BDV?M7;>U*6LZ'W%45=-
MMO!TN"CED7<%2HDD2EBB5W"@ ,P)MQ>WM/[;N7BGJ2>].)KY'I[GL /#3^%_
M\*])_P"+_P#-W_D_]6_'SHSJGM'^4CU[V[VML?K+8VS-]=BUO075^?JMPYO#
M4%/2UV3>JR-%+DJR:OJTDD\E0[3RE]4GK8CV[N'+FZ33221W91&=F5?%F 52
M20,8%!Z8'3=EOFW1Q1QO;:G"JK'PHB68  G)J:G\SU:)_.0J?Y</QH_ELTV5
MS'\O/XV= _*;Y:;$GPG3W6^$Z*V'A-W[5J*V.GJ*[+5F5Q&'5\?+MVEJ:5:E
MJ68LM?41444IN]1&'^63?[A? "XEDBB8&1C)(48 X%&.=5, CA4D8Z.M^%E8
MVA)@C2212$4)&'!(XU ---<D'CP.1U1=_P )MOA5BOE9\]DW_OS;N,W+U+\8
M]HUO86Z,/G<=3YB@R&9W,E1B=N8VKI:F.6.9#,]?D "A4MC0K<-8B[GS=#8V
M8B4T:9J BH(5:,Q!'Y#[">@SR;M_U=R96RL0K3&6:H'$>E3]H'5NW_"DKX<=
M$=C_  UZ?^=_Q6VEL#%8'J/?.3V)O_)=8[9H-J4&0P&]LE_!8ZZKCHZ*G,\^
M&W;04]#$25*_Q*H#A[)XPQR'N<D%T]I,2?$6JZB20RC5YG *DD_8.A!SE8+-
M;K<1T'AFAI0 JQ ].(8"GR)ZTJNNMB;@[2[!V)UEM.&&HW3V+O+;&Q-M4]0S
MI&^0W=6P8^C1VC21PC5-1&"5C9@";*QX,L7$ZVL;2MP168TXT4$G_!U&T$)N
M9%C7BS!17A5C0?X>M\#O.DZJJO\ A03_ "K/@_2[*V5N/JOXU_%OLO#9';V9
MV[0Y2EJ*_<76^\VBBK\?+%+32&GQ>W-M5,7D1F61PXMIC<P[8HXV:\NBQ#22
MQCB?PR(:U^9<C\NI2O74[K:P4%$C<_[TCBE/EH'[>HG\SC^;I\6OY<GROW'\
M8/\ AJOH'N/^[^TME;I_OQ_'=N]>^;^^%&*OP?PS_1OG/']O?1K_ (@WD_5H
M3Z>]\O\ *\N^V_C_ %+IW,NG26X4S7Q%]?3K6]\Q)L\W@^ K]H:NH+QKY:&]
M.M8G^:=_,PZM_F*?Z"O]&GPKV!\/_P#0]_I._C7]QMU8[<W]XO\ 2#_=[[;[
MK[#9^U/!_"?X)/X_)]UK^]DT^#0WFD+EWEYMA\35,TVO12JE=.G5ZN]:ZOEP
MZ!&^;V-YT4B$>C5P;5JU:?Z"\-/SX]5'>Q+T0=>]^Z]UQ?\ 2?\ 8>[+QZT>
MLA/[RC^H;_> /=F\_P NG8_[1?MZWW]H?\>/U]_XCCKO_P!TE![XC>[7_*S;
MG_SV3?\ 'NNO_MQ_R0;#_GEA_P".#I_]QYT->O>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NA'ZG[#R'5^^\)NVA
M:5H*6<4N9HXS;[FAJF45,!%P"2@#QWX65(W_ +/L7\B\V2\E[G#?1UTJ=,R#
M_1(6(UKY9IE:\&"GRZ"_.7+,7-NWRV4E*L-43'\$J@Z&_;AJ<5+#SZO-QV0H
M\MCZ'*8ZHCJ\?DJ.FKZ&JB.I9(:M!)'(I_*NC C_ %_?2FTNH[Z))HF#)(JN
MC#(96 8$?(@UZY_7-L]G(\,JE71F1U/%64D$'Y@BG4SVHZ8Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NJQ?EU_V\%_E)_\ B3/F%_[Z#<'LZV[_
M '%N_P#FG'_U?CZ+KO\ MH/]._\ U:?K1Z_X4>_]OEOE^;&WCZ Y_P#*9;,_
MXK['7*?^X2_[;_CS=1SO!_QR0?+_ )]'5'#"QN 0/]?V>=(U->N/OW5^LS*B
M)I N3P2>?K[4DZ>FT.:D]1C&3:W)'YM[2R1F7IP/QKP_GUP*L#]"+'FYM[K<
M#4*=6++P'76F_J_-R+EO9<8B.O<1UQ(X(_P/NA%.M#!ZQ:&_I_O/O73NL=9
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M0=:9_P#A/-\VUW?-@(]S]&3[8^\/BWU)O#(TD#4R.0I^Q3$25\4[QF[1"G9
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MY-LF =2,UK3B/Y5'2_?/I>?]O>*SE2:0'6N2-)S@B@*DU-*K_+K;&^7?Q/Z
M_FI_&[:-7@]\X]@U/_?+I;N3:X3/#'RYB&-:B"HI5GA\]+4JD<.0H9)8:B&:
M%0QIZNF&@5[A8Q[Q$!6A&58>1_RC_8/4&<K<S7GMU?L2@8'LFA>E'4'R-#1A
MY$<,@X)'6N O_">?YO'=HP;;EZ.&WEG_ ./W.]<B*8PI*OJ%&,0<CYWCN=!I
M0@Y0R_1O803E2YKH9DTUK4$_YJYZEU/>';8E9E22C5K%I&K(_BK2GV,#UL#]
M _%3X:?RB^A<WV;O3-8),WBZ%)>P.^=UX<-E\A/5>B/&82E0UM924\[E8X,;
M1R2RSD*]0]3(OE47Q00;/%J<J*#+TR?D.)_P]1'N6];I[AWBV\6M@QI% "H1
M%_I$! :<2[_M H.@6Z5_G1S_ "4[<AV-\?\ X/?(OL_8J5L=+E]_8RMQ5!/0
M+(KL)JRDJ&7!4,;JMX_O-V4NLG0/W+(6;;?!=OH2.0_.@_GF@_;U??/;V;E^
M+7<75FK8K&7FU<2"%TP-J(^7YT&>K$?E)\/ND/FSU7)LGNS8I@KZK$F7;FY5
MCHXMQ[9K*N/4)*'(4SU<*34\I FA6HJ**H*E7$\9#%?>[?%N"Z9%SY'S'V'H
MBY;YHN^4[D7%H_ ]R&ICD'HRGY<#Q'D>M5S?7_">+YGX7>$^)V+O/IG?6SVJ
MY$Q.[J[<%7L^80%;K+D<9)05<E-(6N#'3U->J\$.038'/RO.'H"I4GC6AI_J
M].IUM/=[:WC+RI.DC9= H<'Y*VL?+-%ZO9_ER?R]-@_RQ^JNPNR^VNP-K97L
M?<&WJ7(]I=B3!,7A-OXC;2RU4U!CJ^MB@K&H/,S35=3.M/\ =&&EO20FG76(
MMIVM=GC8LP).2?( 5\SGJ+>>.<9N?[N-(8V5$_3@B&6.HCC2M2:#S-/7K5"_
MFA?,FE^;7RMW+V3MJ2L'5^V,90=?=3Q5E-+02R8?"--,U=/!(;QS9/(U-;4A
M6CCDC@EIX909(3[!VZ[@-PD,@^$86OH*Y_/)ZGWD3EIN5+%(Y*>*Q,D@!!HY
MI@?8H \ZD?/JNP_3Z6%S_P 3[*0,_+H7,-1U^O7'W?K77O?NO=>]^Z]U)9!9
M&+7//I'^(_-_;X%.MDUZXK^C_D.3_>_>^F7_ -7\NLA_0/\ 7_XK[=3ATDZS
MC]+?[#V_)U8<#UR7_.2?\@?[U[<Z;?AUD]NIPZ9ZR)]#_P %D_WKVX./3:_Y
M3_EZYK^A?]=O=W_S?Y>MOPZ[]J4X=(NI'MU./57X=>]JTX=,]94^G^Q]NIQZ
M;DZY^WNO1]9HP01?\E;>V?/\^DQ^+\_\O4^,7_WDC_8#VHK3J[X'4R(7*7^G
M!/\ L/:A14]-CCU.3A?\?^*^[@9ZKU,B%E_Q]WZJ<GJ7$+\?X^]@5/5P*]2U
ML&0G]*NA;_6!Y_WCVX#4]-2Y'SZWUOY?^1R77/\ PEY[]WIUG538;>N0ZO\
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MR-84$ERP_H)Q^UO\@!^1'5G_ /*OW-\H/FOL3^9E\=_Y@GQI^1W56Q/D!O\
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M#;5W>E='A,G3QY[ 9_&9>*"MQ>2FQ-=%+215-=BY:9*B6D$51%():=:HM &
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MFJLC0R3H"6+_ ,$1'L%"(3<$5MS'+*_>BA:^5:T_:<_EU(MQ[-P- 3;S2M*
M:!@NEF%?0 @$CU-/GUM ]%]_[&^5?1>'[BZ*W/13XW=V%KHL7693'/6-B,Q!
M$4FH<M0"6FD:HQE6RK/"M1&)D >"<PS13L*HIQ<IJ0_[!^?4*;AMDFS7!AND
M(*MW"M"RU\CFE1P-#Y&G6BY_, ^:/S8[D[%WUTG\E=^5-+!UGO?-;:S/6.T:
M8;8VZ*_:]4U.TPI(4CDRD J(#+2U%=)4S!&$D$J(X  VZWTT[F)L $C!_P @
M_9_EZRAY-Y<VW;(H[FVC!\:,,LC=TE"*X)^'CD+0'S'5;C$-_9M^?Q^?]8#D
M_P"^'LC\/UZ&\08#N)/V_P"JO6)PH466QO\ 7WIDT].9_P!CK%[IU[KWOW7N
MO#DD6)LA86_P]W5=77NN0:ZB3_%@%OP-()O_ +'V[U[KG&;H#_4L?]N??NF7
MX]9C^@?Z_P#Q7VZG#I+UG'Z6_P!A[?DZL.!ZY+_G)/\ D#_>O;G3;\.LGMU.
M'3/61/H?^"R?[U[<''IM?\I_R]<U_0O^NWN[_P";_+UM^'7?M2G#I%U(]NIQ
MZJ_#KL:?S?\ V'M6G#IM=/G7\NLJ6MQ>U_S[<!ITU,0.%?SZY>W5;5U2)M5>
MLT;7MQ]+>ZL*&O3<BZ37U/3A&;W'TLI/^^_V_MSIII-6.I<9MIM_0#VI5J=6
MK3/KU.4< #\V_P!Y]N*<]-KPZGI^D>[]:''J7$+?[;_>_=TQTXOKUG]U)SU4
MYZVG?Y O\WGH[XT;'[#^"7S8JZ>@^.G;.8RU=L[>^=H)LWB<54[[I8\7G,!N
M""*.=X=NYJ)8I!4"/[>CG:LDK--/525%/'7.G+,M^ZWEJ*R* '4&C'3D,/4C
MA3B:"E3T.>5-^CLT-M<&B$U1C\(U<5/H*YJ<9-2.CH?\,+?R6:G=Z]T4O\R[
M;*_'8Y1]X/L<=Z;$DI1BHYVF?&C=9KA4ICT4?;&5J=JU8P5:I^Z_?!/_ %SW
M0+X/@?J4TU\-]6JE*Z>%?.E*5\J8Z-/ZJ[>3XOBGP_BIK33IXTU<:?.M:>=<
M]$__ )^/\V;XY=Y]1]6_R]O@G4T==\>^IJ[;-1N_=^UZ&3#X&IBZZHFQFW-K
M;>BFCCEJ\-B$/GEJ= @EF@HOM'ECB>5S7D[ER>VE:]NP0[ Z5;+U8U9F]">%
M#G)K3'1;S3OL,T8M+8@J*:BM-%%X*/4<#48P *YH9;^9K\I?C'OW_A//\,NE
M=B_(SHC>G<FUNL/@OC]S=2[3[>V_N/<V.GVCLRFI<M!7X&CR$V5HYL94JT-6
MDM(C4TH,<P1Q;VAV3;KB+>Y97BD5#)<$.48(0S-2C$4SY9STKW6^@DVE(UD0
MN(X05#J6! 6N :X\_3H(_P#A.O\ S7^M>M]N;U_E\_-/?6S<#T'NC$[FS'4N
M\>W<[C\)MW%_Q6*5]P;2R]=E98**GQ6:CDGJ:03RB(59JJ:Y:MA0*.=^6WF8
M7EJK%Z@.J EB?)@!7(X&GR/KTSRGOR1J;6X8!0"49R H'FI)I]H_,>G1</CM
MUE\3O@5_/_Z(K>N/E-\>-V?#Y-Q[^W]L;N#%]^[=W5A<!A]U;1W1208/<NX8
M\B^/Q^4QF1/V2"JK!+50O0U)8R5F@+[VXN=XV:0212B?L5D,;*6(D0ZE6E2"
M,F@P:XH.D=K#;[9NJ-')&83J(82*0H*,*,:XH<"IR*9)KT"G_"@+Y%[4["_F
MI9'N?X[]V[4[$Q&T-B=(56P.S.I.P:'?-!09':=.*U?X;E,555='%4T&3+3%
M(IKQ5#,[*'9B57)E@T6WF&XC9=3R!E=2I*L ,@@&A&.D_-5ZLEZLL+JVE$(9
M6# ,&)XBHQQZO=[T^2GP7_G=?REMJ4W=OR6^-/QZ^:6Q<;6YG:V%[A[NVWU'
M5478&S:0TE5_D^6R--.^T=Z0,O[J0RP0"HBD(>MQ9C0(6=A><J;B3%%++"31
MBD;.&B8@^0^)?MXBG Y$UU>6G,5D!))'')2H#R*I605'F?A/V<#7B,-O8O\
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M]1%N^T7&Q7,EI=(4EC-&4_94$'S!!!!&""#T4RK^</6]+5U5,FVMWU:4]1-
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MH*)-%J45'7NKE.F-XUW8G3W5'8&3ACILEOKK78N\<A3PL&2.?<^+I:V5%(5
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M575K!2Q$B[!'J)(PY )5-36LON+/;3F5.4.1VW&0:O":<JN1KD:;0BXJ0"[
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5%/_  I:_P"W)OS4_P#+<O\
MW[6P_;<OPG_5Y]>ZM<^*W_9,'QP_\0+T_P#^\]CO=QPZ]T/+7L=) :QTEAJ
M/XN+BX_V(_U_>^O=:B'=?:O\ECY49WMS9O\ .F^-/5'PH^<&Q=V9O%[QI*MM
MT[<R6:P^/JZN#;VZML[]P6(P4V]\1DZ*E)BDEIW]2F)Z,1^(,P2I^+!Z]T:[
M^4KT-VQ\EOY<OS>^/?R+R_?V3^*O>'<_R6ZS^&6;^0T]<N_/]#>[:;^'[>R=
M4<JD>8C59)9JFB%?&K^1)&AB&.:D#;05!!X>77ND3\.?YF6#_E3]/[%^ _\
M-KPN]?CQN+X\X[%]1=)?)BCZQW'O?KOL?:N!>II-MU.*RV!H<U)0Y.BP]'2Q
M5E/5Q0B)4660PMYH8?*^C#=>Z0?S/^5"?S[MM;+^ '\O3:O:>[OB?V7V!L;<
M/S%^<6>ZRS'7.U,+MCKK,)F#@-M/N:EQ57E=UU&5Q..D$9Q<L<5H$\,R/63X
M[3-XF!P\SU[J^_Y7_*SH+^6_\9).ZNXEW'A>E>L_[C;%T[/P3;FJJ6/*S4^(
MQ<:4@EBDDB61J>-BK$J#J(TAB'68(.O='%]VZ]U13_PI:_[<F_-3_P MR_\
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M,U.,$T.,@\0>'0;?RY?BAN'X1?);YF=$[??+93X_[@QG3W<?5.2RCR5#4?\
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MJ"BJ)!9@..0H-UX_)_KR.3[,(8UL%_I$>O389KUM(/;TP3.\CEF):_)/ZO\
M>>?91<2:SJ]?^*Z.HH_# 7R'^;K&+ 7M<ZOZV]L-'J'[.M@_ZO\ 4#UR\G^'
M^\^VO!ZU0>O^K]G63_'\>V.M4IUV!=9/^"?\2/>B:?\ %=6'^7K*@('/]?=H
MVJ?^+ZV5[:'K(MR;7(O];>WF..'24XZY"/3<J3?DB]OJ?]A[=4"@/^?K760Z
MB"JD V!X /\ O'NU _\ J(ZJ#U[_ %_\/=<ZL=5H .N2KJ-A<DD<D6_XGVJ0
M&F>F"]3CK(% _'(U#_;\'V\ >FVD*FG7,*0HM]+FWY]Z;AG_ %<>M:B<GAUF
M'T'^P'M]1D=4KC\NN_:E1GI.QQU[V[TE?CUE3@<_U]N1BK#JH .#USM^/S[5
M@4Z<4!<CK-%P?Z<CZ^VZFO225R:_*M.G&-2"QX-T/T]N],(:G/4E>-/^%O;X
M->E'$#IPC/*'^A'^\>W4.>FT_P O3A[??)ZNW'K/$UOK_6WO2FAZT#0]2?>B
M*=:(IU[WKKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T8WXG?%7N/YI]\[&^.?1&#I<WV'ORI
MKEHWRM8<7CJ"DQ%/+5U^3RE8(Y?M,?0TL,DDCB)Y'.B&"*:IEAAD0;GN46TP
MM/,2%6F!DDDT  J*G_BS@=+=OL)-SE$,7$UR:T 'F2 :#_+CJXC#?R.^C^QM
MPS]-=&?S:?AYVI\IVJLUBL-TBN+R6W:/)Y' H6GQN/W(:RL6KK"T50JI'B&+
M>/4/2)#$%#SC-"HEELYDBP3)6M >!II _F.A+_56*1C''=1-)D!* 5(XBH<G
MRS@_9U1%V7UMOKISL+>G5/9VVLCL[L+KS<N8V?O/:^5">>AR.!G>GJJ=VB>2
M&0)*C:9(I'BE33)$[QLKD:6UPEW&LL9#*P!4CS!_U<#D<#T$IX'M7,<@*LIH
M0?(_ZO/@>(Z0_M[IKKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZM?K/Y478=-_*IQ
M7\T].R\'-LG([MDV]-U8=KU<=?%2IN^IV6,B,H*AZ5XSEH$&AJ6,6<KY"ZA7
M#0YD4[D=NT&M*Z]6*^'XE*4]/GT?_N$_0?7:\5^#3_PS1QK^?#HI_P (_B#V
M3\ZODMUQ\:^KVAQV8WO7U,^=W9D*&>MH,!A<+$U3E<YDO MTI:&EC;0'DB6>
MI>GI!*DE1&?9EN^Z1[/;M/)D+@+4 LQP *_SXT%33'2#:]N?=)EA3%<EJ$A5
M'$FG\N%20*BO7/YS?%FH^$_RL[?^+E9OS&=FUW464V_AJ_>V'P\F IJNHR^&
MQV4G2.DEJ*J2'[.6O>F;5.Q9X6>RZM"^V?<?WO;)<:=&O5VDUI1BO&@XTKPZ
M]NMA^[)W@U:M-.ZE*U4-PJ?6G'HIOLSZ+^CH_ 7X2=@_/_Y%X3H+8><P^S*;
M^[FYM^=@]D;DB:?%[8VYL^ 2U^9R"))$[P+/+1TL:B10U350*[Q1EY4*=[W=
M-D@,S@L:A548+,?*M#3 )^P=&>T;8V[3")33!9FI72H\Z5%<D#\^F3YU_$S/
M_!CY7=N_%7<^Z:'>V:ZFR&V:.HW7C,8^&@KH]TX/&9VFGBI9)ZEX5-+E(1I:
M=FN"3I)TB^S[D-WMDN NG7J[:UII8KQH/3TZINEA^[)W@+:M-,TI6JAN%3Z^
MO12?9GT7]>]^Z]U[W[KW7O?NO=',_E__  SW7\_OE=UI\6=G[D@V5D>P8=XU
MM7O>OP4^XJ/$TNSL)D<S+4UE/3RP-XIFH8Z5&,\:^>HA2Y9E1BK>]U79;9KA
MAJTZ0%KI+%F H#0^M>' 'HRVG;CNLZP@Z:U):FK2 "<BH\Z#CQ/5G%!_)/\
MCYV%EL;L3H7^</\ !/M+M[=&1@P>Q>OLCD*K:"YC(UI*4V/IJZ&LS#FKJYBD
M4$<=#*TTCJB!F*@AP\W3PC7-8SH@RS9.D>M"BC^8Z/1RQ#+VQ7<+N?A7 J?3
M#L?Y'JN3X_\ P$[@[H^>>VOY?6Y#%U/W!D.R]U]9[KFW#1-F(L-4[&I<A6Y2
M=HZ:517014N-J)(7AJ/%4QF.2*4Q2+(3Z]WN.ULC?)WII5@ :5U$*!P-#4Y]
M.'1-:;0]Q=BT<Z&U,I)%::03\JUICUX]'"^%_P#)@WW\W.S_ )W]<=;]W[9Q
ML?PFS^0VZNY:[9%=70;MF_B&Z*#'&D@AJQ/BQDAM>>5%D%2Z+,%TNT9U%>Z\
MV+M45O*T9/CKJIJ T80G\.?C^7#HQVWEL[C+/&)*>"VFNFNK+C^(4^'Y\>J9
M<1B,MN#+8S X'&9#-YS-Y&BQ&&PV(HI,E5U=7DI%AIZ6EIX5>:HJ*B9T2..-
M&=W954%B![%LC"($L0 !4DX  R2:]!F-3*0%!))H ,DDXH/GU>!\B?Y)U1\2
M.VOAMU1\DOF%TWU/+\H-E=C[LW[O/<6&EI<-U]+UYBJ.J-#7U,V1A;,O7Y>J
M?%0O#'3?OQ^304++&#['FW]Y13RP0._@L@50:M('9A6@4Z: 5/'TKT)[SEKZ
M"6&.69%\4.68@!4T!33+#54F@X>M.AYZ=_D*_'WY"[XHNM>C/YN_Q?[:W]D*
M6KKZ7:77_7V2W17&GH IJ*EX*3,R-%2P!E\DSZ8H]2ZW%Q=%<\Z3V2ZYK*5%
MK2K-I%?3,8S\NEL'*<-TVF.[C<\:*H)I^4AZ(-U=_+!RW<W\SK(_RW>M>\MI
M;PDQ6Y]\[<K^_P#;VVYLS@HQUYM^KS&2JGI*:MD988JZCDQ=S7Z?O&1=6IUC
M)U/S"+;;A?O&5)"D1%J,=3Z1DCS'=PX?MZ*(=C\>^-FCU )K(%J!1:G /D>W
MCQ_9T:AOY07P=5F4_P \7X2DJQ4E<).XX_H1GB"/\0;'\>RS^M-Y_P!&^?\
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ML)5,C%9 ^W*>&@J2KV<-(R@ A0#H]P(NGE8TJ<?9Z?LQUD4G*L*[:-J(#!8
M*G@9?[0L*5(K)D?LZW[^B.[NK?DUU=LKNSJK+4VX=I[GH#6XNHFB1*R@G9?'
M5X^MA#.U'D*1]451%J(N-2-)$T<C#N"5;E X\\YXCK%?<K";9YGMY>UAA@#4
M$8(SBH\^M5C_ (4AKNUOD?\ 'XU[2?W!_P!"=:NV0Z_MC,'/5_\ &RI_M/\
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M5'2B"$1XX5;.RBJFEIA)!!/"KW^>/;88;>&=+:)C4E=9D,=0?T]"N<U.32N
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MZAN6B54 M=>?]A[1T*X/2E#XAK_JSU&87MS:WNZ2!*U\^E2N$X]=Z%-R=/\
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MN3,[<@_I'_CW4:[[((KN3[/^?5ZI3%%'34<E14NID92(8Q_5O];_ %O8I9=
MJ>@R)2S=-"OP+BY^M_I]?:-P6->C,28X?S_V.O%@?J/IS]?>@I'5Q)UX2,%*
M<:2P8G\\>_4(%.D:1ZFKUC4@MIM8D6^O]/\ 8>]?2@]+B-/F>LA0\6_Q_/\
MR+VW)!HX=5(U\.L?BYN0?Z_7VWH(ZN2:4ZX&-=0:_P"/;:@N>MF2@_S=26A:
M!%,B%6D74BD$$@_[W;VNDCT+4\2.D2,96QPZC%68\(1_L+7]I1$3GI<M$ZZT
M2#Z*;_[;WOPCU8N.O$-8 B]OS]?;?7E(!ZXV/XY_UA[VKE3UYF!-.I1GG6)H
M4=EB9M;(#]2.!<CU$6_WGGVH-T0M.F!0'UZPHQ!#(%#+<7^OU_XK[2^.Q/5S
MW<?\/7O42_\ 0M<\<?3W<*6SUHLJ^O7%E"VNK#\7][\(GK8_5SZ=<D346"BX
MTZC_ ,@_\4][6(@X'5"RK3AUWH'U4V(_V/M@_%TY6N3UB(8\D&_^ _I[6JH_
MU4ZN)"HH.G;%4J5%26F13!"HDE!!LW/"#_%O^(/M^&$.PKP&?V=)+R4LH4/H
MJ>-:>OS%>A$V-VWV/U!OB@WMU3OO<W7V[,;41_:[AV?F9\+4!"REZ=Y(9$\E
M*P6TD+AX9E!BEB=&/MV>4!P <^H_U?ZN'2&3;;?<8#%,GB#/$5K_ ".?]5>K
M3,%_/A_F [<Q4.$JMU=;;SJ:<,IW+N;K>E6LD!N0&&+;%T;:>%5OLPQ !D+L
M239[R0#'^3_-T#(O;#;Y>XA@/02'_+4_ETA^I?YN/RBJ_EMTCW;\B^W]W[KZ
M^V)O9Y\]LC;V,I<+BX\1N.&HQF4^VP>.2AHZJLI\975'VTU2):D,JZIV9V)*
MUN96E#.QH*8\OV"F>C/<.0[$V4D%G$JR:=08L2S,,@%FS0^G#-:8ZVC/GI\5
MMC?S/_B-M]^J-[[>J,R&H.TNA^PO,\^+J)IX'BDHZYHD>>&CR--))!/:(ST=
M5'%))#(U-)2R'.XV0W&,:31@:J>/E0_M'4,\J[_)R9?-XJN$8>',H%'TU# @
M&F00#2HJ"1BM1IXY7^6)\^<5V&G6LWQ6[=J<[)61T4.5QNUILI@&:H-ED;=%
M.9=NQTP/+2/DU$8YD9>  O\ NBXK3/\ J_.G\^IX;GK;5@\87*Z?0/\ J8K_
M *'A_P"76VI_*;_ERQ_!?JS,;J[0IL+-\B.Q(V3>>1QF5&5H\-AJ-UEI<'23
MA(X6;R)]Q7SH7CEF$4<<CQ4RS3";;-O%FM3\1R?M_P!7^SU!?/7-']:+H%"S
M)&"D9-<K7C3U-!Z\,4J:J#^9U\%\5_,4^/VTZ[K#<FV'[)V/+4;OZ@W8<C'5
MXG*46Y(8/O<:V0IEJ%6CRD=/130U,0=1-3PW/@DE/OVZ6'UZ H1J6ND^6>(_
MD.O<E\T/RA=-XJG0X D4KW(RUTL :9%2",8)\P.M06'^69\^ZC?K]<?[*CW'
M29^/(Q8]LG)M&88$--IM(-SJ/[MO3#4-4R91HEL0S@J?85@VBY=J.#04P>%*
M_;3J>9.>-JM8Q<&XCFU#X:C6/M4DL/S ^76W]_*R^"$'P ^/V>E[%R6)3MKL
M5Z7=?;N3BR$$F-Q5-MF.J_A^,AKBD:O!C::HJIJJH+^)ZB:4I^Q%$["K;=O7
M;U8\*\?04_U?ZN @3G3F9N:;H>&"44E8EH2U#04IZDC@/EQ.3K-?-/\ FA=S
M9KYX=E=X?%OMW<^PMI82+$=9[+JL'5++0YC$;'\ZI79#&5#5>*RM/6Y*JR59
M2K549,=//&&BCF#^PY-N4SW+/'4*#0?,#Y?/CU-&P<CP+M<=G>0JTAK(Y.&5
MGI@&@9=( !(.2#Q'2F7^?M_,#_A"X[^,=2-6+3F!MP/UK']V6_$VA:H4 E_-
MOLA'^- ]NOO5P,#TXT'^;IE?:C:U:K>)_I1(:?9Z_P ^JS.^_DWWY\GMRP[K
M[Z[7W1V/EZ*(PXM<Q+'145&DG+K0XVD6#&T*2'EQ3TD6MOUZB-1+)[F:[-6J
M3_JX=#+:]KL]FC\&T@50>) JS'U)()/ID_LZ+ZWU/^N?I[J,=&HZ]8GZ ^_=
M>Z]8_P!#_MO?NO==>_=>Z[L?Z'_;>_=:KUZQ'U!]^Z]6O77OW6^O>_=>ZY!2
M>1;W[JI:G4M!P#<?H0?\DW]^ZJS CK)^!_KG_B/;J<.MIPZP?VO^0O:H<.FS
MQZDQ\M(1]"1_O'NDG34G6=1<'FUK^[KPZJW:/M'70L".?H1[=5>DPQUE3Z#_
M &/NXQUKKE[<#9ZKPZ[T7YM]?ZB__$>U@X=-^)3KKV\!0],$U 'IUE4790/]
M3[M6F.JLX4BOIUE078#_ %_>@U<=6$P/KU) L#>W-P/=P*]5=QUTH+2,1Q]#
M_P D^W1V],#)ZG1QL 3<>I"!S_7W;I2JG^74I1<BWUN/?NJ2K7[>I04E1;\'
M^O\ 7V\N!TU'Y]31P%'YL+^W3_FZ<DHWY ?X.LT=S:QY_P"*?U]^ /ETWDYZ
MD#Z<_7G_ 'CWYJG/6C4YZSJ;@?X<>[@5'3E*CKE[;I0]-$4-.O>Z]:Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWO:FAZ]6G7$$QFP_MSV_VX6_MQL#\_\ -T["QU+_ *;K
M?CVA_P >/U]_XCCKO_W24'OB+[M?\K-N?_/9-_Q[KK][<?\ )!L/^>6'_C@Z
M?_<>=#7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z'?JKX\]@]I5E-)38VHP.V696JMSY>E>"'1Q?[5&TO62$'TA/1?]
M<B#GW)_)'M/NO.DBLL;06YRUQ*I"Z<? #0R$CAI[?5AU'G.'N7MO**,&=9I^
M"P1L"U?Z9%0@]:Y]%/5M_777>V^L-KT>U=LT[1TE.6FJJR?2\]542V\E14.H
M4/(]@!8!44*B!44 9V<I\J6?)EDEE9K1%RS-0O(YXNY %6/[  %   '6&7,W
M,UUS9=M>7;59L*HJ$C0<%4$F@'[222222>EU[$O0?Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK%^77_;P7^4G_XDSYA?^^@W![.MN_W%
MN_\ FG'_ -7X^BZ[_MH/].__ %:?K26_X451";^<G\QI0MS".@&9SP%"]9;,
M(-_\23_OK^Y)Y) ^@4>A)K_MO]CJ*>8'\2_D4^6DXXUI_L=495U49V"  1Q7
M5;$^J_\ :/\ 4^Q),]>BH0D&M,]-I)+!0+G^GT^G_&O:=>G]9ZZ9F4VM;_7]
M[Z\7/7:G4#?_ %N/?NO(Y0U'7+W[KQD)Z][J5KTY&YZ]_OOZ>_$4'5]=,XZY
M(X26-@@?0X)4^H<?U]N044U/5O$#C/\ A_V.L]55RU<ODDM8<*B\@ _T^O\
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M1?\ 7CW[^K&V_P#*);?\X(O^@.O?UEW+_E+N?^<\O_077O\ 1YL#_GA]G_\
MH,T7_7CW[^K&V_\ *);?\X(O^@.O?UEW+_E+N?\ G/+_ -!=>_T>; _YX?9_
M_H,T7_7CW[^K&V_\HEM_S@B_Z Z]_67<O^4NY_YSR_\ 077O]'FP/^>'V?\
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MO_077O\ 1YL#_GA]G_\ H,T7_7CW[^K&V_\ *);?\X(O^@.O?UEW+_E+N?\
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MO?UEW+_E+N?^<\O_ $%U[_1YL#_GA]G_ /H,T7_7CW[^K&V_\HEM_P X(O\
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M:B!ZP$4:2EN1]/P![%E*]%7AD_\ %]9IH8T3PIZWX#, 2/\ 8?GW9D%.G6C
M3/'_ (OIEFIF4G6+$FUQS]/:$Q$'Y=,.Y7C6O\O3K$(4'UY_QO;WK0.J^/\
M(==BGU$V4D!=7!OQ^?\ ;<>ZE".G0:^?79@"Z;CZ\BY!_P"-^_",D]6#:1GI
M_P 7@Y9UBFD4^%I!&BE;L[Z22%'X46OJ/X^GM3';$Y/265BV!Z5_+_9Z<LZE
M-CXXZ6(1^:<ZJDI<_IMZ;C^ES]?Z^WY(UCXCJEK6M7X>7SZ1C0J[$BZW/ X]
MHV0$XZ7-3RX==&FM]2?]X]UT#JH->NO /]4?]M[]H'6\]>\ _P!4?]M[]H'7
ML]8WC*FRAF%KWM[HPIUL ]8O=>O=98I3$RNHLZL&5P;$$?2Q]^Z]U,^X::83
M5#/*7*M,S$,3QS]1SQ_A[LK=X)^76H*1DGYUZ=,MDCDIB\:&./6TA0A5O?C^
MPJKI"A0 %'TY^OM^XNQ*VD>7'\^MLPH/2AI_+YGILIG6*>.=E+Z'!*V_*V/U
M_P "/;0700>M7 Q^SJ3DLE/D)-<[-XP&*QJ>+M^HG^K,?J?];WZ2=G_S=,I$
M8_\ 5_JX=-PU\6 Y?5];<?T/'Y]MY7JX<#IWH,/-D4JYD4+#20+/63N;"-7O
MH)_Q:QL!R?K^/:R*#Q:GY5/6]0IG%>'V],_B D9!R%/]+WY_K;VE J:=70:N
MLD=.\JNZ*SB- TO-@ ?]M_7^OO5*]4+B+!ZRTU6:24R)%%(2C*!*-0!-_4/I
MR+>_*U.M2Q^(M.%>L,\\DA\KDLTH8F]OKQ;\?C^GOQ->MQ1^",>?6 .2R@<
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MN6-W&H*YC)"L5YL?Q[]UJM>F'*=L=9X3(56)S&^]K8W)T,IAK*"MS,%/+$X
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MM5[6Y]^ZWTF<'V=UWN;(Q8C;V]=M9K*3I+)#C\;EH:N5E@4NY5$8L0J@D\<
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MUG]^Z]U[W[KW7O?NO=>]^Z]U6+\NO^W@O\I/_P 29\PO_?0;@]G6W?[BW?\
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M4U%.L$D-P+6U#ZD_C5_MAS[H8](KU5&+D!C@]8_"XX*N&4*3=""-7T)_I?\
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MTD6U&2S*K_4_U(XN?Z_0?4WM^?:=VT&AST8E]!ZX!22$ 4N3^@BQY-O]>P)
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MKT/^5+6&Z@.N-30T[E##B3BHZV>V_E?_ ,M%F+-_+P^##,?JS?$K8)/'^/\
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M8M+4[66G=5FVOMW*TN&22DW,TJ!<A6PW?%*OVM-)'E2\F.$_)VU7%XXN9Y)
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MCW[1U7'7/41S_3FQ4_CWX)GK5:9ZY"8G\+_L3;V]HK_Q76Q*?E^WK,ANH/\
MQ-_I[WX?5@^.N:C4;?3W95T]:9M767Q ?4D\ _T^ONW6NLGB_5ZOU?X>_=>K
MU+@]" ?6UQ_3VY&//I1&XIP^7'_8ZRZN+<_C_??3VX!3_5_L=/BE//\ :/\
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M24=)2PJTLU34RLJ1HJDEF7@"[#(2ROX["PMC(P4>#%Q('X%]:=1'>(\MY(B
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M_P"=A_Z-]^_UT>7O^CA;?\Y!U[_6VWW_ )0I_P#>1_GZ]_LP72W_ #\C;/\
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MY!U[_6VWW_E"G_WD?Y^O?[,%TM_S\C;/_G8?^C??O]='E[_HX6W_ #D'7O\
M6VWW_E"G_P!Y'^?KW^S!=+?\_(VS_P"=A_Z-]^_UT>7O^CA;?\Y!U[_6VWW_
M )0I_P#>1_GZ]_LP72W_ #\C;/\ YV'_ *-]^_UT>7O^CA;?\Y!U[_6VWW_E
M"G_WD?Y^O?[,%TM_S\C;/_G8?^C??O\ 71Y>_P"CA;?\Y!U[_6VWW_E"G_WD
M?Y^EIMO?VR-X77:^[=O9Z54\CT^+RT-5,HM>[PJYE3C_ %2#V(=HYFV[?O\
M<*Y@G(R1%*CL/M4&H_,=$6Z<N7^R?[EV\T(K0&2-E4_8Q%#^1Z5WL\Z)>O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>ZK%^77_;P7^4G_ .),^87_ +Z#<'LZV[_<6[_YIQ_]7X^B
MZ[_MH/\ 3O\ ]6GZTJO^%$*:_P"<?\R?5_N[X_CZ7^O6&ROZ#W*/(H_Q!?M;
M_CQZBK?I*7TH^2?\=/5*YIP/[7-[6/'_ !'L84'SZ*=0'7(0NH^EA_4D'_>O
M=_A'6]8ZY@!>0/\ #_;^ZEM757?'4F--5O2IN;#T!OK^.>;_ .'NR#JJ#5UZ
M2D8*YTE2'TD%=%C]?]?_ 'CWIHB.M@>G4%X&%N5_/Y)]T*Z>K Z>/7'PO_5/
M]]_L/=>O:AU[[=S]-)_V/_&O>P*];UCJ;#&J([-(BLB@!#>['_:>"./S]/;H
M-!]G5#(.%#]N/\_7 VYM<W^NH_[U[UK'5]8ZSPB)%=A&SR\%!K,:@_0DVO?C
M@<>[ UZHS%O.@ZXRN6M=F)).JXMQ^+?CW2M>D@4)PZVJO^$DNP,1G/G'\@>P
M:^-)\IL'XV#$83R$'Q-OO<..^XE0&_K$.($>H6(21U^CGW&7N/*5BC3R)_S_
M .;H;<C)KN)&/DE/Y_[/6W=_.4[9S727\KOYK]@;<R.3P^>AZ4S&T,3EL+]R
MM72S]G5-)MA*FFDI(Y:BFF@.8UK4*JBF*^=Y(4C:5(YY>MA=WT$9 (,BD@TH
M0O<1G!P.'GPH2:=2#O,Q@M96!(.A@"*U!(H#C(R>/EQZ^2=*I= N@GZ)Z5XM
M&=(_VP'O)%LBG4,%Z"GI3K&(+  QFP 'Y)X_V/O04]:T@YZRPPOZU"BSH05Y
M'%O]X/-O\+W^H]V /#JZU4'3_J_;U]0'_A-AV)EM_P#\HWX]TN9FEJ:KKW.]
MK=<P5$P-S2X'<F2FHD!))*04=5!"OT"B,(!I4>\>.;(/ O7^>?YD=2QRU.9[
M1"?+'5)__"Q;:V*I]R_ G>,=-$,SG]M_)#;&0J4B_<>EVE5[&JJ2-GN=212Y
MNN95TC27<W.K@9>VK5CNE\OT?YF0?Y.@]S[I\./5YZ_\*?Y^CE?\)#4$?P=^
M3*@$ ?+G(VO_ .&1L[V4^X@ O%I_ *_L'1KRD%$+:>%5_P".]!?_ ,+!F"]%
M?"W@$_Z6NTOJP7_ESX[^I'MWVX8"YEKG]+R_TZ_,=)^=F"V\9(8_J?A-#\+?
M,=:&?E /*+;^IF2W/^M)_P 1[F+6I\C^T?\ 074:^(A_#)^W_H?K9(_X37_!
M+N3N[YV]9?**?8V<I/CS\;YMS9[,=@917PU'69_+X7(4.&QN*DD4'*U$,]6E
M54BFUPP0QJ*J6-JBGCG '.N^116QMU8%CY<<<#Y]"SE3:IA*K."%4$U]37[.
MOHC]Y=M[6Z$Z9[3[KWOD:3%;3ZJV!NO?N=K:Z3Q1K!MBBFJV3Z@L\QB$:(OK
M=V5$!9@##MO US(L:"K,P4#U)-!U)LTJP(SL:!023Z "O7R&?@_ P^:GPVNI
M##Y7?' F]U^F\L(3P>?]X]Y&<Q _12_Z3_*.H7L&K/'7^(?X:=?8Y'T'^L/>
M-O4UCAU\;'YB(3\NOE-].?D=W?\ [SN;)^\FMG0FT@_YHQ?\<7J%=R_W(E_Y
MJ/\ \>/1=?%=2HM?\DW'U^H_V/LP*Z>BJ4E2">MM#_A(C&$^9GR>/%S\:*%>
M#?\ 1N?%_P#%1[C7W(%((O\ 3G_!T-^2FK-)_I5_Y^ZV+_\ A2=;_AG[Y)7M
M;^\W09YY^F_=N>P5R3_R4X?^;G_5I^A-S9_N!)]L?_5Q.OFI]'Q_\9RZ@D()
M+=O]5@6%OIG*/@^YPW-:V\_^D_S]1EM&)W/^D_Y^Z^T''_FX_P#@B_[U[QE/
M'J;DX#[!U1__ "Z_Y-_67Q9^17R,^;G:]+1;Z^37>7>7?>\]HO6P4V3QVRMN
M;^W7E<AC(,,'A>6//U^*GIFR-<)@\8EDQ],(X!4R5A_NN^O?PQ0#X8HT7A2I
M50/V8Z)+#9UMII+ALL[,1\@23_EZ-A_-:[-^6G3WP/[[[!^%6T:/=O>&!VM/
M+3.TGGR&'P\JNF9W%@L:U/-#FLY@Z,O5TM#,R(_C>8)6RP1XRN1[+#!<74:7
M+:8RPU'R^PD< 3@GRK7'$+]SDEA@=H%U.!@#C\R :U(&0/.E,\.OD9YO+9[<
MVX<ON/<>7R^X,]N/*Y'.;CS^X*^;*U];7Y69YZJLKJNI9ZFJK*F9WEGEE=I9
M)6=I&9B3[R,MX5AHB !   !P  P!]G4*:FFF.:AB2Q\R>.:USGRZ:! RO.(%
M9E8$-;G\_P#%?=M&DG3TF:/PRXC\Q_EZ/?\ RTOAOG_G)\V^@?C;C:77@-U;
MTQ^?[0JY)/"E+M/9SKD=Q2ZRKJL\N+IZFGI=2V>KF@BNNO4"+F:_&TVC-6C,
M*#%<G_53H]VNP%W-%&!4BC-GR%,_D>OK-]U=K]=?%7X_=C]Q[O6DV_UET3UE
MGMWY&BQT"4:1X_9- \L5!0P1J$\TRPQTU+!&EWE>**-"S*I@**)[Z4(N7D8
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MJ2H=2, P(\P14?/AU UTKQ2A>%#I<'R8&A'GTG'>,EBD3 .UXU!O8-R!]?\
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M#[AQU2E5B,G@?CWLC'UL$T?*R4TU/B$GBE7FS(P8?@^U3;S>,*&>8CS!E?\
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M_C7^SU%',<9-[*U<54?;VC_/U30(6!/Z6L#R+D<?UX]C30>BH1J16M/MH/\
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MF/D!_,X%20.CV_OXMMC,DIH. 'FQ\@!YG_ *DT )Z^4%\K?D1V)\P/D'VO\
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M'Y#H',M@DQ34R2ST\\U11TU9)]J^L(:J[B-V!(,BJ07M^EV*\CV93P^#0>=
M<>5>B])]8)H1D@$CC3%?L/E]G37X0 "%-@.>;_7VGZV9*]9H$#-^ 1:P O\
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M)I6M>-:FM,8Z<YDY@AW:)$C![7J:D<*$>1/5!D$-UUE1R?J6!_UQS[D +Y]
M&<"M*G\NK(_Y=?\ ,Q[9_ER=_0=U=;[3QFYMK97;=1M?M;J+^\=7M3'[II(H
MY#1U%95F'*^#)XNI;[BFJ4H)&3540*@BJIU8CYIV%.94TL C#(916A'VG/\
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MX3I,BLH0L.(&HC(\Z5'SZ,E4?\*PO@(U"\N*Z(^8]9D51?\ )*S9FR:&#4;
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M "Q7U^SJ*+J3ZJ:XNPQ"NS.%(R02:#/#!%0*UH/GT 5?4DUDLS.!)I\=B-1
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M-IN;!0\T94$T!)!S0GR)].BK>S/HNZ][]U[KWOW7NC0]!?"GY7_*7!;MW/\
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MZ:7:^\L?_#:M\=DYJFGIZQ8]37AEFI*E%:_+1L/Q[:LK^'<D\2!PZ@E:BO$
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M;=JM7I-*=1Z\MP1?\O[TIZ989'VC_#UE"-)*(D'JE>.->/RY 'N_G^SK<S!
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M(P"3Z9/\O]0\^D&[\QSW31VEFU),:F&A:-YC420!09X'RK49>OE5COY1F_\
MX_;ZW?\ &UMR=4=S[&K,73;8V?4R9V%]P?Q6I$6F2BS,V5BDHHJ6*JF^XIZB
MFEA98A5W$\"2-_J(:,"/]7R-/V_ET<[3;;Y8W2BX;Q(V%6/B*T:\#D@$ZLT
M'$\:T)!/OY<7Q0PGS(^1U%U=N_,Y'!;-P6ULSO\ W;)B7CAK:JBP5114HHJ.
M25)(X9:FIKZ97D,;F.'RNB^14(](^@8'G_J_P='7..Y#9;?Q[>FMF"5IJ +
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MTC3B."AJKK&Y<PI<EOZE6:E":T^6?Y_Y/7H7[7SG^\'$,<+FI-3JU:1@"N%
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M*.%+?CZ^JW^\^["!%XG/2)]V=ZZ5H*T%<5IY\,?9UZ:CIF&F,@JQ'J*!2/\
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MTDW>42RA00H7M! H"3YEL]QZ(U[-^BWKWOW7NNC]/]B/][]V3CUL<>N;_P#
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M[KW7O?NO=5B_+K_MX+_*3_\ $F?,+_WT&X/9UMW^XMW_ ,TX_P#J_'T77?\
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M6AC&E2!^JE*@6XMIL2;_ %Y]K[6GEIIY<1_A'1+>6T#FKM+4_$11Z&A])/\
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M?7CYUZD4N3>"KCJZ>LK8ZB9U::I:1B[,Q%S(_&O_ &//^-R?;D4WA$::Y/\
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MG2#]]D,5 2N:5K4GAQ%!]F?V>0_;.V!C,-1C<FX**GDADI/+#09.5:F.,3J
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ME:.1]F*>=/3@.F&MAVA4HAIYLC'4&PE62B5@O]0'25V('-KQ7_Q]E$_TLY-
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M_GV^V?\ SC/_ $=[]_K7<O?]&^V_YQCKW^N3OO\ RFS_ .]#_-U[_9?>EO\
MGV^V?_.,_P#1WOW^M=R]_P!&^V_YQCKW^N3OO_*;/_O0_P W7O\ 9?>EO^?;
M[9_\XS_T=[]_K7<O?]&^V_YQCKW^N3OO_*;/_O0_S=>_V7WI;_GV^V?_ #C/
M_1WOW^M=R]_T;[;_ )QCKW^N3OO_ "FS_P"]#_-U[_9?>EO^?;[9_P#.,_\
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M_P IL_\ O0_S=>_V7WI;_GV^V?\ SC/_ $=[]_K7<O?]&^V_YQCKW^N3OO\
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M9FR$Q4\M<Z 56Q!M86O8>W8-S9,  C(J:_Y^KWO+-ON2]X(( -!II_-2./\
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M7]IUDD![Q]GGY_(GHS:VCFI1A\Z:<GAGC_D^7RS1[JE5W4X/"P EW3[=IX5
M"\D&29VYXOQ?_ _3VJEF(&1_(]4.V)J!+<,^G#AY'_53J5#O"EFU1UF'6-G(
M8S4U5(6.G^OD+!CQ^#8?T]I]8.3^W/26ZLFD%(V_(:3_ )/EY=/+;LV]H?11
M9-GU1AI%JXY^; Z0!H+7!_)](^G)M[L+L1 "F/6AJ?Y?ZOY])%VF2,:BQ %>
M(%,_ZO\ 5PZ7FR=U;=J\K0T>43=#4<CEGBQJ)+([ .K".,5')EO^""$)_4#I
M8Q@W \0H(/KC_">B+<MD(&K74"G:"II@^0-3Z</V]'>Q78_3.R8\=,W2ZT\
M>GFJ\KV5O"HW?7S*"/-+3XJGJ\72ZV1;1QST3QJ3J;C@MR1?4Y9J'T4@5Q^9
M_81T'8X4E;3!"7)K\8/:0?G13Y88-^WI,]F_,.?/I3T>P-M/@Z/#UODP&7W#
M%#FZBBAC9PB4>.$*X6B9A(S.T=*TI/+2MP/;09:G/'B:D_X>C,[,Y U@T% H
MTJM/D=(/GY@5/G49Z)_VCGLSW#7OE\QE<IE=PRR,M1-G,E)DS*QXO$6?]LL
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN+_I/^P]['7NLL8'W,A_/VQ
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MPXO:QN"0?=;(KTP[5ZZV;LFHJZK;&'_AD]="D%4_\0JJW4D;:E%JB>4+8_D
M'W[KP4#J'N3JO86[LFV8W#@?XAD7ABIVJ/XI6TGH@!"#1!411\7/.FY_)]^Z
MT5!Z57\ Q/\  /[K_:?[@OX/_ /L?/+_ ,!/#]OXO+K\W^9].KR:_P ZM7/O
MW6Z=)7;?5>PMHY-<QM[ _P /R*0RTZU'\4K:OT3@!QHGJ)8^;#G3<?@^_=:"
M@=3-U==;-WM44E5N?#_Q.>AA>"E?^(55%I21M3"U//$&N?R03[]ULJ#T_8#
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M  =&,PG4?;V]WHL[V/35-)54-93XVBH<XE1(PI@VG_)<=14<-/ 0Q_;),$1
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MB5<A!9;:38:=#"UE^MR;<\ >]G*Y)/7MQE\!T^F55S6M .( &14G]E?RZX9
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M:?E7I4DDE,@'Y@G_  4_R]06BAM8U )YX:,_CVSI ZJ)7]#^WK$8(OIY8O\
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M=>ZK%^77_;P7^4G_ .),^87_ +Z#<'LZV[_<6[_YIQ_]7X^BZ[_MH/\ 3O\
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MP>)[N)\V''\_SZ*AV=T[F^OJB*-\QA=S4<L:SRYC 5!R4"-9;)(ZDLIUF_Y
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M.P<K6QQ#2P_=DI8)R$#!23R.1Z;D^T]Q-(!4+7RXD'_!T3V]LADU&32?32I
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MAF;HZF.:H>4,I5E9@P8%KBS&QL"S$ FUN+#DW8U ?\6./^KRZD*QO(IXJ*0
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M!_XK_9/6*W^\_7VV_3Z\.HK"]N?S^?=.F1CK$5-U&EN203?_ 'GZ^Z$_ZO\
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MI&O@6S:5#&@J\+,?M))ZZ><D>UNQ;KM%G<W%KJDDMXG=O&N%U,R@DT64 ?8
M!TM?]FN[^_Y[W_UUL+_];O8+_P!?'FG_ )3?^S:T_P"M'0I_UGN7/^43_LXN
MO^MW7O\ 9KN_O^>]_P#76PO_ -;O?O\ 7QYI_P"4W_LVM/\ K1U[_6>Y<_Y1
M/^SBZ_ZW=>_V:[O[_GO?_76PO_UN]^_U\>:?^4W_ +-K3_K1U[_6>Y<_Y1/^
MSBZ_ZW=>_P!FN[^_Y[W_ -=;"_\ UN]^_P!?'FG_ )3?^S:T_P"M'7O]9[ES
M_E$_[.+K_K=U[_9KN_O^>]_]=;"__6[W[_7QYI_Y3?\ LVM/^M'7O]9[ES_E
M$_[.+K_K=U[_ &:[O[_GO?\ UUL+_P#6[W[_ %\>:?\ E-_[-K3_ *T=>_UG
MN7/^43_LXNO^MW7O]FN[^_Y[W_UUL+_];O?O]?'FG_E-_P"S:T_ZT=>_UGN7
M/^43_LXNO^MW7O\ 9KN_O^>]_P#76PO_ -;O?O\ 7QYI_P"4W_LVM/\ K1U[
M_6>Y<_Y1/^SBZ_ZW=>_V:[O[_GO?_76PO_UN]^_U\>:?^4W_ +-K3_K1U[_6
M>Y<_Y1/^SBZ_ZW=>_P!FN[^_Y[W_ -=;"_\ UN]^_P!?'FG_ )3?^S:T_P"M
M'7O]9[ES_E$_[.+K_K=U[_9KN_O^>]_]=;"__6[W[_7QYI_Y3?\ LVM/^M'7
MO]9[ES_E$_[.+K_K=U[_ &:[O[_GO?\ UUL+_P#6[W[_ %\>:?\ E-_[-K3_
M *T=>_UGN7/^43_LXNO^MW7O]FN[^_Y[W_UUL+_];O?O]?'FG_E-_P"S:T_Z
MT=>_UGN7/^43_LXNO^MW7O\ 9KN_O^>]_P#76PO_ -;O?O\ 7QYI_P"4W_LV
MM/\ K1U[_6>Y<_Y1/^SBZ_ZW=>_V:[O[_GO?_76PO_UN]^_U\>:?^4W_ +-K
M3_K1U[_6>Y<_Y1/^SBZ_ZW=>_P!FN[^_Y[W_ -=;"_\ UN]^_P!?'FG_ )3?
M^S:T_P"M'7O]9[ES_E$_[.+K_K=U[_9KN_O^>]_]=;"__6[W[_7QYI_Y3?\
MLVM/^M'7O]9[ES_E$_[.+K_K=U[_ &:[O[_GO?\ UUL+_P#6[W[_ %\>:?\
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MVO[J\GU)J0?V?/\ V>BRUM(*:RSBIKFA\CZJ37%/SIQR7K"[TRN($"R28_2
ML>M<1!DW)1E_,I$)8J+$LU[6!].OVS) )1Z?ZOGT;P&&W)TUK\_M'"GR_P!5
M:]=5\6!W92?P^OV/@9LK-%/#1Y?#4AP,\IA%A>"BO&S(6#,P4@V( XX+9(EA
M!+$ CU-/\/1Q;;O>"@179<U 5FU4J*=HX_M]1T%?8G3NX^O:W&P9RAJJ09G'
M)FL?!54S0S>*=I5 =& 8:/$_XYTF_*FR:-=?PY^S/^#H5KO$C1_J+I;T((/E
MG(KTB:? 3.J%82^H@F$27:S $ A0S:B#>P4GG@?@OAQ%@\1QKCIH[I+-B-21
M3\()(SYTK_/_  5Z&C;?1F:R^(EW%EYL5MW;-+5P4TN4SU6N*@,RKJ>FIRXD
M>NK52["EI*:>;BS&._M/=7HC6BC4?0?Y>./]5>M6\4]P0]=.K#%JX -,$4S_
M "^7GT=FDW?\9/C+MZGQ"X7,]@=C97'P2SU><QL>&..CJ+/X_P"'WJY<:[AE
MD6"L66LD4!ID@C>$R!Q/J[MCI) ^S_9'0WB2PVN-3(%D;T!J>'H%:E/4T_P]
M!/O+Y!].[^CBIJCJK(8)&+QPUN(W0*@IH>0L5IY*6"%+N]PK!' 4,S<@,:6M
MM-&>XG\\?Y>@GOK07K5C0H3\OM'FOR/^JE0<S>#Z&S=.IQ&=W=@\F[*Q@W#A
MD@@9IF4A9*BC?)OZ='U6FA%Y-3J$4L3*0NM/Q?,9'\NB6VD2#-0"",<"/Y4\
M_P#".D5E^E,_CJ<Y&GCDRN.5KQY.@ECW)2Z7-UM/1 @ WL=>D@^E]+&WNT<Q
M>BT.?/\ G_D_XOI8=X*8TU%."@G_ %?D/V=9\3U]N))8#Y,C#'-*PCEAQM00
M]RI/) #:M"@MJL-//T]JU<+Y=!]KDRRD*C#." W^10/]1KT,.'WINWJZ@K,_
M6;DF@PNUJ=ILDDM?123+'5".%:=*59TJ_+.X6-*?[B-"VD.T:@.J+<Y8YEI2
MAP./R^WH\V#:[NZN-80:%8G4=7IY]M/+@?LR>D?@]S[V^3&\*;>V\H-N8[:.
MV_M*7#[>DJ(,+$\TK1QU,\DIC45>5KD#F>KG.I4=DCCCA,$<9!#LX)+U-?+_
M &.I%W7=#;1!1X:D&FD,"S8R33C0^7S^=>K'-N1]5Y_; PG9>9I=G4./KJ>-
M\;AZ2GS=/5U,,4,".\.*I:FB*0HHL!4@+Z@K!1J]IIS<VYHL;D?Z5J?X.BZ*
MVV_=8 \\B(_F-:ZA]E>L$71NW=P7I=J=B2[@QM;61I1X##;7I]F02PCD/]Q(
MM3'*WIU"(,/H2U[7#)WQ[;^TC8?:&'^'I&O(T-Z?T+FJ'\"Z"WG^8ZQ;X^.&
MX*33)1[%WM7X\4"TXFJM^TF7O+"%\FA$A,K*0W 68@<"-#>WM59\PK*U:J!Z
M$_Y^BS?>1&M(],"2-3@00"?,X$9]?S^SHO6'VEM8Y%*&MV312&:IIJ6!<I0&
MLJ89U+QN%IYEB]0ED2-]2,3^D6OI8TGW)"E0RGSPP)Z*]AVN2TD ECD'$9!^
M7] ?['1N,GT%NGL?.T.(VZF?Q^VI\73TL&&5THL;32XU$B:%;I&U/&H(*(4*
MNT;JI'D%@W#S*(I""5I\ST+]QY%?<R&B9EJ/3_/C_+\^@CW3\?/X?+E-H3;%
MPM6M'.E"VZ\AE*6AJ9YZ=PKM301,M.(2VI"\D;E6Y( 'LQ7=@[5J/R/12>5Y
M=M0Q!]1\Q_L ]5_]C]29CK[<F5P&8Q:HM+)#+25+4T%6CQUFEX@)Z96@>14E
MC5PK"SW!52;>SJWN!, 3]E>@E=^-MLA4FN-5#44K44\_3I%8?;V.?(Q15='!
M4QL\BRHGDBL"!PVAXK:+$F[ @7-^/9I$J&A_S=()=[G0$\:>>?/'R\_7YGH0
M:W96VX9%IZ?&RT<X"SQM29*5PRSH62WEGG74H8V_42;W N+NB+43C'Y]$TW,
M[DZ:$DG&,X\Z4_G3B#ZD]"GU!V#N[IC*M4;8K/XCA,O$<?GMIYD156-RE+,5
MBDBK*;P!'#QKIU6U+?@@\^TU_M O4HM01D'\OR^S'1MM'.<VV,'N AB;BAP:
M%LBAU<!G(^>./0P[]QFT^P!0;[V!UJ_7X-//'N*# 9Z/(8^FEGE#0/3I54D<
MBI-*YM&92FGQV1>/89MWEVT-',0_ +04(I6OF:UKT(+R*RY@998(YTBD--*U
M=$II\_#!4$4XG)&*=-'=W0.'H]G;4SCRYO<>,SJU"4N=JC#AJNF:CMY::J/V
MTZ?AA&AE9&4F[ DCVY97R7;E1QX4&2,T].FMSL)>2462U5Y%<@$LI ->-2M!
M3CT1'(]=X_$Q5DL=1D"L*/-+#(5G9?LU+/''''$/(QTD+Q8D\\"X.7A%OD_M
M./\ -U:TYKDW)A %I7T!( K]E/S/E^WI![=HJG,Y:HDGB\>$HZD"6B2L4)9+
ML4=_2TSE48,R@JI)"E?U^V1(":?Y<>GGT+MS>*R@P06(K6HK7XJ"E.'R_/HQ
M& [DPO6LZ5N.VOLK?]6E ]-08+<^WXLGB:-JB129##5QD3544<#%6^VD0%]*
ML6((K?6:WL>BM,@X.?\ #T6<KK):EKANY35:%?6GD0:9_,=*7-_-7Y"[GBEV
M]+N>8[4>5*+$;"VSC4P.,A:H @BB@I<>*9W#RN=*2-(I9^5L0/:.TVF"U;52
MK$4K4$T_P]"'<9KK?&6VB?3'4$*%H*_(+0>?'Y^G0F=R[&W[T]LK$;C[(;KS
M;VY=Q4U+5XCJS'[A;/YG1D9%>6KR$-/#44>-@1!(=,F5\@GO'X/(/2_9;ZTK
M$!#0$C50@>GGG\QCY]$7,/MBE@P>6<5["5-*G\@*5\N/1-L;O_<%)7/7UB8C
M)/)(CFEK*/\ R<@^OQZ8W@EM$6L"7!(%](OR8^*\V>%?M'^'I#/LEI,B4UTC
M%!ITFHQQP1^SCY=##M#?>8W?G<7@$Z[V7N7)Y*JBIJ2@J:"JG67RB11&QJ,B
MXAB4*SEP$L 2PT*2/35H:L /M_V>BZ#;K=2-*RFAP2!I!^9TGH:CU]MB+)-/
MGJ+;?661B8K74.&R\VZXXBGJU)21TM0 $8H+)D90"%(DC5"4+H[J149%4GC0
M@$^OI7I9%M:>,C^(OEBH]0?EG\L=6+5_:W259L?;8S6SMA]V;CH8I:&JW/EJ
M2LV[!H@ 5(I8ZZLR514!+@>25"K#UJU^ #I]NNI)6(UJ#Y%33R^74GQW^W+;
MI'(L3NM:N6I4_:#3_5^SC1_)G"X2E.%ZHV7UYM3(K$*1,!4&II8)F@C"?:Q3
MTCXXF1@ L:K3,97&D.2-+439)6;]75I\L4[O]5>O/S1%ML)^F6,L/(MQ'H*'
M)X?;T67=GS1PN^<=78GM7J+"[FQ=<)*.0X/>U7BZFG9HUBEDCJ*BDRS"0%?V
MT>,%E0!BR>GV?1<M.P_2>GY ^GH1T![CFVUW@TNH7U5X)JU5_-'I\J]5A]A4
M&"&1JS@X,B^VJJ=WP[9>>!ZF.,A24E^V18BZZPNH*@<*6"*=0]G\<;HOZAU$
M>=*?Y3T36UW%!(?"RIK0!@W'/D/L\AT#M;MJ-D!AF7G7K!.GD_BY ' MS:_]
M?::@8]BX_P O0IM]PCH&./(@G_50>F/MZ3T&%R<%6&I2XF0&QCE*DZKG]0L&
M/U_/T][\.N*?/HR&X)*M1IX_Q#U_+IXBHZB>&/[BGO*NJ[SL&M9N"0I+?6_Z
MN/;1J&((-.' T_GTV9_%=""./&H.!3Y_X<?/IMJZ#4LKZ4>Q"ZX0IN"#Q<<
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M>#>)G :E<< N#CS)/'CP'7LQMG#8E)8:O-"/+QL%?%T5,*[0%^OGJ%F,"/\
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M(_49]]IM[.U;6 #0%ZD4!K1OG_DZPB^\5R@_,NZ>(E"54#)IVZ1T0/*?#S<
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M=QDTFD>4(C3 K/1+<-:[$>P @9F-"03PR<>GF>I&O(($72$1S3BRC/EP(/\
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MS[+=#YBCDPW\6PDE+0PZ<?/]I-$U6/*9/&J/F*:V3=K99(W:0^#I<2:56LS
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M[KW7O?NO=5B_+K_MX+_*3_\ $F?,+_WT&X/9UMW^XMW_ ,TX_P#J_'T77?\
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MS;<V1%DD53GM !I3_;+QZ+?6_#]HI9H#NS%Q_P"4U+-5TL4U7XU1$"QLFH(
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M_OBMJ^U_-/\ R6[/_J'_ .TA^D/+W_))N?\ F]_U97IW_D;Y_,[4_P"$]/\
M-,W1MS)56'W#MO+_ #>S^!R]$_BFI:W#](;2J*6IA;G3+!/&CH;<,H/NG-T:
MS;S:HPJ&$ (]09W!'5^69&AVNX=30J92#Z$0J1T77_A(A75<?R7^7&-2=UH:
MOHO9]=4TPMI>7'Y]8X7/%]4:550!S]'/^%E7N4/TH#_2?_ O^;ICD,]\P^2?
MX6Z6_P &OY;6T>\.S?YLWRV[E[Y^176OQEZ/^6_R^VCN#IWXU[LR6UJW<L.P
M'R&;S\.13'>:JR%'_ <K2TL-!2TWW5:TDD G1;1RIMXWEK6*SMXXXFD>W@(D
ME56TZJ**:L#*DDG X_/I3M>V">2ZG>2546>8%(V9=5*DUTY."* 9QYUIU:Q_
MPG][1_E]]CM\FZ?^7Q\-NU?CQL7;3];4V]>U.V=U5>ZLANNOKSF#28XO-E\_
M34CX>DA^XDIJ;*^.(Y /]NIF\TQ%SA;WL!B^MF25B&TJ@ "#&:!4^(XK3.GC
MCHVY8FM)ED^DB>-05U,V=1SBNIN \JXKPSU7Y_PE3RT6?^0W\S_.P8S)X6#-
M9GJ?+0X?-48QU92)D<YOR9::KIU9Q!4P!PDL8=@CJR@FU_9QS\GAV]FM0:(X
MJ#4&BQ"H/F#Y=%G)S^)/=-0BKJ:$4(JTAH1Z^O53/\EJCJZ3_A0'T^U52U-,
MM5VK\S)Z4U$#0B1(ME=D0,\>H#6BSPS1DBX#HZ'U*P CYC8-L;4/".W!^7=$
M?\!Z(ME4KNXJ.,DY'S[9!_A'5ZO2N2VG0?\ "M/Y?4^XY\9#ELO\=]L8W8BU
MY02R99>M.KJJ5*+5S]U_!*;,,=/J\"SC].KV$[U6/+MO2M!*Q-/3Q)AG\Z?G
MT([0@;Y/7_?0I]NF'_)7K7L_G1=5_*[(_P Y?N7%4NV.TLIV;V%VAM7(_&Q]
MOPY">NK\;'2T VX^UZB&SVQ[1*FJED44E5#.7:.2.1@,>5+FV3:E+% JJWC5
MI0$DUU#SJ.%>(H!T&>8[>X;<3I#:F*^$17R ^$^5#4GA0U)]>MH/^<[D-LTW
MR:_D'[:WG58"O^0%/\^.B,A4S4RI+6+C(MP;.I]P2HR_N0X^LS0QA4, LSP7
M2Y@DT@'E4.8;\K7P_I9*^FK2VG\Z:OY]#+F(KXEF#37]3'3UTU&K\JZ:_EU2
M-_PK:S^9J?GYT'M>?)54NWL/\/MJ9_%XAWO#!6[DWIOBGKZF-?Q+508K&I(;
M\K3QC^S[%_MQ&HLY'IDS$$^H5$('Y:C^WH+\]2,;F-*X$0('S9V!_;I'[.K
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MF@X?MZ.E\6ME;KIMY)2;6S.,BIJE$ES%1GZZ#!4!2*-[)**NHC4>(>--:N6
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MYCS/3T3_ +>XH-OT$#Z%75X6!@!+6+K]2;'GGCVU]68GTCR_S?[/2*[V\R#
M/\N@$[!Z?VOM0-45&8I,C3SNS?W=DVC1RM,D0( =W)*H3PQ.@#A1]?9C#?/^
M'_+_ +'3%MMP.'KY\:<?]1Z)/OWI?J;<BS1XO!Y#9N0TRRQ5.#R$#0M(=199
M:"59TCB8>EC#,A12-*.01[-(-TF7TZ07?+4%QQ^?"@X]5[;UV!F]G9:HQ^2H
M91 )I(Z2O$5HYU&I@T9 M<C^S^H?D"WL5[??K**$@?\ %]1UNFTR6#50,1D<
M/\W093P2ACJ0C]0M:W O<_[#VJDC ..F[>X>(TI^W]G4-EN1_3Z?\;]HW%.A
M5:S%QJ_U?SZ;)E7@"]P6OQ[:8TZ,M>@C\_Y=0VX!OQ]1[8; Z6H=5*=1FOI-
MK_[#_#VSY=/$]1W!+#_ GGWKHVAP.H\C&Q4,;$G\W]ICPZ.8U H:=-4[R$_C
M_ V'M,Y/2P( WY=,=0=9-U4G_6_I[3/GHTA7IGD6S6M8F_T/MD]*4/5H?\O?
M^;_\R_Y;DU=A>EMTX3=75&:KSE,YTIV?CY]P[?>JF:/RUU"*>JHLAB,A+%&4
M>2CK8HIKJU5!4F*'0%]\Y7M=\[I 5<"@D3#<.!!!!'Y5Q0$#H2[1S!<;1VH0
MR5RC9&3FA%"#_+-2">K*^^?^%5'SX[1V3DMF]8[ Z2Z"JLUCZ_'U^^]K8[*[
MJSU.*Q/&LF)GRF0?'4$R*TA\KXNIE5_&\+PLA+A^S]N[2!M4KO)0@A<*I^VE
M2?R(Z.[KGBXE6D:(E0:G+'\N %/F#UKJ[&[B[3ZU[5P7>.QM_;IV[V]MK=B[
MYP_8E)EI9<JF6,S3R5TM5,9'JI:B1Y/N!/Y%J5DD2H61))%8<36<5Q$8753&
M5TE*=NGR IPIY4X>700BNI()!,K$.#JU5J:_.O&OG7CY];*.UO\ A6-\X<3L
MNFQ6Z.BOC/O;L#'4-;28_L2NPN=PP:2= J5%7BZ+,QPO(6 ,RTM31Q2@!52&
MUR Y/;BV9ZK+(%J*KVD_.AH/RJ#3Y]#).>IPE&C0M0]U2!\L9_/(K\NJ)/D5
M\Y_D9\K?DC1?*;O;=\6]^R<1FMNY3;]!44KT>%QE-M2I2KH<1C<;!-&M%BHY
M4):**59)7DEGEF>IEDF87V6R6^WVYMH@0K AC^(ZA0DFG'TQ0>G0:N]WFO9Q
M/(064@J,Z10UH!7AC.:_/H=OYD7\UGY#_P T/)]1Y7O[9O3&T*CIF@WIC]KI
MT]MW.8!)TWU)C)*LUXS6XMP-*T;8JG\)A: *&DUB2ZE$VQ\NP<OZQ"SMXFFN
MLJ::=5*:57^(^O3N[[Y+O6CQ0@T:J: P^*E:U9OX>E%\TOYO_P E?G5\:^E?
MBSVWL?HW;O7W1&3VCE=HYCKG;6?Q&9J9-EX"JV[2KDJC)[FR]%,DE%5R/*(<
M?3EIPK(4C!B9K:>5[?9IWGB:0LX*D,5(HS!L413Q'KT[N?,,VZQ+#(J *0P*
MA@:@%?-CZ^G7MY_S?_DKOG^7=@?Y9V6V/T;3]$;>QFU,51;LQVVL_#NYH]GY
MZ+<5,TM?+N:;#,[UL2I*5P*AH"50)):0>AY7MX+TWX:3Q"6:A*Z*LI4XT5X'
M&>O3<PS36HLRJ: %6H#:J*01G53RSCHU?6/_  I&^?G4G77QIZEV?MCX\4/7
M_P :NO=I]546$;96?JO[UX+9^"H\!34NZC4[HJ()IS3T,%1]QCJ;&RI5:S&4
MI99:60ONN1+.ZDEE9I=4C,]=2T5F8MCLX9I0DX^>>EMMSA<VR1QA8]**J\&J
MRJ-.>[CCB!Q^6.D?_,#_ )_GR_\ GMU#)\?:K;76_0W2^5.-;>&U>J:?("KS
MBXJ7S0T61R-=63%<0DJ4\@HZ:F@#R1#SR3QVB6^R\EVVT2"8LTCCX2U %^8
M\^.2?L (KU7=>:Y]RC\(*(T/Q!226^5<8^0'VFAIT7'XP?S:OD;\3OA7\A_@
MGUULKI/-=1_);_2U_?O<6]=N9W([CI/],FT\?L[*?PFKH=R8W&0>#&8V"6E^
MXQ%5HJFD>7SQ%85,K_ER#<;J.[=I \6C2%*A3H<N*@J3Q.:$8Z+[+?)K&WDM
MD"%9-6HD-J&M0AI1@. Q@YZ]\8/YM7R-^)WPK^0_P3ZZV5TGFNH_DM_I:_OW
MN+>NW,[D=QTG^F3:>/V=E/X35T.Y,;C(/!C,;!+2_<8BJT532/+YXBL*^O\
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MZ*BV]'B5U!O0:F:#1+(H4ZPNH?IUW U*S9M@W2F*85%>C8]/]I[>W5'3XB/
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MMV+G9@B559A'EFC80+96"(PE90SHKD,6!8DLOT:M0A[N'^KTZ5VKR>3G^?\
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M_P"+Z,(=HB7T_9T+JX+/3TD%//GXZ6DA9Y:V(44]; $\H5"TDB14RA=18D,
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MY'N^>[U;6W!" @S3$=D,=<D^K'@B\6/H Q 3YQYOMN3;-KF<@L:B*(&C2OY
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MDA-+I_FQ<D\:N>.%<+CHOE@\0_+IDJ\15,VMHG*3/*=5.VHNKE3IX],80D7
MX(O_ $/M[QCZ=)9]OU_#_(=0?M#2,/"8P0?#J8+P& #7*@ZC^!<B_P#4>_>,
M?X1^8Z3-9F,]Q/7457/3Q3*DK%3))3PAF]14?2R6=OU* 2'XT@*2![M]0:9
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MN<G(Z2QQ-(0U":^G67Q$1JR2,H#BSM'J8!;$@)^HKK-OI]1?Z>]5 \NE#1.
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M0Y*CQYC65_N*=H[+(;!$<QA&)!MZFN/\![MXO3 2AI3H1MM]9?;NNN6AQ]/
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M>\#"E1T\ME*WET\)MR0022LBE(E2G=!*R,&F9O\ -@69V5-/T((U-8^GAL7
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M%J>4.GJ 0_4"WTO<6_-AQ<\K?%'6OI3_ *O^*Z2E11U(CTV<$I=9 "MRA/\
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M0?52I552+,(XXNCNGY+!&!75JY!-OZ$@>Q)M!I8P_:_^%NHFYHS?2?8/^.]
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M:=)!6ZZK&]N0>??F8,.M^ ?ET]4U?2^4"?!X^H2I:\CR.6 :7QH;H/VVC*,
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MGQ6]/M$RO&:#IUK.%LT'24?K;XYUMX:3ODXB"4NT<6X,+-DS&9.2JZ**CO\
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MR*+ +^2L-R>O1;6B],-10QTDE'1T.TQ#75"O%4U%12&$EX]$9'A/-WO=@E[
M$Z38^Z_5D&G2@V0\A_AZ3-1@$#T\QVQ,8RC13)5F9XG'C&NP"!%T%"4!%@RV
M#>W%F R>M?1 ^74:FH)8%K9<;324#54D56T4-,3J\2D7:55NR1^-23J++J_
MY]W^I'3JP:<4Z9%Q=2T9A*R)*42.*ENX7UW),E@3;_4KJ# <6)]M.RG/KTH$
M)ZXTE!4PPGQR.CZF37$RZ6N+D6)<'3:UK<?3ZWLWXFKK6ED_V.GZEDW%0Q!*
M:HKU!]200*RQW_3Q92A8G\ <_P!/Q[\6 ZJ:_/I:;;V[OW/&GK'V[]Q3U?B@
M:NR=%3QQ,B2C_=KM&LE@H-XW<_@@'CVWXHZVD>KH1.UNG]I8[$8*ICQ4,63D
MC*Y:6AIIJZ)"FF[1KY(U2[W/+78$#TD>]"4UQU<VP/12*_9>)HM6FE(12BZI
M8THAHLNH2E TI7TL;-,!P#>]A[,8YC3KWTP45Z0M;G-M[=,WGRU#B6BU)%3;
M<IS55#:R0@9X@MKZ>1)+_KFWM]&9NF&*IPZ!/,]D8?7,\6'RV0DFU6DR%?#!
M<I;U,J12^F__ #<)^GT^H5:#TA,H'2'K>T)4@:.FV_AHW+Z3454<M<X4DV('
MECC]'!MH%_TDV /OPBJ>O?4#A7I'UW9^:CC\=71X:HI9E\)6"B>FX-B0"KE@
MP^@L;$?7@^U"18KUIIA3/2-RV]%R\;MD,/A)QI#QF2F8LK#DWD9Y/HVHW"*;
M?F_TOH'37BCI%5]=BI2D]/AJ)"=0E,%75.8V%OTEY=/)]0]-@?H/;HCQUHRC
MT/\ J_/IEESSQ*1325"+]05JEE;_ )"#0\V_IJ_V/MZ(%.'3;2ZN'^3INGW-
M*YO4358:Q(=/%)JTBW]H!@?\!?CZ?CV]XC<.FZD^?32NYU8O$]?D8O0VD2QZ
MEXM]%!*_\F^[5ZUTG\C6TE8S>?,(YU'2)89+"_T_4^D?ZP 'O76L#I%5U'JU
M%:JED#7(8,#?_8"Y]WCX]67CTD:NE<']41L"W'I_VW'MTCI4C^6?\/2<JXV
M0$HI-^+?\:]LMCI06KTF*U04:X'!OQ_L?:=N/2Y,@?ZO3IE]ICQZ6CKWO76^
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NN+_I/^P]['7NLR?\  R7_ *AV_P![]J&XG_2G_#TIC_M%
M_+_">OK2_%K_ +)D^.?_ (@CJ+_WG\?[QENO[5_],W^$]3W#\"_8/\'0[^V.
MG.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[JL7Y=?]O!?Y2?_B3/F%_[Z#<'LZV[_<6[_P":<?\ U?CZ+KO^V@_T
M[_\ 5I^B)_(BGI:GYQ_S TK4>2F'R$ZS#JKF)0$Z,Z>Y9@/Z'_57OR+>Q+LD
MBFR@!X]_^%NHPYC@UWLA%>'_ #[T"5=U[)3(8J:*HF:<2E#XVK+'ZZ@NEE 6
MZV])=?S:_LUKZ'H+_3C^$_MZ:*;J'<F1ABJZ7$UTU&UY$-/ T1(8'2SJ)!_K
M+K&IC]+ ^W1.5%*C\QUOZ!I,C ]/]0Z?J?HG?\L,4]-MV<0VDAI%3Q,Q*E4&
MJ190EK@7);CF_!M[J]RP'$?LZNEBT7<<]/-'T[O8^2.MVW5PM&BK_G8)+\ZA
MPLMF(#?B]A8_GVG$[#S_ -7[>GO";^'_ %?LZ;J[IG=M*T[C;M:XY<2/%P5=
M6NU_(;Z&L""4"K?20./;PN3_ !#ILVW]'^?^QTU3=2[QJ[7VM.\ -O,T],0S
M4]B%5%J)&Y!X_/Y]V\<GSZ;>T)X"G\^FR;J3<WJA;;]=&D=0(@T8\:NT:\E'
M+K')R+$:BR_E1^HW^H/"H_9U463GC3IWQO1>]I:@Q_W=KE,=#55+10TJ*ZQT
M:!S<B5M2JG+$Z>!]?=/%/J/V=6%B1T_TO4N_8$*-M3*.^E-+0Q:D*(;+)<$
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M+$@_1KM]/?B:<>GXQXF>F6J<NK*+  $&WMH]V>C..'5P/[<]-&A_I<?Z]O\
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M?YMM;@8L"_\ +7ZP^V#QM.TGSZV\^HQ<W3_?CAHS>_T8_P"\^VFW>Q)KJ?\
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MD<E\..LD,E/44<-)_LXF :*&*J.MT1!@%!UL%+,3J8\L6//M5:<Q;?;##/\
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M .\'IS^I5W_%'_O3?] ==_\ 0-#_ #:_^?6]7?\ H[,#_P!?_>O]<&P_B?\
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MN_\ 1V8'_K_[]_K@V'\3_P"\'KW]2[SUB_WIO^@.O?\ 0-#_ #:_^?6]7?\
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M_P"\'KW]2[SUB_WIO^@.O?\ 0-#_ #:_^?6]7?\ H[,#_P!?_?O]<&P_B?\
MW@]>_J7>>L7^]-_T!U[_ *!H?YM?_/K>KO\ T=F!_P"O_OW^N#8?Q/\ [P>O
M?U+O/6+_ 'IO^@.O?] T/\VO_GUO5W_H[,#_ -?_ '[_ %P;#^)_]X/7OZEW
MGK%_O3?] =>_Z!H?YM?_ #ZWJ[_T=F!_Z_\ OW^N#8?Q/_O!Z]_4N\]8O]Z;
M_H#KW_0-#_-K_P"?6]7?^CLP/_7_ -^_UP;#^)_]X/7OZEWGK%_O3?\ 0'7O
M^@:'^;7_ ,^MZN_]'9@?^O\ []_K@V'\3_[P>O?U+O/6+_>F_P"@.O?] T/\
MVO\ Y];U=_Z.S _]?_?O]<&P_B?_ '@]>_J7>>L7^]-_T!U[_H&A_FU_\^MZ
MN_\ 1V8'_K_[]_K@V'\3_P"\'KW]2[SUB_WIO^@.O?\ 0-#_ #:_^?6]7?\
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M_P#]*NS7_P!B'OU-N_W[/_SA3_K=U[Q;K_?<?_.1O^M?7OX[_.@_[P[^%_\
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M]^IMW^_9_P#G"G_6[KWBW7^^X_\ G(W_ %KZ]_'?YT'_ 'AW\+__ $J[-?\
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M/^MW7O%NO]]Q_P#.1O\ K7U[^._SH/\ O#OX7_\ I5V:_P#L0]^IMW^_9_\
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MN/\ YR-_UKZ]_'?YT'_>'?PO_P#2KLU_]B'OU-N_W[/_ ,X4_P"MW7O%NO\
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MAW\+_P#TJ[-?_8A[]3;O]^S_ /.%/^MW7O%NO]]Q_P#.1O\ K7U[^._SH/\
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MJ[-?_8A[]3;O]^S_ /.%/^MW7O%NO]]Q_P#.1O\ K7U[^._SH/\ O#OX7_\
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M?_.1O^M?7OX[_.@_[P[^%_\ Z5=FO_L0]^IMW^_9_P#G"G_6[KWBW7^^X_\
MG(W_ %KZ]_'?YT'_ 'AW\+__ $J[-?\ V(>_4V[_ '[/_P X4_ZW=>\6Z_WW
M'_SD;_K7U[^._P Z#_O#OX7_ /I5V:_^Q#WZFW?[]G_YPI_UNZ]XMU_ON/\
MYR-_UKZ]_'?YT'_>'?PO_P#2KLU_]B'OU-N_W[/_ ,X4_P"MW7O%NO\ ?<?_
M #D;_K7U[^._SH/^\._A?_Z5=FO_ +$/?J;=_OV?_G"G_6[KWBW7^^X_^<C?
M]:^O?QW^=!_WAW\+_P#TJ[-?_8A[]3;O]^S_ /.%/^MW7O%NO]]Q_P#.1O\
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MZ1XO(EV'NO='>]^Z]U[W[KW7O?NO==,RJI9B%5069F-@ /J2?P![]U[JJ_\
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M4O?NO=:OG2WQZ^2GSQ_F%_S,,?O[^8%\T.F_CU\0_G+UC6]-]4_'SNBHV/\
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M-08FFGG^WB=#[KW6R)M/ G:NUMM;8.8S>X3MO;^&P)W!N7(OE\E7'#TT=/\
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MF]];IR6W7I\MN/,Y:KR,3XZ"KJC28R SP"FD,KGW[KW0%;F^8GRFV'\#?^%
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MBFR<55FL;B<U44,E+A9\E60DT+)-+3)3ET,JGW[KW2&_F']J_.M=^_"'L/\
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MG?S*_B]\P_EUW#\':SX?]F]-_./>NR^T]X8+Y.[EW9LG+[#W9MO;U!MJKKZ
M;9PV4AW1A*VDQ]-4?925..J1+&*=:F-&:I/NO= #U+_)W^5>P_Y;G\W;XC;S
M[AZ9[%[R_F$=^?(SNS9W9\0S&S\)-6]\;=VQ35=7GJ%<9DJO;YEW#C<Q-]G1
MMFEI:.2E45M5+Y=/NO=6#1_"?M5/GA\'_D\<]U^=@?&KX3]P?'#?>*&5R/\
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MQ^/H8VGR>-IC0X[*UJFDFKH&JI)(J>JE]U[IT[=^$W\S#^8%5_&GK7YW[1^
M'6_7/Q[[WZL[XW/WGT!NC=W8.]]P9+IVMCKJ6GV;C,_MC$0; I]PSQNN0J&W
M#D:FGHY'I($GUM*/=>ZV&??NO=:[6V?Y2OR1P_P/_G;?&&JWATL^_P#^9!\R
M_FQ\ANB\K!N7-OB,9A/D;3X2+!4VZJAMNK64&4IFQL_WL=#09*"(-'X*BINV
MGW7NK,_E/\%=E_,O^7YO'X)=QY(T.&W[TWM#8&2W/MZ/[]L;F=DICJO%9J@2
MH2#[C^&9W%T57$DB1^98O'($#L![KW5:_;_Q0_G3?,/X_5_P1^2/97PIZQZ2
MWGCZ'KWOWY<=)YC=F[-_;TV7231PY&CQ&RLY@*/ ;4W%NS&Q&+)U4V?RE)1^
M>J2BIY@T4D?NO='DR7P;W/B_Y@GPR^1_7]5L?"=!_%SX;]V_&63:%3D:V'.+
M+O6LVB< ,;218U\=+CJ.@V]-'4/+DH)4;Q"*"568I[KW3]L+XB]E;7_FE?(;
MYMY#,[(EZH[8^(O170FW,#1Y*NDW!#F>L]P;BRM?45M(^-CQT>-EILK3+!)'
ME9IGD$@DIXE57;W7NO?#;XB]E?'KY.?S)>Z-ZYG9&2VM\P?D/U]VSUE0[8R5
M=6U]%C=J;(PNW*B'.156-HJ>EK7K\?.\:4M561F HS2HY,:^Z]T&'\TWX)=O
M_-O</\N++=3Y_KK!4WQ#_F-_'?Y==EIV!F,EB7K-M=33U4N2H\(,?B<JM3FY
MEF3[:&I:CIG-_)5Q#D^Z]U;/[]U[JG[^9C\'?D/W_P!X_ [Y?_%S,=0Y_M[X
M';\[;W-B^AOD3D<GAMD;OH^Z,)2X*OEJ<AB,=EZO%;BP5/3M48>L_A53'%4N
M6<( &/NO= 5N+X0_S*_D+\\/Y>'SK^0N\?BML?'?#W>G;T%=\8^I-T[JW#14
M6$[HVGF-N9K.0[LRNWJ1]T[FJI)<'X:*3;N#H\?2T]4D=?6S57D3W7NCQ_#C
MXC]C_'WOO^8_V?O;.;/K=N_+_P"3F"[EZUAVAE:ZJR%!BL;LC;NVY(LPE5C:
M."DR7WV*J71*:HK(O"8W,P<M&ONO=5M?"+X,?S8?@+T5E/@ETGF_@YD>FJ+=
M_;66V/\ -[>^=WAE.PXZ3M/+9+.#*[DZ]IL'28O<^[,969*2!';?M%22T\5*
M7EM"T#^Z]T"U=_+6VU\2/Y0WQR^(7RX^4&Q^F.U/CO\ />C[2^%/RRH*#+]E
M8S&=AYKL7<.ZNM<ANB.?#X@4[Y09NLQN86JE@H(Y:EO%E#*]*3[KW0"_S0MO
M_P S_L'?O\ICK[Y>=M_"^EKLO_-7^(<FS>A/A[1[QR-;O*CV9/E,GN#L+.U6
MZ6IY<=C-N4=)',F&IZ6HH:054M14YRLJ8Z"&/W7NK>^YOAG\PNB/G#VU\]OY
M=LOQZWAF/E9L?JW8_P N?CO\D=PYWKG'9JKZ0HZR@VIN_;FZ-O8C/ST.;H<;
M5MCZBCJ\-)25%*SSK,E0JAO=>ZF_&3X!?)"F['^9?S$^8G9'5F[/E[\MNG,;
MT+M;974=#7TVQ.MMD[5I<B^)VOB<KDZ1-P9R6JS&2FKLODZBC@%14!6I<?3Q
MJ(S[KW3WU]\!^X]J?R/J_P#EKY'</6\W>U5_+U[,^*$>YZ+,Y.3:@W'O/9F6
MV]2U;5\F(CRW\&CKJZ%Y9A@S4+"'9*1W"QM[KW1S/@ET;NWXQ_"?XB_''?U?
MM[*;YZ%^-72/3N\<GM*KJ,ABJC*=;[;QV(KIL;/64E!5S4,M322M \U%3RM&
M59X8V)0>Z]U[YV]&[M^3GPG^77QQV#7[>Q>^>^OC5W=T[L[)[MJZC'XJGRG9
M&V\CB*&;)3T=)7U<-#%4U<33O#15$JQAF2&1@$/NO=>^"71N[?C'\)_B+\<=
M_5^WLIOGH7XU=(].[QR>TJNHR&*J,IUOMO'8BNFQL]924%7-0RU-)*T#S45/
M*T95GAC8E![KW0.?RR_B9V/\,_C]OCJKM',;*SFXMR_*'Y2=U4%9L/)5V4HU
MQ7=F]LON/$P2R9#'8N=:^"AKX4JHUIVBCG#K%/.@$C>Z]U5]T#_(^[4V]_)<
M^,GP![0[6Z[V7\MOB7W7D?DYT7WOUK2UG8NW]O;^VOV'N/>.ULA'#F<;@:ZO
MHFQ^::@R,;44#**BH\)F$<;2^Z]T9\=3_P Z3Y&=@]*;<[^[1^+OQ Z+ZL[#
MPV_NW=R?#3?&Z][[R[.CVN9?MMM0MN7!8FCV3M;+.ROE$6;)Y"0".&GJHD23
MS>Z]T:+X8_$SL?X[?('^8SVKO;,;*R>W?EU\H=O=U=:T>U\E75U91XK%;)VY
MMR2#-QU6.HH*:O-=B:EUCIJBLB,#1L9P[-&ONO=$*Z3^%O\ ,L^#7R%^:U=\
M6J#X8=X=0?-CY4;V^54G:OR+[ W?LG>^SZ_LU:6'(8"LQ^$VOF:;=F P"4D+
MX:G3.8PE3/#++2>;S+[KW1.>Y/@E\A_@E_)W_GUXKY ]K['[NR?R6SO??RMQ
M?96TX:["5-?6]H[4P%-N(9'!5E,T> 5,WB:EJ"BI\YEHX<>]/$U8TD3E_=>Z
M'5_B!_-T^6'PSZP^!O=7;OQ&Q?Q:WCUGU5MGN+Y;[*3<[=G;RV#2TV,FJ]N1
M;&J:(;<VSN;-XZ/^'Y+,+NK(TIB,]5244$U2L-+[KW1SOE7_ "_NY,1\D/CS
M\ZOY>^7Z=V?\B>@>ALW\4<_U3W;29&CVAOKK&OJ*?)8[;=9FL-!69G 5VWLQ
M21U>/JXJ*K0L[1U$1B!63W7NE]\6.G_YD6YODMN3Y-_.+N3K7K_9-#UVG7'4
MOPB^+VXLONS9])-4U35-=O#=^X\]B\1D-Q[GE4_;TD=/BZ.@HZ71:.2H5YI?
M=>Z)]U!\,OYL'Q#J/D#\<?BUOCX79+XP]U=[=U]U]==^=OS[NGWWUZG?F6JL
MUF*"79F)H(,)O"IQ=?65#XV0[IQ<4K.&JRB+X#[KW0/)_(_[SF_X3P;C_D]M
MVEU;CNZ8\CO#+;1["^YRN7VU,:3N2J[+P%-D:@8JBR=-]_C$HJ*OGAQ$_P!C
M4RS2T\&0B@1:CW7NCU]=?%3YJ;^^:'PP^:?RE7XR[<W;TU\7/E3TCW3L[H_>
M&YMQX^7*]L;HP59MNIVV<YMZAFJ:#^!82-LD:RHII(*Z1XJ:*I@M(/=>Z+IU
M+\-/YI?\O?:W8WQ6_E\S_"+>_P 2L]O;L+>OQTW)\AMQ;KV/N7J?_2[EJ_-Y
M7#5&W]O;=RF'WG@\'D\C4U&*"9/%3S+(::K$<:"1O=>Z&/)?!G^8!T'\=OA5
MB/B5\T:CLWOWXK56Y\AW9C_E;G=QUVTN\5[&BJI<_3;CJJ:JS><VY+0Y&LFG
MVS)#]_#AD2FHWAGI:= /=>ZZ^.GPD^4^]_Y@E/\ S(_F/M?XL],]B[)^/6Y/
MCOUSU=\6LYFM_P V6IMXY&DR5;F=^[QS. VO495Z)Z4PXK&P8EX*-)IJ@U3S
M/H7W7NC*_P K'O/Y,_(SX>[9[3^6B=3S]N5W97>.U'W!T5B\IB]G9W#]<;PS
M.W<+N3;'\9DDR-9M_<5!BXLCC:Z0(,A05--6Q11Q5"(/=>Z#+^;/\%NW?G;M
M7X,X/J#/]=X"K^-'\R'XS?+[?LG8N8R.'CJML]-4VY(<I1XDXW$Y9JC-S-F*
M8TL,Z4U,X67RUD)50_NO="EV1\3.Q]X?S-_C!\SL9F-E0=6]+?%[Y%]*[JP=
M=DJZ+/3Y7MO+;6K\;/04L>.EQ\M!##A:L5,DN4@E1VB$<$P9F3W7N@$[>_EL
M;G[O_FM[V^6_8%1UUG/BCV7_ "C]X_RZ]][ J,I7/N:LR6^NP*_<.1D^P?$2
M8<X";;]=) 9VRYJ?NB4-"8?WC[KW16-K_#K^=1U'\6_^&W.GNW?AKC^A-N[(
M/0W4GSKRV9WC1=G;;Z[BH_X91>38%!B8L'5;YPV(/V5#6TV]*6C#0P5S+%,#
M&ONO=6G5G6OR^ZLW+\&>LOCOO#J?<7QBZQVYGME?+W<7R)SFY]V]EYN@VQ@\
M30[1KMKY6-:NEK\W69&#)SYZIS-4'G\D4D,C2M+[]U[I&;B[S^3E!_-3ZW^-
MN&3J3+_$O<OPIWWW/O(8_%Y6MWO@=W[2W;0X6@ES%8)$PN.VYNBBRP3"1&.2
MLR%5@]QL#%%CCY/=>Z&_YS=([L^3'PJ^7?QSV%7;?Q>^.^_C+WMTSL[);LJZ
MB@Q=/E.S=L93"T$^2GI*6NJH:"*JK8FG>&BJ)4B#-'#*X"-[KW5?F_?Y5V[>
MUOY6OP8^(&9[)VUUY\I/@GM+X<;[Z:[KVWCY]YX3"]I_$G!X^AHLK%35D.+K
M,G@*NH@R%.ZR4]+4/1U/E\44Z+&/=>Z##LWX>_S0_P"8;-TEU+\_JWX;=$?%
MSJ[MCKCN3NC:WQ8W7NGMW,]K9'J>NBR^&P1DW9MS!4FT-H/F:6EJJV/3D\C4
MB.*&.>G"/))[KW1ZNM_B9V/L_P#F;_)_YG9/,;*GZM[I^+WQTZ5VK@Z')5TN
M>@RO4F6W37Y*>OI9,=%CXJ":'-4@II(LI/*[K*)((0JL_NO=6%3Q>:&:'R2Q
M>6*2+RP/XW7R C4C<Z66]P;<'W[KW6N9\(O@Q_-A^ O164^"72>;^#F1Z:HM
MW]M9;8_S>WOG=X93L..D[3RV2S@RNY.O:;!TF+W/NS&5F2D@1VW[14DM/%2E
MY;0M _NO=-O6?\GCY,; _E,='_R\I^PNHLYOOHSYS;0[WQF_<GNS-U%#E=G;
M6[ID[)+UE0-LI6INBIQ53/%)3?8O2FN&G^("!_*GNO=6=];_ !,['V?_ #-_
MD_\ ,[)YC94_5O=/Q>^.G2NU<'0Y*NEST&5ZDRVZ:_)3U]+)CHL?%030YJD%
M-)%E)Y7=91)!"%5G]U[H-_YY/_;H+^8I_P"*L=G?^X9]^Z]T0%_B!_-T^6'P
MSZP^!O=7;OQ&Q?Q:WCUGU5MGN+Y;[*3<[=G;RV#2TV,FJ]N1;&J:(;<VSN;-
MXZ/^'Y+,+NK(TIB,]5244$U2L-+[KW5E?2/PIW;T]_,4[_\ E!CJG8E!T7V!
M\0_B]\<NMMGXG(U\F:Q]1T17[EEJ!64DN.CH(<;]EE:".E>+*SS.R2"6&(*K
M/[KW0$]S?#/YA=$?.'MKY[?R[9?CUO#,?*S8_5NQ_ES\=_DCN'.]<X[-5?2%
M'64&U-W[<W1M[$9^>AS=#C:ML?44=7AI*2HI6>=9DJ%4-[KW2:ZH^ &[J>H_
MF!?,3^:7OKK[L#L#Y:?'#(=%=C=<]%8#+UVT>O.F]H8G+2UVTMNU510MNO<N
M0K?XAD:W(U[8^*6KK!']ACH;)$?=>ZJP[6Q'SZZG_DM]N[,ZR^=WP.W7_+6V
M7\'^P\)T1\P*;;N\<5VMF]D8G9]90;/V(V$61=KT&=R$45!A9<W#6O7PQ.T5
M/MU<HJSQ>Z]U8#\:_@IW5V!\1/\ A/%G8)MJ[2G^$6VNF.V^ZMM;WK*[%93[
M7+=09# /C<73TN/KX9LM29+,TZS15531Q+''*WF\BB)O=>Z,E_,Q^#OR'[_[
MQ^!WR_\ BYF.H<_V]\#M^=M[FQ?0WR)R.3PVR-WT?=&$I<%7RU.0Q&.R]7BM
MQ8*GIVJ,/6?PJICBJ7+.$ #'W7N@*W%\(?YE?R%^>'\O#YU_(7>/Q6V/COA[
MO3MZ"N^,?4FZ=U;AHJ+"=T;3S&W,UG(=V97;U(^Z=S54DN#\-%)MW!T>/I:>
MJ2.OK9JKR)[KW1N?@9\+.T_B]\0>[^@>P,[L'+;R[*[R^9/96"R6T,KD,AC(
MJ#Y";ISV;PD57-68N@JHZNFI,G3K6I'1RQQRB189*A0KM[KW0!X'^6YWIB_Y
M#<_\K^HW/U4_?\OPUW)\>UW5#G<LVT?XWF*:JBBJ#D&P:YC^&*\Z:I?X#Y@
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M13TF1>ABJ*RFI,BV&^TDJ8:6IDI1/]RM+5>+[>3W7N@RZX^*OS5WY\TOA?\
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M9F"VI_,!W1N?9M3TW@ILAM_I"OW?NRFG&Y<5CD3 T^X5IZNER&,=L=50B/\
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MR6*I\A&$?%8&GJ:<BF99*XR(Q^[]U[JZ/W[KW04]Y=W=8?&WJ#L7OKNK<_\
M<SJ?J?:N4WMV!NO^"Y#<7\/QF&3R5-3]CB:2OR55XTY\=-1S2M]%C8^_=>Z(
M]B?YQ_\ +<S79^U^J*'Y,85<QOC=T?7FRMZ5VQ]T8O9&7W)+,U,-MXWL*JPD
M.QJS</W,<T!QT>X6JQ/%+ 8O-&Z#W7NBF]A?S+]H_%?^:E\M^N/E!WW4[4Z
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MS-?CI9HU?5#*8!)$X#(PY!]U[JO;^7]_W$-?\* O_#,_ED_^^KI_?NO=$/\
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M7)YW=.=S61S='D*E?#2VIL/'YZ:HD6DJ6D/V/NO=*#>'_9.O_"N;_M9]]?\
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M0NU=6P_?$.LB2-/,SF179G]^Z]T!?9VZ_GMOS^2-VSV5L'9_\M'X#_RZ-R?
M+LG>75W2\V!WC\A]VMLSL':5;D<)BYJUJK;6U,%GLQ#D((D"X?<#PY"I61X:
MF=&I7]U[J94[$V9VE\4/^$CFT][87';HVS)O'XN9VIP^0B2LII:O8G1-=F:#
MS1,&CE6GRF-I7:-U*L8RCJ02/?NO=6*?S>.OMF;]^5O\D3:F[=N8G.;<G_F.
M5FY*G#5]!%44TU9L[K[=.9Q\LT+HT<IAR./I);,IN8Q?W[KW4'Y3]>['W'_P
MH*_E<;FSVU,%F,_M_P"'?S;S.%RN1Q\=5-35>W:C;D%!41,X.F:BBSF7$#?6
M(U<S)I9M0]U[H-=\=C=;=$_S>?YM'<79^+JZCJ[87\GCI+M3MO&X"!XZO)8O
M8V1W_-D0HIVAEFKWQ%&]-!)Y5D51&BR(J@K[KW1-^SMU_/;?G\D;MGLK8.S_
M .6C\!_Y=&Y/@%V3O+J[I>; [Q^0^[6V9V#M*MR.$Q<U:U5MK:F"SV8AR$$2
M!</N!X<A4K(\-3.C4K^Z]TQ;:2>OI_\ A'!3;_\ X=/\9O\ 0U62[N&=:DEQ
M#=C4'06$/6*U0J-5\G%DTS(QNE>*@S GR^&WNO=6M_SC<]\?\+MG.T6WL5/5
M?S.=R_!_Y_XWX,Y39>)S>0W+1TV-V'55FZ72HPX-)CZ9XHZ5:&;+Z:9LH8H*
M!_OIO')[KW6/X#X_XIQ_\)\/CG3[PCZQA^-E7_+:VK4]Z/D!118+SU.R$?L"
M7+-(!3_=KGCFC7M)^X*P2ZCY![]U[JA;;&W_ )E[P_E?_P#"7[:VPM^[-ZO^
M3VX^^MP8+J[LO>>!GW9C<!MG([.[!@VMF&Q9*MD:[&=:MC9Z2E>1*:>OC@BD
MDCI69U]U[J[+^1/DL'TOM_Y.? 3MG;%'MKYY?'#N//[M^3^^:VHJ:_(]PT_:
M-0^0V]W(,CDIZG*92FW%CI(*659)Y(\7/3B@B$$ IX5]U[JGS>&T\!OW^1ON
MG8NZ\=!E]K;T_GMYO:>Y<35()(ZK'[C^4,M'64\BD$,D]/-(C @@AB"/?NO=
M6N_\* ,)AL7AOY+ QF(QF.&!_GL?R],)@Q0T$5)]E1-%NR])2>-%^WI3]I2?
MM1Z4_9B]/[::?=>Z*AB<1\_]P_\ "A+^:0?C[V)\1-A[YQ'Q[^&%-U&GR^ZM
MW#V76U'6]5@II,F=AKM?=.V:FCQ$.^3E3FVG>H\E=/2*!%HL_NO=&X_E]=6]
MH;._F6?S%MY=S_*GX?=D]\;PZ*Z/H?D;\?OB+UGNCKFFPF8P<%0^UMS[E@SN
M8W#"<[EMNUDT!8Y454M+'3,8/&@8>Z]U39\7&4_\)6_Y80!!*_S .E%8 WL?
M]FVSAL?Z&Q!_UC[]U[JZ3X=PU<W_  H._G#57;:4!WE1_'KX 4WQ9.8^U:L3
MKNHP&:.[/X&>:I<:^^$8UW(/WA]8\?@M[KW4GYK[=_E0]N=/?SB>C-Q]E0?'
M7([DI>C,?_,&[ZVOMW/3XW#;EW324,FQ:^MJ?')MVOR=,M'CER=)121S!)%B
MS#4\E9',_NO=%9[KW[_,,^'>9^)N3_F>=3? 7^8_\.L)\L/CGM+I3Y!]2[<R
M'6_9VS=V[OE.(VMON3:676NVW55E%DJR-8(]O5KU:)_E:RK?_)?=>ZVI_?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%]
MZ<^+71706^>_.S.JMD';N_?D]V)!VGWENFKW)EMS5><S-%1QX^EE9\K75HH:
M*BHHQ%2T%$M/0TRE_!31F1RWNO=0?E5\2/C_ /-?J:;I'Y*;$E[ ZYDW1M7>
MM/C*+=F:V)6TF7V35I6XO)8_,[=R.)S6.K*2H2ZRTN0B8HSQ.6BD=&]U[H _
MD#_*N^#?R<[)SO=/;G4.5R/=>;V]L#;$7<NU^U]X; W3BZ;K+^+C$' 9K!Y[
M'UN J$BSN5AJYL?)3RY*GJ&I\DU7 $C7W7NG[9O\L[X1; ^+O:GPXVIT9B\5
MT+WK2;BA[MP<6Y\X<SNZHW?$D.4RFX]V?Q/^]>5S5>D:"7(3YIJRRJJS*JJH
M]U[H)=K?R8/Y;NSNU-L]L87X[PM6;&W='V+L'KC,]C;JW'L#;^YHY/,-S8+K
MS(9NJV5B<_YS)/\ >TV#CE%3+-5J1532S/[KW1V\[\=.G-R]_=?_ "@S6T#6
M=Y=6]?;YZLV+O;^\&4IA0X+LBIQU9F:+^&Q5J8BI-748JA;S5%!+41>,K#+&
MKN&]U[I#?*OX6?&?YK[1P.SODAUC0[[I=GYF3<FP]QT>8R.S-P;=R4T7A>OV
M[N3"5>.SN$JY(M*R/1Y"'RA4$H<(H'NO=(_XE_R\OB7\)<AOW<?0/6E5B^P.
MU)*!^S>V]^;VSO;N\L^N)4+2093=>ZLEE\[4T=(@18:8UPIXPJ:8@54CW7NE
MMO[X8?&7M#Y,])?,7??5.(W#\D/CKM_=^U^GNS*C)Y&"?$4.^:>HILA!]C#6
M1XNN)BJZO[>2LH:B2C:>=Z-X'FD9O=>Z6>=^.G3FY>_NO_E!FMH&L[RZMZ^W
MSU9L7>W]X,I3"AP79%3CJS,T7\-BK4Q%2:NHQ5"WFJ*"6HB\96&6-7<-[KW1
M%8_Y*'\MR'?FZ=ZP]#Y>'#[XW/DMZ;SZ4@[EWO!UAELKFA:MJ\EU<FXEV#7"
ML8*\U//MZ2DDE43-3F4:_?NO=#DO\MGX4'XH=D?!VHZ-Q60^*W:^>WGN?>74
M&6W1G<Q1-7;]S9W+7U&.JZK*2Y/"O'N _P 1HOX?74HQM6J3X\4KQH5]U[J3
ML3^75\1NNMG_ !>V+MSKK<$VW_AGV#NOM+XY#<O;>\=XUF SF]8\U#D:R7(Y
M7/UE?FDEBW#E4CI\I4UM- DJK!#&(8!'[KW2,^2_\J[X3_+#M"+NWM'K?=N$
M[B;;HV=F>S^ENY]Y_'S-YG#J4TXO/UVR,]@),_1Q+&J0K7_</3H6CIWB1W5O
M=>Z%"B^ WP_Q'Q)W%\%-N=%;3VC\4=V;1S^R-P]0[*GK]F4U50;I+-DO)D,7
M5TF8-;72.SSUHR/WLLA,CU#.2WOW7NE/\B/A[\=OE;\:MP_$'OGK]][_ !YW
M3B=CX/.; 3=F;VP9J7K?)XO,8:(9;$9*@S<7V>1PV-EU1Y%7F\7CG:2.25']
MU[I!?*W^7I\2_FD_7N2[ZZTJ\IO3J-ZY^J>U-B[YS_4N\=N#*HL59#B-U[7R
M>(SU+2UL*Z*BG%>:>923)$S68>Z]TS]8?RT_A?U!T;WS\>-E]13KU]\I-M[O
MVI\C,CN3L/<^]-T;TH]]8JJPF27/[UR^9K=WUDK8JMJJ:GD_C:O0QR$4!IK+
M;W7NC,]']*=9_'#J#KCH;IK;AVAU5U)M'#;$Z_VNV8K]PF@Q>WXE@I*8UV4J
MJW(U1BC4#R5%7+*WU=V//OW7ND5V/\4.A.VN_?CK\G]_[&?.]X?$]>U4Z#WH
M-T9C%C!#NS$Q8/<P.-H\A3XG*?Q+%PQPC^(4-5]O;R4OAE)<^Z]T8GW[KW1<
M.OOB3\?^K/D3\@_E=L38;X3OOY3T76&/[UWR=TYG)C-P]-8I<)MQ!BZO(3X?
M&?P_&(L)-!CZ5JBWDJ3-+=_?NO=9OCQ\4.A/BHG=$?0VQGV.GR%[[["^3G;H
M;=&8W/\ Q;>_:8HQG<R/XQD*\T K104O^1T?V]##H_R>FBU/J]U[J7NOXO\
M1V]OD/U/\K-R[+?(]\](;/W[L'K+? W)EJ,8[$]G+ N;I#BX*Z/#UGW@IH;2
MU6/FFAT_L21W:_NO=%S^"OPBQWQ!WO\ .[>^/HMO8&'YB?,[?WR;IMH[9SV5
MW1!CHMR8O#8Z>>JK\QIJ9,KN7+X_+[AK::&)*'%S9<X;'F:BQT%1+[KW1AOE
M3\5NB/FMT1O?XT?)?9#]C=*]C/ME]X[.3<V7V<:L[.R]!GL<1D<#7XS*T_V^
M5QE#-^S71^3Q^.37$[HWNO=.O:'QQZ:[EWCT7O[LC9YW%NSXU[_J^S^ELJ-P
MY3$?P;.5V(KL%+6F"AK::FR(;%Y*LA\-=#4P OY!$)41U]U[KEU9\=.G.E=Z
M=Y=A=:;0.V]W_)'L&B[3[FRQW!E,Q_&,[CL30X.&M%/7UM538X)C,;1P^&BA
MIJ<E/(T1E=W;W7NB==Z_R@_@7\A>VMW]Y;RZOWIM+L_LJAH\9VWN7HWOC?GQ
MX;>5/CH33T\>[(-C;DP%/GGAIVDB6>JB>H\3M&9BA 'NO="+VU_+,^"_=OQ?
MV)\--^_'?:3?'#JS-;8W-U?UYM'(93KH[;RFSVG>@RF"RVWZ_&9K%Y./[NM$
MM53Y&.>I2JJTJ9)DJJA9/=>Z-MUGUWM7J'KC8/5&Q:;)46R>L]F;9V!M"BS&
MX,ANRKAQ>SZ*''T$53E,K4UN3R$\=+3Q*]15UD]1,P,DTLDC,Q]U[H,S\6.B
M&[A[:[[;8Q/:_>?5&V.D.TMT_P!Y\P!D]L;-?*28[&_8C(?PZB-.V9R)^XI*
M2"JD\H$D[^./1[KW35A?A[\=MO?$F;X,8?K]Z/XN5'2>?^.TW6?][,W4,=G[
MGQ53A:[$_P :ER3[@!GQM741?=#*BL37Y(ZA)55Q[KW0I=/]3; Z%ZHZTZ0Z
MIP1VOUCT_L/:?677FVVRE9G#C\)L:A@QN+HS6Y&HJZ^K--14T,?FJ:J:>33K
MEE=RS'W7NDQVG\=.G.ZMZ=&]A=E[0.Y-W_&[L&M[3Z9RPW!E,/\ P?.Y'$UV
M#FK33T%;2TV1#XS)5D/AK8:FG!?R+$)41U]U[IE[+^*G0W;_ 'M\</DKV'L=
M\_W3\2I>V)OC_O$;GS&)&!;O#$TV#W.3CJ*OIL5E?XEC*2GA'\1HJL4^GR4O
M@E9G/NO=%G^1/\I?X'_*7N6I[_[:ZASC=K9K"XS;&^MS=>]O;RZ?_O7BL,BQ
M4N,W=2[4SV&I-S44$"+"L>0@G)I_\F9C3_M>_=>Z6.U_Y9GP<V/\?_D+\6-E
M=!X+9WQ]^4V9SV>[JZMVIN+-[;QN0GW)AL3M^J3'+19."7;E)_!\'BJ:*EP\
MM!30+ &@BCD>5W]U[H9^Y?BGT)\@>H]M]%=M[%.Z^J]H[AZPW3M_:XW1F<%]
MO7=-9"ARNW)OOL;D*/(RC'UV.HY"DE6Z5 314K,CNK>Z]T[=M?&_IGO/=G1V
M^.TMGG<^Z/C?V7_I@Z9R8W#E<)_!]Q?PVNQ'\0,./K:2GR _A^1K(O!6Q5--
M=]?A\BHR^Z]T3SLW^4!\".U^Z]X]_;@ZKWG@-_\ 9E?097MNGZQ[YW[U!@MY
M56-)\=3NW;6UMRXC [AFE1GCJ6K,?*:V)VBK/N(SI]^Z]T(& _EB_!C:73OR
M1^/FT.@\-L[I#Y:+&O>75FT-T9[:N%KUBPE#MP)BJ*@RM/%M:+^#8S'TWCP8
MQT>FGC;3K&H^Z]T+GR(^'OQV^5OQJW#\0>^>OWWO\>=TXG8^#SFP$W9F]L&:
MEZWR>+S&&B&6Q&2H,W%]GD<-C9=4>15YO%XYVDCDE1_=>Z GY0_!S%?(?Y<?
MRY_D9]AM[&S_  ;W]W9OH;JJ]P9;^*R4/8VT)-NKM7'8B&V'J*7+Y63#Y6MR
M=;*:NA7;T%#0Q21YFNEI_=>ZL)GACJ(9J>9=<,\4D,J7*W64%6%P01<$_0W]
M^Z]T 'Q6^*W1'PIZ(V1\:/C1LA^N>E>N7W,^SMG/N;+[Q-(=XY>OSV1)R.>K
M\GE:C[C*Y.NF_>KI/'Y/''HB1$7W7NLV'^+_ $=@/DIO/Y>8C9;TGR$[!ZMV
MUTON_?O]Y,M.M7MO:%=+D<=C_P"%2USX6G-/63RO]Q#CHZF35HEF= %'NO=(
MSYC?!KXK?/[K'$=.?+KJ+%=Q==[?WMA>QL'@LEFLKMQJ3,[?BJJ>FK8*W#5^
M.KD/VU;602Q?<^&>":2&>.2-BOOW7N@\_F5_#>A^=?P/[]^'-/B=IV[AVE@=
MJ;<J-RYC*;9QN!K<3E\978K<@&#45=9)M"LHJ;,4F*O'29:HH(<372P4%943
M1^Z]T=G;.!I-K;;V_MB@:1Z';F#Q.!HGF.IS%B((Z>,L?RQ2,7_Q]^Z]T%N"
M^.G3FVN_NP/E!A=H&C[R[2Z^V-U9OK>W]X,I4BNP76]3D:S#47\-EK7Q%,:2
MHRM<WFIZ"*HE\@6:6140+[KW3+UW\5.ANJ>_OD3\H=A;'?!]X_*^+J:'OO>I
MW/F,H,XO1V'DP.UP,;65]1B<7_#<5*\)_A]#2FIOY:KSR@2>_=>Z(SO#^1G_
M "QM\[PS>Z,Y\=ZJ' [IW9'OO=_3& [9WEM?K;,9F.J-<,CE.M\=GZ7959,:
MPB=E?!F)Y0KO&Q%_?NO=&M^47P+^*?S%V%L3KKO7JNERV%ZHR^/S_465V5N'
M*]4YK:-;BHHH*>HVOG=KUN(R^"*00PQ&.DK(H9(HTBEC>-54>Z]T$'7'\I;X
M$=6;RZK[.VOTOE*CM_IO>S=A;-[KW9VWO/?.]),E_#LGB57-;JS&X*[.;CQD
M&-S65IX,9E*VLQE-'4RBFHXBY/OW7NC$8?X=_&S")\HH*;JS$5]!\T<SD<[\
MG</N+)Y'=5!NR?,;?IMJU:5F/R=95T5+256 I(:26EHX*>FD0,S1&1W=O=>Z
M+ST9_*8^!GQQP'3FU^I>G]PX;!?'WNO+?(3IK'YSN[?F^5P&ZLUMI=H3UE&V
M<W-D7>B_N^BTR8Z9I<=$;U$=(M2S3'W7NC+=E_%3H;M_O;XX?)7L/8[Y_NGX
ME2]L3?'_ 'B-SYC$C MWAB:;![G)QU%7TV*RO\2QE)3PC^(T56*?3Y*7P2LS
MGW7NJBOECTYV/_,I_F#_ !"ZJWG\.NT>NOC'_+S^1>:^4&^?DKVW%B,3B=ZY
MO8U L&RMN; @H<Q5Y3+8?*9BJAR67FK*&E@6'$+2312&>(2^Z]U?Y[]U[H'^
M_N@^I/E'TSV)\?>^-FTG8'4/:VW:C:N^]H5M?68E:VBJ'232M7CZBDKZ.>*:
M**6&HIJJ&>"9$EAD21%8>Z]T_P#5/577_2'5W7W2_5FV:':'6/5FRMM]>;#V
MG0O+40T&'VE1Q4%!2+)4233S^&E@C5I)I9)92#)+(\C,Q]U[JM7/_P C7^6-
MN7>VX=W97X[5;8/=^\1V%N_I.B[>WKC.L<KG%DCF_B>0ZQIMPQ;$J)C411SO
M&<!]O)4C[B6%YRTA]U[H^?8GQEZ.[5W-T#N[>^PZ7)9SXN;VE[#Z(EQ^7R.V
MZ?;^6EPU;M_SPT6,K*.BJX5Q&0JJ=*:KIZBEC#*Z0K(B,ONO=%8^1/\ *7^!
M_P I>Y:GO_MKJ'.-VMFL+C-L;ZW-U[V]O+I_^]>*PR+%2XS=U+M3/8:DW-10
M0(L*QY""<FG_ ,F9C3_M>_=>Z6.U_P"69\'-C_'_ .0OQ8V5T'@MG?'WY39G
M/9[NKJW:FXLWMO&Y"?<F&Q.WZI,<M%DX)=N4G\'P>*IHJ7#RT%- L :"*.1Y
M7?W7NA6^1'P]^.WRM^-6X?B#WSU^^]_CSNG$['P><V F[,WM@S4O6^3Q>8PT
M0RV(R5!FXOL\CAL;+JCR*O-XO'.TD<DJ/[KW0=?,/^7/\._GI0=7T?R@ZFFW
MS6=*Y3-9?JG<^ W_ +EZNSN"DW)2Q462CH,]M3,87,QTF1IZ>F6JIC7-3U#4
M]/)+$TM/"Z>Z]TD?DO\ RM/A5\L.PXNW^T>M]SX;MXX"DVEE>U^F^WMW=";C
MRV)H(WBAQF=R^S,WA*S.T443LD:5\E08TLD950 /=>Z,+T7\3?C;\:>BZ'XT
M='],;#V!T118S,XB3K/&X2.MQM;#N173)_Q5*S[A\O+DTD=:R6MDJ):I6*SN
MZ\>_=>Z(YM+^1S_++V9OW:6^<7\?*_(T77N[8-^]<]4;L[=WGO7K[;N;I3>'
M*8/K[+9^MV=C:JG)8PF'#*D&IO"B7]^Z]T?S._'3IS<O?W7_ ,H,UM UG>75
MO7V^>K-B[V_O!E*84."[(J<=69FB_AL5:F(J35U&*H6\U102U$7C*PRQJ[AO
M=>Z+%G_A%CL__-$Z\_F#K1;>P]9U[\,=\?&2NR,&>RM?E]PR[SW90YW&P5.,
MDTX/$XK:-/2YMX:FG,M=EJC<<L=8((,+1&H]U[JPKW[KW1'>O_Y;_P ,^K?A
M?GOY>VQNH),+\1-S[=W[M7.=4GL+=&3:>@[-JZNNS</\>J\U/N6,UE56U+AX
M\PLD.O3 T:*JCW7NJ]]N?\)C?Y(&ULG%E<7\)X994"I-19CY ]HY^AJ$1TE6
M*LQ]=O:HHJV!9HXI!%/!)'Y(XWTZD4CW7NK'NX/Y>WPV[T^)P^#6_P#HG:Z_
M%".GVK24O2^Q:[(]4XVGCV5D:?+8Y*67:U;AZZE$.1I89W\56GG?69_+Y)-7
MNO=5Z["_X31_R1.N=RT.Z\'\%=KY7)8^YIZ/?O:^_P#L[&,2RM>?#;BW7E,3
M5?I M-12"Q(M8GW[KW5KW=W2NT.QOC+VY\>*?KC:.X-B[YZ/WYT]3]2U.<K>
MK<#78S<N"JL.FWI,EMZ!\CMW$U--,*1JG&TK5%#3L9:2)I(HT/NO=)'X/_'&
M3X@?#OXR?%R?<4&[ZWH/I#KCJS*;KI*)\;#DJW:&+IZ2MKX*:22:2GIZNKCF
MEBB:5VCC94+,5)/NO=+G._'3IS<O?W7_ ,H,UM UG>75O7V^>K-B[V_O!E*8
M4."[(J<=69FB_AL5:F(J35U&*H6\U102U$7C*PRQJ[AO=>Z]T'\=.G/C#LO+
M]>]';0.RMH9WL'L/M/*8D[@RFY?+G>U<M59S/5OW&7K:^I05N3K*B80I,M/"
M&\=/%%$JH/=>Z+"O\JOX'K\$W_EIKTA*/A7).*E^G?\ 2;N\L7&[1OG5_>+^
M/_WI_P"/H45EOXW:W^36^U_8]^Z]T9S-?''IK</?77GR<R^SS5]W]4]=[WZI
MV%O3^\.4IQ0X'L6IQU7F*'^&Q5J8FJ-7/B:!O/44,M1%XRL,L:NX;W7NB+Q_
MR4/Y;D._-T[UAZ'R\.'WQN?);TWGTI!W+O>#K#+97-"U;5Y+JY-Q+L&N%8P5
MYJ>?;TE))*HF:G,HU^_=>Z'''?RVOA?B>AZ'XR8[IYZ7HO%=[4OR3P_7\786
MZ5IZ+>%%NE=Z19&CJ?XW]_34L>YE-:,='5KC06>'[3[=VB/NO=#KVU\;^F>\
M]V=';X[2V>=S[H^-_9?^F#IG)C<.5PG\'W%_#:[$?Q PX^MI*?(#^'Y&LB\%
M;%4TUWU^'R*C+[KW7MR?&_IG=O?O67R@W!L\U_>/3NR-_=<]=;U_O#E:48_#
M]GR4$N<I/X;!6QXBK-:^,HCY:F@FFAT$021!WU>Z]U Z=^+G1?0766[>G>IM
MD':O7.^=W=I;[W3MX[FR^=^ZRG=&1K,KN2I^[R5?5UT R-?7U<@CBJ8XJ</H
MIDA145?=>Z1M'\'/B]0?#M_@-2=:/%\3Y.K:[I=^K?[Z;@D8[;R4<D4^/_CC
M95MQW=)9/\H_B_W(O=9A86]U[IB^1O\ +Z^)?RMZOZSZC[JZOES>VNE*C!UW
M3.:V_O7/;%W'M.IV[304E)5;?W5A,G0;CQU0M-3012O'E+U*(JU7F ]^Z]T%
M_7'\I;X$=6;RZK[.VOTOE*CM_IO>S=A;-[KW9VWO/?.]),E_#LGB57-;JS&X
M*[.;CQD&-S65IX,9E*VLQE-'4RBFHXBY/OW7NA#Z=_ET?#WX_?)GN3Y>=-=4
M3]?]X_(%-ROV_EL'O_<J83,U.\JS&9#+Y&7:$N8DVE3Y;)UV(HIZFNI\)#5S
M3>>629GJJIIO=>Z+AG_Y&O\ +&W+O;<.[LK\=JML'N_>(["W?TG1=O;UQG6.
M5SBR1S?Q/(=8TVX8MB5$QJ(HYWC. ^WDJ1]Q+"\Y:0^Z]T?/L3XR]'=J[FZ!
MW=O?8=+DLY\7-[2]A]$2X_+Y';=/M_+2X:MV_P">&BQE91T57"N(R%53I35=
M/44L8972%9$1E]U[JMS^<E6=_=U=!;R_E]]!_$;L_NG<7S/V _6-3WR8</1=
M<=>46Z,G!C\OGMVY&MRU-DHZ_ 8MILMCZ2CQE3)63P111LDQ1']U[JSKX]=(
M;)^-'1'3GQYZVI&HMA=)=9[*ZMVE!*2\AH=CXZGQT$L[LSO+4SI3B6:1W9Y)
M7>1V9V+'W7NF?Y&_&/HOY;==T_4WR(V!0]F==4V]=C=A?W3RF3K\;2RY7KC)
MT^7Q$M2,?54CU=/!7TL+RTDSR4E4@:&J@FA=XV]U[HJ71'\HWX!?'#MS;_=_
M672-5_?_ &'392@ZBGWYV9NOM;';!I<XCQ5E'U]AMSYO+8G9-+/ _@,6'HZ1
M8Z94I(?'2HL(]U[H2?EA_+K^)/S3SFR-X]Z==9>?LGK6.MIM@]N]9]C[EZ2W
M?BZ;)*ZU-!3[GV?EL)F9,7/Y'9Z&:LEHS(1-X/,JR#W7NA#^+'PX^-?PKV+E
M.N_C3U9A^ML#N+<%7N_>-?%75NY,SN#,Y!56IS.X]P9>JK\YG\M4!1Y*NOR%
M1,?IK X]^Z]U Z3^$WQA^.G=GR3^17375M)LKN'Y=YW:VYOD'NZGW'F,M_'J
M[9HR/V-0M!7Y"JQN)8-EJ^2=<;1TB54LOEJEFD2-D]U[J;\6/AK\:/A1M'>^
MQ/B_U5B>I]J]C]H;L[FWKB\7E<EFOO\ <F]A3KD,@\V5K:^HC5XJ2EBBIHI4
MI::&)(J:"*-=/OW7NBL]\_R;/Y>OR-[&WMVEV#TSG\3NCM5V;N:#JON/>?2V
M*WQY52.7^^>$VGG\/B-RM4QQA*B2NHII*E"RSO(&:_NO=&<WA\)_BUOCHOKK
MXSYCIW;M!T1U+N7J_=W7'6>T*NNV!CL17],Y2ES6W):5<%5XZ41T&3HX)VA:
M5H:E@PJHYUDD#>Z]T:;W[KW59_:G\H#^7QW/W)NKO'?G1E35[K[$RF.SG;.V
ML'V=NS:.S]ZUN+OXJS>NQL5G*/9^[*E^!429/"5+5BJB5AG154>Z]T*&-_EQ
M?#3$?'#9GQ(QW3JTGQ\Z^[:HN\MH=?0[[W+&M%N?';QGW]#D4R*Y@95XX]UU
M,U8*22N:B"M]I]O]FJTZ^Z]TP_)S^6)\-?EMV7A.[.U>N]S8;N[ [=_N93=S
M],=M[M^/^ZJC">0S?P3(YS96:P5?E,4)K2)3U<TR1. T/C-[^Z]T-W0OQ"^-
M?QEZ7J?CUTKU%M?:?4&3_O#)N7:%:L^\!G)MWH8\Q5[CK<W/D<CN2NR\;%:V
MJR=75U%6ITSR2+8>_=>Z)-M+^1S_ "R]F;]VEOG%_'ROR-%U[NV#?O7/5&[.
MW=Y[UZ^V[FZ4WARF#Z^RV?K=G8VJIR6,)APRI!J;PHE_?NO=&)^6'\NCXE_-
M/<FP=]]Y[!W#)V9U=3Y#'[ [9ZQ[0W1TANS&T68U_>8R+<>S\QA,M)BJKR2&
M2CEJI*?6QE6-93K]^Z]TR=0_RO?@KT1V'MSMGJ[H;&;>[+V_L/?76]9O>JW?
MN'<F1W!BNS!C!G5WG/E,M6MOBNR(PV+$E?G_ .(URK30QQU*1H$]^Z]T!>W?
MY&7\LK:^Y<;E\1T%G4VAA-Y1]@X#H>L[QW[D>KZ'-15+5JUU-UE/N638RZ*Y
MWJ4IVP34D50WFB@1U0K[KW1R/E3\*OC-\U-H;?V9\CNL,?OFCV;F)-Q;!W#0
MY?([+W!MS(RQ>!J_;NY,'5X[.X.J>+2LCT>0A\JJ@E#A$ ]U[I(?$O\ EY?$
MOX2Y#?NX^@>M*K%]@=J24#]F]M[\WMG>W=Y9]<2H6D@RFZ]U9++YVIHZ1 BP
MTQKA3QA4TQ JI'NO=(OX*_"+'?$'>_SNWOCZ+;V!A^8GS.W]\FZ;:.V<]E=T
M08Z+<F+PV.GGJJ_,::F3*[ER^/R^X:VFAB2AQ<V7.&QYFHL=!42^Z]T97Y&_
M&OI?Y9]8573??NSWWSUS6[GV/O*HP";BRFUR<EUQF*+/8:I%7AZW'UH^SRN/
MI)O&*CQ2Z/%.DD3/&WNO=)+OKX6?%WY/]C?'7MKOGI_;O8_8OQ.[!E[2^/NZ
M<O55U+/MS.3-1R-60+25=-#6)]QC<94BGK(JBF%514=4(?N*6"1/=>Z4^6^,
M?2.<^26T?EUE-F/5?(+8?56Y.D]J;\_O'E8%I=L[NR$&4R.._A4=<F&G-174
MT,GW$V/DJ8].B*9$+*?=>Z)KW9_)I_EY=_=H[W[>WWTQN+&[I[7^U_TSXSK3
MNO?'3^ WQ]KK!.\MM;5W%B,!N22H21XZJ6MQTLU9$1#5R3Q*J#W7NC(YWX*_
M$[<$OQ6%7TQMV@Q7PFW"-V?%_:>VZVOVC@=J9&''-BJ>KIL!BZRCPM=+0T3.
MM']]0U(I)&:>F$4[-(?=>Z-I[]U[JF+OO^3/\;-Q]1]7=+?'[KG#=;;9P7\R
M3J7^8-GZO-=H;RRT."SVT\N,INC([7P]1DLA0_<[FQ<59@8\/JH<%CTS53G(
M*;[_ !U-#4>Z]U<[[]U[H$NK/CITYTKO3O+L+K3:!VWN_P"2/8-%VGW-ECN#
M*9C^,9W'8FAP<-:*>OK:JFQP3&8VCA\-%#34Y*>1HC*[NWNO=-/3GQ7Z'Z!Z
M[WUU1U+L8[5V#V5OGM+LC>N!.Y\QG?O<SW16U.1W+6?=9+(5E;3#(U=7.XB@
MJ(H*<-IIHX550/=>Z#*M_EX_#3*_$K:'P9S?16V]P_%WK_$8/#;'ZTW+E,IN
M1L2NV9'FQU7C\U7U]1N"ERE#+)(T&0CRJUL1=@E0%8@^Z]TA?B__ "M?A3\0
M^RLAW5U+UGN#*=T5VV%V/!V_W%VMNOOS<U!@T.H87$YG>F9SE;B,5<MJIZ.6
M!'U,) P8@^Z]UP^3W\K+X5?+GLRG[H[9ZYW;B^WAM;^XN7[+Z;[FWG\?\SF,
M&""N(W!6[)SV!DS]#$!HA3(?<M3QEXZ=XHW=6]U[H07_ )>OPT7XZ==_$O&=
M#[6VS\=NJ-[;$[&V#U?LROR6R:.ASG6^=BW+BLF9\3745=5U2YZ%:VJ>IJYC
MD)VD>O\ N3++K]U[H1?D-\5.AOE7#TS3]\;'??$/Q][]Z[^3_4:+N?,;8_A6
M^.J!6K@,T3AZ^@->*$9&L_R.L-103^3_ "BFET)I]U[HJ79O\H#X$=K]U[Q[
M^W!U7O/ ;_[,KZ#*]MT_6/?._>H,%O*JQI/CJ=V[:VMN7$8'<,TJ,\=2U9CY
M36Q.T59]Q&=/OW7NA P'\L7X,;2Z=^2/Q\VAT'AMG=(?+18U[RZLVANC/;5P
MM>L6$H=N!,514&5IXMK1?P;&8^F\>#&.CTT\;:=8U'W7NA<^1'P]^.WRM^-6
MX?B#WSU^^]_CSNG$['P><V F[,WM@S4O6^3Q>8PT0RV(R5!FXOL\CAL;+JCR
M*O-XO'.TD<DJ/[KW2FR_QNZ8SO>_7/R8RFSC5=V=3=<[UZFV!O/^\.5@%!@.
MPZC&U67H/X='7)BJHU<^)H&\]10RU$7C(AEC5W#>Z]T0[>_\D/\ EL[^WSOK
M>V4Z.W+@:7M7<T^].V>L>O>]M_=8;%W7EZV1):K(;BV+MW<V,VIE9JYXX_O%
MFQ+15JJ%K(YPSAO=>Z.[O#XI?'W?>4^.67W#UMC/N/B3NJ/>GQWI,%D:_:=%
MMFOAP=9MN)J7'8JKHJ"II8<+75--%2U5-/2QJRLD*O&C+[KW3KN3XW],[M[]
MZR^4&X-GFO[QZ=V1O[KGKK>O]X<K2C'X?L^2@ESE)_#8*V/$59K7QE$?+4T$
MTT.@B"2(.^KW7NO8;XW],X#Y"[V^56)V>:7OCL7K39_3^\=\_P!X<K.*O;NP
MZVNR.*Q_\+DK7P].::LR-9)YX<?'4R:PDLSHJ*ONO="YG<%A-T83+[:W+B,9
MN#;NX,9787.X+-4,63HZVCR<30U-+54TRO#44]1"[I)&Z,CHQ5@02/?NO=59
M=?\ \D+^6CUKOK:N^,!\?\EDZ;K[=[]@=9]8[X[CWOV-L/:V<-0]5'E=M[!S
MVXLCM##5=+-)(:0TV'1*%6*424Z */=>Z.W_ +*GT-_LUO\ L[G]QW_V9O\
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1=>Z][]U[KWOW7NO>_=>Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>timage_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M+#\DVL3J%1ZC_ >M*I0%?, C]C#JP'_A,S_VY&^%7_:@[B_][_=WNC\!^?\
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M^97\D?EEWU_HD;JKM3K?NG:&WGV=O&IW?DON=_;VP&=QVNC%!"WJHL>SN'B
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M>Z*+\I_B5\?OF7UC5=,?)+KG$]K]99/<F#W&VT]R5U7CX?N=O:9*&2.6E*5
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M0_ZN%.E3_+I_X5%[!^7/RAVC\0/D+\8=Z_%3MGLG/4NS-B9*IW!+NBDJ,YD
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MGUX_$WY?X#U>7_PG@_[<N_ K_P 1-GO_ 'I<S[]Y#\_\)ZN?A;\O^.CK3_\
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M.!_+_".G .U?S_XZ>M-+X'_]PG'\V?\ \37M+_WI.N_;9^+\O\HZW'Q;\_\
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M%MM**JPM/E9*W#)F,#N.II:VDS.*=HF8T$4RBQ,;.CG5O4KDTH?V?Y>M(I
M6OEC/V>74CLO^0A_.EH_G_\ 'KY][CWCU!\L>Y9NP^O.Y>]\]+OK';'QN(R^
MV,N(UVOB*?(34,TV-H-OTU,*4TU'3TR@B.*!DB52]5B0V">/$<?3R_ECIIA0
M%<CR&#_D!_S]6V?\*//Y)7=O\S->G^]/BKE,+/WITG@\IL>NZ_W3N.GVC2;A
MPN;JTK:1Z#*531"CS6+R"E3%5S1PL9XA>+2-38;Q*$<>%*_/JX4 4;AQX?+/
M[:?X>J[,A_*Y_P"%%GSL^*&\OCG\\N[-L[1ZTZNV!)-U7U;@=U[3RVX^PMS[
M/I##MW&[HW!@Y*F(8..96>HJ<A6NY>,:(06$Z>,@I1B,<!45-/\ 5Y]:5-9U
M#SXFAQ7/F/Y#/RZ&'XL_R6OGYUA_(.^>GP)WEL?9-)\D?D!VCMW=77.VZ+L_
M#9*BJZ/&9C:E7-)4Y5)GHZ;2N'KM.J=6)O\ @<^#:0P(R2 ,CU^WJPC9PK X
M&HG!QBGIU;-_PG-^!7R2_ET?"#<O1WRFVWMW:&_ZWO'>6_Z7&[<W/1[Q#XS<
M6/QE,C?=X^64*/)2*;!B0W#"_P!:R2&(4(\Z_/AUZ,*6!4UQ\_RXCJLK^67_
M ":_GG\9/YY??WSI[=V)LW"_'G?^X/E/DMO;EQ79F'S-?;M;)R5>'_W$QRO6
MZI4TJVJ 6'+#G2=R-3N(Q4^8\Z_/K:*RG2IJ:#R/J#Z=/W_"AW^3_P#.7^8?
M\UOB;W3\8=E;,W1L7J/KC [9WC7;A['Q^TI(:N#=%9F2L<.1-.\P%"Z$E PO
M9;ZO2-ZP[ J/(>GJ?LZTT;Z2'.:GR/F /('HR'_"AG^2UVK_ #0^H>B-W_'O
M+8"'Y!] 8W<]"-J;TRC8ZESN&S<<;5..I\F%DHZ'+8_(T@TQ/)XW1V\C(44-
MO7X@!'$"A'7BH!->%:@^7^?..JS*K^7#_P *4?G'\5*OX9?+_M3IOHGX_=?=
M;X[%8W#X?*[;S&Y-[3]>4 _NWMO*Y+;%54JN/>LAQR5<U=6P1,0M0\-;(BCW
MLN*48@ ?97'EC_+]O5,2-J ))-.#>?GG_)U;#_PFK^!_S9_ET?'KO/H;Y@;%
MV?M*GRW:./[(ZRK-K;[H-]><9C&K3Y5:N/&SS*XIIZ*E*^I6U747X;WME* @
MBG#T_P G6T*$J5-3GU&,>H'6T#[IUOKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[J/X/\ :_\ DW_C?MOP^O=2/;G7NH_@_P!K_P"3?^-^V_#Z]U(]N=>ZC^#_
M &O_ )-_XW[;\/KW7O!_M?\ R;_QOW[P^O=>\'^U_P#)O_&_?O#Z]U[P?[7_
M ,F_\;]^\/KW7O!_M?\ R;_QOW[P^O=1_;?7NO>_=>ZD>#_:_P#DW_C?MSP^
MO=>\'^U_\F_\;]^\/KW7O!_M?_)O_&_?O#Z]U[P?[7_R;_QOW[P^O=2/;G7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>ZC^?_:/^3O^->V_$Z]U(]N=>Z;_ &GZ]U[W[KW7O?NO=>]^Z]U[W[KW
M4CS_ .T?\G?\:]N>)U[J/[;Z]U[W[KW7O?NO=>]^Z]U[W[KW4CS_ .T?\G?\
M:]N>)U[J/[;Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=2//_M'_)W_ !KVYXG7
MNH_MOKW7O?NO=>]^Z]U[W[KW4CS_ .T?\G?\:]N>)U[J/[;Z]U[W[KW4CS_[
M1_R=_P :]N>)U[J/[;Z]U[W[KW4CS_[1_P G?\:]N>)U[J/[;Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U(\_\ M'_)W_&O;GB=
M>ZC^V^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3A[4=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NN&L?X^T7U1_P!7_%]>ZA>W>O=.'M1U[IO]
MI^O=<?7_ +3_ +S[:^H'S_U?GU;'SZY>W>J]>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW3A[4=>Z][]U[IO\ :?KW4CS_ .T?\G?\:]N>)U[K']S'_M/^V][\8>O3
M_P!-\NIGN_3'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW3?[3]>ZD>?\ VC_D[_C7MSQ.O=>\_P#M'_)W_&O?
MO$Z]U']M]>Z][]U[K/\ <'_4#_DO_C7MOZK_ %4_V>MXZX>>#^L?_4MO^*>]
M>)!ZC^?5]'V_RZR>?_:/^3O^->U/B=-]2/;G7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDOFLD:"F%K7:_O3/0=-QIJ/19-V
M]PQ8=JW\7_'NVO3U=AJIT9C;M8M=M[ Y>_IK*"@R!_Y"H0#_ +R#[;4U%?\
M5PZ=?!(_+^?2K]WZ;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>R_KW7#6/\?=_JC_ *O^+Z]U&\G^'^\^TG7NO>3_  _WGW[KW6/[F/\ K_O?
M_%/?NG/#ZP_>?[2O_)7OVOY_SZ?^E/\ J_XKKWG3^C?[8?\ %??NJ=>^\_VE
M?^2O?M?S_GU?Z4_ZO^*Z]]Y_M*_\E>_:_G_/KWTI_P!7_%=>^\_VE?\ DKW[
M7\_Y]>^E/^K_ (KKWWG^TK_R5[]K^?\ /KWTI_U?\5U[SI_1O]L/^*^_=4Z]
M]Y_M*_\ )7OVOY_SZO\ 2G_5_P 5UU]Z/Z)_R7[]TUX7V]=_>?[2O_)7OVOY
M_P ^G?I3_J_XKKWG3^C?[8?\5]^ZIU[SI_1O]L/^*^_=>ZZGF-OP+ ZK\@?\
M;_XU[?$WTIZH!UR,RC\-_MO^-^V(!]1TX5IUS3](_P!C[;CZ:DZ9-)^ZMI2V
MCZ:>/;FF'_5_Q?5_ /&A_P!7Y=._G3^C?[8?\5]^ZWU[SI_1O]L/^*^_=>Z]
MYT_HW^V'_%??NO=>\Z?T;_;#_BOOW7NO>=/Z-_MA_P 5]^Z]U[SI_1O]L/\
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M[/W9( T'7%#BA^?X_OZEQO\ MKZ;_P"^Y]I/]<BYN?[&#_JITM7EZW3B]?\
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MO-_M"^_>*?\ 4>O>$.O>;_:%]^\4_P"H]>\(=>\W^T+[]XI_U'KWA#KCY/\
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MQ936\/Z_^JE.B?<)!(>T'  %>A#]B3I-U,J_]U_\A_\ $>VX^FX^H/\ E_\
MS>]VQ\NK8^77+W;JW4CW[I/UD^[_ .;?_)__ !KVWX?3GA]1J:H:_P"H-<?T
MM>W_ !/^^M[I]13AUYE ZXU^1HZ*WW-<E)<7 "WO_P 3[U)>06_'KP0OPKTA
MZC?>U:0$UF\MOT?)_P"7C1O]!]?H3[*YM^M(.$]?RZ5+M]R?P'^?^?J.W9FR
MYN8-ZX!3^;Y1_P#>K?ZWMK^M.VG_ (D']O51:2?P_P NEO2Y*FK:,ST_^74M
MOZ7(M;BWLYAO(-PZ892O&O4KSI_1O]L/^*^VM!ZKH/3964V.R=*<?7TM#54U
M0M_L19;_ )_/!L+W^G^'NE[8P[O^C,/RZ<6Y,9U*>@>R'4ZX:<S=?[CR&R^2
M?X>?]RN+/]+4?U_VXX]A.?E+P\V5QX/[>C2#>!$/U5U?X>D_FL)V'5Q+2[HV
M%L3L"GT _?4&2&,JKCZ7-9S<?X'V$MVV&_\ ^)EO'??\T>/_ %5Z,XKNUK5'
M9/D>'\A_@Z1"X6'%LWVFP^ZMJU!^B[0W!_%:6_\ KFI^GL@F6[L!^A!<VWS^
MI@_S=&!GUFC/&P]"I!_U?EU@_B>[H.*?,_(<+_2OVM2Y3_??[;V7?OJ]_P"4
M@_MZT%C](OR7_8ZQ-6=C36,=7WQ5W-M3XS%8OZ?Z_P#L?;37M_<</J.C"*.S
M'$1_X>H@VMV=ES>7$=E5H/YW1VO28Z]N>8<:#[1S65_>?VWU'_.3_/TJ2ZM+
M/AH_VJ'KU)TENBKJ&DKJ?K;$,+L?XC]YOJJ_V'WE18GVTG)=Q<?CC_(]:BWV
MW3_0&/SP/\'3^G6=+A("<QW ,5#?@8/&XG:HX_Q_XU[-/ZFVUO\ Z-_E_P O
M28[M</P7]M?\W3360?'ZE%LSV-G]P6M85>\:O)#D_P!:,#^OM'X6WVW3Z_O*
M? 4#[!3_  ]0XZSI( '#]79[=-N#_OS:L6_\[2?\?Q[6B]VX_P"@>-TY]/N/
M%F"_F.G2";"S*?X9\9$8D6OG6Q.,''^P]HS?6SG]'9_&_.'_ #=5%O<VXS??
ML!/^?J'6X?)2BT'QOZWI:;^M?N&F/^W(IQ[9[9^&WV\/Y_YST^KS#'UCG_:_
MYAT%F<K,!B%\%;UAU535'T_@N$WG6?=_^J9"_P"\>R/<=VMMMF^G,'^;_#U>
M/;[B,>.'?[2!_E'2L6CV?#3[<I*+8V^J;>64P9SAVI1;UJL8*:EN1^].1>Y_
MWW/LWN(D@B/C07%7_P"7CR_9TFA:X)KK32#2NFN>'K_J/74F"CEO_$^N.YSQ
M;_C\J3*?[V/9)-MEE/\ VR7'_.3_ &.EXNI1PN8_]X/_ $$>F@[-ZQF_X'=9
M=R?U_P U;Z_['VFBV+98O[."X_:/\W3T6X7L/]B\?[#_ -!=2*3:G3E)_FNI
MNV:KZ?JQ?_&Q[4K8['#_ *#+_O76GW3<Q^-/V'_..G^/_1C1<MTKOHC\??-2
M+]/^6V1/MZ([+:?V-MUHB\NO^)2_L/7)-^;!PS7H^H<!3S?]7#<FW<7_ ,1;
MVKBYIMC_ &.W1_\ 5'_-TV=FNCQN_P"3?Y^IB=XS1@_PK!]3;?\ H"*W<7U_
M\Y( /:K^M9@_XB^#^2=>/+8\[EV_;_E/4V+MW>E6 (.PNG,7_7[!:G*?[W?V
M8ISK?7']E/'_ ,XR/\G1?<<NVR<4<_F/\XZ<Z3<G8]:&FI>T.K:H "Y.W5!/
M^Q\X)]K+?=]\N_[&^M?^<?\ L=5CV[;K;!2<?8?\QZ4']X>[*&.\M%UYNRE%
M_P#@%DJO&50^GYX/^^_UO:BQY@W';SX,^BY_YH_I?X.J7%CMKBL'U2_;0C_+
MUE_TO9"A'BSG6N^<4WXKJ*@_O-2G_7^R%K?ZWM1#[A?2?V]K_J_/I(W+7U/P
MW0^S@?VYZE_Z<-DW_P" N[_NOZ_P"MO_ +;W7_7+VNG#_5^WK7]3;KY4^W_8
MZA3]V25%EP6Q]U9,$#TY%*/;-'^?H*LV'^W]VD]QY7_W'@_8?]@];_JP;?\
MMV _(D_MJ.DSD.VM^S ^;+]5;#IU/*U^X_[SU7_6(V/T]EL_/6Y X_1_U?*I
MZ40;#'QH[_*E!_.@Z2=3OBBK"/XIWQN#*S?G'[#V[_"K6_ZF@\?[U[)+O?\
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MO_66(_Y9W3 :Z'&['^]=>CGH !_#OC[GZK^OW^W,5B_K[KJL_P#E%Z<-P?\
ME+_F>GZFH^PUM_ .G-J8#Z_Y?GLE2G_W"8?[U[NFW_4?V-K_ ,WIO]GI'<7Z
M#+71/R6O^SU RV9W;B"/[U]P=<[!N+FBP./.4JN>1<3<W(_I[6SB6#_<S<;;
M_FS;S_Y!TT@5_@M';YL<?S_R#I"14U+G5MAD[D[&J;DFNS>2_N+BN/S>T/\
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M\0SO^_7I>/\ ?#\^W+#<OK_]QH/\W5;FT5/]R6_(9/3NFS^P]SV_O=N]\33
M<8':?^XW_P!7/K?GZ6]KK;E>YN?]S)Q_J_+I%/<6T7P+^9S_ ")KT(&VMNX#
M;./7%XJD^TI[A78J1_E8^J\_[#_B?8QV[:X;#^Q]/EQZ+9+QI34T_P!CI3>:
MCM?[^3CB^I3_ ,5]F9$]MQ_P5Z8'=_J_V.I8)O8V^GNL$YNC0]6^'J/+.A^J
MGZW-_P#8_P"/_$^U[0@?ZO\ 8Z\+?[.N_ND_H??O$ZK]-_J_U'KWW2?T/OWB
M=>^F_P!7^H]=?=+_ *G_ 'G_ (U[=IUOZ7KWW2_ZG_>?^->_4Z]]+U[[I?\
M4_[S_P :]^IU[Z7KWW2_ZG_>?^->_4Z]]+U[[I?]3_O/_&O?J=>^EZ]]TO\
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M %*=/E/,GKB9@/\ /UH-K#ZA/Z^U$!^JX_RZ;*Z/A'7/RB)>1_@+?D_T_/\
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M%_P]/_U8'_*4/V=3?],.Z_\ GS^__P#U3_Z-]M?ZX-[_ -&T?\:Z3_U=M_\
ME,'^K\^LQ[?WE_SY[?3?TOD:3_B1[O)S[>C_ )9O[2?\W3?]7+8_\3%_WG_9
MZX?Z7-__ //GMW?^=])_T;[3?ZX6Z_\ 1N'\^M?U=L_^4P=98^U>Q3<?Z'-P
M->UO]_'2?]&>U<//FX3_ /$4?LZ8;8[1?^)76*3L7MQCI@Z=\5O^5W<-$/\
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M_29GV%N*6YGZWZ<M_4?=C_>J?V02\N_\\G\^EXW@?QW'_&?\W6*/J7<%9?\
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MC#]O1*%PO^S$8L'ZT2XO^)@V_H)CQ_O/MS1-%_RFC_>/]CK1B\+CX1^=2/\
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MCU?PAZG^7^;KJ*8+QR?S_O7^^^OOVC_5_J/6O!!XD]=_<#^K?[<?]&^_:/\
M5_J/6O 'SZ #L?%[LARU'FJ.MW95[2- %R%!M+)_PRJI;#FL_P"FW_;?Z_\
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M8)OMVBCE'Z_E_DZ62;>;HDZ3\1_P]+N7LC8T5S_>W!<?2^2/_$$^T7[SMO\
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M9S]BJ/\ 5^?2]Z^ZC&Q,Q4[@J=Q5=94U%#]I_#Z-?X9BKBY'[/YY'U'T^O\
M@1-ROR@^Q3>-X\DWKTDW3?9=W&G2!3/J>H.]^M:7-[D_O91;PQS9!J5Z'^!;
MH7^\F*6Y)/B]5Z*]S]%Y/X'T]E7-O+]M=WGB_71Z_P#?4U/\_6MKW2>UCTZ#
M3B2N#_@'3<,'NZC%X%Z0RI^OC;&)C/Z<\6_WOV7_ $4UQ_RA_P#.3K>M!_OW
M^9_S]0&I,Z56')]4[ W%2#FV R=&I_ZS&]_]A[9-I-;_ *WT-O\ \V9)Z=.!
MU/!V_,=-4N+Z\B_?S?3^[MOC_54&,K#]>?\ EVD#VQ]99_Z-!<I_S;_V.E'U
M4AP)$/\ J^9ZX"JV)0*)L)OSLK:SFZM85F14\?\ 373D_P"]W][^KLT/^)SW
M/^'_ #=:T27'Q*C?R_P5ZR_WOKX?V8.X<_5TQ(Y_T:_Q3Z_UO3W]IYM[F_W_
M "=/?1 YT"O^FITELYNO8:1,=V;C[*W7759U?9M0#;%+57YMX/\ 7_Q_V'LJ
MO>;;:!O"NY[VY/\ !X8'^4]&=ML]V8>U8T3UJ6/^ =*+;-'OG)0>39>Q<'U7
MA0>,_7XO^*Y,?ZT5M1O_ +&W^'Y7V6W7V]?J[;_BW_-;HLN6M;(_JL7^5:#I
MLWMU>V(P55NS<.^Z[/Y*E KJ&@SIM35//_ +PW_/M'O/)EM8)]7-N/ZW^^O]
M1K_+I19[Y%+'H6UQYD<1T-%)MCK+'X*CK,MMK86(:KH%^_;)&E4<@6L?H;VY
MM_K>Y,VBQV;Z/QKGP_Y=!>03,]+<L?3C3I(5=5T&U2*>AVS0;BR#<?9[1V\V
M3-_^"D <_P"O;V@OKS:K3_0/^</ZO1G;"^@%2U/],:4_9TUKM<Y8 8#HG:&)
M@'#5^^_M%O\ 7_E'H_H.?\?93*B;M_8V/YS=.&ZFC^*5OL0?YP>G>GZ=RM6&
M^^S.T, 0NK[#:>R:(7_Z?UGY_P!A[9'(37']M=^#_J^WIQMYA3X;8MZZB?\
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MZ<9=O]CP'G<?66*M;D[<%N/\#4>]?NUX.,_ZW7C-;'@K$?(G_+3KG_"-^_\
M/S-G_P#H,T7_ -4>W*77_*5UZMI_RBG]IZR1X?LCZ#MBA)//&RJ7\>]4N?\
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M?SSUSFV]\C<H+Y/?>%QO/!H6O]?]:G]HI=EWIOQ'JRR;;;Y%OUR/4?8E>/\
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M39986)K\C59*LM_0_P# (^RC^M-Q<?\ */\ \Y.E8L[93@2-]@ '26J=\O"
MN3[WHON /^ &T=MT:C_;VFO[+IMVN[CC?20_\T8DZ>7;E'"*OS8GJ-%F<GD?
M^+9N;O7<!M=OX?@Z7$VO_P!4Y_WKVC\2:X_L)[[_ )P]*#9!/B%L!_S6/6:/
M%]R50\FW\ONW$J#8Y#?>3Q&4I>?^;$(Y/^W]N0;/S"?[*?\ +_4>O&YL%X@?
M[4$'^766I[9W4E?68RKW%L?9AQ5;_#[;JQU6*JJTBPFY^G^\?X^UHYTOY?\
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M_P#E%E_WD]=?WWVK_P ]%AO_ #_TON_]9-N_Y2_^-#_-U[]T[A_RC2?[R?\
M/UP_OGM'_GJ=J_\ G]IO^C/=/ZQV'_*6?VKU3]SW7_*,?]X;KS[ZV/&/WMXX
M3_SY4:_[W[9/--D/]'MO^<AZ<7:[@\%;_5^?3+4]M=;Q#U;@HJH_TQZV_P!O
M]1_O/MG^N-B/^)!_EUL;+<G\/43_ $O;*X$*YVL_PQ^W:P?\3^?9;>>X*0_V
M/?\ ETI78;CS _;TFLEWS#1JU/C]C;ZJ:9B+G(XP8P\<<@6^GLIF]R88_@@&
MOI^+E@W/]NP_P_YNF:/OK)5_$&WL'B0+?\7W<M7C!_O%*/:"+GC<+[^R _U?
MGTM/*RI^)ORI_FZ5([!WQP*?#]>CZ$7WG?Z_\A?Z_LSBYSN;CC]'_P Y>FSR
M];>MW_SBZZ/8N\@EJK:6U\G3@W_W";RI/S_R23_M_; YON5.=/Y'_B^F3LEN
MX[6E!_I*?]CJ='V54Q?\7/K_ ';3'_4T.-&2^O\ C"+^S.RYW^F_MD_U?GTP
M^Q5X7(_P=3(NU-CA;5N5R&+J1]1G<?68SZ?X7'Y_Q]FD/.UOTP=AN1Y?LSTI
M(.PMCU?^9W!A6^O_ "\@#_T-[4GFFQNO^)$0_(]:.RW2?A;^7^?K.^^-MQ?Y
M[<N%_P!;^(4B_P"\6]U/-.V>=Q_@Z8&SW)_"?Y],%?VWL^E7P?WBH:EOQ]@/
MXI]?]B1_O/M)<<Y;7;_Z.:?\7T_;\N73#*D'Y_[%>F*L[?C:_P##-NY^J!%C
M]]]GB:7_ !YK 3^/Z^R6[YZMQ_8_]5L]+OZJS'B?V5K_ "Z2E3VWNFL)MENM
M]K?T^]W'_$ZK_;Q<>R(<V?4?Z/;?\Y/\U>E?]6P,:7/Y4'\Z=,4^[JFL4"?M
M7-5; D"@V/MTJ/\ >*7D^T[W(NS^I=7/_-G_ (OK;6EI;#]2U2O],_['6(8X
MYBQI-N=E;AJ.?\MS^1J]L4MQ_0_TX]L^"-RA\&&"3ISZ[Z4U)4#TI7I;[?ZL
MPLF(ONTFHS0.1O74&2J_N:6F'_*%]Y_6$_X^Q/L/(KI#X4W^KY=%EYOTTYJO
M#\J?;3IQ.S=VT%CMO?>0(?AJ#=>,_B? _P!O_3VLGY.FV[%O/_D_R=-"_63^
MW7CY@_[/4*MH.P:FT68V/LK>@(_X'X_)+B_]Y=2?]M;V7_3[H,&"V/S_ .B2
M.E"RVQ^%Y%^7'_CP/2?J<8ZW$_0K"USSDJ7_ (K[)9MG>X_M;7_JI_L=+A<P
M^5W_ "/^?K)%B,G*#]ITK0"W-Z[)T8'/^O?VY#M5O!_8#IG5#^)_V?[->G>G
MH-TP\T75NU:6HXMJR0MQ_P!4W_$^S+PMT_WQ;>#_ ,U/]GI/_BQ_&_[.IL2]
MH0_\ MA[3/UY&X5;Z?\ 5-[:AAE_Y0;?_G)/_GZJ?H/XV_8.N9R';$9M/M[8
M@%_K_'[_ .]TWMR:>6W_ - L_P#LI'^0].>#8MD,_P#O!'7"+,=F_P#.GV(#
M_AGRW'^M[+IIKFX_Y1_^<HZUX5J/-O\ >3U*DA[7D_YA[8[?XG(U1_\ C;V8
M_3WUS_Q MO\ G)<?Y^MB:V7\;?L7IDJ]L;[JOVJ[:?4_T'_ P57Y_P"J8?CV
MFDVJ7_?%O_SD/^?J_B60_$_V #ICK-IYJ!C][MCI*DMR0N0K&'^]GV7#9G_A
ML_V_[/2TWT/E/>'_ )M=,TNV81;4.CL9S]0]5_O0-OQ_3VP-NE/P&U_G_FZ=
M\6G]D+@_L_S]2*?;D1_S.[^GJ6YX%#CB?^N_M=]'_P OUJG^\=)#)>?P7!^V
MO2GI<,U'=1W#@L53$ ?[@L7BL=_O=O=_I9#_ ,2A^1'5?%D_Y12?MU'_ "=2
M9<?M4<9CN[.UEOIIW'28P?X_G_B?;PMK G]:ZZ;\.Y'PVH_9TP2_Z!T/[V8W
M#NNI"\#^(U>3/_6$?X>W!^[K3K?^[&Y/D!TYT69VY3%6V?TO7>6W-;D<91[9
M'/X_>)^O^^_K[4)NT%OBWM\^M>DTVWLYK<2"GH,]*1MQ]N,I^WQ6U,%27_Y>
M.3JLH3_O7M=/N6XW)J_AQ_M_RUZLNW;>@_6+-^S_ ##IGJ<OO#G^*=L8#;U[
MG^'X_'48^GX_=M[*)+MS\%U_AZ=M["W7^QM?V])VHR.WS8Y;NW/U8^@_AV1I
M#]>?]U$?[U[+I=PMS\>X]&2[-/\ Z!: ?ZOGTV33]96&C<N^ZP_B^2R]N?Z7
M'_$^ZBZM[[XQCJQL;E1^K3K&AV"T'"=CDWM>ADR_X_Y _P")]^7;-OC_  7/
M\O\ /T7E! ?[=/V_[!ZD1OM0']BJ[>I?S_D!RP]U$\, _22\Z7&!SCZBS/VT
MZX+5XJ _L;B[MH_QQCJL?3_6/OW[SF@_T>3JGTU?PVG[1UG&XJ^F%L=OWL!?
M\:SKG^)_[R+?U]TFNKP?V,\GY_\ %]:^@4_$MI^34_R#H9=BY;<6:VS35>Y:
M5:;)U# 6##%&JXXO]+7'^]>Y5Y>W1HH?UO/_ #]!?<K=8&.FAI\^'1;^^8S0
M;A-9NO+9[&;5JL?C:# 9W!9#^%TM-4V_Y3/Z7Y]@+F>&:]N?^%='^SD"WH/B
M\Z^G55/=4^^<$U34)DCOO$,-(BK3JR(M_O/^]CV:V%W=0Q=L6KI'=;:K?VV/
M\'5G?6.'J,MUKUO5T_0."D\^R=GUK5V<W)85@%+3CS6/TU6O;_'V$Y8GNN^'
M;J_//3D#0VQ,)O",G IC^70JTNW-Q1J9X.B.NJ:WY.YK?]%#_>O:*2Q>#_B)
M#_/_ #]5EO[?_E,G_8/\W2ECRF\,'3M//T)L\"D YH*ZC)%[?XG_ 'GW>;?+
MCES_ ',VZ/I*-OM[[X;QL],V7W<O;.TMU[:VWA*W ;DQ1QM?5T%E;[JF%6?V
M%FB :]C_ (_[ 7]O7<D/-EC2S3]G32D[+=!GN*C.?0TZ@;8P77.Y*<C:FXMV
M;"W%3:A7;?H=Q?PJIIJD@"WV<Y]0)O\ D?T ]A[9MBVNYFI->FTF_+_8ZM>7
M5U*/&*JZGY5J.A,BQO>^UU$^%W+@^P,9]?L,]CSBZKU?UEB_W@'_ &WL<5WO
M;?\ 1_J?Y]%A:QO>(*?,''6<]R9W$ZJ;>W5F[,8+6;(8+_?S4X(_H18 ?[>_
M]?9C#[@S1?[F6_\ *G3!Y?6Z_LW!IY''^K]G3S!\A.L:A2*K<;XR6_TR&,K,
M;_O /_11]F,'N58#_/\ \5TVW*MT/+]A'^7IQC[WZGMSOO"W_M:82/\ B?:_
M^O6U?[_/[.FCL%Y_#_/KE+\@NJ(ASNZC)_%HO;(]Q-K/^CGKW]7+O^'^?3&W
MR)Z^<6PM%O#<+$_7";<JLI_M@6O[03>Y>U^?B?X/\->GQRU=G!TC\QU#J.YM
MT9!0NWNHMWU&G^UG&_NN?]CP?][]ETON8?\ 08.KCE]5^*0?ETE\AV/VJP G
MKNI]E4PMQF]RC*$_XW!)^O\ L/9%<>Y.Y7)_XAP_]1'2N#98A_OQOL%.D#/O
MFJF!_C7R#I%%N*#8>VV%_P#;:?Q[(CS--<35_>/^#HY7:Z#%G3_3%_\ 9Z:5
MKMBY"XK=W]T[J!X QZ57_$GVQ-(NY9FGDFZ<#W%H.U47]G688_JE;@=;]M96
MUKBOQ]4!_O%0/;7[OVM/[:UN/\'30OKNY_XDH/LSTY?9].^#_F3^_P"U_K_=
MZK_XI:WN_P!+M_\ RBW/[?\ H?JOU<M?]RT_EU GCZ.#'R;.[*P/(^M#E1_Q
M!^ON_@[.O&UN4_U?\U.JUGN.%RA_E_GZS4N5ZYI*C_?O=V;^VIP;'.K>DX_K
M]W3W'^\^]^);P?JP[CX73YL[HX:T4_9_Q?2MQ^\-^4.J7!=N=5;SI%%_L,]I
MQ-4?\/V@&_I^?9A%SG>;?0V]]:S?S_R=%IVF-\3QSK]G#I60]L;_ ($;^)=6
M_P 6IC>U?LW<-)E1_A<?7\?0D>SY?="YA_W)@B_VM>F6V.VG/Z#D?\U^G1N^
M-MHI&:P6]L#^0N1V_6#^GXY_WW/LSM_=C;%_MT;]O_%=,/RA)/\ !<0_9P_R
M'IWC[^ZK^J[CDI#?_E/QM6_^]C_B?9D/=#:_^4@_LZ:/*=X/P@_[8_Y>NY_D
M)U9'^K<;U1_ZMV,JT_XCVU+[I;6/]'_D.M+RK>$?"/S/3%5?(3;\A P>V]V9
M4!- !QW\+I0/]>Y)_P!B#[1S>ZMO_H/?^SIU>4[C\1 _:>D_D>VNPJM/]Q^T
MMI;64K8UN[-XT3_I_P"6(_XK[)9?<_<+G$*6X_YK2].#E9H\M"Q_TJ_Y!TFJ
MK=&XY8_'GN^]C8"E%[4.U:*FF//^)NW^W/LGN^8;K<?[;<;>V_YN?YNE2[:\
M?PV;-]IZ3L_^A26I\VX>T=W;KF X;^)5@IO]B(@?]X/M"3;_ /$R^\;\DZ4B
M*[_#&%_/J70Y/H^D/^X#K7.;@J187&SJS+"W^M6@>S2T2S@_L;7_ %?M/3;;
M9*WQ70 ^W_,.E#)B-Z[R@JL=M_J#:FRL75J<?_'-U1T1JB?Z_:0KJN;_ (O_
M +'V^NT7?-&;:U\&'[:4_;TEFFCV[X+HLWRKT/6.ZOVS%M'#;2S=%C]PP8>@
M-$36M:]S?\7;_;CW(%ER39V]GX4W?T'Y-R=G++C/2#FZ/IL=>;K[>6<V34FY
M_A]#DCE:6W^-)-;Z?['V'V]LHH9O&LY_\%?\)Z5P[MJ%)%!^9Z@R1][X2ITU
M%-L7L"%P+E,B-MU7^WM:_P#L#[:EV??=L/C3?K?GZ_GTL\3:[T4&I?RK_D/6
M&?L/=,-AN#I+='^)HHZ3*D7_ ,2![*9=Z<_[F6,O[:=6\"W_ -#=1]M?\_3=
M+VAM0_Y_J?='^!79('_%/>AN=IYP7'_9/T]]$_\ &/\ >NO1]E[88C['I[?1
M^MOL-D#_ (@\?[;W[]\VD'^@7'_./K7T+^;K^WJ?_I-D/_ ?IWLFPXL-NTG_
M $:3[=_K)"/^(+=-_0?\,A_:>LW^EW(#_FD78W^-]N?\:_XCV_%OT)_X@=.?
MNU?]^+^T=>_TN,26GZI[*_(8?W;_ *_TX'^'OTW,T/\ R@]4&TUX.O[?\QZY
M_P"FC'?\^^W_ /\ H(CW?^L<'_*+)_O/^QTH_='_ "]6O_.8_P"?K!)W7M3G
M[C9>\0?IQL]/Q_KGVU_6>$_\19/]Y_V.O#:''_$JU_YS-TUR]J=8U7.2V9GS
M]?\ @?UTI_Q_J?\ >O;7[UL[C^VM9/\ >?\ BNG/W;(/AN;7_G*>DG6Y3X]5
MO[U?UQN"DJ1R2-F5>*O_ +"_T]ETUQM;]7%O?6_F/VU_S=,0;H@?\ O]).+'
M_3#_ !4?\0?91-8[:?\ 1[CIP1SKY(?Y?Y^N'\1ZI!O3[O[HH_P/^!7Y_P!M
M[J6MC_H]Q_+_ #]/>-=_PI^W_8ZQKD]@,+?WZ[VJ!^5057_%1[K]3;)QGN?S
MZIKN9_PH/]7V=</^,62V\Q[VRI_J?N6^G^V/]?>_I(9_^4B;_5^?39>4</#7
M]O\ L=9Z>BZIE4_:=5=E;@J1R?OJ&KX_QN*CV['LUO!\=K<=*8[F[(_2ND'\
M_P#"!TM:&K&.'^_<^-U>U3SZLAC:3'?\1;CV80QS6A[-N_P]-F$7/]O>C]O2
MSI\[WA54_P!MB^K,%BJ4_09#<07_ *TZ?S[$B?OJ_AI#8V\/_.3HCG%FA[I&
M/Y#I34<7<']W<S]_0=??WLT8_P#@./I_NS0Z0#]S]QS</HOH_%[?C@B2WV_>
MQMLL/^+^*77_ (\OY?ZCY]%C/8_4@U>F:GS_ -7\^AP]R%T2= +VUDMN5%&F
MV,G'NVFJ@V-SU!G,+@:S<B4M3CS>(\*Y)L>  +W-S<^X^YSOMMD3Z:]\7]G^
MST>;/;R3SZ$T^E":5_D>@MB[.W#2?L_WQQ55S],CL++XOZ?ZR^XX_K']/^C#
M7_G'T+/W*K9(C_[*J]<(NQL]4GG>./IOP31=8Y;+VM_KCVC&[WC_ -M_VC]6
M;;$@\J_;=CKE)N/)U=A_?S?E6/K_ +@>G!C?^MQ!]J-</^C>)_V1_P"SU0VP
M/X5_.[_S#KM:&+(@^7;??FX&N!?)5YVP/]XJ8O\ ;W][@6&^_MOJ)O\ JETA
M:=AP,:_\:_S=.$.TZ:WFAZ"R56;<-G=\6_W@+-[-/W9#_P!&W_JKU;ZE_P#E
M,'Y+US7:-5"+Q=(;#;\?Y=N:E;_>J?V^T#Q_V-KTQ%-!!QNV_9UR38.7G@!_
MT4]3_P"J!_B+#C_J1[>2UO;C^QM;+]L?3D]ZBG-U)^SJ-)U[6(+5/26TF_[4
M6]SB_K_K'_B/:*?:[Z3_ $"G_4;TPAM[BM)&)^:5_P @ZA-AL#1,PS_7?:^W
MZ95.JMP.Y*O+TO/TYHZD6%[?CVQ-MUGM?^YEO<P_/ZAY_P#)TK$S1X1XV^14
M _ZORZDY"GZPH,=BJ[';E[9SU1E%+87"X/<65R%35"WU-_H!;FY_UK\VM>KL
MB?V/UO\ U7''K<&Y7D]:^&*<20*#^?\ EZQ#;CUOJI.J^RJL6_YB#>W\-_WD
M5*CVB.TV<_\ N/!<_P#53_,>KC<V/]O)'^0K_EZ[.P\E*/.O5&"46%OX[OVM
MRWY_P(_Q]^39!;_\1?\ L\'5I-S];H_]DE.G"+:.?QBG5MGI7;H_YV#XLY(\
M?TU<_P"\>U44/T__ "C?]E,9Z3EQ)YR'Y4(ZE"NRF)/@G[CV'B:4W/\ N-VY
M2-_O'W _'M^8^!_;75O^R/IP*&-1:N?S/^?IN?<V*(/\5^0V0(_ICA2XK_>/
MM@/:;^L-I_8C<?\ JF>K>"W'Z,?M_P!GJ"<SU"]QD^Z]WY;_ %MP5B?]:K^T
M3[EM=QQGN?\ JH>O06UY'\,:C]G4VF/QQF(,NXJ2K/%_X]N.L'_6T?\ %/9O
M%/M?XY_^SCIF]AO1_:K^Q1_GZ4>-P'Q[JQ:C&Q:MC;U'*E+_ .OS;VILSL/C
M>,3W_P#-0_YNDCK< 4HW[!_GZ4-)UQU15W\.VMH5I/XQTC"U_P#7/L1:+"^_
MXD1],?57:>3=2&ZAZT90QVW0T@!Y./RM:QY_P*#W3^K=A='_ *Z=>&XW=OY_
MM _R'K >G]IP6\)W52#^N-WIEV/Y'(^Y]L2\F0S_ .K_ &.G1S*WR_9_L]<_
M]$N-8 Q;AWY2?\'WM4_]&W]IOZBV"_\ 7P]>_?MT>*J?R'3?6==;6H1;-;EW
M74$\@5V^*O\ '^ 7_;?[$>T%SL6R6.9IZ]*+;>+LBB*!_M?]D=,<>:Z1V$*F
M>C^PK<E2\9 4 K=T51N?^5TD6]LR;CLNV_K0_K=4D2]OL-C]@'[,]3:;*[YW
M_3?Q7"U6/V#M6J%J&O7&?Q/*55*+_P"O%"+_ .)L?Z^[6V[W&]?V/^+?X>KK
M';;?\0UG[:*#^?\ L]0:_JG94TZU>[-S9K.Y*DL&K,_O3^&D?[U8 >]2\O6-
MW-XU_<1_GT^NZ7-HH%LM!Z 5I_+KS8CH3 S^66NVD]5>YKJW(G+?[UP?]O[4
MK+L-KPG_ .SG_8Z0S&XNQP/V!0/\M.G->Z^HL*?LJ'<-$$^GV. Q>D_]83?_
M &Q]O?URL=M_L?\ K;T\=FN[OC_,G_+U$7NS$5,>K ;2[)SIO8M1;?K,8!_A
M^]_QKVV.>4N/["W_ -7Y=6;89Q_:,H^VG^7INJ.RNRZZW\(Z9SAL+#^.9(R#
MV@N^:+\?[CV!_P!7[.E*[/9T_7E'Y4_V>F*JW=W/5FU;MW/[=MS; ;:_O/\
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MNMC8?$(_\/2T;?<2?V%?YCI%Y'NSJS'C]_>U&I/T-"*L?[T3^/9;/SU8VO\
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MXK_BNGH-X@08'[7/3'4=-5@L15[&J>/ID.N/]Z_RGV73\DW/RZN-S@/$,/\
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M\/&JJ%_K];6_V/NO^([=_;=4_P 9O.%3U$D[%BJN<!AMU[@/(%>N.&-I>?\
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MX_ZI_P"STM@VN#^(_P O\O3=4[OW[E?VH=B4&6IOK>OQFH?[8\>RJ6]N+_\
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ML?%4^(V/L^@%9G,A5Y*I_P!Q=) ;$<_0_0?CW'][S7<-<4Z-$VBWMXB26XG
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M-)_WOVC'.FU1?V,'_&?]CI6_+UW<<6'YR]8$[HW!(A7"]0;YJ_R36K28H_\
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MT?32T0%[_>[TI<4>?]M?W67?[FX_Y9W3AL;1>-V3^5>NO[U=Z?\ /OMG?^A
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M#4U()XUT:6_'(^W!Y]L"VYB_U9ZI+>;4< ?R(ZQ'#=^ '[S*Y'[;^M!E*/\
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M;_X.I]124]53 Y2DH*LBQ%\83]?;<NWQ7_38)3_5_GZ2DNQ]E57^=VCA*O\
M[6&.I!_O7LO&WV/_ "A6_P"V#I1]3<CS/\_\_334[!ZQ3F?;VT:6_(;6<5Q_
MM_:66RVE_P"VJG2OZ_<+?@3TV5.QNIV!AJJ3:=-"1<!<KS_O)''M#]%L"'O)
M_GT]]?=SC]6IZ3=;L_HJ@ FKGVK3?X8_)%O][J?^(]HY=MV(XSTXM]=_ZO\
MBN@QS^4Q-)3^7K;(]@TVV:2NMNK.T.XJI*8XW_E-^S%7;[N:Q_WCD6/L+[AN
MUO#/X-DQCMSP'1]''<;@!]5!"6\L>8Z&K;6^NG,!B*6CQ&X<'2XX_6^2_P J
M_P!8\?\ $^Q[M]_86-O_ +FP5_YI=!*3:=PDN/A/^3IOKOD/L:D'@QG\=SM3
M]!_ \<%_/M/>^X.V[;FW@DN/M^SI^#ERZNA^N0.DI/WAV'E+1;6ZIS9I^?\
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M2#KOJW=E3F*JN_RZNW9MVJRGVU,#_NG[P6\UK>RWF*2T@[8K:GYTZ4[1+?\
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M@\H)ZW<=-23[O[MS>!^Y/&/_ (;6N>?^;UP/K_4^P);[@^\S>->71_[)Y/\
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M#'^E$^7Q/^W_ -R0_P")]LGD2_\ ^4K^7^QT_P#O^V'&W)^VG4:3JKMZCO\
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M]QH#K^<?2K]S;I=?[D,*>?=UU-WQ&IMCMFU[?2[9W<]%M;_HFWM')[D0VO\
M86O[*]>_JL6^*YK^5?\ #TF9N^]SU-_#_HVV\/R:_<=;DSQ_U!'WM?<N\O?@
M_1_U?/J\'**/7PM3?D/\W48=L[HK?^!G:O6VWZ<"UZ';]7E;_P#4Y3[]^^KR
MZ^.Z_8O3[;4EO_:VI/\ S=ITZ4N2Q.1!-=\FR!?_ ( 4*TV+OQ_K_P#$>S*W
M8W?^Y.X_]7.D<T'TA_0L_P \=*_"]>])50-?6;GQV]:@WO6Y[<HR)O\ \L+?
M\5X]BRUY6V0?K2S]%+[U?$T"T^P=+/?.RZ#=^SQM_;M9CL744=?CZ_ M0_\
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M5I^;FOW$%_/]:(K[-X+&[/\ 8V'@_P#-Q/\ +T7331?BE+?D#_DZ<ABOD/D
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MH\J>/\81_3V:'FJ6P_MK'A_J]!TR-NKE)%(^=?\ .>L\'<NQSQ7U=;B""?\
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MB^.^Q/M[Y&LW54$?\['($'_#Z+[61<@#_4.K'FV<\*?S_P @ZP9'J/HS$?\
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MVW]J/]7^KY]*EV:YN> _S?ZORZ9?]-&TYO\ @'AM\U0'U_AVS:OZ_P"/M/\
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MQ\E?[3=V"J3S<OE#^?\ "]O:^#G2P?\ L9_\/^;I-/L=U:\5/\O\_2B@SNW
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MOY]15J.\)N9_O])_VG#_ (_P'_$^WVOM\/3D,.W<<?SZAS4?<TG^>K,A2<<
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M%9^?]A[:_<MU_P!' ?SZM]=9?\HO^#KC_=#LZ/B#>[5/]+_\:)]V_<.X6_\
MH_5?WAMS_AIUX8#M:+_F+DJ[WX(_XIS[\=GW _Z-U076W>G70QG9\=O\LKN;
M_7)T9^OM_P"AW;_1INK_ %FW>G734._V_>F_CEN/^ &YJ/\ WH?Z_NK65VG^
MCW'2>6>PG\EZPR8#-S0U1FVG75=?4T+4+9O.[T_B=537'^O^/K[<796']/\
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MR(/_ ! Y]IWY%LA_O_\ XQTIAYFN/*G[.L?^B/:@Y^ZSO-O^7D#[I-R#8_\
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M9_T?ZC\L]%S2WXX:3^SI_P CMCXZTN"J\_%E\EGJ>D_YU^XZK*51)_ AX/\
ML2/9QNVS<O6\/C0SY_/_ ##K4=Y?LVD@#[0/\_25CV+%5V.,Z(SP_J=W;U('
M_N0MO]O[#7T\-S\&W2=+3=:?[>['Y#IWI.G]S2J:B#8G4NU .;5^.K=SU7/^
M/-_Q[\G)$NX<2B=/1[Q9)YW;?L'^;J=%U)1TP/\ '.R-OXK^G\"VYB<;_O-Q
M[L?;ZVMS_C]]HZ<_K%.P_P 60G[2>I/]S^C*8?[F.R/XN;'FMWJ!]?P!"#[5
M0\O;!:_Z/XWY=-MN>]7'!*?*GE^=.G:C@^->/%J:3K;5]+UH.5^G]+W_ -[]
MGUC;\M0?#X?YU_R=)KJ?>V/ZVK\J?Y>E9#N[I.F!IZ#+=:TMS]66D_XT/Z^S
M9+[E^;C]/T4SVE[/GO\ ]7\NG:/<?5-79H<KL&J_JI2B'^]'VHBNMEK_ ,1_
MY]:^@O%_B_;_ +/3@V,ZXRH/V^(Z_P KQQZZ)3Q_L/:@;9MVX'_B%_J_/I(U
MQ+'YO_A_R=-M;U)UWD!:;96#!/\ J<?S^?\ :O>AR)LL_P"&/^?^0=*#O%VO
M_$D_R_S],*]!]8Z!/!BLAC*KBPP.0K<;]/\ 7'X_U_99)R!M:?#GIV3F&[N/
M[:@^T _Y1UP_T&8J!148K>/8>)N#;[+<@!_WUN/=8>2(?[&&ZF_9U0[RS?%:
MPGKE_HCS$%Q#VMVI1?U"Y.D(_P!X8>[/R--_RE77Y_\ %]*(=Y0_\18/V?[!
MZY_Z+-U?\_A[$_\ /M1_\5]U_J-=_P#*5-_/IG]^I_RB1?L_V.H@ZLJ+'[_M
M?L47)_YB(?C_ %V]T_JOX']MN,W5OKJ\+.#]G42IZUV.!JR?96ZZHG_G8]DJ
M/^(_P]EO[FM(O^)W5_KI(<A /M0_Y^HD?5?4/^[MSUE5_3^([W4?[;B_MO\
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M9BMAS#<?VT_^K_G'TD-W8J,*3]M?\O66+8?9SV^_[CKEO]/X?MRE;Z?UY _
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M-7/N?M=C_P ._P!7V]'EORE>.:D ?G_L=(^H^3.U IIL;A\YE@>;R8X-]/\
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M.8ZZ<3@'2 /Z7M[\;F'I24].L.NIB%R ;G\&WT_V_MH&*;K>?]7^H=>EJ)T
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M]Z]K/W9:0G^PITR;EF_%7_5]G3K493#8XCSU>-HO\ O^^_WOW>5%L?\ 1^D
MAN'\OY=,O]_-HPBQW'CQ^3_#E!_V]_\ BOM'+O5M_O\ ZV-ON3Y?X.H<G:>V
MXC>)<Y5_X8_;M8/K_A;_  _I[2_O^&WX?ZOY]/\ [M<^G[?]CK@.V,8 ?%MK
M=M94?D?PT#_>OI?_ %O:*7G%3GJXV28#RIZ=<Z;L?,UAM0];;FK#Q_P.'\+_
M *_T]WAYGNI^-K-TRVS#SNH?Y=/*[D['E_S'7F#@ YO7;@4_[TOM6NX7M?\
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MJ?[63^7^?I1_4Z6YQ0?RZE+\R^HQ_GM]]L55[@_8Y>I4$?\ GN/LRM_>5/\
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MUI<>0)_(?Y>L7]Y<'_SNMN?^?&D_XK[]^^[?_?L?_.3IK]V3_P#*,W[#_P!
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M[SP:FW/[(/U_UU]L-S3MWETI_=,A_"1_J^WJ&O;VPZ<J'W;49%?RM'BZE/\
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M_!:A3[]^YMP'_$G_ (QUL[CM_P#RBC\[H_Y^N"[5WJ/\]V?D/_08C'_QP/\
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M'JS_ )[O;'_4I?\ KW[K_6?:OX>K?1WOS_:.L![4ZOE)_P!_UM@BY(!C4_\
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M<S68_MYJ_M_R'K0VU_('^?4?_23L;_GM=I_^=R?]>O=_ZTV?^_O\/5?W6_\
M ?\ 5^?3C#V-U]-80;KV>/\ R(T:C_>_>OZQ6G^_Q_/I0=K<?A/^K\^GF#=V
MU*RP@SFVZDV'_+QI#]/^0C;VZ-^L_P#?X_;3_+TTVW,OX3^0)_P=.D4GG%J>
MN(_H1?\ XD^W_P![0S?\2(_Y?YND^DCB.N=Q_4?[?VM\/Y=).LMZP'_=E_\
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M_JG]8D/"V_DO_0'3?ENL=@J_^Y'+U"4M_P!-=NRK/'^QR[?[W[2S<K[?:_\
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MS/RZ5\QW4Z[C<]S>7 GY?ZO3H;8\9B#_ ,NC$>JW/\-HOQ[DZSY=VW_?J?\
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MVQUED*(6XKMW5^KZ?ZX'M%?<T;D?]Q+7_G-^KTIMMJA3XKH?[44_S])%MO\
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MM]ONS741\L=,J]C=T1U%I>F?N2!I/V&X6N?]Y^OLM??-T_Y1_P"72F;;]O\
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MIYQW?&'K/M:2DVCNJJK<F":+'T.1I<I]S?ZDL;VX_P /9CMGN-;;E^C#XO\
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M5GGZ6M?_ &%^/=[[G6VVH?ZAT];[!<L?+]O60=F"K!&+V5OS*D@<+ME<8/\
M7 F4^W3SY-<'_%K4=4&P%1_C%T!_J_+K'+F^V,GS1[ P6W*<@6.[-QGG_P X
MR?=$W3=;O\'@]*);>SL^-SJ^P'K)%A.R<EQD]]8_$W/!VEML@<_]-%8/:3Z'
M=+C^VOO]7\NF_J;1?A3_ 'IO\U>FBJV#M>"TV[]_9S,$ >K.;W_AE)_L.&8_
M[ >TLVS;;_Q,GZ9%ZYQ&H'^U/^QTU++\>\"X"4NU*RIL?2<>VYJHG_%K6 _U
MA_K\^T,</*UO_8P1_GGHSCDW67!+#\Z=*F'M'JND'AH+4A%N:'9%8/\ >33D
M#_;>S]>8MHAXCI)-M&Y'S/\ O6/\(Z>8>W>N2OKWA14I!%Q7)_"KV_QM_P 1
M[W#S9M?^@],ML]WYBO\ /_#3IRIM_P"R*T_L[PP-6+\%\F3_ +Q?_B?9K_6"
MPDX],?NRZM?(_P O\YZ?:?-XVL'^1UU#5*+ VRJ?[X>S6'<T']C)_A_SCI,U
MK<+QM_V4_P W4\0-/P-(^OX/%O\ ;_U]J1=03_Z.>F?IBN?]7^'KOU?U_P"3
MO^-^TGA0_P"H=.5^9_U?GUP,I/!T\<_I_P"-^]E8;C_B/)U3Z?3P(_GUPDI,
M;5@^:BQM8#R?]Q-S_L#S;VW-M,/^^.E"L1YG]O\ Q?3')MK;0^N!VV/\1CJ$
M?[T>?]M[]/LNVCA&>JK>N?\ B3_J_9U(7;.V&4^';& M]#IQE"#_ ,3_ (>R
M]-FV<?Z!'U>&\>N6;]IZ<X*+&T8O!0X\F]B/X26_WKZ?CV9QVT-O_8_ZOY]-
MW$YDXU_;U,U'^I_Y('_%/;OU<'3?TAZPS2-#^+ <W!T_\5_I[WX\%OUHW->L
MHJJ:#ZUMP?P2#_O/M*=QA]?V?\7THTD^73#DMS;6QA^XR>YL!3_2_P#$<C1#
MZ_["_MJ;=+.W/C=:6T9\*#^PC_-TAZCN3:A!@PQW!NBH ))VCBQD?K;_ '>?
MV?\ >/9+-SU;H?TO\9Z,!L%Q/EJ*/GCJ,FZ.TLP-6W^N<?MZG_M5^Z]QZ5^E
MO\Q2'_7_ *^T<>Z;I>8^A\'_  ]>^CM+/XI*_(#'\Z]=O@.VJR]17;ZP6(XY
M.!VVN7_I_P K=[#W:XVK=Y_]R9Z].I>;;PMT/YFG^ GIN?J?-9/TYCMK?5=3
M<D"@OC.?]O\ Z_\ 7_;>T Y+_>7&Z_ET_P#OI;3X;5:_:#USI.ANOZ:H\N5I
M-P9ZH))^_P ]D:O)7O\ 3BP/^\^U-G[:0(/&F_EPZ\W,=Q<&@('RQ7^9Z7M'
MLC9N*YQFW<'2#_:\;?\ VW_(_8BL^5+8_P!C!'T7ONET>);]O3A4;8V[4$BM
MVQ@:OZ<_PVB_I_P;VJFV>VN/[:G29+JY3AJ_G_EZ3=9U9US5_P# C:>!I;<:
MJ#&G#?3_ %S;\_T]EK<I[7_OC_5_/IT;M=C\1/VT/^#IMCZ=V=$&_AE=N[;S
M6%C0;CJQ>YY^H_XGVE?E.VX0_P"+=*(=WNCQ /Y ?Y>L4?7^Z*5BV([2W71$
MW(H-P8RDRQ/^O?\ U_:=^7IH,"^_R?Y3UN3<U<U:-37A0_[ ZRQ8_N&(7H-W
M;4RH''^7[;J\9]?^6%_][][BM=ZC_L9^F3<V=Q@JW[?\YZY^'NA.;]<5AO\
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MTWD^?7$E#?TG_6  ]K_J)S_8]4\%?.G6&:;_ ";ZVM<W)U7O[;N7FN#UNW@
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M038EN%'0,9'<=#N;?M)F>U.M]U8W:^,Q_P!E1/N7;?\ $135)_Y3*S[6]_\
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M?MZU^]KL>0ZZ3J;:_'CR^^Z,_C_?\5:VM_L#[<_JG;?\O'\NM_O:Z'DO[/\
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MZ@IM[2D&LJZ"FXX'\-_BM5_O Y]MPQ;E/TU/],O^K'3K_!,M5CQ9+<==X?\
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M0H:3\?Y"/X5>_P#7U#VFEY1VV?\ MO\ 5^WI]=PE7@U?M%?\%.FQ.I-KZ?\
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MV_(UE /U3TBGYAN#P_/I64>P]F4I_9VC@0+V^O\ %O\ ?'V>_P!4MN@_U?\
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M .KJ3[3#<K0?V,_5C 3Q!_9T".]OX?)V/MS^^1H*O:AQ[?W?-;Z:09;[L?\
M W4+<'Z\6_K^?<=;C])<;E!]9TKBU+$WAC/F!]G0V4B4U-2_Y#1?94W!+8UP
M#<>Y#M+.T2;_ !/I S&Y'>?V]9:>)CH/IXU?4$_U_P!]]/:OQ8;;_1^D_P!-
M7KNLGIU4>>N%&"/T@:A_O/\ 7GVEEW2SCZL+4W7#IIFW%MU^9\U1\W^N1HA_
MO2CVT-\L/]__ .K]O3XV^Y]#_P :Z]%G\%*08<OM]?\ JNI/^C/?OWK;?[__
M ,'7C87 \F_8W^3IYAJ:>;F&N^]4?U8$?\4'^V]J8=SA_P!0ZO\ 3D<13^?4
MC0/\?:WQ?LZ34/46:>"EM4UU8])3 D:,C87_ -A?_;>TTE_#:'];JWTYNA@5
M^R@_R]('-]N; PEHI=RT-74?\Z^A'\6'JXL#!;CGV17_ #IM4'#I?:;#=OY4
M^? ](V3O#%3A?X9L[=>5OQ;^'_PK_>K?[U[#,WN7#_H,'^K^?1NO*+>9 /[?
M\HZC2=R;CEL(>NL@;&]\CNBE(X^GX'M!-[D7_P#H,$7_ #D_ZY]/KR9(!E_Y
M?[/4.3MCL60?Y/L_:%']#_E^X@?_ (W]H_\ 7%O/QP=*/ZJ1_P"C,>H,G8W9
MLHM]IL*E!'U*U>4-K_3VF//.Z3^O3O\ 5JU7C7^0_P %.H<N].S)/^7SM2D%
M_J=N5A_WNH]M3<W;P?\ 1_\ JF.E"[/%Z']H_P W41]P]G(;+N^BI ?J:';M
M(W^]\_[S[*IN:MT_!/TZ-EM!_;C]I)_P])^OPM7G3?<^8K]UW'_ #(92]+[(
M[ZR3<IO\8OKB7_J'Z5VZ0V@_Q=0/SZ91L#!1<4=7G<55#_E0R%61_L>/;<]A
M$?\ ?G\NEGBGY==?P7>=!*9\+OO._P"2_P#*!79.L'U]^A&XVW^XC_\ .:3K
M1AC;XK<4^0Z4%'O??&/(.3S>[:2G_P"=A0XVCW12_P"\_O?7V=6/-6ZV'^B2
M=$]QLMJ__$=?SQTL<1O;/Y6J$6,[5V'5U)!/V6X-M_PFJ_WFI_UOS[&-CS+>
M3#]&ZZ(+K;XURUJ?R)(_ETOH*;N>IO/3Y?K*LO\ 4C'51_XCV,(9MUN/]]S?
MZOLZ*6^C&"''YC_(>L,D??7_ "@?Z,:WBXT+5GZV^O/LON;/??\ ?$?_ #DZ
M50':CQ+?Y>F"HA^1_P#NG^XM^#<*OY_VWT]D\L/,?G!'_P Y!TH'[I]3^P]1
MSMSY&5G%1N[:>)_'^14:CZ?ZP_XCVG&V;U/_ &O5?JK'T)^VIZG4_6_8]8+9
M;N#/:0#?^!8YI!_L;<#F_M;#RC?C_<B>3I.V[6A_L$'YTZ4T76-1R)NR]]U?
M-O3D/Z_[?V>_U8/^_P ],C=0."(/]7V=1!UYEE'BI>U=^C\D-DZ3(G_8@-<?
M[;W7^JTR?V4_^7JBWJW&="_X/EZ=9UV9O6($IW#G4;Z 5^V:8_[R;<>[?N"\
M@_XG=-_71M_H:_SZS?W2[*-O%VLA^A%MMT8][AV>_P#]_P#3IW2T/X?]7\^D
MCN+!]UT*^;"[QH=Q4P#?>T8VW1XNJ 'U^SX^G/UO[#V\)O5K_8S=+K6YLKCX
M@1^9/[>F_8V'W#OS!UV2W#OO=U)31UN0H3@L?]IC*JE_AE[_ 'GBM><6%_\
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M&#H/O>-)AF/^K\NGZHFK;']0)/%@?Q_3CVYX$'^H]6IUP]#_ . '^N?I[?\
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MM:O+]OT[%N5P?ETV2[$V2+?[]G'_ .-W_P"(][&SV_KT[]?<^O39)UYMEO\
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M$-'0_<U9-LA7#GV1[Q=7%C_9=&-JD#](R3,;DJ_WY]Q9 FUKT3'V'OJ;N?\
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M^%TO_G9:_N+]Z]T+>T_L8*=#/;^6KBZ^,_Y>@OR_9':65%X&VIMB &Q^P/\
M%*KZ_P"Q^G^M[CO=?<.\O_\ <>L7Y4Z%UARO;1_V]2?GTA:JOWO6#_+NQ=UD
MD_2A%)C!_P!83["=QS3NK_[D7/\ ,]"6#:=OM_["V_+I,U>$CJ/^!F8W5E+7
MM_$-PU9^GL-7FY7UU_Q)'[.C.W\"VX6_4%MK;<-O]Q-!4_T%=]YE/]Z'LL;=
M;W_BJ#I7##7J1'B,32K^UBJ+5?\ .._WW'MNIN.G^I-34XZE_P"!OV%)Q_O?
M'M@,(.%3T]X%P?3IG&Y=JTW/\4P1_K<'_BGNOC!O(_ZOSZV+:?K%_?7;?_.V
MH/\ >/>O''IU?Z*?_4!T[8_*8K*?\6VKHZH\<4/^/MPDKZ_GTWX)\_\ 5_+J
M;))_L+?[[_;^[],]-5;@<'DK2U>(H14?\KU_X7_MQ[W''/'P)_P]4E;Q^E'A
M]S]A;4_9P^6.=PYN#@MU<U/XX^\_WW]?8UV_GN\V_P"7V<.B2^Y;M[OR_P G
M2_H._L=3 ?WKVEG,"/I][0?[DJ7C_"$#_BON0ML]RH+C^W(/^'H+W/*,W_$<
M]*R#NWJR:#RG>M+#8?6N%7_Q+#_>O8EAYZL8_P"Q%/\ 5\NBYN5+^ Y%?V?Y
M2.@VW/W)D<S_ +B>NVKO#4\G>V;QX^V_ZHH?]VCZ^P7O_N"LV(?V>?Y]'FW<
MGRK^M<?L'IT@:#%T6.D\I_RK(5ES7YRN_P!R=54_GCW#TUY^\KBGIY# '0X_
MW'AZR9[*3XN(30TG]?9\17JEOTB)\KE9; 59Y_Y4#;VRTU.C2*&O2>R_GDHC
MYOO1^.,A[*;]Z?\ %=*EM.DDS8Z$$?=V^G-K>PRS,>C:**'I7[,BS$N5I)HO
MO?X1_P IIK?I].?;]I6GSZ+;[P.A:]FO0;Z]Y?\ :O\ >/\ C7OW7NLNL?X^
M_=>ZB5%'0U/_  ,I*&J_XU_A[]GUZ45ITS3;,VLW[T&)-,!Q]_0Y'^&?[W_K
M^V5DGVW^Q/\ *O5YF^IZ?*:7<F-L</O;=5)!8?Y%79$Y*F%_];_'_#V)(.>-
MSMA0C_".BFXVBVN#6@^WSZ45-V'VK0'Q0Y7:F4''_ [;G\,'^VA ]G,7N7>?
M/^1Z+3R;;'KE1]\[LE@RPSU-UW2SXRN^R:AK=P5>-^Y^G$-S,/8MVSW/EAA%
M("?/A_Q71;<\H"(\3_(]3Z'Y)5U5:W7^;J;?6LH<F5IO]>WLT/N]]-_Q"_;T
ME;DX'\7\NGL=^Y86%+UUF[\"]?D:0_[QI]HIO=>&X_L;9_Y]*%Y*IQN1^SIA
MD[O[-J9[T.RJ# P<_P"7!?XE4\_7_7]E_P#KE2S^<B].#D9!Q->HU5FJ7.**
MG<>X>U:O<5-7??82VW:08VEJ0?\ /?9Q?7Z_X>S#<N8K?<4U>.]/MZ#]OM4]
MK/X*A<X.<T_U'H2\!\@<FH$.Y=D9VLF%[UV$Q]Z7_ _9SWN?]Y]B+;O<1;3@
M1_@Z1W')4USP./G6O^'I?CY"8R0?Y'L;?%2+_4X\C_BOL_/N@I_U#HH_J/,,
M]O[2/\!Z:Y^^=]U"_P"X#K 4O^-?7?3_ '@6]L3^Z]W<?V5D/RK_ )^MCD=(
M_B:O[/\ (.N5+VMW7+]<3M6E)O\ \7 #_B3[83G?>9?[$_RZ=GY0LSQK^T_Y
M^E'2]E]I\M6X?857=?J4JC?_ &_/LZL>=]Z_T7^?1)<\MVC<"1^S_+T[4_;6
M_4%I]C;?JA^30[CT#G_6/_$>S&;G^5/C@_P](_ZJK<9@:GY#I[3NC)A;2]<Y
MVU_K09*EROT_K?\ UO:J+W-AA/ZT$G^K\ND_]3:Y##]A_P _4R/N_&\F;9V[
MJ/DV*4%K7_V'LTB]Q[<_Z .DW]2Y_P"+J#%\@]KR+6B';.[2:>A^_KR*"WT/
MY_K_ *_^\>VY_=>WZV.2KCU'6)NZJVLIA+AMA9VLX(H,CD<E1XT\_P"P M_A
MS_K^TS>Y:3?V/2F#E*:O<WY4KTV#M+L:46@VWM.D%K'^(Y"KRO\ Q/LK//\
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M\L_T=[.^^N+<?PF"P/\ L+>W'EE?]5NWIH4N&(A]3_AZ$XVAO]P#:_\ 6_\
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M!T!\S-QU!HLG@ZVLJ/\ )MJ=@2$Z*JDJ'?Q1Y.8K4JH"223TH BQ@]S/:O\
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M8W;F/I:HWXO_ !>KYY^GLZM^5+>QAZ:N-SN&X]"/C# =J[G3\*<0I_Y"8?\
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MH#A_/K'_ +\S#'][^ TMO]?_ (W[K/\ 1V/3W<W6"?=NS(E$$(YL#>AQUO\
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M@\7_ *?[X^R2\_QC/2RW-?\ 5]O33->.H(Y'*G^OLD8Z^C:']#IJF_5_OO\
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M$?F?RZQG$[KJR1-N.@;\?Y!C^/\ >O:J';IK?IW6/3KG'A=R0$7W?_Z[;?\
M%/=)K64_Z/)U8,I\O]7[.F*3964EG%9!N/\ A=3_ -,../M-#MUY!_H_53=+
MYCI[CQN[*2_@W%C\M<#BOQVKZ?ZX]^_<]Q!UHW-OUX93/TIM7;;^ZIB./X#D
MOZ<?B_N_[PN(.QH-?7A8V[?KP&G6 ;QP$1'WG\0Q0%^:_&_7_;^U(WO_ ']!
MHZ]X7H:]/--F\36"]'54(/!N<G_7VI3>(9ND<UJ1TD]WXO*Y6>CGQEJK'4MQ
M74% /]>W^O[*=RBEF'Z71U:D+Q_U<>D/:&DXFQ-;2U']?X;_ +[Z>R>)YO\
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M_LU^!TJ&SGPO&)_+J-)N;<-6MDIJ#&$?FOMDO];Z>R7]]S#ATL_=]N!0FO\
M+J'_ !+<4PN,Q?D?\ <9?_BOMB6_G'2WZ. ]$C^<O=_;/1_3-)O/8>Z9L=GO
M[\;=P+G)T-'D2::L4N.;'Z_4_P!?Z>U,5Y<+26O&O#[*_P"3H7<B<JV7,%Z;
M>85^WATT[+[7[[[(^$4/9V,RK9_MK/[.S-1CJ3&X"E+3Y&@RLT3$Q ?J ;\"
MWY^OMNZFGG2I)^*A]:5Z8N]BL=NWGZ2@\%:YKCX>E[\0=[_)ZLV!F*_O?$#&
M[DI=SU=)@*7/;=IL;4C%BE@*2K]LH.D2@7_WUG4O)D2M21_EZ1\T[1LK7O@V
M7VU!J/\ 5QZKP/R]^;GR$[AW9L[X^U^W]NTFWQFJ[&;=GQ^+%.]-M>I^V\M5
M4Y**IU36/-S_ +Q[5P[Q-*PR23Y#RJ*^9ZD-N0N7N7[$S7OE0>=3P'D!_+_!
MU<1UWE^V(]D[-I.Q]P8B??W\ HEW168F@62'[[_=FHCC58V_U[G\^T5U?7,X
M_2X5QU$-W96(F/A#U_,4Z6GWN?\ N/%_&JVW]?X8#]/]]_7VQ--<31?'_AZT
M(;<&OTXI^77O+E)9O##N3(6_M?\  0G_ &PN?=(KJ[/^C=-FR7T_P]=ME-T4
MX/\ N8:VHT-J[& <C_#\D_\ (_:N.^N$X].164%R,?R_XOJ7_>3=*#PL<=5*
M +W_ *_[[_#WN+F#<$^#IO\ =-A<?V..L%9N;<=)3B:9<<!?^E9_O-_=9>8]
MQZ:_=R=%O^0WR)3H?K;)=B[H;+9JB&X*+;]'A=N-2JM3/6ZC&3-8G@?[R?\
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ML?&S(=W](]O;WI=Q=T[KI(L/MK#[/VW7OA\30M)G,F89-T9W(0U6EBS*5T2
M*2=.1"<A[;:O%-)YH !C)/\ @IU%4?,E[>2&A\_4_;Y9KQ^0XTZL'[5_F/\
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MZ[^5?_"B7.=;8OYG9;X<?#_-?'+);>A[%'PWH<@^W.PZG;%?**ILABSY?O\
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MI*#STAM_$*Y>>#[);S>YB*Q=&=OMP\^DX^<W9)<_Q<TGY_W'XZWM!]9=W_\
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MAD@/:$VO@?CDZL'K_P 1QU/7'9V-?\AWCNNEYL?]R8_X@^U*K3C<](I8@?\
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MWZ&DHY=N&KIKW^_P.2/U_P!<7]IXH9H>'5C1NG2/>&*_S-9]]B_\*W&_PO\
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M@A@]9BMP964_X6,ZK^?;&]M])M]P?16/2K;(O\8A!'%O\@ZN(WW1;L?-Y:6
M_P 4@JJ\\_\ *4??.CF^]FNI)_(_RZS2Y8$%L!T&0Q^7B'[VW\T!^"?^)]@F
MVMCZCH4QW<)ZY)BLSSX<!7?7_5'_ (K[U].3_J_V>G/K(/\ 57_-TXP[4W-4
M&WVE#BR/K][D+?7W=;'7UZ?<X;?I:[?VG3X.;^)5M7]UD ; ?[[CVI@A^FQT
M3WM[]3TM8QPT_P#P>Q_WQ_U_:N+_ "=%3'-.I,<+<^U'C#IOJ9#^K_??X^UT
M'3-SQZ=8XC)3GST9JZ?\CZ_[SQ[6Q6_C'CTF,].DOEL9MJARN*K,EB* X?\
MW(4/^X\WO4_[X?T]N,!"* FOS].D<LTQZ6F.Q77]3_P#I,'5<@$_Q&W^P]FU
MG:6T_KT37%PP]>EY0X'$4O-%B*&X^M_Q_MO8F@VZW/'HIN+B?I40CQ?L #^A
M_'L3+91?[_\ ]7[.B.:<GRZ=HE /YX_P_P!]S_L?:[2?['_5Z=(?&\^L_A'^
MU?[Q_P 5]UK#_O\ _EUO\NN>IN#;ZW_J?;D2PW'^C],&(CRZ1^XML#+SG)T5
M6:3(4A^PM7\TM_\ 7]DVY;;J_P!'Z-[6Z^F\NDM)MO=4,_.)HJKZ_P#+QO\
M[U?V6_NN[_WQTM^L7UZPQ[>W7_SI_M?_ ")48O\ ["__ !/ND5E=@=>\=>I4
M>T-R3']\8'%&Q/+V]Z_==YTU^\%'2UV_MR#"_=S,#59&JYKJ_P"OU_XG\>SV
MSV[Z#I#<W6KI]]G_ $0=<]!_P]ZT2]+/'^S]I_S]8[&4CGZ7^OM+*?"ZK_N3
MUQEJX(#^]_C>W/MGZF&#A/TYX#-P'3?4;DP-+_G\O0$_ZW_(O:3][Q?ZJ]/_
M $A^?374;DQ.0AJZ*B^_RIJ\?]@/X%C;_P#$^V]PW'Q^K+8:37_#U%QV=FQ5
M!246YL37XH4F/^P&0H3_ !2EM?\ QX_WGV7[?N'@=*&CU<.G#^^&V_\ G<G_
M ,]8_P"*^SS]^Q])?I&_U4ZRQ;CP,O\ R]Z,?Z^3)_XCWO\ ?%K_ +_C_9U[
MZ5OX>G.*NH)/\Q5X\7L/S_Q3VZ=ZM/\ ?_\ /K1M2?+J==OKZ;?[$^[Z?'_T
M?K0AIY?ZOV=80?%_7Z^U/@^)Y_RZ3?[C]!GF]I97[ZKR5']CE?NS;_+N*KGG
MZ<_[W[!^XV%.CZUO@.FJ3%YZ+_/;<K_Z#['\^RZ*RNQ_H/2OZ@#SZYQXS/2_
MM0[<R ^M_OA_7VH%I=?[YZ<U*//J1'M3<=4.108GZ?\  _\ W)^Z0[+>3_Z
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M(%IU&]JO%^?6M Z;:C)4%(/WZP_='B_U_P!8>T O8C_8]+?IB>/485>5J_\
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M_L=-IVN8FMB\OG<3;^N2_B?_ %NM[;;8_ _L>K0[A7CUS$.[H;^&LP65_/\
MEQ_AG^]V]L3)<69_U?Y.G/&M[GJ%5;AS^)GI/XGB11_=6H"*#(_ZGVS+NLT
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M0W)2\UFW*"JIC?\ XL62_P"N X]VBW'Z?ILJ#Y]9$W7@;VK3D,54W^F>QO\
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M_P ?FK^?0!=L?%;JCO>K@J=];*D2OI$4TF[,.!MVO8 <WD2Z_3_D?LQ6Y$O
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M_@I_/I)U/\OGXP#9%/LL;0W%04PR?\>&8QNY)CG*B>_A)FK2N@0V(_8O^/\
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M1UKAU(O4_P"U_P"V]Z\&#Y=,U/0/=^"/_03W7,]N>O\ >&D$VY^V7Z?[S;V
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MXO\ 5YU\ND7U9\[^KNQ-S4FT<GB<SU]69%?L<-D,LU']M45)^D+5D2@T0O\
MD?\ (R?9??BRWZ;P9?\ %!YT\O+Y4Z,]\]NK[;8/'!U4^T8^S-3TR[E_F*]/
MX3<M9AL/MS=6Y<+!6?9UFYJ1J00 "_-'!6*PJA_2]O;&]?>$M+2?Z>$>*M*^
M+FM/6GE]O3UO[6WVXP>.2!\J>?V@CI6]@_.+IO96U=MY[!3UV_YM^T:5FW,+
MB#_")U_A8M-]YY@QQP,Q/"_7VOWCWLVK9XB\-+G3\4;8"5/G3_)^71?LGMYN
MF\S$-V^7K7 X>OIGJ9T9\S.ON[\\-E5&(J]C;P^R^YH</F'_ (N*FFQO)%'6
M<$3'_E7M8_[$^W^4O>&#G67P#IM5K\2D$8_./K7,?(5[RP/''=QKY')]/\)Z
M2'8W\P7JG9&YZK:^W\5N7?JXRL:CS.0VX*3$TC'Z2^%9!^]_MQ_K^R??O?6#
M9[W]*DX\B:BO\NC#9?:^^W2W\<D*?0BI!_(C^7[>E[F/F?TIB^K*7LU<C6Y*
MCS5=_!\+M.CQH3)+DL8!YJ4K^G11A@1_6X]B,^]&U_1_7D48?Z"2 *>1KZ?/
MA3/1-#R%ND]]X&*<:^1S]G'I.]0?.KJWL[=%+LG*8C-;,RN1)_@IW&:-Z:J_
MYLM5Q*&$Q_'^P]EG+OOK9;S).TU+<'S!X?;T9[[[;WVQBH.J@R #7\ATG=Q_
MS#>I<3N(8'!;=W+N+#TM9]E6;GQ!I!!_U2+,MZL?Z]O97??>*@VN8PF 2_\
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M$GV%[/[P%G<3>"(!%Y^)6C4^S%?MX='E[[:7UO!XVH$^E*"O3AVW\^.ONO\
M=]1LS;>WJO?M9A^<S78C(4N)QU.Q%C )%7_+=-SR0/\  ?U5\R^_-OL,FBTA
M685H-534_D">F>7/;6]W106)%16GF/V\*>G0N]8?*/J;M#8.>[$%2,%0[*I
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M@I\$4!-<AZU(^SB*>N:^717+S3!^]/W4.+@$?ZORZ0&R-CUN^-[[.VC55/\
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M*!W:<A'N U$NY$P&&./QGWOC_P"!-C_OC[QP]W_]S(/&_P!CJ3N2O@-.-3T
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MQ5=#X3]]2FY_X!<_Z_Y_XGV5[C"1TM@O:=-@V%BM5I\MFK&]R*_^GL*3"?\
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MV&*#IIKP]*&BH*#'F]'24%+;_G7'_C?M7#;P_/JQFZCUN7Q&/'^656/I";6
MR1MQ<?X^ZR[G$O30MFN>F@[II:J?PX;#YS*#\FAQUK?\1[2_O8^?3WTU.)IU
MC\F\\AQ#1X';]./Q7C^*U7/^O<_7VG_5G]3T]VKUD_NVLU_X_N.ORG_3 /\
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MQ_P]DMS'3I^O3;3YPW_?I!5VX-?0C_C0]N1;ETXUO7/3A3YFBE! K+\_UO\
M[W[>$T4_6C"5_P!1Z<?)QY23;Z<>WXO"Z\0>F3+T%1D/WH>!2&QH#_7@_7^O
MM->;=UZ"XI_JSTQ20U:?Y_$5[#^B-_Q0^R_P?GTL# \".L)CGO\ \ Z^W)_X
MMA]LS>-_H76A3SIUGCHJ^0 PTK#^FIA;_>?>JS=>HHZ<(,'42K>MJC2_X"Q^
MG^OQ[>BM)J]-&X &.E;%$(1X8?\ ??XGV?115Z0_#UGB_L_['_B?=.K?A_U>
MO7I?T'_EI_Q'O9X]()OB/^KSZC^]=-=2!_D_YOQ<_BUO][O?VF-V8NM'J%4Y
M3$4E/^]5X\GZVY/^]^T4E^>K!>HV+H8,OE?O<;E?X!COL,C]_75Q!^Z_UH38
M?4^VK5(;K$4_2*^G-J,BOV=.-?7U&)%ZVKVGE:?^F#R5O]XX]UO4%ITQ;S_5
M^OYCJ!%NZ";C^$Y[GZG7_3_7'_$>R=-UZ63V/3@F>KY.8-MYP?X_[X>WOKO^
M$R=,&U^8ZE?Q++7_ &-NUWTYO]FW_1/M[ZV7_?/3(MQZ_P"K]G6:3-5$) K=
MMU_VP-_U$?7VQ_6*7_?!_P!7Y]4^D'K_ "Z"G?NZL'-BJLPU8J:@_P#*#0C_
M 'KV_;[X;CI*]I0]57]VY:HJ#4?9X>M=0#9JU?X>?]:WL26]QX\>>B64:>K?
M^JJFEEZIZ[@JZS'^?_1GL0UO^L,3!;G_ %N/80W&6QG)^T]&D0N 3]O^?KVZ
MJ3 4$ K,-EJ&D_R[&BOP(R1^UJO^G)]A3=%B\_#_ ,W2^.<GR/0CXW)PYC'F
MMQ@Q]53 ^JX_WW^/L[LIH8_]^=$UQ9&?IYB5D'[Q%(.;FWLWF$=W_P .Z+A:
M16W6?R_]-?\ O/\ QKVG^@'_ "C]>\,>O^K]G0:]T/X^GNS&N:O_ (QQG#?^
MEZ4>PES]<3VNS7]L(*1>",_GT(>581<7]M%\^B*_!G:='N[+]T=E[CJ1D*S8
MW5T^(HB3;[<Y2CJH5/\ YR4;?[<^X/\ :;EP;E#>SZ2!;VDKP_.4D4K]E3T*
M?<V[.V%+* _$Z@_8#7^=*=%FQ&9R%'\7CL['D+1]C]Y_;5GV@N33;<Q5-8?U
M_P \X_P-OZ^P2+MEMS$3QE#Y\R:4_P"/#H2RV<,][XW^^K>G^'_-T<;I+:M)
MA?GI0[2H*804/6/79PU)<7NV-P$$!F-_^;]63['G(>S12[[X+$KIU,3YU$70
M1YBOC?[%XX\Z?L,PKTF=\R0YCY?_ "AR&3M4T^V.H>PFPXO>YCQ%% +?X6O[
M+O<,17&]7*G@9!7[5K3^3'HQVVMOM&WF+BSBOYG/^#KAM?)S8+^6KOI92/#N
M3L>?#4?_ %7Y"G)_Z$]F=I>&RY4GQ_:SK_QA!7_!TTT0N.:[<>BD_M/0?]T8
MNGV?TK\*LMCZIL=NNFVSN/*/]F;3T]/][3Y=".;\2R'^GY]A;FJVAL-JLY8C
M61JN:U +$E03^9Z.>30=PW7<!Y5$7'Y4/^#KCAMJXW'?!KL_L:JM6Y[L+M#&
MXT59-O\ )L9D PM_U5FKF/\ K#^GMRRVDMM$UY)GN0#[=/\ J'2/=[K_ )$-
MO;_V(A4G^?0A?)>2MIOB5\0]H3K_ );N*'%5U90_GFG])_\ 5W_?<^Q)S*D%
MIL&VP0S899)_D*U6OY=%?*Y-SOMW>_,#^0/2FZ1J_P"ZGRT^3^Y,=2T/AZ[Z
MXW171![D7VT<>!Q_7_)/];V4^W2G9))+S_E&M6)ZWS.PW/9K:$_CNE'[>D=T
M'M6GR?Q0^5G=^?8Y+<VZ*3+X..L-S4>IEJZVY_Z:ZJK3_'V:[#L<5WL6X;@Y
M_40@#.!6F?V=/[Y,;#=]NL(.'$_L( _D>@=QSY#>VSOBCTE/5?;T.Y=Z9W+5
ME+;Z09;/?9@W^IM3"K(_U_\ 'W'HN7WB.*PCR4[:@\&E!S^T='T=I#LTM_ND
M7I7]@Z.7\&:&GK?E)\D\U2T@IL=A'R^'HZ$B]J5LKX?]X@H_<R^PVP^!O<D"
M9^GBE;_C5.H[]Q[LW&WV_C?B0#_C)/\ AZ*55109#$?.W=63/W.6&8QF%6P(
M]65W2&)_VU'[AN:,W,LTDV*9_.O_ !70_B_Q:':1#_JI%T,'>-6^.^!7QXP=
MS]_N7.P5Y:]^,8<@+?\ 68>Y#YHNIOZN[1 ?[#O/\C3H-;<PN-^W&X\P /VT
M_P W4'Y3TPV+V+UX^W:HX[.4W1^U\3D*RD_X$:C2_P /_P!A_DEO8"]S[?\
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M!#!2047^24P^OL016T-ITA,YN>LDD?A_WW_$^[_5PV_]MTR:MPZA5&0H(?\
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MA\#0''X?$T-+3_\ *C18ZWU_K^/8PVRSM[;]'H@NKBXN.X_X>LV3DD..J[Z
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MEGKPZ<\'[.HLO\1DXFK*#$T]Q:QY_P ?K[3BG5\CK&$P$?,]9]W_ -1YU?\
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MVM<?['\>RS^JTMQ_8S=5^M XJ.O?P7>D1_R+=V/JR"!?(8X_\;'NAV>[L/\
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M=#?GFYVWE_8S%:'7+,"/VXZ.I\2Z=MG?-3Y([,JJ2MIJC(C,Y6@%N13IEA6
MGZ_V:KGW./M9;3[1S??00>7U*MZX/^;J-N=C#>;+83_Z7]M/\_1.NV<-5;2[
M'^:6P8*2K%-64[;AHA]D3:F&7Q^0'UY'%7_3W!7.UC<[-NLEG#P-T5GS\FZ'
MW+>YPK8V%P?]" _;3H2-_P!/FM^]9? G;F/P.8JZ2:&=*P&BJ33@R5M/2?\
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M[^(/7<F_/CWWY@IZ/PMO',9K"XVW_*WBJ35Q_K59'N$_:/D6YYHV2_BOH/B
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MVL(M^3;_ !]W')E]:\O2[E4?KW(MQ7^TK3)^8K7HPFYILFW>"UA_LH(2WYG
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M8_XGV7#<GN/[:"XA_-Y>E@CB' @_LZX5&]<%XA./O_M[?8$?PZL_X%$_Z_\
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MT#W%/[;LZ,H6],].D.5H,@1]E64%7Q_SLK>_))"/]'ZU*"/+J;XS_2@_V_\
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MV@N.7[/<O[6#IRVOGLS@_L(Z"^KZ+Q$:FHVUF<[M-N2V/_B(RE)R1_NF9O\
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M_OOJ ]B'B2SS'CC_ "]"6\)M="CAI/\ D'^7H1:^*_/%C^/]@1_O/L0N=/\
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MQ5\A_JX]2</TIO6/%4LPWO0#,'FNH*_'_P 5I?IS_6W'^'M';^UNXP?VL_\
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MS_H%/V]+K;<;JVX,?VC_ &>DY_H8ZO\ ^!']VS;^O\3K;?\ 0OT]L_U&VO\
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M2QPQ*:]2$;@P<>I8DU 00CD&_//^^M[<EB>Z_MNJ_K6W2 W"!M_=NR-U4?\
MDM?_ 'KQ^&K0#?[FFW-S_P 5]WV6;]WWA'RK^SIZ<"[MR#PZ-O/_ &/^0O\
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M*'^V)XM["][R%87?1Q;\S75GC!^W_8Z2D_1]+YS-!OS=M':PMD?L\I_O3?\
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MJWZ?3^I/L=;9[>3;G^M<3]!JZYF6SQ;C]N.A,V[UCL?!&^.V[CQ4+>]?D?\
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MKL]4W-%A_M.+&NK\E_4_[;_>/;QG#^?3O@"WZP?P>:K/^Y/+U]63_P H./\
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M/^^/N)>5MQ_=^P[K,/\ 1%6'\I#6O\NA5OUL=RW?;8/2K?LITE=J8.KH]P_
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M_P )Z-YOM*+=?\P7X\[?HR!A]H[:V-44)_&G%4E=DO\ 8^YT>Y@W7F^P$/\
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MO^MR<G_OOR%D\5(EK\*?S\AT(=-=SKY_1'^;#_-U:358C^!?+[9^ N*4[?\
MBAMRA/\ Y"\CR/\ >/<]W&T?0;KMZ0_Z%"#^T?[/4<;3)XFWW,_K.W^'HR.I
M?[0)']0+^YEG?HC\&G4KVEZKU&$/]"HO_M-O:?<KCZC_ '#Z<62GQ=!3C&H=
MMY6L&[*.^8JJ_P#XOM?_ +E?ZWXYO^/803<8HIOU?V=&\:%QCH5:>M&1@,U%
M6&KIA_SKKCZ\\^Q7:2VT_'_)T7D3C_4>N7E3^C?\DCV8Z8?7IO0/7_5^SKL.
M/Z$"W!M;_>![9\&;C#/U;'IUW_E&C_'F^G^M_P#;WO[4P^#KZKGQ?]7KT(.!
M^Y_N)OK_ #=OXU@_]:^JG_WCZ_X>QEM?@_N"]_YK0?;_ &R]!Z>O[ZC^QO\
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M(J;44/'K/+4T5+^]4"S"X _-OS[V28^J*/JL#RZ066WMCX%\%(%J['GU6/\
ML;$#C_6]T:3PSC_5_JIT(['ET7&6_P /0:Y+-Y3-5&J>LO3FX"Z@/]]]?;*+
M(A_R]"N+;(+4<.@WK?/+O;$0D@?:8')5YMS]?]\/81NAX]]T<KBVZ7Z?J'^Q
M]B.3I..I7D_P_P!Y]O:#U36.LD<=A_7_ %^/I_Q'MO\ 6@Z:-.GC'8W)5MS#
M17/]K@#_ 'Q]V7Z>?_1^BB:]A7CTKZ/:/G%ZFM4#BX*W_P"*'Z?X>UL:_P"@
MKT1S[Y7,'2II,124]O#166]SJ(_/^!]NLJ1]%%QN,]QTXWTFQ^H/%O:7P/J>
MFFIUDDC!N-('U_K_ +Q[JVV4ZNC=1I*"E '^0A=1_P!?^OM^VVR&ZQU2"0J.
M/0$X;"4&S>WB*.A:DI]XX+(5WV!LOVM5C*H,"/QIKN/]Z^GN/-HVZ'8-UZ-'
MD:XLC\C3[:C_ "5Z, /U-_L/8]LO/HMDZE>]]-]1_;DG3D?3?5?[L_Y!_P"(
M]V3ATYTV/]/]C[MT8=0_P/\ 7/\ Q'O<W5$X=0I/Q_L?>NGX^O2_YMO]A_O8
M]LOQZ6=07_2?]A[K%Y=*.D3NO;M#N;!U.*RE->G"VH#Q_DMAR3;^IM_OOH4;
MQM'[R73_ *ATKL[GZ*83USYGUZ!3:6P,;DJ&JBFJ\[B\QB<AD<%G?X?D@?\
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M D D"F*'TZL7^76T-R[M^+O8VT]K;<J\_NS(;+:EQF(PHO4SS1M3ECI%R?\
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M=LO)X_;.W\/19=3:I!6EM5DD<?\ *48/];V*?<7W-DYNW0[E%'X)->U6X$5
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M58G F^E^8A/_ *_MCF+F:7F*\GO=&@RG5\@7"X_;0'YXZ7;5RH-DM[&26?\
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M3&DY_P"&_P"'_BNCV] JOS3_  '_ &>A"F("^<F]PU^/]M_Q'X]B&YBKCIV
MTZ8*GZFW^Q_WCV7& 4Z.(C0],$I(46%_5[1B*O1D17H+-\=<;0WH:2LR]+7T
MF0IA>BSF/_W&U5+;^M9>WL.W'*T%QPZ,['=)[3A3[.@UFZ/22Z3[_P"Q:F@M
M;[,5])C3S_S=O[#L_(:S_P!J!_J_/H\AYEG&:"OYGH4-K;0V_L_%?PC;^)&.
MI[WU$ZONN/\ E+M]/]O_ ,4(NL-N@V?^PK_/HEGNY[_^W(/^3[*=*7R+:_-O
M;W]OU<M3'63WOK?6/RI_7_>O=]!ZKJ^1ZB5U1!CZ"LK9B3!2T&3KP?I]>?\
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MTX#44Z"G"CQ;\W?!#Q355!MO)"W/T_WQ]A+:3]/N\\71C)W1@_;TOIX].O\
M-K>Q';9BITU%Q_U>G4!_I_L?>WX=*TX]0YH1-:Y^GT/NW@]/"G4*7]/UMS_6
MWMR&*'IUB>H\B:OK]1Q>]O=OJOI^G5&KJ#-/X+<W/))]TE_6/3Y/RZBR1P<7
ML+_XV]UK-!TH&>L4/T<?UT_\3[:,M)NO#@>@ZW4?XI78C <?;U5::ZN'_3-C
M3_Q)]EV[R^/-X471I;=JZO.F/M)Z52Q"*YO_ %_WFWLQM9?IX>J8/63WZ67Q
M^O?#UST'_#W37\_Y]4Z\7O\ C_>?Z>W!'X_6P*]=6\@-^1_0"_U][\'PNO$4
MZC^B&(I"?V-.HJ;_ $_WG_>O>XFBN!IZ3^$ ?&\^LG$%+_2Y_P!X7_>K>T/'
MIS@.N<=Q?_*M7T X ]F0N/G_ (>KD?+_  ==2#]4L(!GTV!/^']?:>;.?]7G
MUM>DAN=C4S[>HIO\J^ZSI8FW'^XK_#_'\^RS>!X/Z73M@U 3\NE3J I/%";<
M!C_46]G<4_=CI'X/ZU?^+ZD:R>(%:C^E^/K[3:J>G51#7UZP7]'AFM^FZ?[#
M_BGM9XOCM^EZ];K^M_@ZAUN7H,3!]]6UA-/]+?ZWY _WWU]E]_N/A_H]76W^
MJSTEAN=Y9A/18G.U+7;EA28L<_X\$_GV52[W^EX71H-I/' _:?\ -U,@W9C*
MN7PU35V*G/)-=C01Q_K?7V[!OJM^B>FIK": 5&?L..E-Y./I_D?T^G^^/^^_
MK[,^D%?V=9H/V1^./K_A[N!$W6KV'ZCK!#%XI['_ (#5G! _KS_O!]W?]?\
MMNG)CZ=2#(T<PN/\GMQ8?T]^$M.'7LTZ2.7<RY_;3S\5(&2)M;_'_8>R"\8^
M+X73MM!05_U>?2JC>IF/GNM&2+!0/]]_3V(HF\#]+I(8:Y_U?X.NY03<EC;\
MV/\ O X]UUT]>K>"?3KJ7[B>G/@(^YYO:W]?Q].?;</$=:)KUFCI5^Y\\U;:
MH/Z18#_8>[+>3&+P>FY5%:CKLB__ "F?:7-@/S_O/MI9O Z=;NZP,#])BM9]
M;_V?^*W]Z\;K16G#/4GS>CPV'T_I_OO]]_A[OK/7O!QTU94U$V/J8J:J^UJJ
MNBR'V0O8BI]5N?\  _\ %?;IBA\^KQ$XQ7(K]G5!V\?A9\__ )#;EP>.[PWQ
MM5]LX2I&K+2YZE;[>FR/,M524&/I*?[FI/\ K<\#V3/MDTM"9L< 2PIQ^TG]
M@KUD%R_S[RORW;SB&"8W1X  ^7KZ?GU<YL_86W^H\5U]M':T'AP.%VI1['BD
MO>[45+>,_4GE@?:>-5M9JR?;_J_;U!\UY-N5?&/G4_9P_P G0T+_ -%+_P 3
M[/G_ ,W^7I!UQ]M]>ZYO?B]OS]/?FB_U#JP;3UP]^ZKU[VUK/3N@=<TOS:WX
M^OMU9?\ 4>J%=/3E3?4_\$7_ (GVY)TF/'J2EK\6^GYT^U'ZG3+4\NL\+'2;
MJ/U'ZC_6]U,Y'2=03PZS^.EF_ /X)^OU_P!O[MXWS_U?MZ3:3TC-LQ_PO<VX
M\!#;[>KOG<>#_7*6\UO8?LSX%W])U>Y&I0W^K'0D#]X$?6WX/%N#];>SY83;
MT^WI%+W _9U/!!O]?K;WZ<TX=)Q/_J_U'J9$%87(8\\?B_\ QKW54H.F/''I
MU*LIM]>/];_BGMR..&?IDSGJ3" =5_\ #_B?;8AZIU-!J#3VJ"I(N>!?_B?=
MS;](_#!Q7H*^PG!HZS\7L>?\?;PDH.KO%4]4F]U$YG?N5J9013[,I!0T=N/\
MHK_\/Z_7GV&8[+ZR>;];SZ42]KC'5A?6&YJZJVCM;&4.T:[+5%)MC;]OL,C_
M -,E-S_OA[@O<=X\"^\*W-.AK:VH\$F<^9Z$.JW0<; )\UMS=N*)'/W^.^O/
M]"/P/;-[O3[=_:TZ?@C@N^%.H<>^*&7_ #.)SE7_ .0[VF&[^-_H$_\ O'3O
MTGG4?MZEQ[ESU5_P#VEGF)%R*WU?3\^ZRW4H_LH.DX0'B>N_MM\UZCS5F"P%
M/?ZT)&3JO]MR?;4-K=S^O\^K54=!IV]M&AAZK[0R62K:_.Y*#9V?K5-;Q3<T
M@((/];V_I_A[!_/>T?[KI999_,?;QZ-^7+O_ !D"G0%[ _EQ579NRNO>P\'V
MS/A,5NW:^#S>8PN:V\:^II:BNIKS>&45/J_P)M_O7MKE'[L\G-NWVU^)5K*2
M)*8I1J\ ,C[>O;E[S7/+[W-@RG'G7!QT:+?/\MSK+.=:[0VAM3<4^S]U;.%>
M]+O62A&4J,H,H1]S_%H%^U+W:P !)IP;&_N7]U^ZK9WMC%;Q3A9J=P(%).!%
M/2GR_P '0#V;WFOMFOS>LI*XH*_#2O\ A^?'IGZ/_EN;;V7F9,]V?N->P)UP
MV0Q.'PD-"*/'P??TQBFF8ABPE(N ;7^A'(M[3<G_ '3K';/&&XW"RBN=(.>)
M%:FN/]0Z7\W^]MYS"!X5OX)Q4FE>/I_J^WH/<C_*H9\X5Q7;LT&S:BL!>DJ\
M$,CD*6G _P R:K[E4)_QL!_K<^R.Z^Z"LEPTD-\OA^M*5/\ I1@GHQA]^[JW
MMX(3;&J<,X_;3H3>VOY<&R-W[:VEC]@Y^HV9G]B8)-NTE5+CCDX,E 5,E\B%
M4$58N09^;\"UA<'W,/W3[&^@'[NF6,L:G57]5@>-0<?MH?GT3[%[T7FT7D\T
M@UCC0'@"/Y]3>G_Y;NS-G8O="=F9].P\MNG"5^V8O'C_ .'4V.I\D ?N*,M=
MFR/_ #>L/Z6]N<K_ '5;"QMY4NIE>5N%*_IGYFI/^0#I'OWNY>[C.)D! !J>
M%3\OL_GT#%/_ "J97W(5J^YV;97WAK##08*^0^W'X^YU&(.?]8C\^P7;?=&9
M+N(2S@QG!.3\^%:=#N+[P]S I(MTKY#@/VTZ%CN+^6SM;>LN+R/6N;7J^NQF
M%Q^&K\?+1'*8VI@QY98YPP_=6KX7CF]_]B1=S9]TZQW$_P"Z^=5R31B>)X\#
MY^>>@;RM[T7NS#O4GCPH#_D%.EUT3\#=F=6[3W?BMWY6J[&RW8>$7;&YJVHH
MCBZ5,9D?4:>DC(X-PO)/!X('L5\B?=JVSEB*X-[^N[CL5> /KQR?4]$W-?NG
M?<Q-;Z!I$9KG)/V_+HN@_E2:,\!3=S52;1:97\+;= R/@;_='W'W7BU_["WN
M-9/N?*]YK^M3P-7&E2#]G"O4A'[Q=S-;^#].=7A\*TZ%OM_^6WLC=U%M@==[
MBJ>O,OMO;6/VU)YL?_$J7)04%K3U;+]*MN?SS_K?02\T?=3L=TCB_=\P2IJV
MKU.:UK6O00V'WEOMFU>(*@DD4\OE_L]8.K/Y;?7^V-M;KHM]YVMW[G-YXH85
M,U#CQC5QE,!K,E!J-S5$?2?C_6M[MRQ]U:RL8)TO9JRK4@*.T$Y\SYT^?2C?
M/>V]W"X@FMUH*YJ02?MI6@_8>@MQ7\JUOXW2G.=O5&0VC3'4U'18$8[)3T]@
M=/W)8J&Y XO:_L+V'W0O"N"TMPHKGB2/V<.C^^]^GOH/"%N:_/\ V>A>[E_E
MW;9WOGXMQ==9U=@318ZBIJO /C_XECZC^&+HC*V;53$P6X ;D@6_H<<V?=%L
M=V"OMTWA?\*/D2>((_R]$/+7O+>;#XWB#7\Z^N>E7M+X%;!P?7.Y-GY_,5F=
MW!N\X^KJMTQT-+0U%$<8-5,M #PMR0#=N?IP;77[+]U#:[/;6@F/^.+73)4D
M"I-:5/GT@N_=V^N+F"=11.''C@9-/]5.JH_YKOPLDZ^_EG?._>60WU49%=M]
M ;LK*#'4N!_AWW Q\<1)FY( 7R7N+CCZ_0E=[2?==@Y*W>#=3<^,0K<:GB*>
M?^K'2CF7W<DWVTFAEMZ:CQJ. ST0/_A-'\5W[D_EKY7<N/W93[>K8?DOVQ1U
M5)58(Y2G9::DQ;:XS:_EU @ 7/'X-KB?W]^[]'[E;G%?R7)A<*4>E0=-=6:?
MZ;HBY)]R9>7MO:R-NC:*-Q H?A_Y]ZVG]F_#S8F ZWW%UK7UE=FWW@HKLWN>
MXQM4M5C#_D7VBC5X?M"&'-_^**-C]@-LV3;Y[+'ZW >1_P!7^KUZ3;M[A7.Y
M7ZW(QI\OEYUZKO\ EU\%*?:_Q+^7&X*S?Z9?$87XV=XY?'T8P.FH+4NULK60
M*Q+#3<_4_4<\7%O<>>W'W5QRENO[PFO-6F35$/4+GS/^#]G0KYC]WI=ZM_"T
MD:AI.<=V/+K7X_X2F?&27N_X6_(3-TVZO[N5]%\@:&!I*["^6!H,;@*$,?\
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M.;?YI_[&'I<-M'F>H<F\=U2_YG%8+DF_I'Y]N?O^[G_T#K0VY1Y]<_[W;O\
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M0(X' M^/>TBZ2W70C=>RVW11_BU#D;_["YO[--I_W(Z"W-'^X_\ J]>C$O\
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ME]I>G>O45.];4B"&D%_\$!'/'^Q^OM6J.G#I#--#;C)ZP8':51/V?N&GJ?\
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MWMR:+]+QNJD^G4G:E;/58FE@F%ZBG_B%%_3G%_3_ (CVMVF3ZCHLNJ+^=/\
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M7;^?V?Y^EC[/>DG7O?NO==(@ "J/>P*]>ZB5M;0TD'GJ*O[6GY]0/]/]:_\
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M/0C=:2_[^>CM^,?D[#_;^UNV-^OT$N;H/T.C*334W-Q< ?T_K[%WA?;U'?\
MJQUBCF,X_9()O>XM]/\ 7MS_ +;VQX(N_@_1Z;K]+_;YZ3>[=ZX#9&*&7W#E
M:&"F*_Y$!ZJFJJ?^.,(^EO\ 8?X>RO>MP@VB+QCZ]*;>UGOCIA_/TITC^IL9
MD\)M:KFSU(*;(;GS>1W3FZ'Z?;?WFM:(C_8>TNR;=I_VW2B]G%P?LQ^SH6?-
M2SBT//\ B%M[$&DCI%X1ZQ"HYMS_ *Y?_C7NTS4Z>\#5P_U?RZRK(LMR+G^M
M_P#'W3CU3J7[V8O'X]>ZS(9Y!RNGG\G4/][]J@\4'168"1GIPI!4E?IP"?\
M'Z^W+=H>DT\Y_P!7'I2PDP^H?0BP!_XI[76\-.D,[ '_ %?/I]I/WQ?[#F_T
MM8<?[#V81]$TW#IUEIC/#6034-J:JQW\/^M_K_KV]NW=I]=#X/2'@:^G^K_+
MTCNC9ON]@4V/M_E6U<A7[4-S_P ZRL3G_8 >RCDJ\K;^#_HWE_A_R];YB0)<
MZO(T)_9_L=#%!^L_\%/^]CV/7B]>B#IT@_0?^#'_ 'H>VGX]>ZR>#^QJ_P!C
MI_XW]/;M?]'Z8KT'&9ZIV'G:@5=7AS19"K M7T(.,O8?UB)'/UY_U[^PI-R9
M9W?KTLAWB2T\Q0?:3UFP/5NR]MY#^(8_%(^4M?[^MR)R%5P/Z3W'T_QO[6V/
M+%G:?\1S_+KUQN\EV*$_L!'^"O0A^#_:_P#DW_C?L^Z1==!+W%RU^?I;Z?['
MVU"G@9KTYXG4GW3IOKKZV)'N\TWT_7N@8V,YI=\]JXR<*;YS'Y$ZO^57*TEP
M>/Z<>PKL/Z&]SV7X*]+]TS:(W]$C\_\ 57H:/8OZ0=>]I^O=0'CI)"()Q?5R
MI(_V'^P]WFL_$A\#J@?Z7/1?:_KS=.V)ZJ;8]9CZW#U87(_W3S@TBE)'UH:N
MY%OK_:X_/]?<>2<O36/]CT)[;=1)AN/"H\_+(ZBQT?:%5^W!L_!8L$@??U^Y
MERHM?^I/LI_=&]>-_8?X>EQO[1174?LI_L="1L/8L&TC59*LJZ[)[AST?WV;
MSU:-*J +@?@+]+?\4_(\V'E[]V_K]!J\W/ZOM% !2@&*XZ$(V;D6(^EO8D@_
MQ?'2,]./M+UKKWOW7N@3JIEH.X*6:<Z:;<.T\GCB?Q]UBJLB_P#O'L*WDL.W
M[WXTW1JH,ME1?(C^8'0NB[<FY/TM[%4_^+=%FK'77M1U7I+9W=V*PP,2C[S)
M_7["_%O]M_3VS,Z2?H]&=AM5Q<Y\O4= [F]SY/-#PUI'VNFPQXY'/^M]?]X]
MH[MEOST-[#98-K\^@VJ-D;:JI_--B03SQJ_XC_C?LH_=,/0G$[>O^K]O3[C\
M508H>+&TE#1D_2_I_P"-_P"\^U]I## >DMQ,6&3TYQR!5$'X!^OU]K9F,YQT
MV(=.>N4%/4U$_P!O1T35851>WX]TCA\,])+B]\ 4]/V="7AMB5,P6?+'[,A>
M,>UA_OO]M[>\/^/H*WG,=/\ <?/[.A#HL/CJ&F;[.C-(18@D%?I[5R)X?]CT
M$YK@W-:GH-=DR?Q'?_:N;]/V_P!_C<!C[#@G%TG/^WM[!^W_ .,7D\T/2R4%
M8T7SXG]N>AM/T/\ K'V*H>(Z0]1?%:CTV%[:S<\?7Z^WO!^HZ]JJ>BJQ-_H^
MS]9M+)@TN%RE>*_:60R /VMLE_RA'Z?Y;P?\/<+E8MIF\&;X.AI93F==0X\#
M^7^3I=QQF:]0&!YN+C^G_&O];V>?40C^VZ]].3PZ#_<E0=W55'L##59J<CE?
M^+]6T-B,92\>;S?[&_U/LH9OWR_@P]*'F^A@+-^7SZ-+3Q&&E%.?^4$7)'^U
M<6_WG_?6]RQ:[=X$/0 N6!-?7K+[5=7Z</:?KW7/6?\ #W?6>J:!T#50-?=>
M']/_  $V)DN ;\BK(^O^\>PEX==UZ-LK9'YL/\ '0I:/]I_Y-]B_QAZ]%VGY
MCIP]M=5Z:Z^+S@TQ'%:>;?X>VKR S].QF@^SHJVP/N(-I-0_3)8"OR6!K[@C
M_*\56W_V'N-=I[%\+H<S_P",15]1TJ'_ +?_ "#[=M[7_?/3L+>O2:W?/X]L
M;CEGO]K]CD2.;<G_ (@_\1[8WB/Z>+P9O[;I1M$^IJCAT*^U*::FVKMRAK>:
MFDP&/8_[S_QKV/=C_P!Q^@O+0W!IZ]/Q_3_L1_O7LV?CT[!_D'^ =1/=>E'3
M;)_F1_P4^VI>'[>GH>/05]??N8NLR?YW#G=R5]O^JL<_[W[#O)\/C6<\TW^_
M.E%R>\#Y#H0YB-)Y^MO]X(]GY_7F\;JR]HIT"F[K_P!]=NRU%OMZO!9/'W_Z
M:N?^*^P7O](+KH0;;73^>/LZS>[^+_OKHRIZ]<*RX)-OZ?\ $>U,/@S_ -KT
MZU?+IDP,GAW;EO& ;8+'&ON?]Y'^/M'L!\>[\'IO<?AJ?7I?2_VK?0E?^(]C
MJX_M?!Z+[? KU[VST[U%4V6M_P  +?[9O;=/'F@ZL#0'I ))YMWY<\\X+'G_
M &_LDAS>S?ET:4_Q<'^E_EZ5/LWZ9ZYZ?ZG\VXY]^#^!U;5FO24WA.8MMU?V
MX%M./MS]*4D6]EW,!\#_ %>75[,5(/EG]M?]CJ#&*>&G'AM]OIX/LFL,'H];
M_+UR$JGD ^U]RN>F#WG'3-F J5V)FA_X$4^>QB&W%P1S[+EF(E_GUXJ&!^>/
MY="7%_F5_P"#'_B?8N\OSZ).N7NO7NNU42J1:XO?_>#_ $]TN&_2@ZW(*5Z1
MF5_<W)MZ&_T_BC _Z]_9;N'Z-WTKMSVD_P"KSZ67LUZ1]>]^Z]UR-ON?#8_@
M_P"W_'OT7]CTW7N_U>G1-N_?D;U1\;\G)7=A[KDIO[SZ6H-M4"C(9%1CKC_@
M,?2*3AK3WN>+?GV&KB)8KK KT-.6>7;WF+$/EY\!^7S^70-]:?S#/C5VMNO'
M[7PFZ,YM.ORE0,;C&WK@UI(*B<\"$U2F:(7/_*P2/\?ZJDO(&:DJX\^'1UO/
MMYNFS0&:;\J5K3Y#I>]L_,_I[ICL6'J[L"LW13;CK*'!5=.]!@U6G4[@ :,?
M<DW-K\\?X>V)YQ&AA(P/L_XOAT@Y?Y/O-[M/J("/,'/I4?9QX]&8RVYL7UIU
MKE]Z[PG_ (?A]L8BMW'N6L0:RT+$^1!_0W/]?9QM40L[?0/]0-!T$&CEW*X$
M'&ITC[14_P"?H//CY\H>L/DO3;NR76B;GJ</L^?'4N6K<U@DH"TV1)DX"%@.
M5^GM;:2"4U4$#B?SZ?W_ )>N^7"(+RGB&H !I@#T_P W0&]F?S+OBIUAG,EM
MNHSN;W164%4:2K?9&&3,TU/^/35,13'Z?ZFQ_I[3_6QPM2I(K\L@?;T*=M]K
M=[W* 3PV],5XD&OV#_/T83HSY*=.?(K%Y.LZSWA3Y*HQ2:\_MFNQHQ^0A'TU
M5-,"RN!Q]+6]^M+Y9R K4/D".@OS!R]>\K5^L@/V@_Y_\W5+W2Z+#_-MWG+!
M#!Y!W!W"+?2UH9/\/K_L/9?)JFW$12?[\/\ A;J=KZ*'^I7E7P8?\'5U7>WR
M/Z7^/5#29+LG=;8Q\BNNEQ% !D<E4!O^56F;TJ#?\_[#GV:27D=N?\8!)]!U
M!7+_ "ON?-9\*RH/GY=%_P"HOYD'QD[AW!!M'&9S,[>SN5R(QV ;>N#3"TU9
M4'A8DJD\VF_TY( O]?P4ZW5O==M"/GY?R)IT=[S[;;KR]^O/E/0&I/V @=&O
MQ $IJJR?B:JKLFM?8_@#V%[8U,W185&/3I__ ,/:V/IYSU%K*:FEIZR&8\U=
MSS_A]+>V=S/2=>/3GM62HFP&&GF^@H;_ /$?[U;V?[7_ (O;]%=^*W'2G]J^
MF.O>_=>Z][]U[I);D_XN6W_^U[_\:>R+<O[7_5\NE=MP/Y_X3TK?9[TDZ][]
MU[K*GT_V _WL^W!_9S]6?XAT%<_^YC+U<]984^*K108^A46'/%_Z<\?\B]@Y
M1^\/[7H[@_Q88_;T^Q2^'_)X /S]21;V_P#2Q'/^3JI/4')8Z#('_*++4\?8
M5X-_]ZX_WCW26*(=>Z5VU\A497%4=766^Y"F@K^?K_Q/]/\ BOL^VF?QX?SZ
M(+J$(:=+#^W_ ,@_\3[,8O\ +TP_#KA!]8_]9O\ B?;D_G_J\^DB<>GO^W_R
M#_Q/MN7_ "])_+\^D5AQYM[;CFO?[;!XZBY^GJY]A]/\8W&?_FG_ +'2B<40
M?-B?VYZ3^.C;^.[O\W%3_'Q?_J&-(/![#%G*/%\*;HTM@=((_P!6>EF+D7^G
M-K_[;_B?9Q=?H3=, U'7K 'CZWN>/Z?T]IO%EOX>MTIU)ZM>VUS3@WI_XYN0
M8^XM>D%8+_X?7V<<HO-!;]![>X?\8_(="C%^E_\ D'V*8>BCIZ][Z3]!!O\
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MMUA;O_5_+IMI>Z\%65/\,&"W9_>"E6]=@UVT/NJ:XY/Z1;_>?:3^N8_Y1?\
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M03M/8F>JQ8VR.ZU_NM2C_8BTI_']/];VF&_WTW^X<'3IL;91WN!_I<G^=?\
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M^0(_X T' _Q_>'^^_P!M[UXGUTO3M-(]!TK=L82>@IZRMR8!S66)R%?]BO\
M2W[(_P ?^1>Q1M6V^!-XO1/+<UQZ=/T_X_IQ_P 3[/&E\?'5[?MKU[W7ISKC
M_8_Y!_XCW7_1OS_R].?A_P!7KT%\7_'XY'_M2XW_ -S&]D=I_P E*?[/\W1@
MW^XZ?;_GZ67LVZ;Z][]U[J!7T$&1@JZ.:WVU50_8?UY_/^Q'MIX/K8<]>AG*
MG'K_ )_\_2 IJG^$S'#YBU-:PH*[4!]U2G\'ZV/L)^+]+T>_[E\/]1Z=GK((
M:<S&IHAZOUG_ )'_ *_M2)O&Z=\+Y'[?^*Z:,:#N+*T<L7&&Q1-?][;_ ($U
M1X_P''^^^OMJV_QF7IF]_P 6'^0>0Z$_V)>BOKWM1TGZSP_1O]=/][]M3_Z#
M_J].FYO/_5Z](;*$P[DV]42WY&2H;_["_P#Q/LLWK]&[A'1E&*J:>?\ FZ67
MLXZ0]>]^Z]UW$ )ZV?\  M_OO]X]V7^RZ2R"IZUM<'@\3\FOYDFY<1VK&<S@
M:#=V],*=MY(Z89Z;KK4:&@/]*:RA?\/K[#*:[ZZ&K\1%:'U%*5^P4ZRL2^O>
M3>4/\1%!_OZE#4\3]M<GJSKNS^6]\?\ MG/;;J<7)4]9B@I/LJU=@8^FQ0J*
M<'ZN/ "#2_D<DW''M:W+SW;&1<#CG/4.[)[O;GML&?ULXS3_ #\>BG?S0/CE
M'B^J.N>U<'69?/9#K=<?L7.YZM'WU0:&M!-+--_7QU^OFY_SRB_M+>;2;<*)
M.!QD]#?V=YJ7<[ZXVN:@\<^0IGS^WI*?)OY4IO;^7QU'!!F'AWIV=]CLG=='
M3D&W]P1_N;8GZZIQ!$?I].+V]J;^[\2Q53Q!)_+R_G3JW)/*@V_F>X/^@P^O
MYUI^VGV8Z%C'[;R_Q>_E=9NLPPJ<'O?>N+&7W'64UC403=D5,%* ../ML<O/
M-[G\>U=Q!]';@CB6I^6<?L'\^BNXOASGSA^O_8CA^6:C\S_+I@_EB?'SJ7='
M26>[&W?L/;N^-T9K=M9MH+NFB-<*;'XZE@8TX$C"YEU#Z_@?XD>T^T6JW8)*
MZB#@>7KT8>\/,%[MNY?107#0P^'7'VT_V>C<=*_ SK?H;N?*]R[1S.]\<^53
M/M0[,"4O\,H:;/@C[5V\?W+0T=_V/\J%[ ^S9+$1.!#Y</7_ %?EU'>[^X][
MS#8?NR<@C%37%1Y^0\NJUNEPI_FW;T7FP[5[J-_^G4GLH=Z[L!_3_P K=2W?
MK3D+QO01#^706_)C?V(W3_,!WAE.U-N;BW_L;8>[Y\!0[&VY2BLJ9Z#;E(56
MEBISP+U"B:?CZDD<^TE_<1M=$R"HKD$TP#3\L="3D;;/I>5Z0SBUGFX7)X D
M?[/6+Y?]@]1=UXS:-=T9\9NR>I=W[?JC29G*?Z.FP5/44'VP\4>G'L1_P*U7
M?\\?CZ.;CI%"BZ<9&H$$^O#CTFY!VN;EN:XM]SW"VNH7_P":W5V?06Y-PYWI
MCJS>>YZ3+PY#>&R]MU.Z'S%$:&HI\AC":.2HFN.?O;7YY]HKF'Z) QX5/^'J
M"-_7PKZ>&&E5X4->(!X?Y/S^71D4D$B": _=#_#CWZ*ZZ0M0_+IIRN2Y.,QO
M^4YFIX^H/VUQR?IQ_OC[0W0$\N>O+4?8/Y\.EQBZ."AQ=%0P "GI5;C_ !/T
M]C6"+P5Z(9V+3=.GN_3?7O?NO=>]^Z]TDMQ_\#MI?]KL?^XA]D6Y?VO^KY=*
MK7@?L_RGI5_\H_\ R#_T3[/_ "_/I+UR]UZ]UPBO]L+\\L?]M?WJ7]?IM<"O
M0:KIH,U5T<S?Y/E#]_CQP/Z?[S]/87O838S]"&&CP=.OM3U?KJHKX*2"MKIP
M#3TA%K?U]L2C]'ID=*/95'-08.CBE(-1_P #3_Y$C_QOV>;8#X/Y]$E^07_E
M^SI:-_9_X,/:Y./2<\.N$'UC_P!9O^)]OS^?^KSZ1)QZ>U_UR;C5_3Z^Z@TB
MGFZ:/$#I&[2?RY?=]0?[6>7'W_[5E)[#&T*)QXOV]/79I3\O\(ZX;HP5?!7_
M -X-OC[O)48^QK\?>_W5+?\ /T_>_'_%+>V-^VWP/U>F[2Y\C_J/3/3[MP<Y
M-/\ =BCJ3?[^BR'^XVJX_P .+GV7G?(8/[;HZ-JQ\OL_U4ZC39XY-?X5M-?X
MKFC?_+:&QI:6Y_W=-S?VT\OU<WA1=)IE^F%6_9Z]#/M7!T^"P6)Q\7_*(H(_
MUP?];^OL>;=MG[MA\&;H)W-R;QBWE3I7P0@B_P!"0/\ >?\ 8_[Z_M1!B7I%
M.:]9W^G^Q]N/PZ;3CT%>_P#_ #=5_KM_O2^V3PZ:?B/]7IU2;O/_ ("[J_\
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MK[?\@ZU[/YK'_;^_^0?_ -1/R-_]TTWN5A\'063@G^K^'I4_&G_N*@_F$?\
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M<)@*'>M#%C_L\96TCK1UABQF2JV-13&01ED597:]K9HQ/$T_83_L]6("! .
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M0UU/L6>2EV7A,HT3"'PU>321-!<:_(8@.+KM<T]!D_M_U#\^M/DL/,X'[/\
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M<M!M7&6M_#]IG^*57'_39-S_ +[_ %O;4FW;E?\ Z,\_TT/34$L4-2JZCZG
MZ5. V1MG;^'K<+18>V.JVM7MD0,M]U8'_@:+<'GV;0<OPV_Z/@=,/?,YU5%?
M*F*?9TBDV9O'98,G7V7H:O"+H/\ =3=@9J6EL/\ E#K+6-B3QS_4^RX[!?[+
M^M8=+_KK:_Q=C/J.)_+_ %#J5_I/_@Q\.^MFYW;]1:RUY_W]-+S;Z3P_X6^G
MOUGS;-'^C>0=>;:/JA6-@?EP_P!7[.EUA=U;6W1!Y\+EJ"I?@?[C\J5/-_\
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M;S08>AOR+WO[0?NF+_53I_ZYJ=/\42Q$+#2BF@T_ZW^]>S:+UZ9KGCUE\?\
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MJ>QI8K7IRW ^GMGQ9-V "@5X  &GYG-.EVW[/R[[965Q-/<_5DYXQU('H/\
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MV9)M_P!*>B^>_-UT\B<C^U_L-/\ QKVICAU=,NU.@M[K_P"9,]J_^(]SQ_\
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MX7_YM_[Q_P :]Z^H/^K_ (OI5H/4?R?X?[S[?\#I)U(\G^'^\^T_2CKCZ_\
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MA8O%_;G]AIUQ_:-1^-8'^QM_Q7V<1<?X>A!Y=.'B&H$$_6W/^'^P]L&?Q^F
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MW=P.(P4#!OX30XS'74&QUMR?ZVY'U'N5+*S^@B^B_GT +IM;:_4D_LZ44?\
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MTBY ><U%, <3^WI!LG:=6ZM5]K5U'*!;[?#X&EQM+_MA<_[Q["/[\O?]5?\
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MD<W]J)&\+H'33F\X]!?N>=8>SNMJF(<59W+C[$_311CG@_\ $^PIS!&;?>(
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M?\G4.DI-X4O"Y+%Y.F;FV863&U7'_+%)1_O/M--;71%=0T^F:_X.O!EX4/\
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M4^3SN[=Z0/E=N8"&$_Y/A=KX:=%@H:2F4*L0,$3E0I41ZC;+7E;D:RV1(VD
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M 'E\AT^ST./R$!AKJ6@JZ8@<Y'&$?[:Q/^]^U7[LA?JPN3/_ *O]GIKV"_\
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M^N49*JJ@1Q^^6/\ C]!_L/ZF.V<M66V_V,!_U?9TDN[Z2]&2#]F /V]+<P@
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M/^)X]J(/\8_2Z1RC3GHOV^,54[ W55[R@HZVJV?N@T']Z/L1:IQE5C3Q5_\
M4'_QO_#W'V][5^X9OJ.C;:;_ .N7Z?%16GV'A^?2YP><Q64@^\QV7H\I3\_\
M LE;_BO^/_&_:"VOHINGKZQ\B*=1<AN$YIALS9R_W@W#E;8]10"]-2TW%ZVL
M/T_VW^/^Q432'=7\*+U_U?ZO+HBNE_=D.IJ4'^'HVNT\/!MC XG$4O-/BZ(4
M/^V_)_V/N9=JL_W5%!9]1KN-QXA9OG7I5P_J/^L/]['L0R?VT_10.'3K!^@_
M\&/^]#VV_'K?0-[LE$79O5M=?_@2FX]OG_7%$)O^BO89OZG<K'_FYTJM12.0
M?8?\/^;H8W^B_P"LO^]^Q/%_Q(Z+CU/]M]:ZA:#_ (>Z^%]O2CIOK<?#D*6N
MH:]A6TM82>?3];_2WTM;V]?Q0W\-.FK9BE".@*FV-O#:H6':?\/W#MTW_A^
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M_??[S[.(KDS?ZO\ /T7>,!CKV@?X^W]9ZM]0/]7_ !?4>6D7[7F__(-OJ/\
M8^Z2/7JOC=(;KL"?:>(AY/VIR-(?_(55FW^]?U]EO+*?HS]*KR6K_P ^A!T#
M_'V:ZSTG^H'^K_B^O:!_C[]K/7OJ!_J_XOKAXJ/_ %*_[<?\5][\3IOQCZ]<
M] _Q]W\5O3_5^SJWC+_J_P"+ZY>(?ZH?[?\ XU[]XW6_$'I_J_;UU]J/Z?\
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MZC_B]1?Z CC_ 'W'NTT7C_XGU:M.[IOV1KI>U=ST</\ P'RVSZ'/Y!?ZU(M
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M!68UOY6G9M&:F@KJ%JT;^FN X/-OM0+?GD?X^TE[R;MT\5/%/[?+I^V]T>9
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M>(NGS%:?8>JL.[ 98JK^FE;WY_I;V96%_%/T@N5I3J]7I3_F3?4W_B-]G?\
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M,_/UELRE!)5CY?&J\,D\/,4%<\?+I'MNVS2"K\!_JQZ];MG\KG^7]L+^6_\
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M-QV\M[_"^JRU5)\8/EU1XRIS]%C,=DY&$.T]Z^$!<;DL<08@[,4G15DI6\;
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MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJX,E_V\3K/_%9F_P#<\>\3=_\
M^5_'_-'_ *P]2M9_\JU_S?'_ !X='G]SUT">F_VHZ]U/X' M_7^OLNE_0Z<K
MJZQU.F[_ *O[/_$?T]NCQO.G\ND@ZY:Q_C[IXW^K_4>G/JNO4X;T$?[5]"?\
M?:DRS#IR@IUS]I>M=>]J.O=9(O\ ,U7_ %$1_P#0Z^S(?V!_U>?39XC[?\G2
MD]GW1'U$J)@%^GT'X_V'_%1_O/LDOQ4_GTMMEZB^0_ZD?\E?\:]E'B_;TLQT
M'G8^X:' ;+W!DZNM%(&P64%(I^OW3!C<<?ZH@<_B_LHYEW"&PAGZ?VZ-G90/
M7/V4/47J^>@'76TOLZO[N#^!XW_8_P"P_'/%O;?)K_[K<?'_ ,7U;=Y:2&HI
MG^5!T)(F$HT@6OQ?Z_X_3B_L0T^HZ3<.HOB/^/\ R3[ICK7@?/\ EURTC^J?
M\DGV]]*/]_\ ^K]G3?TW^K_4>NR6L;_[ _7Z?X\_[U[I##!T[U/_ ,3]?=YI
MNM=0]!_P]L>/U;'SZX'CZ<W_ -A[=@/U'7JTR.LY^G^5D?X7''^\'_6^OM*+
MBGKU6OIT"O7-5_"MP=C[1J"*.>FSISU!Q_RC;IL!_MIK>PCL-WX$UQ#T;WZ^
M(J,,CACU'_%=#'['?11UD%EN3>X^O']?;1A,'2CK).+Z#]+:O]YM[\)_I^F.
MFM\=!4+^]1XVM;^E_P ?3FX/^/MF:QL[_P#6F@Z<%TRX!I_J_/ISAA$ O2\@
M@WY_Q_PXX]VAB\#IHYX]1Q9>38#Z6]JY_P#&,=;'3APP]I_]Q^M==^WNO=,N
MK_:6_P!M[OX)].D_0'467CQ_?&X\8& DS^Q\>5/X^YQHX'/YTFW^O_O,6V^X
M^!N7@_+H131:H ?1C3[*]&!UI?\ -O\ 7_XU[E>6,CH@:XKU*]E_3O75A_0?
M[;W?QCZ]>ZQQ69K#FX/YM]+?X>U*OX_3!N!]G42]^/I;_B?; @^GZ4C.!UST
M'_#VUX_7L?/KA[4=5ZDW/]3_ +?W6GR'^K\NG/#ZS^V>F^@ES_9='39"LV]M
M:A&[=VM:U'0_\!J7Z#_+:T?YGCZF_P#MO8=W+FJ"W_1A[WZ51;<7 9NU?YG\
ML]-FWNMJBIRM'NSL*L.?W%2*,A04&K5B\6%_Y4XCR3Q_7_7]ZVW89C^M-^M_
M@Z=EO@!HC[0<'^(G]G\^AE\/.O6?^2?]Y^OL3>'CP.D/4+[0_P"K'^V]O>./
M3IOZ7H.\YU7A:O(G,;=K,AM/<1(4UN!&H>H<BH@!\(O]/K[#FY<J0W']C^CT
MMCW,@48!A\_\G31'E>U]ODKD]MX/>^/55?[_  5?_#:GD<#[.<6O_@.1[0B[
MW7:/T? \;^GGIXI9S9#%#Z$ _P"K]O4J/N+!4H7^\.)W;M.ZD%\[MNL/U_I/
M";_[P?;G]=8?]&_U?X.O';68=M#]A_XOIX3N#K&0<[MP!Y^GB/\ QOW4<W6;
M>O3!VR4>7\^N4G:O6L3><;OP?];-D3_O5O\ 6]OR\SV%OTX-INSBA_ETV2=P
M;/EU4^%I-P[BGL6_W!;:J\K8_P!;&Q_WGV5_U]AN/['_ *M]:_<KKEJ ?-AC
MII&;[3W!:GPVT:':L*K?[_=N1.4JN/S]E1D_7_6/M_\ K!NF[_HPP>#_ ,.\
M^G?HK2'+-J^0%!_,_P"7J;0=4T%7*,KO;,Y+>V1TWTUQM2CCZ0T8)O\ [?VY
M#RQ#<?K7G>_56NBG;&-(_P!7$\!T*L%)2T%Z:#3]I:Y/^M?_ (K[%)A\ _H]
M("2W'CUU51>:ZD@>D$W_ #<GVU):>/U6U/'H(:WJ?#4DU9FMEYK(;*S-4IR)
M7!K_ )+:U_W\8!X;<C_#Z^R*7EWZ?_</L].C5=VU=KC4.&?/\_/II_O+V9M(
MVW/M"AW3CJ4L/X[L0_Y5_4F7&@?T'T_'^WNA:]O+#]::#IV"VCE-%8CY-6A_
M/SZ<\5VCL3<THH:/<-'29 _\N2OMC*GG\>&?Z_[#VOM.:(;_ /2_U?X>EK6#
MQ^1^WB.E#52WU$D?:Z?K8C_#_8W]KGA\#I3;FO336RB JK?D<C_6O;V@N)?!
MZ60"N.@LW-OS:FUR9L[GL+B[_BMR-_\ >/Z_[#V0WNY6EET(;:P:3R/01S=Q
M-F)1!L;9.Z]X"QO7'&?W:QG]21659-O97'S1+/\ [CP5Z.X=KT#_ !AA'_,]
M)Z6G[LW2%AK*O:_6F-)-EPJ'<-5S_P W3_DG^\CVBG-[??\ "_\ 5^?1@L5K
M; ',_P!HI_ASURI.G-OPUM)D-RY;-]A9>GN/O=SY$Y*FI?\ JCXI;_7\\?7V
MQ_5Q3_;_ *G2D[S-2D'Z0/ICIMR'3M%03C)==;IS77V0J2/\AH3_ !/'5-O^
M.N-FO<\_2 \?XW]M?N'P<0]/1[R3_N0 W^$?ZORZBQ]@[ZVAIB[$VK_$\?2W
M']]=E@9.F' _X%X[BKI+?GG_ %O;4F[WEM^E/_J_U>7#K<EA;W9K;X^1X_ZO
MV_+H1=M;ZVON^'[O;F4H,E  ?^ 7_ BF_P /">?R/Q_M_:^QW6*XXU_R](GV
MIK3B/\QZ6OD_W=?FWLZZ3==:Q_C[]U[KVL?X^Z:QU?0>L7E_VK_>/^->T_C-
MU?0.LLK>& S3_P!FU[<_7WZ6ZAZ:'0&=C]G[#H=G[FP\NZ:&KS%7A:^CH:+"
M_P"Y*IN;<_L_TL.+#VAW'=X#:M^SH_V+;;CZZ T\ZFOG]G_%=5A4\=;+_E8_
MR:H^HHA[BF2G^SUEY+QZ>:7,PQDPY'_<8#P?]?WKQJ\,](98-/1AOC_/_P 9
M-Q'^&#R)_P"20?\ B?8NY8D\:3\^HP]R?]P?V=6(2FR@G^ON0_!Z@#KO6/P#
M_O7O4I\#IS03US][\'IOKWO77NO>_=>ZX:Q_C[WXW7N@B[DQ=9D^NLK+0'[G
M+X.MQVZ,(.#_ ,>W5F0_\3_K^R'F6SE%A7_5PZ7[!<A;_. <?MZ7N RM)F\1
M@,UCJK[C'SX/[\#ZW_B1_P"*^SVUN/J+*"?_ % ]()[<VUPT!'G_ "%.E5$Q
MFN3]!_3_ !]T\0=,5KQZ<(O.0"!:Y-[?X?[[_>_9DD72:<]/<#\ _6][>W%.
M>D$RTZ?*26USP/Q<?[[_ %O^*>S!+OZ?C!T73BOGTIX);<'D_P"!M_Q'M3;^
M#<=%,U5Z?XI;?3CDCG_??[Z_LS3]#HIN#7_5]O3T*A !8$7O>_/T_P!C[<B'
MC](^'6:GJ+#\BQ^OUM_QKVHB%>B_I*;FWUM7 P$9S<./IJNPM1%?\J)/!'@-
MR#?^JC_B/9-=[[;V_P 9Z=2WN'_W'&/7B.@/VSO"+:.?R];BL/NJHZMRK/7U
M]75[?.-&+G)^M'P@_AQ 'X])-A?\@/;][_<DVF"OTW^K[>C:_P!O*@2L5$GD
M*UJ/V#HT6/R5!FJ:DK,95FMQE8&KJ*OH1<?T((-^#<_4<W^GN4OJX=VA/1"R
MF/B,\#4].G$ _J#_ ,@VT_[?^OMS_<?_ %<>F^/7?G_VC_D[_C7MSK77O/\
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MN)<=7I=)4(HNG.IH/K]IUWLV]S_QTQ-,?^)]F9B\"A^71<<L1_2/^'H6J/\
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M&'^QNFA_U?ET?V6YF+XK:$] OD-M97,=A4>R\EV-O[*X:EP>2SNZ@,C_  P
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M=+X6MMK/C0YN/6E!Z_G_ #ZXT..W;T=/X,#B:[>G5AO>BH1_$<EA#S>Q!/\
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ML/['JC[M)+@\#^7^#H3Q'X@?Z"W'^\>SO3]/GILOKZE^Z]-=-Z?V?^0?;LW
M]67S^SI =F1>;8F^C!;C;]:#_K\7_P!Z/LKYFS!<?:?\/2G;32Y2OJ/\'2FV
MH_EVUMB:_P!,!C"?]C1M_P 5]VY?S8P=);X4N3_IO^?NGN?] _X,/]Z/LP3C
MT_TUS_K'_!1_O9]N6_#_ %?+KW3+E\?09?'U>,R5']WC:JV.K\>/P?Q[+]VV
MB'=H?!FZ51R%"&7CY'H$*GK[>N''AVUEJ#+8T F@Q^>/^54H/UO5_3C_ 'P]
M@.3E>;;/]P^A1:;RL?Q@_EP/Y=1$V'V)E?VLYEZ';V.4V)P7^Y:K_P!X_/N[
M\K[C??[D=.R\P1K_ +CY^W Z%S#X/$;>H*7"XVC-+C:3DWXX_P!<VY/'^^O[
M'5E80V<7Z/1%<LUV<].$U,)EM"0MC?D?X>U4 KT[6G'KAX4_J?\ ;?\ &_=J
MGY_ZORZWX_4CPQ_U'_)8][J?]7_%=5UCKEXQ_JT_Y+_XU[8K_JS_ )NJ^*.O
M>,?ZM/\ DO\ XU[]7_5G_-U[Q1T%6#1<?V7OF@^HRF/VSFK_ .L!1?\ $^PQ
M;-]-N_@_[^/^7I9<3">)?EC^5>A1,2Q?4VMQ]?I^/I_QOV*=9_L>DQE!SUR\
M,?\ 4?\ )8]NU/\ J_XKK6L=>\,?]1_R6/?JG_5_Q77M8Z]X8_ZC_DL>_5/^
MK_BNO:QU[PQ_U'_)8]^J?]7_ !77M8Z]X8_ZC_DL>_5/^K_BNO:QU[PQ_P!1
M_P ECWZI_P!7_%=>UCKWAC_J/^2Q[]4_ZO\ BNO:QU[PQ_U'_)8]^J?]7_%=
M>UCKWAC_ *C_ )+'OU3_ *O^*Z]K'7O#'_4?\ECWZI_U?\5U[6.@QJDT=P;<
M'XJMB9 ?^K-_][]A*\E^GW2#_5Y]*HS6T;_3?Y!_GZ$B*(@%21_7Z_T_V'L4
M.WGTA@F\ND/O"QH:T<?T!_WC^O\ Q'MWP^GA/4_ZO\_54OR%R4U-/5@W!)(_
MH.?;L:47K0E_6'12?Y>DQJ/YI>$EEOYO]EKW+_ULIO\ B/<F0?\ )+3\NL88
M/^5QN?\ FD__ ![K:S]D/4O]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%#^7>5RF%^(_R5W!@ZK)X3-;?^/?
M=>7VSD:!/LJVBK<#@LF*6IA/X()U:K7 LRV8@K5Q0D_(_(X!ZNIJBCYCYC)'
M^;K5&WM\GODC0?\ "33:/R.Q_?/:Z=^SX+;.1J.XH]]5W]Y%E&_4I"/XF9?N
M5@^RCCAL)+\ ?B_NQ9M0:IKZU/6@5TE:"E . ^76WMT!DJG(]*=193-3560S
M.4ZPZSKJZOJS^_4563Q=/YIF/'J-V)/^N2?R?#*BO&@_/'7B*2M3AJ8?8 >A
MO]I^J]44_P S3 ?S*N^N^/C'\1OB-NG>_P ;OCIV71;TW=\I_F?UY28[(9+;
ME)MP2-0;9P\TJ)54.3S$M.%^XLK&6=!K6-)![4Q<0JDBO$_ZO\^>O,&=2S $
MUPII\O+Y^M,4ZK[WGM[Y5?R<OFW\ =NXOYO_ "6^:7QG^;G=<_QXWSTQ\F<C
M0[_W%ALK5T:/3;AVYE,?2T!CCQYDA:I2&*)2%M*9DE6UB/&(R2":9K\A^W/5
M%(A5B0 5%:BGH2/RQFOEGHUWR$^)'\RWYY_-_MG;>^_DSW?\&OY?G4V"VWBN
MD)/BEOG"8S<G8>5K&T9?+9S)O%63XV+'3+,/L:NA?4FAHH_(6=G -5:DA?*G
MGUYPQ84 9SQKY8^S\OGU$_DW=_\ R43Y(_S"OY?O>G>^7^7NW?A'OKK:FZU^
M4V:I(&RM=2]B8QJ^7;NXJJFUID<_@6UPEGU#ST\ZF9T"Z:'5J))K3SR?/KP9
M=*H!IKY8&*?ZJ_:*];(_MOJ_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U'G_L?\A?\1[;DZ]U21_/.)@^*/74GU ^2
M?3"?[:;*<_[S[$?+V'?_ $I_P-U%/O!_R38/^>J#_JY'U:3 \-9!3UL%ZNFJ
MP?5]/U7 /^W]QA<W$,\C_;UD#MLK+! .'3@\( YM?CB]OI?Z<_U_Q]L%#!T:
M>./7K!X4_J?]M_QOW>I^?^K\NM^/T$'8Z^*CJ[7'( X^MA[K(F/]7KU9Y\]5
M!=Y?YS)_ZW_$^W1TT?AZN=ZD_P"96]9_^(WV3_[J*7VD;@.F!_:'[3T*4'ZS
M_P %/^]CVP_#JW0+]0ZO[Q=O:;_=?W[]/^O]H;?X_P!?]Y]@CDC_ '-NO]7K
MT8\R5\&U^S_-T-\'_ <_\$/_ !/N16X#HFGX_L_P=.R?7_8>Z=)^@(^37_,@
M.Z/_ !&>\_\ W&'L ^YW_*OW_P#S1'^'HZY5_P"2E:_E_@/3I\4_^R<NF/\
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MCS>#-UX[<%%58$>M?\M>DMNGM?>&-AHX:3KLI/E*X4.#H<_D;5-54_ZK[*$
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M@Z]XC?PC]IZR?] C_P#+X_Y_5\S_ /T=U/\ _6[WKL_B/\NO>(W\(_:>N/\
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M_;>Q:]S\^JV]OTG6ETJ!;_$_Z_\ 7V7N^KHXB@IQZ9JN8&]CP/I_L/\ ??\
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M*:!U!^?PG_/UPCK.X<6MZO;6T=U4IY+8#(#%_3_EO_Q3WN*]WK;_ -']-_\
M5\NG--G)D$J?G_LUZR_Z2JBF)_C_ %QOO%*"+A<:,M2\_P#4&;?7\>_'FB&V
M_P!S+>XK_P *\2G[*#_#UY;'Q,(Z']E?YD]9X>V=A&_WV9.(J3Q>NQE;BO\
M>B;_ .W]JH>9[,?V/B?[?7TT;5_2OV$'IVC['Z_J[VW?M\<D^G($?\4]F/\
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M _V_^Q_WCWLQ0U_6Z<5:CH*<OW%LO%256+-8<ODJ7_EWX3&564L1_6WI-O\
M#V$MQYPL[";P?\'2N+;)'[O\-!_J_;U$H>Z-D2S>&NJ<C@;@G3G<=68SD_T]
M0'^\C_7]Z;G+;K#IR?9W(QG[*="O'+2STOW, O2UQL;BWTO;_8?X7_XI[$]I
M+];T4D?1GYCKEH'^/M1XOV=.4/4OP?[7_P F_P#&_;/B=:Z#WM+'+D.MMWQT
M_'WN$R  /TX:_P#O0/LFYD'Z/^KY=/;<]) /0_Y#T][2K?OMK[9KO^5G XRO
ML+?4T7_&_=MLF^JLX/\ FG_D/3EXFEF_TU/VL/\ /T_I_9_Y!]G$W ])U\_L
MZ</;75>L$I TZN?K_P 1[K+%7^PZ]T!VY>SLM-EZK;VQL3093(8L!<[G\AZ:
M:F)_I]#-]/Z_ZPX]@W=N>(8[SP;/H[V_:/'75(2 < 5I_EZ3,<_:T\7W<6^L
M?Y+:?L_[KC[7_6O;_B/9'#>;P)O!\<_MZ,OHMMI\/3QB^P-TX&NHZ'?U%@7Q
MV3R!HL?NO!V-*:O_ *;HB1X3_K_['Z$^U^U\W7]A-6\Q_DZ+[G:;:0?IUQQ4
M\:=#I%%I(^GIOQ_2_P#Q/N1O]R9NBHM04ZE1_P"[?]]_7WJ'R_U>G3+>7V=2
M/;?5>F_VHZ]TB^Q<3_&MD;CQ;#_+*O 90G_65K_ZWX]D7,$/U$7@]*+!]# _
M/_9ZG;)R_P#&MH;>S1%CD\%C*VX'_',C_BOMW9I/]UL'5+X4=J>1I_EZ4L6J
MP:H N#;D#Z_\B]F-W" >K&OET$G<>#R-5@Z3<.-HA59C9-><]0T)((JJ4D?>
M06_Y8GGFW^]>PES_ &7U'ZW2K9;H(U/)L?GY=,&$R-!EL31Y/&5AJJ:K('/^
M'X/^P]A2UO?$_6/0K:W^EQTZ ?;_ .O;Z?3Z?\5]F/C?O/\ MO\ K5TA_M^'
M^?I-;0'\6[6JIX5-73;3P!H,A_C590$'_;PW'LKV2#]Z[O\ O*'K6]=D6GU.
M/RZ,9]+J?H>/^->YCFG^I_7Z"8].G#VFZUTQ9600T==4&Y(QU^/IZ;6X_P!C
M[]<S$I/\^KVJTN .@\Z=4?Z.=L(.2U&:_P#/XK=5OS^![#G)$7T]G<=*-U-9
M/SI_*O0H>Q7TDZR2?C_8^VY.G(^@@[#W[4;?^TPFW:,56ZMP6-#0VM]K?_E-
MK/Z?\:]@[FO>?H;/PH?]R?3_ %>?^K[#;;K+Q&JWPCB?7Y#Y=!7A=O4^+J*K
M)5E7_>#<-5;[_/9#G_80_F_L!?2?5PP33?'T*M?TV!@>0'47>V/@S.V\O1"Q
MJ*2@^_HJ\C_@+5$7('_(OZ^_7_9#^SHSV]OJ&'^KRZ%'9>X)\]M+9^9F"B?*
M8/'5N1_QM2$7_KR?<A[+/^]MN@E_U8Z"DMN(G88I7_">G:LD'"W^M^?Q8?7_
M 'KVNN)O'FKTM@%!3_5Y])RHJ--N.?P/]]?^O^^_##-T;0PZ<GIIDE )^@L
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MV9W%Q])_;=5FF\#ATQ[MR--AMOY>LDY%-CM-AQ_E9_/^V]H-_NOW9;3PS?\
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MXE?RQ'^^_P ?9[8[+#80^##^CT@N[HS&ISTK#[40_H=:ZCB"WU>]_P#:;?\
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M[ZO^)/MXFG2E5KUP]L=/]89_T#_@P_WH^[IQZ]U%]N]>ZGW!)']/:9YZ=48
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MK_DHP=&EE_9O^0_P]"NO_ V3_@B_[W[&"_A^W_)T3P\#_J\^I_M/TYTWLWT
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MV7\!%C,2K0Y5SP85_P!7EUDA;7JSBH\,@_[ZZ$U#3M,+BWTO;GV4J]SN=O\
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MU=!^:&N#URK<Y3XB$UDO'I!)/]/];Z>U3#7U2*S^H-.@-SZ0;GJ"V9I!5?\
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MT/%/?4;<W7Z?['W*\P\8?G_DZ"=KC]G^7K/[3=&70!_);_LGSN?_ ,1+N_\
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3?[3]>ZK-WEM;![O\
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M7[KTGZ][]U[KWOW7NH2?7_8>_3]6\OSZ#WM/'#+;(W%0_=K25"T R%!7EO\
ME*Q7[_T_V '^W_H?9/S7-#!8>-T]MI/U(QBO#Y>73CL7<F/WIMC$9ZE UY6@
M"BY ^G,Y_I^./=N5[Z&^A\;K6ZVK1,0>E<1I_K];<^SJ&;ZGIGIP]M]:Z][]
MU[KWOW7NO>U'7NO>T_7NO>_=>Z;P-7]?K;CVY--]-UOI,;BWYM':9(S66QU*
MND%<>H5JHW_YLCG_ '@7]DUWS)9V_P#;>OY]/1V+RC _.N#T7@9?>F1[%S.]
MML8<TF'RV"QN/(W:!B_P.?"/WOJ/<1KODO[]^LM(/T?]^]">+;E$(1SD&M!Z
M]*6;:N1S*!-Y;EK\I2^D#!4;-MG%W L+^'Z\?G5?W>.\OI8?\<G^.7JZ6MO;
M'L4"GG2I_8/\_2RQF&Q&%@,6+I*&CISQ_D(O_P 5/OQM>E.LOY'\^I_^:_V_
M'Y^OO4/C=6'=US(  !(O;V_)']1UKXNO?ZD?7_C?^/O<7^^NO?ZO]7[.H-=3
MT]9CZN&;_*:>IHFX)O\ 47]VFVZTGAZV&(.,4/09=14W\/P.8AK5^[R'][,A
MCJX$?7^&_LP_[:'V&>78_'AGF_WST]?_ !#RQC\SG_!T+?-OH.+\6]B3Q9I^
MF<=</>NG.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW2?H,M_Y2AV[4;0W/+6&
MD_A.[ 0;<_:Y2DO67_U_91+N?[FK-U>.W-Y5?Z/^ FG3C-N+<^_ )L969#:>
MS+?[CZZY.4RM_P#;"BHASS8?\4$6]\QWG,LW^)_H]%%IMB6X[NX_R'^SUFQ^
MPMHT'[T&)H*JH-R:[/\ ^Y2KL;?B>WLK^EAD'@S?VW1B9&M_/'RX=3ZG:>V:
ML^";;FWZO^G^XZC_ .*^]?NNS]9>MB[(R#TD<CUY3_85E+M/,9[9?\5_X'XV
MAR7\5I3]?]TC\\G\_P"P]M26TWA:;.?IRV6I\:0!B.!I0])W:^5RW5V>(S.W
M%Q>S<KH:NK:'_<M2TF4^@KAS^S]/\H_WHV]WV/?OZNS>%_H/3>Y6HW)>T]PR
M!PJ*_P"7RZ,UC,EB,OCZ/*XVKQ^5QM4;8^OH!;_;7_H/^1<^YKM-PAG_ +$]
M!@@@T(((\CUDG^J_3\?]%>W7EF'2N #IEJWO;G^I/^^_V'M,_'HTMP.DYD9=
M(/TLO%_]?G_>+>TJYH>C&'C_ *OGTG9Y0%4_0:1_O/M'/+X/1K"NH=!)O+LS
M:&S+P9O*#^+U!'V.$PBC)Y*I)_Z8XKB_^P'^O^"0WV]VZ?%T<V.T3WG]B/S/
M#^?073YSN#>MVV_B:+K' 5-_]S6YS_$<G?@6@HR?V?9$3?[I^C!T;PPV&U9G
M[B/)<#_-UPHNE]K^89/==9FNQ<N+ 5NY\C_%*7_SEXI+?3CV[;;'%_H_=_+_
M %?MZ>.Y-_H%%'H/\^.A-Q^/QN'IQ%BJ6A@@Y_R&@Q]_^-?[Q[7+!!:_[C]-
MRS3W.;C/Y_ZAU-,]CSJ_Y*]N2R5Z<$(ZBR$6_?"_X7!'^\CC_?#WX3?[]Z8$
MX'^H]!WNOKO8N\;_ ,:QBFH8*:'+T2_P_(TY'%Q5T9^Z(_WWU]HMPY7L]QB\
M4</XO\]>C&UWBXVW@?3]'B#]F?\ !TA:S9?8>QZ3[W9G9U;F,12VKCA.P,=_
M$?\ UH\R_3^GLIO]KFY<@_Q:YU?;CHUL=UM]]G_QZV\$\/T>FW;O:W:^:VOC
M-Q2=3TN4Q&;HA6T5;MG/4_W//Y%'5'_??Z_MFWYEOY/[95_8!_GZ<OMAVJI
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M +W[KTF)!KT(FQ]J'+?Y;4D'&CZVX^ZM^!Q]/Q[5H*_'T!M_WJF(.A"W1O\
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M_=W<?'\.-M5)5?0?Y$/I_P 5]B_E_G/Z_P#1EZ([S:= UKD>?K_/H7X/[?\
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M!^PQ3_\  H;\VP,>;@G@_N_[S>_L-<PS?[@^#\?U'5(1_B;U_A/^K_#T:?\
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M8?+H8C)-$!X5&GC\_P!>?9PMMX\714V#UD>6J(/^6$?D>D?\5]L&@Z9$-?\
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M !3W4_XQ_8],= -VQ-7Y7/;"V_MH8_\ C%+6Y/=O^7>FD^UQK$@S>X]YJ?\
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MYU]2[C 7/YV*;>>YZBL'^4S5F\ZEJMQ*0!RM[?[#W$%LJVUHLJ_#*7"4X:"
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IO]I^O=5U5_\
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M; _X>W[+G*9_B_GUZ?EJW_T D?;GHP>W\[C-TX:FS^%J?XGB<E1&MH:UC?\
M1:X]R/MFY?O%=2] ^_LCMLW@3\:T]:]/3?YNK_WWU(]J4EKTGFQ^S_*.@,Z)
M9*;;6X,(0=.V]_;QPP/^#50E_P")]AWE1R+*9?\ A@_;3_8Z$?,A#W G_B4'
M\NAQ,-ARG-Q_:_XW[$=K/X_1!IIQZDP_H_V)]TGX#JXXGJ,L6I6YXXL?J?K_
M ,C]W'Z!ZK-D5_U>73M2YS,XP TE=7TW/)U#_>P/^)]OI>O)\..BV?:X+G^V
M_P /4N7<&X)8/\JRM95 V.H #Z?TL/;DFZW!XU_;7IJWV:V4]H'[.D\[3SAI
MYZX_ZWT_WW^V]L%OJN/1B(?I^G6+,9.BI_'25>050./L#_C_ +[\^]V]XUKT
MCGVR"ZR:?MZP35];6J9JNMKB>0OWQ)'_ "<+^W+W<VN_BZ]':Q6H_2I^70'=
M[U61I^L\GDJ.JK*6?&5>W[UM$#C:G[858$@O_P L?\.?]X]D6]SM#!X)Z$6P
M0PFY ^1/KG'^?J!1Q=W=<WJMH[A/9>!J@7&&S5>,=DJ:FO\ 6DR(-ZO_ !\Y
M_P!;Z^R3;9+_ &W]:#'S%?\ 5_JX=/W$6W[IVSC3FOE0_P"K_4>G/_3S7+%I
MW-L7M.FKOJ:/^ _?_6WTEA7G_;^S<\S3G_<BWZ1_U3A!I;W"T^VG\J=28.[M
M]54)&TNJ.S[@7-=FGI-MGC_&5;>_0\SW$G]A;R_;GK<W*%L<3W4)^7'J%7O\
M@MY_N97/[7Z^QXY/VA_OODO\+F:](;_X>T;&^W,U>?3UZ+]W;8*0 G[<#_)_
MEZ4.SNM*?;$XRE9N#=&Y,N+'^-;GW >+?2T(O26XX_Y%[--ILYK?'^:G\_\
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M_P 3^G]2+6]EDV^6]F?UIOM/1-N[7$0[5I\N'1@L+V9UD!245-OC!M4%@?\
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M#ZT;GR%:?;T^?\!_ZFY_X+^G_;_U]J/]Q^J?%UW[<DZO'U[W[P^O>)UBL?\
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M6$#-QB1T_P!Y.G^= ?SZY)>\_)YY(YIW"P/_ "E?E4FO^<='[]B#J+^M=/\
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MS_Q7VI\:'I3UUYF_HO\ R5[>H/7^?27ZCY?X>LGC_P ?]X]Z\/I[Q.N6B?\
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M9>/\NBV]P[/S-'F<9V1M'&_Q2HPM"<+N?#41#U.1QG !M^:JD_/^^'L$<Y[
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M5>,KZHL,GDXQD6LM/)(&_3<6U!8FWCQM9_A->BA[]GC$6#5EI]M!Q_9TC_\
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MY-W=492K^/\ F_M:VC?.S854,A75&*/)P2&I+61M-PVHA %KCEA9JM4_8?\
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MWO\ /L,[SSE9[;VUU^?2RSV=[W]<B@X$G%?V=)^EB[9WRGFJB_5FVZH _94
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MWDT?_0Q'^]>Z4W<?\1?^JG2K5MI_XE'_ 'G_ &.L,NY>T?\ GA<:/_)XHO\
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M35%C349M;_BOM,@^@_6FZ9A[L#H*.NZ"?)_QC?\ 6C_*-U5UJ$$_\!L9C?\
M-<_GV1;);_4?K=&<USH[/0?M)Z$>:'58@\\V-O\ >#[,%;3TUTWU,-A8WY^M
MO?IK:O\ L]&7C4Z9JN $6B O>]OZGV5SV_GT8P3UZ2>4Q7FIZR":U535?_ [
M[\6X_P!8?3Z>R^>#Z_\ MNC"";3PZ"F*FW)U?4?>[4I*_/;//-=LB_\ E5+^
M?]Q'TN/^;'L\VS?I=I_0/P_X>G+FW6]SP/K_ )^A<V]N7![KQ/\ &,'6?=4
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M^3ATQVG\D_\ A,A\DNA.E\LV$[3[5WK\C-M;(EFKEQ$=3625>&F&*,Q*JO\
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MDMFXCX3Q(^VO\^C28>LAR4%'74-::ZGK;ALACC:U_P"O'T)_P]SE:;E9W_\
MN'7H#R(R889^?3][>Z?Z][]U[KWOW7NL9(('%R>>?;<LIMCU[KO6/\?=?%^S
MKW39X5_WW_(_;W@=4^EZR7;_ %/^\^WOI/\ 5GJ_6;]O_G9+_MO=_P!;I+^W
M]O\ L]=06TF]]1;_ %_P/:>>::WZL!UDFF"C_>S_ $]Z_P!R>G_AZQ0?H/\
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M/MZ3_(:'_8\?[V/Z^UUK#]"/!Z1NVHG/E4]998X!8I8_4#VJZ>AKTTRQ<?\
M(5_]X_WW^V]I;CI?;=O4&2G_ ,/:'I5@_+IFEH^>3^"/]]_OO]C[07+5X=++
M?'2>J:(,#;45-N.!]/\ 8^R\V_B>G1K#-]/T$>:VC68[*G=&R:PX'=/TK5(_
MR;)W_P"=C"/\/^4BWMRRW,[+-3^?2UE%VM&R/2G#[.EEM#?U#N:HJ\!DJ3^
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M46_VWL,<HGQ$G_U>?2[=S]-<+]@K^SH6@"I#?[4?]YO[%@_QC]#HJX=(#?\
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MV27UW_XLATU_UMKO9QM7&Y_TA_XZW43^[_\ R3K;_GJM_P#JY'U9Q#_F8/\
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M_P""VT_[>][^W?A^=>O=0(#6U&FI&@7&D*>+?UX_U_>AGJS #J31_HD_V/\
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MOPZ!FN[-FR\IQ^P,-_'UIKI6YVOD(Q5+<?BQ'WC#FQ^O%_<=;ISO]/\ V/\
M@Z-;79Z?&:5\JY/^#J :/L*L)EK>RC3U-S_D. H*0?3_ );$<_[#V'IMTON/
M1E]/:C 7\R33KO[KM+"?OT6Z*'=5.1S0YW'?PPB__-^D'O0W^^@ZW]):OY4/
MJ"#_ (1TE^J*Z4[>R^,S--_"\QB\[DC74/\ 49;][_B/82V"[\=>C?<A_C (
MR"!G[.A53Z?['V>)PZIUS]WZ]U[W[KW7O?NO=>]^Z]UW^#_KC_B?>X>FY.N,
M4?\ 7_>/]]]?>A-UYL#H-=WTM?@Z^CWUBJ("HQ5":#/8_P#Y6L6>?I_TQ?\
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M\NMW-O1$;TQ^TCH4A&O!N?U >SJ$?HTZ:+?Y>@3HP8MR;ZHJ@_Y0<W05UO\
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MC]>4TSU[Z<@_\3[]*? Z\6KQZ[L?]6/^2O=/%^SKVH>G77-_Q]/]O_QOW?\
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M$$QQOW-90FOR.HV-LM^]Q;Z_3^O]/I]?9-RG+#;V'2W=@6NO/CT)$4]/.O\
MDU<OZO\ !O\ >_9Y#=0](2#YCK'[,NF>O>5OZ-_R3[4Z).F_J;;Y=>$W%JI.
M+<<\_P!#^+6]HO#QXWU'^?K?U/E3J7Q_JA_R1[W]8>E?67VUU[KWOW7NHL0
M2W/#$_[U[WX!N.O= MF:FGW!VIMJAHR*JFV1_$L[G;'G[O)VHZ*&QL+W'L#W
M6X0[[N__ #1Z7(ABA-3350#_  GH89YFX_V/%O\ >3[&$%U#<=(2".I$@\].
M;$\\@_ZW_&O;L1QGJ@%#T$F;ZLH,A6UNX<)E\CM/,U:G[^OH!_DE7];^:BO?
MD_[X^P?S%R)#N$WC6?Z/1E%N31@*PU#R'F/S)Z:(NL=W2MJRG8^06GTBQP.-
M_AG^P_%AQ_ON/97<\E37[>#+/_AZ42;ZJP5"?MIT)NVMK[=VECGQ>'I#24[
M68\_[U;F_P#A_K^QULMA%L,/@V?1/>NTQJW2K_3R>6/M9//7K?63W[KW0=;M
M/[ _KP0/\>/;+2TAZ9E%&_U<.J1>Q?\ @)O+_P 2+N__ 'L>P_RMP/1ANG$?
M9T73^7>E_P":EAK_ $/QVWJ?]M)1^YZEQMR?Z8_Y.L;MH_Y72Y_YY5_PGK:R
M]AOJ9^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NDKF_\ BSY?_M7Y+_H9O=)_[(_[;I39?[D#\NM(WX/?\RAS
M?_B5.T/_ '>5'O'.Q_L/]LG_ %93KMWS;\=M_P \R_\ 'NCH?\HWMWS_ "Z"
MOE^?0==/_P#;V'X _P#4)W/_ .ZR;V;;'_N=;?\ -4_X).B+W._Z=UO_ -D?
M_:3;];6?<?\ S*GL;_Q'^\__ '43^YHD_P!QI/\ FD_^3KDYR[_R4;7_ )ZX
MO\/6F#\"_P#LF79O_:VWG_[O:KW %M_8C['_ .?.NWGN)_N?_P V+/\ ZLIT
M<X_I7_8^W8>'0-CZ8OBC_P!O=_C1_P"("[H_WI_9[RU_R4_^;?\ UAFZCC[P
MW_3O9?\ I8'_  VO6V_'^?\ 8>YMCZY-=3/;?2CKWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF_VGZ]U2M_/1_P"R5NN/_%D>
MF/\ K97>SC:?^)7^E/\ @?J)/=[_ ))]M_SU0?\ 5V/JRJNR%!B\7)DZVM-)
M38O'FNK1:][\6_VY/O%+F _3.\W62FSJ7AMQZU _GTC]JXVLR];6;TS8^UR&
M5H10X''D _:XP$6X_K*3>HX_WOV1[?%]=_;='DA"8&:&I^WC^WTZ$?V8]7Z
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MV4Q3>!^E_J_U8IT_*/$[AQP"?3T/Y5KT)LL?FIRI^A Y^GT]FTT/U$/6N#=
M+#$-IY:KVS76./JQD:_:5<I-A393C[.W_-GW&E_8_2S5'1];7'UBU_(CYCI6
M!!.. OU_I:UO9=$U/7I:T(''K%K'^/M_P.GM8ZAUM=3X^@K,G/S34G"@@?X?
M[[Z^VY9(2>M*3PZ4FQ,;)BMH8>&M(I:BK;*5]<1S_P 7/]X?G_6]R%MMH]O;
M^-T#[MIGN<9\OV=('#TL&0Q]7V-M^LQXW&N?R60H,><D!]UB_P#,?9"UN?\
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MIHOJXO&]>B=3K-/.F:^8Z;NOMUC=F!\U<?\ <U2_[C\ZQ_Y6C]/>ME:+=?\
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M -D[]U?^(DW=_P"XZ>R_W-_Y(&X?\T1_AZ=Y8_Y*-I]O^1NGKXH_]DW]+_\
MB--K_P#N)[.?9#_E6+#_ $S?X>B;G+_DJ77V?Y>C0^Y?Z#77O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=-_M/U[JN[^8G\B,]\:OC;N+<O7E,*OMK>
MN3VUU%U)!$MVFW%O:H:FQ[W_ %(],B-4(1QJ*\?7V=;':K>RZ6^&H)^T_P"8
M= 7W$YAGY8VTW$%#.P\*$$T!)- #C@2:$^0KT GQ7^,NV?C;U_38IJ^/<_9F
M\4_CW=/9V:'\2R6X<U7_ / B6HJK$_9BX\#$G4>?K>XFO+UD-.(%:$FM37_!
M_L]1QLNQ0;5":"DSG]?@*D "II05H*?(8& *5$;VX[R[$!^A_G#]6L1_K;;G
M'_$>SAA^FG^E _P]1TL&F^NC_P!)"O\ U2B'^3J\?OSHOKOY%;"SO5G;6#H\
MUM_,T>0(9&#5..J/I%74"G_@-4TM_4O&K@?U!#EI=M9W!,8Q_,'U'4J[QL\&
M]6Y@O@"",J1@CS!_9^7[#TA?Y9/='8%9MSN'XM]UY6IR_;?Q'W50["J-T5J!
MILQM[(4CU6WLM+J(9I4AOY.+:66]S:Z'>]O=664_"Y ^98\#_(Y]*5Z/_:W?
MI;J&?;KO^VLSGA_94'H!Q!%>'=4#'5OT']O_ )!_XGV'(^I2ZD>W.O=>]^Z]
MU[W[KW7O?NO=>]^Z]U1S_.'^36[NMNNME_'SK;.U&%WU\@\G78BNS-  )L5M
MC"@KF9U('"U5FAN#9@"GT/L1\L;7'>2!XS0(,_Z8>GVU'Y=0)[]^X4_)U@MK
M;C5+=N$7T$9%2Q_TJ@TKQ:@/'JB/";=V[M7"T> V]1G&8C&6I"38?C_=ON68
MQ*.L$]Q1(U"SBBC 'D ,#IHI7'^C#X+"*YT[.^0_!X^NYZO_ 'FUO:2T_P!R
M)/L?_CYZD3?L;/M5/1/^K:]<]R[?JLY1XVLPD]5MO>6W*FBS77NY:0VGQN2H
M.8I(I5(MS8W'/]/;JP17,<J28(-0?,= BUWBZV%?J;4"M,5%1PIP].MJ+^7E
M\FIOE7\7NN.TMP26WO3K5[6W_CJ0#4^;VPJP53"^DMYXWCF;Z6X_H 89WZP_
M=ES)"_P@D'[1C_9ZZ->UG. Y[V*TW-\221JX S34*TX"H!Q_FZL,@_M_\@_\
M3[*X^I ZD>W.O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6U6?N?
MS#ZV]KCXSKS?\_Q)?^*^\2MU\:X]P/!_X5_UAZEBUH.6O]M_S_T/N+\&&[<S
M%%..-VX+'9^AN>/NL9^?]X/^]>Y#L_&V_??"_P!!^G_V1T'' E@!'DU"/EPZ
M%33_ ,&O]?\ ??X^Q?\ Z-X/173%>IGN_3_7O?NO=>]^Z]U[W[KW7O?NO=8_
M^4'_ 'W]/:SS_P!7KTGZET__ !;J_P#X/3_];![7#_<8_;_EZH?]R?\ 5_#T
M(/L3=$72;S/Z&_Y9K_O7LBNO[?\ ,]++7@/L/^3IHJX?OJ;[>H)%)6J!<'_8
MC_;_ .O]?97-:0_Z#T9*:>E1T#<O660VS.U?UAF/X#3:F%=M.O'\4Q54/\22
M?L^/Z_[#V#IN6IK#_<#_ )P]&(OUE_W+%?Z7 ]9%[/S6WM46^MB9[%-IL,[@
MR=STES:W)U:?S_7_ %A[I#O5W;_VUO)]O39L5D^!A]AP?\_2CQO:VP<FO[.[
ML&[?D9!/X5_O.H ^S6'FRP/]M/H_U?+KS;1=IP4G\Z_X>DSE^RGST]5A.OU&
M4J;Z:W=E>!_"Z3_  ?\  W\_6_\ AQ[#.[\\H?TMM_YS=+H]CF3NDQZ*./\
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M_P U#_S?'_%?=7<1_#U,FR\L?2"LX%?(>0_U?\5TPT>/@IH*2DI:7[6GIO\
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M_P#K_P!;?X?[X>Y'AEA_MN@\;7RQUWHN/\H9CQ^./]?_ &'NVF+[/]7V=/>
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M5.<CK)S5T44"1I3S0S4!=1.\JE7N= +6WX*U(I334?X1Z?+KWBEPI)KJ_+B
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M+JY:X_+^708?)/\ [)X[J_\ $1[L_P#<:/V%_='_ )5_</\ FB/^/=&O*_\
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MLK&9HGPR;JRA:='@B6T3:  1!5^.T8$8&G-#4G_9_P!6>JRKXCE6Q7X5^S/
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M@X</L\OG]G6UK1U-'-2">FL*8!OJ+?3Z\<^]"G7B"#GIJS"4DZ)352_>/?\
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M6(ILG2"('_8+_P 3[EDKWR(_I_DIUSSMKS]WSV]Q"/A(I^VO^;K2"Q^7S_\
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M-[XT8WY8_'3?_3T^6CP6X\F:3<>RMRZK?PS,[<J'JL1DO2;KXYGTFP/!NH+
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M[E.?('!'\NE%B<W1;CAOC*ZAR\%KG[!B#Z?]<^R);DWGQ?I?;GI47\+/[?\
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MK2;<UOY@CT\_\/0I4DT%33B:E8U5.3?C@_\ $>Q,5^H_LNBPG3\NI'A'^/\
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MHLUEYE>1*J1"T<,0LNJ3EX48:5!-<DT^>.'5&U*=3%13 !(%,9X_;3]O2/\
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5P9'_MXM7W_P"\:O\
MY(>\2MU_Q?W _P";'_6'J7+8UY9_YO\ _/W1V[B <_2P']+:?]O[G:7_ !CH
M&D4'6/WKJO7O%_M/^\_\;]O>,>F_IO\ 5_J/7O;/3G6<U%2_^>>.W]!22#_H
MKVW-;Q7/G_/K2IHX=1:B&FK+>>"*P_%YA_O3^Z':$/\ J/\ GZVLY7S/\O\
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M0,EN6CR&'V51B]#@J_TU64%_\_D^1>B_Z9Q_L/<G\K\F3;^?J[S^RXP_9Z]
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M/_"S_DZSDB#Z<"WT'-_]O_KGV5.-71M;BAI\NHU5305=/6T4W^54U6 1^/\
M'_#VW+%]93IP'Q^@CR&1J*"FRVS<E6?=5.+H17X*N^OW.+'_ !%'[D/E:>:
M>#T&]U@#'5^W[>JF/D$@DFJ +_6O/'/Y]RG!,*]!*Y@\^K^.D/\ F2?4'_B)
M^NO_ '44_L8)_8C\ND"_&W^F/^$]"][]UKJ+^/\ D+_B??O]!Z3]!IV,!+NG
MK:B _5G\E6FQ_I1V_P![]@OFH^/=0#HZL5H'/Y?L)Z$JQO\ C^G^Q^O^]^Q[
MXWZU>B7H%_DG_P!D]=U?^(DW?_[CQ^XZ]S/^5?W#_F@/\(Z/^6?^2C:?:/\
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M?]JB+_>S[BKGC_<O_5Z="[8N'YG_  ])KV!.A5U[W[I/TE-S[8H-U4(@K?\
M)*BD'\0H*^@O]U2U1_W=#;_BOM#N&U?7].(YA/\ JI3I,;8WG7Q9?^YV[/\
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ME'F\1DJ UM'64F0.4IZFF3ZVY(_)_P")_/M]Z+\^@%-7;^((IZBAK_J/3A)
M 1 + D&PY_XW[9B3ZCI5]0!T!/>*T20]<TBU@I:^I[3P"T)_QQ843$_X?7V$
MN9[OZ?Z:&8?&_P#+HRY>NRQN2. 4_P Z?YNA5R5?M_#T_P#N<SF"Q/Y_W(9+
M^%?7_66_L5MKV?\ W&?_ %?MZ*H%FN\Q6Y_U?8.DO/V=U130^67LO95-3_FV
M]*0_7_87_P!M[?D1H/[6G3PM[@GX6_9U&7N'J&>7Q1=K=?U4]0/^>NQ7%_Z
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M+ZZPE368[^(X09G>>9HP/N:?'#_-4=)_27(37O[373>'V="'ES:_J1]1QH:
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MN?\ )0M/M_Y]/3U\4?\ LF_I?_Q&FU__ '$]G?LA_P JQ8?Z9O\ #T2<Y?\
M)4NOL_R]&A]R_P!!KKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUQ?^%2"P/_ ":^
M]TCJ4,:]@]':32D'_F*,6/Q_A<G_ %_=EX?F/\O5;@=O^U/^%>BS?S=857M;
M_A-ZK4VE5^6_6R$?U']W\ 2O^\7^OY]T7 7_ %>G3A_U?M;K;#]L=5ZD>?\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TE<W_Q9\O\
M]J_)?]#-[I/_ &1_VW2FR_W('Y=:2/PD_P"93;@_\2AVG_[MZGWCKM_]A_MD
M_P"K2==P.</[2V_YY5_R=',_Y1O=_/\ +H(>7Y]!QT[_ -O8?@#_ -07<O\
M[K)_9GL7_)0MO^:K?]9>B+W._P"G=;_]D?\ VDV_6UKW'_S*GL;_ ,1_O/\
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M5,_X>A*M^.;?73_OO\?8QK^OX/1)Y5ZSV_R#_8W_ -XO[>\'/^KUZ]U+I_\
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M^W]MRK3I2L]>FY\>">--O]O[9^G/^K_BNE/U%>H,E >.=(_KJ/\ QKW[PO\
M5_J'2CQAYU_U?LZ"+N>D@I^M=SU%5]<?28_, ?\ 4!4T\G_$^VYK3Q(^M27
MN"*=-FVL)'O#<=5VSGL&,979ND%'LW;-6?OQAL.MK?4_\77(<SS?[$_GVG_=
MP'ZHX?MZ1;19G;1I)K3B>%2/VX_XKH6GQ,-OVR+'_ 'W6.WDAZ/5O3Y]8?X2
M_P#JT_Y)_P"-^[Z!U[ZW_53KO^&M_5O]]_L/>] _U5ZM]8.LD>, M<6^OU;_
M 'OCW[PA\_V=)_&IQZR_P\?[1_MO^->[^']O^K\^K?7=([=^)S=,,%O7:?\
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MC1</RZ+[7;8W-UU;^&45=NO9K_6A*')Y3%DCZ0?BLH^/I_A8^X0YBY#GM?\
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M\;];HK'\N.&E7^:+C8T-OOOCUO0#_D*:FM[R&V%?#VN,_,=8P6\_U/.%R/\
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M7CUD_P!7^KSZ%7*LH(/K56/^#_)TQ^T/4A]2/?NO=8_3,O\ : #?ZWT_V_\
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M1U-)+2U>#W;MO_(]R[-JP5J,=4"PO^#]I_A;CZ$<<WIU1E,9J*4.0?(C_/\
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M=\O6>X?VUO\ GT81WSQ?"WY8Z:Z7J7KK'3?>Q;>QQJ:7ZBM!R@^EP2)V^O\
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M[BAQ_J\N@F[GV&>Q>M-[;,HOL1F-R;8S^%P"YM@*;[K(4HBA Y^I /)_V_\
M0'>XG+#\V[/+96<^C40?V=+MIO)=MNA<L,#C3RZ*)LC;GSYZ[VE@NO\ !'XX
M38G9^'H\/1_?S9-JG[:@_:.HW -OS<?ZW/N,-@@YSY5A.WP-9B.(DT\)33S_
M -_#_)T*;N\Y=W:;Q&@NJGTD(^72XER?\R*,6C/QEJK_ %U?Q(?]=1[73\P<
M_6_'Z/\ *-?^VCJD-CRV?^4K]I_R1],4NYOYCT?!Q7Q[-C_7)M]?^GWLJFYU
MY^\_I/\ LF7_ +:.EZ[1RV>!F_:?^M'7#^]?\R'_ )U'0?\ MLC_ -?O:?\
MKIS]_!;_ /9./^VCK7[FY<_Y2#^W_H3J;#G?YD4@.G&?'"E6W(J9,G'_ +U,
M+^UL/./N&?*V_P"R=/\ +<=,G:N6H_.;\B?\D'4Z#*_S()/\Z?C+2<?VADQ_
MO5S[.(M_Y_N.'T7_ &3I_P!;^D1@Y;\_JOVG_+UE^\_F-_\ '3XS_P#4K*?]
M'>U/[[]P_P"+;O\ G#'_ -;NDFC8/]\WG_.0]9?XE_,@_P".OQF_\Y\][O\
MOKW$_CV[_G"G_6[JFC8/]\7?_.4]>_B7\R#_ (Z_&;_SGSWMK^L'N%_'M_\
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M[KVC8/\ ?%W_ ,Y3U[^)?S(/^.OQF_\ .?/>_?OKW$_CV[_G"G_6[KVC8/\
M?%W_ ,Y3U[^)?S(/^.OQF_\ .?/>_?OKW$_CV[_G"G_6[KVC8/\ ?%W_ ,Y3
MU[^)?S(/^.OQF_\ .?/>_?OKW$_CV[_G"G_6[KVC8/\ ?%W_ ,Y3U[^)?S(/
M^.OQF_\ .?/>_?OKW$_CV[_G"G_6[KVC8/\ ?%W_ ,Y3U[^)?S(/^.OQF_\
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M\/;:/UJ&;KN"(_6W'X'_ !)][F%:=>7MR>BW=6TYW#VYW-O9N8*6MHM@8?\
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M9Z!LQ]?LZ!CLKK.?<5=2;MV;E/[N=E80?[A\SI*TU53?C'Y#Z_=TP'Y_V_\
M@J;_ %9Z46K4!#97S]:_+I.[.[NJLCAJJJWEUSN?"_P+,Y#;68S6&V]4;SQU
M-D<=_P #-7VO^5TGU_W=_AS[U'.R9I]O^KUZ37QAM316!)R!4 D?SJ/L Z?Y
M>_>IC3^'^];$'@T/\-RPJ?\ 6O\ ;W_WGW6J0=5\5/\ 53J3CM^[GW?**+J+
MJ/LW?,]['-5>W_[G8RW_ &L,L"!_L;>V%US?$GY_ZCTCEW2WVT?XS<*/D#7^
M5!T*.W?BAVKV-,M5WOO/';7P50H>JZQZUK0#4TO(\61S5Q*OTY^TN;?2WMI[
M?1W2_L'^K_/T"-T]R5_L; $D<&8<"?0?YZ='AV3LK;77>WZ7:^S\#2[:P6.8
M/0X7!8\XUF/]2Q/T)_(Y_P!M[,8@L"=O45WNYS[I/6<UKYUKT_\ D,X^JV_P
M_P!]>_NGC=>ZS>V.M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQI
M:BIM>G%K&U_];G_8>W8;GZ/ILV_U?2LH=TE 5R L""5*J![/+;=B#T7W%B/+
M_#TL:>MIJBX@-[<D!;>SLW)'E_J_;T6E2.IOM9U7KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZC5'U3_6?_B/:.Z_S?Y>M^715:>D.S=W9C:]?:DQV6K\
MCG]IZ02*K^)V^\HA]?WH>/S[QXWVP_<%Y_CG^XS]#ZPN1.@89(PW#%,@]+9#
MYK'7<?CB_P#K^T6F&WZ,3%_J_P!1ZS<?U/\ MO\ C?MCP>G/$Z!O?TW\<SV'
MVF+?PT4#9[/6%O\ )0?\C@_PM[!/-^X^-_J^71ELJT!8?8/MKGJ7_:^W/YTD
M^PQ'Z]'\/G]G7O;G2OJ)7T&/R].*/)49JZ< <_GG_D?MID,T..F)(\U'4O86
M5KH:VJVCE*PU0I"*_!5]_P#@52_ZX_XX?Z_L7\O;MX,/A#H+[I8_C_;]O0JR
M!1.)B#Q>P^G/L9Q1> ?"Z0@8_P!7V]!#6.-U=E4E/%>JQ^P,>U?D+<7RF4OS
MS^;^P>T_[XO*_P"^:=*(%^DCH: M@?9G_)T,$?Z3_0'_ %OZ?[SQ[%8'T\/3
M+==^T_5^O>U'7NO>_=>Z][]U[KWOW7NO>_=>Z0'9]EV5F:<_\I9QM%]?^=G6
M#_??7VBW66L/A?ZO7IN#X_VG]@ Z7L40^V\)'%B#S?VJV_\ 0AIUYC0UZY_@
M?ZY_XCVY-UZ/KKWKISKWOW7NO>_=>Z][]U[KWOW7NI'OW2?H(Z,_8=M;CB8?
ML93:N-KK_P".,X]A?;A]/>3C_4?/I8QU1*3ZG_#3H6/]N23_ (?T_P!C_7V*
M/['I-Q^5.L?O7@'UZ<SUU+-XH#-]> 3[K+-TV%ST7K9P:;%TV4GM]QE*_)9V
MNO\ ]7.]_P#>O<2-,-70RM1^D1\A^WI6G_@0?^#GV_-T\./^KTZ1>Z_^ *_Z
MP]WCZ3OQZJE^1$$,HR,%1]:UOL5 _P +?\4]BO;I:\.BJY'1=OY7$E1/_,EP
MHJ/^43H'L:@(_P"JV#_B?>8?)\E-E7[3_DZQ&NO^5UN/^:2_X>MN#S_[1_R=
M_P :]JO$ZDOJ#YT_HW^V'_%?;G2?K'_$_P#:(?\ DKVUK/3WB_;U*]TZMUPX
MG']K]7^ ^@]J?BZ3]8?NH_Z/_MA_Q7VSH/2CKM56)34U)5552H"F_P!?][)_
MWW^#F9C4];_W&P/^+ZZ^ZC_H_P#MA_Q7VWH/6NLGFH_]H_VWM15>F*'KA_$T
M_P!1'_R4/?M!ZOXIZD>Z=-]1ONH_Z/\ [8?\5]M:#THZY^8?2I"K_O(]OUKQ
MZ8IUW//I_H+#D_6U_P#B?>B:]:X]8==+>]I+6_K_ ,;]L7,6:?ZO/Y=.K.3Q
MZTWOY8)U_P ]/Y0S>02"/'_*IPWTOIW'0?T_UQ[B;EDTWF3_ )JO_/KL!]Z.
MV ]C=A->+6'Y?XK#UN1?<4O_ !S7_>?^CO<K:!Z_ZOV=<@/'^W]G4KVIZ9Z]
M[3]*.M-7^6^TM?\ SZ/DW70,U12S9/Y)Q"K/ NN:H"3Q^19>/<3\HL!NKCST
MRM^1!Z[&?>6OJ^PFPVM*4>P/SH;=.MQSSI_1O]L/^*^Y8ZXY]9?NH_Z/_MA_
MQ7W?0>O=3IYU53SZ?H2/S_@/]]_O'O9.K Z]UB]N=)^HPJXZ=0 I(X_7S_QN
M_NPBIU<3%NL_K_VG_>?:#Z@?/_5^?3^/GUBI:HDV-B2/]:]O^)]J?AR.J\.L
M7GB_I)_MA_Q7W?Z@?ZO^+Z:T'IQGG55//I^A(_/^ _WW^\>Z$ZL#IWJ!Y*3_
M %,G^^_V/MWQ%_U =->,?]5>N_NH_P"C_P"V'_%?;.@].]<_.G]&_P!L/^*^
MW>D_7EF6H!%N+'Z?X?\ $^]EJ];(IUZ?] _X,/\ >C[UUKJEO^>4RS?%#K2Q
M^YU?)#IIC<6Y\U=<_7\V]B#EU-4C'^BP_DW46>\"BYVZ ?\ +U;G]DL9ZNGQ
MW_ ?_8'_ 'H>R1^'4K0_%_J^73G[:Z=Z9_:?I1T0WY X"?KZ2JW9BB1LW<-O
M[U8_\XNK-KY$V_W5?_@1_O7T]PES1R[]'<_4=#79I_KH/ISQ'#YCJF+Y&)+)
M2[AE3D?89B_^M]N/:5J5_P 0X=*9Q3CU?I\=O^R>N@/_ !"'3W_NBH?8]L/[
M+\S_ (1T'V^-O],?\)Z&OW;JW7+_ )3/^0?^)]J.O=!A(?NNT*$_\ZG9PO\
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=![N_9N(WAB!CLK3*H
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M3=P1K!ZG@?\ -U)[2_FM[@H=Y9/']2=<8?+[0Q]5]B,UN6LGI'R&D6\U(8U
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MN?>INF+<\:])S..,5D,1N6 G[G%5^.Q^0;_E:I<E_L?]?_D7OUK<?3S=()H
MXTCSK_+H?I"/ WF_I<_U_P!A[E>+]>'H,<#U@]L]4ZAY'(X_'T]96Y*L6DQU
M)CQ7U]<#;D_@<GVIFW/P.FQ(6P*<:==]5X*NKJC,[\S=%]O-GG2AP6/R%C]K
MC ;B_P!>:P@?CGC^MC)WMUL6B'QIN@OO>X^,0@/#C\ST8*G^K_ZR?\3[DVU_
MS_Y.@YY=2?:SK77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW4&LJJ2B7SSE5U*1JM<V'M+//X'#JZJ2>D=DMULUEQQ!MR25
MO_O?LBGW75TO6Q]3TCY:RJK2!4$UQ"_EK?[S]?95<WW1Q;VU.NO97U7J1[4=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL?[?^^O[]XOSZ
MMK/7/\FQ_P"##_>O>XI:=5F;RZD+.;BUP1Z1IY_J?^)]OPQZNJ&#ZKH,NS.I
M>O.X\$NW-_8"ASN/ :OHJZ(_PJIQM2P(-7CZME,U)5WL2I^MOZ7!U/!K3OZ5
M[5NM_L<];?\ V#]OKT3JM^+W>.QYS_HW[2P.^,"WKH\/V;05*U%/?\#*X\6K
MB.?I2V]L:)#QSU*UE[CVNXU^M4CU(IG\B>I5+TM\I<O=J[_1%MFFM_P-_B63
MW'_ZI_Y-_O7M3 A7X^MS>X>VVI_0+']@_GUQ[4^+6!VGTYVSO?,Y;-=K=J8[
MK_.5V#SF9QQQ=+CA<?>'%8Z(&&D(6_!/G''T]J;]O"A?CJ_V>@[MW/-[=7]L
M,+&6&.).,5/KPZ3>S,O!E\?B:Z.J(Q^2P6.K:(-Q]*2Q_P!O8^P\MT=&CJ:;
ME0L/C>G^?I4R_P# D_\ !O9L.'20_%UU72T]+ :V1AX*:]?6BW_*+S^/]A[\
M.M-GA_JX]$DP%=6[IR>4[(RS$97<8(P]C_Q;L-_RB4L5OIY #//_ +?^OLIF
MD9FZEC;K&&T@IY#^9]33_5GI9>TW1]U[W[KW4<N(U\T/()Y '^\_X>_=:(KT
M]])9/^!;NW3U\;?PG*4/]_\ ;-&>?M_K#D(OK^93^?9M9#2NGJ..:[/P)?J#
MQ^$GU]/\/2O^0]7/2]89'!XWU97=N0P.S*&W_9P5/B'_ %A!]O/T0;>-3 G@
M*G]@'^ST,F.Q-/C,3BL91V,.-HL91T(O;_BU_P#%;>]D](J5K\^DMO'?VT]A
MXHU^Y:IJ6HJO\BH:*AH/XA45%0/^52CO:P_XI<_U32W*CXNEEM87%SB#[:U(
M '0+3]M]E9&;7A-FX7;5#:Y&\<\V1J/S_P HE >/;;WGG_A_U9Z$MORL *,2
M33\(('\ZT_;UBI^U.W:*;S56 V9N2G8:A182OJ]N5/\ 3ZU?^Q_'O3W/3DW*
MRD8)_P /0I;,[AVSO&M_A/VU;MK<=,+UFVLW1?85'/\ QR_Y6Q^1X.?;EO*K
MG_4.@[?[3/9BM:CUK4?['0DF$S_7\D_3_#_>/:L'P.BQ:L>LWNW2SKCZ47^B
MC_8_7VGZI@CI/9"H$DYA^G )-_Q_Q7WYFKTNAAQT@=E:::CRV"F%Q@\UD*+D
M?\HN2_>A_P!O?VT.E]SD@^JC^7_%]+'W3I+TH,?%X:8<<@'_ 'W^Q]KV?HMF
MGZ0'=AG_ -$N_(8^#_=FN( _Y5^/-_O%_:>Y^''3NW4^H%?7^=.@,A\/V]'X
MK?;_ &6.^Q_VWLJ?J7;?IR]UZ4=>]^Z]TPY_+T6WZ&IR]=8P0"WVE(/\HJ:E
MA^S2Q?0^6W^/^\>W58OQZ32S^#P_U?/[.ASZ:VQD]K[,IH\W3_;;CS=?7;IS
M-'IXIZC<((^T^O/VH^OL[B30O#J*MVNA>3D@]HI3[!7_  ]"+N/.XO;6*J<Q
MEZJAQE!C*'[VLK:T:C3$_3@<D_7VF,G14#J./RZ6_P ,MFYAL-O+N?=&*K:"
MO[?S./JML458 M13[=VW8XIYAR0*L7G_  ".;^W(8VC0JWGP^P?ZA^SJ'/</
M>H=XG6VA-= SC!<TJ?R_R]'7F'@I*Z_U+K]#];#VXYK_ *OET")A3]O^3KAK
M'^/MCJG7/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UW25]51 ?;_7^IM[5PW_ %LVVK'2
MSHMQTLH(J0:)>" 23>_LZM=U/13=67^H]*3V=]%G3A[4=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z9:FDIYXP:I?O*8 ^D'78_7^S]1[+Y8/'Q-0?ZOSZ=UYQT >;
MZXR&S@<IUZXEQX R&1V);_)C8"YQO %%S?Z#Z?[Q#^^^WHM)OK-M_P"</0CV
M[=!&-,N/+5TCJR+#=EXXP1U==B\SM\68&QRF,JCQS!^0?<6;E#%NIZ%MON!V
MOR!!_8>DA+69_;T_V6X,17U=/;_B_8$?Q.E_WK]C_;>PCNMA>6O#X.A/;7*W
M8QQ]#@]=_P!\]L_\[;'?[;V5^//Z'I[6/7_5^WKH9>OSUX=IXBOJKCG.UY_A
M=)26_'TM[4):371_U5Z33WBVOQ4^SC7H4-K;:@P-!X!6BJR%3D!79VO'_*55
M#FW^Q]R+L-G^[N@Q=7'U>3PX#Y#I!]BR?WES^T=@P7-/E*\9[.VM_P !L9_O
MO]Z]A[F"::^E@M(>ET($89SY"@Z&&*+P_P!?M/\ 7_V'^^_XK[&\/@P?HP]%
M9KT&V]\Q739#^Z6$J_M)ZJB:NSN0/_*+2_3_ &'L#;]O'^A=&ME;!AK(\\?/
MI+0[7P,()AQ./J5'_*?D/]RE3S_O7^W]A5EAN/[:O0CBC(/62IVMMZJXGPU!
M_L*$C_B/= B?ZA_L].@Q_/\ :?\ -UBI<;GL-;^[VY*^DL+FASI_BE*+_P#(
M_:ZWO/ Z2W%DLG$?Y#TL=O[Z$U=_=_=%'_"\S5?\ "/^ M3_ -04W]?8LL=Z
MIPZ(+G;\5&0./J.A,M]S;\?T_-]7^VM:WL633>/#T5TTGKQ^@_UO^)/M!-_8
M]/CC^S_)T'V^/WLQL6 ?G=8K_P#SV4GM%O$]? Z=M5^(>H_PD]")'^?]A[7=
M-R=)K<.XZ';6)K,ID[_;T@L#_P I57;\Q?X#VFO=P^AZ;MT+F@K_ )!_@Z"6
M<;EW"!/N6LK\93U0XVG@3_#/Z_\  R;_ &W^/N/MTW*:^_R]".VL%057-.#'
M/[.L4>SMMFU]NX\_DW?_ (W[1?2_,_RZ,C;?ZL]=18";%#5MG,5V)J+W^Q.1
M.3I?\/V2![50WDVW\?Y?['56M _'_ 1_AZ$+:F\6R;'#96E7%[@H_P#@;07/
MVU52_F:CYL>/8UVK>!=#'^QT&+^S-J2<$>7J#\^E_P"Q!TWUDU/_ *G_ '@^
MZ:QTWI'KT&'9/^10;1S7U.*WUC?K_P!7,^'_ (I[#NZY\#J\5*L/51_+_B^A
M(3Z?['V>];ZY^_=>Z][4=>Z9LW@\/N&@^TR=&U72@W%A>W^M_L+>TTMC#/TP
MMP4R.D#/U[F*4&# ;C_R6WJH,_COXG;_ &)_XCV%+CEZN>C6'<_XA^8/_%=(
M/=.T-Z24%6:C<6!I1Q_P"Q_)_//Y_P!Y]TM>7:?Z/TMDW<>A_/\ V>JP.\=H
MX_"U-573FNR66)R ;-U@O?\ WW/L>[%L<5HE!PZ#]_?_ %4/[.J\^J-H[>WE
M\M^S<7NO(';^,'Q'WOE:O, <TXQKTM;%5?@D7 ]Y?\BW31;7$%-!J8U]*4_S
M=8*\^;!;[AS+N$DWQ&S5/RU'IS@VGG%VCMO>]32_;[4SNXQL^DS'X^X/,@_Z
M=7'N2/%2[GDN"/PTK]G6*G[E%G;6DHS:7DP-/D>'\^C%_++H7:O3W;FW.M^K
M,I'NR:MV'C\L<2E 5%-4_:>J3S<_\"?%]U]/S;\>T>R[B;B.2:0Z:R@G'G_J
MST-?=+D2'DZ[M(=H02D0E0. IY>6.E;T=\1Z/M7XV]S]T9?=U)AZC"_?-MNJ
MJZ'_ ">G&S@)*O[O_"JN+?XW]M7NZ?1WT$*)33P],9S]O0EY,]K/WMLNX[C<
MW);Q*UX8%*"G[*GHK&Q]B5FX,WU;1YBV%V]VENZ@VY29@D<:JJ"&J)'_ %5?
M[W[-KJ](A94P5 6OY@?Y>HTV/EKQ[ZVAN,QSRDT^8!/1B/DM\7LAU?\ (7&]
M1=?_ &6X(NP--9L'#FX^W#FPI#*?IS2_U_V/LHV/>4-I,)>S3ENAUS_[9S[;
MN8M; >-X]?!KP%.@CQ.P-D5'Q][![&S.[*W']B[6[0H-N?W:K/\ @-44^4IC
M:$<?YT6\YYX_V/#C7!9TE2/],(!K^5.@AM_*<2<N73W-U6Z:[9C#_":B@^RE
M/VUZ7'Q]^/W^D7Y#=>=4]@4O]V:+<.*&_:NC3U5%10"E-7%2_4"+[K_7]NW^
M[>#;/)\0 T?.E*T_/HZY+Y#_ '_O=O:7P\ M_C('SK3_ "](3MWJ2LZ[[1[0
MZ_QE3_&8NKJRNJZRJXH+07@'X)'_ "E?U][@W(_3K(,ZR:]%/-?*R[9NMQ9C
MA:*"/SK_ )NCJ[WZ9Z_PW\M7K;?DV[&IJZ#/4?8]":S'BU37Y\?:'"B,&_ 3
M\VMI/X-_91%N)DW%GT9KI_,XKU,6\<NP6_(D$GU%%"">OJ!1O#_R4Z)UUIU%
MF\QVUT1M'>5+6;6Q?<5=C:G$UEO\HJ,>Y %AS_P*OQ_Q/L_NMT1;*:-03I(I
M]G42<M<E7#[OML<_8;I6)'S _P!7GU%[RZ[H]C]T=N[6V75C-[3V-7255764
M=%_Q;S7&QI?^;HI?+]O_ ,1[;MMP$5DK1Y=CQ].DO./*S;5N\\46+>! :>=<
MG_!T/>XOBEC]N?##:GR&K]WJ<]E:O'9BLH2+?<8[<EZ2&A!^AJXBIG_%A[2V
MU^L]Z]NR90\/E@4Z'3^V-O#RQ;[O/<G]902WVBM>D)\<>E8.P^_NL>O>R#_#
M<#N[$UV[KV#>>F%(T]-%R1_GM/OVY77T5I((\.03_+'1![><B-S!N;6>[ -
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MCH!GZ'_BXX"U=?\ Z9?]WP_\5]^AG^DFIT7W8^I%/^+KT.]+4BLIZ.M@_P"
M]3:M)(_Y%[DZTF\>*OY]! BAIY\/Y=9/=NG^D!VE&)=BYAAQ]H^-K"/^U96
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MT#F#MC^71\E=VU%8(/[W[OK,+2*1_N^O-!2W_P!M5^TNY1B>_C5OP1T'\O\
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MP_K=!W<K[S<A1Z?/_5Z]"-2=7[GS=Y]Z[F^Q@JA?^ [448S^OUK>*P_2]O\
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M(W<G^0Y3:>6XO29L8.NN?^=G2?[[\^W&Z=A[JK\J_P ^A0Q\(_I_L3Q_Q/\
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M1D"H]3TS0]<FF_EX;JV+628+_23DNTFS.W-MTF=IZ^JJ*G'U "T \,_[U?\
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MQ7ITD,8^J J?MKPZ&;V/>@WT7_?>T=QS9<;OVG7(N9IZ 8ZOP->X^TJJ4_0
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MV6PM0)]EU?\ N-^O\!SS?Y*>?^4+_CC[!U_RG7^R_;T:VVZ:OB_ETWBMW;2
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M2;;F[PWW_,=S\E4*FF3"9%Z0J/\ )K;?RJRPV_UQ06_UO:^OTAM5^T_L2O\
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MJ>DW4VF_X!9+_EO3?]#K[,_^(WY_Y>D1_P!R/]7ITL?9[T2=<ZBF#"Z+_74
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M=>Z][]U[KWOW7NO>_=>Z][]U[K%%(18 #^@]7^\?3V_XW355ZZ\_!J ?\/\
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MWB*F]OUB7HO\=[HU-?Y].S=X]6Q<1;LHA;\#&U7_ !-./;91#Y=-#1YC^77
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MDU7E/NZW/;BRD>BNS=<-%147' !X6 #Z?[#\>Y6V#E.+93G[<]!.]W$WO"@
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M/^44&Q.N:+$407F]-C*&@QT(_P!M_C[2;WV6I7R;U] 0!U*OMY7>>;#/YP1
M?[TA/7"GW;0[2_F+=T[UW14F"BV7L7=E::RWUI\9AJ( _3ZWM_L?;,42WEN
MOQ4'\B.EO[RAL.:9I9OPZQ_QCHDE;@LWD?BYVUW!-3"G@[$[RP*6Y'[&-%3D
M"?Q]9*D0>S8W2)<JO\40_P _^7J)/#N+C8[C=!Y7Q/Y!@/\  .C!XF@J=]_*
M_:^)V>"6VY\:EP@L?^=;M/D_X?\  ZF_/M-=/X-N WE-3]DG^ST)K.']_P"]
MEHO/;?\ #;=!+AMXT.._E[[XV;#]G39:K[VQ]+F:2UN K2+_ +S2GV^D8END
M/GX8K^RO^3HHCY@_Y"-S'Y"]84^>LCH>OFKBUVU\:/@MMR0"FCIHZ:CK;+_6
MFIF'^O\ 4>T6S3Q?77C?BIT.?<"$[;M&P0#^SUJ/LPW^;I?]\9<?(+YP_'[K
M/:O[U#U*,'D=Q5=&;?;_ ,-O5'G\6O2C_7X]L1#]S6TI/!]5?RS_ ).C#F$_
MUPW[;XHC_N(4;]H*C_*>B[]@=APX3OWYO[R-5]O7-BMQ;!Q ^_\ L+U&XJ^"
M@_V/VHH/)_QOZ+%@UVL ^UA^8I_DZ >Y<P"WWO>)C^$)#_QLG_+TPS[%EZ]I
M_@CB]TTO\/@RE;G-_P!98V, W#EZ&H'^W"@_['VNBN_K99PN*U7]H!Z2[GM0
MY=.SB?R_6K\PQKP^WHJ_>]/+N+XW]M[Y<#RY[YN=#49(_KD*K+U9_P#<GVV&
MD7Q(H_.&?_CI/^7I%+8B>&6]]-XVG_J^@ZW+\=_P'_V!_P!Z'N+WX=9Z0_%_
MJ^73G[:Z=Z][]U[H!>V?^ %=_P &_P"*^_/_ )/\G6QQZH[^1"^2KRW].?\
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M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I+Y#/4N/4(BBKJ@"
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M*4#_ &W'M1M<,*1QQCX 9#_L=>YAYFON:+VZO9!2=0 /]7^KCTJ\[W=O?.]
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M3HD IPU>7GY="'F'D/;.9;-K&YM]2MQ$601^747J'X7]%]+KD3M[!G<66S5
M<-FLOO3(_P ?J%IC;_)/W1S%./\ 8_U'MZ;<Y[AS(XT$\2N<?RX])^7/;_;>
M5K<6UO68#AXU3_,_Y3T%_P#PV;\8O[Q?QG^#;F^SOJ_N;_':C^'V^GBT6O\
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M7CZ<?ZW^\^TEV/T?&FZ3CCCHM_;FULMC*O$=C;;H]&9VL1]_0-_RE4O'-O\
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M5#_>#[]^_OF?]7Y];_=?V]<O[Z2?\J+?[?W[]_?,_P"K\^M?NP==?WSJ/^5
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M^"^>[Z'8_7O;?QW[6S7R-R]9L#!8FLWCN#K['YCQY5A28UY<%IR%-#(E-CY
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M.K;/:KHAZ][]U[J-40?<I6TZV)KKLI(M^>+_ .V][D3Q8_MZ?MI_I;BI\O\
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MKT%T)LV)\IN+>NXLDRB@H*''E96DI&>15KJT)Y5%A8R-&AJ7#BM*GR'&M?\
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M1O\ ;#_BOOW2CKC[]TGZ][4=>ZC^TWB#U_GTIH>G#W?Q?LZUU']UZ3]2H?\
M@#5_\%A_Z&'LS_XA_G_EZN_^Y2_8?^.]"-[$O0<Z"W=W_%V_\AK>P9OG]O\
ML_P='NV_Y3TP^RKI7U(]^Z]U']^Z]U(]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?NO=2/?NO=>]^Z]U#_<_
MWUO;?U/^K_4.E'4CR?X?[S[]XG2?K)[<Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=,66O#C*VWY-_K_JO>CY=&%AE>DE=/Z?[P
M/^*^V]/^K_4.COP#ZGKK6/\ 'V[U3J#G,A]ECJZ_(JKXXD?X7Y]LH?#3HSVR
MQ^HG^SSZ#%-(_?G^BFUO\3;WIZUZ',E!UPX_SW^/T_WWX]ZZ?QQ^7^QT)O76
M./W-;7$Z21_#L<+_ .\<_GVX,]_4=<S7M/T.A6/Z1_P?_B#[VOE^?0,M>L_N
M_5.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[K!=?Z/\ [Q_Q7VWXG6_ 'KUG]N=:ZC^_=>ZRZ!_C[;\3K?@#
MUZQ>W.M=2/?NO=>]^Z]U[W[KW7O?NO=1_?NO=2/?NO=1_?NO=>]^Z]U(]^Z]
MU[W[KW4+2?\ 4G_DH>V_$ZWX ]>LOMSK7670/\?;?B=;\ >O6+VYUKKWOW7N
MO>_=>ZD>_=>Z][]U[KWOW7NO>_=>ZC^_=>ZD>_=>Z][]U[J/[]U[KWOW7NI'
MOW7NH_OW7NI'OW7N@UW6#_#ZSU<$$?3_  ]V\6G6DQ0=5-?) VGJO-]0;'VK
M66J]4=:2_P"KY]%-_EY1_P#8T50+>GX\[V;^G(%,?^(]RU92ZMF0^M/\G6-M
MHOU/.=P/^$O_ ,>ZVB?;'4C=>]^Z]U[W[KW7&@_X'K_P5?\ B?;1^#IZ'^W_
M &=:R7_"8H%_C1\[!_X,P^18_P"2UQ__ !3VRI\(-]I_ETLNX=:#[!_@ZN*^
M>?Q'ZM^>/Q4[3^,_<5!#_=K>.$R&1Q.X\>C2U6 S&$1ZG%9RC'I"U^/K'$F@
MFSZ74BS:A>11&E6^W_5^?^7K5M*6<1K]GV@XZHE_X3@](9;MO8'8?\ROY&=A
M9#O'Y29/.5'PJVGNW<>*;3M[8_QWDH\,:#&*SR$UNY9(FJ:RH^H+.Q?FINW&
MPD;PV.3V_D.G[AC'&&48IJ/SK7_5\^@8_GAX[Y3[C_G7?RP-J_#'<^WMF?(S
M>_QX[TVAM'L/>2:Z7;5)N.IR=)G,ZR %Y:G%81LG+31HCR?<A#&"^D"JZB$"
MX.FG3L) U:N&K_,>G#^6Q/G/Y)/\P;?G\MGY,Y;&;IZP^<F>Q_<7QE^:>:VQ
M38O)[KW6\9IJW;.\<P[-4/5"J,@HDG9_LZY4:.+QY5R-J^AJ,<'(:GK_ *OR
MZ:D7QDTIQ&"M3@?ZOVU]<=;5W;?;G6/Q\Z_W1VOV_N_;W6_6&QZ$[CWQO3=E
M=_!Z&BH;E0SE0SR2.UE5574S>D M];$@BIP!_E\ND4<90T&3\NM>+K';_;'\
M]3Y)=-?*/?.T-T]0?RF_BWO^+LKXV[+WOBY,!G>Z]V[?98Z#>F6QT@U46T<3
MI+XX.A+G6P>3752(V&-0Q\LC^E_J_P!CUZ6F(!2H-5.#3@H/^K_/Y#K9_G_0
M/^##_>C[6/PZ*DX]<?\ =_\ OO\ 4^]?B_U>G5_+\_\ +U3AUK3_ ,-[*^5>
M%D(-?3=^9"K##G_CXH9)8?\ ;^V7P7']+_#T96V4C_TG^ =#?[0]&'2#V>%K
MOF=\=J1" N$V'V7F:XM_RK9)98O]N?:IEJS?83T5R0T$7S*CJV3VNZ*^O>_=
M>ZX^==?VW-_T7O\ ["]O;%<4Z4TQ7H#>L1X]I5M%.;56)S^Y,?P?^FQ?^-_U
M]E\OZ;>)\S_AZ-;(^#%X'R!_ETO/:;I5TCL2/+VYEP;G[/:6,_WBL'LVBX?D
M/\/1-=8?'J>AI]JND'4:*(2 DEKZC^?;2KJZ>S7K6A_X5/QN?Y=_2 'Z?^'
M_C>#S^3#N #_ 'L^V#\(_P!,.ET(R?\ 2'_)U*_X4[?*;:W5/P\Z\^+N1W[_
M *.)_G1W#MKJ;=NZY'_C"8K8&)K8\CO/,^*/[B5V2G:@@(BAE+M4*@(4N1K7
M1 O\1SYXZ>"5<N?P_ED_ZOY]52][?S-?Y:71'\Q#^57\F_@Q\@</N7:^PMEX
M3X'?)3;&(VAE=OA>L]%/0[;RTS5V.QT=8N"G,A:RL=$8\07461NH73FN*''E
MTZTJR,[(.)++D<>/Y9'5@_\ PIL[.KNGE_E.=M839>6[5R.Q_G71;HP^Q]L<
M5V?K,;B9WHL=0>+40V5J&525U'U#3<V'NTN-)X\?\(Z9MUKK!KY?EQZ*5\/-
MW]R=<?SM-I[]_G>=783'?)7Y:]68?-? W>3[E7/;0Z[J8JIEEZ\QE"Q6DQNZ
M(V"TSU:O/,U:0ID_RYI_>@QD%5XL.P^0^7^KSZ?E4&HK@'N \_7/^JOEUM^;
MUZ@Z[[2R>PLKOSKS9V\,QU=N'^^O6N1S^U:#*5N$RV-C:,9;#_<LHQV282R+
MJ0%245B/3I#S&A%0#3A@>7R_R=%BAI*T-*X/V?/K7,^?W:]3_.@[GP7\KKXA
M2?WL^.75G<?7_8'\PKY<8I7RN P\?7M:*^FZ\VME5$=-E-T5M9&0[1$F-U"M
MZ(ZO518]1HV:&K-Z?*I_U$]*Y'\(4;!(HJ^9\ZTK]GV?;CK:%2&EHZ6DH:'_
M ".GI#_#Z%3S?C^G^O?VJ3'#[!T73DMD_;T[^[],=1*;_@1_R /^BO;;<1U>
M'A_J]!U37_.Y;Q_%C8/'T^2_38M_KU=7[-]GC\:=S_PE_P#CK]11[R'3M=O\
M]RL_^TB'JVR/_@./]=O^)]PG=_'_ *O3K)VS_L.N?MCI_KC4?I?_ )!_XCW[
MJR<>@,[,_P"+76_ZP_XCV]#QZHWE_J\^J4>_E/FRG'T8?0_Z_M9"W2<S8ZO(
MZ2E$/4/4W%_^,>==D#_R$4_LANXJRC_5Z=&=N>X_:?\ #T)G^5 MQ_3Z?\1S
MS[8:WAGZ?GAT]-D(_A.Z:+P?\!<P105PX'MF/_%YJ3=.7 UJ:?;TO] _Q]BO
MPOLZ(NLO@3^K?[<?\4]UZ4=8:R80TJSWYOQ;\<?\5]U \#Q_^:?5N-.DUM"'
M_?O44XM_E;')&_\ 1?\ B?9-R[']/9S^-_HW]CTY.:L/EQZ6/L[Z9ZB'FS D
M'Z#CW;P?'Z3]->X,E_!\?6U_UNP )'^%_P#??\C]EEY%X/1E;BI_/_)TEL7A
MS$1+,#69*K/^7UXYM?V2115Z7=/ E;5_E%K$_3\?X_UY]K)K =)Q<D]-&2Q-
M-5DRP$T>1I"/X?D#P#[8N[3_ 'S^?3ZM3CTK,%DSF,/13W'W:D6OQ_L?]]_3
MV:[5+]1#XW17(N@TZ>_9EU3K''^?]A[<CZ3]9/;?2CI,5=":ZFKH?L1]M6V.
MH?[?Z7M^?::^VZ&[B[^KVSFU_L.B[Y78.Y.NLM69_KDG*[=JE^^SVR*X?Y,-
M7_*D?S8_G_>/<([GR1-R]X\UO_UZZ%MOO*[@ MS@TPPX_P"#I:;2[ P6[)/M
MZ,+B\S3?\#L%GV_A=3Q_C?\ /O5OOL,C^%-UJYM&M(:_S'0;]6\?)?Y"3'Z?
MW*Z@)O\ ]0M;_OOK[+N0S-;\QW/_ #SM_DZ;WNGT5I_IC_A/1O\ P'[K[<'@
M'Z_X@6]SS%_OGH'&O'K0T^6/:W_#A7S3[P[>[&AHMX]'_'SLO=?QU^*G5>5F
M;-X"E.Q9OM-T;QEH;".NR^X,JCQ&>5"U/" H;2S 9E^S_(<6VVB7LP!D==(4
MBH0XJ:8K7R]!^1ZCCF>_\23Z?^+)_P!7RZM1_DJUW9&._D[_ #;/6M=DJ*CV
MWV_\W*;XN*'C5J.BQF,63&QX$J-0IAN(U9HK<"761ZB;PA[C6D"\P2)#Y>)H
MID::]_0FLO%%NH/GIK\\G'6M;T?L,;3^.70?R<^+S0]>?*#J'85!VYL#MC$0
MJ,KE\SCXI:K/87=3E6;/4.X91D::MIJM2K^1BP8@K[R=NN3K+?MJAAH*+$I1
M@*D,%R#ZU(\_\AJ$7W3PIRK<#Q^SY4Z^A?\ $3Y!;<^5OQAZ0^26VZ".@QW=
M?5N#WH<-(FHXRLKZ24Y3&(&)8KB\FM7$I/.D_3\G!GF';UV6YDA?*H@8?*H_
MXL=2197/C1$<"&X^O C]HIT9R6:EA7_*;T0/('T_/^%Q[()I:]&(!/\ J_S=
M$@[AW"B_(?IZHV_25NX*_P#N3V#1?8T/!_W)U5&?Z?47_'XM_C[@3GC=?]W]
MOX/JO^7H<<O14VVZU8%:U^P?['0T[/VGEZJN7>.[C05>XAI^PH*-A]KBZ0 \
MF_\ OO\ >;2=LW*O@S>-<?RZ(]WO0%T6_#AGB>A4FQ]-56@J*(@\FYX_%_\
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M=>Z][]U[KWOW7NO>_=>Z3>XOV,,K&XN/Z_\ %/;3]&FT_P"K^72$\@_U2?\
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M8?\ %?=-8ZOH/6;W?JG7O?NO=>]^Z]U[W[KW7O?NO=!?V1UOLOMW:63V)OO
MT68VYG6#U5'5-XV!%_WH38^&L@//^P/UN1[I(H(TD8/^K]O3\0;5J4T(_P!7
M[.B4_P##?F G-)@MQ]X=R;EZQIE9Z'8%7FZ0P+3V)%)5Y"*+[V:CO;D1J/\
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MNO=>\?\ C_O'OW7NO>/_ !_WCW[KW7O'_C_O'OW7NO>/_'_>/?NO=>\?^/\
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M^Z]U[Q_X_P"\>_=>Z]X_\?\ >/?NO=>\?^/^\>_=>Z]X_P#'_>/?NO=>\?\
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MD#2O]$= ;64N:KL[_,MQ&V;'+U-'0FB%"1^D8IKV_P ;$_3W'9M6:[WM;?\
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M>Z][]U[KWOW7NO>_=>Z][]U[J/\ [O\ ]]_J?;?XO]7IT]Y?G_EZIN_G<?\
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MWM/U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWMX1>/UL&G4/F_\ A?\
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MVIF^QL3E#N?$Q;;V[1BOJLI <?Y&R5,*% A2D *M<$7]NBT)/5FN/+Y_ZO\
M/T!'Q"_F#?#?YZTF]<I\0^Y,1WC0=93XZDW?-B,!N#;K4\^[ 32QQ#<&'Q18
M*JL+V%K&X^A+DVVSPCN/3:SQN1X8(K]G1V="?[5_R4/^*>V=!Z6^'U&U#_5#
M_DD^Z>#TFHO7/VQU3KAJ'^J'_))]O^#U>B]8O>^G>O>_=>ZR1_G_ &'OW7NI
MGM/TGZKUZS_FD? 3MSY+;A^$W7GR"VIN7Y*;0W%N_:&Y.K:3:>XJ*6AR_5T\
MU/N%8JVMPS8,K05%-/H_W(VNA%R!?V8364\$?CUSU47,97PJ8_+AUB[,_FE?
M +IOY-X?X9=E?(W;NV/DYE<KL+ 4W5-7LW<\DE1D-^04\^&:6NI<.-OZ*RGJ
M8"Y_BA #K<_@N+ML[Q^)7/\ /_!UI[F*+@/7T_S]6)3.8/\ )Z@?B]@;_7V@
M$1/2VE//IL]WZKU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(O
M=_\ Q;O^0A[W!P/3*<>JD_D9_P "*G_@P_WH>W$^+_5Z]>7^U'Y?Y>BE?R^?
MVOYHF.,O%OCQO$D_ZTU+?W+-K_R2TZQQC_Y7&Y_YI/\ \>'6T;[9ZD3KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWLOZ4=5R?S!NU
M]R[+Z[VMU+U]D:O#[_\ D%N-]BXC+4OIJ<=C8F$F:K8[<B5:=D!_PN?K[D+V
M_P!G6]E^IDS':][9X8JB9]!3/2*]<0,8WX,*GY_ZCU7=GLAMKXW=%;TR^W\(
MD^!ZHV7N;=0QE/\ \",BV&@6<-/_ +34S-_MA[E*VCFW^_1'DS+(B#AV<:C_
M %?+IN;P(XJGSZ)QU/U3\F?D7UKLWOK</S8[%Z[RO8F"I]Y[=V7U#MBB&W,%
M!4.R4U'+]S-'/7U5.5O4JJ,0+>HD^Q5N.X[?L=R]C'MT<GA$*TDS$R25K]M/
MS_RCI(C2S=OCC^7H/4'_ %>G0B]1Y;Y1=A]?]R=,=B9NJZT[NZYSV.VKM7Y%
M8S9KUN+S5 C-409['4%8%HJFJ-,!3SN!=DJ1?\^R3=8=OMY8;FV_4AD34T'B
M80<=)SYT\N''TZ51Q2I0\0:FGS_G3_.#T7/N*A^9?4_:?QNZTC^;F5SL/R%W
MGE=E#*KT_@J#^$?:HEY&I3?[G]7XM_K^Q=LEQL^Z6=U=';_]Q8_$KXLG=^7G
M\NB.\M+V($BXI3Y#T_V/]0Z/AT=UIWEUYE=QY#MWY.U/>^+S&(IZ/&TE5L.A
MV5_")Z.QJ*_RTM]7GA!Y4\_GW'^XW]K?E$M+;P:@4[R^OS\NC:*&:WM_&GGS
M7C_J'KT17J/Y?=K;B^2&&W5N/+RK\5>^^S.S^BNEL4U/3N*#*=>_;F@R JR/
M(RYJJD?6U_5J/L?;ORK:06!ABH+VW@@N9AQ[9<4_VM,>O1=:3SB:DWPC-?\
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M?O!Z]CKWC/\ JA_R3_QOW[P>O8Z]XS_JA_R3_P ;]^\'KV.O>,_ZH?\ )/\
MQOW[P>O8Z]XS_JA_R3_QOW[P>O8Z]XS_ *H?\D_\;]^\'KV.O>,_ZH?\D_\
M&_?O!Z]CJ-I_VI?]O[=\(]6UGK-X/]K_ .3?^-^V^J=!YO"/_)ZW_7_/M1TR
MG'JI;Y&1_P"450^M_P#C7NMO\7[/\O3\']K_ *OGT5#^7W_V]%HO_%<-Z?\
M6VF]RW8_\D^+_:_X1UC7M_\ RM5S_P TG_X]UM!^TW4A]>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]E_2CJGSY\&O?Y4_%,S?\ 3
MLGN.CPH_Z;PU->__ %3%/<U>WZD;=?@4PT/^!NBW<)0'B'S6OV=%][-WML#K
M?8&\][=IR4U)UWC,6D6]IY\%4[@A:BR7^X]0]-&RBKII2..1S[/-LMI]RG2&
MVIXQKX?IQKZCTX=.[@L)B %?]D9^?1"<;\#\IM2G7>'PP^5G971V'W51+N[
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MY$_V_P"0='8S&Z=J[ERN[>E,-V-2[6[5J-D5^>$6WJJ#(9W$4-6%@I\Y%#(
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M<0?_ )(>ZCE^,?Z,?Y=>^K7RT_S_ ,W6./\ F'=$*;3]9=H5@_K74>*/U_\
M(L![5PV*_/I/]3(?-?Y]/L/\RSI6#_,=<=H6-S_P#Q/_ -7#V_\ 0V_SZK]5
M+ZK_ #ZS?\.9].?\\1V?_P">_%?_ %?[O0_/^76M<?JO\^H==_,IZ4K:>K@/
M6?9P+6-Q1XE?_CT^V94/SZVK*.)7^?6*B_F5]404I@GZ_P"T'J;\.*3$*.?K
MQ]X?]]_O.XD'SZ>,CD\5_GU);^97U,;FDZS[/J:X+>BHFHL3;[KGFXK;_4^W
M0@^?6BSG!*T_/AT"U9D\MFYZO,YDELQGV.=KR?\ E9RG-S_B?9A ]>D<T@7
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M:.6'L_U?/H1\N?[D?M_R= '4SB&G  _%S_L?:14KU+4,5.@H>7RU%A] O/\
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M_HWW[/7M ]?]7[.N?^RY/_RJM_ME_P"*>_9Z]H'K_J_9U[_9<G_Y56_VR_\
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M?S,_A7\K-R_R$>S?B#C=T]O_ #?^5JXCI<[AW+7J,EF]R9&@WW@,SF?X<9C
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M1_\ 0H]BG^N>Q7/G=Q_/#_R /5 MQ!_!]F/\O6#_ &6;YZ_\Z#XX?^A;7_\
MU'[O_6_8_P#EZ_:.O4G]4_EUW_LM?SY_YT?QU_\ 0LR'_P!2^U']9MC_ .7C
M]O5--Q_2_8/\_63_ &6GY\?\\M\=_P#T*J__ .I?;7]9-E_Y>/VC_-U6EQZM
M^P?Y^N/^RS_/;_GD_CO_ .A;7_\ U)[>_K9L/^_+G_>1_P! ]4^GN/Z7\O\
M/UC_ -EG^>?_ #R?QW_]"W(?_4GO7];=B_WY<_[R/^@.M_3W'JW\O^@NLO\
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M +)7Z_\ _%C>E?\ K?6^SC9OA;_2/_QU^HG]W_\ DGP?\]=M_P!7XNK<X/\
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M4<&X%O:N&RGG^(],2744?PK7[30?M_S=!5\>?YL'\MWY5[V?KSX__+OIO?\
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M0DR?$S9Z?)C%_*/:V5R.V-Z46V:O;NZML8!:6@Q^Y8*\ 1'*$:@!0W4QW')
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M$CN ^? ]2_YKC#_H+*Z<_P .T_@S?_77;^"]^A6MM^0_P=:8_K_F?\)ZF?\
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M_P"*>_:SU[KW@3^K?[<?\4]^UGKW6;W3KW7O?NO=>]^Z]U[W[KW6'P)_5O\
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MM\:MZ-;Z<":F_P"(]R7:-X6U(?L_R=8U;;+]3SE<C_A+_P VZV>?'5?ZM/\
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MQ_3_ 'GWX$#$E/LZ;ME-F:P]=8G 4&)2U)18^D%3_EM>*$_PR]4 /Z&_]?\
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M_DZF>[=4Z][]U[KWOW7NOG_?\*L>N*KH?^8Q_+S^>1QU9)L:IBV?B]SU^)@
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MQV-WIT1N3H3IC;&4.=Q-=NWJS)=&;%PHRT@AJ-P3MD4GRVY,JM)*AB>G-02
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M67^_5_9UCF^9_P 0*?\ RMOD]TXQX 4;[Q+?7^EI+^Z_0M_J8?Y^MKOUD?\
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M:ZQ_C[+/%^SI5UG\?^/^\>[>'U[KWC_Q_P!X]^\/KW63VYU[K)+_ )0;5/
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M]^/^W_9Z]_K+[/\ \HEO_O*]>_V3SKS_ )]WBO\ ;#_BGOW]:;G_ 'X_[?\
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M^S;F7=I=OO? 5Z9/\N@?[4<A6',FUI<W%J'U+7(!XDT_E3HX[_#_ *^\UO\
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M:#_0IV!Z+?\ 5DJ/]Z_XCV)=B_MXO],W^ = OGS_ ))5[_S0'^7H!?Y9H)^
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MF_P#H'<^G_=5>_\ -$?RZ+[_ "RO^R OBW_XB?#?^Y%1[*^:_P#<MO\ 2_\
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MWD_P_P!Y]^\3KW7O)_A_O/OWB=>Z]Y/\/]Y]^\3KW7O)_A_O/OWB=>Z]Y/\
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-_M1U[J290W !Y]I9I:=>ZR)]/\
M8^W(O\G7NO:Q_C[]XOV=>ZY><W LHO\ UN?I[W,WGU7ZGKE#!55'T^EOZV_W
MK_BGMLFG5N@PW[V_U+U93*_8G8G7^S8#8B+=N>I:5N>?I&'/Y]JH;&XN#4FG
MVGIM[J*+X03]@/\ EZ*1N/\ F>_"3;D_VS=N/N"H-CY=I;*R>4'/^,L*<C_6
M/M7!MDB_B_8#TS+N.K\-/M(Z>-H_S(OA;N]WHZ3NS%87(U?'V>^\76;57C\:
MYZ=P/I^2/\;>[S;;*_X@/M'58KQ5_#7["/\ 8Z.9@\_A-TXBCS>U<M0Y_#5
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M!LUVVYW!2VA U-1 &5FD8+I 4(23D^>*5ZRKN=F;VXV^XW;>[BTAMVM)@/\
M' 202:&@)\^./MI0GK>BQ-%7T. Q5.5U5&-Q^/QS+]+C'&[#_$'_ 'GW.L+^
M)<:I/0?RZX97CBXF,L&:DU_/I2Q_G_8>W(^D_19_ES_V25\F/_$%]@_^Z9_9
MQR]_;Q?:W^#H&<]_\DJ]_P":*_Y>@#_EF_\ 9!'Q2_\ $2X+_K;+[+N;?[8_
MZ7_/U[VI_P"2'!]@_P"/#H_'L.=2'U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]UA\"?U;_;C_BGN^L]>ZS>Z=>ZP^!/ZM_MQ_Q3W?6>O=>\"?U;_;C_ (I[
M]K/7NO>!/ZM_MQ_Q3W[6>O=>\"?U;_;C_BGOVL]>ZS>Z=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NL/@3^K?[<?\4]WUGKW6;W3KW6'P)_5O\ ;C_BGN^L]>ZS
M>Z=>Z][]U[KWOW7NO>_=>ZP^!/ZM_MQ_Q3W?6>O=>\"?U;_;C_BGOVL]>ZS>
MZ=>Z][]U[KWOW7NL/@3^K?[<?\4]WUGKW5*W\^:6OIO@)3QT/%--WMUW29<#
MG]F.+,:/_5HT_P!/<P>RJ(^\-K_B6O[<=1O[GW'TFU,?2-J?M7HT'\J^CV_2
M?R\OBS%MJ4R4:]:351!/_*1D<G6+D!_A:J"@?Z_LA]Q/$N]\NI)OA 6G\Z_S
MZ-^4H-&VVXM\?"!]FD4_EU5Y_P *+*#!CI_XR2S<[@IM_P#9M'33* !X*[&T
M;5PX_*SF"WTX/N0_8I3<S7D?I7Q/MIG_ "=!7W3BAMK>$MPJE/E6H_S] #_.
M1J*ZN^+O\LNOR\4\F6J.HQD,P!S/]XVV=NZB?\21S_C?V?\ MA:V\NY;B9)=
M"*V?MU#HFYON"MI9@"O^;OZC=S_S$_YN_P 9]N;4Q_<?7G6?4N%W5ATQNR-Z
M'9<.8IRBTZFZ5D>4JZ8Y 1E:DPS$D$@D<^[[5R?RYN[#Z=@XCP$I4<*?Q'/V
M],;GS#O&SPEIQ7.>X_X*#_5Y]60_R<OA%%T'M?<GR.W1VKL;M'>GR+HL34XW
M+[&R39'#)BJBMCKY[5^@+6Y*MRL:O5(.4T,"2Q(4">YO-YWFZ:S1&C%O0EG^
M"G'!\SZ]"_DG8AMT'U2C^W)8T K4U%:>0\P?.O6N;U_D/D-F/DY\BNEOC"<G
M-OSY,[NW]U3F&P$HIZB'#1;DJLC7I]^?^+?0!8Q]]7:E'VP<.=!:\S[I:V%A
MM=C<7O&(@$CR !KU'4+37-_=16?"8*:GR(!\OS_;U:=_)$[(V5T9W5W7\0.R
MME8[8GR$RNX*S'4&XZO%"2IRB]=:X\EM!GE#%&HV7[RC\&DU**9&+$1@ GWB
MLGW:T6_MI ]NQKH\D \O0TXCY=";V^NCLSK93DF=1GYU_%Y>M/LI\^KP/GMW
MS#\9OB%W/VMCZL#/18>OV[LMZ?(EM.:W8LE!2.MC:ZM*U6"?]XN/</<E[9_6
M&]ME\UE/B#^D<#J2>:]W&WVGBMPI7TP*'_8ZUV_A1C_B#3?RTODWU9VY\@NJ
M-N]P_(O^\%92X#/[ACHJZ"?KP>3:OW#:&5:A\BTDY]0]-2/KR/<Z<T#=FYAL
M[ZVC<00^'4&(5Q4'Y^A_/J,=I-E<[9.)Y]3/6K5'XL'^7\^CY_R!>]FWCT%O
M?X[9FH@.Y>E]Z?WEVU2U%=H$F#WPH4+^0%H\FM6QX)O( !]?8"]XK,B^^LCA
MK'(:#_FJ>'\Z]"+V\W7Q[<1D_ -)I_1_U4_+HQ.]OYVWP0Z_WAN[86Z-S]J)
MG^O\]N+9.YI*3KFIR$$TNV[T]60TDZN ^GZ&UOR/9%9^U.Z7UL;A70("01I/
M$='5WSA9V\X@[:D5X_GY#JNW,[@H-[_\*!NKMV33WPFX-N[$SVUYZ[T^:FS6
MQ*JJH@8_I$;%1_@?<AV@6'E><\!&^/\ >&..@5?7<-[OENA'=H;_ *N"O_%]
M++^;&TU-_,^_E\U& GFES4;=9Q4[_4ZZ7>4]O]<A_N!_A:W/LK]O8K8;'=W3
M\*L3_O7^QTMYIN&_>\"'XR1^S2.FS+%Z[_A1M1_QMO0(L>V+A^A].P9OMO\
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M!/N(3XC7_3-_L]9?]._\WV0^7[#M4V^G_&*\7^/^0/;HVQ/0_LZ:^L<8[?\
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MH[L&,(3_ %PTX'^QN;>SOEX@31_Z9O\ !T#.?,;5>_\ - ']G0'?RU:>:G^
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M:NIG4@C5#$PN+*.8>9MLY=VN3;]G83A@=+,?//'\S6OY=-[+M&X[IN'U>Z0
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MS$9#9>IRU56"LF540!?U V'M!O7/%UO @)K^F02.-*"G'YG/5]LY8@M)9R5
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MM_\ )<MS<RDVJ?J+'ZK9$BE[GPWIY'_9_P /3\,QA[&^'R/I_L?X.@K^)?\
M,ZW?TU..DOEMC=W5V'P%7)A1O.HHO]_!A;DWH\Y2N!_$J*%K_N-_E"W-C/8+
M[#NX[:9QIC\O/_/T:VMR(SK;[:5P?L]/\'5^NR]Y;4[*VUBMY=?[DPV]-K5S
MF*#+;8KSD(*@_E75@K*0 3R/^*>PD;*6U_M?Y=&T<_C&C8(SGI;^V>GNO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>ZQ/]?\ 8>ZR_P"7KW7?AO\ D7_%T;_C7MZ6
MTNO/K6JV^?\ /KL<W4@@_4\^Z^-X_6^N?NO7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZX5'Y_X(O_0WO1ZU/Q'5
M1GQTFIA_-[^>DY(\/^ASI8W(U?F*WX_H#[DZ\1_W8GVK_DZ@KEJ> \T7M./A
M#]E9>K1]S]O]4;)51N7>^"Q9HE]./7*>6I!_ ,(MP?\ 6]AY+&67B@ZDFYW^
MULQB8_LQT!6;^;_0^.XQF7SN?O\ J.$V_4Q_[;[@F_\ MO9K%RT]UCPR?RZ"
M%Y[E;1!QN /M(Z S='SQVAF<?E<7-U/49S$9.AKJ&LPFZ,G3&FJ*8']V.6&4
M6_W@CV81\EB\;PG9?!].'^'I$/=PK,###+49! \_Y=4*=#9#HK;O\SCY.YO'
M_&'K6HVYM_9/7.:Z]V+4_;?9X;(Y,4?EKJ-Q3B)FE8N;6M<W'(!]Q)L'*=K=
M[]<VB'M42B)6!*U'ATP21C-!\SUTH]U?>#?I?9[:;V*ZNID2Z#"GJR '_BQ0
MC]O5OW9OR?P/=FTJWKGM/X_]>;ZV+FJ8PYS:^?R+UD*'DAD?[8Z6%S8C^@O<
M<>Y9GY/MKT(9T5@IJ&5@"I^1'7-_EOWUWG;]RAELHIK6<BG!_P#+U3=_*BR/
M1G6N^ODWV/-\>]H;EW;L7Y+;IVSU9NE\D5J-MXNG#:<?CA5&Q,2@$3$&W%K7
MO[BGV_Y9M=W,LIUZHW@"@M@5,E6(&"<#)SCKI/\ ?K][=]V6RV"Q:Z/TMS8F
M.3S\:0>'_J]3Y];%&(_F"=>U5/\ ;978^[<2;6+462I<M]?Q;2GN5)^4C%VH
MH ^T?ZOY=<TH_=;;O[&9G/Y'_/T,>"^9'QYS"F!]TU^#O]1G=NU6+'']"C-_
MT+[+9.67M<:*?:#T<6GN!M5SGQP?]L.D/\P=Z;4W7\,OE14;9W9A,I3_ .@G
M?H7[#(TN1"Z\.OJ^G)XL;?D@_P!![>V.T:.:.)T_$3Y9P/\ 5^73/.E]%NNT
M7W@SD5@X^G'.?MZ9?Y>SI_LCWQFJ*KE1T?M%>/\ "&4_C_:?9'S$LT5P8A_"
M/^.]&/MU./W3"?F/^KG1UXXA;_)V'^&JP_XU[#WC-/\ ZCU(7ZZ\?\(ZR^V^
MK=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?NO= =\F>?C;\C_ /Q"'9O^
M\8R8^Q+RT_A7L ^;?X*]%>^#_%93_37JA+^7'\_-T],?##I?K/$_!7Y5]LX_
M;. RE(>R.M]FPYS$5QRV5J*@I1U(G<#1>W#7U \>Y?YPY6.X;@SBYMQ1:5=T
M+\?+/0!Y>W<1V>HPA<#M) X"GK^?[.A,^(?9_P#LXO\ -!W5\A.Q,=_LO.\N
MI^CVZMZ_^-N]'J:#>-?25,KS3YO*+4)3PF@C$DCJ(K,?2 K>IRCWNQ_<6T-;
MQ#QU9-4C-@$$Y)^VOETY97/[SOO%E_2JU:\0,CA0GT%/]5#A?'_O+MG>W\P'
M^8/U#N'>,N:ZSZAV[L/(=:[8EQ="RXF7.8M6E\)*_<+=7*E0=+7-_P 7#]SR
M[86MC;7"?'*#K\LLM3T8V^\S&_EBI3PCDUXBOR_U?ET0_P"&6,_F!?S#NC)-
M\;H^<&]>A=L;4WMO;:&UZ_KK;]!2Y_<V8IZEI6K\M4QRTX2CHUD6CI8(GM^S
MY  %+>Q%OK[7RI.+5K0W DBC%55?TJ'B?D/3[3]I?MGU_,,7CB7P3Z8..&-0
M/I_JK3IP^)VX/GY\ZMF;XZNWE\LLKT5A?C=O[.]9[K[<ZJP<$&[=Y[@AK&\7
MW-3+-!]E0X^F+>J)Q]W=5*NQU*US&=HY,2.Z\#ZH/$2445:.G[: ?+CTSM5S
MN',9,4LO@&,\, 4IZ$$9_/[0.C+_ ,OGY/=L[>QOSBZL^4/8L_:59\(]W24]
M+VP:2FI\ED,1!CJJNEBK)) SM-(D (U.2+E=1LH]E_,O+D5^UL8(]"W39-*$
MK2N?]7Y]&FQ[M+X4IDQX&*>52%/^7HN?3F;^3/SKVJWR2WM_,7_V3';6[<A6
MU/2?0_6N:P-*F-PT;%<;/N8UF0I9LC+*PTBG9)'8>K@$#V8WUE9<NL+&.Q\<
M&IDE%<"E.XGB3Y\./VT);6:?>R+U;UH!3,-!FM#YJQ^>* <,G/1I/AM\F.S.
MR-F?,+XS]\[CVOOCN?XU;?R,;]O[,>E3&;LVWN_&U$N+RI%):EAK$;QM6.%U
M,K@.-2L?9'NFQP6%Y#>11"-GI4 4# Y!/SX="#;MTEOHI;1:T4C!XJ1_J_U8
MZKN^%7S3W!U3\#.@_BQ\9,)0=D_-'N+</9D6Q=K5=6#1[:QLN:J34;JW+K&A
M*2DIHWFIX6.AAJFD-E"N)M^Y5N-WO)KW=:+ H(52?BSEE]!_A\NB39=S2WM?
MHX<2 "OJ:?Y/^*ZL+^76X/E%\/\ ^6MV)O2K^1V:[!^0FVJG961K>XFVSC,/
MHJ=QY>AIZF@QV,>A%$:"$J3"X'G8W-D6RL#-BL[7FC<4MK:.K( =5!YD#T'K
MT(-TO)-JMO'844@]N<T!R<\?]6>AQ[8Z8^9/<^/ZCW?T=\R5^.^+JNJ<%)NO
M;O\ HEQF_AE,Q7B&I;+-55(/VQFU"[<D:2?HY]I[3=[#;;B6REM?%F R,/J/
M^V/5YMON;R$SF7PAJ.:TH/3CU5_LG>7\PW>/S/H?C7U3\]<IWMMWJZMI<U\J
M=_1]1X3;>!P215>F7 15!$PR^7R-.H@6$@")_0+JC,!A<V]C#LOCW,0B;C\"
MC5Z"H&6/#]F?0-[>+^:\T0RB4$=H)->%:^5!_@&?,=6']7=Z]L[A_FJ_*_H?
M-;RKZWIS8'1W7&\]F;0;'T"I0Y#/QXDR5:U6DU@*F=CP]R6Y)MR%+_8K*+:H
M;HUTU5@//-,]'EAN5W-N<UI0 D\?7XQ3^7^JO47Y'=Y=O[&_F,? GI?;&]<E
MA>LNWL3V/5=A;5&.H(DRJX2GE2D,DB^MM,<8 TGBP(YX";E_8;2;:KJYE^%@
MY;_:KCI5NFXS07\45!J)P?3A_GZ+AV+V5\U.Y_YC?R(^'O4'>M1U1U5@>N>M
M=X97=5)A:+<V5V]CZ6C@-6-O/Z'&7S>1KRSS54BO ">?2![$UK:;;M>T)<R1
M@L-)K3(KY#YD^?\ +HJDO+J]OQ;1@'CQ.#4MQKZ ?ZJ]!=@\M_,(ZF^8F3_E
MYX/Y9U_8>-[*Z[Q_9^W/D3VE@H]U[EV9@\;J?./34[R31UM?5*CT](LTAA8E
M)D,1;4IA)%MC[=^]O!KH7Q!&0"R@$C["3^SI$!?Q;C]*9:9I0=M34 < /MX
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MW7NO>_=>ZC^T_7NJN?YB?SIA^.FW:SK;KK*TM9WAN>C&J5.#M?&Y(!OXA4\
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M=>]^Z]UUYS_J1_M_;GA]4^JZBDV_8O\ 3_8_7GZ\6]ZU^%T]X/U764#SD?;
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M%24\,\(+F.^EF$9)L2"+F".2QGLP]U]2QJ'3A@ YH<BAZ.]M,5S!-)'!X)U
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M^=>/_P"C/=_ZO0_\IR_]5NJ?ZY5U_P!&Z;]L7_0?7O\ ARSY#_\ >N7Y"_\
MG7C_ /HSW[^KT/\ RG+_ -5NO?ZY5U_T;IOVQ?\ 0?7+_ARWO[_O7!\@_P#S
MLQ__ $;[]_5V'_E.7_>IO^@.J_ZY5W_T;[C]L/\ UMZQ0_S)^_I@P;^6Y\D
M#?G[S&?CG\*?]Z][?EJW&1?K^V;_ #=-6WNQ?.<[7?#[3;_Y)SUD_P"')N^_
M^];WR0_\[<9_T9[]_5FW_P"4\?\ 53I__74O_P#HVWG[8/\ K=UC/\S+MND'
M@S/\O#Y/4TWT:AIY8*Z]^?H4]T39_P""Y6O^KY=-S^YTK"L^WW8^7Z?^20_X
M>@F[T^>79G;?47:G6-#\ /E1C*OL386Y=J4N:JZ>FEIZ>?(TXA(MH7FX%_I?
M^OX]JK/:4MW247(!4D9_XKHHYFYR&[V=Q8G;KMA-#7'A@'Y5\0&O\OGT;SX;
M;:S>U?BQ\?\ ;NY\958+/X_K'"XW*8G,8\T%1!48^D=ECEA(^GY_V'/]/9-N
M$)CNR(,&F01T)>6+/P-LM_J#PI4_D*]!]W=_+[^,G>4=3DLAU_0[!W756(W)
MLF^UZHV%M.E_\CJSR+EJ4$_[VI@WZ>R_L7U'U&/]7[.BO>_;NQWT4DM@@_I
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M[T1GJ G1O19<2Q=)=2"H@!]7^C+%)]/R/V+,/]O[H-\N-%9;]NSRTC_-T_\
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M"/,5DMLED<A4 _KKZI?34I^; 6O_ +;V$[R^-TVJ0?:>)/4\;/L,&P0"WL,
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MU[KWOW7NO>_=>Z][]U[KWOW7NH\7]G_8_P#$^VKKI/U7#_- [\EZ1^,U?MG
MY@XO?7=5:VR<)5IP:?$0"V6JK@\,],5IC_5:AAQ^3C9+3Q:T\\?Y^D-W/I45
MX+D_;Y?Y^BJ?RU>C8.O.GW[2S-+_ +^WM@RPT(K2 *?;&/M]@EOZUM>!,/\
M!?\ 'V.Z>&FKS/\ @_XOH,RS&1M/DH_G_L#_  ]64^V>F^O>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[H(>\NF=O]^=6[LZSW 5HZ?/2?Q#!9L_IQV2QMQ05+?[3(NH
M'_ W]JX&".4/GP/H?+JYJ6##RXCU!ZJ@^"/R9W'\+^ZMQ?''O#5@^N]P[I6B
MRD5:"T&"SM58465M< XK,"RU-N#&1./TCV'=UL3(WB-C_ .CBSNP5")QIY>8
M\QULQ-"8+T_%K*;?CB_L'O$/3H0P$GKG[UTYU[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U']I^O=2/:CKW7O?
MNO=>]^Z]U']I^O=2/:CKW7O?NO=>]^Z]U']I^O=2/:CKW7O?NO=>]^Z]U[W[
MKW7O?NO=1_:?KW4CVHZ]U[W[KW7O?NO=>]^Z]U']I^O=2/:CKW4O&_\ %RQO
M_!T_Z&/M19_VW^KY](]QX'K4O_E8?]O5>Z/^#_)3_P!W4OO+'G[_ )56V_U?
MCZ@GEG_E8+O_ )M_X!UM>R_VO]A_Q'O$;J>NI'OW2CKWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZC^T_7NO>_=>ZD>U'7NO>_=>Z][]U[KWOW7NO>_=>ZC^T_7NI'
MM1U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NH_M/U[J1[4=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZXB:JIR.+&YM?C^G]?Z'W2.47'Z/5+C&?]7EU0K_ #)/YJ,?6,V9Z$^-
MF7I*[M<VV[O/M2BD:OI]O3Q"QQV.MI-5N#4#=KWI0++:HU%95Y2Y#DN*BX^
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MO?\ E'_DO6OZQ6O^_9/]YZ<\3WOT3N&K&/V]W9U;F:XCBAP_8.*K:KC\:FE
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MKW7O?NO=>]^Z]T0#^8)\L*?XT=45>/V_5L.Y>PTR.W^O*8*%.+I#9:_/J?\
M5P6M':Q6L&H$Z;>U^UQ^*OS/#Y=)+YZ-G@./S/D/]7ET0?\ ED?'Z?:NVLI\
MA=STR+EM\TDF"V%%D@14'!_2OR('Y&2D_;!^GZO8X*4%3Q.!]GF>@S*0QUC@
M,MZ5\AU:_P"V.F.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NI'OW7NH_OW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K-')XO
MWOZ_3W[KW5"78=(_PN_F(;1WMM:V/VUE-W8'=:45$;T_\,['J/M,YC0>?V=3
M21\CZ?CW6ZA\51*/,@_D?+I5:S>'53QH1^8X'K:$E(@JB:;_ ("W('_&_8!Z
M%W6+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=5D_.[^95MKX*;HZ[VMF^JLOV)-V'A-PYQ,ACMYQ;:-/_ ';K9*>,+]Q'
M+_J+FXYX^O(]R'R'[>W7.,2Z968M6FDTR*?+Y] KFOF^VY75F9@H!\P#@BOF
M1T2:F_X4([#@FI2OQ@W:#'?21VQ1CFWU_P" 'N24]C;N#\0_WIN@M_KD6S?Z
M(/\ >1_T%U3_ /%+YI8+XV_+C>OR=R.RZ[=%#O!>RDEV7B\]!B9HE[$R+514
M5$B2$"F#?73?^A'U]S#S3R3=;KL:V)D-"&Q7(U,#U'.U<SVFTWQO*@?"*X/#
MY5'5ND?_  H+Z_7B'XN[RTB 2L@[4H@+_P!;?P^]OI^?<-Q_=]NXG_4F']GZ
MMU(L_NS;?3U\$TK_  #_ *"ZMS^&_P H<;\Q>@L9WOC]HS=?8[(9[.X [9RU
M93[EFA7;TT<(*UD"HY.EQ?T\?ZQ'N$^<^6&V"[6WDNB U>.:4-/+J0^7=W@W
MRS\;Z>N ?3C7CDBN.C4>R+H\Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NI'OW7NH_OW7NO>_=>Z][]U[JF_^:G_, G^-^RZOH[I_<M))WQO?
M!)49#/12&VU\)D+,N0#+;_<C,"/MR&)M^]PQ!]R%R9RW]0_CU[1DGU!_R^G[
M>L>??3W2/+-K^[K(#ZB3"!N$1&-1'FH_F< ^8*3_ "U?@G2[47$_)3OW#5*[
MJK_]RW5VV<Z1%/BZ7('_ (O=?<$_QW($'[;@?;'U?1;^QWO>Y+:1""$'U93_
M (?\W[3U#/MW[>PVUV=XW6C25(MS3*J=((J/,TJQ].T8J6N]O)?[BW'UM?\
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M/J_^,?ZJ= OV7T'TKW+487+]M=8=>=E5^WZ*OH=N5^]<7!GJN&DK26E"_=,
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MS [3V5@</LS9^U:5Z;%;;Q=":"&"F-]31QM<O^;FW)Y^I).)%SNEQNRB2<4
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MW_KN6O\ OBY_WA^L7^S*[%_YYS?7_H.U?_1_OW]2KO\ WXG[/]CI[_71LO\
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M[W6:Y&:,"?\ 3')_P]"GE#:QMFV06PX*-(^07'^ST=H35,'_  (Y/]!P./\
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MW7NH-/\ J3_D+_B??NO=1?:?KW7O?NO=>]^Z]U[W[KW7O?NO==B'[C_)^/\
M8?['_C?NX)&/3KW6LQNV*/MG^;SDJ3('[C%87N8Q$@W_ ,EZQQVF*Q_IJA'N
M1MI':*_Q?X.@AN)UM_M?\/5YDDGE_>_I]?;_ $7=8??NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=![O_ +)Z_P"H=K3;S[(W7A]H;:H21'DLC&96K+_6
M&BA4?Y9-]+G@"WN[4(J33_+]G6XW*&BBI_P=5E;W^</=':_W>-^/>U:/K#9#
M-SVEV)0C)Y.ITCC[#'$-!1?0BR*3_M7NO<^*4'J>/3CJL>4-3Z#AT6VOZB@W
MC7?Q_MK>F]NU]PU)+5M?GLY4O2G^FBE:[G_;B_\ A[\9M?Q$L?F>K"'PQ10%
M'2[P^S=G8"Z8/:V#QI'YQ^*IG_WDEO=0H'5=1\S_ (1TK?V(O\U34M.+6N![
MK^P=/_MZQO'#)Q-34=1_U0^]?9_@Z]]O^'I'Y79&Q\Y"$R^TL'4L/]7BJ=?^
M)]NZ!\NF:L//_#TB:?I;!;=K1F.M=Q[TZIW".:*MV;N.J!''^H&E_P#D[WL2
M:35:@_(]>,6H4(!'G7H>MF_*[Y5=2"FCWSB<'\B=DTW-97TA.V=R4X/X$J?N
M/;_$-_K^[^)_%W#^?3:EHOA[3_+]G#JP+HKY0=-?(F-(-C;@%+N:C+-7==;P
M;['.T@^ET4"U=^+B#G^HO[NVB3AQ]#QZUH?\7#U'#_8Z,?[3]:Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[JL7^:GM27,]";*W5"+P[1[.H(:LV_P"4?<=&(!_MYD/M5"M8P?0_X0.O
M*]'*^H_P$_Y^K ?Y>6_X-\?#+HZMCF,\VW\+E]A9OGG[C;59]O'Q_0(Z_P"W
M]Q]N4'AR@_ET,;&70&^="/S'^QT=GV3=+^O>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KU1_P !/^0F_P"(]W'E^7^7KW1<^[<]GJ[)[>ZGVW5KB\EO+37YVNQYTBFQ
M&*%EY^EK?X_7V.>6MN2Y43M^'_CW41\\[Q*)CMT6?%X5'^A]%\[Q^1_2'P=@
MV9A,]L3L?*MNZ@S?VU?L38M9O*_]WS:9:HQN@C8'DA?P03^/8CLXU>B1.:D?
MC \OMIT%=WN+7D"J&"@'E "3Z\ #T ,?\X_XD19+^&4^TODU_%#)_$3@3TU.
MM5]MI_2:8UUOS_3Z>SB38YPWBN%KZ5'_ $%T26WN?LTN(#<TI_OB4?X8QT+^
MT/YDW1>[^JNX>TZ?#]P8O:O1-'CLIN==R=:U6VJBJ;+,444*22,M2US<AB.
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M./Y>?1<_Y3WQD@ZHZ8G[AW+1_9[M[G-'542MSX-N4=OX53_X&M8?<C\E5O\
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M+ZK@VXL/K^+$^U&WVC/MK)&FH:A4^GQC_+T3\S[G:[;S?:W%_="W/T<P 8@
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M'U6.W3A,%D_345='D5"MD:BAA##Q!V*@@E; D&D%I:3GPJ.6X%O*G[/Y5/\
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M1U[HG/SXZ*7OKXR]F[?I*19]Q[:HAO;9JKR3D\ -+7_K]U1%80/Z^S?EV?\
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M]0ZQVL#;4/ZV%SS[:$<QF_4Z:\<4_P 7ZU>?^% I_P",M_&H&W_,M=Q_[?\
MBD?O*[V(K]+?^+_ W^$=0?[I_P"YMM3_ 'X/^.CK9BV'8]>[1(O_ ,>=MN]O
M\*.F_P")O[QLWN'Z^XF\'T'^#J8-F.B$U]3_ (>E!]?]?_BO^V/LH_6@Z,<-
M_J_U#KOV[X(].O5/7O;76NI'M/THZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWN[\>KVO5+?\][]SX4;3_\ %D=B@?\ GLR-_<\>Q'B_OG/^^?\
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M/Q_U?+HMF4_[*9C_ /$:8?\ Z%'N2MG_ -P!_I^H*WK_ )6/_FQT.Z_YQ/\
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MA0!DU/#%234^I^WH<NF=I5NS=BF'-G_<]FZS)9W/*1S]UDP0/8 Y@E42^&G
M9/4F\C;5-9V?CS?&PH/LZ%NQO^0>#S[#VO7T,C/]3GK#[OTUU(]I^E'7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[VY!_:C[>M'AU25_/#[3AVS\7-K=94M5KK.V^T-N4=80+!L5L6B%;4
MJ?S?S2TI_P ;>Y/]LK/]:64<5H?R45_PTZQF^\SNHBV5[%LBY?PZ?\U#0_\
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M?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=9^?Z#_;_P#&O;NL=:\
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M^5E))?,?&G:E=#S?^$=@<?X?0$?3_#VW)RQ#^!P?S(ZK:^\]Y_Q)C8?8U?\
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M^ZIU(]I^E'7O?NO= ;WGN?,4&%VYM3;"K29KL'(MM^C8CE:8JK3 '\7#"_\
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M^3H$XOE-L,?3;.[CQQ>2C_Z,]J?HQTR9'\B/V'_/US_V:+8W_/+[N_ZFT?\
MU[]M_0#Y];\63U7]A_S]>_V:+8W_ #R^[O\ J;1_]>_?OH!\^O>+)ZK^P_Y^
MO?[-%L;_ )Y?=W_4VC_Z]^_?0#Y]>\63U7]A_P _7O\ 9HMC?\\ON[_J;1_]
M>_?OH!\^O>+)ZK^P_P"?KW^S1;&_YY?=W_4VC_Z]^_?0#Y]>\63U7]A_S]>_
MV:+8W_/+[N_ZFT?_ %[]^^@'SZ]XLGJO[#_GZ+SW7V%@NSLOMNOPU%7T5/BL
M<N.KA7-J)(JR;_C\'VJMU%KTEG=I :GS_P E.NM@]Z;NV3]I1259SVW@;G&Y
M"]O]>&7ZCZ#\CW:>W(Z=259?D?7H[6Q.R-I;_AK9L!5%:BE]5=0Y$ZJNE_Q!
ML ?:"X4,,=/1NT1STM$^G^Q]M0\>MR=2_;/3G1=NY1_QD;H@?US>3/\ ZJ*/
M<@\G_P",QS4]>H@]PL75D?D/\)Z$_=1)VSN*<WYVQDC_ ,E40_WGCV903U9#
M_2/2C<%I%<?\TQ_AZI/_ ):Z@_RM>_\ \?[F_D@/Z_2*<^QCN?\ N3%%\D_9
MCJ#_ &_/_(=O3_3O/Y,_1H?Y0DDX_EZ] 7Y!H\]Q^;G(U_U_-K>RGF94GN''
M])O^/'H2^RGCC8++_FC%QK6GAKU9.U::8B>I_P DI?H.+<_Z_LG10_4GSV_T
M^!UQI<C135"_;UN-K/K92/P/Z_GW=[=CYCIN*:'S!ZHP_F%?"_J?8_Q^^;'R
M?R^3W5V9W!F]M5U7M3+[[R'\3IMKT^5K:=SCMOTNHG&(JEELQ\P X'Y]G.R;
M@([B)"2%)%*_BJ!P_;CJ%/<;D^SL-NW+=@%EN%A?NXF'22WRH*@$TI6F> I;
M'\<H!_LNW2()6E'^A[KL7/YOBX/Q_A_K>R_<H_'E-/XC_@ZD_EN+381?\\\?
M^'HIW\R?OK=W4W3F-Z[ZHGC;NSY.;DQ/3?61HQ_E4%7N0ELAE%-KZJ2G*,#>
MXU<?GVHV2V%T TW",U'#%<$_+B!T3<_;]+M\7@PFD]Z3 *\-6DGA7- I8CS"
MGHQ_Q>^.VS_C-T7LOIK;;))!MO%&ISE2"!45V0R0"UV1J2?[50Z +S?_ !X]
MI+J6-R)?M)^9/'HYY7V6'8-L%@@(  5:DDT'J?7U]3]O5%W\O#YQ=7?&7K_N
MG9F^ME=V[ER61^078.8%=UKUC5;T@%-D:L4I4U&I#K )']#^3_41;QM99%10
M@I&#W,#Y4XDX..H+]L^;H>6H+J&<W<FJ^E6L5O)Q:1F%-*&H (&KABO5R_QJ
M^:VP/E#N#=.U]D;'[KVE4;1PM)G*FN[!ZVJ]GTR???L'[?R2MKN#QJM?FWT]
MD5U9/"=3.AQ7N-/\_4Z\O\P_OQ?!A@N5!-/[(BOGYCH4?D*;;$I(./5OK;9_
MY)O_ ,:]L;=%X0T?T!T@YU/U-J8?^7@_Y.C*21#PE5^MM0_WW^Q]Q>9? ?7U
M.]EF#QND]V!_QYN[@"3_ +@\CQ_U1CV_R_\ [GI_PX=$_-?_ "3)_D>@LZ0/
MAZKV)/\ 75@RA'^NW_$6]R7<MX=P_P!G43<N#P-NA^1_R5ZJ6_E7QC_9(OE.
M>/\ )^P/D#Q]/K1W_P!['L1[JM;N/Y$_\?ZCSD/_ ))5]_II/^K9_P _0Z?R
M;5D_V0#K]IKV7>G9Y(/'#9:#_C?^^O[)-[OJ7(Q_H8Z$'M#:TY? /_*3+_A8
M]6H@^9[$"Q!L>1_3_B3[)(9JIU*Y%)NLHBKH_P#/T%J1;F_XX_UOQ[=[9.D=
M9K;@>J._Y@WPNQM;UG\K/E)V]V;NOM//879.X*SH39N>B.-PG7].6I80*2C/
M-57QJW%:I"Z@S$DV/L2[#?>)+%#$A!8=ZY <4&/G7AZ>O4+>Z?)"W&V;E<WU
MP)11FM68*?HV4FC@T!J"-522P\B!CJRWXBQFH^*WQHGF/I_T)=? FW],/#^/
M9%OD&B23\O\ !U(O)S?4[?9?Z0]!3_,)^2^Y_CET#E\MLF)LIV]V'GJ#J'IK
M#A@3)F=Y*JQ,JKR6I%)"V^AL.;\+MGMUO'JWPJ:G[3_FZ1<_;_/M-E^A3QY1
MX, . 6S0$^0KQ^6?+I4?"?XV8[XO=+;>V U2F3WMD1#O7MK<M=)^_F]Q;H]>
M3KI+WOXT%H[6!O>U[DI;Z47,OAXTG*GU)Z5\E\O_ +ALA!4M,!28T K\S2@R
M>-/RQ3HFO;D2_*[^99U%T7!1+4]7?#3;%9VOOU$(%/4[CW'2I%BZ>YOJ!0Q*
M;_@'CCV<;=/^YK9IA_:.*MZ5X_YJ?GT#MYM1SQOUMMY_W%LL@YXD,@X4\B]?
MGI/6+^7Q7R?'WOSY<_!/.U,9H=L[JK^V>BY*U Y_N[NX!:J.._\ :HZLH_\
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M,N:3);YOM_'6/^X&AYJZK_"8?\H7XY/M5-/Z]71--0N3Z^7^ST;[!;=P&V:
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M7VU=;NTXH]N.%*$U'^#HOVKE*'8I3+#/.X)K7)_94FGY=._\Q60GX+_)\?\
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MQ@1;S5&Y]Y9=B!_RH4<<(_ZV>U,YI @^9/\ @'3MN,L?D!_AZN-^+^,DV_\
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M/\/]Y]^Z]U[R?X?[S[]U[KWD_P /]Y]^Z]U[R?X?[S[]U[KCY?\ !?\ DO\
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M^DM_H8Z+_P"?1=2?^@5A?_J3W[ZR;U?_ (WT7_N?;_\ ?4'_ #C@Z46U]G;
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M+W[2/ET]X/5;_P BOD5E-\Y>JZ6Z%JON92%H-^[[H3_DU/3J;2TE'-Q92?\
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MA.MPR>!/TC]W=9[#W[^_N39_WLX-CD%<8JK.D?T@!'^]_P!/9U8;Y+MWPO\
MY.@?NW)=GO']K#^7$=(3_9:.K/\ LY/_ $(ZK_KW[6_UQO\ ^CT1?ZT^W?\
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M<-7BO]Y*GV;Q<QRVO]H@_:1U'K>U6T0C]""0_:*CKO\ V6[JW^FY?_0CJO\
MHWVH_KA<?T/VGJO^M?MW_#/]Y_V>LG^RU=7?UW'_ .A'5_\ 1GNO]>+CT'[>
MGO\ 6EV[^G^SK'_LMG7%O/?=5O\ M?5?_%+>Z?UZN?G^WK7^M99^@Z[/QGZW
M'!.Z"/\ M?58_P"B?=XN=;KY_MZ\?:VS]!^P]=_[+=U?_J=R_P#H0U/_ $9[
MU_7R?Y?MZW_K6;=_PS]G^SUW_LMO5_\ 3<G_ *$-5_T9[=_KM-\OV]>_UK=N
M_P"&_P"\_P"SUU_LMW5_^IW+_P"A#4_]&>VOZ^3_ "_;U[_6LV[_ (9^S_9Z
MX?[+7UE_JMU?^?\ K/\ BGMW^O=S\_V]:_UJ[3^C_O/4R#X[=5P3---B:[+5
M9_2<UN*KR5*/]B>/\/::?FF>X-7'[2>E4/MAMR_VO[  /\W0S4--!BX*&CHJ
M+'TM)2-R<=R>?P3]/]]]?8?N=QFN).AMMEC]!!4_ZO\ #U,]L=+>O>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z[A_X%47^N?\ >Q[M;_Y>J3\?]7RZ
M&?V-N@UU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!_N'_@>/]]_3V&]X\_M_R='>
MV>72?]D?2WKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH\_
M]C_D+_B/?NO=>]J.O=>]^Z]U[W[KW7O?NO=>]^Z]UP3Z?['W=^/6X.!ZUH_D
M"B=0_P V0Y.4"FQ>8[)Z^S>FW_*)ONACI92/^0'/L>;9-V _,= ^\[)"//21
M^8K_ )NKS?'X?\]_P)_P]J>B[K#[]U[KWOW7NO>_=>ZZDC@E@\%;_E6.JO\
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M'#R*1].#[=^D'2873'@#GHT<<E/,?/ /O:7_ )=MS:W_ !L^T\J>!T\L]?\
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M(_Y.H_\ I!Z__P">MVG_ .A#1_\ %/;7]>++_E*3]H_S=:_<US_RC']G7?\
MI"Z]_P">MV)_Z$%)_P!&>_?UVLO^4F/KW[FN?^49O]7Y==_W]V!_SUFT_P#T
M):3_ *-]V_KM9?\ *6G37[ENO^44_P _\_6.;?\ L<VFAW=M.M(O8C<=(/\
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MNO>_=>Z][]U[K)(-1\?T%3Q;Z_7WZ+K9/U?35UIOW_07\LNA^SQ:GV_OQO\
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M_J'1;>WA@NO B@[*?Y.DEV#*_5V^=C=L;,OA-S3;EH\3F&H3QD:>OMS_ *S
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MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U(\'^U_\
M)O\ QOW[KW4?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U(\'^U_P#)O_&_?NO=1_?NO=>]^Z]U)\/%M7YO]/\
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M]#Q\DNEJ_P"0_P ?NW^B:;L'<G5*]O=>Y;K^/L;9#%<SB:;+HJ328YKRG6(
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M][_['V!8H?IU\&;K)^NJ&HZC^VNO=>]^Z]U[W[KW7-/K_L/=V\_RZW#T1O\
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M8>W4U2? I/\ @ZK$5B^)@/ET8C9WP-[5[&-+7_(SLD[4P )-7U;U<@G<:?\
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M;&PY_H#[Q2WK=QO5R]T%TDM734X^6>A]NMA-:706;R%/V?9T-(-Z?[BUJ?\
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M^S_/UU_PV[NW_GY^!_\ /&_MS_@1;O\ Y2(_]ZZU_P %,G_*.>NO^&W=V?\
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M3^9K\/:SO?9$7<77&,_B?;'7%'6T64PN.34<Y@(_UTWI'.1Q9.F,6NRW-[
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M^[>=-Q@_>]JUY9"BUH1Q+$YJ/D1QZPOY5YGE]L[^/8=[=6<H71AA8$&",TH
M2 I.?(^9&R[2.LM/1S159J:>KH3D*&OH#S5?Q6X_IS[ ;6KFG^?UZRDBGF!/
M^7RI^SK,87<<E>?]]_3WL2^'TB'^-=0]#?T_WGW2A]>E/@]<?>IC]1TW2G1
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M5V)68XXQ(Z8&[4&,C?U8^@-@-90-4\@6'L([EN@G&,GUZ$UIM[0'.!Y#_/\
M/'1RE^J_Z[?[U[*8>/2N3KG_ &_^0?\ B?=I^M)QZY>T_3O4?VHZ3]2/:?I1
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=1_:CI/U(]I^E'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4?VHZ3]2/:
M?I1U']J.D_4CVGZ4=>]^Z]U[W[KW7O?NO=>]^Z]UBU'_ %1_Y)'M[QCTWX?4
MG3_M'_)WOWU?^K/6_I>M=+_A0/N3$':7Q?V>:G5F5S?:^[31Z/TT$%-%1+S?
MF\L+_P"V]Y,_=^-S:O=NW$U/Y 4ZA#W;07=M#Z54?::,?\O5T7Q+QU9A_B=\
M;\-D:-:7)XWX]]7X[*%KW"3XF)U'^L1S_L?<'\WS%K^\8^3$?L4#J4]DA$%M
M##7BIZ,9=K_K^GU]'L-0J@L^CPP0ZO\ 5_GZXD>>W^O?^M[_ .V]WFX'IL=<
M/:+I_KWOW7NO>_=>Z][]U[KWOW7NH_M1TGZ<C^P2/KP#S_OOI[<C\8]:N*>?
M7.G0:L?8<!K'_D(^]6;S6\G3NX0AK?K4]_DQUM+LS^81W3M?=44=%N#-[![=
MV_AZ64Z=-9MG<*9&H'^P6!_]C[RS]VGDW/EV)EXD ?L6O6/_ "(I&\L9OXE/
MY588_P!ZZVOY)?Q?_6/T^GX]XHP3300]9"WP#'K&35?=_7_BE_Z?7VQ+)^CT
MT(!7'4'WKIOJ1[3]*.O>_=>Z][]U[KWOW7NO>_=>ZY>C_:O]X]J/ ZW4]<?:
M?K77O?NO=>]^Z]U[W[KW7O?NO=1_:CI/U(]I^E'7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UF
MD77_ *Y(:WTM;CZ^WHW\(]4GG^GZ]':]@/\ 7N1_O%_:EKN'P>WJLJG_ $#J
MM+^85\ -I_,G:=-F<''1[9[OV?1)3;)W'4G529BE U?W?SNA"%HQS:Y_9OI-
MS;V,.3.8+GEV>C81Z@5Q^9_S^74*>[GM5:>XML$7-Q"0U1FG F/T*L,$<"/G
M0BE?X:_-[>WQ(W96?%SY-XW<V+VOM?+G#K/FQ]]/LJM+<P*"#]QM_4+P>#ZV
MU#DW,N[M;KN@_>%N"%)IX)R5/\\?ZAUB]R-SG?\ )4Z[#OK R1HI,HH%<$GY
M#AD#SQ1LY.QUB,QC\Y04^2PU31Y&AR-&U91U='D3D::IILEP1 #8C\?[U[ 8
MB\#XL_G6O62,ET;[$/\ @H1TY7_'&K5:_P#L;_Z_U_WU_;7B?Z'_ *N/6OI\
M?4?GU"]N];ZF:6MINO\ 7W31_HW6O!ZK1^9_P5_TZYD]W=&YFDV+\A<-2!9,
MY56QV+W53XTV--F..+F_@JOH2/P3<"79-XI6.3^?D?7[?GP/GU%/N)[:'FS3
M?V)TS*10C/CKDZ&]5S]JDU4C(-3N(W[6XO=%1U]W!@:SJWMC'VHJK;.<&FGJ
MS;_@3C9"1&#]/][%[W]B@3I>)IA%"/+K'*]VRXY?N ;LT)X9P?6F/VBGY="D
MWK_9-[?2WTY_WGV[X7@_J]%M?K,=<O>^J]1_:?I1U[W[KW4O0?\ #VHZ2:QU
MP6UN+6M^?=/['J]*]89GBIX3557V=-14_P#P+JZS_<?3^]^%X^3T]4+_ *L=
M!OMC*=C][;GJ.NOB[MEM\9B  9OL&I4T."PEAS+]VQT*!8W)M[H\XVY:R"I]
M?(?/Y='7+W*DW-,S06K8'GQS^7$_ZCU<_P#$CX1[.^,%%5[FKZ^+L?N?<]$W
M][^T,V;Q)?\ Y1:$FWVU"?RW'TMP#;V"=TW9KC]/S/%O\@_S]9.<F\CV_+BZ
M5J[^=<L?]7IP'IYD^#R.OX7_ &/LC1/+H=SP4SUU(=+BP_LBW-OR?:D3^'U4
M+]-TW^TO5^O>_=>Z][]U[KWOW7NO>U'7NO>T_7N@E[N[TZ]^/VQ,MV;VIE7P
M>"QC'@$+49&IM^S34$1_SE4O-V/T_P!N?9SMED;EJ#]GF3Z#Y]$^\\RP<NVY
MN)R H%23@*/.O6O%B\%\A?YN_P BA11TB;1ZFVTFJNJ6!R-!LG"5Y-R?^=CN
MG("_ ]3$'Z4]RHAWJ_3EB'Q?&*N//\)7_.:?F?LZQ]V38[KWRW+5(JM9TJJF
MFN&2G^V%:-3T4>NK.UATCTAUQ\?.L-O=5=8T'\ VEMFCCGIJ)V JJFK3BLJ*
MLV%JJJ_3.O\ 9%K"W @C?M].^2"Y<8'YDGS/Y]9Z\J<LP<JV7T-D *4  %%4
M#@!]GET+R6U-4_BYL?\ 6O\ \B^GLIM_[/\ U?+H1P@> >L'MKJW7O?NO=>]
M^Z]U']J.D_4CVGZ4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW14?EA\QNIOB)M;;^9[%.YMU;@WWFY=M]6
M]:["V^NXMQ9[(1G2U/1T[J%CB#Z5']IM7I!/!%FP\M76])K!.> '$TZ(=TWJ
M&U-%Q3))X#]G1*,E_-3W?UQ1)N;Y&?R]_EAT+U3-D'HJOM6I^RWI%1KE1856
M6I:18JRA4\$ 3@D#T@_D52<B*^8[J"1?4S!OVA23T10<SS/B2)U/I0?Y"?3J
MU_:.\MO=A[5VYOK8.Y*7=.S]SX6BRFVL]BHO'!44]<S*TD:'E6#*W!%Q^;'W
M'=_M<ME<4)J#D$="ZTO/KX3+$*$&A'^KCTK^/Z'_ &__ !KV@AD-STO\#3Z]
M1O=.J]>]^Z]U[W[KW4KD'[:P^GU_WW_%??C^OUOHIW;?RMV9T_WY\<?CUN';
MVZLMN/Y,5>6I=K;@PL%)/B\0,+2"!CD+?J*OJ9K$\6-_JI%>U[&M[%<2L#5J
MTIY4'0;W#<S$\,8./0USY]&JMX?\GYYX^O\ L/\ B/88-I-!T>5U= !MCO*'
M=G>_9G1-/UMVC@)NJMHX/=L?:^<V\M!MK-_WB\9-/@LJ%#5<\7D!G8L2^B3@
M<^SB]V/1 9H0<"M3Y]%D.Y>/*(R1DTIYCCQ_9_L]&%\WTLM[_P"/LG_W!_MN
MCL#5PZAF]P +<WY_V/\ QOV[XWU/3'#(ZQ>]=5Z][]U[KWOW7NO>_=>Z<//_
M +1_R=_QKVGZ4=1_!_M?_)O_ !OVHZ3]!YV=V%B.J^LNP>V-PT5548OKW9.Y
M=YYZBVX3'4U<.UZ5:I?M'L=,MSR3>UC>_P!/:_:]K&\7A0\%&K[:9Z]N.XFQ
MA"BF30?*N,])/XZ]Y;7^1_1/6O>>SL/F,%@NQ]IG<V*VYN2&D3)TU*F0,<C5
M;1?JB+ D#@@ $\$$O;WM2[-=K$_ BHKQZ0[?N)O8C)7(IGRR*]#?[(NC;J/[
M4=)^I'M/THZ][]U[J3'_ ,"*#_@G_%/:ZVX=);C_ "=#/[&71#U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=!YN7_ (NK?]JX_P"]GV&]ZX_ZO0='6U_Y>DE[(^EW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U']J.D_
M4CVGZ4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=1_:CI/U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U(]I^E'7 7N>;\_7_ %_>O&\#JC4Z(/\ *'^7-T=\EZFMWE Z=5]M5'KR
M&\=I8PM1Y-B&).3QK$&H9C;_ "D,)ORP/U]B"UW[P,G!]?\ /T5R[8DXH.Y?
MX2<C[#_J^756N1_EU_/_ *+JJJIZ3W>VX<=3$,9.L>QI]LM]"?5B,BT3<<_V
M"/Z&WLYLM]CF\_R!_P G2&;;=%- _P!Z%?YY'3+5]X_S2^F@/[[; WW7T%*+
M?>;NZ:I]STP_UJRCA/T_X/[,QNUN<1Y'V#I+]#*G C\C_L]/6T/YL6]<;7_P
M_MCI_ 5C$G[S^[=?6;:J/_.?(-(+C_@OM0LD$OQ*/RQ_AZ2/#+^!B/MR/Y4Z
ML1Z;^8?0?>$M+CMN[W?!;QJCI_N/OM_[J9/@V'V4KDT-83_0Z3[VBLW Y]#C
M_8Z3!G/$5'J,_M\^C42TZPGP3D_<4IL;W]N4F'3M:Y%/Y=8_:?JO7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]UZXBY"6_Y!_I[MXOV=7\$^G2 [*[1V#TYMQ-X]E[
MJPVSL._&.2ICUU55?G51T=OO*L6_)('^/M5I4"K&G^'\AQZLR,IHH)/\A^?5
M/O:W\PSNGNG<)ZO^*^U,UM]MQ%,=1Y"@H3N+>&3M:RTRJ"F+IC_J(P/Z7M[9
MDNHK3M44'KQ)ZM';2.-0-:?DH_S_ )]+[J3^45V]V//_ 'Q^279T.R),AKK*
MS 4%8=^9SCZFLKIR*.B!O]6DF-_[/L-;ES 8\UZ-+;:UEPXK3SX#]E*]6==4
M?R\/B!T]54M7B^LH=[YZ :O[V=DY--^S _T%-9<8?^0J(^R2?>Y9N _R]&=M
MM:IQ-!Z 4_V>CPQQBEIZ2CA!I*>EM]C0X]?\DI=-_P!5Q<CD_7^I_K[*_$+]
M&?TXM\GS\_7^73?[>Z3=>]^Z]U[W[KW7O?NO=>]^Z]U(]I^E'4?VHZ3]>]^Z
M]U(]I^E'4?VHZ3]2/:?I1U']J.D_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=2/:?I1URO2'\W_ ,38
M?GVHA_7_ +;I@XX=<ZB:&@H*W)5E=CL1CZ6_W];7C^$TAMQP/Z?[Q_L?:BVV
MZYN\Q4E^T]:N+^WMZ#S_ &]!6_=_2$"^*3O;IBFJ#?D=KXG_ (FHX]G/]6[_
M /WP_P#O(_S]%_[XC'^C+_O/^QUR_P!-_1/_ #_?I;_T;&*_Z_\ O7]5K_\
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M#^1X?X?3JJ3?/\NKY*=4R&HZ#WYB>X=J4O\ P&V;V7;'92GOQX8\BQ%K?X-
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M7PF6*J>%0@U/'A^W(]1UJ]Y>^OVL"*%\2>,,4[JUIQXXK_Q75DFS/YK'PO\
M]EJH.ZJWO/:5#D,)L5:W+=<5.1;';CAS=!3'RXB/" ?=,[58$0E\FFWUMS8*
M7WMU>W&Z^'X"T K%/7N!]*8-?]6>A+'S59[=9&L^*Y)^&E?7_)QKY=5\?,SO
MS=_:/0_\M+YI=O\ 5N3Z<VWM7Y28K>N]\!]Y5;F3%8')2QKCLK5AH?.#6T=/
M+8']04,O#  7<J;==6,E[MMM(1(L:J:Y+ @T8]![>[Z/=(H;N;/?CRH:%:?M
M/Y?ET)G\X+YL_&WLKX6;PZNZE[7VIVOO3L.7:^X::BV#D:;<8Q>&PN5@JZ[*
M9Z:D2./%TRO8".90WF)<BQX*_;[EB?:[]UE4*6 II-< US3AT[S3O]K>V>N.
M?2 #4G'%:5%?\/H.F#YY=5[.[X^0/\H3J#>\-?+M#?6S<AB-Q4]#7"BGFI\5
MB,?*U.*HW"M4&(^8VXB/]>2=<MWK;>NX7"@ETU>&/6B T_S])]Z2&]ELXL=[
M'_+T,_QUS-5_+J^6-1\'M[91T^+_ ,ALMD-^_"K=>?KK)B,EEFT9+8SS*S!=
M<AM3>H6;1*% JV!(=_6+FZR^M.+@5,OR/$K7Y>6?Y\#7;U_JZ_TJT$4@I$H'
MD!Q _F,<,<!TL/CP8U_G)?S A'.+4'0?4PEI1_QS6GH]'^M;CVYN,<<NRVT7
M^B^,*=>$)MKV6G#P_P#*_6'^1Z\%5\3NV@LL4L=+\MN]'M&WX/C_ -['^/\
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MY89/A(VC_-?[,-W%;G^N7I>/]X]DGN!=R2;E%XG#0YK^?1ERC %M+FG^_/\
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MD5-7V   8^=3\SU==M;;>V-D;:@VGLO X39NUJ"C^TPN(PM <=3T[$?5F?\
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M^QZ<@@^FZ]*&:F--/<D\_3^O'^\6_K[?AN/I>O&7Z?KM"12B <&ZGC_#^O\
MA[1/+X$WZGX^MPC4/T.L/EO?_'\?Z_\ L/>XH_ FZ\9]0_U?YNI''^/^W'_%
M/=M9N/T:=._3TSU@8^?GZ'_BGT]T>'PNF9O\:SUCNW^I_P!Y]V\$=5\/J1R?
MQ^"#S[O:0?3]7,)ZX<V_Q_J>/K_OA[U_8?V/5SGCUAY)_P!\/I_M_P"ON_\
MN/TSBG4A([?3@@\7_P!N/=7_ $OT.K3'ZK/^K_5CJ/J'^J'_ "2?=O!ZI1>I
MH)LG/X<@?[$^[I-#I\'I1.#X /\ JX]>8$W'X_UOI?\ WC_BGM.L?T<O7H9_
MJQUCYO\ I_QY/Y]J+1/I^FC!7J,?IS_2X(_WW^M[WX/T_5%H<=>_-^;?UO\
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M7;[=0&]04!O2?978VE;RLEN!_2P0/EZ=&M[)JBH92V/AH03\^'0U9?M+JK9
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MO=>\G^'^\^_=>Z]Y/\/]Y]^Z]TXQS?Y71?FRCC^EB?\ B/>[<9K\^D]S\/\
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M=_M38[7!#P.H"A%/QBG"O1H_BIC=[?$GY_5V#^9DNV]]=T?,78&(R?5'R8K
M:>F&1I:>V2V%3M+9:"G<G32E0#,12A1H<>R7G"RL=YVX-M_8T,SMI&!4<?\
M8]?\"KER2XVNY@.XG$F(FI_DR<<?,\<XJ3,?+ -_P[#_ "SXJAB:J'8W=@>G
M/'Z8:L_TX_I]?Q[)^7+O_D/79^"CR_X.EF^I7?+3[/\ H'IGZTQ=#5?SRODK
M72QL:_#_ !!ZYJ</6BQ^W>N;!"1K< V5V%O\?]?W>=OH.5H5\7@RBI]-0Z=L
MWU\P30^I!/SS)_FZP?->!4_F@?RMJE M-DZVI[=I)F^G_ 6%K7^GY+?[#VCY
M,N9+C8)[;_0QX@_XST_O4@V[=8S\AUS^#24G_#CO\V6$!#6G>O75;1TI:P(J
M4>UB?K^H?[R?;G--Q+<;=:QI_9QK4_D.F^7I!;;K=F7S_P &@4ZP;XS,%;_/
M7Z8CI*R"HKL;\+=Q15V.HK:Z9JRMJ2R#D\@/?ZC_ %A[,=JBT<NSCS\9L?:X
M_P _2>>D_,$%?]]DYX<3_FZY_!3'TE3_ #(_YL^9FIO]R$6[M@48JOX=KJ13
M2&I^XB@!/I9M"CVFYSNB-EL(X='Q1C\M)X=6Y9@IN]X3Y_S(44Z]T_C:2;^>
M%\OJR:FI158CXO\ 7CXVK)M/3/738Y)V!M^H!W'^Q]M;W+-#L$<8_LZ(/RJ.
ME&SP0C>93Q)(_/+_ ,NINYH"G\];J(%B[U'PPW&?N^.2:W(>O_8^_;?,6Y=G
MCBE_4J1X/H=9Q_EZ;N<;Q"2,5/\ S[_AZ"WKCNWY+]V]J?)4_P M[H7XR]8=
M;Q]H5^UNS>\^V&FQU9NW<N%8P354>)QK "[/Y/53L%U:F8:B/9E=[3:V<=H=
MYDNA2,JSQ'#  :?B _GFIXTZ:M]VNKVZG^E-N5'PB6I(^1IQ_;Y<.DG\3L=W
MGA_YS62QGR2[)ZW[5[6IOB%5+G*_K7")MS'XN,5L'VM (_%!*M4!IOI2_J^M
M[^UV]6]NO+Q%G&6B\45$HHX&L?[[[:^?2"SCE.^5DJ!X8I_/.2>/^3H7/Y80
MVU3_ "G_ )KJP1XP[Y;Y-O35(8:IH,#]S.&/TM]F*G66'^"_4"WLEY]MB=GL
M8?[)/"_,"F/\O1MRM'"=SO3QX?M\-?\ BQT^=KLDO\\'XIKM26@.ZX?B]V@W
M;T5/RO\ #GCR0Q@R-KV8TI @_IZ"?:;:96/+,L<_'4^K[*FG3UW+-^\X?!X$
MX_,I_L]7'1DV0 #ZGZ_['W$+P]2!+G'3A[8ZUU[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW6#\#_7/_$>W(^K#@>M6[^>[4C<?RH^''7N6D%-LJ7;N
M&EFJ9?\ ,7WQN:.ER#BW](%4'_@O^'O*/V141VNY,GQBW%?S('4-<[6_[SNK
M;[*_;11_GZV@*;&T^WJ:EV_AJ3'T^(P-#C*3!T./(O34V+L883>Y)/'YX']?
M>.-W>37<-'&!(*?X.I:LK/Z>T)AXFM?M/6KM\K:2FZK_ )\_0&<V&E+@\SO/
M>O1&2W?0T1_A@F??M.,=F%YOI&1IW?SW_P!6;^\CN7KB3<>5;I'[BE0:?.HZ
M@W?YQ#S+:@G.@ 5XT6I'["!^P=!;\Z.R=Z=/?SH\IV9UYU_/VCO;:;;%K=M;
M'PT=3+-DIZO;34R1!:2[$QTQ (%S<?GFYYRSMRS\MA97TQ!6\0#!-5IY=)=Y
MOIHMX"P\"I/_ !IORZ?>]?YH_P I_F1@=W_"C;_Q@PG6O8G;-5%LW/8_,[O<
MY14K)5F:@=,ZN/IJ.JGD '^<6][1"]K(>7^0K'E^4[Q!)XR1C30OY'CQ &?^
M*S3I=?\ .5WNC?1&W; )U4733U[22?\ 5\^K"J;XK9WX=?R;OD5U%O')8[([
MRJM@=C;VWI4XEAE**ER>XYJ.%,=%.A*^6GAC\+2?2]P"18F.OZQ_UCY@@GCC
M\$A'),?F2.'0JFVD66U30C(X"OID^?SX=:XVU.[/D!N;XE;@^)75V&W">K]H
MYW>_?/>59MA6KC44"_9Q1/D67BGP6.*(?#PM54,&:[01Z<B+_E?;=NW".YN)
M%\9J*$'I7_!U$%ONE\]C]);C]$+I#&F*U.*^9K3U/EY];/G\E_,?'_)_#G$Q
M='8.BPVZZ/,1T?>M-D*TUU>^X_5>IK)+F])44?D&.LJTZQ:PX+!F../NS;WT
M&Z2+.!].U!!ZB.F2?EZ?LX]3%[<RV]U9+/"1^C_:BOIQ'VCS_;PIT@OYZO=[
M=;?$W!=-XFLFAW)\BMW/3Y'&8ZT<G\%V:QR.4# >K54RM04X)%K1GZ\V?]G.
M7VW6]GFN?@@;2/L&3_D'5/<K<A]%X0_T84'VL/\ ,#U7K\]_BEM+K#^6[\.<
MQL;<.VZCLSH)8:7=\& S]+DZD3]M$Y2O\@A/'\+W'X(OH?K]?I[D#EG<9]WW
M::"7^R;''-5X_E7H)\TV,.V6<4\ IYKC!I@?MX];!7QN^3^T>VOA[L+Y2;KW
M)2X+;]3UG)N'LC<>2B\\&-RFT:5:'/O5*+EKU-,A4<DZKJ+DCW!7,G+I@W>2
MU@--3!B> %./[.I1V/?8I]N^KE%?0?(Y'^$UZX]?_P P7X1]F;XVQLK8ORCV
M)NK=FYZY*#:>W,+E*N&6JJIO2(%=H18,QM_7FPO[?7DO==I47$L19#P4$5/5
M#S/MVYC]&8?,@@XZI8_D'1'<'>GS=W=D*AY-SR56!6IR"^JHD_B6Z,Q63BQ^
MNJ6B6_\ KW_P]RQ[JVTMIM]N@A).I?/U+?ZOMZ WM_?K=7MP <:F_D*4_GTZ
M_!^=]H?SL_FUM_;5/XL974'<SOC*,@@".MH:]%%[7TU<DEO]A_K>W-^66?EF
MW$\7%5J/M+X_,X_/IG9YA%NT_@G(J?Y#/\Z]0O\ A/U'397LSYJ[PKM,N>FS
M^Q: M5V\_P!OG,KFZB8K_K!!?CF_MGWCB^FMK*R,-86C /[8SU[V^B%S>W)K
MG6W\A_L]3?Y>M7+M3^<Q\W=OX.&GCP,_^E=ZVGHC:F\0S]#4J!>PTBKECM[O
MSZC7'*T#2 >9X>=1_GZIRE<30[]<6Y](_P":MT_?S%OY>?170WQG^:GR;@7-
M[^[L[(W;0;G.[-W9/[E=MTF]-V49%%@Z0 -$[1AZ=JIR9;6"A?5=+[9\X37]
MY;6%I)X4$: U/$5 H!_GZ5<Z['%9[7<2OPU-7B22%(K7R^P?;GJQK^4NJ)_+
MF^+LG(7^#;QU?7]0W#76/^P_XCW'/NCX4^YW7A\:BO\ O1Z&7)%1:P?8O_'!
MU8M_:/UL#<_BW^^X]QQ)-,\/Z/0Y@7ZDYZF>VND_7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TV:!_C[=T#JF@=3_'_
M (_[Q[UXG2C0.LGMOIKIO]J.O=3=8_Q]I^O=<_?NO=-_M1U[IP]I^O=>]^Z]
MU[W[KW7O?NO=>]^Z]U']J.E'7=T_VO\ VWMOP%_U5Z9_1^7[?]GKUU_H_P#O
M'_%?>M$/6_"_U5_V>N>C_?:O^->[>%#_ *AUK5_JSUC\B_@-;_"U_P#>/=X?
M!/6B*=>_RG_FY[<_3ZWGY?RZD>T?5>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KK_-_P!?K_K_ %]^Z]UW[]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[K#/^@?\&'^]'WN/XCT]-QZJWZIZ&[@P
MO\USY2?(G+;.K*#I+?G0VQMC;3WF<E0^"MK,1!AUGIQ2DFN.MH'XM<6Y)N+R
MH^\17^R0[6?[1G5ZU\P17^?0$CVF2VOIKP&I!&/2A<_Y1T'G77Q,[&^5WR8[
M/^2?SKZSCP>TL%A<EU3\7?C]G,I19Z"/ 9>F)RN>JC0M]LN2RB,[Z@ *>9RU
ME")[,#S1!R]:1QV<@U@:Y&)KVGBQIZ])8]EFW.[\6X-<GPF'&N,?;_DIZGI\
M^)/QQ[MZRVO\@_@KW?M.NWQ\2(L#N_&]#][#/X^.=MJ[VL$VS6T)U92*KQ9J
MQ)3-P8Y RV:,CVDW'>UDNH-U3,E"%-174<4/^#IZRV]X8)=O7$8(JF<$5_U?
M,4\^@DZ@QO\ --^$6RXOCELCX]]>?+CK;:[9#'].=GOV10]>U--A:GUTE)GJ
M"LDC*QP7)T2J-#E@)#;@ZDW';.89I;R681E10'6%('H1Y_ZL]%XM[W:Z6D4)
M*8J""?YT/[1Q].C-=#]%_+S%= ?*"I^3O:E1V;W?WW@-]5F*ZOQ69$VW]I25
MV+RD&/PN$UN425FN)4C IE10+M>_L.;AO%B+I1;MJ\,' -0N*4%?V?[/1M;6
M$GAR^(*"0BII0G(.?]5?RQT$'2OP%RG9'\J_K'XD_(/;U3USV5A:',9';]7_
M !"GR]7M'<-/DLG7X/(Q5&.8^.$(TBR!B?K?BP(-9^<UCW9[F&:@<=^1VL"2
M#C[>D-KR^(K#PERP &/, *#Q'EBG0<=\]8_.OY+_ ,LMNG.UNG:^7Y3[2[%Z
MUH:J&AW=B6AW/B]FUK(NZ2WGT1_<PR7J(=?JF'D6X+!-[?N]AM-X;D >'W5-
M10T/'_./^*Z;OK.ZO++P9&_5(/D<$TQ_JX<.DY_,4Z?^=??G;O5?7.W?C%4]
MP?#;K;&;'W!N38F"[8Q77\F],R:- ]-FZJ0BI%'CF#QB,4=D G=+!K^SCE;<
M-FM8IYVF'U$N4?4JE/D?D/3I#OT>YWD]O#X(%LM=5=1(\A04I0\3G)\O4QNT
MOD;_ #*Z*39VV&_EA[1VWM.CJ]M[>6?'_(K"14V,QD0$.JDHHY"L?\-IN3$5
M(4\LOT]D6Y[3LT*2SBX#S^HE4T'V4\O+_-T96E]?L?!AC/@9_ :_X.D5W1TG
M\ROC]\X^U?EQ\3NL]G?(_8_R V1MK;?8O6^4WK2[+KH*S:X BGBGJ7C<1ZX=
M2L%(L;6N 0LV_?-HW[;H]LNI5(B5 RE]![.%">J75GN-G<_5VU5I6F">-?E\
MZ=)[8?Q_^<V[OYBWQH^77R"V%M3#;=H.NNR-J9C;'7FX:/<.*V1C:BCECQ.-
MJJUY9:S-9'+U=6*B62B>2)O)Z2!Z5I?\P[3MNV/8V4JBA84D(-.!%?,DGCCR
M].J6FW[A/?F[E)X"F*5RM3P%*!?]7'HPOQRZ([<V3_,6^=_<V[MFUV)ZM[;P
M75]-UQO-\G0(N5J,'''+4E8)&%1 "D4A)M=?[7/LEYGWRSFV2VM4F'BL(PYX
MU(%#\QGHXV_:?"N99O-JU'IQ_P _7+ =#=P47\V7L+Y)5NSI3TAF/BI@NOL?
MOU\C0"/^,4E9&XH!1W^[+^:-DT:=0-M1MP;7&ZPS<N1;:>,95./F&K]O5/H)
M?WMXM?TM5:9^?Y=9.S>B^W=P?S2OBO\ (##;+GR'3_7/Q_['V%O'=_W]"R4&
M3RDV86FHC1@BLE*//& -))Y_ ]TVO?+:VVB:W\_$=3PQ4^GY]>W':?'OX9:_
MI*:@<*_!_FZ*WM+IWY[?"'Y$?*+<W0GQUV1\LNN_DGV5-V31;PD[,H>N\]B)
M,L\DBT%;-62QRQ0_OVD!32S*"&'L1MO.V<WV5K#/<M$+-]?Q!&!IP-1GAZ?X
M>BJ+;KK:Y9_#)D,P&*$C  /#'EQ\O3SZE]+]#_/^I_F0=2?+?Y)[.VIDMOYO
MKK>VP,KCNM-P+EL9L3&/$\>+Q\OW;R5.7JZNJD6HDG@>75K+:KW MO/,>VP[
M:+*SF3)*@.V)*4IQR:TR?\G2;;MKN7OFNY*^1X?,$_ZC3[//H.NA>I?YDOQ2
M[(^5G:O7/1FV>U]D]P_(C?.6FZ8W5OV@V?7UE/52L^)W;A<KY*JFTR%S25-%
M.S!@Y4H?U(LWC==BYRBBAGE ,:J\:HX4T/!F/S!I3KVW6=_M,L\Q.9@,T) -
M "/Y _Y?+HW/Q.^-/R*S7R-WA\Z/F5!L_:W;5;LD=4=4]1;1R2[BQ^R\$+2L
MU75QM(LF4FB)6--;,S.Q>QL/8/YIYAM;6PCVRVH(R-$RC(1,G/S)Z/M@VN6Y
MN_JKFISJJ<:C\JTQPJ:>GYVM$CZ-8?7Z?X?7GZWO;C_6]QKIT=#80"#!ZD>V
M.F^O>_=>Z][]U[KWOW7NL<'_  (H/^"C_>O:RTX_GTENN _U>G0V>QYT0]>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW08Y_\ XNS?]JL?[V/81WG_ "G_ "]'NW</
MV_X>DSY/\/\ >?9;TKZQ^_=>ZR>3_#_>??NO=8_?NO=9/)_A_O/OW7NL?OW7
MNO>_=>Z][]U[K)Y/\/\ >??NO=8_?NO=9/)_A_O/OW7NO>3_  _WGW[KW6/W
M[KW63R?X?[S[]U[KWD_P_P!Y]^Z]U[R?X?[S[]U[K'[]U[KWOW7NO>_=>ZR>
M3_#_ 'GW[KW6/W[KW7O?NO=9/)_A_O/OW7NO>3_#_>??NO=8_?NO=9/)_A_O
M/OW7NL?OW7NO>_=>Z][]U[K)Y/\ #_>??NO=8_?NO=>]^Z]UD\G^'^\^_=>Z
MQ^_=>Z][]U[KWOW7NO>_=>ZR>3_#_>??NO=8_?NO=>]^Z]U[W[KW7!_I_L?=
M'X=4?ATY^VNK]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2;S\5L)N/BU]F;H-A_U
M 57M59?VO3%QBGVC_#UI ?\ "0_+9K.=K_S.XL[F<SEUHXMFP4PSF=GR2Q:<
MQG2-(J692X-_42";GB[>Q==PZU/V=%$$NB0?Z;_/TA_^$B6Y-R9_YA?S(1F-
MPY[."BV+M),='GMS5F02(R;ORJJ&%3(ZO_CJYN=5PQ)"7=H=4!'H/\W3T,NF
M4?-OF?XNM]=?['_(7L*VW^K^?1SY=>D_'^Q]^CZ<?AUJ+_S8_B=_-K_F4_S&
MMF_%#9V6[4^-/\LC$8ZCQ^<[LVIDD@Q67>BQAR><RV5HJ'+#(Y*J%8PQN(I*
MT1TUHRZNG[I FM+Y+&W%2:>F>B2:*2:0G!:GJ*_9_GI]OIU5_P!=[+^67\A+
M^<_\1_A_L/Y5;S^2GQ_^4^8ZV7<VP]QS5]%'7T'8>5GPKFHP@J\C'0YO'SK]
MS055-(69_2U@9 5DJ0WT6OB"*])5\2-LX.0*FM"/]7RZN-_FP?R[_P":]_,M
M^;NSNF<1VU_LM7\L3;^%I1F=X[$WZ7J*JNQ./%5D<GF=MQ5.-GR&3ER@CQ]!
M"62BB\9G#J6DD]H=MGM[>D(-,_;CUX]*+CQ)%U4JQ\O,GTX</S^?577\IK=_
MR1_ET_ST=P?RJ=C?*/</R[^,V2H=TT&^(TRM;E:'%24> .<_B20(^03;^<P5
M>O@KG@J&IR7,9=B59C.]C%./F,C'^JG^?IFWFD0U(H:5H<G\_MX?GZ];\$?Y
M_P!A[!$G0@/ =5A]O_S>/Y?'0?R,W=\5>[.]\7UQW5LS;$V_]Z8C-[-R=#BZ
M+')@CG26S<4;XYW..6..X<W9@%O]&.#L[*:5/IPZ0+?1N*J 1]N:5^S_ "]%
MF^+O_"B'^5M\L^]L;\?=@=C]@;.WSGLBF!Z_K.V^O_\ 1SB-P5$K2>!,561U
M4S@U>A13&N%&UR $34?=KC:3&.VM/\'7OK8S4FAI]N?VC_B^CD?)3^9U\*OA
MWWAU7\;_ )%]LT_6O;/;&W8=S[$I\MM/*SXTT=765>.CR=;E!%]KC49<;->\
MJZ>0?J1[K:[<+CCP_EUI[]HQ5:'Y'CP_9_/H-O@;_.#^&/\ ,BW[W!UY\7\U
MV-EZOI"D.<W5N?>W7QV?A:JD%8])%D\9FHWD CE2-& K$I9"IOH*L/=9MO\
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M-B<IY=<LX;2K:5MIM[(-HYSDVR[N9^"D@X^7R/\ J_GT<7W*$=_:P1M1N ]
M.%!P/F.'SZ%7Y=_$W8_S%Z?HNMMT9_-;.S&"S6W=\=<]A;>B%1F<!F=OQJBY
M&B1=+-"ZJ!964WLWU"V1[#S(^T2273^9J".*D=.;IR_^\8H(0!1./D"/\XZ2
MV:^'E?O#O;XI_(3>'<^<SV^_B_L;+[:\;;"BQ])NZISE%)!)7U37"X^4E]+>
M,.QT\:6 'M7'SF%@E2*(DW%:"@H:T7/H/]0ITTW+HN+J)Z4$'SRM<_.IQTI]
MM_%+$[;^:78WS&@WKF9\KV3U-@.I:KKJLQE.N.IH=MM1P25#UP;7J'\.! T
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M/U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KAK'^/OW7NJM?G3_-O^*/\
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M:[-8^GJJ6I4-/IC=I%>D,@8E9"ROQ!Z ?9C_ )^/7HT>?@S-]M33]BXZ9/\
MA35B.Y]N?RR?Y/>WOD=1KB^\\%4UF![1I7SU-GEBRN$VMBZ:K+Y&E9XJUM*Q
M%JC6>;W);42ALBK,='H?\(ITY)^DQ/S4_P C7KG_ ,*>GOF_Y(XO?_C'6T?Q
M_J:C; ]N64FJ(?Z7_/UZ<49O^:C?Y.M^ZJ_X%2?\'C_WOV"9>'[>CV'R_/\
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MLIE-P4IR&+=]2M(E!6D@-]751?DD^[;A&7A(C^T=4CD"-4_+[>('5T?\E?\
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M?7D^RV%_'8_9_DZ,WA[ :4JP_FW6I#_PC&_YDA_,9_\ $X]/_P#NMS_M7O\
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MVS-_N-U9/C_VO^0=(G_A48H7^;=_*<:/];X+K8D_XCM6HM[:MD\*.?\ VW^
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MY=WS)H=O5^9ZNZFW9EMM;_FH4UPT-?'F\/GZ!G5213OF%AR$(:7DR0HBVU$
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MF;,[9QV8RTCR1"=12PZD>N<K]%IG!/\ AS93+MW^KRZV;M@*T/\ (_X":='
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M.MD8Q%RHE7QB4!:G;X'_ ,O^JG^4^G7DNI(L*3C@<T\OGPX>0/GT[;I^7?\
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MGE_Q?1)MT0VC>H8;7</%J"WAFF<5J*@-0<.)&?6G0F9_>^X_E_\ -7Y7]/\
M>7S7WM\0NN/C]O"FVSUSTYLS>,/7-3N7&1DQ/N&JRN1F2.I^X11(3(78^7T
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M ,6#_DZ8W*( Y( (\S3U]?M'05?)CMS^;C\Y.I-\_&3J#^7CN#X2P]X8S(;
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M$9KN?8F$R.T-N=C5=6T63Q>,KU9:J!8_\V\A5Y0"RD^O\>VEWJ:U LR/TP*
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MS!N^]PE)G5*^@_XOIZVV6SA_6))%?L_P4KT9L:KBWZ](T_[S_7_#^OL,=_\
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MZ9.EK8EC UFZZ0J*9HM6SZ-3]AX>G2-:LF?.G_'@/7/YYZW%:P_[E*\7(%V
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M &.A#\7^T_[S_P ;]WZ?T'J;;B_^T_2_XO\ U]Z\7]7Q>O?+R]>L?@'^J/\
MMO?O'/IU7KKWOKW430/\?=- ZIH'4SP#_5'_ &WNWCGTZOUDT#_'VQU[KH@
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UCC_/\
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M9<I'?GD+Q8"WN/+OGG>KE_JU"::4II%?V\>A%_5FT_L#$WV T7]G#H'/@_\
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MYD%)V'\@,)\;NZ_C'VW\2>T]\8NHRW6]'VLU%D*?,KCKS3"2>DIZ62BJ)"C
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M?BQTU\N^M7ZJ[GP8RV"CJ),IMC,[;RRXK.X+)T-@M?BJV0$Q32@69&X-[V+
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M3M2/0P-K*O% I>P8&U@#F[VV]NP))[P6I53X484* ?2I]/08Z#YW"VM))C#
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MXC'P0) M.K>,W0CCEBP))U+M>K9I5O)#/X0<:THY:BUX#_+T0?6%=UAEBB\
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MMG/U4_C2X%"1^P5Z,=NEW2W:",PIZMQ)S_M/EUF^3'QE^6F%^66SOG'\./\
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MQ^1S:PY^O^'T]N2-,_6O'^HZY<P'^G/^M[8_53K>+?\ U?\ %=</\R?R6O\
MZ_U'_%/]?VM_XQU3J)=8?^4UN?S]?K_KG_#VDTUZOX_3C[UTWU[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8X/\ @10?\%'^]>UEIQ_/I+=<!_J]
M.AL]CSHAZ][]U[KWOW7NO>_=>Z][]U[KWOW7N@MW/_Q=!_VK1_T+["N\?Y>C
MO;O\_33[(>EO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=8X/^!%!_P4?[U[66G'\^DMUP'^KTZ&SV/.B'
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#/=$%JHU']4:W^PX]A'=_[;_5Z='NWX
MZ2?LMZ5].'M/U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>ZX#]9_UO\ BGM^;K?EUZF_XN6._P"UB?\ H;VY:_VW[?\
M+TU/P_9T-?L>]!OKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#_>$>HT-4!R"%(_U
M_P#D?L.[W#7HSLAQ'27]AGHUZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J?A8_-DJ%N/TESS_ $]K]OAU
M34/KTU=&BG[.A9]CGH.=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2?S5/]WC*N,"
MQ*"W-^$'LHOH?J8*]*[4Z6Z#/R?X?[S["7A]"+6.LGMOIKKWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZPP?H/_!C_ +T/
M>Y/B'3T/'I8;5H0W^Y!C:^H  W^O_(_8GVB/(_U>1Z);Z?\ U?SZ7WL0=%?7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW05YVB^PRI!'^25I%Q?\D<_7Z_[[
M_8@C=+;];H^M+G4O37[+NE77"[_T'^^_V/M_P>MXZY^V.M=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8(*2IFJ#3 W_ $FWU_'M^SA^
MHZO?FG0PT=.E/2B* BP!"WYM<\^QO!;_ $_069B3U.]JNJ]>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=-F3QE/E*?[>HX L>#_O!_P]I9X/'].'5T<J>@LK
M8:NAJFI["]N/R"/K[!#VO0GM[K&.O/\ J/\ L/=).E-UUQ]M]).O>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K$(O,@M_O/^O[]%Y=;I0TZ$+ X
MO[.E^XJA:JY'U_I]/]B?8PV[;_ ->B>\NZXZ5?LXZ+NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[IDS&'ILM3+!.RBRV5C_OO^1>RZ6+ZG[.
MKH^CH.ZO'55%5!YS<-RI!N/S;D?['V%[^V\/H36MQ]5PZ:]8_P ?;'3FL=>L
M_P#4?[[_ &'O=.G/#/K_ "'^?KCK/^'OW@#UZ3=3?:;KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U'\_\
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M^*>_?2MU[ZKKEQ_0_P"W_P"->V]'^K_4>G/&ZY^3_#_>?>O#ZKK'7'0W]/\
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M +Q_T=[]X<'H/Y]>U_;_ "Z]]C1_\JD/^\?]'>_>'!Z#^?7M?V_RZ]]C1_\
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M .52'_>/^CO>O#@]!_/JVO[?Y=<OX?1_\JB_[9?^*^]^ W^JG5=9Z]_#Z/\
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M]X<'H/Y]>U_;_+KWV-'_ ,JD/^\?]'>_>'!Z#^?7M?V_RZ]]C1_\JD/^\?\
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MX<'H/Y]>U_;_ "ZY?P^C_P"51?\ ;+_Q7WOP&_U4ZKK/7'[&C_Y5(?\ >/\
MH[WKPX/0?SZMK^W^77OL:/\ Y5(?]X_Z.]^\.#T'\^O:_M_EU[[&C_Y5(?\
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M_M/U[KWOW7NG#VHZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U%IJD5 )
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M^T_7NG#VHZ]U[W[KW7O?NO=1_/\ [1_R=_QKVWXG7NI'MSKW3?[3]>ZD>?\
MVC_D[_C7MSQ.O=2/;G7NO>_=>Z][]U[KWOW7NH_G_P!H_P"3O^->V_$Z]U(]
MN=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH_G_ -H_Y._XU[;\3KW7O/\ [1_R
M=_QKW[Q.O=>\_P#M'_)W_&O?O$Z]UQIJD5 ) L1]1[L#7K9%.I7NW6NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;_:?KW7O?NO=.'M1U[KWOW7NO
M>_=>Z][]U[J/Y_\ :/\ D[_C7MOQ.O=2/;G7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NH_G_VC_D[_C7MOQ.O=>\_^T?\G?\ &O?O$Z]U']M]>Z</:CKW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U'\_^T?\G?\ &O;?B=>Z]Y_]H_Y._P"-
M>_>)U[KWG_VC_D[_ (U[]XG7NO>?_:/^3O\ C7OWB=>ZD>W.O=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TW^T_7NG#VHZ]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW01[^W]MOKG9NY=Z[TJL7A]K;'P>8WAN;,9",&DI*/:U.:FKJD T
MDN3JT@&YLUKMPWE74"?(9K]G57<Q-I'GC]N.M?;^4+_.=[3^??>&^^GN_.J>
MO>F?[R]81?([XFOL^2MQ[;JZ^R&;RF-GJL@<E6U?^YFCF:@,PI8TN/O"RDCV
MLEM? A,Q'EJ7YBM*_P#%?/I!9[E]7-X )4@Z7K0T:G 4-/+S/F/EULF_Q-/]
M1'_R4/:;0>EOBGHB?\Q?Y+;T^(_P>^2OR5ZXP.W=S;SZ@ZRS>\MO8?=2SRX:
MJJJ66*)XL@M(\=4=*2,RJ6 ) OP#:\*E@0!PX?M ^WIFYN!:H)2<9K3C0 G[
M.E-\'>]]U_)?X:_&KY";^Q&'PN\^[.B^LNS=QX/;*UT=)3UF[\33U]53XY*H
M&I2E*Z;+_6YNP-S0H8BH]0*_ZORZM%.+N-I!^$FG[?\ 9Z.MY_\ :/\ D[_C
M7MCQ.E'7O/\ [1_R=_QKW[Q.O=0ZC(BG(#*I_KS;_BOOVH];"UZKAV]\]ML[
MC_F+;V_EWXKKS<8W=UQT)MWOC>'85=4T9Q I-U5#TM#B:"D+-4R>@!9&\=.0
M2?19&9E0MU(P,@5)Q^7ETD-VRRB+R+%1]HX_G_+JQO\ B9_XYI_R7[3U^8_U
M?GTKH>N4M?\ :W6L4'@'TV(]Z)IUX"O7'^)G_CFG_)?O=?F/]7Y]>H>J7J/Y
M^]L5G\Z?-_RXWV?L1>EH/B&GR(.^3%7+N4YB@KZ*D^S,ID_A7\-M4: GAL5N
M-5V(91I_%\JU\_\ -TD^K7Q?ILUKP\J$D?;Y=74>T/2KJI3^<+_,"SG\N'XI
M4/=>R^O(.SNT=_\ :&S>A^J=JY"=L?C*K<'8=/4S4D^4<.L\U!!%0U;.H<:B
M!R+&ZN)/J%X5R !]O_%=([R;Z4>(30 $GAY>6<9_P]##\'-P?/W<'5^Y,C_,
M#V3T#L3LN+>*':F$^.^:R&<QYPDU##_Q<!DWF<9,5XJ/'J<J6*:@-*7V%JW
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M@G\3/_'-/^2_:>OS'^K\^E%#U[^)G_CFG_)?OU?F/]7Y]>H>O?Q,_P#'-/\
MDOWZOS'^K\^O4/7?WS_\Z^3_ &Z_\4]N4_U8_P _6NI7W">/[JQTVT6_WW^/
M'_$^VJ^?Y?Y>O=1/XF?^.:?\E^]U^8_U?GUNAZ]_$S_QS3_DOWZOS'^K\^O4
M/7OO1_1/^2_;NL])Z'J?Y_\ :/\ D[_C7MCQ.G^L/W\/^^O_ ,4]VJ?3KW7O
MOX?]]?\ XI[]4^G7NIWNW7NM;/\ G0?SD>Q?Y5_>'Q"PN)ZNV;V'TWVY7;KK
MNZJG)/6Y#<-)B=H5V,AE? &FG2G6I6.O>5WJ4E82( PL/;\*%E44Q3YUXTQ3
MHKO=S&W2$\#Y< . .:_ZO*F>KWNKNS-C=R[(VQV9U]N'';EV3OK;V-W?LK=F
M'K&J::IQ.>C>KIJDI);2Q"NK*1J4@AK$,OMA@ *@_/HTC<R'21PQ3'GU6'_*
M^^?_ &U\WMX_/?;O9>T=@;<Q_P 4_EONGH39,FR*6OITR>*PD4$S5N4^^DF9
MZZ)'1D:G$9N6!CL1=W2575_2I_*O^#I/!="[D:.I[4+?9W%?+YJ>/5T7G_VC
M_D[_ (U[3>)THZ)9\UOECLWX2_%?M_Y7[TV]N/>FV>E=LUV[,KM;;RP"MKCY
MEIXHX&K9(8TT.R78RV5?5I/'MZ- ":UQ^7RZTX:) PXMC_5GH5>B^TD[DZ/Z
MH[@FP(P$O9G6^TNP7PT=8M?]D=R4,61-.LM@95X4?3\F_-_>GB\ @4\@>/K0
M]6#ZXRX/ D</3%?Y]#]Y_P#:/^3O^->VO$ZUU[S_ .T?\G?\:]^\3KW4#^)G
M_CFG_)?NU?F/]7Y];H>O?Q,_\<T_Y+]^K\Q_J_/KU#UA>;SIIG %G  '^'MV
M'/'IFXP<=4__ ,N3YZ=H_+KOO^97U;OS:6S]OX#X7_* =$]=Y#:$%;!69/$M
M25O^59ULA/*\M:#2PR!J<1.9'D705T@TTT8 C@:8_P O6HIA,CO7XE+9^WRX
M=63=OR]GGK+=_P#H7_NH.TUVCE/]'8[ ^\_A'\8:B4XG^,_9>H41J2_D\?HU
M6_.OWY2:8I6GG^7^H5Z=>FKNK2N:?ZO\'14?Y=/S4QWS>^-&%[;K-M'97:>T
M=Q;EZF[]ZR1WDJMK[YZ\JQ0[DP161S)'&M8(7B4W*4Q:,MK4^[20"#' BH8>
MA''IFWNC<)XGD0"OS!'^K[>/#JR7W7I_JM_^8Q\Z-K_R^/B=V?\ )[=&VLAO
MF3;$&(PFVMCX[(M%5YC.[RR1H,1BD(#&GC:>9-4@_P WI(2[G5[O'"):U%?0
M?;TQ/<F%!)6@XDTX ?MZJ+V-_-3_ )C/Q^^07PUV=_,D^,?QPV1TM\Z=Q4W7
MG56^/CONG/2Y3:>X=TP4]1CL7NBGRM55+4D4AB$BT>D>9BPDU4_C%C$KK0$$
M'AI/ _ZATCMKN>61#-&5)%3JID54#\SJ_P!5<[1GG_VC_D[_ (U[3>)T9]%I
M^3?R$Z^^+?1W:'R#[:R$>*Z^ZDVMD-Y;DJW5698\4D8@A@6Q_?K9)!#?\$@&
MRB_MT(&8@^7_ !7\^JRS-;QJZY)-!]M/EZ<>J%MM_P S;^<5VCU,OS!ZJ_E=
M=5S_ !?R6!;L# ]>;U[QEQG:6;VL]/\ =19FAIU48^G@K:)340T3X\RD654=
M>2ZL,,AQ2GI7-/VC_!^71:MW.\>O1W8!/E7_ 'DC'#C^?1]\%_-]^+&X?Y:4
MO\SBH.XL%U#2;3R-5N+:,T*5&X*/<N"KUQLFU(X./+EAF7%- ^D  "=E6'6%
M9C4RL0> ].-?3I4;Q%A\;%:\:C33UKPIZFM/\/5=V1_F[?S1.G.IL/\ -[Y*
M_P M'9V!^#]8<-NW<,&P>T/XIV5LK:&XY"J;ES>&FT4M6BT[%ZBD6&F>-[B1
MZ4A#[?\ "#$'@..*5 /YGRZ3V][/(O>E>(!SI)'VJ*9^>//SZV'\%WKUAN3J
M3$]\8S>&(3IW/;1Q._J#?V4RU-C\<F)RM$:Y*PU4A!2,4Q"Z3=E;@@<GVV5*
MF@- <UP!_GZ7131W$?B$9K2F22>J3?C#_.]V#\W?YH=1\,OC)B]N[W^..#Z8
MWON_/]_5$.163-Y[;E?3!J?:[&1:6? P&:19JEXO(TUQ3M&Q15=^F7P]9S05
M+>9/RZ2Q[@99=*8)I1<8!IQ^T'CY];%GG_VC_D[_ (U[1^)TNZUV>KOYSE)W
M_P#SALW_ "]>C-M;4W1T)LS8&_:?>/<U:,A65=7O/KQ=&2H]ML)EQCXG$36H
M*R80E17^8(Y4(0H> 09/ 5J:^8&:'Y=%XW0M)X*&C&E%^1(^(>IX@'/G3A78
MF\_^T?\ )W_&O:?Q.C#JF7^=1\]>VOY<OP]Q7?\ T9M'KK?&],EW#UQUC3[8
M[.HZT8^6'?\ 5FG8/'C)Z,D+K()UA@KD@L23[M:1>*O 'N \_/'2>[NQ;*7)
M.$9L?T14_P AU7_C?FA_PIBP^*EW7NS^59\0-P;3I:"/,_8=>]]0T&5J(& F
M!I:>;>%=*\S!M0840<GD VX5);BNDA?R/^8]);J[F$7B(KD_TAI_G0_YOGU:
M3_+)_F.]??S(OCU5]H[5V?E.L]Z;&W;E.J>X>JMZ9-\I7;=W)@8V^XQSRO&I
MJ$*WM(Z!WC#)I)6Y8ND$/>:C-""?/ATJM;EKM-,5#BH(\P:'_ :^7SH>K4?/
M_M'_ "=_QKVUXG2CIN_B"_T'^\_\4]OZSTSH/2#WEO&@V/LS=F]\I15#8S;6
MW<UN'(C%6NT&!IA4$!C8A[!^-/%B3< WTO>"N<9Q]G3CMX9$HIDT]<U].JB<
M7_-0RO:_\HCL;^9MU%U>FW:O%=;=B;XZ[V3V;D'S$<G]S:NIHZ.3*KC&A*FK
M$;"1:>4'TZ6J K$,\L/C5H/4@<<?ZCT@.YF.,R.<J2#3!!%:C%?,='H^!W?F
MYODS\,OC/\@]\X_"8+>7=72_7G:&XL9M):DX^FJMUT$%=5IC!4L\RTTBO< ,
M?J3<ZA>KIHH#YBO[>E5M.+I#(/(X_P!6.CE_Q-/]1'_R4/=-!ZOXIZKA[/\
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MM[]Y4ZUU#^ZC_H_^V'_%?=-!Z]U[[\?\VO\ J;_QKV[I/^H=>\?IQ\_^T?\
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M@-0@GA\^G9*63QB,#5(NI2!6M/+)P.->/V5Z!K8GP ZWW%_PHP^1_7M=V_\
M)VBQVU/C?UG\B<;N'&]UU6*R\V1SNXYJQ\)D,B:0N^UX;N(L6(M$0!]9LQ]^
M,RF)LD=@-:BO'S/IGJB0%;M'&29'%,E0 !P%>)\_(TZ4G\P'YN[,^0/\T+LK
MX/\ ?GSNS'P*^%?QEZ[VIN+L/)["WU!UWN+L_>^ZQ#4C$+FVBDJ<9B\-#5E9
M8P)59:,G39E,5_"2!2H':HS3BQ]//_+TS-=1RD+))H=N%:@*,9%*?+@:YR,C
MI$?'7YI=-_"7^8E\..A_A]_,>W%\Y?AG\Q]RGI/=_2G8O;47;&;ZZW96.B[>
MS6"S#TB5"8G)9&>*%:3Q1LQ,C2V)CD]ME]1X=M: <?S& /V#JUO<K#I5'UM0
M,QSPJ!0TJ:_Z8CY5X=#OUGL3L_\ G<?-/YOYKM+Y)=X],_"?X<]PU/0'3_3/
MQW[(FZV?<6>V]_E%9NG/Y+14%Z@EX98HVA9T,VF,JJ^NAE)4:B:'  /'YYX=
M7BTWL[A14I4DFN,TH*4)X>1IY>1Z#[X/_'SMGXT_\*/<]U1V;W)V'WUCZ/\
MET[MDZ>[4[0:+,[FFVQ_']OO0XS/5\;$9?)X*L^YIQ72,%J:<4Y58U98T47$
M@*BA)ID$\>/ _,'I)81R"^E63^  J ?M!_//V4SZG<\]E_0EZTYO^%2?QHVU
MDNL/C%\C'WIVO%N#<7RS^._0DNT:'L&8;6IL;GVW)6C*4V#>.Z[D0Q*4R7EU
M\N=-V!]J[64+ZUU**5Q3/RX]$>\P?4H6X#2QJ*@UH,8/#RI3AT]?SK-E=E?
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M\+DEK\=19&("F@KJ#%Y(+8<_Q:QL?]@1_M_:.1J@'A@']M>CF):-3T)'[*=
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MJ,+*]R="O*4>L@B#CUC4, ?+N]6.<?RZ0F;]YRNI/: 05_A4$?SJ./R\^(V
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M58^K^-/;JR8R9ONC+'0[?JG1[<<JZ@_FQ /T'NB]SLQ]#C[.ETZ4MTA'H/\
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MB^N^J?Y8/8F&I*J:H^XK<A6/G,^<AFLH6U%LSE<@6JJM[D>0*JV4* _+<&7
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M7MC))$XQ&".E5JJ.%"LEW+ 715\Q-=*5R"?*H\Z#]G3L]K'N)66;^BM*D*:
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MQP_U?Y.GXW(G:-)*Z16HX$9X\3Y4R>-*<3UNJ^RKH[ZU0O\ A3_F\QM79?\
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MZ/Y,_P TOS?8^U1;_P F3"G_ (CVLMS1I/L/_'ND-UGPO],.K#/@9'K^#_Q
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M;]#;@ZF'2/R,^(O7>[LC/64@\EZ;<FW=O*BTTM?ZM1GIZ1Y8WA8RA%GNZB(
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MC0U'IGA7ACI+,)Y+KN&6B'$$?B6E,9K_ (/+UW<M#_ZEO^23[*:CH]ZUU_\
MA2=U9NK/_!S8?>&S<!D=ZYKXB_)CI?Y,9?%XFBEK:T8#KW+I)F:FGAA1Y&2A
MI94EG8*1'$'E<JEV"^W:B >A!Z+-P3.NG%64#'$@@<2!Y]'=^=M:/DA_*Z^3
M6=Z(I:[MT]R?$O?.2ZNH^LH/[XU6;DWW@J>7'1X2/'"0Y-<B771I!>X50O('
MNP_3+5Q7(Q3CT](?J8%I0T6AH0<BO5"_R(^*_P H,W_PED^/'QXV_P#'#O7+
M?(/;VT>FJ+-]&8CJO.U6[X*G;^;K9:F*LVZM#_%8HX8G1Y"T0"JRM8+[;#TD
M4^@I\O/IJ[MO'MY(\C42>!K0D'@ 3C[*]7 _SF.JNUNT?Y,_R5ZMZRZS[%["
M[1W7T?L_;^$ZZV-LW(;QSE?615^'EDIJ?$X^*:K$D"PS,ZB!F55>ZW'NJ&DC
M_,$#T/#SX=/+'J@2M:JR,1YXKY4J>O=_=2=IY7^15N;J+%]9=BYKMRK^ >#V
M12]5X?:=?DMPS9AMK8^DDQ+8D1'(?Q9*A7A:'Q:ET,A%P![=<B5]=> '^3I)
M/9EK$P 5PV//\751V]OC%\H*WH[_ (3$86G^.G>-1E/CSWIU;F.],9#U+N"L
MK=E4&+AQ2U5=NY10+_=J.%XY%D-65LJ,Q8 6%692>'F3^76_IY/"B!)^ "GS
MI^("O\Z9IYX)^?\ A01T/W?W3U%\)\7TOU#V=VKE=L_/?H/?6\L1UML7);W;
M%XC!UL,];E<BN-IY6@QM'&&\L[JJ"]BRV)]WCDT@C^F#TIN+;Q&C)\D*G\P1
MGTX_ZATH_P#A1ETAW'WE_+ZQVT.ENJ^R>W]]+\DOCYN-]F=7;+R78->M!M_.
M4]1D*YL?CXZIU@I(8Y))7\>D:@2WZF]MQ2A3^8/Y#JU];":I_H,,>IQ]O^K/
M18OGYLWY-_&+^:/\ _YBVP_BAW[\H.G]H?&?>_QT[8VQT%L#(]C[HV\<V$GC
MR38'&QSU<RZ:X^@!5D>*:/4DP.EWQ$#>HTTP?ETD=)D"N/C+JU*8P2,\?7->
M SZ @5\Q-Y_,/^83_,%_E-]O[$^ /R^ZQ^+7Q<^:>T*K<.]^\.B\ML;<<]3O
M.HQE3D,U5;8>)Z_ [+PE#C(Q)E<G'3H:N610UR$5M61!0?"#7-*FHI_J_GU>
MX,SRQN!W,-)P=*%6#5)].TC.#44P,G]^.71G=6$_X4-?S!>[<YU)V9BNEM[?
M#?I;:NS.V\MU[D<7MK-Y3!3X1JS%X_.M#'C:NKA$<OEB2=F'C?4B@<^9]6/Z
M('[*=/VT'@R,_P#3=OE1A3'[/]6.NOE5TGW9N'^?K_+$[GP/3_:6?ZBZ[Z"^
M1.#W_P!HX?9.6R^V<+D-T8K<$5!2Y?.1PR8W&SU4L\(B5Y1ZI54!KJ/=D90=
M.::2/7.?7I#=0S/,LM <^0X"J>@P,?RX=5\;!^,E=_+F^;/S"P7R4_EB[T^;
M/Q(^3O:F:[[Z([SZ>^(U/\M\QL^7=#ZJ_;&9P]+B\UG*2%69$C?3;T-*BA&U
M"TDBD$5!'%3Y_9Y=7ME-E-KCCR^''=3A6M1@4I_,<> .M\ </VKW-\[]W=K=
M=?ROME_!CX6=7;$J-O;'W;W7\0L7T3VIN3<V>B>GFK\332T&-S6&PCTLDBU"
MR2.2J^.0L]3*1IV+9J,#&!4_LZ?10K!5C(4G(JU!GYFA_9Z$$YZV7/:?HPZU
MT/YB72O=>]OYPO\ )[[0V1T_VSO#K3J^K[I;LSL+:>Q\KE\#MP9:GIEHCFLK
M!"]/CA5!61/N66]C;4/:B-Q\)_;^?15=0%I4E )XX X=OG_DZ,S_ #=OY=)_
MF!_&E,?L66HV=\HNC\ZW</Q>[,H[XZJQ&Z]H,LZ4C5)TG[+,^-*;5K4 I33:
MBL+DUM+GPI#KX#*D>1^W_4>GK^R^KCK7O8!7S@C\P1BGG7Y9IU4)_(P^)?RH
M[-^(W\U/8/S6Z:[=Z$[(^7O;F\9<[4=I=69+8L==6]@[2^PKMQ8JBJXZ%LI0
MIEM;J8?V VDM8<>W;J=99*_Q&I-12I\\=)-KLY(4;Q2.T$*,@D:JTR.-">%1
MZ$](3X+XG;WPIZ#I_BI\_P#^2'W!W!W3T!#E]H;5[XZ)_E\)\I</V#BX"9<-
M72;BPN R4<612%HZ>;[Z:PL"95:-E]M2Z7R3D8%*$'IVW)B0Q>&:-W-EA3)J
M!QK]@-3CYT$"O^,GS7^1_P#*"_F@OF_@-U1\5]^?([%3TWQB^,74'3&*ZNWQ
M-M;9-:M?CZ;><.*IZ?[K/3+'(M)1R(KH2ZHJO5,&LTJT.%%1@"F/MI_EZ>2%
MSQ+'2P)U$YX<*G/Y>OR/1Q.KL#NK^9=_)E[9^'W87Q7^4'QE['VA\:MO],/M
MOY&=+9GJ>>MW/L_;L51B\QMI\K#%'G*"GW'C:&19(D]#@+S<%O"1%)ICMIQ&
M2!\OF.FTM6DMPC4/?JH0>!/F#0\#]OK3HFW\H[X-_(_Y.?'?^8KV!\X>A]]=
M(]L?)[I7K+X:;(VOWCL7)8#)4F"Z-V*N%H<\*7*1Q5#4]3E*NEE61(V$TV-1
MP?3Q?QE!KC(]<B@^7V#I#;64LH=Y?B^' (U FN-0!(%2*D>M,9,G_A/3\4OE
MK6;^[H^0/SJZ/[1ZNW7U+\=NC_@#T#A>W-@Y#:LM7LSJF$C(9>B@RD,=0[Y%
M8J:,U42M%-<FY"M>UQ=!R&] % J#@#C\O]7V=.[59R0HZR$58LY-".X_AJWQ
M#S_D*\>E;\ ,_P#(W^37EOD)\*^^/A;\P.[OCX>]>P>Z_C)W[\3_ (ZY7Y$8
MNHPW8M6]1_!LWCMM092OQ.4IY3,005\8*JY,95F:<K(22YI6HX9K\JBAZ>LV
M:U58O!![0I%"  H%,Y!P*9I7..%0VP?QS^7WS=[W_F<?S.^T?B;WAT/A\O\
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MB4TZN%*D'WYF1P W#20:4X_+]O6I(I"P930EU85K@ 'C3S^W_,.A(_FP4?R
MVK\Y/Y3/\P/KOXB_)GY#]5],8KN.B[8V3TCU+EMY[QP4/9E%AA0-5[8IX9<@
MM93>.5)A)I'DI[,5^OMZ%XHZ$ _ZOETQ?6SS.K#B./'[/(?GGRKUL9=;;LD[
M!V3M'>QV?O/:$.\]OX?/3;4[$V[4[:S5##FZ05,U)E\551^3&Y.*HO'54ES8
M@ ^H\(B, CHZ#ER0?+SS0_ZO+HK'\Q3HW<'R*^"_RUZ2V_AFRVX>QNC>Q-O[
M9P]%3O+]WD12)/BX%31K9Y<C&0+"_-[Z2+WAD\$@>@_U?ZCTGNX_'AD'J:4I
MG.,#[/3HJ7\C[N2F[F_E5_&I%>DH=Z]0;!D^.?:.TU I:_";EZ:1<#48C(4[
M6GI<HL=-C7:&5%D D4%;LON[DF=&X"A%?*HQ2OKTDV]=5HZ\34-P(-#FM.(_
M/HOW_"=7I3NKHGX6]I;2[JZ>[*ZDW?DOEQ\A-T8C;_9.R,ML.NJ<9NC+0RTE
M?]IE(H"^-JH0SPOXRK%20S7%Z2N&4C'$_P ^E%A'X14\.Q :XRO\_+JCO^=K
M_*@^6'3G?F:W/\"^G.U.T_BQ\V.X>K>U.^^F>G>K,GOD[:WYUCDUJ'W M!CH
M:A\;B\M3UU;*TQ5(U=JBG;2FAF6)<+2M?B()'H0?\U?\G1)>;=() J#L6H!R
M:@@FF*YJ :^N2<XL\_G9_'KM/?/S-_ET=C]H?&+OWYF?R^.KZ??A[IZ<Z"V!
MF>V<A3[IR#*V*SN:VKB(WRN:H8(VC)&C2[+.EXS)[2ZU+EL?\5TMN[0ST1NX
M&@J0312*$8!I6N?Z-16A(-?/\U39O87RDZ)V1U;_ "[OY-?R(Z@Z9ZL[QZ6[
M:[=WYE?A[6?'[<F8&V<C/C:3&;9V9)BZ3=FX D57)592L_AH,<,2R,OC.J1]
MI590 1Q!)P#C^?3%U =9;PR>U@!EAD?G0^F*>5?2Q'Y69/O3XN?SQNG/G)B/
MAC\N>_\ X[]G?"K#],;JW#\>.DLSVGDL'G)<SD*T-EL5CH3/0B..2C\_W2(>
M&N3]15Y4>$1GA0#B*]*8;=H[HR^@(R#3UX@?+C\^F'/Y+Y'_ ,NO^=3\QODG
MGOAG\N/D5\;/FIU+TO3X_LWXM](97O2JP61Z]IY8):#*8G!TE1.A=GJ8V8JA
M"&&105;EA,  O@ <./V9IPKUZ-/!ED*Q#O=CD&E650348X(/3R K7"4Z8I/F
M=\H/Y^GQM^;>^OA)\B_CU\:X?BKW7U5U_E.T]AS8C)T%)A_NC%5[Q:"FFH]K
M93/Y.NJVQ^,KJJ.L^U2)XE6/0?;U  !J([6&:5_.GKGIJ"222X=_"XLC<" :
M U-3Z @<?,^AH<3^2[T=W1U5W_\ SA<WV?U+V=UQA>U/GYN7>W6F=W_L?+[8
MI]P8.MH)HTRN':OBA_BV-:41J)J=Y%(8>HVTBDCH0?\ 3 _ED=&%ND@8^781
MG KJK^?E\NB@?(#XN;K^&G\USO#Y5=A_R\=P_/[X7_-3;FW:W/MUE\=H/D;N
MGKK=VSX(8*RI7;;4N3R?\.R<:.1+216D,P,?KIPOMX3ATHQ'V8J#^9X?9T6/
M;_23%TC+ZJ5R0#D* :#!H:U.!3-/,5^BXMW_ ""_F!]3CXR?RB]G_$[X>=0P
M5.[.S_D!\H?@?3_'[=F3R419\?!L*CR&%Q.X:&KIIE0?=#0P:\Q*HL0]U68
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L]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>timage_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_003.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
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M=>]^Z]T0#^;%_P!NLOYEG_B@'S(_]]UN/W[KW5;7_"53_MQY\3O_  YOD?\
M^_)W7[]U[K8D]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI8?\ "B3_ +?<?\)S_P#Q:WJ__P!^WUS[
M]U[K=/\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW54O\ ,+^7?SC^
M&.[MC]K]-_"K)?-#XCP;7K(^_,+TYG1'VAMJNI)ZF5,S@<#*'BW-BOL?$M11
MQ(*E9560300^5_?NO=5\_+_Y/_'W^?+_ "U^\.C?Y>G;VS][?(&GRW6N\\Y\
M5.ULG)U%NBM7JK=6-S.7V?N/#5\]'6TE+E:?%U=')5Q//CO,51JO06=?=>ZJ
M'3X?_*[Y?]@]&=/;!_X3>_'[^6%EMF?(GHOLO='S4PN\=N8VIVUB^J-P46;R
M38Q\5@,36Y6?(T^/DIHXZ>IKP\DT9=5!^[A]U[K?8]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW1 /YL7_ &ZR_F6?^* ?,C_WW6X_?NO=5M?\
M)5/^W'GQ._\ #F^1_P#[\G=?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT6 ^I]["D]:+ ==:U_K_O'O>@
M]:UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]
MH/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>
M_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O
M'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_
M[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^
MO^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U
M_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKV
MM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z
M]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6
M.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>
MUCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/
M7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:
M#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'O
MV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q
M[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^
M\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K
M_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?
MZ_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K
M7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.M
M+'_A1&0?YW'_  G/M_WE;U?_ ._;ZY]Z(IUL&O6ZA[UUOKWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZIE_F=_S,/D#\3^T^A_BK\*/AQEOFM\NOD!M7L+L
M;$[&;?%)UYAL!M?KIZ2EJ\WEZ^JLL@FR-?3P0PM4T<)"3:ZV.4TT-1[KW5,.
MV.L=I?S6?E[D?C/_ #1/Y;6Z?Y7_ /,FHNF\C\C?C]\N/BUVM!C<[E,7MK(1
M8:JJ8MRX'[JBK<EB:S(1L:?(5>2=(=5C0N\)E]U[H^.TMT_SQOY:&[MM;.[A
MPF%_F\_#&LW'B=OKWILJ"/K?NG9N-R53)",AN?"#[FDW918V%XGJ)Z;[JKDC
M22HJ:VG4:/?NO=;(_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ(!_-B_[=9?S+/\ Q0#YD?\ ONMQ^_=>ZK:_X2J?]N//B=_X<WR/_P#?D[K]
M^Z]UL2>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NH=3+XV4?U6_P#ON/;\2ZATGF:AZC_<_P"/^^_VWMWP^F=9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9ZTN_^%#<GD_G;_\ "=$_D?*[J[_W[?7/MF5=-.E$+5KUNL>V>GNO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JA'^;1\7/A'\LN_P#XW[+["^?.
M_OY?/SLVKM/=5?\ 'GLOJ7N,=,;DS6V]VU#09?"4DU5/0T^;A-=C(YVI:.OC
MR$!0,2*:I=9?=>Z$O^7=_)GV7\(>[=S_ "H[%^77RO\ G/\ )/<G7%1U)@^V
M?E'V94[X."VQD\A!E:S'X2GJ)ZN6-LC64M&\\T^0J;+"%I$I%J*S[KW7NKHF
M954LQ"JH+,S&P 'U)/X ]^Z]T7C87RU^,_:G<F]/C[UAWCUKV-W'UMMV#=/8
MNP]B;JI=VU> HZN>&FA_C)H))X<94SR5$9CIJB6.I="95B,8+^_=>Z,1[]U[
MH!/E7VINOHOXO?)'NW8>S:GL7?'3O0?</:FS>OJ..>6;.Y7KW;V1R^.PT2TL
M%34M)E*RCAIE$--+*6E CCD>RGW7NM8WXP?"BN^6_P#+%PW\S#M?^:/\U\?\
MM>T.I*SY-2]^;&^3^1V-LWK[*;<I#7#:E%L:CDI]G1[:P4M!)09>BK,=++4,
M^1"U$'EA\/NO=&$D_F\?)#$_\)T^J?YA^1V2B?,CN+8VV^I^O,'D\-#A(LGO
MG>>\*K86$W-'C:OPT\E%E$IUW)!3J!35%+(@C*TL@=?=>Z:/DM_*T^0WQ'^&
MN^?F-T%_,$^=N\OYA?QRV)NSY*[OW5O[NS.]J;4[(KMFT%9G-Q[+R'63U$>V
MAM_*TR5=#AZ2@Q\510M'CRDE5+"?+[KW5]?PU^1F*^7GQ/\ CG\H,-BI<#0]
M]=-=?=HG 3-Y&Q\^[L;3U=7CR]V$GV-5)-!K#$/X]0)!]^Z]T97W[KW1 /YL
M7_;K+^99_P"* ?,C_P!]UN/W[KW5;7_"53_MQY\3O_#F^1__ +\G=?OW7NMB
M3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]TT9&0)*@()O'_P 2?:B&I'2&Z?21]G3?YQ_J3_M_;U#Z])?%^?7O./\
M4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_
M &_OU#Z]>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]
MO[]0^O7O%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V
M_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;
M^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_O
MU#Z]>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0
M^O7O%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#
MZ]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/
MKU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]
M>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O
M%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\
M7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q
M?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y
M]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7
MO./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>
M\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q?GU[
MSC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y]>\X
M_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]
M2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U
M)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q?GU[SC_4
MG_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y]>\X_P!2
M?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?\
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M\Y_U(_V_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/\
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M]YA_A_MC[]H/7O%^?7O,/\/]L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/\
M;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_#_;'W[0>O>+\^O>8?X?[8^_:#U[
MQ?GU[S#_  _VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]>\P_P_VQ]^T'KWB_/KWF
M'^'^V/OV@]>\7Y]>\P_P_P!L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/]L?
M?M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\ #_;'W[0>O>+\^O>8?X?[8^_:#U[Q
M?GU[S#_#_;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_#_ &Q]^T'KWB_/KWF'
M^'^V/OV@]>\7Y]>\P_P_VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]>\P_P /]L??
MM!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/]L??M!Z]XOSZ]YA_A_MC[]H/7O%^?
M7O,/\/\ ;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_#_;'W[0>O>+\^O>8?X?
M[8^_:#U[Q?GU[S#_  _VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]:?O\^5]?\['_
M (3P_P"'RSZG_P!Y[:Z[]DF["A7[#T*^7&U*_P!J_P" ];R/LHZ$O7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T2[YW?R_OBY_,AZ.K.@/E9U^-Y[._BD&
MXMM9C%Y!\!F\!EJ2.2*'+8+*0@RT58D4LL;@K)3U$+O!503P.T9]U[K5DSG_
M  B+^(=1E*J7;7S3^2&)PKR$T5!G-H;8W#51K_26LIZ?&13-_BM#$/\ :??N
MO=6O?RP?^$V_P)_EC]E8_OK;53V%W[\A,)2UM-M3LWN&LH6AV]_%J;[2LEV]
MA,924E#1553"\\?W52U;60Q2R14]1$DDHD]U[K8.]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW1 /YL7_;K+^99_XH!\R/_?=;C]^Z]U6U_P )
M5/\ MQY\3O\ PYOD?_[\G=?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T#O8\I3*4(!M_N/!^E_]V/[$6S*
M2C?Z;_(.@/S1)HF3_2?\_'H._N&_U?\ R;_QKV<:#T&?&'7ON&_U?_)O_&O?
MM!Z]XPZ]]PW^K_Y-_P"->_:#U[QAU[[AO]7_ ,F_\:]^T'KWC#KWW#?ZO_DW
M_C7OV@]>\8=>^X;_ %?_ ";_ ,:]^T'KWC#KWW#?ZO\ Y-_XU[]H/7O&'7ON
M&_U?_)O_ !KW[0>O>,.O?<-_J_\ DW_C7OV@]>\8=>^X;_5_\F_\:]^T'KWC
M#KWW#?ZO_DW_ (U[]H/7O&'7ON&_U?\ R;_QKW[0>O>,.O?<-_J_^3?^->_:
M#U[QAU[[AO\ 5_\ )O\ QKW[0>O>,.O?<-_J_P#DW_C7OV@]>\8=>^X;_5_\
MF_\ &O?M!Z]XPZ]]PW^K_P"3?^->_:#U[QAU[[AO]7_R;_QKW[0>O>,.O?<-
M_J_^3?\ C7OV@]>\8=>^X;_5_P#)O_&O?M!Z]XPZ]]PW^K_Y-_XU[]H/7O&'
M7ON&_P!7_P F_P#&O?M!Z]XPZ]]PW^K_ .3?^->_:#U[QAU[[AO]7_R;_P :
M]^T'KWC#KWW#?ZO_ )-_XU[]H/7O&'7ON&_U?_)O_&O?M!Z]XPZ]]PW^K_Y-
M_P"->_:#U[QAU[[AO]7_ ,F_\:]^T'KWC#KWW#?ZO_DW_C7OV@]>\8=>^X;_
M %?_ ";_ ,:]^T'KWC#KWW#?ZO\ Y-_XU[]H/7O&'7ON&_U?_)O_ !KW[0>O
M>,.O?<-_J_\ DW_C7OV@]>\8=>^X;_5_\F_\:]^T'KWC#KWW#?ZO_DW_ (U[
M]H/7O&'7ON&_U?\ R;_QKW[0>O>,.O?<-_J_^3?^->_:#U[QAU[[AO\ 5_\
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M7OV@]>\8=>^X;_5_\F_\:]^T'KWC#KWW#?ZO_DW_ (U[]H/7O&'7ON&_U?\
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M1'_S3_Y^;H)=;?U_WCV(- Z!?7M;?U_WCW[0.O=>UM_7_>/?M Z]U[6W]?\
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M&U<1UUBOBGV%A>N\;)M>FRU'MRLZ\VY4U&ULI04#&&-:C;V0H:"JIO'+ ZO
MNB:)CK'NO=8?Y.W<>[._OY6_P0[8WWE:[/;TW/\ &SKBGW5G\GI-37U^V:08
MFJKZAE+!YZV6@::1^"[.7*J6*CW7NK)_?NO=4>?S6_YB'\O^I_E__P R;I2F
M^<WP[J.Y:CX=_,7JV#J2#Y-;*EW.^YY=E;BQ*[<3 KFSE6SS94BB% *0U9JS
M]N(O-Z/?NO= ]_PE4_[<>?$[_P .;Y'_ /OR=U^_=>ZV)/?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1>NX/\ B]XS
M_M5#_K=)[%_+O]DW^F_R#J,^=_\ <B/_ )I_\_-T$GL0] OKWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K69[UVEMKY]?SY=O\ QQ[9
M9=[=&?#7HF+L6LZOK(!78BKS65APV0G_ (G3S0^&IBJIMQ;=6KCO+#-#0PT<
MM@]1'[$4#-86)E3#22:=0.=(!X4.,J?]5.G 0!^7\ZT_P<.KG/F=\5_C]\@O
MC#V7UGVML_:5%M+%=>[IJ]N[C7"4=)-M2?%4%3-3YC$3>&V/EQKCS>@")T#Q
M3))#))&Q+:W#VL@=#D$>N?D:>1\^M(Q)IZX/SKUJV_\ "=OYD;KZ/[*QGQ%[
M#VY64G4ORMS&Y]^=-;PFH7IXEW9M:C%!DH8Y]&BJI<G282*ED'D+TU92TBA
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M^+_SQZ!WC@>CMIY+%[>W1VM#-GL'L^GW/2XK&9.GW7C)L8*C&Y'^#TE+5RK
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M5D&,R&.KXY8H3+X//#4/H6NCN(N80T[).N8V0!3Z')H:>>:_M'D>K,*8]/\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6FO\
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MU;34]91U$%725<$532U5-*L\<L<ZADDC=25='4@JP)!!!!M[#?5.JH_YG?\
M-BZP_EOX79-#)M&D[H[<WOD?+2]3T._(MDU%'A88YO-FZ^K&,S4E+ U2D4%-
M&V/O5.9C'(%II?9KM>UMN;$ Z5 RU*Y].(S^?5M.*_L^?^K_ #='T^-/<O\
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MEAAQTL;>Z]U]$WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$
M_FQ?]NLOYEG_ (H!\R/_ 'W6X_?NO=5M?\)5/^W'GQ._\.;Y'_\ OR=U^_=>
MZV)/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW1>NX/^+WC/^U4/^MTGL7\N_V3?Z;_ "#J,^=_]R(_^:?_ #\W02>Q
M#T"^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDKOO:5!O[8^\MB95Y(\7O7
M:FX=I9*2*^I:?<='-1S,NED;4(YF(LZF_P!"/K[V#0UZVK:2#Z&O6JE_+S_F
M"[9_E++V1_+H_F X7<W7E5U7OG<>Y>M.TMN[;JMV8K(XG=TJU:EH*%:BO>FK
MYFEK:&J@I9E*5$U)6I1U5&5E%-_8-N]+FWHVH ,M0"K 4\Z#&/\ "*@]78#_
M #?,5_/H>M^?S</DO\].U9/C9_)^V3#'4XW&+F]_?)SM[ P8^@Q-&Y2-9Z/&
MY."L@I(1/(L8>NQM75U3B5*7%%(C4E.FTQV"^)>&E3VQJ06:A\SZ?8?,9!QU
MX ?[.:</VU_U9\DINKY9_P X/^5A6[:WY\]EZZ^87Q@W#GJ/!;JWYU)2TM-D
MMNS9(CPK%4QX+:;I)*1)XER6*DHZB4+2)D*266&]UM+3="5MM4;@85_A;C7S
M8U_/AY')ZT*$9_EQ'^2G0K?)O_A0O\/Y>B-UXWXQUN_.SN^M\[>R6U=@[0J>
MN,IA(\=E-Q0-2TM5E):I:>*ICIII5<4]!/4S5$BK"IC5S,C,'+\Y<>* B#+-
MJ7X1QI0GR]13UZVH /&OI0')_ET1+^6?\V:S^3E5[U^$O\Q'8^\NK,=N^IP/
M?NP=UXW'OO>/'C?F+I*6LHZN#'R5,ST+28I8@]!%4"#*09&&9#J,R+]RL_WS
M2XM:-2J,/A-5.#FE<$<?*GV#Q&,G_**>G[:_ZN.?^9;\XJO^</)M'X/?RZ]A
M[S[5I-O5F4[UW[N[)4@V-%D(MA8ZK@IJ*DI\H]+-'1+-DT5I:X4OFR+T-/#&
M01*VMMLOW,?J+JB_@4#N-6\\5& #ZXK\J^ P:'CQ^ST_;3_56AX/BQ_PH4^)
ML/1^W,!\L)M^=0]_]>8:FV=O_;"==Y3/0Y/)[7A6EGJ\<]%#4&B-7+$3+29#
M[22DJ3+ 6EBC6ID17/+\P>L(#H<JP9>!X5J1Y>8P?Y=:8 GT^6<?X>JFL]\X
M/DCN;YHO_.ZVY\>]UM\.NM=WXGX\Q09.JH**KFVWDZ"IQ4T4EIIF^]:KR3U+
M5,(DH*?*5%-C#63!9"306,2P_0EQXK5D\RH8>7YJ//RJ:<!U8</E2GS.>/Y'
M_5QZN.[?_P"%'?P=VWU5+N+I>#L3MGMK*X\1[<ZMKME5NSA2U]7$3"N;R=4A
MHDIH9M*2_P .FR$KMZ8593Y5*8N7;AFHX"+YL6!%/L!K^VGVCJH45XU^RN?Y
M=!%C<7_PI/[*VQC?D!C^P_COUG'-C'W%C?B]6[?Q.-R-1!-JGCH9XJ[;N5^W
MGJHA&BQUF]H*B %5DDI9_,0YJVV.J4E;/]IZ?9D?S7K9 !IC^=/]7V8Z$SH#
M_A0]\:Y]MY?:GS2V[NSXW_('K[(Y/:G8&UL9L[*[SQ53E=NS24E:N.-##65V
M/E%3#*LE'7(/M7O$*RJ"F8TGY?FJ&AI(C %6J%-#G(8C^7\N'6BH'G^7_%=
MU\-]Q;@_FJ?S9*?^8IMW8>XMD?&#XH]=5_4'6F8W(T5#69W*34N;2&&HAA,Z
M&=/[VY6OGCAJ66DC7'PS3.TS([MX/W7:?2L07D8.P'!1CS]>T?S^1ZV5 %?R
M'S^?V>7^H@;0OL-]-]>]^Z]U[W[KW6IU_P *B>[=SXC9_P 8_C[BJJHH]L;U
MRN^.SMX)!520BLEV8*"@Q%/*B%4E@A?)9"9DD##RK3R*%:($BKE: .[R'BH
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M/D4:E @K<3&3+.K1E5UOK4W)=>Q+;WC"0=OB5('\!(;%*>1ZL2"?V9/K3/\
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M:@BIH9C&TL0JIEN(;,;\MV;23>-2BH#GR+$4I^PU_P"+Z\!09\^'[>/\J?\
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MJ>FECAJYH#!+HBEHZJ%]B.8;:JDJZ\5![2WS%>!I@GA\Z&KGP\.!\\X^6/\
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MD9SM^\M9*8V42(?PGR^S!P?,4_9GJZM3UKZC_5GI-?R^_P"1]M7XF]WGY/\
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MT_EQZ\S:C^0'[ !T83^9_P#R\/\ AR'IK8G4G^E__0S_ ')[-I.QO[P?Z/\
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MP_(=;./=5=UAC.H>SJ_NR7!0]0TNQ-TR]F2;FTF@_@:T<W\2%4'X:)J7R@J
M68D*H+$#V'(PS, M:U%*<:^5.J+6N.M>W_A,ATK2;9^*G;O>62VM#0[C[/[@
MK]K8/=%13C[BMV_L/'8X(M/(5U"B7.5>7C8"2SSP.&4>)&(AYGFUSA <*HJ/
M1B2?\%.O'  _/_)T(O\ PI+JNK9/@_M'!;FCH*SMG+=U;17I>@AB^YR9J$BJ
M1F7IXX[S_9-C&>*8Z3$U1)1HP,S069Y=U"YJ,*%8OY#33_/3K:@D'\A^=?\
M#QZODZTBW)!UQU_#O)B^[X=D[4BW4Q#*3DHZ" 5Q(=Y'%ZH2_JD8_P!68\DB
M/'K34J:<*]+;WKJO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT'/;?4?6_>_7.Z^I>W-HXK?/7F]L8^)W+MG,QLT,\3,KHRO&T<]/402I'+!/
M#+'/!,B30R)*BN+QR-"P9200:@CRZVK%<CJCG</_  FI_EZ9K<+9K&[D^2FT
M<:9HI!M+;W9&&J<>%C<L8Q+EML9/*Z)!Z6)R9;2/2RMZO9ZG,MRJT.@G^(KG
M^1 _EULGY#^>?Y]6N_$OX2_&WX1[,R>R?CMU[3;0I-P5=/7[JSM97SY[+Y>:
MB\WV[9')5;R5$Z4JSS+!$"D$ =_%$ADD+%%U>27C:I6+'R\@/L H.O%J_P";
MHU_M-U7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7N@Y[;ZCZW[WZYW7U+VYM'%;YZ\WMC'Q.Y=LYF-FAGB9E=&5XVCGIZB"5(
MY8)X98YX)D2:&1)45Q>.1H6#*2"#4$>76U8KD=4<[A_X34_R],UN%LUC=R?)
M3:.-,T4@VEM[LC#5./"QN6,8ERVV,GE=$@]+$Y,MI'I96]7L]3F6Y5:'03_$
M5S_(@?RZV3\A_//\^K7?B7\)?C;\(]F9/9/QVZ]IMH4FX*NGK]U9VLKY\]E\
MO-1>;[=LCDJMY*B=*59YE@B!2" ._BB0R2%BBZO)+QM4K%CY>0'V 4'7BU?\
MW1K_ &FZKU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6I3_/!_[?6_
M\)[/_%MNHO\ W[/7OL*<Q_$GV-_A'4B\C?!+_ID_P-UO;>PUT.^O>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[K7._G7Y6BZJ[9Z,^07<7\G/:_\T?XP['V%
MN'$[ZWE08.@[*W5US5U>22:6:EV7EH,I19S$96 43SR?PNGCIOM)7K<E'%X(
MO?NO=(7HG_A4S_(GEV/A8H>U]R_&6G?&TU0_7&X?C%NF%\?($C3[1UV)@]RX
M8R1+Z0U/6R0Z8[+);0#[KW2@[-_X5E?R4]B8')9?:G??9?=.2HJ":KI-K=;?
M'S>&(K:R6,$K2T\N\,5M3&I-(0 &GR$,(OZI0+^_=>Z.G_+8^?ORS^?V[>P^
MQ-[_  ([$^''Q#Q^U\=_H2W?WSF8Z+>V],M5U>FIJ)-L!*>; XFBI89=#O'5
M0UAF@FI:^5?+%'[KW5O'OW7N@[[<[5V-T9U9V-W1V=G*;;7775&R-S]A[WS]
M6P5*3%[0HYJ^MG.HJ&9*>!]* W=K(MV8#W[KW5"_5WR/_GE_-'H&G^;OQJVM
M\).A.IM]X2;LCXR_%3O#:NX^P]X[RVC4J:O!UVZ-X8G<F-PNV<GNK'^*>BIZ
M/&U,-)%44YK*C5Y"GNO=&G@_FY[1V=_*2JOYH??_ $OV%T=6;:ZZJLCO/X\[
MXQM9MC.0;PI<D=OT^V:7^*T-%4M#F<^:=,?6RT$:R453#621(NM5]U[HFG:?
MRE_GN?%3XZ_\.!=];%^$/8W3>T:2;M7Y"_"KJS;^Y=O;UVAUZZS5554X;?N5
MSIQ.=W1M?%&GJ\I3SX*&DF,-?%0O(5IRWNO=;!_4W:.R>[^K>N.YNM<S#N+K
MSMC8NU.QMCYVGMHK,3O2A@R./J  3I,M+41,5O=22IY!]^Z]T(/OW7NB ?S8
MO^W67\RS_P 4 ^9'_ONMQ^_=>ZK:_P"$JG_;CSXG?^'-\C__ 'Y.Z_?NO=;$
MGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z(;\SOAY0]_8@[SV<L&.[9P..^WHVED$%/F*6EU.M!4LQ"15"%F
M^VG-@"?%,?$5>#&C[P?L%#[K6WUUEICW."/3&Q-$N8UJPBD]#4GPW_"31NTU
M68?:SW.?DR7Z6YJUG(U6 %6A<T&M?48[E\^*YPVOY_=#=/\ >G^X_P#=[,?W
MP_C'\ _NS]A)][][Y/%]K]OI\GF\GITZ;W]\JOZL[A^\/W5]/+]9XO@?3:#X
MOBUIIT\:U_*F:TSUFA^]+;Z;ZSQ4\#1XGBZAHT4KJKPI3K8!^&7PZQ_06)3>
MF\DILGVUFZ PU+QN*B##4U4 7H:5A=9*E[ 5-0+@D>*$^(.\_53[OGL!![56
M_P!=?:9=SF2DCC*6R-0F*,^9P/$?\1%%[1W87^Z7N?)SG+]+:U2SC:H!PTS#
M@[>@_@7RXMF@4V>^.L=I=B9;K/,;IHGKZCJ;L%.SMHPEU\29>'"YK!0SSQLK
M"44]+G:R6(>DI4I!,K7B .3L<S1!@OXETG[*AO\ "HZA&[V^*]>)Y!4PR>+'
MZ!_#DBJ?6BRM3YT/$="#[:Z6] WWGO?/[%V?@ZS:WV2YW<O:73G7]+4Y&/S0
MT\&_]TXC$Y&J* -Y):;&5=;) EM,E0L,;M'&S2IL9ZT<=$<V5_,'DS>SNKIM
MX;)[ V%N_*5NR\AGY<MU_0U&-W/B,U1;F:KK=JR1[GUTU&M=MV9!+7::N-7I
MG_A\M-6Q526T=5U]*W#?S0OCEE)J0UVW>\MJ8H4&7RNX]R;RZCK]NX[!TM+M
M/);XQM1E*B9N$W#M?$Y"NQPI4JI#'%IK$HY&1&WX9^7[?G3KVL=('9/\TWJK
MLS>G5IV=A-Y1;7WOB>UMKR["S6WZ!-W5N\,1F.H8-L4.,CILW48IJ6LPG8E9
MD*O777IJ6"2>M>A_AU=$NS'0?L_R_P";K0>O^K[/\_2GH/YBV"VMM+;.2WWU
M)W=N6/(]&]J]]578.T]K;2Q6*J,)TUC9\IG9TQ<V_:G,T1IK4>/4S4YII,C5
MTL JPLWD30CK^T#S\_RZWKI_J]/SZ%'N#Y^=,]([AW9MW=^VNV:^IV7O#<>T
M,]5[1V0NZX8O[G;/V?OO+Y0K25CU4>)QFV=Y4M3//)31MJH<A#'$\OV*UV@A
M/^KYTZV7 _U?GTC/^',>CXZ+;V6K-A]YX?"YWN=.D:G([EV-1;4EQM?7P[7J
M\;D<AB\GEZ/-KB\MC]XX"MIA3XNHKUI9I)JJAIA35 BWX9^7"O\ J_9UK6.F
MCKCYL[FWWG^H-KY#96ZMFY?+]CU^*W+7;HVE2X_%;JP$D^Y=N_>[1J(<Q65D
M#8?<\&WVJFR%'3--2.[4L,\%73U2^*4Z\'KU95[;ZOU[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=%Z[@_XO>,_[50_ZW2>Q?R[_9-_IO\ (.HSYW_W(C_Y
MI_\ /S=!)[$/0+Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I"]F]9
M[$[DZ_W=U9V=MG&[QV!OK"5FWMU;:RT;/!54M<+,I*,DD4B,%>*6-TEAE5)8
MG25$<71S$0RFA!J"/(];!TY'6OID?Y&?R$Z/S6<R'P(_F0]U]!;(?(9/<&W.
ME<Y-EJW$0UE89&$-358_.T]#6TMF2-7JMLU,Z*BO+)4R^H'O[ZCG6EQ"CL:
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M5S;8QFPL=0T4Z5& JJE*"&3KG;U:5@JH99:LU(FFDI'BI8+"0CT_U5_S]:*
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M\3FTDCR%+CL]08R@Q:5XE_>%75T^/:O<2'R(*Q4E"RJX#F^72W4_932@""G
MTKP^5304\AUY_P"?G]I_U?MZNN]D_5.O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4I_G@_]OK?^
M$]G_ (MMU%_[]GKWV%.8_B3[&_PCJ1>1O@E_TR?X&ZWMO8:Z'?7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]T1[Y\?S%/BE_+3Z83O'Y7]@2[0VUDLNNW-H
M;?PF*EW)G=P9-HVF_A^%QD%GJ9DA1I)99)(:6G0!ZBHB5E+>Z]UJ^9W_ (6Y
M?#FGRABVS\,ODQE\+?BOSNY]K;=JO\XX_P" =/6Y2+_-"-O^!WZV9/HHD?W7
MNK7?Y:'_  I)_E]_S,NU:3H+98[,Z*[US461GV9U[W?B<;C4W&,5#]S40X+*
MXK)Y.@J:Z*G663[.>2EJY(XIGIX9DB=E]U[K8']^Z]U[W[KW1>OEG\<-F_+_
M .,O>WQ>[!K<EB]G]\=7[OZRS6:PJQ-6X]=T4<E/%DJ(3I) U9CIVBJ8!+&T
M9EB02*R7!]U[JC;IKL_^>3\.?CEMSX24_P#+SVM\L.S^GMLX;I7HKYM8;Y-[
M9V=L3,X#!"+$;>W1O? YZO;>M#DL/AXX9LM1P0U4F1GIV6EG0U(D7W7NE[B?
MY(V0K/Y*&\?Y;.\^WQD/D'V%-N'O3<G?>-\V.I8^WLSN5=[PY>F6DAHZA,-2
MY^"DHR5IXYWH$>58XZAE5/=>Z"3NO=G\\GYF_%;=7\O;>O\ +[Z_^/\ V+W1
MLG-_'[Y%_.7+?(K;6\^MX]K;AB?"[GW1L_:N+KY=Z5M9N7!SU$F.Q=;%3RT,
ME44K9-5/);W7NM@+XW=$[,^+_P ?NE?CEUVE0NQ^C>K]D=6;7DK&USS4FR,=
M3X^*IJ6NVNJJA 9IFN=4KNU^??NO=#5[]U[H@'\V+_MUE_,L_P#% /F1_P"^
MZW'[]U[JMK_A*I_VX\^)W_AS?(__ -^3NOW[KW6Q)[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+UW!_Q>\9_VJA_U
MND]B_EW^R;_3?Y!U&?._^Y$?_-/_ )^;H)/8AZ!?7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW22WSL+8_9VU<QL;L?:&VM][,W#2M1
M9S:N[L)3[AQ]7$_]B>DJHY8) #8BZ$J0&%B ?=D<H05)!&01@CK8-.BA]<_R
MRO@%U/N^EW[L+XH=/8;=N/JUR&+S%3MS^/M1U",S)/0Q9&2K@HIHV8E'@BC:
M.PT%=*V4R7\\HTM(Y'H6-#]N<]6\0_+\@!_@'5)6T<)\U/Y(G<7=.!ZM^+V[
M/EO\"^YNQ*[L39M'U4E95YK:E5DH41HJF*AH,K/2O24-/3T4S5-#]G71TE%+
M#74D[34WLY=H=Y12\@CE1=)U_"X!]2>.:^N3BF>K8;]OEQ'Y8QZ>G0>?(3:_
M\Q'^>MFML=??[+MG?A%\4^LZK-[WI<_W?CZ_[O,[C@QM12XJ7P5-%B:VM$D=
M;+3Q_94+4=%#/733UM74)34C/6TEOL57UB61@!1#V@5SG(\OMX8IGK1 &/GQ
M\_V5^?KT,G5?\S+^8S\-M@8GXV?)C^6QWAW7V9UGA*39NRNS^KQDLAB]RT^%
MA>#'/4UF-P&=HJB84U/%Y:JCJI9)0&>:B@G5PZ>3;;:Z;7%,B*34JY 9>&!4
MBO'Y>E3QZL1JR:_ED'_!3_5CRZ&7X$?![OSY"?(OO'^8+_,EZRVWB<_W+L>H
MZMZZ^,^ZL73;CH\7MG))2QR?Q3&5HK%I@M%2I2Q4M0RU#O49&IK:>*6>(!F]
MO(X8UM[<DA6UF3(+/\N%*?Y!3A4Z9M/#[/6@KZ^=?V?X!91LG^6#_+[ZZWG2
M=@[/^)73>+W9CJT9'&9&;;?\7BI*A6UI/245;)44-++$]FB>*F1HB 8RI ]E
M[[A/(-+2.0>(+'/\^J^(?E^0 /\ (='P]H^J=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M:E/\\'_M];_PGL_\6VZB_P#?L]>^PIS'\2?8W^$=2+R-\$O^F3_ W6]M[#70
M[Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM0'_A4!T]V/M;M[^6Y_,:JO
MCC'\N?BU\'][]@9/Y*=+3H^0ABQ^Y:K;U=!E*ZB,-7 V(9<-**JHFI9*2&:F
MHDR,<E%,^CW7N@XVW_PL6_E&4.'IJ*J^&WRWV\:2".&DQ&V^GNLJZCB54'[<
M;MO_ !VA%?4H I0-(#6!.D>Z]U7KN3Y6];_\*"?YKO\ +:W%_+S^".Z.GJGX
M?]]=>]U_([Y1[TPF-VK7Q;8VIN/%[B3'9I]K29''K'%+A,FV$^^RD]74Y*KD
MAHEH(9,C-+[KW7T3_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT0#^;%_VZR_F6?\ B@'S(_\ ?=;C]^Z]U6U_PE4_[<>?$[_PYOD?_P"_)W7[
M]U[K8D]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=%^[=C+YK&$?\ZL#_K+)[%G+[A(V_TW^0=1ISLM;B/_ )I_\_-T
M$WA;_??\C]GWC#H&:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[
M_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ
M]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^
M_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.
MO:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?
M[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]X
MPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[P
MM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?O
MWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7
MO"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1
M^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U
M[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D
M?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H
M/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO
M^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#K
MV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^
M^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,
M.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_
MOO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC
M#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"
MW^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_
M>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]:DW\\1"G\ZW_A/7?\
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MF_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\
M&_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?N
MO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U
M[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[
M7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;
M_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;
M]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]
MH'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O
M!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?
M_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_
M !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW
M[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@
M=>\'^U_\F_\ &_?NO:!UJ#_SW4T?SL/^$\8O>_RTZF_%O^:L]=^R'>>*_8?\
MG0PY7%%D^U?\!ZWF/9+T*NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJ/
M^8Y_.9^%7\K#<?5VV/ECE.RL5D>X<)N7/;*?8NP9-Z12P;2GI*>N$[15,34\
MD<E;3:0R6</=22K >Z]U6Q_T%[?R</\ GK?D+_Z(JK_^K??NO="ATA_PJ7_E
M1?(/NGJ#H/KK<_>E1V#W?VAL#J#8D&7Z9J<72/F>RLM287%I5535;+34[5U;
M ))2I$:%G(-K>_=>ZV,_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]T0#^;%_VZR_F6?^* ?,C_ -]UN/W[KW5;7_"53_MQY\3O_#F^1_\ [\G=
M?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]T%^^8P^1I"?\ E2 _Y/?V=;8VE#]O^0=!+F%=4J_Z7_*>D3X5
M_P!]_P C]F7B=$'A]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^
M1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X
M?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??
M\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/K
MWA7_ 'W_ "/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_
M )'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?
M7O"O^^_Y'[]XG7O#Z]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\
MC]^\3KWA]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P
M^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X?7O"O^^_
MY'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??\C]^\3KW
MA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_ 'W_
M "/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_ )'[]XG7
MO#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y
M'[]XG7O#Z]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA
M]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_
MR/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X?7O"O^^_Y'[]XG7O
M#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[
M_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_ 'W_ "/W[Q.O
M>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_ )'[]XG7O#Z]X5_W
MW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#
MZ]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_P"^
M_P"1^_>)U[P^O>%?]]_R/W[Q.O>'UI\_SZ4"?SL?^$\%OS\L^J/]X[:Z[]D^
MYG45^P_Y.A3RZNE7^U?\!ZWC/97T(^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[JO3^9/_ "U?C;_,Z^.F[>C>^-FX:HSTN&RDG5/;$&-A&?V?G'C)HLIB
M,AH-3%"M2L7WE'Y/MJ^G#05$;JP*^Z]U5Y_)_P#Y..Q^LOB%@NGOYF/\M/\
MER[C[VZIS57M/;W;N*Z%ZZ[4JMX;:BCBDQN2SF0FVV*]\_2NU12U,U4&EK(H
MJ:KEE>JFJ0ONO=6W[3_EE?RV]A;JVUOK8O\ +Y^$&R][;+W!AMV;.WCM/XH;
M#VYE<3E=N5,=9C\GC,A1X"&KH,A05<,,]/403)-!,B2Q.KJK#W7NCO\ OW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(!_-B_[=9?S+/_% /F1_
M[[K<?OW7NJVO^$JG_;CSXG?^'-\C_P#WY.Z_?NO=;$GOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/MWP"6MIB1>U+
M;Z_[6W^/LWV\G2?M_P G0:WN,/(I_H_Y3TDOM%_I_O/_ !OVOJ?3HF\$=>^T
M7^G^\_\ &_?JGTZ]X(Z]]HO]/]Y_XW[]4^G7O!'7OM%_I_O/_&_?JGTZ]X(Z
M]]HO]/\ >?\ C?OU3Z=>\$=>^T7^G^\_\;]^J?3KW@CKWVB_T_WG_C?OU3Z=
M>\$=>^T7^G^\_P#&_?JGTZ]X(Z]]HO\ 3_>?^-^_5/IU[P1U[[1?Z?[S_P ;
M]^J?3KW@CKWVB_T_WG_C?OU3Z=>\$=>^T7^G^\_\;]^J?3KW@CKWVB_T_P!Y
M_P"-^_5/IU[P1U[[1?Z?[S_QOWZI].O>".O?:+_3_>?^-^_5/IU[P1U[[1?Z
M?[S_ ,;]^J?3KW@CKWVB_P!/]Y_XW[]4^G7O!'7OM%_I_O/_ !OWZI].O>".
MO?:+_3_>?^-^_5/IU[P1U[[1?Z?[S_QOWZI].O>".O?:+_3_ 'G_ (W[]4^G
M7O!'7OM%_I_O/_&_?JGTZ]X(Z]]HO]/]Y_XW[]4^G7O!'7OM%_I_O/\ QOWZ
MI].O>".O?:+_ $_WG_C?OU3Z=>\$=>^T7^G^\_\ &_?JGTZ]X(Z]]HO]/]Y_
MXW[]4^G7O!'7OM%_I_O/_&_?JGTZ]X(Z]]HO]/\ >?\ C?OU3Z=>\$=>^T7^
MG^\_\;]^J?3KW@CKWVB_T_WG_C?OU3Z=>\$=>^T7^G^\_P#&_?JGTZ]X(Z]]
MHO\ 3_>?^-^_5/IU[P1U[[1?Z?[S_P ;]^J?3KW@CKWVB_T_WG_C?OU3Z=>\
M$=>^T7^G^\_\;]^J?3KW@CKWVB_T_P!Y_P"-^_5/IU[P1U[[1?Z?[S_QOWZI
M].O>".O?:+_3_>?^-^_5/IU[P1U[[1?Z?[S_ ,;]^J?3KW@CKWVB_P!/]Y_X
MW[]4^G7O!'7OM%_I_O/_ !OWZI].O>".O?:+_3_>?^-^_5/IU[P1U[[1?Z?[
MS_QOWZI].O>".O?:+_3_ 'G_ (W[]4^G7O!'7OM%_I_O/_&_?JGTZ]X(Z]]H
MO]/]Y_XW[]4^G7O!'7OM%_I_O/\ QOWZI].O>".O?:+_ $_WG_C?OU3Z=>\$
M=>^T7^G^\_\ &_?JGTZ]X(Z]]HO]/]Y_XW[]4^G7O!'7OM%_I_O/_&_?JGTZ
M]X(Z]]HO]/\ >?\ C?OU3Z=>\$=>^T7^G^\_\;]^J?3KW@CKWVB_T_WG_C?O
MU3Z=>\$=>^T7^G^\_P#&_?JGTZ]X(Z]]HO\ 3_>?^-^_5/IU[P1U[[1?Z?[S
M_P ;]^J?3KW@CKWVB_T_WG_C?OU3Z=>\$=>^T7^G^\_\;]^J?3KW@CKWVB_T
M_P!Y_P"-^_5/IU[P1U[[1?Z?[S_QOWZI].O>".O?:+_3_>?^-^_5/IU[P1U[
M[1?Z?[S_ ,;]^J?3KW@CKWVB_P!/]Y_XW[]4^G7O!'7OM%_I_O/_ !OWZI].
MO>".O?:+_3_>?^-^_5/IU[P1U[[1?Z?[S_QOWZI].O>".O?:+_3_ 'G_ (W[
M]4^G7O!'7OM%_I_O/_&_?JGTZ]X(Z]]HO]/]Y_XW[]4^G7O!'7OM%_I_O/\
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M_C?OU#Z]>\/KWB_VG_>?^-^_4/KU[P^O>+_:?]Y_XW[]0^O7O#Z]XO\ :?\
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M[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\
M#_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7O
MMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O
M!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%
M^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M
M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /
M]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V
M_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$
M]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y
M]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]
M^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _W
MW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_
M  _WW^W]^\7Y]>\$]:6__"A^/Q_SM_\ A.@/Z_*[J\_^Q;ZY]MNVKIZ--'6Z
MI[;Z<Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL4\\%+!-4U,T5/34\4D
M]143R")$2(%G=W8A515!))(  N??NO=4.?.O_A2-_*N^"XSVW<IWA%\B>W,'
M45F-FZA^,PI>S*V&MQ]2M)4TF2S:U5-M;$3T4QD^ZIZK-I6Q+#,J4DLZ+"_N
MO=4_?%/^=)_.N_FX?*GX^Y#X;_"Z/X]_R],/\BNH).^>VLGCX-SU61V;@-UQ
MR[PHQO/<R8O U3U&WJ*KII\?M["396DJ&,:UVNIIBONO=;M/OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(!_-B_[=9?S+/_% /F1_[[K<?OW7
MNJVO^$JG_;CSXG?^'-\C_P#WY.Z_?NO=;$GOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM+#_A1)_P!O
MN/\ A.?_ .+6]7_^_;ZY]^Z]UNG^_=>Z][]U[KWOW7NO>_=>Z][]U[I'[PW[
MM/85-1UF[,K_  FFKYWIJ23[&IKM;QKK*VIH9F6R\W8 ?XW][ KUHFG2!_V8
MWIG_ )[+_P!=[*__ %#[WH/6M8Z]_LQO3/\ SV7_ *[V5_\ J'W[0>O:QTJ=
MH]L=?[[R4^(VIG_XKD::ADR4U/\ PJMH=,,,D43/KJ::%#9YHQ8,6YN!8$C1
M4CK88'H1?>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6GW
M_P *MOA9_,\^66SNAJOX08?M[L7I#:&U^RZ#Y$=/=5]F288Y:;+S8R?%5=;M
M!<E1C=:TL%'6Q(L='6U,+3Z8H-$LK#W7NM>_X(_)G^0'\:^FNW>HOEA_+][>
MZ#^=.)Z@WAMQM_?*S 5_R3AAW4<56##3T.-.'QTFS\J]3-0UD4J=?4DE&\B
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M=J4">*S@D#230'$;V\^\A[A<\"RW)>3S^Z;ZXAB2Y2_42QQ2S+%XY1X_$>)
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MXN)=)O81&0!XGAR*Z,?,*Q 8#YL@(KYYK8OLW:U!LC:6VMG8N:LJ<?M?!8O
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M2VHA#'[W5]R]QY%V;9;7;Q"OUFSPK/*T0>5HQ!&@0,2**/$9AZ,:CSK?[O\
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MS&&E@BIXC45$E7)I@4*NN65GEE>P%W=V=C<LQ))]X;R.96+&E2230!14YP
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M6C_/GJC9O9'\O[Y@=.YR@-)LK<GQ/[OV@]+B4AIWHZ;^ZN1BII*'RQ3P0U%
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MXR;[RB-12R2I1@XFE=\<9312U+35;Q^>34M@U.JE:]=CX7;<;9Z;1J]_[IR
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MOW7NO>_=>Z][]U[KWOW7NO>_=>ZUDOG1_P!E6]P?]K7 ?^Z;'>SBU_LQ^?\
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M.PLOU^FT-J]>[<V3112Y&&DADR(J-Q5M34R.M#)62(6,9CFA'E6:-Q(XY 7
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MS9>#(04;XE(T#/5+DZ2HF#4VAHYFA3SA8$DD35EE]/DP(/V4ZW>835P*D$=
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MV+U'NC$4&;WQ/@:*BJ>R\%NC.S4\]7#A\A-)%1P[9DBC=:0&:2=2XA5"2SX
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI8?\
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M-X(F8/+XD(9]*G2INUA[]U[KV2R>.PV/K,MF,A18K%XZFEK,ADLE5QT-/!#
M"SRS32LL<4:*"69F"@<DV]^Z]TTY+>.T<-4"DR^ZMMXJJ:*.=:;)9REH9"DM
M]+A)958HUC8VL?Q[]U[J=B<]@\_%+/@LSB<U!!((9IL3D8<BB.1JTLT+N%:Q
M!L3>W/OW7NG7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW527SL_EU]Z_++Y?? [Y(=8_,S>_QVV+\2>R]
MN;X[1Z9VQ1YB>B['H<)N? YZ3#Y5\?N3#T<=//1XFLH;U>-R,8CKI282FN*7
MW7NJ:ODS_P )NOGYWG\D/D#W9LW^=UWWU/M#N+N[M;M/:O5N'PV]):3;6-[!
MSU?EJ';]*U+V=04K4V&I:N*DB,-!31%(5,<$*6C7W7N@1_Z!9_YC_P#WOY^1
MG_GCWY_]MGW[KW1P_P#A/GTS_-)^)'R@_F"_$;YO;\[\[K^/_7=7L_.?'7O'
MN"/<>5Q&>DJ,GEZ.HKMHY7<'WSI3Y/&PT=1DL5%FIXL=5)&\:R_=O6U7NO=;
M5OOW7NHM;746-I9J[(UE+CZ&F3R5%96U"4L4:W U/)(51!<@7)'OW7NJ?OYJ
M7\N#O?\ F)=;[LVKUA\[NT.D-A;CZPQFW)_CWA,-C7V'O*HH:ZNR,Z[NRN+7
M&[ZDQ.YJ6HHL77PXW=-+3B@@U+33/+.)O=>ZHZ[S^4N#^4W\A;X:=@;AZ$VA
M\=L?T+_,A^)O1';W2?6\_P!SMK;:= =DP[<K*?#S>8A<5+1I1,@-9,(9:AJ?
M[VJ\8JYO=>ZVNOFCF,5M[X=?+'/YW(T6'P>#^-'>V8S.7R52E'3TM)C-K96:
MHJ:B:0JD4$$*.[NS!552Q( ]^Z]T27^0S296B_DZ_P O*',>;[M_CCM.KA\]
M2*IOM:^6IGH;,'<!/L9*?0E[QK:,JI4J/=>ZMP]^Z]UHZ?S2^Z/^%1K]8_S&
M-JY;XD?'N+^7^VP_EWM_)]E)N3K\YM>G6Q^X::;."!.SFS'\4&RM54(UP!K/
M/Z1CS/\ Y-[]U[JV?_A*I_VX\^)W_AS?(_\ ]^3NOW[KW6Q)[]U[KWOW7NO>
M_=>Z(UWSELG3=R4,]/7U-!-M['_%C'81X9#&Q@[5[EP=#N..,CG144>&Q<,_
M]8Y$'%^22^8B;C2@@ _V]PH;^2@'I#<,0U1Y>&!]C2 '^0'16=N]J=H9[!U&
M$;?V]=\/!\AMA_'_ !%+@MY/LK(9K9&W:;<.5Q.Z(\O)4T'BKM_3T4=#/EJ>
MH1JE*-TH:G6[W*H[J60:=;-^JD0HVDM&H=@U:C,E*%AQI@])4D=Q2I/>$P:$
MH-1#5Q\7 D<:8/679F^^R,=V[C,-NNMW/AMBUV2ZQV7V5V31[Z@W37XK'8+L
MGNW&;/VODLQ%/+6RU5=FX<'@<MD5DGD7Q34]14_<9!ZZDM#/(LH#E@I**[A@
MQ4":X"*6XU+:48YX$$U-16.1EDH2:=H9J@T'B2A5K6M:T4G/IQ)(FUF=W5NK
MK?)Y?:V_>S,9OGKG;GRB[3[$W'B>R<_CZ&FQFU,QOO&[1Q!Q,5:,&:[)Y6FB
MJ%<T!?[#!U4<S*T]*S;+O+&2KN&03.Y#L  K2A!2NFI(KPX*?4=..[,I(+54
M2,34TH"X44K2I/RX*?ET+G9.[]T9_M7:6Q:7L+=6,PN6I/AI!N.CVMNFIPE0
M4WM4=IR9:,5-%-#5T4F9I\5BUGFAEBG:."%XI$=(W57=2L\JH'8 _3UTL0>X
MS5R""*Z17SP.G9'+2:*FE(^!IQ,E>'K0=!=!E-P[9QVT4K.TN^<G'OJ?O?9&
M6AQ^_J[<&4KX]A]S[(V9M?%XLY3+T-%ALG5XBOEPTF:BK**K_P OGR^0K9ZV
M(52)0[1A:O*=7BJ:.23IN(HU U, "0=.H$')8DG/3&4IW/G6.))-)450*G!H
M=.JH.=1-<]3-DXVKW_\ (2LV-O?=G9>P,;L?$_*+&X/$KWCD<CG<;3R8CX_Y
M<PU6ZZ7)/D:J*AK<[D*UJ:3+5,,32PP2/)34L<2W@0SW&AV=0HF 'B$L!IM6
MRX:IH6)I4CRX#K48\2;0Q8 "2@U'4,0'B#7!8XJ1GTZ-Q\2\OD-S=?0[TS=0
MM1N?L3;'3/86]2(4IB,UN38>V!7%H8U2.%I5IH)"BHJ@O<*+^S7:6,D>MOB<
M1NW^F,25_P '2ZS)= QXL%8_:5%>C5>S3I7U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6EA_PHD_[?<?\)S__
M !:WJ_\ ]^WUS[]U[K=/]^Z]U[W[KW7O?NO=>]^Z]U[W[KW05=R;USFP]D5V
M<V_AY<G7:TI?N@@EAH5G!'W<Z7U.B&P TZ=9760O#645/56-.JJ,CD:[+5U7
MD\G5SUV0KIY*FKJZF0RO(\INS,Q^I/\ O'T''M[IGJ("0002"#<$<?3W[KW5
MC?QK[%W5O/!UN*W#0UE;#M](8*3=DA&F:]@*6=F(:6JC0AM:AKI;RZ7*M*TX
MITZAKT9SW3J_7O?NO=5#?S>NP\7E>O?C[\)'SN#P5=\_>^=O].[UR&X7@2CH
MNL]BQG=7:==5FHJ*>%::JVOC&P:EV*-5YRCB8?N@CW7N@$^ ?R4H?CA\9_YB
M'Q@QF6V[V%G_ .59DNW<[U%2T5=318_+]4;IPF3W_P!41P3T#.K46,Q?W>U9
M9H481S8&9-;SI(J^Z]TKML?S#_FCC-C_  .^3_<?0_1>U_C#\V^P?C1U8VQM
MN[FW+7=B[/J?EJM#1[+SF5EJ:"/ SP3YK)8Z#)XD4\4V+2K51E*Z:GD63W7N
M@&^*_9W?U-)_PH#W+\@\7UGVIL?J_MKMU*_8LFZMPYJGG.V>E=EY&/:M$N1A
M"T>SZS%2U F2-DE2LJJEHH CF1_=>ZN(^-/>/4%;\<OC3629CK'J:3=?0/2>
MXL)U7'O"BH%P]+NC;N-J:'%4,%7/'5/24D,T=/3%H]3QHIY)]^Z]UK _S#_^
MR-O^%6/_ (L/\<O_ 'WO37OW7NMR^IJ:>CIYZRLGAI:2EAEJ:JJJ95@CCC@4
ML\DCL0J(B@EF)  !)-O?NO=!'G-]T_8FR>P<+\?NUNJJCM8[)W(NQ\S55<'8
MN,Q69JZ2:+#Y',XG%Y.DJZW%4V2:G>IIXZZEDJ(E>&.HA=Q(ONO=4I_RM^NM
M_=5_S7/YSNSNSN\-]?(;?%/UY_+(S.X.S=]T]+B))Y]SX7M;)/1XO#T"ICL#
M@<<:HT^/Q],&$-/&K5$]76R5594>Z]T$?\TG^6Y_+VW#O#J/XZ=2_"[X[TOS
M'_F*]R[MQU?W&G4^.W+F-J[7Q2R;A[5[0E2I)B_B6.H*A:7'U53%)3KN',XI
MIHI[BFF]U[K89Z2Z;Z]^/'4/6O1?4V!BVSUKU-LS ;"V3@8G,OVV.VW3I34Z
M,Y]4DI1-4CGEY"SGEC[]U[K6"^>6_9>\_D+\T/F_U[N_:4.]/Y-V>ZFVI\5=
MK5DM <KN3<'54]-OGY!8[$Q3U#U-0-T;5KJ?9*K34OD>OHJF(#R1*3[KW5NO
MS,[5VO\ */XX_#_KWI[=D-?MK^8AW5\<J7;^9HL><XN0ZYQXC[5WL&\"U%+!
M3YCKO:N9QDD\L@BBDR4:))]P\-_=>ZJ=^4>,^%.3_G3_ #"C^9/P<W_\U<?%
M\./A,^P<?L+X1;B^9TFWICE.RAD9JF+;^ SLFWDR2?9JKS>!:TTQ5/(:5M'N
MO=7J? #8'Q/VCTS7[@^(OQ,R7P]V+OC=62R&<ZZW)\::_P"*>8J\AA%2@.2R
M.ULMC,3E$\D4*)3U%11+YX45XBT11C[KW1Y_?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4L_S5OY._P#P
MY]NWI_=/^SC]^_%K_1+MS=6 _A_2,WV:YG^]%325/FR3_?TOD:C^TTP+H.@2
MS'5Z[#W7NM1CXM_R+>ZOG?\ )_YK]=_'3^:U\E-C_''X8=OS?&[*=N=DG,[X
MW#N/?6UHW_O+!0;:H-W[=@H<#C*H>""MFRK/5V$T,3([+#[KW0\U_P#*3W__
M "E/YF'\M/<_R?\ YCOR4[U^-O=_REV/M+KO/[7R63V95T/8FU\[A,QM/;^\
M\!7YS=4&7V=N9X9L;75-'40/'Y//.M+3J5D]U[KZ"GOW7NO>_=>Z CY0?';K
MSY;_ !X[E^,_:\%?-UYW=U]N/KS=+XFH6DK((-P0-$M912NDJ15U#-XJBG=H
MG19HHV9'4%3[KW5)&P?CW_PH.Z*Z.Q'PRZN[=_EW;QZ]V1@<'U-U5\TNQJOL
M"E[ Q6S</1T>.I:[+;,AQM=A<QO7%8^&H%-,=P"BJJ@4DE8>*EV]U[HS>'_D
MJ_'+'?RF=R_RHLCN#<NXME;QVGG)]S]Q9M!D,[5[YSF3&XVWR\<TLJBM@W-'
M3U<5-]P4^WA2B>5T+R/[KW11M_\ PW_GK_)WX_R_ +Y)=_\ P?VS\>]SXENK
MN\_F+U%1;IR7:.]MB0R"EJJ6GV?D\12[2VYN7=6%_P FRTZU]51TTDE6:%75
MHBWNO=;!?4W5VR>D.K>N.F>M<-#MWKSJ?8NU.N=CX*GMHH\3LNA@QV/IP0!J
M,5+3Q*6M=B"QY)]^Z]T(/OW7NB ?S8O^W67\RS_Q0#YD?^^ZW'[]U[JMK_A*
MI_VX\^)W_AS?(_\ ]^3NOW[KW6Q)[]U[KWOW7NO>_=>Z#W<G6NW-U;MVWNW+
M4\-74;?QN0Q,F-JZ&GKZ6LAJ:[&96E:HCFB<_<XK+8>@K*&96#TTRR-&096/
MM/);+*X<^0(I@@Y5A^8*@@^73;1AR"?+_.#_ "(!'IUCR?3_ %5F<8V&R?7.
MR:K%MMS ;06B;;5(B)B]I3FJQ%!$$B4PTN)JF,]"B%11S$RTWBD]7O36<3C2
M46FD+2@^%34#[ <CT/#KW@H132. ' <!D#\O+TZE4O5G6=%@:K:U)U]LNGVW
M7;>H-I5V"AVS1I23XO%25<U-CYH!#XY:.GFKZZ2.%U*))43NJAYI"UA:QA=(
M1:$!2-(H5%2!]@J?VGUZ\(E I04I2E!PSC[,GIB;H;I)]P/NL]2]=+N62KEK
MYLY'L^@BJ9)ZAY)))I95@#2RR232LSL2S%V+$W/MLV$!;5X:5XUTBM?V=:\!
M*UTK7UH*]2-J=(].[&AB@VAU?L/;R05N*R,+XO:]'32+/@?NACY1*(O)KQR5
MM7'2'7_DL4KQ4_CC8I[W%90P? BC(.%'$5I^RIIZ5H.O) D7PJ!]@'EP_97'
MITY9OJGK+<>)DP>=Z_V=D\1+%G(?L*K;E(Z*-S9"#+9 Q?M PR5F6I:6NE="
MKO60PU1;SQ)(MGM(I!I9%(SB@\R&/[2 ?M /$=;:)6%"!^P>9K_AS]N>D5+\
M8OCM/C_X7/TIUG/1&>:JDCFVA12M))5PTM/4R2RM$99GK::AHX:LN[&KAACB
MJ?+&H7VS^[+<BGAI3C\(^0/[:"OK3/5/I8S^%?V#SX_MIGU\^A#VELS'[1GW
M754E14553O#<\FYLD\ZQQ)&8J&AQ=)2T\42(D5-1XS&T,"+8EBC2N2\C'VHB
MA$18C\3:C^P* /D  .G%337YFO\ (#_ .EC[>ZOU[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6EA_PHD_[?<?\
M)S__ !:WJ_\ ]^WUS[]U[K=/]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6.:&*HBE@
MGBCG@GC>&:&9!(CI("K*RL"&5@2""+$<'W[KW5=_?'0\NS9:C=NTJ>2?:<\A
MDKZ",&1\<\A_V):C8FRL>8S9'-M+%U6KTTRTZ#_J#J#+=H9;4WFQ^U\?,@S&
M8"<D\-]M3:@5>H=2+FQ6)3K>]T1]LU.M*M>K/<#@<3MG$T6#P=%#C\9CX1#3
M4T(X ^I9B;L\CL2S,Q+,Q+,23[9X]/<.G?W[KW7O?NO=53=F?RW]L?*3^8!N
M_P"1_P SNL?CI\@_CML'XX;,Z6^*?3O96U8.VUQ>8W)F:W-]A[IS6 W!M\X*
MBR>0:EVMC\=/!69*845%.0V/-1/%4>Z]T _=_P#*/AV=W-D]^_R\>O/BK\9^
MO.Z_AK\G?B/\HNI]M[1CZ-Q.:/8&*FGZ_P!V4E#M#;%905N9V[N*6JIZUZFF
MIYWQ%=+XJJ9Z6&CE]U[HQ_:7PG[4WO\ #KX$?'O%9_K^GWG\6NZ_Y;O9'8&3
MR&5R,6+K*'X>[GVEFMS18::/%2U=15UU+@:Q,8M314D<TKPK52T2,[Q^Z]T&
M&#^"_P F=L[P_FY[6H,MT7DNE?Y@^/[![!ZQW/6;HS^.W/A]X[YZXV]L%<-G
M<0FWJG%1[:IOX-/5MDZ7,U5:_ECC&+&ES[]U[HR'5_\ +H^+$?7OQHJOD#\6
MOBIW!\A^B.D^C>MSW-N?I';G8&7IZ[IW$T-+3RX;<6;P?\<AI*+(T\T^/:]/
M)"6$JQ0RE@/=>ZK_ /E5_*G^0W>70/\ .OZKVGO+IC';A_F0]J=3[YZ.K-Q;
MASE)18JDV)M;8&#K(]UR4VW:N>AJ)*O:N1>%<?3Y-&ADIV>2-WECA]U[HZVQ
M<O\ S:MP;PV[@N].AOY:E%TWF,I3XSLZHV+\F>R]]9@82M/CR*X[#YCI[#8K
M)53TS2*E/5Y2FIY"=,LH6X/NO=&AZ/\ A_\ $KXQUVX,I\;/BY\=/CWD]V4E
M#0;JR/1_26VNIY\G!BWDDIH<A-@<9CY*V&GDEE:))F=8V=V0 L2?=>Z+]\?_
M (F=C=4_S"OYB7RRW%FME5O7/RXV7\)MN=;X7"Y&NJ,W13_&[";OQN<?-TT^
M-IJ&FBJY]P4;4)I<E6-+&DQJ%I65%D]U[J?!\4]^Y/\ F=Y+YL[MSNV<AUCM
M/X3XCXS]*;1@S%;/DL7G-V[TK-R[[S53CI<8F/@&7H<;LNCIZJ#+R5!CH*B&
M2FAC?7-[KW1V]W'=2[4W.VQ8<%4[V7;V:.SJ?=%=/C,9)E132_P],C4TU+75
M-/0M5^$3RQ451+'$7:."5@(V]U[JHGX=_P EGX9=7?&WJW:WRQ^(_P ,?DQ\
MII\/6[N^2/?&^OCYM?M>OW/OO?\ 6U.<W7DTSNY=N+F*S'R9O(5JT(FIZ414
M2P11T=)&BTT?NO=,W\O_ /EV_(/XN]H[+V_VMOG8NZ?C?\2L?\J-H?"C&;2S
M]=6Y"/;?R-W5ALMAZ7<]!782C-%E=A[=Q-3@:/[;,9"EEH:UI%=9"8:?W7NC
M==8_%KL#9?\ ,8^6'R[RF8V=4=;=[?'?XM=2;1PF/R%;+G*;)=(9#?%7EI\E
M328^*@AH:B/<U *1X<G42R-'.)H8 L9E]U[H^WOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[K3(^5/\FK^<;\1_FG\DOE?_ "0/E#L_8FR/F#O#*]H=P]/[ZK<,\M)N/,U=
M77UK0T6\<%N+;62HY:_*9.HHZ@FEJZ):B2C5#!'$[>Z]US^*7\E_^;]\L/F?
M\<OEW_/"^5>T]^;2^(^\</V9T]TML3(XKR5.XL'64U?0-44FT\'MW:V)HH\E
MC\7454T(K*O(+3I0RK'"[2#W7NMS3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=$ _FQ?]NLOYEG_B@'S(_P#?=;C]^Z]U6U_PE4_[<>?$[_PY
MOD?_ ._)W7[]U[K8D]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW15-Z_-GXS;#S-1M_,]FT-9E:.1XJV';F+KMSQPO&;-
M')4T--/2^16!5D$Q=&!#JI]PIS']XGDWE6X:TNMQC,JDAU@CFN0C*:%6:".1
M P((*ZM0(H0.I%VGVHW_ 'F(316K!& *F5XXBP.00LC*U#Q!I0C@>A?ZS[CZ
MQ[BQ<N7ZUWEB-U4M,8Q6PT;O355,9KZ/NJ*H2&LIM>EM'E@0/I.F]C['O*'/
MNS\_0&YV>[BN4%-00D21UX!XW"R1D^0=5)\N@QOW+&X<L2"*_@>$FNDL 4:G
M'2ZDJU*YTDT\^A,]B[HAZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NM+#_A1)_P!ON/\ A.?_ .+6]7_^_;ZY]^Z]UNG^_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NL<T,51%+!/%'/!/&\,T,R"1'20%65E8$
M,K D$$6(X/OW7NH&&PN)V]CJ;$83'TN,QM(K+3T=)&(D762S&P^K,Q))))))
M))/OW'KW#IS]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7S>/F(/YL7\P3,?SJ?GUU?\_>V_C_ -0?RVN]>R>G-A_&?J[M
MC=VS:;(83HW(S19F9%P>3Q5!CIZ?;L)RKULM'75&4KVGHW^QI88)D]U[H1MH
M_ SY-_%/Y4?R7_DC\I_YO'R*^47PI^57R1^.&X=A9/\ O9NS.QOO'+?PS>_7
M>#R^%R^\-P8^3;6YJ^BHX*G+0R5'VJ*6DI88W%;3^Z]U]$'W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$ _FQ?]NLOYEG_B@'S(_]]UN/W[KW
M5;7_  E4_P"W'GQ._P##F^1__OR=U^_=>ZV)/?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5Z?S'NW\_P!;].8O;.V:N;&Y/LS,
M56"KLE3L8Y(\9CX/)71Q..4>I:6GB)!!\32@<FZXL?>VY^N^3.7$M[%S'+?S
M&W:131D@5&>32?)F[4K@A6:E#0B:_8SEF'?MT:>X4.EJ@D53D&5FHA(\PM&;
M_3!>M?+WR>ZS5Z%3I?MC<?2G8VV^P-MU,\<N(KX/XKCXI-"5]!(ZBLH9@;JT
M=1#J4$BZ/ID0JZ*P'OMKS]=^VV\6^Z6K,!&ZB>,'$\!8>)&0<'4M=)/PM1A0
M@'H.<U\MP<V6,ME. =:G0QXQR =KCYJ?VBH-02.MKZGGBJJ>"IA):&HABGB8
M@K=9E#*;'D7!'ON0CB10PX$ C[#GKG(Z&,E3Q!(/VCH%NTODO\>ND,KCL%W%
MW9UAUAF<QCSEL5B]][TH-L3U-*)'A-1#%5SQ/)")8W34H(U*1>X]N*"V "?L
M!/\ @^SH?\G^T_,_N#"]QL6U;AN$43^'))9VD]PD<A4-I8Q(P#4(-#FAKT(V
MR]\;,[(VSB]Y]?;KV[O?:.;A-1B-S;4S-/GZ&I1258PU5+)+#)H<,K /=6!5
M@&! UT%M^Y>O^5;N2PW.WGM+F(Z9;>XB>&:,TK1DD56%0:BHR"",'H!=S?-S
MX?[,W'7;0W5\F>D<#N?&5AQ^0PF2[&Q=/40SJVAH9$-1Z)4DNCJ?4CAD8!E8
M#2MK!(J0.) )&/LZD;:/8#GC?K5;ZRV'=IK=UUI-'8W#(R4J&!$>01D'@001
M4$'HT?O?40]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI8?\*)/^WW'_"<_
M_P 6MZO_ /?M]<^_=>ZW3_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3'N#<F
M"VK0#)[BRE+B,>9XZ4556Q1/)*&*I< \D*W^V][ KUHFG3=MS?FS]WS5-/MG
M<&/S,]'$DU5'12%RB2'2K-=1P3Q[\01UX$'I6^]=;Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7-W3_*\^)?P#^17\R3^8'W
M-\G<MUQ\$/FUTIN[8_R@^/>\JBIH]G4.Z?D'N#%XO([FG2F>:DR(RL^4K*.A
MCJ,49\;/FJ](JB6DK!#2>Z]U5+\!/Y _R0[4[@^&'=._?YHF/^6/\JSXE=B;
M>[M^#.S<%F=TU^1RE)M#(M78>GJ<7D:2@PVW(*/)T=- :BER65,N.@DI**/&
MT\T:4_NO=;QGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(!_-
MB_[=9?S+/_% /F1_[[K<?OW7NJVO^$JG_;CSXG?^'-\C_P#WY.Z_?NO=;$GO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB$_P P
MKI//]M].467VE15&5W)UQEI]PQX>CB:HFJZ"KA,5?%3QKZI*B,+!.J@,SK$\
M:*SNH.,GWJO;F[Y^Y=$E@C27%C+]2L2J6>:(HR2*@!J7 (<  EM!1068=3%[
M*<V0\M;HT=RP2*Y01%V-%20-J0L3P4Y4G &H$D 'K7>(*DJP*LI(92+$$?4$
M?U]\DV4H2"*$8(/$'K-X&O0T=!=+;D[W[*V_L?!4=6U#/74U1NG,Q1%HL=C8
MG!JJJ62Q1'\0=858CRS%(EY;B2O:?VWO/=#>8-NMT8Q:T:[F .F"W#5=BU"
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MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTL/^%$G_ &^X_P"$Y_\
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M6.:L:L;K_<< I!3"I\QJ3-^V(M&O7Z-.KCW[KW1&O^$JG_;CSXG?^'-\C_\
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MPQ^X*62AJGB$Z5F/5E^VIZVKIV]%N2Q*J!3I!J>%205(H:8R,CT/J >O)>!
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M!MM5+8&>BO=][L]@A-Q>S1P1@@:Y75%U'@ 6(J33 &3T#7^S??&7_G].Q_\
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:6'_"B3_M]Q_PG/_\
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MHY)(DD]U[H*/F7\7.]NU_P";#_)?^2^P-C?Q[I+XG?\ #BW^S ;U_O-A\7_
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M>Z&ZBHJ/&T=)CL=24U!CZ"F@HJ&AHH$I888:5!'%##%&%2.*-%5555"JH
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MU[K9Q]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?,/^2WP!R/\U.I_P"%"O\
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M ,<OD//GZ7HCO'JOM^IVM#CJC<E-UUO?'[MDH8\N9EI9*I**>5H$J&IYQ&S
M!C&P!)4^[<.-1]H(_P /1IOG*>Y\LA#N-I<6PDU!#/"\0?32NG6HK34*T]1T
M.OOW0?Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K2P
M_P"%$G_;[C_A.?\ ^+6]7_\ OV^N??NO=;I_OW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*7VQ\W_ (W](?)'X_?$WLK>
MN0P/=WR?IMT5?3FWH]HY;*TE>FT @K/NLM24<V,Q9,LT$,/WE5!YYYHH8M4D
MBJ?=>ZR?-#YM_&[^7[TC7?(?Y4[\EZ\ZKH-R;?VBV:I=N9+=M1+D=SR.E'2T
M^/Q-+65U1(XBFD;1 0D4<DCE40GW[KW0T;9[4VKNWL+L[K'$Q[B7<_4?]R_[
MW/DMJY#$X]O[^T,F0H/X9DZFGCH,O:GC;[C[.HF^UDM%4>.0A3[KW0D>_=>Z
M][]U[KWOW7N@)^-7R2ZC^7'36VN_.BMP5>Z>L=VY;?F#P>;KL%6[;EEJ>M=P
MY7:V8C:CR$%-5QBFS6%R,*LT(658Q+$7BD1V]U[H=O?NO=>]^Z]T!'R5^2?4
M?Q)Z=W+WIW?G<E@=@[8K-MXF9\%MK([TR5;D=YY*DPV&Q6*P^(IJS)Y3*9;+
M5]'24M-3TLDDDLJ\*@9E]U[I;=4]BT';?7>T^R<7MCL'9F.WABDR]'MCM;8F
M2ZQW%1QR.Z+%EMOYB"ERF)JB$U&GJJ:*959=:*38>Z]UB[0[<ZTZ6V[0[L[5
MWI@MB[=RF[-G[#Q>3SU5]LE5FNP<E38C"8NF4!I*BNRF3JZ:GIX8T9Y)'  M
M<CW7NA&]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= _O/O;K78';/2_26Y\S5
M478GR _TC?Z+\1%B*JLBK?\ 13C8LOF_+5Q1/347VU#-&Z^>6/S$Z(M3@CW[
MKW3UUAVYUIW5M[(;MZHWI@M_;7QF[=X[$K-P;;JOOZ,9?K_)5&(S5"E0 (YI
M<;E*2JI9C&S(L\4D>HLC >Z]T(WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZH1_G=_P J;^71\[L!UQ\A?YA_R4[-^,NP/C7A-Q[=H-[[6[5V
M=U7A G9-=C;IE*K=FU]P)-63UE'204<<$T+RR2&)8II'0#W7NJ!?C'_PGA_X
M38?,S=M=L#XP?S,_DKW'OW'8RJS=1L;:_?\ ULF9:BH#$*BM@Q=7U135U324
M[30B::&GDBB+J)&4L![]U[JTOX]?\)%/Y;?QK[]Z/^1>Q>[?F_EM[= ]P=:=
MU[.Q>[.R=AUV*J<KU7FJ+.X^GR<%'UK05<V/FJZ"%*A(*ZGF>$NL4\+E9%]U
M[K:=]^Z]U[W[KW7O?NO=4?\ SF_GC?'#XH?+_P"(WP1Z_K]L=X?)CY$?*GHO
MHCL?9&!W.%7K_"=M9O&XB?+YZHI8JI(,W&F5I)Z+$2:*B>(F:<TT#PRR^Z]U
M:1\G_DCU5\0?C_VO\E^[LXVW^K^G-H9'>.ZZ^"):FHDCH]*04=% SQ_<Y'(5
M4D%+20!P9JF:*($%P??NO=4F[E_F[_S".E.I-N_-#Y-?RK*CKKX*YC*4>5WC
ME]F?(:#L?M;8NS,]*Z8W>NZMB4VW8J)Z+P-1561HJ+/25>*IZEGJP#25 ]^Z
M]UL&[6W/M_>VV=N;SVEEZ'<&U=W8+$;GVSGL9,*BFKL?GZ>.KHJRGD'$D%33
M2QR1L/U*P/Y]^Z]T^^_=>Z(!_-B_[=9?S+/_ !0#YD?^^ZW'[]U[JMK_ (2J
M?]N//B=_X<WR/_\ ?D[K]^Z]UL2>_=>Z][]U[KWOW7NO>_=>ZUG>U/@QU#O'
M^:WT)TIO:;-_(?(;QV5\EOE7\M-U=E319+(9+$[IH9=F;'P52M%!24F*P&W+
MFDQ=-21P&,O)+%XB8?&GT9(-36@)KZU)_FJ_96@H* 94[/S_ 'UCR=>7\&FS
M6.6QV[;HX 5C22-Q=7$@UEB\DM TC.6K@&HK4Y_\TO8%;U5_)S^1/6]5NS)[
MV@V1U[LS;.#W%G:=(<A+BL3NS"0XB'(RQL4K<A1XQ:6GJ:P)$:V:)ZMH87F:
M-=Z- 4$UH\>?/^T7H#>S^XKNW/%A<K&L1EN&=D4U02-#(7*@CM5FJRIG0"%J
M:5ZUR/E?\BOGENK^4QTQT[V?\-Z+K[XOX'8_QWH]G_(6/=:5LF4H]NT%(F J
MFH14N4.:@6)ROA!CUV(6Q]J%H9?B_$Q TL*FC8KP\_Y=92\F\K\N6?.MW?6F
MZ&:^>6_,EGX9 1G=S(NK2/[,U%:YIU:7\>>/Y_U+?C5\ .O=-^+_ ._6VO\
M3_;'VS#_ &0_TX_ZM#J'>9O^G:_]3J?_ *NS]$^^01#=Z_\ "BYE((_T/=8+
MJ!ORN0P@(_UP;BW]??AQC_TS?]75Z'/+0_W7\D_\]-Q_QV7HIWQYZK^>$WQ
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M22=7#J9O:;VTAYY,T]V[K#"533'0-([ GXB& 512M!4U&13-<?\ PY5\F?\
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MN#.[AR<E5EA)E-Q9_(RU67S5>]V/EJJN31J98EC0Z??NO='H_P"%&^(H-V_
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M>/#H-<N>Y^[[-87MK*7OH]PADMY$N))I3"JJ1K2KFA_6S@?"/RO<!# ,I!!
M((-P0?R/:_J'^N_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=:6'_  HD_P"WW'_"<_\ \6MZO_\ ?M]<^_=>ZW3_ '[KW7O?NO=>]^Z]
MU[W[KW7O?NO=47?S5/\ F;76_P#XCI__ '9UGOFQ]^+_ )*^V_\ /'+_ -7C
MUEU]W7_DG77_ #TC_JTO57'O![K(;KWOW7NC-_#3_LJ#IK_PZ_\ XUJ/<W?=
MP_Y7?:O^:\G_ &CS=1_[J?\ *O7O_-(?\?3K9]]]FNN?_7O?NO=%^R/QOV/D
M_E1L[Y>5&5W6G9.R/C]V5\;\5A(:ZC7!R8/M+<>U-SY"JJ*9J%J]\K#7[/QD
M=/*F3CITIY:I)*661XI8?=>Z(-C_ .2A\/\ #?##Y9_!K!YKNK#]6?,OL7,]
MC]K;LI]XXNLW-22UM1AFQV)P%968*IQ>-P.W,;M_$XK$T3X:=*7'0"-FEJ'D
MJ6]U[H=.X?Y</4?<]5\N9\QV9WOM&F^;IZ-QW?E#U]N_%;9^[PG1] V*7;F-
MK?X#/E<5B=SXN2:DS<D&07(RPRR+CJ_&ER??NO="?A?A?U'L_P"2VU?E!UQ5
M;IZPW5@^CJ3X\;FV)L.3%8O:VZML[:D67:\&X\=-B:FLFJ]EL:M<)4462H9*
M:&LJJ6<U-+(($]U[HG65_DX=09&ARG4U-\COECA/A1N'<&5W+N3X#XC?V$AZ
MZK#GLJ^:K\(M=)MR7?U#LVOR,LDM1MZCWG!C'1Y*)84QDTU!)[KW0[]J_P O
M3:6\^V\MW)U+WW\A_B?N3?N)V'M;O#%_'+<>!P&,WOA^M*6IH,-29.BSFW<\
MF'KZ''5)H(LO@FQ666@2&F%9_DM#)2>Z]T,_PX^)?5_P<^/6T/C+TQ5[MK.M
MMC;A[4W#MUM[Y:#.9&(]M;NSN\JZE>JIJ.A26EHLCN"KIZ35 9UHXX%J9JFH
M66IE]U[HF78/\H7JO?$O;VR\7\D/E7UI\7/D)GNP=S]Z?#;KG=NV,-L7<%;V
MQ42U>Z/#55&TJO>NWJ'<E54U<V2I,-NR@AFEGE:!:;S5 G]U[H7.WOY=^V][
M]Y8;Y%]-?(+OWXD=IQ]8;*Z*WME.AJC:=;1[CV3U_5Y6MQ."KL7O/:N[,=12
MXZ?-9'[7(4%-2UL(EL99#%3F'W7N@OV[_)W^,VUNN>R>K<5O_P"1,VV.T_G-
MU?\ S"]SS[@[(HMWY(]@]95>U*\LF4R^%KJ^7$9ZOVACI\G!4SU%06FJH\?5
MX^ TT5-[KW0H=Z?R],7V9W#NGOWIGY._)GX<=L=F83:6U^ZMQ?'//;9>FWC0
M;%BFIL/)F,/O/:^[L-#F\51SR4U)EZ*AI<@E+HIIYJBGB@BB]U[J-NS^5[\:
M,]\-,#\)-MU/976G7^U-\[2[;VQV-LS=\==O:FWML[<\.\X-ZU.<S]%FXLSN
M6LW-"U?75.4H*U*R66430E"JI[KW11?EG\6,E\R/EI\!.B,]U=\A,QL/X']G
M8#N[N'Y7]H4M#A,)OC'[)V[A\GA=MP5^)K,8=T9/</8%-M/*9B&/!4N.IJG;
M-8\E,B_81S>Z]U>E[]U[HC^U_P"7Q\>,%\)9?@#G:3=W870-3A-T8.M7>&X5
MILY(NYL]5[E%4F5P=-AFHLCC,Q5K48^KI(*>>DEIZ:9',\7E;W7N@QZO_EG[
M8V[VSLKM_OWY-?)WYJ9GIZ/<L/0>W?D]GMK9?"[.;=E!)B:[)4^.VUM3;4>?
MW%/B)IZ'^+YTY.MBIIJ@4ST\M762U/NO=!WMO^3YU+@5V/U[7?([Y5[J^)/5
MF]]@=B=6_"7<6\-LR;!P>0ZLSE-N+;E+%64NTZ7?5?M_!9>BHIZ+$5V\*FB3
MPI!-'/2QPT\7NO=#'W!_+OV_V+\A,_\ (_KOY*?)[XR;P[+V_L?:'R PG0.[
M-OX?&;_Q?6XJX\)'F4SNV<_6XK)4-+755&F4P=;BLD**5H14B2*DGI?=>Z@_
M'_\ E>?'7XU4?Q&QG6N=[63$?"O<?RSW'T_B\]N3&Y6.4_,3*Y;+[BI,S(,-
M%4UM+BILQ418GQ3TT\4,<(KY\C*))I?=>Z#FA_D_]$X;:>\MH[<[I^36VJ.H
M^1^?^5W1&3P^\MN1U_3^]-X5FY*_.5W7-9+M266.DSM1NS-C(4>X#GZ:IIYE
MI7C%.GC/NO=#O\>/@Y@/CUN'MCM[-]R=[?)+Y'=O=?[4ZZWGWKW'G<!3YZ7"
M==/F:K!83#46W,%MK:^"HZ*MSN3G0P89)9JB835U14M&C+[KW0U?%+8'975O
MQQZ;Z^[BWMN'L7M#:FQL1B]\;UW;N;^^N4KZ]%+RR9#,?9X]<I6)K$<U6F/I
M8ZAT,L5+3QNL*>Z]T8+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJY_\*"?Y
M,/S<_F>]S_#3N/X9=T=+=*;F^+E!O>MAW7V+V-N[KC-T.;R>5P64PF5VY7;4
MVMGZBFJ\948@S)4BJI)Z>=89("6&M/=>ZHU[8_X3'?\ "B7OJFVM1=Y_S/NI
M>Z*/8VYJ3>FRJ3MCYJ]Y=BQ8?,X]62#+8N/,;!K$Q^3@1W6.J@$<Z!B%< GW
M[KW1VOB=_))_X4C]4?*?XT]I=Z?S<_\ 25TEUK\@.F]_]Q==?[/QWSO'^/[5
MV=N/&Y'<.$_A&8VI38C*_P 5Q%-5TOV==414=3Y?#4R)"[L/=>ZW?/?NO=>]
M^Z]U[W[KW5#W\[_J#MKMG=W\G"IZLZN[%[+INL/YS?PP[1[*J.O]DY/>2;>V
MSM:IR;9/<><?'4U2N)P6.62,U5?5&*DIPRF65+B_NO=&G_G#?#/??SN^ '<_
M1G4.:I]N]XT,VS.VNB<O5R001+N_IS+T>X<-32RU,<D-.F2EH'H3,XT0?<^6
M2\:.C>Z]U5U\AOYEGR_^8OP][ ^%?4'\LGYV]7?/SY"=;;J^.F_QV7U97]<=
M;]>U6]:6;;NYMX?Z5Y%3#Y/ 8RFJJFNPU7C$DGR(:C>".,R CW7NK[/AO\=L
M9\1OBA\<OC!B,O-N&BZ%Z8Z\ZK_O#4#2^0FV=C*>CJ:\K8>,5M3%-,$  C#A
M  % ]^Z]T9/W[KW1 /YL7_;K+^99_P"* ?,C_P!]UN/W[KW5;7_"53_MQY\3
MO_#F^1__ +\G=?OW7NMB3W[KW7O?NO=%A[>^/F3W;VKU[\@NL-Z0=?=U]<[9
MW1L&*NS6#DW7@L]MG>,]'6U^W\]C8JW'5+1+D<=0U='5TM?#/1U,9=EJH)):
M61IT)-5-#]E0>./Y]"K9N8UL[.;;;J,S6LTD<Q56$<L4\895DC8HXKI=E=64
MAU-.T@, WWK\9>V?D<*3 ?*7M#:]5TO'54=7GOCYTSMBKV[C-RMC9EGA@W;N
M+)UU7E\MAFE1&EQ='2XNFJ- BKGKJ=GA:GAL_P 9%/0#]F3G'^SQ%>C.QYIM
M.629=I@D%S0A+RY=7>'4*$PQHBHCT.)&,C+Q0(U"#NT='1XZCI<?CZ2FH*"A
MIH*.AH:.!:6&&&F4)'%%$@5(XXT55554*J@   >U %.@([M*Q9B22222:DDY
M))/$GKU;'534=7#15*T5;+33QTE8].*M8970B.4Q%D$HC<ABA==5K7%[^_'K
M0ZIWP'P ^0M4=^YW?V^M@9K=^?VQ\90[UN^MS;TQFYL[\;]ZUFZWGSE!D,73
M4FW<!N>*6.!L/AJ1Z##^27[:GK")9JPH2PDR6()(C\R0QC8MFHP&]!@9X^9X
M^YQ=H52 #+Y*"HD0+@@Y*_Q'+8K3R$:N^)WR6R-3VON6+*]1[6J^Y.]MG]E[
MVZSV+V'N?9U#4X?%; H]IU.,CWGB\#0;DQU7%F*6+*-48_'T<N46)J66?'1U
MD^ASZ67N-5&IPS*"PQH"TU  C(K4 5X8KTT+V(:11CH0JK%5)KXA>NDD@X-*
M$FE:YH.D1A?Y?/<F-Z^VKM"IW?US55VWOC]\%^H):TY7*F-ZOXP=JU>]LU.F
MK$EQ1U.$EA@Q]QK>K!AG2E@5:AFEV]U4+482%?/_ $.0L?+TX?/TZ=;=(V8M
M1LO.WE_HL80>?KQ^7KPZ&7:'PMW'A-_]4[QR_P#HUKXME_,WY=_(W<6B.>IJ
M*C$=\TN\HL%!"TN,439>AES6#>J25XX8?M7-/4U!IZ?RO)9%2I.G$LCG['UT
M\N/<*_9TGDW ,K*-7=#%&/M317SX=II]O#)Z2FT_AUWKUE3[%RFRLGU'F=P8
M;97S ZAS.)W'G\QA\;28#Y$]B)O'!Y#&34F$JIZBLP./I**EFQ;TU+3.6>&G
MR$4<,<TNDM)(Z$%20)5H2:4=]0\O( "G\^KR7T<VH,& )B:H )+1QZ"#D<22
M:Y/RSTAME?RZ]_8;H3?76>XZKJ'*;MW7G/Y?U3!EE>MKZ847Q2P/66(W#!-/
M/A4J3]Z^TMQC'1BG:.6&LA%2U(:FJ2!J+;F2,H=-283Y\(Q&#Y?T#3[?+IZ7
M=5>4.-5 )Q3%:RM*1Y_TQ7[,5H.A)W_\1N\Z[MCM[<VR\_L?_15VSVQC]X9K
MK:G[)W/TY53TJ["VCM<U\N?VMBGRU)6T>3PF7G;'455!#E8:JG>KR=-)#X@\
M]H^IB*:68&FIE--"+Q45KVG XXR.D\=['H0,#J1*!M*N*ZW:E&-*$,,GA0T!
MZ#7J[X._(7J+;-?@*&D^-G9,V[?BQTI\:=Q5N_\ +YV(8U>M:?<L%;D*!8]N
MUC9.@J1FJ3_<;))C_N/MHR]93>!!(W#920"@T-6-(S6N-(;/ UK7AC[>GI]P
MBN#4ZUI(\@TTSJTT![A3X3G/V=6L[&VP-E;)V?LU<E5YD;2VMM_; R]?_GZH
M8&DAI?N9N6_=G\6M_4?4QY/LT1=  ] !T2NVMB?4D_MZ5/NW5>O>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM+#_A1)_V^X_X3G_^+6]7_P#O
MV^N??NO=;I_OW7NO>_=>Z][]U[KWOW7NO>_=>ZHN_FJ?\S:ZW_\ $=/_ .[.
ML]\V/OQ?\E?;?^>.7_J\>LNONZ_\DZZ_YZ1_U:7JKCW@]UD-U[W[KW1F_AI_
MV5!TU_X=?_QK4>YN^[A_RN^U?\UY/^T>;J/_ '4_Y5Z]_P":0_X^G6S[[[-=
M<_\ KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNF954LQ"JH+,S&P
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M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6EA_PHD_[?<?\
M"<__ ,6MZO\ _?M]<^_=>ZW3_?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ_?SW/\
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MLD*HI<Z8L97LS6'X5023^ "3P/8S]O!7>K7_ )J'_CC]8X?>Z8)[;[Z20/\
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M47CDT^Z]UWV5\Y/B9U-A>N,YO+O+9I@[BV])N_J7%[/:J[*RVY\/!'32S9C
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M_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U7_G.M_\
MA17@_P"9GL[^65-_.5Q\^_\ >/Q&JOEU2]EQ]8XY</#C*7<F5VT<1)2G;GWK
M5YJ,5),) /%XW47U ^_=>ZL _P"&MO\ A2__ -[U-C_^BA@_^QKW[KW7O^&M
MO^%+_P#WO4V/_P"BA@_^QKW[KW7O^&MO^%+_ /WO4V/_ .BA@_\ L:]^Z]U[
M_AK;_A2__P![U-C_ /HH8/\ [&O?NO=>_P"&MO\ A2__ -[U-C_^BA@_^QKW
M[KW7O^&MO^%+_P#WO4V/_P"BA@_^QKW[KW7O^&MO^%+_ /WO4V/_ .BA@_\
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M_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\
MAK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U
M[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QK
MW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/
M_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z
M*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-
MC_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\
M>]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A
M2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:
MV_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]
MU[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O
M?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8
M/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#H
MH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>
M]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]T0+X]]:?\**_D
M)\V/G/\ ";"?SEL?M_=GP7_T$_WOWKE>L,=48[.?Z=\)/FZ/^&P0[<-3!]A%
M 8YO.!J<@IZ??NO=']_X:V_X4O\ _>]38_\ Z*&#_P"QKW[KW7O^&MO^%+__
M 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*&#_[&O?NO=>_X:V_
MX4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\ Z*&#_P"QKW[KW7O^
M&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*&#_[&O?N
MO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\ Z*&#_P"Q
MKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*
M&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\
MZ*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\
MWO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\
M_>]38_\ Z*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V
M_P"%+_\ WO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X
M:V_X4O\ _>]38_\ Z*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z
M]U[_ (:V_P"%+_\ WO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&
MO?NO=>_X:V_X4O\ _>]38_\ Z*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@
M_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__
M **&#_[&O?NO=>_X:V_X4O\ _>]38_\ Z*&#_P"QKW[KW7O^&MO^%+__ 'O4
MV/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*&#_[&O?NO=>_X:V_X4O_
M />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\ Z*&#_P"QKW[KW7O^&MO^
M%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*&#_[&O?NO=>_
MX:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\ Z*&#_P"QKW[K
MW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*&#_[
M&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\ Z*&#
M_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V
M/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]3
M8_\ Z*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%
M+_\ WO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X
M4O\ _>]38_\ Z*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_
M (:V_P"%+_\ WO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO
M=>_X:V_X4O\ _>]38_\ Z*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L
M:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__ **&
M#_[&O?NO=>_X:V_X4O\ _>]38_\ Z*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\
M^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]
M38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\ Z*&#_P"QKW[KW7O^&MO^%+__
M 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*&#_[&O?NO=>_X:V_
MX4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\ Z*&#_P"QKW[KW7O^
M&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*&#_[&O?N
MO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\ Z*&#_P"Q
MKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\ WO4V/_Z*
M&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\
MZ*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\
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MPF2G8Q31I*FET5A[KW0@0004L$--30Q4]-3Q1P4]/!&(D1(@%1$10%5%4
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M&S:K+RR;Q[J[#W;LNCB?)19G'PT>,<XO$!B].WB)FE9V4A5]U[H-OD?\]O\
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M0;KP%))3S0IDJU*57HXJFNES7\1^Y,M335<"I!%'[KW1A/Y5/\P7Y_?S#/\
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MF9Q&V\-0;FVNV?QDV1H:627(X;%U$%=35-31/58VG5V:"05,/NO=)C*]F?\
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MX*HPU/D/#+6T&T)]N;<,+NE(U;/1S5JQ4,E5XX?=>ZK,Z#VW_P *@?@A\/\
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MW+7:8MSX-O+1X>HA/W-A(3#4"+W7NDI_PHV_EO\ S/\ GEWQ_*@WG\4>FO\
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F]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>timage_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_004.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MZ]U[W[KW7O?NO=>]^Z]TL=H516HJ*,GT2Q^9!^!)$0K6'^*OS_P7W[KW2_\
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$N<).6KK
MDG]\CG^@50!_O'OW7NFGW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UF@-G:W'[-2/]O3R@^_
M=>Z5F\6/GHE_ AE8?Z[.H/\ T*/?NO=(WW[KW7O?NO=>]^Z]T57Y(_-WXJ_$
M&?:U/\ENY-O=0'>\.3FVE4;IH-QB@SXPSTJ9:''9/'86OIWFIOOX&G@\HD19
MXW9 LB$NQPO-\ )^S/26ZO8;( S.J \"QH#^WHS.'R^*W#B,7G\%D:+,83.8
MZAR^'RV-J8JS'93%9*FBK<?D:"K@9TEAGAF26*1&*LK!@2#[:Z4@UZ<??NM]
M%*VI\[/B1OOOW.?%S9/>&U=W=^[9KL[CMR=:[:I\]F\QM^KVPO\ OXTS57C<
M/4T5*M"]H*N6>J1(IR('83$1ETPNJZR#0\#Y'I*E]#)(85=2XXJ#5A]H\N/1
M:_\ AZ_^5;_WFKU-_P D[L_^QKV[]%-_ W[#TC_?UE_O^+_>U_S]>_X>O_E6
M_P#>:O4W_).[/_L:]^^BF_@;]AZ]^_K+_?\ %_O:_P"?IYVY_.-_ED;OW#@=
MI[9^876&:W'N?,XO;NW\/11;KDK<MF\U708W%8VDC.W%#2SSU,<48N+LX'O1
MLY5%2C?LZLF]6DC!5FC))  #BI)P!QZ'/Y'?/CX>_$7<.WMJ?)+OG9O4>X=U
MX:;<.W<9N=,WY\MAJ>NEQL]?2OC<3D$*)/"T;!F# CZ6();C@>;X%)IQH*]*
M+K<(+*@FD5*\-1 K3TKT7/\ X>O_ )5O_>:O4W_).[/_ +&O;OT4W\#?L/27
M]_67^_XO][7_ #]>_P"'K_Y5O_>:O4W_ "3NS_[&O?OHIOX&_8>O?OZR_P!_
MQ?[VO^?JS#;FX<-NW;V"W7MROBRNWMS8;%[AP63@65(,CALU0P9+%U\*3QQ.
M$F@J4D4.JL W(!X]I3CHU!KD=//OW6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NBV;2^8'QIWUW[O+XM[2[<VWF_D#U[C:W+[TZMI
M8LNFX]O8S'G""KKJ[[C&PT_C3^\=#ZDG?4*J,K<'VX865=9!H>!\NDRWD3R&
M$.I=14H"-0&,D?F/V]>[P^8'QI^-NZ^L]C=X]N;;ZYW=W)DIL1U?@<W%EY:[
M>F3@R6%P\U#AEQN-KE:1:G<5##I=D]52EN#<>2%I 2H) XT\NO3WD5LRK(ZJ
M7-%!(!8X%!Z\1^WH=MS[GVYLK;F=WAO#.XG;&U=L8FOSVX]QYZOIL5A<'A<5
M325N2RN5R5;)#%!3P10M)++(RJJJ23;W0"N!TH9@HJ< <3U5;UY_/-_EC]K=
MP;=Z-Z]^0E?NG?V[=UKLS;<.,ZB[FEP>8SLDTM/"*7<)V"M)]H[Q$C(/(M*(
M_P!]YEIP90L?;YHUULM!]H_S]$D',=E<RB&.34Y)  5Z$BOGII3'&M.CR?''
MY;?''Y=;>W!NSXV]L;<[;VYM7,Q;=W!F-LQY5:+&9N:AAR4>-GDRF.QY,O@J
M(Y2$#65U)M<>TTD+0FC C[>C.VO(KU2T3JX!H2I!%>-,?;T8OVWTIZ][]U[K
MWOW7NO>_=>Z][]U[KWOW7NFC"9_!;EH3E-N9G%Y_&"NRF,_B6&KZ7)X\Y'"9
M*KPN:H5K:*6>,S4=;05%'51ABT4\$D,@62-U'J4ZT#7AT ?3GS ^-/R![ [/
MZKZ:[<VWO_L'I?)56([3VOA8LN*_9.3H\WD=N5-#F7KL;21+(M;B*JGTQR27
M:![7 )]N/"T8!8$ \"?/I/#>17+,D;JQ0T8 @E34BA].!_9T9/VWTIZ][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z:,SG\%MVGI:O<&9Q>$I:[*8K!T-1EJ^
MEQ\5;F\]D*?$X+"T;U<L0EJZVKJXJ6CIH]4DTTJ11JSLJGU*]:)IQZ=_?NM]
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1;,%\P/C3N;Y#;E^*&![<VWE/D3L[&R9
M?='5--%ESN/"8R+&8?,O75S/C4IEC^US]%*&%0;BI0"[&WMPPL%UD'2>!\ND
MRWD3R&$.I=14I4:@,9(_,?MZ,G[;Z4]>]^Z]U[W[KW7O?NO=>]^Z]TCNPNP-
MF]4;%W=V9V)GZ/:NQ-A;>RN[-X;ER(G:@P.W,'1RY#+Y:M%+#42>*"&!Y)-"
M.=*FP/NRJ7-!DG@.J22+"I=B  "23P &23TENC^]NH_DEUOA>WNC=]8CLCK7
M<51EZ7";OP2UJXO)5&!RM9@\O'3_ ,0I**4F"KQ\T#DQ@:HS:XY][>-HC1@0
M?0]4@N$NE#QL&4UHP-0:&G'[1TCNFOEM\<?D)O;M7KGICMC;?8&]^C\S_=[M
MC;F%3*+7[&S?\6SF"_AN9^^QU'&)/N]M5\%HGD&JE?FP!.WA:, L" >%?/JD
M-Y%<LRQNK%#1@""5.10^G _LZ,7[;Z4]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T][<8KF:/\ HQF4
M_P"(:GE_XFQ]^Z]T*OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z"3.?\ %VK_ /EN?^A5]^Z]TU>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NLT'Z
MV_Y8U'_N/+[]U[I5[Q_X$T?_ "PD_P"MGOW7ND=[]U[KWOW7NO>_=>Z(5_,E
M^"6Q/YAWQ6WST%NO['%;H>/^]'4F^:FD%3/L#M##TU2-NYQ2JM(:2<5$N.RL
M,9#2T59.B%9?&Z*+6X-JX<?F/4>G1;NVV)NT#0O3.5:E=+>1'#\_45'GU2A_
MPGM^<>^]LU^_?Y3?RPIZO:??'QJK=R4/4U+N%VCR.5V?MW(RKNKK4U,S,E3/
M@I)_O\++!)(M5AZ@FG'VV/$DB_<[<&DZ?"W'Y$_ZOV]![E7<77587&)(<+@B
MJ"@_E44X54@BN3U9!_.C_F/T'\O?XK9*?9V0IY_DEW5%E-@]";?AFIY<IC\M
M44T=-G>S7QLD-8TM+MV+(Q3QJ8)(YJ^>AI7TI.SHEL;7ZI\_",L?E_L_[/1M
MO^[C:8*KF1^V-?,L<5H*D@5K\S05%1T%'\BO^6;5_"+H2O[C[IH*ZK^7/R5@
MHMV=I5^XIYJ_/['VY5RRYC!]=3U55453_?F6NDR6XI]0EGKIQ!,TBT,#^[[A
M=_4M1::5PM/\/3/+>S?NN(O)4S2T:0DU(.33B>%34^9KFE*&2_X90_E6_P#>
M%74W_)6[/_LE]L_6S?QM^T]+?W#9?[XB_P!X7_-UK$]2_!GXEYW_ (4;=U?$
MK+]';0KOCCMS:N5KL)U+,V8&V<=5P] ["W1%/"4RB5)*Y#*U%4 U0PURGBU@
M#>6X<6BN&.HG)KGBW0-M=MMWWF:$QH4$8(32-(.F,\/S/[>MH_;G\G+^61M#
M<.!W9MGX>]887<>V,SB]Q;?S%%+NN.MQ.;PM=!DL5DJ20[C8++!/31RQFQLR
M ^R<WDK"A=OV]#1-EM(V#+#&""""$%01D'AUK_?\*%-I;<W]_-2_E8;%WCB:
M;/;1WKD^M]I;IP5;Y?L\UMS<?R,Q&'SF)J_#)$_BJ::LEADT.K:7-B#S[,]K
M)6*4CB!_D;H*\V1K+>6:L 07H0>!!>,$=7T?\,H?RK?^\*NIO^2MV?\ V2^R
MWZV;^-OVGH4?N&R_WQ%_O"_YNO?\,H?RK?\ O"KJ;_DK=G_V2^_?6S?QM^T]
M>_<-E_OB+_>%_P W5F&W-O8;:6WL%M3;E!%BMO;9PV+V]@L9 TKP8[#86A@Q
MN+H(7GDE<I#!3)&I=F8A>23S[2G/1J!3 Z>??NM]%AA^:'Q7E[=[5Z'D[RV)
M0]L=&[*K>Q^WMHY?(3867KS8F-@VS59#=FY\MEZ:AH*:A@BWEC))9VJM*I6(
MQLH8J[X+A0U#0X!I@G_4.DHO83(T6M=:C4RU%5&,D>0R/V]%'PO\[W^53N#L
M4=6XSYE]=G=+UZ8V.KK\%V)A]BSU<CP1QK3]IYC9E!M>1&:H4+-'F&C)O9O2
MUGVL)E744-/Y_LX_RZ+X^8K*63PEF0M^>DUIP:FDG/ 'HUWR:^;WQ/\ AOMK
M&;K^2W>6RNJ\7G(9JC;]-E)Z_,[DW)3TX0U%1MG9NUJ#.YC)1Q^5/(]#0U"K
MK6Y%Q=B*!YS1 2>E]Y?PV"ZYG5!\SD^>!Q)^0!/29^*W\PWX7?-DY.'XP_(#
M9_9^5PM-)6Y7;$=+N+:.]:''1U/V;Y6?8N_<)M;,BC\I5/N_L?"2Z6?UK>TU
MM);_ !J1_@_:,=-V.Z6^Y"L#JU.(%0P\L@@$</,9Z.5--#30RU%1+%!3P123
M3SS2+%###$I>6665RJJJJI+,2  +GVQTOZJJ[*_G@?RJNIMW5&Q]W_,;8DVX
M*2IEHZK^Y&V.S>T<'2U4%4U'/!4[MZPV-O#$QLDB$.&K1I U&R\^UB6$T@J%
M-/G0?X:5Z);CF*RM7T/,M:TQ5J&M,E00/SIT??I'Y!]'_)39D/8?0?:NQNV]
MF2SO2/GMC;AH,[345='?R8[*PTLK3454H%VI:N.&4 ABEB"4SQM$:,"#Z''1
MI!<1W2ZXV5E/FI!'\NEYO/>NS^N=JY_?78&ZMN['V5M7&U&9W-N[=N9QVWMM
M;?Q-(NNJR69S>6J*2FIH(Q^J6:1%']?=54L:#)/D.KNZQ*68@ "I)-  /,D\
M.JU=J_SMOY5V\^QTZJP/S)Z[;=LM?_#*>?+8/L+;6RJNM,T%/'#1=G[EV;B-
MLS^1ZA%B>'+NLG.@MI:RIK"95U%#3^?[./13'S#92R>$LR%OSTFM,!B-).>
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M8U1"K6(QXU%7#"X4-0T. :8)_P!0Z3B]A:1H@ZZU%66HJHQDCR&1^WHFL?\
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MD43K*ET)<M[,IKK;\R2/V="638;*12AAB (I4(H;\B "#\Z] 9_*(^$/S*^
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MDRTN5O(DE7@ZAA7B*BM#QR.M>C_A6-_V0[\??_%K<+_[Z'MGV:[)_:M_I?\
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M6Z G-/\ N=9?\U!_U<CZW#_9)T.^O>_=>Z][]U[KWOW7NM2/XS_]Q4OS,_\
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MHX''4,-4Z22UF2VYV9'EHHH?*JIC:M2[%%+;O?UK>-UX+@_;2G^3_!UK8?\
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M7G7,+3C(15$NJ>EG?3(H$ND:%07;1,P\$$"F:UX_F3T(MGBNXHR+QU=]6"H
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M08^?<>@QN>WQS;S''2BRH'D X/IU-0CA0^&M1Y\>.>MLKY6?%?HGLWX;=R=
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MZ#NT\N2[3*&6X=HAJ_2*FE&K3\9 (-#4**_*IZ-M\!OY6?\ LCOR>^:'R/\
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M+#N[;FP:$5F;R,U.L$24>Z>L&Q-:?+:EIZ^GKJEHX7/L\ ^JM J\4.1Y^?\
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MR_E<9;N'^:=\>/YC\'<^.P.-Z+V5A=H3]22[%J<C7;E.*'9JOD(MZ)NNCCI
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M;%I$5:&JQS>.28%RS(\:JWNVME95 [A0UK\QC(]>BK<-GBW*2*5RP,+:ETD
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M>^27\HSX_?*OXA_'_P"&7:_:/R&J>O/CC5[6JME[TQ.Z^O(.T<VNS=F9S86
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M4]2E?41R+?7WH@CCU96#<"#]G2U]ZZMU[W[KW718*+L0HNJW) %V(51S^22
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MJ*N\T_V]09(S"8Y$=SN'U":-"@5Q3R'[//'"G1UM?+?[MF\<S2.Q6CZB:.U
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M+99 TDGP+Q^9]/\ 5ZCJ_,.ZR6QCM;:GC3&@/'0M::B,GUS2E Q\J= CA_\
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M+:]#!A'87.J&0Z5[5\A\5%/'UX=1GS'M8BO+<>)*?&E-:O7PZNGP8[::L<>
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MZ1<PVKW6ZPHCM$6CHL@K4$>(<4*Y\L'SZL"_X8K_ )B/_?0!\T?_ #A[Q_\
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M,G-5U,6/R-#N6CJ8Z6>>I>FE::F,]0(1/(@OK7Z233Q'$'Y="+8-V_?-N)2
M&!*N!6@84.*^1!!\Z5I4TZM)]H^CKK4C^;/_ '% _P OS_Q"^S_^M?R5]G=O
M_N&_^F_Z!Z VX?\ )<M_^:1_P3=;2_<'_,I>T?\ Q'6]O_>:R?LF3B/M'0W?
M@?L/6M;_ ,).?^R'?D%_XM;FO_?0]3>S?>_[5?\ 2_Y3T"N0O]Q'_P":S?\
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MCJ7-97QA")LQB)L9F9#H4%ZYP+Z3[*+Z#Z>4KY<1]A_U4Z&?+^X_O.T20FK
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MRR6MVH66,!NWS7%:Y85%0:@T(.!@UV*O99T*NO>_=>Z][]U[KWOW7NGG;_\
MQ>*+_@\G_6B7W[KW0K^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[H),Y_Q=J__ );G_H5??NO=-7OW7NO>_=>Z#SMOJS9/>'5_8'3G
M9.+FS?7_ &?M#/[%WIAZ?(Y#$393;.YL=48G,T$64Q-31U5.TL%4Z":GFBD2
M^I&5@#[LCF,AAQ!J/M'34\*W*-&XJK JPR*@BAX9ZT@?B9_*V^%/:?\ /%^<
M/PMWMU=E<I\=^E^F<YN_KO9D78G86.K<-GZ+/_'.@IZR?=>/W-396K B[ RJ
MF*JK)D/W )6\<>@137DB6R2 ]Q:A-!_2^7RZC6SV*UEW6:V9*QI&&5=3X/Z7
MGJK^(\3UO0;1VMA=C;3VQLG;=,]'MW9^WL+M; T<M1/5R4N%V_C:;$XNFDJZ
MJ2665D@I(U,DC,S$78DDGV'":]2<HTB@\NE#[UUOKWOW7NO>_=>Z][]U[KWO
MW7NM<'Y1?\)L/C9\J?D+V[\BMW_(+O';FY>W]Z93>F7P6VZ+87\#Q55DF0&B
MQIR>WJZH,:+$HU2RL2;G@&P-(-U>W0( M!ZU_P _03W#E"WW&9IW>0,Q!(4K
M3  \U/IZ] +_ - F'Q(_[R<^1G_G%UG_ /8I[>_?<G\*_P _\_2/^H5K_'+^
MU/\ H#JP7^6Y_(^Z-_EI=Y;J[UZR[A[8[!SV[.J,YU+5X;?=/M"+$4V(SN[]
MB[QGR=,VW\)C9ON4FV'3Q(&D*:)I+J6TD);O<6NU"L *&N*^A'K\^C7:.68-
MFE,L;.25*48K2A*GR49[>KL_9?T(^J?_ .:K_,\WI\!O]"_7/2OQLWE\F_D#
M\@VWI+U]LW;U/EZS%T.+V NWSN&OR&+VIC\YFLA4EMS4OVU!0TD:M&D\LM7!
MXDCG6V=H+FI9@JBE2?G7[/3HCWG>&VO0L<3RN^K2JCR736M 3^(<!^SJF[ ?
M\*//FW\?,Q@_^'#_ .6OO/K'9V>R5320[DP&R.V^D\Q'#)'6U6/BP>VN\*?*
MTN7J52D*RQ#-8T.$DF4H$\17G:HY?[*0$^E0?\!_R=!U><+BUH;NU=%)(U ,
MOJ0 ' !.,]P\S3RZ/'V7_P *=_Y;VV.J:W>7759VKV?V/)BS-A.GO]'V<V9E
M/XS,A%+0;GWEG:5\+1TT;D?=U6/J\PZ(&:""I<"-DZ;1,QH0 /6H/^#/1E-S
MG8QH65F<^2A&!/YL /MS]E>M@?9.9K=Q[,VCN')4T='D<]MC 9FOI(4ECAI:
MW*8JDKJJFBCG>1U5'G955V9@!8DGGV6$4/0K4U%>B._/_P"1?S&Z!V]U]_LF
MWQ"J/EGO'=]5NN/<=#)N9=J8;86-PE)AOX9E\G7SBGBJ&JZG+^.*A^ZII94I
MYGC;3%*R/VT:2$ZVTCUI6O1?N-S/;*#;Q>*Q-"-82@IQJ?\ !UK/_P N+LG"
M]\?S>\QW+_-IW/N[J3Y_;9JJ/9?QH^.^Z>MLMUMU7B8Y,3E<=A5VUF<CDLFT
M\D:YG(#;V/K6$59-6#)0Y'*U=0BPFMVOA0:8,QG+-4$U^?IY?RX>8/V>3ZN_
M,M^2EPHTQ1:2JA0"*J:G56K4R?,@G&G=I]D74@]>]^Z]T#VROC[TCUUV!V'V
MQLGJW9>WNT>V<C#E.R.Q:+!TC;WWE4TU/%24<.;W34)-6RTU/'"J4U%YA3PB
M_BB2YO=I&8 $F@X#R'3*6\<;,ZJH9J:F %6I@5/$T\O3K6$_D&?]O//YS_\
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MFDHZ1?"E)+F.VC,<-26^)CC%/+A_J]>G;;;+K<KE+J^"((ZF*%2&H:\6.17
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M)R&?Z[W[@L33_=Y7-;+W3B<92^6"#[G(9'!UU'14_GJ9(8TUR3*NN1T47NQ
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MGD?=S$%5)%% X.*UH0:8^7IQZIMEX\DLUM(=30E*/0+J61-0K0TU"AK0 '%
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M.#_FC'_QP='U]INC/K3P_D-_]O?_ .;O_P"'KW'_ /!/[@]G>Y_V,/\ I?\
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=9H/UM_RQJ/\
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MII_,9'<AE57KV%82FC@45JGB:D](=AO9KU9C-34EP\8"\%"A, T!.:Y.3\N
M%;<G<'8VX_YA^[-B[+R>Z,IUM\3_ (9UG9?8?6^VJF*.+LCN7OK=V1I^J=MU
M\(6[U5!A.FLS-0K-J429R-T4$.2T$ CJ>+-0'T"@5_;J'[.EIF9[DH":)%J9
M:"C&1B%SQJ!&V//4/3HLG6W0?\T7N_IQOD5VG\Z-[_%GOW=N.K=[;1^-VU^I
MNGJOHCIFC6&>?;O7G95!O3:68SN;E\<,39NNFS5-)$\\R17$,9]NM)%&=(0,
M.&HDAC\QF@^6/MKTDBMKN=/$>9HW.1&%C,:>BFJEFI^(AA7-*8H<W^65\M<[
M\Y/@WT'\G-U;?I-L[M[!P.?HMWXS%TU528)MV;%WEN/K[<N3VY#655?(N/K:
MW:TU721-4U+0I,())7EB<^V[N#Z:1D]#C[#D?X>E&S7_ .\[:.<BA89'EJ4E
M33)Q4&F>'1\?:;HSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H#/D
MK\<^J_EGTAV#\?>Z<#_>'KOLC#?PG,TL4BT^1H*FGJ8,CAMP8.M:.;[?(8ZM
MHX*VAJ K:)H$)5EU*7(I6A8,IH1TGNK6.]C:*4:E84(_U>8X@^1SUKJ]1_R]
M_P">5_+UQV:Z9^$GR?\ CCW-\:%K<I4==;?[[H,G0;EV$F5K:ROJ&I,7_=G(
MI2.TE49)(:7.5E#+,SSBA@:6129O<V]UW2*RMYZ:4/[?]7S/06M]LW+:AX5M
M+%)$/A$P8,@J<=HSQ]:>@'0T?#S^2[W1EOE11_/;^:EWO@/E)\B]OR8RKZXV
M+MF"LGZLZ[R> KZNKVSDXVK\'M*"5,6TPK,5AL=@\90TE?+-6L:VI83BD]^H
M3PH057S/F?\ 5Y^OR&.G;#EZ0S_5WSB64?"H'8E":4K2M.(P*&IR>[JTC^9-
MT%\A_DW\0.R.FOBOVE2],=W;ER>PZK:O8=9O??'75/A:7;^^MO9[<<+;MZYP
MV?R],:O'8ZJI M-2R"4S>*4K$[L$EI*D,@9Q4"M10'R/KT<[Q;37EN\<#:'.
MG2VIEI1@3E03D CIS_ET=&=^_&SX;=.]*_*#LRF[B[SV7_I"_OQV-1[SWIV#
M3[B_O'VGOC=FV?'N_L+$8+,5?VF'SN/H#]Y21>(TI@BU01QNVKN199"R"BFE
M!0#R \NM[1;36=ND<[:Y!JU-J9JU9B,L 30$#/1VO:?HRZHV_EC_ ,LWOCX7
M?,;^8'\A.T=V]1Y[9?RN[!S.[.N\9L'/;RRFZ,-CLAVEV!O>&'>E%N+86UJ2
MGG%)NNGC9:&MR*B5)%#E LCF-Y=K<1QJH-5%#6GH!C)].@WLNSR[=<7,KE2)
MGU*%)) U.<U4?Q#@3T=?^8]U9\Q.\OC!O+IGX5[PZLZV['[,C;:FYNR.S=W;
MUVG+M'8&0@ECW*VR)MD=>[_J&R]?%_N/CJ'%$:2&HEJ()ONDA*)K5HT<-)4@
M9H #4_.I&.C+=HKB>!H[8JKMC4S,ND'B1I5C7TX4XUQ3I _RJOY<NR_Y;'QC
MQ'5%#/C-Q]L;LJ8=W]Y]A8XU4U-NK?4U)%2_P_ SY&EH:A,)B88Q18J%X*<L
M!+5RPQU-747M>71NWU' X >@Z:V7:$V: 1+DGN=OXF(%?L&* >GSJ>B+]^?R
MF/D;L;^9MLW^8U_+OWIT?U]6[D%3)\E.JNV\_O[:FW.Q*G*5-+2[R.*_N'L#
M?221[CHU6JKDJ8Z7[;,4,.53[F>9A HCO%:$Q2@FGPD4Q^TC_BNBZYV66.^6
M\M2BUQ,KEJ,,<**<D#Y"H!S4];"L1D,<9F1(YBB&5(I&FC20J"Z1RO%"64&X
M#%$)'.D?3V6]"CH-^Z-FY3L;IWMCKW"3T%+FM]]:;[V;B*K*RU$&+ILIN?:V
M5PE!/DIJ2EKI4ITEKD:9HH)G" E4<V4[4T->J.NI2/4$=5A?R2OY?/<W\MKX
MJ=@=&]Y;FZQW7NW=?R#W5VOCLCU1F=U9S;L.W<YUQU1M"DHJVKW?LO8M2M:M
M3L6K>2-*22(120LLS.SI&NW&Z6[<,M0 H&:>I/D3Z]$'+.T2;- T4I4DR%^P
MDBA51YA<]O5O]91TF1I*K'Y"EIJZ@KJ:>CK:*L@BJ:2LI*F)H:FEJJ:9722.
M1'9'1U*LI(((/M!T(NM3_87_  G>[+Z%_FG]?_++H;?/2^-^*&S.Y\7VIC^N
M,]F=\X[L[:V*F2>KS6RMNXG'[ S6)JJ:CJ:IXL3)/FJ1C3"-)@KQEY#E]S$L
M!C8'52E<4-"..>@3#RHUIN"W,101 EM&0RDJ00!0BE349%!BF,W,_P W'X9]
MH?/?X2[Z^-O3^>V%MO?.Y]U]>9V@RO964W#A]IPTFTMV8_.Y&.LKMK[7WC6+
M(\-(RP!*&12Y 9D6[!#8W MI [5H*\..1^71]OVWONEJ\$94,VFA8D##!O($
M^7IT9?X7],;H^.GQ(^-G0N]J_ 93>'3G2?7'6^Y\EM6JR-=MJNSFS]K8W!Y.
MKP59EL7@ZJ6D>6C9H)*BCI9&0@O$ANH:N)!*[,.!).?F>EFWV[6EO'$U"4C1
M33A55 -*@8QT9GVSTLZH6_EH?RM_D!\-/G?\ZOE!V?O#IW.[ ^3NX=_9;86(
MV%N#>N4WAB*;=7<>4["QZ;OQ^X>OMKT5.Z45:D4PHLAD )P54O':0F-Y=K<1
MQJH-5%#6GH!C)].@ULVS2[=<W$SE2)G+*%)) U.V:J/XO(GKW\R_^5O\@/F7
M\[_@K\H.L-X=.X+8'QBW#L'+;]Q&_=P;UQ>\,O3;5[CQ?8603:&/V]U]NBBJ
M'>BHGBA%;D,>#.0K%([R#UG=K;QR*P-6%!2GH1G(]>O;SLTNXW-O,A4"%PS!
MB02-2-BBG^'S(ZOI]EW0EZ][]U[KWOW7NO>_=>ZUT/YIG\IKY==^?,7J'Y\_
M KOC975/??7FT*#9=;2]A560Q=/CTQ/]Z*6BW)M/*46R]^4\[U-%N^JQ^2Q>
M3H! \(UK*YD:'V:6=ZD2&*525)KCCY?,>G04WO8Y[NX2[M)%21!I[N%.[([6
MSW$$$4IZ4R=W!]_?*+X7_#/I'#_*_:>X?F)\Y=UY'<NRJ#:OQHPE1E:3L[=D
MNXMQY;;%;E<_6;5V/C=O8V@P,N.&XLU6T5'24\D,S4\=06ABD3-&DTAT'2G'
MN\OV5KGAQ/KY]&L4\]E;IXX\6;X2(AAC4T-3I QEB:"N!Q *8_D\?(CY+?(S
MKKYF97Y6Y'$2]I]6?S!N^^CWVUMMZ:HVGUWB>N]I=302=?;2R$$$4E9C<?DL
MCDOMZVI:::?S&1W(956U["L)31P**U3Q-2>F-AO9KU9C-34EP\8"\%"A, T!
M.:Y.3\N %;<G<'8VX_YA^[-B[+R>Z,IUM\3_ (9UG9?8?6^VJF*.+LCN7OK=
MV1I^J=MU\(6[U5!A.FLS-0K-J429R-T4$.2T$ CJ>+-0'T"@5_;J'[.EIF9[
MDH":)%J9:"C&1B%SQJ!&V//4/3HLG6W0?\T7N_IQOD5VG\Z-[_%GOW=N.K=[
M;1^-VU^INGJOHCIFC6&>?;O7G95!O3:68SN;E\<,39NNFS5-)$\\R17$,9]N
MM)%&=(0,.&HDAC\QF@^6/MKTDBMKN=/$>9HW.1&%C,:>BFJEFI^(AA7-*8H<
MW^65\M<[\Y/@WT'\G-U;?I-L[M[!P.?HMWXS%TU528)MV;%WEN/K[<N3VY#6
M55?(N/K:W:TU721-4U+0I,())7EB<^V[N#Z:1D]#C[#D?X>E&S7_ .\[:.<B
MA89'EJ4E33)Q4&F>'1\?:;HSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>ZS0?K;_EC4?\ N/+[]U[I5[Q_X$T?_+"3_K9[]U[I'>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HL7^RH==_P"S
MF_[/+_&=Z?Z6?]EB_P!E0_N]_$<'_H[_ -'?^E7_ $O_ ,9_A/\ =S^)?QK^
M)?L?<?Q?[;[;T?9^7][V]XY\/P\4U:OG6E.D/T"?4_55;7X7A4QITZM=>%:U
M^=*>72BZ7^/FV.E=T=_;SQ.:S^X]S?(ON.K[CWKE=Q/C7FHJT;,V?U_M[:>$
M&-H* )BL3BMD4=/11S>::[2O)*[/Q5Y"X /X10?M)_R]/PVZPEV'%VU-]NE5
M_P "CJM'</\ )(ZWRG<_=O>VU?GC_,UZ@WO\@M[5>^NR5Z5^3&UNM,1EJ]JJ
MODP>)--M_J"&::@PU/D'H,-!6U%6U+2JL2R'U,RM=P*J%*1D**"JDG^9Z))>
M75DD>43W*%VU,$D"CT& GD,"M33SZ.?\1/A3_LI%9ONL_P!FU^;7R;_OU3;=
MIOM?EWWS_IHH]G?W>ES,OGV)!_=7;?\ #I:[^,Z<BUYO,M+3BR^+U,3W'CT[
M46G\*TK]N>C#;]M_=^K]6:753^U?7II7A@4K7/V#H[7M/T9=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]T\[?\ ^+Q1?\'D_P"M$OOW7NA7]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW029S_B[5_P#RW/\
MT*OOW7NFKW[KW7O?NO=>]^Z]U[W[KW7O?NO=4N_R9?\ NJY_XVB^='_S+O9A
MN'^A_P#-)/\ +T&^7/\ B5_SV3_\^]#3_+,>7LO"?*?Y=5I>9_EA\K>S\]LR
MK>03))TKTA-2?'/J#[*HO^Y2U=#U=49JG=0(V&8+1:XRLTJ>X[=*X[5'[3W'
M]E:?ET9;;6022FO?(U ?)4_3%.&&":O]MT7GNWNSN?\ F:;IWI\2_A)GZGK[
MXM8C,Y3K[Y;?.BD"/_%J&G%)3[OZ/^)L@^XAR><JHJJ;'9?<TL9H<?%)*U.\
MT_@$SL2K;=\@J:55/\!;Y>8'$_(<4EU++N9,-N=*5*RS#CCBL?JWD6X+FE6%
M!;OT_P!2["Z'ZNV'TUU=@H-L]?=;;8Q>TMIX2!GD%%B,33K!!YIY"7FFD(::
MHG<EY99'D<EF)]I'<N23DG)Z.8HE@4(@HJ@  < !CH2/=>G.O>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ7?Y,
MO_=5S_QM%\Z/_F7>S#</]#_YI)_EZ#?+G_$K_GLG_P"?>AI_EF/+V7A/E/\
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ME@G42Q05$<\$2"[MC:.4.?,'U'0AV?=$WB 3(*>3*34JPXC_ "@XJ"#0<.K
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M=85"I<W:J, "8  ?(!.K8OCETA_LNO4>W.I?]+W>7>O]W:G.U/\ I,^1N_\
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MT?\ 6K1_PK&_[(=^/O\ XM;A?_?0]L^SG9/[5O\ 2_Y1T".??]Q$_P":R_\
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M"<U_F?\ #^72\;M?['*B7^B2.0T\5:#2309P@H.)JM:$D$TIUM[JP8!E(96
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M?]D._'W_ ,6MPO\ [Z'MGV<[)_:M_I?\HZ!'/O\ N(G_ #67_CDG3;UYW/\
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MFC5M:C[F4!?4P)UM@U13 _P_Y&Z W-!T7MDPP?$(J.--<>/YG]O2R_X5G_\
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MP?\ [K*7V3GCT-APZ4GO76^M13^6=_W$I?S0_P#Q$W=O_O[OC1[.KG_<./\
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ML?'2Q@K'410E;FTNU2U)%"O$-4 4XUR>JVG-UHR*KZDD^$QZ')##%!I7.>'
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M/RR_[BD_@+_XKLO_ +R'RO\ 9Q!_N$_^F_RKT";_ /Y+EO\ \TC_ ()NA_\
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M_P"*>_=>Z]_!\I_RH57_ %*;_BGOW7NO?P?*?\J%5_U*;_BGOW7NO?P?*?\
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MG_X*OHWV8;5_;K_MO^.GH-\W?\DZ7_FW_P!74Z,A_)M_[=8_ _\ \5OZ]_\
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MO=>_@>6_Y4)_]LO_ $=[]U[KW\#RW_*A/_ME_P"CO?NO=>_@>6_Y4)_]LO\
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M"?\ VR_]'>_=>Z]_ \M_RH3_ .V7_H[W[KW7OX'EO^5"?_;+_P!'>_=>Z]_
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MR?\ RWG_ ."KZ-]F&U?VZ_[;_CIZ#?-W_).E_P";?_5U.C(?R;?^W6/P/_\
M%;^O?_=:?;%Y_:O_ *9O\/1ALG^X<'_-*/\ XZ.K+O:;HTZ][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZH!_X5'?\ ;BCYS?\ ELW_ ,&'\???NO=?(%]^Z]U]J?\ D>_]
MNA?Y=7_BJ75'_N@A]^Z]U:C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z36\_^//W9_X;6=_]U=5[]UH\.M>+_A*Y_P!NJL;_ .+"=Q?]
M"[6]F6[?VY^P?X!T&.3O^2?']K_\?/6R%[+>A1U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>)MR> .23^/?NO=)S(;FH*/4D!^\G'&F)@(5/
M^US6(_Y)#?XV]H)]P2+ [C\N'[>E\&WO+D]H^?']G2(K\UD,@2)9BD)_Y1X;
MQQ6_HPN2WT_M$_X>R>:[>?B<>@X='$-HD' 5/J>/33[3=*>O>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZET==54$@EI9FC-QJ6
M]XY /Q(AX/\ L?I^/;L4S0FJFG^#IJ6%9A1A7_#T(&*W)35VF&ITTM4;  G]
MF5CQ^V[?0G_4M_L"?9W;7ZS8;!_D>B2YL&ARN1_,=*7V8=%_7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=:F?_"D[^:-\/J?XD?(C^7=M_?==OWY,;YJ>J*7)X+8V-@S6U^LZC9?<VP.
MRLM1]E;MER%%2TE8:/8]33C&4/\ $JZ&IJ*=:NFIH9&G0YVFT<R"6E%%<GSP
M1C]OV= CG'>(%MWM-59&T=HSIHP;N/ 87AQR,4->A?\ Y"7\WOX7=K_'3XQ?
M!%]X9SKKY)=8]7X/KRDVIV/B:3"87L[*;8H(ONY^L-UT&4R]%6M*LUX,;728
MW)2F&8PT4D41E+6XV4D3-(1522:CRJ?/_53Y]*N6M^M[N*.V!*R(BKI84U:5
M )4Y!^S#8)I3K9M]E?0MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH!_X5'?]N*/G-_Y
M;-_\&'\???NO=?(%]^Z]U]J?^1[_ -NA?Y=7_BJ75'_N@A]^Z]U:C[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z36\_\ CS]V?^&UG?\
MW5U7OW6CPZUXO^$KG_;JK&_^+"=Q?]"[6]F6[?VY^P?X!T&.3O\ DGQ_:_\
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MJQ)^ >7<_P"I1!<D_P"M[;EE6$58TZ<BB:8T45Z0.3W/4U>J*CU4D!N"X/\
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MX'Y=1QN/),=O!))$TC."610*C37"T +$T\Z_EUL"?RZO^$[7SC^67:&U:WY
M=3[]^*WQWQ^9AJNPMT=M8"NV-V3F,)CJPC([:V!UMN2FH\O_ !&N$/@@R.2H
M:6AIXY35AZHQQTE2KN]TCA!"'4WE3('VG_-]F.B79^4;F]=6F4QQ@@MJJ'8
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M/_CS]V?^&UG?_=75>_=:/#K7B_X2N?\ ;JK&_P#BPG<7_0NUO9ENW]N?L'^
M=!CD[_DGQ_:__'SULA>RWH4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW2.SNXA!KH\>X,WZ9JE2"L7X9(CS=OZG\?Z_T*KR_P!%
M43CYGT^SY]&MG8:^Y^'D/7I DEB68DDDDDFY)/)))]DA->CL"G77OW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I.939VT<W5??9K:VW,O6^-(?O,IA,
M9D*KQ1W\<7W%72ROI74;+>POQ[07.U6MXVN:&)VI34\:,:#RJP)Z76^Z7-HN
MB*:5%K72DCJ*GY @=5';^PV'I_F;082GQ6-@PK=I=;4C8B&AI8L6U+52;5^Y
MICCTB6(QR>9_(FBS:C<&Y]XF<P6D4?.:0JB"/ZVR70% 2C>!4:0*4-344S7K
M*#8[J63E)IF=S)]'=G66)>H\:AU5K44%#7%.K;L=LK9N'JXZ_$[2VSBZ^$.(
M:W'8'%457$)$:.01U--21.NI6*FS"X)!X]Y8V^T6EHP>*"%&'!DC16%<<0H/
M6,$^ZW5TI26:5U/%6D=E-,\"2.E-[,>D'3#EMJ[7S\T51G=MX'-3P1F&&?+8
M?'Y*:&$L7,44E93S,JZF)T@@7-_:*ZVVVOB#/%'(0* NBN0/EJ!Z66VXW%D"
ML,LD8)J0CLH)]>TCJHSY%87#XWY0TN)QV)QF/Q;9#K]6QM%04M+CRM3#BC4*
M:."*..TFLZQI]5S>]_>)_N#9PV_-,<4<:*A>TJBJH4UT5P !GS]>LG^0[N6?
MEQI'=V?3<][,2V-=,DUQY>G5M-!LC9>*JX:_%[0VOC:ZG+&"MH,!B:.K@+*R
M,8:FGI(W4E6(.EAP2/>5D&SVEJP>*"%&'!EB16'V$*#UC)-N]W<*4DFE93Q5
MI'8'[021TJ/9CT7]>]^Z]U[W[KW7O?NO= Q\H?DQGOCC\2ODMWEL/9'^F/>_
M0O4._>P]O=:XVNJA5;HR^T=OUF7@VW5/AJ',540O3:Y5BII)?$KZ5! (.]NN
M=0\-N(^'[.B3<;;2?$7@?B^1_P!GKYJW7'0?\Y[_ (5&?().S.Q=Q5N'Z(VQ
MEH:2;L;<V/W#LOXH]+XJ;(RP9? ]+[)BEK5S^X(H?,)H*.:OR$ICIH\UEJ6!
MJ>H4UZ*NOH'?RK/Y+GPZ_E,[%J<?TA@J_>W<^Z,6<;V5\B]_Q453V1O*EEJX
M,A)@,;'1114F$P4<]-$U/B,<BAOMX9*V>NJD^Y;W7NK<O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW46:AHJBHHZRHHZ6>KQ
M[S24%5-3Q2U%"]3"U-4/1SNC-$9(W,;E"NI25-P;>_=>Z2/9?96P.F^O]X]K
M=J;OP.P>N.OMNY3=F]=Y[GR$&+P&V]NX:EDK,EE<G75#*J1QQQDVY9C94#,R
MJ?=>Z(=\)OYL'P[^>?QO[P^6W3^\\GMWH'X_;Z["V;V'OGM3%KL*+$8WK/8^
MV^Q-R;^KZ+(54KTF#.)W+'705-5XI!#%)YXH)XYH(O=>ZUI-S?\ "W3XVXSN
MY]L[;^$7;VZ/C[39.JHJCMYNU=K83LRMH(/NTAS.#Z1K=GRT,D<S0PM%!6[T
MQ\OBG+R"*2+PR>Z]UN%_&/Y,]*_,3HKKGY(?'G>V.[ ZD[1P29S:^X:#5%*O
MCGFH<KA,UCI@LU#D\;64L]!D\?4*DU-54\L,JAT(]^Z]T."45''5U%?'24T=
M=5P4M-55J01+5U--1/4R45/45*H'=(6K9FB1F(0S.5 U-?W7NI/OW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>ZH!_P"%1W_;BCYS?^6S?_!A_'WW[KW7R!??
MNO=?:G_D>_\ ;H7^75_XJEU1_P"Z"'W[KW5J/OW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[I-;S_X\_=G_ (;6=_\ =75>_=:/#K7B_P"$
MKG_;JK&_^+"=Q?\ 0NUO9ENW]N?L'^ =!CD[_DGQ_:__ !\];(7LMZ%'7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(;/[A-WHL?)8"Z5%
M2A^OX:*%O][8?[#^I)KV^_ A^T_YO\_1Q96/XW'V#_*>D1[*.CCKWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI][$_P"RX<?_ .):
MZO\ ^MFT?>(O,?\ RNZ?\]UC_P!J_64VP?\ *G-_SQ7G_6?JX+WEUUBSU[W[
MKW7O?NO=5 _)?_LK&D_[677/_6G$>\2_<?\ Y6V/_3V?^%.LH_;W_E67_P!+
M=?\ /_5OWO+3K%SKWOW7NO>_=>Z#+N3N;JOX]]8[P[F[LWWM[K3JW8.+.9W?
MO;=-:M!A<)0&H@HX&GETR/)+//514U+3PI)-/--'#"CRR(C61"YH,D]5=Q&*
MDT'6@G_,W_X5)]]_*?<%=\7?Y5^S^P-@;<W9E_[FT/<-%@:O)_(KM>IJ:Z?'
MPT'4>S,1!E9\!!D@$^SE5*C-R)*I5,94:H0<V^W+'W29^7D/M_U4Z)KC<&D[
M8ZCRKYG[.K;O^$T?\H7YD_ ?.=Q?+#Y:[VK]H;P^1>R<;AC\>3F_[R9R.J7=
M%-N^G[,[HS.JJB&Y(6:MIJ&BIZNL>"'-5YKI!53&GIV+R\5R GX36O\ D'RZ
M?L[-E!+_ (A0C_/\^MR;"R44F-IS04]/1TZAE^TIHHX(:>4L7F1(HE0"[.6X
M OJO^?9M!,)U##\_D>BF>$P,5/Y?,=.OM[IGKWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM4S_A8WVCN'K_\ E%8K
M:>%8#&]X_+7ICJ[=P,KQEMO8G:W:7=5,JJJD.?XMT_C#I:PXU7NH!]U[JH_Y
M);!ZK_E7?\).NO,3T_N3<5)VE_-.Q/QMW1V%G*O+5&9ES6>[RV%@^W>PL'C,
M:T*T>+QM+L[9\VU9?!3QLZ,OFEEJYA,?=>Z"C^1G_),^*'RP_DN?,OY-_*'K
MO#5W8O9+]S4W0?;55GL_C\KU%MCI#944^+WGA7HJA::E<;NH<K_%%>EJQ546
M.6GG$E/*\!]U[JUO_A%1O3<V;_EV?(W9V6R];D=O[(^76;?:E#65-151X&GW
M/U1UED<QC<4L\LBT]))5TKUOVT*I']Q55,]C)/(S>Z]UN/\ OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[J@'_ (5'?]N*/G-_Y;-_\&'\???NO=?(
M%]^Z]U]J?^1[_P!NA?Y=7_BJ75'_ +H(??NO=6H^_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NDUO/_CS]V?\ AM9W_P!U=5[]UH\.M>+_
M (2N?]NJL;_XL)W%_P!"[6]F6[?VY^P?X!T&.3O^2?']K_\ 'SULA>RWH4=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(7<&X-6N@H']/*5%0A_
M5^&BB8?C\,P^OT''U)KZ^KV)^9_R#HXL;'\;_D/\IZ1/LHZ..O>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ?>Q/^RX<?_XE
MKJ__ *V;1]XB\Q_\KNG_ #W6/_:OUE-L'_*G-_SQ7G_6?JX+WEUUBSU[W[KW
M7O?NO=5 _)?_ +*QI/\ M9=<_P#6G$>\2_<?_E;8_P#3V?\ A3K*/V]_Y5E_
M]+=?\_\ 5OWO+3K%SKWOW7NJ!OYM7_"@KXF_RS<?F^MMNUN.^0ORV6*HHJ/I
M+9V;HWQO7F2DQZ5M#D>\=RTLLXPL.FI@D3$Q+/E*A98V6GAII#61K;:R:XSP
M7U]?LZ17-ZMO@9;T]/MZK[_EB?('Y$_\*0?A5\W.@_YBW5]#L?HC+93J^CZS
M[IZ'V_N'K49#=%#N/);NR&%VW4[OR>^:')U&V,ALK#54QM4H$K_MJY',D;!Z
MX1;%U:,YS4'/^JO3-N[7RLKC&*$8ZN0_EJ_R5_A%_*^Q#UW2VS*O?/<N0IZV
MDSWR&[5CPNX.UJS'U\WEGP.!KZ'$XRDP>,TK'$U'B*6E^X6&-JV2JE42^TMQ
M=/<<>'H.'2J"T2WX9/J>/5MOM-TIZ4^V,E]I6?:R-:"L*J+_ $2H^D;?\A7T
MG_8?T]F&W7'A-I/!O\/1=N,'B+J'%?\ !T)/L0=$'7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5%_P \+^7+E?YH
MG\O7L[XU[+KMM8GM[&9S:_;/2&7W;3K)A*3LS8<]6(,;55XCDDQXS.(S&7V^
M<E"":9<L972:%98)?=>Z^<3O/X-_\*&OF%+\=_Y=?;7QX^5N:V-\6XYME=-[
M:WYUI3['Z.ZLPM;#BZ"7+Y?NVDV]A\!EJ2BHH(:>@RF0SN:E@I0]'C'TR-3R
M>Z]UM%_SIOBO\QO@S_)F_E^?RU_@-7[XW>V^=QQ?%OO[;'1_7D57F._,AOG8
MNYM];XK6BBQ>9R>)Q6<W#19NNRGAK:59*;(/!D:B6F\H;W7NKJ_Y /\ +4W#
M_*^_EY[/Z;[)%*O>?9N[<WWCWE2T%9_$*# [YW;B\#@Z#9U%615E9!*,-A=K
M8N@J9:5A#+5Q5,T5UD#-[KW5VGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[J@'_A4=_VXH^<W_ELW_P &'\???NO=?(%]^Z]U]J?^1[_VZ%_EU?\
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MRG_RN?\ U&7G^"?K*[F?_E4_^H2U_P ,/5RGO,#K%'KWOW7NJ:^I/^RRH_\
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M/<;[AM]IO>\QP<N)*J$QZ2=9TN#5I!K)8(N#5CBA/"G4@6%[=;/M+S;^\;.
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M+C<'C*2NFHZB./,)A(:W(5L:1I4YXQ@4L/NO= [_ ,(E/^R%/EO_ .+:1?\
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M3(4,<B,5='JX$=&'!5E:0$$?T/MHSHIH64?F.G1 ["H5OV'KA_%L5_SL\?\
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MZJ!^2_\ V5C2?]K+KG_K3B/>)?N/_P K;'_I[/\ PIUE'[>_\JR_^ENO^?\
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M]U[W[KW3?EO^+5D_^U?6_P#N-)[9N/[-O]*W^ ]/6_\ :+_IE_PCJIWX#_\
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M([.S$DCN9"6/$]'B((P%' ="M[KU;KWOW7NO>_=>ZI][$_[+AQ__ (EKJ_\
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MCH,?-5204<LD6E89&'NO=4:?] 5/\K+_ )_Y\_\ _P!&G\=?_N5??NO=>_Z
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MEEU14;?43XK&X[(]?;IHLKO39L,,-/33U$.,CQ-%#*X6*NJ 96?W7NFG8_\
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MO59.658(*<Y!:=*J>0VCAHZJI6&&9V/"K%(Y)( N2![#=ISQM%]*(8KN!G)
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M4QV%H*K*9:MIL=CJ*(S5595RI#3PQBPN\CD"Y) 4#DD@ $D#W>*)IF"H"2>
M&3U22585+.0 .). .B'=K_)K)YPU."Z^>HP^'N\,^X"&@S&23])- I"M21'D
MAO\ /,+&\7J4CK:N6U@H]Q1F\E_"OV^I_E]O0%W7F1IJI;U5>!;\1^ST'\_L
MZ*2[O([R2.TDDC,[N[%G=V)9G=F))))N2?8K IT%2:Y/7'W[K77O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]T8SH[O&KZ]JX]O[@DGK-EUDY_#S5&WJB9[O6T2#46@8MJJ*=?\
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MO]*W^ ]/6_\ :+_IE_PCJIWX#_\ ,X=R?^(US'_O4;.]XH^PW_)8F_YXY/\
MJ];]9->]?_)*B_YZT_ZLS]6Y>\M.L7^O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z26]=[[>V#A)\[N*L%/31W2FIHRCU^2JK72BQU,SQ^21O]<*HN
MSLJ L%=G927[B.,5/F?(#U/R_P!0Z27E['8(9)#0>0\R?0?/_4>JR^T.W=R=
MG9$O72-C\#32E\7M^GE8TM-8%5J*IK)YZ@J3>5A87(154D&2-LVF/;5[<L?B
M8\3]GH/]1ZC?<]VDW)N["CX5' ?,^I_U#H*/9KT5=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW1ROC)VW)1U</6^X*EFHJQW_ +JU4S7^TK&+RRX9W8_Y
MN8W:G_I)=!?R*%!_,NTZP;B,9'QCU'K^7G\L^70PY:W8J?IY#@_ ?0^GY^7S
MQY]:3_\ -K_GZ_.OYG?)#?W\N+^7ELCL+JW"47:N\NCJF7K>.KR_R.[ZS>TL
MGE]M;@I<?6X.%Y-M85Y<755#08J7[LTE-]Q6Y&&F>IHHR*VLDB76]#BN> Z/
M+F\>9BB5&:8XGH]G\F__ (2MX_IS.=<_*;^8KE5SG:NV<GM/L#K[XT;,S3+M
MOKC=NWLO3;CP^0[8WQ@:^1,]7TM114Q;#8F48M'BD2>KRT$OBC:NMQU55.'
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M7XA?"S^9O\-Z_J_LWY#;)ZMZ?S_9^U]QUG>'7.[.J(_NMS[5J,G51;=@WIN
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK,^?'\UCXP?
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M=?1XZE5E1JFOJH*.G#N;(AFJ'C6Y_ OS[]U[IC_OOLO_ )Z_:_\ Y_\ $_\
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M+^<K_P \'T+_ .CXVW_]1>_=>Z]_T")?SE?^>#Z%_P#1\;;_ /J+W[KW7O\
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z$':-'XZ::M8>JH?QQW_XY1$ZB/\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z36\_^//W9_P"&UG?_ '5U7OW6CPZUXO\
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M6QLAU_V5L%MT24T%-,QI:7);NQ\=7)J18HZDRO\ MH[)[KW6F_\ *7^?KO\
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M(SX6@6*-@+,WFC(!X8'GVQ'RKLLYT)*"QP LZDD_(9Z>?F;>(06>$@#))@D
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M,.[-C;8Z$QN7QV P\]?59O;E%3[&S>T:A8<@9XHFACJH(E1>58*J'W7NA?\
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MK4J\<+&G"I>,GU\^B2_R;NZ>H^G_ /9C?]*?9.R^O?[Q?Z(?X%_>_<.-P/\
M%_X3_I0_BG\._B%1!Y?M_P")T_FT7T^=+VU#V)/<+;Y[[Z?P8WDT^+JT*6I7
MPZ5H#2M#3[.@[R'?0V?C^-(B5\*FM@M:>)6E2*TJ.KC][_.SX:8':N=R&9[V
MZQW+C4QE8E7M_;^<Q^[\IFH9H'ADQ5/@<0V0DG-0)/$59!'9R9&5 S"/;?EO
M<)7"K!*IJ*%E* ?.K4 Z'LW,%C$I9IXB ."NK$_DI)/6NA_+*V?FM^_./K[.
M;4Q$N.P6T*W=N^,XL,\DU-MS;0PF8QU)12UA2-I!)49BEQZ74%_-<J%#E99Y
MSG6UVQTD:K/H0>K,&4DT^Q2>HOY1A-UN2R1KI5=;D>2J590*_:P'SZL?_GE?
M\R_Z _\ #QWK_P"Z3"^PC[;?V\W_ #37_CW0J]P?]QXO^:G_ #Z>BL[ ^?\
M3_&_^7_UOU+U9D(IN]=RU'84LV06&.KINML!D-_[FT9FJ675&V4J([G&TSJX
MC!%5.NCPQU!U=<K'>-VEFF!\!?#^1D(C3 ^7\1_(9R">VYE&T;7%%$09F\2G
MGH!D?)^?\(_,BF"F_P"5]\/]H_*[L?=/9/;&X*?=V/V%GL;5UO6]15U&1W'O
MG<V?EJ*^CR^[_/KDEQ<DT4NM=<KUU0CQ3%8DD6H?YUY@DV.%8(%T:U/Z@%%1
M%P0OHP'^\BE,D$,<G[$F]2M/.=>EA^F35G=LU:O%2?\ >C6N 0?H(=1[$INM
M^O\ ;NU(*>GIIJ*BCER$=*D<<"Y"H57J(85B5%\<(TT\6D >.%!;WA[NMZ=P
MG:3R)HO^E'#]O'[3UEMM=D+"!8_,"K?Z8\?\WV#HN'\Q3Y.1?$'X:]Y]XT]5
M34^Z,%M&HP?7:5*RRI4]D;OD3;6R@::!XI)8Z>MR4=;4HCQG[>EE;6@!=37D
M_8SS%N4%I0Z6<&2E!2-.Y\FHKI! ^9&#T6\U[T.7]NGNZC4B$)4$@R-VH"!F
MFHBO#%<CCUI@_P JO^6Y4?.[K+YN;ZS]%4UM9M3J>HVIT[DZZ2H*UGR!S53'
MO;%Y!:Z-FE=Z2+:\5'7@DZH=QC4)-17WDM[@\Z_U3GL88B #*'F4?\HZ_ITI
MPHVHD>A0<.L=>0.3?ZU07LTH)/AF.%F-?\8;]357C5=*U]0Y!K4]&E_X3=?*
M.IZO^2O8?Q2W;728_ =YX.?.[5H,E,U-]AVSUU3U-14XV"BG@&B?(X4UXJ"T
MD;%\/31:'8KI(O>O8A?646XQ"K0D(Y&:PR<#6O!7I3_3DUZ.?9K>VLKN7;I<
M"4%T#8(ECPPH16K+6N<:.'6[C[QAZR3Z][]U[J@7_A2#V16;,_E]8[:%$;_Z
M7>]^O=G96/7+';!X'%[K[)DG]$3H^FOV1CD\;LG^<UK?QD>Y;]EK$76\^(?]
M!@DD'S+%8J?LD)_*GGU%7O%>FUV?PP*^--'&?D!JEKPSF,#RXU\ND-_PF<Z_
MI<!\*>U-_P N.IH,SV%\A<_2+DXS3O4U^UMF;'V/0X:FJ7C3R**?(Y7-&..1
MB!YBZJ/(2RKWOO/'W6.($TCMUJ/(,[NQI]JZ<_+Y=)_9BS\#:WE(%9+AR#YE
M55%%?L8-_J/6O_\ S/\ ,4OQF_G0]M[_ -GP?PX]>]W=)=UPQ8B!:21\YD-E
M=7=M9V2*%*JG#2U-?E:EY298A*\K,Q36;2[R+ =\Y7B@<U\2"XAJV:#Q)8E\
MC@ "F,4ZBCG6X&R\SR3I4".:WE(7!/Z<4C>8XU-<YKGK8Y_X4@]D5FS/Y?6.
MVA1&_P#I=[WZ]V=E8]<L=L'@<7NOLF2?T1.CZ:_9&.3QNR?YS6M_&1[ACV6L
M1=;SXA_T&"20?,L5BI^R0G\J>?4O^\5Z;79_# KXTT<9^0&J6O#.8P/+C7RZ
M0W_"9SK^EP'PI[4W_+CJ:#,]A?(7/TBY.,T[U-?M;9FQ]CT.&IJEXT\BBGR.
M5S1CCD8@>8NJCR$LJ][[SQ]UCB!-([=:CR#.[L:?:NG/R^72?V8L_ VMY2!6
M2X<@^955117[&#?ZCUK_ /\ ,_S%+\9OYT/;>_\ 9\'\./7O=W27=<,6(@6D
MD?.9#975W;6=DBA2JIPTM37Y6I>4F6(2O*S,4UFTN\BP'?.5XH'-?$@N(:MF
M@\26)?(X  IC%.HHYUN!LO,\DZ5 CFMY2%P3^G%(WF.-37.:YZV_OYM&POE;
MVC\2Y^O?AQ/O*F[=W;V1LO#U$^R-V1;'R,>RJA<N=SMD=U3Y7"K1T&E(15L:
MF/6MHQK+Z&QQY"N]OL=Q6;<@AA1'-'3Q 7IV]M#4UX8IYGK(;G>UOKW;VBVX
ML)G=%!5M!"ENXZJB@IQIGTSUJ4?/W^4E6?R_/ASUOVSVEOZ'>_?O9G>&(VOF
MZ#;3U/\ <79FV9M@;VW!686CK<A!!59;(35N*ADJ<G+'2QA8UA@@L)*BHR'Y
M/]P_ZW[G);P1^';Q0,RZJ:W821J":84!30**^9). ,?^;N0/ZI[:EQ/)XEQ)
M<*K%:Z$4QR,0*Y8EA4L:<  !DG9:_P"$^?\ V[,ZQ_\ $@=O?^]UD_<(>[O_
M "79_P#20_\ 5I.IH]J/^2'!_IIO^KS]79>XSZD;KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN2JSLJ(I9W8*J@7+,QLJ@?U
M)/O8%<#K1-,GH7\91+CZ*"F%M2+JE8?VIG]4C7_US8?X >Q1;P^ @7]OV]!:
MXE\9RW[/LZG^W^F>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NJ;?Y[7\O+NG^9[\!LY\6.@]S]7[1[!R?:?6V^(,QV_FMV
M8#9J8G9U;D*G)T\V0V9LK?\ 7"HD6K40(N.9&(.N1."?=>ZTEO\ H"I_FF_\
M_P#/@!_Z-/Y%?_<J^_=>Z]_T!4_S3?\ G_GP _\ 1I_(K_[E7W[KW7O^@*G^
M:;_S_P ^ '_HT_D5_P#<J^_=>ZW'?^$]/\K_ +]_E-?"_L[XZ?(O=_3^]-[;
MT^3^].Z\7E.E,_O3<>U:?:NX^J>E=BT./R%=OKK_ *XJTR"5?7%=)+%'0RPB
M&6!EG9VDCB]U[J][W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_
M ,*CO^W%'SF_\MF_^##^/OOW7NOD"^_=>Z^U/_(]_P"W0O\ +J_\52ZH_P#=
M!#[]U[JU'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TFM
MY_\ 'G[L_P##:SO_ +JZKW[K1X=:\7_"5S_MU5C?_%A.XO\ H7:WLRW;^W/V
M#_ .@QR=_P D^/[7_P"/GK9"]EO0HZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[H)\^FC,5PYYD1^;?[LAC?\ '_!O89O125OM_P @Z$UD:Q+]G^4]
M,_M+TJZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#RJZBZGK:F>LK.L.O*N
MKJII*BIJJK96VZBIJ)Y6+RS3SRXUV=V9B69B22;D^P_+REM4[%WLK1F8DLS6
M\)))R224J2?,GH]CYHW.%0B7=TJJ  HN)0 !P  >@ ZP?Z&.GO\ GU'6O_H"
M[7_^M?MO^INS_P#*#9_]DT/_ $!U?^MFZ_\ *;=_]E$W_0?2GV]L_:6TDJ8]
MJ;6VYMF.M:-ZQ-O83&85*MX0RQ/4KC:6F$A4.0I:]KFWU]F>W[1:;2"+6&&$
M,06$4:1AB.%="BM/GT77VZ76Z$&YFEF*U"F61Y"H/&FLFGY=*/V8](.O>_=>
MZ*[\LZ)JCKC%U:*2<?NR@DE/JLL%1C<M3,;*I'^<DB%R0/\ &Y (FY4?3<,/
M5#^T%3_GZ#/-2:K=3Z./V$,/\W5=/N0NH]Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NN$DB1(\LKI''&C2222,$2-$!9W=V(   N2?I[]U[K7._F0?S^^IOCP<]U
M'\2C@.[NZZ*IJ</G-[2/+6=1==U4<!\Q@R%%)&-R9&*1U3[;'SK1Q,'$]8TT
M+TC%5WN:Q=J9/KY#_/T:VFV-+W28'IYG_-TX?!G8?:'\W[X,9"E_F?;%K\_A
M8>VX]Y=%]@XS&0=3;LW#@C@IEBW#C*+:]#B:5J&G&<JL?15JT0AK:=[R+/+"
M*J3=NK7T?ZP\Z@\#UZY86$GZ)\J$<>KJ/CG\8.B/B;U[2]8] =<8#KO:L3Q5
M.03%P--F-R96*FBI#G=V;@K'J*W)USQPJAJJV>9PBK&A6-515\4*P"BB@Z+Y
M9FG.IC4]#Y[=Z:Z][]U[KWOW7NO>_=>ZJ*_G0[3KL[\5-O;@H@&BV3VYMG+9
M8,Q 3%9;!;GVT)4 C>[BLR]$@!9!I=C<D*"._;V<17Y4_CB91]H*O_@4] OG
MN RV(8?@D5C]A#)_A8?ET'G\D'>N'JNENW>N5JZ<;@P7:"[UGH"Q6J;#[LVI
MMW!4E6BL0'C6?9DR,4OH++KMY$NK]R+=EN8I:=K1: ?*JNQ(_8XZ2^WTRFVD
MCKW"741\F10#^U3U=Q[CGH?=:Q_\['?F(SO?76VP\?+'45^P>O):S.O%(C_:
M5^\<L]92XN=%<E)4I,53U1#*+QUL9!-^)B]N+5H[>64\'< ?[09/V5:GV@]1
M1[@W*O/%$.*(6/\ MR*#[>VOYCHWW<VVJW:7\E''X;(Q305G^C/I/+S05">.
M>#^\O<&P=R1PS1$*59$RRJ58!EM9AJ!]D.URB?F(L*$>+. 1P-(Y!_DZ/-TC
M,6PA2""(H*@\15XSU65_+T^#VSOF;#W*NZ=Z[EV;/US'L(8>3;])BZV&LFWB
MN^!.^2@R,19E@;:\)18I(BPD<%AZ2!GS9S)+R]X/AHK>)KKJKC1HX4(_B/KT
M$.5N7XM]\7Q&==&BFFGXM?&H/\(Z"KY7_$7<WPN[:V]A=[PQ]C]=9J2',[;W
M!3)6[9I=YX?'U-.N>V_5M3U%>^-R$(E6.98IJG0E1#.I</H"S8]_7F.W8QGP
MI1AAAM!/!A6FH?L\Q\^DF\[&W+\Z^(/%B)J#E=0'%33*GYY\CZ@;(?\ +NJO
MBWF^BZ/<?QFV;0[+@JIX\?V!B*NHERN]L?NREA6HJ,?NG<%?+4U58B_=F6@E
M+K 891X(H?7#'$7-2WL=R4O6+D90\$*\*J!0#AG%:\<]2MRVUG);!K-0JGXA
MQ8-YAB223G%3PI3'1(?YY7_,O^@/_#QWK_[I,+[$?MM_;S?\TU_X]T'_ '!_
MW'B_YJ?\^GHFW\O'^7 OR7QE3VYVW55N(Z? R^(VSCL/6I3Y[>.=ION,;4UZ
MU$?E-+0XZH4W++KGGB\8 B5V80\V\WG:&^GMZ&7!9B*A :$"AXDC\@#Z\"#E
M;E0;FOU%Q_9&H50:%R*@DD< #^9(].(8]%=E]B?RJ_GGC,ON+'56?Q_7&[H<
M5OG"0THIZ?LCJ_(U$%2F4P]-654<8GDIC!E<2S5 6&MIXHY9"BS*RG>+&+GS
M:62,A6D0E&)_LY1Y$@5I^%L94U K3IG:+Z3D;=5:0%T1AK %/$C/!@#BH^(9
MPPTDTKU]'3KOL#:':^Q-H=E[ SE'N79.^]NXG=6UL[02"2ER>%S5'%74%2GY
M5BDP$D;A7C<,CA74@867=K)8RO#*I5T8HRGB&4T(ZS%MKE+R-98F#(ZAE89!
M5A4'K4C_ .%-GR@_BF[.D?B'M_(!J3:U%/W3V13Q&;2V=S4=;MSKW'3,'1 ]
M-0IEJN2-E>ZY*G8%;6;(3V-V+2L^XN.)$$1QP%&<_MT@'Y,.H$][-\J8-O0\
M*S2#/S5!Z?Q$C/X3CS 3^7#_ #L^B_@-\7MM]#0_&G>^[-S+N+=&\=^[SQ6\
M=LX:FW7NG<.1T05ZT,V$GE44N*Q^,QB&661BE"IN 0JFO.GM?>\VW[W?U,2I
MI5(T97)1%'#TRQ9C3S)Z+.3O<NQY6L$M/ E9@6:1U\,!W8\>(.  HKF@'51'
M8'RCQE+\Y,U\POC]M7*]9TX[QI>\=I;.RF:^]J,1F9LW2[JS^#K,EBTHU>@K
M*^2MB:GC54%'4_;%2@(,C67+[MM"[9>.LA\ P,ZKBE"JD ^:KISQU"O'J/;W
MF!$W<[E9JT:^.)E1FS4D,X)!.&.K'#2:4ICKZ6W37:FU^\>INM^X]DU!JMI]
MG[)VWOG 2,'$R8[<N)I<K!35221PNDT/W)AGC=$9)(V5E5@0,)-QL9-LGDMI
M11XG:-A_24E3P^SK,RPO8]Q@CN(C5)$5U.1VL 1QH?/SZT<.QOY_/\Q_;/86
M_-MXO?W72XS;^\]T83'+/U1M.:9:#$YNNH*19IC3@LPCIUU,0+GGWE%MWM#L
MUU;Q2LLU7C1C24TJR@GR^?6->Y>[6[6EQ+$IATI(Z"L>:*Q KW<<=-_RK^8/
MR.^>?\K:?M;OC+XG<F5ZP^=^RMGTDFV=H4&WJ+%[>S/0O8&06LR*8>G5 IKJ
MA*<S3M8O40QK9F 9SE[ERSY1Y@^FM=0$M@[][ZB6%P@H*T_"M:#T)Z:Y@YBO
M.;>7_J+D*3'?JG8A "> YJ<G\3TJ?,@<>KZO^$V^XJ#,_P O?-XNE6=*K:7R
M)['P>3$XA59*FLVQU[N>&>D\<\K&$P;ABCU2+&?)'*H4JH=HH]Z;=H=YU&E)
M+>)A3T!=,XXU0^N*=2A[/7*S[.%%:QS2HU?4Z9,9X4<>F:_;UK=?SL,36[T_
MFY_(O;FW$7(9;<6?Z%VQBJ='"BHS59T/T_@X:,NU@#]TWB8G@$'W-GMC,MIR
MY;R285%N';_2B>9C_+J&?<B!KSF*>),L[6Z+_IF@A4?S/6P=_P *:,%75OP@
MZAS-)!45%)@/DWM:/)&*">H%'2Y7K'M6F@KZRH4.(HA/#%3^24@-+4QH#J8
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M4@5.11"&-3G>S]XK=9.=:V/_  IU_P"R.^B?_%EL9_[Z[LKW-?L9_P E.?\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/MW4I2J@JU'IGB\;D?\=83P2?\58
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MQ^18?X".L$/QYZ<@8NFS(6)4K:;,[CJ5L2#<)49B50>/J!?_ &Y]V/,%X?\
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MW]NW^D/_ !Y>@?SM_N*G_-5?^.2=7-_RH?\ MV3\ O\ Q4/H#_WVFW?99?\
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M )IQ?\>?HTWQP_YD9UC_ .&O2?\ 6R;W*7M]_P D2R_YYT_P=1QS[_R6;O\
MYK-_DZ&SV,>@CU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJQ?\ "NO_ +=N=)?^+O\
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MT=P=H[KC/^?HZG"8%6ZUV:9Y'+@C1DJ&954VO%9?0"/>V[4'^KY]:&3U9/\
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M3VMO/<--CZO<^1V=M7,[G?:>":*IW%EQB\76Y*EQ6.HM1;[BM-$8*4, 'D8
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M (<(RO\ SZW'_P#H65/_ -8/8]_X(&3_ )05_P"R@_\ 6GH$?ZQL?_*8W_.
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M;-U_Y3;O_LHF_P"@^L4_2?3D\,T#]5==(DT4D3-!LO;E/,JR(49H:B#&QNC
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MKW\8RG_*_5?]36_XK[]U[KW\8RG_ "OU7_4UO^*^_=>Z]_&,I_ROU7_4UO\
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MXJJI,@8J:D6HCHZC RAXJN1/=>ZV8?A_\$OB+\!NO*GJWXA=%;.Z3V?D*_\
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M]Q3_ -!'+K4?["99#_O/M*^VQMPJ/L/^>O2I-RD7C0_:/\U.FR79I^L%</\
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M.\U!M3:E!,ZZG;2)*NKD @I( T\[!0 U;>W:Y;2O^P!ZGIS<MRBVJ(RRF@'
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M,L*/55"4$\\LCL(Z>FIIZF4B*%S[2V]NURVE>/\ (#U/1QN.XQ;7$9I30#
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M%OS%=6T:QI83:54*,OP H/\ 0>J]?YHGR#_F$?S%LC\<][;8_DX?-;XY=O\
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MG:V*P1EYZ@_A .3C_5]G3;[_ ";A<I!84=0?UI"IT@5I@U'H:>1Q0TKT-O\
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MOW7NO>_=>Z][]U[J@'_A4=_VXH^<W_ELW_P8?Q]]^Z]U\@7W[KW7VI_Y'O\
MVZ%_EU?^*I=4?^Z"'W[KW1[]XY3[_)&FC:]/0:H18\/47'W#_P"P("#_ (+_
M (^_=>Z2/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[HI?R"_P"/EPO_ &HQ_P"Y]7[=3ATT_'H _=^J=&U^/O\
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M^]B]?]-]3]Y;*K.M-H4&\<[GNQ\7L*EVX]-DLS%A:+$0U.V=^[DJA73O))-
MC4GB:*EG+3(ZQI*]=V+68!8@UKPKY?:!TBV?F"'>RPB5QH )+!0,UIP9O3JW
MKVBZ/>B4_.7Y]= ?R\^M]J]J?(B?>%-M/>.]X.OL-)LS;?\ >>O.XJG YS<<
M255$*^@,<)IMO5)\NIK,%6WJ'M^WMGN3I05(%>-,=(-QW.':D$DY(4MI! )R
M03Y ^0/2W^4ORZZB^'WQYSOR<[CDW+!UAMS^Z'\4EVWA!G<]'_??.XC;N$\6
M(6LI==ZG-P++:7T*6;D#W6&%IVT+QS_+IR]O8]OB,TIHHI4T)XD 8'S/0A]"
M]U;+^1W376_>W7)RQV)VKM3&;SVFV=H%Q>7DP>7B,U!+D,<E15^&1TLQC,C%
M;V-C<"LB&)BIX@T/3MO.MRBR)E6 8'A4$5''JC+Y"_\ "FG^7_T5VIN?JS";
M<[M[O?:&0J\-F=\]68+9$NPY\UCZN>BR%!@,ONO?FVI\@D$E.0:VGI32R7#4
M\TR'5[,8=IEF75@5X5K7^0/09ON<K2QD,7>Y7!*!2H/I4LN1YTQ\ZUZOZZ^W
MC3=B;"V1V!18C-[?H]\[0VUO&DP.Y8*"EW'A*;<V&HLU!B-P4V+R.7I8ZZF2
MM$-6E-5U42RHPCFD0!V+"*&G0J5M0!X5%:'CTK_>NK=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UF@_6
MW_+&H_\ <>7W[KW0U>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[J@'_A4=_VXH^<W_ELW_P &'\???NO=?(%]
M^Z]U]E[^3W6_]BAOY;F.4\?[*CU763#^M\!'#!S_ +"2X_Q'OW7NC1=[_P#'
MD1?]KR@_]QZ[W=./5'X=$W]N]-=#3T/_ ,?O-_VHJ_\ ]R:#W5^'5DX]'']L
M]/=>]^Z]U[W[KW7O?NO=>]^Z]U!R<LD&-R$\3%)8:&KEB< $I)'3R.C $$<$
M \^]CCUH\.B0?Z5^P?\ GI:G_P Y<=_]1^WJ#IFIZ<,3VCOVHRF-@FW%4/#/
MD*.&5#2X\!XY*B-'4E:,'D,1P??J#KU3T=WVQT_U[W[KW7O?NO=>]^Z]U[W[
MKW2:W7O/9^Q,4,[OC=>VMFX0UE+CQF-UYW%[>Q1KZZ3Q45",AEZJCA\TS#3%
M%KU.>%!/OW7NM8C^>I_,L^4'4'RL^%W\N'H"3<O2&TOFKG>J,-O?Y;[=Q\<V
M[*?;797<D'5NY=G=&9W(TU9C:/-8RBFBK\GD-%15TR9C'M *4RQ5,FQGK1QT
M3[J+_A-%\)=F=P8;M7MWL7O?Y&46.SL^Y\WL'L'<.W<9M_?V<GGDK)'W]E]O
M;<I<O6T\L\S5%5%!D*-ZB0 33/$TL4KF@=-ZSUM.]:=AX39.&V/UAL'K?9^Q
M-A[;I,!LW:FT]HT4.!VYM7;E M-BL7A]OX/&4U+34M+2P(L<%/#&B(J!0 /?
MM Z]K/1P/;73O7O?NO=(7LOKC:?;6Q]P]?;VQR9/;NY*%J.LBX6HII599J+)
M4$Q5O%4TTT:3T\H!TO&I((N#M3I->M$5ZHYZ;WWO;^7=\B<UU%V=-45G46\*
M^GFERJ13-0MCJB5Z3 ]E8:F!ET.B(*?,4T9=M,3I^\]-3DJ6'BBHZ;!TGJ_B
MDJZ6OI::NH:FGK**LIX:NCK*2:.HI:NEJ(UFIZFFJ(6=)(Y$<,CJ2&!!!(/M
M+T[TX4L7GJJ: "YFJ(8@/Z^214M]1_7W[KW1B/?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW00YC_BZ5_P#U%2_]#'W[KW3;[]U[KWOW7NO>_=>ZU'O^%&$T--\X
M/Y.5142Q4]/3]QYV:>>:1(H888NW?CJ\LLLKE5555268D  7/L[VO^RE_P!+
M_D;H#<U_[EV/_-4_\?BZ/%\@O^%*?\M?H;?V2Z^QV0[E[ZK,)65V-S6X^B-E
M;5S>RZ#)8^2.&>DI]R;^[ ZYBR*EV=8ZK$C(4K^)BLY4H730[5+,*X7TU'C^
MP'HPON<+.Q?PZLY!(/A@$ CYLR@_E7@:TZM ^&_SM^,7STZ^K^QOC3V)!O'&
MX*NBQ6[,#7X^MV_O+9N3J%FDHZ3<^V<K%!40"H2GD>EJ4$M/.(W\,TACD"HY
M[=[<Z7%#T>6&XP[FGB0,&%:'B"#\P:$=.?RW^;?QD^#77]-V1\F>T,5UY@LI
M6/C=NX\TF2SVZ]VY2/Q&6@VMM+ 4>1R%:T0J(VJ98H##3HXDJ)(HSK]^A@>X
M;2@J>O7VX0[:GB3L%6M/,DGT  )/Y#Y\.J6%_P"%4?\ +<;<BX,[&^6*8QL@
M*,[R;K+K@[;2F+:3EFI4[E?+_;@>HJ,49[?2$GCV8?N::E>W[*Y_P4_GT'/Z
M[V6O3^I3^/0-/_'M7_&>KR?B_P#+#X__ #+ZLHNY/C?V/A^R=B5-=+AJVLQ\
M=9093;NXJ6CH:^MVQNK 96FHJW&Y&"')4\STM7!$QBGBFCUPRQ2.72PM =+B
MAZ$UG>Q7Z>)"P9?4>1H#0CB#D8.>M<[XF_\ <4G\^O\ Q79O_>0^*'LUG_W"
M3_3?Y6Z"-A_R7+C_ )I#_!#U6W_.T_F/?$CY1_-+X0PXFEWGF]F?$#O+>N#^
M2>"W5LQ*>GJL10]K]5KNS%8.B_BE7'E(YJ3K_*PLH:)9!XUO:2X4[?:R1125
M'QJ-.1G!_9QZ*N9=WM[F[MZ&HAE;Q:J<4=*^6?A/"O6WA\#/GM\:OY@&P]V;
M]^,]-N>+:O7&X*3KW)-NG9]/L^:FKCB*/.0X[%4,-;6$TT=/60GCQH"UE!(-
MB2XMGMC1Q0G/&O0]V[<X=U0O 25!TFH(S0'S ]1T>_VGZ,.M6C_A6-_V0[\?
M?_%K<+_[Z'MGV<[)_:M_I?\ *.@1S[_N(G_-9?\ CDG5SOS7[1^+/37PERO8
M/S/V)1=D_'C#XWJV#>>T<CLC&]BT>0K<KN#;&+VI--M'+.D%3X,K5T<ZLUS$
MT8E'*#V76Z.\E(\-FE#3^?0GW*:"W@9[D QC3J!74,D 8H:YIY=%Z[7_ )EW
MP>^(?P5^/O==-M_=NP_CIWEM1-L="[=V)UW14_\  L?6[4R68V_C)]I8[*TL
M>+IQ2TCM''$76/2$(4V'MQ+66>1EXL#5JGY^IZ33[M:[?;I*3IB8*$HII0K4
M"@&,#TQUK6?\)XOYCGPR^'6P]Y],]Q8C=0[[[_\ D#M[![3S&VM@TV?CR.U<
MYA-G[2VG@,ON6;(T1IZ=,Q69&1H&!114F5KZK WW:TDG8,H[0N<CR)/0+Y-W
MBVL8S#(:222]HTDU!"*,@4XUX];IWR5^4G0/PYZKR';_ ,A^Q,'UGU_BI8L;
M3UE?'555=F,K)3SS46W=K;>Q--65N1KI4I9&BI**GE?1&[L%C1W4@BB:8Z5%
M3U(EW>1V*&25@JCB3_D]3Z 9ZI*Q_P#PJ/\ Y9];O1MK5.)^3&(P:U4E..R<
MAU7MF79;Q(H9:Y:'%=CY/<7B<G2H. $EQZHP+$F!V>:E<?97/^;^?0;7G6Q+
ME*N!_&4.D_L);]J]7T]-]U=3?(7KO;W;72/8&V.SNN-TP2S8/=VTLE#D\75M
M33/35M'*R:9*>JIIHW@JZ.I2&>GE1HIHXY%907.AC-&!!]#T*()TN5#QL&4\
M&4@@^7ET*'NG3O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]UF@_6W_+&H_\ <>7W[KW0U>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J@'_A4=_VXH^<W
M_ELW_P &'\???NO=?(%]^Z]U]CG^3/.9_P"5'_+X-[K%\5.I8%']!%MNF5A_
MR5J/^Q]^Z]U8?N7;.*W9CEQ>82:2D6IBJ@L$S0/YH5D1#K4$VM*>/>P:=:(K
MT@?]!^P_^5;)?^?*;_HWW;6>JZ!TH=M=;;7VGD6RF'AK(ZMJ:6D+3UDDZ>&5
MXG<:& %[Q#GWHO7K82G2]]UZMU[W[KW7O?NO= +OOM_([1W)5X.GP]%614T-
M)(L\U1/'(QJ::.=@512."]A[<5*CIMGH>D?_ +,+F/\ GG<;_P"==5_T;[WH
M'6M9Z&/;6Z9]X[&R&:J:2&BEDI\Q3F"!WDC IX)%#:I #<WY]U(H>K U'1%O
M;O373I@_^+UA_P#M:8__ -RX??NO=6.>T_2CKWOW7NO>_=>Z][]U[JI+^:A_
M..^+7\JW8=/4]H5U3OWO'=F)FR'6/0&T*JE_O?N6'S3T4.XMQUE06APF!2H@
M>.7)U0=Y##+'14]7-&\2^Z]UHG8_#_S9O^%._P EZC)U=8V#Z)V1N98O/4?Q
MC _&#XX8JM2G\]#AJ-/N),YN=Z&<2R M6Y2K\J>::CQYB\'NO=?1[Z<Z%QOQ
MS^(O6'0']XLGV&G0_0V"ZTQN]]U0Q2[@SIV3L6';:9^H#/4^"6H6AU>..1A&
MI$89@H)V./6CPZ+E[?Z8Z?=K_P#'S;=_[7N(_P#=A3^_=>ZL3]I^E'7O?NO=
M>]^Z]T5'Y>?&7"_)?K.IPJI24._MNI4Y/8&X)QH%)E"B&?#U\R M]C7K"L,X
M]7C81SA6:((UXWT'JK"O1&OY?'R:S.T\[/\ $KNK[K"[@P&0K<-L*HSD@CJ*
M+(T,[Q5G75?)(S#4K*[XIM15@&ID8WI49V5*]PZJK>1ZNRVQ3FISN/6UQ%*:
MAB>0!3HTJG_DI0!_K^T_3G0X^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@AS'_
M !=*_P#ZBI?^AC[]U[IM]^Z]U[W[KW7O?NO=:;O_  J+V$>U?D5_+ ZO%?\
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M=5/Y)122!&:.WIM<$@$G1&E-%!)]!T,I[B.T77(P51Q)-!G'1,?^'K_Y5O\
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MX_%UMN>R3H<]:HGQ-_[BD_GU_P"*[-_[R'Q0]G4_^X2?Z;_*W0'L/^2Y<?\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4 _\
M"H[_ +<4?.;_ ,MF_P#@P_C[[]U[KY OOW7NOL7_ ,EW_MU!_+]_\5>ZN_\
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M>_=>Z2^3WKM3#5DF/RN<H:&MB6-I*>=V61%E19(R0$/U5@1[L%)ZT6 Z;_\
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MVOELYM"?JV@Q)QO7N+^XP&$H]BT&6BJ?'UM0G749NJ35+.?'9HQ%M[MGB$1
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MCIH7@R=/25V;R/DE>]3'1TL-H,B]DX]5?AU;/[>Z9Z6'7_\ Q^^U?^UYC_\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_P *CO\
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M\(CTZIK'4N+^:S\5H,E0X_<2=J[,BKW*QY+=/7.1I*&-5=$DE=*"KR52R)Y
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M](T+6O\ EB. /\3;W[KW2YP^V%@9:G(Z))5(:.F!U1QD<AI6'#'_  ''^O\
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MBIVAB2>F,E.#.MW1I(Q0JSPPU9J'2?#%!Q\^J#NST;O^8> OPM[[50 !M7&
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M -&^_=>Z]_",7_SKZ3_J1'_T;[]U[KW\(Q?_ #KZ3_J1'_T;[]U[KW\(Q?\
MSKZ3_J1'_P!&^_=>Z]_",7_SKZ3_ *D1_P#1OOW7NO?PC%_\Z^D_ZD1_]&^_
M=>Z]_",7_P Z^D_ZD1_]&^_=>Z]_",7_ ,Z^D_ZD1_\ 1OOW7NO?PC%_\Z^D
M_P"I$?\ T;[]U[KW\(Q?_.OI/^I$?_1OOW7NO?PC%_\ .OI/^I$?_1OOW7NO
M?PC%_P#.OI/^I$?_ $;[]U[KW\(Q?_.OI/\ J1'_ -&^_=>Z]_",7_SKZ3_J
M1'_T;[]U[KW\(Q?_ #KZ3_J1'_T;[]U[KW\(Q?\ SKZ3_J1'_P!&^_=>Z]_"
M,7_SKZ3_ *D1_P#1OOW7NO?PC%_\Z^D_ZD1_]&^_=>Z]_",7_P Z^D_ZD1_]
M&^_=>Z]_",7_ ,Z^D_ZD1_\ 1OOW7NO?PC%_\Z^D_P"I$?\ T;[]U[KW\(Q?
M_.OI/^I$?_1OOW7NO?PC%_\ .OI/^I$?_1OOW7NO?PC%_P#.OI/^I$?_ $;[
M]U[KW\(Q?_.OI/\ J1'_ -&^_=>Z]_",7_SKZ3_J1'_T;[]U[KW\(Q?_ #KZ
M3_J1'_T;[]U[KW\(Q?\ SKZ3_J1'_P!&^_=>Z]_",7_SKZ3_ *D1_P#1OOW7
MNNQB<8"",?1W']:>,_[P5/OW7NIJ1I&H2-$C4?144*H_U@H'OW7NN?OW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NJ ?^%1W_;BCYS?^6S?_!A_'WW[KW7R!??NO=?:G_D>_P#;
MH7^75_XJEU1_[H(??NO='^WIA#3S_P 6IT_8J& JU4<15!X$IM]!)^3_ *K_
M !8>_=>Z07OW7NO>_=>Z(_\ .O\ F)?%'^7/U5+VK\GNR:':\-;'5Q[+V'BA
M%F.R^RLK2B(/B-B;.AFCJ*ME:HB6IK)#!1T@E5ZNI@C8,?=>ZU<?Y?W_  HI
M^?'\Q3^:CUUTYU/\?]H8OX@;ES^3I=U[/I-I9S=F^.O.K:/#5DDG:/8/:]'D
MJ2DHJR.KIHF%Z2FH"U5'C(XJJK>&JF]U[J\+H3_A/]_+8^/ORGWQ\O,%UCN3
M?G9>Z]XY??FW,%VON.DWIUUU/N3.9%\MDLAUOM-\'06D^YEDFII\Y4YR:D9S
M]I+  H7W7NKK/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TX8W&5>5J5IJ2/4QL9'/$<,=P#)*W-
M@/\ ;GZ $^_=>Z&C#8:EPU*(81KF>S5%0P >9P/]C91?TK^/\223[KW3Q[]U
M[KWOW7NO>_=>Z][]U[KWOW7NF[,4<N0Q&5H(6C6:NQM=1Q-*66)9:FFEAC:0
MHKD*"XN0I-OP??NO=$_^!WQSWO\ %WHMNL=_Y3:N8SS;UW!N,5>SZ[+Y#$?8
MY:FQ,-/%]QFL'M^;RJ:!]:_;Z0"+,>;7D;4:]544Z,1V_P!5;3[MZVW=U=O:
MC6KV]N_$SXVI81PR5./JKK/C<SCC.DBI5451%%54TA!TR1*>1<>Z@Z37K9%>
MB8_&'XT?(GJ#X]]K_'CL?=W7.[,#D,#O#$=0Y[$9O=<M=AX-U8G*4#X;<=!D
M]I4BTU"E14I61_:3USQ-43Q@2((B+NP8U'Y]5 (%.E-T%\/JG:OPOE^*G<U=
M@\NV8H][8_.9'9-;75=#3Q[CW)DL[B,CAZS.X3$R?=435$$Z&:CT+/".)$'J
MTSU:HZV!BG0*[ Z?_F4= [4@ZDZSWO\ &WL?K[;T'\.V1N;L:EWQ0;NPV##,
M*3'246)"0(*8$K#%+)E%2/0BR:5$26)5LYZT 1T.?QI^'E7U?@>Z,OW!O).R
M.V?D9-7OVMN7%4\N,Q4>/KJ7*4W\!VY#,D>F*/\ C54XG^UI00\<:P)'!&/>
MG?5PX#AUL+3HOO4OQZ^?OQ7Q.5ZIZ+W3\<=_]2C/Y++;1R/;4&^:'<N ILQ.
M9:FFJ*3:@HHU(DO/*HDKT+NSQZ YA7;,KY-?RZT 1U(HO@OW[!\H.F?E)N7M
MW:?9&\\/E\G/VM2YA,KM3"XS S4$N#PV"ZGPV,V_GKQ4='E:PLN0J:3RSHDA
M*M-,Z^UBA%.O:<UZ,!A/C/OO&_/+>/RBGRVTGV!N'JFEV+18>*OS#;PBR\,&
MUHGJ*K'O@8Z)::^#ELZ9!W]2?M\G375VT^?6Z9KTX_/'XY[W^471:]8[ RFU
M</GEWKM_<9J]X5V7Q^(^QQ--EH:B+[C"X/<$WE8UZ:%^WTD W8<7]&VDUZ\P
MKTW?-GXS[[^2/QTQ'46QLMM+%;DH-Q[1R\U=NNOS%#@VIL!C<C1UB15.'P.=
MJ#(S5:F(&F4$ ZF4V!]&VDUZ\PKT)_R&^.>WOD1T)E>GMSBCBR#8:BEVSGC&
M\W]VMZ8:@,6'SU(VA)/&LC/#4*H5I*:>:+C6?>E;0:];(KT3;LKXA_*7M_X4
M;9^.N^]W]2Y#LW9V\=OS8_>;;HWM5X;.[+V[0Y"GQS9VNJ.OXZP92):]:4VI
M9TF2G6:2<3.Z^[APK5'#JI4D=*_YV?%+Y"_)7:?5>P^L=\[#P.S-LP2U6_\
M;>[\WNG#X_=6;HH\/%MV4MMG:>:FJ*>F$%8?'++3!7F215,BH\>HV"\>ML">
MFO!]=_S2MM8;%[>V_O3X5X7!82@I<7B,3C<3V!24&-QU#"E/245'30[!54CC
M2,*JJ  ![]V_/^77L_+HPF'Z?[L[:^/79O4?RTW'UYD-R[\DS6'H,WU#397^
M$8G;-3B<(V"JY*?<>)PSOD*3*4U55%?&8V00KKOJ"ZJ%-1_/K=*C/14.LNA_
MYEG4VT,=TCM3MKX_MUU@X9\-MWL++XW<V3WQM[;LC.],F.Q4N)6G:6E60I2T
M]5]PD=EC\YC5"MBRG-#U4 CH6OAC\,MV_%KL_OC<65W?C=X;7[)CV?\ W=RD
M^2RM=O>NKL0<S5[CS&\H:K"4%-%-65>8DG1::KK>&(9[B[:=]8'6U6G2P^#'
MQGWW\9-H]I8#?F6VEEJS>_:V9WUBI-HU^8KZ:GQ&1QF*HH*?(/F<#@&2I#4+
MEDC25 "+2$W T[:OV=>44ZS?[+9OG_9[_P#9H/XKM/\ N#_HB_N#_"/OLQ_?
M#^,7O]S_  _^!?9?;?[7_$-?_-OW[5VT^=>MTS7K#\Y_C/OOY-[1ZMP&P\MM
M+$UFR.UL-OK*R;NK\Q04U1B,=C,K13T^/?#8'/L]26KD*I(D2$ WD!L#Y&T_
MLZTPKTT?+SXJ]A=K[YZH[ZZ+WGA-I=V]-33)A*?=T,\NTMQ8::>6JFQF0EHZ
M*OFA?_**B*XB=)8ZIT9H2%E7:/2H/ ]>9:YZ1&Y.D?G1\C]M97KKY!=B=*=4
M=:Y6G:GS]'T)C-VUV[]XTXBD=,17Y;>E770T5$\RPFH-.':9%>%X_&QU>U*N
M17\^O4)X]0-D?#3N/!?R_MZ?$W-9KK5M]927-0[=SF,S>Z*C:34&5W;C]UJ^
M8K*K9E%60RJ_W416&AJ5L(CJ]3!-EP6KUK3BG2:ZYZ"_F)_'3K_ ]6=0=D]!
M;YVG%@:#Q5'9D6\7S/7NX*R@HI=RXG:E;08^".KQ$.0>JEQ3UU-*XA?3)2Q6
M5/?BRL:FO7@".C.?$;XIR?'>AWONK>N[Y.R>[>VLT=P]F[^EADIZ>LJ%GJZF
MEQ&%I9-)CI89*^:1I"D32O)?1'%'!##5VU?8.'6P*='(]TZMU[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5
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MRB[EDD,#!5U)]T]3=B3ZM2WXL/=>ZV%_?NO=?!\_V:+Y,_\ >17>O_HW-_\
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MW[KW7O\ 9HODS_WD5WK_ .C<W_\ _9![]U[KW^S1?)G_ +R*[U_]&YO_ /\
ML@]^Z]TSYKY!=];EI8Z'<7=W;N?HHJA*N*CS79.\\K2Q54<<L*5,=/79J=%D
M5)W0. " ["]B??NO=)C_ $E]C_\ /?[V_P#0JSO_ -7^_=>Z7D7R>^2D,<<,
M/R&[RAAA1(HHHNV=_1QQ1QJ$2.-$SX"JH      ]^Z]US_V:+Y,_]Y%=Z_\
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M]Y%=Z_\ HW-__P#V0>_=>Z]_LT7R9_[R*[U_]&YO_P#^R#W[KW7O]FB^3/\
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M;F__ /[(/?NO=>_V:+Y,_P#>17>O_HW-_P#_ -D'OW7NO?[-%\F?^\BN]?\
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M[]U[KW_0$'\9O^\Z>]?_ $6&P/\ Z[>_=>Z]_P! 0?QF_P"\Z>]?_18; _\
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M"#^,W_>=/>O_ *+#8'_UV]^Z]U[_ * @_C-_WG3WK_Z+#8'_ -=O?NO=>_Z
M@_C-_P!YT]Z_^BPV!_\ 7;W[KW7O^@(/XS?]YT]Z_P#HL-@?_7;W[KW7O^@(
M/XS?]YT]Z_\ HL-@?_7;W[KW7O\ H"#^,W_>=/>O_HL-@?\ UV]^Z]U[_H"#
M^,W_ 'G3WK_Z+#8'_P!=O?NO=>_Z @_C-_WG3WK_ .BPV!_]=O?NO=>_Z @_
MC-_WG3WK_P"BPV!_]=O?NO=>_P"@(/XS?]YT]Z_^BPV!_P#7;W[KW7O^@(/X
MS?\ >=/>O_HL-@?_ %V]^Z]U[_H"#^,W_>=/>O\ Z+#8'_UV]^Z]UK8_S_?Y
M*76O\F_.?%O$]=]X;X[HC^0.*[@R.6FWIMG ;;?;K]:5?6U-11XY<'550F%4
M-\RF4RZ=/@33?4??NO=4J_%?J#'_ "$^3WQQZ#R^9K=NXKO#OGJ#J#)[@QU/
M!69#!8_LOL+;VS*W,T%)4LD<LU+'FFGBCD(5F0*Q )]^Z]UO\?\ 0$'\9O\
MO.GO7_T6&P/_ *[>_=>Z]_T!!_&;_O.GO7_T6&P/_KM[]U[KW_0$'\9O^\Z>
M]?\ T6&P/_KM[]U[KW_0$'\9O^\Z>]?_ $6&P/\ Z[>_=>Z]_P! 0?QF_P"\
MZ>]?_18; _\ KM[]U[KW_0$'\9O^\Z>]?_18; _^NWOW7NO?] 0?QF_[SI[U
M_P#18; _^NWOW7NO?] 0?QF_[SI[U_\ 18; _P#KM[]U[KW_ $!!_&;_ +SI
M[U_]%AL#_P"NWOW7NO?] 0?QF_[SI[U_]%AL#_Z[>_=>Z]_T!!_&;_O.GO7_
M -%AL#_Z[>_=>Z]_T!!_&;_O.GO7_P!%AL#_ .NWOW7NO?\ 0$'\9O\ O.GO
M7_T6&P/_ *[>_=>Z]_T!!_&;_O.GO7_T6&P/_KM[]U[KW_0$'\9O^\Z>]?\
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MUL#:75?5>TL)L+KG86$H]M[,V9MNC3'8#;. QR>*@P^'H(O3#3PKZ8HELJJ
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M[&QU5?/'222/+4U-)24T4;U%94T].CRCW7NM>/(?\*O\MLNA/;W;7\GCY_\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K1W^)&%P_\
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M&DK:3S*$EIR?=>ZR_/S$8K^91_PJP^(?PH[$^RWM\?/A!U=1=B[YZTS5*T.
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M87<G^D]J*(I][48"BWGC.LTJY(XF>3[2CKI*J41LD$$TK1QO[KW5E'_":_\
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MSG_@KO\ ]G9__5']^Z]UJV_SF_YI'_#NORQV[\H?]!G^R^?P#I/:'3W]Q_\
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M/B]C[ZVKF*RA7-X:ODRK?<4E$] B)41H(YF#'0"C>Z]UIJ?'SX-=U=O_ ,V
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M\*N-J?)+X,_S+.L_D[TEW5VKL+87R8VMB.S=KXO"=A[F7;>"[OZ1KMO8+?\
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MY-CXZI7*4,0Q^:BCR+5 J:*FJ4IY14U<T/NO=7H?\)QOAC\E?@9_+4V[\?\
MY7];_P"BKMRA[D[7W75;2_OAL+?/BP&Y<ABY\)7_ ,>ZWW3O#&-YUIW/B6M,
MB6M(BDB_NO=:LO\ PPK_ #8?^']/]G5_V5/_ )QE_P"'?_\ 9H_])?\ IS^-
MO_,B?]G/_P!+']^?[F_Z8O[P?\>__N0_AG\*_B'^Z/M/N?V??NO=?1\]^Z]U
MH2_\*:?Y+7\S#^8/_,*V7WE\0?C7_I=ZMQ/Q>ZYZZR&Z/],?0.P?M]Y8'L#M
MS-Y;#_P3L_M39>1?Q4NYZ&7[A*1H&\^E)6=)%3W7NMES_97.]O\ A@O_ &2K
M^XW_ #DU_P - ?[*Y_HT_O-L[_F>W^R8?Z)_[C?WR_O#_=__ (^#_<?_ !/^
M*_P__=_W?VW[WOW7NM<'_A+_ /R9_P"9-_+M^?7;O=?S%^.'^A_K+='Q W]U
M;@MR_P"F#H7L#[[?>;[HZ W9C,%_!NK>T=[9"+RX_9.4J/NIJ2.G7[70\JR2
M1))[KW6]Y[]U[KWOW7NO>_=>Z*!_,)ZMWWWC\!?G#TIU;@O[T=F]P?$#Y+=6
M]=;:_B>'PG]XM]]@=+[UVGM'!?QG<60Q&/I/N\AEZ>G^ZKJNEIXO)KFECC5G
M'NO=:@7_  E__DS_ ,R;^7;\^NW>Z_F+\</]#_66Z/B!O[JW!;E_TP="]@??
M;[S?='0&[,9@OX-U;VCO;(1>7'[)RE1]U-21TZ_:Z'E622))/=>ZWO/?NO=?
M-EVK_((_FUXW^>;MSYBUOQ.\/QQH/YL.'^2]7V+_ *=OC3)XNDJ7Y?T_:4^]
M?[HQ=R29UM."C-=_#5Q;5YMX12FH_:]^Z]UL3_\ "E/^2GVI_-:ZFZ9[#^-F
M9P<7R)^-C[YIL-L3=F:BV_MSM/8N_4V]5YO 4N;J:.HAH\W1UFTZ6;$RU4U'
M1R)55<55*I:GE@]U[JE?X4]?_P#"OKKGHO9GP"Z[ZSV=T3U=M_"5.R-H]_\
M==7TU/F.E=E4E/4"BQ6+WEMW=&^ZR>EI@HH\:U+M?<-;3K+&(#'#"LD'NO=!
M%\7?^$^?\U_^7U_./Z%^0FPNFJOY6]!=2=X=>9_=WR,K>X>@]H9+L#;6_MIX
MO%]][YBV'OGN:GW,E7C9MZ;A:FI:REFJ*F7'H5EJ!,E1)[KW5O?_  JU_E<?
M.S^91_LAG^R5=&?Z:/\ 0O\ [-'_ *2_^,F].]=?W:_TB_[+K_<W_F;'8.Q/
MO/O/[B97_BW_ '7B^U_?\7EA\GNO=7>?RJOCMW'\;?Y5'Q=^-G=.S_[F=U==
M="UFR]Y;,_O!M;<7\'W++5[BECQO]XMJ9O.XFHNM?$?-2U\\7K_7P;>Z]UJF
M?\)J_P"2=_,X^ '\QBO[X^7'QG_T3=4S?'CL[8L6ZO\ 3+\?M^:MU;ASVPJW
M#XO^!]9]K;SR0\T6%J6\YHQ"GBL\BED#>Z]UOZ>_=>Z][]U[K2>_X5-?RCOY
MA7\QSY!?%K?'PR^/O^F3:_7/3>[=J;SRG^E?I'KS^#9_)[V_B]#0?9=J]E;&
MJ*C73_N>6DAGC7]+.&]/OW7NJ0-F_P J#_A7IUUM/;>P>OLW\VMB;%V;A,;M
MK:&R]F_S1>LML;3VKMS#4D5!A]O[;VYA/E]0T=#14D$"0TU)2PQ111HJ(JJ
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M_6^05ZN@ADQ5?M;:W>O<%3,TBOYR),.T12E8,XD\4<GNO=;3?\B3_A.CL/\
ME19:N^1'<N_,3W;\PMR[-?:"Y?;5-D*;JSIW"9DP5&Z\-ULN8I<?6Y.LKVIH
MJ:IW#D:2AF:EA,%-1T4=36K5>Z]UA_X4I_R4^U/YK74W3/8?QLS.#B^1/QL?
M?--AMB;LS46W]N=I[%WZFWJO-X"ES=31U$-'FZ.LVG2S8F6JFHZ.1*JKBJI5
M+4\L'NO=4K_"GK__ (5]=<]%[,^ 77?6>SNB>KMOX2IV1M'O_NNKZ:GS'2NR
MJ2GJ!18K%[RV[NC?=9/2TP44>-:EVON&MIUEC$!CAA62#W7N@B^+O_"?/^:_
M_+Z_G']"_(387357\K>@NI.\.O,_N[Y&5O</0>T,EV!MK?VT\7B^^]\Q;#WS
MW-3[F2KQLV]-PM34M92S5%3+CT*RU F2HD]U[KZ-&7Q.,S^)R>"S5#39/#YK
M'5N)RV-K(EGH\AC,C32T=?0U<+@AXI8IGCD4\%6(/OW7NOB/?*/X2UG7W\SS
MMS^7]TIG=M;YKZ;Y?9+XW=1Y#&;AES>+JZK<O9<6S-@8'/9J"CFD7)4+9BDQ
MFX(EAF>ER%-5P?NM#=O=>Z^T!\9>A-F?%KX[](_'#KV P;+Z/ZNV5UCM\O<U
M%91;/P%#A3E:Z0\R5-9)2O5U4K>J2:9W;EC[]U[K3S_GH?\ ";3Y%=V?*G(_
MS&_Y8^>PF/[MR^X<!V7OGI^?=4/7VZ).X-HM3Y''=K=.[WS%72XN#*5=5AZ.
MJJ:+(UF)1:Y7K8JHM,\2^Z]T6#LSL'_A9UW9TAEOC+G?CU-A(-V;9R'7V[>U
M-KT_QBV/V;N3"9'&G#9L5'8D7:5)B,7-5P"96RN%I,1,IG:2FJ(G\3K[KW5S
M_P#PG1_D+[A_E/;?[+[Q^16XMI;K^6?=. IMBU6/V/,V7VEU)U719JGW!-M#
M$[IK,9C*G(9#-5V,Q]=G94CCI$;%T5/3B7[>2KJ?=>ZK,_X6\]^8_'].?!_X
MNTZF?*;N[,["[\R[JR@8S']=[6AZ\VXLJ%=3??R=HY4QE39?X<^H>I??NO=;
M1O\ *!^*$_PD_EH_#KXW9/%KAMU[*Z>P^<[$QPJ*JK:D[2[*K,AV?V?3-55M
MI7$6>WCD(8P0JHD:1QJD2(B^Z]U9'[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5@_X5"_RD>R_GWT%U=\C/BIL
M_*[I^7GQ>S\%+A=N;3EBHMX]B]4[JS- V7PN"KI<EBU_B&W<DL.X,;>4.L/\
M32G#5$\2-[KW5]/P/[+[N[<^'_Q\WS\E^M]Q=2?(C(]:;<H>\=A;FPE3M^NQ
M/:>#HDPF]*RBQU14U^G'Y"NH)<EC2E35#[6KB5I6D5[>Z]T;;W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]UJD_P ]ON'_ (4+]??('&;-_E5[$W9N?XX;VZ$V
M3/F]Z;%ZNZEWENS8O<$>_NR:?>>,PN5WC%D*R"2JPF.P32S5%#40Q)5@T4D%
M6'D7W7NJYO\ A.K_ ,)Y?EMTA\O$_F$?S&-K_P!QMR=?INO*]0]:[EWACM[]
ME;H[9WDF4P^9[:W_ )/;>Y,Y2P145)D:]Z2"NJ:RKK*S(I6R)3_:1/5>Z]UO
MG^_=>Z][]U[KWOW7NO>_=>ZTG]X?RU_E?_-&_P"%&%5\L/E5\=][=4?!'XBO
MMW$]0UG96'.+7N[ ]%9C(UFP<=A8*7-U32T>>WIGLCN^1*J*F!PKK1U5,M1-
M(OOW7NMV#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
4=>]^Z]U[W[KW7O?NO=>]^Z]U_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>timage_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_005.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M<_V'N_ ;?A\N*QD^>RGR!HSD9H# \P-&DB,L,2P>Z]TC_BM\O?CS_)4^:_\
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M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIV_X4"?]N9_Y@W_ (@JI_\
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M .0]%MZV4RG4.;GS&YL3N?:^7W?14KT>-R&+SN(\=3*(Y98A(*NF]U[JSO\
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M0OO#?/75/L+K/?VV<IN?)S^#<L*Y(8MEW13U3253P9BJ:G]U[HR>T?Y</>&
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3M_P *!/\
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M_)7[IS,N V]\X]C[2R<>D@]O[.[0Z8PTL;@VDBW7V?LC:VTCZ@04->)5M<J
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M;L_^4'\]-S;2^/G1^UMR8;I*HJ\1N#;G4^P\)G,55#<^VXQ4XW+8S 4M?0U
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M)7RXJ/(4+Y2"$5,^-2K@:OAIR8P)Y:-9#41PDS)9BH7UCGD>_=>Z]D,GC<3
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MO;G77;F4[MSU958W+56Q^V-Y;CV]M R0YBDT4=-BZ\U\=HQDX7J)G,_NO=;
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M:SMCI7J7L^KZCW+C]Y]4U78?7&SMZU/6.\<3)22XK=G7L^Y,-DI=E[EQDM!
MU/7XTTU5"T,91P46WNO=+'>^QMD]F[0W'U]V1L[:W8.PMX8BLP&[MD;WV_B=
MU[0W3@LC$8,AA=Q[:SU)7X;-XBN@8I-35,,L,J&S*1[]U[KVR-C;)ZRVAMSK
M[K?9VUNOMA;/Q%'@-H[(V1M_$[4VAM;!8Z(08_"[<VU@:2@PV$Q%# H2&FIH
M8H8D%E4#W[KW23ZUZ)Z/Z8K]^97I[IOJKJC*=I[JK-]=GY+K7KS:.Q:_L?>^
M1FJ:G(;RWY6;7P^+J-W[JKJBMFDFR.0:HJY7E=FD)9B?=>Z+[VQ_+:_E[][[
M]K^T^ZOA#\4^UNQ\L:9LQOCL'H3K+=FY\VU(S-3OG,OFMM5E9FI(PVG55-,6
MC 0DH H]U[H:]Q?&GXX[OS?4^YMV] =)[HW'T-4559T;N#<756Q,WF^F*NN?
M%R5M5U/E<G@:FOZZJ*R3!T32OAY*-I#1P%B3%'I]U[IRW5T'T5OOL3:7;^]^
ME>I=Y=L[ PNXMM[$[0W5UQL[</8FRMN[OQ>3P>[<!M+>V7PU9N7;F%W1A,U6
M4>1I:.IA@K:6KFBF5XY75O=>Z!KJ?^7S\$NA^PZKMOI3X;_&+J;M"K_B E[!
MZ\Z.ZXVAO!$RU4M;DXZ3<&#V[19*@AKZI%>9()(TD*K<$* /=>Z-_P"_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTK?
M^%H/<W9F)^/GPA^+>V\JNT>L/DQW9O?)=K;XRF0K\7LN@EZD@ZXCV+M_?=;1
M8G(A=MU.5[*JMP2 L9$;; FCIZAH;P^Z]U![Y_X1=_#O-?&NEQGQ?^0/<V!^
M2^"VY45V'[$[.S>U]U]6]HYZKFI,D*/=^U-O;1PM9MC"3T\4M%BJS"5BOCH*
ME:BMBS,D5I/=>Z!/^3C_ #O^U_B9O3L_^3__ #B=PUW7W9W4]+F^O.G^Z.S\
MHL\V+RD6%>7$]4]J;WJ*N>EK\+F<36TM3L_<\\KTU71SQ4\]24DHI&]U[I'_
M /"&/_NJ)_Y9-_\ /<>_=>ZW_/?NO=:EG\][:O\ PH4V7WQ@=Y_RLNV.Q-[?
M&KL?KG(G?G5FW]I_&RK?IS=^UHZ;'YUCFNU-LC<=?MGL#"Y"*NHU2MJYJ:MI
MLA'^S *5/?NO=:?W\G_,_P#"A7&]!=BQ?RBH>QI.AG[?R$G89V=@OC=E<>.W
M?[E[,6O%3-W-CZS<,=9_<U<-=:9A1:-) \ID]^Z]T?;Y!_%3_A7C_, ZZE^-
M/R;V-VAOCJ+=.X=LY;.8+=]9\-.NMLBNP.8IJO#Y7-9[:53MC-R4.#R#)5M3
MQ33%_"'$$K1J![KW7T+?@?\ 'G+?$KX6?%;XR;@SM/N?</1'0G5_5^X=P42S
M1X_+9_:&T<7B,W68N.H>2>+$R92GE^T1R62F" \CW[KW1L??NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U3M_PH$_[<S_ ,P;_P 054_^]5MGW[KW5L>RO^/-VE_X;.!_]U5+[]U[
MI3>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z1O8V^L#U=U[OOLS=4[4NU^NMF[GW
MUN2I5=34^!VCA*[<&8G51RS0X_'R,!^;>_=>Z^3-!_,P[I[R^;FY_P"81\@\
M;%V1G>ROXOBL3U=F<U69+:O4_2N4K*2;:W675R5E.,7@(=M8['4DS5*T"G)Y
M U%95H]55SSM+6R<D6UYR\MQ*VFYG =7XA5_"M/0C)\ZGY4,=;IS7-;;T84&
MJ"*J,O L?Q-7U!P/*GVU T?*CXT_$OY#=,[G^37QPS^W<!#B*5,AV'TIF5I<
M?-0UM1-JJFP>+>?[O:^;@0S2I!3>7&5L4):B>+0PE4V=Q?)<KRSS3;_4)(=,
M<A%3Z AO,?.H9:Y]!2ZM[22!M_Y?F\%T%70&@-,D%?(_+*MY>IVE_P#A*A_,
M)[9^2'1O>/P[[YW1GM_[T^']7L&MZR[#W)4&OSFXNANR*3.TFU]L9S+3UE3D
M,UF>M<]L^LHONZA49\;644(UFG9O<;\P[2=DW:6Q!)049">)1LC]G ^I%>AG
MLNXC==NCNZ48X8>C#!_;Q^P];9GLDZ->O>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JIW^<;_*HZZ_FX?$^3H+
M=.ZZCKC?VSMTT_8_3'9U/0/EH=H;[H\5D\))#G\(E51/GMH[APV6GI:^E6:*
M13X:B)A+3Q@^Z]T"7\@WX)_.7^7U\6>R>D?G5W3!W/NU.XYJSJ2JP_<'8?;F
MT=H].8[86RL#A-M;1D[%PVW\CLW$1[AQN3G3%TU'3T\:2H_C1W91[KW6#^<S
M_(@^-G\W'9]+N?(U$'3ORNV5MZ?!];]_X;%"M:KQ2U!KZ397:>#IYZ%][[,A
MK6E:D+2K7X:2JGDHY LU1!4>Z]T1+_A,C_*+^9?\I_=O\P/;?ROV]L6+$=MC
MXM'JS?G7&^\9O':6^AUY+\D8]Y?P^EFBPV]L(<,N]<2Y&9PV,,Z5R^'R-'.L
M/NO=;8?OW7NDCV!1[@R.P][8_:60H,1NJNVCN2CVSE<K$9\7C-P5.&K8<-D,
ME )8#-0461>.29 Z%HU(U#Z^_=>ZTQ_^$WG\R6A^/NW?E!\._P":M\RL/U;\
MF^N.W]NT&S]F?*7LCK_;\<FTJ_:5'*LV![DS<L-)V1GLQF9F)-3N7+/-0MCW
MH1X9M<ONO=;</^S<?%'_ +R<^/7_ *.CK?\ ^R7W[KW0Z8C+XG<&)Q>>P.4Q
MV;P>;QU%E\+FL16TV2Q.7Q.2IHJS'93%Y&CEFHZ_'5]',DL$\3O'+&ZLK%2#
M[]U[IQ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW5.W_  H$_P"W,_\ ,&_\054_^]5MGW[KW5L>
MRO\ CS=I?^&S@?\ W54OOW7NE-[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H'/D3
MT]A?D-\?N].@-R_\>[WETYV=T]G[U%72#^"]F;*S>R\K>JQ\D-?3?Y#FY/W(
M'69/JA# 'W[KW7QL<WUQO[HK>N]_CMW!MVLV9W%T/N3(]9]A[1R4<L55CLMM
MF9L=!D*-IHH3DMO9VAABK,=7Q!J6NHYHYX7>)U8Y!\F;M;;ELL,$;#Q;=5C=
M?,:113]A X^M1Y=0SS/MT]CNDLKC].9BZMY'4:D?:">'V'SZBR21Q1O+*Z11
M1JSR22,J1QHH+,[NQ"JJ@7)/ 'L5LRHI=R !DDX 'J3T'E4L0JBI. !Y];=?
M_"8SK/Y"="]-_*_^85BNI\CNOK;N7<G6/4FPL?5Q5^-K,[USU"=[YCL/M+#+
M#%/59+;DNZ=R18FEK(X)(8):*KE=9(HGT8\\U[G!O&^RSP']-0$0_P 07B?S
M)-/E3J:.7;";;=ICAE%'8EV'H6X#\@!7Y];KO1WR(ZT[_P #_%=D98)E:2&.
M3.[3R30T^Y,"[$)>KHEDD%10O(;1U<#24\A.G4'#(H99"AH>CX,#T.?NO6^O
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>ZJ!_FM_SJ_BQ_)\_P! O^S+[!^0&^/]F(_TH_W*_P!!>UNNMS?PO_1)_HZ_
MO'_>G^__ &KUE]E][_I-H/L?M/O?)X:CR^'3'Y?=>ZJ _P"@U;^5E_SX/Y__
M /HK/CK_ /=5>_=>Z]_T&K?RLO\ GP?S_P#_ $5GQU_^ZJ]^Z]U;_P#RI/YU
M?Q8_G!_Z>O\ 9:-@_(#8_P#LN_\ HN_OK_ITVMUUMG^*?Z6_](O]W/[K?W [
M5[-^]^R_T95_WWW?V7C\U/XO-JD\7NO=6_>_=>Z;,UC5S.'RV(:4P+E<97XU
MIU02-"M=2RTIE$99 YC$M[7%[6O[]U[K2.?_ (1$?%V)'DD^<_?$<<:L\DC]
M;]>(B(@+,[LV0"JJJ+DG@#W[KW6.G_X1&_%>L@AJJ3YV=Z55-41K+!44_777
M4\$\3BZ20S19%HY(W!N""01[]U[K<8^,?2&+^,OQL^/?QNP>=K]T87X^=']3
M](8C<N5IJ>BRFXL7U1L+ ;#Q^=R5'2,])25^6I, E1-%$3'')(54V ]^Z]T.
M'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZIV_X4"?\ ;F?^8-_X@JI_]ZK;/OW7NK8]E?\ 'F[2
M_P##9P/_ +JJ7W[KW2F]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW51_P#,
M<_DF_!7^9Q5T6\.\-G;DV-W;A\5%A<)\A.E<U1[([:I\12B1J#"YS(U6(SFW
M]ZX*@ED)@ILUCJ[[92RT[P!VN_;75S9RB>TD:-QP920?VCIF>""YC,5P@=3Y
M, 1_/JLKI/\ X2-_R[NO]\8S=W<7:GR=^3F$PM8M51=7]C[SVGM?K;)^"IHJ
MJB&[L?UGLS:.Y=RFGDI"'B;*P4=0DC)-3NI()A>;]O.X1^#>7+NG\-: _:!0
M'\Z]([79]LLW\6V@16]:5(^PFM/RZV@-G;-VEUYM7;^Q=A;9P.S-E[3Q-%@=
ML;4VOBJ+![>V_A<="M/08K#XC&PT]#CZ"D@0+'%$BHH' ]E'1ET&>%^.?4FV
MNTY>XMM[9& WG4T5=1UC8BKJ*'"UIR2,E;65&#A<8[[RI4@NR(BLX$A4R7<V
M+L5TGJND5KTI]^=P]9]89':^+[ W?C=J5>\JFLI-N'++5PT==-C_ +3[WRY-
M*:3&XZ*F-?"'DJI88P95&J[#WH*3P\NMD@<>A(1TD19(V5T=5='1@R.C ,K*
MRDAE8&X(X(]ZZWUR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=$K^=?\OOXL?S&.E\MTG\HNL<%O7%24&9CV9O(X['IV'U1G<Q
M3002;LZQW=-25&2VIG%DHZ=IA"WVU>E.D-9%407B/NO=:9_\E7^5OMSX^?.7
MY2_RT_YD'\N#:/R+V'@<OF=R_';YP;M^*>:K=@Y^;$4./R;[>F[<RF$J-O'
M;_V-6TV3QM!-D:J3"YRDKL9YYI9T6/W7NMKK_AD7^43_ -ZZ/B7_ .B?VO\
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MW<N)CJMH4:?>U%!]M7UL%8V32IBGIP9O%22I3I-$\C*CEELJ,PJ.M%@#0]&
MQ.7Q6>QM%F<'DJ#,8C(P)58_*8NLIZ_'UU-)^B>DK*626GJ(6MPR,0?=*4P>
MK=.'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM'/\ G]=X_P R3Y@?S8_CG_)^_E]=
MW;JZ+-9T_'VIN[-;/[)WQU-C<KN7+8K?>Y,IDNWM]]<4-7NJCV#L_8.TZ?[.
M@5*FEJLIE%U4\]4]%X_=>ZH]^,G\LS^>[\G?D%\VOC'U]_,1W%M7NWX)[RPN
MQ^U-J[[^9/RMV\^]:#>_]Z:;;.\.J\IBMI9O'9W8^[,/MV6JBDRTN%K%H:ZF
M^XI(6G\8]U[K8U_X2/=:]A[<PG\Q?>W?_P @MW]G?*9.XNM_CK\@>G>RZ[.;
MG[&Z"W-\:LOWOCJ2BR_869W?NJ'>V"WC4=@UJ44M$(:.DK,+70I)4$,Z^Z]U
MN,^_=>Z:L[15&3P>9QM'.*:KR&*R-%2U#,Z"GJ*NDF@@G+Q RH(I9 UU!86X
MY]^Z]U\]7-?\(X_Y@FY.P)>V=Q?S*>O,_P!J3U5%73=F9JF[LRO8$U;C,?38
MG'5<N\Z[)3[CDJL?BJ.&F@D-27BIXDC4A%4#W7NFBO\ ^$8GSGRN[X^P<I_,
M/ZER6_8LEC<Q%O>OPO<%9N^/+X;[48?*Q[EJ*R3,IDL4*&#[:<3>6#PIH9="
MV]U[HTG1/_"6W^9AU9W?TWV=NG^:-C]Z[9ZX[5Z\WYN/9L^X>_G@W;@MH;NQ
M&X<OMF9,CF:O'M%GL?CI*5A/%+"1+ZT9;@^Z]UO9>_=>Z][]U[KWOW7NJ:/Y
MI'\T[<W\LGMKX23[XZ:H<W\1?D5VS-U1WM\CY]P2T:_'?)UE3A(-M9++X-HZ
M>@J,'E*/)U>0J*R>KC%-0X6M*13S^""7W7NCH_+SY;?%;X]_$SLSY =]]D]>
M+T*>N=RSR5=5N+#9'$]GX_(X2LI8=F;,2FJ:I=[9C>GW H*.BH!4RU<M0JJI
M!/OW7NM+SXB?R_/DKVM_PD'^1?765QVX\EN_L#?6YOF+\=-AI@J^NW _4NP=
MP]6;SAVW@,%CBV3S=7V7%UON?+X5(XY9:MMPTS11R:HPWNO=;:?\L#YY=(?+
MK^7=T#\D,3V+L>BIL+TGLBD[R@GW1B(*?J7L/:>T<9C^QMO[PJ*EL:N"APN<
MHZAX9ZN&DCJ:!H:E%$4J>_=>ZJ+_ )&<L/RW_F=?SF_YI.R*&KD^/7<79G77
MQOZ!WK5P30P=F8_I3 4&WMY;PVZ77QU&U:^DVIMZKHYM1=ER!BD2*>GFB7W7
MNMJ6>>"E@FJ:F:*GIJ>*2>HJ)Y$B@@@B0R2S32R%8XHHHU+,S$!0+GW[KW6O
M?_+=BC_F+?/?Y-_S<<];-='=9U.X_@Y_+;#U/W>$J>L>OLU6T7R(^2&W!1[C
MR^ K)N[>S5JL9C,K%2T=<VW<;]I,"H'OW7NBM_R)^JNI/D/UC_.YW;\K]E;)
MW_V%V9_- ^7O4W?^8[!Q6*W5G9NH-G[-V)%M_8V6R.X<5)D8]C;)EW%GXL/2
M/#%24""1:>"$1Z%]U[HT7_"6;=6]-V_R3/BI4;TRN9S1PF9[PVKM6OS=565U
M2NR]M]V;\Q> Q5)65LLTTF&VXD$F-H8E;PT=)1QTL2I% B+[KW6PO[]U[KWO
MW7NJ=O\ A0)_VYG_ )@W_B"JG_WJML^_=>ZMCV5_QYNTO_#9P/\ [JJ7W[KW
M2F]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(W??7NRNS=OU6UM^;;QFYL'5@Z
MZ/(PZGIY2I1:N@JXFCK<971JQT3T\D4R7]+#WL$J:CK1 /'H&^@/C5B/CS6[
MQBVOO7=F8VKN:HI:C&[2ST\51C]M24[U#R2T,D7C2:JJON-$DOAB>2*.,2%V
M0.;,^OB.M!:=#)DNQ-AX?=6+V-EMX[:QN\<U2BMQ&V*[,T%+F\C2M)-%'-1X
MZ:=*F=9I*:41Z5)D,4FD'0]JT)%?+K=16G2R]ZZWU[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:@
MO\XSX0_S".K/YOOPM_FV_ +:479WVE!L'XY=Q;5@VEF-Z-LBBW)G-T=>93?&
M^=E[6S&!W%O'JO(;#[./WU133I)MVHPRUU1/#3K'-2^Z]T 7\VG<7\PC^3I_
M-I[#_F9?"CXYU/R"Z,^;/2.RMB=Z;9_NMO[>VUJ+MC8&-HML8BKW%3[#>#,;
M)RU/B]JXBLQ=:7:BR"UN5IBHGE\B>Z]T//\ PEMZ*^<>;WU_,2_F1?-?96<Z
MWSOSKW_LG*;8V_N7 939.8W%7;6SO9N;W=N6CV%G*9,OMOK[$S;QHL3MIJB5
MY*FGIJFP:&*&HJ/=>ZV_O?NO=-V8RM!@<3E,YE:A:7%X;'5N5R54P9EIJ#'4
MTM965#!06*PT\+,0 3Q[]U[KYOWR#_F"?SSOYRNS?G+\NOA#VGN#XB?RW_AU
MM[LC/21;(['JNG=W;@P'3FT*WM/-T\F_=GXX]K;N[>S^PH:7(5^*AK<=MNB@
MK*6B)4RRSU?NO=&\[R_F#?S7/A[_ "C/Y+'\P'X^[CW1V5U#L/KK=$_SFR_9
M&;Q6_*7M>N[(W[M#;O5^+[2K-U565[*:&:;&96A@S]!+'-09#+TRM.S21Q^_
M=>ZW9OC-WQM+Y1_'?H[Y(;$CJX-G]Z]4[#[7V[29"/Q9''XS?6VL=N*#%Y&/
M]*9'%_?FGJ I*B:)M)(L3[KW0X>_=>Z][]U[KWOW7N@R[BZ8ZF^0?7.YNH>\
M.N]H=J]8[RHA0;GV-OG"4.X-NYBG25)X/N<?7Q2Q"HI*F))H)DTS4\R+)&ZN
MJL/=>ZIDZY_X3*?R3>L=_8SL/"?"[$Y_(86LFKL7MSL;M3NCM#8,4LL4T BR
M>P^P.PMQ[8W51PPSL$@S--D80P60J9$1U]U[J^"DI*6@I::AH::GHJ*BIX:2
MCHZ2&.FI:2EIHUAIZ:FIX52&"G@A0(B( JJ   ![]U[JC_O7_A-__)Q^17;F
M?[K[$^(E!2[SW=E*K.;PI^O^S.VNKMJ[GS>0JIJW)9BNVEU[O?;F!Q^2R=74
M/+538^&B>IE8R2%I&9S[KW5O_4/3O570'7&U>H.DNO=I=6=7[(Q_\+VGL78^
M$H=O;;P=&T\M5.M%C<?%#")ZRMJ)*BHF8--4U,KS2N\CNQ]U[J/W;U/A.]^H
M>R.E]S9W>&VMM=I[.SNQ-R9G8&>?:V\J7;VYJ&7%9R/;VY8:>IJL#D*W%U,M
M.*NG5:FG64O"\<H21?=>ZB=!]&=9?&7I7J[X^],[<BVGU9T[LG ; V-@(YYJ
MR6BP&W:"*AI7K\A5/)6Y;,5QC:HKJVH=ZFMK)99YG>61V/NO=5R?)'^2-\'/
MDWVEV?VSN:+OGK3+]\45+C_D1M?H+Y!=F=+==?(:FIJ1\7+_ *9=B;(S6/P&
M\:K)X6:6BK:AXHJBLIYG\SO(=8]U[JSKJWJ_KWI/KG9/4?4^TL-L/K7KG;>*
MVALC9NWJ;[3#;<VWA*6.BQF+H(2TC^&GIXP"SL\DC7=V9V9C[KW2]]^Z]U[W
M[KW5.W_"@3_MS/\ S!O_ !!53_[U6V??NO=6Q[*_X\W:7_ALX'_W54OOW7NE
M-[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBX=__%[K;Y"T5-+N
M:&LP^[<32-2;?WKA93%EL9")9:J*DJ(';[/*8Q:R5I/#*H="SF&2)G9C=7*<
M.JLH;IF^->P_D+UL-S;3[?WSA>PMGXPT</7VX/N*V;=4E.#(:B/+&KHQ4&D$
M+(%2HJJJ:"561))(/&1YRARHIUY01QZ-1[IU;KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z2'8.SL?V)L+>_7^68IBM];0W+L[)N$,A3'[GPU;A*UA&LL)D
M*TU<QTAT)^FH?7W[KW7RZL%\[_EY_(K^-?\ ,'_DG?+?XP9C=.S._-G?)W9W
M4G;'\>FV;!B#W9U!D^KZ'M'KYYML9_!=M=6;BGDQN4EHX<G0UF*J)JN":5*V
M*:A7W7ND+_PZ_P#)#Y[?RS/C!_(2^'WQ*S^X]P5V%ZQV5V;OZFR62WIN'><.
MRNU*7?N/&$VC@-NPT?7&Q<+NNBPN0R^X\ID*N&FHJ:=9HJ2$&I;W7NOIK?!S
MXZR_$7X;_%[XP56;@W+D.A>B>LNK<SN.EII:*CW!G]H;2Q>(W!G**BGJ:R:A
MH<MFZ>HJ((&EE,,4BIJ;3<^Z]T:CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4[?\*!/^W,_P#,
M&_\ $%5/_O5;9]^Z]U;'LK_CS=I?^&S@?_=52^_=>Z4WOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBD?)'XY;G[6RFWNP>M.RLW
MUSV?LRA:BP51%6U<.W<E2FJGK/M,DE"#5T<DDM0ZO.J5,<L),4M/(I!5Q'"X
M85'566N1UE^-N^OD7EZO<.Q_D%UU_!LIM6DIFH.Q,>*>/"[P+3" QB.A:7%3
M5[1$3F6C:*+22CT\+K9O.$XH?RZ\I;@>C9>V^K=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T GR:^3W1/PYZ4WM\A_DCV+A.KN
MI.OZ!:W<.Z,T:F8M-42+3XW"X3$8Z"LS.Y-RYNM=*>@QM!3U%;6U#K'%$[&W
MOW7NM3/M?_A;%\(-MYO,XSJ#XI_)+M+&XZHR])C=Q[FRG7O5^-W ]$[0XO(4
M%(N6WUFZ3"9IT,BO64M-704[(9*02EX4]U[IFZL_X6V?#S/5FWZ7N+X=_(?K
M6*O7&1;AR6R=U]?=JT&WJNIT)DI*=<E+UCDLWB,7(Q83+3054\*EEI5>T1]U
M[K;!^(7S*^-_SNZ4P/R!^+?9F([0ZSSM148XY*@BK,?EL!GJ*."7);8W;MW*
MP4>;VQN7&QU4334=9!%+XI8Y5#121R-[KW1G_?NO=);?53NBBV3O&LV10TF4
MWI2;5W#4[0QM?/\ ;4.1W1!B:N7 4-94^*?[>DJ\LD4<CZ'T(Q.DVM[]U[K5
MT_X3O_.[N/\ F9=-?(/IC^9_7].=H_(3X]]E8G9E)U'VITSLW:?<L&V6VW'6
M9+=&_P#8.4IJ&BKIY<[2S4+/3;;QLE+-C)#5/-)*OC]U[K9>ZKZ(Z/Z*Q$>W
M^D>FNJ>G,!%2P4,6$ZKZ[VAU[B(Z*E5$IJ2/&[1P^(HDI:=(U"1A B!0 !8>
M_=>Z%;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3M_P *!/\ MS/_ #!O_$%5/_O5;9]^
MZ]U;'LK_ (\W:7_ALX'_ -U5+[]U[I3>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBK?)#:?R0KY=M;O^/6^*7'U
M^V$JVRW7V5BQR8S=_D-X6%5D(&I7J1#))$8:B6"*Q62.6*5 QNA3@XZJP;BO
M31\<?DYFNV-P9SK+L7KC/=<=K;1Q RV<H:FDJHL%6T:U5)1?=4+5XCKJ">JE
MJUDAIY/.DM.&EBGE56T[=-(J#4=:5JX/'HX'MOJ_7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]UI)_\+7<=V+4_';X'9%J7)57QPQ7R"WX_=/\
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M<A645=(:6KIHC[KW0V]\Y?\ E =C?\)TNB?E1UW3_$CHO^9#TG@^@<;MC/\
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M3<FP=UP8[(Y+,Q9"@AW%M3)8G+Q45?$H6:)9@DJBS CW[KW0,?\ "L266?\
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M52U/24M%CJ34\T\A2-$0LQ !M[KW2DSWR7[U_G[_ "/W5\?_ (*=X[^^./\
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MM7K#:N/S%3NO<&;K=[;LW-5;.V_G\@M!CH:.DAQ\60GFDE1'%-.1[KW5I_\
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M3?<U4E_'34_F=/-426]*+=C^![]U[J9[]U[J&V1QZ5R8MJ^C7)RTYJX\<U5
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M7NJ&_B?_ "$L)\X?C/UQ\Q?YD?R1^7>^OGI\@=FGNO!]F;5[MW+U^_Q/';^
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M_L?8_4&[.R]D;8[1[-QF?S'7&PMP;DQ6&W1O['[4J,/2[EFV;B,C4T]5N63
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MV^%WRW^!/R)^,_P!["@^6G>'R*^-?9]/6X?:N&W;M':O1O1<VSI:GN;O?O\
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MX6GP> KQ644<\$M-B*LZ%II\;4U7NO=6;?S(OYHM'\ OEI\/.I?DSU9LZE^
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M%+59'*_$[XH56!Q5=%.DVYMQ4_\ ?;/TE9 8Z[%QT]09'G+:O=>Z:=D_-/\
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M X=J2&?X0]E3314S8^G,$4TR_(V-998XB S!5#$7L/?NO=/W^@_^?+_WGU\
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MO9?_ -TA[]U[KW^@_P#GR_\ >?7P _\ 2'>R_P#[I#W[KW7O]!_\^7_O/KX
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MD/?NO=>_T'_SY?\ O/KX ?\ I#O9?_W2'OW7NO?Z#_Y\O_>?7P _](=[+_\
MND/?NO=>_P!!_P#/E_[SZ^ '_I#O9?\ ]TA[]U[KW^@_^?+_ -Y]? #_ -(=
M[+_^Z0]^Z]U[_0?_ #Y?^\^O@!_Z0[V7_P#=(>_=>Z]_H/\ Y\O_ 'GU\ /_
M $AWLO\ ^Z0]^Z]U[_0?_/E_[SZ^ '_I#O9?_P!TA[]U[KW^@_\ GR_]Y]?
M#_TAWLO_ .Z0]^Z]U[_0?_/E_P"\^O@!_P"D.]E__=(>_=>Z]_H/_GR_]Y]?
M #_TAWLO_P"Z0]^Z]U[_ $'_ ,^7_O/KX ?^D.]E_P#W2'OW7NO?Z#_Y\O\
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M -Y]? #_ -(=[+_^Z0]^Z]U[_0?_ #Y?^\^O@!_Z0[V7_P#=(>_=>Z]_H/\
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MNO>_=>ZUMO\ A61_VY0[]_\ $E_'K_W\.U??NO=7_=+_ /,G>I__ !&FQ/\
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'KWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>timage_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_006.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MDO6][ ]C?6EJ!X5O Z!JU,C&.74Q(P:D8(X\>! $>3VTJW5K<7!/B32JQ6E
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MZWF2.Q-T$*.-(*2!L$N%/\)(S4''^3H#?A%_,^_FQ_+[<O07?^9^*?2G4O\
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MF/R&U\SBQD6E2G>NPV8I*#)P4\[P3+%4&E-/,8W$4KZ3[;W+9[G:&"W$92O
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M0?B !"YI4XI4,[YN9LK0S1$$L%T,!J7N(SBHX$D$XK09K0G9Z^^>_P 7LO\
M$;&_+W<?<%#M7H[&8^/';A[)[*V_ENM%.0QDB4%3&N/SN/QN5FGJ<C>*ECCH
M&>L=D%(DNM+D[[5.+CZ94U2>2H1)Y5XH6&!DYQY]&"WT1B\8MI3^)P4\Z<&
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MIGCGT\Z=+K^8;\V=]_S!?^$[_=_R8WG\?:OX[T>ZNR.I,5L_;]9OAM]#,8[
M;ZVW3OGJ6=L-A7AH*JN%9!"CT[N332.)'B:*65G8]K39M\CMTD$ND/5@NFA,
M3FE-39'GG^=1T[NM\VX[4\S(4U%: FM1XBYX#!\L=69?#?J+*=U?R!NN.C=F
MBCQFX>Y/Y=N[NML!((8XHER79NT\ICXII5+1(?)6U_DE8NI8L[,X8E_9!N5T
M+/>'F;(CNM9'J$DK3^71O9P?4[<D0--=N%KZ:DI_EZU2_P"6-B/A+M?H7N38
MWS3_ )C?\P?X!=X]&=@;W;<70O5G>M1U!C*RCH*>!VEQ6 ?:F3GJ=SFN@KZ.
MKH4J'K'DAIV6#3,MI$W][J6=)+2TMKF.55TRM%XAKP[FUB@X$$T%//!Z!NTI
M!'$R7%Q/ \9;5&)- IQ[1I-3\A4U\LCHSG7_ 'EMKX-_RC/DS\S/Y5^.^=&#
MD^07R,ZIZCW_ -B?,RKVAN48%<'2[BDR&]-EC 8V*BR)K,GDZ'!5M?6PO?(S
M0J@\V-<,@GLSN^YPV>X_3_IQ,RK;AQJX4C8L:B@4L *=O#X@>E<5R-OL9+FS
M\;O< F8J=/&KJ *&I(4GUX\".BT?/8?!#=7\MG:_:4_\P#Y$_.WYT]AT75>\
M9,'V+W1E-YT>R*W,3XU]UM/M.,&EVM04B3UF+ITR-1/(*BKABI)'0Q^-9LAO
M(MP\/Z:.V@76ATQJI< -I_4(JYP"=)R!6G'I/NOTSV9;QWGE.EA5R=!)6O8#
M11DC(P32O#JW#Y%]H?"'$_R1?Y8FWOF[\=N]NY.G-V]+]/8G#]O=)PX^C&P]
MP8+ 46/>HJ\I/DH*VAJJB.2O6&$8FNI:X4E1%+&\B0QN&[."[?=KMK.6-)%D
ME.AR?U%+L: :2#P'$BF#Y$@ZN9;==OMQ<H[H4C[E_ =(%3D$<3P!]/.AI5^0
M^V^G?Y;;]-]N?R>?YL&_^Y-U=C]CXBE@^.6U97RN4\65HI_%7Y^AQ1@Q&3>2
MIAH<<V)RFUH*N:2IA:&-Q XC%EC))S!XD>ZV:QA4)\8J4 H1@%JD<2U0U* U
MX]!^Z1-GT/87#.6<#P@P:M1Q(6@\@*%:Y%#CHV'\PCJO_1A_.VZ_[U^<79_R
M$^(_3GR]Z<ZKRN6[]^-6Y9NO<AMO/X;KS#;7RN'3-PX[.!J.CW%A8H\E"M,9
M8<?7T]3+^R/+*6[)=FZV@PVL<4TD#M^E*NO4A=F#!:KFC&F>((&2!TNW2V$&
MXB69Y(TE4#Q(SITL%"T)H<=N?M'D">C%] ]7_P K[M+^:Y\;>NNF/EK_ #7O
MG%W3T_E-J=M;/[QG[FVMVYL/#'9-4<_5XK/Y?([=QN8BVP\<%+3Y*3&R/!43
M9)<6DHK99%C1WEQ?V^VRR2P6=O')5#'X;QRM7M!50Q&H5)75D:2U*4J_;0VD
MU[&B37,SIWA]:O&M,D$TK0X!I@UTUKPX;%[DV-_+!_X4A_+W??RXR=;UQU9\
MH.N]Y4^P>S\SCZB7%"G[3RFT]QT%=)-!'.PQT%;M[(8B:8(4IJJ,^?QQ1NZZ
M>V??=AACMAK>&2KH/B%!(.'F:.#CB.K+,NU[M(\YTK(E%8\#71Y^65(STDOD
MU\J>I?F1_P *(?Y<';70=77[PZAVK5==]+8CMR/!9+&X?<66V5GMS9C,K@ZN
MM@IX<C2XD[EHJ>26!&'E9F\CPR4[&]E8R;;L=U%-VN6UF.HU*K>& 6 R"=)P
M?(<./6KBY2\W6W>/*Z2H>ATL1K) / TJ.'F<];Q_N*NAUUJ3_P C*DIG_G!_
MSTJYX(FK*;Y$=H4D%44!=(JWM#>CS1JWU"2/3P%A]"44GZ#W(_.!_P!UVW#_
M (2/^K470-Y<_P!S+S_FJ?\ C\G22ZX_[B[>_O\ Q$F&_P#?*[*]WN_^5:A_
MYJG_ *NR]5MO^2U-_P TQ_QR+HH'QR^8.TOGYW;\ML[_ #<_YB'>/P\PW46\
M*K%[-^&O7O;\_1>WWHXYLK39;#U<F/IS5;FK,)+14](T$<:9.28M-YI8ZAH(
MU^X;6VSPPKMMLD_B(&:X:/Q6K@@@&H0$'S%*&G$5Z2V=^-QED-[.T6AB!")/
M#%,@U((+$$>1P1Z&G02_RE*CKNBZ+_X4AX/K3'Y;;NQ9/B#W34=:;7W(M2F2
MI-NXC#]IPT%/7"K+50JZ*CJ<?%4"=C,)2?)=]1]KN8C(\VU-(06\5-9%*%BT
M!)%,4)K2F/3I)LX18]P" A=#:0:U"@2TK7.!ZY]>CH_R\_\ N%R^:O\ VK/E
M+_[BX[V3;W_RL47^GM_^?>C/:_\ DC/_ *2;_G[JQK^4)T!COE3_ ,)W^I?C
MEE]R5NT,7W/L'Y/; R.Y\;0)E*BAASW9^]XI*B&GEDBCEE1+Z0T@6]B;@6)1
MS3=FPWMYU )C:%P#P)6*,YZ7;!;B[VQ8B2 ZR*2.(!=QT3[*_P#">[J[^7;T
M%\W?DUM+Y'[^[)R^!^ 'S9VNNU=Q;(QV%II8]W=<Y^E>4U%-5RRH\-PRCQD-
M8@VO<&*\YS;[/;P21HH^I@:JEJU$@]2?7I*W+<6TPSRHSD^!*M&I2A4^@'IT
M1;IW_N$D^5O_ (GW;O\ []3K;V<3?\K-'_I#_P!H[]%J?\D-OM_ZS+T9#Y2?
M]PG/07_:LZ5_][N?V6[7_P K(_\ IYO^.-TNW#_DBK_I(O\ CR] U_.0Z.WW
MN;^4G_(W^2>"QFZ\EL#X[_&WIK"]G5.RP:>OQ5-VQL;KF:ARR5RI,,8L=1M=
MZ6.JEIWACK*JC#$,R)*NY:O4CW*_MFTZII)-&OX2R22C21YUUU(KP!Z1[S:L
M]E:3#52-$U:?B 9$-0?*FG]I!\ND-\HXOY-.;ZXZ9Q%7_,?_ )Q/SOB[MW9@
M8,9\?=A]^8/M/.T$TT7^33Y+;>Y]H45'3Y=*ZIIJ.EH9)DKJBHG;[1)(XIY%
M=VX[FLCL+2QMO#!)E>)HU^=&5S44J21VT&3D5I>BQ**#<74VLBD:R!S\JJRB
MAK0 '-> P:;R_1>P<=U3TET[U=B*O>E?B>MNJ^O=@XNN[)R%-EMQ34^SL11X
MZ"7/U5&D=)4YJ2*F5JZ6!%ADJ3*\2A"H]Q+=3&YE>0A1J9FHHHHU$FB@\!G
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MJFQT5"NY<M%3T\$=?59"HR6(FJE%'&DM14*XCCT*@&5P/\=CA9 LDFV&)$&
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M+_A3//''(Z)4_P JP05"J;!T7?"2!6_J!)&C?ZZ@^]_\L'_J-_ZP]:_Y:O\
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MGO.(MH6MXS-,B)"OA") Z$ T!!\1,T X5Q0UST5<MF>19G$<;,TC>)K8HP-
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M)-*>0(UP&T+JM>PO;W'!Z&'6HE_+YPNU.R/^%&W\SJM^0^%VWGNUMGXG<_\
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M2I!"J*5K@#C7/3>W!Q>7'B%"VB+5H4J*]_&K,:TIDGA3HVW_  F_VY@\9_*
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MON^FYC69:FDCIY(IIZ>?!FOD:!7!EE@@ ((! BY7NEANA%+_ &<ZM!)P^&3
M-34"C4-?+HGWN!I(-:?'$1*G'BF:4!%:BHI\^BM]<=O;8_FC_P TWXX]C;"J
MUS?Q]^!WQ%VO\DC31UK2PMV5\SL3#+M['Y.E,:(*G"[5C>KB,CK/25T,T>B,
MF=2OFMFV+;Y$D%)+B8Q<!B.W/=0_-R!C!ITFCG7=+M&0U2*(2<3EYAVU%/)
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M5Q\.+IZ..."*E2G$$<*K$L810H9:5W8N6)8DL6))8L34DGC6N:].+&J*%
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MBG6&EFJ/OEJ8:QI9*P92+)VKTK'F>H^^45+.TMR0BNZ3K<"[UGQ0VK6<FO\
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M,[LS-_O$U^4K1%CQ&D8TI'FO:/6O$DDGS/3EIM\=H&I5F?+LYU,^*9/IZ 4
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MX(+=OW:3;?%T!3XT3Q-JJ:*_$BA&?MJ/ETLO+!+WP]1(\.19%I3BO &H./\
M57HZ'LKZ7=$W^:_S7^+'PFZMDWA\K-ZTVU=H[OI-QX#"8B?;62W,V?J:6B:6
M;"T\-!15<9J:R!BB).T4;J79G$<<KH8[9M=QNLFBW4LPH30@4%:5-2*#Y])+
MR]BL$US,%'#/F:5H*<3\NB%_R!_AF?B3\%,9GL_L:JZ[[#^3&\LWWQN39>5>
MIJ*[ XG<&F#:>W:F:MB@K7?&;?AI9I5J(4FCJZRK60:[^SCF_=/WG>&C:UB4
M1!@  Y7XF%"1W,32GE3HNY>L?HK<=NDN3(5J25U<%S0U"T!KYUZ%?L[^4CUQ
MF^[.Q._?CU\E/E;\+-\=S54N2[HQ?QI[&H\#M_<V0G6-7S%;@<MB\M0TV;;Q
MW-92I Q>2>8J9ZF>61+#S ZQ+#-%#.J80RJ=2"I- R,C:<\"2.'IT_)M2F0R
M1O)$6^+0PTL<"I5E85QQ !Z,9\9_Y?7QI^+'1N_^A-C[8RV[-L]QS[LK^]-R
M]GYV7>NX-\UN^Z>6DS%;NC*RB.6OGKZ:::-PJ11*LDA2-7DD9T=]N\^X2K*Y
MH4 "!0%6,+P"@8 'ETHM;"*S0QH,,26)-2Q/$L3Q)Z*!L'^2_P!==>[;3IW%
M?,7YUS?%"GJJ_P"V^*'^FVFQFV?X=DYGGGV_)E*'#4N[?[N2RR2>2BAW!!YD
M9XYY98Y9UE,)^8WN&,C0P>*>,V@ZJ_Q:2Q35\]'S&:'I+%LZP@())?#'"/4-
M-/2M-=/EJ^7#'3MD?Y*7Q:K?A5VI\"*7?7>F%Z#[-[TK>]:2CQ&?V[#D=MU%
M77T627 [?J)-L2T\6WJ>HHE\45;25M8JR2 UK731M.9YTNTO=*&1$"$D.0]%
M*:F[ZZB#FA QPX]5?8XGMVMJL$9BP T@K5@U%[>%1YU.>/5O\48BCCB4DK&B
M1J6Y-D%A?Z<\>PV<]'(QUS]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK+?!^M?K#_A
M1Q_-5ZBFQ\U!1=L=']9]T8BKD@^WAJFQ-'LF29H&9(O.7J=U9(,T:NHEIJE&
MD9XV)'.ZIX^R6<H(.B26,CS!9G(^S"#CY$=!>P?PMSN8R"-:1N#Y$*J@_P V
M_D>MFGV!NA1U[W[KW5"'_"EO:*;D_E)=UYEHO(=@;_Z/W=&VIET&MW3C<#JL
M'0&ZYMELRN/5?2& =!AR(^G<XAZB0?\ 5-C_ ).@[S4*V,GR*?\ 'U'^7JWC
MXM;]I>U?C)\<^T**H-71]D=$=1;]I*HK(AEBWAM_'Y&.0K-'#*"Z5 -GA1Q?
MU(INH#%[ ;::2-L%'92/0JQ!X5].CRWE$\:NN0RJP^P@'H=_:;I[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K"U/3O-'4/!"]1"&6&=HE9T#@@A6
M(U*"";V//OU>O=9O?NO=>]^Z]U[W[KW7O?NO==,H8%6 96!5E87!!^H(_(/O
MW7NHU'0T6.IHZ/'TE+04<.OPTE'3I2Q)Y&+MIC0*JZF9B;#DDD\GWLFO7NI7
MO77NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KIE# JP#*P*LK"X(/U!'Y!]^Z]UCA@AIXUAIX8H(4OHBAC$2C42395  N
M23]/K[]U[K+[]U[KWOW7NO>_=>Z][]U[IJRF"P><%&,WAL5F!CJR'(8\93'0
MY#P5%.;QSP^9'\4R$ JZV93R"/>PQ7AUJE>G7WKK?7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= GW%\EOCE\=_[N_P"S =_]
M)]&?WP_B_P#=+_3%VK@NLOXI_=_[7[_^'?QJOHOO?L?OJ+[CPZ_#]Q#Y-/EC
MU*[6PGOJ^!'))IIJT(STK6E=(-*T-/LZ3SW<5K3Q71*UIJ8+6G&E2.%>@3_X
M<L_ER_\ >?WPG_\ 2JMB_P#U^]J_W!??\HT__.&3_H'I/^]K7_?T7_.1/\_7
MO^'+/Y<O_>?WPG_]*JV+_P#7[W[]P7W_ "C3_P#.&3_H'KW[VM?]_1?\Y$_S
M]>_X<L_ER_\ >?WPG_\ 2JMB_P#U^]^_<%]_RC3_ /.&3_H'KW[VM?\ ?T7_
M #D3_/U[_ARS^7+_ -Y_?"?_ -*JV+_]?O?OW!??\HT__.&3_H'KW[VM?]_1
M?\Y$_P _7O\ ARS^7+_WG]\)_P#TJK8O_P!?O?OW!??\HT__ #AD_P"@>O?O
M:U_W]%_SD3_/U[_ARS^7+_WG]\)__2JMB_\ U^]^_<%]_P HT_\ SAD_Z!Z]
M^]K7_?T7_.1/\_7O^'+/Y<O_ 'G]\)__ $JK8O\ ]?O?OW!??\HT_P#SAD_Z
M!Z]^]K7_ ']%_P Y$_S]>_X<L_ER_P#>?WPG_P#2JMB__7[W[]P7W_*-/_SA
MD_Z!Z]^]K7_?T7_.1/\ /U[_ (<L_ER_]Y_?"?\ ]*JV+_\ 7[W[]P7W_*-/
M_P X9/\ H'KW[VM?]_1?\Y$_S]>_X<L_ER_]Y_?"?_TJK8O_ -?O?OW!??\
M*-/_ ,X9/^@>O?O:U_W]%_SD3_/U[_ARS^7+_P!Y_?"?_P!*JV+_ /7[W[]P
M7W_*-/\ \X9/^@>O?O:U_P!_1?\ .1/\_7O^'+/Y<O\ WG]\)_\ TJK8O_U^
M]^_<%]_RC3_\X9/^@>O?O:U_W]%_SD3_ #]>_P"'+/Y<O_>?WPG_ /2JMB__
M %^]^_<%]_RC3_\ .&3_ *!Z]^]K7_?T7_.1/\_7O^'+/Y<O_>?WPG_]*JV+
M_P#7[W[]P7W_ "C3_P#.&3_H'KW[VM?]_1?\Y$_S]>_X<L_ER_\ >?WPG_\
M2JMB_P#U^]^_<%]_RC3_ /.&3_H'KW[VM?\ ?T7_ #D3_/U[_ARS^7+_ -Y_
M?"?_ -*JV+_]?O?OW!??\HT__.&3_H'KW[VM?]_1?\Y$_P _7O\ ARS^7+_W
MG]\)_P#TJK8O_P!?O?OW!??\HT__ #AD_P"@>O?O:U_W]%_SD3_/U[_ARS^7
M+_WG]\)__2JMB_\ U^]^_<%]_P HT_\ SAD_Z!Z]^]K7_?T7_.1/\_7O^'+/
MY<O_ 'G]\)__ $JK8O\ ]?O?OW!??\HT_P#SAD_Z!Z]^]K7_ ']%_P Y$_S]
M>_X<L_ER_P#>?WPG_P#2JMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\
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M_<%]_P HT_\ SAD_Z!Z]^]K7_?T7_.1/\_7O^'+/Y<O_ 'G]\)__ $JK8O\
M]?O?OW!??\HT_P#SAD_Z!Z]^]K7_ ']%_P Y$_S]>_X<L_ER_P#>?WPG_P#2
MJMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\ /U[_ (<L_ER_]Y_?"?\
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M_P X9/\ H'KW[VM?]_1?\Y$_S]>_X<L_ER_]Y_?"?_TJK8O_ -?O?OW!??\
M*-/_ ,X9/^@>O?O:U_W]%_SD3_/U[_ARS^7+_P!Y_?"?_P!*JV+_ /7[W[]P
M7W_*-/\ \X9/^@>O?O:U_P!_1?\ .1/\_7O^'+/Y<O\ WG]\)_\ TJK8O_U^
M]^_<%]_RC3_\X9/^@>O?O:U_W]%_SD3_ #]>_P"'+/Y<O_>?WPG_ /2JMB__
M %^]^_<%]_RC3_\ .&3_ *!Z]^]K7_?T7_.1/\_7O^'+/Y<O_>?WPG_]*JV+
M_P#7[W[]P7W_ "C3_P#.&3_H'KW[VM?]_1?\Y$_S]>_X<L_ER_\ >?WPG_\
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M>_X<L_ER_P#>?WPG_P#2JMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\
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M_<%]_P HT_\ SAD_Z!Z]^]K7_?T7_.1/\_7O^'+/Y<O_ 'G]\)__ $JK8O\
M]?O?OW!??\HT_P#SAD_Z!Z]^]K7_ ']%_P Y$_S]>_X<L_ER_P#>?WPG_P#2
MJMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\ /U[_ (<L_ER_]Y_?"?\
M]*JV+_\ 7[W[]P7W_*-/_P X9/\ H'KW[VM?]_1?\Y$_S]>_X<L_ER_]Y_?"
M?_TJK8O_ -?O?OW!??\ *-/_ ,X9/^@>O?O:U_W]%_SD3_/T:+KKLOKCN#9N
M'[%ZEW_LGM'K[<7\0_N_OOKK=5!O;#5W\(JIZ&K^SRF,GJJ&J^UK:6IIY?'.
MWCGBEB>TD;*"^>WDM7,<JLC"E58%6%145! / U^SI9%,DZAT8,IX%2"#0TXC
M'2V]L].=>]^Z]UK+=F9&/J3_ (5(?'YVHZB"F^37P5S>W&R"0A(9*K;T.[ZT
MK++Y8%++'LFCCL14.&DIU\:K)')$.;>/ZGE^2A'Z5R'(\Z%43Y^;_+@?3H+R
MOX.[I4']2 J#Y5#,W^!?GQ'6S3[ W0HZ][]U[JM;^<7LZ/?/\KGYT866%9UH
MOCQOG>(1E+6;KN%=P(_$<O,;XQ7!TBQ6^N/]:G?+;^'N%N?^'1C_ 'I@O^7H
MLWE=5I,/^%N?V*3_ ).FW^2_OFE[#_E7_!S/T=3!518_HK;VQGEIYEG42]83
M5.VIXRR$@/#/B9(W6^I'5E8!@0+<SQ&'<+@$4_59L^C'4/V@UZULD@DLX2,_
MIJ,>JC2?V$=6=^R+HTZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[HD_S$_EU?#?Y]_Z.O\ 9M>GO]+'^B?^]W]P
M/^,@[IV)]A_?O^&?Q7_CVLYAONONOX-C?^!/F\7A_9\?DEUFVU[Y=;+J^F?1
MKTZNU&KIK3XU:E-1X=%]]M4&YZ?'75IKI[F%*TK\)'H.B3_] ZO\G#_O#W_V
M8+M/_P"S?V;?UXW3_?\ _P!4X?\ K7T7_P!5K#_?7_&Y/^@^O?\ 0.K_ "</
M^\/?_9@NT_\ [-_?OZ\;I_O_ /ZIP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P
M_P"\/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\
M)P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO
M\G#_ +P]_P#9@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J
M_P G#_O#W_V8+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T
M#J_R</\ O#W_ -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\
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MP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\
MZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\
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MS?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\
M[-_?OZ\;I_O_ /ZIP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M
M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3
M_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO\G#_ +P]_P#9
M@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J_P G#_O#W_V8
M+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T#J_R</\ O#W_
M -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?
M_9@NT_\ [-_?OZ\;I_O_ /ZIP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\
M/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[
MP]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO\G#_
M +P]_P#9@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J_P G
M#_O#W_V8+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T#J_R
M</\ O#W_ -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_
M "</^\/?_9@NT_\ [-_?OZ\;I_O_ /ZIP_\ 6OKW]5K#_?7_ !N3_H/KW_0.
MK_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P!
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MZ#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\
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MKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\ [-_?OZ\;I_O_ /ZIP_\
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MR\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\ G#_L]>_JY_R\W/\
MSE_V.O?] ZW_ (-)_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!C
MKW_0.M_X-)_F*?\ HU_^-^_?UR_Y<[/_ )P_[/7OZN?\O-S_ ,Y?]CKW_0.M
M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\ 8Z]_T#K?^#2?
MYBG_ *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z
M-?\ XW[]_7+_ )<[/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW
M[]_7+_ESL_\ G#_L]>_JY_R\W/\ SE_V.O?] ZW_ (-)_F*?^C7_ .-^_?UR
M_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F*?\ HU_^-^_?UR_Y<[/_
M )P_[/7OZN?\O-S_ ,Y?]CKW_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^
MSU[^KG_+S<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?_C?OW]<O^7.S_P"</^SU[^KG
M_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]_7+_ )<[/_G#_L]>_JY_R\W/
M_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\ G#_L]>_JY_R\W/\ SE_V
M.O?] ZW_ (-)_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0
M.M_X-)_F*?\ HU_^-^_?UR_Y<[/_ )P_[/7OZN?\O-S_ ,Y?]CKW_0.M_P"#
M2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\ 8Z]_T#K?^#2?YBG_
M *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\
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M )<[/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\
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M_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F*?\
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M ,Y?]CKW_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\
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MO?\ 0--N7_O:K\R/^I]1_P#9%[]_78?\H=K_ +QU[^K1_P"4FX_YR?['7O\
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M-N7_ +VJ_,C_ *GU'_V1>_?UV'_*':_[QU[^K1_Y2;C_ )R?['7O^@:;<O\
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MDW'_ #D_V.O?] TVY?\ O:K\R/\ J?4?_9%[]_78?\H=K_O'7OZM'_E)N/\
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MH_\ *3<?\Y/]CKW_ $#3;E_[VJ_,C_J?4?\ V1>_?UV'_*':_P"\=>_JT?\
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M)4ZE5KM(.>>9#<R6TS<7M8R3ZDEF/#_3=!?E>,0)/&O!;B0 ?(!0/\'6S/[
MW0HZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZU^_P#A37LN#=/\IWL[.34T<\G6W:G2F]*65X]9ADKLY#MTR(?&
M^AC%GY([ZH_2[+K.KQN,>0I"FYQC^)9 ?GV,W_/O0<YK758N?0H?^-J/\O5T
M/QVWS2]G_'[HOLNAJ8*RB[#Z<ZQWS1U=+,M1'+%NW"4-?')'(A9'1TJ RLK%
M2"""0?85NHC!*Z,*%692#Q!!(Z/X9!*BL,@@$$<""*]#'[8Z<Z][]U[K64_D
M[XQ>J/YMG\]#ID3SI3;@[GV-W+C,;-)&$B3=>5W9F93!$AB6.(1[KHXQHIS^
MU' LDA*(9!US+)]5MNWRD"HCDC)'F$T(/^.D_:33H+[*G@7MY&"::T>A]7#,
M?\/[ .MFOV!>A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1*FOH*.2EBK*VDI)
M:Z84U%'4U*0--(?I'$&8&1S_ *E03_A[]U[KNMKJ+&TTM;D:REH*.'1YJNMJ
M$I8D\C!%U2.51=3,H%SR2 .3[]U[K+!/!500U---%44U1%'/3U$$@E1TE 9'
M1U)5D92"""00;CW[KW46DRN+R$]934&2H*VIQTO@R%/25D=2\#W9=$R(S-$^
MI'%F -U8?@^_=>ZG^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NJQ/YT&QJ7L/^5?\X\!64T%5%C^BMP[Y
M2*HA6=1+UA-3;E@D"N" \,^)CD1K:D=592& (/>6)3#N%N0:?JJN/1CI/[0:
M=%>]QB2SF!S^FQSZJ-0_81U/_DX[T@W]_*X^#&<IJF.JCH?CWLG9;2Q2>4"3
MK:-]NRQD^26S0RXIXV&H:64KHCMXUKS+&8MPN ?]_.?]Z8M_EZWLK:[2$_\
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M-#2ZY*>&.HCD;(30!YE]U[IWZ_\ YBW>&VN]NE.E/G#\*:_XATWRBSN<V?\
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M'\/K<XQ'^;NJI)=92I'/*P6XL=P@/$PB0?\ -O6W^'3T&-\)ANK24<!*4/\
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M #KW%_\ 7CW[P^4/XMR_ZH_] ]>U<R>EA_U6_P _7OX__P *-?\ GB/Y<_\
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M\&<]2YR/&OH,].*3Y"25"52I_G(UIH8W8.#98XWXT(1[KW4O^0,V<KOYRO\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB3?S _Y?\ \=/YE?QMW/\
M&3Y+;=J\IM'+U=/N':VY\#/'C\YMC/XR&HAH-Q8"LEAGCILG1QU53':2"6GJ
M*::HI*J&>EJ)HG]U[J@W*?\ "=WY\;TZ]C^*G9G\]GY([L^"J*=N5735)T]2
MXG<E;M:&ZT^VZW=DFYZN2KIXZ<QT\GW-%4T$T<8OBDB9:>+W7NK%_E;_ "1>
MC^X_Y4L'\J#X[;Q7XO=58O(;!R6%WO+LC_2U6>?:.>@S]?79.C.8VX^4RF=K
M(YGJJILE%IDF+)%XDC@'NO='I[6^$/4??OP=J_@EWE24W8/6F8Z0VQTYG,G+
MB8J*9I=I8ZDI:#<%!!*]8N/RN/R%#2Y&A<32O25<4+I*S1AS[KW5.V(_D$=M
M3_R<^R/Y0O8G\P:3L3:N;WOLO/\ 4O=.0^-4U'6;1PVUMR8G<TNVFPLO8]8,
MQ0/78ZH%&PS%#]@E6\:QSPPPPK[KW5H==_+DZJWQ_+#V7_+$[IR%/VAU[MKX
MF]6?&/)[WEVQ%AIJFIZGVYC,-C-VT.,EJLBF+R=)DL529:BC^_J#1U4<2BIE
M,?D;W7NJP]K_ ,B;Y)8+^4-V+_*3R/\ ,SK<WL_=>Z<(NT.YS\8ZS'Y7 ;-@
MR=/F<IL=:!>T9&KL5DLA3!$8Y6".#'U%9C7I:FEGC6#W7NKL_C)\3NHOBY\>
M.D_CGLK;6#R&V.D^L=F=:XK+9' TQJJY=IT,-))D:LL)6-7D9HY*F<^5OW97
ML2/?NO=$-_EN?RF9?Y;7R,^<W9?7GR)J]X=!?,?L^H[?P?QNK^KDV^NQ\S69
M"OK)3C]PQ;@JH\E1_;Y&6B6,[>HY/MJ:@$DTLE,[S^Z]T+/\U3^61UO_ #2?
MCKC.G=U[^W?TUV+USOC%]M]!=Y[#>23);1W;M^"H@H<F*6.JH3D*/14.)Z9:
MZEE:T<M-5TE7#!4Q>Z]T5W^7W_)T["^.7RSWM\_/FO\ -#=OSU^8V>ZW@Z7V
M5V%F.MJ'J'$[9VM%X6DI*#"8^NKX)*^H>.4-4*]/&L=14_Y,U14U%5+[KW03
M?-#^1;VUV?\ +GN#YE? 7^8-V%\ .R?E-UT>LOEEA,7UK#V_B=U4T%-145-D
M\?3U.:Q#8'+14=&J-/"9)UD9JB@J<;+/7&M]U[JU3^7A\#^G_P"6U\3^M_B7
MTI49K+;6V(N7R66W9N:2.3)9S,[FJ7K,IEZ[PJD,<E342:8X8U$=/3QPTZ:A
M%J;W7N@$^.7\LK_0!_,X^<W\QK_3;_>W_9T=H=8;5_T.?Z-OX#_=K_1OC<-C
M_/\ WA_C];_&/O?X3Y-'\#H?#Y=&N7QZG]U[H5>Z?B!WAV?\ZOBE\KMH_-'M
M7JGIGX_;<WWA>R_B!MR'+MMCL:HW919.EHJ[.O2[KQN*6;#S5U//!]UMC)MK
MI8_') VEX_=>Z/7G<'B=S83,[;S]!3Y7!;@Q60P>:Q=6GDBJ:3+0O!4T\JW%
MXYH9'1A?D$^_=>ZHJHOY1_RJVCTWD?@UUA_,=SVS?Y=&2Q63V91]<571-'N#
MM?";*ST]2:[K_ ]H29^&GAPCT-0^/I\C6;3K,O1X]OMH*@/'#4I[KW1VOD3_
M "Y^M>V>C_C9U7T[NG+?&3=WPJW)L'=_P^[-V%AJ7/OLRLZ[Q,NWJ6CFQ%<R
MT>=P&0V]456.R..J)46KIY-8FBJ(XIT]U[I#_'GX&=TTGR9P?S,^<GR2VO\
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MU[KWOW7NO>_=>Z][]U[K2P_X6V_]D._$+_Q:VM_]Y#.>_=>ZV<OYAOS4VY\
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MUN7>,2'-R3T$.WJ;[=J6.F4M75F3EEIXJ6.);U%1/$B?K'OW7NCE?R^OF_\
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MA\&\W+A<J^273&LCQ[.W=C98ZDM(_CAEC<(J*S>Z]U4WTA35FS*_X ?SOJC
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M%>EH=V3U-'D:*'Z&1<?N7#Y:25M-U>NC!-F4"5?>&Q22YM]SA_L[N!3J]64
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MW?BX:2CI*FJB&>J6B\"3S2CW7NCG_P X#XR=V]_?$C;>1^).S<%NSY5?%[Y
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M\=),Z/!)3&26/W7NB ;)ZU_FZ[]^6?\ +_[:_F?=&=O[_P#AQ\<^ZLMN#I'
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M%DUI+U$?NO=63]Q;QW=_*_\ B;\&NJ?CKT>.^=B[1[?^&'P<W''7[YI]DUN
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M*56>HZ:G:L=/=>ZO*_G0_';N/Y9?RO\ Y>_';X_[/_O_ -Q=H[!P6$V+L_\
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MA*?W[KW5K_;_ &M_,OZY[4Z0^2^Q?CONSNCXY[Z^-='M_OOX";;W9UYC=_;
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MM'N*+!8C-Y^JKGEQM/\ PJGQU 5J5:MDK*JA2BC^\]U[H..O?YQN:ZW^._\
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MQ5LV.VI'DMI8FJKJ-MQ34]9CZE,.)X4^Z\-;#,8M0BD60J??NO=:2GRB[O\
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M*DI2M, HW6V-[@SJ4.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI
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MV(IV"-0I(22H /NO=',_GY&E3XE?'JHC%&=TTG\R#^7W4[ 2:H%/4-F$[(Q
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M"39N>JXX<S#DJ%*:>&JD3$-#/5RPYI)4HX9EN]W&S;9%%#XY2VN[=I));%U
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M^3$@?\=/6S3[ W0HZ][]U[K63_GFQY+KSY\_R-_D#0?:P8S;WRXJ>M=V5M2
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M(/+&R(M84J)51M:!'1+^-2Q .>9.=I]RMWM$18XIYWNG'Q-JDDU!=5!A=(R
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M1^(DQ.6IF$U/4J(LO/JAE6ZR+X:FG>X)&F1#]&'N8_=Y3&U@C"C+:*"#@@U
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MQ4VZJVGIMW[[3$15>,V_'62TKP?[D(9$5L8/NUB]^Z]T=;YA_P O'?6U]F_
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M"/4F]>]^Z]U[W[KW7O?NO=$9_F _\RGZ:_\ %YOY?/\ [^K8WL2\J_[D2_\
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M=<[;JLIB=F;3E29:/$8[/T])7P9?(LB5<$#QBAEUM)&?=>ZK;I/E!OWX>_\
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MZ]U[W[KW7O?NO=$YZ+ ;Y1?.96 96WAT.&4BX(.PL5<$>SF__P!Q;7_2R_\
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MN+L]ML6ZR6UHFB-5C(74S4+(I.79CQ/KT/>3]QFW7;XYYVU.Q>K45:T=@,*
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M6MI>Z"3B*'.@D>:^1_$M&]0%7*G,8WZ"C]L\?;*G @C&H ^1IP\C4>53<![
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MFJ=A9?\ BU?]_1[BG:=H2ZY"-:2H:$3P&-BWMF^Y=MHHHKI&GCA>98F$Z 2
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M[J;L/JE<3V5F=\;FVE0U6%Q^T^FMW[UI9EGK4TJ<KA\'78F*4?;3%HI*Y)$
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M+"MI\;L.B^05?EZ>BI*L!%H:>6@K,$II(H0(@LE,[-$J+([D%F]U[H<>B?\
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M5!;W7NMQ3X(57=U;\)?B)5_)49$?(2I^-/2,W=AS*11US;IDVWCCG'KUI_\
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M>CZO+_E,?]NU_A;_ .(%V9_UJ;V3\\?\EB\_YZ)/^/'HTY9_Y)UM_P T(_\
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MM%,H=&P585!\_P!HX@\0<CK4U[ ZC^8'_">[N?)=U]!-NCY!_P N'?.9H_\
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MML;<F#WAL[=6*HLYMK=.VLI#F\?7T6102055'5T[R05$$R,&1T=E(/!]P=/
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M#Z12G^0'^7H!^X[4VQOG)&/YD_Y.MCK^6]0)COY>_P ':=)&D63XE?'JO+,
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MW<NZDJ)8:C*/0P5607"X>@I*[(U_VE)-524]*U/31M43Q>_=>ZI(_EN_S/\
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MJ6C3)U&' 6JGVY45D<+5#K(LHEQDQ&2I#'*&CG@B-6X2YP]OKGEC]>,^/:L
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M&ABK^A=S['2:>>.F5I>S7@VW!"&E>-2]1-EHXD4,7=W5(U=V5&/>68C-N%N
M*_JHV,X4ZC^P"O17O<@CM)B33]-A^;#2/VDTZS_R;ME0[!_E;?!G!04XI4K_
M (_;-WJT8C6*[]DK)N*22R11 F:3*M(3I);5J9Y&)D:O,LAEW"X)_P!_./\
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M_P E:]_YZ[G_ *O/T)N7O^2?;?\ //#_ -6UZ.)[#W1QU[W[KW7O?NO=%O\
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M?\*TK_22@_ 3C8Y^&/\ ,(^+7SRV@VY.@.Q:/+9W&8^AK-X]:YQ/X'N3!/6
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4O\
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M'#JS\3]IZ-1[WU7KWOW7ND#V/U=U]V[MN;:?9&T\/NW!2R+4PTV4IM4E-41
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MKZJ2=VO^W*Y2K+7IR-].#PZ#C^7I_,&G[:9OCE\DYGV;\H-EUE5MPT^X*'^
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M;LI#"(UGEKLUMC(QIY'5JF10/$<?N[E3G#-O*UA.WX'HL>KB31B4-:T"K(G
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M'+)LCL?&4<<F3Q$TA#,JLVG[G'U! %12.XCE%G0Q3I%-'HBO5T<IPZJ/Z_\
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MI-1C,UCH<K3R:?IKAG22-K?BZGW9':,U4D'U!H?Y=:90PH<_;U5G\F?Y)_\
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M[TOU'M3H?J_9_4>QVRK[4V1CIL9AGS=8N0JVCGJ)JEVGF2*%'<RSR&XB4 6
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M5-73QPO#M3M;=^$ID:)/&LL5&F<:EBDTA;A(0CL-;HSO(SG-O[I;[;J%%SJ
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M]BQ[]U[KW_;6'_X)-_\ 8L>_=>Z]_P!M8?\ X)-_]BQ[]U[KW_;6'_X)-_\
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M?_@DW_V+'OW7NO?]M8?_ ()-_P#8L>_=>Z]_VUA_^"3?_8L>_=>Z]_VUA_\
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M[KW^S$?\+4?^\#_BE_Z&'5O_ -N;W[KW7O\ 9B/^%J/_ '@?\4O_ $,.K?\
M[<WOW7NO?[,1_P +4?\ O _XI?\ H8=6_P#VYO?NO=>_V8C_ (6H_P#>!_Q2
M_P#0PZM_^W-[]U[KW^S$?\+4?^\#_BE_Z&'5O_VYO?NO=>_V8C_A:C_W@?\
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M;W[KW7O]F(_X6H_]X'_%+_T,.K?_ +<WOW7NO?[,1_PM1_[P/^*7_H8=6_\
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M^_=>Z]_LJO\ PLY_[V6_";_T ]E?_<_^_=>Z]_LJO_"SG_O9;\)O_0#V5_\
M<_\ OW7NO?[*K_PLY_[V6_";_P! /97_ -S_ ._=>Z]_LJO_  LY_P"]EOPF
M_P#0#V5_]S_[]U[KW^RJ_P#"SG_O9;\)O_0#V5_]S_[]U[KW^RJ_\+.?^]EO
MPF_] /97_P!S_P"_=>Z]_LJO_"SG_O9;\)O_ $ ]E?\ W/\ []U[KW^RJ_\
M"SG_ +V6_";_ - /97_W/_OW7NO?[*K_ ,+.?^]EOPF_] /97_W/_OW7NO?[
M*K_PLY_[V6_";_T ]E?_ '/_ +]U[KW^RJ_\+.?^]EOPF_\ 0#V5_P#<_P#O
MW7NO?[*K_P +.?\ O9;\)O\ T ]E?_<_^_=>Z]_LJO\ PLY_[V6_";_T ]E?
M_<_^_=>Z]_LJO_"SG_O9;\)O_0#V5_\ <_\ OW7NO?[*K_PLY_[V6_";_P!
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M*79>ZMG[IVBTAQFY=K9N!7EQF7HUFJ(P_CEAF@FGIJF&>GFEB;W7N@'^-_\
M+>VETMW5!\F.W/D'\A_F7\B\+LG)=:[ [3^2V>P5<=I8'.2129*@VIA-LX#;
M>!Q$^8:"'^(Y 8^7)5J(L,U8:91"/=>ZL>]^Z]T77Y?_ /9)?RB_\5U[L_\
M>:R?OW7NM8S_ (14_P#;K+OS_P 7_P"T_P#WW757OW7NMOWW[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIV_\))?^ZN7_ (O56_\ R;]^
MZ]UN)>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM.W^3I
M_P!Q(/\ /D_\AW_N^H??NO=;B7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7N@1[\^2WQ\^+&R5[(^27=/671FQ),E3X:GW5VCO*
MAV91SUE4K/%1TTM=-"*FKD2.1EAB#R%59@NE21[KW2IZG[>ZJ[WV%@.T^E.Q
MMD]L=;;I@EJ=N;[Z\W-1[NQ-:D#M%(:>NH99Z>1HI4>.11)JC=61PK*0/=>Z
M$7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T@,KVKUOA.R-H]/9;>VW*#M/?N
MW-U[OV=L"?)QKE<CBMC24$.7R--1W,ST6/FRF/CFFTB-9*B)-6IP/?NO=!3\
MB?F3\3_B-2;;KOE!\C>F>@J?>-5446U#VOV%C-E/DI*/1Y_LHJZHAEJ4I_)&
M9G1&2$,ID90PO[KW0[;5W7M??6VL%O/96X\%N_:&Z,519W;6Z=LY:#.X[(46
M3C66GJZ*MI9):>JIIXF5XY8Y&1U(*D@^_=>Z?_?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]T2W>/\Q[X ]>=S'X[[[^:'QCV?WFF:QNVY^JMQ]U[?P^;@R69\'V>-J:
M&>O26ER-7]U3>"EE"3S>6/QQMK6_NO=#)WY\EOCY\6-DKV1\DNZ>LNC-B29*
MGPU/NKM'>5#LRCGK*I6>*CII:Z:$5-7(D<C+#$'D*JS!=*DCW7NE3U/V]U5W
MOL+ =I]*=C;)[8ZVW3!+4[<WWUYN:CW=B:U(':*0T]=0RST\C12H\<BB35&Z
MLCA64@>Z]T(OOW7NO>_=>Z][]U[KWOW7NO>_=>Z*Y\C/FY\/OB'-M:E^47R:
MZ0Z"K=[BM?9^/[6['Q>RZG)1XQHDJIZ*FK:F*>HIJ5YX5FF2,Q0M(@D=2Z@^
MZ]T,S=J=8KUN>XSV-L7_ $1KM8[X/:2[MH&V[_!1!]U_%QFA4'&G&?;?N_="
MI\'C]>O3S[]U[H)_CM\R?B?\N:3<E=\7_D;TSW[3[.JJ>BW6>J.PL9O5\;)6
M:_!][%0U$TM,E1XY#"[HJ3!6,;,%-O=>Z,K[]U[KWOW7NO>_=>Z][]U[KWOW
M7NNF954LQ"JH+,S&P 'U)/X ]^Z]T&/5W=?47=NR7[)Z@[*V3V5U]'E=RX-M
M[;+W'2[@Q7W>S:N>@RL KJ:22F9\?6TU1#/:0B.2-U8W4^_=>Z!_H[YV_"[Y
M,[VW1UM\>?E5T#W7O_9<-14[GV=UEVIAMY9&DAHY1!-4/24-7-,]+%.RQO,B
MM$DA",X8@'W7NC7^_=>Z][]U[KWOW7NO>_=>Z][]U[I#]D]F=>=-[%W-V?VS
MO?:W6_7.R\:^8W=OG>V<I]M8K&4D;*AJ:ZNJY(J:FA#NBZY)%6[ 7N1[]U[H
MM72G\Q;X$_)+?=+U?\??F/\ &SNKL>NQV2R])L;J_N+!;VRLE+AT\E54K0X^
MMGJ#!3QD-(_CTH"-1%Q[]U[IYW5\]/A/L;O/&?&3>7RP^/FU_D)F:O&X_&]-
M9WMC"XS<4E5FE5J*D_ADU8M2E96J\9IZ=T6:<,IB1PPO[KW1M/?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]UQ=TB1Y)'6..-6>21V"*JH+DDG@ #DD^_=>Z*)U!_,!^
M#?R![1S/2?1ORY^.O;?;F CRTV3ZZZ\[<PF[,NL> 8)7R145%6335,5$[ 5#
MPK(L)XD*^_=>ZG=X_.WX7?&;>VU^MOD-\JN@>E-_[TAIZG;&SNS>U,-LW(U<
M-9*8(:A*2NJX9DI99U:-)G58GD!17+ @>Z]T:J">"J@AJ:::*HIJB*.>GJ()
M!*CI* R.CJ2K(RD$$$@@W'OW7NLOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJG?YYO8,'6G\I[YJ9Z:4
MQ'+]8X[KZ ("S._:6<Q6VPBJLL3$6RK%O40J!W9)$5D80\J6YN=QMU'E('_)
M 7/_ !WHHWZ80V<Q/FA7\V[1_,]"W_*=V>-C?RSO@G@?MQ2O-\7NG]RST_B$
M!67>^'ILU-K0 6D,N0<O<:M9;5ZK^TW,,GBW]P1G]:3/R#D?Y.G]I71:P@X_
M23_CHZL']D_1AU[W[KW6LW_+AIJ7L?\ GY_SENY#''4U>Q=N]4]+P5[*"\<9
MAQ./F@5FD,@1GV+"&"H4)A6Y2R*PXWIC%L]C'Y,9G(\JAC0_L<_MZ#&VJ'W&
M[?S B6OG0KG_ (Z/V=;,GL#]"?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)7\V_Y>'P[_F,[
M&VAUO\RNH/\ 3'LO8>ZWWOM/#?Z0-T]>_:922CGH&JON-JYO!U<]Z2IFC\<T
M\D/JU>/6%8>Z]T=3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!
M7WCTGUC\D.H>Q>ANZ-L_WSZH[9VIEMD=@;5_C.0V[_$,7G(S%54OWV)JZ')4
MOEC)'DIJR&9?JDBGGW[KW24^+GQ<Z)^%W1.QOC1\:-C?Z->DNM?[S?W*V5_>
M;,;Q^R_OCF,AG\E_N2S^0RN7J?N<OE:^?]^OE\?E\46B%(XT]U[H?_?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3OXD_ /XD_!7_2[_LJW4_\
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!FQ?C'\=NL>U.Q>\>NND.K=C]R=O?\
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M;-;#W+V#42R! [GLW<F:W!&6,?!"09*&-+^H1H@;U ^UO-MQ]3N4[>CZ/]X
M3_GWI/R_"(+*)1YIJ_WLE_\ +U;I[#G1QU[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$!^3_\
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MMOX*NS&*&"R]9AL9597"+.M2*.IJ($>>E$BV604\I:/4!9M-QP??NO=:'/\
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MCN/K^#^\>W'N%=HW3.XG'LLBHS(0&"M:Q]U[K2 ZW[R@_FB?$O\ X3-_RO\
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M,K@,30XV?';4I):&2"CKLB))JV0+4B*G#5/NO=2_YBW_  G7[2^9/\Z;H/\
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MV7MFAW_E-J4_66RMNR[PH#2XW"4C8/;QS=3A<=*\TDF0K,=5Y"8RD+!'%'%
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>=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>timage_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_007.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MZFE5*EJ9Y*<RDTQ8A)&4:K!C:Y3;A9-MT[P.02C%216A(]*TZ>M+D7<2RJ"
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M]U[K%//#30S5-3-%3T]/%)////((D1(@6=W=B%554$DD@ "Y]^Z]UJW?)/\
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M=9ZJ0Q4=-Y%-141!EN86.US[EJ\%"P0%G;\*@ G)X# -!Q/D#TDN;Z*SH)&
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MN&C4Z43+N16@J0!Y5)I@5' GRZ5[OO";1$'859L*M:5-,^N!YGYCUZI/S?\
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M^(X8XPV %)."3@ 9J#/?=X?;?#CA4-)*:+J^$9 SD<:@#('F3BA)#VG\N_\
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MJ.@ZBI]O9C'_ ,/-30O5;?GP&4KL?-))>E6HR^,F"QQ2Z?-'2RD:TBD\:[D
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M5584V8F-/49Z"!O&\M#D8ZI4:&H#)[KW1#JW*9S"?'+M'_A-)MW)?8;WW?\
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7+Y>]O[[^/\
M\8N\N\.M.OXNT]Z=3=<[A[!Q/7LU;/CQE4VK$:RLIEEIH*FH$OV,52\:QT\C
MO(JHJDM[6;?;K=SQQ.VA7=5+\=.HTKDC_#TGNYFMXG=5U%5+!?XJ"M, \?LZ
MI)^ /\R3X,_SI.L=X[4^:'3WQ?P/<&RMT5R8OISM4XO=+3[=,%--29O UVX(
M(:F:2.IDK(:S[,1R4K)&\BI'4QM(*-[V&[Y4E#6[R%& _534O=FJG233A45.
M1^="/:]UM^8(RLJIJ!S&U&P*4(J,C/I@_EUK2?SQN@/A)\3_ )B=#8O^61FE
MQG;+5,VZ=];$ZDWS7=BIMS=,&5QM5M(X=S49*IQ^9K)I*B5,;#6,8!'1-!2T
MZ31"4?\ )]]=;I:RG<,Q4"J[@+J2C!ZG%0*"K'YU/H$>8[6"QN(_I,25)*J2
MU&JI6@S0FN /ECJ[3_A6'+EYOA#\/YMP11P9Z7O:&7-PP\HE9)M')&I5/2GI
M68N!Z%X_ ^GL)^VU/K9:?[Y/_'TZ/^=?]Q4_YJ#_ (X_1[OY@5)7]S_\)]>P
M,-TQN3&[BS4'PS^.N]*B3:>4BS;/A-I':^=S('V;REH:S 8G+H#^F1!)8D!K
M$FQ,MIN\9F6@$SJ0V*,=2BM?X6(/Y=&V[ W%@_A'C&"",U7!-*>H!'Y]4N?R
M-?CC\O/D5\*9J[XV?SA,S\5MO]=;\WI0;R^/V)^.F"[$.WYJV7[Y<I49+(;F
MQ=2]+F:>3[E9&I%A1EFA61F@DTBWFZ^M+*\(N++Q695(D,SIK% . 4C%*?E7
MH.\O6MS<VP,-SH + IX2MI-2>)(.:U_/HTO\H/HOXQ]&?)OYG_.7J/\ F=X[
MY\;[Q/2O>F<[^V'M[XZUO3=16566SM+N2OS?\1K,_7XZH2KRN"J5I7I*$TE2
M*@STE0:4?N%O-&X3W5O!:26AMU#)X;-)K[0FD+\ . PK4U%*$5Z6[#9QPS2W
M"7 F)#:P%T]Q:M?B(X@TQ0UJ#3I"_ [M_P#F9?SULAWYV16_S!Y_@_T-UYNJ
M@VF.F_CIMBFCW#'2[AIJBK0KF_/C<S0QK3K%&F5FR=2U14158@HZ-(;%[>K2
MPY0\.(6_U$K+K\25CHJ#3X1@Y![?($5+=-[9<77,6MS-X,8.G1&!KI2OQ'(X
MC(XYH!T5?^2!MG:&ROY_7R.V;L/MG<W>VU=I;%^0^V<7W#O+,'<.3W$<#E,'
M2U&3J\AH1:YYZJ*;34)JCF0+)%)+&RR.8<UR-+LD#NBQEGC;0@TJH*R$4%33
M!!ITCV%%CW2559G 1AJ8U8D,@-305S4=+'9V[]M_&O\ X5:[_P Y\@9Z3;N+
MWYO;=^-V/O3>$,&)I*23MW8J0;;J8*JJ(C2*J$ZX6.>*0$R5#P.5!GC5J2)K
M[EM!#G1EU6I)"R,2"!Z5#T/D*^G3B2+;;TQD%-8HA.!4HH!!/K0KCS-/7HX7
M_"MKMWK$_%GXX])Q[AP5;VSD_D#1=GTF I<I'4UU-M[;^V=PXZJJYJ:,L\-+
M65V:Q@BDDTB4Q.(M820H@]M;=S=2RT.D1%2:8U%T('VT4]*N=I5%NB5&HR!J
M>= K G^8Z/7C/B5'\V_^$\'2OQ]I:2&IW?N#X+]*[DZQ>4F/1NG8N!QV8P"^
M14DDBCK,A1Q4D[)&S?;5$ZA6U:22ON7[IWJ2?-%N9-5,DHSLK<?D33Y]&:V7
M[PVQ(O-H$TUP-04$</F!UIRUWS_W_P!Q_P J3X\_RHMJTVX<KVV/EME,0F&6
M(?[D-KU,T%=M7"35=?XHH9ZK>^XJQ(88Y?\ )XL/ )Y*:"2..:4%V1+3<I=S
M;2(O!U5]'I1B M:]BU)/$O@$@D 5MS>XLH[%:^)XNFA\UK502W#N( 'D%R0,
M=?0*7X:;IZP_EC5GP=^-^[J78O8F!^+.5Z;ZZ[%ES5;M!*;<]?AI8&W%/D<-
M2RY"AEJ<Y//7S5%)1M.DDKR11%[+[A@;DL]^+N==2F82.H -5U5*@,:$4P 3
M]O4E&R,5J;>(T(C**U:4;30&H'&N:@?9UKP] _R4_P">9UUWOTIV#V5_,9V[
MNWKG8G;?6^\M_P"U(/EUW!N!\GA-L9FBKLKCTH*[:D-%7-6T,$\(IZB9()B_
MCE=8V9@.+[FG9YX)$CM2KLCJC>! -+%2 :AZBAS49'06M=BW**5&>>JAE+#Q
M935002*%:&H\CT"O8/\ *Y^!/\QKYB=W=@?RIOYB<O6WR)PN>S?;O8'6&6V3
MN;&T5%E-V5<GWM?M3<+Q8#*T5)%E'G:LCI(<PE%)71PQR4<*P4A>@YCO-EM(
MX]PM1)$RA(V)6I5> 9:.#BFFH6H%>XU/5)=EM]RN7>SG*2 EG !-&;^$U4C-
M:T+4K3'#J+\0?F-_-2_EQ?S0>AOY</RS[S'RLVEV7NOKW96?PL6YZONVHQE'
MVS4O#09G'[CRM+0;HHCA&D6KJZ>O+00XB.4BD5!32Q7W/;-MWW;Y;^UC\!DJ
M<@1AB@%1I!9<@T730EJ5/'JMC?7NU7<=I<-XH>G"KD!B<U(!P14UK1>'0D?\
M*C<A08GYC?RQ\KE:VDQF,QE1N3(9'(Y"I2C@IX*/=.V))IYYI&6.*&*-69W9
M@JJ"S$ $^TW(*E[2]5022@  R22DN!T_S6P2XM230!R23@ !H^K;?Y['\T[L
M/^7O\:=@Y[XVQ;.SW9W<^^\KL3#[YRC0;IH-NPX#'Q9&MJUH%=H*W*21U5&M
M-'47IT61IYHIE"0RASE#8(]]N&28L$1-9 P6R !7R'K^SY@XYBW9]J@#Q@%F
M;2"> P36GGP_R_+JG3^8;\.OD]1?RP]V?+OYT_S;>U.W\KN+KS8NX^O^C.O#
M3[*V'F,QV3)BY*/$M3XZ2.FW7$@J99HZB/ T8CIXGJ M/3),X$FR;I;MN"6]
ME9QH-9#/)5Y0J5)8%CV&GE4YQ4XZ)]TL)5LVFN;EV(7"I14):@ (4=PKYT&/
M(9ZLV_D _P#;CFE_\NG_ /=AE_9%SM_R5G_YM?\ '$Z-.5_^2>G_ #<_X^W1
M'/\ A(ING;&/Z>^8^!K]QX&BSD_:W4<\.&J\O3TU6Z97&Y*FI76G>19F2IJ(
MI8HB$M)(C(EV4@'/N9&WU$+4-/#(K3%0U3^RHK]HZ+>2''@2"HKXE:5S0J*?
MMH?V=53?R;.@_E!G_G#\N/C9LK^8)F?@G\C,3+G<=NJ<=14':-;O:LV#GJZG
MS-(D.6R^&\%1CZB1JS3&\LT\4LLF@1P.X$'-%[:K9V\[VWCQ$#3^HR"/4JD#
MM!K4"F>%.BC8[:X-S/$L_A.#W=BL9*,U31B*<:X]>K-,Y\#M@;D_FO\ QWI_
MDG_/*HN[/G-T'OKHW)8#K+(_$"7 Y*KI-FYI]W8W;/\ &,3NV7!TM55":NDD
MCE\]73052S5-,U,\"N1+O31;;*+>P,=O*) 7\8LH8J$+49*X-*< 2* U!Z-#
MM@EO4,MV'FC*$+X84E02VGM:F16O$@&I%*=;I'N+^ASUKI?\*C/^W6F5_P#$
M^]0?[WDO8TY _P"2DG^DD_XZ>@WS9_N"_P!J?\>'1B/Y*?RAZ"W)_*:^/6YJ
M/L?:&&PWQ]ZHAV+W7+F<S2X<;:R.PQ(M>V8$DBBBBJ(?'6P22E1/35$4P)+D
M!#S3830[C*K*:R2%DP3J5S44]?3[01Y=*MBNHY;.,JPHB!6_HE0 :^GK]E#Y
M]4%?\)G8JWL_^:'_ #"OD!L(U*=)UVQ>QHDBD67%_O\ </8=!FMJF2A"^%)%
MQ."S@ 9@\%VCC!5Y"HSYZ M=NM()!^H-/H:".+2XK]K+PP:?(=!KE4FXO;B9
M#V'5ZBNM]2FGV \<BOV]"-_PF$IJ9_F]_- K&IX&JX*S%TT%4T2F1(ZO=VY&
MEC1[:E25H82Z@V8QH2"56R7GL_XG8_Z0_P#'(NE/*W^Y-W_IQ_Q^3I&?SB?^
MXDK^6=_X<_P$_P#?MY/VKY5_Y(5W]EQ_U87I)O\ _P E6W_YL_\ 5UNCU?S3
M?YDWS,J_YDW2O\JWX=]E;'^,-9V&NPH-X?(3=F'H]R5K5/8$<M8E-CXJ^GJZ
M6DB@H85C@1(!65^1FCIHZJBCM(Y'R_L=K]!)N-TK2A"0L2DJ#2@J2*'BWV
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M_+DWONA((<+W'_+E[@Z:Z\K6B\A.X>O:WL;<F1C=W58Z=3A\E"D;K(SR23>
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M 'OW7N@X[CZLVGWEU'VCTKOR@@RFR.W>O-Y]9[OQM3"*B.?&;ZQU3C*Z)D)
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M*J:FB_334\"V4((.?[^S4Q'1)0D!W#%P/M#"M/F"?4GI7/RE:7+"3N2M*JA
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M$_N!=T;PHX(V?+.B'436M>YB"<GB#Q/1.O*5N2OB/*ZK@*S]H%*4P 1Y<".
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MO_/U[^]/_"J7_GV_P?\ _.[&?_7_ -^T<O\ \5W_ ,8_Z!Z]JW?TMO\ C?\
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M ,^W^#__ )W8S_Z_^_:.7_XKO_C'_0/7M6[^EM_QO_/U[^]/_"J7_GV_P?\
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M_P!?_?M'+_\ %=_\8_Z!Z]JW?TMO^-_Y^O?WI_X52_\ /M_@_P#^=V,_^O\
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M /SNQG_U_P#?M'+_ /%=_P#&/^@>O:MW]+;_ (W_ )^O?WI_X52_\^W^#_\
MYW8S_P"O_OVCE_\ BN_^,?\ 0/7M6[^EM_QO_/U[^]/_  JE_P"?;_!__P [
ML9_]?_?M'+_\5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_S[?X/_ /G=C/\ Z_\
MOVCE_P#BN_\ C'_0/7M6[^EM_P ;_P _7O[T_P#"J7_GV_P?_P#.[&?_ %_]
M^T<O_P 5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_P ^W^#_ /YW8S_Z_P#OVCE_
M^*[_ .,?] ]>U;OZ6W_&_P#/U[^]/_"J7_GV_P '_P#SNQG_ -?_ '[1R_\
MQ7?_ !C_ *!Z]JW?TMO^-_Y^O?WI_P"%4O\ S[?X/_\ G=C/_K_[]HY?_BN_
M^,?] ]>U;OZ6W_&_\_7O[T_\*I?^?;_!_P#\[L9_]?\ W[1R_P#Q7?\ QC_H
M'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\ K_[]HY?_ (KO_C'_ $#U
M[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W[1R__%=_\8_Z!Z]JW?TM
MO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\ XKO_ (Q_T#U[5N_I;?\
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M ._:.7_XKO\ XQ_T#U[5N_I;?\;_ ,_7O[T_\*I?^?;_  ?_ /.[&?\ U_\
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M]?\ W[1R_P#Q7?\ QC_H'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\
MK_[]HY?_ (KO_C'_ $#U[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W
M[1R__%=_\8_Z!Z]JW?TMO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\
MXKO_ (Q_T#U[5N_I;?\ &_\ /U[^]/\ PJE_Y]O\'_\ SNQG_P!?_?M'+_\
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M /SNQG_U_P#?M'+_ /%=_P#&/^@>O:MW]+;_ (W_ )^O?WI_X52_\^W^#_\
MYW8S_P"O_OVCE_\ BN_^,?\ 0/7M6[^EM_QO_/U[^]/_  JE_P"?;_!__P [
ML9_]?_?M'+_\5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_S[?X/_ /G=C/\ Z_\
MOVCE_P#BN_\ C'_0/7M6[^EM_P ;_P _7O[T_P#"J7_GV_P?_P#.[&?_ %_]
M^T<O_P 5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_P ^W^#_ /YW8S_Z_P#OVCE_
M^*[_ .,?] ]>U;OZ6W_&_P#/U[^]/_"J7_GV_P '_P#SNQG_ -?_ '[1R_\
MQ7?_ !C_ *!Z]JW?TMO^-_Y^O?WI_P"%4O\ S[?X/_\ G=C/_K_[]HY?_BN_
M^,?] ]>U;OZ6W_&_\_7O[T_\*I?^?;_!_P#\[L9_]?\ W[1R_P#Q7?\ QC_H
M'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\ K_[]HY?_ (KO_C'_ $#U
M[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W[1R__%=_\8_Z!Z]JW?TM
MO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\ XKO_ (Q_T#U[5N_I;?\
M&_\ /U[^]/\ PJE_Y]O\'_\ SNQG_P!?_?M'+_\ %=_\8_Z!Z]JW?TMO^-_Y
M^O?WI_X52_\ /M_@_P#^=V,_^O\ []HY?_BN_P#C'_0/7M6[^EM_QO\ S];0
M'L#]";KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBG4?S=
M^->3^8E7\#<1V'29GY.8OJ"N[QSVP\11RY%<9@*&OHL<TF2KHE:DH:Z2?(T3
M1T<LJU+P2K.L9B.KW[KW2F^4WRR^/WPLZ@S7>GR5[&Q?6O7.&JJ+%KD:REJ<
MM5U^1RI9:+$XC%T$-3DLOEJYU98*2DI9IY-+,$T([+[KW19?B_\ S8OAE\L^
MW9^@>O\ ='9.R.[?[L2;TPW5O?G2.[>@,QF,33$K45^#IMV8C%?QB&D(O.*5
MY)(D(D9!&"X]U[H9OF#\[OC'\%=J[3W/\B]^U6WJGL/<D.SNM-C;4VIE>QMT
M;FRDI351;?VU@:/(9G*2P)(CSM#2-' K*9736@;W7ND;\0?YDWQ,^;^X>P-B
M]([QW71]H=61XZLW[U!VUUEN'I3=F.HLN%^TR3[?W1C<7D9L94,VA:J&&2%9
M/VY&1V56]U[H^/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[H(^^.]NJ/C-U#O[O;N_>6)V#U=UIMW(;GW=N?,SB&.&GH
M$+:(D_74550^F*G@C5I9YG2*)6=U!]U[K/T7W1L'Y&],]6=^=5Y&LR_6G<NP
MMK]E;"RN0QDV%GJ<1O*CBK\?/+25*1U%-)+33QL8I461"=+J&! ]U[JNWO;^
M=G\ /C_V?V3U'N+>_:F_]U=+>&/NJLZ+^/F]N\\1L^>59'>CW)F]KX/)8K&5
MU/%%(\]/)5>:G52)D1P4'NO=6.]0=Q]7=^]8;,[HZ:WSM_L7JSL+ TNY=F[W
MVU6"KHJZBJP2LL;D*\;(0R21R(DL,BO%*B2(RCW7NJL=V?S]/Y9VT-S[JQ%5
MVMV3G=E[%WK_ */=[=\[+^/.^MZ];8K*0S14]3#5[\Q> JMMB&AGF1*FHCKY
M*>(W)E*J6'NO=7!8#/X/=6#PVY]LY?&[@VYN+%T&;P.=P];'D:2LH\I$L]-5
M4M1$SQ3T\\+H\<B,5=6#*2#[]U[IV]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%]
M^4_7'=';O0^^NM_CYWM4?&?M;=AVMC\'WC1;+H^P:K T4>:QTV=EH<5D'CHI
MLE6;?BRE'1RRMII:JHAJ[,8 I]U[K5O^#?PEZK^!'_"E9>E>KL_V-OB7,_R?
M\[V7V9VGW!O*HW]NK=^[-V]I4L>7W+N#*5&GSY&O6BI581111(D4:JEPSM[K
MW5@/S?VB._?Y\G\I?J#=\57ENL>@NB?EE\OWVG/61S8NMW)1#%[9P60R&.G7
MQ5%1@*N>"HH9E#ST\TKF+Q1/4F3W7NI7_"@S!5&RNI_@]\PMDQRXKN#XF?S$
M?B[GML[LQH@IZHX/M',':FX\!4U$B/*<-GH<I21U<* ^4QQ!U,7D!]U[J+LS
M:([N_P"%*'>N]=ZQ5>9P_P */Y<W3VU.H\1D*R.OQ^+S/R'W%D<EDL]1T<JZ
MJ/,56.HZN@>I@75)2J(ZB4JM-''[KW4K^9M@JCJ7^:Y_)*^4&PHY<+NS??=?
M='PU[6KL<(*5,_M7M?;#Y2AQN7;0T]7%A\CB:FNH4_1'.7<E9!$R^Z]UL#^_
M=>Z][]U[JN#L_P#F[_RV^F.P=W]5=H_+3KG9G8>PLY6;;W?M7+4F7^YH:['G
M3-3S>+&R1%T-N4D92+$$@W]G%OR_>W2"2.&1E85#!:@CHOEW6V@8H\J*PX@L
M 1T8OXT_,+XT?,3;VX]U_&;MW;7;VWMHYF#;VY,KMJ*KBCI*VJ@6ICIY/NZ:
MF8NT#*_I4BQ^M^/:.]V^?;F"SHR$BH#"A(X5_ETHM[N*[!:)E8 T)4U%>/\
MEZ,I[1]*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUDOYZ7\M[*=^]"?S
M ?EE\DODIV=V1U)T3\5^W=]_$/X>8!8]A;+VIG]M=?*LNZMRM0O][O?<:;BI
MLE78V2L>.#&0U"TR13)Y+^Z]T?/^7%O.OZX_D7_$#L/%1+-E-A_RU.L-YXV%
MG$8>HVOU]3UT*EBD@4-) HN8V ^ND_0^Z]T''_"=CIG%=8_R@_BEEJR*IR^]
M._ML[F^0W;.[=PS19?)[AS7=&7R&7DR&7K;R2Y"<XZHH:<25$DDY@AC6=C*'
M]^Z]U3[AM[;U^'7\OO\ X4_=!=;9+-;:V=\:^_>]JOX_T>,R@PLNTL5\MMOT
M>2:@P,M$BOC:+#RYB6KH%BD62.25G#15#/+[]U[K9+^#GQ0ZLZG_ )<'QP^)
ME5LO#U_7=+\7MA;#WUMC*8^DGAR\NY=OTXW'-DHZ=?M:FHS%=55TU4Z@K)+,
M[@D$'W[KW1%_^$X^7WE3_P M/$]/;TS.7W!/\6OD7\F_B]MS*Y^ICJZUL+U!
MN[(4N*IZAX56.^/I9DI(U0LB001)&1&J*ONO=7P>_=>Z+K\D_EI\<_A_M'";
M]^2W:VWNHMG[DW'%M'!Y[<D57+#49*:EJ:U*1/M*:I<2M2T=3(-2!=,;<WL"
MLLMOFW%BD",[ 5(45(%0*_S'2>XNH[0:I65030%C05XT_ET5K8?\XS^67V=O
MG9G6NPOE_P!:;FWUV'NO;NQME[;H*;+K/D,MNRLAH,=0PF7&1QB6KK*B&)-;
MJNIQJ8"Y]KI>7+Z!2[P2!5!9B5P !4D_8.DJ;Q:RL%66,DD  ,*DG '5E_LE
MZ,NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NM;'_ +NQO_,*/_S5O?NO=*O^:#NVF^&O\TS^5]_,4[*J
MO[O?%>FVSWY\,?D;V?5+6G';.?N:GIJ[966S4M-!)3T.&K=R4ZTM36UDJ4E*
M DDK(0CCW7ND-_.1[WZN^;.[/@+_ "W?B]V+LGN_MSNKYF]%=Y]IT?5VZ(]\
MP;3ZLZ"R$N;W#NG.5F$:OI,7$]7%CX*%:UXUK)?*L :2)2/=>Z4_:/8^WO@5
M_/\ 3W-W]N#&=<?&S^8I\+]F=)[,[AW76SXC 4G:?0^=EJ*+:^5R<L:8;%39
M;;554S4+UE7&:BH_R>G;6[HWNO=-7RN[=V/\^/YQG\L#X\_&;=^W.W]N_!W<
MG:WS*^6N_>OLR=U87:JUNW_X-L/"U>6QHJL/_&L[D9ZQC0O4BJCI=$X58I')
M]U[K9*]^Z]U[W[KW1"^P_P"5W_+S[9WON?LKLOX?]';VW[O7+U6?W7NS<.SH
MLA6U];6F\M34S.=4DKFUR?\  #@>S6#?+RV01QSRJHP%5V  ^0!Z0R[9;3L7
M>*-F/$E%)/YD=4M_\)=MOX7 =:?S :7#8VEQM/0_,C+[?I(:5/&L=%@<>%HZ
M91^(J99I0@_ 8^Q-SW(TDEL6))-K&23YDEJG\^B7E=!&LX44 N'  \@ M.MI
MCV!.A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5;'\Y'_ +=.?S(?_%*/
MDC_[RF3]^Z]T@?Y8FR(^S?Y)?PGZWFJ?LXNP?Y=73^R):NY'B7=>PZ2@:2X#
M$:!4%N%)X^A]^Z]T2'^1_P#.7H7H[^71M[XL_+;N3K'X\?)#^7<=^=#_ "4Z
MW[<WM#L&MQ$'7^5RD^%S4$6?>AJ:_!9;;'V%32UM+%)22D2PT[?M:![KW11_
MC3\;^T/Y@_\ +5_GN=\;2VSF,4O\TKN3OS?GQ!P^X*+(8"JSNTNML1!C>OLI
M+2U]*E52+NBIQEHP8V0Q,CQVA9/?NO=64?#G^<A\)*'^5_UI\B.Z>_NO.N=S
M]$=%[=V?\C>J=U;F3#;PP6^>J<32XK<6UI-L9)X=R3YF7-TTD-! :!IZ\3TT
MD(E$ZL?=>Z4G_"?;IGM7J/\ EH=;YWN[;%=L?M'Y$=D]U?*;=&R<I'505.)7
MO?<==F,;25,5;%#5PU!Q#X^:2.9/+&\K)(=8;W[KW5U_OW7N@*[]^,?Q^^4V
MV,1LOY%=1[)[CVG@,]'NC#;?WUB$S5+39&*GJ*1:R*)SI6H6FJJF,-]0DCC^
MT?:JTOIK!B\#LC$4)0E214&F/+ Z8N+:.Z&F55< UHP!%>%<_;UJ=_S5OB'\
M8_BA_-!_D:4OQNZ0Z]Z7IM\?+K951NZ'8."CPBY%]O\ 8?6JT3503_.-3+65
M0CO^D2O_ %]R/RUN-QN&W[AX\CR:8#IUL6I6.:M*^M!T#-[LXK2[L_"14K**
MZ5 K1XZ5I]O6YS[B[H==>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!K_ *&>G_\ 2S_I[_T4=:_Z=/[D
M_P"C3_31_<7%_P![/[N?=_?_ -W_ .\?VO\ &/X)]]_E'V/WGVOG_>\7D]7O
MW7NE1NW:&TM_[:S>R]][7V[O79VY:";%;CVGNW"4VY,9D*6I%I*:MH*R*:EJ
MJ>0?JCEB9&_(/OW7N@/Z ^&_Q+^*0SH^,WQIZ+Z"?<YC.Y*CJ'JW"]?S5XAT
M:$K)\91TTU3'&44JDCLBL-2J&))]U[H2^V.GNIN^-CYCK+NWK/87;O76?1$S
M6QNRMI4&]L35>*^AIJ#(P5%,\D9),;F/7&WJ1E8 ^_=>Z3/17QI^/'Q?VO5;
M)^.'1O4O1&T:^N;)Y#;O4G7^+Z_I*FI<L?N*F'%TM,M3.-; 22AF53I!"@#W
M[KW0V^_=>Z][]U[KWOW7NM7_ /X3&_\ ,N_YAG_B\&[O_<&'V..=_CM?^>2/
M_"W09Y:X7'_/3)_S[UM >P/T)NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ36\MF;/[%VGN38/8.U-M;[V+O+"9+;6[]E[RP5+N?$Y7&YF)H*S'Y+'5T4]
M'7457 [QS03PO%+&S(ZLI(]^Z]U[9NS-G]=;3VWL'K[:FVMB;%V;A,;MK:&R
M]FX*EVQB<5C<-$L%'C\;CJ&*"CH:*D@1(X8((4BBC54154 >_=>Z+WW/\%_A
M;\C-ZX+LCO[XF_'/NCL';24L.#WKVATUM_?&4IXZ&1)8(5KLC05%0T$,D:M'
M&TC1H;Z5&IK^Z]T9Z@H*'%4-%B\714F-QF-I*:@QV.H*9*."G@HT6.&&&&-5
MCBABC551%4*J@*H  'OW7NBK;K^!'P?WWW#3_(/>OQ!^-&[>\J6KILA%VWN/
MI+;F9W#]S1!Q!5/E:C'25DE7"'/CG>5I4LNAQH33[KW1M/?NO=>]^Z]U[W[K
MW6JG_/9_[>D_R"O_ !;3!_\ OQ.K/<B<G?\ )/W'_FA_UCFZ!W,G^Y=E_P U
M?^?XNMJSW'?0QZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NM7__ (3&_P#,N_YAG_B\&[O_ '!A]CCG?X[7_GDC_P +=!GE
MKA<?\],G_/O6T![ _0FZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4_Y[/\ V])_D%?^+:8/
M_P!^)U9[D3D[_DG[C_S0_P"L<W0.YD_W+LO^:O\ S_%UM6>X[Z&/7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ_P#_  F-
M_P"9=_S#/_%X-W?^X,/L<<[_ !VO_/)'_A;H,\M<+C_GID_Y]ZV@/8'Z$W7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW6JG_/9_P"WI/\ (*_\6TP?_OQ.K/<B<G?\D_<?^:'_
M %CFZ!W,G^Y=E_S5_P"?XNMJSW'?0QZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;VJF#,
M+_1B/I_3_8>U(A!'2)IR#2O\NN/W;?U_WC_C7O?@CK7U!]?Y?['7ONV_K_O'
M_&O?O!'7OJ#Z_P O]CKWW;?U_P!X_P"->_>".O?4'U_E_L=>^[;^O^\?\:]^
M\$=>^H/K_+_8Z]]VW]?]X_XU[]X(Z]]0?7^7^QU[[MOZ_P"\?\:]^\$=>^H/
MK_+_ &.O?=M_7_>/^->_>".O?4'U_E_L=>^[;^O^\?\ &O?O!'7OJ#Z_R_V.
MO?=M_7_>/^->_>".O?4'U_E_L=>^[;^O^\?\:]^\$=>^H/K_ "_V.O?=M_7_
M 'C_ (U[]X(Z]]0?7^7^QU[[MOZ_[Q_QKW[P1U[Z@^O\O]CKWW;?U_WC_C7O
MW@CKWU!]?Y?['7ONV_K_ +Q_QKW[P1U[Z@^O\O\ 8Z]]VW]?]X_XU[]X(Z]]
M0?7^7^QU[[MOZ_[Q_P :]^\$=>^H/K_+_8Z]]VW]?]X_XU[]X(Z]]0?7^7^Q
MU[[MOZ_[Q_QKW[P1U[Z@^O\ +_8Z]]VW]?\ >/\ C7OW@CKWU!]?Y?['7ONV
M_K_O'_&O?O!'7OJ#Z_R_V.I%/,92P)O8 _3_ (U[;D0)T]#(7KU*]L]*.O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NM7_P#X3&_\R[_F&?\ B\&[O_<&'V..=_CM?^>2
M/_"W09Y:X7'_ #TR?\^];0'L#]";KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K53_ )[/_;TG
M^05_XMI@_P#WXG5GN1.3O^2?N/\ S0_ZQS= [F3_ '+LO^:O_/\ %UM6>X[Z
M&/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW2'J*H+43@GD32@\?T8_X>S1$&D?8.B&26C'
M[3_AZP_=K_7_ 'C_ (U[MH'5/&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_
M:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]
MH'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[
M]H'7O&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:
M!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_
M:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]
MH'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:!U[QNGO"3"66>QOIC7\?
MU/\ K#VEN@ !TNL7UD_9TH_:/HSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU?_ /A,
M;_S+O^89_P"+P;N_]P8?8XYW^.U_YY(_\+=!GEKA<?\ /3)_S[UM >P/T)NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NM5/\ GL_]O2?Y!7_BVF#_ /?B=6>Y$Y._Y)^X_P#-
M#_K'-T#N9/\ <NR_YJ_\_P 76U9[COH8]>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= K7U
M[K7UJ@FRU=2OU_H[?X>Q'%$2H^P>0].@/<7)61A_2;_"?EU$_B#_ -3_ +?_
M (U[<\(_Z@.F?JCZ?ZOV=>_B#_U/^W_XU[]X1_U =>^J/I_J_9U[^(/_ %/^
MW_XU[]X1_P!0'7OJCZ?ZOV=>_B#_ -3_ +?_ (U[]X1_U =>^J/I_J_9U[^(
M/_4_[?\ XU[]X1_U =>^J/I_J_9U[^(/_4_[?_C7OWA'_4!U[ZH^G^K]G7OX
M@_\ 4_[?_C7OWA'_ % =>^J/I_J_9U[^(/\ U/\ M_\ C7OWA'_4!U[ZH^G^
MK]G7OX@_]3_M_P#C7OWA'_4!U[ZH^G^K]G7OX@_]3_M_^->_>$?]0'7OJCZ?
MZOV=>_B#_P!3_M_^->_>$?\ 4!U[ZH^G^K]G7OX@_P#4_P"W_P"->_>$?]0'
M7OJCZ?ZOV=>_B#_U/^W_ .->_>$?]0'7OJCZ?ZOV=>_B#_U/^W_XU[]X1_U
M=>^J/I_J_9U[^(/_ %/^W_XU[]X1_P!0'7OJCZ?ZOV=>_B#_ -3_ +?_ (U[
M]X1_U =>^J/I_J_9U[^(/_4_[?\ XU[]X1_U =>^J/I_J_9U[^(/_4_[?_C7
MOWA'_4!U[ZH^G^K]G7OX@_\ 4_[?_C7OWA'_ % =>^J/I_J_9U[^(/\ U/\
MM_\ C7OWA'_4!U[ZH^G^K]G2TV94M/4UH))TP1D?[%O]8>R[<4*J*^O1WLDQ
MD=A\A_AZ$'V4]"/KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5__ .$QO_,N_P"89_XO
M!N[_ -P8?8XYW^.U_P">2/\ PMT&>6N%Q_STR?\ /O6T![ _0FZ][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZU4_Y[/_;TG^05_P"+:8/_ -^)U9[D3D[_ ))^X_\ -#_K'-T#
MN9/]R[+_ )J_\_Q=;5GN.^ACU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T6W*URKE,D/Z9
M"L'^VD;_  ]C.WB_37_2C_ .HJO+H+,X]';_ (\?ETW_ 'Z_[[_D7MWPOETF
M^K'^K_BNO??K_OO^1>_>%\NO?5C_ %?\5U[[]?\ ??\ (O?O"^77OJQ_J_XK
MKWWZ_P"^_P"1>_>%\NO?5C_5_P 5U[[]?]]_R+W[POEU[ZL?ZO\ BNO??K_O
MO^1>_>%\NO?5C_5_Q77OOU_WW_(O?O"^77OJQ_J_XKKWWZ_[[_D7OWA?+KWU
M8_U?\5U[[]?]]_R+W[POEU[ZL?ZO^*Z]]^O^^_Y%[]X7RZ]]6/\ 5_Q77OOU
M_P!]_P B]^\+Y=>^K'^K_BNO??K_ +[_ )%[]X7RZ]]6/]7_ !77OOU_WW_(
MO?O"^77OJQ_J_P"*Z]]^O^^_Y%[]X7RZ]]6/]7_%=>^_7_??\B]^\+Y=>^K'
M^K_BNO??K_OO^1>_>%\NO?5C_5_Q77OOU_WW_(O?O"^77OJQ_J_XKKWWZ_[[
M_D7OWA?+KWU8_P!7_%=>^_7_ 'W_ "+W[POEU[ZL?ZO^*Z]]^O\ OO\ D7OW
MA?+KWU8_U?\ %="/UQ4">MR0']FEB/\ MW_UA[)]X32J_:?\'0IY6F\623_2
MC_#T+?L/]#7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5__ .$QO_,N_P"89_XO!N[_
M -P8?8XYW^.U_P">2/\ PMT&>6N%Q_STR?\ /O6T![ _0FZ][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>ZU4_Y[/_;TG^05_P"+:8/_ -^)U9[D3D[_ ))^X_\ -#_K'-T#N9/]
MR[+_ )J_\_Q=;5GN.^ACU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3W.54JYK, '@93(
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MV=NK;>).4SW8D5,-KX>KU%4>5(VF,XC*/+X'ECCTH5+NRV8+S[T%J>MEJ#I
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1-,[_Q>\S_ -K7(?\
M6Y_<D6G]DG^D7_ .H+W'_<B7_FH__'CTU>U'2/KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z@5&5Q=)J%7DJ"E*?K%161PVYMSJ86YX_U^/=
M&E5.) ^TCIY+>27X58_8I/\ @'3)4;YV;3%EEW/@]2_J6/(Q3D<VM:-F-P?J
M/J/;#7T*\77]H/\ @Z5IM%U)PBD_-"/\('3'/VSL" LISZR,H_3!CZJ8'_69
M8"G_ "=[8;=K=?Q_L#'_ "=+$Y:O7_T.GVL@_P +5ZB_Z7-K3?\ %NIMP9=O
MPF-PTDI/^MK,8^MA]?K[I^]HC\(=O]*I_P M.G/ZLW"_VAC3_3R ?X*]=?Z2
MYY>:/8._9U;A'DPGA75_0L'=0/\ &_\ L/?OWD3PBE/^UI_EZ]^X OQ7-L/L
MDJ?\ Z]_?/?$]C1]95Y5^(WK<[!1$%OIJ1XK@<B]V'Y%Q:_OWUD[?#"?S8#_
M "=>_=5FGQW:_P"UC9OY@]>_C':]3Q#L_ XSZB^1S0K!_K_Y/(#;\_ZP_P!;
MW[QKIN$:K]K5_P '7OI=MCXSR/\ Z2/3_P >'7M'<51^J;8F/7]),25DK?UN
M PD4_P!.2/\ 6]^I>-YQ#_>C_GZ]7:T\KAOM\,#^5.O?W?[0FMY=_P"/I?P5
MI=MP3?7Z\R*#<?CZ>_?3W3?Z*!]B _X>O?6[>O"V9O\ 32L/\'7?]RMYR?\
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MZ]UJI_SV?^WI/\@K_P 6TP?_ +\3JSW(G)W_ "3]Q_YH?]8YN@=S)_N79?\
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MZ-MXC.XG+461^.^_-L]J/+5P4;['Q52N%9W=C#*4:6>(1JE@_AB9)+,ZR("
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M_P!7_%=>^_7_ 'W_ "+W[POEU[ZL?ZO^*Z]]^O\ OO\ D7OWA?+KWU8_U?\
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M"8N;9K3>&WBW&AVN9)]&JHTRNS-&305!#%2:"HS0'I+_ !KZ _V7G:>=VO\
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M1]K\2.(:K*0:4+ZOPG[1HL9)LS#?*+>=#UQ)K@7;C8ZI8I2R?JI0(\M' 8V
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J?\]G_MZ3_(*_\
M%M,'_P"_$ZL]R)R=_P D_<?^:'_6.;H'<R?[EV7_ #5_Y_BZVK/<=]#'KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7N@[[7V-_I(Z_W'L]:B.DJ<G2PR8^JE!*)4
MT$J5$!?2"PC:2)5<@$A&8@$V'O8-#UHBHZJ-R73O:6*RLF&JM@[KDK4F\*&B
MPE1D(9.;!HJB!)(94/\ JED('-R+&SVH=,Z3U9+\9NI\MU?LVN;<:+!N'<U;
M#7UU DHF%-%2(4IX'9&:-I1KE=RI(&L)<Z;^VF->G$%.C(^Z]7Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[IKS>7H]OX;+9W(NR4&%QE=EJUU&HB+'1--(0/R="&P_)]^&>O''546[/
ME/VWN#,S5V)SQVOBUG9L?A\52P,L: G1YI98I)*B0K;66;06N5C0'3[>"#ID
ML3T9+J/Y;X2JV[70=L9%,?G<4T(I<E1XR67^(QSZO]T4L3)%41%;.0J1,&4@
M*0P]U9/3JP?UZ$K_ $];GW'Z.M>F-\[C23TP9;<*Q[1H6O\ 1DGF\D<B_0V,
MD9M]=/O6FG$];U5X#KLT?RCW*+5&6ZVZYI)+ G&4DVXJZ,-^")_/1NP^EPZ_
MX?U]^P.O9/7A\<US89^Q.T.Q-[R2+:6B_BW\"H&O];441FT"_P! LP']0>+>
MU4X=>T>IZ7F Z,ZCVTB+C-@[>DDCL5J<K1_QZ4'_ %0EK34.K?\ !2+?06''
MNNH];T@="E3TU/21)3TE/!2P1@!(:>)844#BP50 /]M[UU;K-[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[H$?D#UI7=I]=U."Q$B+F\;D:7/X:&:00I
M-/11S1&!W:RIY8:B8*20HDT%B%N1930]585'56:]0=I/E!AEZ^W=_$#,(-#8
M*H6,$FVHSE!3B+F_D,OCMSJMS[=U#IK2>K5NA^MZCJWKO'[>R+POFJJKJLUG
M#3,'C6IKPB^-6 ]?A@BAC+7(9D)4Z2/;3&IZ=44'0R>Z]6Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NB\Y2CU9/(MI_5759^O]9&_P ?8O@>B+_I1_@ZC.[MZRN?
MZ;?X3\^H/V/^T_\ )W_&_;OB=)_IO]7^H]>^Q_VG_D[_ (W[]XG7OIO]7^H]
M>^Q_VG_D[_C?OWB=>^F_U?ZCU[['_:?^3O\ C?OWB=>^F_U?ZCU[['_:?^3O
M^-^_>)U[Z;_5_J/7OL?]I_Y._P"-^_>)U[Z;_5_J/7OL?]I_Y._XW[]XG7OI
MO]7^H]>^Q_VG_D[_ (W[]XG7OIO]7^H]>^Q_VG_D[_C?OWB=>^F_U?ZCU[['
M_:?^3O\ C?OWB=>^F_U?ZCU[['_:?^3O^-^_>)U[Z;_5_J/7OL?]I_Y._P"-
M^_>)U[Z;_5_J/7OL?]I_Y._XW[]XG7OIO]7^H]>^Q_VG_D[_ (W[]XG7OIO]
M7^H]>^Q_VG_D[_C?OWB=>^F_U?ZCU[['_:?^3O\ C?OWB=>^F_U?ZCU[['_:
M?^3O^-^_>)U[Z;_5_J/7OL?]I_Y._P"-^_>)U[Z;_5_J/7OL?]I_Y._XW[]X
MG7OIO]7^H]>^Q_VG_D[_ (W[]XG7OIO]7^H]"#U]3^&LR!M8&FB'UO\ VO\
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MO=>]^Z]U[W[KW7O?NO=:J?\ /9_[>D_R"O\ Q;3!_P#OQ.K/<B<G?\D_<?\
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M:+$XC%T$-3DLOEJYU98*2DI9IY-+,$T([+[KW19?B_\ S8OAE\L^W9^@>O\
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M+D88^1^.7'MLSH.++^T=/K9S/P1S]BL?\G4&;>&TX+^;<^WT*C44.8I]5O\
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M-A]PY/&U,&%RM132T]5%408_)/35$D;TLRR+&5:*0$H?=>ZT_MT_S]_YMO\
M*_R-1L3^;I_+,J.P]JX21,;1?+/XR5]3@=MY=$MXJQJEZ3,;8JJNM5D<T_\
M$<!407TRXR%[Q+[KW2N;_A:[_+3&#%0GQO\ G*VY?M$<XEME;!2A\YMJC_B
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M3*\24>#I:8*4M8J$B4 BPM;Z6'OU3UZ@Z?H:>"F4I3P0P(6+E(8UB!) %[*
M+V ]ZZWUF]^Z]U[W[KW0-]MT_G_N_P $Z/XK_P G?;?XC^GL1; Y7Q*?T?\
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MW,F&WA@M\]4XFEQ6XMK2;8R3P[DGS,N;II(:" T#3UXGII(1*)U8^Z]TI/\
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MOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3U[_9P?\ A2K_ -ZY_B]_U/\
M_P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\ M'_;3U[_ &<'_A2K_P!ZY_B]
M_P!3_P#],OOW[@Y,_P"CA=?L/_;'U[][<S_\H=O^T?\ ;3U[_9P?^%*O_>N?
MXO?]3_\ ],OOW[@Y,_Z.%U^P_P#;'U[][<S_ /*';_M'_;3U[_9P?^%*O_>N
M?XO?]3__ -,OOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3U[_9P?\ A2K_
M -ZY_B]_U/\ _P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\ M'_;3U[_ &<'
M_A2K_P!ZY_B]_P!3_P#],OOW[@Y,_P"CA=?L/_;'U[][<S_\H=O^T?\ ;3U[
M_9P?^%*O_>N?XO?]3_\ ],OOW[@Y,_Z.%U^P_P#;'U[][<S_ /*';_M'_;3U
M[_9P?^%*O_>N?XO?]3__ -,OOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3
MU[_9P?\ A2K_ -ZY_B]_U/\ _P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\
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M[]K/7OI^O?9C_'_;_P#&_?M9Z]]/U[[,?X_[?_C?OVL]>^GZ]]F/\?\ ;_\
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M:VS]M0G*9O:V6Z,V5N5):>@5I9Q]GU[EL=N653&K:OMI=8 &FQ^ONO=;3/\
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MOOWC'KW@CKWVT?\ 3_>_^*^_>,>O>".O?;1_T_WO_BOOWC'KW@CKWVT?]/\
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MO>_=>Z][]U[KWOW7NM5/^>S_ -O2?Y!7_BVF#_\ ?B=6>Y$Y._Y)^X_\T/\
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MJ839_P#*D^+&T-A]9E)J:OFQE)C\WC!3YGL7.X'.K$<SD:R:K2&#&SS&:O\
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MYRW!;6;R%+R99QKH&:)E\4!M..W]('U(KCAT2\M33[WO<T]RJ!K:(PG14J)
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M>-I7E::94D5F2AD(#J"2"=:TK3X:4] /MEC--OMU=2*X1(TBB+(P5JA*E6(
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MF-YYA303U>1J?\HK:J=ZFMJI7G8.JH<\V\WS<V21ET2*.%-$44==""N>.*D
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J?\]G_MZ3_(*_\
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MXFE1;C4T>H+<:K$CWX@CKP8'H2)ZB"EADJ*J>&FIXEURSSR+"BC^K,Q"J/\
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MIK'IL[225=48'K9!3Y;'UE.SU$\PD4LY^9>;]GMMWL]2QPDQ2VX-4AR "
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M/F9^/JI&<TIRXG[PWN^O5KH4" &F&8:%-#\O"X>C XQ4"_YCOQ(^/&QOFO\
MRJ_@=\:>JMD[ QN\.XAW-V\]-%+E\UE<=C\KC8EK<QF<C)5Y;+/%B\3NYHQ5
MUTWDE+*#$"Q9?RCOES<[;NFZ7LDCE(/ B\D4N&PJK15&IH_A H/+I+S%MD,-
M[M]C;(B!IC-)YLPCTFK,:EB5#Y8DD^?6W7[@KJ5.O>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NM/C_A2ENKY/?*+Y6?RZ?Y.GQ\[@EZ0VM\UI]]9[NO<\%75
MTJ5^)Q3?;+1Y)*"H@J<CB*+&4>X:F3$L\=/E:K[.&>:-8O)'[KW5>O\ //VI
MV3F.ROY-'_";KI+MW=F:V?0; Z VUW%N.FQG\)DR]+CZF':>WLMEJ5:MH9:?
M;6%V_GLW)CON)*='-+-ZYJ:E:+W7NDIV%\!9O^$W'\W7^4]G?B?W[VSV+U#\
MZ>T&Z([8V'V154%+/5P0Y[:VWLQ]Y)B*6@Q]?1I!OS'5V,BEQ:S4==0.QJY4
MJ+1>Z]U]#SW[KW7O?NO=>]^Z]T4[YM_+[KOX-?'/>_R#[$H<UN-<']AM_877
M.TZ7^)9[>&ZMTR?:;=VCMZB6\E;FL]D7BIZ>*-&8 O*5*1O[]U[K4SD^*W;7
M2/\ .Y_D7]\_*O<2;N^;/S%W+\]NVODE7T4O^XS;PH.NZ6':_7.WHDEEACV]
MU_BJJ2@@D4EZVK>NR$KL]79?=>ZML^;^T1W[_/D_E+]0;OBJ\MUCT%T3\LOE
M^^TYZR.;%UNY*(8O;."R&0QTZ^*HJ,!5SP5%#,H>>GFE<Q>*)ZDR>Z]U*_X4
M&8*HV5U/\'OF%LF.7%=P?$S^8C\7<]MG=F-$%/5'!]HY@[4W'@*FHD1Y3AL]
M#E*2.KA0'RF.(.IB\@/NO=; _OW7NO>_=>Z(7V'_ #1/Y>?4V]]S]:]E_,#H
M[9._=E9>JP&Z]I[AWC%CZV@K:(VEIJF%QJCE0VN#_@1P?9K!L=Y<H)(X)64Y
M#*C$$?(@=(9=SMH&*/+&K#B"Z@C\B>J9/^$O.4Q^<ZG^?6:Q%7!D,5E_FCN+
M*8ROIG\D<]/D,;3RPS1M_:26-U93^01[$O/2&.2V5A0BUC!!X@@L#T2\KN'2
M=@:@W$A!'F"%ZVC_ &!>A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U3S\FLAE*_NG>*91Y3_  Z:@Q^.ADO:.EBIHI(@@_"2>1I?
M\6D9OJ?;R\.F6X]!WUM7Y/&=@[*K<-+-#DH]T82.E: G4QJ:B.)H[#]2RH[(
MR_1E8J>"?>SUH8Z$SY']BYW>?9.Y<355E2F!VIFJ_ 8K#B8B%&P\C4\U08P=
M+33RI(VLC4$*I?2H'O2B@ZVQJ>D7U=GMQP;CQ>S\9NG/[=PN^,WA-OY[^!U+
M1.T62J8H6=% :TJJU@RC45NG*LRG9ZT.K>=B];[.ZXQ@QFU,/!0AE K,A(!/
M5U+#ZO45##R2$GD+<(M[(BCCVR37IX"G2TG@AJ89J:IABJ*>HBD@G@GC$J.D
MH*LCJP*LK*2""""#8^]=;Z X_&CI,Y;^+G9%+YO)YOLQD:Q:37>]_M!4>#3_
M ,V]'CM_8]VU'JND=#A3T]/200TM)!#34M-%'!3TU/$L,<:1 *J(B@*JJ
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M^SHRFU-H;<V1AJ; ;7Q5-B<93#B*!;M(Y #2S2->2:9K#4[L6/ O8 "I->K
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M*WHGL3O#"[@S/9&Z^N,IM&#+&MKL1@*V3$:U$SXK;N.W!.^1R-EIHY*N$1S
M1.[.\D[(W)$-_>W4L*SQP,BQK*CE31I!JH2-3-$ J?$:&HR.J\T;FO-$EG:P
M1RM#),KLYC=0R@JAI4 Z0)*L^%R*'C3<FAAAIH8J>GBBIZ>GBCA@@AC$2(D0
M"JB*H"JJJ   + <#WC^37J7>LOO77NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIO\ G1_/
MN_E??R_9,UM_M_Y%X;?7:N$65*CH_H6.+MK="U$#,KT5;'15$>&P-:NDGQ9K
M,XUM)5APZ:O=>ZU*N\?^%6_\QWYZ=N;+^+7\K+X\;7Z%W/V]N2/9G7>>W;7X
MKLG>N6K:H2K&*6HSR4&Q]OHR:FE6IHLB86C5TR,8#*WNO=;9/\C3XI_/?XG?
M$WL7!?S(.XI.Z/DCVW\B]W=U56;JNS\GVW58O$9[;6T<+1X2LRF0ABACGHZO
M 9"44N/DGQT$51$*>8EI$3W7NKG/?NO=>]^Z]U[W[KW2:WELS9_8NT]R;![!
MVIMK?>Q=Y83);:W?LO>6"I=SXG*XW,Q-!68_)8ZNBGHZZBJX'>.:">%XI8V9
M'5E)'OW7NO;-V9L_KK:>V]@]?;4VUL38NS<)C=M;0V7LW!4NV,3BL;AHE@H\
M?C<=0Q04=#14D")'#!!"D44:JB*J@#W[KW1<-U_ CX/[[[AI_D'O7X@_&C=O
M>5+5TV0B[;W'TEMS,[A^YH@X@JGRM1CI*R2KA#GQSO*TJ670XT)I]U[HVGOW
M7NO>_=>Z][]U[K53_GL_]O2?Y!7_ (MI@_\ WXG5GN1.3O\ DG[C_P T/^L<
MW0.YD_W+LO\ FK_S_%UM6>X[Z&/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7%W6-6=V5$12[NY"@!1<DD\  >_=>Z*1(9_DEO5H%:5>D-B91?,\9*+N')T
MO.D-P30P@\V^J->^J5##?X?MZI\?V=&VBBCACCAAC2*&)$BBBB01JJQBRJJB
MP55    L![IU?KG[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>ZHKW[_ #JZW.[O[;Q'PL^%7<_S5V+\?LI4X[N7MS9N?AV7@Z3^%B=JW^ E
M\9EZK<<\"TTQBBB@@-4B&:G9Z9X9Y9)M?;P11Q-N5Y#9O.H:&)P7=JTTZZ%1
M&IKQ)-.!%00 7/S@7>065M+<K"VF5U(512NH+6I=A3X0,XH<BIH$_F1X?L;^
M7CG?G_\ &/J;)]UT&VMMY7<N<Z=SFZ_]'>7I4V;4>+<M)+5T^*W#%]]A::.H
MJU1*5XZRFC62&4>6+43'E%K+=AM5]*(27">*J^(G>*H:%H^UB0*D@K7(P1T8
MCF$76WG<+1#* I;PR=#=IHPPKY%#@ @TP:$'HG^\_P"?ETO3?';XO]A]/=3Y
M?O3Y(?**II,3MSXG;2WF:;*8K(4=:V*R]/DLNN$JY8H8,K')38Z1L$DF7&FI
M@@BIA/+ (+?VON#>7,-Q*(+>UJ7NG2JLI&I"JZQ4LI!8:NS@26H"43<]0_36
M\L$9EFN*!(%:A# Z6JQ7 4U .GNX@::D"C\V?YN68^"FZ/A[L'M#XQU6[>P_
MDA1U&0[!V5UCVK+NJMVJL-?B:*.DPD7]U(9-ZY2KDKJR*FI_'AXYZNE6G6H$
M<_W,*+EKD1>9X[N6&XT);4T-)&%$E0YJY\6D0 4%C5Z UH:4*K?.:SL3VT<L
M.IIZZ@CEBA!044".LA)8A11:D#A6HP=5?S@<MDOF%L?X@?)OX9=O_$G<G<BL
M_2&YM][IQVYH<R)$J&IER,-+34T.,FJYJ9Z5$I,AE"E8\4$YB#F1=7O(:KM[
M[A97<-TL-!.J*ZE"2!C5EAFM2$Q6E:=;MN:RUXMG<V\D#25,3,58. *YTD@'
M' %O*I%1TM_E1_-?Q'3WR)7X>_&WX[=B?,WY14F ;<FY^O.O,[2[4QN"I_##
M4JF:SL]-D%HI_M)X97!H&BB\U-%)*L]3'&4^R<CM?VG[PO)X[2UU:%DD5F:0
MU([$6A;((XC@2,*:.[GS0MI<?1VT3W%QI+%$*JJ#![V.%K7T/$>HJ(?P/_F5
M[1^9F[>UNE=V=3;W^-OR?Z.,$G9_0W8=7'DZFGII7B@>OQF0C@H_XE00U,T$
M;RM04QTU%),B-#50R,EYFY0DY>2*Y25+BVGKX4\=0#3R8&NEJ>53P(K52 _L
M?,2;PTD+(\,\5/$B>A(KY@C#+Z'%<&E"*EDKOYR.^.R<IVKD_A5\"^X/E]T_
MT?O+(;.['[BP/8>'V%1O)@X5J*^3;>,FI<IDMQ/' PD@ABCADGC:)_VUFB+&
MZ<@QV:QC<KV*TEFC$D431R2-1C1=9&E4!(R233.,'I W-CW+/]%;27"12%))
M Z(*J 6T!B6<BN!05\CT:W-_S(-B8S^7KO;Y_MUIO[;6%V=LZOS+]3]LT,_5
MV6DS"5<.,H<-+4U%'61I'E,I5T4%-704U5#(L\;QH[ZH5)(>4I9=U3:A(CEY
M OBPD2IH(U%Q0BNE0202"*$&G1G-S D6WM?E'4*A;PY 8VU# 4U!H2U " 0:
MBE>N>Z/Y@<.Q_P"6C3?S$]X=60X-*WI3:';])U'+O_6KOV%+10X/%#<+86/U
MY"3)X]5G_@AL\P587L"VX>53<[R=HCD+4G>$RZ/*,G4VC7Y!2::N X]5EWX0
M;;^\70"L*RZ"_FX!5=6GS) !T\3PZ*U\@?YR<GQ_^"_Q(^8>=^.E'5[B^5^X
M,+18SJ2M[I_@5-AL9G*')9"/+5&Y3M2I-7&E-3XMWC_@, "UK'RD4P^X.]I]
MOQNVYW>WK.0+57)D$.HNR,J:0GBBA))IWGA\\%FX\W_N^QM[PQ"MPR#09=(0
M.I:I?PS@4%>T<?ED9>O_ .:9@\[M+OWOKM7X]]L?'CX?=.[0PVY]F_(3N&EG
MVQ4[Z?-U]30TL.W=JU&.@K6BR#0T[4+O7F>H-91I)24QG4^RRZY,>.2"U@GB
MN+N9BKP0D.(:*K=\@.FHJ=5!I723J-.E\/,BLDMQ-%)#;QJ"LLHTF2K,.U"-
M0!H--<MJ TCS+;U__/&DR&^^BI^[_A-W9\>/C3\H<_C-M]!?)/>6X:3+4N3G
MSJP_82Y;#T^/B7#4=:T\;PS+F*P2TI-=$LE+'-)$<W?MOHBG%M>0SW%JK-<6
MZ*RE I-=+,>\BG<-*T/;\1 )9;\Z:I(O&MI88;@JL$S%2&+ 4U*M=%:]N34=
MV #2^WW&/0XZUQO^%"??><ZLP_PKV+E.R\QL?X]]E]ZM%\I,3U[NU]O;MR>U
ML)/AWEAH(J21,C-C#CI<]]PT?[7W@QT<@8R(ON6O:G:DW![R01B2XCMR;;6@
M:)92& +:NW5JTZ0?+4?+J/N?MQ:Q6V4N4A>=1/H8K(8P02!I[J4U5(-:Z1Y]
M0?Y('66Y:7N;Y'=U=";#[>Z(_EK[ZVGMG%?'KJ7N/<==N"IS69@FII*G>&*A
MKZZJEQU#-##D=9#3)6?Q"G$=7**(I';W'O4>""WNWBGW%'<W$L*JH1*4$3%5
M 9ACTTZ2*=U>O<F6K)++-;K)%9,JB&.1F8LU23(H9B44U.,ZJ@UQ3K9']Q'U
M(/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UKA?S]_P"1!N#^<31=+[RZ][^Q'3O9
M_06!WUA=MX+>&T)L_@LW#O:2BJ)8JVNHZF.OQ,L<^.IM%1'0URA&D5J9F*NG
MNO=4)[E^7'\_C^39\;.Q?C3\LOY?_3W>GQ#7J??G7&-[J^.FQ\;L3'XNFW#B
M9J>/+3Y7K[&+AL;C<50-4QNF;V%C:JH,$;R5HTM)4^Z]T<;_ (2M_P V/X&[
M&^%/1?\ +U["[QQO7?RF;L_L*FVWLC>N%K\'19ZI[2W;(V#Q^$SCT[8:LRM?
M+E:."&@:MCK)IF98()51F'NO=;L?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NM7_\ X3&_\R[_ )AG_B\&[O\ W!A]CCG?X[7_
M )Y(_P#"W09Y:X7'_/3)_P ^];0'L#]";KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>ZX221Q1O+*Z1Q1HTDDDC!%54%RS$V   N2?I[]U[HL&8^7O4.)R\F+BDW%F
M8H9FAES&'Q<4M("ATL5>:I@FE0$&S1P,K#E"P()OH/5-8Z%#)=S==8W8B]BM
MN&GJMMSWBH9*52T]14"]J2.G<)**JX.I'52@!>30@+"ND\.K:AQZ"3 ;$W3W
M9E:+?7;]))BMH4LBUFS>KC(=%G"%*S*6TM*[K?\ :=0W)!6.,M')8D#AU4#5
MD]&IAAAIX8J>GBC@@@C2&""%!$B)$ JJJJ JJJ@  "P' ]TZOUD]^Z]U[W[K
MW7O?NO=(C</6G7^ZZU,CN/9VWLQD$T#[ZMQD4LK",657DTAY$ ^BL2O^'O=2
M.M$ ]*R@Q]!BJ.GQ^,HJ3'4%)&(J6AH*9*.&)1SICBC541;D\!0/>NM]2_?N
MO=>]^Z]UJ%_-/XJ]Z=B?\*K_ .7SWK#\;^V=]?&;:WQD_N]O[N.+I_,;GV+C
M:V/$]OA*',;A&.GV_1U2U&1Q8$-36)()*FE 75-#J]U[K;.V]LK9NT34MM3:
M6V=L&L""L.WL#2X4RB*^D2?;11:]-S;5>U^/?NO=:LOR4^.?R#SO_"M/^7U\
MC\'T3W+F?CQLOXA[TVUO'OG%=89O([+Q.2JMG]WTT6/R>Z8:%\'05LE3EL5$
ML$]<DK2UE)&%+5$(?W7NO?)3XY_(/._\*T_Y?7R/P?1/<N9^/&R_B'O3;6\>
M^<5UAF\CLO$Y*JV?W?318_)[IAH7P=!6R5.6Q42P3UR2M+64D84M40A_=>ZK
M?[$ZE[,VQ_.:^<F\/YJ_\K7YJ?S1=J]@[V%'_+GJ.H^MJ[NCKG;NV,WE:^+&
M4-1#E,QB-F8.)\&NWH<I)5>1L96T5=75$+)5&OF]U[H>OY*?0_SM^+/QY_G9
M;%3^7$^V>Z<[WHV_NJ/BUW?M.LVKUCO'"9T9ZDJ]H;1W?-046U=S8ZCHH9*2
MGDI91CI8I<?YFIJ6K\D7NO=4U?(_X=[%^3'56U]M_%C^0M_,>^'G\W&3</7S
M9_>76/7NY.L.C<9N/:5;0G/Y3"5VX-U5E!MW#5*4U9+BG5*&&BF>CD.5JSKJ
M:CW7NK=?YM_\JWY%8ON[^5[_ #".X_CAN'^:-@/CU\6NH_C7_,4Z+V/%-F]P
M;CJ]CXO*+D-[XG%4Z"LS)J,GN#*5K0T[+:LH:'RK!2U5554WNO=&<_E,=-]0
M=L_/&'N7H7^0Q+_+_P#CMTQM?(5NT_DC\E=J9WJ+LAMU93'U&/JJ#!;<GR-5
M15E#54>2EA>I0RP0P+4"2<U$J4L?NO=;7V_:+=^3V-O/'=>YO&[9W]D-I[BH
MMC[DS.-_C-'C\Q54<T>,KJNCN/NJ:DK6@EEAN/*B,E_5[]U[K2S[S_F'?SF.
MP/A;\F?Y87RJ_E-_)#MKYQ=X[=[.Z*P'?'4>PH#U/78+M-:FAASYS=#228.A
M?#XV>K\#??M"[TU/45U7CYFG2#W7NMB_^2W\*.P?Y>?\M'XR?%'MC-4.:[-V
M%A-YY_?8Q$RU-%09/L_<F8W158>CE225*B'#OF/LVJ$D,=7-#+5QK''.L2>Z
M]U:3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[J@_<_\L'Y@_)3Y\=5?)7YF_(GJG>70WQI[4W#V!\?NH^OML55#7Q4M
M1D8\QB:'*5'\.Q,22T==186.JF>HR1K:;&QHPC:JF*2?;\Z6.S;5+9;?;RI/
M<Q+'<32."M0"C:1W8*LU/A*ESDZ1T!Y^6;K<]PCNKR5&B@D9X8D0@Y(8:C49
M!"U^(,%&!J/5^'N,.AQU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]T&W<VR*SLWI_M;K?'5M-C<AV#UMOK9%#D:
MU'DAIYMV8NJH(IY50%VBB>H5F"@L5!MS[]U[KY9F6_DS_P Q?^3?W0>[>[?Y
M9O2'\S'I':Q^ZFRE%2;D[LVG'2T#^6:OFPF%K,5E,>R1!1++N39]=BHTUVAE
M :3W[KW0KY3^<S\6?EU_.4_E+_*>MZAHO@MT[\5L-MOK+L_:5=/1UVV]O&DS
M&Y,C)48J7#8W'E</&^;CC8O@J-HF5W>()J<>Z]U]-SJ?N3J3OC9>-['Z1[/V
M!V]U_E[?PS>O6F[Z#>^+F8QQS:$KL;45-,9%BFB9D\FM0ZZE%Q[]U[H2??NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JG_/9_P"WI/\
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M3@\KD,9F*P4\,XIJ6DW-O;;R3U10+'(D:.X9% +.7-DGFY0GC@ ,UU(S1J"
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MYKC XD=,\T\U)RTB=AED<G3&&T]JBK,3I:@&/+.?('H\GQ+^0%#\JOC7TO\
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MU.W,-D\<,!1;:V>^2?!;6CR]!#XX:N65,A3T[/$M+3*?=>Z:OG;\5]@?,/\
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M38P4=-3'+22U@D;/U<8JY#*U))"D5,DN3>XVVFX_>J63?O J%):2MN&"!-8
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M:DXRNS2VJJBD1'-.JRE9)6C1\C\TP\K/<SR"0RR6[10E%4@.QU58LZD ,J\
MQXX]5/-.PR;\L$2: B3+)('+"J*"** K5)#'C0?/I1_+#XB?-W,_(?;7R@^$
M_P O5V#F</LV7:6<^-7>]1F]S]89,QQ^..KAQV.GE&%J)E6 5$M+C&J#)$DT
M4\>J>*=C8]]VV.T:RW&U\16<.MS!H2Y3U%6'>/0$@9-?(AW=-JO7N!=65QH(
M0J8)=30/Z&BD%3ZL 3@>504?\$/Y;G9O2OR@[O\ G=\JNR>N^P/E%WKMNCVI
MD,/TQMBIVKM+!4.C%"KCH16"&KR,\XPF,C%1-1P2Z(I99O-/5S2!3S-S?#N-
ME#M=C')':P,7!F8/+(Q+T+:11::V[02,^@'3&R<NR6=U+?W3H]Q,H4B-2L:
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M8>CB-!425$Z4UZ?(4,D:OY7$>[[DR\L[:UNTT31W9"Q>#XC$.:41@T:T<FH
M%<JWIGUKS+;W,\]NVJ)[<:G\70H*>;*0[=H%"2:4#+Z](OI3^;=T#WST-\D/
MD]LWJ[Y#8[H;XU8/=N9S79&[-H8# TFY7V?3R54]!M.G;=$E?6UL\"PM&*VD
MQ\*-400U,U/,SQHHW+D6ZVN[M[&22 SW!0"-7=C%K( ,A\.@%3G26- 2 10E
MBRYJ@O[>:[1)1%"'.ME4"30"3H&NIX?B"Y-#0U +:G_"B#X*R]?;3[-@V3\I
MJO:>;RKX;=^3H>FH,A2[/J7J7AIX-S92#-285:FLIQ3U<5-C,GDJH4]3 )H(
MJDR4\9P?:C<Q,]OKMM:C4BF;2TPI4^&K*'(&06956JFA(R2\<_V)B6;3-H)H
MQ$>H19QK925!.#0%F[A4 X%G6^_FG\9NM_C-COE_NWM/#X[X_P";VO@=V;=W
ML*6JE;)0;IB67&T]#CQ!_$9\C6!@JT?VHJ$<.LT<?BET NVY>O+R\-A'$QG#
MLA3':5-&J:T %,FM*>?0EGW>VMK;ZMY (M(8/FA#<*#B2:X%*^5.B)]/?SS/
MA=VSVAL7K#)8/O\ Z5;MBNI,?T]O_O/JM=C[9W8^19$IFPV4BR5>Q@J'FI52
M:KIJ6(M40*7#2  3;A[;;C8P/.I@F\($S1P2B22&G'6M!G!PI:E#7AT1VG.M
MG=2K$1+'XE/">6,HDM?X"?M'&E:BE:]' ^6_SW^/7PP?8V([7R.[\[O_ +0J
MZRCZVZEZMV=5]A;HSC8\#S-0XNC /B1V2/R331(TC!$9F#!2#8^6;OF#6T 4
M)$ 9)9'6.*,'AJ9B!GT%3T<;GO5OM&D2EBTA(1$5G=R!4T503CUX=!K\2/YH
MGQM^7_8F?Z6VYB>WNF^]MM8B;/Y3I#Y#]?-UIN44-.RAZF*F6KKZ2<+')#,T
M:5K3K!(LK1*@<HLW[DR[V");AS%- S:5GMY!+$6I6E: CS&0,@TZ2[3S);[N
MYB421RJ-1BF0QR!:TK3((^PFE16G0I],?.#J;O?Y-?)+XL;%P/8#;T^++;:@
M[(W=D\9C(=NS5.Z$+0T>+JZ?+U.1GJ87CJ8YEJ,53*DE/.JLX52Z+<.7)]LL
MK>^D9-%UK\-06\0",T)8%0 #4$48X(X=*;/>8KZYGM4#:H-&MB!H.L5%"&)Q
M3-0,^O2;ZD_F$])=S?)?Y,_&#:^![(H=S_$['-D.U=^YW$XJGVQ>-XXWI\?5
MTV9J\I-41DU.I9L13J/M:@:KJ@D=O^5[C;K*VO9&C*W1(B0%O$[<5(*!0.%*
M,>(ZK:;Y#>7,]JH<-!IUL0NCN%10AB?MJ!PZ)MUC_/O^%O;F'Z^EV9L_Y$Y#
M?7:'94/7.SNG:?8.'RVYYHYJO$X\;BJJ?&[DKL7C-N'(99:9*BLRT%1/-2UJ
MTU),(-3"&_\ ;#<=M:02/ $BCUO+K98P=+OH!>-6:32E:*I #+4BO1-9<\6=
M^J&-9=4CZ5CT!GIJ5"Y".P5 6I5B":-0&G2Z[^_G;_"[H?L+>G6M)2]U=[9W
MJVKEI>X,C\>^MAV!BMH"C:1*R;/96?(8VAABQ\D,J57V\U2\$J20NGFBEC1-
MM7MUN.Z1),?!@645A%Q((VF)I0(M&)+5&FH -0:T(Z?O^<K.Q=HQXDIC-)?!
M0R+$,U+G  %#6A)%.&#U8WT)WUU5\F^I=G=W]*;KI=Y]<;ZH):[ YNFADI&O
M2RR4]335-/.D<]+64=5%-!/!+&KQRHRD< D);GMD^S3O;7*%)$-&4_94$$5!
M!!!!&"#4=""QOHMRB6>!@R.*JP_9YY!!P0<@X/3AW?O#<_7G2W;V_P#9.W#O
M'>>QNK]_[PVCM$/X_P"*Y3;.)JZV@QNK4FG[ZK@BAOK6VN]Q]?;>WP)=3QQR
M-H1Y$5GXZ%9@"WY UZ<NI6AB=T74RJS*H_$0"0,TXG'6E/U%\W/E/W#1_%SL
M[I/YT?);N?\ F*=T=TUE)N_XA4*&3JG [2QN?R-(YSN%IJ!L9C*6>@AQ]0]:
MD<M33T51+(5A\,=4<BMRY:LMM-S;W-E;P[?#""EV:_523&)2-#%P7.HD:,*2
M/RZANPWNYW 030W,LEY+(0UL*?3I$)376H4Z!IIW9>AQZ];U'O&KJ:^O>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>ZU4_Y[/_ &])_D%?^+:8/_WXG5GN1.3O^2?N
M/_-#_K'-T#N9/]R[+_FK_P _Q=;5GN.^ACU[W[KW7O?NO=>]^Z]T5C(_\9G[
MM@PX'W'7W3%0E?EKC5%6[@E+"*!@3ID2CT-J&DZ2DR-Z9E]W^$?;U3XC]G1I
M_=.K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= A\A_CETU\K>K,U
MTIWYM"3??66X:W"Y#-;83<N7VF*B7;U5%6T;/5X2OQM>%AJH8I-"U01F1=:L
M!;V9;3N]QL4ZW-J^B1=05M*M34"IPZL,@D<.D6X[=#NL)@N%U(U*K5EKI(89
M4@\0//H0]A;&VIUAL;9O6NP\-!MW8_7VU=O[)V=@*::6HCH<7M6DBH:"D22>
M26>1:>E@BC#R2O(P74[LQ+%)=7+WDCS2DL[LSNQXLS$L3CU)KTH@A6V18T%%
M50J@< JB@'Y =*SVQT[U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO= M\A?D7TA\4.HMW=\?(GLG;/4W4NQJ6"JW+O3==6::GA-;*
ME/34\4<:R5%76UE3)%#34M/#+45$SI%#$\C!3[KW5=/7/\]#^7?V#O\ ZVZ[
MR&^NV^GLAW+DJ3"]1;E^1'QQWUT'M[<M=DO":.BQ&X=TX'&8B>JKUJ(&IHVJ
MT,X=!'=W16]U[H^GRF^67Q^^%G4&:[T^2O8V+ZUZYPU518M<C64M3EJNOR.5
M++18G$8N@AJ<EE\M7.K+!24E+-/)I9@FA'9?=>Z++\7_ .;%\,OEGV[/T#U_
MNCLG9'=O]V)-Z8;JWOSI'=O0&8S&)IB5J*_!TV[,1BOXQ#2$7G%*\DD2$2,@
MC!<>Z]U9+[]U[KWOW7NO>_=>ZU?_ /A,;_S+O^89_P"+P;N_]P8?8XYW^.U_
MYY(_\+=!GEKA<?\ /3)_S[UM >P/T)NO>_=>Z][]U[I-[PW5BMD[9S.ZLU+X
ML=AJ*6KE (#2,.(X8[D RSR%(T!-BS"Y Y][ KUHFG0,=%;0R=6N0[BWNIEW
MSV!&M330R*0N-Q4A#4E' K7*"2-8G:_.D1JUG$A?;'RZJH\^C%^Z]7Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K3Z^:F2^1E=_PH+P4^T\
MO\6=N;MZXZ1VKEOBY)\SL]N'%[,JJ6LPCK6RTBX!Q4-GUSM?NHT2/HB\M"9A
M>JAIKS[RXEE'RHWBBZ9)+AA<_2+&900P*@F3&C2L=3QJU.!/42;TUT_,"^$8
M R0 P?4,XC(((8@)^.I< <*+7B!0PWQ@V5\@^^_YQ6V?DOW%\DOY>V;WW\<^
ME]R]>]R]9?#?-[ZRTE1B:_&YV+'SY&3<6'EQIFILIN*A-5.NX@L2T--2?;+4
M))<HWJ\LMLY?:RMK>_"7$RRPRW:P@!@4U:?#:I[4( T_B)K2G1CM=I=WN[BZ
MGFM"T,1CDCMC(25.HKJUC&6!KJ_"!3CU3/\ SE.YNH/EA\T=[]X=$;*[%R_0
M/3=)UCTC\L.^NKZR)Z'<9K,K.(&HYBDF/NU+1-08ZJK))*>OFH*=Q%]O#3R3
MR'[=;?/L>W);73Q"XG,D]G!*#6,JG$^8XZF"T*@G-2P .YTNX]TO&G@60PPA
M(;J:-A1PS5H/(TR 34$TJ* $WT_S?]X])?'W^210['^-+X/;_4';M)TEUOTT
M=M3B6"LPVY:F'=,LT4S%WJI,MAL5D):F=V:6<SS2RN979O<7^WUM<;MS()+P
M,TL1FEFU5JKH"@KPII=E ' 4 X=#OG*XAV_9"ML55'6..+32A1B&QZU0-GS%
M3T">[?D!\.^E_P#A.KMS9F WAUQE,GV?\7L/L"CV+A<IC:W*5?8F_::-\^\V
M/24U'WF$W#-7UM5+)&'@2D#@Z_"K&,&U7^Y<WL[+)^G=F0NP8 6\;=N:?"R!
M57R-0.D4M_:67+B@,G?;! H(J9G6C8'F')+>8H2>'1#OE1U-NSI7XC_R NDO
MDLF5Q'Q\D[4K]U?(M-YI]K2X\;_W5A,VN.SDE0%^P;"[2SVX*>*&1H]$$=8C
MJ?MCXQ1L.X1[I?[[<V=#<>"5MO#KJ8)&Z:D XEG2-B>.HBG'HAWBS?;[3:8+
MFO@B53/XE**69&TL3P"JSJ!PH#7AT>[_ (4$;^Z[^1^U/AK\(/CEFMG=B]_[
M_P"_=L;KVAA>OZ^'/'$8:'#Y7"T\M1-BEJ1C<=53Y2"HN  *;&S5.GPTQ<!C
MVGMY-G>[W.[5DMX[=T=G% [ET?2-5-344BGJP'%AT>^X4J[BMM8V[!IWG5E"
MY*J%==1TUH*M6OHI/X3T*7SOZDZ1^9/S5V=C/C7\[H?CO_,Q^&FPX<#(F[ML
M97#T%=0R1R5D,"5F0@I:62L<[BDEEEQKY=9*&MFBJ:2= &A+^6=PN>7-M=KV
MR^HVZ\>O:ZU#*:5[22!^G@-H[E!5AFJW?+2'>[U1:W/@WMJOFI(*L*_B !^+
MBNJ@-",BBB_E/_,_Y*]D?*#Y0_&3Y=8[IGN#LOXT["I<AD_EATQA\;5+7+CZ
MFE@_@-=D\=2T,%=-*E=424RPX^D:.2BR,%3#YT/MKGGEVQL[*VO]O,L4=R[
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MQ!!XD]7T?R(_CQN/XX?!.FV[F.WNMNZ\'OGMC>?96P-W]2U.8KL$F&S5'B*
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z)'\R?@=U)\X\G\9)^Y,YO<;;^,7R(V?\
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M[O7/5U539?>KHVN.ORI#?;XYB."D'K$BW_$ZM9A&1<=HZH>XTZ-4 % 50
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M=Q.,P&W\5C<'@L+04F*PV%P]#%C*2DI<?&L4%-2TT"I#3T\$2*D<:(J(H"J
M !["CNTK%F))))))J23Q))XGH0*H44& , #@!T'/=/1/3GR+V+7=:=Y];[2[
M1V+D*B"LFV[N_$QY2%*BEU"*JIF8":DK(@[A*B"2.9 S!7 9@5>W[E<;5*)K
M:1XG& R,5-#Q&.(/F#CI/=V<5^ABF170\58 C'V^?SZ*!U7_ "DOY<'3&.W#
MC-B?$KK)(-TX;,;>S53O#^)=G5;T6?A-/64T5?N:OS%=213PDJ13U$5@3IL3
M?V?[ASUN^YLK374I*E64*1&H934'3&$%1ZTZ*;+E;;MO4K%!& P*DL"Y*MQ%
M7+&A]*TZ/1L#8&RNJ]E;8ZYZYVQA]F;%V9AZ/ ;6VM@*-:"CHJ.@73%##$OT
M Y+,27=RSNS.S,0U<W,EY(TLK%W<EF9C4L3Q)/1U#"EN@CC 55 "J!0 #@ .
ME?[8Z=Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF7<F%_O)M
MW/[=_BF6P?\ 'L+E<+_&L#/'2UU'_%()(/NJ*6:*>*.KI_)Y(6>"1%D52R.
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M3944D\#W[KW6E7M[YV?#+^=-VY/W#_,+^=7QV^./\N7J?LJ>7X]_R[]V_(/
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MAQ.X:27/Y.HI&<M3P1TU;%2$K2EZVD@1GE&^YTVW>Y1>M?[C:]J>)91-)1F
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M^\=SWRRRS1P>&0.WPG8EC_I@!7.10=>V/:)C.+B:TM+95':D:1O-KJ1J\15
M44\A4^M.K[_<9=#?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4_Y[/\
MV])_D%?^+:8/_P!^)U9[D3D[_DG[C_S0_P"L<W0.YD_W+LO^:O\ S_%UM6>X
M[Z&/3)N7/T&U=OYG<F4?QX_"8VKR=41]2M(A?0OUN[D!5%KEB .3[V!7K1-.
M@8^.F KX-HY'?F>2VYNTLQ4;PR3'DI35+-]A IY/B2%FDC!/I6;3Q:WO;'RZ
MT@Z,%[KU;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU?_\ A,;_
M ,R[_F&?^+P;N_\ <&'V..=_CM?^>2/_  MT&>6N%Q_STR?\^];0'L#]";HK
M^XO^,G?(#;^V$!GVQT_1INK/E;-&^7R(4T,#?4%H5$<@X_LSH;'W<8'V]4/<
M?LZ-![IU?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB*_$O^7STM\.>S
M?DSV[UUN+LS=6]_E=OM>P>S,CV/FL9EU@JUR&;R9@Q*8W#XDTU(]7GJYG69J
MF5@L(:4^.Y$V^\UW/,$-M;S+&J6L?AQB-6%1I1:MJ9JFD8X4''&>B/:=@@V>
M6>:,N6N'\20N0<U9J"BK05<^I^?1ZO89Z/.O>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4_Y
M[/\ V])_D%?^+:8/_P!^)U9[D3D[_DG[C_S0_P"L<W0.YD_W+LO^:O\ S_%U
MM6>X[Z&/1:/D%43[IK=@],8V61:C?V>AK=Q&!M+18? ,)ZAB?[)=DU(3P3"R
M_D>[KC/5&SCHR-/3P4E/!24L204U+#%3T\$2Z%1(5"HB@<!54  ?T]TZOUF]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:O_ /PF-_YEW_,,
M_P#%X-W?^X,/L<<[_':_\\D?^%N@SRUPN/\ GID_Y]ZV7]V[CHMH;9SNZ,B?
M\CP6+K,E*@.DN:9"4B4GC7*^E%_VIA[! %>A*33H(_CIMNMQFQ&W7G 'W1V3
MDJK>V;J"I#%<JQ>EC!/J$8@(D"DG0TK@$CWMCGK2CH??=>K=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJI_
MSV?^WI/\@K_Q;3!_^_$ZL]R)R=_R3]Q_YH?]8YN@=S)_N79?\U?^?XNMJSW'
M?0QZ+'U+_O\ _M/LSMF6TV+QU0G7&RI?U*:;$$25DT?]4GF,;HX/^[)5XM;W
M8X%.J+DUZ,Y[KU?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[K5_P#^$QO_ #+O^89_XO!N[_W!A]CCG?X[7_GDC_PMT&>6N%Q_STR?\^]7
MT?(*HEW56[ Z8Q\C_<;]W!!7[B\+E3'A]O-]Q4,UOH7=-2$FQ: K]2#[!2XS
MT(VSCHRD,,5/%%!!&L4,$:0PQ(-*JL8 50/P   /=.K]9/?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ
MI_SV?^WI/\@K_P 6TP?_ +\3JSW(G)W_ "3]Q_YH?]8YN@=S)_N79?\ -7_G
M^+K92[QWC)LCK'<^6I&D&6JZ08/!K"-4AK,V?MXFC']IX0[2@<W\9X/T,>J*
MGH7L:#IZZLV;'L'K_:VU5C1*G&XN!LF4L0U95_O5;7_M U$DFDG^R%'T ]Z)
MJ>M@4'0@>]=;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
MU?\ _A,;_P R[_F&?^+P;N_]P8?8XYW^.U_YY(_\+=!GEKA<?\],G_/O5\_5
MX&^.Y.UNR9!Y<=M^:GZRVM*1J4+B;29!D/TLT^AU(N2LS#@?4$G IT(QDUZ,
MS[KU?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>ZU4_Y[/\ V])_D%?^+:8/_P!^)U9[D3D[_DG[C_S0
M_P"L<W0.YD_W+LO^:O\ S_%UL)]D#^_?=G6'72WEQ6THY^T-S1@:U+4#&''(
MWXXGN&!^J3@\_0QZ,"O0N.33HS/NO5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>ZU0/^$\&\$V'\>OYFVZC(J3XSYE;V_AVL7#5=
M70P04BD?4AJF2*_]%N?H/8YYV%7M?^>2+_"W08Y;-%N/^>F3_GWK9DZ,VBVR
MNK=IXFH1ER530#-Y@N27-5FR:F19"?J\0D6(G^D8Y/U((8U/0E44'0M^Z]6Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NM5/^>T0/YI/\@LDV ^6F#))X^G8G5GN1.3O^2?N/\ S0_Z
MQS= [F3_ '+LO^:O_/\ %UL*="#^]FX>U>VYK2+NO=+X#;LI-_\ <7M=1#"\
M9^FF>Z!K$@O$3Q]3'K8QT+ESGHS'NO5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HNGR
MF^67Q^^%G4&:[T^2O8V+ZUZYPU518M<C64M3EJNOR.5++18G$8N@AJ<EE\M7
M.K+!24E+-/)I9@FA'9?=>Z++\7_YL7PR^6?;L_0/7^Z.R=D=V_W8DWIANK>_
M.D=V] 9C,8FF)6HK\'3;LQ&*_C$-(1><4KR21(1(R",%Q[KW5DOOW7NO>_=>
MZ][]U[K3J_X3_P ;;MQGRJZN"F6ASW\P?>VZ=Q1 <&BVCC893%(;V$<^N4<_
MVU6WJL".^=<-:G_ETC_PMT%N6\B<?\O,G^3K<5]@3H4]>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW53'>W\[/X ?'_L_LGJ/
M<6]^U-_[JZ6\,?=59T7\?-[=YXC9\\JR.]'N3-[7P>2Q6,KJ>**1YZ>2J\U.
MJD3(C@H/=>ZL>Z?[AZP^0'66R^YNE][X#L?J[L3!TFY-E[UVS5_>T5?1U@.B
M6)B%=&5@R212(DL,BO%*B2(RCW7NA)]^Z]U[W[KW6H[_ ,*):BJI/Y@7\DNK
MH9)(JZE[^KJBCEA%W66'>O6C1LHL?4' (X^ON1>3?]P-Q_YH_P#6.;H&\R_[
ME6?_ #5_Y_BZVI^L=IIL;K_:>U@B1S8G#4J5X06!JJ@>:K<?\'J9)6_V/N.R
M:]#$"@Z7?O76^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7N^;^T1W[_ #Y/Y2_4&[XJ
MO+=8]!=$_++Y?OM.>LCFQ=;N2B&+VS@LAD,=.OBJ*C 5<\%10S*'GIYI7,7B
MB>I,GNO=2O\ A09@JC974_P>^86R8Y<5W!\3/YB/Q=SVV=V8T04]4<'VCF#M
M3<> J:B1'E.&ST.4I(ZN% ?*8X@ZF+R ^Z]UL#^_=>Z][]U[HEV^OYC?P&ZQ
MWAN+K[L;YD_&O8V^=HY2HPFZ-H;K[BP>"R./K*0VEIJRCJ:V.>GF0VNCH"/Z
M>S.'9;RY4/'!*RG(98V(/V$"G2*7<K>%BKRQJPX@NH(_(GK5U_X3U_*3XE=$
MY'YO[R[V^1W2?4J;J^1>Z7Z[?L7L?%;3&7I,D4GJ*W&_>U,/W4$4:TH,D>I0
M*A>?5[&W.&UW-VUL(HI'*VT8;2C-I/=@T!H<'H,\O7T$ G9Y$4-/(5U,!48R
M*G/'K9?_ .'5OY:/_>>GQ+_]'QMS_P"N'L'?U>O_ /E'G_YQ/_FZ$7[WM/\
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M]^][3_?T7_.1?\_7O^'5OY:/_>>GQ+_]'QMS_P"N'OW]7K__ )1Y_P#G$_\
MFZ]^][3_ ']%_P Y%_S]>_X=6_EH_P#>>GQ+_P#1\;<_^N'OW]7K_P#Y1Y_^
M<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_WGI\2__1\;<_\ KA[]_5Z__P"4>?\
MYQ/_ )NO?O>T_P!_1?\ .1?\_7O^'5OY:/\ WGI\2_\ T?&W/_KA[]_5Z_\
M^4>?_G$_^;KW[WM/]_1?\Y%_S]>_X=6_EH_]YZ?$O_T?&W/_ *X>_?U>O_\
ME'G_ .<3_P";KW[WM/\ ?T7_ #D7_/U[_AU;^6C_ -YZ?$O_ -'QMS_ZX>_?
MU>O_ /E'G_YQ/_FZ]^][3_?T7_.1?\_7O^'5OY:/_>>GQ+_]'QMS_P"N'OW]
M7K__ )1Y_P#G$_\ FZ]^][3_ ']%_P Y%_S]>_X=6_EH_P#>>GQ+_P#1\;<_
M^N'OW]7K_P#Y1Y_^<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_WGI\2__1\;<_\
MKA[]_5Z__P"4>?\ YQ/_ )NO?O>T_P!_1?\ .1?\_7O^'5OY:/\ WGI\2_\
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M_1\;<_\ KA[]_5Z__P"4>?\ YQ/_ )NO?O>T_P!_1?\ .1?\_7O^'5OY:/\
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M /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\ Z/C;G_UP]^_J]?\
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M -</?OZO7_\ RCS_ /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\
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M>_>]I_OZ+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7#W[^KU__ ,H\_P#SB?\
MS=>_>]I_OZ+_ )R+_GZ]_P .K?RT?^\]/B7_ .CXVY_]</?OZO7_ /RCS_\
M.)_\W7OWO:?[^B_YR+_GZ]_PZM_+1_[ST^)?_H^-N?\ UP]^_J]?_P#*//\
M\XG_ ,W7OWO:?[^B_P"<B_Y^O?\ #JW\M'_O/3XE_P#H^-N?_7#W[^KU_P#\
MH\__ #B?_-U[][VG^_HO^<B_Y^O?\.K?RT?^\]/B7_Z/C;G_ -</?OZO7_\
MRCS_ /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\ Z/C;G_UP]^_J
M]?\ _*//_P XG_S=>_>]I_OZ+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7#W[^
MKU__ ,H\_P#SB?\ S=>_>]I_OZ+_ )R+_GZ]_P .K?RT?^\]/B7_ .CXVY_]
M</?OZO7_ /RCS_\ .)_\W7OWO:?[^B_YR+_GZ]_PZM_+1_[ST^)?_H^-N?\
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M1_[ST^)?_H^-N?\ UP]^_J]?_P#*//\ \XG_ ,W7OWO:?[^B_P"<B_Y^O?\
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MY^O?\.K?RT?^\]/B7_Z/C;G_ -</?OZO7_\ RCS_ /.)_P#-U[][VG^_HO\
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M3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\
M5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?
M_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_
M /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UX
MW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-
MT_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^
M_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_O
MW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__
M &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\
M]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!
M=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7
M:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_
M .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O
M_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_
MWA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'
M_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7
M^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U
M?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?2%
M[1_X3W?R@MN=9]B[APWQ%^SS&"V)N[,XJK_T^=GU'BJ<7CZB>"3QR[U>)]$J
M*VET96M9E()'N\?.^Z,P!FXD?Z'%Z_\ -/JK<KV !_2_XW)_T'U4I_(3_E$_
MR\OFE\"*3NGY+_'S_25V9+W%V/M5]R_Z6-\;.O08%<>:2#[/ ;EQ6/'B,\OK
M^U\C:O6[6%A)S?S1?;7?-#!+I0*A T1MDK4Y9"?Y]$W+VQ6E]:K)*FIB6J=3
MC@Q' ,!U=+_T#J_R</\ O#W_ -F"[3_^S?V&/Z\;I_O_ /ZIP_\ 6OH[_JM8
M?[Z_XW)_T'U[_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[
MZ_XW)_T'U[_H'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_
MOK_C<G_0?7O^@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK
M_C<G_0?7O^@=7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^
MO^-R?]!]>_Z!U?Y.'_>'O_LP7:?_ -F_OW]>-T_W_P#]4X?^M?7OZK6'^^O^
M-R?]!]>_Z!U?Y.'_ 'A[_P"S!=I__9O[]_7C=/\ ?_\ U3A_ZU]>_JM8?[Z_
MXW)_T'U[_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[Z_XW
M)_T'U[_H'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_OK_C
M<G_0?7O^@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK_C<G
M_0?7O^@=7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^O^-R
M?]!]>_Z!U?Y.'_>'O_LP7:?_ -F_OW]>-T_W_P#]4X?^M?7OZK6'^^O^-R?]
M!]>_Z!U?Y.'_ 'A[_P"S!=I__9O[]_7C=/\ ?_\ U3A_ZU]>_JM8?[Z_XW)_
MT'U[_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[Z_XW)_T'
MU[_H'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_OK_C<G_0
M?7O^@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK_C<G_0?7
MO^@=7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^O^-R?]!]
M>_Z!U?Y.'_>'O_LP7:?_ -F_OW]>-T_W_P#]4X?^M?7OZK6'^^O^-R?]!]>_
MZ!U?Y.'_ 'A[_P"S!=I__9O[]_7C=/\ ?_\ U3A_ZU]>_JM8?[Z_XW)_T'U[
M_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[Z_XW)_T'U[_H
M'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_OK_C<G_0?7O^
M@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK_C<G_0?7O^@=
M7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^O^-R?]!]$C_F
M2_R-/Y6G07P,^5W='4OQ>_NGV7UKTON[=FR=R?Z;.Q<[]ED,7"&@J/L\GNZL
MQ]3H;G1/2RQM_:0^S39><-QN[R&*2:JO*BL/#B%06 (J$!_9TAW+ERRM[>61
M(Z,L;$'7(:$*2.+$=)C^59_)$_E@?)'^7O\ %OO'NGXR?WS[1[&Z^J,YO+='
M^FCL+;OWE4F4R%.)?LL3NRAQU/:&")=,%)$GIOIU$DWW[F_<;*\FBBEHB2,%
M'AQ&@'S*$_M/6MKY<L[FVCD>.K,BDG6XJ2/DP'5@?_0.K_)P_P"\/?\ V8+M
M/_[-_91_7C=/]_\ _5.'_K7TO_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!
M=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7
M:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_
M .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O
M_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_
MWA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'
M_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7
M^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U
M?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O
M^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_
M *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\
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M3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\
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M_9O[I_7C=/\ ?_\ U3A_ZU]6_JM8?[Z_XW)_T'U[_H'5_DX?]X>_^S!=I_\
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ML,T(_"1ZGK3Z_FQ?RLO@A\9OGM_*)Z5Z0Z+.R>LOE'\AL3L3O;;([/WEN/\
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MP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\
MZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\
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M>?V=!JYV:VCW.*W"?IM&69=3Y-)#QU5_"//K8!_Z!U?Y.'_>'O\ [,%VG_\
M9O[!G]>-T_W_ /\ 5.'_ *U]"7^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I
M_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\
M[,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^
MS!=I_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>
M'O\ [,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]
MX>_^S!=I_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y
M.'_>'O\ [,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_
MDX?]X>_^S!=I_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z
M!U?Y.'_>'O\ [,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\
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MU[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?UXW3_?\ _P!4X?\
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M .S!=I__ &;^PK_7C=/]_P#_ %3A_P"M?1[_ %6L/]]?\;D_Z#Z]_P! ZO\
M)P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO
M\G#_ +P]_P#9@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J
M_P G#_O#W_V8+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T
M#J_R</\ O#W_ -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\
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MW3@[I$CR2.L<<:L\DCL$5507))/  '))]^Z]TF?[[[+_ .>OVO\ ^?\ I/\
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MZ]U[W[KW7O?NO=5R_P PC<G\Q>IQ77'3/\NSKWJ^FWAW"F\Z3L3Y5]S;E6/
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MI0[I6CP6YL3%4U-528*NSV.D2!\;1QTD/AE^YD299:1*3W7NDU_+M^)?2/\
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HC_\RSY)[@^'WP!^7WR8V?\
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MZVFQ\6XJS"8_(8W(;<EEJRD$<F3QF1J31NT\"C(0TBRSI3M/J]U[JD#XY?\
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M7>_16Z\5F,^:M9:W#;WV=0YM:_:^3HI8*7+;=R.$DI:P179V2:54]U[HQ_\
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MXZHZ ZQW'W;VWA=_['W/U/E,3LS:?W/W^[QB-TX3#93(;7A^TG*Y6BHZF@F
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M@M[]U[JLC8'\T3+=V]%?/GNSK#M7XH;?V-\<?G'U?\;^E.W]_P",W/D=I9#
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MDJ8XIJ>(43"5A+$CHMPZJP('NO=41;O_ )BOSH[!V_\ RUJKXVX_XN[,RO\
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MTYG_ (]1YSK3:N^*SYJ[FKMC;'P&;Q><K]V93967@W;0E*]AELK!+B73*P>
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MMZ6EBBQ"R)7YJ16JJAH9:6F]U[K%G.QOYTG4^$P??6]NL_B%WOM"HS>R!O\
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MSU#9_)XVC6AK:2K6J93,L/NO=5![P^)GRDS'P![6V3COCEWC/O&L_P"$Q_\
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MQN^=[;]WULZOQN"7.D8I\%/)M^*5Y:Z&:6."CCA@IQ-D9:RA]U[IKZ3^<O\
M,2D^.G\M[YO]V]T]293"_)SY@=+?#WMOXR]>=,T]#@?M.U=WY#K9-U8[<]=5
M'<T>X5SM%3YF6+5%BTIIYL;'CW:".LG]U[JP'^>UE9,%_*B^6^<AQ>2S<V&P
M_565BPN'IS5U=8V.WWM:9:6EB',M34%!'$@Y9V4?GW[KW11OB/N[?'??\T#=
MT_\ ,UZJR'4GR7V?UA@>Z/Y;G0&;W+0[PV;@=@[II11[GRV)J*3519;N[!Y$
MOC]V5&N?^$4%120[>E;&5=;6UGNO=$CZNW_\Y?C=\2OYQ_S/Z<^077FT-A?%
M_P#FB_S,^TML?'ZLZ:I-X4^\Z#979%?7[EHMW;@KJA<KC9\H/OJ3&G!FD%"L
M=/5U,E>\TM+#[KW1T/FQ\[N\<'VSWUMGKCYBYCK'(]6[)V?N+J7H[X?_  8W
M+\^L\:_*;1BS=4O>5=2;,S..V=3UM?DJ5J#$4.4PU<V)A@RSYEDK9*2E]U[H
M,/AUV?W3\K?YJ7\O+Y6[H[#H]KOWU_(BR7>>X^M,!LJ@FH*1-U;RZG;-[?HZ
M^HUY#["OW!6Q9.*HD=JRE$"T*S202.3[KW0<[7^5?\PC>7\E3$?S$_D]V[T7
MV?EN^9/AK%M;X[-\9,%4;6P-/OSO?9FUQG*BHR4]?49K,9+;E>*UHJBF6DQF
M4:&;'QH:-'E]U[K;*]^Z]UJ[]@=@=B_#CY^_SS?FSF=Y4O;X^,/PC^*'<. Z
MURO7>#P1KJ;+T'=\NW=M+GZ>FERF*HL+-1K'45M.&J,C!*S5JRF"(#W7NCH5
MG</SD^(?:'\O_+?(WY&;(^2&Q/FYW5A?C3V7L#"])8OJV/9VZ]^[+W'NS"Y;
M9.1QU9/D*O;M)5[7K,?5TF;FR57-#4PUD5?!)$U/-[KW2A_DL=H?.CY1?$SI
M_P"9OS%[XV'NU?D/U51;@VUT;UUTQ0[&QNWA!E*R*AS!SHK*C*Y/(9O$PTT]
M;321QT=-43&.C18XM4ONO=%"_FJ_.SY%?%3Y-_)P?'G$=+P;\Z_^!7\OS>.P
M-R[ZZ]I*VLFR?R%^4]1UOE<9E\]#3RYEMM-A9',5'&SQT=7-/D(8)*EA[]U[
MHWNU.]OEE\9?G52_'/Y%=Z8'Y0=:]F?"7O'Y5XG*8SI;'=19?;6;^/6=VIC<
MKA\9'AZJJBR6WLS2;I$E)%7&IR=)/3:),C6)+Z?=>ZK0[KWA\XODC\+OY:7S
M6[2^0'75?UM\G/GE_*T[@W'\8L-T]18F@VE@NR>V=H97:M#MG=,=6,_D,SBV
MJ<1!F)\JU73UX^[EHZ3%Z(T/NO='FW9\^_D3A?Y8G\U;Y4TN<VQ'VS\3OD!_
M,>Z_Z;KIMKTS4--C?C+O?.X#:D-;1&T=?(E#C:9:EY&UU,C.Q*EE"^Z]TI\#
MVY\[OF5VU\S\+\=OD1L3XU[<^'&XNO>F]AX/,=,8WLT;WWME^O=N;[RF1WI5
M9.:.IQ>T_/NK'8V"DP:T5=XJ:IK_ .)EIHZ2#W7NJ[#G_DKU/WQ_PHI[X['W
MUUEN7L/KW^5)\:.UMT=6T.Q,=O[8T^<3K/NG,XW"QU.4Q]!6;@VKMNMH,C1Q
M-68RFDSN/K-65IDD4(/=>Z/YUQWI\K?E-W-M'XK]&]P;6^)^TND_@+\2/D)V
M9V#MGIS!;]RV=W!\DX<S!AL'A,/F(_[NX#:V#I=IY"2J$6.FJ*AZN"DI),;'
M2F2;W7NBR=?_ ,PGYZ_(KN?X2?%7:?9'4?4>_MV=I_S9/CG\MNW,9U8NZH:K
M)?R[-P;0PM#NG8V#R594T]!4[@3*2M]C7UU31T35\LLAR(QT%+6>Z]U9_P#R
MX>]>]^RI/F3TM\B=Y[?[3W_\._EIF_C]0]P8'9L'7DFZ,+5[0VAO'$Y'*X2C
MEEQU#FJ>GW4:.K-%XJ2=Z83PT].)#$ONO=%D@WU_,7^2WS5_F;]/=1_*/KKX
M\=2?#W=?QYVST-%!T5B>RLIE\_V3U-MK>F4HMY39F18FVE%DLQ"RC&R467F%
M341)DZ*.D@,WNO=5X?%[N?Y,?S&?YC'37R*Z5[2VY\1Y>]?Y#WQA[&[8S%!U
MW2]M9JCR=3V]V=!%BMLTVX0<'%C6RHR4L]77T%7.:6&EAIX5>IEJZ?W7NAUQ
MG\R3Y$[Q^+?Q>J>R_E#UM\?.P-T]E_-?I;NK>?27QYSGR&[5W=7_ !3WID=A
M8[+=3=28_;^]*:.ER%32Q9/<%=D,?E*'!F2EHTHIHL@*BC]U[I[Z'_F"_/7M
M;X,?/#/=9[9WQWS\@OBM\O\ #=%[&W+G/C#5]+;\RNP\S3[!SV4W)7=1YIL$
MTN]]N[6W3F9Z7&"/'PYJ6BHY(:",5(I9O=>Z#7*_S;^U>FOCG\G=Z;7^25%\
MI=\8'+_%;8/4_7W>WQ!W1T!W!L?<'R(WBVS<AD-\=:XG X"HWAMRA>JIJW"0
M[?P]/692JHZK"_=335,%7%[KW1M?@Q\R/DON?Y<8?H/=F5^5?R4Z.W]U%O\
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MO.5NXZC;F:7&U,./QF.6LAG3W7N@+_F(]6[_ $^6G\V7>>X^VH=TT&W-S?R
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M4;6@V3N[&;9ZN3^"U=-19.KQKUF9J):FGIZS%RX])JOW7NB^=R_('Y(?.O\
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MSNW:.]JFCK\6?O=EX38E7B<=#2T5'/'B:S"X.$S1U-14S---.1.L92-/=>Z
M+H'^63M#I?M#J?L?>/R0^2_R3H_C7MW<>TOB?L#OK<6W,SB.N:+=% N&J)\;
M+AMM87+[ASD>WPV(@S.XLIE\G!C9JJ!*G76ULL_NO=)[M+^4]U9VEO;L_P"Z
M[X^1>U?C?WYV31]P?(?X8;6S^WHNO]Z[B6:BJ,E49&6MVW6[PQN+W//CJ27/
MXC%;IH,9F'%0:NE;[_("J]U[JRG>>T<;O?9&[-A9&2IH</N_:N=VC738PQPS
M0TV?I):*5J<O')$DL<4K&/5$R!@+JPX/NO=5IM_*BV%M+!?'7_9?/DK\F_C#
MV9\=_BSUG\-(.Y>I<IL[)9;=^P>I:*"DPF.WIBMT[.W%M3*UV.ECJ:NCR%/M
MZCK*&IK:X4<L%-524Q]U[H3L!_+3^/>TM@?%+KO:V0[%Q6*^)GR?J_E]M[,U
M&Y8,[E]U;XSF)WGC,UE=Z9*OH:F?+2YZ;?6;KZYX/LY6K?!X9(:6,TS>Z]T=
MO?VP]F=I[&WEUGV-MK$;SZ_["VMGMD[WVAN"C7(4.4Q.Z*66BR./K('],M-6
M4D\L4B'AD8CW[KW53*?R:]H5VV\5TIO'YM_.OL3X;X>/"8R'X:;V[+VUE-JU
MF%VX\<E'M7,;@CVA#V'F=IP^&"-L?5;Q<U-+&M%6SU5&9*>3W7NA\W__ "P?
MC?V=#\[J/>4^^,A0?/W)=09_L.DI\G08T[5RO1&TL'M/:F8V+/3XR.IPN5PH
MV[BLK25,\U9)3Y:%:B$QPJM.ONO=%#[5^'F8^4W\Q_X0Y3L'I7NRIV#_ "T]
ML[JSVX/EEW#E]KT-#VSFL]0[1KMJ8W'XK;]8\V;&'W9B8=R5]97[>PD6,SN"
MIAC*65*P5">Z]U:5C_C3LG&_+3=WS%AS.Z7[&WG\=>NOC3DMORU5(<)'A.L]
MR[IW30UD$ HUKERLU=NW(1SN^0>!H(J=8Z>.199)?=>ZK4;^2#UAA]G?!_9_
M6?S ^974<7P Z_W5L7HK*;1S'7F=D\V\FG6MW%D:+<W7>?PYW/\ 8U,]!%D:
M/&T<L%#+-3Q:%J)S+[KW1GNM/Y>--M/NCH'O_M'Y7?)_Y+]H_&^#Y&8WKS/]
MU5.Q*<?P[Y+XW9N/S&-K(=I;&VM%-2XX[+I:G'E5CFCJ*ZO^YFJH6IHJ7W7N
MA5^4'P[V]\C\YUGV/@^U.T_COWWTS_>BDZQ[^Z3EP/\ '\?C-^BB7<&"J:/=
M&#W)MW+X+-_PW&O44E?A:A5J*.EJ:=H9X0Y]U[HNG7'\I#X[[-^/'RB^.>]]
M_P#?7>N#^77=\_R.[6[%[9WW1ONZ+>SX_:]-!N/!9K 8G!#!Y''9/:6+R^/:
MEI8TQN0!6@CIL?%2T-/[KW4.I_E3;7WQM[NS'?(CY;?+GY.[G[B^+W<?P_Q^
M^.T]Q[.P<^T]F]Z8[^';@;;N'VALS;.V)-Q5<:4[MF,M@\G6EH(X@ZTSU$$_
MNO=&;[2^&/6O;>%^'>#W#N+?%#2_"CN[K3OCK*7#5U!!)DLMU;M;<&TJ"ESI
MGQU0L^.GQ^XZV6=*1:.9JB.%HYXXUDBD]U[I-].?R_NB.C?F-\G_ )N;*?=Q
M[6^5F,V70;WP>4RM/58#$R[8HJ&BR-;MVA2CBJ,=6;K3#[?DS;/63+6S8J@E
M"1-"=7NO= %OS^4KUQNW,=P87:WR9^6'3?QT^1.]\]V/WS\3.I=Z;<V[L_<&
M9WG(L^XZBDR=1M:MWUM.GW54JT^8IMN[OQ4%542U-3&D%15U4LWNO=*/N_\
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%W7NO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>tlucid_sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlucid_sig.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5&7\S'_ (4)_P O3^61E*_KO?\
MO/*]U?(&@D6"OZ#Z..$W+N_:DTD..JXQV5F*_+8W;'7328_)Q5,=)7U7\6GI
MW$D-%)&=?OW7NJ?-J_\ "D7^:OW5TUV/\N^C_P"3)24WP\ZCV_NSL+>7:_:/
M?3;1QM;UQM+%OGLED]J;GWAMWKG';ORE+AZ.4M%M['[AEGJY(Z6G@EGTQS>Z
M]UL>_P K;^8_U/\ S4/B+M/Y5]48/)[-2MW!N#8?8/7.<RN)S6<ZX[(VG]C+
MF]KY')8>0TU9!4XG+T&6QT[Q4E158C)TD\M-3O*84]U[JQ/W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4)_S;/\ A0I\
M,?Y5(J.N\L:_Y!_*2IH):G'?'WK?,8VCEVN9\9/78?)=Q[WJDKL=UMA,G,L*
M)%'2Y7//'4)418N6FU3+[KW1ZOY7/S![(^?'P=Z3^7':/2U/T#G>Z:+<VXL1
MUU3[EJ]UQP[+I-W9W"[-W*F6K\'MZJDI]X[?QD&4IPU,H>EJHI$)21??NO=6
M!>_=>Z][]U[HDGS'_F._"'X [:7<GRV^1W774,E7CZS)8+:.3RCYGLK=M/0/
M2153;.ZRVW!E]^;H2"?(4Z2R4>/E@IS.C3/&AU#W7NM6+Y/?\+8OC/LW)9'"
M?$OXE]H=Y"DR!HX=[=L;QQ'2>UZVD6GE+YC#X/%8;LO=F1IGJPB105T6%G>)
MF=_$RB-O=>Z+#L;_ (5&?SP^^,W@]W?'/^4AA>S.GZT1^2CV-T#\N^WLWFRK
MU4TYP?9NQ<[1[7I@]&T(4' 5NAHW<ZED5(O=>ZMO^#7_  IEH.R/DCL7X7?S
M(_A?W!_+D^1W9]5@L?ULW9>-W9C=E[MK]UUHQ.SZ;,X?L?9_7^_>OSO+.)-0
MXJIEI,KB:FIBTR5\#,$'NO=;4_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ1]5V'L"@W=C>OZ[?.SZ/?F9@J*K$;)JMS86GW=E::EIFK*JHQNVYJU,S704
MU&C2R/%"RI&"Q(47]^Z]TL/?NO=>]^Z]U[W[KW4>KJZ6@I:FNKJFGHJ*BIYJ
MNLK*N:.FI:2EIHVFJ*FIJ)F2&"G@A0N[N0JJ"20![]U[K3Q_F1?\*X.EOCWW
M#_LNGP%Z<A^:?9-%FQM7.;]_CV4QG5/]\:FK_A5!M'KFFVSB\ONCMW,-EV6"
M26B-!CY)&2.CJ:UG8Q>Z]UM)?%#-?(W<GQOZ:W'\N=O]>;1^2FX-BXC.=P;2
MZII<Y1["VIN[+(^0GVO@H-R;CW?E]6W:.HAHZMY,G6QRUT,SPR&%HP/=>Z&3
M=F[=K;#VUG=Z;XW)@=G;/VOBZS-[EW5NC+T&!V[M_#8^%JBNRN:S64J*7'8S
M'4<"%Y9II$C11<D#W[KW6LG\GO\ A7'_ "I>D<9V-0]1;A['^4/8>S*@XK;N
M V!LW-;5V+OC-QY"3'UJXWM'>6.H\9%MO&M"\LF5IZ*N@JH-,E M:CJ??NO=
M;$WQU[BC^0W0O3G>\&Q=[=90=P];;.[(INO^R,=3XC?FT*;>."HL[38+=>,I
M*JM@H<U0P5JK-&)"5/Z@K75?=>Z&;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:3_P#PHO\ ^%(J?&AMU_!C
MX!;VI*KY# S87O'OK;\U+D*'I!+Z*[86Q*NU115W:\RWCR-8 \6WD)B35D2Q
MH?=>Z*5_)3_X3N=<[3ZXR/\ -%_G4G$4NW7P^3[?P72'?>16FV_A-N5-MQ5?
M='ROK=U587(Y7/)-)51[6RFM(XIA+F1+63MCJ/W7NB<?S;?YMO?/\];OS9/\
ML#^6#LO<E5\6,ANS;N&QN.Q. R.V*OO3)8/,8V3&;_[ Q\^.I)^N.A^O:^&G
MR%)29&"E6D^W3(Y%(YXZ:FH_=>ZWR_Y5G\O_ &C_ "R_A!T]\3=M9.FW+F=J
M45=N/LW>U-1-0)OKM7=M1_%=Z[CBI9)9IX<:M8R4&.25WEBQ5#2QN2R$^_=>
MZL1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)RDWCM'(;DRFS:#=.W*W>&#H
M:3)YK:E)G,94[DP^-KW:.@R&4P4-4^4Q]#6NA6&66)(Y""%)M[]U[I1^_=>Z
M][]U[KWOW7NM13_A1=_PHDH/@-B\Y\,_AMN'%9KYH;BP\2[^[ IACLWAOC#@
M,U2K/2F2DG6LH,EW1F\;.E1CL=4QO#B*2:*OJXW,M)!/[KW6L%_(._D3]M?S
M8.Y?]F]^5DV[J/X<[>["K=S[VWCNJLR=9O;Y;=BTV>DRNYMF[?SF6EFRN2V[
M69[S+O+=3R22M*\U!1RODGJJG%^Z]U]57"X7$;;PV)V[M_&4.%P.!QE!A<)A
ML72PT.,Q.(Q=+%0XW&8ZBITCIZ2AH*.!(H8D54CC0*H  ]^Z]TG^Q.Q=A]1[
M%W9V=VCO#;G7_7>Q,%D-S;RWKN[+T6!VUMG;^*@:IR&6S.7R,T%'0T5+"A+.
M[@7L!<D ^Z]U\_3^;Q_PKUWMN/,;MZ$_E:TZ;0V92.^'RORZW3B1/O+<TJ?>
M4^1;IW8V:I'H-J8,GQ&FS>8BJ,E4J7,5#0E8YY/=>ZH[_EJ?R3OYA'\[7L#,
M=Y9_=NY]L]19S/U2]C?,KO\ JMT[\R&[\WCX7Q]=!LY,YEH=T=T[IQT]!'1U
M+#)4]#1-'XJFOAD186]U[KZ$_P !_P#A/9_*[_ERXC%;DQW4^$[M[=H:K&FH
M[]^3,6WM\[DI\W45U51XK^YN"R./I>O>NI369W[*D;$8VGR=2I@CJ:NLF1)/
M?NO=+_\ FW?SJOBE_*/ZGJ'WA6X[L+Y#9G R#IWXT;4R='2[CSE2:>2#$9?>
M$T"5*]>=:4<\:_<9*>!Y9(D:.AIZJ>T7OW7NOFM]+4OS7_X4)?S;-D9'>^Y\
MO6]H=F;MVWN+?>[=D5&3VWMWX[=#=>Y'%MF\EUU'5S;D.Q,%L/%S6PD1>H>J
MW)7PO/)/75\T\ONO=?9 ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TG
M,'O':.YZW/8[;6Z=N;AR&U<BN(W108/.8S+5NV\L\*U"XO/4M!55$^'R+4[!
MQ!4+'*4(;3;GW[KW2C]^Z]UQ=TB1Y)'6..-6>21V"(B("S.[,0JJJBY)X ]^
MZ]UIT[L_X4D?([Y&_P VW9/\O;^5ST5TGWMU12=@3;([&[C[(I.QZQ\]C]LO
M"_:6_P#9>9V?NK X79W7.P(J.OC@R^0H,U%GI(X7I42.>F^Y]U[K<8]^Z]U[
MW[KW7O?NO=>]^Z]T7KY0_*SX]_##IO=/?GR:[1VUU-U;M&F>;(9_<-2YJ<C6
MF*22DV_M?!T4=5G=W;JRIB*4>+QM-55]6XM%$UC;W7NM'GY#_P#"@_\ F*_S
M7.P>TNA_Y1>UJ/XF_&WJ_;66W?W9\T>W<GC=M9;8?5>+H6J\GV3V1V!6T>:V
MC\=-I:,9D32P8],SNNOIZ;S4<T,T=120^Z]U1_\ R3O@K\E_Y@'\W#;G8O5?
M=O8N\>O_ (T]\XGN3M3YM9B+>E+F]R;/V!O*.?:TT=5N^NEW+%O[O/$X6*DH
ML3DZF>LHJ"JJ):R*:GHJB)_=>Z^N7[]U[KWOW7ND9V)V+L/J/8N[.SNT=X;<
MZ_Z[V)@LAN;>6]=W9>BP.VML[?Q4#5.0RV9R^1F@HZ&BI84)9W<"]@+D@'W7
MNOG._P Z_P#GC=M_S&>B>[\?\<MU[L^,W\M7;>1J.K<3OC);:K<?VW\_>WWJ
M(/+UO@,<^?PTF Z9QV#<9G.PO-'44.$,39B":MR%%M\^Z]T\?\)&/Y0,/<?8
MTG\SSOO;<-7UIT[N&NV]\7=OY2-Y(-V]Q8K53;A[3GHY$%/4X3JT3?:XEV\J
M2;CDDG7Q38E"_NO=;['S&^9WQU^!?16ZOD1\F^PL9L#KS;$$J0":2"?<>\,^
M:6IJL;LO8F :>"KW3O'-BE=:6B@-R%:21HH(Y94]U[KYTW\W+^:SWU\Q^O,'
MWU\K<7E>I/B]VA-4[C_EZ_RXZ7)3TF9[PP>W\C11XKY;_-6KH*B"JJ>F:&MU
M5&W,0IIAN_*HD.(08FBKMPU/NO=0_P#A,/\ R+U^<G9>/^<?RBVG62?$GI?=
M\9ZXVCF:6:EQWR'[:VM64]7X9X:B)?XYU)U_DXT_B^B]%F,K&<6[RQ4^5IA[
MKW7U"5554*H"JH"JJ@!54"P  X  ]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>ZU,OY_/_"A^F^%$^0^#OP/EA[,^?6]'QNV,IG\#BJ7>V*^/%3N=X:7
M%T$&WEI<M3[W[ZS7WD*X?;STU134#U$55D(ICX,=6^Z]T)'_  G_ /Y-/<'Q
M0J]R?S"?Y@>^=]=F?S#?D'M:JQ=?3;TWQFMVUG3/6^Y:O'9ZOVIN/(U>1JXM
MQ]E[BKZ"FERTCR5%'AHZ>.@H-!%9-5>Z]UM"^_=>Z][]U[KWOW7NO>_=>Z!/
MY'?(?J/XG='=F?(OO;=E+LKJCJ7:V0W;O#/U$<E1-'0T* 08[%8^ -5YC<&;
MKI(J/'4,"O45M;/%!$K/(H/NO=:WO\D'^>)\YOYOGRS[XIG^,/3?6OP2ZKQ<
MTU/OVFB["/:V(W#EP\>Q-G97==9NS)=?[RW1G(J2?(9"EH,/C%Q5"H#2S%H)
M*CW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:EG_  I:
M_GS'^7_U_4?#GXK;BA?YD]L[<>7=.],75TTS_&SKK+0HL><*+(\L?:N\Z2=A
M@862V.I!)DI2KB@CJ?=>ZU4?Y*_QY^(_QIH:'^;%_-$RE+F=J8G.5\OP;^*2
M4T&]^]?F!W7A<O34=5OK:75-9/%6[KVSM+=N1I*+&5]<\>(GW%,TU944\5%&
M]3[KW5PWR ^.W\]W_A2-ONAI>P>O<G_+<_ELP;E3*[0V5W#%E<)N++XO%UD\
M%!NK=O6'DPW8_;N_!)2&LH5R-)MW:L*RQ-15%P*R;W7NMJC^5[_)Z^'G\J'K
MJLVS\?MK56>[*W524T/9O?>^5H\EV?OYH!3N,<]?!!%2;7V?3U5.LM/A<:D%
M$DG[LOGJ2\[^Z]U:G[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK/_F[[H^=N
MU_@=V^?Y;VR*W>_RQW')MG9^R/X7+MM<SM'#;ESU'CMX[YP46[,KB,'+G]N[
M;DJ&H6FD=:6KDCJ3%*L#1M[KW5)7_"=/^13\C_@SV=V+\^/GCOW(Y+Y6=Q[%
MR&S*3KG^^4^^\QM/#;MS6'W/O3.=N]APYO,X_?F_L_D-OXY%@IYZRDQ_V\LK
M5=7-.GVGNO=;<OOW7NO>_=>ZUT/^%"G\[G;7\JWH1>N.J,A19KYK=YX#*P=2
MX0P09&CZMVT=>-R7=&\:>=)J(18FID,6"Q\ZO_%LHA)C>DI:LK[KW6I%_(S_
M .$\?;/\S[>Q^<'SV?=^"^*VZ-S9K>KTV9R&;PG:WROW/G*Z7,Y/-X_*HE+E
M<-UQE\O72SY#<23Q5F4D+18X^N2MI_=>Z^FYU_U_L?JC8^TNL^L]I;?V'U[L
M/;^+VILS9FU,7283;>V-MX2DBH,3A<+B:"*&DH,?04D*QQQQJ  /Z^_=>ZC=
MF]E["Z9Z\WKVQVENO"[&ZYZYVSF-X[VW?N&MBQ^%V[MK 4,V1RN5R%7,0D<%
M+2P,;"[NUE4%B ?=>Z^35_/A_GU=J?S5NS*WK#J^LW'UM\']A9J3^XO73U$V
M-RW;&2QU2#2]G=LTM--XJNLDDA6;$8>0R4V&BTN==8TDH]U[H]G_  G=_P"$
MW^1^:TFV/FM\X]NYK;?Q,HZRDS'4?5%4LN(SWR3JZ&KCF3/9SRQ"MQ/1J/"8
M]<?BJ]R$D4TD5$IGJ?=>ZW'OYLG\W_XO?R,^D>G-OU?3.?W=N;L+";NVY\<^
MB^K<=B-D;'@QW5N+V_'7#<6ZI:5L+L#96%J-T8FC(H,?ELE>M5H,?+%'/)%[
MKW6AO\A?^%2GS@^0VX=R;TSFR]A[?W'A<O3Y#XW;>QE;6Y#IOX\Y"@K:VKQ'
M:4O5&:Q];3=W_(?;K2TTF(W%O'(Y+;6#KJ..NQNV:2LM,/=>Z)A\'OY6G\R?
M^=KWGG>R,-0[TW'B-X;G&4[A^8G>M3N)]BPU3U<=!E9AO')0U%7V'NK%TE+X
MH<)AS4STZ0Q0R"CIM,B>Z]U]0?\ E0?RBOC)_*2Z/J>M.E*6JWAV3O1J#)=T
M]];KH,?#OSM#.4,<OV=(5HU:+;&P=NO4S+A<#3R20422R2S2U==/55M1[KW5
MJGOW7NO>_=>Z:L[G<)M?"9?<NY<OC-O[=V_C*[-9W.YJNIL9A\-A\932UN2R
MF4R5;+#1T&/H*.%Y9II76..-2S$ $^_=>ZTBN\O^%0GR9^1G\QOJ'XG_ ,G_
M ./N)^0W66&['I<1OS-9S;^4RF=^0>#H\O24F[\CLVLCKL30].]68+#FIFBW
M/E/*6?Q5M0M/1QM35?NO=;Q*DE02I4D E6TZE)%RITEEN/\  D>_=>Z[]^Z]
MU0M_PH8K?YGN0^%6/ZU_E>;$WKN/L/M+>-9MSN3=_6N4PN)[%V+T[2;5S62R
MJ[+R&3S^"K\/F=V96&GH6R&.,V0@IO+%3B.>HBFC]U[K0L_DY_SL-F_R5MN?
M(9I?BMV1W[\G>\]XXG$]F3;X[>/3FT-B;?ZVGSJXC!' ML+L?<NY]]/N7<>7
MERM3D(\3)3F:.G1+PS25/NO=6%]I_P#"V;YS9V-8>F_B=\6^MPTP,]3OVL[2
M[8K13""$>.C;#[MZIHH*AJM)&,DM/4)X7"",.OE;W7NB =\?\*B/YPGRVV#N
M[X^P;JZVV90=U8,]8U>/Z%ZDJ<5V!E:?==8,95X79^9K<YN_=%#G=U4E:<2#
M0,*LQ3VI3%4LLP]U[HF'PHZG_G9?#CM:K[J^%'Q3^<.Q>U*K:F;V'4[JVK\,
M-_\ 8-7_ '8S-7A<KF\2F.W7U!O'$4S5%1AZ-WFCIDJ41=(D5)'5_=>ZV-NK
M>Q/^%NE=E<7E<5MWLW+4HKZ.:IP7:6P?@-M7%9:GHL@AFQ>4&],7M+,8N@R/
MC,4TM+54%5]NY>*>/TR+[KW6WM_+(["_FW[MV=6X_P#FE?'OXY]6;D@PM-DM
MO[OZ0[1&:S.2R53+1RS;6WKUOCWWGM7$U^,I*V1),KB=UU='-443HE((WBJ)
M/=>ZM3]^Z]T0W^8O_,7^./\ +'^..XOD7\B]Q?;T5/YL1U]U]B)J5]]]N;[>
MEEJ,7L?8^+J)4^XK:C1Y*NKDTT>+HU>IJ72-.?=>Z^;GMJ@^?7_"G_YG;N[>
M[_[&7I+X9=%+7;D[%WGD<C)COCU\1>G*8U.7J<!M./+2X[![C[7S6#IG:IR5
M9:OK_%]U7RP8VEIZ>#W7NC5)@-U?S6-Z8;^37_(YZVR'07\K_J_<E%E/DW\I
MLI@LC!4=ZYC%RTM-D>ZOD%NZ"FP^3WI-7KCD79^SY9X<AG)*>"66.AQ]&HPO
MNO=;^O\ +Z_E]?''^6I\<=K?&SXV;6_A6W\5IRV\MY99:6IWWVOONII:>GS7
M8786:IZ>F_BNX,K]LB1QHD='CJ..&CHX8*2"&%/=>Z._[]U[H*^[>[^I?CAU
M=O#NKO/?^VNL.K-A8MLONS>N[,A%C<-B:,21P0J\LEY*FMKJN:."FIH5DJ*J
MHD2*)'D=5/NO=:"7=/R5^2W_  J$^1V]NM=H[GW!\2_Y)GQ+R\O87?W;&36'
M#5NX]N;3I*K-)N'>516&;&YCL/-8S$U%5@,"Z5.+VG2,<ID8JNIA@CF]U[JB
M./;&4_G:?S-^@OAG\3]L93J/XC;+K8NEOC?L9)<SEZ#I#XJ;"J*O.[[[>W2U
M7!6/4]E[]QM'6;DSM?D2]3D]QY"EQTU9*L=*X]U[KZ5ORK^97P2_D.?!WKO"
M[GF@VOL+JW8F*ZT^/?0VV<A2U_9W:$VU,?18^#%;<I,M6BMRM5Y)TK,]GZ^4
MQ12U#U-9.]1.JS>Z]UJ!?(?L7?>Z=I8S^>-_/*HES"92I8_RLOY11RLN+VEG
MY] K-J;Y[+VKEZB*OCZ]Q,E939?<%=4T<F5SL"Q/5J*63%81_=>ZK5_E@_R_
M_E)_PHP_F![\^1?RESVZ).B,#N6@W#\C>V*&)\/AUI8#2MM+XV]-)*\]/A:I
M]NHE-24M(LT&VL! *BH83S425ONO=?5AZVZWV%T]L#9O5?5NTL%L/KGKW;F)
MVCLG9NV:"'&8';6V\'1Q4&*Q&+H8 (X*6DI854?5F-V8LQ)/NO=+;W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]UIO?\*)/^%%L7Q*3</P5^!FYH-P?+G.+_=_
MM'M7;GBS--\?8LD%@_NMM80I5097N_)).$"!9$V^KAG5JYHXX?=>Z=O^$ZW_
M  G[RGQ6J:#^87\]*"7=OS-[!@KMT;!V-O&1-S5W1T>[V;(Y/>N[LGE37U63
M[]W0E9(U55>5I<+%4S0^1ZN:H:/W7NMPOW[KW7O?NO=5K_S*OYCU+_+5ZE;N
M[=GQ1^3??W6&+HJFOWOOGH?&=69?;?6%-#645!3S=@P;K[0VOO7&TE?49"-E
MK:+"9#&T\*2O55-.55']U[K4Y[/_ .%Q.-ARD])TQ_+QKLCA46,TV?[/^1%/
MALI4.64RQS[1VIU/G:2C5$5@KKFYRY8$JNFS^Z]U7]V1_P +3/YE6XJ]_P#1
MMT3\0.ML)X(EC@R.T>U-^;A6ITK]Q-+FJOM? X:2!W7]J-<2C1JQ#/(;$>Z]
MU5[\QOYP7\V+^<UMG#_'+>T>3[+VGM[.UO9\W3/QHZ:RJ-F)\=X:#'9C=>*V
ME!N7=.>P&RFR92B%5,]+!45BRS^6H%-)%[KW0L_R^&_X4F?$O:^9Z?\ @7T%
M\W^J-F=B;KJ-^9ZG3X:++MK*;G&UZ*C_ (MD^P.XNFLCC,0LVW=O014T,F4I
MJ:60*L$;5$]I/=>ZNDZU^6W_  K\Z0["Z]Q7=^<Z0HJ;LC)5.WMG[0^9^[?Y
M>'4F(W%7QM39/+Y/#0X??74?<F[*G:^%I9ZJIH\+49">.@%1(M%*\:%/=>ZW
MG/B-O+Y.;\Z/VQN+Y=]7=5=2=UU-QF]N]+]FUO:W7F1Q[T=#58_<6$W!D-OX
M&JQRY(U,BOCB^32F,-TKZM'63W[KW1F/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U2
M'_/-_G#]??RF/B]7Y[%UNWMQ_*OM;&YC!_''J_)EJY9\S%$E-6]E;OQ-)/3U
M8Z^V++5QS5 :6F_B=7XZ&*57D>2+W7NOG&?RH/Y>_P @/YZW\PS.UG:N\MRY
M_:2[H3N[YG=Z9MY:O,28#-9V6IJ<!CZN$TE-!OKM&MII\9A88_'!C::.HJXX
M'IL:U.WNO=?7&ZQ^./0?3&&VE@>J^F^M=BX_8NV=N;/VFVW-F8#'9##;;VEA
M8]N;<Q=/EH*!<HT.)PD0IHB\S.(B02=37]U[I<]@=@;'ZHV/NWLSLS=NW]A]
M>[#V_E-U[SWGNO*4F$VWMC;>$I):_+9K-9:OEAI*#'T%)"TDDDC  #^OOW7N
MJ/OY>O\ PH!^/G\S?YK=G?%GXN=(]V;BZOZWZ^K=ZR_*;,8@87861J:++P8N
MGH,AM.OHX-Q;/QVZ!4ZL'-E)*?)9"2GJ4?'4ZP-(?=>Z-!_-@_FS?'+^5'\?
M<UV7VIG</G^X-P;?SYZ$Z#@R\=)N_MS=V/BAIZ6(10PUM;@MB8O*Y"E_C><>
MGDAH*9R(TGJG@IIO=>Z!?^1M\Y_Y@O\ ,-^.&9^27S3^-G4GQ]V+O#(4-5\<
MJ[8$V^\/G>T-FRS9:6NWED=B;WR^ZZO$;/DIFH(L-ECE$;<#)4UD-%#0/13U
M'NO=8/YK_P#/P^%'\J.B_NAOS*UO='R3R= U9@?CEU?DL14;HQ<,M)!5X[,=
MJYRIGDQW5>V\C'60M3O61U&5KXI/+0X^KACFDB]U[J@_?ORV_P"%#7S(Z?S?
MS*[6[XZ%_D:_R^\/05>:CW%OO&4P[3W%MO)XVB&VGPF-W/MG<W:>[]T9K*A*
M?#T\$FQSF):]OLJ:L<4D9]U[HMO_  E,^;_\V/Y6?.K?6#[2^1'>'?\ \3<'
MU]OC=O>%9WAN'</9.%VSO'-QX^DZXQNP]W;HDR-;LO<M?N&$24V#H:N#%MA8
M,G(M$'5)4]U[K;[_ )K/\V7XV_RFOC_4=N=SU<V[.P-QS?P/ISHK;%;1IOOM
M#=,\=2\943F2/:^Q<+'2R5&8S]8GVM'#%X8$J\C/14%5[KW5>W\AC^;!_,4_
MFPU7;/<'=GQ4Z0Z7^'>!KLE@^LNRMJY+L2CWANS>=//CT?9V&HMS9//8OL+'
M[7I_N3F]Q01X&BAJY*>CIZ:>=*T4ONO=;*'OW7NM5G^;I_PJ9^+/P#S6;Z-^
M,>(P/R]^36'KLKA-V08G<_V72O3^9Q4K459CM\[RPT-?4;NW?C\HKP5&W\*R
M/2R4]1%75^/J(TAF]U[K6%^7GS?_ .%++]*P_/#Y.?)C<OP9ZAKMR;2SO1_5
MT6XMM?'C<?:F6;,055#M/K#HC;=%D.W]_8#$TT*Y#+)OE),35X:0M5U%53R>
M,^Z]T=_^4-_*"^0O\ZCY)9/^;Y_-P;(9[I_>.?I-S]9=59;'28"E[Z3"E(-L
MTU-MM2G]UOC%L^EI8Z:AI%_>W1XB6DEIGJ:FO]U[KZ#U;7;1Z\VI-79&LVYL
M;8VS<'KJ*RMJ,9MG:FU-MX2C"AYJB=Z+$8/!XC'TX%V,5/3PI_95>/=>Z)Y\
M-/Y@G1GSVR7=.0^-='OK>'3W3VX\1LF@^1%;MB;!]-]R[S>KW71[UQ'2.<R4
M\&5W]B>MY]O4J9+-1446&JI,K3C'U-8JS/'[KW6E'_PL4_FG97<F_MO?RM.H
MMP-3[0V/#MCL[Y53X^8@[BWMD::BW-U7U?634U;IDQ.TL-4TVX\A330LDV1K
M,8ZLDE P;W7NJL/^$V_\E _S.._*[O#O7#3-\+OCON3'IO:F,Y@_TQ]H4L>*
MW!BNFX-,,DAVY'B*R"NW/*KPS)CJFGIH6$E;YJ?W7NOJ_P"&PV)V[B,5M_ 8
MR@PF"P6-H<-A<-BJ2#'XO$8G&4L5%C<9C:"ECBI:*@H*.!(H88U6..- J@
M>_=>Z+?\M_A9\6_G9U7-TO\ +/IC:7='7K5QRV/QFXXJZDRNV\Y]E5XU=Q;-
MW7@JW%;KV9N*/'U\T"U^*K:2J\,SQERCLI]U[JK[I?\ X3/?R6^D=V0[SP_P
MXPF_LQ2-(:.D[HWYV/V]M.G21H6,<VP=\[JR^Q,LJF'TM7XVK=0S -9B/?NO
M=&Z^??\ ,L^$/\I/I#&;I[[W5A-F0?P:OI.G^@^N\?A6[&[#_@,4$1P?6G7U
M+48FDIL/CIJNG@J,A4-0X3&&HB%34PF2,/[KW6E[N/\ G7_S\?YQV[-Y4_\
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M9(] ]<9MZ6OH>J\/4 M2)O+)4]-3U&Z*VG'IJR<;!++2TK5%9[KW0Z?S=_\
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MXQAP'FDV_05<DC@9.:*EK8?=>ZW+D1(D2.-%CCC54CC10B(B *J(J@*JJHL
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M?RF8LGL_L3N1_EE_.?[>Q$6;[R[<GWGE=^;>^"F,W#01S0T^T]X962;/;O\
MEQNO$5<3)N>MJ/N]H4*15N+CIJRHH<@WNO=5_P#\N'X6[2^2O;U%4?('Y<=2
M_ [X]XC;C[AW[VYVWV)@M@[WWQUGN6;>^P\_@_CQLC.9/%9ONG*;CJ=LYG;V
M1.,CJ\5BQYTR/D8I05?NO=;!'<__  H!^)'\OKH6L^"G_"?/H^MVM19J1Z/=
M_P T.S=LU=5V'O\ W1E:."F;=^SMJ;KHWW?NS>%1+5F&DK]UTE#28=H?M,?@
M!2"F>/W7NA*_D[_\)I?D9\S^V*'YU?S<(]\XKKO<N8@[#CZ@[,R6=_TZ?(7-
M5DDU1'D.VGR,\&X^O]CNT,#O2U+1YG*4S"%8Z*G"RR^Z]U9K_P +/,ANKKW^
M7'\4NL^NJ3^Z'2V3^2^'V[NC![6C.!V\L6SNJ=Y5G6>RIL9BOM<<VVZ9*.MK
M:?'M&::.IQ%-,B!Z:)D]U[K7*^!W_"C+>?\ +F_EO;&^$?PG^+.VJ;Y-9_?G
M8>Z>R/D+O2L&Z<7N3=V^=X20;6RFV>IL%B:"NW/O&CZ[@PN!IY<KE):>GDP\
M/^1UL4HAB]U[JR[^7S_PGF^;/\S;LE_G_P#SN-[]Q5FV\MAZ7.;7Z6WAN#)8
M[OOMO$QMD,YC=LYREI_LY/CKU:D]>_VN#Q]/198M5S+!28D:*B;W7NJ,_P"3
M1\F_@=M;^:Q)\R/YC^7Q'6'4W7F+WUW%U#M+#]<;T[#V/A^Y\;F=NX[I/K;;
MVR]E;4WC7X/:?56UZ^IGVHK4]+C<)-MK%QK-3K#"OOW7NKQ?FI_PHM^>_P#-
MF[B7X'_R7^K>R.NMN[Z.;P==V1CH(*7O[>VUV9<7DMS#/T]3+A?CGUY24M7Y
M:C*+5C,PF:!AD*&4FFD]U[K30^4G2'87QK^1O=O0/;67Q^>[1Z@[+W;L'L3,
MXFIW'7XS);UV[EZFAW-5T&5W9A-NYW.4DN8CF,>0DI$BR"VJ8'FIY8II/=>Z
MW&?Y1'P!^<?\X;HGXS=2?)'#U/Q1_DN_&_";7KJ+J7K*CR77>2^<?9.'>&OW
M%NS-UIKVW/NM-Y;TCJLQG-TU!BQU U7]GMZ(5PEK\;[KW6KW\=>\^\.J?YA5
M?VS\$^F7Q_?.2[.[>Q_QIZR_T;5.]]S]39GL)]V;?P$.TNLGFRN(K=\]:[9S
MLT&/@RU+F<;CJFG^XEIY7IHY8_=>ZWN_Y5O_  G#W_O'LS&?S"/YVN\,Y\F?
ME'N"HBW5@.A>Q=SCL3:NR*J:<97$S=N5LTU?A]V9C;U142"CVMCY&VCB%;QF
M.K"QQT_NO=:RG\[3>F:^'?\ PI4W_P#(7?.P<CN?!]4_)3XA_)'!;3K]>(Q_
M9'7W7VT>D]VT.#P.6KZ"NQ[X2OCVC48'[B*&II:.II9Z=HR]-)"ONO=60]V_
M\*:?YJW\U'?@^)/\I[XQ9;I//;T7+4Z97964@[1[\GVJF0QV/7<M1OS,X;:?
M6_16#$56J9+*2P.,3-71+#FX9$CJ)?=>ZON_DV?\)P>O?A'N>#Y=_-K==-\L
M/GAN$Q;@DW%N6KR.[]B]/;BKU>HRV0VM7;I63,[^['GFG\=1NK*H)8Q&!004
MI::>I]U[K8%^5/RIZ*^%G16_/D=\CM^8SKSJKKS&-7YG,U[>6MR-;+>+$[9V
MSB8C]]N+=NXJ[338['4RO4550X50 &9?=>Z^6]\R?E]_,(_X4[?.[:O2OQ^Z
M\W-3=18#/5,?3'2\536)U]TYLZ:?^'Y7O;Y"[KQU/68:BST^.?5D<I,LJ4B2
M)B,/%4U$Z1U_NO=?1._E%?RFNB_Y2?QJI>G>M9VWKV?N^6@W)WSW9DZ):/-]
MF[XBHEI[4%"9JK^[&P=N(ST^$PT<LBTL#/-/)45U15U4_NO=5Q?\*YNW.R.K
M_P"3UNW"=?TN0..[H[YZ@ZC[.S.,R%1CJC;O6]4NZ>P:VJFEI;25&/W#NKKW
M$8&JIRR1U%-F)(Y-4;-&_NO=:K__  F6_D0T?SXW['\T?EALVIK/AWU/N<TF
MQ=D9VC>#$_)#L[;]1#-58^LIZN"V>Z>V16*(\UH!H\QDU.*:22.GRE.ONO=;
M3'_"LCYEYKXI?RL<OU1L&LJ,)N[Y@;UQWQ\^\Q;4U-)BNJAA\AN?M>&.-[@T
M.Y-L8:/;51&D9_R+.RV,;!&]^Z]U6)_PCA_EA[9P_7&ZOYHO9^$I\GO3>64W
M=U)\9UK%6HBVOLS!5;;?[0[!Q\99HX<_N?<M)5[>AF*B>EH<=6HC>.OD!]U[
MK3Z_F_\ SZ[%_F-?/3O+OO>==FH=J4>[<SL+IC9>6@KL:.O^HMGY6LQ6T<%_
M \A3T=7A\UD:>%LEF$FACJ&R]94>0+943W7NMJ3HOX*_,3^8'\8=W_/S^:!U
MI7=4_ GX-_%[LSL3X$_RP>L,)E-F;6WA#U9U%N#.[+S^5Z^&7CW!)@(\?B8:
M>DDS-2NX-XU;V=J3!MX<K[KW6J9_*U[7^?/7/R SNVOY:.S<IGOE=W-L"OZM
MV_NC:6SJ/=W8>Q-EY3/8#,;RR.SJG<DE1L780R\>&I:/);ERE(9,5CY)/MJR
M@::29O=>Z^AA_)T_X3C;0^)F[:#YH?S!-U-\M?GUGIZ7=)RF]<WD.Q-E]/[H
M)$RYG%Y?=7W.5['[3I%6)7W)DS*E#+ IQL<3I]W+[KW5WW\R[NO?WQO_ )>_
MS2[YZKTQ]D=2_&?N+?.R*UZ=ZN/$;FP.R,Q68G<$M*JL*F';M6BU[HUHV6G(
M<JFIA[KW7R$?Y:/\P3 ? CYAR_,[L[X_8_Y@]BX;;N]*[K^C[&[&K]O1;;[O
MW;D\940=W;BRM5M/?60WOFL1C7RZ+32_9U+Y#*)7K715%(GD]U[J[JIV7_.G
M_P"%"FV=_?*[Y?[LWQU)_+OZ.V=O3MS)8;8FR=P[:Z[SV&Z]VC/NW(;9^,W2
M%/-D=Q]]=B9O^#&&ASF;J\Q3XVHJ9D&2+1QXR7W7NJT?Y-_\I3<G\XWYA;DV
M/M*FR'3GQ?ZR6CW?WAO#'Y@9[/["V7G*C)T6R-E[:R>;QE73[C[-WO58>H6"
M>IHZ>@$5%D*TP1I!%0R>Z]UL:?\ "@C_ (3&;!ZTZ3P_RQ_EE]=5.#QG1G7>
M-P7>OQWQ=5D,]7[HV1LZ@J6E[SVED<Q7UV>S?8.,Q\8_O/0/)/)FJ6,5],$K
M8*J/(^Z]U</_ ,)O/YQOQ<^;'Q[VO\93M#ISXV?+?JG;]/C-Q],]<;0VKU9L
M?MC;^#I)(:7LSI_:NWJ;'8N:-,32+_',131^;#U0>1(Q0RT[CW7NCX?\*%/]
M(W_#,'\P+_19]O\ WF_T+TO\3^Y^X\?^CG^_FSO],.G[;]S[C_1'_'/%?]OR
MZ?)Z-7OW7NM'C_A/3_/6^!O\H;XV]];-[PZ%[^WO\@>WNY8MT_W[Z=VAU3D\
M3D^JL!LC:^)V/LG<6X]Y=I[(W'1S;:W=/NBOC@BH*VD5<QK5Q(\H7W7NK/-S
M?\*;/YG'\S+?F5^.7\F?X(Y/;&:R$J8RI[FWI%!VONG9&'S6-RL=#O'<L4N,
MQ/1G2;P5E)+)2S[EKMQX^HDHO$BSRS" >Z]T W\PC^1YV-\2/Y;?S'_F;_S)
M^\L]\X_GUD-L[,VO@J?,;CW'F.J>CG[J[.VKU7D<Y3Y'*M3Y+>^:V/3]D5D^
MW84I<-MS!9#[;[3'-X(9A[KW11/^$XO\R;^5K_*JZ*^5?R.^2V9W1F_FWN[<
M(V#UEUGM+K#<NY-V9+H_"[<V]N2"DVAV!-@:;KG:$>_^R:NHAS461W!1RNFW
M\?,T#K'$7]U[H5]R?)G^<C_PJB[@SO2G1%#)\8?@+M_<V.I=^4^,K\S0=8;<
MQ.A78]R[_HJ>AS?>?8$V+K6K*?:=(*?%>3[61Z.FT#)^_=>ZLY_F3?$RJ_X3
M??"WX9?(G^6QA<G79CI_Y2[:K_F!OW<,$[U_R.QFX.MMY;0PU)WK782OHJR+
MJ\Y?-U]!B,'"6Q6%RF=AJ:<+D%CJ)?=>ZK-^8G_"S3Y*]^?'S=74'Q^^*^VO
MBUO[?&#J=M9[NH=TY'M?.X3$92BDHLU4]=;?;J[KJFVEN2IBE9:7(5=7EVH5
M8M%'YQ'/'[KW1#OY1?\ PFC^8G\QO([>[2[AQNX?BK\1Y*G%9&?L;>>WY:7L
M3M/!R5325U%TOL?+K3U,\5900%(]QY6*+"PM41S4R90QS4P]U[KZ>'PL^"_Q
M>_E\]+XOH?XJ=6X7K;9%)+'D<W5TZ_?;MWYN44D%%5;P["W75*V7W=NBM@ID
M0U%2Y2"!$IZ=(*:**%/=>Z-Q[]U[KY.7\NW^4AVW_/$[4^1WS ^:'S?V/T*F
M+[XRV"[TJNQ:NCRWR SN\J&APVX-SXB@V%NK<>TZ7KG:6"V]D8</B:ZNEEH,
M4U"]%38Z6'&24Z^Z]U8Q\FOC3_PDY_ED]=5N#W/G=_?S./D-C(L_1T?7^Q/D
MIN.NER6YJ:JCI7H-];W^.V7ZWZPZQQ> K:D1212S5692*"4"CKYXG0^Z]U0[
MT5_+J^:7\ZGY&;JWM\-?ACL3H;IG-YQJ&CK]MX?-=>_%;I?!4$-1%28>N[(S
M5-G,UO7<2?:LV0:E&9SE56SLR4=/2"&GIO=>Z^@A_+Q_X3!_RXOB!TVNV^_.
MIMA_,[NK<JXRMW[V=W%M*GRV!I*Z@BJ@F&ZQV3DJC(8_9>VX):Z77)>;)9$A
M&JYW6*GB@]U[H_O_  R+_*)_[UT?$O\ ]$_M?_ZD]^Z]T!?8/_";_P#DH]DT
M,-%FO@?U_A/MIJBHIJSK[>W;_6==%/4Q^-GFGV!V)MT9&&(<QP5:U%/&W*Q@
M^_=>Z(AW+_PCP_E)=BT97KE_DA\?LC',TT-1L'MN/=V.D!6H"TM?C^X-N=B5
M<]&AF4V@JZ6<F)?W;%]?NO=7,?RROA3V+_+V^.E#\4MP]X8OOOJ[K7(/3=$;
MHJ>MZ;KKL3;^PJYZBJ?8_8IQ&X,UMS>M=MRN>U!FZ6#&35-'*(:BEUTZSS>Z
M]T%O;'\C'^55WM\H<Y\P^X_B'LOL?O'<];2Y7<N0W3N/?^0V)N7-4F*3")FM
MR]1_WLCZKW)D)L9$B3??X>IBFE19W1JA1,/=>ZM3PF#PFV</C-O;;P^+V_@,
M+14^-P^#PF/I,3A\3CJ2-8:6@QF,H(:>BH**FB4+'%$B(B@  #W[KW1*?F__
M "TOA#_,;VWMS;/S%Z#VWVXFS):V79FXGR>Y=H;YVB,G)1S92EV]OS8V:VWN
M['8O+2XZG:KH5K#0U;01F:%RBD>Z]T'/Q/\ Y./\LGX1Y#$Y_P"./PZZDVAO
M/!QS+B^QMQ4&3[/[,H):J4SU=3C^P^T<IO+=^+GJ)&(/VE9 D<5HHU2%5C'N
MO=68>_=>Z26_-A;([2V7NGKCLK:6W-^]?[XP62VQO'9>[\/0;@VQNC;N8I9*
M+*X3.X3*05./RF,R%)*T<L,T;HZFQ'OW7NJT.E/Y&W\I;X\]FOW#U/\ !CIG
M!]AKFUW'CLWG(=S[_I=MYJ- L%?LO;O8>X]U;8V-)2%0T"X>CH4@D]<:J_J]
M^Z]T??OSX\])?*3J;=/17R$ZSVKVSU'O6FHZ;<NQ=W4'WN&KQC:ZFRF*JHO$
M\%7C<GB,G10U-'5TLL%525$22PR(ZJP]U[H,/B5\$?A_\$]ER[!^)'Q]Z\Z0
MV_6)1IF)]K8R>JW3N8T%/%2T<^\=^9^JS&^MZ5=/#"-,^6R59-J+-JU,Q/NO
M=3_EM\)OBI\[NM$ZA^6_26S^[=A4^0DR^+QFY5R=#E-NYB6AJ<9)FMH[MVYD
M<)N_9V:?'UDL)K,77T=3XW*Z[>_=>Z;?BG\#/AQ\'L!7[;^)WQSZPZ/H<N*<
M9RNV?@$&YMPBDC$=*-R;SRLN2W?N,4RCT??5U1H)8BQ9B?=>Z-O[]U[KWOW7
MNO>_=>ZI[_FJ?R2/AM_-JP&WI^\:'<VP>WMDT?\ #=D]Z]8SXJ@WWB\(U6U;
M-M;.09G&Y7"[LVI-42R.M+5P>6EDE=Z6>G9Y"_NO=:\W7_\ PA]Z#QNX\U5=
MI_/KM_>6T9Z]9-NX3K_I;9G6FX\7BQ/7L]'FMT[BWIVQC,_7M324J"I@P^-C
M#PROX")D2#W7NMDSX!?R7?Y=O\M<1Y?XT]#XN/LUJ2:CKN\>QZM^P^Y*R"JI
MJ6EKX*/=^:B\>T:#)QT:&IHMOTN(Q\S@LT!))/NO=6H^_=>ZJSP/\D_^5GMW
MY/;J^8=%\,NIZSOK=V[*??U?N'/4^:W+M?%[]@KERS[XVKUCG\QDNLMH[NJL
MW&F0DR&-Q%-5?Q%35JZU+R2O[KW5G>7Q&+W!B<I@<YCZ/+X7-XZMQ&8Q61IX
MJO'Y/%Y*FEH\ACZZDG5X:JCK:29XY8W!5T8@@@^_=>ZU6/YL/S(^"?\ PG0^
M,^<V)\$/CWT=UC\Q/DI05\/7NUMC;;P5)D\!B)&JZ6H[H[3JI6J-S9;9NUJV
MGDAP6.J)9*?(9A!!$J4T%9)#[KW6N7_(#_D2[^_FD]H9#^87\_ZK=V>^.+[\
MR6Y:?'[SJ\Q)O'Y<=BID#7YK(Y7-5Y6NFZKH\N[)E:^.4R9>K22A@9%CJ9(_
M=>ZWR/FE_*,_E\_/[8O6G7OR3^/&W,[A.F*7^&]2U6R<CG.KLWUY@S2QT4NU
M]M97KS);<GI]GST\$6O#R^7&>2"&40":&*1/=>Z3GPU_DM_RR/@3E:;=/QM^
M)VP=O]@TDT]32]H[UGSW:_9F/J:J"EI:B7 ;S[-RVZ\OM".:GHT5H,,^.IN9
M&\>J:9I/=>ZM']^Z]T$G>70O2_R8ZSW#TU\@>L-E]P=6;K6B_O!L7?V"HMP[
M>R,N-K8,EBZQJ*NCD%/D<5DJ6*HI*J(QU%+41K)$Z.H8>Z]T2OXL?R<?Y8WP
MKW>O8/QL^''5.P=_0U%?58_?.27<G8N\L'+DY6EK!MG=':&X-Z9S:T+ZBBQ8
MZ>ECBA_:15C]'OW7NK+_ '[KW6I/\H/^$??P+^1OR6[&[^Q/=O?W3&![6W?F
M=^;LZGV)_<;)8'';HW+5-D]R3;(SF[=OYK);=Q&7SD]16BAJ8\C#1R5+0TO@
MI$@IXO=>ZOT^"O\ +A^'7\M_K23K#XE=/87KV@R31S[MW=5RS[B[)W_71O++
M'6[XW[F&J=P9T4\D[FFI3+'CZ!7*4E/!&='OW7N@@[D_DN?RO_D+\G*GY?\
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MEGWQM7K'/YC)=9;1W=59N-,A)D,;B*:J_B*FK5UJ7DE?W7NK.\OB,7N#$Y3
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D[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>toruka_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 toruka_logo.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MLOE\[73. LN2KJO)5+R.=*JC5$LTA)+6 '^L/<C06MI91Z+:WCBB X(H4?R
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M[-]JV+=-ZD*;?;%E'Q.<(OVL<5^0J?ET%^9><N7.4H%FWS<5C=A6.):M(_\
MI46II\S11YGHK&8^;>*BE9,!L'(5L'JT5&8SE-BY0;C26HJ*@RZ-<7N!.+?U
M/L=V_MC<,H-WNR*WI&A8?M9D_P '4+7_ -XJQ1RNU\L2R1^37$RQG_>424'_
M 'KH*MY?+[?^X:&;';>QV-V?%4(8YJZCFGR.9564*PI*Z=:>GI"P+>M8/*MP
M4=2+D^VWV[VFSE6:\F>Y8&H1@%3\U%2?LK3U!Z!7,'OQS/NML]KM5I#8(XHT
MB$R2C_2N0JKYY"ZAY$$5Z SK_KW=/:>Y4PV"AEJ)I9149;+U7E>CQE/*[--7
MY*ILQU.0VE;F29_2H)O[%.[[O8[%9&YNF 4"D<:TJQ'!5'^H <>HVY6Y5WKG
M7>%L-N1F=FUW%P]2L:DY>1O4YH.+' \^K>]C;.P?6NT,=MK&.L6/Q%-)+5U]
M24B>KJ6U3Y#*5LA;0C32:G-VTQ1@(+*HMCQNFXW6];C->SBLTC45%S0<%5?L
M&/F<\3UG?RYL&W<H[%:;19'3:0(2\CT!9OB>1SP!8U)\@,# '0*;U^6/6FUJ
MB:@P_P!_O*OA+([X80Q8=)%^L;9>J=5G!XL]-%41GGU7%O8FVSD#>[]%EN-%
MM"<CQ:EZ?Z0</L8@]1WS%[W\G[++):V)EO[E<$V]!$#Z>*Q ;[4#CY] S6?-
MW).)10=>4-.Q6T+5FXZBL"-_JI4AP]"9%/\ J0R'_'V)8_;&$:?&WAB//3&!
M^RKMU'\_WB[M@_TW*D:FG:7N"U/M B2OV5'V]%B['[<WMVE5Q3[GR"?94KM)
M087'QM2X>A=E*-+%3-)+)-4%21Y9GEE )4,%-O8XV;E[;-BC9;&$^*PH\KY=
MOD3@ ?( #\^H<YMY[YBYTGCDWBZ'TR&L5O$"L2'A4+4DM3\3$GB 0,=&F^,7
M059'68_LS>=&U-'36JMIX6JB*U$E1P8,_6PR &&* 7:D1AK=[3>E5C+@/GCF
MR-HYMDVV343VW$JG%/.-3YD_B/IV^9I-/LY[8SQSVO.',%N4"]]C;N*-J\IG
M!X ?@!R31\46N+YJ[GI)JK9NSZ>:.2KH4R&=R<:D,].*L04>+1R+Z'E2&H8J
M;'3H:UF!-O;.QD5-RW%U(C;3$A]:5+?LJ/Y]4^\-O,#R[!L,3@SQZ[F8#BNJ
MB1@^A-'-/2A\QTX?"3#SK3[_ -P2(!3338/#TLM@2\]*F0K:]+VNHCCJZ8\'
MG5S]![:]SKE2^TV@/> \C#Y'2J_X&Z4_=UL)5AYGW1E_19H;=#_24.[C\@Z?
MM^76'YMX>4_W!W B7A7^-X>I?U>B5OL*VA3]17]Q$J#] ?1]3^+>V-RO^[:T
M)[NR11\NY6_9CJGWBMO<KRQNBK^D#-;N?0G0Z#TR _[//RQ_"C<E(DF]=I3.
MB5E0,=GZ%2P#U$, EH,B #:_V[2TY%KDAR?Q[W[F64A&V;@H)C&J%_D31E_;
MW?LZI]WC=X%/,.Q.P%PVBZC'FP%4D_WFJ?M/IT>W*9.APN-R&7R50E+C\71U
M-?75,ALD%+20O//*Q_HD:$_X^XK@@EN9HK>%"TSL$51YDF@'[>LE;R[M]OM+
MF^NY0EK#&TLCG@%4$DG[ .J.\E4U>ZMRU]9!3M)7[CSM54PTL>DL]7F*^26.
MG3]*ZFFJ H^@O[RAA2.PLHHW>D4,04L?1%I7]@ZYQWDT^][S=7$,1-S>73.L
M8XEI7)"CRK5J=7?8O%Q8_"8["D(\-#BJ/%E5NL;14U)'2$+8(0C(G' X]XP3
MSM-<S7-3J:0O^9->NC-G9I:[?:V! ,<<*PT'"BJ%^6*#JD*NI:_:6YZNC<>/
M)[9SL].PE0C36X>O:/UQW!L)Z?D7]Y/1/%N-C'(,P3Q X_A=?\QZYSW,-SL.
M]3P'%Y9W17(_'$],C[5ZN#SN$VUW=UI%3S-JQ.ZL3197&UD6F2HQ=9)"M11U
M4=PNFJH*ABDJ'22 \;6!8>\=K6YO>6-[9U'^,02-&ZG@P!H0?DPR#]A'6>FY
M;=L_N)RBL,AK87L"30R#XHV(U(P]&0X(^U3Q/53.]]C;KZMW.^'S<$^/KZ.=
M:K%Y6D::.FKHH90]-E,16J(V90Z@@J5DAD&E@KJ0)_VO=+#?;$7%JP>)AIDC
M:E5)&5=?]0(R*CK!WF/EO>^2]X-CN,;17,;:X)XZA7 -5DB?' TX94X-".AY
MV=\O^P<!1PT&X<=C-X14\8CBK:IYL;F'"KI055;3+-2U6@ >IJ?RN;EW8F_L
M*;C[=[1=R-+9S26[$U*K1D_)30C]M/0=29L'OSS1M=NEKNMI#?HHHLCDQRGT
MU.H96^W1J/F2>A5PWS:Q4LR1[@V%D*&"ZB2JP^;I\I+8L=3+15E!B5&E;6'G
M-S?Z>R&Y]LKA5)L]U1W\ED0J/]Z#/_@Z&NW_ 'B;&20+NO+,L47F]O*LA_WA
MTB_X]T:?8?:.R.R:1ZG:>;@K9H%#5F,F#4F6H02 &J<?/IF$18V$J:X6/"N2
M#[ FZ['N>RR!-PMBJGX7&4;[&&*_+C\NIIY:YRY=YM@:;8]Q61U%9(6[9$_T
MR-1J?,54^1/15_E!T-6YBHG[(V70/5UQB7^]6%HXR]15B%52/-T%-$A>>H6)
M0M5&MV9560*3Y"1WR-S7%;(NR[G*%BK^A*QP*\48G@*_"?M'IU"_O)[97&X2
MR<V\O6Q>ZT_X[;QBK/04$J*!5F PX&2 & KJJ3OK[M+>O6&0DK-K9,P0U#H<
MAB*R,U6(R/CN%%91,R$2H.!+$T4ZBX#@$@R-N^Q;9OD*QWT%6'P2+AUKZ'T^
M1J/EU ?*W.O,7)MT\^RWFF-C^K;R#5$]/XDJ,C^)2K>5:=&DHOFYE8XXADNO
M<?5RA+3O1;BJ<?'))_JXHI\1DVA3_:2[G_:O8%E]L8"6\'>'5:X#1AL?,AUK
M_+J9[?[Q=XJH+KE6)WIW&.=D!/J 8I*#Y5/V]"_L[Y<];;BJ(J+.PY/9U5*Z
MHD^26.MQ!9SI16R5%>2GY_4\T$42 W+VO8.[E[?;U9HTMJR7,8R0F'_WD\?L
M!)^70\V#WSY0W:5+;<5FL)V( :>C15/_  Q/A^9954>O1HZ:IIZRGAJZ.H@J
MJ6IB2>GJ::6.>GGAD4/'-#-$S1RQ2*059200>/8%='C=HY$*R*:%6%"".((/
M ]3+%+%/%'-!*KPN R.A!5@<@@C!!'F.LWNO3G7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW0*=Z=M4_4^T374X@J-RYAY:';E#-=HVJ$16J<C4HI5GHL9'(K, 1KD>-+
M@,6 FY6Y???]P$3$K91T:9AQIY*/Z3?R%3Y4ZCWW(YXAY'V(W485]WG)CM(F
MX%@.Z1AQ*1@@GU)5:BM15/%#O'LW=6B,9/=6Z\]4LQ+/YJJID"EF9I)&2"EI
M*:%/R8X((EMZ47B>F;;=CL*G1!81+]@'[,DD_:2?4]83)'S!SCO>E/&O=[N7
M)R:LQX\31551]BJ!Y =&QVU\*L[5TL-1NK>-!A:AU#R8[$XR3,O$&!M')735
MN-@29+C5HCE2]P&(]7L 7ON9:QR,EAMKR(.#R-HK\PH5C3[2#\NIPVC[O.XS
MPQR[WS!'!*<F*",RD?(NSQ@$>= P]">/0FX'X8[$H9TFSVX=PYY4)/VD(I,/
M2R\\+/X5JZPII_XYS1F_-_Q[)+OW)W652MI9PQ$_B-7(^RM!^T'H8;9]W[EB
MVE63<MSNKH#_ $,:8E/VZ0S_ +&'1I=M;5V[L[%Q8;;&'HL+C8>5IJ.+29'L
M 9JF=R]15U+ #5+*[R-;DGV!+V_O-QG:YOKAI9S^)C_(#@!\A0=31M&R[5L-
MFFW[/81V]HO!(Q2I]6.69CYEB2?7JN'Y)=ZUV\LU7;*VQ7R4^S,14/25TM)*
MRC<V1IY"M1-/+&0)L/2S+IIX@6CE9/,2UXA',O)?*L6VVT6YWT0.Y2#4@8?V
M:G@ /)R.)XCX<9KB7[N>Y-SO^XW/+NS7178(&,<K(:?42*:,21QB4X4<&(UF
MO;I#WJ_H'?7:,:Y+'PT^&V[Y&C.?R_ECIZ@QNT<R8RFB1ZC(R1.A4E0L(<%6
MD#"WLXWSFW:MB8PS,9;RG]E'2H]-1.%K^WY=!7DSVOYDYS07=LBV^TUI]5/4
M!J&A$:@:I"#CR6N"P..C%S?"%/M!X.QG->!=C-M<"DD-F] 5,ZTT(N1ZKO\
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MN]P;KW1D@ J*#+4U4Y"I'&HTPTU)31* !Z(:>!/[*+P+%6PV3;M(TPV$"?D
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MQ]WD\6VV6%R(M(EFIYDDZ%/V4K3Y@^74]^P/*MO]+?\ -MU"#<F0VUJ6_"H
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M6B=HJ6B6P8TP9I);Z9?& R/&_,W/L*Q26.Q.6E/:UQP"CST5R3_2X#B*X(R
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M)-19&GC5Y9WPRRF2>ER"BY6G#&&4#3&J-8/('+//ERL\5COD@>%B%6<@!E/
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MW[KW7O?NO=>]^Z]U[W[KW56WR_R4M9VRM$TC-#B-LXBDBBNVB-JF2LR,K!2
MODD^\%V%R0J@GT@"=?;N%8]@,H7NDG=B?L 4?X.L,??F[>XYW2W+DQP6<2*O
MD"Q=R:>IU"I^0].C1?$+ TF-ZI&8B1/O-QYS)U55/I_=,6.E_A=)3,U@3%":
M61U'(#3,?S[ ON'=23;]].Q/APQ*JCRJPU$_::@?D.IF]B=M@M.2%OD4?47=
MQ(\C>=$;PU7[!I)'S8^O1I_8$ZFCKWOW7NL4\$%5#+35,,513SQO#/!/&DL,
MT,BE)(I8I R21R(2&4@@@V/NRLR,KHQ#@U!&""/,'UZI)''+&\4J!HF!5E8
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MDLI-69_<>:J8*2F@IX2[NS,(J/'8ZB@73%"A;3'&B_4DF[%B94M+3;]DL!#
MJQ642EF)/YEF8\3ZD]8T;GNF^<X[V;N\>2ZW:X<(B(*_)8XT'!1Y ?:<DGI=
M]G=%[QZNQF"R^7C2MQ^5HH#D*JB7R083-2F1GPM9(KR!G2(+HG%HIGUJE]-R
M5;'S3MV^SW=O;G3+&QT*W%T'XQ^?$<0*5X]";G+VUW[DRRVR_O5$EK-&OC/&
M*B&4UK$QJ?*E&X,:@<,J_ISY*[AZSI(MO9>B;<VU(W)I:9JDP9/#K(P,BXVJ
MD6:*2DN2WVTBA=9]+Q@M<OYCY*L][D:\MY? OR.YJ55_],,$'^D/S!Z/N0?=
M_=.4+=-JW"W-YLJGL7522('B$8U!3ST&F>#*.C5I\Q.IS1_<M2[N2?\ ./\
MX11-57"%O3(,M]D06&D7F')%P!<@!'VZW_Q- >WT?QZVI_QS5_+J:Q[]<CFW
M\8Q7PE_WUX2ZN%>/B:/E\7\L]%D[@^4.>[!H*K;6VZ&3;&V:Q&AR#/4+-F<Q
M3L!KIJF:$+#0T,H],D,1<RK=6D*,R>QOR[R-:;1+'>WLHGOE-4 %$0^H!RS#
MR)I3R%17J'>??>7<N:;:?:-GMFL]GD&F4DUFE4\58C"(>!45U#!:A*]!UU1T
MGNGMELQ+B3'CL9B:.I8Y6MCD^SJLP("]!A8'6VJ:HD93,XU"FA.M@2T:.<;_
M ,SV'+XMUGJ\\C#]-3D)7N<_(#@/Q''J0%.1_;O>>>#?R61$-G!&WZ\@.AI:
M52($>9--1SH7)!)4%$4E7NWK/=HG@-=MO=6VZYDDC==$]/.GID@GC;5#4TE3
M"UF4ZX9X7_M(P)-)(]OWO;]+:9K"9:@C@1Y$'B"#^8/H1T'()]]Y.WT21F2T
MWNTDH0<$$<58<&1A]JLI\P>CS[.^9^WZBDB@WUMW)8W(JJK)7[>6&OQM0P'J
MF:DJZJFK:$$_1%:I_P"#?TBW<?;:\21FVN\1X?)9JJP^50"K?;V_9UDCL'W@
MMJFACBYDVJ:&[&#+:@/&?GI9E=/L&O[>G+<_S-V514TJ;4P&<SN0TL(9,DE/
MA\6K$E5=Y%GK*^4+;44\$>H6&L$DABQ]MMSE=3?W<44/F$J[?X O\S]G2S>?
MO \N6T3KLFV7-S=4[3*%BC_,U9S3C32*\*CR(=O'>F[.SMRMF<_4393+5TD=
M'04-)"_@I8I)2M)BL101^1DB$DED0:Y9';4[/(S,96VW;-OV.R%M:($MU&IW
M8Y)IEG;&<?( <*#'6,^_\P[YSEN_U^YRM-?2$1Q11@Z5!/;'$@J0*F@&6)R2
M6))-OUU\.)*ZAILIV/F:O&R5$<<PV[@_MQ6TP<:Q'D<I4Q55.DX'#Q0Q.%_$
MM_I'V\^XXBE>#9K97 -/&EK0_P"E4$&GH2?RZG/E3V!:XMX;SFW<)(G<!OI+
M;3J7SI)(P85]0JFG\70I97X<]7U=)XL97[HQ%8L86.K7(4M=&\@!'DJJ6IHO
MW58FY6)X>0+$"X)%![C;Y')JGB@DCKE=)7'R(;'Y@]#2]]@^3)X-%I<7D$X%
M XD5P3ZLK)GY@%?E3HDG;?2>ZNI*V'^)F/*X&ND:+&;BHHI(Z6>507^TK8',
MC8[(>-2PB9W5U!,;OI?3)O+_ #/8<P1MX-8[M15X6.0/53^)?GBGF!4=8Z\\
M^W>]<C7$?U9$^V2FD-U&"%)_A=37PWIFE2"*Z6-#01^H/E%GNO\ 'TVV]RT,
MNZ-M4BB*@D2I$.:Q%. =--3S3!X:^BB^D<,IC:)?2L@150$W,7(MINTKWMC*
M(+ULN"*HY]2!E6/F16OF*U/0NY"]YMRY7M8=HWFV:\VA.V)@U)HE_A4MAT'D
MI(*C :@"@S3_ #$ZG6C%2E+NZ2<K?[ 8BB6I5M((5Y&RPHAZC:ZRMR#^+7!(
M]NM_,F@O;A?X];4_XYJ_EU,#>_7(XM_&6.^,M/[+PEU</,^)H^7Q'HJ7<7R4
MW'V92R[?Q5(=L;3D8?=4<=2:C)9@(VI!DZQ$A1*0%0PIHETZOUO)9=(]Y<Y*
ML]DD6[N)/'OQ\+$45/\ 2C.?Z1_(#/4)<_>[V[<WPOM=A ;/9&^- VJ27_FH
MP  7^@,?Q%L4F?&?INKWUN:EW9F:1DV?MJLBJM4T;"/.9BF=9:7'0:AHFI::
M55DJCRND"(C]PE6^=N8X]KL9-OMI/]V,ZZ<<40X+'T)&%_;Y=*/9_D"?F/=X
M-]W" C8;20."PQ-*IJJ+ZJIR_EP7S-+3?<$]9H=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2>W7NG#;+V]E-S9^I%+
MB\33F>=P TDKLRQT]+3QW'EJJNH=8XEN-3L!<#GVLL+&YW*\@L;1-4\C4 \O
M4D^@ R?ET5;WO.W\O[7>;QN<VBR@34Q\SY*JCS9F( 'F2.J?>V.S<EVKNJ;<
M=?04.-BCB^RQM'201":#'12.]/'75XC6IR-4-9+.YT*Q(C1%.GWD3L&R0[#8
M+9Q2N[$ZG9B:%CQTKP4?9GU)/6!O/'.-WSMO3[K<VL<,:KX<,:*-0C!) =Z:
MG;/$X&=( QT_[1^//;&\Z*+)XW;3T.,J$UT];G*JGQ*5*$722GIJEQ7RPR#E
M)!"8F!N&(]I-PYPV#;96@FO=<X-&6(%Z?:1V@CS%:_+HTV+VJYWY@MTO+3:?
M"M&%4DN6$6H>H5N\@^1TT/D>G'<WQF[?VS2RUTFW8\U20"1II-O5L.3F1([G
M6*#]G)RJRJ6&B%B!^JQX]LV7.W+M](L0O#%(> F4J/\ >LJ/S/2O>/9[GS9X
M'N6VM;B!02QM7$A 'GH[9#7Y*?G3H-]A;URW6^[,?NC%TM#45V->6-Z3*4<<
M\<D,JF&JA!D3[BAJ&C)430LDJ7(N5+*QSNVV6^];?+8SNPB>A#(:9&0?1A\C
M4'[:'H(\L<Q7W*.^6V\V<$;W,)*M',H((.&&1J1J8U+1APX$@VO]<]V;"[)H
M:>3%Y>EQ^9:-/N]N9.HAI<K33Z1Y$@CD9!D:=6_3-!J4@C4$8E1 6\\L[KLL
MKK<6[/; ]LR E"/F?PGY'^8SUF]RG[A<L\W6T3V-\D=^1^I:3,%E4^= ::U'
M\2U'K0XZ$_(9/&XFF>MRN0H<91Q F2KR%7!14T8 ))>>IDCB0 "_)^GLDAAF
MN'$4$3/(>"H"3^P5/0PN;NULH6N+RYCB@7)>5@JC[2Q '5?WR(^1^*W'CZ[8
M.QEH\IBJM?#G-Q5=&E1!/H=7%-@H:R(@>-TYK2FH,+P$664RWR?R9<6<T6[;
MH6CG7,4*FA'S<@_\9_WKS'6+_NM[M6.ZVESRQRV(YK.0:;F[=0RFA^&$,/(_
MZ)3YIY/T4O:.P]W[\K6Q^TL!7YJ>+1]P].B1TE()"1&U;7U#PT-&LA4Z3+(F
MJQM>Q]R!N.Z[=M40FW"[2)#P!XG_ $JBK'\AU!FP\L;]S-<-;;%M<MQ(M-14
M (M>&MV(1:^52*^70UR?$KN-*<SKC\%-+I)^SCSM**@D!"%#3+%2:F+$#]VU
MU/-K$AE?<'EPOI,LH7^(H:?RJ?Y=2(_L9S\L7B"WM6?_ 'V)EU>7J O_ !KR
M^RH$;GVEN79F2?$;IPM?A,@H+K#6PE%GC!*^>DJ$+TU;3E@0)(7="01>X/L5
M6.X66Y0BXL+E)8?53P/H1Q4_(@'J--YV+>.7KLV.];=+;W0R%D&&'JK"JNOS
M4D?/H[72?R?PF)V=68'?45-05&T\1Y,#+BJ.&D3/4E.%BBQ$=#31PTD&8$CJ
M%90D4J$N^@H[/&/,W(]U/N,=WM3,Z7$E)1(23&3DN6-24_:0<"M0!D5[=^\F
MW6>P7&V\RJD4UC!6V:% HF5: 1!% 59:TI2BL*DTH22@]D]@97LW=E9NG*4=
M!0SU*14U-1X^FBC6"CI[K3135"QI49*J56LT\Q9VX5=,:I&DB;+M$&Q[?'8P
M2NZJ2S,Y.2>) K11\ACSR:DP-S=S1>\X[Y<;S>6\4<C@(D<2@:47X06H&D;U
M9JD\!10%"VVK\;^W-V4D60I=M?PJ@G1)*>IW!50XHS1ORKI12E\EXV0ZE8PA
M64@J3<>RN_YSY>V^1H7O?$E!H5A!>G^V';_/H2;+[1\];W EU%M/@6S %7NF
M$=0?,(:R4IFI4 CA7KANOXY]M[1I)<A6[9;)8^G0R3U>!JJ?+>%!<N\E'3L,
MDL<:C4S^#QJO)8<^[6'.7+VX2+#'>Z)B:!904K_MCV_E6O5-[]IN>=B@>ZGV
MCQK515GM6$M!\T'ZE!Q)TT XGI(=8]B9/K#==)N?&4=!D#&K4U91UU/$YJ*"
M9D^ZBI:MHI*C&U3HMEFBY!X8.A9&,-\V>'?+"2QFE=*]RLI.&' D5HP^1_*A
MST0\F\V7G)N]P[Q9V\4M!HDCD4'4A(U!6H6C8@88?F"*@FU[S^3>$S6T*7;>
MQ8Z?(/NO#++GZK)T<-0N#IJDZ7P_V=2DU/)F@T;"1RKQP+I>(L[*\<?\K<D7
M5MN+WNZDH+>2D2H2-9'X]0H='H.)R#0 @SG[D>\.VWVQ0[3RTJ3-?6^JY>50
MPA5L&+0P*F7!J:$**%22002S;&T-S[TR(Q6U<)D,W7:5>2*BA+I3QLP035E0
MY2FHJ?60/)*Z)<VO[DN^W&QVR'Q[^Z2*+@"QXGT XD_( GK'G9MAWGF&Z^BV
M7;I;FYI4K&,*.%68T5!7S8@=#FOQ+[D-+]P<;A%ET:OL6SU']U?23X]:AJ+6
M"+?Y[3<_6W/L+'W Y<$FCQI=-?BT&G_07\NI*'L9S\8?%^FM@]*^'XRZOLK3
M17_;4Z!+=FR-V;%KQC-VX&OPE6X+0BJC5J>J1;:GHJZG>:AKHT+ ,T,CJIX)
MO[$^W[IM^ZQ>/M]VDL?GIXC[5-&7\P.HYWSEO?.6KD6F^;9+;3'*ZP"K#S*.
MI*.!YZ2:=' ^/WR3P^W\ =F;[%+C*' XRIGP&7H**.!:N"D22IDQ-924D:1R
M96?U&&8!352$K(3,P>2.N;N2[F[NQN6U:GEE<"6-VK0G&L$_@'F/PCAC GKV
MN]W;#;-L/+_,VB&WM86:UGC0 ,J@L8G50 93G2WXSAN\U8LW;?9]?VMNN;<%
M7046-IH8OLL71T\$(J8L?&[-",A7*@J*^J-[DNQ1"2(U5;W&_+VQQ;!8+:1R
ML[DZI&)-"WGI7@H_F?.O4.\]<Y7/.V]OND]K'#"J^'!&BC4$!QK>FIV^TT'!
M0!Q>]H_'GMC>5%%D\=MEZ'&5$?DIZ[.55/B$J$(#1O!353C(2PS*;I*L)B8<
MAK>TVX<X;!MLK037NN<&C+$"]/M([01YBM?ET9;%[5<\;_;QW=KM!BLW%4DN
M66(,/(A6/B$'R.FA'GTX[E^,W;^VJ66M?;L>;I81(TLFW:V')S(J7]:X\>')
MS*ZK<>.%R!];'CVQ9<[\NWKK$+PQ.> F!4?[UE1^9Z5[O[/<^;1"]P=J6YA6
MI8VCB0@#ST=LAK\E/SIT&VP]Z93KG=>/W/C*2@J:[&2R(])E*..HB>.0&*HB
M!D3ST-24N%FA9)8S<7TEE8[W7;;?>;":QGD=8G%0T9H:^1QAA\C4']AZ"/+/
M,-[REOEKO-I!&]S"2#',H((.&&1J1J8#+1A]A(-KW7'=VPNRJ&"3&9:FQN9*
MJM7MS*U,%+E:>>PUK3I(R+DJ:Y],L&I2" P1KJ("WGEG==EE99[=GMOPS1@E
M2/G3X3\C^51GK-SE/W$Y9YOMHWLKY(K^G?:3,%D4^= :>(O]):CUH<="CD,G
MC<33/6Y7(4.,HX@3)5Y"K@HJ:, $DO/4R1Q( !?D_3V1PPS7#B*")GD/!4!)
M_8*GH97-W:V4+7%Y<QQ0+DO*P51]I8@#H@/R(^1^*W!CZ[8.Q11Y7%U:&#.;
MBJ:1*BGFTN;TF#BJHBMT=0?O=-P>8/[,ON6>3^3+BTFBW;=-4<ZFL4*FA'S<
M@_\ &?\ >O3K&#W5]VK'<[2YY8Y:$<]I(-%S=NH93_1A##_JI3_2>3=%(VCL
M/=^_*UL?M+ 5^:GBT?</3HD=)2"0D1M6U]0\-#1K(5.DRR)JL;7L?<A;CNNW
M;5$)MPNTB0\ >)_TJBK'\AU!>P\L;]S-<-;;%M<MQ(M-14 (M>&MV(1:^52*
M^70UO\2NXUI?N%Q^"DETEOLDSM**J^E6T:Y%CHM1)T_YZUP>;6)#(]P>7"^@
MRRA?XBAI_P!!?RZD5O8SGT0^*+>U+T_LQ,-7#A4@)\OB_EGH"=S[1W-LS(MB
M=TX3(82O ++%6PE$GC4Z3-1U*EZ6MI]7'DA=TOQ>_L56.XV.Y0BXL+I)8O53
MP^1'%3\B >HSWG8=XY>NS8[UMTMM<\0L@PP]5855Q\U)'SZ/Y\8.]*?/TE#U
MIN*.BH,QC:/P[:JZ6"GH:3+T-)'J;'O2TZ10196EA4N"BA:B-6) D4F2)>>.
M5GM))=[LV9[9VK,K$L48_BJ:DJ3C/ T\CC*#V<]R8MU@MN4-U6.+<(8]-HZ!
M465$'P:5 42*N<"C $\0=1T?<:]9!=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5?GS2WG4-7;7V#32LE+%2-N?*(K<
M3SSS5..Q4<E@+?:QTU0^DDW\RFW /N7/;7;4$5]NSKWEO C/H  S_MJO[#UB
M[]X3F"4W&S<L0N1"$^LG _$262('_2A7-/F#Y#I/?$[J+';JKJ_?VY*.*NQ6
M!K%H,'05,:RTM7FUBCJ:BLJ89 4FBQ<$T7C4@JTTNKZQ6*OG_F&:PBBVFRD*
MSRKKE=<$)6@4'R+$&OR'SZ*_8_D2UWFXN>:-WMUDLK:3PK:)Q56F #,[ X(C
M!&GB"QKQ7JR3W#'66W7O?NO=%2[O^-&-["GJ-T;2FI<'NZ1=593S+X\1GG0&
MTE3X8WDHLDXL#.JLDEAK6Y,@'O+'.T^SJECN"M+MX^$C+Q_(5/<OR\O(^74)
M^XWM#:<U22;QLDB6V^D?J*V(IJ>;4!*2?T@"#^(?B%>VYNLM_P"SZF6FW%M+
M-T'B;3]T*&6JQLO-M5/E*-9\?4*?ZI*UOS[EZQWS:-Q17L]PB>OX=0##[5-&
M'YCK%G>.3>:=AF>'=-BN8])IK"%HS_I9$U(WY'I)009'*SPTU-#6Y*I6-(:>
MG@CGK)Q$ALD4,48DD$:E[!5%@3[,&:&!6=V5$K4DT KZD^O1%%%>7\D<,,<L
MTP4*B*&<T'  "IH*\!T8WK3XN[^WG54]5N2CJ=E[=!62>IRD'CS-5&""T%!A
MY2M3%*Z_22I6*-0=0$A&@@W>N>MIVV-TLI%N;S@!&>P?-G&"/DM3]G'J6>4/
M9CF??YXIMX@?;]IP6>84E8>:I$>Y21YN !QHW#JS':.T,!L; T.W-MT,=#C:
M&.R@6:>IF8#S5E;/8-4UE0PU.Y_U@ H $)[AN%WNEW+>WLI>=C^0'D%'D!Y#
MK+_8]CVSES;;;:=IMA%9Q"@ XL?-G/%F8Y)/^"@Z4OM%T;](+L?KO =F;9K-
MNYRG0LZ22XO(A%-7B,D$(IZZDDX92C6$B7"RQW1N#[-MFWB[V2^CO+5S@T=/
M)U\U/^0^1R.@SS9RKMG-^SW&T[E$#4$PRT[HI*=KJ?EYC@PJ#@]4PYW#5VW<
MUEL!DHQ'D,-D:S&5B"^D5%%424\IC+!2T3M'=&MZE(/Y]Y)6ES%>6MO=PFL,
MJ!U^QA4?GUS[W/;[G:=QOMKO%I=6\KPR#RU(Q4T]0:5!\QGHZWQ&ZEQV42J[
M,W#1QU@HZY\=M:DJ8P\"55,J-6YLQN"DTD$D@AIR;B.1)&MK6-EC/W"Y@F@*
M;):2%=2ZYV4YH?A3Y5XGU! X5ZR']B^1[2[2;G#=+<2:)#%9(XJ RTUS4X$@
MG2OH0QXT(L%]Q'UE'U[W[KW5>/RUZAQV$--V3MRCCHZ?)5XH=T45-'HIUR%2
MLDE+F8XU]$)K7C:.HL%5IBCV+R.3,'M_S#-<Z]EO)"SHNN!FXZ1Q2OG3B/E4
M< .L5O?+D2TV_P +F_:;<1QRR^'>QH*+K:I64#@-1%'\BQ4\222;;=P5=N?/
M8?;N,0/7YO)4>,I VK0LU9.D*R2E0Q6&'7K=K'2BD_CW(]Y=16-I<WDY_2B0
MNWV 5H/F?+J -IVRYWG<[#:;-:W-Q,L*>@+$"IIY#B?0 ]70=?;!P'7&VJ';
M> IDCC@C1JZN,:"LRU>4 J,C72@:I)IGOI%],261 %4 8U[ONUWO-[+>W;DL
M3VKY(ODJCR _F<G/70;E?EG;.4]GMMHVN$!$ ,DE.Z1Z=TCGS8G\@* 4  Z6
M_LLZ$723WMLK;_8&WJW;>XZ)*NBJT)BE  JJ"K56$%?036+4]73L;@CAA=6#
M(S*3#;-SN]IO(KVRD*RJ<CR8>:L/,'_9&>B3F'E[:^9]KN-HW:W#VT@P?Q(W
MDZ'\++Y'\C4$CJF'>6UZ_96Z<[M7)D-68/(343RJI1*F)2'I:R-"69(:VD=)
MD!)(5Q?GWDEMM_%N=A:W\']G*@:GH>!!^:FH_+KGUS!LMSR[O6Y;)>&L]M*8
MRPP&'%7 S0.I##Y'HT_Q-ZCQ^Z:^NW_N.CBK<5@*Q*#!4-2BRTU7G$BCJ:BM
MJ(7!66+%P31&-2"K32ZN#%8@3G_F&:QBBVBRD*SRKKE=<$)6@4'R+$&OR'SZ
MFKV/Y%M=YN;GFC=K<26=M)X5M&XJK3 !F=@<$1@C3Q&HUXKU9'[ACK+;KWOW
M7NBH]X_&C']AU%1NC:4U)A-W2#7703J8\1GV4']VI:&-Y*+*,+?OJKI+:TBW
M)D ]Y7YVFV=$L=P5I=N'PD?''\A7XE^6*>1\NH3]Q_:&UYKEDWG9)$MM].9%
M;$4]/-J E)/Z0!!_$*]PKWW-UEO_ &?4RTVXMI9N@\3:?NA0RU6-EYMJI\I1
MK/CZA3_5)6M^?<O6.^;1N**]GN$3U_#J 8?:IHP_,=8L[QR;S3L,SP[IL5S'
MI--80M&?]+(FI&_(])&"'(9.>"EIHJS(5.A8::F@CGJY_&I)6*"&,22:%+&R
MJ+"_LQ9H8%:1V5$K5B: ?:3T111W=])'!#')--32B*&<T'  "IIG@.C&];?%
MWL#>=53U6XJ*HV7MW4CU%5EH3%F*F*X+0X_#2::I)G'TDJ5AC4'4-9&@@W>N
M>MHVV-TLY!<WG +&:H#ZL_"GR6I^SCU+'*/LQS1O\T4V[0-M^U8+/,*2L/1(
MCW GU?2!Q[N'5F.T=H8#8V!HMN;:H(Z#&T26  #5%5.0/-6UT]@]565#"[NW
M^  "@*(2W#<;O=+N6\O92\S'\@/(*/(#R'^7K,#8]BVOES;;?:=HM1%9QC '
M%CYLYXL[>9/^"@Z4WM%T;](7L3K[;_96VJS;F?IT994:3'9!8T-9B,@%(@R%
M%(1J22-N'4$++&61KJQ'LTV?=[O9;V.]M'R,.GDZ^:L/0_R.1GH-\U<K;7S=
MM%QM.Z1 JPK%* -<3T[70^1'F.#"JG!/5.%3#G>O]WS0%VH-P[1SSH)8BUH<
MEAZTA)HF(7R0-+"&4_ID0@_0^\CD:UW?;E:FNSN(JT/FKKP/H:'\CU@)+'N7
M*V_R1ZC%NMA=$:A7#Q/@CA5214>H^1ZNJVKGH-T[9V_N2F7QP9W#8[+)%>YA
M^_I(JEH&/Y>!I"A_Q7WC1?VCV-[=V3FKQ2-&3ZZ217\^NAFS;E%O.T;9NT(I
M%<V\<X'IK4-3[16G3_[2=&?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=55?+A9E[BK#(%"/@,$U/964F$0RHQ8L2';SHXNMA
M:P^H/N>?;XJ>78]/$3/7[:C_ "4ZPJ]]5D'/LQ<=IM(2N/*C#\^X'A]G1POB
M<],W3.'6#3Y8\OGTK-(Y^Y.2ED77_5OM'B_Y!M[CKG\..9+DM\)CC*_9I'^6
MO4]>R+1'V^VX1TUB><24_B\0G/STE?RZ,G[!?4M]>]^Z]U[W[KW6&HJ:>DB>
M>JGAIH(P2\U1*D,2  DEY)&5%  _)]V1'D8(BEF/  5/3<LL4*-)-(J1CBS$
M #[2<=0*7.8.LE\%#F,35SM=O#2Y"CGE;D MXX9F<\D<V_/MV2UNHUURV\BK
MZLI _F.DT.X;?._AV]]"\ASI1U)_8#7IU]L=+>O>_=>Z][]U[KWOW7NJ>_D8
M]')W5OQJ'_,C(4"/PH_RR+"XR/(<+Q_P/27_ !/YYO[R*Y-$B\L[4)?BT,1]
MA=BO_&:=8&>[+0-[A\S&W_L_%C!_TPAC#_\ &Z]6.?'B@&.Z8V' $"&7%U%>
MP 8:CD\G79#6=?J)<5(-_I_3BWN&N;Y?&YDW9JUI($_WE57_ "=99^UEJ+3V
M_P"68@M-4!E_YR.\E<^NK_-CH:/8:ZD#KWOW7N@$^3CTB=);S%7<B08)*8+I
MUFK_ +QXEH-&HBP4J6>W/C#?7Z>Q9R0)#S/MOA^6LG[/#>O^KUZC+WA:!?;K
MF'QQ4$0A:<=7CQ:?V'C\J]5]?&Z2EC[LV(U9I\)K,K&FHV'W4NW\M%0_E?5]
MZ\=OZG^OT]RYSH'/+.ZB/XM*'\A(FK_C->L6_:-H5]Q.6C/\&N4"O\1@E"?\
M;(ZN ]X[]9X]>]^Z]U[W[KW54_RUI$INY,C,D1C;(8/ U<KE=/G=*0T E!L-
M8$5$J7Y_1;\6]SU[?R%^7(5+5"2NH^6=5/VM7\^L*/?.!(>?KF18Z&6VAD8_
MQ$*4K\\(!^71Q/B=-32],XA(&0RT^8S\-:%_4M2V1DJ$63^K_9SPG_@I'N.>
M?U=>9+DN#I,<97[-(&/S!ZGSV1DA?V^VY8R-:3SK)3R;Q"PK\])7\J=&4]@O
MJ6^O>_=>Z][]U[K#45-/21//53PTT$8)>:HE2&)  22\DC*B@ ?D^[(CR,$1
M2S'@ *GIN66*%&DFD5(QQ9B !]I..F^ESF"K)O!19C$U51)ZA#2Y"CGF>P"Z
MO'%,SM8 "]O;SVMU&NJ6WD5!YLI _F.DT.X;=._AV]]"\ASI1U)/Y UZ=O:?
MI;U[W[KW7O?NO=>]^Z]U3_\ )%Z23NS?;4>GPBLQ2/I-Q]W%M_$1U][D^H5R
M27_H?>1')8D'+&U"3XM+G\O$?3_QFG6!WNXT+>XO,I@IHUQ T_B$$0?_ (W7
MJQ_X_I4)TWL 5-_(<(76]O\ @/)6U<E)] /^45D]PSS:4/,>[&/X?%_G05_G
M7K+7VP65>0>5Q-\?TP(_TI9BO_&:=##[#O0\Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HA7S0V//+_=OL*C@>2*GA.VLVZ*
M2($,\U;AJB73<+&\U141,[  ,8UO=E'N5_;7=$7ZW:)&HS'QX@?/ #C[: &G
MVGK&;[P?+DCKM'--O$2J+])<D#@*EXF/H-3.I/J5'F.@V^+O<V/V!E:W:.YZ
MA:3;6Y*N*II<C)84^'SNB.E\U8W'BH,C3QQQRRFXA:&-CI0R.ISSURW-NT$6
MXV*:KV%2K(.+IDT'JRFI \ZGSH.@C[,^X%KRQ>7&Q;Q*(]HNY Z3'A%-0+5_
M1)% !;\)52:+J(L[CDCFCCFAD26*5%DBEC97CDC=0R21NI*NCJ0002"#[A!E
M*DJP(8&A!\NLQ597571@4(J",@@\"#Y@]<_>NK=$P[P^4E/MB>IVKUS)19/.
M1>2')[B8+5XW#S M&]+CXB#!D<C$1=W;53Q&RD2-J5))Y7Y%>^5+_>59+4Y2
M'@SCU8\54_M/R%*X_>XWO/%LLDVR\J-'-N2U6:Z/='$>!5!P>0>9-54XHQJ
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M_LY0"S+3^,^:?TCD'C4<(M]W_;'9;/;[CFO97ALW0CQ[8E4CDKYPC 64_P
MPPX -742+;VY]P[3KURFVLUD<)7JN@U..JI:9Y([AC#.L;!*B!B 2D@9#;D>
MY/O+&SW"(P7MLDL7'2X!I\QZ'YCK'/:MYW;8[H7FS[A+;7-*%XF*U'HP&&'R
M-1T+S_)SNV2C^S.\R!]#4I@]N1UA0*%$?G3$AA:U]8 D)^K'V'1R1RP)/$_=
MO^U+R4_9K_V/ET.V]X_<5H/ /,'^W$, :GI41?SX_/H+ -W]A[B OF]V[ERL
M@4%FJLID:@BP%V8R/'30)_73%"@_LJ.#[_==L]G_ *%;V48^2J/]D_M)]3T"
MQ^_N:]U _P 8OMXF-,ZI'/\ AHJ_DJCT ZLE^/GQ_AZT@&Y]S+#5;WK:=XDC
MC=9J3;M'.+24E-(MTGR-0G$\XNJJ3%&=.MY86YNYM;>W-C9$KM:FM3@R$>9]
M%'D/S.: 9<>UOM='RA%^^-X"OS'(I4 &JP(>*J>#.P^)O3M7%2SYVQ\C]F]9
M338:!'W/NJ(6EPU!.L--CF90R#+Y(QS1TLC W\,:2S 6U*@96*;8.3-RWM5N
M6/@6!X2.*EO](N*_:2!Z$]&7/'NSL')TDEA&IO-Z S;Q$!4]/%DH0I/\(#-Z
M@ @]$ZR_R\[:R%09,>^WL%3ACHIZ+$+5G1<Z1--E9J]I) /J5$8)_LCZ>Y&M
M_;SE^%*3":5_,L]/V! O^7J [_WWYXNI2UI]);15PL<6K'S,A>I^8 ^P=!AN
MON[M+>M++0;@WAD9L=-J67'4,='AZ*:)B3X*F'$TU$*R$7MIF,E["]SS[/+#
MEC8ML=9;3;D$PX.Y+D'U!<M0_93H&[W[C<Z<PPO:[GOTK6C5U11!(E(/X6$2
MIK7Y-7J#U5U^>R]XX_;!S./PD-1>:IJJVHB2HE@B93+38FE=E;(9.2,DQQBP
M 4LQ '+N_;N-DVZ:^^F>5AA54&@)X%S^%1YG\ATGY(Y6_KAO]KLYW"*VC;N=
MY& 8J.*Q*?CD(X#A@DX&3E]_?'C:%%LB#<>U9L;M>IV;B(Z2>/(5$5+1Y^@@
M+%$J*J0+KW'//(?%(;FJD<1MR498VY2YPW&3<WL[]7G2YD+ H"6C8^@_WV ,
MC\(%1YUR ]S_ &JV&'EV+==EDALIMO@$;"5@J3(O ,Q_T<L>UC\;'2>((('A
M,]FMMY"'+8#*Y##9*"XBK<;534E0$)!>)I(70O#)I =&NCCA@1Q[EJZM+:]A
M:WN[=)(3Q5P"/MSYCUXCK%_;MSW':+J.^VN]EM[M>$D+%6IY@D'*FF0<'S'0
MW47RD[KHXDB;=-/6JA72U;@L')+I4 :'EBQ\,D@-N68E^?K[#$O(O+,C%A8%
M2?X9'I^PL?\ -U(UM[T>X=NBHV\I* >,D,)-/0E44G\\_/H8MD_,_*PU$%)O
M_;M'64;,J2Y?;ODI*V!/^.TN+JYYZ:M;5]1'+367D D6(<W/VV@9'DVF\99.
M(CFRI^08 %?S!Z'W+GW@KQ)8X.:-I1X":&>TJK*/4QL2K_.C+C@#P)V*:LV=
MVEM"5J6:BW)M7<5'+2S:=1CEC;TRPRQN$J*.MI9 #I8)+#(H/# 'W&3Q[CL6
MX*)%:&_A8,/4>A'D0?S!'60\,^P\Y[$[0R1W>RW<91J<"#@@@T*NI\C1E(\B
M.JPNY/C_ +GZPK:K(44%5G-E/*S46<@C\LV/B<W2EST4*C[.>*^D3Z13S<$%
M68QK./+?-MCOD4<,KK%N8'=$<!CZQD\0?3B/F,G#CG_VNWGDVXFN[:)[GEXM
M6.X45*#R68 =I'#532V.!.D(S:/<O9NQJ>.BVWN[)4F/BXBQE4*;*XZ%-1=H
MZ:BRL%;3T:2,Q+>%8R2;WOS[,MPY;V3=',M[MZ-,>+K5&/VLI!/YUZ#^Q>X'
M./+<26^T[[*EHOPPOIDC ]%617" ^>FGKQZG[F[X[9W=2S4&9WGD?L)PR2T6
M,AHL+!+$VJ\$QQ%+135,!#6*RLX8?6]O;5CRIR_M[K+;;:GBC(9RSD'U&LD
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MSD;X_+8]X:V@KZ*:4054 E8T>6Q-8%AE:%I824<!)(Y$*L%=642[MFYV&^V
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ME*B1FD>;%O78)GD8$&21<)5X^.5R6N=8:YY-S[/[3FSF*R4)!NDF@8 DTO\
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MD*,D T!ITJ^G^V,QU-N9<M1*U;B*X14VX,,9"D>0HD<LLL)OHBR-'K9H)""
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MRDTLF1Q]?BI3)$;^2DFGB@,FGZAXR1;D&WLWM[S;]QC;Z6ZAGCIW!&5Q0^1
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M%MNVWQ!+'<%=V1115F0CQ*4P X96IZZJ8X#U\,MUSY/9^X]IU,QD.V,I3UE
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M?#"DT\F*GRR?KM'K[%]F;-RFVLC%']Q)$]3A:UE!DQF:ABD%#6QM^I4#N4E
M(\D+NMQ>_N)]CW>?9-Q@O86.@'3(O\2$]RG_  CT(!ZR<YRY6LN;]@O=GNT7
MQ2I>WD/&.4 Z''GQ-&]5)'GU3[M3/Y'8F\<-GX%EAR&V\S#434]PDCBEG\5?
M02$W 6JI_)"_^TN?>1-_:0[KMMS:,089HB WVBJM^1H1U@;LFYW?+',&W[FB
MLMU9W 9TX$Z6I(A_TRU4_;U=_3SQ55/!54[K+!4PQ3PR*;K)%,BR1NI_*NC
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M%F]%%3_+K1( J30?/H)?]FT^*O\ WDS\??\ T<W7/_V2>WOH[S_E$E_WEO\
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MM' BO0FM[B*YC$D1QYCS!]#T=3V5]/\ 5 ?_  ID_P"W3G:O_B3ND_\ WO\
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M>.-W2G@;L7#TRS3LH*PQ-4U$<89K O(J_5@",^0#_P BBQ_TLG_5MNB[=?\
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M8RR)3-#()>5=_?E_<UN&!:S<:)T'$KY,/FIR/7(J*UZ17UH+N H,2#*D^O\
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M-3U%%#V7N6JEKXT7R0U>*Q^,JT=EF4+!?N+O*7VYQ;=;O6"U!#^GB'XA\](
M'R.H="G9[8Q0&9QW/D?Z7R_;_@IUM.^X[Z-^B^_+3_LE7Y,_^*^]S?\ ON=R
M>U-G_N9:?\U5_P"/#JDG]G)_I3_@Z^.3[ROZ 76_+_PD:_[),^4W_BQ.)_\
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MOK8-&OPXPR]Z+(*$N*]KBN./25_V<+J7_CANW_SS4G_UU]K_ /6ZY@_BM_\
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MW91S[,=KVB_WFX^FL("\@%6/!5'JQ.!_A/D#T0\Q\T;)RG8?O'?+P10$Z44
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M:[_W6GV8>V?_ "4-S_YHK_Q[HB^\/_R0N7_^>MO^K9Z.3C/^+;C_ /J!I/\
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MJQJ104()/1FMU]/];[TAIHLYM3%,U)44\\-504T6,K0D$RS/2/5T*P3R454
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MB>A&I'4,IHP#"JD&A (\Q7HLOS"_YE+!_P"';AO_ '$ROL;>W7_*P-_SSO\
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MSVEU(%8NN@&XL;_T]RI[:AFBYA5/C*Q ?;2:G6-?W@FC2ZY$>:G@B2Y+5%<
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M_P!Y#;_O(3D?_E5MK_YN?]7I.L%?>3_IY',?_4/_ -HL'0!^Q9U&/5V75/\
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M']RQUC'U:/\ #W_F4L__ (=N9_\ <3%>X+]Q?^5@7_GG3_"_69_L-_RHS?\
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0O]*/\'6?W7ISKWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ex10-43_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-43_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !\ '(# 2(  A$! Q$!_\0
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M:@Y1?5/^]Z>N[>FS[C(;/;>_99Y9)8E4.BEN.O<5KU6MK5HI'FED\R9Q@MC
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CSCFBB@=A,#!&!@]:38FW;M7;Z8XIU% K(****!A1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>ex10-44_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-44_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ![ '(# 2(  A$! Q$!_\0
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MY6<V)I>UA:U_ZUUZ71FW5F;5$BA?=%,VPK(,[2>XJ::TBLK8SEGE>,?)YC9
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MN74^+MW=7U];:=X-U._^QSM#(]N^\ @D<X7C.*V_"_Q)T_Q#J[:-<V-WI6K
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ML[:?B<M\2?!][XO\/6FG:=);Q-#<I*?.)"[0I&!@'UK6\2>$[#Q3X;;1[Y
M$'E2*.8G X9?\.XK5GG>-RJ]T&SC.6S3W\S[4@#D(021M],=ZCWK(OGC=Z=D
M>63?#_QCJ^BZ/X?UK4[&73+&Y#RRH[F2:(?=4@CJ!D=>X]*[H>!?"8_YES3/
M_ 9/\*UVEE$4I'59-N<9PO'..]-DE=;4.DH;YOO%<9%4W)D\\%?3H<CX/\&7
M_A'Q3K3VTMO_ &!?-YL,"DAX7],8QCDCKV%=S3(FWQ*QSR,\C!I]9R;;U-XI
I):!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>ex10-48_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-48_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L &0# 2(  A$! Q$!_\0
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>ex10-49_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-49_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L &0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ J*
M>5(8FDD.%%++-'#&7D8*OJ:S9[A+PQI&&\I6#.[#  %7&+?H<]:LH*R?O=$/
MFU/9"S&WD3CY&8<&D^RRBW\_[3)YN-V<\?3%,O+R&XB^SQ99I#@$C 'O40=Q
MI_EESY7G!-_^S6RCIIH>=.JI3:D^9):6TL_E\M2:W@DNX!<27$@=ONA#@"E@
MU%]AC,3RRH2&*CBHPQMX[R.W.8T *G^Z3UIME<16.Z*0Y#?.K@9R#0XW3TOV
M%&IR2BD^7>[WN_GY]34MKB.X3<F00<$'J#4]927"073W !>"4#YD&<$>M7[>
MXBN 6C;..OM6,HVU6QZ-&LI+ED]?ZU)J***@Z0HHHH *#THH/0T 9FH21K<6
MK2$>6&.5_D:CU"YB>)(XSO&X,X3GY13K.&">.22<*\I<AMW:JX2T1VC6Z=8B
M<$!>/IFNF*6W8\6K*I*+DK)3\]?Z_(MW0@N[%UA*,P7* =131<VG]F;,K]W&
MSOGZ4V]@M[>T\V+:CK@H5ZFI)H[6:S,S! 2N=PZ@TE:RWM<TES\\OAYN7Y6(
M[">WALMDC!&&=ZMU-+8"&&%I'VQ[V)7=_=[4:?% ]J)G"O(3EBW44EFL%W+-
M)+M=MV #V7VHE;WMR:7-^[VO9V_X/_ &VMS$EW/@[(9#E2>%)[U)#+$^K,86
M4#9AL'AC5::.U5VA%RRQ9Y4+N _'M5B>VM([ O&%!495P><TVEYZDP=2UM+1
M=]_71>7_  QJ"EJ&V9F@C+_>*@FIJYVK'L1?,DPHHHI%!2'H:6B@#'M[2.]6
M2XE9MSL1A3C&*/*D139BX@V'CG[V*6Z@:.X2.VD:-IB=P'3W-03V;6B #;*)
M#MRPY5CWS75%WZGASCR)^YMN[[W_ !UO\B6ZL([6V\Z)SOCZ;CD&E_LR,6>\
MNWF ;\YXSUZ4Z2U,-OYMQ,\HB&=G;-)+;W4UJ9'N.2-QC P,>E)2?\Q3I13;
M]GTVOMY[_P!6&VEA'=6QFE8[Y/[IP!3;.R6X,C3L<H?+ 7C@4ZSMIWA,T4WD
MACE8QR*?!";E6F65H9LE9-G0D=Z;DU?7_@$TZ46H/DUM]_G^NO<;Y4EMFVCG
M@",>-_WA1-IL4-H75VWH-P)/!/TJ&*S>6:6V;:"IR\I&2V>E2QVC_:Q:3S.\
M6W<HSU]C0W;J*,>96=/39:[/^NQIVTAE@1R,%E!Q4U-50H  P!3JY6>W%-))
MA11104%%%% %6ZM3,$9&V2(<JU5)_/.V"Z"[9#A9$[-VK5JM>6S7$.%.'4[E
M/N*TA+HSDKT;IRCOV[_TC/NTNA$%N'5H,@.4'./>D$\AL?*#\>;Y6_VI]VU[
M-:.A@5 !ECNSGZ5)BU_LK 9?+VYZ\YK6]DK]S@<6ZDN5M+EZ_EZ?YD*2/9QW
M,4;;EB *D]LTVT6XWN+5P8^-[2="W?%3Z<8/L!W$$MGS-QYJ&P-Q#&[0PB2%
MF.W)P:;>Y*5W3=W:SVW7_ Z?(DC$\4[PP[9)V^:21N@]!5JVM9$F:>=PTI&!
MCH!19V\D;R338\R0\@= /2KE8RET1Z%"CHI2OY+M_P $****S.P**** "BJU
M]?VNFV4MY>SI!;Q#<\CG  K@9/C7X528A%U"6%3@SI;_ "?SJE%RV1+DENST
M>BL[1=>TWQ#IZWVEW27$#<97JI]".H-<A>_&'PS8ZC<V,B:@TUM(T4GEV^X9
M!P>]"BWHD#DEJV=^1Q54Z?;>8'$*YSFL+PU\0/#WBJ=K;3KMA=*,F"=-CX]0
M._X5;B\6Z;+XPE\,+YW]HQ0^>V4^3;QWS[BG:2(DJ<[-I,TY+"WEDWM$NZK"
MH$ "@ #H!69XC\0V/A?19=5U#S/LT14-Y:[FY.!Q5+6?&FE:%X=M=<O//^QW
M.PQ[$RWSC(R,TO>:&HP@VTK'1453GU.SM-+;4KF98;18Q*TCG "XS5'PWXFL
M_%-@U]80W26VXJDD\>P28[KSR*5G:Y=UL;5%<O?>/]!T_P 60^&YYY!?RE0"
M%^12W0$YX-=10TUN":>P4444AGD_Q:+ZGXC\*>')96CL+ZYS/@XW8( _F?SK
MTJVTFPL[!;&"R@2U5=@B"#;CW%<]X_\ !8\7Z5"+>?[-J5F_FVL_8-Z'V/%<
MU%XA^*5G;BPE\+VUU<J-@O!+\C?[1%:_%%),QVDVT5/#5NGAGXXZGHFF_)IU
MW:^>T"_=1L!N/3&3^=4_ 6O:)HGC'QG_ &Q?6MKYM]^[\\@;L,^<?F*ZWP'X
M)O\ 1]0O?$/B"Y2YUR^X?9RL2]=H_3\JR/"/@$-XF\3W7B+1898;B[WV;3 -
ME2S$D>G45HY1UOV1'++2R,C5+[3?$OQB\/3>%0LS6QW7ES F$*^Y[\<?C6K8
M_P#)QVH?]@T?R2K>B>%]4\$^/YSI%CY_AS4QND"D9M7_ )D?T-/\9^%==@\7
M6OC'PLL<U]%'Y5Q:R''FKTX_#^5*ZO;R'9I7\RS\9S_Q;+4?^ND7_H8KG/B9
M_P D9T'M\MK_ .@"G:O8^//B*+?2M3TB+1=*659+AR^YGQV K?\ B?X9OM7\
M#VNDZ+:&=X)8PL88#"*,=Z(M1Y4^X2N[M'!2^*+?X@>*-'T/4)YK#PV HC!!
M7[7(H P3V!/'_P"NO;;ZZLO#>@37)1(+.R@+!%& %4< 5SGB#P#8>(/!EMI(
MA2TN;6)3:R(,>3(!S^!/6N.U.P\>^(?"5AX8U#3'C<7*I=WWF J\*G@GW]?I
M2?+.UM$"O&]]68EOX;;Q%X!UCQ5<31+KMU<F^MLN-R*AX4?7'Z"O8/!'B)/%
M'A.QU,$>:R;)AGI(O#5@K\&_!RJ!]CN#@=?M#<U6\!^'-6\'>*=9TM;9V\/3
MGSK6<L#L;T/?I_*B;C).S'!2BU<](HHS16!N!Z54$\HBE=@O[LD8'?%6ZC(&
M2,#!Z^],B2;V976[+1S,$QY:YY[\4&Y<6WFD#.0/:IRJX/RCD<^]*L:*NT*
M.N,4[HCDGW*_VL_9/-*C<3A1ZFB2[(@BD0#YSCGM4^U1_".#QQ2JJ\?*.N>E
M%UV#DG_-T*TERZ)$=F"_4'M3YKDQ,1@<)N^IS4KHCCYE!P>](R*S#<H.!QD4
M70<L];,8TD@GC4!=K@GFD>X*I(VT?(VT5,0"P..12%5(((&">:5T-QEK9D3S
M2) 'PK-G'!XJ:)A)&KY!R,\4T1(4V;1M],5(@ & , 4-H<5*]V]!U%%%(T/_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ? ) # 2(  A$! Q$!_\0
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M_&VI:[I6B2:UI^N-=>'IK&'4/M.G0WD$46_4;'4+8PR1WTV\&V+AA&R.I7D
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M\0>)OBW>3_VEX<U[PCJVO//X8U*73H--LK+QI>WSZ1 )#+>PW$<#P6G[(44
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FTG71K*_$*RULK_9L&HPFW^PMHFE ^=]N!\TW7R>61Y;[\H ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>41
<FILENAME>abio-20240331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 13 23:21:12 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://www.arcabiopharma.com/20240331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:abio="http://www.arcabiopharma.com/20240331" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" id="abio_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="abio_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" id="abio_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" id="abio_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Statements of Operations (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3" id="abio_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Statements of Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" id="abio_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies" id="abio_r_ARCAandSummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - ARCA and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/NetLossPerShare" id="abio_r_NetLossPerShare">
        <link:definition>008 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures" id="abio_r_FairValueDisclosures">
        <link:definition>009 - Disclosure - Fair Value Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment" id="abio_r_PropertyandEquipment">
        <link:definition>010 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements" id="abio_r_RelatedPartyArrangements">
        <link:definition>011 - Disclosure - Related Party Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies" id="abio_r_CommitmentsandContingencies">
        <link:definition>012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EquityFinancings" id="abio_r_EquityFinancings">
        <link:definition>013 - Disclosure - Equity Financings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation" id="abio_r_SharebasedCompensation">
        <link:definition>014 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans" id="abio_r_EmployeeBenefitPlans">
        <link:definition>015 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxes" id="abio_r_IncomeTaxes">
        <link:definition>016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SubsequentEvents" id="abio_r_SubsequentEvents">
        <link:definition>017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy" id="abio_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables" id="abio_r_NetLossPerShareTables">
        <link:definition>996001 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables" id="abio_r_PropertyandEquipmentTables">
        <link:definition>996002 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables" id="abio_r_CommitmentsandContingenciesTables">
        <link:definition>996003 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables" id="abio_r_SharebasedCompensationTables">
        <link:definition>996004 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables" id="abio_r_IncomeTaxesTables">
        <link:definition>996005 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails" id="abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable" id="abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable">
        <link:definition>996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails" id="abio_r_FairValueDisclosuresDetails">
        <link:definition>996008 - Disclosure - Fair Value Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails" id="abio_r_PropertyandEquipmentDetails">
        <link:definition>996009 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable" id="abio_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails" id="abio_r_RelatedPartyArrangementsDetails">
        <link:definition>996011 - Disclosure - Related Party Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails" id="abio_r_CommitmentsandContingenciesDetails">
        <link:definition>996012 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" id="abio_r_ScheduleofFutureMinimumCommitmentsDueTable">
        <link:definition>996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a4bY39FGh5gLIYnmd1AwOGy2evgYTBuMezrcHZ8hWGuIKmV96PSoFEqIafU9sj92aZRi6oN90zR+hQ0m6IzU+mpUZ5p5Jpyw5MoU2z9VITI83t6K3dnZhN1mRoerAP0g68d23td+x0S1w==] CSR-->
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails" id="abio_r_EquityFinancingsDetails">
        <link:definition>996014 - Disclosure - Equity Financings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails" id="abio_r_SharebasedCompensationDetails">
        <link:definition>996015 - Disclosure - Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" id="abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable">
        <link:definition>996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable" id="abio_r_ScheduleofStockOptionActivitiesTable">
        <link:definition>996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable" id="abio_r_ScheduleofRSUActivityTable">
        <link:definition>996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable" id="abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable">
        <link:definition>996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails" id="abio_r_EmployeeBenefitPlansDetails">
        <link:definition>996020 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails" id="abio_r_IncomeTaxesDetails">
        <link:definition>996021 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" id="abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable">
        <link:definition>996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" id="abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable">
        <link:definition>996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" id="abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0">
        <link:definition>996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0" id="abio_r_ScheduleofPropertyandEquipmentTable0">
        <link:definition>996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" id="abio_r_ScheduleofFutureMinimumCommitmentsDueTable0">
        <link:definition>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0" id="abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0">
        <link:definition>996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0" id="abio_r_ScheduleofStockOptionActivitiesTable0">
        <link:definition>996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails" id="abio_r_SubsequentEventsDetails">
        <link:definition>996029 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfFutureMinimumCommitmentsDueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
  <xs:element name="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfStockOptionActivitiesAbstract"/>
  <xs:element name="ScheduleOfRsuActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfRsuActivityAbstract"/>
  <xs:element name="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
  <xs:element name="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract2"/>
  <xs:element name="CostsAndExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CostsAndExpensesAbstract0"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract4"/>
  <xs:element name="PotentiallyDilutiveSecuritiesExcludedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsAbstract"/>
  <xs:element name="PotentiallyDilutiveSecuritiesExcludedAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
  <xs:element name="ResearchAndDevelopmentExpenseReversed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ResearchAndDevelopmentExpenseReversed"/>
  <xs:element name="DescriptionOfBusinessPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DescriptionOfBusinessPolicyTextBlock"/>
  <xs:element name="LiquidityAndGoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_LiquidityAndGoingConcernPolicyTextBlock"/>
  <xs:element name="ComprehensiveLossPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ComprehensiveLossPolicyPolicyTextBlock"/>
  <xs:element name="AccruedOutsourcingExpensesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
  <xs:element name="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
  <xs:element name="DeferredTaxAssetResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetResearchAndDevelopment"/>
  <xs:element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsLeaseLiabilities"/>
  <xs:element name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
  <xs:element name="FairValueDisclosuresDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_FairValueDisclosuresDetailsTable"/>
  <xs:element name="FairValueDisclosuresDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FairValueDisclosuresDetailsLineItems"/>
  <xs:element name="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
  <xs:element name="RelatedPartyArrangementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_RelatedPartyArrangementsDetailsTable"/>
  <xs:element name="PaymentOfUnrestrictedResearchGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PaymentOfUnrestrictedResearchGrants"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="RetentionBonuses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_RetentionBonuses"/>
  <xs:element name="PercentageOfRetentionBonuses" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageOfRetentionBonuses"/>
  <xs:element name="RetentionBonusPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_RetentionBonusPaid"/>
  <xs:element name="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" type="dtr:areaItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
  <xs:element name="LesseeOperatingSubleaseTermOfContract" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_LesseeOperatingSubleaseTermOfContract"/>
  <xs:element name="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
  <xs:element name="OperatingLeasesExtendedExpiryYearsAndMonth" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
  <xs:element name="PercentageOfBaseRentToBePaidMonthly" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageOfBaseRentToBePaidMonthly"/>
  <xs:element name="EquityFinancingsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_EquityFinancingsDetailsTable"/>
  <xs:element name="EquityFinancingsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_EquityFinancingsDetailsLineItems"/>
  <xs:element name="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
  <xs:element name="SellingCommissionPerAdditionalSharesSoldPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
  <xs:element name="SharebasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_SharebasedCompensationDetailsTable"/>
  <xs:element name="SharebasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SharebasedCompensationDetailsLineItems"/>
  <xs:element name="PercentageHoldingForStockOptionsExercisePrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageHoldingForStockOptionsExercisePrice"/>
  <xs:element name="PurchaseAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PurchaseAggregateShares"/>
  <xs:element name="EmployeeBenefitPlansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_EmployeeBenefitPlansDetailsTable"/>
  <xs:element name="EmployeeBenefitPlansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_EmployeeBenefitPlansDetailsLineItems"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_IncomeTaxesDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OperatingLossCarryforwardsExpirationYear"/>
  <xs:element name="DeferredTaxAssetsAndLiabilitiesValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
  <xs:element name="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SubsequentEventsDetailsLineItems"/>
  <xs:element name="NumberOfConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NumberOfConsecutiveTradingDays"/>
  <xs:element name="ThresholdAmountOfAdjustedExchangeRatio" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ThresholdAmountOfAdjustedExchangeRatio"/>
  <xs:element name="ThresholdAmountOfDeclaredCashDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ThresholdAmountOfDeclaredCashDividend"/>
  <xs:element name="SubscriptionAgreementReceiptAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_SubscriptionAgreementReceiptAmount"/>
  <xs:element name="PaymentOfOtherPartyTerminationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PaymentOfOtherPartyTerminationFee"/>
  <xs:element name="MinimumPercentageOfOriginallyIssuedShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_MinimumPercentageOfOriginallyIssuedShares"/>
  <xs:element name="MinimumPercentageOfOriginallyIssuedOutstanding" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
  <xs:element name="InitiallySpecifiedPercentageForBeneficialNumberOfShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
  <xs:element name="ExceptedNumberOfBoardMembers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ExceptedNumberOfBoardMembers"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_AggregatePurchasePrice"/>
  <xs:element name="NumberOfMonthsBaseSalary" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NumberOfMonthsBaseSalary"/>
  <xs:element name="CashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_CashPayment"/>
  <xs:element name="IncreaseOfRetentionBonusToEachExecutive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_IncreaseOfRetentionBonusToEachExecutive"/>
  <xs:element name="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
  <xs:element name="ArcaBiopharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ArcaBiopharmaIncMember"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="ClinicalDevelopmentDecisionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ClinicalDevelopmentDecisionMember"/>
  <xs:element name="CommonStockAndPreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CommonStockAndPreFundedWarrantsMember"/>
  <xs:element name="FirstMergerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FirstMergerMember"/>
  <xs:element name="FirstThreePercentPayContributionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FirstThreePercentPayContributionMember"/>
  <xs:element name="IncentiveStockOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_IncentiveStockOptionMember"/>
  <xs:element name="JonesTradingInstitutionalServicesLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_JonesTradingInstitutionalServicesLLCMember"/>
  <xs:element name="MergerAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_MergerAgreementMember"/>
  <xs:element name="NewCapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NewCapitalOnDemandSalesAgreementMember"/>
  <xs:element name="NextTwoPercentPayContributionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NextTwoPercentPayContributionMember"/>
  <xs:element name="OrukaTherapeuticsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OrukaTherapeuticsIncMember"/>
  <xs:element name="PatentAssignmentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PatentAssignmentAgreementMember"/>
  <xs:element name="SecondAmendmentOfCertainRetentionBonusLettersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
  <xs:element name="SeperationAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SeperationAgreementMember"/>
  <xs:element name="ThomasAKeuerAndCJeffreyDekkerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
  <xs:element name="TwoThousandAndThirteenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_TwoThousandAndThirteenPlanMember"/>
  <xs:element name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
  <xs:element name="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
  <xs:element name="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
  <xs:element name="WeightedAverageSharesOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_WeightedAverageSharesOutstandingAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>42
<FILENAME>abio-20240331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 13 23:21:12 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingExpense" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a4bY39FGh5gLIYnmd1AwOGy2evgYTBuMezrcHZ8hWGuIKmV96PSoFEqIafU9sj92aZRi6oN90zR+hQ0m6IzU+mpUZ5p5Jpyw5MoU2z9VITI83t6K3dnZhN1eDLtnP4zVcvTUZF6k9Jo7g==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>43
<FILENAME>abio-20240331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 13 23:21:12 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ShareholdersEquityType2or3" roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPolicies" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShare" roleURI="http://www.arcabiopharma.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosures" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipment" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangements" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingencies" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancings" roleURI="http://www.arcabiopharma.com/role/EquityFinancings"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensation" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlans" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxes" roleURI="http://www.arcabiopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEvents" roleURI="http://www.arcabiopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_AccountingPoliciesByPolicy" roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShareTables" roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentTables" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesTables" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationTables" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesTables" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofRSUActivityTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosuresDetails" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentDetails" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangementsDetails" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesDetails" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancingsDetails" roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationDetails" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlansDetails" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesDetails" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEventsDetails" roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#DocumentAndEntityInformation" roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_ResearchAndDevelopmentExpenseReversed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosures">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangements">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/EquityFinancings">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlans">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/NetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abio_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a4bY39FGh5gLIYnmd1AwOGy2evgYTBuMezrcHZ8hWGuIKmV96PSoFEqIafU9sj92aZRi6oN90zR+hQ0m6IzU+mpUZ5p5Jpyw5MoU2z9VITI83t6K3dnZhN1aVZbp1NGDTsMze+shC9drA==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails">
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueDisclosuresDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_RelatedPartyArrangementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_ResearchAndDevelopmentExpenseReversed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_PaymentOfUnrestrictedResearchGrants" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_PatentAssignmentAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="abio_ClinicalDevelopmentDecisionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_RetentionBonuses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PercentageOfRetentionBonuses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_RetentionBonusPaid" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringCharges" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_LesseeOperatingSubleaseTermOfContract" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/EquityFinancingsDetails">
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_EquityFinancingsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="dei_LegalEntityAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_SharebasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndThirteenPlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalOwnerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="abio_IncentiveStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_PurchaseAggregateShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails">
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="abio_EmployeeBenefitPlansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="abio_FirstThreePercentPayContributionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="abio_NextTwoPercentPayContributionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LatestTaxYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_OperatingLossCarryforwardsExpirationYear" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OpenTaxYear" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_OwnershipAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_MergerAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_FirstMergerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_SeperationAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abio_CommonStockAndPreFundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PresidentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_PresidentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_ArcaBiopharmaIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_OrukaTherapeuticsIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_NumberOfConsecutiveTradingDays" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubscriptionAgreementReceiptAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_PaymentOfOtherPartyTerminationFee" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ExceptedNumberOfBoardMembers" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_AggregatePurchasePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_NumberOfMonthsBaseSalary" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_CashPayment" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_RetentionBonuses" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="8" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>44
<FILENAME>abio-20240331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 13 23:21:12 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">ARCA and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Shares of Common Stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Arrangements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Minimum Commitments Due [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total remaining lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity Financings [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract_lbl" xml:lang="en-US">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Purchase options shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfRsuActivityAbstract_lbl" xml:lang="en-US">Schedule of RSU Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="abio_ScheduleOfRsuActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of Shares, RSUs outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefit Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract_lbl" xml:lang="en-US">Schedule of Stock Option Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="abio_ScheduleOfStockOptionActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset &#8211; operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract" xlink:to="abio_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued expenses and other liabilities - related party (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract0" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract0" xlink:to="abio_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl" xml:lang="en-US">Related party expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract1" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract1" xlink:to="abio_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract2" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract2" xlink:to="abio_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_WeightedAverageSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CostsAndExpensesAbstract0" xlink:href="abio-20240331.xsd#abio_CostsAndExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CostsAndExpensesAbstract0_lbl" xml:lang="en-US">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CostsAndExpensesAbstract0" xlink:to="abio_CostsAndExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract3" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract3" xlink:to="abio_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract4" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract4" xlink:to="abio_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common stock upon vesting of Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use asset &#8211; operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xml:lang="en-US">Income tax refund received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of noncash investing and financing transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Leased assets and operating lease liabilities &#8211; amended lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss from disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ARCA and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Shares of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl" xml:lang="en-US">Potentially dilutive securities, excluded:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities, excluded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Commitments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity Financings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSU Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Non-cash, Share-based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee Benefit Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Benefit Attributable to Our Loss from Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal income tax benefit at statutory rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl" xml:lang="en-US">Deferred tax asset adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US">Charitable contribution carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Capitalized intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl" xml:lang="en-US">Potentially dilutive securities, excluded:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed lease interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: Current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Vested and released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Outstanding stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Unvested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Lab Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Computer software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0" xml:lang="en-US">Computer Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US">Restructuring Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xml:lang="en-US">Retirement Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl" xml:lang="en-US">Off-balance-sheet concentrations of credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xml:lang="en-US">Fair value hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xml:lang="en-US">Debt outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl" xml:lang="en-US">Payment of unrestricted research grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_RetentionBonuses_lbl" xml:lang="en-US">Amount of retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_RetentionBonuses_lbl0" xml:lang="en-US">Retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageOfRetentionBonuses_lbl" xml:lang="en-US">Percentage of retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_RetentionBonusPaid_lbl" xml:lang="en-US">Retention bonus paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US">Remains unpaid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Workforce reduction percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US">Number of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Restructuring charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Square feet (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lease renewal option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl" xml:lang="en-US">Square feet office facilities (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl" xml:lang="en-US">Sublease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl" xml:lang="en-US">Lessee operating lease description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl" xml:lang="en-US">Royalty obligations (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US">Indicates (true false) whether lessee has option to extend operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl" xml:lang="en-US">Additional operating lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl" xml:lang="en-US">Percentage Of Base Rent To Be Paid Monthly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl" xml:lang="en-US">Aggregate offering price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl" xml:lang="en-US">Percentage of commission rate equal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Reserved shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Stock options award, vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock options award, expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Percentage of exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PurchaseAggregateShares_lbl" xml:lang="en-US">Purchase aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Stock awards granted service period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xml:lang="en-US">Matching contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Employee&#8217;s contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Equal contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Company&apos;s contribution (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carryforwards expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Operating loss carryforwards, limitations on use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Tax credit carryforward, limitations on use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl" xml:lang="en-US">Increase in net deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US">Reserve for uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Interest or penalties recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US">Number of consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Percentage of ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Percentage of noncontrolling ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl" xml:lang="en-US">Adjusted exchange ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl" xml:lang="en-US">Declared cash dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl" xml:lang="en-US">Subscription agreement receipt amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl" xml:lang="en-US">Payment of other party termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Preferred stock convertible shares issuable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl" xml:lang="en-US">Initially specified percentage for beneficial number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl" xml:lang="en-US">Excepted number of board members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NumberOfMonthsBaseSalary_lbl" xml:lang="en-US">Number of months base salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CashPayment_lbl" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl" xml:lang="en-US">Increase of retention bonus to each executive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl" xml:lang="en-US">Description of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates in the Preparation of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl" xml:lang="en-US">Accrued Outsourcing Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl0" xml:lang="en-US">Money Market Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value Measurements, Recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a4bY39FGh5gLIYnmd1AwOGy2evgYTBuMezrcHZ8hWGuIKmV96PSoFEqIafU9sj92aZRi6oN90zR+hQ0m6IzU+mpUZ5p5Jpyw5MoU2z9VITI83t6K3dnZhN1FswMEN9I7N62z9fGe79mpA==] CSR-->
    <loc xlink:type="locator" xlink:label="abio_ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl" xml:lang="en-US">Clinical Development Decision [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl0" xml:lang="en-US">Clinical development decisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xml:lang="en-US">One-time Termination Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl" xml:lang="en-US">University Medical Center of Johannes Gutenberg University Mainz</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl0" xml:lang="en-US">University Medical Center Of Johannes Gutenberg University Mainz</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PatentAssignmentAgreementMember_lbl" xml:lang="en-US">Patent Assignment Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl" xml:lang="en-US">Jones Trading</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">2020 Sales Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xml:lang="en-US">2020 Equity Incentive Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncentiveStockOptionMember_lbl" xml:lang="en-US">Incentive Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalOwnerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xml:lang="en-US">Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl" xml:lang="en-US">2013 Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FirstThreePercentPayContributionMember_lbl" xml:lang="en-US">First 3% of pay contributed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NextTwoPercentPayContributionMember_lbl" xml:lang="en-US">Next 2% of pay contributed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xml:lang="en-US">Earliest Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LatestTaxYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LatestTaxYearMember_lbl" xml:lang="en-US">Latest Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ArcaBiopharmaIncMember_lbl" xml:lang="en-US">ARCA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl" xml:lang="en-US">ARCA and Oruka</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FirstMergerMember_lbl" xml:lang="en-US">First Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OrukaTherapeuticsIncMember_lbl" xml:lang="en-US">Oruka Therapeutics Inc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl" xml:lang="en-US">Common Stock and Pre Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SeperationAgreementMember_lbl" xml:lang="en-US">Seperation Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PresidentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_PresidentMember_lbl" xml:lang="en-US">Thomas A. Keuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PresidentMember" xlink:to="srt_PresidentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl" xml:lang="en-US">Second Amendment of Certain Retention Bonus Letters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">C. Jeffrey Dekker</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl" xml:lang="en-US">Thomas A. Keuer and C. Jeffrey Dekker [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueDisclosuresDetailsTable_lbl" xml:lang="en-US">Fair Value Disclosures (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="abio_FairValueDisclosuresDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueDisclosuresDetailsLineItems_lbl" xml:lang="en-US">Fair Value Disclosures (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueDisclosuresDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RelatedPartyArrangementsDetailsTable_lbl" xml:lang="en-US">Related Party Arrangements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RelatedPartyArrangementsDetailsTable" xlink:to="abio_RelatedPartyArrangementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Arrangements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US">Type of Restructuring [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="abio_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EquityFinancingsDetailsTable_lbl" xml:lang="en-US">Equity Financings (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="abio_EquityFinancingsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EquityFinancingsDetailsLineItems_lbl" xml:lang="en-US">Equity Financings (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_EquityFinancingsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SharebasedCompensationDetailsTable_lbl" xml:lang="en-US">Share-based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="abio_SharebasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SharebasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Share-based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_SharebasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xml:lang="en-US">Retirement Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EmployeeBenefitPlansDetailsTable_lbl" xml:lang="en-US">Employee Benefit Plans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EmployeeBenefitPlansDetailsTable" xlink:to="abio_EmployeeBenefitPlansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems_lbl" xml:lang="en-US">Employee Benefit Plans (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="abio_EmployeeBenefitPlansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US">Tax Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="abio_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="abio_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Accrued outsourcing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AggregatePurchasePrice_lbl0" xml:lang="en-US">Aggregate purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl0" xml:lang="en-US">Area of real estate property sublease additional office facilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CashPayment_lbl0" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl0" xml:lang="en-US">Common stock, authorized offering amount under agreement to sell.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive loss policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl0" xml:lang="en-US">Deferred tax assets and liabilities valuation allowance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl0" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl0" xml:lang="en-US">Description of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl0" xml:lang="en-US">Excepted Number of Board Members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl0" xml:lang="en-US">Fair value assets between hierarchy levels transfers amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl0" xml:lang="en-US">Adjustment of the carrying value of deferred tax assets during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl0" xml:lang="en-US">Increase of retention bonus to each executive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl0" xml:lang="en-US">Initially specified percentage for beneficial number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl0" xml:lang="en-US">Lessee operating sublease term of contract.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">Liquidity and going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl0" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl0" xml:lang="en-US">Minimum percentage of originally issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl0" xml:lang="en-US">Number of consecutive trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NumberOfMonthsBaseSalary_lbl0" xml:lang="en-US">Number of months base salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl0" xml:lang="en-US">Operating loss carryforwards expiration year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl0" xml:lang="en-US">Payment of other party termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl0" xml:lang="en-US">Payment of unrestricted research grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl0" xml:lang="en-US">Minimum ownership percentage for 110% fair market value on the grant date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl0" xml:lang="en-US">Percentage of base rent to be paid monthly.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageOfRetentionBonuses_lbl0" xml:lang="en-US">Percentage of retention bonuses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl0" xml:lang="en-US">Potential upfront and milestone obligations and royalty obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PurchaseAggregateShares_lbl0" xml:lang="en-US">Purchase aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl0" xml:lang="en-US">Research and development expense (reversed).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_RetentionBonusPaid_lbl0" xml:lang="en-US">Retention bonus paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_RetentionBonuses_lbl1" xml:lang="en-US">Retention bonuses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl0" xml:lang="en-US">Selling commission per additional shares sold percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl0" xml:lang="en-US">Subscription agreement receipt amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl0" xml:lang="en-US">Threshold amount of adjusted exchange ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl0" xml:lang="en-US">Threshold amount of declared cash dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl0" xml:lang="en-US">Valuation allowance deferred tax assets and liabilities change in amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl0" xml:lang="en-US">Arca Biopharma Inc and Oruka Therapeutics Inc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ArcaBiopharmaIncMember_lbl0" xml:lang="en-US">ARCA biopharma inc member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital on demand sales agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl1" xml:lang="en-US">Clinical Development Decision Member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl0" xml:lang="en-US">Common stock and pre funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FirstMergerMember_lbl0" xml:lang="en-US">First Merge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FirstThreePercentPayContributionMember_lbl0" xml:lang="en-US">First three percent pay contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncentiveStockOptionMember_lbl0" xml:lang="en-US">Incentive stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl0" xml:lang="en-US">JonesTrading Institutional Services LLC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MergerAgreementMember_lbl0" xml:lang="en-US">Merger agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">New Capital on Demand Sales Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NextTwoPercentPayContributionMember_lbl0" xml:lang="en-US">Next two percent pay contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_OrukaTherapeuticsIncMember_lbl0" xml:lang="en-US">Oruka therapeutics inc member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PatentAssignmentAgreementMember_lbl0" xml:lang="en-US">Patent assignment agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl0" xml:lang="en-US">Second amendment of certain retention bonus letters.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SeperationAgreementMember_lbl0" xml:lang="en-US">Seperation agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl0" xml:lang="en-US">Thomas A. Keuer and C. Jeffrey Dekker.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl0" xml:lang="en-US">Two thousand and thirteen plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two thousand and twenty equity incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl1" xml:lang="en-US">University medical center of Johannes Gutenberg university Mainz.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl1" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity And Going Concern Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl1" xml:lang="en-US">Excepted Number Of Board Members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl0" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarliestTaxYearMember_lbl0" xml:lang="en-US">Earliest Tax Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenTaxYear_lbl0" xml:lang="en-US">Open Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl1" xml:lang="en-US">Jones Trading Institutional Services LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="abio_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl1" xml:lang="en-US">Threshold Amount Of Declared Cash Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl1" xml:lang="en-US">New Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl1" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl1" xml:lang="en-US">Two Thousand And Twenty Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PatentAssignmentAgreementMember_lbl1" xml:lang="en-US">Patent Assignment Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl1" xml:lang="en-US">Two Thousand And Thirteen Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl1" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl0" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl1" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl1" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl1" xml:lang="en-US">Software and Software Development Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl0" xml:lang="en-US">Proceeds from Income Tax Refunds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl0" xml:lang="en-US">Tax Credit Carryforward, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Net Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl0" xml:lang="en-US">Operating Leases Extended Expiry Years And Month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract2" xlink:to="abio_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract1" xlink:to="abio_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract4" xlink:to="abio_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract3" xlink:to="abio_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract0" xlink:to="abio_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageOfRetentionBonuses_lbl1" xml:lang="en-US">Percentage Of Retention Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl1" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ArcaBiopharmaIncMember_lbl1" xml:lang="en-US">Arca Biopharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl1" xml:lang="en-US">Payment Of Unrestricted Research Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract" xlink:to="abio_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl1" xml:lang="en-US">Minimum Percentage Of Originally Issued Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CashPayment_lbl1" xml:lang="en-US">Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl0" xml:lang="en-US">Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl0" xml:lang="en-US">Lessee, Operating Lease, Assumptions and Judgments, Allocation of Lease and Nonlease Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl1" xml:lang="en-US">Common Stock And Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FirstThreePercentPayContributionMember_lbl1" xml:lang="en-US">First Three Percent Pay Contribution Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl0" xml:lang="en-US">Restructuring Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees&apos; Gross Pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl1" xml:lang="en-US">Percentage Of Base Rent To Be Paid Monthly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl1" xml:lang="en-US">Fair Value Assets Between Hierarchy Levels Transfers Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl1" xml:lang="en-US">Selling Commission Per Additional Shares Sold Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RetentionBonusPaid_lbl1" xml:lang="en-US">Retention Bonus Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_WeightedAverageSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Shares Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl0" xml:lang="en-US">Area of Real Estate Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl0" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl0" xml:lang="en-US">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl1" xml:lang="en-US">Thomas AKeuer And CJeffrey Dekker Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl1" xml:lang="en-US">Accrued Outsourcing Expenses Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl1" xml:lang="en-US">Increase Of Retention Bonus To Each Executive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl1" xml:lang="en-US">Threshold Amount Of Adjusted Exchange Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NumberOfMonthsBaseSalary_lbl1" xml:lang="en-US">Number Of Months Base Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl1" xml:lang="en-US">Number Of Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl1" xml:lang="en-US">Percentage Holding For Stock Options Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FirstMergerMember_lbl1" xml:lang="en-US">First Merger Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl1" xml:lang="en-US">Minimum Percentage Of Originally Issued Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MergerAgreementMember_lbl1" xml:lang="en-US">Merger Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl1" xml:lang="en-US">Valuation Allowance Deferred Tax Assets And Liabilities Change In Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl1" xml:lang="en-US">Payment Of Other Party Termination Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl2" xml:lang="en-US">Clinical Development Decision Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LatestTaxYearMember_lbl0" xml:lang="en-US">Latest Tax Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SeperationAgreementMember_lbl1" xml:lang="en-US">Seperation Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RetentionBonuses_lbl2" xml:lang="en-US">Retention Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalOwnerMember_lbl0" xml:lang="en-US">Principal Owner [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CostsAndExpensesAbstract0_lbl0" xml:lang="en-US">Costs And Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CostsAndExpensesAbstract0" xlink:to="abio_CostsAndExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl1" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl1" xml:lang="en-US">Arca Biopharma Inc And Oruka Therapeutics Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl0" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OrukaTherapeuticsIncMember_lbl1" xml:lang="en-US">Oruka Therapeutics Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl1" xml:lang="en-US">Potential Upfront And Milestone Obligations And Royalty Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl0" xml:lang="en-US">Defined Contribution Plan, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NextTwoPercentPayContributionMember_lbl1" xml:lang="en-US">Next Two Percent Pay Contribution Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl1" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl0" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl1" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl1" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Assets And Liabilities Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl1" xml:lang="en-US">Research And Development Expense Reversed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PresidentMember_lbl0" xml:lang="en-US">President [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PresidentMember" xlink:to="srt_PresidentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Non Cash Share Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl1" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl1" xml:lang="en-US">Area Of Real Estate Property Sublease Additional Office Facilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl0" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl1" xml:lang="en-US">Common Stock Authorized Offering Amount Under Agreement To Sell</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AggregatePurchasePrice_lbl1" xml:lang="en-US">Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl0" xml:lang="en-US">One-time Termination Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl0" xml:lang="en-US">Potentially Dilutive Securities Excluded Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Business Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl1" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl0" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl1" xml:lang="en-US">Deferred Tax Asset Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncentiveStockOptionMember_lbl1" xml:lang="en-US">Incentive Stock Option Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl0" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PurchaseAggregateShares_lbl1" xml:lang="en-US">Purchase Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl2" xml:lang="en-US">University Medical Center Of Johannes Gutenberg University Mainz Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl1" xml:lang="en-US">Lessee Operating Sublease Term Of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl1" xml:lang="en-US">Initially Specified Percentage For Beneficial Number Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl0" xml:lang="en-US">Restructuring Reserve, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0" xml:lang="en-US">Retirement Benefits [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl1" xml:lang="en-US">Subscription Agreement Receipt Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl0" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl1" xml:lang="en-US">Second Amendment Of Certain Retention Bonus Letters Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl0" xml:lang="en-US">Interest and Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Comprehensive Loss Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl0" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl1" xml:lang="en-US">Income Tax Reconciliation Adjustment To Deferred Tax Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl0" xml:lang="en-US">Potentially Dilutive Securities Excluded Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl0" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>45
<FILENAME>abio-20240331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 13 23:21:12 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ShareholdersEquityType2or3" roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPolicies" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShare" roleURI="http://www.arcabiopharma.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosures" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipment" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangements" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingencies" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancings" roleURI="http://www.arcabiopharma.com/role/EquityFinancings"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensation" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlans" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxes" roleURI="http://www.arcabiopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEvents" roleURI="http://www.arcabiopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_AccountingPoliciesByPolicy" roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShareTables" roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentTables" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesTables" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationTables" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesTables" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofRSUActivityTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosuresDetails" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentDetails" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangementsDetails" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesDetails" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancingsDetails" roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationDetails" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlansDetails" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesDetails" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEventsDetails" roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#DocumentAndEntityInformation" roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_StockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="WeightedAverageSharesOutstandingAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ResearchAndDevelopmentExpenseReversed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosures">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangements">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/EquityFinancings">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlans">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfBusinessPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityAndGoingConcernPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ComprehensiveLossPolicyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AccruedOutsourcingExpensesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/NetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PotentiallyDilutiveSecuritiesExcludedAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a4bY39FGh5gLIYnmd1AwOGy2evgYTBuMezrcHZ8hWGuIKmV96PSoFEqIafU9sj92aZRi6oN90zR+hQ0m6IzU+mpUZ5p5Jpyw5MoU2z9VITI83t6K3dnZhN1gZiMzGbZ7AjWaJnZWZuXYg==] CSR-->
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetResearchAndDevelopment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsLeaseLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PotentiallyDilutiveSecuritiesExcludedAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="FairValueDisclosuresDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyArrangementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ResearchAndDevelopmentExpenseReversed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="PaymentOfUnrestrictedResearchGrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ClinicalDevelopmentDecisionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PatentAssignmentAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RetentionBonuses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PercentageOfRetentionBonuses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RetentionBonusPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringCharges" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LesseeOperatingSubleaseTermOfContract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="OperatingLeasesExtendedExpiryYearsAndMonth" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PercentageOfBaseRentToBePaidMonthly" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/EquityFinancingsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityFinancingsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="NewCapitalOnDemandSalesAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="dei_LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="JonesTradingInstitutionalServicesLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="EquityFinancingsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="SellingCommissionPerAdditionalSharesSoldPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="SharebasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="IncentiveStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalOwnerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_PrincipalOwnerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandAndTwentyEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandAndThirteenPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="SharebasedCompensationDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="PercentageHoldingForStockOptionsExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="PurchaseAggregateShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="EmployeeBenefitPlansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="FirstThreePercentPayContributionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="NextTwoPercentPayContributionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="EmployeeBenefitPlansDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_EarliestTaxYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LatestTaxYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_LatestTaxYearMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="OperatingLossCarryforwardsExpirationYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="DeferredTaxAssetsAndLiabilitiesValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OpenTaxYear" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MergerAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="FirstMergerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SeperationAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SecondAmendmentOfCertainRetentionBonusLettersMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PresidentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_PresidentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ThomasAKeuerAndCJeffreyDekkerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="ArcaBiopharmaIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="OrukaTherapeuticsIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockAndPreFundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_OwnershipAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfConsecutiveTradingDays" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ThresholdAmountOfAdjustedExchangeRatio" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ThresholdAmountOfDeclaredCashDividend" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="SubscriptionAgreementReceiptAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PaymentOfOtherPartyTerminationFee" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="MinimumPercentageOfOriginallyIssuedShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="MinimumPercentageOfOriginallyIssuedOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="InitiallySpecifiedPercentageForBeneficialNumberOfShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ExceptedNumberOfBoardMembers" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AggregatePurchasePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfMonthsBaseSalary" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="CashPayment" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="IncreaseOfRetentionBonusToEachExecutive" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="RetentionBonuses" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="abio-20240331.xsd#abio_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074635200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCA BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872080091376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,903<span></span>
</td>
<td class="nump">$ 37,431<span></span>
</td>
<td class="nump">$ 42,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">36,670<span></span>
</td>
<td class="nump">37,592<span></span>
</td>
<td class="nump">42,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset &#8211; operating</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,706<span></span>
</td>
<td class="nump">37,861<span></span>
</td>
<td class="nump">43,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">225,861<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(190,750)<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">35,125<span></span>
</td>
<td class="nump">37,020<span></span>
</td>
<td class="nump">41,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 36,706<span></span>
</td>
<td class="nump">$ 37,861<span></span>
</td>
<td class="nump">$ 43,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872152318960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities - related party (in Dollars)</a></td>
<td class="nump">$ 968<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities - related party (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872147882192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,317<span></span>
</td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="nump">$ 6,283<span></span>
</td>
<td class="nump">$ 5,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">4,749<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">2,482<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">7,296<span></span>
</td>
<td class="nump">10,596<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,482)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
<td class="num">(7,296)<span></span>
</td>
<td class="num">(10,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="num">$ (1,346)<span></span>
</td>
<td class="num">$ (5,339)<span></span>
</td>
<td class="num">$ (9,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_WeightedAverageSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">14,415,877<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_WeightedAverageSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_WeightedAverageSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872080255904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">14,415,877<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ResearchAndDevelopmentExpenseReversed', window );">Related party expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="num">$ (91)<span></span>
</td>
<td class="nump">$ 432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ResearchAndDevelopmentExpenseReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense (reversed).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ResearchAndDevelopmentExpenseReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872078650400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 224,505<span></span>
</td>
<td class="num">$ (173,476)<span></span>
</td>
<td class="nump">$ 51,043<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,926)<span></span>
</td>
<td class="num">(9,926)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
<td class="nump">$ 41,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,265<span></span>
</td>
<td class="num">(184,748)<span></span>
</td>
<td class="nump">40,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
<td class="nump">$ 41,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of Restricted Stock Units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,339)<span></span>
</td>
<td class="num">(5,339)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="nump">$ 37,020<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,265<span></span>
</td>
<td class="num">(184,748)<span></span>
</td>
<td class="nump">$ 40,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,452<span></span>
</td>
<td class="num">(186,228)<span></span>
</td>
<td class="nump">39,238<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,606<span></span>
</td>
<td class="num">(187,652)<span></span>
</td>
<td class="nump">37,968<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of Restricted Stock Units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="nump">$ 37,020<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 225,861<span></span>
</td>
<td class="num">$ (190,750)<span></span>
</td>
<td class="nump">$ 35,125<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872078524496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="num">$ (1,346)<span></span>
</td>
<td class="num">$ (5,339)<span></span>
</td>
<td class="num">$ (9,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset &#8211; operating</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(606)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(526)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="num">(5,014)<span></span>
</td>
<td class="num">(10,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="num">(5,014)<span></span>
</td>
<td class="num">(10,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">37,431<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
<td class="nump">53,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">35,903<span></span>
</td>
<td class="nump">40,850<span></span>
</td>
<td class="nump">37,431<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Income tax refund received</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets and operating lease liabilities &#8211; amended lease term</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074813968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ARCA and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ARCA and Summary of Significant Accounting Policies</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074736064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">664,857</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-112; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">755,857</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-69; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">795,960</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074839520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were <span style="-sec-ix-hidden: hidden-fact-113"><span style="-sec-ix-hidden: hidden-fact-114">no</span></span> marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $35.9&#160;million and $37.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-115">no</span> transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#8217;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, ARCA had $37.4&#160;million and $42.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-72"><span style="-sec-ix-hidden: hidden-fact-73">no</span></span> transfers between any fair value hierarchy levels in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did <span style="-sec-ix-hidden: hidden-fact-70"><span style="-sec-ix-hidden: hidden-fact-71">not</span></span> have any debt outstanding.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074704192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consist of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(215</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $3,000 and $4,000 respectively.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consist of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">44</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">229</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(204</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $15,000 and $20,000, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074648928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Arrangements</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872077099216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000. See Note&#160;10.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-119">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was <span style="-sec-ix-hidden: hidden-fact-117">29</span>&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the lease liability was $48,000, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $23,000 and $33,000, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of March&#160;31, 2024 is <span style="-sec-ix-hidden: hidden-fact-118">0.5</span>&#160;years. The discount rate for the operating lease is 7%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">&#8364;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $311,000, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-76">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA implemented a strategic reduction of the workforce by approximately 67%, or 12 employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#8217;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits, none of which remains unpaid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Lease</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term is 42&#160;months beginning October&#160;1, 2020 and includes an option to renew for an additional 36<span class="nobreak"> </span>month term at the then prevailing rental rate. The exercise of the lease renewal option is at ARCA&#8217;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was <span style="-sec-ix-hidden: hidden-fact-74">29</span>&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">96</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">314</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(34</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $119,000 and $125,000, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the lease liability was $280,000 and the current portion is included in accrued expenses and other liabilities and the non<span class="nobreak">-current</span> portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $127,000 and $131,000, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of December&#160;31, 2023 is <span style="-sec-ix-hidden: hidden-fact-75">3.2</span>&#160;years. The weighted<span class="nobreak">-average</span> discount rate for the operating lease is 7%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro License</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074784224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity Financings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Financings</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;">Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $0.001 per share (&#8220;ARCA common stock&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No sales were made under the Sales Agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See &#8220;Financing Transaction&#8221; discussion in Note&#160;10 below.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;22, 2020, ARCA entered into a Capital on Demand<span class="Superscript" style="vertical-align:super;font-size:58%;">TM</span> Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $0.001 per share (&#8220;ARCA&#160;common stock&#8221;), having an aggregate offering price of up to $54.0&#160;million (the &#8220;Shares&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No sales were made in 2023 or 2022.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one<span class="nobreak">-third</span> of ARCA&#8217;s public float in any 12<span class="nobreak">-month</span> period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872078428720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">163</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-120; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-121; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-122; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12,862</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17.45</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">502,517</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.71</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.55</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,816</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s equity incentive plan, <span class="Italic" style="font-style:italic;font-weight:normal;">the 2020 Equity Incentive Plan </span>(the &#8220;Equity Plan&#8221;),<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is 1,167,425<span class="nobreak"> </span>shares.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase 601,900<span class="nobreak"> </span>shares with a weighted average exercise price of $3.45 per share were outstanding under the Equity Plan, and 459,718<span class="nobreak"> </span>shares were reserved for future awards.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of <span style="-sec-ix-hidden: hidden-fact-98">three</span> to <span style="-sec-ix-hidden: hidden-fact-99">four</span>&#160;years from the date of grant and have a maximum term of <span style="-sec-ix-hidden: hidden-fact-100">ten</span>&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase 14,807<span class="nobreak"> </span>shares with a weighted average exercise price of $57.73 per share were outstanding under the 2013 plan.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not grant options in 2023. ARCA granted options to purchase an aggregate of 60,000<span class="nobreak"> </span>shares of ARCA common stock in the year ended December&#160;31, 2022. The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.5&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.56</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.87</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">904,123</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.59</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.31</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(259,163</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.74</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.62</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.29</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(88,253</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11.68</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">463,068</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.28</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.29</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,661</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#8217;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in<span class="nobreak">-the-money</span> options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $367,000 which is expected to be recognized over a weighted average period of <span style="-sec-ix-hidden: hidden-fact-101">1.1</span>&#160;years. ARCA recognizes compensation costs for its share<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA granted restricted stock units (&#8220;RSUs&#8221;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight<span class="nobreak">-line</span> basis over the respective vesting period. The stock awards granted had a requisite service period of <span style="-sec-ix-hidden: hidden-fact-102">one</span> year.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-97; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, there was no unrecognized compensation cost related to unvested stock awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-cash Stock-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">160</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">686</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">556</p>	</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not recognize any tax benefit related to employee stock<span class="nobreak">-based</span> compensation cost as a result of the full valuation allowance on its net deferred tax assets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872078688288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Employee Benefit Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has a 401(k)&#160;plan and makes a matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions. ARCA adopted the plan in 2006 and contributed $56,000 and $96,000 for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074747248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#8217;s deferred tax assets will not be realized. ARCA&#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has <span style="-sec-ix-hidden: hidden-fact-123">no</span> reserve for uncertain tax positions.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective June&#160;1, 2005, ARCA changed from an S<span class="nobreak">-Corporation</span> to a C<span class="nobreak">-Corporation</span>. As an S<span class="nobreak">-Corporation</span>, the net operating loss carryforwards were distributed to ARCA&#8217;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#8217;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning <span style="-sec-ix-hidden: hidden-fact-109">2025</span> through <span style="-sec-ix-hidden: hidden-fact-110">2037</span>. The net operating loss carryforwards beginning in 2018, have no expiration. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#8217;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $55.5&#160;million at December&#160;31, 2023, reflecting an increase of approximately $1.2&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,121</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,085</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(192</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(357</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">186</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,159</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,254</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51,190</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,008</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">371</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">951</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">979</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">354</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">356</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">232</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,594</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,461</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(55,531</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(54,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(84</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-107; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-108; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#8217;s open tax&#160;years extend back to <span style="-sec-ix-hidden: hidden-fact-111">2009</span>. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#8217;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has no reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. No interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872079943264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#8220;Out of the Money Options&#8221;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the financing transaction described below) will own approximately 97.62% of the combined company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately 2.38% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">adjusted to the extent that ARCA&#8217;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5,000,000.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to ARCA&#8217;s transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series&#160;B Preferred Stock&#8221;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of five (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock (together, the &#8220;PIPE Securities&#8221;) for an aggregate purchase price of approximately $275.0&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (12)&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $25,000, less applicable withholdings. The severance benefits were conditioned on the non<span class="nobreak">-revocation</span> by Dr.&#160;Bristow of a legal release of claims.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;Plan&#8221;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment of Thomas Keuer as President</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#8217;s Chief Operating Officer, to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on April&#160;3, 2024.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872080437872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_DescriptionOfBusinessPolicyTextBlock', window );">Description of Business</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates in the Preparation of Financial Statements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ComprehensiveLossPolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_AccruedOutsourcingExpensesPolicyTextBlock', window );">Accrued Outsourcing Expenses</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AccruedOutsourcingExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued outsourcing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AccruedOutsourcingExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DescriptionOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DescriptionOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074825984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Shares of Common Stock</a></td>
<td class="text">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">664,857</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-112; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">755,857</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-69; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">795,960</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074752720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">Property and equipment consist of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(215</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
<td class="text">Property and equipment consist of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">44</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">229</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(204</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074832736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Commitments Due</a></td>
<td class="text">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
<td class="text">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">96</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">314</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(34</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872079326816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.5&#160;years</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.56</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.87</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activities</a></td>
<td class="text">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-121; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-122; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12,862</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17.45</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">502,517</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.71</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.55</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,816</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">904,123</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.59</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.31</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(259,163</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.74</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.62</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.29</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(88,253</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11.68</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">463,068</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.28</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.29</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,661</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-97; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash, Share-based Compensation Expense</a></td>
<td class="text">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">163</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-120; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">160</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">686</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">556</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074667728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Benefit Attributable to Our Loss from Operations</a></td>
<td class="text">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,121</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,085</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(192</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(357</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">186</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,159</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,254</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net deferred tax assets and liabilities</a></td>
<td class="text">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">

					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51,190</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,008</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">371</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">951</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">979</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">354</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">356</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">232</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,594</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,461</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(55,531</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(54,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(84</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-107; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-108; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872077782160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ARCA and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset', window );">Off-balance-sheet concentrations of credit risk</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872076038640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">755,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">795,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">664,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentiallyDilutiveSecuritiesExcludedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872140476704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_FairValueDisclosuresDetailsLineItems', window );"><strong>Fair Value Disclosures (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount', window );">Fair value hierarchy</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value Measurements, Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_FairValueDisclosuresDetailsLineItems', window );"><strong>Fair Value Disclosures (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 42.4<span></span>
</td>
<td class="nump">$ 35.9<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assets between hierarchy levels transfers amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueDisclosuresDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_FairValueDisclosuresDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872077741440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872077835600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872119818976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Arrangements (Details) - Chief Executive Officer [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ResearchAndDevelopmentExpenseReversed', window );">Related party expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="num">$ (91,000)<span></span>
</td>
<td class="nump">$ 432,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PaymentOfUnrestrictedResearchGrants', window );">Payment of unrestricted research grants</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PaymentOfUnrestrictedResearchGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of unrestricted research grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PaymentOfUnrestrictedResearchGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ResearchAndDevelopmentExpenseReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense (reversed).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ResearchAndDevelopmentExpenseReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872077980240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th">
<div>Aug. 29, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PercentageOfRetentionBonuses', window );">Percentage of retention bonuses</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_RetentionBonusPaid', window );">Retention bonus paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Remains unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce reduction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease renewal option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to renew for an additional 36 month term at the then prevailing rental rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to extend the lease term six (6)&#160;months through September&#160;2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities', window );">Square feet office facilities (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_LesseeOperatingSubleaseTermOfContract', window );">Sublease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent', window );">Lessee operating lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 73 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Indicates (true false) whether lessee has option to extend operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_OperatingLeasesExtendedExpiryYearsAndMonth', window );">Additional operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">September&#160;2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PercentageOfBaseRentToBePaidMonthly', window );">Percentage Of Base Rent To Be Paid Monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember', window );">Clinical development decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Patent Assignment Agreement | University Medical Center Of Johannes Gutenberg University Mainz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations', window );">Royalty obligations (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense | One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of real estate property sublease additional office facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LesseeOperatingSubleaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sublease term of contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_LesseeOperatingSubleaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_OperatingLeasesExtendedExpiryYearsAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_OperatingLeasesExtendedExpiryYearsAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfBaseRentToBePaidMonthly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of base rent to be paid monthly.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageOfBaseRentToBePaidMonthly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfRetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageOfRetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential upfront and milestone obligations and royalty obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonusPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retention bonus paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonusPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of assumptions and judgments used by lessee for allocating contract between lease and nonlease components for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_PatentAssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_PatentAssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872080471552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract', window );"><strong>Schedule of Future Minimum Commitments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed lease interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfFutureMinimumCommitmentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872077794128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember', window );">Jones Trading</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage', window );">Percentage of commission rate equal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember', window );">Sales Agreement | Jones Trading</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell', window );">Aggregate offering price (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember', window );">2020 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, authorized offering amount under agreement to sell.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EquityFinancingsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_EquityFinancingsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling commission per additional shares sold percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SellingCommissionPerAdditionalSharesSoldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872082710624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">904,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options award, expiration</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,167,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">601,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares</a></td>
<td class="nump">459,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Options granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PurchaseAggregateShares', window );">Purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">14,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 57.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options award, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PercentageHoldingForStockOptionsExercisePrice', window );">Exercise price per share</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options award, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember', window );">Incentive Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember', window );">Incentive Stock Option | Stockholders | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">1 year 36 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Stock awards granted service period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageHoldingForStockOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum ownership percentage for 110% fair market value on the grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageHoldingForStockOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PurchaseAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PurchaseAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SharebasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SharebasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872080036800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract', window );"><strong>Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">107.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share (in Dollars per share)</a></td>
<td class="nump">$ 1.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872078703840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Stock Option Activities - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ScheduleOfStockOptionActivitiesAbstract', window );"><strong>Schedule of Stock Option Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Options outstanding, ending balance</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable, ending balance</a></td>
<td class="nump">463,068<span></span>
</td>
<td class="nump">502,517<span></span>
</td>
<td class="nump">463,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable, ending balance</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options vested and expected to vest, ending balance</a></td>
<td class="nump">616,661<span></span>
</td>
<td class="nump">645,816<span></span>
</td>
<td class="nump">616,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,862)<span></span>
</td>
<td class="num">(88,253)<span></span>
</td>
<td class="num">(259,163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.45<span></span>
</td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfStockOptionActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfStockOptionActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872214747136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of RSU Activity - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ScheduleOfRsuActivityAbstract', window );"><strong>Schedule of RSU Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, RSUs outstanding, beginning of period</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, RSUs outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, RSUs outstanding, Vested and released</a></td>
<td class="num">(91,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, RSUs outstanding, Forfeited and cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, RSUs outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfRsuActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfRsuActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872076082480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074656784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Matching contribution</a></td>
<td class="text">matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution (in Dollars)</a></td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember', window );">First 3% of pay contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employee&#8217;s contribution percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Equal contribution percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember', window );">Next 2% of pay contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employee&#8217;s contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Equal contribution percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EmployeeBenefitPlansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_EmployeeBenefitPlansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872078502944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 208,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Operating loss carryforwards, limitations on use</a></td>
<td class="text">The net operating loss carryforwards beginning in 2018, have no expiration.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount', window );">Increase in net deferred tax assets and liabilities</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Reserve for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and experimentation credits</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforward, limitations on use</a></td>
<td class="text">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets and liabilities valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance deferred tax assets and liabilities change in amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872079609600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract', window );"><strong>Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax benefit at statutory rates</a></td>
<td class="num">$ (1,121)<span></span>
</td>
<td class="num">$ (2,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal benefit</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and experimentation credits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset', window );">Deferred tax asset adjustment</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,159<span></span>
</td>
<td class="nump">2,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment of the carrying value of deferred tax assets during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872082629760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 51,190<span></span>
</td>
<td class="nump">$ 50,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contribution carryforwards</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and experimentation credits</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_DeferredTaxAssetResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Capitalized intangibles</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued compensation</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">55,594<span></span>
</td>
<td class="nump">54,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(55,531)<span></span>
</td>
<td class="num">(54,372)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872074753248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">755,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">795,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">664,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentiallyDilutiveSecuritiesExcludedAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872077731840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872079531408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract', window );"><strong>Schedule of Future Minimum Commitments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed lease interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfFutureMinimumCommitmentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872080448224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872147880816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Stock Option Activities - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ScheduleOfStockOptionActivitiesAbstract', window );"><strong>Schedule of Stock Option Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Options outstanding, ending balance</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable, ending balance</a></td>
<td class="nump">463,068<span></span>
</td>
<td class="nump">502,517<span></span>
</td>
<td class="nump">463,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable, ending balance</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options vested and expected to vest, ending balance</a></td>
<td class="nump">616,661<span></span>
</td>
<td class="nump">645,816<span></span>
</td>
<td class="nump">616,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,862)<span></span>
</td>
<td class="num">(88,253)<span></span>
</td>
<td class="num">(259,163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.45<span></span>
</td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfStockOptionActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfStockOptionActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139872079840032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 20, 2024</div></th>
<th class="th"><div>Apr. 03, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ThresholdAmountOfDeclaredCashDividend', window );">Declared cash dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ThresholdAmountOfAdjustedExchangeRatio', window );">Adjusted exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA | ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of noncontrolling ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares', window );">Initially specified percentage for beneficial number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Oruka Therapeutics Inc | Common Stock and Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_AggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_MinimumPercentageOfOriginallyIssuedShares', window );">Minimum percentage of originally issued outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_MinimumPercentageOfOriginallyIssuedOutstanding', window );">Minimum percentage of originally issued outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Thomas A. Keuer and C. Jeffrey Dekker [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Retention bonuses</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember', window );">Merger Agreement | ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_PaymentOfOtherPartyTerminationFee', window );">Payment of other party termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember', window );">Merger Agreement | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubscriptionAgreementReceiptAmount', window );">Subscription agreement receipt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember', window );">Merger Agreement | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember', window );">First Merger | Oruka Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_ExceptedNumberOfBoardMembers', window );">Excepted number of board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember', window );">First Merger | Series B Preferred Stock | ARCA | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock convertible shares issuable (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_SeperationAgreementMember', window );">Seperation Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_NumberOfMonthsBaseSalary', window );">Number of months base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_CashPayment', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember', window );">Second Amendment of Certain Retention Bonus Letters | Thomas A. Keuer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_IncreaseOfRetentionBonusToEachExecutive', window );">Increase of retention bonus to each executive</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember', window );">Second Amendment of Certain Retention Bonus Letters | C. Jeffrey Dekker</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abio_IncreaseOfRetentionBonusToEachExecutive', window );">Increase of retention bonus to each executive</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ExceptedNumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excepted Number of Board Members</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ExceptedNumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncreaseOfRetentionBonusToEachExecutive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase of retention bonus to each executive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncreaseOfRetentionBonusToEachExecutive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initially specified percentage for beneficial number of shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfOriginallyIssuedOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of originally issued outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_MinimumPercentageOfOriginallyIssuedOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfOriginallyIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of originally issued shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_MinimumPercentageOfOriginallyIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfMonthsBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of months base salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_NumberOfMonthsBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PaymentOfOtherPartyTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of other party termination fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PaymentOfOtherPartyTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SubscriptionAgreementReceiptAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement receipt amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SubscriptionAgreementReceiptAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ThresholdAmountOfAdjustedExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of adjusted exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ThresholdAmountOfAdjustedExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ThresholdAmountOfDeclaredCashDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of declared cash dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ThresholdAmountOfDeclaredCashDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_ArcaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_ArcaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_OrukaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_OrukaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=abio_CommonStockAndPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=abio_CommonStockAndPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abio_ThomasAKeuerAndCJeffreyDekkerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abio_ThomasAKeuerAndCJeffreyDekkerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_SeperationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_SeperationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>95
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-_BI =),P/=K(?2A8Q9H/E[B?U!+ P04    " !8J:U8/$U+5J0%   R&0
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M8W**\CM1]N@4M>I$N>/)R:_FG/AU:K_.__HMB6XCNND,#=-T[);E+J!C&F=
MOQLX'(_:QJ]0/'$[K-T.>]T^0B+>_A")UYN_=7GNI<LC;,IR',!<$V<4 [H'
MS?OXP72-SUWOS7N*^>\IMGHGL9,:N'4-W*MJD,L:('@5#0"#KEJ4,L/&)C!:
M&^\<81KCUIX[Q]Q/S-9V.\<XMM7::7KCR$F![M19SU! BHR7GY=ZMFXGOJA3
MM#6_,*=+LV/>%^U'V2W\DR][%_&%W<7BA$I@*T(9@Y%8*2W[@7+ 2:X.O&?"
MQ?&I;B/10@&5 /%\2P@_#F2 NBGS_@)02P,$%     @ 6*FM6'$#! '^!@
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M.B[4#W+R[V:,"B!3:.($M0*(F!- >J@I.T0A2;HG.+ZI:,% -)&XBY]Z72^
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MU8XJGA20U6T$!=% (:[--MF'T<!);RK'PO%O@8Y7LQ0'D ;5U*(U*%:K-3=
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M]M!$>VBB_?8FVMVD^_?OHTW3I.&J@U;C#G5;4@R+P.\7^X=IG<AJ_S/-$VG
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MY*U0ZSD G_.+1^D--QA^&>_%?P%02P,$%     @ 6*FM6*9S0XCJ P  KPT
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M\>#"14LX:XY&Q&:E5(;_<H+!'@TG@WU;4:QV)VI$!!B,X1!+B)Y*Y?)E<@5
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M7B]59067N--@JJ)@^N4.A3JO@E'0#CSP4V[=0+A>ENR$>[0?RYVF7MBQ9+Q
M:;B2H/&X"C:CQ7;BUOL%?W(\FXLV.$\.2CVZSJ_9*HB<(!286L? Z.\)MRB$
M(R(9_S2<06?2 2_;+?O/WG?RY< ,;I7XBV<V7P7S #(\LDK8!W7^!1M_$L>7
M*F'\%\[UVF0:0%H9JXH&3 H*+NM_]MS$X0(PC[X"B!M _*V <0,8>T=K9=ZM
M>V;9>JG5&;1;36RNX6/CT>0-EVX7]U;3+"><7?]&B?)>&0,[U+#/F4;XX0]V
M$&A^7(:6#+AE8=J0W=5D\5?(QO!!29L;^$EFF/7@M]?QH_@*04B>=>[%K7MW
M\57&#TS?P'@TA#B*)WV"KL/O,>W@XRMRQEVTQYYO_.W1_KPY&*LIF__NBW=-
M-^FG<R=\84J6XBJ@(VQ0/V&P?OMF-(W>]?GZ2F3_\7S2>3ZYQK[>4_G)*H&@
MCK!3%J7E3(@7N.>B<@>YCH9QTUM5%'3 ]U:ECWTQN6[H#E-6&83-PW9#9:94
MVF(&#"2%7KC04^4#FR/]-"(4=;ZARS>@;$GS+EV R<QO_!!(*I07JK-6M>E4
M>WMI+=TXZ9 S6G! E(#/J:B<@:-6A3=."\O*,E_)".R&.LY.:4E)X@UXS5X#
M:JXRFG$;),FQ&]A7)/F[M:6*ZK"QK>VC$E3.N3PM!ET,!BX&[C,>['KI,:TT
MMQS-L'-P,?B]LL92X(BK,:5*YZ6!Z209SB<)3*>3X3R9#3[*)S1N;TBDU3QU
MS1I126[-X.V;>3R*W\'M:!A%T:"%SY+$P?OR^Y42XP69;C.""@ 6!]J'M@BT
M21'_KY+BDP^)+\IU1K@(O%):C*;#632#6309WDZC[TZ+%GZ;.'A?I0HO;L<"
M]<D_&@QY6TE;7Y3=:/<NV?CK./QW>?VHH<-QXB1:X)&@T<TL"4#7#X6Z8U7I
M[]J#LG1S^V9.;RO4;@'-'Q7%K.DX ]UK;?T%4$L#!!0    ( %BIK5@T0P3U
M\ (  'X(   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;+U66VO;,!1^
MSZ\0WA@ME-J6G5ZR))!F+1NL$-I='L8>%/LX%K4E5Y*;=K]^1[+CIN!F+8R"
M;=W.]^E<I',\7DMUHW, 0^[+0NB)EQM3C7Q?)SF43!_*"@2N9%*5S.!0K7Q=
M*6"I Y6%3X/@R"\9%]YT[.86:CJ6M2FX@(4BNBY+IA[.H)#KB1=ZFXDKOLJ-
MG?"GXXJMX!K,]VJA<.1W+"DO06@N!5&03;Q9.)K'5MX)_."PUEM]8BU92GEC
M!U_2B1=8A:" Q%@&ALT=S*$H+!&J<=MR>MV6%KC=W[!?.-O1EB73,)?%3YZ:
M?.*=>"2%C-6%N9+KS]#:,[1\B2RT^Y)U(QL-/9+4VLBR!:,&)1=-R^Y;/VP!
M3H)G +0%T)<"HA80.4,;S9Q9GYAAT[&2:Z*L-++9CO.-0Z,U7-@H7AN%JQQQ
M9KI0>""4>2!,I.3\MN85ALB0O6]L68#>'_L&-[&B?M(2GC6$]!G"B%Q*87)-
MSD4*:0]^OAL?TAT$/EK7F4@W)I[1G8R73!V2*#P@-*!QGT*[X9\@Z>#1#G6B
MSN.1XXM>Y_%?LZ4V"D_U[SZ?-Y1Q/Z6]Z2-=L00F'EYE#>H.O.F'=^%1\+'/
MWO]$]L3ZN+,^WL4^O<8TE-8%$)F1?D_TF;^;\PD/=!Y-).8:;>Q.)@>2R0)3
M%A<KLL<%SLA:H[S>'PW.M>&8$" =X%%)<AOL 48=RB4H-YC+LJH-#A[)(_(
M3.G!>Q*=-I^O;+FU/FS7PRAP[T6M!#>U J=DQN]M7W=BT;%]NGVTS,R:H?!F
MF_#(/I12]\Z2I"[KPJJ,*0NCE'#6)$7D9J54AO]Q$X,]&@X'^[:AV/0[ZH (
M,&C#,;YAT'=@WLK]3YS^]A&(XQ=&X/1U$: N D'\SPB$ 7[HL.^:^5LIO@2U
M<I5/HY-K89ILW\UVQ77F:HK_*-Y49CSD*RXT*2!#:'!XC+5,-=6N&1A9N8*Q
ME ;+C^OF^(, R@K@>B:EV0SL!MTOQ_0O4$L#!!0    ( %BIK5CF.JO#(0,
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MI(0E;;A]K]9OH<MGX/@*Q8W_)>O6=Y"&I&B,5:(#8P2"R?9+'SH=M@"C^ E
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M#&@WB:GWR@N&O4'4BNM?9,6#J)N@B0$5^B3N)=290P7$;$F'S".?=J.@CBE
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M;M,P%/T5*R T)+:D21O02"-U+0@>!E6KP0/BP75N$FN.'6RG'7^/[:2A15D
M:2^-[=QS[KGW-L?)0<A[50)H]% QKN9>J75][?N*E%!A=25JX.9-+F2%M=G*
MPE>U!)PY4,7\, ABO\*4>VGBSM8R342C&>6PED@U587ESQM@XC#W)M[Q8$.+
M4ML#/TUJ7, 6]%V]EF;G]RP9K8 K*CB2D,^]Q>1Z&=MX%_"%PD&=K)&M9"?$
MO=U\S.9>8 4! Z(M S://2R!,4MD9/SH.+T^I06>KH_L[UWMII8=5K 4["O-
M=#GWWG@H@QPW3&_$X0-T]<PL'Q%,N5]T:&/CR$.D45I4'=@HJ"AOG_BAZ\,)
M( P? 80=(/Q70-0!(E=HJ\R5M<(:IXD4!R1MM&&S"]<;AS;54&ZGN-72O*4&
MI]/%9KE F&=HVXX1B1QM:<%I3@GF&BT($0W7E!=H+1@E%!2Z6('&E*F7B:^-
M!$ODDR[=39LN?"1=A&X%UZ5"[W@&V0!^.8Z?A",$OJF];T!X;,!-.,IXB^45
MBB:O4!B$4W2W7:&+YT.%+<=I5D!ZFFB8YDQ>U,\G<KS1$\[GVV*GM#0?R/>A
M ;7YIL/YK&E<JQH3F'O&%13(/7CIBV>3.'@[U)0G(CMKS;1OS72,/=W 'G@#
M0S6VP)D#6A_;IT'B[T^%CT6<J9GU:F:C:C[G^>4.,\P)7+;^2X19<S,(ZU?*
M#HY(R*A&DJK[(=6SOZH>BSA3'?>JXU'5GYIJ!])J4U 8<]9#ND8I_O<?TY+%
M)R5,_BC!/W&S"F3A3%XA]S]OC:T_[>^1A;-/_W=X>PF9C[N@IO<,<@,-KEZ;
MULG6V-N-%K7SQIW0QFG=LC1W(4@;8-[G0NCCQB;H;]?T%U!+ P04    " !8
MJ:U8C*U*BW(#  #1$   &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6RU
MF&N/VCH0AO^*E2-5IU*[N9"$RP&D+LE1C]0+6K3M9V\R@+5)3&T'MO_^V$XV
M!=:D5/)^(;[,^]B>L289I@?*'OD60*"GLJCXS-D*L9NX+L^V4&)^0W=0R9DU
M9246LLLV+M\QP+D6E84;>%[LEIA4SGRJQY9L/J6U*$@%2X9X79:8_;R%@AYF
MCN\\#]R1S5:H 7<^W>$-K$#<[Y9,]MR.DI,2*DYHA1BL9\X'?Y+ZGA)HBV\$
M#ORHC=11'BA]5)W_\IGCJ1U! 9E0""P?>UA 42B2W,>/%NIT:RKA<?N9_J\^
MO#S, ^:PH,5WDHOMS!DY*(<UK@MQ1P\?H3U0I'@9+;C^18?6UG-05G-!RU8L
M=U"2JGGBI]811P+),0N"5A"<"\(+@D$K&)P+X@N"L!6$UZX0M0)]=+<YNW9<
M@@6>3QD](*:L)4TUM/>U6OJ+5.JBK 23LT3JQ/R+O(N?*.=H"0RMMI@!^CL!
M@4G!WZ+W:"4O9EX7@.@:+:F 2A!<%#]10HI:1;B1<#6]H&4I([\2-'N42JXG
MIJZ0FU1+N5F[H=MF0\&%#0W09UJ)+4=IE4-NT"?]>C_H ;C2.YV+@F<7W0:]
MQ,^8W:"!_PX%7A :-K2X7CXPG:=?GD#6*T^OEP<]SAAT]V6@>8,+O.-+D#]?
M @Y9S8@@P-\A>,J*6CI^8@I]PP[-;)43)WR',Y@Y,NEQ8'MPYF_^\F/O'Y/;
M;<(2F[#4$NPD0&$7H+"/?GV 3/%IT+%&JU?,?AZ'T2B,IN[^V/,OS891-(J&
MIV:)@>;'0^_,+#70QM$X]CJS$S]$G1^B7C]\K047N,I)M4%<YR2Z4Z\F8TKJ
M1?WIO;0)2VS"4DNPDWC$73SB5TP<L<T V80E-F&I)=A)@(9=@(:OESB&UR4.
M@UD<ODP<!C-3XGAI-O3"BXECU/EAU.N'^VH/7$ N/X.Y8"13S2:!U!41QO31
M"_S3VVD3EMB$I99@)U$9=U$9OV+Z&-L,D$U88A.66H*=!,CW?E42WNLED'ZV
M>>_(%)T6=)P5QK[G>6<IQM9ZZ6_7:[SI'I5H);"-KHTYRFA=B>;KNQOMZN\/
MNNH\&[_U)PO?,)ZH>EV7A+_P3;$O"Y -J3@J8"V7\FZ&\C. -?5STQ%TIPO$
M!RIDN:F;6\ Y,&4@Y]=41K;MJ 6Z?S'F_P-02P,$%     @ 6*FM6*_,GM4N
M P  $0T  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULM9==;YLP%(;_
MRA&KID[J0@+DJTLB-675*C52U:K=Q;0+!TZ"58-3VR2MM!\_&PA+.H+6EMTD
M-ISWM<]C8PZC#1</,D)4\!2S1(ZM2*G5J6W+(,*8R!9?8:+O++B(B=)=L;3E
M2B ),U',;*?=[MDQH8DU&677KL5DQ%/%:(+7 F0:QT0\3Y'QS=CJ6-L+-W09
M*7/!GHQ69(FWJ.Y6UT+W[-(EI#$FDO($!"[&UEGGU!^:^"S@GN)&[K3!9#+G
M_,%T+L.QU3830H:!,@Y$_ZWQ'!DS1GH:CX6G50YIA+OMK?M%EKO.94XDGG/V
MG88J&EL#"T)<D)2I&[[YAD4^7>,7<":S7]CDL;V>!4$J%8\+L9Y!3)/\GSP5
M''8$'>^ P"D$SDM!]X# +03N2\&A*7F%P,O(Y*ED''RBR&0D^ :$B=9NII'!
MS-0Z?9J89;]50M^E6J<F%X0*N"<L1?"I#!B7J4 )QSXJ0IG\!)_A[M:'XZ-/
M< 0T@1EE3*^7'-E*CVX\[* 8Z3P?R3DPD@LSGJA(PM<DQ+!"[]?K.TZ-@:W3
M+G-WMKE/G5I''X,6N)T3<-J.4Y50O7Q&1"GWJO+Y]]'=FFS<<B7=S,]]ZTK^
MN-(*N%08RY\5TYWF]EZUO3E^3N6*!#BV]/DB4:S1FGS\T.FUOU2A:]+,;\AL
M#ZM78O7JW'.LZPQK1%$0$43/5?1J7:KG"%7@&O+QW^^SAZM;XNK6XO)QKD"_
M7J0B24B3916J6H=7H'J#S^$]]OY)[?'JE;QZM;ST(?*@'] Y0Y 8I((JBE6'
MZ[36YK5/YQO,*C?9^WWVH/5+:/U::%>X1@8=^ 4[A]X,B3GQ=$FBY G<&)A"
M;T =I%\;^ PY:;A(D[ 2<.V0KP7<I)G?D-D>ZD&)>O!_WRJ#)K$V:>8W9+:'
M=5AB'=;NX',B(\#'E.HWB]FP5>1RAV'F8*KW]<1S6KK06.\2^3O([;:&^T%^
M15!_QRG/P-XI(F,4RZP8EQ#P-%%Y/5E>+>O]LZS,M?^$YQ\+^E%;TD0"PX66
MMEM]?;B*O #/.XJOLI)TSI4N<+-FI+]94)@ ?7_!N=IVS #E5]#D-U!+ P04
M    " !8J:U884U-ZI8"  #-!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6RM5=]/VS 0_E>L#$T@;>1GV=2UD6C3B3T@53"VAVD/;G)M+)(XV$X+
M^^MWMM.L0(B8Q$MB7[[O.]_Y<C?9<7$K<P!%[LNBDE,G5ZH>NZY,<RBI/.4U
M5/AES45)%6[%QI6U )H94EFX@>>=N25EE1-/C&TIX@EO5,$J6 HBF[*DXF$&
M!=]-'=_9&Z[8)E?:X,:3FF[@&M1-O12X<SN5C)502<8K(F ]=<[]\2+2> /X
MP6 G#]9$1[+B_%9OOF53Q],'@@)2I14HOK8PAZ+00GB,NU;3Z5QJXN%ZK_[5
MQ(ZQK*B$.2]^LDSE4^>S0S)8TZ905WQW 6T\(ZV7\D*:)]E9[ C!:2,5+ULR
MGJ!DE7W3^S8/!P34Z2<$+2%X2HA>((0M(7Q*.'N!$+6$Z+4>1BW!A.[:V$WB
M$JIH/!%\1X1&HYI>F.P;-N:+5;I.KI7 KPQY*EX*+#FA'@BM,K*X:UB-1:#(
M<0**LD*>D(_DYCHAQT<GY(BPBGS/>2,1*R>N0O=:Q$U;5S/K*GC!54@N>:5R
M2195!ED//QGF^\& @(MQ=\$'^^!GP:#B)16G)/0_D, +HIX#S5]/#_OB&:8G
MD [2%Z^G!P/)"+M*"(U>^'^5\.M\)97 __EWWXU;R:A?4O>XL:QI"E,'FY@$
ML04G?O_./_.^]&7[+<62MQ1;O)'8HWN)NGN)AM3QGE$T9=3V5;P;6G*AV!]K
M@'N<&!+Z[L;*CHRL'A?;&*ML>YCPYXCH,2)YCO!'CR&+YY# ZR V8O>@/Y4@
M-F8P2)+RIE*V0#MK-WO.3<M]8I_YX[G?8T]P5MG1\D_>#CK\1S>LDJ2 -;KR
M3C_A084='G:C>&VZXXHK[+5FF>.\!:$!^'W-N=IOM(-N@L=_ 5!+ P04
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M#QW-.D;@N4: A/F0L  2%D+"(B!8PR\WM5]N/BSKW$ :!Q+F0\("2%@("8N
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M#8UCM]S2^X?*&M#W5$ISVEB"^D6-?@-02P,$%     @ 6*FM6 ?"F^J:!0
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M'',4Q>P#N */8GDNMC$&9 D>.0E_@K\VF="M#'/$(\R$U+?'.7C_[@-X!PS
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MI'D!GX^$T*N)<5#VM_$?4$L#!!0    ( %BIK5C^V W'DP,  +H0   9
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M2!!F@7Z_X5P]#LP&=6<:_P102P,$%     @ 6*FM6#@$*<9Y!@  \B0  !D
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M \6R1 _ ]W/.U>:+GJ"^YC3Y%U!+ P04    " !8J:U8 PQG07 #  "V"@
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M-H#W&\[5ZXT^$=4GX.A?4$L#!!0    ( %BIK5B,K4J+<@,  -$0   9
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MNH6X? (X6X)/OW*Z49,JP5M$)*:)> <NP$+=:\L\(8"MP)'R"_!]@<#;-^_
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M [H#*_KY)S=T?M%)8Y(L-DF6&"([$3'H10S&V*-/1(B"H%5*^QUM\1.%ES]
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M2W496FR<=%5^V%09OE'E;<W/2#CY7OT/8T?Q^0G%)]&;Q>D)Q2-G[6/EW=;
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M<(*+7[CWUH]#<&GW)1QL_1B"6B)#+9&?6AQ1_9KP^ 9FOVIOKU !!DO-=M0
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M7CXF [\=O?4]2S?*$SKP[\Y>?UODZNJ59Z\G;TY.6G?G5[O^,P.<^X&3]/(
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M_K*\;J*$PPO. ?YKOO\"4$L#!!0    ( %BIK5B,3^J/N@$  .X<   3
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MM-9E<\AGW6_.Z2=02P$"% ,4    " !8J:U8!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %BIK5@0
M0+MI[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( %BIK5B97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 6*FM6#4UDDGC @
MR @  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( %BIK5@\34M6I 4  #(9   8              " @28+
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !8J:U83WGW
MO'8#  "7#@  &               @($ $0  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ 6*FM6-;=!;E?!   \A(  !@
M ("!K!0  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( %BI
MK5@DG/U;[0(  * )   8              " @4$9  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " !8J:U8<0,$ ?X&  !Y,P  &
M        @(%D'   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ 6*FM6!ATZGOQ!@  9R@  !@              ("!F",  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( %BIK5B2U I3=14  "5/   8
M              " @;\J  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " !8J:U8IG-#B.H#  "O#0  &               @(%J0   >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 6*FM6"4I #,;!
M&@T  !D              ("!BD0  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " !8J:U8"E\:%C<#  ":"0  &0              @('<
M2   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %BIK5CV
M<"0RJP,  +\+   9              " @4I,  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ 6*FM6+D-CLC!"P  IR@  !D
M     ("!+%   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M" !8J:U8CB?]); %   V#P  &0              @($D7   >&PO=V]R:W-H
M965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %BIK5AK[@C!Y0<  .X6   9
M              " @0MB  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!
M A0#%     @ 6*FM6"@UGHZ3 @  _@4  !D              ("!)VH  'AL
M+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !8J:U8WWJ0&*4(
M  ";%P  &0              @('Q;   >&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;%!+ 0(4 Q0    ( %BIK5@SC&G.;@X  &PJ   9              "
M@<UU  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 6*FM
M6!!EGH; %@  R%D  !D              ("!<H0  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " !8J:U8\J_[;&,#  "Y"0  &0
M        @(%IFP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( %BIK5@T0P3U\ (  'X(   9              " @0.?  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ 6*FM6.8ZJ\,A P  9@@
M !D              ("!*J(  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " !8J:U8P_F?K]T%  ">$@  &0              @(&"I0
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( %BIK5B^M\FG
M_ 0   $,   9              " @9:K  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ 6*FM6)3(3(*; @  :0<  !D
M ("!R;   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !8
MJ:U8C*U*BW(#  #1$   &0              @(&;LP  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( %BIK5BOS)[5+@,  !$-   9
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M970S,2YX;6Q02P$"% ,4    " !8J:U8_-JOR5 #  !9#0  &0
M    @($\T@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M %BIK5A1B1;A8P0  /\>   9              " @</5  !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ 6*FM6*=$M\-W!P  K$@  !D
M             ("!7=H  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " !8J:U84<59#^ "  !=!P  &0              @($+X@  >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( %BIK5@'PIOJF@4
M /@@   9              " @2+E  !X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ 6*FM6)P4S+=N P  ZPX  !D              ("!
M\^H  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !8J:U8
M_M@-QY,#  "Z$   &0              @(&8[@  >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( %BIK5@?$ZL^8P,  *4.   9
M      " @6+R  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ 6*FM6#@$*<9Y!@  \B0  !D              ("!_/4  'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !8J:U8 PQG07 #  "V"@
M&0              @(&L_   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( %BIK5C_5&F$!P0   T/   9              " @5,  0!X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ 6*FM6(RM2HMR
M P  T1   !D              ("!D00! 'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " !8J:U8KBZCLRH$  "W&0  &0
M@($Z" $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( %BI
MK5CIC!S9^P(  $8*   9              " @9L, 0!X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ 6*FM6/[8#<>3 P  NA   !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !8J:U8EXJ[',     3 @  "P
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52P4&     #@ .  _#P  W"T!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>154</ContextCount>
  <ElementCount>247</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Operations (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Statements of Operations (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - ARCA and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>ARCA and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Fair Value Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/FairValueDisclosures</Role>
      <ShortName>Fair Value Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Related Party Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/RelatedPartyArrangements</Role>
      <ShortName>Related Party Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Equity Financings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EquityFinancings</Role>
      <ShortName>Equity Financings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>ARCA and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Fair Value Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/FairValueDisclosuresDetails</Role>
      <ShortName>Fair Value Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/FairValueDisclosures</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Property and Equipment (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Related Party Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails</Role>
      <ShortName>Related Party Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/RelatedPartyArrangements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Equity Financings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EquityFinancingsDetails</Role>
      <ShortName>Equity Financings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/EquityFinancings</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensationDetails</Role>
      <ShortName>Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Stock Option Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of RSU Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0</Role>
      <ShortName>Property and Equipment (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Stock Option Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0205122-01.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SubsequentEvents</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 19 fact(s) appearing in ix:hidden were eligible for transformation: abio:LesseeOperatingSubleaseTermOfContract, abio:OperatingLossCarryforwardsExpirationYear, us-gaap:EarningsPerShareDiluted, us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1, us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  ea0205122-01.htm 32175, 32176, 32177, 32178, 32179, 32180, 32181, 32182, 32243, 32244, 32267, 32268, 32269, 32270, 32271, 32278, 32279, 32286, 32287</Log>
  </Logs>
  <InputFiles>
    <File>abio-20240331.xsd</File>
    <File>abio-20240331_cal.xml</File>
    <File>abio-20240331_def.xml</File>
    <File>abio-20240331_lab.xml</File>
    <File>abio-20240331_pre.xml</File>
    <File doctype="S-4" isDefinitelyFs="true" isUsgaap="true" original="ea0205122-01.htm">ea0205122-01.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tarca_001.jpg</File>
    <File>timage_001.jpg</File>
    <File>timage_002.jpg</File>
    <File>timage_003.jpg</File>
    <File>timage_004.jpg</File>
    <File>timage_005.jpg</File>
    <File>timage_006.jpg</File>
    <File>timage_007.jpg</File>
    <File>tlucid_sig.jpg</File>
    <File>toruka_logo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="650">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0205122-01.htm": {
   "nsprefix": "abio",
   "nsuri": "http://www.arcabiopharma.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "abio-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "abio-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abio-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "abio-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abio-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0205122-01.htm"
     ]
    }
   },
   "keyStandard": 208,
   "keyCustom": 39,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 20,
   "hidden": {
    "total": 126,
    "http://fasb.org/us-gaap/2023": 117,
    "http://www.arcabiopharma.com/20240331": 7,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 154,
   "entityCount": 1,
   "segmentCount": 50,
   "elementCount": 408,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 650,
    "http://xbrl.sec.gov/dei/2023": 8
   },
   "report": {
    "R1": {
     "role": "http://www.arcabiopharma.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Balance Sheets (Unaudited)",
     "shortName": "Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OtherAccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Statements of Operations (Unaudited)",
     "shortName": "Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "004 - Statement - Statements of Operations (Unaudited) (Parentheticals)",
     "shortName": "Statements of Operations (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
     "longName": "005 - Statement - Statements of Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Statements of Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
     "longName": "006 - Statement - Statements of Cash Flows (Unaudited)",
     "shortName": "Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies",
     "longName": "007 - Disclosure - ARCA and Summary of Significant Accounting Policies",
     "shortName": "ARCA and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.arcabiopharma.com/role/NetLossPerShare",
     "longName": "008 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.arcabiopharma.com/role/FairValueDisclosures",
     "longName": "009 - Disclosure - Fair Value Disclosures",
     "shortName": "Fair Value Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipment",
     "longName": "010 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.arcabiopharma.com/role/RelatedPartyArrangements",
     "longName": "011 - Disclosure - Related Party Arrangements",
     "shortName": "Related Party Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingencies",
     "longName": "012 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.arcabiopharma.com/role/EquityFinancings",
     "longName": "013 - Disclosure - Equity Financings",
     "shortName": "Equity Financings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensation",
     "longName": "014 - Disclosure - Share-based Compensation",
     "shortName": "Share-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.arcabiopharma.com/role/EmployeeBenefitPlans",
     "longName": "015 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxes",
     "longName": "016 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.arcabiopharma.com/role/SubsequentEvents",
     "longName": "017 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "abio:DescriptionOfBusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "abio:DescriptionOfBusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.arcabiopharma.com/role/NetLossPerShareTables",
     "longName": "996001 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipmentTables",
     "longName": "996002 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables",
     "longName": "996003 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensationTables",
     "longName": "996004 - Disclosure - Share-based Compensation (Tables)",
     "shortName": "Share-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxesTables",
     "longName": "996005 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails",
     "longName": "996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)",
     "shortName": "ARCA and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
     "longName": "996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "shortName": "Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails",
     "longName": "996008 - Disclosure - Fair Value Disclosures (Details)",
     "shortName": "Fair Value Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipmentDetails",
     "longName": "996009 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment",
     "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails",
     "longName": "996011 - Disclosure - Related Party Arrangements (Details)",
     "shortName": "Related Party Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c127",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c127",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
     "longName": "996012 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "abio:RetentionBonuses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "abio:RetentionBonuses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
     "longName": "996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
     "longName": "996014 - Disclosure - Equity Financings (Details)",
     "shortName": "Equity Financings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c93",
      "name": "abio:SellingCommissionPerAdditionalSharesSoldPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
     "longName": "996015 - Disclosure - Share-based Compensation (Details)",
     "shortName": "Share-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c16",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable",
     "longName": "996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
     "shortName": "Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
     "longName": "996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "shortName": "Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable",
     "longName": "996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity",
     "shortName": "Share-based Compensation (Details) - Schedule of RSU Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
     "longName": "996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "shortName": "Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails",
     "longName": "996020 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxesDetails",
     "longName": "996021 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable",
     "longName": "996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
     "shortName": "Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable",
     "longName": "996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities",
     "shortName": "Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0",
     "longName": "996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "shortName": "Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0",
     "longName": "996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment",
     "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0",
     "longName": "996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0",
     "longName": "996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "shortName": "Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
     "longName": "996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "shortName": "Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://www.arcabiopharma.com/role/SubsequentEventsDetails",
     "longName": "996029 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c141",
      "name": "abio:ThresholdAmountOfDeclaredCashDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c141",
      "name": "abio:ThresholdAmountOfDeclaredCashDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-01.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ARCA and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r524"
     ]
    },
    "abio_AccruedOutsourcingExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AccruedOutsourcingExpensesPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Outsourcing Expenses",
        "documentation": "Accrued outsourcing expenses.",
        "label": "Accrued Outsourcing Expenses Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r87",
      "r390"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r412",
      "r546",
      "r547",
      "r548",
      "r655",
      "r671"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r240"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AggregatePurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "documentation": "Aggregate purchase price.",
        "label": "Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total expenses",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r283"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ArcaBiopharmaIncAndOrukaTherapeuticsIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA and Oruka",
        "documentation": "Arca Biopharma Inc and Oruka Therapeutics Inc",
        "label": "Arca Biopharma Inc And Oruka Therapeutics Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ArcaBiopharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ArcaBiopharmaIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA",
        "documentation": "ARCA biopharma inc member.",
        "label": "Arca Biopharma Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet (in Square Feet)",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet office facilities (in Square Feet)",
        "documentation": "Area of real estate property sublease additional office facilities.",
        "label": "Area Of Real Estate Property Sublease Additional Office Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r89",
      "r109",
      "r144",
      "r156",
      "r160",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r309",
      "r311",
      "r330",
      "r383",
      "r446",
      "r524",
      "r535",
      "r559",
      "r560",
      "r661"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r109",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r309",
      "r311",
      "r330",
      "r524",
      "r559",
      "r560",
      "r661"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r169",
      "r379",
      "r552"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "abio_CapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement",
        "documentation": "Capital on demand sales agreement.",
        "label": "Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r85",
      "r499"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r51",
      "r107"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r51"
     ]
    },
    "abio_CashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment",
        "documentation": "Cash payment",
        "label": "Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "verboseLabel": "Chief Executive Officer [Member]",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "C. Jeffrey Dekker",
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r90",
      "r91",
      "r92",
      "r109",
      "r131",
      "r132",
      "r134",
      "r136",
      "r142",
      "r143",
      "r166",
      "r183",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r195",
      "r196",
      "r200",
      "r203",
      "r209",
      "r330",
      "r403",
      "r404",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r434",
      "r455",
      "r477",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r537",
      "r544",
      "r549"
     ]
    },
    "abio_ClinicalDevelopmentDecisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ClinicalDevelopmentDecisionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Development Decision [Member]",
        "verboseLabel": "Clinical development decisions",
        "documentation": "Clinical Development Decision Member.",
        "label": "Clinical Development Decision Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r35",
      "r384",
      "r433"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r177",
      "r178",
      "r496",
      "r558"
     ]
    },
    "abio_CommitmentsandContingenciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommonStockAndPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommonStockAndPreFundedWarrantsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock and Pre Funded Warrants [Member]",
        "documentation": "Common stock and pre funded warrants",
        "label": "Common Stock And Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommonStockAuthorizedOfferingAmountUnderAgreementToSell",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price (in Dollars)",
        "documentation": "Common stock, authorized offering amount under agreement to sell.",
        "label": "Common Stock Authorized Offering Amount Under Agreement To Sell"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserved shares",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r530",
      "r531",
      "r532",
      "r533",
      "r546",
      "r547",
      "r655",
      "r670",
      "r671"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r434"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r40",
      "r434",
      "r452",
      "r671",
      "r672"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r386",
      "r524"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ComprehensiveLossPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ComprehensiveLossPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "documentation": "Comprehensive loss policy.",
        "label": "Comprehensive Loss Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r73"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r192",
      "r198",
      "r356",
      "r500",
      "r502"
     ]
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt outstanding",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.",
        "label": "Deferred Tax Asset Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsAndLiabilitiesValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "documentation": "Deferred tax assets and liabilities valuation allowance.",
        "label": "Deferred Tax Assets And Liabilities Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charitable contribution carryforwards",
        "label": "Deferred Tax Assets, Charitable Contribution Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r654"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "abio_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax liability",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimentation credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r654"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r654"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r654"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r654"
     ]
    },
    "abio_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's contribution (in Dollars)",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equal contribution percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee\u2019s contribution percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
      "http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r22"
     ]
    },
    "abio_DescriptionOfBusinessPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DescriptionOfBusinessPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "documentation": "Description of business.",
        "label": "Description Of Business Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matching contribution",
        "label": "Defined Contribution Plan, Description",
        "documentation": "Description of defined contribution pension and other postretirement plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r241",
      "r272",
      "r273",
      "r275",
      "r519"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earliest Tax Year",
        "label": "Earliest Tax Year [Member]",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r129",
      "r131",
      "r134",
      "r135",
      "r136",
      "r140",
      "r321",
      "r322",
      "r380",
      "r393",
      "r503"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r131",
      "r134",
      "r135",
      "r136",
      "r140",
      "r321",
      "r322",
      "r380",
      "r393",
      "r503"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r137",
      "r138",
      "r139"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r290",
      "r304"
     ]
    },
    "abio_EmployeeBenefitPlansDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EmployeeBenefitPlansDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_EmployeeBenefitPlansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EmployeeBenefitPlansDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "verboseLabel": "Lab Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r81",
      "r98",
      "r99",
      "r100",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r141",
      "r167",
      "r168",
      "r210",
      "r276",
      "r277",
      "r278",
      "r300",
      "r301",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r349",
      "r396",
      "r397",
      "r398",
      "r412",
      "r477"
     ]
    },
    "abio_EquityFinancingsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EquityFinancingsDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_EquityFinancingsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EquityFinancingsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ExceptedNumberOfBoardMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ExceptedNumberOfBoardMembers",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excepted number of board members",
        "documentation": "Excepted Number of Board Members",
        "label": "Excepted Number Of Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueAssetsBetweenHierarchyLevelsTransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value hierarchy",
        "documentation": "Fair value assets between hierarchy levels transfers amount.",
        "label": "Fair Value Assets Between Hierarchy Levels Transfers Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r325",
      "r361",
      "r362",
      "r363",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureOffbalanceSheetRisksAmountAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance-sheet concentrations of credit risk",
        "label": "Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Asset",
        "documentation": "The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueDisclosuresDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueDisclosuresDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueDisclosuresDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueDisclosuresDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r214",
      "r219",
      "r325",
      "r361",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r361",
      "r362",
      "r363",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r328"
     ]
    },
    "abio_FirstMergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FirstMergerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Merger",
        "documentation": "First Merge",
        "label": "First Merger Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FirstThreePercentPayContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FirstThreePercentPayContributionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First 3% of pay contributed",
        "documentation": "First three percent pay contribution.",
        "label": "First Three Percent Pay Contribution Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "verboseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r457"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "verboseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "abio_IncentiveStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncentiveStockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Stock Option",
        "documentation": "Incentive stock option.",
        "label": "Incentive Stock Option Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r173",
      "r462"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r462"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r286",
      "r291",
      "r293",
      "r298",
      "r302",
      "r305",
      "r306",
      "r307",
      "r408"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest or penalties recognized",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r79",
      "r126",
      "r127",
      "r147",
      "r289",
      "r303",
      "r394"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r287",
      "r288",
      "r293",
      "r294",
      "r297",
      "r299",
      "r402"
     ]
    },
    "abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxReconciliationAdjustmentToDeferredTaxAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset adjustment",
        "documentation": "Adjustment of the carrying value of deferred tax assets during the year.",
        "label": "Income Tax Reconciliation Adjustment To Deferred Tax Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal income tax benefit at statutory rates",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax benefit, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and experimentation credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "abio_IncomeTaxesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxesDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "abio_IncreaseOfRetentionBonusToEachExecutive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncreaseOfRetentionBonusToEachExecutive",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of retention bonus to each executive",
        "documentation": "Increase of retention bonus to each executive.",
        "label": "Increase Of Retention Bonus To Each Executive"
       }
      }
     },
     "auth_ref": []
    },
    "abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "InitiallySpecifiedPercentageForBeneficialNumberOfShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initially specified percentage for beneficial number of shares",
        "documentation": "Initially specified percentage for beneficial number of shares",
        "label": "Initially Specified Percentage For Beneficial Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income",
        "label": "Interest and Other Income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r105",
      "r106"
     ]
    },
    "abio_JonesTradingInstitutionalServicesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "JonesTradingInstitutionalServicesLLCMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jones Trading",
        "documentation": "JonesTrading Institutional Services LLC.",
        "label": "Jones Trading Institutional Services LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LatestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LatestTaxYearMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Latest Tax Year",
        "label": "Latest Tax Year [Member]",
        "documentation": "Latest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee operating lease description",
        "label": "Lessee, Operating Lease, Assumptions and Judgments, Allocation of Lease and Nonlease Component",
        "documentation": "Description of assumptions and judgments used by lessee for allocating contract between lease and nonlease components for operating lease."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indicates (true false) whether lessee has option to extend operating lease",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Commitments Due",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total remaining lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed lease interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal option",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "abio_LesseeOperatingSubleaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "LesseeOperatingSubleaseTermOfContract",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease term",
        "documentation": "Lessee operating sublease term of contract.",
        "label": "Lessee Operating Sublease Term Of Contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r109",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r310",
      "r311",
      "r312",
      "r330",
      "r432",
      "r504",
      "r535",
      "r559",
      "r661",
      "r662"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r68",
      "r388",
      "r524",
      "r545",
      "r553",
      "r656"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r84",
      "r109",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r310",
      "r311",
      "r312",
      "r330",
      "r524",
      "r559",
      "r661",
      "r662"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve for uncertain tax positions",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "abio_LiquidityAndGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Going Concern",
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r233",
      "r365",
      "r395",
      "r424",
      "r425",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r497",
      "r498",
      "r507",
      "r514",
      "r518",
      "r525",
      "r561",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "abio_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Agreement",
        "documentation": "Merger agreement",
        "label": "Merger Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r233",
      "r365",
      "r395",
      "r424",
      "r425",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r497",
      "r498",
      "r507",
      "r514",
      "r518",
      "r525",
      "r561",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "abio_MinimumPercentageOfOriginallyIssuedOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MinimumPercentageOfOriginallyIssuedOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum percentage of originally issued outstanding",
        "documentation": "Minimum percentage of originally issued outstanding",
        "label": "Minimum Percentage Of Originally Issued Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "abio_MinimumPercentageOfOriginallyIssuedShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MinimumPercentageOfOriginallyIssuedShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum percentage of originally issued outstanding",
        "documentation": "Minimum percentage of originally issued shares",
        "label": "Minimum Percentage Of Originally Issued Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of noncontrolling ownership interest",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership interest",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "verboseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r53",
      "r69",
      "r82",
      "r95",
      "r96",
      "r100",
      "r109",
      "r118",
      "r120",
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r133",
      "r144",
      "r155",
      "r159",
      "r161",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r322",
      "r330",
      "r392",
      "r454",
      "r475",
      "r476",
      "r505",
      "r534",
      "r559"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "abio_NewCapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NewCapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Sales Agreement",
        "documentation": "New Capital on Demand Sales Agreement.",
        "label": "New Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NextTwoPercentPayContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NextTwoPercentPayContributionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Next 2% of pay contributed",
        "documentation": "Next two percent pay contribution.",
        "label": "Next Two Percent Pay Contribution Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing and financing transactions:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NumberOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NumberOfConsecutiveTradingDays",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of consecutive trading days",
        "documentation": "Number of consecutive trading days.",
        "label": "Number Of Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NumberOfMonthsBaseSalary": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NumberOfMonthsBaseSalary",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of months base salary",
        "documentation": "Number of months base salary",
        "label": "Number Of Months Base Salary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OneTimeTerminationBenefitsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time Termination Benefits",
        "label": "One-time Termination Benefits [Member]",
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r511"
     ]
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open Tax Year",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r155",
      "r159",
      "r161",
      "r505"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r523"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r344"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset \u2013 operating",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use asset \u2013 operating",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r523"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r523"
     ]
    },
    "abio_OperatingLeasesExtendedExpiryYearsAndMonth": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OperatingLeasesExtendedExpiryYearsAndMonth",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional operating lease term",
        "label": "Operating Leases Extended Expiry Years And Month"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "abio_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration year",
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r54",
      "r55",
      "r66"
     ]
    },
    "abio_OrukaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OrukaTherapeuticsIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka Therapeutics Inc",
        "documentation": "Oruka therapeutics inc member.",
        "label": "Oruka Therapeutics Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "verboseLabel": "Accrued expenses and other liabilities - related party (in Dollars)",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r524"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other loss",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PatentAssignmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PatentAssignmentAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Assignment Agreement",
        "documentation": "Patent assignment agreement.",
        "label": "Patent Assignment Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PaymentOfOtherPartyTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PaymentOfOtherPartyTerminationFee",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of other party termination fee",
        "documentation": "Payment of other party termination fee",
        "label": "Payment Of Other Party Termination Fee"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PaymentOfUnrestrictedResearchGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PaymentOfUnrestrictedResearchGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of unrestricted research grants",
        "documentation": "Payment of unrestricted research grants.",
        "label": "Payment Of Unrestricted Research Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r517"
     ]
    },
    "abio_PercentageHoldingForStockOptionsExercisePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageHoldingForStockOptionsExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share",
        "documentation": "Minimum ownership percentage for 110% fair market value on the grant date.",
        "label": "Percentage Holding For Stock Options Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PercentageOfBaseRentToBePaidMonthly": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageOfBaseRentToBePaidMonthly",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Base Rent To Be Paid Monthly",
        "documentation": "Percentage of base rent to be paid monthly.",
        "label": "Percentage Of Base Rent To Be Paid Monthly"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PercentageOfRetentionBonuses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageOfRetentionBonuses",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of retention bonuses",
        "documentation": "Percentage of retention bonuses.",
        "label": "Percentage Of Retention Bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ]
    },
    "abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligations (in Euro)",
        "documentation": "Potential upfront and milestone obligations and royalty obligations.",
        "label": "Potential Upfront And Milestone Obligations And Royalty Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PotentiallyDilutiveSecuritiesExcludedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentiallyDilutiveSecuritiesExcludedAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded:",
        "label": "Potentially Dilutive Securities Excluded Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PotentiallyDilutiveSecuritiesExcludedAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentiallyDilutiveSecuritiesExcludedAbstract0",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded:",
        "label": "Potentially Dilutive Securities Excluded Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock convertible shares issuable (in Shares)",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r195"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r434"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r195"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r434",
      "r452",
      "r671",
      "r672"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r385",
      "r524"
     ]
    },
    "srt_PresidentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PresidentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thomas A. Keuer",
        "label": "President [Member]"
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_PrincipalOwnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrincipalOwnerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders",
        "label": "Principal Owner [Member]",
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIncomeTaxRefunds",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax refund received",
        "label": "Proceeds from Income Tax Refunds",
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r52"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r74",
      "r77",
      "r78"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r86",
      "r391"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r382",
      "r391",
      "r524"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r74",
      "r77",
      "r389"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "abio_PurchaseAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PurchaseAggregateShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase aggregate shares",
        "documentation": "Purchase aggregate shares.",
        "label": "Purchase Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r212",
      "r233",
      "r267",
      "r268",
      "r269",
      "r364",
      "r365",
      "r395",
      "r424",
      "r425",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r497",
      "r498",
      "r507",
      "r514",
      "r518",
      "r525",
      "r528",
      "r554",
      "r561",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r212",
      "r233",
      "r267",
      "r268",
      "r269",
      "r364",
      "r365",
      "r395",
      "r424",
      "r425",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r497",
      "r498",
      "r507",
      "r514",
      "r518",
      "r525",
      "r528",
      "r554",
      "r561",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "abio_RelatedPartyArrangementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RelatedPartyArrangementsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r353",
      "r354",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r451",
      "r453",
      "r484"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r353",
      "r354",
      "r355",
      "r356",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r451",
      "r453",
      "r484"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r660"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r462"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r353",
      "r354",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r451",
      "r453",
      "r484",
      "r660"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Arrangements",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r354",
      "r357",
      "r409",
      "r410",
      "r411",
      "r460",
      "r461",
      "r462",
      "r481",
      "r483"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r192",
      "r198",
      "r356",
      "r501",
      "r502"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r285",
      "r669"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "abio_ResearchAndDevelopmentExpenseReversed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ResearchAndDevelopmentExpenseReversed",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party expense",
        "documentation": "Research and development expense (reversed).",
        "label": "Research And Development Expense Reversed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock units",
        "verboseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Workforce reduction percentage",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r174",
      "r175",
      "r555"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r175",
      "r176"
     ]
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remains unpaid",
        "label": "Restructuring Reserve, Current",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r556",
      "r557"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r61",
      "r387",
      "r399",
      "r400",
      "r407",
      "r435",
      "r524"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r167",
      "r168",
      "r276",
      "r277",
      "r278",
      "r300",
      "r301",
      "r313",
      "r315",
      "r316",
      "r318",
      "r320",
      "r396",
      "r398",
      "r412",
      "r671"
     ]
    },
    "abio_RetentionBonusPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RetentionBonusPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retention bonus paid",
        "documentation": "Retention bonus paid.",
        "label": "Retention Bonus Paid"
       }
      }
     },
     "auth_ref": []
    },
    "abio_RetentionBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RetentionBonuses",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of retention bonuses",
        "verboseLabel": "Retention bonuses",
        "documentation": "Retention bonuses.",
        "label": "Retention Bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r518",
      "r538",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r518",
      "r538",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r109",
      "r145",
      "r146",
      "r154",
      "r157",
      "r158",
      "r162",
      "r163",
      "r164",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r330",
      "r381",
      "r559"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased assets and operating lease liabilities \u2013 amended lease term",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r523"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Shares of Common Stock",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net deferred tax assets and liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Non-cash, Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfFutureMinimumCommitmentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfFutureMinimumCommitmentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Commitments Due [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfNonCashShareBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Non Cash Share Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially Dilutive Shares of Common Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "abio_ScheduleOfRsuActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfRsuActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSU Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activities",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "abio_ScheduleOfStockOptionActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfStockOptionActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SecondAmendmentOfCertainRetentionBonusLettersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SecondAmendmentOfCertainRetentionBonusLettersMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Amendment of Certain Retention Bonus Letters",
        "documentation": "Second amendment of certain retention bonus letters.",
        "label": "Second Amendment Of Certain Retention Bonus Letters Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r163",
      "r506"
     ]
    },
    "abio_SellingCommissionPerAdditionalSharesSoldPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SellingCommissionPerAdditionalSharesSoldPercentage",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission rate equal",
        "documentation": "Selling commission per additional shares sold percentage.",
        "label": "Selling Commission Per Additional Shares Sold Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SeperationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SeperationAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seperation Agreement",
        "documentation": "Seperation agreement",
        "label": "Seperation Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r562"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance expense",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards granted service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options award, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, RSUs outstanding, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, RSUs outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, RSUs outstanding, beginning of period",
        "periodEndLabel": "Number of Shares, RSUs outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period",
        "periodEndLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, RSUs outstanding, Vested and released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issuable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value per share (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Options outstanding, ending balance",
        "terseLabel": "Purchase options shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Options outstanding, ending balance",
        "terseLabel": "Weighted average exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r245",
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r279",
      "r280",
      "r281",
      "r282"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options award, expiration",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "abio_SharebasedCompensationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SharebasedCompensationDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SharebasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SharebasedCompensationDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "verboseLabel": "Computer Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r90",
      "r91",
      "r92",
      "r109",
      "r131",
      "r132",
      "r134",
      "r136",
      "r142",
      "r143",
      "r166",
      "r183",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r195",
      "r196",
      "r200",
      "r203",
      "r209",
      "r330",
      "r403",
      "r404",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r434",
      "r455",
      "r477",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r537",
      "r544",
      "r549"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14",
      "r81",
      "r98",
      "r99",
      "r100",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r141",
      "r167",
      "r168",
      "r210",
      "r276",
      "r277",
      "r278",
      "r300",
      "r301",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r349",
      "r396",
      "r397",
      "r398",
      "r412",
      "r477"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r141",
      "r366",
      "r401",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r456",
      "r457",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r529"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r141",
      "r366",
      "r401",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r456",
      "r457",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r529"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r39",
      "r40",
      "r61",
      "r403",
      "r477",
      "r491"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of Restricted Stock Units (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r39",
      "r40",
      "r61"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r39",
      "r40",
      "r61",
      "r251"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of Restricted Stock Units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r39",
      "r40",
      "r61"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding stock options",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r56",
      "r436",
      "r452",
      "r478",
      "r479",
      "r524",
      "r535",
      "r545",
      "r553",
      "r656",
      "r671"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Financings",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r108",
      "r194",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r319",
      "r480",
      "r482",
      "r495"
     ]
    },
    "abio_SubscriptionAgreementReceiptAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubscriptionAgreementReceiptAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription agreement receipt amount",
        "documentation": "Subscription agreement receipt amount",
        "label": "Subscription Agreement Receipt Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "verboseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SubsequentEventsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubsequentEventsDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r360"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimentation credits",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, limitations on use",
        "label": "Tax Credit Carryforward, Description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, limitations on use",
        "label": "Tax Credit Carryforward, Limitations on Use",
        "documentation": "Description of the limitation related to use of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "abio_ThomasAKeuerAndCJeffreyDekkerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThomasAKeuerAndCJeffreyDekkerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thomas A. Keuer and C. Jeffrey Dekker [Member]",
        "documentation": "Thomas A. Keuer and C. Jeffrey Dekker.",
        "label": "Thomas AKeuer And CJeffrey Dekker Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ThresholdAmountOfAdjustedExchangeRatio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThresholdAmountOfAdjustedExchangeRatio",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted exchange ratio",
        "documentation": "Threshold amount of adjusted exchange ratio.",
        "label": "Threshold Amount Of Adjusted Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ThresholdAmountOfDeclaredCashDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThresholdAmountOfDeclaredCashDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Declared cash dividend",
        "documentation": "Threshold amount of declared cash dividend.",
        "label": "Threshold Amount Of Declared Cash Dividend"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r551",
      "r659"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_TwoThousandAndThirteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "TwoThousandAndThirteenPlanMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Plan",
        "documentation": "Two thousand and thirteen plan.",
        "label": "Two Thousand And Thirteen Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan",
        "documentation": "Two thousand and twenty equity incentive plan.",
        "label": "Two Thousand And Twenty Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r175",
      "r176"
     ]
    },
    "abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "University Medical Center of Johannes Gutenberg University Mainz",
        "verboseLabel": "University Medical Center Of Johannes Gutenberg University Mainz",
        "documentation": "University medical center of Johannes Gutenberg university Mainz.",
        "label": "University Medical Center Of Johannes Gutenberg University Mainz Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Estimates in the Preparation of Financial Statements",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r71",
      "r72",
      "r75",
      "r76"
     ]
    },
    "abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in net deferred tax assets and liabilities",
        "documentation": "Valuation allowance deferred tax assets and liabilities change in amount.",
        "label": "Valuation Allowance Deferred Tax Assets And Liabilities Change In Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r136"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r136"
     ]
    },
    "abio_WeightedAverageSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "WeightedAverageSharesOutstandingAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding:",
        "label": "Weighted Average Shares Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001213900-24-042529-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-042529-xbrl.zip
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M\-BZ\3WK!BVL1LMJMHZ;C>-&T[H?=*QFO?DFK/+#^SD[9O883Y"%73S!'K^
M;L_P$ 4N/]G[%B"7# EV]BR0RX.RE._SQ12SD[T(TQ"QA]<^'=66KVK0?FO/
MXHB.,+]%$\RFR,;+"D((1&WT0/SI&-$)$A*(.F_JK58C[L@EWM>U*O,'ZLI^
MFO5ZJR9>/R"&X^+S3/E92Y9N'!T=U>3;N&C 5!+$;R(!HI997K, HE'[]>:Z
M+\=N618P.GQ9/@GYH!:^C(L*\3<<$H?3_!&!%S4!7-1H[M=;^ZLZH@S1C"/Q
M&$>>C?>$_OQ@64(?D.?Y''%0X.AA]'@Z)=[0_Q ]@H=B5(]C)GIX:,EQ/A90
M3O88F4Q=P8]\-J9X>+(G!-R/Q?K-10^O 65<! : ^B[6DUB;4G^**2? 4D('
M9 .9VNNBBM<UZ!.[URO(>[4/NQ)G2O&+BP-],IBSDJR45#NCR<'#%Y<+^B0>
MR9%J1S+9R'UQF:!/.W!SJ5J32A0>@!R6^..^=U5@)63;'=]CODL<8?=/D2MF
M='^,,5@;XH2R_T9_4Q9**$L,8D7 ![!TL +U0<GD^@!_1Y4M69M9K^X]%#@$
M6OW[^UJZ=K;I@&&GZWV0?Z?U-ZH?%=%675>1=$5]MRDJ4I5C-FIK=&1FU"YY
M^NT.41B',>8$L#$CVM)UBEAL&K-HO5IO.I_6BE@%L5?@[TWP<JB59*;+?<@1
M;HW!5HK!Y=_,\H=6=RH<22A9S<C=$&<Z*0NJ%=+Z9@M:JRFZ,=-]^#\>^ZX#
MP=GYMX#PA6BAZ=/6&K.:8ME!6>/Q0,MCG_OVUZC=O_WU7;-Q^$\K;+]PNE8L
MYL_7#F+C"]>?*6?FLD"N/&ODO=62)QJR1$N5;=V JW:OTT:>TP\F$T07_K!/
M1AX9@KWR>-NV_<#CQ!O= 5DV^-1K)&Y6LYC=0V#TC##;]5E ,?Q'=&!!#U;4
MA9RAJTZL52]6W$TU-0OHOL7\VF?L#E-I0]<(3;\KINQ=FC)HPA)M6-"()5O)
M8:2B8TG'!2+T9^0&>#6*ZY,LMT Q,4=I8D0[EFPH\5PQ72J"5@3=A?F$!9@A
MX0A,,\%";H%"@AKU-$%Q.]+@+5NJ""HBJ(==X46 I\T7;4J1-PH]@C62E(4*
MXO%&(TU3U)(EF[*2;55+3Z%7.)D0+L<*=!Q<0+%R8R_C5^C*%<5IC6::L$1K
M<FJMM9?'6<78DK$P]+D@'H+1\D;K-&5>ZB.O1BO-3!18K5JHC)U1>"R2TH[8
MA<0>DQBRH7&V2.'$>9.F1S:T+UNRDDU5<T8_9R93UU]@?(H]@,_O7.2EYDU>
M@6*'X2 S?:)VK*@A2[94S:$B@L),X #-4\M.\GF!*7N;YB*L:\G*%0.%5BQX
M8/A; "*?/V9<M<S+ BXR68-5 U;80D5(80XHDZXY7<B_%NL)'W4Q+4E'1V_K
M]4S DY.]^8<X7Q.V:+V*'^9F\"KR5!F= 7IP4Y8MOT0Q99G@)YO=L5Z%K55I
MUBWR"#E4:8H5\Y6)??)S"EK.*LI,XM4<YHI+9Q*?:?XR$9(V=M5/O8K(HJ@I
MAT-MP4+ZC".HBKDM?/4<NK)O"Z)<25,FD$HZ[Y5M_ Z[AF>8(^(^8_,P;L"$
MWDQLML4NHO4JZK%2@P++:H^Q$[C8'][Y' 0GR'479\0-.'G$TOPQ?RA6,=^3
M1RODY%HWN5NU4&B+,U%AGNL:DRQ,=01#*$<"B!4C":N$QPPDF/"H2*4>&^]N
MYAD#73F3.9_9AL[?[=1/ZXHX?;221YRNG EQF6UJ5<12$;>Q059%DBKSJRQ?
ME)L63)KN9ZN-;K7]O=/M[[S96E2V,,.PR79XY4,]/\V01Z)!<?VA!DGD9MOD
M!?:WHC/7 E\$',;V!D28!)/$^)X%6&>("ZL9+*S9S79#?E-6.<1B16#6&@$X
M__W*(#_5_?<O-S\?_.??O]K38/[9.SARG@X?1Y\7WOU9,+L\I$>'GYJ_WP\6
MS#U\M)_J[D=>XWW\\>FP]77>L*]Y_<O%1;/_J?8X/^U\KC\Z??IY]NWTXO'N
MXVSDLD-R6NL<?AM]= F^][SZ;?N@VR%';S[=^K]WQYU/UWS4&QY>C]_=W?Z*
M?CW\MK@X0F\>/K>.+B['!Z/KJ\_>Q&FT9]W+11,#JL%I<(.?J/W3EW?C7RZ#
MJT^3GX_>WO7]B_-O5VAX?\1^/VJB+SWRUK\]JC_U?AS_7WWR]NKI_L?)]/[+
MP?3@XW0Q.[CQ[YM/1S]?#:[>M?C;3RW'^S*^;4QZ/J;MN_KH[3NGV>+.C_-Z
MOS$[.?F/U>GWQ(?*.S]NDF?^5&6*(L+L^8;,\9/*RWQ>0C6/+GU)@X4JDZU3
M)U6K-6KS->J<<3(1'MPOF(S&\&_[$5,TPI?@R/$S>+$,S==V#Q5+U[:M&448
MF<1>L2:D5K,E/"O&9T4 +8G0$A"3N0/=(?9*H7(52J;%NE,!H6US\DAXO &F
MT!E-A>)X)'OX8U.=D-U;8?_6"D!%N"GAO?Y]-&P+'<V98L7D9K)Z&Y,+G<:<
M+JHHU)#06]^S$1OGK]SG<_&G=A$PKU^L IG\X,8J &CV!9Q_J*M&F"H%V?A<
M:ZZ#KBEG$+DV,XG$_'.NE;.^Q1YZ'E\YKXMBJ68F#;B^A5XQLZG-79(0Z7B;
M<TH> B[,)/>[ 15;ET/J3U87#>A,\-;-%5KD9B9QF$]]R@JO"BUG<1*3Q7T+
M4(4;M )7XD*%RBR;KMN8@P284NQP-$>,89DA=@E4<PO=<-/:Q2%[,Y-[-%(1
ML4$?([  @A5BD,G*!(I*'79_(*/^_!,9=1/%R*3@JD,9Y=PB5BJ$ND+QRI')
MY%4[Q"7;D%+17EROT&/,).^J_:@_292O4HH-&C )^YZ?R:LB_1=,YJJT0E?#
M1 V>G_.K$KH[^28S=S-/4:;0^F?3>.EO-*ND@2E19[X=B!6O#3X8+)E\<>6)
M2\@3%P%H2Q1,PN@[S:B%Y)]MX77)YJQ$>_\#IO1];>U>;?$P?+1V [=\#$_)
M9.I3;GFY-ZHKKO6VPLO=KWU;-J>I(OZW']?;%X_V&\W]5N/UG#GQ)<4;HA!"
MA[<D;X8BKK<-"M5E[GD(6'Q'>[+2"*&IK%/#+F?+9L3=T:WMQB+W>G85GJ*:
M\O]L"<1 ._)OH3=D)*X@J#A8]6K,0OI' <QH@%H)"I9MK'-@*CK#]NN1_UAC
MQ#8!D2XN_ECK..HT^KD$V>O)7NPF=)>!;#L1R+8?&*?(AF$/+RB7M_(?PS,(
M2ZXXG@BCL&>AJ-3)'J>!N%I<EH+&B.\,9#TGH)$Q]HCK"M<G+LM@U0,#&HBW
ME]0/IG$G!)I/K+2&.-?'5R6J)G@KH\0F<&L?#.3>_"Q*&8?C&5*8J4>NPU[&
MD= #3=A[E:0]%L1G <HH7QX\ ZD@ZNW$8?BI(@POH[@;X388!]V6UR#>\KI8
MV_(JX[ \1PP3;<'\+-IC@3[:<H<%UI;KU?Y*&0=E ]1)QV=]$.X]^;,R8$%+
M(V$6T@;PZR7$7]<N.IGBC1**T-A,A&8)16AJ1>CX3,Z>R,:R$NF3&IK&X\N(
MW_KC!<G!M)%6O2FA"&^T(N1M%6,[H-(ZG\]M-W#*9'DW@ZO1ONRZ5!H9U= T
M\FPT,"4P&1OB564&>IAA1.TQ&)\S_(A=7T;:D1WJ8?%3D>+G%9/23GP/<T07
M>?(.D<L*! [?/80_[P0O\ /AVP^#&7ZU=W&&F4V)#*ZZP]. $0\S%E[$-\!S
M?NI"[!6+[W!ZS..'6TJ_O4X;X%2+>4V^!<0A,I]RZ8.R=GP8?>J54%)3J)JY
M+"(JBL>@ C KY 6 LFX)A35$J@QPVK8-_3G=@,O?6X71BEV($@IK#E:MR,LP
ML8=MT N(@B2HMO-[P&2^;."GS7^)K=<VTJ@L>;I@OF7<P6"$NS!\UV-AB'\3
ME^0:(X83P?*?1_@L=#.Y$S5Z(FW:'=XSO*M9H)+=AKYW)+P&O]HF:"Y1B@[^
MOK"SYO#C,=2D=O" K]9E+<2ZE9C7X Z(CM@?[Y<:H539L&7E<!*<8C[#V/N)
M8"HLP>):V $6_OPX.';MB;B^[GN:]^=J]E;R:&9ZP3TVI=-V([PJ9;A#"_$_
M, $>Z!#(84-3\:H@MX%V8="_&_<F\/7IJJ+K;DI'MREDI3M;W$")+-TF8'5$
M][",Y'WOU/<"]EV]E.?J= :J<NZ"?HCC3B.QOZ>03X0BT[#<"P<B6G3F5-TA
M4N[42 :L3K8VQ4@,!W+/F?AUT?@$1C^ OL$9;3N./(2&W.YP2&Q\@>R46RT(
M1=#*=JJZ=52Y/6Z5]EYC6*YQM-'HC>*6!IA.ND,QT;-YSIC$ETZ6&"%5SM(X
MAW@_'5)?GIN\(2XL5J#&W0>7C*)]5L_I^0OD\D7B8:F7WN?(I9LCRX&6X1D[
MGT,_#A;;-H0N/L/*+MJ\@1['ILO3=]2-#<#J\N()6RF.*_1D5N(4"WLB*[N+
M<AET%4B-C(JKM4KG7VEQZO164;%$SE0A0G5<G/@BLQWPL4_)$W; UF,A11A3
MW8/BT_:(8APFU?K8=4OL9FTKD>YX(+R7N73P61F#_F'*K%;&\'/2ON\ZJYGT
MW%G][(5]"\AJ)=%>QU:ZB6Z 5GWF25>W1#/>$*=V[WW)_$^@!R#!A4\3IR5A
MR8,"A(%+2.QGZ_,N5RD3N+HU.:#V6+BV(S  X+=$'Z>G.)7/7EI$!3*5!ZJY
M,Z=TD[(0J]KZ:*J6:$8:H50QF;U-IW0$JB#J3$RV3HD(TX%3*^,J+O 9ZR!*
M%T.?SA!UF P-)"81'JS+-Q*/_K (I@#I1N>4UL[/BNQ\N.?JNOXL_"BMM'[A
MYK(HO81LV8+&.V.1O;_RRK_I\ES1E!]1Y7\$7#HSI\6I_38FOV*)#%XA0K75
MNPTF#YC*I!C#MCPO-Z!(>&%G:,%*D<PK@*B<RX,QN%AC<"E#!>X.P_,C(M5C
M2]7N"6 ESE0;"J#3W4P39]AVP?5TQ+<V9^21.-@K<[+>#+\FOH5^X@."R[1
M#]L8'NW,9'^O=<T O%+YE]NL73[&5.XTB^PW\21-%[C,ZWDQ=IW*1Y^*)G.?
M74I&4-MU%U>,!=A9CPO_L$R..=)GRBN.%@)483+_#$(GX>J#$!*>].Y/L4V&
M!"=R7A<^#>,U&TK$*\AN>-]%@+(=<%VN?F[C*2P-<8U3'^*!&RS^DUK%B<?Q
M"+]TS*+%IS['&^=+X@3*6LJJC%ZV K&&N7A$Y(8,$]LT?0!#%Z7RO3+@M$=T
M8&V.;'B9J4K"5&K@E0?=@-CI$Q$#_QS9X_-YY)"664Y3$=1>5)O:Z#2^>0B:
M@SBQ2X.O: #+,YIBJ&XS>!Q.YZ1Y=?P)(KDZ^_V"H<W JDU/JIER"K>20C$3
MIX0CM^N=X8GX<67D8K;T),LAD0E$]<$X%[P)&[F)D_ 0(!"Q*U82Z0H!FFW@
M>LX=Q1>!.*CP"Z+RE&1)!#0"J3S83"@#DBGX(^40)PM("UV$ISCRW6 ID2>+
MQ.T,I=$_0Y3:#XO$DO&($SMRY1!-@TSC;7V$I9E%Z:,K;]D1<ON8/H*GQJZO
M.^60;P.D*AT-%;ED!C\?E,Y!QK,_P3IFB%*3B<5S/ICY9;8F)A"5:W5Y/<8"
M]U"981/.=)LQ,O+D-6SETL<B>-I#4;;O.6UXXH1YN ZF' 18#Q^N,><0O)=#
MVFT@:T<@ODVI9*RJ@6FV00 G:W_" 5A=S^E\Q,,AQ8LS_/5K6;PN$XAJ^68^
MU _$QR90=S FE&/LB5,:)1&N")]J]4Y5G,&;17@>=.GZE%;* K!*,N\](NZF
M@&HWV!&!4P?>B0341W^,/'"(+@.8T-#$*%$2A'TJQR@\%[YF(VMU!:CJ1UBZ
MR1]A*<^U,ULC5\V+U,V741.K/8/RB&Z,5'=01W-Y=WDD-4(I")4W98=7^4I=
M_W]02P,$%     @ 6*FM6,^&Q;$D"P  0'X  !4   !A8FEO+3(P,C0P,S,Q
M7V-A;"YX;6SM76MSXC@6_3Z_PLM^V:TIFE<G-*FDIP@)&1)"6!X]G4Q-=3FV
M *5MB99D'OGU*YDW^(V,H:L_3=KCZ%R=HWMU=24YEW],3$,9 4(A1E>IW(=L
M2@%(PSI$_:M4MYTNMRNU6NJ/SXKRV^6_TFGE#B! 5 9TY76J5+ Y;&M0Z1 5
MT1XFIO(?9OY722L#QH87F<QX//Z@\7>H!@F@V"(:H.*!DD[S!A=-5@@0#5XH
MCQ@IC^I4R164?.$BG[O(Y95NIZ+DL_F/LU_Y[=* Z/NK2H'"[4;T*K6&-'DE
MQ@=,^IE\-EO(+%Y,S=Z\F(@'&^^/"_;;N5*IE+'_[_)5"IU>Y,WF,E\?ZVUM
M $PU#1%E*M($ (47U'Y8QYK*;"9][5)<WQ#_2B]>2XM'Z5P^7<A]F% ]->--
M42X)-D +]!3;\@LV'8*K%(7FT! &V<\&!/2N4NHKQ&G!8+8P:^+?XLDW\JV"
M$<4&U 7WUZHANM(> ,!2BFBZVZIM=$(EFOB]X4 EIBHTS(BW,JZ-9&Q#Y5M:
MXX/3!&W&?S8!BF[L=CO<7NFV5E0ZJ!IX'-G(90."32GFB;&K6P; O:K%+ (>
M(8*F97)'-B$31- ;"W345]%@"*-#-"N+Z!7D3,J..KGFL:D'69DQ E\M)N 8
M?K)('5/:(]A\&HK0Q=V3[M/#R' 9>;Z[LJ8!F YZ@!"@,W6B4@H859%N0/ZF
M 1D$>_4U:.LRO3WX6,K&-$:SL_Z(WFBJH5F&K6*=V[[1*S!A .E 7_1+H.P5
M,Q?C@^,:6-O ,L3$@LD"RE!?@7&5LFBZKZK#;V5;F(K%=1(A<9UF80[E]MA3
M3$^EK_8\,_]%/M_D"QE@,+IX(A0IV&HXM[T2.K21(IB5D1W3;G]8<*0:@O,R
MJZB$3'FZ\44U+"#9^&"8"[4W]2Z3S=YQ-1?6\1]WQ-Z<P^=O9*AEFG9K:<@G
MFL7OB^C@HQ[#H9G#1 >$YW I90Q@?\#$C[-H&UJK)S8 ),Y1Y0"P,;2.4@<G
M5N:DY[=(W\.-8_'?U4!(CEDG2IW9W!["44/.? 9&_3K@J71+M/C4ZU)@H\H>
MT9Y8JR%Q7/S[,.0RNJ-HT2288[%IDT]XC$<S$<F&8MIM2)?"$^I(PHR3&-X4
MS;4HR/*-53!K8*3%'>77,(XT%+D0,J?]XP[M44BOKQ+G>.95!X ]QDA9T[#%
M4XVF.A5Y<4P)IC-(PDF9NU(;TY<+01)3L5N^=,)3P-=4AE@PQ#Z"_/$2CZ#!
MM E G,SD;18^-(U8!Q#)!RSS^10$\F/,?<+;,_3&%W.3G=L<NKC.MP?'\23<
M"\!I? F&+]XQ!2O_!-R1,;<H%5&C-L/:]P$V>*-49)AL*ED4!X!]RD:K^IRH
M@6 DR )(D^_'7D@)9R/NFFW4B;RHDIB2-,F\)FR;%4?=S@DAV25T, 4<F7'U
MWZCN@%%LQ.\TG^B$%GS8;U(B>:E<UG4H+%6-I@KU&JJH0\A48PU7]I+('_ 4
MO"$(;U*7URW 5(B ?JL2Q$,?Y<FE95IV^G\#>E"#LO./ ("G(%00WN9"G<FN
M@_"9*O:,Q!?N>(H-GG2X9/->:?QI=<KI+?<:]&5F:WOV\T'V;+>/CD0M&"PR
M_]O)$" J/9W=;3^RN\X.?1E<QK)N0@0I$RV/P+QER8;[H26:DKBJMCZ,??GR
M\]>PTQX%O ]BC_@&C("![4V#>,3QQDIVL@NDC0]94DN""WMF$4.<"XK+Q]<0
MCD2#W3X[ECU64NWZ1'J/#*,!6&RL;[:=>(7)L:N.9*^_YAJ"HK!=0PP00,6F
MI5W5G0%)IMT%).'<S9=]-VXD[JW;[38PPEM>%<>N@Q-,LB''?_R[TK-;*$BO
M3<0)Y9?+4[_1*Q:<$M%*D^ 1Y-9<3[M4Y*W+0%#6>#H2QUY(".!?H3W0T ZI
MX_JXWR)*8@7X!@P)T.",#)[EFI@P^&[_4[(@7DC)1_X]Q/&D4/*6C^<IKW7D
MF.:-L/ G[G?AZ78I6$?:WN,S"[CFN+JXG<6;C\,K74!.VB'=B'.M4$=-E34B
MAL4-F/VWAK8.$4G/FOWP3MS; A#J4KN6(Y_[.:/8E?2 SBQO;/[]U^.7LW_^
M_JH-K<DS.BOI[\51_WF*NC?6^*Y(2L6'_%NW,Z5&<:2]9XU[EF%M</]>+'R?
MY+0ZR[Y4J_GV0V8TN:X\9T=ZFSR/?UQ71\W[<=^@17B=J11_].\-"+H(91OE
MLZ<*+'U\:."WIT'EH<[ZK5ZQ/OC4;'Q5OQ9_3*LE]>/K<Z%4O1N<]>NU9V3J
MN?+XZ6Z:!]RJSK7U"-Z)]N?+I\%?=U;MP?Q2.F^V<?7V1TWM=4OTK9177UKP
M'#=*V??6[X/_9<WSVGOW=W/8?3D;GMT/I^.S1]S-OY>^U#JU3P5V_E#0T<N@
MD0,W=8::']^_:*-.]Z5Z_KUTCXO]JZM_E$J[)2Z7_CSCWVM$SEWA7$9]R]'S
MMDYS+5:]JSGQ@/X1TIS$E[&RHV H+>8CHRAC9-RI$(E%QQ-JJP9XZFV<;%\>
M:Y>];Q ,],2GNZ#4SN7\M%/:D./I]D":'R.,Y=Y2(,A$MX)D.ZP3I7,52PX%
M*IE"KHX;'E++'=2?*P"[,+LHPV2=BXZR:GTU- (TB5J?$W#D6A]/X>WSC!U<
MUGAL(\#UCI3L$XC!@8]SU>NA_\:)Q1 $N^W01;T-OG6AN<7M)5";5\ Y].:#
MM3>;@$"L[WJ<9EBZ7=[7!BKJ@Q;/?F][/:#)'AP'-C[IDSS):+55R0X<FGTV
M-G\1Z!<DI)Y7=@&N0J0B+8'9R0GXU^@((9+KV>K#;IB&^.)0Q#5/'?"$#;C<
MSUE,FS?23^ 'AMWC*EQ B 87IS,&Q@@\8L0&TN_-134CV4MV(8?%QIG=R,2[
M36IQRO\,5-(9XX147Z G?33[ '(OB98Z\X9"Y^(F%<A6^,DN_P^F](QKR7>4
MPEA0Q19)4&P;/O$J[*'DGI'MOHF<5-H4^3.&D?=-9W#S,P]S5/F%1D>4_2JF
MLR9;0,,\&S9F1W9<D,JL"G1Q]E]<#[%XJ]/5[_,4/*[N2K$MX9G69X1LU5IE
M:B+Q8)R+9?9E(;Z,$]\'-I;OQ+$#&@K]Y!5WYU7"Z6K[>Z0NP&7]S:+V.K.#
M;^9WOOE+#A^6<_G.:91V$UWW!! K.F%NR9!$%YQ];69IQ8%<;P<UV1QW?X_;
MI5'J#6X7U(I=Q*JA[9%#Q87_&86&@<?SS[$?0-<P!AV[V\KDWO66N-3AP!]4
MN"70+I3:M_D.H[H#[HF+Z\3D[A&Q= (WKL-_A#QR/71G9-\1^3=+7$ B1\J=
M]E;+4=ZN_6GH'B9CE>BT;;V^ 8U/O'R80!+/+8V]C$DX#_76?_/2QGZD2_[<
MVHXY/%83:"_AQ=>?[/6\B.#K=L6M?! 33E?O0 1+OKVS8\0R:&_@QC05AD4_
M76W]:)54L;572=O@SE\E"+22#-A4X@57?V5",2-UV;%K&\;Z&!KB$QXUQ'@"
M#+G+QW(V,A1TLJO'/7S+DT^W18.L8+EX-L^2UZ]W<7OF23-UOO]5P51VD3H6
M$T]V9$C11^:MEN@6'LTX.85@+X-NERLK>\_&=&-';^=L6L")>+>5$Y E*!^[
MUTMD3K_R_R:((T32!VN]^NT]G1+YW_ Y?&TU8/'T-"7RJ([FI=S)VG72E7\>
MP'^VT!*M@P:DPE.O];^QL]<QN^T(NF:+YU^@\I]5/%HZME6WNP!AZ(G+7]8P
M#W6?*"SZZ0@:F5^/CV\=[6'R;"KNXY@_Z7'R%C!5R+4A3[TJI%Q$<38NB;XZ
M&Y)X9A[[<407 3R_1.OD@I?+OV NXO#_ 5!+ P04    " !8J:U8GAM^Z7\^
M   ^Z0, %0   &%B:6\M,C R-# S,S%?9&5F+GAM;.U];7?C-I+N]_T5WKY?
M[CUS.OTVF:1SDKM'?NMQ8EN^DIQ,9L^>')J$)*8IT@%(V^I??P&0E$B*( $0
M19!N?]@=1RVA"O44@$*A7G[\KZ=-</2 ,/&C\*=7[[YY^^H(A6[D^>'JIU>W
M\]>3^<G%Q:O_^K]'1__QXW^^?GWT"84(.S'RCNZV1R?1YG[N^D<+[(1D&>'-
MT?^.-__GZ/71.H[O?WCSYO'Q\1N7?H>X/D8D2K"+"/O@Z/5K.F ^Y E&;, ?
MCJZB\.C*V1Z]^W#T_L,/[]_]\.[]T>WBY.C]V_=_3W_R'S\&?OCYSB'HB/(=
MDI]>%2@]W>'@FPBOWKQ_^_;#F_R+K])O_O#$/BA]__$#__:[CQ\_ON'_NOLJ
M\>N^2(=]]^9?5Y=S=XTVSFL_)+$3NHP \7\@_,/+R'5B+LE6OHZ$WV#_]3K_
MVFOVT>MW[U]_>/?-$_%V+-+O>/&.3'& ;]^D__B*R>OHZ$<<!6B&ED=\BC_$
MVWOTTROB;^X#QCG_;(W1\J=7SIT?O6:B?OLAI?6_V"=_X#].HI!$@>\QD(Z=
M@,UYOD8H?G7$AKZ=791FZV"7_>Y^[>"-P\!^P[[U1CC(&ZX)L)S^<>-@%,9K
M%/NN$Q CC%?'A)K'!5V-&S2/Z=\;2D^;]^HXE%]H7DV)O6584S.94Q;0.@H\
MNAN>_97X\79!!WD?X0]*G#<,D^J(<;&?.&1]'D2/V@+>#?#&U)XQF9U,G-";
M)YN-@[?1<NZO0G])\0KCB>M&21C3 ^:&TG=]I*88:B,;F] UBB\C0FX0YO@J
ML5S]K3&FSAT?_^H$"3KUB1M$),&*PJP=P!A[-SBZ1SC>4KC80KA7WK]J!S#&
MW@P%3/GI;A)O)YB:,"N^O:A)4#B(V?-@L_%C/BX5!5VY3,>IF::Z=IK&,;6+
MIEO>N1_2DY*.KL;@P8\-[IA\[3&3RF-F*PH)M]34M_;#(8R)CGXWVB)T3&WL
MI1_?4&-#47QU QA;+^DQO'">%+6N^#N3>"9W!/V54&4^>U!>M@<_-LC8X3%T
MO.5_;=4..O$P!IFMG$T+YRY0A+=^!(,LUIT"&GPV#&/4+A-NL1H\MX_&60?<
M'S68;AS('+^%;46#R<-?&[M&N&OD)0&*EC=13)'SG2#8GOI!$OL/B,N&1$L&
M;!3.X\C]S,FK"5B+@D%-V=,7K2G=^0C',W:*[8F=)S&U=Z_\T-\DF\)*.TU0
MESFT#FM>T<Y([&^8&?H;\E=K^K^3!X2=%?I$[='XE/[#SLXO[=*:$]2E!@ A
M5^_I/=M?)B[5?C_.=T;-N34,:-)TV=&;S6\S.MLN;!\, \+L=12Z#EG7[^]G
M3^S/3HHE/S[(]'9'0F8^3^(8^W=)S"C&T33!S,Q9XF@SO6<N<,I3)U73)@>#
M+8H]M$08(R]VGAQ"$#<Y I]^,^B\K&1'-WEIUCHEW\(?Q&^A9BDZ.[7G)!X0
M1 7;#D[=>;2/"V$:26]FNM-2(&#>XA"?D[K3:1K1%/]*ON-3%#N^XJN%%@%3
MLZMSYNI,HFD<4[S6[2TZO#:-8XI7D8M7A]^VL?KQ1.AP+C&<R7.MZ@G685DT
M!K3/1(?7YI&,2K;&2:PEW89Q3"V]@I=&A\6:GQO$ON)"UD)=,(8!+D\C-V&K
M=4)W1KI6X^U%R")TU!\]&@?*@*8_E>54$/:21ZVP>)=O^00\GU)E84FOZ=7!
M28+XU5%&ILCX;@P_C-_0G[S)OO/F\.?]\!IM'#_49C7]]?X4@&!V38? ;G*'
M7N\(J_%;-T!AAP(1,!?,ZPW:W"&L*-W23W<K"X)+>OU3XXW]8,<1U5-Z1V'+
MZI+2+G&%GNCUTD->SA?[<:>HJXPFI1I$;HE4P$+8(IQ3"IP[%/ST*B&O5XYS
M_\<N"&>ZS,Y5)[B)".=Z<D=B[+CQH?!(+H.E0^ZX(++QJ!C??WB#@ICDG[!-
M[ ,7IA+)=&TK3V?"/1$G"68!14#\U]/8,;Q'?8++K%-,<U8R?5%5]NS7S(FD
M!V$<M<HJPA["/[VBU[YT-?S K@S(^^E5C).B0T<9&Q:41,\<]C_,D'MP G9"
M3N(3!^,M->?X%<4P5G(TW^Q73^_H-6IL$2Y)\;7"IP/=-%XC7.+4,$XU!$J:
M-EQ8ZD238?!.O(0Z[VV0>]I81%\O]?=FI9XYZ\/5):*7N1E[()LN;PGBQ$VO
M@D9:^QF,YHAI$5[[.M&"+/<AL1LLO^7DCJ1KXX@UDK*[C'0Q:Y8>T"+;;Z+,
M"PY]Q!1HC,]L$\@J ^:#<;,M)05RWHQ0^KDT,G'_W;BX+_=/J+#7F 9"XX.E
M26H95-^:7QGI"Q"Y<;;L60O(,JLG8O/*TJZBI14CD!+(127W86?/,H><&D:G
MG9Y=(T -*@GIP5QMTC/-=>D8\)BU$-OY:H>/5YO8VHTU4V<4^-DTJG74@$6#
M?=;]=IK3W<(9T:WTQGGID9!C!N _S )84!6X-31N@VXG^N_,NZ3W,1"3@SP\
MLX[H!DHV;3E=?!HEE^'UO5'3CL>3E=*PP=ZGA(3&MXZ:I);!]-'XLKK!66PP
MIP[QKE-'P:I_M$TWRQZV&O%(/+OI[G!9L#+(^UIU>)LK1 6#0[E(.*,UW02>
MQ^5 %ZSC>Q?AB7/OQTY0X,"TRZ"=X&C6BHSP)*XY.KC-6.Q6B+PS!X<LVI!>
MM))-PF_&IU1HKF_ZX)$@:!$W>34NXB<C1!!/T*&:@9L)MM]-M0"JDQ/85EBP
MZJG5" Y1*[DQ6M[M,LSA:[ E6'C:FW)\VC[>K\>XM6KII\YA;)1C=$'_-'U_
MJR'081WL1LMR\&!8+67I&E=Q'AO9J-@'6)3WG;((#@\!>J>DZG86\&_]](J@
M55IOR*3[I9B^P8L>TD7'Y//DFU:@)DI@VU!M9' C9B6%+!_D#9("BQD44#W-
M@K+[0.AT'\(-<E(<1)K7X2.AIQ)@Y6)KA\LX5G^\[1TM<+SR+ 9HP)CLP$RR
M(N6KDKD" -15(6;?FN$EM:>(P,E%!+;CO3R%*ID1DD^@XG73W;])]6**.;=>
MJ4@*J,M32'0@[V^-H,G*#^K]NDP_K>LP2>)UA/TO^[L-"&X'Q$:PQMK$U?JT
M;0JC"T*27O#)" W@N4<9F%Q&[0&*IE"9)C$KG,XJS/< 39':&/$I2:L]-+'C
MFT]/9Y,,Q1%L=%*":XT#Z0@9\''41&D0[E!9A(3G4%.8B!%L0(XA$94QV'-"
M";4&@IB"!.X,:B0U2G#J3J#&&!";CP75+A=ZVVME%*# (1&53@%JA =89>6_
M"!#G0C(6WYM;,"NKN$A*8&Z:M&U20(E.O T5#"/(B@1F+!C&IXV:/4.X34&+
M,+7*#"@&:H8(HE-BV?.GZ $%$4]GA$&JF9;%Y:0"5(O 0'QJNPCLG$'3KLZ#
M\6U:NRIHU$@&RC&V(Y5NOJQ@+10,!0HC616UP@'Q?5V$,:*&&LN^YO[ME*!Q
M:Z66B,U5H7#DBT0$5%* T[B.PJBR%B'>8^K(C,,.$TM)9L/2 N8:Q6![57EL
MNW<]!10J(I$I#*"5:IM%=.:>,:"KB9#,.):$6$I@%02J)(\=XKO J*0T[%U#
MVI2Q"9),/H8O'[RH:*6AQH'_I7[-""J42@]FU=,NL38412-1OT%GF508N$[8
MG*;+ T8@EH\:;2MX:NEO<9DIRE?64S,43^1AY/)+W/)+W++EN&5RO"T5I.\M
MC+F.\(BCFFOEV$N0,WAD<RE =G@1S0T:+,)-.JK9##:@D<S]!9MK!"]K8R,;
MP/P2OZP:OVP^:%GYCM/X6#"CGV!2#9807'#D1AIND(J*.,#B^:NW6]Z]S'BT
MBHC*& (BA!*">E41W(0RNM !+*K4A[N^M.4IX0+M^V;)N2SE[2[H>.\C_.&5
M@>O9RVWRY3:I T2JB:QA513RTD[F+Y#-M*!@,GAE;!$63&YEA1;(+;&>!I1/
M7^J2**68I;.]7DXPM6;K:!F_'0I1L7I#- ,,Y+VP$/8*<BT\'-^FX=2X/PBB
M@:5OA0:+7H% T4S+XCNQ-"HMT@(*:JG69@)RG]02&<5B$0FH]:+X4K#*W&U/
MMT#52U[) /)*C/M2.+TTO>@TP:SY-L)^E.;HS1")L>_&6;[EY-'!WB=L/BY,
MCX<Q8*HI7:@0,P$[J;K5\7.-6#6U""^1'[,NY_T K\#/"))@#0B]-;1-SZ+\
M,R%IQ>E%)#"8ZIMNSQ ]-H@?HSG"#[Z+T@G-D!NM4OE#5,8%9W?HR>_P>,%D
MSW\M$<5R*-8'$S<T0; ;I,6ZHYX'T>.K#F?.KBQG/AA4UF4CJ6XQ\6R\&QP]
M^%2>Q]M;PL+7=ODK$S?V']("HC 3TV!@& =C ^:51:$L8! OR]>R5^EK=/M>
M9MKO53CUV)$5NGZ 2I07D=W5"<*BU8+R:JL7!B*P@(Y3=(^1ZW/+B*5.;R(<
M^U_X?QI6C"9*-OUUD&NJJ!B-DC8=.Y43;6R17&0!*.-0E;SM&O?]J((Z*F#K
M/\]1*M^13)NB]42^AE4ODB^4!_,3G3AC?AK.G0!-EZ5^V[MFVX;QE23Z=2QN
M603 6FK3^6"VKYRB]'\+,\@<(W 5BF0)#R(,4-*B4Y$G4+.@&A98,GS>+!2B
MA[H427M>0G4E;X&T1IX@5S@!Z7TOT#[1/*!J-^W=/**'8H5ZW#UDH-*:'!S1
M*CWK)26,PGD@S=ZV6G'?<G!(&T@_HY7:)&"HQ]]:!:N4^<^K_^RO:SU"K\C.
M,U('52!D2IW /G18>^"P74^K ^XJT@5[BJWCX")\0,3F0U83 \_A(:M1P##=
M'IQM'BG@T@LX1J4[.2O0!^0842!L<R7KKX12/P(%*8-5.Y"?BK7%_ R@5I$R
MF.M:P$36[M3>_MW$P'/8OQL%#!*<)\^(-82'N*@E5H(>W(#[-^. _1\[*QZ<
M@)TG^ZA0]@_T'"E_4/AF&LIW:)>Z0>+Q>J'NV@E7:$:7P=ERB<P7NN^7^5%M
M)GT#VWIGZ%T[AZ1L-FOZ6UGAQE01+E9CGMS?IXGX3I OJ8MP&>&-4]>UW=3;
MO"35$85@20M2)MZX4XEU%HY.CU7CSL+RZ';/ 36MK:NROI,23'4#:M"X"'GD
MG/*=OO4OG*<96B:A9WI/;B1E.2!?'Z=F <+=[Z+0I8SN+Y6AM[-%>48!U+5.
MFNX DF1DKW+RLFSO<Z>5#5X.<IO>I;G/%V%^9)]'N!P6E_OX32<J=^'$XB&H
MO!I*J>9=I"]7NKS7I)S)[&3BA-X\V6P<O(V6<W\5^DO?97[&])V8919&@>^R
MVZJV178X%E30O)B0;L,CO'+"+(ITG\*4AA[?T$.7G0/L/Z?+3(N<8+>GD%.?
M,(P3C.BW&V6[H @>4TX^&Q9([^Q;C45M5;-2\'#OR,K$0?6Z_*FQR"(L=UUS
MGT&7D6Y\0RU#,1VK=XXN_3A4]+IWQ3YW?,S3C_?KM,/Q53<:D(8WDNIP!Z@;
M%TK9FVE9-/UD<"RJ?(O0!MD+(W\K=HK/Q-J:+WQY!E+_=GH=UH!P\#V\4$M"
MB;3%%2*-=\6MH2#70:Z:4L%\C-E-CIMYK_2+MM77Y@=:-ZWD.E2?JQ\9?LVH
M4!Y.J?\FL&5:FNBNF?[+>6PV?IH%1H\:>G]B=QX49GX"W:INV8B3RHB%VQ94
M9W45VMTJU[72@5I0BL0MOFSJ:$*UZ)V*F"5?(GM=8&D1Q9UKDG0H.)\.!74G
M+P^N7]R\6C_R.HH1_**0IVNQ;68M?LW5-X72&^!94E]?3/,8V4]ZNBR7*^,'
M+F\EOB>8Q]H"+8Z.S&A;;=)TCXMTH=985V[L6G=F%*I4P:0K.@-<PWGNV3$*
MZ> QNPMV\+@5I<*#B&(?H_*5$LX2E*;<Q1>1EN_/$[)N*.1X1RJ380\FH38;
M5HU#5=4H.2NT!3\\+_<NA@1UL0YWHX"OK29*7?*,JX-"K99&4M:SQ-M K"2+
M-@AM@,?+/+DCZ*^$M3)YV#GF=,-#RT.!Q8,*R&C?D"H#@MV(A'0LQT<VPU8.
M7!6*:GB[^&'(P/&6_[7MH.0CC+CA?3E/$7&Q?Y_&71PGQ \1(:DT!/HNZ%(J
M-9 ]*T8N5$5!)&9#?CGA2_^OQ/>8YR'T/D4L&ST*781#'3ADQ[+X]J4 B;1D
MP&)ZZ<W0)]-EA>=M(S2=U[HD4<OEZ92"P&3EV%XD1R\?\[% &4<A_=--7Q[[
MP%.9_)B059=M>XD<'8QO"9HNSTCL;YS8>%YM9?#![YXBH4B4GM%-,V0/0)7<
M-]!%)4=S/&&RDC*$21-EQVH8X]0[ZI//)QC18Y?]9=SM)Z8T(JR:Y-6:I&<T
MI@IVD4F3M7IE50-/7I3MF44:UC[SJV*T9N[1!U[$5\("$1C[DD.-P9I0$DV&
MR_>F<,E9O:07/H1X.A'PX=5$:3S;8*.\,I ^&MD&N7ID=?988\4HP2Y/G^?E
MYK4<%_*CC<)[H2"<_++<XG=6=YRB%=M&9^B>-03HYZHL1W,\2TI2ACF$#0X/
MO2!4@NC4F!UZBAY0$/%S,5.DS%=J%C\9BB.R+:0$F(/7V$O!8'.,Z7WVAGO!
MK59ZMO*H 1 \=3@8^O[:2;HYV&8+1.[>%6%W5R&9T3A Q(+*@6DKPVLS473!
M*H=WBD@=:;[HW%TC+V'=2"84:L\/$K:PYLA-,"_H=O;$"B@ACU7X8(LQR5.(
M^THT!6#0II&BDJ *@<T0 \/K,OPZ+\BO(]&O=W?4($XFLTE]0T_E:TA,VJ^2
ME_RD)D^3H(+-E1.SK73+Q0CK@5+C8,292EH"'^*I5)_#T6W%O:1RE,R:@Y2
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M.XW7""_63I@IQG44/G GR+!>T93Y'L*J;M 9(VM9'4RH3B$]3&$TV5\FIS0
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M90JE%14J@ZA7 05W5:+M52@M/H&CV,OT,':>'*Z'3N@%6>/34L>5#A=W2N9
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ME@Z1@+GL#P1CMNP@(W&R]M'RW ^=T/6=8+I<^F[]?4X+AZ;1+91V, !)H[Q
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MTQD&F9%(N5A'059(=+J<>'\FK(OVV9/+"WC-F+DI:4Q+#3625:HDG?:HZ^[
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MO<$!*)QK)TYW] 1R7-"]BQ=_;#:WS?3F;R/O]:"%\2V(2*0A'X'H$,2-0;_
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M=K5+(*",#$3D:(F*H<@IQUJ^=_5G_9X5V8=$FO=WR2P7X1-.;(BG:.+9B*<
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MJG?(.G"CKX^UJ=L#Z\_]T E=\/\)M9F-)R\A5VH/7<WU:80^["F_LR3U-W
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M93%<^Q-+Q*3XA#:=M'&6R2@-C!:NH;>U#E#.PM1/=S?XT0>Q"-,K9S.,IT*
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MBX=[AVP2L$_9%P3MC4V_[@C"5*L1.)#( ZP$ZC\C>[#DP43A*+)I1A/H;YE
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M$8<F?*L]*EM%(6\K2#^T?*>3LD720+ N"GKYQ\(B,),(1?M<<VD7V"HK7*=
M&'1X$:*367<*E(M1]_)'[ \XT9DCG,2\IA$CHM#\[W2O^9^5\Z>-4VWM_H8K
MGV7\Z(1Y/MQ)%"91X'M%UN<UX12\P<$_EZO\^<D): -G:C6?ED]SY.M;_S'T
M"2W!;F;I E"/A,!S?9S<X9?T.!B_!ZIQ],U+MNDERO;,S<F"WOMNL\W&B7=P
M'^0 H@HB*D#:O1C:DNS:DX,-WFEJ@OT2^5-M6?D\%@)<I<BT1 ;2!PHR@%66
MLBODG4QK:X+0$!N]"#]WC;T,'C$61"@]J.KL/^%;[&8Q?:L^>W&#S,,>!-Y
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M1LY*B_=1EZ#@0ZM>RW["4 "-_+!X(L?Y(T8?8LBT.25_1%R,U$Q2$:811'$
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M%3T\E+,@B(.(I&W"2R:D=]%J5D-ZM#&K<6>T(F(2P:2?60Y=Z<E0!14H7/P
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MGS$.Z]&3R5WLA,F*<$[4G$%2X4\+L+E,+FT<V\)KGVAX[;H8;[/^WQ"^EN4
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M:5 !&T[OJ>58JZ=A7R;70P9Z4$/K-0V*L<9X#<73GS!4;5.X',B\[&J@C#_
MJN'54JRV'(Q@M$6'1S]F5>Y[=0+H9F5?XB3!^!(<O!,;7FTSF3\26["1N=+H
MMW9-*P5NU?+Z.Q:I$^1![C=Q'IH'7"'WG#S16LMAKP[-J-=>&2WY)1#&(PX
M*B!8\]_WYEP5$="+'-K.@UO\R)(FME%LRN^J-J>%EM<J>,FR:]A8Z^ZK7ORL
MM5Y37KRF_5Z4A2:6V2E^PD%$;;-<J-D\(\N9RHP6K'8%M%0J:W-C+?OV>W"6
MESA5.HS;,9-U^:(U2^"62HP\VN]H$@'4P<!T/2\-'-L:61Y24(B'95TEZLM!
M=V_*;D+I/XJ657>F/8ZETQAW]LLPD<< 015#\KT="T^53\)*2O+W<[U2(U&(
M=Q^=^!-.S[/02UCD\,B2(IG$0I$0(2*R%"_X&+&O$?T<_<(&_,-VM8]6IM5*
M><@7//*!\83CATB7^D=*Y+=[GQ^#Z$?:1LFYX\=0K1=?A%MRM;L$P^?M))NU
M;2;S.[8%&UG56C("T2$'B TZ0'08>BO:OQ8D28&7O#AUD<#\1N[ 2+2;<PY8
M?208E^XC[.6/V$DRUCPUN<%N%L?D CWMIFZ;TO050@4IA4U>CFAN;YM"IL!<
MH;1U$6-\ST.?'=^!G6CK5[Q"_&B.<3-1QQ-Q[$C'/D_B])\G:Q^ORJ#]Y6KE
MNSA65P\$!*<:R+\JM= %W=@-K@,1V7LAC$#E$)2/L;'M%?D$<J.RUM$-K):]
MK8"/:#M+B&_9MAJ7#\66_8^__(_#0_3+3Q]__,,_?ODO=YN]_!S^X5OOMV^>
M'G_>A?>GV?.';^)OO_GAW;_N[W9)\,V3^]M1\'WZ)KW%W__VS?M/+V_=R_3H
MO\_/W]W^\.;IY?CDYZ,G[S;^^?G7X_.GZ^^?'X/D&__XS<DWOSY^'_CX/@R/
MKA9_6)[XWW[]PU7TK^7ZY(?+]/%F]<WE^D_75__E_-<WO^[.OW6^?OCY_;?G
M']9_>+R\^#G<>&\7S\L/NW>88'5WG'W$O\7NW__[3^N?/F07/VQ^_/:/U[?1
M^=FO%\[J_MOD7]^^<_[[QO]C=/7MT6\W_WO]?X\V?[SX[?Y_;[;W__V'[1^^
MW^Z>__ QNG_WV[<_7MQ=_.E]^L<?WGOA?Z^OWIXGSQ_/KKZ]^.;JC^2OJP_X
MFV\WV\5?__H/=')[<WBH\3YY0G[CNT[ N7%/L>M#BWF1FI.%1'1",1\-T862
M3+'EXW@G/2I&6MYA_3A6Q44HD6+L Z=%[:EC)=1^!8<\CD->/M1JV,HTG#G2
M?R)>AOC.WV"N+AJK8I%.XV3LG,Z\\Z(+)5DCE! ?ICYXJ+D*><5(FW<;58[6
M6J6HT$ GN.4^)"=WG/CI[B/V0(Y/,-0K7JZ^C]9.&.+D0Y;BD,SPR'WI^.%O
M/8Z6H7,8/W@&(BP1R.I;E(-%#"X$&Q>040D:\=\#<)LU%$82DU)KCD%ATZ?=
M"#B+SD*Y6"Q[BL7_%PJ=@S:O1 J)_HLD\1]#.,++>K8]U%P7#*/Q?!W(2&O,
MIC0]L!R&RG%6*WXHLH<K+-N]>OV@O>PAP;]F$"WS))&0X;$KPCF,1Z>(L&@I
M<,V^1?1CJV\4K2RJA95(5VC%02Q%1W1P[%-\+N_JPXFOY>O-R_]L_=0)EN$I
MWCBA=^L$.-'1Y2IP3!>+5,!)MC?A4Y$J-U^Y29D]7$4GM67KW'Z^CXA5D;?$
MN@B3U$\SN%LYP2V.GWP7)Y>7)SVDI@<XPX7\U#&3B! %@'((]@2H/\-*.>I)
M NW"?_AY+"6D",KX]5@-+XD@D64>(:E"LF!;]F-852Q0G0AZ/7B>H[MUE"4$
M\"+T[IX)R!WD5$)#*2[6M8<X]8-H^G3KA5V;;+%!J!R%8)C-'D\ZC*Q:]?0F
M2\]S$-[Q\L+THSV*U^$9E*3&Y.U]!VP]=0OI73RJ-O&?0,%W/&@W<!"&EN;-
M&^P_6?>CYY'6%G%>QMTB-7BFMP@_N6R+L&^L;1$1O4N6-O#7;T*0*U&:/L/2
M27H<J2W#C7K[Y'C(DS?RTY&.0&R(53NLFQ5\@=:VY0YHFN*'KK\E)ATTXIS$
ML2><PDKQDB8>;9EET"W05CE_%?;42Y%(UC:&(;[VXQ3C<)CMW01BN@5F!SY2
M _OM^YG9TU)^R$QH\5H')'^=;;9!M,-=1\A@U2&?QX+^D"(CZQ.2?R\^;RPH
MDTZN\1JE?;5::N7<CY,4&K'BO$7-M;,[@5;0_D/6TPI1!&7<3Z2&ERPW 0:C
M]_\+@B.VS@ZYQ4#LV7,_]F-:J8%Z$$)+EJ[P2TJTW&!!4H%CVB^D@).L'PD9
MB=ZU"Y %;Z,RJSA7HQH)!I8&F>30V@-N/*F]/G]798\[YZ4H^WCBQ/%N%<7/
M3FREO7<[=T25/$:R9IPX\#%15\[+SP3L-):,< [3T0U"+&3F2_XME1#XVFZR
M52N3:H:+=(WZA3$NH1#RI/(AFL&XYA @(:N31[\4B8:5BGER]M0JY4F6I^M)
M(\MSCOUHNW;BC7,1NCW,#LE0T[WNA%C(RMW=G"QL]K5K)795Q4Z^I+'83&[4
MRSC[Y-RM<>QL,3%)W&08]]LAFC8_>V'7(BRT:!@=::\:H@[KI++430B=@)R/
M.'[$L4ZPA'BDV9;H(A1DSROT6W$(A&G!:"5ZU;U<NKH!Y2]C8IP<U[M-3Q-/
MVS*3C5*74FRD!2YA!#I&52MR.LCFS42!>_42E^V+UE$7U+'"!+.OOZPVRK"I
MT4"@U0?&/K1V;$AI7'=O-9:C:V$,-"?:;0=S/.YM)= !B!\!,4Q6GV1[F ?=
MMH!>Q?]-%%)%0<P-HCF@$!CV?G+BV G%";#R@O\*D RK 26DY,7^R=C\-05L
M2S(<L?&H & [(: _#_D^ (JDT54SMWB+69,4'6M3/MKT!46*B=22*+Z?0T)
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MDU3+ :@<,9O'HQZ\[6HX+"+'J'W)RU_^W<<Q%&LQ)WSRN>V+H12WSH;EJ!Q
MU>[5XD>!7,Y$*#NYW]D/NY5,@P65^B^3?#YO&9;=MXGB]I/[,'I(B#8'0^@B
MW&8I:.S0]0.?]2'<T>$G@9,DT\KTV&@:?@"=:AVR9QGJE*;?S>2R/+6\"7?1
M%,36"]\O43KU$S>( )_D%*>.'X@NVK+4]2X@1EX6E5#I5N'<0/3[?.B7EM_;
M>[&JRH!7H85NIFH+<,FML+_PU"YPML6GZT;6+4+""]><Q$AXA^I'%STMQ(=O
M<K?8_II("9 I85)!1BFS@Q_<II-,BU(?MI6BI$R54<*ZN2R2J9Q5G=,9C:OI
MPJ:_P,WEX4R5K0H)10V=I14.QA%I$7I74>A4O^$F$^9O#X_ZZCF[V>"N?LA)
MJXD$!&X$]16>,"^3]'+-_WN9KG&,TK43HOJ@6=R^-06E%J*E05#=:.-Z_]/)
MXJ_D\QA^-Y/AH=A26)(J8\G]V,F]EE:W(P55 1CPH"=IG+EI!M?:201(/H]9
M 9+B(<L-!WF)5J@V8C8"U,D]7H#:E]Y7@*!(P0W>$MZLG027!75.X+D*QULX
MP_NEUW34H%"?RY!3KA=2TD.S^EB:5F.X2$5OIA8E*_H10Z=6(Y3T\E-ZKA*C
M EH8$!G&H>MKN,%489EXC>Z#4$LQMWPT>T3FQ[>ZQFQ4<^O!Q%H]-U7Z:!9Z
MZIZBG[>L#SQ#6JLO7D/%3>A&FY_(R9UI?6G5]QSUL/_/,P)4(:D]P>Y7C]'3
M&S*$G93DA^J0;  RX#G;GU.6CTP_L7RVR0@-G!:N0\\[RK*7\\I-X6/_@ZD5
M@$DMT89(>^)Y-:;]4<:X(E!A3KGS.]>OU6A+ K7?P=()Q-P;7A<J.I(B?GN9
MB[3(SPHE6@R)SA:'PG'NIN-=]4T>:;B ]E/T_^ ""*5P"2,FJWPP"8I&"S1-
ML !9? 4,D'JD;/BC)I2OFBMK*AIK["UZ<X5Y1ZN6R4,SZ8NHIFVI)N4GJ>\Z
M >+C,BVGG4HX4+H5]M:EF[,\I=:SJ*^4- U\)/,OV<BJZ]00X^QM5H<7%,G#
MOK+I;98K@#'F*NK&I341@8Y$_-!9.8C4&5;56E8CB&[][S;H_0QW15 FKWEJ
M* T0J%FX@/KQ4$VPACE^JJB'U&<'\:1'E'0:LW5SQ4A(XUR*SU';"68GOJ6=
M:_6XEI95ZQYK19;4,0[QRJ>0-7Q-74 ,^A$Z4)'Y$?)A*!]'!65FL<"JK*K\
M""JTF$!P>CJA5 "9"M]4049;A,3^J!F)48M+2I4NV@&<=\X+2[N<)FYD#[KA
M:)'Z[+(8$><%L<]L7Z4[>%*+!A$L33N(R'EA+>_YCO>363)=LQDLRMN!2HN\
ML&&(']=26-6."*GP=$^D.JFA>05C14_(!!J1'K*Q)B]9$AS::];0SV?V@M;!
MB/+<:5NPUKM9$V _:Z5MO#DKMP6+GK(@MDEF( ]R6Z1K\9K>^SL_A6(M%Z'G
M/_E>Y@0_^>F:YA) C/7:W]Y%B@$6JA[^OC.:N&)KX"4[G@ *Q+Q6<*P6D!_
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M72-P:IT&:I#FFI#<=_$BR= CH%DS7/HNWR/HK#6<02'N;$ZA#(IQ9_W)9LI
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M6!(N0<24EK4:VFZYGX& @V+8C.O+U<+[5Y8P65B#EK\!E2]WON2C\^T"RK(
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M;"J/5>TLVA./$OXL40\GZ\N 3-R4KY>WN*4D<-Y]K\KJH*K664S"3WQSP!+
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MY$P-O@_&?RBA7T3L[V'$Y@_9Z1']Q,+X;FZR-XAGG>_KFKK!YM331#Y^1N2
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M8*1HY+BLPS(.7[:61QT2U4"<UQ)AYL[*1E0C%6/52=D]/\WV4U!Q0HKNX5V
M8^B]IPY+IUU!10)BTCR.&J*\%HW5(&Z+U/+[H8Y/-GN)Q .W/$;79+'!/N8T
M\3Z4"97 0FS#9O,*T*;'65FV<LUR[M^,<8^MG#<Y.4;WR M$-;<9F3;CLKH[
M543:PC*PP%FGFI5T(=!![A)\NWZ^BMPJ> /7::2CN.+3@7=D-B6P#(;1[+1*
M]H 5A>GY7FR3(LI;7XBWDI@P<->K$HG=G:;@O]0QR7+O%T'+9> '!3M@XAVP
M"LU8W,]Z/FF8RX^Q 'VT$A77W<*6ER@T9BCSL&U?G!7$56 *7,VL9H^").<Z
M#88:NN35HAG++JOG$]33 (3T#AV*7<.BBW'8O-"UZ6R3W!(.6;K&%4;DE,)G
MU;NOIN>P-##+#S42NTR>+V!/-7KFLD#H9<13Q:;+$L$F-J(:;DM"5]7P[%Y5
M9"Y@=&TP4>:JFH-G%71^J2T89FV!@JMDH)P ,!N='FYS4S=Z*RVH0CR05W?5
M2H-*'@ZD\,!XM4&FQ,"F\-35NTZPU94&+X4&?<OAI>Z@Y[J#QI>A&?N$<;.0
MP5-S%9.#-!!K7_):N%@D>6'S1;MXE1>3%<%3K.JPV+8S<KDYM3RR71]0<[=+
MZ#.==:6*?<@[59NCL,U2^KTRB^7D>@Y<,WCO _+A5==+W'398U<S&9S:[RTO
M=^=AWIV55,U\87XWN<54\ZF$@8]XAT+X"W0SKF&,66GW:ZL9!2'"CBG.1FYF
M9?@#.4.;]+4FJ[EP$8-X)()L(&=$?LVXAK'G9$79PC>K&7_%7F>&PB252$:V
M(^M89;LY?(%^(P'':AR#**24%5\-FS()+X-8SI #5'M2GE__0;E+<$,O.HUC
M^PX1'"P89A)VBE2]U).IR%"JGDSCM(:2IJ L+E4\C@@CZDH %C7$,\1N;]@-
MD\KQR8-#%I\(?+JC'@WCD+\F?VV[ 35DQRI<1?<EXHWY K)$.(P(>*U'=WJ&
M\F:DHRTJ; ?KS:%WJ?L[HO%PA^N@YJ8B%G/K4+3@[A/RJ1###+$#CN(0S1&Y
MQRZ*%SY#;K#R!103W>"-DSL()[!1X\Q+S&YWD>>3IB\G[^H,?8B,4R#G_Z^W
M_;C_ Y=3-6/T^X#$_N*)OS#F^X,+KM7['[@(VYBEWQBD4ICVTGR/'+H^]8*'
M5QT[;D^7*213[1@:474P8\RJ<GA7)+C'C)F'VQO*LY]W-:,3-\3W<8MY,PO3
M(& H#G&#U L'ES*+K<[5>#Z>A[[VMWLF=F27\XJY2^N[V$,Y"J\#NSO>"(G#
M.%4E+8(9(=D<JG6,&$87QTSW%Y--0$+\5?PKL/8T8;+[DF9RZV6UIY'7MA_'
M\T-J9SP7;KIDRYQ0BL(LJ8;:!JBBMWT"]:4TZG*Q:4[2FN!\W ;:I:Y&\CR,
M2!V';8?O/SG8YXN<^G/'0],E6R9;6+B]\ISXC5LDP -K@B32YV(K9&6@$; '
M;63"EDVX-3M&\3\S"TWBO^8*;&41#R2Y1](Q5>&HY2&?%:3RCCO)D UQK$'?
M7:50VGPX4=\0+<*OX*B&@UF[Z2$%?\FL8?^R+V&UW3@'7OYEQFIXAG4J *,
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M$'I%@CM$PNV5Y_@A;XC^)<(5X3%#6[8>^UC$K\U=#;\+),^O]A#)D-W#,5S
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M_Q /V2Y=C8 1AAHTN)PJ1N?D-RN6+5W(*(V;&O$C5,>>I9NJ,E""7[\.XFE
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M=XI(:8Z+G*7$)@/'\HN\BM2DV (ZNJ+?^T!F5"V[1/.&'YB9'[]80:/GU62
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M+S6(EIW-.DXKLL7.85$@<HU)B)#?35QE(':SRB4%5+%V^.?_P9IIV1=%@,%
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MP\Z>,Y]A031D]S_D@[O>JMA'89J560K91Z#GB<;1+45?(@;WY)[]7_?DH")
M0YE!M6B49_Q6,T!A[G 3 (VCM09>26%UB#H?2*90FY*(5NF-@K$VFY:/")PN
M,\7R)AYX*W%8*<Z6V!VY\$4U=RP6[F7GTS+3?1GXSOZ3[-0R(R^,JMCM;LM&
MW<X-BE9E:J>$I0M$5HA,5@0)^ H59-6_M/K WL;BFL7:23\2588Q1:I%EKE?
M#5RM*Y8)^#JB=/BC^/V&\49#W>M_;3O#L4T"#>L&>]!0DX,;^(L)HV.Q$>5!
M1_'];X:8F\W)/ S\B)ZCD.-0DI ZW$&;*RU&P;U> -Q0^!(-^'!U6*SU>%3T
MY&JY9&O8<8$@(^Y:-0Z;&[!%61LD5N%Z=1Y,KCXB\QJ''K,@9_X"W^-%Y'A
M,W:KX0Y]<S5P!""/K;-L?L?A6HQNYJ[[&M]=!R?,AJO,%E>56@M&*\^\K6I;
M*\DV_NE/&N?HKA@+\$+)]+6(HPC1CILNS>\2 ZP4:W-*CM88+4^Q[_@N=KSI
M<HE=E;GO+6)I@C[L'='(%TM7JNLUVWUT\BN*V+7:7QS]@I9+@K;'Z/-GI5NM
M#!Q+URPI^4CQP?(P(\8M<<LX\AQ*ITO1K-F$;UZ+QU8O5U7GO)Y1$".?-;M
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M-O#LLNO=OH4?W@:S*7\+K]4.*H<'A]57\AWK6Y#_CN78EL-_.^]>O@W4/HP
M3@('J1Q4:@?56F*0 Y\/4P/!W^5;]V[A.-7C@\I)8C'PY-?\U=0JE<.W^//
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MM_/;[ZS7K_>;5\UV_RW\W;MN-OHW/=FPZ>;\W_ GZW=8HW-U?=GLMSKM$KN
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MWM#9\&^956!\ 9P1!F)F^P#F=MM-#V+"<KE,^J'QW@BZ!T,BT& <B8@=A4M
M.PFR7M?F\ 6Q0(K.0"@5W3F''._72'0!C(^*B$?JI/A?H6&K=7(5KD'\FKU.
MA8U, (@QY-*P;'6POFPT"]0&MRU!+77*K0"@?9BGU5GT2QY>BAB:>6$- 0KG
MJ-8^B#^B\)(NKC<J""IH^H #PCB$&PZ%!JI4B2.%+!@]2P1P,9U_@_"\.8">
M$MM D5;<@+KJ^'(?=*L]((W<%XL\7]"'[\X-$FN3DUH#2@1*+:R$W 2M:"%G
M?Z^4*Y4JQK[(W23E_LS4U]$PI/XEI" *AL:WZ1"34]..JZ5*I9*_:A5JL "2
M2PM!V;1$!MU@)J:A*WW$G;I3 ?@NXCK,Y/,\,A1A,9"CB9@=UUU*$E?#Q.@S
M0156H*U$.O8=+\51=.B,_&5HR:J'[]?$2+R]NX=?'J@#GJ3.T>TM9"<%*&HL
M&2D'1E_$Q?\J3F5+-Y^Z>*OHVF', SAW/IO'6&/X5VAYV8NB?;S_X*=OGM(T
M+%\)%'@'"8!BKU7SU#ON(UA0SH3X'/-P(1;8\O65R+R#=H80N[#"U@Q_/$?;
MN.\##F!J\^R-.L([#"@"_9BN#F>#>?"4E8@X]:PA7[Q=U0)XA*N E6*H)(J+
MXL0#SQ#RBC'S0<<PA?8*T,!>'[[)>00F=+U(@%Q14+T6*DQ#/GZ-BX[M-'=2
M316W&6V"?^/>T/*YW".>\^N[%'F/F/"\"+3DCHT@L>"T "VNV.,3PW**7L_)
MTD$U*REHJ^7YI:S4C:FZ+JJE'H>=(W&A%?M3VPJ$>40!6>@8M#3!96("HE6S
MW:MFYP9>&=H4DX@6:>,QZAE3HKG24FD(6C1GAQ3H8:H$[CG&<&\0 @"F(M4A
M6Y7Q58 >43NJ*)!!^M C+"/: A!&FEV)I3%%,D*QR$BQ4N^"]@%TSII06R>A
M_Y#9P19_1J0,T\V_T6/PQOORT;O#ZH-E/!DN'L^;E?)<+H*T;W%J$66N4"D=
MIIW"B$N=C*63L70RUIYX%Y]L,I;FJ9OCJ0M"102/C20C8A(YXI%P$?D%&M<@
MET7'C,7ADCD:R\VLAK_W>MEZAC*VOHU,BYE;10E!!EL@(YJFE-52RE6><E)*
MP_; -3P3;]4$W7<8N!X*C7AYOJAZ -?FH8&1BA6 O$?0+\QFJ$TE-+3<)R(5
M#9/R,F$?,)\KYDXJ1HNLTD(4-M2;)/NNL&$AAJ(I15K:%NT>YD"LI@(%<$N^
MZP!/P?Q#=-I3824<[_4@#$BDM WA(C6<-X4K*)/#D7\KL$FHLU(F"=J6A767
M"(O(J!NJ>A%S5Z TO:CJ 6EZ.&';\$WC+V%N95>&]Q4. #UZRD@K?D]X>_&\
M"R[I?NPJIS_M'Y_ _5H>XP"T9*U==',B870B%N%.N<.D9VF]4U&;3:H44V,F
MRGD(RI1[2N(&%A^@L*5(RFS< MF\)=W*38-,!!, 6+<NUG(S*/(@4F@2/G)I
MK8'[$$;NU$ 1+Q'>I.CVEGF)WE"J+.&H. "T^\"GOQ^7*X*L Z6T817R1N<5
MLZC,2'*?<JVP<EJ4P!D3<WNM02AG*@ .@98B&SA&S$7W$9O 4WK@WVL@>B]6
M ]7>-&/9/F/IY(<_ 1V(82H**A&F!C)8D$7:QL"F*&)EWA<LS CI,"Z*'0")
M2=ADC<B4D0IT23XR'[)%ZQER+R#;&QE=71&,L9I-/PZ.*'8,CT(LA9-J-"@M
M_CZ92M%.&^%5-&UD9\W"_/LLXJ+]V"(K-KJ"8:E_KQVOB!<X/HR.!('RY^\L
M-_1A%FEW 6KEN1.Z$;1+DNU1WE CX7=KN[+" (AYGO"8XS7Y<<TD8'W\38E%
M/CUD"?"$Y:B0DU0DSJH^=M6T43K:2TH4M283;EKBO!99CZ5M4Q#[;=XRT4\4
MC!X349#9[:8\OG,;C5>]JCM*2AXPD3U;XD!]5AK.0T,!RM)_*^Y?!3O&U&=J
M8!:+-17A58\,/V%C P' ]EU!(84,@ BJJ&BJ)@>!CE] 3!<^&='4?&7WH>M?
M&C\;C+%27TG%':8B\P22T!()G$4)W,A!E=H/W@- LB$L0HHG+,*6"*W'W(X<
M)MNZ1D&)+1&X2/\FSR4NNGA4/68A%3Z<+]86R?*IQV.1OO^8!8*821@]"C'(
M*%,K)D)M?_.X'2&TS[K<5IZ$F,#GX'F^5)#!=P2([[K*;A(\NP+=BA:;8WXY
MKM(6JL>'61*MK3)[)SRW$C*+$<51JZAI86B4X7I*%2[R7V4MB6L%1@BM7E"-
MF=+=A,96*%8I"R;&9"443??>R0BOM?+AZ3\4].5;<=*.PBC1(4/67R.]5I3&
MLDGAA#.R?!GNCW6S8$4)W5.0M431ID00:#!& \ZFHCV7'\/I^_*[ZM;/(6&R
M5LR,(LA$/%4I#A8'\%+6*9G<$+BE N.#@ 3%VD7J023PY9@4;H@3J?F'EC<,
M)[C;8;:<V),7!A]@[A8R"T;#>_[8FF)@)/H78;"HJ*QP-E Y=:HYB\"TY.*L
MT4IW!^S:QO@?M$6N;PRB+(K\@0ML-=D92I+,W<J,E92;/=<*I&(_,_:L1YB%
M2I'PG1>.D'\QH,/:M%)1<L[]4T"I9I);8Y)R<=7<9._>(FW62UZL;8G@.D=9
MNF,IV9]-!JZM*$S]O-6)<G]H5+1G4'EH5Q9I1B0$-@(0BJ-2?)=HI$ $2ZD7
M.=I(,):SJVRIXDRI.'-I@)H*YBR9JV8LQ;4,8TQ1-MS4$14Q%IH7P_#X"@?6
MZ?Y<CZ;N..P*:)>,:B L3-=0JQU.OWTP+7]J&[,S.$<;)CX8V&XB&&*5_TI,
M5E9&7!7@73 70,@$[+$H^NDA-%K1-M(.4Q&0F1!?((5_S]WT^XUL.K7U.)"^
MO" L2=>(UF%).BQ)AR7IL*3O+LC$=S[O.Y?Y]Z!?VY21=R?E>8;5 50ZO)2*
M)YPKDZ)M\3#B:(X3)GY5#"HYC13K02[ +V@,$.37'C>U\J2!6$R8'BY1'B&/
M,U8?(@ZDBL5NG]."GA#D_)@S^V%E@[.GUG"%_G94HD602NB0]H;IXE/7$4DC
MH"RZH>=(N)&Q)BCSH++/"$/)(#&@<0BBXHL42M2=8?OI3B91"?&DI8=,Y<*(
M*<M7 &0)\3(/!)+"K.%_%4"7A*' G>\%UK[\8_)D2<[12:RL[([J'"PA.]5R
M+L8\%F8EA-8)@'B<MIWU&R_RI:3,<8N#@VA(Y)"4;R[<G[Y4H)9GDD8II#+K
M9@KSH)]K(I0$.)U:);+-+5I&*CUGL6FTE!<-(\ND9.-W1$I/81P$>J:G%"<1
M&4,  8WAF%-@S28<%8[#O\EV7DK3D&M;66>BU"DK"0?2E(9V(IC4 ^51'2H<
M<&@'L8LK<6K)LY$ZZ*74M]&#Y;/C=X?'47\BG)2^&+Q).SQ2+"H5YM92T'E-
M@<"&K;18N$&521;]@G.TW3*K*HXV+QUKFK5QFE7;"<VB7$G5;TM!N^AAI1S#
M ;$[-&53%RYA20"JE:Y,1" ])Q)ATX\@+I6#,\";&!LH^.IJT1EDPE$"'!SL
MV/4 (HC;D_-"(%"U4J'<]%73X /W87+)_']+<=T;;[)%LO3Y860I?2WQ\9$)
M$<UGXC[6(04U30IV2 H.OQLI2"(QQ<\(;X61FS*2S8TN2.E-FZII,'+?2ASR
MB%\.>'#/N<.J9X6KWY$.A*4U<A:Q6R5(>BU]8.N[(C9?6'P :\E UHB9*+69
M"7U*)A3$ 86E."(67<BV<N%C91^5%."@HJ>B^F/05*XK8P"?7$<%M6>>$@ZR
M21B$9%B0(6"K)#;,)1KG/+0TFP*H9TFU05\L>45]F00:1FM,R<VE9.2[#(=8
M82])PM^5&"N6T2.,78?D'VJ2OT.2?[0W)%_Y?>-*D,9]W/6<&K "W D#&<B'
M\!+_-@SMJ2$2K79#K%I*,DI"?$>NIQFO9RV(/](0OT.(/]XJQ#=E[ )G#;Q!
M"36M5D0L2^S?QM =L"NC(/#I5XX582)^G,UW*N D*@=,X(;,[TJ]6*O4WB\S
M->-(XM4QY>0.D:\"Z(X!D08H)IDA1G#8PN.-3V-H$JAKJ4[$5/S!\&P+K:/<
M",9D+8#+,E2978]/T!*:PJ(+N1]&1[@N#D5!MB45A"P]\E;*T(.%,8"8A!.*
M0!&^9V67Q=/(&5C8L5P'-BXBO1TEG<9=%XN"#+#GLA%*'10?DC4\YD38G%N-
M(Q-PQ8$5A"),B4QR13$-.65L\LQ<FM#L@-"\VRJAP9BYT4P!L&LY@1)0?[Z^
M^LPN+Z^1^Z7U)%CWE-/B960^Y7I-PP&P/E6!ANR$%C!1#+(96?X0$&,&V*PJ
M25V K(VV%+&8PVI4A#N%=50/ZA[](V,7X+_ANE.D+[BJW.@R7#\W96"/$:0F
MSL%@X3$Q,P8'TT+R00>C(H76(2'O-!O>(7:\WXG@&4<:S\=RB:I-4EMR,,(#
ME2HJ59]*<*0'Z.MUH.F]AJ8=0M/)GD!3$RB3.^-*^[U6Z7US4-7L75^O!4\G
M&IYV"$^GNX"G$J.L.&:8H..Z:+W"S()2',T/?(X[OLR>\\A@*1*<D$^2_BR"
M5F6N]QU7JG$B(S8JH0.O4#[?/19@%,$%F?R2)'PFOFXDE[$.R)YJD-UE[$$E
M%V8?$_Z3--^(T)=D98_\0!20UB)SK'#+BT;O44T<>)B2";"O.PV$]6S@_]04
M/D3XM7"2.S<0G=]'QIT;=619;.(4^MQRSQ-JKF]E#/DB<V5:ODR<P%K>[$J$
M!CBO+G"H(XEU)/'^!I8^Z4ABS58WSU;S8_H>PU;[(,GYQC 0KD119&$0^A;Y
M(0V1FHB%$[E'S40F/)EBD[;7%H>$4KRJ,TLS;B^*9Q6>&&2^[DBGUNTB(OTQ
M2>-*(Y@/:\="<',UTD3?MTQJ^$GY>$E*M B(2N5%B\S3*Z.@TY1RW4>UJ*AT
MOERLS A_T&I/*TO6FE?U.EJLM$U&B_*XJ!4B6@ E8[+]<#IUO2 NLN(+HWDV
MB"!=WN$>\68PDV4 DQL4'H*H# P*L7,RK&'*)@<%,:AQX$'",5$0'!Y(4D(>
M4@S\Y).I^"557CX9X)JI79\*AYT_CC+[%/58HZ((V:")N3(O$02CTOD)4%7<
M1J_ W744=7Y0$;?K1)QAG![=+9W*LE)]I3R85(D:1E+[R(L7S ,Y*E<+UUE\
MD4;"=K3L N-&-%]5*4&J%\_N/0NS5$2O!P1286TG6[WKR9 4!5;QK(:M2?LN
M2+M(- 8X&84VW1'(=9Z1*-:?=?<5Q/[X:0^@("8J7*<0PNBQ1-B.K!] N(&6
M)54C-79\IHJS+?-#HN\WM8BI5'$?SM D!F" GDC[5A4/4HA)Q#.O*,7Z#:@_
M=;J9\A*;V8A&KQV@UR/O_LJEQIT8&"0MJ0,0*9(5XDH+V' A?PVD#*"8-6[U
MUI7@(L%*1!N@,+0^9 D1)/2P),;,#46$E&&NA6:2)-DSV8B7< S]7!X/9F76
M:K/K>K??:MQ<UKLE]GOGAO6^=&XN+UBCWFU^NKF\_)TU.NU>ZZ+99?TO3795
M[_>;W1Z[:/4:-[U>\X+=M/$W%?G7ZOW,/M4;_4ZWI_#LO/FYU6ZWVI]9!V?[
MW&358];Y1,/5&XW.U76]_3O^?-WM_/8[Z_7K_>95L]U_"W_WKIN-_DVOO+ _
MO,:UC>?-QM4X1:FE(:7*"K0AB9R$Q- 1=9Z2T2X>5@J<"UF:YW9S04>8%_:5
MX!SE&?C72_-1U9.+"EZ;2DZ-R&] /$X90=P#,LL<D)WE559QKU3*E7]$UK\A
M2+?&U.=G3'U2/YV1(9$L@NS'2J42O2('2MCZR/ 8L(K\!ZTR:-G%A7GYJV+"
M'D3?=-W[!O8$<PZJQ]%JQP*(JC5EY*'1S CTSZ,G4V;,A&E(?H\0,/\M =S\
MUP (B2\E%BG8/4Q\1>";_$) </(;!"K\FZK8#@U;0J08+#U09?XQ>/N#/.CC
MT_*[VC_0DBN0&FVJ]/]#M/%:SH?Y>WF%#3%AF'^]@G%>?127D24=!#1_W'O&
M],D2D&3)GBT9WN<-9C1I9'K':E^P>Y]AA1I4]'[F(88O3A70O@W,EP"_Z8$6
M0W2U7#M9#Z!!,P[X ;#!(5 JQT6@S0*Y,C'JX\X>]^%IN5IY' $II!]/EG1L
MVV%7[%A!FG%IW'L<7;<_V]QR\J@%?/(^:B:Z1TQ4\]#M\= -9*E<8XR]J137
MQMCB(]:9DOP,6J+,44FK4IH]:_;\_8];L^>]8\\;($>" #6CR,3E!$AS?,WQ
M7P[')TO;P')A)EBPB"'7;%FSY;TY;LV6]XXM%^6>%'-3BC2F(]>ND_UV4[:Y
M%8SGFPJA+A?U26BXDXGE4RD^1X;WD=\OV79C&#^3\MQC<P/+C_^DR!T_]2J&
M!\+J59:QB%7"YA/#&443#N%)^EQ4X%L0TP)WIC.+BP$*GXYJ&@>'X6'Q%@KF
M&7K6A JUN*,1=WRNO7]/!H3[ZP5N8>%4<W.ET>( 1!A[1*5R1/N4B6')UK0I
MKV2Z7"3E1Y&+<[,KRH*O+B"OTSYTVL?^4<8GG?;Q99W!=GC5Q!<>>M%DPUE$
M0>Y<0-K-D)!XPD<S0=+KSUN=ZR_U[E4=Y/-VH_S3P'O[L5JIOJ^PQAA3PEG7
M<."_OQJS$NN%H*1B6 H]]2OW Y!_L#1'B34Z L=/*I5:M4@.^E)[[I=_>OKP
MVU^D4,T#R<:AH=WIMQI-#'C#8+96_9)=-9M]"H>#KX"<_/RE<WF!,76M-KML
M-6_P^WJ[?5/\Y$)Y6-/]AX)#CCC<=^<SKE2:3,9R-U]=7ZLG^Z:>2%QL]=B7
M9K=Y_CO[W/JEV8Y*'5/!A$6M.C;5ID-E>5!38]?9E+Z1UT'C@2.5)V7VF'88
MHM%Q;E9B:O,P.I:%PO!.BBS=U 9T6/[^8^-J$*(Z_8VB)+1IZ $0<O^LB _J
M'.@GUM8$V*RA.YOHSB;[V-E$5RYZ\AU($N3E23<AR?8>B;N2Y#48V7W;@#UN
M3**Q^,DW#UF"Q;I_B.X?HON'/-7^(9H^/_E.'VO2YZ?1[.-AE$5#\Y/OX@'0
MS'4CC]4;>>BF&[KIQG[0A>TVW0"ZX.F^&Z:&Y"??(",AKSVL1X:&@2??UF(M
M&%C4V4+#PI-O21'#PIYUI?B@"^;KR&D=.;V_82)/.G):\ZFGT(<F8UQ\B:UH
M4KUC-/@^K7X/;E1'5K=\>$ZL;PDH]2G!-BX'C 0 JXRJX"(6A9=A_*RHI)II
M(^67932)OJ_=%+]=5@E]9'WCYJ8)Q*Y"!(3-4($:VKAABQBPG8IEZHKO+^#[
M*)1)Q>$J[VX4"96B36@>"F2N+?!0BV(W2\JM0?7<C:!43+^H<\&*!(QUR#D0
M!T7*[2R)KI+D<VB[/HFA$1&6">^)S8OJQX_;4IG55Y^P)(88&SE9T;L-XXA/
ML#!NE2(@$H>#1Z&YRO['W?^.M;5%7QJ0:2=81AM.1V1L&"/T0!ADLZ%',.L%
M9),_088-HKH/B] K"Q$*RE73&1@\D!U05/3T H$&\ SDZ@F!&_LK=+UP@JN6
M;Y;PL\?_"BU/NC 6.A53M#;KK'WDH;(H&6%^CO5'JY:>\NK?/>G5OW_2JS_)
M63T[)73+:TRZ#M8+)3C640RLKR'\H-G<R#R&NW7T9K6";1ZNL\M%C='2B23K
M+.VHS'[%J "968#$\0D#V;$0=Y1<3(YE&4B"_5#8U X]8&V+06<Q6,C(29#Y
M0.C"8$**]8JGA'^X=:<R?L:P.NXGFW9E+SL[NPKSD.LNYV&'#%L1EB+AK%@>
MN%(KL[8;8 A(!$9+7WHZ-U\EFUH>ZF5B0V6,3T%?NKS#IAO!(0:JQYR,2TJ$
M("2?2004Z0I13T;XK-MVQII%)A'/M"CXV7+N+!F>@G*BO/V<E&R1-5QFS3ON
M($ABXQB +R?S9CYUD:EC?X5 ,Z1+$M_'N#:9!12 \BFZ'3JDMYDRVM.5DC/
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MC'M ('9 (,/H<P[@1((<4))_1)0-BUP84Q\HC/JD?CHC(DG4COU8J52B5^1
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M&+^>2K"_'UOPLS#"C0V?WG*GA%;PJS'\*[0 4U%AM&V<P+ )2[@7S!B<&7<
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MI D<%[;OB9 =$Y%S48H/V:$T8WQ.C!%S5"SGCI-# UD+)9"A)H$^7!&U2-J
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M1H"]_E2DT#QC+JVAT(NWE9(9=[F)N]<D\7V'O0]6+,H110&*7#J*WTN7W]C
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MB]H4X1>WCO!58J'Y].,;81/"#LJ#T'.P'#^,/IEBA5IIH.#.';?=*4V+3;:
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M=G*E_Y.WE$*29=/? 3:IDT%^GUQ/!=,)I8FZY%*$ VNI-".5T%+T5CV$A7D
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MC+??WCP;N#TXRYD?"JD?:KWMV>;@-"TZXI<)/2U9U@O3!VP7*)1Z9:D_:J)
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M4Y68,%Q415Z1>0?+.:NRW+J/F '2);QI3:E 6/=;6,R%9'K$L!*@"9-1*XU
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M^!K<8EWH5ON"W2Y5Z__<F&W(=9,FR^I*@X0?)2^:IEOA8V[_O/(>;0E'#SX
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MP<(I\AC]GZGM+5V'^PBCR3E#Q"#CHB"N(/0SD5EW0*AD4B5_)[_O^CD.GM6
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M:(]C5 N(-JQ'J4P%R44CR2E4RABWPR!>;JVABD<_%"S9#3B/'V'"B6&($O0
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MG]WZ9@+(3#?F.0%W?+5?4J\'A.?#403&R9(7.YDF?1=]XHTPQHAV^#@4B;5
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M_OUC?L@#D4W>]SFQ?Q$7JM]:7G5M[F+_I*N[08#/>Q]:SE IK:'^1Q;JQR[
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M<M613G?G_8;>X+@FL 3-U^ B]&B<B%!?2X!=\6F)&J5/$'XJH&CA%3C7M:3
M38$!^Y3F48N"E7EC@< ?\D?%/-B"C&20LM'7*>\?<K3ZH#CG\A.H[;3Y+\Z4
M-.9QEE_QQI3G\*,L$GQ9X-=KNDZ['QFEUML?FA\PPL5/RU73026(#]T#O0@:
M+6)B>HF5=W/)NYLGJI@[DR6URBZ,\E&%:@D\G;+U3R833%6C!>^M)X8IO[>$
M=!K)X/D3LV.^!WKK6<J&L76,(DKI PW,CGX3N+/.<'B .M2U,9&7$^*:+44!
M_"%;3 50O'_7!M Y4$S8K\J\#7DHJAS"L[C]UIW<.PN.#5)<!,X7 Y\I XJ
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M*4?>&+83%Z@PU2<GY4**UTGL0N&4,R;KYX:\YF;H_)P,-;&30WG8!XA*4KB
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MSG=N8,(:<O/RNM2 (6+03=40ZL&;ZZ8:#CQ86DU^JQ#!&'\K3AE >OUB\P;
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M:M>K7=_3&W5O.=W\SX&!8ZLIK:9T+U,"&8*+%16_-W5NQTI!JU&M1G4OHV)
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M3S;47YVDAPSP"YR!6!#H<06=N6G9B1[@NHT^<E=WT3AN98R)10;2G.&QI*W
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M@*N8R,1$](D,+OF9\FU=;NCL(;.B\-W/1-L<($<KI[U*<-*N4X#5@MM_=);
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M+!3](<H5?R$^P\7F>44:'CZ NR;VPYVRPG@++IF7@6+2A5R01*HA=SP6*)%
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MM[Y=;[S^S5MWBB[]VGRV&M>]C:LL$#&>K).YF*5NK$H"$!*Y-T$N*1 7UII
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MXWH54:?[2#5<^&"AP:UW.4'A-8* QYU(<W/G?QMVE;*?;B7)3C)YB;I5A91
M'J"MZE\K3%I29#$;-\>9P+4&^-M(QH7@>4WQ?O2'YJM1RD@61!5:(T'H8#,>
M)$L%*^.4@G99<I>L2DC-YUVXIR$BE(/&TCBJ6[5$'[5[U@$HP4?8%T^^4"?H
M3=YN<__B%E*F/[^K7 #4/]_U_/MFKSWV3Y[I9MF%[8Q(W0=E<4CE6F23OKL!
MYL%;@S[,7@[-LJ-,V,GE;::*?U% TZ <1<.9<@U=X.WXE4,J!1-8UT/X.^VA
M+[U9\+0\?;(PF_];9Y);+J@3*#[)J-<D/H5MD1@=MOZ#\NA_[]ZYW8 \<4-2
MFJZ5_+)^'I]#/L^B="(C)&/#R3VV":3']*PB1)H/Q<13H/_:M_E07*A,&;<P
MX93G4T1@K?FF.]"WN][O#YBAF5M1HAV86YM+YO0E878GV?'Q,W3+#X%3DGT"
M5[.TCTC-R< B.0(/L:ROFTK4$>8NB!ZXL\T9K(I749;ODM@(>S>==".L.D_%
M5CA6 M])1BX<\S?>Z,C$.;"Y95I&+!//P_V9P2$C38=#CEX"4IX P#=0MZ!4
MS.^2U"WS.M"L0; W5H4SR5!W#>4O"2JLK$!]E..T]XU9/[C78+/3EJ2#ZT>-
M-]$(\M%U-H>AH^U@7RDQT#Y7HX_2F9KJ-TU^ICAI1)CBO.&Z6V>/R*#>Q+%
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M;V:DF=_LQ9>9OD NG)'QG Z7E*EMP:H/3,#MED*[;= (1;R:!#EDL@)WI'
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M&-GM@LFK@<K'?_WB[?RGJKJ."CM_;XZERS:<;?BI;-@]64]5BK%CV&DD?%Q
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MUYKNS W.G!'9AI_"\=W>P)%PCBTEBD1#G9MA*7@CJO%6$M'TW_!IA3ST+L^
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M(\75"L(L5GUW+IOQ;/@8CN69N1A4Q..>M7'5\2L))I+YFK*5/L%.J6W/!.H
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M0S@E^MHI9@73I*U/.N])Y8/0-Z)B?.%C/@NZ6S>;))_%W.G4[Z9-WF8->7H
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MJ6(NR=D(4Q,$0WFH[*QZ4*IU8D1JZ&T;V&G%IPY.;F8[SP"GIP8X_28#G#+
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M.?PH"9ZK'S_5&: ^1>1!D&]C3OIPN@?2C[N(/BY<'4FXR2V<UU[UW8G ?:*
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M#&Z6-:%2;AJM3$]*''>0J%J@Z [8Y4#Q-T<^F];P<O7>^<P5!W:?3=TPH@4
MH.J\NNF:$W%6B*KQO:9':<D14Q"! XM@O?X=!U-W7.;UY#)#14='=)UB13V"
M-@SE^S62ZG87=N$DSE9GR>24&Z>4V:IG9SM<6+M9+>!\ZB&VU6[M%OD-SRDE
M4, ]U>P6'J^I=Y[\^SY8BT#0 />[$RZND>Z_O>^-#EW;;1I$$F0. MI7!_GP
M=NV['HUGS\M,2(HG!$I>[7Q=-43),C GV,,>GV(V(  ][R;P]4K5+DR]015)
MB'J'S;[:GB0'?+>?0Z))!PG]S[.M@=VID!V>,.,L[CAD+#5L@1,(Q$2#N%K"
M1;KID4EU-1_PL,D)82W;%^YQ5T<%+"5J(SCV]0%VI"_[KW]^'UXVJ&?&WEE7
M Q^YA?;?@\WK078\%9,WO,5T6LO3LCT]=" 0N')NOK,4=SE9-Y;6;D[\,(K<
MVJ1)=X'_*UA*S)IM;'B9H2?[',_M<_@]&X:NF18KD9E8^.YL@>J;DOKH=V+9
M"]$S"*H8AH.H\&]_(J(Q\UMH;R$)%+<-K?[N+C-LZR##Y[TC<1W\KC2770$R
M6GP(2;;SNKJNVHKS<13NBC*=U(AUD"!4,HX*+4-)U7/:D>\A>NN'CNF$C*O!
M?1GMV8MMZI\#!9C/$Z:<-VW=T&PK%"EXS]?C>RES&'=\MJ#14D(8A /S^^6%
M^%PJ2)=\J>GY,*'ICE2"A*[[:GI6(#,1#G%J**)&GQN@7KW<SE"E^+XW5<]J
MB9QNB!#?4R^ '6]O@"BB,1.]Y#<+Z\/L"0 >^I@,,G&L&LK_GK@MB81WSJHK
MJ;>9".UXZRUBKC'L N!!\R+0#$^_G%6Z6KW=;)P=NPLV9R4CB\4ET\QT1F52
M=Q0O<YF2%_;[PYPXCRH(1K4JEHVD@1C*-J9+MXQ\.%OO%X20=WBO,"/:QB@N
MC5P!J7W\:-[,S*B>(:-/"QG]78:,9LAH3HN_M+2X/\^\GZ*\M;%JLO4RKCL#
MN:!LIW.*2WH]!-9QQ_.IM8)]FU%JYDE9R?NV[^C!ILEU%C>2S[TVB/NTL)R.
MG$%E&?IC7V\JI3XAB%/.KC^?@_T5HB8R%4F0>VKF892<CQB3Y$21ES(%E'+#
MC;O#7A/(VN8;9/L*$_W:$,Q#8E(,-S!FA3@X QZZ0S7B#;J=M&*&0F=1[LVZ
MH79M$!X,?U$;%"FURF,WE+X](AJQ.H.*CDAPX@9I>TX_'7D=R@PIO6]48XKN
M.EU:40+= ^$2.*KWP[=FREAP(58_,J!3KICY"*.+Z%8XP^TF;/'M0[ 5&J5(
M8_'6D7Q@FC?W9H*[;E_(6^84GW[ LF(D)2^>KH=/>7+8D/KD][H2CH?($..+
M$JL>F/*V;M,KH>@IV=E2@$_QQ'L+IX".'V(#8>0=>N;1H^X&=^YF:K<2(YJ@
MPV_22DTQ>=YA/IO;B(=B<1]>Z"N;[+Z0G:002PZ)[0-WW-5;G\VBD$[*^#V)
MC-<L(SH[#_[NS0#B&?Q2F_HCI3H)9,!27FY,1"SO3P5@-?E0N A?XHX"FV,K
MCW18NO?D9E3ZHKTMBHXNHSV"L#"OD<DA:>PS@P->NA?TMCTSU--99$T:]V!J
MV42@/9\T<89W$AN3KU]:/4C[T.?=K4T,%G&V=3@=CXT]JH ^RQ[*<R/!5"GB
M[G=[4Y=NTTL933BY 2JF#:SK UK4?WLX#V-U4"RB[+2&K1P2P%Y8/  -L5WR
M23-.U=N#LH!%XJZ1\N=1^6?QJ7*;:$0%KD=#%24<*_9=W(T%WB"2J52R0JW]
M4$7 U:D<QL*:$*"+UWX2=B3FJHU0%CZ;Q6GRN!RQT^>O-PJ+DR0A5 \'JQN[
M[7!7B(O*0QS<OY%591!MO#Z-^ :@JQ6)86S(V?A?AHX&C!V/@@Q!'U?@#K2!
M4(:.$HZC*"&6*RH+-Q%"O!"]*SZOMN(N_B"("\[G@I-;$KARI!( ,%1X(XE+
M>!DIV^3CDWY3;UG$EX>SI/X-1(>F'D]MN2.?CJWO_B1<7K$[.'WP*6;(*XBD
M8 (\T$X%(+I>4",L5/S0>Z_<+K3GGA)LM-9PX,)$KEG$L\DP]-,V6E3HZ#+$
M_3,@N+<8;R!\-T&E^YPRV?$@E7ORU2;*HO-Y>N3S"W05[DH73)_WA+2IKSIQ
MQN40@]Z.E*NVSJF7/C@\WX/'DWP5!?\Y!7KP./(V>G<+M&ON,@*&L.O<O[W%
M!XYW%$:4!HQ'6*%VSR4*GL'[LGQ+TR-X02:'MPG]66*O5,)QJZ4,%C?L8S/Q
M"&]R.];5*H%&:,IU)<Q8!$$VD5QV3%^\8SK1$:&W35 R/?KK8=-A=T\ ["*%
MK9IT4'#:MK,R]!1U"E,W,#]R($ZU6PG.=ZB/B,(@AAC@"FYKM4)S97/*R;6?
M#$;R(".)4)KQ&^U!HPL_T2?'% 37"5J,HF AIT[6B[4=3NK&[OO'4S\0H8V.
M[KW;LJX)D<]7?*LR"L.JH40#1. T2=601$&#O7&[.E34 E4/+'A0;KRS$/5U
M><RL( G/JZIUDU=5O9R$]"0'ZD&X)V@K2B;20];@K*<J+/O:--4;\B0:=]U1
M7'8W0M\5XMNQ$\YRD,-S\T0]3GP*VNO7!RSCU>G8&5&N5&MX:T15W1ML*G\2
MZI%"C> %<GD+3^X;W*NM1V<FYOUJ]>?NEEZ7-.V%!*>W+7CGSMH/;$#K<J@3
M4 NSY:CC[F?E!#SE/5^3"%UT$D6A/9.;056^7$4O:/L+1SR)9#86ELS!&:%%
MZ75:)#]ZD<L;=])SC2UY@I_&6J  /VK@,:=U>T&9/LBH021W7RD%P!EF1<0$
MPIPA:B/D%]RWD]I+QUM\I(!%[_'[E*2;S[!&[TD!)@^%5$K-J0,X1-D7EL'1
M-FD;H,1S26*<GA];%R%F--:S-N41VI!RY[0'RC'&.\D3K2M8/Q+6M+IHP^)<
MKG8(!P5J8&R9E)YMA_<,W= KP )]>MY9X$"!NN*VS%D1A9!\%E3N:39A21(X
M1V/E8)4 5[?-><X/XD*+LM_JGAZ"E'O.C!G;3)=5EB$(0[0-SOJ,%!&:O2#*
M03SIQDTWS41V&97TU*BDWV=44D8EY3/\1Y_AD2T$KJ1@!%;>-\C);?;5P3<H
M' E]6FZ82B5$D<*9$#&OHRP+IW9+A=Z5QPQ[CA]I>?*'R/E^)[@>;G,U8LH-
MWW^TTLVC009%QY#T0V2-#SUI#!6;40G"#T/]AW+2P4WO>H!S*3U#>W#V0Y_!
M#XW<F>"4:K^HM A7U4?$J^J?FBQ+L#4XK= %\! 4]^4F<C<CA\?_0--V 07B
MXQB3V0EU/]4XJ;>(P<^3&T%)8>( <Z%(+\9D"U07T-]PPF'LN#XYG.I1NUTX
M)(1[!YMV%V'(Q2R]J(!\G1D)M"/6F&DKL"+]+@J/#XE>&I\5#^U <0<<)7R2
M$E.A//,0[7/.\0^I)#]G1/R I/:%J>/9+732HG"#NI?</\%*TQWIHDIJPU;!
M/1"K==^5V]#?2ML,PF5ZJ=6 ,$-JJXI\037 2UH(:"WJ(@"/-%W MG"X+0ED
M.SHX">5OR[YEB-?7G$OT(7/87'W#U'WSC*&9]+E2C=; S:9;D+5+PB38#L$_
M6C;?8D+B<!LH2)IZ'.D+-3I="DZ**Q3I-E.5Y*+/<M'G_:1S,]GJ5;<W70,N
MLU53M==$?J"(:U;X5;  +_2(!4^*CO1]@@ARCJ([C92WEC9%8TENT3:UVUTM
M6-4PKLD&?W2;32V^RL[ODC%1@UPT<92E*,,2H%B_]QE^?*DD$T @S8&D2BA+
M7=7V9-^<^@@-2+7=%5=3YWK0"NL516B3K,)!Z4G#I(9=S. ZA@5F<@SEZMFS
M>7F?<]LOG^%T8"TU_2[0_"D46[L)DWZ%M[(3\18JJ&')ZL$+H_B3H-D]70Q8
MR=,X)9EB3UN93=U=YMPSZUR&5<'M.#:$N=A:%14XM\IZP>>?8(]!%R/ " )1
M=QNLMA$S!G3XEGO3V9&(I^8\9Q#4'>YJ]156:$D#T(EFU(S'BTB=QA,B$K%$
M)"SC$[7S-Z(-IA-Z2_,6!1',?+5L.4SIPEED3V.3VLA-B<F4(%;73;>F,3@S
M&YW)^S&'@E/PW..+U0I<86CT:%2B@HWC6G-*$MFVD[,0$-5S^HE"P7A^O$J5
M-R@Q&^!,H= FN^@,\6VW1X_YSM'N<[3HG'K*@Q"-#9$2[@*\JVOA H/@9KHS
MS!;RH.8J7/Y<(13G@G$CZ4V/W(SS$@Z1+NI!9,N;4^R$3.C<&BB=37Y]M?K&
M/5:'VO64,6-2ZL5DC&#L&HA?M9;SG9I!T.Q-21YWC3$J&97->5"G"GW^!@-'
M&XM ZQINIQ ^UWDAV;D?5#VOMD(<"XZ &M7@>SM/N!4I1KB[-#0I](X%M;!(
M5L;SF!S4I. S0U#WH$&;INXZA9^N=E6U79>;C_2=@]M83L0]K-AI_P<W ",E
M1K4B#:-0T&:O%E$_-MM])7LH91GK#6TWQ-3/)"F5;][2JY/](NK;N?@,2)'U
M61D85L(7G^"DY<X<?JN^(<BM+7IB<A:X0K\MEPQZ['Y-'XI%BSX IHGJ%';&
MY-P$!4KX*Z;1_*?_#DF]XBRB_Z7X&@C)3%;^$Q6QA:X"^#H5/%7R&'2E,3>T
M9WU*AGKD96E6C/Z-1:1G.TM$T*M'?",.6=3M%S@G[\]'<6_.0(,Q3-+PF?#,
M#.KU4L/A(K3%IYB6F,K9D3/!6^"+9GKI*-EHMJ0I04;2!9F1BR^_W[@?DCW!
M8O7Y7]XNL;X+WY.Z1H9?_"'<0I:KNB"/N[M-,>4CRW4--/,<.NV]=7LL*@F*
MX'3X,KA&H93$P*OW]2 S8/W/A:@)9I$0]\7V/SNC*2D[RH&)GE$A/3:@5;H*
M/XPZW%T[[[V=][LB ?I?,7.Q9XTQ:09SR!964T+!_Z)^89?+@W(_LLG]XD]
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MP? UC"=@CB>Q>F*WI4MDYJ6,P7IJ#-8?,P8K8[#R@?_I,5C642ZFCF+PC/M
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MA+W_#P0!IY(,_Z?[^>J7] ,RJM>OWKQ]]Q;_^NS-KXIPF)"LT-I9!C&CE^@
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MPY>X%K.4,-'U'_D-W/'$D P7*U$ICPD)SFJK3[+,#'6/85HDV(QN7O5@OQ^
M;FY0O;,S2,PI 86+?0 8(2=HH\ ]S^W*C)669< GHZA=@JCF[JY7L7S5;'T/
MRM<<KUYBS56"=@J65')RA.26BHN<[8\O.F@B)%N*-J/L-G+\H$\LXH\4)B/_
MG6@F0:\W" T?E+0('@NV5L'F@#>AVR$B;TG $QP4P-E^XVRUT]?&%)=&6\R>
M#07WKZN5%3[Y!JQF/9Y&I1D [' VKX!8D"O P7H$^G+;D(?J(,E7;\)EY0AF
MXVN[=L%.P\D>6ZN_?U#41G\_1Z<34HC2@ GX=#@VY'0;9@<*Z6>$F7R>A$ ]
M!VDO/DC[,A+DE&35D$1*+.ZY43)\'7&4"%LLH;1;EOTS5^[6C:S P:<(B"YB
M&^>-;NKJMC#;0,![Q#KO?NTP>K^:P^/,P-PW7- !4?L=I+#*N@D:P>>+Z2N@
M\#P,E X7LZG1_#A'784*TS.60]/G<R'>8B-.5'<,QPR;%2=JEXL^;. *>I\C
M/OOJ"*4T9'W3G8VD<WKJ;RIW(656<0YH/7IF.N!L!83M#'NSW/54*'D9RX:8
MI0#(B:RK/G3=4D^ MI[C,Z/81?[2-2F8=:<C09[*GEQT.N][$ID3O&$O*>49
M=3?3)C)^PS#+7D"3Z&NPVO5 =\!98L6Z [.YVM3GC)I*B;1\*P)?0/1E-+H_
M^+-^Q<[^]=D']!^^_.8[C>=1'=3,O>)8[NYLLN2 A*JK)PE7#IV9*@J#N#XY
M]ZP(<@0K3&I(E8+:7+Y+3#TL]&%VN$:N3%LLV((9O0\B<^6%UW=-/B6E9>LU
M>Q&'RAGD-B@@D+'B\\J(>LA[<(,Z:"UV[+HF0;_X* CJ_>?V0EW4%PKDFA.A
M=8[6[I32F;0@UKVT<Q0H$* V:TH@A0\1=8$6T&7OMQ^KZHAO*WC)?=4]M[/C
MPF#-P($^ K15 +_5\1BHC:Z(WE,!@K9^U(8T^F?BA*4Y[ZN]G+(!'CRM*\E;
M-:]#F:<OMYNNSP]I(Q1BCJC:(/M"V"OAZ9NM3KAX'P ]BUK;X)1BYRW4E)7F
M;;@$#\OT4AD>]BAXV.L,#\OPL.RJ?WIXF/0&2#5F*>6!N#+*=C!;98 AJ'C4
MYK^_><^GVG^_>S_X-$VREWM"/AG*$:&S-_*$XB8@Z<*(E938NS!-1A-"3XE_
MT=Y 0:^2J-:=<QP+A)EM=T+G86C1G@%(Y@?]I$%R-CLT*SF;_9RM"(@'DJUU
MU.9-F4@PI]U0^RI8;CZV7!FQJ06/KP\NORCLK @8R G5.#<!I2\TUC@[1.M!
M2PXL$UV;2S.7FK?36R9',U%H;4$[E 9=>!Q)VW;3T%-Y9OT3S#OSY/X8*V;-
M.NKL8?*_J,K+*,MQO^W+6TY5V='Z<IR4NEBM[2@Z1E..@V(VU#OIV>:,*:&9
MX\2C0Z.P[<'<=\T65]?,&'U)6%GU,O,Y6P092<C.9 <H?V]7336.$)S9N!A)
M.@Y[(FRCNJ\FP&BP?W>[BH3S.F=#5?_3O5JB>*N0\I<,@ 0E:PCBW'2-NYGT
M9;B!;?G]'T]KZEB< )<8)$;&4(\^8Q(_7VB4LE,HO2FD?Q8__!13YMR##>_U
MW-1"FSN6 G/QME!MW8H*$#'I4 C*N8M]O;[,PV=Y6R[$I#-P+L><23I>Y"FC
MGC*P74E$P_KP U,?H$YJ+^;OHTH/8=)SUOW%9]U#UA%@)J_BAB.:-BO#*ME0
M2-OP.^[I"0[$'DXYGYQ&?DZ14]7S,^><;\QF[0 "Z7 ^U*3JC-:7[=U6-HFV
M1(+.L(,>L7.,A5"#HN&M*9,Y[/NT)"[(FZ'+CGC2ZWW7N5?;E@#X(KTZ"@]8
M<NB!#<>]X$%4MJ1)UYLJEZHGW*1<PRY650T/]2+) 9.<Q9C3P3G@?+PI\K3<
MEL<QB!UBKZS">XHK-LR6VAWU[*'C9/H=?:':/5*/,[!K6;?37N+@4%NALJ8;
MN&]T3@KDD=KT/12K Z4:L-LS!6>C+WL4=3*<3401):4(@=S)T2_)[6BW>M!.
M)8MT"N/\7/J;^87ASZ_?\'\D63T3WS-POP_8SWSLQK@QR99#WI(TT>EQ^-#V
M[\YLCY,M,2)KTJ/_#I+=Z9GMUO XG^IB%4E8+_L!^?S]>9R_<S&L29^^I@V@
M%\P[7-GWM-/PAL$%7JMF4DP$'W<*X!G04T%UZQ*X][F>>BC'1)J2,A#BD/:*
MD'$!P)"V1,O";T\L"1+5J'Y 1.8=41\+9(?BF:%M/[D-/D0H^CX&2COOU+QP
MEC=G:ZF[OCQMA<[T)('-3#$UK2;#)29\)@7P =53G()A&OO5SL6Y+;AUHAGC
M"\KE]O5Q\%20$](> 4R-PT)82BU7"IL9JK+?["N0+]!I3_+<5=/PW7Q5KQH6
M$32>8I5@<3^_,YV!?.9D_XN^NW<AV_C!>%L//_.9%^+6G/!WJ4CS:TN(\>7=
M[.G#(T(A++2VB4)$,]W;9#\+<JJSC0U;E*H 1]"L]*F7VC'XS!2&X(A2D_)*
M0X@Q @C=#+.GFO>IW0I2UFTS-W6G(8Y71![#GB0U!=[,0@0ETERSP05C/M*S
MD=+26"RBUFRJ*$K@^509)?J*D.7C8#0*P\SOMN7!&0*)/- +*!1/2TA3BNK"
MZ!=.B1W!JCV\/CYVA,Z7WOTUIYS15.#,U53LD; T*$ @IP:\*&K=T3]K(\XR
M[#6$8,K[R[]P6^^U.ZXJIL *Q(N4AW3A:]?R!]HI>T++@4R*&^)I5%T3HGJ:
MJEV )U&!*.Z@IGWK("$',ILG353.XO1@8H8@=UOMJA:OL;QV!]K 4'?.[4N.
ME%BV?YQ"F05+Q>;4N^EHJR:D'G'6(KXB<O$(* I10=NL>8^Q>U/__]A[UQXW
MCFM=^*\0P7L &^A,+#D[-P$!9-G.UDE\;$CVWN^W@R99G&FKV4WW94;,KS^U
MKK6JNIKDC$=C::._)-:0[$O5JJIU>=;S^!=8XXD[Z)?!Z&$T=2_@[RT\!I],
M3/5-:B!9/@PTBYP#Q&T/8[/S[]BQ %ZU,1DW.3>(23+$3U@O _0B[2O5?CUV
M/8$'0SXG;C16KA"0\E&1YDD^?PA=#+?T.%@,,W1PQ# K5'#6@I=0ZLGEO^<Z
MB,]1_,'^A?SL)V!P +%UPBG+(+B?_>;>;[E\97*5E,SKPP, JM3HR&9_?RG9
M3.P0=&/MIDX%!D,0@B5/..LIIQR09]=KE,$4B73;10+9,[\ZI6B9MM3$RY1;
ML/I0L5U8W1;8WF/#]KY<8'L+;&\Y?C\\;"^!1&@+"K2+2G!/)UEYZT,F3@A&
M 2<'DU'L"EAO2W_D_;%;J-KP5ROL@^AL#T.4J+RRLG-I4PY]_]X94<%=G7H4
M_AL6#EU#?*OVN0K1X> .-V=Y8MV1QNK Y!'8"P"\0+6/0I-3%/45/L!K<COM
M,+C]85!N>23SP0P* !"QPD98'>.,8\EU#QJ-!/9)SWP23X#=VKZVI'@!=*1$
MO,2P 44];*G%_$V)3DNHPE,245QVPRJ@*+.0*"E]"%HB"8G_$3?;_F%* 5%@
MVB)?9*=FWD9&AI(7_@/'0$\<G+AQ$3]-^-0#!;QIH;Y:O50( 8A(59IJ.MO2
MC30JV@2O+9!5'Q)9.*&0 8$T!/,(MS"U/AZ:(Q2!IA:QBU%%_MH^IV(5)[ V
MT HVD\2J*ZVNVKC*,!DRI+'6=&^4)L THN;Y(6E?B7)2E$+O/X$<^BN[=-[8
MQ9(DR^'SW^ ]*,=_XFV^/Z==EKEHN(8 0KX9P2S]6_G?JRKH/>L$,Z ;VI/N
ML_EYXX;TU<;=H^RP8 3^1^2S3*)3MZZ?KMXRF1!6/5V',)$@D:S]>HR2Y7,2
M/(52$;9NO_9/W)*0YU#]?M-VW4CF2Z5Z3-K#)_NV<5"_'T6*(U\158 74Z-)
M\E\W5W/VBR82Y(8)_\T'IY8U E; 7W!):_WV::T^)E2PAF5M+6<;J;QFL-]O
MZ#HO8__ZC?UI^/(KUC"/K@RC#9:D,MVXNW; DZ7&'N^^?"]G%+["/7[L$,%U
M7'WM8!N&O5LWU^\!'HOGRK>\U%[V*%K^2M=7?#'YVBM:6JL?=!>?D+L]^^N?
M_VQ)Z=)+;;WW EIEWE^LU@[T3?U1-@Y..N^)SOG97_ GKZY6\*L_OU@]_^)9
M>J4?NQ($T%Y*N\-/;U^N?GCYXYO7W__(S'AAE0Y"<-5( 0HVA#G.%WHR6^4Y
M\6W<5.2[Z=["9[#JJL,?LK"(T'?M7=7YFX6]+=SQKF=I01;\ FL0A BIHQ 8
MGYC*)'0AG]H[VG5[=+AW7A.%J-3N," +0P@28*7?<! 3P\QA% W]6WNON0T;
MJP B+(@\0EO\U[;J_*JKC\3#)_\JU',&%T&AH]X]]ZZ%'T?0YP)3!08"QRQ^
M>'O_\^I0<4\T]:<@9)_N2@$DN*MM=V7\9]=<@T\85\(QQ0U5;4N-*M*Q>=^K
M.-FO(F4554<)BAO^17ULUP,>&3D%"0AD> ,L$<2T^4SH-N2=;OQ2HZ&TPTK6
M()5"K/"WJ"M5,H9&)SX!)FL7>]N=KU=[SPW))$W-NNT/X +TT%Y7886:D@NS
M281PV*XAWO?!"ARS+$9":X?V'%5^J["275NJ J;2>: UI\58E5#QAP.V@-3:
M@O5OK#I0 $_E;>@D\U[S-=JHUF?#4CX:3R""W:1%AEP?C:'FL3B+:?<1 @ZX
MOS' &**:/-ZX)=EL/O5"^Q&L%^_\7U-_DO>G^#?E>]3Z]%;:,\,PS/WFAB1N
MF X;@T8$H 4.L&RYWXY_<)<6W_VC]]U#D'IN6UQ!S1!A-]2E2/UH5.LU[GM(
MXDSR$7$<J!!RRM@L[O*3LNXCZY Z+X5),()XM$-.NYZ;3&AK^^8G)0+R__D=
M?46R%4+R2[VD!$;PO_-.2\@XL-A>Y*1'L"\V(FP79\9V\X!\U<9=MT-5FN,O
MNH;-X\+1,Y3OG+(\$I@!&P=A>(G(ZC $\KZH]80R*+"IE0<W^M%)^MB)MU)Q
M1N86\-I(->1]]VNSP"*W]9V#OE9L@6\$,3'%95"J.LK']EPO)BDR\:[QV]KN
MMOJAA1T;M:6CL,,X'(;OA^G""5[%73H;RB)/1[U@YS,S'\*S56$_)X^Q?1WP
M:9!I4MIXKJ"S1:D?Z9)C3V&/Q$VIN=']RPZ ;W7"! 1SUGF?&-.#:S?<^9O1
M+E:W=W/)+!C\F  :RQ%^N5[RB\GS%91AX-'D7#;-\-7J1W4<3Z!QR,_=6'-$
M5SA=M=HC+^!W\*!9!C+RZD^IWJ:*D4&(EP6$N>4.J(T<.VZS!$1*_ PI$!F@
M2Y+QX% 3QZE6NFCI<6RE9&,\>MA&K1UF9P;/KP<,(()B,I 'C(V(BMROR@,V
MEJ@?UJ[$095)UQU - 1I?;?I>J#EC?M8%%!B >-@GMDZ6#S]B*-)7GV71Z&$
M,@<)O<M>5R$EHPZX-(!1I.Y'Z(!_H\*4=/K)V,)&#F38@[^$*JYC%PUO67-R
MGYDJQ)P&*$693'JK#,"VYH&HW=C/@$WEJ\Z]KZ1/5":'@@N@!<%LI&6M9I[>
M+00VJ/VHV83SR2*B;%#RP%-'X &\Y7*#IPE%D[WQME;_]+_9^OA7SMF?_JET
M>T M &(L"JOSFPYA_*&6)MLUVA<RT*)QX*7_J7*>L22KCR4<X:BBU!.M7\Z"
M7?P>DO. X<;4JBU=0?\H(<@7CK$%K/388*4_+F"E!:RT)!8^ML3"2\PGO9..
M0?+ECO[T+WW, MFE=T7P-('?98M'(#&*!AV5LWZC8-7ED"_Q#BZF,VVC3"MS
MAH%GD\BL%\(J8+66(4WF$AH(D1/(HSJ$_IAHDJ>AY9+K>.K2(&JX(-3]/F:9
M&B/.G_>)*#*>\H=\';[?*^*-,AD0.ADO'^*/SED@QK=?OS1W-D2R)PAD;0*C
MG#YM)@Z0U1+2S]GUHLLALU0X$,3%IA4527^(I(-\F=1$_*>W1(SE_P3L>WC]
M+;)08-NOK+:2@B;@]]F'L,7_Z+1$D23Y;>O )3$G"9M43E1/\/<[N$L0&S2#
M&GKU+)\V./Z=(!-5941'IO%Q1]M<N\ZH_TG80W@"?@H)3J?7PHP5JZC #^#.
MF8FQ"KLJDO(IMDA_HZ?!UPDE]1MZZQ]X(AX&>6+C)E)WOR=@*3)W (4U''8'
M&/'<#A+]+E/W>/YQ;NG_(]R3G,'.O>OO_OZFZM_UWI(T8(_M][5W9VMH7X(2
MX ]8O=8$T%+.^MB]SGF& \H:,FQB$'@LU>=M9IY.>(=4C3@X/67).&E4$&<'
M[!G*VH&;2MOW%1S74HBU_9#E]M9/E!^OQ?%[:L>O T$T/W\'%&ORD[*N&LT"
M\^P7!,8"/UW^&TY+[Y^)K:"7X8_M7;6E7"%"!:\[9YA2!A3V[,IKH$&E ^=E
M^ 8Y2VAW\,7*[C('WF5L%M$*DM/EW>:F0<4J@?FT2MP50UX00A,4R:!/N.J$
M#:(:TN9&[FCD=D3,M==^+)UV)6+O?G8E:0*>82YAM$*/IG\CI!VSSU\DKX:
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M3$CV<]IG,?97[*9$F@MIU8(#>VP<V'\L.+ %![9X1A^>M&H2SNB!-'6*H++
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MI2Y"3YUM[4:K%2+V4 M9P&Q/#F:;K\+5?B[[37E0CI)UU9K#P]]F[$&YP!\
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MJW^Y\N8XX[N^W?OG$W#X2T@_;\K5:VRTZ5<OO0E]!E=@C;3++[091$I-8S$
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MX*W9>)$B([>AQFE4>YC#OL>+H',H-4#(!B,E=\6T4KPZ_ %Y&,5M\"8E\K;
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M,'IP3]!QVCJIHLDDZ?-$A[^4D: VAO7L#<G"Q#6EY?#]V _?V*9,G5"-"NU
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M1AD'NKQ[7U&AO1_:S;N;ML9&:?"9JKX;#]25G.#+%?N^Y&&>LDL+(ZE(Y=R
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M$%3((MOFR%0@U3U+8]A3/(*R)19BC!5/*;DH^JU0!8[6*1H^'A 7+9TK<_S
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MB)F49.L\T?B@IU0-^U\?BZ$AHF4V4P-+:0 W$OU5"[?B7\*C;*I#27"8O?X
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M#9VB^%?.:LE@TH&^UMU]"? _C0 _%5;G:05;HT@&Q?,@]UADFDHI#G.\7!%
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M]]VA(RN>"H559 3& =A;,G#IX4*8I+<R-X@O(G&4B!9)E=JX4U;%#_):\M,
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M<[MXBFCI\(^!A ^/2%HIP5U-EE VB2^R*?XA.RQ9!%13?.'T\<*G9EO\?,G
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M'AWLO:7(%Z0"@07S_0 <W"V,RI&0C4116KO;BIN3@Z@+\TNBDMMDR*@^DO1
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M0NV"<A441EAGUCP/V4#+CDE(OVU&_]>]__+G>,SXY8&;%$_T1*]D@$DKN/<
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M<M^F)]T?RBHM5^>E]"*HKF"CJ3/?W_G;LU1"Z>W1AR/$D7@9=L32JEL (FB
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M3'0IO)P0H&V\U^:'T#:5N@:KUX"EUI)]!8"NL99(-O156MYJ:;/<!XG YHB
M[ RK@YER=AX-9?IT]G&ZPBJFZ<5&3[H2T<0+Q(R&E_7QJBYP+86= 63I;R"=
M-4&4!P/XD<+SC.,-5EK7[9V\9+K+J+(?&)V5*NN/WAW&UCM])INO_GGLL0^4
M=%>TXWV6WOI4L6B&%X)H]5OLIUB2NY_.T4F4N 2^V)3]#8 40T86NLU]Y"A<
M+]B$[0UD7=:X=])Z<>\W#B 9E">LC[]'/*?;$DB5@U\E,]G-7/ZR7)OE=X(2
MB&5%AS06Q+J\]2,U$B5+#)O1<DC_-M!H,*T;AU :RH$TL]1Q"(IR_>"?I(3=
M7[$6\#-%3?DOS/P^_ID(D/9LIY2)_9:,%3+%+?"&O%8(\BL_5"UG&B0O]^W7
MKU])8LZ@E<6^7[,_N"Z;=Y10,V8M*458 ''K+1"X8_86P2,')@]#J A^PBS6
M/&KX^'UP/I/'D"KB)%L)S^[OW[X3'1.XPEN_BOP_5_\%[&3'U5?^P6%O_PX2
M2#3.S[XH("OX):U>&:XW#OIVL1K4"T'#"I*[([;\$<\3C?=*,N(J0XL9XSO_
M9^\7_*>DH?01Q9TA0GL\WY+KP"_%5Z>#&<G7,.\,0Z_DH$FF4V6\D@M"O<+(
M[8;'$XDE/,P(8)6Y39%>4#I?5:B"W00U0,*Y]<Y,:O*-4&R36BKP_ E!U<OF
M&$YFA'SA@&=[*F/F#D2'R-[)8"6Y$% F0G&F:@E,QE*)>AX@,9__#\C,$EE?
M'R%+FAF<V*_;JF/?9'(J9%OF@K?Q_./<R/]'>!LY/V/N77_W]W]PHO8-<&-^
M2T2@<Z?PXB1^C$[B5)=6*E@<DO$_@\AN.*E5 S;[DZ#?3/]&E47ZSXF2<[AF
M1LZ9/IQ1K>5?4K3$5X_4G>W#Q!+/](D^7T:KECY8%)\_%C]SOR@^/[[B,W*#
M+#K/"R_5_S2=9S+V3U_J&=WM>PD\TWT?5^.9K[G(/"^.Z5-"4Q&$:%1WB:J0
M^]+V)?7=:G\\=57[2:]P_?EU"%255,PHIQ4%V3]4>XL.JV2M^F#]F@N'EFW:
M=N5+LB8P P#,"/(<PJ!&-HH8&NG\7IS(WU"].8 CI_/)U8X=4#VU)!N'M$Q*
M]TN9,*16@VH/D?2B'G0.GY^4NXI0ZR*CXI:( [3]E1LW$J.B[& Q1Q\#Q.JC
M8+NT'H;/A#D;)&'3+7X7$WG#-EG8Y!'??69U)*IT@2(4KB. 3;V7/DQ2<^?L
M5<2HG"Y:;9$@)@K.E6':;B%-6C!?CXWY^LN"^5HP7\MA^^'EZ* W1 (6/*/&
MWL4A%K70;9!S,DB1)\>A$3 5@'*/>D9!U(:N1X44/D6$4IT%H7RL4W;;F@MM
M5)W9 ]-J801#!+;"D!=T-Q'LOG,LXCW1:L+T45K$"'$JGL$3[7*5+((C5,$5
MR7F=5SH!!O$:%+NN)<I%^;MM;T+44VZJJ#XH%U%RR!-JR)_7J#H=!%XL[9(0
M#",Z8$Y31>-DB7/CPE4<XQFHDR 7<I>"9[$$3#!%:!/KN5\0V#[EG#)DQ/;=
MCJ:%WWM[1.E<&N!49F31VEA]JJ(HE VP O%WF*<AMD6<@K$)6(HPL%C-,_7@
MS'?27!R7'<U YIB/3?2AP4Q.^467 K6@+B'S)Q R_RNP@%!#L_CI[3A@"(TT
M<N8[EW$'S(#<EMCUR6+7;R%O@$5\0!SX_Z>:%$],5,!:\V><[Y92&_U_F'SZ
M-^\#PPWN3F0JG9\BTF.$;&9*%F&W"#I(,8(%+3O8=)A7'Z7%2!D(4WI[(/J%
M\SQ0!^[$(:""!ZL(!<+D2"#>DA=1P01A-]B;W]9*<Q (EVJ0DQTI@/:7Q)@=
M<JU7*[-&PGGNW]#5.]V<>5BP.S75>46=39)4HC("IG 3D :M*;Y:<@V2=8TH
M!AL'V[P?]#FTYI2J8*)06!$:UD\: IZ!Z(?R7;^.ZB=+\X-P:L"+[&I@<%H.
MAH_]8)@IVND9G[JME+-WW@[:?;59@5JT=]6(;(0;7@LES*):'./UI."7T8)F
MP2[FRMB 6P5_5:58^4LD'XL@,./N>W/>=*T^F5IJ B::'&K!-T_L/V_@6*-=
M2 M^:]*"Z[I=@Q'@=!\C-ACH,Q^2>>*"8(%I4:M3X.\*_/ZKVQ:,5].[08_1
MEIGC)FR_>S?7P),+/=%5?X,^^"]CM5522GZ22(1SZS98P6+)XQ[:(9#,#\CO
M0837?D&M6? ID4A'?P."C=?4Q!2M.&D]YR5WXV=.=&#,2HQ+W$?NY]=[^G.%
M'GJ**^5&YN__Z_77,S#<9W^-@+O \@<D/;RHJ$/!S[#K#QWPV(U-\ D*\PC^
M%$%!>H(^3*9*ZC/E 78XF>4\:A5FOBLK$E2Q [': P[T )$E+C:DV^L/(#O
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MHM\Y17V7I9I$K-P%*\54J.MNJ\T\BAQ[<1?S7<SW(>9+HJ$S]%]#^WO^W+*
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M#QTE"O%"05XP029=U"QZJ X.4O]%0C:+R[0&6O[M5.7QG,IDO+#I.*N:F8*
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M@)@)3&&ZNFHS2 .QF1!@Z@&)O W&=LS?4U"ZL^PII]XE1@]/#:OY'<IY\ K
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M%/P5#KDDS(3>+TH]-!Q?Q1+P?%M)YN"2XBO*W\PO86)-Z 6QV%*;^NA]H9_
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MW.I"%BG)EA5GMH#WG>U8$EDLGCK7YSP'ENAZ#O)>]G!2*IC)=GW09=\ZAX=
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MW,XM&_[O?VXU,*YS,.)3/,)N@66GESJRXT3W(J^9YJ@_GKD^B/A/,$)RM6;
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M.&P;:Y\ #^><PZP2E?E49G3$08 ^==;3]%Z__E>P@@&B:9(,I$00<!.B<B%
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MD*XS]!*(;&K:4^A[*;<]2/'<Q'-SJW,3S&6V8ZRBI/&9_G2#HVPYH^YC2$<
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MLNFP0R@CP"<9Q!03(X$+4XX*\7PXO5&_,_9(Z6FG9K?K3:/.%OD2]T@.W-;
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MQMVB<D2N D#/*+[W98IP=#T+HS5(%.5IV='*DTP/!IJ(FC,L>HYVZNLE%)2
M1?'K^1"$6K8G@2/S%748/^)L(_Z;O:(3P1Q?[/7S'F"Y6BPZX*""O#>O[4H5
M./XCE2<4(#K\G$^"_MZ:0VBM?=-:GTO(#1J@ML>'Q9<!A#=<QECED-VE8Z//
MWJ( Q/NCYC%9T/Y=\= 93:+?Y8W%,>+[4G0S] /T*\JTN8-_JZ^J7D#;#+CK
M-5)KI?5&Z);;C;D*>XF$?3M)+N8-)-G8-Z"ZEI81U WZN7@E:_T_ KA '[.K
MUXR7E"8"F^" KQ);?IK\T55U9YER6I[7Q0@M.ZIKL@X:6"+["?JIM+;+&O$W
M(*)KT9?1-T2,W]H U;%  C_'K<,L!9P"ID+#U;H0^HO?+MZ\^_19Y*G/J]:<
MA&51* 7.9M.?/]WR^8];/G^^Y?,7L^0G?.2STY/DEWW.'T+Z$2ICQ@<Y&ZYE
M@C>(>C;L=+6T:8>#]UA^7)0N_$Z^:-X)PC0Q?81OIS2$P=Z4W,-L_?F6SY]L
M^?S9D5[=EJ<\U?YCUQY0I$^2IYCO2\LAG[+1.YP(#*DXJD[FUH#XZHL^FQR@
M@<J/?PV69$[E0T74):!!Z;[H4<,7;+?@XJH"A83#KNB&,T^7BO)W;C%S)I]I
MT[B7D1I8"^=>&+RL8.+6=)#CQ76RDYX)#KJ7P9WS\P..UVFR _K9G4M'?^P8
MX4116/U(#;"<-\^5T_Y*QPH*VIFQ;^223($)L96L[0^F;/J3*0TH,WB1$;9-
M[UACY(I-@KF38#I)[@C;!D636'A4 ,U/&]8X-8O&A,2>+X1/M72T ?5[F,0+
M>R\RU2Z5B,[?;%:2K]]_--:I*&3WQ(UHQK:LGAY#-L0NGXSATF-KP8-I+?@(
MTP\A8_<_-L"(BO-8H%:.(R81U4NGUZ<ACV>5_I,B'OYPJM/(G9P)*J7OIT[>
M'"9+2N<K390U<:\)?/CWP5@&>Z[OX)F/A$&A (P'D"Z!MA0!I1P+[KM?@_WA
M:++I$(0A'57P9!(R3B9P]<-V*]Q\V;#<!)LS^.]:3B $=%,\UW<-"@X:;^V^
MV8$@2D:O.D(]VNAY_[L*XWOU4SW9YZ'<4S7=Y[?[2C X^4?/Z1Y\B?[CV<QI
M$<(FT8+8$#'YLRZZ6JNEZ7<PO;^,F(0,I_!S+S$7P[3<E D2;_Q*JU5(YSLS
MB7O;V+^['&]>]\G88%LST-I6_Z;W\/PD>5>UX+28%[3U1]O.%2BED1')[N!=
MIJIWG$JU6A<IOY;0 [KI!PIIN2G4(5GQ4Q1V9'0D3XYPT$/#09]&.&B$@T9W
M__#N/O;U!^W5V<A8=[0NJ;5_Y'Z'9XJ0Y^(.\?UFHWOA8;9_+T%>M;+D>07]
M&2AB 1=70+8&MP9C6E>%685-:S*D8V@N6TA/:O.K-Z0K"RC![+/Y"'813B-M
MO8=D1#TS[4^M85]RVV@O,S84P3+6>>I/$ V_J[T>E>3)>2)*Z6C?M,E;-7R^
M'9^ $_%I:.3A($449KWHRRD4W!00ZCFD2WL]ZI.]'W5;$SXDX@V56&_68_]E
MV9?*%<'0SNB'Y(9EK<"N?&D+B^19W]L,2F4_31Z9 HZOZ_\'PYU^_H+%,"\Q
MM",&.#.PI<]>KQQ8^55%UVK4.JVU;D$PFKZFD\V=23HW7 4#@>)/_O'F\U_^
M\O[MK_(1AF9::Q\F9T,\<$6^8.(XOSY]\-10+.+'(GXLXO^?+.+'./6P<>J3
MH8$;UGK!#1TG4KLG6KV[TK/U"/5 ^)S,:1FD;19O&P#NF4";=?BA-<.6F]T[
M,>!_[IN!WJ?>@W1 \HZ_'?&?^ZZ&<9<!%0!V<4,PQJ;3#E2M_RS#,]UPUWOE
ML]#[1DPRTWU[]^(=G;$DZ*=/+R^!$*-UP[6I[3>E>2Q6K!$9L4(O[EO3$^XK
M24).Z$"F\%5@&A*A$WN^BBVG;T:\PG 91WC!$9ZJ=N)[TK[V5;Z"@XO@WB!K
M5Y^)&3F+A\-AS3A6$^\[OF$OR8_.P7S3?V"9^]H^E!P-A_)]27]?=U]2<)EA
MB2;@']V'87(FD)1YG==-:W8  3V7*6!O"-5CZ7^2=$'Q.3R'@:)$5LH'#!WY
M1(2&D8SRVW5#E(:%WF&FIQ<R)QZ[6=_\B9K5AI 'W#1\+N%PBP9!ABDFNA<T
MG^F,\S4'='4B;0[PRX,MN,[5S<QVR,"-<"'+]*LW_N+$TLJ3ZJ$T!^;0U!\=
M]G.@HJF(F%XO)"\-,'"9%[L0;Q).P[2+)A?N  ^\H58S.$%PE68,=J.T!'0$
M00V;KD%](HM./WJF94AO'Y?%&UY-UFE/"M0N9FS26@E3\23(P<S7K6I($,BL
M=/=%VNY%ULC]#LPQ<XU_8OZB?#7O:LHS-]+5H9]AI^=9FCQF"F\9:U4=BLI:
MWT>U.(JQ;(B4&%IP%MAJ%4SP[_*<O'*P_K4B7&8PWMC/,YJ(,>[/QXKVZP';
MK_=XI']'/%>T6D?$C!M_/".2_FU*?+:U/F-PTE]*X'?%O*#-VM*$6 N1GH1;
MVDYP2"LKS"5KY24-[<2_OP_W,S><,':;\8.--$78O"2PWVUE?Z195V!F2S-%
M?1P(+I;;1X$'^SID62/8[W]VV>6*'03,GJ/%;TS',&/FW3;82%,7<4F'PB4]
MB_G>AX9+.B(P*4WR3+_QGWXZ.WOQ0B\45F$=JGUN\%TZ5"&=LJ,_M8M2.:!'
M]?DOKY+?7WW\[=7'Z$X=S9WRWMF;5E]D$7IK.7X2>EQH1H'Y%()%X/R>_)O+
M!UR;^QQ("4JA;J[TRK# #CD\B)_/GCS9P;\S\]2D;1_C0.U_P<=-+R';@UV9
M10"]=UZH?DZ!)_Z)IY3+S2C7NP FJL:_+< $=KTI.F20*P'?D[L(W9ZZO 1B
M&XIO:5:I]K!6D!_G#.NFZDZ2_[4]LEHP,LA4J&5'Z8^<BM*UFMH_["Q(5N Z
M&IZBKH2L@^3U=WL<"_M'5S6K%ATE2O1*;Z[RQ97A@3(IY5U&'W]2:D*B_H$#
MFV /7FHY?JV%/OF]PBF'9N_&!>S)V?,=!"PV(C[\:/P7[>I=UD0_Z IKM"1'
ML"3/_7K_<T,5-15T$Q-:F5(V%=C?P'DO@+D54L!^T Y1;FJ2MTT+2+;+?($#
M&"CJ+ $/ I5#)(^ZPOC3+39>IT6G )6*/55XA[R\KHIK!+"M*B=XU[=I9D@3
MTS4-UNGTPBNL2W9EWN;2<9TW7X9,4=ZRM0[)@+)@ 7H4TA5P7844LOC0^O/+
M.ET![C(O]9+!@%C(-NU0_46UB(V[405.1T94-Q!1UJ9V8C?$J8GI;UZG>2%@
M.H>4[GV9_)[6BROZU_D+K)B?SY*5@IJT20CO]?9@1WEF*Q7RAI?Y<)4V/%;O
M'%A^RGP!!A/-IOXNE%=7<]B'5I\LK;JK3-MC(/ZJ4I -&JK:*L@-GR/!1?WN
MXL/B/'ET\<OYZ=GCY!'<G,W"2[G\9[@\6X#'A$IVU@>_\+^JI2+3_VHE/5*J
M',6B:;LLA_E+# CD>Z>+*W 0,C0<>=/BA8#&+%_J_P0A-&#".E]!'ZR""DJZ
MT/]19@C;C*C:XRNG-V52P-)8!AHC%-N3A3FH@-0,75EPBC"'50#' L(20-M
M=G+7@TFR!N5O0G?P<BRE! ,=Q@$&)-H6OHWM']A/4)L^SOG 2,H#H+L'X/A2
M<.$,.*"GRGEFH/-L6S0/>X*ENJQ@MZ86'L7_Z.(_9@"VSD0'CB!@R\%>?NW#
M(P2:T\M,G3IF1!QK@05CFVU.&<"#[&^%NH3@#>:'5S5,JJL*M4G>OOV0/!+5
MCG\2E8[&'X>D@+:=$3LHFO> ;N=#OKUC@XV_RG8_P;FO4D#TZ<'":W#1.A#Z
MY67G'1/73>AOY:+3P1.Y#^!>Z&NM*^VIP&ITD*Y*Y-+W'18,\9JT,- A=@5>
M._T>6F682L'O-7_A957>I)L9-.U 1_8NQ"TS=V:>\]KU3@F-XK;])TDR/S5?
MU?I!JRNWE'"=I_-<FM5Y(YF%E+=P>N_V?6]177US=?737NHJ'558=]97K)P\
M#82"1]J#' 3H(,E,).!Y_S ]3E]SG=:V'RMT?TJ>&"+EU,R=@UBAP_XYQ[=^
MPBZUS/XT5_Q-/WQ:5V8M,+%*/PMC6?16( ]#G:A_<J9E67,3RY5*=62UU"JO
MJ]5V[3EZ_)==C<YTK9;0"1>,E08[Q)/*U==U 8D=BM+6%3;+@+,=5M",=AF_
MZB VB@?[Z ?[M==M:";,4]"+]*[.N7]RYI[[9-W-M;&#$6EEJ5W:!0>?46L_
ME)>KM?:%#GJY\08:>;X7K4WJZ8Y*VQ1")O13&KBV=0M]A\W23=LK.F#R*.''
ME_"W-#8*7B-TI)&@9^ M'T+& 26Y@Y@CFY(KX\V8D.\3]O1-,Q?34IKW/=JV
MI_>U*LU4($8Y#9H"=CE?%H8T]N#:)RGRD?V7P[?=38#RD9Q%G+4>BNSLB9S7
M58KT S7VW4)(8VXAG?HKRG!0+VF-'.D2@17Y'UWN,V!RG/5&WSYM&+%<-C#_
M8*=$+-4%]XT]"1Y&14-QK+S$%83B(UMV@X52/]3R?B<!&3FH\"VDP=M/=A!Z
MH,U'LY?88JK,)JB8&)7:JJE3U";:.<> +6 Z>F[:'?Q:?#[:L/TR8E$]?W,'
MY/E#=D#V%7(+#$"I%J0G0/AA@+ :K"MT2;=@\HFO\%*N8!)L 38$279CJB@R
MR47$YJ$1FS]&Q.9#0VQ&)KGOXHU/FDA/-$(F4Y %J-C%KV'4Q2K] O_I\[@W
MXB5/F2YH>:>NK6W^^'8S:/BK?"L(_QJ8,++ AAQI4-/X5?[PE^J:OFS^\EN=
MYOAL6EBN#8OSX X\Q*QW9?P1;EL#?<XY,^P-UW?#@Y'@.1SV)K:T1->=9=I]
M:/S-@UABT7:$%ED6.>,<L7\2AQY3RXBAV\4^=6S<[$4=6YT.52!=02:AV_ 9
M\#UT,,BANF%PH)VIM$L 4X7Q-^)CS S<96;##);'_E2! TNCM'_R8 -*P_/8
ME6&8B(V/)L'= +0(M\UA7<.WXK)#,0E=>&>OTLP^G^!1=CP?/)O.RQ E'&-B
MRZIU)VFDGA07X"9_3AZ=/=Y-0&XPA#1AGGY<).F!!/L"_=U:^[K@ZC[*^8J]
M$(U%-=2_/],_DE^1.%M$%LT.-.\/?UXKJ1SZ0\H";]E]!_#\^D;NG3#*Q]>(
ME>31J.[GY-&Y\UB! X[;TZTS$=I&*:"O7'>M;8B>?)W\1G4<HR]!5%*/GO ]
M]\!K(0^<XEDJ* #.CZ?6/H>W=YVS"J" Q:68&[_ #KK<%T3[HBQ>#F\*%:XF
M'+E+Z;W?+;S;:Z>EL#$)J+;*MJ2'5T<C$2X!2QQ*+007%M.W#S,_\&);>2EO
M#?K+!-X. BP ^B).&$+8K]*O^2K_%[*S]'&I)E^IC;>V*7ESY4(<@H+)*2N9
M. 095J),#2C^*%M'EZU?5'NCE"=@Y\]$P)#EV/G  !I&?$ST=K;GFUJ5KO3W
M6K&!?E$ S<T23++6YUK.\"<P7QD9=Y"I0D@W(&-<;%C*V#_):S>ORRK96\F.
MZL_:U*W!0)3;;P.U87*Q\TFQ/%B:%,6VEPP-ATM^"A0X7@PTU;@A RELH,D*
M7&ECRH%?^P+V= BDI^I40:G:W@V(;VRMZC9OE'S91?;;.I'>^D[+],9^?X;<
M H7*+N$\+\1FV"/@NB;N1:F$L<"-<KZ"%\X501[#L:\;*#>&*UBO^ZWV;<MY
M5U_J;4X+_29*YAY)5^N?]15.9LF;<G%B )?F^R8EO/WH^T45J9SL?O;=./)?
M'*08;VU4DBH#.,80A#PS_*A0.'<)9=(\SYB<D5\JA-T<>'F[0$TI4@7D0MH<
M$A):0&G6C),C'Z\1AM^Z-T-YN#QN2LP"IAX%'7XE(W6*_(O^]E55942!9,@$
MW2^1#P).BD?-Y%85O?"-OD\E4WGRE'HPLT$$3HZ4OE(C Q4#RZ;0FB[&5+R$
M1B=:P 515H.2@)]1?PP26^ N6F2$]K!@&/5DH!>*; O]0Y"L<>[@1=I<26T2
MK&+$%'UK\_3T^Z[G>2U385LV%A!33G*K$B;+X#4D&SSJ-M5H(I)@71#OUQOH
M">>44JWN5;:M<<^$K[-LSY#UK,6$@<!B%:N5D(5 _30'F )L/'/(07[6 :5L
M3S+.6*.-8E=DUFWA0XB2+-U$O?)M]<JS[7D 3LWRU%\KAC8R F\GZ!6Y:!MV
MA[1.$2[4$6?(<2LFTP@.4JET4ZHSMI0SRVK%O9;D$TXB"[E/%JX:<=+?7CQ_
M/%Y4)M''&+H0/K7"W[=_;:^ER'[3,WV202.J4+).^IR8CD2X+@K/>)?E3L$$
M<'4DY\].7:OJ(_0(2M=:_YI+/5)6HVY,2K4A&'#"F3>]X%QHVR6@!9.SR-=4
M;M.' H@DT2M':I"%*<3:X9DN^@S"#%.JPF2/LVYYQ#T2TJYUA7C(O#10;>9-
MV<!2N_](@<)\>:BO>&K-\,%S/S[J/\?(&^+V?7,GVQ%3]DI*7KB"SI6=9DK>
MN^7Z[GE:]HX;MP!U<Z6X/#GV;30*BT*E6LWJ_0'. .Q(6ZAUR^WN0%F8SMQJ
M4[_53SL>ERK@__56=>W\/#+F1?S5H?%7SR/^*N*OHF/W#?!75L\/.B/7^1I]
M FT K@-6R;-%@/-P/!4P0Z;Q.;]&IPFF(*+-X3B%DG/&U8(.!":3'5BYI@,T
M$72.PD LQ%M47;V@[ 1W1ES!@(E%A6/6M3AH/Z0JU1"?T;_^)'?.H^L)NVZM
M)16X3'<$I171AR#WRDE".AMCM@'OX]XH76'Z$<PY/*UELC?#V2?=")-+Z5V'
M&-9- I6Q1-HG;.M\WK6$/\ ^##\I:^'>6B. &Z5]LM5*93E1A^@73*&F]%0R
M@YN7<:5G=!_2U"S@#>62D@T*%F5-,G!$ONXBB$ @S(TBG"9&S ^GD?OY8J<Q
MWTM9^:O?Z<90)5EPQ@9Q21(F+\5KQ815(\]\]H*!-5K-7(&\?75W:)&N@08Q
MH>9F.!Q2!/*]LZ]!IW'J$.D%U:F]K%[M*LV)#G JE\YP0:<N:WZ&XNU?UBU0
M32[,YBT,&U[CKA8RD$!VM-S(@J312X>*5=U2;D(+/<PLI!@2]B2T*:;69KSW
M9E!)"#1S>4ON-S^!GKZLL*J=,O@)T$,(P^S%-$:V,/^/6RHU'6(3:V1N<EIR
M^(0+N4JUZ5FHCNB><!9EKA>WN"JU'W6YL6?)79OW)IFB+'-?GH=NM)5WA^:#
MHC\:%\24:% 'F9D;SIA'33_VQB$5FW%+M3.+@MG+X-\N4<B,@A9Y8#X7[14T
M?I &!8=1[H<QF6WB3AV(WFA9TF9IO;P9DC-ZC74.$>9HR.XU"O;2P3"1R>88
MZ#V;T!'":A=F&XP^J^42YOO&A-?]T]#^XG)S#G-=]M4RY85'O^5W).V:36#>
MTW#.DU(C6,$F%C<9214&F6]/J)TD;Z@&WM<P^]#NS<:N/IJI,QLWDRR2<E)A
M]J"CHP38(;0(<DKD#(WE<>+1.,+1> VBUS\2B9;DO$C^VI7<]GSFERTR'2E<
MXV"]>9Z9@T(U+C1JSY_:MS_CE"(>*APM#**CY0/[*XJ)JO@\1X)@*8S;!.0C
MUMY<V ?D\1([U;V,*;X\S[-K'C.FUID*^.0Y/>+X,L#L:$=7.SFF1"_T<OBP
MVA$ *PNV51#ZF?[#I3)3*D:5!#T >@O,T(R[A*./5L"M)R. P>'1;EDA9),0
MY&@+N;#LS>3J$ZH$EH+S]_1=T4] J'H&C?$Y#;0SK,JHIKQR#G*DT*0/_<&S
M4S.+T8[]L[XJSC7DIH_DUZXF\(?4&P%%5&6CR,,=J^(P Q)HO0SD"C1)V>FW
M7'4-YK+9D2*X%1%WZ6,*G^XO7#.A!&*I97R]V]F!F^&.AQKV:5N_ (=&C23H
M+0@(8"F V(*@6B5/7\@U]#&YQ?FP? ---\>;94F&T9#?#4-3LQIZ04S 1'=&
MCVRTE*&E*8,I:!@1BK>^PCDRRSUU?/*>?M'>5+=^TK#E="%6LK-C?J/_W72N
M7RB\QQ*#>:L&43?Z$4':AA,,"MF&3<+=S<)CIX9% 5"X7BJ5L:#P.#<_"N$F
MKM&"QZ]:6N$T.0N5BA/U@26%?N\$3@C7FR*F^[B6]WTY;F ]"Y5"153B,8<0
M'TW+2\SLO-11TTM6RF_?OIRA'+W641<%5/J_]&:__3#K_:V!/Z(\_C5=5'/M
M!XR<OW^H]-K0G9\D'WJ4*\'U;8=.V>;)?6Y/5!\OX3M,;O+FC6U&Y*HC'&=(
MT.1HD?J=;3#"&2 7G3M<:^FEPF8\ 1XL0.@UC31_[O@(8_V.\> =R^4=OE-V
M>GU%ZKQPLC,D:(Z5#_@UH[@LRFP"<J$>HZE!?6]H:A#@3?T_7U.P3T,>'2?%
M8[Q/IB852L;;<N-PARJSD2%98EIL=-0ZS)Q0ZK/OR'$Q'+/*#CE1E/+CF)<Q
M43XFI#60-?A'KN.=,OD$_GJ9)[]5559#&$0= A\K<"AGR8>3E[9)P/^)Z11X
MA.-L6\I'$SH44LQSZ(V2P]8'B8)?U:CB\12^R"7L:\=9]J;(O*Y2Q-#8&UC(
M$4![2@2[- H(*#$&TW\821;YSO?,==D\PJ^ZQYK%L83W\'TNM'TYUUS>K*TQ
M#3O'@35MZ9ZEG+H9Z;NA/H,-!67 ,<9UJ@[CR]H;U8[^DKLOV XWM0=W4X\I
M43KBJL8Z2KQ4=*U&[D("*[>9S!N<)!<-)LQ-#"*W3JF I;W^\-VI]YP*#<U"
M>VU^N\PPT&,4E)/,DW!\[UJ%+?Z:4@02.S"Y^):CA3OJA6D]OE\L9@8!8\OT
M&D^'6W=@;#0%:&RG]"W^"X]B6H^\([B]O"'(-@$K@3,\I9?QS'(*[+F0*S4'
M7QU!\.=N#L_\P,?YHC9N==O6S5-G"DAK"[45L=Q'SJR(V3HT9NM%Q&Q%S%;T
MT^_LIT^ M$@(T""P05H(?&>59FAHQ.9#JA6=7I^!IP1")^[)&"DGAII/Q_QW
M[CQU^7=Z-A<#1/+IP/"$72N'2,=QU/(E J16:T7P'2_?.5D\95HK\0ZP,59[
MUS&JO->H\D=?6'^TJ92Q,).+B&G9I;77_?1D5#JWE)FQ\@-M2C#+:@V:<:&/
MBU!S<<.3=@&U8W:[POPHHF88)?-'>->17@5X'&_JUI+/G(+RU9SXTD;7J5]!
M28G"6DT58^ $6Z1*:N,FU>O/IBB%D9CCX=-$P#M"Y82>KZ'V\QBM Y34 BSK
MSR4"!6(:R&Q,AL'7@+!98%O8QCZY/UXJ_2!%7N(K\?C"L(S[_5=PHP;]-AHT
MK",#^O/\=%*![EQ2WZIDJ8QBNDB13E]^ !+OSJC \NWT(23E.%D']J>U>'?;
MI6J+29 1QA-\F _H6%P8'OQ5U;20\JN92E!8,4QS%S?B(A!LE2/.N2 "+I,R
MX'/;PP(3  NR"%2&&H,%@V:[-(1RYB9NY7@ 4^_13.1[)!G0>RNIP\Z4ZQH9
M3>Y<2<K?K:E%0W%^[-V.O1SI*D9.>X:[5IR6-4ED>2E]E*U]+R5#\ :5=D 9
MEY1QJ2V#Z/;U1B5W?"4'I6Y/C?TH:NP0^@J!+I<@*P[W$90O:B2QA:[(I*ZT
MFKVJ&M9!+'=1%AZ"P;/20!;O=SN5Z\S8NUM+!]5=JNH+]O%^;6& Y34:&(#E
ME^"B 33*(O8LC91H)\O#F5G<F4&CA<FH0M>,XO9-5$]0GO8HYT^*EX7":O>\
MUD]&-K^Y4@KA,2)#-)L4^T8P_ISH[@=Q8V"H-*L@F8RI.WFM3=(V(FQ5R^0'
M_92GI_C_J405_K&L#'[Q_)G\(LKH-U*)02D5A<B:\LFT^S^F#.5-@V-O4B<&
M-VM)[3!$%&"BUI%*1[3:*UU8EB?7PYZ08)L!P$OJUTOQ^H;JC=)!R4=AV#/J
ME[^U[*[6A?#$TQQ'GT7)]ED6U&$X[$[<<M[&VL4HO^@VC:%SCQYH/"K?2)WO
M>!J.0E;3 [/L 2J!_KG")U!S3(<YE9D7*0GU%X^ZSG:P)BB[E(W[X>S,6(:>
M23 T:R:[IK_^X^G6KXLG;8EHG(> :D-X_D(*P3YSJ87[DM>C0 D^UY*G\QJ8
M0]%OJ5I39E=?I:?KA_,SSTI>0@>O]SO_PIROO 2)(!N*9\3*A*@[^K/30 #W
MQQX9E36F>./,WK0\D>HR76P"O>D$MNEM;%+-]8E"";$ZB:""6ON"DZN5H<-8
M.DR)5%C!P1>S*YPG#U:%N 04N(5Q,DIROWEER3P%&.$H!^@X+R#ZYK@4?&CX
MX07_T "C>GBO>@WS]/1V8W&4#FZY#^0'%SOK6373]1D<*?WH%^=I DGPF2EC
M;8$YF2Q]N)_=D]%@1B34X?ZSDT+:=;OA>UI_< L[]-Q7 ;]RT%Y-26V(SB</
MEPMGL2W#N!<]:@4?=WI95S?ME6V5!]HYZ,3EEO&EEU3\G;0C/XRC8;5<7B%)
M'B;%> 8E\U(9-BS2(>MT0P21I2&.E>2Z3,F#KPDDY^<^'=.N6SUX%) 7*R"
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M;J]/N?G1OM#HNQ#AJV&R7ERE1:$=0B*W$TI4+:T@T0"PX(&-4-M1--=11Y5
MD]N,C[YJ_(PJ/:S)*+O#Z^1QFP[ACLL.,! KXF"%:3MS).E=X(5MS$7IZF'4
M9<:U>E&/X+IM_#O*A'N2O"^M2J*7ZL3@7.E%V#%5++ET'*Y3>J^E2-<-_:GJ
M6DE:1P*1X]'DA ]JB"GG^?0I]A1NKZ3WD+P8KEBUKH/6V&782 #9JUDE.3K
MWA#F=*U ;Y5ME-=C^D9YLXMO9(/P<9G[Q@BANW@Z(9$<<7J\AKT>-8U'?(VT
MUF.)#3C3)>Y3'>[[BX?@N*Q/X01WPIEMHZY_KT^FO[DCI1U,=2<FO.G+O:S*
MFY2F5NA?SQ&_:3 J;N(,C00BY* @373I*(+/3D_. BV-O8XGM[^1>L/JG+ %
M]!L[%O&'LY.?GL&1^.'\Y/09GXV"?*#4FX.8:MM1.*"\ ^U=/!G?JDJTS31,
MU& >B5=ZJ -$=D!?^O&Q[<X8^,^R6;M1^"W(T#RD#')9Z*-UJ'V#0DLNKQ8F
MW(Y!&;VG,,N!?=%QE;ARWF?@PW6E15W-W<[$<?0B3 :QS!H]C!X4S_QN44*)
MHI7^*EP!6A6=/W.4%<1S"&'ERH385Y!1OA?4  &J2#4M;J*]1A9LGP^-.1S=
M%MXQ 1NR'_O]IYB5Z5H=:JI)+F;SP'G+I":&YJKTE/[(M,CP&W7 18: E<V+
MFPS0_P&>"E=I1''OQ=<:+NUXELGE\&H4\IMXU:%;W9?V"O@LH)41.20L_UW?
MH V8(*88'H0@_4Y,#R ,>4DS@*9!72QL  (F/O4L*)31$AXKL!\)W@.< V?G
M^.'3,6OI&L*]A-L:O)EC<O=/!>QLD @O(7-=9^$P97:(((CYH7T-P2FU+0[E
M/EL8C\NWK+GT;0Z\\GW/0+@E3Z0;?1.G@V/$]-RC8$4*R0B /1  ]NST-")@
M(P(VFJ@CFJAJ0 )_[I9IWE54;617_J5IE?L-AKB5F).VCMYV3CR:\6;LE]_Z
MN4IQ/-A,VIO6JFR<2B>W%<X!L9G;3FM.\]E;Z/=,_5B-FR$)NZ;]DJ6.L+%F
MG#D^HZ!EW<XK:2!.,[<;1BJWMG<&8:/FAR^]']HF)N1SZ'%$>=V3]$V*<@_^
M2OKE<]Q5VKGQC3-S@\'=: M:\P_/9\].<6P;7T0_ [X@ES, 7P_4U\J12]M%
M(($IKP1WC-,5D!#V-X]&+-/?$B[&5_6-?M;H 1\)$[E/1+A3_O1AUM8P3C3@
M32?7<9)<M%1;E ?8F1;&Y;+C]ER3%.TW 4ZU]SHDD9P&PM9 1+48'"D%HK,!
M)P#\)511F0WJ=:/9-NJ'93K WF/MDDST']V+8$+)X;WBJ&K/NI>DP8*948$9
ML5*B!Z/D@;92-[TZE1E] ^6CIVX^K@H,5_<V^K7>>^P3==&__IS!X +]S#I,
M"= /VZW6S%FBK:W*RUFB8\H4N%(44[MP@RYK="8F];;K3:LUQ,*H3D>_Y?A)
M2)=I#],V%N-[/_^9SM%;9^T7O'9^#3-A09V[HWE!=>DX@Z<?8HZZ^KJQ@\+_
M2_\;@;)=XQ-&XKA"GS+R4.4%4)8)$2SAN1\['BTTW_=K#"YE9G^ !69KG?%[
M[GDPA0@_PXL?TB';]X (N2/V%M^1)'B">7'77!PO_DU_EF*OJ5A<+F>*#((6
M:*4#A ,!W0S.>@1/.#*6!2;PT P1,Y1G.]B!9X4BV:4_@%ET_<0X$'")@2BZ
M #^9F02$JK-6*P#Q567/P4L+M&;<DK9LN3G:XSK:H70BI3TG>S]50G'[J046
MV)A>EMPTXQ\Q1873*],:4 >,[C+OTP'!>'G<P2@@"XCQV)Q#G>#1O[SO@7QA
M#Y,*$J_5O!X01CYU)[?+J^Z=X#3, [NAT+!4%A<XSO@@#.\>K[N9:7V+H;7H
MMN'[&F=,]L>T3C$\11%]2$4 JU+ ?QFHE7LH/(\"RK<4%_R.#?*AG/5:XSMI
MV7<J%$<1/4Z4+FIRVO'E"1WW6=#]ABD 64. M*;7KXN'>1^\XJ%""G]&)?G:
MAPM8;-\):"#"6+*JP ;485#!:*-;82M/#K9N#*!VC;9LH+6GD-JN'MP1\_!V
M/T)Q&C&"A4(RT'176@40 (VI>&&T #@(6G;'H%<"TJ&G'7%^>!/HH-*"X7XX
M1F07\KC[B]]F/=#X.*T2IDWZZ6^FKYRBA+.MT91@ >GTB<2Z>:'76>0-"<I!
MY;!6_ZS,L![15^.6UK2%7^4KDIBKO''>&+PK9]95ORZQ[][30EAVC@!0UGI3
M9?3F1+M(VSNE[<84BUXBY*!:.&3/3IW/X&V>G88FTTRIFC%=P ']3A&L<<4B
M%N?[\W$P4MS7RPF&D$_DT_M#\;@U/M?I#OOQV$6Y=9$[^P!"H#A>@SMT/L9O
MRO7CUY$\9SPSQXT+^NF3NY;O)DM@AAM@YN'9S/!G+*6C%;Q%"H6K,R8+8XA"
M?9]_/"4H>=I=B8_?U]V7%&4\]1-)Q-NI(#>4H9P!=E5B7^9S"8R6XB0PG5"R
MD38)/!S>9,O@6-T!P0!KJA<;I-"&:VHY4-Y5);6,*3+'UYKU /TNX^P\77R1
M3BC]MKL6'1%#X!]Y,B-,\. PP;,($XPPP>@)W/^H:1X]J$-5K*(BDDL8129B
M^D::P$)&(RWTBK,-6F=&-10#*I+4G=\R34IR*S;((.FYEQ#<<VHA^*_LOO89
M9-@QP 214Z9V4?Q38REA5*&7!9@>] O;JO<.5WNKVA,U$@:Y<.A)I$H-/7U8
MVJZ[?*J2W'>46J1IA^(U<>9<[\&V:I=I'A;SI/:)L7UR2S;ECRX5NG>23'<;
M96PS$;^3&+C"B$Y2*:,Z_'"M/_A2\D'.O* &R/%;*7?'&90/*NYY<92X!Z2"
MCM(H !$_-@[^,F_=F=>AN>2,-XER<WRB (?/ZE@S T-5+I7-M?N;?%+:W.5H
M#]Z4BY/D$:/X^'-&U3V>#42L1R7IS)$2YHV=9TAM'PKESI ZL[,%P]_73T?'
MY1'7"@1[KC>H6]@"!<+NP[@X&0LC#S/T*"QWFYVI:#&W='^]D(([ 4IOW8_Q
M6;2]:!EYKE7  KH" * EO0T$Y")@E*V-/#IS?"1M)?-5MW+=&X[.B5O 9#.T
M^: E]=(9VV;EN7[3MDEYT]S9/R>/SGGE#L++3.?@]P8.7X@->Y8\>A+\=< Y
M"U*,^[.*GCI[Z,QR"20^8$$CX[ZL%)K!2&,#QLA?#,X7X]O^3"[P,V=APF8'
MBR-P2-36W]+*XQOJ??33K@[ %DJPK?;?NO/@WX<<^;P=L"F,N@N()W63CG88
M$0_=BH[#@Q1%(V\3%MUU!@1IZ+L#SJ3SWE3@Y(<?=[?%PGM@S20-/>-QZ67G
MMH21\!(7-=JT*$'?U/7L5RF;=?5%C2HC=AY*YUVGI96;P=0^' $-S7TX 3KY
M.'9%4U8<5-H]8E[P+2@T'YL-"81LDPN"H5]6N*/P?5/A"UO+0XW7/7AKGVA1
M@TX9^-7[Y;(&5W,YEO2?5SGZLT'XCLU?WF#88.?W;1N(^N?])Z(2R0T?08L'
M@SF5JW61@TO<'FX@JI=W@PO;(-,X_:*#>E,D;SU_=-3<A2:/IN2M<7!HZ![Q
MZXW]O@GB&+&W+?'][S/1M 2"8I4AN<QMAINZ$U[G4H_F]/PJ_:(&PT\M,1Z^
MS8G4@/\^.<<N-])?8.Z[.31R9 KHU2DWD-=98ELH)%DP7EXP2#K86TPX<"#M
M)W8#J]&WQ@9VJ84WO#[>9$A=])(P]FK86];58)D;JLP7"^AED]?JOSUWE.JN
MIR4=8I^G2RXV0=*#.S = EMSYI:?'BX;DMM]Q]>.3*CU=_1N\VFO7=&TJ&FG
M']*(JNN[+$0,(7;K5BL[BP6GL $3?UD2(:!7EC#5L.'FN_4Q9_NA_B'U--IX
M9"W#6;6WTI_^M%K[CH\\JW8K;^B=9M6&33LDOBC\<1&]\XUD<_4_/.C2:.LC
M')3"C8QDF;U1@0XYY=V&W5;HXGA5-??NIDB&"X/[1?*NB,HY/"KG/*)R(BHG
MQMV'C[O?2--0+7-3?X?V9>X%FL@@!@N*EE]WS\HBFP\Q<V%CPWYQS]3U?CH5
MI4G/W0!R/YK%0B>(1K6VU4GB9"GPK905\$1,/%>MVJXN)5:G9!C9\,$&47K5
MV-'Q?8CYJ.^E#C_F>IEIT([CQ6_</S$VE3K7[[\,#JV:0H9%43E.Y<71F4^G
MJWQF*.+(U-_Q#N0]LY1]$,;.'<VLN>#CW_)Y PKNUZXLZ>G^OW2U_CEY67?M
M J*JMV\_&! (?7D, \*#107_<9T'<K>]3.KH6'$9\GV0>>($%'&0"9/P#6\J
M)*9OU+:9WKABR-4$EQM/Z-%/J&E PGB?FX$S1]=".MD,O268\H)8.BMP<:H2
MI5+[.6E25Y!RZ"?4J)*/(LC9"!&]F<U3S^A,:$61?IUAQUH!2:(.<S356M7M
M!O[<=#66&6!AE,KPIW6S,D%B,K_BJI]";ANE[.A2]ERDC.3*B)GW?KY;*?,/
M2Q2S(XK9!:3XJRE9F_(Q_JJ@]14*%&_?OF22WQNF%WY)V?(9?O2HK2X52 )Y
M,FSD/QBC>'$)YLN:^\"]7E95H38S! \UJA#H6_\:,\_7"'D&LYU= ZPU*I,N
MW<VLNW&=X^@'GH@6R9L%#P=[/;;FW=T#C">"SDRM3,L)^A [/E \A\=6]V=G
M8RW]YC1.N?<[XA#ZO?R24C"E (%T^S6Q"Q$HCREWZ^U. D@;4!6VMA!<GML'
M3*L9+$-_D8^296AIL,C6M4DQ$GI'J?XVUL6*-EM]^_['5>28*"").K.V+^I\
M33&8$0S1AHZ>\Z,O 4N06LRJ1<>%RTHT,GS+ETN<1#!75VFQE(/1MT&&G7,F
M7@[J["ARQU>D6_CAIIP;ZY5.ZMH=.Z-,N@!3!&5SP]71\7KW'YUJ"*KCTVA+
M@T9CPP#!>.0U^N+&S8\2=P2)^T6U-U"T#H@=28_VK0I&44^40":%S,+Y^]&9
MJ5H07&V'0&OF15D&XZ^?ZXMBG:FWIQ68RN*JKLI\D31?<B0%!V0)_FI&T%;$
MXU@:4=2)6DIZ^6K.V'EK-?&J?;K;Q(EV4*A+/6^Q&'PX;.R+R+<:#EN)5]='
M3#4.CF0ZRXF>LUFZ@U.3A'N(3#KH/H5R_X1NU[^NX,"G3G-U2%?$\_TM^7)W
MRZ&S"[-"^(L="5DM%FDCO63A(7E$IS, Y_3ER.4O1%3/;DZ19)+&.L<8$"<X
M6<=Q:MMT<049ZX9POU?Y/&^)S*>MHD@^,)'TE69 ^R+X/3!8F$K&@^N-.KPR
MT(+F20N2M!=D>M07$TF'&;!FZEN#9K>.$.IH6X*Q=_$.SG95'$Z/F-J*5P ]
M\O&:0KQ%'JJ(>+L=XNU)1+Q%Q%NTQ/>>;C!=LGOB>@A=AI$\=;#J349&=3(J
MA8)YDSP:IEOD6?*2V81_QZBMX2H+UU7P*U),L<SL],NT\2.S@4?@@=:!]Q2&
MZI##H:XMKA_ ;-J)A;P:<G_W6WL-D)[CKX#GH>V_WE M6A*&Y7!>R(+"[#('
MA;2JL,\''0 /W(X/%9W.HXOZ^>EM15VF8@DUV8B8RTN.[_8X[S:4IMHVD/50
M?;-[#\9$3>9E7GFHI;*#!K8M'LI$)H-*D(D24UK8:&3'[%)1C*/N1WXPX,#!
M5*F#BM;FT^J\^>*47"DZ?DR):!ASZ,7T\C70D(5VX3:V&#%S8K=,/S=^V"'U
MVM9'].=<>L\#[6E%Q^&>3U:49M6Z#<R_#-P &D[AH"',!"?7,1ERV=8;,F:A
M7:0WS3OC-*5ZHQB<><O0^7K)#'<2?[U4=8M-J2VZ6+\J /(9&J8/VA,C8=0_
M^PC'C-[,VUSKHM0$@Y\(O?!+\FZ4U^]_JM:)TUYBG-RBH:)[@/G[1)S^))98
MUK1]U3A)KX:Y)6LMOCPB>@9F6()1SO74JEI*BA$=08$XN ,QJ;VM _ZC3$DC
MYUP5U0TUD%&0G5)4RN[ 9Y,T8M@E#;:D?[SG50$('Y;?.S>OC=6^$+1E?[#K
M4"RF)F*>G9-#,#D1D][T*VD=_8B-O_H7RS37"^!1L=:AP#9([(?&%D':M1[-
M$38FZE70^(5H4XY0_)T6$F&O-+8B;1@1D/VSXC8'1-/*%\8G?*=LB8(XX'UL
MT(XFJ&=XPEV:^"R=%M%\18/ #0="B)K!:\WWDF3,OSFH'OB&:%A<<%2LM2I.
MMLLGH07U@PI$:R!LH,U!I\_(5\<PEBL3<+,YD+'+5 1[PL1.^>P!Q*_+CZ[?
MO=X@:''/+,_#I 5CHX*B '9I) 4>-J+.XXI9WGNCHZXX@JX('Z%]5,,NWMZW
M5!*_2)%2R"-@48<QX=YB/^(8K<;DH>E7QB)OVR;>9G( <9/I $*SON.0.=[C
MS',E'Z4])6?J%'F;Y,UM- BXEGCRG>5P,[WP-SJ=3X8K.:@1T9T:^MCBGL^2
M1W->/]Y2<$)TUTE=.W'5WB6\5V">868? (LIJL9:-@BGD%Y H<>9(DV$#4[
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M>^& IIB8-?_WX:SY2<7Q["PJCJ@X[E-Q"/S]=KK!#R5"NH'/_@P*'9!*(&]
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M#O5Q;EW7J&574+0IGW':!!DF_H"^Y'RIXU'M1WSQ SY]ZK10<2BJWPY)NC!
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M=UI=UY /)WS2W ]PDKSN:O@3Q$;"[ C1F3MR+R^O:#%Y>8BES-4BU<N!FVV
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M2B84,O*7"HJ38LJ9D9K3Y,J]V8NQHJ,&=+A:WY1+/)A(34XOJC:;YE@ 0KL
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MG'=KG1;H20;#93<.4!FBW:[?J_9T@2'T:Y)4$>[8D907M*U18I\J52M3I3%
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M 3$V3Y%F4Y!-P>VFX/W#3KNQI#:? [+=]]"TO6/*!,-V'^MX;/?M-A+\/I^
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M1C@AG3$$U"BHRV^A;>:!; =*,QK<T+^=)+7N2+2JDV&?O0/3YQ-=@J];P&)
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M5B+#<"XF"A;0J'$KD&4LR3DVT5F&.)4(%9W#V@X%&IJ%<P]1=)2'8@);&T<
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M[$!)6&N)CO$KEVEV5-L14VB *@44*5;-Y>S*$!J+#CP[F-9+#O3V33D!O^K
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M6Y*5NU:'UHW-S!!'G^DLIS3B I\+E]4XS0 (SLM:FC9UOIWDKVZ816W991P
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M@/W>:7>>].\K+3#F^E1IIB>4?-^DE[4I3.&9B<XG-G7P19R'0\SDFJB_<YW
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M^;U"@A1,-FQACEW+I(=,@D:RF08@V/#)+=%#<!J]:GX3.S2,J]2[1Y5"_!7
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M'030CV%XF0^10B+8\C>=A4+(TQ&*&@!:IH2I#X^\699,R7V0X,'>CH9@VV#
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M[3EJLT^$H@:-=VQ5DS>$7N65442]J5BL(X%;!-C=-\#N^9,(L(L NV@3?GF
MG1S3$O/A(P;;TU/G>2I$H%YC>( U_JG5.S@P'N?_/6;%4,23&J^90YSX58S)
MP)PA:.&XL\]&,H.;6YN/.QZC?1%X6 /J(7X<Q=WH(1Y+?=]<:RA/7 A6@D?
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M4(?O^:SZZR'M7U_?ZRR @(4]:T%A3/1?%_5JFHQ*^5)YL9]478MH64Z8>.Y
M@",<FZQDCTHW_%-*DAAXL!6]@4X&2MU-?)X5NM^^A7KAFJ.>FYO*+#CI,!'5
M5(6FQF@FF-4G6E1#LKK1HU1CN,RB)B4TF=#>E+S-C%4YX>4X,<*MA?D8'5EG
M?U7DW.5G_5EGW$Z(W(V*4?J38Q=B[[-7H+_EBC32[?D>4B",W\73W>R9O;4,
MZ&GZY,D3 C N:K:75+%1N,R<ROZ]P>7GPIN>O5 GE#NT &2R2(:/#Y_$6- M
M!\E0NJ"(++0H-ZJFO3&+=5J%B;[D"W;16LSU$-D-(F3NWB%SSR-D[K%!YB*[
MP5>QXK=LU^%.1-5(]+GYP1'S8*;;6E0CP0^I6[/LOT+2@PG"[4X\*::&(>)9
MCV:'ZSHUV@A@,0BTY(TS6*A &*L8FN3)P8LG^+>C[X$#?6,DYY&\C*OIQ%>0
M] (:(ZJYE( \<0P9,Z0_N$1CC5II0&)DI=3P)KAA;K)&-@:KDFO*)#MZA8DB
M&VN^FIF4] ):"]./[ANA-K!&5(/P#A[?)[T.%4,:([O4BIB9,./2$]EM3-X8
MJWG$L9ICXWB<HN,1HS0/FJ+H>7V@G\ ;)?8!W'\-,W9C/A4^"G"= M7 .^3,
MW]Z+T I*9VWC]UAIA-8D=GAQ14(S2BL8KI3D1X41\:H,M[:]J]OLK&D%LR)X
MDT-P[PO6;L_3Y-F39]\*P*>76'&^^K5J;+?&="PP01? ^RV5X\^VQQ&E(C[3
M=^"O?W_P[7?/GV[N.;[A>!'R2/,P:N#D<=QEOW5-2V.V,8Q>/#_(E!,#JV[Y
M5.'9>?KTAQ?_X-E9'2P/DF.%O*TEASTD)&>R1K9,,8R8('J("LUQR>3I-+E[
MDL)6XN.FDI;IR0!S'F#=,9Z"Z09IV?-JLQDHB(AE+@G&W,T5S!.S[]S1RW5#
MPB '%=@2IS.>V B-'!?4_0-^05 E(,Z,W60\%36K-;/D(35=@]IP5<PTVE,U
MD*F_OCB0DE'08@73$E,F[T*2]12\\NE7B"\);V^JHZ=YX'N/>@9NW6;IE3'$
MFLX'4,Y6$9)2$J7@Q\.E]?<&<=AU4_"^Q."8LNVWX*?=DE&-Z02DQ55]CM'4
MCNJ#:[OY0EE\=O#\'_]A]UY@5$]LR 040SOQG@'V88/2&<\)CT38W!T$4DFJ
M"<Z-YNYQMW1R4O[Q_<%W3[_0K!PD'RD);18]H/A(%EW=,G6 %Q,>3\90KIMZ
M&U[F*^_$;PSXDP\R-NZQ_@'?T]/UB-1&+"OQ<)"F(B*%;30H^E9(\<[.U4!S
M;JNQ_V#*VD$0W.LZ@V9\J<!Y*IBOF<N$?N,X.D$%:DJ%X(C 9T6M4+.,4'V/
M:07D:0LW5W,8 /G=K9M'PPV!XE^,&*..1ND@>6UZ</J@Y.JNNPW4%5)--%IH
MGB5E(&ZO\(7=0[+CT#54.-6%L2:]340R]^PEXO)<#9/]E8S<LK%I."T(KP\7
MX>&3/'WQE'?EYB*Q>'3_+GZ5]: 8^O6OKFIS8KR;":YJS\0\B,.!>N/-88\6
M()]JCDE#;,N'2L)2T]D,(,N^T)[(N;67Z05S8&.R;C^$5?G)T?'K'?_W#P.!
M^?'M?R\?M;!@SQ3^X3=P_!&.X =\95"P_G?M>J5_P#J C=+U[=]=6/7A!.R;
MV]2?S;H"3*Z>/K+3^!?6&=^)#I.+>'629]^O/K^$.0 A6_\ :UZ #'PS \?^
M$_V.2"JW_E\;N7&:ZLG+0QMN18XKQ20@K,.0E;$1\/&0+YY%U?X(]D'7>,%>
MB_RS5PQ56Y34**G;2ZK@"ET%DK.(AA+KA;)NU-QA1X*FF[6UM$BW0CSZ5 8)
M/'WRY#^B:$?1OKMH!Q;"B$@+ 6THKDL$K*R*-8IKH)\W>)8]8YL]?[8SX(ZA
M#M^PZZ+41ZF_N]0/C=U ]!WS9]99]E(.8[05QE?&D'9CR=Z=$8?IK?"I%KS>
MSZ=2H!G3HA;^Q6210?T")SA@A^5,K-E#G[FZ:N\F=PJOIQC&H!Z%%,M4Q(J!
MGDR!&1<I?)NZJ0%$@O1]0R,P]P]F9*::'%,)&'*8H'*E0%-_>=T\,.UJM1I4
M2C/EX9P;ZHWFG[R (,=)A8RNXM;O><L>OY<]WVUU]Q"=Z);'3W43)H)>13AZ
MVVJWA_1K=<)\>H4\D%6]QNA<^)VKE0R>LX^Q+$V38O'<BIA]N]+[('62ZV\A
MCK?=:B-Q)8M)7XI,3RF!Z-<^@L.E/^JR*G4PRN^?C8&:OH(CB/'?TF..4!><
MB*XZV#&3^JXCG+C1<M4BO<-Y\- : T=Z5XWAB@.H[32W^Y:!!6^#V@)K$HGF
MF<%M(=_O'9,PU'XTDH5&Y/.](Y^_C<CGB'R.MD:T->[/UI#&OTWO]"0V-"&^
M,E6-V_BB$IQYW);'?H ?QM<1I_^#JM4%_/P8@<NY<_;WD!@.[0D,;G%F>6$(
M#4+/KJHO5"FX0J15J^8=.7'[/K[-*P]O]7(E^=R@NG^R@G3J ;UNM%_- OAO
MJM#I0A),9M4:EN\*<UR??BO&^AZ!BOP:E5\0ZYM(,5J=]M>GW[\( #KW4<6*
MB4E;OQK$MEV!B?3>@"U.M'K49)+"011CY\';DM!=G18_CAAV#!][+CWN!J>M
MV<9K$_HJ*HP)^[>G7]1'VX\Z(^J,.T$3)C.OP^28!>SLN7BVZM4T^)5+V^6"
M+:!G;QK6,$R9J2&D(FZ%N!7NO!5VRY3MW=!$CSP2<C(:4T!98W\TQ%S";5J"
M]QI.]FS_ALS;2%'FSDP?8YFIB3-(\E7F##(I)\I>W3+MY+.2;2Q7+6TWNC!!
ME;KL%-S_UEFGD1FLQRLT=W8CMGX$P[T=5PH*A_QXFKW$^ATC[AA#:1\\\^2S
MM%6.^MED#C?-3.BS,\E,P91M53TL]1KI)?O=P7=[<U//O6VKUW@\Q./AEL?#
MS<X5D?;0_R>@$@=P37&'P)[A&@=FXS,%%D%E_%]?F%O!/>C0B-9^E.$[R?"'
M7?!J&QR!K2WY$;3]P*2?=D48U. *=H9U!:8JUO*>=J6"X[257L-4*D/G(/;Y
MS5R)F#C2/9+_:^I=7E.(8">S2,[/7U0]OQS_6;!(SY]RH;:M-8<W74GYN>V*
M+"".1;\(ZML78;V5'P&Y6U4P 7KDO!X^]^G37F796&E22C5%]U= ]-$NZP=8
MUM>TK$=V68_,LKZVRWKBQG+@[X6G+R,;QN-EPS@*\4M!->([."R/X+",'!D/
M5LOUH<?VN+%/7!HNE^Q]8^+TO.GM21E@<=M=F1E26V"S-^*^[YLWL57<$1<7
MS:R=S*Q \KL2\P!U3O7+7#]=RC^0 1\.=IOPA'?]I-M^7R=G7:4]%WFDG<A/
MAX<?J&)1875W:9J_-ZWAQ:??RU>FL)&SP7">PG:FOD67.3**"!FK9]U-]# Q
M5<M\UGIMP7IH[EJ*?2F?LN\QZ2,X>T/#QU"5G!T?"?MZ8X(I]KN9*FA8S:76
M[?!LC_LW[M\M]N^1,#^8.!UQT"$'0=GT6Y0%TC=(Y0?8R2B%40IO=8H4A<2L
M\41H_$B1(UU!)I%E)PEMZA!!05SX'35,PJ,$E"F%3[GWK.DP"2<)WXI8.:8I
MP"=#3A&K>2=WZ2:9/+I4]0C><BL'F1Z8@0@PNN 'BI2C9,)#*!IIO/QH#W]U
MFFP3=O/K4F\]OE)"L9/UUUS"Z3H1ID)3U$@O:L&B*B^VN)3 -]+'LYK!1'NM
M0(M<S<"<Y&**^;SNAEV"V'N$XY[Z+LR1),>SBB?,\(2:!_])+783R0VL=K"D
M8&5YUK&[^+BU'MGU8XW)O=68O(AV2ZPQB79*M%-VME/.QXCR)PUF(G[7T@7=
MA@S@J.P(MF.:]]T,HYGHVC-=9%&Q%]>H8D@'7\#@YVL;-P]-F;Z-TI44[U V
MM#]>'6,-A1AF>P3;[0]1O44M'@:;!Z00Y;= >FKXH$C)FH5=B+B_U#-C57:5
M-Q5SUR(G-C=15>4GXK.=U17_@]I8%O+K5GWV?N>X*U9UM8"=PF@Y<X%-@T]L
MSF _!CM5. <'G.NWV+1QF\5M=C_;[,43RYQ,NXW4O9P!Z*:-2+=TNR5&53@)
M8>VD<,6ZCK;R1<%?F2OB:[K5JA#GDFIAD,78]<8]/HIR'>7ZR\AUSP0;5=E@
MB!'12 K.*<LX_BI# <=:+4O>/F02OH7 1Q&/(OZ%1+QIJGGN^DYQ7,]T)@]K
MK?,2EA&LF4)ZU*B5=5WXQ^]4DZE_16&-PGI_YORL*CLPK$$+8OLT(FA?DVY$
M&< ,93D'7Y)QO!-Q?'AM"M]7A8GFFWL0$U(.@J9J\UD0W?>"V?8G).F"1L/8
M_B0%%1P %ZXIA &L41JUX:H6OH"S!=+SQU$A--URJ=SYL<DYP$-BMM[G$IR9
MGE?@_F<=51;!L VQ \YFEM=P@%4U]N)9Y'/L)8)WJ=;:4!B*9[,A?# 8V#V%
M%-KJ@NN,N $>-MQ0:UBT GVL4%71L8B715T3=<W]Z!IBE)/&(3;*)C66V":S
M\?J7[&&E7546ZU[@*]/PBK4DS3@*QNAW#.K-JZ;MF92C$AT1/U&J[U6J1?!Z
MAAXWRS#%'7*>O?H?:KEZ^3[!WO3)J@+K;FW/+0^[W2N9_'X*PAW+S!Z/'']5
M8LO(M:4(:$V-&HW]9;QF#K/ZV NNY^T9&0BU\$RZ:#!$D=Q-)$'D)+'%YJ@)
MY1LL2M/-8$ERA4VAN<NF^HRUAWF5-53^C] 5MON)T6>QGV@N9&1R Y[+ 6HH
M"FP4V)UUZ(C-R0WP0L2O,W@=+IB 6V0>L(E[G;.P4H_!+=+#?NDH^G\IJ.HY
M#L$1;>![BWP82QO;M",[Q^;[WY1OEOT33>FX?>Z&VB"L1D.Q%-P97C#%-%T%
MB;N1I,0#J7ID)1+E<*T35C6V2G:\#<@+8YICHU1_4&0('<GA\($NMZPK'ML)
M5H>9=@],)X,_I]7W:6S@$0)&P5@/^+6.=L>0SZ5;C$ &K/LO@I0\B#&U3#L3
M*-*1MJ>W1Y/$5HP/4+[[KDHPQB?</ N8>]XX5BUG:MUL6TEKN1WHW*&^IIDN
MX)ZU)7E-E NY-/-+G754U]C2L40%5"DS.ZFF*FEC9AH]UU[E\$559<E"H;PY
MZH=>9PLTX%Q[VH Z5GH3]P;(I^6@L=[MAAFF5VX:IQ<<7JZJDN/7_1R-'4H?
MHO50%=)4[69B8-@!.5_DSL"PX[2&AE..E[E>>& <"5"3Z9POV&A&8INRFKHT
MM0E9'%KA WO09YR;GA#F^GV:%9I1]!*YIW+*J'MX8@VZ3V-W9;XO&$3Z"@,@
MUU7]"8Z"%:I_O/%,S3]-I "ZE<DXX&J"-BC 2VT8_0[_773(%R)39GN1#D3>
M&65#04L-L1D(9K$^2,(]VEZ"4AW;I%RT)?*\MKIZ^.P](Q%.$,S%[-LDEE$,
MS[]&I@H,.S3U4"3VT\3;0I?J2H?'$1[?'0(C*>!?6_JQX5B0&H9'S.PFUW7>
MPA&!M05T%%9\&KK.T+1)]_P!HA#A.81L9^;!_//]@^20$B3^ASQFC F#&*_'
MM_%8E<:G$JQD%IM2M5C.21(HYH38NJNZ0JH9G$&;$:HF.F9[:N"N:SRILNYE
MJ9TVWVZEN2W)SBO,+S.UQ.7@91_GFD^H\&#58P.56-QR[\4MW\7BEEC<$EVE
M^W>53A:N.0.>+<V$26.X7(/+IFT]LF_AY,00<W.)D3+5(O2"7'C/?R O'Y22
MG,!R]TSJ/?%<*O4%G'94D%)*$'#2AJU*8\6:NE#K-_D^T]],>XLQ9V1H:!\D
M)XO@A3"*T94FP')/ QQY?2;V90_*Q.(I')$'QI1G0]%-/#LJ< ="ZR&5JE>3
MNX)OE8EL-&Q:S'1H2"%Y?Z97F@0K(5ZZBIB:D8/AHH2MDR6E:7!BV0_[$5QJ
M23H(XS+CX>BLN(8*=A%M?Q(G>TN5:>ZT#7::&1N+WHPK@-F[FN4VE]$;08S,
M?'EU,^XTF.KHG))3OXG)7'9+75== ZH"D6"(HT.\&.X!*@PW%,[(]3$,8!*,
MCJ5*JN%'Y$B")2C220/ODX.[#=,-PBHAAC9?"L+43W<%* )0#[#O,^:73J>O
MPZ*>(D-AA!VJUKC+%_U<!KX2=7 R2#BB.;%-?-T;C,_CPX1.AALE$DD^&B))
MEJ/W',J.C)$/IM@^$J1C"ZY(BG1RJ@$WVJJKYY=H:VSLQT7!!-". 6,]0?=,
M+B.[;?MQPY4/UZ'&N9( HCGXJ</!>([&TMU/C'] =Q]/UH<X62ECA3#O=6K:
M/&4W<%[]X)(;+):>>+$42B,'7FXC$\9X8_,X<2((ACQ*WX(MKREQ>-FCP=ZN
MXX=G&.PR5B/7(8'WLBO:?%6LB</[\(8Q3>U+8J7QAN<%+S<-B5P-3'UPC/"6
MVQ?)Q'_T!APRA*>N+9&)UG/+#/Q+WHWP$?*,4BMJX75]"2NXW8*\--DG?RE7
M6E9^),=*J[9Y6L87R;&L'V[YJ(D5^)(SOFG">P/L5N/3CH$SM-:VDAZ>*X*G
M7..MT>#-RX[8%)"\'3?AG".[\KKX3W,^I:Z1"V(206.@_B>N>NO"J_D</$<I
M?I56,ZYJG$\Y.1W8]FTV3'U_N.QW8F<6FL,L'A$/<$2<!VD H4G,!(T:F"YJ
M&PF<@$G<8/],"0BYZJ/8"TQYTTU3U V>HEUT-<FBRG[KA ,!DRG(V@\[#2,R
M%%Y:%"S^:W.2< ,J5"N-]&N"F[H_C=I+Y7I3;)&Z%E;^?1RA6^_7M291)I^2
MU0]\HE9$9OAOVRJ*MY.I[?**DOCE33>H&UHM(:83L\".LGP4?!*ZJB&?<*5J
MZGY@*J\H_J2DM52KM1>!@JT,RX@])JVOV+6750V:A/4@Y]IR5B[#W/_$LZ@M
MY?!IX2QXQ\@]RF7T:1^]3_NK]#^+3NTC=6JE0=UFKY;UG^DU%U(P3K=L65!_
M31,[%Y2&Z8=GVISW>C;LW@;FX;WMOH=]PUQ&#_N/XV&;E7[DSO74,+^,7VV[
M/5+HV_I/HG_"$=WD@\MU?RIW>R'U[",-1B=GUC.L;K?8M_?/-PK@<.F^,K=]
MX^SM[K%SNI;[JY#O4(9@]H#1S6"V0H_<C&Q;9SSR$T<(U[U!N+Z/$*X(X8IV
MZ6,(ZTV=4'>.Z)D;QV!>#.;=,IAWGS(9HWF/.)I'JWK$\GY&\HY21I]&V,I#
MGQW'G^=Z19IVC,39%H'DY;PF@A+I=^)<5M$5_Z9F-M,J+=/-O,YGW$+F ]U6
M%<F[ZB!Y-L4Z^C?XFQ1%1WG&0.K..BQJ@SNN7#DV!M"P*XS,1(.7P!LF'L&0
M7]32U_U47,F11/*DO C(EJ_#/B:^T_,MWBD=N2TI8^N-*5+W?4KM&.I[3('O
M(  Q"ON\^62F5;?9=@;"FW2\]%G ]JEX',,AF;D=!A>6@: BVQN&E^D+CC%3
M<;[)]1=<-"HE^'THVCUP KB@#TR17_DW7I+?+_W=Z:Q/#MNQV6>3R:Q!+PI[
MG^\\S8-P515@RB2\$5"O( OHA1LIV(?,V&GB8DHF;U2%PC^8MM9&]["P/=E[
M(6^&IJN>=ZVM=C>WI_H ;2)<""C>>[[OE0Y,!M1\T._8M'(AIC"RC:VO4++M
MNSS'X^9^Z!74LZQPWF9'B>F_]H(20-SW+!-P3;16'[&U"H?[7&==+519QQP]
M=GD1MF"/F#X 7$,=K=>'.Z8_W$9;^27?C98P@DL'P."8Z3XU+1''\PD^"PBQ
M'KESJG<O39$&5C*SJIJB7H!+Z[7)0HM6J?4*_J.9! )OO<FVMN[3F49*-]9=
M/X+B,[5;9V'FIY\HWWB\T@EMWBO,/8[D[5PER\H^/2:H'VX[5,L5%B]MSDFG
M8\)*$HV-(6Q8!HOZP%1E_JB)];9U>+WE=O:6DO[@)%\8#\.(D)3BN9,V+YNV
M[H2+FZ0,FXBA$>[2<MYH[&G+#YM[VG<@KT$!EG_J)A\Q VJK)2U'0C M9)1E
M78'4RFA<P0N.O\^$Z1K>SFM0X+VO2?,Q*3/'$@TM(]X(WYG,Q*Y&[[7A];,S
MY.H\MYLAHHR1C@C6([AY&MA,(F,HJ^:=4)PV!J=@F2?61$>3U\YO[=^K%OC[
M8-".9F.XK,@[>2L=FDKXV+ZF,<90J[8%1SN-E>D+#<4J%[=^WE!GNR ))XHW
MZ7"KG$T"7&:DKZN'WL^Y+PLZ"V<M&--&S3VYDT,;-B*U'P9J=(,"9Y_9K72X
MT+=97D+/7*J&X@8SK<M F"0@)?<6)ODQ-VV3;".C;/]X"/;F_K1M,C!'X'.N
M_L5OG=J@A%#7FY2\L9L]2NT#2.T=7:TW[]^^.CX]2]Z_3MZ??OSY,#EZ_\LO
M[]\E9^?OCWZ&C^33#Z?'KX]/3X]?R1=G;]Y_?/LJ>??^/#D[?O<J.7F7G+\Y
M/C&7\T5'QZ?G)Z]/C@[/C\^2C^_.3][B1?],3H^/CD_^ZS@Y3-X>GY\?G^+#
MST\/WYW]<G)^?O@V>7WZ_A>\,CG^WT=O#M_]!%?^=/SN//GUY/P-/.GL_/3C
MT?G)^W=GR6L8(%YX]A'&]NX5WVIJ" <])U& -I$L*2)M[@%I\_>(M(E(FQA$
M?#Q!Q%<VUT,!$B;U=-;2ZZHHJFOC-K#)$Z.(#Q<VN<'F-)P-AJ/)7\NJOY9B
M,2.9C,!X*8NQD1/:1O!NS!*2;\K1'0IF-!*A:*N6V&63)O^<E+"Z[G<9C<5D
M]85KB7T!-/N]K]^JZYKBE3\7.B_3Y.>:VB?JY$<"<QVINDA>J>7L$\SCIQP_
M0'Z>,CGOZA8=[ ^("D_>J/H:?XWO=*9@LMO+Y.>N^*3J,B?O5M<\(4N-[O$P
M@S)\]VB\/P01G \FLXQ#$RGM4%1,3%T6]HA(CX\_2S+2Z#N2B ^X-3+:5(?U
M;UT)NPSD!60WO,69+C&R_U^8HO-^\IIJM'B_G&/$J:MQ-/^K4J5*?JK*N2JN
M=#,ZG%]TAN 0,QB6SP^J*Y+_I\O+0O5? @YH7</U1]R)G<59SVO=JGH=,W:/
M^+ ]-$V*C=#2!Y)R/M6$Q<G\C!U>=U+.X46KVN(^427%,_A!>>$,02 FV7')
M""NLO,6KS>+-P\7+@\6#G]OL@X1T0[8TN"5>)+@%/@K/X6!5*PT*:]ZD* T'
M@EU(?3R L#G?@"2C 'L);X(5GE[%EH7*(<ZC0SV4HY2.E7^%)#,5 ],F4QF2
M3+FRR10!ZVU?_T=10(;;-CZDSP""&8'AP0$9W?:!T&UG!MT6U>(C5HNG)HJK
M7-9)2NKS"%IXR'*-L; VHF]5CNV2.]B1\)NU"[M["W9M%\SLXS1$9)UU,V.J
M5/ ?]VE*S=O F+]DB(-)U*>FCI!3>_SM@HH%_/(%@V?%7DY^QZT4=0/:ATP*
M= F?-C_$3E:QD]4NG:S,*8YLTQ>J-'4UU-"JNC9&NZFN<5<OD5NZCATSH]SM
M)G?<@=Y)7!2D*$@["9+?634*412BG83(UT2J<&"K*%!1H'82*%?.B]!.S#>[
M>HN!(V+ B&3C8]S%]H2(\A?E;R?YNZH8BBBHT(6T-8&1>DT^1!")40MK_J\X
MG^5B;=B1D*F><NH7O=1^(W**76%E)3917&IMBN<HO&5:X+)LFUO,M.!HF8(@
MX);R?F:'$^4_RO].\J]MC;6C7")1Q0@V-L;!J2]<8'6TTS"6^ZFYL)U19JXJ
MFVZY5".;Z)H:C2"@D]J@J"M=LJQ/F18I1=2QZKA0U_#7176EZQ*_0J2^A(--
M:]?:7LQWG[<VN2T-DEX*B1:!XLLUG#GPG%F-J;O&A)OD4HG*(^N#;NGFHB?L
M.QH4?HG(T[S.Z)?KN!GC9MQI,X[(GEY@[^-F2$X"&\S6G^2EP2M;&I0S3;%1
M?LJS)\_-+GCUT]%;CXW-LL&H3QKW%>VQ*+]1?G>+D0:<0U&,HACM)$:NX[CE
M)FFX^+6O!3G)Y$J^%GE!A2%2X'9V?&1]1C6?=V /K#DGO\#UYN[ G-PR]DV%
M39AC5"-*\)TDV/2I3QCC0;:COHHB%45J9Y$J<K;N8O0^RM#._@66&Q*$C3S:
M*$=1CG:2(WC?@B*?NA8>S@(Q?1B3C$(5A6HWH4+&K *9;SI/N*(T/0)IZH^Z
MK$K]58J8,\M-</AEK\@Y=A.(-<YWKW'^1ZQQCC7.\:2*)]6=,D%7\,Z9I'.&
M)U=(-B-9HX0YQ7+J,V#1?@G2MBK.33*(H5PG5WE52+. 3"\49D215JHVY<1,
M6#,X)Z-T1ZO^=JXB'I)M5:\95Y-CHCU%+N9E+CV;O;Y14<ZBG.T8'M47[#9B
MKQ L].$D-\I&%*HH5#N>PNISK-^),G0W@!T<>M5:,R]$H4 JC$C1)S-=ZD7>
M)O#D>/I%(=M5R,JKO*X,*#*JK"A-=XO$-QT!8J,$10FZ(X)+95=Y@U1?"QV!
M"U&>=@66"JC?8WT0/#['L)K+?"48:;58Y 4V#(K2%J5M-VE;U?D5(D6I]X!J
M58*MJ[!&,4I4E*B=)&H<MVR#_$PQC^2!88W5&!W62^HW&>4PRN$]R*&P+*'(
M8?(:!:ZZ+L%WA/-T8_>XR'KZ0&1<-Q!MJ9H[4RXQI2<+VZ0)MAS,%SG3ZIK<
MH>F9_:FLK@N=74AW':HWQGI,</JND!+5:^=*#5S\RHGVYB')54?5<H6#PDH+
M^F"FFISY \68DPN1"RSG.TG=?S6#Z3(5G:("7?.NMC(5VOY04[]=N__&V%2R
M(61B9 !\Q R 1]65!I^Q;5XB?"/KN.C]QZX!Y=<TR0?;(C1RD/\^_*?(QVTX
M4"\5\H[;RG%.Y@Z:0?LEXJH).F\5ZCI%_ZTKJ?>I8_Q&-H,<*56O:[QC::JL
MTR1SY:[PO+S*Z#S2Y9S(%-AL\KLKCI*'()XA+SO\20?_*K@%F*J+7%.KQ@I5
MW8ULZ*8O85Z.%;A[;VTU%Z:Z T0&*=VNT?P2-89*J#F9]"G3MNZ7M!WO!P9V
MS,R6H/SF2EA6&V,Y@F3#L"C;WM6--DSLW$4/#O^5:I K%7UH+'BGP95>:EZ<
M:&SZ;%L@2>&]I/*MSC=Z?(A-.4B<R!1-%<J-IZ=M87\.\@,7L$CA UPCW5ZI
MO5@L>6O/K=XI-E<XK=C6B:22L"Y8\M=? :2'_/ID*M)71LM_)\N?^S>BR3>?
MUYW&14;=#8M >T6M::-D.;6%I<;L2_5)\^[AOHHYHG1F'4DG[%GC19C^9HX>
MFHO C;=*4;I55\\OJ8LZ'  @R?BIXQM!S!GS:FRXD_V)B<;@)MZ30RCL_3JD
MD%[4U=)N+U0TDI0%/>.:453,7-T5+=HAYD;[,>@3M]Q.6Z[1V)F$V-'3Y +=
MHS19D>,5BC\^'<O.T?FNA8\&@S^U(SMGE@\3))(MMWE[K(/-,=[4$W:";:;!
M@2C;@1X' Q(#6X'L;OH]]YEO3)/4Y/3L8[.?LHY8,914_$#:]:8-H[^Y!V-V
M"L:.6S[E-K2&@/H*6?71%B%V.)PG:8E*!LI"?G/#E,2M'+?R;O@*Z^M8+P:D
M\ (M.--WH4(!)([Q1-BG\) )C#GI5Y-*!PGZ:$.SB!0\);2\/3D6MIXIJBQ[
M^,$O^@8O^5LR6 1Z.T0X#]W&4? ,Q+H;&0,=JW:WI<[_ &TR$VL5C_60^X4^
MP17EEY-),,V/@WX4(TTJ<("6F<@C>O>7@1D@39=X/R_HYGZ:M"QJ@D>@"?XP
MU1H4X^0NO[+A^!3S#CY4&RT>:C!_NFG=GK:?"!\=?TJM@==L#UA.5/SZMPK^
MF2"52%<;9[WWJTTUC;%O:ZQIW*FF\=LGL:8QUC3&4S*>DG<HT0&C%QQ0;4W.
M%1A^:!G:DPL-X(Y<WXM.H2.IM?B"F9Z!.4>&)SI[(&=U=:WE?B][E^/%?I@(
MG5D\()N706#+>(OZ\PK32W2B,O_S,F_)\<S9YFSH%G]]]B)]\N1)-!T?P:;X
M&N5?9=4*\V9-"TH];RY[UIU)ACA2^Y2K0LB4Q+#*A5 A>BVN))+)'25K4TW2
MV!* T70(E?8JEZ;"I_0>@K=&%U$:')H.6G#=,)-'WF;)M7:<??\DOQ121GQZ
M5V.,JQE0TW[[Y!^'#C( \FACT;.J[)I@OZ[J"EXN6.FR(C'ZRW]^@[XES(G,
MM>]!P@WEE5(>JM>!4)H'R@"N02[1/57PLW7*B@!<6,I'+?#NVLVP-> Q=Z;!
M^V0G%Z/=RZXTS0_AV72"4S,REXFR0>?4-FE.75":1YEIU$JF_QKFU2I<T&#X
M#?K.'!.LA6N0.S3"#ZK"&RSX_1*T(,77U;5(#/9CWB(:3HKSTC@SE>E3:XN;
M@JNCAHP:<C<-Z3G,-JM,7'6TGRF>3DQC80 ]!VF^JC!5O?:#Z=Y^<PSN0BQE
M F(4EN_SP ]H9EEACMPC2GJ4]#ODAC ^>E&F'+Y<H$(M0*^6F"=MNIG\>S)9
M%.R24?8TSL&XL/">=X[#B8SI)))O<"DF3E6P?L'!SZ^T.5=E4)-X$WB4B1#'
MS&G<';OM#D],;Q:S'\A 3*WY@Q;85?6I=XI@*;\NV/)\23SA]+TQ<#'QLG1;
M+?Q=K<$UA%^1 >]96N$Q-9^C*8EF^5*WEU76 TG C;#Y2"^<&SQ'\D/.-.=3
MKVV+D9>!!<P)1X'G4M-04L,"I>3N(!6P6<4NO5;YE;9 )()<B8W*T"</[\49
M5M_-V.[Q.%PR+:DUD?\3OGQ!=UUT91950U0-NU4PH!2G9E=(MZZZ6N+9R"$E
M!BP0$19,#FP C?2T(3L,;#%L:-W:;.D$2C#U/5_>0(UYN&1<:\]A%QR"\2H1
MCAA&D)X^>8(A)*/5U 7\] )SOWMTT/+0Z,>->. KE6=)1QM*?P8IX_RRU&<G
MJPJVK/!^P;;3U]R(#'R]:K'O6HIE%8]E2:9#L#%]\B7;;=NA2BL'.-4WI)>Q
MA0R%!U1R?5D5.C7S2JDOTBN@47*]2# ]S$1EH%+%P\9[7]=5>9%5^(JS]4U+
M$S5(U" [(B'AGBA8"X5@W0KAB?#!]25(+S9;#K:'*T7!,AN[1?FL;VQXATCU
M"%B9<32YB0(:!71W- $ABU 0BTIQ791+E_B"B$K1B]ZY6&(0Q[,E\5$DHTCN
M))(6.DWQ^"K+%VN#5_$M"?1U4E^U6CBI&"<F(&'"X5[X(C!I(E(S2NINDFHD
MJE@;+WT%YJUX!'6U5H7AR67+7I)#32)!9OA1?<&IK9X!VJL>(MT[[QI8.\UJ
M5D)C\>2/PKMK_@,]2;^ ^1ZDF(V&!GVRY%)=:2.FV43(6-@I)@0_BG84[=T0
M]#;N:>#O:#\@;T&)L<*,,>">\#F30\0PX*(8X4.7-;TI7(Q1RBC$48AWUL]8
ML=!4Q96'%4.YS2HCJ-0.':;D B-9D2CE 0@*WE4MINQMM5JP D&(4VKR\P;#
M-/!%4ZP]^@+JJWT!PS,!VD9A'-,F95V>EM.PN?1/ &^]:2U^4#)(5:E;J88)
MBECV\@-] $I0SO&U_^4^)6IR?@MXV])$/C& /5^[XIL]%P.P5>,2#Z#F;)HZ
MYS)8HO'Z?5MUR='AZ7F0>F&ZBA!97FVPS,V&>EN_=! LEZHVA3JC]>]>\'MA
MXL+(46**';.JF[6]VN!)9B(ND\2@G)_A=C5 ^VG2K3BB8N+T&NERAC%Y.8SL
M4QP[0YI<5%6&7BZ67ZS =OJ<+X-2+[GS;"T].H(;@6 D<]7 3]OI22%" TP=
MP'K\]<7!$]9'H (*>,S!AA*/V+8JEGCL5N+Q-)9XQ!*/:)_<OWWB^(V^%(,2
M'<%P.L*904Z^Y5%"B^ /P:7$<[@+;Q).P>-C3?+(DCSQN&>V).89W9XL*4BR
MKR-'4G3O_TSN_9^)(^D^Z)%(;T64;]QN.X:$'P>IRB8R%3Z9(YM*9%.)*N!W
M _K[]GN:W">KVEC /C&"WR\"6\(5/-1G+_[#_,P=J*PJ>L>Q%P95EAF;K.51
M4_D:+L**()W]L!7#VR8--7'N^T.2(=^&%:[VP,_>XQTQG!# D6>%,,DZ<_X1
M$]BBG8$5>02-9@W:FYL)NW[_Y7U3S;W\@EQS&Q<G*LRH,!]*8=X["]6M.*BB
M@$<!OXV /P:2F"B[47;_%/0%-@5Q<Y5MW!1Q4^RT*1Z8Z>"ZY/R8](EX4,*#
MN$?B'GD,1<U#V=^B='GO<)^']OAJF/=^E*'==S&S]<_O4*9,]X@[/^[\+PN+
MMZ(:XN('.'@+@Y<@V@WA@=A-])$([Q^&Y?4N&/E(6![1K/>&9GT6T:P1S1I;
MO#Z>%J_OJO*;,S+VF7@L=G!], #RL9I?CK12)JCP!"0YT\V\SF<83=%%=9WV
M?TN4-_8PSVL3<$3XSK#5*4%/2RINPK*67*J6:]?N:ZQ'YVBF?C-W,IC1%\R=
MK6!EZE*O*05&?#V*/L]+K-:B7.],E9_HYV!HYXV W/SVUG ELO^!6\U1)0;3
M;&PI2J,KUL+A+']%2.HC,+&_1FNZ87V)4@M+( 0LV, =I*2@J#^X=>J"FL!G
M'?. +]0\+_+6H$S0_.Y*P8VE"%DEN!Q(KHUIH$B7L$/F!M?!["R'F,_@I4\^
MU!6( 3)BU<'G)R7F/&*^-PKX;@*^Z.H2>R&@O$U'Y5>4(S A^;S$AEN,@^SG
MNO*VES=FW&C)S*]\.?<KP!]AI834@D9AC\+^Y:-]IK@<Y[CCUA+<A>&B0O7N
M@(>>!/=%/*KF**T/@\_7\XXMCAYK-0RV92KIG)Q\8Q3;(+2'U.>TE5_(XK-*
MCPIRI&B)0KNKT+*E4%"S($H01FJ6WS7R<%@F) A/7HX<3?3-TY?)4BM3Q!H<
M=!PA0&<$A(1^07Z.5P/C(UFQB@C_B0GL74Q)OSO&[9_HWVFIN&20?"Q3UFVR
M\I*6+G4"#\HHQ<R<5_(%#8*_DGJ<RD5+]IG0^[KJBLR5/:\QRXZ\PW.IXBFT
MRC8HV"CYOYODFR787O37W+W+(/?PQRFR59-0F-)^/&)K, %[,CSXY;AHXJ]+
MD*%+52P&N B#030DPLVX#(_<9H3!?>PN-PC\UK9$:!6?>Y5N-+N$@J1[1O'_
MW<3?6Y5@!]#R^<6)!)BM!9=MZQ/]PL1 U(FIRY&V!J19C'Q-2;*('$IHI?Q*
MG[("D;1:VL!^^(]5K2?.$JD]-8?)(B\5\2+L8Y"Y*JY0<*(A&PW9G7 4B.X9
M+R)6L$H7:GFKDF(G^-*77C8DUA';&@B$;?CET&.5R"UW]Z&3);6/=2?-2*7Q
M#\E>+@B^O!1"-"G80"Z%#@\TKNU 8C78DR6&H9'%3CZ$VXHNN:BK;I4:U4%I
MJ@4E9QA>Z+&O>)4=3,0RGIDQY5&--,N<YQQ(@6]A'Q*>N&XN\U4X42Y)1/V>
M7&7H$UL9ZA=:AE4FY"FCZ.$?5U4[O,(<G/US>'.B#:[;RP<3S10P]DY25'D&
M/]SZQE04VCS<Z[N3>E.V#9=Q,+!!]>:]#BX&)J(^OXL^%SI132PO3F./%$4$
M*KKVZ4:-E%HUWT,UUZ;2AQQ%/#F0F;05Q4]Y</)7:3O4O#\,E88]9M MJ*I/
M6/[=:6,-+52.C#?U)]V:+X3L4DJ+^HI+.)NF-0NQFCF=/>PA%2WUWYL]%^P)
M>DI2S1 &8;[W#EKB/[U"T+Z( W/1854\+&$FS1%8(H)/?=878A9:+D-F!-@C
MRIX$2[5.3+)PE^@.%BG4K/'=\4)$;F,P#OP"G^@%OF]*V;"OWE[F=29W[R<9
ML:6Y B\!/'#CMX^%!E(YN=TX+7/LK%)HE"P\6J9,,R*<*Y0<+RT,!X7&<C:-
M.<+VON*Y8+FB0<(049Y@R;G2!'5'HXO44RIR"ON1J"+_I(LU]]7"!S.@_:PC
M\CB0 [(3]X1\& LY<$Q9K:[+?;!2%]%?>@3GZQ\&C$ZB/IHK1:H5E#Y6:UK8
MW#+-AP]O+]]3,-*,IV^"D\N NHUL2)&<.<+9[PW._CS"V2.</1Z&\3"\VV%X
MHST)QAU6\0[-R9G"IE&2M$$SD:/H$S8B>9_B-19($X2I'61+93(*R<O<D,:<
M:2)O#+F8Z:9YULV)HCCK@JC1R L-(H.%NHZ8J$>PL;[&/01"C>$;$.WKBK^W
M<9@,+ [7[$1<52J&WQ'::G!77"[?\T 9).B[FZGOV%Y0Z4(OEVJ]3C!\9?=2
M3BPS/%_\M^_"DA>XX-T<J@Y&?E%SF^I.CCFZVR'$K/^>\F;>N.+^C?OWCF<@
M9G@T[1)FOQX(?B+X1V*O7_ F@8G![RQA)V(3)"I&'1=89JV2 %]RH:ZJFHX=
M0\0D]\?=67&K ?% A5!C^FDSW5YK#!H%E5BQA#_NAZ_B/*,0Z-2!)?>70ZM1
M2[WK,_J'GGP$ZZ:%SV95ZZN\ZK#GF7EL%C,-#X$),FG\,!S<1P*!R2YU;Z 5
M Q$X023"?*SLF# *\[$I^LM_VK"[D9A-T?=DS_9RJ34,3I=S[O>,"3-1T00Z
ML-FX*=393%.VA/B:,J99]^_W NXG[>X::E:'<.5& )Y[2O+X7S!.F29[,X,6
M8+HD9F;F?BU9SJD-Z\B-N%9R8_\\-0DBQH-,)R>L-TDZ '9OBRDA>EC>)MC_
M@FCI]14RMOG=#B\UIQCR2[P;P[@X=92S;XJ\4;9=C(5DR<L97BG*/%YK;-C#
MV#,+I*1Q2Q>F$34RX.Q&K68[#_!#)N<;1[6HBH+*-T<R,[G7QC;PI_F7@R0-
M)DQP]'!G\+ IE6OMC93M&N7];$6\O0ALR/6U@"T'=GV0HB/@Q.#%IOL#3':O
MVIL[24-Q]MH:X>R[9?(DCY-$"^_+W"4-Y? (OH-'EZ#1J6LV<<[X/0W<N2.D
M8ID;D1>!F*N5"?GQ_J4F3[IUH0^>"BDOB.?&0YP;YZ-]I;!7EO0Y$\WAI8N)
M9P Y]%8(\MJ3CEUEE6CDK4Y07 4[BBAF8_2P1&38Z8>2IV/N @$Y)O-*XS5X
M^[QE]4"KF#8"H 4Z5KUFI[&V^*3U:O C3US9]M%9'T!^ZP)NR^=@&<665>:U
M&ZG=%T;TPRM(L[;5<#]$!I9'P\#R(QWAIYH[N#&<-#DB%%(D8WDP;?:1 M+C
MY^1(NS_7YF_(R0)O?.F!K3@PX/A<ANBK$2,.82X&AX'GOA 1IA:8P3 QV.J@
M1[&49*3";HO?[M,;UZ'L!6#/35F)"5;$OF;T6IYXC1+G>3WOEHAO0M.[-XGQ
M '\(QX])REOLY!CT S?@L9[-#':D.\N]!MP.1>A9J60%6X2Y=V1?DL]%QW:V
M-?K*.3RWQ5^E]VG;IY+_ZD.GTA#FK=RQG(%E4U2KI=1C"RX?Z2\"\0\KQ,24
M(:,HG;A%&$#Q>H5-F1CIF(&13OK) B^EMJ7_ZL0_9C\ME13BG!AP3#8"IE(7
M"\DQDLY;:N&VYX;IG)VHL9W;K,LNJ/H'/!0&[J% SU7#@%5<%6R95G;$AJ]J
MC.5ZS>$\YTG7%&:2&@IVL[EKA,\PG-HPKF*V5<;?&_3OH'6]U"@9 U3<?T5]
MD3@6YG5RL13^_B,7?4 C-5-E)'"=(R:8;=F;6T^9@'=4B0^@$D]",5%FM_5.
MR*P3[.CM]GFZI?9:=EB^3 UWK;.$V<'%( !"@HV*DYLMFKCQHNKJL<"QH(:9
M;<J]'=R#MYS_DBGY/R:Z8U\4M[V$HP(-UNM6Z&7V;S='$B12[=8V"-8^4>R.
M^[YN?*FXB7['331<#K>1^N?I;3=*1"@_@ES;'P:49<W'+>%6DV;D..1J"T6U
M&PH+[S- 88U"K?ST="3XCHCH>T-$?QL1T1$1'0_?>/CN?/B:&C[7GSB()@8G
MLCU-&<"<_=8QB71C,XQCV?.)5##H7,_S& U#S;%*N#&UD5+#.[1>LZXVCI.M
MIT2?;"2E):A/^GU& Y7LV1 GBN]KXL\;BBC#P42/YR$\GL5@M3)=4'<O+)H.
M4 SH[A0F]"-YQ7H;Z=Q5J%(/#D(&8\;H9=\ '<\"4$^B":\+GGY?1O(DCN)Q
MVL[)GH3N.(K"_)M2P\]J")=7!8MY&S6T/\11QVSMH\G6GIJM=^:2'<FAJ;:/
M"=N'RUYAB@$A<C/X.84>N\D4KJUS0@"A)#A*C<T3<:^/;G(\XA4V2<6B#:\V
M _<PKCH&?[5F]CO>QY9701@W4"4AE [EQ& *#:+00.2L+H:["K$-:A,2IXF<
M@ '13>.]*$TS6_<!>GRG?<&4<$[83HYAB#BZA',"9Z-!%"Z=9RXUB_<%C;L'
M3E_!*;]BS:>+($AEL(;7L!$,Z?Y!<FXI*$ -$Y!%)H\@0:"0+W5!<$P;\*9_
MX_L)H86D2P@8=@&*FS4L!:FE04*9O 9!YE/P; *D_*W%)V.2$+[&K:PIL8/K
M[$3HS#$0'<X%)9AS<H[!2F7EXY6^?6%/7S^UX^Y,21Z2E'MZ@VC8/8"2^6"E
M\9[%#[/@,RP;&0HARUHH7NUUE82I'-KD-"K#(Y:'Y"V,30[S^3,'J:7$+K(.
MF3H;3WUA7NNWJO:JSP)N+J2V<YU:;7Q>..E8X:5&G1$B&OD880\+AQ>1H*IF
MBKZ1R<)T9J8*S,F\L6IOUV'"AD8>&5Z>0ZPV &,<IVILN!JL9=RO-#C*L1'P
M84X443"W>Y]-IC^K5JR2M]+9\H6<!;MJ\#396YOGS['M3*&S"^VL9;O<>'25
M]F8PB:ZI?3_/%@",$;>LKI7EH$*T$G?RQCI O33OJW+TB>5H@XMDROV>WF=:
M:$5QM,^^>V96ZM5/1V_3Z3'T4"(E6?-XYLZK%:WVIOLRDOC?4U/$<.B\GH"Y
MT(&VICE  !95818"K;#O+-/1)P@.IF&DQXDG R(2M#+4")J.%C?-\O+@MZVE
M_8_QA.J YPO^##:>=X3A7!SP))PZ7\@>L X70\]:M1:U(+JA,9I%8+NX*T0[
MS57'6*\9YG=SF1\B;?(%Z?H2ZT8SGDAI7-![@C*V%1ZN<Z1WI"RPG2YZB>@0
M/6:'"%,!;06&='2#?J<F@@(S$HQIE70-=QC3-=K:A0=.)Y.TJEG'+')N;.^X
MNYF G.IPFJHJIXQPWYP=+:E!-XO]*3K=4MGDQ&6[HL<3)HK]BVK><<S6B]CX
MELQ,TTBID,5#59FN4?W1MX,K!147L-A*%T-SGU")[U),0PJ]DC%X;@P\&&4;
M;P6/#>.VU*B ;VI1?^.C/.AW>LPJTJH,?Z$':_V)SQ"W(>T)QU5'>)35'7=)
MX+GWKY5'Y2Z^[7'_^1,2U?$C5L<G\(AEZ2I 4&).8"EK.E;15GME [DD3=*M
M,ZKL1U%J8-VQUP3_DPN.;1@!YQ.^KZON@NVC)O],C<E*RC9@.,MT9"4-;0BG
M;[HEPU.]?K*,M:ZON'A4N$C$GP3CNX)+C"5KCYU<9&_MHF1@"B\+=%H9.2Z]
MT\ LI)+#:P).6U]830'2-Y\VV,#V$H\)./)T$_YRPSNGME27^G28OK4#QMS4
M@[ACO$M=@%^-/!)PR,$FR9<P;46%/+](%:QFV.:3:'0SM039@7_\UF472S9W
M%U1V*PZ-.9(7U")W7C5R+F*NHJ3[.?_/-LX5?YM^1%=G>3.#M=/R!/A)1X[M
MB/\A1-KY,I4H* +M\+R'8P(AVM++@YOQ8E25+C%M3>8@"T@T6N?+O$1 N<K@
M'Q(+N=*]7U(@H\X;NF='S@76J7#^4@*=!D?N?%<C0CEFD,R"U&Z=<LJ677MU
MUI.+9SQ_]P((U:Y;+M>F:="9E19"SR(ZVYHX&T3G('G-!VJVW?63^PK\'3"'
M6%/+YI(;D,]%U92+KEC@'P%"W1H"1AQDXC 6P@%QMKM"T84I'^[#U&[ +[Z5
M#B()9X2<W3OD[$6$G$7(6314OTR%/P*.V)N@Q7;>*YY II;3F#U$\; BE]?&
MODTQ?=^6I -.>+9\GBY,?*#!Z#BZ!MVD0Q<'[9 KY=JD6_-);*EY5ZPLI$4Z
MI CI1[W4M0=LX4HV]H<<%YC\!'SY1E,5*X)%RI&4J:GU_7&-O6UB?NX!)'0G
M,XPD;PEB1Z)G[19_]8U5Y00[MS[TBEB0M.D/B)QT899766B/M"(+_!=_?-1N
M+PC4J2N5%\Q,-P89PC\9!XA1(FQ;35NP2>9= ^N%[A^Z^!\/SB3PSW7ALBTQ
MM".=H%":\[8S)5LX+_*+D]+&J_SYHGX[G#5:=?7\$HM[,+'W.5EK93M!P8P6
M/$&VC6A5AI:K_@P> TV*V7=FLF^U .N;9]^?=;,2(XL0PUF/.)QUZ$*GUN./
ML:H'3B\8-\Y%G]%C#-,-N1^_U^!!PO[R4@U^PE#Z"5DH5N-AL::ZSEC?60KE
M;QN?/TA.@G (I5Z9QM;C)PI>*Y84/H*JAJ^Q@&%ID(;851>)"URNB[)#0J*\
MQS1Q#,@CE"'^1A)E[MM>)HQI!N4792_1-0$YN/5NB4S.4?1W$OTM$\^"36-0
ME0#1/(&?R@);NLT]'V)$[F8(WN6"BK8FBA(_1;R_'2IGUU-&F$PLQH5&P&B>
M)5?M$!,B7B-,!VR\QOT6]]N7W&]%OFBEN>]O7<FBOZJKRWPFS"&FHRN)/1?G
MS!2G178[0"+]>13J+RS4C6KS1BAQO!#)"M&,F5?7$% 13R218[#N(<#TWJ$]
MGLD?>)E@%)LR%(]!,7IF4;/LI%E<.-.$++;0,S92C-<7$KP$5?).-9GZEP^'
MQC2'K3H8UH!Y:'Y"^P67NC(*_R?82YW&TZTH4HRE$8VGQ^@A?F7#C\D'6]E
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M&/1W]_B==1UQ@*&S0YR:Q"++BZJMG^!O2A H<YH"\4S/F:BK+G*X?$%67L1
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M4#5]TS;=KML%B(AVA0MDT,=B @_B)O,EXC4TZ:C_*W*-(NFUB@B=N+&]_N"
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MRHC1:P;[N^T-V ZM8^A3I4R]*0'G,%Z!OXV ]7_[A% ^H>@::@'. S38JSQ
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M?/L1G&^?YRGFP+V'M\4IH'R.?YT4DT1'NM J#](S2,_@E]L M+A7TO-')>&
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M7<DO*#Y3.WJ6:,!V((J-^\RUY(M\U%I!U4],^[,TUA&Z:*$E-EFH2T.5Z(^
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MQ/8?*=#UB):E;7SB:);IF$< "WCP:!=>C]*A>"^9:0S))BEMU];+G7\K"1J
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M\/PUAYRI"ZWF+8L!HX8FC,YR[;7 (9K]) &(Z@60S0@_G.H<E F0O4F:=.C
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M>UKS1"Z)*Q65&3DVZQ=\9"Y@6[+[L:H;H1.\@Y4C0#:821>3 8;0SI@3@+:
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M ]6F;[W\?Y3Q%/ PX.&#W<OU[MDFJ(H!$&\/$,_X>L>?A]E/+[?_]FA[\"C
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MYE=?WNO[=ZZ*%K]37_3HO06.VQ>HU/"5Y>FR)-YZB5G& 40"B'Q'$+E!@D%
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M@_P,\O-VES?D[3X <1J.(H8LO,U?[G 4\=X 2H@1!@39O.4.1Q'O$8"$&$$
MD$U;[F#2W", >?JT=Q 4D( ?F[3<X23B/0*0O7[O\%G(@PX LD'+'4XBWB,
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M#H_$S..<^03@@CLFA\FR#BCB<CH##IM:@T']B1X*>/=O^WPFMR=BE0.!SF8
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MNS7/GHO >SA9&8$7Y[M:3['#E^WNBHC<%;T'Z!AH'4\ J$"9AFFM6U6M'=7
M]<[B]9Z\_Q-'NI7EC*N*GWL Z6U6/#I547,R\I,:;:%AVNX4?_B5G)HGZ%N)
MD^FR#<F>WMEJPN3><E#QI[=1*VS(4?M@Q1U9/UNLX8K"$+]#&W=ARV?4\=4X
MXZ>\4,E  ?M[+_GYURO5SY,@"V"EZ7,6\^\][9T[3]-<#?COW['&BZXZT_&M
M\K,N'#P!_H(]V_JJQ'G*OQ3YILKW7\*72=#/S/LX[$0__1X%F0F\T1=K$Q=[
M_M)=*Y\>[]EA(0&Z/>[J?__0?6J;ML+F'+8[*_;F%8&QLP+C>[CD'_1)#9@;
M'\-38+!E6<"?/F,JPW)B@?[>^_$9_]L3-OP8V?#3VJ@5-N1U^W#%QL7">I\D
MZRUK[5HSKFCMEVKL,_2"YL]^$**?D:]&IRM]_R['A@F%8D^Y$UJ_'IAWG+$K
MEKXNI0$R?T>G+%^X=V;;--2:$I?<HL)H\T&D'XE^3]"ZG_%5>_UYC)_;,=W!
MK]HI_*H]O__U.L$>"K]X?SLY.3M[]^[-(E_KH^M==G?/Z;*=RG8VW-)Q"H#O
M*9 _F^_>V2\"+NC^/&L*@)0J<E,^8E./\\+21]_B<.X+MU3MV?4UOU>'H_0]
M7"=?6;7OX8O.B];+_9?"-H1M/&@WVI>=^UA>X22;XB15U>:'7W]\]#QE!?KN
MM@]>BUC<%6+^X=?#]LL7CYY^129N-<]8W1\H/.-!><;1Z];+SJO[<EJ)@TH<
M5#OBH,)^W$_:225"=%N6=^,)<-]Y^^Q(NWJDRPOW/%1;6O*RDW)=-R<7IB5,
M:UN]8=_)=.IV1_C8X^-C?+J$C=W=*R?*@1PJ40Y$.=@IMZ P+6%:RS*M.WLJ
M7TAVW6:=E[C5?^[NJ>AN@POS2YSYH<AND=U/Q!OY%J&2O&[[".X=Q#DP\(:[
MS8\S(^W<179W=Y9+;9_L?BH)>\*TMF9YM\\;*7QLQ_F8I MNM6-2SM>.GZ\G
MDL$H2L*V+.]#>R6%8^T^QUJ4/TEXT83Z*/">]]^0I@S8V>$^&_NZ(XW3BL"I
M1T7@<6XY$,0P8IAWRSN/^FWNU:[S!>$+Q>CXA,NWAS=1?R9"..>6[O2Y\^89
M-D\IH8+2%;I?D>X^3YC[SG"X*4+1]#Y(:5QIWN^K-"WZ[AYC7P%LRQ -/,29
M\A',I&'TG8.E1@^7N:-O>\?>0*7]))BX[0M*0TM59B%3L5N*KL5_-=.(9QA@
M8P.$=*>A,FR\;O1 8/#9*,#.PO&W:7'%S_ YG:A^EL\L2QR%4P][&IMF$[$#
MRC(/LO4-\&;OUD^POPM<EGA$M-QIQGU&C@ ">E3PPC<X]X2HLT6 K]3!(N61
M*\_O 05I'-E$A=0/(PX5C%%OE_MH/61I=;(93G"E)IG+"EZVZ$@L9 7V0-0<
M8_AET3&^<'M"O*9WOIC[3GP1'FIJ1:3)IAC#'A"USV>>>X+H8VOXP/+'U\XJ
M&I0X2?'+Y@_V[!@>Y0%_?[CAHQU@F4S_OH_VNM#<YP'J5E]7 :0YIXG6 =&X
M2U">[@]E.)C+(/V:"@;[QE@S*RLJ#-0-GK-,LT)LYP)GZCI&EJ(R9*XM\P<Q
M,7@.(K7?!L"<)OX4#QYRZ'$>9L$$CF<(SPN)04Q40CCNH/1P9RC=K$JS0^=G
M.-,IW)]B&[: 6[J-@RRXYC9-ZAOJ7J@U)4 C#0UB,O\K7&OZ!%&#IGZ<AP,/
M=3%B$<11B".I6^SG-(GA[[_RP35Q_-Y4-T)4_1PU-.",Y15*%:+4A=Y0^8AZ
M1#/$.V#-KA-_G,)C"9\(&!/P-AJJ!Y.#?:/G3Q*_C]WL9IX;9,1G@>?%?=(B
M2R4Q_CB&%<"V5E[JAWXRI85,1R ;Z*\0?FY:$96,S7J4>S[2%@*;G,!3\H@A
MEF#)J1&<[V%#+Y_Z%V(ECHI@&0F=;_5M8.%"E-%P^53YMK?3C;+]A31\OX_[
M1"L,M *\WN_#6$S#(VI&".?:@[4(_L,DA0-K>^_R!(7)F&3)4@U1TU3A_]&*
MPH('U'WM=J3P,?#EM*Z7HE.VA/TL WV[)0?<5!SC),:V)BBAL5O2=ZPF]@$C
MO8$4'R")()W7".F#-$*21DAW:83T<E\:(6U;(Z0'Z(1T))V0'EDGI(O+W_]Y
M[)W][]G)[U_._W56ZH8DBO?&%.]WMO$1:A&A<MT#'Q6H9DD+^'J"[=0+=10N
M&(+VR"T:+Y+\JV]:B\)#5,-UU!,Z'O>H92:^#%29MO=6]?T<]$G]%)\KKI%:
MX"I0KX)0]T0FBYQ[1H)-7_.*09[@--#L1U6/_!9]FH[3S(D&D2<)*L%6;8I1
MD44?P;4J6EAFI:Y0\Z;.#HB/?M(?E;P/,&C3C_)V%(_1DZ*^30@T%+4OO5A^
MS;HV+M?J_:(*-FG"6UO<+ZKPB$B[J&73L@^Z[?VCA\9:%K#E=:G[L]E$W]L7
MQ1\K 9\7\/D=WZCE-V0K&*+PPZUM%/4Y3@-4"X4I"E/<\8U:@2D>M \.A"D*
M4VQ@BL>321Q$&06'3OULGL9XY[+:HZ>+_U>Y#.[^#FVE.%GPG+IC!41##H(_
MD8ONK*]L*X !/_BWB<*8\#]#%42//@E][@OG2)EF^EZW)D D_]0SU1^&G>PL
M)[GO .Z\5"6P-Q*5!O@U1>1/1H$:>F?6XWO!'E_A+,)9MIRSK&Y!"&>Y7\[R
M3O62W$^F3+3=%QQUNB<H'-'916??#9W]LY^'WO_D013ZCU]C%Q&Z.\LMROG6
MB5"0>)1'?1+G4:I"4M&O5#]1&<A581["/+9FN47_WCKF<3Q)@E"G?.V+\BW*
MMRC?O_XC]B/?^RV.8/-NE+3'$1&Z/<LM^O?6B5!VAW]4 ]RQ)^,,%Z:Q.\LM
M>O?6,0U'[^Z\N@>]6Q)51._>-;W[./DKC[SC:S^Y%1AX$:!;M-RB=6^= +U2
M41 GWK] V?9L>DK+>T?P38J<X%_@Z6F>B#(NO&2+EEN4\:WC)4[=<[>[2!EO
M@CU]OZ7@L^M#<WC]NF;][Q\*;?5*@+/Q)(RG5 AP?)THKHAO F1X?["=&':/
M8M]6@K&;LWN,CO8Q:?,IU9GL@K"Q*=11!HD G:J\!01".?&3C& C$0:BV+M0
M91F"?9DM;'F3/$ESG\% 087H5S?42U1?(5)<&97+ K7%0^_'%_O[K?W]?1J+
M;X#7S+5QE!..Q='^3_@/XF<X][<02JP!%RQ!H#@#"X;0&2@#VMXY7!I'D<;@
M(!K$A\)L8#A!!/.@C\6DG=E6Y@:3[X]@, .OTSI\W6F].'Q1/Q9/#R,=^1H4
MCU>_'X_'" 2"6*N(#TC@'GZ0('[%5U@$C<;'\)[F;=X )M;2JTWX)@@*I]'H
MND<_X?6U*9A'M,((F/)O0H4%"AZ%..<4SFU8AA@Y>,&WTD4IHYP0.3)<7=WR
M>'Z8QK@?-Z"WIXPN6%DP&JVF"(0V#.)!T/>N-0RJ1J<UT*1P/'-";R(Z) 1:
M)(@IKYU%F>O%B%,(-P\">#*"TN&-Z+$/-$CMV(=M1:"8\FCL$^+;2"7I*)C@
M%M"+O@5C6&-8&UY-WQOF83AMH+-!$.8.I1'FG(:(X5U&D+O$#U*-GWL-"W:-
MX*Q(^]W]?;W0L#1(D#!,#5<;7;>]XVC*B(.EE7%V??YNQJ"R>H>OW*T41.<-
M\-9S/K'J!BD007CJ"0_!)V&OB1$9NB:.%.>9Q_A#DR1@//4]^ ?!&O%<15ZG
M6SJ>%A#H&= J,(GH6B%E )_+DCBT_&:&@2&C@PD&B-HS"R[$8)YH>?=4I(9!
M5CZ2Q":Y8"1FI.8HCIIXL;I!X,ZBO!W'Y"-*L4*.!A_@EF"<_N+M!<]XA,7;
M)_Z4R9DI'5Y=F7Z=7-@+S(,0FE+Y">(5]6!=\VCB!P,M6,RD$6(3UAHX$Q(\
M?3701]39)'JJ?6R_#Z,G(>.B<AZPG,(GY!%^KQ!$-3'X5823Z< P(SAGPYKA
M="Q7*8%],E#L7G"CAT*;V_ 4V+ T&, !'!0PI\";(@TQVT<6@5";##5=9JW8
M8G;BC90?(HQM"&>(%@R^F]D#D*M5,J>V 'KQ<.WK"1R>![]4[L2W7,?QP$-O
M#RY<A-?AC4$S[:]&^B51Q'0/;#G&YQ34#HS[5L%U\"]* ,_NN=E-^.Z[=[,&
M@EO,E^TW7S2Z\P7!W\X4S@E(]X-:,KK,8FVVC'G>$M;,X8LEK)G#=5DSU1%:
MWKU00Q_04["3 H);P^!(#9_1PG$QK.5QR);:W8T<8[;,6BS$@H,DI;6")4Y2
MO:"$F C+F+%$7H<)(X=RDX?R%&Q&FWCYO2>R_+!U'T=X^_J="SBE L:D59D"
M0HO2R8,#N64'#P:^YH.WG.] <R;OQXYV#*5 @*28X7Z9F2!;*(R1N3OEFXU*
ME+8EO&!8V8>RLHH#L/HI1B*OH]3HGW&D[85"\RPOE?"7AQ'Z.LMD;4+?/&\)
M+G.P#)<Y.*H3^NV9%]ZO#.]VCQZ3#*]IZG I31VDJ<.=FCITI*G#MC5UV%Q/
M!Y'6]R>MF_0^[43YJ-(4^Q%:LQT$A)7F,R:$%GY+>:R]?,*"*4@>P-WN**@4
M#S!>HD+"/XS_/ V^51WH]>.[=Y>Z]F3;)S^(*[NR'.3++JW'*J[L\HWWX<DN
MOV&K'=F2/[4M^5-7^7B,VOAIN=UJ^92@$Z.^#;.XLS=LV9JDA=0TM&[8F);)
M#9G$+ BL=P2-W\$-20"\)$!]&4RV=';;2[U^@86I:,0)")7K_%X0!MJLSC+L
MU=CR$)(DB'130!@5LO@)/(?2%$8Q&>-N>YFQ_Q7&,L:0J$_-;H"[!;W<VJF%
M70\#84E/DAV3(.QS46?0K*=(WBBW:J0V@T7SS&6866 65B>OX-!QU:CK+W7&
M8><![NKLDLZ.$&0#;TGS:MN6X0V[6Z33&+$:I.BNZ--S67J]>MEMO>YTO]^@
M'_M3F*/U1OII-1\'YYH$?>NJG/W&P^7GQ8\S]HK!M\LLOFYCB>T?348"*XQ*
MP9M-=Z.6F^4#M(,-42EYB!PO@YL@C=T62+'NUXFRFZ^!>P8!$YOO]+5>(JO(
MB[G+9;_HB,E>W25OI^,(&D209BI9<*C;WJ?8I$7I#E:P.P-E&T+/I9FATSL+
M5@CX_FSW+&F**?Z3]?M/NN(_>;K^$],3\U!Z8C[*GIBGYY=G)U\N+J4EYL/8
M!7=L25EH(*5.E UI\$ZDFA0D;ZS&/>[\N#CM^M2FV.7A5S^) H^(6PTXK]Y?
M*OPV4L:;,7"]6<WQK*-UAL:7B62Y:[2N>-8;XPA;.-_.6E,!C'NT?K;6:3>[
ML\4Z*$2/]P.TLY8A$YJH46IA788JP$=P0'[V)4CC=WR1=>;.U@(>+9.JL?H!
M^ @&W5OTI=V![E.'\.>$;SMK#=\NDP-R'^1^/_S'!M)/_7'O*[#1K\$6+ND]
M<1#).ME,80=,)^@'$VM3<T?GY 9!"_2^,X7,E9!?\B0+E5M!=OBZU7EQN*GZ
M,78\%:_73T:7EQ.T,G4-RV=Y"&7O*F5GY4;@Z !U6J@'V(2==A5L@I'V^J*[
MF!*0X(+FV*5QXQE/GW,<@J@?YN3?+5*K2L^7-!]Q4ZW?374@;JHG[Z9Z_?K5
MOCBJ'IFCZN/QER]GEU?>V[/S3[]Y5[^__7@.7YQZ7RZ\8^]?%U_.O(MWWO'E
MR;%W!53YS_<7'T[Q\HH3JZ"0CE#((Z.0SY<7GR^NCC]XGR[:7H<53K(INV^T
M8O[^S/MT?'5Z_#],(][YU=7OQY].SCQS:R/HC"2[;$NRBVZ?(L[IC9D/QVQ\
M$F]-P8; 8H2Q4F@]MOA;,B/\]*N'"0*EC!,+[Z$*?V\UU:&P?.EA9>]+84;,
MN8P?ARH(^3S[<82FJS;B62; _JF4W_\6 0B'H'6 +73%;]%)G*6A6TO<]><5
M4?:B6KAEO7S- ]29?!.X  VM(OVT6V *S+O?3> +QF,U"!C$Q/I!\0'OR'+7
MPRO[G/%GG7>(":5%WB&]"EZ;A^0-&";Q>.9999?F)S\=^/_V/@3L/[C,0[.P
M1R\.CO9\FT<Z\.B+WC/*)4'C,[B!,8O)OPF3WZ$1>E'-IO*!5OT\";*IH7J?
M"'!)$JOD?\6W405CI]L^>&WIVZ7A@M;[_@2+\PV=\Z5 ^[T 4Y#ACPEFYNS=
M":KG&:-I4!PM\68.MIY[H)UC\Z?R^F7[1>=AY^)X[_HJX=P\8'QCD\-E>66+
M4K<QO!(&XX"GQ/MM?>R1TNX>WO!^&*><5HS_M<GD/QZURQA&;>]W2E,R[^\'
M23\?XU+T,9$M3R@S;$")J#T*DC2P3%I$F]^'2AQ\#<<@-:EJ_N"OG!!6\@FF
M9P&A1ZXT"(9+S2=(O3"^)?*'A:Z9#AT"X!KP:G:!Y2 7H@R/C7$&PYB6>96)
M>Y7)9N:5+7T>KX,;6NKAT*DB,.*5'@]6,Z+D#IRJ6)=$9U_5W6\OB'048X@&
M3)QVNN@.'E,*?/VV@,@,::3H"H;7_L7A'>'FF]# '"4+SGN9_>!6YI'Z!GM%
M.&0F#$:Q6#_A3$,W)C8_W(6W,2Q9P1T-:;-BE9G@9]V;6CKW,@SZJ)"U&MY<
MH^G5<3?B 11*$#K;4 ALP#FTK;+<-TQ.R[0:18)9$U':0,$6@4#URWS,/ N4
MX :Y1X\U4L_(#-)27,6<I9.6+ 7D'CR]Q*:Y*H>)D,ITACY&H@N>Z23.^N,X
M!^;?FVI66\_O]X"T!XJ+A1#Z:X%=\(S/C?K65W#UK.P1BMY,<2)GB,?#EB8)
M'=BR>>Q^RI1;2J)VL&R-K'2TWI*",\" EB7(5*<]T--85'Z;8H5\1D_[&3[3
M^W(X*D$6PB.0T+K[;TIG8B4D*[TS/-OJ\/5Q:M-;.F\\9+N3:>-D,<Z;97Y_
MQ%4":QC4<03"28,@F+--)V;NXDC!V1;[X"ZYX-%$]S\G\21.Q2>W0;[&5EB-
M*Z;DB=GKH 5L#<\P((,*=D[?&*"4_'<>)-KH[9'6Y0C; INWI VXWKN*]@A_
M7VN^BG6PUV26SJ2#D<SMPYO3H$#/Y+OT8,LE52VT]_"F*#<I8X[5[3K*V##"
M 2)S3BD_!01P2E<ZSK;%#QJIR-6S=59-C.%---'<-5CDO2M;P:P0F.*_GYS"
MGSK7&F?9E$V_PI'8Y*.H\2#>">O8=005M4=.K9%WW._#T85OPREM-9UCJO6*
ML)D+[6<8T$K1UB]%LVR5@^YO:)((QM"BF5])*ZPKHH//):NC>5-$&=L2IM5;
M/\="#"4WW*"/MY\9KSPZOY$<?*.*S7C*C?*DS[H>EAYEVZM+L-(#IE=8HX%_
M<G@!5O&!&IBCD^G.KU_O$>S=[?P9;^=,D*$FN"!UBI( =E\)8(>2 /9T$\#$
M6-Q&8U'+ZW^![BPFXD9=7_YPB#55A!]P$S-"$^*/_!4G!+"QV'1!:X>\5%@R
M0$_0;B[MK8>'9SK;P-@DV#V'L#(88%5_K0SJQ[>I*6>HRRBI:G@F>\0QCRAG
MPSLW*IWQ/H >U$O).K-M5$:^OC/UQ\J$VOR4)I+6^MU6)^_CWX[//UU]T81M
M-+7%PV4<E"3^"JO7G&!/(]7/)B,8%+Z6,[DH-M/2^[)@C>3@;>;@:?4>B-FB
MDE H.YY5I9>A[$]QAII[@>&U\C.L!Z48&>8'6!01BS<[U5[REG;2\'%"91Z+
M/0Q&VA+T342*[^B9HZ<&0G\;HK\%>U.ARP:J/,ZS$0B*_V">'(H(!*-)")3P
M7BAS\>N<HF'"]KD7&JW&>]QKG.,BI+P!4C[1B0"S[@:2?E1T7:@FR+SF)E'>
M1I8RQM2-#13F9%D>?*74&D-U3J^92\4D6PHCUZ2O7^6$@C;;(]4H'3T%JT=H
M^C!EW RO<]19)A Y-(BH042@:I+8LS&/:$BA"8Q\W :IHNK9)$<V!&R1O(H&
MC"YR\Q4,%EWDCXLD.[^O/8)( ;S;?2Q3-L=#'XU9C1R>A@E@!#N*>0WVUG7I
MR.\N+FOTXQ65(*''M=/C J<B7#KK^OD^2L 2'&+,;R^.+T^Q9,M #UUY\._%
MQX]GGTZO3$67ICX@'T,WBTMXVA47@U07BW-Y;<[E(W$N/UWG<E$[VI7:T<=<
M.]IMJ!T]_OW+^XO+\__O[-2[>G]\>>:=?SJY/#N^DOK1'0I'2/WHCM:/(HP,
M&*X#2E/5MC+=?0)V3<8)#X'Q&)53O/S"LS3//["'=VF=DZM&RVZH8_-ZK8T^
M:WL7VG&OB85)@K2B-X,@G80^:!A!% 81K&D8DQ9AF$OQ7T.+-4\Z6.U)R_S7
M1A,84;*4ZEX'Z6=PM'TR%<EMAKLR5MI-MMX]H!P1C8.X-');%M]M*6;_:VJM
M;N,\'' _-AM$,H&6H9FB\7=F,1;]S9NJGM61F95;R49K,+$5R:FI2%[7E!90
MM:'EEG$CH&R\QQSPWU;( 8?C14.Z5)C@Y)W")2X$ZKI6:%%EN?8).\F@5":U
MB=>CIR:YT<$9D\56R?@JY8"N?U!U%#X[4*=NLJ#^1(VIC.O&#T+2X=U98'18
MUWK6SU*TJ.W5HMXADS!AHGFB4O2LC<;]YNZ%D6HDNI&C88L/*IVSL(\3/_&O
M$W\RHE.>9$'?Y(:>_ZNTWT;@P_%&I0W=TXG"=E&FUU7ZB^SY_>^YENM?:GAT
MP<$1PY&V@#^:!&B0O2<PXEBW"H/K35:)9N'<#H@D(/RW5M$]N(-Z.D?=[;Y<
MH[IK%5V,VNI<YWA8<]U&]>YB6TY8?FH(&CAY&M/UQ_WV_GX'8SR\AUR3?;22
M1@R/GP&Y:7X#U[94;C#"66M G+P-1Y 4-_B74\TCEN,8/$P)8Z?E*9^JQ_&#
MBU,P270=R8!Z;ILHO0^V!NU-'J18,&0 M3%W'S//6K.E1YS&5@1[22.,AZ;$
M4?2&[=4;WOK]K]BO40N@2Z<@5U2)[1$K7ZIBOD:]3V?*K;AGV:K&>ZTY<2>.
M5S&BP4PJRE)"W:^MEX/93C%W,2W%M!0><H]NW[0,DW -#\\('&H'X!):)N%@
M,?A?X<$F<BM2UUE5V0YT0PUXYKK6?49DT8A"RS:+K;*KQ7!#LR!#<OPV),+K
MC,$E^2NC2CDB"C-@:YFI2<I-<VSD&:"? 7]NA/M\L&.PZ"C70&86\'JS76KN
M^8QX)3 FK9DXJ<C.<L]5I.H%9 TFPR1.4^K-.LPSK!IV\!G0J-/=P&$&_.<R
MC5^'0<3-AN$!,X_GIK ,?F#Z2)BVYKJ->X'1T]>."ML.6??Q712]0BW J;XF
M:Q3MSP27A,S>A([;XCC8J S^9 NYYWO<&($"K^MA Z%25V&ZD] =*E%/X8^;
MP#I;PGFM.Z'9/L+N)K68#9'SDP*#</K1L&CI)FC 2?.L'N61XZBDQ"(+T[C#
M7CH)@?)+.I-)?F6.]"EN>P=+:$JN3L+^/*UE&^]7K2OO[JZW>0Z][_6CZ6<O
M%SUNT;HO>&#=*._BQES"P[>LS4?(<MH><@S29W-MP4WY3VW:>)WL;QQXJ'RB
M?-_K^:$6_=OC>JV1DZNH/N1[Q$P6D,!&(+$/=4'\I;ENLYG *WJ,H&9(8O/Z
M$YM?2&+STTUL%C7S_M3,LV]]-5E@$6^!BVC6]%UR@&P(H9FE<;0LR-/#V<XZ
M!%FU]PT.[#P_WB!6NC#>.D58@P:)3S9IRV9!INAEI@%IZ'CK\L.+,4L0!NJ(
M=83DMVI%/2:=I#QM<>CRLW%@G)'B9BE)8I;;P6E7-N@)@ 6,%EQ*:\)K2 'M
M>$.8EAG%G+.H,*VAWK>F'4-@PL#K,X<)+^Z<SDX#TT:C#M:P1?"A$X*QL2$N
M'7/H3;W0OT6VI$MI$P009</$F9&3&%3,K:9E$4VS#*%#FYUJM)_@)@@5MH;P
MTX4P0@4[K;> V][[ D=P]G9C,TV06T](6/!0FJTN'CZQ<H8D7 KUM12(A6.@
M.^1FA12PB*@> :;B4)AXWGBC^!8=.JV9P'CMXL^U035\1=W$8-?K<7:UJZ<R
M+#0PE9\@+$!:9/SP^I>0,U--GJZK]R:FK"FSUN^8,,?D,-5^7)"$.JTL[^'2
M$3@NX^DWJ30ZV8.ZB[""8+RIJ7G>&-_HQ7V@&\S?HK3% 3G+J*$1>].XEP >
M0ASDF/MB UTVQ!GPO=0/IWP8_1[<SZENB8\U^,YNZ88^[1H BG1$HX+S&U]'
ML&<T!^Y^850AQU.GD4Y@R%,F*6HPY*7 9D/8DZ+1BD.;">)"X$8:_85\>+6.
M@HS[#!%F*G6ZH1?I.G]8,7B;Z!9;K%L< W<'VD,7;>*= NL@&]^>R$LZ?Z)+
M;$R7^%PQ'4Y_._G0JH3/$T72Q07(\^TV:D&)C:O,;A:-2?@W"KKIQGBE>K9&
MY:4Y24X.]Q8?[C,W/$222:R#[;<.M 96/O/S*EF#S&0!H4E16!0%ZM^0%17"
MX,065Q@^\#4HIQD#HY]S@Q;;]LVIQG/C)FLKR2M%21;7Y;6*)@ZGH*/<XFI>
M*31V_(0&?D55)<"NJ)%82&E?Q7H,_(SU3\HF!X5)AU(*)*.FQ2&0=LI/+,#,
M[0C@'PF<;P*3+9X$JNS],%G"MJM@L7]I>0/KZK;)'+&FM(] ^J.@%[";3]H$
M[:[@$^3G;4=^9B!D"P'7]U,.5:!G^]I',+IED3FUN!S-\^+,@79>!FK4A7>^
M'_#D)48A]+L5 +8U/?F6 EI>AL[.G0XJVNWG^0/L.IF5 "VLR+(H%#;/RXZL
M-:M$FJ/!R9SJCF?!^JBP3&/E+$AGG(O?QD?'0NXJ,&0,9.]BF&$7KK?DU92$
MQT>,I;L,"0N>KM"XX.G>(YZN:#."J;LLINYB:$/!U97TTWM+/WTIZ:=/-_VT
MP-4]$%S=QXRK>U"CA*/PN3S[U]DEB!I&=+_Z_.'\BR#J[HZ;5Q!U'S&BKFF:
M5UNK6,UK;*AN*R>YT</0)#9V5J([!N\JDFZ#]QEV6E_P?%W(*>L#A=W<F%NV
MZMK63H_S+$?')9K+R^3%EFL':BYR(6ZOB#(OD< *F.8O%'W'C#[G9RYFKR9G
M4,BZ.!;&T>SWX*\XXCR<F:L,_(>=F?:FK6N")0BT=X34:+-*2--N<;D%(Q([
M*8?5E(;2:$HN6.\B6M^6+PDM/8@G&95!@]V2Z\ .#=8@*]M*Z<:,@#JVM1D@
MX_>K !F?:Z=A<V9#BNDA:E"D5M1E5+!CQWXPN0]-M>BE@U''P(ND#,S%<*"@
M-4D[<8*ZV[4_WSU36.5B82I*4. %_&"=0[GM'3>_ISS,(K^Z1M;,+9(RJ=OA
MM'RB%K]3"U20V^C-[=,9KZ;K^QK)*#+3M0*26P>.>\3]@@A%L$W]G4E)K\EQ
MR>K8ESCO-J!IO9U6.-*E)A4.>?%V%(&RV=@*TXT3W9O/NMR:-4[_PD#,+3S-
M#3VN3OLM(,'L5BFNK[,UA;N*Z5H+B[#I_@FV#JA\M!$2E6LLZC>"*WU")Y-_
MH:"$IZ)PF)L;YZ(=ED -UX+'B)B(3NE!:UVJPL)WNO3-6 QS63S=,U(A!W%0
M^.3)5#CEAI(VZN2H509JR["6[ H"HKH*[BE[N@$_ V9*S<OH,G:/;WHGD\*>
M4&8*J5E:0ZPA#&P=[0T35IH6%,:9UQBY5ZVQ:GC!>91FRA_4BN51[$2)+2=W
MBSF ^2I4_V;':(93=W7?3T>4TZPHDPZ4MYX*XUN-<T8,W.>:-ZV6PRJ\*]Y
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M(H?E'@^+[XU@F0UXB:9US#\'HWSB75.H.,-C 1=GB)JB$7&->L?^$3A(NNF
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M/,-BF42?XZ^NY?S4XAX&K;1MK813'U7AC?'+^%SAJW/=M51VK:9=JVDL4E%
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M6SWP4-GSA"M[L)8L5&_)(IRG0R)BVXW:IZ0GR.77)MJH$4'G;K02U',GV\(
MY0:] [A>V3K\1@.ITF!MH)!IH\GT!,^;NI%"=SKF%]SR(*B3N*:*QVN[;IV
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M*Q";YU5@6-K=1[T"%RO *^?Q!0^Z>X_7P1':@E[YT$LBJO0R=,-?N(WAIBD
MEDA%?4/B%5>;#5)9O/H:_T8[QT>_/ALYC]ST1_'][G;T1UWYHXTWH:\+&?\7
M#4D\RH!Z:5^YBH[69-;V5SK<\EBYUK@A2HAKLOHFK>7=Z')3)BLR@1++M^]K
M@C?ZS32_C$&],.("'F%AP'O<^4Z7UE8?1^^\1_C1D, M&&TH"*79]%=P551]
M9+AF%6WFD+4W>VNMQKBY]8754QE'M(N1EB.YV3! QKD<C#9QO: 90I-^2;P_
M73,Z>H'KQ>#G;-R, 8@#,4<>*E\K3!*NL6FH]D+>3@L/BF@+BNB47'2,Q:8'
MKP$X&!_61KWU!I<_2]H9)HCM;27A9R]>[(?\;>U=N]&'  M3;L?5Y,ND=GW.
MXY:\P;)"&,.841>0OF3C&/G]&?R >#L^^H8?YL7@[8OOVS!]U-6:_3HM_2:8
M3W)-X^+XM[4N#CH4*U>F>_'\0=HVVD!P*NA>CH/XY8Z^J=B.^76&RRPW@@@)
MF\8MEH0CC%%>?'J?^RGD5ACJ/YY\_8<IYSDR0;UW&R3(0W[^B>?GD13^\?C#
M\>?3H^_I8@G;[=F-_0P XY"JWYIQH#MR([>PM)P"MO_E#U[>SG3^ZO+PC^(\
MGL4!P/FSU[*)/LW([ZV\JWL1MO[U'&K;W\FK[<-UVK )$4^5:QX/0B/)4?3Y
MXZ>SCS_U3.O__F3L3P=,M)VDO 92DD=E4F6R>)A/GELO@.2+NU0("N^OL<)N
MLP98UVCG\.2G9[BG#LE$.F*O_V>;H=@Y//KY6323[B)QM/^\9XQ7Y/2;Q1?Z
MSIXO-BMKRL.PFT4L+[*8)O=I\L ^+&(<G='*%DMN6.;:F,4, #67\O,WT8L7
MS&)DVL %D,<5(/PO%6U(1V%1N8ZWUY@4>V;$!Z]>1RR1(.ZC.[_X]_H"IBFY
M(06H.Z*.-JC"FSI#;JIBJCJ5AW'TD^LC>A02OFE]BJU3H&_B&[8:QM7Q8.2&
M:@$]/4=:;BNXV--WQT[F.=?(M4-L4,UL]6P,P.9&YU(FV",7/YT*2L1T<0C*
M?&]['%OM20=-^?B:\J3=<LY7%*H:Z&24B;@>TV1D-56KN9[%1F\TV=-C9<@'
MO;C)SBKZKVAW_/KEWK,-7^>WJC\;>+%%4 :09'6TKPS;SEPJ^%'E2TEYBM[(
M^0@CE5XYWTVIC[W3&TSJ=J.G>9?(*=L ;&I2^^YX<%5=M6P#7^ZXCPPK2_)8
M[R41WT"9 NZPY!G31M"O#0Q>8O6W:YAD!QV& FT+2,LQ%84$6E7=S-8:<//P
M+RT"@6O8[P;UL1U,9)6T#E9B#]9M];ZO$02>HBI#:J\8KO$LU#=\_O24<5=R
M_Z0M$QHA678 CICR/D]\E9E\UCX! ;R2@Y.(4^@5Z$(YCNRA%:T))'R@+QKP
M$@^-E]C?W1WP$G]>O(1H0WW3A^)['M;W_!K[<&7FV]LE4?O.BC[)41:O*A)!
M\V_FH[_Q*>+C$/V/W=U=^Q-]D"?H?.KJ:%?_!X."6L/ RNY11;(<_)>SXNJH
MR)IE_OTK.]B%B(A&8_A9]+"9%>TC4I,T8%P2__67%_9GP7E6:90#'7XB4]BC
MA^O?(0;>JNI?6>HV_TP"T?5L_-E]5[?0R/5S[T\LV@?>'T2Z_;] YC#W2_#S
MD>&BTBH/"Q^T*]<PMN3%_G@?>VO$!ZJ'__\ JI#4T.8.MC3@%9V"X@KG@91A
MS7C1EI;4F:N>_ NXZFED6'I\^I>_R\8'>NCH_7]CI(^LA5[?2PG=-<1\X/@^
M'^I>NRXRV8I$'BWBTNJ-_:Z(9']/GF.U^\-@(W;JK_6LYXC]N8Y5UV1VVR_8
MW7B!=P#WQONO[G;^KA9IG7Q/.S*E,Y475V6\ZCA4AGZT=Z,&77CSYCQ_.7ZQ
M_WMKQP[E..C%^]O[WBX_J*JLP7_K96^.BD517J<ZZ=_*O]_'YGGM#JQE"/M;
M]#^.CHZ/3T[>W&0'O;W%T=\XLW<^X+TG^>#N)_G@]B>Y]37I2_D;;!UW'.51
M7<<1]%W?K+O$3WY<)WR3BWQOU\6!'M1@^:S!29,]Z7_P0>O!6.47=!'?XC4M
M&:N:%:F<O_R]JF]\Z1UG@[S9X<E/?ST\^CGZSTGYU[_O?-* K#',GMW6,GO[
MC1_T:U]XS3U^K3YX:-/+J(AK3:]O?2=^ZZ+O[XU?OQZ4\%-3PH&=MFHYE]TH
MI;LIL[WQ[IXHL3QIZC+.!MWU+>HN:SH>?..[<GLG</]@O/_BOAJKWXL;--9C
M:ZR=W?$/>R,Z*L_WG['JL0 !_J\/]%_[+W]X)-=L<,,&-^R;.D\/Z(8=.:#'
M_G.&Z2%C_I8SYNK)H#4G0!EJ!#S[PUL!W^J%_Z=>],%9>9*JZM&=E=WQR^>B
MI[IB.G=]GK]_Y^OE!$BBBE;H^SO$W3L:Z;UX_>+-0PSO+W\_>/G=G\8;^U;U
M\.!X#8[7MZ)]R?%Z_G)$KM:KE[[CM;N[;QVO1_.[AI38X(M]\T?L 7TQYWC%
M=?0/N&+[SX>[_FG?]7_J11]\KB>IDK;@<SU_\2?RN5Z\&'RNIZZ'!Y]K\+F^
M%>U+/M?!:_A<+W:-S_4_L_H-NUU[C^]V#2[6X&)]4R?J(;&_1S\R1_8'*7H^
MY\K/,R[G'&[XIWW#_ZD7??"TGJ1FV@(4[^#UG\C3.G@]>%I/70\/GM;@:7TK
MVG>'#LD^8(4O7EWC:>V_&#)<@_LU'+.M9+A. SHHL6V.CWX%J;+R#5<CN8+^
M9[Q<O?'9<0^BPT/F.Z\&(^&)&PE_ZD4?G+4GJ<>V 45\]6=RUO8'9^VIZ^'!
M61N<M6]%^^X@(8:TV.N] (JX]WB>VM[N7;)B?ZP#=+T)\W+\_(?!A'GJA\A[
M_?.;+9K?XKF]=<U7T#Z'MIIY[?EDJA&P\[:9CJ/+:@P>UO$H^O5,@BTO=Z/)
M:ODL&HR$)VHD_+D7?7_\<@@Z?4N:[M7C:KK=:U-NP9.?AT_>GK/V6^;W<F]P
MVP:-_"1<M3VR^.]M90ZNVN^@>U_V>6X'>_#<GK\6S^U3=YKMY:!P?E\RV3_!
M\@Z1^3^4PKF%L7?WR/6[HDJD00CG&TT[$K'Z5C5YL%=_];J-LD^;%[1^XX'\
M9#"9GN*B[PYZ;=!K?W\^WO\6ZO(.'B@!^?S_#H[LH)6?A#%/^G=P9+\E_=N=
M+MG9'^^^'$6OQR]WKW5DK\E"<NLW[M@T-"%\[":$00MCCX'=M2)-YO-D6M.>
M+>)_DRT?<1/=:.?UB^^BH]-G8]<=D+[RG33,1*O)$W0?%MTVB]?CZ*BC'6;7
M6PY_.3*O2,?)>(0_!)?<>3.IIF6Z<NV2-BCJ)]YN@N;^+W]_2P^1>^ZO#_*\
MGX\_&RY';L[Z&&V;K])Z$54T@A2MKI$JE.:ER2RZ)(\J;] 0-BF73<V83^S$
M6X_VA-;R-*_0_33.$_103BK:''3B1CNV&!UE+Y)H%M/1\':$?G^EO^?W2V_(
MM"IR]&^FC_((:.P5/>[KJI31H!7V(M%=T_Z5[F7<_IG^4WM !A-JJI2;7O\C
MSN1+XZZR0II)7=3TQ[Q93FBM305BT'221PM0;)E.T0$0P]'VIMRX^L4;^8^7
MN_*_-"SOT^?ZZ=XN9UI-.V[;9?Q..\=G(@3I_A<-^M=1%"L^=X1FX!=-.DNR
M-$]ZN\'2XM/AF+F.L+29:5S*C--IA$;BOW&DG]LG$'O4V<^6FWRW^]!Z+KXL
MX'_)_WCY;>Q#>*(_G9T]Z(E^D.?Y)WI9T,9H.V5TZNZ0V4]%6N%0E,D%3@'.
MW] T=POWE157/N^F5_05J2!:\F*:<H=;_BR.#EY^YT)44!A=+9F-^A:YA>YC
M_7C+8]37.C=+8FPP_AQ'+UZTQA&H6]:6=)3HI<$HQFB96:55;6?+2C:IFJRN
M3)??68+V\9'A%Q[ACV4BZQ$=O/X.+:YIT%5B?N =3'HA:U+7'!@C[CC[[2[D
MTE_:=1[VM4BP+7%6%9$>)!K._G?2%CAJZC1+_RU=BW$7S?[9Y-*RO-46&+.)
M5VD2].JFHSF%EJ=1LN;!L"I6JM.8?H!^XD;/LHYJ*<U9V5SH@\DL^>S6"X.-
MHY=[K<WRHYC![/!:6B.W[?PTC+U*_M68)?9_GF)7PH<G==PC9).LF'Y)2B-I
MLZ)*1A&YE--%]'R\W_,C$EM[62SHT-):T%M6M!CHO4IW]B*=I+S/_KAJ.L4\
MMZ*I_0\V5=K[YUM69BG=^^GTL9490Q:O<Z8NBW1V'W6VV8_-OJX5JCKEB79%
M;_PE: >#('!OC\\_A]W<WR=Q64<G9-HU)-R?T=(]C/(,=]3C-G8WQA2=?Z,M
MZ+PO>%OFNBV)=K5B74Y+%\\N85_,HO<GY?&)W]@=V@E:N^'+397Q_NB'W5=J
M;,GQ'D6K+)XFDZ)'-ZA2S9PY&0@-B]&4[%'6K#6$AG19S[.J%6DY6BS[J,F:
M1_7A_4]O3UGKODOH8I0[@5;A5ZAEVH;H<$[S+^ER.\UM.WBVLW WT4U*7W<S
M'\F@1/7#T8CV1KO/=XT^B]Y].+17G[2U=\M4VUT0?V=&STYHIZ:D@*?)JB8S
M=X=,__W]W3>'9_PO>V^>T;NS]1(BDU;+"GMFMD\>15=43M:>*'H>FZP3=H@F
MN$QS?C?M,SE5DV0:-U#:+&WTZ"KE.XZ>CQ-=K^UE/B^+951?%;3U\D#(Q&61
M74)1%[BK;G%1V!S<(B:['(Y:F:SH50D=QUB6B6]"ZT;1JGA3H!?"9[N(:64J
M7&*ZYKRL:<U3;/*D7HAX%'Q'DY' X8,+S$NE#__M/1=2D$Y3&AF2@H=G1X=8
M[+T?WI!UD<1YG*W)QC%>(__.,W'BZ91T#YO=U@(Z>7<8Q2NZ<2\Q,[)G>D4T
MF9+1[D2T@I]<L1\0V1?3H$DJ=^1>Q<KE12VK1QX2J8,E+8'*MLI\91;NF6<Y
MB7 >D.F05E^\*[XP5I=TLC-G'H] E$7/LB])8KJN>B8%\4[,A.@AN^/=%P<B
MCIMO)FFRY]GZAT[M5 U-F7;5R2/.[:*H5GSCJ'U&I_8"KCM$].#Y=]C=YZ^^
MDY'3^ETCEZ8M873PZG7$2I)\77K^LOCW^@(!B8N$%GN]2F3\P6$F*S6),R-^
M]A"*^4)_OH#!23)LI^5;.=XKX,UBA1]BF-'. US8A^_.WMHW'I87]%+ZY[,1
M[<NT8/,60S8JJE*M)O,V%MV<K66U;LU*Q+02.391'?AD1=-8+4I,QO=21-'J
M2ETMBFB6BM O8CK##[=6XNK?]ED_DKZD+2Y3TF//^'+ 2)[_\%U+2[F1RSEY
MM!UQ,S'"QT>+UG!'"!!P\I[U'FYWIF@WY-ZO<?]!W4BX#EKE^<%WI)NSK._"
MQO5A1F:?.#)>3UQ)H,O[)+0P6D>Y:G]..M0$+T;P)).L6)D+.Y;U-O;B7V?I
MI03FK>5X=O;8C9E_'Z-Q6YV9D?)":HO^7_^E1O:K]4(2CZMX7;6Z:--OZ1?2
M0SORQHXL&C\GF!ZGSZ)P/=K?Y&61+WKSB'0BD=L4^T-_1R/>4MI1WM!/Y[2=
MWY\E%Q#/-RB@+&@BY))/O]!YV]_=Z_9"YEE3+?Z0(O5(?H@5J?U-)^0_XVA1
M)O/_^LO_^/SQ:'=WC]P2)-1PM(]H8M"A__G76/Q!^K__[S_I@)O=D#J_CY-_
MDL7+E7\6)[]WA^T)_W.E)8&#Y_EPGF<[^;HA!/-T4J:9\:5@+9 K1?NHH2D_
M6U+'TX4)!]&5Y7_D/T7NW1F"WI)'<@;GCOJ\6/7J&=N-;,X8PW&G]_)Y!KOD
M!WQ%;QW_C60-O+V'$:&VO&_TTZ<ND%^'<;@X=_=W1]3KX&E&O1C$\R QK]>O
M?Y>@%P!+=[+:%+;T:1'38N!BN1"OQ?R!K+:$-KOR(B]#Y&MKD2]C*N],FBG]
M C'Q:+&>E<5T028 *9YG$@+/$2+/))Y"7T;\@CS)@C3+;?P%SCOV?V_??F\S
MY$-Z";_\WL6 ^.6<A+ZPZ0O:WUE$YC7Y8QG"(=!5*V00$X[\I B/+">(]6@"
MPWT>P0=+6==P.&1FW0=U]37D=-!?B_:R=11,BG(CATFOI#4O;7SC1\R6QZ3A
M+.1#DHN"7!/D(6X?0)*0#^U(C.R^AC DS'&QUE!-6OH>PSCZQR(A14J.V2H\
MB?[:7"'5DF0D&S.)F.!"JJO ]4#0;)FTG\(+RL,9<0B) P6<9*FA\Y$GHW/J
MK79,YFE3UHN>&5_8I;+QR]LF8B18,2L0Z^/Q]O[.R)@-U^31HH&JD(MPFF2(
M\U6W];E'"@@AM9"1O^^">+<Y"RZ@ - &[]CI$M'!&"MXK9_>\8R8]I'39?HP
M3,T[;3E  B8>FME<)4\;*2R( ?T!41ZX"'6BF<V,$Y4:"LR3IBS89UZF-0(<
MK9B&"=Y^.#;!6]D9>Z#E.5REX,W]DJ,'],%2+!,ZQAQUX;654.NR(-749$@Z
MBFL/A,R'8Y-\BZ&V&-G2?GQ=V$F03Y[0;\827&>1G2192J^OK(PN$#2^*J(F
M3TF2.4W9LP5N;2U\PYTJQ&Y6A4$&3=9W#QA/F[*4DV3BJC9NY@!:M)SO3_X6
M[>P]DSFEK"* E(!>@&VU7J[B>E%D:SJPHTCC/VNW(7>3L0Z1JA"'Y@QRY7\V
M*W&-<(HY@R81_44V'KV1=$M-]XRHL25M#9F>2Q8!F@^<VY+,3:"2UE6=(#M,
M\H$XUH=C>5;%9O,HVMG7:=>+LF@N%D:/(VI>TG['%T6>5LN1T;PQCQ7"5<G(
M7&)A:N\ +X9F?H>(,X;F5,2MKD1[G=%12ZLB8_7J*QN2_%4L&H]'1MN\+%2&
MZ4<JTWJ=X6_\E][0.AG5?A2:(\%F#'P,J\03T1&68Y8 DS.!B)*ROQK);5"0
M&B\O)3+)Z")ZKYQ%.Z4P)0/8%\>MHZM8<S[AZ:II29-:8&6: IBZ8)[.[DYK
MBLLBVOF2%U<Y)L+QPF=TZ31D):1+/C!R5AA3D#0U&QR<+> 7FICE..K4 S8=
MXF+9]._Y0I*!?ES;ID">?C3;Y%,JR:54"RP>[?$DL7<&O"ZHFZ^,$R0%\F+W
M.[,_'^AF6D2'RP0P#XES'S>0)_H/N;LS+TT(JZR(8%/ X[NM^G/ILO8@59M:
M(X2\#,ZA. U7I15#^&ZS$8=G44M+8.I]A[,M)'[^PTI*H&IOLH?[!U+[UPAG
MA]-)4[,JA5EF99!5KEZI[T\$4V/P-''$5RJC_*I06A>%Y!1H4(\?IA^<]B?O
MM!N[Y\CD)"%($B6NX:2<JX<Q..Q;<]A9U^#>-7:*8%!"8(C-(;=21-;7@DNO
M@#HV'$E'A'?6X<F(/I@*<E82T_SWXY-(L=G1\]WO-(WM!,*ZG'BH]:-YH,6D
MC@4VHPZWFJX"36"K50#+-+3W(9AF\\4LB H#9[ F0]8?Z)Y](SE"-X 0;HD/
M)85;U4$V&Q]XV[#_-OKQ^,/QY].CG@$=GEAS/L#P()DZH__D=R=?Z1L(N09+
M>I62F<G[@\TQ ^]YCX&QF+=M;#;6]J)^0^MHS(#P1KMBP\G#H]#5S^.2-:>C
MC+ P)RL,SL='!*5S&(!3^LJ\R?2VQ!4N$L%1A>C\TR%=<662.$BJ08X(< 61
M7]B'M -9,B(9V.V;K8R@$S#5PDKAIFX-#_#>.,"=D/N0D)V1,=QW984.%(VC
M:!D#-$2_AQCPQ&FT5;."GXYI?:#Q&\>,CO(7-7.-X+LC.4#1MP3S:XD ^3CT
M)*BH*J5U0UJEN.VQ]1'.S@%3Z ;TX2CZ_/'3V<>?>A[T?W^R#S)'J0N84&O!
M%RE'DB23;\D:#K%80!S7@5E0''E"'"% ULB#&YC2DSAZV3,F4G3UXE[%3W(7
M "V!(]U:9M97J'WALY7/4)46E&B0HUGC,?G&*7MA#U![<=Z0\KXB!57R&>Y<
M/MY7ET"Z"U0K/.@U@J7L-(L&NE:O;&H%00C9:](J %HZ'GB@_F0EH3I(Y2[3
M:D/[P]ND Y!"X>+OI(N3&8.LRN0RI2.OE]$O.?XH@SROV=QOZ*#(*T]BNKX^
MD_?^); 2.,D7+_5@R!W$'@W0A/1)7HOK[P7)]W?W7HRCMW[HN3%102P8HL-N
M1_);WXH2K\*- S!B;:!E:@:\=KZGW?9+O=,X!D/"GDB 3Z-E6BRI$;[S!+<*
M?E9PVCSEFPX_3;Z2"B730-S2U 1='0YO9(%X7ED(G>##$Q=]ZXTP<Z3'3M$O
MSWK($]11*/=DSY(,[S$/U.!I/G5/$Y)O5,IG,JP'CW)K5M'IW -G]X>RK%K%
M\9+B\Q:J4<JT.&((O791^I5];!7E[$VE\45>P+K6U*RX%Q.H-O:IK(Y27\+&
M/S=R'7BC&$]3\XP  QY'V*RDYA1H%I-@B+J@Q\#>!QZFA,*M\9-J? UT\J<!
M.CE )^\%G=P?H),#='*XMQ[AWLIQV%2KVSCA3_'DB,:B-YEZ-NR8)&*U&Y0+
MKII1$(,Z?7>L=5VF9HDNEJ9BOP,Q3-Q-* 7W"Z+N&^'CT94)7HXZYBSB9:VD
MW -%3ER#)3A/O-=<4G+;A;<T^4GV^N/AXGID(HIRFMI:@G%TTM2 <89#\7%W
M?D#CT]GQT>GYZ<</-T=!@"V!"SI5UU"]%(VGN.M>9H)4%;8WG:_]6]XK,7-)
M7$U[>B@LWT9T*)*VU1+:DFYUG#B(S>"6B#=9< *0% F:)/[@87H LE2-3'69
MF#0HJX>&D;"H"_+9-470I@T_8TLFGBX2DSUD;$YH=]D T!0+[(MM9<*T'5:/
M1GBZ5O8RK=+:%A0MUA7Y4G$^LH8=9,ZXU!OBTQG:'QRK)^]8O?-B.Y_2E;#7
M#,[5-M-U]@""8@1ZA',94U)!C*I$8,7!!9Z_VG]S'1JW$^;5 <+?A*%,2;^1
MX@\KRH:\P_9 UB.!4MOKPMO#GARLABIO"])N07![;FZ!6WD\ /TITTT4H[V=
M412ID)2;$-@6G>RA?A\/[>LPT$#$Y 7@A1T(YWF:)5V&0W"N)!_=F2_U<M$<
MI(Z:?)G4$5W!;%OEB0M]Y E;<>62K0[<HQ!,VO(K)N=S44P@A,C_'<[DMA4S
M8NXWPQ3\%,P&9,%:JQ;!&( 8WG1*D>'G,X@&(!DZX8/VZ0*EK\E&=[PB#X,Y
MV(S\<2K A0:%IXJ!Y,H"PAP4'4B%@O/?#=8OJ<+,5:Y9E4-_<4*N* 86M&Q8
M'XV!##N7HC#Q2B^406=D."]X<PW7B,0PD[A*)ZFE4?#T,KDN6M8O0E#?R2.*
M.,FC"&>\Z>CCKZ?O^E IKVT:E08!0+,.'#F/"KR.WFI/8ZX.%Y="#7*H,[K0
M25]6BW1E[8/KTBGA;#=-_0&6L'U(E[": ,K:E%63>+OK9V=YYV2W&9@5'#3#
M_JF[R8258%K+);&K0B*ILP^'GZ;[&X_N$(72.]?DCQ8;X0,\3L[T+*V4M\[H
MA&J0GVW)#P<0@*I*OI(FK9C=IV7U8(=EIY!-!P+8QIPD=<.&H;"$6N]$K3>&
M!3N=X6TQLS2V$D$B"",RPKR"3WFU#[F/P7/85G=63@%NK,"FR$  2Y[HXQFE
MG,<;*\DB0,QX&/G#">#\*!SRWL'KQ"^:-RT(9?<+.,Q3\'>+5O"ON.J@$!TB
M($\L G*"LC]6B&=)14['-*F& ,CV,'<.#RF'2<RQ62\TF32%W$X:PN?H)+M3
MGB$TEST5NM9Y@\@KCC.3 K0NJ)$M6C5E*%P-,2,3+Q5,+V/V*JXQE APO8$3
MK/3,PW/\IYB>4 M98DF=KK&GE!9VEMC(K$_MQO ^N7PQAC8G;H=2VEPJBQ]D
M1C%78J6XF2;G;!BP4'&JP7D'Y(F7I-TTT*SF)=.XD9\O/R//M=+-2)5TE8T4
MS*:7;M ;LU\%OFEA7&_.9+B3S$W&MX9LX%]1 0A/*\[(?&]]KE@#93+'(JA1
MY1O-043>F##N8ZYCC:<*S#J=V_F[Q517T4<E6;&$Z^!_5Z4E'(+WCI';,+H]
M+5%?N]::(::R/![3H3/HBC+X.2(P@R&V74/,NM"!J3"-JX4:5O0OR;^:E#F=
M^<#CZ/T<E].%NFM[HVA_E]G\)2\3HLM9SX5FB-WE0(-)MQIFQB:1H&.Q1AR*
MGOQB@]210:/T18B;$\]B)0^%4*9THJ:UYB9%!QK-QIPL#"H.?,[;N\L*<.1<
M5I9^06%AB14*(PWV;(VC]P:J.%TH9<TT+:?-$CJ5;G<>,#.QR:&2 H*J6296
MPWGZ#U='7 %+#94B;-?,KNS56#L(JE>^('%&,4&]1@VH.*5WK<R&D"YF#21%
MIXR.NBJ+_,++Y$H:+_FZH#'7O GQ99QFK#OFUGHIC?425461FU$B^=LQT#<2
MKH%8>ZI%" /M-; 96'#.7.O^0TV*C83@EKTNON#=42S#U^[FP%<W@*X>''1U
M,("N!M#57][O/\V]_D.XXG?K6O@31V/D\IC1JJ[9;O\XR4!?[;6C'<(I3SV<
M,G"T_;ZI2@G=PE&>T^5<5)IMDE!(!Y O-C])R2R5I"'Y 'L*VTO9V"NN<@',
MLZ6([%+)00JH9SQ68ZDFD[]<H95T3G:DGN/"G6.&SJ49&<3 T:WBM7#W^(/D
MY!N2_TG 2#9RF=:>7,20EMH^TX#MLH,XS3H0!C@+(EN=0BC" DG*BRMDD<@%
MF'62I;C,<@[_EE&J3H80W>B0,RE*M-#%-=L>MKR1Y-.,LR-$/]@%3\4N."J6
MJZ1./:3/8 $,%L"@BD-5?*0%S.^] N/*--EAAHIKF4_:[(%!'=W[D_YR<2_4
M)@2B0?,.!L1+$D!ZOQDB.L<TQ5$XL2Q.& D?=HMC1&21 S>?9G0WG-;VPL&=
M0=X\_4^6S"Y,[7=RJ5S8]#4X^Y)0T99\=EIW6 I%]4=%4Y/!@57,DSDB<'JY
M>4TWQ%+A_JUQ+N7DBL\\$6-FR<$VN7R04*\DW@:VQZ#MC-?XLP/U&8(+#=)?
M24>5\F4>U#ATE.^C>:^I>>\2F3!A,I*"R%FCU(K:HM O3C=M]]@P3"XUC[;1
MI:_R-F%MZV@V,<N:P5%V3S7N_$)]75E?_,)5K>)Y(L M/,A/YQ4Y]T)*2FUX
MBNJ:25-S70?_E(4O]B$,](0L)ILDNHK+G&0*]LP%, V2KTMYI-*@M!-:_?YD
ML$BWH ;?\?9;L[*#!)4VTE9 M="\;6FSV%[U@6XXJZ(C*]>)A]69^1$;GTB^
M5H9U(IX);Q_ROJZK6<E:R\_HF!?H 9. /0],$@0&3LK513>#D3<KN'%J&1WN
M)YT[P,I8,B@+T[_3K3-70MEN:M)R"O.>)\B5!!/DE$2]@'OH[8Y)9MR**?$&
M +;D2HS:CKL&!]506O23H3F3H3E5Z,;'$K.QO\.)WA(C4RMY3S]LZ/0QIRJZ
M9S%;N#H)ET:$YC'GP3P4P]0Y$E+$>2TF8)(6=3)=Y().<Y]9F0?C*5*R)F)9
M)5F&?]?JG4KY<;1!%R/!6R XL,ND"A_XN:A\O)I]G=QD02[2- >S>;^1K1@*
M8B4D00VM0LWE?J-6Q,3+%;+8FYSE(-/;YM.H8%2JO2;6B]AS-C\JZLRK(!5!
MUNZ)IO*S)/NJG]1)Z%VE^!>F$D, <)7Y]Z)/Z&OUY:B[GDRHQFZ^;<9V'JX2
ME88*K!9H].C"7:;-,FAFYRU(E;C;)N@N.O+BF/YB7KF76&KJE*V]?YK^>EIR
MTRHZ'D4BS'X&VIB\265+8H451-I#R N"0EZ_YG89?P$ZQU0)XQ)O,JGC<I@#
MV<CX D7>: D(2D'!!FF0RTU_B%$]W1C5S[ZJE=XUJI'/F]4J&]AOM]^N1@Q:
M]-6PO1\$PR[G/P<@ARS.M%HDL_"J))NB0K$=7<IT8--5EGB?)](JEOO:>(R.
M&Q8*7=(S48J6?_'3J25?A(3P8,S%+=>\Y1C-UOJ)U_UD+IX+J[,V/\.E<IJ1
MYBF%5P\!BBZ.7[6.BJ8VUS^OT(;\<B]=I3=-5"F%,06:S\8\/.R3+<"J%VDY
MZV5B+>NU+3=CIWM:MT93E!=D"OW;^.%RQ4UBUV X1>DD66J6?MJKEP3I1%FG
M5=("M!EV!9$&7JSNM]M: \LHSWR!JPR1@4196X,?6.(H23\D>NOZM*]*G@>'
M,[TL@*K:H/*K%^Y68>AN$2%^L:3C+!!FX-J2RK*15+PF7+OOAJ 5>9.U]$7C
M6$7?2L$U'4<GN)UH8W4_'>S4+(\!'?]8%LT*G/YDS28K>_$)A'5FC1GC4DZ9
M ]J%7R9Q#6J+0.0-530:16.HK=]SKVI=2.\\NE>9L^0Y:YLL@2! 5!3;9F%D
M1Q$<B#0]XA+#GY*:%M %$IVSZ[!N@T6]!:T/N0V$8$. <7[;0OPIIDW$-T[S
MZ;A+KFR>$K$)-/OP;A>KH+FX5[X1"0$/W0)9^F_(L"/B!$R.=!FT<5'%%_:4
MND/YKP9&[GGZE7:2Z8$3\U4Z-DE^42_4'60UY UU-G*% ,OX:[HD@[I,V-?+
MT>U]5LB=L+>[NZ2772%R.XM3G+@S_U .Y'8#SO+!<9;/!YSE@+,<KKS'[PML
M3"JV. -7PIEE9 F&=QZ;EG*Y^:9DV>3Z(&UX":?CQY\_17",<".I,9MMU-*U
MHC2=MF/L+C@T"L-U9*C3-*DZ_1)?&$]DA@L*/8PT*Q-X-J%9-P1)GG*0Y$?'
M-* -@JZ!] P*X^$C(W;]X=LT]:(H4VUOVQLVKI4'!0TALQ%W/4G$(<T*G#_I
MI\A_P!C1*&.*6M$2SZ6A =%]*>5:TA5TA&)2>/5:ZH]4^D@*4S6?,@JS&!I]
M\-,9]!#.Q?.?I>FA]$*?<3O=2K^N-(NC0(.,T&Q@E=F,B'#W\[^2GU<(O>%F
M,:E-A"KPP21Y6-UU+][(@AO,W$US4:]$,UQ@;77)I:AQ;HD83_33DZ*81<AP
M\XB.BFK)I V'Y.Z8(-/).PERV"A3[;HO<?P$R]5D%]HK@30\XR%Y&D=Q'L_B
M4?0^B3/2TO*?UPR>?R0=_&2N@M1C=(8G7=SGCS9Z6N$+W/<UL0 5M%1,3%,4
M(S=^!]G--YX7C6LC*"_6$=_VK6EYY_<*@8:MG3-IP"PS-](&9U\5%K9U=2*@
MV_@B.),7Y%UB(!(;D@1!NU#\<YB&D KCH&60V7;73MG_P9*^;G["AD$JT16^
MF/$(>CG6H'WFY;S[!QT?-":YY,N8F3,&@> )LISPJ(MY=UE[1P%CRXR0#3$O
M')%]PIU\_9=*A7V6\@)R>2='R&P)I8/'F_RL;1EA0>PYW1<9/.+,%GU[KQA'
M;Z6;.19 @J10UUZO)M1$D@[#@HX,?:(M[5X[)UT7R/:L]=F$394Y]H 71P^_
M76WTSF2:2-A@7GJ;UIE.02H4)Y*"(L57-JNZ%?I40JM6N,.DL W&P5=PP4;P
M2.7YY',@(@U*(D5;3*& YQP;K1@T(F$S5:W=^Z#=1%CZU]S;%SVFS1DS&',D
M*SF39T2VP]9[_C1AP+_16@BLO:XPQ>,;>_?K[OF)1)QOX>C0:V?&$*W![-M>
M:!2*Q:Q_:K6SP+FLE<0<L?F:5:#TS-#8HT0T'12206TF("G7454G*^^YJB#Q
M)&F(ZQ,Z^4%:Z3DO0W Q]1[TPJ9Y:9"JM-)%B>Z,JS*9^FU(G9>H&2RG7^V"
M!*IXL@[N:;V.72\G7T]K#S>$6>R]G>:;PS2P6%9AT443<X.L1)2;70A3I6+A
M&!Q4MD21N"KG);ID<7\W&!Y#6F$+9^=AE*"50\X2C>6A^A39B6CO8/7U#5W7
MJRQ>_XTV'WD\0:+3(TRGKO8_K1+E__%?)/2?E0,'*6Z(F3C<4?/ZW?B<^XZH
MB$^K9])J)M(GR03RV7[?8F$-R+)>F\[Q9DCFU'KOUL>9QF3&DEXD2SAN:T8@
M+0VWIQ#DJA'#3>BO8+4@XZQO\ =8+8QWEY'7V4=W3 :'91HIOI()63.0-L[3
M)8>T>I>6K7>)J^4-6>K00I[%Z!=9 E\.&R9+EZDF$TF5N"X1\.U^<FOR"0&S
M=-J%^QG.^5,\YT=;.>1OY6Z5>[4- X%G(%F_*0=IR'2_Q,TG]9#T/6PZQP],
MN.#TPSL7+5@)J$&")&@K63LYC9;@G9DD7 %CL8&"%\"+/KR3['CX^<@4W63B
MHO!#Y-'=<: TQU%759";UJNVAZ,FVU-_6O "X5S W8"/&XLRBX%_D!M;ZT \
MB&4GEJ;U5 X.A<-A0('12DH<%B!5W!M&IGXI(.K9Z$EF.BB2=N44LO5F.18O
M^H>+"'B_5?6(T67'O8*\X=U^D0]-IL@,8;FV_F _G[X7/"RH Y^1,63\3FC5
M'GVI4\L<07RW/$(1&Y"5OQ,<;#,WA=O<5L\#;EL*B(ZW[\8(I258KZ3B8>1>
MZ]TCWOQ1^:9QD-0LEVV/@A@ E'@6K\;1.]E&#\NQ-]J8%)>5V(M4\QF&SIDN
M68&<T6TP0=7\W(07I(^< <J"3]7XN1(FB4O\5M9'N>?9)-]<F.#.X]1^762)
M!AWB247:TTFP$F33J_@8L? '"16+X%HFM%,%;=5R'*!BKIGW!3!  H8U$XOG
M<SKKM>FMYPS8&,2QEO\WF#^9[;@4<VXEJF(Q8FJQI45+B.FA+HF=K[%'/,NE
MJKCGK:FM,54GSAZ1&AP.:_B@G9'P")8](@]VM,2V,UH"H?2]YLNO6:".93$)
ML)Z%821?S,9*HAT!A)MLGM*_!OLB0"D-?&GX!2LI+@E[*+GA^67]HN@S9E#?
MM--$VE@48M^9ZW2)^'#*=]614J6D7=C!%-DZ-^CEZB)M-C7@F4MCN6C ;TC'
M:<U^9E,A?+BI693$SOX=W=<'4^D;,970M_K<]JU^+%/IAL2,.3X"Y;\A;H#S
M:%KD6*]D$S1K[WS/<!@9IA1G3YDP@GIA^*J</EH8K6K]Q3;A-@6OG_SR4C;B
M?B$QC$[H=D,"2$+17C=PCN=PBW!AA%]+.@WTUW'*!;,V!6/B04EB [S6+[DH
M)&K$J%<F@5RB4LGBVN@%4O=!D]G;E<%SAWB')]#V])PP(<5'YDU1^D!<8W4R
M9)M)95$=4ET'1QMH_P8XVOW@:"\&.-H 1QOL@L>'H\&#\2D>;'$<K5<QI5O-
MW!IQ]'*WCR$\ML4A5^AJ=D4'/\N**T.2;OHOA=>>%W,0L_)00!8P)/7C\*:Z
M]M9C3C0:I$9,+$LW$ 1TE24C#:!P9'ZE'+[T.'>7_V,!9^Z&QV\\M_M2'05E
MB+"5:Y09&G\!E;SM'[@^L: 'F(OS@J(FO<^GZVFF\4QC"CB<NZUZN>"TQ2PZ
MB>GV_UR"HN =1V>TL2[O;8S-$>> ?.)"ZJ$==W3LI9O"#6I_61\$(TFIF1D<
M*)]RE0T<&:X'LF:.IITXSB!&AEI=E99&&7IU[\V#P["5)LPBTS,E?Y/]<E@"
M2#&+5R@>%E-!+UFW#[4!#>#W;<1 ^ZNS(A'X0$7_76E/88%3%!K'ZT+GD+'-
MJ%*()PU!<*9KF[^(^;2@=S"+N]_OS+/]_>":H]*V=7EPRPT_3>Y_Y;IZHN@=
M?L;6=5=PBJNZV7#S(P"8I5EL9NTAIZ>6 : V.5&B"\<%8+]4\;?&D7-)&(>&
M![(;\G-!?S<%>O!%9-C%7$-HKU__X/8:)KZ@M/XMOI!1F1IZL)T9T8 BO^!(
MSGV#DHAPLL;C]*W\E\L :TQ%-ETVHFP3Z8?12PS0JG ;XR:Q\TFPTIIU)CN,
M4B[8OEJTQ<BJJ(2*PLJL]:DD"09PEPG)=+_62^VIYF9 899 1]=7Q=V62WJ>
MZ&)WRY_)?3G^&ZUQJE&W+@0T/B3)AJBJH, _%E3YA-M2Q :%)P1A.Q(XZQDU
M KRV-P^6)Y,@/WV7/(,7S\1'5W"?*]J7(#O=_]HPN[3_;N%70ZG>%N\#AR=+
MN8\,+: #(9J !]1%%E^UT87AO4%N!@=,I3M9(5KT,JUPJ*<&]RG][,2RL-!*
M%[ADZA6@55P;+S&&Z-%&8G/!?6P\.J1\H'GY2ESB'H5&6?3U;+E="PKA^VMS
M$@HGU;(^[X:T<5N;(N#H-M-H3"79X99+D)FN,]'(F>$:D\:,,? 5R6@QXS!1
MU]UE\^ !!G(4+EOE*Y+G&S\>,0BQ("M>,V.BWF1*N2P7QY-MDQ[AYV*6+.31
M+16L#V/RTTGV/FF%_!3D2#O?HVGL$ST:0-#FT=8%7'Y6GMB"\4T7)Z@;"(Q*
MFL<*!-DY+?-X"E1#*RMG2_5GWA>B@-M6LUT6UQ% Y?U*6%M9,PHP42UVQE;A
MM4)TA2DA*+*=,](TQ!";X\N AI 7PV :;/H9)44V_^PCL09%O!T6(@MH$RNL
M,I[K*'"C-HRV27*1YMWTVU9^.C1[;1DXH7:/Z23[9GSW&%Q*:)HR:H@S;H7-
M#!421YB5L:<M+-IQOB&>GJ5O[*W*P(L--%[8D& XVGSL)$N6YEJ8%F3A8"5$
M]?GJID3"6J<@&J0'/VWMM:HI+Q,ZQCQ"HV-\M6@1@18KZ+IMLH'I;P-*P4W:
M5_'4"\4MKJ1M4='5:J=3+]N[0IDF:$--U4TD*L]H8\/4'H))'U4'?S9"8WJ:
MFGJFM1DZ/+,4MQP75QCQC*7_G8<4X*LE-;@/T]MJ;774V?'/YU9'\=(;[#NR
MZ--ZHS[1;[FF2VCXGBPGH5MZ'HZ/,Y%U%>ZJDF;ZCT7"BTN/@XP&:%X;G9$J
M$-[]P"S81%5,UCYRU:!5??_7+PSS037VIM-H"L.,#!U8S]:[]Z:6]#$ QKKQ
M>F1;EWB=P(,<VE=;SIJ[+K"SY"J3![+M8G-:7KMV\R)IH >7UV2HXCH$1?MK
M/-Q$WT9.^1/4B.9_.[7) [SC>R,48:+Y 9[,I7-:UG)#=OMTWAFMDI@KW[R
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M[[81:>-(*5;(S,29)Q$MWN94*B-(06OYKR;SO#3CXOJNPP.3Z("ZNQ_J[M6
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M8]/M$;@EN"@+TK$L#4&+ILX8,WL956)>N_%*&/NG[X[#]W@953H<[!![:D?
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M"8:+HU2?N!>8 !:-Q3%LL10D5R("+3TJ(%9"]>&[47@A6[I8](V4S*6M#^#
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M1JA&AN;J<V5,;L5+P11=;%ZG=7);YHD+!+!1&IG(8E&7O:CBW<QZG5&80DN
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M!775EF%1/4*F\Y"\_?Y=R$+"D;Z$XX>S:+DIZ[RAF(%_:E_/+]^MCP-$ZX<
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M+Q5AM</8*/>%-S=6W@_X$;IML84>,;<P8 0^*0+$B;'@;@@4$9*.;Z:0=]A
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M_+2JV] A9H5JE7$;L2[3*OWDJ_1MWN2G])+A4Z#?;BF'9ZNGDBP7BLC*"#W
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M6LL1<2\'#\!) :@L\T5^$9]^%W53+B^0KH^+(-+*.7C+\?E8EEO3,+'D3=#
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M[^G=+W/^T<MWNWX416?R5LF]*(#H#FX*G^5DPR>ZO D3]^DQ<8\G3-R$B9N
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MZF@R:YCS_#3W;,S)II!%KC,YRSY4]44E_%D<VJE5B^S<O,Z;I9T#:M3;8=Y
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ML[H&+&_>=R:];L2%L[C^G0<^YK1"8YK3J/2K>?L'V*UV_H!IA%*\@W%NP14
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M[T-%U:T1(2@S;#OT!]D+3 ]P_]RSP;,C0=<N\1EU%$(XN#5_<9IC4*SED:7
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M/1D!22;X=&22$98NE83 9$R?=@FD3?A.H(:W]R"^XD^', #\KP2Y4.B#,YR
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M,AD<K-^=>YCHXEEM:Z8A(V (;Z&$,2K2;O5<'ID-8?V')3PX6[T(K@CA],Q
MQ-;3(8E,!!-(6)+B2$JLVA$66R];U:NRKD#%S%TXR7'G*Y[J1]?C:WF#AR^X
MX,<_G'4MP$+=!(,?-OA$T_N"9OB\T R7P>A_<:XO\;7#"RWPA0?-GU@HXYN"
M:#\J2HY[!EEWG1AW,TZ?49%2WJ 16ZF'  7.C#)Y*KA=5+U0@"A7BI>BMO3+
M-%0N 91Y BC@IYLYFH^W>7Z,SL,ZU1Q3RGK2CP/\G<"&9&](/$P^:L%>B.R
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M5+GEI]!B(YG8\-(R1V^H,Z.TU!+E,ZZ<D;S3J]6AIC/: I0.]?T@]JTE0'E
MC&*"_KX/\3W'52PDX!*.?$)4]]GJ'QQ-%.T&E<X3+\.P >N^+4$<S0T,=NFT
M22&IW>BA?DM##M>!38Y9(TW-,8DB >$VG)^C:\XT,=,'%FZ>!=[TR>%-3Q=X
MTP)O6DZ]!^#FR8J26NQJ/N].]YYUZGBBKV95,#-+R]VY@_#,HBV&DU-8)B5
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MS"R_-_;[08_+\YV&!S&):M21S['17G.T(%S(?%YD)6:@D_J-BP>Y_!.BK9Q
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MG(>>/8>2L <QC[_$8+?IQ",V9Z;ELO5 ;1^7VY590J,A?^WXPM@\E /+=I[
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M[().T#$DZC=,N!<6@6.EFZ)2SI'GOO"/#Q :(34?09%F+>1Y14M%LN=A+$6
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M9,KZWB("[Y6/_0S_";_/5!3UF)ISV&G\"/^-% 0'[2%)C@:O_9P,"5@(.*1
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M90>YI@'W(<+<BUA1N;:JN*\S(XW,^"K_'/0A]>[AG8!-FH:13D3)4\H-7E,
MK2THM>.KN>C_OKV[B;V)7<%*7L+J?P^T&8ZH",*)U3F'*ID#V!AJ$$1-+LA/
M)/KYM>/A9N*'7@':U19.+U9)[&-'LO?!E[B2VJ'V&M1<V .5!8HO($$*<M/L
MMRWLLV*!UBM&];_^?[!<::'OT40)?:H8/L#2S(!J'_,+K&WP::9)K?^#PG;(
ME(X4<H7[GYVI3&>LUN UFMKC3WCFA[55QJT.V=K7_HE$2);DK\H.38I4.G%)
M5(9#7,!/"$?4]%A3$^#HB !OXS"*6= 0%)E@ 0XX6"<91=,PE;P>%6J7A%HW
ME]W\*S&CS+QLQPUY5ZRA(&,0P],PUTZM9$O)!:(>]:HZ!6%8MJ5?=]G,P-0<
MBZ&?4YIF(PT'RH$6E=G0L  $:B8QG(YH"F452=;)TY*1U YA7.2<,*'MF<,I
MYGP'V#LC6$4HZ<B9,TWOVC0=W:5I:L<V+K/&AL<E>9/=@6*/!EEP#T T#E*F
MXHXP$A*M#N363$$B9A,Z(7%,J3\R#VSB71UV+TO:?OW*)MV/KPLMIGXOC1B:
M(C0KF8L;;.CW$GFW8B?>EX>6$.+;CQ*XZA)CLXQ26=N&_384%PA*- 23OT:J
MFR"-7GBEX278 $OO;3C_CXI^>$_&P'O?P_\4<W_\E![A*M8<5GCC6.&7#BO\
M<+'"SDS87@_HB'5XN]])Q4HF^XGC_K3& !I91P6AQE*7>(.V;6*;%92T6,NH
MP Q&%L*1^ZFG%B&\G.*A2=H_R\+<@.]TDH/*MZCBQ=)H/;)OK3!Q=J/DAX6Z
MDBPLQ3B") :7)[0\<THFG?O1"F>AZ2I<[N*,:KZ"M.>UG05GFV\M28%8G6S-
M R, \EIN(! P,F^TE/9': W[Z;+O?=:<2]8= @:0H#MNF"?/*,AJZ!G-92)?
M;EM1I-A[DU 2<*A ]UFNN[RG@HK@5DMDD5\:$K6"KFP.(T911K,CH9*'4HG3
MY4D$ZY=>BKIWGDG@6^/V"$1C7GV6L(U/;_$GCV[E5#[N$PD)E#B"8E[.%T!.
MF00>:*[4^IX*@EN!99<+# TBJ@(#AGK<?,T[!D8"44NL3U%5VEA< B]1+Z06
MR+G*6OA@^$QT2Z5%A2*$:A!_D)'K3XLP>T"'/^%@ 4C\?Q?<?A5'_$445)"V
MB,8#HYNNVK&60^][WP2QOR:8X7+&,"RD\3N-\$=".%??9AL5T7@<W5-0Q^20
MEACQ4]DY<25_@F^93+!K=A3AOZFHF()W12RS?>6LK1ZUW8 N)XRW)8PY&,L=
M>C"@L1Z*1%-PKRT PACL, LB2B$A  C\LDX<&"U XP89%";]ZH4P2RQAE6#*
MZ 8)+8EVD\Q!/$,E*:801J8ABB5(I+HDZ5/$.Z#Y)JLQ#E5V&%+%L*O/]HX,
MQ];QE8 40&WDGN&(4 D/U7!Z"0W>/,<@B5F)8X=ML,-7 B-4CP,_6C ZI@Y^
M,,W"9]0^X#RAD2W%F%0(0^ZPIRX&NFB,M1X(*S-/J8$@CSKMZ6Y+.C4%MT#C
MG.-BPAB]:B511L-2*;F#%G),V<.@G"N,W)?0&&^I$>.V3H++HPH<DT:CQ]I=
M'"0*9O?LT@@LJT55LT2M!"+*&'!N?&UZ5/4DSX%LA0]=T<!:)W[*MEUVST&6
M7)-$<3=MLFEH:+I9@([:X?78&%<"G>>*+M#A_@E=17F70C%XM=)-%[4RM0/3
M>4T\ZRG#6:J#Z"59#[QE$)2!4I.LK -"Z*,)?<*U7Q'&(G4N)^P)P5:C:[1(
M%>CEU$P TJ!*^P[XWZ?6-5B,T6,3JARPH=*R(@\/<EF;]/E-3)??VUIW\PMC
M')0@U&<IMJXPKX6S:0[Z,GP%1$J$/+*A=VUY%+AGZSRK;5?ZWK\,OHG7X9UX
MG\UCOYK'UB_T/@/#HJ]I3?FV)RDTOS9X19JI+4UA^2S:5D;H*# B)WJS,:>8
MH?U4+#R9D%"V\W]\,*CO 7>(,_>DHDO-'(PJY@$(9))=YV84!.#1*X@),9.K
MXT2RC;[.QM*+HM=C,F[43=LIKJW:<:9QC@@FQ#]P^QM&VAEU5C=\M#^)570Z
M%:HEH1:/UHQN)$[!:9"'D)O>_GCRC [P9LH_#]D4XW;O ;:+G!918UPWY;V+
MUFG=".RW!3N_*S;9D9MH>B]%>@P6J+PUBH[C_K F.425(8XPD=J05ERC]\3L
MUU-\Y18QN7+X@3Z7"8]E#HIYP;(8FPT%##1O+$^_#_.7GD3-D\D9-5RDC0("
M3MM/RDZ4^AV1OC*E>#I]05H[G$KM+4CF5PWV?/O;'_.=9DTP6.3"9QJY_ J;
M<8*A;G^7+Q?J%1I!*WGY\$49"=X>.S^[2L^!<1%%*J^5#YEM?,0%!<]?\S7R
M(SX=;W2\^/$:]@#QB:^ 2L"SAZ5BX)JNXP+;=?]9+;74))EIXU;,RQJ\D?Y;
M6Z*=91_$%#I848.]R!!Q8OZURSS6K'^X-(*BG=S7CDT<FUR'3< =G'.)1BI^
M&%G3"+>(D@NR6D&FBZ7+CD-(TX9H.BBWE .UB-48U,97!@P*^ )N^N'C+UFO
M,G.[QC.5&:6D7O&AH@H,?).S*([,'9E?D\RU:6>2+^@\")79..$L+R8ZG$!D
M&BX4+L21GB.]ZY&>4M]E@!QWGZ?FC:6C:TR32FQ*NS8!]@B9\+P30OASBCF[
MJM%2AM4TDK>5XKEWC5Z)HWE'\]>B^1D-!6HC\C;[VU B^+L9SA.('.$YPKL6
MX96UEQE%928**]]Z6'  RT44$1FE7#)$I?Z9/9##&F'1A;[0Q&HGN5L'.C=<
MPQ+?7&_5QAZJF;TG:4>0R8X/'!_<P.B8-X8X:D?/BE?B!Z8=>H>=[-PP1Y:;
M($L]GZ=7Z:*.B,L9#]G!P=(9?LZS4C.@.?XK56P14^:'THW4X%9QG5J9\Q5H
M$(U],F%T$VG([;B\H^(=H.+ZJN,$7.U]).TBRO78\[+ZEP@:T_0]6Q9SR!E$
MZ;@0X,8T]>&_"P8MZ#"89)G4"G&-U)R,*:K6E/6OW60 5^VSZ6J?YP-7[>.J
M?9RF=)KRVIH2B,3"I2&XL&S8SFTO3(,EN[]YMLQRI:.C.E!D>]7F0[LM@[C@
M%$NUO'-G^^T 1>\C\;)CC>,_(VE*4X*&Q%\64%!+B-U1G:.Z:U$=H355)H/N
M$7V\5@(>0YT$SF8O&;<+=JCZ$X)#4K+?)-\KX4N$;JM)/0)$H^M:4_3- )/S
MNAT/;( 'RM2GBM,DBDSZJ%,"NZBEH[Q-2E\^@O-R8 H!<PD]U2X*2;::!F%H
MYNIY']*FB6*?6J;S)%,>$H1@7+7(N0E7F'WO2$9)WRJKC))J(:6$G 'VU%YW
M@;DEE/>."1P3;#JC1+-QV:;@IG$FDPD;,TM2@ITXPG.$=RW",YFB'A>R3O /
MC L$&%:?J"D5$0EF*J>*!$:HYBK".1-8M0'?8#/Q9=EHW.K(WO%+OAF9$JE-
MT^I'$!49SPZP;%V,,#A;U]'\1H4M:7!=.NA;G>LM\X!-B5ZUZX88%MS$PFH3
MN\(QLR8^-C)(CGX=_5Z%?J=%2J+5#[#)L:)P0>?L#; ;J"3,LF+KT%?L$V/A
MJ-KD-6$"=#LG9V\XVKTVA-#.WEM=N!E0J#T]D)7^6(9<5;!]<_\[C6)*EGZ$
M8AGH!\=AQ:K$'2[\I1Y"JE)%LRT<M3IJO9EUO-H\L&T *R66M2E]I'I'CHX<
MKQ>D#8JT@OP/DJPR^ALIC7KK%R!D@[)W3"E!??A7WO,B=8:Y83N:@"K>_V$:
MAF0X4S-H07#;@Q,H)!R2#:V[GH$'Q\,%D"XT(NOKNU.9R< M9G!&5:IP(B^[
MBFA,D[.8%2G=;8'-\8NYE.6<T\Q#7AH/ L_<F)]MM)8X :7,QYGIN">P?2#S
MV5%E<]>53'GTZB 3LP8 OV6:@?&2>#Z(:>H@15Q+Z16*PQD1Y&?-?ZI.KF#Z
M)](-YTS]S7*#VK.I9[GIK(4CBX%F?4QM]+ Y @W$^.7$(])DDZ(EYK;D[CK4
MJHS(6EZ"VS6PA5V+5TM[,"X"L]Z[;*N"C:."<$%&.772&.M))M+)2/>#:LG"
MU%[2+_NXH7=0[]1D5W+8N\L5';B[J,?J;R ]'*4'H)TI,M87-J(@FXW?[8*.
MT7Z-G%O'8&;)>JXETDJX2MDS2PY8Z5XBE^]!WR*J&/MA:B2G?9:BDTV@J594
MXB3,UIK7$+7;G;E6-.7RBCC2;= *X)BH45I1SA61/F189]'.*J1]+J>,IM?<
M]SX(4\GUV55(2^;*TBL3CA3][H3;(-8ZX&#C+MB3;!8N>LW>,(U^,&4/&*W(
M:3Z)F<!<GRM:?US@+ZQF0#J]5CF 7K4BP$)?]QKP:\=#V]#2]GPEFZ%4M25A
M1<P69F*3C>8KO1RKMYTT9;O _KS2M!.[JB'K\0 0%LY^9O4Q,XQLTV8W4Y/J
MY;[%86X3.*L#56^W9[KN8F<IGUTO5#$8%)BH<:[52'R6E<I)^BUZHE9LL[@:
M<F#;H3;ZK+R/+B$,:OWT2I4#&J_@/N?2[E'5]YYN9[$^;23?WM?]Y'"HE367
M#'X[YPI+!A59(FCJAU%6/DN_:,LCK)O[DA#'QFT](A9E6M'A2_#,I*36;8I,
M!"X>4M[8#[[C4ZA>7G>IJIE<(H2;C;TD;$,M3SM[23H!L@4!\E8%?I&9%HIQ
M 8>5%!F!(YH.8 OB5Y--F%ETCRW/4B[: 7=N$@8\ITPL=23C>5((&*[9PHPJ
M<51LFZ_&*"Z?P$WHD(K$*ZTVI.M[[W"0N;D!3GV2:QM][K0<XKP-:F:9&:3O
M&*DVCFO\B-XLM06 5-W5>N5AXT0M;ZG_.0[^ID%)<9<D,3Q6Y15;5.<&5!CA
M\;#P'A,\,6!C0$;,HSL! @4[$]>E:W]%;9.;9.1JFZY7VS1TM4VNMLEI[]MR
MH5<,!,6.J,V&U+^K]$REIKNTC-M9T9J#)O3H/+*QKQ$;P9,KVOK9JQ\2!0[\
M;"8S-"/NS%H)8]<;#Y<SZ9MMEGML!\@@(1-W0ZO:5F0XYU4;$]I=& U&QWVO
M;)@[)IN#1J@@X'].(^^QH7%6S!<6A!\U,7449XWO7:2)]G;%Y>'91C]F8$>Q
M)^6?@X5 *]36>!G/RA*P?5.>)%5QZ?O>5V4:3%<.X@/<(0QJ&0DB[9"^:2-C
MSE,,1Y),^"T$!VFB 2RGLJHO>E5RLM+$FGZSN85\ 4O2>^]CQ#_3"0YK:5_(
MT/Q21BRJ5/3>Q 1/]>R&VCN4J04]>5G>P[D/MR^ _A?X/BER[RP\)ZXCS#5W
M,%\V! ^PVL8DCS5OIODH2[[ >::4A[4%2[-]OG]9+V<3EZ!A]7E=O&GWI-HI
M>QVY1.*:$F%Z--F_"S]%SYVGDQWVO;<Z?8 F/@Y':H9ZVF(-6OATAE)ZTO
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M(*OU3MF/!AWOIW3C<1(7]*7T$9+;,$JUJ^40YJ/U^R/R%.YOQLSCLQP<<FN
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M,7P)6+;A,Q2021S,,'_:M,7_68U6=$OE"X*>/DC0DP0]W2KHZ9D$/4G0D\B
M]R\#+A#[UJF0UU@>>AZLXZ^5?8V3INI57XO54/VLHIT"BRN[_J*:6NJCV+S2
M%$V@L.-&4D63Q_*<CG2 8^#ZEK*](/=%R9<B5/121\EES)WI,O>(&Z$U[')N
MD5W&+<';2X5M<\Y$&+C:-QS'\2P-H](VUR\])GZ4)70'&*U-!P@;/QK\;(45
M9[W<2M2V,H0Q,?ZH8R4V;MSUT7&_N<RXKU#)S+U(^:"EHNW FC"6L(QI-6%>
MESVS"?J18?6W7#D>RD]'M6!UTSM.BV_<KJ\S3!V5!+S8P'C@4//.X;6&L0R#
MV6P3/N=0;G42=/EF5 ("=%OII!Y<>6-;=SBF?L-ZU E"2Z'1HG40-E 8'%+.
M=G!SG;S8TC92+NU9XA3YQ$DTQ@B7K,6G)^SJGB*2D&IJ0E12^52%TR%PLY*'
M_710;P@_)J=P'7 <$K^4L;N$M&')6 Q O07T1 VO G ';+75%A+VW"\ X*'*
MKY6*O=_]N"3HAM[@2 Y(/S/X==]LQ6OG*.VGY>FCJG*:9IYCV6%SN7$,&2%R
MU;S?.W&Q&]@7'4;KC70P!A8GZFE.NO?H;2Y(6X+OQO.;A+A=4&I*0N:,ND2@
ME=$(K3Q88F'0:@IIDPF7&[=F^"B#!*E-;S',8,MD\K@S);B)JRVWWA59V;(8
M=TL65QKSA,5]ET3,(D7^,(6Q>HM5,B,SZW!O^/\8/2HZ5HW<G=3MF,RY+"G.
M3,CK7G]02ESP7XSV8XS6(X,E"<69E50K(6-:$1P73BR;\;*B^5 [@%OY('.O
MUI^.>BX#0E?$$IX(/V?UT0]3'2R.)5$*I.,X0A@SCZZEE2=^&I H2^Z")!6X
MWISH9L.F'3<%<@^*3:R9U)D6HGIFZ2'F4=!C9(./R"UDG1T^]?/&'U30]RXH
M?% G@N!/=+5LA-><YR:.:YVO*+A,@2;R?$8U0QAR&K=KQ_PL5;!(\F9@L0BI
M1+!S 6*8N\VTZ4S+J>2/.M?"P1FVBI=8L:V,%6MD=/#5O0,&P9H1)FCR0._?
MHS .[QL&018:\O?6DT9Z/(I?.F!!LX@QRR4R&A>5+#CJ#Q8+9U9/01L71D^P
MBQ@G,]NHUBPX,W4*  RP1,%CY/259RB=T#RD^38'9F?:>8[!+DSLC#N5:*]E
M\8W7]3G .QC^$V-),RU3V CQ)V@K*H?@Z@=$(1VK5BDSX%CJ&UQ-?*FEE4NX
MH$M*P3/Y0>8$:X:T+RV%%;25*BOCK]"UZZ7:TH9!0S^CFD02T;3O'8-T7L2D
M,Y9O4/*DO47,WQM-5%!$)J*)@JU@ ^W2BO<8]XR;W<=FM3F&[,^]MSY2#OAN
M[_63/EZ>\:Z&VLJ&0DF>:PX$$I>VF5VG^&U,-3 T8ZF"K/?^?=]KV.I;\I><
MF[#A=83)E&9'>A#&K>$-WY F-=/U>=RKJ@$]9E%&%"UU,%@2]'L4*J<G-AM9
M 7,HFK(;!Q>6X1 B?:]$>H29M*,R?H-L%6DR2S(*=:&T%#1Z<+*&T>QST$TR
MSOGHM5X?*]<:0)E&^F44A4.$*@2'$^Y,0%XG"/>\651D%!:B"80Q@!M"T=.Y
M(Z1(L"J-*\E8+0:YTYATT*QDZF;I[#U7"Z'U4(!%51LA/:HS7(^T*Z./UTXN
MG$Y5@))R-"]-[VR@N?FL^]Y[/AO,Q\I7ORO/9!CK+"3]Z@@@+R$Z[#R;>4%"
MY \S.56YUNI!M/*9I4%"JQ,A@X+F8*T5?QA A"AL@"@<E^;=IO]E$5J29N78
M(^#<4[(*NL%73:B@RE*-^DUE\FR#(6H^B+GPR!I+GE=R1F)M]3I[*Z852R$H
MB8E:?TS4<XF)DI@H21S=HL113-M&;?N8_9S(N<Z N(Q,5LZ%4S[E]R*X9"L^
M_G*JBT)(#N*&#=)6_(13\3GDO2ST$V:C(LN,# $/1'.,7=-IW66P#@;PL$++
ME8QL&+9C'0ZS4B>IONV&^K J,?&O%.@/"C4,-?/9Q$5&Z#2@$"+2K_[H7_2]
M7X^/S_HLGGPA&1Z?=WVFF;HAOLAX@$T)!Y/.9>J4Z&*_]4HENKH ZQM8O <M
M9T[9I8PR)/#5>NEB\K/#T8(R4'#H%2P0D86*4'6\EU=BJ4S,8/, '6]O96FZ
M[D35ZQX'KJ5?NQ@<+Q2_326LR.>>-1(7RC."G53N=Q*"GI$2.< Y0#/!BZ,2
MR;&'J)2 WLG:$V;V)6GF1K[9FCOLT_"SA"L5E%+F*$Q'Q10EY)'2.3D.X#$<
M8;8'_6)B+E-3,>'/DOH,T0Q%(_II2@X.=J%U7R+??ZIT.)H?4+GL&0(JW""Y
MK'ECN@Q-'ROZ%ER8AA:(%16"$ MWV%3(S 4XWB4_H8'" A^7X&!T$\?=)NCD
M/R9AI.I1DVZQM9+;S2RW2]'ZD8W2<,C$"]W9: _Q0S)&ERZ6?=+#V@FB=JDM
MI%XZ9QHP.<K4-2>VQ%QI:98FW^;ELW^%SV0"+VQ,I44S(B@V]*1M1Z:F?-ZD
MLEWDW!92PG>F2997CNW/B@!@@;_%7WBPG?["!R'AW:;(Y[$V$9Z[[N.WCOOX
M5#,5$>8V:6K"W$TC'.B )>W>FG$1H)KA=4&L=5A-(+ EVZC>FK[]&X,'=$BF
M68HNH&2%!B-D1/@J6;)U-$29IMF2,HHQ$4YXF [)LR$0%!]1C1>?8T\*E"6Y
M4X(*;/&H:\SR@T<X)H)S' L29[-<MX28^G\F*9?9JG, LUJ.04HS,[Z--T/S
M,(JML%(_U<%W9IUVCSJ:J+OZ7VE#MV%IVD^'^Z#]CIR"/65F/?&@J<I?>Y/D
MFLN446VFLKH=U[&S+2/TN:'PZTIVFL WNUW03Q3N-/0C&BJ;*#AL$E+#N%-(
M+>5$%/QTW(@KS7E?X^0ZMA9R%G[Q?P#O09;*>5(=!JKBP*;CHY644NPU1X,U
M%W P\U(5*+=E733-B\0%D0K@!W\66:XQ(\0R^ C)?CKO6X4U6!X?;*FP?))D
ME7!1BO\Q:2C<UR/35M:*1\EDB<\KXSN9N:RFS<NUZ/JZ1@=K#IGEA2V:D2LJ
M;8G^8G3.7D[TN0:)8E3B:G5<!],>)+MZ*O7=C-S*T9LF!&FD:\48[.W5,(JD
M7FORUH0,P:;0R\,28Y<.I7#0B$\SY+J1.B&]T%"WS.LHD5]AD#??O2E6PG$#
M1@DR.['R?YXDH.=<XC'3WR ^<264.2?2C]!RJ0%5Y)JMEVLHQ.3I&Z).&$,
M6$N((V+,AH,DIZ#P4PU#<E5VI5CB/=F<KFL_#3);X@AEENDL2N8*;0,VSI6S
M,+KK]-AWRD07K1EQ-"Z[UA-C!G+"B1<'#+O.^##E<%UM9(@;=AV.6RXR(Q]1
MM]&.!5^,)DE4+G>:!"JR?-P<HJE,J>M>V! !?6;E3(9PC[BT*9"QGDW%(:'2
M[);\_A1@9+,'B>;B@%9H<W?9=BQUFQ;MNU]!/)OYP7(><DV]Z+!BR$*>J"U
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M6R=MQ# ^%O;@I ]L7XVS-D22UX@. M\"W[>%;S<1?!E8-1D5!(>N?(#&_!!
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M[_]+?Z!LC=^6A__;P8:/W$W<7V-W[<J!DSY@SOSERY9#OTK"X(ZG7I_OOGL
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M]<(Q8SMRA3&+@9@X"H&L_@?W6@%B7LXH#36 P5N]#F?$?H,:[ $MNT#44Y<
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M)3 /DF/E$/F(]2ETBHS], *H: 'I\K(H2@W/K6<RXJM,<JWQ*;H6'%DZ:I=
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M,!D?X)KYL*]Q:"#1=%U0TUF4S)5RMR']N3= .-Y7NJ*Z+5$;W=[,O7^N]?L
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M0KZ%?"])OM\P^:;X,/JK4N][ Q1=*+A8'1[8I=VG-5N(]0]+K)U2\2QRVP2
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M[_P*A+I[0HZ V5RTVCV.D&7WL]_KMAR6^M[WS0&210EM$&!CL:SWZU_6 A
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M4QWD/)L'5'"B@&O0-) RW7< I S@!?!:0W60\VP>4(&4 =>@:2!ENN\ 2!G
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MH2>&Z,DQ8L^-)M'0L[KUK)S^L9[>O8#6@5@;N -UU& @@7-MJ-I& N?I\=]
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M\3?]O]D@%C7RF<%9I>%!\9\353P_W?,/FG9/Z ?><.V=%ET"%N'']X!4MAX
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MGFJMR.A@P+/2:"G5OX=_)U$\EGF: -&# M'#VLL]G^@!-TW"S4^\P 6 >&"
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M &,(ZP9W14_YKB,='K*\RXAU[_0"\@MGY7!5 ,X**"#*#-"4.[]'*#W0NO2
MY)B%CB<J#YSAV/7=*.:]NK\SP#A@7%>F6&*%JP[ 6()HKGK)V:?OJJ=?GI(F
M'C,7S<!&M=>SU8L@-E0*Z%33=*IK]SKG4"FM35=],1(H#PP2>+7!RZL?.($#
M ,::IF>KUY: 5T.GBO7.]MEY&RJEM>D"K]94>6"0P*L/'9S  0!C3=.SU0MV
MP*NA4\5X]1F*R/4V7&#5FJH.S!%8M6F51W.@84#2SK.<&I3M6WNJF%RC>?AP
M].;L>/0"8  P.%RF G< G*9I>K9ZD1E<;.A40:=.[.XICJ[T-EUPLC55'A@D
M\&I4S&$PSQ:B'J(ZKFLL5O?:D_U7Q]T%L>-9P83QDCC_WF(_)LR/6 3 !F ?
M+IN$TP;>V30]0VT<=&KCVKB3BRY42FO3A4"(ILH#@P1>?>C@! X &&N:GJ$V
M#CJUH4Z=V1?(XM7<=(%7:ZH\,$C@U8<.3N  @+&FZ1EJXZ!3J(UKN.$"J]94
M=6".P*I-JXW#4D)2#].,@JO"X#9-SU"X!9W:4*<N[;,V!I;I;;K@ 6JJ/#!(
MX-4HW,*HL_P>;;&8RUCD%E?>=QG71W\0C)EU[ 51],(:A<$XK>D*?-1R <.U
M)9@U32PG_2&89O%+8V$$!%![Z5Z]@@J2K(4D'Z-P:1LXO35/'LJP-64HL\JC
M-^AY"'IH%.P 1S3 $=##&@J!(,E:2/(QZF] #Z$,H(>@APV '>"(!C@">EA#
M/0LD60M)/D89"<@A5 'D$.00!2)-6$I(J@$&$A9/ XL'-Z:&L@Q(LA:2?(QJ
M"#@R4 8X,J"'J'/ @!K4-.A>TW 3/[#0<E5E@QI,\\*V?!8#K8'6)I'$-5B?
ML=BA&]F##[^50@;@@U%.). $< (*8NCR@H( ,QHFU'4DRP,?0$$ )X 34! S
M( :8 <S02*CK2,@&/H"" $X )Z @VUY>Y/]"4DU97I!E6+>&"74=:;_ !Y!E
MP G@!!1DV\NK:XXI>FE/]VB+>:<<E+Z:.PNAVY[L/_OTHT^78U&L$E"!W<!N
MD^@A^![XGD9"O9/6V1#@V@3XY!PM;^"Q'[ " ,'!^LR#&& &,$,CH=Y)1VP(
M<(T"?-'M="'!8'X'K01 <3 _TR &F ',T$BH=]+L&@(,YJ<Y+(/Y&:4$0'$P
M/Z2T&[B4D%0#C"&L&ZR;1D*]DT[6$&#D)&@,R?!/#%( (#A8'ZH(T*EZ"XP%
M%0,U5@RH5M4 :@"UKERPQ/L>2::#1R[=5F<2+Z*!4>"YPV6HY*J7G'WZKGKZ
MY4EGXC%S,0Q\4WL]6[V*84.E@$XU3Z=PT*J_\:HO#@+U@4D"LS9X>?4#IWVQ
M ,PA!)YM7>%6+QEI!L6&<FUAXFVW<P+5TMJ6U4NTH428E ORW:#EU0^P$((S
M'-' N6LHUFD&YX9.U:938-JZ&RZ$M#55'9@CL&K3JH[F0,. \12H1J7]UIY'
M)M=H'CX<O3D[9G"Q 08'S%3@#H#3-$W/5J\U@XL-G4+FF''&"VZVMNH#DP1F
MC>(YC."9[*R@KFLL?O?:D_T7U-T%L>-90?S 0C6%QSI6M74O;,MG,= <:'ZX
M5!,^'4AIT_0,%7;0*;0):KCA0HQ$4]6!.0*K/G1P0@$0\*RQ"H?J.B@7JNL.
MQI:ANDYO)4)U'<@W $L#?@!$ ^=&=1UT2E.= M/6W7 AI*VIZL <@56;5EV'
MI82D'J89!5>%P6V:GJ'T"SJ%E*:&&R[X?YJJ#LP16#7*OC S;:,-J<9J8U%:
M7'G?Q5V?6&QY010!F@'-A\L;WWK.X)O5;9W2]89!0N@]YXKI'V>>OK..<]9%
M+L_V<WE^!K1I4]<%/6N*GO'$4[O=OH1R:6W8:@V(0(UV8*Z0>@HF?L" !8;0
M7&@#$Y]H4P(&/6N*GA$3/[?;Y^=0+JT-&YBXWFH$)@XF#L "0S@(: ,3GVA3
M& 8]:XJ>$1,_04!<;ZL&&JZW#H&&@X:C:LS\I82D'IQI!9%MKA&&PSC1II(,
M>M84/2.'\=+N]$ZA7%H;-OB,>JL1?$8P<52:8<#8[*ZI54?UV2R(H_I,3SP!
M7!\<OX1#UUPFBL#)!-5GT#-4GQVB84/@1&\U0N $3-P@P%IN>>&GU^VG%R!L
M4H*7"=I[U5+>!9S8*DYLB9D 5@ KH"3-65Y0$F!'0X5[]3H7X 0H"6 %L )*
M@I*$!BPE)%4SHXB3=7V-L?Y'%3A9G^H>2A*@9RA)."##AI-UO=4()^M@XBA)
M$"4)/0R_0?F!CL&^HS?_(QZ7#2V'-I2N9PV"\3CPK>C!"6E]@B2.8L?GRVE;
M?2=R!U(KZ%?6T/42^B9 ':!^N"QT7VZ?L:BG&TW%>0:*%*!3=>M4Y\0^;7?L
MS@G&!>MMO^J-HD"#8)5 K@U=7B3^F>&T(T,'M0BFXP02_P K3= %4!+MH0;8
M >S04+A1BZ 93H"2 %::H N@)*A%,&$I(:F:&44<EFMG@W$LH;V>'6K= 72J
M-ITZ:5_:EV<G]ME9%XJEM0'#:;FF*@2S!'9M6GW!'&@8D+2S4'RV*0!1>^!(
MKM$\?#AZ<W9\7UEL5$<)!Z9*3-4 91U:QDVG4R6L"0ME+8?EQ''H]I.8"[85
M!UFA1QP,OCT$'BUHI$H\+%1WP*2"[Z.HOT$N IIG+-*]0ZWX@)YMH7E&N]4Y
M@6YI;=?0.T-O+4+O#!!Q@P +:9?(CS)$N%$)HAE.(.T2L-($70 ET1YJ@!W
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M5G$]RI\4RR(_F'L/2[V(-=V4[(OY';7$EM*.B@W]?$O;^?(+NT\\A[X["+R
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M2*\93C@4  @.UF?Z\B*?5/-\TC[R20$&1O$-1.(0B=-0N.O(*P5.Z.^7 %8
M*Z D35E>75,=T2TVYT,B_1%P8LKRPL,!%6FH<"/]43.<@(<#6&F"+H"2: \U
MP Y@AX;"C?1'P+ IR[NG]$?")&?PC<4OC85F9-%H+]T[R8.$)-<OR<?=$XBQ
M&6XY-&&G8X>1%P5NB"1)#;%B#TF2 X !P, H#H)X'>)U&@HWDB0UPPD<(0)6
MFJ +H"0'F"2)A$B844"'YLL+;P:THZ'"C81(S7 "W@Q@I0FZ $JB/=0 .X =
M&@HW$B(!PZ8L+_I!FITS _C=3QXD!+@V >Z>7T!ZS7#"H0! <+ ^TY<7J8Z:
MISH.D>H(,#"*;R 2ATB<AL*-5$?-< *'@X"5)N@"*,D!ICJB'V3.AT3Z(^#$
ME.5=E;F46,HC6</@D=M%JS.)%Y&6*/#<X3+$9]5+SCY]5SW]\J';Q&,=8XD2
MHK;:Z]GJF9@;*@5T"CK5<)W2T7;5=Y@([8'V@%@;O+SZ@1-( &"L:7JV>CXQ
MB#5T"CH%:@!J !@#C#58SU;/=0<U@$X5=*ICMT_;4"FM31=";IHJ#PP2>#52
M]W4%B#VD[H^0N@\P.&"F H< G*9I>K9Z%0&<;.@4=,HTVP4O&]ICBO: 6!]@
M 0J*36H/>W  ^MHU%JM[[<F^ZP>/WMP%L>-9P82%3DQK9K$?$^9'+ )@ [ /
METW":P/O;)J>H<0'.K6A3IW;W<LSJ)36I@N!$$V5!P8)O/K0P0D< ##6-#U#
MA0]T:F.=NNAVNE J< -P ^"8R3@&;H 2'^A4G3K5L\_;YU IK4T78FZ:*@\,
M$GBU:24^6$I(ZF&:4;!5&-RFZ1GJ3Z!3FS9YZ-CM=@\ZI;7M@@NHJ?; (H%8
MH_X$ U *;OKV:E*,16X-IED=O?GH#X(QLXZ]((I>6*,P&*>E*8&/DA1@N+8$
M<Y.YFKG!W*0_!-,L?FDLC(  :B_=JQ>"0)*UD.1CU%]L Z>WYLE#&;:F#&56
M>?0&O=M #XV"G35P!/ !5JA/&0,$&#4#.DDPK%XSK1[8,\S?#O(T5LW4AR1K
M(<G'2)!'4 3*@* (Z"%2WYNQE)!4 PPD+)X&%@^.3 T)YY!D+23Y&'G>\&2@
M#?!DP _WG1^E9P8WLK5KIS3& K86V=HW\0,++5?E;*O) 2]LRV<QT!IH;1))
M1"X#G'B-A+J.%&W@@U%.). $< (*8NCR[I*"& L4&O@L!=R:E# %V+&MO&#@
M!&"X:3 ,Z@;JMI/CW,WS4H$/\ 0!)X 34)!M+R^2("&IIBPOR#*L6\.$NH[<
M1^ #R#+@!' ""K+]0VX]\^S0*37GT&PO]XZ#TE=S.UUW]W^:Q?NETN58%*LD
M/& WL-LD>@B^![ZGD5#OI#$J!+B^P2CVY2DZ?\!G/V 5 (:#]YD',4AU1*JC
MAL*-5$? L"G+"_<;U*UA0KV3%IP08'2@UAR6X8 ;I01 <3 _9)@:N)205 .,
M(:P;K)M&0KV3[IH08!P1:@W*\% ,4@%@.'@?TGK1/G,+G 4IO#6F\*K^F0!J
M +6N7+#$^QY)IH-'+MU69Q(OHH%1X+G#9:CDJI><??JN>OKE26?B,7,Q#'Q3
M>SU;/:UX0Z6 3C5/IW#4JK_QJB\. O6!20*S-GAY]0,GL # 6-/T;/6$;3!K
MZ!1T"M0 U  P!AAKL)ZM7DP :@"=0M#-...%H)NVZ@.3!&:-R@@#EQ*2>G!F
M%'P5!K=I>K9ZL09\0.@4?$#CC!=\0&W5!R8)S!JU)V@I/]E9/4K76/SNM2?[
MKT>Y"V+'LX+X@86JJ[QUK$I37MB6SV*@.=#\<*DF?#J0TJ;I&0I4H%/HL]%X
MTX4HB:;* X,$7GWHX 0. !AKFIZA/ 4ZA?-'< .SEA?< #@&;K#]W"34IT"G
MP T:;[P0==-6?6"2P*Q1GV+@4D)2#\Z,@J_"X#9-SU"? IU"WD7C31<\0$V5
M!P8)O!K5*9B,LM&&5&.UL2@MKKSO&I1/++:\((H S8#FP^6-;SUG\,WJMD[I
M>L,@(?2><\7TCS-/WUG'/>N2]M*-6?S26!#3C6J6P>_HS<^ -FW*3Z!G3=&S
MHS?'IW:O=PGETMJPU1H0@1KMP%R]@$:!B1\N8.V+(0#10,!WH'+[KE.!>AFN
M7LA%!4T 34 @H3& !KZP2/?V7;L"/6N*GAV].>[9YVUD,.EMV!"PTUN-$+ #
M$T==B_E+"4D].-,*+MM<(PR?<:)-K0OTK"EZ1C[CI=T^.8-R:6W8X#/JK4;P
M&<'$40F#.2VSNY;Z]:B.076,7I()N :_A$/7?":*P,D$U3'0,U3''*)A0^!$
M;S5"X 1,W"# 6FYYX:?7[:<7(&Q2@I<)V@_54H<"G  , X8!PX#AO:;W R>V
MBA-;<A !*X 54)*F+"_2L"&IIBRO?D%7G'(T-SR+T\0\MT<:-O0,:=@'8]AP
MFJBW&N$T$4P<:=@B#;N'@01(N=8QV'?TYG_$X[*AY="&TO6L03 >![X5/3@A
MK4^0Q%'L^'PY;:OO1.Y :@7]RAJZ7D+?!*@#U ^7A:+#H^$T%><92,R&3M4^
MO?'$/NF<VA?G:("FM_VJ-XH"#8)5 KDV='F1^&>&TXX,'>1? X8;N[R 8<!P
M0X4;^=>:X<26G$' "F %E*0IRXO\:TBJ*<NK7X 5AQD(Q39-SPXUUQHZ59M.
MG;0O[8OS2[MWB3QKO0T83@@U52&8);!KTW*JYT##@*2=A>*S30&(V@-'<HWF
MX</1F[/CA\H"BSK2UM$]/!<.02J[CG'3:?=P:\)"F;]N.7$<NOTDYH)MQ4&6
MW!X'@V\/@4<+&JFT=@L9[3"IX/LH9&Z0BX"& 8OI[&%FN4//MM PH-WJ(=-=
M;[N&?@%Z:Q'Z!8"(&P182+M$?I0APHWL=\"P*<L+& 8,-U2XD?VN&4YLR4$$
MK !60$F:LKS(?H>DFK*\^@5=<<C1W/ L#A/SW/XP,^*A9ULY3&QWH5M:VS4<
M)NJM13A,!!$W.E&^NOGXO\0//)N5_S:')23N7T=>$CTT!4$*D:<+NFF*(-WZ
M8D\9@/0J\NQ+MS]Z\QM)OY\N^,>8/CS(%CNW(J[X2]7;'[VY9<QR!H-@3%=Z
MHCTA38IIV>/ BA^8E?A.,G1Y+^Y)&%@C_B5K$/!'C>AW]*V^Z],/(]=W_('K
M>);KBP_%;N"W?ON5/]X;!7*__3ITOTMQR63DCR\?&BD<VZ^M4*MET?N1 M-_
MU0\QU_'2#2W'>W2>HA(W>"7HM6075N[9Z4HM<9W"ZPF0L(KK4?ZD6!;YP=Q[
M6.I%K.FF9%_,[Z@EMI1V5&SHYUO:SI=?V'WB.?3=0> %]")][E*0T'8OT@I-
MX$U->-.M0!?'>@C9Z#]'/]W=7+?;G:,WHAK'"D;6-;T8?3WZ[5='ZC?]Y[]^
M(P5/=T-6[]ST_V:#6-3SW) %"]TA>]E987N*_YRHHAYZ+G=(&WYY>=FFI^2/
MD$G!AU4NO\/=[P?><.V]%_5,BQ#E>T!*7 ^D3&]8,B]OZ0VJC,N\ESUZ\^GF
M[OVM=7=C_?7IZJ]W'^_>O[,^?[FQ?K_Y\N>5=7WSZ=W[3[?TN^N;/]]^_$0_
M_/[QT]6GZX]7?U@?/XD/W7V\^50R(M.-UK1LM[Z-OKQ<?Z?GZ_D6]KG3LMZQ
M:!"Z$V[V.3QPZO G"^]9.&_[!%K3L^FYB7IB=?=D>BS9FX7K&]^ZFH2N)VEZ
MS[:Z[>Z);5U]N;ZRK9LP^>;8UN]N&,5J:ZS;I&^+&K-;QCE=[M>6  HB=JZO
MB*#ZV]5]R-B8_LH)(CE@@P?QU_)EK3'_,;(>W?A!W$%<1SV#^*7XV>K3C<><
M=#ITL<#SGJS@D?/)*.E'[M!UPB<N3?P-6O*MY-<>7<^3MRC=@3_+S,NH.U;^
MC9Z WY[_+4K"[^YW_B]Z/3=^:O&_1^R?1+WMS/?MBLL]!HDWM$(V=LBW>O:E
MQ(.+'\0;#4A@Z)7<.+)\9RR* __]TT6WF[[VW0,C'Y<EY A&MO71'[3$GSNO
M^:VYH4T?D_9N'(F+\^=SN59&1;6<;B1)0$Q*&43\S8N?.>8_JR>XEI]0-WSQ
M:D:A/_WQ=6RL,I]<+,PRV)(^OWQ&H9T7$IC5HBK?O$M$__70C2:>0Z39]3WR
MP%[VO4 08ZDEB_]703)S2'ESLY14>6HPDI@P"5G!+/B!>+FC-R]'"3W^4%W%
M>G3"D!:>9-YSN)\8!PIL"H6M-CWHP$O$?8[=%_)!\C?GMTS\[RSBUY#?_T+_
M"-T!_\4MOX9U/&0CX6[VF1<\OI!*T^?CH7P>'LG#E=A$K@XA&S#W.[FXEI^,
M^R34).+I'*GUWC0JO*K0WN*;]AWN&]._^8.\_Z&T^@OWB5]#;;:O-OW]J(V2
MVEM:?=J6JU0J7>XQD8B-R/WA1D!(<@YR4R%F2E"4$ NY4M=ZN^A:MC+#_"'$
ML^4_*R[5L=OM=K6$6^JE,HVHDF<R@8Z7FI:B/%OD\9%/1QKY)&_SFFL4A'S[
M0C[8K9!+>&8_6#AP!;I)JD]",4E"DHB(35&U OZMXP*1D=^.4C)AN>,Q(V(4
M,^)*Q&"#D%_XNJ0@)$G)6(I:QIWF6 !:EX4/."/D2H?H,K'K)S+\R6T1_W*4
M.%,"&) $N#Y7!TZQ%+/TR<9$$>=USO#O)(HYK<HBJ#-FAS]WNI#\;0=,VJF1
M)QC<C(ZUX#MMWW>Z(CF2LAE.68<4C;DL9:'4%@6^3&4RR8\?R!2XT8QPNWZ>
MB LQ5TY%=GLE7Q'W%.A%N9>25XFHZ!*(CX4L4P:I'S81I>@;%TY:Q1%SXX2;
M,I)6^DHX=1XLSH-"NCQ)^&3BN0,1!IQ9J>SB3NI<0'9W(+M_B<V9^GUS'3W^
MVW[@A$/^D:%+U#@.PBD@"LF)G6_\/$BZC!Q*!P/FD=L9,_%U+GO*41P0X'*!
MS.N' O8"[,Z"[0/SA*23C4B(R)#@LO'$"YX8L[/'XE)(\A<E7LSA-W.8L]>K
M=%E;W$>>/K.*1N4>FE^$*U_G_'64/6TPH.>(+!)_+O7))."NNX)@_J(D(&'@
M\7LK!\2>L0N%E<^,A$,NPY"L!+V+8XV#H3LBU<G'R.0'^)4%\-#+5KT/N4ZA
MV$*ZY,AQ0WXPF["YKT-Z%@Q<X:%D@8_"S8O;FJX.;1;A!O.5I\;'[W)CE;-I
M-1T* A&VC0@?<Y9I%'CD+*=!KC1R)90IWW)*^@\_)FR@;$OPZ'.P#X,?[EA>
MJ=LZ^243\9S2#YP)/V!.S:52SU0*U,FR)91JE/!PF&II)9I<D79PV2"]DY9R
MQ6?J7;9Z6WDH&5+DNL$A<N+P[ MWX@A-4<:9AP>SH/<T,%J.4CS_$J<76WF)
MUC)+FL5'BEO=N[!/3]KV^>GE<H[CG$?@2T7(0 19+%(&1ZD8%H)"ULFY?=II
MV[V3];U5L6]JN10<YHA0"G6*O!<"-17AH2I')K\]E02P^O6J::!-K^V^F'?[
M&J)3%2_@$M.46U^+>,N'I->@]TCO-C_N4>#28HG_=(@FJ!.+3GID(;VQ.9&1
MTNXO$R,19I2H"-]^+N%2#7*"D7(9UY_0$Z8/H PA"4H2BV_X06QY[MA-E_?8
M49',@AWV64R:&SV0?'ED !E]+&,.)6*?+>N+'+-)70AY-%%4S)]/6VUY2S)^
MGF#PQ_T7^;.1T'&CBN]US\O?3!]%?FV^F"FBE<J9LNITAZ$X\^NG+T7:SN_X
M1$M.]^0O]2O].^)0D]"2'@_48SJ"OD@F0M O=S&+,8G#CW0!IVO23^@9R,F6
MEQ@Z3Q7*MR#/Z ORC)!GM%:>T3GRC XWSP@^2FT^2KEH>D8(%'5*W?HA=TT+
MOC YW:1TUL]G93LF",APCG61UBTS+S]W9NP@IVGJY$3$KB(BLJ&(!)0,W*S5
MENYYSL,28ALE8WH[VL](?&GJ(U=1S"*YG,?P<[2IZ,^)$,EX7 @JW!$/C%0(
M)SNGEX]6W6E;_)SIS32O*LW,;Q.*_I*A.D&DYTPB0M?TI_1/KX2!$$AO_20.
M@V:SRJV<08FMMM7C_\O5[5_KM /O397\N=;?U\0 0I)%6M#_''7GY/U+M:NH
M9E.OT-F@(J#BV@L+!4Y6+Q3H+E\HD)8%G+<N3W=:R%11A31;AG3]X2M_TBW#
M[>5.$ORV4'>T*+NOE,UW34B3J?;I:GE][_])W/C)NI91"/?_292Y%?#V9!U7
M^/LOK-_ZX:]O_N(AU.L*:*K*"9Q?_ 257;9TJGNQ\](IOCED .3FG&!SYFU.
MK]TZ7[&PK7Z$K0!88.L&.?+YTNC:X/9S&$B-^UVP18&DQU?\8%@D7D[C3/RG
M3RR6/USS0(GXK)/^)DW5%#EV(_G_T\#1GY+VOEB PFN/9^GT5N)CP(PY@'[2
MZK2!&<",YTMLA$N9JKK$@5OA7*J8,,\\7X5O'99*SJOZ-HE[@1C/WYS35F_%
MW0&.'B2._B*AD\-E&#VXDVV0HVY.4S&[;I,0%+J>[F)VW6SV2./;U2R\H:9D
MP/0UWZI;M'S/*WZS1@U[W7N_JZ,W^30R0 >@8X_0T6N=K;B^:T '>N;5CR$\
MP[?QX+$*3IROV-1UIYTCH0H[;!_YR[;<4[BB<$6U<D5GRE5@$< <X71J  ^Z
M6<FC-YT3^[3=L3LGH(T ";B70(O%(:K6"6 "WN7!:\(.O4L<?L+CU-[C_+A.
M<70A'>$VF9"C*CZ4;45)."+^D=R:GA*'.'ISW%F4F]ELM0"!-<;+W3!3:L.O
MSSYI=YUA89IVBS>00!R]Z9WV[+/+4[O3[@"X %S:>M[- "ZX0/4C&&_$!.C:
M(!JPH6[L>L@AE,CD. )B!H@9:!4SN MXL[YE.GK R( ?'XACOZ\IX,9"F6X6
M_>C-6?O,/N^=V^TVV#& ZU <^WT!%WR2+>0$\19FP*[#\>RA1?OU[.<.A>>_
M&@5!S*>,CTI[(]O"BKZN64=!*16%AZEL$?N28+K4(+9[(IN_YGO$\E$&[NA)
M_5+]BT]*HF5[Z0Y9<$^2^:#^K!;%>IE>*:\OA3ZSEYNUF?V:^P]?TSGK];6\
M8'HT#EA"ED4OT/GNN5"BG0[1ZDB[P(_:*\9H=2[J&:/U4380CZRS<[M[TK&[
MW=--^KDO:LLN%BJ=(N6J[J!IO_,A1DKM?@C'_/Z'?.!31?/YM/7M=&9K;H*
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M2IA*;4TE/&18[Z+U%@7W. >'-8<UKW:."T'TK$-*L?^#/[0^^M]YF^4PDF.
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M'T^_TO\*+IN(EH!C^C4]>6N>%GS0-+#1B$%FJU6[727Q0Q"*SN772L:%0P4
MVQF W<U@1[HGD?P];UO/W6G>H9![96MX9B4/ZG35RY3\.9OW!B>JQ=5<3$ED
MN6:;Q[PQ=K?]6MRZ]$7QI\[K%Q7##8$)VF""$$8I,P #X]C,?P<BV/&%_S9J
M508*>VL$"C,A$/_WG@].E?&\:ICA3>W]V(T]&6(+?&9]Y[,V>(1)3%V58"%G
MJY)K'L<\,A@E_;$;J["<([^AZ%4^@FBK[KA9F$S$S"1?RV8)ODZGWY!(/02/
M?+ZB;:4AR,IG'CM/?""(;26^&!P5T+7#1U>,"/@G<=78&Z)4MGHR7\R_=8@6
M#>50K&"6"8I(FVS'&_$X!O.>TL_1G\?B4?CJT+J, \X26>CFL+LR<"?^PI]6
MV@57KE#NW01]K/P^7_3\QJ0O(J<#I6\BFS33QHA?I[LCUD..TYJ[ZK*AKS,:
MN>%8CEG(;^+8^9LL6_R4ZZRL8LV\W3,O ^ ]H049'O.O\>U)?#5*R.9K%*;!
M:;D9@G[R**]CC1E+1PN5Y46V*BZ_M1H-0?L1R!=*8X?R??D#JJE'8FA37'7E
MEO4NFUV9?5XLC'P^QYIX"=U$O3/_.K]WYC3HMPB5N]HJ3IPK7'88B'&*HD,S
M^16B7[?<=OX@ EFC="S.O(OG!R?GQ-@I"(Q:/'Y5M6Q<F(4?1&\C+BUD5GTT
M-U0TR.\*7R<^M=KAA](\;F?Q"6 MZY;)G8ZFCSCU<*;^3][746NI"$\-V/VN
MPO<L\')QKT[WM75%&YE"<B6)J^%I7MXYWQB?&U+$_AJN;+T?C<0$[[S7^H?S
M*&3T\TJNM7HHQ2R%?7'*/GPJ=N*"8]'=+T/8!=-H,5_>#,;SSN5FWA]NC>W<
M3@^5)EF81LW9Y&:8T"47E.'4Q1?C\?S"J5R5/7Z&D92M=7HX.4S?V.;&G^XF
M)O"I1QDR6DU^!SGEQQV+1Q+_3\;BN0G,],1R<N:]L K.=\?UQ&OQ20-0"4-4
MX@^7".M0,(9M*<5'9=*_JZ!@0;"\Z?UM$JZ(B&\BT3@4R5A<'Y+),]*?G4_G
M-$"Z#:'#LW2>4EK!1WZH>; 5<DNW'/) IMM/THF415XTDCR=I1/5!?601*+P
M4D/65Q-G)1/V7*?O$K5+0[KRP#EVHY&340B.!+G%R.&'G-DYS4#(\YXJ^"@%
M=<I'[%!,(Q13NN6*YV2F9%LZ^F&1>@G&[@N3QL833MIME<0A1[]&^:$QI$12
MZ"6AMU.!YPP\%)<A4127$4*>,;BB79QY")D9DEXS;USE(0O9.=+HJ;_TK+7,
MY7_P*Z36><C?BKO>CB">TP&VRC^9O?Q4W;@VKN25$_LDZ>+'+PJ?1DF<A PJ
M:H:*_BZ&''UV7#GBZ%/@<]L2R2%'6U+4*VYNYH/]C)C+04R3]!G]XC,BN*YW
M</US!A^(K^\6'C[G!J^6(POVL[[1@QJ8ID[H8G*['EWZD5RF41(*\ZB87]G1
M*D:OLQ.]9,)_7ODXKMJ3)&,S&T@6-V,1I\MN]%#A$E8.X%-)O'($G1C%)V/V
M/!J<7E<0@, :N3]DN$T9/9G;.@D>Q9OF++J=-^?\RR(H+B;DB5"<.Q&#_FR5
MSNEX_$UXI(U/W0ZGM(G?3"5.#-+;>>Z8$%V%>'A\5*8'BW\+DA*,\F<&J?N<
M$8\I[<ES$<6*LE\50IKV-'R?8S[RO29)."!98?8<ZB]?)'+];_QZW+&6%[,%
MU^ 1+.E]R#P+Q6'N21KB?/Q]2ETJ:%4E35%7RF?JNGX5+9O2O8@-DE"Z..I&
M(@*MKI1F#D\=+7*1<M_AN2?9RJKO$!31@@2A?-$XQ[LR;0FFB_D8)-Y04+A8
M1,G5%//\AO&3E9;UE@V<)&+/Z?!48W,JR5DJ45;'(TF@Q96Z6;F"_,M*#@I2
M,T./*[\]2%]&I<>3; R^D1W'T&7D'M>>>WR"W&/=<H_W,'09'')3#EF0A6(A
MHQ0"81,D&<@-IR6S.B2"(ZP<V0$1)74L5<3#9QO3,H1!%F241O4;$X>^WQWQ
M>UIP>G@1D12,;NB.1OS(,B;S/I25+#S6*8_<N4EQ>%AQ7HR"FU\1\A%16Q$&
M$9:1#6AQHC25@M[N&XO5)."Y"63\6N682OY\5M __O7%\1I!EH;)0#Z3YWYC
MGOL0!,-I/"6SY/DOIA<5\>'RD4@:Q%41I/0?HIVAEX^*P]O:26IC=KS[OV2F
M 0&C3$[FM(D?^:HL'76<5A$)%_LCG('%03@A#IF$9P5](LTA8N1DD%YR:8VX
M'LIKR@0>>H))P$>.+Y')(_FHX_%?T",I?1:'![,N3X4'4Q%H%*G>2[YC%(BA
MW4%.Y\933>315#=2K^Z*K M' 45Z*EE,R\B?8*;94H+'J\!E+GH[X!Z#<+F8
MA(W,W4.\2>-XTZV0)QERO%+>F/3\$(3:%RPN$V;*SA"&5J<G D0I=&31HFFB
M>+XT>R;A+TKSDY86A99*IH$L[,9$+KTQ5NCXWZ)7,_OR]H^O8ZWWQ',C]<67
M9&F%07K%CSO(WN3_%C]-V*NA&PT6;N+)Q<*V#%O:Q_E=&2H.GOJ)Y[&XA-39
M,A[);+6SUU6'2=WS#;LXS#]DBICODFWG3* BNR'/L&=5'R(&$5M"Q'B8VQ$)
MN\(K7D3?BS65@B9S>LG/-3G,<9;:?[)$/:(,M!<OS4UA"1Y?<Y</D@O)74=R
M_TXR<*Q1:*>06R6O(%C;)UCIV>5 G,=)YSF?#BC###)Y4 2)ULACM!X?F#C]
M^4Y_]F-:04_$_5P_]PM$G':PV^]SI66C%8BU&\V>BG96.Y"O)%+6<3XA;<A;
MMXGXDA--XRTJUB)KQ(8+ BU3]TY$EUZDI2SB'%_%SH*LZ&$:9K*G]RK%V"Q9
MWR+J_M.$\70=2+)G5LE/,W"?>6MW9,LX&WTR\>)IF"N77IA_OCBXEPHD3#N'
M3UY!YKG\:-?.SH!]1LOBRF*E1U_&Q,5I^&7K\O*7])WC@ /T3$K#PN<5R;;J
M4%;D]TY3L:"V.U#;M7+)[07)Y,MK?N$0P<E2P!E/,>%*FU:Z9_7M*UU=KD\:
M91XP-I15:YD%JLS_GBNHLBY3A73M0B'MRN_<KRPML650G+2W&OM>NJ.76?,\
MA8-6WXE<TM,:<B\YPZ<]($U,KRT0H?BB<Y='YL_,6/?"YY6IY]0N"2<>[UC"
M"UM4KHW*X?W&%!E8 CP $#L B-ML'Y:7\C2_O92VQ7X,V$18X%)5-S9R%P1-
MKCX_8Y*F-RME$\=IM)<.SV,49*"HR*2V_&N<'TAK,9\HV3F]K045<T]Y_ P^
M5H/CB_2A14-*WB.)"^#TJLX@3IPLI7LYX.%>ATR2<T?3HK_G2_P@YSLZX^'L
MFI?&!WVZ1)H4PI-%V5A5\:L\45EBLKK(MJQU<%'6Z\2Y]A9YB>>/DDMH35%3
MI*>DB9N%S%6>Q>D[7G ?*%N:*_^!J.U U#X%:\&=:!27T"_\V'M:VOG!T;Z6
M1_MO>9G22]7Z!Z?\.JCE<Z?\@FYDQ_R5=67ME:+=A?8<Q2OU5KO2"M'SQ44I
MG.2(WQ=EM0Q%\4,8)/<R\+,@_)564PKV%,?D$\K&E37XG5>^SWYDK43$^]50
M2)@&"H_Y8ZLLC.OB^[V;OE_6',_*E>UF66B+5W Y[CK#*Y^Y:AH$62DH0"KP
MDE\[Y;\%RJHB!8*T+B3$:,>.DHC:2R).41*!D@APG>V71#P3SBC%M-]G$;GJ
MCHO<3,PWF]P!%3T95S&56<>Z0G"06U[5*)(>Q@OX\)FHY)PO<0<1IIXZ4:H8
M,+WOM )Q4:?$A5WP%O2&66X1;.O84;-CRJGLT[*.!4GM*GW\GI[:+^3*/W?7
M?OFN(N7^F1VF[PW2[XF/%T-B:?6V:I&>E6*F[=.G[<Y=F>]/6NNG^?SE*A:Y
MW7.3]9=^T:%Z8-Y=778)Y37.GNHHDM89V OH;KEZ.E_C7"B?GCYLL5-)62R/
M15KQ2(RK5>1K_IJ_$)W%9%=06=*N*A^FZU55 Y%_X&DE];2+2Z@DRN(%V>5*
M[4(% K^<//*-5UIXIA9>%O&F9?FK*HC,WA"54:*B7E5),>LXUP25H&EZH/VB
M5$E?F9R]]%N,4GG/G? _/@A9BBV/GB0FGRX[\J;[$/X*P%5QG"7>,&1CQZ55
MKX[\B.IF,;& 1(.YXJ6/K]*GLGY/_"&78G[4?L=G9"@A64W&^,H>OTTORC63
MA?=*J.CNG&5FB0]ID9Q<_WX2T3VB2 U@SOS#=#)!J?5I^GUW/&9#5]8!J:-9
M(>)Q[A72?J:!-YPN]BP&%S/!JFX@^XJ5KR_$/MM?P7)E7H4 B7O>=8"?/XMC
M3S4A+ W+JCOSQ[X/>'3.NEM.F(<!BZ8FS\DW(1.GG*4F9?,RG>8X?\DD=?74
M*B#JNX/PTN_9P!(AC6K(G1*1W]V0A/9/J4UYG61>Q!Y%URZAG0O;V[XH)Q@L
M%<F992:%B7L\*&D7$Y?\BDZ5]J)\IE605*K6;#I0EM_1V6B<@IUO.):>7N8L
M=;%3N6C17.J:OG@]%^=GK<1**Y*W5D_:$K^H*6O+2?-GZ1'Y;"5N38A''+N^
M&\O/\R-?6C.1WO5BN?RN<A?Z*MM6@=+$9/D?5%ET-H G>W,<A&A\$,)[86>]
MJNMO+3V[];T=;WT^R-STK5\IU*X$H$0Q/_J#7(TYW]3%^PEVLH.A1J6!:*JW
M6,$TY]J&9H7I0Z:\3'<\84/. **8NT&Q4O=HZH$*G59M-00UC@H#TM0=9ZLG
ML?TZ=N'\F.MG\I>?*X>N[GZ\G;:<_,;AMAL%EKW5S?L#)L^MEW(OITWU"H&;
M*64MI4[FKKI.;WGIK[(?;A0SM;.Y*$F?%B?Q%6-[YEB9^?Q,(7IV'^C91%,=
MM]Q!QY)%6;R<+DA"3CLY(8UCGO8DYA7U!9,O-^GI\Q"%XZ=A6>%?\4: OF3T
M(U5K\4,$AH@%QUG$@@>UX1>; 3W7_,O2+WG+96I;Z#)C)+-6.'**R6#Z'!6R
MS2-D;C2=]A,R)K\A]:;4\9![^/<DK:(&B#XZ)Y;SQ)QTVHNL8&Q9-[X8#L32
MFLB9');B;!T1,G!\G[O7N6E$"[JA9N6\*FROWH%KD.LG(L]0Q8-ER'(: 7##
M-$3FBJX_*[W7G8I^2'XPOST6[2]_A@6]NY!K:[S*OTUW;CK.Z[^= ?$/=WO-
M^9_ER)EQ)/7SGI_<(IKQDCY^YP\>3__PX$ZB;*;=<Q<1?'O,8^MR ED6!LXJ
M!PN!=1G>$[<5$9.J>Y>*EHK')$4\B]TXB=-9.8L>4_6LX@$BL3;%9W6&P20;
MP)8%[M/CU<*U><(4$8,Y9*7H04S;^.5[QPHFI,Z*TG!L)#;M6700.WY/D,:_
MMSRH\/?B2Y[>3<;K!%]+978:DN,Q-S_@.\J 1H:@T6U.O*Z$G_#:NE5]Y/Z4
M-E4F>^<G$>Z<I,PV:2Q @YJF*3SUG+?S&/(!G\*&1N($G/-^_EFAQ_D/BT,"
MP2-R;?3&N=>?>^^657+<)*#:I;D_J@YBP@$O'3JJ)A@R12_DL,:4?\P97WA7
MO$WFXJF5D@M5]0(S<)HVZ"90G::^#!Y<-B*WB0T2P7,"[L-(3X/Q)B%\$9_M
M>DUO0)=;/&[I(1 ?L-&/&LF7]2=?GB'Y$LF7(!S;3[Y,>[?>WX>,EQW:PLH)
M]B_.74?NB-BP.G&UCD_;T[/594<0I09QDH2\<Z[(ZY(_1C*5(,O^&>0F\BK3
M5\&LN=U+V77!(*H3;WF:DS(#7L1?,N6QB$%&LB26[O642R65!]&\N[0(^06$
MH"#"9A#AJ^%W<0;P*8AY/_(O,BE8)G-R&<P3Y<^BB[/C2:\J]>/IJV.5'[9]
MBJSX7\K['/7TOGQZT0!DF(2*4!;]:,9$12T?O!.*+F)I@IM*4ROVL)@)KQ4C
M:C*X[<LWYSI(&CUT4B:;L5A1<).YHO$J]Y@EO;3P@4KH>,HR8<+\ALG>6],*
M+G\HH^1JX&;^^ME3R*6;@QAS0OO\'>>[)=D*IU/M5U_@\OJNO8A H9V<1!<E
MQQ');^+,1GA\S'\06EH:0?#_V?O2YK:-;-'/;WY%E^?FE?R*9D@M7G-=)<MV
MK(FW*SF3>S^E0+ I(@8!!HMDWE__SM+=:( @1<FB3$HG-9-0)-#KV5?C2XX2
M<D<5W.G5=9P%;FAK-:YJYT%CS!1D]]"UBZWYGRS*8)E'5@ZKF%'/'TXEY<[9
M745)%@2,8^H-A0%^00@85U]8EVE6ZT&P1\]5)L!6#+6]G)<Q5NTWFZ<X5%52
M9&Y($6G^=%-#@)DV^!,A:6@>>]O6<;=AO2I]F;,LP5ZU43--HVANBELLM1GR
M[7R$B"@<&.D"J A17L^)E[?0$):&X-Y,D!S9+_XNT9'988F#FF+@5LU!@F:#
M-U28Z(.%[36:<]#V>1\F$H_665UW5B+%&[H8".NX;"$H$JJT8:%*I\Q[&25W
M>WM6-KZL38;$+MUZZ18OLO>ZM]:=?_.,GXQG+K W=P30#>?%KQDJI9,S(ET=
M"NZH*B6%41:6$U3:3.@&D":3:=Z6(V%RS*OJS.99I,R8BV,C+*QO@_S0H"I&
MS!')Q<I[08\JTDD_"MTTE$1K)W6*]$8:Z#"@8&_5/I5U4$EQ>ZG??*WZS<!2
M62SGA!O;VK1-&*-FCY@,$9E<+MV>3X3C>8E!G%O$++DR<#2 ''6"L\5@+H7U
M!;RO!=Z4I^52\KR4F)N&4---KIT?I!>)]K+BGAZX%$03*>BRX5A)JIBA;UDT
M@00.1_TMH)D19>HA%6HT88@CW[Y(03D<I&#YSGPRB#>;RW2VO]$>!F0!S9&_
MHM^+:[+ZZAI)\L;5QM^XY&60M>-TILW)*KAM%O#Y^-VOKJTQ&C]L5N%<>S(7
M<(&W.R)W'B>_V)KB9MEC#?J )Y*0^15F=C%8K,#PM0=.G<E<CUY6;5[ 5T*#
MA 9=AP8%!9?-';#B6[1PV]:T7(_E&I?V A.)%PU,SO_%_O]YFR>^CQC6&F(P
M6UAKP=(RWN_CQPOB!W?-$?R\]U.;KZ1&_9@,V-J/EMHLIJIB!KR- L)-/8PS
M8M&2TPJT&(*_*&%$R*60RU7(Y9*"!FS&==G;C72UQ;1"] <!QFL#8QY@[CVR
M.]UQ8F$'W6?%68"?IK$>XG])(!\QW+I2W,[?L8,%NI.ZV$YVHJKTC.^[>-@
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MU+J\FN6G\9'3$,Z3X*"_]RM>=G_O=0<+6DR8M.WG55)F!5"9QKX9.<6/#BN
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MB$2;<KPW(=*WDYT_:3)Z=&LIT/J-?33P%6Q]NP?[G=TG^T(AA$)LD=)T*84
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MH 7C\%D<'1H*B(P?*$>&457P UV+(;S:91G!P)8MQ5&.%T8B.<;,P#GS0$?
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MSF E\7?&N.P/A#+'"G.K-[_69JVDH+G!ZC_SB_C#QV@2Y6-U.@[&K(V_2N$
M?DO'MR.NF/IERX25#OR5Y"!_X!3P0%62X/%^9W]_U[YK;;#7N3.OTL#CSOY!
M;V[,&[K31HF!@R=[G2=/GEQC!^[F>:"EMV^+*[1H_%<_*V>Y]:P=-W,Z[5NQ
MD/I]FV@<E[,X =33A@#>R8F#,QA@]NP+RT\7WU^PZ!NR"3SA85YE,_3UP)X
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M>?OVQ64ZZ)UK,WQ]C7+5EL!;:[VBD=<;53WO(>WW*OL5JH5O@RB; (P6?I*
ME[UKDAMJZ'N*X?%YF$732A=OC:"O!]ESJ\X5)9QM1X2E$VZHL++M9[Y61>X:
M'<JWEC)M6F/R!R]W>S9[7RB'4(X?23GVNH^O>+[7H!R /" \ZN*1D) ;(R$H
M@MYYXG$5.O&D__UTHJ&$+]&ZZ2=!A0U A:9^\.#E3VO2@$7;%6UWH[3=ST$6
MG*5)2US%#2FXN_=&P16)=%..5W39;>*^H,MB2[%[H<H*C=B4XQ6M=4N)Q=/N
M@9 )45KO/2;<GM(J;EM19+=!D<7\ %,O#BNJW9 "NR<*K BGHL!N$+W9-$XL
M"JS0"%%@A5B( BL*K&#"!BJPHJR*LKI1RNJ'\#>=)$%+0_,;4UOW16T5D534
MU@VB/)O&?Q^\['?VG_4[C_<?"XT0&B%JJQ"+9<3BH-L7,B%JZ[W'A'6KK<_$
M[RJJ[/:HLC=016FHWK@"OI_\ KZO;0'?YZ++BIRZ?;JLG*6 ZI:H5'*6FR_6
MBZ!R?4&EIE%,&]+^M'A188!XH$1LO^O8\.#E^^ BT]AZX;=81\D-^9P.Q.<D
MPL\6RNGB<Q*?D]"(NWN\XG/:4F(A/J>M44X%$[;8YR2Y?J*\;I'R>IC]52;J
M\"S(+H)8&(3(D:)K;@!IV#2FR0UK^[NM-MW["L)"(;9?TQ0*<6,4XO\);=@Z
M]5+ _P89I/@\16V\+VKC43#1&=8Z+;,BUC?D\WPL/D^1,D4/W2!:LWELMK__
MK--_O"\40BB$Z*%"(40/%3U4P/_6]%!Q:8INNO&ZZ6D 4Q9C]5L9?PVR)!)^
M(+*B:),;0!TVD5F*5U,HA&B30B%$FQ1M4L!?O)JB.=YCS?&SAN'4NR"[N+$\
MSK[X-$7&%"UT@RC-YC'97>IW(3TOA$C<-454TM=NGEJ@]"AT8NN44D$%R>3<
M:@P4Y76SE=>C((O5ZV R^ K??!6OIXB2HF]N G'8-+8I7D^A$'=2V10*(5[/
M>ZQ@"OB+UW,C,4L4Q\U6''_+HKR($JU>!;&4 !*A4-3&32 -F\@516T4"B%J
MHU (41M%;13PE]1+424W!QTV0I4\C&.E70/"U&] .+0-"%4 _U,(RE.U\TQA
M8&V:Y ]O*-[VB<3;BI@JBNP&$:;-X].[V#2EUWG:EWA;(1)W2I>5(,.;IQ9/
M]KH'0B>V3J\55/BA\;;_H ^HS.*WWC7A5Z,T+9*TT*/&W=#&"(J4 08+&K7%
M\!/UHU./#F")RC\_M;O?Q74K;^'JKS(OHM',?&G^>JZB!([M4334Z1F Y]C\
M; Y%/;(C^5#_0E5 H)[Q[SX *8(@ """G\^G #V/3O19&0?9"Q6F<0J;&\0
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M[*TL$_G)HV1^F0OE 0X9_IP:'H+"93#5)0@LH!$<)V$7Y(3=OCJ"09!8P"6
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M>;U%'7&>>LNHOKF4&ZQH-%1O7"NF3WXKIM>V%=/S54MRW#GP%X8KLN'6GZ6
MZL;+ALVS%*O(YHDO N]"3H3S;=59"JAN/.<3JXA81;8.)42L$%J]9<<K8H6
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MCD(5A&%:)@4 &9Q7-NFH . 6@ '^UG&N+W V,V6'MN_F@BL:IYFA@WD0#6D
M/$C]#?96T'%XP^/+00F$$_[H"@[\,!S Z_J4E5\#!0]DP527113F-31XJP=9
M&60SAL;'!(S[%002F"]E:0"W.8-MGM;><R!;!]B=BS$P86"@21%$";IP$(CB
M( F*-)L!_\T",MC@^P%!4Y'R)ASS#091C, (/^ P45)JX_M)\7GX+M19@E\-
M=1YFT8 7]#$M# KW\=6B_<P>XJE\!D%!7\ WV3@M<WV4INCF820+DJOBV5ET
M#L=S)5PRR,.8Y,;K+K$ZO!>K@U@=KF5U>"Q6AWMO=>B+(G+'%)$_WKTY>:/^
MY]/OZNCPHWI[_/&U^O )OCG^^/;3R8?#+\>?/HJ2<FL"&BDB($?E):&QE3^B
M!.\-Q)PT 1DDTW^7459I+_C$FV\A+/7,""Z'\"J*!$;<SH8D8!4HM%]$Q;@#
MLD2L4:9*RB#NJ+]!LH--Q3-Z*2RSC"46%,1 #&P(=1Q.D^)H_L(4CDQK.7US
M!)H"+#]+$_0*QS/6$^QO$Q#HC%"G+O0@CPI<6U!4PE[-A@)K!5BBL)T+'<?X
MW\;2>*O52JJE=A:L-<KS$B4U/(?&6NO[@%75L/(87<EA&SY&]$L;"#YX>7%Q
MT<UUV#U+SPTRB;IS6]@4Q*!P3(*O"._G0103/QUEFI@J($UV1JH'J/#%.$O+
ML[&*BMS!Y<W=?P 4=Q"EW3"=&!CHT$R'A(3JA$$:E_(67C,*2&^!U> W-\1_
M.=R]V@C_Y48X,OC>^O[32Q; F@?@VI!) Q&L-+=J'&/8$$]W5&9)E(])_\GR
M$N ,'SX%U .$-(O=VPD>\D=XH7^P,[1_+21R0"K3-&&:$.1 '@=P$M,L"#$>
M!6^: (P-/ T\9QJ8EZ!E3E"%0_6.<!_F)HIQ$<$^[+)!WW+D& A#E]> "K4#
ME>$PTWD.3XX(F P!@?-A.,R0CN/"SC4)ZR61<C0) W%FHJJ_A7K*NP*M.1J9
ME8*Z#,B39K!*LAZ[MS!Z(;U,\^[4*!^IEWA!9MDYLILD+5"C+IB;K&::%L*U
M9L*%!A/&GCI',J:$K,'KZGA[N@!O]QW:PU6SB>4RPTV$?!JAHZ-*6+T!;0UB
M0E1$<'6'+*=8 P?]G -=U95IM>8&V6'K#YEL+GD4V31A,9D803P C28G*#9/
MGP*0Z)RW_$I])L1 $\LIOOX0ES70S.R'SC[$8X]!+M:5@?:#!CZ0==$ MN!\
M.ZJ^[J H@A#)&4A1^IL&--/?QM$@,O)1CK^5,7Y?V;"&:*XQ,ERLSY$&^K@9
M#-*R,-3"D@W_/'!YR^]JF&K&9C,G<+_8BH@U"4D72*4 K")K=6N%J8$.@Q*(
M1:@S&@[!P,F<"]Y!0I=.HJ+030'4P7%6QH;B961NP!'<L$A=A<C<(I')01^,
M(X1D !8?2@P0K6;?]>VP#H09X=8S"8TMD'(+D'(\4K.T5!=I&0]5''W53.__
M+G5> ,D)2Y;]1EDZX:L'^8=N!Q2T&,0R(/(:Q43W#MST1<:6:W@4_>% #J?C
M-*&1=43Z6FTD%,3)$I_&<7I!)F\K;CVW($!!I^W)30X8;,!QK]?%V'@#""&,
M&DQS_5S93R]<&&K/FFS5/WN]GGO%"T56GF6X4#WS'S2<_>,Z*5?]O?N;RMUX
M#-ZV(>+[3[M/=J\;(@[C/'CYC_D <4 ! IH_,3Q_:PG&!F1>S1L]#7]I.-5_
M&60_O^SW^D]ZZFA<9B!]GH!D,%9_!+...BU1C0+4I*?^ $(Q :D)!@,=]9-1
M1WN]W3[]?%@4@'%'5B]"@33319#-Z-<O.GZN=I[L]HP"^6R_]V@71Y;LJR4X
M=M-9+H1V]SW%9?%Q'P /NG:"%I.TA11M:XG9NGV\B]UQ_Y^]=VUN&]FNAC_G
M_ H49Y*RJR@-"5XDV0ZK:%D^5L4CZ9$TR9M/+@AHFC@& 0XNLI5?_^[=#8#@
M5;R!!,B52C*R1.+2W7OMM>^S46Q>7H2$&5VO:Y?$0OC3M%"^$&0F?HQLAU=Z
MM@6NQ08XI_(D@-=2@&<X8=\85+4_NTIF:GJSU1@A%K8YQVU6ZF26$FFW$B72
MKK7G>%7.+NJU\2C9*H51,%AR,EC8$V$H.R+C\Y&&:<:6R7AE3&]HL\>&'17L
MBE'A@>H2;E$V5&QU5YF@)^T<Z=503IV1CVG2CT37,(45^;'?^-F39A%=R(]=
M8U5YU: OGUA:RV8X'B&+'XN,%-,./;K#KJK:JW/-,A7P2ZTZ-^)4QG=SC?5O
M2A A FOE$LR0@(^&^T-MPD??^\&.SDO#<=Y)7'O(^C_YU]HC;9_VF=37.Q2L
M(75L^ZEC9T@=*W3JV$<CL,T3WI.3S[XQ6(56CJ6'75Q<($/LT#+$'N@\_=>7
MVZ^?KNZUN_O;N]N'[M<'[?9>^W1]?W7Y2#_<W/YY?2-3Q1ZTS[?WBB+H-;VE
M=6]N_N*BMJNKQ^N;?R*1;)<,F%9BBOIF:*_\FTJ-#VQ+YD<EM-1@1CGT H,C
M-3.I9AKL8\K*(4^YVRJ?3!N0&<R7R>9YW$=.DE3?-.984>=)3LF\=(\J_]I-
M6+-ZP$$4<)A2\X4I[&>5'S%1@I>X"(/$NF/6.O%6]/+VT)AN'A7$N4%J6U:E
MR?/^ORR?:)UJUVYJ?53']BEYO4"]G^D-AMG,M,D,P)56UQ??#3\U/^2N)S'U
MV8]@N_(!#/=ESJ6#(9TA6AXK+622IR3)J@E.M;OT8K$=\S3*E^'(/"R#G5D&
M<]WRW9!) IV$^6[U=3SWS 4-RZMJRG</[-])E9?<Y8\OCO$S4!F0M"=$!^V@
MSWK!L)YE0H;KA81Q(Q>$A/.Q])B??8]@A[Y%&#XD<94)'B/TI8^['NTU'Q4C
M;;''^,IW&5,'5>TIXFBQ3$\)A/C!EXP+P<8AG2Z07DE>78C7])"$4GE*XIP?
MOIC,BGR2.9UA#.#C%YFAM*HJ)RF#@Q* Z7+/-C\G'3<&8I_36]QD_>*,AT4J
MI[J*SE%9RX2W*CMQQFHS7L>:@>3,#B.Y_NJE&7<Y#VMB+S5#9EJJ%*>)%T@N
M)7-\IG*%5"IBDJ Q=K;H:G*YU;K0<V?OF+[JK+OEJ++G*Q. S-9 QB5(,7S'
ME@E_ACO+X\A.CA4\CHEU,.-*C=6NM)('DT% "AQ.S4Y.C6.$!W%FD'FV"S-6
M:1SQS+Q#U@BIK$72+\%<NW/ BEYV8&O4U,99QDL0,X J:]'1)]K93\A740S
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M^E3@-SU2^K28?S"TOL\$Y[?'V\M:K5[IR"P&S>MIETRXI&P;*FA+__-O'TC
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MYL-.Z-15IU9M^/7I)]7C)UU>>4>.J)<6J(JHM^&:!6@5VC;8$'26,"V 8P>
M8_"4;9@U?&#<8&%8MXVP+K@#N$/IEA?< =P!W"%W.5L]M_J8R,,9R /( \A#
MZ987Y"'!.;3G!(O(7>!6S^(N#XF 6.U*K%[I6GVQ02;1C0BO7=,;B*]>$*S8
ML/JBTKFH7NC( "J/LMU> A%D'1VN81T<V/(6#[!@'1P*M,$ZV$(F/ZP#B-5J
MUL$F90;K&P?U6@W&0=ET+8R#8HOZDL8!&F^CL.#0"@LV;%;_T7 ,UQ15[9,P
MQ>!)^(J*-NI53:_I.B:VP-(N>M4":GA+.29C(3?7:UER7EN)FU]Z@X'GRK$X
MLM(WN(W"(#1<WN64JM<R##V0GQHGZ?5*I]ZL-NNU:AT3<H"(I;*'T*GCP*#R
MU8E"1RH:V^A]#@$H@0"LP!5V,CVO7M.9'X 7@!> %P 6P0L*)AKH_GXD$K"8
M&-3W0 P:E8ZNMZJU=AWL .S@^-@!@IM(#\K]=&^C!3S.<)D4_>)4'EW/3=,O
MD=#3K'3JYXUJLZ9#Y>>ODW)+S8'X[SL_YVCE E2X\+ #1UF)V0,<9?,":&B8
M?Q0"L)@][\%-UJITFO5J^PRY-0=!F2'I19'T5U7=VDGP;73<1V)\>1+CKX,@
MXM1VS>N1NN.44%I.4E9:-*0?GT40TDHJ::%/W-._?=L,A:5)E:;]1:H+W?IA
MI"+O'0IZA=E5>F/]Q'4)/ Q;POH4^;0W:@252F(? 93\6/>GX5LW(KSM??;\
MGK##2*:P+YG=WJYT+NK56JV&&E2 75FM&I@IB$D7Z%!O(QE]2V/)S]&"%BUH
MH15+M[S0BF4'C8V<=XL_$O\*P:RY\K.-K.\M:> +:&!H8&C@TBTO-'#900,:
MN-QIV=M1P'H-"A@*N*@: OD8)1("*!3PW8-=7O!=P!/@:9_ITUOBNW7P7?#=
MHFH(\-T2"4$A% HZ=2,A^= 2DF4>W\F3$0B+$Y*'P@T,SKF#NH&]5Z(D8^AB
M$%(@Q,$N+SQ"Y0<-9.86-#-7U^&F@5:$5BS=\D(KEA\TH!6WGRZ+L[O_BM/F
M!NU;NM:_HB <T",$CUZ7MH>O;SAWAFU=NY?&T*:]E'XKZ;:ZS'BM[L7?D1T0
MRCT(_]DVA:I5O1>F]]V55_EOPXG$<LU@SBJ=]CGFH4*W0[<#'Z';#RH1MP&+
M%Q9O46$;B0FE$@*@/)AAV2 &F ',*-"A1L??LAS=A4Z?=NE]/N?P^8#=0MR7
MT%1;R(5%P]XA\F.+GA][(T+-\0(TW86%5]Q\V F=^I,.L_>3C[56'X:+5&S@
M.;:UZ=>GGU2/GW1YY1TYHEY:H"JBWH9K%J!5:-M@0]!9PK0 CAT CL%3MF'6
M\(%Q@X5AW2;"NN .X ZE6UYP!W '<(?<Y6SUW.IC(@\MD >0!Y"'TBTOR$."
M<R3*AOE#A"=@$6 1Q<GB+@^)@%CM2JS>+*X>:VV0270CPFO7] ;BJQ<$V;2?
M0.[UR:+\GXM*IU5M-"Z0 50:9;N]!"+(>AZR/IEM4>F\A3:%=7"\@ 7KX%"@
M#=;!%C+Y81U K%:S#C8I,]C .*C78!R43=?"."BVJ"]I'*#Q-@H+#JVP8*..
M]I7.1\,Q7%-4M4_"%(,GX2LJVJA7-;VF-S 6!9;V<54M?'1(-VOZ:8N^:WD1
MJ8$YWT[^./6D]=68OUY:_"L:"]@8#!<'$\;LA=I*YL*E-QAX[D/HF3]D\7%P
M&X5!:+B\RZGU4,L8#8'\U+C=4*]TZLUJJU:OUIN-&<9#BM0 :8#TT9EH>>+V
M F,.Z)V?#;<AFO\.\EJTL@^0J]**YR[)U8K.6,FK^G07X0=7?T=V^+)4EY:Z
MSH0*1 I$"D0*1.IPD!I$:@>"N^\:&#"ITLIGSDSJ; ],JE'IZ'JK>M8\ YT"
MG0*=*@"=4DD&!Y-BL/7(ZD+,GJ90OX/\%*9T9_?<!\*T@3!MS'=>*?(YSXWP
M+)',UZQTZN?GQ'SJ8#YE4\U;S>H#1FQ7X:*Z!V;#$6,3O+ E]_+ "[N+</9^
MJX3@A"VM>.;KA*WOP0?;JG0:9]6:7H,A4C9EOUU#!!A1%(Q(^/5<O:T*DOXA
M?^"*(_YM9D_I.;_UG"CH?[ND9Q7^H>SLF&UY3C=-=E9?>V=-N4"SM[8Q>;M*
MYT$(S3!-;T [\T(+J-UX(:U1Z&F?;==P3=MP:(V,4,A)4O'6??C#LI_5=J5[
M='__Y2!W91O2MFA/$G'C4#HC+_U?_$/(X#QQ0\UP?AHOP01&OI/T*2[ SCP[
M1^?E=<9>3Z*[-KX>DY^4RZ(^F'D/+7X1;;0IZ1>S.ZK)+:4=E1MZ]T#;>7(O
MOD>.0=\U/<>C%WEBRD@'\/-)*SE5,^3]((_4=@1]JB(N/5+ZM)A_,+2^SVSI
MM\?;RUJM7NG(PD[-ZVF7S->D;!L*FNE__NT#"7@*]T9@FR>\)R?$I 9BA3V1
M^IGNS?3L4:\1,Y-W23?Z2T'[\TJUM>[VRI+81:#Q[)&<;@<U1C?<6$=W[R^[
MVL?KV[LOW?L_NU7M^N;R],.3_T?GX;'[>/7GU<WC@W;[6;OL/GS1/G^]_9^'
M<77^0>KMUVN)[PS?.!EM>YI&1##R[RFL$48XQC @>$E^2O[T3B*DA#KMMUJM
MEGXEPU.U#**&6BW^#Q_&?ZQ3\]Q<NN;Y\LL<ZT&M_0S3.7[L^@9VQ8QK+S0W
MFJN;&_KRYD:\#>VSTXO-JZ07>G>PV 7SD_.&D+@R*/QGY0R;,V]S&K73L[.=
M6M[+F,V7>=/WBYUHXAQLY:7T\%QC^;)O^+=T9'S;$AF]MY1*_E]A^(%V1?>T
MIML2O&I-0]651]6]"JQ'OM8%UG0-;,[<S6F>UG=;' !-5TY-MTJ+'< AX+"<
MF],Z;:RX.X##8X5#'?P>_/Y0UWI>;D69%!T\7-OT<$%3[4]3K5&(0GL9]KTH
M,%PK>)N'IAHUFGTRS!_??2]RK7?:;Y>75U>?/[\_UN:SVPFKS$R9*F8@]DB:
MSUX:05_K.70UK>=[ \T;"M\(.1V',Q>?[= 6P;MC27M>>,.",H.RKWF>::/+
M+2]0:=NH-$9!AA.Y0D-,6YG=S::](G@ *'(%BIP2Q($KP!40E1*N.8@* .5@
M 66%PUT_O=C8PP:@ %$!KLS&%4S(*J*3DG?O6T%K1I:0"7W_,E'IW(A0<[P@
M@#8%$R^3@EV^]IOO+S^*^9+Y-W-!/\@MNP]QGC$:N=[&:.32FFP0V/T/.#Y:
MN0"1+3SL $<*B2,@LEMV+^,\%XC(;C(,91,B>U;I7%0O]#:(+(@L!'9U(HL$
M:L0FCB<VT;7^%06A;#7(+0A]03K,M.F(NW'0@G_+/YN<,!T%PM)H[^9D2X/-
MP2HLCPY'0D"Q$P*.]7 C([I@0(%$(^#*(<@".$GAH0;8 >PHXN%&\G/!@ *<
MY*!P!<G/A74PEG>H36/_,E'I?!)#7YBVP2$H:%2P\3(IV37"=J4%BZ)%Z\#"
M=Y[LC+.[O>EM>:4X9]5IU[6Z X_.U/_)?RXWJ_&\TJFWD!M2/M,,@@HE V):
M_N4%,05F'-JASCEY&6=W-\1TDY3EC8GI!3=A!S$%,86@YAXK0((RX@<EB1]D
M%0D/3U;GR.N=1('0:*E%J"3E/WX[U^OU]^H?:7XR2!H,NS*I:.C<8NK<8SW4
MB#B4Y>SF%G&X373I5V$$XIYO>=O[*Q!=UKU9[7SU:RC<0"QE[>FU2N<"):JP
M]B"]T#Q@JR6%&& &,*-(AQIAB+*<W=S"$/FPU3JQU2;8*M@JI!=U#(A#'&,<
MXJ%O^'01@SN@F-Z E0=J&F"SE4[10G,64W,>ZZ%&A*$L9S>W"(-4K1]9LUYF
M%.MREIE>Z;3/$4B :08AA8(!*2TIQ  S@!E%.M0())3E[.862-B$E#8JG58+
MI!2D%$*:?[P M0R((90DAL#3/+2>[PTTRPZ&7F X7-$P]+E<(7S1#-?2Q-^1
M/>1V[*!C,.'*I)"A88NI88_U4&\CKK#\"3X)A'EB_SKIVQ;MUCM-_9=.K!F>
MM&KO-9SPS4_XN5[7<<1A2!VU$ #F00W+!C' #&!&D0XUO/ME.;NY>??_:=@N
M>V-NW0?#$;>]N]@'<^?0\ETE/IC5)J_JS4H'G37!52&[^3O]X>"'@[^ #OY+
MNL-W,3$AE2O/ NG<=VSCR78P+15&7/ET+R8(%7N"T+$>;DQ++1A0Y$32@2O
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M;.F&]!0O['D.P19O]"Y/<&N#$]S,GN"/7[\-"GUV'>)LZHLG0R^0^_S.B\+
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MQ=PRSTF6I6=CRVJZLZ*O1IB=B':K8)7@2_Y5L6([*1LAV/074'2O=T+<-U$
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M9OS@@T-[A1W/HFSV/)A5\(U>.K&?X 6RJ5WP_OEW+77>-=Y+,T\DRX1H63<
MX=YSY$WAQ]_P$9T$QW-2K.]8B@[NXF%M&XPGY#C/66Y?C.?B1><),C\%DZ];
MZN3M$7A6-&#=ZU[W?WX^,?36AY!= 30X.! !;[V!P_OL[(E;,8(%N^SW'8L'
MBV1-#G@+#AC%PP8FNEUX"MB>XT4^X#X(*@)@1FN$'\$Q6P-V#\*-$K$ZT8K2
MS&1O6J;-AX#UV?U<$X1E1G[PS,P(:0#[PX-O!J$#UN_W6<]WX7/;K[(OL8?B
MQ3^:WO/RX3DADR3N'D<6C\!M3NA@W_%,#UR?BY?9#JIJ6;R !2IQQ\&G]GF
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M1+?57V\]<WW=Z\VUZMD7:F"[PZQ%Y[)0,$.A[WG<'<LZ">1& 0PW /N!M[&
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M. ACD#)R%%FN%O,Q-#$<Z',9YH;<=<LRF(Y L41\(?Y-*$O^UJ!C Z 8(O6
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M(&]'Q'XG5HY:FS.H-!F2+7Z73=9)"C-)[8]DZ_:[?"[=YD_8*2T_>B^694?
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M^3\QZG/TR-V'1+F&,.$#&-JYO K,$2X0XP116&YLPV E?.4,S $AP0M'^"R
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MZ+FU!S_96:73K%=;#9TQ\R%@9F;UHK#ZB[J."^YOAF<Y+;[8:?&4_'E"75Y
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M422BYC!$66AW>V&([<!5O=(Q6@Q7&:XR^_(Y!@Y$'&,@XKYO!O 0$RN@6/X
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ML)(318+L1Z38K@],@G_8#C!FY >A]@:_5]3V 7].214NHV<#G\+V$L.8R)W
MTWWAA<Z3T +QY, &P95A!-)#/ (AFRXL@ >4^$3,%P*]!U$R@/%EZE9@10M(
M*IG&SR$P&<QAZ*.MBW.8_6!XF!D!,UEN#**G2JSDQY'F.C!A)<: 9DSK[QC$
MC_P;I,HC2J^N(F.<2]?QE(P)-!_E2:XL@I)O?5,F/SMAPEHHW&!9U'#GC3$
MZ:I$H@/L/B5UY%.3JV26=55-"MXP>U; >KCX$P4<Z$GT!"TT75CXG4F+YFNE
M18.EQ9:EQ6U.6C2J&@B,9A74E^OZSU(_K\;.DDOA_R/8->T+\1,82%T0-,&P
M-@]02-K4GOOPWE$. WL^S;?2.?&?/2QJ3QA6"^-NZ-B.LKJ(!1-].'ZGG-3U
M&,U,#DI=<*U]_GR9&QIQ$YY*2++\-.57W^I TY'26VZ#^(>I/1" $3$@FU B
MM;EKF#R7;LR-[1* W@Q'']&)+2SU@'<QD$S@.AA7ZZBAJ&G VI'SB8 >PC<@
MF\= B!21?75- F%J3OC5G? S_I.<$E%7I8\8[] P#L(8C6=XR7/?L?HPVX$/
M="@E[\ $516$57H!+"VZ,1.0&,)[PI[*# 59_6P"/0:)5D'UY$@YB!(0F"?"
MNC?TV^1PJM,D G+6=:5ZD)B,A#TN!:VVE,-JRS(* +6"(A:-R&(6/>"C: )Q
M\.0\X6W9757CEYHIMXJ?G"",U%!SE&-.*%2P^S4?U@*@<58C5!>\5:U,]A7S
MEV &0]$%,[Y??VU0YT>C!<MR+W"O\^LBG^.#3="GB<#@)J<G5R-'H"FN1BY,
M9@,:WD$ONRVU-EA KM,;$>#O"1L7&=5STI,#Z'GHAZC&<;;PS1R9T0/22T1&
MD&<<XDH:'*"#)[*40G(U"=I%);G;9V],Y9=22T,-XCT8SAU83Z"\00+;A/+T
M\[-VE08DSUZM  1>I\:;K,9W8-&G]FLOCJB^E\Q7)^0'?_9AK,!IMA@*>J3F
M>XJS+$37"4-E!#CRBD HJG6%YOF('6.0'E8"K3.7DVCHI@_KQ<C4L/<A>D9!
MD=: &NEZ),5(WD[\;?OP-,^/2+^Z8+)GG@HX-P*)/WH!0[\(ATU/*H_Q[1DA
MB#/]#7B7%(\ 'K6=,/3=.$4EK@/V@9W*8AQU3<-8.X;7)</I]<4LM)*/]S.]
M#T3<A6?_X<.D+GU8\L![C9MWR6?E/+VG3?;T[BCN\!K?;KJE1)RTJ9K:U;7]
MNZN27M;%NSK9LD[8@9?7%D^4!830*C+)70*2&8$@R#+T.(@>0F%,$P)[P@8U
M0$>?D*H"2O.(?$!CY(]] BA!S@C3(=\"R!PD4\T3*/(1M $<H@YD^-RL]J&O
M$#AE$+NI>?&@*_%YX(0_$"&%ON60GT-Z/<$207>NAI%6,[ DX,RX@C."/U5K
MED"]]D.,X#<; *,-\"RL3CF1T1E+?I7I*<)/8_<RK-630]D5RC.CGN4)B?YP
M+4!IV )@8(0?I(U!3MZDB.;T^BSMTLZXA)3-@VI21/02K1?X \TU20%+\]01
M67_4\J?EKF\^Y8_+]9R?PC[YCPC\J9-R$DR&Z;&W^J)C;\#EGC]UZBTB7WU
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M^[X01'^AE-07&#A;KJBO,;.H+TRU-\>MJEYY$N([DZJ1"U=R7-P1-Q[6'_4
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M[V(;&H)"29W(5%&F6O$%!C3F\#VS(K/BZUFQ,<F*&5)5Y/UJBFTL2[$,Y[<
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M4?.9R++0[N($KCV#TQ:#4P:GS*Q\)K+P01<^$[GY,Y$7EA4/8M>,A UJ:!B
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M]L@#$0X%_/TDW%$-F6^R>R)RUH)NCC M 2,8P@BB(!:3([\3E&?UU00=^Q
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M=LD)Y022W%,MP/*U\\;BA(NK)[=6+S@]>Z_^K=;S0B[<1S6Z.RRL+(M3+UF
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MF3RSJ@WC((Q-CQ2:3(RA>0Q,U&@](5V H7#=JG0T1D "I"+I7]5D-_MHH ;
MLX+<LO@HRBP\?1\F+2)#U%WP7C/ 9+7XI8"QWC"R,.?ZYM-*,;U+>BGIRZ^
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M>YPCI=Y(3Y+]Y5$ PWK/,38PA3Q-7")$->="XJ3$C+$R4TX2Y!-'?VH:D<]
M)?QB(&"=-O>[H(/.[W2D:TXE$OJ<QO7&9223\X7U>JW^SS1/A9*:AJ%XIR6?
MDI_>4<H+Y:YHO];K]?26S-'#Y 0L9L9$6EW]@\D%O[RF7HH^'NU+Q5$NQTE-
ML\XESCA0K,:MKW%6=,:S%QXA;:Y^A-18_@BIVH?V:>V\M78YE86G;WFQ"U;X
M S<$^!5EW/]46KPY\S:G4:^=[K:&P3)'H2^WG9!YOA,0OH7SS\OD8^;[D*T'
MPA_&$.:+A#!7"&$H0RH/8_)H?#/EP5JL[?:C[5Z4K<>UUO-*:I1)"1K'MFDK
M;$ZSIM=9";(2G*,$T4!?H-Y8.+)P+-NFK; YK5ICQ=UAX7A<PK&Q#>S/I8&W
MY\OBTL ;+PW\Q]PR50=?NF_A"PNJ_<N^YMLLE[BA)JJEE2=%JV+(57@7TK=1
M:YQOL8TJD_'&BG&N4F1QQ>8Q*DPL[-E1Y"L9V%ZJB8S1JG1TO7E47618A1=:
MQ+$*+[GL8Q6^D+X;M?:*\H-5>"%5N%X0%=X&%=YNO*3"N;DS^Z$.S0]UEZM&
M)YZ$ZP_ET0E6-XQ6BXE6UXP7%;BS<VEE6?&0!S=T7M_QM297%(VI%A8U-^K<
M?HK;3S%Z*-WR,GI@],#HH8 ^M_*@!V:G_;H!VP5Q V+GJ.EZ4)OW G*&&GL&
M"^\9?, ^":P!&<@?+Y#?>\/LL@FNHB$/CJ,7VB.X3?YBSMHGIB]*;M[9\>7F
M,:(IS/(RHF&YRXCFF+R4C&A*RUDO>2F+ FG.\0SMBY!&>BFI@R75MIO3NH:+
M8.Z@Q/>J!2]G$PG5R[X=RHY.V#'>B4;D85ZCLN5KWY2CR$:]TJ%;-)_NT:)Q
MT=\P+;F_2G%+69,[5X.?NBYHCH?'U;$#\-"%=\@RWF:HZEV&KZTLN8$%7UA"
MLDPE([F&UNHUM%J@\-M<,?)X*T:>\N;,VYQFNZ:O&-];$Y)S/9@RU8-1"E:[
MC:,P,CW<@6V4A]%9K^U)KW%M2"Y_5O9-6V%SN#8DJ[L%Z@XLTR[8MGZ/2B(K
MY<?%(EE:'M"FL;1D:;D9:?EO^DO5C[\ :H,1TN>KG]@+/I1_? T<2[ ,/4 9
M>EP;M<*&<)%=EINOD9MW8F Z'OI8\*]+N!/CA['ITM\/(AC0AS>.)WES),P@
M?,OU>G=U&F(SD00^#;'QTQ")F](?NRDEAU"$4G\O__@H+('V72Z>V3CX!)V%
M+RPHO"C[FF\US9O+I14Q VEAH_47,I#F=,L, M-[I)Z='T93'9 OGLW 5H(O
M$YZ1+JQE&[,W]$JGK;>KI_533L/>4)[P$HF^"P ]_<35/;F\ .." USS7<L=
M%B1\&*"@],VXMQQDO KN-?:%>A.7FO*F)0$(BCW,Q,)QB&WG9R%BH])IUD[;
M1P6'&0H46E2N'D]@4;E743GS3(G>.,V)1RQX^<Z. _3BSQ2-W9=%8W=ET9C&
M&#+A!8PL&'DIV*AT3FN-UJPC&UQSG6,)!QQ+^ -X#(-S#-59O;,EQ.K]=555
M=AT!(*D57GM@U#B^_4?@A^'2,8 F6#Q&M5ZO'Y7-PR$ 9O1C#P$P!BC,\K*W
MGV7&H1$U ]NRT.[RP';#+OYP)5R[03<_]@6NM;GX(*O[LGKT)]>2D[W907L,
M#MI$ZK.+EN5UF9#L\K;8XE9X.K?"XU9X175!L)>S5$S '@M6HV43,2PS6&84
MB:B+A T-QH:,#5DOEFUY"^H.9-<?N_X*Y?K[Y <] 8+%UDP/R-#T+.&Z[ AD
M25U@L#?A$2E=HVW@6=/Z(:*3THJNXB',-\5-)%4B-@Y$>.'95S^'3D!/2&/P
M2Z>5MBL=W:B>M0V.L6_(&[*F+-BIOY9%QV[.E+]E\,/@YW@%UC;QT"+1QA*-
M/<IL9&S,R&!V*G\J[[J&Q0:3>T_!]#BM-5ML>3!.8G<^9_>RB[\T+O[E2CE_
MF>Y+RP"2Y?N1X'/N8W^H^+Q5SBK29Y5.N]FJGC'B+I'K;*.^?I80[!!C/%/6
MY2V><-HFQ&$QQM6O]\UR;$(P9^W A#B$@MSG6)"[P<7I&!N5U9?/)]/V77N[
M7IK*V\UZI=.NG1E<>9M#/T<:^A$2+"#=<NB'X4"AEI?MMM+(M,(BE *&?J[&
M(G>UT$]3KW1:=:/:TKF!:'F\JQSZ*:B$X- /XYEC%TX<^BFY&./0#YL0S%G[
M-B%V&_K)&!";"_TT92]6G2T+QD8<^F&I6/#0SWP9."_TH^?%70-#/ZT=-%WE
MDT <#BI-..A)A$G%+_%S*"S\(_+I:PX/,60HU/)RQZN2088"QF+^1?).GI$G
M:??@XU>O/IW3;*K3.7J;#:D->4&Y]4')V9\#+8P,RB=B6&9P5*.@],W(MQQD
M7-P0PLNX=X.1A18?*F$PP)$%%I:EB"RL+!J7##BT5SAK\@M]P(A"AZ['I7"\
MV%1B,_\$NMAVGN1M*:'>W?UY*+2Y<8>X!7LN@L6D":*CCB("_E,?(I0B$R_4
M3/?9'(43SH=WE+:A"G9FQ@Y/JM%S<M,C,:3EUV/R2EH6>6%F'IJ:B#;>E/3&
M[(YJM*6PH[2A7^]A.T_NQ&/LFG"OY;L^3*2+J2K8]^/$.%=@.R/UX)W?>VX<
M]@^2IL[@I0E5&9L+LZ0T94R^#(2=J?4#%&V_/MQ>UNMZI4,11,WO:2A'X/;P
M]]],$@^_P/_^ZW?@\&0W -4YU@GNR0F J8%884\J1[NOC<WMJ]$<1\\:$X/3
M)^S76:(FKVH5/0">\](-]ET[W9 YJZ96J N7PNT7=Y<7VH?KVZ]_7MQ]N:AJ
MUS>7M=^[P6^=F]N'JWOMX5;[='US<7-Y??%9NW^X>+CZ<G7S<$]7O/GFF;&-
MG7[>_OX;CJ*3L/]B?2S "!C"^*(@%I-*^-JS_(%X,']^=$++]<,X$$AJ'US?
M^C%6BT:S?M: J:?D^&=!T]=HD5]+A!3E3ZCP_'P&&3[YH"?6D2_ZU/O6)J@W
MYV^E!2&W4H.]%.$$?; 8V;P8&4N$:T\S+0O6#%MO:<].U-?^N+CX6M5,M$\D
M& 3XX?K/=$'8]V/7UKI"&P;^DV,+6W-ZFA-I3J@-8#R:Z_P0[DB+8!I@-4;X
M(0*, GOK!_@<5#TH1BC$?_H^U&S1$T& &0#F3PWV640A# ,NQ+OA/3!9%S;%
MKN5O,[N.ZT0CS!M05\"K!-S@B1X,Q\=!+7BX+0"TVQK,#>]ZA+MD[6J\L1=C
M36N\A72E0Z19TS[& M^&U\>P%$$$>!P&,+X!5@1>+?7K4#TOI"R'_*.J-!.M
M;X8P=%QZS(6 A\"P9BVY^0@O"B.:CR>B67.2:P.3=QWQ!"2.E^*O/5@C[U$;
M^J$S'@R\+K;DGX%P395\@9</J6IWJ(5Q]R\P2O!K\1-8QY-#HH6#'0GC$.<.
M]\5#'"F*=7QR%=<F(+*LTNRD<%"LNKC-*0AHSU>,#\,"CGP2:(N-EUJ.,)E)
M#:7#+!MEL391)@Y856#B?;^/NZ'X.P8NN7I"*)0JCQ.K_ATO_:XO5D!S'Y#7
M/F>L?8JI??2Z4C_CC=3D3L[30;Q[A=F]+R)X%(%V\1@(\K@P;-@A;+CUM(MA
MX+@J+T^FY4G%5M74S@!3*7 WXZMKTD6W0?S#K&IDO2"4\)2"G=S;JC:,@S"&
M%42E]-QWK#X@E($/RLU'I:,-S @>$5;IJ1G]A0]#WUS84[$14"G/IO,$MX#B
MQE]!SMM*.X(J19T#$,CQY@QC:AY2*P[P:XF><  T#S4W^I(^)]H'53)H1Q/F
MX;N E?QGU*4PZ-"Q'3,8)1!)0@><0!P\.4]X&Z"%H3]&*OCC0(X(KX6'#LT@
M2GX)341=Z#Z$$48!$(A<@^J"AZJ)?W("0!QJLG-G.&-3Z8(9WZ\_=5A^1\*M
M\:QKVL-XEP"!.NC2L"6@^3L&RNZ-"$3TA(VKH/"71!(Q3#H$OJ;AP#<Y:>3Y
MQ"V5SDD/MGZ,2_S@T?2<_\BUBN%5 8V&L' HJ]SWM'M!RZQ8HWWVQE1:1HW]
M&JG=@^'< 5@#,*)=^C:Y9/3SLW:5!C2@:=18ENU"EMWGQ06\:2"1<D8TJ*V;
M%@AF)*6("\@4I5%OBG^J6DH PK3Z^+LWA]@R+1(2FJ-0)SXV$2$#D'JP]P R
MM3= SVZ,5\O+PCG7.6$8DW2EL?4 SWL6WI21"6 5A%;@= 7:=F!YO$W1/BP"
M1L>037T73;M42-,&2@/,$B!2@8\\RF/$88P'1/R<&X]ENE8L+0]GVOR<M<[:
M&_P6C3^C_O[JI]7',(MVAWQ(7^KOW\(R=S>VS,,@,;+DB*<78]55N <&$Z$<
MWP?M:_K\>[F3)MFJ9%2I]5<K5WW5:EFO7PF? E0X(1"1L-"AF$52R8+ \\#4
M@D&/U&@SNM>T_P)+D09D+J%<B>7>V*\?^;.)X;<H-_2%?#%G5\T7GC1%T&O/
M&H..^&3UWIKV+54M4AK-%3^ P4"_*5*<$$)3*O^#;P:VG#60D7#11R'=)GCT
M0MV)8 %,(=2U)@8LQU/&W<AV<=&Z<:1\//"#.M0!H\E4^ZIFVKIKM*6*O++\
M?!NGD.6+[XF1IF*D"6?3JEHPI&#A+B3@)'D_JF4'V&0(*R;9&Y8-)AQ(YQ1-
M&X]1 2.I4*MFREAKNI"P@C11^2!<G+&@F'X_?$ X<F.&MOFW8NPO9O #2.#S
MYTOMC9JN_#V='.(3*99!=KQ9Y+_0&V<SX].V.4H<$V;7\=_)9/+;WB6LH;#B
M"![\("?RT1Q-9,V<5CI3I],4!UKCV^47R6K ^T* 8_0YZ@,I:F\:ZA[ZR1F
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MK.U\>(XKN, %7.>S?Q$SZU(6.=#6QN'V-IMZ7Q$9+BS_@>L<%VV1GP5:!PQ
M2PNHD)!Z*7$"8?6;/_8U15=P7S2=GLVTB$B)7C.T8QFX[R-U+R=_20(+VG.>
M1Y5+P: ZQR)5J;$DU9J%I&8O 6;JB(*R.7N_1K6>(7<OIAZ0,$PHW](K1F=,
M@L*&GY3R+UPG!-!,Z.2D:%E,K]-D9Z!6*06NE9]T"^D)U5@1#Y*/[:<TC##S
MTK1 0\YCNJW!_^#<%R*FVI#+%;C=V=XX[+0[G>G>>5:&4\&*,L_&;ZP.SM>B
MYC@_3U%[L2D9.Y 46\<':VDU00EAT<1'G8<B4Q#@_\F,2_:'FR;Y!9!\$^%%
M7WG!GF-"70OE++E\)0>[KC;8M;O.7)R#7=_FO7*P*P>[<K!KK8)=MQ8.=NUQ
ML.L+![M2GFQ+%422'ENLN43E'-"B:R1B$]4Y<?U!43ZN] BWT4>JG(QD";G#
M!&QC)U'&O7DZ;>R 4MA:5*1'^_[(O<6*".0!D68A5 [N,""'?!%!I(HWA?<+
MB_=4*\%.ELM519@R3TPG^^=PZ*.&Y<ME&#W7<FVAV>A/RLXT-2[*-2F*!SMW
M=59P%L4IX*$IQ[0[H#"D0)[S!$X!XR FN94 GU6VLQOT0VE+Z$,3]LL3RA"J
M^;?9R@NZY!%7\X.K^O=P_;1*$XP4XXR#R,NDLP@MQW"3@-JA3.=,K5V[Y!^2
M=YV;"$NWL<A^=3D7M&Y(=QLVVE Q9;09Z:0K[6:0;[YX[BTGL$PR,MHLD#"3
MKY,@U!@;YM7:45@[^^BQU(0J>*#L!'=4 -<ZJA+H*"]'OF"Y+@KXO853N)'
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M%U@.#,EP3E7\_J+MH7?V-@Z[E9[':JQR%$XM6N%.^Y$M2<R.DY"BI'7X\V'
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MJ&.C-<U<[)T?!  J_\E\-,,93(NC,=WWC_956W+)+U$DF>[G.+MQC@9CP%/
M?U=":"Q)1DSJ/&X'=J"#0(D( ?0B?X]H5*1(B'&:P]#?L33SN0&R+>2V I'<
MZ0O,50*@R6*"RG3DIC3(XIO#AFJP.?B,[ZG-#LQN8;K3T  R(?W3YP:R.%0S
M8 PLK:0O%'J)@::K$NM O?$$YF3%-*U< #X--+XT.WXUS$B;,=M42U5D$ :'
M<0 K,I #\$'8*;ZG41MOR(L22<6(:- RX8)0N@"<14&!)O2 XL,0@%.)E'I(
M0H/!DLP;E4X9YH=O/="JAED PH[<&&X=SR'%TV<J\#I4H,*&3G=?88L?N;<(
M>")$5@WH+ $5'XP'.9/!O[-0<73@_C[P]\2Y$2'0>[S[,I#_"%$8D&3D*B41
M&)#^"% >V+&1HG-2\^^CHPLC3+,.7G<=_)L/!'4P%33$:/ZR:%Y YRJ<'X$2
M6,3M2 GW9#4I,S?4+EP0*'$X+T)A$7CCW<@'TH]57%'<E>*W"]K%C5)#0=H-
M;Y*68K2PM_^Z6H25G9>(\B3P98+<2?VDI5)+X9"W C-E<4*B:%\9[=K.T>QT
MD59A R-W@/S;<Y,1\Y[7U51)1@ !!;@,JJR8^H/B$C(+^ &-#  :L4C@ND&&
M(%UK<(L0#)"%5VJK>.KI212GPRCP(Z6HW,3NF&044J,HKPA!+76'0SW*L;:U
M:&!R (;#D%175&<(U*46(^TQ*+[YE*.DN)MDG);P>XO[F>!:2#V%61!<<\W'
M.9;V'WHQ%]QHL47AV[;@H/72C0'3\"U[[V((LY!TJ97NAY1JI:Q.:=-TR+G@
MK1"5)&_8@9JG<G& [QG6<T:<GM+^X-P&\(X2);4>+8UUP]B%0\M(*&T[)[=
MBOQAI3Q=L66*$\A%3#B!%"F4T6*!-(F0I$UX-RX2 G7.N,OR.<,B,B'U':TC
M*Q7DM+ T99I(9AHFZ!D%F5,V"@V*N \X=@E,J=#STV;$7Q/AR=_A<K.B20]_
M#!.!TP=N6C#C(0S@K!A $8?2HEB\5+P;2W'7\%K8;TM)[(0+!'4(X'X_(ZA@
MZOGBU/,(N2_0@2Q(*X Y%%C[(R>D-B:B\84H7G[5"!^**"%=!,9[*[DMB 0
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MIT!]%N]&4_<!W>ULLFXY2RW4P5%(WJ)J6A9_R.EZ$"'^T=.AN)%"/RJ5SC"
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MTOVG7Z70?V"!M^1/Q2A!FLBX"@HTZ$(]=Z&?,XQ4%^64WI@9P<A#2GG0T<A
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M4\[>% T^>\D(J@\LVQK,G*;U7:R*A2U^4YX;>)FTA/=U5UD5AJ,*6U=SG&7
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M3PXV9:1:,5)M[^\S1M6:<W&@:4U1A_D1B]7K3IQ8 F R]N;PC --&:EJ7>6
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MJ?"X=%BM ZL?13$Q$9C+1]X<T:A(7!"[-'>@OV-IVW,#9#G(*04BM-,70#V
MW2593!"8CMR4!EE@7W=^$,#F/.'?PN;@,[ZG-CLPNX7I3D,#M(3@3Y\;2.!0
MS2  "&DE?:%02:#800-)# -=Q!,MF"NF:>4"\&D@UZ79\:MA1JJ'V:9:JB)Y
M&$$1P\!A!CP<'QPX])Y&8[PAC*R@RR0"0<N$"T+) / 3F;SL0 K4'88 _$FD
MQ$+2%0R69-ZH=,HP/WSK@0HTS +@%W)CN'4\AQ1/GS'^A3"^8&3/0A<8L00Y
MO,KQ R9U9^3>(O")$%DSH+0$5APS'N1,!?_.0L7!@=O[P,\3YT:$0-_Q_LN
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M$>3I+7OO8@BSD/ZD34@/FX@L*= V#M$IY[JE0EXM,ZF)*E<'-" +I5@R;<R
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M(XX/@-IY6& =7HD\W]5*+Y">68-)'J*'4VFY>0ZN0_6@JEO:9GEY#_L%R@D
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MRKKZ=:Z8N/_8/B3FXXDPI<NQ$N:BB0 \\7%7F_$S5Z@]5TBW_Y7FI[!CKG5
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M*,6>=&$P%-X7Y-2^O Y#*A6Y]SC:G\ER?>].WX&K$JFZZIYNW*A+R0O:<V_
MW.R2CO?%"%I<N"(P.)Q6G$2,=JPXS9B8.#W,H6(Z_@#="7'^YI;4F%,]%4A*
M[$ ?=KW:0&%<\BO05_Q"%1R$4Z]453CDPYQ*B;-3EDR.:4+M:<*_,U5U3_)5
M=<_UL62NL#&(_O>/:QPGR<_3=.AH+WQF$J#4 SG7,3+]A?C$.,9%3#0$\W%6
M*Z'8'8SJF9EOLWE4$ZL5YD/-6B=-X6>TOHZE,'4W=+YHC.<HO0%*K3V<DXT=
MB-;O0/2.'8C8@>CE%Y4=B-B!:'OIYVFF9B9*?#S55*5L44E#)I[/70$EC =_
MT8V:*>EQ5PB_3=,W4$9\D\5=98]7Y6,=+#RB(\D=922(%I=$S1J$BB&YB3<$
MN8W;V6VB='1=1D>%VR31-HEW>U*E;*8O(C$4!W5P92)(2IB96\HT\2]69Z$,
MQ91+"MOS?%//(^,#K[ZF)P<RPG3YIBFE*E/2I'A2J 22_"I_%SN7V+C$]F$F
M9^C+4.>WP%G2*?/215/SDD0:HIIOKJ_;Q71'A8IN,VL*OW8H:@N+Z.%;S,Q^
ML,:FRI$3)9F9PLRHJ-[P7$NZ0PNO8-'2D@GUSF=\K]@$Q8SX72YX4G_XIX#%
MO8_D17*:T4$9^5\$^75JN)"*+"UM/-!5*^_@U.OX)F- H/P>6,[$#[1&[_E5
MH<?);TRSQM3LJY F'?,]3<IK36- #N@'8*((U'VF"@E+LX6V4P>EBG0EJNOZ
M>U/YE$:2"4WZB$I?1;=O[+'OIIU6_:LLZD&Y3\RSE *EX&ED%@#CG^!I2HN2
M2W^J.FR\[:YO3E(WO;3#JL@ENJNT,="-'.B,>XJ^ U=3IS(C3D%8T23FIB5Q
MN9N?MOE8^FP7H_G)Y/N=#9]DFO6P<&A47=ED8^5V5"9+4$+]=/D=8Y=#YX'4
M-V 99+A'"J3O<!SM>96%^22ZD,(F=4<R\*&3/FH$4?<6NC>/>[UA6G<>W6^D
M)P:MF;B.%<UB!J?DV%)48AIS25&BH1-EW.[HEJ2M?>C@E=J"B:D]X0>F6_HR
MQ3!!B95XR=1+,['43*T IVN?/%,&2$S0,='S5*$F)Y^38BR&*J,J)7<J9G9.
M;\[R]U/S\Y;,=OGDZ1G[Y <CV+1) .]<7"X\.U,Y# S_+/AB#A.^GE0WS+@M
M&KU"47,Z,KI\,OKB9OQF[, A!\'D1G"BRX\D9#V9R'P%:+/,JBZ7NG=,=)GD
MMO&IQS#IED"?I/NR!-:,S\^>ZD;E#B_!:)3J:SBOO*B;+AAH<A>%CZS_G@FV
MU]D-BF'URT75ET S?)2F.U;\#B#(F3K0:)K"3<P"WS5>/F0;2-,Q^4LVDDC!
MK.=ZV@YKY;77RK^ L/J,^P@5@QM2#$XB8(V#.#+94$X5X[_)Y-UBG?UE(L4H
MS$:QD^C!K\ <^J# 8,ELBN@1D^#PI#(69M1!45CU'^E^)E^:" LD,!5V2E<G
M)C/!=&ND*F+>?L?$X20I[JE7H;0Q5:,Q"2OCWG+CU&4CU6"3Z**P;* 49H=,
MD'ZO8X,FY$4]K.P0T<N (N P-ZJ#H3;>$,L00"O:NPP>B2>QFR2-R;252Q@7
M@] .U61C"DP1H._6$X>LT]>$:K"YRB5EBY8XR"MFK4S!VOF;?,24_6"9B5%6
MEWBJ["J4FRM1;O28T7N#IE[+JO()T!H%FJ-H$(4^HG8QP$YE?EN9\*>0+JB8
MVDN-MWJMR9<E&Z"5K'A22<;W"M:G0@[!I3*+4;2DJ^QHVNTRL[>HCKIRYM=^
M0%)?0RQ[.&E^ JD=&HUS/]71T=F.5"SIZG@R5+'*2;#D2*T9Z-BVU-Z"%9.K
M RXIL:)(@LLP<BJ-<9W;,?IB(V^28LZ[ ?%#GA7+R(LRF*&=BS)'Q0+3UC96
MF*3)QPJ>@;*PJ,E%R(7SAL&>7CP9R""#Z\9FG.:[+& +Y4PT.:M]/&4JU'#H
MN"K")]=0QSK#S^&-ZYD5E:TP)Y67:84@PT!V%:0J<.:D6NP3MW:?N,,N^\2Q
M3]S++RK[Q*W@$\<$Z:D$*;?$^8541U;?+R<\PG* RM@J!;/A$UE%=[UD(D>Q
MAL6FUTF9,F4^DJ%6$:9/A5CD:(S=%JZ-VC*%(91Z]6?>OD"=:B]P%\A?5GNH
M[Z#M7&J[>\$CZH<#X?.TX9MMNA.DG9INXH)=0(?-H3'@Q-AHW!EY@X#BHBZ5
M*T^8CM8GXWFV& !M[C"3+*94+<AHM8E*CZ%V%7JT^9U6I=DX7GOC^(5'#J:W
MXCL[*-<B#;A:CPC7(^/0H;(89>N-SK2=RO@7).91Y7U!U_'&!CTTT@2:K:I=
M:C G"0;60='X$Q0@5'C -HDV5.$!-'N3E8NLEO/.%"55IT-]\58F#?%5@82W
MHF/-V1)]5M'/29ZMG'=<ZC06YIS%RBIA*PLD.8C!R]2_=#Z5DK>J59&>2AA%
MG3;9LE36;S.7RGR-P<9A_JXQVS<3XVU'QDB*R=ME+N/4,NN7BT9/"OGZ]RHG
M2W%K%1S2*7&,WCNN\TVZSMCW=3PX6IK+.I!-NZ7"SRF-7[IM=-4V>JF@$&M?
M[S"R\CI83,)%?XVP73"Q:_I&:Y#8^249C6W9-MU"T3:!PZAZ3 XL'AE>E?.7
M2]4013&U9N505#$.LCCA'L9L9/=)X6&T0CVHA&?Y?'1);C=,]Q7<$8E-)]I<
M@>OP_H1\X7+H>9M5'5!\D>J XKW:<R<I5I>?9PP]=70N/=M<SQCBIRK5Q4,R
M],/G(RF4\SJ^;NH*CT+K*016WG'^BA<6 ;&GRR>IO)$YB3"/L:E712G:#M25
M*N6>$ MN0$!CF)H+$(I^"<-LB43%&3/!'HB3*IPZS:FA>X:%LH,P4AH/[3!=
M8%,5YL9+H61?S[UB'GT2H GAUX* GG B2>(BO\,F\]0YU>H?O)4&'(.$-%JH
M#H[)=8BJK%.EFW(@\7/O+1F18M>>0="2 :5SEIFOU%UNJ554\)$/M4E:H[MG
M,<NO@:']+F)2&)G?:HF-,3EWL/"1*6I[V/UG=N:ILRI#E@)#->.8K96"B0"?
M(I>Z9O*65,D9D]9'E[ G\:AD*^5Q-@E@E>1'5QM=HC;V,F/);+8T!BNGUE+U
MQ&F :3KPCO5!NFXQ7PJJ1DDI#KKN!0GNS@=GX26LR7F81$89;J9_3J[#^M?9
M0BC)R<UM$KKV+8\-8@6I]@K2M;15Q:\+Y?)QHJ :=^U5X'L^KOE$6:E9>]J0
MZ+SPK"_ G="BI\MX=_</%#I_.KGY:+QS3FZ^PG.=])$*V==]J]>N;>6>6&F[
MZ(E,,VM>&R]L(U9?K:'Q6W_JV'I QUW=\NLD@ 9&O/QHTXR,2C.1WEB02J(R
M/*E1Z$C(.*T?E:;7FL; @FWEXN&H?%>8IM'S8IWSA0#3F2B-JF-]U9X8R@D<
MX%&X[;E&4K4BK59EPC%S28M-#Y-,,HE@"-2-GJK2ET]>?7GVN^X9B:4D)U3&
M;Q[)@(I;4IFKU5L4O[9TL&;'.ADJMV0TE[73BL!J[.FD ?8/_!C=:U3CQ-5U
MFYE2P]FV58QO4<?2DZ&FN#"OY[FY$V[H5TY@-G^-ZIF9EE0+1W\=)2$-RQ&Y
MG#3P!A_03Z?=POD'#2*I0SOV']*ICI,0VL+4AM5SJRF1$VA29?R$DZ<+"3TQ
M[R@9T.G-B0^0S*3W!$*J%VJE Y+:5"B <.Y$E)^"U"I"!163S*WS&\#0.ND-
MU:&"D:_603(>))7&L#<CZ)UPLY:' :AT2L$C3+;.0*"ER-D[)"9RT,X=6./T
MI$_'(QM] UN3CJ$8ZES]#EFF)TXTY]F&MR5)<<U,(E<R52?72X0==&."SMI^
MT:^\E#NS0-Z(0,[O@$J!_./-_6Z=PCAKWK9>9:3GVS?=U^^MBPE*")G444T?
MM\[28VYN,V##PO9#5@&8)\@W-H,%CI=6ATC -&,*"A0FP6ZU'=?13H!)4H=L
M2YCE6#OB4K_)&Q-VPMAHBU\[-YK5D#4'5A 6S?HK#IQPZ-B1R>L,G8VG%+B*
MMJ0$)M*S6^EH">MSJ$^]2I:H!=M\EO_-GF%.><;N7>MS[^JQ>Q>[=[W\HK)[
MUPKN76HE]W=])9]B)"-?Z]'L!VM)_2%:EWUNCSY9PI161L2J9J35/^BH!O1O
MU-( RYA^_P#$!_1'P&['P[0$>P/0WA"?%;]9_'\U,3O1YEJ3X9<(U24E>SC5
MBOGG]*:4[70;4PO,PLCLPJ@LN,9BDKW"-B% 21Z$D8_7KD@A7Q'S]>,0:??K
M]V;Q%'].H&&/9,O>#4YLJ[#9>ET@#/]," RP 5=,0R 2YB_SU7OB0D1JK)^Z
MW6[R$]U0AJX0=XJLKOX/2ATDI]BQH+Q7UI_.\-_2HT^N_8=3WXTGWMYATMFQ
M6FU]ZJ@M:&R8[-'3E.SFF)C>3(J*Y;]1W>Y!@_IS7$6SA=-/:=/,?PR+6=8V
M?IP^JP^(V99O,A_1SCS(?* V9_83W"\X7O)^!(U#;S;56+ZAKMINN S'!YV#
M@W\B556'$TDC_>\ 22P0R/E5:^&%/C2-<X=MM_K_T#/\2S3DR8;)+AM,M_B"
M[MP+,LO2Z^P?K[8J#V,GDGN R38<1L]_",2T9*4,X%<N%!QCQ/5_M?:;MF@K
M+,YAYV#%U2GH>P#& /8H D#UPPR*GBSHA'HNM%98<N3^CUJ^:=DQ>QZ1^VXC
M9.X@3YPVI;]G5KE TT['(KB$+1,X0[G76XVPY>^J#66J;#T]<]37(?JAD87K
M/47?(K'#WB&Y_V%;*_84[<QY2I<#=/@KZ#]&)A^E,"+L;W>!#R-Y;_UT>GI^
M_NG3AQ_)Z8\5(#2''BM#326F'*R.*0<O)'7G( "K^VXM[\ZJP\]DR)LCWGN]
M;LJ\>QFJG2M!D:EF1?$ME#]M_HSLU,Y=^,*:\I=MG_-5IO=M[SFFMQQ2_J3W
MTZ-;BR[/SS*HX:5)1A&56OV?=QY35MC?!YVC%?&#-_/+;>96O]?NOND^$W%D
MDL@DL98D,9#P7Z<YG)#I7VVFE^G?MDM,LY49,YCS;><./CYF2R&3P*:3P*0L
M;BYG-Q7<U;%VC/',"YD7UA-*ZB=5F1<R+]SN'?SVN7@A<T#F@+7B@.0<RU#-
M]*ZN].Z);F=EJ_/$)N=[OZ][O[S0CEU9TQB4K937S#B?SCB?>"KX4.W:H3H\
M8N/H=A!C)A?,W9K)W:B"N;7?.83VAGX,@%/1HOERKO>]QXB9FD:=;J&882?"
M6M,X/E];?K[0KW'_:+^:R5$R%8J>Y?#Z[0^O?_.LX?6X)]0'5V)& =>4-^A:
MYSV]$D$TXZ#Z]5EK?YQK*Q.=A^%ON=HR%L4,4GYH3(9GW<!4P1R>6%=)39F;
MI%;,::;F#"ZS=67*RIS<!5(EQW^%C>O\DO-?FR22:D]\$DZ@,@W_)H4;C6U,
M4/<)5#[5V8N+MO6Y<]5)\E4FSV=S44+O=1KG-+$4I0\3N1HY'O8WV[GB8#)M
MZE2%5)97N-8T<#PLW.EF<BK_O'_8Z9;G)+/T[H8MZ>I2/B*R;'AR($V7S(2K
MZ5;#G9_S5Y21/OL,5@A.B_UDR@D[H87Y[HE(8-XO77/69+(TY8M*?JYG2U==
M]Y $8![#:&9R:WEWKS'98MK$C^I14FF#[S85)* L@^+N#I.415+E"I>J/BI-
MH:[9JZ;*Y <K[#*5IQ+. 6:BM*GBC)Y&-8DK]"PI&8#9T]"A&7-+PR/!U*>$
M:U$ IU/8J@136M )?W$5./?XR!6P'=K+.@=BJ%)4/#BPSX>Q3H6ID4]GPL3$
MD)0(>I0IBHM?XFZ- +0J!JX22X>91-24&A1[ 4WU]CO=?U+I'DRW-NE8)S!-
ML4?IW_*IJ]/]"^<KM,=R&.L:NS"CE+FTF)!/9YP^S)V8W_%AW!AG(CTN'=RU
MNMJ]*JL;I4D;Z2AAVE#H NR#AP _]52!$'6.DB/=03 )8TS5JO?L/'KDD6ML
M4G8CU%*!7,KC36L2XD(,3<[5.2# 3'>4_-/+[<W",8=5@W_ 8S\?=)<^[)C7
M3[_8#&1YK, 9680Z4<DN,3G5S=-F+3)I5RFQO/;C2K.2>Z7-49+[F#+-CV(L
MBJ$>RZT];+6J%.7%)1KFBI:![ XH0TL% *B:(*E84,68$9?F1LW<82/< 4Z.
M)PD/TZVDLC%38 @5G\$ $3&EO)K_U8DJLS!:NLL(TW,H+C)%]U)$SZ%WKF)/
M]<%M6U,W#@E<-1P6-W];%Q4?F@H0JB=4DP!:PZHQ*LDUU?E)RB%0HN2Y"D*)
M3"E*'CP_LT6ES^309.8MS)\SF<@AEB>@I-0(G1I*EIGQCG61+=6^\HI1'1R8
M.Y5Y*?EIJ9!,JI>K?-&YOA:GHY1:++T]5(7L[Q$=2+4W-'-94 FQ8S%,;+@T
MC:EL@CFP\:"$IH10%.=(6E'JX+9#L,>"2$1D1S/:A6D5)*0G0SRS26/$?%6A
M09U[VQHX(Z -0IV#$TR&&Z1I9 5P@5GHA'DAE19CP3,#N\F?.#;59\*278$#
M^KNM1@%_?TN&,->=?';;#$Q0-Q,6KLNA8)>'<J(27>LFK >@-+8K519LS,:
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MR\]74[P%F"749GJ9)3"*,4M@EL#G:VO.5U,< Y@EU&5Z7]H'@"%KZR%K&1\
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MWJTYZ=TA)[WCI'<OOZB<]([K3TYW(KL"UZ"L53QK+L&"P)HV&&.?9!I4P2X
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M\6-7;B]2L7J_!:>*06MW=":V";*!FPW<O)E9 K($K,WTLH&;M^JV3"\;N-G
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M7)U*P&E.I,O0PD&=QD$8(W%8BM4E%H8(OHI,Y*SCC5PQF8C(#T![]Q^D"]P
M*$<H.]9%OBZP*9Z+RGUH.%G;RBGO5'F66,5$?)-HL:XJ+RM'L3=$R#'=@WT
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M^^_VIF2YR.2Y+BA0 [G8ZI\*UXY=8?)%?Y$14.=P3*X<ADO_1[@Q/=%AP&#
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MA^%]PF43,^,"$V;&A2K"S)7[F!PWA1QSZ3X6@DR.FRP$,6-<& <8TL=8P%C
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M$!-OHKU(S\A2,L'F4\;^B^C,Y6BR'V19MRUKO?[=<#?DF3.L,!A6)O6WR D
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MQ_89V.^R-HY[.5>;79EL3QOUCR'YH-81VMCTEHV6V6A[*LC$40U0Z]\R<'[
MX#PX]45J,DS+7S)OST^(J*B[S<#K&M%?*!.<TS4RWV=;8-56QR29^:@QTT?Z
MR8M!/D RA.>'L?UDX]W+GS'[*[ ??KM\5]X>P)9A;'DR2S(G:R-+BA2>Q-5
MIZ%.:Z>DWL>'E!2WU0^7"JHN*2LPXY6S) FN0^P.9 +/=<"_(]RPL;)J,G0/
M#QVPV2Z9YE@)HWG6S7OZ"6;N):RFX >3)\TUR&QU9J-E[.E]?-H"%!G4MT"
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M-JCW1LA$<1K?'&9*BM;^CG JP("N[?2*+0)9L:A$P!)Y$?DP!98@)9L#YSI
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MBLT&9&YT#U^QCU$]**4/JKYE ]-,P#@G*>R40W*G!39A ]DS7%"EZ<R?ZZ#
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M#J(H"C[*$7#P\<\B3'7@71V<>&_C*<Y;*KX)2@I*]IY%8(ZBE#\50.P'M5M
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M:[[P<! H"J+ 8N?)W\"B:(0"AP*'P@\>I"N@:(4"?QTE=S=^]-<$=E140L%
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M<Y,7R%2,]@<.U^-#;+NF2-%DPZ':NZG,9B-]E NS<DFCOK+I4QN"-W\P%?O
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M]Y9H+GP83BXFV(U<:'(4\](ZW$U38H1/UW'V"!HN;XL.EG,$#W.*<9/9=6)
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M-^^C7;*#P#Z,>VV<^R?]+@*-8_SGLHWZEM+*YO\W/6*U:<8%@Q*J(='%3/,
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MO+O'\[A_PF)W%XS?D'XIR%0USY]RQ"OI-[)*UBV1^5?%!BD!FJ9NSN:5''K
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MX;#_<77UF[12D%F5^1-&^ F10P1.DGR&-&_;!GYO<"WX_CO+TH&AE4>:R:#
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M$#%O:;XPLUAG$.[=;HMKYLV@9*%K;X:7PSM0QV)NE(RC,#<#X.B=T4"M)D^
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M@QV'HJUG%G-X2]X2,''D'34Z@"*$DYC=@/+8[+KYS.Q!OF.(#T?KID;$_J9
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MCU@THCL?)](W,<A!O@2!.A_OY& .4MCTRGN/3\_\:7R,M"G6.3%YN66G+3O
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M$B-2=O6%CUT@ND, H;=9LU"^"$J&[2^+9CCF93(.J(ZY,Y12LZZ9TBW'O;3
M#1/* &W?]\(5<M&N6Q843ZB-IT#N1(TVEK2&MYZL+MVG##IEUF@"T6O9U=DN
MJ=FU#/JM_?WZ^G?+T.6 C< NO4I:!Z[ *;58E\'%0)?:QU1T96)6!VXS] M\
M_9UE!#.+\C-,[=73)_];O6&L(8"6(.'PG?$U,(E)(F#6K&KI%:2H0\%W2+!Y
MDB'M"?*TSY+Z2087IW]V32O.HWD\)8C *4V:JC0S#QE26'SKGUJI@ G?5AUT
MF4Q$_4!$B@M[$7"/4:FN+)"7TRHF&*SS<-N;NNHVR.V-XF'N7J6-6B77A@DZ
M4A98W]%@:&),4!D28B?/<<.Y=GU6T/A'D%]+$^X7B'I;!):8YO!ZZ(.EO& C
M"D9>"J/.U)TE(2@OLJJXCSNUI;J,?G.5-8!H^0"OTP#BG#+@3BX'@Q 4\.E'
M;FC0DC2W;2_+RDV/XX ,^FS!QNFH3&.;M3<P:LQT&KV2[XJ,9>.NZ@#RGH41
M"V_<P9T'!7ADJU*P85E5[PG(0X-2*1UW,^CT"I@=O_VBQ*%Z_$8@U1BL\0RK
M,>F9C\<) >)#207%:&03.ZRWN'XMOF:34];>Q2BS,EFU$I@;CASA%J%S,.&J
M*-RJ>$2M]+: )GHA+L]GHKE(%A=7SQ8'PE2"PZ1-^]]E=0<E5)D&8EAX8)H!
MNW+FNL@-)]+Q8]86VRPIN?#JK3U.HW=/_L^1 -R1(?D)6AP&0&\RYN^YV"Q$
M@T<7!;Z^-R]73Z]E2GH/1^4Z: /LZFK;%1NQ9ZP]P#_ZG=9'@(;7;IU@2S08
M^22V(M2&^/[SKIX>]NZO@*K[[K&AZE22D2P]Q!913H/ZI[=10:AV*OWAS<=F
MC3G'UVMK(S' RDP4Z*:J)/0L_N[7I$F3?P__+ S8 PU7(^6I7BWN.K+?>"_F
MET^6_+3+\.V<;4(I&S/*JKBEV@MKC(S96K/*F!!,Z0^V:P5+5)*SBHZ(D=42
M_\ "@ T?(N9 ,4< G=[.<(34M^#>W+FQJ\R!DO-)M /83PZ9,A"?KFDXPPJ9
M\]L\NZ-#"?UNXU:0CT+."[4M4JQPJQMH_,&$<[<@SVMSXSKF+]S ^ NDU<Q*
M9%2%P359H0]C):ETOMG]MT5',Y,=%NOZ_0IF ?*'YHXUU"B#$<6-(>!]M+E]
M8#+PA7FJD8R_*OSLW[#=,^^B [MH_47Z,#G,[3GPNR ]W^_%U%_[>-SP4W<2
M#8^X0.P6@J,9#0^QKI_E:ERN-E\&N81'M_D/L.#-WGA3V+<AU!H1LE\.*>7
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M\,]C; 9K/$+> " YNPS%1Y<:.Z929/,B%QUP7JINK$2@C7&D+YX_742KI,B
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MI<7-'5S1ELWI<!M[L0G[-11L"!)4*V3U)49+3UB'9?&8",^R=HZL#8O:9_9
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MW;]/LAPY7P$Q8QMPB/O,,]RK4U/0X#^Y/R7^W9@1)Q T-H=.5M!'V/=25_F
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M1*[B,01YK;N)&CVDG[:JD=MB>#])LV8%<#J2L0*L'GJ8,=DLSU2VSDO+PLF
MO=\MS[F^GR5P0#I2Y9*/=1#_>"?PZQ2VSUTN]6N%RP\E.E@:<T3$PO3?*?4"
MHO;0= 2$(FA23$IQ!JSA\,$A%EX53NTGO?1IS83R0>L'B?!>8#O8!!]>!O4U
M&G*]4%, W,%(A@\CW1)"-_N02 UQ$Q(*TR1B1;,+NL"[%;F0P?IH0YK:D[;.
M.:AE.,\V9MLB+#BZ2Z IAV!" ?/;4>(7*V<'49 'Y  ?ZZP>U * ,NVEAWU'
MR<TA=V,@P2.+/,QN>EA7^(H:%\S:XQ&77JCFM;PI4"R*PM;PP[\;,WV<(;<
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ME"N_05!3F]C9H)/**!]H1<D4 V#8PE/\FK<7+R1(\JI*\5+_^V^O]/>S57I
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M(U%+J'EJ\Q;]+;8B,))N(:=E5;KX79JM,S3 -=K \X$NF$"0^O7F#56-CX5
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M?9.0VP02$;.'/_'Z1QJEM,T F"]O176)NAH A)ZX?>"0]Z#*L!^IO$SU!Z<
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M5)*Y[U"-4>$9!_%PHV2#U5[."P]!/HV-X#$=7X6]W/$<QN A$KMJ-(\#L2D
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M!!Q='G66VL2].I-?B!<UI (XM$7G$-6A$-4W<XA*\IB$"WSKD2OA7O\7IGH
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M6U;W5D E6-;3_6FEXFA&/HNBN@-]<II"^N%\A82 , Q;_74TU)?I?&QV;9%
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MF$ZE*%(H?FG\@F#ZWV?9KO>FR@@FZT P=@%U-$"U.X9I2\V+-6K.DB*F +3
MOVV5*G:]VGW!$<[4OP)?L*U"%32#MV?P]GV#M[^9P=LS>'NV:;Y #_#727!V
MY5MS,$$B%=I: &\5U91C02$%;!2S.9*72#&:"AG$?I"1JM)5EK6?/<1H$D&9
M/B)Y>)10$X? \!^Z#%A;.IOPJ[%H3H[:8==?PWY4#&%&\AQ \KR8D3P#2)[6
M(SE^E=40!P9R%RBPFY"K>AG]=-C[<(&!@3)FK] YK(+NU3A;EP7"GFL-S[O
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M;=/75%O[4FS%RMB=UPS+GDNWI\2'Q%0H*HD$V565U5YF3:MKI5'E;+?$=W*
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MK&R9EVZR52?V-3QA>/WZJ%]!XK*>?K(J<L*UY;?FO(-R!B*WPY.- F<^D(2
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M]:CA[P^:F9' 2R$'ODYJG-^Q 25UHD1JN E-)/7HO!%@79W.':!>,8A$^Y;
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M")8?=G"<F079UR\AMTTPYFK(CA(P(M*Y5-9U0?;KJFXE4"QVT- H8GT#NRE
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MR2[I%(U(V('&'4I"?3O;M?1MY3-XA2^?XLLGYN7= 'Z'!LQ)C;U1Y\ET:=K
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M.;6)2YDY47EY]6O@*UAU*F$'V-;:9>46D6PW:\??,&N4E"%]LJ-D@2<?3D_
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M-NCSIP=/_EUK2[*Y5[Q!FN7(H*;?8+VUXUA-6NW*93+J?4_AS,#_+J_TWG<
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MTN)1LHH*!FAX=@K#>EER&\T:Q:0YJ2#,8?SE4CF+2&9]I^9:EY^AG4"<O^0
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M^,QKIM3NI0=\%T'Y,],IP%JO8+D2!PL9A!^%,?88'/+X+L(C9_@W6\X8(1G
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M5MC3GB2"PLXY5"P_U#@CN"YE&=PP2D/7ITG63<H$!UO 3_:'G#_RTZ;\%<U
M9U!9[;ZKB<QJDN-U&)!5V.'KX;N?W.CV&Z _G,!@8?-UN%E'="PTG/MGZRM^
M=\26.\)O+=U$QS1Q(SH&;-LBD'@G%E-7,Q\=CVD.?4M;JRLQ!88X$KVJC+77
M.NPTF,E3EP(\(P28:"NBH:'@G\E?:O"(SFD8C,NLS0U>KO<L;28'@_@&#.+C
M8!#_GM53E>=)H<JVQBXS0@D_HK,;<M@_E#AE)[;QB7$0QK1QH[>E=5U6*@Y,
M=]O B-.AFS6(.#J9<[G3088\P^R\X+"+TT2F@VH/A^B'EIGMQ"$Z*QJ$U3I\
MS*=EBZD=W$KU"RP]H&:\-6ZULQQV;%46V93!5/.LK@6,\BJ94C!Y3+YD+\3B
M%GE0C(1?WOKU;B1;GZ5^]T,Z?RU6.:E4@JZZNTKF5D0ATZH;2F9N5@TS@P-&
M&=;FP@88J&,UH8CGI<!F]#"&T'\Z0\[53H(AZKVUD,&8(AMLA<@9><)UZK6.
MH_643%1'D<%9%K-5"A/=BYT"CK)0)G9<@SPD@M.JM3V#W";7"953.G5 3IR(
M"D7L*#TBQ7TJZ,9"3)DD^'.F-R)%Q>R&;=P-"S=]__)5Q%D3^Z9UBY25F1"$
M8^E/?R?HF)=$K)EF=Z",,PC?'UI[MA/"]\16!KU)KEY$_]5669UF?DOS$:S8
M<*@:#LPYU4J0'6)R.'C,5;</&Y.@XNE!_@,;/Y7@\$L%'R>5PB35>5*E3$,V
MLS]@X"\S<)B:;7YZGX,!Q' QS18YPZ%UO1/]@3>CAI%.[QP?2JE5@(-XU.=?
MDSY@R)H+V7P::C^8,&"7_4H1G4UTW1+>EE85[62>-4;V4/:T1J/Q3V>O<#&E
M*EIE<XY$X3R+8,? _%?+E5/N0D6E8::4MN =#!T%90,Z^L8=@J!&42NB#C3/
M7_5,^N*/@JJ3Z?LZ>ID)NR__6&>'S<?>/F$N:(=JF_0/\A[7#*]F14E]$ TS
M<F>IS3:^4)@BYUI*:=&1VJGF1L?=+"T\"UF5<4%WLIG#T3'*X?'(&%I2F$R=
MR<;C1[N-:[/@Y"YQS7B72X7IZJ7-"F<7UWCORU6W-C4.?"UA^)."ZC\+>!I9
M [ 7VSD53);V-'@G$$61=>#@@9?^]D04AV37:9@@WRB_1$]FIV_C2PVXCIE)
MV\/^.X=/BIUO8 L;\V),&W,50\=E)H#/3?)<MAW*,D-ET%#T%\Q5V$1;HLGO
MI:EX%[6K.W$Z3FJ,^(R,(&T%A@$DE*9-8""/A3*@\'+($H2/*RNP[M7O-,#\
M5US!ZQEA[)3Y17,@,U&DZAH]+KIEQC6<MOIGRR;?I5K>B9G;-IM\EQ-'>K]0
MF7 ->0>EL#55PAO1;4M!1=]#!4NZ!TDM(6"B<<BI^CLUS,!PL!C60R$2Q\AP
M*:$X7+6BD;JE27&:FZ/=/U_8@Z6AE#* E9U;Y%5I',/OMWJ4SD"<>K.AD1L1
M@XE)#J:A>23F4M"R/[1"?2?$R-L2-5I%X"W8AESU,R*A0JV]+\3!Z04<F*Q=
MZB/S##L+9;77*+RL;*1VAD7/"REE?V\IRNA\QE;_HJ*=JW2IH8?2 _(*I%M=
MHM"-3"'E1+>[#.'0418E[\09_$BY"0;,C.KHG1@.JFIMIS*FD\"#QS1B)9X0
MU^K5CG[6M*PSY0,OH& !1@YADFVJYI".>?7/<%:3K*"0I$E3F,$.L4U*E&WS
MG<O93*K,^Y,@+Z"+2O1[,4&-_<9]P8/H-25^*)_T9YN>ZWQYHOO/8>AVOE 4
MDO2F!C9.3F1_'/A;NRRA7#&4*]YNN>+C4*X8RA7O7<\"KVABE:;CR,U[';G!
MGU@J'9;R\^0+A;:I.D6YF%NG"H6<56+%Q40 =8.D'_S_[+UK;]Q&MC;Z^9Q?
M063>V9  2M'%E\0^.X LRXG>[=B&Y$P0# 8;U62U5#&;[.%%;<VO/^M6Q2*;
M+;5LR6';M8$]L=ADL5BU:EV?M=82VZ=(%AJCM8[0.82)@-$"%IRTXOEEJ2HN
M44+)DZ!:)7K%2)(\/_"#%>]MC=!.^4]R3RG$FN"B4Q/ZBER^HI[;<BBDEK<6
MLUZM+@Q\Y4"=KM;X'9X7=O*,9D4*2Z)3"H%2Q.]J5<#/]?MM%]_6-(:/,;4M
M/<>F..7C4"/;@1WOK?7Z'VHW8?B35FP-E0Q4R26"LON1S7E14<TIGB;HGWDQ
M,PDFIL*^H.U$3@-V.'@=Q>XX[6#KK+1U+H*G0:P<RYW>M:6\QF3MW#J7IY\U
MER?K3N4*RTHE*A.M@6!W&)0;T5K=V$X _;8FYWQVBYHC?XJ%Z6+"I.NRQVZ9
MTB8?*N<.[2#QDF;69%04L"WQPBS;@D/$5<.<3-PW[=B<0AZ+QT;:@',/\'Y0
MVHH:K_\[QFQLJ6-Y3:[M2UR]5O@BS//7W6<'YL5HP/FRCH!A5;A,+#95,U H
M"1+">,,9O+/&''O^!<&+%/N>ME4+_&+%$PKIJQ0^$J$H_&9[ Q46LN+,-KP7
MP]+B=VZRH!=8L8V^F8_R(/A)8E9.*6'KW"N1AM5?+9((B[YZ,("*"AV6VA;!
M3;DAA!<3Z%<PZ[8TP%7#.;;D*7W/40\@788G"Z_/I!93VNII=FN\ %YMZHSU
M  )*_-GD26OOV[\JOXZ;:[0^'$RGOO"<RVQ7B$+G7;BEMPN2</Q-0)UHO29:
MO+ZH(EA,S-(9]VN+7]MJE+Q9L)MRTI'CT&&7(EH#^0,>4F928&WQJBDU.X?$
MQR,-W7U@WJ1+H%[3$!?3:0',DJ' ]2UZ;[?)[3Y^QM0M;\$*LJ*8DDI*F+QI
MEQ;C]JAUBF7:#Z 5(-Y"^7M3FZX^497Q'$O^!V -VV4NXBVL>PHWCM9@< [&
M%FCFJM&@0'NCV0Q!\:,/[%K0+E=JEY=!N[1Q+,2$C2MR=<2GUR3:-[.D0UJR
M%.9>F?C42TN@9B)MT2/"8X(^LK6_';VP5MU+K!B,SBEAHY5@^J(<UK![FRVS
M&T=3Y#USU$%,B@T4%-4:GC>U^/!AN-QVE" @,C%!E"6&&"3A_02H2EJ5J^ K
MJD:B6"/R&Y1<<@J(8"']$AKM)UK#FRQJ_WG0?BHIJ8]1@ P':M,AML28ME'S
M;GH$:H?&UI#R!MUNLX^?/-O;B^:[L]UH"VGCCZ+\$!V3# !ZV8X]]4+F3:M+
MT!S&+_H+#0MSM(TS%GGL55%R9:7Y%^!:J!W'_FSIZ^2'[E?Z?;P<HG!_]VFO
MK)$7-O6JU/(+N7U1!4N $ >"5=2BJ7LUMY)B#K**.OE]CQOVPO^:;F&0I6MM
ML?T[?5MUB<71)SHK%H.C\70Q.+L$1P]"8Z70,"'\VJE2BXP -\^HT45@I1%2
M3X=W2N>DTVOG->M-)85O/+W=JZ4F+F;X@Y$-1;XS;R8P0+? *J6D6+^MJ^8V
MU"5P14,%]P/"TEG#3V29$[_0$ZJ%J;EJL@O=0L']J8C.7Q-&1=JL-;!5V:KJ
M0V3+\#>AF#05.:0M@A+N('&TJD[]LIOYN6.P<228N[@U%?M5^NS[!C\$LUJ.
MIM@/!4VBV'6[PW\FE/*G*(52JMGR'ZWBX)HR;#F6WT+YWPD+1PO(*R.<=&F[
M T!#31MT;O+C .NE79*J=?4E?@.6IU.4&<+"8!OH\8U#]W4_WH/W=3^SUWJP
M4QP07V(-_J$,J\$] KG+]YJJ:LB^22@OA009[;L3Z=P9"Z4*F#Q44LQ90T+U
M*L]AW1.O\4<OX70-XE]Q$,3"O:V,H%0WY+OIGVL#%H?Z]FKGFA/4Y V\ O5,
MLIT34R;-#'-T;<1"UH4J[9,IR$M.S7E<#7M*RRC*@1+,*\YF+S2![<QX.D%8
MKQ36?P9AW>VFCGG1I:['6-U02^15BM])APLI\.9?-;F]B*?#^X$^U?]-0KG3
M*#,?L.@[=A**FFJH;:^<T5)/=3F4PX^M8X#G2L@6):\(5_)")0CYN GEQ1^8
MJ'EKMZ)S#GMWD#T!4YIR2T/.(6-3C6;#?^22+=3:N1>P>JUY)YFTGF/5WVJ7
MZW]F1R2V(Q8/&]BV];5F.7C#S\M.62E TIITXLE"ES'BX!)N"PYDD8J#UNX"
M+J%KNHT%?\ECY\9)]91DJ+6H>E'^F58$7E.5NW-I9WD&&$BG3:+PZZKM;_T$
MJ''D;4ABGC5<:$&0[?PW#T8U"V1X%F<S50%%P'2P/'*K.?H#3O4,<7="3KI!
M;P/?#$9BYX:50[1O&1K#JI*=Z[U1NB/TWK@;_7ZI<T+LUOW#*0/T3Z=<KNQE
MH,/.+[!([G@"B0V?Q)B]T0,;,L&03@;F;*O?=&9E93]!/EB'MZ];7&I2);B1
M7NOOAK=/L2]H=UQ4K1P,9(B)M/S*OKMPC,=4W>C:KKWE=W9+]1=-]!.?;R&0
M44)9?%H<6PKXQ(!/?%A\XI. 3PSXQ&\.GX@U0(@Y1_7UW,8.V/I$':-B;0P4
MO+0ANXZ%@A>/]SVR6+!^FY2;"/5!:5HXZVM?9-_Y%J_K4JVL3U;5J^ZHN&H<
M.E8L2H_2=1JP4NEVU"BQHB@7KB[XO\-  Q$RMBIW+NK6LK[HI?[XBLAMZ;2L
M,,*W\+-#HV)O3&KD[7VYNY:[YA1EDTDXJ/7343NY69-=M*YW,@1BBH%BO)@B
M)T,KAO5C=G2N$O<DI@]C2P8N2P4W+*UA?_8BQ?^/R&_;U"FU-B+]FH)ZH<K*
M5W[DBZ1)E4,A= +_' 43]U:;I$%ZDRC$%NOC]'V<M$4.>4]VP+)+W=@GFOJ/
MQD,$\O/1T;ME!;\%(7FJOK<RM&[DERF+YN*2-ID"4^(+@4,5WV VQ+8<;NH%
M7#K#>3_$7FYW=LV+5@YM4@HBV^Z!TR_1_:(RH PP#O"&Y5EA<GJBF*#A3,M@
M?GAJUXXZ!.[J0%3<6-S/Q(>-PII436D=QQ,-7#*WK$A2:9!(D!8)2Y)6 W:,
M#Q'JC3\P;U_IQ-M!?2XKYEPIMT[T[]YFZX:; 4@7>,0\7](>^ W72HL4ED6&
M3^%,H>6 +*89^HBJ$U5AJ)3?\A^,S0Z?C/?#4'$"0S0L2SLVL76?V>PHO'<V
M,1>-D6)-MF4"T%*17;4-+CFF6H(V@(OZSG/H6:C8G+(GU[3$/S'5\<=[<]]U
M5.%Q2^5_CJC<^QEERE'FZA2HX$)'KT'EBTXM+I].]XM,Y1]&Y%?[5[ 7@[WX
ML/;BTV O!GNQ*ZL.[SO4M &- D[?1+^?OG]S<GX>_?[+R=G)VU>L+'$!7RZ]
M0FYKBK<NI6.QZD'@-%?5MM?RF]NSJ4EQY5H,]54'QIK)0KPI=HA*=FC7O^O%
MP/;WX/S_W?&C! V4>05\P?[+_O2,6!OQJ.AO>WM[[A$9R.,^Q KK:$_^@S2"
ML@8G5@[/*F+JI"MGQ>*XR)I9OO/(3?:25WG_P%(<#98Z3O/"W=GAJQZ=RG4\
M;LM7Z70O7P;*\BX*Z5I&<>A=(E[A7V!VX5]!*L6_>XDI/%AWH+WEV^#IY[+.
MAX]W'SW].XH6/DG(Y.G_#U'H ,-?WI;O*!/N(O_O[V"<[W[BO>AS:J*9KY)1
MWX<&L)I-[R/XZ>VO[X[>_/%,SA^N[?=U^BW0:7>@FREW?_?@A[L1+EB6M=X!
MUI8 0\J+1:GF?6*VP?>PW/WE?G*X>_#XLQA%?VWA7^5/G\+('W^[C-Q_;/_!
M.7M@[/?)V.^@8/[053#OM K47)&F0  W#!$\:^9S7:*_&M[ZMFP^*/1S ?O3
M#1!/%4>G>=)3^KYIH7.'4Q:DT%^[_D$LC6D+'T8L]9Q;"V"MQ0(Y7+0_1V17
MKGL.,&&8X@*[3:J=VX25_T4/?Q!M]R':[*$*LB3(DHU9_Q')DN"K"A;-^-G^
M=S^]N Y>JL#3Q[/<@86/8<<""]\@%OX>*_,$+AZX^'B6^Z&X.&&5B%?< #/8
M/[@WG$' Q'T2)LXY9!@05Q<N;]G/;C]OYI1XZ= . 2#WM0BL )"['2#W0P#(
MC1H@]T)5)MG!/=EY5:K97;33[P+JZJM0>0+J:EQBY68[:+7>\&-7;^A]Y VA
M=BZQ(KI ,+&"B36>Y1Z1HRS$S0.<:P,EQDC@7$=GQT?1B].W[WXY.OOU*$"Y
M0OA]4]<_B*0Q;6& <@6Q-@]0KB!+-G+]1R1+@@,L6#/C9_L!RA4\5.-:[L#"
MQ[!C@85O$ L/4*[ Q4>VW '*%:!< <KU[0JL .6Z'<KU8X!R!2C7!D"Y0E1D
M'=?CHQ]VGQX$;->(#*,E9O#/<V "__/+V]<O3\[^%0=[*80V-FC]'X. V M^
ML='ZQ>Z!_P?V?[]^,5C\2U-]3YV^%; A[+I)'34[_3*#XRSP_?$L]XC8?-#[
MOY#>'_C^@ZK]SAGYC(_&_][\?T$<!+M@@]8_"(PQ;6$0&%^!P#A*4^Q&%@R#
M( DV:?U') F"AR@P_O$S_N]^"B9 \ B-?;D#6Q_#C@6V'MCZYE%M8.NC7>[
MUL>P8X&M![:^>50;V/IHE_NAV/I:B0^AK7O(>PAY#R'O8=QY#_M[(?'AZTY\
M&+UT.OA"_)1FF^JD*%5MBOP9]6_/3$X5W.9SG:?F8W046&Y@N0_,<O<#RQT;
MR^WR7';,O)W\J9.:7#4#NM_M^]/]TSIQ8&(FA1W?WSN$6>(4'!7\<I=4Z2^X
M^U3^\E/WGMQ7=O-__'%@]Z\*.,R?YX[P;J,I+$V@)W]>P!?=5@_4_W@YO&P-
MONR)B+!_][E_PGCO?0-?O3W[-7K[*J):K5[N673^V[MW;\_>1T<_GYV<_'KR
MYOVJ[>WH3X?WIC_):AP\0F_/J(W[]Y>F6K:7HZT:K__7WWXX.$!7R2W6\RBT
MO1':^K1^^\^W(UC+F4IUI/(THK.@T\CD=8'9,B"]CN:ER:+#.#K8.W@41Y-K
MNE'-BOPB6M56/HY4]%)G:J%*#5I).9=%P:W3&[5SXL$9X;[%S%DFIH#3#;_=
MMO+KKOKA"%:]TT-A7(N.Q(]$3-.M0(# ::D\]][&4;CGFQSA@B,'PA5EBMB-
MCM6<7+#_@64'5C6KHJ:"?P('TB:/)@W6$ZZC AXI%Z;24:JGAK;H4F59=*FN
M- U7ZFH.NK:!/V=:Y2!%*V!W26DF.&X154UR*>/#L/C$K[J\@.WUI!"P1SOZ
M1&?%8GMW+4'^Z#X$^0JEZ'[\(X\>>I=%0SH[.3Y]?_3Z/.@_*P[![[^<G)T<
MG<? R/.D*?$$9-?1PM271)+ZHTX:8N[(E%*= 3F7UW06BFDL1R:F6VT@ F\\
MJN&C+#V?-Q/XL9RO%APD[:,%< AX=[&@P]1,*I,:!2^#X\GOV3S&]\J4U9AD
M3+01J];2S8B6KBN>EPC\]#2.7K\^[I!X9F:F!EK.C)J8#)/#$SDC&T?(YW 9
M/GO4.\.BMVM>Y)XTQ7U[E\$E8"CR(7CI3!?E!<CG_X@2"_M*HEFY!V?J&L0O
MV",:5B2-BA)NF,\S^A'^GI;%+*KAPU"JTW_G35DU"I[$"[#3+.5KRS4W;?/[
M>LD(]S[NK/GBTL &;IEM6FIBPOY971C0TV;X-PLZI (B%T^,Q:T,M(*M:LHK
M<P7: %V="05QN8?VMT^1:WC?EI'IVM?=.,NE\RCS7;H.A&MGW,X1WHG<2/3>
MSC-QU,R+W*-:?"U,&MW&EISQ=H,?""=%U]&T*.'-*W78NKC02/J;2O<CI/;U
MK(!O6IUEQQ)27*IJ'?FLUT?*&#Z^$YV#F948E=$Q+3N6%U#V69/I:/\PW3ED
MHYP>.OF8P"+!\3Q*:C(B26SDS6P"-^"?L 2Z\HXYG.P9G"UZ/TX0EM4DJN97
M;,2)6 XICV#/PVE8YS3 D##Q)F&N+)P<90RL0*XK=URL^($[2)5J94Z?M7?-
MODMX1ZG_W1A4ONI+57?.66<H.'1ND+!YJS;OS=O?X^@][N"KMV<G,2X>GCT4
MY@6JHYF^4*A73 HXH;P7<U76!B:"W Z=Z+C(N/=34$#P2]=:Z\</[3S:G"W8
MW^59R.L$4GOP=/[Q>6JJ>::NG\&V(&_<F60% 2(XG+K^_[HMV0#N?ZS+6H&H
M>HF"D17 ,8F!58[;U1Y;<>GV'+<#WEJ\$4[="AUW-WH%-B&. 4;(O*BT,%.?
MS_$!Y8-(9YCFUWMS^_. \WB]T_ODOCGEX\/1'],MM3UX3@_OY9S*LF^2X7(,
M)[,N&Z:?<Y7I$1U3L6&(K"NQ6H7:(_+8@*&MDZ8$ Q6=:=4E!N8K^(:E6TG=
M;N\E%0//#FD9>" 3U$;PBH(37YHK1>L!UFM=*ACB<\:;-@C"K_ RF+\+5:;M
MN'"W.,J[0^+-W4'Q8XDK 2=*+_ RW,(7O E3?UX8V)!=#HK5I3@=]'2*4P=>
MHPT_!,I7@O[[HB3C0OZ:*7PI*0MDL5B' -K]Q<PD8O[4]#FEJ3X0_R)#J+HT
M<V?:V ]93V?[)CG1)'"B@2A[QQ3X5=5 CF/2'#HLB4Z&FL_+X@J] =-AKY8-
MT1/N<@;[BE;\^_:@5NX.:_O#IZ$)=(1.9#L$*/53..DP9!KE.@$K#/V"H+G+
M0T-3D9]>@_:?7/NO#*=RY:E,PJGL1G/(,S7:$XB.>]2+;W:@D3\]]EQW+/?@
M[A*_.B4<6=_?M\(MZ!SP^%H\#KADZK89L$* %L;2B_KS(M]_=W9I4UI!/(>E
M*U"#F %G2/#J;0'X)?N"H74?YZR@B ?_."LJ_/,E?&M@#RO90QK80X<]D%"9
MCC'R@4=H$U<2F,0(%W,M$XQX)5D2OE4!C!2!B>S90.LL9C-E2G$^C)/#?[4$
M2.)HGH%]HW& R^LY&C@)K56,5_ %%_ L#)24F@.G%&*?3DO,<096IZ+,Z#QN
M+2E#0?ZJ9I,J:683&"#1Z*"!*QC!;(<V4QB97H"7X#2+"QR=.653U>[.):O9
ML\: #0 KY;GUK"$0''F2->R9E36H2"3 !!$S4%.PE[S?>*7&2&R"RAZM -R8
M%K#'-=AAI<X4:X_$:=OW)T53UGPQ=E?)E06/%R ^E)U:IA;;9*S")E+F VP'
M=N^T$Z!5J\7QY<W<W4^+5"PPQE5$5T6MVX Z+I+(4<$R6&@$!90S%,>+2PKV
M\A+U!@1Y1?O $A/4VH_7G8_9=EO!,A+_ZD?FR"#M("D*L()ILC/U00MT8XDD
MU]M;5@2T\M$?<*TLD8J):)"Z")5;*_+%MQ\,OZ"3$59U 51!/V$(A4UT,O2G
MXN,K]44!O_<%<LC*#%F9]YJ5^7(G)&6.+BGSR^5DANC>+6K008CN#>FJ) /_
M4: (B\Y 6RA-,KY0W_N>79\45SH'GE*AT/50=1U@^AT#X=^D+?PE0FDG'Q,]
MK\D7X_18T&%GIA;5\%QSM.-@*]G^(HZ2$_R;=6CTE0PDWBQ#QSAVBSJ?=W):
M4&5[)YI;^T^?5Q&[W4C)G3>3S"099DOD14.F2UTQQ(/C/,72J'@#CQ!<.7]I
M_.56\NT17,=>:V_$6)MN'8AB\:&Q*];>E-(%-))$]"><@2IE3DSF7?0S<+R2
M#' PC8Z:^K)H[76?3 E&C%2*A\:P*4)12HPD+HHF2]'V)RZ_DG ):L1&')A#
M]EUTDMC$LZ8BG@A[ -AU>JFS(?]H;U%*?24K!;M$ZE/_?@+9P^*!PC:S]BJ\
M"58ZCL3\H@ F'*L+L:$M4K,#-XM^!X91-#4G9UB^<@%69JDR#Q3MS#1R8^!^
M3XO^8&PNKDL'-W$0#QZ''W;%TK?-0!  ^#6.7S$%"(9[R'FS!@MB?\C@B'21
M;/,MV)8B86T69E>Z/[=;FQX)%I3T,M<WST7>FVJRM>DGH1"PF)7]8G+(=&FC
MMS3*/U:^9;YZB> %9-(GJM*QN#*60^B.'G!<NFJ)XPXG@N+G_H&X>1]P:E/0
MG<M><&\@7,JD=J%,7O'J,6_ .<)FP:*J+,B%OS8"^*:HD0BM:PAW"3@ IEMD
ME;98LS:%HBY5.<"O9PIQ+[S'F$P4MXJ $ V&QR:2'^*\6!UG8UHDC3TCDVOK
M>$Q@8,XR$:S+$&$>3:<F,Z #X7LZ!V<87+*-0_*8...9MNCW591O0'5+\041
M[W>T5904!Q^ YBL_FR8F>*O#I-@/YT,>\P261V\GI)91_FN)JFU<M2OWA5T6
M97G,5!R7 YYR =<,K(GU=BY->N#6>UJE]>;Y0 O99>PX%?&'U^ICU/X%IS'/
MB;$)FA(V -9?P)=(C#R+CI9S6>!2H"Q5$55(1?9,DB 69W,$"Z10OP!=9]*P
MBL"I>[TE1: GJ!+\P56[H*2X4T28;ZR6\OR&Z-U/+H0YV:-)'P7G!H9(0!BY
M-$+/7A5-;X+:2C^:2Z#6.1A#I7VW_;7GTV\CV/[0IJH:>"6E>@$KNL(R$QP_
M8.FO=Z8-Y3K:!WXG45M7VS1M/N]L=9%ZZBNR:CX'TX:TAM=JP:'U*^(1_>4"
MDZU,C&PG?O#<VCYV5>CR0.@=T?#V*RGF(_LV5]?=D6&)$NU"-O("W$;8CVIZ
MC90'J^--6:"^SS<C'P>A03"7,0478[8LO--*U >3:BH67CMPFH&,/F[SIG@Q
M4LM 6#%&&6GR1DN^ ^4Y#)A71&#7VQ8L93=2N)H- 6DPZ@V169NJM?+-G$A,
M#@7XR?,G<.6.5?XE2@M&N&JKI&*Z)^@#-<- #.I+6-8[6LJ#<6>Q:F8S%\W#
MX9WXA^D3?\M*K5)\'3*F:TNQ0?G[2_$=*Y6_GL(G>F",6WDI[*M'"4R#8LDN
M6\(85;3LS>.:$O-E<>^,$($H]43! $==CWQ"],!1U6&('@R6GT.J^P>:OJ,#
M&=X2-0BA@A&&"GX#>9FM[:(7LWFFV3$B M0KG>9S/Q##&<MS\M2XL@>K?3!Q
M=%DL-.9U\+/B_ZLC3:$&E?Y9-.R29?]85<.8<BA\I"F\2)YH_;D6Y8V&?8D>
M1%8&:*R;/F.55W%"7E5Z'NWXUBEFD3?;-!7\=+)KG$A!T\>)#SN%GF<O)D?O
M+1[>K:/M._BW!(/[8KOCY#I"\26XJW?BY@J*SE\:_3@=]$$,%5&(7>:E!^FR
M\&@@".L37L)HHRAAEHR(+H)D2U)%FR2!Q(D6Q?+8?"B!>#"W*9>1[G <Z(6W
M^VU5@N\DU*'$(&$9-D)4V^CJ83A)?ZF_^)3EC82^T*-%+#Z"X0VB:NF/U*"!
MGZ<2&W.^J]@J_%*#Q-G;E (M#[?"#L@<%.ZJ]?'02W::>1QA[*VL=/?E<*)L
M,K6X%9-B-C&Y_ $_X_Z8J4G<%9-WW) 6_.M70F'?8V8^:#[UF 1M\=Q\LBPT
MV0DQR8Z"(UQJP7ER(21T_PC<4X8'A6"AD5E4G#U"/W46D:,H71>@Y18"YS5T
MNAWDE?,[Y0^RKTH;Y/1?+3!8_N*4Y:GWASQ>$J?2YHHKOG !T-4)7 $0&@"A
M]PP(/0B T  (#2Z=%5+_47#I=%PZK"::O*.='ZNY2C#D^3;/QE2S?MF[ _IX
MM]Q"W\]:9#J[MIK3D+:?V&]%E6+ REBV>)0?3(J[L#UZ1')$UGLCQS *1DM-
MX4T<:K6%RM^("[E3QH9P+"V(9>6;;$E:<A+74B',O:3TWNU>&%S$=R/)QX&?
M^/SDM 60H3/GX[BYA]10PRE_P+AEX3LFQ/5 ?@6^(]UVP#DT(2@&VG=L(.B,
M@W6H9;A<N#YLS@/Z1AT;D0*.G;C[X&NFRF15%X&VTFNQ$83C'!8C(ACK:_8B
MSNNYG0G\W>(@>F/<E^^W-9LIEMUB-Z\=V9$;%XW?^;Q A%C:EO.W-C%B@\!R
M;A"WHBMJ/<RFJZ0X$KBL]K(F>;HS[\'LFH1B'Z?+ %-VGS-Z%/@Z[!><@"TB
MS&F392W$E,+HIB:3?9M13.P%H,%R-:,<8Y5PAZ&JUBJ-W0GHO]L[#;GSP0_[
MW67/NLM?#L09AFZ4 ,,-J-B98#OQ-S,UM+:Q_3+OJ.(5G)6I:NN-C\/1_>2C
MNY03LNL@'<SAR6?MA=DI]80HUAX>4;FFXH03I)K%8H(6P\_8<H!P>J24X%*X
M?S<:S"<08 ^]P4(&EN2)E/D$I8WKRXLP\)#:,FUX85(T<T>.5 Q6DL&1N-!_
MQ7#Y'(2;*9-FADB&!*;>2C@!O*B:/5>#;^F 9KAB*;.A26=:I+OV\1*R>O3I
M%6?!#U=17'ZSORW\'<P)T9!'-$U"\!MT-Z(+4Z](^PD*[AU/TI.@X/K,[DT1
MG1<@R4U-OXV(Y2VKMUU.-XSM]E&6]659-!>7?C*:&(M5[&Q%%HX7#&_EX%TK
M88ES")\UI %<FHEI&VBH#X+Y=;J1%1Z/=Q_=6(AMG?N,JXK<QBD8KTIQ!8UB
M]M8->W*O&T;AE61XPV8-TE 5X7]A/T8%HPE<\FX+]C1P29]+OA0$?-LBY33'
MK+[Q\TS6*3C%CR9N%3#.__H/3&$%-)@@[9/,5)<V IEDJ"^BFI]Y20%LOB27
M.FTR&&UJG,9&NM_)<6N;(9P!*^YGFA(BO&HV.'13ZC8+R.>\KM813XR#PF07
MIIKU(P>8:,$6AHRB7-BLFX_71,DS:E:6Q(PI4V4^D).]I-JVV4*IRTI,NQ5I
M/;^&76W*^] W)1]Q#FR[U+>GBYZ(6;MB8TUE=6E6="]-F>XP+MLYA[TL](TX
MH%:</AW380Q"YVX+]D,0.CY-GVF!?ZD6]2$Y3:9-CQIGG]H;?-/R4?P]"\G1
M"B50QH]KQAS>@7AE'T99NDIX?IKES55I0U>I^_$2;EF/-J.W!ESK$]?.#C'0
M%KHV (6>LM/?M0;9B%T9I>NVR3/J5=66A_A(BC#HKY0\/.QNKYS'?R-6?I3G
M <,NU$X*8Q%@=)0624KJ/QR-D[8.:P6'IRV:@C=Y/[(Y(HA),\-#D?92@WT5
M7!KN=D97I:%<9U;9O?"9!^(L2M+VFQRM!RR1H5$IS]2B>M[MM^D?U+00GUB_
M>G<?(NK%\[HN_ULJAMN*.54GR_GFASH]-@,!/ZP)\4UJ/']9U2P;Y5J*B@T$
MNU!W;8/"Q'5<W1TX3*A1807@N%LQ")@5J,5PAJ6( O?=&JX*1RS!KV/5C19S
MQ#9'1:S7]K8STD(*3$G6;V5K%;5]/.)NLJ[- I.8H:+:7[$?$>M7-.K5>!@N
M!;;]*;6NAE;=%:AJNVH/E*C:ZC#"#@=?JLWT.46K=.J/]##%JFZ8@Q2PTNEZ
M#PQ7MUI:S5Z)Z=6%O_Z2*E6RSHQ6"&ST+TT:>M]E-G@^)UKG4=IDK(H!BS$I
M_'M%^8JAGBC(^F#AFIFEI;31SJGMTGD&RVO*<,*GO/:C=;%-W(]0.ZBR\<08
M-FLDYM_6<EM.*M08%$@T'6B;$KJ4>+@,:$.633P^[G<M/[$#,NZ5Y1$Z@]B_
MLG;]T!4K2+R;ZQ/2;(9J'O)7NL]>]D&W^ 57MA$.8)/5%JV$?DE.2[HR1>;J
MA%"A?''33S-CF]N1#FSW@+K@314.)GISSI (J\BCXYX:V!54:\13JX7+,BQ#
M"D2MJ&O4D4U1 DHW)XF16[Z3(D8UA#@#LVTOL%3:BGWI>!NWN0TY4B%'ZF%S
MI Y#CE3(D>IJ,T_O0YL9M_(B%HG']#.UZ+9^Z94CO$T!AJ_1=;6-;-Q*XI:-
M]]Q#!"ADV1:WDBUNQ1DFI(CPH@G%'8@QPY9$N()TQ;I)L10W9AGJHMP3<AG"
M9-B%Z[5&-;.Y,@025BEE1&?7=\BA$=&_7A'BH$+_E:6Z.MI>W*IZJ(SY&MQ:
MJE]:<%$VC+^U*EM;=$L\ +&S_^.N9DW&*2-*R.BW:/08P1^NP#TW%W+I]H+=
M7V7Y#Q^OVV82RSSL)-P,EEZ.+@-E,L%:"(.0_DL(1)E@E_AU3JCU+M#JN=.Z
M?";#^?M2YT]_H?.WE!:EV((JJ( B.^VIYL.5@0]<B?P<<+TAT!T(/;M)-*%#
M/[DLJ&#J0'1=YH-&SN!TG*&)XV#M6A 8ID+X*WD8X0*=M7\WFJ(574CJK9V#
MER?4=AP3D#\PBQFZDDJ449+&6G NC)N*3385YPU%Q]CHI*AR%PXQ4ZEN^P['
M'<Q 1]*;TOK,L)$:0WW[ U[!-_>]:U]H8?IEK:,MNPPKOHPHI"FO@%$!ISOV
MK5,7\,7/P.0;5(JF1;FZ=C9^8&8<4[)A+HQ6:9M"3,9\]\/;]H.?\MWD"$\^
MY,6">BQZ:2#RF;$/!I%7GC<3*D?2SX\> D[G2&:&)**KD3;T]9\D4@,K7LF*
MI\.L^ $07+\/'-9.+^,579/1Z:>Y[+;3&:H&-0B37V%'RXM6Q2F+1&OR"E%H
MD+Q_Y-3#8$ALW^K(>(![X_NP/ZC&BG_NX24?VZUVB<2")4;,5DJGAZ<#EFY'
MG28IJVP(KWN)I[K &5"L]K0ZC&4- ^[.&U28UBG(U;Y=D6!VW'L5A"HJ,^N8
M",/$ G3RCB?OQP"=[/2%DZRY\:'S!ZHFMRE^A*3G.N*$D&>\EKBZITU)$0N*
M"%!$3OJT.D:G%7P_=1B>@A(AI<I3.S VYHBDA<R2Q/1JB%-HQLVI#W.QT>A:
MFNDJ"A?:EC1YRW"7+=$M-C@YO'O!VHL\:$.*<%_*"E_- 1D+GA)#4#!L@_TN
M)@R-.>$((WS(>_I@#!0E_!.M0&]2IO*_U2D+-J_ZIG!/5S'#%XG2LH77UVWY
M_?1>R6\@/VL"DP7BZ^6-CNA8" AQ^VOK7_#E,N\V)+%>*A&/:>%&= Q8<4-(
MT$9LIH7:[N^-:0U9CE5D'6LGKD05&$KBZL J;[S7:WV'QJ6^DA@S!7M%6E%6
M,%YM36KKS[1JMG.[3IO,A<:7WM5ID],5:4$WOB-1[.\-*\=[GZD<;Y)"_*NI
M$IUE*M=%4V$E*RE7,:*S&]PJ?VEVST:0\9$S$,9$N-&;HC5=5@J.B>W<R5[H
MMF$ 2Q Q=(QWNU>TBBQ#<Y$S&LZK6]4#L(5#])<"QC?B$)WD-49Z'7T^!QNV
M0:<ZDE+U'%&&5 :\0E([R8!BRR(W"?OW9Z:JQ#_Z2B65@?F/R99<<K'X>$[R
MD?#'MW;]1-<+\GAX9VFY[BJ=OP8!S3K57*O=5GXR/O@9"P:TN&B.=+21#SA@
M<,,$GFP=#%0FGP+;L\)VC)=I# 6D+"R%@<WBUE[Z:LE4<GA:K+2*II?**-1H
M]SJ.;LX7),BD@;,L:JND&/@W>UC-(M<N(%8!/XR0PY4-UR1@ $-;7E]18H0'
M^?7\1";G0^5/M=.'DWK)4ET+62GX<VJID5QC+=76/M7".KQ[^2KBTAWMYU8-
ME@4RFIU<"/5=)@?K^)*Z=JFIA\M]!0[\EV+--X(#'W7:C3Z/_F]3FBHUW8X*
M(]BQ87\U')@+PO"0,A*[2H]PUG6_"B27?<33@UF,K1-5/,0O-5Q6I<9>'!>J
M3#E1=MH^P %I2OQH4[#X[<N9E,"+\\3,,P[36QP>_8&#465:K[A7-\1GY8 7
MB;/GWZ9NHM^:@>NE1K2?[938]2@,*&?/R*WC%S1EN>#X"$7?Q,<M!76:R<RT
M3=Z =69-A9KCGQZM</*$QGZCKI!-0ZE8$5 ,K']YO7+)_1"F5.85R!6.X))*
M*230$SK^%"2:B:(1!:%[_ZIWT@^_Y92-1+]7T4OJ;9+4\K!M]^PN=^B$?#6V
MJ#$2!PFA3)E9Q6%_EI:VU\G@5CLROM1 <Y([(86$TG:IN<YZ/UF#F\+2AFYD
MA9S]/>3#X^$QL31C7R@"X=#Q(VJ3MLH@%7#/0@Y%R*%XV!R*1R&'(N10?',Y
M%*P]2*;>:I%I6W^1=E AS[Y:Q;(=II'O)<P>U9L#_0;>1E864%(SHP2)HM4R
M.IH-JGBM=PQ>>-45^_#-5X;1>31-T!LI>$]O9H_:K1\UX)?C?N4X,,CU"[B2
M;WP' A#XEV,2^*L*&5R9;;;D;M.3A>Q01W0IX36%UB;72$1KHL>^21/\2^2J
M;,3I.*K0G8[4-Z*CL0(@!AS*II\CCXL]G!@R+R_I?'(M1>PQST5 ]F+C<74@
MSMCI&+?L[.J"Y(%G(DNUF'Q.LJ'$?%JVZFN#ZGQ)<V<C5FY=J,Z77#B2^[DV
M4K.E<U#R%D,M^?<..RVUJRC):PB@++YRIFSN?9KJC+*]4E<33""'C)LD][.G
M:/C5<S@>L*(E3EMRXKHMBHP^E=F\/5RVH(I,8AB+TGXNS6/X&U?/TIN(AS$?
MFKEC,XC\X&@%JDBB,@5)^Y=FI6T$*WE3H%0K"1T+9'A&I#HBQM+V)!RHZ"6E
M&B4G(C/8<<I4G2XQ1=F&PK#;,YDA>#C?M>6>Z'S&K0Q&83O3Z;7%=DL5\ 5P
MN*I QANYY(E.%^P0:EKS]'VY1*2-.(/G%/QE1.*HCMZ1J^=3=JOU].0=IY#B
MP>.23 6>$%_SM<:^J1ME6\#BA8Y3H45P>D42:$ I,::[]99$;,-952:G<(\+
M =_4\<F&.6X?N8!IL&*_O CR 2RJV^_BI/3V%_\#=Z-3BJQ3P/[/)KVP@"0E
M81T*B\WFFL(]G:4!PLFH<!H'5=;<EAMVA*V,=];*P$?:-$^>S8S;YW":BO;!
MMUXZ"BE55 D/@P'4*):;T/>G1]$L5)IJ;9O3)=$"^!MQ[_EEJ2I.GZ.D:.Z\
M-SR25+ ;^,&285L7K%/RR_8:@S6&5U&[C$JZLI$8L:EZ)#Y:S4ZO)NN!KQS(
M(6^5M.%Y56 +1K,BI7Y]O0:=0T&_;A,Y6ORV R-"U*0L JN,E)B3)\,[WEOK
M]3_4;L+P)ZW8&BIGH9)+1&?WHYOSHJ)\:)XF\,F\F)D$A')380,1*6S&BK%7
M]_J.TPXR>:5,O@@:L4ACRYW>M6GF8Y+*M\[EA\^:RY-UIW*%*<^)RB321/@[
M=""/:*UNK!!L>V#Z%<=)[[=X7<R<=+7@V7PH;1:B<F9[!Y*7-+,FHX(5MLYJ
M*BS; D3$I&!.)F9&.S;G5\=B66"]+%1._MV@4M(+H%A1HUMY@/Y%6]Y07I-K
M^Q)72PB^"!/3=??9@7DQ+'"^K"-@"  N$XM-U4Q=<!4+!A[.X)TU=BCB7Q#%
M2'$:&/]*F8R5C[8TSX3"3RJ%CT0X"K_9WE D2>.J_+! = J0Q?#<I.DML)H
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M6Y2!0.](H(\>E$#GS20S"2@Z,%:2H7J,.V<('B=*5UKXG!:!/1<%[,1*#VE
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MND90GPU*6W46OZ1$ZSEM TC$8J5@#;OZ6#KM1J>Y-5\M;*&3C;%<W-8KJ>O
ML +Z2QLLN3N?%Y@;YVT#.A#;N'2W;$[9B5/37-MST%9RDE+2?BW@IKZ$(_4?
M3MS'&I4FIXB&*^O3"8#[9[]W4A=%DZ6\-Z8&2QF.JT<UP/_*MHSRT/+OVG7
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MW<#*$EOA5_E&##P,9Q/,CH3_)E.FF,8X]ZH!$ZL]O/SG*O;#YCW(,B)]Y(%
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MG4;3/UW4])6"1-S-WE&SJI)Q6#M1UT%K+Q[H23N6V<7-L\/-W.(P%A,O<*G
M0T^ZS("^&H=95S=)O4<E\C+O5D%V89;'0EV8;YZRHRW22.IP-A[94]29H^3A
M.IMXR0&F/6)8ZH(B#=7N-8F\/L8PC23QTTG;,>QNKK;)I"SP!LIX$O;[KMQ!
MY_P5^RJX$,VP9A@1$2>1=ZN2 LC 01T:9G?0E%57@8W85)4N\>'.2%](ZHW]
MY#G[MX@LCC%0N4=1T1C.A7[+9=%2UMQ3P-.#)A@[JJI1> )^[U+PE.+KII(4
M#94:-ZNLXSQ+X4WD!MIK4T:<J&HQ- X#%5*<+^0W5]B?#O/6[5%V9JL2H8Z#
M*_BK61W(EYL$DN'^%4:6%^N"_G:%?,"-F>ZTB[GPN%FTH)H4R\ T-7%R0Q>)
M+(F1VB,]\%*,)P^4FHW# 8@1MEW-5!AE11X&50Z!UM[4JB^DW.L:V4X3X]5#
M3!2@U"%+Y=% U4#[.@7K-N39"R69IGLB;*>KF.48/D0JQ=- ICJ688:.BNHL
M%%D@8^:,)F_$F\QX*AG/#C.>,E<7:(UR?E\IWO,GH!&V#<W@L=?#'&I$'3*\
MS]60ZDFWT&@2B43GC5 Y,"1$]^P07E0^*I"JH@@ML/+=.[FO\8H42KW/BZ6'
ML7PF_#SR>IXZ5J -W*P'$\86V)'5 2O(./#OB\$$&:^B5ZHU5[W0PZQF&M74
M=]+ E"\M(W&&DBP/<YE!=+5%"Y@7*9B^EI"RRY!260Q+>H6HG$QS\(^50I^3
M)WD[9[FHPDC%)Y76=&CD0H=486>E]%BO&=W@E?+G3B^GX KU-Z&#3DJ[(JU/
M.CV$S*G9!_(0>UF*H4(,E78,B76LZMRV^$,]3@M8EZ@UD<YOHHM98]DHZL98
MN_?;=K1&9EXCWV]9$EUG9.DKH[IZ;LD@8;I%[95H)-2J:H^87U+5OI@JQAX[
MQP^#&RK!E7G#TA@^6^FJUB+>4;-A->=+N-JX^K\/8L'^LI.KF;9<TL*H["L7
M>$Y_0JYN2..1N)^B1?.C[P:K!&#_QPZW['"[7(?;?7:X98=;GO.GS7DG]W4;
MR\4OL"!;Y&#VNJ RA9Z<.7^>7)\=7UTY?WXYOCP^_ZR6B89S>'ETZ/2\$+H*
M=S=@C>MO4U%D"D$=/&SZ'BI^0PX3#><R*_^9F>>FB'2N:T%(@_CF@R),N@"P
MVD2@": D1)BX5PKKL#JQ'6CSV_^27\;NN_]#6YKYH^&TF^WNML:NA-1)-> L
MW"+UVB)U>5/8U+6: )S_,$ .J.B[DQ@ 57_2/_U":P*!N_-3L]DTMZ@'6;!-
M:TCB--4_J%RX2&/#HO)6.5*MZ9O+\.XH]--QL+5C&CN2$]YJ:U6EAPV,NGXT
M5^86)$O!U?<HL]/?DHI,?PW":GVI]%YK6\?ZBA3._D+JG/T-"C[^74CM(Q^6
M?U!S^C*X^YT:YYWV]G[W'[@F2QC"U9'^V\'5&E;*Z6EY0T:AF^ _WL!SWGSX
MNQJ_M\E@'88R_Z#9@]O:;N\O-K9W(R\16Z#2?="9(+R+W$EQO+6IHVJX0=,0
M$O[C36>=A[Z[L[V_]S2Y_IL<W=PJ3E#X*A?QY]@15"_AK=E+=/NA)7I&OVG9
MII?*>!NXXI=T,A$1)EM *EZR:.<W?CGT@D_1A\<L+[OKN[S8M^TO>;EY"/Y>
MY\AFD#?_6/^0U8>'WXCZ]L$.+T"KM !]O/^E#/%9A!E!5G+X._O;NPM"2,&
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M;Y;+\5R%1;+S,.U4,L.36+N,/NQ(+!LZ5^P]&7+FS:E:(N$SAXI,O)FKM&U
M0,'"ELQGU8>-,R53, >^1&!!5/QI2UCY<S#5M8#]>.L?QM,V3;)S\YF3 -OZ
M&\]$3>E'-K(CYZDC &U4,293DQ1_7M$P9HVJ7JK^_%M+-@'0V]>Q<L8TE+WL
MX<C V?D/V>CP$@N--OT>FO,&J6MF'8ES@%Y5=*Y1B9#9]@6]O=.^,G"75=>)
M4C_3B*DC,3L]$H*MO!H-KP3YF +J!D0MHKU_*5;CBB6])R2@9FV<O8J6%,PS
M&@%4%_>YRD8C?)/P7UX/XA+G@IGDWAO0;S16@"J^H^TX9^";[\@TO!%D]J'Q
MTQ7?&FHM:JCC]HGK6>=1[CA, VMR]:%\OI>PQ@0Y3ST:KNSW:4RF6'\TQU/_
M4I4Z-8+AN$6=1]_ $,\A_PA4@AI]NTI^!IB./I!T#I0)7@;4"$TW88B9>5-T
M6,'MNMPNRWH"Q3H@!7?/1E80STS$XYUG;!<<?>_$O=<3CU__E0YN\M9GG/4P
M)0KTK]2%_3DEXC+!JC!LY.61.#NP6MPJ5?PL!E3Z]E*@"4W0,-'HDL%\(Z\/
M,1U[0/,W<32@K[#8@IBAA87ZC+87I$+X[R"-M-@K8W)/)'=HF7JZ7]$<P[+M
M'%HGSG;05)!(6[890+5^65J\8,H&2K7GWAM/Y)E'T)3ICD88WHM9H!N9%9).
MU8P<Y::-B*,T>-J"J"Q&Y!!M5#!.Q]C!'*T8>'1P3!ZI6GWM"5%MBD.ISGJ4
M*W&)3MZ,BD_;F R+,-U)9#52F@C9J4%#,R#Y3N6KA#,&>HR]4;YAVD:WZ(E'
MWH)MSP<>UWM];T(>J4'ERE+@T(UI,&GHJTGP(SSQRJ#0>J+ETSKT9$+O$H^+
MA]9 &1R<G;?'TOR,%\#V+<Z9%Q]ESZW,6E7A'*5D/QO,8>I33*BT?UO<&:3+
M\]&5C!R  UI,[47">*FIWJG4U _PYV+",V9T+\'HM$/E]:BX;XI4\8PB+%?A
MR,,<8U$!+IC=,_F1\+/M7*B698[KH3R ,H$DEA1FAU+2_4;Z2,+V2CJON'$>
M(.1IA66VL)Q\ #"$#@,7Z'K2ETD8Y<&:_#VN]M8JW$EG[72GW'_..SP]\AZS
MP[)-+>_09 6A PA6I9=0I;\L59)G,GHIR+8.)G= Z7HKUVKWN^T41H@L"O(Y
M$ (D&$UH"1E)M"N/76N[9-VE<]M56G+0R&(M.8-I J?+:*?D@(.[GR"6N@4O
M#TR.10 $!)VBH8PD6"< AJZ'D1X'>9"J'F=M%ALF18GOC;U$)6$Q7N1(NA,\
M6+LW<# 4RA1)X*C_,"V%=^'G*(GU)DOR;G*Z1FKNYC*M&6"EC9*U>:RJWXXK
MJS)R%0PG]@1\JY@ F1=91UK(LUUX^IT;%:K<XL3#KL+(T5^P)X@'GGS*M-=(
MQ?L8B%X"B/3@?\:=''DS/(=[:! 6O4-+7""T5VXQX2H>#V393<O<I;+-B+TU
MG\<3J=0EDU(8%AW": >AO#PEB=>>FQ;'H7KME+8DU*770;]@/]!+52JG(.\X
MIXP*#]X'[]"A,<6<)<H;3F:9H22'M(GTXEDA= O,WN;,C!4TL\I]0@Z3-:.>
M=J"QL@'11KQJFD25VU](E5[=HA0187-SKM.Y]U>%Y^9FOY#Z= '_6YU.4OMU
MNY42.J.%6M3QSKE%O:1G<XUC,E(;?>F3GG_)U/J0W^OGPNJ$W6DYCGU8Z,2#
M$0"Y"L'66EW)>(V*9BN5.H"Q]L!JW=7;;3NSG&6-D&N4_EWQ*</C-7.BJS@_
M"/NR+,F7I<N^+.S+PN1U^?E!E*UF>O/[5TJF)7.H4;9MF[UKT8S0WB&K=5'O
M(-&7>6IO\U?YPEQ"L901G.+7=2$7*[C!)3J77\I+@K">/;3MAT>Q+3%L,*XJ
M@U-)J'A/^A)[4M\RCF554>4VB>Q8]\9@;!67G-]0G/G^%TM$6Y2W&.>2MT6%
MJ3^0_F?947+V*DQ*,47][10$\VU43$ I&F93&5Z0 G)%(!'R)53%L]3U1SE:
M/=>PF2,[[((\T\G,[1)%*G;Y=*#C^&%P4YG3UC8>E6H;.Y@S*7]F4K[#I'S5
M2/D+LG+7\08PXZU6$UJ)33!2\*6]FK/?"_W!H^>^U;8F_^"@9/9O0]#EITQ_
MR[Z,FC#5 !CJ> (CHT;Z(_3(C'7%@-B=5[HKJ<%O[]_BLSY,:3'/WS/,G\+=
M9Y_ =K/==<ZC])N+1^61.Q%IXO7CAG,2]+=AN)&RP$=D"<!\+GPW*$PS$P$F
M L]*!'[C$M5,!) (M)D(U)((G#K,!%X=$S@>3_SP7@A%"2YTVAUF!,P(ELT(
M3ID1K#4CR-:/11Y6R_6C#$;F7#[FP9%G7"XN#B^O5?W($^=]+WK[X>3L\_GE
M[X?7)^=GSMGYM7-Y_)]_G%P>?W).SIR+R_/__A_GZOKP^OCWX[/KM_#WU<7Q
MT?4?5\P5GILKV(WIHF[;UVW1-\\N#2>)&$MI:#>WY;/4[7**G-;>Y/N[@1=/
M?!>6 "_PO0"ZZ(<$\_+.JO]5$G("'1@',N)?G0=_HBB',))G(.>492J**R6J
M\\(2Y24P6?W7(U&SQ.6$^EHF-/8HY(7FD_#155E431@?Y#[[0>[AY=&A5!8B
M^I@A(5?G-$OS_NG7H]-MJ8!7\NQ/_M'J[N23O,M+LQSDJMIBL1J'I]3WON@C
M@9D#PDAF/Y<.#O*O!-B("[3#Q"TK3U/C!$$QI>:B!J7P,&>EL%T1>%;J*J_+
M./4H -MRK,BG--6%RWOR_04739ETP?1H4^8I<^,L8!##GDMCYT*5'$'%9&'J
M5ID/#SX(O:L*JXN_--1XJ.=0?CUT"U&>)RI-Y?1]SD(O=0,Y&KD7XU"KK/8-
M<D])G%NX/HTP*CS""N_9:3:2CTGD89I4'1!A@BCLX&45?Q$K=Q4*N=ALF!A@
MV&\.*1Z<'-\I%%8%I:([B$@2%70/HYU2Y")>EZN!J6)->O?YB<A%G&1)6F;(
MAY?WS'5U-@.*31^Z^ A5B\(%V0R"?")1NU$]X7OBU@BR1WXOY"@P06=VDZ&N
MAS,YY1!0+'D\G8>6:D1&WIC"65T3&F)'SX[<@:S_8B)A9'0]M8A:5^I+I-(X
MD.2E <#U,/79X^8%@'H*<WMUPUP9G 1:-1>B4B@XR&M*68OMC  8Y2TS9,_
M7,OS90TA]Q&(.Q> VJ,ZC9^4S$ ,\84RF9$!9Y.P.2\(GAU:/Q>>6I<O T[M
MI"(D1D%H=&8JC:?V$K."151M7F^,%67BE(9A#.,M4T,8MS9[5;#<R"@YK#M
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M_%18)8<M5X"*R2"/0YF05GH"8L[X %UXT#.MX62H0,IK"KO,@(5,I<W+PQY
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MO 0*["X%!2S-+\HU6F+L [I?LI2U>@V49@Q[/36V#S+,[&CS^!A31("Z^OA
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M#">P%\N.K"R_!^4+-)T&2>7457;'"6P%^I3,7'Q'9SK+_:@P.-(>T)#:@_W
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M@C\Q[2=:;#^&01KG:6V!;Q+-O1[!Y,3.8</Y3:0B4BSWD^@+S)]G%1%KMU_
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M5[+#%]N %Q#V#I0LO$-U [!-8#,0B (*JZ8I'"[2OVG^=_3E*S9\R0AW\"B
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MG-]2_YL;!3_(JOAW^H#$\ -]''BW\DLC'I>77U@J*J2B#W,IHBJY4*/E0/]
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M@%^Z4>0&\F(6BQ<4BW__:;_=[KY[*>%0F<ECQPT&;V':X_Y(#%(?YF7DW@J
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M(\)$0E$$GG509?](6 J'F&<=2]FW:TY7>EGO_Q $"4M!<M("05N^V/!BQ'_
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M3.ET0C"-.S$[,W,7-4]BG+V8[2?*GSB*+ 6+?2H4JQ7I K/_ U!+ P04
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MA/L6\^-%:9YV>H#<Z_\R&Z+QQB.W@WBNPM%A8;.6=&(9Q/A)0]^:\FS"SIR
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M&:7LA1.SIR1F61T[59K0'-> -IS(@,]B8/PZ'F$XKES$1MBC<#$>B<!^F)5
M7JC/MVN<\:^_[,>_[>T;O0&6AM8=S)A]Z)O#7D_YIT0[7K0;='NV,IW6HU0I
MD)LN7,^$]Y+]^B13<2U9D2PPQBOR%0S'XX5R$:5OUQR!S9-U30&&B@+LXGC
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M[P0?X ?3<*PU9\I6FPA*TQ-O)<_C'0C*4,?N-:F7WZ,1/E=)\ZTI#T04#VV
M'RE&8K=>*X9&YVUHBL1K@E0="1\5<\_5&>:?&P[%A =T/<R/-F2H$Z9$N="A
M?!<N$M5L[PZII/46/,0Z-S43B1S=QMY+%65U7KK ,?FU-XG&TCZY9FGL(>@H
M,&<X9A.K/<SJ=<F16*8_HW!+Y,SEV$RO(IMR%*05X5%&EQ66=I &9F2BK8Z
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MA- WG 0:@G%VT?]QA7%'2_7ARX?"_XP+-G ZFJP);\_KLQ0[!5]K_K'U6 1
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M//5638/60.^I2$QSANI'-?<N4,>*<-9K<CW01YRK.CD2VG<5S<$J*(W*LM2
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M<<7K(^ _#6<P-;LJ(UV@2_U<.QZ\0$>0L%]K&\<V8XFIQ?Z(+7*O2*$M,J3
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M0Q+LO%E$[,Q==ICU>*>R:"L\ #X56^SA8OEJ#T-FI'NGR5Y2BL\GZ\]&^;5
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M'0+MF@I0MX>@:5>I*6L0/:IWR/#H*:Z^:+F0&W\\KY)+Y^C"^X8,)*.M1;Q
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MSX!5O(G^A4LX;> D@51.4J)7)(JGU"$#3NF5-7TB;"YJG/Q]1=>X\%6;"[*
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MH\D3?@1ATC@ND.<F80]KS:5399Z;)S'QK^D6G1>,I4_F%+?=2>I,>K(".S+
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M,?10:R/'8!6*.P2Z]'B:S(V:C29X-&%B8R174+QBKQEN!5]HMV"+9WEVSB_
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M8,^]QFQ5J@?R&4%P$- >_;4X_R(%S($F[40_HH;2Q&4P_R1LLE#0,")WX:,
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MIN=VJQ&#',4>+E#-@;3G.0+21R@;NU%,2D)?RU DR:?TYF6R@=B))KY(^#-
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MJY&6E4[O*+)6KF@]J\/5GT8@CFPMXHG&V3)RN.F=XCU6JCEC,E!%G[I80(]
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M^2'V^_CD'5H2^UVX6KL:&<3"IM/F*E5\74H2RN:21YT"3T$V)].35^81WU:
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MP /R Z\"UZAH0$ VO\4[$X73,!-;<@32!I^ A$D$_E0IJU\&=;#!,(AE<-N
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M T2\"8@;&C0RK-G &8&XHY@]6 V/JC$KN^2I11>0>6*4IZDA'C@E-!8&AHU
M60 A,]484HA>._H5V&* &8W.0 '4GP;L1;19:'QD"+5D"S(IF,-<P[G7VB3
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M/1GLFQMR5HF1.'CU74(S#IN-",%\IBV]7;7I%/\(BA59>):G=/VX8MS^P;S
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MY8?SDW\0Z?\T^/G3^_\'4$L#!!0    ( %FIK5CW>3,RA@L  %T]   >
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MR=QGJ[A>I EQ2;[HMG =K U%?./3A.\0L@Y,0R^7E+1" 2<(W;YD**@5<!Y
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MRVEBCMA]21VQ&==3B8VTM'O$+"V9Q8+V=V6V==P[.3[[DLBQ-*#7V=_O;9]
MDXLU&1Z0X=-L7.1'/Y1%17S4/SD_8Z=GY^<7_<%@^/[URZWNEOU]==$_#;^]
M &.E8Z';D4I3GA?BD(5OWV/ON8Q-0DN[3\B/O=%E('\CM)$13X,KC<J][/Y"
M*B9FRV*J-QJ$79[>WMZ3I>5&@_55Z[3'RA@U6R4?P3Y"5Q+N[8/B_VU]BY\/
MEQ_?]MGHS=EE_^+LXVAX>M5BP_>GG0>%TM;Q[NX..]6B($78E=%"F!8[*64:
MRVS*=O>PKY1&@/3! W+]C:<FX;,6>]=GW=W]@SU'>Y,7-@1JW7V]X;O7[.KR
M].66^++3;>_O_[?;W>E\RJ=;K'\^>KFUXF!\7#HV!.%?.AK[N98IV]WO77V\
M.#9);YO^MM@NK/FK)YJW6A9&9H*=\#3]E97I'!"32W'H^-S^[.>YDIF94>P9
MQ3[H\IJS42(TST6)W ,^PRSJ-!LGBNN8J0D;2"TBHW3Q*]N%6 P$U^Q=T;%.
M;OU@%_P4/P\9G[$\%;P0,7DS1U:UCDUD@5JG9SR%!R="T\U/\'NS81* _)9K
MV3.Z_C2-/Y?J")7 KJ"T_U3;2\]I]=>PLK[Y5,URGBU6MO."<383LS%DX5G<
M;$0)EYJHJE*S?AFC;<&^F31&B Z80 $G.;Y$L!E* VE6YBICS^1SMJ!]$3BE
MPDA< R5>Z<.>\AF*\H?)1$8@\>]2%+0H TN!5&X2!D.!4B&*9J/@1A833OL6
M9"=2QJO0 BOP E$AX07+8\RCZZE691:S*!'1-;MS/W0E&B#BW<'S7*L;ZQ>G
M U\&9+,Q7K#*01WVFV!H"!9L5D8)2Y6Z)B)S\AW8V,WD4RJ:2Z\20WL+B%I8
MRVDY+DG[(@@'Z><P :V<*C#(>!8)DJ<F.1+ 0!@NTV+MQE-=D$>#=S@,6@A#
M@H'D6*1J3MX3+.:HX-9;\T1"?,A$[H*:$>W0-Y)X9C7)X6@M0%,[+ -F@@ +
MY*S"ZPR,(R-O!!N !Z&LXV'V@Z,-O'O#*K"'QS^TPZZS)-.+C'"FLHKQ\+A#
MWUF_8(6"(6&G7 .%:!_'J6@V)FAZU3R 8]5H+5:4XT^X0(;VV<!&DXN_"J0M
MZ[:Y3%.X%KCAZ#QCEJFL_;E$?S21^%48A2!0>06QO-0([H*\CY_-QL[N0:O;
M[;(B 5B^"B=B#BTLM1;+D:G!OQ3LG]T.-N]LR#&T_(J6UQ--RX4WSYCX(G0D
M(0:Z%D!-D,1(?RX$)I1\8/]K0-?QL;%M1:2O=?(!I1;17GIKBG69/E@;L/Y\
M+7>Z@*C?;3:L36^0E@+UI;L*I)6X3#&W4)[;/7@2F-8IL-L$I,8/GF5PLBXX
MTH;?MNKZD)&>LYWM_7\U&]^D+3BB%\8P2;JX!WE#<<LGF% (9-B*IMO8,>KK
M:HP!5V('-/D$.$$&LV[\!KL5(/N20+6B)&!N2C(F0>J>)DXKXDD6)\]:)S4;
MFX3S67(I'92;54#6(N4D.;=;^!3C#.5RA/DFF%.SS,X^8[Y94.W$0E+E(J7L
M0)ZIR"/Q4851&2JCC2P7DTLA7(UX#%U,/W8ZHBM;K&8<,H])73V(>)'8@A\R
M(:4XO=G+9+K"X).\ZRY5R0VBN8H4F*""&DF\62S(]#);,S)6D",*&:/S"<V&
M3QXRLW7=R4,.PB*[&QF(U(2TI.N*X)98F4(^XSL=_,_Y@O(V\;*IBN%#0QR(
M)3/HDJ8>55C XQM;LN-2A_R><D2KC5(;TA;>G@+M<!I7MHJBDLHL\JQ6VJ*7
M3$D-@R5AL8T43&8)FSKLE!Q EA46ONVQ[3I7%",J5!T$VC*U$(BGN.HPH2,Z
M.%B0+(T44:#Y(@*(\=)>(](SOB"7H'Z@W<,]8X4R0-3C@_UHF1X<%M'OS,:E
M1LFB&"!;*@T$4_*S+3,9#5%"*%&E::M).T=Y @B-YC<B1<4C3PA;A"-*6?!\
M.T?ZI.X T,]BBQIKU-CY-Y*Y\QPPL@R=92,P$X(R9''$ K9;-$* !(F(W(MU
M:SVO2U0HNE0-8A65A%O'!.LI*@$KFW9M>:B$)EQ'$32V0MHJOBF!>EVM0?Q>
MEJM41M1L6RK"5@@VT6KFD$/RX>^/!LU?UA[>8O:/=IN]DB*-#]D%GXHC4/Q<
M4N,-QJS=]L?=O<'P/T$JQZMM5(XEN[D)W-ON /*0O:!K_F U7#M),0JQG<X!
M!"S@@KA^#EF3OAY/O6UPW2# &."^;H\%4 \I<RMU7:@7&V0B0;^79<TTVV0;
M9X['AXEW/G #TP[-"7/!$D0/BV41E91\;8\2CGJ6V=EF(PI]JJJ\5HF0\JE:
M55GE&7+4C=3&)_""94(@1_B.UY&EE,[3 @.=2I%>XG:B(@B>BCQ1F8RJ%(-R
MOAZQS,]^1!63)IKYHH.>W-?U944/K9AC^ SJRXZPTU'+'2VT6'V$LCGNO4*A
M=WF(?IXJG=M2V&R\KF;BYS5++(U RRV1H(RS"B?[IFF'O0YVM-9%>KJ=3JO>
M(_3ZML,Q_!JY#$$EG%MB6PPI(F@Z<R/(8E770/#1YK9!O8!T6.!]JW86@@H"
M%:5[G@)512RX0E-;X\\>_+F2:%6-D[@NZKW><O7$N\:/%PJJ7<-WR]Z/^C3?
M5W+7R=.6][R(^6>')1J9:&K.54$F\D!RU6S)T0KL^Z.ZK&,7SZFB9@KE[^KL
M%+-@:E'1;'RD$YA;IT0KLXFS@*_OWB0T>S'D".19:C](FUF&>3_R 12FG& @
MO]OIMKYZO'#'CH$?K8%##*=B7?4L03T;YVZJLC+[N<[9-S2CCQ7N_7 Z2, 8
M.+>60.N%5A':Y2J;-QNOJO."VNDD69F/D;_:]B2-P!<C<]5P[Z;,VM#,P\'D
MC5H>;WB05.&A*(3<C$18VM2850\,J&+8HQ*'S5D9J@-A!J.1,',A,DL[#+SA
MS)'UT9HR&J>US?\MJEAS5:9V2E EQ=+ZF6GH/L,I%H5>E)9 LFTOZRNE2]JU
M]G0"X6#=9<C8,U>K\ESI:Q<()"F8 *9ER!NAD+KB1)ZA*%F200*)Z6C9F<!V
M[/B*>_C!7L'>;(\,9749BX2G$S]C9G2V06>FGO'757T4(]"W#[BY/QOPN@>4
MW?^4>^U8FPTG[NE(]7 !0X?(#?FHY1^E@%Y)C]@+.<W<D;;EIP7 0NB.5+[P
M!V?8CSIAW .6V<*-66[64154**MA[M'&2I*[4";!7.3)/P@Q5IL,MM0J73W-
M^,F>_JY7+>XOR!TO9:R]:D&/XK_ZLH7K_;=".W_K_8H7![??K]CX'@:MNT*J
M0)9$IU9_5/]]_#<RV_ "P)_3*B?\9]/ER$/#UMT*?GM(VRZVV3F?V_+ WJ9"
M9@^M_BKU%KM(.H/.&I/:"Q$/ &W[N2>S>SQ:_K4!;H';=[64LE+?IB\1']X)
M]_6P^!M"_7ZX77M18Y/*WXZ9/Z?]':PW$W]8A/_5K^#=<:BT>^0?ZA2'2"R%
M^3N=,?VT Q_7Q-MWO=QG,-PVO3OJ7B:E=T[_!U!+ P04    " !9J:U83PLU
M2ED[  "T/P$ '@   &5A,#(P-3$R,C Q97@Q,"TT-5]A<F-A8FEO+FAT;>U]
MZV_<QI+O]P'F?^!Z<0,)H&5)CIT3VVM<V582W4WDP%;6.%CL!P[9HV',(>?P
M(7GVK[_UZA?9'$FV+#^D@X,DFAEV-[NKZ_FKJF>_G?SQ^_/IY-EOAP>OX-\1
M_N_9R=')[X?/GSW@?\.W#^3K9R]>O_IG]/;DG[\?_L>]>56V3Z*]W54;G>1+
MU43'ZCQZ4RV3,N8/XNBMJO/Y/7@0'OU3/]>J#^W]I,A/RR=1G9\NVJ?1,JE/
M<_AS]][S9R^>'WY8Y+.\A:%W?GST[,$+6,F?O3', T^CP7 TQ@_EK%D]#3_,
M"Y]517:)U3N+@Y_J^=HZ*9MY52^?1-UJI>HT:92_E%25K:KO/3\Z?G7XQ_'1
M+T<O#TZ.7A]/)P>_OCD\_./P^&1L81^[)IFX4/-6/LG+3.&(NSN/\O*>V9,;
MGO;DMZ.W46\;(K,+T\E6NU#1#T7VKZYZ^NROYP>GM5)+&.#9@[^>_U#3Q]M1
MWL#DF8J2,HMH9U46Y65;14D35?/HOW_X]Y\?__3ST_^)H_W=_1^CF6K/E2JC
MUW7W/HE.%JI.5JIK\Q3>Y:A,=^(HB5ZI(CE/:A6E5;VJZJ3-JW*PFI?5<I64
M:W<M,2W"S!AMV5\?P9LOR[Q5RGU@Y[:<]+NCD^/#MV\/3WZ+3GX[.'ERXPNX
MU,7_G+._^^WPS>'!6YP^CA; C8HUD-=RI5KXX70"G**IRB9:)&<*:!2^4=&R
M A*L5=&E;5*V$9!TH^HS18\E90ZK!!+/\EJE;54#L== [_,\A9%B_",OHPI(
MMH[29)6D>8L/=&6AFB:"C]<1$OBJKL[R#&[,>=XN(KA&_^J25L%RZJJ%88'N
MX;=UU9TN8+BF ]Z6*AQ;_S+*F:YA6KHE47*:P ];^+RJL[S$G]1Y\YZN8EHD
M^;*A.Y+0V(WY.2QH"0O*F[P\C:JNQ9_#9WD]G> [PTOAZ^LGS_AE8+J96B3%
M7'XM&[.^>?+^NJ@+M^)%E=39= (;\\H2".^2,*ZHQ\_H"8^S+I"\@#[K95X"
MB;2+I(V)JNH,J K/HP5IE[9T+K5JX2@CH(H"J(%X< 8'E<'?33R=N!.?YT6!
MSZKEBJAZ"0_2PT@_^,_3"LE@EC0Y[$P"Q-0V45,5*E(?5JIL5!P5>3++B[Q=
M.V0)(PG91OHV$>W 4,[LTPFNED;L9DV>Y4!U<"+SNEJ"9*YI'7IT^&(G.BC:
M!5T '&3>U67>+(A*YS!"ZMX+W*\9RI8D2KNFA?.MU[0WYW#%FE6MD@Q6B 2<
MPA5+EO"BT5\H$[+H;0LWI;D/KPQ_.%*';PM?XUD'MP-O+TFY%5P6)!QW8V>J
MR-69:N2H3O,S6$S:U34\@:3U7K4P.)R+&1H.!K[,8)S>NRP3'"Y*SI*\2&8%
M[6Z.UUJVH>V >U0E,#$X'V1GL$!XPV7>R0TGAD(<3'U("U@ZS B;25<]:A)@
M;RU0?FSY5XS4JMF7?6M]E#"SPPF\+:K">T,,;J;PK/(RA=U'Y@(+AG/_&Z9$
MBJZ$HF"C:$I<TGW8H:8#DC^=3I &3IFQ 1^&_T!:JF!Y=':\P!:I 9:\1(JN
M>>\CN!>\RTD!,YY7'6B4PMKA2&;$45O9/\L"S4&&WV@Z ;)5Q7PGLMH$'11<
ML0I/"WZ:MP6_6)\QK[JZZ42,X%1&Q_E5E: #%3"WV=+H]^0\V@)JAF,J43K0
M[<#-H:?QW/A&.[I9ZFEE.ZA91?"A1Z _U U^VT0OX:+QTA3>(]"[G,F=B6/8
M]@:O1H;'\P E'.[Y.6P&T%9&C&8Z&:XNZJEJ&Z;S.![10&"]+]:P6<W&E0'U
M#I86V+?>RGA@;PU D3!T Y0APEDH:C$4MO0#NEEP-]H(K(YV00=3 ]43^9=5
MJ^_?F8KU^]5JALI'B1RXP$VA&? #Y$Z-OOR>-JWU9I=,<;BE6LZ4%2XD16*C
MB#"W]6\R<09XQ15RZB&EWDEO!6J:B"(40=.)PWOZ?)I.='C;B=<(UU-,TT"2
M\'57@,R$LQ+1C8-:Z8U_T?AR5'='812I@"XD5U+OL;._>/DNL[]HN\*@=8Y&
M+;!@8<TS10HT7KZF[:MMFB>!8MQ6Z?M%561X_?AF)[X8:18D>!*^9TG3H-#V
M%J ?@<])*YNY;Z1I<&UT'<<L\#2!VTXHJ!DU$6X;2'S0EF*TH#I\A ZF5"EP
M=-0&@45[)Z1Y;D=Z AQ2-2M0XU 1BWKW;J]C?=N3[(PNOZC#OB44>R<,XJ"2
M@RH*I"MX&US6"BFY1?$%HB!9K0K@'*CF@3@"5=O0A2CK;'?"VG&]>=DI:XRZ
M;S.O02$AF=>568?V&/*QDD8CN23#H50"2FL<OJ6RVTY#H$<VD7%Q@:X'EQJ.
M$HZ&/M#V+]P[,$+PRK(M+F*7%13\P4;=JF<"DD$-_P9&4Q6=6 59M4*ZT JC
M*!2D]L+/&R S<X(9+C:C=<X:T#T[TB7@UT#G,?R(K,0L!YX)1A/Y#4#U)?*F
M6=$GV_ BC3Y+CP/YJ/HISG?[B,*;]]_NWX]^R561/8G^3$[54QC\7YV"@X<U
M1/?OBU_^V:NC__+]W_?;:@4_V5\9%_K]6=6"2?HD>HR?S<B&-Y^]*)+T?;2W
M\PC6"I209["2H4=]U;K^PV</8-;  F; !M_?GR$)P"I7M&IW48\#:\*%7G5*
M9VL>X-[P=MPF2O'8A[U"TTE6P71X16MU"MH+77E'=%NCGN[9)HN'.8Y1-AO7
M\2?#J@:Y4YK7*9C^+?Z.[??I!,T(813(]K4"2V(#ARJUF8"<0?L!R#Q #Z"9
MR:X\[AMHP( :>*[Q&(B> CT&( FG$_%_KCV[.6\&BXH#XDTD;IN\5^2>RK19
M;[P1*-+Q_WUGI+'E2_%-BM\%^2GZ3$B>-J3N]23AS4<%OC@I'[]^!T,A/?_R
M^LVA*%6P5>B+ 1/82B][@H94$RTS[:F%-)68:,YH.O$&$NR=(&HT;,@F\U;N
M2X:4B:(*%2ZZ"$E-3FF6E;PHG&)>%45UWHQ&/')0_//T,V[N+Z^/3]PI[S?M
MN@#.#-)YF126O>+O1L_^BZ]R;P=YOHVCK<FW[4?5V.FD3TW<''00#5(!FDI@
M&-=+"H$P9Q/-NL<_+M*7@342^3![T:[2,5\9LIV0SH8"DCW=/>L]-@Y4Y(,%
MJ$^M=F*?LK,.'=\M4]^3"T[N^H]L[TO$$6G2K62;J>#/NDJ5RM#Q.IV\)N_2
MR0(NL_,YGA,'P7#?WN3D;_7N-9.,<_*LVO;\J/B 552#'KB,?&3(UT&HP.K>
MBIPM8+TX290#CYBMQ3ZTQC19:(:-O49&E(-@P5A Q\Y&]N0QU\G4'%T/V\QN
M/$G&X3ZTYF$*(%=TBI++CB+C&-%&[L3V9<V<*LU7Z Q&3P7<%;MOH],:;W>"
M\0WG 6^?Z\ ^[TPG?WK.9W^7]F27XN!1.&+1>,KQJT-M^HYOT]]==HIB ;8'
M?IL4R)[!,,>O)0BYK#KX&C8DSSB^T+9B;!F3G)TW8M>C9X?"*<0%G$.,10,(
MG2MK!10X YE4\EM/)^0%I=\[>XD6$GH%,% *3S1-1[*,0PN1.';ABWF?!A**
M9\ 4IU4%+"BA:"Y;BPD\#M/6_4?L6TTG$C@B@J=-QUE1=:M6JZJQ%V&C9\JR
M+=>[2^]3HPD(I&U?-09.G,$4CM,$%;6N4;P&6D]OR69+49?J8/CSA"+:R3DP
MZQM4FKX@ YR%&.!-<[K %9[1%9Y./H;378JA15?A9\!P'/XDP;:+^52TF4W-
MKLZFIA/#IR[#4?Q]T$QEY!($^4H49"OYG,-UU\4PHH_F%QX0X&GT[.BYIJMG
M#XY@;^&#174.0]?\-W"ZH7-2'FG0PS0*0*$],+MO#HJ@8BBL-8O"6,@XRQ4;
MTMW,A)3)\T4.'P](P<9XDPSEC]DBA!041KG4.BK#<=BVD*]$WW1\^: YXBI?
M+E!YK->::@DR@'^82"XOP40I> R)%_F;)"HK;L;MX)OIMF<^Z(T ;0#.VE )
MTD+T)[&6=XL*&1#\"^\L_ @_AO]ZVZ7HRP>!PTSUN&KQRJ'C@ZD#+7X.=^K@
M+!^8Z]R- X<]G?0XH,=&\7%8!(X[X)X.-]P:L$..:>=DJ\C"8\U4EK"?+>/&
M=.@:]*.!2A@[OHH@PY.7628?\F6WO-!BBBXRF&)]B>%BN*K>95CH(E_*1FGV
MZ6Q=F&626H6'"")RWG,1(4\[)QJ83NP.AMC"K&NOL,W"1:J2F0W"9'   >>A
MB@TOSG@Y84J-Y4H-'5)O 3X2B,\I:-\&M>B/VMKIY,*])7&DDG3A;$PA\0:4
M'V&VNQ/]@H3<U2A,&G-_M"@>6,=L-;-L8>9G_$67X.U]:R;+FR7\-H$3I.4[
M/LE5K8"KYRD<H+D)$@-A-I\X[TDRIBM:.6N::^1]OUJWR[?A'.JO;T/49/]I
M]'I%@:XGN$HAJ:?1?R5%AU_?5%#E\N)NF#K@QU-V \NAN(F[#7H#GD8GZQ6\
MYT&=S/+T:70,3)@WZ;C"5]_WPBKZ*?SF6PKY?'&"_#:NS;[X5 ],4,,J(<9F
M-"&/2$> -3/4P26V\2TC1CA"/(Y7(Y'/EIAK7I&C3#C]=.*J2@.QAHL0[RY%
MNJR8HV\\-^\%@F_$2Q21DTA\_I_F);J$0C+T#P;4O>E$ZWM6&_MD0]ES_,&J
MBXZ5V,W^/7*].\>RC5)?GHU#DIFVW$*VASC_J%2G0,Y*9Q<@QE_QDAL"YY[7
M57F:58*[MH>Z,YV@SY^ M'9"L7R(6-2'',Z\6U4>=-%8T8*W(;)=]<U_0X56
MV@<P5H*'0"^:@>]DC&M_ST"'5;+6\2D/Z9"0RCC/&27LP,NV;&!VA2>1=;5$
M535Z62O=&'_MEBS18J1-,FG:A7^]FN@QW2\< #[]B?[@^,&V$(SC1_NZN=:W
MP5L?"F]]B0"O?-9IJ/%%V_M=6=T4KGFW4&CV --@%]%&P="CVCV7:O<=JL5[
M8V ,9'3T_#F6(1)?U]YUS! JX)YEP-L%4M!T>4NLQO&7E>+?<2\ZS/@W,*"6
M. TY<\@Z<"XT6M\,]4<#>4X_YW=B.V-TPNU>@@SS%. :L8%9YC5YTAA@P4(1
M?;>U$OFDWUN+,Q(15E)I3^R&EQ:^C5;+O[J\QH_\J&BJ25D9<T8SMCXL0Z3S
M>9*?2:RE5D5>PK@@MAH+_J*L,.>&() 2O0/H1H,3$H'ML'LOPFNA:*062]8G
M?N&]. '=/OJP,0GDFD];9^'1[YRU:K\FJ4<)1:!I[TA $ H<<;GT2L8[@*A>
M5;>.V]G9K5O!9"@D\DX3KP8;RGW/X3B9EO%T76'?PWB8_ D'V)0R@8#$!<TI
M.:V3U2(F76TN<3I6V(81@>D$CBJE8Y^AWQSO$ZL$*\K6*72@;P4S.HZ*D<LK
MNMI%+&T#R9'#Z(996D!+LAS$P)(M]PJJY-<3K,7/Z3G2*-?TIC/7*4;[ XO7
MYZ&C891W01[]4LW1B8=$D9_9:(T'I,5S-1EL7EXNYME4:Z6&(5,GJNY$?J:3
M\T5%"3R?\7Q$(T8?)$R?L7KIA9]*%DN\1OX-.VO1SX9U#GA\>L,S/##^F@GM
M(GF3U!561@#!;D- &%Z##TP(Z"_"10MXW#T@1U>6UZ!L4=S>_J&A0.D[W"T@
MG^4:UFO _R0W]4QIM X%<1IQ8==J#E*M3"WMFIGF";KY0MCJJY-$F"*B,#T(
MC.#F""+JTT,(U= CC\:A#[)YV"WJK$J-7WV?$PH3(/?YN4+QV#@1%^2SK2 )
M7-Q@X["^7C01E0WASV('Z2=5QLK&IQPRR($K7OR1<_[$>T_Y_)]VSHZ[V]P\
M]U*,IL426%(1&K*MD*_)2>2U*0)PCNE'RPIV.9&[AB%CMI=1J1'\0%(@N<Z9
M<"D%IDU.56^&R)W R1('P5'GE)!-%(4($OA#(J^C VB@2=X,?1*W0KNZC$O]
MX9WW7+SG#[\+[_GW1+\<^ <^/IV,XH(Y)!EP(CO\UOB32<$Q0<5F8, R]Y (
MMPL]T@("391/T Q)0,CPFV7$K>!/6QF=;\4*8@BS#;S:9KKTI+\;S;@NPQ%E
M;<ARM&%L)^KQD%5<P7->%"[I^:1S!#]Z!3H<@IVCU+<V*I!-TC85:M6Q3V94
M[D1U+N1O[?M^XH'U%OG&FQON\$E5/'^X_KYFYX5;U(<4ZR:TR0=R<[NF'N<0
MSE30\..:$"Z&)PA ,/?53Z5/2KOEM(6DI)JD*!^QHU4KQPA))(&;XO_S!#4:
MUP!5O+?BYF(MD5.!W%PI"J8, 'M.D1U0L<B9L)5O?X11ZL:_,*%4( FR$GKA
MK6;;U+!PU';\^#2G\CD&E]M;YU-] EMY?W%!;7E+E]ZQ15\<S=FP0HF[G2*U
M;/??8@SNV'N5R'^3.X3%IZWRQYU+X^?>Y2W6K;EF>%P?']P/EU)X800>=\XK
MTK%2@H"B 94T[S&Q@>Y8LZH8@YGE35J=(<X2[4*$K<:!8&D( <IP,2!>#KI>
M")N[/B!6 .-&'JT@R.UK)[5OXT(\,M@)*L7 *?N.%_/3R'\(>9"*#QZMN#3A
M9J#V4N/&)*(?X[>W*8 U[^<FX1BLD""Z8.OA[G:4)>O&R8\DF;1J*3G!\VXA
MBZ#"2<;1K?\0Y=I#G-,--&53]"YH^S_5A=M\]*CH'6CQL_9 NA MC4(I>,=7
M59-KUWM/JNT@R'<QND@^$.=J*E32R 4"[QD\'-?1;&LH,&9"292 M4:5,?Y!
MEWCD\AS1>8U(VI)5DS9Y;W$97MJQ'Z^K%44;8-,M=^%=RS!1 V-MO!"0U/D2
MWH^ _8,J-T- K)LT,L+3//3]3G2 VH@^,=P!YT6X1 DO=H# <'3E1Q3^-9RT
M@Y%AA\6[KW,,N 0)U5RIG%IW["8.Y0Z+?TBO@%"^AM":.V9YT_C,'^^<2>),
M^O&[<"9]<=K[-F[(XQTGKX_07BPI_G3@763GOE(]@/LA,^,>ODPKZ(+B;!DC
MJ+1C?:!S<)4$Y*<TBRNP!BF!E'L.@@'#%%C@(#FK:C)W$U,YT.9^6"#;@12*
M774SW.L57,-T/)D)9 8(02PA?%JL8W&L2(D%KJU@D'A<80%%HL7*\4SNYHD>
MM5J1,FVM7QU[9TV#K7K2[EF'\*6?EGPDLOKNFI#?X/9EYZ,OKII1&=W+;% @
MG;+I9D \_50YJP2)5NB 3B/)C(ZJVAHZ(LJS*NVHO)Y)'<DIW)LX+AQ'F1OS
MITD6E?-++X9LD^XTX4A*WSE%K\60#1-3H'XCAQY!\\&Z@3;ES[,)8B1WH&Y8
M"J%;1>.V4"^]4>(^]$M, 'O)SLCGMI :AP2$JG6I"5_QP^J',IK*AHOMFSFM
M6]TBINLUAVVEDL$]+95"DU3EM+=H__AC\0.._)BR5E'Y+W"F9L'!3P,/JYUT
M<M<0*=<V1"AE>1P 6H\"&+1E:O#U_!-2=4^_IF?&HVY=Y_2G22"R[#B42G\[
M?/>$W/IK1;@!_V[[1E.(@ ?UC!DAB;6HE-18<6R'Q[H2AZ[8DY@;FUBC6""D
MQ-P#MH)R):V4^>GG%=-2<!1<:(2]/\A.*YVB+UI8S:NNCI; +"HLORV8&3T<
MBS;!D3F%^^BF/B%?,!F&R^3OJD:)?%:U9HY7"*]GPH+;^LKZ6E'@15+-W$DU
M!-E7U=TR9C<NC0OV)PEPELGN>-.)+2B/U;=.2QVT_PRK@>5P; 2O%)4S'E\,
MTLC&&3%UG!W/L:8OA-'A<;ZLT)PLF(]H6JQ6>>F P:2R,>[-BMB'<V2$_<^
MRYRIVB;$]E+YM_(S>AVS#.NQE['E+Z^PZVUD#!2T/9)B 5E?XU6^QMMG#'GC
MI,",';3+/3P^,?/Y1.E+-MB"P(^3676F;!6+_ESF4C=TF]%CT6PLI_$8-L#6
MLPH,":K-8$S_ @K5X#W$\CB%3VG] O*Q=NCM[;I^/))H^C; 3N3,5QO-E/0R
M;-$#ZC@0ZYLPKL)5E,,BETM@T(5.Q;P4(I"?,N/8*EP:#DTI00)D.JUAWYSZ
MR,%3JNQ>FOJ)2Z5:<6<21HP]@+ '?F.?WEA..7=0LQI=DJB?\?;037ES-6*-
M2;*[)(JQ"363N.)TKJY(:BD'!MH'J1T6"\EJ$FT)*FK3R<&,JC4F%,;46BKK
M368VJ6='F"MO6\2$2BFC.?#>E#\?.F2W11-5BH6;EZ/8B&U=DL%YZ%EU%4E3
M-S+T:T'4LVNQS8L>>7"UQW:1U<DY60G(Q;&NAE_66W3 \+,($J!4?GQ-<V/V
M>S=F1H@#],IZ&DPU'QHP&]4:4D(V:3!EM8'9V!MI>8[X1"O;_ )$<"X@$Z_U
MA,\<L#=1F^L@TE7JD>B*![+7!)61AD?1WUV=-Z (T[BX$;8$L5;-[0F0I!UR
M&\W@?5G;XSI&?6M<72JT=0Z:0)"BB*]AH(%'=8@EXD?H6/5-<3@Q1?GYI6M3
M*LSM@D!>!O,C7;A%M"G+ >3'_9I:YPL$(:':8?:(NYTTE2VM(*]A[[&\T"4N
MLECJXX(QD(>#[AF.-FA,K .$F"MQR2@G5!Q6P'KUU4:TM$$\BTOMC]^>GESO
M)RR9C*N+5PY+S#-5.AF8QNDT1/A,)UJ8QY(O37Q*KHS463*Y&:-OC(7.#'U5
MM3W*6Z$/7B9N\.@N;B!Q@T??1=S@>Z)?!BD>D9+ZGO/KQ[T/U)1JLX5C*N1[
MFEIE.^P@KA2'6$<R(7M"W3FU-&4?N0J%>C?X)X.N7 KSHJNC4>J]@&0024.]
M#.FGCD/>4518!YQU</-(-@-#)0V .;3SN4+FKI6KM% )ZZ\@"\Z0*<.,.A2_
M ^=G51O']^BAT:S_&%,.VJ8'S0TP8@(+D0+"^FSO' W@@$7[<JD$&N*GH6XJ
M-,#93@&;5A1V<3%Y$$+L%TD(O9['=BG&BX-Z)4,6G;V,6\;D!N[3@)X7-AYZ
M9-+#;PPV+;K$G@6\R6Q=B:Y]T0*MCP5W?(YRV$!0309:2MF19-I8*MLT]<5;
M<RNDZY9B[F0C?H'25D3SH9J1>;@DN[&<N*.AV Y *"!?N6%?57%34,2Z=*6!
MBAXZW>[&2_M:(D1 3TG0) O1T:@X-]!#C52D6)U##T+=&H0Z7(44=F9-O=$\
M)(?%= Q=MC4Z,:#"'I("-#W$2[/RI@T*9]#A^L@"XMWAMHWT 2*-Q79N!>/N
MC((N'XZRZ2N7<N\79:*LLKM)J2T1O.>K59W \[4UT%"Y13M$JY@BD(P6G%(K
MQ77O-7:P7)"I#\3"Z'U9G8/,.%7:G)(D+]HHS8@1>XWW6KBBYB &#!PS^-?-
MCPB<C%]Y)5^NNG9POO->'3G-W'24BJL07%K 22T+7>W4BW,YW?BD0$[?JZ?$
M78B&&LS2X$'%%H8E*%..2L]T:9< # N96,*XT9;8P4@Q5Z[EJ*T,BT:]CD*N
MGE/Z(L%/.1$!R=\7\-<@^&\%QYZ[_G%=@7RH_,'=J<XI($$YCW*WA[8]464P
MB'UIA5 +#22=<?U(?&9-_@%1HX]]U*B.7P\!H]H!JQH)O%%W*>.6;6!]?:WE
MXC#!F)"SGJ5>XD&P9G:PNF["3M:M?!O!X.@0-%#2@%=01X?)>QMS98BHTF[$
MX4]\X '5F I(8#LE,4@G! TCPPWB6ET!3XJ[V2'@0*33/<B'O,AG/HPVS$>M
MFC6=%,GYE7S\CW?O9P@-A?57F0884>1=IT8EKJAB"#!Q9^SNBYA>$GJV<0^C
MED&]T+!EDX U?I5&[:BKVFX^DY:P0F-@IW:1@F@6* UET"<%]4,:(%H>T#%9
M7<+F.'&4^JF@H70V&1<WB%T$E<@P06,T-M&M+\/FVPX,%W=9$%6\@9\<J^N'
M/V%!%T3JAE V@NK,HZV#;<UPYCEP&+C66WN//H+E4"K=\.2=]J#:USH:ZN8R
MYF#!U3GY=\5)RQR$T$X!RA+1ZV^'*).<F^ZT1D)] (FA1!,.PU;F_*NY[#&%
M 34+)BUC#3L#J]CZR=\66HO>&X[9#-T'.J9#<R3,N+9>(%L@^(.S"F0-;D0;
MGDR!>E1VT?%XZ]!:M&AS."I?RO#9<*%I64$N,5 <@Y/X9)"- @G$ 9FY%$:I
M])K#^Q&ADN/NQZU01"[CF'U\YY@5Q^SC.\?L5T:_6Z=AUT=:H:\-9:U1B:Y#
M-;@(4S:0CY3%IST=++_=+N#C:Q) J%&*=.*4%FED=7MJ1$^%X'B4Y/N U#K+
M"W6* ?+*J6*O.S/J&OZ8.EE4U&2:,NOU&)>$UXYA:X<[BT"&,@CLB:4?O8>7
MXP0N(X&":%J*AKH++0>>KC(*N^\QJ1PC>]JG<.5C'O>F R4VW#K A!_=,KUP
MV^M2K1N9![0#':V$HYBAOVK).=3A9#3*::\,M>LBD!]-[]I"FDYFN*Z^6K65
MUW(9J)!.2&-D[/V5-W![I "EXTC75>3\;H">4T4J?+"%"?1\*T3XUF)0( 4D
MJW;B2<&NQ*NHJ9V&;A9ELZ@8X<$)EJ:0H9AK;NL,2CSD!)'&+5"=G%6Y";-C
MF12P8M983ZNA#NFDU<$?=;<R2/ZN-"WJJ52Y3>K@93N%/ZG\0Z\"W4@2MUX3
M<2X&4YBN*.)+<VJSS"BS4:%OV+SUL!2G<VW#%;(WU&H-+%T*K55.9PJIQ(IJ
M<04\P07?.';"MG4W7N1A9+W7'EPUVLW$MB,9+R_WL<'!*[L(*6)UYR-$A+C<
MZT!'%+_EX.8V*:WN.CBS!4IC+D\2]_@";79JW$2DA<!M@L.@UE]E57 58939
MC ]#4D(?R%E2T+#6K["%OIL5(92LP@'< :BDH42*'G[6",YM2E5K01F8ZYN)
M\GP^)RULH3/:AOG2?:E\V9ABEC.R#C6(S0W5F-L81SPJ#M?KB8_0,7KI#HR]
M%YE.L"6C%_49M&/$QM6VUL25^C!^\1S+;R,3]"?)!'V#7NE<Z@/90[J=->2/
M) CK"/<M<D'WG3#LDQKS&8XX#"]1YF 0[@CG,K)CW)8$<>L:ZV$%;KUIH8_&
MD.&<$E-65P]W7+0UX^Y4\9']O'NQY]0T!MD80* \&$=?"2R5(!K]Y8;7U9+C
MT//<(5\=<^P.4=@ZHD0.S,NO;'SZH7UHU"GQ$%X):J5]E@-2'PU<A<]X.AFA
M_W!'4W=)B;2S=((8@B,0C[9%> >1X+%TD#'E;[! [T9(>#Q2B*9'Y:&04Z#1
MK89BF0IN1HW6VFC_#74^S#^$ZFW:'AFM]'[ET'K@),2%@+L-N&!L?A^OW ^V
M_"20_[&F!ZP8A';)3(ROQQT1.+QDW_!6*,&7\4__=.>?%O_T3W?^Z:^,?CE#
M.J#\]!6?8&;,U47]!8I0J.I%K!M7<'TPA[=III=MK.KTDU_522P*MNLX%8/L
MF(:K5V:8 GR&2#B"0W@NB7X9<X=3LJN#$^\SO]B9 /?(?^/OZ6@.S*U@G38'
M]^9H;8,6%&R0A!66*;%3)POU5*3R.F@S=N \43*=?!DXCS?K.*)G#- C^!N3
M;/<Y0#VWXUID(QS9S?6_!$VA8H8,S1"GIWU67@=(*< D&1^5% 6F(J73298L
MDU-I&86B&/,,Y_% P_>>TN?G0&]U"(EXJ$9#Z\^<-@IET]442:3R31A56:+[
M/>'L6=_<"M6QQ R[<"4^IW^T&-"QETUH V#"M5M09J@$15KG,^T(5 P2SXU9
M[-1CO$SR]?85"[":LM#!@W1S_F@U 5RE4WPQ=W.1Q0]X$=@P[KL;;(9E[1R7
MG/Q:^F6:!E#P1F=5RA'/KEU4=?Z_4IK&M6KZ)3:9E@B8EMI,V,"AIHN*FF4+
MSDS61LY@ES;\<CK&M6ORG,B9W.,YW*L'C5.N8\3'A7Y:U:NT%*Y^ZIT:5D-R
M[U]M-NS"UJ8ME?'),9]='M49*J;"4"NUXVU,AA,$=+1$4P4&+%%>2/2HEY4]
M@I3W MMU+\D8?E10HKT5!0:S':I-2\U2R3"N=/E4'62^GQ8Y[BR#"ZNR6>0K
M(-#V7"FOLZH%2*4Z)-^.4!Q&IA1U!1J+^:I:FI>)$V+36FPI<#.Q^-^)0?NU
MD$=KI-O2<@DUAJ)47[S7[EP:)\*]9?4F]. ,[E)NAVQ4@U"R&VFD8K>"%)&2
M%*RP7(<!8:"L?@E +_&@"6BA7%2HC<[@W;  3Z[O0@;D!S(U58R?,45[X7JL
MN@+]/[)R?<QU:Q?A]-<C!94D(Z5K\ K["%L']#%T]6B&O_;I5&J'.Q+25OFE
MQEQSIV*;WYA!D^_6!A_FQWA0MZWD]CDZ@XA8K^35(/,6X*816!X7T!6Q\(#&
MT2LAQBZY9T[OE5X^T,"7;\M)>_YZT^I.OWS(Y^^(INM0IU"OU_I4U%>G_ ("
MGUF7\+6GH#(1FRH66.>,H1ZW@]-1 LYQOS84'!)U/0OT:C$YP65;)[AS_1B.
M0)\^ BAFF:QN-$I^&@VJ]W*2@^7/\0NG^OE7&QG]-N*W5ZAU_8\[U[.XGO_Q
M7;B>OSCM?1LWY!^"<#BNRON''T M;/(SD(9/IY.W77V&4"#D2F_(Z_$4Q)N(
MG:? I$"Z<<WH(Y\QPJWJ0."SF74[(1(GBU"M;IN3Z)0<)+TB($+$52YQ925'
M8PQ9-BUEBA!V$C4 AEV"!$(W@:MSC-COJ-]PTGHJ0>.C,JWJ556[259K^'$C
M_B"G3IZI,^KF%\7<Y4J*B9$:X[6;ZMO5!EV&)G$$C*G,9/BBU=E5G(RODB)@
M0E@ G>WI(GE7O*WD+2 M$R%;=9ZRVAY"H07E>UX:-)=?1J1-WG.A@$J*K;M%
MLZR2[+@2=1\7N&K<R,5H!QP@WOSR8)T,^S*!F;Q(RE-3_/8 O=[6HT&)J-@R
MKJJMD9>IE/8IQMIR# 0^):3=L!X>86Q-I]MD/D=AET5D$%#S0UM@?C,=,0T)
M=+37VJVE=#;VY-CZ^"K2!>>EV&\_9"%.@/+O:AVX4SB ?BO3J@W+L.EWT*?%
M^X?49Z")N.-P!]=2_H(\$8I,H+SA-696J]]P3^U([ Q1U-C*_0&[S6@N&X3K
MEAVW<>,F!+E-GR4===,@7+S"\]R5U;G0GV+;4GN9D%E@&T8&AU#WYOZ-1'/8
MU*^D.\0%(=RB.J$]L\YR,Y@++EW5VG5/.KE0DYTI"D[DO+)<9YSO=E@\,[?/
MIGO_76ZJ;=>&ZY)XQBV=K(D:V&2FD#6,5OKF%H&Q>$K)?8B51?*L ]92YX%^
MZK5_?AY7P!M>PM"+?!5S/]4(":-#S%);=]AEP%0@T?WD5T5B7;G3B;(526S2
MNJD)69^I1KN_M;_$7V 8?D46ML,D GN(UY)Z9"34E)X<( +-YPQA-"\;;?HM
MDP_YLEOJLY,UT#2HTMK$K/FXKUEOA5.?16^\,&+QZ0Q7RT5392-(.3!00=.V
M('&*#">2]M O\\[OI,LX>BD_B:U%Q7Q+UATD,60X! D/1:F0B4EW!6=);:"H
M5Q_0):ND>2A?VSLD)[W*NBG[#60C)TG*[M[0+]A:AHJ* +D ;2R9XA!-+HU9
M! "(4#3"=(OWAQ=)?14PU:9R>XGY,:"8AK>-6=>ZX8O;4;2_&>%WYX0$6Y[8
MO..MX*/I,'ZLM4?!G8:1Q4'T0R-&C\T.L+>;]U;&Q/!)8?K/6BM!>_)Z('/N
M,JUC'"I%_8VCM\C7C)^)E2E->Z*4^JF;W%*($_EI5K=V%P_M  VF$YV4RG@?
M=,Z[PRDI\>&'#F<UYR/F4G^#W/;NG+>#LK*1Z(M8==(D/&AA:.")2X9(E7+=
M;?Z-T<YI+*OEY?-A6Q0IIMW+*K-CF4"[:5_LD:QUJO<5B5C<J,B[$\\,,WKC
MK3CP0;C-1$YMNW+7B;QV^F9:S[X]1#\C&SD &XY<?+@^$XU]7).A8O?))L4A
MTDK;C:EDCG,<%!7IDX F-+<N[U'GD":Q0=00D#^&N:"0D2WVC3#WZWRSR+[8
MG9O^QMST/]^YZ<5-__.=F_[VW)"?Q4U_2'FXVGYXT_-:^HTF0Y@BZQ4=A$5#
M:JVH*R+"G Z2[H.T%*.R"(,F^RX("6!3DHOZ#5+S;U^+1BIHQMY[K6UYPL])
M5:LV]9@>5]&LQ+)G8^@@CB2UF[LT]C*5\;L&X:#K2K+\152ODCS[V"EO>I^_
MH(]NSMX/7?E7"K#!3I#_F4[5 %M679TN$@%/-@FH]%N8;9@(XDE_O3W$N9-A
ME[<!=YMI#0]ZZ5(EI2S Q=[Z60'4YU(/!LR&HPD''.W8^_GACP0SH= $ELO%
M!>;+O$CJ'I**\/$2;JCJM?8LH\<&>1>5G:SJ6T$(Y&3 PM4A9NC4?M@25Q\J
MIL/2$-L:USH D#DV_-5&1']8<,@QT*M78#[H"1[>>W0/ZX90F+31FCI0!N*<
ML?_E"EMA F6X(HOWE93OWF!Y,[9UGC]SB'DU$=Q!\M%/8[F[G+DA:] [)Z%>
M'=/JH;RP-2_%H@I%-;MJ)?:)79N4%L;RP0T8*=+V-8"&\P.Z=U;)IZUR;U>4
MKE==G9CPM3EM5K(.T-FF/^*(IC7X!_P8?24,)Y18HDZ)1MG0 0%TM4YKEA*[
M2C?Q12CT6B6U2:MWZ#A5B6 VN2\;IX3K^'(DX66\55=T(D07^1!LY(?OZ<>X
M$$(6];:#\C6[XSC9FRHJ*EQ]$VZ6T'34BTOK,2'>$L(VC]QTCG!L^\F*@4B^
M['2,"IU7F]Y4F:&25MP>B\J \QEXZ.5DE:2H+[GA&:\YLE.!CIF; '(Q5B1E
M_OJ@VA1K8RD+.@G7N#L9@3)J(#:7$*(8M#0.:!?6.2*EH AF8L': IN5X/UT
M(M%[*1J5UVZ 1>I;8?>2+5^H,05R;%K^V_P8I]#*$58<K$^10#&= 0UY/]>#
M?)W(4,D!7SO]#RG)R'KE9UT#U[2A$\9 ]*"XSS8J0M@B#KA0LZJZ!MD1OA"*
M0W*EXVN0XD;1QX1:VDFNB4F-H;A^<Q$^ZHMSPF^$7^\)OQ85=DT<>CKQ<3(C
M.'P&[F,1C;-!)V _JJYA5?IF9H&4+-,9759"--=#OCNC!GS%GB]X0?!YBN.;
MC!V@T:1\#UR!VUF#WI#EH(',.T:C^(PUK0I,DZB30JIU2IM77AT&&U.'._2P
M_[KG)_EMSZKWW,*@5H6B=C(Z#XLCJ:B8Z90$22D:!C#O"/ZFW:9[NW=^4_&;
M[NW>.4YOSQW9V]>>4U9*C.9^ZQR-7C3:UFZDO$J$@+@5>3%6G+,CDJXC&9S#
MJE_T2(-52]FX=<57ON1*B>AJ;J4$,!=2)&02AT*[M-\LV#26QDB;0(8< -H
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M@O]4-3"+$KX"]D/7!=1M-G'!A<T-?5)>%J:J%W8%A ;  :G5!0^PV<H@;5_
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MPV]$X=B/7LI<]1*(!]NZMG6(@J7,>4F=Q21\1P*?KE<*@80&>F5&2<7F1)1
MW3CG.BNLR[(P81-^N]0=46>8LM%0KQV3K3UF<E8U+7Z(#N^R0G=^+AI;#( Y
M]YWBWTY$W*W(WBN5^Y2T[>"KWU;7U _$1V[;7M4:95*)28>N?317W<4XX3!A
MY@J/_M86,\<$^"GJKP.F,(* X@]$C!7=."?M@*&H!9P14'P4MEYP>0&?^X)9
MYUH::&(_!83ZU<-R_FINX$_K]+WSM3E][WQ=3M_=0M^/-]G))]T?WP)1\4^<
M]%; +5? ,+#EP9E^9S[ [_L%,W)V53;W@1A(EYW"#H9/'C\Q6.9[BKKL =P
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M2KYX]@>%^7Q&=:>S.FF7 CBVEET[CL2O&P;O5JHP#3?B-5E]Q0[WI#PC&!/
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MIA_.[,KEE(>!"\X]KQ8:9]$F)W[(PS5<WN6%2X:'8^58"H\MX8J2(R!4"?V
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M:= XR8- .<"O%V4^!:H_Z3*L1'D+>EN9D@^8]*B4)GKX\,?[%!ND1"AX:B?
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MJ$404_RNX,AA1^&XD-'C#BF?)-O!LUG]/&38_E72F/2!>+\VCX'<"'&(]<G
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M%?I1:37G0%U7S9#3A-(?)E,8^'<>;!C-27PU$&RTP[0T]%X[@WD& <U $Z+
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M%YGS6&"760PJ<BQK8(,FDIJF&@?Y-9XTGCT6.@!]FXR2QY%;=LI%7NW@"Y%
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MQEH+\/A(G$GP7/5FP$1F!0^YK%N;B]9:U2WKSLUTO5PPE?.T ,>F4T&311=
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MR8?V)8+=/@JDM*@5DU9760?4C-#>_BGO.](=511#H- R)VX[;4[WI6E)P.
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M^6'O25CY?I0=/\4K/0+#\VLH^7.+C?>D'40N;F[%][H=(AUUR)(P $[0*KD
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M/:N7[$4JHVZ+G]P!#-K',]:S,?&2M<)=J!BB08H+W;V+F ,C.KO59',./<5
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M$/J Z6I$()S&\!MBR!3^BKN,VV9:5AG]L+J"SX#U-2^+&OR[G'Z-%!E7)DH
M)G! H$M 9%V724;XM[2-^]T"<0=XA?_'T:3-\\T&8.%S@@JMK>B42*HMP!6#
M=<N4]D<$DJZN((F,E%P1)LP5^)F0W!U\D+Y-<15?&00@2CTB5^_CN&!1MWF#
M"P(!\=_';9T5IH8=XZI\XO6;J<$_KJ[0(2(Z!5)Y7#5T)!!UY@-)-]B8^3 '
MF-4(%@;F7P 6V,,-@A4^)2PFB-J*WI8- JUNX,3X=_PC4+6Y*N$GQO@L7GB'
MJ0Q095:VB*%D"AAHXC'0"_$$G0$!U0)]+/Q#U&64EPPZPKCWI[0D<+5%!9JE
M+&"U!7P'F!J$-!T4 #7)LT0D%XGI<@R;B!%W-9 >HL@=Z2'Y8R H\ "K[B'7
MO0(U&EW$>5PMA/%^G:/^!#A.RAQ4CV(CI+$1@C !XP[A/#=%35! E(D"$V$Z
M"G0N$>4\7K J+)1_HS%NHJ9-($G_Z^GSG='.S@[H8-3L8/:,\"U",-)QDI15
M&J/,[BH1R_%$2'&5XGL5G".JDZE)6Z&0NAW_ 8=!<1'/YX!46AIT=)LP,O$A
M7'M:DI-5 UA(?_D;I<.,C;\8;#<K09<#=5YG@ 9<9EXVP&=XRCA%$<J*HQC<
M=9K52658%O2^!^^P> >1U! S7P$V"F9$$!N5 4JMV"9"W9*1%13JQ0#;OQYN
MB5;\,NU)(M(G2*1'1='&^>K*J[)H:R)3!-U=<M!3%( FDA>(9@!/91*#3\5(
MZ+@T8@YH=T9$-<:O1 ULQ* P!V _W?D&/T&4C2!<76$8HF@W\J2NQ&];9$4?
M@2N'ITM>4L[K$,54019/+##A[^DIP=BLV)(D\QA8DC;-A(EG\/3.;?S-)P/Q
MZ(X4S\"0)@7ER!3I$HD<9#-:J@%C):!TK]E.@N_Z &: @9*H46AG]90M7U]2
MH" A"8W<#YLI(_AWX2&,]B2* ;B*,$Q'0U796<P1"$@#VE!*)MV$/T%+;0&1
M+4(<6IC&8'V!E97':/Z#&BZB7^(*7MQ]UDQUY23.#4H<VK #+>N$\(\ G)MI
M!N^[KZ,Z@]7K1Z UGFY%)W^VH%>9#R\"40JN#H)O,2C=7I4@D%=7 &#'&7!@
M4U9UUVZG1T+WJ:<_KBITRA#Q8",E[Z-RK@HX I<-; $0<4]W2(%$8$&#&2(X
M6EWI[@AM!& 16@=53!7!]EL3_6MG"][>';%^ 7R;#Z9*T,@'FQX(V/R)5"+&
MYB3.*H32>V!8?EU(@NRX?($,IOLHF!Z4_/@H0)ZI8>_!,0)!H@N>=WS4T)]!
M1I4_,("N@:]P42;"^F6T'F]$>\^^L6#H/UVR/BH+LTDD"GP DJ"J12$/V)C(
M]>OC#?K3&(0A\K4\V5\>#3(33Y!],@ !$<J'; ;K@)'%P 0\-%,RN4 HY#ER
M:4U2 %<LP V)GCSGA\B*(W^)Q#LY<\"E:)4NZ',L]]B";*NA S$6NMK".NIV
M\<K,8A#-8/F!T=J"L8G;%2G3E5C-M"K;JRG(*>5LW LB/[7RU(<,R<NK$C;E
M81VIP HKE@F@@&Z0%&S8833(7*03F#&CTP*CL7BPLSQF6\XMCC_!@5)R.6I!
MQG6'\!Z!' K6^W^;F]&/F<G3E]$9. C[\-*?+7KUL':TN:FAZ^/3_PE3<9M-
M.8=']N8VG[?)F:.7T7/\G:3%]'>O\A@$SN[6,PSAE'F6PDZ&DGN^(72P#5\=
MV, 8..+]YMB@E_,29 _NVM_4\X$]X48_]I,>:+81-@R.+QFSS\@O,8699$T-
M>\Y :> ;Z+93"N?O&W\CWT+I,9SG"\R!<9A7@#M 3,_0DP$/#[W=+,GF* +%
MB!>! &)0MDRO@1QK*Y**ND!TQ0%)D"&S.(6O7<=9'HM%.L32W6"! ?L@.C8-
MO%:3&F7[0;_J-IH52=Z2&^V=R&X3I5F5C5O/TXG9*6<K$1>8>&^.+!3[VP88
MKZ[<3,&R]?>R7F_ ?X)R]9XFA\;A \13D[/]2^851Q,F$PI'9'431 @#)'6A
M9%]'D("="6R9+$8<5E4;?%*5,_X$@AK^S>)813>H9G!7#3M+E!G&YV;@R4U@
MI3R;92!T8Z"XE.( B-6<HRF3""'O4(!4 _NH'-+%_*>/?L%NUG/DN9,/Z,D#
M(,]--ANW54WZAEGNLFN&5?H,,1IJZIA^*\$3MA *<+1J4KJ&UT:L)"VY/ASK
MCEB_%H8\;\:Y^ ID/I/[PH$Y"KH5CI [ 7U6<PCO"IG.;'8UFSPXI.@QB)$O
MU-Q;V#69F@#KP/D5!HO0RD%B'P---!2:PFA$6Q#_$!!@%VF9M @YLOR0+_3P
M7S(%?(<4\*9,8B\&2]XFF+PSBG>4U?LHEP<L)P/Z7L=Y!D<OLG@(M!BV&Z,Q
M [:)>+Q^%,^22U/%U\!6"$,-/XX\:0!B9EFLQT8K"V/2F@4-?A5<@>+*L ,,
MEEP)(KM[!B0VBM)C7!(^@R% Q#%Z,QAZ58^&!<BCBNY]3X&39O,WLC5==G-?
M\AF3Z%(2%HIO>)IXN.%U%W<D;# 2(*Y)W! ]C#1*,3-Q@<2/^!<3WF9Y$#,V
M50+BTY>0PD'(<.AP,W7<IK/]? GL/V^F9(/3UO\HQS:B3]IF)%D"DBMU4[4)
M9MA&8003T:[RG+3(C0&02""M1WG\H&\M@(^!TBQGT4%2BXV(Q*3P-5C3(TTD
M*_!%/,44K=_OL.(8A_!7\'/JT$:L/!SBM\LB)X[D/:2<&=" /;"9<()+<V(R
MTLEKXHO"#^N7G$WIR&.)8.9QC>&612_VQ(AF% ^'Q, WZ<8O!TG7"X^=BDEV
MC=^P(LCD E#4X'>1=1AQ$+%5DR(B:X4%'%(MIJ#!+=W!X]5"$U&<7G-DNB=0
MO&7WQ43L;C;P)Y5':K%DD;9!#+Z.VUJL6YL?Y.!B=TO+]O*1N1=_4T@_;9%1
M) PM64!1 L:0P9@C/3B H)&$W"G=(@\CI_'N,><"\&US"HK']MCX1,?#%A!$
M! &BH'E;S<O:L#7<D0:/* >ZY!N73#/P)R00WR"WR*<@0HHG9K[!5"9 DQF6
ME!;"6!F49!O%E69F-H9?:.:Q=KR"&8^^J%>QS/8N9D/%U0)I56=I%E<98H%D
M WPLSXANV[G$87RD#DBE4!BP F?J,)2R-?17M:KJCN& IB(*:,_0H" 0"-:2
MDG89_-WFQMM8EB."9%AQ!N\Q40QI^!>DX9.D:O&P[UPNDK5Y( M%-AOF\#MQ
M$'(]XT+S=NO9ALN$2#()20O=1@HG63(EJYSW!T8:YE9;3$I<QXD(!HV9W2HY
MUK.,PXR2@(!G?'* !:UO <)YCB%7K"4)O8S2+T+RSV:+-"Q-^,1*/@Q(J(5I
MG,.3]HJ5! E1@ ,O1ON)S/[; U][^QIO?(FK7["'M1_]#\:HX<^?*RYV_Z/V
MZTG#D-C.P':8&3PP* #VH\O%',YY5,7C+-F/WH(#ST!Z6^+1]X+(F+Z%?_E'
M1^T^0?'.#LJA"Y S%.]:73F+V1G7$)ZM?5+68^,7/4<,195Y=$:!IP&Q=8=5
MU#/DG'FP#CM874'>Q:B!FA@J^%(38^JNBHZS.J:BGL5&5-YOF["T5(\D\3QK
M@%[1");@>H7J>$*)''@11<-\CD+WP^K*$8H$MMN+$1D[*0?AU3@<D")J.UF7
MP I?UHQ.1A6;E;E6QQ9%9%2;>2RFEK/E"2J5H>I)-KA8?5)9XD P<J2I2E(!
M'%@$2:RQS$B7@B\F>9PA"*YBS.'T0C,<'>*,!GM)8C!0+% =)<046A#5S)Z$
M%Z(,#.HN#SJ$"04WU4EN,+Q87XFE3C24$>(C9-]DVEDRT)VC2'0=FQKR?9<J
MKY7.21_ZWJ+": ;&6,:IK81@TU$6%PXO1R%>SAF88?XS4('+WHWD50Z[4L%<
MQ?3 BACVA>P!"'^NOL&$D]F#BG=U95WS[S5X>?BD5! @Z1NR%H!_Q(&Y:U,;
MRX@(85ELHG/HT2Y_Z*%*G$6I9$5J\.V=K6=9\6FL]\XG,.<:8=349IT[9A3Z
MT&S0V&QRG7W0%*=?;:(V5H^.E!*/:)U.U;&KET(;'7P[KI1<7>'/!7E6S$(2
M*F$'F[0#Q7=8(S) *O<MR )WLH53:#V6BZ=B% 5 2?&B<K@L"L1!W>@*P%9:
MR^6JNRBA'NXU99<TIHJ5I52_NN*=9=^&+T?@!]T@?$=.!?$N/+AUZ1D%'6%"
MW"E.39-/-C;@?E.FXDZ KJY,8W&7 QQIG;)+;O\=J Q\\(']GO\ JXWO9+6%
ME-E@$9%U1@0?3 ]4)>#+[CD6B=EX"/^Y$$&VC!?*!+P.K$A5[A/2H<B>J_8Q
M;"APYJJ4>E7=NLWU=?G]C#R5WW$CMB[LH3V,_QP.$\2A%!.1YT[B+RFU8@M+
MR"HSR]J993(!KI?CC#DH84&H0;E**U:X&(Z\1(X*BOFE!8%6EU/MCA;T%N33
MD.7R;E9D8R"D5VV*!7KGH&Z+A.(=I/X2VNCNB^^?4>R8<H;PUKK7U_+NU?G1
M\@HG1[ABAUV!ASP'F6"P&XX"S2JDJO5:7\8U[:^C4KMAM*9&81B4+>D?!5A5
MD!?N&]XDS% V74L>V(N%RN9<RIO1IT87RC.NI$%??4GY#*;0<K;\09IE5)0T
MB=:/-CIZR2ODD:C?("ON1^NOU%*FW#_9^,3M!-'(!VB(]5Z=O*FL)NJ]NT^Y
MP?77O$U*=@91+BD=XE]2:EF_0DA;KG&R,$SA%:7;6C%1,UF#*6GP=$CL2*!5
M]9!'1-$2&K(9FI"*UH,B@ WK7MEZ9JRVRDHPZ#N%!GE\ Q"Q-0@C^R8ETB6P
M(]&(:.^[W>=J9)^U8(8GT<^\S0NN($>>$J=I@%$ O-C2RH>V1CL5%:B9H;],
MJ>8P7RAQJN GV2S6#H8ULTF&-5=CL(FPNM%;E^HB^.V1B[W[^9KXPZ:Z.&$Q
M.6<OM9J<4T(H_9<8/!UCB13Y8Z@-W=T-0@'1&98%!Z& W]@+^:QA@(AXX_YA
M@$IJ_S T3&3R$[;BG$M@%*M*8G+^:Z-.U6W'&7#X5;\!^2#O^,4P]XT#W"L&
M<!_GC/&3-<YSY$)*H]54'^\]1G_/>5Q=^>*\Q\]B^E!YKBV.4DN$M-XML08?
MCN0,LCS=W4';0L379S0*[PY'/_D:>9;(\Y.OD>=/Z@EV\MDHX18HO:Y4P)*E
M*RU5Y+5[59)40;W)W3.=PFOJ=LQC28ZUA=2:4TF)9_*AN-_$6++FT_TU83.X
M:!V8#7!(^:*6C/=#B5Z>G04!E5=JN3N6RQ1 &1.C?9 V=,E=*VA+2PP1)3:9
MSH'G6KD@HQ7]MD_A/HKD,:5/EWSC1S$)8^RWUHZ&M&S'S<B3L:LK*F3A\+[H
MW:7?]BH1R->?M=A)A7KU ^BOFIO/*$=0E&+D,,[9+.@4R&HPNO)*364Z =D2
MP._3(2UPOPTNQ=P8:P$> K0=;MV\(ZXP1T.IN/)$[]_:SZVB&SPO^4H@ST%D
M;BW)-O0GV]P8=.A> @JK69RO'6[9"35.*3X*L4FQ:K#?ST&<5!GQ/L;2@"RQ
M/\F;:T%5@FA(VPZ2@5H"KD]!J@^+/KG]!U/M8-TCR9,LJ=',YM?>@@4+EGB2
MES45YI'C]$JK.\\J\#R3C@#J30WI[]D/M; EJ0V#4B<3S&GHMD'^>'N9$>L"
MOP^<[%IXQ&>\/<N.X)O41LN4L]HV$?0W+H5V&HIP6H@\3&XME/J6E!UR4#(8
M=5)X4K6.PAFHP7;W5P[+\#Y_M[8.=9[S^7.IIG%5>;UJO"4IM&[#*I%"G%YG
M,K %VT?;NEYV;NVYBX$MJ\(L7"QE6F8)DX7$E>  &%S"AU,,;I%BFZ-"YLY_
M_%B)[6(6Q>(R450W$-*V3+6[G\<?6AT+=U].,^R_/(LK (T]'T<CSBDTQ0S^
MNQM.HN53MCP,48E)]7'9%OVN-3*FNHBD4/HUCFIPL48,FC$QSFDWS)><,,&G
MC71X4@F;:P?H3UW ?5(\C;==&:QB-45W$H@]@.\T"S-[?N<]BIZUF<[O9U8"
MQ<!RB40N_0J3L/;9S>3@N!FGC+S3<)$IUK$1:?M%24,@C#P(4L"$-D$E[ITO
M>\U0^/F492Q-M9C%[\&6Y0P^%747="PV=$ X28A/B@I\_-8,'%A#XIKRP+WV
MZ[C8[FI<>28ZQ?IK:MT-QFK0%Y)RCN"U*X*AS:W]9C8NT\QF[C$B,N>@HG<L
MJA2 %_ACN,BXX=@T%TPN.0*/Y.E _1,Q[N?2^\D&RH4WH,BO7+W;.04?0?8N
MT ; 5(G7(N!*,Q/YDW;>]ML#"NMRI*!%"J8WX)':8T!")Q>.8 &B1$R+\H8:
MA<T':O[@V4:BN[G*<TR%@W:0QJ2EBG>M/4$L+2OXXV4X3$L:X5IM:\K>5?@Y
MCJP#X55Q4<_)@KFA<41$L#@/AEM8R/-:DM'H5&YDY"X*G-$0H6$Z/&&FB'-:
MZ /_]T@ @[T2.'&LQG!.VWBY1ST+4#+.6*BC0&Z\!_"!ZW#%0ZL<X4M%/J++
M8D\R^-T.+&2 U15&S,BBA9;SCE&',;D1Y56)E0T'^TG?CR3,Z:4P@A["F3$B
M9Q.9U$:"K[[!!!S5\NK'*>6$;BA7?Z,8*VD:'/ZMHA$K!5LJB91]P;)D.RZE
M!M *UC6C9$*1D?9 1MJ*CMM* @BIA#Q9/Q#RK9'6LWQSL#CNSR1=V/.O/3"3
MMI2),L(R$Y-B^=4(Y]SP<#)L:LHE<8"\:X=8+;AM;J$E!>'".JE&YD_\&PPQ
MS 5AHR4#9:!ST,]P&2S$VRPGF_,RP9D*6MWK%?4.0$W'G/A*V3<4>M/\ OL<
M).$6FJV/WM9+-]B/ [DP<1+;FS&7-79DPNI*FF%G &9$B _CFH0H%E?',Z!P
MG/#4UBXQ$8K0&37*2D:%5"?A0$KLA%!OK=\3#X_WQ:$X-OUF)=K]N@D[XH$F
M1JFECREEDRXL_7!Y!7U\"U,H987>?2ZVCP\!OQ1P)+V=9+CA.?77W/U9.4-Q
M^2'Z:4DO@-.K]*2&#/'#,+QG>2MKK @?4368,>_YR'^T1:+\*MX@-B:"4X-P
MH/ B\4U%:.=Z!G#Q8H&I!QF;':NG7!/$&IE&[)'&D8D_#/H.WA^])W2?<1%/
MOZ8I)$WQ]/]BFN+OT.9#AB4Q OED*_H)EC0%(*,"IL4&J,OX@_F'1R!!;[W"
MLI\C-+0VX<#@B:!NZ=<#B,H@$:WE838TKAG45"Q&"F+);Z09J&<+!&$@.]%U
M=<6KVSJ3(+P?3Q3-A%X.-JJ#P*=>-8V0S2WV9)<:$_.J!K13&E2,+8GY?N<G
M;V)5:IPC@?8UN_8999!J>07 -^K6HE#G(,VL:@"4V8PC$P !_<[3%R]>.-66
M2K\6* NL8A*M>)W5-GC(GO<,3T5M=X$).A(#M*RH=10K)[RO>W \X=\">GM%
M<+U.;W\+/H1VGXY8J2E2/+6;D7[$NC$[B@! 33Y/B/:EK=6VV;&A::=^>:&+
M$V&^[)7WC9A,9]I4#N SE;9M^I$MU^=*Y4ZZ>7:/_K6[M;-#+T<T8JZQ'6\T
M[Y'7&;!*[#+63.I0@8.XQ+^QJL U-DB?KY:, 2;B]SQQEQPI&F[!R/ @,8Q\
M'AK*V =;O9S!7[Q8FIO-VJ TLZ$TM\'HCK(Q2N6RSVS8S0?7(,XIV%;*#!I:
M>V,DP*X5VB0#YH@YGB)(0@9I<QS763U2> "&T0]JO&9#FWXC8]4?M\.H1X:T
M8<A @(S0&>ZT5L<\8P$K9#"!ZR$SI&B)<PSB<G4%8+45_5H(M83126IWU"V(
MX>LF[S*7:PVAU"5JFH:/0.R@O&8YBXH^Q]1:F1KL:2(_&0"H7GLJO;3]VDZ>
MH.R\_Z#9B%I*G7PX]59'BI#I[8&PP)%#:*Z'I[ [Q9)<+\<ZSACVU(VL$PS\
M[>GL&DWSA$D?1,V,68*X  @]:7/Q*F^!W"A:<A1"+85=_6$Y==W.YFXDDQN1
M1[_"(YFJX&"$8T/'1S,J@\IQNH.W["BZPM*U29Q1H1! :UZ9IK>F7T:MU"BG
MJ%D=X2<\?<%Z:;\S[679>1DQ=$+C,@E4TH331O@,7-\W!7,&N8\-!@QHV-EY
M'1+7Z>B3%HY03Y&2EGZ? Q\N .S/Z*&I0K=ARB-<:2U';B+SGC)PA,FX0XM]
M<A@*A(QI,B&%B6IM&KGG5B@40C'2H?!10*-8[8)2V'&FOZM^G:4?&'D"E@5:
M'J#K7%T9DXK,=H8=V%&S'.=T<';D40XRWGBQ[+CL5"=M,T:_"21+4F5C6,C)
M64H;X$8POB6I4&^,"T8A/=EI;9Z=%T>^S>,2@\';]WF31T2K,\_V(N\'*0SC
M:@9#7,FT*HLR+Z_PVAU6-I+54DF?L\+)"IE,=LH?.=7(\#GBIC6V(+J3\CX]
MOPCOK>C6AR.D1:U$67V;=4!%UB'ZQXQWA#NJ*.9D/.7(8M,4=/V IIR#0AF[
M@!7.8I>*?)88SC\LSH 95_!FCNR\;YW(,.E;!!1UJ;18W"/UK(N*.$#%.@7C
M67*#'R 13V^PA:PH+2) );W& <WGYAGJBM4531IZ]EBG:-HSI"B^6G *$4P^
M:[@(%07C:20.RX*@II"RF$JH!(C%U>#W9[V@F"W,YA08'E7L[EY0?!Q'$](0
M_LEBG1KAF6]A:X!?0N6WPZRN>%?!&/4J76.EK6= *=Y]@ 6O3$6Q?D#?.:&:
M7O#3<^1WKT^#!RX6BQ%5J=O'_>H9,@4%<.S::O=8$'UT@W&KJ# -SYTR:7W'
M#M>EGIO,'+3P0M,_\IJP.@2B?J5:W[KDAF\X@AV#/?+WF32$3=!_#[A_F:HD
M./;1@Q8<TBCY5?0<^TIT/0:Z%X6.+_+LZZ5'DZM@/O(["@7Z#*)&*-3&)G3$
M',U/H ]95>##NPYWG=Z>V%#YZ\^+HN:R8-5/6 "H4<J/JO_[+!^_3S#XV==@
ML 2#G_TC@L&/B9[O#!,_W0J,TW]V<!CO .$B?KDG+(C8=>OZ.T86ZU>O%5L+
MMKP1*21^Y=::.P*TX@IH71)&3GTEO,S,LG%AUV6HC<KW"PSC=]$?VT-W#(/.
MOC.N+9+AS+CA"+G=EG01^,7FGN<Z'!4G]T9L@SX<P8H, *DQ21KDRK9+JB6E
M@<OEUN\X*)H[C?,@D.VKO0Z  MP,F;##H8YE\!44^W:D-[N0[@=9V(''_AAL
M'=&GCZDW[%J=@QD5C>U]KK3UV1L(0L'3PM H3:\490D%VP"U:W/<6ETY]1R$
MU.0QEFO0'4YSYQXZ/.BQ.&#JS[V0D"E9;S2$(@2+:]$#&"?3S:B=VR>H8(?#
M6/U1&>[;G:$9:5NIN=B;4.)R(CW$$A7;%$*TKA%E#2!OR.UN^&KG#HM@](:U
M,6^_A"I#ER;CN)4.X_A'^+(@?)&.006!?^ U(;KL1^$-X;,7+4VHO,B;)#XL
M7!QT=;E.^)@\73O.CXMD/8KP&KA[_:7=^<!YN*$ M1DWJ)9\>VB<@@C/L(I"
MBN%E7@V'5<<XB;7?O,-U3/Z)[<JV8=8?B$O;CS\0387W!O7_% P?$6!'-[%7
M%B5W-EE?9#F^/,1PUUMO.#O[WN$.G-"+>:P^,TKX$>Y',L&WO!W?2A[!'87!
MI]?E9D$M]LFSB6%-;BMBK@#/&&3P\D5AK!PKG%**PNE>-J3!WX[\#[=#=-<!
MH?A?GH[*,_#24UM/!QN5V<ZT54DBRON/7QK0F)9+N>I0K(S;DO%!/*O#^"YG
M;@>)8\5VA&$9MH\&304UEF1$R[( [4B+0;L[#12YMU74%2+?[SFX5FPN+I8=
M##'U- <-W]9,5&4MPF$M'@2=P@0#;$9+B"D0C?N(E]MA4^P'382WPY3>DOE=
MV$=A,U*!5+VLJ%!PH87BN!T;<-A"-&SFZ]-_P$BBU(Z5HEM?2#PV1F^9Z!"S
MWH>@>L.(%.W"=AFYTAUW@TRE]LM ]QE=*CL;9U=X-Y74(&0\*PSDWMT?'0FJ
MU4+R0H]QRJ/C,$@)L"H*4VEX$<2J/R+1Y63\6S26G_,D]OCOEE*<3.'-CDE0
M82.$;BS;!>/ :1[%W52Z![8-&/NL-A7%2Z]CUHR\S'2B^4XN(8<Q?)D[C>:+
ME*%XK2YN0+6[$P5.Q67A]P%<;XAF!>9E+;EU/2)9 YR<E&IYNMG&#^+6X2 )
MJZ?]U!J;R9[GA0E*J@WWSO7X&=STYL9A,K?FJR>DD<PJ]INXPMOZ%MZ$4?)2
M\&+(3(;':*+3KR"28:<2XH_"BJ;NC=\\/];>!1B2_;#C?)]<)?I(<K\QOE5/
M\!38"<<"GI3.2"TU_W*X<B*.K^:+/^M(D=M"L\^_AF8E-/O\'Q&:_1(&63_;
MHOE4,J9KGQ(NW \NG>\YW4_$18,!$VJ;-'D_?4L7V=KC4Y?NI1\F=#V)YZIX
ML\)D5!B/ 7/E/BQ9O!EC-E<(RB>/;_CN)NWB!9JV+6&]45II:=BG(6D68^\J
M-T[S_"LU)^Q1[;TV-#U:+ -:%0T?3'')3"[8[>J*BD8J%^FU?'+MC+8 #HZ.
M%J'$UZ&JZN-9:Y&W.'73T_0JVXCB[_I+OGAKE^Y>PTF2[=Q.65A=.9+X&,^)
MJYQO<FL,I1,\#;5-9]8- /V&DN_DB.OG'8*Y-T3N+0+=E);S?G&?SE2X:S$T
M?G1>Y(2KA'%8#3<<I=OA6[C7X>.OK@R='S/+_HKA:OP&NWV#9Y-[A:D@)>,V
MH-@/"@P-@AO>2*CY72O\V#0WQ@R6'W[1I$F7PIT&A8,<,CUQ13\L&R^[8S'*
M*W9/R:CU!N%'1YR0;FZ?>M&=O30 06>V>4826S!@3IO&W \!=,L<=H#7<EF.
M]?SK 9]_<"+ ZDK=HIEG4E-'[E81URH_ZAB41(!$0)JCJJ-U=>CENB8TR+BB
M/D-OSJ0;MY(1&[++:MKU:=A#F0?=UVE6SRD$$]MQH9)[&LDDJ%'85TF79&<I
MFKO#M?,LB<%X;)&31Y[4'G%,C;Y[$R^TB=/8&X="&KH3] &W\5P4@.TTF_N0
M<C%^?:U307<L$ A;.\2?]V]HEJIW5+#=1)O7)%#XB0QXRUV/".HPOAEQ^1LI
M=_BQMO-<Q-J?P$(<1>)Y)PAD_"#'V/7-8XLUT7M+&HEY]AC&=0W?"$T#S+"
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M1R^61L.*Z\JI,K"Y<)P60*R<V'@0CUS%W*[80UX>EP)/45)1AT9.[4UX_PJ
M,9F:Y+UZB0L7GY>[UWV50V <GE?ITZ'%)5@5VM$:5JLPV>BZL68=:$JD^-*_
M%C2IC5QJZJ,GRN6^2";SSE#<+QFU>R3"I*X:6W3\J)L*,UMO2_'@14>?$R]A
MHQ$%B]D3I9;UB(<NF89GQP<-Q=LT@PZM.Q!>E>$!E,SD-#2C$"^IP2&L6FW
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MO"S3&]23H%FR"5\!8HJQPD#>(9+@E\;T4N4:6=D*=&-4=W>^B8(!XUT5@5.
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MOVO3BCSY%!Y\M?P]_)0<I++=7N7)Z&MTN/\4Z*$N\VP<HD$9]S$._*A^A+9
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M>ZM6TV('[7+Y[A7&-WR7]0W(BGJ!Y419RCN%_KNK,"7!8^"M;TI0LU4&_3+
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MD0#7)F?5:#'#.,&(W"6ILI]76S$*[ZU*";L,>%B>I0NA$8V#J-,A;I8'8:Z
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MF<,A<-DLO3?@>USE*HZ5HYA=AA/\UX:$FM6<YET+1 +)/VI@8E:-4DLI;OB
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MZ$35+K'I.<VXFAMZ!51L.)^;IQDO',TXI",&1V46#51CXZ/V5A]OG5PHN)9
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M'&0K.FV;2,RX%,K?TX;\?Z9G)V7A2L/W\'?#1@R1<<8C*QXU\&L6R/,@>N'
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M0I\Q@3OG7+@K W&<$]1[7/ZLUNKP(=XMJ[F,@VR1CV%]@8(RV6_E;W=/6&*
M9FRKL)N%E%<M&2IG88(&I''J%UV[M:+=#)_UK3HDFWC3N5YCK1<&HK*14=\
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ML$03+LB:@2"+X7*I0#9?;L-WH.FXJJK/ME>JNG*A[EE8QRHZZ*\#7A V?(6
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M<JR>-&D]R-0;A0526'XW70A+6R<KNU^?7U]X-OS56#70/M4A&X.6S+%RIGB
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M]@?N#TT4%B15;#'.6,X5=XM*5_! 85V8YD;9"!3IY6 )ST(/ZU]I,7L)9W5
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M5*>UQ1=A(+GY$8R%"LS.L\[3&>R=285OTH,WXY#'[LVA%$/8G5?G%V>O"]
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M*Q%@5KS#8#__<N\H1VZID;K?DI$)M*Z8K[P"!AFBEI[+EE#(GP#4R]$?-U*
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M#T7#M!T_V/6[B#[J@^)":A(>XB*ZVX6!#<$XGBS-._D)W_Z$$>X,QJ;C<J[
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M:MZOW2/G96\Z1=D<J"0[]I)1WCKLY>0O4$L#!!0    ( %FIK5@8KIL5U0(
M )\(   >    96$P,C U,3(R,#%E>#DY+3$Q7V%R8V%B:6\N:'1MM59M;]HP
M$/Z.Q'\X16JU28' :*<5TDB\=:W$*()\Z4<G,6 MMC/;&72_?N>\T*ZCTRH5
M/A!?[L[/\YPOMOW;\-LL:#;\V^EP@D^P/S^\"V?3P/?*)WJ]RNV/[B</L H?
M9M-K9RV%Z4.WDQD(&:<:YG0'2\F)<,L7+JRH8FL'$S%U\=:\ 7"B-DSTP89V
M!F#HWK1(RC;X2K'-UCB!/PJF^RV+F(&KJW:WZWLCY+TX(>*YB'0V.!%&3(6A
MJI UED*C!49"1&%..$V :" P88K&1JH32GU&HY;[CEA.,%R.AQ QF6V)XL2%
M.Q&W@6E8LY2)#6I<T@W31A'#I("5(89R6PLT;J3BL&I=-!L?S);">9K\R.7@
M>/RY*IP?8<?,%FSXBL:Y8H8A5R(2F.[C+1$;"F/).=/:9N<BH>IE\#!&\#5T
MKWH]MU@%G#[!!;$<FHV*Q)_Q-7@;U4$LA<!%L_-CAJ*6$,H&.XX>K=NNM0M9
MKG1.RE5?YBF%B]X7"_PW';=L#%LN4?0&$\V&#7NE=%8N$8_E,TU+!=935D+G
M69;2TBX8XNQ%MZUSDRL*G/((RU)1B211B362JA=U[8DECYB@2;.!H\P"KF6:
MRIWE6?J%SCDOV54YG*H-55@G)*9E70RKSWJKGBABL45JKR4G@%;??A5[7'NS
M<1#_)+H2V7['KG[GG<$)5DS$R#)]=$_',AR.9E,83V>SU6(XOIM_O78Z3F$O
MAI-);;\9=,<2L[6AG;,!MHO";ZH58R>03%/<7ZJ14YPX?KBL 7Y295A,TGHC
M,C)SJE/)#R<POK<LY]?.IP.E:NY(&B-Y'T8IB;]#MWV)%+5,6>($GO9@C"NO
ML"?"7)F4XL$V>9KU4!$<XM_RC9R>E::EV2]:UN=0@<LSW$9O[N?A*X%.8+?V
MON_9F.=4_ANA9R'@WQ@O]1=@QV&J63]WSISCE?&*ECE1.WKV@E'>..S%Y#=0
M2P,$%     @ 6:FM6#AO XXA!0  +!0  !T   !E83 R,#4Q,C(P,65X.3DM
M-5]A<F-A8FEO+FAT;<U86V_B.!1^1^(_G$6:JBM!N4R[LZ4,4KAT!RUM$61G
MU$>3F,1J8F=LIX7]]7OL)!1:Z'9FJ;:ME,2QS^7[SL4QG2_NU;A;+G6^#)T!
MWL'\==R1.QYV._7LCK/U?+K3NQG<PLR]'0\_5Q:"ZS8T&XD&E\54P35]@*F(
M":]F+ZHPHY(M*BB(HI,?E;N F,B \3:8I8T+T'2I:R1B ;Z2+ AUI=OI=8?+
MD,V9/N)SE5R<GY^<=>H]]'UR&*N5;J;X8 JW87B4:RHMCK[@"D<@%C!./>9#
MGR1,DPBNB+RC&M6-Q_WWC:W2O2(K:'ZL0JO1.GW/?O8$D;ZA>L D];20ZH#*
MG6G?@3D324AD3*HPXM[) =4W&\U/#>B'J?1"F!*.UV]DA:M3IBDJ;!S0UC>J
M=,RXPB2M0O\&?F\T6LWW'-@I;<.4!DQI2303'&:::!K;PN*9M4LAX^QI5CO-
M'L0BNYO(E4MO%[K#UQN-YU0JD\DZI&#3NOV>'?Y&(:22SE?@Y?U."^LZXUZ4
M*A,QQ")2"2)AW PCJFWV^1A''YQ$LJA<:F4MIEI(/Z]G,]A5B'!\%/G?4V%C
M?23MXZ] %#B<TR7T4&,5"/<+S9(NT%_N43.2%-^FW*?2C,JED!*?\4!!KG,B
MA4K0?JJP&F.$OH*CV"<JO(";',Z^]E[8LSY;.-7<NT*YB[-75 9HO%#:(]Y=
M( 5Z5"[E*9"M>(5LAE^9684E0Q3& Q9"[M)B^-BOZ2FT:KFTI?R2<>Q2#+$Z
M_CU30MJP;2UY'K_"-./6H42*Y0I44<SUY)%I22,L=1X4#.)4(A3F2FS=+)<8
MOQ?1O5EAR35@;F1Z1P"Q2)+05#-//<D.NZ!(CRH\A S;K$KQ\H(GR%ZL@$!"
MI"[RKX!8+JWM;K"^IU&!Z5& [0F.#:+<I]W+USF,\.<4%BQ"Z")CS=2,K3>Q
MR#&42SID:EU\^)@)8 $0#C3[EBI2_00Y@8!9ZHPZQ$<#84:Y/"I%(P*XT$#\
M&"6/F^A(2+29\$1,X8&AP<P;#[T)!-:$6)1+";8MDW$/(<9JTQ])OZ>8!'Y>
M9S.DUN#]5/0X?)%*IADV'<>S-#?//^(GAT& ?/@HN4G:]O+'B(J\A&4:465S
M K&ED257[;!E5@R77DAX0*$OXI@IVZTV;3V^7@<%LR-.H\#V+LNJ167-'[?6
M5&%R2(KL(RG8"0QEZ(W-*A-5PE?KE#+6]J3-!M,Q)=R$*1? _AD7/N9&UI6M
M(#6UD@F62T_8M8W0=,&76-I@8S?<DX-O(T\4NDYO/(3^<#R>39S^Z/J/SY5&
MQ8XGSF!0C'_8Z /S=6B6-CY<P%Q(A%+S1!211.%G1O%4L>>FCCLM#-PCP<PC
M4?&1KT52R<]6'7=0K,J5GS8^K"?_.R]?*9:7QFBM8(6;J*IF%!U(^R/K>#8<
M[(7TFZ'+&*DI]C?-+#T*HR!>IC]'6AZ$N=!:Q&WH1;@!0O/D#/U3(F)^I5M7
M]1?/3[O\?AM?GVGM7-Y<NUNS"Q*S:-7^MS \TS3^JS\:0-^9C%QG#%?.],^A
M.\L!&B-[XO,ZG'5;3=UW]?U80XJMTO6+(@7LNSU'ZI=H.L0Y^B>\.L.CVY@N
ML3EK;)?./:UB!\!V?QD)(?\7CXS&6R'OX/K6=+I6Z\W:=/9_ +5OMY'\4JOA
MYRJ-?#Q%XI97FQ#<[6NU;F<P^EK8>A73&UM'94MZLP;-PKRC66T[VEGA'VKH
MYM<-'^M;3AZ:W;KYM2_[^<_\2O@/4$L#!!0    ( %FIK5A\_M!%U (  -4(
M   =    96$P,C U,3(R,#%E>#DY+39?87)C86)I;RYH=&W-5FUOVC 0_H[$
M?SA%:K5)O'6TU0HI$F]=JS&*(%_ZT4D,6(OMS'9&NU^_NR30KJ/3JA5I?,!V
M[L[/<X_/+_YU\&72JU;\ZW%_A"W0SP]N@LFXYS>+%JW-TNP/;D=WL CN)N-+
M;ZF5Z\!)*W40",DM3/D&YEHR52L^U&#!C5AZ&(BAL]?&=4$RLQ*J ^3:ZH+C
M]Z[.$K'"3T:LUL[K^8/>^'XM0N'@XJ)Q[C<'2'MV6,!C%=JT>T"HB"O'38XU
MU,KB")R&D,.421X#L\!@) R/G#9O2L/;Y?9F$_;GPSZ$0J=K9B2KP8V*&B L
M+$4BU H3F?.5L,XP)[2"A6..2TH8!U?:2%C43ZN5=V[-X3B)OV6ZN]__V.3&
M][ 1;@WDON!19H03R)6I&,;WT9JI%8>AEE)82]&9BKEY[MR/$'P))Q?M=BV7
M&J>/477B4*V4)'[UWX(W,#N(M%*X,C0_1AA.A#!MH'[X0&9:T!JDF;$9*Y9V
MGB4<3ML?"?AW.K5B]4DNE1> 4-4*N;T@':7+U$/1)DF1 5D*)6R6I@DOQCE#
MG#TOJ67F,L-!<AFB+"654#,3TR N"\YN+9&6H5 \KE:PEQ+@4B>)WA#/PJYL
M)F7!KHR1W*RX09V0F-5;,2@_LI8UD?MBB6RM1$X!+[=YZ;L_]VIEE_QCTF62
MC?]YFRR$BI!E\E [',N@/YB,83B>3!:S_O!F^NG2:WGY>-8?C;;C5X-N1.S6
MY-HZZF*Y&-Q3]0@K@:66XUE6]KS\<O&#^1;@.S=.1"S9'GI.IUYY ?G!"(:W
MQ')ZZ7W842KG#K5S6G9@D+#H*YPTSI"BU8F(=^'_KES3-F'"-H;CJL#G!/<>
MJ8@7XNB1XDY>[.+?_)4)/J%8M^('+WCNY#P[PO/_ZG8:O.#H]>@RZ/A-\GE*
MY:\1V@0!?\9XKD$.MA^FG/6\=>3M5Z:9UU_O$)7=I&=)\4ZAY\Q/4$L#!!0
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MTIJ%2(F<:7WZWZUB@^1*VC_>4)L)\VKGF?[E=@F['FD1Q=PA-S5=8MGE?\1
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MN*_]SBGO=E#BY2-LN'F?)2OF;Z<0!5IGCDPA3R7BUE3 4&:IO)0W)"%80)A
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M_@?H$-&+YC$J9-+A>0ZM0(F'IUW,3D?I?2XPQN7-U"\]$M=_NYL"@>&2P_F
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MK_3J?KK[Z7YY/DUE K,^<E,FY19/,FC1_DS]/2'Z=H@*+:A1:N;'N<B]O]\
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M'^A!"G1"#>>-T)6WC.(4P34$R=TS78:1_2HR?&&%8=49U)$=U0=PT]2>_ 3
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MDG77!U(&Y'5$R2[JDR;K5\S;Q0:2<W 5SVM7T^ CL"WI9W(-H\'<.VZ_.QH
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M)(OT%^4%# >2XQ&NMEPJ'[T>>TG-[W_*ZH%W@=XCF^US@W(J3,&-E%&P]M=
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MT>3 VS;5J$XK2@OBJM6,R*O+<[KAS'">"W),C:&5QHPA3E0/X$Q(Y20F!&L
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MW^[';,EP"<FZR;J&;6'4/P1[,Z:R1&2IV44P5<IV"+S,WKS&Q+9#>Z/!U=+
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M==AW:_J9JJG>CLC/EA/SH)%?(.&NE<<%[KG1+*T7*#ZHTH;,TO=RPN-OI)\
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M*YE%:MW%RZAE52IYO?@J0C]U10,:YP!5-0*/'[\?-:"JA.3'B1LD),QLZ8S
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M-987'D5:]F[W;V]W:1-+&AD9O2^BPT>V1]S-K96_)KQ[<&%1^^W\" #==2S
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MV.5X+7?*QHD=M%KR+/H)?T)&O$<*"HGSM/=G7T7/0E$,M ?Z3(&TM=ZHCD=
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MBID#H_K9!3%"3,2L)1EO%&F1W965?8+@:TFYU#6_:-7GE]&D<#]8&E(4]].
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M12>N@J+NB[CHG/0?]D;X'_H@+Z+M>X]5^ L+>Z--G.NF9PQD*;W#5K>@3_U
M"_K,6&:5M[)!B,+(/<WP;A$[%U*3:55D#L*X"BXWG.HC"G:[:9-3"Q24EW'2
M[(Z.TGRV97B1;WOP$*9(L'&K]JKECPQ7MWQ(=8K&G<I(A]+!X,-Y.YO22(RE
M)U!,G8G:+B<_IVUU Q(Q",-+I"XIB Y6D\C-AQOZ2.<CX"6-M!%K->$C@!"%
M8<MLEX'5#8/^VA[$329U7.+>H_QJFMYTHS"J/Y:^_I1!K8A.8&])0^+T> D7
M%OESY.!F)R^#J;!Q]TM7RHO<O&ZC;=K3IZ'D:M$Q&Q$RM>5(0SW7'F6./@B;
M/Y4^O,8Y3$I5_Q&&82F'CRW!X2U-H4X3F1$;F_Y\@#%"OW-6'2QLHH\KK/\$
M;O4@MXWNEV6]+:TKMU>H&NY7ZX<#OL/T1#\A6;V77HZXHV,Z1ODJ9H7SI4(Q
MHIU*$@I]!*>#E7SPQ;WVB;K62O1IA!81AIR6Z*UXV#<-O"BCXB<AI7IF0*4"
M)2"\BR(49LSKM,U4O$#45_?^$\GXET[NWY=-$K+0-;MH T-# SQ!((7XV[MI
M%5!,0?GU['=?)B--<3=.R765F/ZLC]APY]1*UG2;N3EB,K:_ZS[3>=!3D$2&
M]S01^ AHU)1'DJ:GG&MJ%]>S7)9*Y4[ ,RL^G90B__8Y%EG7Z3"*^>1:>^Q6
M-\\E'O2)'EHR$C@WMU]#?5K6;V@X4&N 'YI))@^F8L15T%=*R,\!FSOZ*G=*
MWALB^@:@7:.O$ 2,U $/+2/$O!G(1-2U*W1*53.TP,YLZ7ML;]^Y1%=1LQ41
M(->\DK"-ED9"(6VR@@>)5?]8*3JOH=,C?:< *^?IA6IP<U3K=FS58>WF(A,5
M-<&V7JQY1^: "(K&. >F':\\)NL(.\];J8HGB'IC4&$C%_6?0X&^/FN,^M=>
M0ZU<. SRPL"-#[DJXJZLU\5@TI0_:0<[^L<3784IU>\;$-!&Q4GP=''V(-!U
MI_&-4U<]UMM7T_)BP04=S")"4Q3K!GFY)>YL5Y48-;:"U=Y!\ BCSZ_.PS'*
M<.J[\6=+DM/9M,!6 B99BH80R(E3[-A4>_]NB'9HZ:N7?>3)6[XP%,28),T7
M%\:PO/V6QKG;PT2J?.V!;SEE!7F?U>G8WLD**(40A'WLD8@-5$L(:41N0,SK
MV?'Z)V7B_V!NLW(TXFT=;+:+YZDS$!IG9!#*,6;8B4X]% B(/\U;+2X*C^E3
MFR3-#8)>B?.6W:H(1NB2<,K-SKM6U-^6U2UGNZZ7?Y@ ZMA-INQ0_%B :=SP
M&',D?"YZ+B(S"8+@CWR47/FI"0]=@5YMQZVM+LN+PY<V^D?F/,TWL[OAU;R:
M5.PPF6\GPF_ WT$-4FX&G7KFCGMJ=&;9J;&<XZGKR-OPW0[=M]I*WQM:\%WV
ML"[5X&M!HD#QXNVAZ$Y )WRB+ S^X<_TXG-RTYMNZTHQ"CID4K@UM9P#*M0X
M5D^9%A>"Y;$^,V@J%8\5AY;HB_\@3$.0+?&?+=*/I+K;,KWSC*4'_J93*NK"
M4XG 7Z/?"H9-S+.U95\(1.1$B"IJN9DD9.>'*6"NIN#"@WZZ:R>8^JD^[DA$
MKS>O4X1]BFW\=:I[85V>?D _/X?/8O'L8$&H84O(=#8Q3G#_6!O]*S(X"8&>
M:3_V=>J7:I:$ZQN5G9Q)YK,_>8T)W_E0Q12""XM^0M0VW'EN[J*S"_,YG#!$
ME9(W5%\(&1C!W]SS83XL>GA3RX5O95A8/7T8DFEM51?SK'KA&IK@60-BL;BN
M="M0(1=$)?7YB4B$Q"$JR[D/=$;G[P4K3ST6G";9%!4" B,#GT4=G7$#IQY&
MWD1$JHHEEN;\I-Z2L:/H[21GA3LPY;H^&1_[(]G,.H^5:GM0O:?XP4BX3L\>
M.+4:].4#6&WW+H!91DD:!]1+7WC2;Y1PI"R8RO4E5(4=+DWYJ]T'/4[#-\M>
M,9E%J7%6^P_0P4G#6'Q%9ITJLMB.L57G>T;K[;@-MH1]3(SEZ-$D?0A"FN0\
M]HP]XV!<44-7Z<:+Q9#Y>#I-SODV)G.RO%_*O4/*+\8[I/0+^WNDB? S'".,
MRE(_KK_^]*H,>J4@\&+=!2S?*UNA^M6?[(Z+ /C=:DGYZ:>LO':0WMYJ)&;V
M#NOU;F5[NK[XQ;L <4V<R9:])5U$U!G-GS+'JUMXZ:SL?C@_4MMM$"?*?O(V
MPEF3@KXANU/_=Z)D@-SGBFP>504,R/ ?16+X*L$$I\QI#8V")3N-1Y7VCFGR
MIM,F!:SW+M,HNYV9'?8Q,WP$#H2N:Y[QYXY#+!F&9V#EH!CD#\'9B,H)W5#"
M,(**6^O,"H>+$>':RQ=S2^J+JY'=[M=%'VHT'0B#<T)R \PM3KF;_K"U$7 R
M<W FJ#C"MV\:6'Y[MKF5Y++EH'"1J9PS 0^N/X!9I\$=,6I_G$*;X L-WC06
M@AKV3C:9%2?D1HF7PRE4N=Q?J-$4<;*VRM?DYP!;SRP2I#>J@L6'SQ,XU&0B
MY#BSW%5B*&(*\Q*3*_' ^CE:2(CIQ<5G=*>HE74J@[O#?CL=NO$'WULZY[.]
M#L]H7UN9;K2/ C4Q4YY_RNYO0X;8<\1Z_R'D"A%1:7B): ,N(.YIN<C_'&^R
M;^L*K@M@&VZV ]!D]44Y2-GP9,TOJR'#?,XHB0IS)!;U\*WH?L?D5T19PQCD
M02,AY5E:'>N#>6"7&-YP,<Y&E5)'=(%7UY,4812]@L*\/(SIBAA]_!9?.!-+
M5/\U;:+LT?%''+_D]/CBLJMC:/:^+C:11XJI*/1T4FEM%P+XP&RMP4HEHL+&
M%6/ZD\0X7$?"EX 8KK3/XWZT*#DG$#4,CQSM9^JJ3G4Q5A-^U)< )2\J2R''
M3\X!;5/"B:E$%'O9HTF:^\/N^RS@:K2;XZ*SOJPYP4^45L2;M 3;5?N]<#XU
MAS%?//PYZQU/B'YN3B#$@$G[B]FF_K=$-X*C/H0;G>7] 1UFSMFU^EG9_[YO
M?'VZU;;W&U>:G9'\BM$CP%9S )=))B^#NISZK;(O(@*(^I^>W'44%?"Y5+V2
M+RRXE,5YX"LS,.RB[,\;IUYHJQ$087G_!5V9WV%L(MJJE,X0_^^\0]"1W'[S
M^BP<'V'5.-.9.J2(EN99QKP@Z]"'F&YF#QI!<H4TT.CLIMBP1&9*$@SNQQ%Y
MFM:6C)V#[/'&SW'F5AI@ECSN*K>&K C[M"#JER%L!.A*6Y*,[6]%WNZL\^"?
M:L+=WL6#X6UBI&6^Z@%:*DU9S^@A<9<6!Q([^YQZQ>R^Z3C6&$W<&R79GB*A
MNE&$B?.Z?E)E7KLB*9U>$I"5YG$8GF@>#20-%0GZ&9B$*JK&51*KT>0D4]#=
MEIT@%?9R""YWZW];K"ZF\P<?%N,16AYB#EL0^OY8=+W;U"4.3C=;7W2,I_OT
M@!43NRR:&VNF(K3MU-U+8'FC#H^+RU8RF^.$ W[,$Z-6#;Y=E&..#/O8P)H\
M]5)I0DE9O-R*$3WR-:1<N8LHP0;IJ>!O1O]HA+7)]$D*4G"E/4L?2<F]GS^J
MG[_EZL^4^F2D>X2G3[@DGU%*E171E<*'2^^%" 6+1/[9+Q%!-EY(?DVC/$50
MSU25Y5( 6+/NV%:,$ZJQ'\#7C;GLW2MC7^.D)?!)"^]9XMO>"N=61'O5XZC\
MWWN1N5F+<Q@*:445ZWF+N*>]WV2E?0V-%UQK)G%R?(Q8B^R^+&MD%:N))\(Y
MJ .CR0RS<F2Q--Q,%J*<4__.QY9HQ*#:\/[A</1ZCH# V'RP6 ^-CYM4-Q^1
MA)!>\TWV#-XM>Q(M>!7A[UKS[/B[L1 (*3N3X&MM:W?82A@"7.G],\M:U&"3
M6'QDESEUA8-7\TE FW7+VA U*EU<]_J.V:FZ\P#?'/^ :G2!J/HN.:1['"1!
M1B.?4:;^[GL<?*->7'^<"6MN'"%(*LIG6W-&01'?+V#\UCXG.4?K?$?552U/
M(E4 [A84-/[[S=U+Q&% :68?9);A]A%0FY\_L2Z[DYAEQ1C)=SV'3ZQL_^WK
MBH/4%2F8"S4:499IYX-)EY]S/3;-"NH>DSRV#DU0>1^'8GVU6!-?Z0Y\9YR7
M3N1MN7@&WY)L$43M>N0C8*DZ#=O0>FA+<YW]UL3FCP,UMQID4E9$@G%R\JL?
M>FQMKA(EP$_]%Q$BIK7@B.U5,:K$A6E].U#6C2N!]*J"FFLF552&+S@^-A=S
M2+.']]PA6@^7;JTE?9X^F'<^E!O,ORT=69JLD([**0KXO)]>>UZA;%#A"#IE
MX'CV6<;0C+#@_?@X<JY"JO$,G#^_%FL^C%D-WAN)F/K%H2<4IC\")CM0,$][
M%Z/Y:;\AMD&=J>$;9'$A"*EV6_"W\^_!M>-X[]A'P!]UC6U:NGM H<UR 9&6
M+@(Y"DVT$3/QX8P])<\/I*7 ='I%)%GQ@^;4L6 +_EMUA+' =,EWMBH-G^/@
MS><R7TP QH9965WGJNV>-5@]2<0U*&@3EGP+!/,'A[+\,'O'[N-T&,+5'9F]
MN'0!_0,C71Z&]:L4.<TN^) ]]\$LO)5*(:'?9CT\P!*8[0!5]4C(B&"$?CWM
M*V NA%N,RN)#!_Q:VP:KKN]%D?[8_CTJ1O9.E;NL$PJC0G#>X2H,_R$/CX8\
M9_W]5!(1]LUX.!O7D?:V')>4_<SS62<.@>[876O0<?2RSL(H_0F"_'*S3N>)
MY,C1AD1#V7T)^[X@!*4\<6@^N22BAO-PI*UKK<NJ2>P%>;@9V(TBVY?</.7\
M^ )L_RQ1Y:8I<M :B(C4DQ"!.9>18VWO07A>;]\1C_G\Q6Q#:'BWX-L:(UL8
M5V$H56P<5T0,57Y9SMF$"%5QI*<Q6S<=E01<,LM:DVWTF#VJ/A#[B E B ,"
M< G08I+)MZ[H)Z;[WG0#)-AGI=RIQ1OH39SP-A_VEI!6\-S#:)8:NS@3Y!-?
M-'>HKE\9/Z2^X?/II/BI 9$A(=B40*MQ*E%6Q4'QM"%Z Y9ZC@.&8S?=""PL
M$K;0..+(W/R?/W[D!4:&AL92^B7&QJ9R!&:D9J E& 2BZ0M!( #PWW"Y#XN?
M7S"N#?F#FR';P&H(Q:G4"@3(3K\7TTKYM]+5&&$HZ>;N\6MX;1PLB2Z/('TJ
M!LY4VE[V5A\IY>L<ICCTXW_!0KD-?&AS$A.  %]VHVR/[)=P.UD<E;E4RJ6J
MOWZS@JM<ACX3_29&S; )E["( 9-MZAGZK3V1.&_7TWL-NIP".2P$^O"W"6E^
MKKZT !4=E%#&U[2"0/E*]V+XHGM2R@*HM526_9SHO==^4B?D&O+\R#7#FMH(
MSH1#@JLF#U+\L73!],5XQW-'^[6*Z"^<SM1H!G[1F^9ZMT2XN/R,GS\EAA&%
M;+G&2>)4#^--_Q47>XX^X\K@BA(=5=;$,K H*+:VD2JVK. )B"HGL;2T$J*I
M,3C.ZXW8]2F8I]8VAD[LW&?/3COP)?..9"5A!_U@PAME(,U11UVAN6]T#35[
MZQ%/(T9JUJE6680RW($5P@(6MFIN?6B3;^(XI^:HO4KJ/G/\+G!7[QTR6@?$
M&\3U42#;W>S\#$+<D]F=?""[('3BDEO]W:=TW[*]--A89A<DRX$S/M/VLFO-
MB.DVV,ZU)D+G8SNHJ=,[&ZY6$?],KLG"/]WZ@Z6JL[-;6I4\=:GC_,EL;\\4
M-#EII6$9+9J5GQW*X>6125]%ER^GD<&I[KCKBK V29EX+9P*YYO(UEXCKPUO
M5>TG4LY@&BEXE3*4X'!ZRC8#B#3095I$99(!K_ [J6*$,ESNI703O)I1%2Y(
M',CDE=<6;Q/?1535D$>*:7SK,Z3+E0J'T&&V,U(1N V8,6R^(GO?B] OE5:T
MFZI[<A<!019=Z:V%)3=,CR)R;=P?24Q$+4PUGV_\L2E3J#B$7AE'1@K;2B)X
M??C_S@D,Y 4L?8ZB@G? MDM">:O=,EXV)93VYJ>;G;T4#!H 2)[+'1Y1\)V^
M60O]Z/$$#D2+'59I)#NFTRWDF^S/@QL'RG?HV&I>2[:VAB\HO2]L6U/6"/+=
M)8\&3Q94L$D&__X_[JGP#1L0U%40\!T:5Q)Y4V )J\;US8 X@^EH3;^XAT)"
M-(]C1 BH%]/L1N"+*G"6LAH[(]QP<HQ_-:6DL&6OHYJR_J)1^8O>/+VD.?WG
M)%]SO1]H3+9Q&^:,:*<(ZZW:^+5-_[(;^U7=A_A"L> V ].*3_VB]Q\4%91[
M9&6)'XH'</3WW0SLW1"XU 5AS30]#N_$V^9YP]RV<H_7G)?IB^A4A!4IVS/8
M]'+R)X7,H;M^T>VM\XEBI']=61^R9NN&H'VQ4=-"=J6+,GN426(F(8I,(-!P
MPH[FN*0QZ&OZ^R6SPF)NA'[-!ID<:(GWS,]B_?3U/SB^=<"5"/D1/ML[.M9>
MX;9EBYH(*6R+5>7K8Z@B^6M9$<!7>,3F,*567L49;S_7/B&9Z6=&64^]?H"]
MXGJ^EMDTM^[I551,[YT#XAS5S;W,E.O+I4KO7#%QUF):YIO(TB^#Q*P3*N)S
MZAT,#+O^1)5];:@3;8CD9JVF'YK9S\#4#-K?^?FAG]X'4J'C?.CT^Y05@8,B
MN2X&>/(+<1 )GKKKXGW-J-*U0&P!Y'D$O%I*T4OO;R_.7?_UFYDNUO6H\'4K
M!Y_-&R_TK&AO1/Y.4S!I17>H_M:[SD/V6;&NKAZ],; 7^@@@6;2=U&<=-:.0
M]JFOTF5Z*!@K(_+CGX%"5_[I 55WU^Z!?,@\W;FOH7ZQ?OGL]4?PZY@<:^+>
M>!C]N-3Q&A^?(P:+?52Q'8+4;-V[%NCY049NWY%&OP.>1+F##3\OE$URP<.&
MX*1^%/SK/3 N%BI&$10Q&A:&2'>0\'5K!"$%]V_9QY5P?GP>43I@:*[UM?K\
MTZZZ!?V6?A>($71<11C-B-#/$L:!] .2]H)/-ZK%BQZ/ )?)(7G)?&7IA,4Y
M-VJT<90GRH<6_')"8 6U66Q$)B6HXK*&I&>N4=/$8+9/HO;#V^\X'W$Q+I (
MQ+ HP)*H).;YP;V/@*ED1%H),8,U"_>N[6KKRJ7 +HTM%:2Q_&ND#4O4_6M,
MN:;5CX$9'H#32>(M,I_9Z#[VI"[\K_F/LW,-#@1&9-O2<L\.7C2SIS2%V_>4
M9M)\=],ZN!/U;<9&+\AW+YP,4@G-[&X?]T< Y6E$%.D%DV]<F_-"F5.GSNQ0
MCEVX(#0@S3V7I;+>9O#3K7L?>*;<IDUY103I5/-"D*TN^/0&XK4UO^6E\DMN
M9<]5S#5F]'KWBEF</M22B?PUP$#L;6I%:*R!JSZRAA ");H@1#I,6Q,8GE7<
MNT%/GOVC9WQ297IJ>.T3G1D=N=NN.77T<8PPIN6@/ #!*,5I7=X46/JI"588
MFXJ2)8SM]9A^(1+.)^V@0+89PZ)PPVH%8P?V<O98UBGSPNPP94H[7[CM^ZU_
MDGQ'_9$TL'-<1#BL<TQIW6Z2?2\K(S(P%#DO)S> >P+GI3@D^P;Q!;#$"&GT
M\1_CN!QG+_L!,6%E%/%'0*\2M G,C6'R1O$@^(\2>+U'KHC?J"7A.9'J,VX0
M7&2'[AIOJJZ'#Q;YRV+SL(2K?UBUUN7$X"9<D>@D<TIEH;[?2<+UCQ=?^2PN
M+'F#D"7-1\ _Q;'<?!$DI(31 QLF4EK>S(%E%+K*9-5PA_L!J SFC?LE^2,D
M^1'P]6^?L-LSIPW>-UZ'$2N@.'[GO45NS"REI?Q$W+(BYZR>SSAX3MGYIK\C
MQ.YI 0B+?^*IM3,+-2D\KG>'ZN'M#N=XA+E*_G)+8M'&-.;3Y**4\,]&E\UY
M'6@8*_8(^(0XCC+XUX(?X3J;2V9!",^*LPWT[ T1";-)]WA_)V:D==YDLI9+
M#@QCVG SA*B BISQLO*O&:L+[+1NF5IQG(4B)W$T7G7_3AFHPU*-[Y^25M?5
M!9W\?#G1/0Y4Y$MU['I=E8'S-XYYR-C=)Y6[>'AN\"5!F_48=MJ ]<YX<,L\
M@90NL>!A&I(R(V,./!&*Z7SQM\-@$?;FDP43)V<L5/4U2&<RO^_+3,8*5E;0
MX7X\_5GQ-QUN.<*W)^TY#D03(++-WQYECE77KTX> =>Y+C?62R#ABMF&7=I+
M+"H9PUQC%?)S&%;?SU\2_CCSA3OR!>_**")8GKZ!B_P(S&SA$;#M7^" 6[];
M]FQOB>>R9>JD)374O?^:\O:NT[F1YEC+-!;D@8M+C6LSC6 9*!,;ZG//>'G)
M6@EJ\2JLO./-MH.] ?-+*\L)^NMMU-,^ KK8))]W^V@S?O1!=%76K?LG-:JY
M@6H]>IZI;GSU?0!+'+3=:>7IV?FM]Y#OFX-7.#->5^$.>:!&X2]Z#0P7#!'$
M0%[(]C7+]$5STIQF9N-555\JKP,98[53"H#:,^-V,+&DH*^Y)R*W0['?"$ER
MC!_$G,@:YE'F9,VME<>+&E$V^&?/[&2V29M8S%N\I508EX.8F%*60TSTE N=
M2)&,\A$@C/ !7M[25PDV[LY4*M8L' (3[8RS$6D1B;NC:YW0O+XI<4M\BM04
MY/$3U_57[=)H_J1PJ.BSJJORHG['4TX<FMQ1[_$D:ZE!:6V\2QB,IMWPV3M
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M-_H]2I;52'7CZ,IN9CCZ:+2):N:*W'ZHZSIX2_*N:7#??J&(X?6-/:]?*6V
M8D#*JR$49+M<#H[V.$SA9%275NB5B ]\>6FG,"DB$@::M+[AZME% 8$ZNNA"
MFPEYD:B\V-)2YT> 62B:>M0-8@^G+;RLH0<735=RI[V+*M:6E_(<C$9A&':Z
MJHPG2N+RMWF1^&K1WJ\0)G^ZSX/0<GQ_**6&,^$UVD[M\G+'JL'3&9O5R9=*
M3:6@<C?C6+;#&9[TD(9FQ/D[\,'=Q8AZ8M8$4CX54[N]HMCM0(?9VAH\KS!<
M*3>!S!4I<R]*:AGZ*R@/%[\N!QX2^H_XD1+3%Y P'RX[8LNS3XYWS,S.UZ=R
M)V94T@26.4ECAA:'@:7) K]ESN#$2ENP_TVXB?VCAG _RL^U=5751,]YSPX]
M64#"$ODJ5.*:R:#6VNWPIHQZ/%M53)H&:4K:IFL$>J4B<2)1=G(O,IK\+KQ#
M:9VAJOJUS=)<=+'K#D6.5CH]>(+*\:Q>P]3V&NU'I+;E*TK@NX%"1"*%UC+C
M>->Z9P#\NU;NIMT:LPM'29Z3)Q&X5NCN:OAJ2%DRP5;Y/W5WG4%-;6N;<ZP@
MX$6*M! 10@E->@?IG5 2.B*84 ]$@:" %(.T *$9>N^$)B M- 7I>"P0I46$
M !=I EY J3?[SCCSS??]^W[<.??.[%]K]MIK[[7?>=?S/._[KG5R(F>N7WUC
M]V:,E5D6X/,O_FSH_*[>-N4H14UV>CG=E<^A+U[_!9>:763VRA8FR'GH,/)Q
MY\.$[[&Z+ED^K84:[ZU?4L<*B+;@.^EK?TB98+9XD&X,<)AY1:<Z@;[$]..7
M&L/>N"5G6+6;$ 1W7E%Z8H#[FG$:C;QSA/U+U+__#5I7NG-T_Y6>K#49S5@@
MYE[[OMV K8/5,F6T3]W8V>?^5$X<Z+8BWF9Q+AFS%4?#Z&\VNQ3O__V3<LH0
MU<<_E*\-')4I8,T$G22WHB]96VH9">X*HAW5U:4Q6NO(I,V7-VCC!'92E\J=
MLJ%^6:NBKA1*'0GRV&G:5#?>'C_]W) +2OS<"H8(H*K=/FX,),(O)XDOL=O-
MTI88J[<Z((T :1B'X8H58WZ@P"T'_5.)Q>H,V6<7K5 3*2A9NN6\2\VR/.DT
ME-&]_##PC(X[)+2!=+VN.@)_,+@]:+ P^.XV :.4^.<7,B)KSEZ$LS6CM, #
M]]2\1Q8DDF:Y$#U)>[D@E=FKI-;3US-3OCOMS%\I[<=F:LH;7_5@W?5[JI&C
MJ=R$,@.[\ULU$K>3QVY\!#:/+P=81_S\GQI]J@(E33](1L?*SB?.9B^\L+>N
MU2L4(^O>CI6N3>XN5O-EZ/R0]SD!$*9SX6522I !VLICUX)+8=Z)P>R-<[41
MKE)!&+WUIWKRAY6>BS5WM6SQ22FGC8"Y?OK?RP@"=-Q_A%QJ_L%<])HL738[
MPK%$\>*QA[RQG2"\>F?BQMFJRBX[>6N9YYO%:1F5$EK,^C,LL$52%6US8.[W
M3,-1%1+$ZA&?:N]Y'YX>5N\H9FX$\6[*YD26,Z&0V.Q(B >PT4_I*YK_U)KL
M]B6U+?N7U44/*6[/& @RQG@W?DQFNAUX^!JCS$6]=JO#L$7S/: S5&D2%80"
M>D(C6-J@8E!4+268-#ZX^N;6[AN8UE*N1'O3A^;?"S&"X3".)@[C;!;ZSG^Q
M#+.V;:6DNJ<#ON-,C$ISDM>PN5R)Q9$L-!@@:,(HC37R"!,+"H)0XMTA\0"7
M+07GA#5*H0Z$K-D-+%Q\,52RKYJ:]V%QK@!,B2=3J)3PR?99[$LN(WO1KS==
M]X >"OD>';=<6$_5?+-O%/%$=72F<9L-/)F!;X]9IX\@W$OP$BWL* G1H]7M
M'SGTBV1PA7V->X;(QL8 S9&J@-AC-^84G:G6;8KG/ Y:C8EM\G?X5/241)K2
M)."J#]_JUS"Y; ^Z=UXI0XU+LS):TJSO73^ B")/[W4.UC>$_1$6RULOW6[6
M=)3AF;&6AI*=YAZ]((.E2_WJ>9]HL<L&5^+- $2WDVW;T UQL):-3NI<9RB]
M??3<].')>(=I';.",;R:S=<HK88]S9I0E@OFM2P;LI+5'>:Q(KA@MB(+TTXV
M<[X]9OX^M+=.IH:8-!25$2F.]8;$ZMS@+0;23 A3Y]/*2E?6;L;ID*PR?/[+
M"#:8K<CO(D!,Y+WR*C,IH44U%+E!ZI'&_%2H>Y/O@([JMX9ECO;QRF1]KL?'
M%^F#RY> Q#.;\JPM)NI<]\B3=>8G8PK"]S88"<RV39V7P&8F&C(E# R%X ,T
MFP?66 5'_U3BO):?&&IRM-?'?->(-M#ZOQ]=R?DQ0BZNO%S97[&2E92][R9C
M9YJH_7),BU":@VVZ97CS&TR560O(B5C#M\4"!Z(X7GGP(M?EG"6IRE/F"@)+
MX7'DU[M@*4>^(G_!\=YR0Y0$;KA/6_DW9X$4,&_]=2"Q.I97<?",+N/DXXL7
MZN][FWGN>>JN?;=PE[587H?VJ32-\,V\^BBI$$) J2#K,T1OGAAS\M"0::UF
M%<F@X1!VX9@'M=B%81>]OI/TZHY5I7I>#C\JD]])(/&R1=J]RFBWRK@TQ#E9
M#AH<<?J?'P9W&0<G=8]TA>:*=;?&3-=2VIE&M+#&^H.3%C_O?U_<8;/+R0M#
MR9LAU'8$T]^W&(^R]>GNDZOMKF*V,N?YPAD1BX6@]LX^3Y_%HIK'!<)UHNN:
M<:Y%PR9L+-WA2SFB/&!;"STYU^KJXY311GU(AFZ7 ,T%R2'@"%V$KAY#7!&4
M6-5$K'J.L!"G _3,]<Q?LMK@Y\+KG8H51_Z%':<J]Z15<3B5N22?#8?IHM)T
MCFQO8YQIA4(!%#<7R,4KV(@8OFM7B:_(6D48O.,%Z.I4KL$*;&1:9']_84:I
MIVXJ!:&GKL=TQX;;&(J+RS9&H#Y QS,B9"'2D^\&G[W_4$-GR,P.( :_'LW'
M+M.@J[KD%[4/^0[J*N1^FLTZFJ<,IXP4EP\MB/2/M]<&J-U]_DEP@N4HC9TA
MGF:.6;_BH::GF*!+!XJE,DH.7EW!9F=T:64SVQ<T2>T#PL)Y65<B74.@TL9G
M=-:G-N*:M&D@UOXX>A>,/QGWZU(0$V &M9Y^RI6XJ-VDS/?DNPQY8L)-&E'!
MEO'H[G"4LA>+<ZFA/;;C-Q[:[/VM?$,SGS,1HC"<4/Z<BVE RXA9$O1=TA@;
MPM#N]<Y:CT!P?#"QF,LO+B(H(=A8G$*I?MD%E&0,D349=H-!GZ0\CI/G6+XE
MD>WMLA5F+<WWVD>@[RU>'N&ZJ4]DI*VBX:9A<EXZW*^K[G@:Q=&XE1N4B*O"
M5<456[)=0" X:!<#\4(D&*!Y_K],R3)AVZ2M#>9CL^5\E#/M&SGVC2%IH'W=
MTS_;F-B5SQ[NX(37SN71$1+*_U!2H<SH+90F&"??KY +6' $J95/I_&P,&1#
M#832D((4]G&+8W1/#5<_>$)%UQ;*J^36D#'XALVN:S(UGGCMP.?<,-(!G-H<
M+O"XJ/0SW"1NEG D+)I0<Y5CVW=("U\RP&&C8V^2T8^$KGNS#?!;B5[S8FBT
MZK4$%C_'54W\$;I,NH4<$2RY.M_Y-/O ?&^$W_OPJWL*'&:@[1[\]_(A>>?E
M,"LULLSA2A _.\UQW_J5XY@0.UI0-/H09F6[F?C;DS8A*;'DN<YPANQ[E=AF
M@61\/=Y!N)J0!O4@#B*)UQ3]_V9L:XF  ,D?.B]Z6(^Q<]/(HOH9Z4TH6]Z
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M6NO9?H4&R4*VS&V?[XY:O;%#1P6.X?EJ\U^!P&Y+Q9\1%T_EL\[H$J2.G67
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MV_>7SR%5E7A8P'SN9.YQYCAD!7Q,JU:T9%JN!DX13MB/SW(6<]#2=_0/&*Y
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M'S,\NOQE/'$J?M&F,1(U,YG*M],@ULC.7ZY+?7^B*''&Q"2$#/ZRNQ,\ 0U
M41^[GX_@@I7JF8I$__!O7#@U87!T(7E'8S#K]PY.Z1W+3O7E*QHGU_Q2YRNG
M989_)?QYNZGG42 !+( B+OF0QFNCPRMBSN!<GJ A,C-GW]H\RM9C8IXP(AUX
MMOOE=<*5 RY+;EZD)I(''7S\$_!#*X/**@P"-9SQ:=&3X46K+WM#GX).I[$
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MRNI$%'QH!L%AD#_" L8;TXT)OS"*5^C ?@U,"0RCH8T"+Y7*0I!7J-.Z*_
M!%KCAX# X5A@T/$/BI/_@&*/21"5!;W@!^.X*SCO @M4'&W-]>]C@7N8X/:5
M8BR@CV-F#AA.+C@(?!(<%&CRC\:G/WMW(IT@JPW_4^$USJ"O5Y$7J+._<OW?
MD\O;!G;%KW))8X4"+QX<H3NW_[7?5@TC".F VVL:M]<V[D+NES*!/7\P6!YT
M8TH@%_R0/S+UC^ 2D8_3G^5QJO#9^R^6_!%(ZBR>_ 3'5H/.?S1T*@MI1N<V
M_P'V7WCL'Z4.U_@MXU0#ODKKQ$EILW$)F?TWK4U_]H"403$:.+!+=?\.-OV_
M@O1'/(O ?F)4)A98;?RCR$L0>!XS\H]I?*:B/='1"1?<VFC:/9-_V<7LSQ4$
M/C6 D)Q8( 6RN1=8,X\CC']MY/,"LO)A:6<:$W^&1'<.7Z'==8XQ5MLG6XI8
M@'$="[AU'E@%=Y_@.&1KKNOP7R/G:IWS-6BF/1,0$F>!@.Y_NA>CL "\\Y*R
M\_A5IX\^5'!5:DN=O* %"YB&X$CP3 _X'5!: T-UNEL<H+4OW<^7VFPV)E%;
M/P/.+,]VVZ?;+VM\]H*W?GIIPV4N8<^I/4_C.^(Z&;! *M3"MD/:6T Y?0UR
M1#K_?A(M.#G9<!GH>#6X</F*6I[)Z-;;QP5]-H@<[DW/X_(O/ %^[U5N\B3E
MD>0%A@HT#]ZL,=D9A,\^>*PV^%L=#H7JVS(8.$43J .Z<AP> "R1F.DFCMG@
M\\28([:+5 C"8W<)=;F3L)2 035A@7J_SDWF'/04M%_P:BT%$[JU])^G[BUU
M@M GKEC ]@ R*A-X9@9A[#Q*TT:1UD"^ZKN +K\EK!MB@>*OGR!;>YW!5Y"S
MR69T2B\N>SS9^^EXY84%?ICB4KIV+$"F50O9$P9G&F/2;^&XKZ8#?8DKEI:,
MEDZU:=$$TYT^L(-A+"!I^R?.GUV)BG5C@<\#&#LKU--'S9B.R[.]?BP09 Z9
ME;8Z)K?\B_@OXK^(_R+^B_@OXK^(_R+^B_@OXK^(_R+^B_@OXK^(_R+^B_@O
MXK^(_R+^B_A_+>+-U+.][LFMA#00?L!+M]?#&&L;^ZOH10C+OD5TZI*(N(^A
M;EA5&Q;@;16"VH 7!.=:!G6_KDF!!FF*:COR'!Q:,_-:?*,7ZPJHL0!M#%'Q
M8W"DA,WXHQ@*QB0N_Q??NCL-SPGM,8*Z8U(79RD_1K& ,#C'\[GPV_@:-+\/
MU;ZN:AG]MSLE;1_->8=(/A6$("Q5X+>#PS#*$0ZU.EW,*ST$ZG7(>QND*[>6
M9Z5IKYAH ]P0BX^"\M[6QVV-J3ZK&V22SJ)R5&E1,TX%*7'1A=XU2"HUO/\M
M^?4UZ#/8N10ILTV@31=F,?T$?-_W/B+-^Z?)5+^=0TERBJBAEMPF3W&8@CS;
MFVH:;]7)Q]$%W89Q4:?A+LE?3JX5#JQ_!LNFPT24'NQURRKG6A +ZYZ ;>%9
M>._3"HRC1?.Q )<$0@%.8W#@I$;*\(!(X5#BB0M)RVK6[-L"N8L[8T'#YKMT
M[,#++@BT8"D=$?^U>U>M;_9 6T-+9TM1YT*U;!7?EH?5YY O[GXXCRO=3;(&
MHE,VVMIZ,O4;%V\@7T?-M#K,C2OY'',)H[& ;*[GI<KJ_>^1;,P"/+/LE46E
M;P/ TCYUU!YS10>33^[%Y=SX6*MLCE_I9^48.O?#BQCTBXGGAM]GTWCIV3;U
M&Y_TG:>&4W[\KE?.XK:0;C0X)1GUFK,C5"D?4M,3::DE11M]OJU#"-MFTJT6
MR)>LN1Q#?)&=7ABOA]]\>J*325(XH9^XP!=>3Q55VU&Q0)Y_^M6$+Y,PZ#TR
MS#]3Z_K*$<+9:CY[Y6%#_&*?Z]"L4P9[0VKB6)V)0K::UW5'L$$X3>/[L//3
M3!=#[71E[;9/^>.9)U0UYU(Y3>*P%[^%?I/$EG#86+$[:QC&O"W/NT$UBWXE
M]_8!VW.;&J,J<?H(NWEC7=;<UT123F1#6H#,$^E!L.S[3X(VXZ>W@@/*+)"'
M2MQ7+M$AIE])$1;JY:1.J\Q\KA?,)YY<S>K>+^T<3OI%>LEOQ?:@#>-F&_34
MTK-X7D3P61<.ZHR9E!++C^/W:</+6\5!YN8SGGL_ZKD"9!\4UQ;3=#[# N+Z
MW)>*9?NCC<P\;]9>OH\N/TDQ$$VU%S]^ZRT<4PVC)R[+0%JKG?8T?=3,"_5#
MY5:_XLI+G-B(]8Y> '%RP&<JQ0 #\?EH/R5P=+((BW =BW].U"N56EX$X5+(
MCD_'T \\D67I-JZV=5?VB&M0=Z65EZ?QR.]*TI)/PZGL)LX*"DK9J5_$Q#U?
MG:C0_70[*R+UW?'"=5??][&A0R5AWU5@W[P5P4+2754FQB@KJ-SQIVSW%5OU
MM&I9O\%0+CXY:\&RQ+GMNMGXO."XD8VYX_G&W#F\0RHL0/S8R]W1;2[#Z5??
MV\]!SO"4GQE"-^M*I$Q^%L6YL^8\R^,B"Z5"$73SI!&/VYX$&O@:W;W?V5R2
M(*KLQX7?\NMK24#'^)?"L2&/$1EI0?;17O8S70G":RS*NQI/D2O:HT(TS*>?
M;"CB,[,SDZ5LXH*D7(=\T18^U.K7'<LH/0R<XK0O.MP9:,!%^]HT?QX#_!34
M^'E$=76=*)$14IY#?+@+%15RRFRD>6R0QLK68HZXUK^9EPVIECM]ENUY@B#8
M4X@DKCX(2E**-3"*X[EGBA_4$Z(>0>3NP^_+T4BZI,K('#36]%TYHV9V0FQA
MZ-[)475 CM6"=UTWO\C1^,!;OUR+9T/>"DJSB;F&?<FJ;JXCM&<^,XN:-X-2
MD>FO5^Y2!1F A(X0@N+.NJ5)CAQR'-/KGX44XLIVB3FUJ@TBZ)4N.C?F&M;&
M_9(NI02EEVY4:X$G(!_'%85FD[G?!O@WJN6GT24;ZJ1;W.NVLZOCNH%7@V3W
MTFX\<)&7F#CU5O/Y7JSBZ((2K]E&W##\_+$Q6=/:E'/R ;<^"SO/&[Q#9_9$
M2996SD.CJQ3">;U[/]4/EJ78TC/<!.:;+21>JTRC54HR7S3'/\\HJRQ7THM;
MOCED=+NC D%+TB35J2KO 1 OAJI0+$N@R*&6IAL?=#Y28#(N=*;15A\K/4YV
M5]ZKV;UCZ.L>537;(K6H*4"%UB=KM;!B 4,Q(X&"A(E3GZ;9C19&[75G*ZM]
M8QCUEO1>@5T6#5^L7'RNCD5AX N=()>UB&J %N6YD]+6TQ/M?]4V[K7=$YL5
M8'#5$<13*L9\65)<0K7W.UJ23H5-?UB\3*10F?$&[43QD^1KR6KK:]%JU?DV
M'X+EO!W=ZQ94(FR.!@_1T&7$*5/")PUY(/?NK TE0M4R!_\3%9P@*LPD!F1X
M8J4*#J=\JN!U8[-7S+QP'>*(!<"F2]:^S-2_2TLI^715?*P:VJ,]-#4+[/4B
MXMI)O&LM>/M@KGNWB\DO4,^;AF-L+!R&OZ$[.C.V6+4[#F(>O*W^X*PZP]<0
M<9M,>7O(GI0701R:9YZ*UU[LIZ??18&0"WB:+F[T)21[![ZT(7._8Z^V*%>?
MW^#D9= W+_\BI8P'RGQ\(Z](86^(MF7$ZDZ/':D[7G CY/L+,JMK,BO*$D ]
M<-B/=M\&B]#7/:8?HD;OEGZ++58*T;.U\:UKO2YX87ZT\_IE/T)[P&?Y+!?Z
M;:IS!&UI(9><$#PQ8.^WP\O,KQ[A7;@9Q"4 IF&?"2:Y]"^2/T(\4GS%K,;&
M^>WBY%?24D-ME^?1-VEU7M: Y_3WI&SUDM\ R3T+"7K[_,?,\R0I]A^D#A<M
M. *SMV]")H\0V1QMKP[]LRKNZ>WQ?I6&.L60#@RED5\Z*<W-R6,!Z]NB,Y_Y
M;R?<N_#.M5C<)!.U^0+317= D(=(#H'E;4E3(FK?)YYX[KRA#$K'U27VHX3Q
MM3%;[$+BS]S=@UW;N7M PR7+/ZL_3'S:6/"$HZJ&9YG)?^UE5#RF^$[)S\;/
M^Z!"ZHV#H;(47:W>8LON[S-[COQ&)0OEU&,8S++M9PW=>[UEO=2;KS%+8('L
M.\Y[-T?5]65\C,K"ZR8,X VEFL4?U#M4KM\.5<-TEL9<SF?<Z\6[BC2+9Q@N
M+FGZ?6/79FOK% L(0/.1-SLR-BJKBTB&S )>=/FG&JJ)<WPYS$M49(B'B)TI
MMO0R!1)O,PDFI%6[<?F ]/7Z.D=@5Q#MGZRO4F.["S*R/PN^:HIWY6BH&?\]
M%P+>2L^!BQ-A%(L/#L-*>,#/$3^>-/8^Y]T^-!XV98Z0YPLAM*6;UL%':9!Z
M4;M='R]833,[;R9)2+\R-GIB8FX/AW<=8P%CF':#GSHBY^"\W*_PK5J!K\ 6
M/?*06]F7I1G)& PA/MII+7'E* \>NL("LYNHQ9[P7NG.]$LF'].W3PTZ'8Q+
M7F=FIO[B4./GNJY+DCA-!ND'9P?R^3=Z.S#RTU]X7$Q<Y2BII\3S<RFI6>MU
M9Q"EG#Q%8?+-MUR-F#>[LZ=AA2VWUUNQ@*".UZ,4NJ=.U853^?0&<>EZ:=S.
MI2=!ZAC!8Y:0W;>4?B0^]HNI=98@L&7*<(MGB5$65659W&L%'BA=')UPORMA
M$'ZMV/II"\C*Q_FEYO%OJW36<,QBKC64@\]9Q(-#Q(5>V;_@]Q+RG?60 ;YL
M'&23N"D8N@J>O/!^EE[LMW&$2.&U4&,H,+1=/G8*;WB<YR GJ31E.0=I?#XR
M=76YW\B^3#X[5=*A(WI'.S5 SLBMTI9O;.E;4BX]?CQ,5:PCC09EG@L!:5SZ
MN[R["+:@[C@NA5.#,V!JG L-T?)OW\50:L:.E\-*CXYO]F&!%8@[1P@2VJF2
M@0E2+%\2%5+>U].?Z+[D5!N]E0[6]SSA3(+4G%\>R55$D\^.175DZ4;D@1NP
M0%A1CMOVMRF57VD?U87X'O,\_]4YU<*&WI@W\PX(V$<TI2E+$D^P@_8=BA9.
M/JJVV29]X'4Z:0V&=(%.F>?M$7KF X\^=ZA<_903E8?<J%Y(T_'# FZ0Q:!Z
M.Y@RA7DZ?M'$CHQ"FCL+ZU=='A4"7-9^9Z?$U8*NTOYASRBY_A2(M&7"#4P+
MH(-&RR00#O%UJQ_0[=;)4:&WTL"'ZF98(/L.%J#8:=*2<70G)MDXDE&ZU."?
M'UC-#J$O9834X,;ZF_"G84K=$E2_-C#])O2I,]49/4YJ1!EAD/,$;]ZG)_90
M;:C6"3X[7VA?_PDIZ?R\J_QXN$/*QL3C<'SUI!,WXG,LT"L#8RL>B/P&FI$*
MW19$&3#D:K4W!'CEJ-ASIIQ?D0<@GM(K0]QU$YK41+>^O9QN1\*J#$[V@LNV
M)F4"E\H#3K0MSY"Y[?K3[2A8S?]O!Z9KC-H#%]NF_\,30H%+;?_SD:%!L X6
ML-G[^8BX3W9L>@KZ>QJ=PMD/OI)G4L(59!CPHKC%G^=5$=E7G&484$AP-^96
M),3%>^/_>L>_'7\[VLX,8PZW,(ND5T58X.#^ZR^XRE^^12;'=6F7?^EJ(@%3
MTS_FLW0Z"H%!4 UH/94CTK[E^LYOKS8L1.W-7BM;1C:ALNJSFM*V;=2DC"N2
MF!\;.G@+\Y(*EL[A=M+VVFBV,5HHNJC# @D^UXYF*:PDC_)@\[ "?8N080/5
ML%VDL+ *Z^.G*EXZV1[D+,QD51[!>8',=:J'X$&,6^$L@;H3>'@\D'_J,KJ-
MFY".).L=,ZU=*NGC;YS'J2TZWS:.;%>V=O>?(L""3Q*?[NRQ5#L?,N%G2J7W
MV'*:M?$,^<86-*C=3=#@2E*#FX8"FJ^N7B+89MNB=A^\"#;! OP!-P?N-SG=
M5JT9@4E5_=+BN&=&5]^"FCF&J^B>N8K(51<8?\G;.@CE,PG8"<0W2 C>C=TW
MPXR@B(O).AO4:2/ 19 9A&'3HP3?\4'0949 :E$9AI/>6$WF\3,VONB"ASQ"
M"J]M^VQU!!1J67M%+@V<BA!LIY!1&=Z&=34#+$";CJM3)#>W7'ZN=8AW"-],
M];T64==[FSA5+=X(D&!I5;Q(T7J;G0.>Y>M^9XWR91'EQ=3HCB)_["^R\'T.
M]H'M,#W[-KJ-[/-?+7YCNQZ7G&\#LV(@@E.\895'Z!$#R2KBJ,M]^[N3"2-7
M:%XQA&X71A%V\Z:'CF()UZIJ:E[,H(C"@S>'=U1UJD#G,R8S\_."57$^$#9,
M<-J]Q]TX.8^\1W)[71GC%0(6JIFKVTH^Z//5:%K@-3;$E%HH=S&$[4QFIKS#
M KA\V-I0[0D-]./53UZQIOV$9ZI53:>53EME&V6E]W5956T3+XH^HE)'@ <L
MG?0JL#G'_KAHS%,YA H<+?5,?YT<M#;ZJ+U#:3U>@]U9B)+;Z5UNN>18NF:4
M0H,M]<URER"-;I3YH1:?KT&B02T6\ =M;#YL<6_3XM:W^HTCQ(*\RY*F9LG[
M"OYI606>W)=.>G"DHFP>'QZ)2** RO@51-ZT3B%$#N1*+-?_\U:!AC\*VEP4
M[\[+K"%F!QLTT!TF3K[WI)Y(9Z3X<X1ZGH/*C>($!'DYSE_=%>WDH?O>AK*K
MK&631W>Q@$.9'Q/ZT:I-WWIA?%.:4QFBW"Y;\_X(52C2-%I();XK\1IT7..V
M3-LI>QGL7$J;9CNY453_%&4\74U]$OA(7-Y@9JC-CY*;AYW49/CFKUG"!)@>
ME*=,-EO8B="R?YS7W0GIQYR3AKQ;^S1X;%1;5-3@1.=K?+Q45*S7DR'V\1ZN
MMOV>=+@))A'2!760>U"L I,?O+2;N N_(0F[J(![I_DA+>E+<Z_%W<B2RIBE
M:PAX1Q_7$9O&G(\V >0>V9-&0RI.O2<H2S*=7B=<.$]4R>HEN5^/;1L8!]&C
MK2[Y7 "  $TN?;#3*"6/L'YBH@-+E=C' K''E]JQFCV<3SW[ZJ['>JG&J0M(
M?V 6@&B/AD#.H %DA9RPQ_?E$5<H^\HY2L,HD8DJ[C1)Z7HV$6.A1^<CY0/-
M=> D9TK!D6:V#&YXP.-Y?S?"9#\;M&6.<#=<,J YV8K)(*L@WLP+Z:!\AS3T
M[<HH"0JBPXGD"\H(/HLC>@ 6PID@I/6)1HH1YYI!%:_\UF'-A=0:)OQA,DLN
MO=D>)9&QE!KZVB&50G?.<1B"M!^>Y$R3'2C_)?((,7-!H]CUP0-GRX_PN6!H
M5MHKM>?EAU^JXVW#65/N IBMC'%,VG%%,TWG_<7C3WDN*=HC%7.'^1$?/^B<
MHJ'N&A%;W_+>TM#=98%'9.6I]&6+P90^U;VD=-*A5A-?[Z%\N^%CU N!*K"O
MC7-Y)VU\33C<-)T/4K&08?=G#-\?&V5/G"#S?NO/_N3VP..Z=W1D^*L,3E)8
M0'5<M49<"M\ ?I5PD:# (!/"%/@),I=P*L60/Y=CVGB@&[U@YV-A:&&MGHDG
M?[-.#>\CD?T!&1F#"O][,@XK#5(@*$D#PM>7"<K<U"(+%T,H*F(.P0,!ZFYD
M8V&#UFP].JXN=K2A)LE2QR6ADNF]W@KC7/HH P^MKU[7FYM937D/0!N8X,2%
MC)30A#GP]U'7R.'I1O^P<Q\.->I[>G?O'SC&EC5$*#0UMG"FM4RB$C[>4!1>
MW:]Y?*!IL5F!J9D=[0WM53+HTXR7!>I$A/NIBB)X&2*?W=% ',^4 0_Q98Q6
M9FTP0=>KOMX:EPVRK9@]]B]#FI,:\M^(+AR^;;Q?0'/3FV!%-M1L?3 PI-A-
M:[,YESP' CX-\-^.Z/]5'&RU[9TQX/W#-JBB6CG>-O-SZG7DCSN]51$)L8A6
M-ZHX7Q!LGZ:WC6:$?*1H?(=P6<=_O^:B[<FDRZM>WJ#)QX8^P: %=6\AGN#\
MDBF\J-H39G\</^&2(C\#'8>CS28-08*='\$_6G\AFM &RF_\G#D*5$DG-+L;
MJ.UO5O+[*HY,?<U5/3-.4Z8&K2%:3.EL0YXD76*!1R'5-5FY-Y4Y02IJU5##
MFT(]WX;D?'%^Y])303!@M#P_-R^>5%:*F<,"T(+ RZ(! #2[=;AYNSR_U(&4
M(>7F4:K>MSP:.XJYM9JBMCL>31N(;5267#[&:ON8+OE!7R,,-'QQDI9"NG8(
MGYSLK@9S2'L8R&\((<!E>!8\6:XV@4Z8[Q>RPO4)X!^=&\A.U7K_A-G^RO<S
MU&)%9OT4&A(G?N^%6,S.'H,, 4J@$QSF[I*=?O(/,0<_DNL\4*Q<^AFKJ:=U
M+\X.WB'F21N+U*$"I#4'^/AQU:2U3"O3V/UPXR,L\.P$P9](J891G-B82+UO
M3!XGA"OSV.PB>\NO)W/!R^-XY'Q/VEAH,2$=X?-SCORYQJ6E&,@Z0L_-4^&!
M,<AAN*A/N\Z#8EJJX6VQ]3/V^$0:X]KWJ49>T3HLSYZD' -/LP.#9>J6IG=@
MES(T&M_Q'T9[8MA.O7/+]CCRXQ_&YAUJ$H=GE@BEQCXE:IFBHW"O(4 W-XZY
MEM_2 M\;>_GR\3>>"JO3_B([!W?;^\+U.LI5'+M[DLEKNWC/BYP;"QOGWS1A
M =,+L1Y0#.8A9D35?FG]0W2U:N_3"Y][@6\[) I-7DQ)8I(UZS\[D>*3EN-U
MN^\W1HZF]#<<NKY)B#F<P(QH5+WJ:U9/@A[W;_\:?\6_X(_,S)B8X!"I6&^H
M'SKA^);@U6^4?="U$BI30L,3&0<12.NX9$?H)J2:3%PQ$:>:)W>41E:4ET[M
MUM<*PE(98Q)QQ1JY/;Y$(DF"8'KB9KU#KK:P\Z;VG=S6\=WK+V+C1]6,US_2
M)%O#WBS0?&2@G 9/?44\W\D.C]N4QT\]!&U[[U1%]-;!Y5VM7OR"0K5=9_TE
MV-*@#!K:BEKLMD2&PK6\*%/5T69Y9R?][^^($3NDK/%WKUJ.V4.*\_0 SI"R
M_D-<E;XQKM[I97=8M58S:*SI/^88S5-AABSG \0V?@)/P*M,1GYN%@T5'K #
M$FBS+B*IHMJD(46-38+/8G Y.%=[E3EH],>[-[Q7G8/C,:ZYO[J$I:(O2*#@
MAH-^$_O!^I(,X_[R(9>E45!O)'AE)W-W.!KO"6@9+!"[X\M1?/<=*^P0W2XN
MLNMF6E-JM>7,@ DJ% A>C*<<Y02(R&0A:5)?QDD7T&:H=^+__&XBP(PMX-G^
MA0^SPMQ7_A:=/'/HR<YN7)AEBN:M/%YM6>+XX"#KY)R?-\97KRU?'\*HK$)'
M&O;NLJ$5BRL\=%^80"(/2ZI;Z(7+O^<+T$SY7L,">Q#MD38_@^]27H\25?46
M6X&)*_#:%@,7R9!WWKC\>%/S)<B;;2I'8-P$;GPEHYB6UW>]93E(OG,"'3D]
M[W:,4.^U9+MZCR0P:*Q"-F_HM*-APOK%W"0H\L,3,J231!WK,A:(O!RY7&IR
M"M"G+I\>*;D@7=SNR4[Q%9<^<G>]_1IEV:"IXX'H<#9).6%$N^^DB2+4P<-7
M.7(V@=GSZ."@:5B_3I&X>Q6F8T8ZP"Z*/>%)'30?"YA<3FL_YN+=PBA.D;LP
MR[B<[ 5L6?QWJAG^GW:PHQ71"9W>VR"Z2Q4K,TB,U:DFE!%7=Q#ZT&*.SG$\
M_=/GSY\IE+COY\+.@XDNB<^EF-!U$SG_NW'_[?COW6$D.%QSZ2=XF((%>C*/
M2+% T+7E4Y]F2$LSY.@)&-4)4IJ&S,MC<K  <N)$R>H;V%,Q'., E2YP4D-F
M<\[\%+_3*!WN>.F6LV7*2DC^HTA*=4.?O*LEL[TEP6BJ"'('$EGI<T:SJM):
M6[K<N;S9>G^M0/_.YV2;E61MC@T?DM<AJFM/'<==M"YPC&]SUW4FGCBO8#&J
MWB_@PKL9"Z@9-!S'C[34R4H2OGBQ4DXY(!J 9Y*\\^JY#89]?DZ[P#-+5/:+
ME!7- 6-HJM4 +ET=)Y5)FFMTI-82^)8BR?LPHERHX7E6'F!*EZBH9F>5#]>J
M&6E,^V;#5E"Q05DFTE]%!G9_/.RQ\Z%*3.E9V:%UJ?X9J[^3#;CAZ>V>-(#%
M/.E[%*<:B]7,U)2/+56^;!AX&2G=W@ _L2D*2"8^#Q!J=WXS8Q+K(VJO##T_
MT8 ;*"7FXM>IE'FWP D>W@XS=]214<P5W(Y\^5!4CG@M;#3;V5EUY7RTMD24
MWW/T)R:U:?&G$_T+6%I6M,FQ#-^QBZ%B>SL/J5K)MZG/MD&NS[<E+SO4;M@3
MGWIS1&:X_C(SL-F(3S^6_)GT(2X_N9I$;3E6ACTB.3-G@^B-@77GS'I/C&!%
MJ M#\L_IAC!HNK+O)=R81)7M]'BL5?RG[99N[""==6[<O>CD<CIZ$.MC6(]Z
MA<2]*M2[*TS0+J^Z9[]!T,"=/S<@C.?'I;(;'IH_N>%DUSMA6QI'\"1ZF"J"
M#NF,3'+9KA9Q=":3TCJ^U.$+;R$NN#BS#[O?L-*UD7?V\G7FX-0-EMRWV4Q4
M'8^+XTLCN,SUB'FBK\7@>[>V/#.."31WKZW[?F,S^NB#'O,T2U#CYK4%&9AI
MHJBGFU,9C\/[&U0JU-!!9;X/>+;L3J[B=77W5T'6YOP?$LRP0-VH_5YF/E24
MZ5[>-WD]XQT.,YVY>Z^2*OL-M[\M0'6-KN;1D1^IFO:]Y*]0]Q]%:X4\R8!$
M["3IZQM:B>G!V-A[/WLTQQ%7: 2\<6<)#'8];EZ9C^UXYCU/F/SF @U%RH!+
MOLYG1JW NN5-5;ABX>UR&7 +AO'HWFRCU'8XQ!S4WT2V\=;Y20YZE$.]RKG'
MXX?*<,FU+>FS:/5HZ9?T3[T'M4U21L@>X5,E*@RRV'<43W4QW)*3G:S^%3T.
MVY:A#5Y)%G;6/1(AN#AV$%M?W'()GNS1^N!:T_Q1][G0L+$6LU$63W2K/8WP
M[7'J)%N@(V.%%ZGC0C4C\U+F6W4O=:E:,75[ +-KL^^CH):IP5*N:B4GXN'M
MS=N+=V^*F;VJF&L4-M"=.&\8X[DW.JY2\ICR=OG@"9_D&.R-/.=L:ILZ327Y
M1=FHV^XI:1H9$X^S+N96BIKI>TKPHK5-/UR%T4<(J4T33J W ))K]7"3W%!C
M.=CQT@E+&E?C>%&JRMJZK*)P.M-7\JM7?_7YH$TYJU,:#.CW""7]J9 <OV'.
M[(U1:VQ/>SK\A.EZ9:I]=%'(Z<J5C/3H<U\,.:_$]S4;U;10]1Y//O5D*5['
M>%.9:ZP_Y("JJ%IID^0+TK9ET$Q ,'7\;9XOJ4=LT_DPAI:#^3 \C>1N^(3?
M?8/BI'MQ"HX% @7WT*$@A68:*>_::RNS(E%=ZYT?\R/:OSU4IJ+H*P0+A+;O
MA>^TG7^C<_VN1-\N:J@2&I_X2;BMSA +B#TGN3..G]B3H]7?>'K(>C,KJ&4S
MY55#JZ<)6? 7\HL ?$3MSZGZ*IF7#CEKDU)&/7-L-D]\5"N'3-VH(XF4AK*/
MML?-,TP]5'8VA9N:ZP9XJC"'P4&,MVHJ3=.RPKQM7@H9M/-43$[JWQU%@#ZR
M.24,"!:9Q"RNDFM54R^\L><@3S]"*LS?%\HSK=O8E-"_RE%;?.!&_^%4Y4[S
MH5_/5W1C+U\;I89RV^IQQN<HFHT(YYD0:[\S#0FNMOGAX9TMXVF@G98-[E!"
MGV40E*Y-8,\Z6#^M/P4/GC5PY1A]+!JRHM$8$P+I[2CBB\ZJ&'=\&CXB[VLF
M]>+ 9]+;,]0F[EM]Z(_HR=T>T2ZIN-4UU]YWYB$0^[KZ7*J+8Q7I]\OR*YA*
M'_(:YZ*2[_KC:GC^G*7Q5$E8P*O7V)2'[X:27&_W\R^+4\3SZ9HD$SM8@%/+
MM3F8L;4F_7; @Y,'DVL\*Q1WBTJ%V'45%%!&M'SDS&FN-.+ C$=P[D!F)%3A
M.+W'C=EJ)!(Z#P^X EG_ZKXD*H850Y@>Q^D=O+%4?$;7@G>C,>U@YB6&MK[(
M)@I97?_%<_R.('1;7]1;>/#1RL&77*OZ_O$J(8<$X\S,U-MM95+J%_AA6[P0
MYX)HL%"")<$5$^UPT ,18'J"'=,]"DY:G&_DV>+1XC<(%DVD@EFU/+MC3L,W
MU!;ZIBUNQPM<?^/4F>B]@'(:]<6#3<% B$?1I'G(%?^H%O/N(/M)5E&%.N+F
MEHS>$+=IY4Y5\.?W'(D1X+#@("A'U(02=7\:I'M4\:RN$%_N@I'2\0@A\,J0
M6KH:&D3YZ*&EQ& JY&FE<CXJ.FP 7'+U%.34-[M)KK01'$?L"6HN<6QN?/BQ
MZW$5?I]TW/KU2A7QT2>?$D[:/V>[5P7PI4!,XZ7;51A?'TV9G,5S&T*&LZ>D
MW>\\UC'5WY1?"8,$.Y.Q+!]O!_8YZ^*HVJ9TV\6"T59)TL<T1)^2R,B 3^)3
M&28L!<TG>3HRFF"U+F5(L[_-0UTJD<.OB"GW?C]T:IM:OJ-XLW;K\6BEX7L_
MMQ^]K=)+B&-0KDQIZ* !/.G#P3$R>5'#XU:JR^^&HVIP]\5&T6:,[U0O8XU&
MXH%&<7Y6_DTGPW-2!E5#599]XJF%()E*W^A[/>0"; 5[>=F&YOH$J\0U)1(!
MQZ61560<5/X6:RUE32<L[SZ\HRBWMXW(H&RJ;7'7BL1K8;\=E*[1>@ZYSKE-
MB 7""FWG;/"KY$\GAE=_<B . T$,C*$DQL.=T-.B 39E3=T9ANJ\D!]-+$=?
M>.;6,3]-20^HT.WW:/+)N+37-(.'(-!JY"OE>?_IG:9#JF<_3%E4[^AR!=V+
MF35P,G?:V'(+NLBH%@ZH+"UWDB.^N$!Y0ZL7/(;BJ.CX7'FI[=6+M'6F4?ZZ
M(!*5"35<[K&U-Y< ,U=-6W;L(CSH];LZ6-L8MRPH+WA9KA"^A(RBQ8B[(R N
M'\43<7,5'IDS>)M])%!_1LT)?B[;+J+.F.ACOO4="]2<7_)F"/V&#(ZFS=$U
MC%-8[6.!BNGJKF>%J* ;*+0,'/^:E+"4#GZ/\7@A 7.[-2]R#?YT)AG,?/)K
M=#5DS'8ZVHF"+BN+6?*J[4B)+.2(NY.=" 6I8T8^__.-+;F1QD4DW7?>>  Z
MG*!K*1%2EW*H"M;'G.U019=[!4C&_UI=S@N*O$)[).49D%3PUJZIT= R;\[)
MY1'FYD1+VHO:&S)[L\).KU!][%'<^,(E7Y9+ [%  EO(GOP;1BG_*G9[XI[2
MF@,\]0M(1<+:=&Z>> F/#V>N"QAV"?'QY^WR\<LC>5*RLM8_4MJG'L[[#*B3
MK2"O:3)I-L@523JP$A1LKA8V&&$Y4356:[$DZIP)K%#]WG-<\L@VSB,/M7Q"
MJ="$=ME(&?:$N,C(.(^%4_@C8+<(2A Y BKP-WPRM3VW8I.N@P5GX<9)"F]<
M)!G-T1#$2%-FI/&+F?T3)%7RPGX1&OQUSMXI][T\=< [SHQ25F$\U%-SM/L)
M&I[\NDU8!P])]8YCM\<*[>XB@1BYS5TL%?* WM\Y!?,5PSFOPB3YVW@-:IF]
M$&.^-<*\J:U. RMU42X\1V&"/DZPV*)AU>PAF*]+;:\]MFZ@H"<C3>3,S=.6
M)]-M9YT^N^U[/P-K L\LMQ;1_U_LJ%9#15Z"@A$SLD*G\1T-6("F<SM35A(+
M_+Z.%$1O'& .VK8NC;& YM(O&>W]*])3\GWO1Y<V,*G_;H+\[?COU5%IE6YU
MNF^UQHD%WCU<I\6@R+JWM]RP@"?NM?X!<A(L&U.-!9K"T(^PP"0,F=B9L4/V
M&OP-M*%L3:*Z&"V[A0R@SQHO7[S+4-R6][4,GOG,^% =S\<D(X=G;=#JI7@S
M8?54'H3BSVW0^-S5 H'?JRCR\\W--+>XB:;5_'QJY#LI';_7M[23LMBO>Y?=
M:K-8$7.V2NA%#SXP&V2IDHIS?T6G]Z ("Y1ZSS?][M5_DFPCU#!B*D7FR.(4
M\5(XM?Z"$0&_EL9%A:!E ;W*%2-5''^Q9CATW/P(^=I'5/:1GYJ"V(DD3_"/
M).Y9&N6/UU<-'44*DC5HZ>4$7/#NX37UJC!Z/[^<?6YYE? 1G33&MW<U[&ZF
M4O[5+J\RTFUBZB%<BV'L<UVF=2U%8E;F#4J_00U5$C0I-X5KFBOH52GRT7K,
M7G6/?=A:=,+&F'B"H(7F4R5C0_IABJAR RG*R%0C'ER<=/;L1@7+1!,UZ#U/
MSZ-Z]>?F)RDSH3^C)ZY6@RK83PRXW817R"OF#%X4J7'8E0UJ=B46ZE5(AW.-
M%W0Q6&*2@R8K630G$HP3?#Y]0$P);6U<!C"B-IAFO:;A[.;1V=M\4)];#L(_
M\HUT?)086,/N)^O][D<@&]&I;F*C/,L.1YL.P^,6URPT2:8E0>!$9*]OVE3(
M:M[W7:VO\LFP:#H>FSY^XP7IZ,^;23FN7D!]U&!;<E%,XLU/J:R',%3'8G%0
M_3TA^A%4IX/ZD]ZM2D,9UVO*?.]Z?Y]9D+F<#W$[F%*'.3KCSS6\46]*+D3Z
M38PT-+UZ/@]@1DX#()[-[SRVN34=T/$56"#H]_ZQY$5A355_$;6/$HR:NL\@
ME"4I<2POSOR,C=Q#T-X9DZ-Y[;1 F8[9,NCQ9;DB]2#?I)4@N'EX U/#,AW<
M.YV!5&6?S\[2ZLXQF[XKD1RJ_)9.IUPRVITX6NZ'G0&K8OGOJ?7^0 .!U>D"
MLMU ;]UEC,T%I)=<ENF:2&N6&9.H3TF]7QA[ IF0,9'\Z/0DPI%>6!6^<)MJ
MKNM2)'< C.J4#?5PJZ$H X-/R2WT?)7X#%[VGJ8:G-C;46@N#]+%@Y$5]XL3
M8TRX;I2?$<^ZI!'2"Z(ZTU54 FXI&JPP2@1_/3I"*KYRV^9FDJ$R&:(K.Y:(
MEGB_]:)WZ./M&^]:K[" '-'.GLT+\GZTU3 L/;-D&;8M MK N<&M3T.^CR^D
M@J@S8]]3PGE4#-6T10YZ"Y3!3?$$7$:MG,F?$Q5O$2 :6$GT+TXT<I_EVI74
M74I7P*M@T_XRTU%5E5^FT;W.ZHF*FIQ4R*PWSZS&V 0B6<BD'=%L\R^??G6,
MXZ1;?GF%*EER%CW,ZKQCR:+S <7,W'Z7OS $N9LS=T+0("RZU>J,S/(N^'K'
MBJ1 2=AO-EFH<.LN%G!J;W'/\]K=U1BGH=#,^IU:Q=T#A2KNE(SSYU(>K2Y7
M:^B]F7X#$@BM0OR40$]FP&+(E&NM7[QX7ABM7FZ?GVL0*L-5V3:;T2,@253I
M'4-:*U(_5Q3A,XC8PO3+5\UGK60>*Y/A_?GO07E(Q39BQ<YH;,.9NU9WK>Z<
M39>N/-K4[@7EMHM),M&)^*BCM6L7R,I1<*>KS%""B6XG<&CQU"CU.[?V8>Y;
M>G0X=UF8[4NAD4><.VH:=W/,Q(C:7_@XO7P&W"J,=ST^-20;)"P##>>+-)6S
MK4";-TZ]PTL6O.<MI"ETUS2O>:W3TS]D4;S[S.4N/*+.W"19$A1SZ5-EM+R/
MRSS#MN(2=\""EN%:.3.-DFIY=%F:)T)1JGVOH]F?WS6:MA),NLX2G+UT)5/X
MN99$2J1^:?&I\07DXVB3.&%F0/0[I^(72(H5-:?H8G:MDN$R:D/M,L'2!514
M\\FIWBC*FRW2R[2##5.S,1IIVN9YES&(24;4Y=#VQ3>1@^]R"90\2I7EC3_2
M.R=B**<W-H.*TGXFW$H3'7H(2'@S.$R[K C/#&UNP5*XX,<.DC+>R2/7WP\8
M:<G[^[V6E].&$TU;O&L;#C3R@:E6NULW_X:DZ]B-N.2_C;FKI4LF-;K&LSJP
MYNSUV]_.6'5^@JK^?F/<Y,]W>!_,!Y\1-YM]45J6LFNN>&5VYRI!C>EHAHE7
MS>*1B^/#RZ:2- I]1D]=S:2V[)G"YA";L?S@7)5683*;4<NZNG1#G&90K)V+
MKOF6$UD!C%A -LRUT>*3.)G_ C$^]_WH&E!R3AXS-66+C74]^^/R$,'$<FX6
MU P-R1,!%@.J$H@[['&:^;M<G05BD/KT3LV%E @#[ZM>6<OZ"GX^4GWU1KWK
MW(4Z<RMX<KYZT^:'ZOA 4Y*;3.+3.9'P5,M(7X9*^2A[.M#V"6M-[>DZ[0U^
MI>#?O(F% UVL3U.]OOMQX)&J, T//"ZR<$N_?UHKIGAKR>O[ O@YD]$1) Y"
M>[@I"%T5ZX=EK#D?3IK&AJ?T]671/WJWF,A3DL\3KJ,_8/(0D+?47MX14]L@
MH+N$S&R^M70))4@Q&L&5W6"EE%J,VJ[KA-;[_I6.)7>;P_NJ*\GO[^64V1I9
MD:81]U6V*1*R_EZ9J7">D84*ZP/3X&UO_,76P6H\BHO]'6K8Y;32Z2=Q:I_;
M;\L]:>-($ZYS597BE76U#]2A<L']6]MJ9&U?<24)-$\ZW6M!B'-D[1 +Q/1?
M66G633]'8($ Y=+LH>I0B0QDZPK\C :N=>Z>!U9T=Z-EFZC@;TV$AUD21Z(J
M,)7>.94##8T"CC'UDO=%W1>6\4Y6L<#G&"R@%]QQ]3&""B'70/+"\PIWL+33
MGVZ>[OX:'OB2<#<QATXD:?B7WPI;=N+Z@*)G49C->>O*G/%[54>KX4((3$E]
MO*7ZFNH* F-9,-QD&>_)K%?-HT=MTE\5<FTY:0"H!<)L3GZ?G?:'5CH] <\B
MS-S VLQ1HP;34>RC950KN;BB25?'_G1]Z8B>YP5/!7V6Q+VRW#N6UJXW2PP.
M$5I.3VNO"5GG6?;]:M5[&RU''%ES3FX0RKTKW$(P,!K4 ,*)H)/VZ)7G6,%7
M1>X7WJA>%Z<@^9\AS,)D;RL6D2:YKD46MR,Y=<'(JS:)Z$6_-UY*MZX3WL%0
M($;M4H>-U[?N5PW\.-*^I[<SP!Q! A8_+H]H99^!6 5,R#\!K2,"NL)#Y]Y)
M_,AR(@ZYT(^J833*D=.U9MB_C@MKF(.=31[I$?////!22\*5A NIM+L#Q%-R
MU[HL7%^.7/:VE[$9028W1H/-?007/*]0W?<_-24;:C.FG*,@4:?#H0^DK/ 5
MJ)#4LI:F%ZO^/O&[5-SL_P=[;Q44U]<M^C;!$D* !$EP@@8(20BNC5MP=X);
M@.#:-!(@$)S@@<8;=P\:I-%@C5N"N]-8R^5_;]6NVG>?4W7V.0_G>_A>Q\-<
M8XT:]IMKSC5*MN-E#]'-SZ^4JKMW76,?8+,2<7":YF7YI=%IIV#'G2+2*A2K
MB-)B?2W=M+/9>"_%W*<)*H;?F0\5:P8VMJ-FM>VW;VSS;3Y$>NQ""1/=[!$8
M0 U<+^.=+RL". \\5;/;;%$ZN3S;5191OIPVM**/@FSLTR_U-V$ ^G.&JV:?
M0%)Q9IL3I4ZU FFH^^XKJ4K.5*Y-7?0VF/GA\!Q7S#7>TM/#"K]1B:I-M/-W
M7D;<?$%-8EH)/2!P?E;((NM)&]6C!VNKLZBX]C9GP2B/I>?Q W8T-92C\A -
M97?CS%<7F6:A_YS9C2$4YCY=NT&/@$.+1Q+G$KOF HWN@1DQCC\&94P47NL
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MAJX"9DA_=AGQJ&5?V'^S(DGV?E2'5FIBD),_;ZB;VH@;A_9C$)C&]? 315"
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M%_PJ%\0 [!WCKN*<^#?5@-L37XRKB7'<P)/K5?QN%6-\/((XM0S^) I-].K
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M8;W1]-@BAP@<"I#3DW7"KI/\("=W\\/',D..0>(KZ08?X 0IXA[ NK&S'>"
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M:&J/,M74%GSRO?77:3:#-4I-#:N7*(UK;P0!TW<SJ0666/0MBXHJ..S>/<(
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M.O:5V T9YL31)PG1/ Y;\?"$+=!"!&^]ZEUOUA#ZAB6= ,)RUF##&79):/X
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M&F0A"'^$/P#7Q00YEQ#>P,$1%SCDJ++MQ_CD_6-G\X2=Q@D.0JG"SX/?RD/
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MG068KG1-- +<45[/DJBV5'?@Z.OL^N)<5;9&9I(6SU+/\\''"W=2^[CC*Q,
MYHN6&0(UXIPTJ?.*D>[0OD@ZSF( K_HS-G?$E>FSTR0D$>,0%DBKO,7HMYVJ
M.FHW7C<D+FE,_%9<S/KO11&NC;IF0RFY7GDVPO 1M;M=#8&GLF <<&'OLML4
M/T@Q4^]W1S;WF.QTYM.VUA1/@_CA]3G<SG]'['IFZZ<6@R1/T?Z2HJ1J.<[
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MUO<R28T\BKPO#6.@QFEQW,O(HR&M@M!F&[^H[P<U=0AAK-!\QS=9.<5#M?6
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MGRAXA)TZB>T-GB5288+237Z7X5K=C5\.W+X[5Z#V#2\*F-#@1,?6W].4Q*,
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M6V2PO1L)^==510AK-86L !UVQ/\B[BV#X@C;=L$A00()$ @DN+L[P=UE<+=
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M9+WI/L[N.AJ/H:1LHH#W6I05]YXYI4\;?W'8.<CAC ,9-94,:FQ95(:6EX%
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MCAX-)NA$AZ_/^Y[UR?*RF)U@C@$9Z?IY0--6B>_&24?[_&3X]ME(]N4],Q*
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MG%9E4BKRF6]]3I;?\Y %T,MZDFBRY*_4RNMJ+GXC0>E8'5R^G71':V'*Z[I
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M^]^"L:&'6Y%&&4/A);'T<\72,9&]3YVUS:V_F>H57_1\J^#7X4?' 8V\UIA
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MYJ_8"GV+@C;N9$$1/9NI>ADF52IH/B: >\H*1N["/GDAN)/ZC)<[)4N-S\J
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MRFYWO57XFJ/76(5T!1A9<<+TV17TW@X$?<M&S\A6TU0]U+FR.6'H'\'^\H$
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M3D..\K,WAJ:1'MDNX*49@EL"JK?Y0Q>L^BYW*#!3K( ,6?*XYH2&T6 *_Z3
M.?[P7)%E 9M'D#RRR$6&2E)Y(_NXPF*(GB?.<A-O)@R/,V!6'K(F"AD]W>E
M&3P K^+2(,*U LF=K/Z7?MXVA$+>)=W[8/,,YV6V=:MN%;7@+OB895X)[ES
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M7U3KW%QKM&XRN9Z7'@F8"Z["#.:*_KLWW)WHTQ*"(L=)%<:%/8&53P"/\@]
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M&!'\B#%$SBJ<ZCWS*;:@.CX0U /,"LKF]S/ ()[+ZR&!,;'IRJ/IZ<D#@"8
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MFK2&Z*JZ7GA> 8%;:N?9<R95_F=?-0^YX=6,O? ]M:'6UFF"9@]*I2,X;KI
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MY_7*" CI)[2FEQ7^5![T>?<%P_UD:SJ8#%.37!> 80:C;P$7&F.)E??_1PI
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MW2JKHG_-)D2<[J6\0Z:J>?^Y!,.D N^218*L'U1N3S13[BNA 700^*#Q[[,
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MCQV#-W9&_=(SRT7*R8!1UYF'AJOJD*?*^L^QS5\_[RJ]+C@AJID[$O=G^<S
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M456 7:I:PMF!.FAWVT? FN/NV+LR9,K/\U8LGF#M@(%F$LKT^:M? M:B+\C
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M.U9+F0$[W/R608<S$:GTF,.JJ0!(,>Z>P&_8Y<F>\6Y@EX][?DEB%&<LR<P
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MX9)^G\</VBTRMI!2CQT\RC:Z+[#WS$*FTJA2T<][-Y?YQ-ZV "6VLXB% <C
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MWN/J [2AH,87CL^E*5:?/;P:TFWE.O/1#<W@%;^BF-7Q2)+^?+T*-QDR]0@
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MHJ0BX_2^A)\-9"1<?+;+G5#&IWB)PJW1E.K&/0;W+IS=7"9H&$6M!<BP]][
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M.&GHY]$;>RW_[6T->,ZR\BCBVD?)V<4NO6GT5F?IU'2M.H@U/#_3G1MKK[F
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M)*"IZ<K1%C5@FI?,4H.)Z)GSA_3/>:S1:',1'N ]";NUYW@=_3$'8#>D+*=
M,V)L]6:J7NN4$#X21TX8.,!%>==PEY] 38Z*K7>SHK803N?=:\"+A;XI=I')
MUD(2;8,[:]^!,=#)^U317C_,<=_;8<I#_!8#T6?DA(=8 "E8OXPK.E>G&/?<
MV1&TZ'J472QB_<?S'R@.8=18HS:CR2+6\, V7X.8K[Y#0!WG!M?W1'4G^Q(X
MJR^U3L?EA3%2]PUKB&K^QR<!2/=QXW TU";%P5.(+2PM26*6C:G4C&*,UFJP
M-6@B=7F0:8%O[*C<-7WP;.$;Y9M9\EWQVE7EUA3; 7"7#F/9.1()S$=]W7U7
M,K(YCV8;J,:QF63[HTO:12EVBA&[94FP9@T.DSMVC$_'R5Z 3&?E*.AI;TR_
MG5QH$("MA#4."QGK9@Q WEZ*O/!P6WX+IHE>?G$=VO!:XC \(CE7\*OZY=G0
M=R:]<!"XOT[4UF%78 ^%!12[2;49.L61GLI"F4Z"VCO]]CHUG_ C',0]/TIJ
M*=&#')W*V_"*EF7/N%R?-D*C)PL2!)G;8P/#D(3S:>E#/Q\>V49E@>HAP;FI
MB:E.E$:CT_6,"L63S;2NH6NJX'&-C'EOPU"[7']8PWG3+[%I_=,+;SR[M'B*
MF!#K1T_-\R/C<LA&FR\U!,J&[&FJZ24VL8#$W]\-.Y-/\-/7*4U[*G% EJHJ
MY+Z4;\D3NDT2^\RRJ/W>:VAO_\MW,S6#?!D,P*]"4=[X?UG7^W"=IG/XRBUA
M(X"8D]9%89NH1QYH''RGA5!.Z%MS=N>?TRTKOAK]4!A46:K(Y:JQ(/N<,B*K
MT/DQLP<;C95:3A#8(,@H^5UF*@3(X)0M\TZ)O]S2\AW1N%;'WU?. I7L":Z!
MDR(Q8N)XWNR<3-E'VS^8>B$D55/UE6\^C@D3:7^V[<XQ4G2/V_25+7XZ-7MV
MMCNIE66M%JEUSE,_W?V@^9RU'GVJDC\UU4^KCN(P8<-[R,A;;['G3@O,K?JL
MT(0W=WJHU$"@['R&Z&WTUB2AIR[3_MUD'<(!ZH)S,6N]QY%\99_17QR?'P"A
M=;X6@M472YXAU-SK:0.TQNCK5":8I,,&/P$K>2;I PIG)3%_=A9C)%'^#5B
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MI.;J*#-X@\%FW__N-Q9 #S*!K OOP^XFU7S7=5I-SNH<(>?S0FC?2IBO,Q;
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M*#;O;WW$'M.>_Q9<,/A^N9/U<@O2?Q?6(CH[5AK_*:8UM$.ZF1(7+):!!0S
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M]^\P)/*5P%=JN:].OYU"4KW$I*!+0Q3Q%YB8H1E\?P_A^?^IY9!W&Y1B>[4
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MDAF; M$@= 1$:CGQ*YUEU/-4/2W'"5T_#[N0@9!!=/;/.&MG!HW*0%H4(-6
M]9OVRR9U'GVEJ7D: 3\;R2VHUXG+=<!5F%5]U%3@WE]5PAR,=J[PZQ'"0MPH
M0^D+G?9RCM7'GJ;.A<WE-]SS;@51/8+JYGI:>$GSU#1R^/HI:Q""<)RQZT1I
MN?\EF.=_^HX5& 7X5TPJN[;5\[%V1UF.']DG_?WX[18)L%UF&@5@W!?8ED-*
MH #N#W<214 ")-;<]T*WCC^KTX\[3P\UNY559CR*?M+F70J>!]IAXB^>TIK,
MDUP_T5_X&:;Y9_\N^/H]UD&=W"8Q:.;:P-S<G+7,?/7.Z,7?UR@ FGL0NJ9!
M()?L_$$^#^!A+DQZM50?,AOV.-W\?_\,;D_9#!'^0O3NWDX)<%GXTW?"$#!W
M?M1M7>U,[V-$U-L-95FY3.@N]XV]WGD(7=+  M8=L(+RKA@N+"T-P!-5N9?3
M.;Z>-SN/;J%WW<Y:!]"P@U Q*T]C_&U=^NA^73U#6Z\T>-NA+29K6*!]>8UO
M+)5U7%!QLJJY?$6B:NOZWWDY:[F=*>?.YKJO)8GZ%*J@M_DVN=+NU/^^_P7#
MW+>^35(3WASO5S<%NU,WS7KZP=R/<6TA&OB^).P9F.%ZYYEK48X$LLE9!'8&
MI?+B"6I.8H0?/_$::M^K7IP]I?>LVHDJWVT^JX[M@]J2%OR7_*4<>MDBA-05
M6(DU'ODA7W?;#$&_OB%%IMTS^J<N,CQM@N[$%RA7DO36(6?XE;!T'KJ4F(4W
M;H;#F5\OB,VUFU^VLFW&.G"![&_O!*,71N<_"AXDY!NJL$'_[F\AI1XB]O@S
M0AU;[BO+O;3<NANRS"*ER>?C^.<V!:C5J+)Q.TQB Q$KL3T23H55DRHC_S0#
MMI(Y^?0'!']SR2*V4 #*/V3>BW;SQ:]'/\M9RHN!1RD8[<1\%?]C0=(E7<YW
MC1ML5X/=VG.+EL%7#*O+'OTUI_@))T4#P*AL5Z;"W6B23$6[^JX.PTM&!W]2
M_>3<*NZ]6!0@!<*R\'7=F,_J@TA#_T@H!5X4TJW;Z3U]QFX@L@A\ W:(.V(D
M+"U)#'F98SG[P.Y^/[/Z6E+\-$4?Y"O[YX6/6[.Y?$Z)QC:V]9<?&/=IB?#,
M7HDFZI%X49G5Q9P2JY *$ +)4$3D8Q_OLAY3ZQ\S5@IEKCP3T3U[[*;FO]%Y
M/[W,;WIJ'?I*1&.1*SFCT>\'(D9=43.UUD7?Q[/MD?.5+3WK6-[^ ,_G>_3%
MV;_[C'8RDU/\CO;?%,<T'#8'5P6;/CZ #\L/#-_^QM[\;@J^J>[.P&V12 ?@
M.A 2W7K.C,O^^^[H7^1>F[J'9T (-2^9E1W4>3M,,BYM&SA(RR U^JX]$<1$
M2VL6++"XWY$Q1*(Y%_2U>U'O^4H<5\4N.0@W%=?S['F>X\%'S13I\].^M=S9
MB8>48ZKZ )Y2DQ2">C*!R)]RB4M9Y_'W"TMNJP7N"]D0*T=!L@'R9FT=W8/<
M0F-F7=;<V4X><QC%0%#<F_B&<Y"GHPOUGN&T;D' ,]A0(.Y4&7I%ROSJO\*)
M^/;X+3;& )\RUR."/-9+$FVW!:XENUT(=M4[78/U=!/9UF\J!*)1/9!"FJ:J
M#J7B:*^XP >H[.*?07>7FDD\EDJ2?JU/E5-E.[^:V(<,Z8UKPQX";Q /(SVB
M5EQ."92^1^,'S:M>%ZONZP[&SJ="-M:R[I:*K-\T#6E8=TE;(BP94P8O+DE@
M7.@T7PM,/VU9L@SF-8X^F@7A']X/K'*:1:%EL/1']FH=;%.K]%X(E]^+[9(L
M22MWW DU^>]HGXSH%RPO!W9X2YH*4<6G66AH9!L4/MLOV7,J="B-4$=C%62I
MQ9=.C0GOW?CY6(15E=#0 QP4R9:J#.\[_*A%5, 0]H7Q?40[!4Z[E_C.-.BZ
M-HB+,EI=#B)C[J'WX6?MF_;G_:!^TY6$H&F_V%QZ-3Q>V)7<XY.D'.R>[9-^
M[59T0%;$^[N@% 7(#5U2XIS^^J:J7#J0TO!59/1_V;"Y&22R",PD9-Q_S+$[
M5496/FZB ),]>_D^0\D*-YIW4+ZVU+N@/Q9]</[C3=T2J].Y?P<O!W:MS(EN
M"&57I)>M#:CWX_V<LQ_S]ND#^EM:4_+V)C96LRE*"8*FS<GB4 "9K@K,&CR.
M]>'CV&>G^ST"+U/_2PE\Z.(=IG-$H'6PY6-TIY,NPG@A1R5.M_QQGA7P*/6!
M\;K^".$YDT9CAA]F 3TU]W!DN<3PF[92ZK0$7T9V[_T !'CL#Z[(]6_4$' X
M,P2\6%^9#GV+ NA+3+9:SUJ9XCW-OX7A<>,!!>B=[7K!>&KNO^W>1R$[T[?\
M9:'-]P0'"I<X]9<U!JUTKU1/VS"T8SDCBY #KB@ R4D0%($L0/@R-+"8T>;*
MIZ, 'Z1G(CL@(@>"*OE$[RO);EM;6<31:SD+:HV3K8.58DMZ6ED?I2'58A>[
MJ;=H\+1D+>42$&4CXTU9-PYG7^57VFD(YM>_BXO[B#W%D(X=^IK2C;M0$&SY
MSO8N"8^3LGO@Y+B@<AHG";[E :!;&+5&]BTVHU_Y['Z0_8 "8!DG??IH_1BZ
M)W:I)7?P^@Y4+WL2=E)FJ#^9T AI8UR#=>+[?MR;Y7=M*P.VE5E<OX?\]U:/
M8O:U8&\4#+YVG9B^]_9Q2^A;O)7@G6T5N)=U 79Q6Y<O"I;8^*J"H[*K?J=.
MO4L6"_*/[;LFAS"5=@:D"[+9ZGW0V_^0'T5>XB2&7$DU*:YF>AUEKT/E:/Y.
M:Z:I8&UF2'+:%P7@/MGYW'UZOUC7*?1TQ2^[+3L'_Z[K<LR3OE<FN5/I7^-,
M!$SHUQI*(U7'G\O:+^?X4/+)MGH@QGQ#2:-_B+7\V;OO8 YF??WV9I.D]_/$
M-"D'VTX>?=O-N[8L1N>2SWD^M D_;U<60X_GCL.'W-+XJ'F!Z)!&-M#,5OD'
MM%M$@R1T<TMVT,$/!3!;NW,O<-ZM=-IO>4-+3:A #6QN2+,F4%=OJ=PC8T"(
M(/2%=:>F1%1S3:3BWK,(4\[4SXT&VPR39"9; (T2ZVOR1:YQDP$8=!]J%;=_
MKZNW'?$A-HTBG\'D]*8XY7W\L@&J3*<4!#-]YFBG_G624&CKA%I((]+0<E1T
M8[67\N<UQDV<S$Q*3>'1&(. @ C(.AVV>>6WOR0^<2*EP!CY340/!;#.3\OE
MK%5*(@9N;] 7<_-V;\$SZ+._GDJ1RE5C)QFVLJL<GV/@7O"TU =#3,2/7#<^
M=ZH4!A06IM'@V:,;_E+B $J4:&Z=1]RTG\)N@0_]M\-G"AL9Q@]Q*Y)]FY;Z
M(?XW)TV2P6XZ!CKX@Q-%0)C.S<)UB;B:FD1%2+Q>5FI^]=<S\H D\-GT?O('
MGE6+'8^E@L;6M'5M6E46)>!;Z_=_"62QIRTP*W?^.-NI\%39=N2*)&9@Q_[5
M2D0[*J_-0FB^NO6QE[SO[N&[1 '.YFZ$SF'ULAEEOZC#;*\3MDY<&Q'=H,][
M7^9,,8YROF=F4/*M+WUG2"C,E4;PO4D'4SX7.JFH8-9<Q]-C_?".M>/WR';P
M[>%&>][/.!;)F^QBN*)/=)DC:[,#IL\FC4_/_CZV2V%'\@HC]26&.8VNBC#$
MLA^ ]UZXO !P(752NW4Z"961,0%QC3W?V><KOKELDV3Y:VLXSI\3+%G@5RVJ
MW&?X);TT5L/R&Z4F;F_\D)T01:.V'D)/%?]  X'O+-7DL[$@)MK>XNS<D'#&
M]9NIU9$H!HVF,MGK63D3OD%F@337=\=O/KES@B\%8L8E\O\ ?;2T['E4Q@FX
MLQ,B?U?<#$#O%WL$I?'.#&_U40"^O(35T=4 [2L9=*SN*X;'?:I.6AO63(@I
M6IML-ZUSB*W_"T,/O1GK>N'+4AH%NJ.7-%%.)O9\Z1L>"5,DPI2MI&;Q&)4X
M7:)%M@Z[F,\+%35KT,2T"5(S!#-+FR)Y?U>0K!V8Q-%4DNF^)< J!0H5YQ[W
M3KOFS+9?+3.X4[>77UVMC7_8$V4CM844#BE_A:1C'T!8E7R3TZNM2?M[YP0E
M$E5$K_GDF-,H8KC4(O1.=10=PJRCM>,F8W)2B7\*H$4_0RM19I!VMWR >MX'
MUX8]?W+EU:VM=N14)?_# )()!1!XWS\^.:3(G"V]$T-Q8T02^4YW0/C>J\;
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M3>/<@UD7$V^_JX05ZJD)Z8<S<Y;';J<-.!Z S7P[V?5#'(]QPK1],]YJ@3C
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M*?)_7>_UFG.M[>IC@EFO[Y=PV#H?!]#)HV0):N:Y*Y0^T+$3XU:D67$K>2L
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M_V%F&Q+HOZ=V>/8;'ECHL]D\?]J&[1%_87]+:/GHTG_L8OA3#<)D*WS4:>%
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MK%U$82=ASXWD-=S68)]ER=>DKM_;NK])6C4O#69''))F0MR+)<\](Z/G\KX
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M<K\@ 3&<7^ *CB$KTG6-:8#?PS&'24?P<8^%J$NXJGJ\L5CWBZ5L4,G.IE\
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M#WNPR_J[[A^UU[04K%M"80L]58)47-H'3*X,!3FLH=1EECCE0R_I,)WS$H&
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M!3IB6=U;* V01ER4)PULG"W(?J*HH=Y9=Y1R$;$7Y92)GNNNB/"O.Y7L!WW
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M[=,J)7IB40K5GQQVBB*9>D7F7*?NDQ\&F7LCU8GH[G 3",\R\[+@'WH,2W4
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MM1SGI'&M[(["O<7%E3K^?B]5R[?9 _U96J(_^9C(A%9FT5Y@QTR[Z[J/8")
MZ.L3^P;_*6!G5GY,T=)77-'AR):T5=I_GNX%U^JZ/#3($>!AP8>CSSQZU2!<
M<# "I&^(L?**AV UC/>=< ,TW@]L"I)NZFHRCM*WY#YN4+-_39#^CK4VH6(+
MP4^O(\&W@L8,0,/;BS>?W5*OE<)<M*Z)2PGKDI.M=FP)280;M,D]G\%H9'GU
M"*6:<G;YCO4#S@E#_0H^\)G'#;^U-@C%XN/50S3/E>T4P!V?Y!O1WV,1?E)_
MY84XC7YI(,_ T#F$2C;!Y'.Y[D;OM$FOUN1+;DHNSN&B/V_?Y3S_P=7TD:\
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M'!_^2?@0]];8C^OV.SL]QWH_)%0L,9P_:+OC+YHU2S>8 <?TVQ=!-M_I7Z
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M5W0TK;96R[U,K]9ZDZN607M($3+&O#^:<R.T!6\+M63N0VMVKINC2F<5Q\B
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M0NR]KD?K"A+_8LAK^J-C&?CG^G1*;;<A.AK!%],'_K?M#\S^Q^W]Y@[M*D+
M!C',3)-J+P/M)44V5:' HGH9WG[@WRDUH*YZK*"&@N[^NI[7W'Q@7Z\=:5V<
MGMD9 +B+I,U3==B!>?_=UB9U@N+*&WX^4AS!3BLA)5N?K5T;9FA_('^2Z*.5
M,9M08\?*_D5?9C)R0W<Y<CO[@_(L63DQ&A!'4D9@Y>O8\-<N[I>#;$,:ZT0:
MN*!27G$'4D&WT_;AOK?J'67&/'RJ$*DSVJ(3S?J(V)MQ;B:%".$(02M]74J0
M]K=X,A5\ KT"<"'M(%)&:EC,K1"CI2-EKL.#;2O.3&5]X>X>VH2V;59B0&7Y
MFEU'UU0W(ZZ2]ZO$M)TP9R"I?P$0#BXJOC6VK(>%U8?>!2H0!*B^A 0='UH2
M!AGCM;K"#1#N*PO^YQTW/4LAE>CM;64M%U>PIOVOH31HS\_K:S^?BF[PCNWP
ML#>EE^99,YWU378K R(<ES87-CEZP!'"L0]2,_W?J$6#15)2*[TWSC]9N;C)
M$F^E0Y/9_!X!@P)5RL9Q63CG<_!R/_4_$QM-Y>Y+^J[R,6O^:HM+($P5;:IW
MU:V,\1/#)BZ?@"K*<7W3=Q;JDW)KMOIX_!^V9]KUIP6P=RIVBD/Q DP1]1*\
MM2>W?A'^%0D,C3H9016V2N'C@6ROM4.GB0FJVVZ1) ^7W79F%^KVKUOS:WEY
M%/7FAT.P RIQ]5)A@V?>K*Y.ZN$^Z3\:"QY^TD<-&HNQ$+_,=SF>?A=1&%HB
M@ +$ &%_"3T],J*8DA54V2AT2_R0:#/H0Q17%WNO[[J33T^W*2ZIJMKHMAP5
M':-@30<LEV)J'AN']!JTRMA0A?4**'Y\8;J=MG8^.4MAN4)>A=>B%4.X=HR.
M21G+UM*[9].1L_4;4DGRRK=CA;N/'1MU2>]B:6SC!3+_A:,53$^6(5J7J+;7
M>I#?D#80JL8H(T*_S7E!J=NAPK8$V^ Q/+^6,%.],#96;2^_JP:VN.[8W'@=
MF[?I9'C6!_LAWXW636G/7Y+E4FC3RB/R'X.F*?XNCW@?SSP0?_]^E$Y>2"-]
M(2!@LB6/%Q0HK_>/&\$,W3E?R<=:2LD/6=5% 39OQ>;H62-9V>Y_O.ZACLG:
M;!FW_DB@/G3E:(*QK9R^9Z$B6"$MM5/IDP)<I6EDLM"*C]+K+; 90+)-0DW1
M9W\]HI\#UXLO(O8,UBQ./\_B\'NUDJ94B^VZKW>;7Y#,^##TF;"JS\YJ D>W
M38.HY!EK1S]VR$P/=(+(>S&HQ/4R2W*&IIBWWD//KHE.]&?W3V@VEGHK@BAE
M 6Q$Y/>?,+ RE;N.T8)R] LA6=0H ).8"TW4.0KP[W:@<VP>ID_#90PQ97?6
M(AGG"#]Z5UY08OY;O>^@*>94V)RKUHUPN?:5?=-OCWMB$<+1(/A.T,VU_^72
M0DL IR>YMLU\N?G.3$\@^6?\DIB47>GL<OEMYNZ36'C=C(M=]M%\$>Y]N6**
M@P,H.IJSO]&6;7.:,7< *&' *BA>@).K%Q[.%EAHH$:!!UX]/G=X420[%G=)
M9[(7D0S/.TT\D>W-/Y,8L#&-]>&#IJ#W>-,V&*P9GV5SI]T9KDLR?SV53%O3
MERC=^JQZ4KE,YBMI\DR_O(7:+)',!:B@]Z]?#6A4]IM 6@A;BGV4]AM,TVLV
M!'IP=>!>?^MKZS7T-Z$@*N5#[F\XNRT=QX1/!W1[$-$A1'C1?U#YYZAS\0B_
M(NG(_W<3S$6B<#X!HW==",E@S]$ 5#<M._P:6%,B/CP%FAZM?R+])H4=C.^R
MW,,:LRH\O.;KT%05+P#@X=V2IFR1/@=(6]3;J"22JW]AYM%Y[R<;W@4-3\U5
MJ'>EDP^G&V<8LWMRFQW#V+'!QY'FV,;NXJ#$R7'E=W3/IS[/3/U^V^YJ=B$H
MV/!6[_U6-([U>B+%6\G?2Y7_A''P@M9?Z]WC[EX.'OAOJ>HY:-4H;!6']PR^
MP: 4*<*>SR$4C;L\:".<VC=Q10%(C@KP$*WD/-/N]]?]*_=S_Y4[8HK5?=TP
M)AF'9+B$.'Y7;53QV>C*1\HD/)ZNWIL_,39$Z\#_=F2E^O_*D16,=D55 G3G
M?FHS%?KY.DD2>N3?FNGCH-KRX%LE/VOU&\/X0GMUX1)Q_SF >PS1H19I_+@5
M<X.^&#Y5UHD-I"=GA10_2=OJFUQ9-95H"555<@1DH_,$RZ<*2/_*^/PVH-3%
M)^5E%]WFZ1>M:R?VZ89J,^:KLES'Z^^[CYM+WZ:OIEOH))MFD<9PZA0#%."/
MD>^MCWN6UKS]8>P!"I#J75YDB<F\J"VM#>=HI+69R<[HU\ WYR)(SLI+'=SY
M81K^R0GV6L<T0$.*IW0PZ9RSET":4GTRE)0QTYW5#A1DRH2#(2]2\KO$<E3\
M?/8'[0Y7/FW3"+P0''?$?:<$ 9V,CB87-7G]NT_8\ ]8J1P:1'PL O>?<A#@
MAN2,?5W5O9GY5&[XTR5ZB(&_C@3_&/?MSBNM/W<)X7@  9'B+9_$6SF^HUPH
M<W?P]%8"C!\>'7UJ>A73,Q8+&6CZ)VR F#CU&8OVYP2=3_T[T33JSQO9]+CD
M M/5\'9U[Z57L<O$Y86+YEW:S*ERYX<:#^H9+NLZ7 [:TOU\D^S#25'ZHL&I
M@-JM?4G&L_%3"F$NGOI,Z:M@MKAD#.<]OCVU;Y"A##C5$<TE8J#1XQC.=&%,
MI3'CJGZ<-=@$LQ*S2./)B#(9$#1B.?:3XR?"%-(!:KX=VN9CCPDA;BPI5C3W
M#+CUZ=CI5V8FDE_K9ET6<ZU(W2BN-X/26T]I9X"*.<M66.,>WJ^W>?UC^YZ.
METFHSC[;*C4$V4+:[D 0+,6P3K7=ZOH'AZJF-DC#Y9681[9G&>GK YKOS<YW
MX<QI"Y&7DQLE>WGIZD2,28:;X:\7ODIWPINBRDQ]G6QSU4D.^D"F^^$):BFT
M@?HJY\M-[IGA-I8Y5VCOT(=WOH%W9\];VBW_J$73"9<\R/B?C%0%PK]?9O'0
MR,[QGNAUM0Z"-GW*\"Y1@.=__L15]VY:Q"<5E,(2>Y(6*&JN\,7K4 #\0B(^
M?Y7M&EF,;DQ#V"_RMS;^:@#L6(SO*O(PIO87UMV\:(I6$4:,;SBE][!L_ ;1
M&G(./QC?J8/[Q^(-F1$]#]PNMR<WRX:%WT]TF==HWLZGY>4)+[U@EU=KR@EY
MG9N?FV K]IB8./XI#-RKITYYK,)[H7)$+J046R(70\QR:7K7/CBC)J7DA%[2
MEF'_+O"H/;BV4QW*1!?Z-]T6<=B37=&&)(:<2^0,(F+@AVT\WKCE1N._528>
M=6^TR$0HP\-+4_<O]2M]1!76.8$:^(PZHDJ.+Q09HT!@K&^ST]2W5"XSZ[JP
MRW.ZT!&PI'$8=.#*=V"6E-B@&AGH_*"/^$871_.T UY4+:^Q2-H>J>V8GZ_!
M _VLX30S^B1;6$^ZB.9V[IIF:6KAI+[8L&:U?D8GO*,FLJRJ;Y/^H:(*GU;(
MQA4?.'T(\_D1IT?"2NAX]KN^HW[6I6<X++==&/RH," :K?H:JF0:*N\K/GFB
M[$PS[<)6)Y1E!;Q:)BKX8@84J?2ZSFN@^YT-'T(L#/EA_3&Q*CHMI9U?R9*5
MB1F900$\6 [*&LMFZ5KUTJO+:##=.=_""E-7W@7JF$6E,6KS'3KR%*9VV-R9
MDXVF\U*6L-X$6@5\N::HG&)?H9*]Z^:+ JF[!=KN!F+*+XHV2T*?:#<* .$E
MC%I9/[]L:\O_<MW K>V. @RLQ8A(G$LR-]2TI'^7T>UPTG*@+_S>,_7*)A'C
M[<Q7A7O?%T:7#4E7Q-UT/V$;L9R:@:U4N^/A8XF5%>^BP1.%9A^M^NH)) TI
MN^[ T1]KU>+67CJK2BW[TRF>1O[@G90_-;N$42/+]H64E ( S8@$9S.CQ9BI
M3!1 4>K7VNX^6#+[3G[P"=,Z])@OMWN^-G&;01@Y&CW2H0PI9?":N=2?-@=O
MVD\56VUO[%I8@@\MHD73K%GQ2@MLS:(Z:R*P113_,IUA3.T7"%R4X*LM !_4
MY)<'<CIRQ0.*>(U%B=F1SQZP09XH .[Y@+;BA=@& 6O_0TS^OL1Y;)&HPN-1
MMCL#=,;_W:"BVB]RNG@'#H:;Z8#,W7M%Y),#2'T2O_==IV-^>OG*%K*N/=.@
M98B):']X%?H6%+5V1_![U;T9?RXZ:8]/RV5VW0DTI:4Q]U'31U'603+07J.U
M*9G%3).2Z4W=4DVI]Z:(=DR+JM8MD.'[;X9+R8[7KBT3>*H\?S[S_*8I^'=.
M 4#*3)4J('6-A\JVH9?0DW:A&_BSQ:S?+9(B[B\FCH_A*Q+0]HNEG0;8FY($
M>@^+J=)AK9F6RM+D6N\BHJ[%3>TBI86)XNSL[')PUVGR<A51] J1N5^P+ A]
M"(B)?G$I92D]DF(-3:56%!.)<H:E_92:T(,N^G6N1GHB6%UWYT!^82=&!7<)
MYP^</\>N+7M\)+JCEY<BT"; ZEHG?K4:ZHJ1_3,Q#%J:]N4!(JSI.D5$@V -
M,,G/@%E6B;PMSK2C#5_8=WQ.@2"]O4$8W:0 ?4M.%?IDI>L*\?[L*K\&!1-,
MR69="07XI-T)$M@0G:5;_C'.\-],XNP=03BE'KSF?M$A#&/"NQY6OO@G.7:=
MX/<CQE.0%4UR8E(/*=B(V1BD9(==-^*VZ^0-W784"A#2_^?T\5&_:_Y%(@JP
M%>%Y,X8":)/DIO"B (-Z2TB[)^JPL\>" OSP@"QH(M10@![T%JG;/-C-;6/7
M@AHR2^J7CR-4\CUD\LG1*W1\0BU,'Z@:1;NJ7!8L?FTT[7ZUJTA+&&7+3V?S
MGX@ORDTOQ]%E>)<NLJ@LAGEU'T8NN24V&%7/_8:,)?*73Y*F-:(50_</%Y/"
M8(XEB'F<_QG2J''C&'JG8OEGM?.@<VBM&;+#S^7+72N* G@[((SP)H[%M*>/
MR]U5[$A#>].M(7_-?YA>L3J""TA,3GA#H2=;[D T]6KLS4N! YF$^(HXQ7-C
M +1[2W*TH>].9M$PI5E2&X%V@-C]XBC>I7?$G4)#!*[U>6!H*6/G24VKR]BD
M >M+BKVZ%,1GDC54 7U*4"9]P1C%8&L*,5W9F'U_7&D.4C_&2,\.TD#C S!'
M\?!VYVC/N3*,.5)8L-3)%]JXA0_@6_]I$=F<N7^*Y3:I(UC 4]QL/%N&/DQH
M/6 ]V#X^&7U_"H&=JR;IYX0"%$+.JD!3* #.UIUO.-P1T7^/+/;:)%"K#!#]
M5TOWYM:<3$Y\1G,6=$Q9*JK2%I.M.81G?GE]11;"K!NPDQY2RDTDPUA#>]FY
MXW'X"B0Q&?=ZY#D&<5^V%V6 7NB.VE]M.ET/BE"[+RV]TN*DX('I [I]'UQ(
MMO#0T=PP]X[(FNY-55F*B=O)]N 5H?:FQ1?Z(/*9F20!07?UTD'ZI&&+/N ;
MZH5%MM2X&?&O AI_J;XLV9FNEWY@,D5FHF$_^VTEN3@5\_E2\I_CR5ITZF"4
M_#WPHU?VNZXD]MEEZ,#A.K?=%?C"8]4WH:1PT==U6WZ$$]HF)F]VPOD(!D;W
MF9([;6SW'HFPESK/'PQ_ZY]4)QLNE5?61!H$#Q2PWS,8V:TP="[_2@#_>/%\
MGE/P906X4(5=[WLW )Q[RGE\:FFB5?R3A0]M[3E'1U).!>M'KZUT-Q.I%,*+
M]M/5&*2^X2ZBM=/&D2!G38P;HKC@I=HUY+8#X8>^;F>V&3\H#S1-6WKPWBCK
M/\%AY].*H53QMJ$"ED21+TK<^H=<P+GM96"4+VQQV?:<G$;" 5)<B78/GY,;
M[6V=-+[/8@4&D&_J_1A1/%2';+6<]7NI(0Y%IPK$A'%B#/I[1H>.HLX7$EV]
M:5G8[Y_/R,; \DED\!)*5FR#X[/EHOF^FI>@?RM2VJE8()@VCTQ7+2G[4^\7
M:P4)YA%WC?Z6V=98>_)1&*TZV:("0O",C*Y'FIHW.]KQS^KE?_I'G94F'[=Z
M$)ORTZQ<U-D=+WY7MVF?CZX[.-YM.+NFK*^$-O>NEVR/<S',;>*MR]18;%I?
M&;2M/_GBANE-^\!6@"QL\I ]IG1-\.PTSM\IC@]\.654L00O10'X8[9#SWUW
M"/8.U!+7AL FB+3C=HNQ^1:_4-M=']^JID(5E5<./RQR"WR.>^6Y5)+#&3:U
MK/&L $3S5( QKB/]D'7'#7V#U 0@/KTBF#Y)X+/;F]5;7RK6>@/I#<E8=R_G
M1GPKMA[:^D.DI3%S )=?'9PHY @%"$,!**LA9#Y_(LH\5B<'W(O6%C(\OTZ-
MI/::\5V3Z1K7+?'*Q'BSP6Q9OO+5XBP=_^F88+AE<4&NN3;^,FU-Z779#K+Q
MR(O-P>WT"K3NEI!O6SDBG\)NBNE6_T8V6::-^5/@HSR:E"5HYN@R+_H_T%D9
M,_7X]%'?6[/-V7[:6DB;_'T_DF$E!KH]LXF<"%AM6EVD.]^\OD4R1+>A "M,
MV)T,O@TH +O0+@H@D0#I;SU$ 9KH+J2K48!L'<AF4#$*X+PK8_0_(:/_?[M/
ML!Q XR@B+ R4#RE+'=*OO4AZ+UT1P5M8@E:4F."Z+\U87;(Q]/+5QJZXQ/<=
MDO:CCRLC1I-RH>)^_(HD%\_"">/=0R1O[4QM5C_OL:1HE#>O;Q#T(T9C^W=6
M*%$ UU#UT_]1W8C^O[L BK@X1*Z^0!2@ .?O_/Z@ &O2S1)9]FLGG&N(J1AD
M5?^$^]K-.*08<E__:'7]Q.$^,"!IP3NXV?(QF^<-R)1#SF3(AD1TB_I3*%;M
M(N:OJ4]?*,])62+<(-!2$7OZV:>-K IBF<6@ERWA5',_OW3_X&PZ+=HZG7EV
M*" P.2,:!HH0'&D@ -PO/[ZGG?92X<G9%X^F/V2-["Y4$QV;>SQ\;-YRO;K9
M* J2N7&+-<!Y#RGM,($%?2 8%:_L>5UE^VR ^1%BO<IMS#]9HC/ BZR4^)*>
MF=?GKY>*17=(9]_1^AUZ39 5[B#EJ*.H80L]?R4Y5!@T=;$OE[Y;Y:L*5J,M
MD14=B&./URE1(7]W(XS\]N##$OP-[IZG<-B2IJ[[\@?6'.>CXS%I.,4 K6Z5
M:ADX1J,]\YEC\=V#GX1H->GAVYJ-/QN(U?X5=Z\6I*%VND\2ANA,@6W8YE;3
MM?C+KME=)#O$UK["O3'_%T&:=WVU1GHX"I!0<KE_+?BM(W#ML+>CH(6A)V=_
M+SI'3<-_JNQ_-6%54,3I./&F#*5>@N[?-=W%C%1BIL<)$L436,EKRQ+\<A*7
M\0%N7U;=ETT<WIE<TNUP?W",:IE;HWB@$I1%QC8UDE.IS<Y,GSOX2:JQM^P6
MY01+"G4PAXBF%PN<"YQYV62!L*&3$NGVM_P?/V!D3J9=2D*A\'NL2SIN^Z5R
M0L%E*QH7<W6B# 6$[,>@[Y\#L6-I'*];Q;""\GPL6><[X!V-BYK7JQ,BV?VK
MS9&?VGQI..J)OFLP86+,@!J(*F2EB:: Z3#SN-7WTW7-QJ:*[XC>>OY"*WXT
MEE*M\5G]?7J"V=',,;JHA3=WF?/K.N=7I>@L>E/7N@)-IF?O)T.R\3:TA,J2
MLM(O(?D--A?>=KU^1+7E[ECB( _1!-)C:YS@]&-AC6U1?74+!Q.G*Q# []!X
M&UD%!<H6UTW<F?8W.[Z,#%8GI4LN3;C9/#K8#R#PN]R#[.A/9Z38[-QD,]!U
ML?+PCWM*?3SYZ[9":A\SJ##=Y:[&I,('-*]N""YW8?]5.Z7:EYW'^2X[K^!B
M=9L;K/Q=DZ_X38RDA#SU[Z$4\6+GBA<_Y&FIN^L/[D*DNY_=^-6,)S7Z+&T0
M7K3</<XOC3G^*_%9JW3FGSGIV,V*ZXJTX$N8U1IH7K8J3:U0\8M3U$Y\WRJ7
M\MED1GJ.\5+1+4IH;X!L$M^Z?US=+5SWM&7R&AWZRI+RV1M<%J:Z H(9F#A.
M,>S0F&OEB5-3WXZH;@XP*UR!M>RS<DD;$J]4%G9YVR]JY1C- XMD(@;_[>TS
M>?VR+#Z?YM"D0?.>MOT*\PP%+N9?PAC@T851;0MW%/+3*@S"T-!",%*@W/EP
M1T*TZGCLXG3G]%+C1+7R;KM#3,2JFB:ER^DU+F=4_;EMX\WVFW3S9+\D?TQ^
M055-\4]$*KH^BZVAD7)]Y!^?88"!RPY\&!P?O]:O)ZAQJUV<[]D_>5%FE#7G
MM'K@/A6-G;O"? Z@ 6TZEB#K_:91X\H2E=1&RD7@743B\&=RBD:A7@*64XE_
MJ<WZ3J?B-Z'AB:*YQA+V6E5\DT#O'X)XG&]GJ%G%>T"DSG9GTW!GJ9\Q_^G8
MEX-CT;E[>$YI5B/ZJKC[)S8T"T#KS8S.>/U)+!])&K/J<@H$UG:*NH,(#9E,
M<'ZL4$1V&@MJ8"<&,[ K F6E53AJ]JDWWCT?<6)"&Y;SCO]X]3S';[#J& 4P
MA4ER6WPATE;^*0A/DIVZ/!:4.J^LFMI<\_6S0=JLD=6Z;MUDBXDUNI[)-CQX
MEC1]JMEB.Q,QT^#KF?I$'_]WC\W9^[TVME,$!\1>%^,,&*:I<,ORM[J$@>&8
MUMBR2D-[LVGU0G;/[&MT0;T+ZT;#%S;)+^:J[R/'KPG=':1^0O]2;8@33VY
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M(NR';FE1B\V\.LMN@+YWJI%>&7D)00G.5[_49P;16%"&PRGQXBY&&WN'UYB
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MWND6U??QX!^D;TR 7UH/FHKJY,=']^<&]%&VSC3;5<+C6D*Y,#ZQIBPG1?-
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M2] 1 ;!_<8@*Z%TB "@P\'D"X',;.370*!#JBTCQV(=2-_]_I]W*!%]6V"8
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MH5"%Y-OX"XCM<Q)?)#FP^3C1A'G298_1_:Q,HGI:C#UT'PPJ0.W75!AJO(,
M&V8( %D\<JG!([!:[K%4$\7?I*HTB;8"Y'34BM!$/H<+W62*+Z*@>&L\4MQ4
MGJQ#VH"TIX I&](SS7S -%(![QZ[\=,JH_K\5,_BW7C22@V5E)Q;)+9A8G<[
MVU0$6H# G;6&Y1SL2_F*&T^H96.\_M6H8PF-"NG>.V,Z9YVVWT:$V$BTWB
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M_D3L,*,3%DP(@(@#2\A^7>I\99_)L0P2OAD\BO^SNB.\:8+F6R( 1AT0.)/
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M;OFBZC+(.94JDN,R\<]*V @"@%-FW[ YSL?@+UVB7IS>FEH(_@G'3^$_GPF
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MM.A3>:E)^Y;:P;^JH+PY_V'0^O:#0]W@J8/2SK*5BCC!PDS.=S>/Q<0:&S&
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M[*\RS?YYSG\?GH78'!;'$QH,Z:VU?PQ2C\E25D)YK_]FE+5FF'W8":K6^OH
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M7:9XO7=&@MJ2SF#*)FWR53IALVO\4O*Y%5;U/#K1Q'\-7-'"ERY61+\R.#"
M$J2;F<>ZKD*&6@-UEYGFX1?\;GDX'($N<1;79]TY8%GH&<(9+)'!^;9XNDN3
M&*H+J)W.N*0?&RTG5M:\#FK;'=%*-EV86SJ,?53F>Z-3_AQJL@W^[(8!5 I?
MK;8CW2W8Z!7*7PD*WXFP!OC<B=>!S8B*:2OWOJG0V &(C^$H#91"762+!GWS
MY-FV[*YZ[Z*)R.S\0[BPG"6I<5L9W /'QR&L.,RI.43OX"8P_0&74=+@D\9
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M+GEIRFF:=96\G6#$K\;7(6(&XS3&;W<NG3G,A"9.=Z<H/VUEP<ISAN"G1&L
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M@:)7P5"]EL4RHR$'[D19>D8;:UP5;D*E'*L290)\?!T"M[[3,V2$+P0I@T(
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MF-&ZS/#R-5_" *C0SP\.TH+Z=/]>"C/Q9&<\44L**Q"7/7]JP>XRX^'1)V/
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M-W$B5"%DDIL\;"=[M=1?OEY4'/<.^XP)^=J7<+'*-_0Z;6Q9XNW\!M%P;O_
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MM5?3E",U"_E@.["93<&_U ?BJR9K)2O)[GBXJ8N=Z3/'"#(."[,&Y6H"P(T
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M8T_87B^*U5_A;P$F6)$<O!#VFS9(/:\C I8&FKN)1^]N4OAM?9VLB>[W+20
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M0+^)MA6EM&G+O?9TWI1"]>+B:ZQV6MRI%<16I@T)_A^_0;6$B<%V_L"&# @
MAF<CXKAC]NA?R'G\\CP!\$.. -C$AK'8$0#>U)B7!$"U 1*RN%\TE[\N>,2I
MPLM\AF>D+\<.TV6!%L'0W<>K?O@MY!<H <"E](C]H'0;CA$F #B5C'-EQ!Z_
M:>@UN/[*MM[,!#PA]KUW@WH5KY14'#'<B\M+P$H4]_$"%+M@O1.)=?27N#ZR
M6?%DE;[_7JC%#83")P@ !T38%R3^%DI*' W5^,KE#!1+/TSVZ?_JPG.\B"$
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MO<L_N=O]R_Q3R.SFD9)6"I-B8QJXD&M'=:H*C CY^@04Z7LB2P DG!K0O"8
M?+5;ZH^4_*W-P3N6!(#JZ"3.>3>9+CCP4!((0H<O=#)JM;E>-5-UO0R4P7<=
M/-E-]DU"YHMPU?".9T&5;<&]TT51?!GC*RU?,H3PP=W=MN#4[J)7@L"=1O P
M<MF9QRP8K(O3K/BNH_[@N]!MT1HA$9&N_'W PF\"P,"=H]"#I1!*ISP;>*$N
M +482;FU<H0:YW8"^3Y^#TMC:@>^G<L_X<?,S<Y OZVY>?;A\MNFRXP%A:3&
ML*E+YZ_0;!XFC"7R0HLE=YMG4BMXHFBPT?B#O4DU528ENV'- Q/$J^D:+F[?
M$@9Q- 4N%7WJ0%'V8]!!+/= SJ.FWTLJL#!(X@EOB@B/UE3NJN_)AY6K??D;
MU%PYYZ))M53N>1]RO]&])OM#/4N](P77X?BAQRP#7 J$WHIAM5N0OKR*L-S*
MR&D"5UXZX:!W-5&P.4D$YY>.P>VW$2E<GQ0,GARD0JH2J1RKA7,D6-JI-XHW
MM/!Y8]85Z5M&$^J@2:YMP.4+OXEH_\D)0]A^%66,4YGSJ3_\(ON34!:Y"G6Z
MX>\H.5E0S$G57R:3$K+S(%T-R/E#R M34[(DT_/ E*Q/'IW7ATQ_1;9C9N8R
M^N'-J334G"!)-RD3(_UZ;;JO+2WTE:!DAYTXY0WG">$IH[=IM_Z@4[^M1-6R
MJF4$<B<[J(%+"0 6#%[^9,SV -MI5,(!5@R2R4NTLFQB>FA!5JMW1BR4KK P
M&%.W7EC(+/0YO7T60VUK4_G8%0*@L@7_Y63\^M=S6L2KP!%(XST@Z"@HD>V5
MD,O3%'YNG@'SN_QOC$>\0&1F"5C 946*G8)$VXQ('9-R)/@*/_<TSFJ++-YC
M@M-GR,ITAIW"<Y8 T'WK@#E GRZQY=$ADY)RMP44]F/>%35"K(+XV1*8^?Z$
M:T0JGU26(-!%+3TXF*^]J84+K69EIBF9YWMNLIZ_JQ&@2IE3S61>$).R5;G-
MC99@D]0;J(E.!;[O1H-,KW49QSWH*>2]Z068+0S-U'%R7PJ?5&\ K&@W.%DT
MY2$>*4Q,Q^6_)C1:6$6&ZM @1(H8N&XL3&_G_"1W3K5P]-'=8ZYV*MXW9+H9
M&)J&U3E<*+D*+STTLF%ECKHM@G7TUYI^3>V&T"4Y+&P*K]_ #.!2RS>NZ*ZU
MV*26;3^9$2K+K%2RW?(CIJ;!(P!71@! H#M#UW*0808[FVI;@N#:-,M<AXCP
M\OQ3)&CLHMIYP 3G(%8U>:\ >!#F[Y*NX]'I.6'\=S92ADT59R%#/@T[NS@!
MU$I.1FGZZ3P_(@! .UO<=P@ Y#1(-QK?]N<"RBJIHOEKTNE/0YFFY4?XTONM
M,] !+-3E&(5,.^?JJI&"R;;7KV-"D1D&Z->=7;Y)B/5:M45$>%$X;'H>_LN^
M=8**Z7RZ)N+F\3HN%49.OP2L#U*7XW(8KOW6AEE<#ONMO:9?]8RB[A[/IB\>
M/O^Q>O*18Y\%1\A&F"9F9;[W&B2+NE+K5=M9:)N9>EXCQ5<"P&:Q\_GS+=A+
M?26SLZ"I2$SDSD+VE@3%U-<E3:P!+'"I%"Q68E+%1/8^SY:3^^#XU-%]LL'Q
M.5<'TY:<FY4IE=W#_.VW!^!0J-]D3 NMH<7VYJ,/, 0</Q/J'UUM&#0 (6N0
M85Z5C@,9C':CU1"*(=LBM<J1<<M$I;?I?5YGQ2S+W#D+)RJOA7:=2=A%>0BZ
M>_MX\A,Z2YH:HG+Z= 7Y#J7D.NYJ *V=YDF%MX4$]!, 9M1681=E"76VTQO@
M:8=36& XIR3_C7,"(*/FRYQBB-?SK04T$O,?<.#E?W6@5I< (+?!6^;[Y('>
MZ]S&CX7!UI3"W)3%3$QDO^>G2-,94)CRJZ-IM&?OBE&?@H%?/4E/5C]-EG68
MA6%<"8#+FZ_C_CC4@Z,+%T*L/=**RO)H(]Z\N]G72"QK&X]+TR=P_: A@2?E
M!APW-*XZ0G@2)6YU8'( U$07TOE58@:=IM,LY62XK,I=JM(3^:4@<.'T[VDW
MZ1[8V1[!0J9W'U[_&1G])EOZ'3D92Q.YN!/IT=H;@I6H:%%I1<;-[]OU#QO(
M-5=CR$E/4[=\"G=>>P&Q9I/G#7@)T3'U-T#S5A(;_E/CNXF"XT79<G\3H%7R
MAEKEVNWMW-%.9$1/@Y030 F^E98659)WI+C%;9E L1\823(]?MFQB878C/&)
MT;L1T](*6E[*4=N7B?;^U*K+*+B+2PZK#&*)4YDL0Y)>/J*>I'_VG7\2&YN8
MBTTSFNBY&S]-I_#(*[QHD^R?Y[R7%Y=4"DU)-:.I5&F?1;IP [\BZ$AV"B)0
M%,DLX)QR*POCG$#I(<V> P"P\!)MW[QF*F=J E*KPFTEG6Y""V5$ T)<+R!-
MXIJ7G5<BA)CL,:SRJ5;4%:#$JSAZ_1,6]S]EQN_VU<F9Q8QO(;FU ?9#@.X(
MTB:!2S,$ /_[;3=L)S;/H$7/NB[,8C)T,8?HA+<4QU0-\Q3BG?(>Q(Y+.1GY
MG1.C3(+%/>-)DTN,B'V3..[VJ+N))Q@'+98V(F8:B)W4QUGM"K>U]!^SVH+I
M,W,IVL8&7,1LIO,:Z;(F6JY ^ !2QMQ!W&%DQJ)$/9X/K3$<'Y^4\"#"X\63
MTNQ;S'<TD7T5+*2/;'JP"<4=FAH1HQRUE9U[5P;XMIZ/A,Z1.PE.^S5^-;<5
MG;@CQ')L]'.LD5@;4H[O%!1&]J49&:MSMS-HZ*?7PZC3R%9)H/YT_*[EKIZ>
MM)*J[AO);_\-?J3M:Q7&4M[H87S^_?(=N;1'1=@\  7I^?$56RGPX@3CV&1>
M<V2CJ) P.8@[IIT$RQ_22DHZ,151;#$FE>9N68;T$W_NR9#^<"QU?#QDGD?C
M/I529NED&0G232NP)07Q,MQY5EW8</RC[L>KL9E7F/DP":3X+IR2IG_U)+90
M,:"?<1QR.<6R+VIEPTN5@[3@),;FYMDOL]EY^?:YX33FPJCNNI(KLW\7MTA7
MY&C'7)XOS4Z$N%O/EF1]Y'4NL;3-Y)T!D&X3GUN4L'*ORZ]+(_#61PI!BH.2
M ]\34C3[Z9@X)5G*2\HBA]Z)7[U\@SO-.P@P^X<TUZ21$:(^)%''_;> RI$*
M)(V,;]I1K]: F,_&&B->)\84J7BQ2(8",P!>*D44W_M/H.%C*ELB4J9I0VV3
MO*:#['1JW_L$[OQ))R4T8V("@;K(]@A)9FM^M63E737=6N =2K0&4!)TC-3I
M%(+_) HX4Z9S&,7WCR)F /*D0)"EP&NBS J+&>(8+E,)7;I*AZ8H.X7)=N^1
M+CEITF-<*,0=&WB5@W>\IN Z3?>'&Z$W28REJF?PF-6]\D^YN:Q+U-UX!A"O
M  LI&]]FMD,[,C?<%AYY>_,8%TOP'VK;D/):R=![=<,Y3^!O4MIC_X)TO0Z.
MZYK4I!W]*2DM$W&OK$0-S\A',?T;TNVZJNH//O(7E62K.S[-RN5U]J'FO?F5
MM.( 1CV6F.+D0L$5"4:JP-G9P%EDVS()G[UT=$P/S@4W4(Z0_J!>_71V8#^"
M@G1HZ:4T)Z?NI8K2L@H7-K,R8J6'>5VA>$+:8$,_HU%\48K<LJ%:/QNE(3V"
MBGQQCY2V5"[E*!:KVX7%B0]EK7C*'CX)E[O]+X2('#=/W=;04V0BNRS G^#2
M@F]%T-61(FS80Z40C%I*I-FU>2@1'S/Z=P@ (VZD'GP-?JX(<]9<FUX]#*OR
MF K=_)*S@%TDT=;?*-HW!PAUQH/?,@G%#&]3?WRX\0_/165E?[A75A[U29ZJ
M[X:(1=L$1J6;Q$R)CU\H6[C?+2R&:,J^XBW5Y"4 C'4@))ZY8UF4RR98G.*6
M/5N<29D8F/,VBD:&&T@ZL165 OG09&(\.9D%D(BBBD\#46NQD#I'U@JW*N"@
M$J?(H25=@$E);.^&V-<\$I1S^EG>]JRD]JX<! ?2*7A[$U\RR\@6TA>$R%MN
M;I6+@U2<(@R6R<\G2USAFV(%7*0%#(4HZ$"@)KH&AJ;7RX*9C<FP="JD.^U8
MW4D4N.$4*[>4X%M&+/1BHXYZ )F_-NG<8?#!S%GNT\38%/GK\[PIF=>C<:JT
MI",K2'=4Y:8:E!ABVK+-IK[&"(/52Y?@I(8W-H_61=" \MYMI[7;R4Z4:53;
M!5=FZ$DD+[<=JN7BP28I&' [;:+0J6_12,$W]"AT 4_,Y:C(/01_2G!1]GU5
MB>%;:;9A=/$\J?\*<U:.Q9R)R>369%T/;7^8;,MQ9*CM'(Z4 Z<,H*ID<X;A
M^#!/3C/$A*>AC0-2\D]X[F@594DR-L!Y'P/<2E0V53#D)38XD@I9%A87ESDA
MCIL1V[VZ4O=$'J9"$PQ)/[\%(1!29O2K%<6E>;I41.'2\0*Q..J1$OI!@Z%_
MR7+%4BVX3Q5@)].:*],"/2/!OUY#59TB@;NH)%;U.6]B+L^3<'INB@%2VN11
M@AXZV<0RCWI/\RSFW_BK25>_2L,3);"4Q/#0CSM9XUP10$W26:-ISE1-AE(Z
M-BTH]*FUJ3EEN.J5YV'_:'E(2.85(TIIVG+CFG&1 F#IU_^F62C4.ZCB]<EJ
MSL?U?0WDX>]OJW20\L(,=YX?J5-_="CIZ<Z6R9H @NC\)LFB5M:M9^H<!YI2
M3Z.<B>#S'O@3)4<B SC575$)9ST] WW[GI'K-?_&\3?;,,K=B1\:VE)0;V/=
MQQ")"1$Q'8@7@%1Y/\<?'GRPEUNXTWGU<>2[R+.)X+8+4HJ=8A-3/KZ=G#!1
M6=-AB:6,3].2Z8SP?DX*+ZJB8M-22>.NU"XC]ZL";2U AF<]WS1I\U;F A )
M6DVVARPJ"89"$6 V36;2G?N(T;KAO,$=E,4FI.5B@X((/4V.+71V8KSQ7(NT
M3VV4NT<@CJ@XCY*M%?=K6J<\YPQENF.(=IZ4 ('"V%S%YQJ,$E%:*0)]3NN;
M7@ .DCH X,Y(5:&Q\03U!,JH3(I+ES"1_]8;(E56&F9>5U>X=(W!#6E(0VD_
M0M.=0+I<05EYV=5FHJ97LS?V,/1=!D(8KY""^B2#,S5S5MO-;37]QX*VH-$@
M" $I^5>T!<H?);JM9/.U5JRIWLGE6_X311?_+S(M+BD302":C]<BKCI&.O'2
M]TQ0D6S;-VM:UM^#2DR\$^P4O,TH'O;G\MQYU$28-7TH<NL2Y?"^;, :7R#\
MCW%J@3'_N] --'4ILX1KV0+C9_!B!>PD_NNHV-BTE-80E587F(!*71&DV'*T
M9"<ER"5%H"A)@]$/SA#%+#!V)R*\0("9= >4?RK]^'KG(!T=A_'MSD'.^SQ7
M#GIH:?XQ;L]*RRIIA=S_5-!HJRKJBM:AB9I%*C__6!K!2;C!54--_]G;20_%
MP#*&_^PD^NP%:'#M@@TD!N//V#$QKUXT.R:ZTW_*7.JZ*7]*T:WRE*5FO5OO
M;,.]OKZ]^)>D(WIBB,YT:4",.\&I^\O[":H=$@2,G3?X7D \V.2?!KR Z#Q]
M(;,",<V $Z-2HLUH_-TI2VXU(8*.,9Y3"ZAB^A;<1=H\HU1@X(AU7E9V[@=W
MUUBJ^'1T@Q 5Z2.=_SM9TYLI\.98\\+B^^_OL](),8OHH6_^VQ,<]M*I!:\G
M"A;SWN1H2*""C\U$R9$^I&&F869&6T5>55$/> Z@V"#!Z_/_>.C3[.WA%G[A
M"K:$ #C@>_V- %A4;5?*]5[<%5W$3J;BZ^#C08LG8^!R,*89YRY. - *LN#]
M'>X/LKW'W[O!@Z6WW!X]P:_B-7]$X:#XFPCG[FR'X1/^,WHSNL01YX-@[22I
M*?%VMO9'_*X.Y"9WX"BN^K]6MX:X4([D*!$QI92B#X_*HC^SG@=R?&[SC*/5
MND&6>22Z&MX3?7*<65.3W?DLVYU,]%N%<54K\S$T)HZ#WGU0//_H^ L-Y96'
MA[4!6Y/^WWAE1)3CTJ:)P*XG $)/U8IQ#@=VWEDM_,F"AUNM12:^OY^<KX'K
M+H"!XQ,RL5_"M*.T!:._)J-RM'R4"X#EF(5=B90\ERLZ*>^.F<2U$VL2>&Y7
ME5*MIA<[)I;]X79D(P"VV$--:\RTT'@[:3^6Q U/E9;O 2?K)2VJS_QW*EM
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M"9U'57MK\[WR%10[1\!\M=SW3V3A?4K%.,$!'N@&7HH N U<>W)0[+-\$.C
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MK==D=;7N%)*;D%_/?!7PJ7A^1M6?7/=,2RDEC,J_?(S!(]@UNH 9-^PZ]7A
MMV*0>MGA*!%9SLAE:V#]I^1&48,08VH13IMTY[^V$X4KA@:JW!7F99G'6Z]@
M9SK3O?D)W<2ZI5ZUQ^_E)\U3S'_NY3STO-WD9[4[OVE+[VIFM(QZD86LL6:S
MDC1E*LO*K:H6<G&)%VL-[? 4N'[Z8-& :H!F.RJSJ,':\>I8BE2=.MZT)7:3
MHE9:2FK7L#=!KF+K62O>@@ 8UOC0!!:GC[X*W_QQ(.R8 3\C %[BHFS\VGWN
M#X1/^QX=BS+?$Z<9 S<[' 7= :YE8%M1,]V@P[,S$$7C.]>XY?#>^+1O?0SM
M "V>@SW/#EO^RT^!SFWGF.*=UL/71H_"$29X_<1U,/BV[YKFX4T*9:#D 7TM
MII=G^9-SFX/J1-[[ :-!1>];'WEZ<*UB#6D2+BF?V2TN%; 6.E&WC 5PHCLJ
M/HX._FRX8.N6D!GVO(^2J ".LQGL6 >5T!^%X-6[*[%-5;=W1#,_"WT&+\<N
M#=:*<\Y(G\&:1W:V8YQE9Y=.1>]>U=/7<XIH?B7 K.!1:?8G2T@AMC2VRF9-
M[%EJ6,U]8WF5"EM4&EG_ZTW%:;Z/E'_33]##_%ZWBQ'CG\PC,GU1+BK4 ZF*
MUR6L4\[>-N^SP]=&^[LS/Q_<VNEI:;,8M(^?O<@ARXCQK!0^^(6;2BB%%E<F
MQWX4W*PL@\BSI WT.1QM;[WF8[?ZJ$<+U=SA9/0>HZ\P\UV^M62]4E<CY3"T
M=?[L87H56&POFD=-J%JVKSMJQX5Y+0700#0AVMC\X#-9X8B@RT^I$0_H#]'W
M<FAN&7Y_$\)(S,9AZ+E[5*\W^!V05^;GW'?G_0^/Q<->,O/3O?GFO-QO-#9N
MZ"/RSA1A^FY,2-W P(#VCB:C6P*'#I.I ."I_=BMV6\CNC<9GV;T02)6UY74
MVV06Z/J:[^2)O ,8DM6,T7(!G ^7Q@-OO/K 8V7V$_*'7,7&?EH(IA9>$N"9
M8QM3T\)3,BG4PO*C"R=H@ ;G0QL(@"5)V-5P.6+1<_TH/J>?ZC9:-,O !F2$
MKF!.6Q46F68";\E5!WS(5J ]*1N>1!KC\,;91<T54DN%93?N>9MT?J<YO<WV
M??9.BJIS&AV=X"9]ON;O3"("$&.WT"*F9#_-LJ&V-QZ'3.-R2@F &.K7S&?:
M$PY#[U>!3H'PWOQ$G.:,G!Y\?/S)RVG+UZ&S-M22CSJ\#]I00EGO^1/[C,TG
MH7HB1^H"V@AMQE3V6$T7;B[#SFS/L^+[\B:U!4W7W9*"S?,LS]<+G\E8/Q+A
M%:HJ<0/$ !('BF_A8&)?7N%4XPI'3^E-'9L8&5O.7K>Y!2WPBZK:T"+4C?0@
MPQ/J4O>+R>L8TYJ*A<EIF\#V?)Q_BV8?F>C=@7DK4.P,L*FP*[@IST:!IN!U
MM3ZRY[9@$0SMX]=2B\.C2]3G3-(BID>C!R9.4S_P^E5,"T6V-T=%OJ0]3N5Y
M(%OYH8%_02GW6YCUFQ0Z ^HG> I$LTBAL%J\7W;%Z.'6FO31\)68.9"4LMT.
M75U4WTYW=6NXT>LW<Q>^/CL8FOKC6Q@._;WA'FU-30W]!#U=73U*=XY[_6P:
MC!X5\8!3T$[MJ#.9]-W"I"Q^:2$Z/4][Q9!865,;[5)3_?M*@BHLW14"U 7E
M&HMUF.G0D^^XV5QGY&>+!]TO\6<_G4X6)F8_OV3GTV_M;!(5B!(*?A(O?S<W
MK@)#[@'13)%^:;WPNS3)I52JO!8TA:=7YO3XWK/'(0 U>%^ 1>%K_+90PM@R
MV))B_JUPOF,S9<V_FGK'\,$]B%*,KFKFPC&NM/Z LZ&MM:I9B(6LK;))2MH4
MHB3/OWOHX,-7E;UU0\<TV?K6_'FL)U(HR8RL__+H#3B7YM'1,<.7Z:92R$N
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M9'&N"\RR&6^YBD+I'CD2!I(0$,+]N#PB8 G$><#J#&T$G8Y<*1,\71?T'1%
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M?5 ]SQW)DZOT8K9(.:[_MGJD:EG==*G<Y+0[!N:5PB5:K?7N)7VS*>A/P S
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M?3+@_)IVT_.[D ]P%^?N+L/7#\KRAKTME)I=]<<-^'AQU:SNZLJBLI)D-P&
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M]$W]^_7.6-0)Q63E?2)@50DXT O\]GSYT8D/PAMF)__T+ *AN!>;%)I_\_K
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M*!,!O>.J1,!'IDZ1WR,$7&R+* &ZAV6N;H$[3/UEY^\&-L-SD,>!E'S5]T=
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MRN)V"6AI"Y&6%R2^+$W"F<324=0-Q19?>:2OE7*VH;.&D]0.](E;3U"071Q
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MP%Z*PWU4&@TJUT3:.G[D'>2F\#<ML4NVGEJR];66]7)!I4P:W#(:K D7^_)
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M,JB<>G>]LX"IW!&D5];R=="00_)**PU*'.K:B :$[7:%AOO:]J%4&JUBW98
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M=\B73%K&Y/)M7X/+X]<R<IR<]DJC>(_@RE'$,BO.I49D!K0KN)]4?RBN=BL
MXWL=R\&%NC(9PR4XY+6ME_99JMM^)(3(JO2^I231Y US%W#CBY#3WPQ3Q,*!
MO?;NP?TM[=H"-4YP7,*DE:K,M#8,&?YF?<AF99+!\U'VD2W%TB92M9I)$"-X
M^1(-$(+J4^HEW"G*P7&XR^5I#26NN<;TOO"JF'] ?D>\_,?%H"](A@]E%:_<
ML=J*U[\;4Z6O!"=;MPHS_,K#2";?633K:ZWB/].6GC&D*E=Q(N>K?HF#W4@5
M)R5=I?_@U!>4K!NRT&)I!1IX(MK4B"NC6;OK6<XM?&#]]>*XI#>_X$/;!YJQ
MX$3!0VB_D<]J'C%_EH+#37] KD4^[CN]>7M>7E[3O6BSO5H3PR%^=DIK^V>Z
M!X0_^--:*_P(@CJ2HACS^75@X_0+H#HK9:@+0:4.#CZ4E"==UXJ]U /9RA?@
ML&7<7]</+^SDJ(^']K1?Y3W_[+9UBS 5ON-QOIB7Z#39J83Z'8?L%[XT%XHO
M!IE@NRZFX6!YRX/JV0TYJOH\I^ZDJZRMXCX@@/X]POW<?CM*8IRIN.J9[KAE
MF;/:\K/2G1;VU2&,R*V[_PRG)Y/EV/2&F;^<-U'[GEXC;O6G^)_*Q^Q.G'F/
MB5E/X))/UES>UM:45-H]4V7@;RB+P[]5:<F=CV1KVB7(#4TOT[70:K&LFZQ-
M;FA%/L?EIOZ( ] +.T?*JE3+W[$J4>%-AG[2-](@? KT<56EG-RBL=3R4B2(
M&,U*W4VD@?_J>YJ)M;PV'!?/R16+!VPOQD5\2_PUOB[M3%7NY7BL"J<M1DP#
MM1L"]_ NL>\:+M)W1^T59$%;[1_&\O,$9<%7%2T2TEI:EMK&1,H7+_?6<VL$
MM*OD=8E>CK7\94DD=/'[>YK)H/(9DQ805!WL^ X/$?#4U+70FK@]2Q6@:R)B
M# HKRA=KR,<A#EES?SAHO?482UK9Z/[9PS6J\JW]CZ67X>>[CEUU9\>CJMFT
MI*0<^S2UCZ(M7_6'<M?B")Y(Q0$6!$0Y\PW1@+<]O;+EYJ29I*.4NGR\+))S
ME9)BM@=J= B*L*!*[65K9CN$BNFY_C;=76GAX3'C%QFWQ,@/4ZLMB-R5#]$%
M9(P\\DA*:K-8YS3[;'6%, !S47#:KYK:R+X _40\7>Q9%:))-$"7(>*-%[7X
MDXKZT3LO;GE:YFX=Z*7%"3 M+_#[^Z0[!)?EG+_;SF\&YEPI@O5LS7Q."<66
MM\[65)J2ONJM-8:Y0I:[<3O"M>Z$7LK5=<9F*:U<5 T9H5E9>F">C8'I[$UB
M@)B;@9W^)=8$O%Q%F0;A<8:D&9_ZN"$@^V3.0Y/XUQG14>>Y3%X+L3],2=-
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M.JJ8XRNA 03KB,KO.G9[=WL7F9;[PE.0QP.3#Z]\.*$IK7@42+^)HJ?4L?8
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M"SQ7>"^%^O>R%0+?\E>!'JA/O4F/,>=_-[^G>_@%;:S3;W1<!H_4D=XAS=[
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M[P3)0])I:2S_0A]E43]S2*$L5%$EO(".O79TK[*:O,_0KL(T)41P'EXMN9L
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M')_/S:DN?"/8\;,P76HM/0QOJ.I; I5/)94'IV.BUSN%$V#!W&^P.@Z/Q7@
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M]^F.<<?_W''.P^\A>9AC9V3NM>;\OOFMO=;<=I2_@ Y[+YOGWO.&3=+\I?O
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MI/!E9%C4(_OH9NU:E12@R%NYF_@RSQX<2:D8S9:*G'K@P.$M@/#2CZ!E=%E
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M!&<\-]'##4A>+F)^(K30DUNH*.EV'R=8%!#Z"[UR?;+QKB/\$ ^]1%VWP#"
M$"YW4)6!"P"WD091 SLE/ 8<Q453O-SO$^RO,Q;#G>NE0D= 8/MI ;O+!M+Z
MD>S"'7>2KP<2(AQ-JAT?@K(QF0_I39R6(@TF%:5?%D<7)_<ZPW,>:F<8PTI
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MOVHG*]P?.M75;)H7Q:I":5@N;IU4&&A!8,*@K/-ZCT7UA:]&5'U2+VO^:.3
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M^'G/7&BD-^D1PQ"'?#F[(U4-OF ?SQ[;\L'@;W2B&\XU<4! BOIS0L[8WEM
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MZ+C.=\+.NJ=ZUB4$TG2&9'K6>Y^CC1*HQ1Q[ 9X#5".HZ$949FZFCX#,'5F
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MUW@I.'Z<%/Z52@9*NPM'Q?@++8K\21VT\TRSZ.#[4DOQYH6N[6"93[,B'#4
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M7Z*7?#=<;/+6N^FT/JWMYR+R1Z9_?K(WJ+>T^.++N)5N+F?1NBD3^RK.Q!W
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M$;7&#8>/B M2EZXE:C"3BMX$ +/)#W=O*,4T[XG/KX>@?%J@"K<\L;UUPN@
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MCVC%5*KQ[5;1 @!!%\2GYVSS#;]YR"7 '&='MJ] 3"L,($8.A)?;S7R'>$:
M7/I[Q97PYY*D:88^MU^3QZDRM0N"LT,*'5>9A[Z)3CBF*<<JVB@GM<2#R<>S
M)BWC'V82"P_/BR%M&6'"XDZ[N@:59Z-R%W;* ?[+M3,&MHT&LV$U;XX07S4]
MHNF&R?.TTTN@<<P11OG._+3UI*#"7CRN\L?+?[A''V:OIE# Y^ H*9[F#?K2
M=RRMW[U)%<D3S(X)078*GBUH+N<1F"(RP^X*9 !YIT-M6VERN#91IZ(9]\*7
M)2Q=386I()E%:T+9@)W&F,!!?!XQI$*K_F&6SG)VDOH.P 9+U9Y!' :D;*,L
M],:X(L9C..1U,&@<-AP5-;CDQP4[5_??"^J-@&5J^O6J>WD4%(KS8O)YR=7$
M:I1H[;D)7IPG>%XPVK\'D^,4P4DY!9"@WWL\$FJF UIU4=VKPQ334?A"7##Y
M7;!%TKDI&9$LE[1EX(%YNY!D;3<HU7]B5I2$))!$=CLAK;*+Y)2W(*STTZ2+
M?1 )JE_I75N]OUM!H;?-Q=,[P _9_K-UBP([$4.%=;YF7*?7B_29Z47YQQ.;
MG+53IG9/'I2-YJHX[!:?^OJ=T"99T;0_Y?R6VQ52_."*WVQX#J"M>L*R'@[
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M@*:1#X;>4@B+%T-;:;/*0O@'Z?2:<CX2DAP6#8KKU=E?KD2]6CBS.I21JP=
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M9$L&-#;U9DU!VCKGE)+R9J$N?XR&.+ 71*?(P_/Z9V?8M6VFORNDE,2QH7%
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MF\G4241$A/Q/Y?OU=C>^:.3V6S&BGZ^ZG6-_SVO01>+"%!6X?]C5=A=O:-S
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MUBD&V<Z]]F3-A<@NO !V)F?7</%E$FKIX;[WU]/OF88E9B2 K]@=Q/L.!5\
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M.]P)1O)-( XSTN9W84;4M,PGOF'C],.0,QW?3G'Y0N]8U0I 7I'N9M-[W1=
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M-01CV7>:=W%B6:BWU.KV<CA_1^M*R&-1A;WG",;QJY>G;A"5OHO[RKO/<B^
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MVXC-D*^(%VB+;LCAQ3K>_)*GP:WXRO)0T,Z59'X:C9S'MGJ2X;9F&WV*]S/
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M//CHF8%A@4U(Z;.N8-=<3,J01Q)6R*HG_U>M<RB,T'O_\7N/9.:E\R7E:!E
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MYY>4:9F+,M*J[FC88<M9AQ O=M3::!3A>[.GR :;WR+9,/#%%/C2D3]TCVU
M\_'^E7NN?5UVS3E'DTD)P1BS^#, _$&J;>&>RL\X\UR;;KP<)^QF*9#NZ+I"
M<6S9![_=TLDMY0NT.1]*=_S0#B6+5&><GKXJR'_'#65:3*SO)C"-*\I4.GJ-
M3F>4+]73[(Y%&R9T@8%:^;N&:DE*/$_AWD_1EU!.&8MRVF.-%YCX]B_=YE/
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M+!)Y6UM]"A5X!HPZ3R&+G@&G#/<RXQL72AW__F]<6_E^1LK?/4XBG@%A5\\
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M DV;L\;$MT=D!FS3QWIZBF"=-\>ZB0@>]\!63H1M]7!)):-2,!-2_Q#<_CF
MSX=&G6;KDZBA?54)VB\&>/T6,/ ;H4!NP*M'OP_]6I+KV1DO=O=G/JW.)3DK
MW]E,:AWR;,;D9*3DV3>''K[O+$F!$RYP3I(]8K2@T'<SW3LG7^62$7RWM1G8
M$Y_2D'T&M+47KESA2X:;F)*B U3T.Y^4&O;S)5JNK5G@XCT3R"G%NIM+^E[0
M>"'15U^HPZG4' E%C&J\^-G$TUJJ[<S8+)-4$,UJ2J4&MGJ0"/CZQ@+G$DEW
M\0QHF"5=<17QO3NOH+NFC99\.@PL7XT5\/Y&*V.](S#."1$1#\-YK>A):F#+
M;  7R?+5[^<CUA(H25)H4A16RIPM)?-O>3E,5X"%*Z'7>KU(T9V743F\4VF%
MCUF:D/)-SG8?# N5EVH904X=T25QG>BU;=04AP4_ \@0GIU.?/J"FKP4U*")
M:2MQP@A@4B*"R\&5YQ.R?QG&"-@N/SVC950.W%A""!DE/TD6G/?8KFH706H&
MA^JOH9*Y;R&_7J^2]M N6ZC'M1PP7B)-9)Q?]-"!3R-Z#^UI="K .?=J]<C^
M1XFFW=F!:YH^3E!O?L!QB:TK,)&1B@3;4>EQ8]FBOR0+@47I,2<VHK']B!/9
M/*FA@@+8R%3UQ# 0AK \N1R>\N^7*.J5^Y!...CG/N&U:BAK7MM"QS?N>A['
MD4:I>A]]C3PVA?5TK*LGM47A>06)!:ZG?ZNR2RX6-&-\JS@C&!DXP6D^K,?F
M,0[5$&DM\T@I,_]=/Y/+3BE(;V'RNU41?&FT0,C@"]0B[IF?9%0*]OBCQB66
MEGMAFJ&/35J81V,/^T@2\.5VLY>ZBO5U0N\A=TC5A,7Q^?7#;P>+QJYJ"74.
MHJ%&<YLQ2SH::3X.1?_Z6%BZV="?;YQA[8%3*UV*5#IU%YHA9%@5IV5*CU$'
M9\?YW,R&\E'IZ!6<4&Z ]AZ>X=&)\]:I9,NI,9GWB=-3I]=O%Z?:Q:Y]O,6T
M;#NKL7+]G[.C)EPZ0PI5&<4*J6=H2#F8 9-R>#)3LKZ;X!<] G(3G2$])66O
MPPN4+VR[ZK0F:&\Z4S#1Q@9$@"VZY3W \_H\[[OKQH1_02_<PG]SX*334??@
MH#[N8>4K+T*P.0LY4/=CW[6O- ^E3,Z4.Y:?FH?A _:XBK8"<>%+G8@%>E&)
M]E:;JG%ZPYAZ.Q"0$F^L<'9_>E3TR#7-=KH%SU.1CM/F<J1^O(KICN2R8,=F
M;"-%P(RM:^7S8/<#"T'.2H=:CS18^<K;V$H( 5/NI)87ID*;J25E%]7,B&'3
M53)5LLFP@64H99E9-1J=WNPMT[__RI"X!0S'?/LE@%?Z<-K^]^><&S?Q,%(M
MK+A#8L%"DLVXO1[)2)<]N<?Y0)EG@(!X 7C7[\'Z:FBZ\C 'YS!Q^7!VY;-H
MD-)L@%)<2LU"W/S6*@Z'_&(5%#.\$(M2S5P%)KM"Q]TW?C_ >;IE5]=8GN.I
ME0.!1MU?G?W^KM)M>_X>AQ)6^.X69CB7>^L+]H<C79X!S(&>_@Z'9K$2;0WW
MPL[7?V4M;Q+T;/> ^TXVYQ0YV4*F*-7.\#KE$I:.QBMMIC2(NW@Q=8"HW8]&
MXCCR[-J*]-,;NW7OG/>36$F#BB7O','$Y[3=8AV7V"LU*M@Q06S86!'HA227
M%L>'"VT%E] [CN_03"^,.QNK5I#\[)7\^I"3*H3T9-BIYE&LHV3I[J"-A%_%
MC'LO%WORNH%=60^EJ)!9DRDCR9=6KRWD:B,B=8 Y)ZPNIC%=9,84@^)X]A/V
MK&$L'ZSPI6'0<F4I09[.Q210,,#B&8 E?W>'R/,\KX!Y!2[>GLLL/ ,H.__:
M74-("5IU ZL?%D*6;MG%7PIR'PF*%1=C5@A<O=,)& +F4K%#''C3RC(,#5Z?
M=1!.'BE966?JQ$V9J,A9FR^>;.9HIB;F^QHY39()C5)_M(#'5/=5C96H^[5O
M1U$'ZA_2/?8^ PKVQY\!^6LR+,/+M2WS3SCP.^UXI\T6W_(">O;+V)C,"1Q2
M!483 U[C]\II%UA >UO44?S+47&O:)?&"Y/6&?JL)L7M32XILCW Y79*8.^K
M>LB:3UW &.@5:SS> '&*T:ZQQ0[&LJW=C-MMW^/R=_E']5N]"[I?!2:.=:D3
MGG2C+E<M3P^K1@O.-NYB":E/?$[B@9-C4,SJHM6L54M:;&LA3+O ;0)(,:S4
MQ_^<)%RU_LX=9^A(K,T.=;!$4:M(/9*;'2MU8"_,HOB!Z\*!RH<KB<% T)Y)
MJ*CV/24XZ!=O:'[W>>A=BW_\;=Z?^AU0GV3GD@E+SA$H9>/0X>%O>UO=ZN3.
M9QJ6>\ME[Z>\-"21GDP';_N(./E/1T+XT]";:CEMQ8N[+0ZL^V= )OVJ<TF7
M5Y*XH4 X._'!OV08)JYN*P^\SK@3C/^6,8)?D]-"2*4Y7X3#VNM*WC>EA+<[
M\3CAMW]GX7+VX\0T?-E$H:LI(+V9M577*[/MJ^B7:TZ=9I*&!::TZ(BI7V\3
M"B<H0^ :[+;MKZ@0/-_='\7NBW].HA#*AY1$H0+3NX'S,]TJ3:2\:, @#'V6
M<&]PYD()XY_ZNX/']EOMY6< @QB&[>EZW7J7QLYO>^?O>R=G9:NW-7'ZO@%]
M757V554<7H]_+*%1VY37;*B<<Q"8(.>[8;Y1 3<$0^#QZ,U*J5N1C6XTJ8#;
M>^5:5G)-U/T?V9)9A\YK$T2GOQGM= UH2JU&2H1I6)A\W.HPZGP%SY\!/TJ^
M>YU.W''[U0(_;SD/'K??/%G34<WB7T]:JW)Z&E <'+V=F!(2<_MX(2B:>*$;
M(?20=4B88T!VLOSI+UI+P+=F-B6F[)P6;@KIRT&L5I!=?4&FRD8^MR>$\-UW
M91FZR:+,QX+=HYY 7*@P75(/:J#R7X61!-BRB96)W 4>VY=1+ZC&3D/ZG]-#
M4/3.T46S74RRP\[X=D\(0@^B(&O&J"4G7D^C667.I%V[DL&P=KH=O!0<!4@,
M00#8*@O1FTEZ1P9%/""ME]A=CA>J5:6*2AZ_.+3D<!7+U$1^[8\$Q[;]<XS,
MD;,9Y$<:YL<A.R"TR&O!Z1%Z[+^@ZVA2RX6^,_G1OL$OE*ZCLAPI5+ .5*[J
MS*+[O/^V(B7!WUL+<0A$U*"-Y<^F?6QK3!D8962*HXF"OZ*'G9X*U(6CMVS&
MZ%4X^^08G*6<@E'?I&MZXDMC\Z]RJ,G&:"<XJ$<+C_#LO;R@VL&8\%^86FKT
MYBZYPTF;/*$9E4X_K.2X.<7E:ZISU:_MEN&6I,Y7X-4E-:261:\"QAQ%55$J
MAWD\V/D#EF>M0N#3!IK?I-Z53*=0Q%H'>Q.% !AI?0Y:][URMG;6$$SIVCJ5
M@*KP2Y812\K0 D[/SRM&2)+XRTBBQL,&HY+B[_R_G7N'->?A%@^$7:_S^M%3
M/+#22;P[.7^Z?@L/XN?B4J/6"B+1HC(.8[K96LJOY@RV9^\N?3RP!;&':A2\
M]]B'_0"7O$=(S-'[-Q1,O>GAAFDT0K/VQW!W[@H6S( /-I^VNC#:[ZL;?3<:
MO22I)*3%C>S#KDT-,_FC?\R:VU8=,I7U875"+J4U#+ O?5BRCP*/;"K?C#M%
MK$_.G3*^!,^E1S$:S&.E:HE,;Q/3IAV(NGV;\G1MXY:VM+(R/J!4I-?ZQLZ?
M4V#:^ QX]PS8HULS^]G3V3KL][EU\>BTHJNUX!]OR:1).#+F-GH9[^_\FBOW
MIXSXGSU^GZ/R.ON::_.N6G-9<T7(1ST]'^'&DP9',/E';FGWG0XT1+C9C^J$
MF=TY89-YM2UISB)I++)F?%9,2:NFM>G12Y5_M"C];NZ\OBR0\V9]^&"M:V&-
M('59U*0DZSBOI6# VMYRR1NKMDNY@STN?V]\1C4%#!FYB'*[VJW &M%Z9V[I
MI\&Q<C+[[5P@_ L)0TRR_(?%8K8M"5^]_^JHFIF[_>>+6)"[5,23=)NO=@>P
MJSA0SRDO+W%XVVO(KUWHR>:\+):0EATR M&:PZ).U=)*BV#;&>+Z"%D 0\ <
M70URSP#Z%>,1R_!U0C5%0Y+'ZO<2WLD'@ /X5!XWO51*U:@ZMI_199GTU2])
M3PFBQ#V>QYWO^L\ /E7UM4637-JA8].TI27OIER'"M]J/$D.JK\>KA)<7*;R
MY8WE=6V,8"4U3AC6G7EIK)& 3G+'W,F"^:Y10%0V?M.(W.N6=^('&%A(FWWU
MV,\)%@7>E.1H4@YE#@7-^0*/D>.H53DW;P] _TUJ![(GEJ?([H2:+[Y3H,?7
MSP +EH?IFZL-BL/-I\('A5O?C4^VT.'$A8W;!.#O9X!'&NUMY-G"8\U*P>.-
MVC. ]K@^<!4ZBMZ/]/GX#$C +7@:SL/YOR,UZCXK'_Q.5GW_EXS=-C_1VJD9
MIF((;V%28[W'*XW; $./I[[G7D@DK[0ZD).#4^"K[Y"989W=XL<+XG=C)V;.
M"REQ$9U?8,C$J%[?NQ?3X2?:TR[_TS66_P7^F\M4!_E_,91M'ECV72XQ?FX+
M"PH1)H3N\$ T=;1'M?6(I[8.UHM]#$&MY5_PU(P_&L2$.VM<$V*P3'Y<T9X%
M/P,2<0L#_<.$=D[WI/[M]:<"R8S<S]MG>D2< NF>!E6E51EYM$7N/A(#?9"^
MCC?);\KC(XIW[&:OGP%XYA3"+Z9U.=ZFCB!-*+A*9L1\\W8B!^42X\U)JXGY
MF'6^Y7)>7W->P("8DN] 6JZ2^=-J'I9T>P<_N-+:,?YS>QQ3968EL$'5 +AL
MG,9@ L<:8]3#9W//R5!2^E F)<1Q!R=VQ6\9"+*XN6Y;U(\ATEB:%EPV>^W[
MUW.&&<*4)E)3BC_2."S;J-4O@B9J09:WK8# =V ?0-%Y36"9Y-PX-$"0$,4C
MZEU\I(1>=&LW?'=M)+'T9]*D2$5(F\A,)UF[_7.T;2XCS3I__\]J0+1 (^KA
M!\--9QR$3=OOD[3-N]!I#;=%[+F^^I'@N4_.R/;1TT-F/B[Q:LR\/?V]5TY0
M>,-:@5([L-Y9=/9$ WVO3=SN\1[3U/'M"K/2U8%(@MW!4?%U'U.^DH7D&VDG
M4'KGT+C;]9S;7<M3-N\0YD$=:VE\\RQ)!1YW&$UW1CX;<BOWS/9.SC9L-W0U
M:3D+=I4TG!!8/N!G_4'YSH-MI=1;GV 729M 9_C7Z_>2.R>QH LD.EN+XMP]
M(X:+/4Z  Z]H[Q")P!0F!? &V#9:M3\#N"6P"MO)'%\'X>6Q<\S4K/R.6M,Y
MS5WBV_$ZLR%#&66J&.H=)TB]ZDS__-7B@-VIEVEQM:5%OD@!-WY5TZ+X<H4F
M?(5WIZ)J=$[KS-]8JQ.A)Z= '93)"=&2U1?W#=*23\+L$.Y@-DG".<>-.BM-
M!;]&HB(#DT76GCJ6\S(<387'R9-^(*[1XYH"= @8:>5ZM@O_-CA=( -86]U#
MO_%</@- &L0K?WDYKY;8/N1$%.<5)86-CC)G"5C::PZ01BW>F_8>M<0__>Y[
M/?O#]P\ ;^IQOX@;]VZ5%Z$EEU[=KZ.E +8]J&R]\DY'4$W;6X?*-K)JUW 7
MW7NNXBA/Y'Y88XOY"#:-3]2XR5]? \]N,?9NE\ZJ7^TE%%(L>@>S#!S=MWR-
M82!,=>W,:K#N:2:2+MF%;Q',%WI0/!:N9?U4_]BZKO!:6WSQX%==>77AB+UN
MM( :2CYQTD\K+9Q^.\EX8=KE9H11]'8_#?$$@*0"=I"B=\;5P+*J]5:/.3*C
M2"%'? B%LU31>EXY<HZABXCPTI.5G"J"_I5Z"R N((\@*RV%MF?\<8VEZK[)
M\LQ>D=TFU\YZ*=XX#2$2L_$KG?M$< @N@^FB^I&8):&/V[E A3W6-863"%F_
M F?S\9H_.((['/?#5H2WU@<F=W[5P7IW7:DLZ)@EK$TS2ER9W^L-(4YFMME^
M2.,89CH1JD^)*9\W)U?$C=32[J[OOB[5OJ&[O/8S56LU0$W2&$G6^(,;MWZY
M<IV7&9Y;_^==^<H/#>E'B0_%>J72*F-*&BK86-%V1288?[DM&#Q7EMA7Q11-
M*@/7Z38/(!(AY-]>5F$%4NHM1&.4JN-M[:P$%M"TM9YAX1$.JB4D%'-)-21'
M$_ M#5<D59:5 HQYL62 *]G9E8A":GX-G@*Y5B-J+_.0BNF6UU!ZB0 @F<5!
M7.MH7215E[C#&TJ!# -0('.$>=S^&<FH;KS,1O MYD[#33RW()UZ0E&KS+(]
MR.9!@MRVE4YW&KQ]B5@B&4W$$2#V2*NE!>I_7Q=2@HX:*E'F9;&Z#M;%NV+B
M5!;.KSE]!'B00_I:&_:4TP:MS"L$F?V+=6"6?W#XE$W6TC.DJ:NB7MW#$"ZG
MB)>7<\UXDIGD3MO-U5J<GE:!Z@(12N85=;F480,6'Z)T2O2'>B/)<#YP*DG6
M>_$6%%P<'=,5'CX#"#I<VSF=G"6:LCH? ]\GE&-%N9-/=2J5</ DD>\IX=LS
M>^+K'0<Z8G2F:->+*]^Z(0-CN8^7-B@RE*N^[-*28O W#0O-E^90@!URO'0]
M*I*&/X#O AB#K]M:7#589-O\9 G]!9]Z3CQ/:[\BV2R/6>W>-3_,]S"+US+3
MX.Y1SL1T1I-D1#. RRS<W WF?GQ%M-&N9!S)B4ZMS-6V>J(15-/Q[M]Y^ OM
MZUZ;0;2W/G4MD,U]51._FI[1FHBKR"M1R4[>2VG=*K;MVXF28'>DJ7=-46)J
MKR2ALP:2+.OWXU $U6=MJZ=T'U]@%+?N$8:2M-Y,T@EGC$"&-1F7FF8V=5GM
M=G:/V L[X)/4[,:'3$0.=FP,C<E&[2V2'A)D9Y]DLZ0P?EJ<UM?+YC0U^AY[
M#<O)):X'##9RL-N7YF-">P@UU/'"VA/D8[SU5*IS$^E^!>HB)^7:#SJ<366D
M!GBDN7<FSTZTYQ0P_,X,[4F4 ";';>S\:8Y5;1AG=AP.-A Y$\/E=(1PU:^U
M@.I@=H\8O*SMQ+9BM1]OM74D-L3_<P4T:,S<3Q2V\[/+8_YV2*:LO*I7BA^N
M1HR-EG!U+8!?R4H3P\NY2L*NGC1,N42&\8A13-R4[U7"3K>,=Q$8O!IAW\J2
M@MH S+ ?J"3XV9'0/J335C;G(7@5J*_?8)3_/O=U#U7'HR/(YJZ3L^LKJRVC
M1KX1,O0X#]?^JTY1V1(-KWJ9A0G8,Y_;@. #UGM&9?A2L2>:?=P3>I+HVPMU
M[2UKI-G>471S2?)BCR3HBNQ]/DHUCS:P1LRBY(RR2K<XM>8=@@6B&S2XEQ*_
M87B@4C42LB ,5W[@]DL:WG+913J'93PHT[^PT-C_3R'.'=A6V#;UT;QPRI(-
MV&:S?4PUCI9U]FUXIR*%E7Q=)R'9O"($3>4='P1' ?R5[ ;BYGV>@_K@"VS=
MO5WX5CG7?_G4C>T7ZWFU(;55":ML\UJ&K;J3ZN/RL&@D5SGPK\XIA<444YMS
M4%6>\YI"PB+^JC:.N@U'XFG\N;KZ3E.1-#>,WOP4-GM2#[GK\4MLZGK-9I21
M&C"J"6_QT.\T1C=O?:%&D'P-'K1C3/]!G*B]R%03^\'B"O455X9X?HQ-IX_&
M735R2HI$^X94+7"<(7G5T^-"08N2LJ;,'&V.V%;7=L<[+_M'62A_DY$^$RF[
MHU4,_4L,10INIE]&CWG\0O.CQ<7#-+(OM=X=:JBQ&]3ION_%)S=.(6X9-9^H
MZHT7VGQIRS:'C5V<8-B3#NJ;E>URX!78BLFD2ZTF.*C-9V<7Y4-#)J%&62!$
MC+XZA&N[^W0TF2JH>AAQ?8'COQH$2;;/G\8XU6IPZ?[.JV;WKZ?V\Z/3P8Z<
M_IEO8*ZQ@BZ(]2) ^?U:>C>7[4X"^#\/U-?+OW/:4,T)]KTG9'N,E)YW\-BY
MB*?A3: .9(]2;/9N@_*4<]&;1#%O/!K*=S]UW5LDJC4W$I7JE7\TTB,A=GH_
MIU//)5L6$1&F'Q$?<L @PPHP[:6K[6XU!7%_HY6['GXOW[_V$.EB551#I#,W
M@]!A%C01CYLB4.X:J-/6C94]H<[G*BV 2<X: WW\[PF=+I4704>;,\U+#S9<
MG>4_YV>MPH78\P,@Z7ABZM23F%&RKP^[3]W)?>-#UH>7M$?((M\#7I$\M1Q\
M'')*_#4K_:@;RV&D1I\ ]/V*-FW_6:K..EH%M70M&%S4SJG0O#ON689V?J1^
ML::O5AWOLU-9'JVJI?*2+]W$>J(W4.D98)8/DCR*XLC/"$$)EH(N'<2<G2T/
MZB&^=<1Y> K&7<C4)?^L&B> 5X8/8W/Y'35@<V-VO'V5?LA858]W#0TM)')U
M7FN^!BLW@^SV/9Y@;#]YTQ$^<\1Q#:.!@D2?D.7S-[463#[/ )Y+CU$I=U]Y
MJ_,LXV[Q9CL!2-8=XN[=7;/R(JUHVJH<, 3\VX%&N?_>+-F[S!O'5]WQ5[M,
M->CH@6U&9N.)D>95*F-8?AGK:P6B'S.2,KU6YFWNK]S(29\&=>%<!UO(*:>_
M&654&G0RR,"03.-FRIKT[2/0XD';[DV+,]/HWT BRDI;=JU3ZB]!4A]=:P);
M'>B&06;6,ZN8+WU9J!PSOGC[;C_F,3$'I2PG]V($ >@2ZZ<?9J:4D>PZ?P8#
M-V[K<LH2)C>=%1O(]A//;U8J);CB8^!IC\<()4$[^D2[L6T:3BXI06V6RM)
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M>92GO&E^*0.9*J=8392]\)I;^0!2<>/.N 'POS8_<O[5_JC9%5HM+455QXU
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M)62*J$?&*&@,H'?K:)76#- 4^A(T4UB\PH._5*>+V)TCD?KVY*?O96BM(NM
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M<#9+SIM1III#_I.9'TUM=>;(IEH^ZPOG&I5G?!&T[+$:HF(B.9C8.0J[-P2
M3TMH7 1<3WZ0%@%!C+;*MT3JN$4=8WBM%X" @C^73^K*<+TBVH>]I0YAN)2W
M$'U!])KX+)<;\-8S"QXU9B-4@\%E4E>K.&'WBFA;=NKQB?O>AX,,XYDQDO&O
MU^YM'907Q"]KM\L2X1?-3&XDT#R6 7X7,P(BR?";?<&L+<\\P#Y\"@D\V[V2
M;8=ZN#9*4&!?0W*AF-AF6R+_]')/]7RG)'HI_&O;5LVO>NJ%,*Q$7L6WP8D
M(M;(.;E=)_V];TD>YF>7V\?)!ML8]]L]>-VTQ=WZ]I5E0X2U/1YJA&+J:ILW
MOWDYBG85+?ZIV?32G!FC$K=E0/J5+V'>>'G2J#=8@SLAGM^%P(5K4E%6(%]$
MVG2I^[F\_BW?$X>PS^54PI@E3[KUHY!O1HXJA[:5@C/Z9-B*UG743Q^#$MNH
M(VK90_KG3]R+#6[C=!&R[E9'[K_\OAH]O/^AB)[U=MYC7"F4OS@MI8X.8_.9
M6WG;?B>\HWX/WITVG0X-# P@K8,=UJS/U4QN.LV+O-!6,ZP'JVSM)M-39ZAL
M4V1/YK1RA+$13U7X:SM[:,E,F<7"B24W@3R=Q]W<%QI1S-!X;09*C\&WAB\4
MQ_\SQ1DZ<$4BG:_H799';NHZS&LNFWD+)*QRM#5:?D4<YHG?['B^<='^B. ,
M@C0'2F=51S(F_U/WBFHVRH\&VF4P-3"M2F$EO*)FW !QQ>L?2'3[CR>Y.M'+
MTA<QNH%BOMJ:I_>'6/#1JPU94S1(2&C)RAPLHA$*P:%!<8S7P%/JAAN&3X4*
M\2/SNT8F8\PEI3FE3"B DY<\37"%.;BBD>%P,9T*\4Z_3_!GGB!,[L.X>W%=
M+!E^LY!@/M2@.XA"A.9UB\6=F*.X3.[J2MB41W4Y\NO]9=;Z&G\!S'J6@VLW
MG97_ADBEUUNA;$\5MLNNOW"_DO@)U.6ZLSCC,FJ-07 V5J5DD*D"!U^RDJ"Q
MYA;4]FU+9YO\2)PJ(^R1ZI+3@[$)VIM0+1ZJGT**]@]\40#+XT]02Z1&<HNN
MI.B#[!PPG-!5D:[JLHG*12JN:N3UDR:[ZY/F+<3\O$CQDIXG>MPWGY[K_ '>
MH!JSZ43HL-_1@0)@43"']]5S+G.3<C).E'#MS^_#MWTSV352IA**4R2"7F'K
MDI@G#^DWFQ_U,RZN$;E*=8&W;K\I'Q]P3VQ7,EF9T['HV.B1BU!C3LW4>I(5
MP&3/9=;?:*KG.OEZQ51%I.2J*2M3VW)JAKW$0 'JI%=JO9+&)E(JK2HQ&N3*
M[IGC4Y\ZL6 KH_W/V[?10K#_(%C!\57.(C4A_]2D\?Y:<+W!.5+A&E)06F8<
M\]8"O:+)J'64# FI9-PZ+J=&'&P8U#.D-+]U>?:2<;O<8';E>0]_^.WFY2#0
MD5%'H_ 5"F"R$B"HO3_GYL(@S4T'O.GQ[OVOHA[^;P)U_9V "P'I)9\KG]N$
M)G3\_DDQ4H+A:*E46T#!V/WZS3^?L%+QC9>[*D+H3#?=[SP^!3#?IVYCV[HQ
M%!_RS\?]='$0ND.6'?%!Z<3N@+=EAH=GN@3%>HG4/+Q!OOBL1 >:O09_]QNZ
M82]/)=JGU>T:ISS8HAA @^%VHA4FG\@?<!_\#MJY_!=;77)-:[\VFF9&X.Q8
M1>/JZ,F)<GB+/L@] %_(+M$>%]P=^)W^XXM+@L@6?UP4H'^I%P7H^R.[SP][
M:KID_1>63[E/?_U1 ,E-%* MH0<YNN&" DPI+$+NKL<@5R4;?9LN&Y"-:\:_
M&3O();^;>Q3@S\9I[L8=#/NIQ?OT6NG!'NG'T/WOEC8U%*"6X0D%>&;W@$0!
M&E" K^V,UQ.+?8LH@!T*\&4=!?@I*7M<4@]IDEB1_3M]M8$,:#)_<K@YO:65
MV+AYBGS<^Q<%;68]R+X'B8??-TB/ 13 E=[_*;EWZ9\31M:A '^/4U" (^4^
MR/^A%5>G5RC 4M^&1-_?!*('AZ.-/_'74X^7TI]1@ *73!3 6/H!B?7CYM^;
M6:( KS[('F?60^J1/Y!W/?]>T1VRHFR& MBXM4'VBX[Z'A]L^NYG3C?.Q-WZ
M3A^([B8\4 "7'O\GR+7;S8_3QYU0Y#+PYH$UH!D%D"8R10'V5]A1@(7$0!0@
MN#D !8#\@OPT27RP/=HX0@&:(;UND'TZQNN9Q;[_LR5N'@ES3Q^0@TC/5<B*
MH-E_F^'_ V;PZEF6Q73JW::^6;^"DE6,VX\<JQJD[S(FM:8[4B463"U)P^Y3
M_X ;GI:I)%U_'GLEQKRV96N?&$K#@_P4,<^47SLZQ<I1/5ZHK3CSCP 072>G
MFM^-RLHD?OBY]-K<PI)I946-6#UJ1$ZMQ3WDE"\.X&B?'@N2F@1@KD4WX/$5
MHJ6^QA98\NQI6C8<:E3J+!RS_CTY LVZ2P%=;&(;7O6<+GZ!N7]P8W-DDZSL
MU]XEP\/4/@#0:9+XZ?D##TK^JZ35_P;^'P-5PW?>*( ;)E('<ILJ8PDY+5QE
M^-EV>D-QBG2$H0 &.P==IP\.LK-]3\:!E8G[>QCSC),*^P%O7V;#[NT.LW;C
M"-]&W8.K5I"Q.X_R?9V"*6S$QZ/EHU^1 =;['<34$A*6!T+(.2_]XB%=3>'1
MR?&N!>*#1K0[H55\$9/[BXV"\D:W.<Z*@Q>N] UH" 7EENQJ/>L<B8N*<(RC
M'0FY#]_0;<2M )2[E?>)CK^[M/LOF_@;$!B;]X$!>+2RS]*&)_23*^O*1V=@
M>S!P6O4;K(CG,ZWA.UB*X,LXDJJ #) 7(U:>8,1:VG1"X\*5$B*_TG[ ]<>,
MMJ;>[QD,6K_.KP%$1X8_H7!Y/C0ZA@_\I^X;/.>R4V4;;G[S3G[ZQ_EAQS5A
M3<IQ1T][22E4EA[RFN$5S[_;?B(@B&E<&A)T8ZTP,5/'/Z1)];395%9E6C&3
MC8+P> D(#C]?J_0;;:?4G[/4S[;.Z/TR +/6)\9! 3Y1<S[W9?REQ';OPG!(
M''CKB*G\:*XIOD"79Q$BE!_Z9T-[J^V";780I&BB"IN@%R5/AWQZ3W[^3W.3
M":6R]]LGT3*0/:SZQZHZ^%6[:M?)2?YG^J@*UR>EGU6E.4811UJ\COF@3')0
M\9M):(@R_\?,MWO>Z=@(CV.'3M[!6GQR*33$1T6XO^M6657]P(<MC+CRVU:S
M;=A6B3YS^I^0#+WS(^76M3RY65?.%<% 13]?<:@LZ_1 \(%K-2:/M,#,Z.XA
M2UX51^UJ0*S$TLAPG/90GVUHF6'9>3=Y=(X]3_2/X.L$M;4OD$'XCH4UH.[C
M+I#X?,W4-(18/6;)1":DN"Y'&<FIG32^,#Y3%LY7G(.GW/C6G4*?<[XB#&M]
M5NR,0;G<NGT6!L42@4K\UN^2;1^R=##* &KK=JOZN?$%JC&)+ Z(_B#I!C';
MV>I?B;7P#YIK 0/X*_=G:TR9NRLS_(Q[9I2?P;12YG6L#S+>$,A'&S&7A^"@
MZ7I^4QDVT>JMPXZ?2CH\)BK7.O*#IY(K@#/'3EUX1M)BI4>$B[OT_PH>4S''
M&!@X)D(57M3@SNF^?ZC(6JS*<N"%LT1:6]_0@O-F4_(+"#S#MT>FIUO.E.GX
MQA.XM[V<8JXQ%\?8MB6O7NJ)[VV002HN!X<K+IW%KX>/*CU.V;'L3PXWR^*Y
MVI[T7S]T6=.0L\93X%;E30,]I6*4$7/%R&FI/-BQ-#"Y@?&/-TQ"O??3A!J]
MM)UJ1,@W<%0XG9:/@4$2SDR^;RA"B[@'<U%SWZ![2&&A1Z2F4HP>^XK<R'Z6
M\(-,WFB:4CQ00;5\5-ZR+%]29Z]VXI6S^9.;VZ>$7-8A*:'9->">T,P@YY)U
M83J=X]FVXX9&XFP5B,) 0)Z.]ST2[49N5\Q/C\Y9U<OVDQ)'M\>T+DQ;P8#>
M]35'Y3! KSN/R>S[CD[N+S_%>NO^^2$4X-S4<6<86Z>)WBAIC!6\8 VM4=E5
M#AYFJ= 9N#*Y$2.V4,9Z/!\>L(:1(82B$Y[+3DQ;RJK;,U5G.-ED5[(Y_) 6
M7!FC"Y(4-QD]&Q'M!/<_2ZR_6DP .A:[*<S>W..NBN'O%M!G1I<3*(AK%S;T
MC)2'[P=")%  :UA?@)[4?7W$:" I7.*C%X&WUS&%)A;OA .7*]OF^]8E3I^P
M25RPL[LDP./4\37I0@[1BX7(2,6"CX]OQO7U='4W#QN\R%2*N1VJD7<,PEJ.
M8,[H=&5QG87-7^[*S5RGH@27<QEA=6AU0.=E<_('(@<;ZRFX^*^'C.B=T!/6
MNDJA)A%>&ONRDDH.13R(ZB%RFH[1W_D<63*;(=Z+BW&_6&15;;6?P0.,WUO*
M=:-\,Z"FIM'I5+D7_S.>N&B V5'-5#V8<L\PE\AQ>#"I_UF*X^!4B;(ATNB
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MLQF]@?Y63CNEJ=ASQ/?Y 3$1J+09L"W9QG^UK>GZJIPI7X5I]2(@%\95IFG
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M=$)J1)2KPX/C8=-(E]P,R"\4P+[T1Q/VZ#^&^4"/]5!0+X&U'L+UU_!]+TV
M65;3Y<_DE\IP4=4C\@6U,]WT#GA@!E;&XM:W>WGOQM1=B-L#/6O!!U&/,9;
MI00Y6_:<PF0+ZC<A$_>)Z"C <6_^O-A9+0^0S[1+)1[0CP*(!0"S06VVE<1J
M?"1) H?%?]HL #VWC(5/D/)[Y))___=T>JDVG?9,3=QVMA<@7I:T:)V\:=71
M@;)_.4X<,WL)K#D=(B:66!XQW'^%>&/8(06$<? 8IZ&5;!E9:_V+NT1HS_L+
MQ6.W^@<0Y[KL5.W32XA 5^F(GO#(09DBWT]H\FI=+1M6QWSU@0J&X&QLZ$F9
M.[#+=8,O,$ S(\3X\QF;)T70ANHP4U\VO^T\_:G7X_EQ)2>F(U(CCJ59*&:6
ME5YSB-_[[9^TZ4F,0'9+=K;&!O:(\@5=(^O?NX1T]S]ZH.=H![]'1) E,TF'
MIL=91V-.U8<\IG#*'*7OH\;%X<50OVA\X9:8;7UQ@G,EP[,A(<"#8+?B!T;@
MI5<5SE2FJ@QL=/,U2U$[APA72Z=3"&LJ<9KP:+AMSSK>="N ISW*,0FC&9T.
M&I,9;CEKX5Q!3W$\T.@I.1=CO(R792L569YZRN(<A$,R9*N/@0Q@/7<;%0K9
M4<>^ VI<AR?*0\V$':WM@K^X4I2G ?V"%*[0-]163?Y:#D_Q?M%>Z$W[QW60
MO*5017J51/6O))E& %[/,!1 3N;;^<EX_QFB+:SR0'1,Q^:(@2K[K1=2GW/<
M2/.17GGZE_FA@"P&K;\>60Y0GHVM_1@A9M3F28+[C&7 PV?+CCD;WQ"AV-U-
M_&/T$04P>? _C#2F^+$+='1MSA09%9+D*YU-P6HKR3K$#,(&R8FA3:$O[*^'
M3Z, !H_F&D_<B*[NFL_=D'0Z\PC.OT07X_?&G]RH.?;UWAS(O>*<DRWQWYB/
M 3^9;R'*6FTEZ;%]Z61V!_1$X5H&6O-O!H;.E50!F['4K+Z6MA::UW]4*-#7
M3W>PZ/68;<18([7V)K8]Q\\_.##@Y;A//&K$:)*V5S3COD#H  @$BYW=<10!
ML:R7#R/_V1F*2.4Q?SZ'DI71+'V:4)!>3ZJ:_C^5B^6V62"8824%?Y#2W^S*
MR]\]T0L#5>:G]W8N6M+2N5_H\W"4V8'+#_#_]\VOG61.$NNK<33?I8!T#Z%;
M:"U/U&*KB8@G_N-EAIXM<(T['F*--8;DU3W>QWYKY,I37X]W;_/OQKOLH@@\
M]QDP_V/-WZ>N5F37@!0*4.L6>*1,SW14:54.IC?UUV22&G[FWK:]G/4Q4"9R
M;3;10/Z]5T*-GY64QVP*GU*Y&_/^(VAG)4X.H?,6M ,W;DY44=2C;%\\1\)6
M.*$\7([P#[6QS!0-NT_290>C08#__/57EYF]+/^O,HKT/V0!PV+79,&9L/E]
MI-M-GQ-M- J@"AF$9Z$ +>83CYSUM8+#]0\<F@F0VQ!@+ K@^PCY9MN%G$<!
M9B5N-<&KLNA/H8_TSY&_$#__*S3JOX'_NL#_M14 3+(<SAZ2&U_-)[&996@R
M>GL"Y:]TH'HZ?-\EMP]."E(&J,CGJY/4^XJ8_$E<L3)>/M4C*0XY?L=M@*Z)
M;D_E&#0#/N21ZV;]*1R"3Q#,M J(YW%AQY16)EL;SE%T+*A12H5O+S+]7OEV
MX\7H7T*#(#\0BF4W%6E21>KG?W)[B:?F&VUG$816P0@7K#PQVT;^( , Y2MZ
M-0O>.]B(M6H+JV)$'=E[$94*!4BAN14S5F(-:TZONJ8QU+32 ?TF],>$7V6X
MO8?7N#=UF[ZU=)%D^R<9RHIN^UHJ0GHDC1+57XY)"87%?/9V7(O?YZY,CA18
MMNDV3\'97+G,9702%53WB0-&&CJ5Y*LNV2A^2Q9.9X1&->)77_$D#R/[-J6/
MY.K5FRD.T:KK4J@9$J#?H(_IG*I%:'G?OKS'K\T,"OSZX*\:/*M43@<1@%I9
MAO"#]<&SBM)@J2M>T&N5NC_+<2DB7,EEMDR=K!';0P!U'N GM@/02G9TA7%9
MDEPZ<=/LH<BOP) Z !RDP*2C0HP ) =*9ZKZ)ZI-@XO>A)*R];F*C$S_^]IF
M6[-8=/U9QD<71;["2%*,:NQK&>4VB]O9F@DM<HI+$)I,@K'!56TRK\-EB]6E
M.O;S5 ,+MCY(MSP"M8 QMS<YI8ILGGR-(V8ZP8I]S9>=&/BQ29IM744*L_G
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M&UV'+HX099D@X:*FQ2EJNLM*<Q;3<K@33.CRN_P O@>A_,;54),N,0-&1[Q
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MI21<TM59<B5(9%YI17K_;4O:+DS38C%$QJU]QW0W)J6#,E6HS7965U7Q++]
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M.6FB.(\$\<$O4):>NO<N6#3MLAE+_?!B-G;0'>P]<^?.*O?G3LS]0=TG&3\
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M[HO%1K>^Y\>^E[US)PY)3R3W&<R)] B&\T$]@HO0KH$X(&M8*[.(Q=C.]8W
M9\TU!_$,%1G<5Y^0Q_0[*9F^9@2E,QF:R\2+8\SQ[S2OGIB0AZMY[?>8EO>,
M  "K@E[6$EG" OP%KH%.Q=!SWJVE8U,(7YOY(/_1@,L 3QN@R0%6 XG4JKD=
M0V(N(&JGSBWB9&#O,<Y)8V-^^H8G9O7OCRD-  6E:/LL.I:XN,4LX<&RWS!2
M%PF> 1UMHI"KKK]$&C7B/,9ZIM,>8[NRXV%-C#17VO.R8*,U+Q=]<4F=TTS/
MTH>011-5LJ\[L*BN\$%=(T^Y>6LTMO$LHA'R)]UG=A8KOZ]7OD^1'D.?T&C&
M:^Q)'XF?/"AJV6:2'3;?5<[,;Z?+]BJ/6]>)J]V.DLF,O?CF0T*AQVG2.E6>
M)\9]QZXC0ZRX* I<!)IITS>;PK$-WS!I,6 4S=DP]0:VLJ<I^V<;5B5+NS>G
M!1I)8/%("F764+7K33'EMM CU0R&8^D_(>YB5'1Y(TI=0 -"F1'SO%_H?^+R
MW)>E3WZN]?T6]R\;Q?@-&IIZ5NU6A6V*(V\E=AU=78N&&8HD'_8>#,G-QSU8
M"=/$*D+9%KC.,#Q'@K'_VU2H,-..D_RSL+V2#W+U#]11TM)13S91W^VTE+JC
M5K'1^!$F+%;2V6LBON"9??H+$)J:',8 )HIG3NN17JQD&M' BB1C3!$'/B-^
M;&B0;,<ZSHV#CMGIA>SUZYUZ%U[CZ-5PO<3C$[M,B%/^2%;6LZBR,->J&-<'
MTS*DMPP7+:5^J4R"@TA_!^+ZPPIX+F0-HMBR37MV1 /DWSU]LU! "=UW4WZ9
M5+3J$ /KX+:P/^J73_B,#^G:&[^^?^/AKQDKX_OOK;-/ R Y&KNSF?.3T\<D
M<XR>A$@#@A*,<6?O,D4XR+V!KLN4MEWUC4R$S<03Y=4JC>.:V@'(9VKG%7V)
MBS^*SZEQU1AI&TAK0R7&L%5_31OP:.!BTDW,JT1.*K>(9WN"$\F=3/Q.'V*O
M#--DW)7J#B9L4S?8U3HQ]EF?^^JO$Q\5RFCX0#T&;(UMXO&1)Y?*/?YI'QX9
M'QG&"KV] I#D"L\L,[&^GO 4JXR-HD;-VE<RQ%RYJIQG$9,Z$N3]$=^83>('
MBOB+FIMV":>E[+2'#&PR+V3@IY/"*ZH^ECC[O5L_J7<:<+!".+8%:7[&#O*6
MHT6GYE8QLK.)ZF1F+#NWH9YL]X01$&1$;8W_*N50^/:$@5U\RNE02>M'A==+
M'#/P0:OS";"$X+\E70%UEN4Y8R)XS[ :$%640>ML <\L]-6(*"(Q^QFI2<,/
M!>U23-)!Q%*TS/Z<"LKH-;74D)>:ZEYAVCYJ\@PI?"CC4;S[YI*5X/7_1@XY
M;H2!+I/A"0 ^!?L2*ZX"[X4BN%?8S$%V?^Z:X'OH/Z4U\5Z;FTTWQ5&$E CV
M\6^5(9Y)K<NH8]XW4XRB0VR?>5Q?>'I/;>VP-)8A8K *(<P*;*8;@[D:%TZ^
MB4T3P6#<.6]B.&;UQ $W[GCA!G6];J5XM2]98>'+RB^6_UZ]G&A:YE7/N6A9
M/F@.A@1$L7;?];UE1G%&$< 35X9IETE&F!W>4VQO*YA,3A/I.Y/)WMT17%%\
M./Z39L7%T*-CXEA3FGUQ=7[!7NIAU86G8VQ8YS6#2B"T([$)X<EK#-N0+L/B
M!&E G,,ABQN(=UH1-5H]GMQ:WG.:FD9'K^+/;'+^E,YM;BD*Z^[B&_KT76PN
MF9BF.D5U(S!5;Y_NO_+TY<283QK>Q-ZS^4Q\^T4I0) 3B[#I [WT!9XA#G#\
MBJ\V-5^3'/@@)7A:&B[<@V&\7Q5;T/7D9@D)E0*6)O6KVSJW&3;*J$>.'/V@
M+#?1/_97Q[77AQ\Y_R:GI;;AXG$]/:>V_3%<9]X3/DB+ '9 5"Z+;9-+((8;
M<>^A4C7V9,NLCBUY2ER,7Q!WUN"@;^%1?5[2 Y<=H:D_/C4^.LEY9?*;NQ!@
MH?1X(>0:/BC#C&G!*=J1EF#8+&+;^:!H;(^*#^9988]7Y5N= O@@9_;;+/G:
M\]ME(S9T^:G(F_3?".H'PM>2!N<]GLG,Y=3?*BU #9<<[JMC@NAGF.QRIM8*
MEE%%XX.N[NLM*O1.@X_F<3IVCM00$=<X],\42DA>7J7'RMXX.NA.+9,N\6;F
MA+CEFXJR=R[6HA\?1>.K7P\"U4(WI'*!#^J>_<K[MQ;>2Z[&IF,'0A I.A[;
M9F&8E+6,\A@:LD&^7-]D!.U(5HIJ<]O;*+4Q:\$3Q*7.GY@1O<&=.KF&;^I.
M"3=ZZ%CT0F>B:6KDNW3 EF("^#CD$B9B S[G]DF+/,_2VVOG>(F?;3=7AW\*
M)*G()7@:.3(NAKB6X=,Z1.*;W>]X/GL,/,[?6(VX?:0!4QHPPN<X]GQ0L[K_
MX58K[P$?M+<6MU0%Q$UZQX /"O(" UZNN)3S$*LX^Y7CO=.Q6+%,Y8-NA3D&
MW*6T8W8X8V_8K!K2];W%%E$# MX#?0JRFYFI/MD9MA[D*NMO.88?<?&4;/NB
M:W;T[(.R&IB5,;#P$/K<99[94R#KM6B_AQEO*;25?N/F<*(88B+;I7(,Q1,3
M,22Y^@-5]$#PW#/6#-HU^F2ZOUT*SFUC=5HVY'&H\=CRLN%\[G.:)Q )4Y<P
M%R2JS61]I[2&=!S3Q_,B7R?@608/-Q")!R(,/@B/;JT*Y(.>>/6MV' UGJ_D
ME=(R1<1>31)306-1BB:0\T4B^O^\^E&0FY+U\;#)>6 5$0>7A 0!7HJ\_#2.
M1NL]M1QEP@UA1S%3RYZ%(/!A$)3^W8[]C6S7CNE&[7HQJ*WE\;NE^V_%M:UP
MB!<=AKI&N\$W6IP_CAJ>*VIBF4)5]^46K* W]@?<N73>,_@_@2V8=($:@QWR
MG#1C<T.AC:(5Y_543/QBWWMJ0PZ^S1GEBO9SE5T*R9Q(C,DO#$JYKGHK]; M
MRNX#8"?B-J"+YMQ5@@3W+><84<.F%;+.B1C$B4-T]W34]8J)KO*$B0NA+?&?
M8?3H:&2;ZW74JU-+:TXYP3+%?F>KRY /+$?O[AP>38 OKK17IM)$L:D0.T[\
M)G99F%&JP\3E-1G\R4!\<F>A7&!N37'^(YN_[JE0WCI9(9\&U5,5J!@WZH/!
M<8MKHF/N'FLKW0-:HZ+ 8A8$%C-3]TN@ 2 )KZ!G67 T)IN=N)-83_I[$X<3
M7R!!)#:\IX@HWF+4I]()\;K \UHRU<_1$0'>7CJK?LC;6<D*RAFV3JJC\<XR
M4LE(P+#\PP?) \3]DPU?UC'<02Q4!G-G. ;;B4V_%%%;GB?)Z2WV4P&<G"H:
M-=A*MJ!C$)'317GHM8=&T#=4=Y4EA5V0Z$%K\^+"G.NN-P^WG10YU_?@3H&5
MWTC],]FY9!;!V4=6,),/NJV>?1P=1L<?S-D=E_,(=/C^H<WI"KYSP%P[B.MR
M^N;(L&59^$5WB7M/_XV!&32Q'M5C8@?VMKHJV0:FTHL&G3[T+>KN3,.9UADU
M2J4$$:VE^ AU>I</ND8F#@W1IQ]UN7BU*)R,O2XB8GC[H6_"R,A!K>]K"7V6
MP[I3Z_E=]BIW IHZT38CB,&\G@U5,]PV6$Y9GFF8G:$#'.DZNL*X(#!2L]SA
M@E*[>Z?B[LSMQ]JBLDV>%Z<G5TJ+"A!'_2;K*Y'T:.G/E_/IT!65G4PE;J>6
MS0JT_\R[/A9OCQX$D=N%M_.89:OB)>-:Z#(-5S?O[Q>+?)X^'-RZL<&<@RPH
M*H0\CE%S)% ,CMY, #Q!P0KSCS[L35X,F\ E!FYU"AS0@"!5WMPO]=U$+*?.
M8GNB$(LE&N-ZHM&4NH!])Z6H^PZ:F<^?[-AZ35"L?#2S=.2%DC;*DF+,CE9]
M Q+#E@^2-EW^<>8[/98R@)'F>>YO+4._<8L>SBDK<\TYMW-F0M],$<\%MB9Z
MAKRC0WT1P==966A-4JQ&M-')M9.__.'*H^:+N?_IFP$2;W?FL-?I\1;;G,;M
M&3C\#[68'K8H']2@M0*L#Z.MY6/Z##T"-!/[1?&MCB6CJ(EW"WG"$V/",6_2
MF@K!!AJ^K*AHW\#,#J:(?),TF''<(29XOI'Y<;4ORXMS.E"]YIK2L.5H;_)9
M(/U@J\256CXHJ8,IQ(G?Z58XX)QE8.?#OO#NZ\1Q!YYK@1=77,91KHM??'QP
MU&#M2PW:Q]>Z.Y4[_DS+[^AG6%K#[O]=Z/[.7U?H,J"?+P5C^*!C$#CF&UMB
M''H;SLG@]DQ!H6'W _I[.4KCP>^D?6&;_;G3:BV)KZ.T_IN6*%GU\*PO".LO
M+*@ ?OM<:V,)%5'/-MTD@[^  #CKQ&9VRZ?6.FW8UN^:/3&H?VZ^%9V=5U,H
M>[_)XINRA9-UB76)^^5/]T?7;S+*](_\>@$!0-KJ__5,0;,';(<#L8P\SJ:A
M;3-1SE6JAUW".%5S);6,-1;X-552_=M4X_3DIRE@ (VNS;+$XCCI=\DQZG=R
M?N[*[JA( ![46,RN!JWWW89ASK.P]][);"*&9S:3,TSW>/9P\4"R)^K\?N76
M'[_:S1+%#/Y(#]G,C)GY>W3HZ7::YL5SQ\$G?E> 1'K&:]]TT! $2L$",[-D
M7X]S+0#[B,M>)6=CU=&IKC^WGOT,'.1$C %8H34ASX@Z1PXT<W1SWYMUDC0T
M26O>AP<YK?D-V0R-/9E-R$Z_>#'Z8IK\GP";&#-.%4(,N7,\7Z@L3V((L\9Y
MMN,_/S[(AN_ ZU'GY18$O8P_:?PV4Q>\.64<$W<,;F.6])'2P'WG6(U9'UR8
M+^U6.RZ5$<R;E=8#K&QGIMGO@17C%+LGRRKHEYLMY,C/V5\:_113NVPNZ:@&
M *#^OO1]NFPI'A-FN.SXR- VN_&PDZ?\@59B%>DF_4SOEGSIX8X!9I0&ODD>
M#N3%.?]<8913#W*3VW8CE34C>?0G(V[('%KOX*+*K5>1Y^"P)L<2-21^6]/@
M@GLF%?V!<)#A\)V3S@?].<'^C7&*I.&5R:I%&0Q@H]'^SQ&>6=H7+I;5VGLP
M;GIG!=XAI608>B1*6K[[9MYB^^:GCF&*_L%A9T&#PCL^B,#&' #%'L36YX-:
MP$\.SP=^ <1/@$72;.788G8V%&IG[2HK-?8&V)3)1FH!25U]OFS:]IT]4D"A
M^)G2E.:?)>ONGKD^%@_=#/]BE D"68W'_5]6$&,WH$9WPI>CN-U$N^)ML ;O
M,<:$G=@(3=7X0DL2E6_<2:UWG;2+O<%Z.N8CFZ6O?NZ*K7%\ >6G\"<K6$].
MPELQ 0?8#AL?\H;T_][>8*.>[C2X%\M)PE2P]1,X]HS2CV&R6-G89G9!O3(;
M%W?0D;"Z29VVHY "VVVN3;4LM>R8G%\L:7.\7GSM]<+W\J+8RJLE\=F+5RP!
M;3$L+V4:$/B@Y!4L5ID<>5 S0XUBK%20E/D@A;(HYDUV?!9]NGV&,IN*V+25
M>WZ[Y6TCR\OP*#$V1[[KO"(;B?3"?AM.P3^%P:PEK*.HZ,(RLU9$.C&3X^$,
M30/P7PF7SD8L"TYBS^%YEE9.4<@>,.R!-3T&3TP//"9B5P;+M!1^49#OOO/V
M_8>BQQ_5C#C17O]EQP+B'VZR-8U3VH=^)W"E)GX;H\GMORW3LELJ1)0&0I$H
M;;%QLD9ZCR,+^\#54^.\I>P8<U2W@5D[FE<I&9.H*.YEOO(TKS+CMG/D"F Y
M%A@V^1_9Y[8I1;\2@?36N/SC!_U%_E;&QDJG8C(?)+??C(#,#WAOC/J/%G9,
MH:LQGH60>GR)U;6?#61B?E[DW8]F<CT:0&J41BW >W*:UW'+4]SF7T[?*WO!
MR\=HX(L01Z<PR\T*YA0?I%9"U C9#%[3]'<Q;M@.YK7,')1'M[M*=68T.$:3
MV3#[0.@F9.JCT#)>J@18V2[;*POP+G(6]"_2$Q;.%ZN$S:+8Z8R#K_,"OH?)
M.&EFDJLSSZ=Z=XQF$GWKU0G/>\[B))HQM@]^OE]@)"?,__@4$! @)&3UK4\U
M9YUZ7)B"6A9$8"4P""9F0W!9CL$ZQ=1RPMACWQ^@1<SWCMH_FTCRF'A^(X#=
M3' 8,E>8G1FFR]Y_9N7FZ9<T=A<3@S2;-C".CDX5%6EB66MP1_:)BUT_L$OK
M4[<".&:1[.3)J5L$:>:I&?@QI;HQ^_B8+W3[!-D]QMQR:ZOZ7-OFJH::V7YJ
M>;NJVGM+_;\E_PVS5P3D1G!Q=8;ZVXSX$"5XZR4?U </Y7:P<4GKEZ3NPJ.A
MTBJ4N"HM#4>?23]O,_/L#KK\EN1E9IR;S5#[CJ&NO2[<]-GRHVCMI)M_E*P
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M[%O</G0OE:AG4<X7T7W['HX]_"4_8F.KJFJ<@PF]:Q0!MDO<_]-CK>C189U
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M-@3?D[OY(&_V+]R2J8*'YA;:VFMV=YI!MW]CE]K[Q.2H!>*T:D"PK&96\ND
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ML2]&1%NZ 7Z:7C6K8\[M5R:K;2?#>ROGZ[O6!I):$#B<J\_*.G5H6LSS12"
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M(A*NL ]>.2[&B<3>E!\93@M='Q/7:OIEN7"BW2RV+EAG@1"(5'0:'3%I0BG
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M0AFM\X9+7=4F;+NOE^8&NUY0>? IRODCZI08NC+ '_)G@,\FNV,;-Z_8(7X
M)U1GKN2&J07$F6Y=RADN+>YTQ"MG(^IW)J-7JVK&+1[ ^O3D3:Z5'^G3-Y.[
M"\NY,)ET>9WZEP^#;<#\/8KS=?<$\Q\V-9F]T!A"T=@!']N.6HQZC/*!^WIG
MM1P?<^@HFDW7^5*S]'6^NM;V\>BHPSV9565!/1.AP>LIM@NEKOD 0(G^X(,B
M:7T:G("-OH4=E>_:M#^(BO/R=W<VY"=VR+Z8."JZQ\7'I_QM'?/VI66]$_!7
MGY]43QYL17Q=4H:I/62DOS-Q,<LP\BQZ!9,Z)%> #!047VYC_F"W1:YJ1SDN
MHN.J52@3G[12F_?CY",+*37T\AW*U.T:L3B5/:'\5@,S^<?S%Q\B[^U8Z/YN
M>"VV; 4PX5/<WK SW*@MW@Y;G,$'S2\[%?L?M&QKA07.+K?]U.C,BC43J-8(
M!0<\E7D.8XPN*EW8:'&0\WU2LCJ=+VC+E2V\A7]<\Q*D!,SOY S\#VPZO!.>
M ^YI78%WVB_LV#DMD"YOF<Z&$Q? %C[98PWNQ9^RAVJ98OYJ65&!+H&[$O3L
M/MBU!JB 4";JA$%<01'^WOJZ*YXAW<0R*F2',O?G-#HKDT+CN8U*Y+_WS?+#
MW ,C;18-G'\2NKSG&GZ%U;CO.2SFY7[H6_DDZEU%0 F)EDDM[E^04Q9"!B35
M^<)R]T/2K5V=@:>[V0TX>\&4TO$#,<8_&/RT?0QWC ?%I&T)IF@9U**E(G1@
MXQ9F#&DP]UP $@(5D7<PTZAK&K8G"@L(R#E%Y>049C/>ZBZ7YOQ&;QDRV_+<
MRDD'KZ1R(U5P*G8?ZA6T?&T %O;4>35$$P><S">ER>F8S#%CKO%S5PUUE/A_
MB?+O^Z1<$RYZWMO;U ["ATB/P&RD[N0?WA=R4,G.YG;S%#&M'.0,],0S"'@/
M8<)=F"4JUK(B3RW2EZB9THJ?6*X4RJB89P7I/^\L=0OQH9?E'SM&K$*3DF^M
MQ=]PS/9TNNL)V.G!(Z/D+MJ20RO/#M='F5=GTB^G;S@P>$_%.0P5HCK*[9N*
M&/1/-03&FUIE8F.3D_O8U:@2D8XZHZ&D,354[^'AOEA@;@=33#5K8ED+@+^&
MC9GE@$_PS"ZQX-DO=DKGH,\QSVE!N<F=?) (OA^Q%I,M+VPMA6/;3 U$QSP7
M)GEXRJT660S^*$RT/+SCXSYWB*U'F\*E9*MPVR$"]+#\KYC2M8K<6:BX!F"_
MRA7NQ'D&@N$^36SF^^_KS(>/0IK;CTB\'/@JYRYW);?T77/EI>VT%[: ))MS
M'Z[R0<OZC21C'[-$["UB8GD('^0\N#N-[+#@7F6W-%3OU[@-FUA:C:E16E%T
M[3W%L^]GT#DP*,)0'*(0&QZ;JI^?D.O@$3K1I$S6)(%W:0-Q;W26=D1JUSRK
MB'I-]0&9H34_A7QM1N?];DV_5G[X>$SUW%FAL0N8/N%CSKXU'^(_G$W]7UL4
M 'M1_V?.!<K-99^BP)5XUAC'#W0JK<X/W%,T/ZX05U.TFA'38]>($G'?BQ1J
M.TXKI?V$W;K@&U,76"NGXWQ3RJ>@VO;VZ>3:\"M_'=X,0B60$TU#<$7D-!'&
MX@ ]K!G:/;"X).^PSVZI>YY7C##-I=H1KC;.]%^.$+5\EWC$OM9WO_JD%^]T
MA87H#_S1481IUW4\($!EF8D+;LQ:CN X16X>BF8)?J.GK'*M%R>W4=( OKP+
M?4$N)D*#-\-:NH;&3YX^?G8G33,THD'#1.>TN8OR37K38NXYJ_+3R#\^ U1L
MH(C@2LSN'-XXE :50IWW]\3FQL73SC3)+?B<$HSJ&>]JE'D6PB $=J66E(;G
M7U3:L3 TSBD42B@T*K2)=V;J7H I CKGL$E;FN#2/N%^1Z$8644;V(@ J&B)
MYK.P@#/C'&.66#<Y=*D>$I90'YMZQ*;FKC+N6&0?;&&-'#GF,J$#-S,P?51Q
MR?7.\ZN0=>HE3>PK<J_<Q[#+?-"-@X(=2W(3 8':^N*0L@[Y1%=(IP5K;QQ8
M3H\V"*3JUE>SN[DQ D=OSP0DP9(2K)_XD;^(YF;ECS]0=E!E.:Q*3^" B"RE
M(C&?9VG:O,?> ]'B$M-)N+-HC7F<-;*RW8OG'XH]%U>3+BOKG_VJF4%!^< 6
MQ\/=FQ_.("%_/W3/3_'$-:2@=N*0]%C:EX&HVY 8WJ.#$]O/%D%3Q'&B"]>K
M_2?4RZ!V#>]_2SO!+"95+"DVVBOF.*0P+SKOSR5]CYW!FB-KKT,/[P,UY8,2
M11AUFP-+JR^WO'!=IB/3+;1IL;9?Q#S-H@#O[NCI3J50^9W$T\^SD?_ER&Z$
MJ5UGS&KVEIM:RWJZ%86\<>2#9$MW2BN;6+HK)A@UGCNM)\X=L?4.VK/*^WN/
MW':#\"30E<W>U.BR;R6&;-T>\PVLL,",61\O%:O_-&4DO_G?-Y=JT3]_?%WT
M%4[(3W/)4)-U8CFL39)$ K ^F&#V>I7F (FGCT DV_?]FWYCP)GEPPZ_A&F\
M7_&]. &?=P-Y].2GA>=)QW5-=(T(2B/?7DUV#@#XG"? I9-3;=! "E7&9IX2
MV(%^VH-:8K+73':;E*E8,HKG)EE??.X$Q<[@N9?]RCNO6/#9C&[S'GCXC++A
MT:2?*&&KVJ5LT"@@("!L&H%AV(<I!.J @D[-8.:*"Q)EQ'7Y[!T7@Y56AZ#H
M54-;9V*^+-4K!)KDQA7DMML8W-BT_^2[(ZE:ER14*6S5H\VX4VZF>'A5)N<U
M5VP#%Z^5.#_05?DVL^<ILJ.7%B&V@$8@XAH=AMJL;39OM)UP>VIZ!+G1U\>]
M<:G@O(B?X_@%A_IH&;Q[AEK*!4GB%: H'6G%:'%V&*PEMS8^Z#VN5TYZIZ8D
M)'$N;*UO#_> Z\+N:6"&5ATLT';94SNJ6H1 G^R>%Y1-8_W_/I:581P4P6\8
M\O<C0_"KQ]-L  ]DO]TQ[^8$6)\CW':T#=I5W=K,A]O$T2,02\O=]TA&34W5
M<<+14UK^/H;'?33+D$)"8\O$<Q;KXFKZSG>/Q[R;F\J'(^EOZ)L\L[>,$T^Q
MM\*2.>*-ZFM(+%-\JZ6(8N^2LCY3'NK@Y(/U#6P?*OBZZ/=\[,'"A_LI*DCO
MUW*0X9--^$=-_PKMGGM9G'%XG-&.,[!MS)G"WMR*R([;-FM$=7R63XXH:]W\
MMY+NC6M D2REIV MWFD?NI_<M12%$<YG5LK@JR_TAEG*2<K191Z%8.=^_G_L
MO6=0TVL4/LB]%JZ(<"VHB!B]@$B7+C47$1 0D!*0$B+2I(M (BU145 00J\"
M"D(HTDLD0")20D=Z"2%"Z"5 $)*0$#;\9S_LARVSNW=F=V?V2X;Y38"WG/,\
MSSF_\Y[74%ASTX8C6 U$&*,(6=E]QB'7=EJ9RE*[:=M$LQDUJI &A3<Z;1XP
M,KM\FI[/AEJZN^]=^]WQ,56$/Z-[L!G.#Q2M-#SQMY.EL:GMSS.ZG$!*E1&#
M$/TXWNU=0243M$YAH38V@14=#B<GZ./4 .<E^)KPM:WEZ6OV3Y9<IB[OVUUU
M#7S>/TK@!IRS-+;5,=H&/:@9$)4<H7*B82=PRC8_8A.X"-F.6KRF(5(ELJJ=
M3J^B*N;#W*8ZK<=N>N:+$!K 9;:Q(3RB'3VQ64("VA?+/.V\/RJ(*!E?/2\E
M;\8)76 Z8=?8;D=HXD0Q>W/(=8)FT';ED.LME3+SO2\L= .^V^N[7T8;H?=/
M]+C4!$O?RWH2 5"1JHP\+9Y46M0V8(ZI4@!IYFDF#+V=YP#3^6%<)RUL8V!^
M8WN'@?#M)TPRC>=SVW(.N::!-]DJ,,H@O@^[G2Y,KFL4"? 3SD@J^M+Y<W:I
MU%!>L.!SS[^UV^^F\HHLM>[JG>_A;&&,L!EK15L?RF_DT\_> ,3@_E:7*]7@
M/X-KA#T/4R()581NRO8CO3+@!)^[A+03[_,G->REURN2];+$X^/_FD65O#]G
M=E1T<%2I7[)%=]Y6K&)KA+UB.VN5-M<(28FCX>"PSP3BZ%AM*$0,#+8UB&[W
MSFY BT:H"ENK1_-X[H#?%P?%9>95BQS3[WBV/LB!*! 9PXF#2%:_!ZC/&.CM
M&,8'J./8E);<I#">ZM5 \_,.RI;U"FVMJSIHF+2D$',_>@:\>=V\5D^YBSH-
MLK^,;[YJ<OR'76J>K2<WYX\EL5:WCRIZE%E?&N6<8(=<7:37C:@R5:OL4]4A
M%<_#_%K]CN$:=VY@T(63J-8GBY^[3.G@.IJ215?\5^19FTQ!VY44.P=KF=5$
MSE[6BRWC(@^RQA"]&EBLG;NB_4U46:@!)VQKQ[XBI'O#C>H?K*O%)9=/UZG9
M1>\;X NUI<,&%U;T%%M3<FQ<DPUY=4"YQ- O^ Y@1'C9<&XOFE'.:B5.'KRR
M&46H^R-XJ@[,H@B3WF_=$-?@ZNOJ9679/BV&EC$%^"&>:,:8$:"V:SSX\0D4
MTP/XE,,*ANQC')X;6)3:SF*X0]'4H6G(/_LP%'"P22@G=U:U!Q>KYM-EWW@Q
M?+99U73[:\4,$Z$8AR<O.WM07TPYZ\9UCQ5_R<2<+$F\7[Q:P+&L833\/$*1
M?_&$S3:J# [; +P4]AL'7F.22C7( ;3<?WUCB1,:I&<N&&B]^JI=>-:'@8T/
M]X3^S'TV(%1^]S.:3[\P)\[@RROQL2$.Y]4+'K4O:+1W9QBQ$EI9_&PHZ;(G
M.LI8^Y"+[0)08'N'12XW?15*4Z%_<#L_[Z-]3EI 9;7(!U.7+&CDUC% J_KY
MT^73.R4X3W16_=&!LX$%8 LX;4>. ?<#O ;C$Y7N^#"'0W4?NZ"U9Y";!*&,
M28FXTG:WHG.?KS.1LQG38 $'PW\,%A\U/3_.]SVT(LCN +>MRQ@.:Z4?0+8,
MYI&N81)KUQ)G7NQ?:]XDI0F+IQ.S:A!^)FF&2L_FGVX+2:F]S/_N8]+>*%]U
MN3K(TIV:G P/^9*'2E>R,#AJ"=05)C1-QRV>VNJ91T!&O</$=5@.=#\B3M!E
M2D#MRD1 C.SNUREQ+OG:!&>(L*QZ7(2?B;!N3^)K*[^_HT^!TE$8FAGA])R<
MJP]B,84JM#BCJU@MMAHW08\9!)]"WU8*EEQ1/:Z64S,M%",%,;>_3Y_8'B2[
M%G8/2Y\S2,ETC[\OBGH/ C>/8VBM?N^:4[;7YI=VQ"BQ:QF3@C)E.]SS0 AT
MP/;AQH>4()_PBZJ>WA]DIXNBU 2L5:)S4NO6MG>:/(Q!MH(O\Y6*YCNP:\23
M@#[57VE^+,(TL"=&9H3!QK18ANFRG1'";##4#GK26>Q]2%_=R/"H<6+^#UZX
MN&2=6D.J"_.IIUU<1A\KQ9_O*)XX8O02.-L-R W7I1URO6#Q,1#; ?(C:NP9
MNC!.PR_@R;[0O*F!>.2D$!:)N9W\39+A^?PRQ[DK!+Y56OW>,(_ZRA:PO J2
MM?W!=?DH'>(K]P;86S$O-\"_,+M3,2^[32^KVB;QPU!^.N!M9+&JZ>JTDM4C
MT^6IX-B&S'[=1H7&D 2:Z6))H@,@,MJD,2(?/S0\*AJT6P,*/NHH@]\BSP&=
M6>&;N$7@)).@5K,&W>2 <E*Z[,+:(VBD-:;TADYTQWIL8_U\S.V41U-W)!0@
MX='%@4:>T9U--U45N66.,J3VD+^PO @5P,MF@62ZV% P+B+C6F8>\: N=>*0
M2Q6-A;UPU>!3-QWF0'F$5(/Z7A:W8<PTLT;0-C'Q.)14:Y4XW&[D:'_W)Q!#
M^[<.1ATC0,X!DU7Q<N\@LMH/O>'I&T>O!+26F<:S9CV2/+PX5V?Y[*C,=7 K
M!C-^ R.2R__NPF:R(*;7U\FSX/5K-4_[]F2%9@F.^.7"]9WV.^IWW$+"=3M7
M8!VAI!_[=NNX'1MZU,V^9;.HVE"\B'U3T9X+XT'.KW7I#>L5SV#_B;X& \.K
M79&H@J+/7P0L1JR6I"2=/T4"@RAEF_]_!NG_,(,4NN2G3R$EY9YB@\/\)Y29
MH9>PH6MD&U@@I;^+,H7Y )?,E9@4\A-Y]SE+3$M8+-Q!2=YJM&VX20ET[JM3
MQHV$E[I']RO\!P,YEMLC=R0.%>D'6/72V@ .@'U#RW4#DK-'=6PKJ:!)(^5V
MF-M>#T7SP;FN>/R3)3OZ+:]9HZ*Q[+RX9VL7=CZ=.WK/$?X3V,FL4Z%1'>A=
M6]RU&O;E>Y >O_?AXPD,M<'PS;':NNP8]-X>>^H@ZALM;JS3@,]=Z%5Y19XW
MW*-(0;[N F]>7OX/M[,=0YQ-<L=;'G*IFR5D1PQE!> :#>8VV_AB5OM;6_TH
MQ.G<,ZH=:S/,GIK\J45(/>%A_4++DZ=[IF,]&E(+9]VZYD7_O..QFG<OJ8^#
MM7G_B:JX)_6%??&02V$@ G(#[F439O>)[C0CK+/CO*"_QP")>[)BUL^0JF'8
M@8KUT8*H&R^_XF=5L&Y9T,>W3QF>GBT>5OL@]F"K1T8\JY>#E^=SYNEB5,"O
M-"J,'?ZB(EZKHHK9*$ZUUR AI/S#4VIGRW]8C8_MQ8U\M_2]D=!B;:GTXL2#
MF9L%1;>*=S*>SN*;-4T>#=U;.!C'"$/FN'<"&4Y; U^U3])L?%GZ[2R[&2WW
M47OW;UC[]2_3&Y.$GL=#P\XW2PD)WIZ9-] J_8M]Y'PV(+%7=K5S*/W#KE7R
M0Q.+RJ,E#\""#KGD*/-M8?'TG9U21NC"/LR=]7[Y6F0?RWQ@UPPZY/)T+W)_
M[<I^=%BJAL^86^5/:[=G H10>4-A1^UR2<E:Z0WA>_K7K3E2)XUT41W!2/#U
M2R0DS9/Z9>?7''&32EK0;/\1W%]8.5]I[/KD[R2K4643Z!:1B=2*:7-1O;:4
M8D88,C"+R?^47S#X=+[()O,HX* ]#./P/>#O5>U_6?[T.JSV)1?L;9I-* P2
MM#L.A[*8F'#:>#$IP_/KV)/7X(SWGR).-4GZ!^VF\,?&4SXZ6-1$EMZ*^<6!
MN&-=+"2SWX]N=I+,-O.9 MO'4=*I&JTRM:&G*<\;PNODOU",RGN^6[IXGI2,
M$3>AT=OR\BIRKMX[Y'*VE!X:;HF//F['D29("#C,BE&,PSX-N\U 45/@"AM]
MA&'()6VKW\C =0IR1BC+G[S0O=>QW&+M@\FN#\@*B?3,Y/_UZ#Y!U$M2XLMK
MC$%TIF2ZS'5.B(<)DFLU6TQC->^AG<.LV1!%UC\SAUSG:@B$2G0%WJ2+*N3O
MVXQL",D]D%THW0EV4-8G$0@PB:B9%YK7S$0LS:-/);6;*71ZE+3Y?TK@\/EE
M*N0D(IU;AP6E@][14W;T\VM":7-UUDN=,#?@@B_,?]Q'=MNQ([K$X4"%7%)8
MTK>D,E^K=J4+15#0I6W-)D@4S0BN>/SD#Z)@Z"M;20O:-/;CY$.N7N2B]CB]
M9E@KIAJNY6L6=Q P2KI8DU%VR*5BE_5BWD,!U)#-; JX<Z;"/"5$O.#V7%7E
M$T<>I4S/"*L=[;><>7+":JEK.PQ%JN(L97(#F/I^9&=O >8*BQL);QE\U%0H
MY^[^[,"_25$#=KI!!;^=(=HYYG/0KA,3(Q);'G^]\Z'5L'7[!7^K?S@#BY!;
M'-BR1\.A&Y"(.]J?!G9G_JP@&^S<H/=1F?"NB88/<=?4RVJ&K0B)5PNNB9+]
MU=R*^GHGHYV->5=,'LRZ4L?N@HY*622@!FW]^!E +XG,W;ONYNRJ,]HLLQTZ
M#S&B?!6&&F&D?S,<"3T^GBSOWQ>JR 7X'AW>.W95EJ(-]\4,GKYY]D P0VL<
M\X=&*,/;%[[)]@HE+. >6P6-!<PA70^Y;AV061C:S/>B;AOMQ:]=?N7?*Z;5
M!+5;ML\Y]?_I@P.+GH3V9.9BQ,Z<BJ(A,30]9R^6.CM(V&#;CRT4@&J$S98#
M/ZM0.K7.C.2J4R>SR7J3!+_RN7RVH-[\Q(7+Z95!]DMGW@%==>U-FB6>MNJ>
M")"V/':D+CQ&L[VHS%)5N9:<:OIFDWJN?]B3->&&G$F('.Q2Y\?%)6)S6M8G
MPF5-$[[!\BG&H['R5)RJ;4*$N'8(2M'J&D+40E?$:(C)$?."WQH'YA>X=RS7
M$+'?7%8?X-J:>[90X31MZF66HS4Z]!<,/D2LO6-W*D#@];T?Y/K%Y;R>XS_N
M.2?6W !%3'OSFCLCDXBAGW%+JO<I TD 'BR8%3 !(B N834VR7*A@?W]7;[=
MF&A>L+9E#;3#\K2.ME&(D=UJT=-_2LK>HUX\+1&['Z'TK/O7T1%W2!:-8>,[
M,\:VQIW4ONX6*NX3M-1M]CK4>+:#N5*^1GC!H.6</SV%./?LQ?X5Z:]6H_%S
M:PHO>##O%"Y0JBV'1K2$S=+:+RQ7<7PW@J^/'LKZ><B5[DT4&\$!2^%"@0;M
M_>4;<=\H'"5(NJCJN+(Q/>#E$I*#D<8*'7<A9@6<,*Q5B5CT\/ L=1Y.ZAQY
M-Q>IMO)#,Y&C 4(P) YIKA]R+?I1$8M0,_EJU.K,"KUY>[@ 6LX7)0:6#>&M
ML'!%F\"-0O9MY0>=YSYE7AV]7I@H_87:^#7O_@V>K^PUXB.K[>#/F0#1JN G
MB7+2_.0@ZI_*(@$%J;23TP#X&M$K8ROF%W['B7YZT-;L-5@\BZZ6L%(B0R+8
M^B!W0D.78)&6E>0O&YKUQG<4&I,J/"H#TYL'&N53,B2N&_@P]0QE-*T*%FIE
MCG%LGC"&Z"+/=WQG6PH#6$VH==F\?C_L!T9?K09)$/<\M$;57#=EDF"/<5E/
MW$TYYEW@Z1O]$?1@V]!D3\[(*S)W[D]N*B?RL(:-'7*=UP"X<]0B(HGS41T<
MFP*TIIFU;\9E2]4]"U237 GXZ1J2)(/QHEJ.#W7%Q0 $CO]<+#ZAE. JGD)T
M/:?S%\B= PJJ[&#@WK+<HL0A5W35)(D9>53W]N]_R&A!KN$B6RCH;]K.A<U#
MKN3+J]GO=0;#7VWSS]'PLO63](^Q81E?PPWNV5!L/4^XBGY;7K[1<9!J_5K=
M)D9*L[_K>NKEUZ5'0MLL($R1\780<"?4:PE-W4@CCVWUAGV=.+"O8CNP8 R1
M;P'- 7%]H-]OA5U/CA"9 8$^Z_KPD*M$/I6RJMT+02\\)"0E;)=L$S];<522
M87D1_8_&XE5@^J5>#O1C,<Q*C6,+*#QOE!Y4U>&W]3$Y<&W(3N%>I+B,#'2(
M4 >Z((.AR=Y%TR/UT2*.$_2"TJ]G#R+5A40-./%2Y8:WP4 YBFT<WEBCWK,$
M^[XQSJJKA[2P6W\$&O3R^#0V^8/+LB8O9^?:ZM3LB3A=U)OZ+3C]QORADVM?
MJ]WN5MN&@#;1(>_K-L?-'@.OL'E@-H_#.(3W9MO]<9;GA@3[K$]Y^@9VE6 _
M4]THD,QT0#]TN<T?VSX\1%Z;S9(Q3.P=_CH(LAILJ\)+!3=%_^,71/F0]O_:
MH@:AW%>YIS7,YFAMUS:7KWWO7[]:3UTOIS*2)A])I_[LGE>XW%FD?=?WXY[?
M*0&'T70,3]'J2K%"X)I=PF#/U>?O+PI*7CBZ_NG?:]P,7UBA'./, *MB514(
M B)ZML:?AX6"1_E@T@0#^LR3S));)7PZE5[I[,L5ZIYI=/YT+A_3:0@'$2OF
MN3LVL^GE:#K'GB_#T) -4R*]['7KKT9 /M.B1J'98^I1/2&9_B!27-X^IM"[
M0[+\==[%TA\NPY=47W\I!9EW 3Z'CV-.::N'B3+,FCE()@;<$6$@Z]C2OP>>
MK.<B[9/(.(==6/O712]$7VKAC-J5!RF^[O#-J_W'O$9<'=^O/+CSU?MRVNO8
MFYF?1C4'/O^/5U[=^";V ]8'>FA]J-E"7I#F00-X$DRN SP+M):3B)F<G 8Z
M^/'V$W]03*I8;H8*RED(_X=/YCK)7E_^4K@@H#1:I7<5]%<$,?3K(5<?8(Z/
MR:C:8L*"Y$PI/C55C4SO3=\B"BF.N?FB2UE;\4PSQMB?C+YXKKS>TXXWVT$I
M28MW)*GI@J)1I577YU-'+Z\?L#+9!MF'7)Q0L1LXR]UJ&DGQ>35R5)Y_NT[6
M# K3,O63?<;@85,)H6E^-/OA>><?(+=28-- L^H9!P$+9P\IR<6SADJUYXTV
M 1S TMMQ9\ 7&Z-FS?"D=Z2K8A,:XF=_AN.W:OQ]IDQ((-N7'2UU6%F*]TG]
MD"M^L]_6/[ZNJZ1#XQ)%3"N;IL[9SMYUX81()XBDK:S%:XJ,ML#-'5'Z<#I]
MY5O(FMRVU+&MI'EW1YBUN_]&6+^&5_OD!>:XV#=HX(2#M352(BL1V75&6?:N
MT96G*!1$N@9O;8<DAN:+LZK9-Z' 5B"20"YI-)"OKLF*><[ZS# D6@ED\8N!
MD_,=;*!^WEAR6XMT!B]4-JCB=23V0DFLQ]2M);XJ,_4_.,08^(IM##FEX<P(
M0LB0D(=<?VO@-,:9234AY35H3]6+[J742=Y%/A"ID>#OJRYO $II=_+Z(O]S
MH3C1[Z:*C.+7Z,A[H 1.$.'%]C[D.M$(6_(=I2M&K/(><H%_2;*5$ J #R0Y
M]'IV3'KG++F$H*5LTG"CVWS.5/5\JN>'Z;[T0J7*_N21_HL0&1<QJZ.J0O1"
MQ7<.&39&L'V$HA@<:I!ED:@'Q2AB[NGZS;:O'6.,E,QUA<%6LX;9Z;K=Y!$A
M*8&+&7"R8+11<.Z=-;)G02+2-MJ*PPS[+''$DICE1%9)&B-A#I?J%?B[\5I!
M?;A!*P^VW^>[ZH6@WW]>?E[;N*CFG^0DUJ%BF'/?4Z0XND3=]6S/A:%:CM87
MSJ&V0EL#*WR&PYXZ?OL1]JI\+9:L,VP+Q\?E(?TL?>TP@DFG+3]Z^PB[!CQ9
MJ;Z98_<F,M50-)9'<GJ:@X5?$3\.N2(@6WF<3PT-V.,0#))Q=5-F>Y*)EY\
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M/?]ST%!)^5R?27+AYXI/(;;%)2(Y5S#W;[XB!V8JN5X/K0B\KTY;&'_ 2F6
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M=W%^K8G6+?W@3#4,OZ]("D\S& ]ME!G_)OSCLHC33G:&X<NLBFWEP>YM@W]
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M>#V\+(4[BX]ASEJ'MY@#T#/OO.H9!W_TP?S1%I[P+]8W[U-;8X8; A37NQQ
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MM,UN2+PIN\@ &^,CU6#:P0*BE[<Q4MR103)6"_: U"!?D^<.J:TMZ,*UK[O
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MAD^<VU^K$@J4DGWHR<X ZLFO /G#,"^<WRO4,L9I9JVYF%NEI2=A^B:62!&
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M:B+SUVZ BDS4+/;"K!@C3H!1S +$[;F7,;/0?KP0-'Y9G\VK($F5G#D%OIB
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MVU-P.W1*UD7M.KZR5NC'ET@8K3Y"#\ S(/0R;6C05;RRFNB@UO55J//:S-V
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MB@KZ<9XT<1IRX+EQL>'\V+SIB,M]B*9J4CNR7<>9'[F'^ _0_9LL)IZ=*A^
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MS5FJMSISM97P9LQ_T]K!X8I1&)GO"_;5M)*&*.CQ?(C3I*CP%32ITPQ5GS0
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M02V824W5C)4ID;R(QK^W#?RNI?C6"F*2=24'4#MP'!^9+<DV=Y\NKB@SQ_W
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M[<H]+!]DM<+4S#?EQU%OMUBR]BCM\/7B971[+[.=V#6SVY0=(GMXM&9X-$Y
M44(Z+YK:SE^&V7O?XYKZVR-Z.@+<<I@8>6"*<$/"N6/*TN^O<=\9<MLCG!QV
M)&6)QY/&\_IK_WQW\NC=%:LRW1(MGU,67JXE,"1H&KFID+;1]??U60P;_8=W
M>S;4TPQPCXA!WU1#T<A1#?! 5^W8E>@TDAS'PDW9LJ!. /US6[YYZ@#53@/H
M$# .Q-@W\DQZIIN;O8<6\<&EQE7G<U_%4F5P\(:9%B$O=ZYR-"7:ZE11DV72
MQD;&]P]M><];6],DSH1S 40?5OMG4@%'L2.MO=)\96O+$;OW^>UWST!O2_ZD
MJ[AE$Z2(9".&'%:!O2/\5=?=/S)<;QR_N._CM?%5IB#S( 'YWJ(2I>Y>;(\9
MPK34=FK7*7A03VT%(BZXB8>@CR/$U!%@61"$-8 $C\9)6<H>C@;X7@Q]K, C
M'G1,6[W#\E8N@RY+4BN$8FZS8@5>GC V$20<T0"/"4)#=;<YXEX*CF_%HD^'
M($;ISM4 D\/T,#2L&?I>PX3REV+]'^Q5*UF2T";44?N4M]#S@SEN).CJ3B%!
M-HX=E-I:VT3Y0P.,+R9]?>(7_QWJ<W9Y->K9A1%SRK@;ZAPV?P&F&HDB);?*
M?:IV C$JRCIZ5_IK@$<6#$0@.A4S*OG8^@J'G^CNPPXHU68?H-#&H,+K)*XT
M@CO6L/7#$PU00I-KG[)6#>RTFX;XTJ$5-[+KN4BD5^<E__+K.&&:H'.3]CCU
M*[4G\RCWLLSD:JDC_?6&M^:E<PF>W-Y+$$V)"L3Z;?U(NDS=&X^?U*F6/#X)
MCT"BWZ!GDBZK(X\Q^O\@*(E<^H9+[L.]UP!L;" Q8FF+.GTW.!;<U I'9L^S
M!51@7\4G9'[Q":U3R5PG+X'(-5'DVR"%1B;KIW*]SMAP;_/4BXV*6@Y%&)_=
M.^. #]W*<)A9Q2=7-'XV\QK1\Y(X(O'%YD9X_?-_!>%S8K9ST>TE4>T.PJ]G
M,]*/0C%C)HV'$C,&4%LY= 0JD#I0SK%/:8 %7=[J"B>388P>RLU"U*\CDEC5
MZ167Z9DRT]V/WOE_/HDI]J]^6S*%P?'64I1R=>HA&MGC\+:!1G$2-V_0B;=T
MN)0]G>4_9_@&IFQ'6IG_8?NO_*G]EHC9(<;=_^+U%_^ZP?RDP_VWK=,&FC?7
MZ+)B%S+>""K)TW!ZF4Y[*C8%>V"!\W'&E?A%^70':)$L%X;LC):3;J()_E!6
M*_0!^7A,]:)? Y1].^1PR^AS18!E7A3<>JSY+F5@9FUR2(S54LCWA!LOA>'4
MKQ=/BJ;Z+NIJN-AT:\?/A@TKP5JU\BS)K?RZTV'J,,K8S]$-.&L^'>]V^XOW
MQ,.[L[\?P&*0S:+1()^*VHK@ U9II\:G0SF#3$:104D; 9/VG\!QZTYZKT(#
M4#*BX'_<+/([RA2G91D@S:3__-*&_XT73V5 EY3'V@A>*BQ[%VN /.8NA7AP
MM#9;O'PH<M%%O^3>.TW#X^U7GHEQ$3DG3,[O"4)!"E3%[9@AU0!T(9R^HT-"
M4VFGE[;I.=_,+M%"/-,R-UIUEP0>SM2K")4<6ND:_:O=,%+25"VL>D<?X[8[
MN$UF*BQ>E88=&C?"<GIPSLW2!V=4>\BT.=IJ?-'64+R2K%#ZY=U5AGP\W'GY
M:)3DXBQE^P8LPWM:E9@,F"FF'D3F5\R]BA+7ODDAO]GR4N'!N/ER'0+>F8D=
M]&Y&C HZ%Q8U6-I^-=7Z44;WNF>+4>]72_#^9P1ZP@)]PC7_GHI]._0C;8S=
M)IA.US%ROM\5],7R#S!-R4TZLKK#=?O)C3!U[V,?W(/LO)Q/O>/ZSID3&S<%
MXKBTWK!^I-O6SGXEERI/'/N5X]?<1UC1Y!&S/\>N]YCMMGJ4E9L'F\]<^HS9
MT.$15N%CMOZ>]T94(!!/?L_3 #BJKP;(-;>>3\INFT1]@U\)'X]"7:>80V '
M.,"W7Q*E>A?5X?DGK6$KK)+O/*Z;:8C.G+/:3IKI5Z(4Q5Y 'O$6)USS:O>\
M,<'WDOGZ0!Q0JJL*G;KYKTBWV_[O@(?OHRI^QQ6$?#6A12=SSXP/!^CR.T2E
MYJ!8]>M8?2&F=RS55A&GL-!QYSJ28I'1]<F1.H&/MPRQ57EZZ6H 6\C+W_;-
M);3A,E*]9GOT1V^U,OPN.>J@Z8%F2[/[Q/#/QW11<X.V^<D7=V')<J,D+0CW
M[!7JHW[(JS=2[=N[17+P[3'Q]+'%=#DF9RI1P\XGI=TM/F_)B!?!U=1'35"!
MC:PU*06PQXW"2Z:?:J[JRK*](BV=-("J'_&BY\12\/V$8924=BAV-/GM?/_W
M_'.X: ^W$Q"G,).]7>B,I=?GIFYN%,=WPTBT&EGOT^YVU^VIDIMI@MAVDV79
MT+F?)T3J"<@Z*:X'6L50^ZB[SY*SPF9@D8L;PS0^4W]Y3L%N#:!/#HY)\*'&
M-$N&AJ:38_$:8#G?!'([>39K:9HA>40]7<\L-X]=<KE+ [0<.H9.BEA=B:JB
M1?HG,--KR&$3WD_V*J.E6%BDG"'K'79:+8Q_S9CC-AG'=ID\@UH\/829(;FX
MC?*[$5NRU*M)W7WE=AGBO?*I@CPISLE,9SCI_BSC1TM*?PI8=@:E3\?)R&=S
M_#+K8M##SE.H?JEY;HP9 ZG%]6+B[/!E4AX[W&9F3H2H^CWWF\C44&L</=B/
MB#IN<S^;F>]*%7V8JI=]#_DZOBG*Y,34F^M\TE?I.81\W7VO0+B)>'Z?WI+6
MT6V95(5_ P*UJ*R*!N?. @N;[$LEP8SU5%.)SA_NH<;ZY%>7H\[OU#'%5.CG
M62<Q_.3G0%)SZ8:8BW?GO?N^O?NQU4>8H/9RJ.G@U42;O.M0K?4[TEOO?R6@
M_@_ >_S/;2%[N A3NYDK4.V#OJB(J;]2U"G+.OV<PY[I38*CXA1_3OV)C1F=
M@KB.I,QO4->M4,LIP58[]K8/?4]_)MJGW.*,Z?$ES>-%W[X_TWUT.<+!OH/2
M1YBX5F@Y=S%LO[M[3!\MIJCV(2%54]MZ+J&[6%:,4=PX\7PB,73=Z0YETP8&
M4WJMN][%'J/KRV93-PNT#Q]YE\BZS=2_VJJXP;PC;&SX_;FSI(1HI[S%\+_G
M@$?XF.X167<9]!'-UE\/P7=E]Y=DH2WD'^(.YVY%WOIEH?X6#TD.D1%]6V.0
MZTN,T1]6WR*?X)4 "HV&%#7P9[J@>ZD_G%])?'S'C/;BN/G%;X%T_ ]19;?3
M2<.1D*L06Z73-+:I$2F6\C3 ;@LO;=/G:AVN:#44\ZHU=(31-/?$A<JU;V33
MY[T(\1N]V%G\"CJ :@E&,U24]='E,B-HJ-YJ,_T-TJO<XKH:M!9-!M^Q9[:%
MO$FXA2TC[#L;":]ZY'F$AVAW+8#8D48QR<(QJ,^T57R:[==(5Q_^COE:<TUR
M+,G9*'9^LZ7>9>9<7-_R 5"D!ZM8)=\.E'4[CD@%OJ D2GGA0AS)\B-TOU\=
MXW@Y(JTP<'&=3]C29K:X%?QA$3V;G@5RL!3T,[$DJ%Z/_13S%@IZ50,4LO(4
MCYM;PFX2=RY"%S%OZ^/N=+3?_7V^*5$#S'[Q(7 K%@-ZUV 2;\$AZ5HV7/?+
M#^A:P_=S]\Y;U-Q;H>RG.9TSF[TT5U3-=9DAYEY-E&!LMX/1^21,RS^*P#D>
M(IKWC+@";9)&O ]$O/68I9;3 ^1=3M#XL;%$+S:&BXS,[_[0X (2=L3U;5:7
MK5->L/=S)5<;R++75IF(2%NYLPUN0N)S>ALPNL^:VO07R9/<; CR^NXB#$P?
MC<+(-5GO.BV5?LX3:.C.U#>5(SM20PNIQ2&B/J+S:C,AZ>LK0[YQF(&7'J;_
MJ()(VSELZ+/S"? DU+?M+U'XC9$UT[_@^ SPFDC+=Q*9S,,)/] 0*V4!%E%,
M#![)G=?&/4&B7R\Q:G%\X#,V.GB(;E$YLWA*P;]\TD&6/YIBLPJ&Z:/G.*$M
M,J/9'Q+/GRTA"%E)U;0T,$D#1)I)/9GL=^/NC.:R7ZH(HWE8S#[P+#AHH51.
M["@SQ58L0!5C^ Y]1CZC$C*O0/(""\=U25?#;Z@L3N=U$W&W<0,>SO>SLENQ
M0-(YYY0U["5??A3L(R:9;VU_)X=:51';2MM%^GWEN"3/S+''^S>4^CAYWQC2
M .?CT(T83KRV.(-*A.:2BCX!PBC%\5416_84S8!5"8&0']C0\BG,.6IP_FLS
M2>A&*O\@Z'_\+$,+S7<R$"R1"LJP3K0QH[G+SZCUH^_Q5;#4JWR2%G8[R2@;
MPL[UJ=D19PN]T0(FN^./2'^49-1-XLIK'GC47X#; >II<$#P8/19GKK#.J=K
MN8H4A.1O\QJUCNX<Z%B/8[M=X_K8#3[!R1/Q4GB8!]&+EMOGUFP"&2T?M@[+
M;^L:_NG-4"_;HE19W>V7A8_#81I@[?=@BDM5?Y@*ZE.>X>R.2A7D9S3 KM)2
M5E,_V$74(?C:VDEF)D7WO)X)<5>K#GW1[V+7H;O</D7AQ-'JZY+JBGJ3!5EE
M![77F<\9G^2!"&]TE\W0E[ EILW#R*+F<QB3D@0=J[L':0(61D6I*9O-LFTO
M8I&H=*TZ)>C*T&C.L1DVA+!6';!'YW-=']Q'9,I:6&"['*9GQEUWIVI+4]/N
MSKDK-G8N)1WTH?PPEBW9S/;ZT;>"3&--6"43Y[?O3.X<5L,]5F9+HTN'ND@V
M,0J+P,S.8^3NZ/[GGQ=YR]CT*,Q#L<03,Q;Y:FE;/UA)QF2AH?V.Q)7ZGW'[
M]J$&J;RMD7>W6#>D1U!G[%:NO'V@7@*+,S7 G]8ML<&X&;D07X7_O6'/FZ%(
M^MI1#; %BUFCD2!Y*9OG&H2%U.0$S)&M!#Q"#_IQ+EY"S'R%T<)I<!&U"37.
M#=E%JDU22SMY<VHQUR*?34-W"D6R\P%(\=)HJ;BGN#-F9B6"T0?U59[_IZY
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M L3=F_'9_-6X< Y;M&$6 G+FO!-/Q5PNL]M!^BM(J^RR1VE4?%Q-'^%VH^V
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ML"-.[1D)_X66S6*D'\04R,^ (A&"Q>GTQ +Z+].KB33CEUM1O-76B+\9SD%
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M4:6^I#W%*9\EZX0I6(=3M-._\@B2&)+'CWFM63AJ.44QBADSQ8M;2V8-,0*
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M1/)#C[;+!D-;?4+WKIG35I1P23.Q<N3A#GDNJJA32E2/UD &0Y$1-,4$F_=
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M\+@=DM,W[LN-X4RR KTSTGV/2!UNW2U>&&>";MO_^QN#,##R?;$,_A9+5\:
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M)8(J8^HX23P#QX[(5:),U341"A#6"J#K+-J8/GP8:&70 J<Q<[':B]UW@"M
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M=#G8XII7%3P4)8HQ_._,;"I9O]H(WL/:H%H33OHE501MD$4"P4/-.ZH"9ES
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M*I^]" >?+&Z-N4-MB4-L4H#!I.RL@3Q<\&BVN,L %Z+OP]=EE)4-_45=4G'
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MCI@ BJ06 :A+? 6?YIN:9GABVM%.81[9>]'.&485VZ,EU8D*8K_?Z)X"L'@
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M/8F-J1)3TYH)?L>Y9\1Z$XH=) %4:?F<+P:Q_G*V#;IYSX-J6'EWK'\M(NL
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M;IK<GM3H#$J[T:!BIR_4G3WY"L&/3EQ[(]5"[YYGOO$MF<#8Q8;X1>>FNJ3
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M5"@48 _Q\^A-9QGB3U0D.^##^:F)%5UPKMDY5KD4=JQ"]N_4=#[X04VR#A4
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M/8["TN?X0<&>R,MI5#.KVVL28AI7$J'MEI;5K9RK;Y:FI/P@3IRZV_0:08P
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MAF?F(>4R%2DX3J>!8&\7&J1;<GM7@6E:([, ZM]]KU2O+AJ&3RLQBZ<0_&2
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M*1IE8!H3149>^T0$O+S"RQI<@=I*')4=],>@SW\_VF>(")K"5'3G,C7H@.H
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M-6T>3/+_HQ:)Z80TWX_3VX6KD'7O<7 Q;@P]=@(0&)74PFEYGW0U&]NE"<'
M^ R9FVV=V?C3E0,W>K-.)6(9WRCQZOQ/-WY9]EA/J!B#UP\@QNL<#C$Z6V%.
MML P&N/"G"7 YC1[%^-5^V^7M<<E,\Q/.I8DYU=%:U$Y"%M7$_<^ZOZM4?,,
M,:PW!0CM=^@SKX"E>L-&0%OU;\O=4EJ^K71YUV=WCIJ<!'TQFH6N/U+;W&M
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M/'RTJR;U1P07M*Q23LYE8V=,&7TK.<8/<OH/4# _F=.N-_]-EK(U_^AH?4S
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MI]]J5$-VT0N!46,1%9J_M?I[L/VNZ?5*D/H!O,7X0W=/_ZM-H#B94LU)>7K
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MS6%]@DVI7[0H3&>/>G.9?'V %G7@S9RXIBY4 R#!6O_$F?#)/X=_6D\JV]W
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M43]0B;/>+7F0_S,O#5WYS_TJADA1T+6!WLH9M=ZLN;$R?/A^R1UEBP'\4N,
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MF/??X^;^ %EM+[I5(\01\;*W'=!9<1J!!JWY@&=$C?9H0=;_?;(M1?GQS&/
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MNMI\CI\DS!W@INY(A4>#47(E5)VN[G,ZX?4A H?_]"8:,75[%=DW<7GZC\A
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MCS-+R8^.X'90IN:UK;N5_.W3GQ6M!X_@9I*>4(E*70J75V$TJ,8\2M7D<>B
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M2)_;ZDVZQM T QR4=&JML8H-4G* KS?4F#';QVH,*U*[! CR84QF@GU6BO(
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M;(/0EX5+L?7VD,5V3R7KVME9J\+=@7=KA7&I 'ZJS5HZ'%'H@97V'E#50 T
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MX+,P&RD).<C,F@_WP&<J$%9514&6/WXX!UFZJW-*8AEV=?TKK,0F'4O)F1L
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ME\J"]ME!:CR+^CR*L*)K-)Z"52!LO2M3EHN6WNM<\6H&+/M,(NW]VE T>:C
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M\B>!N8_*")=W%#ZE[O,$<J].U2S<>4&E;^QA#1F)IS/>S^(O@-0A=3UV5T_
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MY,8ZRW?&.:AMZ4!H-C(OR'_/(C,^T46HN3OZJP(1D8@NXMT99LD+LHVNE?U
M+85A]H3<ZC9V*XS6.K[F>*Z]]@T1:DA7>=>QAW]B>K@8CIR4TEV$GWYHY@-K
M67]!5D_"/5?:3XX\_&MV)QMOD7 Y9\1H!EV8=TZ! !*S>-1:ELUB@QGA3KOL
M;30WLA&0,!-?'-'.UHFZ6J7Q:%#DS_3N[/C+-KO_$\8,<O+$#+#F<&[;'7IA
MG__LWS \^78>\]:(<K53AEBI&M1,J4W=JP1I"0C"E&\Z I9].C1<&HZP$L#1
M.YYB^;M#VY?WHFVY/M]P@KU$9V%_62N!N-%QY\XCE+>F'(Y?8%C#57<;8^L'
MB$&1X!8)]GIZT="HEBM$:7FG;T\Y)4E,:NCDG5P0J5:2,8.]F9@Y4UAWWLQB
M]2H0C6#BVXT?1G\#S( PRX;.I.>O2U] Y\Q4X:2S#0XDQ\]PED<?4-6;G4<U
M9N,[B'N<,;TUK=16!QE9XQ8C'D1E%;%]CV.%Y%^EQHWN,":L$&N8 #CQ7H*X
M L,G94;ZYRY,XAG=P@\F=1JG@OUV3'P&:',ZXEZLYY[B2Y1%OS;3Q(!YR/&"
MW1R,,Y7Z)=(G1\C40<&@-M L];?A9%/92Z/+37![2>A"E:>8BQ;FZP)V4+;)
MB_X!*!P>W<>2N6';A-KK4XO_ $X7,#-. FG2\CBT_.0(LN.^R=F.%PSYAJ^?
M,G)ATYO 0 -5=%#=YTJM5C<9^M?N_UE[1MO,QOX%:R!\'V$2) A6/63T^;MH
M#&;\AJ/GX6H'ZSGO%W,*Q$LA4"-SQI\!:JBSB_W=UV'5[B,SMU7QMH[&,!]$
MT)<TN^ $S@-Y,.N!@"EA,E-YECZ,6PCX6W" *Q<-_*+*GX^C9G!SIJ"LE#4&
M$B>?2 *B1+''J4>P&(+L)I(,UK!FYMIJY9"97-V?9[E%@4"(U]P'@1O!\&I-
ME^U5(%BE7OQ+(TDB?[L*9ZN1L0H]L1>JUCVO8)DA^)3(NMW-? Y8L65;(!F5
MG/AK8I7>AQ)4'G/MB?T!Q@D5!WP!(XU"]D2B?$H[O$W6F%*:KA9UQ(WQ;\%1
MFY'9OQ6(+;K?J+5R@VT[1MG6V+T+BR:D"Z[%'_C'4^>2S;/6GI"X99:,D*_G
M=^O@Z8R+2T>?^$B ^"2./,47O2]J2GLNLN?-UJ.!\\W*G0\^-H#4?I@K_YE2
M#_S(/@E#R@&3KO7@"E%>]7WW!I^:""1C'L)1J5<I%2(;QDO[7EN;,4\)TA(S
M%T!C9T3,5,S7^\==%*FXI:>0&5ZN6H/55YN'#*E_$\PIUU:,GF=*H(H:%>+'
M:QD&L/R,FZ+9SN7[EOFA!<R7_3=?88]H+FBFFXU'OYC6^5A@'%-L;#P4?>EN
M^8.([C4\6FI6:F!JZN?5*1PS=?R!3_4M2NSPQV3EO//ONN_=ZKMR^\,N!2(U
M +.@/^@FF!*)CN(A/</?(=!US2256=10_9T^8V*@W'HZ$_26I59^'-[?T*3M
MPV[5MJY;U7BQ<']OP 6]/3G_8:'M#,:O"7Q#!-"JO'70;%[B.C6F-VVS^UN[
MOBR9,C8Q&&5H<F''YU\/Y:4'XSDA8FA04M@!^K7%-_KU,=:(^<109Q>/]/RW
MQUI<G7\<O/DA=(<"\2C#XA+A4Q_1/;FV]=&I8UD>=?^-/+*1HS<6_;K9633M
M*.6->7;MSUI]2"4:'2QT92K/;1G"U6V,XK\/<?KU98HI+IY=:IV<TI64O[ZB
M^[-]?[)O1"CG^HI=K#V]G*[^HI[+Z]8_?G5Z:WO)X$L3%KO5_B>_;ZI\$%U^
M%&:*E]3TLLYBE<8>2@]<9RD;EP7_'B4J#0,_/$+H 8TV#JUN6J7G HU*[1W:
M).>N/4DTNF9!]_,CZWCFZO<$2F)=S.1V_R@0IO]QU1:*[,C1#2[54:L]YH7T
MX7:=84Z',0P',]X=2^#'7KL7(_P8Y^G^POG"MX5ZW\)2HC]=U78\3(&N';QW
MY)Y%145G#L\[.['"0&/O]P%68Q+63S3F-94E=L?+-U]M/H_18&3I-$KI%,RX
MSM\&J7R=4'3LZO/4:9N=8@V<Y&8AB!* GXG_+HP)LCPN<R@"Z,;$J;S1\]XG
M_'M)QV:#)3;AFW3IH\V=$DD!@V+VT'>IMF -]'/(8/]?#&V&K^QUC)[5V1NO
MUT397A0G2OV+E4#"O2!/7=ND_ME<H=(>:GXJH\O'K<F&]_S#7^?^J,Q>(;E;
M/(:3:.^W5Y>7E#*(K@N=71L;KH:.IW?]!+4#+F1@2.<2K]R1>_QMSV/$/[!=
MN61V&#!%_^6K=K]GP;S9 NFVP6=YL^YLTB"C'O62I5.*VQ;;)*[KZR)NN=?>
MWB]R.K).^D'B.>%^2D_O[0(H?(-<,,B%0N7X0J]YD\/?7D5(9NG?K3X'F7K'
MZ^SQ9F%7[:SG7>8(%L9/R<M@+>GN8GK2&Q<=7T\:GC?&;3?X+^KLC?BTK!T3
M8*1MH]:UYQL++B2'H^QE%JY;XI-?_/7UPZ[[W\<UBV.)=^H:91/\[K\P55<A
M@->BXQ>( N0+,U/BBT*RM!'OG5+3YK9#]VVAKF[2-H:F[N#!UQ<1]^Y-3#@
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MH<,^!@DN\617%W:JA*3?D[56MM@\4""\T]-K'GF40"S[ZX*XLO]6RZ_.T[=
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M3#LY[4Y5H;%RQA+NKQ@0X)K$H50!D$]T/][GNEUR6CB A/(Y=.H#V=6<+<\
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MVAW@,Y67H^;'+WQE_L+G,D3D4+SZ^JZA,X;O=8_4;J#-(!T9DU'LE !=CAZ
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M:Z&2:M$-SC$5L&[WY\L]0[&+J!G!FT,!M#,9R]D]/^ YX%\)>>RA7ZPJ!DD
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M$9D0LKC7?$I+O7R?^VBW%O]A#E"K@+GCLY)"RHCYFQQ#&[/?478-$KS:[)>
MPO./@;J#PM^L(R@6]/#R.@LC*6FE'3.WW6O>X?F-UA5'A+QI]$H[C @&0%7
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M.??!IU/\+,2M>JG0*&&1!N##UR+7.1YS=&<!":YWFQTZ%+"-J/E-,U0(OUU
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M<@MPNUI(0M2"YL\;B<$D^=G,8#7T.QG1UMK@)E%\=@ 2D_MVIC&W!FB>S7Q
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M:MC@VF HZE=Z]2.E#1*@/:7@V62V7YCJJFAR?BQV=D#=OM49+PC\T/S>6>Q
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MF=0*:3EO&U"3^TFQ7/@LP)4/4>3TXO,H#F.68CVM'>M83D'Q7.<*%W7*3P_
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MM7HH:P.$5_@+*+[U$<,G=$%")[>'L%AO?DI6249,9,IOE"YABD*UQ4!Q'56
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M!>>]R[4(M8&LV-O)9!X#OVQ^(WQZ]/H3H( BGQ!#$PQ+D[/]-V+T'3P>O-%
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M2WOQZ^4%=?;(GVOEJ9%W9WE'_B-RT]JZ7C1FNS>++"@9.Y=% O++M1IO456
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M!!JA72Z+;R(:K]+*Y#JX3-KK!Y%B)!"MD%W!N*'@T*'><R<^YS?<GCVF<OL
MCL8Z3M?:\_CO71<W7Z4RVS#.NA[SF4EO1 G><W@5Y:YYC]SZI=/0_YRXC-ZS
M^D,".7MR%+3&G@8/B=!,N>=#(SVO%D8+AA\PHA,&Z+":+]M)FI;WE9#CWAQV
MSV=Z#E1+[1S#&#_1OQ62NJO29>B=AJV;W7HX].0>M63;X)DO\T\T-Z\<_$>$
MR5%#R\.VZR:NV&"UA_VH'5"\X7D/-%%.WOVQ("7L8W:F1]&?&49]G5PZW\$L
MJW[=U?9"MY.D2<LSMSA<",_$?=#3TR1R:?UEM7O-;:29^C27_1V5]L/K.?M6
M>T5BN)S*>7*[GRN#,"4['/1TZ5R?\_(-<,^"O$O5V3]2PSQ0ENGXFI(D@1"7
MJ5P=#EZ*INO6G@V0%V#893IU)+R74R_>9X7@E7,-ZY=X7&(M.H@C32'#5*F
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MQ<HXN3&X(-(.5CTHS8^G59_2&+NE$./F.%B#G'O"I")P&+LF70TVN(01\7:
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M%Z4J?^M\"5^JEE#-6 %.[6?=?,>8AQ*4'LDW,0G-AXV\)@AJ0WS77H\^XO5
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M2?Q)58ZEU0#=P=R&0OJN:SKRW!8L-&2>BV=C9V73H:,)*ZN<3@-<Y;3(_"Z
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MZ A8(($<6BN1(7!.25U'0'Z%UG//+DB+?,L\J@7@E\Z8E"[/ZSSS2]UO(/O
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MA06]C 9H C-M^K:IU0A_/<6(X:-AOJJ[>!';2HU^2^ZU7@S;\C_]3AR$I/F
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M:#P]NKY<$=<C&H5H=T.B+""K%&E&I?_*?#)FI??+;FO^/L6G]311$<<)<0;
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MPURI@CZ)T&!G^Z:W1^><[/N_KN4_M-\!3!/[]#I'!EM/PS.[[Q/0RPH(C6)
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ME8XBYJ^7O:/C1M?L-0'/[ \9(@2B(/K9\O35_A#[B"JSE,.0G=<(&P!;>!I
M3R_N[IM[J#:C5JG&+(T2*)'5<*F*/E4.5=%HT?*XKG5BF([E\NW3.^@M9N<U
M((*2R"C3X*R*Z'7[:_\HG&6I@>-&C05P2T8I90)&%RV(0%]H)E: D"IX!M^W
MVJ/=ORM)MYF:5BM2]\$MH21I4=.QWZX_^RM$S6J]I("[+,=[T7P_Y_.GK2;I
MN9)[>;-/T5_+"7PZU6?9-?X5D@$Q%RU@P/2JD'J#'C21%=.B7??W&IZP@89;
M8M^@E<!7MW>T.?QD=JA;>9Q6KU/N;%X.%PR\."99&M[*V$^^M6)8-5C3EKI[
M$0?TM0<6Z*2%2\TNWM@)9B!J\W"2;(*_JWJO1[ /OQCLN4T;PJJJA7;8I+CK
M[ Y2.W%NC.NLP9\4PYB"(^E'%&&(ELR[JK&-A;NXJ2ZGQ+#$T;O'P-V4M5?F
M:[9H&[IK>:M?2G579?PJEBEUW@=:;'OV!3A"DG6O1E\BNKU:=SD:;/FH:'38
M%2<O)X8-RW=B[[%M1 H.=H7NG_Z1S/J!M1* PM246)>$RG3KD7AACAC6L1VQ
MA [C!T&975'1;U(B?2?4BK]]N.<I>R;Y;?7]?H*(1+IYW_IS$NF^[&,-=Z7M
M(:__0(@%Y-RH*"TR6[^ 8F(+),<O%+V5AJR_NG(Q0FOZA]QZ/-[N_EB.BW-?
MO'91BS4X59P/J0Y5?PI=10PSZ 02HUA]Z@,QA>MC\^9&Q4++DH2N.0,"4KQ$
M&,9 &H3J)\KI]08!!83?\UN=7MX]%<OU$/1\5_^5+K6BQSBQ9/W);,6 =SO*
MG=?S@9G0,Z P]@T"HC[,S"BZ'6GG;6ZWO[K;8<_I6[L3]I6FQA;L>G;G06;$
M=;7@G=[P>TIS/55@Q:W%0W*PS@@QK*CSP-_4QX*?I354X"32>1UM)T]E=0)]
M9[:ZG4=8.3XAO0+_S7K3.J6MZAS&]OP:Z1Y7=N3DON*DA>*0TMH4+P+YN!8%
MS4H*@X?Y/B[+J3.DC):TGF^A'7\(.DHU0FHQ0K*]1V-T)0/WP>A"%=)0&-O'
MJ.13BH#8SZOETT]VDY3L8@,[[7UL+_S[36YUVQVOVWZ*!NO_.;+D/CCO:(\.
MC^D0 C,MUQ2A0=%E93B_G&45 *HHFIQL,S(1PV1)*WQ4_.R3/9#AE7'/9)5S
M[?? V&3\*/KF5_I]>HVO=P1F_E(EIUIWYW7<WVQ\,5FRRKJCG1WR@+M$@I*1
M@_R5$,3YJ"O3!5E+F6/7FZ$IEDN3^<S3@X*E#P4-W6Z))J%H#9<XI$#=)8^D
M]M'69MU-H['8<N188Q/U*G5Y10R3MI97"=SP_5R&L#)MWT\,@4]'<0GE0<SL
M&6N^2H^ES0$\VXLIX3:+JW> !G#(B.%W9!5R5GWWK^ZJSDBV).-LR(I5L8/0
M[ T]:*%1@<QA$/DL.]8(U34NQ(*](EVHFM,!W(C Y-?>7G85%KY&V-I2VR@$
MTGFYX8@@)HJ?W^Z0?^O68?S"T>80=1/UNCGAM131X_N4LF8RM5&HM,\$L&JU
M]4N]N03^\\OM&$[(  8P/4(LU^&8X25&[FWBM?T#W#ZWSY^_?"ZLZ]P:Y)A
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MA) -) O/*KXV;509NQ&8/X+*K1KM$2RPE7^=ZA/#&DQ-Q3!SL%7_U:>'.P7
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MHA[+W 7<(HYP-$(4E!ZD=PPG(4B?)LCLW1:W%PJFBB:!6F_VNPL'C!WMGB)
MJ_TH#H8EP2;,+3]W&N+N]^2A:X!E[NOS]IX_^'>"U2<,N.XDTJTK_T@?C$5F
M+#*"7C*BAHZ/=;<L!+SYY',1$VPW+(8]VC+DF5'89;&M%J1::ZE$ S#!J<J)
MS7,^5L/,&\GW]X7MOH::U<\5&.FKQKR7:,$(_C_A#]#O(JBM9./D>:@FLY>K
M]JWN?4[^RM[G3XS)9[_UBF%_@ 3?N02K\>_58>5\@YM[4V*SCEU#;5F]U1+5
M6568/6H(.S=2FRK[,O*UUR3;9?*OCY"EVC_!=@ZZXOX.)_IMW5&,9_Y&-H2E
M%?H6CEJ$CET[ZF^V:X4A2@IZ.-/(=!OF*<DH9&;J:+?.R!;->ZH=7;ZA1#.G
MA[!M:T34Y)E,MKP8MN4K/(5O]0\;4Q4H-]]16E?^&S"?S JX=E<379Q6';-W
M^E5/\O  Z7I9\^T,+5[<F)#L-A--:6(?82H<"[2)!-5H008?,O42A< \$'LM
MF4@<-M?3DI[6,X3?&KHVT=8D?W%@VUWP_2YI.0G3KWY/UFDKTNA^>>?W'EYR
M\'DQ[#U30H7K(,>4T]F$&9GF2UWQD.O\KH(Y43CG*);V9:*?5]B$YS#K5K*?
M .-48Y=0/.=Q^DB8,!A8^MAF!5W0]4D#EEFX@%V9/GZNXP2_T:5.X9:G;E3J
MTZL$OLP)V)IMR7N(+[ ^PO$,DC$./KY<(V$4C:N<8OG12SO^NHIB-HEASQ^+
M_Q])5QX(U?K^IU6WTM0MJ<345:F$NMF7F5Q)$BH)628)(2;[UCB52@F3B+(-
M)6.)L8]]DBU)(V,?C"7+S-C-8K8SO^/[\^<8SCGO^[R?Y;S/^SPP?-B@S03&
MKF^Q6B^B<"7R(+=6[N$#.&1S@L5]G'%7 ?!A,] @>)DZL' C]?U8?2\HE.+?
M2/_+H'?4QO/<R^>>7T4OTG S5P+M$4J^?%UX+*"4YW[H!>)SK;VTH\U%#2OL
MUZ9;0"TR30@/#W;5(.D,A2C8>+IQ/H?][>\V<:82FHFHHX0Y9@IY7-<V.@WS
M[1=S9,7RM>?AY.\Q;EM3DAFV[FW> >_1 M@^NIBDL.*^6%!)F1CJE'ET/*J6
M>J;^TFA[9KJ"V@WXBE1A@FY4CI9:2*]/RF%I\Q.Z>&]GY0+HYP6>I_@6XO00
MH01V2TN #WG]78$^NEJ5@CZ99_E> ?C -)OV\29-\2\V[[6Z E?##[)^HW]V
MO&U3N?JNG+[L]46H2^G4WRN!M:FI42$Q%BXE7Q62L>/0[G.BJP8>_  ]VF)$
M!ASBU$NS5@O@LQ%'+<OB@M7>?:$[+;A# Z)8:=<#$_@C'E$CDQ)8<V';BV'
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M-DXTFM<(8<1,+_(-]!75I^G"FF+_N_D_->[F9$(F2WK;>M*(N&'-1_<*-]'
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MJR!N*?#>M/8P$'-**L>N$N7> AEN[[QD1#^BBOSBM@0V9](_I/6GLP/##_"
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MY6X?$I66("2!PACG,H6)EL5_D:P4XNK;ZKR%4&RKG/V&4@TD;-%427B<SF"
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MFPLAWQ%<"[;S7&RR\961@,61MC'-HH2BP,L%8T6/S@;?'< '2?VZT__6E"R
MNN"K%";+9 <I,VE?H*GOX6I?W8^G' ::.]&JIEX"CZ^0NJ[K9=][F//NK7&K
M4II]*.G3F*)MMF9F_5KE\QPKV#E;7)J\<0@_T::GR;+5)I6L,T6?'_[3N:8A
M>!7L&UOI"*SISYF<927G'#=&M:>$N4S.!'K=74YIK8X^0.!7A9APD'<#(KM#
MC]?=G*BF!P9<'R<^$AJ$;CYY=JK-5LOJ%^+O$6M=_"^I>789(FFK8?S<FG^$
MQP[IR*=E&;KR[H'\;SP>-G$_HX1S\\.BK:G#A<?0Y V;'TMRD7$<3/'X&I%_
MEX?ML*@\ ZNC*U6YEP2X5U=PHRX;Y2J6C3"[>,\/?;"W8!6,B2$X5^?!1N.J
M/O>/804E'R]+9TL+4X1P!5]S:AVZA$8A7H]%C=X#D:NVJ=+.G&C1 NZ5&'*4
M/QTR712L+(;T^'VRU7KH&VMK\\Z]F-G9D^#T5M&(>T%]!LF:J@@3Z9_VZ0%I
MIT28^]F0UM.: LW."H8>YI&(>(?Z?*3=.FS019BHCZZ>H$ELY@7\P">J(TDG
M<CAF\4W W:%23F?,W@KT(C*\#>Y@8FZ\30CD+2#*F#OP/0E2^T6W%A^I4U[!
MD?R,KGGEMP?*?LP=>#PBO^5C'1*VRDJ9.]G1/A)F(7Q!$Y!\IWS[:2^[RT):
M>F2]+L0'9)"OC^V\\%AZH?^:^\L<+B>!6HV)\ZC&1#9>CB"JRNL4Y,*Q%_8R
M9Q&G%S3_B:JJW(C/UE@="YGL.5=1+D%#!XRM TM6Z D?--:<E&^>>W"O39(P
M=:6D=^G\98*74J\=^PT)\8)'&[IXTX LQY+1L=GG?IFQURWVQ'Q=W9^\JE(\
MD^!/9>P+HF;?L['%'Q\_4ETFWXZ_\(HA24+2]?37M \?A@1)F0:!GSEW$N6]
M+J92D!L?VM>NF8+7\RQD[24K7)._MM_+E^;HV7O] .9 [D7>^\NQ.**JBI-,
M2?.M>T/Z6P]+;?#EA(,[_",+5JGY2^U?#4*]IH8Z7+Q9_4[-;U)^#,G?&NGN
M7Z@VT'CW;_#&F")<>_[P:#GM 'XFS3_25CKORWG-;]9]E!1X2=/60_GQWGSZ
MYU,A.HD1JQ;^"]JOL%+OYS,SST,?!CQ4UE-X\@H!LUC;Y!EPJB>,AN,Y/4B/
M9 (<<+JU>>AJB>>+.JVM*VG=KH?X3T<G>?XJEYKR%S&,SE+IFG<9\CFG-:,+
MT2=R14VAY7.YJ1%ZIS0L^J[:EBT+[)4M(M,/5'X^4IVB_F%9ZV-W2%1[/N*L
MZ-%TN>B$!2QJY.7[+^T;_@+A:=1M1&I)5F2TZM^CCXKEZX&:+K/QDE$&G+KB
M.H%S'EU[-9]*Q_H[Z=EN+@5>BZ;^M0W)]'#[G.OBG<4XSMTRD61<HE:9 %](
ML!HI.,9_O<_&Y+EY!^^;O[-+4:$EV4M=L.VL%-. <$WYY8 @HA3<T.%E--1S
MPVJQ'QL5_F<Q9*EZRX\TMVY1:H_+W%6F#6[F2ED9)_9+\(NPAY,)C[W.)<E\
MWNVMNV.KM)"FY*GD7TUNU=_Y6V-'H\UJPT_025O01UP;XJ)?%C%D6^V?MW'^
M4>O*I<FSI"VMKA9;6X??]MIA+P_,#]&%\/9S*V_)'F6O'VNYD=5?*ET!'\B]
M7VWKV3CD=<IR>4LR>7N4DZJ1;_DJ!KF!:?_+A]?42MY[X,DCQ*-1(CRXD?+M
M\_TB57G52_(V_,RA]9[/">\-V[ Q3:N89T?_N?QJ=>5J#E(%PO?W>M1_^#.V
MZM#> VI??A_401JGA-[)I/<X=88/*<<FY PEX+Q9QA8^8UE%Z-ST'0&F:IL/
M[Y-X;H(OBW.UP=(O$)?Q$&+%VJ0X9W0A;Y5,[?PL0<\*G$V>U=>A2EE'S#RP
M ((R;+4?><&JS'P'?;JNK+@9J/3!=CB84D)PA*M-M.\E'MR$/29K,.0:#.0*
M-.-<B-4@.0U_XVD2]NBJ@59Q,2DD,M!^Q-U$#'D&6:]/BL+(.I$5>D2OLX>K
M3EY_,%Z;O3^17IDF71MQ@(\9ZA-#9$$E#/":R,7X]/F4L^=:W:N.O0("<+S_
MXD3 F"MX2& DFM0 ZZ&37;!TV[_LO@3L#5]9%6FT&/(<)@'U-\<-1(KLI2VZ
MX[V*B17EF;T]U!$5L[/[QP#C3M,"IS8Q)$??4=]=+5EY*]77HQUF'W#RC*#&
MH4?7$/X+> UDK'3_]<<:5SJ*<*RUHPR,LF$8!Z:DF$R.$WPD3<WHPOL$%>]F
M89&@4<BYI-7PGQ$_=?'+>@C>??C'12&2"EI]=G@JAM@WI\\V8)CDB?6"D+"D
MYO->'V50^#O]+SQ=R-()6'@)$4!VM554F;%@2X@5E!>7(+*;K::S[;.=*:SI
M.[JXE?]M8-\GY ++: YL*4( (Y0 4SCGN?/E]3_\1/GY1I[@/J( %O*E<K5F
MVVS!^'8*;K)C@VGQ\M,U^1N(06S;Z02I=[2/M\;ZTM*:)C/K#GQTZ)/P.LBR
MYZ)AX>!U^E?U5[ UNEGAXIGB_(Q#O9^8R?(S];6[W\,W;7#Q$ 'DH:_H';W3
M;"^C?^X;+=Z;SG?<:5SN218 [*KT5\>@SAL3 _]_V]M 8V@<SVA@_N4\*1,@
MK@$RC'D[E?!<,:0!+4J@4]\'T6=TY])))^,GW[XM,!NR=LE"]%-Q:W@"#.>6
M]O8<GI$\?W=(>R,0=S5^N+R_S$*TV/4;Q03'R\20( 7)AW/)MTG)J9V_&8&V
MR"$J97GM -S$$-?4:?[^.3&$NTM$U0-)?^<]Q9"+(GB1Z/*@&$)7UA")(<%_
M4CA^WVCP T5S^6P\;=#V;6N7(Q<K88@^<20NUHQ/C\1 ET#:+1F$HMS' :9L
M0PA<0V!TBRUK>6X!7ME]]L7'S@X FDO&Y]%<M*8*Q)#=4$'?>'_"IY@V"X/S
M4&YUY)K&M<5!DO:GD#W/LP_M0=_';\0 SI%U1G5+3F@"]#%_S7EML:JO2I#G
MWT-FPQ@B>HUQ(B8[I)T-6S43_<- OJ$8;YV#OHYMOH-;)O:)?!FQVH()OVF*
M?9[Y1>H<:K:=I<['>&DKC@O0X3EW6-O&]B[ ^=20A*N#%=/<3P%&+Y^$]6E$
M(B;?X^;7\"O&-3?-A45E88QXH+,,)*=H''DUI;T[L?$%UBQOLH,QFR_("O-$
M<Q.\1<;5]1U!HGU)*19K)"LMKR<;5(935<&C0$3> _;Q$-S633)X;AYL*:Q+
M.]Q31'1,"SDYX,DH73OID <MV@>+)-_7!.N) ?8NP%LQY-,MU$+R49'G@E0I
M\UK@GB ]7Y9J_F!RE+_!>/P.%PZK*V#8W60RMI X^I-X)/R8F<#C#D:;?VX>
MU\N?Q_,:.S,L[D7)@'G-N2[^BXSGUL=]#=%+-[OD:SQN%)3[^)67,J%<!A36
M1]/2I[9F%;KD">%'JP:[4#TVJ915T.G %_?9M#1!/,#=:HQ?416MB"%>V*85
MIUH :G)D>[P*W()#=YY?U_1P:>K>_@3K1V!&-<$X1WK%$#1#CX&@U I"_/?=
MEIJ"FBPA;4\X^1(;B4,[,(YXWN ']OCL4WAR_]CRX95RFPK%!K,\'E0 WS;<
MCNA ],QV(1'-PD2#/&DFJ,"1 +-W_I=G#(8%\_*%(RGQMD[V'YHWX/Z,',L]
MGCEW":R,]KS7L"X/<:Z2"5UL7PBY_; D@9(D=92W875&!V0&Y-X*SA!#RC$.
M$,/ON?+!YD6B'1/T?D]>K$_I.)PDLIL!Z8^B#+8@\OW?H55:?A-B54V?TS[F
MU.4#@>^R).]LL/X^BKZO)N_Q]6&3\[X+'\P1IC#/K3/NO[U.&,_\[9PJ^!1E
M_RY+X4$9'^="^P$JS0".R=V?'^[/PW-#K)%\:>%^H KV:!LYRW\?'8\S-WJ8
M*?(!:NQ%"YA_*D>[/I"3U3,:$N1)#X1V'#WFN,BG^D]HD>@G8FZT(\Z_AL"2
MYH;LS *N</SU;X:G#I'P7/U?:'**0=@N,._D\^'AYMY[(6N^$RO/KO?E:/=;
M]Z' C6+(WDP'I+X ?3?)'3^;7"K=+IQ.28S9X.^-EH26]RHOWJG(R!,+[+X,
M.HJJ=$BPU4^9=!)8.V1Q4$<C[_JNTE/><[=BK7=>--PB9(+\X:'/ZN4@-1,L
M)EZ1_;.%3JM0];<10V(D&25DA>O>(0M.)?CZBB'R:]C/:-K:?Z%9 J.0IR<9
M#>>-]-;WS,"+ZX)09_PVX+*3D,OK=T=3\H*PF$80MF0LZJLT+N 96, 8CJ*1
M96S:^SX1RM4N08HQHSB3H=7+8@)-O8'&P$1FR@*B^<_[,-2$LK+7M/ ^_C#H
M_,HUAI))?;%-7801[/6>B4V?:WEI?"0I[_#M6QJ/)4O>[#'O$3P^ZZ6%?CQE
MF,>O+ ^^_S-9H#/;&=K(69P86NXI:1J,$D*&9-O+?6"UU=/64L*8]T"4&'((
ML(:3*<R?N[GJHJ272J[:L]]=\"9@"FC2X20'^%\^_SW_Z^D@ 6PU^_$TLX$H
M(!<RR[;*A:C4N61-"A#-712I\N26M^6&&<:#U7%OYQ1'H'VS8LBN!7Z[#[_M
M_9W;M@LS%@/MDZTV,B)O,83"7UD8@S'X.Y8,PIDS#R4S]@MHI*_DN59)A1H7
M!B-J1=.#T56C[%>&VM9/#%3#P6+26!*%O13'+Q)#]G68="^%XKVDZ@1*_X@A
MI1']Z+M<K["V=_KO$E#YK-.\]9_WI]3.Y.7];R1JHN$H>TF="U0*D)*I#Z>1
M!Y6TW5LYP4+BH/T0-#\95G<<F+MV!_J B&FM*A!Y=V5A?XPMA$7P0BRNKP$H
M/%=9-%=7"W!A3L3C!1])XRQ]SB?L[P)8"FC3E5'F(XC6[&@E,K]@:TRO?O@S
M^?/TE[GW0///RSB"X/<4G=*?XC6DM;8'U.X(P& BC;C<67O+/Y*T$@XR@4<Q
MIDGO6[Q1<5:_ !N0)#3%.']#],QW N;NR.',@Z LCC(+LA<&_N%[CUMV:OW.
ME>87=7@6[A%0^BOH(6W$U-^]49$OU->[4$J,4>71=#_R?I%H$@MGT3<#=?P0
M1O7G'L^(+Q+#4#>=B[_=_5&:[0-%4$15(EQL_?_:G-DOS!AN(]1VS]P],AW+
M*I,2C5/33QM9*28:U(A(/&E0??"-D67?MO=(3WT)?E,@\4':2GE_)KN9,2*&
M1$> 5XUG<7$._*+N!P)'OI\W&[%$,A:J+1OT$:)"R]M!"[:B&6M+K6B<]B,>
MQ;;/7/-_K9!/%.Q9[YV%@RTY4^/W&Q$L_;^<4+D&JZH=S\R[CWCM@AA#]@V$
M5NB^%$-FN+!F4#,KA]8DU!**(6-\",;^ 2/D[?G+]#\,H:S:*"UXR%-6WG_+
MF;>H47J5HX[P626.7:9O/ [Z]0=4B"$KYXXA'%,22SBSQQ=IR;L!8]C(S UJ
M(KJPA"U[T([J\S*L3P7MB(J2O0'VX_)4ZJBN:HS/.VO&3>B=V+;YH_^]I[\_
M@A^9]=_AEP_]E5XLAGQ'SX)K('5 >/,I=0K&=DE]T(>[7:J@/\$$UN@KR,!;
M]]9O:(.E;O_K:V O]!@$4HMX;$_7#!4)6(XFK3X60U*JZ+_#*:E59AQ"GM\H
M ^$\!T4P$$LJ\WPZ8KHKNM1*=[/JC*FS&#**=O]+1T9'FET@^7>,K_;O4-MT
M?<.']ND"KJ)2PG;3&*EVEAB2<!3XBXDNX]0K#U)@L,CH_QQU:]XT[WF6BL>W
MISW >A2FI*7^B'.[FWGI-&XHMYX)EAZ5KR+U<7Q=&Y1NE-O_)HHAWUQ%T3%Z
M(C_F:'Q2<GBO>QBIGX6O4&@=M/N$PJ\I_0L,HQD V_SONB(GL!;],S#R,[D'
M(7%;??-,A^.ACW=:=XT_U@C#+QKF OTK;(Z+_$<]V,PN,22+.?NJ;,4@)FRX
M4&#?996^[?ASH0CH!NJKNHJ0('_VDO0=724^\!.V1%(9X&NOB_3-?RX"5=9&
M_"M#^36W+=8^BB&>MCA=UC,I?G:0-*@Z/%G$3U*VO65:'Y'<KD$Y)Z6.&'YG
M,99IUG?X><DQH$0]$B,SO"K_DFZF(&SU=WT'(TI>+9:%U?[6ND5(^Q607V*V
ML(I?LEP/3H;>C!=(_5G4';^'TOIW;$=0@V8\(ZG DV?.O&X# GX&JIAI&MNK
M6&TI?WU=2Q<GE 75M( :Q,1XOZKW!+FH<OEZ,**'Q]*A+OY386F[/:2W>)8?
M>?_ "*(^4"50W0LIB &5S+70Y()T"J-%!_Q%FA-5(?X9(/Z& &<$1M;W.:^H
MM8^3(B6$1RH<!2*6$,C[ BMG:K+(.09.+3&RN\3I52@6H;) ]8%.,>0_5KOE
M >4T8B&P?$8^*A-F\B18XA$%? E-<KW-U';>YTN0$O+-2;<Z3-$C/5];; '4
MF*GZ>A\#(3)?6/G!Q1N,&F&5H@.E7DOS_'KT_@Y+,.COD$HY>^O-%VPC,R69
M[2#N 7,UNQ>V")WW*U$6H40-9!O8KJJ?&OTW%ZZM$! .@[N$-_N$(#;VCN<:
MAQ<O"XNSNMJJD.VVW[ZKZJ(@<[^VT'YI!459*B@.(G'Q#_#5U7$1EDKC_K49
MUH\XW\S S0D)T#0R;$FE&1],N';-,6-O0LP)VB45[2>C644\HZP$:Z T$\5/
M7/S<UZ=/"=*CB8XDCIADCBMOW^^51AOXHT8;>$3M)N!&SEFB6=-K66%XY!RR
MH'> ,4'%S]]!=KC/?_W<KC#.&?]^QHL=3:Y1&B]9/&^GM83Z(('I;(0S7/4#
M. 04< P*)V5D[D@2$?3??8Z3/<-7R4W/@/,L55A)^/R#<::O).::R-%WP(QC
M;B3@+%5:)&1)H(QAS&_J[4",T+OH.,^P7S!JJ/+QFM%N\SG%D$R4_,/,6>3<
M/0ERZ' V<?7N>ODM3^Y%*!'IZ=Y8/2Z[1KV.@7$+E$3 5'LW2D3,KQYMTM,/
MDH1ELYM*M-;D5BBU:TM%3F UXIT72@I/. 1;%;@<+Q5#[GM*GK=2 +VS^I)-
MXL"W:O&2!JH/F8BJU*;)BV^/(%XS%$5FS!>--I.DX3>()>,FPB Z!U$B6=EH
M/[0<&^V_3.2&(&]X*1[7$!J:7Q-I63KA>&$&3P&J)&8<2K*3!+0+,TV;7DVW
M<_SW<1GG*RE=TW/MW'$T*,"'1/B?897VV^:FYK;;#77> RF1BG/".#:"01J&
M5[I"IRG5$.*\]')P9KL@MKFO)W:]E%#"H636Z[<SE0!8UM??HV#>)"75SMK6
M]O7='P+$BIH8LK1)0A67-,,DD=\K50PIZML(G:*/-JC07MVZ._]W3S?B,/B-
MRH_$A'ED AX]O_-L/)99\D6\&IA?< D"MQ:-32E]T36=8J"N1].U(%Z8Z'T
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MK[_C^>MNZ!?=]J00N5-X[RF<M%\IN?L=_J3R)E3SF900BO\3I_$!*GE;Q-"
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MAF, J&UP\PYWQ]C)ED'?8\([+XXM<H6O:90G5W10PJK!!$5:= X<QK:G\78
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MBJ<#EV/3N%^+$W2^XW5]SOFF(UD9X:MK1+R5I]?Y!S4Z_K7XZ(W=%/E6TSA
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MTV_A>'DJW[YBS;7VG'W%#IER\VMN,U_UX_5%:]@K[,$1H'TJ<!3W^J;[$BM
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M-S5),8ZMM%0)]_E]XG)A1<V\@QCI@SW3?]W&G:X!_,F2@8HH"L-GF>\M_WU
M!EEN]A=;2)\2[^W166%K+H_53^X]IF_^&"1$BM"H6W\H0RZ8O"575$5(A=H!
MY3U>M@MA6416WPW":ZG%S!->NJ[+S0)U*H"G]D%TIZD)D>ZS=KQ'JQT4_Y6!
MNBU7.5\>P)V V]M@,A4548Q ZR HO;04':YRH0KLEI$XG\OV]3:Z^#FX4Z>S
M2!Z)P?=79TD]#^+,6'&ABV:K4ZVGTXX9(N,32;M%Z""QK2CM3-\RP_!D4&J>
MU'P>.L"WNZ"J;@-3+A?0'T@4!.H,[NH(I'%]BA1.R!J!7>DLARP2.ZL7MU&9
M\^PT<I0T(''%90C]4[ '8]'/NIRM!!0&'0&/KT/Y"@Q=HKB$\IEGU%XF?2>Q
M49H&6Z<B15?QZ9WG@S[! #Q7+>?2KN>M[A1(K S40NR_'I5CZ$_O*] @#&*Y
MI,GTT;CS'O3W%^:O'51UE(%6BR9>(G/M3/+.\?).7*F9@ /J8YVD*Y)3_FY/
M&[X_>LB [BF=E:#JCWR>9^^"W4@=N_0GE.608V-F_#-KY[F0*<D7D@2*'\3=
M^;C04!9.<J%D_\6K)COL&5!)J2UXR/2YK]Q=W''CNN\;$J*D50;J/:H/94=7
MZ_B/&VYA;Q[MS2@JRENT^"1,?V90U.5?LFG%)3!D\M4!*7"10>$<7C0JCR :
MCTF+#- ;)^I^6V>0&X[+E_[LJU]R$IF^.'*G3D";DSOL^B!V3W@?>CR;7!/8
M#U\$>WI\?!>@B8+#*+4=P<>!=N7WSQ1?,4A5--UYP_Z/)]<; 15'[LV3J &H
M2J6B48!$*; W-\E%^.[?B\17G+EY8D3"NJJ4ABNR<VG6/_?X*9A+).4*(A17
MQKL!1G;B30F92LY$WZJ3@?:M35L3H2#TMP_Q:V>,-WWC_11<<V"." S'W;>D
M4%L:<A*_U*:LA-W?98Q?/$9CNXW,0.H,/U$)5/@KA[+X(SD:E_&@,\;CQ)J(
MSL .=N#M=O_96P>"'A(HRZ.,D[/.3*6,2OV=8FBPSV\W3MW U>T?\MJW9D "
M)<[KQ=?YWJ UQSZIJ(B3^/#:HC3F:X<EZ]U>H6O7'YDP,])8Q>)_C%+'O9DI
MDO&R^.K/^*:K<I">)>>@L8!+*N+^GWN4$/246V/:H^&MUI!-2ALSR=_XG!:-
MG+M[2S[$/O;%9!R(C;"2"Y@@AFIYB\J;[^V::0=G7^WZ6@SM,X!W KSQP(UJ
MNTA/_:][NAGCYL5(< "T/0-WWG$7M=RDW$MS#?)J_;;6:0W/1AGHC%?#C UN
MJ03""%R(8[">EMTZ]Y:F$\VX>D,&RMZKGKD7):XE$)[N\/'Z=!9+M7XV/@+<
M4CD<RBS*Q@Y=$+U)Q@U]/$*M2+@^%6>]]</Z:TFMSVW,G&HVH!&-E<^_\4])
M>Q<0GR%U.4X=^]/LI0Z*;TS(S PA!U8:T1U>X08[%^4T]4_86BC.#HD1^BUT
MIL6.;1I.YBP85M&_.S(_UH?)0+_[AN8CWRJRCG>XIAZ6<T A-)M8TRX#!;ML
M40F_/G\_W.6YILCCCQ=,"**K25DSK*GSR6M ^]-W077*A9RM=C+0B61XP*X"
M5HAO O]%29/)TP93)GF*%;PW"L=]*1&OIZ*ZD[4G__JUU6/=M$3@D*8\*6X:
M;<R*#<*_G8#Z&NR^&"OT8?HRM'4.#]14SHL6'NR!O,"3.RX%?!SY>'HF\4(3
M>,RY84\< L,[XMJ)D[^2'S)0K; _P&IONCI6878V_4E]$=N,]?-B7[KA<;!P
MO8%K$*QQ++F_#A8Z24 [%)26C44_<RVM*? Z'J>=<#H98IN;]3I.Z?LR3/&I
M8BG\$&JDZI=3S,0X4%>]8#\!QA_ V77KZXIS43^M$)\]MZ?,'I&2M&,_ S=2
MSC;:A>I>]]V=#/].#=J*?4(:@_CSW;0P"UHLW?>L2'PXGF'7V-^2<%#Z2;/O
M&7HI]*R+ &H='!:I:?V\@0:X1!P.M?5],A@1DXL_(T;XNO/ZTGTP2R=N?=BY
MNX+K0[I:-;M"$=%,=,ZA^A9"KTQ*::>NIE3A[5(&*O$F2M'C+LQ4QY<G-AVQ
MZY@!*$X&Y4)?+C!$=2F.1<UZA[("PR=?[#IK,]6BZ_^AT?N,C9>^[B64^I34
M.X)P$M5?6'@[3>=!8<'UM7%=UI&4-&/4<9H1DSBJ?3!E[*%FREL+L:<S> BY
MQ1_>7DEZT_-I%G'CGMZ;TWU]04[;X]I@L-M!TK:[&34*L2/ =QXD2&?S1 5A
MLV;Z$>QP4Z:8C4X7@3>ZI,@U[?"<&PL^,U85VH#6:AZ\V3^TPRSN2TY!HS%4
MD&B<*;@[][HHU?[T*9?'*O'K21ED/52W3^AM/,'J-^8[]IWZR\,2XK;EP7I"
M*OC-I!+&0#2;[=8CV%7R"!58HX?&G+Z9-JI2/S4_3[@6=*Y"=Z?Y7ET[+9"A
M5AMHK$;TR#=8K#-FZEU.==Z$%4P.7DLXLOF]\PTAYRE[C,J(_:AN>^DW.6Z#
M%;3?.A\K+):<?(\G)8;^DLZ\I=GOVT5%K:G3/'ZZKQKRF_;H]-(/B]1X$/PH
M2_N\2+K)E:D^%J)\=6QBS(KR^E_"_O1#Z9AY\M4+26-M^E2+C,3Q%.S^. 6C
M;5"!%:0YE 6;P2>,5DN'882".T(=ZL[@&PE.AS_DWL_):JZJ[L3/]&T$W5H2
MZ%7C:+0Z#GK&SQ_>%G#G4;9:@J)5\ ,<O?;0-"[@_@R36/BF5B]&?]MQ-$3(
M+\KE(9HZ7SUFH)H'*KD)PX3QS9KE$>E3*C<JG9H ,UZ,;ABZZ\4!&G \TYVG
MX#.L)UPH%8TJOI.;,Q$1:547\3RP!E[4VH+324I#%LM 2?#U&CS2#U*2RM-R
M3 Y\^W/!\/B%2-3>1GJ>EF5E6>5;S;^:K"A]4G/#6RZCX4SRV*V 1(;XNW>G
M\[W^;=PMN+, >+@+_U$ZGH0D+%:\R_.\0 XQK!V< OY*7HIW8PM<EG?H6]62
MZA(X\(,/;WMJEC0X[=_JM_;9:1GH^A$U,T-<-D74DT1R:\JM^;XE2LM0]W[&
MM93'F+8NN_@:GINC^XAUX0169Y@Q0!7@GQ!#%5UF>2'NNO#XT7TC/U$!"-M=
M1NO-=*W/H;NR#KS?1.I:QBA@_7G]?,<17]Z[.UK&6;<M4]3>^*&Z2=+?W,\A
MPK@GS 1)Q4-_:NJ^C^/$5W;5IYU&VO?W?;]^^[(^BQ2]DE/L?CUH5'I^-A4^
M=/$#>K:*%Q"6%/KW[Z_2O^%]BB^%RL]5V V#+B5?7*:%.)V9/K\1P'GO&*T^
M8!AHH"TNB'R_.?5S/QJ^6#=H8GEA?]$5/VT2?%%A&'=6VNW+8EVJ"RK8J;#V
MT)6#R-N+]/1;_%_LA_ -9F<@MG+[FI@K].2&TYL&NV=7H#3(E&*0#)1%^RT#
MS4 P.2/&+3+0DA\4IHS'Z_,\H6/7VT+8BF3XWLW>N7XIUW'EORI7IM)C[_!?
MB!E .0RQ.&@8)B5U=&1!K\E 6M<>](Z'$<>&([BAE;N5E,QV#V5\/V:0GG]O
MCPRD&;  (HASR,.8XZA>K9#A2-?O01_\3WV]B_XUY?8F_#WM8N<D9.W%P$W0
MV)V0!P9WQF6@]E^IAZOSO?5T'C95AJ1?SBZ ;TKY_BG!2F.=J^<#\?/!;5/I
M1I_'@;F6".S^7[?_:;%:(T9AC LJQ;2C1%S4HR*AG42ZUR>IL;BH-<A!,YN^
M'.YSK[K]?>U<:/D:R:4_ ;LMYJ_.+SY/^8:F+?[S1Y*\&U[7,'SLIU[M&SB[
MYX1NSP>Q1ER4340F2CS$>N;^ I>D]KBX&+AY+A4><;=\[/FP1MUI)V3*UH3=
M@\VWGV_=96>CIG2/-;!%[E]!WD 8#S2#JS4CUC=H_WY4?$9IR[T=34=6QQF_
MD+*;QW^O>7$Q\/KY%/?9)FE<[0)V!K-A8GR?:_.@ZK,ZRTW)!5[SG83X1CU+
MIGKQG9F=SV&G8FESBH/I1@R,..M;]3@FIOVO[?]L*@8M?Z._P=(N%C6,_CN1
M*-S>E9P(N*AZNO:=)[YY,UICB&9^OZ\9>H'V\W&G'3Q^[??BMZ<KCU8 G0(9
MZ*]P:+4XGYFD@HC:VNYWI<?CSM/JG<+;_E.SSKU?JE%_2%4D48NB20ON:OC@
MSQ1IVF&DI=#GKIX#)RHDY#+#E2LY>;J).1]YJ,=]B]-CKN]723UP3FZ*7DT-
MPXY+>[5XR8:^+;_AN@<=LJ2%7E#$Y5MC[+3!4]\X[UP^)@UV!;T:);47>?$/
M]/B@Q_.:? UJRYV&7H]OO'?"TQ3.FTQB17]<(P.I+F :Q9JC#;,,K98\OVWD
MJPX5Y\30=H-S)>+O8R:(B<H:O%QZZ9BNUAIKI5>/IBJX,Z5IU=XA.;-#'[A]
M'ZAI2Z0?+RP%R16X'U\4KP]_@YA.$(MN:ZN/&=.IOOT%9MY&QWPJP_Y20GD9
M;&2Z+=)\!S>$NHU,8)0-2W%<]+6THY*JD!QRF\.#"/V@'&E!WO?IDKXPISEH
MM/M7^O)!LR/M"RC[V[OUIG",@'^M'<1Y5.;4C]%C-\U,OO3-KGPE6PJQXQV=
M4]NCP#^7N'/'"@'[@&)?,W!@JU[E&<95YX6-P)&NXS4WWMZ0EF]OW3'D-KIE
M:2&>P7KQ8L99<_KTCNN>;]'?8B*K@WR,1#4BC0SO!WCE\_C9GF2>VM@\.^F\
MUI,J[.(8J0I]1O>HYGS_+^CQEA5(&Y0AWH 8)2D>7;GDD*"E6K_KR'2\&6R%
M_J [7&^I1'IIU(IBJO5 W-@#_#@L*#)K)8(A[*(%W]"?2R;=2)^96J_WZ)G5
M3CT1$5'RK!6JPI<@;%)NV06",!=H44M2J@A/SVBK#[U!^N/OI&U!RD*C:L0
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M&I#35QL2!6)&HE;G_C2,CLE H_MD(.VWIM)J,:;=@"('@Q4MO3W2KTL8\3.
MWB8#L3;)#=U'NC$7F($0,A2&DKX8?U"31P^H3G.]BZ7M"YK39A/'MU3.A<U;
M6<9O'N?G-V>4[!:-@TA=TC"1D\*%GH%ER]9CT9FJ*4+?IL./OJD]YD8K)G_N
MM).RSN!5$G,GG+#<5>HV0S3<))^;6N(<KGZ>"U*KGN4K;5C[>."^9M2V*Y_)
M<BO0_Q(ZU<9+='E3]T"*P.8?K3NF>#4]O]%QZE1R9(Y?0MZ*2N[YX7;)0^CB
M[NG]8=@_$DR]>&] \^ON;U,8B$G1^(1KB<+3&# ._R^QH1[0:B0,#GU?OOU
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M#OVMCDS30!G(H/W'K/2Q6ON%$\M5 %BDGR3 = P(7ZV]-;]\3IV'*>UJ5F1
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M,!P[<JYM35>E)BX]]GU*WB_&\=\!QMT+BN2Z123"7^"%0L(MI06H37 !UKT
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M=I,%9AN,GYM%&\)%@61)[- %<S:8B;P8)7%RYW'$.QL@RV$@B50.##)0SX]
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MD)4 _R-=C/=Z=9/. /:&OE'>:*]\V22PTO@V9N1I@CSAH[LB/ADEVA#.#"2
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M*@PLTO_-))!-/@O ED^R2OW$\5YYQ2.E@ZK*2P@;S=VN#_SO[]IS!W4D6-X
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MG4>$R3?O N-K2B6P#<N(L@@1*WY6FZ$]$OWNHU6CYA'[Q,$_!1$ %43;IC_
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MJCIBFB.I19ULN>YPIS<6@5J93'OK8GJS*RJQ;_[IX,OUJWU@*_ 3[OHQSD)
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M<4,Z[ 51R0,TP@N67_%;\<K<:^*$+C'0?,8_(.;>OEZ_9PHMW"YK"6RQH)@
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M@+&*B< W6;%;_^&92\KRPN).FL/>JPO+I?6:2"S2HV'5Z\*P$2OM0P7R.U5
MM;ED^2Z.(U+CI?YWZ]_C00KH?BLOI7FU#VFK!B5EUMA66>&@,I ##5ZU&4=#
MRE[G*7.,.!:HLO34X#HT<S_\TB/5O@$XZYU!I[>OF9[SM0L*'E>FM0OA=BQ0
M?_8"'1F5D!\8.0&?08H<I;#M/&1&:*^ @\H6 !$Y^LM-O/RYDUW)>1S4?C'D
MN;U/,0H2O^5V--- $S4=ZW#RS47ABZ8U=(8FAYML)7S'_E=S=OIME:<'@WSN
MAJ'<+8F6S0.DJ!]N%W1)H\X9(5P-="_J^3N<$E 96E+8VBDE1EMZ<>'MP_$*
M)86(WT\K-GIN6 E$#'??N00&);(DB O>#'A;E7UI-2*]XP\UZ EST'2U\8A(
MU^)!(** Q3[CHW7>[VU!X$7TA\;-I5:/ @[_BD*,AHHQ"0-/,1F;0:+$?GJ;
MY].=V1<PJR_JF4AA!C6^4MB%)%60( *$.<X@7PHKCJ4BJNF]XKV/L-F!??)\
M]A$"P)]1 @\&W9'8E2WO,Y"]*I0Q^IT<+J5A[]G\]!>9\(ZB7I!$Q?%PGH8M
M9>TAI8AZJD?E7=(HHB7SH?G;)ZO)(DC05-,&YM=O]E_._[6WK6SB3DHLI+ <
M TB&2V'X"*J C?VYK%FYG+[BNTJ#D@ PF>UTFDW,&'9S8B:U:CGY_9-1IQPF
M*5Z2PH(J]#M-2OH'I;!?(=G?JX-W1_R3OW9X9J/>B24FIJ5*.[?T??9W19<5
M\)XH(J@&DON<QF)R).\6V?=W@L#6'#B.?U'/VZ-T8'M+5N3WG&/6?Z6P"B8N
M@P56J I!S)PISA?>;P_\!BB=814E(=JD[^@EGR\T7[V\BN_GB7)5]2NB(E;8
M&81I?3SO#7X)9@!!PIU@F<)?[",EY+P]771N=D*"NS48]G7?K@^IYU:23G9^
M\#W_Z"+(1JO3R^-^Y&]X:';X _!"=((^7UO[AZ(J08F^Z-?&@BQMTLH78@KC
MS+1;>!\-[;YFUP6M-2<6$:_C2>)KR\5*?)T+;]\&'&6O.8#_W$\2LJ?MMNZ]
MX"(C# %ZN?>^R\3V].>\Z(&CV;WV+ ER>>^[$K,-R&:G%[AE_7JJH>&)&?SI
M4<F[:3D-DNGX:<1="?Z_RM'\)XV#OMRV#/]TB]'@^?4EDF,GE&*>8SFAIB M
M&?-*1Y.%&5U'ZB9GLC8]^2XF+^(OLX$Y.H_>VU< U^0$^KRIKOV3$83.Y6Q%
M\N6 7A0?ZXF+R,-&IN445>_X6(&I,[_8-KG4KU! @/RFO)+"EZ4@BBECN"=_
MJ"YC@\@ '0-_TP/K+^1@B93,Q><:]\;IV#82'27!%H?J0!CJT=^YWE^LZSCX
MF>_MOZ=6FPC*6)D_A)0YNT=>1"D)PKU'2["2='9!^Z0$1TS5*7AZ>J+,;*#9
M^KV5E1*PJV+OW2>[7H L<H5\7!:+ 19+[NJNGEN7VBQF==*-1$AQ(H/^6[DF
M"-FZW&PZKTMWOIW$0 Q'E)Z #%+@6\X'AU^ U<<^#-?D?$%8)I(]1,! UCLI
MK$&V$*E9/\9?8I.\]^]0F$ M^&@'*;)1U.!OZY]K"B.@</"JMN;(=&59JHM:
MF,&1='--1Y#%YUD?-+A0C\__X6V0_#;.TMMSN#XYUWVG+=')O4$*.Y!*2(//
MF671EQ<5EG>)I# EU.#)@*JA.: /< 21+:E_^HD'8'M6#GK_).&,K^=_K@PF
MT9.;ECX@6DC5.R \\D#/,KZ/N6N!?3Z'7H2I95@RIA-P_IZ2B-CT".]'5R?[
M!;;T0E#G+C"8I,E"+.D[NO5<1/1,"D/T*M"M-DJ *'IA^0#7X7[F')E?GHJ7
MUXAH#B7#S67%1D4,O^0+#II7BA37^S3=Y!+Y2VAWTXZ7;^4249!5#7C&D^2>
MU\9A[-R\VF5 B_<,^P$C[;]64MAO21A7Q@005(!F4;P.(8=C(2:-"G<?_KSE
M?A!*XD8#5?K2T[+0^WL=9P,C0WSHTU*8"N\.8!!AM7=E8F)%&2A762P;EMF&
MWL@YN;(LTMV1+2DE37@2H FJ7J(41DVTF4.>T3$15:?WQ^%Y, 5.J\_:0DMD
MP9()N:XS]\"2.T(#2_#W((X+-GD(9NZ#8>+74\TAEL_?Z2P2!(&;N4;.'ABF
MGO7IO39WC..A /WB\]V>"V-'<TC#B%%DT=6A-NU$BC 74=^QB=M*0RDK7U%&
MM(CQJ2K]O<:54[#5$67_$FWL5M; ])AJ65C"TXLLHR^-[2BPYW,NEH\OI.LT
M_#V.<!9@+\M9FEIN 0L0#!_KG!F$8[_L^ZZ.OQQ]-0_./_H(FD>?U^=0E==.
M6<TH+*)MSR)5&$\-A!A,$G,K?U.[3N)(QHXINI#T%XE80"TLU]A2X#O8&VYO
M"!P!!$20M;P41LA&S$AAD=/6H5V *A^H%@$_IE5O7L"-@$M,Q'7=,<BL7*6P
M !Y&-D/B].GUO=6D:\OE!092]P9^G)(?WN\FLL1[U;U^&4?4JT0LT:ZOA2Y&
MS!,8L4'H8:(VL-P')/ZJ7_2J(J 1PG+VN:9#IG6%9^@70Z!H_<"Z-*)A*DO%
M 6_ WA,2$B'!UB2B-'+.C5 ;]A]\TT1<,RDA$F/%J+1I4;' 1PJ[.HKBRWDB
MN?F>LL5N;JZLJ;11K\Y<[!3B;S[(8TX)C^">0WH2AV0?EPFE*!J)&KGNL6-I
M%6&(;BZ;MS'7@P+O!?>)4-NU1CJWNO5X;88O=\/QGAOWEZ@('8JL1K)/L=,V
MYJ_1SXR/YO%:GB#(6!=\83C  1+SOX4]+17!\/S E:+3CN[NUGVYR:&/_[IX
M:Y7V5>_4:V YSCWU??C$:#5RE9(4AB*W;VFS4R^CEX%8T5*Z?27WG_%JLR/(
M@I.=.(7.Q*W',<>U:%ZNN6J&>7FS$-&9\]>YH+0E" ,3A@1PO5R:N=1ZS\"K
MM+8_Z0:"]8[XLY5N^8TZ ]M1J&RMGN4&'NG"5/32S/OJN]B34MCN:=-+1=I9
MVX'R]U7$['E.=Y2J9%Z"+5U@[.P9!%HZO8.\5;<"!W0M8KGT\1*\A'0!QZ-3
M)9/]'ZV!]+'DQ'PS?S8MIO7!R=RK#M]#MU'44!\KQI;0*<N=UK7FEFN*.8*>
M/NS';3_Q##B#LV%WI7;!5>_5RC8K+*TX\/KOP5)8(TC"N1O5W %2^ #7$B1;
M:7N>JJMM!CZSTZR$,4"O?JMJ<I*Y_.D>;U@V9YO'79K0#OML)H-:D(%'N':-
MS<C*2B9IWD:;R-PA=_C)]J!/LWKI7[-/36@/R0X^EV=M#  5;*2P@W4 C_2P
MV'WG,_@4?'SZ\IQ<Z";14T1RH,$_KK*WY_WB.WJ)I&</MUFTC[ME>W$$\-&2
M\)Y2L3C$4R_\F7T"SYV8'*0FM',,C"_.;4SIW8,8%484G;)O*]?N47VB[M1Q
MIL)U38%H8[A&?@1[_.(F$GR^]KT[HI;H'WP?(;&<%K$>OL\*KS[[+F3X8X((
MF.8&K2R.!GC'K /@BPK%S?-Q4MC"7 S$[G 6 M_&Y.E'4MCG#9OE)\5Y!TU)
M-)R'__E\LK44ME6 FP ]OSSM>]]F%&5;T]%_[JCN+92I7"?YIJ,I=LQ"A]1+
MTVR)CP?F;DAA3,0LWJQNJYF+.^[+2/M==OG1W;.'ZBPDF88V.[K[MYXJM4*Q
MA5X@@CJ0N/<MQ9._GP7\(]Q<'1;9(*F0A"=Y2=(M^#VR(B6@ ?/5D,P/W!S@
M,S*J^&*5Q(/"!PJY=3CR]'-9^R "TO=P)#3>0.3<@Y/=MU[V$!J]V,N+X(12
M;3\OXS%^NP^\EJX?\Q$1?T=-6+\ABM[WOF*3W[,=QG$_'L[2^&NN$Q1 J[=Y
M%V[39V3'Y;GTVXN3<3VF+77;V+L2OV25ORZ5W?+[E3G[2%1>X]7@S5PSL=,8
MZ*#?L.UIYEDD1.X?R7>HSGO<M4 \"IS13ZHW6_GOF89X< 52G.5YM,5;<N$H
MION<OAI %&)%1W!9CX8WIA<>$6VW%%#QS1I9L\&/EQJ(7G3?D-4!YRS00H Q
M3(ES'Y'"4J$GR%)Z&EV(9&1/NYB^)3NZO#NS:\D(8#HJ3V)97$=1I7)L_,&N
MK\'DF\W#/#)]$:T*"9(/>OGKH(>'0-$Y8U@V=>_]ZW9*?WZ\X)?F@XL(.D"8
MBZWC[/KL,T5DZZT)T"\@F]A;X08XGZI4M*P][MB]?.#B^G(8PL KQJ_A> 4I
M#'Z_!;2!D+9(HAPW,$3==%7D#]H;;*+Q@]0R!^R&D][/*U_T>%L+]"BOX'!M
M5B?/RK*%YFT/!]>A"FW$25<\1[-^=EDZZD3]&?+?\QXEPD)^Z45JV&15<4"S
M>!\JD36'__K^5>VF-J!ONJ/8/]2J6&V7F.0RW1943%!!S!FHWGE-98O:*NS>
M0J&O+J2V#5%@[?WU"X+QV0?'.Q/:&&(*DLU8?I.W381$IV'2:(?=0%&;M;-$
M2:RG>MX]M!$<3MK/P+S0W#R_<:W0H5_Q)#0U]YET>@]J?@DD4 B85:$+O8N(
MR5E5WG+'!HIS"8)]*!T*-4&]\T,DB10&*N>PXQ$_Z(7LMCNT&K>K:Q/]__9%
M C^.Q[/0O,03W%9QTR-9 5ET9OI&4'!MQ!*9OVXZ@]MZ;L->'%''CZ$2WMC^
M0 H+[_26J!8<I&-Y6)>L?R2XI'[6P+-#DFJQF ^T=<)]'P2E^W0.IV%EWO[L
MCN:5'Y<;VU694.5 G[OV)(3$)"G7*W&21:0VB+G_0G,"V6CGP_WNQV[:=>4@
M&M?[;GCLZ3'?V[[Q\,SLUPFGH<PQ..KE]@ #D^N>R'A&/B XQI+HQ3_]MP0T
MT].]9*<DR9IV@_GJ.LJSSQ2Q^8:!2MKS]SS4^V[=_\X7YE_O35$1YTIA(ZL%
M)"$9^W0']I1!E?+K.8:#LLK2(HC1L/4X/( &R: 6HW.+P^>L8UTG3WRY]G?Y
MO,2\DRM[P=:'IG>1^.^7%$8DBHU*+Q_UK4VC"&7%NX :N.]4_3<KQ?!"(V4<
M'^OQK=:1L,TLMO_&/_B6W\B3ETP@1U*K.$8;,$DL!^B2HV66O^3[!3XOLID>
M7R8W=UB-/UMM++['Z@Y 0"%].XCO\_-\$*X<KQYZ$P]WF5%"O^,$TC85/7OT
M7M"(23X(%)5#89YG\^\+=BVB6UP9J+2O^K8/W#/XF8NGY=7BD86/Y8'7&1X8
MOPVB!M#*$K**"P -@XF=>SJOP]&7O<H-;]MTU"W!42;SH=W<^A4C@Y_?<5=A
M5C2.A5O'"EEG9/I;S\]3P7=#JMJ/PF[U+DU;&D?73^2T^9WZ'IXKA_Z0*H9S
MZ6.,@9[YWWK^&LE:8F'+698Z =3AIIZD+JSG**9#+K5&?U[>3%.^OVN=C7 S
M\".4(D8/G?&9?V.6"B*%]: J/6.ZS]]7[K&QSLZ:"K@)#52E95CB*SV*P @)
ML<J?W$OPC<E-6V^XU-V#R4>H" $D5[_E8.5;N4];IMO=/B6D^\&+:;Q=: 'R
M#PHB/;G[C$E429CDTUWBO#RC4OM[XK0_>S:2DK#R9-6WC0ZH:_!@_ZS<2:P\
MFQ>D1X$8:>E8IW&OM8V*("I._Y"VCIL49O+"#2@<ZV>:DDVCS2KXD)_<I,^3
MQC5]%VB]6;5X)FC_Y(R#7>!G^6DV@N$Q]T7@,QV7Y"2Z)(%DB]B2)H4ANX,]
MJPOS[CX??&I,')-@R^IW71"Z#\K,]B!6\4K?2&%W,','9Z\"YH&3W!:0+\H*
M#&H0< 9^?#N["IL-1PJ/T4[]#G0?PM2HGJY(V'-I@643G;N!>V8[?.%H-E =
MY.0FK.\>L?T*R0A=4TMFL.3(M]:&.]PO@<WSM07DT$ 4E[=,_FS<OIO(SM1W
MAOK(R<L3)<F9AI6U79*LD*@J&4M'=*U=IQ36-4\048J-B9!A;P7U<S?OR4=H
M?.IB[D#-F_>86\EGDO!BI(A,'$U6H]SX<GN]<T[(N@GE@-Q:J@2/I0A!^G$S
M-ZK^$9D(^Y9KJO"%"[!KHQ!G>:)7\WA87BAK^B5OLOM)<&N*H,DJ@58HOAWS
MIBS?KS,W??CI#7XF =_R,-?NQL<EFRWFR(%3*QS9,DN4&I3ATXZ;>E>"20B(
M".-2)XGDAT1];<XE ZO=*Y_+W_ Z@[\&GV MA/H$AWRC<)$>&KK*C4,EZL\;
M/!@>@7.ROQUW!3BA:ZWO'[*_$2<S2^Z=K?.D.;E?TS@27#0)KFB/'])\2M:%
MKVQ^V2T'^T'^I%NZ;M:++_1-+B/ KP&R^R'+'>_5E[4XV(+2B+7T%*YS7AA+
MJ#JF"^:NW^C5%*7)0:!XN,=7F0I"^>L)?2^&1/X^0Q\RA@25Z^NYCBN0-MD)
M6V6'K&Y[LXEPAAX^2>/P?_J)I20/(0G*..T>ZW!WS*%-.W9E9F?"[]M=UB\A
M"EF,%H_'I(Y 8^]UTU?9?J%Q]R &_6-6GM?#]7A<,I/EWDF*MS<UYFVOA>.I
MN.SESG!2V/N@ 1P^,>MO0OJW%E/3';]D6&QSC-#E7_GLY7NZ$V,)B#8I3.$^
M&B\<;F]9%]^"+Y7IO:I%F@X"5^>#Q,GAT;*%P-0*V5Z!;PN3S%^N<7.?*85M
MAF0QJ)G'Q^G7<$.%<!Z.CR=A$ ZL2MZ+VXDYLM@<*2RCIO3,57G]1.%S?^CF
MB%]:6XV%-"QK^?YHQ OJN-R'IXW>57&1#%*S%U]^]')EU31H]5'XGRL8.<#0
M.U)FYVM$@X)^B/W:+9= LTVO(1^?A$(>MDAKU,>AN+TGZ=E_',(H.9D5@G%<
M4.6@N6.@&K/-F> ;IWOOG [X59[?*S8BP15:LM;.1KT ]:?9DYGZFOV]7M05
M'!)[IQ2&60;IGSTUJBFSKRXY#$.$#S4+_EIB"CRR9NGF\O$W3<_)LN\"IB@6
M*>2MQ[GILS<#YV#--LEK"! 500W=(*%M+2Q[C@[6K-FZOIF1A!J@GBS\1V?F
M@R()J<3&[JMY6[=ACHI,1D@#Y>^#AFWV\2G@?AO[&(((/HI"C0+S"!;RT7FK
M07,#:N++K?Z!SHRIV_BXY'O.>"GLV+BW%W]9&@3)C6U</L!MVV2&OZB1*R^R
M$2.)8L?N7>:^AX^$O=BW KH*SM*?YAAE'=']BH,0KX<=BM^%N".%O<3QBN:'
MSGP-_'3<8=_:P\)OYWC6Y7C34(<7GFVMCBQ^;N[@>_LU&LF?GZ>5S&C#J1"<
MWC2+6WZW>WRFB4E\IQJ+R<!NIZ4O S4C95[OC;$-G6\5CQP#!GW-;#^'N.N3
M4/<O%R,U(^%B&Q/;:[?,.4YZ094'TF;G*F(1;_\PBRR_E_FG%.3_#KUV>32'
M_._',+UWT*A\#GG?/_BVAKR8%O+*[_V&GE=>^I^;IF[AV^[E400['<()DC 2
M_8E>T<Z)[9+=2GZ06XA19N8EFZ!@^%D*X_Q&TMY@-M2/^<3<V50QBXO9A0;M
M#-"B.P#2H^V,WB$8Q$JJM3-7B_M=-P!4&*@&Z<@OS]9B'6YYOJP=IEA/5$:4
MF,%=YIK?N<R:_B@5*(J?+32C^.N-Q4 $ARLS.?O&D]LO5GE_N=:?<+5JVP:[
MV<!HU/[9#AH_=Q6@I'N3-_:MK!(N6 \-I0$S0?C>*3%2]Y#"3@#1,WLFK:0P
MOV<H#^##U)^@N,KU_S\:BUM,@F1QV/(9RPI=GJ'.N&H+XIT4MK-P>__\AR1:
MC_W)R+RHXOWO$@'T6_4*/=N1S[8W?/7, XY]^F*T3\EAE$>JL3,X\^7:<]$U
M.$/ \3M)CL8MR!//S$Y6L8+2,\!@TI^E"?QC]];AQ2G<NY7%>M6\$-;40&PO
MI_^&_NKP#>[-2_(']OR>3SYW:L?A:^_"#L5DI\/J!Y\_J\I_VZ^2\Z;6:L_C
M"^(F^(A(5Q/R&YNH@["S"Q>":PT$EOE_:]<"1^7#$2W?<8@/_/E>JDE?5=DG
M-5Z$KY_9:"PP?R/AM]Z),J>:E76&'A<M+>M6;=T0<-!S[1K4O,[Y[_ZQ>FXQ
MO[^1EPZR*\]NW6CT(V3'3["N&W\3J$*,R_-QCY[Z!NA^83J;<I0!!M"(8BG3
M8@D^9OI6P0C^V)))WN(08A&=QYUT=3\ZG9YT\@O#D=IC:4V5-S/:8;TVC]PC
MDVYEJ)/3M6-?_MQ$9E?9-]OAB[*IJ:D"Q3'"KO3#!8\!_;V/L6)0"HO=*2/P
M]7EF)7[.)_=CYFN%*/@ :DB_>18<A&1$M=]*UXD[VA-W ZN?MD3%E*QWZ<EN
MDGLS6EZ=5F\?^T5S7HMF>C#3&.]]^N_"N2XD_/2+R1L^]EXNFRI.7X&=V7-"
M[\("HJ5GF-YB*4@+OB@H;A_:@>Q-(E _Z],*9DV+Y!B0$[]M&WMR[IVVG<+E
M]@FO6W:8GS>ZSFA4JL4D:#_*0-<?TRRL'2O]$U-CD7OU[IX%A.YS-:Y/V<"H
MSNO8:-M>5=D#^$F+"7%E.7)T.WV&(HYEKB%P'/&/ Q/GAO[3=_!_4F[^]ZGH
M__L7N4")!TB)C4*#+5>>E8O?O5DN;+9:\L=VB2?NA[.H7;SFI]1X67$/8F3*
M:8Q935]\CYX&1: 1PS!!+#2%_FX\?.8YD)*]T#/Q.,Q0"ON[1H_T5G199[FK
MH\UD9S2Z-^<[+51['>V\@M^$QQ.?L2CM>*S 8[F.3%EY+413O?;%@EY26&(6
MGE2&'7L$QR';&;4SD"2='/&R$??,J=M >DR_3?U<4"!TM?/>0QY@TX59[DJ@
MSJ'P82"UBO/XC9\6!(!)_HUTD!AD7!X$5% @=](=\+;_#&KV00IC92+:,Z2"
MD->$3B*B3)"?=HH86W;KHNQ))Q)#C K'E92G6Y: ]U*8_L?Z*IJG3&%4_-G!
M.%75=?&[[7BW_K)"$'0["?!@QW*EL**9);OI,6I>"$2-9)?7Y"S0+#;DO6Z=
M/.C?4[-!P$#+%BFLHJ26; >(H^? /F!F:NKMDH1"E,*,5<5>E3K#B\>R25DS
MA&P(M(%?0?*>"!JN19QTM.PO0B,EZ%+G7#I%@A5L %5H7IRY%T/?+OOA72_K
M?S)R'*] F)X)Q7+!.I$FOW86(:S%[';89/T8HR4_B5ST.='5M?Z)L<(!^OQA
M^@CCWO':]+3VP$MS43\&JJZ%M7639164W;^A9H&J?Y']5KP3#<6X[ILA/Q'-
M1B:IA2XAV\2OI; 5>BH+0[V%BQRX9[_:E*MQI]))]35:0.^_7,?E+(C#D4G'
M"PX71$CRI+!+;)&'S9&SV$:X4#;UY4M7UQC7(YOW=UVRD<'ED#;V<#5>I WN
M9Z6MPI0@_JJFE6VO]TV*@&&GC/0'PH%,LL.!)#->;>E_U40$RM<W$+5[KBR)
M-8,9W^*>AZ3/M9'9%201O1"ATV#BRO8HW=Q[7.\2O"6U6B(O)/?]459)2Z[B
MSD-F3.7,)4JR9X><%@CBP>7<#/+0M&:+@#-7F*3S5TD*LX3",]KCTQ>@;!](
M7WS1 _[YNMP3X7]#L2E(9:>GI.<(/"1G=VI5B;R\)!KKX//*/\6)>_?C0%>?
M--Y;2:A .0QPE(L4/H&0O.O8[3YX _BB@MM:7"\;#:(FIXTN><XPV])+\]9H
MI_1:C;MK&4;$)!ZRH,#G9E[%@C>XV\HG33:@R*I,+%@F]W& 0?$_AOV3 NP+
MO'&3-TQ)1J_BVU/?')1X?^P80PQ_A[.4V[%>95RP?Y<D'+%(,C-I(<!&$4>E
ML':]3?P!X=U\^-#-E)CD0B5).NPJ(;_Y] ::&/.>.7R,T/-JBPC1B#2,L>/[
M'W3LQ0-!_T]%_O^)0#)VHUX[>;-JY(,]GC>\%,"2>S*,_:UY(,*MHS34NF>6
M(9OZ +Y$8AR2PE(I122AJK!&%_H,6<<,9P9=(CE'=8+H5;<_R=DN=:ID3A')
M]DC^EI!;[^XYF-9C7K(A3?%&G(UX$:<:I;FG[,(Z7]I4\H@H+Z!BVY-LK;?H
M_;90_)1=FK*['W@0.:W)W+?'I^REWJW?*;BJ4:%=XG(NB6B$V3@9Z9OX@V6K
MR<,M%D):#$^="C3P%%,M2X(<]\C,J?]^&2EWI)%EA,<="U/7D9FQ/LS]/5F>
M/XZJ>O IHO43?O%!X*T80W??Z.='_0%<^NHR+_C0H)S*:IDUX#:#=V3[2T4]
M@[A93Z.NH$_'OX$O-=- #$PCT<Z-<Q#\\]'BOQO-N]Y?7#X";(W6+,Y1'IRI
MN8CF*\'%6TC#$@%)@0::)2;^9[WZ$MQRBS9]L#0LH!7-;/DPENA0:."XG/F^
MC0%OMEH 9O8!H>D>XQ813;)+%('N3LD[7?59*HCH WZ)3#0%@3?/LF.'?"P?
M<N-&T](>&<]P0>3>BXMWPW;;'JIAAZM*GNLW5[R^X3ZY\!I.I#!D\<<;>THY
ME'& TN'>O^-PL?.H4P05R352-I=X1);HC(Y!<XCB2!K./Q.]D9WH^OPR"D S
M9P_=5YD&N^<(ZKHV:P+7GK^7W7^.11$\VCHV11IP72?)0C#W 2:)DA5<^&!$
M5(I8B*"UJ4S5'_0V-+QR:-^?(R=37Y?O 0I62&'^/ V[M[8&8I+SI6N;C*=S
M2 9 06T_[O54<^^;Y;*5%O_9&9+[1))[[@#1II-]"/Y''D[4SMT]0>)M10F^
MZ9X;#H',R00T"[_/@<]BG:GLZ+-L96[R R+:E\MM<435HXQ?%=CN7"F%H8,<
MZ%2A1+^VJ>+MG-UCER7!<GU(I4>%E4F7M$:6-Y"Q%X?[?IK?>W+FK/#BQE5O
M?W^K><<Y""1_C5)G"T\*@]Z:[#8#NLTRM#/@?R4U1X+_LR\"?IG>4$/C7S5P
M0Z\_S16\DYM)2;$MU3X<O]_Z04(<.7(+67LYQ2\(0^X<W()SR#FS<F:E_.>1
MCKKE)!GO*W<#L?0(^S5B9:,:DTVZBZ6!,-#XBKP]))1"J19O6ST&1D"=O-)R
M$F(6NCK+(V6YU5K@YL7'F1S]X;='XG^YAZ0+O1F'(Z@Y Z.*OOJZ<4(O<(^(
M]5'YR\[Q +:F3_6D9-_(W,6:-5< 9+[D];D0A"*2DH+0JP,/M>.KJXX=VNEX
MJ)CKJ0G7'OU=H/>]_VZVR\E;$8<UV:],]WT$VGYA)=@J- W\4KW+578C59QL
M;Y3HT*EQ,:#-\(3L-E'@I>]^279Y5MQ2WSTI=LP%ON)=#TW1?6^0Q5 1+?(D
M$*O5,8(<P/WJRK&NZ.5MI_B<$^B"UGYS2OR@%9\Y23QB*<Y*P.WI$W_SF60I
MASV>0"P$; :PQ4<JDA=IVW#0'1_E$N(?$*O ^A+<7>R$P[MP^&FCI :+1]F/
M/J4VMV,X.ZZ$[8[Y]<3G/$'DK#\^=9#%%#L\]^Z_&:B<W&,2BN;FH213HFX2
MG!-<>;-_%E[CZ_#B*T],42Z4PNIU H .AR8-Q. LP$X7[U6ZM-S6'2?(1=2W
MCP)_ST*V#^X3;:N7?(.HPA69",LTH3Q'"ANMI9OIJ5;R X&,>$A61A ],J=7
MM=Q@*SH'Z6[4'\%D/J_OG=#9Z-_=*',_BEQG-BB;%_.YRVS75OW"U9/ARO6)
MN+.)+L%'7H"H<3T'LJLP]>9%^(18B$56BK*O?3>R*9KJG5++897>V3$.D%U\
M$.)$1M&Y*"X@,!*/[3WGU>*7SB>A3?R#+)]Z].7D$FNW*6B<2F$E],T>,$("
M KLHGW YT]IBFE@OR:.ZW^N1#I_\K!^[0$T9FM2T(Z.RLO$L9^[-FMW^CT0)
MZ/*7LT$+DZ :\%2#]HPS))-80LWYF"\,J78EB91$6B<P"+F84(>OF![]Q-@4
M9$EB4\RL.[)W[MD_]<\YA;([KA3+SP"$L3[DEX@N_DZ DDE#/'82 *^2P_M,
M.9B0%+HD2+3MEWYBVERQR+*G\LTW %L6C"K.W+LZ*:G"K?!CG]A)Z?HD3_GR
MW9"=*6496-/JSG*%IXXD18MRB2WFE: SH*SO7O@V"5%0^^>31]G/A1A_S4OO
M#__Z57_*^B% [_^25TAH^T=FF4).]F#5/O <=WNDDPF)2>H6!6X[W>#Q ]Z,
MFYS5\FP9Z-\5,AR\22W[[RS9,78']!;7VH[29X,Z)HZY9"Y4[R,M0/$^,7?3
M[Q/'<!-@"$YWZ71\G>>=,K/+N:1CE[3D>:%N/59+-GMUHQY_[5NCGQCH"^23
M2ZLC*\'Y&J$&8D84$I*D@/:+/.#_63;4,@SH$U>>.,-9Z?4D SX50F($('#X
MBNLC3BCF^Y#F99L.-<C1I_K6+C-HB+'DX=/[*G05MY:4BCX5?3ZJ35I[RB^T
M^X>;O!4#__*L?F-%&K!2T2?OL;WGND6"0'<SB[V]S]U#^]1FTT.'+XQ%_$TR
M8(%+ JYC80-[BS]<DQOX8(J/M^ 0^+I/M^ [F6SQ"@C>'!FMJ<29K+]PC9=#
MW?UGRO%Q$4JK8GI#[Y_YK7>F5R:LDP%-P=LHO;(839C\9;WBN"S2#B>+63*"
ME?R\F9'D>;.\9]QMD_V=G:N_K27R40-*>1DGG4@M8LDU[:"[Y^^EL3]\&^0/
M^OQ;EW<O5OCQ,21):<V(/A8C1T<S>FI."666-7KZ<W6B;73.HYS2^NL=I4PI
M;)6?CA1V?ZZEW%*"8K"[N /(Z\'!FM&XNNLW#4"=^R#9C, C.%UO%".:.GQZ
MM]AY;1>I@;8^)ST**O%2V(L*XQU=*S>M7XD8WGU+"JL.NAGW-SA@:E.%]YT1
MF,H_%_!RX/:4MZ%*9NR%F4PHACI?@]S5)+I-DAU=K?&":H8^RU:8"^A1_C/K
M^CEBA_/3,0:2:KAK,G0YVJJU;DG$C,)T[9SEITI#Z/WM!(9]I\97/?Q_43W[
MV\ ED#8D=ISMK>1$L.',&M%O_9J@ @F5X%NWG"69'4KP#?\9ES ZOA2T7.G@
M/I\;'C K[S :N+)R=N^:R>P<!J-M9O&+[;>/NPX>IKN\:[#>DJ;)S:-_N([E
M./RD[1S0G&#] U$S>W<[-/W%;O*''5M2[4W][GI6OML4?(5E<=7R,XG14A@D
M%W 9KB8^O1JJ6S1W[%I_M,#C44,.]*"-#AV1YTVP_$A922Q!LKH;LM4#" 17
M-TR[O3_FR.F_VDS#>2'K3(H4%O8#R://*P]YWBU&,^\1$0\!!N=6>0SMQ7T!
M;I'SVCT_5F$S,[\ T=M E<)JIO3[)0UE0.T]*'ZCA!OPB"![./^#%%;B,V9,
MU&:>0L'?-3@B927DT6FC'BFL!\''NNX?.-X%?E#A E_9E&X]\A>$"X+!%G?<
MQ&57"#<?)/5*L&*CTG9F.PT:MT9BCMX]@ DT.C#E5W0GMC!FB=CG:+;J2R(<
MR^(]3L'?&-0RNH:I*RR+&KV"TXD@=UOOX/3,G,VM-9;"HBYLD\*V,-[R'%\N
M258!B"7E3S24'GYER!^5%-262$KMV)\'?MK<P5O\O:FJ"\U]WI7/],YWR>D/
M>=9=>28^#:DN%^YZFK;]L!V)9P]D*2ZXQDIANS<B<%>)"EZOUMQ2C'IR)@&(
M2%6MI_&G7EI?*ES:K 2ORBIH=K2ESS:8S8)+C*N+GCWP]X^DL"#\HF7G::^-
MI%_R> \ A[SY4(<@7JKR83U O+<* 19W,.IGYDCT$]"<PH4=G2_0'C/T(F!*
M(]8WFIMY>WO7-M^Y@RM^Y.1_:P)ZFL^01&B70Y()OZ/9T%S77XPQD,*4#.$4
M?*GM[U.[:PVN07IK^IV[?<OGI\\\^8,:*^F,PC%1D0G_[^,> #&#*:PF!01$
M)KY0%5._H5CM@2%*XS=H^?K#8UWOT';NUV^)7B]T66GIP"<J6.);D-I6OQW*
M?!B<N3J^?BUBR?H[$&:#=R(%I<:"2]A%=J&KZ^,CXEN\++PL:/]J&SC(8LQ0
M/'<B^@W7_F?I6,?8=M9F*Y(AA2'NR#.P#?$2$[MIL'YI+GEC?6M(?>?"#S9=
M+9.8B\#ODZ$@9G&NIJT](-"2+]%E#YTQQQ2M\"=>D,*0TY0RQ;,$"1!__6\N
M6W%"VRC*MY5YO8-8K.XF^5RC;EBA[W]Q'Y;0#G^H8[>J3 K+7R=S"?P$_ @\
M;5<XE!^]A#<U^C[%6C*.:AI[B%6'B(C,@4RUZ*N%XH"!W0C:;[WXAC].N\4;
M"F_4IGT$'R$7I^_:J7:OS]D.@66AO&G^0-#3[.,_XT^"*HQT^+P5ESM!/E/O
M(<FK$*T'/D5<5W#!M2#%;N(A+[TO+]%+M]O(>E)8]TU-R;;;F)* [VI+^5+8
M8VA02>=$N?>G(>(VI9Q!KAZH\3 M6UKFU1\A%1P!H=:OA]PJ7DTPJ0ET*% _
M(X=HQ2UPFC,\!THAD8QUZX#):VEQSL&%RFLEG>J=ULM9^#8K/$AO<<7BO1<Q
MQ(KQ53V>\:\C;SMZS9Q%+#BA> 1TY/F\X=/0C^=++D=MZ/I<9G98$:=GX=Y@
M(N.84&8)AE,I(GG/ 6:ET\*C5(AF_TDZX^EE82'2O365M;P+M7A==#JN%Q)*
M78'7B5I03-AKE$.V[/ZAYI25DH,O2](:Q^'%+X%A*8Q04T#;P6MA+A\:&GMR
MJS>CJ-^GY&WWKKMMGFL7?,86;[@ PQ?'^E=5K8!/T?_.#&L97IL]I*?,S7QP
MZ!LMP-9KNN9ZV_MLB)IO?RKO^;CR.]CT7.!$^CL]=/UW. D=?SMSL/3S+(:[
M#0I/H+KB(@XE<(\.HL]'9H(#AQ"QP"<C&Z$Y?9VD&M'2<]3SQX\H57Q^&L*D
MMX,Z5ALA5N4F$6G7P6^KP#K0(8_]?E;<)(6IFJG5GD"ARB-GC 2-"#B;1YL,
M+-P2DEOTGW+'Q^3*/#Y_!>+%0T;QF+_NP9RU@Z"B//]+3>D:R6ZP\3]ZV+0T
M,2 YK:Z6]0G%0M=/Y"$1"XHO585 W4' [WS-A67F$32- 5JZWGXFOG<=/OK5
M87TX/>O+HZ9NH.?QR$V@#^O^0ET*^PPGBH<LUP=3S&Z_+[WTKGIA *]R$SG<
M^W#3#%;D)CH3^5B G>RIS<9Q'#.W>T%F1"[5.[7F77*-OO[NU!/-&OD@&32<
MH][YA>C27?@:&Q5SBO'N!F>EJWF?+2YSBADY'H+1T6].=!7B&$7<'EQS#4)4
M?^W/<K',*Z$R%=,-T\]NQ-2'V.AA[:0PXD:,B.<T(LNUD5DB"+ .PK!SQT2Z
M$]PJUMDW93_@[6,S$2*JZ+&=9SIX4+X/:.NI33L]*S(RW4_T$>2VGNG/501*
MR&-Y=61'_D$0=BA@3!ATS"O8\P(\9]K]IMU:+0P"]T7O_.'.[()5CXH%PA_J
M0N9[*2Q52Z2+<TQ ,YT)PEJ,BDGJ>(G 9T*N[4<]^[?C;"[0;1T: YE&+L1*
M"GF/!2$]].>$_N6EN-[N8J^#(76=H<Q]D>)FVC3DKM&BD^'-1X#O9!IRT:>C
M0N7U+$D7N"J%N2-&:SE4>]53-#LX"C$<V3ENF&\/L?R5I&%,:JSC&])WLK#6
M_IC"(PS0U*5[W73$Y.=X48"NT[_^L%@E*[*XR-A(1"FAVMEOL3= 9KF!<M6[
M_<VEL-AO'*50%>,&A\'D;."N;5.,$&BYELYMM8MH'[^,N \!H+7V7U!SP:=3
MM!B.$\_)^/T \A\IR0L5,X)*R5JV>.Y;1]$9*8S26G/[=N'?Y89;MYT8WTZ6
MG';\_DV6G6$!\=/<*I%Z"6]E>\ANTK"1I,2WC$;K"J$+%7*,"D\<M/N#8_Z%
M_&^8HW-A8(O]:: :*Z3WAD4">>"Q M60O^@VTP#A4V5YH81YXP(=K9,(=D J
M-#"G& I+%M#P;E.+CM#$PZH("XE^<R3X/A>!<P4P-"EL'8B:G'6B=+''E%U)
M1V"I-,N;(>C/=[Q(8^B!**0KDU<%<1DO4_T!*>R#<JZ'58A*CPKQ]!>U=P&M
MG4:F#X PCP4K1%_SS'>@*7D ZU8)O;S!+%E&-VBNVU%AU8RE]>[6-L]2T^[+
M!U?<O!Q[SU3=4%",08KN 3V\\;Y_T,_:]@1B2 S?=#^EC<<6V3.&5]$G7]G?
M:3W3_>Z2HU59W-TP!+MHR6BM+'9V[KNG+6(PVP#S";\D0U"'CYSAR+Z&'LZ^
M _WNJG';&:V3!P=Q98TEBFCPYTTI##O-['MF<@=Z1H@T4<5Z'OG7E@N<'\M\
M=P+3J"R3LM53"0>136WF9LC3N51Q1,9##()2@')1%?N@!*JTVB/0W,TZZ-P6
MNTD4)$0Q>KAZ-\8("I4ZMD(24>"#:W9BW4;1<V/B#IA"-")]C"4A(J>9QWE%
M6.8C1^X.*2PE GDT]KFN>^@S*6S[T;[6JW[F[K)#*/@-#<3A%3JBWA*5IP3N
M<J9X8S).>%TQ!E$O9O4\RQSB_-B>2RM/\/)V]8W=#[U'Q]?R:*I/)=C4@1@F
M36WK*37R>+M-3&KIM?#0%<R+D5[.T&M6-! ?]Y;"5G<SS]$R$T4N>2 A29?>
MO6+AA;C2*ZO_[/&'_RRN]:^/65=S&SSD)H6%NBSO&1:HQ_12)2AB1C@+BW26
M?YOSO-[N55:>V.N]Y7*E'![.SSZW70"')-*7A)$7==.%G#]T-U.3E?=G0A(*
M*V1_#^+X1^%D?M#U@"=VN(X#FC30@@K<#:Y#Q-M;DJNU<TW,GUIXUI 48SXT
M$\362@N7MQL9OR9QDT*2.ZXEAG<>O>-,24Y']N'S<Z(8G0E(AB5(L3>B*5U'
M,VT@1GL3XI\<H])-E).0H;A^"VE#3-RGPBO7C2 GJ66J12K-5/GO-*4:OHY6
M7S?$:U,5TP?\SR5WCH,QA>)>\;O &]R-7V\OMT75[;9!YT:/-CPH\SVQ9\6G
M@F^-4EA[25'0G;W#(WXNZV28FT!#/:O\F M%JHR4V>V)EH#U3O=D_@G+*'T*
M>NRB$#LS($^E63+MWH.'RF6YD'3,2!L]TXAJ92O/ZQ-IMTX 6W.C"%X/<P+
M_8F-9692&+-]@RC@G.XAB8L3H1]LVGOGV9K#SRUSZ^:M.1,:(:0QAGWIZX(#
M$+QM[YA%+F[K4/^5X34S7AD3DV"6.GO$[9959W)%?[SM7\2DQ0TC!(OT.&&"
MY[\:@^BNSY@]V-'8A=_VLY;D;)FK6T7PYJRQE22%A:<G/TS9E8H6P" F <?>
MWU!K0\L$>^3[08I),GCM]SH$)0574DDLT"YK&]S]SN$ ?G=T5BJJ4$5-J\9H
M*=<<@(C5O;DG$TK'[/%U;RLEIFH@H26]!O]9@[#']4"R_W+0IW\3JD"V(YM)
M&#+7,-",08TB/&Y=S]>#7,4G\*=^ 7!4EB]R^U133+P=[/9]$^8DJ.CSA]/:
MJYC]59;OS[XPRC7K_6$)E-<0GV=IU_Q&0+2HR699$9K2 CQI:/#W+M()H*W=
MP:3EC7^1&"O:NP9W:&8_.JJ&X@L)1T.EZA#$]FS923$P+ G3ZWMMQU"*F)8/
MPP"1C&G@Z&4@8,"9(DXZ+[Y3Q*=U\B"A=+_4J%=(70)9Z =8EXTV>TJ)78HN
M^LDD])7!X>MS\4;IE^:LI_[?FH;]W[ZP)"^AP4?^\A,U[4%!3\;\/)XY/D,]
M\ZR,PD^98@UMD'+Z>&^;M'.Y;9J#!::%MWM\DLO;S:UO1:ZUW1Z5FF&8Z-E#
MJVE0.%AXY6Y74<,3.=EM%[T<$N+^UNU\LN:V@(IP0LJ5-(6F>@\5]]GA2:"[
MIS]X2YPV9&4YOE1%#+PHL*]X'KX-1(8-\%TZ[J5F9)GG;3YQ9>+RIRTSVBT.
MUN-NZM$J+K!G*7F=K[.2+R8<H5"H*7$3%:9'TLSE/ME[U"@(?,5M_/K%V0RU
M/[]HYXN)?L_(]-B]F.)NK_(V:ED0<O_>C=YEZ@D7O!\6E28KOLZ(N]9QZ%TC
MWO8%0VONF;JA'C'JX_H(@^P]5H5K4^M6O<5=FNVL*9B<.7@4L_K8N"'0+>"P
M(S*D,#^@$<[29SF8A3WU/3WP)_'_V$',ATMAR1!5'J^U 4YZO%A GHNF&+*H
MH_$6]X+F2P+%O>MMU4<J=;IP<]MM&M9]<D[Y9<&_9AQWZG!<RN]7JYSC,6E]
MG>#5\IB$BW.[%2.CKW=^5B2-5JH-%52?.2DH.E ^$GU#@OL[4RQ2&%6][+?S
M:%1:Q,,'0H+???%I][F6F=NQCIY[#EV]@/V>FYZ;?OM+C IZ0*,Z\@UF7&.L
M1;NWZ/4=Z_10V KEB AA[?!+/UJJ#(4Q>Q\WGBGN# **1-M );=_659$<O.F
ML,)CQ'G;X)?DDEWB9_<]%+5OHDY]HI@ZB,@["2?R7-<K#@1&[XFYU44^;FEL
M\>;K2-/3Q5:RI=K5'=G=@]7'/LF8_^VJ$SR90M\/T?@=O^NO42I9/EJP(."4
MD HCK@O_O^W _D_EJIP@305<:[#(W;-O5W%T-G]VZ[?^:)7.>O<(5:[CIPKB
MA)'JL%Q0='%+I3=3Q14.\Y)M0BK*=$VW!+WM7_R7;NM/[JP.&7ZW4S,U<?]9
MI=EGUI.'(6V^-AU1?V0.4;^\[ME&>JK<S[RKRBF X@.I'W\I#T2?'MD9VBLK
MKME( QZX,PDKSGH4&=W@.G'&###Z.%J-%$9'#49[M%B?/RG9!\0+A'*#<S8Z
M@[?E%Z#XDTEX&2^YN)PG=X"JDPT"_Z85["6]8D7Z@L7\LPTGP+[E#L8?Y:K7
M7M!M8NHY+K=/K-'_D]KH@D>XW<QW0+8GPO'"7Q+, (I'N;5KZM!@DE+Q:<X:
MHH()JN3T,4=>'XJGB.BSL^"N&*RI*AH$(,J_W$Z0DEY3]=E3_>R',;'>FM,<
MM-/]>XL6DT\2L7O95)N]IJM1\-XZI"X-RW&H"XK?-Y<8! FB:Z',K4#,Z?8X
MVE?'JL2C$$<4"(-HG1,3L\,_GC.;^4^[^DVKL+OZ;P+;6SF;\3&'3@;XI#@Y
ME0 7 >5?=O8%(Z(8KIX)1S<EW2)'4@B^!^(-E^B:\]?PBW/ZJ)\A/E-3HL;:
M-# QMS8=7+>\GJ%7+H5Y IJ+/KFTY^+*%XSTS"&C_TET]/1/"DK!H@NEL!OG
MYS0\[I1PN]&]BS]3@)I8AMI#Q- WB>;GSB: N@4T*_9SFFKU&"+\:TAT>BK8
MZ+3^53A\X=@1#0\($7EDFK@[B/V!/X1^6&I7EKI(F6@/BNCO>Z=VNNQKF2OT
M\_&3>126:VXN:1K-Q_%Q]_+V9K0(.]EJQB%?+6$!P1'(XO:QQ<V[W'(>'YU^
MO6?<ZQ505H28#^D.880)"RL@19HG24[@;H!B X_(.Q6;A"\O8GZH,\<)#'-_
MX18;D2)H#$,5U__V#6/@AG;?%*F_+ER5[Y_H"-=V6/U<2!_$R_)_!VY2_J_&
MB1 27Y+WLC2RZ55Z=_%:7EK:CG^C8Y)?+,;Y/^945U8EJE@[L3*0?6#T*/!Z
M;&I6/YP ?P-%^3+=<G'0%AJ\ QXO,+I6$&2JMPX^,3U)D]A )L?%"LZ#6LMK
MLN@ /ST/[1L>[]/?I+1ZKDS]OLE^)K.!CEW\2;(#S#&OSH6&)+3RM0'X59KO
MZRK%KPG!Y;A%=E1 U>5'IY&D(VJP<<<IOZ'=D&[["[]'_S8XA[ C3UT^KFZY
M'5&2G'63NX;3G]'EV7PA9)2&G6ET7C@[%IF7";WDC\T(KHJ$5'SP7W\9CG=:
MI/S6>6"K1=_CX5==\.)4X?I*8[7LH_?@"Q<B0X!>X: $( ]^?BC$,@+EQK?*
MFX7,]_P')]+;T-=IBT"]$"!(,%F)<$(/^9*"Y68UT<JOP^SS\T\3:<*7>N$!
MENP+_I5W*G"OI+ K0&RJ31\IPSX DL$!Q$H'>-:LX][5]J5)K8Y/MM_ROSYB
MC*KR[F/LW82&CX>J.9Y5G84T"H;-W3(9.5W6"!BQV/>+;?,[<A9WB%SJ,WH4
M/!_X=9],_WT3B(U&DTIG<@E-"0'\G9-]UBWHA5$IS'S*1NES^?+9TB=QA_.S
M-B/190K[HD)P4?K)K<.__X@D+:$9[7=/Z.$SP'J+TF>E#GV9$(/W?G)/SN_E
M\R5NZ>U:ITE)!$29OY8MV3I@X.*1*5)@Q&6WI3TA]1T)/#7VGO_LYO\?^+BJ
M2N,0]@G'S^(</A03B2.('2 HFR+<=W#21:LW+>HI>F"FQKK5Q)3+. AIQN%\
MG".!K?Q:&,A%=495KI'"_AIU!96T<^:^G-K5ZO<@[CM6U9#G\RE.BR]<:LBO
M6X42ALA7#AML$NMO'#JOM#T5U?B.O8-TE5&2W)=>KLW8N:I]1&>'DW8LED7L
MHK/ ^KY' HT_2 Y0U/%.21PWUK($9[ +:7J8TK( RX@,V\"WU, !X<3NH[DI
M1O#:V]#CMP.%8-9Y9_4['J2^'T WUR=F3FC2$2/?_QR!-O%>"U,#VL#XR7Z&
M+$<<$N,;"GF(F?+RD89C"DSLD/P,Y.6B&4SI,ZW OC^Z&W1=CS&.HLC#/9XW
MXL71MHC1Y,8*I.0G3N*0I#X\$!-B *'X\"_[_=/?@:5C_WT\)41.-7.O@6-N
MKW :Q2N&- ;W_0,A  ?W@F2SBV>#2?U3A7/,]*_]@L&R(*=.C1%:A<C&V:],
M_W=N7+84UOQ(M3=4@AAS&+6??"!IT)GR.=W/\SKU_-^K>R>7"/&3T^V^=_H2
M_>!+["^5KK&4OK+!W!VH>?@H)F9HSMA+0N '*JB]#I;"G$V[S@-/T=_^J9Y,
M^#6N#5+JK*6PS>3VWLA;XS/^"U]2B8(]"(;Z/.UJD_88. XX4F/FCCU4\PQZ
M+4F2WS8\$_(JAW?P0GN=?&C'E1V':TXM5S<L(=1GM@> ]J>OVRJZ]O^ ^^)G
MSI8RF:JA0OI2;"9._X7<QY(JP'?\?CFHTW?^9SG0: 6PTAGJS4"^BXZX5T;@
M\ZQ:?$_^$)R2^D8?Q\"\$5ZBZ@?M1I:?"+BQ P/2SAG$IG^;!/U0\P@3"(2X
MD5Z%YU\I*^"$6.NR^RXG5%HB#+T?3^#) $G!:SC>V\.;ZSAO)%Z7!5_86J"T
MX+]\&C<"+3\GJ#[G#Y_H"G/3['YO\()BTM[U>XG"@3\?;F_3O42M7369L<-N
M+[.6F]5='Y8#*GTESR51[AA(82M<7(I(_U*75Q66$RH+^M7_#>)S1+*4+ )>
MTN]I+(()V&A*EQ16@&E=\(4CE"NYX]6ZV6/M1L,?7Q;G/'N/@'L9A=G2),!H
M+YJ7C/P^[(B=\>B3)"DMI@K=IO3I2SX&]W).7YH4AJR%C\SIWG'IN8ZTWC']
M\QRB=Z<^<\P'FQJ;<7#'WA>OGD-V$'=%@F97</?WG<_ I=CH Y%]5/Q01J'A
M9^;ZNTE_'.(+%]7O-%0TQG)QC L./WK_)E*Y/GO#2)?IG2^3-"^HB@$:UN6"
MV1>A0U7<4519-:_+F"AR$SFA>B/WGJ>2+V'(PK.T,>PZ=VR_'6@59F\4+H4Q
M,"V#^5+80>IQR<ISH9*FY6(S<N$_)Q<1V?J_5.JDL,M3U3E['7DAI>TZ%;WD
MH;W_B[(W#VLB^]9&2VFE[5;3SBA"G!%1<4:14"(B*@(J @I"5!04A(@,"B&4
M2BLJ2E14E"DB0I0I"$*80D#$B(@! @0($&5.0A@SD*$JM]+].^>[SW?O_9YS
M_Q)YJJC::Z_UKO?=>]=:^/6](WG$+^BM(CQBU.8I],7S;&20N<2/T$7OA-'4
M:VH=\ %I'/;)EMC\#-D6'Z,!JDY29)9#:X7YN10IB;'WL\5K5*_FL%5L^M-C
MVQN#!:PW[=PX3WN>Q4]HZ;MN5=14NP98?A$O#E1@?1##'CV*QUB+H"%_ $.-
MDI!F@%L;JNPV'?)T7',3:H,JD)0?.0.Z;PY7"5I/1JVV=K4V4\_(9/WQER73
M<0P4PV77*LQD72OIT9Q4U[>90A,EZU*=VVX]8V!  SP)4LC77[/ADL]["[=W
M+[%II":;+S%^&?Z?7=XE>A%S#1:U,NPFJ1*"K!HQ&2G%> ZMYD/]I/LM)W]&
M)G35/=$5!,KBM=QL?B?J0-=CL/3T4%(> P=H (SU<KP5PE2[MA6!XD'4KO$V
M+!B?%T+I,J<=CX#ZE^6PA*BY6")$!=/I:GSC&&A)Z\?7O;8MZ4UY$1,P\LMK
M9C,[X?N=:/6;/E3D#V!'F;3BR91-EFF5J+<^(TQ(" 5YB_ ]"]65-$5X[V]?
MH,D56[57,@WK/+)9(J@E)7;@5BQ8S=W+^=/S)U9,@KI'$:DX))E7QV\ZL;(8
MGAMW:OMQ?$?S0P?*B*RQELL-T@![ST(]COFY>&RY:;F^):W\B<'[ELK'YML>
M0P3$2ON]R\;:!MOWACQ1EQE5!O5A ^HKI1<G5>:_J_Z"_NKJ<KUC?</$["H;
MKP'F^#I ;6<HYSPOPL1[*P6A73;TT$F.(Z^!<OSTG)TK4O*9P^]SJJ97\N$^
MXH)%\R.@@K=X1ZF1!"3$[WLA' Z;L)V*7$'*V#&]U@VWZ1S$[N4MN<9E@&U#
M4/ZUK_A6BM$CDY2H^;+XNJW'='5BPV3/;)VJ4^G/S?<%F-_WRV=6SO#IZ!5<
MLI25Q> I(F02QMVA9<37C)5N_Q"]+/J,8*ND31DT9]&&IA@2V,VD%0T421&2
MWON604[R7!8YL#O\@6,A%L\$?R'CR!3QO)]/K&GCE')%>?=K.DXO(&&\:/M6
M&\_6>O]A^9BY4*4CWR^[BQJ?)I6M[->7E$=+F2U(9LC\R;5]$UNH+XV&J=@Q
MR4[5(C0!UR)!R!%M9?JV<J0Z*Q842H=,NM!;WWJ^QTJO=G)!41,&-5J,T&P]
MQB[MLZ-L[AU;A*N^,^R!F=8T<T)E_E-[)KTK7IU\*5"PM-Q,9N3SQ\Z<F5EK
M778TG-VJ 49.Y&9J@!X;,43EC@^#W\MKYU9C)$KGB^>YBW2BQZ\*9B9'M<?=
M6@>>\QH2V'QZ./)KT\G->P;'<'^;[LF<H*3KVO[YP?;,!_ L2\FT?'M<UN*P
M+OS4]58>K4,B!8_V3T.,8I1SU_7*+"DBE;/7#T\CU:LF]T>)E5._[YC8C9OS
M5^L?-WV-OUK<MM(= GMNR/:.1T##X48F1PV3&.]$'@>R'MK;GZ$75@(PX1R:
M*BT; L">,6EZE<%O\'93M1>N#-O<F!1KR1_S;9'9?X-&]#1 (J5/$#E!R61Q
M':=^'W+Z9Q/T<]Z8P6KMJ;%2W2D5D]P2?I^M<E2Q/C)S)A'2>E$6_PYVV)*)
ME\*\2B5!K/0B>U1J@$#2ODA_MOH$,NRF3QD.XAPD@:8\KH\2L1D!6^6!NEQ*
MH\!G;C&1>5CY8\'AF?)2#6!'(GV8[RJ3#-[G6+J\\]I:<J6\,\D;-#ZS23(P
M2)$!JM;!(&03>%@L+CRS(?8W\J3$4-)OU'$EPOY"KYH*JIWVXM_AU32C4T6K
MM2>KB#)L7]UN_^P(PG2&_NBVQ26KRN> S\,7G%YDY:6,.:,!RE4+[N_T>KMX
M[+(H>C:*PFT)ABDN',Z!G!,W&&PA2@VQ 9<T0(0$58;<66(<C:7SV!22\5-(
MHU4)?*HOQG[2GC@!I=('U8 \=38J+ARI&VQ/=>Q)UWV.IPTBMHA\]/PRR<?'
MYC7:<LE%I4Z<X.P=^9.18 ^.5U-OSMCJF3!PMU/_+UL5-,4O6E1.=I!^PD_Z
M(]7P,)$S+O#YIV_R/A__)OO#-NKPF <WP9N#S[ *FUJR8DF>[:[3KF1U_Q"'
M4%P/GAVR2T]GU5C9S3[Y#.\O6S7PB:_M=H[KZ$E/^DM2E;5U3R\7:V"F?F^F
M?J+E3'Z_*%*H)GAPD+OGS9I3[A0T+_%)).'ZC[U9\W5/15@KR<I7&N"0"JJ.
M@<=;RH-$7 P=%"Y!CH#C^&#8\%5:2.Q;3I.3PEL#;#TTC:'];#V_J_HW?$[3
MG:SEP3?]1<<?+ZD\-['4C3C^F*:SU)[%'2><2^P^-P;FXS;?9B]E3>)NC&3#
M6S3 M<3#6<;H9,6LA<:W!\(NE=I#%/O+FZ>A8U?A/#WHQWI5-N!7\]/GKDF6
M"N>Y/\Q:9"=9HP'P,BQ*<7:IAFBE^Z36#@:[89H%'2O2%K9\^2TR,6-';)GJ
M..R(6I;+0.C.39:DJPDI*<<L^UV5-TF>[4HO)#-8D(31]D<W"F_L,0YM=2/\
MVH$?^^T4-)NNMLW?U/W-5#=]5US"PY24JSSOJ"56AVT7K9V9>02;I^3#MWH[
MX,P?IG]F7"A>PTU?^J#RSQB\4OOLW+MMBA G7'B-C*K4UA :IUUO-:>=+K^
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MI)%IJ@"$[G95M.S+'-RSQ-LH"7H7.Y 4[MOSAW25CLJ9.7;)AMFZ'M=LA6R
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MO<P&\Z2]C7/J:\MV)FG+_06G1TFP4UNU2Q[?UPE2"HA<3X%NVY O&OHW;#6
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M2<I>K&1A>V&HFZQV_+#R6OC1=3JT2]A><8Y/%FG?/\6.CI[^7H&=15Y4<J3
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M?=PZ:/ @ [/X.;+RR9H_,DM3V:.1_EY()G_43,^?]]M>4QGN+[MP;@959@A
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MR#WTP?/:TJ.>VD)R&=],QS6 N_)QR&RSI)0(;"PO9WYBAI\M?!,E161ZJE?
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M!ILP;5Y#/\3/<LP&W+$8+IHGQV5+2V3\@++X&F6URE:A/(Z4+:_U_:CORGZ
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M?7,Q4IE4JZPT@*D[/F0/.FEU:R &%9X>+HP?,)I<?+NG0.$1:G"(KDX=:?]
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M/T%406P"WV#&?D1JN*N0B1)2K$, 9DKE[:>/RJ'6A+E)2XX6SZ2@M#KH[CR
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MR4)%14!%!*6)BDHG1 0$B4F)J"@H44%0$2+2@QB0)G0A(DI4I&\"! @0NB1
M:-*0KG(J:^^[[_GNN<^YW[E_X$DHJF;5?.=XQZ@YYSM<-\!4JINAD%_2T;H%
MU/#&H]S=I* 86=B:ZMA;?+NT[:!GX^PL)U-6UY5XG!DXL5B[-29]%Q S;@4Y
M*DXD;% 7H.SI,ER*+[,."0_$I/O=AVS7/)8<\ (!BW?3;JD%)OL_/"+>;&ZY
MBI27[9QXFCTZ/4#B037=,CNO1TJ$@-8.Z<071]"'"'VZZ<O.4=I.H'PS>5>
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M1?27Q,RSV3VFBT8YZ/AM:U;O?[/T> Y%?F'O@=<5/2!=XSA$PXCZOE+,'Y;
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M3!OI7INTXI^UE@NTLQ[9E?8V.;O,K3W5"8:K0[I=V'U@*4-=X8XW[$;.-<G
M^I96-;T$M0>DF8#7<-<6; 6_R4J^1_]IT?>R=UMB!CP(7G/X76E)81:).4<C
MB'-&<FMJFE6FJ5$O:=%W?[^4\G6D@;2K)3%A52S[00]YM.+9,P5=WG[M0E5%
MBO'W $=C^M!A02U(<OV=$0B9:-+F,-".R?>A4X*0BSH?/BL1O]!*1+\WBA<P
MV>0Z]WR.Q?^4NYIVVIO7ZHG9E-<CH]R\V-:6J77_?:D2D821\,4D[SNZ<FQ
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M[@9-+%J],6SIC()2G*VW[N-U4\KMD<-JX_D'&P=)]A(:Y-EYA9_HMTFA!73
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M[ QUN!1XTH:2IM,1]M*^WU<2 \M1*4K$!CB!RGOW"&3X;,4M#.2UE- "U#'
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M'CT;?CO4-0E>7=1IZV++[^=J=SG7;WZV\';G[_=4LBQ3%/I/+9"N0YJ)1G(
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M>J_#*B5"^SVUGF8./J85'.NJM"P3O)W\^9%X\V#_7:(D[+0D02&61W=%1K0
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MS. !1%N%S>V2MR1AUF>G!<2MJAD&3)?F)*\.*48*:2.4DT<*ZJ>?Z<TE1(X
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M^7>&^K['/?OW7SAE<&V!VT'S* U[(;OK8;S$LP+&J!A*P*HC7KZM\KBABQW
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M;?_EY@T3)=QQ.KUD"I]5!8G2]'I6?.Z+5-BD^@6U; $ON'%WP%6[PA6>!F[
M%8N=I1"W+8@?[UT =LJ_6,\8S/-/>-OU3YJ6/ N9_9@KQ-J<-@^:YXV<+(%H
MWZK;,3-3'MV6EB>^>_-J[A=V]RZVL@KN2A.[!!;UF$-X+V7)?=)D21\\3-\_
MOU]N\ML&\3_*NZMEA5.0ZD"64 !?&5S'.%Z7(>_%RTLX).72&*'"T"PRGS4$
MX TCS8#?/^HEL)H?>-$GCFX3, ,75IF8$5'3J E(IBV78],.W%Y*@X](8 =I
M*!%V" )[2GDJ0>I!'>KGB&.0[C0R/"<-9O7M!(N>B'&S6DV9".L(+H ,<:7-
MW=9'%%;_--Q+AW0YA+#)\X@*D?>[_ML(02W2 .:76,>?H;12/Q_9V?OY!7K'
M;K F&E(2W(>0A+&^G3CM:2L)S(4'7XP)>S\PK6#Z.:R_DS/6L9!R]ZP0LL4+
MGDEY&+' <T LS*TBF?;$7WV&F4>RI2_(9498?C9J@P\S(>\NQOFG$) ^IU )
M3%6</VL1;[@F^&YFPF(,ABPEFRB^2J<%EQGX=&L[P/HGG!J0A!;G\@U&BU]+
M"5"_'(DF6O=00TA%LI:Y:H-.*31Y!FXJYGGPIU6PS<9?$)\_N^6J72M3CYQK
MWO/Y7258O"H//GR13E,H!,\8:%Z]^_1.0@BS_=3/,0F,9&U2\.2)*([0M!W]
MXFN>!/:TM!\C0$6R143!NIGX"-98/7P^U/018:;T3(S,<O)S]%] 0@?RP##0
M"&9\M.<2&O XPPA.'>#?>@OL'UMRQ3[$5U6M[Q8;?X8O-%^M@>I P1@VE#(S
MVQ4-'<\QEY\]T=,*U+57U$K7ND*C\ZF"(W/W"[C: BD=;" OSGC0O W2Y>%4
M9>-X<V[G;L1Q<;GOV\!CMZ3B$!@RJ?@$^\5L8)T<[I#GX41- L_;V"D)S";^
MRI]]TC^4+_>>:\B'>C^0$DJ%ZDH:C[0\DVU+&JIZ,=U$K,804RDX;^*R%B-(
M2SX+G;'28<4WJ*?N7&!\WOK37^YJ X1E>'EK"$.+FET1Y[1VD*^\%N0'4.Y-
M"W.)26F=<N:Y]A<UK:3TY(!8 JLVH"5WCX.K.J*5>T+S09,%5NIY5(X =6O&
M[M5ANY3LU)W7;9T6+V-0UN9+^^8Q[&&!HC=_P9;$VNO_(23\M\A-JR]<'9XS
M-0GT,O1B],Y*H\0/('0,_;)#Z?GO,T( )EG27%H','\,B3OA\=?"'9.RAB.0
M"^5!5]Z!R)992(:67X;<Z);2ET[@MP4$^04&*Z2BU3]6L:ODEV6U:>CU]DU9
M1'%:Z\HAOI7>S_T/[;$[N]5L:900.BR1R0'B37X<J:8]@\K4<!D%&75==FN_
M;WY+8VE6]&)KHYQ96?T5X8O@44.^9;DI[Z2NA9<:TUN#N0"G9":Y'2&PIQ-O
M[[P.@KDXV43:%:=I@Q8,='BE.K&..3CI<8?"7]E*+_>Z$$Y>LA>'?@ITE+4>
MZT$&_X=TW!97%B33O2AJ('LHG:E%OK(IWMT_3Z6H?5RW9]L'K,^E]^,TR+QX
MQ6O1^ EM'3!J"B9I1+J3G*+#WBEA@J:E\9&Q*KG6=7F7G3IN7I4LA+KM9DML
M9+G(FHYS)>QHC&"?U3* 3RN(Q?8K*?7&!NT5.:@/*G!G-XV0.Q.5<![=[AVW
MOQ)0?CP9%J(RA]VQ/A5QWO"</HY/A9)_=S\(UDS8PU7I[-9P"^RX*"NV#1X>
MP+/+COV$\&RLO.S\;"6&)WVD\>F'B']UB6G+SR"R$??&2P]YF5A3';Y.!&J.
M>Z'-)H,5+/VBG [%K\Q&Q3/@^EVZ\$2@L:HLK^K02?_DY%36.BA>RBV"5JP8
M#&9:<KX-7HM!I9'H0&1Y3I ?31-OA2CK##VHNQ:K%$[6\/=XYN/K!0;FBQ]C
M_$_]UK-T*H(6SC%*IXB'PGQ),X=UTRZL-7BZ!;D7G\'EOVGMRG(NE*N(O!:%
M!&S&I+AOT-&D$XQ("S;U-@UC'R=F8C +BVBN#*01(H%5X5VL&L9:-SD<(T[?
M8IC6>OV."/YB9:DF77Z:3F0D%<<&[FF0I,O(Y,N?Z4IHAF*LY.DU$+#M_4@J
M<N(I?&$.L[Q"D8C%&'BG&H.GX%U!G#VZ*#K+E;%61T26/=$PQE@;=_7W+?Y-
M'L9XV"5\?P"R^O[5%/;,&:4R4V(B9:WC<WY[Z+:_3E[)XL$UFZLT;B0G' ,V
M;3K").V6P"A(-+GPY1<SH'UN.T$QXQR!8/H9:JN;),2E2& ^YZ/BH%5NF2<\
MLCQH<R;#(HV*_FH<K]S?1?@6I5H/-W@15OT'".9_4-6^@[&VN:"T']-Z:U>/
M/N1'!\,0OT+PE:V_[3&O=2\D-;;9_K(&NAW?QSEGL=WKM8L^]C=C?3WG+TEU
M#4Y\@5_(6+>PTK6@5V7^R#QTE50)7,LI#O Z9)*@021F2F!4\O5P"K?P#C:S
M[^$4,K>G@=WQ7HV/6_!+NY46+DY>Y8TTGP%H(IO-M&' 61_ "W%V72CX1)LS
M3?$8RR%?*_";W;4/S%_W^!%Z5!U%LW#*$JB)$9"<''VK$]:%[":5)*;M"LBV
M^]9UY"#DH.ES-NJARJZXG='(\2[;SLL7J%/"<)[0<:@>>XON0JQ;.]BY[=S[
M:!5M NH1@('^-81+L?C$,BD1"BQ=-FKDME:3HH%<X E.["GR3K)*30\ID9=+
M^@+M_)Q*GBCHOK_SZZ\D-1RO; S$/)BDA?@(V_S3WF5EQZY;W*NW$=G.G^@O
M0;B7V7U(C( 8,XV0VE63PW/V@LP9Q)O6?)23L$>JN%J3XS=VQXL,H3Z?E5F^
M6;K5HG0X!MT=U)^%6WU]W-WW'0E5(Y29?831'1,]0+(R+!+/6]5TR>>'0_ %
M_W9*P) E\(M_6![3H3EUOM2+ EH]-1%AO%JQH:6 ,T8"LP8HW6$)'08G[#EV
MTKSEOZT\O- *?OM-ZVSE+E7%*P92Y5OC59$L+R,N7]E[/CX=W6+^YP_\NW!6
MI(,3#UIOLE'?L3^KT78Y-&GU1[FWE4^XW4'7TF<'_2INY56((RHGD!%=W58;
MYXZ0)N1!8OXU?4+H;^18_./ %0]0D-?>.5/2(W,Q4\YB[P6D.R.8YH#*UYF:
MM9QF[<E:KO(&P*9NJ3QYWJP!_0R'2&7;O2;LS0 >4-CFZ]! WYG1AUOD'MC=
MM"N=G)5:,)RXG2L$ZGTX)G*?=:2XQXVWR:)</Y;IP^L:@SN8Q61GY("VT@PI
MT/@E7C%*>BE<G*$ZRDWQI3C+ JM.>\L1_C(15O_YNTG(/E[2G<$.:1G-0EPN
MB?&W/QH]%H<A],VO3,[+$F+7M;3$3>-S2Z327B>0^^C$^_,N.Z$WF0BW+QQA
MB!_7UIP72>@+.M)DMT<HC5 ?_UOP*SE!$MA&@ !D%%]_;!,)31H.MW:BB(G?
M&XWD]7P8]]-R,@BKHT,SEB"4B,KEA\H-G.:^>/>%@+\!?F>'_I?([+J=G@Y;
M_KDC +9-'CE-4NF-KY' C-D7=.-5GE5-#9V'>PQ%)']S]1WQ,C2\=%9!'$3@
M*)(6NY\C4V4!DUWZ)-_EAS)M-CU)+\S#LUK:)V=-B;IK'ZM]KKF/C.@)S=5V
MM(*NMSZ8I+,?-T'5=94%I-;1I?/Q#)H?T2^_2^:P+6SS97-]9GOF:<6L,,9K
M_:&?:#&R9VP@=U,^C@/8IYS8/4+5Q/A7YS?!A:/D_K!W/FS="@8"^]U@YW\8
M&G\RF!Z#T!.\ %9<KD0(+%DE"5M+FB6-AX')*V:PA5B,(=O!9 Z0IJTFTCP)
M.Z\G,&TEES]2NBI?-:#];@>U)+9$&T#5PSO!UU7O';W;>N5W>1-WN%I=SI+
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M+HNWW*<2=.:OIYOS_MR)#5D4"[>!].S_"Q#]__HA_@,T8B*0>Z%#D]C4Q]R
M.MS=J;!+_- GWOPABPTL,6[^6FOP6?^U9;TW+A;J_][WS/1@P3WC-WF*VTH7
M*7OF62U9CT(*+."LD?9>P4S.__X6NKVM 5J])VG^=B3$B1\ZY(WGSLFNC+1W
M^]=.;<7@;W&),2]*"O[/H_=)-#T<A_\J3?<2F)*4R&&P%3P&*27N4XV+T//\
M;6N5PX7'>SX%MZ.#_SKU_FSS]S12?7]<8FB08,,,5HZNX1A&Y"/D='(',;?"
M1U>V-F9PP,-FEI.^?>1?Y_+A]3C1;). P+YCVA%77+248?H]0I Y8+TST2TO
M\P^@;6NR_&A*\:H&]P-F"?] L)'6VJRYMC,GR]Y@ZB<$%*:NI]K?P#M/Z]U9
M?<@CX2,0;Q-V+-NW4@D^5QX^<[<W ,[BGK0#X'SZ.$,1&\3CV/-#GDI@T4PO
MCNB;@T6TN!4%ZDE9H0I5D[_2:WJ$R5^*G)+F!J8_Q[K-.7W32X-3!I%\#K*'
MKSQPJ%-W K+X<#@XZG!Y&/XG',V2?OSW_MM"^W;'YJA!":RL4&N<E1/QIY_'
M?I9:0^C)RSIQ**&(QEB/G ;KL2\$LUC27 BIC^'D]G"?89W5AC@($W]UPYT3
M?\7BIT?JG)GR/5,* -^ K4-6N'KI6W+LI]8"\YAO$**HYN=,MI=UUTZN7,Y,
MC;#&7E8T,IU(0V^@-T86,LMS*\ [0L?G.NL0NY6SXJ%YK^FRTGO"\?S=_0M7
MQ"MV/Y@9:YJN486]81 $26!1#'E_#]6R^UPD1P*+3TLB\^#38,X<*L.1I1DI
MSG$H[22PEXG4(2GAS(+R$-ZI(!IS87+S=C.:4O7S1?/W_?:>^S3)NY_N@\^J
MU&)]TMFA8T .8K=IXD'57WBIML=_K>A-39GYGY-__U$?VO^X 2<#DD1P 0ZK
M983N83;8Q?S]F>3SL/+F>]M"6]_E8^CE)R-:[V^;;06]F%+I)N^D0?ZLSCD\
M!]1TE)8TP2O$9^!2A7;IZ\SKM^I#>UB?8]8.)YT;\'<]'0<B+@"5.![(+&OQ
MSF<V\9^H*HJ.MA'V%A5V@+__XA8W-H[2S6A@Y(J1+P?EKMG#O6'2CO_(_O ,
M,N@*)+E97.=I_C_A6#CJGQ<^U$$^891+#/$3A\YLWP=#6NR1P&8OB Y/&@J1
MK&4__@#WC;P19-0YU)$KFB:4>)(FW&1>$?*)7>U (TA[F,CZ/BR%/& <<2XP
MX3:ITXJ?+X$A44P0ORS;5S\@;TJE<)AU- >;[]O>G&%-L:4P./.C <W1$UP(
MF.!PBOJ"<ZL*"LXH7HM07_-G:D$EP>,>D-'6RH5([,V(\"?>@1'G*6LIJ56D
M!_/4F\^?/EKC#CG&:5'Z.QL$/ICO0&Q_&$649T %/6F0:M]>W<2?B37SE&E&
M"Z.D/P2A?T\DXS?LF<EXPMNU9KY/_UD*>:92^?71' DLG?&/RG9(^I:^&E"G
M0P8!)VV,%F01/1.0Z"[+I.Z].9]A],W2797))*V8SLX;C&,$A[VCHJ];95E*
M8!5228<.CFP!'9-.#:'=;B"(W<$8?BK!+YIS!S6?^[9T_B&RY=B<XD6@YQ9)
M2,?=OU,CWW5YF)M2PSV)1/*#DW[X2I]_2<10ZU;GN!KGX]ZRXL>JT/'IP024
MP%[V9O6.@(RW&<O!-QJR:[)AI3KC\@1Q=-_K@7TJWSTGVDP' O5?W]H<]VCL
MP8M;SO>IGWERZ_=%9=\P&3+$+-\+FJ3/.M;>^;?8D-N1^X&A:M54L+SL5_/\
M5YM+P9D@?1>G[/2<?8\A>#A4UWNC1U /.K?EYD+QRGJKI%C(IC&Y0J A].,2
M72JNI)HJUV$_1(]<%II[K1+;%V=GO#!WT.G\N6=3Y%*WRRI9L%)7I9E_!1D\
M(X%5?F7;4^_;A5H@3[QRZV"%1>*6J&4Q[E &3[@>9_$9D<YVT'*YOZ6=>E,I
M5HLZQF06ETI@SK/4T]OBQ,*J[([AS>%_DBRAF(#:S6:6"1(8991H34(^XYQK
MVAJ*2")?U;6ZC=0#CG&/8'=RX[['AB%[1=X6GW%?PO,%T\9TT;7#@ZD[[7,>
MV;:U]=,]@67S[Q!^GG!WQG,H+()2&PDV<5=L(H75=5[E+?4>Q-JS>/2;9;^=
M(P$\@Q,I.8=NVX## ]JW1&*^$9Z_!<)PUG#Q-INVF\]SCU&YO;M5+O@K8)V'
M?T]75FTIR/SV120\MH <UK!4V ?\(A%(:+Z12.\TC<;:#>2T?#5QF5F_2#-S
MFW3=H-9\=[Z[##Y?O%\!JL3[JK0@9[W*UP/=,7_'TEXF11Q%SR4GY1S<JP$1
MI^:=5O;=^>6C&!4/;LDJ0Q0OB/LY,[/3^YQ87D"%2+.D3:?]O#;I^0:[QUY?
M+]P(,X7B5_;HDCV2WW$=A!>_F!4_4?;1G]#-FR=(8?"F)D>I.55L TJ?,HQA
M6BTV H](8)H7OW7"D(>G0)+8LX]JSNU\DQZ^'Y>=&@_)=%MN@&<L2=]]>F5T
M8W0MDZ&?!7WWLP@XW1KQD(B>E!7%]^]L?.6#*4O7$5TEL4%$K7V1W@E]))IG
ME66\Q\$P,RCFPW<W]\BG;=T;<FQQ_)YQ(%(XQ%UM*48\;.72:=Q(SJM7;Z9#
M2K3=PZ8TRP!Z;@01_M@R%I1&8R60._T^G/WQ6-">E;DU7+ ,MC2W[+; Z)X6
M.]4Y%006<AN'&4=>5Y-F=!/M!T:*3+AM[JS3U7$LM=/X4P >U4]9PA83[-*/
M4TF#&:#3BN5M %X*H@_%B%6W_W8_3W%IY2E.ORT]293 BAW,$6YBJ]ZPN4#=
MYR'2A=9>3!2]"KL$A']MZ4VL9^34L2O@<Q*8-V*6*9MAW;V@[#\#VJ0L+UP-
M5W3HL7):L&U6?Q_F=@Y7Y_1#!EIM=7,\^XHV8&9_%9<QU6OTV65+KX)*Z(;E
MM;=SB;9NO[:."Q]E9,1;.Y%T=![G+M)K%T@36VZN^9[Z6U.\-E.6B2&,TO$^
M,:E:&6+T[=#\QP?WMLN_0HZ6F_TS B^O R.%$)>2,\+XLQ[Z#!&-W;Z5K,,%
M<-0;YQI#_ZCY]D3IJ2,>"+N<F6&LV'1TQB0=S^30G,SM7VF]9RD)%#ZY>[?5
MG/LYQE_V60;"<^RTEHZ*#XRQPX"?HOBV'L>"-U&:-XKQ<WSH6;<00T@3#80Z
M[&WD\G9<@O/A:.ERA./=G^SF7:9*A<8%Z8OI1*Q1EKT.SPOX=@/Z_G@\GPR&
M^)M?4@49V!,3 S40@2BNVO/XR%_#G13D+_D%OU-8!(- P.8]ZRY.+A_5@KYI
M5H4@]7BDZ F+*.)=%T\!G]_,^?C#OS0WK<C@I^N13),YUJO7%E?YT=!79*\$
M5D4?L&E5&-*OEET*WN,[@>_(+/V2-3(I>WL>ZRSS.K+&C#AWLPWH6D,12A.Q
MT^WIFD6$<F"G[G:Q\%EBGSWF*"PY]HW3Z:):[KG*_6?[$["@YLB*RQ"Q9"2
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MUZ/P=B$Y0"^VBSXJU62=H28)2:A=PH&W6*  OJ")30B:T9M#.&O=4J*;/RL
MZU;,!DG9PK!BRQZM;4K"1.;C64LCZ'5'-C>"OM7]2RZ<=45A:G[ZUST)+(QW
MJ2SW:+=^R,=O*=\?YB+\-0=JL(,H+JEBR' '9<R?D7' \9_(!49CFQ,IP66-
MP2F<DI$IU/*'FS4^IVUVS8#4A7VCD2+K8<@'GOOCL#[25_F:(NX YG@ELC_^
MI'O_GY^8^)\?I-X,M0+=)+"7_!BVF#[!#G/8-=2UO+]C4/^H>X4,X%32<^.+
M7?S: D ART%?^6;1I59H$2)R!2J+)N58S2-[')I_![;9?#U,:<;&B(][:TVB
MEBG70,^%N!1L^(%'-+4?)XO+ E;GR:6<S8Z]&7K)^F\RZ()$/_2E5M!T=5O-
M["/L)+ M8^)RRS)?UY%\#;>2U<&O5@8ZZ,Z8,[3_+0PI!VP6TT(]B:=%G=C[
MC$=8MXT7WVO[^VM%ZGV[\5#3U]3[K!K.J4H40IS !A$PKIV*M<_BF(8=K168
MLL&9-<7YE$^,:!YE<0T-&^X_EB^BY!$5;D_++=\Z$CP;-.5[R=#JFVWHQ"]H
M;R&<IW%7?HJ';1RR%O78+JI,!I#DK&WVU&BCQE?M'CV.TGO$NC98E89_6")\
MJ52O^C(#/H?_Q7/=NO$H?-H$4AVR-D3H1:W+N(/XSG;0QUIVA/U?'V!YATQ&
M@[$4>V#T%Y<.8O+X!U:,<P#N:V@MZY @'#(M^:_#*SDAJ:3H;J&_*<25@J+/
M#-,<^ KE(<QUX#/(&WMVX-]#X7&/H3H<I0@PDWX'C?L-;E%FIJ@6#A"H"[(K
M/78/E9 J\!XFSX.[FC^P!65Z6\Y%Q2#[HUVKXSKA,ZA_J$WCFX;00-8"="=^
MS3VIEX)YFXA^^,LWN&0&]I9[ZCH#COLEQ'M^+]E-Y;DP/\[\\R\O=D1:N07T
M]#!/),>4D&3^2?W&2BY[XL'!SZ7XC]X->XBD\FV"2ONF]8&NX%L%E3']GO.Z
M7]-1ENR*ZKU%]#J]%J_[NNG&]#GM M+,J?AY4>=&N(".OHNH2SJ,ATSS ^GQ
MQN$/,_BYWT++$*ZU?K]O7PW^3G&[!00_7KXJ7[#K[E&?=^GC=:_%V[DZ\ 7M
M\T\.@?[XU^5 @S]3=W;PU9H\F 3V&IX4Z)>8.E 1ES'@E31A;E^J<TB;\>C\
ME$I_=M:[Q9%?O3'K);"00+ZU6Z6CKU&@IK -^O/9\\S@@6YOOX(FN_E_?Z<\
M[8G_7=W+ZW/ZE^TV??]K/&VSC8D4"JW((KCOKM;*V[,G)3",4;OY8(YMPDZP
M:@W^4$3RTQG"/%MC\ARRXY.7E-+:]UH--J7C[@X@.S673(SO)$*GR^R G*<(
M/;'UU)C;55LPN--#%\K!+V44J!7.@4CU7B -,Q<3599/]:N0W@7!&!@H;$/_
M-^/^WR%($IB[4& )BM*4MR-C26?"$"'6C58WGR@X68W^J(B K^WM_WA?<6#H
M:MKK\+'Y,Q.'G5B>6F^.EKPQ'/YDXH:8Y9N*3@%N%R"G*>7"#SNT>3\M[9YL
M61,2^5O\5"U%";GXD7T5\:F7UGSB]<P[BTJ.PPMJWZ83WG^'KTG(Q1<<87ED
M>:#WQMD=N!?^%/EC0"70 ,I^?505_W)5["KM7/F](6IBT!C/GKC;YH!:?6.K
MIY;<Y8/AE\^D'7LTUK+ ^"/V@%R1>PPLW&P(_$:T+G7P5=OYS96<9JWB!>UK
MV8%IGKD:5HX]6ZW_1ND8M'LK':1A/9RSJG:]1Q:*83$O[B3-A-'^9#J7?+^[
M)RS?91^U_>F9Y8[DYSS7D__5CV4(OX&Z@2C[[SS0_]\'V?TY$ACQE;642A<!
M"Y>P]:TB*%E6W+]2$K&C0M;X_Y1$%D3)PG7_GI@T$<S$\7IU=%7Z*\(%D?Q!
M+VR@WYM<=NY;-'+HUK0&_K:U-_!K XBDYJ^(0"/01HH$[P*%MXC$"U96@.:B
M7T9*_4C!EM /I[=>_B=#5X;C ]2:" =H;SE#5*^(NAWP"6D>O08:/KYA*KJB
MNKRJ!W!-.OWOJ6:+:'&WC;@$!T6@755%\KQ@7FH'NQ>?LCG10P*#SUE*8%LY
MVA7 PV ;SY]^==.R_VH:],0R$)\RX S-S"8U/<V%CR^+GPV6;D%.'+=^_6!,
M&(U]V=\B<!&$M_4T.P4]W!TDIS;1\=40'X6-AA*!?-6^I 9R!^#5[9KX<Z13
M9?I7IU,)Y/C#XK+.>?-(^(3;(D3KEX/8 I>BN58);)N\_0\5Y9\9\1>)CJ/V
MZW\$?#@0>CA#\7GC=6HTK5.C5!II@*_LL?[0S8.KD:Q%!KS4H&RW\'/83SVT
M2)^9_)4%#\4JN1=7S=:RN\Y #C)]"B(5QL\KFM!4P(G)1MV]$EAI.4EZE7]4
M:D1OYG2;<;S-K[:P"[07G,0_&5Y\-0;I?[Y>&>R3_8B[M$2#J!R.!%85M#?Q
M?@X#1NH?)<^"ZQ42Q(N>$&!0NW?Q!*E=&J#"@O:2)F?>3H]',K)=4^EW @[@
M-JXYM.O JWL%OTTU8M9*J8U2XESHNVF=DK;;X &_@T]>)Q1,B97/MJ+,K,QL
MUM@J7KV:YW7GC 16N8K+3S8OZ9CB?ON[T*\K[J.4N/U4^<BLR+)[N!;P?=C@
M LF9Q9#='OG=_@O9!+RD4]8L2V W@?%+HE/CM+&Q0-F4/\Y/]2(56]>+]+22
MQPW"_QWF=.VV'7K4UJ/\@+?' ]]>43^5!)]U;!%D5J? >:%5CFU,#W$-6*R\
M3^]>SJP>S2U3V'X=?"-=%"//ZS@Y[R>%+\,<- :,/RF!=X#1\NUP$7I!H6"'
MONP5^Y;_E",R%U6<2\6)4MY09:[)H/205:( ^]:1FNX&;=++#C<BG.Y#&01[
M"X382)T=$?W]P%IYS>ER^$=4Q&EFS'/D?%4>ACL5HPDM8;<P/B%'A2?FH<1O
M%J(="QSS>C=A%"Q5Z(-A<Z(_.K_H!+?CC+=<\U95WOVZ>K'E11WJ)-SO@1;<
M"KPR!N+*T!_2A=%F0:3NJ;9=W#6N,ETK@KE0-U,.V4^D@L </V\-N(%+O8&H
M^D\(?[U9)]@QF<P7+@#PV<@2P6[ .#GI;$1$U1K$<;?>W5%F<K:?DTW64+@-
M/3)2&A/Z8ME&[.SY5"RT(27I>D$?2$5^Z@7"C8X",8W)<6WA*1\RHJZ/:V7:
M*ZD8PF?1:/?9?;IPFM]'PXR)MHT)K.!LO?[?/3];Y7*L;J145ZSN'8EKL)YO
MVKK*$\_,6"3G&TPTQ>M(8&,?5KHWXY?]@CPKK]9=^KO:KG0KCIC9SIMUG2#]
M>FQ?M^H?<O+5NT>TI;#C".-;RFIXBTC\3IJ4J9X)L?A0(MH!;"@,+57>($(]
M&-7Q/C@Z5V3\04XW7R^;15H;!#T'I)CB2'\[V5IH5%0WS#5\$NSJ\1D_+M^B
M?"PTP8]BH=+)FPD?:OE5<ORNMUZ'R6#'L._3+1K"C_*"9$3L8PWZ,_=.D<>N
M-\$VXLBLQ,/12ZX4VNZ67JL1K2(U$/BA!JGV)7?*/WO@Q*;%1?B:9$E@<GHV
MV-NC_BCY3((0)9(/PV6WUJ5DE#71JMY_S*;T)^#]+9TS ])#MO+Q,R=Q J5'
ML*II[*J9PP->$IC/C,&900EL;B;R_(Y:VUI"?+T!W>#=J9:E#.2TE.]@K\;3
M'<:DZ+&)T:,4N@-^XN]6,'F';?9OXS-159W):K+A*;+B#+!) JL@+ M%ZJ1X
M]@'PQ.LQN(5'X*:XB38Z\<@^F@BS-?(N)OKGV(-_H-0=FI!@QJ0_7F!!6WV2
MNRT6OK4%CE[P_Y.7TPKM>WI63.NO>#ZGAUZ-T#+7)E%')X<Z*CI3USDQHVX_
ME*6R?ZZ8Y-S3S*28;0SB.@8;&T>O*LO4$/4JLRLR/4O'HE(!00%'N9D@U) ?
MHT*81;^C]-P_%0$\2PB]&/."M \*!PM6YB[BN;@:95^=5XJF1)%2*$*H6"DL
M2 ^6%4A@MDZ"\DX7NW2";$7!W[VAK2\F4Q.A)O@, R6:I>17,UM2'R4V,*8\
M!B=IE^76I1LN2YF,)4-;^?' R6=RAZ?Z=KZ;]A'PNG8&"O'".&_9_*SQIM@[
M6G#\1:??/53%!)GE^WY9?:"96/>T:;G@ R :+,VRR-;RB4DGPPR*WCF# AG<
M/03Q'101G(R<$ O52),.CS[NVX$3(PLY#+\HZX^[GK,F&R4P-IQ<\/!ZXN/V
M5=KLO,LF2^$0%]%SI')SU?7@Z1 A4(<GB.0)51GF*/2)9RH_D<Z]H29OW_F
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MR(=S>13.V_Q/%O0=P.>1 )"/]R-3EKF3!@XN)ES6A[I$>8H8)83 ;8'@S>Y
MOQM/5L,'PVC-N9[N#0%RRCL#5/*5)+"RO<"T=0=<@!,0?.1/U7")*F<76(;]
M;L*6_?)_?:-R])%-'<6.R4XB]7-0Y1 ]QHOSCWTC\UJG_P?,)O5-$MAX$3=
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MRN8[&U@B_%#N=!$V<_,ZN'U[< :J+U6_5)5@W)V[+IO$]P<)G7V/_P@4_G9
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MO=4,^P'GXBE?&IFPHI#-YT3'HZ#0C5!#E<*_#65_#;YU^<6KOCA@A>$\=)/
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MIW5H4@[/%'H[%L:]/MJ&/W#.]HL-.O+GP64D+U(G%<>_DXHT9(N$FSR^),I
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MPN8[@;?9VX)^=)%>,XQQ9N@[.(9#Y#KR9"_H":U@2[X ^A^HJW4]S;F/JNT
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M,;=,2[!MV'<Z)WGO#@TKS6/[;M^*N"7KZ:"DPFE,G=SH6$1%UC_$AU$A8E$
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MSPBG"6,"2,8L8@)N*YX+Y:0&"9#"R4P+8\JY1\_WA,$NOW&Y3%WEBK_1LO;
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M;;'FJC*_]^V%9DD@HRZ#"4>HEL^@BT%$$"EL-<B<Z/XE@3SKM*HW3YC=>WB
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M3B+^%M5Z<"D7G%<A#I)GTH5X"62;QMP_-7]RLWA1GC!&U(I:GI^BO ;&LGS
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MB/UO[>?T>!8><2_E<GG.UTGMC%PN[X.>^O=VL909I@S8[/*[H":!N$-6WAW
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M/6(8QSI//:#31(333?^48$K#<55!%=K2;SO&&\HT&+D=,3Y# KWM&T;!QKQ
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M$B60[;-ARX4&8[+*:>+*_^--#ZH8Q]\D-?Z[P;,Y>OP)G,(/Y=*)H0@<X[4
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M-AVQ=_I?#<)N&+D%J+@[I*@S^!!5H-7HO3+O5S3EW;;M F[1%EK)"SRF?4A
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MY['?N3I &%?*6R)I %)$4G8V$V7;CQI">?MT.?T5IG[097$PVR?GP1 P82*
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M_5Y@27.Q02"F+-#:2<VSKP3BMV3NU^ZBI3GY]PG/46C=49J^/I?5KM7O%B[
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M?2,;#4NT-C0WDWZ\P8>D\ZIW*J9"](GK:'@WV%;,69?G-I3*K@35(Z'OR9>
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M^NCE+=EY=:]A2_\4H [Q'#',NI=!'7_D*@'\XLR-@GN:6,L'#K<SOG/6C&.
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M\M#9^X:-4.P@(1^F8"F2,WS\*@[!.9B<W>G&Z$$=@$Q"!DAITO9;T?J%L,V
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M?,LN<&V@PZ:#8D0%<Y8\0.<=]$*M_ -&$H.<H*N:!"Q/EE@4!7!,1;!!/^^
M;\"\4@GA'C!^LUB,N$8?F4I.(8]]\N> "1\-YC%3&O\;!Y17S7LA?$X-=5^E
M59#4[2TVU_4/5>J6==H9KS=YE.R#=7^63:D5(\QU3RM:'I)S5Z'T]'53W$E?
MF-AGZ812,2+1;P-W9Z++^*O2 7V#"\C-?YE*_-TJ&;,^:>>82NNF)0Q#K6^5
MUL/JS2["^W+N+Z$9@QU]?1E"DR,5OK"!+!Z^'96WD^/(^/HCU8A0,'^TIO;>
MV=$-KL8%IN WB'JCL?FS?MDE5^4SA)[AXQ?79;_=G4[\Z>"PV?(RAU%3_1<J
M _(6W?X!%I1/HI84_NP+2P*S)(6Z1B92R3,?Q0CCS6)$U[%(GG9-F'"JKIJW
MN[BD]A;MIK9.-_UWV]C&>PY=YZ;QF5:=F\%A#5-5D4ECH31[_7FW1]T!ZQM/
M";^QY:]6-U*EV%X.=8CPTYD.^).@R[@ >04S'C<H_^06Z4+D*-U_W/VAB+2$
M\C>;/?ZJ[?:3[-^>LT\5NSQG2ZN>WW]WB!P7[>9<VU(8&4(;O.4,;(G5<\9+
M"F-PRO9X40$]J^H9KFI!X'$F#=5G%BSQ8[N]?)>DO"T+!;/"6' 4%ZDX;3YM
M1-+^GX_.TE<X IEZS9?/%"0LK124E.VS8R\CE>R>%_YN11QM\'QY3.5]ZA4Y
M5:LDV8C["&*K8/MR8X_\V!/&V8UGH,1@7!DJP4R)'#:"_M6]Q<-+P^31R-[6
MRX8F*%;N-I6&'*1"#GX3Z=%\U_>V84WV_D;'4_&9?_>& 8-UXXD_/N;O'+BA
M:%82=>RKPL6M,DG*=\"/R/#O*JD7+HP!TOC"R3P8K,IJ,^&[\?!O 0K2"WZM
M-?M 8*6[$RHHNL-5H^?^N<'P.!G7Y5D[3CKN6F(74NFVC=@XEG,^ZDJ6N6K+
M*PK00<M;;W.JZ8U#A%DHY6*TW>C,7<RGLG6E#89&F[U9,^[JX^/+[MAWX-XJ
M1BEI??P0:\:FC 1IQVY#)],V%UN=K'LS%#AT/IGI!:1+[:?G X_N_-HB/!@;
MUH;G!$_UE*4,GU]P+!V@[S ^4"%YME/E^KIT.3 Y;^O_B)!5\&/_-R)D5F6W
M!(3?>N6<BM4_-?05H3$X6K>DXK]4J/MU$1S!L",_.79'Q)-I(%6$K"!+R9+.
M[+*(T?+:(D_(J&3,?R80N!$0>]Z@9*E<Q/T."T ^R#'2IZR[*:%@>DGOCO;N
MLV+$MR+V&HW7:Q CIH:0AGX-P>_G1<#_]+.Z 1[L W$BW?S_MJ7E)\ 49\^T
M&+&J"X@>*/0@N?M$Y/'I2-$O^,^+K(."G7Z&[=@S?%GH5I&@YXM*$0P 9]J;
M[25G@3'FAT)47;8@.-SPB/L3;[ 7SQ$C9D2X=RUN2#[R\E4WYHU6+?5;]S1_
MSV&Z]^.'S_8GVGAJ+PDM=EL"/]Z$4?$S4'VOMM?MI'K15UCZZ.Z+9B>(FG=#
M"9+=AK/"[J&N/?S>][,6;L5_AG\-L!(T24K6!"J\R)LAF1>Z!LF<[F5<K>8#
M:_23R%YOD-J.E^VG21\EEU07>]%?QZ)', O:C_5:[DXT2XI*^4#7\DQ+J1UQ
M@])*T6KPM7&!\DI'UUUMT67S;+Y'@',@ZCL3^ ICK20(P)@3J5!_@:R3(5(E
M0;Y^5;HQ]^;C%*+.K?6%LYJ6VN+1X:1T_GQNH^T9:V#@6< A,6(=F8Y:XFQZ
MTR1/96>O\L^_TDMTDU1(LU/%578,^L)4$ZSG@S]%'9"'7T\\V#<36<U:^$]D
M/\B(I_48P_20" G)ZN.O!J?OTI5*C(?&G9F:/[C0_+AI>6H0:G&7&%&]1)CU
MA/4LYPI]](P^TAKJW+,B9U1$Y?D=#3+B%W'QJSTEKV$Y^+$KBDV@U7H4PI E
M@B%LYX(W:R!56C8BA&J($>[<]F+_@Q;5AK"BU2U7T:A:JE[]A301*R[03J6L
MA)]Q>WB1S4Q8[7$""77MI![(0A5BS^+Y]2=0O7AVV-!+,$"=P-.>$5#)Q^95
MRN>W*)N*7!]BOE,EA;CD^C\/O\$:LF@PJGX]GAU*N3I76YT3@!#L,\4I7(Y%
MD;_9^%A!=!&73T>[[+$E][2T.3=\>FG9,2<?4*4YN<3??-.A0'#MW9&@PJ\]
MK\4("7<R48$-[CZT5)5;;.ZN4[(B?['?MIO@C;9YE?\1VEOUV=W5-U&Q9=I(
M\2LXI#O]G85?<JOZ>-L59;;-Z*\P2Z88H?'BA]?Q P/VYK%=%L^&H\%B3JYM
MH-<(Q30ZPM6CU5=O<.A"*/@:OY"M6^AI!S%.$^9^PO(,-:L;OE!^(:)MO'S<
M:R $W:S(Z<C9X77>#1CVZABT?/>WKX%0!=($AFK?X>0IE]<M[]F]E3A)$=8:
M4^9^%X:YW_DSGG4NM3(:4Y?^S<;7RL(<&.Q#4406L+9QM"M)R$AF9POYACX5
MYKF1.BICTLU"D?('#=UWYK0 [ $&*<B35HV7 YO>H7I61-*"+3)&PNJ2(:P%
M^#UXX_Q>!G9]F<JJC9"8D>EO9-MRO>I1V$9)C]<Q3A#+/^1]QM@<J6F ]9=H
M_# A6BA_U%?W_--[UYZU?9)5U\BT)Z%BQ(@CGS3YUC>2)7\*7T,K#OI5(9XN
MQY;217NGOG>$ONE!#@ $XVS*HWCE?RSF:F2FLXI1(>&_"D]31+D'J/#>X$"'
M"X57!A^01P8W.M!5U75^\A2*7]9-/IOP*ATD\G>^S@06 )^[<UKL8 A<C59"
MR^;!@G=' L<_;K41IK $CVKRV$LC,<(RI&=^BQC!^T?>=MH3'#\&ZM5*#<ZF
M-@///D1%%$WM<[_-^?4RS0*_.@(Q_P7+.4ZHHUX):Z.'\%=<!CT==S<3KDOF
M7*CW=-24]_J>\R]FFXEMI>O#W66C]/%;]GK+7WS8<CX4-M?+;UR,F$YXPL(I
M]F--NVOO>+OJZFK?HAS\/#P$U:/F@4OAVNCY4$.]T1]6(_>/LC'9Y&EU-BSW
M;4-,*F^%+3/SW*#8GF6B_B/@E Y\@(@!U+R*CWG!DP[(Q,HKM#- #K581AY5
MM,$S5_V4PLUXJ"4[E5G5D?^\35EAB1$HV&(KY56^3Q:BV&?H9-M)(=\C\Y4I
MZ9F1H/(ERC?F8R%%C A1@5*<T&?!V;5IZC2!C9LSP_2CZ(ZV8=!)_8_4L\(5
M(=_"<TDT/%CYZAN+XB#--5D',#]5Y$/DA8)99^F9(3\#;[\<S)DXCI^23* <
MAD]@SOZN9PF#:X.G;UU;_\83RR83RTX9=CSHFBE22A""O2 F;!%I:UUDORQ&
ME($U8&-M63X[K%J(8E.$:)+#:##WIO/+,'6V$!_R%QN',WRSH\9M+^Q;T*M%
MI4,;@L%IQ#(SV_6QUN." FR!J'@Q+B;>D"+"J+VIC!JPEPG/._,V]T.#F9.K
M=57YE_+5?FP9$/V$!^\JGD+&*47WBG3V#82]1(@1SU*MCZ[.BN8&;".4W\R4
M7CASUU;>((+.R]T9^[L3W)*[_*+XK=R!<_>!>=X3@.'S]>,[WH/O:2<F_U-F
MQ M./ \F?"C]%^?PZ8^*?OUO6"=-/M/6OU=%DGZ?^D6V*L_WD9IC=T'!T(7P
MO,,@<3M]#B3N7:O9L6PK_C4%EO77DT;_0BQ+1O* ;QWR+A;^/?_6BQII;^DF
MUC=&W)X:H6"@&TUK;]D/(PZP&KR[7O?A.;X"JCQ5R8=V )=.]^D)H02PYR]Q
MNTK/=)E(H!@&%MD)(N[DX,X?T1$*<79S\;;/,SE+J&819GCJZP/U!-DXY^YV
MAVHQ8E]9B+]EVXU'C30*6,''8=",WF%50YB?$X@*J"ED&8?;?M55B N%^:A
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M+)"8VYI>LA+NJNV]VZW=7]W0%*"U.GM/P4^=E?R"E2W2:!D6RF_4VF)B^LY
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MP]2LD;75U7(Q0BB#PE1EB1%^W080140NY\Q4&0RW+-5WM*NYGU- 82\!/6_
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M6U@B;4>7*.84MW'>_EW$7?=8C# +D$<*;?KNU'RNU=H8;!EP 1B%C(2#SG<
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M9 IV=I8'6=T3/M)M/,SG+W=1&$-3]V&=W37._VI?J7\3$]R*R89?O3-L#_<
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M(')"5X&/RDHXNEYM*[]K6]?Y:M&G9&QI$TX46=V? R^%DH$V_]JZ::90CZU
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M?UE1Y-VC,#N</<7I1_#KN68!""LH0_J>QH;0V"!^MGFC>)+T&QK1%UE=IM&
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M]D^UER>;MG4[[3HL&9*)O)G>CW:]W9-W\SBAO;!Z'5XE)5&3;/0:_<+:MNF
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MJJEO5J-PGFB-D!#JR5=%&EU!L+?1.-S+_!OFE/XT5@G$KR]\(N*]O'[OYI:
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MY"H><WDCRP?2OX\SJ&"*PK:%7"%*K-5CMJU4,&M/,UI-$!!P%U1"I(C8Q.7
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ML \P.7.!,;=4?0^V.*J98=]\BS))T4MD2ZN91JKD)09RO446';J>$I.L6?Q
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M !L?2^U0O-8"+-@":+:Q+OAFX8'BBA4V[;V8E0&EOHJB>Y/&;PJU>VRX]MW
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M.E%$_=<-#K!7-)0U'R ?6!@!J/L U/?J4O)I*2+7O[_U4/NBJE$WD,&!'HL
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M&="OU:+XBOM,_H+#>9]PV;$!RBW4][(2'QQIIAT0E3LL!XH^Y88^;:T^ME*
MN(TY#L.3=J!,6*/!+6U17,@>M*WIB_H1"KM84%KC]MJJ\>4S6343YC&VNWVS
MF47*E@*"Z[E58MVF$Q*C)(+(6XJX]PY:($=)C$P-OOCY)"/?,,5&6Y:17A*;
MY<0K.)BG\Q-%MFS-R@6NK4>DPQ/C>7>L(&+I1-D&_SU3-;PSQ6F[,[QNA?:J
MTBX;).%^_P.-RFI"5<U2Q%:!Q>M($_3*2OO4E1&DJ7D3A9=V5%U8WG:O P9J
M:&8V3[7&T-ASF?"[&R*H4=NSP2Z[P0LQ0N0M"M)2]HA>0.]Y6YW7GT"RG>M
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M-7N#PBWKW%A:WBP8#0K<9++G9@'_6/X+B;XFD 6;$B(/^(8D\43BAR$1WL>
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M][MV\)**0CV[#>B_9OX:2[:;&:4S'RY9;^<P1Y$2G:YY'BRO,[63PTWWB"_
MAL#?0",WJ2/I]FQXQ@&HM+3R549_<&Q"V'7A]Z\6JNB>#38S%<X^%-@*JUH!
M69(GL%6W7J3XM#VZ1:CM?*,Z8==:8;BA\0Z]^;TOLN!+FV$K.\%3>YL[AJD?
M<NCG65Z9ZT,3KBWO< M6<RJ;W-;KHX0".P+Y>NTU$4+2G(#R![I.GB#O=TW7
MVT]>I'230.X_1CZ_LUJ_LZ7M*INS:Z]EQ[GVEHTK'B_2W;(F4*+<SN000%/^
M2=#]_,H/[?CJ=:08DJH4C6#T^=I6IGK(2@.7X"05]U _+^UT"Q?<RPM[1"\#
M*/7K2+HFOK9Y5K[\N^ATM>=^5J\?K=UL.I!]+TW/#VB0KYUC5^I&TC18DA..
M<QM)^;S&63>MCH(@@?NU^A<43UIE>\?]DJ%&K==#'VEWHDYF4MBVWDLZ*N\'
M(UZ ) G.TR9C$WKF*!L=QMK!EQATC=&=9LX/G12)=J%'^.F\7=3D]@&>KV5,
M'F'UTH,R:\?MW]Y\J.NTT;OJM>+[E7AAWU'E/1<>SJ1\_HW#-33D%;CKX68<
M-M_A_"I*2TO[^BMJXY\>;(_Z*Q>B+S(G_<.)=#$Z>&'2K227-?+IS\TQ#.+(
M^19)SE/.W[CASD\]%7'E#/5BBXJ#ZX]TK7RYYK;'3OKG\P$;E)9;&5_.YHEB
MG;.=]]P=>QP3?!NB30KL5R)/+@/<5>*:*P4U_YA715'-@2 M)R'32T3!!>M_
M[77YW%^[[JA;88%XJX;WC:2L]8>!KU[W]G'/_,A5.E[Y>L>4T%3XA^W9@X0^
MB520X1"\S"(%OB#;^TL[![8 ?S@<>/I])!"S #XT<E#BDV][X.4/!T'I-HM]
M$J/1Y-1WIZ(WYF<$*_^-PK$G1'DGVN3 &+N).03P2'-!'K#^G:WBA!G&IH\'
MF&I2K;PPG8BP:P$=54V1>;REU%/G?8*L5JKUJ4IWG;^B^L?F>'Z%J(@] F/F
MDDM2NX::NU&SJH-&1JZ"CK!]55VL!.L0C)N &. ?5\E@D(JEUL6''#N.LK0?
M6^P5(@#6LU@;G.G1O#'>>CS]Z@(?[I64P)Q3L<=O11!U@=G;P2,J*9F&FJ;!
M"E3T>K9]+Q[;9=)00,6<#SG?QV P*-11'=^J:OV,T(T]EIO3UP6O/K3XV))#
M^\YYKAQVJ.S>="]P^M+#M<9+FYOSC Z3SPT2+</NR"N#NJN6NPO.?^M5#^@2
M^^AW]U0=\ATJ:_K6VUT)EGU(3:EK>6NT;%E0YP;-F'57AE]MZ2[8Z-.]\891
M0*+C=@F/O?2%N.W7FZF97M+.8A.7HH,FHJ*R$%N*/MF];,>VGVZ\-_R0W&_I
MEZ[?RNS9_M3HA4[JXW/K:AD=BR8RP 1II)7GI<J]1 '&4A)T#>K*^7=JA]^\
M"G"'-F#DYS\@_."M["N^#4[6E2.@G>MR^A4X'_W;J$!)Q/P;T+#R,=-_7HP>
MHUUZ&U,VQ@@G?+A'1'CWD;Z["!=RU.1,;J*==ORH$5=FDZZ'CY#P4Z(R^OH_
M8UJ8 S6);"FE?0U,$8;]/OR>H+=?#IG+'?KY=V@)3M*(.7::@?D2_S6.%LYX
M^PM3?PPA>\_#(-'J?%!D^KH\5BGVM/K#>-+>XIFVK@4.AO3X9W#S>B(=87C8
M*W%.'Z502:.X[?U1_JIJTR#*3WZA<'OD7;::(T*&AOJ?*E"OVIE\0Z&; K6*
M9IH-]CT3@O&IRWL2_C)9O F1I B0>C6+XZ>VB92AGQ&P9]RC36@E(7&&GRQ<
M-&[S;_-UM14!=]H MM)#W2 S+#CBF *%"6^#<X,Z'RI0#G*<16-#:8%3\2KY
M(<V_%QM6W\7,K&-R\_C")MXUP<>PTKSZF':PCK]AD*H3>J6KU8?+L]M3*+!<
MLCR8(4^\Y[_XVB0A@\G+"=]>5/7V&ZX32&.W<AXXGOJP84X#K_)JB"7')Y\V
M($I;^,3F%+6K"#F-EB-X^@(/#\NF*4,42"1K+O_B2"#+5!ZNNC06F3#+=M!J
M&1"U4FGR" @A4R=]$2DN8"-2+JT3YZ47E]1B1#_LO%SC"'4^?#+<SU: 256V
M:K/&.E?6Q=S:\T.S45_KZ//45(#?< ,<PE8HOTJLA3"(PE9K"0V,_J0G >_R
M<QM'/4($*_VP6A<\>"6/^L "87!H@"IYO/&7Y=]^XB %JD.\\?ONG%!"R$N/
M8J<LC\UGG;=\2*\#/QD!=4]H?#F3,X4;5G%*\(RN>R<A!*DOIB9^&MXS@_F9
M' G>]#>#_S.%[/_Z@S<<[\S,R&F5E9%L90Y"0BY+A%&LP/T;W22(%>;LR* )
MP,)6G:J;]G8#R:IK3XV8*4$L-BR%:ZE'(]N# GVO*S=GX Y4EP1">N"WZO1'
MK@FKK*.:?R2G_PRQ[JKSUZE9:-TY,5%OH-/0XBNW?-7U?3!#32-[PBQ\>=^F
M@.:2K@-XA\]?W;GC-C^J!KNG@_IL3]L9O#2^A_#GR?&T2=_IV '#VO)"(-S*
M>NW9T1G!_396]@'FC,ZK'/B(_3DB;PP"KQ58J-(<MQJMBF!'#(>I+9@+7-!J
MW@[IPC+2=3M>Y9[?76<?;9$\;%[7 <]YRRKBDEUNW3=:$-YUP$%^5*F@T'XY
MD3+0T;/L3%WP*@4J0?^HZ":&LP'\"18@-NZIXQ>D*RT/"FAXM6WT)MW(PWR%
M@41ZPO;S";.3IXGT<U#I8@.)NKJJ%L"%X@]Z3YQ^I(O(!Y6P9Q@N_A9M/FG+
M-X@3>F/"F#]C]]E^I8M!W^?YNC2[.&!?[#_M%SL<,LREU6$O.XYX<5.K/,.$
M7MF]25D567MS]#URM33E1F1U.%15@!FN62/#3 +TGMC<2EG8DD!5XGUC</^I
M["LTTUBUTFHE([,0_:E$=^ZTCE&"^-58TWD%:DG/K4L+9#%Q?R%2$"*)5P$8
MG!"62UB<#I:5^?!!Z_U 1VVN#.U16U3&U=_:W->%VYK8U],LN5!_U5SB@@,2
M Z9^28)896FVLRF2H!(9 A$VR+* WZ"N/$'<WW75LO2[G,^<):F0LCQ>@=HD
MLE+*^&@V-U^"I?/()1O)EC@?;+4'>UIM3"Z-$+K)0<9\Y#('VR#AY]!-DZ[(
M=$6](,L52H-P$R;^= EH&BWZ_D?6V"=??.9*6JO*["=N,5V>!G7U=X"X>@U&
MTL3>5J@RX)SY4\2U*4N,-M7\2(X77OZP&3*9?Q\FX]U-?@Z9.Z>GK"$(*@K&
M[&N2.1_JVKYXN>5CKF%D(P /2^@T"D3N'"QTEP/_/(SL H< . ./%"A$>GT,
MKTF;8],V0?83YC,\2 TJ$-%6*%"9 MSZ8#W/]0$0@40*>N;EW79J*&E!DL&#
M:+_SPH'OCS=Z' CG7Q\?;Y;G^&W$53T <X\I]V\EGGE+P(>-\OL\RS5G2(RX
MF,U!S&1E<3AHP=[ZFFIU!&@TQIP[9BS+<2-KRZ4/_WOP=K]>W,O@EY>]"RHA
M"^G\6^N>HY4BR[!E!U0-MU^<+Z@!X2N)\S%I4?D[*1I)*?\MP9+;]-2\'22P
M:^X.?.;XO&Z(^\XY?46V[177Y2_#C#Z[+MJ,%#Y&Q10"8U"X:@Z:@8P YNSU
MG5I\N/1PVV0;%A!<!>]=ZTJ*C)DTON:4KN>W'(C9&1GHFSVP)Z!T&Z(Q@2XY
M2(%-5TN#^NL*3R1KF'<ARO(!.H1M\(]FC#=YLI$0"3G(O0>&UU*L$\@6ZHU%
MPE<ST=:<7K'S( )H^!.L;(#3/'UU[^_*TNJOPNL%JY5'K)]&IDB3MVV'E5X?
MP,&H6&;\?"8IXG=8#&6_.)\Q>=+Z6%B!>GB2\!DW$[2%RTTL"0E6MPMW7_S@
MB]FY/_*\+!?.I]MPH2-PS>307C]U5>Q1EW?//67H2;92I8&?NRXIG6-=4I<_
M/#DY]?!]+<-*WRB1*-)[J15EC-?J>K[OB.F/G=IATC^#K>@!$0E;I-$1QXSE
MS=_O-)O/O9=Z17X(V:'?D9ZUX:? Y;KYH6JJGM<SFZ??APVS<TY'SZ E1[3B
M&^\9DRY\>963>DLB(!X=Y9C*@':K>[%;;B^ <_D'J$)P,(V9SOIU/("31)(2
M1<Q)DU)6L'-P,T/=._=BC)KLBAGB<6$1E[FN^F):NO:ZH>R,Q=Y@PX)U"PRI
MXCAM4(CA%3?X=L=%Y?ODU*8G UH6+G6&U"Z>/[GXL>Z9L?=CYPSY'"YH)?C/
M/!FSN)._!OWN6[O;P1>'];HG[N5L/>G -UZ(5B:2Y6<9/7Z_W9<,@D["(&YN
MK!JZX;W,I<S P,5)?$TUA--#$:3NNGG[C*,F6WFHB$@DBR_('AR)?CI6JD#=
M,%*KK=&>ECV+D"V8"#D4?"601HO)3<W!469X=2[:".7:$NA_Z0/M >C[Z^?%
M1RL)\\603(NUS>)P.N<HZA96?B<)9Y@0E=HZNQYTHG-:4[?=!?>$\3>7_<Z:
M-)I(HI5Y<3*% JTCW)X3,$L98VFD*U"@AIW#5>I#9=_\19KRI-TO%S]>_.@6
MR@KL$/*W#!7PUULN.W--7<,T7AV1>.NDFP.T;P)=4D;W_=:!74 A._Z&119[
M"-L_!D52'W?4DMMM\S<K4%D -U)NR^A-%< NAUA@#G0B_Z*R6.9^C T7PTP9
M1];%YC<1< T4L)WF=PN!D>PDO[2Q+A4@ZY^2;IM$-.4\<9*[*#]Q8GN1548+
M^"F:2*G^%%:%,FVZ#R61;TSAZ55X375SLN>E>X!9#&T PYDTH()$%YB*8-$D
M^=@RTS88.]9"G<1J64B)W)H7_[J8NEP%ZCN.9\J%'R(HGI AIW6P6QV":-'>
M4Q9Y_L6?KB*D;8+8NZG^XW)0.9L1U8>FRLD9<-4',GW2A+QB'6MI;+$3Y ;S
MP.#>*S/;YN-*R7[UU_60Z30X3?JD0#DK4%_#<09VQ/QJSO_DQ>W$W_)/$7Z
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M'M9;K0]K:=(E[FDNB9Z]!M?W%%C5-ME^.D?[/7YJ VE4>PN_GG?;7-PZVJI
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M%G[Q7@TP,,&KVSZ$H<^-W-]U24WI;SG!I'C(80.[>9.)^:@21&J#M2;PF6S
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MEJ$EAD'>['1R#EFU@-+?UOX0M9O:"0\$#+JG^-"[)L?73^87DP(<SOGU)[Z
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MF>$4MQ-3^**WO!>1UG&'B)?QY7B3819DWIP>$_S7!REIIBW5#:I 9'[D/.6
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MBI:?^$]F*DH7ZF^TW?3M4_[[KK&9PED=F\L?E#F2(1"9/SF%=KO7IU-^><0
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M&5+LZWIZDH+K41G>A)PYHU5XIEKMYK!W_*#Z_S/$[7&6>FT@N@?ZM#U7;5P
M$U;R/<QLLC<G.+ZL!#[1\3?D6:=%EM6'4UM*\MWA7$F[OA6-K+)EK3U*29&(
M&<A&>P>LD ^$\+7BZK1 (9"4XUJQ@#/G_]0!_Y_A_?]P5W4+/M3F 5XU_;>.
MU5/)3U_@!2UCM<Z8F[@,8W!I".@9YVY<UCNA4P7:"S$A*M4&Y^NBK2;:N'+
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M4#KX+'[:7_V/ -:JR ORDF$8*H=AIZ:(,YIWN<Z:*OHT^X!K'8I\DFC40[<
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MC1NQ*WI"AP<W*%'^B'AWRADP8RKQ@?9S1CS/ 54/T&^B,<^ <YGZ'=/_G3&
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M*S!Y);$HZ9W>7Y)(LG7(7_XL$YA[)DQV"18\D.)F4 A.5@A@2@_:".3B_#&
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MQ#3 M\/3BSV=>\"/!]&#S+5*NN60N[\NP6+A.8*\IK\?Y.1)S'=\R38S*U?
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M5T:/I=QH^V??OOF_(\"5SV$CZ. +.KAA.43W;$FSG[^/GY.,0$@L+S,>7AO
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M9)R2KMGE;64&_G1^ZR72)\V!<]5)@R[=(J4!'/\:H@O"Z[_.W7V":<6\QG^
M^(%1Y@NL<\X'&W#:15=8]-AH(6(H>"Z3S_GK'\NF5^:"57_UX_U'NWK]SR[Y
MOSGP@,^/%;WD^&?@[,8ZJG4?6+=)<39QWJ<K(A SZHA^@<.VR7;EPJYV/N;@
MY>NPT"3W'\L-WCDS)NYE\J&FX7V=>28ZOFRG]I#_2F>;AC\#BR5A":P+3A&!
MK"T=6 (^&">40.MHQ%@(8]1G3C8K9(#6G*2714/\<S>(/'T,&\O!W!,#1CDN
MDQ2-.PK[IQ'+?0V.,Q 3D\)/8D">37W5$:)L)BKO2/SG1A+D$@7E?_N1SOY?
M]:M=7)^T!182L1\Q[.S';V3T5&OT0HK%V#[6^?X<#?.7/-VR>JUTR\:W-+\Z
M:SB.=S)GJV0/6@9^.'73I_< 20MW[=3<U7%F8 FY8Z$#-0'V3OE,)PK* LB%
M 9R0F9^N=_)W!LBRL?.G.RTI8N"GAL2OGC@V<=14MNF^&[!GR3X,62AST^Z.
M??LD$S  <Q@T0H'V'9N0N6!J%6$_HG_<[ZK+7@=[<)3:^,Y$0]# (59W.<\7
M>YZ[.%W56]Y200UV$P,;AU4$TI>)XP/]<T$^B*L^I6/5ES=T\X*F&:*?G4#G
M/0$:/K^@W=V9F4/CB@%E*+1/_K)QVZQU]3$3Y'BM"*4>R6EV&_1+_-S7?M38
M/1LW>07,6:)CR;.T&?77,YT#E1L3?K$Z/_0D5 ](SXF!EY9QJ,4;1N/WPG@2
M2.C$)1%G*T_8F-%CB_%;ZB7AT9S6?'ZB<?;\QP9G?JHE+W*WSAHZ_?;/)NNW
M^&S-XQ.J8N#U5>M0H4Y2:MK>EM@^@7=D>W<U+MF]>>PA$K,HT)$/U"!6JA66
MPDU8;,9G)X*6_H'*F<XV$ 9IF&.R-M<Y2@^; 1)*>Q-LT&_\<FCTA:7*:"T<
MP?ULF8+2]&KB'.EU+[5<O^_\=EY'JPU%[\94\RQ58?_;(5;@;DE^J1)<* TO
M?9<7RL4( <2"-_1L[(>B*W70+^=:YMU?J,<=E"5:L_5$SJQ)6<5:M;&Z+# 4
MTD@V??'Y<^3]^W&[/^*P<!L#6R,;8W!8STB8&X*>:6.\-31O/=>;=Y&/*4K+
M6<RI%L!**^;&G-<P[ANK%"IXBJ OQ'5BX.%.&'?-'41$W7H8'RLZI!=6>EEE
M-,9<>3UMY/L\WE*Y/&'L$>D:8X;[!31'G@$0XU.[IM1G9A0_#%;&:N;/Z?D.
M]S_J.TU4L!&\%0,1P=J#=<J0P0_%7WZZ)WN=3$_L7!J!/)[LCFJRPQ]J\=-+
MSGK;Z?)K6=IYQ6AJ]OTZJ_*C'#GXN,\'D-GV5D2M$ ;:RAN=?L0%&UN-D3X/
MP'I$"2[6P,67HRZ:W5W_=4">V6[F[*GGA:F)J[!DRYW:8(6$4%#5 %48G);?
M.WIM,/_[9I:B=UZ K!=!E^JE4A+#81J<=V_)4L:9?II3_#'-R.@1(.Y%6X8.
M"LX^=U!PA_'T]5/$P.UQ!#U,X,15G"/V&JX>G1[%G1Q9FFIYQ_LI<"LM*WR\
M2=;0>DJCKLMJ3#$F+P;'=??=+1J7<Q'F]/>]<E.**AAOM;OK&F\[%7!<1!Z0
M[R_7?B[C&MR7%&2J^.(=1B;-.%/ 1QVJV@!;% -+DZ+)GH#NYK<-"B<? XJH
MA>"+\9,GAKS<65\HMYYL"N*GHUY4)I'0PN&YZ8WGW[\7 T,,XD"\Y5%KVTOV
MZMJ'8^I.F1$*435>-UNV:Y44I$4#IK>=P3"KM*4Y/.\@C\4\RQD<5(Z>I>2;
MP$8"[S]HV!J*2E3#M$QVE3-R%\H#Q("/.Y%64O@BVO,&W=!G"WSV3(07F]3!
M<.;$:#=L?/LCG;U6AU<]SH"@9G[?74.7 V$IY G8K=E<R9/8CL415^MWIB5_
M&YG"""*S<'*=)._]8N SGDM1;"B]O..,9I.*=%9=P([ G%^Q@J31SR2</7:R
M'957Z?=H)O%5K[P\6O3V*UIU(X(:;8"6</GOB(8#L5/N'"<V(I=85-F7=M[@
M@8.C/:*K%A^(:I+/['IX:'1G_#<<GZ2>U<@+F3U=W<Z+Z*O$KK:_NQ3H2PI&
MOOIRTQ.0?PJO>ZF49"0@5_FPI^7<9WU.KMEYO3KWC!JEU8;S?/;X(J5H=_[;
MW]N*[@=G'H5,\YPJM)OM0M@7V$.G@ESF Q@UMNP/[[W]D@F2K,FQ;B@_)@8L
M6ZK2^V:BE,X8>BO"75 G@VB_9&<)L5LU;B28*1:0'OF>0"D6.LB*@94!=$&#
M@2T'# \ N=N%J@?=Q<!!ZUMC(@R+/:!K<?GA[26\X 3MMOU<>9\;MCSK]&$=
MU\4,1&.K7;?NDG;WX*LBSFQ;MN9.1F4<.4[G#/CR49,?0X07/0C%W%>-7;AX
MG[KB)(\)&]\$N2=QJ;6?AO]0XK$V% =*^[ )-]&1-4.:<*_RX]:^^1).\"TI
MZ2F.72 &A@]*@+T[N43>_DBZ9[T^<!LQXS-[<\)U]BZQ@OC6P@> L< <S*6J
M.3]TT-P9%L>$<C8XM(C@X.P(/W07'#::G[[U9[)D86%'Q0 :DNHS_O+G=LZA
MD .K*(LC/&^W@:Y L'%;_*WU!JN>P'H0HQ7F0>8SHKGN00:E)/Y25HZ'L!GA
MXG%%#Q):6=X6[4>*SDG %2>77Z^Q^J)0^N(2_D)2JY<FN[>\$+>N/F51*5W#
M;RZWI4>OJ$>7Y(?BYEZ]52E['3%*9<^;68GP?6">/I:"N:^EMO;V>:E7!XB;
MEYHGRSSB<[\7"O<:(KIX3)'#0#\?-T;4-K@<D:X'1E+CLJ;?P."S^N\[ZUY!
M,06:5PG%)DZ[;5!]G/NY(4&2C/A-#"2@+]0)HB6P[TSFFY.9;_7T?P589D*O
M&;ECG0H?0JGR)U^_N *6Q0T8[82-_M$+RSL-'18#N]&08I='S/S >;6^DY9O
M7-L5C28:(=OW0^=/V\(8PHJ-A>4'O4YM' \&>SN0V$9*5U<<@@-'!CVWYKX,
MM)9+0)\^!$J?UR4V_?SE E]03L$6">:*=-6R*XKR_&(2(C?@Z_W;)E2GUF;]
M"'XEN MAXRP%<'K@V1)&]WC?V=B 5CX/5'^>,-AL1SC",+/]A3C7K[&4O"A<
MHL@\F75?:I>?P/FX[7"L5/O47SZM4^&, #E_2#8"!^4#+I%^%_:!@54%X:[G
M%MGOOF\A3PHKT%&GVCDQDPN'PL*K-RLE&ZB]^^&Q^X7EP3+R0MP,T3W8^8X3
MG2.W$YYK4[3CW)6WA7<2D/BSO9/E QX;.7LL3.%%*=BR2G((FR5M8<E>DR9#
M[NV9WK6KXKJ2P>0Z"[#Q>4L[NI0/HNYJO2'4^H*<X>038TN0PSI>3L+<J<RA
MH2&N)<W8B6;>9LG(I9;=TZF.OM5QN]/=#8-FW1F%MKC"2>3N'1O$0-ZWAX@>
M@5GW?44G1S$@8XG\N"91FJTWYFF6'Y%\&")Y7._0N?+*G#</1]LUMHF!K[YB
MX#KRP7<JC%\=[+T(CUBN&0@NZ?B+99_9[@I^O33'10B11(-:-AB=RP\F2E##
M#PQ7]J.$*4-JC'W425KG2!?!9YNLU^V ^"]]!,]P'2F*_ DS<[,5@1L-]9X@
M[.P6H(69%5[H1P^,GB.F^-ZJI8ER.VBSV=FXEI1+\3>';RK>RY+DQ,X0UT7I
M/LNBWA81P70#>5@G)*-N;&IN))5LQG\UN8TR)GHNRBTFA*4?&(YJ!Q_<<AW+
M2Q^P\X>/GD@&)< %/]@6Q2)01!P6V[I\;ZGH;H"M^\D'UF6/A!A3?_<Z3,LQ
M;G&[53N<L_?L6SOKY<;>V#N^VX=..QSUNF^#$4CADC?-NC,)BI1:V)-V4[U+
M;,HEG=IAY#2505Z6Q-_!A!P\<'A_63Y!X"DA*IRYC0&@.M&24K5.9+?\8BL\
MD/-"#Q'KF$T?6@7E0@-@G9Z@5A';B+=BS:T$KXH!#\1H$J>[@O,$D0,2X O(
M@'DR;I'NHW>'_=O<)M=GAPC&)P]BPR[RU4A[SO,VJJ363N?\&/5Q>0A(H*?R
M?/-:,7 CN%9QPBYBJFI'P/:'3+X)DI_3&EU29,6KDE$ZNAD85SGJ,S$ 21@]
MI<*=@'*XMXJ*6/1.I7D7P*?'VC_HDV;T<J=?D;^ 45#!\NO:[T)IZT7:T4JM
M&?E8-^=\"3;^^--L '1Y"XZZ,^+[44-MR#%O1H[_[2UM-[B]^E?3*G6[(S2,
MV)]>WZ'0A(?]E6A"U7?58H#!F-5@.]J"C^P-M)FDAK:Y$_?L[&Y5IXN!V+1L
M![LUZNL'7IPCR%]^F5DO8OFX^YWH+"Y+^5X8J6Z\6T9O7&$ 9<,_PMH-6_#0
M;-;WT4^\.D=NF: )*_7-?-^@3+S!AC?Q1%W5F,S26.D2UWLY;#+GU?SO]:5]
MIS8V[=^T9G+B6T_/]W=>&<9 X-;9W02?@FRBZI=O94NXB>/MQ@252>YSM4M1
M2.1B2/"UB39<5BKY*G)9Z_D8;\7;'YY<O@!P/])4^6F"YCMNB/MAB7?A7!CH
M\]>1, TO.R\T(\%TWVW.FN$!Z\Z/T[M4URB^S_GRX>P%+4!%$9\\4=O[2^OM
M8$@L7UOQW1T9N:41% L^[Y.%7)KG?5CH+]4-'<9?M0AZ-JU 72A\S,;X^<JZ
M;Q)$#G%5$QL*GIW0O8[U F$;E3)2/R?E&6]R8'5J2O#WOM^P8EWOJ[%WT6O5
M3,PCE:Z-.")>8'\%/U$8?#WR>L]3SV\O$L!O2$/I,6Q]7CWD%C^$S>53Y"H*
M$!L\=R;HV_UN:?@R(4/:<A9+'J;.'NCIA\V=-HG/^F7\0N<GMZ<6:6Q;>U'M
M0O5OI#>QN;2XX%U[3UO^:_)\^T>YT?K'5S]DA!BEND??CJUOOCB,:$&J$W;A
M,[^W"5]R.Y!A:3L.F<!-V*5JV\^>-]AU[:AK.&K+:?O>LW *#5).#,SE=,^5
M2DV0ECB6YX_(VZE53)9Y"HR,D --T*NV[8YLZC]Q2@*)0!_<>_RDV^.LG0/;
M>1#XTHG<_GFH-C"1]!@T2MO@^MB?F0@A-NX)[XC^;A5Y.$I;#$1YS7Q6H'Z%
M^F3>QR@_H9]LX9%<UAE&-79.EVT[$!L/:3 JWWQSG9L)8+8]/T6[3"B UX:P
MJRNZ/NDTWELE"55TB,2'6K02*VEBP"ZU''55YYI EY:WS"RS- MXV3DW$6>%
M=D_F*!\C\ ?NAC1_*O6N#B:%E>7OF-Q&DD24HEOJB1_-H"&L*(X9\5?7$.)L
MNX3YXKT;$O.RR#>7K%OMK=O&NK_#IH-CJ4W#AEVM:Y08M)UAJ9 ")O4IENX5
M]8/ A?&V%\I?"] YW/&B%"+-*5+\E5)%3GE/A'!<Y66Y@'Q-^II! Z,R-14)
M71[6<Y!> &!*LV* +)KL4[L8I!@?%,Y4"I2K@TS?^<#[!Y6GS\/GUU1"&_[6
M)AF^(+M$IRZHB1P3URG6*4CS_UN/W]+KC1!O4@Y_VU4IIXBA04J]/O7#-VD6
M?;*TY2.WZ+P6Z]^(AAX11NHQ C?6<VO2FQ_YFO'EFTOF+:E-EZ'O@6HQJDS"
M"%V9\%^LG?U?/=#AW6*S0F)?D=-L!?D2])$E.PN211P!.G"A@HW'+M)A ^!3
M,4#@S,E_'LMF1D./MBV+C 2!>,%<;9)RK-WF+9&?.)%7@SRV%=>"Y3E*\EY0
M!UF1-N;OR70NNB:ZPIJ2.FIGT;\(@\\\4FP[A;?H/!"6-31(2WKF2*Q;5[BR
M^L'JPSN4HT1&@I:._EH%T>I326Q22BME=M#(X7^;L?YU>]*3M^=#FWCEG*RP
M)UVONMI#Y<NF[_VL-4MCG-DCO^$);[*W)&ENLGU[OVM[7ZCR97MY!I0LLW;Y
M)M_F6NW..,7PI&.G^;YLYPZ%_[;'-($Z6+-_58 ;S8,E8J"!M$!RYP8'XOT1
M?7]UQZ&2_(,#LQ4'_KT?:.RP( :V?1<#3LL-DWQ"%- +8 [ELS]/8_]G5R03
M@<*15.;'IG_HIX;D&(RVV,YX]$"W/U3"0IP0+V\LP;?[G;9^__,1(>XM[R:I
M<]H<3?_*/EU:%4-V-=B^<CJ@_L6X0,9E(OYY56;)4T,Y:-M-U+P,7OX+*7:.
M'/EET*J2#'O3-+L[20<W5["A*J<N6$_/1 PTU]U 2) >98G+ME.?\U)]'M#Y
MH-U09]N,8L?,0/G!N)XU>-G#2*YKIT<-Y(C=+=CNU34[W;=Q=JCA=\[J._9N
M7Z;;+*VLMW#?O#HP,<G$^!*&\MPI)NNRFU-5D'9#>KA>PJ=GWU?C$C378#_H
M;"Z"PP)D'[!B-#)SM#8=UFJM[<KUV'K]P Y^7,"3G"9K.7-+:XY71/!7_H/5
M><F"&Q[OOL1%<#8^A4G5E[#T@Q6:&G1]FF)GJ3C%%7^HF;8?#0^ +3(3IF'/
M%.#ME1$"2JF*6B&O).WZI?6#D_9J=8B%O:P,YF,W<$@_C!\0R,,Y' ZM)5#8
MW@Z-U8/N544:KP"*H[Z&$(4U)M8("=#QV4T=EI4R,*^1->?RN[H8N478I%!9
M=.XO9Z,78J ],81T68KA%BCZOL7_A/GD%\4Y5G#B=L= DR*/[53'H'/WD*LH
M-:($M:4IZQG,"Q&L5Z#A-E/%<6P?4V%_<3<BJ+(;)< [.QG'YSJU/3" 2S)/
M-^=P,2FIT?05@-ODZ!CBL/91V%MVLW.1JWQ\\*6!\[:K0AP,I^'/1=O;Z5&Z
M@6O\MMEIGGG0^Z6:^4,,P+.N.Z$7D8.[ZTY*=I3(B) Y,%GFI?1FU8): JBN
MISS>@F8/725LZV9]E%'41"XAQO56BX'Y7M(.4A6J'@SU0!=5XV?1"WV8$3;?
MO_BZA..( 2TT2VC7CR7E>4\EXQ8FL,,CBU/1HCMLE'Q]&B4L%"++A U1N,0.
M/4I)0;R=G[O>9O=O9(^KPV3.PS3%M2L[(^#I-30460!F&=[STPN];S/R]?66
M5G+(N (A;L^\,J$3MCGPR6B (;/E6_-KVJZ^A-+>&LKDPT?K846YC7,ZU#'6
MG]C]->F XEFH5$EHK-_I,%MDO_6:&7:D!:X>?LJN_PWA0WU\R B*Z0190HZA
M 2WCN(4 ',+\8RBL/'O!1^YI'L&MPV7Z:)E 0YG-R)FIJTZ+#X91^C(F-CR[
MOND$,QLGM#$\+C HLJ<&>VZ]/W(=S-%;3UP^M$C3]9(M5O&JO'*+7NJN\FVT
MR,X#,3MHJ'DL&KI\:ZW@IE<#/)K)?Z\E>,UNILMWF-78.RU.]<<1*_IXF3OV
M5A V[M$$6MNRR6R?^!S]74)P.IA463K4WXNJ.\AY(]T[3B?H@9RGF:D?/R#N
M:SY.C1$#\5X\Z:=PXN LNG=G4D6PB8F>?G-ND2"PR.T!<G5)OOG1[/7 *J;\
M""(63;[B.[+3*W+@T\G5J"'0MY#7][GO%H*RK N'!UDMI<T+/O+3#-Q"M'F;
M-;8X7K-JZ,A6F(9TRO:B$ UOA-=L-"H1HW"Y7.5N=V2>7O1[^V!DO]D]:\T'
M\0O&EYZPE!?(*T[KOF_->Y:!7/ 4\C>C$\((2_NJ3XRM!5M?J((MW7G41NW/
MONXV2Z]X1EV?["W&M0Y5NOSN[KE^A2)XZ[1&V7,4ML]KW"R'R=]6ICA<;47,
MXX_?,U?K?, 0F2%J*&X0R_>J@)"ON\I"D>'[N^/'CJW8<5&B&[FP>IVW1^>@
M=V7>:5\[/:UMQ/MW%WA5+-,+2>NC6F*_2\^!789/%!=7<+(S([Z=PD7I!S^8
MO,LFN??/A12OE_W>D2)?'J+"Y 1UM\\J4"+S,IMKC-CHCWV\U:E9 F?^SJ8?
ML?R0:(@TUA?H7A]X276!!9J^.86-TIIU5SPT!I_'.J:[(<.#X06^U<.]_NX?
M+EJ'#7P4V25R=,$MG[/RRQ;OC44BX0LD-P>/:.,-QD+_J8:IVAB>AD>/\8LA
M:AA,'O#Y[+)H3Q,])THHDLO/W7>&:W;/RMZYV/,A$)1S<("0"M:*$W_,KPMK
MS[I[,T0_U'RC?CYZ[Z^F\BMG >Z5+I;(*B/$5L_79J[_YFIJZ4"!?/^]F6=;
M$9N/A$*[Q,"[1/=U?<NUA/)E7N\\W.I5"?(59J)$ZSL_6G+79G6( 34_2S2N
MU0LBE4]3? +/M[[S?:"#X0:,>@@8D2VD9N6DGIVB6SM%);2A^%$;0Z>*ROV=
M4K<MK-T&XD0LNZNE<7'A;S=]AF:'4!5P#))[;26ZC+,N[>W ]KDQJ"DXP'S[
M7D9^[R8\C0;4Q]U*>C^E2T<_'I3MEH^+#7+R[$WHOBQORRE#S^G[N&8/9SF>
M;SN7KK@)HPIVL_,<)N[9?'N7'BEW4D'63;^;$40\6D4 ;-X@1DF-G2$_($<Q
MH!BHX=4Y%Y2GJQG:\%M-7Z"N5>VC<A"7=?I3E2EZ7/*ME3!L2'2/.-"+?_9A
MU4)*S71"+>- PZ_HB/X/5Y6>W+18/K7:ZUP-9ZJCOQ00+UI3.JF#&P^C!T>&
M7ICXG.B2@BR:D,+U@L)U)%R2]+#M2VW;W-LRJ(HR'+RT*D!7L@GZ<S12^9[#
M%G'&=7KZ+;T=TI>"=D]51P\J![C_"O9%>IH7MCL5"KK+7>M.\1W?R_Q)X.+A
M2 \J6M;Q,%R9KQS6V^:B$NA4^M"M>G]9AC^WI(5?/93L&_LU\C$CM]^&5,@5
M5DOI1AWRLK93+S-;'X[/N:RRK^^6R8Q>.]4[KL?_7D9+4MHDO>M4=%\3(>[.
M]NA7>W%2ZY06LS)U;*R"3D]=# BNL!/!+14PEZ^Y7OZT B^(M^.&#=HU<,Z$
MZ&-'7 -344UCW#Y!#D1AX'<QG;3WNN/<1)WNY"<F.O?X<<'ZS>\2C>8M4RK\
MO-OG[+<=/U6V=*TF2--Q"2\WFM ?NBVZ95D(@H[JBV]:=&6E/87%)+U=I)3:
MH=4:1_LY-O!<U&(G,VX(WH@=<V0.=NDVS0NB/1K?9<GY6,4?U[,T-.3L \F'
M]Q@$4FDWN=ORV>UH&ZV/#,U%)R,Q(&W,P;J4.HQR45M4H\*_W=L^(XW GO-=
MY+JVR4_FY3LX?>BQ^CBCWM8E&G33%F"RR;S#GKM?7Q]UA2.$?F6G(=<U=,WB
MIU8!*[XE&!GUX_YTKQS_5%A&Z)1?=20+T9B9]XEKUZ:@$)7=S)AQ\+VL<1C(
M/$6DVVMO',4J\;-OFAE*$(WV6-)9]D#_E]B"'1T'$FSTE,:1KJ4>)KO<\]6^
MW8=L-1$MR?3]PF+H^&T_A0O>-SEZF@J&=W.@B?;)Z;M'=4SPVXA*PGBZ0$NY
M[]F$_/NZ;0D^W6\@?*RA;*!FD?V0R'.K;&V-&#@K^H [1[@O/#W53/W*V&T:
M>+OT$./Z7L-7.;TW&'WA]\W!Q7,[Y U8$U2Z77S)MDG---VT]M3'I4?;)@2,
MH=Y?1VI6UQ&][T0%0 Y6F"4];FTG=;?^ ?>T;F[?!/Z7,)YV?=>O^COE#^5D
M.X(';;<\LNJ/AY&%=_OOD)*F4=VC%HX'RMH'#:&QQ0N]/^7-MNU9P:KT!4Z(
M@8=[X1(?"J<[[T)P9:CTBS-R?[N%?O8?;J%O*"$-[_<3PB'EH901 :*A6Z0_
ME"5!MP9#>#6H ,X@5QAU?<V"8__6<O-  %8,;&EN$@.#>HC\4*'!XK^TW+3K
M=T!TR][[>@-]1XDN D?1LW/DW)JOK/A!'<I%^^8!\H3&4<2]=VFG*6.D441M
MWP9&?+W(X_WUP4>/O!NV^3UP_[IWX 181SL$4FO.<OE@-53=>*LR[AMZC0<^
MW5B55)3Q9@U2X1UNJ96RZR?Z9]3,D'P97@P4T(Y:) 0T!F#9)+8$FM12THF7
M2E!,D%W;#[>!\7/:XWPHB8@TL!2^@/+H5B<:=*-]%E*6FS*B'%.F$02^">7X
M$1QP71A\D4"!E/N/-6R_Y.^=@!^ZMMY\6 Y\9.XJ!M["1KL1,\$Q)E4&TI>N
M=F%,COWFZ-]JO95/_7;PRV'46_X"BU!(VB:9.1,P*.>?5%#=06Z]F7,WC'>]
M$\M1>OM#/8H)7\![E#9M!-.T^=I( ]\;FLPIJ>F?O:60DZ=/GIF$X4]4KB8+
MTVZ3ANK*H:01?8<PCE41@P(NV0D5UO?05QHND;D!"A*H)\L5 V@F^V2L2-2^
M]VQD@K+("5J/&&HIY5/-L32(/+BL?6RBK!BQIN9;0FR#(G>^BV)A9>&>EP)6
MPQE6)534@C9'<=$'W^FE(*P5L<&&MIB%P-3FSJ!^H9XJ9,@RNL61)GM M-<>
M1G]\:AZ:@IIZ_!.:=H&P;%S> %<U3N7F3=>IMT;I8B /3>[8PSYXY\7B=M:J
MD%:C,QLZ+Z9DYRUK?5W?.+,IXO$L]4TE/$=[VRZ9:H;,&])UZX;GR2<=&B@.
M89T/P]&C)[M?=W1;=+99?57=ZSJ4"I!Z]@BF[K2@79OZ50^]7]]V#ZUW:,6.
M$](_JU:#^JF!H7JY=1?.0K=*FF!V.: *-J:R: )=H_]Y9K;I75):N6]2H(^W
MD7?W=RAV@&CM<$!W[[63Y;%*%YSRWHHV_.@>P_B;--M)S]H1"+$+R'/Z3@K&
M\7=&1HU&PQ^L@K4(QW)OZ=\51C6")ZA1"F^T)IN<Z9",#\QI5J9H2N9#<D.G
MQ0@G"7VCZ[)!'#4P<W..T/1@(49/_\ +P[;=Z[\4O+H=E=Z O4>L>EK?H.ZQ
MN?)4YRKLDZ"6\7'RQ,'O^TD>H=_A=>'8HL8T(^$S2-N'[!24P^L=L'/%\=O!
M-V755;262%8^ =7N?$0>$\38]6K)5C,YU5_QJ4V-)7&CSQNDK^W045K4'X(5
M@;6/UO0&;6N[4-SZSO))-Q(X:480HB[$GU_C [. U2V-0/8^!/9QV=>U8RH/
MN'&G0^"R9^3EP^K,G!#/+"UZME[?@3Q41R+SL?Z<1UZ:WT^,M.;> #HG6PZD
M,\V6'DA6CN?0>?)ZQ!_I]*1I%AS)4[^4]SH44APQCH?.ERZ83).&/9YK+;CV
MS1JS4'TJ :>Z=3R0T\[+72R%-@.L5=6G!U>G."B)4/KE C"3'\5 _%^'Y<ND
M>%Z9A6:/00=GVR;9/K-5>\UY: Z&BR/^N(7-G:?OV/Z[9\ .X_,"+I4^Z),,
M8HA<E(LC7>/O1^,^-"/[X"P:PO; LVA/)\];L$E(FW$"1Z:9'"2G9S8C9E>%
M.K%M-T;J4^?OM\W@[\#3VN-K!Q#H19KQLIQ%T^CR-6#B98[C>Q_XLO)A>.;'
M[@Z*F96V<-/O#1BR,*)/O@Q*RU#K<VU%/_^<=6)LNYT8V'[H# 1W-.)2E^LL
M'K%E^U;K'(GN?'!*0>4T,W1Z+4F *GKU9:*,EG^&GC.P]?L"D\ 5#*1]U3MQ
MO'L3<3*GX4X1=O'-!438F!B@!NO%NK5R%YFLW@UGZ= E;R);E0;[2X#:DB8&
M1@=1DMR)$P.YH7TIT!B<("2:B8%RQ#2D^ Q^R^/E?T^=W,T?=VAWC6@68(K$
MPLZR'FNH<C2+WIBQ]@,$3VN;^74IZ=L('0LS>E[$8*,+,=T!^L&:@L---5.-
M7T "Q(<8(T$5+F?IRB0?Q__^FK[_Y  -OU\,K) 6RD-JLZ\@_&1[I6/T8A0W
M7T*G\4(D9? R\_X>>@Z.B9@C]0BHK[JKI.B=,U=B/PM<O4!6-189(F7 ;*('
M:Y+.$F[\/E^^ZPI*:88A!@Z(]'B%HHV/[GQ?J]:.Z--__M=YCT%2.QF4J37[
M"FA:$Y261(BQD.[\F6GXQ(::,68FJIM$URX=F:KP*))XRO]02>1_8B!OES1W
MN2[NV3&KI%/:PYA<T9 ::0-N+3_OO7?@NP*/8_#+\J$0HIV*)!<UFDSA92+R
MM I,8YARWCZ<;%S9GLW^!(IH3#39*Y05&2F^ZEV_0.OHR\O^WW(@^=?%P^?_
M?/&08S,B <?;^<0 G$84=5XU3>0%<>9,YD.H\TQ1&%O"]B2.>AXYC!81+\6*
M ;GH1V#W#[TWX/@'./\F)%/ N2,&/I1.0G=)PL#<N*""Y?=\_FS#9)^#_J+
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MG/%L[31WJ^I]8D.DP6@^JC1!=GQ>D=UX==0Z^S'IT!]/H\('QF:!<XE_:?;
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M(']^R#*_HRI OEO7!4-;["V3JH$B0"*.;SU4:JG<U7H"ATC-WATH'R<$GCV
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M3**5:PW=30A<549T<C:*Z"L9N'1\K[[?*03<J)RM42)9*=-9+-GT.[?UWID
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M_P['KC34X$Z>!_V8,8%NEW[MDL94W>^.\J&?-Z[$F9GMVFG9VZ:HDNP4G6<
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M+K-NH[9]D(3""/G^-4+-!]W3HZ ?ESI7)BDS),J>Z0G4O4<.!#!W8=>C/HT
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MS#[RI#8\0#6B1G,3R!T54EYB2#R.RW9Q-!FLB@T$Q%>6-Z(XC1=AKB-PUBI
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M$".,_^X]H/_-#S*@Y@#2*\IY0BW[==%MWH&O.V4'BB78RX,1A3*,\:VP4FB
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MFSGLC$^E @B#_?$!K]SCP"7*K]1->T8>W/1&KWADV=Z5^^&R8O%L=GI?L(U
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M5=IM'Z^9*U$2B?NA.A0#*QJ #.7 [\.E]$!OKZ"FZDC"&#EPB(\FET#Q/#F
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M97[H[/9DTOU?8H[1I2;*%SE'C.B'.0_1)!M:Z5,:WQ+J FN0G>'?-_&-^I;
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MYMK*N'.O9:N+((<[WE)X5@N$:OH<M0/<(8,-W]YL_GKW\WLF%L:GCOIN20.
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M44D>^ 3\+-._M1:RQ1#X=]DUSI-Z]&:[I/JV!)]B0;N;871MXR2I7MX!N:&
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MI>R1AA&_%17-*;?MGQ"86Q2TX^GWDC7=Y^+']W.ZEFFD'+PO$V]U>W\V\D.
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MD"M1Y%/R@#1[F]2#+.+82H!67DE1B1=OF9)@!%+L-L% 0SY/GB(GD>9!+\?
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MYK,2,J^PD/_>L&BJ1H^T*]=,/.2LG2I.,#<\F&>T\OB8RY*,L%L],]4+'T@
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M@U!'T2,0NQ7,7(-FM(H3SL','.]7$@_.9G\;Q1SZ1@<7(P%2V01JVRP["7"
MYV+>CQ8/$D_ 3?RP$H"0*)Y!02GP]PQ8++E_$PM&G(!Z '*?].R6 "][D5 Y
MAOL%*8@7)Y*$4(U8A,MAX\0)R <(;F307KC%\&P+:B.Y04S+ D]O)U,SA-H5
M?T(F7*$V;J4$8&R9K<=YJ P4!_XH% Q7C!7RD8XTI% ;7#FK#^YPBX^S+<@O
M09RPW1;*L0')UAR?""]X@.7*,)BC#')-=WZ=+\=8246/N6I,D@]2QQVAX,)2
M-JP&AO!P(<8LK_[5%Y33:@*?C8Z7H/ 1>NQ0.*2J7;8I'M.1YX4:UN8R*"NJ
M+1$QI\#?:!CY[QHV.^\@M58HX_!/9$GX=V3)X/CH;Y$ O<>]&Z 0?PD@X#.H
MAR7 N!<G@,L0(KC,X,KVWVK\;^BQD0"=S=]47G-6Y9UF&Y'$2V!@W%O2SKY5
M+Q:0\PE@/GY:$6)ZI9!G=&LD0'M#L& M7P*0?!BT^3'P\IK-\NZ"ZC>:52)P
M]/K?F=* S4  C=JV1(,[#GW. ?/3IC4@IET*.*/SK9, @9($, ?SVV"6.R0
M.9*CD"\!_G$HS-^'(OSYH4B_57KA-Z5O)_]=Z<_^SBRP_SX+6=!/L^#RV[&X
M?Q\+_3-;N.E#$-,E60+,Z-4(N9,</O0%"OXV3SQ<C@3 I>T(;. ]&6EE[L;?
M)!51HQ!LM@;C716YQ<A!A_U  AR!M2R=,3Q$3=C2A=S 6=!!^]S>J9._UY@I
ME^8>W.[I61(8?C+%+;W^V+D4L_)7!_:1VSL_UU_D?*0GG[[C='OHT',9ME,J
MM1MR?%.:3[SKN7A!62$PE3:]_(9J]1M\IP/A53PT%RGZGMRO5VDN F-L="Y
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M-F"+]^:JSQ60J3'/U,4R A.B% KEZ)Q7W XNA692:**&[=BJ9J/#WNX4T"E
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M4SN/6G I#,CZV<,&;&UG59L$.M((],/T#Q2M;15Y\1<O4L53;"W.\/&Y3-!
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MF"W F>G:!FX,6?ZGGW*_W_K7'2B'=NN5C=-W'/I_]KN\_F?7_Y6?7P3^;&-
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M_<FM-I[.3I/X:\T01=)G)_BXRK4'*CJ^KV><0B0DY!BT"V58BM&D\*:3F+1
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M[KY$R?Y%EH8FZP/XU)UKI8>1'458;4 OT]9+=>\NI%;^.H>684\K9X3.$][
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MVJ^_%!9[G8#!2151KG>36\A@1#;"D V(G]S$0C&\W!#,0,6PW^V8Y7]C8+J
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M8=RE/3JTR%1(>$J'MR%+@=0DU_VA8'X"DC#XBB,\W>5!&;N:RYU/Y12@U)9
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MIH?/:)&(Y(-BVY",@M9N14$!6RK4%*/B84:9T<M9!,SPP*)Y)8 )A.1(AIB
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MIB9>;84W1I)V)KY*98P^E?*!C!'H)TXUEE9GJF 50>_OM%&PI "SNO!&)G(
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M2='D\;7_-H'+OT]% #U=1";;)10@IM!EY@L%"(<W]Z,7#*>C!S9Z\VTJ<!0
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MJ4-]D]Y,$%MVJ  %T,E$$4:+NA)^"1/Y"%() AY\ZY!RQ%;VJNMO;Z55.XT
MRYF"7G5?>3?'X3]@Q-9=\H!B50S1G(1,PZB\+O(G<W["TAT<<O8=4@"-!8AE
M9$%%WCF?9WT@O!0%0%@/8!7FF]*T*S#:\#[H$_+P27!_ JC62V^Q@(HA(G.S
M8&="6L\&9@.:#R/R&$_HRBC<"+M\+X,IXTS3XZ+*NI"ZP#SL._YM[MI/[:8Z
MN4\ (66C"H1@1LC"9.[4@K&_\2]XT OH9?[E6-#<:M=]$,/RP>!6GIMXW1Y\
MB *TM1YA/?<K0FZWJ@X)T"-:=^E>6*6069VI6[K@[U0W:>JT=*CM7$><4!(B
M.[<=:P3"IWSCSM._E7%O='*]ORG@:BQY?P([YBHY(2WOJ$X]?^O%[$-JVG28
M(^E/_?&S!M+!G/+A8FQ6X+<%"L#05QRY.OVSZ^,' P]_O/9W7\EY^(8BN"=Z
MW^+$*,O7(!B&(+C3K23Y$8^;#%,[!/:H7.S]).\&U9S\6"#RT;02G+:<O;K:
M?Z>=XL8OB0P&^XQ3CBV!)"/!;Y".PJ\Z6\%]; M5#[U:_#E?!&P(+.FI*>B%
M24X4O^:XK:B-'@/EUR5NQKP\9IQ[FQ(5(7G;A>U@AD-?S_[XK=XDP[M/ER>?
MV!@?O6%[O!^#"R:^W!"(K'3MX7-<\:3CJB@:9RM7K!9WG&%QVO1M"X+M?W<7
MDYRW<V#X)+Z\,%Y^+*"[/7AVD/Y.6U;.*1C NMS<_$7HJI_"A-$R>-T#S@8>
MG?U(?>:MS\/\X8Q#NH/>#9I^!D$06FH9E;W/P)NK5^V:>)S$%"$G0.^DI]S(
M&I@EL4AKOTE3N4\WJ%0@,22K50F7.9+91TY+S7PXR]+I6F&C]3SJG'=.GOJ1
MLX$5QL!LLL:0#3,T%5!!H+8= >YUVC]>7<]X!MOB#V*&0C9]TPXVJ>$EG<83
MK\ZO>X_CHGM=_5N#G"1B>RZ"HPJ?*D044(#%^9;)3X=$+YY8$D3!$%*H\U>M
M80K0X$-- &WLP"<.=PC?L$<Q&!^]_T2VA?,XB.@UXCL<L^I#[JUJA=(;&_"#
MV(E@>&T1UJ?SNKO>=Y MW#^U;BC25D!FRC/#:"F8V%9_[1#>" E+U)I W,>"
M6V>\GMD[5/,OS[0IZ:EI*(H;"?S(>QK"JLQ\M=#+ XP,/ZH-[Y4I=D([7.^]
M^@HP/+=<CO/.'O+H(!QJ,HHO>WT<UF#(">I_X8[0/:+BPQ#X5E8.GI\DU).Y
M;X>LE/F*F$E<L*V4QH?9#\T]/.A;)(;0WKZ,\RM_[GDFY&J\DI@<GBXEI*YX
MK,HCI9K!8ZI,T%I^EO<=?+@U#!H<ZY8_GE$!&0M2"WW)'BO#%WJK,$:>;KZV
M#$;L0R>PWG].0]NW(53I=[M.Q/?H<F'6I#6 P(*@%@E1$_P5JVAH$=W)W)KR
M+TBAN]-;>.] ).Y&)U1UUXE-X&9?K= 4J7G-[U&XL2\.RJ$?["?0.D_N?#P]
MKY30'*UR)H8H*[0D)5 ,ZJ< /&M"Q'B+S 2F@VUMR] 4:[+CCERDOM&Y\D<\
M;R5)7)]0=0='HR$,J(#E0O*9T2K9=Q840#D(?\A,5!DK(Q7N/\(M'MGIW+YM
M0UJIF;$@-75:I$M'GC&"DH0NKS/.P@-+Z]:W)8V+X\)L 7"W]BK2-M2#JR;(
M ?#'G5?Y*M'<1;?_<V,:):M(;)&2@+D(=?3DQ7!5N VKD(-=%^!A!8][Q\WW
MK%@TL,-0K2>-<'L-;=[JR"R$9<W4]IK[\QKO]:+W4A]SB,V20\X&Y1AMN6L2
M#WE^\C1P9_K>,3IZ<V0ZTUD*ZB,$6GHW;\%#0;36OI(NK EJTB5X3-G&!USU
M9.A)\X)UCF5>[(+(@1(#E\RCWU=B=S)BY16+.8)C.2-:O!X>&[UM21G\ CQ.
M:4M9W;$7UF\4#6^<37PR\%$M,!DWCX9==E;P92>"DC=WEN)&9[C)DDU0%/B=
MG4/[U%1:B=L1C?7W9=L*014;H^VFSERY%O.L\3LO[5VSWZ;_--N$H@_L!"IK
M)<ZJVJFWW!U=40N]D/S= \[_8Y-8;XHAYPB 1;*R,WD5;D"?M?9YK_4C<7'[
M!^;$WV1E4B/FA'EU%S>V44VPP?KVY/QJU$!),$[UJHHY"'%\Z3)]U^#Y5N[L
MIACCU1S6,=?R,53Y\->@3[<.-*_RBATZ53M8.4UX&T7>QH=P=PZQRZJ0C>%=
M@I'I> J01G[@\N480S+!U!6.R-IJU$NG.:O?$]7C=%A\\-P^_$F0_N(Z0[G:
MPZ$V=+K'+09X%.[]ME[&TM#>M^LR9_55 T1\)RE J4HY>B=UI..*YH%E\A''
M0EA,\M&:Q]ZC98G]T).886G;3*FTI4!]9=:?93HT@S5\7YX6"E>Z,3JJY$6_
M\.W$QJT,6FAQ/-AEK!L/1DT;3DLL>W!]>FC+8/Y4\4B2 M IB1OTPB:ZKC5A
M@8MS^V+MN+T"3WE7;K?-L,^0[HWR&NE%@Q>:S>N0<!";N""=C:LOE$6+EG.[
MHO;6G(S(D-J&.X-YJHOQI[*$LP*;OWOM(^%+!_8.SIU7/MZJXGSKH>YLX/9@
M[%C.[0YY;"#VR&DEZ-BTUAKG_&4*PN-*UX%8SM^E]G+1[EJN]K=5/;[?@_')
M, K)QI1)AXFQ2Y5XE\7*:9X;OBFY)\"T\W (_12BR(?-#ZFP#YU__.C!=569
M;[PVY^%-9(>$2=1+E, (/7U[BBCGV>3+@XM\89UIPGUBSFIPJ=ZD:W)ZUZ*%
M@NM>B9PIT5W\FN?.T8Q8M5,.Z?Z()W L7X.\UZ,;)/?!!4-=L^!3Z95$JLZA
M]A'6*74A(DZ<[:&-DQJDD=32$A,FUJW&)GZ*.DBR2$7T%'\NZ0(%H/&$SL)K
MPD"@6Q3@XL8,G^V[05PS!>!_Y>:C 1WV&1=CD\RJ"WZFFFY='K4+&<435-O#
MW8EUSK*J:]BUM7IS8PE;2!SH8$4C+7@20H]J[:"+ZB;.2#/Y;)%[)WR0\7^.
M$$8PML;$9GL;@R+FA&L)OH@;K,7#HEGR'T45DK^<+]RTK1Q#;V]<Q)JC+LV%
MWT50-].H3/$_8!K"'^HXM'M43;+,,'UL%_T\VEM#O?Q!+NMP]?7)E2JRN/DI
M,!2?"5Y04-<X;'VY GX$LZ\;[K,0%O-RWG9"Y<J4$[Y$R 1?_1G;>L_0N"$
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MP.5]R(4%K:=?Y81O'G;[*,3(4TVP1_U7K[F_'S*J-CIA"J$ ^O"^IHE@NJW
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M:JWW7;5J%?>UV>' [JB8M+P/O)/;%]!PX=OU#5YG)#4<6NO]YD35E3D72QA
M7*=YL=C@61&AEEB?MC[.U.'E&WR"U<Q8_I%V!66_H9N>1\JOW!+37U:H9LOA
M0AP;AYQN^N;&.%_P7L!&&>$SS[5T)H7H;1FL^,7_QF33%JW0#Z3-IV2XWMII
M#K?>B%IE/=)<F-E%=\1 $@UW+T^,ZAW<=5=:3_]BE\2::"[JLYOF*$3?\<(N
M(LG'+)*Y*%B?GE2F,2NGH3PQ.Q9GE#_^,.Z'_6Y->;LZ67;-\HRII(RNER[8
MEVDRT*+KRU3P0^4OU$X5ZH9[H-/RNEWW#$Z?VC"PJSV,MBI$>O">=$M </)I
MD:L\(G_Z<Z2.[(YPE\LI&]GFOIN\D9HO7J8(YJZHVGN"R6W=N#UO\P9TK M'
M=<W'.N(?M@A(4?58T'H!6[#*68RA@W8WK\  >+PI4(=X 4W_/1C_*PF2SA34
MS-]@<FD3IG5V3+5>]H'T?!6+S7^J8J&/_O4J%H$_P"\LK@3HK)HX4@S. X23
MT78(CC]G32?VY#]UQ[$%=-+&MA =!29_IKUAX1RE+L+OI4E79I/9;MQR2&4^
M6O#;Q2R:H008>$89F"^80/U=WW;*]LN$8DP;SMJ3)98L9,<[>3^Z7F:;_SQP
M<.<VGQ<F8PNPV\)A8"?%A*,)=-9L$SPW*T_(Z8Z,/E6E(Q,A*,4[)\ZHC!@$
MB)I[:AK!3=Q)!DV(V/KU\1U(7A1])/;A$1AX=?T#571QW]W5A(Z53]0<MLTL
MLL3IW9^+HT2L:91N7[)WJNG^T_;O>!)FI#%VKEA$UD29+7>=96+Z>AYW9F7H
M4E8$MH%W^QCJ$AXS]B(MEW+'>O-/7JZ8U'HUQ.P:'[$% NOC>'=>-CK)1,UB
M?DI6F.7I;3-=;J-?1\1NMY1EP_4AVVRA0]K_6W*I1W?B/$04^8_@O#/<OU!9
MF_3QN@<V^ZYM-73KSW40)[W^9(SIP^;NN%QM/E^-J28]Y_7E\NI70NTTTO !
MV@;;=%9&V5QYZ7%C W+H%6J#90>^=*1#/_3$CD%B:>+,KGRM+.ZFGHDJ,SO.
MJL8?G;>W/MO],S8V./UIA!"<P R@'ZC.0;WWIVZC#7A&X?.%8TS^G8Q[/J;S
M/^N%JDBH@?PF']$&<-2>:=0C+A!1:IK.4(+3SX*O2&*R60'(0 Q1H,DDWJM2
M"=.I3G/F8D2XE ,O86#XBAL_'S+*J^ ]1F/_W?&#W['.K^ O@;;S1BQ99% T
M)^%-]N[-UY 'V#(^(]_5XN>&/Z462^7[D#6;OAQ[>M,^28]W>&-D91UZ'?I)
MU;.4TF?GPU8\+B 3N3VO<>6GZC U?*\U/]4<:7Y.*"3WY2;#&7Y[C=CV1HRS
MW0R*_S(@@Y])-C@M,NJB$>TG:IN!.=6<,Y,Z]Z6M)STZ =7@N %NZ5UU/RR#
MIW[K4K1SGO)CW;B1P##EEO!AR"BK/IK,I),KBM<IK-0#Y/RN'0*FFG:-G%V]
M(N#N8$/K= 3_./,I$.0C(E5)Z*!'HV0EQ]S+5W%";9 >NH2']+S-AV'@_;+O
M4&E+[^R>X"Q+TE=,M2,D^]ICY/.^+M,1SWC*QC?3_2/4H7.@6D;PK8F>Y.S;
M>UWJWH=5, ,6;<]M&MAG[A4I\%T:TA/W*#J<JN,I5IW8Y.!H&WH4+6-V]LZJ
M"WKG/87^/CPCTI\,7-1P&A0* ]N$=]*;S6T+^$Y@&BY=/ME_^/^TYUHGI9!Q
M-59B!<B0Q\BWC>.P5.W8;GQE^H<>_Y#VDERPD3)$(J1Y,]1M9UHE7!4&7N %
MZ>W_ZR5ZCSEX @9<8$"!EZ[<GNXK-=*NCL8*)+J(AZBT6 7P0XQS&8J!F?"6
MZB+\U[?Q<A5Q<<09ZW[4,='[Q \?>P_MG%*8._PB/(?[5?S:%9%Y(%G5;L/
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MCZ'$LQ<N+NV @<'DM%=S>!BX%CY-E,RAW248F)0F](?Y2-0ID=6I+/+RTND
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M>.<F%*>HZ'O)48Q\HE4+ Z%>F)W^RNX32_VUUU#<JW8PQL\R<GHCM(Z>_%P
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M]:P+L)5#C>+E?TSS44THF<N=D6>Y%1,!::Z,Y72:U<2YD LEF6*Z9I334]=
M39D7\E-Z&.+5(X=:1Y\?3D4]1:CGQ2STP878'OVP?J?,2R!\_(M4@Q1JECCW
M?-V9N>NZ3?R#(N,JT8D^[#FC7#N79/8;>QNW>K8 =RC<_JW6DW[G,<DX]+P,
M728)=6J;M322A0,FT'KJ,:@!NM8C7RQ(*\ 9D1#=Z\EIC1J^$TDC-E5MN=9.
M<:DYM2;Z2PV55,]<ZGZH=->%S7UA0TY^;N"]8LEDHG/8?<WNZ>O;W\[:LYT0
M8ZBO"S124M?.RK%'?[ - C@151D?:>3V-@M.;K2SML<2)<L%82E)*=2[34T6
MIE D(\XTP7K* -GDNFZF$Y'L=G$C?]7P6!-DVWO++Z/"->_;AR_:;X=6!3U;
M+%Q<QD8K'U$98EW@!+NQB0:3D?E2;@1!U8@[[>#8WA [P(9\8IM;<:KN![R1
MN<#-+36+5WS&43DTP:GALOW,F-$@I;/,9V',4;^2DKK]CM#[!L,9##^0[?!-
MMSJ>T2,.F9CX-E;KXMVKT:((9COY;%ZK;F[?*/109?;E+[L,OB^0_TQ#>7Y:
M'6JQ-=YX)I,V,YH<6=A4_RIYY8^C&RHVAS\!%V,JM*7M^-]$]@D)LQG?^"?M
M!,B[59M%8%V]L_R5YB$*RUXD7J,_>3T>K+82/S\#(1!I1SJ+8TDX%S*Y<)KB
M=X98UY_BJ4'R.[9SM[ZJ]Q82[SVJJP^Y,)--D>D\UQYV=Q7TT4L[#_RXW1>L
M9"<7@\%">Z96L(R ,B#P3TYI1N1M=*10@ZC"=B&+1\'MZK\][BQSKT&_,^;*
MD]ZU,OOR4ZRD2O<YBXXOBWDGTVI61QVRA5J+R4V.D<Y(\U%,Z:V5W96#%U"+
M!IN;$TG&+$->;UUB]X8#7+^N?>'O?V2)6J^^EE"S00X,X,'++BRW,U>L^M^P
M,<-J]M%>GYO5O_D2\$LB]M[&]HDQB11J!V'+>?^-ZP_$9@DIY[S_A13V3Y39
M% 9^((8J#0Q%]AGC/9\L(WN_\Z55\ERDV4=5]9$K5LRV7K\W4K5K:J6K1G6;
M/))ZZ=ZG)1D535?DI6' H)YO/\L A%\]BV?RU;_G!>9K+3UQ-4AH*:T^= BR
MQ<MCAM'3+V13QAX+@ST:Q;',24\#BQ/I]4&N)K0Y"\S<QC:4!V:[)0P<KWU<
ME]\#*5+D^J$(<2SF4TIR9Z^)IK5/VZ7K&3OK2-JW1<&SRNUIU^T_ONBF=^@M
M"E,\;49,&5\F!CMPWC!0 QD]W38S'IPG</X7PXDJU(@X.%]IK%"[K9D?PH$F
MY][/?,K0-?7>_U&CN/VVKNB=OSR%YHHN\K8R(V:F'3PE5Y@OC4@4AW''XGN8
MMAM"-6[#P+E+,/"0DO_Q.F]MC]"]Y")+P4E&_N#T@YNG%I]N\'^F(7ID1[(V
M]&J_P8P=9_R@,'NBCIS)\\EK3NY9'TE_?D;59LOQQ;F9?;?IQ++![F6EY_-H
M7OT%JVP_#;[2NND76+WD_>;FVMM*H:#N??IU&]2?%.'4_,[+KQR=C$\0__J_
M?D<#C30:@TNW!?N/7@83U4--B%1K5V<PJQ93DLG5L%Q&XB?1^]%ZI:-@X6L8
MF#4'J0;6:A,W13B9]"^8<S'YJM"WL+<2["_\1K"OK*SOP'S1?LV-/W]9:"U2
M3D3D?-?>3T!+OBW9_V_/"G%^WSA*?1S#HNAVH3J]$CBGZ?4AT'>2$SA0.6$G
M;KN.KB_]"E:=$2?S!8_QS3!P.QIR)$UEG@3YQB"MD* & _W%Q1C>^UKA(EPV
M#&Q/H_"3(=O[O;T2L*=-G\#.]3'*0.7Y$.Z:R4.;YL]D79%'=;83.AGB/RBZ
M'^IS:TGC6D)Z[IVWF-:Q/V-ONKWMHU\?Z//#,#"W#L-0Q S@@_-13-!A3EOC
M\_QYL"C\2Z]/_RGX^B^)E:XTE YU@Y5H^H7QGAL\H_\:_D-$ ]A'%8_.'RJ\
M"P-V7&0S9S)'^+_IV>1+4B'5DZ,T/?G3OSW)D3K<]CE&(GRW.Q-8T9F>1ABX
MR$!_+[8JY\?>X\' >A@X31EB3))3QM1_4_)>EP@& <^Z, IW7JEY'CFWKJ^G
M<*Y=L3W&)\QNIC;Q?-_KW-)Z10/VFRN,&WU@4-F)J\G$9YRQAH]+I(*CV(RD
MM'VX\0+>!:;=LPLWNH4)W2XN;[#"!U_-U+>^>/WL]B/UK_>N\ NY-/,W>7B9
M9^.GWS]\^656U^$]MLOV]:]KQ?]=?(MPE(^:7.9KDIHNR\6U&KTBD'Y(B7MA
MIP9HLB+#@$,1NCF]N2@(&A]ITG\268:,V:#VG)]<7 0#NQXQ**]R72R>?&S5
MSQ7.A+>?L_K0!_IAMS<_%_+:XN@F]?GKGWF1JBCUK3?7.[G5@76MZ?K*KQ$:
M4I-C#$K?XO?(3L;G^8H%N7_0IQPE?<\H0:<W]"1G5VIUMSAHIM_ +EXK]C@?
MI^(^0!]X$"Q$N:4T/<2^UNU52I;3.;Q6L$D<K+@&,Y39.5V**?3'JIH)6UKG
M?E1UMH3B%E6#!27D@N&HV!#(D+NFU\5IF<"!._A^44/+;ABXB>E7M*5F)1O\
M9>K@/V:^_F;#E2$8")\5AT.S8DQF[OZ!U?Y7"T?S;ZPH/;<+!BAN3V' -PTY
MA'_A)N4F(P"'&2M_;LO<#[9(UJO,\8'TXU)KK&P(]ZV)/!(720^++R4O44[F
M:C#>M+J(6&<-B/QRD2D=.NIV=3\,3&:!=08P0 Q[KR]9$S:;8*!)FPX=5C[I
MP'^C%=P7474!!H;M;I[,IPA24[$B@YQ>.[E(?)!(Z7U$D=W,R4+=1U3H0.OY
M )>::YB()/'<6.'L@=;,<K=HH7HF8X:3>Y R1#,(2-?9<RU2EM!;F$MZ5Y2=
MV_6ZC\%1B!S<G1"EM/0<N+(?<JN98&P?7A+'+>=YR;[?H[7NVL7+UMW(/ITL
M]F9_M,Q@60D_W7 ;J1;'OQ _\\)5+!A",-@+_;C?RCPW6>-'0L7IY\!>@V.0
M_V>MDL:<K+[2+>)<NQGVA@ 2T[9X# 9^]C<H!M&.#,JT"5%RTSX']*T*<YI+
M=RQUS)&[@%A[6?U#'RT$D3E0(33)[SK _/@\Z7V*N2# 7D1>,ZL[XIPWBT^O
M%#?D8PSV+G@$\(Y2M]V[FR @92&)KG3(GK10RZB_XG(6J.(?KQ[[XUI*%H[P
MA'3P>9C?2.;G?=_.)Z\;?-$F"L>1KDQ_=C5.U%$>D"&1NK1??/1C7>V>U,@8
MO'$^;$%#=O*[%:2:^+YD [8 CQ6RYDC7,[4>B"G'=\K<*X_SF\4,K\,,8(\Y
M'+';]33XL!WV@D%PE]!Z?>_3)#-WM8)=W3L+F_(U133!,WR4B^96QM#<UZ3/
M4M_#(:/ DK%:YVKNCKX7@)R&G,9Z:NU;1-3H4XPK#&BHQ7::DW8<B5C2("Q.
MBWM?.1G*:SQBAK((ZSET=AVVV<3*X+EQ^O.4]_?W3LM<?1=H^>69X\+$A)&O
M\:_[K*M)G_CF,! ICQROI9TU\"@5Z $;10N7WU@.9+JC.]./K*-\?XNX1]J"
M4Y!H\]DVGHP]$Y\6E%C'LJ'K?]K)M=W_?G%9@U'JJ5:,N[%,CTJTK#I$^:P0
M^E'3RG:3VI)4*>.949.JMY5:&B[CX,'"L+B$$\ZGPX]_,5N+4=N0>&IZNO<K
M\?-5Z_/<!XX",!,&Y+@K?])B/)4[_!6$CLK$P0!2_)J$@L&P/1A,,J3<L1=*
MT$69NNC&2]"G;>?8C__>:,/D*BHS##Z+=_Y.+_,GC_^<B?G-4@Q_&?2;%/GS
M+I0L F><82 TN#D:9QQS\%#RQ6!19O=!.QTP*EW+\LH'R_AK+K7]8XR-;_8O
MS"Y6.&<YE$9I%GVP,02YF9X_R_(423=;NA<LQ^QN%Y$]9[M#NSW;#ZF^U= (
M'0"-%?24)@[J&1U&WWI.I%[=>]MT,.NSVYG0;XT'%5<L$;RY9<=_ ?:B'ZIM
M@.8O$]+^_LC^X;>LX^$0(?']3K?YG6<KL5%4OD2&7QA:>?[_%K_--+ =?2N:
M&TUD93XE1^>/[5J'I^:E/.1V?B@)#_^R0A4<YYGK7Y$2"+6&.V& NNZM=0$^
M7C3X#E5@O9[.#8FD!?Z25'( ^CZ:!P-;?_!#O#CY5T7^5>:J%EC+(4JI\+#*
M8Q@(4>M;X+P5=7?GC.Q3,+-[S1P7Q5-PGHI26S-M$MR!Y5//$)@ZW5H*9T)V
MY;A8?W6[^& Y1ALUW"J6)5":0U#N-E2'"]<Q<_FR!<)D\W_J^(N:$6PLCSZ!
M3FU4-A>$@!S9[*XO-&,H3UY'>--@7S1'VYFZ%@;DQZU(<\82)_ T?SI% :S-
M[0:9,/#$@*5"?I391)^C?*'W*^I!$HM7F-<" P3$W.CX#=5@^_;B$R$2J<7D
ML=RFXI-@X#&EY%9OOT#XN 2E!\DFK8@<O=\N>3XX4:9=#,YE"NTGXCGO1JDK
MH$R.;#&7]5\'J;CM%W_70BF>9G#)IO397G'] P4L#*PSN'H/!F)K0\7UR I?
M2JDGQ)< ",96GE-@Y9CH.*03LX$X;+:=$J%<F;/'@.?@)_F09O>?E('8KTC&
M4E8$.(:I:8A_[IY7QE46W?:^;(5IA\[J#M)7(SA@I=>>>@'1=,AM)?L9H<3:
M@B66*1(?J:OPFGOB9EO$):7_!AG]=?+[1Q'R,V$0M! &FB/)#WEN3 IF1O9U
M5P#Z@%!EM/X_!0S_]8:L,@%"),&P9(0/ 8U+R8$!9W&PR.!SS(5#'!;A?T7W
M!V5$RV#@!3B _DQ OL$@+C8QU86XGW/"^2O*SI#SX^C8N;PZMRG>#A?*)$:B
MES)'F>6#J#$K48S-2"YZ^Z]_AJSPS"<N]>PM15J'L.V=7CZW<K<%E?@^Q[RE
M=1\,*%%-%10/>IOV1$( 5ZR_1$?[T[Z32TOP>%V\Z8U%^!Z:PHC*#"HWLG2J
M>YCDW._F=$M3P]WPW&+E!W9QQ%'U>LHI0_NTQ_TSBCN;%+TS%U!'&C*9,MC?
MNX??K.:,".F.K)HZW*59?77_-5.+IM9H.:51L+PK3J5IKV-3\T ]WH& GIS
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M\F7[<LC#4#?86PH+PJCF5-3 ZB.H-5@EXJ4K!\4:34"Y<@"UDA5PCL#^&C6
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M8\! 1B5@Q3LP06\Y@6+?BB/^7U]%E#OU.2)K=? >2+@DI;D*U)QN<4"63R;
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M<QS4\5"+GU)(W8U<Q"^6D!UEH>+L24@SJLO^5>=:>IZ]9=Y>*6^CS#3F6L/
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M[+3O5-@<ENVVE^9<8D^,0^OGMIM)TA<$E9$O3\$551F&67S3@]E"G7:/Z@I
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M"$W 'R)/W\)O[Y"/3;G\B'+_O>6O&FIK!W<IPO)XQ8!;GA8TV]J:7SYR@"
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MM(S2.^S)*Q1Y4)GN*'O]B^]Y;S[7 $R.>"Z"8/4ZL=Q5=B WFEQ5B#)?2J6
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M# I@K*3"MF"?J5VG@O/"OCF<%)QZ]]+LHK= !>6VZ6Z,L3"03L,56QE6Z2]
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M$+BO/=T@)'<(DEZ81:)*"T00-R%/P-)@J9YE?!W4KPNF\!.#^I-R_K-!4/9
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MLGW[7[.05YJ+145HHM8LEI&E]-"((7"]IM_7[V/:YWZ]E'SS6LKN$!Y_WO1
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MN\T6QS:_Z2IGYL_VQ*2LE87AYGD57WA"E"3<XW?GI@BEP:4_M CNA+I2%8^
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MD^T;V@U]]QO,XO?SY?[66?4/] [Y)P?2Y5KA+08U&=?!( 13CWM" &R3N2D
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M^[;22E<7?F_C[0M:*][S[K-]?7$ >&@ W!,<U-WKOB,I+LAIT*B!<M7:S/N
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M+TD 9#)]4?(=.?Z05@R!20Z!6?-Q!?S(_  RY[T V/=+M(DF:EUCJ]WR'Q)
M2$*[?AE#X09]TU8?8%"3^)G\H=X*B?ATVM'U*HQ2 0!9ZB@>,,ZZ-D_KZYE0
M,%I. _BO2D'5)X91,(HU=<:?26_D0RQ6V4F4@4(.;RL B)(^QMK6*LIY0?C_
M0!F."2G#4\DE!9Y9-\U#=G^) %#0A>7%GOOM(VB=A$D!$%Z(8^*1'(5.,[]^
M#0U* +KO-3_:I_RO3_.7 *'P09=EPO27!</^^M/?CGE:%G'_?OGRPRO\I^3R
MI']TT7\-:Y=#TI'+(6GTWW[Z]Z_^2['R7[_P(<E" -B1^H@YH5BC_U X]@<Q
M82O^:.A;SR2N.H=;"'O?LL?7]SQ&6P#$:KO;N<-1/,37RL-W=,U/4&:R9B=O
M*^Y/NW'AY]3[36.[QVCGQ-M*4\JB@%3GWJ(A,O_J>,I\/;;56$Y_9-P5E(L2
M %*8U^V2>W3@'8A]DS9BI;L1_4O0UO3$A<O&L*%(#S$10WN8E&XK3'Z!;J6C
M$!R@)6+&@XV-1W1,Y/><>BD U-EEQ9>"9T<.'CI^93)C5PHT8_!Q6>B^.SY%
MEF!!%;GXL7=-R@Z31D9<7UG'Y;_6EMKZXAD"((#)>A!8'-*AXO:/B@.CA1\2
MQ_(U]7/*$NZ9,Z',;ALHCC9$;G_CPA8 *;O1B]9@Z]+NX/.X 9I;/6FM OT3
MOT(#CR:#M_F:!,N4\$RUG%&Z-;79^VH[.#"8A=E[\D"N *B]C,F>J8[V3,01
M1++S_.JBH+H*O-ZMCV&:F-<1B-DLXYV5V&PH*WHGQMOOT7[AG0YG"@!8[/6E
M<O/3O" =KY+]!&8 )!=3T/S:+=QKB>0JE\,=8'V)+%^*"\U(>**\-"7^^>QM
M=:L;E@Z1Q^13UDSI/(O@7^&(7%-](6Y6NTWNB^:K<84=WQGC1LZ$0M%3<KI"
MOZ[E<R=VDD0C<#OR7P<LYA@OYQ^ .D*NR'+F-'O18@OYFO^T[O8?B87^(;H2
M;BH S#'#T5,S.Q:IH:WQL"G(O#\)A> 4M(.QV3ZD@3/<F(U^L=7\!!=?1ROU
M;FYATSC_Y$8SO7,5U+@Z,0%0S(J!^0]YN[ \>HS@PZLU'FI3=/S=)9/-42G/
M,'5M3<&&-9;7085@9-7-V^VQ"A%+K+8E^GO7GGU+K^/U.5^]P9H>2,/"-E*%
MP_!7=+5(.OSF0QWW#:J#J4G2?B0:!X62JS+)$(-B-VR<7-;)X0SJ)U!I5$Z?
M )@B]GF(I@B-Y8<)\+?/F=YAZ9NA%2)D[DPJ07X.:UV2BK.=:'2IZ?3<60.>
MA3(<%VR^MY0_W)/-:66QC[4WT\FCFWHU$;YZLMOZ&^ARO92EP*O&\:IQ3IXI
MYQ,QN5<@?&Q% <MYN(?M=\!^WPKN-J*# -A[2*9.FA0&'['<(0 "::[L_3P$
MWV&1@]8>?+;%:)7V3:79#8'?C*QZ^9C!6!"'<#-4&%]LO&<EJ\/*B?N=\IG8
M7P:^&RN2W<JHZ4;_9X+ZKQ%L=XSV%0 Y%UQ12A[0RKX(GGR; FZ"L^A'O"<
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MNMVZ:$K+U+SB@[W@6U/S,Y?2:]%^$O))[5574F2@B\(UQ0R7EJ<_GA9<=\G
MMV@(@)O67WK6RJ.IQNS=I5[WV<^#R6/M@?.I1S[_*$;HW@22@>4C"@"58"?V
MW=W(;*DT3P (%_V\2FI^'(8N -KFQ_77RJV@B?Y]4\]_:0CLOQYH,F5?7Y!)
MK]SK[DYZ0S<K)5CV4^^6^E$M&3E?*+02PK:@/=+-K8L^T^\=GD!?0KK=[:/@
MJZ[FSK>U+[[]?+I?=(OQ$W^C21DSO>KC!OTPIW-)^WFM+(RMZ8%1MC2/"%[Q
M43%OB I4K&Q+YRI-2.T<T7MD:?TJ^D;6>[//@/$ZD6;)80N%O8='-=/V(<R.
M(KNWQC1MW44^,7@A'IXLREZW.-G!C)RG](86^8UR.C6?Q_K0^>1''WZX9S$5
M579);674_V@^'_KRVH^>35[L/)8L=>I.EZW)VY H_;,T0S+^8=W&]VL>8C*Q
M%T&8T+8@!<!.Y@-I<;(A3QQ*/,\R_EN7Z(O#D.)<#@I#Q52CED"2S7BJ'_5'
M[YL6/GNN9JA]@$+)5"H!+UF,I/L5]W_Y; !5V7BT\,&:TV+H#_CTMU_G'# 9
MT?8=>=ETJ\VYJB[-">:R:UCB]5]GOTEHBWN/-6400GFXA(#E["4!\(2Y0RU&
MIVG$UP=PCYP/]?,G.?H8P6S\(E=Z9'2?TJ9 7,?4YAO=LZBL\&]&4#'%K:JV
M<W=7Q(=OYNSK]Z8/LAR:5KS=Z'G8;*SIIF8L]N"SZ)B+=R.U,$Y<[1T(]>:Z
M( & S<>P1+D>D9_:JM(<68"8-QK3N<Q_RH=0\$N>M;3MQ/_0 \IS00 48KY3
MY_"_B)PH%\&+$P RR_$8T?CXSBN1F33ESU,157H6IN&TWIA2_X3 <(\MLD:V
MFO8O76*GY&HN$;1B@J[T+9]C,HE9R.V/)%?OK.QVPGMHAN4]/)AB)/JCA&P
MBR2.%('ZBW!K5L+/JM&C5Y1KNIV\;Q2/#C^./N[3FAYUK+;-??ODD]Q]$FN!
M+9]7$8E3A@5V6?!/3Y_.34A02^(ZG[VL30G./]Q(I8<G>?S?V2Y_ED"-C@@)
M5":F6W@=$7>=2,-RB*+Z-@AVH$&0_(3__\AV^Z>RM/[<P-^(]3_^NU_VY9/]
M6-R"D&0@^BJ0(AFJ&KL%P$%,K+I^<&QZ=I^)AB_"W3QP7J;&V4',=+CS\;[A
MN2R=-$<U 7!HPP%>+@QQ0\R.^^G[9^$7P/3N3(6=2IQ&#"C(TV&3;%_+4LA(
MAW!=?9C,R B$^Q</U)AM_&:<1W=FUJ'6,6X<5]KB16:N!1_W_70C=(XN\.X+
M)^R"(\7'[(P0Z4F!=V6/M[&P"X83B;!*B@BJH_%R.&IT>B(#1;X$:\]*>LB'
M]8/UWZ8\O.3T.S4,%X^GKH3)@V2XC2X[#VGKCID%.R=XJQTVHQ>X!,35X@S8
M FYWLQAV2:5(;-]FWD78$4SH1^P&TOTGW#NPEQIY<G'LT$;4@)*RIL>,_V?D
MSJ14+K:2RDV/Z>]$O<@Q$K\.:YR ,I\V?!IK'.)'QJSQ_FH>^ RD0B/.%=+6
MS1K#>R['R5 I+U[[3+E&PT?:8<X<_&^_^)R]P_M)PY")Z3Z5KC;>EHEFD?QR
M_6N+HSU&0UU!F>(%N3/?3BLZ=%A8H'U-FR@SBM6D??=!:)NSB>(WW  O5"ZK
M]L?MQ!A>Z%@;E$E8V#"=,-&CD D>GKK43G7_:B:K'Y7X7C,\X.:4J]+QM$/A
M*;!)>1&.?5_7\\G#QFU;Y2H,)ILH%X9,5%.'DX0D"F<X_1$TM2-V"J<I&&W@
MYZ.Y]]+CLA_UJU=?I[[Y"4W)+[MS</P^J>WC:RH76F43>W3'@GV$4G%1K,1A
M.%2$>9EXM<,<HR+Y1%;;PM JG';0OS)P12:WJ^OT26J!"'^U:NP.S+"B//TY
M:OIJB>3\HI-[48;72;E[9OP$[ :OI]:!%T_I?$Q-)G0V#G7PGL<:"0"+ZMIA
M/B8=K/S!.\N7YI\B?%]88(!VZMR@W^B!<V&Y\=FOF/&OVI3E??6W'?8W%:9_
M8A/]@OZ'FR$-0M#4B4:EA0K7=_%$2*2L=]K;G>O7][R\Y:>Y"9M,HK9W8 =.
M/N[QA*5R:[@0%Z5B6EQ%M0&ZI3U'96IJ7$OH<71L6)@+9RH/:5)2#F6(LV7Q
M84*.FC;4168(80M_5@#,R//XV\&E9Y@D%2Z9*WM' !CQMPBW$S69M.AV@T03
MFB>,!5X 4"7!N0X2J@8$(3,*.8@)Z@<!,,9;)( 1S_2%+#/(@9-9@JE4A@EA
M*(U:.20 ,)*LF Y22ZRN " O3>#Y,COP0O\S-3.9+0"X@\A.TAB-2KPAO$Z=
M^YE&6AQK%  +H(:3 #A?K "2N'B&Y?(#4F?DL]$L+)]#%=X5,C&3B!GC^(P)
M;PKG8UCXR6\#0GLQ \Z3QB:IE3%\'FE&X4-+'[7^\*!"3<5^8\,[S%%*;^F+
M)-4=_$?_A[TWCX?R;?_&IU3:I$U$3&D1A3:4929)DIA*2&)$R#(FV;).(BHQ
MH2)BR$X,6<8^24SV93 8C'T;8RRSF/V9/I_GN>_G_MWW_7R_]_/<O^?[>OU>
MOW^\7JXYK_.\KNL\SN-X'^=Y'.^CGQB>%#3SM,#UE*':N9=AGBV]OVP/RWCB
M2D9*B,21+K-N_HVMRMPJQ;I9&5C&E#/KW=T-#&D!0*5LFGQ(U$, N A,DM!B
M^D^8*.0P8#87ERK,)X$OB.O2R5Y)YMM3LY=\MURW=IA8)#S=&'Y4'I.4#W0N
MAW_1-9QJ!$$;&*CSO7H/]]>-6?,N_Y+(WHGY-/G=+UHDPBKDV!/3X#Z)PQE9
MZ0* 1\+B$VX/L*#0N!),$+JCERN3?B8]J'TD4<'V&/.?_2J'9:"8*-@Z[U(J
M/8+T'Q6H-GZWQR6-!EY!,TD0-P,-/(U&<R\SYSL&B0TB=@9;V-<]\3JO!FH?
M)LXD^?8]>ID1(5J]!]OJ46FK @Z;W1]O?:7ST)JJND9KL.Z,C(U3L<RU\1O[
MAK1#GZAUBO3*M"<9T-WG2+H_E<5I\;]XZ2R/M851D+( < $="3[R)&'(NKUJ
MN?;(8)D84R;.%OXYU-;./_]LPN33<^*E^9D!JIG?CZ$:0\Z*GN<85%(D[Z?[
M>@D >M?G,H Q8XA>31F8-L\Y$)NS\X'G#52;!P^U8@#GZ7A=DA0 3&KU:5R?
MK%,"0)Y.:.IT_@"B_ 64F<8/?BGZK&SU$W94G%75RO]<=92/Z+PI ,SU-R+H
M!E4(,U\@\R>V&-'9C_5OY//AS#B^>[6P-YZP2_#L'[(.9J<3$7W6#;P5#SZ=
MWWF?QP1RUA$U*;7\9+:JL#<CQ-S 3V%G6&%GXLQ&H5?)T0E@#B.HX_Q5?S)/
MDV:U Y$='0]FF9\%\FXOQ:X*!9V;WLFG@3O_LG#0!J/6$AJ$6K90N),8Y8<1
M!$0P/X\D +0(%RM5KR!Y7I2M) #4I(3=O&8AF9)ZJ0 ;GS9\\59JK;NH@M[[
M3" TYSD"26-$4]WCW26J7Z3WURI]JV/'F8AVO0 W],/;L:D"@!"!P2CBH9!%
M_^#:AXQ9LW];A,4?F\Y_Q#S_90>W'+$ )B&*&$E-\R::S3,'RE$L+1X3Q#O#
M W:3[:/]"^')I-:UPN!'E(8DAU 'ICGI"W0)_+!!86$3X.3Y/7O\YC(![(C=
M3PY71>[!*GH:DU03K:45UX!P$3+?) WQE)=)K.1+U$3IUI@./;%T.7D=9!/F
MQV)Y7TD^M6HTE;TZ0-'L>$E-1L<U>_?IV'[EDU<>T+JFGETR3K96R<S-EF]T
MOCN(+=#HO1FN9>)TW\H"FLBMM>!!9\E[U:-F$VH+AXVCYS,+MFZY9%X5D?/0
M1@3@H0UIT.W_.6)$#'(>M5*5&="!5#MK7".T6M:M?FS*^YC!4U3*W2 ?FX-,
MVX)C<[9!*4\IX;'']1%G@NU_T6.JS<GV==]53KOK;KHKH79'/ %DGV;*,>!O
MPW$0#G6J<A^@;Q J:6 "R@?)WX?'TW$C;.9EJ"_W\3P\-ND9Q69PT,LJ5MH;
M_[K#66HQ7#OH>C8ZFJXD)H3'$3S$7)[LDI$*S9\MMRDXT/_(*,L.E_2>J%/D
MH&WV37SJ&2("GY=! K?F3V7?_>6B*1YL%Q#A<D<(2V%)@SXX!T4J+EP[<H\K
M(O0RHF&@I_.9L]U*IF9$6KT 8+&XL&5&W-%FR-]*]N*8B\'4-40#@W8;H[*\
M""I/N,U$X.J&R3";F'L^%/.))@_7$#.I.P@B$%>R.47F\Y7IX.Y>URH8,;R!
MK^KM>)U^Y1!"A3J4GG,!>)B-5#AL.G#A@C=4**@>YP6 9H+(B/N1/8@<6A1L
MQA['Y4'B:C03M1!-UX<( L#.&# -4L6[2)\_>C!^17Q(TZ0O,'RA^?C*!&:7
MU3/SH)/S/C.C.<.A[/N3$ (/[A/]76_&<-XB0HUQ+9"C"QY#7XGN&4(I!3S5
M T*XT.'UA8/U%Y((&%&F4D(8=Z$<B3[0Q\=H!PSC+U>DC-?U* H <MD&5H@3
M<*M78*-'D8GB>[[S7IP]PBN=FZ:C5[_ECYB5$I.FD3 SN'>6F!4_DCW)XZP'
MB#/-S* 29A;R_3NV<<,9P)H9#_%'RM YM#A1 )#H;2CBZ,#<@[^LNX#T*X+K
MH3/76=YN6C(/*2H%0UZ<\X4^60J/89_UR%G?Q^;JFB05>*8R#X@\>SX8\K"V
M:27;Y1V Y:T&JPZ4N0G:"7K/$B_RPFQ[JGUUC0]>@3[VQD_.&X;R;[-?+R7_
MH[R9W^1#:1$])%0[=D*G$KT +A?.[MI\_1-1-E+?:(K:*I>]7EP2/4TJ.Q77
M.766/NNZN%//N64J?K7C^SZQX_PXGG&%I.A@;7BW,KTCK,UI_*@0,)R9DVW7
M'K%OZ8_R]?'*>W%?R?RY^)&99V.(I+Q# SSXJBNKA.E@,C8L44Q9RATJ,WJ;
MUZ$9%S;4._[\_DZI7L1K]VV&&^[*WD1T)MFH:8]@$BJ?*A_HVYO-:0F=TC'D
M!^EI@967@FDD<VMP]3M&CH2/QRW#2^,W[-[_:LXAN]B\F',O7B<1[G5\70C4
M&O-IVJY['J1[!WLT)@?YIFIAX0.MK[=/%;!#?+GL1;U6M!#%G[V^,P'8QNVT
MQ+?6Y#NU,&PV)XR=U0M9I<_!WWY4!P]-C D5/XPFU[+7V"GMJE 3&_<"X5Z=
M?Y]N_'\*Y/Z#;.;?W3_X5;L(IPF!T:_:R@M0ZE*!36XGZRV=X+](?0>6 'G3
MX)8:@::!7@UP;;GU^44E:;>WI3*?9MXY%C_!Y?ZLNW2/; :74<(<EC'Z_*&R
MT1NF0LHW>".?SWKWXP-0VUO.T_+CC^N%]J%-S=GBNF^[S--?ZGOV'@*N1:XK
MC]Z3Q>%UZ#S^7"6S?]_Q;T+5O 1+ BE]N#:6M<?,---++'/[M]"%UY?!74'
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M:M$?WJCF'BAB(Y"50-NA\1<=_!T(RVVT]5.K<\"J451>Z4?X??'S,Z)Z0)/
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M @!A'CN]!SLK]>=D"P6/A1TE\)^32?_/MB3L_]R4^3\UW2X _/ [">&UIUQ
M%/1XH/B0  QWM]A?Y&YSOP#P5\%[$L_?A[NA@AC,JU<K</7Z"D5QD0$$[NX=
MO]OSE_^4Z9/@;B1G0#B0OY)U]G+H+&2U+=9D:;ZP/[^%LO/>_>2&ZJJZ+UGA
MVH%B=OL\*/[OBG5V6#]S>-R^:+S..$KTJ[9G2O!3EH#;! ")L\BY:%F))2VY
MV98#,U8!;_"'+^*F]?@;Q8E]2P@51(H4/$G6TA*2W&CO0_5RNS[GK+5C&P;?
M8'#,#X,W_H 3";KP08R-XWS)B#ATEKDAX,,OO?>JCGMN&:SW/HGC16=$&\Z@
MR9NKOB66!*JMLA )K.BO%L.NO2&_S^K^_L#['Z.-?Q';",%5IJR#J 6;9!*T
MH!B<E/4J^\Y!%SGUJ/ R]^N_8R3[ASF])3S3N4#3"'-%&O[9\BSAR]KJ^4G)
M6]PL<B]YB31$L=8WW&$^<;ZWN&"+Z4&MP2AS4&V\_H5'I)YG7/8K*SDW+LZ[
MU>3HJ\!ZJ<.\VHV5K7&G+[$'"ZC?'1Y>B7IG,,A@T;]BGW"OLWRY)9@I7DGO
M)>['Q84/T-4H5CCN7&Y(>QTA<(QDJJC -QT=2[K7%!P7%,Z"847NW(=.R.EU
MB:LN!R4_#.91PF<I;G4JO;NM[F2=;XP"*5I%^B_(CJ:^B;.#2B 2+6XP7>Q\
M?%W*M7*KKZ0%=P*9:EG:<E<U))L(J[TDFX?Y51[-E2)$2<ZFYZ+9#QL1V[@"
M0&=7:QP/3ZP,B<JUQ1S>VQVK%D*&G(7>9(?T90H *0) $ )=A&M80]_![JK
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MAGEB=>?SLI5HV5QQ!*]6$DP%KT"\5Z:#I3B:Q9'UZZ_!SNAU?X_W!^N*AP6
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M9)W./P>J[[_.<5B\-M(LTE2QQ7D^WL45G/ =>!@TM+(P?/66VN736[Y< @@
M$(^:JFD=WJ.]ZP<::.#XVU%+ES!@*+V6VK3"[L%_M6'V_5O)9?^)K?VG)ERM
MD_9')/&; -<YMNO:/!"KOJN!8IP;,V =AU&?80WZ^>YS5%]:S<[JG)QUD-SY
MIBWVJ/B"U!X$G5=8/()6%PVWLKQR<R#*1'<^*<?V\[JI!44*C+I:XB8$V-#I
M\5+?35JM&U9.%<:#]>^XV*&.R$$4C9A7IC9$Y^?G9SIHR^S]+@ \9US ,O=]
MF@&)M$LI\]+2^-9A7A!X,\<!LXX3+[X+)%[V!Y<N2]_POWBX[-!=/=3X# G*
M1-EJO:[#XI:=EFAS>IL_)N[5TE3VZXR [O$U6= )J0P^Z]7O&;R??Y@3>;1X
M1:U,C*]V]G2P2G!&#)UQ/#39-Z@0/W^TYBUR0FD;KW1.1T,%1M"0 [\8:#K+
M43+6O+!;=[.LSOXSR&\<(X3XQ6Y; W!LT#LB<J/ADKO3W,S1//&-&QB$UB\-
M[];]5LZKU9"*GF)E-.^7!"I;YFM5E3R:X,\NQ2==\ \T$4,_#8MKGAWD82ZZ
M^RP'7?JTC:\LCQV;0[.+,0\ZH9O+\+,-:<2GL*"RFJ)/UK55RPG6!(ROV.',
MEG&,\?$34R^^?'JVQ>5&EOD6 <#D(EB7QC!PK3#<C$/*]$,UI^2B'".:PG1I
M4_Y[W@1W/+\):0"_(B+<E@I>OEPG]$I%96)+Q:AE.>5!:AL)KW#)^H$%I\";
M'@#TD?*CG9FS.KBF<R^J('LNGV)T[7IM.TVV2M ^NN\NHA$!"GN ,:3Q?7WH
M3;1V^E)?,WQ7IG^BS;>._HE$I=HRH_?P3< ?O<#!E?+8JI!3V>&B0U),J]9(
MW^@3T@EC+"3=-'NI8,(RE2=R/=P ;<V(N.D-];AC6\PK(!!=BW-\HN$<4AAN
MR<UJ>LMYA=? 2LOK]B4]^0"5>,# 7E =GL)DOFMAOPPF'<4S^V]A0S-Z*G+6
MI'C9N16%N61M2?O9 ,]M1<L)P6VC=TL'@NBU)XM/LVY^E4J63]1\[;[W_$G]
MRHV4>@' TMZ=N5WE,.#NQ-%9$Q0*]JKE6UQ(,GB!XS_>7VO<QU/#9!&3#8J+
MB HB']NG?<T<=[C:H?:(F5LII;GFAU[_F9]A^QRP'0#8)?HMJ9+J*S5_<?LI
MEG=0W:C,2?(>='S;KBJBM7X_\7P@=5?W$%'<=8Q)=0(I8V:8]790V;AVQ Z-
M"&K2?) >(6,''X[#P'T_^<IXPKU/;E&YD(K.-K:D=#_[86NLG9_H]6:4) 2Y
M/BHTG(^X+4WC#MR:@I1$/EU*CGC]->\=7UK?STPI,GB'.#VB1,O&L39<?&/3
MO/39YXVZX#$!P*(U8](AZL1*7L.4.#NW9]:-#K&&Z?35869(0S*FHE4!NAZG
M!OT^!ROGN*PY2=[LO9M^,H++SI-T[-J@'4=7&(3ASBK/Z9_?SDK91']<3K0Z
M>.*C*FAC63:[UK^]GV=!D-4OSRTWN ,+RB4$W.MS8!Y+4"YX$V@LTSMS=WM5
MN?-!9.(%P(: #>N #90"@F\T+4AW__Q(#0XX;W#GV5TZ">JM8.9]LC,%/6AE
M\3!YONJI%=6KL6P%_?J@]D<+O(H)NCFGT5+*25Y+ '!]OD&$6-VQ IJ^I7_>
M].9=-CW_U,FOSN.)7:8@5(F.P9"L4;_,/A_&+OJ@EH(KQ5KX?B]"G_BHDW],
M0L7573!R[<?B+$ZIY=D[.BIGC<420(4PSS9HS0>8^_/MG]XB?P8'W>GHT3KH
ME+L>(9)HS]-+[:@>1_[,&UD,D,9,4(T=?6N<F1$Z5M\\[#PM^+TAVDYL=B68
MS#F#3/&];O%=HWB.K[P1.S:O0+?K>GN9A&G-S  #V9JG,8[N%ZO0#KB/E#:8
MN@AF89H8W:<5G?(QB3)Z*/'%@:=W1^=$]CDZ*O11=DVV2?KD.KD>__X>\]-Y
MQ920Z<.Y>15A>_E!X3._R0QUJ_&(GU\9X,<]CG7JM/[[\04G3Q99!SX-0AB]
MY^RTELQ3NF%TXV:12V7UL/5KAV.<\]JL"OT)WJ'&&/T#>6=.3=]NR&B(+X )
M )B7WSRO7/SMG5_2UX?HBITX%QX)-([.3KMPP>O"YF*O]^^Q"Y62E1@.F;/S
MP0GD2G5*U#CR^T\)4)U3[@.$T[PG?QU1P[$O6?8:6Q'B03:<D?XG(96F@0"P
M,0<[_5IH,T 4&.YWM;YYG<X&/OIV5_-B4-<_KI4[IS&,6O$&,PK M+,,O5H/
MH<QF7ZN&BM/]:?$,V;G.?T(N_U]1*.L_4]WV)\E< +!&C-;6:L@E(0OE!N<[
M_KW&^K=C_ ^(E?Z&3NFOAPQ_H3CZ/QG\/W#8_T@X^+NHD\_(+D0=5]P-*_?Y
MVR0?;5)FS/=J:^;6^^\5RIZL4U_J/81Q@RI^U)H#<N#5!T'IOG1D#7_#\*(
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MB/P"4>!(W)U$RGCN^'&5G:.]B=W>S=V9Q9SHP  ")+9>NDX1O6#]\-6=^M8
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MZ!^29Q=@.FN9B=6*YF:I#S\\K\FC(Y)VZV,.H%/M<YT1@&S_5T#QL%'[T6.
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MB5+_)45.N1<UUSK5:_1$K*M7H_#.('N4$KS(<\]?;RQS8JG1R.7\WHW>VRS
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MGB<99MPL@\T^ 79P>NXY&EHMD-'N>^6O#GB8'-]67[-P2[TOUG[1*F\Q/ZM
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MN%U(DAA_J9*&XXX<-S.J1VE;O':_#*ZK.W2;NBJBFQRA<7K@[7QQV[GY[Q.
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MO!<8/<-S8?8%R()0*2=;5"OR/EP:,GLAP,'N4A,"!UROVA%L>2:[)R;R##X
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M0X0F[LZM?LCYKVY(^_^A.?S_E26HSQX(6$L#H?XW#S\,^\"^9A/- 1RKZ^4
M*I4RNI7Q9/Z'C^CP7."TZ--N+FYD?(9ZP16F;@TK=_W<@W<2P)[LS56M*M[O
M#$B'ZA5,?+S\GC=%+ Z^@= ^N@6D?QW?9+6/!7$#4DWI(EN*++A6_EXU%+'!
ME^B)SS6B<?=1IVCW\:MN,Y:<%X00=JF\)52YJE5U %@*S[#8^C3*^C 2ING)
M 4A,]%<'T@B3C%0/>ZZB-Z@T[\>(O&[OUM=\5"TNE%A]8^YQCH;$74+Z)> $
M+4/TZB\JU^= [F$M)/-9A6ROHB9Z' >@;%?"M@&>"P0^]9ZH,ZJ*U-G1[F^5
MUPVW;JY[]%5UE1QQ_JB%H(8ABZP\V6BNUJ!PLTC+J.Z\A.7SMZL>\ZD,6"<+
MMKQ-&KWRQ_>W&!CK@L?_\=U>+H8DP"AI=!,"[-HS2(\+_>>@\S+[P1KN$59G
M&ZQY!F]2+O@ 5M;J_"PA!CZU-7/UGL_TIITBPQ9J:]WH\+RX=M,!T8@Y1^$Z
MM"1]S9RPN5MLF N=3;03\AV'7:@7"<\>%^UGEI9P %=]=N'QHM^'">N/O<0J
M5SK&7M3\5/STY^83I\ST(=5;E#/^QV7$KSVOU!4QHX;)E)8K-_6DR<SWM:-N
MGFCV$9A19VXBP>7G1]0BL>S3HTRRJL[,NO9:&BQDV[MK=V\HM42*(>XY\RQL
M^)SF"/V<[^<[?K]\U?_HZYJ=*+X_G7?"_+6&9?&1DA6D\"FG[7R&JMS^6$AB
M,!<=47U7X%7?KYL.->2]N'?G\&2CB>8VZ[PX'%P?";L5BBQ0P[ %<"75377Y
M-T+6,-V+U5=R:SS67!UB/\A:O!W]10U>#?"XR1[O-9L3$+_^,B=*X-@^<&L)
MR/0T!4U9 C=_W)-"S=M%>^]:\C\(@-IZ0%^!UH<)"NZKX(74"DQN*ZJ+K(_5
M+U\I*%$SR,BH?W/.0MA#Z/3GREQU 6VCDZ5Y_ZQZ3:Y<-A&+8L4B:Q -DI<W
M\,!+P<C.S+^=MY39T+F@K</LAR)AI9GY>1T[WLW ]R=HZE:"PXJ#:@2_P?-S
MIU*/8N.MWX:P_UP8)Q*&D#QSD,[^9W"WICTGD_XWJJ,N](F H>9=,V8&V*U[
M8Q%53?CNML6P0 <^V>SVIPW@/%(J&H<6+S;TE/<Y]*D4N. Z!M9E*.#YSE/0
M0SX=7I+966!-VG9)?^,=0Z0"A5)T8XMM>Y #V$CU?LL!G'&')%@8K9VMQN<S
MCH(H8H4_4>NKL>MCNQ,3H AS%<61P88!D%V,HNG9@6NN E$RU3?8.;9=#4_$
M(LP/>AY^]9&/!R$&R5 =QM"MUKJ'-U/G(,RK>CG@&T\4>OW1L' SNE]5A9*8
MRA7W_+R5O9Y"<:UR"L\=4T;E4D&!JZ"]W$L=0P_/U4:#Z8\#P!%5;<C#]YL'
M(_O9Z/E!%+SQ7N1M)GR<>(C16;&5"BS:27)=Y]OHHKZA=7BQ2C1J)3X<^-@\
M*YQTZ%J D[3AL.R]^%^ R?RTZ_6I#(U*/=GJH0L@=>S@8M_;(PFO\\\;'#DW
M/4\R> >CV*_859*\=TT176(%I.5'3X"%-%%@Y_DK78V.$K&JZIZ""O(?>V,^
MQCI&BXKK'8YS3SA,O!NA\FY:6Z?%$!*WC+L6:7\::JQ#WSL#3_ 8@T\;8;NR
M60<T*>'PHJR+.ER1TO*G!\60=^ =H0Y2BBE[)"XLW1YE=A9$P1LQ8$#(/[VB
MWDTW3'Q]CBE]=:B%-UB&><"=V>@DJ,HIL X[D@09)OCQ4Z+9 J0Q@LW\X=Z6
MM7')1Q:!^ZF1/9.[)$E<*=5NX+U^H7F"L6NLY=3]EF"3YOCO3XZ-15=W2KX^
M[MBC#T'J)_2Y-KZ DG/@C:&CP)KZPW"I!QQ NJT:Q:(*VXNT9':AOHW1(_-;
M6@@)+!F3Y%17"\1T5>6&:;^#?:?3W(_#R:8ZDK%9NEF J]C2N=H,/](BJ>^=
M^)T;X[=,!Y!EL?#'RR]J@)T<@ ;2(\?+B2TRW.'- ;SM #X)Y !&^3&Y0C,<
M@!MQ"G0 *!GJ75Q#8 NL_ZHFEBNW*@1[/-B;K!X_=QR%Q"EKQU9[Y@SCQ.^6
M^W_;RXPM39&RNJ_\CX:@)$$0<VERY$'P,6J^C()CS''P.#6)+;!OB*L&\*]$
M2C/1YJ@+>2*I:J? 8S3HL(O;C%1%.SK5V7OYG\U^4UX(X<';4YEZ/_=4B2__
MX;?J\KIX:'/,70-JA[F9G*VDM+:E1#'!;9$<F9V!%00Z%Q?SUN\6_H%=<.4
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M&%0Q=C?R%HWRJ!\E)UL8^[-=%CJ6\O@3T(5:XL@-;SNZ=M[;7I\C5*EG)6Y
MYICI5YKCX>B*N 5DCLGO?<MWX@O"Z"OUJT<Y@'8B$K<X]O4)"\A3L \%\MFV
M8<!6'H71L$.;U7ZM+9#N88T"^RNACC18ZJ-(Z/"$\-QXH'\7%[(O3?AR3<B.
M2);<(G>V8X/AGH/[E\ZN*$*-A [7B&_/]D&'61C,H8&F:+IJ8-0/0>]J1BSD
M[Y0X<-(>0X\#.$)"(BVG$QK8CJP7F(KE6\>H;K$'0 ]2U]P*(J=>+%=5"7$
M[X0P=;;0F<BR[5U8;DOERMM^W#(6PN6%:+(IYCKU^SX.P#QT)JWTN<768^]=
M]"_R/^+;H4:0\U1Y0H3$?\S4O^%^P1?, H/8XN &[D=%9HW5V.5#3M(0&[&_
MWG$ KP)B;/CI65)[RJ<=X+6&:U@'4,-2+[,;GJ2EC 5P  ]5_QZ?#PVQJI@X
MG3WT]C,;#@!<U0B?K%L/8>,I*V&1$D!O.K_-P!*,Q-Y:C;YG*QI,%.]'C#G!
MY_4D.8 ,9 !K,@+>-%3_$UZ0[B[/G(8G8;@8U'ZB+GFD+YS[\CO$SJ,.VYYB
MNY,,'2^G+PHU-;Z>>3?-!K=E8]^K#4D+N]WY[*3HF DHY:UJJYKX\=/&AXFU
M9T><;HO7?S#W69/V>87TP%\;/GWV3&]3'[!+&;AC)A2RW:C!@K27?%W",9QE
MUL,6&]AHI!TA\B*=RX1#Z]&)6  V@28I,@F7CS1AWE\Z1GURU'VMY\\:N&-<
MS>'>C_Q;[XUV%,[$ECB$=@PE(;7*3P4_ ?\9LWO8:YXN75WQ\41!Y*/#/'@Q
M6W<"=X/[=[6&@5?9FD&PK5>3$*#J5GXH0VA$*4QF6L7 \]&!F1MGWVU\+!E8
MN__--;7;Z&/6TWSSDF3,1)W9G6OM#MBP2N5-(#]P&4TA2>1@/TRP"^PC^T(G
M*K5"4Z%L'L0N\G'E-%HGZ'!TD9H*<6N*_;@<WNTXAZ;,[*YL>N<PT*'3*D/K
M*]"8/]?.7;LV8#82;)^OA@B<(UR]Y*$LSB]G'KKXSQN]'TY+V!+Y/QK3[ESJ
MY9(I+WQGK\#]CD'D'0X@J3//YB@=!U?DG]_96BFJO\0!W);],B#R 0V^._>S
ML"2L)D^Y[K#\KJD(ZG)E];&,FRA186,GW[.K724X6ZC%0_<+5@>6?\XWN1QO
MG(V>9Z-W"_R7]2\;FU6R0^C"B\RJXM#KD!X%^CSS$]L*V\6?%:E&Q3V@XKT#
MBCF %<^BFE+"LX?*VI[X3^UKPM5CAUIFW&?;,B]U&R>D>-_+'A&]_%*TLJ)2
M<<K4,(#D-6\EK<LC#O14M0N(QJ,7$!NPV;_([RNP)]J)&CBP,E&H/ PY%^KX
M _*\=_YF53?5[%H"(_3:&^'BXI,ZI_HOWRQR5W++3\PISZLBKNT^,KOQ&UY(
M648'7-:.BM%_J@<XK(Y'\_K?"^3!XW>-USO KSK@-\2>D_ Q87JS#_U#(F9+
MZB'*X[BAA2#M T^[+Q05?A.@\J>W:9YJ/'.U^/G@3<R(9EX!(\1SYBT).(?:
M6LY]<F3F-(5IAN^RA\L5*] =X:H]J?2MC2!,O<FZAY*DT=KZAQHXZ!-=8WB;
M;M9N,KNT<?;=L_Q/#2TV(C=P3XZ+%*D&CVGE#^H&^ML(3'IJEW_(4=Y)F04\
MJ>6GDW \!<]V2YA#6"1F2XN8CB1".G=0]2JKZ/<39M4%FY4&962FK7AGM?3=
M<N-I;*U C-A=E)+)W5<#NAHF.IH/FS3CG[]TJXB[*\T!X*/O#SWY_(Z"2O>E
MV?N;8:?5;&.JU++H%.;6Z@2AQ#TT*33P2OL:&5=;/7P1W8DI_:K?\.#964S$
M@SZ)0ZX75 8'M>B7&173YX+O(\BBQK?W*T$[R3,\%CK,+QQ VM^L:1"E9@&G
M&V372B)C*NIOW85Y/5%=Y+%Y59"@5?/LK+D;7=JM=-_GU?POE@63#5!)H\N$
MW,E/-FS8 A?5ZI&OQ.4*NUOWQ[CCAE>7M8_2:YF?VKFPYKD"MJ/4$S'8NRTH
MAY90 J]^.&W!6O[B,NJ?^LGF(O.^8S.Q65H)1NYX&>*-PK#?0/9GF)'0>5G+
M6]_ _D6JQR#)T*T8^KM4MKT_L*.,KD]-;)F$7/)5#.#YI?:AY.-MM^/83PR-
MN!]9.;D%R;-2I(U;?PIA%C8'JB[W]3?&21 (D>,%]8I$(;L4%_EI%/]%-M\9
M)6Z(@UB"A>$WB OD?F(7_[X-(/UKN%]KX) X_(^C^P;R:N1MZEQIK\.;K5/%
MXC=LK3Y8_BQ7\Z/-91> I4/'PP,=!/$GR\F_K-U/"DSQH&UT14N94K DI#!]
MBAT>P?4)6RO2D&E=Q(9SY/5PW9P67H],Y"?'O&F#+LOA)Z;#R:TK%.$7'(!T
M-3/P#'PE-3]^[">)OMU3#7*+/!',#E<]7O\ #H*G1S@S)VL0=)]M6 L[9_U]
MF[24,L\=>ZFL H)5:'I[4H-#Z:^0\VPK2DF?%F;3H(HW[?D_.?D/W'VN&:FK
MA8L)8N72-N?DC?5=[2!<]2GL_R8=3>^ *Q-? +N:<B,EX$JB-7]$T$5LK7G:
MO5OJ'("19X=Z>'"7BOTP-"JWW7/\RT$C4R?'[VV%_>WZ7UX:MTH.';!\[>[L
M&2#P3T&_9%< ]-Q4?('?(]^<B..A:AQ CPJ]+3QY=X52F ])1%.61L[RM=$+
M"2[NNFD]7A[^5LQ(@1V5](W*/=YS$U>=BRT?9U27NN$24UZF*-E>%O)^>JWB
M][[3OG2V+<3/AQ(DX8H3^YK?&HY87:ZK]X:K8A>#F/DTY:85(A=Y .NOK<>V
MKO(NC]<WT"^^:N*"1<*Y-#O5=X^[R.UYUP-,3:^O'5-R;7$#7QW,3SXHIJ(M
M/57^TM?T7T?T!I1:ISGV/02>"V$E;1*IAU?;U]E9RQ/T%,6SJ_7LE;H/]0J2
M)[Y+Z9NO?PN=VGCA<_85$$KV 47G7!G.TC/;? >[JX,7-<5ME;*]%(D=R$S:
M8>B3 !JP@JT=- 2[6+8'=%Z[5#+K2E+>A$2DHRT?6 P:%Y@[9N5FF=?9.NKD
M-8,>HKU_"NU'96."0G7I$=AEG.GF"#=BPZ<? @^5U"E1(/,\&MNH-K%D\D3#
MQQ:G/?'\BO,A(!PF-4!R\ZSOYXH1Q&Z%VJ61]5M1C\I_D6Z5FWJU=:Z2B\BV
M/$T/-QFJ^L7^>0+HCGJ=1:/Y#)"8]\)7YGJ8^&RLS S/W7"9I56\??@HO;""
MED@=B7 A6%I7%M BU2+<LG%]SH&4!Y=2P<^D>]]*)C?&:%/+K4=/E(J \J!L
M*"3))H/1F.]U )'$>SX."7GDTI\9DL#V '8SZ";AT4LQJ<S9T"T4@V>6 VA;
MG6[I#=+1G[XQH+2K^FY,L1B%2N(M,3$=F'8JMI*^6G!U(ALE12L]=(1LUC-Z
M9A9#-XF>7QQ.),V*HK:Z9;9XF.+T_DPN8N:M*,@MH&\RLR<3"X275?._M1E:
M&%EJ@$"1.P2*#%\P5VLK,-7D$TO03B;+/"3@/KS?AP,(699G2G>O,[FH]<N^
M/0&"OWT4>Q KE<I:8H1YKVG2X4E%!I.W>081NT)%FS=-W K:(HZ7<^$Q$_2J
M..;R$IO :EV6_'\6J?W_<V]3^?1?MUO_D^00V"HVN$>LDJ%J!%GG@>IL$>0'
MDAQ=$:Y 6:Z_L6Q1O8W_UP0XJRNVE\:B(7^ N\BP/Q;O2/VW19_</#K6S(ZH
M.>I8\*Y M8G$$R?!%<@%QG@W5=1#STXTH C^MQ ?L8NJ60&%P0C,ZJXG0F*)
M*EPZ1#B!>C'45=Z^(E_M/VRDA&; &+Y_SZD*K4C=<&_*RH5W%O'!&"IVF!5=
MK:>"& 2@K?[UA5-<T]Q![@Z7BT%L<,8@U(JM3QG7K_SM!8QA>F%BJQB.1?_K
MO0"O]^YIQ-^.1F:N;+M\OR863.X-UG$MRO;?7@9H>"UR !^^<0#E3SF [Q&O
M@Q"4[2 ,')F+= +)_E=WW_O/6LA-RSDS^L@<)O2/]8.TX@,2=_?-P:NL+_+O
M$0TA0WL,(R?V^3KS8/50()02@.:G:+'U10>9!1A\IVWO&*M\(")?@R(G6RYV
MD$KFLTY=S<U"=^A?+6)+0D]H:16*)>KLL3,U#FKYA4H^C$@7LK8F)1R;&H[^
M!GZU1X5&Z'"!,H+MCA7903MZPSY"NA8+]OAE1O%J7BD]%=W>HI]A,$U9?SJO
M=7C2F-&[\*?]]V=NSD>HCW]@A 0]E;".Y^E ,:-RC__*D$L>C'6WYJ=D_(#-
M\%-2V4&@VQ3WG!J;.96MT+8@C!:5O=.Z9M"W#-U&UM]T4?N0E5-$F=52\M#5
MN9$.DBZZ(.PTN(VM6,/<%YI1FEZ =PYE83X-2,>UIG\+KT78F'1^RBLG46XK
ML#1@&QP ;/28D(*_AR>7.EDP0*XH9A]D6HT(@B2[X(_3*</GMD2R*R(//XKE
MC<KT.=>V ]F4Q;P:XS\]DT]M.)AY+,7TB(QE\V1^[<?[4@XA8O2#D?[MD&6<
M5M]HVT"3SX$#>#Q^.!N%P^]"@5N/ES/8I,FA5>1"=$40&S\"RBG;R5@:I=#X
M.("B\$$QM8NBMOK_;-TKJ9D[:6NJ*_U&OM#PTC0AO8-G1H.%72"]+9*XQ=M$
M@R,7>S?8;L V9=A7#N#*)NPV6#3\W8_=%UO2+U'G;W[=XU5M*[D=VEW0D1"2
M7.ACWOE8 6L?=P&LK%0X=4AS638OR-_/Z",K 5P'4DHKX=LT,KAU:WO[@D5,
ML/WV6[8M?".=-=P+O)97'\(!7/=.L(*FP"4K)B-303^7\W/:G)[F411YLT13
M.YP5<+NY>N+W_.N.*RHVG-)"Z"FG2Z1.]!YTDM_#>AMH/I;A/]ER2)UU*P0>
MW5F4A052A)C04L@VL#.G'IY$5Z5/PF\B$+>(7Y ;^:ZJO.AP[\E"M1E$H2-A
MXL/0%[%K0P=N8&@.@S.E \?.665$7=Q_TL4.DE/WT3.E!-'YC4[&?W,D+8>6
M=P!W#=8[L0F0JZJX"@X@97&+'S$_;+H=\Z"^=<0&ZCGTV.W9]HCP=BJ9\G;[
MUTB7EI+[+N'"YOOW5>^>:I;4,'3DR,),[?IZK$MG3J'KS&,MT'4 <^E99$\,
M>DN%K3>!W\+2WX:KT+\,@W(&;)U+(N5F5&N.?QT-0XDD/BSW':F)1?D\N%&H
MC="ZQ3ARXLZI3,@#! G^U&,',.,M+<R-0HZ%^"?B.6YNT$^W6?5U,)[@ !UK
MYKL5OE92_1 !.%E?3(XH21H5F3UD=N&5J>&"F=E'ER69V=YSV3--2UJ5--OC
M@W+'LN$MV\ZR7^/WW96&N' YN:EL'=?8EMG.V%-9JY'Y[$? [@^2_5C!,*AD
M? H6O4,CMO]9R />4G_X25]3RT)7[-[OB[D" R:S;M).)LZ&<P=V59PK?T.Z
MWK.R,J-_QE\X*A?YVW7K(!)?"&=;0#H.S.(HC4MKOU=JS4TN3HJ^GNQ5VQEV
M6D\+FT'ZF.C?+ZZT#K48VK9,4"K??U_TM;XA),3"B;< !EY6?^"?>?3*X5JI
MN+_5!%&T &,U'?;I\BW$#-"/-J1'AW$ "KS8#T@11D9Q"BK$(WVXW/V93?3)
M^_&U9%'5(O'90C??Z[<>1MX_'^ JWGKLX8^(8MMV$02YZ :=+T6Y3VN#%UF:
MB?VZY,RV(&X@Y1K9UO"NL&?A6!PSFB!:U/\EW;6.]N0P G3(OV:FM":R;V;H
M48_5F'(K9GS!OOT!13U>GK0]'K66)/)<Q@C'@BW/#I)E7^%1ZI &31PK-C72
M@4LYX&"=)]CD)R2V([ 3ON!U>@;I0;,UF)X(6Q&M]0FH,LUM7Y-6RNG4>Y<1
M+]QOH9F<!IW/_-'Z7/BN@*T<7Y'*G4[8C87CD/:A[%\L_8.AO@ .("'49;'I
MVZ(3O/$9^*&G]X+L)GRQ@DIO^4 _5*NZ'N[1,TX_5*T6Y#V_^76B/8F@A-\Y
M2Z[B[>, ^'-:<7<&%+=U9?55:]H]I0L*SB?Y:?"5T>A[PWB$?L29UQV&](^&
M+XP>_IEEII]'+GQ@QDK0OU)T')F;NR$4!;4-Q@*MZ];3BY/4L]5CJW9//>V1
MC86+C#,I6*&DS-;ON=(;F,G^S(CN2U8?^HC/!IZ.L+!S6]P@22(%LHX6J\:1
M$!NGFYCG%?[P;^+8IS<G:SXO!';02<PA\!/#\!YR\8].\L<DN]4BS(N-J=G"
ML4-N/\N<YHK>I"@@6H;$!RIN1ITX=(^MHMK[3AX\STL?7MUBP <;LW(%^^ZJ
M):"[_IBLHI"KJ//;CS$6%/\U3SR36K&SY9Y+GLPS0#8WE,=[%:!S.G!5<Z@Q
MAK%L]2K$<==1S;R1#UO;GQ>5.USZN#;:ZGYK/+R]+Z<D:XE^<OX!$K\X=+R;
MF:K6"6)NEP"[,Y(PJF6L,].+WW/SEOT^='  P=FQ42[0*-]Y!GPZ$E83D"<G
MK4CXA'S>K)8 T\-1ND-W^HRH+M'S)@B[3 [@%GZN<YP#Z*J9PS75[ZY$SI,F
M2QK#W5-@ZX)CJ^?-3<TM=)47L_#7<>^%0V8W]^E-ESV(MGENW=I KM\6B;"+
M8G( BRO&!'//V[>+?,*?4\723^)W#?$F'(!\SPI=IU<QM68A#;X?F^QM3;;]
M7!F*+@G*;9U0&CE/$Y>R[K/_7HB?>=IA:#93^LGL1XCX=<7E@G*ARPFPBLI@
MGCB@=!1#)B-^(NLRJNM4Y!_W#$7<XN 1.*CX$UG_ZZ#MH>IZ"[C"!(;9P+;R
M2B?)]8W4\.=M!=?V$ EJ5Q+?.X(<C(R"%\)S+:YM&]'-OP:,? ^JI!5,)LS"
M>K"_.(#/V7ADHP5Y']=3P^7J$5@A&LW")=QFE_BK-&'F_%#ODM@W0NK+N&C%
M\I&BPH^G[S;MQ=G#<2.JS!W_B^7L[OI^MMA[X)8>V\I6EMD7>5NOMZX,]GF$
M7I>#M)T=G/B*N>$[7U"Q8&Z9$7OW5_S-B%:^$B?G@MR8YO=FMOJ[\N2D20!>
MMUCV8S1PF0-P*3@RCMQ(XP 6?"F2#@%)K>AD9'?\YY_UYZC:VF]0'AYU-9B;
M9B%Q.F^U$8(27+"B>Y]:J%4@;=XVMR+X,54G8#"/')0<?CW /L2IGV5%.A;H
MI;M/'WI^'VP1-C_X*YS*UL8*L9W"I4CR;]64T;*]2C"!I_;-3.?5&.Q=PLLL
MX$'%%5'_<V\?.X?'*/L<D'#]H*=E4US$4Y1UU7/'IQM*A1?4R:BY!I?[YK=M
ML[#R\E"DV6-;KH/&TSD 2I):GXT./8$#4#RT1HP% K-?1F!**\0@DGPS*2FR
M-Q1/6SA)?6/PIB6"K-.?G7Z_-_A>;\G^>=BCU.KNAQNM?HA1MEA\+E&"[XL2
M^IN NGJLZ^!+N)K\W&@]Y&N2-O,A"8D062G8TSNRB5&HS'V96E)P<W0YY/KV
MK="'9L=ESR=\ZNE[;Z3_/<D ;<& _@K3&HZY:'>6 >+'H[P\PZ4_-W_2YR%L
MT;=?LSUA[7K<J)+<8S,E ;7=D8=ZB&\P7!__5*L**E:Y9B%O$8/<'P.^;*AE
M$BJ(..]Q+>T-Q!C$\*S+0W6DP4=6A@6GW]WN%)Q^!,3'JHZ:ZBWFAV9X>5(7
M5U95Y!1Z?USB"L "_:ANN.C?=Y/XKQZ";4(],S?^N1L[IK/+BJC]U"UO]HJE
M8N8W"N_&S4*M:$2G[70=6^;GR;"L0H5R$9U K+7_JDWI5QG7_*YCG9>5VAHT
M"T=?4(_"8<^4)\A?YN>KZFYKX'0O\R_^,5Y/R7IC](^T]+[N\"TFZ$H^!Y!&
M;%IZ=K9:E%3.OK]=)ZB-6LW'X#VW/>U$CI6[TQ4:#+=.0)2-B0/\;F@0NOH-
MY%Q-Q%%37E;5<B*3!*0!\NG[W9F_@?BLADG8I3U&IFID:HU?LBT=6^&L#7/6
MBQ55>LEF.A4<IG_:E7%US;>[A10A.1MV.[ SX!<*/5\&U&[HW_\VG3*<19MP
MN!^N<<?/>O@,90NO+7RD?#8/A>(&K-J0=E_\'RX]QHK]L?.LOD**>,T!#!R
MB@\T[.'WB)M0URO+;%L_&L[Z?V:0_M\2.:]%>%.""M7<Z\*&9W,G<B<*1R!
MX'$Q6I*O9TY6\_T@M[Q7CI(/,BG/H6(:*X=7J+2KX[>?>1;?6DN:X<(7 N^V
MB7N]EN^%MQMVY[COS!(RN_TFH[34T<WM^DW@FOKXN"4<\[>G! ACP]ZH[F6C
M[6+03_J]KBSQ[6X24Z%ST7:S#!5G<OI.&6UN-+W]%?O0*,$<%)/ B$%9G?=F
MZYQ6]-0NO' B=6-63X0!@Y=W8M!ORG.@)PT^DW>(Y@-NYL^GAID@?HR)N[L@
MY"[/(@M1BD?M^?9]^0!VR0>/+*?_6S4R@BX!5R&3B'(AX"B\<+BP!;<%G%KZ
MY07]S JJ !L&K#>_'SL^4(<:)4CZT91'W8ZYX5Z<)9>+E[U?+FV\O_S173G7
M[*>RRL(D_ML\-:5+-_W>:0J7K+Y?BK<=_)ASXX[KU@P$WYL\'<\!Q,#7-4=\
MG?>\8J?/X(PC^@O^8^7^XS@&V9*N4>, 3B+M.8!UB!'9%FV*?,O0V=6QYK*V
MQEN0V0;V4R(-M8)D-4UD--L@SF('YU2OEK&[(K(R@[B>[#-]<_/H%,HQG%1$
M=YZLL<AVK3F<Y62RFL(:C.Z:-Z]_).@B*6O<>./6WK"PD?YHPM$/)\G.U,JJ
M,Y!E5KKQF,EAG;SM;?"O%3^O!+8_K)-G#NKID9% \DZ:\!QAI8]4?7\SFBI_
M^I>*\A6WO<2LFY?U)2(G8]-D?A]SC L3\?5;3; LK] IDLGXF#(CM6+H:](<
MXC)<H(WG?KL'V'X!T^,=P $T-0=Y7CL7,?%UPM"^-@S1DJD>E_S[M]<)19O>
M]KE8/;^ ]HB#AJ0\X+7^;-/D;H/U><8MZB^,JV&1$&ZR(S/QA]/R#=NC(V=@
M<!L2 SMM$Y@K?NM@1 BX\S%<E.N$#3Y.BOUV??"3[3F4#=GXZ$V/!W:Y< "G
M$5 .8 T#(?_MG("@AF[#RIGN7+>/KQ.&[YHOMJVBH7!9SYR^W2,R5RFPJVJH
M([\H90W7 +HO1FYQ +,!;3I#@P)2,5$DO\Q.+]FZ%%DEKI_<J]Q>F MS)_UF
ME7, *A:OF36JIX]O!DVAFWM>-QK^\VVD[L P?%+5D9^0797>??]92 =B^5Z5
M=7LVC/8%EH,K+6KU/N7+1B/U/!Q^>-(X@(NQB$/J@?G*!\=^(ZBL7XCA8EG2
M< _B!QCFO],(W#5=[\R870^? /<O,_&N01867J =,]V%[$85>\?-=LW/[:W\
M6>>EIV*N^-S7$'<[[O-/\=/( M[086:][2DMR9>N+ '@3ZE9NG\].X)X236,
MGL$E=O,-FUG3YCL-X2\F"/(W-#!E-F5%EQ^U2@NGDY%-@S^,G ;OF74CFF?G
M?A1_D>@WF'P>(*11>4EP$P "A\,'#>HNYXPG4HM=FX"KVRIP4+@E<",+.F_Q
M]DO]@@1B5ND0!U#  80O:P#7P3ONR=$CJCD]9UDH)L@&Q92.GEUW"!JF5$P,
M1CQ^531.9=T>3U6K5+$[NE^B<^@CGW)*=92,I6NO7KL@:"'V^XB(M!#D ^/:
M&$KE)K(LQ\)H]SZXRV( WL(!R+V$S&.96Y DO@:V2;I\QJK7UHBM[PA$E WN
M#4AD+A5TH'>H3@HBPF\RW[Q][#MYXXJQ^L2'(U)9@FZY2E<4+S/,9//B/?8B
M)[\>3 "_VD3S 9=%33 4Z5TKHN@\LPJ;YN+A2<;$$W;12:D'_#V(B+#0JN[S
MA"3Q<@NEM!_1Y[.#%RT?]<]V1?59A]Q=%A(;ZO:=LE@ L+DV_#FW;]^E%UOH
MT9?8:4AG%HAKHI_8+LBCD;+APJOKL4"NHCF%AZ[V)*WU-*R&5ZA42+^9N*T>
M&)KQ\K9CJTQS-RSN6R%.%RIQHMRA%ODK)L^JIL;71XJ.0/(5'2PZ^7OF'_5#
MM_98V,YODNS3Z/&S_/% _/!B4H3'CWO)$8@)$9-:AI#;K((_Q7%D9N?-?'9B
MU*-GD<O1L98$EB%F:OSH T6=K'F#%+M^FLG6=]$+\&D(3++ZZ+3*%HCM0K"9
M3WKJ:?"Z8/*<[";F)UVLHZL8G^O&>H>]&2)<*5R?8_2X^$2MB?'+U]+[E_:O
MUH_61N'>1Y]E!_^=#'TQ27/0#SD_P8:/]B<U$N-M72@[;(%T&\KIW#+]:E5,
MQ!R&*HB?*'68:Y(S3W58=6K2_93S(/V8ZS*JM<,A[J60YK80;;5P2@<AWN]6
M+_6=??YO"4 2PZ(L$$EIX@!>WP__1(3(4WC0U4GS^P.5M''DB::C]1(W)JKT
M],UBVW4-#9M=+Q?FA <8'=.7J^";[FMY#BX@4B#S' #$ -CKQJ^%RI5B>Z'U
MY#D 7L%=%I+].%V'B05+!R3"%X1III77(KVK52&1?\X'7BE3,%W_]&SEWA_G
M&[N/3"]E5N04B,O=+<YQEF[3GK@8K>_'%M[>&>BS=3E#-^7UV<+-#VH:<P#C
M3_DY $,K#H"U(Q#9Y04I8>)T\2?9"?"HW/I*6]A&67T#L$^_C4BNIB01%."5
M$U9@" T[)WH)/FWT7HB.@4NU(JCU1XO>06;4S#,GQRJ@O+<Y  +\^39=B2OC
M?GDF?0BV8(.] >R<90LH<%&  OM>4WS3-A^[Q>-\BR UKX7^'86*<JOO[C H
MZ3]E]=-*\&5FSAWL>\.Y&,VQMJS-2W_@D#(6;(HDE634@#I)'^AGP< OX;MF
MN*W3N]\I60Y,YR7OF/3\TIIA^>$P?!#-^_&Z5U5G\5RSPV=0C.+9+A.G65AY
M2D5P>Z*6^>6S1AK\A021P,EKKWGV"@W0EZ,OT/O[VX ;PT5DMO+F)G(6"=FZ
ML^?- ?A7(AY_V)P=YV5B&WI;OK.N,*"[H?T,MD#W4%B_^[K\_,36E6AOBX70
MFGS,$QM/;WJ>R2-%I<V%#?K>X0!C+;4%P?.O+N;,M?->(A@!H!70HOW,?#::
MT&L^>^C*S=!%VA_X9QK5%7*# YC6^SN1;!9QETH,],_=(2"E@_!>"\J-_?Z!
M#1.^C_W.,CVUKL6;#;J(6]^6:,''QAE_=97^X79^Z9BCX3EU007^&VQ>>"$+
M"4Z+7U/.NS"+/XS%</VT7'DE._1)#3?@7L?.-VVMS,7VT ]L)LTFM6>DD#XF
M+K63/Y+TITLD6WOZYI_ZCKX=5/0Z9J=:!HP3_G*T2/.IV7$?9\]D7'HX+ATD
MT^=J>>T5G\S'F>A85^O02)T<2*==&OM>^Q@'(%9]/;R3_138I0<AC)Y!CYZ)
M.$T,MEOQ$-1[-F#XQ]'!^EK%19O=24N[[<VE@E>M^<9648#,A&ED&2LN(V]_
MW 0B#K_+QZ.)9$KMN/9Z>"<#VS\X.4K?I%9V?ZD(K&AO-G61W!IN/]P[41/Z
M%GX"J&&5KT_V]8+\OE@:CRW+.>4$3/W,<.U#L@6X0=M;D6T"V?5VX !V:K[3
M6A![\@2V05ZP_!B\?8A6Q;];XPR9ZF;3_N)/X&+O'KR2 UC>7ID<7:[[[T8A
M_C,6AFY!IK1XF&?@=6%6KK@MDNSP/C;:X W>L>?MOZ_;B@(-<@!"KESX0=R&
M_LPE__8/J-A@U=U@7"(%_7?Z8_]I"^^BOSY?1-* T'^-^SE*@[I2B<Z==4^5
MY;9_>PL75T]^K<]9/?LSQ+(4=;+R^D"I[J?&H=< 9>L7Z;6_3QU'S)VHR(#P
M(VQ.L;3 (4"7N\^%.(!#8M1K=6'3*RH?QU.?P7$$OTKT ZT2#L!,];7D+ M1
MHXG+3O>IX@#X:4T$#@#*;Y._DG0,,D#B4A,J+96%6R$*F8Y2@J:Y7+]BB4N@
M&3KTXO!OJ[QRF>MCHBUO":E^)6%'*]TJ,L8_R_S:(#KK&50FOC4^<7UI[L6M
M._Y1SBR=BF$A(<V:(6PZQ%L+HR=:E<G?J#/GOF@-EXN5-(??@#\'K=<\#00^
M#&_=)8_4K-]L/&_0/3KQ7?O+8%?3JQR4HT@(<*DP+SXB.]7UAH\2 S)3;24X
M]=R'N0'_[=Y;T>FT:6-S&I8V'C#2!1;A_XB0K%*Y,E/L(7 8'.6-?*!_K2%F
M+5B(G8@!9)]@Z9A>23L4 :!OF^_5+&(:V*NKPFL%R\ DK%B8>.G%>%4WT-<R
M-1?1Y,[[E'N21GI\V:&+,MO6+@<Y@&AE$[D)-EJNPFN$EQLTQ-G[77M_0_+A
M(PS9Z&@+1+'=),G%\C@'H ZOA=>&;::(1"9_!X7BF! "PGOW#W59+.<1]R5_
MTTE$:#V5U=30^?\S%3-@LYJF.IT=QS8.Q@AR !';.V4JUBN(*"9\$CYKQYJE
MU@9$/X0M)[$J=]:!:,=\@,E)N.4!8DXJFN]E#V&-[R?I>(SM**@%2T-94=E\
M&"'=N(F:FFN5[X7=:NNU2*0F!1DIURLZCK^WH[87)\@FW-!J%AR@.W<]Y1B=
M;L*51*037 [&=4!=:ON>MS#1I!\J[E#,:4FQODD?4U//<)H\,-$S$+?@6Y+S
M*$&ZX;W)@[.MS:4L:+FA%U"_W]CZ'/?IVWBZJ@0'( R?!B$[HF:2G![7N*#!
MZJ9KZ9L5*U([?/U%Y+6F=IH6Z)#V(>8G,ZU8])N,UV[AB9#*KJ0#&SSEI]=?
M^8BZ@<I%>I#V2LS2T%KTQ8P\5@,'(,.T03J#5?9*^F+K_-A B@73>Z*\96AE
M ,8-4Z:0N1=_4RC1O2L#()ZZUZ-U[H-G'T0,CS((WA[=Y28IA!J#:)7:TL73
M]V\2ZJL?7',^E_8R/&!PF>:P/]NM2S^Z)M5;J.#(Q[/G<'O8IMA751\TV=!;
M/"3J#I2GD)HZ%EG^W\HW_-N% "$""W<HP,KSF2<>>\^\$=A',MJP*?)5%9D?
MQD'?$[OTZ-_FP!JT2?["O!V\JR=O1$;0*8L7ECZRX@,'&8K/D![7-)2!L[NW
M3W>ERJZ1?UF*N!PUUT1>/\,!(/-,GDQ<' L2(>4(?,MO.R-\QD)R+E0([,<!
MW,1'U>$WX>75T<5!'<PT(BNK8IY@&S8L<MIA_F:Y?')[6Y&NI;5'.-Q+ZC+L
M:G##M=8A)N/JO)?^9(@=72[HLNF;5X>LD65O146VY!4\^PG!UPT?*EB_-+@E
M?!I']R\99WVF'*7[<P!2/:^Z^O]XOI@4#=,:$K'Q[?5.\Z<GD\0GJ]Z9JUK'
MZ1GIY^3E+<>GO3')%CDN)V>L]!IU8WVG&O#TJ]&(<%]V?T>Z5/6X4)+'A:*G
MU_]!?=I?"YY,XGY]I,U.Y.@:_F\/+_"M06I@,[F>/3(H^CJ%7+S( <BV//;=
MGKS[*WCLG. ]=(>IWM%EN$C2$S,-EE2G>I%'G!TT1+'H3("JT,N\;3$7%$9V
MS?+5R69I"46 +ZY(:H5MO;W9'X:B?PT(:JM[/0B1H$TVTL_UU7UX/2Y@!KD8
MFNH4DZ9<9';+ODG^M(Z!X)'[A[6<#GTI+BJ8'8L8ZG]:7Q[_X)JUABK4]1^9
M*!B,%EX-=TT-*$O ^>V5A)YNGDG.1[=%Q:8R_*K 831BN^?FYO!,X-A8A%!I
M:*J7/86!G8.&4%F1,U%*G\=#O04'WP07Y,VC$CF 7X7 'S*@UF_?P;T8S\#4
MD-J:_487#KXR#C@]=V<6ETWX0IN6'>ZS1!Y]EZ,%$*LZK]Y^B_4+NFW1AOQJ
MZ[PE[\*\14^%#8C&F1! WC5!1// 16LRB>9YM_V78SKJ3<7+?_([WSQU,C=_
MI5PH:EYY1;VAT]PFD< 8:NYY^/!NYJ"^S@D-#H!GE52$B1B_6*,6,?Q&B6Y>
M?E;,"7$C96^#)%]5_X@YMHK_BI2(% X/(XBJ?,Q?J4Y_E]@<F+N%&WQ;T2-8
MP.M4F-?6V(?9'*^_6Y\IKGG>5R%1LBU14F^#,D3$C&I6]WPSY95"/[V0<0#?
MGTWQ$VAA#3 "2B"YTJZ?W*U#'0]CY1*00/##\+H1X$U2I "SJVC% -]%X[&>
M9\CD,E(+*[;#/ ;25.)=7=V69MX?"D:V7 T(CCI\8#";..:)LQ]5D0%.JCTU
MNW"JZ]O^IZYW#_GU36 #Q[]5[QTM>+%P1#$7I(MJ5N< G%4/[D77AF)F,7C^
M!3+70)%J<$=RR4",A>VA[/R"_"2QW,] [9P$,PNSD=V+5WX?UW<VOS"YXU)/
MI!T]>^;/D9S+GY&OV)/OBW:"/;SE#W6#@AT2ML19=NEBWM&V993%V@KV]KK!
M^D@J%+47!'K?:>X/,1J8*D0&E.\_H"1FXV>FI[)69% HK(WZU9QHV:L8STND
M3=0\OC[6?,CQDSNL!6K"1F_X7Q[=.9H_O>E\N64A//H+#YXINA\K!M9ECM!]
M-Z(%QB=,D6)Y]1J#@6NSA&<FZVF!>B*8U'VEA1F'DP_LW(2?M4C8KS'0OGM-
M3O]VE#?AMF/ B;8K)\ZH^R\UL,J9>YJ_UBW46@E4\Q1U8W5$^GU4FV&H[U)Y
M> H]@CG$EIY2?C6! #;\6)@EIKZ,=@V(MO X;S<W'I;DXR3MIJYW13D>(FS]
MM4TWXN[JV-W$NE>U59TB*@IZLU<?>^5K^2Y$PER0_!O^>M5K-<4#ZN<4A]_E
M?^L)[F>RPU650664U'E^/2_8?'J)VE'/@!@^-ATT AF'Q9WQ'TGI2CACHFBZ
M#_O"%=V'/G/NA*6V,ZO!?6QV!.8][PXB[B3\$&IZ\:N9)U'FXUX&0F['O3#D
MQW=CG&&>$FK:.VG[SM(CMA-0G$MAFN$?PE*K]E)%RE>"[.3]5H\7:0JNM X[
M2YWZ+/LYY9S_TL:'LGO?3D"@!Z/L[X=()CE-RED/&?*E^-(S8FY_#HSO&W K
MNJJ+^GJ& 1^<_Z.SA5B(#@QW[PE7:*$*P3SE&GJ8[SJ=*[HCV_!]$3\&0U0_
M!DK=R$S,,BX_HC2Z7^)4>2V [WCC>SK\<Y$*?>WUV'N"5FZ:>B$7;\@;?,!$
MVB>>%'IY__LY@=]K'( *$Z:56L4V@M^$O61$%X8)S0W4"1!91F.IC9YQ5L,1
MW+C[Q&RZ[&;_Z8\XHWFQJ]GY 6G)\2$IL#^-S,,TUU+/\]B>N'97]YG+B>2\
MPL/&/[2E[$ "7D*$BD&KXIJ^*,BE\ 8W>!2",%#,HA]E_HD$SBICVL7('>%!
MXW6R*9,V%EXT%9U5V=K=ZCJLX%9^?$:BJGYC;XA,07ZB\E'#<N.SRX K&T@3
MM<C!LO5ZV=I09NCS.TVR$?R=!42O)(*M1#SZ^'4</OK+T^"]8Z%B,8N=L2RZ
M;<SJVM?=S0U&<?XSFQJ,;]7QB>3U^K[?^I_&PKQY/@RC6A^?TKRB+WZ7(BYC
M8UR07PENJM'NM;\L6YEN4/5]BJ?S-90>"IY0<?]^6?XQ@-?GCB(#/E.RF/$!
MO+R^OB"U,5RANC]UOGZ79, B@9?)Q^2A0\Z!X.;(FJYI]YV31E##PO.*I7HY
M1^Q!#SPTRAMH4E$.A-N)8T]_/(S3/?-X^5M!B3I_EV,FC!A$N/9S-VKVH--P
MYX+-*H4+M#76\75X0JH(O81I\7F6UMNX/CG7%NXS2=!\8N]'!9_WAR+;G/L>
MMEJM99&O#SQCC3=_RASVVB<V,4>P+:DX6ND5]<5JE%')6_%CP ='+\N(6T_]
MZ4F;W'\GH1EW_CZ,/WH1T>5_>4T^#@FN/TGCL3 /GQBO4YB$B(9%A1D%+$RO
M@HO'^LB/$OL[UT24]MW0.:0 U7X7Q&O4E&?_CS+M?HU<2_U=OM$3PR?[S80?
M?&:?I&U[J*36)3I2E7AG?H'#0;H,F4<!0<:_!SB N68D!4B.@#>-0V_JGYG@
MOS>S&B S9H?^WP,6R=+@:E#+Q[;IF]E.OK?3P%"!I&\V=@5)4GX*B*40;RJB
M+LH TT192@^W9-O"CM6?-**!)%N\GA- 2K%D-_5#/(\[8SO-YE-E-3%C^?G-
MC=6YWB=B2D_Y9$=F1*)&7S%^%"$ZL^/&DO.@<7G?SH=>_<P!-$9"/C]Z\^ K
MF,?CW.40%]<Y$53 (4J/5^'CS^5UFBQO]/!RX4[S_R#O/8.:[KZVT2@B*B(6
MP$*)BH*(@( 4*8F("(B BH" $.D=1'I+0&Y!I E(+Z%7(?30(QWIO04($#H$
M2("01O)R/Q_.S#OGF3/OA^?,_,^<CUF?\MMK[VM=U]IKK]4,[SO<G?M+@W3#
M4C(%\\ Q1X0Z$FXF1:S!![*XVCUE7#)!_;ZC"&\H1\,EXV1]%M5LL^/5-B4R
M;[RTDOBP[PO/?.@IL/$$<RX?MUF(O'M!\OV5=6%ZD;N=S(>([4DP'D@ 6V1"
M$=E,YZHWP/$=GXXN71=&2KI%_&IU,GP4S"K__!^AHKR>X>^YW[D_*[,>*Q;@
MH?"<NA8>57;TL#XI84]^2:;EM2BAW>_U!H^^YEL/12M!<--Z>=VMOASW\0]>
M,SP^A<4%OUG/1?=^!C5^%L%MG:BYHB[='T,=>!V^7T#X1Z@![0HI;C\K#%$.
M$Y'3<?(483>R^F*@F*E=2ZBN32PP$F;R/TK9?NBT\32+GKU%KSW:<FS;@(UK
M@Y BA8EI8+&':]F>*AI*RBHJD3E-O%R2P+ N\^;@L<2P<A2%1H?-*^;AP],>
M9M0<-RF\:+Y0=!J#"SC1,^1_6VO,6EV;+!7D+V$#/:39_]Z&D=X#!VY!U]8O
M3NROI[<'+7<*@SPQAF/+TC5:48*A;;T7+LQ&7.[H1D;DY#\JXHR18.L>>9R\
M(\Z7_>JJ"W$RZPSR]L;9?Y@'J5UD"EIPZ8C02^+<*W9=/4KH0(0INH]1T6)A
MZ6'W&UQ:*T62GL3Q*/*!D$(K/@_ZN\6TODU=9?U 91UL\-<5HO-%F%>*NS
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MWQ2W98D'6$P$UQX<9QSH/N#(P";O,0"G"A@ ,4.J7_C6*P9@M3*"M+6738;
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MJ[NKS[C=W,XW=V;_Y36?6O*Z,%K3ZFE9<<2GSNA)]=OETN.^,8 ?LZUM+4S
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MVE*&](;@UHO]0NG6L'[6)9C:;OKQ+FHE:B3E^N]Z!H!-X]>L-Q>Y(ZQ/H=_
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MT&=.\Z7=3@Q 8II,.5W0>;A10K9/:R1KI\_3\IWNR.OD @++HXU(UB,V=X[
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M=5IJ!,,UOS>JS:2CMG\,\=U>R\*,PF_)%U=0M[#D%@: ?S $<KK&HPTC&\X
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M0+XX7 1^PM;H;7=YB,['2KT;PUY/ZOIF^'!EJ,<X7_=67"@/(8<J-BT36L,
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MZLX,0 \8._<.01,4#V( A/E^(">/I6C),B>!FPA2@UO+Q+R)&J0QY91'=C(
MK\"M<^^C".UT??!5D(-[POX-'/#7![;%F?$I#!PF50,QQGDC:ZS9OT^C6H6+
MA;D5J]?QXY<?.OV@M%ZL)FSZ"U]6.2OL^[$_.V0O:E68GCGR^%*&0C'=$%:
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MB;A_IT=\QL'DX31C8"*&.N( ,U.F+T,A*[QW4J*687_F')'X^"ZL3.<[,0;
M8F6D+6IOIK9\^X?-UDB#>D$_$4G2?M^_E^QR<CKA8OLAZ*8X_?M RUVM&E)3
MHX]C\71,'J*TG+3I99? I?)K2"E]_$C<9)L&<'HFG0@+BQH\69H.G:RMCV4T
MU!]5DOUXL5_^+BP,QE>FJ%H'?3>!>^W.M[IC'%7F8Z(X61%,*S7&-Z0JA\H:
MWK25D'J\;/8LH2A\)LG]\N]<EHHMV5(6X)Z;Z>W0,E2Z;50O#3B8@6BZYDU;
MW'+JW<0$0>3%>=D:?1B RJ.$=QY=INZ1K1T>I<K7D_Z,?"\BEKQ;5KFV8+]!
M<+ S*17RB^%5LJ@=N6X$A5-0_2/JA:(?KFT0#D&?\(O#+^DOIT5R$TF>,PP
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M2L,!DYU)\8Y\YTYM'% ;&K(2U))US")/MUUM HNB^95UB^^F+S69Q% 1_ES
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M4,S3*:EQ]+5XR_/4%P;-ZOV%@A3ML$;+GBTFZI*!Y\RW?@S:H?-56"$8"FG
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MI(#BN("]0;%N"W)#W;A#%6T^LZV1*(/JA?C8L_([;,TU%ETSKL29O)76!=3
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ME7?-/A>^\,&W 0:+:E;,:Q8"!+\H"BF>2D%F[!=<U;(@.%:H[,5K.+[%-.6
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M?*'VF2^<GU;!\['N39?8IJ#GJ5HJ##?MKR?;-HDP]7D[47I7W;%N04H)-T+
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M)I!/]F9.4K9K$!\!U2A)F=U-K=X^-U\05?7C!M(/-'UU4U@OT&,UYN] N;^
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M N39I;&MLJSUB).PJV(;7(6YAQR#IRZF:YW8O*M@@[&,,1G 7L[%C75;E+@
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M_/2]PQ1>L17D<XYICV4)CJ)%W.2L\U@DI.U@X%V.E -MIQ</!IX$TM$;THQ
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MZ*63(S.J838[++G=!6MKL/!4F^UN L8/@!\=$6=ZN]Z03S:2>?,ZJR Y<TO
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M2W_L)P_/A:)IH 1.9G.B_A5N'TZ$.(SMLIC3E7J)6QN)@)OB"PS8:VQR$A)
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M./ZT/EB^4X"D9T,S;"/5\7F"JZ[DSZS6^$EVIQ;N/RTB1.9 U5/"M4_RF[6
M";DBV\HBD1XR]-EU_6J$<-6?Z/?\[CRI[[7KKMNT_O[C59 .W@-K=&)5W"*[
MF;B*75@$#^76MW!LK/16QJ4A72?U]=P+#:SV8G9<C!SM$U3'UMGZ-/L15FP\
M"JS<2H_*0=%KU\K?K.V*0U'%J$+@0,[ 3_1G\B$+8TY )V.!>N7WSW6,VQ2K
MLL>]*S' I^"DX?$.WU*" 7Q8%NKI:7E>L#/O#5K&#BRM,!8<EGE:F?*@WKL9
M6 ]18)NYK%WW54F52D-#>:@%=D>;%V@"CEX3,YXP(ZS4*+YU?:VWW;O#%Y[Z
M=3.ND\ _266RG',,W^+%;PO"&21R-\7<W?2[(P^QY.-^2[-3TNY-^W%\5_H\
M:N$#/0H_OJS_)#?*+*WHD3'ZJ/-VO-?\S;[7TIMH64H9[KH[N/6 LYUG&IYK
M3QX\E,'LF?:@4&>HCAT8P91>=Q[2KV,&X[D!Q+4\1+2_P5SHXJ6.+S/S<)(&
MLY(W +:,XD6?%ZU?[A#%!0#74'QS:#59%9:N*T<;<\8/C+;44J;S_^8SON,&
MH$5/95)4PWD */D&>J<C)0CKTQG+([BWU<\:YR9@>?#M(#$,P^I"QE=T;6L#
MP<?9B3?TU[ZS[H?,FKVH"Z&FF@'=B+OK865]-$K@Y&I ;^-)@$XV<XE&AIT)
MB=0-H!_Z!9^7"@#^"U"//ZX'1%+0\?0$PV5&T+O6!$''&\ F&*UCJQ8;R'O:
MN?5Y<"\\\NVC4$IJTNKY^* H@9#RS(U)!0-9!>T(,_EB^JCR\F,M=5J6D\9*
M&AQP%EJP53#+XC)9O]8YG'O0<R#M0$V,N0%L +%P&^3.PO]98?#_32)K_Q]N
M^/9)/>VV/T(&MGO82+F_9#N#\&?"\*.?$: ^46[X..Q<>ZG_8U\Z+$ZK]C)1
M?6.O^8!]^E\"AWW_6"'[0E0^\:6' ^=TB:X2LRQI4?:4!2-E*6?P.:"8*)@F
M+C#JW#RGV#YB<M*7R7YUS5E>(<$K?#3 *QP.CP'W6:URV)YY.ITGCF"#QY;\
MFL00D"._VOJ+Q+G]YD?N_CQLL;D3$>5YI?D6,2QYI2V]>0;!^8HF--%+*MH?
M*F0*R=33TYP:PP3HM-*?QH19G$C9_0GN/9>1M%LO1%/@-/#)S8'E0M</%XTX
MMIU0%3CRA@N@QFI+7$5-BY(8865W+G"]^W8I#RD]@PQ[5TAQMD#*OXK[<9CX
MN;0M#^ASR>X-P)SHW_#M<OMQ\*BO^ <USQMN:XU\:\,$9-CEU\Q(R/!(Y@W@
M)<@2?_<0$85@ "<<H^_-@9E;TDI1V,==_VG,A=.FF7UJ2&#^/7'$%+&H>Y:3
MYCD]; :U5V/@XV*MG :^L]=BB"[3BM4JTJ"90 ^YHG;5-Z7&W[((V&H9WF4O
M[/4V:[5+Q[GI@:Q\M7!"&5A*?,@KG_UU6)_Z%;9S-,VGL!!7?<I2WL!NSM%*
ML=XPS7>?<<B!QH&Z+&R=^WGSBUS%&T!?BJIICHUN\->H.Z,GDSP]>$*&5DZ:
M^H\_)Q\MK A"Z"*1506X(GBKOK86R$:@/+X!1(('@#A!?.1>JPRMOK<'POQ(
MXWL*?Z0WM8"Q3\RW@KB'#0*OZ70?'R[/+4:H#K+*1/'02T$#+/43'#GNT#Q%
MKY*"':&V6V/*(7\_!TQ:1-_O%:?C)B;+$)(9WV^7K&R4H,5MX'D/'1'8B[FE
MD:0__XKTB+*VVHDT,9L; &(]R6%F:D(N.0G8R"$L\N7H$?VGGN=_!<-^QPPX
ML!^44^@9:HX&<=#)%,"&)AX*CPZ7",F%*MVK,UW7!,[:[>X:NMGXJVA=S*#C
M<8$GP<68I$Y8HO2#DXGUGB^K_NJ>P>[XTMU_,;#G-0KGD,ZBJKZRD.S7@TE1
M_2;4G)*OF"%#<DG)Y7Z597'_S;IZ <CBI!LJW*ST.8.FK4BX)!) ;ABGT?\M
MF0.D6G"T5X''!N+QGL']S8@@.*_D"+(1YJN\YQA?<* 1D<&6<L3:^;D*IR&B
ML_7BP?-6!V%&216>.V?1&.XA3ZT9&5)L]",7XH.]B;<CK]SQ?$.IH].9_K[@
MJ50FD([OA^65I[#4&3M\[Q)B ,F+[P#1X;OVVRI_+,\Z?#W=2]J0W]D?FJNF
MS/8M!\T5Y5;V36EN,@?I>^8_W:=DTGQ9]/.H8UJ^E(;KZ@$%#HARZPB?OW@)
M7<X=#) 1SE<@(=K>L=O4(BL:/L 1XW]?2L2M6Z'"YN&4H)?NEFKZGRX@O5'Q
M\ %4$C+3DR6FJY_[U9G1[3BN;UW;G#5N4YSPS>9H>M6-[I@LVX;4B$< Z@H>
MG/=UA@355$E0$T5V@4*YM1>^YVG@N$]N+NXI/AODAM^?7TA;.^X'QP ?MEMZ
ME"OT'N4<1OV4IDS#/=1J$'J=;!G(%+!(14=!F2*G$))GH\4?X<104^--W#!;
M%DZW0:3Y2A%?.A'=;<JGJ969'6FM[DHH<ULY98!O 7LUMN<2<1'S0%)_N3-@
MCVKA']+#Z3:!V,.*TM+?ZO')Y7V!XYZL-P#'>$D?E^U4DOZBJMA>[NE0$I'H
M4)-QOFHU2-"W.IPO?O=*0NU6?D_HZL0O\K]$AMO,&?7H87^%\GKIPIV%\B\W
M@#5Y:=JEC-U3'B3[S"Y#[N'CU45Q_JT7IU=^CKYD']R7%?QFD,Y7,& 32^6@
M&NE=R<'D^1>I@"G'KS*);)_O+1^3/U6#\&OP11\Y8ZN?4H%_SK#B SCPF;_V
M^=&87=#ND7'AR>VT0FA4K8]M[><;P*O*J+0KZ(3[<O^@D].JET.M$?FT90W8
M_%'$/;X8BM;Z1R&!.P9O?ME3 F8B9/ _)-1:>EX.44<%>ZU]3/C$LZO]IC*)
M(7P&G8>50?A[^3XY6(;O0:KIQQK$V,</CS)_\KZQX>)V73+_V"0A\8#]4V]I
M=-!K+AJK"4\+<-[>X]PIQ2_<I'+@]4M==Z?UT:WOE,+KMY!C_'&X%GQ1(;9A
M5@>?CTCAP:_0JF%:W*]\=1;K6W@;55\)$[T2F]?):+M>L.U-+"+2V1 0BUQ^
MRXI!*CYVIYD(1IT3C(6H0 Q1]S^=]G9D%[P1+W\ 3-*-J0<G0/HK0Y=@^%#H
M,<>_TG@V;=\6)K XTP=)P(&J%T06+BAK-@YL!^FF!#=KDO=L5@NZD;L[_=)N
ML2$=S_R1=Q]->5)H:?V-BPF;*"#]JDWEK27_^&TQ$; V$BPHT3""U;12N("Y
MNP/_J$)4SRZL+N[I6^.Q.Z3[+=5^[M4HGZG37QG5)E;E Q8Z]'?*-2(*OY;S
M&C%77A:HVQ_&7SX+IM9)=P:#$I8[D4JTT!?W H/R3>$R.A/'>,Z9/,FX5E@2
M1LC2+4K+ ^SD>(X3&I7,:+#2L0_/Q/962#IMYY:45 I383_',.<71LIGA$/?
M5[W4N\#\>:5;>/857SS=>']P2ICC;-&Y0C%? '/NTR(?VPZW<^A7_L664Q9(
M&A5DX94L**&UP]31D"B_&N@HAP MX!E]@[%D*C./-4;P;78]^$N?E6WUH7U0
M$W;B) UYW+^TH+-,F4)UM=WN+^26":FM,3+Z/*'!2DWR\MWD6(&@]$3&G>0!
M?>UF>1JC'^D&[YZ1A*7JAW:]P5E%*8K=<PLI^]0 _R%GK7C.J)=RG0 (E!US
MP4+08I6PI&-5I 0',AC%3G"E=;63%5L\,IXQ.*5Y5 &3-"JZ-[!=>@,(X]GX
MHH-""7+GZ=<]]%G18#(_)2&KR;M,OP&4SA24\^TSA#+!9M_<CN^Z!X+P!8]L
M,4VNL#98#3H%P(>!R,;NHZ4CI>8;0,D7:264#I)]H5,J;1INXY$@/$6!'EU5
MM2QU]?&HY-6VXXRO^RG%*7Q'P7*\;_]/_+HX\&0"YV[78A99*W>JEUL7I[49
M'F"#P_\Z(_6M&OB7#N)P3"=(9$,_U@5-G MB<D-X.$#B@:Q7:9N>/>$7/5B[
MM'+(2,1\FBL]/">OO&]:5_F.JWA$;@P;:[3IYPOKL.[[6@O&!NLVFX$S%4\K
M#(C2)Q19UFA*#6/O7WWAVAP5P&]*DFU6]H%3?D'"6@;6P&C& [+-I"GAY/ 5
M9QV\"O8B9437H]N;Z6J>CFE$!2_QP\.!7C9/-T)%<[P*75*JMCYZP/7TR-Y<
MBKMG8.0:TEC S^"6I$Q2O.H3(K/=X75)LYY"1Z;'<ZJ#BP&!12: 5- %'/]_
M/TPCC8VU$G^?3\\-'D6%.MLOI35PVN:=T+36_6FZ)TGM3:/<M+!3H,!J0MCI
MIPJKPGW2$3_??>=I&U BR[%U?Y4G7&?@WR2DQO_VX=^(&CC>HOQ5!>.!)?&C
M_U,41)PV?GF3(3"6072:)B;*4GTA?[NP@^]@:4HW]SE/E4#)$+MHR@-><MY4
M,$\OYO0]KT D0/O[Y>GNW>ZFJP]*"L1:W'^+P,'!ATBMW6@GX+H"FG7$D]_*
M?:3G0!^51[  OA#-UP,UD@6OM*V<!CUNG#/ZDN2 I,_.3VVF^QZJ<&>$I$/)
MN>"@M/-)?@0TA"VJ,!%LNC--G:0D%Y3I751\ [ 'P1I+JPLBY=[2B!$;B'(K
MK/JHKA?F9]@IX?]@B-%/L-GXO\T+N%B\WG[D!LYI="&P.%@1'X[].>/3PB)M
MR8@R2?OBL-1:5#<^<UE/O;O+\&'YN>!W@Z,]9@#G2YDNDAFPDQPZ..SS21=
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M\+_<(;3$2#9/U!:N%OWP+DH'9W:LD09^!E+'%-BU7[*T7OJLBX '?+M'DMQ
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MVD^W#_B70G_XT,$#1^B.[M\''*/!AW9[_I>'M$=T]/L/[SL"'#UV"MB_C^[
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MBQ" $F=K51 SH4@0*-H5L03*P4WR>Q"8SB*R@$":.():!2>8S>,W6 ?6GH%
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M";;4B_3?(B@$DP@::E . D?T0:"2R^<."#0D32"HY.0!VOP6OE'X/0)>_Z"
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MB2$*%EK9Y NOHX@??>9;=0TZ;G$77%9AL;:JL.GNGA2ZTC-E=E=TJX_M36Y
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M#*[RQ<@)\^28#E,S\;=5@WG=M146:_KZ!6E>R1->5C;1-T;G<1RHO:\<_#T
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M@@:JW[E=]\2A2MJ=JS*>*6:/=<6+/]'\^;!'>-FH6HM, $< #(X^PFO'L:O
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M"DF>JC;@'QR11U9B=U^,D4'WD6S[ICK,4BP MGN"0('>U YC3KMW0>O>N.8
MZ0/0K_35"6>=?[-I<:0L]?3OK#':%#K[-):QB9G,0G'_#+B[16/U;)QC+FQ0
M+=D^MMD1=96BIPWU[F'&RYU*MP/5B<TR4_)L4T]7:@@ W5O=83?;"_%B8/SU
MP0(!(('7<% +Q-NG11, ? M9TVFR 0<E.779Z(%?;NYOPB4MBN2TS]TK=4FJ
M3UF48Y"\,KDV*VET;V,LN(,5;>V)]=Y95EU;LW!B;\.^JF-)G(^7Q.>)B,WW
M:' 7W@1 9LX]7 LH)>I8"^7_D.]160"+%=[>#[9=^.9LJ']/\:S+W,Z2I7V/
MU&UD9'SR+1=$;,(M^F\,I/U'0<]XP9%6KX3-@\S/LPX?@K6"V.V>@;]S"DEK
MC7</C(\%EY%#,T#B7XS>_+YYFLW1P$7OQ0LO)9_C#>M_)"7@MS"!&R5WJC5=
M,C[.\,V8ZNYI_3A$0U(+V('B,"W(59YQI3P4_D!YJ%;C/D&CQ_G,*_=A- -<
MZ_F=CZ_#0VZ(M991>]FXG-P8= M^AHWJ"=[$ET%'7F$1N#X"(+T.>L(0P%_5
MPF86(#"V1B72@L&25WY.2$NQP9]&2/3+:8,3AU;+R;3<7VI+:(GQT08IPE\I
M,E;.%N?'U6KB31^,@?MRB:^#,JO* &)?</^ Y<0$0&CA_&[IUPO1M%D)$**%
MK1WCB@W#K>Q%I  M'?EFIB6"'&I^_%L7I?6?U=(ULVI?=Z&BT-2>D&-3SJC,
M8PM++M$QBD2@Q'XR_ZG7X1?YS@2!RZB[WUJ3^BSVT^>V^/2=O@2,\#!*]2V0
M?Q,]6KP#WNC%3>.)=!RBPC.9?40"NA?T&XIU%G;T6]YI6GS61Z1QLE!J?9;Y
M8UX4$NIBKEGHI3ZAJB$4TS-,\H=2K^,S/,VVNN6^C<58UM._Q('WP.U!38]!
M)CO59>3&7$'W8#' G6%=85PSGMBOJ-\O;WYQ (8-MQ!9 [UTG=54C4/ZR]5P
M+?6,?,)9?@392R3!,VIC$YW?VW%N(Q NVLH5DU-:.A.J!EIMMWVOIK^^0RTT
MW+&S<N2#)4J/KKWB3$TD .X)7,':D?N^K#OI_RN&COBBKC6FTE>G#.H0C<9V
MJYYE1@>_WD^KCM96_N[0?O5!]I$21;<D1>?+W.A!DHK!NP6Q[2\5P]N.>D9?
M60J]F"!?\YD6=Q&?!%6U+K^.UZ+;K_+ &6*]&\3+2-61JE&SC:VVJK_*NL.[
M_3_+U#N_^:0UKOG]HSR"3[2/"N21[<ID^13^.DE5\'W9<<FM*QD=JBO.L\>E
M);(:&F>PSLA0LN^9A[\<OV^78'_ND<5*(>*QPO45-*89W;M8C\+=ZWJDLPKE
MJ$IBD!VNQ-&MN)>Y004"5A6-Z]90?5WD3=VTP<GW_+T=,U1]9.(Z<$3=/ZA5
MNIHQY?@4M+.*7,+E;GW'*_DY[?-'J>^_GXX^:S6V.J,TR.9Y,O<HXF.3$6O!
MQ\]%W>$)7Z&CQ#TR]/;&%K7C_I(_6+GS@B'?;.R/T<H3>-@ )+L(5PY*"L6)
MG*LZM>02 "H$P';:U=Y,C7_$]1(!H$  ;!WLM:"I?G;Y9Z)@=$/8:@* %.,=
ML"&!%?(*B?A4YC8'\E9D&<\/?Y90=AN<=;K3+$X O'9:'YP"#CC!G:7\_YP_
M1#>?5[E6;%ZB:VP]EN8%5U(+NAF58Z%W#']>[9 D<''UDBVVY]ML[]QY%L@\
MY3A'YQ@'72.7-Z("EH_O[?PK>$  :/L07:I@+3R N@0 ?^GJQ9U&O [C .KJ
MW'&_I&1* E.4OW@'4L/A&22H-7H=[#@7V#_:J8?1@G2>3\@S\U1XTPH^">L]
MITI<=J02&BFB0D(3A%=S-5M-3]$^!,!?!0P<LZ6"UP/VM^/I?//K%C5A>03
MR>#UV2ZJI0M_",NYV?,\6W0/[S*7'MX#16SZH6 A6,E65P9<JJ2L?&WI=GT
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MR3![_M.FN-H2!ZV?4%]5S%,DBA0O+2;?L;_BQ@?\^L\Z&Y@T L""O>5JLY$
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M'*3O"4MXQ^=QBSK[Y8?BV0EYTDJ<$BUS_"]?QMXNKVG7T:?#^!)#[<A?,9\
M(V\%F5CL-;:8UC92L=>W?Y X82L"ZN:RI"/>>]K.3YDNJ=14B?<PDM*^4-^<
MFTRLX[*\';1(&F7#%GW997-?IT>#,[ 9)GCG%7C"B%-1RO&/,.BJQZBU.U#"
MZLR<'WH7&P?B4 =CD4U[@?WU_A2/?^:PB(XQ<C I3(F3*0[I&,@%I]OFX=F?
M)/M.)YH\O<3.[B*C?#WWBM1'S;A.VEO;B.KM7Y\O#(/U@(+JCW%[3A,AB]F?
M*-+6T[Q@.([1U[N,(]-9$2C8:KU-0&7[UCL-1CJK574SZ!#UHX@[D<6/L@97
M-A<Z'[&\<>!R^"P4([5^@:S*E !0IJZ/L!SK3$G&*S=BUR";E^ G!N%;0R<-
M$Y!D^_4-0;AGV@FI/6>)O4-N?EY^8<3+2,Y2739W^<B+!>YY965O 8 +W5]V
MU1+-"D[_KS@>;$R= '@TOWJVIX$U7_"N8UJE#D+UK32;N+BV['0A&1+'/=Q.
M(-\TJ@L*8JJR& M+1<^DVOSZ=)_WK)2RVKH\_\XC1+Q@/K ?NDJ'*R< T@;=
M>.KQ- 3 =V^Q^M?>Y&9/BR4SYQELV$&*._=X4+R+I&4_*-26'BFE!42%5:[@
MF>-XV/IL;@@O]]]M0BL++&_@4@B ; ,]W. ZXT:'5[<33@#37]^FXHFV1]\<
MF0$RLR%+#DX5W'9>!,D]KB^KFP,*RCA).8J>"1\*D.A0?1G+O\9=2'K@0'Q4
M&Y5_<Z'OPU64)0%0;P02&L)I4J0SG>[4,Q'58"?\[5("P%4*DT7T(F)$WGV&
ME802!\SD]M]] Q/8;4WCA_)@9K%K&;):F"$ZJZ/;*&'&Y99NAY:U2)DTEX7#
M:\K00#+^. %H.FEH!Z@%-G?AK"$6+3JFU:#QAW=:#,+P1568<:0PI&!]\79&
M1K'B(VB-S*2 </TNW32=X4Q9YXL!EI]Q\%_!>6TN[:%^G],.WG"^UEJU[#%X
MGA;9^-K=)A\<SZU?R'8 >3IX3YGC]MO%)R?M)]"@P(,-MS6ESI\)L@\3.RFO
M6G FB;;Z(<%F%=MZ8V 1J%'D^'Y-T"T]3@/9I_FRRCKJ&=I)G5S*5N!]C +J
ML61>2FJYY!W/D%K!)"$926[66YW91=U=QDKEN6Q&G"S:HUT )5V:1<!UUH^E
MYCX4+9SH!X+5.QW\:U36Y6^U!"QE4P&DO'V/6%X^/%/L%&'S==D9J@U/OK=S
MAZ4NIEU;OVAV\B?9<I=27O;]X_IXB]C5M5[8L4X0T%5]N&M["IV"K>BU\.;0
MV\HP=G"R[M]Q6> J[AR^]I(ESY.,/=OPLXR#99CB0DOYVU62>;NCD?<5\0D_
M0*11B>/"'CX/"0!]7K,-S5YV?7%+3:4$AYM)FB3J:HHTN<*7?WJ!CW_A#8$#
M_LMS*%"\-%@NK&CK1:O>S:"WWL"75AO@TI0$_=*\PN*N)SREE9XU$#=JLH\7
MOX'EOD<O ZPS!Z(S?+FT:SZ/%(7E/Q9FPYUT<YW5K69;-= E#T?;EMC<[A-Y
MD%CZ1,^(6M?]AKE49.(8-J P<P7TYCS7@D!.F[T;<($ETM4[NPQ$ITY1F:1>
M3^S2?V#;%DF_JD"1&LL)YXO.N=?X((:V[ ./!3Q^X,H/-T[CH6_UC?H"AM_@
MM&$-U(!(=XBX;L#)IS>?7$W:.J5N(9*;$P1O?9"RN5FGYZT )\F2^#!6V' Q
M]_"Y).O2W=[8Q :*,!CCJWFRH:[6D'VTR#@-W]0\W6Z@B_.@SI8?@E9P^_ES
MC??EY3U#:-G"3R39<EKZ7',>ZJ6\^(EV'^K/*3H"'T9(+E ;DE9"U'.O/MGN
M3JV_:6':UB5)Z4!>$"<YH\)+MO#25(+JV8$@Q$G[]5=*U>Q*;[=N8+)TQ >\
M*V+)^7!NNW1+(SXK=EQ:#B[>TC3J4MSCPMC20RHQT\G;2!O)F1T&NZ*ASCHF
ME%EF^F)3SM[U<Q2"Y^'H/3M+;ON!N(<4E\;$9,QG=JWF[<)(]J%L87.7+3]6
M7"NE$^?MX^Q1HF9]VYTJ?^J+T]J:'DIBZF=RM3BVZMW?74 ;N=)&CS:%R:=(
MV%?K3MX33,NP4$&S5!252?S@E]%+TDD;MHO_49@>']?M&TS3SX@UU-3IU^(
MYCP%SQDWN/3;&R;B]+NXO.H^%P"#*[LNCA<$YX8H ]0=[9\X2/2OY>BN$'WG
M1 _CYPWN'ZD! 3&[THU?_%Z3A?WZINR.X+$=7?E5--M3;3T27Y@076(5F9)G
MZJYWC5'Y#7.,;KQBQK3%96V@M;W1WI3W_>2O>*O^H;Q']6XF5JX3QRE'3<T-
MBA!XBZZ);W*R;?\[;8KO7;DC94]$?#=V([*B#?94EJ%=+<#N0 ( SM ]>?9&
M*WYFMA-A@G!=/6 (:3K8Y7MN,*MO6=58NN%0D/*8^8:>4#>9GDUMKW"R'DFB
M&13>+>AEHT^E1W:1LPC #>L?+:0SX%7U-FEMY"L,?O/9Q6-&Z88(_( $_F-8
M29#FV]A746Y'OR<!EAN.@2&5/O)+G_'F(.;C\%Y\)B:_K5+2+L@[YA RGY8Z
MXWD/NI"$<0FGUK?CHN?[5%)6XB7<L.E9D$_YC2HF83VKOQ&G/V(K1]?#3>V9
M)0(QCFR1L88?QJ:*OK.XH=QL.F)F,B4>O9;9&=MYO4#A@D/A:'GBTY)<ON?V
M]J;>.8H!,=.@_K4ENZ^,+9N!PQ%ST@1 \,SU@[LU/NI30A;'_#<"5W@.C)(J
M')ZV\_]RY [++RR0O]VY<'.7_%E-%:R@,5*EE-\H](]H4O%&3< I";>&2<WD
M[M8QG5K,-4/IOH=-Z5^'7>C+A]A!D<J"S[2^)[.]3.3"E359!1TJZ/K .H/F
M-KGV,-FP'?*%FU/SC]4*R?D?!6UOCQRTWWR^TE)IO;H_G!QOLRI!4^*0#G)(
MUMZ]>\.+135:NZ^66D2>T5P -9&_Z^+]YIA'Z1B1YEEN</O#,G>3J\5K^]7W
M\)^:(=\\8_DAYE?J]R3-:4CNNE@(TOE0J+&KUDQ^NB-*KR;L8L(S](B-:H->
M<62 +>'QM1N2CT2F(MC).@>4V$X^91>DY1D:* /RQ34!O:5?CQZT2IY"U?\*
M9.7O=Y; GR?6HPB 4"YMM[[8E:.W.8ZTT)U6BA[UMI*ME8(X!?QB0;>=19YC
MG.'5 AJL.Z"$;/X5?) DZ34%UDT#CG8?F0:-6N$#H?KT%">59A6(//!)/L<H
M@Y')L([+5).C6GCM$I*R!L=*GZ;LJ)C7W:G\)0CN_DT]@B8*8&5C_9)&\7+"
M)MQK0D^];!_B88R=@#S\/&0\:W!$H7@8B^.Z>_?3%ME-'F=+25BY>?6)PP%5
MA-+'S" [0=#W36X+EGNE"4UM8)J<=%4H:V]JF8+":4:D]44*FC6$9^RW^^2?
MUA=Y=#:?=!?W'*XE!RI@*+!-4TPMDE:.AP::W@JOW%YT25ZJ:]JULZM75V!-
MRFS_ W]7_>#YW;L.["5I"E1:>34)/1OTCH-]!=+TMOJD>05Q &QV";AD%.(/
M7!!JKJX0N]H-C=\<:S@9BGO#>%(VRY!I:F[$8&8+NY'6L:1^I\I64.%Q+I[K
M;)$4PC;M.%VF'Q^TPJI%(=1EE7SUU[6+OWYJ9L1(^?I9YKB96!H:K(+<#&$+
M&NG\Q1H?LR@B!BLDS-9*=AIYFM85> 676;Z-6B!'7_?(=:%$N3:M$1M"K IE
MT*T7C8;&8O,\X?N3L>$*/K3N5+@SGA6S&G&F([LSO<TC/-WR"4AP7V=I52%7
MGEG"+ZAXZF,ER_?NQ4@)93_Q)=\"'7HA/F>1ZQ+ZURV5.HV'T*0<!Q36=R^,
MR]\.,(XI.YF0?H,A ,#AJ<9(/=Q;S-EHSEZ!8X1WF,^-VE>!\5\T%-'JKAE5
M$JK.B"5WJRNZK]17M*FRB]EC$<)Z%VA@,W75DA%MO^Z_->D51>CH%!Z5+'J2
M,3*^3\SASF8P7_;=( #X0-_:#QB<EV;U9BVB-AD'H3N]KS2/R/D[9H6.K3,S
ME7+Q)#4>H-O4LAC[C-0^TK=&$:2YE9<F7S_\\97/24O9'9HLD3?>@#2;QZB&
M*X^XY$1F-<\9\4'(;RYMX7]!IR>EA[7491;KW;:DO,591GL,-/->K)B9B5Y4
MD=H3MV%DLV1>?5,[^ <]=V2L/%O.G@Z4'@ $'GBR$'E\PF93G4;(J<*5QOS<
M\NU/]5XNU!M^URQ//Z67*);)VVPLQ:#.$JUH%M,V!$6>)=E__?'3*-L4SN_X
M\+,A+&Y4 S4**6%CZ@GR(@ H&*&)$):9.*]N\_:6M+;=<.MMQ7J=/_K4E26N
M77%GGE.X6W8;7WJ/2+BL>EFD_$:UBS[QC"#FFOZ1Q2$_/1"!"N-GNQ.2T%)_
M#_O%^B$S-V>K11_^J1]= V3[CWCR>;J&AS2T+I?2?]$@JQRZW),HQZ(<N;C?
M\_.+#=L?CM<.D(Z=KR7RL]H)@.NE>+-TR/>I<M=E+%>->Y%] 9V*F[<\;3'C
M'3%>J]LK=5T:/'FR&Y:O;6IB57C\6K.+A6;*?JYS8"+7L'\ 4TTXEH'9H!S]
MYGV!!8&N^??^CSBJ@B2]MD5_%LQ0>QZ=@B6-S&7\!5(S/@X<;\?WZK4D4Q9R
M#PE]^X/K\H7YSMLT;+Q:7F_8EQR3/S()W)?YRBFQ[T@ 9.:;;XO].Y6U_Z$B
M)!NQ*5._&]0X&ZB"R%2@;O-#^5LQ439Z#]J*VMM%I)O2F(G&^/E]8%=<"?:U
MB?%]\"R#YK:NP=T8^= 0KOLAF@JI)OH\\6/T.TP8-8V#PP'7.P-6/AR]:OG1
MCY[?GS;QKWHX)KY7V6AU+Y6O3NB-Z6T*%<I$O@(_(Y.QK:/'*2OZX;+ #@-@
MSSM<TQ20&8?"G=3.1X"N!XGB6*?2I1/W$5"'NM 'O\#%T%FCZ3XL:BJ@!6[F
M5N\<HPQ9+LGBTG^3<NV=XOV;>,ZX7F;+C^!> 3K=<D/LFPO'%V0G/AK@9FD)
M (>_]<(YZN#V0-M'L+WL(9R):QX!,%\]T?;]4_<^Q^3\ H-B2_2>"CX=^'76
MS65+Y.?N7^FK&/^^8D(2.[%BWP2N\WNT?-<=Q"$-Q0WC'VX%AC:X2R+?:+Y<
ME^3Q\AHP-5-ZD.)HFIH2PO7\4X?-2RH-J9SO&TM%ITIF]>ST9M?.D3AT/0>C
M.W3 D6JU8!E>BQ;H,O;I&M4%OG!EBC(INMO=<UOX5,$T(F2FP8I-98-<PX1-
MPJJJUP5 M,S=FL?H&QSH3*;1IY@[^LS;H-65(X,=F]0@X_-,8F$L=56&WWA4
M-/CW.EU4'=68 20YS&0L^-(G,&)G8G(.)K&G!T-KQ]M;,AUS!,!%2<J%[@ZI
MH(ENT&>^^?G':>OU=8?]>F,;I26)SI>+,R]%Y!6&F=[<'Y,SM UV-,8:]%,1
M'ZM)]_GKW3:S;1H]G&4T.3L\-=7G4CMAJE4E!K38#3@SN:*L:O8S/Z.MSJ.D
MQ%;9ETGYDH\3RVP:!=%6$V80$(M_ Q+V(\E9W>V"0/82/TMD!BX\V(J-@E%+
MMCONR+3/2?;;PTO!WR9<HQ<B9M)F^*=Z=\I!D7[<?E(NJL+QNCH9?=%F3[.1
ML[2^P,SLX:GY/F4P]C.: % YOJN@[U+15-:S"XR57*(SJGL4YT;Z(AYQ>&J;
MBH&04ZO(I0]E>':/]\O2]C[7(;>.9T'JH<W6,[QS^LS7&HFH!\6)WPUT-G\O
M'3WJ+Y_@.H:]L0<&B^)7$(@)>R]D^9B>GKC+:?+@)W4?3Y< K6)PG\Y0<%B"
M%7F K@"S\>LYY*PS$WPVO\H?!O9;:FR:>'1S$3DX.=FL4UDGXYT]S2,H.1)&
M%B.3"U!/Y.-[IJJ/UE;.ECUWGB%_R=+N/#J4Y,(*!<CR)FJJGT2R[I7X;GV^
M@_4?.JM<#EX2/W6K_XC79;8]=1AXR]$IN$_M*YB_>W6+2@9I$NB5DH869QVE
MHWS6&.WXG4N:7&EO?B]1?EO$*'QZR",GD?W$)*/V4[0^0.^SARPD4%XR=2AR
MC1RZAI;S) #\0 T$P.Q6-[H=T[U'L3,TJ82&^2_O!T(1&P=O6K*S)-Q  67X
M\AVF%J!7H!3,:!'#I):+:>-S*-:@G3@H<E(]RF!JY6O+1$KI[@G[9O-_SG_.
M4];"I5YW 6.SAV3Z:9@TE]G+5158FYG[$-[BRGV_74</8!:6'#JNG/J%6N3B
MK_C%]YB0EC/=TS;_"U=K]0D T\ BTT'K@ABAE![X \ZA]*_[3/NWGF\S3)KO
MI#8>>'R"J3CI5D>776A7;0^IS\5?.5B<RM6Q:Y/H=O!^8%*.HBN*0&Y*9'[1
MJ:Z+8I_H2/=]U5A.]6B(CN?Z<VE^[RK#\()"95FAVD7 \I:'L&PPGGTDJ"^,
M ""-^4S7VL8S$;%,_;!WL7N=J3V!.\>8%Z*117'K9\AV1<HA.3H;/;1EFA-2
M/CUOW3C;/VWZ>.*P]O$]W,_1;S"T.BME?!GGI3?L15UZX[T73523;Y"Y#G<-
M<#O;0>@]%40-4%<3Q:J;FEP6JOPO6;CB"EW[>^Q6^KW.R.7%/!8?Z9JDER&]
MR^-W CWA3J;UMK)\WAD-8QLYF(":L4H]]AHOTT">5_,#-Y92M!WE3.O]^QTM
M0TG,>1K0#PXV)<Z:8[Z-C&Q+I6"ZX#;<#UPI7VT'J#]MIN?2+I.C-W:Z'2/_
MS 5CMW(:Y(F<[E9D2,2-^H&KQ8KUL[+>SVFY!.Y&;+M ^;\/N)Q<GAUK;K^5
MMGE/M/.FD(3SK#Q7J=/#K BC./"$J9^C(5MV[3HHW.!9L^#/H*$#(DQ#SE=D
MAE"'Q;EXRTD^2$W=H$K@$8>/J^&!--UTZY'>I*2&DPNO/G?^]5'#J8/TJ=&[
MHF>E/X9IG;26X /J#@4]8R-?N;\/+*M=0YX^0:%P37--(/ H:EUKAR(GZ]&(
M9+BWR^Q\7;-M6['-+GEWS:,Q?P5K?F28P([WT-3IKD 2CY+AD=:B>Z;=&VWX
MD%32<%T9_7O!CH.SR E[9N F=A22>NG,/$=Q"./!&!OST<T&+,KT9F&O<6Y-
M/;ZT9\<T^GDM>]?$1'OMYGXC?9@ 1VK^0(4 7^R<..FTA<;'$JBQ44%&65B:
MCNZU^H6<5%(BU3[V@E@5Q31@JQOKYT EHFUR-JZ0S-3^8^D@GM=$#UJH$MOI
M6GXY<<>T&=TLGT??:6--'CZSYW)<YAS*\$A-<0?^9>B*J;0VIE!BS^_(Q@RQ
M>?87"%7__I_D^5/Q]-C-:$M]&7DV.Y:55>?>W/W2K9S==F[6Q(F/3HI:M_;[
MCX)\MGC%*.K%%#$EBV1MPRSV9^Z>'K?(BM[3!DO%FEQ55S ^L0;%Y_2HQP[8
M"3%=!*93>!W>Z0D(TWCE,I@\J)8"Z9 S,K2V(%?3!TIJR)FHV"J.;=8-J*Z7
M0'F3A4[>[>Z6K!F_>!K3];9AV_**] 61TVN,NI? 8=1,^Z OC,&,T&]0U(N>
M8]#!%MY6TE4M! 5=.#\#1'I_/%HIO-? BB.1B=Q,UF)?5"*/NUWK?6FV>*EE
M ;2@O A<$,ZD TAZS,H 5ALH+=<.)OW"=BE[-(?WYW@#2X'[U#;^!06*:84
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M&Q.9]3A +07,\[+/9-;6'4KZ@6D:O-N]Z9[XA0H6DS.*Q+S\/ -6.VY7ZOT
MZSM_1^QA_\@SB9E!PZEFQ' MUI8 \*@C -"XGV1NZ'J,,\A_X9I5?<;$Q*(,
MD ,[='?;<?\D,!Q6YF^WRT2,RE6NCF."[H[Y.BW9+ZAY0LD,H@6-K?)!\Q,P
MI4-&J1P-L'E("<8/;,;DZO"]L=!C!#D9GA?SKUMQQ;;-6@D I4SCV N,%G5G
MW@+^7FVG':NWWUNWZ 6Z-0BF8VXM"'VU#H;LS[N(4S(_5+M/=AU=&5/C,:S>
M3@ (,)9UM4>',$^9+C59("JWIQER&%=GQ2,[VZV.MV6"V+NL1LC(A4B52]$,
M7L^V)8:TS204F4O"PE)HG]>U@?,+\4X+!NH[QGSM$3,>.UMS%-XJQ(ZW&"K/
M%++HC'VK%Q4!F9,^)A.^I5XSED8?K:)KGVXM8FP=J6A)0@E1.#.OAVPPL.9B
M;DQ4RPQ!9\X@LX@ECR-BN](1+6A^$Y?.A ZUC#YGU1J1)+6H:<RTX6;E$4/@
M!T7#$2&XG$%R+%LR<;BWFB<.F#:AV)/CG",0>&NCC6)E"AZGN4.O?"SV1I32
MVS-%;FEU^5O=7E>D,:0ZOF!@5(3Y^7<>G:;^!B$]OUS?Y,WIQS9*EQ5#YIB)
MXV'\4T)[6R-XUJ%VW:=5&'':4&\K]V6_-5&V"<UX,"N.FY,O4A^?SI2TMRD;
MT-C[$#Z309X8E4W791%9YMC\S,$X(R7S.1(+^I1S</2E9H-ZRKS?O,!?KHI;
M$BC8*AE^*[/']0?)UH^ENN-?[=K#!J*37<Z\7N14&UIORTJ5KUDCLUJ-]4E+
M;%+*X1%%"?&+A<'?GTH#Q\Q11WEOB=R?2"/$E"'%>VZ.6Q7?)IN7Z*9-/S?8
M'XNN5OQ8$BW"0W)G/#T]C9B6QE"+E10J<E'9D:19O:EY?6KL.LOLY@N>NE1A
M"=&7G?*.D!8.PPMH=<A?R:'_^XJ[%;\(@(]SC_!C<OAZI2WS?MB4V(G;P<U\
M&1\"X#4K 9 !0J$\;_O_<7CC?Q$:Q\/7]!>A^!>P@?-S --B]A')6(&HUK-Q
M^-D-1&:.J[:TBSX=N\IE3[Q?F;W5F! [O]A5(]+-%,<2SH,_OM%D9%]Q)X\,
MVJ]UL@&60!<YI>YI)UV=X#B.Y1[^Z2CS3:-:!(H%CB4&'BQAQW"WD!0QB%%/
MKWK?K:"-+>F!JFI=:;<)$VZ':B\1(]Y.X9_:9#\L;^'NA%U73(#NME!>TTOA
M+,Q:C'R6TBS2V?%.62AR)>T/ *K00>> 09<_44<UH!O+<^I7"L2H@;[-W%PM
MFV62\ODQLBQ$1_%JAS]WPZ556#:OH"R304W40\IH+*WWN-%#5O'6F&9_O(/>
M;*[]X.,43,@ALIUL#8ZE6*;8.D3.7$7@B6%E-FQ3FFQ^*+/(!]8Q>UH)2D=W
M!J*S-ETG9Z:8#J_/4-.Y7J-Q6IQIX,8(8M]HVQ>^*Z"Z-_XY9X ,UI264>96
M#\ZGK*:C GN3%[1KXU2T7\GV4 TZO;BUUM7J2QM;C:-&X0B L1@(#&N)NS'-
M1"'#K.E5Y"%_,-<Z],QG/M!6",RN^D8JY:"[DUQ>G T/6S@4=N;2>W&)Y\TF
MFU["9SCECEC1B6D 8%M3*NG5 A[:E^4R'<ZH$#LT 3%$&<[FX^()@$^#%YL\
M^US-WG7)\9N07_?YL6(O:N?^<WQ8L73Y5CK8^\PSV<]Y:ZQ2^R3+IBSP8CPX
ML JX^]7C*XE-,4875WW X%IS>NW4(0<5FRVM8<*/+D;5X,UG+48>MPU.29]5
M-9MXP5V:^@9"QIOEE<M^M,FQBTA*D[,'TA091[&I"<IJ\05XXJEN\HZ$1H2\
MVD)3BJN1-?;>?WL5$D  \,N8ZG) N(Y#1IBPI#CK+8$8T%6K'\>MC"HT,)DG
MQ_Q.+=S[CVL2I$+Y):5EHW(["WU3T:&FIC+2X!G%@ \\U.PWN!MNNJ6J> %M
MA'.O<7T=:9'1$Z8Z8#C?N)@S#1H[]6O:M3[3^4N1SK^[ J(,RJ8X:ZO'4TX1
M/80+W/STV \]J9.&9SNEP[&6WHUONPX:Y<#00;9;PYH8COY*3NW?53SS7^M&
M46$*<34G%I+=*Z"7*C6BXRK\S1[V+K@'W*:]63,THM%%>*;0+EF[TG1F^00C
MZP1:8\\+F]PL^MISR%G'\S-<0QL#'A?WW:L;:A=(I G@PT '=P(A]8ZP07$"
MX*WG4:,B;. : G\UJ,[ZA#.>.)BU\RN?"0!2);PYZ$=_K8/$#9N8'^L51P//
MXW-LO79]%MT;X#-6U!0S<+G@OL6J-Q*D&>NEXT8R@V^X')=CN+*S:1(X;(C/
MY27H7W>%K^1TDV<>$ !+ OX!9ENT,RD"=F@B<<57#=A^ 5/J+TUX:O5JW%'^
MH)[P9"QM8YH[[7)EC:UAG&)YZM59_S+1C8HA_!O@S:#'+D/ODPB _B&G@"];
M^&R$N&OR.C33T"W1W\[.677PTF66#I?MX=:]QYO'<S6/>648Q6W[M;Z1ZZ;3
M;$PYV,EILYE[[:0VY"Q'QY7CE>FZL<Z[,O,T%'&!H:(+NVJ]\[[SHA(I,G,_
M=O3F]E8V4A)H)=ZW:Z_]*LAG=UC*6K^U8KA48J-+9%=L.ZU3N(,@6YS^K'D_
MPH]($-I@& )@LG6XR@/$U/8<M](?$(DP&8(L32/".+[O! Y7'U?PMYENF!@U
MOO* *\5TCG=J\)$E/^>Q'M-@;R5RT1M+/L^VACX2 $Q-!DNIIH5/MX*B-\_B
MQS+-E+LFI."9K P:L9%%A173FV7O21PRUG0KMH,"B=1:Y)SLO06)"IQZI:)X
M"8!. );H]-J0[N<A31UL@3OG>&DH8A[C$4"D^_.)3>??LZ_D^(O-V?^S%.NM
M/E=Q9OLYQV5,1TT:EGA3?"]L%!3G18."G<8SX4:)WC<S-W$R/-?\?VVZCZ@$
M;/'%3B$,!"N;F>Q=(.AJ,7(>+3O1BIWO.COT@2\TSB(VN/-3K@-$6=:5X^X9
MO@V<HO]\1>FR]:U@B4GA]<]'0P=]F"OPT[;4H"V!2 ;IL-F&D]H>2Q2UI ?F
M5 O.^HCM4-#:&AP<:3\5H1#,.2U)?L43DM0+DLI745SVNR,,=/48:Y$[P+UE
M^L6@K3_\/0".5\SJG!5GA&!:FV5,<#=V7#LJMM0R%<:4C PRII.-.+5HN=-*
M[(6J1UK9R:6EJ09TY(Z]AD>T5,B]V+9%Q*I3[7V2M ^NK3P?\<+Q7SCBB'%"
M)D;:@2U@;JFWL%:,V5E7<YA%8:A;>+\I2.7$_%:S7="M !VD1/D<NG ('20#
MVT%)QI"Y/.?G-K^B=N=!78T2@W/-_EGR#:UA.6G/T?$Q.+L(J[0+>UNGP3A[
M_%LJN>DK'I]B!>K#N+)KGMS#[J/.DK$GAT)>YB@AO!60O(Z$8\FN-W:E<HYA
M8BK+[GW!5#-/]4F+==6]UGZ-T-!?W=)JMF(7LO)*TG1T.E?*\LM2E)[8941>
M'VLO3G2I:W)Q5_U0  ?'T?B^U(W<Q_KI[F]V./9"5^) WS2.K/H_I_Y2^+:#
MPUX_$&@!I0F@V)%\]1%#:/[NDLVY)LQ04Z4G(B;V;MUK)17ZG$[!Y+Q*A^!A
M[4)>W5JRVIM'-+09T[Z%V?=I6EMB[HW/S210UZ8+W0#VAW+A9=6I)6Q'V[>.
M<J'0+) =YDJ2<\Y*"*[M!/EFQ/OF$"9YU+=U*@9"0V\K[U*/,^-6#G5QD&:G
M=DZF$J[J.+;/YK:V_T B5$!AL]N@<7]DY/'5#[P>N!/HAR#S.  !P#R\=QQ;
M]H_&MG^ XK]:,0+\*I[ZPNAL;&VS/]85)%@&C1'$-6)J]T#^QR0:R\4JZK%Q
M8;Q!*V6(L9\V/"51(J]$F5/).<M*,E*4%6V+\E2C7FNIGDA/--T4G<?QFF#E
M-1<V2LK:Z +J$5T)UQ8*.ES:LI'<F^+)FD$SK@@"@.$S]1'GQ23R^R+O)!2:
MT'K(1AG](QB.DP-;00#P03IQ+?AK.S'9I1C0O*G_+(BU36M7]8&8XT1GG6C1
M4N<.6[=MCI-2?'>YN\K[WCK*W:K$,?ARV7)8A#US(JMPV_D!UV=_<]GG+WYH
MQW\QQ7#0]F3_:N5[T& YQ4D_1Z6=0(,BXDP,>U6K6)+/]5\B;4I?DS,T+G8*
M'25!8B_M_WU^%[8<=+9TLS7W:/<&Z'S?^"GQI^.0B18^_"E>87?N(7*:PFRO
M_G07RP3S;8?^MOEM\]OFKV,S7C _=(L4)#&/T3 E (!\3;%G2W5^J$GS-',3
M(E(N;SY;=G^6>B9$#!^/6G.^[,I5_!7 \']^Q%4)+),)Y8G9Q14VQ=KMFLU]
MVPGZL14T,V!=UZWBZ=KNZ/7#5:)<8I3^?9=Q@E5>QU+;<2AW6<NCIGX]-3+=
MT7ZAXO.:=\V9G*$;:X.8_JR)=P3 ^UZK \/RIN?:0G2)2W<.Y\>2%:\;+N/Y
M*,PU%<2I^LD<YQV?__QRF!Q-1-B:G)548DPMCHSYB:6K;+M"A&F^1@(@Q?RU
MMYX^\-;(I.HL%88/EE;1UW]\[].S&AJ^UMH#<65<JS6EYA+%E.Z(OEY'C8H6
MM6[<5SQRUB7\_\3=>O^E%>]N_OS8F]J=LQ'-=%2G8>F2>"I* *CA9>&! YNJ
MO?A$?) TB;D+GFD7ACB56&<GSK@Z H "/;]-I#S$N;@-:S]#GX*"SB?IJ=L>
MD=;@Y^>;B-.W#8$#SH/JB5C\V^2WR6^3?Y2)\4>0]#T<:+ 93SD(A/:;%?P9
M/&:W-Z]UY%@0 !QR@QI42J!1 0R%R<@I\[K-7X7!_T^"X2,B(-%@WJ"8W+W#
MO\ZO6NTE@BN!+/Z/L&_<&&8;T7>[E;<;^9&002N/ZD6GO(H.*X>>\MXQJ^7.
MP6@5>3K6,C^_EM<BS[D4B.@*NXKC,5^-F?&+$D7CGTMOD"SG[[.;BF]+3]1F
M/$A@<U_. V^<](Z:Y6[2OO04^I@S'CC11.8]N(^W >Y]WLT!]B.K)"FQ =9!
MI#A3#/,,PGR9WZW>_X;S*D\5C>SSQ [;Y78+%"+D5IUU/[_+\2RUA+;E_A Y
MI6HZ;^9@I=:S.>2L&^0W)/[%%,$W.V+-U-_/C>?6CQ  .]W'S%-XDC]!\2=/
M>A*-SAD'5D,6'7(&Q:L1 -&G8NLBN5Z[5T_-<9D$ -WY;/PM_99^2__72B5
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MMJ(.*\:H:A_ID:14<9:6K21O%I7>V&D=J]\&KB3CZH[O;"),D,3 3R#G/9V
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M72)SS S5@;;^L-Y3M)'#9FEAPN,_/@H)7D6>)XL%NT'?07[F+MM1Q4K.YI]
M/W(L L0']'K1\V1U\[WSZ#6%J-)(SDW1V9OJ4'*=5GOO ?-W,HO!TL,.^LH%
M0J%E*7CDK(F+0"<P!@ZDI5N89=)V/C&/VAW7RY(Z Y)(=D9(^C K'WK\O/?M
M-J6P=L\0,'&'UMLQ1&"&\OP+564J5XG!]!YFZ8Z S9& 90 8NS#'1.Z'>+V$
M9OR.X4)D[:LU2(S'2,.,:S&J#"[2HC<_ C\A)(/T=+N77C_N2\L/X_9=<WQW
MZSR&#*1*2JJAJH$+"\,/=75U]T:TAD>>U@P_IQ9Z'\.9_Z24WCTO5$_SXEL
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M:.4S'V/*D3PQCH=\3*B#"%.N\?:!@2LV3R43)Y+J.E\#)[]*K%:M,R)> LI
MN-TW">E>F:>!^$ZNGQ0I)YQ-H/9L?@\H)?"\H'CG1GEGBMD,C&H\A8WOM.;7
MMR^K72+KZWQP "?4_(.^*R*EB*R?RZZS3N$OJ:.BT/3Y*X'/F2-ADO)K^0()
M0/*-_+-H:\=,,"IJLQLS<T*2N\7P64^*:'J)&/*T9[N- Z.-/4)%+J&01]6B
M$:)I3A9/!<\-:?G,-BL2VEW4;\>_,^U1N7B<28P#.'S;< &CBLBN0G" .1KH
MKQ+HD3E6#'K0NEV.?Y7.E3)@<(;QO7";OOUW.8,'W$&2I[ZZCV3>KVY$%C!K
MA==H*=?$C>B-#>A8ZC_L8&E2.<H5CL=KYZU/;BW6''R^L%\VB#5O8 B2>C8I
MY5)9+%JTF$ZQF-93&1N;!.K1-DHM77@,&@JJVJY,WB'VHP?&4CDLRI<;=S+K
MLC==O!8M$JV3N,HX3]+#A!^83E7XC"R/&!_L5\^;$4OSVER4LM(?+-%\N\O=
MCEP<V&NQ!!;V3,BSU)RA-1TH6>#YA6BG-O,XIO@:\G>[2.X $.K@*U0"*XRI
MGS>96!O&7*(C+Y/2]U%-J!:2@&O8K@]!_YZX.L@.ZN\YY!2G?4"2$),7'&G(
MP;4<1Y76I3_9LY(J'FV ],U=/KQ5+2'?V/;03WT_8&=VLM4>(15T= &OMWWO
M9$S7RCM6T+TN^-+'"/Z^H'-X2)HST\0Q+$Q10$=QX VV\*^W1&S^!Z7=FE0<
M($C_]TZ  F8*JX0#$(BR;2\8@M*OR(Y-*_Q#PCLD7;GZVBYL.N8FKY0/!M9<
M#5LVO#F^&5E2N!EC%>N;+A24KAIP $Z^"+.^;VL7Q]^O(C#M]J(S6IJF)S36
M9R[O]_]$7,4N=C?NPI\[6,!A)4/3!GKCU)C7)L&!;=^5>.C4A95O>RS3<;;.
M-/VYB_Z?F?M_G9\-D1;LM\%AJ0X.&4.[.SYAWE:!7NR+7K/I]$S F"FX/!?7
MS3N,#Q6B6D=/%3$C==VJM<@*QFBY#$8Y2L9 C$\7-MDG#AN0]!8'V'()QP%V
MR@.R=]JG2\NQNCS0O1R^/Z3YP4]E A?BU6(1C25O?&E11[SR]V-".&[81:2\
MKI",2=3]25U&.K-8]";"F<^\7?/QW<<*O5,T7*5*0RITSR3*:S^T,DS1G-1!
M2%AMY,DJ1<YLW'+I9($V178ET;J*(UN*A>DKX1(^NOHY=YZ<,ZWSFJ2E77 Y
M5Q$"?4/U7PR9<CY0H[8* J02I^IF]330;KKL+_;YMID6M^CK'[\55])PR79X
M!'[(V1UV5^CVY"I\<GOI^Y*PA*Q3^L737PW%XF8!J._O;E$U?$"WJ3KT^_C5
M.NE!.ZV,8HW6LV#'3WUR0P,3%13-)>VHIJ$;[;:-:DG2^.!RVEX7M.:5 =!.
M9^9;#LQ[[IE_TZOD=[10G*PK#6*D):3A[2%W/>O:"1KV9X4R=IUO4HU69[#2
M:YU>YM&*;!=&DX 93/ 9?G%+M%):#Q0Q=U+?),T.=/Y.PCNU2U_3Y1(.VBI(
MS:ZB$)R9V!=+I1K[/G$G'D7]\9XB]9B2^\ [Z47_NGJ$F$!'2J(]\0S$!30:
MW4;-6;LS^5#8 &/DE0IA2-(9X4:O@MM]4YK=F.<[HYT1?I B#[K!*L&>.NE$
M':&/TJU!<N46?S*B2!N@)='_S^%UEQ*PIP%(3V<EOX?-@1/#9D;TP-BFH""C
M'J0_L59D#XNYI4(+%ACG=F%28GY=8F68S[%JC78J)L[.U \L*],#)K HAE<0
M?DP@,7[,Z:IM''@]SI;QN')[FHKN5BQ\A*8D+.^C,K'.EX^=MTQY5!];MM>9
M>4+TQ,K@A3T;/J+9HO2*;WML0<X]<9TD/W4?.%A*:SK^SN^R/HZ^QYW^MDIH
MCC/J1B2555X@9X)TBN[[A;H,+8Y&+K;EAFZA>7EJ=>=<*V/6SE]VSRS&@O9#
MP0[OZ5(XY(G</0?:?8,9;#C8IFK4P:"G GV UE119QUCDVNIKE_P0<-0$&VV
M<E\82W1=PSS#2K<:K-H-!/V2WEC_Y]?;"'6!37$^J/Y(BR>O@[/TBSYB,&DB
MXJRJ4N=,Z+&8_UV&STH%BRBQJT8XW_V4??JM0B:)2SUY_X>E=CW*D594.;T$
MG&_@I^<S^^IO@\32XLK&NT7?6\]OV&0ZIQ0J6&H$L-:$*Q?_\J@E+$3DM1_R
MI:%'7+7E$W:0F3.^7ZV??K#U56V'6HH&+QJ?YF72R.E&=>M^&09:U@VQG"7H
M43HTW;/.Y!&6 NN;OP9J3]YVT;6O4Q2Y(.5,A2M:>*T#"]FUA34T@WA+)K5D
MU4O9TG-65DS9SA]1 ;PR:,.V>@:Y'E*2IC$RM7F7?MM#ELI5B23.S\TV%G.Z
MHLT(OOT8!Z[!*("Z,%[R+WI 50J_*=UX 0VV:*N$]!%N_\]T&$5NOSZ9^ESO
M#<%FL7S#.+F/7&M2@-]$T=MJJ'3A?Q00^$_!_Y8*HI&TQM[U4,L+&ILDIV7X
MB3"YMT_1CD7>/57FCCS^R8&?("DDB7ANV*E&^VB4$W2$!)_Y8YEQ@/*,A<+M
M)OI6[!=?2ZR7TPPFAN':[V(GLE5^+/AR:L9DR>Z@I$[-;7\PF#[8/]]4GD+#
M.$L_4;7_[A/^_.0=#O*0[5-=5*2#>-,]^LB+__<C\S9I\"YO'2)MU>?<<W$7
M&16X5]:?,S^[V+7'+3*1U;4I>(JFY_SZ(MJF:E0W/T"?5E(8K#V:#WQ=K!RG
M&GUG6HD(Z0N+[-SF3=[?*:TW1= I3=-EFE8GN</&2O8T/H<M5JT$G_=HA P1
M.Z5PJB9E4_DI*"B0V'TI0&H/L IAE4VC\?J1>3:)-$A"T$A86?N,E!_["I8=
M-S^5FD$K/:OFGVIHH8 8Z.D"]U,7A&_'#ZF$%R-J]?3<+=E@81S/60.I.(S9
M0^_A=9I2=+E^A*KW=T&-E6QEI!7OM4W/CDQ+9<\"32V#"H=!&K5,+!KU)W,&
M.<)S?LQ=Y,J3PNX#ZKU?84R%6;[E'L]_?W@I5?JYPSFB,KAS?ZBVGO_EWH-%
MQ"RMQ\LPZGNTKSDT51045-[$3(R/ZTSTT&IUD#O2NL)S..$?I6::[N-Q.$.4
M1#O)/,+=TT-4'131ND1%"S)K^2#QK;C"NXEGTR"X("<O%X[TJ!42^-D Y[#G
M;]@RCV-,("47JCG*Y91[7-YT(1O9@S5A&"@H@00L[/'67MX_+"Z'G(\,Z-C6
M)5[.XCF8"._$H,5N(<U;BH:]=,)[&77!94\VQ++36>3[*Z3QZ4<X;<G2*6-H
MGB:JO)G9UAGT<]:DXY'11R2"V7?_C\;,U_Y1*ZU\A2=*-&8D"A1@EBW5/N+1
M%A!L,.\O5,O>'UG_C*DY]US^@=K/Q;0$$.^;SM6Z&[;VU(E*+UPF57SPI@4I
M$4F"]8"G%#7- 9RIXO/BR3F)=U<26,/TC)BMK6__5>,Y7X?FU^OV>0F#YF:3
M5897GDH?]OQED+S#2W0:GY%4\Z2/X5V_^Z9'A_3;013J3^,O*1U#Y/^Z2B['
M?R1F,Y"YU-(\-K]JQ(SX9BX7N&($4)&)VQI#1VZ??:<[FM!/*^LA;VVVW+TE
MR^YS?.G?[]\OJJT^(Y_RZ@^72^%4 +*<GI0(R*J1V*-:IZC/>S!L$EARM24]
MA/&W%AP@Y4+G0H&^>V$R;<):Q[-GZ-WQGF'%U7>?*KG$KI[D6>'0J+X?D;MT
M>C?%1OGO_2;[N[C:(XDK%AS@5\R?W'69[HSQ \V-36QLDUII@*P'GN:B>)MP
M -O5-DC4T75Q=3V]*'/#A\Q?@C0Z:8\2L%Q?8<7Y:/&=KX4[?FW4*8^?>M+O
M(D%7_Y?4(V.;]U-$I(\]; Q,BQJ,C-[$WAL;E+OM=D?Z_.6I:7.JL08.(&2%
M T2*&G]!R^S&TOT-M 8)F"*J*&//V"?.]]LJ!XL#;CCYO8^63F*\CP.4R!14
M#1Q\]<]<WQ7%[BI=3[V#CACB ,4<4]_.83.S:3-ED(SQO8,*FENNSG\PBKM^
M&<KFRZJJDZ.H*1OEMKE<5B/6QQP1OZJB9<_KDT1IAG*P]TO;#2:[.%O$R4R>
MZFH)C>Z4WZP1IK@-ECX)'JAWIY^"F#=_$3%XJ$+2"SE,^AFC6OM6(/YG!R&!
MQAW&R$)$@#DZZ4K'QI/M<!<T'U<GS>TRA&HPV(GH80).3Y2I4-=91KZ.,1=^
MK-NE=30]ENJ5FMM96S/,HG,54H5T-O,V+.-QV>M*/')Q6;D_"Z]L"V2F9Y43
ME[,F%)W^":9<L&=TAZ:<7^,M3,+5VK\&I-EX/+1_6"^A\8/4E2B\E/^/&R6A
M11$S=\RELM5SMHB!W:TZS-+>@Z'=\O1,P2I31Q%-*GH(W.? WO/)QB^=ZRD;
M=N?-HW1_.K"I\,9')>XS-7F%\MX\'A,"K^\E8[WTHTZ^GM=]:<2^'Y7X%TTU
M'(DC8&*HW"3WYQ'S4S? ?:K4\13$G#!R=)?[N[-^Z2UW#S1_HLQ3QXJZMJ9/
M\B.V]4.$OZH&*/D8O,UIA2?S7^=_[I:->9#4I_D5J4UTO#.+SEVU&EMCV4YU
M@O@X[U\K%Q/*\Y/H/9+^W3NED9\7Z5F@O$O-N'N^24? ::_\A/\1&HH*6&>7
M6C YP=/>@?UQA+#ZAX>=<M1A'V4M+$GD"U6''0PSJDP6^2P\35SL2WD;Q3Y)
M"/2T&9MQF%%OW7[\=A"EEZ[!L&M/_:KFD6*3]DW A>-Y#!9O;9Q8#@M)8=**
M/\REE5*U"#U'\DJ=N@UY%58P;Z)"I(-GGT(8+'(M[A9PJQY%:IL6Q8.W.U(>
M%X%8Z0+79E\:-E:U:W8O@Y\L#,2]/4&42F:\@0@^2?;%BPPQ&W*24PFVI2='
M34R7@7R+$;_C[L+A%2KZK+KIRK8WTU?+S$BEV<^B>LLNKUR:T"+%G@;E^GXY
M"RDDV?65C>?=JRNEQ4,&4YI&PB^5R#1>]HR_PA3:Q:DY/",.N#!8:.V)\71.
MG'%Y6#[M=%AR7".W;M?Y*$NV,^SY$55(+G64^!(*!]B+'$)%";HKKK8(3Q8X
M;Q3W<>]/+Z_61;I"6&"6U,OI+2R*[ 3D-Q_<\;WLJA2OK_(EO6K=Y]TM0O,6
M%Z(P($<? ]KFWXGW3'.;ZX??OCESC3[L(9[DEWCHKYKO/>5BW]JY".$)[(@%
MU7V"'SH?T-[/4C;:K$+\'B</O,OTBFAP9@#NR]R/9G]Y0+\]ZTYUR]EY0ZQL
M#F9'P52+%$TK=682B->S R9/OG_X05,NY"?I5SHH$@=@$8 R>[Z97J!A7Y71
M<?&Y5Y:=/;#."7<\F8O(91'4F=:0DD\)F,\H$RI.)U,W']1C[[<LMF"\2$-*
M8#5GR=ZWI$I$S)\C@TZ8&"/G[W9P,>J13_9[< @+3?$**\FV(W/Q>JE"QPP=
MGT3..0IG\NXG??7\NA;K+GR-S.7BWIN0D F.+?\*]"@K??B"3:R#6.:F^*J+
MYX@##B!8&M24R45/*HKT!18SD,0X6?U>K>>]A']3#Z-2#3774-W:Z@C6[0I<
M/'>I/EZ<ZS=(G)=4WF.;*)4O!Y<MAA"M]3 &2D;)XP!-/3P(=Q<!WXAZY.YA
M_N+[J>7&"+0HW7;7G:O"0L; %W([9QSVJ[FP@KPO@^;Y@9Q>$0JO$]SL/[TJ
M:[2V332H> KQ]!3E[HSU7VZ)M+;H3F")DR77VP0  %< P/%N_J-N)JV<&L -
M'</1>U:5+)DZ*NRA4K87;\K_H9#V/P7_P53D_R"!4?N0Z%61GP=6EXX@^(#W
M&K: SBGV.I ,Z-HMJYS5FM#;%*P=CVHH\]$VDA)FE:+GHHW3F]*;U%.ZETGP
MPEW70(,\8Q=)SX->\(=,2<DT-B_50'@ES,&1O;,)Z1&M$$5/%SII08KP7.%:
M(%D5H<WA+YKQK\/[U@HVUKIX$,@CA\$!Q,N)ZL]%/2](?YFEIQ,=%E2+)CP8
MFVL71NL6NU*FYT1O[ECE_4(1G_-F2FDWBVS,C+R)N4>< +IKD<)9N/;L<98
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M09S*?Z;XOS_*T,'!?FM[LZ0D@]I8U="Z" XO2G@?^?*WS@A+9"<GTW/6Y&C
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M$'QG!8](=]F[&-::,4M8([_1R_7CW:O??D7S:6A[C-(B9<;0-BIAUIM8.['
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MQ_M[$_3?WCRV!!YSBBA.73C[8\QM2C- S%J38A/;=YL98YT2XW)Y.S-+^IS
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MCNLYE[L$Q%4-J&E\)C1YTL;49$:A-Z)&0HO/5938\4O-^;2EY9D?45%>)3B
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M]]6"GI:,O;SL+*01?=0V3^WDR=KOKI987?GHM%OA/7TF))*Q_6,L@[LT$E4
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M4XIJ?FEP:<V@RX<OL>$!:FLH4S.RTZ5D&K'S]4^HFROHJPBKYYO$$INJ!(H
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M=KH2')N!G2A :59NG5A9I'A*'+(B22D:\IC]-?<28L%^U?R/_6;E-RG>=E*
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MP%*!" J(W]&YUCE! 1J\=1 !]BJ!JXM@Z@ +$_<T%Q-;9RT];]]OC_W6LV'
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MJ"85EU0D?@5BZ8!#V4+#1RG?/#@Y$[/AQ3WZ[=AE"F[_TJQA=NOE/)F% ^U
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MG%+Y:EYLGPZ-'>&.K[J=MT8PY[K^]C%@//?L$'M<(O+DRR!EH6K<X PZ_LQ
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M2-NY1$Y-IPG2&><:J#C ^O2]WPXF1D,KG KA;'@YL/#9E6J!)"XT3_.#!Z
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M4^K-DSV]"(AH;%\#'^%87P.A:K/G^15N]OV_1U(+601PWM>=)B$"'5" !!2
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M?+3#\'9CSKG_ZYZS:T%J'WH.$P"W$Y3$Y36%%E3Y32E.T[B\Z.F19YF$DBD
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M4_%2]TS#)WJ) 'ZK,;(IM[T]-#/HS7Z9,F,:<W@&:ZPH%S6-C2YIW]^>]:2
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M"TIR(D/'V2?Z0P;O/H]CBPN#<K$:FMX4N%F@&OO.[RV=UK7DQ"GKV:7XA8B
M>\;Q*Z?'S,#^X<C843TK>K@/Q=R8!2501O"-3(3 7?':YQRZ?/+*:NP2$M'W
M(WB?6I26'.CT,PP<5'Y;47 OI ">^E'HOL\H%\CC3-6\?GD">>85AD+(M$CL
M16*6+/?(4N)?4[RQ.A6R!2FG^I&C"+2PLSKS'3,6-3ZK'.HT&K$8",R2P7-\
M*BRM/R:#PJ5@5BQBTZG,@)G&@^*BIW"7;<)K>?9E6Z.&HM*3-64\@6)=UM\!
MB0QP"<Q&E]=A;Z>E^IV>=45VN^V6 @W5HPMZNB57YM74U)7A&L;Q7+HJVHI&
M-0X\)>[:)&)_%O0KZAS)/_&W5G1W,C<O&7G0/?QI\,D#A:/7WFR[9DL9^FME
MXV]@L#QD4YW2,JXSVX1/Z6U+BL7!>R;V"R:59\8/[FN21J.C-QJ]'YW\(R6;
M_@G\0P!_9TN^?S@@Y]'>[.+@(H'J[E'FAN#<-C#5)/Z74"OB(X+%-[EKL%+^
MAZ^</BVF80C>HQF5^O80YP)WM1)+//FJ(Z</?95AQ".""%".Z8K(291X<!W&
M5GZ<GAVY$_YBEI&CV#4[Q*8W! ?A'V%;%V5,5GR,90^_]ZV5'& O+TV5H_-3
MXYD;1!L"HTD:8QW,R]\7B8&HJ$=:P>HFI&*I1FFH@+(=V;_-F&8Q\=)@!K5V
M6 &_<"R6T=>(WG49VW$>_5$'<]5= KL-PFQ1XL-*6&/_)]N;[$G0I+O6=N+Z
MSWL%/S]2Y*7X'>DDIPFFP'[77\.8F8K-Z*UMN:CB\[T)%*4(]@8"AN[I8)_=
M$C;,\D06"H YI/5:'-GTXO7D^3U*#S0.%.27#\>[,G90CBN5,FIKY#^OJ5K>
ML4M_*YJ\?38 M[IALP?^W$S="-,1</&EGS:] LQ*/'9N%H0:\5B-"O;Z%&3'
MD?'S%!0XR#.8$6MZHRLH-Q"8M'.(+KX8'K!2J',,UC\94LB29O8_9>XJVX =
M\%2+ICD&>?LPP41"Y@]M*^^7.V2R::<6/ES='C.R+5.-0#089S[[S-5XI@S$
MF@2&HH!\B&3-=N:O2'05?S1^CR(FW?O[8LH3<P=OZ)#.2/XCFU*E7U2XTD0!
MO4;%"<<J,8'?F<V@W]8W9!Z$U$E7::XEXOM\CH.2IS&VJ^<<1\RDW\07#-=+
M';IV+KL!>51MA0,.KQ;K6$<KP+D:Y==6\5+Z+\HS_=\!J'/\$MCQ])EI6:4[
M,I-^TK#)U3^P.--S'5J7L9)=M/ D^'P0O=#9JMUL2NY+&SGT2V36[&<G)*$3
M4-XQM515(^[MKF< DA .A;$_+^\O.G<+!5281^F(VH$^L2NY_PS340045S:!
M6#Y56+VQ\DD@^;A*]_#^ROLB=DO6/:$VL]GL(;3=#U3H1#UC[-QYT[/+2GGM
M']6H#QD$GCJN!6HOB<>H[@8I.:66LOQ,-_-!D**[_8UN?14%,II#7482W7HE
M/=#KJOB\;9 QXTW>(F!HO7_$M*8GL]Y'*Q'6&C1 :PMS#_-,5KG TA7Q'K<3
MC Z>VKT@M,X=FZ8CZIJ51CLDI6,$-,/RNO<97-;;T'2JC93&.V;MS/4\5ME0
MOX];1C'ZX+K"LI)"5\4&?M4BJJW;A:$J1"^S"T1%92F*B"LX?OWUZ-OM%E#K
MK;>!U:?X<(7OB[12')QKVT%;[U R/O$>WG(*E1Z&N;'MFD8JVD(64S8K"9.*
M5!-'_8R/A-Q6&=F,/T76QG;0O5QZ2S]G[L/=)Y]K3_QTKQ"K%VPJMA)RART*
MF CLDWZ^APAMB&16,K\H<)Z%0<7\6E+1A%+Z6&$,=&>O24F&(3XGZ8C_ODI,
MA$KN]-L_NFXT_L'@>#!&DUU0XV!PK@)<VU[?KH!F?E:7:].47Y\^!V&X''W*
M#)Q!OG5CNZ23CZX _>C7M\5^5,)S@2_M'+EQ<F%T]BS0>>^$F3@>V*DDFUIX
M7G8WNU_2756SV@6.ARXB*LSA615VMXJU4SL"OQK@Q X?!M2O"-;..Z6*QT;H
MV=/N'FN#/QZR;T1+TP63>C\R*98L])"/R^\?TT9KK.<6(-MEWJ4Y3NJ->&6T
MSZ!TF;0W;2]GLH:&IR=II0W8\Q4YK*B%J]O%709<?%E_=8G,I627FZEPY@>;
M<5!D4ZV,^U;[=3[QJ8BMZ-CGPDQK]N<B=JOS3/\1//T_@7\HP-@0TO89N'?&
M?/#]"H W7JBX=J*PZ=\M9%# ?Z!I_OO B\PAF@9@^B((C8XI).A &!L7FR5;
M;)WW5>#EA9#.#Y91%3G0K->\.M];]N<PQM",5^^_*M7R/E/Q?/"GRK6HKT(I
M5 .7C-/O8;ZL$O=EY)P+3 =PN0?F%;?9!B!+W+%[H095GBEX(AF=UL;;=!55
M#KR5 2&&1BW;N8SQ>=&UO7%U=)]ES:[7B[YQO!2X] K(!DDY^[D?#Y&5H]R5
M;9VX))Y/$PS)=)U$"Z2KU/H\8@Y<=_<R:0^V</NFT8';34)W.Z^5)D44_NG)
MFF2XDA3/-'E_W.]ZN$63_ZM S!>97C%]23EY^7X>5=9@)^EK?.(S,NQ:=M0H
MZO2"ZLE@K3H'R%0AE!2MPXU49:WNF=.F3G\G=TT40-,R8C^N )D^&[/,; 2+
M-9I<2"+GS'P-?&/%MW5N]X133&+^X9OM%^>R9W/5[&TO3YL.YQS(ZB-']8(G
MU?K>_.%P!?!&1P'QW$ :HVB"P?CIM,ZO9+=E.1;\N_-*C%Q0PX]BN^TX?F(E
M%_SK6>J\0F55PZW#)]/^87_=<AL?K_0VU.[[W?P6\@T\X!*S,[QFA'%=2[]]
M34SHDTO.F#N9V@:]S98*4#6QEKZRKA9[<XW.)5%=JY;V2QFO":IU8:D4) -K
M^8U*:ZJ_CY1L,7Y;J,D1<-_*KW#=_>_JP8L+ 98K8!/-QCH"*&%BQ$I*@&X-
MNNGP!^N=]=R,AB6_W5=.89*^UH(+.R@CH=^WV&L(]HL'25> M2O YZW,=2G\
MSV(X9)WM3%"L--@,W_7!:7B&GJ>N=?[8KZR]63]T,[DBF=>-BS>'[<X@":+F
MF&14:O_W1'JO /_UI.._'FC4-Z!+3$Q:-57OOMV]=7E-3[,<V\LO<67_E)G_
M<X#\<#QW/&'1_0IP=_@*T%FV?06XQ 5Y_KZ4.W[Y;WS *V'!9,?F9('Z[-'%
M_+EZX4>5N+3S)%\6)CG))*V!KUU6;ZQ3)E^7VM'VZ+.\O(T$";S/B#@+0@^_
M^3AO-LCP(.1V@ZFV-Q/@$6O>.,#JF Q2'7283(!H=%\!AN,ATP@7/XI-B*V\
MT,GT&N+BR=P58$A[&C';<MY_!0 66EX!-GH1.XN(?WF3V17 --CD"I ;58%?
M8[R3=J^AL;#&NK1@9^'G'+*N@OEQ1ETX15)T3@[W3.C#9MF.-M8.,G]Q\)?%
M&"\KGHX'HZ?=@TBP:)+)O2(N*VKK:$4;+7>=K*E,:=UL,93_@W_9X]JN U>
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MJ&\9[%8HOW@P%HXT=?Q'R,/_$_C?6[F<D[E><040<RV[ APR( B[.[+?9@Z
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M%C@&(#,0J'=EP<RN%OVCE@7QN+XH>T?G3]RGN69 5,RKQHGN]XT87?/:N<4
M82R==1TD=N-15_W2'I(CB&4?G"XI@#-233NOR<4Q+VBL@S+A Q+DB9("%2TS
MB]W QSE.C9(.#78>#C/B#-A5C ]J^NL0$0!(YA=.K9M6?STOVC.E87F35:#]
M3 ^*;[AP(8>U@ ;4JG_@4W$.K6KS)M&9>>>#1V"(NS]YL]\WM$]]8Y/N7EM#
M/L]9R>BB2(H?AJ))*D!81%BD3CZ]"I)+\^?@P,:@PKGYW,8]U?3:%FJ+ [7E
M$=0'4@Y6_GEDQ!3_UQ%U=1"'(B?^13QC'*5''7NOR/T'-7^]3'RM>;4BHO_A
M-P*EFG-=9S+(NMFPV3KH4-O=.:<W;&<Y488=<7O.9T@(_J@C^P#H*)6CGA*'
M[U*DC!ZQ2<IH2A/49Z]9=_"O\=0!9<=C"\ZG\1E=ZB#NT8SEP=/D0*\;)\N"
MS69ZIV3+I<N9_/L.N>T%824\Y?9#2"LO59::'OE66]Z='O?QJ6Z=OQ75'OYI
M^*O) __OGRZFTG%Y 73G38?2(3B6$TCO$N2'UT]J$?QO:1*;EC!;=<U6(6@X
M)[N>@5+*HB$^ILDP8-H?&9]67JU*EVEN,+;SIWMYFP@(I5_E$G/YME2]%X _
MKML?F<9M'897GYV(OKE3SFWO.H\\>GVBH<LV(Z=>?<?2K>K:PQWK.P;,7N@J
MUBV.483_V@KGX'!TNYO&AFCNSCET6=)!//R%DD*RIA6P6B_75D_9.\KV;N0<
M;^]3)=J&G]N[E5*S[9Q$0!]()FD1W+^&\UEWK\>5EQ%$]CMNJ)=E32$T1J,+
MU8W%+]LE7E+-3O!;D31?66BZZ=^,X;)YA5](,L]5TW;5-T7P77G;\2GCI\WJ
MU4&F 6+AWBK!"V;(C461UN'N>GVV2=(%=[/O84I?>G\*3UVVE&K[@ARN$(+>
MG\/%=8B %J8 M2M(E+T.(N!S9O]@MDBI_X79'@\USRU-+XL ?VX6XLQ4P^;.
MG8,KHED/?V931Y:6#TZI9E1%F9QH:XIH6ZWD0_R^FCP2?GSOT93VG6&CJK?'
M1QICB5\QQ3YQ#-++TC(;--V^+DP]ASD=C<,^=Q8'WU&)/.2F6GFSS><)S6JR
MG9Y<H*%C&+&A:''%F7S/[=?\5.O#YP2T$4GOURFF%.'G>,&96U)28$<"?_S@
M31QZ_[NN3MV3Z^B>4$JI&[]"T286L2J2M;JZ-QJ$Z " ?K:L:YM^Y43 1D/S
M4<Y@.^$-2##V(JJF=S/( "W!=UMA1>AQDI9ZQ&YNM6^I:-N[#99?3J-/!]-+
MS1X5+2G;?^%+NL7_D\<+5"%<<PXX1M6 M;;:J37W$^:QP]!;)FWWD!();[-#
M>YF<&0+XWK;]3+L5ULEHEK;,< 6!!FOBD-F842]GOI%)Q"4XNM<<:QSN(G=3
MWNJ%>;V.(;OMHV*VSYGK!6\EQF+Y>CPLT"/MW[#Y6J^PE?3XG&N^8EGLZYTC
MRYZA5(HM[KOQ)GS*+ZQ39*('"[01RP^"GN-S"69S9J&>RQQN3M-7"=E5RKC1
M6]$613K?XN'E<S31J*D-Q[O-*+G-S9=$I70J#SS%S$>0/+[(2Q!SKY]68L,
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M8]^0H1@9F23BTIGCBTKR\O)+@N/"PN)N%H?1V*6PN<D_NOEN+9925U>'IQ0
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M%Y:H(/&@O$Z7HXO%;X<M)$3YD9W19DB1 C4NX(Q#K*:Y>JP,>>FA:]+2)1-
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M1%;][H3ZKF=S>]I_U7UX,H._>U),4U>;=[DH(<M(6)NF@)\;S^]T$:TGY6[
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M@^\1SCG>47ZB+Z1Y1E4@]15+$PU<E/*[0L0'?VQ5Q6<K#)F1OQ$+?B!8MME
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MK>89O7$5[>B"L@P-&]]ANN>#-#QPATM0"0I!*=81K^W E[<>'TCUX^@[MZD
M=W>SYMCIYGXWB\L*4N0OW\>,+0\H*^WC^M;2Y[CP)CR9B859,85Y]+S7_UP[
MB8HI'&R[$,M]XZX'F9M*G[A$6Z)@TD/>DWC' S?_8C]KD9I8RVK)/^+X/Z+A
MK"$\K3 I0Q#"Q4O?>%*5]U2%Y#,#AS5FFLTH[-XBU>[Q/P[P6'./1ZBUR8XV
M-Z[Z!(2O/TA$FT2#EK)@;/12:W./,AO@92M)'&>?1<1/_S8V0!A)Y90XZ57>
M+/BL(JA.8[3^#601Z$VPW)(O,G,9_/K5'CQWP]+%?+@7Q^J8Q?Z!#5RGHO[5
MSCS583'9>B<LLH8[32N)]\:S&9N(X<#)%AT7Q1\;E!^:6'X+MU957-3;K8&!
M\:-O+O)=.?>DS_5[1]V/2-\+/6H-&!'6+TV]ULMZ]\XS(,W8HJRI %&&4-V#
MU<,K2MR-XB!^PMR5:B>'4!=B"H9)N!MJ1A#3DYK6[!_)0Y'YZD[S+!M]'/4]
M=5)J>T\.O<K5*1(CEW>KYJBH^:'I"S_;ZI@6[AD)G_+"[9[1A>MJ'U8\)9AE
MV5.,A"[P11K(L$Z5_ I!W4G'1Y]O(9B (8-*'^48K/?C[-R0"8'Z41OX-70Z
M/7K,M-NM6&@;G<85'9Q8J/X[Q:#+H58EKRKGE?7[K-<13MS!9Q)]]<3QB+&V
M7)KKM4;([E8?F5;(P6R705PZ2U[,6>@!>T&[J;@&P8<296;&G"NY0^W156@*
MZRT-Z.3(:)F^V!BWPW,OFM]U5R:O$G-V[+V-72H3\6^N[&#&3/V/YCG14*;D
MF8:&)HNFHR>?OX^N%(N.V%6KYI<K\SQND%"9-M &F=*<;F8W3786'WRR1K(+
M=R \ASOA 7I;K[5J*YPB,XI_)Q_EMN5M_IP99RL>A0!+""_'&PM?RJ>G]$BJ
MOP86B(OET"*=DB/DX5"H@L"LJ?_BJ@,Y>F,@!P,O\W&E#_]S@W6])?)SIZIQ
M4,6I[_J7-)Q\YR0J72H%);(T&1><UN]Q&F949LG0S$&M:/<%Q4(,SY'9F$/2
MG0!*HK?>S3?&GN965W U%_!$Q^:4B#:59WG*2GW[N>,K&WI133VQ*K^X;/)B
M4:Q*QG7*!D98#DL*#9 @#K66-9X'@]NFI]FJ+L*JC^"@1=-;J;/JL!JV,%_'
M7V+PPJH;<56Y,Y]ZIP76 YA\(R,%??4N+JO3Z6BLX1'#D53 BTQ=*D!)KDII
MQ1Q2,$0\%D5NKT.&M*F /R"+<U1 61SY-!4 /0GX5_]-R&[ 305<DNQ=/,C^
M.EBSF=G.<6TZ4W<7-7_>VKTW.KE'6_,<U]FVFNWQ%SH[YU1"#)\]7TXN-N9[
MKW-R0< !(D.(G9U"7@BRV!H82HSC:@ 5=;8=S9):<[OVK62%M<9ZQP;NJ%UJ
M38)%7/D0P[+D+.S4_Y4+B(^\M<.-)G'4D;,@:6%R]Z(X-+6[*I*:[A@:6^P$
M3J_T#C?D/Y_!J9N>XA70TQS.O 2G!3M71=I<QE:7D3M)E$ LSZX%OU2J..FK
M"YU:5QNI%ZR*0>W%.E>\K-';=!M.X].\.5Y6$0(8UV1GOK3\)=5G52R^XLYS
M\P$:\,E=W<XC78,H*7W$B#?(LBU.[D:O#Q:L5^222OMO?D-GVBJ^CHP,'#;3
M3>[Q$11[=+&,SV1',D4O-2&T#WKG?@+- W JS5<@YU]0 02$)@W^YX8Q4+K^
M)E.BLSM1CPHXWM*GV?JOG! JH*;J1,X45C2%$4D%^(_1,MG#>V^I@,V3-N>T
MW#.LD0H(%:$"YO:EE"B1S$I'K"<+A/Q7^7N_A!D_A7R+ 54-<182V73)OZKW
M35&-0?('(MT!;D?A9<4W6-25)V7\V)\123]=801M8_W[GNILQ=NA>FR))]72
M7I#_DH$#+4B#,-K7F7Y2 >E9@Q03?8C,FX C*L"'K%I* KZ8]MB/E7GW>U$
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M@MEN^@OY@T--_-W*3-=U52X6^Z'*[*_>%_Q*%Z9_.UI5,G7TI)-$R8+%*A5
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M3E,;/3LSU;*8"\ZBT@]*+2I1FH1OOS2O/<'7\]1"-1J].3EAEH]R3.U===3
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M 1.S(0,%C.O(]<'A%L#UPY)$_+-932TT9KF/!9HRY_-NK/<M:@@!710O:)]
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M"NI^SVQ=B"H:V/M\3BZL[YW=1G&)*1DZ^(:G%#7TS>U<XN: &WCW7+M->!L
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M_+L7E(RH\PB-#E/$);#?^ (NP-Q&D6S)K^&UMHRZI]GEHKAR?G(+];U?ZA&
M&T([HP]9\;[5OOH'+)81UX:=@5D"%:JL6&&C0(G*#ZP9R"YY-!5>Y=$_HK]_
MUP)/1'B1G126 KM@*E;[#!1IKRH4 \.DZ$#;_U96+,3+,9!N3\Q,*MO@ +H?
M53_Q .0OJMEZ_N]L'/]Q!)X5<[2R#ER/>T^50<DD?Q1ODT^!5LJ',??P.LHX
MX!_1XYU-,E&'W5BH?Q0T4Q> -OW-*?G_]V?B_[# (/.9-PQ4I06&C_=1X8-2
M?&I7=/IGZ#7ZU]"RH4P<,)*-5U)8^E?-1W51K">0E?).>F0-N-=E#;[P M(D
M*EH;+[>=.6\1+/5T6"G9SFU6POMN2]I&'OJ"X9U$UBN#5>\7E0]Y>R@&#Z\%
M#IPF[" 9']P8*J"ZUOT>N_AE",07/O_\BRF4*"9KP%PP:>=^"X@GLC"\BBFN
MRZHPJ[1GS8[KCZVB>3I][.L<.:Z^]@\/T(ZY#Z;S\;D\@*:T\*1J10Y],+_9
M-?AMD5$? MF?+1M:A7$8(HK\D:[\L!WD+QS0&BFH^VY>4I66:Z0YLSC!-T<A
MGX7$G/]VH@IO<4FP3!N*.3;W5$#!7%]K-3Q8#V1WO#KJB /"RK&ZK><IS:HX
M@&U_&-O=W'BJ#24,[!@#+TV9'5RT+DYCKORPS*TH/1RPZ' F@OG6"$8SG!]D
MI5XP(IF;T9?]5SC@'GH.!V3DI]5C5J$)<@?SSYGR:P/-O4(=W?;]A_A<$!A)
M&J,RI?E:5V$38A':R)POB"Y*[I.)'AJ+E;T_?J-5\;)*(GL[O<V&"NUZ=KUL
M &%X[%L2YC!PS)*4%#-&=E[<S\$_]B M=<(OS&LY;UX<0E\_+K+9;UZXF]L]
M;*9T,:\F3<YV6.U$'WQ-*N%!PNJ'C0N:%+?,<B5>&"EW 7N,5I/PK2?J2J=X
M_K6\BP/B7:\VRK6AO>)5.*"BW.6*9JEMZ>=IXOE9(AK+=UZ# \"F_\;$H+?R
ML,178>6!V$H< .W"(ELW=P:>;2QWN"PT!RWXN;=PERW.SSB9+K=;_3'0NA'%
M*"Q#K'S/C%S]OMH=.RXMV9M%;2(/F"5SGV]-,*QYGAPLN/[OI=.M6F>^)! #
M9#KP@"_"3QGV;-%UC<ITU=$=/5YL;]&?MPJ?&?#Y1=ZP<U#7W:&^JG[ 1%7(
M$?"R2 !& @^]JSLE_>./?X,*+$8B]-:.B:S2-6&"+S&H:/AT8\<&27=&9&-Y
M"5+D'7(#OINV,)_,6<%D]F&P*S&AT=?J3Z_YVQ.-Y43&R#*]& <([0TQDV^3
M6@E_YGT>VA-PD1%&2C2<GL<8"91$%1F/2C^X^YR&N4D>L>4]C\YP<2JM3UMD
M[!#_#&?4=[)P/(%'NVT6;U>\-F:^1ZOZR$7Y27RO7N\-#>UV&AZVRM]]146*
MS\Y?//DP%OHF*Q]PD]1U-85*+*U'SRVTPWQ%R@-?ZN^G735"#/<&83<%"QI3
MC)DMQ=G&QG]Q0LAFGB@BHX[N"%"QC'W" 0$;AF^M*4"N*<)3_=+(Z)-311+^
M6>.^AU&J:HH D>^=)YMY<3T,X]F]1SWKL!Y0HI'?6Y?AR.8*F+BKB[/Q@!'D
MK<VS 1_=K&Z;C1]ACYB?^0@D[?D(7'"QQGVDM/9BGV8>5Z1X:=<6#<L6=_Q=
MKE.M5D;P@TN:=E4EH)FNU?DT_]]&\MED&>TNAM1Q\.3OIE"Z)Y5)PRNO'2Z-
MTR76WB9S-?$ZA#C:Y:8+"C,Y$\DRZ9A'R$K<D7E@P.K%G"LV(KP\0C*>\51*
M"/-A[^;P3DL*8A#6BB;)/=9]'34^=_&Z<J75:FWKQ(>I7ELFV7?/F4V996J%
MJ_"TARW1CGD:R'"1X*$C^@ <<@SG'"[*N@_$-%3(R %!.A/A(#42I*?5%6PL
M_7]-0;(%,]J=YWP-F]N3NY8Y'2N32I@HY0Q;$D&T+JZ27_,[__RL=M7G?FG8
M,-=05VBWG3W)-JX4(U>R5Q2@=)9EWY,/Q8>O?S,JRU81G1"NJFV@*.L#'[_Q
M\W!>EWJUM^>4'# Z*31J/;3ZRY*EV_R$S\1X.%+).AKA<:H52DN\D@LT,OJ]
M_=7N]=4SG:0_I]^'^K?YS=P)G5RY3/Y8,#_:5R 0OJW^/W6FL/]KCS)UDO$>
MQ-O6PG8+6=8Y8^3WI%$D=/WWY[E@0MA33_<U 93#J#+EJ_3'#S^L?7LI.I;7
MAJXL])".?7>SD"V"/-$" &+5 6)%R4<-X.:&Z+5$HV4_OVS(%&NEV+2;CO7V
MV]36ZS7%$;TZ;]QKDB2:/'% )^?C7';R)O\14?X/18*.40&(5;M(NEL!5#I!
MR[QQ$D[TJG9M$PP,;FAYA?T4E/-1SQH[$F%:OQTU P_XT'P)%KQ:1$36AZAD
M3>\Y+1TY;5!<N-@>5$RX?98Z<-9OMTN7+HI'_;R.6+9KXR8E"?&_S!&),:[B
M=BG1&'W_(%Z41NH[U=Y6%]HU5_+_9=Y4]W,+W[## =GT<3C@DX,/=,7I+Z_B
M0O\#2$+F-U%\$G'  2@7Z);NWV,C_7]G-.8?+ZB2OH1C7T] ]R7^'I#I'H N
MJ.5Q #<;#BA-QPOD_[7N)_V31Q>/*L!)D"[GDQ&C\CTWHQ^KV%,O=E1A#JW@
MWLV1CG&=R,;O6D5C#(I=K^KV2OB_CHWJJ7W2,V/,BC *=ECNV9"4SY=MK)U)
MK::D&!?5R_6$Q=P'@S4U-R<?0W_Y!;H=-%>9M4+CEOK)?9OSET ,Q9!'5-I:
M^_?LCD5-,F#N F4[N]K:@@(ZPT&QT-9?_==C>?28,U/<D#-';!'GXF_MQ?QY
M>M;4+UM=I?=UYTV\7AM;*+RM8REX#(Z7?:ZKP%(O:4!RDHVU/ 7U+ZW4*@6D
M?<W/6$OTDHV;D22#+:>D&^>!>315F9Y!JLP8V80C>7@7(EAIC@J#%#;*TT/C
M3W/VMA*ZIW<RP*3]H$0T>._4N75_U3ZH.!E4*WS"[69('DOD>")$2\M$!/I=
MCK*9Q+!L*6%7]U/(=UH3P8_>9"VDY9K5Y:>T@BN0Z\:5&T\#O"1U=66UKU )
M#2H)*QD:";[;G=1"$3*$Z)9ER!F/;%[\KW&,I&"_G\A^742OME"U/9GP@[7Q
MS\O:VAN.*5JAREAZF7\"2+1>(IAX/$!ZA!R>&L0XH]65H6]GH2TL.."=V8E7
MB;H6AOXB,0T'A#!"]#M+6N6=R0^BQ#T<UAU_IBD+VA#/]NAVC(A3>,I*/!+X
MK*6T)E!#^T)8AM(]G><-Y7J=FUT9W0X'>_W* J&S-QRR:/.Q.^3ZFX]C0L%Y
M@ATG8%AI-G+SV!UKP"CS]@_$9O;";XK.I*=6\'ES%^R$1FN_;M=-M(G'DYY;
M3RE6IFZ&^Z>ZZOV*5$8!PKWOBTJ_0N#(4R'5A+%G-WYVDSX(NJ5S^^L[K_)S
MS&-M>^?!*\Q$:WQHU^+S%"?DZ&*]%&S.*)_(:!TM,34_#V7EI_/?8"_O8%-?
M*<PK2: 7$JM-?/;@9&_8\9%%7-0#:$P#^8F5(\]ZRL_K]WZ0?"!:O>X5 #KL
M _7!L(?%A:UKI;,X8):O<JDT]0*.3 \!U3FU+MV&-O&A&LXQ F''I3B@B6O'
M%?7$&XI4/E@R$CF"(23]SBD3T2M\YR$X0$3/'/8,R6COO'=W AYWVZ(6.=MA
M@412T!,J'5K^G#&DXZ]K(#7U>>3^M5TEIM#;YJ$/VPF"<U@N4YLP/P.?GN[2
M!=KYZR?"_/1_K!WP?):!,S%6%ON!8+519@^?W35MFDF:>3:H)^/MXE]KFA(:
ME!)*"DL04+1U*.6*_]3=1U?<0A%"*2/SWCX(.B&FQ&<N(&0X;1BI4D.K^25F
M30#L*@NBP!Q X]7^[&E.U@TG!WA#E*?SGHDU8.Y9F".YS]PE;G=77^4GS<8Q
MFKZR*="HDD^RZVU.'9L**&'7G= 81V&'P/U9%ZCP/@.)1\D4@;ZJ]NV%.=\/
M2;)-CATWSCMQ0"C:D;X!JPQ)Z-MI,G6G+WIV]4S+%S.T-A]WNDPI*S<[VV@8
M+)[4*P^*EXB6D=$H+G61[9H))_D^2L"1>YYX.,-;GZ;A/Z2>3G(G\ 7UF.T*
M[(3RPN3$:FWYHN.8T!89J$^!QVOZ3O+*=;519S]ZY+61KO$9%@?S[%,#X6!.
M'71KQ6'LMNU9*4*X.@$',,1@J>;XQ[W%<UO6GA 6:W^BO2%127K][0G]UKJJ
MD-!(OZ8F]U_4]TU=8HQ;H^.&DJF!=3P>_A7%#B@ %!E.GJU%17OEFQ\P10VI
M$!VG@*431@O5.DXNZ^PB[)ISU"#B/A./#JVJO 2M.*SDV;/#SNY>EEO+Q7)?
MA1GYI*8>?1PC#Q%"C4!#X[<25I-*2LUD!FI*^?5^E KHW *+>09<RJ^!Y#%Q
MLU^1(&ED63>B.9G[0 &%B*RS$ZR>T!U=ZHWJZU!^HBJKDVE2Z+ :JD%JD? @
M;ICQE5U;\);;:,Z]VPN\=;,&ZBE?Y8^W?9K.RX9WTXHSEDP^--3N]\P:Z3-J
M)L_#&[TWW.!^SLX859;=HEX;#Q^'<"4'.U90D4&.+&AZ05>9X<:W-;'&AL[<
MI/= (=L((-$K(59J4HQ!M,9[G^QY[I10#:0W.L-YH(=]/L<S4K_@1EQEU8-$
M$F]'O0/79^LBJ\ Q.[<MWKGO5WIDUB94YOU,UM>44=]$/S_5!CV=5>;X6/70
M=5BQ]"E=)-OF>XZBMQ<RW![07QF!T,$;GX4$/?,0"9P67K&BEK%\D;RQ<EL*
MUF^DK]\AE1K@!<\+X0 \WY'V!,%QP%J]&PX0"KMXN+,,3I+JP1J(YS<$LJY+
M>;G<MV&L>[:!*"V^*%<V:?0#N>I:00P64J]EE4EXBUA-R"A__6K]^*?R<B];
M,42'(DN10-KIN.AG5#5KP_O[&MAAJ8_B<7?=^\GJN9@,?TZ&QTZ: K>-0]K+
M3[:BH+\B6\P\Y> 7?$MF-.!Q8E:J8S[(N&>W(VC23<HFT7WSF5,:K/J$GKQ@
M+3S$/B?'5X+2J"\O:Z!Z_PM90SRC#O=8\4@\[2"_(7,XJN7R><E:Q.L[3Y5X
M[+J4PU<C'U,&ZFZ+8Y(ML>KHX$RLH)-+$WZ8C.=\ PLUHZ\7._>:^KP&F96;
M:S?V&6WN(6[D+$2;U*B]3-(<3D^/[E&-?;T:.44:5_KA#/5=W&$Z6_-:S7@/
MB!?67VPQ*KO\2>77(^X7V@_$7EBH/ND<N:K>Z<(33>\^K)$X8[$?'Q.F6O!B
ML'W*RP^; /M9Q"]>]?,\A)MQ"S'O?^L7BKFSL#A=]*84@XV=_5(W@1X7?9FV
MJ419VZ#A."U-S_'6N$W0&.GO*BYM7;4$7F$-GUC_PJAH?6\(#E#T=YV-18("
MO/.Z=U03F72$R.I$%E=ZG"^YFB)E,70#=J4IHEP[WZ_UJZK$]ND:!-GK/123
M&V-XS'9)8/K%MBYJT@M/OB1FWH/MMSYY19]48O4"6IO?["*^G5"]21O5CPV^
M+4-\ %^(GDKRCU(J*RVPY^1/S:_T-AWKTJFN+%!H6:Q]L?ZU\.%(9=C/%'ZM
MO.\!4.<GZL-9_8'FE0T!9 ([I8\=:MC&B=Y3HO119_:?MEG88AIZ[X>717VA
M9Z(CUI?3DK[.&"29L[59=(JZC9F!)MIVJ?9^G4U;/:XJJQTZZ=#-)?:P=;Z
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M48"UWBOP>%GFP&J4,!L >S^[:/<<PA26MKOGO<0/VE,3".3 =L!J;%V2R+?
M?:U5T:_Z!Q*X-_@%='Q2\"#"]P$G)EJO$ 9A7ERXD-#;G//9>[8%-YA[+/!.
MM0/F'B=:PFS+I!.DY!3ZA"<R/2\]BXQF1]$\9C+L08;=[WSY-Z&T]%LMX_Z#
M%S6Z\Y*Y(S*-M9)\+J<)@\5[4G.S]6([7V35VF9.;R'"PQ?&ZP5\# W%Z!ZO
M1/NLK,5:ZKPLM>!?U=2_P4LC3'F3((\,!VAL/V\.R;$++JNAM2XH^F(5_3 &
M[<M>@0,D0>N2O%=,;UL%O6_-\QC:$<NI%L\]W>-[GBW<->R@7$'M^,F3DB5G
MX[J<^AS5^JF?)KK!UV'$'J6/U&OMSQK>Y0G[O'S1:V:\O6P6E0+-N.^V,_'6
M9X!]HV-5Y"9\P.*<F%!81O5;A^U3'W*56A!/9,EGVYS?E@*>U#K2$G>RPZ)>
MITW&!>4$(V@Y1V>$?V^/+S4L&9I!1=7QB)894GXBB-6O0/!]I1OH,<68H-1K
MJT"L;A->\"A)V)1X]!M\M#+FA3QI<*/6E*'06[5[Z^/I\.EA00Q+E)7<V.5K
MM"O,G*9&6\]TWBJ(BFI](F"@,4X=8G=7ED6T^ %E"-=V O,KB-MR>JTIWM<@
MXD)?@> U//QA03IX\JK[JT]-F&15BV>IEK)?Y&>E/F1?B,WC)FSR>%>X9FUO
M^<HB1+<_4JH7FW9F-^;EJRU)"?9YP7K4)'NXJ^K%X&CHMMS#=%^UN,$;>3&'
M=O5%W&^^NSSGUT$0MB!N"?X2IQXUY(QHC\KO-W>_0+4Q_"G,*PZWRS@NHZK]
ME$>E3!M,_B4X9H3C6'R]M1M/E1O]7%U:8TWJ:RZC7?>;!AK]7-;.Q:TD#/P'
M: 36\G_D1#/*F#VT"KH;DY2IP4U6#^!1M:7L]8Q$Q7U7EDJ"7*\7J@06 $>D
M(-(K0O3X?-5TYL D_RC1#;D_VP[I1LT)&YTXG.49N"=AL/JV(\L0N96RX6)=
MRY7\4%*[6E.]+$M-"94(&=Y,.L#_H45#FQ =1_^5P>Z@SQV%A[P_9G0>LFK2
M_P;%7(5EN7W'XEW2E^WBS7@6J+UA9@KU92W[QL1C*DXP,]L<3:FC*J90A8RZ
M9[WV[!=+B@VQ?O]'$H5);Z.66FJ!'5)[# ZP!:V/>G[OLJ9)IU;YT"K)$K\R
M,7;S.?5DLM/"9K4XM<,?D:'V!48_/Z?FR8C<040:O$:0[JJ]]OPF<P,_#[,V
M14J7CJZVSGA?OI;RC:B< *KJDES5FZ3'DHS9)47T"@_"@RBE209N]Q3U[J9%
M8RKM6I//75Q-6^>?]^* )*2ZO8Z6=QDQ$WSFS$?)N>!9>F>X 5=MO+,,XM*N
M6R",^)?#NYBHZH<1?9?QC7T6Y(Y9=6VY'IMH7ZY0"N$FR,M6#;THX3MS=DUZ
MU704*="P8I:]J*'=LK39Y*$N1,!)C=BJ.:)!VR!] 3TM'@E/];M'].MA<9^U
M V>67LRGJ,=G]V)F-6G3WG/J*J<0:&^)"<?*ABB+DA,KL@$D ^G%VO<P)S@@
M#FGIV__37LIFC\XC1D?XB;[ULU:[-TC-&,-'//>L-FIYP2Y-D"1#J[YJ*^*'
MG_0>:L(W"/6"L6:S/2A/M:9>BR'+H]CL@0F^1&)6Q=4U:/MDX8H@761'>(_M
M6WH5;P^RI*R\7@L/NO =IX0GG%%_-VMYC]7CW!3ZY7@F4U$+;STM\EBJZ@ F
M0M//K;T9&Y*''LN+TC\S6%N4O*:-]]]MV1^[.V7K?EM(Q4HXFWME_U:>1C/2
MUU<I7^_F..R;(#"3L>-0K#HR4@2WY:#T^Y&'VT0;N\XP'.#,PIEKI^XEI<2E
M3O5P1'^D=8@59>^?M$@C3E@@9; G47O<-]4>V>&,6 A92M/\.FQ5%#_(*^+*
MX>S,$U5/_IG</HJ</5W.XA:G#;!H1/^&UEKHK!W4U\QOVVJPE,:OE#/U054W
M.IV0B.-XVPTS#D; S<3!1SJ-_3@@8!^R6((#:M1/^[',WQ=;YT5QP,:7C*..
M45X<\'$=!\!SI,1PP'+O8@8:XT<X%SF-]L8!CCB B>GN<1CFVPH.2,TX<[M\
M@ -^L\B&H4)Q@/BLL>CK%AF)+RSABCE<:4O'!I^BZ+3DO5=#9"W4 6J$VN95
M''@;^KOYKCL,G1R  X2AFRC?F?)5V  H$L2=M1B+\4)<E<]E;.VR1G6Z)CTE
MY""RF>JUGF:9F5/INFD&BDQA3[V0U5#NL9@8XSEC!;395&F%KSV),9,*O672
MY65&&5^=(DQI%T#U8ZM]O;)N[^X3CN\#>M)1G>859_7&92\+,9X3S_>\A.*]
M)N/O>.0]SPI)&_[#*07?/K8?83H:7Y?O&4Z R_.W!C[W#B6I]799FO^&N-&]
M"G^[GD@O6U]8D=0TJ'9[L\^RXC(_*E%84>+3A^I<%2NX!G(M1HC]"ZF$Q_C=
M:3=3WH)D8\*7.D%/@E4"LK,)$2UQ_T_."L6A6#X:LT,?\.ZKOZ=7M/^0%_B*
MWW% 1 T4 P.?_CV%W"[^UYI*4#9P1GX;7_C"T@P4Y&?36&??2%TB>.O-N<1S
MYEJL<)AAWW<38@OBS#[Y](^JC-*Q(35V6A2T#V[)UXPZCPW\B"-GIF>Z9>HA
MG/8QDJ9,AH=+J&*%8(7DQ]9M')"9UAI_CD$TKN( 63P60\HBAA<$+ZGFP,-C
MKKM12U@,^( *ZQ(9W0':5#XLWDQTC_J\Q=4R5KP$75#9/_%::"1U;GKU3K*9
M5^K^Q_(8_T&3M>FX$"WAR @'CO=D-X;-'U7NN$D;NI'DPJ%/#?>C+$,^OZ'0
M*+YQC22).;O8'AF=7?9O'A\6#>ZZ;@P>\54$FF]BR52U9]*\CL5=UV W[Z@6
MSJ+%>(HC^S>?(;A]1/D9_<22OW^AK=(;$>U=F;MC69)C)BP1Q?Q@QW!,5OU.
MO)EF>OCJHO-:W;.&PL<8MMMK-\G:V\LDJB:3_51'\V67UN7[3%,N[,>,JM9(
M_%TXO3=-$821^<6QX3&5/DTM^H)FQ(*W@^!U[]:BE/KF/CL0?]*(?!RKS,JF
MJ;"SIBFT1RNKN"V\,._-GVPMIOLN8WV49<%LR':%M^<BI*+EK0L&#$$L?MP;
M&HTHK+VISS$U*E-WKN;M='=_F-V1J39TV:>;+:^[]T7\.-W'V':TPE'#;S,C
M3J8!BY#WA;1TR]C K\HM<.EK\_7FC"F<CR?9@MYI52.$A(8WQ#C-3JEAQRTX
M( WF#]W*@F)_-[>B\Z#2:'G4)1^V#H$##CJPA_@ LKOT/RFBSU6PP<CHD[.#
M_^[@Z/)VOHWR(V54A,O-7W#H?0>_F\4/IY[[W_7PDCJ=[7#4EI6O*W;<XG>4
M9;5V3+&G/ZJZJ_'^L=&WWT227=\3JJ<X3>E),$STB,;!%D1QF\6<?5&1[!-#
M-\*14T6("(93'V7GS--;]ZS,EF/1;1TYY/H$=ES1/DG\CK77O'B'OZ;WQG9=
MR=:CO#=ESUEC$.MS&V])KWW4L?(Y#3)UK@@)%_RJ$\\J<T0<UI^G?DD&1YE!
MA^ MX%--, ZP,D7\UW&[7J[B W@K%;H#'PFS90_/4?/^#U ]"S/1T5>T1G,U
MDL$IOUR8VA52B\MQ0&.==3?BNY]5I:N4ZHFNKUEW;>1U)X-/]RF^#B#O&/'F
MT]#FW_(U@9T0E6URA%'<F>!1Y7[*N4-2KG>$ ,F;_"\W\J2*5_Y)\04G',1'
M]2L@HU&D6=Y-Q-PUZF=.6<FLAY;3_83]&;*ZFZ;?F!IOOI1-X%R#Z]Y:W;QU
MO2 FB]29B__UE$#6NX_>(\RL'Y:QS)_--R@,]J62C9.%!<:5M8H--^*.P:YZ
MPW\MN)/QO56J@1#E<]8RB5"/H3X@=\YO@C0Q!81^LW%N/9#TF==]?G]C]3-7
M04@ 012U*JQ(/5';(*BT60:.1 Z[>V867FNRC_KJ(OY=7(N,@XW3^<%[-06.
MWZ 'OB)PB*A\?2V6PMTRP;-G_[Z4H.C+>(68B5)FPW#R2^N"*%%VW:^/7H;I
M>@/SUP);9EG2>(F;)?RFC?[M\_^PF+*P>]'EO1-A0A<[8D4['^Z$?NU0))Q0
M8M7JH[#_,G-'%(,^'#9]OA6'N8<U!S&W)@7V+*:%'4TY;VO6UC+O!MO8VBRF
M6GLWZQ_U'M$DM]/2/OP]71U3*NDIFR-&!%>H)QZ>-Y*L(.@BHUTUC4 BAI@F
M;WR]H\/$]E7.C@H?9+*[$%%?Q/Z_OLD0 I6VKD?*8U?[\9)<TR,<\$$(>OQ+
M_7(6_SL'\C^VG?R&P@$8IJ5&0?&?K:F03MU"N GJJ/P1S$/R-SQ0K&!7Y&XO
MG+HMB;FS**^G2:Y@V8*$OL[B*VU1^Y"L3+BQ'ULHVKE-^ /V[O(QQ]5KU.F-
MC;3ZD;)EU\\/?SC%%)+,=B>7DQ<^F";,A*)LO5QM\#0E%96QT7[<[\3+E^VK
MU'BO4HKG],K)0P]1?A U9&C\153"N,9S(JB**>BWWL3Z#A<3E]2JB/%#ZD]'
MKNK[YR[<K(?4*Z+>S&']5SH]\'%Q"=4!$7:L^:4]_+ISRFTEV-=VM%^%:?O4
M4F"O[_VSOPO>?GD4!YS?I?IMAA&H F-NF-CN[;N>DX''H?$-UPQP0*\W%)4'
M7HWQJH-6JH4%V*OC '*E7B3[/50T#N#9Z]$P+X"!G%;<_/0Y)M%^["S/]\XM
M-"#-3'J]'5;74??%Z+@J-;6E>1L:=,<?-HU2&68X W1KD[^2T8\=)_R&5'8]
M["R .@L-9J*:7(+?*X&6B*TA'%!EC>_E&PYH(KK 1T V!!5V!X_H+NZ:=2\-
M8S]LZT\?9!Q'WT. SAISV8=0VGCEMZ4+:+WH=QCJ"WS^G1/V^T:BVN#N:5\]
M5\4$X^@=Z_I>EJN#4C3M5K!/-[A%RBX69RARQ5Y.F4FB7&-GWQ.-'E9K]VL6
M+(@E#4I@^,3RPS$6_!KE'ST[-8;MO:3_IXFRJYH%4[M!GX&7E4"/&PA]-ZK>
M85.&+9%EZP?&Q!0BL6T3WE3&3FH_MA!+LC^+=HYT=3P8' ;[P^#C*I;Q;)^T
MK@:XXV^]VF$Q&&S.>KJJ+;.EZ(3M.V-4?"/"LV/W'4FCM1M3^O+5BX(?3'-J
MDF)U5!L'F"(LB04X$?0[<F'*C*$A+.]\4^EL4MYR+_)\RHB*H :FI;=7^*-7
M_=/0!K].=3R]DG$\UX3&Y(VXFE<^72^Q&'Z!S(JFQ"Z-UU]52=EBOON>0EOV
MO%OE.15BR'^\^1U>JLM0]Z%M+&Q]U!(K8]:_FHU5\]><:Q4(M$8XZ?<M]BQ0
MZDY*ZLHLZF@B;P[OI'_;9A@^]:E!ZBW,IL;F\T6X'@\VFVB<#+[*86N_(VS/
MM5GBYU9GQ\;?,T>L]EVG5K$'/B9E +=LK35*S63W1F@_F/S!^NC:>X?G08J9
M[/6%O4"+!\9Y5WU]$X/?A/$XP!RC-/=.[7L;YNM>2^.LW[2%,]UFE]-D0/O<
M<^:LI;'EVBDI0S%?<O\H0NB+O/!4U<=%>>@,8MBWWXCJ4H@KRV_''!WJG@_@
MM:NPG-3<(B=X?$G"'X[P.28YFJ"^L&MQ'0'QP%A-81L."&'WCT!<!I0?V?X!
MR6\4>4^MH&I:N6J'#ON[S(P^A3VJ91UVIDS],%-_(UV*Z_,T4U*?JZY_@PQC
M8E[/!9NB>6$LAWK-*ZZQVI?DXYO?,(5HWZ<;Z/IK\O:WLXVEPM<HA365OJS]
M++O))7%9!8H&]T:@W$_O:3KOEZ6NP)202*5@2G7Y>K\G]9?CMM[J;USFQ[4%
MK#W&;<_U0!R\DOD)!FSAB31VF?D,=^G&N_/G#/C68R(<6-?( *A4),+'=VB*
M'_0Q4EI5K6@@T"H&>X/J 8G.H_D%LVBL GA(>:5[_6)8/P5N1HOU7*\0Y_AY
M:2(P>S^4\-XCE[,NI\%>U<CLDEAMGF=WLOTL!2^HA:ITM"7.XO@5F>XO/N.7
M%_]R [02_;!9%CR# TBDZ_^8&LU;V#FPUHLQ\+<)OR@8!E[?WA(F"'XA!!4W
MZ6_&VN,  6@PGIZK4S95I0H6B&3]0<LW##U<!!V\BI]$%W.9%WZ4]PUK1V ;
MRXNZ6>OST/-U"5:VN9]77-IEF]0E"5@ICH]Q -_Q-M;"LFY1&C;QT74B]CL=
M^5=)* %*)SB6B#>]"B4.Y0Y?S,4!,O++D%?CSI/PPMJ5!1H_5EI5N*8T$]5,
M%W[MJ/12G>>I?+H;-SV8$&L;YQCS_9LGV.19J2$\\MTJ\NT6/L(1)413M4?%
MC9NPZG*J1ZR4#]6<E/I.M:*>G!(O7U1@+@,-,+[SJ8E\3;8[49$(D](/\ZA+
MU+%!TU![\#M/9WT#/6L'V_S<&FEX_.L?W/QR/W^U=1#]B1)0+5^C-LPF4/K9
MUE;*T#J<&<9G6). D%#I"N]N$[RC:*))6_C 5A% ^5IF2^/#%"<.J-S JK9>
MI B"T>=84;2M([;/[+1US271PPR=:(EG;NJ80-[(? PGX>JT[!HX,=_//ZQL
MA[>IY,"?R4P>,2_B.H%0$5J(B&@;G#>2N<?+$.S=JS!9H54C95%V]P,[J5:>
MM*.X25J>WIVBB?'G9<^9$TY"2E2MV7)IZD8(MQG>']T#QEILD>E?H,>PB^RC
MU#>8ZQ?M2XRL/WQ3[<_U#B[L*W9$]!T0B A8A3C:3;7!%TX=,Q]K U.EO2$<
MS]Z0)9Q2W/_$ATE&^#<)7*1*O*_O]=?[(SKC>%Y &_<4+LLB%XX@=WB3R5]4
M*/Q 9V+MS!AT^(T*S1;]+>.B(LX,O8?,K_%;0D9@$S'Y6:8O<8";&=8AXV+%
MD]AYOZH3!XA%;\8?\X&6=.E5AX\$_[ 9-,?47O9?A+B($*4-(GB6[_9A:8WD
MU?5Z$">H>35'_KB2#YDI9=_NR<H\(;TK'-4U&%*YW:$8&T""T019JZN44 P8
M?4_G\]1;^"'X\NQ'P<EOA\,"<DIY?>?C710/YB:*XF@U\,RE[:)GQ.313(V1
M.@?HM7>TP9G+Y(Q1A(-KN"&QN-F3E-Z]ID#BXB<ON3(_NPMYG:A5_3H^KA+H
M*WC8FL!^P^ 3R8-8:5":[ZW%8T3NO"I#%\,=4CT=#1T4\QRU3*>^A-CN"E47
M7WHS)^:G^](=-&&36!_XVSN3Y!:Q\[S&",=UD<#-7TY,I:FY:.<(*?5'WV?1
M+@W9#V&6OW5DY2Q_Q HI*3WO^%U1Q:3.[?JL1CLO,_YY>7GRZGAJ0.[ 70OZ
M^^]^&+P**B%AXGB@\T&-56BX7';XC_JQ^87;84>6A6LJ7&25+Q 3NN"S,%K7
MR%CM%T;_80DN\;FRGJR";C A;3 T[U;73;'G1>ZTZC*4KR:_Z?2R19/_N@V/
M0+&[CG,7 032N6!;!>20,:PR_%N)^V]%&XA&9RPTWXQOSL'_\@<.V)S%@_6$
M Y7]Z*CF)4P]K+5G(>;8R-R[9'3_JNK(T7W/]SLS@!"5VYIK[."KJA4ZN_@B
M9T;VO8.4]>GXF#+? MW.:I*V]J<;R.X$$^7'%KGO?HJ6/<_0Q/9(JSE&#8WT
M"/^(M%$$GM"KV!?K%+1Q_?HNL>48[M2(6?$UR_?S0[EB@A%E_3LM+8MIT5,9
M#+"-E5WGU3ID&0=_G=@Y?U+;JCL] R(Q_O>XSG!4K(';Z?ZP*@N_T%&LHNR#
MO&XY15WI!W=I@:/A#!E5[)PHXA%$UN9U#I=2D,YVJ;3$\YO,:??4+]3.N\NC
MX\SZ,U;R>\FE$G:Y3'% _^CYE/B3^0FT"!&5M54!"XH0GJHGQH5896*85KZS
MZN8YP2*2'">M?M][+)P07E)B8U4X#@]?76:Z=QR0HVQ-\X-&]";%-L.G(SJ-
M%/W?@>VC@ECI#.3)\":>"GW.]L !A]+G8-@Y>,\<!RCC *ERA7JCJP$\_4MI
M/<$T/PRT,8>1G+S%^LR8K9^W0.XN=V'D+J+QCFB!XP!;"T'=NF<+DQ>#&;"3
MQGR1^YX_U1@:8!PM1WZF7/EVN;G=5VNGVC*2,MR-,+",BS6(.H5P"SQ!AK8?
M]XO%XH#YKM18EA"OAHE(N?<H_8LXGUO"&N%G4/%RE P.X$8L3$TV&^D>9J].
M,9+I?_I&Q;P\E^9:B^RQ&F%MY[YM];A1G5)&N2[P6) OQL&Z5VFO+T_UC=&L
MP^) 7@/\A"UZ=B0-R<A)4QC$=5OIHP;4#@@^*=>)QGR%A5GZ\V$MH(+0N&?;
MBZ(+9Y-,WHV)E;YJ58(:D^Z(ZNQ>A'&#S'66YZPY]'OWWFBN56IHRS,)K-FM
MQS[NT.W;;WVKZ7;'6.OC<HL_=!#-.>*7R%3[-U<H<T&ZU;^**8*.?KX%RK(W
M1P7VS,(]S81:\3B.LX'0>Y^G(W1[H><S/'GQXI=S$U;=9<K[GH'34-HVTSB5
MF9Z>15'!NH/254\X_%B'*,90. _]*7SXA@H-61/%JS>"QB 9O>&]<ME!*Q'*
M';NDKR$DGPA8#;<B:C.#!%\&ODP/<)(]CD8)0WG+.B_Z9]/\:K&/O4@,;1\C
M;ZX6S08$3Z(I*&K1?"[[3G(,>3#7=8N%URF&_E$JN:K<<@X2D:HZNDJ&G/'!
MW_;*&%&:'R;4WMU1N$JCX$7Y#JVPJY/=S1R-H7T-8B&EQ0$/_[B-\N" C]7(
MA(,E:'_'.Z>%_J_^H1SY@3('JLD5324(7D%'&V1>S]+)\IFX\&KTDT9WW=MS
M4[2&0&6T ^33+V7-C<R,VASHMZP6Q7K[O>I:3X7?K=MVI9@(!O\"L5GE6769
MF]6C6$^S>UA19[.-4DSN3S_'[(8JHC 4R;&\T^#BNP&]WVT:(\@]>/8:1&MT
M7]'O;GIZR#W>R5$7\JV=0;NDOAH/DKJ8L@#8P :](D>-V[?P)V]/=Z0V'!]K
M(<<^!7<FMH2+[[)Y37Z9RH\NW,&TX/$%;]1WA-DZ_)AZ^>"5E[K96<C-=3A]
MY/I4JK;5F\?/;&:S]YT;>9@1L[/@:OC%X<^ ?757+2TKCG 22%ZZ+M=R>(7Q
M/978DB^*/WI7[-N.4)Y<\\\*]GG8:B-UI;5S"')E,"^0T2O ]\#%S\,8]H.U
M*UM?*)^_K;9+46'JSQ:. VZ8JLWCRMOMJ@G1-DI&[EY=LB8W+#C"N1Q40M2N
M@;@U&^]?3SFKLZ>7V[T5I25/S!"VV8/:S,)J-HGHF3,W9+&S7]= 'O;\OB68
M$FQF^GFX'P;=$,>C@.L7XT<O$]SBMUW?^[GSKB$87K.5*8 @FOVU$*0W5Y#*
M3U4B64_T/5<=+GEJCMB*&UVG69*DEXYZ4!$Q^9N@G?+C;<JCJ]V&+M<NGNDN
MMYBE("FY>/6YV>.M4AP@:AH\A,G!!H)I6L3_0&QL+<O?^OO,I((\]P.:-3CQ
MG*5ZP$;JA2Q<TY)IN2 RMW!N-RGGM6WD<N+P2K**VNI<!+T_HYZO7J2&5$ U
M-N#>"5%AR\*/C_PF;[?9W,;\35[H3SJ I6KU<4!H(M88!VRQ7B6:(34;C-#!
M&(H+\!%X7XWJBO7J_-#L#WB)[S07:=:#IW%2-Z%1T%OH9F.4\S92\RQV=[I@
M&H'95J-!O=VR1,>._SJ48!O=SM&K'C<\FE3O,C&3*J1&W=LW.3F<1@5A=K!:
M1N5>&Q!U$Z])TV4$[]=4$6,N.&U4UZ;W1LR==_R]1'K+\(60T'XK^T+.V&2'
MHTD!6:Q7NB53EVRG_7,:#DHD#B@ 2=%LB?3SPKTFT!YW^M*.8AUEA7H2%*R%
MKL5/3H"_X!$B+=_ ,.;E&12]'2B.GE_:OP/-PP%/O(I!*-[AOW\RP7@S?P,/
M\%''81V@PX2%K0D;*_,^&&@WZ(N1*24.@"?=9WZ9?1OC(:I;L25.Z+X6^WHS
MQJ:P(&]^AK)44<_"P&W7Z&ML4F&"-E^I^JA1LGQG=_B[$6@!:$:L;">C%<)6
M:>'_.+$S1IHEYSU40B#\SWO#T&;3*106S[C[U?V]](P*S98S7B#\3>4)-3]F
M+Z %2[U;YA WV&*U58G8'9EF9^8]1:=+\WU>]?/H!KR(B7FURV5"YO[?PVZ"
M:FB?[&/S3]<X-<(9CQ]<HQIJ)LCH8UVF&BA_W\K8Z+HZ[>$-TT6R,T= ;*O,
MZ+E^TJ)A+-X)(CSRIO%"XGUA@K45%N&Q^0^)>'7=DBY+*E^<>;W7$?4Z]X-_
MK'^[0UK T+)T%I#&_Q,QCGB;9.WUEN["2I]LC5).,$5GK+I4C&>)"!RKKXV!
MENXO'F%M=-.HC]&MC?I5 @:?1,YMQN0;:VEOSA2'Q^:)%:4US[U6"2 =6G.G
M%7;7NYM;%$7*DI.?':^APC1[,*?$K2M+^%X*FJCHO6\<-=^4Z,L1,Y>[($V3
M1\20Z7-XG/E'K.3@0N.>&@YXK*+>W3WL;_/;7WG&[$DM+VI.TQ()ZOX^;61>
MB0YVV"<)BO:P@/08G^7L*E3(*FJK)^27%F<%Y3W+T[R!92CZM&E4TR\:B)!5
M$'6("3_D0'K*#B;X^;Y0,;VC$F)7$:?W\%,!5]-;!W[--3M5EV\_84@$0OU"
MW65K+P"=5# O/NV+7T!S@UT-YT2OI8W2YNGYHO& -WY@^MTDS;"NH,1)O*[6
M,3]YYOM;+*3[05'7E*BJ]%]RYCE&%N9XZ#EJ#00HAN>L%I@=?F]%>X;UF&%$
MQ<=Q #3ZC=_B[E4CM 8'1$45]H&.U2.P+M#)GJT0Z ,P^EWT23T.Z/H,1F,"
ME=#:^._65)=FQWRRWTNQ&V;003,4UC0F "0//A[$4^&[2%L-!6JRD8P!,]?I
M_>9$VBD)%<9&'UUKD70JG1J=TU^<VY! "G?G@0!*MBJ6\<U"KT>SUZ6^7ND6
MN';1_T _AP9E_,0&UFI7NQR 2/=U*B\=:2VU GT/R2X2CROQ3@CKV[SHP, :
MQ6\']_(08U#T1HHCC#J<Q>B0SOU+I;F6WZ4RLL*"F2;U7WJU<@:6[_C.$)),
MKGHV6C%+_&HB<</40<4\G0?%P_;1(EQVPY>./1%NRVTAUX-WU:NR(9@2*2YH
MI>4AWRI,=GHT17(Y<O:M"[9/'A)K/FOR0:*QQT>SE[5#S<".ZX3RR_NDD0N[
MK!L4UY3O>02\^H+-![UIPYKPS>Y!O>'R5"D%DRGG]V&@9,G7(M4+_WS@\Q_F
MM5+></=5=&4C"98&?:)-V.H=.+5X\6C&;ZCY;6.KZPJ$ETU?>V\_0<FW/6I@
M3*]C/=+V;:S=Q(^9:[P!Z0/V-AFN**-,IMC0)8Z"\NV;8"M)9Q-LWW W'[J'
M-PP'C,I,+UU%^[%-!:@CMMS^Y!]&SXAI._-&;JL&)ZIV5/CZ%7N;!HKY;%.+
M5C>@[1$##5H3(88I5KWF1S0>I&ODA)E^PB'MYUF=J+.:2/WWA'M,#[":_K"+
MH\/^DAT_U[5HFS\-TS8].FYUL^Y@+Y/4^=G:O/0RIN9J[T5>\CE,FD>/*EN&
MJ[PZI\+H>N*KQ\=/8EZ.ISTFD^3W\:,->O?MJ>R9E,W'D9MLJ^^'=3(^XQ>T
M(I3G?M21N$T5R;$'00BMAW941[^7S7BJ+9W%%>U*!-%L?6G[RC<T\.=C-MJM
MO(JP:H#(+[!O$[,TG#EW4A,AJF5,M<HY!S7G0>L7[VR;'NZHQZ0YP\2AV3#L
MPMY0[<+7X6<4WL[A';K110Y*GQ_O%FQ&Z80Z.!39_WC'5;"3%?J.32[*;G2B
M@.?=G&#N!Y*1T\=!R[Q?)9SHU8FU->RC/L'>0$6&/S9K+BP]:J"NA-6NSAKU
MK(09EMM[MRB+U#Z*=L0!! 4%NX;<>GSV:]O%7-9]UHX[?K84RC)1^7G'@T)[
MX;RA.W?[Y'7?<-&-!.!W-_]6@PERBHSM\Y+RJX;%S)&;2V)6:1;OK;ZI2;)+
M$4!%H9]PP "D I*A>ZK&V/A4O-_ZS1.(M0F?M1?B)@=]W-R$J(HILS&"V,]N
M/P AJ\XX8?-&P?ZX:K7(:L+SQ1P#O+XB=N3:Q/"/$QR@OWZRW5R<Q',>:AUF
MHA^5^^#VKQI:^N/KH:M?O)S21T\A4Q49AS_ ZV>-L-"Y.>A ]LK.6NUY;W0X
M]!?D[G'I7/N#(9>;L%E\W.HY2EV,O*Y%YMXHEL5J5!BRWBVLI+B.%GNM6#;K
M3I.4<V$V_1L'5&%=@NZ/US3UP1+.J&5B\N*MB5N331_XA(<SG#FT]G5L;LQ@
M+5KO>)MYCMT/%*S\V>ZM#MF[9"=MM*QZ.O$32IT>E=0OR"[.0Q-C70'Q(6_7
M>P 1E'ZJD^C=/=D'J@9ICDX--O >N%3Q4A&;+9MW0N/\/^V:ML;1(WHQ6'!R
M]^)%]*1/^/H%Y6$_O^;W?54<$%18FM=S<./4*]8<]LR6T5A&>U#W:T*X,ZSZ
M_JMU^VG.A)"-W/A)E1^@1O,CJNX+,[&;X#WL<(:TW_B57?/=?NQJFR/G'X/C
MQ^"VYX&LVO I^.[H@B V^EF8UO"DB9_9%",A*+C+*2TX88Z.NWM\;H+1\=;%
M_>MT*LQZH97I&8C'N;ZOF6X)]+!F.HH;Q]6SQ:JJ4X^LF[_2> ]D D1$ !T-
MB+=X"97B[W9Q FM-A XV[1/^:+ D2>W F.Z71'$(ANT@8K[TK1S3^%&(2#X*
M%'\H&QQDQ_YY1,*]<Z>OC?9!M(/33+(VQXK9X:E!4V?6D#_5GM4QJ,VW[.!"
M%29WFH?%&M8-MK<T0(LA90'HCII"D$@C/L79[TLTCHT_6Z29&(P=L'C"SM]-
M]_$ETBB5 *&VTZGF_H[J\&8X2DK8\3H;8>(QJ-MW)M_Z[)[V68VJLZO)69BI
M$\/ ]]MC:T5(TSZXGV'^0]4;H:_M=VW;5Q^;OA[MM5:D %3;6BM_=1YM:17<
M^QM"[,]P %G7#K9ZKSP.-'B7MWNW.:)UM>,@,NHBZ;QVK,TEIZL98@ZIG&H1
M%:R[/")(TNI\Q&\_O6JB/\8-:;C#&I[1@97=(NNS8]Y!9H(F[LN?KN\Z4R'U
M OFABZ*>8&PX,YYG[_G-\E;M0%UE,HC 'P/;QZ(=3M45G%0&&*.M/)=TG18Z
M5&E?T<PN%$^GRKO:V/\I_IQ9%'HCC_6VO!C;IRXVW;?TBL2KBQ'4FU.=#O4
M5?\/_<6&5FFHM_?^R!9SYM[0P1(B5C5Z L[J[GT3X2]\J]=:VP5A;*)FR7NQ
MYY.2,2S0KK#QO*8LBYM*ZH"!GN[QBBK)G*^#S]0L@_ROH@3+[O?DZ46)%>",
MS>/579</._M7_0>([83@^@I&F.1TFC+,^XOPU6#\+Z>%DP:QW4>)?0B'+Y.4
M=UD2_,N&RO-[)C;<DRZ*,#??0([46%ZG.@UUV?^*%VXKI0(-]V<IUF?UD298
MG-T@TP5V'>Z:$L?U?27++,]0!@5#AT[^9 Q'+AA,2]K6BY0;>>M*<3Q)SYHQ
M60UJ=QH8@E &A1HV#;HL];V!F1YVZ@KS"/$9"'-98=?M5V,]J,+I4\3F9Q0=
M$VB9LUDQ8?G/RLQK%X:2/E,J;;G)Y:\I@&.$3K9@$"H,9S#*UDO$0GWZ8B##
M$_)(\J9L1;)4^S;B<^V))$1&0E=165N"OG2AU5M732Y%O#JH^+9,3*C.RQ$)
MV(NAGNK!!Z4 BOHE=/(D7Z&LOKMO\I>#[2#%@QO%'4-93=";966@U7M]+A&H
MB(DDT_V+DY8"R('91GYA)NWIZ5G27@)(^ 6+*$]SW6'R8TZ'@B?;F*-D^R(6
M.4X6I9256!$K@<X1?CT:UA]$N?.0T<\6;_K>W<:6@#1\"5N3>_I^M]S%T*,H
MEZHG)TZ-8*Y[OH.M4T$_;.+4Y\1GQ^WW[G 6+G(^4G**,F38B9/_<M7,-EAZ
M+5&?Y^'E9UI)M< A#I1G*J2%T;GZFT]1FG A0]2]L('HDZCJJB7HM?/AGO*U
M\4,X*A;AX/M%_;=)R+&]E)KM^2-KG4D#<N<PN'B8[7)#JIM^4WND=/2C:7'P
M(T7ZK_;8H\G?1L91DAF/VA*65\!D)H"&I0)X4U*^RKG4MK;#EW,E)\M=D3U+
MSC @G\QL6*KQC[\.BJ V4-??==LLQN@5Z=NTUNE4#Y]<DEAZZU]KQT(*C<'.
MDS62LH8!W8(/*?6D<O4,KO6K[!;,83LJN\TM\G_'H,6^\?#J';/%OQ,+I5WA
M>B+3PUKJ"UY^O824:05!CQS?MJ*W_&QGRWJOBJ&Y>(R^]7"X=9\%.FB-Q[.*
MHR%[..!"8^EXYR+CR\R"=NR0-P1RP%-159M'#1D_O3L%%R^FJO$08O0.8L#H
M*7L<4![]=*NAI3GN'-&1C2PJM[/6"]>(BBKJ-+*"T;X!F&4KS&;(MKK1*7O(
MU<P*;SJ6IXSJ<XJ:X1KA$[[_A;COC&LZ7-:,%44!"ZC4J(!(ERXE!$3I$#H"
M DKO2.]$146I @("0NA5>HF $*6%(H3>0I%>0PD0$M(VGK-G[]E[]\/>+[O?
MDE_^22;_=V:>YWEGWHG?WRHC] NRHW+U3 .6,!^;F7ICL=?]RP;O+)$)'%^"
M!KVKRZL0^IPLFUF94!>KPYWW./G0TU1]F/_)U^_<TQJ8K,FA3A"(214=OG%^
MO2G[Y>CBPP=$Y1P.L:V5X8F5W?[*6.BYIFFN88+@Y*@%^ZE/E0\S&V/?Q\%E
MFV7>OWBL<T_4Q3U46\K8K^9Q;7ZR.(\-6^"DACZ/_DG+YBVN/QO*AF.[\ O^
MH_OWGI>9!R5J8 %&L+X^!;DBSC*:W0D4<_9(OX;9OH5PG>UGCU#Z5^8SRLJD
MRQU& Q=*U+E+S4%)4R%(V:6T6ZA;#Y\O,$<^3AQ*QORE.Y!NCGBT,NF$$3F
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M)HYG,*PHA^>@O$8R_IVQ$#(6P (RCG\!!3.MC(W/<P77+NNZAGMJOY=O\LI
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M:H7:MUS\1^]6W=XZ%4",IEL6I;":P2CG16IQ 3+$M[ -1._L*1I0+#>#22/
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M\PZLU3O].Q"&95("E&QVD@O71W)9_LNQ^.D,,,:0+$X%1.;V;Y';812G'BJ
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M_(J-HB:PV:6IWB%W^@$UM;ACQ>V<[1K<8[*K8^153M<:ZT9>O@'8MV5*)&)
M0^)[2W5S_V8-H7)*>*P:H:T/80]A1\X+#6T X"^@8U?NVB3]/SFYP!GM#]HT
MC.=&(NLJU_0A$3BH_PW3=Y=Q%-2SV(XRRKHE^4=FS_S'"\OQH2B]>XP9-$#R
M3A81]ED8Y*3K:66_QM= TU=W07&?I#%3J^T= 9SMF1[XWJ7ACI+FH@ZGG2CD
M3;EP9Z?88M(G>59V0K'^\@4KGETJ HD*R"#NKNG!@ZT\7EQV^_UA2HFU8\JT
M2^+>YT&$V(@)_6M,U@>J&(#G9XW8F)UP#QV0:BU<(8]P-]JL[_4)*<_#:A72
M-92A'(E;-,JCU<R-V=+78/_,K.3S0T?IIZ4.0/+I"7#Q]_AE&!H #'55P[?$
MY=#8E+EZ:A%@HK\VPS\)ZK(,X%/&)[,^SDI<%8(F*1_MW]HNF:I^]>6P*9S7
MA]C:%,M+O2^8/].2(RY\'-LF%1+DP(FKV?.ZY,[T;J;A^]O5/YBNB,NWHN\(
M'PO,X09E%5I0/J/5QN&-9O>#S!PC76]F)NF(Q"J>3*[2^=SAS=Y[0EMB)]>J
MI%TUM$QCBO1GH:(-_*(4!QPNHCC1.*EA^PL[*9=%/ 4Z,F[5M<,&D8J[BG9V
M-/%FK/'L%0#IF;A]5;4LN6!S$.=*Z(,ZRUI.0_:>PJ!0=M_V.H\_:6I.1_:9
MOE]'9K2]]CR.AV%<0F18RI5%U6=C?^>GHRC]MMXA&)-W)_NK6N;L)YX5_?M#
M>!UN%48%;<&H:]I[%5,8K_&ML#W0^_;*S&3RTN[?8:?G.$*PE3:.!HB)&VTH
M.'G,'AV--#>V<1S[E"W,U4JZ9RXT1)":,^@U"IGLQM)LJ31ZD!X7%05JVQN^
MU\DI[A..4OSF,AQ-6>);7Z^K\Z1!?;:=-R+:) R*E\DU^*' I:-K,4D10*0C
M6IRU1LVV,_/+5WFBXE^;T1166WGK4'*7T?9NW/"*L74XR/D*?G#@/Q:[6*>_
M3S,D&[Q";MM"JUJ!89#8L\-F5O*AA"([-C>J6-#I^9_U?4?B$&9<D2#\ &->
M=R#464)%G<9 163B&V8"ENCNRQN64U\(&I#4+CN%]-Z+[)[W3;.< B[WM>0-
M>@08.6Q#90:!KN_M_OHL0VKKC5E@X'GP#[D7SJZ0U7!19R?@IV;-PG01<_AE
ME@,LSO:[#(59=NSS%ZJ*4F\)I%6C].K%3&?KFIM1A!/(=N'"PZ6[/K8E.E[(
MN6^-TS:46QX'OV/O0Q%]Q>AFL4N"LX:<QMEQL=P/B^(OE .<$<2 X=[--.8S
M=D V-X":(.D.^&WJ7*6@NS;B?":Y*H^)O;?AGO]@TA?U319EO'J!:+-& W;_
M[)Z@=M0\[J]Y<@.Z_SEA?>X*?^SFH4_XJ-W.303?/%!N[)D;M3.L33I]9.R!
MR01".7U54B.U9/1H21>QLJP<N^A>Y][PJ1!'_T);!#\&)A@K3S_T8?!5>:&#
M;7Z5NG:=U %3%S&]M?^CBALU90^41CWLJ\&&C3*7-3F$ L/U/=;87,DIW& <
MG!W=[F-NAPS?HYW?-3XRS>HY1&T<',W-WF4QU=E638LGAF*UO)GQDL@PP:GA
M"A_5[-&-T>6789*CT;;]2_:K9WJ%#?<CN?-3:F23V?XR<-TK-5NL.M4Y[S$>
M.[[KN.)I^%J6'O+9#0(J)72)\@TX5HFLYS?*$Y=)."PM7!D&#A1? VU+Q&.B
MJIOMCOPSY"?R9^PKG^9$!@$H,LI[AL*#7;86$P36NNF@A4++K4(-NL^&2 S'
MJYYN)IX#O&_="/V:40:M!!<*K2A>Y/<C&A@LF6;O3,%U'#C:W&M/#1_I.?(;
M5:!K\>B]#J'9DVNH)]TK*0J<.5+R6K"V<QXV\R86<:EF^MMLYVZISMH54G?)
M0$';R@NJZ6D8(B[7)S?2_/'JL2U84 O)\(U&/ZFVE?)*8]D;F2HE[.XQ@CBH
MK@?9^(7GY*+,7&11:>>QP/*:)'ZHM:I5E4OC1S6#CV*1KW(+*\)K71IN.Q/
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M4%B0G5OX*R7MXP?PA])8BG_^U1=!7-Z7-2V^C^'Z(*=#LB$'^!IH19NAL>J
M!G39!A">X$\.>&1]]!#N)P@G21D,VSN'Z15X>A!&VVBA <3EF>T,I+.%(T>'
M"4!V;$.G<%D,U_%N:@T%-44<YMA688/'>TX5J&2]>].U75$>5A@%;I5 99SA
MS[0/ Q7) G>/GCP.=&/ZVKXFWCYTPG$6$K>!1W!KL7A)!*^?.S;>6Q('>3JP
M1QT?9FS4>H3<+"3[^*\V>0([EK6?AT5E558+/@_K67>N9/J8Z=4UP*286=*D
M5%&!]?21ZC@V%N#EWE3L>49^Y8WD>CE-^AL^<0R.)0.CFU_9 .UIS<)ZN0NL
MM20]Y-S-0*,4FT>A;\!?L1,WD OHYU<?-( -6F4T27=,N]%Y[">]L.E).[OL
MQK%9U/$N0>QLTC8RG24RK*D@Z"^LP;U SNNT'SR4%]GGJ#)*&O2NTS"!_:UD
MOG RP]!4CNP&6.Z()R*#;,:4SH-4P7D+;J5N7\K]!V8@N:P74;%T-1]!\J8@
M'S*JNU9%CJ-H:R"WZ>/#;L%RV9L7[98HRT\JH5@NYC.[[/#Z0V+^ZQ\/#X=X
M!#"V-:&S*CTDG'/W9.?: ,3;,GIT- @\V2^KHIV"P8PH,A<JKW2^BG$UM\ '
M1U([9^S9EUKB;H1'C!*#157;/JR)"9241G/!..79<8@,M]M,'SK9AX*%]=0C
M'FP'ZZ:W3VT*R"UL*C:D C+H(@>"\I>I/"7K70BUNV4:*AL_DMC7.A*[.VM:
M[EKU30\H,XY/O^Z'J/<\[]TG?ZP3BO%&8$S^NQX-H5K@ZE!%GG22H[PC3[2_
M=.JARG6EYZH9D'9P":O1Q4C:=<N6KSG+ZO H)J$[N XN/Y#K9S=AGVIZ[KU;
MZ'*A5JX7.2DR;6PL",.T?8S!:ZKI-W"U6V&S^'HAE_>]?E!/5#4V!.#-O@&=
M*H8M@T[3U<)J,Z(;[K VP/T$"6@ X:OE\Z0E*OZ\9NXDHOH6/",NSU.DQ-6\
M;40\<=$%$1Z7BK_;F_EG,<0V<(BG0C9^\>5??>U+?23D<:.7B;6[LWZ64GK<
MKK\3A\PFEFSF*NJ=*:"*AF')6#&Y$RZ/6+Z_".K[XLNR&85<T6YNWI0T-[LF
M)?*8L/! G8S]=2$__#04 YMVYRNCI6& W'E-5K%K$&-&K3%G=P6R%:FSM@7(
M'H&50KD-;QPI,"+""S;-BV6[Q5)K!X._*7V+BB(=N2&8N1/_&Z6 \(U$ V"P
M)+ +C59KDZ5PP-:(?<J=$5T5M-:[V(9UUS4YXUOH'X1S+:*^H%=1"/]SC S.
M<$V"V7!:D,69]:/RXJ\)&P<HD\3"Q5]VEZG)A<$TBL:&'Q@&WG8(D)^/^.@B
M7]]8/0C1QU)2#F.1K=*9J\UQY@X1L[NCXY:^'&S0&JIJVU98:O'HIGEI^>*=
MJ95&K8V@$><C5O//@9A6=E4S/9V-+D=*J4YKT; 9^'^' ]*B 6\JMJ8F0</@
MXGI/=<_"W2-)2'V]VN=)N#Q[,Z3&5QDCO6A4TV&DNYXAOU_[!"^F;6_E]]2Q
MP7)>5"J;Q"\*PA^XD79&A;5F@X^*"NW@B = 4[5-T%Z0AVEV8.(*O,![RS!B
M1+$+-V>E[S%WOFGR2-@[JQ6(?R'18V@5$O5L;]W&@%"04_>-_@\-4#:=FDV4
MCR#YON.#5*^1N86A]*=!QQ+_.(#HG-#=$"F@ 9R,:$!9YD- X;_:R[#__P2\
M86C F5<N&A \@ 88,OVC/BO^=PP:]'$':?R@Q;8:T8 <O=6F:Q63_T)9^&\"
MMKF=7WA3<$>-J$)ZS,^;HPICH4Z;NU67\2FX5Y:84FDO9?522H/(-XL3*958
M;;[$>L3$LFH*TI-H^[3:QN_-K3:M_J]RIOG/VINZ*8&2U7J,%R[4U@O1@)N3
M:G$7:)XP\_F ?>H^[7"?N8N![3".@\I.T+*@4[?LSR5Q7<^[?F<"^1Z.G.I1
M92QUC:SZY+=K/Z<QG/S.X+2_@1X.H"?OH\S-E43*Y,CI7K?8J$KYXT@3-6GQ
MG_5M6"F[Z:ZO3'G(>Q;#,0FL+*^OY&AT,.1/^LT^\VH?XX2Q'V;:6F]"S"S<
M$\L+@GE;(KP%4OY$Z.,\ME-3S:K]#GL?4T/*7EP03?I*LT6-5D)-G@SFS_K_
M\7.O<T#YW.>UH>3]:F[(D,4^R@''>-&-=^:@#7$MJ"?SY,A6Y8)*:ZTMOJ?#
MWT7#=/7O2FS.VE0E@I*XL6UYBK(,O3DYO]/TY1D44@)?X0#>OFY  \SAF=^0
M?4[7PB_T_QQ&')4MZ$.>/<%_Y1W8=_0X3W!7!@WXOH[,6&T.ATC)^%&<1/2^
M:VY!4<"/][I5^;TY$\UYI4;'@/;+S(9!);QQ)64^C4YW>42IX-BW$\5:L^-_
MJFZ5!3T_O*ON#PK;)TBB]&O3WD>"?<X5F&I'BC\P6C+&*C[-9#SK_P)_%%6O
M =<;AY9IH $Q4N?+=W&(1#1 Q%YW?=DH3CH<UMK9N M'"0NF#VRQOM'.VKN&
M0MKF\!2,=23<JFYVUZ+?XX07,AH9:#_)Z"$Q^QF((6\M\M?M^19D,_'XS#@E
M:$#N:2RQ7=P/+R=JL<6-!6%9U7]/KJGI]L2%T::"O-\!2CN+LBG+AWOHP#0F
MBTFL26J=O,6= \BU!K7QG2OQZ%$=R!+5KB-0^U56L.2._3LHYE5BCEJ88J2X
M(FZ(A^X IXNX17&JC^[W.80;Z2I4M/28RRQBPC(>JX,Q<)<M$[ O>(&XJM2K
M'OTA^=_%D.$#:KJ"KQ-/8*9"TO'<_$!@V4!@[S'WW^&)8UP/(M&X'O4=&RQ[
MI#^8N#%5B;*(H3BZSXC/.L/8;?# CO^Q:_WK%I?81]D]"KC";]NL,C\ 2[OX
M66U8.PB?X#D[@VE9HBN,/ODR[]K\]X%;?G(QBE@[ERVZ0 ,H Y[YL0\JU[<I
M(_\L:<\GK K(Z E6PP.4G<?M#\4<]N])K*@TXOMUIG'25V']T\3ZBY#/O-,"
M[@*]1OY-4A#&&W6G*^E]E-LNSW!:/'R;P^Z3,K^Z($>!'+O?7A]S2!CYW_%+
MXG^<Z:T]3/[V_KV&VOG=(Y*:4(KFSNN.ES6R+<XJD3U RD._6D13! WI9N^.
MZY :9VPQ&M W@%O]OK1:</,>BK\O]ZZ/7&M+[70[:Z@0B[5DSYN;FU*.W-_\
M:1BE-N&CRPH"J510?,40*-'_T07LH9K'G8RH]A:?X$)-ULZI@O.:P_FU3$V;
M.*K(RQJ_K9 O,0%-.32T=(RB!AQ*:[U]M,M2R\$T&FI:[V8$7R3_$*[X$O5A
MUJLW-94/>8&JJ$X^,"(YZFF=3B3C6B=6G^B75]KX)>&D ,%2YW2>G4 -^I#_
M*\=OCC.FH$)2"TM48UY?SYKM;!T^<JLY XV[4TK"@HF".[\4;?=;NBRP+RP0
MLK+]!7M;QOS$*5:\KN2(JATFUOZ+F]D6L,H(2J[HITM;'6%9 SG^W6\FJ&A[
M98'2=Z_0\[/I5=#)6&P(^+,H+MW4=!Y:Z1EE1'8=7]@&YM!)_F9G\D'B36^5
MV;WKN$Z6F;[]Y+-/+Y[_8&K94[=!5<#%PBN$(=?/=VF>E^+QY;L5_WK<A,FH
M)\B<TL.K%'*PJW;(/UWP/]@&W"Z@:,#ZF1P:@!6'JE5^P%J.Z?]"#[1_#SQ-
M&;MIUD,#AES1@'<5#R4R]3]>:DP**&)\W*<4]);3WG#H7B4^"T[[4$I/_B?,
MUW@63!FEQ"]['#"%&WP/"F[S&!)*\_O,=L4Y:NNE>LH&+/A>#G!A8&!P[XZN
MK]B ]5-RP@2_.N47O:+SU%] O5#A#U05^VJ4_+>P7@<"L/W,K@9@=U$#ORLD
M$OV^U%!,?;PT;'9Q(Y'^.H\JI<N"C:^A](?H5QE)?/D0F[4$[N^VD?.?7@9(
M3L;OC=M-@=O=_]U7>^]1\%%4V=+=@?>5Q^)AV;<&7_[R+]W:<#+CS]>)RT..
M9:%J#47K_4>(Z\R)[/YI"UX;4S4^-?FKZ5/L/'>O(3:LY; 73UY8>U%^GBI,
M=/.PT-4<4E%ZQF3+SBX2%D6R,8D&+/MX_M]Z4>Z<GH8Y:PF? ?O@IP!Q.F4-
M8U-38PT2)A(\$D8U#1T# QWULSYB#04JB5AQ]F((8Z#DPZQ(6/"/F?./438R
MGO.]MCQ9Y'1XIVEA)V2RUWF<:H@#,;^04S'2""XO_Y!O<54LJJGPRFBEGR%:
M1Q>O(QCN5GM=7C;)P+N0X0B%ZM*9[=QA67R^;EL+2_3#'!T&MN +NUN]*BLN
MSLU-(X"6V*V50!0+<U+)4\D_B7?M0BT^"\O.* -L-$Q5TZ%?+Q9@SPF8UU:-
M:ASL6YYJ=2ISNWI8.?NZ$M"H:!$7@N-8DHOSOBO2DT8^7XX&T 4\;K6O_)3N
MMA,RO'9-RD&3"4/8 SVQDO*"Z7\-/XSCXE5:@*%M9FA[Z"$?9K"624$2K,"I
M.MBQ1"BY'W_0,1>J:G(_>_ON:'3B0'(C??@H,F^^F<P=:-PP\[S! [ZT# .)
MIG<*,EF=WM8-KSNGX!2':9$H''Y@B108V!4"2AX&B14YS3]U)_#Q)-!T;W5@
M%JZ\4RY_D/ST2G9%K,*%US!QP_KZGTJ7V]6Q2:)Q.;$?OL=4>[\T<&<C:Y!"
M$F?2>*?S$&(M^LBC 34J9^&H<^$<-.#2T?T:#;"0NLZ^I5N8\;- T=\IO*,=
M/2QO//Q@571PCP94>\Y("@OR'Q[-!"V-3T5^%1_C)FVKTYHN\'_OPG5UG?ML
M8R8AV.G5?0:7_T')OT#BIL_:_")W'\KXR(->VQ7!&"@]]P^& O[G&-!_9C%"
M\4-/^?'\&!<U^]#*7]6D60DGP5**)?LFE163.BU*G"F4-+26C? 3L[4V>2^T
M!H,^%'JM*D<J;:ET,BR$S.=LJ\O).[EN^N!?:)?A?8_X#J%DE7D5/:WQQXW6
M(:.O@0#)@@]VISZV.(Z^<2B#I:'.0<1E*$FDM7N ;:4E&A#AC=HX;EEMOJ95
M8V[7+?MTMZ!QI9T-_J7DK=EJK;3:Y#Z]?VML6.RNUU5FUULWX@,FV-(Y7=VB
MN["^<:X5&NNO2*#IG)%^WB3+,F]L60?7T]O*+UC-N&N^)CT>AC-?+&>$-D'?
MI]S8L?)"VN>>*.!98KY['!_":A;TP=8"8NS-IS_HQIXH($K^R?O1Q_6Z7>EJ
M [5V0]9, U+Z,NNR539.1<X^/6N(L<!YA2(HQ92TV0I%5 /+HFG[@)1'4,'$
MH1M6GSW$'%!#>_<7J3UUJAXUI,F'*YZ/&JKF/WD08<>'"O_X,X8AI.),K..%
M*/I=FM_"G1CTI2E$09T<)X1NG^777MJ!\.9UE#6CZW,1 P8S/,6!5X#< CW,
MP"#,#P)4<B !Z0PW-.!)&[X'W8 $";,T1ZL=VYLT93 O18'I&H*[=]6&T=?6
MKP"[-#<V-XWFJ;M!V**(I2(3N$^9LMJ6CUZNH'VZGPA^'QQ=(:MRX'P_9W_Q
M31.#V)M4A*2_1T4M@V.&"&F(4A _0$2Y10TA])#C4B9^N<NMP<OS@[03BY*@
M:BAPX8^YA]#,LOZ^TG(%ESO^U?S=%)V"CEYTJN@H#U[8GTXYXHFIP!&JP"_<
M?[FH2UFS<;7#XA#!W?!+BOHM\,IK \?M^)J)2S:<XF=]-IJ/P)2/E*:VY=HC
MC!4>2!-"%\1[7'<#K;^@8V@S W&O7/?T<%)!A>LOFK=I?_3K49:^-Z 9:*BJ
M]3;T;YL/6_)GJQ [TU]$!BB/D4BO= T\T9+0<R;+S8/\Y2WRSSJSHK-2YEQK
M7C@AQ1D0; G,<%@R_RP!Z__LG"W8*P-10[D8-YZ7F(,DU")ARNM11\/K=VI5
M4B)'JN4'2Q:-Z2WBLD2MXETU[3XN62#+*H$)"XCLYRF/<JL3< [$T#4\RELC
M+S#:UMXL\FB^'^.)=NK78,4"Y[[0G0G'-\9+W8T]-,V"AJ]R;-U"7%_OO_Y.
M(SAMBT]6PGV#A0QUR<()T+ _21!M3S4&+XF72[8WSM76+P/%1>O.EB-;:N85
M>;4I_(Z!695\=11B.)C].J.U%$4E+5/WK3*Q_-A1[SW%0Z>9(W$PG-7H[R3.
MNC)H'/R@=_6.U",,5892N=9';Q\)B )TO]4Y4_1^^"KNZ9?P .JGR($3D_;Y
MU5?"<WVF6ZUG<5SW"V59$)>+C9K[(;VXXB7]"%+%<S=!PO'-G1%NPNI6N4\)
M;OI+3H6/HPQ3XP2*<0IAE(GJDT+62\3^6?L7EP.V0\("G\04&.0<7TX5\\LG
M5+_IRLT,\"IDER-! QA ,:K'*!,:X5:4#HAC+ G$4F_EX%;XG'<!%FKN6-97
M!V5FJ1:J'_\S9P'%9 XEJ[J]L-'4F5.0Q3V?W' E3U\6=,W.M_@^S*2FT!!>
M^%R,#8N$Y&F Q>G5VFRYJ"7\9ZH1=@%^G0.N+$<@GOSO;%(P3K!6A#.9*;(2
MY4^72??4(VO M@67WT/W<;2+/6II(4V"2;Y\9E[@A8YED0=<_+AX,_ KQ,X9
M8>_^]'A2EM20/&4+ASD&8PLZ]4%KZ*<TPYT8H7US\G)9HKUM 34!"[4"D=(9
M8/N[^X<,%F2C%! -$#Z:6EZ>0DXU*VRQ]-+6@5?=TWA*4"SV3;WS L0-]G[J
MEED<<J$K(M3'K_VTL1-#@K+XYFWWTPOD)-]7:Y>ZG3&4^Q8=!I72ZY]Q=Q6V
M#V9@K2T"/:<8D\8XV57C?Y!C3%UT8Y;9&&J/(]0?SR%[T( $Y@/4QPR9<$05
MLE7*%!FR<% #/9[M@F-.K31'.^KH;$*N)?H(@D=DA<9A5+(O$T)P]@@3:[!3
M.W6[)26=?P_FIN04:]AY"6.>;LD)DK_RL9IMK[PT;CJ,'G)ZX'63K+J4,S]?
M[><&O\U1?'KZV3DUS.JS6HSI,$/ (<_F@ :R6RAS-B?_\'[H+ OLB:(#%+DT
M^%>TW54[A-8Q#/PLU+XKIJ8)N!.EH\[Q&]>P^<U=""@75Y^Z>;^A0;+VS73;
MYLZ'9!DX0KIZ%=;:R^348OT)1^_'6RZM;L#5/_L30;&.#XU'@"YBV?6":IML
M9"S.& :3;,5T=-O$[SALC=2"-L%KZ%/*PAFJ6<)]#[E[$BGWA?.BV&_%9,."
M4C]$"@ATL>:YM#ETEJ;G6Q=C\N&I2-R$75)7;S5<]Q.NKWM;6%%6#A4H4P?B
MU+%U?/L8]2140?EO:(_:MA&R73J9QE%V_+AM&J& K/7\NE!< CX,&%DU,O-9
M*1R<=1ALB<*W_2B_/L8M5V+#E^;O-#.M_XPTS,>^U)LT2'2\F]+NEUECN,[C
M?@(,S.^@(C2 .]+C0'RD_*!K^L*HLKR1FC02<B$H2IQ-/.(7J8L&C)X@@J['
M/AZK16<]0I'-*H0COEQ@<43T3AS?L/RTO-VP!.)-D0YV;IZ)87R*%Z2PCW"?
MP!V.GV0B869OLBY3_R4H5<J5^'92\92'+N42#= KVD=V-PW8F]?5@R-YLR7<
MN&R*(K(^3<;C^D'&&4+1@._=;L=KW>O0,3?D-"*X)4"]D"\*S 1+]C^H2R)0
M:/Y2J$A80Z+0! =N+O%I3FFWA! Q;P59*=.H\PJY7M?@%.=B7(+O7H&X8RM8
MY/\H,E[CO7K2(H+9S@YY9;'>JHS2H>.2TO9S0:S!0 ,G.W16(\NB1UF!#GUG
M>8TU#NHI]U/0*G&S:&_F);]"AQ] $YR11DV$OM_%IJUS'7E$QO-9G:D^(LW;
M\Z>)O!+O E/?7$IOHDST#WR9D'"H&G19JCI;0%7N>9F(U:]"OW[Z_=Z,)UG#
M3VK$K7;&+J)ZT0#V]- !XX4SV0V0B7T+LZ_S0-4UH8/*S(I1._^L2,!P$MG/
M_I;+/5/UZ>8N2AQ.![TES3^\.C,AJ;GND:2S9V4MM$*_#U7X?^>VF9^CS L]
MV3:7KA^9KTNP0HH2Q SE7]=B#0.\M :*\1X1B<^AB, :9UHEPJ8/2HE3.BZ+
MN_YZP#\.#W,+UJS,/^\K1&DR@,(V)I$]LN: ,P_NGY!HR7+):G++'4"8XY"I
M7AMAWDPJA7L;E08).*?,(;GM*?O5+M''-PN'!2D6Q*](C;GU7KT@D:EX],E*
MI,((UX]H"<0"5>C!3^]'#LT[S)DRV<"OY,EJ*T-Y:FMDF1([MES(_0).[S)B
M3&-Z_R &*=D_U5XZB879E#""<9Z:;27AA&W2%\]AA=[XB[AQP#)MZ&6=FAC!
M+D'/B@3*L2DVU-BGAO(<CS(3KPK)+@*.VA/NR!#[2/-%-(#P&BA+LMA\LM$[
M>3 2'-FO.S-K7RIU<$PYBMI/.L1MFRORB7 [_PR!\HXH"+HS:?.V<;.QA%GG
M\E8=Q3O7U?!_"RGSVQ5(U8OR"O '" ^E?5]^'87YJE;[<6LV-*PI[%1,P4/>
M+2ID+,;T-&V31KJM&96VC08,' \CNFL\\.U\QCU4KY=%&N!M.RO-CB]UTNUU
MJ)1E]1HJ+V=B^S14%-4]!0WR[Q(2$G44HN0WEEG=K-]^WWR4&K!(A' K/HAW
M#Q:.YE<EGA@""*K?LK'GQP4Z$<CU(8#"8]([OR8N_356I=E]"8JDN)"6O5KV
M>'<M8M75B=%-;>J.I0<6YR)^NM?+[EHCM@[MP>2[Q9LEN1"EN8RO18;[C9N9
MWX;JPH$^Q2%?^_$Z%0A&"]NM%(4,RAM3*949%*C]2R=^T^IMQ*5B$!<]:8C+
M>D7N-W33V(8&K(E+GIR%;WK^J?A-,]34)NXA=0?IA"?I.J9'\=7GO8'YGQE0
MHYX[=4*MA4*><Z9$,%Z]W/B:1"6K):<5Q9=_2$%)1I\,S(F9QGQ<K'#[:QV4
MI5A1FA:W(OHW9I'4GT_^#R4BEBU?^UO4TQ=\,MDK46UMT62R1G'],[)RT7V:
MVG-SL]K]55J3&I/OKDATM ;_8'R8%/(T[P!D?3G.SZQC1BF/SZ$!;TRW$R[
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M%RG-CS?Z']8Z%T80 (6MGC!FQKN:*K)UEY*%PT'7WH0(BW>%]*A'1IP/HPF
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MH%*7NJVE[:WNY<7TU=+@78())VXA_\*MS.K]2=&@X[D6Q><EJ=VUN0-(%,L
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MU8&19+4B<< W^@*>A1@-?7Z@0=2 =)%GTW^+4[O]22"5].$&^&B?,Y_E6(
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MY3KJKA,QXZEJDHI'!6Q-47-"C"+L[1SB7=*-T++I(ON&@?+^]9>5@4^B"KG
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MIYP^JEP;_CT<UM9UG92X)<>O: [5)]'W.-N.Q!T/$W\MP*'U.Y*;E?S\:P3
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MAME*73,1$?:.[IM'FCG\Y#<D*MYI#'RAAG%^=A==Q7^\K#7=:\W<ZG>#=1(
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MN\+F9FCX%L91_(V%&^<#OV1WAU#0Z[<G;EPDW1AS-"A/?RF1&4_W.U:M[:D
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MR 8B@.=R6W4_6_UP/V7/07H-QT5QJJE)!&Y@)>FQEOO:LG3Z4,;@NY;[1KH
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M-3 SQAHK;/VG2.Q(13YLB2>^_R1(#V']KC/RCUZB>3)]V.A%T=]\7[3X2W;
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MN-(4ZA9CB@.GC8Z VFN,;[3-6L"RPHT=VT@B8&UE<"G9UL!<:Q3/:8&Y <'
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MX>OEEO4)S*EW2#*THPR?@#9%E6$=SS;61?N(P $DG@ E F.MZSX$9=#)YGR
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MG:I[_4X^VZ]).Z54K3FN>] ^XYN-3;G&@#Z[T*B7I[71U5!E._3^S5_4=$2
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M?I5?V/_.=RH,DUM;PU.ZD+ Y]D:?_K.0[QG!)V-TH!BTT,?#U/C=_%_[=3A
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MQSV6=%(,,U;KO2%9HI+,#\(#?@0Y8ZA]FW0SNF@*8UUN9I%VE^6![R6(2N(
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M&1EB49S6^KM&74_N"Z.BB^LT@\ =_^W5N0E=?--TAF*'\]2\_V]:&_-YGGM
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M Q=6(WA"7(V#?_]N2LP'#PL**F3QX/2YT+>:VA1I%8%12%#G0Z$+M7CJ*!P
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MBBAPX+ 9EOJLX^,N@F%9R*",3]_;SJ=^^5J\ZKQ;RX2['D5)4_Z#0G$4.?U
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M*MEYU3Y/\>#LA&H+?K?NAU5D(3/NJ8CO+4&+/,'4-9C.OG[:-AHV3V$P)<1
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MR90E\/'6P3"*KPJ&+"ZZ.*CV )4_0]&YH!?5([ #_7+ <?7,QIMK$58'-,0
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M8@ ?,KH-T!LW)QI[H_T+;Q < Q"]@?#Q&PA?N '6<O (*;"O'PW>&L8 KLG
M%&!D_ W4>B_WW:1@_GEVDK+-MGP\OI9_>/!HI](=ZFB!+&>*.VA&]R]X%V6
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MM7[H6J7[\/!DI3#XGA(:TR.1+%5J"#X6C-"Z!TU@6.Q_<8HM9(A0Q;WGQK2
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ME^P2[D6!F'#*H4<@PJ1\.*,W:::D07\,HKXTT?KE1+N,0P;RTHU(&Y+4#.5
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MV&1H-F2;/A6.ZX<.\A[+:8IM,^"L2!?PP$^[3WA@^HN53S.#"6*AC"#8[7A
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M6G')Q*.IC+)J1^+'ZG1!WTWG=@:_E0]UJ@KNR3?GY!?DQ=NLL<4K+$<K9'E
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MV"2[P_$]NFNN;*_N*B7-1A@+<]$=EF>A=,_ZH^%J/)=J#E/U:](%H_K!- *
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M)"[Y/.^C(1W@>.44V=COXO?UH?]&C<G==Y8?/@44T[\I L]=5SMW_#J];24
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MJ#LDVP:<^&V?7OH0*ADUC=R/^-_<86%O&D.WV3S1-WLA2Q&O98**;'[(O54
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M)AQ$I6R[Z[;ON:9I(9M7DA\8_EDL^?Z=?'JA6LRUO;-(/6BKD<#[4A%V>("
M4V_C :3_F5 >S5C@@5[C*CQ X @$=KAVED=5,<9P$+DY?$S8Y4,WR81/>M*<
MM"/&;+8'5"WY#C3YCW'&&&@\F/R&ACPJV\S2[L++K-2SM^[>'V'NPW!3%C-I
MQP@L# ]\6]_1)BQ1W__W-);I#,<:'MB:+\LB.'T1/'"9H?4L3^O[^BQ^>0C#
MR2$.5XP7D7@@)!O)<)I^]K$"K2__WE;L5:&O>&"^=RKMV,$*>J2MN35EO;UN
MQ'O\?!E;5W 7#X1>G33>YQD^M*B'.OI_QYWK,XM!+*0QC..!G;WA-J-.[[_Q
M;GB?0SWS2*PF'@C7*&-!-*?J\AZ UEI+<4O(Z-0 :.P^XP1EU,A0VBYI#'WG
MR</?7N^_YMU&5TU_+8AT\+C@7=EP!XKD_*QV@YL(IX<UK2$V-U892Y(R,E3\
M/Y:U53,F$S_6ZVV)[?!D;#VQQ ,/2W97>+NI4DF>,CHO@U;ET-V@-,WYS2=K
MH'_VCI0=L?.5)WC ?NDHYV1RE"ZY4GA8$L9=XR&[W*GRJY3ZA06MI5X^IEB?
M34+PAC1-'C=S>#K4V-N2F.,5D;XFC_4E<&?^SY^$E4W'H;<J_54PWL=WIZ^"
M=[4A!Y)',25P5KM+J1/47OS<P$0-%E7EHDO[#,5-QZK(J7!;*UM X6IN2,XC
MY@A%<M-51VDNN;K@5.,TQ>L%^A1>1 XR<@R=^0K'NGC@Z@RJL7EZC'X$9Z8/
M8PG)2A QU-4>]KR^H_A5[%KI[C5]MABA1C$1BICN[PIRVO.W5C/S"TI26+'M
M9;L9),:0JHH4M;2.*C:4!/6D8TC0"^F]; !3-Z%?*%I2+*IO_NMD)N]0:VH=
M&PIGCX^Y7BW<(DQBR1_^$/!ZH9++WWW/T&7HQ8 B9_2NV&/FE,PKS>0JKK*;
MYD)FZ@.G4W5_!1^;0RDHWFG+RS,*+W?R1U\A03B$Z^>!5-V8L$Z;8DLQ.'[0
M .^Q?AY5'!Z8-#Y$X90_EI3./)7\%^KE.7\BYFT 0[!,*Z8M ]BXZ]Q"A?T_
MZ_# 8H'A(FA7G<$TEVD[DC<=YW?)*J;9>1J&=A.;F!+XW3V)1C_FM)'" [YW
M$:>'S=X)F@_FA"R):7MN^6=US;%[R,YGC-?(M-JC\$#P)#JO0.#Q=?DWZF8&
MLB'%/1L%+WF:IGR*+B%6;O(N<^(!<8:G>&#E> **E3G;(K3OOG&/-LY3\BT>
MZ-^IQ@,GH6<KP /ISQ"?2S#;?M?PP)=Y!SQP0$4X%?@K B8;@_) 8A@ZJ7[U
MVKGR=A3*]C>Y4VZB31I]?*XK5H@X4.XVMU<(3$GUZPLPJ$JJ!3Y0$PTR+'7F
MZ+OI]DRNX?/9(9N0_:=JYH^NFB&&WU[O&F;X\4G%Q<<FD!$Z+75(@Q"*0_!N
MD[ZI/A_%NXR[/<A6F<+Y[S;U;II3>* .T6"84<,2KLI->7/04>6&@BHE>];S
M\N"%&T@U#=&H[R22"&/GX":[_>H.\0F"HZR>Q>0-F2 ,_30[;W[W(3HU O4T
M7*#O$67])U1^I=KW&YKES?';G9)J?SG'ZU6)TX^F2[ZI68#JJ6_/MUF6W_%=
MXK2?M0[3A160#Z'TDV%"547DF4F?%554?UHHJG<Q/ET67%VYOS/)V R=.QD0
M<','[_'A?*8:)Z3M3&$9:X6DLMZYU8T\7P2J_,4.'-BCV3+;(*B.OA$H>=>5
M)(';/7'(72.K5I6F<TG,I!7=M4)$9*-?4"M/\TC'J\3]/,M.1<??H:WQ +MR
M LZP\@[=F'1RFSO$;_/K!8>IB;&Q1Z"W\RNEFD(Z77&6R+&[MNPP/0ZBO)_J
MO8)5_$CDBYWS@\Q2C!_7!IH=7)HC;N,</Q1O):W34K6YV3<.[_\=%<8%4L=C
MSX;\I.'F+S4+UES<LI6^#[A05)8EWWADD:U%>1)(MCQIU04I1N&DY##F#+L'
MK,YSUI7@1((\T!#@-RFN[43\7PBJ/+\-^"VI)5ZI>S;CQ+8_>)6$%U=OP[#A
M5U >VASI6P[E/?16\.%]>P?]RQ^ZX<KE<VN?YH]=7>XU''G)+F)!I(EL,2)M
MB^$C74;R&CVRU<-*S6%-8OYUU@_MX=:WDT*U(2]Z'N<>D?(*R._TO,_X&KLA
MI=*A&< TY9-.(.V(/?5%LIZ9Q;U)P]K=07A%RN#HA,<2^.5!"Y7K\DX]A$)7
MJMR)CF5GW<7LU4UUE#WKY93,$(3'0C[%-&5DE?KYQ:<<!%TK'_F==[D6 )U5
MG3F<B_@\@[:?P5!#&<[,ZNZE,^4>3T/3XX&)#&B"-HXC00.Z&7@6?->+^/>5
M#ORII.2/_KJL%*5%J(4=P6[&Y6E'K!1E01M\KA%,G.T,Y&DH>"-A8[5BW#_V
MMW^NA(8<5YGC 92Q/AZH&?"QG#\5)E#IF5\2$A!L)A[(,=X.S_?X!<+TT!'^
MQ_L1/CS0(-MS%"+9!&TWA:#G8W E^@<Q1@=XH)V#%[T./JD :2V>M3W]=PG@
M:JBKI;JC0R'.7Y&BR:1<5X+;3GY(PT6#^>EAK?O'!PS1#JA3'?],F8_^K!<.
MDUR;NWY,"T?B*-@.B0^4;BMR[7:*]PQT"T9PE3_FVE5DHHJ:BAB*5F";_ :H
M2BT.22J8J2\/@WS6#?]^GSCH;LS[8>+X:["+1&RKR<.:)-&/P=I\"44Y+7,[
ML>1EE4C-,9*WYJ7-)'R95-&Z=)I/F",E5I*<UE]J7RC2 7W:PCQXYXBR/B("
M^Y+82HS5TM"FWA7:Y>1^9C%^ZEC]..PV0@LUF<+$:NLZR-244"P5<<G,D[&M
MZ4'4U>*C)PUE5B=&Q@DE<L+)JHZK3E@&4&\&&'W?UQ6-CBK8-%I"?Z_UV/3X
M4C]88EN-)7KAL:2%\%P4&;;B^]QB 47H<L?5L[1_5!9RVK-P0IBI7V<O?I%H
MP^X_36SE(;R2W2FO=.776$FOA+I3_#V9\*37<WS@+K<RK6_KJ8BUE)*(,3J3
MLL,(PXU)^4@SX>*VB9JP(K@U25&Q57;3+/N#O/XLB,;'LL#N-5,%1(7,D\
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MHRLIA7@D,:K<J*M1=;WHX"[(V G6UC$JC !)V-4)V!74U%2[SS$W1TI!(2'
MJ-R"DM*2HA0!3SD! 2V(9PH4&JI-1!-!8^9F^-!/EI<*#M4:,?Z%7ZW(Z3FM
MNS%]'GA@O74,G5E^>:K&7TRK/DDB1WF5\!O6X*:_WRNO]%.-*%755@.F*@O"
MBW)2I-2C<QY'T+!1T'(KLAPL!!(Z7-=M3/F'88]!^=.DH^;%F7ZE,PZ[;7M0
M@;"[Q'KUC"U-C?PS[&^9GSKX;SV:]HY V>F*/L:^&^I<O!"TQ?1L#%O8EEZ)
M%(!$_NPS3>>35"['&!NO+ (*BW\HSM4#_K0S9:EV1!X8JKXJ^SGXYX;2F6&#
M!>[L=^1UP4SWE3[]%]-O3[\4/]A+4,SJZ/&U!')&M;[.E;B@]</:6T%-=UOF
MI'>I$CXK0A/D9O:F4&/S@G+2 7471>7,HD+#&)5APC,)H2'JTP_=HJ^MDM^3
M'(XF'\H+L.N1LV9//)?SW_;[,"1I_GH3Y40>_IU=/+N6*,BYH@R7;.3&., A
M\ -H>:AT<:GE^:EN=9-NZ3[CZ2WL'MHXB@9.;KR[F-61 4>Z\H[,>Q#P8.DT
M.UKF#GPJ*O#4#L3_ "?9+&D5'H/STY4&3^N04<W,!ON."#P_QT*FFOR*@RG*
M9\43D;JH[FYX9MQE(OM%DZ;O>=)SU,IHZQ7J.3R]JZV1D@U[$T5ZA08XP47_
M@ /66+Q%P)6IG1OC91TW=KDE] MGKJ-F(-(^C>KIMSIC\7E0C7BB6\\H-D23
M<U-9$(FG2B.U::Z5W$B*1D@NE2XB  W@NBN4X%U9N&40#&DWXI[8<"0/6;_S
MI7GZ5,B:M%N"1N25OV&$7Q5?"N>#5?_M^>=GI?WO1V(#8 #6/5G1-Q"(K^G2
M&RS("T O_6, P#,ELE@0<8^G.*'+<4T0VXS#7_@XMG#[+DU3WB4[FQ9%^B<>
MXT88$\:G1<$]:E/]\@8@!9&]T8EABE-)P6^!?X@Z%B;[,(S%A/ &*3^\*2Q\
MO!H->)T>G8=M-1*5X%%TU4]BJE0)D&'18\<APU!Y1*7.TPO#CS<8?+(I;8_\
M/.<CG[A'T<KP4K?)[=56]U8J2P#,C :22![1K:["^FZ#.EI*?4]_T\;>VC=P
MSE=Q]O729@P#GG@!C6R>;+Z<1YE[JFD0%26/V9@+;I@%PX2G\Q<4AAOO[?'Q
M#W)@M1=]8SA-4U6#\*9B-!2V;N' '85/[F9J?_&$\BD9K54>+F/GL_>OXWKA
MF@/SWE[J!]&2>BQ9\3S"/<5.<,B/]YXHQ:%1AH245'5SQK<'V=,]SB T(,GM
MG-DN"D&XQQY6U+XE:,CT-=W#;&\EA"MT1FVOE]6=Z^-5L'>NW#FKXRL=\Z@2
MO$J.'W\3^B6NZD^/>%@_$^(1BV3?T$P/K'A<R XL3/'&K;3GYJY-]HB=YW+Z
M" 6#$C6(D3%0$4NDW^?$WK9HKS:B;WM)I^>K-]OFZ_!7RW],ZR9M9<%];CRN
MDJ?';/3LCY1\H.WK*<43M/W4*OY7'T#.0\LU%A75&A8L4&EVN0P*P@=R*:>E
M6$QR)Y2WAAQUBIIU.NI,>3R/Q2>1'V/-F3J2>;"KUROJZC4+PTO8?'W (ND)
M/CYGQTV-V^LB1S/U1^G[$?.\[>V\FE^^UCUUE>>JMB@\21UG1'RN?BA+G<@E
MJ\\D1T":+Y/\)'AJEJV/:DS+X'#DL\%C(6W5/V^,QQXV0'$!X,>8B(F8*8%S
ML\:K*?)O4W!]XJ"7[E\J7\BS T,-NI2$"I@?E^E2H0$L44GGWJO7+M-I71 H
M3'Z6'W'F15#'Y% Q.BXF/T-N*)-06N@P8:T1SZG&\Y/4O? B(X)EDM!"2>'=
ML%#=G<9"3HV2MY 0[?2[.CR(@ PS" K)1<EOO1FX]7:CA]"K*#&%$N, 4M24
M_=YG4FK9E8>(M_Y;+!]N:+(S<>90<R5P<N45._6B*>'-,W([DJO_RL-CT'ER
M4:8R44T(51M45]JKOB@/P(OM^_[>SLIU_[&;]GKM-_5-%TD*+*UQAA[/]#=C
M\K<S\!G:^J11&BE7(7,HLSU_NMCV5,IM(&($#> U2-8+;387P;^$2U@<VA3$
MZ_KSPC2<44_J^7RYS*5,\K-2?;;=2A>6G$M4!9D8&<T=EF2E@S&CBZQZ25JJ
M-X\T@\A=?PJVV1C'9XDC/_F32F6<L\J<<Q?D"<D?L=\-G,LT*>@\%RR(*8Y\
MZ3=EC%<C]$$)GY%%7/&>^S$#MQW:?"6OF+U!B- Z>R^K.J?X9&LWO6-K?.PZ
MB_;$!7<R'6AQF\'Q8H6FL+B22?4Z-"4V[[DL8:PD'*003T]?@'U^SVU/K1/:
MFGFGS;YA<;*\-23Z_F#4CRSQ]?-8%FBN58Y>#V2SO^5S6IO#A[C8#EYU$\P"
MNIB)N-R@QSB <5G N$:'S^"\%TNF9W:Y5VI%)4'X+*5%#1=YFZ-ZY^-"* H8
MDNN9D)N1JY)G"0U1S\_]]LPX04VLW^L[[[]GZ8DJL!?5/&;B2S):\R%8!)'D
M)YR7.T(WXP;V8 '@5O\Y2P5?!$[[4FN/C7!)S8LB>_J9O:'T=C?LXVZ;1P/5
M%ZIVS4>7\ZE#\5 S$SJLI_B"O8PGOV.);#QHB&M_M?2=9-N.A;@=%L=6RQB$
MCM P3E"9A%*9QA/"0GVZEAL@%L06X>(,+B]X8CKLR0;\$_*_XS[HPC*7K3#8
ME$ >\1WWM&Z"0M& =[Q'!#:N1XY5;)'[+8?^OZ<.^3EOHS#DU=43]^]N:YFW
M"^3P:G^YJ*JH=3!1Q\JT]N[&YOR9!"R!X:ULL=-7P7,')WYYDJ9XXA4 @;<8
M*AL/.25=U$J<PQM>+C2X%<75'3&^<-22ZBO.B,>L%(AU+L]\O4)F\9K,<A:\
MP##1.U4''')"] Z>9I$11+41-#$0ME%G#H]-N6J<=ZVZUL+_7/HN9X;)&EC(
MX^]T;9\Z;G.^E'T&P<XKM&1VSWWQW9+>KWCT,+UVN2VT><%(5#'G^TC5F^1(
M9NYXFR?[RH4%6!]L,^\#J'#GW9^LL0ZQ2]J @X?UH5+F+MAZBKL2DH7<=%9?
M#'KG-PP<O0NNN2J\PEO=HJZ.*\X%.RLJM-E@=TMS349'YF\%2YM(0P.OI0;;
M#_<P3\5P\PIVU5.F'0>=#MX<\0[;E!^-S>LPA+PHEM14Y7DB5>QX *.]N6"!
MW[K6+_,6E-JF?_XQAFW#7#-.P]B!10$XVQOU\6\D^T]N2XZU62@A+$U*'7;R
ML/G++KADA#^"V]70@-[.V;Q9_#QV[W*1\5'];=[X1T)GOD/?@&9IS_\I&Y__
M]N"-%[F+"V1LKF92KZ&!EWUVEE1WA=-%.")I_MJF*)94BR&TO&;<UC+,4K9U
MBS9>D3NH.8S$XO7?(QXK!N1 VT_PV3=$T&D9TT0ZT97H&>S::%Y;&%%3]_9H
M,*)6X"5Y(NS+V_/I25/X)I%(]^ A65#(:[,P^F"! FHU??4 *-#E* @-"$[O
MIT'07A!WH9)WA^#M8):R&,J&Z7E9>_+M)J=;M_5%*:M*SE/C2J(G#9R.1Q3!
MIM6#M$3/:<+"&H.QA46D '];0]H&ET4#5H67KZ+ ?5%H@!CXA^B%W3WY*>9:
M,]/T?K_WJ6'09OB;+M_Z5L]>RN)AS. 1'JA[[FEHY,PD99!JP+PSZ>=(#?R6
MA]\WT\DC_L $^V^W(&1*R[4T]]8:S?@7O_VG\ELP:Z-C\H-A)%Z!+7@N]Y[8
MAL)?-1+&M(T#3RZ8:G@BP&.1J7<5XW?_;A.UMN*_AFG_>J>5[:%%G>!846A(
M)#TQ8R\\F2K#,"ZLK:F,,3$.'1P O\4-2^A5,6KL ZZ>AT$MW^^[2>0:J<J4
M$:I.M&._^*B-&SU(UK,J.T994K!N,]W6U5_LJI>OI#(^6OC[!>9'C*T/]+^8
MW2^C75M[,!^-Z:6)!P5TJI>]>,#Y4#I>AFA=K#,K;50/ICPFV$33N%O^[(BA
MQZ:OI=D\OZ>5AUJN&4)#:_GM='0J5FU-W'R$H_1JK9MA0]]>*,[URNI9ZF>V
M5[$W3(7KGM/RX-9=.8_3/<5M$36*5<O:0:9PA2+VC)3]7$HF17FD2XEW8S4P
M"DBGVKQ?ATV?;=%;6\G/+&#]/18OSJ2 >9>9@7N@A&M]!X^SR*+RV<U$[*,Q
MZ>8T^.V"P_!3;IL'06NX,^#GVEHQ,'&E '[3;!K_?<KW^_/GO86$X6_CC0T;
M%/&*L=PM+<,\UD(.=\:]XFXB!?X.4ABP?\.IQO6G'Y#,%O>GD\.7,Z-<\W9B
MY/?YN[H*,R;@)/@B$"F,B:CVC07GBZ[L^-]2.6/\K\<\*_<<N*4IYTVVVX?:
M/CHH%4\EN.K$J.6%XX9?1VXMS==F!;311,W-NT9LY(</<VO-IN5!4R 0VHB<
M>T@%MAX6F"_-0P/"A47M;*?9<L%K(3J&;OF#'%M Y(&@BG[(3DOJK_E%J<GJ
M28P"N(A45IR5T=M!]?6\1<KC&=4?SNJ%Y$P_Z33GE4-")>F>3!9X/**M3[2W
M87ZW(]KG*1JYQ-;B\FZX<!WA4HT&G&6C/I^A >R140NI',)MT^6"&)5U1/@G
MR^I)?7P9<UK60?AL#LY:PB5/U?=,PTCZ/:R@'T%*?]X&8*F#S'@UTF5R-')2
MTC^%VMFB2OQS ;_WQGR*=X'_]S36!@\655=2VIUB"(?]F>R5CCE4G/3?-TW!
M42_X+.PCHFI_1-*1FDXD236?$.SXX&+*8J5<I)LBPI"##XN5F48C[ISPR2VI
M/[(1]SQ^MZK"_BG>-RF1[D*[.:CT]B@#2D[X:4UEM7#,&;%P>$[?]HE7+%7S
MS/F4*NVZ[3#VJW"^1D[GI\SU.M#O;EA/!112]/F_%> GSW@]]XIH$*AVA<JH
MM-*,(-4-,X#18Z!YN+/8(6HIB+:!NJ2H4R?J&Q;F^.$$SN;Y_I=A!SL5D$[&
M/>AD#V]WMNNU_G2T?T/".T1078O4G1)@Y2WVUDH[#.\;EJS/[Y)0B&$3Z.N7
MUA?ZQ":LT*5.^/J*[XQ^8SX^59)IPE! L$KMJY]5=S+01"#$8]Z.W&=LD-@\
MVO*P_053+^&J3F"4 *3DR::9D:;K]EEPR8%W=<5PRJ*>VZ@+ K%FHPRJ-SP4
MJ<M:>"GUI$]-V(;UX'ERLEUNZ!=0N6FG.:O;*NZ)+,,3?0'O]TR[FY^"Y@][
MFV<52N2:[2OR<1-_I!N(A'*<V1Y!LG?1 +@1>"S=^*"U!74*S@*N&"S==4;\
M1@.(42]1/T7#P/BH-\HXB8?WOFH<46T 2N.PD9B)6V!K]3K./S'RX+YNK&:R
MU.S,-7_*(@&JRCA^LRQAMGX]1JW9D5?[1,<]/E>FA%F@_N[XO&HU#\=RVY$4
M M^G[(]0,#%4/[QK^P4[0N99DF:X&W>IKC@\C8YU4J(])3)^/ML;$X_Q-LH&
M86<?WU'\HK @TX019ZCD@P#5X,"K=TRF$&K 2FDQ:",G;JH1V,]BME5W/"32
M.F2C\+'^X-5(R6+3.G_Y,.W$O),-'KT1I:PDVU>9.3$Z*<-$JD0E@T''3(GX
M!(\AEYIY2EK+JAVQO0%26>Y;0D@62OG;HJT\K56NIF[,!E3])^Y=,<YP$1#E
M87#.<8.!!A!0[J,!C0H<Y5&UR_.#: #W-$IXI&@!>$7%@2A$ T0@84._$6@
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M,3,.(X3F/V53]-7(W:37^E;&PD4X9<-^QHKCO>F>X63PXLEWR]F,4[I0[TC
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M\*\$F']V @RV+E28U,SN^A"3$UR+S;$CNIYX?4M@*QY[EP%.1:8]<AW7:NT
M#Z/TXR CSFW_R>;[HVXZ*995[1X]=Y&7D'AE2F/UD\2RGI.'E97@-@NB+KH"
MJK()L\/>X]IS1@-:'N*<TV2EP8%44V([/.#F:/!O 2C8,5'9[G_H@23Q%G (
M& 7$;ESS_7/LLY(T71!<=)M;81^0R# C[!^3I];*8G8X:[F#'(2J:5ONF>3F
MY$^5*"N_B)9_N4!77@0L]X"D!RP>*1+ZY/>XJ-S#6L&7M6C K[:S8]@V&I"
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MN_&BO?UMC5>Z6O^2S/QG2F:./7'OLMC)1P,T"2N -\Y[Z^DWWCZQ1T7Q=C'
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MI$/Z6B"[N]+[ [ :8[R%C8WMJ1#W3[6)"^>?I\5J%]7E,! (4[X#AO>.F;D
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M3;=S1D09<EE0'!B^_*J6_6A.3[7>TFHE9R\B4W=K07<> Z1-8; $.5C\V9$
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M29\SB8#S1Z#54U$B0 Y?LHX3&!UG4_,PILJ@ZH3O%6QBOF1T"&Y/;IUBBJ#
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MW,+ ML1&%7_UYR$\I)DW]2A K1%(!+Y_?9U+%?>#X)KF5]4B@-,_SFMX/1?
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M:@I,I MRKN+B&]%*GI->GOV&4M\&O%QVF%_M0C5_ZV@[\^/SS%5]F%PMC@(
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MKVBK[.&DM@+G:Q;%C FT476Q4^KG",6%F\'7K\J9_ A_=_V:IZ7.LRSA1^F
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M\/_I$F+6JXJ=>+:=<>,7(6BKALMC&67L.Q6?/FI63G2AQ%\*SF'HGM!@&_&
MRLN[5Z: \3D]678>U85-/]D2-/& NYFID8?$D02 ].R?O&\%:-T-TWBQ@<KQ
M?5-^7C2;>N3C-CC4XUR6U5I\!C26"TA\%]J2RN<F=XW\V;SG;AEW%V_\A_X!
M"(LMF"<W79; =M\2\/U-2 #L+ $/X -MZT"@IRV7?A'^[TDG?\)[H2B#$Q R
M^GRO&??4]<#LE,-J+WUG0>)KDWWU0D*3[?N:Y(6>RL8-,RTSKNN3;:9<N%%Q
M_[J\%"D7X0SE+TYKKM<(?GWP+^+,?Z'@?_J <ZCM4H$LZY$<L?GVD6)T)AY@
MF%9X.3[N)1Z_M[ZHJ9^H\KOE?<EE@"H!.T.P@9<Y]T^&X,-O-,P-6^N\MJ\:
M7!@]78%>7![% 0L>-#?-*UR[)9L*9!ALPSB-S>' A++&99N/VN<U7\!_<V75
M8])*+\'7U%D?B&!/ M -8>"Q-:%#U5VM0K8700SP)=9;H!W-2H));0V2XP%/
MOA5UO5Q!#JL>&F!>*,8@L(ZRA*H@QZE39&JF0A#YKDC$YRIC#!,1/W#YQ>5+
M$(@66#M#66^I,#+RC2#K!^,_KK'F.!+"2WK_]7$9M^OM57%CTY9]J 66E9$%
M2UDZ.EH<JH^JC:JWCXU/:&D.=D=WT;%(-'W3(E"^RPN!M(V@J%#7C9[]?-3'
M2E""<;?_5Q39$4_^A7'5.S2]F2.V)WP^3K,E7BZX=_E41,[WW;B:VM2*JI<M
M%UMQ0+X^A+4RMRHHWLVGPBT'U(8'G*LZ'RGC[*&L]3K=B/6?34W.V:?A\D[Z
MAF?-$LHJ?CK=3EVI]UZ/%]4U5EM,RNC(!+;]*-YZ%5N2&T)/; 5:\KPXU\,8
M[2SXW6BE]Z4_K_U#5ECH_6HY4FVOM7A&3>F:N]T;"W*=1H]6=SK%S5179^S"
M&^MNJW<0AE? !1T(5X2(KNF=7U_HT!6N#O\-HW;M+<W3O:Y-+/CMFB[3#6:L
MWV;HR3?;43&N6G6PAKER)R8A_[W-'$[O66LLCB3RD*FWW'UX)A+(S]^7\\JQ
MNYQU:&@H5W(8#&&1DW2F^GH1/5Y">;AQB*6L<G\1_.GU\;L(5FH-M;_BS);K
M _=$9X?6C'8U*[%X0PLUBQ)R"O%(1L6)VI/J+MJ4]U3BRZ^CR[XV-5XIDNL3
M#*!;]W>H6GN@;=]IPEB379Q@)5R4>4STA96"R<+UT=J@3M-ZLCZ/G+J:FY"0
MK19U9M&@TF^ M/_S$WT03].1V9FHD)6ZP_$@;P,=9@#L<>CK*ZQH7EZ0&4IY
M);2N1*U%R(Z8S.6 WF]BHX_")7B!%Z/<CA2R?YX=5GQ-(K) CVBO@'41F5O=
M@@A1HKZZ:3:CWCY5XWTL=GS6UYHW(V5?51?LXJ&\]D37SM?--Z[!AIMSTB+F
MQ0%5SJ.(;J+%90D\(*2RB\NGOL8![5B;NVYR^+)P54&+V&1#2Q$#?_P1,['G
MO]7D1$/S^IR--:IQ\@5=R%H!R=$F=NG]@X6VSYW6WR9<ILS>"U-]EW2TD)G@
MMBDQ40ZU#>@N["MB)2ZY9N+)?%OA^^S@OL1YC*>NH&+Q9EL@#T!FJ%#::YNJ
MJ3:F4R=8B_NPFJ5HF19\HZO?=6,/HO3OY,K7WA^F#QY;:X<E*NT[76O</D(R
M$3#<O4<W.JX#-H61M!3Y(AP5/O6:_]M,[7]$4*TQ#GXE""%*6@M;T(4V!X"8
ML3= E[=XWQS__E'G2V%Y&&=&2H95 HL?C[" 4.3 <6WYLPMZHY5+=YA!*"/7
M^/RU@JWOPA9B;25Y$=ZW>KJ)H@?/8<UEOAK%[%QD#" H:P6IGWG6JW?5%+D/
M[@NIG[^@^Z+_99*'9_L%T65+7L+/W\+/M4$7D>MR>$#NJU@\8/^21P\KS4$'
M>7!46<,/2MT]6M %ZR!E$R2*N-WLO53]8371Y'EIOK:R76/W8=)NQ.&6@[#0
MN+#PO=YO[;MKS-$?1L,NSWV>0W]YGQD?L2_";]:O+^-LXJ4"#1?U@-%-V07E
M[Z2^?IU):HZ 9&U?).;9UP4KD&#;L[*R"CO!227S=S6T]!;E!2]F!1A;IAI;
M_MUK0/Y*@281@0Q$X 'U5+[K>$"?%1[PN^T<?3DP4?R7B^PX'M!]AEL@PS3"
M#S4;<_  U]N$)69[W.\_JV44RO'=1;=%B17G'=2 MK-78C8]CRZG!K4+D& N
MMVJCO,@/8HMXXVP9B>5_4U^U"P!U*M$HX@%1FG>PA,)=HS/RLXOZ:X4&U![B
MYD<EPYVWBGKP ,?+^-E_'K40IKXWILA6D*++!E1Z&)WC@J.+"B3\+R]?R%?[
MA[9DG%G5XRO)5SO4<RZB>".=MRQ!$Y>^D&4%&?=,L;E&(S?30-\_V8SCD!5L
M)IU&KXN[W-4>_\=K6?]3K=ZO2#+F%0_\C>@LGT49()[Q9@@5-[YW'K46XTU2
M)NZUMM_HLQ8P,'#<PU!(ZZ=PKE?T6KX??SK+FN#)(C31M9;P]$2<4-*1.JH$
MLPA/@6 X-1H12XA?BQ6(.6"6F(CFL7#+M4F147#T@H3]OA:H%<B.5GWJHEEI
M_J*=+2/4:_/)>$?[8Y[B^^+)4E.-<^]1-PAF)XI )A7V8X+V6@DZ5(;Q-]&4
ML^\,_!!-G5!WH]'9NS5H[KSO<#H^<SBE/C)I9<_-X]Y!N6!==4?=2%PK-"8T
MV2A;N<)MO\[J;QGWHZ@*B&D%,6KR,-.,(I18.) 1SX '%7M%IGI!#W0P4A)4
M S>+4Z"!N=*R=A,RQ<KWT87?I=FKQCEQ@9M ;%#DN0\'S-&BU\+;"P^H'FFG
MCVD%DDSU82-BRB/I!15+(_+[(_+T(,>6)C=.]67>,(5]O,4M- 7TWOD+P\$R
M%58GC[OW^@TI.+Q7"DH#:?7M#X]&M2$R>DH2[29)"FI$5]7EF,6?6+)ISJD7
M75FT6#-X[/#%M.7%=GB9HI6VQ@L*S;#;[YZ^E7R^*=,W/^#5BZRI<Z)JW#+I
MI=75SB'I9R*)!#[R)L8#9C@V8:A))W[LC1W0)L)DZ"1Y&HI0AP[:@H:&F[ >
M'A4K7W$N_(:1G["W;X!^G=VLO&#L,C#'7?\!],<#]-)#L"<<F/58#-;GGY^5
MCZ3\W&4B\+2?B2E!G$&;*2"6-B+GJUI$2F@P<7[^QU?5 J/1']U9846L1_O@
MFMJ(3M8 -M+HXFS.W\69 !"S>,3C\MR6^/7XKQ*5'N;MU72Q:(BJT;AKU[]5
MVBGSG-D(4X4HJ-L\$[?&_ET8Q8FSEO*9"9'[N[J]Y&\ND%BV2Z%<OOWF?/NP
MME!AI8=1N*H3L7.A3/"51@17=/_2?_5DS#>]MQMY_.K]QI]49X:3FXKQJ-TR
M"J8OVWE*K*')=E7WQCHM+(-F7HMTOWC^[=*E*> !^1'I> "L<A)VP;CGC&N\
M]+0YT'1@'VAM"8B<1"562:!;Q77>OG;:C]U=B*\392>K%#]ZZR[M7,\^FURW
ML^OT<\XQID?9XQJ356A&>8Q\OF5>3-R06OZ#/)8%GV(D'O#)'1.YQ[2#TY,8
M*FNB%]!H< '121Q)3+08QW5K3FI;%'H?\5>?)F"S9[6HM6(U:0)I#+_;YW05
M5Y52Q<HHT;%J'@826.*,T=]PT?\;?[_#NG=#X/Q3BV9]TM<N,'6&!RY$KC,:
M-]Y^R4RNH1QG8GKL(D2%-?-7VHB^18_CV&&C!ICGHZ!_8'S&?YUMZ&T5%W.N
M*X?J9=R,6K (F\8#/K-LRM0SSP.'"*T+<H0W/>RARBT_')NBYW6B2+*+'";^
M?OP=#]#PAVSA @G+$NP_4E3YW3ZJ.TK"HPJWGG0B^WC+*SNHU(J\6&,4F+D+
MB6,4 9>=LMW#+(.6=-+O'3[*<??U/[]#,87B00I1:QG4U_/;3$!$/)Z[B:H_
ML%#.R^XVS_U\P% FG,=B]\9217?:6!?VD'4<.5S?>*8&79(\@?5WH:(Q_BA+
M-0S")?5KJS\E)G+&Y]'C].P#PX+JNM%3!A1O_FKI DH5WNZH(CW1TU$?=GNY
MN$CP.K>=7&%$1 X1IV?QZF4:F.DY],^K9?X?3LU%VXC/AM35C1#K51X\(-0J
M^T=:I[6+TYO/Q@Q:<TV^^[OY2X-K:U] =B0]J\7]:KAYN7MCET==[/^G$&>A
M2-(L]TFMYLV'M0FO;.,5T"I?S7&_3D_[Z[;$VGF.CK8V"SS][T'^N$:5S0JQ
M%V0F*3='WSI5 DWJ 4BATT&G.J*3\J^G5CWQ@))35UN*30H&C?6G_H,QM<)N
MFH[9^3=-[:-$BD@G\8#7F$#<#YAEU<L1TX^,M K<??',)_1S?G])YOQ?( CE
MDV,Q/L[);)DI#3_-:-E3^/?8Q/^+!$.JBM%E>  #MP*:",().O GR.@N42@8
M/F2/\O* '$F=DZ>=5P[[P$I.(TU6T9"R^G;:",2 4__U 175P;)NS=6M]6Z'
M@7CX3M#+K]K9Q&_>L]QVZTZ[1W!H,8CC:Y C,,'WHOX0 +$\K+L"MW;I?KCJ
M/#"/H*@('2<',+^);\HYN$[4=:QQX_V<Q/NSNHOYZ6U3B)"<*(?M^@5/^9:]
MA6"IS<A 2N85VC0)ZCMP NA?Q0-X*=<ZQJ"]8\ONX^??QR;BF\)MW]6BQZHD
M[O'+*H4/NGM86Q<>QAF$>%ELVBRZ%LB'D"O(RBBL%PJ/:VH>K]NFB,83NOIM
MZ.\1]+\,NI84I$5<?1< ((M1NN1)7NF+]K3>*L]T7-QB&CYTY[Z5$XR2A?X<
M @XS7:+^0%NV&%LFO5POR_=%J]%?FRHQU0*LE[X\Y+]I(C_FHG\R!("8"'*J
MNOQU$7V!9-J;15CA6LJ30H!Q!\^]BXX65EQ%UHD_ <@F_C]?W_SFVX!*/BSX
M70^QEAA;X[#?:RW9P?"* )VEC3('TA=H%4ULE^8,6!S4ONP<T2KM$@L+WP8_
M;*V[25==T7BFC]@'P7P4<%3H/Y0;.FV(#\]41\Z_+S2IIY;:<P-;Z5+M'7$_
M=G87_Q27)3I9>E"J[?.A^*0H[%)MM)>/A)W)U9F+0T4CZA+T>GTJ7%-PKXW_
MQ"X&G4-CYOR.CKI8JG'JOB&_++BJ4PW*#S5GZ. 1"^91^>'DC)H- S]EPV&>
M%EFQ;WHTDK+R,H/ZK7CMAR",]CX5;@VWU.2(U=INN;3=$LA5D[O+ZR)'97?W
MZ4HX@+080/@C(HSAF[]EF/8_%I"$LZG'/%(,;V,I= /ME%R5VBQT8#CYUO%.
M8(S<:*93<R%'(>\]ZF,+#1[P /:Z_OPQS"9O;B7V0\$,SBFAHT$)>,^X'H-E
MWW:/=_40'FU3AP=Q_.3"I3VSQ -B0VKN.D; ;Y*@@"?^?OR1KO+G'X']KC_5
M(LMSX?/JD+N1)34.YGB Z:.  NS'TZ#?GJUL+,BN5S&NB4LF4,D3RCE#B;^Z
MCV:ISKM36,[+TRGVL#UZK  >0&ETB@>H_%V!U;^Y((5R$H'L)'@%E[5+*.:'
M!X@?K/.WPN/K?V+J>_>;=UH*9ND#:686_"KAC3Y##Y,ZE@JR%MV><>NG(%I^
M-JK&/K>]$Z47]S7@&3'!3@NLL=</D4VX/Y$K4[B0].A_V'D9=@;RP ]NX*2@
MFUXSEW/Z[-\\5%8#C=HX N\"U[<.*2M;%4\AV@Z+.8,.L!AZ>"Z7Z&)7W_K1
MTY1YU;D=)A@BRIJ;NQK17'L7/*/QX[ BDTW8PCOYLB_N3']72/;;N*;LJUOQ
MU'=SG[0W9BB(:@$AIZNI@&<<'PEU97Y]N_\%63H^WK%U^#LZ_\*RJ'ZD@!D'
MVPR,W'E/F/*N,7_+49ZMYKFNKA47K*TNRT/T5@;X0HI :H3WPG[WJVTFAR#4
M@Y0__A LNJ\<=!51/&DB_<G_RJ4J-?Y)'\5XP 89YJ=8)'(59[Q0B=PH$N\-
M;*HW&NW9 ]<&M0\9:,^!B+2:/*A%%V*]G/73:!*R*I/J"R<D;TN2"P_=(I<2
M[#[J(C1E:&R%!/D;YP3[D\=T%+C&T4O1,3_W*M. S4#1YZS:A=H3&QDT%_G&
MNFP&=/\B)FZ9N;OK7F90;I:PYTD,R;-;:?'=YJF$8<H&(A=QVL:WX?$P]0FW
MD(Z]2!$FX_=MGV)KFNS=QF52]J3G^DQ,RR)IHQ=]@KGU.=NI!N)*[!B,I#-"
M Z(F!H<U6&.'6%MW%G2[_G?A4.&]Y<,),2&UL29@R><)!CR@XI&M\QG,H:7Y
MG8L:6MSK,>-3 6R+,+A6X-V;KC,J/&!8X7$M<)==CQ(]5%-1USG/+=V&\SXN
M$N.B":><!0VHIK+-%.Q<>XL'7$L@@_9L/<0#LOP*'$M&X#9X@'4>6>-%Q2YH
MUQ7!/M:3=RS%"Q]3*<_% [[%B  /I*<=JV1^A1SA 4^W3N97).U _*?>P6@/
M01@R6!>JF7(=8[S)!D=WU:7\TL* OD4>'6\CVA%?3P-Q3CFB0$ZX/FE.!U9
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MR#=PE?EQ#TVB>L=A,P2UO46/>71Y#L?+(Q:[0WB&4A04A0=\W4I8@,3@QO
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MKISS'/:&BMLN:M%KZY*?.?3*NU&4F/X2/"!#Y[G']95SM>JWA&J_M2@D=SH
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MF(JCA1$"[<*A@,GS3W<3G.&M:E:7=D"N:K!7L" R0P%+R;H8_%B5G*SD'3Y
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MGWO_'^[7N;)6UAIKS#'?=ZPYWG'-@(>Z0TEUK*JURIX0K)83NP'+=<90>O^
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MTT6P#*1&%:HT#N[ /?<-/U5MGL9;=UT9%U?)O/PN LY:2/<':7N/+(8 9]/
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MDUTW(DE)#6\V?B"3^C]B*[<9*"GI'^KKZ8[K*U1/Z(U/O"R)A]$RYS%S@G0
M +(WF:3^DSSM_EV.9TMH[KJ51F?GU568P?GFJRK[_=D_I'$&^_V21FV-MU^_
M%">N_#(Q_I9(POZ(UVK#D<U6L)\UYCUY2JUE8#3A' BXOG7;EZBGXZ6![2KO
MDE >+OC<BFG$X+C[!205XQ^ _WS.8L!SPP[1&>+L#G_LZ(;Z&3D$_G2F[/26
M?WQ!63F!QXRI#O+5.1,(&79A<UVXXI _*482@%/S^&T_[?"RZS@J3F$.Y;$
M&>$M:IQ/K+B^Y0] J9U2"3QFNS_SM@V^*&7OP<?2>]*3#MDW1_ZPC&4OR2G?
M9&CEI 'M!_(];$_(D6B)G7$[[S@:&W?5$8&OH!YC 651X,&IS6O^+<TI(["4
MR\V'W:IUFQ,.OB:[KT]'O'TO"!\31ZVH_< "K%WIV0=_R6O%=^K]WI9UX7C"
M%O)R'TG+HQ+)2_&CC_ (_UIH3.S94+7QD-G'Z-23X#%TW]8=W&UNN)3_1F#T
M,^^)6D<X/6SV5?9P?64 >JA.?&(%N=;WUM$UK-=7IKDGT?NC^EE+/SF,.:&2
M#.IK2"*EOP:,V^;@>JK9SAW"4[XYVOKP6DEYL )'$)*KCN%80/A#%,O))@-F
M*-P)_1X+4&0(5S:[D'D-3?7& @*AF\YR?X:P@.;ORD6QUPT0TC<;1=K%:^/[
MF]NKD0VF99>ACJ%;;+5(BQ_[E5B H?%I/R9LWMDH,79.(Z@X/_;D&D-^?3R1
M(ZGO[<O4"TXS'SNFBK7YXW0BM5LJ)J.%_'40%0//"6G/!Z;,GHDSS'TO'APF
M 49G$/)1\M8J4AS<5E08)J&K<6[J87&,?V#PYP,7:@8MLAV,'#0R/$KCJV0/
M8BZD@>L6JHX;K!WF3<S(FC-J7VIEJV(!/)J(ZC<'L3&MZCZ&@?6S2?'+ 4JX
M.&(G$.#S&&3@2NW\]+HMY%F KYT5%A"RMAJ11T2/9*3-:EA1=>0NB$:/2=&5
M)]X9WX0.A'S F0C(#$Y51RG=?QS; R7LI@ZRUR\5Z050R"K@Z0C%O0!V'.;&
M7GL>#(Z@<X!H"@8N9'39-<YZ+E@ @XS Q@&*0QT+$,4"=G:\*Z''GA@-LTC4
MI],JXXN1H<4>!,CBT;G2(I+AXU%BT?G^<D(DB_G%]8G_X(\+ZS><MBQDL06(
M-.(VG0\*4^^Y=PRN4S1LA74,TY:6;G@$>SE[0S..*3 6ZR<C<J]?K2\M5A=
M-4S92&N4[M$;3R9P:>V@AV]KWI9D!*:D]F&&,.I+4M#BXVI4>-,.^^7-G!2$
MN$K!QU"NZ).+"[KRN$]=O=:W!W]&XS;5(L+"89*FQ,;1"F;WQ]?'>(;%8 C1
M+;!Z-/&%PDI;^P3\J;!59.+X; R^*:(LF>OAY\3^W?'%9"$A8=4#Y^F=X+Z6
M./\)>0RE[O'JPXL.^F"R\8U:BLOF8R\$%H 8A*+KUDNKG67U[;WW^;C8,Q@4
M02Q<(VO!O445+GPB!.-W0;G)L3X.]Z;8GPE7^!G=&-RT*2\<-4$N?0K2'[$F
M:C, XNZ\<T[ $^?F6?.GD5S%4)*AV_SSJWS$C/9BHRVXJN%BE8UA\%FX/KGZ
MQ^U9QZ-67R>KK4,_)\Z\\(9\T,.)T=X4$'YL<8OH,,\C=3XM+6U42[#L^]JO
M+\L]/@  MU\ ;GT(##+T/39&K4Z:VZ"7I>SQ)B<#LFT#S5'P%L]+AIH&WS4Z
M\./4N8R!5H[$)08C.0M20K[$PGNJ\0/K/HU\3TI+!$CM"!,OY!U 3:8U4+W)
MR>^.I@^[)O: T+PL,T2^>:]BU+.8/PGX@+ONAL,D7"GX7P?05_-05 %8.#H#
M7=7HIN_&MSX)SV@H#3#S=.6K459N%*/B<9NTVA'%<(=SGXD().=6F.B!*D9O
M.7(;'9,13*=$^_48?)1[=2J^Z/OMW'A:E?*;D".RT/EE8-_I3IZ/$9H;7G#1
M>#QO)IJXPN$X!G)%#'^$4TPE,\369V4EY,LD%_3(ZTLJ?N+5$RTC[7S_A,X3
MZ;PWKE08R8\G&VR1JF"(/G!S9^YE22CO5/0:+W^!$<C6;",ASK#'4%H=U\8*
MT->/[V<EG%A:=.I8]2F;C 619*H^2<L#<5>O0'37"%^D$$;JNKOY)$WW R?
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M9,SV0R$>EQ!)],)#UZUGR0;? DD81-YNE(L0I)FVE' YF*HK./DT\A#8;I8
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M9ED?R#T)N<NR<W?MX5^A*MJ*4E#X6-*SCLO(OZ+1J?\B.Q_^MQ;P_/?9J$)
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MJ2_P)FVJI\Y<WHO%8K<&'8.(3)KQ$5:AQ2[W8<#!8@$W&_B*D)I#7K(PQU>
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M!W@L^_N\8P]'S=0Q2ELDP^!]\UCT%/#HLD7:XDG'LAIXT"(7>JY>53-'NGX
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MM;X!+]NLL "D(RZ&+S3]M8A-UL1I_O_-F!!U5 E8_"#28@!J-3%Y'NJM=7/
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MYGLZI%K:*0"<5FS:NG1^^I(U151__L6-6@CI79W9:T6@F\$N%G#OS0ARNS4
ME8+<KZT<AHU_;6DI TYG@'E %IPY\*F [-82GW6OR>9[FWZ[!=WCHYTF/.2\
M'6[4:=^[TXT. -M1T!YYB\;([9,MJ7[^(O7"+]G$DDDT.03]6K)O\"RDB0ZW
M+/XC;"S  O8?_5.][W43CD[E!V[$80$$,J)@H 8[;2HJ',PFONU.W>)P;,%,
MM*9'1*2BUV;V0U:LC,\)]NBK'+GXT[/@NAOM-F3X:=$_?&/WU3@0Q@O>J$+C
M/-J,Z\(M(##H,GIFPL?7^X"O=*+-9^Z''5&QYQL'CL(>^@T3)W#HV.^F5][Z
M*#:*! *[F,6,5X_P.!0<-2D>!1'*<^VSU)M[/ /1JPK3P!1@&,8.E"$6L.AT
M)H9.; 5>TYYC 6.::))K,A4@V 3<@0/= 18G9_I,AQ"9KC!$Q^#)ZIU=>/*1
MK<_Y!HJK'DIZG^/60-R;=W.524C>%/YVBBSQ[ZRC!@41#* /KB^D RQJK7&7
M5P/_DB0]6:Y(?XBYL;A</77O6'YA<;[!^ <'Z=VP@*76Z?;9>=RJ@.,,+AC\
ML50Q<+^D!0J*!1B1Y\NCZ]R-?U0=IUY^3M-PN:/Z]+*PD3649VM[EXI#2L_R
MM4A)S(N"&'X^9&27ZM(_O8>5I#@KDH G2L#+/SO%X&7.)FE^Y66!X.DWSZE;
M=IID0>OC1)"A(#9-!1XFO3.%FG+]$?+:4'M> '-W@L1Y1P"P!#B.!22=TJ\]
MQW!B 2<F':OQIPH=:=K]P.BV"?3YNS:WDX-J)J? IY>>X3TV2\[3?Z#3IYT'
MYJM&U<^NCVO#JER]B^ +E'US&N?K>7G]TM4C]$U[A"$FS"=?XJ]5&/@:%+CW
M_2;_#_:^.RS*;LGS-2 FQ  J$AJ)DD2RDEI$,MBD!@&Q)6<0)*=6D)QSDIQS
MSD*+"$W..4K..32AZ=YN[^SSS-Z],[L[]]YOG)V//XOWK:Y3YU35K^K4.>]Y
M J-%5UCW0J_K'OSB:73@1EG#94*IZPT36:8>I&C1 +&[B=X'-J=1Q^-8@,9L
M;NC@3*A&H%O'P#&3T2/*?.B@66*VN\7A4+GJ6;(]^=U:LQK:C=LW2RBO4<@D
M[<9*$HZ=JYC(SE*":<K MO>I78W&Z10#J)G%+G.TB!"VQ?+G8($C"-C%IOD'
M1AO\5!CD;#4=X>*^O>7:N]FUN\P:(4M>>.42JYGF8 7'TQI)')+5TK&,"?H:
M=NYK2M,"BW$H4P[,5*FC5XJ<-3AODD;?A\Y2@C)_:6TEB'VIEYU)$TDY<=A#
M*1_;3I9,TN:KX)GJ>3X-\Z!?R/S#NE?VM=\E1N3UN%9@@4@>T&D0_GOOGH7_
M;% Z".#B3"IBHPGT#+$[BCAZ@A'&A]SY:WCIBN&[FEB@4A[./HV&XF\TFB3!
MAZW2Q+_%D9'/Q>4MNXGY]8"+]5?'*.3,Y%BGGB[L0*[?V$$$ZH8\^.%")HE)
MG0Q7/E#AIKSI/_2!J:KD]L('4I@#C/]E:/=,9N9 47/Q2T'EXN=N;4GO4W#8
MSN4K ;]N['X_?GLHKJ\'J33L WG$1G)0;:@G+QT9J-KS\PFUGZ=@D)DP\:L,
M"25$#P(&[\K(Q +",2!,-FK#H-"04C]S9=)#1I#TR>SJ76.'U 2&9X+N!*&,
M:C<CC-V(? .)$29"3L^7(:A7A;\0:,2TP)J>36#W1+S'R&FEV;J05VDQ::V[
MK07;3"S2K+.PHLA^.=817?]!(#(K+2,]TX.D+$R.YA%("7\7*0,X>AC-(L$G
M,CH@Q(,NX$>9'PJ2D/M&$8=M=O6..84)B(Y42RV<2KO4#@@9^;9MC*$R(U,,
MDV4SI(:,,X<I>85TG@S)X>:D!(7:E3S" NBI7?@MX??H_D84HX1=NBIR*MGO
MZPFCCKFI.0M!<,X;1POUS>J).XO;STPCN7MT^1@DR*&/A5-\B_H1WJT$;Z3D
M$]8FWV*!5_M(96>7M?CB 4WZX5.-//Y^_9X" 3/3SD3?S!]:EN$_HR*&+I.0
M&<2,IF=GQZ3%&E&FQTJ$Q 35H&0FZI]Q'GU)8%"CNK]KOSIA'9IT?8?>C+NL
MF^;2SXC;$Q?.A-9U\BGV";! "0KG*A.\F+# EX&$K5D;"'%VU917XYP5"=G%
M;MTTQZMCZ@,!*RLO6@9*TU;]):AO1_*BMNX4VKO<P/RK_I-?QI 3M$B_PY_I
MH*,QSZ[2"X&,G/(G)!3:*6IUA!]3-GUJ3+.0J7JD'A\2"+D=S'()%V9CA9B;
M5GX&)/I*OSN0@ D'J.Z.'4-%=[GTAV8KY6SH-!'%'.'6&H'^T3^CK&;3@D7E
MZBSW<]-N/?2A:6$5E842O2]N$KRR69(1-C28.YAP:I+[GUTE_$<1>D1QJ,<O
M'7XF)H,%1/'Y'.^_!M3EM%C @P0+C'Z ,TRCY<@2\9_YI#B+WX"/RF"BT $]
MY+&X$%@+.LZ!S^W\RS$@8Y\=/LQLV/$!%O!=GSYM<98_M &??DY<0;1-GEL'
MSU=;8@%NKZ.'RT7HT/%QN^-@^'>//2Q A-&WZ-ADF4/(:<6!!LY$I*K7; L$
M[!:93FJ-+/2^*T(;527H'(@:&!P+F90T)%)*C/D?9?V,@-*$4'C'R2C0P>]0
MQ*JXI<'#SEZO\(P5[-62:X2=*.0KG&,F\\W5]TSK]6DV%!Y;9]/8#CJ&.%\;
M(1/>[D2;'K4.DL-RBW;G8<5VS;WCIV%@7Y+W S+GM?DDWL%!K9#('-:!?3\"
MV8AR"$T_<EY?F5Y_UB1P4M9D02G!P]V\=-S+E]:'^^I:7](GB"(+^B09%Z-D
MMMYIGW+-(_=$UJ^;W='*=J)]?]#]3KL(2D0\J5/L% 9'19KS,Q$\TV6(^2#?
M^- _HOKNSR!]IYK[??3"SX-&[B5ETG<]-J@-,;Y04T3H?;TO<7>?VUD."U2E
M85S@L[5\F%T0B5 ?''7EU[U0"KC\E+X]Z#@-W$#\%@-//-P!S0?@YO0V&'6$
M-D9ME)XR(7#8(*0&Q8T%JB/!>ZH8N%]^@.LKM-(R.$83QB[K'#("6P'E&W1K
M\W'76ISV?CWTS%N\./ %:K<3X%5546>_XS*16,;\V2QW*$!+.TO?D%SQ >@-
M:'O_\=<2O_?^39RK2M*^(=\&]"2%5$%G%[K1B?"MFUC@$.R<A$N=AS=@6VHX
M>3"<B,7EJ)/42G@]8C4-L0^"CN+2F2_C3X4BT'7U;*:3I:)H+K,-]I!3 =.-
M=8N)P2$<+&KXZ2A19ODZ%O2U11G:S>Z;$/H47=K.&I"I5,M!ES,JIV>QGXFF
M3:EW>F Z=Z'MU[6K$NP8$IRW,=?:)$;C(N79:9W)AO P9I[]U&*;RK^Z%B.%
MTT8GXJ0JGIQXP07W8.P1+KGW32S' JB(Q/%[B>/@$QT,E;\M#'45=)P*0K^W
M489MAR6>/IP.AAV55Q>>[0O);=BBSG+^Y9(6@1;8)LY,.O5QOR[1RWVL6LY/
M/@M&/_*B'X$_/4'F\T7]P )1IUR4"NX3+IW#1YJH(0T#CJC1. W#]JH2!0M6
M7B=*HE<L']:#+HEG&3Y=MS7GKQZ[JB8WY9'@I/Y24O=9<C(M8_L&>J6/Y>AG
MT61'E'$^20MWE+S":X(W0ZD/K)S=K_88Y'_9!9_#X0)A6C.HA6#A=X3;Z\ED
M46^7!K4:D_JGU@2/)]._(650W;%9G7*EMV.8+H)KC!^(4 6IY'Y8SUS-P/!A
M 4>+O7T. :%HTNV'F>A^R EASBX&"F,6ON*<=LRSRT>\/7WL='!/<M;QJF#"
MM-\"6/,@\]7ZJN9IY1YYK"GO>7<RWNY1#3LVZ3A/-H12I)O'8@*X/(E(L;=#
MVR?\K1BK=#UM6"Z_%%U0&96?K4RN3*ONB2%4D"NM)<N77%C,2B3=M8VJ<&_4
M[L7;WR4E+Q4Y&<>\'H!O"N*;HA[\T_VQ\@6<003BX!2)\R(NR<"MIY^-1Z=X
MJ8+Q4*^^"9=^VF$F1= (^(YJ32T6L);'^>K5KK_5<V<=/(T%=N;-"T\5=.$H
MLK/1IP>J,X-P)Z<,QT2_#+=2QL"TG+B-E9S<%:8<Q@&?GVZ.WK.Q9E::XA':
MP^8$U7,X5A+3^F83MB/?^N<X>$KF'\F6XCPP:["T'JDL2%%*UML?L2H)6G<I
M::X33(EGKAO^2T@4;5'MTUXVWN79/7J4]2XT(\>"(O0HR4.F!?-44<+DW#Z4
M\838Z7R=8:PUJ9Y3N[;.4$ V?=N2'-1%B&[%%\G-%I@9'<*@6+2XT.CI1OY6
M+).KP^+T?75=9=)!OD[^4T3BO48LL+B%;A?6?7=B,G<F=NG#3Q.%@SR-!U=.
M^0QL4#!MNW+H^8SM29?R<DXU1[GV\/SD5CGY@3VE&:N=1E%<HJAS*]LX::K/
M\3!YL 5GO=U'$"SP U^A%O-:]U_@(6X!1[)00*%"DU_?6VN[%ZYE(&5$8($K
M;*7RY;17KM$K[TB%1TK[Q[^0H^&1Y>YS25'-M7&I_ZL5M,(>-E6K1*3& &;Y
MDIR<[Z-CQ+1DJW9+3RR4\[GH@<I%IR)%Q]YW_+@L4DKC#L;1'W8F!S]!;8T1
MJP_Q*\V6'$U,T@S/FCPL3#6P'THYK\Y%I]^5%/SLXM[62Z5\][=?7-;R?U6K
MK9]3NYV[>%/DWD6JR]3XE1!6_V:? 7-$/S'.MX!\T4A_MZUMD391P"<3%P\\
MS,P:(S@K-(ST'\W0GGW73S)X+;??R&&O_+U=+%N:SYL[(58KDS:W[VACVHEE
M/A%J-M4W2GJ5R2HD5G#QKE1J%&VY'0^=)?S^N /T^6>9"]*%Y!$BW+>;Y-V1
MS+<;'X>]^G*I[@;5VM#)[U93^\>7X50M.HD7XGJP +^ QIS$>]NAC8W.VNIZ
MEDW'_-'A,B&;A-$J_[LZM*K5O&^70RD7Y*IM[VYF97U4-E5_"4W.0?(%2GVR
MZ@AZD.M44:$"O5 E/X3@\ ]ZZUM)E,#6)IEN]>W[6)04< ?Z+"=QAH)I:=#'
M2::W$+HWG-ANDNK8OX2P@'/(WEW;<*Q?WXR/MN5=&3LV7>Q)S#7D8"0?KD)4
M?=-Z=,AV29TY$:0A'V]#5I,VR+J$U/=_F;TY.GOKYB,BD4YG#!S\RC=EC,9S
M8^N<F7F-))U1.LD[HWPGPL1"$?@>@(' [H"C;6?&ZP)&6>IKAFL.XPGNLA-.
MU(E^21X?K]NIJEELU>8X'N&L^C)):J7021<D)= OH4H8G,?SZ..C\O*U,3>"
MRX+*\X[64RO%(K4W=XU5U8U";D21\!P'E:22<F>*3><B9L"(NT_&<R_4"DO8
M,;9NQ2X9JR+#QT[YYC.-!C9=*W[HIH:IY8<9RBOTQ#92OY1:R<U996(08^+A
M]FYRJ3H-2_S([!A! JY,Z]D=8#;A:A<B>M&Q,$#AVP_L[!5*$,Y)["*.SG98
M%B"NZ,(5E^ZQ$4$L@#/WN=NVA,K*>A4L^^5LMCJ6_9N9K68NM2+#T>OE)&4'
M*=DK-Y<8/.E:!G[0<$1',M#7&(4H9(]_6RP[*\.\U60K&Z,I29":8[V.N&V[
MG+5W0<X$V=V!SMKZ.Z=&K++6P/OE\R0>0IZ]8_09_[[&2_G)NI]L^<-2%P.X
M4_R)> K?[1VL3;,C(H?%T0.;%GZ:"V-.A>7;Y)6SO'L8]$&]P#L#7D\6\\7=
MZ:G\H%K,M%.?.9M?38ZQ4?W2N]X,WZM?38[28YQC1ZG (K9#JVU)"AY$)LOB
MG$*.AS-E8E6M) 6O[VLHKE"?-\[D44+3>@B>%%D8.?+\L@GJZ0Z68^O]Q#VF
MU?SX <J5&@&(L5E^V AW78AOP:KI5%^# 3-7>-R']QO>*YRD HVZ%C5V:=RG
MD7:&<QF^$!KQE\FBM$SE-2;BK$D/?/41%B%4\:3FIR^=.K299(#[3WJ>\P!!
M/*8&R82+Q(V/"X\+=\*LG!4W9 _/OME,+6/FL<#-C@.,DH5V91IX0@CI/G$$
M+VW9%,JO659M5?CHP6PSES9(_A1"3FJ3=^_29&,^,PO24TQ8$URUL5+]O4?R
M-8MBNB1AF>?>10='ZX?68&1GS,[27+>FL]&H@U!W^$B=WG 9I<FG=G/?":CY
M1FZ#3O%&@%LA.\SG^\RC^=Q'\U^#>Y2:-4)N4CBEE<2\KIZ5LVS,S#>+[*/W
M,7[Q2![RX)QLSW6,YKWNA35TC2/DV,1&96?UAM\D96;-X=#A^H."EK9AVRX+
M(X,/X<=M==65%3_"HT_B$TMXZ?D5K[J47\BS4I)A#)EG4$Q7T*RI,:FX_NWJ
M56V$18QP'<T8K_>A88?"7>IBG3PWX^=4TE7(%_#V:0\XA:NUC8D-J/4Q(GVJ
MUCCQ(97!N9#,W.SOFW6)\3[.1G%C HD/M@<57K6>*N4(B"K<XE 68WV9G':G
MKM985+0O;J.>L@U\0^]Z>6$T== 3L<OHK\6-.0KNF#N4.TES[T9B(%'3?*5"
M3!+A&:U]!T0&.J9EXWHK.48YI,9&R2-,(GG>TC$K.]8EYZ$A(>&W$:A2E>2;
M?#M*S] GQ#?D/V<%9%3IDIQQ4>.F-?U\$(39N::.V \+D-3<F:E4UJZ!S57"
MYOA/M>>8&5H@<C+T<JXP<&Q.X*,UNQO+W?-ZV;DMPQU%XD%*4%;_V]R^0C>1
M%,::K)T"QCI*/:%]70+W?U@^@E( 6( ]^SC!7Z+B1.EWR:)_IZ-$(XCCQUA@
M/ L<M85A1JG"-WWQ6;U:]]_BESS_B(DSG,=^]>CK/K1'2@Y*'"KYM4@VG0Y"
MQTZ>WW"2>^&,N,[]59F88R'% 3>)6L<@):=]=C;GZ -C^P.!HY]N)88I<E9<
MQ25)][2ET'&G\ Q^(WS)\.,Z\=$N;^%95O'TJ7_"J*N0X!=^U=-"E5\_/)BZ
M&+4W.C&RM9@X!&O+33G99!6BT$24\();WLY-,1'IV6J["Y7OC/>5&MCH3P6*
M!\;><V>$2&G&M1S3.PT@)62(DEKJPH*@KI0:X,H:@W0O&+[QL!R^X8#?I/V,
M2FW,#Q1Z35C!#__?=)<B,PG>>V*5>' -MRHG7<"585ZR""JW1-O5.LK'N+>#
M;L1AAM383R;JQUR%^+_PWZOKS_T%M< ;>08[LGFW:E8S/YYURC4-(,D(=' Y
MD\H/)E!/V!&^D.)7?R@\N%X77W5X%]78;U"1L=:D/+,7G9/_@C^'/[V8HYV<
MMHG;].YK1I]0R?27D;RJ8EI%^).YZHMF%,/OL  S>\2@$^2#7-@$&'3ZP/"M
M<>^UENK)A/+\&V";GL;S$O>[?@9(!=;$D%Q1F'^>$T%22N-^TKC4_VY9R#3.
MHV.V\B[H3M43M:MO*NX(^"=US)24<;&)W860AJ7[5E(&I\9?4?4U-)"BM6Q0
MN>CBDK$R]>4W,9V_AW#Q6=!1S3 6&%!&['/@_M%O\9LAR3]3TK]F>M.LM0)%
M4NL'9GU]?2!$*K:ME2)D-C?A&:WCRB@EY3MJ-Z(&$,R8']+/CH)]@'<+Q&.!
M;G%1+)!]ALMI'6VYN936-TH)7BHV"#Y]XVS5R&U&4BQ9MDQ&%_ ]@OI,Y,(X
M&S(SR@O:CVY#Q'G]@"PX%=T3F'(J+CU+3D J*Q]TOS#%>2_*F'I]:#S3&EV*
M@Z"]_]/(2]+^4[*-KVK4GQ+(J?@:L0S6]&GD"MMC <'II:"]5(.%>K:MA(9E
M.8\A\D:R^#<P17/*\3)A >N,;KDFF;#TO,V)/+4WFL)[+=UR0:\3R:.-$EEI
M<CS=R:4DV)0Y<..NCS)SMC[R$QUW (7$N'JOZA^+1(SQO!:$68,UM9@%:*2?
M%F>[ITOQ^<Y1)<E0LAJ)48JV+TCKW63Q%@^R$WES(,&-%.&K=#1)!N=6U-NQ
M5>V0Y;D03^@\.<ZYUS)PUDD!,\]9XP)='[S5@@F!CXMC 8O-/*/!<-74QHV$
MA/_]S%Z2[>+H1 S;7F@NT@P]Z4(7/C(HG<,*=8$*E,A_"[QMR#2O*'*1G.IR
M9:7R7$:T05+_:<17Q%+HQ/3Q3!L6.&"O5;91IPI OII;VXEC3HBB%U4+RGGC
M*3(66Q-K+/TQB#G\ ]$+\2&PN[E+Q6)FYDUY:R:G3-5?8CRH** ]4GFF#BW7
MU(]9JBH5KSB+)OIV1CT1=""+[W3-P/M1G5$7CL$ZY-U1]])#<6+'AE+41?)$
M"Y&X3&/O1U;;+[=]J.A#>6+OJ9YWE/I1))<L6%SO4=% ZZ5.4W?%V^<VG64*
M#C5D4Q@FW[H%0%]" 0 HNC!5,_WF=_-=_P$"05S@)2]V1<G]#MIXX@/5YWGP
M^30M3"/N,=FWOYF?^H<3XD6NQ*JM/Z9)+HSIWK\BQ1N&!>AO@D?PAR6U_Y,/
M2Y)A 89'L>P+8F@$:7WF[+"R-/AGJ=F8D>K9#,YIV>C_=77H?QE@1MZF'6'Y
M]J@<LKKT:7YM99$UJ9KLD)- 2.H/K:*CMD>Q*96TX6VZ#)EN"9=UQ!WT(WIO
MB; ^OX?'G 646SCG_/U(:7B:\5!"9-_BM2UQZV1(R-3(61BBME%G6%G[B;UO
M&[I[FR$N^U!K3 V=<;0CJUPXAGO+M_@U+Z?Q]HZ#T'"-C',E%OA<-R-L@ 4X
M,:W'/N,()L[49"?8AY^5GINK;V[T)T25:6[7@B]47&II.J2W-7DH"@ET>,)1
M9M-X?T]$7(Q$_LHM%J\:E,83M-/17.\T24VA^7XF,K!T;%)A2$/]V3W2\L/\
M\WU*=5 18LVH=A7)?N7AX<&GN]!Y%OVLK/@SQ18D?K^8VO4%%FB:,\<"8Q6%
M6, J:CR[,2,Q2&QI\B13O'1N&JUF1WR6SX1 W?EU*OT^Q&Q_Z?\\D3)"R9]Y
M#N!P^:C4U/?*3V8=0_1?EE<K5^%"V;MG%_'K1_-?OR*6G^OKYEM0XZ)_E5G=
MM_KS.Z[H[!2'M)ZT_,[@D3=XZ%U>C 4Z[>9>J5^ ^HZ[3(>EW^86SP0--5><
M8R9@)XN-XZ-9/?>)!G6/:F+;>W\U%JDXBS$!DR:URL^A;ML6=/C6M2%#)X4^
MA*0E!T![Z2+ZW KI%5L2GK]I@M CP'ZGWX6<7B\?RXPXR1XLJ!K-6149',J2
M2Y<Z]2\^X10+\6*LS-I17%0OO+O"3)?^\W-T<WGUSY#.;,CC_+=AE&23<5SS
MC!HSIY!WU[]O."^HJ(=^-C#4:9[_6O4F7H6FLE.*%/I.83'5A;#%O$+P[12Z
M42IY[=MPLAW.0?[MW4'0+N'\C8:CP2+5$H&''P(JR9\%CG\S6[=6D]Z!A?N6
M&"L:Z><E4PG(UV<,OS=K0-R%#GX:\LD4Y2%] ]U7CN@QN:G2US_XG>[<&S&E
MVW)4Y01YIK.S2Y..T\^[6T#! H1S*@UO6]8]NG@G3!<%+,Y5%O?JL32Y*C*W
M9DNEQY9\MM]X<1*GV5!Y":VFJD*HSA!_?0!JJ=JKJ"J2)Z(A U&]'$Q@22HK
MQ>TX<+>XU,\OT6;-1?K_;M?SP[A+:@6_1H$=Q'#K8:A9<>ER4HM>,TT(2PG,
M0LB&X9GP4*BT+]1V5X6^(<2^&JTQ]6W "#<P2-P]>VT!8EW3#1PDPJR_L^L:
M'!]OO,PRHVX\XSTQXBLXQ+?%-"3UV>K(1*GETP3+FS=C&+08_TBW=*'C/\DW
M,=@]9LLUBLP@'520OA]Q?H..,4K!(OMN%1;0.</'U ?_'_5'_DW"BIU?D]#C
M>[0*S'P30_(#GP.1ZJ(_@U-6R@^>\=&>673B@6/Y?W*(P%^H'WL[L0U\;#&O
M[,AX%#_(W1?\]';C1Y]4.EP2J4(-;Q#",=(6_K<&&ZSF.K!&A*BKV%(WJ 5I
M:0F [/J@NKR)L 64YU3SEEFOR(LQ%A/;S8&\ED:8QG5&']T,-ZAH(_[JB<*$
MS#V527A7^W&I\]'&],<XT0PG5<-]OK>'BW!3,ZJBIG<?!$ 95@("NILUL9KE
M4V>MHZ.QT@]DRZ#[WX-XI ]X0GN1!?$<)&SJHLHX&8L-=J-PX6+.61/SMM',
M[IX5%KA\S+[;]>EV?:*S@25KG=E@-6\L?_3<:D!$J+$'3WC&HUX^*CF] M8
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MVB,K/2L=3BG+B4OY^L18X#M*^[1H,7RZ[/Z;%%O^402UE94<YB\2D.MAX/V
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M9X0D_/Z$S74FB)28A-R-!JCDG.3WG"S@W-8D KPP7+J[_%WK!%XK8#(WK'\
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M#]6E^FOX]W'XNI?K0_CLT! 6V$J>QI<'CW/Q:WAKYX]W[,>;.$<\CYC;Q6B
MCDS1>5A@LA#9_4N?Z#+$QEPB -ZQ=67&27HPXHIW3$&G?WC@J;< ;U=:G+)
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MS.X9XO2YYHJS!N9_:!1C7$H*+*Z+F376=W-;1_H(R]AE T5J$I(D>8P4I@;
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M"TV8U%SDU*8MQ71M=[(WW!BC%D,B=7\Z,/'ITU:^6]SU3#I8KSN#0*QKEU:
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M;4]]J^G6(^*I\T<;@Q,YY3,S(4>:#IXY.TV(^._$=J+1KSM>5MXC7=]VS:_
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MNHTTU=]U+=R=[A&!K[NY+;R^^?*,P,.'3\H_LB[G"SC^>R#&IU_RCSQ^5;^
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MDB. J57O,7@4F*  %!/4/\,$K6FR\KT/W+/$F//ZUUW%03>8H%8L N#I%O<
M9RA B*09?;IQ!S";\X45K&6+9@Q=)&\!LL=)A8_F\1QN[1)GL</^/M9QLY93
MLM-OZU$-]OLY7OR3?43%:]<=3)T0PPX'GZ%U*M8JKU64#\0K\V>X_O7:485\
M-VPY"L@LI1F(<,=]GSMC&_.$Z,K ]/"#TVL$-S_8_5 !7P?[Z6#^3NR,-?Z6
MFL]7>FK?H/6/2^NB%QJ?CXZW]5UPXWKWB0-)UN!E7-EA@IRLMP%0X]Z,A&WU
ML,:U:=N+8N 4Z CTCK:J/&P+CF5M\M:S'CK_+R^P_WH P")0&!'WO23I3VV
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MU>S',OIKR/(,9\PS@GX;;9ATRXPA ?1^D6:+WPFQVP6")2BOKV()X4OW8IB
M>2+E@AX/,U:#S*P#))S[YRVE:9^:$#S;$?T2-HMIRC[DV/^MG:L/9WKMX^LI
MIXM>UCE>DF1/(@?)D;<BIB05H[)Y;9PHBL:A9F73'"?D=7E9DMA)7K=60B9C
M.XC):V+>9RERF&'&;&VV\_-<U_//<UW/_^<Z5_]^_KJOW_W]?KZ?S^>^?W=H
ML+#N<2H5Y]SM$G#<GSG4! Q4WU)\<Z@"E(41'A5ODK492S]/L]KP*S"V.>[V
M/#]58TX!<F5":%^H[+J;8RHT<*I\ZV LM6'9L5M#HZ3A2]K)0N/C*3Z;L1M)
M\W_O"1DP)ST".FPE"7BSW@<!&C16BRF!.9L=MMH+6^!4-"R39@.*8X1B*[Q!
M(S/U_?O8W%"19UMY^9"[M-#W3$@ZWN5HQ,9S,16;@Q4@([#8JPR)LJ-5QDBM
MA6&!-Y#Y]]KXU*=5H@BA$\_D58WHQ7C+1:<326/2B/#+]@'G^][W73SQ+T?8
M69?M%YRTC'3)<0!WW +D5&*_ I20A>]MDVSHQK+ 8>[ZR(:X'<V6JS4NJ7[9
M*E267RI0[F.JV9#]/RV8/%W.IV#-,?PWTLW4Z%,K6(]-?4A!C?5W,:C6T;U#
M(4%D_^.EJRR']TU^EJ<2*1V9#1<Z=0$780,47B1#4T84[Y&]MEH$*(.X'B%/
MH4<EO;$-0+-1IHN)S5S[0]]-MP?.-'LI0#J\V/X&L_097XR]/O6(/E774%?.
MXX05+'$E^_$6.A7 HK=9]\#6!00QN+5:&#9M$)[Q7@&"072J2 *"K1:]KG2$
MGB0E)O"?9'Q2@ XAV0YW^\7.XZTSZ^) PX,$] +-0A[(W1)#D63AG/@!R79T
M#V12T^)7+2T.O<'L^T,2ZJ_,VND;/NEYC:_@BY8V/0.(G-DU-8+>=82+WLJ+
M/[/-@9:J@8K7 .LW>1[Z+JA2:GL%ISDZ//%Q;H?D@71TKK&@KC[I[HI<V'[1
MR0JJVO"95S@TOA=C'M=3HO>3L]<%]1W?YP7%/PY-$1L^509TY?22LUPU4]8F
MC\2-M\KFY=%Y-C:X79RZ6 'C*_=.L,A^:;YPM6)T8.D#/YV0.\9!7?"@60VR
M(2V&NL^?GDP;V,6PWQYK,Z!"QJ,7& DI9+*Z ^*\.L)!A:P4!_K/,T5#&V&0
M)%/DWT60^ (;0A?I\'LGEV^'TQ9,B3FQQ.JH2/8%@#"J[=&7,=;(<%2+6P5B
M<TOZVW#_GG$+]5WG*$=.).8XJ?$FS3<LTS[Y93L_AI3UT;1')V=N?/?:LVKL
M;Y^VO@NG\JBO9>[@>W)!!../V5A>C2ACF[CG4WN@V0H)\Z"SOW^=C4::'/>'
MW731#NT!2%.2=:M,9C F5ZL0O$1?L1YBN:4L[/QU8@3%1-0LY[-*[*-PO\PU
MLK-&7X]H>P;245>L=[9*;.,I^1!+?Y5$LJ_AP6O^H4?UKYANO\'@<?88*4!3
MP 16>2&!GD6RF;I8\)1>0221U2US V=RNS"J(^L1#[PHOR>Z(NX.CG)XX^KF
M%BGR*+V6&B=#;_/DXQ?> <Z^']^>+5=]5@E4JH8O?<HY:K'+/5K6/$ZW%,5/
MB]A6)_,I-ACEO)_@X0W6?H<#<R%^V<]?AEZK(&-VGLY*#"ZYUP1S=MH'"V4#
M)) D5RN3Y4@])%2TM:L(TM;5L],T$[H7@NN_7'MPOMN))IJY/H_\FA_STCJN
MI'N@;\#1.?_9\]%;U8%7R8\S,DZ1*2EDA(G[(6!@760V%S*!ZH]%]SK-]\8A
M,8-8VZ(8>L2D4?3IOD4YCS);(=QG7%5A.*>D8;R[H7;A3RXZ^T._DMKMP9)1
M:6)MP=4TAZ!$]2R@>N--4YE+).@7IHS!?((_*;LWC+3T6J;]7I_=8".$TAFG
M/=? )_C;<W]&4==K!+<94J[9#3OA^( TSTA0'0%K'AAXG5,-AW<23E8-*&<5
M ;:!D;X'YV8.37[WL1IN,7+</FR?7W)G4)BNSY_+FEWI%C7H%<M?ZO9_>FA8
M>$QM"7%_XZZ]F(![)G;Q&>)V"6G0W+5S(=&#DI>EDM@L,6?@SO;@R5SK5 IY
MO#%7HVM84UL4JG*L^!)Q6["A67Z\?F)(2;L'HDE*W3$&Z(*:K6W^]T9(&@S;
M%0)K9V-<4]57**76RYN_O&:IGN,'W>28<,QW%GP$/GCVW"KZ(HU\MA03[KT1
M[KE#9YX"*J!&HLXA&45!NR(D03.5C^3\S@7MK5<7"TDDM./06)';QU$3]TQ6
M-,UM$=>*/'QX>PG24R>#7)IZP"?9Z847-:6\IO<'@%.];<TK\9,AR)$/>R+2
MWG )'I?_S<D/V3\T1GMMU0AM,R&,T+.5,]N>6-V 1^LA2\[>;^WV N7Y&2<4
MOW4MC<YZ7&0@L &ZZ^:&=H5,F=;A<T3<>89 HEY7^Y G">$<54&E(@C#0JN
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MJ*.G SAR],@1Z2/2  "# )!^XNH3X./OZO/RBKS,3<#M>WH&QPB PW+N\ K
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M7@=Y/IZ*OB5J/-:;;6D>KW+'J%OF S-)R7Y!*VPZ[ZS!&OP 2SU3Z1_ AUU
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MLIUU.)7:H+"4<BLBN%8C^XU?'3QI"286JRCH*LJ?6Y"_N?[\]UB98-'0_'+
M.OW+&GK7O$EG;-31#YC4D6$]OC/"Q65*36;[^LO!U]^QR(+H=]Y)\FF[KD*9
MZ,;HI>R$.!Y=2RUV-TI,NO'=P:!*F.?V\M^!X/ZW-K@UTBATL^ =BBZM.52-
M 1!!+^+'*6<_]^XV-6<3O/>)[/69?5[!.$'6%TC_EA.I4UCMW$FJK#VA!%:9
MV[&0E4L-RF@U2LANYV6[4,W%Y*YSAHLW: BUH7G=/MGE:5KM+ACJH!S1<9D!
M>(-U>,Y$8)SB +$D]H'R=*=@(Q:+B84,]VO;H,@QXF(U<)3I16NV':[*4:.#
M+A[<#T,@L01*OWAB*V?1SG-.PX4!D/5)HZ;<&A<@T!K45%-*A\K!++[DQ[,=
M,RE^Z[@WL G(.^!(YS5#D!F0OH,/*OA#JC$0W7FZNF?OS !<,Z;C<5Z0__4[
MF@+2>]<(A?5R/&RU4.\752H&)78T0Z\%O]NK5LBU2W]]Z2QJ-3/@,]12XWF2
MP">3'0T=O(&,&RL<EB:_\/Q4!L-:6_L2/VIPO_3AS<_'[#4D61D/.Z]*?)20
MYA2TN=5].SY;P728=TK;[,278S.GN01MW+,N!U202Q'_<UB8G=FRIF!HLGN\
M)'&.39?Z31RU#I*B/EH7,]'FU92Y$M*"T<EQ6O*CIIPVL#V+*PCZIL!%?5QN
M*!2Q&V<6617+O T7K9TFD4()]EHSUU6#X84RQN\("D;EBZ7T+&GP@T#R7-'M
M1K^&1BT6_!0+3XBQ<TF?ZA>M1+9].&T/.-PA%!O,2G>!L6JF>O^>3$?-<?LY
M4-EW[^_MAY"K2+>_]@VLL<=30"7/[E!CG8E6TB![&'>JI]=?.661U[+@08'&
M$JES<18XR/>S0I37-$A?\";.KCLFO.@5M$JB"FD/:ZKBE/=*B74^BX(780/.
MFQL3T8VN^9T'2ZO?/P[NF?\%A TB8Y%D79__4<P,&H:NWU%^YFFS,@Z))C(
M*"J'&U%].8-ZZA(<M:<TUC+J(@=U>C1XKX8+ZG2/KB#S9JIYCGPX01^R9["E
M_%T#2O.;L).@WQDA6A'SIW>P""&$)!ETU* B(RTD"26O)GO;O;S*U,Q GS]P
MDOVACN6ZJ#O_F<.#1@.E_W6:?^\N[4>H.I.[;<JPZ:CY7O,-^*^ 6'^B=]AT
MQ"M""I9+ 1=9[3L>G.D7RW=L=/1CLASK,X)&5.X+_H^_;FP?$KT ^M_-$O>[
MYQ']@F\I6M-H&;H2T,MV+;V*?I[8&U>EUI>@6;O0,ENPI1XFN)WNR0" Y)9*
M\P1:]4S.MI2Y"5R2/[49S@WA !)C?/Y&TP/_*$.)$GKV+TT6Z!=-(]K2'C.O
M7T4G.X]V@2)< ]I^V#81^BJQXVYDYX4(KO=YN.UJ2+9&PZ^#&/_*W<=+&+ZF
MJM.96=\R/;_SO(U_)>SZ:(>329D>T2-V?6!*N6?L$N^6[F+^4]K%J)PE\1[;
M@C\'8:C])<'(=5SK1WS"J)J^RT[K)2+&QCQ53[FAK-[0TE1=3,-"V-K T'I!
M1S'24-20V#B*A6VDR2YFD'SF3MH%?Z,$;B7#U",HP"UT^1]R[>X$-=D&)3.#
MA4 YTJ=07UW(CZQ?ZNM&30MDH%!GQ)(Z'7YE/1G2UF)+W*[1-V-E J):Z.^Q
MP2# )O0!#805$@;Y;'Q])R,.GAG-0S@0Q[5NF)^Y<55GBA=SQ0EVYG-RIAC\
MO;^CI<B0M&OSGT6.;GCEJH 87=Q;8P^.1<4Z@J>&.^<1)VU'YBMN9^"MP>]"
M'<3IXAR3VD_A;J21IW&?#&]X>H<N27ZQTKY $32\;35R9Y^4\&/;LW&HZ'\R
MRYP+:M,5BF8 PEX%0XLZQXSF"RTH3YT&X!ZK6;GY%B'+N&_G>I]LMO'V VR7
MF==;_^5(%2G9-#49<U8F=K3-?[OG7B0'R3^FJ\WI>*XM* K^9^;3J?W5*X?M
M]QB]N&4W:%/#%&])E#"L7?<JFX[6O-*QN>@9C4?KMK6?!;].AHQ\*9X8_J2$
M]73<1OGI;:DE>+69/WRP_!8M_*''O*6L^X;NX4J=E#OTYE=O'\H(R(4T8AB;
M_OB=>+6&Z._@CRD+[]7>9B! WI)?R^QF65J*L,=<M(T$V/207*TO>CL4!J^&
ME-<Y,O6V(.4&#4._-TJ;6!-:)-!JZ+Q:)&KCOK@GX5,_R:)<C:/&-T-BH/&*
M<M]I>:SN$>LZ.9[)<-U ;\E]UGT5I_SVE<'!SN.VEH5%3=TX2.Y86^PR%TE6
M8*O,'BH3N^2T\=8P H?#H3S$ONY-8]0#)\K)LO?)8=Z85L=*5,[)F'[CF0JF
M0/7\I'CMFMZ5J(>8_2^+:9+N?UQS,Z,>K@.)[V._"O4N!VV3NX.%2,2]6YMJ
MFENQRR>\?WPCA. KKZS95 PWOAA2][6VT#X>2.Q=,VA+BILGR1DO7G>/_W#W
M0IIG$J_B42NXZS7FFWX!C6VU4,BT)C61PJMT#W0WQ"4 T18SL_91W/))</8?
MV<_CWOT8:^67Q =P_)\5A""NK+TE'O1S]I;BSLY<MJ?IT._?I@9:7$9AV1J'
M)TVVK.CV=>N+"9L6W*1DE*,#E<^K<]+&<$QEU2JC]?-/X]E:M/V24_LBHH'K
ME0$"5<GK4'OK=XW]DY\/^I]QM\5\[#J,H^(2 FT:FFY+Q6+?+>BVR"X@ZJ@^
MLT#V&SISX^K1&,TK(!<+LD4 L%=) UD!$7'?%K/2?$%84[*1N)3#>V]\K=9$
M^*Z1@<(3[K2GA2%C2%5-?LTO#( )5)%C47[*3DHU_43BA*_Y]G1'1@1Z?UX]
M^9>+/,YGG&I2*D=:JJTUE A_H6_#KB,B&]LU#Q>\K+):P:NJM_@]+_"1!'/\
M!D*;0^FFVQ;-_7N/=75H,10!]*V,P!&;P"2*L%UJSQ@B&2%B+=M!'XZ^6 OJ
MNR9"QD:#B)($A?$UH%RCMIE6V!. LQV06"I+\:2A*&I;_O!*' 4'.\\W)V1!
MG(R=ID&P6'2%$RZC=5S=]RG)[(7:,:CGN%+X,;[1\TNW+I@T:MP9<X0[@^,.
M./&&BA;,S Y/,64 ;A7']GM'4#+&;<";/BX[&BM[\R3=.N1%SYW1L:DO$ZYJ
M_@' OEYL?8.@AT@&S-6S(708/L7+OZ @4_7=-.#Z6]U"8!W3+69PTVZ+TZ[+
MTBG;& 9@/T SRFX;S(RJ; 9 HG_9@ 2CQ-**U^UBK=<IT!FDK!/-ZUO/G-H[
MI!*TL[=DFD_-&U1S[7&Z0-CJ/G_;$(:G%X:2FS"Z=,\ROWE)SNU>]<D>N*C.
MX3@_2S>QZWDG1NM!QBY8."^JQD?DY_V!?@FIW[225F?9AD%:D1+[:,^=MAF#
M=3$OG7%,?T2Z G4G^_:FP,.AJ"?3ON*?WY-M5XH64K9N=05P;&GO"=.8GPAZ
M%^ 0ZN))_(U3#*E2(A?\,M^9WVG#3J%>&YFL#6,F>)15G361'J=!G;\O0U6\
MY-Q8I_"X$T(]AI1^@N'B!(D!R J5\WG\>2KDFQ[I9!YXB3Q.VGG5XVT[@,NH
M>M^?-XZG)TZ$!,9BDV[3D@TK_!7/M]4_I-4J1?-SI=G\=2@/S]MVTH.@/>!9
MT-(*O97N#.LR%XJ>/@L!E]>2;1?4$AQIZ>.-0W7[?HB 6LO-) CY=-5*D7"A
M0C7/IJ41^_U75X>+))M)8^+C3%9<<<- ^UPHF42;-W5-YC1Q^F-J"HI^ZOF&
M"CNA!A5=01UR!2(\P'9/YRLHTF7[YOBF-W<_$U0%4E)^#6K91<4\TM&23<B"
MAS_XD]0S,,1D<A^[4^@OL=HTW)YLE4:P5^3J_G+AEIKR*V+)CD&3<SAK9FD!
M7K)X2JW*55E0Y[C5PZ^A0\588.6-X(<59K]%@9(?1'\WX7&F,#,&X';LTHNM
M:1^BS +]*;IKW6L='35<+TT4+U,;6Q3JZ*T:YCKHM:G>,MN[T2K8C7>_[M+Y
MQ.1CGI+[4W<XOI??OVW%2,&D7?$.L\5XH8MO:/-@CE[#S]-7Z&>#<_;J,_:L
MMU+F;<]P-R@C#!812Q?+-]+?.3E9L^C,8+ )O'H? [$"!J@-H'Q;A>F@@79:
M;L'WHH)/TZW,^#Q/,Z$T3@KQ:F;H;DVN&$;#N!"RW>M),%'Z_>T;4*N=$IGU
MUAV8G5=(V'! ",H DY&/5?^6EM/A  H?Q%P$9;)F7J?=,$HH[6@U.&WA<9CD
MS.U#*#VTZ%58JH#+!HQ22I-NH\GB-*]*9373'-=#WF 50E"_;<H:X$47HE+*
M5A%LKY G,=@T)+(R/CQ.O" ^SS/LD5&_GIZ MO1A'Y2O_\VTWG_44&-"!UJ3
MZ9Q2F\N+4^/K#,#BFVKYD-Y-(8&!.O?0EA6D0-F80(5!_%H/BW6HN??ER* F
MN)7M=IIG'J[C1:^(Y\1\9F61T.QS_3UXXQA2Y("# 3C#4X3WZKP[S #T'IN1
M]:2%KDE*VJ NS4S:V&@G?T\5[Y :6I2G:$01G3#6_:Z$/_G11.$'8);0PADW
M$>WX!Z;]3(4XC&:!IBHW3R]I58$%=_; N"^A8SD3LN\B0F?"A?R\;!;+X6"I
M90?LAC?A&ZJ"Y\ZNF+R?5_"'[(*;-6*NV:F%BTGG$,RWB]7\>RC#?U5AVB>]
M@ZM^E05Z]T6O'51H/EV6\#<VVB%:2\11BQ_36_4MU34$:R7SLG,B>"U@^??3
MXM7][Q/['SEQW?JP\+(M8)5W]5N5UD#3[K3Y?]_700CE<_#5O1W:3_3LDPRA
MS>Z%W8D>;V)A%P-PX[+7F'7X3^+7W;ZR!,4:\'*@^8O\9Z.3)5E=NESJ]W.K
M/:[H:7P\Q?1X:'V+EP%X_YEV.WJ^;6%-=A%?CH@17] UOX?%^VS3=]=PBPU(
M!F!!_=)4K8G$L$K]%E_ZQ?K=)COP@'&CH+)P=-_<':#<A\5DX2M%><PVZV,
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M2 9"G&_LF Z;A)IIVYJP^T&O5)D83H[HN(2^_"3TL6,\K.6-R1@TZ[>%R:%
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MNU"!R7'+]?9<9[MY0[CKNO>Q@\<O;Y/AX?D=DZ&;Q@_*Q4?&S$Q,31DXD\'
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M7D/V,8:"_W3#]?91@X!#-, )>P8?_+CH'[]WQ&Q%MH /O273 #1 5O5".0T
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M'=KUU<V3X'F9!!_-QV*.B%36Z![CR<&=X1B9,Y$Q5\:"51B&P@,S,\->#3%
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MBJ/\- V &]A!,A*(1C]0/?GN4K)H@$]AE-O5M?6S2N =3-K'&56!.JKJWHG
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M@4#$_R_/^>9)=-0>#&YW]+S#-ON?:?*JUKNT:Z_ (0!,[>B34_XHLAS[5MC
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MQT[B-5L 6//!)$C>YR->\,6,EY,@<%K)^>7UQL@.K]=CY#NGX6K%8CET*B8
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MMPJO5(=?IMLA]775#YO+WU)X$Z0\5)X6:D1%?>!)4%.,HV$G;]IJGV7WM>.
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MU4:0P*+8'B#)QB^B$SW3&-5OZ>R7VRWB9IQ6E&W-%53I(T\%M%D$"JURN(=
MQ<565/:M[1WEYD'[E="MSX53F)/4<TG3CV(Z+.MKFS,SL9B4N)>. HEB#<<G
M3#)[N=^W"XN2EXKAA<553C81N7DTCXT^*WG&IO7^>.'Y2&O%.,?9,\#5U\V$
MU[ UW;E(?&QDPMCP@:YIF=1N[1_GY,\L_<HIGI$4!I7?616J#?4B(XG*,T'A
M"_SX>:(O L6MP&/!7;V!]/=WH[NL#;DZ-SHPVH/V"WUXU(#;WJ*T1:3>LXZ*
M0  ;UKZ4%>3R:M4,F>":A[_NB*W0DR<5.:B ^T-+U>1OH8HXA>%I2^6JXTT?
MG?U,L6G6K\;D@NU 7/<\2MGM,%2LKE36R-BD)H.UL-/>Z<70#TWV,5:Z9HFZ
MK1&UL\8G" ?BP#R;YC)G5V@LZ5XU=VFX(Z'2<$MQ$E.7_CO9C#U4,@12YK<0
M?BL^[J!0[19A)?N+@"#?A[H$81U:D/+WV&U- B>:MN'^*<2["1GY56['R:_2
M=$?PWI.F(QE2FRZ.'I4&5]</4%SEM&:NOAJED9;@Q >6-.B/YG&K*&FGV22[
M31A1"XX';P)//V[)\[=M:4/OO2O+0-U"@-CJ07EU,G3Z?<P_?J\)8JP"7?/<
MCAE7HY.L>B8I-7U;^>*GXOCKD]B@TI_Y^05?"@IS<@KAN;FY\(B$V-B$V^O%
MS@+.>:;.Z\7%OPPCK@;<>_S^_6\E;P" ,P\3=S))88*2/],<[PH4><*TP'M1
M=!\[K5&VL@O?I/1O5U3,H&"RGTHR$+QI%3.60<U'*Y<Y$WK&Q^3K#6Q_Y0:F
MF_;<<V;]3-,-]U/ET6:C'T#/^L#P?"3!V=?19.LC=+<97NVG>"/2'?(5R*8C
M8KBI$M/50<<5V#OS05"0[\6HX5COOL8.-XH60^01W U^@>:+@K@+"#+^ 9#R
M^ID@$*A:EL_QA2/LE;N@97-3D7V'(S<&DW(G,*.,X4_$+0.1AZ5PHV*XF6;;
M7N\-%=IZ^)\<.)H%VZ];51!/1D%>(O#Q+%"-!]MYVQ?<V2X]3E5L?F&"=TPJ
MNXWDDYM<.SQC2H1*78 ;KU[QIKS.6HZ?HJWC.8P'FB#;.I084C!]6MN4NY-=
MUT?H8!%56E*=7!/[9)D^@O7%W\G(B-_SH@(*+3_42)J2+^V5]/QR2(EJR%F(
MRJW)=MP'=?N>O>"]61J(K@S4J?#3T3M4'&EW5:S?S$)$S;!Q.VQON->U0P80
M?Q7$1K-&?_FK+NX7'/[QM\$AGAA_/T<'6YH;(/R?N=_]OTF(CH22K3;=/]49
MCN"<7CTX03 ]&\N$!OZR%[>O_O2!!JX3<B^[U_;:WJPQ3FP7C/QS\&4"GY^M
MK]=GN=+[;NDMTEM*GYI=965&MT_WWVV)P#Y*>1P>_3R)FD88)OWL=N'NNX,4
MUW6^(/Q6/[>DQ(G7^&G",WF[U[WL17 K736.&#6DK]L_4WCS#R8\\V,8[#KB
M:YL[A:;8I)4?ULF*#O8T*M_3"EUM-_XE9*I:TV8G!'[>]<R'?[THY SFX3=:
M@W=(K\E1%&DJX %T*0L_OWC)UF=KD#P]S^_GK^_7M;?>X'H[')OU)''CF&-X
M<S73U7'7LGX\,^JU>).ZTZ^>'Q,V)7RE8<[Z#0)%)MB@?#&R'!70PY@]WR>Y
M>!E_@QBR)Z342+CH=ZO,S\1A9\,U13/0#;C*T+NM87D2=QN<]P93-7S8V=&&
M0PJ+*HLUXM.O-CH7T50Y-_^O.RFT=:V7[WHOEJ&OA[*1K8BM1IGA7DMRMW(#
M^TJ]0;$I&>:""JVP&3;-6^]G67L%!39>\>7D]#FL;PC>?5N0U,X<E9$)'D(2
M5//^RY15_'NO#^<'QQ.7FTXL!!"HR^4@(=E)!5CM??/HBWHLD.<@?UX-%WC9
MB5:";KB)&D_"F-S7C63QOBOBFCI<GXR^>S2^U!LW>Q4_81V#VERRLJKTV()^
MLO0ELPG4.PMDA%>++V3+B^Z*/'C3R4US^@8F=4^U[?.<<D<T%.1%&]P?:M^'
MBGXM:.2(26TX1OPS(;3_<,)C_I[*1"S3[FJ!+*(;FJ 0_=<&+G_S^&+Y+"A/
MRL5!1/IIM$Y,VR_QVVM"DJ!$KY5-2X$U\3KF0Y;Z>H;J#J;JL\+(>LEM*-'B
M5AL](K-_42Y\ =8C.M*Y6")QD(;M:JK)"AHG8K\=:/]8P#,S1Z?,FR&U^)Q_
M=%>::8(M+X+N)7S2L&(F6*UGEBK]@L 8)<<S0U,;6X#DR$W3TDG6F[]Z7+,F
M)[&E3Q E&SY\&AJ^/9H3CX3GN&]QWV02D6(Q:"M(2;8:/DO7M1+?[0LM0@=Q
M2=_(;XF(Z;38'YORVRJJ#Y>*N,JZEJM8-^[_3.5MD'7#]K:J96+84MF AF!I
MH-UUS8641X92^FK<-(#I>$H#A"GS1J#<:+N=.P/QRNI)<TF9)AYCVW208"H
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M%MOEIZ(SD8_XE)CX'(29T_<UZB'J6BX7K)29 ^L8?7$?^?]_^_&O!/;HE^2
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M6D-/T'WA>.VBH\/SN-;T (ZZQ_*!?XB;EK S<+/]U:[?I?ZQW=9IS[2$-\&
M181!+D5.XXZ><*'S1X_1MN+BZ/IW T/(0W1M+C"*M!.!"6I V)/#-DZQ(V;/
M-EVXOG0;B5BMM([IJ0AQ&?7IZ;SOM+.'>]O'YD:E-&2\W)R(@FS/7\TM>C4N
MO?*70=[DF]G;X/&(+C<11'+.X O\V*9)3.^BH&UI3CG<II<77O0A':A<;$ R
MOL#VAUI#]]T?AZ&/@/)!D__'7=W_!N&-:";)8 ^UQ&<="IE+V&&HW<(.C:-J
M/5S=>F>"=/P6)"Q0+]RV2U.*6QUW07TN(AHX$81U;.^(^A66I!^ER<B;^E=H
M6+2"[$PQ4F)LX2+GD:3QB!P_!V5[W'Q* )TJ9_T1LW3 1G:I^0S[D;NG ^+2
MV,R^32C!;=+=-=:UP2I>R.Y[KW.N2Z"&O_,,S3X5)093 6U2Z-18'.G:I^WG
MUNZ$SKX-X9;=.-])<@!FH,[VF[Y>7SPK>W8?!C7W7'TV0 1F*FW0?CO6Y5C.
M1(!>USYF%!M4GGS"UA3*!17#?9RA M:5JY'A"U2 \F'*Q#=7RS@5I"P#F_WV
M5]&9F48D^Z7I:8PLDY$>T I<'5"B$6BN%7+!B(7WNA'W&=:\H_3W]WT%7D2X
M<V;<+MC32.Q8CN'9 P,/P!Q5/AJI,B]MQ,Y*6EZC/U,!^]I]OC$TFRT"?3M%
M.ADEI0<7MMDA=YQ<8SX8Q74CNK*:4=6,X.3M[,%R*+)S6X.L.EN1@+X%_K27
MKU?48^R4\SZD"TDP\B1/*E[2IP*$T42-09T%!<5ER'B33,/1NC#!"9?QJE6Y
M"<46$OP6@QH*@#)^N%?@B#$-'C#7M?G>L^)"YRLY4!+B1K//LVJY:^N>6.[1
MM.,[ <[WG0(K*YW6U@6&;<(R4C*=;>[!X6'2YVPC;NL*%OV\?]:JVKR=_/O
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M)UC=\F/_O#2'@FZ<B$ALQ9N<\_"+L:Q/?-6$KR1IS+^Y=:+_NA@ >;:57PS
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MOJ9$"O,#+L0S '/))W.VB1LZHL^.T]H8@-W?ET#D@G]<'/\C7)PVN@%<WF0
M6'8HOL3%%DMIN;:-^+<@3AA_^Q;L2=4LIM:;(/:ANJ%A<(8[.,G\=K&"7A]<
M6B;EK>M2=%*< F]1T=/2KVE/F%:!= %E<NX-_M@OU.^[#DJJ[*I:VPBK,IJZ
M,/X\M!EM3,M*KGJW)Y,5J9?_86K:Y8:"7!Y+0;N1_:9TF>C;,:?ATI/.!TKF
M]J<'A';03=E!"@Q NCSZ8GI/]N34=5B,$R<:NSUM*9VW1[$H#Y\OFVZM4,V>
MPR#SPHKU;"<%DFHJ)6\FH3/>_C$@<MG@!C/0&'+2[IYJ0%KJ[)X[,UH/O%(B
M%'[3R(MW%\L.E$2-AG?DWD["D_JW_,(K&8!'U=_P7 _RXX)R*7T1C\/G<*:6
M3..TY\ZB#M.^4J6)2DTJS.[<0[W9#85WA 9@%7C>85'"(0&-WZSE=]&GD"6E
MIXL]\)D''_G3\.:NF_F9:5\,!_2MDKIJQ;@7E^-:F)^F2..G>W$WUB'!SJ!T
MU! T1D'_+>X!'^;@:+1"SLGSZ =$WXCV?OK!%%%V^N*0-L1&/.UMO%):YWQU
M\J3QPGZ?U(@1^$%"GZ;E&0DX^8DF-88!F-5C +K[&(#+G#W;QV2>DP1091>H
M@K2IO2EH9H@T-9C&MG;>-A,HX.I4.$A++?5$*WN-VEY5))1T7C2OQ."CE?.1
M;[U8ELJB'3'[8UXVKJUR1QFEZTM,Z\8MI>^Q%*^SK530D.%GEU54W%LW<ZC^
MWT(DO$&A>DU\7X;\K;"^#?(3OTJZ/&BL&H.])BZ2U-(&?**0@KOW&S=L=+=G
M!:%U1)H:S0 HLE;0$"HV^\ NZ^7A(W1=*?W1/O(8Q\UQ^&,E .A"F,.TNR2[
M^Y.U\'-(M =LAHL6[^ ,XWOO](KXZ5#4+=+5G_7D>NLMY4T:D0'()+>SUKZG
M7MWKHXKJC8/^?"6-@7+"R4R$J]I\-H87KRF<G0[Z-H7:%N \Q:-W=]H"5KHV
MDN'SYQ;>7QVL*Q-OJ0^6CY;P)Y3CJ'E0N9N<W[V6,0V@3YI@?Q+G4EP?[H9*
M9I;CPMFCL-3WLT<2<,EBZ<8 C[,;7S A Q:9N@_W#^[##)^F7NX5W1 ]691-
M)T]IC7'$%+JS@OZ*UR0#(-#88%1<HNBC'P\20; M/GFPP;IM@+P*4:V^GV4I
M*I]2+\MM^4KNFE6^Y^/(O_B?_ZT&;0HS80J!,K42!F#^D:U@N-UB8[$Y[0^Z
M908J,5<H>+09(6%/(F$K"1<#K/PD=/Q7!K$<&!<7+X]%;-B[1KDXX.OM9[WN
M[N,I(:97^'-RHL]'N34+O!-:9;H)"6-H>PS"B!NIY#N_VKN]/#33ZD4;@D"\
MG+<(613_\:S1"U-U# "?2$ E%C:[ZPC9=JR0"5%SV,HN;O0^N!$S9U/4*!A9
MW"Z8F5,#*P-?85IR20=4"<44Q]QT(YK[&FZEE%8]N@ R"VW"40CE&\]V-FT.
M9[*W&K^%?6C:>&UVC*@G5T]K972HWEG>T]&WV+:-AYF96/1J:\.U74\R>HQ_
M90"DJU;\)X!]:A6*DPI-#0([!.3:-KT;[;?*I,/X,'_^BTJ81B41<==?!>A1
M\-(%U?>8??.+J6=D/5Y'PLR*NT<Z.1Z.#-UT8<J6%L+02BIM#RGIKV*TM!W(
MG UDB4W$-,8-%0HIPC$=78:2BQ]ITM@]AO5N<_9 ,_F)&>V:&G=B0<<+H:*2
M;&\_V;Q$>U=AF^OCO<Q/Y6, I(#I6/.]2?K5=\2/RU6Z#8^5(V9S.7T4>F^:
M./YD '@Q-SY[DKH\MJ9KR;\ONI657%6J:S2Y4\L#GD][FFEAOUO+)Z2RB;U:
MM3Q-ZV7^=Z@3 R !_3 &["NCVB\@M@OH"C1-RM9H<\[B-EN"4DB! "%G?'VN
M",/-UMB0JXXO3ST%=JI64@O<BNY_$C2S,55]D'$^*/':+H?7/Y*MF3, ,H-P
MNC./_Y1N:PA<!41+87I^^*TIH&"XI!>U_VBT1+Y@E8]#B,-P\5N]^4#A9UC[
MI*:J+3_KQ2%9UB?21IUWGS#E2#E3Q'[L6I7,N"GN M1,ZUBY)[P;9&6CD<DU
M&Z[#G5"<E(0 VFH^3S(:'YXP[-_MNUIV]WVGV9\GZ54FWN3VB]"O?"7J5(9P
M0DALQ-[*J>S2$>ZWQ;)-WJ@;(7PAK.^FE5T3LJ\UB&5-\KR!<X6EMD!B]5QR
M%/FRN^U@U;T[:C+U;@(5I\0BLN59XX %CE?;1=3OEEHP !>>+RZI4HV^=.WV
M3H34H0S+[5)V7PAS;UG$T#8414#7H?/BT '!5K+*G?@EI%)%^!7_",>'(6@A
MHVEN-<21CY6HX0]AOJFI2V6]JW)22S[/I<NEEWSKVM-IBQKX/'DIK'+GK(3'
M0&O*'8S)!3?Q,?J'D2]A=2#QA"D?<'9Y^ZO2BX<^G,]2:9T6**?@0S;:,TKU
M*.A\^,.#J"Y@_)$3I!CLKP)X03HXU5NO('R8F0G_7!GBXWGQK[AKO82P\=RJ
MTNXEM^C2G)HBC?.PQ^^WOU9I"/ZWL/'CCH@2[$Y+9F@<^]FPW_LJ_D*XWKQP
M?*)) ;2WZ[&=LY]$>7C'MSPPXS<&FI.S1-12,&#9=1UKF011K6L6\<"T#GT0
MIL:&Y<G,%_$E$3<^[/#;S]$'AB*K/Z7',- 5^@]<DQAJ2BG+CI1K,F!@F.$Q
M)+H[[*EKHJBH<$;D<5]<IR/,1\+,H$[OFKK5.8V<6WW"6S&.QB\.OI;SQEW;
MF>-^]6*KO&%G[H9;Z#5,FU&%B:F(<6T/JZB4/H>,;;T>^X&TCJSN^DWOKOB[
M20_ IQ.4?_ZN=\Y$($-9 "+H?6#KW)Z$%V, ZLE*\"#62TIB>C0+]F^OQNU<
M GWVG='KHG^$44IM^*I^9[OT=U7P9MA_AV$%7GO-#, [G@"054#NBU ANI7"
M<7&]#U8G)=<U8+(W>%:%+]SQ?M@[C7%V3#PL.-?#I>05Z?6@^\P[]N:6^E#P
M2M8M_H+(/P2*7 O8?7 BUKX78WKGV.^]'%3W16O'&(_&>1L,GZ6B,/@2F.F/
MU$[P*]W@ZH%SE.#)+&=FN!I:99W$5,8'SX,^ 5\1/J>*FV0)F3<HJ7GYSU$V
M\31ODPIK9S:^^HV&6,7%^]-F!Z/=WDG#8*,._O7"=R-R!N/H!HC %3%Q*ZTE
M*R$+VO?SFELRU/TK43F$O_,W;CW."=9B/=+BHX8/-G;3-1F 0<%SM FXIK_1
M=G;9ATVV-&LV\7.LN%;_MTFEI'"3AS39*'=2E:F*=N/M-&5HRZ!X87AO3=#F
MM_H='2V9^LO'%1Z.X"8/LJ4U9MI&/%V->GE)=>]<'^WXJ8EIVM&[&JPESU-<
M'?"^9LG&SG'>NNF_$XY- _: =%/;J]!,J.&\8O+R,QQVW"]+GB]SR']N9\H2
M+5@G#[7U#%WATN4Q66AGYSBRE33EX1/AE_/B3$-GW#$<V^IF>C_7H=G<G33@
MBO4.7^!R2 <51,-BE=[6Q&F'%BA=W];>CK=&)Q=^K]H5]9RN'%K8D_1G<S<R
M7DIZXF8U_]U^)>Y+IZQ2UT@Z,YJE!Q0/;J]([[)1X:$&5#1M&LY9ZZL\NHL!
MJM5L[%I^=%Y0M!69";GJ]:LQ_))N V[V@4?-L3>"2%'T''&+JOS1/B8[F* F
M\[.EPE!Y$G[X "J\O<JQ*TV%X^/:9U'<M_ 5S<WPD*-/V?63UOGUM]L\>=(E
M7AAO!X=EWW%^G:'762LO=NW7LY:>H0N+->"KJJ>]CV=E:KIO,VG3 O<?#?C9
MJ/E'N:05Z HK _!>N)@!"*ZH/2$\A_^#!8G_QQD.?1D >;R-IC0-AOHT)W]5
M#9S4;4P3I(J1QF2>MZI;JT:5D*V??- _K5J88\"N^_B>Z,2WTU,G0K("VOXZ
MY-2Y*0:@Q_17FNF9E=C[/&$MBLQ8I&,\5E29KC 95H6".)L.\(BI:W>PAFEP
M;@NIU?2.@>\C\J39F:/NSP"<!^%O<EHR /RVV1E6:R6)\FRV>#JRTW"$"PHO
M'20)NN&5LSY*%NKNK^WO7UT))Y;IW+@6E^FL'O \EM#ZTV$2]X<B8J61)NBU
MH/F#+2DDIZSXOM+F+Z9XPGAQ'<)NBIM6!71AID+8@MQG^^N:>UO\>9Y0:%WB
M0$376,]58R.9,;R];P73F/@P(2[0]D)4^MEK61Y;A[D?H0/%BQ/HN'CNJ/9E
M_J+-^ 2]R:E^?G$543V9@^+*CTLOP\=2+*('R(F?),'2D4^_,J<<@THMWKN]
MX;7BNO,QE$2V\N?57"2M;<YV'6X\6UN;S99]:.B/<OT%J01)?NI<W"S]AH$\
MG.."12GIW^7PBO]:,KX4F9=S8S[Q')P,/GDS'5LU:X:BZ!?;+9&B9J$ADIBL
MY>/PR:/'"V5'G9IOCF($,=?GA,YH[MY;&"Y,V:A___#D1C62":$/CS2IRVJT
MNF &0(36VLA&S.C8OS2/SYGIJ0/>74/J0XMO!+2*$V!MGD*-2UB[!A&Y6#7*
M_?VRF)<N:>H=8G=ZP1UWF&$L),24&@!]B$L"@1B M.)>V_3L>5I1@Y-IQ[.=
M8NR#%A=T*Y:HXPIA<S@(7\(>!X"QW (?;TR'Z325!&CH\%<W=)J N-E]%_/?
MZK;0S2=[DSJ84R9/8P!(Q;W*9-HN- 6"IM@A[_,X$/6#_')#MYZUX+/[+LI>
M1[86SYIM';_'*?TR&M(W25Z&Y%J;.&WNKMU)T^@V:N?3\/G"[)[\R5$\V1_4
M5I4(D@$EQ_<<U_[]/71X)NPK_.CH%;EC7FJ_>2@+J]Y4$,7/Z;#2&.DK^+D,
MJU3,<NFY:1M+V5A3[_K\KK*GB+0A?1/[![3?A;[@1=>PI;QG#M!V$^%$&&C0
M'5/\4AF G:*J);LS'C*RSXO!M*3RI\6Q3NIE:/=GL]W/C6%-M_0TK75N#C>.
MWU6WZS[9+ZS9ICP_?S>WIY@:498'CXNJ>,VC!M@EA#7>]?SMM%N<^L7BC3].
MGVSO5D 8@"R)XW;N'0FF#O0B'C( .*CZR0_6#0/YWPC;9PH)%7QPB?MZ5_/-
M+[\K=WN$D[F?#&>KOJG^1S428UN*EHW7Y>9P609 4AG]5_?(\HYE!#6'7.3%
MDO8UU>5KK[T4X@+LU6XSE\+(IJR8Q\WUNYX/'%^<'#!*T*]\U'R:S4?KKV'1
M.S\)ALK$4?-+R\S&C/6U5.O@A&!A5Z=3EATZ<AI?\PW=*Z03#T^R2'Q>[EID
M^K)W04;C>JKJLGI 8H%[*O^3NF]:RN+JC31*9%5QZJ*4JL549JFK+DPM,XA+
M:<V^&!M2@MLID[);VU[.,F>1-#&"RDK$1V;"[CB4%H.PE_K2=IXUI/$MO^$>
MT2QE/WYTDM<!1_<"]0,KZ;=)G#_B"J>@K,R1&H2NG)D+&;J+^_,P5U"S[ML!
M]^/&W\3.NX1P(#3]7_@*5O&AN1)_)<6N.WUND^XSTM+3E]5E3N+5[823,DB:
M6[Q_4?G2MICV1VRF.(W(M+)@S,.ZY6Q C2'%S;LA;O$OG*5NE+_H)GPN.-:E
M\D5K?^+O??ISQ/#;%7[1W@NY3(47M1!UW&:  5$^ANM#=\RW3_*I>X!H!=Y9
M#FPT)H.GRUX;',&$TFY36JWU[A<4H8?,S5/78[-2^I>DV-DS+M;+GK7ERRPO
MR6DX#2NY#.ZY$\0[$P\G&[_;^3;$1(GS_71W/QX/ 2O_<9<.\9QN,OAAM?WB
MS/IL7P-=$#F2S"(NI1T=G5G;Z'/#)6&<(G#CQM[YC2>OI4.J_!LT_\W1J0B/
M!%YMDDR=TB7(14A']1KIJ"=U.@G=JD1/CCPK%"@JSR_5<MVXE:@7#4\(.ZSK
MWIQ]'2P0,DH-H_ECP:4I'0ORYVP<TRK/=QA5U]8,/W:*!"?M+.[]N5)-(;"[
M'CTM;;]_\<QV:9M(?*[QSU8>X?.JJFKJCVO'P6(<_+*W8!6?QDS&HE\:7E:V
M5CWO OLD4,K;890$5<%L')L6!:S8>A]XOI)@\Z798Z^W5FC96MS"(N209=(?
MHW@NCAS7UGN8B(N*JR\5/5_1J/CRZG==%I^2M5C+><^L,<T?B@K6ZA@E'82<
M"@B*+^YF ,YT&YL,4Z3&;.T2"\K18[+*8%GC"V+J"GXOKLL8]MTPN?9J]KQ4
MJHRRU9_JFH]=X =(I* ! U!@N]CZAIZAP@ <RT +GPTS +JYG4@T!75H3*<3
MV+8G=Z'SN00E2NXN,VYFM1TI;B_NNY)!1&#4L7F$)H^AVU&HQB+5J,0WJYY.
M3[<]SZ\R<*%CK\HH+":8U;_:E,8O?S3- %S"MJ(0T!\, "(7GPPQ/=0Y@L+I
M%TBVZT8P4#.T\Z'M$J@3&D=%#@T<(8%-NX>A.?-0'QK;7-HAJ&[G"#F@J0==
MM-:^^7'A^/0,DC4,Y9E81LL.XVOM.KZD^.\DE2C4O"H#,! 5 !7"13[P;-]X
M>)83A,L>1^5O#!9E^8X*:+I[L"RV+05<6\5-M]POS\]5S()>C3<3$CH5:,MG
M_6S\MR]:=Y*9/DN\)E<!-&]Z?'N4.X0:[36P2+P;^KI[=,MC!9,?Y!Z>V'LP
MI_9R=>.>V^MF9?38 _S%H('BZH GL@E=S9)1/WZ\*(O]"OM0$*W/7%5>#K3&
M<$._[;URNL6Q'38;-WSLVUP2<N7C:WS<VOKQ5KTD]^0+0Y)X7\^8QP"&5Y -
MGOY:71S3KW4Z2-2L),AM?:W,3LM1NFOKY+2M<5Z>N>(M:0CYJFZQ]1T&H P6
M_"%<9PS/1>^9D5$J\W&!&"M<:B['6\RR:@RV>UK%V>CEZA))X5IWO^3E/'1\
M7OC0>&QLM[.P=1+^+?X_&K_^:<HYEMRPLI%7^-AC)RTCTZRK8?^VEC.URU25
M1^^2YC^V&."1-9G@ES AMW7GETL:9ZROOQ4]"32E10/T9\"!6JKU=EQG!%4R
MM&NM!?V#WHG-P.*T=ME6TOC\ER1YK),'C(:Q#7&D[PORSBZOQWXB'QIU@,F6
M01M"7!P]FDFE?T^@X&1K FIIGH8!9= /-YM V9S]<7%?*!F3EFBV5K?P6Z&2
M'00K&[[:FL!H[2^)!.Q!>IL[C71ZO,^<M&=<[[R0F1/SK*DM!O;9%,T<]PUF
MS,Q=QHR!^BWGG]$HUJTPERDE%X5X3/(!:15S?4/!31$=X*ZUOD$2][T<E3(Z
M/.[@[:%#\C>^_>OHL_'>:,$WF8_")]=A,?_8^#,Z]J[>#3L3N0U:5D-"D)C"
MPNGKP!2E31:B0#BE=(;]WJ=R&]*@1[2NKK*_*7+]6W?RF)%^3,5;[7W'X,P"
M@2)]?T)Y,=4"*MI:3&N@"ZW"[SQKZR=S.I$(U+FP#J)T,S'EX#J,/K U]R/_
M*]I3]^ L;QE_INY9\7B.CX4%A6^<?&^_@16=+<KSF6/J/D'B2[IY[L IJCGI
MDM?BI46";3060:O)PUKG(QL&C(U#^GB(=M+<J*NQ$5X_AV(\4L\.%^4IA 8/
M)!<FBYBD)[D*;=1]6D/#R5IX(#&/[@3J4VH,J?)C<KKG(B4A7"[T'5XQ;F"6
M 6!5<?(([\S?))3,97#=+>AQ5BSV][]9FON@V?6>ZTN[+ZZ2I?IQQ<5O8DUG
MVC>9^)>_FTXUI T3O#YC76C=T"Q<X'Z\$VD5W2]@Q+D;L>C521,GHOW.Z3G5
MLAKP>%*R)%'7/OH2E+OL$UV>NKS]4ABL*CW17V=<K<EDA+^I=K2FD(Y6U&=Y
M(H[^@@D!_B9*1>% =YM%#$]Z0P"O;X A!.*#^M:00_\^[SS5Y.[<U;=EE<TC
MYKQ>[%;4[5P=EU@0*9/XMHQ)DY_HWM#>_#H5=Q>D=&@YQ1P% :HS /=1[WEB
M(V:5M3!*>R*(!L+@;';HM($U7'&T6LJ2S9/0VI& 2>H>T=/7]1Y_K<]JH@:\
M%Y<N8G)RS;ICSK8O?]D4R@#(;"_;T3H:>4T7"2-MH>KK]&X,Z@[D+&<8225$
MS&"*)_9;0,,E6%9AF0C\XP7-%@A$VMNSX/+$ZET,N,9 PU'FK>63L$FX">T;
MW4IY?@XWR$WU8O;,.A\.+^,9!;$U2'AOQ?5AE.(5$*5*2@JV4Y;ZT!>O:]VM
MY*0=G$B5S^+2:OU&ZXT<I<W03T?4N)ZV@9F]DP<Q/<X"@0&@5NQ<6!;LM"GO
M=\>?LPL(,!]W'RC-P%^,?,51*TG5(D[!]G-?+\FMX+#F<.W?6"^\'9O::):]
MO%;?S52 B:158BB,*D9+#(Z@FI'9['Z1<IW\J]!S$=/&V-)JH<U&F^$V,IO&
MKX9]8P4\6'R^<\MJ NKHY-/D6BI\S<+=YK$[V+'PS,-#/^8,F"AB%C1I0FP0
M]XLN/RJ/J8D[#G:AH448=NPK>/@S/^3$EG7?'M#W8/S\Z"_A5<RBO[W<JN46
MX<?LT=.GL1E)Z3VQ97:*HL3*(F;'9AB .PS LL<4M#>B2,7 KVA_-BRD"3+D
M1$/BQ1?6"Z="DB&>P>42>LN0(O1,") %)4)V[IZ^4D3/0V\!R;=2O"<-W(2'
MQY^:OV7V;).6#$IG"X2*#=92 VJ5^IAVMM$;L#V@,D+EKBW>B%DA##YW@&B0
MO[O/F@AR-#MAC[CMQPP(L.!8A)*QJ@Z'TQV^V]H9+"^0FUA]!B!RDS!$"0-1
M?'.W-4U.:@IHHJ9?TM>AW%C4>L 1^9A(WX5>HY\Z[J:O0/V0?:.K=! YQT9E
M4K^,&1:>@[)SB?/;;"N:$]#+<BX:A$K83/.SM]3B<11?0,QQU6?LE.+%M.[I
MZZS+T7WV#6,(-0<O6/3 N(%!TQ>W0.&\_ (_4PFC&^>Y3VH][;G13:&WPL%D
MTQ^YV;;G$&5.^^0!U-_3#VG9_NJ8J<S^1EV2S<_9^2SE&G+*)RL;R]>_;. L
M;B7TC4R6'W4*BB45^I)O&[*P(5]T0D+%Z('0?J5R,AHML2)(%)P_U[D=B\!<
M%;\:M@A*+QHE/)ST)1$N50$3+5JSTW$\Q^D#6\C6&=D,B1J%LU_1CFX^=7>*
M8A??"CV,)[2.0!>9E!Y$]9U@:J_<\!FZ$?=D4*AO.C* ]T(#::X3I^00#+'1
M+''\@E<93J[U/K LEDU9I_'N=8(-C)?+7(OBTD\E/*]^O+%5,0'R)T1(Q.6>
M LVKH?H:%QO-:):4"*(E-8P\9&:O>.31)4RW>!Y0<#3Z17Y.S7V+C%>.'0LI
M<YS?K4.L%K[&_NUS$*)AW?:>?EOS?4E<DMOUQ<CKZ=B0,AFZ$;1W(I\:_"L$
M77.4WEP#$D2^"FW #4W;"B*?+$LZG#F[V&,TYKB*04@[_SK5U.[>6D&S+UVP
MU' 3=BL08N6_Z??@\*0RP][_>W:8N&<7F7,W,N?>E\C[C]4ONK(_91%]K/$&
MK&JO?VJ3&;'S@N9LV?=:LUJ!U22)0 C0A+ 8]P5-J6X6+73&22XF)O$7?,WO
MGX=5LQC^(7U7JEZI!V;$DJ1U8];TR\@CY><5>L%CJ]02:+NORM-MOSGH'?I=
M]V<%>%XREN==$HZGN4%2.<)R<OK92KR2>F+%+'?6Y0CL@Q@7"P>$5*U/H!ML
MQ8UFUEMW(#76 S;>_7:52):9]:']_01Y5]QM.%EW9ZQ81@;]]6;@^3^W+4]S
M]_Z^^J3D7N49[S4-8= GXEXEZ@%J:9O6[Z2+.WQ,Z4NE;%X3MK#@LNXDGA.4
M.^>R6C-N7QTIX>E\2.:8/B=M?II=2O>[YD6Q/\\XK;[IGUN:KA-<V_K<L[;\
M.'Y Y^K1N1E%EL[NR3L&!](E^FMO+4E_ HZ+*T:A\R#4'TAQ!D BKG2VJ7Y;
MK!63*TE_/#E/5!Y%./Y8)J4IWL7\=.1V/0"![<ER2MR6!K606)7'148&,.W^
MKL=!,"<S!PLWX0=EWBTMLYYSA_L; 0HJCX( #_^ZSO/4Q*1A0J[/U4TF+R:8
MUJ/B>% #JN,1^7=25P40.N\%)>D"SZ)VE2'Z]*.9DW?U%M"]L_27MKWD:E"J
M_L"E_!E;1220@-ULII\)( Q-*X<T'N$JI)2BY)'%:\K#JK5R77.8J>/V@_'F
MP]B1N@0#@PYN'7[3.)G'/TXJ_\*NTJ^ :6TJ'#1;NB6V;1(HJ&*S?TYCVP*5
M&98,EUOI(USZ-8T @N1Z>O;3T6Y<#U?X6)KWC#FB/"<]=9\9RF3>HUTQ437\
M34KTY*K9K-?B4'_\!YP8JI4!P%>%)JR#$J!K# #E''GQF VB,8:7(,23JR@X
MLLM1Y_%4SQ+J;RB0OK6D,CJ43U#I]>#<;66"MM2__7[8?]<099Z(7J3C*._"
M.-BP8_QB$G-@53VRK*$M6D]_Q6_/6,M+6VR*?E)8J.A$_' [>J];?6JHRK?Z
M7+=2^= 7_$BDH/#BFIMA0E-)\.O=;Q.<>F,?=TXX5OJ?\J+)/V'#-^-1(Q-5
M,3&GAQQ^M5_C@MT^Y>>PY(.,TVZ \Q/9]F^=*+#3IQ8;-33ADEF#N3"(^J65
M#E-T*MI)LDGXH4-;\KL?WQQY<WE3QOQEO^GF/5U*D_=+.6=X\Q1A9B:ERF)$
MQ.9OUM4/@RZ0G(4.CVRTW/"L@JBZOP"GK]'PR!)_NV/1FXDD%+Z,+^G\I_G,
MF=&13HFOP_OP-2ZNSP>+B<,N:ZV)Q$6G[1MKB(!:DJF#_[=.XT+^)WY[Z@B^
M'NG'+PLT]1H_^G[I6K S,C5&RG.Q0(<ADHDS]X)++EX*EI_#;!S_V_P[F(,V
M"TK>UF, Y+<B1H^#9K'%T]G6[]<'<$V-.7>JRNUFAI+Z'!O/7DL_QR^GK3<>
M.3!2R"HKIG3?+,^<2^-TTWDUIC91S]T_7=RF?]0'3<L]$"E&'=F<;!OB_@>-
M&^N@%$ZB]EKNTBJ]7_Z0?6MP9@M$LF< AN7)Z<=" H.VOVS7/AX+0,_2SQR/
M8J:86O4J Z!U /4G\]I2V*[%JK3:;&*M_Y\+[@C;RB*=_8J_>\5AAI8FH6!"
MH.*1\]B+:@_5&E*73@!AH+,YP,8^V7-+N:+Q=>#2[Z'(A2''6X5O-IP*\S\L
ML3[<U;@0[T^HZ\]=ANY=I7K0J Q \J1G:,TZMG/7<E'>?OO9SBR0E2Y%B!X]
M2^WR$ 4:$ZP@ ?4A4;\/&YD:D<2I'V4U["R:OEB%*Y^1%3V/#.Z/@I,M(5!I
M7.:#[>6M'>FEJCXXW"I<1V0,<:9@BF)54AD*@=8&0&PYJX/1+ GQ-U@U5'<S
M6(^:O=?-[,&[!E3'H#NQO,;,(8RD"S( MT4%!X$QQ]Y[G-1$6B(U (D,#GTS
M70S?"<NH#VGT.3BBZ?.@_BH<>-%@J^V.U[/V',,X>+YX]7*QJC@ITT)(,+8T
MO^AMCFS\2=:;?"IKZ!>J *)L99783/TZ[8_%$(%4#Y+-] PBI(5X7]<G#+7+
M $ =7KD=]BDT$<'3H0VOQ%HD4Z9\91T/\./V$2+QD6Z9&R7"&[E,&HC?C5A@
M>\0 *-EF 0?(#:!/<F-] 39SE!YB8S4#D#[9E0/KW<X>B)NQYI@\-AS]18;0
MIE(LGY6]$I /)T6Z168)B6L;YS1$O]05>@C[.@0G:\I33X7F8\$,P.EPPZWX
MQ+#")GF;.;HU5!)I2+..;PTQE:9I@K+65:+S,2%]+'!YTF)2VF\&23,(%W\=
M34/"J*+!\T>=^#9.;$AA -%_VMPKQ3J"J$GM@TS,IGT,"AWN:[0-U>WRO!BL
MF;.!^BO;+BV=>[PIDPV>5US9;AS@&< CL-/?R1THDKTFN*J-85+9UG\^K?G_
M9X-'S_QK:F&^[J#@C31=R.-TL7C=[#-BP3^77^K(7GL6ZY:78N1X;[HGVG'T
MKF/V7=N3A#5(!D!6XNB])OTJF6G=3@Q B^S)#MK?*(J)YG&S&@JZRT\+9@!P
M'?4G5@'-%H9ERX^51)=\F+!D!1N? 8-GIK[ 8*(<QA< _\BE-$[^Y8Z)EJ"8
M />R\C%UNSH3OC23M>!6C$THJZR\O=ID+EOD3%XL3,#J?721,';,2IU[="[;
M7VKF3_HFUDS0_R2S<A(%F *\'<Y4@>+0W-3<\U*X^]\H^U3)R:.J+R1<=_:'
M3+SHV4L\C0V(JG+OYN/YVJ7-031Z(?/+>-*KDAI_(]%:],N)DY.IRVQ)P&L0
M^6<'T!]>E&?%G3Q[K>1KJU17N/3Q]EY5PQYU70I;!?S1 MG-@H1&;N6T#QB-
MC>JI-B.95/=DFA)UJTU&(R]A<[2"^6$*1T-4M/M@R1S/^@B(%?D;+8OJ.PKL
MHV=^K Q7(^FCN3QKOF[&Y?>XM[#CNA3+*G9#$$$OB,?-+8=]+)$[3M^FGF86
M<TN)2K$92C,'TM/V>KC._F3_LW>;H"0<L#%,CKHA/H-9?+W%TZ;/GC+*_K:A
MZG)&AU/UWANC#[,A#J\=W'8S%(4>97Z\K25S25;C) ?4R4GF^F\STSD=F%97
ME"]6JZ9:.7'F>EAA=O<!Z?N09PE)[FK0]GE=OSV/X]JT.9]%7\DM*XC+W<0V
MN4?#X^>?SO8L)#^+8 JD,M"@[9+FGC>6B<HK$.RV_G+C3VNML0S/_)ST,)+&
M%!43BR^G#[=G=[R!]"Z0[EH#&^_.CHL8)Z))"_!/J3XSQW(JFU@/Z/_7]F+_
MM1J^H+W)I@;N=/34L2I"2<+1(VX8/^L,E9SDOO#:4]>$V\\+'SY6TC%",&_P
MY.,ST@<W.WX?:+J') C+9KZ\!I/S/_^=:5!KSTXD\X<CHU.T7ZB<R=#041R/
M$6W,#97>^(CF1G68SKT9O%EP^-$/<NTG_FVVQ06>3D2)XJ+\A%(>BBVMS>5%
MDC:MR+Y4F/AMXD>*3/5BGB SX%RA:S'54I#_]A#T$[#7:U6P1_3<0$ONH_W!
MKFV;5NKMNAS6[W(KTF*V=:^GQ:OQ84MCE-G]+)2L)DIR6I'K8C^X^<%$%)]0
M969&Z1@3V.K^;8-2_XKN9DO^,YXFN,WT)'T,0*#;R2LN*[8]1XJE$:T=E![?
M"_SP*<A[#(.NE?M]_*#"Q!Y9S!%5O*7WX?,/$ILY W"C9T05;* : 9O#6$3F
M(,&1/BE&VJ&&X9%,D$E WF( VA/H0)HQI? ;70DJ+3RX2!G?2U]8M?X%#ZB'
M^_KO0YV<R6P.!)5O;:,>%GK+M;4(B9=+< 9@2^E\+AN/H\_$Y$*)RH(K%POO
MQPX#02;,"%(O[@-#O6S&Z"^  ^E+. M/WA0<JM^V_INLLN:H$NJ&Z3OLT;E%
MJ(E:<L?!@,U6I^/MJ-N:3?(:PK"X&P^_7H-=E $/:[++ED0P17%$B%H-25_W
MH(&^-=@[R\YM5!6,=O%4/FHEBQL&EE93Q"KJ=F6#^@F&E4$Y#T:$'_JSQWFJ
M;]GUG)S.%PXME7UK; SH)/)1F\AI;&)_;^FO*,"KFPEI,UE_]TOQJ.]85DV$
M@KJ4/^@_D;\T_\/AE7S.G!C"A^B0<]X]V\:$*RU&Z^1MD$D4L8*:L0NE&KR
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M)V8[5H_W(>31 3*PSQBI.E@_,0;:C:<XNU]@U::&$[4R9'T/![LW:;]>',
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MFG&]4G):5C<1+FR'3'V4+2^WX5S$"-CRD)U1! -XI%PGJ4TW:VRK(>Q]0;W
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MNXO:L]V;Q%@+ME&+7ZJ] AID[SFX>"->NL*1V+203NDSE^ZYM2:T;K[@9>$
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M*&TA^;*Q!H>WW6F@#Z&FE7PR#=S^@E]N&,;Z_0CGHMCMKPXV@9YM56\ 8^@
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MVG2=V\6^AGR8QU)^'LH<X23F-6C$4FV9'!Y8LOQ,49Q#;G@!P^=@#/>8:%+
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M]N&_9WVRJUV*[_09%7A4T<NEP98+8SB1$^$1+]<2 YCA7SF4+\L*'?-A>O7
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M\RH%%Y333DT\A%*EC7=KL68J%.3>HPS].@5EGK-3';[N/IRX_J8CS6KTL$1
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MFW_BBR,,."V9JETF@/&I98[#Y(Q)"P3-0<%Z=7<BA#OI)'2ALAJ]4-(WM8C
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M]D=X<%?O/V!#4J!E>IZ!P2_HS^I?36V&2Z,-^D"/?Q0F:>$Y9=&&@N<YZY^
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M*<>UTF3 WN/XV=]C'FEPR?+I[V!6,A*?SIT>PR*> 6[$$BUY#VO5#V<M!<\
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M49?(PZ*D6JB\NYF[2925P,\B&X]=AEQ%7O:5KF8E!VV"=W)&)XA ?GB"K4S
M;8PF6HK.CX_3RB)7&[/TG6*\.WRS8 YFYN4FFGSQT22V4*06RHF>3&>7HP<
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MG_:Z>FFO.A.ZK!F+:PA<4RWB-O'5BXNE*GX,U8LOMB_N+='BJ:;K?Y&30J=
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M6'NKH#C:Z-UW0@@$@H3@%IS 8,'='8*[NP=WG0 ! L'=!W>WP2'!W=V"N^O
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MYVR9N)K[] ,:=N,,8E!18Z5AC^A(LH+2FAF5';"]+>AA 3Q35R=)NNH-,JS
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MM9N_GK]#NUG>+1E!18T3J.5$K!D2M.V1,TL;X<U/9KY7Z!U!L(VV1^2ADOE
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MY?SZ5%4=2_;$*A6$ UQH/ /THPLZRHFYP3#TS&S4AN G=P)7I128'%W(O61
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MC?AC#]Y5=DIM=Z!Z@L 6 JA-FP[Z)R4EZ.A-B\=M"O.Q\B)L+9[D]"0)M%\
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MI+RE^6:8^9>[M.&5E:@T]YKI8E44I5"-DT%)*VU"X.@,*+)&9NU)+2TW5DN
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M*CGDP)P84&/L7X8!YVM3W!?*]H[VIBCZ4H2QP=I\&BJD$SIB*&E9G5"6L"N
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M *OG(L#0.5)AM1=IX'NGM+*UH./, ^:&F8A54FH/ILEZ^4_ Y1$T;(/I'M#
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M;F'D7VA_7AW.N<2N2AHF0,! H-3K?])_3B%5<I<^#EJE<11F@=?3RJWJ!!1
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MY?[^XY<" V6Z&6F@V]D_RU+:8DS075D]HRHM'Z,!!N2A*'=%^JSD(?6?M5X
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M*7&US[(X5$+UYC=H>\K_]UA]2.8QNC;K\1< 6KL$&^&UJI/K&&7M*'>"VJ'
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MO%M' K3@F!$PEQWGQ91FA#"YP;*B$9K5)HN-RS2:NV7I-<V2WS%U!"X5AX4
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M)!4.FECGDLXND58TI<0MS9KLUL5.CE:QBX5[8=%*>:59YK5^F&1^8FG&J**
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MRB:N00Y6JFYE3(QJ5;R2.E,*PPJ1JP+\BK?"=DY3GLE[WL%,S'WS=#DD'YU
M1.;I=\DW%X1C.*6VEI"?-F*X]D<MK>Z,VT=9R7XI,U=S46OBLP9NG<*&@6TO
M:@\\"OC?Q]MW-YVI&.?V\J_EQC H7[IIU!.I]"C[[^UM%4^^^IJ_D][D%J=)
MZ*2E5^YJ_3Y)2*=!2W:"E;!"2M TUW7+QTTU.-^<;Z+\2GOH*6MN8O&4E0SO
MVXWQT5"8L"]?V0U*+22%^J+7,;I_%]'<[^![W+N</O96_/ZTUUQ S(.[F89#
MXEOO>DUBXO34]-O!6\]ASX9P76+>I#@-:>"ZR<RV;56%[29K_.LG@4'9GTOK
MZ2+4\;(WS_ISGD9HF0;M!9<][6^@K3E^%C]=C/)61*3:-C.BZST2\!/BSWA%
MX^C6Y/07[ C/@QG%[_%#AR86Y3>KK-1.%(@74PC8/ZG*2\?D]V[TA,NR[!F2
MN\<JE_V*OHSG@6YH>(U<DW"+J$"QGH*/L+AW+:F_Q/N!QX":7RY[N[@D7I1'
M3PRJ_3DS4I;81T4;^HLR?>B#Z>HW+07?0R@8$76ZNG<NPM#2E_QZ?F?1-2YS
M$(MX@* 5J^#:.J++N7[=M&21L-+L?@GVJ?K1WST:F&HSZ!]<3U08>%5^Y'(4
MI5;R?UW HX]G'(C6F&KH+NZ_7.L931K[<!<R0/QG_;T!E:>(?4')>Y8?M_==
M0JZ,$*ZN+:.S")C+I./W+'#C_2I5UL(;#!^F5A\/%^G6)FH#286&P$S9DCTK
MYI*2SGV/I%^\LAP? H#E:87:$Y*F7JL[*X,WK1IX*O3B!83*6)@)6]O./Y1-
MB]R7"SFJJ<@CN,N$R>O($Q)BC,!-H@3$2,"7([@P].^.Z<ERQ!*$LS6K_,[G
MK5KJX5B4G\JRT1)5RK?PMI%KTO#BFIO=3[B!B5/JNG&UY;^AO-5JBL]0Z2.'
M+S*&?L6UOCLB?<+@V=-?_T?<1+-YHTA$4<E;\EX_V,Q2*TEC1)?/I=@6&HQ[
M <,RS>,[ZX()^(K>C,\@ :RWTH[0N8Z@WT@ UQON;1^4_#807]C@$5S^_544
MI9Z92;6G;^%;.KEP]1#9<S>WUQ!<Z!#6V=2/R?X0)""5TP,M1'.B]GV.IN1T
M18E"@TX 7\D/HI+*UT2Z=K_GR^,JY&1DF:<FV#:9LP-^F&4^S<!?@-PHQO3>
MVFG=O@4GKX)(-E*N0^PV?"UB.IG7%K"QKBKB?&V5*]%QZ^,KOK5_QIQ!S;^K
MT?0_F"_9B0CTE<!NBI#S7"'95\>TJ:P$)3W,J#)H;#^?!P 15+9KGAF)C/4%
M@OYNL%E171H_)(#C)/3!IHFQ&HN1G:P40U5<W?NAQKNMLT0-C()R]U7\B\'9
M.?W&+J@6:2ETA*H*\?*TWS3R)Z&Z2=SJ"O%HA]=EZ2^"W"BR\&95WDZ7 5^+
MB",!V.@Y@$O[3XWB'N@!4U:$V:232H1%F) @2J%75"^0 (S[F_0IOXZ9Y9YY
MT:[SF"U_^?Q%&BYY>Z[XCAQPQVL]!WV%FA%9#FJQ!)(8'!9@48&G]8+X^RI\
MX0F9(9K(A8OT8TX3S[QHTF=9"Z2FOT=%,8"W69DR%1A[J/_/@^0_60A(VF[-
M_HIN@67->.*4'<)7KG[8W[<L&'Q:=-5HPZ63B"KWC=$Q(Z&7>%9KQCTO0QYN
MK:6P7W_ Q@1K,774:F@D&?NW1RD9TP54<IG/+$)IQ!*6]3@6@FT^D^E1%W>'
MXOGV>?-VCKOFY<9=A*Y5Z<!A-QOM8MSNQQ _^XR(#A<],%O"L%N?-$WXD#3C
MZ,#$EO47 K.S%F\^6586>AV)WRW<R>@JY3^&K)<VYX^)UVD+4C10GFJUR&U_
MH4:;S=<+#G=0KN>4P99+*G"2\ K:VYL"?8=@"K7MK$*I>LYBFIIP$(L4),[;
M_,DV==PS,'9W-O;XP_TYVY)DEEK/]@[2:-F/&HE\+_#SOYCQT_LH'3"..36]
M1&5O+2;%[_A1\D?\XNI@,3C0X?4W_=C"AZGE3] V;E&1(0QZFE?6Z0=W7@*1
MWODXG1S5U'A0FUI;E+VA<HR'FM0.<(Y6A+2FFJ0S10R-?]U,)M*14*YAE9&2
M,!&M/ZZUNW[AC*<Z5!H0P+:$F?F,!F38T:S-N($1/(!IK5I?B2YF?.OMBN8;
MB-#V06D6D]3PK=M'W,)(SMYL$O]9(%T.GO,YV.@[AIK0+PM^YX%2$9(=6M@2
MI$)G%"4)><^Z7P=0X:-+H+W^I7*G>'2T=NM%'VW50ZP1*V!*+23'\[KJ6X68
M 9]S8_F$YS_KY_Q$^F8<(BQ2<JWG2;#+V:FN0;UL(8_-(@UXZT]WQ_Z.\7,T
MXX]M*"\Z[@AJ[AC3_6?^/O,+?I_( _%EZ%\WCS/I!3IW\J2CW]@(O2HC5R/E
M>EE_!V_"$ZW1_F4W.%A:\$'2]O1W9*Q5;P/!K[2="LD&H&IY]_?6$*Q?@?I\
M8JPQKUB?[J%\)H3*E>^<_]R-1'C OCI@=FPL.FM">)8SZOBU/"45TWN GN$&
M,8$#QBQF"P'52E.?!F03,K;X3N*E4DV9OP;$U:=?]C<.$K'8#)^MM44(?BIK
M>Y4W^.U L4%J1%BCR^!]IQ1 M:/Y4LQM3$K>!FX^MRBQ;KAZXQPU[#!PN^C@
MZPWUM<L9F]54&?KNR_C&@7,^NE;WZZY)MEU)CCB]3//TYS%WPI^@Q;^!/C/-
MS;;)*&HR9K1:2KD+);_2M'9@EY44YH$,7P@DWWW.Y'V:U93MD@)S=T6[HYWJ
M&DH0%KM9]D-5G/GM%M>_\XG7MMDP+:3:S)HMRHU:*#[815WG66 N!@EI#7N<
M="6)\N"@TIG =/IT;K_^0, "QGD.$[6^I^OOQ8U;9SL;M7<*9[287FJBSYHA
M6P+C24@ ;ID_R37$%AX-$Z[.725,1P),_Z)YN;OL"&2.5_1,*D^NYRVTA=*(
M1V41R8=ZOS7+^PIE%M?24F1*#C=JT, =QK\'3W^(>[_@6MN7&!50+)04@:)L
MY5N-2WDY:,_RYP:?-QYS'^MH!9TVG"?XU1=U+Y@35$8Q _Z]=?IZ3/T8"8BG
M84%\A$_V7$I]HFFY#:H44_@;3+RW.#=<2>7KJA.^3^E/3PH[;'B%BJ%BQ#O;
M!GLY(ZUZV-YW:V <3HKU.=0J*8CH+>N+-]9JV\1!I8RCK8E#P/A=VNRX $",
MV+1N5KHZ+/+2I1A!>I5$,LI>-5;<]/S.87D([A2S0:0TET ?(VSOI&)9TH1>
M+J<22<:=?#>HO7%.V:9V(\^U:/OJG='=!#C_5H@SAJ2O J="EU>UH8#EO,+W
M5N.2Y8I&3:VLYW0O2LC-I@ISI@LT5$*1MS:KY[":*OKQPH<^<Q7//47MZOGA
MGE];DU4MX<L_C'V.Y"4V^Z5LUOE] W'QK0*I7Q2)54F3WLV^2(]?<,!)/K(#
M3!S7$F1H*+\KM%8ZW"@BG]8U3RLL+?_LI?*5:2C&45+:&PE@Z8@!^;A#_5UQ
M!XV2L_ $T"!;ZTM^.XUBHH[M8L(8S;4#98;6-;##Y^ZL6,/;L@MRWWA79,V=
MPB?Z]7]RW+<#0ZQRODFQD,7R%QCRE@KABSZI$&F5N=,^(Y?9C.>!&0=;08.M
M]G_0?"OPO=6&>R$T0)1B7->6'Z^SU!P,=PN6_%HFJB8[BB*6TV]%[W#6TNP"
M^H?:>6"4O:@.Z^7+%X/GP"1P^IU4V*#?UXE@\O95QJ[@C[%TZ%N_@R?4\9XH
M$P:_"/_-8;L#+5L\BEOH-WO_HS;86-%-.9XT09,C33V3VH 4$FSTLO7@3U%?
M9NM-W11L^:"%'U>G\S0!+>U0Z)8RT\2THZY%M%OC^M.&\UPIT\L9<QM\+JIG
MFL&F6C-K^69WC3N,9TZS^*A8MS:$>!VEA*KYF2BS1?QWA(L?M97CB>LYY#:3
MSU%F)[,_E2 !R> ^I=J;J/DL#)<IX:K&5JXF >F/#B,'D8>'%0P:=@VB4?HM
MK &*6J'9/>2@ZO)HLF+&<+ZR@F3F;=T@5K90BY6BY#6'Q"]Q3U%97XOP8;Z6
MK7C7+_BVEWO:=#%/6Q=%4Y-3!C1I @T6&16!5GASDAIM5DQ-:_@0.%X+#*ZF
MTS ($91YX-"['-)$^JTN);8%64CR+\4Q_.KY5I37\]O, YN8*C?,:J^L;(4P
M2N$-\$R65::A)?X=:2_A2YD_9?+D>)>T07(U&HPMK-FW:OD;EFKOSN5V\_$B
M?U2(%U<0OE']-@4>[2 S2D$"AB**Q/0=#=N/^5?N>\XN-HW4E*<^WB(!FP)0
MQ4,A)."3FJG-MFY8]?08 Y_Y<R-L]IPKU>GQ?B+SXFBF*%8;8G4?]PO&I0KJ
MQ'B!(6G6_?=6[^AI2XC6\ZFI@PI(TET,:CMTJ)PJHPH^%_->/"-WHHU.%^.
M<"@5W:PN":=L%NX<KAS!0.>.KO;?_GY8/CD7]A1O.[]9H@1ODMH1\1'A").%
M0-MN,XSS\-]:@YS8:\N.[[SCS^F>EDKB9QA2&@=S]*@ :TPO@+^-W<H,&CB6
M!N5%OBBWQ2IEB;\#T!@3K7^:CO1AVNTI33F,V2*8;EF9.T3,[V;%@S@ZR:>O
M1^6*^%:%!=9/K"?M['!V^V<_L]:!8\IZ-Z7HG31BF-+IH^/3++P8ONGF6A?$
M(J@_QIG*;$>3M;]^9J'.WH]JU8#5FJB%N?!Y3<XTMVA!N4W$$:@[HB_UXSG3
MZ!=R@FTMV8N*3[_;SFQA)KZ:-W&S772MH56O]6(^70D,?)^:5^H[J!P=$N]P
MWL8\! J2#[N"&2@UIM7=+N.$I_G?U[:6>FTGZ[#*VCZ[7ESN^W/6OXGV545'
M*B&4$P<;%2-[ @  /!=RG[4+'S<@U-"?3FH+46?92-!5G\F/M_%F_>=<EW]>
MP<*T'XOT!<I.%,TO\H62+UUXUG<KW/5]_#G#,4WX+36*+5KVPC6SDG!;M1*A
M'4N&P8L1_)2S2&7/'C&!T-6RFY(RJ:K,F"S*RY1K<M13N*PO)S5QYX)J8@7?
MY%;95D_>T7(72N?KZ['>0=Q0O;;*/S]=+5:@]D(<$0%S#;7VK!5-G#U6JR\,
M BJ+&+W)X3Y2O$,>%VPC1*IC1!_.^M5L6\'6H*DR38DR%6,*S6H)&VQE6_U9
MN"A79A_;UW9B0G$Y5 ;K_$ 6.=7$\]WLHYC-BYK2)I#VEM@'>!>LZ@+7PG5T
MO=L!T;H/BC.HBAFS;SY?U"[IW7K#.S=,S5GG-&LZC_)A>KI6:BN?Z*52K5 "
MF5=P?7,(*9WU$ZPS^N<3T\7D&8%!_SPQ#96E7WC'MB[+'L"L89 8'OUL3X-=
M^C)LU/.2R3<6H96AMT*UW\4BM-C2^1XN#:/2"\Q>:.NI[WQSTLR?X.!KP2D0
MGISP:=V%D$Q$R?3(U UO^#)"Z*8D:.#5Q"2[POQ)O&[/Y7'<")4L!FM"=IIZ
M&8NF[B0MN7,?6$G?/D(DD[6N[Q)0^YK\<P7*<ZS"I%Y)3TLJ#",<4,JJ@N^;
M_K^&?Q??(@:/1D^/VX-QY)L[WU\G'R#@QT<_YAK&9<$J^M6JDQ,;>R1?K:U+
MZ,*(3#5Q7D5(4"2?<&Z^)&4%&O^SDX[?PDOTS]L9_ME*KUN<Z*_#K'M;UD9>
M]_)G^VN1SP!<NO'F0S LY>X "< Z&D$"FM7N.)3HCZ@X1(2FT6 <$/9V$E\D
M@)TZXM"OZGQQVQ**WE;N@<KD;><?=(S>^)?@$U53IP<_3F:YZL/*6BVH?R H
M)S^[I+BW@[DTD#3R;("U/N;5A<.EO0?9RYQ  W(1_C@,\W*KU> 4Y9)BW&)<
M=E><K>5FL$4D,(G/9NIE,7ETSS!_@H*&:\).9B-K'_S936K831!7MY!8=G=5
MGU!4D5:]S2ULW\:@4 X6I3^/P2/FN,[$"R/FRWO%*JFKB5H<K1Z'5\S2Y!/2
M<EN[TSM%82@8DX*I1EC $JZ6PW-T6@Y2(O3T=MV#T621PV:C/NE>2JPAI)?5
MTGKL*ZN.3K[1"/F<;#".CFS4"=)$+%<MN\X;5+PR+D55$J!(2HO!E4P=,N&.
M9\74E:T5IY-9TP#5%\T7765^, 4J=U/F*P^1X\$(@4][U;-X2G' 53)*_=%/
M98&5GZ>D#C'/BI_M8?WP>@YTNMP]AZ??<$RNLI1ULFF<4&9>S$\A 7C".U5B
M[ZXLZ"MM:K[)O77Q,SMK%""+#ZPBBL4.GB2T.E7E W8__[9/_R=PN<L]P?[,
M%56,%TQ@4Y+;A<\LY;\0DR+/Q8Y_W3/US_DOXL3U]B?%@DB AK<0]>"MP;C
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M"8!((@%O">#W/@C*.I@+$K "\65" B9*Y[KN_:]/_B]B#E8[*B"KXY#1#T@
MR! )"&5'Z'==9ZUB( &7I8U<2(!1Q]TUZC4\#XP$")HA =G>UX_J']4_JG]4
M_ZC^4?VC^D?UC^H?U3^J?U1_:=5Z4'N[T<SO0%/CG0(YS!P_..J%2]QU==X>
MN"D[VO%YG(:7[-H@QE@B,TM#RHYLK6VLM\Y&5]ZN)S/5Q]4&PHXV&SY1EO;_
M3-)$U5975\?#13&J*XA32"AV-1[T)*(-DE"BI^+HJ)O,^,?4Z0ZY6TB)Y2,!
MP3*^_NYYQ8'IF[/=^BM+=H'O\<E8&R^%.^O+:V'&JD/4 WG1O]0%K5EF^\J
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M7T,"*OQ(D "-<M"JT5D+:%>L PEXMX\$,.'>]:S>?^-\R'"'JZM=511%=T@
MHJ0'"="]O;[2[;F_0@(H$A!!!ZN7.%7G3DA NR@2,!]X!$*,W-_=GK5"NI"
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M-AT\$2'NJWN3VGK^S<Y0HIW__V#N/;R:WL(VT9QCX5@041"I41'I(%TIB8J
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M %O6?:*TJ!A4;HJE3ER?^)GZBLD;JGJW'C( BOMU%-^]ZX1SH6L#AO_J/&4
M>GH$:9S_Y>]\_!^\IF&UA_CU!1TD227)S0,]E@W@^]ZM!"24%Y.^8/)&1'RM
M=,22J]-3<E?!RM[;Y.LA'+08*)[WS]K7Q1)+\Y;;,4WK4V<1W?LAW$0]\DY>
MV&RP^>.>W3O0](PS-J2S.?.+!I=4OUGSI&6)P63M[GZ\.:K]8Z[,(PV2'_XY
M[RD/@D<)3587?K3D#VE%+.-H?17'S9B7UN<AR&.6;<A/94&AG[OLFYT2<S2G
M?[TDP] 5%FFH]J*5==FO#4!^<V,-?H<D0Z,A(<.HYIMWF7[X.]U&-YRXM51
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MO?38U&SV5__\[I\%D9ROFJ6"FE$OHIX F+XR#O$-VJV^6U6)F%5 WCK F@5
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MRF,]6RQ_NK_D?(,^+ &)\9Q'C;1I&54KC)WOL,K^"W+^7_KZ%!N!"QV4,Q=
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M$XS<]%I(SLH=Q,'LW9T- X:^&7E7V04\#J4OZ)%,CVSS,!>@;?8-D$_L \F
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M>Z^M(DI4(@/L2YI(;WSVSM1)9[":)!S-C47XPAXVFN+$#40>9VO9GGU$"TD
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M:KM\C+&IGNG=B&41X@O+UK_]D%I)^C]].1=6XCXI*"!EC@R@B(**;A$@KHL
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M,U?)@&U'A NG_T\H:-][#^^+_@ [/#Z$GXF<<I,!YLKG+[<7;_O!0K(<<\F
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M0V+D*#)!"38/;7R6EVOV-ZZEUO+.SKA=ZN#=:;-,%BP/%O!;S'^9D5+UP#+
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M'YYB:] \68JG036FR"-S?543E,CF'!G8K6TGQM2(IF!,[[7*\XAY8V2\;_W
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MHM#GQ5M?AD\WI9=:%%7D9<=:=91CLN+\"QSU,PO=%36UDS[:?&'7B[B0NN+
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MBM0+3B>(OXV: P.Y#\\>?0W,G1EUL>%,3LR]QBGRV_SG"!4)<(,=V.3"A67
MJ&SI](]%(N-I"/PZ%A!(;NNA]\$_OT=VFE"/ ]M5V,U]^]1#BB*TX]CMR8[L
M4DQ!VDLM>J"VII$F(JBC#692_^;5X[[:>O#1WGCQ^NIB91Y%T//@D;R.#1+
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MDE[=,98&I%,M\1/K6ZJ5V/X\&@I13:/:S.S4K!JJSRX.3RO(D4IZ4"'X^D'
MI4D.,!9^_E_%^&V/2R9G*Q<$:]G1+>L82(X'VT U1N)QGKA;>)=.B[SDQ^L,
M23*2U>4C8[H=E2_U%56L-7_+49!7G03XGRW6ATDE 1(Y^IV5-8>/8>W$]HW=
M-!\9:\BZ,E8-PKA& J!$0V/A7-)IZ$(T7>6@QE7K#^9+3^ZQKCU6K;ZC8/0E
MRK] [JO$MS0>\JO?NOTPIR3R'H]/3,L;[4L0Z2T.[-PL(>.7X^]4_N6CQRD+
M#'V\*4_)IRYKE2\M;>+Q3MRP+L^P2"E6[,YU3VO^> !YNA!NBLZL$;J'$6_
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MH6Q?5^#V3G7=IL=C(WOW'"T];:=QC2M:0U6TQ<J1@R.-VMPM[#+DF2R@)MJ
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M]<M%'U;;3OI#B]WNJ.V%=A?DWTYW^CAC8C05@'A?-)=>-)U&7UG;:>DNHX-
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MC]B@]"M-RPIWFQ\JP3W#<OKW2*7+J2=)QCHZ;V@,)WH8L@[TQ?[ :8FOCOS
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M:'G>[U:ZGT#KAE5_VKO9W>?S87:<:A.'KH/%G(M2:ZK\RQ.GSJ+(1S]][B_
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MNR4#C6,<ZB/<C$+X,3PO8-UJ1OR7=SS_>5!]2@VSUAVW/9P)[D&O/,&;:XM
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MNY,L4CC5^(H?0@74JE]X$JOLGJ!=RO%:4HJDNM"M+(3\2 -1?R[ETY.Y"CE
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MJ>V\LV68+]-CXT/"[QO&7>?OV]P/E)V86,;65BK<A'5^VO]<KPM'])> )?>
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M]L6I[=X35?]@?WUVIN^*]7AE84D&NG(%AEL6O$41:@]=Z%J<6(*DO>\%558
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MD.9@9@!ZH*W=J:8CKEC#('^C?4VG_R6(Z[9D=!]K!!2,MH@'DC*W =<DTW#
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M1Z.)_^&)1"K3MX</)@B*N)%=]6ANW<X"$(6<$S'=O#3^!UP(*]O#VXDD_!O
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M^1[GAL>_"]3\SS;\BQMKOY9CF4.$932.7!9IYZ('L4K$QYG<WXHYR8DNA B
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M'/[C_.CBXO2D8BC!91U5-"YMRI)7R>L_AZ>25TYK7#1@&:=JY&IC2,N-N+B
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M^X>0_9V2P<L"@YDN6BQW\H%&P^@TP[5YK;7/B"=S/GKW8UT1_5MO%3E49:-
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M&?T-]R),X&(:*F!MR5!UWKT8/WJ4I7M1],(QK&?"3I&G9/>>XBIGG%]_7.S
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M_0=O$6N.[7L#2/) :X3%@B_NA3GR"PHPYUK( 6]I7\8]43@+V;0^VIBH%YI
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MDR$\N4@$I]HIU*S5UNF08:SG_S!R1I_.@\DA/&:F>SQE+.+VY5[6>/*65RC
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M"L?VR_/G2G#QUCVZF/.83WCR;) ;9"01TJW452HIJW2EZ]W?QO:\R,TEQ&C
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M4:%T:9XH"D!0BG5I<<]*7*H3H).P,L0O(0YP?L;5?6V22'@KJ']/-IR0P2C
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MSV''ZAE!#P3'4 !,(_A._$<N:CMGU@]P:P_WE)<24S!QBW+-TW&B\=^^ Q2
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M*$H<CC/V!)[9*M=Y"X9A7&@>WXQ/+NHUWRE?$=BM_>9</*^N3C=H/.7U4D
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MY3P[[MY\>']P%HQ"&91,@^P%B5V=ZVGN&I//CNU!0P">D'\A_;SI/9V[9CE
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M=]P;4U=?L]SAFH$I6./[WN%]HL7+JT;/RMFEX"^8%<CX+==1)J2XN)A8"P#
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MRL/X;O\N2_U0%K/J$'[--2.#<GA=R^!J^U8VK+7.#"0C*S395&C>=X9RLBZ
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MN\7K&>('QI;L:1];>)JL15B<S7JG--A+9D]W#5@ ^$W?UF#N3#.>G*H7G[6
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M;_:&/?X]&AJ;%[=-K/PGUA)Y8D/R2S5?9PMB+]'=4OL=8:'RAU)=_NS$ X&
M6]B<%0P[A.E"-D+A$$^7&U4U^[9D@:$W[#:$5,-!U"WG"QK3]K@%<?@?>W\9
MU6<+YU'56\NWFOKG7I=%B+TA[)!?+[HT/,Z6M\K-,X.)%0%"C.3U=47E:7YY
MF;_6>W:3%\2P>R@59.#'L"]&/N(-:_O'DN@I:V3D9?AQ2V4[R,=E262PR&W)
M^;U#6F>[\5(=B!"$K><ZFVJ?74..5(@@"]XN"7L\(4$RK+)IF:/+P"V![0>3
M@,'6\5Q-CZ6?$,GB<_7B<WZ/EGXB1PO2[8D'2?L7?P  = G=8&F M)+C:;-S
M<_-(G[7=FC2K!1)K_ISYQ9YI5Z*5FO>OA?2%QX^59;]V[P+:@?3*F@J>3!1.
M1#1CQ+#.HE&S9U[GLJ^K>GP*.J1T:HK2F7T@_7Y-WX;9EV,X0T13:^Y3Q"<3
MY AY[Q;CE! ZZ94P?D]JNZI=^WD*6[D6%DAJS><1B,@>,G;B)?5144DA6W#3
M?*;S.U".[#,!Q:CJ8U&-;I@DYJYV1<E=M!=-V.\MU'J+V&^X\[\*<#1CK#S]
MEI]#77L^['?<-W"?V2KW^[L=6,DN70M6-IG[V\PJ,JWH@[;>[/UZE+&KW^["
M?LTQN>PZZ8\)L\I&VS8QA^]VUQ%*MO,?9$[+$E+LVJ/?_8HAU3!A4Y0FZ_#I
M^231T*938D4[<1X1KO/W]\;^KQJ 8>S*RBMR> $&BS&.),1K/9*FDG5>N^HU
M'D= %65;W2.6<RH,[KUSZGUZ-N<"J]EA#R=QW%/OC[H?_@/@<7L8D<U#N(G[
MVJ>?*W! 0[0#W)_$A)+-*4(V\U/JZ/I@7>I45C\YUC!S&^DI#\G\H?DM"^1$
M4%]5O0ZHEBU!ULO?2&,)P+RK&&953@2;6M*E?XWW=>VQRZ$,2>S&2-A6I7I,
M)/Q&,ZDB+*J7$OXI"9 %F<:26 =-Y3CY<="=5_A$4'QW5HSG2_^(2A'%FO6&
MN_G+3,V!DA=R'_GK\'/97E5&6+LGL/3Y<XUP]Y[.NRT32RLYR4F(8FT;@R^R
MQ4>M1L%F$"HX7(* +_NVKQIWQA%A7T2]];_TL_W]25#%"0O*@OIH(6/; /5^
M=Z-@$'C:BXJ&[B4*'U[?(+%N,%;X%AH0>G@@>Y[1 XF 1/OZ0"UT3H^O?U="
M &^T(#?=$SN42^#W\XK0@-C>$ZJ%-,46<:GS!I\S]I.N4TI['A=0A9-.NW;%
ML];M]$]J8D:/S!68E=+8-7*G1J65JL<TQ,1R,4?U [HB+K++ @>NCYR8(#)F
M@<3MKY :!Q71BVG': !/RLQ-U31Q"ZV]5/TYB@$8-%^;ZDP;]:3..U8PB!@,
M;H3-$TI2@(28!3-#7K.Q8!97J_,?BHKF\J4V]4WLQ;=EI)[=-!K0JN*^D+&/
MBTQ80P-2G-" 7D()L"-D/0D-V,&,1+IZ9_Q_FGZQ_-NF7S0;4 3#/&3X+G0M
M=&SSG.R?2?^?E]IMEH/R&%A&M*%5LS"DN5Z&L+)YUT/=-\'=SJ((.=80%A28
M?>]A[FE\;76QHC((NVI2<ZB(E9LNI/3I_GS8M=*@H^T^1;!U:?XG3^I:(O\'
M=SN?[/ M?M4YKM5D=+$E-E;S00,L5PD?.@E/3E<*1V[B(AE:FN"&TZ/*S>*2
M:  [Y4ER#AH@1WZ?)]9JO5-<0>Z7=/_=-:[5ZJJ^04H<)SQP?2D5,VO,/7UL
MSQ\_41B+Y6CGGKWL*'GE=$N2[8XCC&OATY0?W?>L2;!8WC+-D'G#%%\LU65_
M44A!Y& $R=N(Z6'RLHQV6I^.;6BJH=BG [^@Q=KY@#M@BB?S0;?46=]O')'2
MDO6+4PN]BI$[!9U>!6'7:G[7R$[1*\H-L0@46 S<360GF]O!J^P#?OY9BU\P
MK QDQ_E$-!E==U#I0'2O;(8[7;S82I\3_J(5R!41CEMM'^;U)QP0CS? -S$7
M_=1(B;0NC%B<R\X&3ORKW-K8133 %",4Y$C<8@RK^30)F:_#L/SNB[F,LY+'
M!Z\N@E"*JA@ZGXVY-MO4^\O(&(SXJ#(@?<XJJ1L;LGK_1AOF@ &<T(WX431@
MR*3TY7P++"+5PFUS.3/-JZ65BR2W9,#8G-54W[JP.VZ+(R#]%6;[>6'U[@DI
M"OIEQ'CL&P^<FC?N(>54"F=0I71C%! Q5M$D_/<T99*$SH3LDD-JETYNC:@?
M$B)1: !ST8G^UL"GVTQ8:\ 3&@08F=^B<_\H$5'VKJ8EM6 =#7B^DQ$[,U6\
M^#WCV:N=VP-U*(ZFA6NG)'D50S*BM*Z28(N"PB\[5DRYX6NQ>YZPQ0:V3Y_C
MS&TTI0^$.LJ((JPR")#!-).4#2?$TRQ*K W6M1;7+!\UU;AB+X/P4/0GA33A
M%6X1AW,M:(#-+X'Z[PM)8BLU#=K,H4+U#2IS U*IO=-CIFKR=T"4AB+]=UX_
MIL61E36C.?+MG.@X+Q_K*XW(+6&Y75K**8D1@4U"#9=_J:A!X_] $OMMP'CH
MO.$_L/^GBW:[%?(K1D26UX!F/ICME4JK6U[>WKI.10-(8G/X#R]J7,V@;=<!
MQ!_1 $>/&_D+:F.DYJ&UKY0TO=CKC)F&WQGK*YDHI]02$PAO^/S)H0F$(7(3
MV,@_[8ETGJ,D7/"PVS@^KR%M/.(Y2[-3-F+@J&4NVH;SGL4U63*_R!M8*[;F
M&O32M^Z#Y9GR;BUZYU"/+O,[0X>I$=O(!_LJWU&&R_SB''NJ86U6<%7"<>_E
MJBOKAL=WW-;WV"KT0(9Z4![-/ (J0ERI+]W:8RO;.ZD,]-HFM.2*;*).W-2N
M!PV\_^%6_ &3X_[-Y+)"@ F.,?<BR\6YLFAO,NVS#IPOK%SLKM5./P?M12P7
MULQ/%!\@K_J@QXCF1? "Z63!?^90'D>F+&.C1'W.8?U7@^W\7UU/U+JB8]^=
MXSQ_D;- ;E[SH@JWM$NGU8FDM>R.4&%^-%UN"9%,':<";:1$0*)GRF'\UN.Y
M-D$;*4V*#SKXS"S=H[]")A]Z,2WQ&_C":8F_34<DD+B(%_M$PD7OTE+:Z$TM
M/T=906C$)WI<G@W:NJTBL)#0"S?[ O(IL9*&GTIA,[IC:6LH/&N+,4FUVL[<
M\GF0<_$B50F1EHG\>EGB(7]XRZ(<V:'#Q)TK]B)CZSNQDRGXZZN2YW+,DD0;
M[2N>?4YE;8MFM29R&\2LZ0%P"C6$V8.[(N]."]S/9/O:Z^;%H..I6W=F?%U;
M"E&']YLXB<4M^Z7RK;V"D^A.72>KK2.R$SQR"@OB]9ERY)\4!KA3-OOFFS<T
MR42\YC4S?B5&.$04)7.WCQ>F5ML:@N)B9:4D#V J!.Y%8#OBXF;IS+''G?U?
MXAW[>ZZD-!J0/$DYK(EL:;>5//YE+W,P*\[C?ONLV':EA'T6^*O._$G/A_OU
MDM/Z$\&]<0-JTM=YOT.M<LLOE\%'27N1<*VB[V=&B[ PAV'KC#!%Q9^U3\AE
M>9XY2R[$)?5! LE:R^AY3/7IEOQQTB6-9D+"WB<SI2C(W/6=;EZ*_?69PUW=
MA_[RBSQ<:UVU3\$A7(R6T U_L(?>Z2#I?$G0XE$;!CWTS],D$S;JYQ!QD7U\
M_B69MPH# J;_T%31@(<-WDO6H@$)B2-L4Z#73EKS-JON7O9X8>\=20LC"1I*
M8$8/ATI+-G0'%HIN7]!$B&UOE86Y;"$K&VS)T0"$JP_MLDLE2&/" 1PFQM=B
MM5/R59[7\4")DO*=+ ^3F96Z^:V^=_=O2](N!PJ?D*6<>K7]%Y<T^!MBU2(;
M@'N9[?08^-Z_ +SNF[X>VS7)$?JK#^I3=&[AL<(7.B=:63HG1E<SQW>E!)W8
MY _]VC';PY ,"9L]J!\P<Z_H'IZ7GM(+R[.=M;U0.R"3Y[[Q3DW/3$A>)KZG
M4%8'%GFH;$]E^:1R"B2M>X]J5^$][*JD]R8]0<P!KDC0Z"Y*J3>G>Z]9M964
MWMJO95'(TGKGA$FI>;UT3BBJ4N/ FEBQYO)=2/57K(LXK6[GYK/L=M^W,. U
M(T="QJ63RP4*SDN%%![;_N']ISO9_I</U%6A 9_E#U@7((/39<U==AIU?LXM
M[?IG0/#$:$C5*_J':P)/M>FYY?I5=_O6CL?F]-1QH$S&:]"J7IH7H9OQP]AJ
M_<]Y*XZ*5M+Q5<281DU2]<(+PZ658E[@3P@9(R<)1\K"SG\\2+6U&X;6%_;Q
M>GO?"^D<)Y8B.5Y]&Y$NPL(33V9"\>P=D-6OO1/?]9&OU^-;*NDWNV5G/8NT
MLC&RNFOA>HN+_I_QV.49/@"N,GXS(1XTX%Y\WX2;K*K/%8((BW=YIV"KU\Q4
MN]K4-4%WK6?5.3I9M/QD^0:Y]S-V\C[?;%)=D.@9:7W"W-/5A"I_\;?5&9>'
MDG[:42JQ?8)\W9^HH_%D+[W^WVK@?U$,()2>S])E\A'86'86S":R6^$E8OU3
M.MF':(DTU-29L.&7?LB [8.G\<P\0E<S+SP&-4T*F2U:HQG#:H/)%[W+5-JM
M(=]:JHE<IXT/T("-@J/4>I'4LO,[#A?N'LB.0X+XY,X]? (_;04\6W L99!L
MNKJA9K2_8,Z@Q1$?E4Y>N!7#==X]#-;;A3"F9Z)L#%1"VZX+$ 7(Z!G?IA;O
M]3,_U<(KAY(=VMQ.UR4!^_KUHK*<_.LW]MQ?M@9D4[M[:)E!DR3'4;Y+*LV*
MPMX5KDZHOZ9 "8PL1[9MP2,S?VT?A!\4"3^[/IQ=-%%<N-YZ;!#=9;ZQ6RQ:
MRG,HRC_?OSK+PJ6W]Y.9/]>_R#2,U6F8-(60)@7H>E DLLG1$QE!/9BX?@$?
MCD18G"W< $]PV\7?N9YW+*<Y_"0O;JYFNYCDI/=5-=^\9G@,COFZ537OYJ^N
M2>559-JGMFZMOEK\4D\+L\V"%EXGI1A617CBBN@Y;MAXL.@W>CF%;&R67?5;
MZ#BE<A"*#K4QNR@8Q/=3]9PZ"$.1W=LIK'&=&1)G>28;2<RD3O#L8/A!R)?<
ML8.VT1QD]06.0XX?AJ)Q+V_4238)L&]N9X3S02B\6]9 +_<7^$32:VQ^^2FM
ML.S"K]G)%L+BA9B_BI.+A*?[6*0W0QKR2WF#7X2DTSNX'I2];-E([ DSLS,7
MH(>#UU! VLCBPJR*S/(#PR9YWL<:0A&ZYB%*,:T:W;"![0%2W8<2M+_K>31!
MOF5>5^1Y&V2W/S?Q&FST:JGB3G*(2LUAB_YNJWSS98GXX43[Z)#FE_P@:CUU
M.D[$2VDX]^?)5TM[8@-&(R_+=@AS-3+6<1%>MZXC)N?)M^A,$+$HE7IAE,'D
MO0B4$1J :S4N$VUZ&7\,:ZT!W!4R+ HI-EL["N=2OY%XMC4C]95<>]\;#1#3
MP3I76,NB9@^Q.U\^&2&\,3"*R*C<DA7[3RCA"6WW.Y\626SS%Q8:?<Q_S2,&
M\$JU;7!3,D.9Y'64WP0*%<&L"G0"/>C#DPTI\:IC[M(NKD5GOQV0H_&_RTL3
MR2D+PN"2%YF_ CHBZ@P0.L@RE!*$G7UBR&<-I:[G<WC$[,3M6W"L*"T#"_'Q
M%>&=XKU$.B:.-!Z9/G-8^2X5GV7AZ0AB7>+-2W53<:W9O-2QW02P?&-I_FQF
M\K%P/ 22=Y1"8/*%*W]K4$>TC19LAWW5[Z"LT &YVRF>Y?=<,_/(J(P<80L1
M0 6@WM92+R0;BXG!=; DQNW;XQ:)!\N+"K5N%HWF2Z*-A:P%]2B&[X4(PR0(
M%R17[ZG3L'P5PCF,&PF&:"]&FFYSI=_Z[A(CZ*BYKB+Q"'[!-W_X*[/4F?'P
M2V,DK0K9!V#2R>V<$N=S['_UD/)_"NJQVMIQ*^B*3/#.KR>%,=8O?_>[')F:
M&/_,W:KK6Q9?&$W[H"]01J[/4.E.7Q-6AODU-@X,-4>?R>&(Y^\!RE7/F!^G
M''>TL^,-UWC$1/+Q>\BGM7-7$.0HM531!)I@-%O*\T7&NTG$AK4J^-3C$Y_6
MI/"]IDGY; [O!Q1LC4T4WJU7#4VXN8Z$EQW C6V.?=B$=>3F./7E/"'<U3=]
M[4'@GQ"2,4^$Y+%)KM\[UZ>_=E2N9FL-&BRV:#TM8?B.7='=.KD.E.+@^V_&
M^E^*L,C102CZ<KEYNK@555E'^VQJ''1$[GQ;F&N2!<]T?=&FLK:*@G2I1!V(
MN(B4RI!.<F<8T5P%K,M&4UKWR,<AIC V8''/PU&OL ;*#$PP.EPDLRPIZHSP
M;9_M'^Q[/CDN77?Q8I"VSRH-#?"W^&(>H6"]8^[C,M=?[]WP-&_"IHG9E#K0
MD/:\>=01-<[5S5TX18K3=H[8MA'[8DO=\S3G^E;1RI'0B;:)<IX?.[)FFR-9
MS$1Z'DS5@D7<7E\[GO=4/_VV)5PP9(ULX'+AA[ !R*0D1U;[>."#W&?SSWD?
MQV4^791%["9N\E\X)BV8Z@2P68%H\;FZ?;]ZQ?(OCA/,<;&U!!F1K!*2$753
M' EM]WHS[4#^,?A)[D?7GGT[3"RV282ESOW[V*Y1R^S,+ ]YC>_A<*]L[?O+
M ;ED4+$-''0B*2M_UUUZFG6@.5G[@@;#\.K*$+]31Q,NX^LOQ)WSH8E0I8O(
M$T[$+2G)N*+\SM,'?0/\LT&7!A/2]-(RAEQG33Z?R12U0IBY#+S:8V3(E$V-
MY PQAN@!,!;2!][21$Y<!V2A 4F]+N<C$J<%\*7<BD,YQPP2KY288OQR6'%F
MWH*WN+]H5E%>15D"/KMC3%-!R4*T-.ODPW[5+V#N?N6#MI^SZ?]LV6+F-RE7
M-*O=/P.-IE8*!4ZO#=Y+5>TVD/5=;CL_&E=J[+?I5E=FRHZH[9CX%"C+A3,>
M9EN ,=3V(KV(-SYO+ZN0K=? =31@>.ED7REQ^$?%SO[U'/DAPM]$! WPFCC0
MI[R)#4QO%SI7XDC(SLK^/IC6NU+$Y>V&S\H+XI)6E:8GKQU_=F&T VT2Z=U@
M\#W-@)->TBZ1U_BX4CM"N/?,[-<0D?$S"++R]H4S;YTUL)%DFT#Y(_PR_&/E
M!NN+U_&"C=S*RNH$3M)\(#&&X&0B#$-XUH);6*\#+T&] P[.05<WI82F(91^
M[FY *Z0A@GC4\\>/'P=*=XPVRSHF#WSCV]Y/S@<\CPTB;<SL6]UUG I7I5.-
M+B@KR-?B9L_!((E-A_++[8.*P8E?(AQ-7@7E)W5)V\Y/DI3/9I+"\W38Z%_7
M2%%JN<SB#7BF)V\6I//%JV5YK*OU1'_ \(T\GQJ$Q3&8_AB\WBY"B3&'9WZO
MH&L73F-JHV/N[ O%*5;%]9OR+T(88^E&Z*I%F(N+$\QI /*_W5[-:,!1U,R:
MB,5FV'=>[OR%RR R!:VG]]F ;Y^J+:N5JM][5L7,<4JUQ>&.!BR(E: L!]$
MBGH8Z_GN33\4 PR^H %4&65#-YUM?[>?]E\4+>4Y5..LPO,,M0YK7YK5??!M
M=WA1IE8DU-I>_[FAHD:T\" Y45</[V-9BLIA\MS*@2^L*C$O*D%FWOR+S,-8
MM4[/BZM3'D*F F"<7N:K2R*U7 -9\9_Q*@MI3W:U'NQ=6IQ8(*@<;GKA.0C(
MP9ME1R1?Z4"^>Z,?\$#^Y8AR>%:3_ .-&+I'4VKJK_N83B;)N'D90Y$J0I;&
MA0GY3O--0787S/15BU/&K??SR>.S T5]+>^)JK?H%TAJT]QM/K%H6R\0$'&T
M8ANT3L!:D%@)>RP!?'CPA*R.40P\W5&Q:78<BOALQP3W%6DRZW;#P?-/J/ Y
M/=]CBAQYIS1(U91 LR2:SF<>)5,W67J44*VX$M_ZBFTS0J5M0XCW387)XVS0
MD(-J1O3)N"6$/<B FDO_<*<8IR\_UU9X>M(S,JD0<68L_JV-ZG\IUY_B\"E"
MF8EM8(AQ<F]/Q4;&,6W6>\K!-@&WG]^0P0C7=@&C3=\ZY:KF,@$"?K)Z*%G8
MBT H'R<?#I_5 FNUFB:;:.0;:\:VZ68VZ/!J0A#"Y<"^#&4&H0#&"W1S1/.V
M05HN5."(MH6"<K<?"WNM#Y85R+STV7KKN3''&+J^XEG\0XI.OUB7Z45$BKZS
M/$@]NALS05]#@7ERCG;AR)+KEC*X"<_T(G1Z7J3&346+/4 ]9%GPRB<-N[1!
MF'+'^AWKIT4RF"<N9C6O5/\P3W0.Y;A\OK.\*84&A"C#-=$ 3]&"W[\AOT+V
M)Z"#&%CX)'4-C()[0#$[H_>?['CX]_@NZC;%J9 6(YO,[C@VA6X_% 5THBH&
M)DUAZ>7RX3*@Y&)SP@L!V>2TL_BZ ]F)2*_,7:](J:6E^4N[HH >N[(VJ:<\
MN %9!=_?.8ZV-$O>>?$Y@H[]QY6ZQ.T]C[6EJVE5\7_]5%_1=.ZN<<C>O%![
M,QLPCXAH^_9N]X+?+<?QU6N/R_><_9KL"GA) U-J6F-2%#%Y(-ZJR5<Z;S18
M +[;6V7^L@\*@:O3)P\[[1QB%C]67?U,K6F9KO"6 C84N7W9"TGQ4CYDMA.U
M=7&4E0332XUOO9%Z,JBH&I\2V)Z=0N;K.K&^P>LTRN_EF].C(@RU+S\0;SI0
MXI.QJ+B@$')8F<() 'XJR4^]G] ]E?5\NX8DI>\71F,_+,$B4.:UEYC,B@H4
MP&GCE!9^_(]_6_DW S8<2&0QK*%WX' ]YWC)/\+VXQXXU>-F(S$04/HB=Y8T
M+5F:=?PCN1*MONB!C+;I^Q**1XFRS_$B/*6QM2].8B7J>X!"6)J(0NJD;:XA
M?",;N0]%/$'(F'B4,GBP+$7L8_/COVB36V@ @\"B@(Z/+>+>;%W\/479:4/*
M>?*#XJ+E[U6]M>^%\ /Z=&6YU$)5Y,5)V6RV'<:U]%_9T\M-TZ=I$6IT$\)/
M)^%WU;_^8HY1S;S=IKF,?!E@%=Z"S/-RX*0U%;FH$H&Z\?"W".4L3%VR*19&
MO^7,\N4W*%K3SI:FN+QJ$)+-#(-,\6& ;VB\-*L)(A$-B*R$W8@%7!']RZYH
M%2 W@3$9F!LE&)XQH74]TM!0H>2FVNN^U_PC9]&# D? VQAYDY[$T:[<TP!G
M(AI2OU>_R93 Z!2GG*M,+C?(EH@!&N88U7/8?7BI7F'@@[-/^+%EVMBE]P3[
M\DMRP5P3/L=[I.-N,/\2<O[TQJ+Q_7Q""&E]((EQ?KK07(BUNW^DW>8;F7SM
M?IF^4&#SA8$\A/%P<V44,OS,Y-SM?LGYL_>N E8^!G9!U=?+)2V1ME+^Y5W3
M!^ U+1?Y)Z=G?$1:0:FV&S&ZZ_I>Q5;/N28G7NO=QYRQPU\O:/$6H@W"?1.-
M+$%1;Z)>V3.S&KE[VRM/?(*UI\S--H>DZ.,M#C;'9.M:<T=*W=&6?-_HA:>P
M%PZ9TU &T8NQ:$[(3#WN^:V!Y% &T"$T $&_?W#Q_1QJ#N&D0Y@@1\5U-L\K
M="RN<WB.4^LY76HU'(8^4[+SE%UMXB=T^X>:[^&)YHY*J^+'J_.]_C2]49PN
M:_*L^4+6YOF<H2:R"@WXJOJC_ 2AV9BSLQP)'@K-]7MNGQ8*?^8^JC5AA^>[
M=2S[+&T689@5/\(R+/UI4&O%IDH/[W591 K>S*"L,LMD#YT3QOB_1 -8MAG;
MY9"_4&;@H8EWFF:$O9 8/FKR9MHU[=V!E6+.-0_C=KZWS#O.+2.DE"Y/ZJ =
MW,E[I;4>.P3<O5I)L\QK";J;8=(';:-W9L%'<:H;+/.4H= 650\[-""*F+RA
MNJ$<MGR=GQW4;)[U&2XRT.P3[MQUV^2TZ['6Y( Z[MU<QE^_PPZ"(6G4<,E+
M#F2Y,!JP-FWM ^H^CP"ZN0E8'8BW+U0[M'?%>FK6"[-!#6/NXW,H T(<FO*"
M=R=]!0R<(4X5-1"X'O6)#!AQD4G8!(0K T^T@?"S%@?X(1K0 $&2H@$](I<8
M"-6J_7B&(Q6Z7O;[,< =>.9Y]=CI AF[#]U*I[ZJ;Z-0-3Z(^#<9#SLBX4OD
MBCR)_?M[XMOS36]01* 305%[^Y3FZFC#$"R0\I,R/D'VTLQFMAFB,ZJ;Z:+Q
MT#^O4=0+3EZ@%-J<X<N.T+Z*B/EB<#@UYU$XE0GYC(B^?MA3 9&H[_%>\B?@
M+B77.%+=69?>9 P_8)&0+ IIE+[=0P</:JRQO7?J+L=N1T[P>"P$JU>EV%]T
M0, */BXOAB44%)N]. ^C,;G3L?)"RYHVL%CM9](DS[<ZP(,0AB[@%LL<&D#6
M8O#\R!L!76,6'JFMK[U<T!Y!X!I$ZE;-,LM_\(_Q[1%CVS'/*[$<[&QD>C*N
M=#_,7U,1^TR#^@2WH=+AZ9KSQLEJ]Q2'@WZSP*,G%)/:@3P+G%J5-+?+"E(W
MYC?Y11J)^FK'!+ =O^4>#3.3J'OX/PG;VP\9?%<S,X#_DY A<FBENM8%@6]D
M0*Q')9.2GUXFU2,F>E33P\N=A1\1 8KSOX>[P+UM0J_[4.:N(,T9K3^)EJG+
MRD&;PW]L8;\LGSS\R_EO_CY_!-_O\W>8^7^H>^NH.*,L7[0" 0)! H'@[H4%
MER !@KN[NP<I'"J!A.#N! J'PET#! @.02LX)'APAX*B>*3GW;[3]]V^:[K?
MFYE^?W+6JO-QSMYG[]_V3\G@C4J;!_I[KU[XB3!O4<.9E^X!XZ*K%RYMU=37
MJN"[MJM*\ FC#Q[R</L2>.6)5$H"%WY"5E:_"5X%#P&YFM1N6NY,TUJF\TK^
M04)SNP95-S4WK8P>4&XVUV35.QZR!ZDR2S0U,P&Q-]% ')8IJ9E5L<7"#KLT
M"0K8B;+#O2%XS;09!W.BS@^74%$8\N2G)"E&F0A[;CE DI F,@2OTA_6OK%Z
MF@Y7.7[>6+_*"T[ZL3^J/M6J_,D\4,M'^![07J#P(850*!+8Q4 >1:!3!!K0
MEF\546KMA2EHSIQ(\SLO7=B,O>1<'@7B .G;26SX<MEEM8\/ ="!\ ;H+O]2
MJ^&V94JU@'>1/)>KO<Y'7Q8A^C@724 V]DN16O!F+6+C1FV;AUGG$HV#2S*P
MKE=;=TT00\G5$6H_S:SQZ9%CR6(*44(/#+>./=_8^ILU%-LC+-:7CM^58!O/
MK<K/ZF)=7*P<H.DU"#C&17/8E*6LU) V?H3!>>9,?F!I\4NU,"RBQE'H=R6;
M&G<8X6 19BO8_4IJY3\?GS&OB@>_N"@YP[V.6Y+ ;0<+?Q$8-_-AQ)T)Y6T1
M(++AP#6,=4F ]+D:N\@PI#2DS)0,)/=JD&HJZAE8G,K\YJ1\,%-A1_9@]GO
M=A$B0\!U_>&-C5C5=/(%7EYW& G(E'>*70IJ_1*Q\B_BU"RLF)),*BS[]KE?
MQ7ZWR &XO8*SD?B(0=^/-#7A 5N_O0=\@-T#N#F@)^.VYWBG(G#!"0F&3K'
MR1Z]JY6?"\D=D!_CS37P8<//.<>K1!S8*<^E$PL)KX?9$_M$TW_DE2>F]/%;
MM3/8/6C;L:#_FQ/1L\<7LXAS_>/J P;J3]=19TVD:Z[,K-T"NR592_KV%UC+
M]ZS?L'<JO'DF_F'F:6<R1<*?T@]A_VIX%9@=G&W2U1AL >:5R#8):&P2[UWF
MNQU8<SN==7;UY&^Z-)Y38#)6/=L?VGFIHYTU4KOQL4^9+[]*61PP\C.2K&WP
MH[+XWK*AQ-GSU2QZ3V^)4P^D^[*"^-I!=328^%:M#1CP//!B97KPD#AWSRU]
MD<ZEW*!CE?B7<6&+L1CH!6,Y&;MRXS/-&7[]9]W84W]$=$'3[7:Q1&;)V5.D
MH9'3KYR]13-ZD8!?8.<'X9]&S7@[8%,QWU'2S)2_T-ABDM1L.59A16K6=CI?
M4;U,X?6\0P>'@Z8"*A^?"P8=QF"<X2'?@!^P5\8] .02BX"K?#IP_F1^0%75
M<X%.Y1(U3[!_(QGVU:;>KPR4F,%J1Z =N=P=S\%98X#MX"8SWG:E8W**AR3P
M1!3XK^>]ZJJY_+$$1Z5:GS.1GC<:=QLR6O:$]32VFSTU,I&W"9]XQ"[E2S^3
M1I:ZMO8G$H'S9\##SN1!7.9D33T3QAK6RPZX87 OQM+V$6#:H1%U$[OK9,0U
MO\M5Q95K',$C<7U^YVIRB+VK_3=,7&S2URIP.-&KY\HQ#^DYB.F*_C!C7=\>
MQ8;^(C:'_^;+A0Z/S&,6"=BK]\@'TP!J6F)U2DCJB"5:#&R+8XX>G.HVB1M<
MW]5LPOQ5IGZB@CU9+\>N28^N]V]YS _[0W/^H3=5Q1E!Q^<!_.):$1N;]QZ;
M71(CY,E-W!\<77NV#J?.GIQ[BVA%&K_JQXN"L%YN!K:G7&XM5P1!WGW7Q5%A
MG_&8K/J,KMEH, 4Z5H@:1.?^(0G(+(9NQNI=T?_^=;?:7@(SK)G6/4SD_NI^
MG>QGS7.B]4[DT='GK/6ABX" .[&O_ <]PFM.JH_A/\-^?OW10=_Y<,FBHSE/
M Z81TDB' $':D_8-TSFW0T1V>6O-MI/YV?/IMCY5>)EEU N"L@X)#]&/K\1Q
M&]!+PPQ)K$.8-48[%RH2*'NMW#V=EU?(LC49951$Y_#X^1*<I' P?\<D93^)
M-S@,-_^L[611+)B7>XMY2E<Z4TJ7"ZKSEJ"53,TK&+8L+SWU'8UA)VI!Q(H7
ML9GGD!7A$4Z,D?-Y]-$]&][MTW\F27,;3JI(AB_U4G)-)/Y]E9R6V%[E_\\\
M#$Y^B$&D:.#5]1!BP/_H 4=SN88MKK[D(8(0>W3ABZL%F@T=/9X7+AOKP@V&
MN*^=&>FVJ9_<35:') "3)778%62>?:+692MCRG^PCR.\5\?QMO40/T6<P CR
MO;B-W@7J1TW-@\HZ=MH^&$-<*48#PKBO'C4*&EMB'\B\8!.K%< Q 2FGST(_
MBD]L,-@FO?%:D]Q0 QTV?;N>G<PR6R<>R(FYWJRSJRQ?$'L^TQ$P$^#1S,B<
M6IP?5UVKW5+J""3?<002)"O0 G"<%UZ_0%T.R*O_>R?^4?& ';BV!<^P%DUP
M$-^0@@<2FQP=@JM]_I!8L:P&8*?[- +28WYR;.%C.W*ZU4P[GW@ K5/#7<JL
MZV0N(GU[ ;8>IZC%3&9NN]*=1F3891; E<&<F,S%CG)F8=14YOH9B ]% O,#
M Q3--6OVD]8H2^@H6[,/ M0 _"]2#2!YF6;ZJ]VNTN=*[Y#4T;S'^\7XDI$@
MJ]:;;J9(RCX%#K8Q3$$-/CH3A[=ZFC&OH^*"A??,I\6<SH[WX)K; M0CH\6>
M_I>NJ,+-G;Q'02DM++^Z+1VACO7\L(9G6[78OWE]:X^G%1CYDM[S*WC'Y$D7
M(8;GE,]OQS0N+WR#2DY&K+U5;2%!ZX[U8G9+0F722N\/5=MR1#D]"-7;')RB
M9#BH?(AWU,])10S+-)LG*3P<$EQE_*WY1; +CER'=Z#$1*<E;I/C];1>Q;EP
MWEF2M@B!L_*F]$5O"U0=:X' ;X2G.GY.+S>C>'4G0VKB=#_[+_._O<LF']4U
M(LKI5[>M\1,-ML-+*0SI(DWMTY5+*(:&%$D/\#WO&2><E"\D\O*H>$*3<!2D
M58+WW_,4*TJ^+T6+9=T#L#B06D$"R5,_!F!W$O-WDTF>JBE\YP>)!2LZ?)N+
MVBNLJ4'9BD%>)PX.4&6/^L%.VN_3U._K3!7ER598^CT4ZYXC(' *J]R.V^NL
M[ 9S*EC">"YV!<:9V9;(?/7_2!" 6=\#A"M/5&:[AD>VF?RKZLA(RF^(/?>]
M,OW6BW73ZDUQFA_3%OG.=+R9MU^3P399AM'K>6M;K1B$C[48O6.[*9W[3K@K
M48-UKM<Q2-^0GJ0V;0&OF9)PX-N3.'6=5]^GWG0YMD-#$RI2O ?$+0KZ-UCR
M1Q[-LS&M)2HQ:*#8)@&GGA>FPJ YLDRRU3R#-DN<F/< L- ]P,^R:V,O +C3
M\ '<,X&$82 Z#,!UJM%_K<#Y8PQF<YB=J<S= QC J1!_,*=I[L%1_.*KXGHS
MYE,(XPV]E8_;#?UB5@['4-S\C)%FDH_64')!T:BT"M?)3>8C ?$6S3'"/MWG
M B4/XJKC'M +!?=\ !]!NNZRV*GO OX$  7A>:=12$*UTX#U;2^0A,8]@"GF
MZ/BHZ38RK=+>45S32VYX7WQE)?W:?]%=P_97&$4.3_73I$Q@I'Z=[]HG8!0E
MIVJC-H\*N^8#55OEC/JR0JLN"<F39P76/]D<V#>CVC Y1B8946*C5,S([X\S
M(-V9$S(B[%H9DL //,$A]N^80[V.9,G;--8Y6#<DBEE28_UL8H-5LXGXA*?-
M*5+&VH6SK&?7^2O^X)_&0NEE97G::#J/=+3U >+O\+[^63OZ$\\OO ?T5'7M
M9R.IP6M]KN"[#9Z533/;>\!&G<16=-?9T6MJ#_!&)GBK KRYB^A* ]^UWP-^
MCB-95_O-[M9J<KH#E^\!C$ZK\+W6>T#Y^$166M<&Q.5!,1_? V"-.VL!>%[N
M?V7H%P\H;KE/8\*,M!W29 ]T^,UKI&5C+=%.1&3/&.,!;U+VIOEB_9XN.MN$
M8VI=O6W)%'FN@J&K43I=:=%4W9^SO[,:E:V$&!89\3LDVA=1N<A8,NI]KALC
M%(=IE"2T0 8/MQ #\0=I\T8G>\KO:2G$OV_X%J_&,*89TL'*3O);S$7B9/6+
M0-?@2L:<R4"# 7W_$3L#/RA]7*@TB=I,65F8PGD49<60;' KO"F% ,U VQ[$
M..$TI4NF(D+VCSLJ)Q7@[X_!ZY^^N[:D52(E]T5<^E34-K.<79>LHF4#T+1H
MULKQDV4<'!9^DM*Z,W*\?@0TSQ 3'_?&M?JR"?T2( ?TY?E<$">K%8K$__;,
MGWW9.R!HEPOK%RHNS;&->&YT*)(*O:#2P>,5,?P!W])\[C?S !4IK[[L2E,8
MU]GD6;2CF1K2:;;?-= ?,R+4&-%K9$M]N0O'8MFMT<'M=-RU!S*%/-DB:IWO
MF'K$5)3SZS4J7H@NW$_B1K<P))?M)4;I?F^K!RL'I:MS-P/T>LWL5&L&)>Q#
M?..>!234;#1K;> ,=:%^\X;7;PCWM&>BS^C+39S/UW2QD3!<*]U$?VZ&6MV)
M",:8%VV1^<7Q[4\RM3^+LA*><;&8>11F<B8U1DP"LS4ZQ/ 2!GJ^\O,JJI^+
MSON%S8)5= \T6:'DN(T7U)M$FD[2H9-7E\0[1_\'VPX\*HU\X+^S![%(>+0Q
MBSPQZ+*D>GB0B8UIB(M%,&QC!Y(.WH!X/O#C&1C6M-LA\4N$NPW,UEEG)Z>3
M5GL;*9^17&I#.OQQIO!.MLC"'?XX2/(2>.7\8&P/=4U)WP-TT_(EW+HV4H@7
MF>^,@ZLEEAPFIO_I<AR)#+Q3@QVNSS%F"UE8AL'OX7I*')Q:Q(NWNN%3TS:[
M)X5\])X34^F9=>9$NJ+).%2*GPO9;: A:(4.>,EBW]HW(1-)%P?RM'F>)C0G
M$RH.9UHZ_$+0:DDJBXW;H./K\ANMD"<I:)CT866:#;EYI1:2TLH@(THN! QI
M?P]@#^[/O^Y%+'N_V%]IQUD1P?T"5VADP5U+]7?TJ(U8::0K"O5>3Z2+XTN-
MDI!_=#OLV+HI7T#B2A'7[/E9]BIM6>-ZR'Y; 6,#4P3'U[H?_)2%$L-%./\L
M=>/%8L\+4\RW(;EW#:AZ^[BL*?S51I(@9K>+N,"+R^4#T^R5:]S>O>5YA:L6
MRNFF/30;T>'"BO"O'U.QPAEP*"94*#R[Z1H\91/96#X>.=LNVM@SR\;*_,G+
ME8!M^.(GS"2Y>%*N8=*9#_?D)<_@3R0<,*O]YP%H'9^SVGDSKMOG<"M$^OPJ
M2ODK->K37FYD6->DBIGBT6__+D_F8V3W0HK!ZJ^,.1[]"'N02RGO4XT26N+,
M^''5P!"MYP\[:1NYP2'@GK": )]''RJ14OP9NZ/BQ,11Y=^MQ0TM3/.;C /Q
M>QF--[_%VI9Z\0@[4.Q:>5L-/;!,K!P\Y1X@/MII] @R N[QKO%3/IPNJZQ:
MF*^(&QIK-M*+R6)4XL=Y,W>3X;#@*.S(4N;(NN%K0OHS53X]?3GYX=,VX,$L
M2\3"'GAS '8K!_^HYX,KM_GBE;_WE_;^ZHX @F#8DHJ,":02@@WT!)&*?DM1
MY^11M$")A#_F?O_LB7K^PQ9O._]7QD47)(KJU:Q$IR:7C,R3]5$4=:'PXD:/
M7PZ/97R#%L>PF'3Q<(<S]X"_GP+_X1[P(?Y@JWB/*]VH L96[%B][KUBR(6;
M1+HH=#>K:</C2/NAE[.,^/7T&M-!U8A@0)][F5@;,/ E[X\OH/"/$EQX<$1;
M=%!+J,*7U"[";H??!0;5V]5P4 M7BQSTU=\F>^XC+=1MD1;@EU3AUV)R+7ON
MKU!=UQU\F"Z1^&0C?$2M(L#13EEHK^.G0]K%Y)F$2;[!$>Q&#TK.^O3YIJ$2
MM8&YHC9_I)E8=B>2+C!O]1XPTMO>S*BJY:9B(N8CZXJ=R,^'PYZ0.4A7P,OK
M:W]V_8.@4F1&@5)<%I.5#B9Z6N_WUF&VD*P_#WX!%E_Z'?M/0/((O+'JS8.3
MI.WOWY(<?)H&BDN7M$D6VCA2%K*"6=S;L]PZ)#G)*1.YY<=4MAH2-6889CQ?
M?JGA!7R5&_D,"QB>NDZM>LU '#TSP"B:X2A:JR%+]<9+[<N^P.)^,&4/BKU4
M2ZY7=6:FU;L!U*TG>\:#A4C[U4&!ICI>&:XQO,UYR81BF\J$7;HDUTE8O;$L
ME!_D.@0Y+'DT&C]K7F9<*DUDHW"B9.V<L_,>4K#T1*@_P^CR$1-&V2#;];M!
ME'8(/7AD+/T>$! #[FFH/D\,/7X>$QM,<@]X&1=E)MH4ZJKZ;M]0M,F'-"ZO
M8D7,Z;/:SX"DQQ?O_'E(AE1;:0WX9=E83?/#]#1KM5L?/XE+]].]3=DX/EP'
M8HHP4$YV2'P,DZ"7I3('T;B0'U1=9QXL\;-"52F==G$#6X[%WYQ[BWWR%_SO
MSC;^!S3""R7&V%ZK\E.X_PV[+C.1C$[BL V/CH*TFHJ:5 S[V;AH1:TT-C?;
MJ_8:;76#<,"?U&!=&;FS>J1&\O2X"O,9Z77DE-88 P&_A)?%[CK'<R)&QLB\
MM11,"I%7;$^)&)[]<1%:!9 ''.".S;]Z52=RZ[XF&-:S3UG9?-4YN#R']6UP
MPL:=O"J1#.$J&YF'J?";K;2,-I.4,,5W6?_MPX^]H']76AI*?%>L2^3:U$!\
MV[$I*XYL9SUNWDCAY(E5@#&6)C05*[QY*ROO][D^=^I=5EV4<9Q/+%/RI"0S
MRCL"Q^#O9=^?Z82CQBB4X+8A51H;-.\!0,CF;%QD5:HBPJYG/&8&3D:RB[]5
MDB!0Q4W*'$YP(F1CKI/\3/)%B_@5@PI^ 0J.@]03?FHW4SU<8.$S3W6GV(JN
M?ZZEXG_*0O[ #/A2W8Q#XGCC]]'=AKW8#JA^\O-59^,LIF6D;V&8_7HF:8%O
M4:0V 1M[R&A%\:^4]S0A['_IP_O":MTVH(K' &?[1-IK$N1MV-04V!10XGD\
MDK"WOP][W+!_W?*^= %V@6/I=-S/R+57GE?5:N9?) 0*TEE'CBNNU,-IPY;)
M(7=$EZ8KU;]SCM\[ZH-6]J *N:,R;Q*^9% 69<K$?O)8YQLNS/1(2;ZTJ<HO
M K$=P?9D'"8RYMKU@@XS XV-R!M.3<PTY,24,[ ^!T]_.^SZHI#RV+W-QCS;
MXH2G%EV,L?'9+, HR"GW^:\#L+O;]Y+=E8W]SI_0%8=Y,;-F03'9[^3$.,VL
MI>6"A(0P6WE@*>M:>8(YNCZ,P587#QI6A+'RR<B9S.MMQU'9?Y$SK*)I<&CR
MLAD!-&O^G32DP=5?_9YDWXJ8_05IO4/C[GB<5JG-\=$MY:.O/DZEYONA&58"
MB,X/QZD["6>/3,"]U)*^&P2'^Q@_F_-NE=C [P>,^&Y1O?YM[$:NV[46U1&Y
M$US9^Y!PV$KLX[P8?0.1F%F+?3,E%5CN,2XZ=C--G-K4)8W%H$.Y9_@-)MZ=
ME@72-/3+CYG:I"UU</^#YDPJC[V>K86V#:Q#7E]44O)I:P?Y367KU4)9?KV)
MH8MS^%G*0A_Q0C"!R,KP;2Y[="XN26S0Q\--08(OT8X&\Q'BUHG^8F'<!,!H
M0"Y ]!WACM,EI.0?*/O\ZP*,%TGT-OH>0-E)^_)&YI3:L_WL^I42L.O(66P8
M.<;Z:GS^<0F\]![ ]1K/0T5@M4G['H!*?0JJ<>O^C"8[<ZUR?.:D,XZC8KIP
M77]R]4A'2Z54CB'=I2B\Q"=.'2=O@4?W)SG^6[P:8AY5SF9RZ.O<@(PYU&_H
M*7%P?V+G8W(C>3JF(MH8A8NI2(FAR>)+I<FXOQ)0;?7[JC<%1N_G8"P!)I6+
MQ47>1^P6D1!<@33F-#N:9U@5<[N@VB[VXB5CC6NO?;K*2<0N;M'B#/B%_VSA
M%1,3=M@2)6FCR)6GI6.\R$RO1FA(%$T2'H5%9F'#YG@$YZB18@[:NP%M9G[X
MA3IDQ,W73IP64708MWDU?W'&^8JMI?Q*3VVS/+Z7TN8-X<A+;G)[C>RO?2J:
M94_D=QT82QZ/<R;)=)>H#O+'2)_MF>.Y>OT'*UW_9D%_*XPLW*:D-%+X9XY@
MF"^3)%!$$:NNK@8X/"Q/$X7??57C,-LVJ[=-? HL7LJ.T3IMAGM<BD((D(KK
MCKA>+D&->@+CB\**+:E3C8];&A6:8":.4:H)T^,QY4X5Y_%^NT!#_<UJC]%G
M43@K$N5-]"KZZ"D8MV[1>,#XD8TYU-P7%T-2!L'5;N"2G$811_SQ45RBLVZM
M3"A#SOOJ6+-Q^K9@[LL7$FOC9^]_CXW!R&_>T^3EP5'#%^E$1*X+T/F&;$[2
MSQU%%H 1].8>[8$SFGR5ZTAJ%#F^4JOV ">W#BFWUF";5%Y-EQ&?/"011V;<
MK\2P4.QOD?DUVPI-0VC%1Z0QUYCO]@/=^?K=DTNA@^IX1CS.G-US'="&MP'W
M@$J?L(75=GI/#29IM\.Q@HR2)9*;0>.$JIRR5 7:>'0T?8RV&N#7ES32:0)U
M!H.3RA6QQ=$56#7B'\CP9V*PA][FK?_%@@AY(FX>*\9V5SN=_?^@ 3YDR_T>
MX'H ;[\'1+8O@V]SJRX9-U;A;//@<6WJ"W=_QBVUOP28QS#!ZS&3KQXP[15X
M$8J4 /_J6X;<+FQWA ?-/=B>!P/S>'?Z<?G!KQ_^4)9P[KH W;15NX]+<_Z_
M22WC.A1/W@7'!X&S=[_OSI';U7FCK[^33EDT*B?)8'DJ"Y(19?R4F%J7_341
M*]U4^&>"KKRUG'JW3=@O\5G@N.L!151W?+S<_JGH$R%Z#$KFMH9(.+86L(T*
M^/59(.).*$XZI]%[OWKS(Z+['I!B>[:4?8N !FB]O>Q2U?ZAX_J@CGQ !79[
MID]"@D<L+OKDVM^HEQ>"^&Q#)0BEA%@_*C4D\4T[?,_2$Y5M:C^78GV'E::P
M('J=29 B_H8/Q!#?LLL/2:V&FRP$%5WT*]@V!]Z\)8'%B91//-+=[>U\? \0
M,XM99>-IZ)!<GG$YT=OH8PQ<]&&<O8LPM.<FQ<Y^G)_I:*QJ62>B@?YZ)I3Z
M>/2#-JR<E>\X:(]^:)]Y3'Q^Q9GMXL6&\>(S$B4J>4W@4Q9FPN]%95,?$@R]
MP+6>E4W[*]B-(6_EN3N!O8]17H^Y%TZVK!/MGM[U+V/_=W?O^=^/0VPT.T[L
M@L=3LTH<G_SNNIO:"!KM/$+H4I\-2_2(Q :U(;_O(?V-$*B5S7>])O)_*T\D
M5[&&+]/.'.'5\Z<[%07SA.0CMNK:K098,U8>UY5=*NS*F.B\DA\K9>AW8X6)
M:_,W<B"!-)1/S<:NUL/L/)UQH*>]%62!;DX(]XJ\43UK][)RS6L@L+%"L4&$
MHN$V@(Z@[E5\A!JC9U.QMEFP^_:/?$<R:O&XKM[J1!*W%#/J2PF7]3Y^3L>V
MA)K%[:?*O[H^;;]<L!S4^MW.(\VV4UJ"#2(S^&E;SXWR=;9XV2O3RU[LGT,!
M>+1QN2/J/RQ/&_C\1&UE4_W9PU[1*J?4J.%H)J>2YB48"ELF8.K*:E9@/GX6
M=*"?5\I'3Q-+7XEO3-4X J]&A KT!_@IG&K!O=QVCR(DZ%ZFZ+R*_>1TL%2D
MN[P(@M46QB'7REA(V02R390_T =U99&-W(*M5*O9^XTVQ[U,23JC?*)-%C-9
MV5'E"[;+<3%2[%=BWHD CBABZX8NC *R_/H#'/%CQ,UP5-@48_FU#,^?(?R1
M?F*_3N3\-1'VR+<=K%_:1GPMUZ,H(X[NVNM7['E>3L@F=$JSQ>2>3FU"-RV@
M=0&>A[1^E)8D,],,N;U>EU.+P=$KI^=#0(HL;W\> E^4&?H[]F0^HAD8)5W=
MMD%3VHO%;R[DV)@I"G*Y:U(GI\/:VA-ETY5I;0.--^-MWMYL-?Y)P0?B _/"
MI:G.MMOSK<.!=Q29R=QJ'*_:"@=)G"+.ATC/V\I1Q'K34K5<3DE*9&-FT4P4
M:Q!QFGS$^,LTOO,&JM*LC_$O8S_@.;3]2UE2?Z=4F'K,RLW99![1@/0^Z!S=
ME]LU^9AQ7;VL_:JD3@M-JPT<JJD44C%K.-?&IFN=R%NBP_!81;.P%Q]W5Z[M
MRM /805O1A387I],);K&72M#!H.V6_#T][O6;D<L$$\6@X;"1K6Q U&,JWB]
M;&R*!K=9ZG@<2R.K\KD8H'3UO-0:#_^%7UP4O".K-9@/X;L4!(*U!L?L'71/
M9BMES66S0A:.G?WO(&'#/[G/UBX;75]D9&;AZ37O6(>$.+*D#R@POGK]H<+\
M]D'T>_[=-Z '_OZ\Q#\.#.9:32,_"P+9&;N9G,!625XM\OX(&/?>C[9='W%9
MZ.\>%R[OMG9BM:WXIIWQF]7Z=&KL.9PVXL(QY@F!1]5O3PL_+$F^VHJD'@;]
M#2]<_O>R6*\MI&2=OMV<*W7I=_NXT"N1"<L7LI@0168SS!#@".%2A59T#;,5
MB3B9!SZ[SIX+> X5&;%Q0PY=#TW!<?M6R94LUII6K"0T.*DRBTK&K'=^TU8.
MC\*>*['Z9VQ:T;<G02.X/&-_>P:!W2FFE>CD/(5B3.5 DFLO\\,86')1";]2
M\H]XOUR8[SF1#1_'EIG7T&Z=P-%_A\G/' ?=';_[Z"_QK\)G.[47U'?)Q"-J
M"&&1!Y3B1X;G3^E\;B?V[\(%\K@#NRL=!\OM3#_V@TK"EWUM4X#0_"')VYG&
M9_&6%;EET46ZXFWHC_*AQ9FL:^9DPH11MY-$>^;3^6OGU+2=(BC7SS_#I:?.
MK8Q<]F,"E>9)@/9WJBQL9:98E =*6$YL:,8S&>8H_2G"K ;J 9^,>@.[NF?4
M-M?GR)D# Z5V,CD*VE[.W]RE_2"G=SC<#Q9IM('V6[NG7UNE)K;EK#D:N'Y,
M&HQD#*^8)(Z87!Q)^+&DGA,[T'&A^E]4FIV!U-&9"8(B]NX!V4>NT\EEK]B\
M+M(4L08;7\IV:V_4I#PCH/^(BMDDGHKVU#%\08%]2F@]_=GB@5&@'1%!A[BR
MSON[N DK!W>.NW7LB6]=Z9HE\&HCW@#4<^:_?..'%9*P+[IHOZH*:49-"4R>
MD5N&B/LODG)@C3 PZ2=1)G0K/@IG#XWY3JPY(SM2/D62K1'K1R;MPC@ZTL=A
M37/S3.<3]7D'&CR?6T22_*U3>#<U'0GU\46]1(V@U#_CV_M+D%*[ZY<N^%+5
MC*#KQ-R'"WDZ3^TQ6T]]JB]Q-LZ,\!<O6/64V/@LL54''C"KC.X$@N>Y EWO
M =\PIU=OQZTZ^MN;;U,$$; DI+@_I2'8&O*;&(&:=S0/5OQKNFL9#=([[FX=
M>NT.4_TFV=4NY_GE"DR 5^>,RZ_4%I:"4Z^I7R;X**:J#(=ZI"2O3VVD?"F6
M+X* )8$^ED]_/9;_25DI.]'K&L C<XSIY1N[,D>D:Q?%649E=GVGZ8742.Q!
M=:S.'*)3BS$F0D:YA=U%OS*R6J/59W$>[[10DR_2;\^D.D][<@"B]F9%[OWN
MUV Z1,SB/8#UAMC:>XL4ZG#J!\2/6FD1\0O\1/ZY#U@L&QVZIX\H5%'51_<W
M,$]^7[6RC^/ODJ90(FNV<O,?'"(W!?8^C&8:6&A/\W<UG#M9]+'_R4N>)1:?
MD?("2Y1(-$6'I]:R[/';;P<CCP88'BA"NAO6-@M?M.%93@J!-/KS>U,/+&^W
M[EYN/:VQW]T[Y>>CMJQA/]-1/6;$-=K/*4LTG(/21SKJ,^EJEX+)OL\%0U[>
M4%R DW4:_( BRK'B93EM(9V96 MD"PJZ^:QY9:]/E"@B%;]XT+.QH4@^?N8<
MU#I-^:=:; +CE'?M2A+1L+?[O0:.^</(LZXI1CY349Z7[X#(Y/%9<:A>Y.!T
M@S"VCKW1(S$.94VC*?T\H/)E]M:>5;J: [WL^ICJDW-S1Y+ </I"O5LO\D);
MU@D1"/WF&4:X^ ?UV,;"5;/A/7@$&'@PG7ZXNJFS%)#4ZI]H'&/KZ8NP6"EM
M51S*?TJPH"S2(<X%&J2)ZG<LU2/-CGG!8C^56]\VJHO8:SCKX6BZ?1:ICE(T
MXXL:EZ-H?2RR#F7XO?LJ*]4'5]]*8)HVD4?!R8_7%)4"-2BW7/V1[LY!H. ]
MX..C0-=#YY$+P1$*')\>)*)O$W=U^&<[E6&Z]SFLIC96_KMI56*L,HY4&X1#
MP#0G@X;1TG XK?62?(O:B4L =A/U@CAUPQ&/Z.GT'0M':>!$,Q2U(+L@I[+:
MJ+L-?<'<7E/QO=GY-PZ\H7?B4E_\NQP=,QT7'/V'1<*!OX$_(XM3RS)U<H2M
MLJ49$MH2JV(+B<SE:4)P.OHVM##ROO+O273\.Z$=?0_@C;OU<1M;1>BL/$B>
M932?6BZF>\"0Z0C2/_<>4!XUR<4#'A+?1MHKW0,H7"-6$<SMR&6UD]M[ "[G
MG\$6LV+[TH<#B#17\4'P[K>@YZ<8B$2+6YN'GU;#8 &Q_J2@'@/+$%:F3/E?
M820K!C8IWQS+2=IYN6MTU#$9LA[]P?U^/\PDQ!FO,!Q^G,^:75[2"W;^*J\N
MZ->D"'*AI-(Y<?*/^PD7AB91)D[:L="6V6;C;Q4;Y&IQ=:!CE"<#@?Y"*U?_
M<$=_BFEI%>Q&(H(^-%%\!;ZS,9H(?#JTC.7TCSHZCQ-5WFW\ 1O-%\RC>#'9
M>U]\.+_N=BXLDM?['#B6+?CO,[+738VHIQ_0^5=8E,8R#$^^&;,M+7#(HRXW
M#9-U0<'3!>K%R5AM=YVF7J<@OG+KM')V+W0M<6X0.J _[_"_2820?HZ!2H73
M#1<P+]KMJ /SPFK)]']Q)H/X8GMT2$^;Q<Q."S0Q9HD"\A*+><VX,Z'P2E[%
M$.X)IZ!-)U5SLQ\F7)M =:&2%'M'<=DO*BR>,!K*"\221,(/W=2X6O.1P-MK
MQK@"?.F6WQM5I:6+YUX1],]@IS+)H\YG\@G0$STP_M=T/DDE41W<?DP:PWVJ
M3:S>XIYSR+OI-Q_BT3 L.\ %Q8HS*>8\.(+DS8P06.5F*4*J;<(Z4<U=G??D
MA2$ E<,!=AQ(CW24P.WT6[=W\(^J=3@VR6:D2!$V3=I'_^3BZF^E&#Z=Z2^;
M*<]S/HGQ>,9J%VBI0S]L&:1183/Z.:G%HYX:&IV^)\FCD\]?R:LZY=#]3H(S
M;)&+U^!HY :77[-8X"#^;97HUVI\C;/=_HX/;?]=*&>G#=%U#ZA3@LO< R+W
MEB&W8]9W#^*VT@W!T"WEQ3SL14PK6*+&PGQ7@I- M07V#4NKI4HM0-"7KB\F
MZ5>I(;X(7F,8N0:$B23\C7&]^U$B41UYL8FTNGQX0IY\M]NUWBVQQ7E\9D.<
M <P29.EP!F$AY7=)3ASIRU4+7HBYW-TK#]]1;R?R^-[-'0</W\^-.*:\K#%5
M[QUS2TNJ8_)S,//?:LH7Q<R;Z#\;EJ<)/?B>OF=R^&%8]Q[ '@<)R%HO_ET)
M#5V/&W0<QCK\,C(KFM@MQV3H1]?]_4R!_J._2%@6?GQ"N!U*3I-E?'Z LW>F
MUVUP_NPHJ!;<+&+U#]P=3D!<HT"S/,CUYJ#RM[KY8@">Z^SV*58LE.% M<UA
MY^</J<RRW;2P'#0&]$QM39F[G4Q0#3\92)F2%[%U"L_I6>"^N@<H]L[<,2^
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M?8'GI]%?5R_8J+,7X<:N/IAIA2%=1!F]LS))A64A1=)R8F)OL(_'L",E]>2
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MR;!86R<1[KET>Y 1^#339#%!FJ*_@O@C4;A021(ZU3NOIRM^=+,>;F1DBZ/
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M;+=/G!8!69#@\-=R]2Y>N/7'K@AOB;EH+(#>9G"3E@E-P"9K!;S?-U8T3/%
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M+57^>@==\='5C@Q4+'U8?J/M8/^PK]8G$?QAF!6[ZG<QA9]M'\$-D;*JN-2
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MX\<!HABT!A[*5@Y,SNFWGH^.=/=/\C??["+TR:DX,,E0*=)C\G/JO0PL+:E
MNIOND#P+35\CWK<UWV#42 #M +J%#M?T*]>"?#E^M][* F\O:\)_#>?^B^G$
M<!].]7YQ>"O(7#JT&#9(U _BO>I>SV^A?\U0_=7>D%'/H;%P*Z\DP)JJHXI%
M2U*6VO35#Z%L1;+]94NA4]Z='3AU/?AT/ZL>>V E^B9TUH>:O/CW476+<S(<
M;>6])Y3G5,>&R9;>80.GAO<-A^?'[6<:N<I1WX$,81*:H04/'^0R\OW N^F(
M-1/6MK0'3P79%7K(EUZ!C2Z=36,Q5>LIBQ=3-@BE8W^HBD:4Y6659D1D$ZI*
M4TY.*78*/OJJU(4;TM^VOXS^]XBU#*=-VJG#X<L)TMQJ?OQJ\]_:C2YB0\.?
MFE;K]J^&0>>A-EN.#@2%U72O-6*4-E/(?II*623T<19EQREI>)1#BP+/]![<
MEJB;9B0 XS'"/I4F^1#1?WS85=L&@FL,'95M';9$#=IB=B4>8+;6N)#I4VG!
MI(1)D@1;M28FJ;@@$"MY26*.CR5>LTUSV3NKH\!">-OO9@OGO*.'IYYE;^IB
M':].M?K(UH!HH+*\MCL%6T5]QAS@[BJ"W]][\1A.<?+>9[I_4=BRI,N+[!7Q
M_]/\  *R1 +X[4+ K.[9]H??K\\J$99S6/V!%K:I]5/W]4L^+^EYZIZ;;[K$
M"&%L<S1*\/8H9O1,3 E) G6V0[)[<&FZY0U+\L8'^S->/3)!23-L/[A4_^7>
M[K/U9<(+6 5BOJBW.+!M[;;QNIU/%:W6]SG2,B=C;,F9"M*2-)MF#LZ22J<N
MSE1X9T*-!2CM#CL0HOXLRS2S-QWM8?3_ [Y94?U?._?1H[UL<*%[!R2@J<G'
MG82_^A1LL3OEL:KZET)\N *K0Z]M#QOKTHUM!$&'G=*44UVRW_*F:;A%/MP4
MTULJY,H^@SR%!>0EF^<'EXSWESRZSF*:Z<P7;75HIT"\ISFI)8[=DI>=F/,!
M#,U,LAG]*HP510S1*%Q,::\DXY[A8%I-F!P [I:^Y5!<8Y4&W/KXY8Q"7;!U
M7-B4+]M<RGFY:6T9R>/)<78Y$PL-$_!B>Z9[YK7-)843>E1S"$E4(=8Y7'@J
MXQ)@!:4<]G'N_0X%A#@<-7OO:%FY+!B#50+@)<ES7<$T$YRO(SCNTZ>!!&Q6
M(@%XUZVH8XB1VA+WR,79EK\?/_PSWOK7. W$;@(V\WOOD]=N(8G[W"=7Z-!*
MT^I_MT\0Q(?79BF%[M8 ?OBSI8U"^S2EIB[(AGE6  D@97VF-AA#KFWLNRKQ
M^-I4]-G4?L)KW?L&)"!0S,?H"4(NU,4O;\+N-@<)&);8>PZ/=GX&UD("&,%?
MM9WCZ0*8(Q58D0#CZ-3@V-JS1I9)SM\K8I/4\PF?GCP#? X)-59O+')R:%AB
M/XLJWTSUNV63/5!$LUY[<O/$VV;))PDVY17XF^=O6$#]M4-NEP>GX<>W]J0$
MTV%-ZAM0\LWBS+UP8/:=%R5Z]93VHR6W#_Y!>!K6&WNN.5.66,$08;+,D<TA
MNTHM,13C>$GT\A-\_1,.Q&BZD <-IVT"EMPKK@\,FYW:\+>(U01M+H]_I6_Y
M[Y"D."'PE$EB/1UO,G$E)J39O(_0-D3QF4?KF3X ?)3D&YWF77".)CB)'EDQ
MT(VAAA:<+]5P:% 6%/*B 2YIJ'?'?:ALFFX+$2HN0+WZ!,C1?6V]>>K&VV(Q
M1TVM_=:1O*A->E9FKMU&EA*+H'FXFNDE-6)2+R<8Y7/Q+G@.": 33[F-]>0(
MW/*1!0F;&VV0KLU8**;NZWSEZ!-E,5PFJT9G/E)!VU?DGHR/?JH:_-Q*8L4+
M:J!72[P+I/6)UQ^&W-+,C,X 0U59!3;Q%10F#7@C.#FIA+03LGLM<F160TPD
M9:5^MKV(T4PF*N60S+1<$]KBWI^@3:\N%KJV38$%N33Q^-S"H,R**VV8N=.U
MD=$1IA<3D4?>F\DLCS\^>:08E6M/B6D65;EES"1\"CGY05X/7]:[;KX8_3?J
M*)^?=+]TR0?#L'@KW;<;G>WZ5^KSM%(CFRPLB?'A8H+6 44O3$Q4^$U])2RY
M)854RHMB7*P02V5*);5[_:MRV%A^D5M[\,[\PSR["'WJ;:^4,S^3&56;+OD&
M>I_/;>N(%V55WI//))PN?A""CE)$##^!UI.DDK+R)VK=EZ(GJ0+5=H[NN?^#
MY 4O?&Z<5WQP=6NR8H[K1W4UM7A>.)Y&V<%2BE1$YR8*A_XAVJ,O&*)SFJU_
MT(VA?E[I.[!;X&J>>Y>RK+RF/)#4^.6TDJHP"[<JBXRTH*,X?YSKIM@S75+)
M%SDOA=Z&_A$E'>!]Z KY(/Y6N+SYP7)[XI(^ML=ZA>+VU=5[OQ?6(<<*#N/-
M.+AN))S2BCQ,(PJJ8X(7 <K44&YVWA.R;]C3N.>DUH2SI.%5=W9&AV5]^S\O
MR;;GF^N)WZBC)F4QOY%8BC.!V%<)"W(4]W$I40Z\*#B5*((-DFQ,/E5&S:UO
MAY;]DY"'!O:G!^D3>FL>3M9YBUSD=1WRX^84967TV[[@[XG+D.IAHNC9+I0%
M&>%1/?&"0,=:._C+'J$LRMV[58*#+3B[+=$G/+22CI15#<X^B4OP8I:M0F7Q
M<8K#X,*468F"#S$!MM:N9R 2\'7U&%C*9C"#!+#YQ!''%M6EF]@4_42YW!T9
M'MFBZMEBR'N-O5;[_J=X]/ZIB1G4-YWF:TE,FOPR=XR 98CV@M>*))R]>2%G
M^#6*Y(8JUM>7T&?6* 5XC(-H/4"CA]C1CHC%S#8U"RM7BY99\<M3A2@KJ=>G
M*)2UJ,65")55XF;>=;8.VX";\R7(G"6H;__X(OM^(V_Q%CHR7GY=[7;$O$4>
M4(CW1GO,>$]Z7BR!.5VUO6$_S271S0^2=K:J'D@7F*\PL1S5&Y"5/RR_-=8>
M=S7 XX%6FC=9RCTK67 4/:<0)9CH!C5H^^&%QI^%O6T<V>KMB@2PMM6:G$]T
MMKUK'&QRX=&O'[4-$X2&"889&EI4C.ZA%]9\ANH"LAU(@>0_EO60@ =]$>)U
MA=1UW:+/$.<7-E.]:016-IFWO.+ (16E$7DJ*:TOSA(<4!8!E:2R%7J;7=Q[
M%/YGNYNPY,^.#&P];6E/T'<Q;7OIF5-<F ^#CT#WF^RJ8!1Q#A=(0!\=)>&,
M)&9VYY8.XBI5F#3J'/V0>$H6\]&DW^1(V]LI,*B._.F[!T']\-;/7@@>:0OI
MT_U/587  ML3T8E7;Y,?5G:EUO%<V+=L0?O,7579CE1L)][-5B=H<(!LP<0^
M7R\.K*3@\3!;P40E]S9RE[VTSW8QZ60\^(-D64NMXG-<^3?.IC1%7:9[ZYJ,
ME>_YW_6&,HA(:LO+' BS9E3_F)@<<LV+E@LJ5U-[F&_^ZF<D@/(ZOYMU8_3A
MQ>EQC=_Z)@VK*B<ASA<#[P.^AF6W?+M@5Y/!5V/BH-9T&*9H!2K&?^EWCB"@
MSTL$"E#"_L :[O\1U@ K:]-\,+;DG]/?^01O78_*&-6A&FS&NWA/[L6'EE6S
M<.WG3*G1"+XRY#@_26^,[IENP,#35(D22\%N("YG'3=(;#%,SV6#B4O-^.85
M@2?P=GF;'5,#SI69/[U' D3D^DH9E,2(TK2^D"I/JY_U(^STA]PMPWO@36UJ
MPZOWTF%Q10D9 B@:!;1WYO/?E29_.4'Q/&Q-QZE]+;\[*^-HOU<YZ2S(>GOC
ME-8YO"%W;/5+RF==1)#1-48%]0SW1=4CY72%S*WAQ83FNOU((G:$'UO&KV=R
MZ9Q*>6!6(,;RPQ=@L/=: P=;)>%];:Q7D3TC8WU=^*?,,Z^M-ZT<CK"C,77%
M5@9S>7[U3@PQ*S'3II[M4SP-_NC[D0D),%_9 V6;-8; J#K>*'2<YF5(O7J$
M5^9WMB=:WL!@B\#:>A%_)'@1K\2G]@WSHU#N$^QT]8'3U2TDH!<<+^#&R];G
M?3"GFRO"8%&T[S#WXD=/7*96]RS1YDG<QW3VT.AX)*!>7?CY$DX>S(;@:!%S
MNQM!NL2&4_A$X="2R+FBJ.*VD"JS=[5)^ZBP;$74(?+KIHHZ51"8\M%NOP?]
M_XO]9<>AMSX/ODW"6>B#<S;;#+Y.'OBC$D+'F^GU, &VJK;WT)IQPE.558H3
M[;H\O+!!/2)&DF?.H@3>. 4G:G1W;ZO)4!L]5CYB#D>=_^8"Q^<A >R[3PX+
M<DO'+QL?7%Y"_?/+"Y4E@A>TL,ZMJY'-'H4='H0/L6;@L$$59%]=7E4Z^F_U
MCJH;\3PFG\3?W@6YDT/+G!FSW1^DM#UNV'] .F[4D_6XI3XYODZ>5;;2$!T#
M7>(-4W)'3F6IW%>[=8V)B*)+]AQ(.!QU:R+R,/ GM++L-7?04J*UW/KB+3_)
M#*I >-9/ R>"IIS2O**< ;%JY:G)84+SK0#S5%)2C6*&IZ^PZ_GEQZ40!H1L
M:_H8("E5K_[<LTMO.^(M*^*'&;"/W]RB)K4@V!$LG:CI[K:DFGR1]1FQM^+C
MN;P=K-%)A/-5W%[9FO16FIJ\SLYI0P87DX_3[ ; H1Y_90+%[_5T-<G_)1DX
M*X+R3.,QVEM?5C3PGT8EI6X(1;C'(?;6Y(KLN?:Z+8':Q8J<8VK7-)?[>E:F
M'PT]MSU0$,U3 Z.02UJ6@^I!ODLFC7%7Z%OKQ&(5)_P-WDZXWI*5"6RP#8(*
M;O5G55+]I^<CW\ECLFXOS+^1<$RTG)65E=27*UFP&P@Q9GD!>RYR:/K<WFJ2
M.=?UPO#^/^(GFD:'I]0=(B"KKTY$,Y-9:BN<I\6_A%;E) 8NS[>*NCVV 5&B
M 32-IB_HEK%[)H=._KA$^F8/)EZA2F/)VXQ4/VA(8<+X5%.+L<16GEA?+LY>
M17F62I3K=<];XWA"(U-Q,:4_#:- #^9VEMC')F(((8\$4.4=ZC7WF%SG=Y6M
M#X;H]M5F1N=9&\Q,L )WH@A^#1AY3K0Q9ID]KOLF*2D8()H,M?L%I$?MP3W?
M_Q11?G 8O=2,:NULIK-CP4LVLCS7SY'HF<KDE*=HYNLZ6I96EOSA5/[I%^,
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M8^)0I3(VI2S-PG6AB='SX: W=<NM,(R3G*ZIHER."J=K!X$5*=<UIRU0?!6
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MI.@=<$_5>K3)0"+97W(BTL[YLYFPKV)A\N5#^;.! .PH$HMSV,A.YYIEL<F
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M$EGQ6[>3R4*$P0'M(C$LF%V@'(^DRCJBKU>QCU8>A^LK)V.UQ=UW+R& BI)
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M!FT0_Z&-8*V1MU*;2&1HK&5-:(=2]F-J8ALQ38V9%T)<G>IAXAUS%R7_,_P
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M<HOH&(M3$DO]&H^;=;N%$Q<7[PL%'=^1/\PJN9#S'?>4@W\8$>1H]Z8+&<0
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MD>RN<?A (M(CF##^M$"? )7I+G%S>9A-A_K$?L7]A'P)UBR?A/3^7D\K,)I
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M=_I^DY**AQC 724,H($ F84!I/E?^].G:[_8#S89<"VQN=<N  Y*&0,8;"F
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MA'3-S:<-DB[A\'?\ .2V)CBD"YZ7-YD$BE9PF<31,;?C2@V0DX9YVZY8+'2
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MI-DM[EES>-9F/ZNO799S?N4XV]6XZ0I0%3B764AW !H(^A-L5""Z I,3RZ@
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MS-\QY0<<_9/.+<S*\=C:7][WJPGJT#NL)IU4P+;UKRC+TEDQ)QW0AL(%1CN
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M\90\]<E[ZM<AKG#%<X\9)]E5:\R5GALR_",7^BAW\I-B)IO<1.XXZW__6L[
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MIY8IW[4MV].[O1S"@Y*7D'\8T\7]K4)M2[*/IUR^IO[P,?"?7J.^_!8^1S$
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MMG;O!WFXI35O]-9-B15Y-41.L.H$><T6N$*4U)6B_#-2LS[&6,1B2J3WN84
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MLK)W"LF+G$X<22+NC*(%Y%TRI!N'<3BQAITCT->OAMUD=!,AGH4^YY;QYWM
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MJS-[AA>D%05+2IT6P^]-%1@+=H?S\4NHAK=;BHGIJ?[&<E'-+B_5RO_9*H?
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M1$5:1#P>8AJNJ(8+>?'L_=1#O$T+8!LK>':-%Q,LSD5>1331F?#/B0W7AL&
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M$ER+W@O7@+4U+472%OCZ0;==Z8M\3/_GC.:#KAC)Z.1WG,!JOJ'Y"QU[JS5
M$.U/+!,"0[R3U2:65ZR+ONP>A[^H7.'Y>CSX/K&5Z]P<X>ZIRNB\UW]6V@K]
M2^[L$1Y%ASA(U#B0,=N'.%G]8BB3@4T6-6]<6?P.G33%F=0(V0B:=PQ9"&6%
M1%0;2J8\E?271A?,!=#\D#W%!'U&.I<P1VS^2%RH]N'T/-BW</(]GD#A*SQ&
M%*3.^3F\=M=ZK!&A53FH<P:D<NE9>W13N=KCG'S>&&4/Q34<1PB].Y!92T L
MCM%S%6SMEO,E6^U!,U#XL7)!#3 6=J+A\QB+V>(4?O9SC%Z"GV(NAOGK9(#N
M\%9F=C*WMTL6OS,_%[1WHB\"MK:Y^5G%:1$)]IT,P/&1+JT8=0;<756XSN]F
MP#MO655O!9V?HRU9YT2QKD5R/HHT&O4/B?E@;V]5E&\L9YES35.JJG.&R:W]
MEW*.C,4KEY,ODF7_/8FX_S$PJDNY/A":B6OH(,\V*BO=C-'Z25I#[3B/I=N$
MSV G3/M2GWXD#G*6; Y/"AM*>H_HJ3CWR:KI"]T$G:U2SNUYJTL%L+&?([T1
M*UE]U%K"9C"?%4T%<"@XCJU?[L_\\U>,($M1$QSMI"-RA-_#N;0(1S_$0JJ3
M+6SU8F&7MV9PRH1P"?=Y,#?1;NKV!3LU^67M.[>1XTOQDC]L$/+Z&:=NYI+O
M/Z "?H,H,I%<F?%5FBYVOV739_<@9KQ!Q ODE>;BY(9W]8Q_MP'YCR)>, WK
MHHDD;1QG)W.9!^4Z>TS1-/#&D6X!Y0]H09&"^N#P($;E!=9)5(\>%O8JLWE3
M;K).=L^WO%?AN3_-,F=3 6FN%8BF#XU65( H)#3%@M\T<M('2'IXP-#+WJ7C
MD)66$>H+#YIT'OIIYY!G9_,L[07?<NC+G@=267H_= W4+G('\]%<2_H!?T>^
M'X(*X,7/:Y(K!5PF0J[T;N!3;VX%']?4''P6B6J?^XJXN;I23?#]I<I(!31G
M8S8V2.6$'B8]+H,F>\GC8DF:BUI[A4R$],C,MRU0[$: G18_@V#DY\30&C^9
M/3<&<_('$C<A@/5X(3?$N%X$+2WD"(6#K?SX.7451/AFOP>#"RT3G'4-UWCO
M-G>Q.]4?/EXB;%-<4%UNCJ*+D+)&%\T1DX!:1+P^@^BX G(*P5H0"+)QVD@>
M[UYTXDS"]HL\?5%)DLILEI22_/*INV*06"PQK*OK4^JF+R]$&D1(<[000?7H
ME/,2#>B$Q<E51S["M#SZ'+EN]VSJ1M0XZYG7PZ\(]SOJ>+J>Q@>YE#\?\RT/
M4PYI-X_DI;]Z\5/9R?.V%'(O\!/H#T2S/XUCNJ*3M,@=\_6[<Q2G.4P[)%HV
M,S&+A2U".LAMX];%X98J*58-P=U+!@8<"ES^*D9K%S'7OY[D$49H9R92NJBY
M&[28VX9.A'2/N:]#HU5VA!Q?R8_);Z-G:UZ\XNJDL96@;+LW!3LP^$3'V"/-
MV Z#6<I@<N!%00_O#HTFW4C&MAJ<3T$&,9Z\ $RBZ^%H'&\H'D1W%Y(T!\F!
MTS[X-GR73ZWW$>^0F]Y>D!#/Y>!<'.ESPST#"8,K-WE=%.5BLF2OM8)T=7:8
M:&ZDQA.[SY+<?>5:J?.<W7UL8.'5\+R^5\OBG*U?:(:.T;[ UC[L>?*G+Y_;
M@T4#@7?R?"_]MW;./9[I_8_CWWYU4JF<2DEERB4BG*@)QW9*)5&B$*N46PR)
MFA5F':(3<LNEB.5^F4W(G9:S7&9,N83-+)<U&<.$C?E^?^O_W^/W.']V'H_^
M??[UO7P^K_?S]7D\OE^<*CNX /\#[:1_![A*Z!P;"PJI!!WQ<&/8X>O((^EL
MW-JW!B:ZT>J*]V/'^")D0["_8"?3T$J@ :.KY.C_NEO;J94=3-IOS&EX!7H2
MMD/ B &^'0(T+"/I30Y"F1 >^,<(FF>T(;)?A+)Y1AWS4LM9PX: &,Q4>KA-
M?*Y_>]H?]U\PD1A!?/W*^$X'(1N\HMS5([Y >UG8="MHA@>G#2C)6;[L0J $
M5=:T]AZU <DEZ^-%@;AG9<5\M,M<A$-[IZT=-R@%QF=?P\X?%\<-.=/\/EL+
M_P2O*LDR6;?&>)Y+]@,#IB9,@G;UF;9PD[@!T86WV:SCG?S:T>;+#654% )[
M#[^MGFK_P<;60;WYZIL^"VFSTQMIG;?K^O9X_JPH84ZY%)F6 /HJ*R!<1ZO7
MM[,=<7-5FO[I!>3JE/_$.DYH'Q(>G\*H]KD:]/G*6UB8G$VX)&:4Z6AUVDB]
MPH3IW D!]R1O05<(,%[&5^#3,0["!%']+ ?G7G<W>Q9EYNJJ-;\R$^";-D66
M/93>/N[M5:YG%Y/=_KFX.#='9=U1Q\V^OT7MR2LJ]L,((AD9H%MCJ:2),H)4
M9FBO':[GH!<AP"ODPL#JZL=DI97R,MGJ"9.UOYQ_]."U2?W4@;#,E$2BACS&
MJ7M#HN'3 R^;=W1,2,.9W,7UDC 09T-ZH\4HO*9<) 3L+T9L]&'D37948MO\
M$FKW7==0KUUB6+J=OI34[A-;GTW_P/4_;V,9U;;1K.^,>N)I@LHL+E]+ZVI7
MW9*]G(0) <^MV[J>.G> <6-8VDP*1Q>?.B-DOK^WOJ?X:UP"<F\=(ZY\?N]8
M8)_M:&Y)JO\MXFM'X\*TM")#I6.GC\EC##0&NJW5M9J?&9R0!E$W7E4PS\Y@
M?UPEQ-,AP !6 GJL(!4IKNFD8&T_#!\3^(TEBOG;^AAB;^BH>F1D]N&D^$T/
MLE9BSA^=H[!/N14]N3DKC5?L__S)ST_P8X*SB^N_Y@^PY(+]G&@JD7&WII5H
M=>C\%PDVJJQO=^WJC1)&8[1*U!*[LUF3[48*IS\UX<XJ5Y..=&M_*H: V?32
M)&4YA(G4-=A4F?N2=R).OU(>$Z\:;%*!A;&FWT( L][$=(_EZ?"_+]'LS%-I
M-N./["PC@IXSW?$',BU23I9[.>[(A*\069R/8?9GQT[9)A@YN;^^O"VLMW73
MI5=8[6$4RPG,+51B9X2W91&O(=SV19!QWGT0@*>FX'6=5[IF'D' LAU* 0)*
MAYLX-7H4[AZ\F*JQNO9#]%)EZ<JRGKB-P.-S9KD$>BHXOS*"!)/MFR& OT0)
M_2R]O"0O".!M)GR3N[XZ[0V"T6" AG@Y6Y<[ R.)OY\[&H"HYXPG4X)*@8 T
M 0%Q&5D4P_4+D^26]XM;=5.UXUMFJE*2B_WM^N0IF,UO@EUI\@%O1M YB5="
M#A5&39<0O =U8R;G&LI;HL@QN1&:?6V?T9S#_J6G#*[I@#S@+V*)YU1'R>XM
M)U*>(]7%/!()U\J6_6'6QC\#T:D=L/!F2:$H3V@^YN'B^'7"A)6S8E;L5)4\
M%HMVQ+;LJ5"V=EQK5;JIUZ;76GY.<5O.]C-Y?2F3.&G-0(';QR19H(MT!<40
MZ!=X8E:_/J;?>]%>M=#X&?%.+:R)A<MPA T,R"\$?+*46/ORYK]]L#D' >\\
MBPK'TQ3"#MM&Q+R[\5&:^CMFX\2;0_(G"**+%!<):=@4EY8EVM:_2A*:CR-;
M5[EZ[M-6&3L]/L\<1O=0X_9ZI!Z#C[:F:71<B,R_NO-(JFB+0AHVFLJ5VN\#
M\":G/;JAKD=<XH?\@O](H+>.\>;=)R$@(<,NAA\Z*8H87@GW^JP%!_&RE@]S
M\H>/:ST5GTAM(A[;U=_:\^1&=F;Y2WNW_4XW+2_/4Z5MM1ETYM I]?4RH]6,
MQJ?S!B.I[[H>RG..5@4N3BKE]2 W+KOZ3G72'PZN5"BGYD9@&0)FY<9HMM&^
M._13FC?#-!-W%105%0:(Y2I>23M[8I"S^"9>7R\*IV@QJ^>+5]'C1@BC*P)#
MP4[;J=(OJ9Q[&3<I_HJF]35+.R]@^(:ZS,Y1AJ@T,S:RRN<JPBKLLLTEJO46
M!*+<^#Y,*GLD61Y>B)DB/.,<I20>@TV+6#VX@CG9T=LM'%0PMPI)\H1#P#F?
M?1BK>U>*2]QARC>L:U3I> RZ8N#][*CF2+N9TJ_R#W9ERJ33I4.<+[TW2B:'
M'OZEFB&($*57_'8927_,A7\:NL:9"Z^X^\*W\OF[;SRT>^%!"+BSP#I0O4L;
MZPYO6/!OM5:[,GEW0^[C7\LL-X>K_RYUI4L%[1QN@:3UK3MF>&[B^B1X$KE9
M$W'C]C359BW^:.A3L5)EG9G/>W2 35]SC=;B[8/KNKB="#5<4G95=M 3=NA(
M&4E#;"+UK'H]ZG#R$ 3L!34EMT6KC5BV^2T!F#0!OIYD=PY@5# ^G8$M5)LQ
M= !@9VEZ-C;?*?#>]@[A(RTU#^_O'SKN_E&$\=\#8J]D9Q[:GWG\2Z3G\*&L
MY'51_/T'DI/"%*]LWZ#R_L[W\Y4B&:$G!#SB!58+!T%I7]T/N@0>%$_$\*SL
MI\'Q00A0J%)&N<T/OAS6C2LS5-<Y R<>UZ_9?'XK/"2P-S<E\JPFOUS%@N@F
M:ZM2L.62H+&7\D4' C;V3^N]0#+27TGER*-YV%3F#6CJ8D#8LQ1'4R+6"A7?
MLP>'4LVYE*$P5_^D^J#2C78P!Y_1JD5CXZB25>TS= .:%7^="Y$=3/P-#."T
M$_TAX BI:*Z_?-G@=17!-J1%Y,B2S^B;R\'Y27ZO?=H(/YE(5(Q/W5B3DU]
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MS*K2LJ49LBNH" %3R7B^]0EE=KIAB?/\2PCXQ&@$V^0DZB@PN.N[JP9TM$*
MKW/HZD('GHI<32Q=]>)SZN%^5R@\(P@@902OQBN+SE5+E@@;(> ;]T4<R'R[
MNL)_#@&1^!5UY^6>?DJ@SW 9GG$7 E#&QOC_A&I!@"HB<Z:F^K%PE:V\1RA-
M4DHM*T[A%PT'":UTYO?2673/A0"?&F/2?(WKK%XL@7;QR'+VNC5:,L91AJ16
M;-TCG=DD\\)MY#6[^\RL_NH_2M;^&-M_JYK5YM2;A5-3TD\U1FL_]>59]1 K
M%^6E%OPC6.=/\!/\(P -_A=02P,$%     @ 6:FM6&K%?!H&@P, C^D$  X
M  !T:6UA9V5?,# W+FIP9^2[=5!<7[0FVG@@2((DP9/@FN $)P0/-- X 8([
M!'<ZD*#!78)+0V/!H0D0@GMPA^!NC30-3??PN_?.U,R=.W7_N5/OO7JKJL^I
MVOO4/NM\2[_=YV#F,'\!CU04E!4 6-A86-Q8W   Y@C K6'KXN'B;NORZ;D
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M.,KY^)!MP.3S7G6\OPM9RN(B&.:W:.ME38'WW<>RHJAX15!C5A:H/77"C%_
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M408"@TMO_3SX]6:8IRE/B\+O3!:O_)5LEFBL?<.*]<MDB,+R2]<Y.>WY;;$
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M]5"R9F-#0Y_:'JC]9)>,TKJMO^H?#;TX.O,V'6F[ -3]\[)[V/1Q@K/NTB;
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MA/R. 4C%99C2-^X,Q(5VD-^DT4ZUREF;6RP;?1/'(U7E:$<\6=+$/\VU_WB
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M<CL.R.,M-S<9.RBD\%N7W&MH95AV?EG4\VY_)F/30*K6HA3S)S+^1%&)2T
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M#^?%E(& JZ1<$N\WTA-]&(#N+*0%=-<9=P2^OO4$,O:'H]>QT#;2UXX!XQC
MZG2]9)1O*UHI-=>IXZZPXQU=&P; HAJ'O#_II16-P5^L&%EL(,Y_(+>F)+=
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M'^#\U#9R8#CM';GDH)U2UP[$\F+:#\Q#<&, ,=W2:TQHJ3O.S5S$O3&WRS"
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M3.WV;&+IRCQA'R)K^YU"LESQT3NJCH8L-/OM3BR1R+QIQB[+0,*/$&^V^GA
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M/ VITYNL]$M2:N%0SG_J'##.=P>2NGN^(<>A<N:!I^J<[&!U<GJ&0&(__>D
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M&**(BI;/KYPLW7KD5,C5!14B3#(WS^9&=-24IPI@/^/?F \=T3'"QD(%=\Q
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M[/Q"A34#TV\ ?8$0&&2,-[I5SMN'Y=_N<C)A>0WP$<>OS=(]"7>G2S])UQL
M7??1@J=/O8&"\QX[U$+63(Q&75Q35$^&=%.]3<S4-6_E5Y\'=]R3TVANZ]P'
M.K FL6* :HXX2;YBPWT/[2$_%L?!1^UTNOJ4BT$F:315E 0(ZF+3@J#H?TSG
ME2DX7E$\TBGI!M"-G68]#A"RT7I] X#!( 4)>*E \C,';/@-P!G2]U69#<.#
MR]T5&, 5M<NZ.\OU+=*Y2O:ME'RUOGS7G#DBR.16#NVB% BR)X)QYT7EL3*[
M4H+TP9HZU+]@FT0R4U9BTC&E@R[L7Q*(]HW$J<__8N59S'CG*_.31T7*N;_1
M=.3I USV#BZT,>?R%B=I\V5!0$SN+594Q3'>FRY6FW,U[XU\'F_7@[\!>%XP
M$[LXIW$K7.DJ=?^I_4AL>6*6'T,30!J#V7U@UC)YGV2?7"XB_&5=4]7B4!<Q
M_-FX2Y):4UM3VD.KF7V^BG.>XOF'3%'7;?=63U)!S@Z8-MPX'T,V<5EX[1/-
MNWIOBMY J_S=E9/%@ISUDW(_MWRR%\Y]FF3*L5.+Y[+!Q]VNV/,],!^D61*R
MUX<+U8J'CW+AUT%XX]4K;QS1#6"U,>&B*@FR^<7_XAUDYLL>Y\WM/N<PA6!J
M;P!&IODSN"E(FN3P8,>VYF3'8./:JITK)$8\*Z*5E'P-3>5GM7O)X:)_0?1^
MED-"CO=?8(N):D[N%YLP2@)CB_AT*<?]DOPZJ,H0EKEJ7*T)R0=Z%%?-PTO.
MS:N:N[YJ"4B7I/C>&#(**8..$K\=^JCQ61_*!=@(A]?%\;X\5X&?Y,1&,M:N
MMTMN_#A^N/T8V2&*E[^04/Q@5VOJ4N.B!:3ZW/UGK\2*GDD0"5K.?$O'Y^+P
M(@?;;0*G[N7>='1FOOLSMJGR#_I;15X$.X!8WH@C\JDH4P.!C#"4CIFDN6AX
M\3D])TR-[L3Y;@XU.S>U.=O8'#1PP073; 5)OF62)Z<'%<#4%!]WELA>NQ.L
MBO_?['\+K1["S6<O'"22*:#IY3J3UB<+)65.FWE#WYSW2A&SDE%64FI$TZ<&
M>A^;S=5W!1<.M56G+?>G2?73-Y--;._<8WLYXJB4@389<J?=BQ*0U^4S>ZU'
M3=S$F?>5'EV2*SB$-X0,>V.L@T/Z<=U7ZK@18>G:#</!A>/%=K.RGV<AIF!8
MKT,R5V%9X:+HM#LS/(O^WGY^_+.2?E&9;2$R;W!NHAV)\+PWT:JFOU.1BF52
M7C5QW5 88P6/1H!ATZZDX)!_G=*&Z;(!C3$BB;K0L]Y7?(S!86=R:MMB" B[
M 0PWXJF*OQYG#_: B<_W6-.E;=S\.3>[W'J7IJ7S21JJQ?6IF^>=+ 4TGKT*
M60J/J%Y312B#PLNZR.Z544K6HQJPQ-@_N:4_V7L?Z/>.I+/0Y]63,//_!!MU
MM&7X+_XTI.9[.B?_>I^<]^5Z@?X_Q&X_1 @8"Q0*(L&XGW_MIVC%!QFS1-RB
MX ^I1K9KU#S).GYY>9KQ#G-4P@V YO?F>]^,&FB LOAS/\HQM0?Z"J?#\8G)
M(CW8&52!Y*0BY^JZZJ35SP""N.I. ,]5V:^0+/XEMTK;>C7*,Q 1W4G<9U*1
M^_QR#%ZRS, KK93NL>]PEHNY@9#S4X^=;.!V42^*%%K<XTY7C7R8O'L#.,*K
MV/5EE133B"UDCH)J0*6+[Z:<(Q%.V1R19-F:CFP".R&309>1@@+#9.E732'R
M43&/2KE)TQ^IBO>!,.:_I=_X15GQMF>3&JD!,+2OGL8JS@YE_VHC;9DYV$2)
M,7+A:7QQS9+MNZK/?E^RHK>.*-(/!F>C^[76#A97>I?3Z)!(0RG?E\&)/(SE
M,6@UR8]Y&.J.EDM%E;.N*QU<?[NM'^OO 3SS9+#;JAG?Z1ED4[JC+E!R\V)_
M!(6J:&D,G<_^WF#;7&K6>-$<,RMYU_6[RGQFCP#UU !=>7@#7W?V 5(;B./V
M\+X!R,G T6MCVK>12ZL!;Y)AL9'RSWR_H7( 9UJQFN!>.*0D"SXI6=?LRNZW
M">V$]_,*:=@^*.X=&NOP/6K@/AZMQ]M9<  3N,ZH]V\ <%G(:01\BV5WW_V\
M>-\LXY0XI,L@;,#:4]J(-7%I0L-?0K>E$3M@U(QX/[[@#$OIY@:Z"J?^-R\X
MFO*(/ %I,8#](PBQL=M#3V< -U8&]ZZ[X_EZ.#@]BBP9'8149'1+U9CB9S?8
M?3CN#!'VZ-S_P!FE<FF^WP),_NEC\?R6.-YTC*9L;2^7ER*S?*>0'N-PL@;:
MJ[P26"M%DL\5LE7NI-/FX+F5O)Z.?+/$NUJ#WCQCA'FNN(R:+M'* 9(;N'8+
MA7#6Z[_ IAO WTB)L1N Q7\E&KM)'.IJH?H6Y1O!$$&M\05L)3!YZ>M&N6SQ
M7 BJU2\"V6LIR2PAR+"H 14ER,P0P4:$=#[-'Y[6E*=E>E,W8="J3T,+\3V*
MLL#Q#'G_;2#$".$:^OP%E$7-4?D'J(Z9MX/-B[PM;>L9L31FG^G6J*LUSB;J
MF<Z]OUAWV("-=M1X<-7 6RNQ\&U33.'U+0;*-B3]@]'+S<E(,\53E8W1 63J
M6^>.GXRQ[SWT%^?W52^V9:9E/&"CAH:=(IHZ8GEBJJ4UXC/W-<F50-@JG]>A
MSW /,+*X.6G_BEL(MCB+6E*KDSISF2XZOMU<-<7*Y9UNI%)_50J6LS[=-1 7
M2_L^8%)&KJ S.QEI8\&ZV@-J^#UQ:Y6ZJ-+2+]HT^G<-="P!_P! P']]BU\>
MR94OAFQ-A^1/MJ+#R8KZ42L_5T(<6D_K7T1]V^GU*/?5$FGA5'AM^7=&]\$[
M2*5<^W]/=>:O[7CNR"G[>J#A>.6,QA"#;6S".OQ,_YB\&9U/$%M@7(A?@PC^
M.TP^ZNF!0=^<::-P64J^+'S,_-5]6_ '_*0H<;;\VYDA,/4K"S> K;;YCI.<
MU:W3N0F;/RNKPXJ^/D)N./[Y1/H];G3:<,<8:>Q1L7VF3X)&Q79Q<FD5"K'!
MS;.8"O@='_8)&51&<P/X<A<'JKRZ%73WFY;@C"WM<-&,)3BM8RB7&VK"B+9E
M,"K&O:\LKWMNJTR)GX<JLF;FA:%^8P0WF[U3>&]U::SO$=0"#.$?W43A2PY"
MI_?A.\VX 4DN$S^6OB7&/JN=%QDIEH:3^NO^=YG$Q404^4TU)^*F^L,[H3#2
MC$<J_QW A6]YG_:M][*Y0UZ1=?P>RX _DW/W%W+;E'RBCXM!9C77[BS]'?=3
M[NXYYN4-\ P8-*L.ZW%PX2L>UIKQ?5N:?K7"T3?]1#\[:>?6/9HA:S*L)-)<
MFQWHD8.8QK<W (F'F:R,:&30O-G #VG%C12MK88D"CZ''1Y_.=UF)TT*(_<Y
M.\=]D=3293^0'2(S0<=(XF/)':&62\,'TQ9D^!?G'F<55VOJBQTCP&V'0?@V
M\\3ULP[)]H%]]^E%L8Q\1I:^U::LGF^57V6SEY8DX(^_%>M8&!C?%0]U3_9H
M26!E]VHUG!10:;G4UYN #W3)XF;P2C> WV%EN1BJ>:1_XAYP6QY=RW,Z5MXP
M:_9C_@F*IS%BJ[SG*.M7SX+=HW%=B>=/H.R(_*_/C/7 .HR$3.T'2+=X'*PC
MC=AF)Z5WN;?O6.--2-!9PKIAT#5Q\*]]J8NHJ/98Z89%9UZW7W6\U:E>V._<
M#G$?-L1.YA0M5(AJ5302_NOV:3Y^RXA"7R##1@URBL$'>*V.8?#F6&?E8<F1
MQLKH\<R>5/#*Z)(O<U@-+_Q97(;W^86U;'Z386!I3&91:7;@_*FOW4ZR%&U
M6789,BAW#N.&:\/;9@GAQEL?8!0A+]H7]F.39]["8\!HEU(YK4/R:HJ^40AY
MM+#Z]VCF%F$?_>G$^_Q[>B\FG=KWB</OL]2RT02./&FYU .NF00$AP#1OJL9
M2E5Z+=+ CE!95[GVSBG>:4,[4:%,>KN<OBG"G;+R!.;(_OX?4WWLP_'21..5
M0T=ML_U!YA'%] U^1Q+51+X?<+3/(TK%O9X:\_!L?/]EQ_Z"K#C.%?)?'X^0
M_V6%X?_W .5Q-OQN2P+FVU]FE3ZM_66S[_47FEK'2T$3Z"RSE%XKD;PR%PQ^
M15C.]'%& =8?^Q4M-)\B82:8N3SE@"Q8<'CR^"X_ ;4GZ)(T@ 8X5B#]/=Q=
MA\Z6G^#IC",%>7#G#8!$[>&5N^"M:([ W'X6\>=^5?_(;P JD-TQ[!S.^_'U
M(?;A.K ;MQJ">W@%1%[W%1N="+'&QM)66;3B,2D'<BV1ZQ^R.;A]G+'BAG#X
MSFR'/]=4B("I\G>:DAF0WF02KN41GCR8?W_U(RN+Q$XO-&/L^'JH6J+=PV>G
M1 29EMAG__Y8XJ@BN;W0'DX3U:53IR96_OS!ZYA'@&&4GX#[4D'&,,J+6WND
MX%'.%Q1!\!"KD'E%XWS1TJ,O]WGK<YVI8. XEO8L6G@D?/#)AD,7)%7VX,RB
MW+_CPTZ0WB8SB</&939AJ/L[8K#'9+&K>XP[JC_33!#HNHY^4?>*R4S&IS>X
M0A5D'\]!!3*T?;$<D!XR.BNM1OLBWG%2_X5-+BDIK-OS50[]'D?V ,WWKN5G
M[R>=2]B=&%*%"ZE9V.A?[K+CK2SZ/=:,SB@.58ZRMK'8$NF\]@16Q68L(4)$
M3(Q+EI8%CBH9]6:&Y53EE946%;^U-FF"95?D1-!Q9K^U^L(&L=O&CGR7X1[\
M&?",B9(Z04_A'MMA!:]:H6:@@_?6DMM$?1/O5=DS0+J-.!%K0](OFN+7@A9X
MJL>XQO=(MII_]J1'%TL&00X^<\?,G4NF-KZHW4OSC;*J_*A(RV$CVXL&0YB,
M ;57[:3V^/A$)UG-B.A]^W1C9FMOU#^MJ2QR@\G'GQSE3?[P"8;:PI1EOJJM
M)@DP/'LTS;T8?4>\NE $E.GP$6!49HQ).>';F!L]CE79@(2NB6!D"Q4Y1=GJ
M+N5(GK'PR88-6CD5YA<.6[N89P=^*,LOSOZP8)^?GNRX!7NU5_"]#DN!,OVY
M)+/^@9PQC(1W\+T\BR5^HON14N"KCJ7UY3QA$*],;#K\^<-;-6*Y40K=/;Y2
M/T;_W7\9Q'S)N7;4_F?(H[)C-<0_?,@C<Y8<V/KX>-C.G?/=+"4LA9#FP1&(
MU'D;%E7U#&P*5C=B$M>>8)] W#$=A;2W\L@SW/5]3RT9H$M'7$95E/_TL4YX
M($?#%I^IYRHCK6Z]-6]N&%$4-\T8Y4/##-Q/8,I7T U @")I^9IJ0AI>YV\_
M@<S*3T>50U4::M]F'JF)&"]K43T4>Z3Y];>ED^$7)T\QUV_3'MQ)V_9I\?%L
M3U<E!_PQ;Z:(R!X]O7>/^F[&J:A#$^:O2SW*"R6<NL$O;XWLIM(%H FG\AZ?
M?<53U9ZH;/>Y. 0-%E75MG#57H:XV9N&V$H%\407]NRX'/Q.>Q_ I&ST)#Y"
M)@;&!7,J*<K'IK&G.]=EYUF(9+@QH0+JE)^943Z]>O,1EC].8R>&89@:S'JZ
M'&"_Y 5Y7,_&PG&/H7U<?FP!G!4H;#'4B!'#2>)-%IB.3O;*[4]7F:N;3A,L
M:YB;E^@#-2ZLR7S?1/*G+MOZ4-,-NXO G-AB!JUR:41WE;+S]-\H*;6=R<Y>
M*Z5^_#C]G%3 "90.4\.J%3F!_A:[S*,NTE,[^3V-OYMD.GT$L%J.\IGXO,,'
M0'X'M#,%HX]Q8P/,8VW8! 3VP8>N;[$_K Y<LYDV:M"6>\]RPYLFMX1ICM7B
MG4&!'[9@/#B1;S.+\.%)]>?(C"SWB[?!1(];PD$'Y 8(!*&Z(*]+-NSH7:U'
M\\!ZM:]-GQI]D:BV]T0DYA,N2TX\>/$*>YJQ\=7=CZM?QF_TJN)CMQOJ:U-#
M!+JS)WM Y>MO;4O=?,^Y;8E9>X9_S0BODR&Q'Y.Z:;PL:O<F.VDH9H9K450#
M7I2])B;[=[7B#6<6:9+3UM![9O@AV@U*1399RL2GWY4_::D35XWM3/0=0[YV
ML.(U<:% ^J!5FZD+24,R02HJL$H*(M!DWZEA2VIJ?'/W8!>_&,A4(5)96%(L
MC![]HB$BHV'DT*1I]2*;EO?/;/[.EJ));/Q>2$^!OU=J 4%BU"/(S*<S9NUL
M-CRE/Z[]= F=XF5TT3%PB!\JZB?%2!VSM?I=BQG<JQ&]3L2 9)O5XZB50,HK
M3R+*7DLY)RM3Y'->LEPGJ+[]I)O^NSYTD9;/8A N^$E](#GLG.H9327L-]Q.
MX1-XM$.NX=X2*UV@117^U=BI4;G?=R%CG\Z#ML[9M]=MM7<F!U1BEZ=]J7V]
MNV1U#>HP/*';3INEI3248[HCLFK9*N]_(3S8LSU8%(R'G#E^]HM?PX6TF.]O
M-*IJ*W\"A;TFB=N]90G!V*W""> 06Z7D\5L?B4-4Q=+'0TT4+6[$X.+(_V%V
M>50- VGP!VBRA@0) :G>!Z=\ZQJ]_G]#K)PP:CJ/C,,E7#1_)W7I+@,A 2CA
M*JTV.]XM2#](@>[6A]Q4=(AF/P80[(W[0O':'8S"\&$H>#N:^/+XR3'&!9U&
MO$CE_H[0%140DB+1'4<6B$H:<7KW9DPD]OANCR4EI57;*^V =&\K;*M&*.NI
M3OT-P&G=:T8+.+%V-J89NAF]CZ^IJIK,!W?F1Z2?8$[WIZ^_!KX\ %==&37B
M^F,CX%?)6,D;@,\TRV:5ZPU@.:UC^S9UQD+#@H_Q&WTW ''@SNQNMT/'VHL;
MP-!4F[.$D(>-]_7:E#ZVULFU'']PD%VYG/K!\_WT['B7K&WJ%7I>IM"<[Y@C
M+AG*6U04_7=*[U>#=C@%I*-6[_$$QWV"96%/N?'?=9CP$+6]=[A"I_>_M38K
M>$M>ZV%HQ*KZP_9FCL^+NXZ^[4&BT<$*^P(E@0=%%I9'H1W4C'Z^XBO,&^HZ
MFK#^ 5,C9CV#;=[%TMN%1*C%)#0@:.*(+AXW+W/\S%P&+6;^L 8/?<PI!!0"
MF$@H/K\P47&CBQ(N?)U#>/TNU"%R]R'>C'5(/0^2K/+.8^7'KMO"DFDCP7S&
MH@ FO0RU?,0J:TQC*T9]=<K,G^I*<8>ZZ&1*N<>V./X\64Z3G=NTW:/6 \U?
M2Z1;EN-(=I<7O&X_&JA6C])!W;.)J;Y;S_R&RH1@DZ18?E8:HX!S[86(O *F
M\S.N_K3HV*H:M&5TU&SV)*^MW[IXMT3Y6OB@P4B\T(M*9A#X\PG-1U6UB+];
M\MM.(U^/4,)7D![EN>OBR#Z#E[?RY>N8K#@6)E3V;["] _0=2 QE<.G:Z<L1
MVN%"/[@*._-N[UA(*U^1'1EO&XK#TV%KW_MD_^FS9AN:MC:D>S:@WQG7,]<F
M9R[U4I= 3UV&(#Q_C'J2QUZO[BQD=.I^XP.F> Q_Z5N!]Z_SR:C2&7"([+2.
MK5VA+2J#"=RB"(&<<<DK)EX>/$7XX26.,P@3M.4EJXYC],.ESK>%S33C+D[[
M_>4F#M^Q+Y7YVM<FO5SL'CQRQJW,C>B-Z'PO[;O/#8N AM\S+ZI8X2E(;=)A
ME36O^D;WIO^/4,1@Y^/7;*"[OCE/QV>+"5_NI6RYV(_+^]IRU(<7+D02EQN;
M%.7E?QSH,Y0\Z\(X!1OB;<R"PN9O .P7#:8<J0M#<2%?%X/ '+2+2#JUFO%R
M<5T=PPJQNO==NKH\G/FE?=,VF^G<=LZ*["]J*%VQJ-&^9T%^A4X(U=(7Q'5L
MN)QP K%7LO1'TOK2>7=3#9,FN\@*HBQO ''3#*0QOGJ,1GC*N1-8BJ>;5.7X
M,209.5,CH?CAX@;P]EBPI]>F6EWC5)$I44!0E%PMOK @KHO>KL_09G.*B6^S
M+C27"AOFKWR2'RX17)O'_&:V_LCZ_L#Z0ZH)*712,]^Z3&79Q_+K'-W$7T0!
MGFP?]_]*@]=)>E>VKM9T3KE"SP5G^H.#0LHB%N97&OMT,FE81*+=V-6B\8^F
MW8CF6V*,PVD+TM-5M[[$T7A4_#;$QES47H.D[XO3SIG P RS]17>)G-CN40-
M7N GX8.DVH+9 (+?B6M@7D_T_F>>CC7N54(KI+:AOK_#X.)*:_$RH2>T"AZ
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M,F%*4Y9#PWM2'TR4?8#4%W^"XQS;P&^7_'([AD%D@>G@86CTDC$I6;+TAM$
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MSOQ^YOAZ0NL,=#(S,>OQV%0-6A;^<N(/3;7C;(V:9,NE*>W_DJ.0_S\'HO-
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M0@M)?>BJV*'BCU/'W_.3X'/?//G[@6Q@\14H<^5^H[B .44CQ[MYIK9WYSY
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ML/;0"-X, MW#J#K()L+T8 \$R$!@IY8>!(9!P/?_^/1> :9OG"A.]*TC+('
M&RU2L\I]" @DCG0344=[X:9$7M1^"^'4<+D3,1:SA=K!;FRHXWGBB#ZH!A#
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MGI;?-%U_;E^\\'A@Q[.X1,[X8K42O6+QZ4"X#2T>!7,+4)R*C'DC>R:'/>W
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M/2AZK;9A0:)H>N^W)H_?FE1LJWSX,H.X9?LCYHK2O8!K0^Y"0;_O&):9JJS
M[D/Q]2 PI8X^,S3*-S0VBF$XPM4AB)#>&:' "[?[FKPKQG=?W4SYUBX7O#_&
M)U7]WFZ1EIM6<3;FBX@NQ?;OH- 2%9A,+5&:2[)[LA:J]S%& E2FPVXHN@K:
M1HR1!7=$1A+3U]HXY_ZP%C%E">C1D_C0)JBNVZ!:2GY4Q_KY?[@G_C)\7TW&
M])4V"/!+J:L[/^XR?:&^93]KVH8*&7?E3<X-+RPOJGM06T)=A? *>J,G.;-D
MK:PX>('MP6DE^LL('I)2>+.0)N4VBH/XQ-MU'U[V(@$W6VGON)XV>A3MTE3V
MXM5:&\W3H@'+K,S< F6Y(V6[N"OE_,R/ [7.]#.ZPDZ6M#LGN)A_8)<\H46M
MXZ_!BV]16K^=7L:0::6A>L+B@8D(T9BF( @_ XDUM7%._#Q4>V$.!)XX.6)'
M8$BG5<>XBD7NDA496?Y:WALI+1K?K9H5KL46EJ1=BS9"++OD^E7OU9@\K?=7
M^7KEC(;A^Z? &26(V1*/,VU)D6ZLD!( ?,_X<F(P[HASL?VO-NN_/Z"\& 1J
MBU$[Y!#\X.]+I?*(SR4K$J:0.X^)^I@.[1($JA9#LU31[>LM>, XBE5YXC)^
M[R@^*;[6RJI4J_\!IS0E0^5+[0)^54?+7"7EDTJ\-\[-H&$9XCN1&[Z%!Z6U
M,B=)1HT)08>4P%"5DGGSSO(>R;:]6/?%".^&LL/2E)(K\SC*I2Z]9PSUT717
M!YLB M[8FXCFQ_TL.AO%R8Z&94*>[\E,[M/@04#=U6/O5S.TI;E[GGL39>V6
MU+'./&PDPWY":<R'*C$V+<1^[N7+YD\..J..Y;K:HA>&=)OM>"!M2^-&->(U
M.%53WEH/"_P^T26Y_=1,=[,CIE(2[H1GGD@LV.&=*R2LK+:A#8P1Y;7P?;'&
M[X-SQ6EY5'A[R<BDXK + \$Y2VYJ-.:1;;_]'?E/49.<0!$(Q&"V=]82-ZJ/
M>$N(K+ON>YC:80'=9#2L],7J8@E-.;8\:WM@H&-!)ZJZO T$@+LLG688 ?X/
M"DS;B- S^F;  > E>WO449+.,]U:2DF>@V@)58%OQCFBWGR#9N^<R&RTL'4I
MVX4("1WY1C'H;.6[&3!Y/I&P8GV7&VO[D.J;Q:IJ]TN1*"-:CFA[>HZ#J"?9
M.XMQ,3V/2M]0GYSZ=JH5*%NQC3!3>\/\IX6;Q\!_'J#7LA,) I5J<"%6O%9$
M%.3HIR6!Y,K^1(,$-IE.HA+\_.&D77)I2!$\3E]]];W=NL)[#Y/&C!3;VZ<N
MI^C03BG-+/Z^V$H13NJER^3-XL9<;V4]'[YB7:UX?VM;]L"#^: '!#@E,)7B
M99)G*R^3F<Z]C)YRU9!/]F*(Q],:.?B\4>5WY-/24I8KZJ]<>TY*0:GA81#&
M(]F#0)+WFRY48QA5'.8%5?!]M=$H\84?3#*_TEK->$IK50J*+UEX'7'S\_OP
MZ&K=7LQM?G+'PE)02,K]3?3OMV-I;BX<M'ISI!+U";;;[#6P(Z3$@NNN@OP:
M.GE;'.&A-_]8;+/!.2GW1]]T)>U0M(-E$G.;C/53M,B'GOO/&;RVI$4^O)=;
M;B')"!>>:SP+II\# K%!1@NP6@=]!]_>@\NCTH/;"6X.7S*@&CK3^G4X9G<+
M1B5M&@>-P48-%ZJ(>,5Y=3YG7HX@ ^??UZO"28+I5TC8;]DZFA,;^>& BC16
M*(%%V/X2[ET/%<-@#%YW:O5;FF?G9#QI37/-M*.-1V3=P6A$W27V[B'Z#NW/
M"IPJ$:3F/*\E_R!+JDC"?'I,,C5+5Q\8"CU!,_644&?G@1^LOX&WV$_%]\ C
M,P6:US^L3,9E85AO5^@^6@\R^Y7^_;;\'@@\PR)Z1374=\(>E\<\E"1&\H*
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M0 <$DKH)=5P'9^#38V8@@)N&VE1?C4;-)E>!0"?588OX_75+$'BYBII'XD&
MSD@/%GYX#?NGK U_.^#&,D_ @-KY6=5;4O!'D*G5WDNVK&:+;Y6>MZQ!IE:H
MT,A_]OP*_T$IISJ<_3\I1@IT@Q'I,P8"_R@TSYEAS21]0OVC/HV1F6S5X/Z_
MMGO^PU__Q[>%?7_,&0MC7 J#LPZ0 G?IS!K@1-\*W9#Z:%_$F$SHX;$$'@/'
M$O@' B?+L>OE6,3YDL$!Y/"A)#RHF$GS2OHJBVQ_BG13F^$UN!+JNZ^Q'/$Z
M") <N_*W.+A^ARR?RO+-.83G[4$WIJD(ZD?PW^&6 N$^= ,AD[Q,2(3M!X*
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M'C,')Q57BWZ:BCN?'\<*SCRQ111!2V5UY?E<RLIV.H@G*/@U9W$F2XU$:OJ
MG%%C]4W8/&U;^%/]%]Z/B>80.M=Q&W<+.6JL MG8O<!R<9:366ERK]08I2FU
MHB2J-%BYPZ\OFV^?(JT3WXC_-.5Y@:4@D(#:'E\*;T 3=,<@_!(+UNXLW[OT
M'.LPY2\'/L.K4PM;$H6U.Z>;VRZ[B<UQ6+']N'*1\,5HF[#6=Y[][2,]&@K:
ME/"0.;1CBGD$#R_E]:+34,WDS;BG]>(OH%S=WGL,A1+X1\[S[K_:I_/2*')%
MQ53HU46NY)CETRHF&A@_*)X]M:K0_=P\:M1 (\2@@>4U+5F:K[X+F]I/NXL_
M7K-J/$RJB-H[O:CY1PGJ7PQH(FX*/B^N*##=H 6!4P2?VBOVR,>J-X.AC/][
M*[WV5_BG_R9;[O^S!S@V6&PF@+WN T$>4?G>\1_Z,9L$:<]FM?4R^HLL:2@.
MU2YY\&[7=-M]R3DN^>P1QAQGT^K4NU\W(=T]QEB)DN%UL#J0#5F])K[F),LO
M*S8W8>25E>E>CPN(35@3*DLH\?88NY8>N6)R496U!J=FRN*2^&;+AGC5'M\M
M\VC-&%OFTK:=S;V-F5UX[&#R<=6+?S!\N8.UM75K7^)B7O#$-9YXQ-V2!%]A
MT:=;/2H4;J+;7\\5Z[9(/TY:03NX;+I.!^E!(=N_]J>VA/*LIE8.U^.F][Z/
MP%8<K 1WHQOCXEZN';I4S;<IJ*'LM34_%2(*XW,':*(,$QNN!_Y>OP1 X'Q+
M^P8/?"[[_=+:TN?V]?-$?N^0 _$MF).5*U9P<*B"+D?<_6$<C;K&)J+%VX>O
M38DAU5+Q^GMV-E%Y4^@Z,I!$E/SP;'*[>CB<:B_\JB\^=LVQ;L (\M+I;D4X
ME70U6UXL0^C'@7+17,5D6U6M:;W,]-P/=O=K+)R<S?0,'7><^+1.VYCQ/ S^
MP',&_FE)NFG /5 G'W$^A>\Y;W-R>X$J"'PFQ?W)P1@A5#S9ME3^?B.:T:@J
MM^9H;K(Y:U+;\5.>^;4#<8%GT%J-?,PK%66EW"<,)36B\ 1'O>EMR&U'#T8G
M3)7G5IE7B@247"^R\XE/#/,I\;P1Y]NK>"[]C+0:19&\%C56&Z-<6(@$\__#
M=IC;F5E?Y=TLWAO&(<C))/)51RO5,PZLZ(ZRFIOI[N%R Q\IPC('WPP&)^=P
MN*Z/J>L.2&@X3*ZNL#2T5Y ]=W*>/M!)CZ_+A0=:WN*_*,E6NX+(>"O#($<[
MG(/Q<W!,RX 6?=OE@0T;_3\$*TMT54=4-FM20^/CXX$">(A@;1Y[RO@ O'$9
M43]M:Q5\1IWCDA*U?JQG[':-  )7Q.% CDVS[>N?K,'\[Q\7,DD(*CU<8%7Z
M./D*_FM =# @(!8^A36\J$W]2L0V,\##]*%@M<;7)[CKL!&:%;E^I)-,X^B1
MNFC%WMZO=A"@ZG!:;ET4P[)N'B*05?&&YO[:;:>OR-/,)7%^+0Q9KEL]SW*R
MSC/>K0Q76/E?[])R_9*D5.]K-Z'@)2NVFM!&FSS*=2@/ L#RA0GXQ'OX/"EV
M:8E0-1EPB_A/#QC?WOX=+,;:$%/,0* @J?%+RR;7H061,D@J@I"/6M+'<Z4>
MC:CDLOX[JIQND*G[99\2JS\1]8RQ$^.W43[>(OM8_+<]-=R!MF+5SN?F9]S"
M=\>^JDV@QP,^!/D727IPZ_,.MO$YU-RD_D6+.$=<0=^$)WNT.\\=3$)^]I=[
MP>C&T<S;XJ5$Y2GWBI%]UR%F[?H[Z,0JC[.XKED7ES4O0KG\>P0BKU_6T$B!
M ZOY^IUV^U[7ZF!D@W@-3A$36\WR;9]UA_V ';]Y8%HU[50QAF'V<&YP_F(\
MN8OM,:^87UACKGZ7<+%J>YZU+H@YL'TC6.(=@F?%_DELF"&++?9T'&EVE%$+
M[),$XQT;=^\S1",472V=)0[NY*'?,1F\(=.?OKS6RW(0:(NU>6#)V;G.W/\E
M_[NHS\W;7'DAK&?(A[[:&PK$F%WD4%:HP1G=_F?*;O@$X0M!("[98<.G>]0X
M;A,$TBLK")/57ODD#A*";.0_%" +"L1CL[)L)#)B.@O5]T]\V[,_>_#*(>#N
M0HR.&4\M0-9ZJH_>O=UVI+:)47!:F9MKAQUA"0*OOTYO[<MD'V#?_-!Z$-%D
M+O-\G<]$*."SE$N#>D1S?Q.%(')/ZU:OKL*O$ZLJW6J64:.?!A(,VKC><Q1+
M7]FN.:TT0'["Y3KP"J K2"?X>U'_U7'2GP3TGWWYC&YL8EP_F3"CL,^ZLF:<
M4P 7V-XU]CT4(<)GEP+7A_\IH,CKD1#X[WE\Z&_7ED/T0>:[4VV1P,QA))%E
M]R<@;<B9R^JL@K0R9OT+CG_T6* _A<U52=A4WI&&&HRL-W1BPPD_'!X'Z,2S
MG[7A#,X+HKOS6?G38UWD*3(*\G$-MN'?@5@="+12S04U)(40]7TL>A.ZBR5<
MIRM=\=8M&P6U.Z=R)!.\S0YK7YKAU,@$8HGB7R8^WE-&*&=FMW-RQ'S0?9QY
MY0._(%0D@HDTD"OJP1#&;5;1^BOP[Z$I^_[! ='3XAV3BZNK$0V/SU#2.E:'
M=SOY?/9_+JX'._^R]84D$CHCJ.,6('$NEK4T5D@M^2))]/0ZCY^'_L.>A];-
M^C'I*9TX:EQWV[[0'G;>'B>CQ#V5WM@8)Y*55%]6>B?VGL@KJ-^Y\MV=W3TL
M#]GCH=>[SC4AOHX%"PEMO5->2:5(^^>;VP.%YI7.VA87\J-:Z(/%PJGYG'XV
MJ1@LS;*Z/5.7*<RJ-SYSD!P%:\DO9<39[IFP,^LGMVARZC45-&JTRZL8+9A'
M2DW-Q[Q6RR^Y4BCR*>MU\LUD&#G5$SX%E8O=H]+%)5Z"DJ=<FBJG)D5'F;0;
M@Z_E6@3$QG$T:''/"!\PY!2,@L"+TQPW$_)H>S34C?CN+]WXO&8:Z1D6%[I6
MO9G P!_'+\-2Z%-_1FZP.>[&C%S>YT):D5S;RW$MO"+*2X5L-&UH,LIR[994
MWN+Z^_UK236CXWF.TVK:TB.1VA>107D#NBPZ85G"[WY*U9/%WMU-U5IOM[[0
M77<F=\4J1^+^ DP=)?%^\QYQX,<:TU!W^Y#L@RA&2XF!7J4[-N<,/H9V7&;V
M*RN6B4K2,6><7&0,>I)K(JVVRH*=:!^[,)R@?J_$W40B[K)L=!QT(Y6G0>]
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M]B:IF(H[8\XJVJ;$ZKT5OT5_V])SGG,D1BZL*Y;#MJ3@I5>>Z!V)V^@PB(W
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MWY6')1P$#J-"W>O4+ZWB*867!2([R1N(J ,IO_$=8A%I3C!?[;.F&)!C@R!
M9G)H7"$CW H"2^S](,#"#%-PT?'-K;@I#5<2Y+0L(#B=.D\- FJ*OYOE>DZZ
M4.'2B;YUQ@52A8QKF]^(.BL8-+$G?M(8!"(R\329XR]4L8<[;($N^X<P7#]:
M_/ 6J_DI(DL=MM9KL\(:!%1YJ3:A&!SOJS80. F3O$5JMNW )^+-BER*J08!
MUI8Z G5+:.?!+582$74%=%-EZEV/G#?#:T#@D3,D[T9]Y: V4<HP52V--* ;
MX?=O W7O#DUWFE'N=ON9'T&@(OM  K>QF7RFKNK((I=0SGR>V:6GEM=%WS*U
M0]_IYX_LS&!%_XF7WQ]5EEYHOO1!X=?1S4E'VD&=7 LM!1=DW,,D_0F,RRN:
M06J>P)$:SV09:7JT_X 15;Y5FWKIEO;,?+N"^D6'Z-EE>RP_M[G?^3FH$9WX
M]9.>U;]@E-$F;U-.]'S>,';^MQ/UA.V14#4XO?&;KAG!T7P9M?@G4K%<_/(L
MC^+3Z)N2N']]-N$V=VGD3=6ZR_Z[A,:;!8^+^(8*3YC8,WWH?6>_MM\X:&]0
M1V/#MV2QH+RDI*CA:4-60#R*-2P@*_;\.V.71C;V,_=_/KS%LH)FD!XO$XL%
M@7'#NKCZO7KT9*WDRQ[5X F8NOL4=^5-X1LJ6OR<HHYG++6U!K5;(3HO?[1B
M/OB0?)ALEZP1_AY._=;-VWJ_O]?G]-&79@].!0VL$QUR'GEIL2<F>N;64E9N
MN%"P+H>[_+-<'4$.4C/+?RD(3U @\-T"/D\RC3O=>).+:!"HNG/$Y(IJL0<!
MJ4@0>%-#L3U\(>)@*9KHL_*<RLSW]5^=7?Y)@-N;R?*+9)OM5T0)<R PRTI'
MRG97^QT?CN5N@X" '.-L/4M$$O( E\&U14;,)J#P]J/)O\\QR['J^$ &CR1P
M_PQCOK(34R1P@ZSJ6-^N.OP#$"")D_,_U/K/@4 .91U6H9]@6HJ$7X(OP\=!
MH+GNZ/>9=J2/YBX(Z*^N8'ZP'B:3XO??M?R(0[\5S''_?\O^E^4Y8>6Z0E$.
M@Y<B]E8AC6@3]@Q"4"O4LU#IV5[$)B'Q8GVC,>6_8RW]+P&XT/WXNOISWA&3
M1>X*<+SH?B-:VO\,C9B(LTG/(KJR;CM"58&]_:+(X"@35%Y>7D1+A9=#JW4K
M-TKEUK8,$KH>YG25[/7X76_KR7%/;Q/,MV?/<[>JO%FNLE+>#(]*BGPHKZZJ
M>E*!XM(//QXV-H3?/]ZW@ES_;W??"F)JY*"K8UFF8>UQ)I?R1@%:I<:#YE56
M?#+=A^9F]LS"_$C.</EFW?PVH2[RR&=FY_BH*"^=HU\J4N1BIN</1!NMN#LI
M>XO]6ER;*2E^J:4_T%TEI&*JR60=?#-2NWG?RVR#6R,XS5C^'7F^0U:F[<)@
MH'Y[&J[6"U<FB1.NJ^RT%I N-1O345$8&J'H$G(05=764EH@7/5$<\3?F?UY
M=Z>-^MG/AT-5-[Q2S]2\6I.>JL9Y--N]%\\:ZUXKZ _N<NQP?R(U3YM.R1-_
M[VQPJ]36(V8;S5<T\,[6:P8W0BL_:F#G19G%K,47+-;7/X_7Z2H,&I5XS\.=
M'"6NB3/I-&<SBY[D%!G OM?(F]%/NC:S_9Z9]DJ788,QNPXP5.>4$:R=B;1Q
MR]K(6)%)=<P]_:I@<,"7)[?X8P5;*B),!,L/<%)D\2!T>+Y*O3/(&;:2N:CE
MM?7D1!^LR(/.PCNHQ4P"1S-8FV#S0YCZGG3WEXF/45K]_3XE4I:/^EH 2UF^
M@HQ(D7@:+<G8RC=TW4B&RCCUNO*W 2$N,W?&AS-Y<)6F%IO4!E]8-D=V8VCH
M<^I_WAVZN^#)]>;AC_9;6TI98D.%82^VDD_MK/SPKIG;"K%RXF/9GCPXY+NY
M/&9L&YE&/<)W=N,KS<L!>FXT#X6\WO2UJ%3OV&)#W5.MFI]>=7IMD[LU%=M7
M5JKL!3EHZF)C-]$NSE\66W_9NZ]=4#T=P!"\E,*OT?Y+,2.\$F?0YDE^J?45
M>TL5Y5=)I25(<86"F9;#QL>/U9VI5=RN1F]N08+Z;]Y$0 L3>5YVBF_B!$WJ
M[_1Q4]$6_6S%*-"-LJ47 ,^]!'ULBU=>LC()'E%QR^M7;M\SSJW:$NZWS,E(
MC4UR*!M\8QE+IA.I^$KO(7G -Q"077^]D.<?'GS[JEU3:9%H@H(KWF5"LK*8
MVQ[!UFP]G8U$M.@J2%6&*W%F1I*%B]P^$?[K#<.D,%*U[0![7\;80,# S,AQ
MU8%2S+@V? P*<>:TLL8TZ:H8G>$K[Q-!,K0+MZXV:@RO6%'E</.:&]W,S@92
M%D]L=")KMY@CA@F]Y6($ZV75/+5/7R<9&9"B"@'T=AR4D<W(&PKAA9F&@]<>
M/:33>GU4\D4;4=3I1559X&SF'F'K%KX6F"\>>\%NJM*:6>MI^$U#FP=GE=_:
MU=3\"!8[XM$(@# J/ZP*-Z0I"\PV]X.F:WEUCB<ZC% N%*P^7C">@PF;K7M=
MTZME#@BW"P[FJ4IY>]&1B:_0:?.L5D=Q)._ME)^I7[.97[WUTL$^:LQ$*XT(
M-?5O8DW(Q"M*8?IG8@J]%DM<99-#O\\KVWV.E[YP;:CK\J.T$,:[E)-X=9-3
M&7J-DSZY?>.R@D-7H3++'4ZD%#C/,72>+< AYH*8\APGWP>)3FI7DP>I=6:+
MD>9F+9AW%Y.^GG_JMH1AA%=X.#]V$*P2PUH[>]4O>(>;TI7?B=9G,+#,0AC$
M&BS53W<$][YG.)0+2[EJIO[1SVOGI()*TL$X+$1PW.=4U \S8</'[HQ031UK
MWJV1ZI64C# ASU&*&*$F1H63YV;<^5;3E8OK_'&9=Z4=WRK<GX<7+$GLE(G7
MJ\"@8K#2"M\59%[[6L=;=$!:02YG09+RVP#Y-_TJ)WC97S%=8=>__ZTB02^=
M#-$7Q)Z*R1#;LV$N%W_K&YB[:>P1WR[W[-LS>YZ\P"%.!N7-T-=0+<G^9I/[
M?F\>R50*ONGU*D;J::H%[RV.>X:NDZ+=R/T-E%BWG53Y"\WZEB:=0II$=*C0
M1UN;=X]RS8C7/G.42K3Z^<62+0PJ'KCY>L$N5.]M/'%D$MO*B<IVZ9G)>!RH
M D%+G+>)5;S^ZK9LN:APX^4;[VH8A2E5'.R\7.3)'NK70>O_TQ>[FY)O%:<[
MYDWT%7NL7M*]NG9]W@:?)-VZE_4A$^X/_R81*-!@_YZ4T?G^SG##$.@$D[?3
M2)=GUY\1@MH:\XA*PSD$A9G)R?5;^S41>XU(A8H)E<VF&T>7<XF4T:5[A=^R
MS)%5S]P7\$TTJHHS!,1=0_BD3[;C$!I^#>\/^<5\6^UI730;^T$)U6;1$HK
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ML&7!<\\S(;0AA.'3%$(E-\#>SV)_>$U'N4XSG<<13D!ZIB&S\MR(563:Q;Q
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M'Y*>#%)VOPR25[V1=Q *9V6:!-N-51T9&OP_G_[(WR["LG0=-H/VSS:,H2V
M)Y=B];%?;+)^07Y3OYN]O,A4N;XU.2<;9WLU5U[H4%05!A"&\.UV,CYVB]^#
M3*/S9B&AT;O 1=JK"HA7&0Q-T':^"KVE_;#5SMYS\8-HI,YJJ_;%7Q))G"Z
M11=':QLWM)>]:):C%18?#""XPE_@!C+E S\^01$B;JT.*?R(M.W/4:%TE#%4
MU/=?GPD/6X'\AJTJH2LN:-J0(D!)]!P&T.V/^".*^U$A!J!S$VV$IA'/P0#L
M@>OMJ/6&BBLA^"2P!"5; 22D';NU7N(GQ@$G!K-(:M__EOQ6<C*AS/2.F$'*
M)^"P.QC *PR@W#_F:$2/K!V$I,:[YN8@^!_U=041>!?/_V4C7?,(.2*>;#S
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MW"WLO,%")6> ,FZ]]<KJ$?"DK&O^J!V-A5H]L2T$@4Z\VB\;C*\C]5O#;\I
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M!@.@-;VB^0;9D[T2BC@\@+%D[35<J8P6B9NA)S& 5\ >5,NZ6];_"&RT]Z)
M:&4,(!(!__[/D91]X )P\^AJ%>*5X?O?5_V-KGH@ZJ^R5MI'J4MA'3J# =Q2
MO ^(U\N+ZA4+P(ZQY*3<XUMD\B?ZPX1XN6O\+X94,WF4<#L\%6VX/%R_VAI
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MN_<-\6>K\_.8-'I("O$MY::WI&'E>GHOE(WOP>+<#-NYN#=GS.M;>A7%[=U
M%6X#HBD!MPHY#AR(Q[8EAE=T.?IM=\':VE+S,T-:2$-ZQ;9*.;68=,*L$M,>
M)?+/XJM3GO(>^]]DNT.)IST/1_+V13-2BW]M>91;ZKU(D@*5]YJ!*@J+I?B)
M)H>I+ R?Z2Z&&@1"R]P)L(S27V900[ZW\?Q8@'1[MI]T43DX*B1E!M^)Z-?
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MHGT.H#;Q1R$7\T\_++V)TS/,CUU<]_1@'0HPC_-)/="1_YN%Y4!FXNM;T1A
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MH='E3!LZ[='\NP7-P>=3[*4.U^?A&(#$_AG44>7F 7+9YP'J_HK@,NW 4PS
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M:5/Y*K6%Q2XLZN-3?7S/#;D:!"I96.NO&\B8[O)4DKZ0EB.]"QERRUR'"DN
MM;6PQ\AX23=4MF8*;VWL+=$;[79*-1[&NJ;1]C,YC"Q;TESV/STRTW!BJA_2
MJL+S2T^N;%XNTG9J+2B@GRK#US.D@ S7E[AXTR;SMT0V."V)>"V(JE(+?661
MVRX3&XCZG#Z]+Y#L$4!<,J%F2$^AM0$BK"F;:NO.^#NV[:L:9G4[4109H0MY
MMJ)G[I1;^C'I%1* C8 ;08M\'VV)FQ]^0'U8-.#3J./?Y.FG>44K2?+.\KM2
MDGYQ*O6*'F!*4R"2HT#B>8L(60:W;N;7@,QKG1:H#=AC9F/1N[QSJ32G?O$
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MY/(.#,7K?GTQB+&C7$<8PWXF8GI=^<'JVOAU]>6/1:]A:'-VLFW(HI>>O;L
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M;R[+@3PSYWXQAN "HX.^O5<J,:_YOT09O;LXS^U^3=P>J2']3,.T4YOY4M^
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M5A@A-""'1(\_?P=Q)$K5C#,K"+B#;?D-\XO&PRRHYZNG6;]H##U21LNR1M"
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MUU!O%Y!J@N"8PS?R2G1V(*58[,F71GOQ^-_ OVLZ(HO*#BKZKS+P[>Z,_M&
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M;E]&J"24YI55*CC+?^S=LE-3XL+42,W,,%&'1-'W,RKLB-!P&[DREN,F!C!
M2!C4F0B)]&9DU'I".(Q3J".$#-<7S2,5W:X)J]ZXU8*^,"=*F_U0ME$.9_Z)
M\J09F*WQY,*;6#1^X9'QPIB^+['&22FAU6?B4UV\+$'IEB?S:O?ZNBF<ZU-2
MN$-)>0%ER>U.P\UR$!ECO3]#=&BXQO>L$"&/PE<3&80+IPVS/NO\37J9Y$D;
ME&\VZ(LKO+3:]3ZI0_F=AW'"^/GH%0FK7\7IFI-H:9'@E#VD#385"^PK>IOY
MUU5++AK& !.DVU6$=%4-#9T(S@&K"-!#MKJ!\H,#SM%I%D-2$D8YI^8<CI%Z
M(:\D*UR10(HL#B<M0T)H09"B_:R/2\/X4XB\2-S]['7;@SPX&<+-L,FQX495
M4L3FA%(FHVSAVV^JG$X;J(SQO*S,7Y=B)L77EG1P"X(''?VGT[L/VQL#LTL&
M=O@0!Y&OTMB%;06X!:1!FL>4+R4)[@\=P2"8_=3'E Y\#][HAF4#".3%W^"Q
M0%J__+"DO1>O#*#B==]Y;[\R.Z_O6>US*B;;XB%SF$UF6-WLO# LX,_0F@]R
MJX"%Z.G^M L!D3-_*:NNE8'U#*;;<&Y:%ZA7%$86A<=UT[P5A<9!-4/,FR48
MS7FK,'7,GWH]@^''G>Y9'4;_DP8=I\CLMG'O2!N";I;F6:.G^0N^35D'$VW7
M [SF8.N=6@*M,9Z!>^H(<DY#9>K/X*47[Q8JZ3!L M.5DR.;ISNYC0SG^\&4
M[HUA=?W,^?=T]GJ>8 ')?V/'2"<X$<]<LED>R^=CQO%7,^+J%C_ _W3"$"KC
M.\\M\Z]KUDY+@(6R-O?O_,=P9VF#(+;/L=CP)-7L)!GEBF]NZ[Z%*C2QX@=H
M1SWKB&W?VLB'+[%;14,RNC@^4_0SD<*@XO.)F4F>V,X[('0ICP8\ZD!YO6(P
M_#*_.CK:FK?()T%$+LOB?'$TS_>S^@'/J*1B2RG;]%.^W**EO@+@%(Q5;+9%
M='6P%/7<,&67YLZ7G2KN' ]WC"&V5JG$&'6ILWN.%B(K))\$]S&J;)27E"\U
M&QP9<[\0SM5ER9:R]WNI6>:N@E.3;PIT/VHH_I^@W_]9"<#<IM-'3 57V!N%
M,OHT3$]>[;X[3YIV\1HG?(I]SCG4S5Z,F?H%A/F%^A9:^6&W3=VO>:^E+-YL
MD>Y;?HA\&T=RZ<\6#1=[RCW/8DW@U&0$GLZ]HVM\S1EAKJP7(HK<24MUK0RX
M2>8+FE=^1EIY5VYW6-SXA1Z?J(MH=;K*NRI1(X'FMSW?8,)N\R2CD.9*Z=#W
MQ\O]L_HA,<X.+8@2JZ(T!FWYS?>8!@K^;N<\P85R&8IXTF,9UJ"?5=5$L.S)
MTJJRW!XGW$8!/(64HZK%!#Q32'[:KA[.-X,2^J%HHBO:$*WJ!T_Q&UZY75)_
MP?-<8UXWZ,Y:'EX+]N^ ]^TQ.[[>@ZU%QH,4)'"J1@8XGR#H</O'.E4<0_?:
MJ7#U:=CN#)!2\-#R<1[8%.Z]$/ZY>(F('WPD [%9-V1[6I!W$U(83JO\*>Z6
M*37U5NJFI-3]O?3>P67%R5)6X\PR5[NK(FL=6=04PX*F465^.#R5V/R:XE&>
M*3!G8Z5N,FQ_H?2[^UI]AX)C=:G87+IB)>MVM7W T _*H365"SV?G^64P;>:
M($Z@Z*W8T9_<1#.VX,ATWA8=V.7,VBI5E$[EEEGS)>?V4^@IY0?2?.G&7R,_
ME_Q?79;[^\J^O5C>;P^KJVM87!#QQ>?]B&E(_8+QV]ZU;3&[E=,%+XT/<[L.
M0%C7=U;_/_NH[K_4$N@G[W<PCEB\C6G-VX5%IUU#+^Y&0>6R\ZJR]0H*\6*H
M]*\#3]X>_[G8P;._\G!_U8'F#E[X_N7J1J3/99#PY:+L+7 %#5CON-V@;O\5
MW?[7"CJ]H)7_-2MH)=Q]R ##A<Z>H*"KD=WG:P^IK"Y&5?YQZ(/1$S7P\T*K
M:V79O1E3T6$9#:CS9!X8#6?3(HLBAN6EA11+'<73*_[*5.(<K\(U!85BW]E!
M5J7^60R2K1&!9W;9V3OZ14RH'F7J]R[!?^<RQ<#JXEA/PV/3HC:)\$1)D^=5
M6R:?[WL..Y/HL%)K=O$=&IQ59V9QFX\EI6#WH\\XT--7:,!G/^3'XN(Y?0R$
M\_HU#7<3#U=8P3(I./)U5# 53A*>V<T5_#:UE;=)V+;NM*!C+8U(ISL(7ZK"
M?[9E+@)Q'PW@*+]!E@40F5\OMC3*,+C[!1YEC@Y?.KDH-< GK7B^P@Z&J?#$
M8Y[):_,3#NLR$>$^4-%5I9MD<COGP*F=@*IP^%:Z>_U]EC^M@CA  Q8GP+':
M**Y"?#0@@$7+-^ZU"$K^)@8YA@:4N;KA;:M<OAA$V:(!HR?N]59-QSDQ_QZO
M?^]X9->'<GQ.S.(+Q7&U!5ZMVF0G N\E-Y9]DAQ[V(8I-TF2G'B*UWRL6-#U
MN?I*QOMY,;KU(6BGB,H+3S3 1#",-KD O.0AI%)BFEW 7G)CKY1O_1UK)*[W
MTO+$2;F-9#8/\V]IX+_>!=]&X9DH$! 'F(H&G(JCO.=6OXH\<7$*5TY%>+9Q
M-#QV6/D^>""IQ'QS\&(HAM'"7@G$ R&H8 Z52U&-D;1N:+@+\_K%?M@H3>,'
M=QC='0L>O(XO/W& ,_I>[-5*^JQ $]QW7\1814I28TQ0FT=;%Z02%3@E/*%1
MQ[^M/W)2U]UW-]RSE:CG5 ]PD5 T8$VVG@M'28-DF*OT 0CKI:%Z7H!GK5SX
MQ53Q(:'T1T'3<*6SB#L*^00-H!=?'#W#]P?_+&]ULK4?@IIIGSEY'@7,+OAK
M-$[H,@W.VMNO]G%&OOKFS__X@-VE/+*@0 V'BP,U02\W2/[G &+0A<KH\/AI
M"D(<F8*@@J<CN@\[F@]?0!>I2C[-HP$#">N]8W/^ENJVMHCJQ*_(E9<:V[XD
M(H$C9;)\<65IY73!%**]=^9 B*>Q[)LG/Z=OC'!URMK40$;;H%P]G/R1[DM3
MU5U15_WPC9R+"0L-\Z-WR0;0!+*AVCAB/O*LKMT:$&L2X7GG$>'4N.(VM.^/
MF-#QNLK0:";X[NU20[^C :'^DL@YGT;$BA\8P=-4TJ!BON%1(1-<=2K"XC2Y
M:4W0ZKSE24E&-9X,U?Q5=9[D+9>3[C$MJ89)Y$YE2*G^F#W_[BV?7JW*-Z-8
MP*_1@!V6V2PZ-"!-_!=*\V:ROC6=;5G_"?B(*JJVEK2B>Z$UR^THLO>%U) '
M,74CF8*U<S-27UUC0DOJM"[I;+<>^'/SQLG]J-()]3QJNI.4=@#\DCN!AKA#
MUR\481R&>+ZB,]"QOK+</\'?+A1:MM*DM]R?/&!Q,>1U]:MW!DPH$E=8>B.L
M8QK"DAW90Q1/VC[;TMBY;7-:A09P'8?I0[<*C&6<5E"+Z1A"#;N7(3/[0U&"
M+RJIHI?XR+6&IY4T* >^+K WYD?G)+/PA,UHW6?==+\S966:'6YXZZ^B?L,3
M9&MK H)M1_B& 3G56K1Y,;>RXX;T^#[ET+ZJ(=E\4LFE)5+#SFI3#&').'5=
M,RO.'^88I,(5E'E-P/X0HGHW1\](BVX"5;"7ORIIAW W\\,&R1+D9LQP%!],
M^]/&.]BE_R$U0O\A@7@J#T7HN7B#E;?I"=_?I>Y?2GP54-Y[K'6(.HZ&A.<)
M)L[A'/D^_QS#!(K)"8&T%#ZV]Q!QQXQ^+&_YS3LOY#4C.<[A(=XB3]W2BVQU
M"QZOET_?SBCA;=Z7 \!X-F.Q'A6IR3;-CI?W)!(D_49*<&9':;X9J*?5C%/R
MRBE_2'5_==AXFP8^@@"/^WIN:'\WRE_(@,+U:WSQ+<</WNWH^7THW0\_  8U
MO+9=#ZID^?ACTRJ=#>=M4G91M!R.>MTT7B;FQ?N^I<8VE^GYCF5&:Z[<J*$@
MQ<_N/B48#X]>*DF[JDFH^R@.ZV\O=NH_4<1\KL*0'?..L\#Z>X(V:/T>5J;L
M*^P\5SC%MNP(.-*8%YQB#-^[FDW(/^ :_G)5,*L3,+I =LTI("VXNU3UWJ5I
MJVS8BOVDWMO @P4OW=\%0>9<SS^I*#--)]"_ 1"K<SE:;#M,#SGV$A6X3OZ=
MZC[#.!/YMMBD3+][+ =VKT".2(SR2']Z>Q%LU:B?]?0*6$SQAD P&5!+Q/1V
M]\6"M5SY/7ZJ)T#& %OPR^.0=+L"U(OM1FU5OU34>S3@92N0#E^W8W%^=;D\
MO>9B40"3P"C5YB1I7IZX1>$85\DMD"&$#6*+#),Q@4C4NAQ-#^&+[>J6'W#1
M8RDI4]N8"Y=\@\P$9>/QJRF!G@B);:,!UCKEI92SG@1/$]6K98*2&+4*L_A@
M?L6JRZ?P4D3.74#$'1\3*SKEZ_0QWM*&*F\>#.!U'K3)+,.N7]3U.9"Y\,.G
M!SXD>0WYXS0_]E'0V6<)U^N#4.=8!ZSH[&46V!(9S=;8+QTE_&B4$*CO?IG*
MP*S!/IP?N$)Z$2]'J Z8-ICXS(7::W:I[>':K+XC49]\9-?J] +%\IU5[XE-
M,R>>%I,%V/N%'!C.(S<Z[B.9YXG2C0RC!.=+#Z.7LT?/7TP<"":3KO(EQ4>G
MTS6];!;-?*S+TRHO5;MAN[LYKHV17^BUP4/B<C&,X]?NWZR 5[5/R"C/KGK!
MQL@ :;QHPJ%8>U5@V^BYS.2P/M'+MP#*3ZDF?2;#P)E?>>%-_TW&[H> TBG%
MSO$I%8(#KE@,3ADU.V_L%0^\ZDR+,=_N>'L7]4)K>7U3/C!)O\/"<:!6CZXD
M(2*<V-BWSXW;#HDR*4U3XW(7XU?)"+;;HA"QRYAY_<*JV?B9PX3*(X;HCT$]
MRKF^GU_=M^W\%#^V7-D<LNW%244;CC5F97Y"MEGQ-B1W3#6X>R+TY#%G!PU8
ML'Q1\<1I1QF&J)6LUV]! U($;X;=CQWN@L[7<*5^53N[#W,">>'9TKA, 5;.
M9G;.<7&$JG+K9/&D[V(>V+MBTQ7-S,LV[+\\>E86>Q54^/*-Y916_<-(RA-:
M3<ND%PZ4<TKE@RN[!+JMC!UDV3X$Q($E;X<>AY\P#-0!H/H7LJ?K"+4QTL[T
M#)$Y,(T''K=;O1$,QAVB-*O3LGI,O9I9+"F%X)K\-JDA"5)3V<S,4K8-8?\R
MP5:8'&:+\_*KX3R\M]_#8_!34VPY@=WHTYC';T3J>C\&9?^:XB$#"-QCXSKR
M7)Y8,GX[5B#A=1B.L4YWY2XW]-"4EU634BN)%C/K=W9T-\(F\0KSQ$5L:HI*
MR'"%HLCI@"86#2#^D#@WTETZX,BV5K2DLR:=51#=W@%UM+A8^9H'G0DI]_OV
M1&2D#I;?M6"G__!2/P,(H96-?U+(1:KS@Z>:56ZP+$DXU#%!0:N=[A+/MW'Q
M%QH@R5N3/P:HT.TC )#>]R47]D#JA18(D_MR; H-H %;[B>3:[/PFWG]+$N_
M;$3U\NL#)]!9L@9=+?V"#FYI795=Y$_3CHM0$DS1I TJKW4BD#LW8P25AR(=
MB%W#BYF]=J&L>0%^ZIZD-S-"Q#M$=-[/6%[R17W[8W5)-B&V NNP1-+P[2C'
MHK[#25)3<^R5&D&+FIKU/3IVZX\?7=79NW^=Y?8@\U"FQICB3DB57>YORXM3
MG4PM$=LK3D*U#2'["V+NLC/N-V;.$Z/1>1$T"HF$_,]F-F894G^^*=>^)")Z
M!FI+6TO^QGC8T5_O*C[O[MD@R=76($$VGL];5ITA5<UI2_ZE>R*<_[= <<U1
MR@W5&?'L!)3?4_IGE0INGK,"*P:F[0"F;7<CI246R];J*3'*S)@UX*T]\.-R
MR@R83%S03VMYQ^PN;/N=#PN9SSAQ7@CJ0;R+U86O]6!>SDDN&HK<"'J-:?7Q
M<-LP=CV][D*ECIXZ>%(BP5%<OZNS6R9M&",/)T_]0]L*1:L1B)*TB*U?:^':
M$(F&K.G> ^+C[+[^=?X:+G<N7("QGEK)6WSW>^(HW=:4M@YS-$"D8N]H--[7
MV'+#]_G:SKLCQ_0EQ5K,=W,0KM%Z]N=FT_)1MO$3N5L%*5X@6KN':\ER,N7"
M<](CJOHN.UP_'"SAA&VI5N2[9+D6)V\<7AW>TOK+5;QR4QS44&D_=E5Q*29?
M8'@TKI[[9N&1H>XH3&.,W(KQ<.\($Z;[;UQ+S;BC)'C(-M0'8\R+@&$$W6]L
MIX/(RUZ'K#H.-& ^ML_"@PO[O?EOT+&!-+61 EFF\-5O13E8$DBU;&RBBD#S
M"_TTVZ41+*L%X\Y5(SDYMKB5[?%CJ3 F@)0B',4BDA@JS1XRI]V6UUKAPBVZ
M\[%A;':^6,D=(9!'ZG*V;.Q[)I""#,:@0M+"J/$[S"L,)+W10!&A 7$(EI-C
M&KC9AK&"2<<K;<]0C7%DX(AI;;N  (BZKV14E7F_M/"=T1T)Z:^7%L<LW8Q4
M5QO5-'Q3%*+KQG!'<9I2_FZ 46Y\![!Y.D]?H %?K5#<6$=HP!*I?_3KU8UZ
M-"!3#@WXN8SE;?<9BCSK1P/$S^NPJX!O'?^_0C>Y=J=Z[W+/CY:BTT=X7(Z*
M[]@R:05AC8:RS8RBOVIC[$=_X205V).CO4FG:?,;S\)KH3G'H.$+*R4'JJV8
M/G6STZ9BUU=KQ#ZNLIA:@M$UGH$]$KCK\=C>XSC!DE+/W.EE4BH@U&7$N>T8
MK;X6#@=&V[G!/E:LIT_59Z0F#OT_TRV?(S">X5Z,*2JB-L;-J[7-#!C5_)_5
M^@NJZ&&4/KYSBB0^Q4H%51_\;4(\GG4EK;HK@?08U*Z3@YAP,19FY&DM:)2,
MU2FRJ5ZK^VQF4>]?2J9U+!ZTSW<P^Z[B1W]UB#0-N:Y<F%Q50P-LC8F@TUZ7
MY9IKLW6S,6\[9F"9S?/.W>E.5B;5\*X!;3'2"@BJ;7K*VU9O=AV>'L!U+)4P
M'10X%OQ_ZN[ L#38HG^:P>#S/C #1]X@[.+RBK)4DW!^E5*1:D   !G_AH01
M/V!_29C[J5_=7EA-9Q<X8BOG8Q^#P="5?'QL_!OL4W6(_'7]R_O=Z7C_E+E-
M1CP9DM:2EMD0GDO>(MQD6E( *4RRC);;5NW;A2G4\,9*/ C"A;:X!]3^.ZY-
M_G?!_[T 1Z2UVM8'7"CBV;![4:'AK^7NJ>-TU%,P3RIKO>_*:_\-9*3$HQD9
M.U4S;4Z>J-$M+9HO3Q]'D25_][P< KSF3.6,$R\I!-]<K1I^TJ;>P]W/_G!>
MC\]22Z/FAY;Z0]J(/W?,*VC.**UTT8"5%J%95&(%$ VHZ@S87[:O1:8#TRKP
M$1U^IJM@)D$T0-&BA3W&W+-W9W?>(]K,3[*SH#C%P>&P,LL^?$8BLCM?;2@]
ME>YIF@>[S3SRTQTRGFUIR/J[%C;^P^[?%==/3^D,"'\+D:E("PD*?\1NN\^^
MK>>5&TWGX4W5IPFZOYGP_NYGD*-C8&)S9)W*QWVGCBZ'ZQ\:..GM>;8*:5N?
M(UW\/W^W]?GP/9B5WI*^JZL@6+AD?_+=^=JXX[[RVHJA?OQ->Z<V82*1 (_2
MUZ[I-S%$IKU*W?'6?!SSZ8JE(1JW6C![:9]B?MCFQ9%+C*O)R_0(FM(#UZ:R
M *-$(.Q1;)@%R,Z?2E(W]%>06)7SY(:8Z-\UG7:)]KFCLJA\--P]F*_W.H+W
MC I6ECN346*+(M"REEK,*GAK;NN1'8?XI;,YCR9ADG=+9VN?]NAV69J-Z+0
M 6R6/W)E?QG7Z*Y:K!;H1A9T)'[)/Z[-QRK7QZ[XTM/%<FVIO;W%!UKV,OT)
M4TN-YNGLM&SL4M(<A%RA;,O>7=<@?U#,OG:@9@8D1RHF57!7S7Y9QVL_GSW#
MKGG]UL)KFD*?% ]/05NN_B6*K+*63NPJN$@EPX/S<WGC9CMG3?ZDUPM3)0-;
M3+K[%IEJ7!::@?53[XR7?;-='<$O*C_JR[I>$)\NTCSJ8/WE:6S_2RAD\N
MQ;=Q,5T &5UO?<88\V&#=Z*"5<!#1(RRYH5"FJ'J+,=+B+P$PYVEO55BZ3Z.
M>(5*2-C0$MFPDM@($!ZF5F<3)J&8O/&EJ7V\P\Y<6HYA+QGSCO6FI24M;)O^
M"QESLKP17(3GTFA/:,P8&T6.!/5OUX+) SC\?'<-MC<*0R* &3#EG!_V[+ Y
MMC#K/9B=<QW_N89&[]!0M6BA@*7E8[(P\?WEUYYH0%=,6!;'<ZPLY@#^,^.
MC&K&"8?^5L_2#ZTH/0S5 G-"5_-=F$61O,1YOB-DD\U$H81Z?_E)N^=,N_L4
MA1#FK*%*58.5SCEJ-C>&JJ%!R-@AG"O]"W2RF[-*S<QY3$-MHKOS<S21\>\_
MIUF*&**A6[L<SKJVY**%W R*8GB2%'$%"@O>:Q#U^"Y^WE)93G4Z]KX!4"!M
MT!^IAPB2=WXD5_HGHSX[O@S9 <Q(U[V 'TLE(#Q7GW.PDL-M3&)Q=(MLLI=>
M*Y6$BFJ5$F/DA$P-IZ-#B7)28\NE3-%_V)$XO2GS#@$/[O[5*U6CM4.\Y:O;
M3HNKZ9/3O)#G9L?*7;"#8/M#*$@^N*C@1L\O1.;C>Q=>Z?05LM2U$/:P030
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MPW7ZF!;51Z&1^1$PRQA3FA,Q4<KVS=DS!><#&G__3GPCF>[GTQK94X]Q=@T
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M=)VN(#3?KW2E2+$A31JB-40K2V2B3_**._F[3,(7K_'2NJDO.Z5%MH *H>7
MK&?Y[%KVQ3"<\1"['%X,5?+B[.[-?[?F:66A9X$)/CTYFW>Y2L34R^?(WB?'
M6,<SZ(&OTTT]:(*4_:$$:TECO0RVBN8TF.S[IOYZ3/7O\#:5Y_=R]-RUJNZ^
ML)-P"_AB"F:/EB4N<+?J, SXWGTPIT@#@8U8^C2:CJK+J&IQ92N6>BM^C]]Y
MO<>#7?WP_"]P&?'G"$-0A?[FM]1^I;E^"WB'[D<]130OQ5).3[;#0PI[O$U-
MCMC%FIVKAM1MCD^%=;J<M-/M[&'<O8GT7J[*OU./>V-L[J!@P^5_.R?ID=J.
M(+3>+C"5$ON/J:^WM'I #HHI=/XZKOQJY&5DZ9 6^-E<4O)DS?1&,31FN4M#
MNRNJ/Y*%=3U<1T%&FU*B,>3['2:71*D@!]8N?@[G#OE ^TQZNL^JC%9@)=4.
M">5%I0/:T^ON12E1+\.[?TMI0@8VRK+TWQ<6%F7X\M5B_8X=N,.45I>=Z)D.
MTH#:@]FK1U47<I;[L0>8?85VK@7#I2RZ5K\'W&F_Q@GJB2Y%G&;#N\$DH?%1
MPRPF"K3OZ"U??%Y;\"]C^&>DZR^IZ"<QMX!T'W07\/B#H ]FN6O?;?@60%F%
M1LIAB+=Y!XS> +>*0:B+BESQ3U<O_XW AT80;NT8U%3XN>J#S8X;T%.^H&B4
MP4IZ+JA8Y .!0CKA#._V[\(8Y3?B^SAG^6]W:LTOJ(W.Q:5/#97<)8T3H#'%
MJ:2:*@("!>\R20E8PU?MU)WY^?P^S]M7TRV%TU4]?)1'ZQ?.8@;)AWVP*UTU
M=A\1B\)AQI0/OBNY!1A=3QON39P1GKD6R;#_F?CQ>I+B%%G>^QVCG91,=V/Q
MEZ:<9L#%\/A<_9;3^[RR)?]=?15^QC$$C@,]0=S^Q'#D\7@(9J:VMR"1\A/M
M#X=))<U\^%+3&]1\%EB[U:=MIOP-/KEQW->S\_EI/;-()WG[O5VB+"O((]M/
M]Q7H[F6\I1V3;(E_)E+P8&MZ!(HA!*%;KR]\?4+I-IG4' ,'9J_)>;\U'([L
M.YH,=PTU\0B)')32_QZ?&I!19H"EOC*4XQ=)+_B4DFUKQ8]-H)>VT^TWQR]2
M,'+'<-"506:W .[AG3EC]=\+"NW4+E:"]"19%_/I3A7Z*O7>17C\RJ[K2.'H
MN@@\DD3*EZV16*7\DQK,T.*0C?</ H6GYWQ*KJ VGE!CQ\7:F9D6(^<'5@>!
MK?6V&61Z.QLE44ZC73*X9RID51EYJY^46HT2@P*OZO<FH.] _R [L?_[#00O
MSG<Y'\ G*;,:&QZJ?\L\$I]N'<>K\5"(3R28\ TH%BC&=5*#?>&KZ\FN7HE7
MC#01%YD@?O"W<-LMH$OZCO4W=1Y9"^/?<-SLW *F./^*5 P9$X:H^Q;@S]T+
MWG$Y F&J__I%V[CUS.,15"3:XK*B\_S5"?^1<,=;GQ[3=>+=A6LE7]!<NL0"
M'T*VT]E)D177YIB]GH%2^C[%,! (1+#+\EW',9N/"]UES<J7__38%0N=CF(;
M6\)OX:P.DD.'+%X>MN^^J?CQ]7!_OAG;MY=@@)*?@9)!3!):T6?I8 TMRB\,
MH;*'E>9_IK=)^*OE(^=*L,7[46]EZN[A+6!W/ME$M[PU[OU![.!,>D"*@"/]
M)$G@BAQ1(+;T1#(;I0S;@!*?\VA_%+W/V&[Y8ZJ]!>WS?4Q0SH"HK7/@9#CL
MP+EO>+\]JAT\>GA^E)5ZO!7H8M+0;463P>J79G^QR7E/N^$7'^]@A*8Z94#2
M,7DBBS;['2-M8G\(?M3R[8/32(/[Y<*/1D'B-\&"GX97]BQZQW34-VCU=V"E
M]K0VD7Z^*YX?UF59=W\DQ0?>3?W@/_YT6][YYSY'ZU2K=V!7D\W[O(XEREAH
M[82.EI"$B-^'(V]OH.:5NO/@NSC_^^VV&9X$7D<FAQQ+3;D'BPN?9#W?M"?6
MF!R!@J'NI)2C(9FONY0(!DK)!K_+OW@]R_=]-U>7J8#EL-WT?\"!*]]\EOXP
M\TU71Y;YX*5^2$RZO!7P]^?'5\'@.[OMSO[4HKAN 4+@NX2F@'18&>GI3#3%
M.08_QBB=JYXNI.=  L/J?$Q0AVW\SXY_2H;X19LP?C47*$?$LBK:>SYL:8%]
ML@]H)OE):O#Q;BD<<GHU4?X!D1B]'.SURS*DDN!8:XZ7V754T)%3:U,+T-O&
M1T<"2M2V"E<N,_! .#A.C*V_KHRLQW73''GZ]G6\,KT='<CKL,QF+0?-]-+'
M$W[2L9 #=/>_KF25('*J'#HP31"_-SI3L9#5:U-]?=%8[?E\>@#R4^=@_?OO
M-68D9!UFMYDWKZ']K?O@-%E970E+8F^!M.KK+: _;%.5"14Q]M?.RH8F(NO%
MMR#0864-= =SLVN:*,1ZU9[7YN9Y.B%TY3=5]7-,R\J.S6[[6 ](;[=B9_A*
MMD\?!R?#8,3K,)83.72)0 ^UC+A=V'C< GB.4EM!S3[33I;F@:G'1P7;N^_W
M*L+D$]/I2?RB*T7">+4UQ=3'I$MI+W?4;1[:[\"H_FJ.E@Q#.F,,C/?0;1?@
MDY?SE..M(JD>H^@FE'_+]77%ZB[ZT(*?@YA<6#LIF\QQ=>.;D'1Q'TQ7FDI$
MM_SC\RM[$H#A@G_^JSIPTBW@Q/82A(8'N:#3,";&\#]AP/&E0?)JENM'-1Y
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M,-3<%_3\Z38ED?;D]@]C.M-X;7>A3WO(^X>9BS,),PQYYD[6LO0%'#JP83B
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MT[%\Q44G@,@)-\(154HZ=(-[J]16F#68ZQGZ2)$*<V \4$\W:ZS_.7\W=2_
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M21$EQS^MM+&=K-W8',VP@$EZH"/]9$<6AA\+)N$A%7ZA="O^%=+_(A=:_V-
M*IA!)-5[ !EAGXV8>VA[DMMXXO?NO.O!" 8Z_%6X\&2!QAOJAK-I2>JR2;D4
MW(E9B(S*C6HG867@'[1#G5+0C+[\PN?%N?V/]BM5H[UOH)%;CAQ]ZG(EV@W4
MB<LBW\KI1;7WACD?];J6=M\.#;WZ?E3^V6,J=:OT&^:+*USN"AG#8'JL&WC.
MTWPN=5<FW9 ^68I>=45E/.>L$5DM3QV,.3FJ6B\M7U_WF["@SE0/DV;5UM-[
M%6ZSTHC;5"E#^0DA..)PR;G17RAMZ2!-K40O>WCD2-YU+'.W@1HMF\+GJL))
M.P>^X>1-_^!. "66#Z64WM(/8C!/Q>N7VU='N#Z [^MW4"Y8;^W.H\"NGM3!
MA,(LJIMN5_Z\K&E#V>,:N?V6;I^#P44%\2@\M/+N1EB+:#2CDD,-]8-%M9(>
M_MC<2PY@[IT$O:"2_0.LE[?B_ P3V685$C2V)8U(<Z7-CF&.X^Y-;;0B+P'*
M20:]'(29H451+]_&1*GF*G\CVUT[1?G\\">(7>T*8FS-4ST+SX[HNH:8>BH?
MK^KI/Y#RIQ5DFC0,2>CH1.</SDGAWF9FEL;WB3$?410Q;ZE:209$C-(/I:]R
M=6=^C-U*?:?U(R4JZK45V5L\$$GC5D^QX$(MSS/ ;D-2?*BZAHC="NWWQ(Z8
M""I7]ZCP:M3)!=*383!'D+^'3C=I_NK]5CYEQ:'@*I5[0-/@C#/FL/*/Y3B6
M:)*HI!I[00&SG>SR_:)E#;XJ_==Q?AE4,I^H4XC/2WGFW:I&8;T*(H>%-'F3
M!!.5?1&1>B@OWWH=EJ%L\[/LDAJ#=]\PFR7TS1_>D(QQOWV9C2ONANXZ)2T<
MJ&\S@AV=1;5STZ\\<SL'+BB!F#5?3Z?CA0W)2"8'HPR9#VEN<*2<80IN<;"I
M#V]IJU#;GN+@2%^CSGN#O- ':BB'I3>^U_268I0^<B1A+TWD>BU9K,"*FI(W
M/"F[_OB$"9N&R"Q <43.6YZ  EF(0,_Q\^/5P+4SM_BJTT>0"L_5L5#7O "$
M*B.YIG9Z<DX5!M27SXY7PG1(^2Q= XH?-5)Z%YY%( 8BE\M=_ND[;?'%*]D[
MBBB9XGO&ENTFZA4U&XML1L*;4D!_<58LBJC9L$$1V,VQ3@Z@NBX8=0X\??&*
M_#4Y:I5/PB>\@,'#G>N:\XDG$P$%!\?1"H73^LU5ZRQ'TUH^PH#.PWWFTM;S
M5+GO8?R>H('M"G8<Z#9CZ;N(G ([8[UBZR1IIM[[^)(]YD4;&]YTT5K::,'R
M@I(& !_ [T4(_T>980$/(*Z!J"T %,ZAQ)ZD7727#"GH>"CM2L^U?4!9S*6]
M@]1S&"FUWBW5@=N"!@X#O :'K-S/I[9*OT^A.<P0./#PO&$P+RKHM=7W99@;
MJ =F?(W,V,KQ+2>U2UJT_5H@"YNE5_B&YR)'(P_&0;7>4F'R^)+J1<#S*H=N
M0FW/CNJ-7,%;P.OR!O)/&VH7AZ,"2*7\1W5M6[7\-6Z.,28W$@U-RCM'CQLR
ML871^%?X*W,RW)B&YKIJ)&0]@IGX)++7GA0APMU-S5,+0\G]O8).U1&Q!+*F
M[A<DJ'1-"AF+=( *D#9I^9^O03VSK;IDVX47HVWE6>M.^XCQ.LHGPY;1-:U6
MTS\PQR@[;Z@5C;'114WX3Z487(\9"#-U8YCT.+2?89NCD3JA2'.010G.L^@D
MXE><''3*@)N6U+01]FH6 $PN;<J41NG3SRD<:&6Y,GM<G9/8O\)YF?<>C\E
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M]J9_T$&3#,%^N64@6>2;KZ$%2<"E;:SF2F&:ZQGJVC%ZZ!#YL3<0]QLF*(Q
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MJ=VM$7@D7X^C)$MAIU$JE_^J)_7F,ZSOZQQ[M!5:6Z$XK<_<*>%U6<D+Y'(
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M'GT;=7E[>T?@JZ*?'L&@)](J%ELM!8:2N@#"Y-<@@LQ4%<^,K9T5A0"D#0Z
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MOE)RV.!7LU&%7.KLG\\*%HB*-=LX9J -@Z<$.P[.V]=)<*CQ5*)Z%415.L'
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M.*S3U 3U8@:\*N?XG\AG74W#>V4=6?G,B U]H- ]19EU".\$6AAHYZB&$<D
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MPR^N%4+2SU=4A3B57?2\6K %4LSBI(*\-R-(:6+V_'&IP.O2FS1X[ ] ]^_
MBB^ZD,H.-]]D_U60D4(+E\LUR,N"9\>8ALFN*G6RV&3F9^3A:U[$ 'ZV%UR3
M/VJB!RWM=A22*[S'SL;J!$?'SW:X)V"NCA7?](5\)S'ZCIQZ"K1QZDF3"SB
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M*3[0<L?46R) []IE[5\_W!,V0P)8Z##[=_G(TQ' )&4VJ$&>#5KP)/"CJ3[
MOV@(,:_OX22K@"'5$FMP>[I;?]JP'?BCB2MH/R ?S"_C\.#)/@?*49V*)<U5
M=@K>+HK047/[<&,I\\\1M;&&2L-T8G_ESXSOLUTRM"[7FQN5-<AV[\G9@>6X
M/!3/[\.DAO5TV5I;W228K?!=P3OV;%#7)<L%4^0E(/FEH%]W'+W5ZUC&F.X-
M#W(/W%Q,E:^]-#RSJ'W,I%/SSEG*;XL]IMH*<D4ZYXKUH,>KG8\JMAWVQB/K
M[^!;&Z%E@%)]]@#\_\$&+6N :2_>'TY(9;!!BE(KGTLL6H/7(EC.57K0;>Y
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M_. 6#RA[N;9MS\=G5\70)J3LNNR\&*7L/N>UM;QN<Z,1A:1;:\63+W2D'Q8
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M8I5CG2 6IHZTXST=1IO$"GH@\XP\7WS//%+:V7JYR%/NW#F3YG,\9AOB6_W
M<*U4-66,4;_-!OD@*=(8ZDYQ[9G^\;K@PO1I&]P%7U-'T"Q/^<)-,P7(\E\F
M2W[P-'&'W$?ZIZMO:Q;Y8^.C11Z' Y[!XD*0*!V23#%9?74B<[2VZ.?^0KND
M6@8E@MDG+UXE)Z"2XC6?VV>N5__D=L3)TRR!CO (W1'K$B=]Q1O4E@J1-X"/
M!/-9L-GNF$KQA)8A9LDXMU/!#3%?Q\)AH=0:1)+D][9;DW+HT]L^U@6^$+,?
M%4/?A40@//<C3W_,#3_<W!:=<I<9OH9.5'NJ,65[JFE;,/JC)[7^$\=VR2.>
M6PSQ"E67O%6J9<^K8ZAS:1?M#(4@ FVFVE8ZQQZ>4>C^(UX-@%U3-D@TQ!4M
M%Y*P(9N D8\U8'INX"(P/$BP(\3,W]5WF*RP6<H&5016Y-^2I-F)^2]4WH1E
M8FW>O;BP7HJ/*IRZC2&\'FRVA<1FE4<+ 07=P<&.[/(88L^GTXOK<V;A-B'#
M%76S%=ZY6<!Z.*^LYFV!\B[=J5I#CNP+':5?S!=-<;F(F.I^'/]HR>G9:KM!
M4QM3_'UV)A9PC>/T;$^*H.F6W@>"DW]*1\P&I;2;ZE>L5':P%A,^'A @@N,)
MJO11^NX1/%HGFBY=7;5%O^68Z9OFP4ST+QH\[Z8)]_KA#U??(/)E-C*[@V;A
MJ%,LR\R\ZI_[195@V:8TS]U+O1/T3\7.B)G/4XQH8I4OOO^IJZ]1GK>&J@SW
MJ5>?ERYA!,_H;'AZI">GD.>TT\N$ (_+?F&#$@ZF,AE<,]"3(1#'P#)LTT^-
M4A4T_F9CRN"(E1J^FH88)$M$D672:]2:,KZZR.%];D;TP4JJI9W/I7U*_./>
M#TCB+F9);L@$\']X#0N^$"BT'/)CW6"N?Q=GAW+?Z'^NR 9)UZ:X>CN:QN#>
MXSI\0FL6(ZS'</M'(A5XG;"/;"#=YEWE?<W)1\B-@_(4GV7M':%"UN\ 87'V
M[1H:_D _&$)PM4V+M6=544HKW^41255!>I6(F/Y^GYC.>+7NUQ^F,%^V;,+*
MFLZ^L'[@L;7&HVB.J+!R*FP=#L+!G=1N,IO5!5#/>RFD^E'!W:K*"4+YA-&>
MRTZ'<P'51F1MKU%#]RVYR#$KNUW&T%.U52*JE]O,\90T87T1:- 0=UE3NNOG
MLC'BBH.78=RM:<)2T40&MAQ1JFC>1E0-P?@_KM%2E.?WJNGXZO31/Y6T?_=N
MU%L/D0QOB//OVL7QD+^ L?_$M&;Y87CV'>="1AEOJ*?0F^AHO \"N>+[0Y%'
M9AG7F<[;[979\6FM9D\EGE#)=W_B3GZ0!^QN_%G388&13NFCGC3=JA5B4([&
M$!LD ]!."/--]M2!S92M++[!T)_Y8$)MOTKII:HK',9JWR%+$^N>R-9Y#HOS
MB$IP9ECQ7C,V,=6+Q79W).;@W*N'JO3X&F@&!T2JJ6*-NA'*D9[W;9:85COF
M,; GAD2TA2SL/$P]4[H&R<[K67P?<?4UXV'?2C\)I<B7%? A0J(D3(,V=5'<
M%>A6Y*YA9_^R_DZ_"X291=<WWMK'JLM8D*-WHE:]9#ME&F=LW]3O2_)\]$T*
M>%XOZ;EE$^L]X!5U9JFT Z)^N36ZW^RB5^*$SND7_CF7-HBG\!DKVE\?\MF@
MI?0'/ZFKW1U02]KA6V(-THE4KCQ5<U=B&F<>)Z)]L[0YX?S#_*N$B(BR]TLU
MYFKEC!,.!5@,GTFO]%&(W',]8,QBB]%IRO=(/M'H\WC))<-.7,P?E/ZX?3X$
M.3.S3D62KT%X2K5G$Q5][+@N+/QUM^9;(L]@FZCGB0N#3=/FW6HFI2I]N8=[
M4&*T._KC;06HQ3C3:G7U/76N2J4;?<N(4F^+,TGG3(V6:A9*K$YKF0K9'I/1
M.YO\_NU;C^O%;M^+_JI@.-CJH0&)T/V$F<5R/AAFMA!@*'UZ1AWAU.[*(^;=
M"32WLL RX;Y_/ANT^6[&#AT__I"E>Y]'U;-\K_&TL2-VJEHBA^[F$A/0[.+D
MX@,G_]78R5Q1M<"N(L*.+)J?6L!9D6?*65YX;48@LWQ3Y5&-C7"%\Y1J<8DR
ME\.P=V.VFIU6Z)7P[I$VO=!\CXMO.R-TPXIR3M@J5%$/S\Q5>(&7^;=JRW_.
MUJOZ>#-#)\Q4.1:^##3/3 1O"Z(M]:M"J)D2:] G"TCI2\+B$6&$I"%K<8_K
M\1(C5PHO/0X^_*+<!ANT[+[E5_&=?!NQ$F2T4*1RI 0IA-B;X4-O!O>/,!X:
M]$RB_6C[GQR4#;@Y$[_" D*&?.NM)5323_RE<9IZPF&,W#C,*\GXB)8IZ>LH
MW5SG2A9T(L(TQ\=G\@V:BU!AJB<LZN1OW2E;R'G?[NSAYI#='5$BPRUMRJEY
M>O=<Q4DK!YVHSUK!8PV&H^A;T*5JS1IJ4'[MDLQH3O;41$\?!W)^O29Y&=M#
MHDVM:8O 7):F^E_RDRK#\L.%-227?.LF[SP."\C;KQ0H!F PC$5EK&S++F1/
M;"%2? ::DS<YR_ ;SC#8JVH_8N>[SL>G1ZHH=>Y/5)7Y,#V=M8^3*Q(-D_:Y
MYK:DGB\71O]B3VX<N3.[\QL=^M?:I3(&ORF5VV'Q)_J31)]J/E)]Q*.7HKY9
M'"V192U8']YJ,K8B;W42DEVVGZ[[T&M48=;G5D&$_.GG0%>>OV4YHG_;S@17
M[L] X_9E*LM4CR"7?NXX0>S%*VPB99.F;9!D]!M2ER N-KN0R",0SK<'<:GE
M376$:EV)&QG^<O;PLD(>AAJS;2_YR/<:Z#)?ZP'Q6W"WIL;,K$#@,XE*A?J3
M/T^ZXS5J$19VY,#3^2H7/BE!!;):![Q5J%5)^H:*@J@G%[JL'*S$EX GK3##
M/S!DH6.^IBC#Z4S^:E7G2LN:2'FJD+/K_A'O_-MWPJH%!&IHQR<Z.VW$2+]=
M=(Z_?@"[JM." 2)?[#OMJ\_*$:I-]?X.=Q.RGSK>NMO_93:C'ARIAM>L"E%%
MO!+U>>*(T!)S]7[8IPT;,]]KA!V_VH _VQ"M=K:TP[Q-WXHK/:#(_B ?4)'.
MS.JF3*&.V!3P)<*513RV+C#2'85E"+S*^;*D)-K6XEH>9(^,MH%T*26KRL>A
M"**8IVJ"*E]3K:,'E:P:S?_*N YTAT3!+(.W8DN#8D+"9MB@RWM9I\JW)S9%
MAZ>?=$9WF\_=L,KL&SD1V>)M.Z$?F^%.0BU#*NHH%>U+E?Z0T1<?A/4-KS\Y
MC/VUF:8>OCE<>\S05*8P\8!6A9!]0F:J#T\'N99@\[XN[R35$2E)N!;'"G_Z
MM#,/S'0!*AY9ADW'=>S]B.8MJK\<O7!XD2/NM9"PW\$@"Q/86GGYLR-^81[W
MC'PF@=3 69'T^P"DS4KS;GT-8OY#6.XS]S6:UM=^&/-E(LLJ.:)!=_)H8:'U
M76.Q!IH^^G)3*JVE/S*C5KP\J!:_O>^*@'U2DO>EH-2Y7+W5VX++(WHU(,;:
MJ40J[)VZ@R FK"@LK!0H)!;?Y\1I3;J*?@9Z5$C"9&)^_ZG*-WH[JY_2&%E[
MDTBIEL//YBYA"PNF??#EJ<[-5:.J'A?->"I=)E)\OT>=->Y0&+U:<T3_8D,T
M(&==VMF@&Y175CZQ26CQ@I#[7F*K79PS1+C-)]?XLH@ I-QHA\;!:,()-:EG
M/X@P&P4CF=_GVR%Y_IJY4EU<#;0_P[\(+5^I"7% M3'\A@4A=4KJY#5T;*;J
MMB'27G[\TQE7;[)U<">1IS'RS'P+.4+J2]7N^<DHF-)H<^<Q0'<%PVX5I:U'
MK:F!(XE!N92>V.39*UM0J9]^W]F@=EC_-C:_E@UR^9&U1WD7BT 5=RS5VLGH
M2F>_:W^<,V6CYS7O9V.GWU8OAKE"4PRD792,S;9<VK?.+X "//DG!L%<93V&
M\H2(H#)G&AE#:LH<_JA BFP8T>]C$-K'45[V6V-&;8@.)3.RFEH_K77F(95\
MA]?B&.]\KXG9PKI?0IZ25E9\H4MI=D8+:X-H9;#-R-M&/O:18C43&UMKGZIF
MN)/[RL:#"&=UH%"=\#ZDL_]Y(C:\QUG<7;1MOB)MO:O(*2^ON"0,R:UYY>ZY
M"$ &E! W=I3G9]MUHTK!:*1+UWKL=U4Q[@F!%[@ 2'=,7L=W/WP*7^4J=>)D
M_RD3HX$1LM<WY4OQA@J/>P$EUMLAB6V@:;)!GDS6>M\*R3":VY\KR#]L?DUF
MM(59E. WKRPS.'/K8"VK<%7%MA9,W+07D>;AV/ITRCD7-3PVH"MYN:RM\_4[
MUDH&,2@O68B1Q!3M\^G#;YPTV(S("-G[MA+JO%LVT;N[MSYENER1=-+IG!F'
M\(N\"'<3GF=.5>D.K^S<K:YJ/06JEK=;M77*'&B4]5K( M&&DH=7?>)#*O"[
MK<8&;7\+O1TYP>_* [\A;3>-G8[7?Q<I=/7>>^E'0P^N<>5KQVH L%W(YWUX
M$G>Y5^ASXS"SMW(7W>UZ>V"?SPEIX>VB(JBR4M[0!%]\$BP?UV]BYG!=.0GZ
MV/NAB%)(PT7A=.W@0M-SNUR"M[!:<7* 3/2TF5WJVVU'Q;(>!=O7(LJ$!<I9
M+B2#?:+J.N:9@Z?C]*VGW_8E!>NW%1)=)-8#/52R(=9;BW_DAQ4DZ9\-N,@'
M"'.!K'D2+&W05F^B<6R\_L&-C%.%2F?(F]%+R05)]M8HE^[W&&$;4:Q$0W)6
MEOYEC*F5]K7#<]9UX"3E/DP<6*8&[4822FV$?&P06U*V[/TF ,CFT8-@"UOC
M^_A3B]XS>40!;B (;6V=D@;O,;QDK/_L-/"S?/0:&W/+_S* ;[=9WD(]F$_H
M%$!4T%4"A\L"5T+@8&^$':N 814_\]0\7]L;/F;>&EHZG9%RQ%0_K</4=.3[
MMM6%GVNL^=!K.$ZUY,P_X^\"9-:_PL?LV1=B!&^"HX?]>?LVLKHVO2GD@_!7
M_4.4"8D*A?,AGXKZ2 ?U=<A'_G4]91)E%9;R4QW.\VM6$CTW1URN9+DM1X@>
M?E6HZI-AP*YZT%.:^E K!66@\9094-QBA#0737-]IO1C/_:(3OVJ?=G!^S#=
MJ&/!/+XE^E=^U^=_S/_B\+K<.)8;&W1'"MJND@6H)+7GT1LA"ZO!A<R:$!5F
M)YV1G!NI&E-(Q$<V(7&/83]5K*/:5+X-FY */TZ9O*C(Q' 8BJ5A=21)IOH7
M@<&QMOO,N*HJO*0*;Q_9S,KH@8=8S)LW4TH;/UKXD!^!G:[M5_JO/#WR9.R
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MHA^/F'$C^B8?.M9799.K5<GRM\:I*]R!#XZXL267Z,=>G<7NZ*"/>;(M^JQ
M)<SF^7"X]0Q>$^W@R080_$WVNYSGD@W>7+RPB[>BYDXE]1E\B&IX,FU7>2E*
M52+;I:SJT1>NXK6R%8JH"HU4R#N@% WO$K8";9T)K[E#)/W"K^=WA>2.->-
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M\ZA9(XA]K8"9.'GD8-02$AVT[-/2]NQ_(1W.U/Q+E15/PRR%!IQ?IQKI"$I
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MT2QL,\;0/VP]-A JODHFX:]61.BS@X;:L0"M#,V64&UO&,6NUP;4US.YZ-X
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MN?(IYL"]:J[V/#Q530_-T &$L8U82D9C>T<%]YMQAEL7#/^%?WL/SCS;;[N
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MWEY?YVM([; RT7Q37EZH8)YH]J^A_OL[Y[WW B(CR5(DFO $4:P<JPP>$"B
MG#'1CND:-,%:E=VH?0ZSV]G?-Y/B#_=;F\%:#:$ZDQ6%"GB59)G/@1D6YKM+
MJZM><RD+I0C]B+@X%RI#OWW?RW;:4M78C:!1)\<@ L'SS9</#M]MBS._(F8"
MO1"QK-D]FS?:?,^8?BLLZI$7UW9*Z1B><%9?%EE)\_) B$8BWDG8,J!,DD'
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M>X1&:HA%"->H3"C3OQUE(9O5N>AJ7YW1^C<X07Z?+^LZ@]VVUR)._L(B AK
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M04]UY0Q,9,]O#F^=OY'M/\#W:2<TDNY.##/)@:%]?4R2,FS@#(=8 )-/SI@
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M^S^<'[3$V52XO5*FA$=F&BD(LHO)F5B8201H\J9UE3$,:_E?(/F$G/1E$B+
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MT34D_@G\251ZEYF)QO;ZE1WKSXF@^[LX-7.HMW[=X\<CHJ]^I8B>7T_^\%]
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MK7[2Y7C6B84>1AX-%SHU5-OS/5/O@>*V+0&SF$ZMB?;U>)UXZTFIJ*=758'
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M"0W(*PC;"6B'HT3FL*&5JA=:@"K!8I<#=D8G!X%_7[Q6?E1S5Q31#"!1,WM
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M%S 7;0B'UB@<^[=L7O+%VXWRRJ#W-)Z^OK=-16+E:9:MA>WQQVX"@0F*DM$
MFM&1F1<14>1L4#I23@^ A%XX%*+8DUD42G]<&%RJ;$:RT<>S3#H7W.YFYAL8
MV9I+XB:)I59>[.V^DQW^>_V9]$F.08?34P$%1'"Z<S+K$<$"[3O\3D+^+!$[
MCF 1^Q/QW^P]/E87#]1V709>*O)[NJII6HSHCV2<K4<EW3^7##SUO\[C'XZ:
M%'+F<=/D=%ZFP8?2WJ$OI%NFB;Q*1M+**Q)HW;GT3S'@<@\]*4X2_V));[Y2
M)B/VUHN7;>UY)HWH;AW%@GSYPO-EH].?WPJV\[,?9$5T#*L6_ -BNO_6(+2;
M[%K:%/ZB\L$4&SOCPH(8O:?=\I4M=3Y8^'?6Z6Q1W/VJ#P?CDRN^2P5QK$V+
M.](X 7<[PC27@,J?#% ^>$1WS19]CL;O9T#>@O0:N>.A^R4[\&]V:1?/KDZN
M_H+>GQ=.T;MS8I9$"L]4L#VN#S20.#-ISG3P4E+>I&:4"Q;T/_5;D%3R[FX<
M9\Q[_V0/+C;R.^D88@]Y=SB+X]'V8AMHYK40CH6L^(;W^XXOUF6+8M;]-&Z3
M\9G5?7:9KYT':+H<*=!KDZ.19W7ZC60LZOFAT+6SC4P13HA[<(3R"_<.D2<1
M@"75;UL_"0#GMLP#J>\%M46SMYT'R)Z[*\4Y9P):O*OR<?VJ]3;I?Q(*C02;
M53+(6]-0AT\6SH/FP:V9' ^+[5VYM$"JZ!<-"Y*6OJ\%\]=O+VK^EA/=._XW
M>UU;E/7W@^3[.>("2K70'^1U(9X$6"3PT#_%ZX,/XL;)N\SA)5UW7CI'9?;@
M[(ZX"G,3MK5'&J%-1?D%!L:@@P"94E)>.E8O;48G5E^TA/.\KMTJ3!F;G*1>
M.4H.1@5V\\C\QP%#G[Y .Q9F\L;?45RXJZ[B/< ZC@L6ESGL29O;#ZY9F9[$
M\C'ABS_US.6 BT.0&X]?#D3/9>3'2;=XN(BS7JTO]>#E;PI$A L0S!M@Y"UM
MBZY:/6*IB!,2*1O"'^8.A?J5T7IXJA44?H%,$0D5#MODW]U2"AQNTG"!R#7O
M]Z@!4-_,XHMJ/U5\^;Y^I:*X3T[2^E2.3DZ1P))KX.'+G%8*3J3#FO>936E^
MT1R! \-^2"G4\25'H9X2"5PB>S#F\[.;7(I^6]",KWHSA]^7%-".")9$+U:5
MX".Q#VWQ/#?GMSE64'H,B(IB5@;Q7L]'KM9A%/JF$?<78353FP,KND]"03V/
MD[YUK,PV2ZPWGL^NB%QOJJB+"!5]3TI/L;6ND;UR+_J_WV5K2LIRZMC%TIMD
M18$\ABV6XZ&@/E""M*TU!B@,W^"([+A42^L]*G<OF<FB?.>.>RWX9ESP.D]R
M](<\MCSQ5T@#/NZAM:.%X$"Y'@KI,%+TB3L*WQW]0S%X)]@;UWZ,+JO'M;+A
M4 @WH?:^"[!/] NH+G"Y\.!6BE-*?@ XO$'SAO6=N@NBWY*N^0GHOC!4V(J3
MAVRDMB#.V,.ITR*-&(5O-]3Z+P)6XA;I_\N$/=&8R"UI?$8,O''BE-,&;"+7
MKR'LNH:B4^;MQU6_GYG>N18-[3WJ:OG[MMHJ<@BY$OR^!ZI*HB?D[2!51LB_
MZ>KV2I-GR+=C*=GZU,\; ,/&\*EW02\#"=HP20CME8R]9P,T;J&R*O_Q!ZV0
MW:6,M'X!0_PM/<OW0"D#0.4=6B$/3JM/<46HF0$"1Y"4BNJO;>+RXYZ:Y)%:
M&/N6'O,S4H/M.O/35349(HL1F7\V?G_LK8>3M38Q='J?3M7>MOZM5! R'_?_
MG]X+?(QEK!@3(H=W*CFQ(=);?;Q*CN(HB<NQ/A2ZF;#G2HD\X+5@,CMG$Y*Q
M.K"!/GT=<OCGC+%9;K NAB6MK."@GAP;IO%#]*F$<B43"6_HIK=/]C\QR#+
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M9?+(@T#:G)/SANFX=?/'&0!6 AW>:O!Z<MS:<V.GUBF[+*,D/[]17%5?OE(
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M_5"+$Q.DW-TRH >M*O0>M-04TC8 <?9!AX8P3 U39B7.K%BB31T"WSF*D,?
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MQ[Z&1\I?.),Q.1.2.^XSD-T'NJ86G5'SW_C=]#!G=&6@VR99BM_$.;T[7@6
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M](O6[CV=O N:<VHI;=#04Y6*Z2@9$XYKD #B9T%];B)A?7W@=H20Y26M-]B
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M1V?>E+VQ.'Y!Z+Y[ ARWH\G0+\IPF<N;OU5'PF(25\G[1IW;$?A+S6E)5[.
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MEB[4I]0$RP?5.0"P"Y"B6H=&:\](FHT]3) B9,W,EP<=N$/3)+0'1(0N6V9
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MCK>M<\_R"D>^'&\JZ9E,S8]/@))"A'@"K?'XYIK"&XE!+=Y*%J&V4;K<3W$
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M_5^")V!Z/EL][B_":_VA5Z;MW-D31 3NV<E%\7_\T!*P4XXG  TXB3Z-_'R
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M;D7QZ1Z19V=N$"LR9RMME6ZQ>>V9F^^.WWH875:CQ!T9&[A5-\IP)0STTR(
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MP? B/P%]\5]<^:]N2I$ =TN$[*0CEWFU+R@X,T&*PZN<[QZ_[7*40W<L3IG
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M;E0Y,AFHQ/N,D..2VK#'R+O>(]F'3?2VZHPBP9E,%7KCOLQ]N]9&.&RJM N
M_Q6(P\2B2^=6:+6%66)BK;-_1JKYMMB3<,N$\WIU"U\+XZ/PB-P"0!&,:*'T
MTF;*%22%<3BXH[YDC SYT>E=7CUJCA[S#,R\JIRQ)#,;*1<^FPFI\SLV-&V
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MW+R\YGFL_:[.#5):6#85X4[:;9*_:(5*"@09J-R5;52/=9B>23HW*P08R+X
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M@AK$7BN9P.(7(4+T7D$]Z5=SEQ[R K$5MSZ;"S#_Z;3LIK70NJD0D\H[=\I
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M]X_:++D3SF44^-^0.6L%$.2>_[V7 OUGX#\#_QGXS\#_8@![,OU?4$L#!!0
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M.&P /#8< C;<ZR!<T5^6R/ (<(!_ P45&0D1#0$='@[PYJ\8^9\O_UOY5X6
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M2P=WG_1L?:*S*CI&EP_O!>7U[7QCLBO!8RM'#\Q""@;V?K$Y59WCJ\>/KZL
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MLQT ;&J@BU]%8?R-?491D6&NO9=>I:WMT=RU!HF]S\,<B6LRY7FO^5HPQL<
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M4$!R]W')KL^^%)"7QO%O0JWU,6D\\WG\L15A'"F0&\'CU1$XB8PBH;OAXD8
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M[B>QUDLSN2@5$[VX6EX6G4-,[_FF?G1O<5,_=0]WI'DT>V'Y0!VXZQ^7?5%
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MK539>#%;FFJV0Z-T/LUR*)+,>R2J/LU=2T"83CDN;<=X01^<Q1U>?/ B_RN
M\DLY[X]+=X+3%(SLN,3&PX$'BB;8FF*'BR]6^EYH5;5]0_Z?&1T^R@L%/\+
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M!.B,AD )^6[WOYBX=E 876NAZ%9A4GJPKORAJBXL1(B6%>,$8S?,.Y+^.4Q
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M3@\7 2,T"U$A4A28^-)D0<:7H^-155%B04J2R)3CI/IE0,<QP@%ZQ/  =75
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M'8DX[^ZNZ^OD&1H"I; M-!/NX#?VH@_B*<)EI?OI2W=!W? 7)V5'(:OX=LS
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MQ!C%%?R";+WI+\P,5'LM7,^Z*/['$W7"[#VC?'Y-I3],U BS$7X0B 2;=A/
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M9CY-6X:GL\6CH!XD?HZ>+NRQ?,19]FMK/TS8W+!J:$GI;XD9TBX!\ C#A=/
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M!IZ\D4B/$ZT8GSH_4:P]8-GP^/M]XC@C?[6LSL)I.V.#WX,+@9)K'KXS#Z8
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M1 ]1M5<D#SJ-R>E!4ML'W%(\ H1O_>8.I7KSZ8HLC\6WS- 2^Q'D<]SAUM\
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M*4!5![/YE=(KESF*=AULW:JC4,;'AVFH'EUPY>_<E.J[6I3+V$T;O']5WRY
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M)48TAWEP<?"_#>DH]G]Q%S'-0<:%S P,!"_UN4.#*P*];2@T]8#/R&5S\F^
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M*LF$EOI([&GQCK*X3%'PA17\D?MJL943PMSHZY.\W)^>MO=@N*@*1:*9)&2
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MHE\[8;7L: Z:6N15H492NP1ND_D'EYSZ)&2,-Z[9)UWLUP9QLT3NXVHCCF0
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M3GM92;R1W'F 21<2X5,'4FVT;U7J'LS*^L8=':;#%G5MFHH7.?1K<G(=C??
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MT??SX[C6GW&V&6VLN," 0-MAGA#L;+*ARGOBI+-M:U^4, D;1<P\\IL\+M@
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M"-]!&@\X7/X.4,Q#+A9D= ,18WH!K"D^^KT )D?G@4^Q/C[[9\"==T:WB2\
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MZ!L\?+>$F+O!)K71:^-HEGY2.861^\.09Z[L5BX8/8^PW9ENN+ETT!:GOK6
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M;,7=9L?T5K5%1QZ2/PWZCK7 X(DQR8JNE<JNU:#:\YC#SD@4HQJ'SOC;PG
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MNNJ54.4^$5_?KJ#[5)HV&_S79$8ECJX;N-MD^-@&^=A(Z8NHW2I6#C@#:IG
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M%*88S!];- G8-^QJY<XGJ]#(FQ$![\12PC1S"MT^CF=\7[C.PC"QE"GHK:Q
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M4^2&4K[9WBS'18*2I:DPD<XJYRKE7.53\'@FD:#TC-T/]Q_K"2U<"!X,+4M
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M^+BJ1C=K96I>?8&AHTY0B+ST_)=<-R'!:L[?XWWZC-@;JSRQB3_.VXF ]L#
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M@FW,*"\!L;H>@:;IYQF<U545KH][5S[V[2/"'ZAKJWPD "S*\2&=PE^O,Q&
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MV+NHNSU/+(PK<P<:;@7L#%1YQ7AYQSL!/,*_XEXR_ +2><AX$=0"G)G(%H,
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MX._QKR5WA)G_!5!+ 0(4 Q0    ( %BIK5AD6.(>[A$  'NY   1
M      "  0    !A8FEO+3(P,C0P,S,Q+GAS9%!+ 0(4 Q0    ( %BIK5C/
MAL6Q) L  $!^   5              "  1T2  !A8FEO+3(P,C0P,S,Q7V-A
M;"YX;6Q02P$"% ,4    " !8J:U8GAM^Z7\^   ^Z0, %0
M@ %T'0  86)I;RTR,#(T,#,S,5]D968N>&UL4$L! A0#%     @ 6*FM6*D
MW)\DCP  I@D' !4              ( !)EP  &%B:6\M,C R-# S,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( %BIK5@5^2(D2CX  -P)!  5              "
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M-#!?87)C86)I;RYH=&U02P$"% ,4    " !9J:U8\VY>J,U#  "Y8P$ '@
M            @ '86 X 96$P,C U,3(R,#%E>#$P+30Q7V%R8V%B:6\N:'1M
M4$L! A0#%     @ 6:FM6&QWT8I:*   73P! !X              ( !X9P.
M &5A,#(P-3$R,C Q97@Q,"TT,E]A<F-A8FEO+FAT;5!+ 0(4 Q0    ( %FI
MK5CW>3,RA@L  %T]   >              "  7?%#@!E83 R,#4Q,C(P,65X
M,3 M-#-?87)C86)I;RYH=&U02P$"% ,4    " !9J:U8O]HIFND*  !Z*@
M'@              @ $YT0X 96$P,C U,3(R,#%E>#$P+30T7V%R8V%B:6\N
M:'1M4$L! A0#%     @ 6:FM6$\+-4I9.P  M#\! !X              ( !
M7MP. &5A,#(P-3$R,C Q97@Q,"TT-5]A<F-A8FEO+FAT;5!+ 0(4 Q0    (
M %FIK5A_SP-WJS4  *+^   >              "  ?,7#P!E83 R,#4Q,C(P
M,65X,3 M-#9?87)C86)I;RYH=&U02P$"% ,4    " !9J:U8!0&FY?XQ  "
M#P$ '@              @ ':30\ 96$P,C U,3(R,#%E>#$P+30W7V%R8V%B
M:6\N:'1M4$L! A0#%     @ 6:FM6*83_S>$,@  N/   !X
M ( !%( / &5A,#(P-3$R,C Q97@Q,"TT.%]A<F-A8FEO+FAT;5!+ 0(4 Q0
M   ( %FIK5B>7:8,G3(  (/5   >              "  =2R#P!E83 R,#4Q
M,C(P,65X,3 M-#E?87)C86)I;RYH=&U02P$"% ,4    " !9J:U8UA6*F!\"
M   ?#@  '0              @ &MY0\ 96$P,C U,3(R,#%E>#(Q+3%?87)C
M86)I;RYH=&U02P$"% ,4    " !9J:U8?Q-N5-H!  !!!@  '0
M    @ $'Z \ 96$P,C U,3(R,#%E>#(S+3%?87)C86)I;RYH=&U02P$"% ,4
M    " !9J:U8XLB)7MT!   _!0  '0              @ $<Z@\ 96$P,C U
M,3(R,#%E>#(S+3)?87)C86)I;RYH=&U02P$"% ,4    " !9J:U83G(;6(Y3
M   =  ( '               @ $T[ \ 96$P,C U,3(R,#%E>#,M-5]A<F-A
M8FEO+FAT;5!+ 0(4 Q0    ( %FIK5C]68W:QS0  '62 0 <
M  "  ?P_$ !E83 R,#4Q,C(P,65X,RTV7V%R8V%B:6\N:'1M4$L! A0#%
M  @ 6:FM6#I<GV4<9P  \4(" !P              ( !_700 &5A,#(P-3$R
M,C Q97@T+3-?87)C86)I;RYH=&U02P$"% ,4    " !9J:U8.2YK1-4"  "C
M"   '@              @ %3W!  96$P,C U,3(R,#%E>#DY+3$P7V%R8V%B
M:6\N:'1M4$L! A0#%     @ 6:FM6!BNFQ75 @  GP@  !X
M ( !9-\0 &5A,#(P-3$R,C Q97@Y.2TQ,5]A<F-A8FEO+FAT;5!+ 0(4 Q0
M   ( %FIK5@X;P..(04  "P4   =              "  77B$ !E83 R,#4Q
M,C(P,65X.3DM-5]A<F-A8FEO+FAT;5!+ 0(4 Q0    ( %FIK5A\_M!%U (
M -4(   =              "  ='G$ !E83 R,#4Q,C(P,65X.3DM-E]A<F-A
M8FEO+FAT;5!+ 0(4 Q0    ( %FIK5@F4UI_T@(  ,4(   =
M  "  >#J$ !E83 R,#4Q,C(P,65X.3DM-U]A<F-A8FEO+FAT;5!+ 0(4 Q0
M   ( %FIK5BD9K["TP(  ,D(   =              "  >WM$ !E83 R,#4Q
M,C(P,65X.3DM.%]A<F-A8FEO+FAT;5!+ 0(4 Q0    ( %FIK5C^_*J0SP(
M *$(   =              "  ?OP$ !E83 R,#4Q,C(P,65X.3DM.5]A<F-A
M8FEO+FAT;5!+ 0(4 Q0    ( %FIK5@'_X#06=4  $?O   -
M  "  07T$ !T87)C85\P,#$N:G!G4$L! A0#%     @ 6:FM6/!%&/7;"P<
M]6T(  X              ( !B<D1 '1I;6%G95\P,#$N:G!G4$L! A0#%
M  @ 6:FM6/D9RESK% P (.\-  X              ( !D-48 '1I;6%G95\P
M,#(N:G!G4$L! A0#%     @ 6:FM6/XQ)9)P0 ( ^J #  X
M ( !I^HD '1I;6%G95\P,#,N:G!G4$L! A0#%     @ 6:FM6+D.()/AI0,
M6^$$  X              ( !0RLG '1I;6%G95\P,#0N:G!G4$L! A0#%
M  @ 6:FM6.JV,R\_2@$ E=D!  X              ( !4-$J '1I;6%G95\P
M,#4N:G!G4$L! A0#%     @ 6:FM6-%3Y5=BY0, *] $  X
M ( !NQLL '1I;6%G95\P,#8N:G!G4$L! A0#%     @ 6:FM6&K%?!H&@P,
MC^D$  X              ( !20$P '1I;6%G95\P,#<N:G!G4$L! A0#%
M  @ 6:FM6-)'GSXB:0  1W,   X              ( !>X0S '1L=6-I9%]S
M:6<N:G!G4$L! A0#%     @ 6:FM6'7KF&+N:P$ KWT!  \
L ( !R>TS '1O<G5K85]L;V=O+FIP9U!+!08     *  H /(*  #D634    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>ea0205122-01_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abio="http://www.arcabiopharma.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abio-20240331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abio:ClinicalDevelopmentDecisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2020-08-29</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-29</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abio:UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:PatentAssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-22</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-22</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndThirteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:FirstThreePercentPayContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:NextTwoPercentPayContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SeperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:PresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-20</startDate>
            <endDate>2024-04-20</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-20</startDate>
            <endDate>2024-04-20</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abio:ThomasAKeuerAndCJeffreyDekkerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-20</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-35018">S-4</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-30">ARCA BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-41">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-167">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-179">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-193">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="-3" id="ixv-35019" unitRef="usd">37431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-35020" unitRef="usd">42445000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent contextRef="c1" decimals="-3" id="ixv-35021" unitRef="usd">161000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-35022" unitRef="usd">254000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="-3" id="ixv-35023" unitRef="usd">37592000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-35024" unitRef="usd">42699000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-35025" unitRef="usd">247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-35026" unitRef="usd">343000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-35027" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-35028" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="-3" id="ixv-35029" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="-3" id="ixv-35030" unitRef="usd">18000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-35031" unitRef="usd">37861000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-35032" unitRef="usd">43085000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="-3" id="ixv-35033" unitRef="usd">362000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" id="ixv-35034" unitRef="usd">334000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-35035" unitRef="usd">100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-35036" unitRef="usd">173000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-35037" unitRef="usd">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-35038" unitRef="usd">216000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-35039" unitRef="usd">175000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-35040" unitRef="usd">625000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-35041" unitRef="usd">637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-35042" unitRef="usd">1132000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-35043" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-35044" unitRef="usd">280000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="-3" id="ixv-35045" unitRef="usd">841000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-35046" unitRef="usd">1412000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-35047"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-35048"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-35049"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-35050"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-35051"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-35052"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-35053"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-35054"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-35055"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-35056"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-35057"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-35058"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-35059"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-35060"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-35061"
      unitRef="shares">14410143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-35062"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="-3" id="ixv-35063" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ixv-35064" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c1" decimals="-3" id="ixv-35065" unitRef="usd">225747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="-3" id="ixv-35066" unitRef="usd">225061000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-35067" unitRef="usd">-188741000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-35068" unitRef="usd">-183402000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-35069" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-35070" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="-3" id="ixv-35071" unitRef="usd">37861000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-35072" unitRef="usd">43085000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-35073" unitRef="usd">6283000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-35074" unitRef="usd">5847000</us-gaap:GeneralAndAdministrativeExpense>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c8" decimals="-3" id="ixv-35075" unitRef="usd">-91000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c9" decimals="-3" id="ixv-35076" unitRef="usd">432000</abio:ResearchAndDevelopmentExpenseReversed>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-35077" unitRef="usd">1013000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-35078" unitRef="usd">4749000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="-3" id="ixv-35079" unitRef="usd">7296000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="-3" id="ixv-35080" unitRef="usd">10596000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" id="ixv-35081" unitRef="usd">-7296000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-35082" unitRef="usd">-10596000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c6" decimals="-3" id="ixv-35083" unitRef="usd">1957000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c7" decimals="-3" id="ixv-35084" unitRef="usd">675000</us-gaap:InterestAndOtherIncome>
    <us-gaap:OtherNonoperatingExpense contextRef="c7" decimals="-3" id="ixv-35085" unitRef="usd">5000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-35086" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-35087" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-35088"
      unitRef="usdPershares">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-35089"
      unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="0"
      id="ixv-35090"
      unitRef="shares">14415877</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="0"
      id="ixv-35091"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c13"
      decimals="0"
      id="ixv-35092"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="-3" id="ixv-35093" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="-3" id="ixv-35094" unitRef="usd">224505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-35095" unitRef="usd">-173476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-35096" unitRef="usd">51043000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c18" decimals="-3" id="ixv-35097" unitRef="usd">556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c7" decimals="-3" id="ixv-35098" unitRef="usd">556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c19" decimals="-3" id="ixv-35099" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-35100" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="0"
      id="ixv-35101"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-35102" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-35103" unitRef="usd">225061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-35104" unitRef="usd">-183402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-35105" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c23"
      decimals="0"
      id="ixv-35106"
      unitRef="shares">91000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c24" decimals="-3" id="ixv-35107" unitRef="usd">686000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c6" decimals="-3" id="ixv-35108" unitRef="usd">686000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c25" decimals="-3" id="ixv-35109" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-35110" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-35111"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-35112" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-35113" unitRef="usd">225747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-35114" unitRef="usd">-188741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-35115" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-35116" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-35117" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="-3" id="ixv-35118" unitRef="usd">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="-3" id="ixv-35119" unitRef="usd">20000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c6" decimals="-3" id="ixv-35120" unitRef="usd">96000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c7" decimals="-3" id="ixv-35121" unitRef="usd">94000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-35122" unitRef="usd">686000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-35123" unitRef="usd">556000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c7" decimals="-3" id="ixv-35124" unitRef="usd">-5000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c6" decimals="-3" id="ixv-35125" unitRef="usd">-93000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c7" decimals="-3" id="ixv-35126" unitRef="usd">-808000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c6" decimals="-3" id="ixv-35127" unitRef="usd">-6000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c6" decimals="-3" id="ixv-35128" unitRef="usd">28000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c7" decimals="-3" id="ixv-35129" unitRef="usd">-783000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c6" decimals="-3" id="ixv-35130" unitRef="usd">-73000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c7" decimals="-3" id="ixv-35131" unitRef="usd">-752000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c6" decimals="-3" id="ixv-35132" unitRef="usd">-526000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c7" decimals="-3" id="ixv-35133" unitRef="usd">-934000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-35134" unitRef="usd">-5014000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-35135" unitRef="usd">-10912000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="-3" id="ixv-35136" unitRef="usd">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-35137" unitRef="usd">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c6" decimals="-3" id="ixv-35138" unitRef="usd">-5014000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c7" decimals="-3" id="ixv-35139" unitRef="usd">-10914000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-35140" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c16" decimals="-3" id="ixv-35141" unitRef="usd">53359000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-35142" unitRef="usd">37431000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-35143" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c6" id="ixv-19958">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(1)&#160;ARCA and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical&lt;span class="nobreak"&gt;-stage&lt;/span&gt; biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp;amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#x2019;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#x2019;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of ARCA&#x2019;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#x2019;s activities through the date of filing of the Annual Report on Form&#160;10&lt;span class="nobreak"&gt;-K&lt;/span&gt;.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accounting Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;property and equipment is depreciated using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s December&#160;31, 2023 and 2022 balance sheets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#x201c;CROs&#x201d;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre&lt;span class="nobreak"&gt;-approval&lt;/span&gt; of any changes in scope of the services to be performed. Certain significant vendors may also provide &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <abio:DescriptionOfBusinessPolicyTextBlock contextRef="c6" id="ixv-19961">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical&lt;span class="nobreak"&gt;-stage&lt;/span&gt; biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp;amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#x2019;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.&lt;/p&gt;</abio:DescriptionOfBusinessPolicyTextBlock>
    <abio:LiquidityAndGoingConcernPolicyTextBlock contextRef="c6" id="ixv-19969">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#x2019;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;</abio:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:Revenues contextRef="c6" decimals="INF" id="ixv-35144" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c6" id="ixv-20019">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of ARCA&#x2019;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#x2019;s activities through the date of filing of the Annual Report on Form&#160;10&lt;span class="nobreak"&gt;-K&lt;/span&gt;.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c6" id="ixv-20025">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c6" id="ixv-20030">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accounting Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c6" id="ixv-20035">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c6" id="ixv-20040">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset contextRef="c1" decimals="INF" id="ixv-35145" unitRef="usd">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c6" id="ixv-20046">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;property and equipment is depreciated using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <abio:ComprehensiveLossPolicyPolicyTextBlock contextRef="c6" id="ixv-20065">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;</abio:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c6" id="ixv-20071">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s December&#160;31, 2023 and 2022 balance sheets.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <abio:AccruedOutsourcingExpensesPolicyTextBlock contextRef="c6" id="ixv-20080">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;</abio:AccruedOutsourcingExpensesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c6" id="ixv-20085">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c6" decimals="0" id="ixv-35146" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c6" id="ixv-20090">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#x201c;CROs&#x201d;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre&lt;span class="nobreak"&gt;-approval&lt;/span&gt; of any changes in scope of the services to be performed. Certain significant vendors may also provide &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c6" id="ixv-20113">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c6" id="ixv-20121">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c6" id="ixv-20126">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(2)&#160;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#x2019;s potentially dilutive shares include stock options and restricted stock units.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-69; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;795,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c6" id="ixv-35147">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-69; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;795,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c62"
      decimals="0"
      id="ixv-35148"
      unitRef="shares">616707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c63"
      decimals="0"
      id="ixv-35149"
      unitRef="shares">704960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c65"
      decimals="0"
      id="ixv-35150"
      unitRef="shares">91000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c6"
      decimals="0"
      id="ixv-35151"
      unitRef="shares">616707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c7"
      decimals="0"
      id="ixv-35152"
      unitRef="shares">795960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c6" id="ixv-20191">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(3)&#160;Fair Value Disclosures&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#x201c;exit price&#x201d;). Inputs used to measure fair value are classified into the following hierarchy:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 1 &#x2014;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#x2019;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 2 &#x2014;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#x2019;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 3 &#x2014;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023 and 2022, ARCA had $37.4&#160;million and $42.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were &lt;span style="-sec-ix-hidden: hidden-fact-72"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-73"&gt;no&lt;/span&gt;&lt;/span&gt; transfers between any fair value hierarchy levels in 2023 or 2022.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Fair Value of Other Financial Instruments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did &lt;span style="-sec-ix-hidden: hidden-fact-70"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-71"&gt;not&lt;/span&gt;&lt;/span&gt; have any debt outstanding.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c66" decimals="-5" id="ixv-35153" unitRef="usd">37400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c67" decimals="-5" id="ixv-35154" unitRef="usd">42400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c6" id="ixv-20212">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(4)&#160;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;44&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;229&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(204&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $15,000 and $20,000, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c6" id="ixv-35155">Property and equipment consist of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;44&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;229&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(204&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c69" id="ixv-35156">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c69" decimals="-3" id="ixv-35157" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c70" decimals="-3" id="ixv-35158" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c71" id="ixv-35159">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c71" decimals="-3" id="ixv-35160" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c72" decimals="-3" id="ixv-35161" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c73" id="ixv-35162">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c73" decimals="-3" id="ixv-35163" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c74" decimals="-3" id="ixv-35164" unitRef="usd">44000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c75" id="ixv-35165">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c75" decimals="-3" id="ixv-35166" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c76" decimals="-3" id="ixv-35167" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="-3" id="ixv-35168" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" id="ixv-35169" unitRef="usd">229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-35170" unitRef="usd">212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-35171" unitRef="usd">204000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-35172" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-35173" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="-3" id="ixv-35174" unitRef="usd">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="-3" id="ixv-35175" unitRef="usd">20000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c6" id="ixv-20372">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(5)&#160;Related Party Arrangements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Transactions with ARCA&#x2019;s President and Chief Executive Officer&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#x2019;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#x2019;s financial condition, and can be deferred or terminated at ARCA&#x2019;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c77" decimals="0" id="ixv-35176" unitRef="usd">-91000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c78" decimals="0" id="ixv-35177" unitRef="usd">432000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:PaymentOfUnrestrictedResearchGrants contextRef="c79" decimals="0" id="ixv-35178" unitRef="usd">125000</abio:PaymentOfUnrestrictedResearchGrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c6" id="ixv-20385">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(6)&#160;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has or is subject to the following commitments and contingencies:&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Employment Agreements and Reduction of Workforce&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2022, ARCA&#x2019;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $311,000, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#x2019;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#x2019;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, &lt;span style="-sec-ix-hidden: hidden-fact-76"&gt;none&lt;/span&gt; of which remains unpaid.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2022, ARCA implemented a strategic reduction of the workforce by approximately 67%, or 12 employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#x2019;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one&lt;span class="nobreak"&gt;-time&lt;/span&gt; termination benefits, none of which remains unpaid.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Operating Lease&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#x2019;s primary business office effective October&#160;1, 2020 (&#x201c;October&#160;2020 Lease&#x201d;). The lease term is 42&#160;months beginning October&#160;1, 2020 and includes an option to renew for an additional 36&lt;span class="nobreak"&gt; &lt;/span&gt;month term at the then prevailing rental rate. The exercise of the lease renewal option is at ARCA&#x2019;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#x201c;2021 Lease&#x201d;). The sublease term was &lt;span style="-sec-ix-hidden: hidden-fact-74"&gt;29&lt;/span&gt;&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non&lt;span class="nobreak"&gt;-lease&lt;/span&gt; component that is not included in the lease obligation.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;93&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;96&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;100&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;314&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(34&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $119,000 and $125,000, respectively.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, the lease liability was $280,000 and the current portion is included in accrued expenses and other liabilities and the non&lt;span class="nobreak"&gt;-current&lt;/span&gt; portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $127,000 and $131,000, respectively. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; remaining lease term for the operating lease as of December&#160;31, 2023 is &lt;span style="-sec-ix-hidden: hidden-fact-75"&gt;3.2&lt;/span&gt;&#160;years. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; discount rate for the operating lease is 7%.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Patent Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In July&#160;2021, ARCA entered into a patent assignment agreement (the &#x201c;Agreement&#x201d;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the terms of the Agreement, ARCA received exclusive world&lt;span class="nobreak"&gt;-wide&lt;/span&gt; patent rights relating to the use of rNAPc2 as a potential treatment for COVID&lt;span class="nobreak"&gt;-19&lt;/span&gt;, and other indications, based on the research and discoveries from Univ.&lt;span class="nobreak"&gt;-Prof&lt;/span&gt;. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#x201c;CTH&#x201d;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#x20ac;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Gencaro License&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <abio:RetentionBonuses contextRef="c80" decimals="0" id="ixv-35179" unitRef="usd">265000</abio:RetentionBonuses>
    <abio:PercentageOfRetentionBonuses contextRef="c81" decimals="2" id="ixv-35180" unitRef="pure">0.50</abio:PercentageOfRetentionBonuses>
    <abio:RetentionBonusPaid contextRef="c6" decimals="0" id="ixv-35181" unitRef="usd">86000</abio:RetentionBonusPaid>
    <abio:RetentionBonuses contextRef="c1" decimals="0" id="ixv-35182" unitRef="usd">311000</abio:RetentionBonuses>
    <us-gaap:SeveranceCosts1 contextRef="c6" decimals="0" id="ixv-35183" unitRef="usd">159000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c7" decimals="2" id="ixv-35184" unitRef="pure">0.67</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated contextRef="c7" decimals="0" id="ixv-35185" unitRef="pure">12</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringCharges contextRef="c82" decimals="0" id="ixv-35186" unitRef="usd">755000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c83" decimals="0" id="ixv-35187" unitRef="usd">470000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c84" decimals="0" id="ixv-35188" unitRef="usd">285000</us-gaap:RestructuringCharges>
    <us-gaap:AreaOfRealEstateProperty contextRef="c85" decimals="0" id="ixv-35189" unitRef="sqft">5200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c85" id="ixv-35190">P42M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="c86" id="ixv-20402">option to renew for an additional 36 month term at the then prevailing rental rate.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c85" id="ixv-35191">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities contextRef="c87" decimals="0" id="ixv-35192" unitRef="sqft">3000</abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities>
    <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent contextRef="c6" id="ixv-20406">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c6" id="ixv-35193">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;93&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;96&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;100&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;314&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(34&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c1" decimals="-3" id="ixv-35194" unitRef="usd">93000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c1" decimals="-3" id="ixv-35195" unitRef="usd">96000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c1" decimals="-3" id="ixv-35196" unitRef="usd">100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c1" decimals="-3" id="ixv-35197" unitRef="usd">25000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c1" decimals="-3" id="ixv-35198" unitRef="usd">314000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c1" decimals="-3" id="ixv-35199" unitRef="usd">34000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="-3" id="ixv-35200" unitRef="usd">76000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-35201" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c89" decimals="0" id="ixv-35202" unitRef="usd">119000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c90" decimals="0" id="ixv-35203" unitRef="usd">125000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseLiability contextRef="c1" decimals="0" id="ixv-35204" unitRef="usd">280000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c6" decimals="0" id="ixv-35205" unitRef="usd">127000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c7" decimals="0" id="ixv-35206" unitRef="usd">131000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c1" decimals="2" id="ixv-35207" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations contextRef="c91" decimals="-5" id="ixv-35208" unitRef="eur">1600000</abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c6" id="ixv-20518">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(7)&#160;Equity Financings&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;At the Market Equity Financing&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On July&#160;22, 2020, ARCA entered into a Capital on Demand&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;TM&lt;/span&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with JonesTrading Institutional Services LLC, as agent (&#x201c;JonesTrading&#x201d;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#x2019;s common stock, par value $0.001 per share (&#x201c;ARCA&#160;common stock&#x201d;), having an aggregate offering price of up to $54.0&#160;million (the &#x201c;Shares&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;No sales were made in 2023 or 2022.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#x2019;s registration statement on Form&#160;S&lt;span class="nobreak"&gt;-3&lt;/span&gt; (No.&#160;333&lt;span class="nobreak"&gt;-254585&lt;/span&gt;). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one&lt;span class="nobreak"&gt;-third&lt;/span&gt; of ARCA&#x2019;s public float in any 12&lt;span class="nobreak"&gt;-month&lt;/span&gt; period.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c92"
      decimals="INF"
      id="ixv-35209"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell contextRef="c92" decimals="-5" id="ixv-35210" unitRef="usd">54000000</abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell>
    <abio:SellingCommissionPerAdditionalSharesSoldPercentage contextRef="c93" decimals="3" id="ixv-35211" unitRef="pure">0.03</abio:SellingCommissionPerAdditionalSharesSoldPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c94"
      decimals="0"
      id="ixv-35212"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c95"
      decimals="0"
      id="ixv-35213"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c6" id="ixv-20545">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(8)&#160;Share-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s equity incentive plan, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;the 2020 Equity Incentive Plan &lt;/span&gt;(the &#x201c;Equity Plan&#x201d;),&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt; &lt;/span&gt;was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is 1,167,425&lt;span class="nobreak"&gt; &lt;/span&gt;shares.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase 601,900&lt;span class="nobreak"&gt; &lt;/span&gt;shares with a weighted average exercise price of $3.45 per share were outstanding under the Equity Plan, and 459,718&lt;span class="nobreak"&gt; &lt;/span&gt;shares were reserved for future awards.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of &lt;span style="-sec-ix-hidden: hidden-fact-98"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden: hidden-fact-99"&gt;four&lt;/span&gt;&#160;years from the date of grant and have a maximum term of &lt;span style="-sec-ix-hidden: hidden-fact-100"&gt;ten&lt;/span&gt;&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase 14,807&lt;span class="nobreak"&gt; &lt;/span&gt;shares with a weighted average exercise price of $57.73 per share were outstanding under the 2013 plan.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA did not grant options in 2023. ARCA granted options to purchase an aggregate of 60,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of ARCA common stock in the year ended December&#160;31, 2022. The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; model with the following assumptions and had the following estimated weighted average grant date fair value per share:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected term&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.5&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free interest rate&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.56&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected dividend yield&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.87&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A summary of ARCA&#x2019;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in&#160;years)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;904,123&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.59&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.31&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(259,163&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.74&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.62&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.29&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;18&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(88,253&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;11.68&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;463,068&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.28&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.29&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,661&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#x2019;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in&lt;span class="nobreak"&gt;-the-money&lt;/span&gt; options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $367,000 which is expected to be recognized over a weighted average period of &lt;span style="-sec-ix-hidden: hidden-fact-101"&gt;1.1&lt;/span&gt;&#160;years. ARCA recognizes compensation costs for its share&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA granted restricted stock units (&#x201c;RSUs&#x201d;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the respective vesting period. The stock awards granted had a requisite service period of &lt;span style="-sec-ix-hidden: hidden-fact-102"&gt;one&lt;/span&gt; year.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-97; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, there was no unrecognized compensation cost related to unvested stock awards.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Non-cash Stock-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;526&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;423&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;160&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;133&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;686&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;556&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA did not recognize any tax benefit related to employee stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost as a result of the full valuation allowance on its net deferred tax assets.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c96"
      decimals="INF"
      id="ixv-35214"
      unitRef="shares">1167425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c97"
      decimals="INF"
      id="ixv-35215"
      unitRef="shares">601900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c97"
      decimals="2"
      id="ixv-35216"
      unitRef="usdPershares">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c97"
      decimals="INF"
      id="ixv-35217"
      unitRef="shares">459718</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c100"
      decimals="INF"
      id="ixv-35218"
      unitRef="pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <abio:PercentageHoldingForStockOptionsExercisePrice
      contextRef="c98"
      decimals="INF"
      id="ixv-35219"
      unitRef="pure">0.10</abio:PercentageHoldingForStockOptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c101"
      decimals="INF"
      id="ixv-35220"
      unitRef="pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c102"
      decimals="INF"
      id="ixv-35221"
      unitRef="shares">14807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c102"
      decimals="2"
      id="ixv-35222"
      unitRef="usdPershares">57.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c103"
      decimals="INF"
      id="ixv-35223"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <abio:PurchaseAggregateShares
      contextRef="c104"
      decimals="0"
      id="ixv-35224"
      unitRef="shares">60000</abio:PurchaseAggregateShares>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c6" id="ixv-20576">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; model with the following assumptions and had the following estimated weighted average grant date fair value per share:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected term&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.5&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected volatility&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free interest rate&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.56&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected dividend yield&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.87&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c6" id="ixv-35225">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c6" decimals="2" id="ixv-35226" unitRef="pure">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c6" decimals="4" id="ixv-35227" unitRef="pure">0.0356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c6" decimals="2" id="ixv-35228" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      decimals="2"
      id="ixv-35229"
      unitRef="usdPershares">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c6" id="ixv-35230">A summary of ARCA&#x2019;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in&#160;years)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;904,123&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.59&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.31&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(259,163&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.74&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.62&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.29&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;18&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(88,253&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;11.68&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;463,068&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.28&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.29&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,661&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c16"
      decimals="INF"
      id="ixv-35231"
      unitRef="shares">904123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c16"
      decimals="2"
      id="ixv-35232"
      unitRef="usdPershares">5.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c7"
      decimals="INF"
      id="ixv-35233"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-35234"
      unitRef="usdPershares">2.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-35235"
      unitRef="shares">259163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-35236"
      unitRef="usdPershares">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-35237"
      unitRef="shares">704960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-35238"
      unitRef="usdPershares">5.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c7" id="ixv-35239">P8Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c2" decimals="-3" id="ixv-35240" unitRef="usd">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-35241"
      unitRef="shares">88253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      decimals="2"
      id="ixv-35242"
      unitRef="usdPershares">11.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-35243"
      unitRef="shares">616707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-35244"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c6" id="ixv-35245">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-35246"
      unitRef="shares">463068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-35247"
      unitRef="usdPershares">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c6" id="ixv-35248">P7Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-35249"
      unitRef="shares">616661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-35250"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c6" id="ixv-35251">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c105" decimals="0" id="ixv-35252" unitRef="usd">367000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c6" id="ixv-35253">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-97; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-35254"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c7"
      decimals="2"
      id="ixv-35255"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-35256"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c2"
      decimals="2"
      id="ixv-35257"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-35258"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      decimals="2"
      id="ixv-35259"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c108"
      decimals="INF"
      id="ixv-35260"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c6" id="ixv-21058">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;526&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;423&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;160&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;133&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;686&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;556&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c89" decimals="-3" id="ixv-35261" unitRef="usd">526000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c90" decimals="-3" id="ixv-35262" unitRef="usd">423000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c109"
      decimals="-3"
      id="ixv-35263"
      unitRef="usd">160000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c110"
      decimals="-3"
      id="ixv-35264"
      unitRef="usd">133000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c6" decimals="-3" id="ixv-35265" unitRef="usd">686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="-3" id="ixv-35266" unitRef="usd">556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c6" id="ixv-21121">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(9)&#160;Employee Benefit Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has a 401(k)&#160;plan and makes a matching contribution equal to 100% of the employee&#x2019;s first 3% of the employee&#x2019;s contributions and 50% of the employee&#x2019;s next 2% of contributions. ARCA adopted the plan in 2006 and contributed $56,000 and $96,000 for the&#160;years ended December&#160;31, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans contextRef="c6" id="ixv-35267">matching contribution equal to 100% of the employee&#x2019;s first 3% of the employee&#x2019;s contributions and 50% of the employee&#x2019;s next 2% of contributions.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c111"
      decimals="INF"
      id="ixv-35268"
      unitRef="pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c111"
      decimals="2"
      id="ixv-35269"
      unitRef="pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c112"
      decimals="2"
      id="ixv-35270"
      unitRef="pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c112"
      decimals="2"
      id="ixv-35271"
      unitRef="pure">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c6" decimals="0" id="ixv-35272" unitRef="usd">56000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c7" decimals="0" id="ixv-35273" unitRef="usd">96000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c6" id="ixv-21125">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;(&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;10)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective June&#160;1, 2005, ARCA changed from an S&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt; to a C&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt;. As an S&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt;, the net operating loss carryforwards were distributed to ARCA&#x2019;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#x2019;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning &lt;span style="-sec-ix-hidden: hidden-fact-109"&gt;2025&lt;/span&gt; through &lt;span style="-sec-ix-hidden: hidden-fact-110"&gt;2037&lt;/span&gt;. The net operating loss carryforwards beginning in 2018, have no expiration. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#x2019;s net operating loss carryforwards may be limited.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#x2019;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $55.5&#160;million at December&#160;31, 2023, reflecting an increase of approximately $1.2&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Income tax benefit attributable to ARCA&#x2019;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;U.S.&#160;federal income tax benefit at statutory rates&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,121&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,085&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State income tax benefit, net of federal benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(192&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(357&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax asset adjustment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;47&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;186&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,159&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,254&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Income tax benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#x2019;s net deferred tax assets and liabilities consisted of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net operating loss carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;51,190&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;50,008&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Charitable contribution carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;371&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;393&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized research and development costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;951&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;979&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized intangibles&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;354&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;356&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;232&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;205&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lease liabilities&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;69&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total deferred tax assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;55,594&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;54,461&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(55,531&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(54,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;63&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;89&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Right-of-use asset&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(84&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net deferred tax liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-107; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-108; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#x2019;s open tax&#160;years extend back to &lt;span style="-sec-ix-hidden: hidden-fact-111"&gt;2009&lt;/span&gt;. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#x2019;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has no reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. No interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c1" decimals="-5" id="ixv-35274" unitRef="usd">208100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c113"
      decimals="-5"
      id="ixv-35275"
      unitRef="usd">2400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c6" id="ixv-35276">The net operating loss carryforwards beginning in 2018, have no expiration.</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="c116" id="ixv-35277">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#x2019;s net operating loss carryforwards may be limited.</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance contextRef="c1" decimals="-5" id="ixv-35278" unitRef="usd">55500000</abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance>
    <abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount contextRef="c6" decimals="-5" id="ixv-35279" unitRef="usd">1200000</abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c6" id="ixv-35280">Income tax benefit attributable to ARCA&#x2019;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;U.S.&#160;federal income tax benefit at statutory rates&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,121&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,085&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State income tax benefit, net of federal benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(192&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(357&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax asset adjustment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;47&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;186&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,159&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,254&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Income tax benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="2" id="ixv-35281" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="2" id="ixv-35282" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="-3" id="ixv-35283" unitRef="usd">-1121000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="-3" id="ixv-35284" unitRef="usd">-2085000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c6" decimals="-3" id="ixv-35285" unitRef="usd">-192000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c7" decimals="-3" id="ixv-35286" unitRef="usd">-357000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset contextRef="c6" decimals="-3" id="ixv-35287" unitRef="usd">47000</abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset>
    <abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset contextRef="c7" decimals="-3" id="ixv-35288" unitRef="usd">2000</abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c6" decimals="-3" id="ixv-35289" unitRef="usd">107000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c7" decimals="-3" id="ixv-35290" unitRef="usd">186000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c6" decimals="-3" id="ixv-35291" unitRef="usd">1159000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c7" decimals="-3" id="ixv-35292" unitRef="usd">2254000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c6" id="ixv-35293">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#x2019;s net deferred tax assets and liabilities consisted of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net operating loss carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;51,190&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;50,008&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Charitable contribution carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;371&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;393&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized research and development costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;951&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;979&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized intangibles&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;354&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;356&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;232&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;205&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lease liabilities&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;69&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total deferred tax assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;55,594&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;54,461&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(55,531&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(54,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;63&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;89&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Right-of-use asset&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(84&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net deferred tax liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-107; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-108; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c1" decimals="-3" id="ixv-35294" unitRef="usd">51190000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c2" decimals="-3" id="ixv-35295" unitRef="usd">50008000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="c1" decimals="-3" id="ixv-35296" unitRef="usd">371000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="c2" decimals="-3" id="ixv-35297" unitRef="usd">393000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c1" decimals="-3" id="ixv-35298" unitRef="usd">2420000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c2" decimals="-3" id="ixv-35299" unitRef="usd">2420000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <abio:DeferredTaxAssetResearchAndDevelopment contextRef="c1" decimals="-3" id="ixv-35300" unitRef="usd">951000</abio:DeferredTaxAssetResearchAndDevelopment>
    <abio:DeferredTaxAssetResearchAndDevelopment contextRef="c2" decimals="-3" id="ixv-35301" unitRef="usd">979000</abio:DeferredTaxAssetResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c1" decimals="-3" id="ixv-35302" unitRef="usd">354000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c2" decimals="-3" id="ixv-35303" unitRef="usd">356000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c1" decimals="-3" id="ixv-35304" unitRef="usd">232000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c2" decimals="-3" id="ixv-35305" unitRef="usd">205000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c1" decimals="-3" id="ixv-35306" unitRef="usd">7000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c2" decimals="-3" id="ixv-35307" unitRef="usd">6000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <abio:DeferredTaxAssetsLeaseLiabilities contextRef="c1" decimals="-3" id="ixv-35308" unitRef="usd">69000</abio:DeferredTaxAssetsLeaseLiabilities>
    <abio:DeferredTaxAssetsLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-35309" unitRef="usd">94000</abio:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross contextRef="c1" decimals="-3" id="ixv-35310" unitRef="usd">55594000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="-3" id="ixv-35311" unitRef="usd">54461000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="-3" id="ixv-35312" unitRef="usd">55531000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="-3" id="ixv-35313" unitRef="usd">54372000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c1" decimals="-3" id="ixv-35314" unitRef="usd">63000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c2" decimals="-3" id="ixv-35315" unitRef="usd">89000</us-gaap:DeferredTaxAssetsNet>
    <abio:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-35316" unitRef="usd">61000</abio:DeferredTaxLiabilitiesRightOfUseAsset>
    <abio:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-35317" unitRef="usd">84000</abio:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-35318" unitRef="usd">2000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-35319" unitRef="usd">5000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="c1" decimals="INF" id="ixv-35320" unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="c2" decimals="0" id="ixv-35321" unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c6" decimals="0" id="ixv-35322" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c7" decimals="0" id="ixv-35323" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-35324" unitRef="usd">35903000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="-3" id="ixv-35325" unitRef="usd">37431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-35326" unitRef="usd">767000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c1" decimals="-3" id="ixv-35327" unitRef="usd">161000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="-3" id="ixv-35328" unitRef="usd">36670000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="-3" id="ixv-35329" unitRef="usd">37592000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="-3" id="ixv-35330" unitRef="usd">17000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-35331" unitRef="usd">247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-35332" unitRef="usd">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-35333" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c5" decimals="-3" id="ixv-35334" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="-3" id="ixv-35335" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c5" decimals="-3" id="ixv-35336" unitRef="usd">36706000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-35337" unitRef="usd">37861000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c5" decimals="-3" id="ixv-35338" unitRef="usd">529000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="-3" id="ixv-35339" unitRef="usd">362000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-35340" unitRef="usd">84000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-35341" unitRef="usd">100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-35342" unitRef="usd">968000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-35343" unitRef="usd">175000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-35344" unitRef="usd">1581000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-35345" unitRef="usd">637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-35346" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c5" decimals="-3" id="ixv-35347" unitRef="usd">1581000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c1" decimals="-3" id="ixv-35348" unitRef="usd">841000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c5"
      decimals="INF"
      id="ixv-35349"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-35350"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="ixv-35351"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-35352"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-35353"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-35354"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-35355"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-35356"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c5" decimals="-3" id="ixv-35357" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c1" decimals="-3" id="ixv-35358" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c5" decimals="-3" id="ixv-35359" unitRef="usd">225861000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c1" decimals="-3" id="ixv-35360" unitRef="usd">225747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c5" decimals="-3" id="ixv-35361" unitRef="usd">-190750000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-35362" unitRef="usd">-188741000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-35363" unitRef="usd">35125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-35364" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="-3" id="ixv-35365" unitRef="usd">36706000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="-3" id="ixv-35366" unitRef="usd">37861000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-35367" unitRef="usd">2317000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c10" decimals="-3" id="ixv-35368" unitRef="usd">1406000</us-gaap:GeneralAndAdministrativeExpense>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c11" decimals="-3" id="ixv-35369" unitRef="usd">0</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c12" decimals="-3" id="ixv-35370" unitRef="usd">108000</abio:ResearchAndDevelopmentExpenseReversed>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-35371" unitRef="usd">165000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c10" decimals="-3" id="ixv-35372" unitRef="usd">390000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-35373" unitRef="usd">2482000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c10" decimals="-3" id="ixv-35374" unitRef="usd">1796000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-35375" unitRef="usd">-2482000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c10" decimals="-3" id="ixv-35376" unitRef="usd">-1796000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c0" decimals="-3" id="ixv-35377" unitRef="usd">473000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c10" decimals="-3" id="ixv-35378" unitRef="usd">450000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-35379" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-35380" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-35381"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c10"
      decimals="2"
      id="ixv-35382"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-35383"
      unitRef="shares">14501143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c10"
      decimals="0"
      id="ixv-35384"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="0"
      id="ixv-35385"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-35386" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-35387" unitRef="usd">225061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-35388" unitRef="usd">-183402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-35389" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c30" decimals="-3" id="ixv-35390" unitRef="usd">204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c10" decimals="-3" id="ixv-35391" unitRef="usd">204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" id="ixv-35392" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-35393" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c32"
      decimals="0"
      id="ixv-35394"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" id="ixv-35395" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" id="ixv-35396" unitRef="usd">225265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" id="ixv-35397" unitRef="usd">-184748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" id="ixv-35398" unitRef="usd">40531000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c37" decimals="-3" id="ixv-35399" unitRef="usd">187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c39" decimals="-3" id="ixv-35400" unitRef="usd">187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" id="ixv-35401" unitRef="usd">-1480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c39" decimals="-3" id="ixv-35402" unitRef="usd">-1480000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c40"
      decimals="0"
      id="ixv-35403"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" id="ixv-35404" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" id="ixv-35405" unitRef="usd">225452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" id="ixv-35406" unitRef="usd">-186228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" id="ixv-35407" unitRef="usd">39238000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c45" decimals="-3" id="ixv-35408" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c47" decimals="-3" id="ixv-35409" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c46" decimals="-3" id="ixv-35410" unitRef="usd">-1424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c47" decimals="-3" id="ixv-35411" unitRef="usd">-1424000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c48"
      decimals="0"
      id="ixv-35412"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c48" decimals="-3" id="ixv-35413" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c49" decimals="-3" id="ixv-35414" unitRef="usd">225606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" id="ixv-35415" unitRef="usd">-187652000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="-3" id="ixv-35416" unitRef="usd">37968000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c52"
      decimals="0"
      id="ixv-35417"
      unitRef="shares">91000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c53" decimals="-3" id="ixv-35418" unitRef="usd">141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c55" decimals="-3" id="ixv-35419" unitRef="usd">141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c54" decimals="-3" id="ixv-35420" unitRef="usd">-1089000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c55" decimals="-3" id="ixv-35421" unitRef="usd">-1089000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-35422"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-35423" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-35424" unitRef="usd">225747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-35425" unitRef="usd">-188741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-35426" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c57" decimals="-3" id="ixv-35427" unitRef="usd">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="-3" id="ixv-35428" unitRef="usd">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c58" decimals="-3" id="ixv-35429" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-35430" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c59"
      decimals="0"
      id="ixv-35431"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c59" decimals="-3" id="ixv-35432" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c60" decimals="-3" id="ixv-35433" unitRef="usd">225861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c61" decimals="-3" id="ixv-35434" unitRef="usd">-190750000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-35435" unitRef="usd">35125000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-35436" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-35437" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-35438" unitRef="usd">3000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c10" decimals="-3" id="ixv-35439" unitRef="usd">4000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="-3" id="ixv-35440" unitRef="usd">16000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c10" decimals="-3" id="ixv-35441" unitRef="usd">25000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-35442" unitRef="usd">114000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c10" decimals="-3" id="ixv-35443" unitRef="usd">204000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="-3" id="ixv-35444" unitRef="usd">606000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c10" decimals="-3" id="ixv-35445" unitRef="usd">598000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" id="ixv-35446" unitRef="usd">167000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c10" decimals="-3" id="ixv-35447" unitRef="usd">32000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c0" decimals="-3" id="ixv-35448" unitRef="usd">-16000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c10" decimals="-3" id="ixv-35449" unitRef="usd">62000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="-3" id="ixv-35450" unitRef="usd">803000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c10" decimals="-3" id="ixv-35451" unitRef="usd">22000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-35452" unitRef="usd">-1528000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c10" decimals="-3" id="ixv-35453" unitRef="usd">-1595000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-35454" unitRef="usd">-1528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c10" decimals="-3" id="ixv-35455" unitRef="usd">-1595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-35456" unitRef="usd">37431000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-35457" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-35458" unitRef="usd">35903000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c35" decimals="-3" id="ixv-35459" unitRef="usd">40850000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-35460" unitRef="usd">214000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-23356">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(1)&#160;ARCA and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#x201c;Board&#x201d;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;I&#x201d;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;II&#x201d;) and Oruka Therapeutics, Inc., a Delaware corporation (&#x201c;Oruka&lt;span class="CharOverride-1" style="text-decoration:underline;"&gt;&#x201d;&lt;/span&gt;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;). The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time&lt;span class="nobreak"&gt;-consuming&lt;/span&gt; and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the timing and outcome of the strategic review process;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the consummation of any particular strategic transactions, including the Merger;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S&lt;span class="nobreak"&gt;-X&lt;/span&gt;.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <abio:DescriptionOfBusinessPolicyTextBlock contextRef="c0" id="ixv-23359">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#x201c;Board&#x201d;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;I&#x201d;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;II&#x201d;) and Oruka Therapeutics, Inc., a Delaware corporation (&#x201c;Oruka&lt;span class="CharOverride-1" style="text-decoration:underline;"&gt;&#x201d;&lt;/span&gt;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;). The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.&lt;/p&gt;</abio:DescriptionOfBusinessPolicyTextBlock>
    <abio:LiquidityAndGoingConcernPolicyTextBlock contextRef="c0" id="ixv-23374">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time&lt;span class="nobreak"&gt;-consuming&lt;/span&gt; and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the timing and outcome of the strategic review process;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the consummation of any particular strategic transactions, including the Merger;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;</abio:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:Revenues contextRef="c0" decimals="INF" id="ixv-35461" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-23436">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S&lt;span class="nobreak"&gt;-X&lt;/span&gt;.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-23456">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset contextRef="c5" decimals="INF" id="ixv-35462" unitRef="usd">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset>
    <abio:ComprehensiveLossPolicyPolicyTextBlock contextRef="c0" id="ixv-23462">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.&lt;/p&gt;</abio:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-23468">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <abio:AccruedOutsourcingExpensesPolicyTextBlock contextRef="c0" id="ixv-23477">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;</abio:AccruedOutsourcingExpensesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-23482">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-23495">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(2)&#160;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#x2019;s potentially dilutive shares include stock options and restricted stock units.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;664,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-112; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;755,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-35463">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;664,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-112; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;755,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c117"
      decimals="0"
      id="ixv-35464"
      unitRef="shares">645845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c118"
      decimals="0"
      id="ixv-35465"
      unitRef="shares">664857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c120"
      decimals="0"
      id="ixv-35466"
      unitRef="shares">91000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="0"
      id="ixv-35467"
      unitRef="shares">645845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c10"
      decimals="0"
      id="ixv-35468"
      unitRef="shares">755857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-23552">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(3)&#160;Fair Value Disclosures&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;There were &lt;span style="-sec-ix-hidden: hidden-fact-113"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-114"&gt;no&lt;/span&gt;&lt;/span&gt; marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#x201c;exit price&#x201d;). Inputs used to measure fair value are classified into the following hierarchy:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 1 &#x2014;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#x2019;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 2 &#x2014;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 3 &#x2014;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $35.9&#160;million and $37.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were &lt;span style="-sec-ix-hidden: hidden-fact-115"&gt;no&lt;/span&gt; transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Fair Value of Other Financial Instruments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c121"
      decimals="-5"
      id="ixv-35469"
      unitRef="usd">35900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c66" decimals="-5" id="ixv-35470" unitRef="usd">37400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-23581">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(4)&#160;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(215&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $3,000 and $4,000 respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-35471">Property and equipment consist of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(215&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c122" id="ixv-35472">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c122"
      decimals="-3"
      id="ixv-35473"
      unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c69" decimals="-3" id="ixv-35474" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c123" id="ixv-35475">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c123"
      decimals="-3"
      id="ixv-35476"
      unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c71" decimals="-3" id="ixv-35477" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c124" id="ixv-35478">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c124"
      decimals="-3"
      id="ixv-35479"
      unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c73" decimals="-3" id="ixv-35480" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c125" id="ixv-35481">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c125"
      decimals="-3"
      id="ixv-35482"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c75" decimals="-3" id="ixv-35483" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-35484" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="-3" id="ixv-35485" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-35486" unitRef="usd">215000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-35487" unitRef="usd">212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-35488" unitRef="usd">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-35489" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-35490" unitRef="usd">3000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c10" decimals="-3" id="ixv-35491" unitRef="usd">4000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-23741">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(5)&#160;Related Party Arrangements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Transactions with ARCA&#x2019;s Former President and Chief Executive Officer&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#x2019;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#x2019;s financial condition, and can be deferred or terminated at ARCA&#x2019;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c127" decimals="0" id="ixv-35492" unitRef="usd">0</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c126" decimals="0" id="ixv-35493" unitRef="usd">108000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:PaymentOfUnrestrictedResearchGrants contextRef="c77" decimals="0" id="ixv-35494" unitRef="usd">125000</abio:PaymentOfUnrestrictedResearchGrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-23747">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(6)&#160;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has or is subject to the following commitments and contingencies.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Employment Agreements and Reduction of Workforce&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2022, ARCA&#x2019;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000. See Note&#160;10.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#x2019;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#x2019;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, &lt;span style="-sec-ix-hidden: hidden-fact-119"&gt;none&lt;/span&gt; of which remains unpaid.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#x2019;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#x201c;October&#160;2020 Lease&#x201d;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#x201c;2021 Lease&#x201d;). The sublease term was &lt;span style="-sec-ix-hidden: hidden-fact-117"&gt;29&lt;/span&gt;&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non&lt;span class="nobreak"&gt;-lease&lt;/span&gt; component that is not included in the lease obligation.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(48&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of March&#160;31, 2024, the lease liability was $48,000, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $23,000 and $33,000, respectively. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; remaining lease term for the operating lease as of March&#160;31, 2024 is &lt;span style="-sec-ix-hidden: hidden-fact-118"&gt;0.5&lt;/span&gt;&#160;years. The discount rate for the operating lease is 7%.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Patent Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In July&#160;2021, ARCA entered into a patent assignment agreement (the &#x201c;Agreement&#x201d;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the terms of the Agreement, ARCA received exclusive world&lt;span class="nobreak"&gt;-wide&lt;/span&gt; patent rights relating to the use of rNAPc2 as a potential treatment for COVID&lt;span class="nobreak"&gt;-19&lt;/span&gt;, and other indications, based on the research and discoveries from Univ.&lt;span class="nobreak"&gt;-Prof&lt;/span&gt;. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#x201c;CTH&#x201d;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;&#x20ac;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <abio:RetentionBonuses contextRef="c80" decimals="0" id="ixv-35495" unitRef="usd">265000</abio:RetentionBonuses>
    <abio:PercentageOfRetentionBonuses contextRef="c81" decimals="2" id="ixv-35496" unitRef="pure">0.50</abio:PercentageOfRetentionBonuses>
    <abio:RetentionBonusPaid contextRef="c6" decimals="0" id="ixv-35497" unitRef="usd">86000</abio:RetentionBonusPaid>
    <abio:RetentionBonuses contextRef="c5" decimals="0" id="ixv-35498" unitRef="usd">311000</abio:RetentionBonuses>
    <abio:RetentionBonuses contextRef="c128" decimals="0" id="ixv-35499" unitRef="usd">444000</abio:RetentionBonuses>
    <us-gaap:SeveranceCosts1 contextRef="c6" decimals="0" id="ixv-35500" unitRef="usd">159000</us-gaap:SeveranceCosts1>
    <us-gaap:AreaOfRealEstateProperty contextRef="c85" decimals="0" id="ixv-35501" unitRef="sqft">5200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c85" id="ixv-35502">P42M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="c0" id="ixv-35503">to extend the lease term six (6)&#160;months through September&#160;2024</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="c0" id="ixv-35504">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c5" id="ixv-35505">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <abio:OperatingLeasesExtendedExpiryYearsAndMonth contextRef="c0" id="ixv-35506">September&#160;2024</abio:OperatingLeasesExtendedExpiryYearsAndMonth>
    <abio:PercentageOfBaseRentToBePaidMonthly contextRef="c0" decimals="2" id="ixv-35508" unitRef="pure">1.25</abio:PercentageOfBaseRentToBePaidMonthly>
    <abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities contextRef="c87" decimals="0" id="ixv-35509" unitRef="sqft">3000</abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities>
    <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent contextRef="c0" id="ixv-23776">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-35510">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(48&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c5" decimals="-3" id="ixv-35511" unitRef="usd">49000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c5" decimals="-3" id="ixv-35512" unitRef="usd">49000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c5" decimals="-3" id="ixv-35513" unitRef="usd">1000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-35514" unitRef="usd">48000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseCost contextRef="c130" decimals="0" id="ixv-35515" unitRef="usd">22000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c131" decimals="0" id="ixv-35516" unitRef="usd">31000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseLiability contextRef="c5" decimals="0" id="ixv-35517" unitRef="usd">48000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-35518" unitRef="usd">23000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c10" decimals="0" id="ixv-35519" unitRef="usd">33000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="2" id="ixv-35520" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations contextRef="c91" decimals="-5" id="ixv-35521" unitRef="eur">1600000</abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-23855">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(7)&#160;&lt;/span&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;"&gt;Equity Financings&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;At the Market Equity Financing&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2020, ARCA entered into a Capital on Demand&#x2122; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with JonesTrading Institutional Services LLC, as agent (&#x201c;JonesTrading&#x201d;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#x2019;s common stock, par value $0.001 per share (&#x201c;ARCA common stock&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#x2019;s registration statement on Form&#160;S&lt;span class="nobreak"&gt;-3&lt;/span&gt; (No.&#160;333&lt;span class="nobreak"&gt;-254585&lt;/span&gt;), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;No sales were made under the Sales Agreement in 2024 or 2023.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Merger Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;See &#x201c;Financing Transaction&#x201d; discussion in Note&#160;10 below.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c132"
      decimals="INF"
      id="ixv-35522"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c133"
      decimals="INF"
      id="ixv-35523"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c134"
      decimals="INF"
      id="ixv-35524"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-23869">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(8)&#160;Share-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;"&gt;For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense in the statements of operations (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Three&#160;Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;163&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-120; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;41&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#x2019;s stock incentive plans were as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;42,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.64&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-121; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-122; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(12,862&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17.45&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;502,517&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.71&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.55&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,816&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-23873">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense in the statements of operations (in thousands):&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Three&#160;Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;163&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-120; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;41&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c130"
      decimals="-3"
      id="ixv-35525"
      unitRef="usd">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c131"
      decimals="-3"
      id="ixv-35526"
      unitRef="usd">163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c136"
      decimals="-3"
      id="ixv-35527"
      unitRef="usd">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-35528" unitRef="usd">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c10" decimals="-3" id="ixv-35529" unitRef="usd">204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-35530">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#x2019;s stock incentive plans were as follows:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;

					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;42,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.64&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-121; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-122; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(12,862&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17.45&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;502,517&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.71&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.55&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,816&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-35531"
      unitRef="shares">616707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-35532"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c137" id="ixv-35533">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="INF"
      id="ixv-35534"
      unitRef="shares">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-35535"
      unitRef="usdPershares">1.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-35536"
      unitRef="shares">12862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-35537"
      unitRef="usdPershares">17.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-35538"
      unitRef="shares">645845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-35539"
      unitRef="usdPershares">4.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-35540">P6Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-35541"
      unitRef="shares">502517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-35542"
      unitRef="usdPershares">4.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-35543">P6Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-35544"
      unitRef="shares">645816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-35545"
      unitRef="usdPershares">4.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-35546">P6Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-24083">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(9)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#x2019;s deferred tax assets will not be realized. ARCA&#x2019;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has &lt;span style="-sec-ix-hidden: hidden-fact-123"&gt;no&lt;/span&gt; reserve for uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-24088">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(10)&#160;Subsequent Events&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Merger Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#x201c;Exchange Ratio&#x201d;), (b)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#x201c;Out of the Money Options&#x201d;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#x201c;Parent Closing Price&#x201d;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants in the financing transaction described below) will own approximately 97.62% of the combined company and pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders will own approximately 2.38% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;adjusted to the extent that ARCA&#x2019;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders equal in the aggregate to ARCA&#x2019;s reasonable, good faith approximation of the amount by which ARCA&#x2019;s net cash (as determined pursuant to the Merger Agreement) will exceed $5,000,000.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#x201c;ARCA Voting Proposals&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non&lt;span class="nobreak"&gt;-solicitation&lt;/span&gt; of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#x201c;Registration Statement&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#x2019;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott&lt;span class="nobreak"&gt;-Rodino&lt;/span&gt; Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders to ARCA&#x2019;s transfer agent for further distribution to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders. Each party&#x2019;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non&lt;span class="nobreak"&gt;-Voting&lt;/span&gt; Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#x201c;Certificate of Designation&#x201d;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non&lt;span class="nobreak"&gt;-Voting&lt;/span&gt; Convertible Preferred Stock, par value $0.001 per share (the &#x201c;Series&#160;B Preferred Stock&#x201d;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as&lt;span class="nobreak"&gt;-if-converted-to-ARCA&lt;/span&gt; common stock &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding&lt;span class="nobreak"&gt;-up&lt;/span&gt; of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to 1,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;At the effective time of the First Merger (the &#x201c;First Effective Time&#x201d;), the combined company&#x2019;s board of directors is expected to consist of five (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#x2019;s chief executive officer.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Financing Transaction&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to purchase shares of Oruka common stock (together, the &#x201c;PIPE Securities&#x201d;) for an aggregate purchase price of approximately $275.0&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#x2019;s employment and service as a director.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with Dr.&#160;Bristow&#x2019;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#x201c;Separation Agreement&#x201d;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (12)&#160;months of Dr.&#160;Bristow&#x2019;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $25,000, less applicable withholdings. The severance benefits were conditioned on the non&lt;span class="nobreak"&gt;-revocation&lt;/span&gt; by Dr.&#160;Bristow of a legal release of claims.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#x201c;Consulting Agreement&#x201d;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#x2019;s 2020 Equity Incentive Plan (the &#x201c;Plan&#x201d;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Appointment of Thomas Keuer as President&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#x2019;s Chief Operating Officer, to serve as ARCA&#x2019;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#x2019;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8&lt;span class="nobreak"&gt;-K&lt;/span&gt; filed with the SEC on April&#160;3, 2024.&lt;/p&gt;
		&lt;p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#x201c;Payment Event Date&#x201d; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <abio:NumberOfConsecutiveTradingDays contextRef="c138" id="ixv-35547">P5D</abio:NumberOfConsecutiveTradingDays>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c139"
      decimals="4"
      id="ixv-35548"
      unitRef="pure">0.9762</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c140"
      decimals="4"
      id="ixv-35549"
      unitRef="pure">0.0238</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <abio:ThresholdAmountOfAdjustedExchangeRatio
      contextRef="c138"
      decimals="-5"
      id="ixv-35550"
      unitRef="usd">5000000</abio:ThresholdAmountOfAdjustedExchangeRatio>
    <abio:ThresholdAmountOfDeclaredCashDividend contextRef="c141" decimals="0" id="ixv-35551" unitRef="usd">5000000</abio:ThresholdAmountOfDeclaredCashDividend>
    <abio:SubscriptionAgreementReceiptAmount
      contextRef="c142"
      decimals="INF"
      id="ixv-35552"
      unitRef="usd">175000000</abio:SubscriptionAgreementReceiptAmount>
    <abio:PaymentOfOtherPartyTerminationFee contextRef="c143" decimals="0" id="ixv-35553" unitRef="usd">440000</abio:PaymentOfOtherPartyTerminationFee>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c144"
      decimals="INF"
      id="ixv-35554"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <abio:MinimumPercentageOfOriginallyIssuedShares
      contextRef="c145"
      decimals="2"
      id="ixv-35555"
      unitRef="pure">0.30</abio:MinimumPercentageOfOriginallyIssuedShares>
    <abio:MinimumPercentageOfOriginallyIssuedOutstanding
      contextRef="c145"
      decimals="2"
      id="ixv-35556"
      unitRef="pure">0.30</abio:MinimumPercentageOfOriginallyIssuedOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c146"
      decimals="0"
      id="ixv-35557"
      unitRef="shares">1000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares
      contextRef="c147"
      decimals="4"
      id="ixv-35558"
      unitRef="pure">0.0999</abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares>
    <abio:ExceptedNumberOfBoardMembers
      contextRef="c148"
      decimals="0"
      id="ixv-35559"
      unitRef="pure">5</abio:ExceptedNumberOfBoardMembers>
    <abio:AggregatePurchasePrice
      contextRef="c149"
      decimals="-5"
      id="ixv-35560"
      unitRef="usd">275000000</abio:AggregatePurchasePrice>
    <abio:NumberOfMonthsBaseSalary contextRef="c150" id="ixv-35561">P12M</abio:NumberOfMonthsBaseSalary>
    <abio:CashPayment contextRef="c150" decimals="0" id="ixv-35562" unitRef="usd">25000</abio:CashPayment>
    <abio:IncreaseOfRetentionBonusToEachExecutive contextRef="c151" decimals="0" id="ixv-35563" unitRef="usd">200000</abio:IncreaseOfRetentionBonusToEachExecutive>
    <abio:IncreaseOfRetentionBonusToEachExecutive contextRef="c152" decimals="0" id="ixv-35564" unitRef="usd">200000</abio:IncreaseOfRetentionBonusToEachExecutive>
    <abio:RetentionBonuses contextRef="c153" decimals="0" id="ixv-35565" unitRef="usd">165000</abio:RetentionBonuses>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c5"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="c6"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="hidden-fact-6"
      unitRef="usdPershares">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="hidden-fact-7"
      unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="hidden-fact-8"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="hidden-fact-9"
      unitRef="shares">14415877</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c10"
      decimals="2"
      id="hidden-fact-10"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-11"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c10"
      decimals="0"
      id="hidden-fact-12"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-13"
      unitRef="shares">14501143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c17"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c19"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c17"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c23"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c24"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c25"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c6"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c23"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c25"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c29"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c31"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c30"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c36"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c38"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c36"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c37"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c44"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c46"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c44"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c45"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c52"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c53"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c54"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c55"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c52"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c54"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c52"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c53"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c56"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c58"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c56"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c57"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c6"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="c7"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c6"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c6"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c6"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c7"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c6"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c7"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c6"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c7"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c0"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c10"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c0"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c10"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c10"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c0"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c10"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c10"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c64"
      id="hidden-fact-69"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="c1"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="c2"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c6"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c68"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:LesseeOperatingSubleaseTermOfContract contextRef="c88" id="hidden-fact-74">P29M</abio:LesseeOperatingSubleaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c1" id="hidden-fact-75">P3Y73D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:RestructuringReserveCurrent
      contextRef="c1"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c7"
      id="hidden-fact-77"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      id="hidden-fact-78"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c6"
      id="hidden-fact-79"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      id="hidden-fact-80"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c6"
      id="hidden-fact-81"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      id="hidden-fact-82"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c1"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c1"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="c1"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c16"
      id="hidden-fact-86"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c16"
      id="hidden-fact-87"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c7"
      id="hidden-fact-88"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c7"
      id="hidden-fact-89"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c7"
      id="hidden-fact-90"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c7"
      id="hidden-fact-91"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c6"
      id="hidden-fact-92"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      id="hidden-fact-93"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c6"
      id="hidden-fact-94"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c6"
      id="hidden-fact-95"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c1"
      id="hidden-fact-96"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c1"
      id="hidden-fact-97"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c98" id="hidden-fact-98">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c99" id="hidden-fact-99">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c6" id="hidden-fact-100">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c106" id="hidden-fact-101">P1Y36D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c107" id="hidden-fact-102">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c6"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c7"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c1"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:OperatingLossCarryforwardsExpirationYear contextRef="c114" id="hidden-fact-109">2025</abio:OperatingLossCarryforwardsExpirationYear>
    <abio:OperatingLossCarryforwardsExpirationYear contextRef="c115" id="hidden-fact-110">2037</abio:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OpenTaxYear contextRef="c6" id="hidden-fact-111">2009</us-gaap:OpenTaxYear>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c119"
      id="hidden-fact-112"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c5"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c1"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c0"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c5"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:LesseeOperatingSubleaseTermOfContract contextRef="c129" id="hidden-fact-117">P29M</abio:LesseeOperatingSubleaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="hidden-fact-118">P6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:RestructuringReserveCurrent
      contextRef="c1"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c135"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-121"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-122"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="c5"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-35692">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-35693">0000907654</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
